PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Huang, MC; Liao, JJ; Bonasera, S; Longo, DL; Goetzl, EJ				Huang, Mei-Chuan; Liao, Jia-Jun; Bonasera, Stephen; Longo, Dan L.; Goetzl, Edward J.			Nuclear factor-kappa B-dependent reversal of aging-induced alterations in T cell cytokines	FASEB JOURNAL			English	Article						immunosenescence; inflammation; autoimmunity; phytochemicals	IMMUNE RISK PHENOTYPE; CUTTING EDGE; LATE-LIFE; ACTIVATION; AGE; INTERLEUKIN-18; LYMPHOCYTES; INHIBITION; EXPRESSION; ALPHA	Immunosenescence is characterized by decreases in protective immune responses and increases in inflammation and autoimmunity. The T helper (Th) 17 subset of cluster-of-differentiation (CD) 4 T cells, which is identified by its generation of interleukin (IL)-17, is implicated in autoimmune pathogenesis. To elucidate immunosenescent changes in Th17 cell cytokines, splenic CD4 T cells from 22-to 24-month-old (old) mice and 6-to 10-wk-old (young) mice were incubated on anti-CD3 plus anti-CD28 (anti-T cell antigen receptor) antibodies. After 96 h, T cells of old C57BL/6 and CBA mice generated up to 20-fold more IL-17 and up to 3-fold more IL-6 than those of young mice; T cells of young mice generated up to 5-fold more IL-21 than those of old mice; and no difference was found for IFN-gamma. At 24 h, cytokine mRNA levels paralleled 96 h cytokine concentrations. Naive CD4 T cells from old mice incubated on anti-T cell antigen receptor antibodies with transforming growth factor-beta, IL-1, IL-6, and IL-23 to induce de novo differentiation of Th17 cells had more IL-17 mRNA and produced more IL-17 than those of young mice. BAY11-7082 and the phytochemicals triptolide and butein suppressed nuclear concentrations of nuclear factor-kappa B and secreted levels of IL-17, IL-21, and IFN-gamma in parallel, with greater potency in Th17 cells from young than old mice. Pharmacological correction of altered generation of Th17 cell cytokines in immunosenescence represents a novel therapeutic approach to aging-induced inflammatory diseases.	[Huang, Mei-Chuan; Liao, Jia-Jun; Bonasera, Stephen; Goetzl, Edward J.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Longo, Dan L.] NIA, NIH, Baltimore, MD 21224 USA	University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Goetzl, EJ (corresponding author), Univ Calif San Francisco, Dept Med, Room UB8B,533 Parnassus 4th Ave, San Francisco, CA 94143 USA.	edward.goetzl@ucsf.edu	Longo, Dan L./F-6022-2011	Bonasera, Stephen/0000-0001-6808-2821	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031809] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R21AG026043] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NHLBI NIH HHS [R0-1 HL31809] Funding Source: Medline; NIA NIH HHS [R21 AG026043] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Agrawal A, 2007, J IMMUNOL, V178, P6912, DOI 10.4049/jimmunol.178.11.6912; Barker BR, 2007, J IMMUNOL, V179, P3596, DOI 10.4049/jimmunol.179.6.3596; Chan MA, 1999, PHYTOTHER RES, V13, P464, DOI 10.1002/(SICI)1099-1573(199909)13:6&lt;464::AID-PTR483&gt;3.0.CO;2-4; Dai R, 2007, J IMMUNOL, V179, P1776, DOI 10.4049/jimmunol.179.3.1776; Dinarello CA, 2006, AM J CLIN NUTR, V83, p447S; Ferrucci L, 2005, BLOOD, V105, P2294, DOI 10.1182/blood-2004-07-2599; Frayling TM, 2007, J GERONTOL A-BIOL, V62, P73, DOI 10.1093/gerona/62.1.73; Gangemi S, 2003, EXP GERONTOL, V38, P669, DOI 10.1016/S0531-5565(03)00061-5; Graeler M, 2002, FASEB J, V16, P1874, DOI 10.1096/fj.02-0548com; Greten FR, 2007, CELL, V130, P918, DOI 10.1016/j.cell.2007.07.009; Haynes L, 2005, IMMUNOL REV, V205, P220, DOI 10.1111/j.0105-2896.2005.00255.x; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Korn T, 2007, NATURE, V448, P484, DOI 10.1038/nature05970; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Liao JJ, 2007, J IMMUNOL, V178, P5425, DOI 10.4049/jimmunol.178.9.5425; Liu H, 2000, ACTA PHARMACOL SIN, V21, P782; Liu HJ, 2007, SCIENCE, V317, P803, DOI 10.1126/science.1143578; LONGO DL, 2003, FUNDAMENTAL IMMUNOLO, P1043; Lustgarten J, 2004, J IMMUNOL, V173, P4510, DOI 10.4049/jimmunol.173.7.4510; Marko MG, 2007, J IMMUNOL, V178, P1443, DOI 10.4049/jimmunol.178.3.1443; McDonald DR, 2007, J ALLERGY CLIN IMMUN, V120, P900, DOI 10.1016/j.jaci.2007.08.035; NAGELKERKEN L, 1991, EUR J IMMUNOL, V21, P273, DOI 10.1002/eji.1830210206; Nishioka T, 2006, J IMMUNOL, V176, P6586, DOI 10.4049/jimmunol.176.11.6586; Pandey MK, 2007, J BIOL CHEM, V282, P17340, DOI 10.1074/jbc.M700890200; Pawelec G, 2006, EXP GERONTOL, V41, P1239, DOI 10.1016/j.exger.2006.09.005; Pelletier M, 2007, THESCIENTIFICWORLDJO, V7, P1715, DOI 10.1100/tsw.2007.275; Ponnappan S, 2004, EXP GERONTOL, V39, P559, DOI 10.1016/j.exger.2003.12.012; Puel A, 2004, CURR OPIN IMMUNOL, V16, P34, DOI 10.1016/j.coi.2003.11.013; Rea IM, 1999, EXP GERONTOL, V34, P79, DOI 10.1016/S0531-5565(98)00058-8; Sharma S, 2006, J IMMUNOL, V177, P8348, DOI 10.4049/jimmunol.177.12.8348; Shibata W, 2007, J IMMUNOL, V179, P2681, DOI 10.4049/jimmunol.179.5.2681; Tanaka A, 2007, J INVEST DERMATOL, V127, P855, DOI 10.1038/sj.jid.5700603; Timm JA, 1999, J IMMUNOL, V162, P711; Trebilcock GU, 1996, GERONTOLOGY, V42, P137, DOI 10.1159/000213785; Trebilcock GU, 1998, MECH AGEING DEV, V102, P149, DOI 10.1016/S0047-6374(97)00160-7; Wikby A, 2005, J GERONTOL A-BIOL, V60, P556, DOI 10.1093/gerona/60.5.556; Wikby A, 2006, MECH AGEING DEV, V127, P695, DOI 10.1016/j.mad.2006.04.003; Zhao L, 2007, J LEUKOCYTE BIOL, V81, P1386, DOI 10.1189/jlb.0506364	38	54	58	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2142	2150		10.1096/fj.07-103721	http://dx.doi.org/10.1096/fj.07-103721			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18267981				2022-12-25	WOS:000257292500006
J	D'Assoro, AB; Busby, R; Acu, ID; Quatraro, C; Reinholz, MM; Farrugia, DJ; Schroeder, MA; Allen, C; Stivala, F; Galanis, E; Salisbury, JL				D'Assoro, A. B.; Busby, R.; Acu, I. D.; Quatraro, C.; Reinholz, M. M.; Farrugia, D. J.; Schroeder, M. A.; Allen, C.; Stivala, F.; Galanis, E.; Salisbury, J. L.			Impaired p53 function leads to centrosome amplification, acquired ER alpha phenotypic heterogeneity and distant metastases in breast cancer MCF-7 xenografts	ONCOGENE			English	Article						cell cycle; estrogen independence; mitosis; tumor progression	CELL-CYCLE PROGRESSION; CHROMOSOME INSTABILITY; DIFFERENTIAL REGULATION; GENOMIC INSTABILITY; ENDOCRINE THERAPY; ESTROGEN; RECEPTOR; EXPRESSION; MDM2; OVEREXPRESSION	In this study, we establish an MCF-7 xenograft model that mimics the progression of human breast carcinomas typified by loss of p53 integrity, development of centrosome amplification, acquired estrogen receptor (ER alpha) heterogeneity, overexpression of Mdm2 and metastatic spread from the primary tumor to distant organs. MCF-7 cells with abrogated p53 function (vMCF-7D(np53)) maintained nuclear ERa expression and normal centrosome characteristics in vitro. However, following mitogen stimulation, they developed centrosome amplification and a higher frequency of aberrant mitotic spindles. Centrosome amplification was dependent on cdk2/cyclin activity since treatment with the small molecule inhibitor SU9516 suppressed centriole reduplication. In contrast to the parental MCF-7 cells, when introduced into nude mice as xenografts, tumors derived from the vMCF-7(DNp53) cell line developed a strikingly altered phenotype characterized by increased tumor growth, higher tumor histopathology grade, centrosome amplification, loss of nuclear ERa expression, increased expression of Mdm-2 oncoprotein and resistance to the antiestrogen tamoxifen. Importantly, while MCF-7 xenografts did not develop distant metastases, primary tumors derived from vMCF-7(DNp53) cells gave rise to lung metastases. Taken together, these observations indicate that abrogation of p53 function and consequent deregulation of the G1/S cell cycle transition leads to centrosome amplification responsible for breast cancer progression.	[D'Assoro, A. B.; Busby, R.; Acu, I. D.; Quatraro, C.; Farrugia, D. J.; Salisbury, J. L.] Mayo Clin, Coll Med, Tumor Biol Program, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; [Allen, C.; Galanis, E.] Mayo Clin, Coll Med, Dept Mol Med, Rochester, MN 55905 USA; [Reinholz, M. M.] Mayo Clin, Coll Med, Dept Lab Med & Expt Pathol, Rochester, MN 55905 USA; [D'Assoro, A. B.] Univ Catania, Dept Biomed Sci, Catania, Italy	Mayo Clinic; Mayo Clinic; Mayo Clinic; University of Catania	Salisbury, JL (corresponding author), Mayo Clin, Coll Med, Tumor Biol Program, Dept Biochem & Mol Biol, Guggenheim 14,200 1st St SW, Rochester, MN 55905 USA.	Salisbury@mayo.edu	Farrugia, Daniel/E-4752-2015	Salisbury, Jeffrey/0000-0001-9257-4578	NCI NIH HHS [R01 CA072836-09, CA72836, R01 CA072836, BC022276] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072836] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akli S, 2004, CANCER RES, V64, P3198, DOI 10.1158/0008-5472.CAN-03-3672; Angeloni SV, 2004, J ENDOCRINOL, V180, P497, DOI 10.1677/joe.0.1800497; Bennett RA, 2004, ONCOGENE, V23, P6823, DOI 10.1038/sj.onc.1207561; Bindels EMJ, 2002, ONCOGENE, V21, P8158, DOI 10.1038/sj.onc.1206012; Brinkley BR, 1998, CELL MOTIL CYTOSKEL, V41, P281, DOI 10.1002/(SICI)1097-0169(1998)41:4<281::AID-CM1>3.0.CO;2-C; Calaf GM, 2006, INT J ONCOL, V28, P285; Caldon CE, 2006, J CELL BIOCHEM, V97, P261, DOI 10.1002/jcb.20690; Cicatiello L, 2004, MOL CELL BIOL, V24, P7260, DOI 10.1128/MCB.24.16.7260-7274.2004; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; D'Assoro AB, 2004, ONCOGENE, V23, P4068, DOI 10.1038/sj.onc.1207568; D'Assoro AB, 2001, MARC MALPIG SYMP SER, V7, P103; Daniels MJ, 2004, SCIENCE, V306, P876, DOI 10.1126/science.1102574; Duensing A, 2007, ONCOGENE, V26, P6280, DOI 10.1038/sj.onc.1210456; Duensing A, 2006, ONCOGENE, V25, P2943, DOI 10.1038/sj.onc.1209310; Duensing A, 2006, CELL CYCLE, V5, P2899, DOI 10.4161/cc.5.24.3567; Duong V, 2007, CANCER RES, V67, P5513, DOI 10.1158/0008-5472.CAN-07-0967; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 2007, NAT REV CANCER, V7, P911, DOI 10.1038/nrc2249; Giacinti L, 2006, ONCOLOGIST, V11, P1, DOI 10.1634/theoncologist.11-1-1; Glass AG, 2007, JNCI-J NATL CANCER I, V99, P1152, DOI 10.1093/jnci/djm059; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Hasegawa K, 2006, CLIN CANCER RES, V12, P1868, DOI 10.1158/1078-0432.CCR-05-1803; Helguero LA, 2005, ONCOGENE, V24, P6605, DOI 10.1038/sj.onc.1208807; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Hwang HC, 2005, ONCOGENE, V24, P2776, DOI 10.1038/sj.onc.1208613; Ingle JN, 2004, CLIN CANCER RES, V10, p362S, DOI 10.1158/1078-0432.CCR-031200; Joe AK, 2005, ANTICANCER RES, V25, P273; Kawamura K, 2004, CANCER RES, V64, P4800, DOI 10.1158/0008-5472.CAN-03-3908; Kinyamu HK, 2003, MOL CELL BIOL, V23, P5867, DOI 10.1128/MCB.23.16.5867-5881.2003; Knippschild U, 1996, ONCOGENE, V12, P1755; Kurokawa H, 2000, CANCER RES, V60, P5887; Kurokawa H, 2003, CLIN CANCER RES, V9, p511S; Kurokawa L, 2001, CLIN CANCER RES, V7, p4436S; Lee S, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1367; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lewis JS, 2005, ONCOL RES, V15, P113, DOI 10.3727/096504005776367924; Li JJ, 2004, P NATL ACAD SCI USA, V101, P18123, DOI 10.1073/pnas.0408273101; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Mailand N, 2005, CELL, V122, P915, DOI 10.1016/j.cell.2005.08.013; Mawson A, 2005, MOL CELL ENDOCRINOL, V229, P161, DOI 10.1016/j.mce.2004.08.002; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; Medina D, 2003, CANCER RES, V63, P1067; Sluder G, 2000, CURR TOP DEV BIOL, V49, P267; Span PN, 2003, ONCOGENE, V22, P4898, DOI 10.1038/sj.onc.1206818; Suizu F, 2006, MOL CELL BIOL, V26, P1463, DOI 10.1128/MCB.26.4.1463-1479.2006; Torres EM, 2007, SCIENCE, V317, P916, DOI 10.1126/science.1142210; Turbin DA, 2006, MODERN PATHOL, V19, P69, DOI 10.1038/modpathol.3800484	49	21	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	28					3901	3911		10.1038/onc.2008.18	http://dx.doi.org/10.1038/onc.2008.18			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	318JZ	18264135	Green Accepted			2022-12-25	WOS:000257089000002
J	Nittka, S; Bohm, C; Zentgraf, H; Neumaier, M				Nittka, S.; Boehm, C.; Zentgraf, H.; Neumaier, M.			The CEACAM1-mediated apoptosis pathway is activated by CEA and triggers dual cleavage of CEACAM1	ONCOGENE			English	Article						CEACAM1; apoptosis; CEA; caspases	CELL-ADHESION MOLECULE; CARCINOEMBRYONIC ANTIGEN FAMILY; BILIARY GLYCOPROTEIN CD66A; C-CAM; COLORECTAL CARCINOMAS; CYTOPLASMIC DOMAIN; EPITHELIAL-CELLS; HUMAN COLON; EXPRESSION; MEMBERS	Marked reduction in apoptosis is a hallmark of early colon tumour growth and the vast majority of these tumours exhibit a loss of expression of the glycoprotein carcinoembryonic-antigen-related cell adhesion molecule 1 (CEACAM1). We recently reported that the CEACAM1 functions as a mediator of apoptosis implicating this cell surface protein in early tumour development. However, the mechanistic involvement of CEACAM1 in cell death pathways is unclear. Here, we show that apoptosis triggers cleavage of the long form of CEACAM1 (CEACAM1-4L) at intracellular and extracellular sites in Jurkat cells and HEK293 cells. Signalling through CEACAM1 leads to caspase activation including caspase-1 and -3 and also involves non-caspase proteases. Moreover, we provide evidence that the naturally occurring CEACAM family member CEA is an inducer of CEACAM1-mediated apoptosis in HT29 colon cancer cells, an effect that depends on the abundance of CEACAM1 on the cell surface. Together, our results demonstrate that the CEACAM1-dependent cell death pathway involves dual cleavage of CEACAM1 and caspase activation and can be activated by CEA.	[Nittka, S.; Neumaier, M.] Univ Heidelberg, Inst Clin Chem, Univ Hosp Mannheim, D-68167 Mannheim, Germany; [Boehm, C.; Zentgraf, H.] German Canc Res Ctr, Dept Appl Tumor Virol, D-6900 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)	Neumaier, M (corresponding author), Univ Heidelberg, Inst Clin Chem, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	michael.neumaier@ikc.ma.uni-heidelberg.de						BARANOV V, 1994, CANCER RES, V54, P3305; BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267; BRUMMER J, 1995, ONCOGENE, V11, P1649; Charbonneau J, 1999, CELL ADHES COMMUN, V7, P233, DOI 10.3109/15419069909010805; Edlund M, 1998, FEBS LETT, V425, P166, DOI 10.1016/S0014-5793(98)00222-1; Edlund M, 1996, J BIOL CHEM, V271, P1393, DOI 10.1074/jbc.271.3.1393; Fournes B, 2001, ONCOGENE, V20, P219, DOI 10.1038/sj.onc.1204058; Frangsmyr L, 1999, TUMOR BIOL, V20, P277, DOI 10.1159/000030075; FRANGSMYR L, 1995, CANCER RES, V55, P2963; Hammarstrom S, 1999, SEMIN CANCER BIOL, V9, P67, DOI 10.1006/scbi.1998.0119; HEFTA SA, 1988, P NATL ACAD SCI USA, V85, P4648, DOI 10.1073/pnas.85.13.4648; Hilbi H, 1998, J BIOL CHEM, V273, P32895, DOI 10.1074/jbc.273.49.32895; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; Houde C, 2003, J BIOL CHEM, V278, P16929, DOI 10.1074/jbc.M301842200; Huang J, 1999, J CELL SCI, V112, P4193; Huber M, 1999, J BIOL CHEM, V274, P335, DOI 10.1074/jbc.274.1.335; Kirshner J, 2003, P NATL ACAD SCI USA, V100, P521, DOI 10.1073/pnas.232711199; Kunath T, 1995, ONCOGENE, V11, P2375; Liu KB, 2003, J IMMUNOL, V170, P6329, DOI 10.4049/jimmunol.170.12.6329; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Nittka S, 2004, ONCOGENE, V23, P9306, DOI 10.1038/sj.onc.1208259; Nollau P, 1997, AM J PATHOL, V151, P521; Nollau P, 1997, CANCER RES, V57, P2354; Obrink B, 1997, CURR OPIN CELL BIOL, V9, P616, DOI 10.1016/S0955-0674(97)80114-7; PAXTON RJ, 1987, P NATL ACAD SCI USA, V84, P920, DOI 10.1073/pnas.84.4.920; RONCUCCI L, 1991, HUM PATHOL, V22, P287, DOI 10.1016/0046-8177(91)90163-J; Singer BB, 2000, CANCER RES, V60, P1236; Vancompernolle K, 1998, FEBS LETT, V438, P150, DOI 10.1016/S0014-5793(98)01275-7; Watt SM, 2001, BLOOD, V98, P1469, DOI 10.1182/blood.V98.5.1469	29	23	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2008	27	26					3721	3728		10.1038/sj.onc.1211033	http://dx.doi.org/10.1038/sj.onc.1211033			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18278069				2022-12-25	WOS:000256659300009
J	De Filette, M; Martens, W; Roose, K; Deroo, T; Vervalle, F; Bentahir, M; Vandekerckhove, J; Fiers, W; Saelens, X				De Filette, Marina; Martens, Wouter; Roose, Kenny; Deroo, Tom; Vervalle, Frederik; Bentahir, Mostafa; Vandekerckhove, Joel; Fiers, Walter; Saelens, Xavier			An influenza A vaccine based on tetrameric ectodomain of matrix protein 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; M2 PROTEIN; VIRUS-REPLICATION; ANTIBODY-RESPONSE; DISULFIDE BONDS; NEURAMINIDASE; ELECTROPHORESIS; HEMAGGLUTININ; RECOMBINANT; EXPRESSION	Matrix protein 2 (M2) of influenza A is a tetrameric type III membrane protein that functions as a proton-selective channel. The extracellular domain (M2e) has remained nearly invariable since the first human influenza strain was isolated in 1933. By linking a modified form of the leucine zipper of the yeast transcription factor GCN4 to M2e, we obtained a recombinant tetrameric protein, M2e-tGCN4. This protein mimics the quaternary structure of the ectodomain of the natural M2 protein. M2e-tGCN4 was purified, biochemically characterized, and used to immunize BALB/c mice. High M2e-specific serum IgG antibody titers were obtained following either intraperitoneal or intranasal administration. Immunized mice were protected fully against a potentially lethal influenza A virus challenge. Antibodies raised by M2e-tGCN4 immunization specifically bound to the surface of influenza-infected cells and to an M2-expressing cell line. Using a M2e peptide competition enzymelinked immunosorbent assay with M2-expressing cells as target, we obtained evidence that M2e-tGCN4 induces antibodies that are specific for the native tetrameric M2 ectodomain. Therefore, fusion of an oligomerization domain to the extracellular part of a transmembrane protein allows it to mimic the natural quaternary structure and can promote the induction of oligomer- specific antibodies.	[De Filette, Marina; Martens, Wouter; Roose, Kenny; Deroo, Tom; Vervalle, Frederik; Bentahir, Mostafa; Fiers, Walter; Saelens, Xavier] Univ Ghent, Dept Mol Biol, Ghent, Belgium; [Vandekerckhove, Joel] Univ Ghent, Dept Biochem, Ghent, Belgium; [De Filette, Marina; Martens, Wouter; Roose, Kenny; Deroo, Tom; Vervalle, Frederik; Fiers, Walter; Saelens, Xavier] Vlaams Inst Biotechnol VIB, Dept Mol Biomed Res, Ghent, Belgium; [Vandekerckhove, Joel] Vlaams Inst Biotechnol VIB, Dept Med Prot Res, Ghent, Belgium	Ghent University; Ghent University; Flanders Institute for Biotechnology (VIB); Flanders Institute for Biotechnology (VIB)	Saelens, X (corresponding author), Univ Ghent VIB, Dept Mol Biol Med Res, Technol Pk 927,B9052, Ghent, Belgium.	xavier.saelens@dmbr.ugent.be	Saelens, Xavier/N-5728-2015	, Xavier/0000-0002-3861-6965	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI055632] Funding Source: NIH RePORTER; NIAID NIH HHS [5R01AI055632] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLACK RA, 1993, J GEN VIROL, V74, P143, DOI 10.1099/0022-1317-74-1-143; BRYAN JK, 1977, ANAL BIOCHEM, V78, P513, DOI 10.1016/0003-2697(77)90111-7; BUCHER DJ, 1972, J VIROL, V10, P60, DOI 10.1128/JVI.10.1.60-66.1972; Cox NJ, 1999, LANCET, V354, P1277, DOI 10.1016/S0140-6736(99)01241-6; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; De Filette M, 2006, VACCINE, V24, P544, DOI 10.1016/j.vaccine.2005.08.061; De Filette M, 2005, VIROLOGY, V337, P149, DOI 10.1016/j.virol.2005.04.004; Deroo T, 1996, VACCINE, V14, P561, DOI 10.1016/0264-410X(95)00157-V; Feng JQ, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-102; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HOLSINGER LJ, 1991, VIROLOGY, V183, P32, DOI 10.1016/0042-6822(91)90115-R; LAVER WG, 1969, VIROLOGY, V38, P105, DOI 10.1016/0042-6822(69)90132-9; Liu WL, 2003, FEMS IMMUNOL MED MIC, V35, P141, DOI 10.1016/S0928-8244(03)00009-9; MERTENS N, 1995, GENE, V164, P9, DOI 10.1016/0378-1119(95)00505-Z; Mould JA, 2003, DEV CELL, V5, P175, DOI 10.1016/S1534-5807(03)00190-4; Mozdzanowska K, 2003, VACCINE, V21, P2616, DOI 10.1016/S0264-410X(03)00040-9; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Neirynck S, 1999, NAT MED, V5, P1157, DOI 10.1038/13484; Nichol KL, 2006, J INFECT DIS, V194, pS111, DOI 10.1086/507544; Pinto LH, 2006, J BIOL CHEM, V281, P8997, DOI 10.1074/jbc.R500020200; SUGRUE RJ, 1991, VIROLOGY, V180, P617, DOI 10.1016/0042-6822(91)90075-M; TREANOR JJ, 1990, J VIROL, V64, P1375, DOI 10.1128/JVI.64.3.1375-1377.1990; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; WARD CW, 1983, FEBS LETT, V153, P29, DOI 10.1016/0014-5793(83)80113-6; WATERMAN MJ, 1996, NUCLEIC ACIDS RES, V22, P3113; WILEY DC, 1977, VIROLOGY, V79, P446, DOI 10.1016/0042-6822(77)90371-3; ZEBEDEE SL, 1985, J VIROL, V56, P502, DOI 10.1128/JVI.56.2.502-511.1985	27	108	135	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11382	11387		10.1074/jbc.M800650200	http://dx.doi.org/10.1074/jbc.M800650200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18252707	Green Published, hybrid			2022-12-25	WOS:000255067400035
J	Gilberthorpe, NJ; Poole, RK				Gilberthorpe, Nicola J.; Poole, Robert K.			Nitric oxide homeostasis in Salmonella typhimurium - Roles of respiratory nitrate reductase and flavohemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTERICA SEROVAR TYPHIMURIUM; COLI FLAVOHAEMOGLOBIN HMP; ESCHERICHIA-COLI; NITROSATIVE STRESS; GENE-EXPRESSION; CYTOCHROME BD; IN-VITRO; FNR; BACTERIAL; SYNTHASE	Nitric oxide (NO) is generated in biological systems primarily via the activity of NO synthases and nitrate and nitrite reductases. Here we show that Salmonella enterica serovar Typhimurium (S. typhimurium) grown anaerobically with nitrate is capable of generating polarographically detectable NO after nitrite (NO2-) addition. NO accumulation is sensitive to the NO scavenger 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide. Neither an fnr mutant nor an fnr hmp double mutant produces NO, indicating the involvement in NO evolution from NO2- of protein(s) positively regulated by FNR. Contrary to previous findings in Escherichia coli, we demonstrate that neither the periplasmic nitrite reductase (NrfA) nor the cytoplasmic nitrite reductase (NirB) is involved in NO production in S. typhimurium. However, mutant cells lacking the membrane-bound nitrate reductase, NarGHI, and membranes derived from these cells are unable to produce NO, demonstrating that, in wild-type S. typhimurium, this enzyme is responsible for NO production. Membrane terminal oxidases cannot account for the NO levels measured. The nitrate reductase inhibitor, azide, abrogates NO evolution by Salmonella, and production of NO occurs only in the absence from the assays of nitrate; both features reveal a marked similarity between the NO-generating activities of this bacterium and plants. Unlike the situation in E. coli, an S. typhimurium hmp mutant produces NO both aerobically and anaerobically. Under aerobic conditions, when a functional flavohemoglobin is present, no NO is detectable. We propose a homeostatic mechanism in S. typhimurium, in which NO produced from NO2- by nitrate reductase derepresses Hmp expression (via FNR and NsrR) and NorV expression (via NorR) and thus limits NO toxicity.	[Gilberthorpe, Nicola J.; Poole, Robert K.] Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Poole, RK (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England.	r.poole@sheffield.ac.uk			Biotechnology and Biological Sciences Research Council [BB/E015883/1] Funding Source: Medline; BBSRC [BB/E015883/1] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Adak S, 2002, J BIOL CHEM, V277, P16167, DOI 10.1074/jbc.M201136200; Adak S, 2002, P NATL ACAD SCI USA, V99, P107, DOI 10.1073/pnas.012470099; Bang IS, 2006, J BIOL CHEM, V281, P28039, DOI 10.1074/jbc.M605174200; Bertero MG, 2003, NAT STRUCT BIOL, V10, P681, DOI 10.1038/nsb969; Bodenmiller DM, 2006, J BACTERIOL, V188, P874, DOI 10.1128/JB.188.3.874-881.2006; Borisov VB, 2004, FEBS LETT, V576, P201, DOI 10.1016/j.febslet.2004.09.013; Borisov VB, 2001, J BIOL CHEM, V276, P22095, DOI 10.1074/jbc.M011542200; Browning DF, 2000, MOL MICROBIOL, V37, P1258, DOI 10.1046/j.1365-2958.2000.02087.x; Browning DF, 2002, MOL MICROBIOL, V43, P687, DOI 10.1046/j.1365-2958.2002.02776.x; CALMELS S, 1988, J GEN MICROBIOL, V134, P221; Campbell WH, 2001, CELL MOL LIFE SCI, V58, P194, DOI 10.1007/PL00000847; Castello PR, 2006, CELL METAB, V3, P277, DOI 10.1016/j.cmet.2006.02.011; CHEN YJ, 1994, BIOCHEM BIOPH RES CO, V203, P1251, DOI 10.1006/bbrc.1994.2317; Choi WS, 1997, BIOCHEM BIOPH RES CO, V237, P554, DOI 10.1006/bbrc.1997.7189; Constantinidou C, 2006, J BIOL CHEM, V281, P4802, DOI 10.1074/jbc.M512312200; Corker H, 2003, J BIOL CHEM, V278, P31584, DOI 10.1074/jbc.M303282200; COSTA C, 1990, FEBS LETT, V276, P67, DOI 10.1016/0014-5793(90)80508-G; Crawford MJ, 1998, J BIOL CHEM, V273, P12543, DOI 10.1074/jbc.273.20.12543; Cruz-Ramos H, 2002, EMBO J, V21, P3235, DOI 10.1093/emboj/cdf339; DARWIN AJ, 1995, J MOL BIOL, V251, P15, DOI 10.1006/jmbi.1995.0412; Fang FC, 2004, NAT REV MICROBIOL, V2, P820, DOI 10.1038/nrmicro1004; Filenko N, 2007, J BACTERIOL, V189, P4410, DOI 10.1128/JB.00080-07; Gardner AM, 2003, J BIOL CHEM, V278, P10081, DOI 10.1074/jbc.M212462200; Gardner AM, 2002, J BIOL CHEM, V277, P8166, DOI 10.1074/jbc.M110470200; Gardner AM, 2002, J BIOL CHEM, V277, P8172, DOI 10.1074/jbc.M110471200; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; GENNIS RB, 1999, RESP ESCHERICHIA COL; Gilberthorpe NJ, 2007, MICROBIOL-SGM, V153, P1756, DOI 10.1099/mic.0.2006/003731-0; Gonzalez PJ, 2006, J INORG BIOCHEM, V100, P1015, DOI 10.1016/j.jinorgbio.2005.11.024; HADDOCK BA, 1976, BIOCHEM J, V154, P285, DOI 10.1042/bj1540285; Han XN, 2004, SHOCK, V21, P261, DOI 10.1097/01.shk.0000112346.38599.10; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; HOCHSTEIN LI, 1988, ANNU REV MICROBIOL, V42, P231, DOI 10.1146/annurev.mi.42.100188.001311; JI XB, 1988, BIOCHEM BIOPH RES CO, V157, P106, DOI 10.1016/S0006-291X(88)80018-4; JI XB, 1988, APPL ENVIRON MICROB, V54, P1791, DOI 10.1128/AEM.54.7.1791-1794.1988; Kalnenieks U, 1998, FEMS MICROBIOL LETT, V168, P91; Kers JA, 2004, NATURE, V429, P79, DOI 10.1038/nature02504; Kim SO, 1999, FEBS LETT, V445, P389, DOI 10.1016/S0014-5793(99)00157-X; KITA K, 1986, METHOD ENZYMOL, V126, P94; Lundberg JO, 2004, NAT REV MICROBIOL, V2, P593, DOI 10.1038/nrmicro929; Maloy SR., 1996, GENETIC ANAL PATHOGE; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Martin MJ, 2001, CURR PHARM DESIGN, V7, P881, DOI 10.2174/1381612013397645; McKnight GM, 1997, GUT, V40, P211, DOI 10.1136/gut.40.2.211; Metheringham R, 1997, MICROBIOL-UK, V143, P2647, DOI 10.1099/00221287-143-8-2647; Mills CE, 2001, BIOCHEM J, V353, P207, DOI 10.1042/0264-6021:3530207; Mills PC, 2005, BIOCHEM SOC T, V33, P198, DOI 10.1042/BST0330198; Modolo LV, 2005, FEBS LETT, V579, P3814, DOI 10.1016/j.febslet.2005.05.078; Morozkina EV, 2007, BIOCHEMISTRY-MOSCOW+, V72, P1151, DOI 10.1134/S0006297907100124; Murphy KC, 1998, J BACTERIOL, V180, P2063, DOI 10.1128/JB.180.8.2063-2071.1998; Pant K, 2002, BIOCHEMISTRY-US, V41, P11071, DOI 10.1021/bi0263715; Poock SR, 2002, J BIOL CHEM, V277, P23664, DOI 10.1074/jbc.M200731200; POOLE RK, 1977, J GEN MICROBIOL, V99, P369, DOI 10.1099/00221287-99-2-369; Poole RK, 1996, J BACTERIOL, V178, P5487, DOI 10.1128/jb.178.18.5487-5492.1996; Poole RK, 2005, BIOCHEM SOC T, V33, P176, DOI 10.1042/BST0330176; POOLE RK, 1979, BIOCHEM J, V184, P379, DOI 10.1042/bj1840379; Pullan ST, 2007, J BACTERIOL, V189, P1845, DOI 10.1128/JB.01354-06; RALT D, 1988, J BACTERIOL, V170, P359, DOI 10.1128/jb.170.1.359-364.1988; Resta-Lenert S, 2005, AM J PHYSIOL-GASTR L, V289, pG153, DOI 10.1152/ajpgi.00395.2004; Rinaldo S, 2007, J BIOL CHEM, V282, P14761, DOI 10.1074/jbc.M700933200; Rockel P, 2002, J EXP BOT, V53, P103, DOI 10.1093/jexbot/53.366.103; Simon J, 2002, FEMS MICROBIOL REV, V26, P285, DOI 10.1111/j.1574-6976.2002.tb00616.x; Sobko T, 2006, FREE RADICAL BIO MED, V41, P985, DOI 10.1016/j.freeradbiomed.2006.06.020; Spector MP, 1999, MICROBIOL-SGM, V145, P3035, DOI 10.1099/00221287-145-11-3035; Spiro S, 2007, FEMS MICROBIOL REV, V31, P193, DOI 10.1111/j.1574-6976.2006.00061.x; Stachura J, 1996, J PHYSIOL PHARMACOL, V47, P131; Stevanin TM, 2002, INFECT IMMUN, V70, P4399, DOI 10.1128/IAI.70.8.4399-4405.2002; STEWART V, 1993, MOL MICROBIOL, V9, P425, DOI 10.1111/j.1365-2958.1993.tb01704.x; Vazquez-Torres A, 2001, TRENDS MICROBIOL, V9, P29, DOI 10.1016/S0966-842X(00)01897-7; Weiss B, 2006, J BACTERIOL, V188, P829, DOI 10.1128/JB.188.3.829-833.2006; Yamasaki H, 2000, FEBS LETT, V468, P89, DOI 10.1016/S0014-5793(00)01203-5; Yamasaki H, 1999, TRENDS PLANT SCI, V4, P128, DOI 10.1016/S1360-1385(99)01393-X; Yamasaki H, 2000, PHILOS T R SOC B, V355, P1477, DOI 10.1098/rstb.2000.0708; Zhao ZW, 2003, BIOCHEMISTRY-US, V42, P14225, DOI 10.1021/bi0350856; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	75	101	101	5	19	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11146	11154		10.1074/jbc.M708019200	http://dx.doi.org/10.1074/jbc.M708019200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18285340	hybrid			2022-12-25	WOS:000255067400010
J	Kihara, A; Sakuraba, H; Ikeda, M; Denpoh, A; Igarashi, Y				Kihara, Akio; Sakuraba, Hiroko; Ikeda, Mika; Denpoh, Aki; Igarashi, Yasuyuki			Membrane topology and essential amino acid residues of Phs1, a 3-hydroxyacyl-CoA dehydratase involved in very long-chain fatty acid elongation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MYOTUBULAR MYOPATHY; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; CERAMIDE SYNTHASE; YEAST; GENE; IDENTIFICATION; TRAFFICKING; EXPLORATION; DISRUPTION	Yeast Phs1 is the 3-hydroxyacyl-CoA dehydratase that catalyzes the third reaction of the four-step cycle in the elongation of very long-chain fatty acids (VLCFAs). In yeast, the hydrophobic backbone of sphingolipids, ceramide, consists of a long-chain base and an amide-linked C26 VLCFA. Therefore, defects in VLCFA synthesis would be expected to greatly affect sphingolipid synthesis. In fact, in this study we found that reduced Phs1 levels result in significant impairment of the conversion of ceramide to inositol phosphorylceramide. Phs1 proteins are conserved among eukaryotes, constituting a novel protein family. Phs1 family members exhibit no sequence similarity to other dehydratase families, so their active site sequence and catalytic mechanism have been completely unknown. Here, by mutating 22 residues conserved among Phs1 family members, we identified six amino acid residues important in Phs1 function, two of which (Tyr-149 and Glu-156) are indispensable. We also examined the membrane topology of Phs1 using an N-glycosylation reporter assay. Our results suggest that Phs1 is a membrane-spanning protein that traverses the membrane six times and has an N terminus and C terminus facing the cytosol. The important amino acids are concentrated in or near two of the six proposed transmembrane regions. Thus, we also propose a catalytic mechanism for Phs1 that is not unlike mechanisms used by other hydratases active in lipid synthesis.	[Kihara, Akio; Sakuraba, Hiroko; Ikeda, Mika; Denpoh, Aki; Igarashi, Yasuyuki] Hokkaido Univ, Fac Pharmaceut Sci, Lab Biomembrane & Biofunct Chem, Kita Ku, Sapporo, Hokkaido 0600812, Japan; [Igarashi, Yasuyuki] Hokkaido Univ, Fac Adv Life Sci, Lab Biomembrane & Biofunct Chem, Sapporo, Hokkaido 0010021, Japan	Hokkaido University; Hokkaido University	Kihara, A (corresponding author), Hokkaido Univ, Fac Pharmaceut Sci, Lab Biomembrane & Biofunct Chem, Kita Ku, Kita 12 Jo,Nishi 6 Choume, Sapporo, Hokkaido 0600812, Japan.	kihara@pharm.hokudai.ac.jp	KIHARA, AKIO/A-3802-2012	KIHARA, AKIO/0000-0001-5889-0788				Black PN, 2007, BBA-MOL CELL BIOL L, V1771, P286, DOI 10.1016/j.bbalip.2006.05.003; Blondeau F, 2000, HUM MOL GENET, V9, P2223, DOI 10.1093/oxfordjournals.hmg.a018913; Brachmann CB, 1998, YEAST, V14, P115; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; David D, 1998, J CELL BIOL, V143, P1167, DOI 10.1083/jcb.143.5.1167; Denic V, 2007, CELL, V130, P663, DOI 10.1016/j.cell.2007.06.031; Farwanah H, 2005, ANAL BIOANAL CHEM, V383, P632, DOI 10.1007/s00216-005-0044-3; FUJITA M, 2008, IN PRESS BIOCH BIOPH; Gavin AC, 2006, NATURE, V440, P631, DOI 10.1038/nature04532; Hakomori S, 2004, AN ACAD BRAS CIENC, V76, P553, DOI 10.1590/S0001-37652004000300010; Han GS, 2002, J BIOL CHEM, V277, P35440, DOI 10.1074/jbc.M205620200; Han GS, 2004, J BIOL CHEM, V279, P53707, DOI 10.1074/jbc.M410014200; Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Kageyama-Yahara N, 2006, BIOCHEM J, V398, P585, DOI 10.1042/BJ20060697; Kihara A, 2002, J BIOL CHEM, V277, P30048, DOI 10.1074/jbc.M203385200; Kihara A, 2007, PROG LIPID RES, V46, P126, DOI 10.1016/j.plipres.2007.03.001; Kohlwein SD, 2001, MOL CELL BIOL, V21, P109, DOI 10.1128/MCB.21.1.109-125.2001; Krogan NJ, 2006, NATURE, V440, P637, DOI 10.1038/nature04670; Kvam E, 2005, MOL BIOL CELL, V16, P3987, DOI 10.1091/mbc.e05-04-0290; Laporte J, 1996, NAT GENET, V13, P175, DOI 10.1038/ng0696-175; Leonard AE, 2004, PROG LIPID RES, V43, P36, DOI 10.1016/S0163-7827(03)00040-7; Levine TP, 2000, MOL BIOL CELL, V11, P2267, DOI 10.1091/mbc.11.7.2267; Li DX, 2000, GENE, V256, P237, DOI 10.1016/S0378-1119(00)00347-4; Liu YJ, 1997, BIOCHEMISTRY-US, V36, P10675, DOI 10.1021/bi970430a; Miller JP, 2005, P NATL ACAD SCI USA, V102, P12123, DOI 10.1073/pnas.0505482102; Mnaimneh S, 2004, CELL, V118, P31, DOI 10.1016/j.cell.2004.06.013; OSEI P, 1989, J BIOL CHEM, V264, P6844; Pele M, 2005, HUM MOL GENET, V14, P1417, DOI 10.1093/hmg/ddi151; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Ponec M, 2003, J INVEST DERMATOL, V120, P581, DOI 10.1046/j.1523-1747.2003.12103.x; POULOS A, 1987, BIOCHEM J, V248, P961, DOI 10.1042/bj2480961; REVARDEL E, 1995, BBA-GENE STRUCT EXPR, V1263, P261, DOI 10.1016/0167-4781(95)00124-Y; Roberts P, 2003, MOL BIOL CELL, V14, P129, DOI 10.1091/mbc.E02-08-0483; Rossler H, 2003, MOL GENET GENOMICS, V269, P290, DOI 10.1007/s00438-003-0836-0; Sandhoff R, 2005, J BIOL CHEM, V280, P27310, DOI 10.1074/jbc.M502775200; Schneiter R, 2004, BIOCHEM J, V381, P941, DOI 10.1042/BJ20040320; Schneiter R, 1996, MOL CELL BIOL, V16, P7161; Schuldiner M, 2005, CELL, V123, P507, DOI 10.1016/j.cell.2005.08.031; Schweizer E, 2004, MICROBIOL MOL BIOL R, V68, P501, DOI 10.1128/MMBR.68.3.501-517.2004; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; Strahl T, 2007, BBA-MOL CELL BIOL L, V1771, P353, DOI 10.1016/j.bbalip.2007.01.015; Taylor GS, 2000, P NATL ACAD SCI USA, V97, P8910, DOI 10.1073/pnas.160255697; Tronchere H, 2004, J BIOL CHEM, V279, P7304, DOI 10.1074/jbc.M311071200; Uemura S, 2007, J BIOL CHEM, V282, P8613, DOI 10.1074/jbc.M606649200; Vallee B, 2005, EMBO J, V24, P730, DOI 10.1038/sj.emboj.7600562; Wang B, 2004, MOL CELL BIOL, V24, P2767, DOI 10.1128/MCB.24.7.2767-2778.2004; Watkins PA, 1998, J BIOL CHEM, V273, P18210, DOI 10.1074/jbc.273.29.18210; White SW, 2005, ANNU REV BIOCHEM, V74, P791, DOI 10.1146/annurev.biochem.74.082803.133524	49	49	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11199	11209		10.1074/jbc.M708993200	http://dx.doi.org/10.1074/jbc.M708993200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18272525	hybrid			2022-12-25	WOS:000255067400015
J	Leskovar, A; Wegele, H; Werbeck, ND; Buchner, J; Reinstein, J				Leskovar, Adriane; Wegele, Harald; Werbeck, Nicolas D.; Buchner, Johannes; Reinstein, Jochen			The ATPase cycle of the mitochondrial Hsp90 analog trap1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK; MOLECULAR CHAPERONE; CRYSTAL-STRUCTURE; IN-VIVO; ESSENTIAL PROTEIN; BINDING; COMPLEX; HSP70; INHIBITION; RECEPTOR	Hsp90 is an ATP-dependent molecular chaperone whose mechanism is not yet understood in detail. Here, we present the first ATPase cycle for the mitochondrial member of the Hsp90 family called Trap1 (tumor necrosis factor receptor-associated protein 1). Using biochemical, thermodynamic, and rapid kinetic methods we dissected the kinetics of the nucleotide-regulated rearrangements between the open and the closed conformations. Surprisingly, upon ATP binding, Trap1 shifts predominantly to the closed conformation (70%), but, unlike cytosolic Hsp90 from yeast, this process is rather slow at 0.076 s(-1). Because reopening (0.034 s(-1)) is about ten times faster than hydrolysis (k(hyd) = 0.0039 s(-1)), which is the rate-limiting step, Trap1 is not able to commit ATP to hydrolysis. The proposed ATPase cycle was further scrutinized by a global fitting procedure that utilizes all relevant experimental data simultaneously. This analysis corroborates our model of a two-step binding mechanism of ATP followed by irreversible ATP hydrolysis and a one-step product ( ADP) release.	[Leskovar, Adriane; Werbeck, Nicolas D.; Reinstein, Jochen] Max Planck Inst Med Res, Dept Biomol Mech, D-69120 Heidelberg, Germany; [Wegele, Harald; Buchner, Johannes] Tech Univ Munich, Dept Chem, D-85747 Garching, Germany	Max Planck Society; Technical University of Munich	Reinstein, J (corresponding author), Max Planck Inst Med Res, Dept Biomol Mech, Jahnstr 29, D-69120 Heidelberg, Germany.	Jochen.Reinstein@mpimf-heidelberg.mpg.de	Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				Adam H., 1962, METHODEN ENZYMATISCH, P573; Ali MMU, 2006, NATURE, V440, P1013, DOI 10.1038/nature04716; BARDWELL JCA, 1984, P NATL ACAD SCI-BIOL, V81, P848, DOI 10.1073/pnas.81.3.848; BERNASCONI CF, 1976, RELAXATION KINETICS, P20; Birnby DA, 2000, GENETICS, V155, P85; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Chen CF, 1996, MOL CELL BIOL, V16, P4691; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; Dollins DE, 2007, MOL CELL, V28, P41, DOI 10.1016/j.molcel.2007.08.024; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; EHRESMAN.B, 1973, ANAL BIOCHEM, V54, P454, DOI 10.1016/0003-2697(73)90374-6; Felts SJ, 2000, J BIOL CHEM, V275, P3305, DOI 10.1074/jbc.275.5.3305; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Frey S, 2007, J BIOL CHEM, V282, P35612, DOI 10.1074/jbc.M704647200; Immormino RM, 2004, J BIOL CHEM, V279, P46162, DOI 10.1074/jbc.M405253200; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Jez JM, 2003, CHEM BIOL, V10, P361, DOI 10.1016/S1074-5521(03)00075-9; Kang BH, 2007, CELL, V131, P257, DOI 10.1016/j.cell.2007.08.028; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Ladbury JE, 1996, CHEM BIOL, V3, P791, DOI 10.1016/S1074-5521(96)90063-0; McLaughlin SH, 2004, J MOL BIOL, V344, P813, DOI 10.1016/j.jmb.2004.09.055; Morita T, 2004, J CELL SCI, V117, P5759, DOI 10.1242/jcs.01499; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Richter K, 2006, J BIOL CHEM, V281, P11301, DOI 10.1074/jbc.M510142200; RICHTER K, 2005, PROTEIN FOLDING HDB, P768; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Scheibel T, 1999, MOL MICROBIOL, V34, P701, DOI 10.1046/j.1365-2958.1999.01632.x; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; SCHLEE S, 2004, PROTEIN FOLDING HDB, P105; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Schulte TW, 1999, MOL ENDOCRINOL, V13, P1435, DOI 10.1210/me.13.9.1435; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; Shiau AK, 2006, CELL, V127, P329, DOI 10.1016/j.cell.2006.09.027; Simmons AD, 1999, HUM MOL GENET, V8, P2155, DOI 10.1093/hmg/8.12.2155; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; Wegele H, 2006, J MOL BIOL, V356, P802, DOI 10.1016/j.jmb.2005.12.008; Wegele H, 2004, REV PHYSIOL BIOCH P, V151, P1, DOI 10.1007/s10254-003-0021-1; Weikl T, 2000, J MOL BIOL, V303, P583, DOI 10.1006/jmbi.2000.4157; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WU XM, 1992, BIOCHEMISTRY-US, V31, P2123, DOI 10.1021/bi00122a033; Yamaguchi H, 2005, EXP CELL RES, V303, P415, DOI 10.1016/j.yexcr.2004.10.005; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; Yue L, 1999, GENETICS, V151, P1065	55	81	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11677	11688		10.1074/jbc.M709516200	http://dx.doi.org/10.1074/jbc.M709516200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18287101	hybrid, Green Published			2022-12-25	WOS:000255067400068
J	Runge, S; Thogersen, H; Madsen, K; Lau, J; Rudolph, R				Runge, Steffen; Thogersen, Henning; Madsen, Kjeld; Lau, Jesper; Rudolph, Rainer			Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; N-TERMINAL DOMAIN; GLP-1 RECEPTOR; SPATIAL APPROXIMATION; AMINO-TERMINUS; MID-REGION; AGONIST; BINDING; SECRETIN; EXENDIN-4	The glucagon-like peptide-1 receptor (GLP-1R) belongs to Family B1 of the seven-transmembrane G protein-coupled receptors, and its natural agonist ligand is the peptide hormone glucagon-like peptide-1 (GLP-1). GLP-1 is involved in glucose homeostasis, and activation of GLP-1R in the plasma membrane of pancreatic beta-cells potentiates glucose-dependent insulin secretion. The N-terminal extracellular domain (nGLP-1R) is an important ligand binding domain that binds GLP-1 and the homologous peptide Exendin-4 with differential affinity. Exendin-4 has a C-terminal extension of nine amino acid residues known as the "Trp cage", which is absent in GLP-1. The Trp cage was believed to interact with nGLP-1R and thereby explain the superior affinity of Exendin-4. However, the molecular details that govern ligand binding and specificity of nGLP-1R remain undefined. Here we report the crystal structure of human nGLP-1R in complex with the antagonist Exendin-4(9 39) solved by the multiwavelength anomalous dispersion method to 2.2 A resolution. The structure reveals that Exendin-4(9-39) is an amphipathic alpha-helix forming both hydrophobic and hydrophilic interactions with nGLP-1R. The Trp cage of Exendin-4 is not involved in binding to nGLP-1R. The hydrophobic binding site of nGLP-1R is defined by discontinuous segments including primarily a well defined alpha-helix in the N terminus of nGLP-1R and a loop between two antiparallel beta-strands. The structure provides for the first time detailed molecular insight into ligand binding of the human GLP-1 receptor, an established target for treatment of type 2 diabetes.	[Runge, Steffen; Thogersen, Henning] Novo Nordisk, Dept Struct & Biophys Chem, DK-2760 Malov, Denmark; [Madsen, Kjeld; Lau, Jesper] Novo Nordisk, Dept Prot & Peptide Chem, DK-2760 Malov, Denmark; [Rudolph, Rainer] Univ Halle Wittenberg, Inst Biotechnol, D-06120 Halle, Germany	Novo Nordisk; Novo Nordisk; Martin Luther University Halle Wittenberg	Runge, S (corresponding author), Nov Nordisk Pk G8S439, DK-2760 Malov, Denmark.	sffr@novonordisk.com	Lau, Jesper/G-3834-2011					ADELHORST K, 1994, J BIOL CHEM, V269, P6275; Al-Sabah S, 2003, FEBS LETT, V553, P342, DOI 10.1016/S0014-5793(03)01043-3; Al-Sabah S, 2003, BRIT J PHARMACOL, V140, P339, DOI 10.1038/sj.bjp.0705453; Andersen NH, 2002, BIOORGAN MED CHEM, V10, P79, DOI 10.1016/S0968-0896(01)00263-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bazarsuren A, 2002, BIOPHYS CHEM, V96, P305, DOI 10.1016/S0301-4622(02)00023-6; CARRUTHERS CJL, 1994, J BIOL CHEM, V269, P29321; de Maturana RL, 2003, J BIOL CHEM, V278, P10195, DOI 10.1074/jbc.M212147200; Dong MQ, 2006, MOL PHARMACOL, V70, P206, DOI 10.1124/mol.105.021840; Dong MQ, 2005, MOL ENDOCRINOL, V19, P1821, DOI 10.1210/me.2004-0421; Dong MQ, 2004, J BIOL CHEM, V279, P2894, DOI 10.1074/jbc.M310407200; Dong MQ, 2003, J BIOL CHEM, V278, P48300, DOI 10.1074/jbc.M309166200; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Foord SM, 2005, PHARMACOL REV, V57, P279, DOI 10.1124/pr.57.2.5; GOKE R, 1993, J BIOL CHEM, V268, P19650; Grace CRR, 2007, P NATL ACAD SCI USA, V104, P4858, DOI 10.1073/pnas.0700682104; Grauschopf U, 2000, BIOCHEMISTRY-US, V39, P8878, DOI 10.1021/bi0001426; Graziano MP, 1996, RECEPTOR CHANNEL, V4, P9; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Lisenbee CS, 2005, J BIOL CHEM, V280, P12330, DOI 10.1074/jbc.M414016200; MATURANA RL, 2004, PROTEIN PEPTIDE LETT, V11, P15; MontroseRafizadeh C, 1997, J BIOL CHEM, V272, P21201, DOI 10.1074/jbc.272.34.21201; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Neidigh JW, 2001, BIOCHEMISTRY-US, V40, P13188, DOI 10.1021/bi010902s; Neidigh JW, 2002, NAT STRUCT BIOL, V9, P425, DOI 10.1038/nsb798; PARTHIER C, 2007, P NATL ACAD SCI USA; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Perrin MH, 2001, J BIOL CHEM, V276, P31528, DOI 10.1074/jbc.M101838200; Runge S, 2003, BRIT J PHARMACOL, V138, P787, DOI 10.1038/sj.bjp.0705120; Runge S, 2003, J BIOL CHEM, V278, P28005, DOI 10.1074/jbc.M301085200; Runge S, 2007, BIOCHEMISTRY-US, V46, P5830, DOI 10.1021/bi062309m; Solano RM, 2001, J BIOL CHEM, V276, P1084, DOI 10.1074/jbc.M007686200; Sun CH, 2007, P NATL ACAD SCI USA, V104, P7875, DOI 10.1073/pnas.0611397104; THORENS B, 1993, DIABETES, V42, P1678, DOI 10.2337/diabetes.42.11.1678; Tibaduiza EC, 2001, J BIOL CHEM, V276, P37787; VAN EB, 1996, PEPTIDES, V17, P565; Vonrhein Clemens, 2007, Methods Mol Biol, V364, P215, DOI 10.1385/1-59745-266-1:215; Wilmen A, 1997, PEPTIDES, V18, P301, DOI 10.1016/S0196-9781(96)00321-X; Wittelsberger A, 2006, BIOCHEMISTRY-US, V45, P2027, DOI 10.1021/bi051833a	40	244	271	2	45	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11340	11347		10.1074/jbc.M708740200	http://dx.doi.org/10.1074/jbc.M708740200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18287102	hybrid			2022-12-25	WOS:000255067400030
J	Soeda, A; Inagaki, A; Oka, N; Ikegame, Y; Aoki, H; Yoshimura, SI; Nakashima, S; Kunisada, T; Iwama, T				Soeda, Akio; Inagaki, Akihito; Oka, Naoki; Ikegame, Yuka; Aoki, Hitomi; Yoshimura, Shin-ichi; Nakashima, Shigeru; Kunisada, Takahiro; Iwama, Toru			Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-RECEPTOR; NEURAL PROGENITORS; IN-VITRO; CANCER; KINASE; EGF; INHIBITION; APOPTOSIS; AKT; IDENTIFICATION	A cancer stem cell population in malignant brain tumors takes an essential part in brain tumor initiation, growth, and recurrence. Growth factors, such as epidermal growth factor, fibroblast growth factor-2, vascular endothelial growth factor, platelet-derived growth factor, and hepatocyte growth factor, are shown to support the proliferation of neural stem cells and also may play key roles in gliomagenesis. However, the responsible growth factor(s), which controls maintenance of brain tumor stem cells, is not yet uncovered. We have established three cancer stem cell lines from human gliomas. These cells were immunoreactive with the neuronal progenitor markers, nestin and CD133, and established tumors that closely resembled the features of original tumor upon transplantation into mouse brain. Three cell lines retained their self-renewal ability and proliferation only in the presence of epidermal growth factor (>2.5 ng/ml). In sharp contrast, other growth factors, including fibroblast growth factor-2, failed to support maintenance of these cells. The tyrosine kinase inhibitors of epidermal growth factor signaling (AG1478 and gefitinib) suppressed the proliferation and self-renewal of these cells. Gefitinib inhibited phosphorylation of epidermal growth factor receptor as well as Akt kinase and extracellular signal-regulated kinase 1/2. Flow cytometric analysis revealed that epidermal growth factor concentration-dependently increased the population of CD133-positive cells. Gefitinib significantly reduced CD133-positive fractions and also induced their apoptosis. These results indicate that maintenance of human brain tumor stem cells absolutely requires epidermal growth factor and that tyrosine kinase inhibitors of epidermal growth factor signaling potentially inhibit proliferation and induce apoptosis of these cells.	[Soeda, Akio; Oka, Naoki; Ikegame, Yuka; Yoshimura, Shin-ichi; Iwama, Toru] Gifu Univ, Grad Sch Med, Dept Neurosurg, Gifu 5011194, Japan; [Inagaki, Akihito; Aoki, Hitomi; Kunisada, Takahiro] Gifu Univ, Grad Sch Med, Dept Tissue & Organ Dev Regenerat & Adv Med Sch, Gifu 5011194, Japan; [Nakashima, Shigeru] Gifu Univ, Grad Sch Med, Dept Cell Signaling, Gifu 5011194, Japan	Gifu University; Gifu University; Gifu University	Soeda, A (corresponding author), Univ Pittsburgh, Pittsburgh Canc Inst, Dept Med, Div Hematol Oncol, Res Pavil Hillman Canc Ctr,Suite G1,5150 Ave, Pittsburgh, PA 15232 USA.	akio.soeda@gmail.com	Ikegame, Yuka/AAU-8880-2020	Iwama, Toru/0000-0002-9426-284X; Ikegame, Yuka/0000-0002-8932-9798				Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Andrae J, 2001, MOL CELL NEUROSCI, V17, P1001, DOI 10.1006/mcne.2001.0989; Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Beier D, 2007, CANCER RES, V67, P4010, DOI 10.1158/0008-5472.CAN-06-4180; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; DAHLSTRAND J, 1992, CANCER RES, V52, P5334; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Doetsch F, 2002, NEURON, V36, P1021, DOI 10.1016/S0896-6273(02)01133-9; Dowlati A, 2004, MOL CANCER THER, V3, P459; Fukazawa H, 2002, MOL CANCER THER, V1, P303; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; Gritti A, 1999, J NEUROSCI, V19, P3287; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Ho R, 2005, CANCER RES, V65, P9868, DOI 10.1158/0008-5472.CAN-04-2426; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; HOPEWELL JW, 1975, J PATHOL, V117, P101, DOI 10.1002/path.1711170208; Ignatova TN, 2002, GLIA, V39, P193, DOI 10.1002/glia.10094; Inagaki A, 2007, BIOCHEM BIOPH RES CO, V361, P586, DOI 10.1016/j.bbrc.2007.07.037; Janmaat ML, 2003, CLIN CANCER RES, V9, P2316; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Kari C, 2003, CANCER RES, V63, P1; Kokuzawa J, 2003, MOL CELL NEUROSCI, V24, P190, DOI 10.1016/S1044-7431(03)00160-X; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Nunes M, 2004, MOL CANCER THER, V3, P21; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Oka N, 2007, BIOCHEM BIOPH RES CO, V360, P553, DOI 10.1016/j.bbrc.2007.06.094; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Ono M, 2004, MOL CANCER THER, V3, P465; Palmer TD, 1999, J NEUROSCI, V19, P8487; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; Sanai N, 2005, NEW ENGL J MED, V353, P811, DOI 10.1056/NEJMra043666; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; SCHLEGEL J, 1994, INT J CANCER, V56, P72; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Smith JS, 2001, JNCI-J NATL CANCER I, V93, P1246, DOI 10.1093/jnci/93.16.1246; Taylor MD, 2005, CANCER CELL, V8, P323, DOI 10.1016/j.ccr.2005.09.001; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; vanderValk P, 1997, ANN ONCOL, V8, P1023, DOI 10.1023/A:1008265905505; Wakeling AE, 2002, CANCER RES, V62, P5749; Wang J, 2008, INT J CANCER, V122, P761, DOI 10.1002/ijc.23130; Woodburn JR, 1999, PHARMACOL THERAPEUT, V82, P241, DOI 10.1016/S0163-7258(98)00045-X; Yoshimura S, 1997, MOL BRAIN RES, V45, P90, DOI 10.1016/S0169-328X(96)00239-2; Yuan XP, 2004, ONCOGENE, V23, P9392, DOI 10.1038/sj.onc.1208311; Zhou YH, 2003, CLIN CANCER RES, V9, P3369	51	138	144	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10958	10966		10.1074/jbc.M704205200	http://dx.doi.org/10.1074/jbc.M704205200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18292095	hybrid			2022-12-25	WOS:000254894700077
J	Buggia-Prevot, V; Sevalle, J; Rossner, S; Checler, F				Buggia-Prevot, Virginie; Sevalle, Jean; Rossner, Steffen; Checler, Frederic			NF kappa B-dependent control of BACE1 promoter transactivation by A beta 42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; DEGRADING ENZYME NEPRILYSIN; ALZHEIMERS BETA-SECRETASE; APP INTRACELLULAR DOMAIN; GAMMA-SECRETASE; TRANSCRIPTIONAL CONTROL; NUCLEAR TRANSLOCATION; ASPARTYL PROTEASE; ALPHA-SECRETASE; CELL-SURVIVAL	beta-Amyloid (A beta) peptides that accumulate in Alzheimer disease are generated from the beta-amyloid precursor protein (beta APP) by cleavages by beta-secretase BACE1 and by presenilin-dependent beta-secretase activities. Very few data document a putative cross-talk between these proteases and the regulatory mechanisms underlying such interaction. We show that presenilin deficiency lowers BACE1 maturation and affects both BACE1 activity and promoter transactivation. The specific beta-secretase inhibitor DFK167 triggers the decrease of BACE1 activity in wild-type but not in presenilin-deficient fibroblasts. This decrease is also elicited by catalytically inactive beta-secretase. The overexpression of APP intracellular domain (AICD), the gamma/epsilon-secretase-derived C-terminal product of beta-amyloid precursor protein, does not modulate BACE1 activity or promoter transactivation in fibroblasts and does not alter BACE1 expression in AICD transgenic brains of mice. A DFK167-sensitive increase of BACE1 activity is observed in cells overexpressing APP epsilon (the N-terminal product of beta APP generated by epsilon-secretase cleavage harboring the A domain but lacking the AICD sequence), suggesting that the production of A beta could account for the modulation of BACE1. Accordingly, we show that HEK293 cells overexpressing wild-type beta APP exhibit a DFK167-sensitive increase in BACE1 promoter transactivation that is increased by the A beta-potentiating Swedish mutation. This effect was mimicked by exogenous application of A beta 42 but not A beta 40 or by transient transfection of cDNA encoding A beta 42 sequence. The I kappa B kinase inhibitor BMS345541 prevents A beta-induced BACE1 promoter transactivation suggesting that NF kappa B could mediate this A beta-associated phenotype. Accordingly, the overexpression of wild-type or Swedish mutated beta APP does not modify the transactivation of BACE1 promoter constructs lacking NF kappa B-responsive element. Furthermore, APP/beta-amyloid precursor protein-like protein deficiency does not affect BACE1 activity and expression. Overall, these data suggest that physiological levels of endogenous A beta are not sufficient per se to modulate BACE1 promoter transactivation but that exacerbated A beta production linked to wild-type or Swedish mutated beta APP overexpression modulates BACE1 promoter transactivation and activity via an NF kappa B-dependent pathway.	[Buggia-Prevot, Virginie; Sevalle, Jean; Checler, Frederic] CNRS, Inst Pharmacol Mol & Cellulaire, Equipe Labellisee Fondat Rech Med, UMR6097 UNSA, F-06560 Valbonne, France; [Rossner, Steffen] Univ Leipzig, Dept Neurochem, D-04109 Leipzig, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Leipzig University	Checler, F (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, Equipe Labellisee Fondat Rech Med, UMR6097 UNSA, F-06560 Valbonne, France.	checler@ipmc.cnrs.fr	Rossner, Steffen/A-5184-2017; Checler, Frederic/C-1241-2009	Checler, Frederic/0000-0003-2098-1750				ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; Andrau D, 2003, J BIOL CHEM, V278, P25859, DOI 10.1074/jbc.M302622200; Annaert WG, 2001, NEURON, V32, P579, DOI 10.1016/S0896-6273(01)00512-8; Armogida M, 2001, NAT CELL BIOL, V3, P1030, DOI 10.1038/ncb1101-1030; Arvanitis DN, 2007, J NEUROCHEM, V103, P216, DOI 10.1111/j.1471-4159.2007.04704.x; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Barelli HL, 1997, MOL MED, V3, P695, DOI 10.1007/BF03401708; Beglopoulos V, 2004, J BIOL CHEM, V279, P46907, DOI 10.1074/jbc.M409544200; Benjannet S, 1997, J BIOL CHEM, V272, P26210, DOI 10.1074/jbc.272.42.26210; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Bourne KZ, 2007, J NEUROSCI RES, V85, P1194, DOI 10.1002/jnr.21252; Burke JR, 2003, J BIOL CHEM, V278, P1450, DOI 10.1074/jbc.M209677200; Caccamo A, 2005, NEUROBIOL AGING, V26, P645, DOI 10.1016/j.neurobiolaging.2004.06.013; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Carson JA, 2002, J NEUROCHEM, V81, P1, DOI 10.1046/j.1471-4159.2002.00855.x; Chang KA, 2006, MOL CELL BIOL, V26, P4327, DOI 10.1128/MCB.02393-05; Checler F, 1999, IUBMB LIFE, V48, P33, DOI 10.1080/152165499307396; CHECLER F, 1995, J NEUROCHEM, V65, P1431; Chevallier N, 1997, BRIT J PHARMACOL, V121, P556, DOI 10.1038/sj.bjp.0701151; Cisse MA, 2006, BIOCHEM BIOPH RES CO, V347, P254, DOI 10.1016/j.bbrc.2006.06.065; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; da Costa CA, 2006, J NEUROSCI, V26, P6377, DOI 10.1523/JNEUROSCI.0651-06.2006; da Costa CA, 2002, P NATL ACAD SCI USA, V99, P4043, DOI 10.1073/pnas.062059899; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Eckman EA, 2005, BIOCHEM SOC T, V33, P1101, DOI 10.1042/BST0331101; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; FELSENSTEIN KM, 1994, NAT GENET, V6, P251, DOI 10.1038/ng0394-251; Ge YW, 2004, FASEB J, V18, P1037, DOI 10.1096/fj.03-1379fje; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; Haniu M, 2000, J BIOL CHEM, V275, P21099, DOI 10.1074/jbc.M002095200; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Heber S, 2000, J NEUROSCI, V20, P7951; Hebert SS, 2003, NEUROBIOL DIS, V13, P238, DOI 10.1016/S0969-9961(03)00035-4; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Hersh LB, 2003, CURR PHARM DESIGN, V9, P449, DOI 10.2174/1381612033391676; Hu XY, 2006, NAT NEUROSCI, V9, P1520, DOI 10.1038/nn1797; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Kume H, 2004, INT J MOL MED, V13, P121; Kuzuya A, 2007, J NEUROSCI RES, V85, P153, DOI 10.1002/jnr.21104; Lai MT, 2006, J NEUROCHEM, V96, P118, DOI 10.1111/j.1471-4159.2005.03528.x; Lange-Dohna C, 2003, J NEUROSCI RES, V73, P73, DOI 10.1002/jnr.10639; Lefranc-Jullien S, 2006, J NEUROCHEM, V97, P807, DOI 10.1111/j.1471-4159.2006.03748.x; Lefranc-Jullien S, 2005, BRIT J PHARMACOL, V145, P228, DOI 10.1038/sj.bjp.0706183; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; MALONEY B, 2006, SOC NEUR ANN M ATL G; McCarthy JV, 2005, BIOCHEM SOC T, V33, P568, DOI 10.1042/BST0330568; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Ohyagi Y, 2005, FASEB J, V19, P255, DOI 10.1096/fj.04-2637fje; Pardossi-Piquard R, 2005, NEURON, V46, P541, DOI 10.1016/j.neuron.2005.04.008; Pardossi-Piquard R, 2007, NEURON, V53, P483, DOI 10.1016/j.neuron.2007.01.024; Paris D, 2007, NEUROSCI LETT, V415, P11, DOI 10.1016/j.neulet.2006.12.029; Passer Brent, 2000, Journal of Alzheimer's Disease, V2, P289; Popescu BO, 2004, J ALZHEIMERS DIS, V6, P123; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Ryan KA, 2005, J CELL BIOL, V171, P327, DOI 10.1083/jcb.200505078; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; Shirotani K, 2001, J BIOL CHEM, V276, P21895, DOI 10.1074/jbc.M008511200; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Thinakaran G, 2004, PHARMACOL RES, V50, P411, DOI 10.1016/j.phrs.2003.12.026; Tong LQ, 2001, J BIOL CHEM, V276, P17301, DOI 10.1074/jbc.M010450200; Uemura K, 2003, J NEUROSCI RES, V74, P184, DOI 10.1002/jnr.10753; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vassar R, 2001, J MOL NEUROSCI, V17, P157, DOI 10.1385/JMN:17:2:157; von Rotz RC, 2004, J CELL SCI, V117, P4435, DOI 10.1242/jcs.01323; Walsh DM, 2007, J NEUROCHEM, V101, P1172, DOI 10.1111/j.1471-4159.2006.04426.x; Willem M, 2006, SCIENCE, V314, P664, DOI 10.1126/science.1132341; Wilson CA, 2003, J NEUROSCI RES, V74, P361, DOI 10.1002/jnr.10776; Wilson CA, 2002, NAT NEUROSCI, V5, P849, DOI 10.1038/nn898; Wolfe MS, 1998, J MED CHEM, V41, P6, DOI 10.1021/jm970621b; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Zhang YW, 2007, P NATL ACAD SCI USA, V104, P10613, DOI 10.1073/pnas.0703903104	79	113	118	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					10037	10047		10.1074/jbc.M706579200	http://dx.doi.org/10.1074/jbc.M706579200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18263584	hybrid			2022-12-25	WOS:000254671600058
J	Davidich, MI; Bornholdt, S				Davidich, Maria I.; Bornholdt, Stefan			Boolean Network Model Predicts Cell Cycle Sequence of Fission Yeast	PLOS ONE			English	Article								A Boolean network model of the cell-cycle regulatory network of fission yeast (Schizosaccharomyces Pombe) is constructed solely on the basis of the known biochemical interaction topology. Simulating the model in the computer faithfully reproduces the known activity sequence of regulatory proteins along the cell cycle of the living cell. Contrary to existing differential equation models, no parameters enter the model except the structure of the regulatory circuitry. The dynamical properties of the model indicate that the biological dynamical sequence is robustly implemented in the regulatory network, with the biological stationary state G1 corresponding to the dominant attractor in state space, and with the biological regulatory sequence being a strongly attractive trajectory. Comparing the fission yeast cell-cycle model to a similar model of the corresponding network in S. cerevisiae, a remarkable difference in circuitry, as well as dynamics is observed. While the latter operates in a strongly damped mode, driven by external excitation, the S. pombe network represents an auto-excited system with external damping.	[Davidich, Maria I.; Bornholdt, Stefan] Univ Bremen, Inst Theoret Phys, Bremen, Germany	University of Bremen	Davidich, MI (corresponding author), Univ Bremen, Inst Theoret Phys, Bremen, Germany.	bornholdt@itp.uni-bremen.de						Albert R, 2003, J THEOR BIOL, V223, P1, DOI 10.1016/S0022-5193(03)00035-3; Alon U, 1999, NATURE, V397, P168, DOI 10.1038/16483; Batagelj V., 1998, CONNECTIONS, V21, P47, DOI DOI 10.1017/CB09780511996368; Bornholdt S, 2005, SCIENCE, V310, P449, DOI 10.1126/science.1119959; Braunewell S, 2007, J THEOR BIOL, V245, P638, DOI 10.1016/j.jtbi.2006.11.012; Buck V, 2003, J CELL SCI, V116, P4263; CORREABORDES J, 1995, CELL, V83, P1001, DOI 10.1016/0092-8674(95)90215-5; Espinosa-soto C, 2004, PLANT CELL, V16, P2923, DOI 10.1105/tpc.104.021725; Faure A, 2006, BIOINFORMATICS, V22, pE124, DOI 10.1093/bioinformatics/btl210; Forsburg SL, 1999, TRENDS GENET, V15, P340, DOI 10.1016/S0168-9525(99)01798-9; GILLESPIE DT, 1976, J COMPUT PHYS, V22, P403, DOI 10.1016/0021-9991(76)90041-3; GILLESPIE DT, 1977, J PHYS CHEM-US, V81, P2340, DOI 10.1021/j100540a008; GLASS L, 1973, J THEOR BIOL, V39, P103, DOI 10.1016/0022-5193(73)90208-7; Gunsalus KC, 2005, NATURE, V436, P861, DOI 10.1038/nature03876; Hasty J, 2001, NAT REV GENET, V2, P268, DOI 10.1038/35066056; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; Kauffman S.A., 1993, ORIGINS ORDER; KAUFFMAN SA, 1969, J THEOR BIOL, V22, P437, DOI 10.1016/0022-5193(69)90015-0; Li FT, 2004, P NATL ACAD SCI USA, V101, P4781, DOI 10.1073/pnas.0305937101; Li S, 2006, PLOS BIOL, V4, P1732, DOI 10.1371/journal.pbio.0040312; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MARTINCASTELLAN.C, 1996, J EMBO, V15, P839; Mendoza L, 1999, BIOINFORMATICS, V15, P593, DOI 10.1093/bioinformatics/15.7.593; Novak B, 2001, CHAOS, V11, P277, DOI 10.1063/1.1345725; Novak B, 1997, P NATL ACAD SCI USA, V94, P9147, DOI 10.1073/pnas.94.17.9147; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Sanchez L, 2001, J THEOR BIOL, V211, P115, DOI 10.1006/jtbi.2001.2335; Simanis V, 2003, J CELL SCI, V116, P4263, DOI 10.1242/jcs.00807; Smolen P, 2000, NEURON, V26, P567, DOI 10.1016/S0896-6273(00)81194-0; Sveiczer A, 2000, P NATL ACAD SCI USA, V97, P7865, DOI 10.1073/pnas.97.14.7865; Thum KE, 2003, PLANT PHYSIOL, V132, P440, DOI 10.1104/pp.103.022780; Trautmann S, 2001, CURR BIOL, V11, P931, DOI 10.1016/S0960-9822(01)00268-8; Tyson JJ, 2002, BIOESSAYS, V24, P1095, DOI 10.1002/bies.10191; Tyson JJ, 2003, CURR OPIN CELL BIOL, V15, P221, DOI 10.1016/S0955-0674(03)00017-6; Tyson JJ, 2001, NAT REV MOL CELL BIO, V2, P908, DOI 10.1038/35103078; van Riel NAW, 2006, BRIEF BIOINFORM, V7, P364, DOI 10.1093/bib/bbl040; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Yamaguchi S, 2000, EMBO J, V19, P3968, DOI 10.1093/emboj/19.15.3968	38	333	341	1	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2008	3	2							e1672	10.1371/journal.pone.0001672	http://dx.doi.org/10.1371/journal.pone.0001672			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XS	18301750	Green Published, Green Submitted, gold			2022-12-25	WOS:000260586500017
J	Nackerdien, ZE; Keynan, A; Bassler, BL; Lederberg, J; Thaler, DS				Nackerdien, Zeena E.; Keynan, Alexander; Bassler, Bonnie L.; Lederberg, Joshua; Thaler, David S.			Quorum Sensing Influences Vibrio harveyi Growth Rates in a Manner Not Fully Accounted For by the Marker Effect of Bioluminescence	PLOS ONE			English	Article								Background: The light-emitting Vibrios provide excellent material for studying the interaction of cellular communication with growth rate because bioluminescence is a convenient marker for quorum sensing. However, the use of bioluminescence as a marker is complicated because bioluminescence itself may affect growth rate, e. g. by diverting energy. Methodology/Principal Findings: The marker effect was explored via growth rate studies in isogenic Vibrio harveyi (Vh) strains altered in quorum sensing on the one hand, and bioluminescence on the other. By hypothesis, growth rate is energy limited: mutants deficient in quorum sensing grow faster because wild type quorum sensing unleashes bioluminescence and bioluminescence diverts energy. Findings reported here confirm a role for bioluminescence in limiting Vh growth rate, at least under the conditions tested. However, the results argue that the bioluminescence is insufficient to explain the relationship of growth rate and quorum sensing in Vh. A Vh mutant null for all genes encoding the bioluminescence pathway grew faster than wild type but not as fast as null mutants in quorum sensing. Vh quorum sensing mutants showed altered growth rates that do not always rank with their relative increase or decrease in bioluminescence. In addition, the cell-free culture fluids of a rapidly growing Vibrio parahaemolyticus (Vp) strain increased the growth rate of wild type Vh without significantly altering Vh's bioluminescence. The same cell-free culture fluid increased the bioluminescence of Vh quorum mutants. Conclusions/Significance: The effect of quorum sensing on Vh growth rate can be either positive or negative and includes both bioluminescence-dependent and independent components. Bioluminescence tends to slow growth rate but not enough to account for the effects of quorum sensing on growth rate.	[Nackerdien, Zeena E.; Lederberg, Joshua; Thaler, David S.] Rockefeller Univ, Raymond & Beverly Sackler Lab Mol Genet & Informa, New York, NY 10021 USA; [Keynan, Alexander] Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, Jerusalem, Israel; [Bassler, Bonnie L.] Princeton Univ, Howard Hughes Med Inst, Dept Mol Biol, Princeton, NJ USA	Rockefeller University; Hebrew University of Jerusalem; Howard Hughes Medical Institute; Princeton University	Nackerdien, ZE (corresponding author), Rockefeller Univ, Raymond & Beverly Sackler Lab Mol Genet & Informa, 1230 York Ave, New York, NY 10021 USA.	thalerd@rockefeller.edu		Bassler, Bonnie/0000-0002-0043-746X	ARO [46938-LS]; Sloan Foundation; HHMI NIH [R01 GM 065859]; NSF [MCB-0343821]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065859] Funding Source: NIH RePORTER	ARO; Sloan Foundation(Alfred P. Sloan Foundation); HHMI NIH(Howard Hughes Medical InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by ARO project grant 46938-LS to JL and Sloan Foundation support to JL and DST. BLB acknowledges HHMI, NIH grants R01 GM 065859, and NSF grant MCB-0343821. We are grateful to Jack Rudin for his support of AK in New York.	Aiyar SE, 2002, J BACTERIOL, V184, P1349, DOI 10.1128/JB.184.5.1349-1358.2002; BASSLER BL, 1993, MOL MICROBIOL, V9, P773, DOI 10.1111/j.1365-2958.1993.tb01737.x; BASSLER BL, 1994, MOL MICROBIOL, V13, P273, DOI 10.1111/j.1365-2958.1994.tb00422.x; Bassler BL, 1997, J BACTERIOL, V179, P4043, DOI 10.1128/jb.179.12.4043-4045.1997; Beste DJV, 2007, J BACTERIOL, V189, P3969, DOI 10.1128/JB.01787-06; Bettenbrock K, 2007, J BACTERIOL, V189, P6891, DOI 10.1128/JB.00819-07; BLOT M, 1994, MOL GEN GENET, V242, P595, DOI 10.1007/BF00285283; Brauer MJ, 2005, MOL BIOL CELL, V16, P2503, DOI 10.1091/mbc.E04-11-0968; Camilli A, 2006, SCIENCE, V311, P1113, DOI 10.1126/science.1121357; Carbonell X, 2002, MICROBIOL RES, V157, P257, DOI 10.1078/0944-5013-00167; Chatterjee J, 2002, MOL MICROBIOL, V46, P101, DOI 10.1046/j.1365-2958.2002.03128.x; Colwell RR, 2000, NONCULTURABLE MICROO; Czyz A, 2003, LUMINESCENCE, V18, P140, DOI 10.1002/bio.715; DAVIS K, 2005, APPL ENV MICROBIOL, V71; Diggle SP, 2007, PHILOS T R SOC B, V362, P1241, DOI 10.1098/rstb.2007.2049; DITTA G, 1980, P NATL ACAD SCI-BIOL, V77, P7347, DOI 10.1073/pnas.77.12.7347; Freeman JA, 1999, MOL MICROBIOL, V31, P665, DOI 10.1046/j.1365-2958.1999.01208.x; Freshney R.I., 2005, CULTURE ANIMAL CELLS, DOI [10.1002/0471747599.CAC022, DOI 10.1002/0471747599.CAC022]; HASTINGS JW, 1977, ANNU REV MICROBIOL, V31, P549, DOI 10.1146/annurev.mi.31.100177.003001; Hastings JW, 1999, J BACTERIOL, V181, P2667, DOI 10.1128/JB.181.9.2667-2668.1999; Henke JM, 2004, J BACTERIOL, V186, P6902, DOI 10.1128/JB.186.20.6902-6914.2004; Henke JM, 2004, J BACTERIOL, V186, P3794, DOI 10.1128/JB.186.12.3794-3805.2004; Higgins DA, 2007, NATURE, V450, P883, DOI 10.1038/nature06284; Ingraham J. L., 1983, GROWTH BACTERIAL CEL; JACOB F, 1977, SCIENCE, V196, P1161, DOI 10.1126/science.860134; Jaques S, 2006, J BACTERIOL, V188, P2625, DOI 10.1128/JB.188.7.2625-2635.2006; Kaeberlein T, 2002, SCIENCE, V296, P1127, DOI 10.1126/science.1070633; KAPRELYANTS AS, 1993, APPL ENVIRON MICROB, V59, P3187, DOI 10.1128/AEM.59.10.3187-3196.1993; Karlin S, 2001, J BACTERIOL, V183, P5025, DOI 10.1128/JB.183.17.5025-5040.2001; Kendall MM, 2007, INFECT IMMUN, V75, P4875, DOI 10.1128/IAI.00550-07; Lazazzera BA, 2000, CURR OPIN MICROBIOL, V3, P177, DOI 10.1016/S1369-5274(00)00072-2; LEDERBERG J, 1957, J BACTERIOL, V73, P144, DOI 10.1128/JB.73.1.144-144.1957; LEDERBERG J, 1958, J BACTERIOL, V75, P143, DOI 10.1128/JB.75.2.143-160.1958; Lilley BN, 2000, MOL MICROBIOL, V36, P940, DOI 10.1046/j.1365-2958.2000.01913.x; Lupp C, 2004, J BACTERIOL, V186, P3873, DOI 10.1128/JB.186.12.3873-3881.2004; Makino K, 2003, LANCET, V361, P743, DOI 10.1016/S0140-6736(03)12659-1; McCarter LL, 1998, J BACTERIOL, V180, P3166, DOI 10.1128/JB.180.12.3166-3173.1998; Mok KC, 2003, EMBO J, V22, P870, DOI 10.1093/emboj/cdg085; NEALSON KH, 1979, MICROBIOL REV, V43, P496, DOI 10.1128/MMBR.43.4.496-518.1979; NEALSON KH, 1970, J BACTERIOL, V104, P313, DOI 10.1128/JB.104.1.313-322.1970; Neidhardt FC, 1999, J BACTERIOL, V181, P7405, DOI 10.1128/JB.181.24.7405-7408.1999; Rappe MS, 2003, ANNU REV MICROBIOL, V57, P369, DOI 10.1146/annurev.micro.57.030502.090759; Redfield RJ, 2002, TRENDS MICROBIOL, V10, P365, DOI 10.1016/S0966-842X(02)02400-9; Sambrook J., 2002, MOL CLONING LAB MANU; Shapiro JA, 1997, BACTERIA MULTICELLUL; SIMIDU U, 1985, APPL ENVIRON MICROB, V50, P781, DOI 10.1128/AEM.50.4.781-790.1985; Sperandio V, 2001, J BACTERIOL, V183, P5187, DOI 10.1128/JB.183.17.5187-5197.2001; Stabb EV, 2005, ASM NEWS, V71, P223; Stabb EV, 2004, J BACTERIOL, V186, P2906, DOI 10.1128/JB.186.9.2906-2908.2004; STABB EV, 2004, JBACTERIOL, V186, P1205; Surette MG, 1999, P NATL ACAD SCI USA, V96, P1639, DOI 10.1073/pnas.96.4.1639; Swift S, 1996, TRENDS BIOCHEM SCI, V21, P214; Tannock GW, 2005, APPL ENVIRON MICROB, V71, P8419, DOI 10.1128/AEM.71.12.8419-8425.2005; TOMASZ A, 1965, NATURE, V208, P155, DOI 10.1038/208155a0; Turovskiy Y, 2007, ADV APPL MICROBIOL, V62, P191, DOI 10.1016/S0065-2164(07)62007-3; Vasil ML, 2003, J BACTERIOL, V185, P2061, DOI 10.1128/JB.185.7.2061-2065.2003; Yim G, 2007, PHILOS T R SOC B, V362, P1195, DOI 10.1098/rstb.2007.2044; Zhu J, 2002, P NATL ACAD SCI USA, V99, P3129, DOI 10.1073/pnas.052694299	58	27	32	1	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2008	3	2							e1671	10.1371/journal.pone.0001671	http://dx.doi.org/10.1371/journal.pone.0001671			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XS	18301749	Green Published, gold			2022-12-25	WOS:000260586500016
J	Vinod, PK; Sengupta, N; Bhat, PJ; Venkatesh, KV				Vinod, P. K.; Sengupta, Neelanjan; Bhat, P. J.; Venkatesh, K. V.			Integration of Global Signaling Pathways, cAMP-PKA, MAPK and TOR in the Regulation of FLO11	PLOS ONE			English	Article							PROTEIN-KINASE-A; YEAST SACCHAROMYCES-CEREVISIAE; RAS/CYCLIC AMP PATHWAY; KELCH-REPEAT PROTEINS; G-ALPHA SUBUNIT; FILAMENTOUS GROWTH; PSEUDOHYPHAL DIFFERENTIATION; TRANSLATION INITIATION; G(1) ARREST; NITROGEN	The budding yeast, Saccharomyces cerevisiae, responds to various environmental cues by invoking specific adaptive mechanisms for their survival. Under nitrogen limitation, S. cerevisiae undergoes a dimorphic filamentous transition called pseudohyphae, which helps the cell to forage for nutrients and reach an environment conducive for growth. This transition is governed by a complex network of signaling pathways, namely cAMP-PKA, MAPK and TOR, which controls the transcriptional activation of FLO11, a flocculin gene that encodes a cell wall protein. However, little is known about how these pathways co-ordinate to govern the conversion of nutritional availability into gene expression. Here, we have analyzed an integrative network comprised of cAMP-PKA, MAPK and TOR pathways with respect to the availability of nitrogen source using experimental and steady state modeling approach. Our experiments demonstrate that the steady state expression of FLO11 was bistable over a range of inducing ammonium sulphate concentration based on the preculturing condition. We also show that yeast switched from FLO11 expression to accumulation of trehalose, a STRE response controlled by a transcriptional activator Msn2/4, with decrease in the inducing concentration to complete starvation. Steady state analysis of the integrative network revealed the relationship between the environment, signaling cascades and the expression of FLO11. We demonstrate that the double negative feedback loop in TOR pathway can elicit a bistable response, to differentiate between vegetative growth, filamentous growth and STRE response. Negative feedback on TOR pathway function to restrict the expression of FLO11 under nitrogen starved condition and also with re-addition of nitrogen to starved cells. In general, we show that these global signaling pathways respond with specific sensitivity to regulate the expression of FLO11 under nitrogen limitation. The holistic steady state modeling approach of the integrative network revealed how the global signaling pathways could differentiate between multiple phenotypes.	[Vinod, P. K.; Bhat, P. J.; Venkatesh, K. V.] Indian Inst Technol, Sch Biosci & Bioengn, Bombay 400076, Maharashtra, India; [Sengupta, Neelanjan; Venkatesh, K. V.] Indian Inst Technol, Dept Chem Engn, Bombay, Maharashtra, India	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Bombay; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Bombay	Vinod, PK (corresponding author), Indian Inst Technol, Sch Biosci & Bioengn, Bombay 400076, Maharashtra, India.	venks@che.iitb.ac.in		Venkatesh, Kareenhalli V./0000-0001-7397-5472; Vinod, P K/0000-0003-2968-498X; Sengupta, Neelanjan/0000-0003-4381-9588	Department of Science and Technology, India [Swarnajayanti fellowship]	Department of Science and Technology, India(Department of Science & Technology (India))	. V. Venkatesh acknowledges the financial support from the Swarnajayanti fellowship, Department of Science and Technology, India.	Adams A, 1997, METHODS YEAST GENETI; Ahn SH, 1999, MOL BIOL CELL, V10, P3301, DOI 10.1091/mbc.10.10.3301; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Batlle M, 2003, J CELL SCI, V116, P701, DOI 10.1242/jcs.00266; Berset C, 1998, P NATL ACAD SCI USA, V95, P4264, DOI 10.1073/pnas.95.8.4264; Biswas K, 2005, MOL MICROBIOL, V56, P649, DOI 10.1111/j.1365-2958.2005.04576.x; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Cherkasova VA, 2003, GENE DEV, V17, P859, DOI 10.1101/gad.1069003; Cooper TG, 2002, FEMS MICROBIOL REV, V26, P223, DOI 10.1111/j.1574-6976.2002.tb00612.x; Crespo JL, 2002, MICROBIOL MOL BIOL R, V66, P579, DOI 10.1128/MMBR.66.4.579-591.2002; Cullen PJ, 2004, GENE DEV, V18, P1695, DOI 10.1101/gad.1178604; Cutler NS, 2001, MOL BIOL CELL, V12, P4103, DOI 10.1091/mbc.12.12.4103; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; Ferrell JE, 2001, CHAOS, V11, P227, DOI 10.1063/1.1349894; Francois J, 2001, FEMS MICROBIOL REV, V25, P125, DOI 10.1111/j.1574-6976.2001.tb00574.x; Gagiano M, 2002, FEMS YEAST RES, V2, P433, DOI 10.1016/S1567-1356(02)00133-2; Gallego C, 1997, EMBO J, V16, P7196, DOI 10.1093/emboj/16.23.7196; Gancedo JM, 2001, FEMS MICROBIOL REV, V25, P107, DOI 10.1016/S0168-6445(00)00056-5; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; Gorner W, 2002, EMBO J, V21, P135, DOI 10.1093/emboj/21.1.135; Harashima T, 2005, MOL BIOL CELL, V16, P4557, DOI 10.1091/mbc.E05-05-0403; Harashima T, 2002, MOL CELL, V10, P163, DOI 10.1016/S1097-2765(02)00569-5; Harashima T, 2006, MOL CELL, V22, P819, DOI 10.1016/j.molcel.2006.05.011; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; HOJEONG KEH, 2003, COMMUN SOIL SCI PLAN, V34, P2193; Hounsa CG, 1998, MICROBIOL-UK, V144, P671, DOI 10.1099/00221287-144-3-671; HUBLER L, 1993, MOL CELL BIOL, V13, P6274, DOI 10.1128/MCB.13.10.6274; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; KOSHLAND DE, 1982, SCIENCE, V217, P220, DOI 10.1126/science.7089556; KRON SJ, 1994, MOL BIOL CELL, V5, P1003, DOI 10.1091/mbc.5.9.1003; Liu CB, 1998, BIOTECHNOL TECH, V12, P941, DOI 10.1023/A:1008881915907; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; Lo WS, 1996, J BACTERIOL, V178, P7144, DOI 10.1128/jb.178.24.7144-7151.1996; Lo WS, 1998, MOL BIOL CELL, V9, P161, DOI 10.1091/mbc.9.1.161; Loeb JDJ, 1999, GENETICS, V153, P1535; Lorenz MC, 2000, GENETICS, V154, P609; Lorenz MC, 1997, EMBO J, V16, P7008, DOI 10.1093/emboj/16.23.7008; Lorenz MC, 1998, EMBO J, V17, P1236, DOI 10.1093/emboj/17.5.1236; MARKWARDT DD, 1995, J BACTERIOL, V177, P6761, DOI 10.1128/jb.177.23.6761-6765.1995; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; O'Rourke SM, 2004, MOL BIOL CELL, V15, P532, DOI 10.1091/mbc.E03-07-0521; Oehlen LJWM, 1998, J BIOL CHEM, V273, P25089, DOI 10.1074/jbc.273.39.25089; Pan XW, 2000, MOL CELL BIOL, V20, P8364, DOI 10.1128/MCB.20.22.8364-8372.2000; Pan XW, 1999, MOL CELL BIOL, V19, P4874; Parrou JL, 1999, YEAST, V15, P191, DOI 10.1002/(SICI)1097-0061(199902)15:3<191::AID-YEA358>3.0.CO;2-O; Peeters T, 2006, P NATL ACAD SCI USA, V103, P13034, DOI 10.1073/pnas.0509644103; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; Rohde JR, 2003, CURR TOP MICROBIOL, V279, P53; Rua D, 2001, CURR OPIN MICROBIOL, V4, P720, DOI 10.1016/S1369-5274(01)00274-0; Rupp S, 1999, EMBO J, V18, P1257, DOI 10.1093/emboj/18.5.1257; Santhanam A, 2004, EUKARYOT CELL, V3, P1261, DOI 10.1128/EC.3.5.1261-1271.2004; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Sengupta N, 2007, BIOPHYS CHEM, V125, P59, DOI 10.1016/j.bpc.2006.06.012; Stanhill A, 1999, MOL CELL BIOL, V19, P7529; Van Nuland A, 2006, MOL MICROBIOL, V59, P1485, DOI 10.1111/j.1365-2958.2005.05043.x; Zurita-Martinez SA, 2005, EUKARYOT CELL, V4, P63, DOI 10.1128/EC.4.1.63-71.2005	59	49	49	4	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2008	3	2							e1663	10.1371/journal.pone.0001663	http://dx.doi.org/10.1371/journal.pone.0001663			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XS	18301741	Green Submitted, Green Published, gold			2022-12-25	WOS:000260586500008
J	Rowley, AH; Baker, SC; Shulman, ST; Garcia, FL; Fox, LM; Kos, IM; Crawford, SE; Russo, PA; Hammadeh, R; Takahashi, K; Orenstein, JM				Rowley, Anne H.; Baker, Susan C.; Shulman, Stanford T.; Garcia, Francesca L.; Fox, Linda M.; Kos, Ian M.; Crawford, Susan E.; Russo, Pierre A.; Hammadeh, Rashid; Takahashi, Kei; Orenstein, Jan M.			RNA-Containing Cytoplasmic Inclusion Bodies in Ciliated Bronchial Epithelium Months to Years after Acute Kawasaki Disease	PLOS ONE			English	Article								Background: Kawasaki Disease (KD) is the most common cause of acquired heart disease in children in developed nations. The KD etiologic agent is unknown but likely to be a ubiquitous microbe that usually causes asymptomatic childhood infection, resulting in KD only in genetically susceptible individuals. KD synthetic antibodies made from prevalent IgA gene sequences in KD arterial tissue detect intracytoplasmic inclusion bodies (ICI) resembling viral ICI in acute KD but not control infant ciliated bronchial epithelium. The prevalence of ICI in late-stage KD fatalities and in older individuals with non-KD illness should be low, unless persistent infection is common. Methods and Principal Findings: Lung tissue from late-stage KD fatalities and non-infant controls was examined by light microscopy for the presence of ICI. Nucleic acid stains and transmission electron microscopy (TEM) were performed on tissues that were strongly positive for ICI. ICI were present in ciliated bronchial epithelium in 6/7 (86%) late-stage KD fatalities and 7/27 (26%) controls ages 9-84 years (p=0.01). Nucleic acid stains revealed RNA but not DNA within the ICI. ICI were also identified in lung macrophages in some KD cases. TEM of bronchial epithelium and macrophages from KD cases revealed finely granular homogeneous ICI. Significance: These findings are consistent with a previously unidentified, ubiquitous RNA virus that forms ICI and can result in persistent infection in bronchial epithelium and macrophages as the etiologic agent of KD.	[Rowley, Anne H.; Shulman, Stanford T.; Garcia, Francesca L.; Kos, Ian M.] Northwestern Univ, Dept Pediat, Feinberg Sch Med, Childrens Mem Hosp,Ctr Kawasaki Dis, Chicago, IL 60611 USA; [Rowley, Anne H.] Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, Chicago, IL USA; [Crawford, Susan E.] Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL USA; [Baker, Susan C.] Loyola Univ, Stritch Sch Med, Dept Microbiol & Immunol, Maywood, IL USA; [Fox, Linda M.; Hammadeh, Rashid] Loyola Univ, Stritch Sch Med, Dept Pathol, Maywood, IL USA; [Russo, Pierre A.] Childrens Hosp Philadelphia, Dept Pathol, Philadelphia, PA USA; [Orenstein, Jan M.] George Washington Univ, Sch Med, Dept Pathol, Washington, DC USA; [Takahashi, Kei] Toho Univ, Sch Med, Dept Pathol, Tokyo, Japan	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Loyola University Chicago; Loyola University Chicago; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; George Washington University; Toho University	Rowley, AH (corresponding author), Northwestern Univ, Dept Pediat, Feinberg Sch Med, Childrens Mem Hosp,Ctr Kawasaki Dis, Chicago, IL 60611 USA.	a-rowley@northwestern.edu		Rowley, Anne/0000-0003-4695-6676	NIH [HL63771]; Kawasaki Disease Fund of Children's Memorial Hospital; Research Funding Committee of Loyola University Stritch School of Medicine [109703]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063771] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Kawasaki Disease Fund of Children's Memorial Hospital; Research Funding Committee of Loyola University Stritch School of Medicine; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by NIH HL63771 (to AHR), the Kawasaki Disease Fund of Children's Memorial Hospital, and the Research Funding Committee of Loyola University Stritch School of Medicine, LU#109703 (to SCB). Sponsors/funders did not have any role in the design and conduct of the study, data collection analysis, and interpretation, or in preparation, review or approval of the manuscript.	AMANO S, 1980, ACTA PATHOL JAPON, V30, P681; Carlos TS, 2005, J VIROL, V79, P14112, DOI 10.1128/JVI.79.22.14112-14121.2005; Chatziandreou N, 2002, VIROLOGY, V293, P234, DOI 10.1006/viro.2001.1302; Debiaggi M, 2006, J INFECT DIS, V194, P474, DOI 10.1086/505881; FEARNS R, 1994, J GEN VIROL, V75, P3525, DOI 10.1099/0022-1317-75-12-3525; Johnson RM, 2001, CLIN INFECT DIS, V32, P1628, DOI 10.1086/320523; Kaiser L, 2006, AM J RESP CRIT CARE, V174, P1392, DOI 10.1164/rccm.200604-489OC; MUCHMORE HG, 1981, NATURE, V289, P187, DOI 10.1038/289187a0; NARANG HK, 1982, INFECT IMMUN, V36, P310, DOI 10.1128/IAI.36.1.310-319.1982; Roweley AH, 2007, NELSON TXB PEDIAT, P1036; Rowley AH, 2000, J INFECT DIS, V182, P1183, DOI 10.1086/315832; Rowley AH, 2005, J IMMUNOL, V175, P8386, DOI 10.4049/jimmunol.175.12.8386; Rowley AH, 2005, J INFECT DIS, V192, P1757, DOI 10.1086/497171; Rowley AH, 2004, J INFECT DIS, V190, P856, DOI 10.1086/422648; Rowley AH, 1997, J IMMUNOL, V159, P5946; Rowley AH, 2001, J IMMUNOL, V166, P1334, DOI 10.4049/jimmunol.166.2.1334; Rowley AH, 2007, CURR OPIN PEDIATR, V19, P71, DOI 10.1097/MOP.0b013e328012720f; Stankovic K, 2007, J INFECTION, V55, P488, DOI 10.1016/j.jinf.2007.09.005	18	68	69	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1582	10.1371/journal.pone.0001582	http://dx.doi.org/10.1371/journal.pone.0001582			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270572	Green Submitted, Green Published, gold			2022-12-25	WOS:000260535900018
J	Knowles, TG; Kestin, SC; Haslam, SM; Brown, SN; Green, LE; Butterworth, A; Pope, SJ; Pfeiffer, D; Nicol, CJ				Knowles, Toby G.; Kestin, Steve C.; Haslam, Susan M.; Brown, Steven N.; Green, Laura E.; Butterworth, Andrew; Pope, Stuart J.; Pfeiffer, Dirk; Nicol, Christine J.			Leg Disorders in Broiler Chickens: Prevalence, Risk Factors and Prevention	PLOS ONE			English	Article								Broiler (meat) chickens have been subjected to intense genetic selection. In the past 50 years, broiler growth rates have increased by over 300% (from 25 g per day to 100 g per day). There is growing societal concern that many broiler chickens have impaired locomotion or are even unable to walk. Here we present the results of a comprehensive survey of commercial flocks which quantifies the risk factors for poor locomotion in broiler chickens. We assessed the walking ability of 51,000 birds, representing 4.8 million birds within 176 flocks. We also obtained information on approximately 150 different management factors associated with each flock. At a mean age of 40 days, over 27.6% of birds in our study showed poor locomotion and 3.3% were almost unable to walk. The high prevalence of poor locomotion occurred despite culling policies designed to remove severely lame birds from flocks. We show that the primary risk factors associated with impaired locomotion and poor leg health are those specifically associated with rate of growth. Factors significantly associated with high gait score included the age of the bird (older birds), visit (second visit to same flock), bird genotype, not feeding whole wheat, a shorter dark period during the day, higher stocking density at the time of assessment, no use of antibiotic, and the use of intact feed pellets. The welfare implications are profound. Worldwide approximately 2 x 10(10) broilers are reared within similar husbandry systems. We identify a range of management factors that could be altered to reduce leg health problems, but implementation of these changes would be likely to reduce growth rate and production. A debate on the sustainability of current practice in the production of this important food source is required.	[Knowles, Toby G.; Kestin, Steve C.; Haslam, Susan M.; Brown, Steven N.; Butterworth, Andrew; Pope, Stuart J.; Nicol, Christine J.] Univ Bristol, Sch Vet Sci, Bristol BS18 7DU, Avon, England; [Green, Laura E.] Univ Warwick, Biol Sci, Ecol & Epidemiol Grp, Coventry, W Midlands, England; [Pfeiffer, Dirk] Royal Veterinary Coll, Royal Coll St, London, England	University of Bristol; University of Warwick; University of London; University of London Royal Veterinary College	Knowles, TG (corresponding author), Univ Bristol, Sch Vet Sci, Bristol BS18 7DU, Avon, England.	Toby.Knowles@bristol.ac.uk	Green, Laura/G-8345-2011; Nicol, Christine J/B-4841-2011; Pfeiffer, Dirk U/C-5002-2009; Knowles, Toby G/A-2026-2008	Green, Laura/0000-0003-2957-8773; Nicol, Christine J/0000-0001-6734-2177; Pfeiffer, Dirk U/0000-0001-7000-0530; Knowles, Toby G/0000-0002-3845-0942; Butterworth, Andrew/0000-0002-5904-8397	UK Department of Environment, Food and Rural Affairs [AW0230]	UK Department of Environment, Food and Rural Affairs(Department for Environment, Food & Rural Affairs (DEFRA))	This study was carried out with funding from the UK Department of Environment, Food and Rural Affairs (Grant AW0230) with whom the design and execution were agreed. When reviewing the paper Defra have suggested modifications to the terminology used to describe broiler lameness within the paper which the authors have accepted.	Bessei W, 2006, WORLD POULTRY SCI J, V62, P455, DOI 10.1079/WPS2005108; Bradshaw RH, 2002, AVIAN POULT BIOL REV, V13, P45, DOI 10.3184/147020602783698421; Brickett KE, 2007, POULTRY SCI, V86, P2117, DOI 10.1093/ps/86.10.2117; Butterworth A, 2002, ANIM WELFARE, V11, P89; CLASSEN HL, 1989, POULTRY SCI, V68, P873, DOI 10.3382/ps.0680873; Danbury TC, 2000, VET REC, V146, P307, DOI 10.1136/vr.146.11.307; Dawkins MS, 2004, NATURE, V427, P342, DOI 10.1038/nature02226; *FARM AN WELF COUN, 1992, 0910 FAWC; Hall C, 2007, ANIM WELFARE, V16, P499; Kestin SC, 1999, POULTRY SCI, V78, P1085, DOI 10.1093/ps/78.8.1085; KESTIN SC, 1992, VET REC, V131, P190, DOI 10.1136/vr.131.9.190; Kestin SC, 2001, VET REC, V148, P195, DOI 10.1136/vr.148.7.195; Laster CP, 1999, POULTRY SCI, V78, P197, DOI 10.1093/ps/78.2.197; Mc Geown D, 1999, VET REC, V144, P668, DOI 10.1136/vr.144.24.668; Moller AP, 1999, APPL ANIM BEHAV SCI, V62, P57, DOI 10.1016/S0168-1591(98)00213-5; Reiter K, 2006, ARCH GEFLUGELKD, V70, P208; Reiter K, 2001, ARCH GEFLUGELKD, V65, P137; Sanotra GS, 2003, ANIM WELFARE, V12, P677; Sanotra GS, 2001, WORLD POULTRY SCI J, V57, P55, DOI 10.1079/WPS20010006; Scientific Committee on Animal Health and Animal Welfare, 2000, WELF CHICK KEPT MEAT; Su G, 1999, POULTRY SCI, V78, P949, DOI 10.1093/ps/78.7.949; Weeks CA, 2002, VET REC, V151, P762; Weeks CA, 2000, APPL ANIM BEHAV SCI, V67, P111, DOI 10.1016/S0168-1591(99)00102-1; 2007, IND LIVESTOCK PRODUC; [No title captured]; 2005, COMPASSION WORLD FAR	26	248	252	4	107	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2008	3	2							e1545	10.1371/journal.pone.0001545	http://dx.doi.org/10.1371/journal.pone.0001545			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367EQ	18253493	Green Published, gold, Green Submitted			2022-12-25	WOS:000260535700017
J	Lees, F; Baillie, M; Gettinby, G; Revie, CW				Lees, Fiona; Baillie, Mark; Gettinby, George; Revie, Crawford W.			The Efficacy of Emamectin Benzoate against Infestations of Lepeophtheirus salmonis on Farmed Atlantic Salmon (Salmo salar L) in Scotland, 2002-2006	PLOS ONE			English	Article							CALIGUS-ELONGATUS NORDMANN; SEA LICE INFESTATIONS; ORAL TREATMENT; PARASITIC COPEPODS; BRITISH-COLUMBIA; FIELD TRIALS; KROYER; MANAGEMENT; INFECTION; ABUNDANCE	Background: Infestations of the parasitic copepod Lepeophtheirus salmonis, commonly referred to as sea lice, represent a major challenge to commercial salmon aquaculture. Dependence on a limited number of theraputants to control such infestations has led to concerns of reduced sensitivity in some sea lice populations. This study investigates trends in the efficacy of the in-feed treatment emamectin benzoate in Scotland, the active ingredient most widely used across all salmon producing regions. Methodology/Principal Findings: Study data were drawn from over 50 commercial Atlantic salmon farms on the west coast of Scotland between 2002 and 2006. An epi-informatics approach was adopted whereby available farm records, descriptive epidemiological summaries and statistical linear modelling methods were used to identify factors that significantly affect sea lice abundance following treatment with emamectin benzoate (SLICE (R), Schering Plough Animal Health). The results show that although sea lice infestations are reduced following the application of emamectin benzoate, not all treatments are effective. Specifically there is evidence of variation across geographical regions and a reduction in efficacy over time. Conclusions/Significance: Reduced sensitivity and potential resistance to currently available medicines are constant threats to maintaining control of sea lice populations on Atlantic salmon farms. There is a need for on-going monitoring of emamectin benzoate treatment efficacy together with reasons for any apparent reduction in performance. In addition, strategic rotation of medicines should be encouraged and empirical evidence for the benefit of such strategies more fully evaluated.	[Lees, Fiona; Baillie, Mark; Revie, Crawford W.] Univ Strathclyde, Dept Comp & Inform Sci, Glasgow, Lanark, Scotland; [Lees, Fiona; Gettinby, George] Univ Strathclyde, Dept Stat & Modelling Sci, Glasgow, Lanark, Scotland	University of Strathclyde; University of Strathclyde	Lees, F (corresponding author), Univ Strathclyde, Dept Comp & Inform Sci, Glasgow, Lanark, Scotland.	crawford.revie@cis.strath.ac.uk	Revie, Crawford/B-5002-2011	Revie, Crawford/0000-0002-5018-0340; Baillie, Mark/0000-0002-5618-0667				Armstrong R, 2000, CAN VET J, V41, P607; Bjorn PA, 2002, ICES J MAR SCI, V59, P131, DOI 10.1006/jmsc.2001.1143; Bron J. E., 1993, Pathogens of wild and farmed fish: sea lice., P263; BRON JE, 1993, J FISH DIS, V16, P487, DOI 10.1111/j.1365-2761.1993.tb00882.x; Butler JRA, 2002, PEST MANAG SCI, V58, P595, DOI 10.1002/ps.490; *COGP WORK GROUP, 2005, COD GOOD PRACT SCOTT; Denholm I, 2002, PEST MANAG SCI, V58, P528, DOI 10.1002/ps.482; Grant A. N., 1993, Pathogens of wild and farmed fish: sea lice., P255; Gustafson L, 2006, J FISH DIS, V29, P621, DOI 10.1111/j.1365-2761.2006.00761.x; Heuch PA, 2005, AQUACULTURE, V246, P79, DOI 10.1016/j.aquaculture.2004.12.027; *INT COUNC EXPL SE, 2007, 2007ACFM13 WGNAS ICE; Johnson SC, 2004, ZOOL STUD, V43, P229; Kabata Z., 1979, PARASITIC COPEPODA B; LEES F, 2008, J FISH DIS IN PRESS; McKibben MA, 2004, AQUAC RES, V35, P742, DOI 10.1111/j.1365-2109.2004.01096.x; Morton A, 2004, CAN J FISH AQUAT SCI, V61, P147, DOI 10.1139/F04-016; Pike AW, 2000, ADV PARASIT, V44, P233; Rae GH, 2002, PEST MANAG SCI, V58, P515, DOI 10.1002/ps.491; Ramstad A, 2002, DIS AQUAT ORGAN, V50, P29, DOI 10.3354/dao050029; Revie CW, 2007, PREV VET MED, V81, P135, DOI 10.1016/j.prevetmed.2007.04.004; Revie CW, 2003, DIS AQUAT ORGAN, V57, P85, DOI 10.3354/dao057085; Revie CW, 2002, VET REC, V151, P753; Revie CW, 2002, PEST MANAG SCI, V58, P576, DOI 10.1002/ps.476; Revie CW, 2002, J FISH DIS, V25, P391, DOI 10.1046/j.1365-2761.2002.00388.x; Saksida S, 2007, AQUAC RES, V38, P219, DOI 10.1111/j.1365-2109.2007.01651.x; SEARCH Consortium, 2006, SEA LIC RES CHEM HDB; Stone J, 2000, DIS AQUAT ORGAN, V41, P141, DOI 10.3354/dao041141; Stone J, 2000, AQUACULTURE, V186, P205, DOI 10.1016/S0044-8486(99)00374-9; Stone J, 1999, J FISH DIS, V22, P261, DOI 10.1046/j.1365-2761.1999.00176.x; Stone J, 2000, J FISH DIS, V23, P185, DOI 10.1046/j.1365-2761.2000.00233.x; Treasurer J., 1994, Fish Farmer, V17, P46; Treasurer JW, 2000, AQUACULTURE, V187, P247, DOI 10.1016/S0044-8486(00)00309-4; Treasurer JW, 2002, BULL EUR ASSN FISH P, V22, P375; Westcott JD, 2004, AQUAC RES, V35, P784, DOI 10.1111/j.1365-2109.2004.01101.x; WOOTTEN R, 1982, P ROY SOC EDINB B, V81, P185, DOI 10.1017/S0269727000003389	35	139	140	0	54	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2008	3	2							e1549	10.1371/journal.pone.0001549	http://dx.doi.org/10.1371/journal.pone.0001549			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367EQ	18253496	Green Published, Green Submitted, Green Accepted, gold			2022-12-25	WOS:000260535700020
J	Kim, RS; Seitz, AR; Shams, L				Kim, Robyn S.; Seitz, Aaron R.; Shams, Ladan			Benefits of Stimulus Congruency for Multisensory Facilitation of Visual Learning	PLOS ONE			English	Article							AUDITORY-CORTEX; MOTION; DISCRIMINATION; SOUND; ORIENTATION; PLASTICITY; PERCEPTION; MODULATION; ACTIVATION; TACTILE	Studies of perceptual learning have largely focused on unisensory stimuli. However, multisensory interactions are ubiquitous in perception, even at early processing stages, and thus can potentially play a role in learning. Here, we examine the effect of auditory-visual congruency on visual learning. Methodology/Principle Findings. Subjects were trained over five days on a visual motion coherence detection task with either congruent audiovisual, or incongruent audiovisual stimuli. Comparing performance on visual-only trials, we find that training with congruent audiovisual stimuli produces significantly better learning than training with incongruent audiovisual stimuli or with only visual stimuli. Conclusions/Significance. This advantage from stimulus congruency during training suggests that the benefits of multisensory training may result from audiovisual interactions at a perceptual rather than cognitive level.	[Kim, Robyn S.; Shams, Ladan] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA; [Seitz, Aaron R.] Boston Univ, Dept Psychol, Boston, MA USA	University of California System; University of California Los Angeles; Boston University	Shams, L (corresponding author), Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA.	ladan@psych.ucla.edu			NSF [predoctoral fellowship]; UCLA [Academic Senate, Career Development]; Naval Research Laboratory	NSF(National Science Foundation (NSF)); UCLA(University of California System); Naval Research Laboratory(United States Department of Defense)	RK was supported by an NSF predoctoral fellowship. This project was partially supported by a UCLA Academic Senate grant and Career Development grant and Naval Research Laboratory grant to LS. The funders had no role in the design and conduct of the study, nor in the collection, analysis, and interpretation of the data, nor in the preparation, review, or approval of the manuscript.	Amedi A, 2001, NAT NEUROSCI, V4, P324, DOI 10.1038/85201; Bahrick LE, 2002, DEV PSYCHOBIOL, V41, P352, DOI 10.1002/dev.10049; BALL K, 1981, J EXP PSYCHOL HUMAN, V7, P780, DOI 10.1037/0096-1523.7.4.780; BRITTEN KH, 1992, J NEUROSCI, V12, P4745; Calvert GA, 1997, SCIENCE, V276, P593, DOI 10.1126/science.276.5312.593; Carlsen R, 1999, DEV PSYCHOBIOL, V35, P215, DOI 10.1002/(SICI)1098-2302(199911)35:3<215::AID-DEV6>3.3.CO;2-F; Dinse HR, 2003, SCIENCE, V301, P91, DOI 10.1126/science.1085423; Falchier A, 2002, J NEUROSCI, V22, P5749; Foxe JJ, 2000, COGNITIVE BRAIN RES, V10, P77, DOI 10.1016/S0926-6410(00)00024-0; Ghazanfar AA, 2006, TRENDS COGN SCI, V10, P278, DOI 10.1016/j.tics.2006.04.008; Heeger DJ, 1999, J NEUROSCI, V19, P7162, DOI 10.1523/JNEUROSCI.19-16-07162.1999; LEVINSON E, 1975, NATURE, V254, P692, DOI 10.1038/254692a0; Li W, 2004, NAT NEUROSCI, V7, P651, DOI 10.1038/nn1255; LOFTUS GR, 1994, PSYCHON B REV, V1, P476, DOI 10.3758/BF03210951; MOORE C, 2006, INT MULT RES FOR DUB, P18; QIAN N, 1994, J NEUROSCI, V14, P7357; RECANZONE GH, 1993, J NEUROSCI, V13, P87; Rockland KS, 2003, INT J PSYCHOPHYSIOL, V50, P19, DOI 10.1016/S0167-8760(03)00121-1; Schoups A, 2001, NATURE, V412, P549, DOI 10.1038/35087601; Seitz AR, 2007, CURR OPIN NEUROBIOL, V17, P148, DOI 10.1016/j.conb.2007.02.004; Seitz AR, 2006, CURR BIOL, V16, P1422, DOI 10.1016/j.cub.2006.05.048; Seitzt AR, 2005, P NATL ACAD SCI USA, V102, P14895, DOI 10.1073/pnas.0505765102; Shams L, 2005, NEUROSCI LETT, V378, P76, DOI 10.1016/j.neulet.2004.12.035; Shimojo S, 2001, CURR OPIN NEUROBIOL, V11, P505, DOI 10.1016/S0959-4388(00)00241-5; Watkins S, 2006, NEUROIMAGE, V31, P1247, DOI 10.1016/j.neuroimage.2006.01.016; Zangaladze A, 1999, NATURE, V401, P587, DOI 10.1038/44139	26	79	80	1	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1532	10.1371/journal.pone.0001532	http://dx.doi.org/10.1371/journal.pone.0001532			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	366SR	18231612	Green Published, gold, Green Submitted			2022-12-25	WOS:000260504200039
J	Sayer, JM; Liu, FL; Ishima, R; Weber, IT; Louis, JM				Sayer, Jane M.; Liu, Fengling; Ishima, Rieko; Weber, Irene T.; Louis, John M.			Effect of the active site D25N mutation on the structure, stability, and ligand binding of the mature HIV-1 protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; RESOLUTION CRYSTAL-STRUCTURES; DRUG-RESISTANCE; RETROVIRAL PROTEASES; SUBSTRATE COMPLEX; VIRAL INFECTIVITY; DIMER STABILITY; INHIBITION; MUTANTS; MONOMER	All aspartic proteases, including retroviral proteases, share the triplet DTG critical for the active site geometry and catalytic function. These residues interact closely in the active, dimeric structure of HIV-1 protease (PR). We have systematically assessed the effect of the D25N mutation on the structure and stability of the mature PR monomer and dimer. The D25N mutation (PRD25N) increases the equilibrium dimer dissociation constant by a factor > 100-fold (1.3 +/- 0.09 mu M) relative to PR. In the absence of inhibitor, NMR studies reveal clear structural differences between PR and PRD25N in the relatively mobile P1 loop (residues 79-83) and flap regions, and differential scanning calorimetric analyses show that the mutation lowers the stabilities of both the monomer and dimer folds by 5 and 7.3 C, respectively. Only minimal differences are observed in high resolution crystal structures of PRD25N complexed to darunavir (DRV), a potent clinical inhibitor, or a non-hydrolyzable substrate analogue, Ac-Thr-Ile-Nle-r-Nle-Gln-Arg-NH2 (RPB), as compared with PR center dot DRV and PR center dot RPB complexes. Although complexation with RPB stabilizes both dimers, the effect on their T-m is smaller for PRD25N (6.2 degrees C) than for PR (8.7 degrees C). The Tm of PRD25N center dot DRV increases by only 3 C relative to free PRD25N, as compared with a 22 degrees C increase for PR center dot DRV, and the mutation increases the ligand dissociation constant of PRD25N . DRV by a factor of similar to 10(6) relative to PR center dot DRV. These results suggest that interactions mediated by the catalytic Asp residues make a major contribution to the tight binding of DRV to PR.	[Sayer, Jane M.; Louis, John M.] NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA; [Liu, Fengling; Weber, Irene T.] Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA; [Ishima, Rieko] Univ Pittsburgh, Sch Med, Dept Biol Struct, Pittsburgh, PA 15260 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University System of Georgia; Georgia State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Louis, JM (corresponding author), NIDDK, Chem Phys Lab, NIH, Bldg 5,Rm B2-29, Bethesda, MD 20892 USA.	johnl@intra.niddk.nih.gov		Louis, John M/0000-0002-0052-1899	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062920] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 DK999999] Funding Source: Medline; NIGMS NIH HHS [R01 GM062920-10, R01 GM062920-09, GM62920, R01 GM062920] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABE LM, 1995, P NATL ACAD SCI USA, V92, P10069, DOI 10.1073/pnas.92.22.10069; Beissinger M, 1996, EUR J BIOCHEM, V237, P383, DOI 10.1111/j.1432-1033.1996.0383k.x; BRANDTS JF, 1990, BIOCHEMISTRY-US, V29, P6927, DOI 10.1021/bi00481a024; Erickson JW, 1996, ANNU REV PHARMACOL, V36, P545, DOI 10.1146/annurev.pa.36.040196.002553; Freedberg DI, 2002, PROTEIN SCI, V11, P221, DOI 10.1110/ps.33202; Ishima R, 2003, J BIOL CHEM, V278, P43311, DOI 10.1074/jbc.M307549200; Ishima R, 2001, J BIOL CHEM, V276, P49110, DOI 10.1074/jbc.M108136200; Ishima R, 2001, J MOL BIOL, V305, P515, DOI 10.1006/jmbi.2000.4321; Ishima R, 2007, J BIOL CHEM, V282, P17190, DOI 10.1074/jbc.M701304200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAPLAN AH, 1994, J VIROL, V68, P6782, DOI 10.1128/JVI.68.10.6782-6786.1994; KAPLAN AH, 1993, J VIROL, V67, P4050, DOI 10.1128/JVI.67.7.4050-4055.1993; KARACOSTAS V, 1993, VIROLOGY, V193, P661, DOI 10.1006/viro.1993.1174; Katoh E, 2003, PROTEIN SCI, V12, P1376, DOI 10.1110/ps.0300703; King NM, 2004, J VIROL, V78, P12012, DOI 10.1128/JVI.78.21.12012-12021.2004; Klei HE, 2007, J VIROL, V81, P9525, DOI 10.1128/JVI.02503-05; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; Kovalevsky AY, 2006, J MOL BIOL, V363, P161, DOI 10.1016/j.jmb.2006.08.007; KRAUSSLICH HG, 1991, P NATL ACAD SCI USA, V88, P3213, DOI 10.1073/pnas.88.8.3213; Liu FL, 2006, J MOL BIOL, V358, P1191, DOI 10.1016/j.jmb.2006.02.076; Liu FL, 2005, J MOL BIOL, V354, P789, DOI 10.1016/j.jmb.2005.09.095; Louis J M, 2000, Adv Pharmacol, V49, P111; Louis JM, 1999, NAT STRUCT BIOL, V6, P868; Louis JM, 2007, ADV PHARMACOL, V55, P261, DOI 10.1016/S1054-3589(07)55008-8; Mahalingam B, 2004, EUR J BIOCHEM, V271, P1516, DOI 10.1111/j.1432-1033.2004.04060.x; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0; Prabu-Jeyabalan M, 2000, J MOL BIOL, V301, P1207, DOI 10.1006/jmbi.2000.4018; RODRIGUEZ EJ, 1993, BIOCHEMISTRY-US, V32, P12380, DOI 10.1021/bi00097a015; Rodriguez-Barrios F, 2004, CURR TOP MED CHEM, V4, P991, DOI 10.2174/1568026043388529; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SHRAKE A, 1992, BIOPOLYMERS, V32, P925, DOI 10.1002/bip.360320804; Sluis-Cremer N, 2002, EUR J BIOCHEM, V269, P5103, DOI 10.1046/j.1432-1033.2002.03216.x; Stoll V, 2002, BIOORGAN MED CHEM, V10, P2803, DOI 10.1016/S0968-0896(02)00051-2; Strisovsky K, 2000, PROTEIN SCI, V9, P1631, DOI 10.1110/ps.9.9.1631; Temesgen Z, 2006, EXPERT OPIN PHARMACO, V7, P1541, DOI 10.1517/14656566.7.12.1541; Tie YF, 2005, FEBS J, V272, P5265, DOI 10.1111/j.1742-4658.2005.04923.x; Tie YF, 2004, J MOL BIOL, V338, P341, DOI 10.1016/j.jmb.2004.02.052; WEBER IT, 1990, J BIOL CHEM, V265, P10492; WEBER IT, 2007, FRONTIERS DRUG DESIG, V3, P45; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; Wondrak EM, 1996, BIOCHEMISTRY-US, V35, P12957, DOI 10.1021/bi960984y; Xie D, 1999, PROTEIN SCI, V8, P1702, DOI 10.1110/ps.8.8.1702	46	66	67	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2008	283	19					13459	13470		10.1074/jbc.M708506200	http://dx.doi.org/10.1074/jbc.M708506200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295UQ	18281688	Green Published, hybrid			2022-12-25	WOS:000255499800085
J	Hoffmann, E; Ashouri, J; Wolter, S; Doerrie, A; Dittrich-Breiholz, O; Schneider, H; Wagner, EF; Troppmair, J; Mackman, N; Kracht, M				Hoffmann, Elke; Ashouri, Judith; Wolter, Sabine; Doerrie, Anneke; Dittrich-Breiholz, Oliver; Schneider, Heike; Wagner, Erwin F.; Troppmair, Jakob; Mackman, Nigel; Kracht, Michael			Transcriptional regulation of EGR-1 by the interleukin-1-JNK-MKK7-c-Jun pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; SIGNAL-TRANSDUCTION PATHWAYS; NECROSIS-FACTOR-ALPHA; GROWTH-RESPONSE FACTOR-1; HUMAN MONOCYTIC CELLS; C-JUN; GENE-EXPRESSION; INFLAMMATORY CYTOKINES; 3T3 FIBROBLASTS	The proinflammatory cytokine interleukin (IL)-1 activates several hundred genes within the same cell. This occurs in part by activation of the MKK7-JNK-c-Jun signaling pathway whose precise role in the regulation of individual inflammatory genes is still incompletely understood. To identify the genes that are under specific control of activated JNK, we used a JNK-MKK7 fusion protein. Genome-wide microarray analysis revealed EGR-1 as the transcript that was most strongly induced by JNK-MKK7. IL-1-stimulated EGR-1 mRNA and protein expression were impaired in cells lacking JNK or c-Jun. Transcriptional activation of the EGR-1 promoter by JNK-MKK7 or by IL-1 required a single upstream AP-1 site and three distal serum-response elements (SRE). Reconstitution experiments in c-Jun-deficient cells revealed that c-Jun is required for EGR-1 transcription through both the AP-1 site and the distal SREs. By chromatin immunoprecipitation analysis, we found IL-1-inducible recruitment of c-Jun to the AP-1 site and to the region containing the three distal SREs. These experiments suggest that c-Jun plays a dual role in EGR-1 transcription. It directly binds to the AP-1 element, and at the same time it is essential for promoter activation through the three distal SREs by an indirect unknown mechanism. As predicted by TRANSFAC analysis and verified by ChIP experiments, IL-1-induced EGR-1 protein binds to the promoter regions of inflammatory mediators such as IL-6, IL-8, and CCL2. Furthermore, short interfering RNA-mediated suppression of EGR-1 partially suppresses IL-1-inducible transcription of IL-8, IL-6, and CCL2. In summary, we provide novel evidence for a complex c-Jun-mediated mechanism that is essential for inducible EGR-1 expression. We identify this pathway as a previously unrecognized part of a multistep gene regulatory network that controls cytokine and chemokine expression via the IL-1-MKK7-JNK- c-Jun-EGR-1 pathway.	[Kracht, Michael] Univ Giessen, Rudolf Buchheim Inst Pharmakol, D-35392 Giessen, Germany; [Hoffmann, Elke; Ashouri, Judith; Wolter, Sabine; Doerrie, Anneke; Dittrich-Breiholz, Oliver; Schneider, Heike; Kracht, Michael] Hannover Med Sch, Inst Pharmacol, D-30625 Hannover, Germany; [Wagner, Erwin F.] Inst Mol Pathol, A-1030 Vienna, Austria; [Troppmair, Jakob] Innsbruck Med Univ, Dept Gen & Transplant Surg, Daniel Swarovski Res Lab, A-6020 Innsbruck, Austria; [Mackman, Nigel] Scripps Res Inst, La Jolla, CA 92037 USA	Justus Liebig University Giessen; Hannover Medical School; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Medical University of Innsbruck; Scripps Research Institute	Kracht, M (corresponding author), Univ Giessen, Rudolf Buchheim Inst Pharmakol, Frankfurter Str 107, D-35392 Giessen, Germany.	Michael.Kracht@pharma.med.uni-giessen.de		Hoffmann-Lucke, Elke/0000-0002-2437-0140; Ashouri, Judith/0000-0001-8405-7503; Troppmair, Jakob/0000-0002-0611-3837; Kracht, Michael/0000-0002-8501-043X; Wagner, Erwin F/0000-0001-7872-0196	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048872] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL048872, R01 HL048872-08] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aicher WK, 1999, RHEUMATOL INT, V18, P207, DOI 10.1007/s002960050086; Al-Sarraj A, 2005, J CELL BIOCHEM, V94, P153, DOI 10.1002/jcb.20305; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Boekhoudt GH, 2003, J IMMUNOL, V170, P4139, DOI 10.4049/jimmunol.170.8.4139; Decker EL, 1998, J BIOL CHEM, V273, P26923, DOI 10.1074/jbc.273.41.26923; Fitzgerald KA, 1999, J IMMUNOL, V162, P4920; Florin L, 2004, ONCOGENE, V23, P7005, DOI 10.1038/sj.onc.1207938; Gineitis D, 2001, J BIOL CHEM, V276, P24531, DOI 10.1074/jbc.M102678200; Giri RK, 2003, J IMMUNOL, V170, P5281, DOI 10.4049/jimmunol.170.10.5281; Granet C, 2004, CYTOKINE, V26, P169, DOI 10.1016/j.cyto.2004.03.002; Guha M, 2001, BLOOD, V98, P1429, DOI 10.1182/blood.V98.5.1429; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han SY, 2002, J BIOL CHEM, V277, P47167, DOI 10.1074/jbc.M204270200; Hoffmann E, 2005, J BIOL CHEM, V280, P9706, DOI 10.1074/jbc.M407071200; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; Janknecht R, 1997, J BIOL CHEM, V272, P4219, DOI 10.1074/jbc.272.7.4219; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1998, J MOL MED-JMM, V76, P613, DOI 10.1007/s001090050258; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Kracht M, 2002, CYTOKINE, V20, P91, DOI 10.1006/cyto.2002.0895; Krause A, 1998, J BIOL CHEM, V273, P23681, DOI 10.1074/jbc.273.37.23681; Krones-Herzig A, 2005, CANCER RES, V65, P5133, DOI 10.1158/0008-5472.CAN-04-3742; Kumar SN, 2000, MOL IMMUNOL, V37, P623, DOI 10.1016/S0161-5890(00)00097-3; Maltzman JS, 1996, J EXP MED, V183, P1747, DOI 10.1084/jem.183.4.1747; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Okada M, 2001, FASEB J, V15, P2757, DOI 10.1096/fj.01-0490fje; Pawlinski R, 2003, BLOOD, V101, P3940, DOI 10.1182/blood-2002-07-2303; Rennefahrt U, 2004, CANCER LETT, V215, P113, DOI 10.1016/j.canlet.2004.05.015; Rennefahrt UEE, 2002, J BIOL CHEM, V277, P29510, DOI 10.1074/jbc.M203010200; Rolli-Derkinderen M, 2003, J BIOL CHEM, V278, P18859, DOI 10.1074/jbc.M211696200; Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shin SY, 2006, EXP MOL MED, V38, P677, DOI 10.1038/emm.2006.80; Silverman ES, 2001, AM J RESP CRIT CARE, V163, P778, DOI 10.1164/ajrccm.163.3.2003123; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; Thiefes A, 2005, J BIOL CHEM, V280, P27728, DOI 10.1074/jbc.M411657200; Thiefes A, 2006, EMBO REP, V7, P838, DOI 10.1038/sj.embor.7400754; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wingender E, 1996, NUCLEIC ACIDS RES, V24, P238, DOI 10.1093/nar/24.1.238; Wolter S, 2002, J BIOL CHEM, V277, P3576, DOI 10.1074/jbc.M105800200; WORLEY PF, 1991, P NATL ACAD SCI USA, V88, P5106, DOI 10.1073/pnas.88.12.5106; Yan SF, 2000, NAT MED, V6, P1355, DOI 10.1038/82168; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	60	63	66	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2008	283	18					12120	12128		10.1074/jbc.M800583200	http://dx.doi.org/10.1074/jbc.M800583200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	293MS	18281687	hybrid			2022-12-25	WOS:000255340000028
J	Choi, SH; Czifra, G; Kedei, N; Lewin, NE; Lazar, J; Pu, YM; Marquez, VE; Blumberg, PM				Choi, Sung Hee; Czifra, Gabriella; Kedei, Noemi; Lewin, Nancy E.; Lazar, Jozsef; Pu, Yongmei; Marquez, Victor E.; Blumberg, Peter M.			Characterization of the interaction of phorbol esters with the C1 domain of MRCK (myotonic dystrophy kinase-related Cdc42 binding kinase) alpha/beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; DIACYLGLYCEROL KINASES; PKC-ALPHA; ACTIVATION; RECEPTORS; MECHANISM; EFFECTORS; CALCIUM; SIGNALS; DELTA	C1 domains mediate the recognition and subsequent signaling response to diacylglycerol and phorbol esters by protein kinase C (PKC) and by several other families of signal-transducing proteins such as the chimerins or RasGRP. MRCK(myotonic dystrophy kinase-related Cdc42 binding kinase), a member of the dystrophia myotonica protein kinase family that functions downstream of Cdc42, contains a C1 domain with substantial homology to that of the diacylglycerol/phorbol ester-responsive C1 domains and has been reported to bind phorbol ester. We have characterized here the interaction of the C1 domains of the two MRCK isoforms alpha and beta with phorbol ester. The MRCK C1 domains bind [20-H-3] phorbol 12,13-dibutyrate with K-d values of 10 and 17 nM, respectively, reflecting 60-90-fold weaker affinity compared with the protein kinase C delta C1b domain. In contrast to binding by the C1b domain of PKC delta, the binding by the C1 domains of MRCK alpha and beta was fully dependent on the presence of phosphatidylserine. Comparison of ligand binding selectivity showed resemblance to that by the C1b domain of PKC alpha and marked contrast to that of the C1b domain of PKC delta. In intact cells, as in the binding assays, the MRCK C1 domains required 50-100-fold higher concentrations of phorbol ester for induction of membrane translocation. We conclude that additional structural elements within the MRCK structure are necessary if the C1 domains of MRCK are to respond to phorbol ester at concentrations comparable with those that modulate PKC.	[Choi, Sung Hee; Czifra, Gabriella; Kedei, Noemi; Lewin, Nancy E.; Lazar, Jozsef; Pu, Yongmei; Blumberg, Peter M.] NCI, Lab Canc Biol & genet, Natl Inst Hlth, Bethesda, MD 20892 USA; [Marquez, Victor E.] NCI, Med Chem Lab, Ctr Canc Res, Natl Inst Hlth, Frederick, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Blumberg, PM (corresponding author), NCI, Lab Canc Biol & genet, Natl Inst Hlth, Bldg 37 Rm 4048B 37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.	blumberg@dc37a.nci.nih.gov	Marquez, Victor/AAP-3549-2021		Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC005270, Z01BC010942, ZIABC005270, ZIABC010942] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARECES LB, 1994, J BIOL CHEM, V269, P19553; Brose N, 2002, J CELL SCI, V115, P4399, DOI 10.1242/jcs.00122; Canagarajah B, 2004, CELL, V119, P407, DOI 10.1016/j.cell.2004.10.012; Colon-Gonzalez F, 2006, BBA-MOL CELL BIOL L, V1761, P827, DOI 10.1016/j.bbalip.2006.05.001; Corbalan-Garcia S, 2006, BBA-MOL CELL BIOL L, V1761, P633, DOI 10.1016/j.bbalip.2006.04.015; DRIEDGER PE, 1977, CANCER RES, V37, P3257; Garcia P, 2006, FASEB J, V20, P1142, DOI 10.1096/fj.05-5262com; Garcia-Bermejo ML, 2002, J BIOL CHEM, V277, P645, DOI 10.1074/jbc.M107639200; Hurley JH, 1997, PROTEIN SCI, V6, P477; Irie K, 2004, BIOORGAN MED CHEM, V12, P4575, DOI 10.1016/j.bmc.2004.07.008; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P10777, DOI 10.1074/jbc.270.18.10777; KONIG B, 1985, J CELL BIOCHEM, V29, P37, DOI 10.1002/jcb.240290105; Lambert QT, 2006, METHOD ENZYMOL, V407, P82, DOI 10.1016/S0076-6879(05)07008-4; Leung T, 1998, MOL CELL BIOL, V18, P130, DOI 10.1128/MCB.18.1.130; Lewin Nancy E, 2003, Methods Mol Biol, V233, P129; Luo B, 2004, CELL SIGNAL, V16, P983, DOI 10.1016/j.cellsig.2004.03.016; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Oliva JL, 2005, GROWTH FACTORS, V23, P245, DOI 10.1080/08977190500366043; Pu YM, 2005, J BIOL CHEM, V280, P27329, DOI 10.1074/jbc.M414132200; Pu YM, 2006, J BIOL CHEM, V281, P33773, DOI 10.1074/jbc.M606560200; Rozengurt E, 2005, J BIOL CHEM, V280, P13205, DOI 10.1074/jbc.R500002200; Silinsky EM, 2003, BRIT J PHARMACOL, V138, P1191, DOI 10.1038/sj.bjp.0705213; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; Tan I, 2001, MOL CELL BIOL, V21, P2767, DOI 10.1128/MCB.21.8.2767-2778.2001; Topham MK, 2006, J CELL BIOCHEM, V97, P474, DOI 10.1002/jcb.20704; Wakelam MJO, 1998, BBA-MOL CELL BIOL L, V1436, P117, DOI 10.1016/S0005-2760(98)00123-4; Wang H, 2006, BIOCHEM SOC T, V34, P855, DOI 10.1042/BST0340855; Wang QMJ, 2006, TRENDS PHARMACOL SCI, V27, P317, DOI 10.1016/j.tips.2006.04.003; Yang CF, 2003, TRENDS PHARMACOL SCI, V24, P602, DOI 10.1016/j.tips.2003.09.003; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	31	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10543	10549		10.1074/jbc.M707463200	http://dx.doi.org/10.1074/jbc.M707463200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18263588	Green Published, hybrid			2022-12-25	WOS:000254894700036
J	Gara, SK; Grumati, P; Urciuolo, A; Bonaldo, P; Kobbe, B; Koch, M; Paulsson, M; Wagener, R				Gara, Sudheer Kumar; Grumati, Paolo; Urciuolo, Anna; Bonaldo, Paolo; Kobbe, Birgit; Koch, Manuel; Paulsson, Mats; Wagener, Raimund			Three novel collagen VI chains with high homology to the alpha 3 chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL MUSCULAR-DYSTROPHY; AMINO-ACID-SEQUENCE; ALPHA-3(VI) CHAIN; SUSCEPTIBILITY LOCI; BETHLEM MYOPATHY; A-DOMAIN; MITOCHONDRIAL DYSFUNCTION; MICROFIBRIL FORMATION; VONWILLEBRAND-FACTOR; SWEDISH POPULATION	Here we describe three novel collagen VI chains, alpha 4, alpha 5, and alpha 6. The corresponding genes are arranged in tandem on mouse chromosome 9. The new chains structurally resemble the collagen VI alpha 3 chain. Each chain consists of sevenvon Willebrand factor A domains followed by a collagenous domain, two C-terminal von Willebrand factor A domains, and a unique domain. In addition, the collagen VI alpha 4 chain carries a Kunitz domain at the C terminus, whereas the collagen VI alpha 5 chain contains an additional von Willebrand factor A domain and a unique domain. The size of the collagenous domains and the position of the structurally important cysteine residues within these domains are identical between the collagen VI alpha 3, alpha 4, alpha 5, and alpha 6 chains. In mouse, the new chains are found in or close to basement membranes. Collagen VI alpha 1 chain-deficient mice lack expression of the new collagen VI chains implicating that the new chains may substitute for the alpha 3 chain, probably forming alpha 1 alpha 2 alpha 4, alpha 1 alpha 2 alpha 5, or alpha 1 alpha 2 alpha 6 heterotrimers. Due to a large scale pericentric inversion, the human COL6A4 gene on chromosome 3 was broken into two pieces and became a non-processed pseudogene. Recently COL6A5 was linked to atopic dermatitis and designated COL29A1. The identification of novel collagen VI chains carries implications for the etiology of atopic dermatitis as well as Bethlem myopathy and Ullrich congenital muscular dystrophy.	[Gara, Sudheer Kumar; Kobbe, Birgit; Koch, Manuel; Paulsson, Mats; Wagener, Raimund] Univ Cologne, Inst Biochem 2, Fac Med, Ctr Biochem, D-50931 Cologne, Germany; [Koch, Manuel] Univ Cologne, Fac Med, Ctr Mol Med, D-50931 Cologne, Germany; [Koch, Manuel] Univ Cologne, Fac Med, Dept Dermatol, D-50931 Cologne, Germany; [Grumati, Paolo; Urciuolo, Anna; Bonaldo, Paolo] Univ Padua, Dept Histol Microbiol & Med Biotechnol, I-35121 Padua, Italy	University of Cologne; University of Cologne; University of Cologne; University of Padua	Wagener, R (corresponding author), Univ Cologne, Inst Biochem 2, Fac Med, Ctr Biochem, Stelzmann Str 52, D-50931 Cologne, Germany.	raimund.wagener@uni-koeln.de	Gara, Sudheer Kumar/E-8084-2016; Grumati, Paolo/AAA-5787-2019; Koch, Manuel/AAG-9914-2021	Koch, Manuel/0000-0002-2962-7814; Bonaldo, Paolo/0000-0002-9571-8140; Urciuolo, Anna/0000-0001-7571-9747	Fondazione Telethon Funding Source: Custom; Telethon [GGP04113] Funding Source: Medline	Fondazione Telethon(Fondazione Telethon); Telethon(Fondazione Telethon)		Angelin A, 2007, P NATL ACAD SCI USA, V104, P991, DOI 10.1073/pnas.0610270104; Baker NL, 2005, HUM MOL GENET, V14, P279, DOI 10.1093/hmg/ddi025; Ball S, 2003, J BIOL CHEM, V278, P15326, DOI 10.1074/jbc.M209977200; Ball SG, 2001, J BIOL CHEM, V276, P7422, DOI 10.1074/jbc.M002816200; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; Bischof JM, 2006, HUM MUTAT, V27, P545, DOI 10.1002/humu.20335; Bonaldo P, 1998, HUM MOL GENET, V7, P2135, DOI 10.1093/hmg/7.13.2135; BONALDO P, 1990, BIOCHEMISTRY-US, V29, P1245, DOI 10.1021/bi00457a021; Bradley M, 2002, HUM MOL GENET, V11, P1539, DOI 10.1093/hmg/11.13.1539; BROWN JC, 1994, MATRIX BIOL, V14, P287, DOI 10.1016/0945-053X(94)90194-5; Bu LM, 2006, ALLERGY, V61, P617, DOI 10.1111/j.1398-9995.2006.01072.x; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; CHU ML, 1988, J BIOL CHEM, V263, P18601; CHU ML, 1989, EMBO J, V8, P1939, DOI 10.1002/j.1460-2075.1989.tb03598.x; COLOMBATTI A, 1987, J BIOL CHEM, V262, P14454; COLOMBATTI A, 1989, MATRIX, V9, P177, DOI 10.1016/S0934-8832(89)80048-4; Dziadek M, 2002, MATRIX BIOL, V21, P227, DOI 10.1016/S0945-053X(02)00009-4; ENGVALL E, 1986, J CELL BIOL, V102, P703, DOI 10.1083/jcb.102.3.703; Finnis ML, 1997, J BIOL CHEM, V272, P22817, DOI 10.1074/jbc.272.36.22817; Fitzgerald J, 2001, J BIOL CHEM, V276, P187, DOI 10.1074/jbc.M008173200; FURTHMAYR H, 1983, BIOCHEM J, V211, P303, DOI 10.1042/bj2110303; Irwin WA, 2003, NAT GENET, V35, P367, DOI 10.1038/ng1270; Knupp C, 2001, EMBO J, V20, P372, DOI 10.1093/emboj/20.3.372; Lamande SR, 2006, J BIOL CHEM, V281, P16607, DOI 10.1074/jbc.M510192200; Lamande SR, 1998, J BIOL CHEM, V273, P7423, DOI 10.1074/jbc.273.13.7423; Lampe AK, 2005, J MED GENET, V42, P673, DOI 10.1136/jmg.2002.002311; Lampe AK, 2005, J MED GENET, V42, P108, DOI 10.1136/jmg.2004.023754; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lucioli S, 2005, NEUROLOGY, V64, P1931, DOI 10.1212/01.WNL.0000163990.00057.66; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; Muzny DM, 2006, NATURE, V440, P1194, DOI 10.1038/nature04728; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; PERKINS SJ, 1994, J MOL BIOL, V238, P104, DOI 10.1006/jmbi.1994.1271; PERONA JJ, 1993, J MOL BIOL, V230, P919, DOI 10.1006/jmbi.1993.1210; Persikov AV, 2005, J BIOL CHEM, V280, P19343, DOI 10.1074/jbc.M501657200; PFAFF M, 1993, EXP CELL RES, V206, P167, DOI 10.1006/excr.1993.1134; Sengle G, 2003, J BIOL CHEM, V278, P50240, DOI 10.1074/jbc.M307794200; Sipila L, 2007, J BIOL CHEM, V282, P33381, DOI 10.1074/jbc.M704198200; Soderhall C, 2007, PLOS BIOL, V5, P1952, DOI 10.1371/journal.pbio.0050242; TILLET E, 1994, EUR J BIOCHEM, V221, P177, DOI 10.1111/j.1432-1033.1994.tb18727.x; Veit G, 2006, J BIOL CHEM, V281, P3494, DOI 10.1074/jbc.M509333200; Whittaker CA, 2002, MOL BIOL CELL, V13, P3369, DOI 10.1091/mbc.E02-05-0259; Wiberg C, 2003, J BIOL CHEM, V278, P37698, DOI 10.1074/jbc.M304638200	44	117	124	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10658	10670		10.1074/jbc.M709540200	http://dx.doi.org/10.1074/jbc.M709540200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18276594	hybrid			2022-12-25	WOS:000254894700048
J	Takaya, T; Kawamura, T; Morimoto, T; Ono, K; Kita, T; Shimatsu, A; Hasegawa, K				Takaya, Tomohide; Kawamura, Teruhisa; Morimoto, Tatsuya; Ono, Koh; Kita, Toru; Shimatsu, Akira; Hasegawa, Koji			Identification of p300-targeted acetylated residues in GATA4 during hypertrophic responses in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; CREB-BINDING PROTEIN; HEAVY-CHAIN GENE; EMBRYONIC STEM-CELLS; MOLECULAR-CLONING; COACTIVATOR P300; HEART-FAILURE; IN-VIVO; EXPRESSION; DIFFERENTIATION	A zinc finger protein, GATA4, is one of the hypertrophy-responsive transcription factors and increases its DNA binding and transcriptional activities in response to hypertrophic stimuli in cardiac myocytes. Activation of GATA4 during this process is mediated, in part, through acetylation by intrinsic histone acetyltransferases such as a transcriptional coactivator p300. However, p300-targeted acetylated sites of GATA4 during myocardial cell hypertrophy have not been identified. By mutational analysis, we showed that 4 lysine residues located between amino acids 311 and 322 are required for synergistic activation of atrial natriuretic factor and endothelin-1 promoters by GATA4 and p300. A tetra-mutant GATA4, in which these 4 lysine residues were simultaneously mutated, retained the ability to localize in nuclei and to interact with cofactors including FOG-2, GATA6, and p300 but lacked p300-induced acetylation, DNA binding, and transcriptional activities. Furthermore, coexpression of the tetra-mutant GATA4 with wild-type GATA4 impaired the p300-induced acetylation, DNA binding, and transcriptional activities of the wild type. When we expressed the tetra-mutant GATA4 in neonatal rat cardiac myocytes using a lentivirus vector, this mutant suppressed phenylephrine-induced increases in cell size, protein synthesis, and expression of hypertrophy-responsive genes. However, its expression did not affect the basal state. Thus, we have identified the most critical lysine residues acting as p300-mediated acetylation targets in GATA4 during hypertrophic responses in cardiac myocytes. The results also demonstrate that GATA4 with simultaneous mutation of these sites specifically suppresses hypertrophic responses as a dominant-negative form, providing further evidence for the acetylation of GATA4 as one of critical nuclear events in myocardial cell hypertrophy.	[Takaya, Tomohide; Kawamura, Teruhisa; Morimoto, Tatsuya; Hasegawa, Koji] Natl Hosp Org, Div Translat Res, Kyoto Med Ctr, Fushimi Ku, Kyoto 6128555, Japan; [Shimatsu, Akira] Natl Hosp Org, Clin Res Inst, Kyoto Med Ctr, Fushimi Ku, Kyoto 6128555, Japan; [Takaya, Tomohide; Ono, Koh; Kita, Toru] Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Hasegawa, K (corresponding author), Natl Hosp Org, Div Translat Res, Kyoto Med Ctr, Fushimi Ku, 1-1 Mukaihata Cho, Kyoto 6128555, Japan.	koj@kuhp.kyoto-u.ac.jp	Takaya, Tomohide/D-6372-2012; Shimatsu, Akira/I-3856-2019	Takaya, Tomohide/0000-0002-3610-0906; 				ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Chan HM, 2001, J CELL SCI, V114, P2363; Charron F, 1999, MOL CELL BIOL, V19, P4355; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Dai YS, 2001, J BIOL CHEM, V276, P37178, DOI 10.1074/jbc.M103731200; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Gheorghiu I, 2001, J BIOL CHEM, V276, P44331, DOI 10.1074/jbc.M107591200; Hasegawa K, 1997, J BIOL CHEM, V272, P20049, DOI 10.1074/jbc.272.32.20049; Hasegawa K, 1997, CIRCULATION, V96, P3943; Hayakawa F, 2004, J LEUKOCYTE BIOL, V75, P529, DOI 10.1189/jlb.0603289; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Hidaka K, 2003, FASEB J, V17, P740, DOI 10.1096/fj.02-0104fje; Hirai M, 2004, J BIOL CHEM, V279, P37640, DOI 10.1074/jbc.M401737200; Hosseinkhani M, 2007, BIOCHEM BIOPH RES CO, V356, P386, DOI 10.1016/j.bbrc.2007.02.151; Hung HL, 1999, MOL CELL BIOL, V19, P3496; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; Iwanaga Y, 1998, CIRCULATION, V98, P2065, DOI 10.1161/01.CIR.98.19.2065; Kaburagi S, 1999, CIRCULATION, V99, P292, DOI 10.1161/01.CIR.99.2.292; Kawamura T, 2005, J BIOL CHEM, V280, P19682, DOI 10.1074/jbc.M412428200; Lamonica JM, 2006, BLOOD, V108, P3736, DOI 10.1182/blood-2006-07-032847; Liang QR, 2001, J BIOL CHEM, V276, P30245, DOI 10.1074/jbc.M102174200; Lu JR, 1999, MOL CELL BIOL, V19, P4495; Miyamoto S, 2006, CIRCULATION, V113, P679, DOI 10.1161/CIRCULATIONAHA.105.585182; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Morimoto T, 1999, J BIOL CHEM, V274, P12811, DOI 10.1074/jbc.274.18.12811; Morimoto T, 2000, J BIOL CHEM, V275, P13721, DOI 10.1074/jbc.275.18.13721; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Morrisey EE, 1997, J BIOL CHEM, V272, P8515, DOI 10.1074/jbc.272.13.8515; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Peterkin T, 2005, SEMIN CELL DEV BIOL, V16, P83, DOI 10.1016/j.semcdb.2004.10.003; Pikkarainen S, 2004, CARDIOVASC RES, V63, P196, DOI 10.1016/j.cardiores.2004.03.025; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Suzuki E, 1996, GENOMICS, V38, P283, DOI 10.1006/geno.1996.0630; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Tanaka Y, 2000, MECH DEVELOP, V95, P133, DOI 10.1016/S0925-4773(00)00360-9; Wada H, 2002, J CELL BIOL, V156, P983, DOI 10.1083/jcb.200106057; Wada H, 2000, J BIOL CHEM, V275, P25330, DOI 10.1074/jbc.M000828200; Yamagata T, 2000, EMBO J, V19, P4676, DOI 10.1093/emboj/19.17.4676; Yanazume T, 2003, MOL CELL BIOL, V23, P3593, DOI 10.1128/MCB.23.10.3593-3606.2003; Yanazume T, 2002, J BIOL CHEM, V277, P8618, DOI 10.1074/jbc.M107924200; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4	45	73	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9828	9835		10.1074/jbc.M707391200	http://dx.doi.org/10.1074/jbc.M707391200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18252717	hybrid, Green Submitted			2022-12-25	WOS:000254671600038
J	Pages, D; Rose, J; Conrod, S; Cuine, S; Carrier, P; Heulin, T; Achouak, W				Pages, Delphine; Rose, Jerome; Conrod, Sandrine; Cuine, Stephane; Carrier, Patrick; Heulin, Thierry; Achouak, Wafa			Heavy Metal Tolerance in Stenotrophomonas maltophilia	PLOS ONE			English	Article								Stenotrophomonas maltophilia is an aerobic, non-fermentative Gram-negative bacterium widespread in the environment. S. maltophilia Sm777 exhibits innate resistance to multiple antimicrobial agents. Furthermore, this bacterium tolerates high levels (0.1 to 50 mM) of various toxic metals, such as Cd, Pb, Co, Zn, Hg, Ag, selenite, tellurite and uranyl. S. maltophilia Sm777 was able to grow in the presence of 50 mM selenite and 25 mM tellurite and to reduce them to elemental selenium (Se-0) and tellurium (Te-0) respectively. Transmission electron microscopy and energy dispersive X-ray analysis showed cytoplasmic nanometer-sized electron-dense Se-0 granules and Te-0 crystals. Moreover, this bacterium can withstand up to 2 mM CdCl2 and accumulate this metal up to 4% of its biomass. The analysis of soluble thiols in response to ten different metals showed eightfold increase of the intracellular pool of cysteine only in response to cadmium. Measurements by Cd K-edge EXAFS spectroscopy indicated the formation of Cd-S clusters in strain Sm777. Cysteine is likely to be involved in Cd tolerance and in CdS-clusters formation. Our data suggest that besides high tolerance to antibiotics by efflux mechanisms, S. maltophilia Sm777 has developed at least two different mechanisms to overcome metal toxicity, reduction of oxyanions to non-toxic elemental ions and detoxification of Cd into CdS.	[Pages, Delphine; Conrod, Sandrine; Heulin, Thierry; Achouak, Wafa] CEA, DSV, IBEB, LEMiRE, St Paul Les Durance, France; [Pages, Delphine; Conrod, Sandrine; Heulin, Thierry; Achouak, Wafa] CNRS, UMR Biol Veget & Microbiol Environm, Saint Paul lez Durance, France; [Pages, Delphine; Conrod, Sandrine; Heulin, Thierry; Achouak, Wafa] Aix Marseille Univ, Saint Paul lez Durance, France; [Rose, Jerome] Univ Aix Marseille, UMR 6635 CNRS, CEREGE, IFR 112 PMSE Europole lArbois, Aix En Provence, France; [Cuine, Stephane; Carrier, Patrick] LB3M, SBVME, IBEB, DSV, CEA, Saint Paul lez Durance, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; PSL Research University Paris; College de France; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); CEA	Achouak, W (corresponding author), CEA, DSV, IBEB, LEMiRE, St Paul Les Durance, France.	wafa.achouak@cea.fr	, HEULIN/C-1689-2010; ROSE, Jerome/J-5063-2017; Achouak, Wafa/AAX-8916-2021; BM30, Beamline FAME/G-9313-2012	ROSE, Jerome/0000-0003-3071-8147; Achouak, Wafa/0000-0003-4297-6661; 	French Toxicologie Nucleaire Environnementale program	French Toxicologie Nucleaire Environnementale program	This work was supported by the French Toxicologie Nucleaire Environnementale program 2001 06. The funder did not contribute to the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript.	Alonso A, 2000, ANTIMICROB AGENTS CH, V44, P3079, DOI 10.1128/AAC.44.11.3079-3086.2000; Alonso A, 2000, ANTIMICROB AGENTS CH, V44, P1778, DOI 10.1128/AAC.44.7.1778-1782.2000; Berg G., 1994, Archives of Phytopathology and Plant Protection, V29, P249, DOI 10.1080/03235409409383116; Berg G, 2005, ENVIRON MICROBIOL, V7, P1673, DOI 10.1111/j.1462-2920.2005.00891.x; BINKS PR, 1995, APPL ENVIRON MICROB, V61, P1318, DOI 10.1128/AEM.61.4.1318-1322.1995; DEBETTE J, 1980, CAN J MICROBIOL, V26, P460, DOI 10.1139/m80-076; Dignani MC, 2003, SEMIN RESP CRIT CARE, V24, P89, DOI 10.1055/s-2003-37920; Dungan RS, 2003, ENVIRON MICROBIOL, V5, P287, DOI 10.1046/j.1462-2920.2003.00410.x; Fauchon M, 2002, MOL CELL, V9, P713, DOI 10.1016/S1097-2765(02)00500-2; Heuer H, 1999, FEMS MICROBIOL ECOL, V28, P357, DOI 10.1111/j.1574-6941.1999.tb00590.x; Holmes JD, 1997, MICROBIOL-UK, V143, P2521, DOI 10.1099/00221287-143-8-2521; Juhasz AL, 2000, LETT APPL MICROBIOL, V30, P396, DOI 10.1046/j.1472-765x.2000.00733.x; KNUDSEN GR, 1988, APPL ENVIRON MICROB, V54, P343, DOI 10.1128/AEM.54.2.343-347.1988; KREDICH NM, 1973, J BIOL CHEM, V248, P6187; LAMBERT B, 1989, TRENDS BIOTECHNOL, V7, P215, DOI 10.1016/0167-7799(89)90107-8; Lee EY, 2002, J AIR WASTE MANAGE, V52, P400, DOI 10.1080/10473289.2002.10470796; Li XZ, 2002, ANTIMICROB AGENTS CH, V46, P333, DOI 10.1128/AAC.46.2.333-343.2002; Michalovicz A., 1991, LOGICIELS CHIMIE, P102; Pages D, 2007, ENVIRON MICROBIOL, V9, P2820, DOI 10.1111/j.1462-2920.2007.01394.x; Park S, 2003, J BACTERIOL, V185, P1942, DOI 10.1128/JB.185.6.1942-1950.2003; Quinn JP, 1998, CLIN INFECT DIS, V27, pS117, DOI 10.1086/514912; REHR JJ, 1990, PHYS REV B, V41, P8139, DOI 10.1103/PhysRevB.41.8139; Rijstenbil JW, 1996, MAR BIOL, V127, P45, DOI 10.1007/BF00993642; Sauge-Merle S, 2003, APPL ENVIRON MICROB, V69, P490, DOI 10.1128/AEM.69.1.490-494.2003; Sharma PK, 2000, APPL ENVIRON MICROB, V66, P3083, DOI 10.1128/AEM.66.7.3083-3087.2000; Teo B.K., 1986, INORGANIC CHEM CONCE; Valdezate S, 2001, ANTIMICROB AGENTS CH, V45, P1581, DOI 10.1128/AAC.45.5.1581-1584.2001; Wang CL, 2001, APPL MICROBIOL BIOT, V56, P425, DOI 10.1007/s002530100660; Whipps JM, 2001, J EXP BOT, V52, P487, DOI 10.1093/jexbot/52.suppl_1.487; YAMAZAKI E, 1989, FEMS MICROBIOL LETT, V60, P85, DOI 10.1016/0378-1097(89)90082-7; ZABINSKY SI, 1995, PHYS REV B, V52, P2995, DOI 10.1103/PhysRevB.52.2995; Zhang L, 2001, ANTIMICROB AGENTS CH, V45, P3497, DOI 10.1128/AAC.45.12.3497-3503.2001	32	88	94	3	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2008	3	2							e1539	10.1371/journal.pone.0001539	http://dx.doi.org/10.1371/journal.pone.0001539			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367EQ	18253487	Green Published, gold			2022-12-25	WOS:000260535700011
J	Williams, SA; Stanley, P				Williams, Suzannah A.; Stanley, Pamela			Mouse fertility is enhanced by oocyte-specific loss of core 1-derived O-glycans	FASEB JOURNAL			English	Article						multiple-oocyte follicles; T-synthase; ovulation rate	FOLLICLE-STIMULATING-HORMONE; INCREASED OVULATION RATE; GROWTH-DIFFERENTIATION FACTOR-9; ZONA-PELLUCIDA; FEMALE MICE; TRANSGENIC MICE; POLYOVULAR FOLLICLES; NEONATAL EXPOSURE; OVARIAN-FOLLICLE; RECEPTOR	Regulation of the number of eggs ovulated by different mammalian species remains poorly understood. Here we show that oocyte-specific deletion at the primary follicle stage of core 1 beta 1,3-galactosyl-transferase (T-synthase; generates core 1-derived O-glycans), leads to a sustained increase in fertility. T-syn mutant females ovulated 30-50% more eggs and had a sustained increase in litter size compared to controls. Ovarian weights and follicle numbers were greater in mutants, but follicular apoptosis was not decreased. The number of follicles entering the growing pool was unaltered, but 3-wk mutants ovulated fewer eggs, suggesting that increased fertility results from prolonged follicle development. T-syn mutant ovaries also contained numerous multiple-oocyte follicles (MOFs) that appeared to form by adjacent, predominantly preantral, follicles joining-a new mechanism for MOF generation. Ovulation of multiple eggs from MOFs was not the reason for increased fertility based on ovulated egg and corpora lutea numbers. Thus, the absence of T- synthase caused modified follicular development, leading to the maturation and ovulation of more follicles, to MOF formation at late stages of folliculogenesis, and to increased fertility. These results identify novel roles for glycoproteins from the oocyte as suppressors of fertility and regulators of follicular integrity in the mouse.	[Williams, Suzannah A.; Stanley, Pamela] Albert Einstein Coll Med, Dept Cell Biol, New York, NY 10461 USA	Yeshiva University	Stanley, P (corresponding author), Albert Einstein Coll Med, Dept Cell Biol, New York, NY 10461 USA.	stanley@aecom.yu.edu		Stanley, Pamela/0000-0001-5704-3747; Williams, Suzannah/0000-0003-1798-976X	NATIONAL CANCER INSTITUTE [R01CA030645] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA030645-26, R01 CA030645-27, R01 CA030645-25A1, R01 CA030645] Funding Source: Medline; PHS HHS [P01 13330, NCI R01 30645] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alfieri JA, 2003, J CELL SCI, V116, P2149, DOI 10.1242/jcs.00430; Barnett KR, 2006, HUM REPROD UPDATE, V12, P537, DOI 10.1093/humupd/dml022; Boja ES, 2003, J BIOL CHEM, V278, P34189, DOI 10.1074/jbc.M304026200; CHEN F, 1994, MOL ENDOCRINOL, V8, P1434, DOI 10.1210/me.8.10.1434; Danilovich N, 2000, ENDOCRINOLOGY, V141, P4295, DOI 10.1210/en.141.11.4295; Danilovich N, 2002, BIOL REPROD, V67, P361, DOI 10.1095/biolreprod67.2.361; Dong JW, 1996, NATURE, V383, P531, DOI 10.1038/383531a0; Dube JL, 1998, MOL ENDOCRINOL, V12, P1809, DOI 10.1210/me.12.12.1809; Durlinger ALL, 1999, ENDOCRINOLOGY, V140, P5789, DOI 10.1210/en.140.12.5789; Ellies LG, 1998, IMMUNITY, V9, P881, DOI 10.1016/S1074-7613(00)80653-6; Galloway SM, 2000, NAT GENET, V25, P279, DOI 10.1038/77033; Hahn KL, 2005, DEVELOPMENT, V132, P817, DOI 10.1242/dev.01601; Hanrahan JP, 2004, BIOL REPROD, V70, P900, DOI 10.1095/biolreprod.103.023093; Hsu SY, 1996, ENDOCRINOLOGY, V137, P4837, DOI 10.1210/en.137.11.4837; IGUCHI T, 1988, BIOL REPROD, V39, P689, DOI 10.1095/biolreprod39.3.689; IGUCHI T, 1986, TERATOLOGY, V34, P29, DOI 10.1002/tera.1420340105; Irving-Rodgers HF, 2006, SEMIN REPROD MED, V24, P195, DOI 10.1055/s-2006-948549; Jefferson W, 2006, BIOL REPROD, V74, P161, DOI 10.1095/biolreprod.105.045724; Jefferson WN, 2002, BIOL REPROD, V67, P1285, DOI 10.1095/biolreprod67.4.1285; Ju TZ, 2002, P NATL ACAD SCI USA, V99, P16613, DOI 10.1073/pnas.262438199; Ju TZ, 2002, J BIOL CHEM, V277, P178, DOI 10.1074/jbc.M109060200; Kipp JL, 2007, ENDOCRINOLOGY, V148, P1968, DOI 10.1210/en.2006-1083; Kumar TR, 1999, MOL ENDOCRINOL, V13, P851, DOI 10.1210/me.13.6.851; Lan ZJ, 2003, EMBO J, V22, P4070, DOI 10.1093/emboj/cdg405; Lewandoski M, 1997, CURR BIOL, V7, P148, DOI 10.1016/S0960-9822(06)00059-5; Lowe JB, 2003, ANNU REV BIOCHEM, V72, P643, DOI 10.1146/annurev.biochem.72.121801.161809; Lu LC, 2006, METHOD ENZYMOL, V417, P127, DOI 10.1016/S0076-6879(06)17010-X; MCGRATH SA, 1995, MOL ENDOCRINOL, V9, P131, DOI 10.1210/me.9.1.131; McMullen ML, 2001, ENDOCRINOLOGY, V142, P5005, DOI 10.1210/en.142.11.5005; Mulsant P, 2001, P NATL ACAD SCI USA, V98, P5104, DOI 10.1073/pnas.091577598; NAAR EM, 1991, BIOL REPROD, V45, P178, DOI 10.1095/biolreprod45.1.178; NAGDAS SK, 1994, BIOL REPROD, V51, P262, DOI 10.1095/biolreprod51.2.262; Patsoula E, 2001, REPRODUCTION, V121, P455, DOI 10.1530/rep.0.1210455; PEDERSEN T, 1968, J REPROD FERTIL, V17, P555, DOI 10.1530/jrf.0.0170555; Pepling ME, 2001, DEV BIOL, V234, P339, DOI 10.1006/dbio.2001.0269; PHILPOTT CC, 1987, DEV BIOL, V121, P568, DOI 10.1016/0012-1606(87)90192-8; Racki WJ, 2006, DEVELOPMENT, V133, P4527, DOI 10.1242/dev.02651; Roby KF, 1999, BIOL REPROD, V61, P1616, DOI 10.1095/biolreprod61.6.1616; Shi SL, 2004, MOL CELL BIOL, V24, P9920, DOI 10.1128/MCB.24.22.9920-9929.2004; Slot KA, 2006, REPRODUCTION, V131, P525, DOI 10.1530/rep.1.00946; Souza CJH, 2001, J ENDOCRINOL, V169, pR1, DOI 10.1677/joe.0.169R001; THALL AD, 1995, J BIOL CHEM, V270, P21437, DOI 10.1074/jbc.270.37.21437; Thomas AD, 2001, REPRODUCTION, V122, P537, DOI 10.1530/reprod/122.4.537; Wassarman PM, 1997, P ROY SOC B-BIOL SCI, V264, P323, DOI 10.1098/rspb.1997.0046; Williams SA, 2007, J CELL SCI, V120, P1341, DOI 10.1242/jcs.004291; Wilson T, 2001, BIOL REPROD, V64, P1225, DOI 10.1095/biolreprod64.4.1225; Xia LJ, 2004, J CELL BIOL, V164, P451, DOI 10.1083/jcb.200311112; Yan CN, 2001, MOL ENDOCRINOL, V15, P854, DOI 10.1210/me.15.6.854; Yang YZ, 2003, BIOL REPROD, V69, P1294, DOI 10.1095/biolreprod.103.015610; Yu RN, 1998, NAT GENET, V20, P353, DOI 10.1038/3822	50	33	33	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2273	2284		10.1096/fj.07-101709	http://dx.doi.org/10.1096/fj.07-101709			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18276833	Green Accepted			2022-12-25	WOS:000257292500020
J	De Franceschi, L; Platt, OS; Malpeli, G; Janin, A; Scarpa, A; Leboeuf, C; Beuzard, Y; Payen, E; Brugnara, C				De Franceschi, Lucia; Platt, Orah S.; Malpeli, Giorgio; Janin, Anne; Scarpa, Aldo; Leboeuf, Christophe; Beuzard, Yves; Payen, Emmanuel; Brugnara, Carlo			Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice	FASEB JOURNAL			English	Article						inflammatory response; lung injury; vascular remodeling; hypoxia; endothelin-1	ACUTE CHEST SYNDROME; ACUTE LUNG INJURY; SMOOTH-MUSCLE-CELLS; NITRIC-OXIDE; PROSTACYCLIN ANALOGS; ENDOTHELIN ANTAGONISM; PLASMA ENDOTHELIN-1; PROSTAGLANDIN E-2; TISSUE FACTOR; UP-REGULATION	Pulmonary arterial hypertension (PAH) is one of the leading causes of morbidity and mortality in adult patients with sickle cell disease (SCD). Here, we developed a model to study the early stage of PAH in SCD. We exposed wild-type and transgenic sickle cell SAD (Hbbs/Hbbs) mice to hypoxia (8% O-2) for 7 days. Prolonged hypoxia in SAD mice only induced 1) increased neutrophil count in both bronchoalveoal lavage (BAL) and peripheral circulation; 2) increased BAL IL1 beta, IL10, IL6, and TNF-alpha; and 3) up-regulation of the genes endothelin-1, cyclo-oxygenase-2, angiotensin-converting-enzyme, and IL-1 beta, suggesting that amplified inflammatory response and activation of the endothelin-1 system may contribute to the early phase of PAH in SCD. Since phosphodiesterases (PDEs) are involved in pulmonary vascular tone regulation, we evaluated gene expression of phosphodiesterase-4 (PDE-4) isoforms and of PDE-1, -2, -3, -7, -8, which are the main cyclic-adenosine-monophosphate hydrolyzing enzymes. In SAD mouse lungs, prolonged hypoxia significantly increased PDE-4 and -1 gene expressions. The PDE-4 inhibitor, rolipram, prevented the hypoxia-induced PDE-4 and -1 gene up-regulation and interfered with the development of PAH, most likely through modulation of both vascular tone and inflammatory factors. This finding supports a possible therapeutic use of PDEs inhibitors in the earlier phases of PAH in SCD.	[De Franceschi, Lucia] Univ Verona, Policlin GB Rossi, Sect Internal Med, Dept Clin & Expt Med, I-37134 Verona, Italy; [Malpeli, Giorgio; Scarpa, Aldo] Univ Verona, Sect Anat Pathol, Dept Pathol, I-37134 Verona, Italy; [Platt, Orah S.] Harvard Univ, Childrens Hosp, Sch Med, Lab Med, Boston, MA 02115 USA; [Platt, Orah S.] Harvard Univ, Childrens Hosp, Sch Med, Pathol Lab, Boston, MA 02115 USA; [Janin, Anne; Leboeuf, Christophe] Hop St Louis, INSERM 02 20, Pathol Lab, Paris, France; [Beuzard, Yves; Payen, Emmanuel] Hop St Louis, INSERM, Lab Gene Therapy & Hematol Dis, U 733, Paris, France	University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	De Franceschi, L (corresponding author), Univ Verona, Policlin GB Rossi, Sect Internal Med, Dept Clin & Expt Med, Ple L Scuro 10, I-37134 Verona, Italy.	lucia.defranceschi@univr.it	Brugnara, Carlo/A-8041-2010; DE FRANCESCHI, Lucia/AAB-8652-2022; Leboeuf, christophe/H-4583-2012; Payen, Emmanuel/S-5357-2018; scarpa, aldo/K-6832-2016	Brugnara, Carlo/0000-0001-8192-8713; DE FRANCESCHI, Lucia/0000-0001-7093-777X; Leboeuf, christophe/0000-0002-6537-0550; Payen, Emmanuel/0000-0002-1329-2327; scarpa, aldo/0000-0003-1678-739X; Malpeli, Giorgio/0000-0002-2996-2903	NIDDK NIH HHS [DK504221] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ariga M, 2004, J IMMUNOL, V173, P7531, DOI 10.4049/jimmunol.173.12.7531; BALLAS SK, 1992, BLOOD, V79, P2154, DOI 10.1182/blood.V79.8.2154.2154; Ben Driss A, 2000, CIRCULATION, V101, P2764, DOI 10.1161/01.CIR.101.23.2764; Bender AT, 2006, PHARMACOL REV, V58, P488, DOI 10.1124/pr.58.3.5; Bleiweis MS, 1999, ANN THORAC SURG, V67, P194, DOI 10.1016/S0003-4975(98)01310-1; Bowers R, 2004, AM J RESP CRIT CARE, V169, P764, DOI 10.1164/rccm.200301-147OC; Budhiraja R, 2004, CIRCULATION, V109, P159, DOI 10.1161/01.CIR.0000102381.57477.50; Castro O, 2003, BLOOD, V101, P1257, DOI 10.1182/blood-2002-03-0948; CHRISTMAN BW, 1992, NEW ENGL J MED, V327, P70, DOI 10.1056/NEJM199207093270202; Conran N, 2004, AM J HEMATOL, V76, P343, DOI 10.1002/ajh.20129; Corbel M, 2002, J PHARMACOL EXP THER, V301, P258, DOI 10.1124/jpet.301.1.258; Cosby K, 2003, NAT MED, V9, P1498, DOI 10.1038/nm954; de Franceschi L, 2003, BLOOD, V102, P1087, DOI 10.1182/blood-2002-07-2135; de Moraes VLG, 1998, BRIT J PHARMACOL, V123, P631; Derchi G, 2005, ANN NY ACAD SCI, V1054, P471, DOI 10.1196/annals.1345.070; Derchi G, 2005, HAEMATOLOGICA, V90, P452; Dorfmuller P, 2003, EUR RESPIR J, V22, P358, DOI 10.1183/09031936.03.00038903; Dorfmuller P, 2002, AM J RESP CRIT CARE, V165, P534, DOI 10.1164/rccm.2012112; El-Haroun H, 2004, CIRC RES, V94, P353, DOI 10.1161/01.RES.0000111801.48626.F4; Fartoukh M, 1998, CHEST, V114, p50S, DOI 10.1378/chest.114.1_Supplement.50S; Fike CD, 2005, J APPL PHYSIOL, V99, P670, DOI 10.1152/japplphysiol.01337.2004; Finsnes F, 1997, AM J RESP CRIT CARE, V155, P1404, DOI 10.1164/ajrccm.155.4.9105086; Finsnes F, 2001, AM J PHYSIOL-LUNG C, V280, pL659, DOI 10.1152/ajplung.2001.280.4.L659; Frid MG, 2006, AM J PATHOL, V168, P659, DOI 10.2353/ajpath.2006.050599; FULTON RM, 1952, BRIT HEART J, V14, P413; Gale DD, 2003, PULM PHARMACOL THER, V16, P97, DOI 10.1016/S1094-5539(02)00175-X; Gamanuma M, 2003, CELL SIGNAL, V15, P565, DOI 10.1016/S0898-6568(02)00146-8; Geraci MW, 1999, J CLIN INVEST, V103, P1509, DOI 10.1172/JCI5911; Gladwin MT, 2004, NEW ENGL J MED, V350, P886, DOI 10.1056/NEJMoa035477; Gomez-Alamillo C, 2003, HYPERTENSION, V42, P831, DOI 10.1161/01.HYP.0000088854.04562.DA; Graido-Gonzalez E, 1998, BLOOD, V92, P2551, DOI 10.1182/blood.V92.7.2551.2551_2551_2555; Hagen M, 2007, AM J PHYSIOL-LUNG C, V292, pL1473, DOI 10.1152/ajplung.00197.2006; Hammerman SI, 1997, AM J RESP CRIT CARE, V156, P280, DOI 10.1164/ajrccm.156.1.9611085; Haque AK, 2002, HUM PATHOL, V33, P1037, DOI 10.1053/hupa.2002.128059; HAYNES J, 1992, AM J PHYSIOL, V262, pH511, DOI 10.1152/ajpheart.1992.262.2.H511; Hoshikawa Y, 2001, AM J RESP CRIT CARE, V164, P314, DOI 10.1164/ajrccm.164.2.2010150; Hsu LL, 2007, BLOOD, V109, P3088, DOI 10.1182/blood-2006-08-039438; Huang Z, 2005, J CLIN INVEST, V115, P2099, DOI 10.1172/JCI24650; Humbert M, 1998, CHEST, V114, p80S, DOI 10.1378/chest.114.1_Supplement.80S; Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712; Jin SLC, 2002, P NATL ACAD SCI USA, V99, P7628, DOI 10.1073/pnas.122041599; Kato GJ, 2005, BRIT J HAEMATOL, V130, P943, DOI 10.1111/j.1365-2141.2005.05701.x; Kaur K, 2000, ANN INTERN MED, V132, P165, DOI 10.7326/0003-4819-132-2-200001180-00019; Kim D, 2001, CIRCULATION, V104, P2338, DOI 10.1161/hc4401.098432; Lam CF, 2005, AM J PHYSIOL-HEART C, V289, pH2334, DOI 10.1152/ajpheart.00375.2005; Langleben D, 1999, CIRCULATION, V99, P3266, DOI 10.1161/01.CIR.99.25.3266; Levi M, 2001, CIRCULATION, V103, P2014; Machado RF, 2005, BRIT J HAEMATOL, V130, P445, DOI 10.1111/j.1365-2141.2005.05625.x; Machado RF, 2005, BRIT J HAEMATOL, V129, P449, DOI 10.1111/j.1365-2141.2005.05432.x; Merkus D, 2007, J PHYSIOL-LONDON, V580, P907, DOI 10.1113/jphysiol.2006.127118; Miotla JM, 1998, AM J RESP CELL MOL, V18, P411, DOI 10.1165/ajrcmb.18.3.2913; Omori K, 2007, CIRC RES, V100, P309, DOI 10.1161/01.RES.0000256354.95791.f1; Palmer LA, 2007, J CLIN INVEST, V117, P2592, DOI 10.1172/JCI29444; Phillips PG, 2005, AM J PHYSIOL-LUNG C, V288, pL103, DOI 10.1152/ajplung.00095.2004; Platt OS, 2000, NEW ENGL J MED, V342, P1904, DOI 10.1056/NEJM200006223422510; PLATT OS, 1994, NEW ENGL J MED, V330, P783, DOI 10.1056/NEJM199403173301110; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; Pritchard KA, 2004, AM J PHYSIOL-LUNG C, V286, pL705, DOI 10.1152/ajplung.00288.2002; RABE KF, 1994, AM J PHYSIOL, V266, pL536, DOI 10.1152/ajplung.1994.266.5.L536; Rybicki AC, 1998, BLOOD, V92, P2594, DOI 10.1182/blood.V92.7.2594.2594_2594_2596; Said SI, 2006, AM J PHYSIOL-LUNG C, V291, pL547, DOI 10.1152/ajplung.00546.2005; Santing RE, 2001, EUR J PHARMACOL, V429, P335, DOI 10.1016/S0014-2999(01)01333-4; Schermuly RT, 2001, AM J RESP CRIT CARE, V164, P1694, DOI 10.1164/ajrccm.164.9.2105060; Sheares KKK, 2004, AM J PHYSIOL-LUNG C, V287, pL919, DOI 10.1152/ajplung.00012.2004; Solovey A, 2004, BLOOD, V104, P840, DOI 10.1182/blood-2003-10-3719; Solovey A, 1998, J CLIN INVEST, V101, P1899, DOI 10.1172/JCI1932; Solovey AA, 2001, BLOOD, V97, P1937, DOI 10.1182/blood.V97.7.1937; Steinbauer M, 2000, SHOCK, V14, P163, DOI 10.1097/00024382-200014020-00015; Steinberg MH, 1999, NEW ENGL J MED, V340, P1021, DOI 10.1056/NEJM199904013401307; Stenmark KR, 2006, CIRC RES, V99, P675, DOI 10.1161/01.RES.0000243584.45145.3f; Strukova S, 2006, FRONT BIOSCI-LANDMRK, V11, P59, DOI 10.2741/1780; Stuart MJ, 1999, BLOOD, V94, P1555, DOI 10.1182/blood.V94.5.1555.417k36_1555_1560; Tang HF, 2005, AM J RESP CRIT CARE, V171, P823, DOI 10.1164/rccm.200406-771OC; Tharaux PL, 2005, NEPHROL DIAL TRANSPL, V20, P2408, DOI 10.1093/ndt/gfi111; Toward TJ, 2004, AM J RESP CRIT CARE, V169, P227, DOI 10.1164/rccm.200211-1372OC; TRUDEL M, 1994, BLOOD, V84, P3189; Tuder RM, 2002, AM J RESP CELL MOL, V26, P171, DOI 10.1165/ajrcmb.26.2.f230; Tuder RM, 2007, CLIN CHEST MED, V28, P23, DOI 10.1016/j.ccm.2006.11.010; TURNER CR, 1993, CIRC SHOCK, V39, P237; Vichinsky EP, 2004, NEW ENGL J MED, V350, P857, DOI 10.1056/NEJMp038250; Villagra J, 2007, BLOOD, V110, P2166, DOI 10.1182/blood-2006-12-061697; Voelkel NF, 1998, CHEST, V114, p225S, DOI 10.1378/chest.114.3_Supplement.225S; Wagner RS, 1997, J PHARMACOL EXP THER, V282, P1650; Wang HC, 2007, J MOL BIOL, V371, P302, DOI 10.1016/j.jmb.2007.05.060; Werdehoff SG, 1998, AM J HEMATOL, V58, P195, DOI 10.1002/(SICI)1096-8652(199807)58:3<195::AID-AJH6>3.0.CO;2-M; Wood KC, 2006, FREE RADICAL BIO MED, V40, P1443, DOI 10.1016/j.freeradbiomed.2005.12.015; Wort SJ, 2002, MOL PHARMACOL, V62, P1147, DOI 10.1124/mol.62.5.1147; Zhao L, 2001, CIRCULATION, V104, P424, DOI 10.1161/hc2901.093117	88	23	23	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1849	1860		10.1096/fj.07-098921	http://dx.doi.org/10.1096/fj.07-098921			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18245171				2022-12-25	WOS:000256352700025
J	Puissant, A; Grosso, S; Jacquel, A; Belhacene, N; Colosetti, P; Cassuto, JP; Auberger, P				Puissant, Alexandre; Grosso, Sebastien; Jacquel, Arnaud; Belhacene, Nathalie; Colosetti, Pascal; Cassuto, Jill-Patrice; Auberger, Patrick			Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol	FASEB JOURNAL			English	Article						caspase-dependent cell death; caspase-independent cell death; anticancer therapy; BCR-ABL inhibitors	TYROSINE KINASE INHIBITOR; CHRONIC MYELOID-LEUKEMIA; ACTIVATED PROTEIN-KINASE; SMALL-INTERFERING-RNA; BCR-ABL; ERYTHROID-DIFFERENTIATION; INDUCED APOPTOSIS; BLAST-CRISIS; K562 CELLS; PHILADELPHIA-CHROMOSOME	Imatinib is successfully used in the treatment of chronic myelogenous leukemia (CML), and the main mechanisms of resistance in refractory patients are now partially understood. In the present study, we investigated the mechanism of action of resveratrol in imatinib-sensitive (IM-S) and -resistant (IM-R) CML cell lines. Resveratrol induced loss of viability and apoptosis in IM-S and IM-R in a time- and dose-dependent fashion. Inhibition of cell viability was detected for concentrations of resveratrol as low as 5 mu M, and the IC50 values for viability, clonogenic assays, apoptosis, and erythroid differentiation were in the 10-25 mu M range. The effect of imatinib and resveratrol was additive in IM-S but not in IM-R clones in which the resveratrol effect was already maximal. The effect of resveratrol on apoptosis was partially rescued by zVAD-fmk, suggesting a caspase-independent contribution. Resveratrol action was independent of BCR-ABL expression and phosphorylation, and in agreement was additive to BCR-ABL silencing. Finally, phytoalexin inhibited the growth of BaF3 cells expressing mutant BCR-ABL proteins found in resistant patients, including the multiresistant T315I mutation. Our findings show that resveratrol induces apoptosis, caspase-independent death, and differentiation that collectively contribute to the specific elimination of CML cells. Resveratrol should provide therapeutic benefits in IM-R patients and in other hematopoietic malignancies.	[Puissant, Alexandre; Grosso, Sebastien; Jacquel, Arnaud; Belhacene, Nathalie; Colosetti, Pascal; Auberger, Patrick] Fac Med Nice, INSERM, U526, F-06107 Nice 2, France; [Puissant, Alexandre; Grosso, Sebastien; Jacquel, Arnaud; Belhacene, Nathalie; Colosetti, Pascal; Auberger, Patrick] Univ Nice Sophia Antipolis, Sophia Antipolis, France; [Cassuto, Jill-Patrice] Ctr Hosp Univ, Serv Hematol Clin, Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice	Auberger, P (corresponding author), Fac Med Nice, INSERM, U526, Ave Valombrose, F-06107 Nice 2, France.	auberger@unice.fr	Colosetti, Pascal/ABH-4585-2020; Jacquel, Arnaud/AAJ-4760-2021; Jacquel, Arnaud/O-1928-2017; PUISSANT, ALEXANDRE/O-9575-2016; AUBERGER, Patrick/G-1491-2013; Puissant, Alexandre/AAF-3875-2021	Jacquel, Arnaud/0000-0001-5062-8048; Jacquel, Arnaud/0000-0001-5062-8048; PUISSANT, ALEXANDRE/0000-0002-3997-9282; AUBERGER, Patrick/0000-0002-2481-8275; Puissant, Alexandre/0000-0002-3997-9282				Athar M, 2007, TOXICOL APPL PHARM, V224, P274, DOI 10.1016/j.taap.2006.12.025; Bhardwaj A, 2007, BLOOD, V109, P2293, DOI 10.1182/blood-2006-02-003988; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; BUCHDUNGER E, 1995, P NATL ACAD SCI USA, V92, P2558, DOI 10.1073/pnas.92.7.2558; CLARKSON B, 1993, LEUKEMIA, V7, P1683; Dan S, 1998, CELL DEATH DIFFER, V5, P710, DOI 10.1038/sj.cdd.4400400; Dasgupta B, 2007, P NATL ACAD SCI USA, V104, P7217, DOI 10.1073/pnas.0610068104; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Donato NJ, 2003, BLOOD, V101, P690, DOI 10.1182/blood.V101.2.690; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; Gao XH, 2002, J NUTR, V132, P2076, DOI 10.1093/jn/132.7.2076; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Herrant M, 2004, ONCOGENE, V23, P7863, DOI 10.1038/sj.onc.1208069; Horvath Z, 2006, EXP HEMATOL, V34, P1377, DOI 10.1016/j.exphem.2006.05.018; Jacquel A, 2007, ONCOGENE, V26, P2445, DOI 10.1038/sj.onc.1210034; Jacquel A, 2006, ONCOGENE, V25, P781, DOI 10.1038/sj.onc.1209119; Jacquel A, 2003, FASEB J, V17, P2160, DOI 10.1096/fj.03-0322fje; Kawano T, 2004, MOL CELL BIOCHEM, V258, P25, DOI 10.1023/B:MCBI.0000012830.96393.b9; Kohmura K, 2004, J CELL PHYSIOL, V198, P370, DOI 10.1002/jcp.10426; Koschmieder S, 2005, BLOOD, V105, P324, DOI 10.1182/blood-2003-12-4369; le Coutre P, 2000, BLOOD, V95, P1758, DOI 10.1182/blood.V95.5.1758.005a41_1758_1766; Luzi C, 2004, BIOCHEM PHARMACOL, V68, P2019, DOI 10.1016/j.bcp.2004.07.002; Maccarrone M, 1999, EUR J BIOCHEM, V265, P27, DOI 10.1046/j.1432-1327.1999.00630.x; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; Mahon FX, 2003, BLOOD, V101, P2368, DOI 10.1182/blood.V101.6.2368; Morotti A, 2006, AM J HEMATOL, V81, P938, DOI 10.1002/ajh.20732; Neering SJ, 2007, BLOOD, V110, P2578, DOI 10.1182/blood-2007-02-073031; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Park CE, 2007, EXP MOL MED, V39, P222, DOI 10.1038/emm.2007.25; Rangatia J, 2006, LEUKEMIA, V20, P68, DOI 10.1038/sj.leu.2403999; Ren RB, 2002, ONCOGENE, V21, P8629, DOI 10.1038/sj.onc.1206090; Rodrigue CM, 2001, BRIT J HAEMATOL, V113, P500, DOI 10.1046/j.1365-2141.2001.02746.x; Sawyers CL, 2002, BLOOD, V99, P3530, DOI 10.1182/blood.V99.10.3530; Scherr M, 2003, BLOOD, V101, P1566, DOI 10.1182/blood-2002-06-1685; Shen M, 2006, VASC PHARMACOL, V45, P122, DOI 10.1016/j.vph.2006.04.002; Steelman LS, 2004, LEUKEMIA, V18, P189, DOI 10.1038/sj.leu.2403241; Tsan MF, 2002, LEUKEMIA LYMPHOMA, V43, P983, DOI 10.1080/10428190290021669; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Zang MW, 2006, DIABETES, V55, P2180, DOI 10.2337/db05-1188	42	59	63	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1894	1904		10.1096/fj.07-101394	http://dx.doi.org/10.1096/fj.07-101394			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18245170				2022-12-25	WOS:000256352700029
J	Hanley, KP; Oakley, F; Sugden, S; Wilson, DI; Mann, DA; Hanley, NA				Hanley, Karen Piper; Oakley, Fiona; Sugden, Sarah; Wilson, David I.; Mann, Derek A.; Hanley, Neil A.			Ectopic SOX9 mediates extracellular matrix deposition characteristic of organ fibrosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE INHIBITOR; HUMAN PANCREAS DEVELOPMENT; TRANSCRIPTION FACTOR SOX9; NEURAL CREST DEVELOPMENT; AUTOSOMAL SEX REVERSAL; SRY-RELATED GENE; CAMPOMELIC DYSPLASIA; MESENCHYMAL TRANSITION; LIVER FIBROSIS; INTESTINAL EPITHELIUM	Appropriate temporospatial expression of the transcription factor SOX9 is important for normal development of a wide range of organs. Here, we show that when SOX9 is expressed ectopically, target genes become expressed that are associated with disease. Histone deacetylase inhibitors in clinical trials for cancer therapy induced SOX9 expression via enhanced recruitment of nuclear factor Y (NF-Y) to CCAAT elements in the SOX9 proximal promoter. The effect of histone deacetylase inhibitors could be elicited in cells that normally lack SOX9, such as hepatocytes. In human fetal hepatocytes, this aberrant induction of SOX9 protein caused ectopic expression of COL2A1 and COMP1 that encode extracellular matrix (ECM) components normally associated with chondrogenesis. Previously, ectopic expression of this "chondrogenic" profile has been implicated in vascular calcification. More broadly, inappropriate ECM deposition is a hallmark of fibrosis. We demonstrated that induction of SOX9 expression also occurred during activation of fibrogenic cells from the adult liver when the transcription factor was responsible for expression of the major component of fibrotic ECM, type 1 collagen. These combined data identify new aspects in the regulation of SOX9 expression. They support a role for SOX9 beyond normal development as a transcriptional regulator in the pathology of fibrosis.	[Hanley, Karen Piper; Sugden, Sarah; Wilson, David I.; Hanley, Neil A.] Univ Southampton, Southampton Gen Hosp, Div Human Genet, Southampton SO16 6YD, Hants, England; [Hanley, Karen Piper; Sugden, Sarah; Wilson, David I.; Hanley, Neil A.] Univ Southampton, Southampton Gen Hosp, Ctr Human Dev Stem Cells & Regenerat, Southampton SO16 6YD, Hants, England; [Oakley, Fiona; Mann, Derek A.] Newcastle Univ, Inst Cellular Med, Liver Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of Southampton; University of Southampton; Newcastle University - UK	Hanley, KP (corresponding author), Univ Southampton, Southampton Gen Hosp, Div Human Genet, Duthie Bldg,Mailpoint 808,Tremona Rd, Southampton SO16 6YD, Hants, England.	k.piper@soton.ac.uk; n.a.hanley@soton.ac.uk	Piper Hanley, Karen/O-8676-2015; Wilson, David/A-6264-2010	Piper Hanley, Karen/0000-0001-9473-9647; Wilson, David/0000-0001-8779-2060; Sugden, Sarah/0000-0003-2071-4038; Hanley, Neil/0000-0003-3234-4038; Mann, Derek/0000-0003-0950-243X	Medical Research Council [G0401643] Funding Source: Medline; Wellcome Trust Funding Source: Medline; Department of Health Funding Source: Medline; MRC [G0401643] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Department of Health; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Akiyama H, 2005, P NATL ACAD SCI USA, V102, P14665, DOI 10.1073/pnas.0504750102; Akiyama H, 2004, P NATL ACAD SCI USA, V101, P6502, DOI 10.1073/pnas.0401711101; Bagheri-Fam S, 2001, GENOMICS, V78, P73, DOI 10.1006/geno.2001.6648; Bagheri-Fam S, 2006, DEV BIOL, V291, P382, DOI 10.1016/j.ydbio.2005.11.013; Bastide P, 2007, J CELL BIOL, V178, P635, DOI 10.1083/jcb.200704152; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bennett MR, 2007, NEPHRON EXP NEPHROL, V107, pE30, DOI 10.1159/000106775; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Cheung M, 2003, DEVELOPMENT, V130, P5681, DOI 10.1242/dev.00808; Colter DC, 2005, MATRIX BIOL, V24, P185, DOI 10.1016/j.matbio.2005.04.001; daSilva SM, 1996, NAT GENET, V14, P62, DOI 10.1038/ng0996-62; Deutsch G, 2001, DEVELOPMENT, V128, P871; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; Friedman SL, 2006, J GASTROEN HEPATOL, V21, pS79, DOI 10.1111/j.1440-1746.2006.04585.x; Glaser KB, 2007, BIOCHEM PHARMACOL, V74, P659, DOI 10.1016/j.bcp.2007.04.007; Hanley NA, 2000, MECH DEVELOP, V91, P403, DOI 10.1016/S0925-4773(99)00307-X; Hanley NA, 2001, MOL ENDOCRINOL, V15, P57, DOI 10.1210/me.15.1.57; Hardikar AA, 2003, P NATL ACAD SCI USA, V100, P7117, DOI 10.1073/pnas.1232230100; Hearn T, 2005, DIABETES, V54, P1581, DOI 10.2337/diabetes.54.5.1581; Henderson NC, 2007, CLIN SCI, V112, P265, DOI 10.1042/CS20060242; Horb ME, 2003, CURR BIOL, V13, P105, DOI 10.1016/S0960-9822(02)01434-3; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Iredale JP, 2007, J CLIN INVEST, V117, P539, DOI 10.1172/JCI30542; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kawakami Y, 2006, CURR OPIN CELL BIOL, V18, P723, DOI 10.1016/j.ceb.2006.10.007; Kent J, 1996, DEVELOPMENT, V122, P2813; Kypriotou M, 2007, J BIOL CHEM, V282, P32000, DOI 10.1074/jbc.M705197200; Lincoln J, 2007, DEV BIOL, V305, P120, DOI 10.1016/j.ydbio.2007.02.002; Liu CJ, 2007, FRONT BIOSCI, V12, P3899, DOI 10.2741/2359; Mori-Akiyama Y, 2007, GASTROENTEROLOGY, V133, P539, DOI 10.1053/j.gastro.2007.05.020; Naitoh M, 2005, GENES CELLS, V10, P1081, DOI 10.1111/j.1365-2443.2005.00902.x; Neven E, 2007, KIDNEY INT, V72, P574, DOI 10.1038/sj.ki.5002353; Niki T, 1999, HEPATOLOGY, V29, P858, DOI 10.1002/hep.510290328; Pfeifer D, 1999, AM J HUM GENET, V65, P111, DOI 10.1086/302455; Piera-Velazquez S, 2007, EXP CELL RES, V313, P1069, DOI 10.1016/j.yexcr.2007.01.001; Piper K, 2002, MECH DEVELOP, V116, P223, DOI 10.1016/S0925-4773(02)00145-4; Piper K, 2004, J ENDOCRINOL, V181, P11, DOI 10.1677/joe.0.1810011; Ramirez F, 2006, MATRIX BIOL, V25, P365, DOI 10.1016/j.matbio.2006.05.002; Rombouts K, 2002, EXP CELL RES, V278, P184, DOI 10.1006/excr.2002.5577; Schaefer JF, 2003, OSTEOARTHR CARTILAGE, V11, P233, DOI 10.1016/S1063-4584(02)00354-0; Seymour PA, 2007, P NATL ACAD SCI USA, V104, P1865, DOI 10.1073/pnas.0609217104; Shen CN, 2000, NAT CELL BIOL, V2, P879, DOI 10.1038/35046522; Smart DE, 2006, HEPATOLOGY, V44, P1432, DOI 10.1002/hep.21436; Spokony RF, 2002, DEVELOPMENT, V129, P421; Sumi E, 2007, AM J PATHOL, V170, P1854, DOI 10.2353/ajpath.2007.060899; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; Xu L, 2005, GUT, V54, P142, DOI 10.1136/gut.2004.042127; Ylostalo J, 2006, STEM CELLS, V24, P642, DOI 10.1634/stemcells.2005-0270; Yu CD, 2003, AM J PATHOL, V163, P1653, DOI 10.1016/S0002-9440(10)63522-5; Zeisberg EM, 2007, NAT MED, V13, P952, DOI 10.1038/nm1613; Zeisberg M, 2007, J BIOL CHEM, V282, P23337, DOI 10.1074/jbc.M700194200	51	88	93	3	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2008	283	20					14063	14071		10.1074/jbc.M707390200	http://dx.doi.org/10.1074/jbc.M707390200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299AM	18296708	hybrid			2022-12-25	WOS:000255728200060
J	Boutilier, J; Ceni, C; Pagdala, PC; Forgie, A; Neet, KE; Barker, PA				Boutilier, Jacqueline; Ceni, Claire; Pagdala, Promila C.; Forgie, Alison; Neet, Kenneth E.; Barker, Philip A.			Proneurotrophins require endocytosis and intracellular proteolysis to induce TrkA activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; P75 NEUROTROPHIN RECEPTOR; SIGNALING ENDOSOME; ALZHEIMERS-DISEASE; PRO-PEPTIDE; CELL-DEATH; PROTEIN; BRAIN; FURIN; NGF	The uncleaved, pro-form of nerve growth factor (proNGF) functions as a pro-apoptotic ligand for the p75 neurotrophin receptor (p75NTR). However, some reports have indicated that proneurotrophins bind and activate Trk receptors. In this study, we have examined proneurotrophin receptor binding and activation properties in an attempt to reconcile these findings. We show that proNGF readily binds p75NTR expressed in HEK293T cells but does not interact with TrkA expressed under similar circumstances. Importantly, proNGF activates TrkA tyrosine phosphorylation, induces Erk and Akt activation, and causes PC12 cell differentiation. We show that inhibiting endocytosis or furin activity reduced TrkA activation induced by proNGF but not that induced by mature NGF and that proNGF123, a mutant form of NGF lacking dibasic cleavage sites in the prodomain, does not induce TrkA phosphorylation in PC12 cells. Therefore, endocytosis and cleavage appear to be prerequisites for proNGF-induced TrkA activity. We also found that proBDNF induces activation of TrkB in cerebellar granule neurons and that proBDNF cleavage by furin and metalloproteases facilitates this effect. Taken together, these data indicate that under physiological conditions, proneurotrophins do not directly bind or activate Trk receptors. However, endocytosis and cleavage of proneurotrophins produce processed forms of neurotrophins that are capable of inducing Trk activation.	McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; [Boutilier, Jacqueline; Ceni, Claire; Barker, Philip A.] Rosalind Franklin Univ Med & Sci, Dept Biochem & Mol Biol, N Chicago, IL 60064 USA; [Forgie, Alison] Rinat Neurosci, San Francisco, CA 94080 USA	McGill University; Rosalind Franklin University Medical & Science	Barker, PA (corresponding author), McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	phil.barker@mcgill.ca			NINDS NIH HHS [NS24380] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024380] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Althaus HH, 2006, J NEUROCHEM, V98, P506, DOI 10.1111/j.1471-4159.2006.03891.x; Band AM, 2001, FEBS LETT, V505, P118, DOI 10.1016/S0014-5793(01)02798-3; Beattie MS, 2002, NEURON, V36, P375, DOI 10.1016/S0896-6273(02)01005-X; Bierl MA, 2005, NEUROSCI LETT, V380, P133, DOI 10.1016/j.neulet.2005.01.029; Bronfman FC, 2003, J NEUROSCI, V23, P3209; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Chen CD, 2001, EMBO J, V20, P6277, DOI 10.1093/emboj/20.22.6277; Chen YW, 2001, P NATL ACAD SCI USA, V98, P7218, DOI 10.1073/pnas.131076098; Fahnestock M, 2004, J NEUROCHEM, V89, P581, DOI 10.1111/j.1471-4159.2004.02360.x; Fahnestock M, 2001, MOL CELL NEUROSCI, V18, P210, DOI 10.1006/mcne.2001.1016; Fayard B, 2005, J NEUROSCI RES, V80, P18, DOI 10.1002/jnr.20432; Flanagan JG, 2000, METHOD ENZYMOL, V327, P198, DOI 10.1016/S0076-6879(00)27277-7; Harrington AW, 2004, P NATL ACAD SCI USA, V101, P6226, DOI 10.1073/pnas.0305755101; Hasan W, 2003, J NEUROBIOL, V57, P38, DOI 10.1002/neu.10250; Hauburger A, 2007, FEBS LETT, V581, P4159, DOI 10.1016/j.febslet.2007.07.063; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Howe CL, 2004, J NEUROBIOL, V58, P207, DOI 10.1002/neu.10323; Howe CL, 2001, NEURON, V32, P801, DOI 10.1016/S0896-6273(01)00526-8; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Iglesias-Bartolome R, 2006, FEBS J, V273, P1744, DOI 10.1111/j.1742-4658.2006.05194.x; JEANNETEAU F, 2006, NOVART FDN SYMP, V276, P189; JEANNETEAU F, 2006, NOVART FDN SYMP, V276, P187; Jeanneteau Freddy, 2006, Novartis Found Symp, V276, P181; Kliemannel M, 2007, PROTEIN SCI, V16, P411, DOI 10.1110/ps.062376207; Le Borgne R, 2006, CURR OPIN CELL BIOL, V18, P213, DOI 10.1016/j.ceb.2006.02.011; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Michalski B, 2003, MOL BRAIN RES, V111, P148, DOI 10.1016/S0169-328X(03)00003-2; Nykjaer A, 2004, NATURE, V427, P843, DOI 10.1038/nature02319; Pagadala PC, 2006, P NATL ACAD SCI USA, V103, P17939, DOI 10.1073/pnas.0604139103; Paoletti F, 2006, BIOCHEM SOC T, V34, P605, DOI 10.1042/BST0340605; Peng SY, 2005, J NEUROCHEM, V93, P1412, DOI 10.1111/j.1471-4159.2005.03135.x; Peters EMJ, 2006, J HISTOCHEM CYTOCHEM, V54, P275, DOI 10.1369/jhc.4A6585.2005; Roux PP, 2002, PROG NEUROBIOL, V67, P203, DOI 10.1016/S0301-0082(02)00016-3; Roux PP, 1999, J NEUROSCI, V19, P6887, DOI 10.1523/JNEUROSCI.19-16-06887.1999; Scott GK, 2003, EMBO J, V22, P6234, DOI 10.1093/emboj/cdg596; Scott GK, 2006, EMBO J, V25, P4423, DOI 10.1038/sj.emboj.7601336; Seidah NG, 1996, FEBS LETT, V379, P247, DOI 10.1016/0014-5793(95)01520-5; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Woo NH, 2005, NAT NEUROSCI, V8, P1069, DOI 10.1038/nn1510; Zhang YZ, 2000, J NEUROSCI, V20, P5671, DOI 10.1523/JNEUROSCI.20-15-05671.2000	40	46	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2008	283	19					12709	12716		10.1074/jbc.M710018200	http://dx.doi.org/10.1074/jbc.M710018200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295UQ	18299325	hybrid, Green Published			2022-12-25	WOS:000255499800006
J	Tornaletti, S; Park-Snyder, S; Hanawalt, PC				Tornaletti, Silvia; Park-Snyder, Shaun; Hanawalt, Philip C.			G4-forming sequences in the non-transcribed DNA strand pose blocks to T7 RNA polymerase and mammalian RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN SWITCH REGIONS; G4 DNA; TRANSCRIPTION ELONGATION; TEMPLATE DNA; RAT-LIVER; PURIFICATION; GENE; TRANSLOCATION; HYPERMUTATION; COMPLEXES	DNA sequences rich in runs of guanine have the potential to form G4 DNA, a four-stranded non-canonical DNA structure stabilized by formation and stacking of G quartets, planar arrays of four hydrogen-bonded guanines. It was reported recently that G4 DNA can be generated in Escherichia coli during transcription of plasmids containing G-rich sequences in the non-transcribed strand. In addition, a stable RNA/DNA hybrid is formed with the transcribed strand. These novel structures, termed G loops, are suppressed in recQ(+) strains, suggesting that their persistence may generate genomic instability and that the RecQ helicase may be involved in their dissolution. However, little is known about how such non-canonical DNA structures are processed when encountered by an elongating polymerase. To assess whether G4-forming sequences interfere with transcription, we studied their effect on transcription elongation by T7 RNA polymerase and mammalian RNA polymerase II. We used a reconstituted transcription system in vitro with purified polymerase and initiation factors and with substrates containing G-rich sequences in either the transcribed or non-transcribed strand downstream of the T7 promoter or the adenovirus major late promoter. We report that G-rich sequences located in the transcribed strand do not affect transcription by either polymerase, but when the sequences are located in the non-transcribed strand, they partially arrest both polymerases. The efficiency of arrest increases with negative supercoiling and also with multiple rounds of transcription compared with single events.	[Tornaletti, Silvia] Univ Florida, Dept Anat & Cell Biol, Coll Med, Gainesville, FL 32610 USA; [Tornaletti, Silvia; Park-Snyder, Shaun; Hanawalt, Philip C.] Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	State University System of Florida; University of Florida; Stanford University	Tornaletti, S (corresponding author), Univ Florida, Dept Anat & Cell Biol, Coll Med, Gainesville, FL 32610 USA.	silviat@ufl.edu			NCI NIH HHS [R01 CA077712, CA-77712] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077712, R56CA077712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cheung I, 2002, NAT GENET, V31, P405, DOI [10.1038/ng928, 10.1038/417405a]; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; Conaway RC, 1996, METHOD ENZYMOL, V273, P194; Daniels GA, 1995, NUCLEIC ACIDS RES, V23, P5006, DOI 10.1093/nar/23.24.5006; Davis JT, 2004, ANGEW CHEM INT EDIT, V43, P668, DOI 10.1002/anie.200300589; Duquette ML, 2005, ONCOGENE, V24, P5791, DOI 10.1038/sj.onc.1208746; Duquette ML, 2004, GENE DEV, V18, P1618, DOI 10.1101/gad.1200804; Grabczyk E, 2000, NUCLEIC ACIDS RES, V28, P2815, DOI 10.1093/nar/28.14.2815; GRABCZYK E, 1995, J BIOL CHEM, V270, P1791, DOI 10.1074/jbc.270.4.1791; GU WG, 1993, J BIOL CHEM, V268, P25604; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HSU CL, 1993, MOL CELL BIOL, V13, P4826, DOI 10.1128/MCB.13.8.4826; Huber MD, 2006, J MOL BIOL, V358, P1071, DOI 10.1016/j.jmb.2006.01.077; Larson ED, 2005, CURR BIOL, V15, P470, DOI 10.1016/j.cub.2004.12.077; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; MACDONALD LE, 1994, J MOL BIOL, V238, P145, DOI 10.1006/jmbi.1994.1277; Maizels N, 2005, ANNU REV GENET, V39, P23, DOI 10.1146/annurev.genet.39.073003.110544; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; Paeschke K, 2005, NAT STRUCT MOL BIOL, V12, P847, DOI 10.1038/nsmb982; Phan AT, 2006, CURR OPIN STRUC BIOL, V16, P288, DOI 10.1016/j.sbi.2006.05.011; REINES D, 1991, ANAL BIOCHEM, V196, P367, DOI 10.1016/0003-2697(91)90480-H; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; Scicchitano DA, 2004, DNA REPAIR, V3, P1537, DOI 10.1016/j.dnarep.2004.06.004; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; Sun H, 2001, P NATL ACAD SCI USA, V98, P12444, DOI 10.1073/pnas.231479198; Tornaletti S, 2005, MUTAT RES-FUND MOL M, V577, P131, DOI 10.1016/j.mrfmmm.2005.03.014; Tornaletti S, 1999, BIOCHIMIE, V81, P139, DOI 10.1016/S0300-9084(99)80046-7; Tornaletti S, 2003, J BIOL CHEM, V278, P35791, DOI 10.1074/jbc.M305394200; Tornaletti S, 1999, J BIOL CHEM, V274, P24124, DOI 10.1074/jbc.274.34.24124; Viswanathan A, 1998, J BIOL CHEM, V273, P21276, DOI 10.1074/jbc.273.33.21276; Wang GL, 2006, MUTAT RES-FUND MOL M, V598, P103, DOI 10.1016/j.mrfmmm.2006.01.019; Wright BE, 2004, GENES IMMUN, V5, P176, DOI 10.1038/sj.gene.6364053	33	56	56	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2008	283	19					12756	12762		10.1074/jbc.M705003200	http://dx.doi.org/10.1074/jbc.M705003200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295UQ	18292094	Green Published, hybrid			2022-12-25	WOS:000255499800011
J	Sbia, M; Parnell, EJ; Yu, Y; Olsen, AE; Kretschmann, KL; Voth, WP; Stillman, DJ				Sbia, Mohammed; Parnell, Emily J.; Yu, Yaxin; Olsen, Aileen E.; Kretschmann, Kelsi L.; Voth, Warren P.; Stillman, David J.			Regulation of the yeast Ace2 transcription factor during the cell cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; BINDING PROTEIN; FORKHEAD GENES; MITOTIC EXIT; HO PROMOTER; DNA-BINDING; KINASE; SWI5; MORPHOGENESIS; NETWORK	Previous studies have revealed many parallels in the cell cycle regulation of the Ace2 and Swi5 transcription factors. Although both proteins begin entry into the nucleus near the start of mitosis, here we show that Ace2 accumulates in the nucleus and binds DNA about 10 min later in the cell cycle than Swi5. We used chimeric fusions to identify the N-terminal region of Ace2 as responsible for the delay, and this same region of Ace2 was required for interaction with Cbk1, a kinase necessary for both transcriptional activation by Ace2 and asymmetric distribution of Ace2. Ace2 and Swi5 also showed differences in prevalence during the cell cycle. Swi5 is apparently degraded soon after nuclear entry, whereas constant Ace2 levels throughout the cell cycle suggest Ace2 is exported from the nucleus. Our work suggests that the precise timing of Ace2 accumulation in the nucleus involves both a nuclear export sequence and a nuclear localization signal, whose activities are regulated by phosphorylation.	[Sbia, Mohammed; Parnell, Emily J.; Yu, Yaxin; Olsen, Aileen E.; Kretschmann, Kelsi L.; Voth, Warren P.; Stillman, David J.] Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah	Stillman, DJ (corresponding author), Univ Utah, Dept Pathol, 15 N Med Dr E, Salt Lake City, UT 84112 USA.	david.stillman@utah.edu		Stillman, David/0000-0002-5268-2416	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007115] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32-DK007115] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Archambault V, 2004, MOL CELL, V14, P699, DOI 10.1016/j.molcel.2004.05.025; Bhoite LT, 2001, GENE DEV, V15, P2457, DOI 10.1101/gad.921601; Bhoite LT, 1998, MOL CELL BIOL, V18, P6436, DOI 10.1128/MCB.18.11.6436; Bidlingmaier S, 2001, MOL CELL BIOL, V21, P2449, DOI 10.1128/MCB.21.7.2449-2462.2001; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; Burke D., 2000, METHODS YEAST GENETI; Colman-Lerner A, 2001, CELL, V107, P739, DOI 10.1016/S0092-8674(01)00596-7; DOHRMANN PR, 1992, GENE DEV, V6, P93, DOI 10.1101/gad.6.1.93; Dohrmann PR, 1996, MOL CELL BIOL, V16, P1746; Eriksson P, 2004, MOL CELL BIOL, V24, P6419, DOI 10.1128/MCB.24.14.6419-6429.2004; Hollenhorst PC, 2000, GENETICS, V154, P1533; Jansen JM, 2006, J CELL BIOL, V175, P755, DOI 10.1083/jcb.200604107; Jensen TH, 2000, MOL CELL BIOL, V20, P8047, DOI 10.1128/MCB.20.21.8047-8058.2000; Kasten MM, 1996, MOL CELL BIOL, V16, P4215; Koranda M, 2000, NATURE, V406, P94, DOI 10.1038/35017589; Kumar R, 2000, CURR BIOL, V10, P896, DOI 10.1016/S0960-9822(00)00618-7; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mason PB, 2005, MOL CELL, V17, P831, DOI 10.1016/j.molcel.2005.02.017; McBride HJ, 1999, J BIOL CHEM, V274, P21029, DOI 10.1074/jbc.274.30.21029; McBride HJ, 1997, MOL CELL BIOL, V17, P2669, DOI 10.1128/MCB.17.5.2669; Measday V, 2000, MOL MICROBIOL, V35, P825, DOI 10.1046/j.1365-2958.2000.01754.x; Meimoun A, 2000, MOL BIOL CELL, V11, P915, DOI 10.1091/mbc.11.3.915; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; NASMYTH K, 1987, CELL, V49, P549, DOI 10.1016/0092-8674(87)90457-0; Nelson B, 2003, MOL BIOL CELL, V14, P3782, DOI 10.1091/mbc.E03-01-0018; O'Conallain C, 1999, MOL GEN GENET, V262, P275, DOI 10.1007/s004380051084; Pic A, 2000, EMBO J, V19, P3750, DOI 10.1093/emboj/19.14.3750; Poon IKH, 2005, TRAFFIC, V6, P173, DOI 10.1111/j.1600-0854.2005.00268.x; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Racki WJ, 2000, EMBO J, V19, P4524, DOI 10.1093/emboj/19.17.4524; Stegmeier F, 2004, ANNU REV GENET, V38, P203, DOI 10.1146/annurev.genet.38.072902.093051; TEBB G, 1993, GENE DEV, V7, P517, DOI 10.1101/gad.7.3.517; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Voth WP, 2007, EMBO J, V26, P4324, DOI 10.1038/sj.emboj.7601859; Voth WP, 2005, EUKARYOT CELL, V4, P1018, DOI 10.1128/EC.4.6.1018-1028.2005; Weiss EL, 2002, J CELL BIOL, V158, P885, DOI 10.1083/jcb.200203094; Zhu GF, 2000, NATURE, V406, P90, DOI 10.1038/35017581	39	42	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11135	11145		10.1074/jbc.M800196200	http://dx.doi.org/10.1074/jbc.M800196200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18292088	hybrid, Green Published			2022-12-25	WOS:000255067400009
J	Messick, TE; Russell, NS; Iwata, AJ; Sarachan, KL; Shiekhattar, R; Shanks, JR; Reyes-Turcu, FE; Wilkinson, KD; Marmorstein, R				Messick, Troy Eugene; Russell, Nathaniel Scott; Iwata, Ayaka Jennifer; Sarachan, Kathryn Lorenz; Shiekhattar, Ramin; Shanks, John R.; Reyes-Turcu, Francisca E.; Wilkinson, Keith D.; Marmorstein, Ronen			Structural basis for ubiquitin recognition by the OTU1 ovarian tumor domain protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DEUBIQUITINATING ENZYME; CRYSTAL-STRUCTURE; CYSTEINE PROTEASES; REVEALS; DEGRADATION; MECHANISMS; GENERATION; FAMILY; GENE	Ubiquitination of proteins modifies protein function by either altering their activities, promoting their degradation, or altering their subcellular localization. Deubiquitinating enzymes are proteases that reverse this ubiquitination. Previous studies demonstrate that proteins that contain an ovarian tumor (OTU) domain possess deubiquitinating activity. This domain of similar to 130 amino acids is weakly similar to the papain family of proteases and is highly conserved from yeast to mammals. Here we report structural and functional studies on the OTU domain-containing protein from yeast, Otu1. We show that Otu1 binds polyubiquitin chain analogs more tightly than monoubiquitin and preferentially hydrolyzes longer polyubiquitin chains with Lys(48) linkages, having little or no activity on Lys(63)- and Lys(29)-linked chains. We also show that Otu1 interacts with Cdc48, a regulator of the ER-associated degradation pathway. We also report the x-ray crystal structure of the OTU domain of Otu1 covalently complexed with ubiquitin and carry out structure-guided mutagenesis revealing a novel mode of ubiquitin recognition and a variation on the papain protease catalytic site configuration that appears to be conserved within the OTU family of ubiquitin hydrolases. Together, these studies provide new insights into ubiquitin binding and hydrolysis by yeast Otu1 and other OTU domain-containing proteins.	[Messick, Troy Eugene; Iwata, Ayaka Jennifer; Sarachan, Kathryn Lorenz; Shiekhattar, Ramin; Marmorstein, Ronen] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; [Iwata, Ayaka Jennifer; Sarachan, Kathryn Lorenz; Marmorstein, Ronen] Univ Penn, Dept Chem, Philadelphia, PA 19104 USA; [Iwata, Ayaka Jennifer; Sarachan, Kathryn Lorenz; Marmorstein, Ronen] Univ Penn, Grad Div Mol Biophys & Biochem, Philadelphia, PA 19104 USA; [Russell, Nathaniel Scott; Shanks, John R.; Reyes-Turcu, Francisca E.; Wilkinson, Keith D.] Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; [Russell, Nathaniel Scott; Shanks, John R.; Wilkinson, Keith D.] Emory Univ, Sch Med, Grad Div Biol & Biomed Sci, Atlanta, GA 30322 USA	The Wistar Institute; University of Pennsylvania; University of Pennsylvania; Emory University; Emory University	Marmorstein, R (corresponding author), 3601 Spruce St, Philadelphia, PA USA.	marmor@wistar.org		Messick, Troy/0000-0001-7914-1524; Sarachan, Kathryn/0000-0003-2511-1404	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030308, T32GM008275] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30308, T32 GM008275] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alam SL, 2004, EMBO J, V23, P1411, DOI 10.1038/sj.emboj.7600114; Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Babst M, 2005, TRAFFIC, V6, P2, DOI 10.1111/j.1600-0854.2004.00246.x; Borodovsky A, 2002, CHEM BIOL, V9, P1149, DOI 10.1016/S1074-5521(02)00248-X; Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Evans PC, 2003, J BIOL CHEM, V278, P23180, DOI 10.1074/jbc.M301863200; Evans PC, 2004, BIOCHEM J, V378, P727, DOI 10.1042/BJ20031377; Fang S, 2004, CELL MOL LIFE SCI, V61, P1546, DOI 10.1007/s00018-004-4129-5; Glenn LE, 2001, MECH DEVELOP, V102, P181, DOI 10.1016/S0925-4773(01)00314-8; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; Hicke L, 2005, NAT REV MOL CELL BIO, V6, P610, DOI 10.1038/nrm1701; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6; Hu M, 2005, EMBO J, V24, P3747, DOI 10.1038/sj.emboj.7600832; Kattenhorn LM, 2005, MOL CELL, V19, P547, DOI 10.1016/j.molcel.2005.07.003; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Lee S, 2006, NAT STRUCT MOL BIOL, V13, P264, DOI 10.1038/nsmb1064; Makarova KS, 2000, TRENDS BIOCHEM SCI, V25, P50, DOI 10.1016/S0968-0004(99)01530-3; Misaghi S, 2005, J BIOL CHEM, V280, P1512, DOI 10.1074/jbc.M410770200; Morris RJ, 2003, METHOD ENZYMOL, V374, P229, DOI 10.1016/S0076-6879(03)74011-7; Nanao MH, 2004, EMBO REP, V5, P783, DOI 10.1038/sj.embor.7400201; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Penengo L, 2006, CELL, V124, P1183, DOI 10.1016/j.cell.2006.02.020; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Reinstein E, 2006, ANN INTERN MED, V145, P676, DOI 10.7326/0003-4819-145-9-200611070-00010; Reyes-Turcu FE, 2006, CELL, V124, P1197, DOI 10.1016/j.cell.2006.02.038; RODESCH C, 1995, GENETICS, V141, P191; Rumpf S, 2006, MOL CELL, V21, P261, DOI 10.1016/j.molcel.2005.12.014; RUSSELL NS, 2005, THESIS EMORY U ATLAN; SASS GL, 1995, DEV BIOL, V167, P201, DOI 10.1006/dbio.1995.1017; Schlieker C, 2007, MOL CELL, V25, P677, DOI 10.1016/j.molcel.2007.01.033; Shcherbik N, 2007, MOL CELL, V25, P385, DOI 10.1016/j.molcel.2007.01.024; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; STEINHAUER WR, 1989, MOL CELL BIOL, V9, P5726, DOI 10.1128/MCB.9.12.5726; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794	38	83	85	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					11038	11049		10.1074/jbc.M704398200	http://dx.doi.org/10.1074/jbc.M704398200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18270205	Green Published, hybrid			2022-12-25	WOS:000254894700084
J	Tong, Q; Hirschler-Laszkiewicz, I; Zhang, W; Conrad, K; Neagley, DW; Barber, DL; Cheung, JY; Miller, BA				Tong, Qin; Hirschler-Laszkiewicz, Iwona; Zhang, Wenyi; Conrad, Kathleen; Neagley, David W.; Barber, Dwayne L.; Cheung, Joseph Y.; Miller, Barbara A.			TRPC3 is the erythropoietin-regulated calcium channel in human erythroid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE ERYTHROLEUKEMIA-CELLS; OPERATED CA2+ CHANNELS; PLASMA-MEMBRANE; SIGNAL-TRANSDUCTION; HUMAN ERYTHROBLASTS; CATION CHANNELS; PHOSPHOLIPASE C-GAMMA-1; MOLECULAR MECHANISMS; FURA RED; RECEPTOR	Erythropoietin (Epo) stimulates a significant increase in the intracellular calcium concentration ([Ca2+](i)) through activation of the murine transient receptor potential channel TRPC2, but TRPC2 is a pseudogene in humans. TRPC3 expression increases on normal human erythroid progenitors during differentiation. Here, we determined that erythropoietin regulates calcium influx through TRPC3. Epo stimulation of HEK 293T cells transfected with Epo receptor and TRPC3 resulted in a dose-dependent increase in [Ca2+](i), which required extracellular calcium influx. Treatment with the phospholipase C (PLC) inhibitor U-73122 or down-regulation of PLC gamma 1 by RNA interference inhibited the Epo-stimulated increase in [Ca2+](i) in TRPC3-transfected HEK 293T cells and in primary human erythroid precursors, demonstrating a requirement for PLC. TRPC3 associated with PLC gamma, and substitution of predicted PLC gamma Src homology 2 binding sites (Y226F, Y555F, Y648F, and Y674F) on TRPC3 reduced the interaction of TRPC3 with PLC gamma and inhibited the rise in [Ca2+](i). Substitution of Tyr(226) alone with phenylalanine significantly reduced the Epo-stimulated increase in [Ca2+](i) but not the association of PLC gamma with TRPC3. PLC activation results in production of inositol 1,4,5-trisphosphate (IP3). To determine whether IP3 is involved in Epo activation of TRPC3, TRPC3 mutants were prepared with substitution or deletion of COOH-terminal IP3 receptor (IP3R) binding domains. In cells expressing TRPC3 with mutant IP3R binding sites and Epo receptor, interaction of IP3R with TRPC3 was abolished, and Epo-modulated increase in [Ca2+](i) was reduced. Our data demonstrate that Epo modulates TRPC3 activation through a PLC gamma-mediated process that requires interaction of PLC gamma and IP3R with TRPC3. They also show that TRPC3 Tyr(226) is critical in Epo-dependent activation of TRPC3. These data demonstrate a redundancy of TRPC channel activation mechanisms by widely different agonists.	[Miller, Barbara A.] Penn State Univ, Milton S Hershey Med Ctr, Dept Biochem & Mol Biol, Coll Med, Hershey, PA 17033 USA; [Tong, Qin; Hirschler-Laszkiewicz, Iwona; Zhang, Wenyi; Conrad, Kathleen; Neagley, David W.; Miller, Barbara A.] Penn State Univ, Milton S Hershey Med Ctr, Dept Pediat, Coll Med, Hershey, PA 17033 USA; [Barber, Dwayne L.] Ontario Canc Inst, Div Stem Cells & Dev Biol, Toronto, ON M5G 2M9, Canada; [Cheung, Joseph Y.] Thomas Jefferson Univ, Div Nephrol, Philadelphia, PA 19107 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Jefferson University	Miller, BA (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Dept Pediat, Coll Med, POB 850, Hershey, PA 17033 USA.	bmiller3@psu.edu		Barber, Dwayne/0000-0001-5528-8150	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074854, R01HL058672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046778] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL58672, R01 HL74854] Funding Source: Medline; NIDDK NIH HHS [R01 DK46778] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bony V, 1999, BRIT J HAEMATOL, V107, P263, DOI 10.1046/j.1365-2141.1999.01721.x; Boudot C, 1999, J BIOL CHEM, V274, P33966, DOI 10.1074/jbc.274.48.33966; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Cayouette S, 2004, J BIOL CHEM, V279, P7241, DOI 10.1074/jbc.M312042200; Cheung JY, 1997, BLOOD, V89, P92, DOI 10.1182/blood.V89.1.92.92_92_100; CHEUNG JY, 1992, J CLIN INVEST, V90, P1850, DOI 10.1172/JCI116061; Cheung JY, 2001, NEPHRON, V87, P215, DOI 10.1159/000045918; Chu X, 2005, CELL CALCIUM, V37, P173, DOI 10.1016/j.ceca.2004.08.005; Chu X, 2004, J BIOL CHEM, V279, P10514, DOI 10.1074/jbc.M308478200; Chu X, 2002, J BIOL CHEM, V277, P34375, DOI 10.1074/jbc.M205541200; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Di Giacomo V, 2005, J CELL PHYSIOL, V202, P831, DOI 10.1002/jcp.20179; Dietrich A, 2005, PFLUG ARCH EUR J PHY, V451, P72, DOI 10.1007/s00424-005-1460-0; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GILLO B, 1993, BLOOD, V81, P783; Goel M, 2002, J BIOL CHEM, V277, P48303, DOI 10.1074/jbc.M207882200; Gudermann Thomas, 2004, Novartis Found Symp, V258, P103; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; HENSOLD JO, 1991, BLOOD, V77, P1362; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Kaushansky K, 2006, NEW ENGL J MED, V354, P2034, DOI 10.1056/NEJMra052706; Kawasaki BT, 2006, P NATL ACAD SCI USA, V103, P335, DOI 10.1073/pnas.0508030102; Kim JY, 2006, J BIOL CHEM, V281, P32540, DOI 10.1074/jbc.M602496200; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; KUREBAYASHI N, 1993, BIOPHYS J, V64, P1934, DOI 10.1016/S0006-3495(93)81564-9; Kwon YK, 2003, J CELL BIOL, V163, P375, DOI 10.1083/jcb.200301131; Liao HJ, 2002, J BIOL CHEM, V277, P9335, DOI 10.1074/jbc.M109955200; Liu XB, 2003, J BIOL CHEM, V278, P11337, DOI 10.1074/jbc.M213271200; Marrero MB, 1998, KIDNEY INT, V53, P1259, DOI 10.1046/j.1523-1755.1998.00887.x; MASONGARCIA M, 1992, AM J PHYSIOL, V262, pC1197; MASUDA S, 1993, J BIOL CHEM, V268, P11208; MILLER BA, 1989, BLOOD, V73, P1188; Miller BA, 1999, J BIOL CHEM, V274, P20465, DOI 10.1074/jbc.274.29.20465; MILLER BA, 1988, J CLIN INVEST, V82, P309, DOI 10.1172/JCI113588; MISITI J, 1979, J CLIN INVEST, V64, P1573, DOI 10.1172/JCI109618; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 2001, Sci STKE, V2001, pre1, DOI 10.1126/stke.2001.90.re1; Nilius B, 2007, PHYSIOL REV, V87, P165, DOI 10.1152/physrev.00021.2006; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Ogilvie M, 2000, J BIOL CHEM, V275, P39754, DOI 10.1074/jbc.M004999200; Pope SH, 2000, EUR J HAEMATOL, V64, P292, DOI 10.1034/j.1600-0609.2000.90032.x; Ramos-Franco J, 2000, BIOPHYS J, V79, P1388, DOI 10.1016/S0006-3495(00)76391-0; REN HY, 1994, J BIOL CHEM, V269, P19633; Richmond TD, 2005, TRENDS CELL BIOL, V15, P146, DOI 10.1016/j.tcb.2005.01.007; Smyth JT, 2006, J BIOL CHEM, V281, P11712, DOI 10.1074/jbc.M510541200; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; Tong Q, 2004, AM J PHYSIOL-CELL PH, V287, pC1667, DOI 10.1152/ajpcell.00265.2004; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; van Rossum DB, 2005, NATURE, V434, P99, DOI 10.1038/nature03340; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; Vazquez G, 2003, J BIOL CHEM, V278, P21649, DOI 10.1074/jbc.M302162200; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; Venkatachalam K, 2007, ANNU REV BIOCHEM, V76, P387, DOI 10.1146/annurev.biochem.75.103004.142819; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; Wedel BJ, 2003, J BIOL CHEM, V278, P25758, DOI 10.1074/jbc.M303890200; Wu YM, 1997, AM J PHYSIOL-HEART C, V273, pH2161, DOI 10.1152/ajpheart.1997.273.5.H2161; Zhang MY, 1998, BLOOD, V92, P1225, DOI 10.1182/blood.V92.4.1225.416k20_1225_1234	59	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10385	10395		10.1074/jbc.M710231200	http://dx.doi.org/10.1074/jbc.M710231200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18276585	Green Published, hybrid			2022-12-25	WOS:000254894700019
J	Ariga, M; Nedachi, T; Katagiri, H; Kanzaki, M				Ariga, Miyako; Nedachi, Taku; Katagiri, Hideki; Kanzaki, Makoto			Functional role of sortilin in myogenesis and development of insulin-responsive glucose transport system in C2C12 myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; L6 MUSCLE-CELLS; STIMULATED GLUT4 TRANSLOCATION; AFFINITY RECEPTOR P75(NTR); P75 NEUROTROPHIN RECEPTOR; SKELETAL-MUSCLE; 3T3-L1 ADIPOCYTES; SORTILIN/NEUROTENSIN RECEPTOR-3; GLUT4-CONTAINING VESICLES; STORAGE COMPARTMENT	Sortilin has been implicated in the formation of insulin-responsive GLUT4 storage vesicles in adipocytes by regulating sorting events between the trans-Golgi-network and endosomes. We herein show that sortilin serves as a potent myogenic differentiation stimulator for C2C12 myocytes by cooperatively functioning with p75NTR, which subsequently further contributes to development of the insulin-responsive glucose transport system in C2C12 myotubes. Sortilin expression was up-regulated upon C2C12 differentiation, and overexpression of sortilin in C2C12 cells significantly stimulated myogenic differentiation, a response that was completely abolished by either anti-p75NTR- or anti-nerve growth factor (NGF)-neutralizing antibodies. Importantly, small interference RNA-mediated suppression of endogenous sortilin significantly inhibited C2C12 differentiation, indicating the physiological significance of sortilin expression in the process of myogenesis. Although sortilin overexpression in C2C12 myotubes improved insulin-induced 2-deoxyglucose uptake, as previously reported, this effect apparently resulted from a decrease in the cellular content of GLUT1 and an increase in GLUT4 via differentiation dependent alterations at both the gene transcriptional and the post-translational level. In addition, cellular contents of Ubc9 and SUMO-modified proteins appeared to be increased by sortilin overexpression. Taken together, these data demonstrate that sortilin is involved not only in development of the insulin-responsive glucose transport system in myocytes, but is also directly involved in muscle differentiation via modulation of proNGF-p75NTR.	[Ariga, Miyako; Nedachi, Taku; Kanzaki, Makoto] Tohoku Univ, Div Biomat Biomed Engn Re Org, Aoba Ku, Sendai, Miyagi 9808575, Japan; [Ariga, Miyako; Katagiri, Hideki] Tohoku Univ, Grad Sch Pharmaceut Sci, 21st Century COE Program Cpmprehens Res, Sendai, Miyagi 9808575, Japan; [Ariga, Miyako; Katagiri, Hideki] Tohoku Univ, Grad Sch Pharmaceut Sci, Educ Ctr Planning Drug Dev & Clin Evaluat, Sendai, Miyagi 9808575, Japan; [Ariga, Miyako; Katagiri, Hideki] Tohoku Univ, Grad Sch Med, Ctr Translat & Adv Anim Res, Div Adv Therapeut Metab Dis, Sendai, Miyagi 9808575, Japan	Tohoku University; Tohoku University; Tohoku University; Tohoku University	Kanzaki, M (corresponding author), Tohoku Univ, Div Biomat Biomed Engn Re Org, Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	kanzakimakoto@mac.com	Kanzaki, Makoto/H-6680-2017	Kanzaki, Makoto/0000-0002-6884-2955; Nedachi, Taku/0000-0003-4462-0618				Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Bronfman FC, 2004, EMBO REP, V5, P867, DOI 10.1038/sj.embor.7400219; Castellani L, 2006, J BIOL CHEM, V281, P15249, DOI 10.1074/jbc.M601390200; Charrasse S, 2002, J CELL BIOL, V158, P953, DOI 10.1083/jcb.200202034; Charrasse S, 2006, MOL BIOL CELL, V17, P749, DOI 10.1091/mbc.E05-04-0284; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; DEHERREROS AG, 1989, J BIOL CHEM, V264, P9885; Erck C, 1998, J CELL PHYSIOL, V176, P22, DOI 10.1002/(SICI)1097-4652(199807)176:1<22::AID-JCP3>3.0.CO;2-A; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; FLORINI JR, 1991, J BIOL CHEM, V266, P15917; Giorgino F, 2000, P NATL ACAD SCI USA, V97, P1125, DOI 10.1073/pnas.97.3.1125; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; Hermans-Borgmeyer I, 1999, MOL BRAIN RES, V65, P216, DOI 10.1016/S0169-328X(99)00022-4; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; Kanzaki M, 2004, J BIOL CHEM, V279, P30622, DOI 10.1074/jbc.M401443200; Kanzaki M, 2006, ENDOCR J, V53, P267, DOI 10.1507/endocrj.KR-65; Koistinen HA, 2002, ANN MED, V34, P410, DOI 10.1080/078538902321012351; Lefrancois S, 2003, EMBO J, V22, P6430, DOI 10.1093/emboj/cdg629; Li LV, 2005, MOL ENDOCRINOL, V19, P2145, DOI 10.1210/me.2005-0032; Lin BZ, 1997, J BIOL CHEM, V272, P24145, DOI 10.1074/jbc.272.39.24145; Liu LB, 2007, DIABETES, V56, P1977, DOI 10.2337/db06-1100; Mazella J, 1998, J BIOL CHEM, V273, P26273, DOI 10.1074/jbc.273.41.26273; Mazella J, 2001, CELL SIGNAL, V13, P1, DOI 10.1016/S0898-6568(00)00130-3; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; MITSUMOTO Y, 1992, J BIOL CHEM, V267, P4957; MITSUMOTO Y, 1991, BIOCHEM BIOPH RES CO, V175, P652, DOI 10.1016/0006-291X(91)91615-J; Mizuguchi H, 1999, HUM GENE THER, V10, P2013, DOI 10.1089/10430349950017374; Mizuguchi H, 1998, HUM GENE THER, V9, P2577, DOI 10.1089/hum.1998.9.17-2577; Morris NJ, 1998, J BIOL CHEM, V273, P3582, DOI 10.1074/jbc.273.6.3582; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; Nedachi T, 2006, AM J PHYSIOL-ENDOC M, V291, pE817, DOI 10.1152/ajpendo.00194.2006; Nielsen MS, 1999, J BIOL CHEM, V274, P8832, DOI 10.1074/jbc.274.13.8832; Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180; Nishiyama T, 2004, J BIOL CHEM, V279, P47311, DOI 10.1074/jbc.M403546200; NUUTILA P, 1994, AM J PHYSIOL-ENDOC M, V267, pE941, DOI 10.1152/ajpendo.1994.267.6.E941; Nykjaer A, 2004, NATURE, V427, P843, DOI 10.1038/nature02319; Onishi M, 1996, EXP HEMATOL, V24, P324; Passino MA, 2007, SCIENCE, V315, P1853, DOI 10.1126/science.1137603; Peters EMJ, 2006, AM J PATHOL, V168, P221, DOI 10.2353/ajpath.2006.050163; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; Ralston E, 1996, J CELL SCI, V109, P2967; RALSTON E, 1993, J CELL BIOL, V120, P399, DOI 10.1083/jcb.120.2.399; Reddypalli S, 2005, J CELL PHYSIOL, V204, P819, DOI 10.1002/jcp.20330; Rende M, 2000, INT J DEV NEUROSCI, V18, P869, DOI 10.1016/S0736-5748(00)00041-1; Riquelme C, 2006, EXP CELL RES, V312, P2132, DOI 10.1016/j.yexcr.2006.03.016; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; Rudich A, 2003, ACTA PHYSIOL SCAND, V178, P297, DOI 10.1046/j.1365-201X.2003.01163.x; SANTALUCIA T, 1992, ENDOCRINOLOGY, V130, P837, DOI 10.1210/en.130.2.837; Seidl K, 1998, J CELL PHYSIOL, V176, P10, DOI 10.1002/(SICI)1097-4652(199807)176:1<10::AID-JCP2>3.0.CO;2-B; Shi J, 2005, DEV CELL, V9, P99, DOI 10.1016/j.devcel.2005.04.004; Shi J, 2007, J BIOL CHEM, V282, P9008, DOI 10.1074/jbc.M608971200; Shiba T, 2002, NATURE, V415, P937, DOI 10.1038/415937a; SHIBATA H, 1995, J BIOL CHEM, V270, P11489, DOI 10.1074/jbc.270.19.11489; Shibata H, 1996, J BIOL CHEM, V271, P9704, DOI 10.1074/jbc.271.16.9704; Shimokawa T, 1998, BIOCHEM BIOPH RES CO, V246, P287, DOI 10.1006/bbrc.1998.8600; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; Teng HK, 2005, J NEUROSCI, V25, P5455, DOI 10.1523/JNEUROSCI.5123-04.2005; Tortorella LL, 2002, AM J PHYSIOL-ENDOC M, V283, pE514, DOI 10.1152/ajpendo.00092.2002; WALKER PS, 1990, J BIOL CHEM, V265, P1516; Watson RT, 2004, EMBO J, V23, P2059, DOI 10.1038/sj.emboj.7600159; Wilson VG, 2001, EXP CELL RES, V271, P57, DOI 10.1006/excr.2001.5366; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Yamashita T, 2003, NAT NEUROSCI, V6, P461, DOI 10.1038/nn1045; Zeng JB, 2004, MOL REPROD DEV, V68, P469, DOI 10.1002/mrd.20097	65	45	46	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					10208	10220		10.1074/jbc.M710604200	http://dx.doi.org/10.1074/jbc.M710604200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18258592	hybrid			2022-12-25	WOS:000254671600073
J	Ghosh, AK; Ramakrishnan, G; Rajasekharan, R				Ghosh, Ananda K.; Ramakrishnan, Geetha; Rajasekharan, Ram			YLR099C (ICT1) encodes a soluble Acyl-CoA-dependent lysophosphatidic acid acyltransferase responsible for enhanced phospholipid synthesis on organic solvent stress in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA/BETA-HYDROLASE FOLD; ESCHERICHIA-COLI; CHOLESTEROL ACYLTRANSFERASE; TOLERANCE; YEAST; BIOSYNTHESIS; MEMBRANE; PROTEIN; TOLUENE; ADAPTATION	One of the major determinants of organic solvent tolerance is the increase in membrane phospholipids. Here we report for the first time that an increase in the synthesis of phosphatidic acid is responsible for enhanced phospholipid synthesis that confers tolerance to the organic solvent in Saccharomyces cerevisiae. This increase in phosphatidic acid formation is because of the induction of Ict1p, a soluble oleoyl-CoA: lysophosphatidic acid acyltransferase. YLR099C (ICT1) was reported to be maximally expressed during solvent tolerance (Miura, S., Zou, W., Ueda, M., and Tanaka, A. (2000) Appl. Environ. Microbiol. 66, 4883 4889); however, its physiological significance was not understood. In silico analysis revealed the absence of any transmembrane domain in Ict1p. Domain analysis showed that it has a hydrolase/acyltransferase domain with a distinct lipid-binding motif and a lysophospholipase domain. Analysis of ict1 Delta strain showed a drastic reduction in phosphatidic acid suggesting the role of Ict1p in phosphatidic acid biosynthesis. Overexpression of Ict1p in S. cerevisiae showed an increase in phosphatidic acid and other phospholipids on organic solvent exposure. To understand the biochemical function of Ict1p, the gene was cloned and expressed in Escherichia coli. The purified recombinant enzyme was found to specifically acylate lysophosphatidic acid. Specific activity of Ict1p was found to be higher for oleoyl-CoA as compared with palmitoyl- and stearoyl-CoAs. This study provides a mechanism for organic solvent tolerance from the point of membrane dynamics in S. cerevisiae.	[Ghosh, Ananda K.; Ramakrishnan, Geetha; Rajasekharan, Ram] Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India; [Rajasekharan, Ram] Monash Univ, Sch Arts & Sci, Petaling Jaya 46150, Malaysia	Indian Institute of Science (IISC) - Bangalore; Monash University; Monash University Sunway	Rajasekharan, R (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	lipid@biochem.iisc.ernet.in	Rajasekharan, Ram/R-2257-2019; R, Rajasekharan/D-3420-2009	Ram, Rajasekharan/0000-0002-4114-0654; Rajasekharan, Ram/0000-0002-2124-6013				Akiyama M, 2003, J INVEST DERMATOL, V121, P1029, DOI 10.1046/j.1523-1747.2003.12520.x; Athenstaedt K, 1999, EUR J BIOCHEM, V266, P1, DOI 10.1046/j.1432-1327.1999.00822.x; Benghezal M, 2007, J BIOL CHEM, V282, P30845, DOI 10.1074/jbc.M702719200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BUCKLEY JT, 1983, BIOCHEMISTRY-US, V22, P5490, DOI 10.1021/bi00293a006; COLEMAN J, 1990, J BIOL CHEM, V265, P17215; Engvall E, 1980, Methods Enzymol, V70, P419; Felsenstein J, 1996, METHOD ENZYMOL, V266, P418; Gangar A, 2001, J BIOL CHEM, V276, P10290, DOI 10.1074/jbc.M009550200; Heath RJ, 1998, J BACTERIOL, V180, P1425, DOI 10.1128/JB.180.6.1425-1430.1998; HEIPIEPER HJ, 1994, APPL ENVIRON MICROB, V60, P4440, DOI 10.1128/AEM.60.12.4440-4444.1994; HILTON S, 1991, J BIOL CHEM, V266, P997; INGRAM LO, 1986, TRENDS BIOTECHNOL, V4, P40, DOI 10.1016/0167-7799(86)90152-6; INOUE A, 1989, NATURE, V338, P264, DOI 10.1038/338264a0; Jain S, 2007, J BIOL CHEM, V282, P30562, DOI 10.1074/jbc.M706326200; Jonas A, 2000, BBA-MOL CELL BIOL L, V1529, P245, DOI 10.1016/S1388-1981(00)00153-0; Matsui K, 2006, APPL MICROBIOL BIOT, V71, P75, DOI 10.1007/s00253-006-0328-3; MELCHIOR DL, 1982, CURR TOP MEMBR TRANS, V17, P263; Miura S, 2000, APPL ENVIRON MICROB, V66, P4883, DOI 10.1128/AEM.66.11.4883-4889.2000; NAGIEC MM, 1993, J BIOL CHEM, V268, P22156; Nardini M, 1999, CURR OPIN STRUC BIOL, V9, P732, DOI 10.1016/S0959-440X(99)00037-8; Okazaki K, 2006, PLANT PHYSIOL, V141, P546, DOI 10.1104/pp.105.075796; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Pinkart HC, 1997, J BACTERIOL, V179, P4219, DOI 10.1128/jb.179.13.4219-4226.1997; Ramos JL, 2002, ANNU REV MICROBIOL, V56, P743, DOI 10.1146/annurev.micro.56.012302.161038; Ramos JL, 1997, J BIOL CHEM, V272, P3887, DOI 10.1074/jbc.272.7.3887; RIKHOT WR, 2006, BIOL CHEM, V281, P36588; RUSSELL NJ, 1985, J GEN MICROBIOL, V131, P781; Saha S, 2006, PLANT PHYSIOL, V141, P1533, DOI 10.1104/pp.106.082198; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Saulnier-Blache JS, 2000, J LIPID RES, V41, P1947; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Simon GM, 2006, J BIOL CHEM, V281, P26465, DOI 10.1074/jbc.M604660200; Singh SR, 2004, NUCLEIC ACIDS RES, V32, P201, DOI 10.1093/nar/gkh163; Tamaki H, 2007, J BIOL CHEM, V282, P34288, DOI 10.1074/jbc.M704509200; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wei YY, 1999, NAT STRUCT BIOL, V6, P340; WOLDRINGH CL, 1973, J BACTERIOL, V114, P1359, DOI 10.1128/JB.114.3.1359-1361.1973	38	53	56	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9768	9775		10.1074/jbc.M708418200	http://dx.doi.org/10.1074/jbc.M708418200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18252723	Green Published, hybrid			2022-12-25	WOS:000254671600031
J	Ecroyd, H; Koudelka, T; Thorn, DC; Williams, DM; Devlin, G; Hoffmann, P; Carver, JA				Ecroyd, Heath; Koudelka, Tomas; Thorn, David C.; Williams, Danielle M.; Devlin, Glyn; Hoffmann, Peter; Carver, John A.			Dissociation from the oligomeric state is the rate-limiting step in fibril formation by kappa-casein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE MAMMARY-GLAND; CORPORA-AMYLACEA; PROTEIN AGGREGATION; AMYLOID FIBRILS; IN-VITRO; SEQUENCE; PREDICTION; BEHAVIOR; REVEALS	Amyloid fibrils are aggregated and precipitated forms of protein in which the protein exists in highly ordered, long, unbranching threadlike formations that are stable and resistant to degradation by proteases. Fibril formation is an ordered process that typically involves the unfolding of a protein to partially folded states that subsequently interact and aggregate through a nucleation-dependent mechanism. Here we report on studies investigating the molecular basis of the inherent propensity of the milk protein, kappa-casein, to form amyloid fibrils. Using reduced and carboxymethylated kappa-casein ( RCM kappa-CN), we show that fibril formation is accompanied by a characteristic increase in thioflavin T fluorescence intensity, solution turbidity, and beta-sheet content of the protein. However, the lag phase of RCM kappa-CN fibril formation is independent of protein concentration, and the rate of fibril formation does not increase upon the addition of seeds ( preformed fibrils). Therefore, its mechanism of fibril formation differs from the archetypal nucleation-dependent aggregation mechanism. By digestion with trypsin or proteinase K and identification by mass spectrometry, we have determined that the region from Tyr(25) to Lys(86) is incorporated into the core of the fibrils. We suggest that this region, which is predicted to be aggregation-prone, accounts for the amyloidogenic nature of kappa-casein. Based on these data, we propose that fibril formation by RCM kappa-CN occurs through a novel mechanism whereby the rate-limiting step is the dissociation of an amyloidogenic precursor from an oligomeric state rather than the formation of stable nuclei, as has been described for most other fibril-forming systems.	[Ecroyd, Heath; Koudelka, Tomas; Thorn, David C.; Williams, Danielle M.; Carver, John A.] Univ Adelaide, Sch Chem & Phys, Adelaide, SA 5005, Australia; [Koudelka, Tomas; Hoffmann, Peter] Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia; [Devlin, Glyn] Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England	University of Adelaide; University of Adelaide; University of Cambridge	Ecroyd, H (corresponding author), Univ Adelaide, Sch Chem & Phys, Adelaide, SA 5005, Australia.	heath.ecroyd@adelaide.edu.au	Thorn, David/GSD-6867-2022; Carver, John Adrian/J-3825-2014; Ecroyd, Heath/E-7140-2015; Hoffmann, Peter/U-5996-2017	Thorn, David/0000-0002-7332-2292; Carver, John Adrian/0000-0002-2441-8108; Hoffmann, Peter/0000-0001-8493-2208; Ecroyd, Heath/0000-0001-7574-0044				BEEMS RB, 1978, VET PATHOL, V15, P347, DOI 10.1177/030098587801500309; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; Cappai R, 2005, FASEB J, V19, P1377, DOI 10.1096/fj.04-3437fje; Chiti F, 2003, NATURE, V424, P805, DOI 10.1038/nature01891; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; Claudon C, 1998, TISSUE CELL, V30, P589, DOI 10.1016/S0040-8166(98)80040-2; de la Paz ML, 2004, P NATL ACAD SCI USA, V101, P87, DOI 10.1073/pnas.2634884100; DEKRUIF CG, 1991, EUR J BIOCHEM, V200, P431, DOI 10.1111/j.1432-1033.1991.tb16201.x; Dobson CM, 2004, METHODS, V34, P4, DOI 10.1016/j.ymeth.2004.03.002; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Dubay KF, 2004, J MOL BIOL, V341, P1317, DOI 10.1016/j.jmb.2004.06.043; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; Ecroyd H, 2007, BIOCHEM J, V401, P129, DOI 10.1042/BJ20060981; Fandrich M, 2002, EMBO J, V21, P5682, DOI 10.1093/emboj/cdf573; Fandrich M, 2001, NATURE, V410, P165, DOI 10.1038/35065514; Farrell HM, 2003, J PROTEIN CHEM, V22, P259, DOI 10.1023/A:1025020503769; Fernandez-Escamilla AM, 2004, NAT BIOTECHNOL, V22, P1302, DOI 10.1038/nbt1012; FOX PF, 1998, ADV DAIRY CHEM, P165; Fox PF, 2003, ADV DAIRY CHEM 1 PRO, P9; Groves ML, 1998, J PROTEIN CHEM, V17, P73, DOI 10.1023/A:1022518613574; Guijarro JI, 1998, P NATL ACAD SCI USA, V95, P4224, DOI 10.1073/pnas.95.8.4224; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; KUMOSINSKI TF, 1993, J DAIRY SCI, V76, P2507, DOI 10.3168/jds.S0022-0302(93)77586-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai ZH, 1996, BIOCHEMISTRY-US, V35, P6470, DOI 10.1021/bi952501g; Li, 1999, Genome Inform Ser Workshop Genome Inform, V10, P30; Morgan PE, 2005, J AGR FOOD CHEM, V53, P2670, DOI 10.1021/jf048329h; Myers SL, 2006, RAPID COMMUN MASS SP, V20, P1628, DOI 10.1002/rcm.2482; NICKERSON SC, 1987, CYTOBIOS, V51, P81; NICKERSON SC, 1985, J DAIRY SCI, V68, P709, DOI 10.3168/jds.S0022-0302(85)80877-8; Niewold TA, 1999, AMYLOID, V6, P244, DOI 10.3109/13506129909007335; Nilsson MR, 2004, METHODS, V34, P151, DOI 10.1016/j.ymeth.2004.03.012; Pawar AP, 2005, J MOL BIOL, V350, P379, DOI 10.1016/j.jmb.2005.04.016; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; Prilusky J, 2005, BIOINFORMATICS, V21, P3435, DOI 10.1093/bioinformatics/bti537; RASMUSSEN LK, 1992, EUR J BIOCHEM, V207, P215, DOI 10.1111/j.1432-1033.1992.tb17040.x; REID IM, 1972, J COMP PATHOL, V82, P409, DOI 10.1016/0021-9975(72)90040-0; Ritter C, 2005, NATURE, V435, P844, DOI 10.1038/nature03793; Romero P, 2001, PROTEINS, V42, P38, DOI 10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; SUSI H, 1986, METHOD ENZYMOL, V130, P290; Syme CD, 2002, EUR J BIOCHEM, V269, P148, DOI 10.1046/j.0014-2956.2001.02633.x; Taniyama H, 2000, VET PATHOL, V37, P104, DOI 10.1354/vp.37-1-104; Thorn DC, 2005, BIOCHEMISTRY-US, V44, P17027, DOI 10.1021/bi051352r; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; VREEMAN HJ, 1981, BIOPHYS CHEM, V14, P185, DOI 10.1016/0301-4622(81)85018-1; Zandomeneghi G, 2004, PROTEIN SCI, V13, P3314, DOI 10.1110/ps.041024904	49	66	67	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9012	9022		10.1074/jbc.M709928200	http://dx.doi.org/10.1074/jbc.M709928200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18245081	Green Published, hybrid			2022-12-25	WOS:000254465800031
J	Hocking, HG; Herbert, AP; Kavanagh, D; Soares, DC; Ferreira, VP; Pangburn, MK; Uhrin, D; Barlow, PN				Hocking, Henry G.; Herbert, Andrew P.; Kavanagh, David; Soares, Dinesh C.; Ferreira, Viviana P.; Pangburn, Michael K.; Uhrin, Dusan; Barlow, Paul N.			Structure of the N-terminal region of complement factor H and conformational implications of disease-linked sequence variations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE COFACTOR PROTEIN; ALTERNATIVE PATHWAY; REGULATORY DOMAINS; BINDING-SITES; NEUTRON-SCATTERING; CRYSTAL-STRUCTURE; COMPONENT C3; NMR; DECAY; ACTIVATION	Factor H is a regulatory glycoprotein of the complement system. We expressed the three N-terminal complement control protein modules of human factor H (FH1-3) and confirmed FH1-3 to be the minimal unit with cofactor activity for C3b proteolysis by factor I. We reconstructed FH1-3 from NMR-derived structures of FH1-2 and FH2-3 revealing an similar to 105-angstrom-long rod-like arrangement of the modules. In structural comparisons with other C3b-engaging proteins, factor H module 3 most closely resembles factor B module 3, consistent with factor H competing with factor B for binding C3b. Factor H modules 1, 2, and 3 each has a similar backbone structure to first, second, and third modules, respectively, of functional sites in decay accelerating factor and complement receptor type 1; the equivalent intermodular tilt and twist angles are also broadly similar. Resemblance between molecular surfaces is closest for first modules but absent in the case of second modules. Substitution of buried Val-62 with Ile (a factor H single nucleotide polymorphism potentially protective for age-related macular degeneration and dense deposit disease) causes rearrangements within the module 1 core and increases thermal stability but does not disturb the interface with module 2. Replacement of partially exposed (in module 1) Arg-53 by His (an atypical hemolytic uremic syndrome-linked mutation) did not impair structural integrity at 37 C, but this FH1-2 mutant was less stable at higher temperatures; furthermore, chemical shift differences indicated potential for small structural changes at the module 1-2 interface.	[Hocking, Henry G.; Herbert, Andrew P.; Kavanagh, David; Soares, Dinesh C.; Uhrin, Dusan; Barlow, Paul N.] Univ Edinburgh, Sch Chem, Edinburgh Biomol NMR Unit, Edinburgh EH9 3JJ, Midlothian, Scotland; [Hocking, Henry G.; Herbert, Andrew P.; Kavanagh, David; Soares, Dinesh C.; Uhrin, Dusan; Barlow, Paul N.] Univ Edinburgh, Sch Biol Sci, Edinburgh EH9 3JJ, Midlothian, Scotland; [Soares, Dinesh C.] Univ Edinburgh, Western Gen Hosp, Mol Med Ctr, Med Genet Sect, Edinburgh EH4 2XU, Midlothian, Scotland; [Ferreira, Viviana P.; Pangburn, Michael K.] Univ Texas Hlth Sci Ctr Tyler, Dept Biochem, Tyler, TX 75708 USA	University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Texas System; University of Texas-Health Sciences Center at Tyler (UTHSCT)	Barlow, PN (corresponding author), Univ Edinburgh, Sch Chem, Edinburgh Biomol NMR Unit, Joseph Black Chem Bldg,W Mains Rd, Edinburgh EH9 3JJ, Midlothian, Scotland.	Paul.Barlow@ed.ac.uk	Soares, Dinesh C/A-4425-2012; Kavanagh, David/E-8498-2011; Herbert, Andy P/F-6693-2010; Barlow, Paul N/G-2853-2011; Herbert, Andrew P/C-4755-2008; Mohammed, Imran/J-8271-2012	Soares, Dinesh C/0000-0001-7557-0495; Kavanagh, David/0000-0003-4718-0072; Herbert, Andy P/0000-0002-4549-6965; Herbert, Andrew P/0000-0002-4549-6965; Mohammed, Imran/0000-0002-8412-0768; Ferreira, Viviana/0000-0001-8923-5671; Hocking, Henry/0000-0003-0933-9265	Medical Research Council Funding Source: Medline; Wellcome Trust Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315; Alam MN, 2004, J IMMUNOL METHODS, V293, P107, DOI 10.1016/j.jim.2004.07.005; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Ball G, 2006, J MAGN RESON, V180, P127, DOI 10.1016/j.jmr.2006.01.017; BARLOW PN, 1993, J MOL BIOL, V232, P268, DOI 10.1006/jmbi.1993.1381; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Biro A, 2006, MOL DIAGN THER, V10, P303, DOI 10.1007/BF03256205; Blackmore TK, 1998, J IMMUNOL, V160, P3342; Blom AM, 2001, J BIOL CHEM, V276, P27136, DOI 10.1074/jbc.M102445200; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; Brodbeck WG, 1996, J IMMUNOL, V156, P2528; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Canutescu AA, 2003, PROTEIN SCI, V12, P2001, DOI 10.1110/ps.03154503; Casasnovas JM, 1999, EMBO J, V18, P2911, DOI 10.1093/emboj/18.11.2911; Cavanagh J, 2007, PROTEIN NMR SPECTROSCOPY: PRINCIPLES AND PRACTICE, 2ND EDITION, P1; de Cordoba SR, 1999, MOL IMMUNOL, V36, P803, DOI 10.1016/S0161-5890(99)00100-5; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Ferreira VP, 2006, J IMMUNOL, V177, P6308, DOI 10.4049/jimmunol.177.9.6308; Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8; Fraczkiewicz R, 1998, J COMPUT CHEM, V19, P319, DOI 10.1002/(SICI)1096-987X(199802)19:3<319::AID-JCC6>3.0.CO;2-W; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; Golovanov AP, 2004, J AM CHEM SOC, V126, P8933, DOI 10.1021/ja049297h; GORDON DL, 1995, J IMMUNOL, V155, P348; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102; Harris CL, 2007, J IMMUNOL, V178, P352, DOI 10.4049/jimmunol.178.1.352; Hellwage J, 2002, J IMMUNOL, V169, P6935, DOI 10.4049/jimmunol.169.12.6935; Herbert AP, 2006, J BIOL CHEM, V281, P16512, DOI 10.1074/jbc.M513611200; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11259, DOI 10.1021/bi00093a001; Janssen BJC, 2006, NATURE, V444, P213, DOI 10.1038/nature05172; Janssen BJC, 2005, NATURE, V437, P505, DOI 10.1038/nature04005; Jenkins HT, 2006, J BIOL CHEM, V281, P3690, DOI 10.1074/jbc.M511563200; Jokiranta TS, 2000, J BIOL CHEM, V275, P27657; Jokiranta TS, 2005, AM J PATHOL, V167, P1173, DOI 10.1016/S0002-9440(10)61205-9; Jokiranta TS, 1996, FEBS LETT, V393, P297; Kavanagh D, 2006, BRIT MED BULL, V77-78, P5, DOI 10.1093/bmb/ldl004; Kirkitadze MD, 2001, IMMUNOL REV, V180, P146, DOI 10.1034/j.1600-065X.2001.1800113.x; KRISTENSEN T, 1986, P NATL ACAD SCI USA, V83, P3963, DOI 10.1073/pnas.83.11.3963; Krych-Goldberg M, 2001, IMMUNOL REV, V180, P112, DOI 10.1034/j.1600-065X.2001.1800110.x; Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017; KUHN S, 1995, J IMMUNOL, V155, P5663; Kuttner-Kondo LA, 2001, J IMMUNOL, V167, P2164, DOI 10.4049/jimmunol.167.4.2164; Kuttner-Kondo L, 2007, J BIOL CHEM, V282, P18552, DOI 10.1074/jbc.M611650200; Liszewski MK, 2000, J BIOL CHEM, V275, P37692, DOI 10.1074/jbc.M004650200; Lukacik P, 2004, P NATL ACAD SCI USA, V101, P1279, DOI 10.1073/pnas.0307200101; McRae JL, 2002, GENETICA, V114, P157, DOI 10.1023/A:1015114512924; MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982; Milder FJ, 2007, NAT STRUCT MOL BIOL, V14, P224, DOI 10.1038/nsmb1210; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Mullick J, 2005, J VIROL, V79, P12382, DOI 10.1128/JVI.79.19.12382-12393.2005; Murthy KHM, 2001, CELL, V104, P301, DOI 10.1016/S0092-8674(01)00214-8; Nishida N, 2006, P NATL ACAD SCI USA, V103, P19737, DOI 10.1073/pnas.0609791104; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Pangburn MK, 2000, J IMMUNOL, V164, P4742, DOI 10.4049/jimmunol.164.9.4742; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; Perkins SJ, 2002, BIOCHEM SOC T, V30, P996, DOI 10.1042/bst0300996; Perkins SJ, 2008, METHOD CELL BIOL, V84, P375, DOI 10.1016/S0091-679X(07)84013-1; Permi P, 1999, J MAGN RESON, V141, P44, DOI 10.1006/jmre.1999.1886; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sass HJ, 2001, J BIOMOL NMR, V21, P275, DOI 10.1023/A:1012998006281; Saunders RE, 2007, HUM MUTAT, V28, P222, DOI 10.1002/humu.20435; Schubert M, 2002, J BIOMOL NMR, V24, P149, DOI 10.1023/A:1020997118364; Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996; Shindyalov IN, 1998, PROTEIN ENG, V11, P739, DOI 10.1093/protein/11.9.739; Sitkoff D, 1996, J PHYS CHEM-US, V100, P2744, DOI 10.1021/jp952986i; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; Smith BO, 2002, CELL, V108, P769, DOI 10.1016/S0092-8674(02)00672-4; Soares DC, 2005, STRUCTURAL BIOLOGY OF THE COMPLEMENT SYSTEM, P19; Soares DC, 2005, PROTEIN ENG DES SEL, V18, P379, DOI 10.1093/protein/gzi039; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tina KG, 2007, NUCLEIC ACIDS RES, V35, pW473, DOI 10.1093/nar/gkm423; Tjandra N, 1995, J AM CHEM SOC, V117, P12562, DOI 10.1021/ja00155a020; Vranken WF, 2005, PROTEINS, V59, P687, DOI 10.1002/prot.20449; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; Wiesmann C, 2006, NATURE, V444, P217, DOI 10.1038/nature05263; Zuiderweg ERP, 2002, BIOCHEMISTRY-US, V41, P1, DOI 10.1021/bi011870b	81	52	54	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9475	9487		10.1074/jbc.M709587200	http://dx.doi.org/10.1074/jbc.M709587200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18252712	Green Published, hybrid			2022-12-25	WOS:000254465800077
J	Itoh, S; Kim, HW; Nakagawa, O; Ozumi, K; Lessner, SM; Aoki, H; Akram, K; McKinney, RD; Ushio-Fukai, M; Fukai, T				Itoh, Shinichi; Kim, Ha Won; Nakagawa, Osamu; Ozumi, Kiyoshi; Lessner, Susan M.; Aoki, Hiroki; Akram, Kamran; McKinney, Ronald D.; Ushio-Fukai, Masuko; Fukai, Tohru			Novel role of antioxidant-1 (Atox1) as a copper-dependent transcription factor involved in cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-LOCALIZATION SIGNAL; ANGIOTENSIN-II; LYSYL OXIDASE; DNA-BINDING; PROTEIN; GENE; TETRATHIOMOLYBDATE; METALLOCHAPERONE; METALLOTHIONEIN; CERULOPLASMIN	Copper plays a fundamental role in regulating cell growth. Many types of human cancer tissues have higher copper levels than normal tissues. Copper can also induce gene expression. However, transcription factors that mediate copper-induced cell proliferation have not been identified in mammals. Here we show that antioxidant-1 (Atox1), previously appreciated as a copper chaperone, represents a novel copper-dependent transcription factor that mediates copper-induced cell proliferation. Stimulation of mouse embryonic fibroblasts (MEFs) with copper markedly increased cell proliferation, cyclin D1 expression, and entry into S phase, which were completely abolished in Atox1(-/-) MEFs. Promoter analysis and EMSA revealed that copper stimulates the Atox1 binding to a previously undescribed cis element in the cyclin D1 promoter. The ChIP assay confirms that copper stimulates Atox1 binding to the DNA in vivo. Transfection of Atox1 fused to the DNA-binding domain of Gal4 demonstrated a copper-dependent transactivation in various cell types, including endothelial and cancer cells. Furthermore, Atox1 translocated to the nucleus in response to copper through its highly conserved C-terminal KKTGK motif and N-terminal copper-binding sites. Finally, the functional role of nuclear Atox1 is demonstrated by the observation that re-expression of nuclear-targeted Atox1 in Atox1(-/-) MEFs rescued the defective copper- induced cell proliferation. Thus, Atox1 functions as a novel transcription factor that, when activated by copper, undergoes nuclear translocation, DNA binding, and transactivation, thereby contributing to cell proliferation.	[Itoh, Shinichi; Kim, Ha Won; Ozumi, Kiyoshi; Akram, Kamran; Ushio-Fukai, Masuko; Fukai, Tohru] Emory Univ, Sch Med, Div Cardiol, Dept Med, Atlanta, GA 30322 USA; [Kim, Ha Won; Ozumi, Kiyoshi; McKinney, Ronald D.; Fukai, Tohru] Univ Illinois, Cardiovasc Res Ctr, Dept Med, Cardiol Sect, Chicago, IL 60612 USA; [Kim, Ha Won; Ozumi, Kiyoshi; McKinney, Ronald D.; Fukai, Tohru] Univ Illinois, Cardiovasc Res Ctr, Dept Pharmacol, Chicago, IL 60612 USA; [Nakagawa, Osamu] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Cardiol, Dallas, TX 75390 USA; [Nakagawa, Osamu] Univ Texas SW Med Ctr Dallas, Dept Mol Biol, Div Cardiol, Dallas, TX 75390 USA; [Lessner, Susan M.] Univ S Carolina, Sch Med, Dept Cell & Dev Biol & Anat, Columbia, SC 29208 USA; [Akram, Kamran] Yamaguchi Univ, Sch Med, Dept Mol Cardiovasc Biol, Yamaguchi 7558505, Japan; [McKinney, Ronald D.; Ushio-Fukai, Masuko] Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA	Emory University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Yamaguchi University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Fukai, T (corresponding author), 835 S Wolcott,M-C868,E403 MSB, Chicago, IL 60612 USA.	tfukai@uic.edu		Lessner, Susan/0000-0002-8409-5216; Kim, Ha Won/0000-0001-6272-4248	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077524, P01HL058000, R01HL070187] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 077524, R01 HL077524, R01 HL 70187, P01 HL 58000] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNOLD M, 1961, CANCER RES, V21, P761; Birkaya B, 2005, J NEUROBIOL, V63, P49, DOI 10.1002/neu.20114; Brewer GJ, 2005, CURR CANCER DRUG TAR, V5, P195, DOI 10.2174/1568009053765807; Brewer GJ, 2000, CLIN CANCER RES, V6, P1; Chan CK, 1998, GENE THER, V5, P1204, DOI 10.1038/sj.gt.3300708; CHU FF, 1985, BIOCHEM BIOPH RES CO, V126, P15, DOI 10.1016/0006-291X(85)90565-0; Culotta V.C., 2001, METABOLIC MOL BASES, P3105; Daniel KG, 2004, FRONT BIOSCI-LANDMRK, V9, P2652, DOI 10.2741/1424; FISCHERFANTUZZI L, 1988, MOL CELL BIOL, V8, P5495, DOI 10.1128/MCB.8.12.5495; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; FUCHS AG, 1989, ONCOLOGY, V46, P183; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; Goodman VL, 2004, ENDOCR-RELAT CANCER, V11, P255, DOI 10.1677/erc.0.0110255; Hamza I, 2003, P NATL ACAD SCI USA, V100, P1215, DOI 10.1073/pnas.0336230100; Hamza I, 2001, P NATL ACAD SCI USA, V98, P6848, DOI 10.1073/pnas.111058498; Harris ED, 2004, NUTR REV, V62, P60, DOI 10.1301/nr.2004.feb.60-64; Hellman NE, 2002, ANNU REV NUTR, V22, P439, DOI 10.1146/annurev.nutr.22.012502.114457; Hu GF, 1998, J CELL BIOCHEM, V69, P326, DOI 10.1002/(SICI)1097-4644(19980601)69:3<326::AID-JCB10>3.0.CO;2-A; Hung IH, 1998, J BIOL CHEM, V273, P1749, DOI 10.1074/jbc.273.3.1749; Huster D, 2006, AM J PATHOL, V168, P423, DOI 10.2353/ajpath.2006.050312; Jeney V, 2005, CIRC RES, V96, P723, DOI 10.1161/01.RES.0000162001.57896.66; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kim HW, 2007, CIRC RES, V101, P409, DOI 10.1161/CIRCRESAHA.107.153791; Lin SJ, 1997, J BIOL CHEM, V272, P9215; LINDER MC, 1991, BIOCH COPPER, P1; Mandinov L, 2003, P NATL ACAD SCI USA, V100, P6700, DOI 10.1073/pnas.1231994100; MCAUSLAN BR, 1980, T OPHTHAL SOC UK, V100, P354; Moore SDP, 2002, MAMM GENOME, V13, P563, DOI 10.1007/s00335-002-2172-9; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Palmeri D, 1999, MOL CELL BIOL, V19, P1218; Payne SL, 2005, CANCER RES, V65, P11429, DOI 10.1158/0008-5472.CAN-05-1274; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Percival SS, 1998, AM J CLIN NUTR, V67, p1064S, DOI 10.1093/ajcn/67.5.1064S; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Redman BG, 2003, CLIN CANCER RES, V9, P1666; Rosenzweig AC, 2001, ACCOUNTS CHEM RES, V34, P119, DOI 10.1021/ar000012p; Rucker RB, 1998, AM J CLIN NUTR, V67, p996S, DOI 10.1093/ajcn/67.5.996S; Sen CK, 2002, AM J PHYSIOL-HEART C, V282, pH1821, DOI 10.1152/ajpheart.01015.2001; Ushio-Fukai M, 2002, CIRC RES, V91, P1160, DOI 10.1161/01.RES.0000046227.65158.F8; Ushio-Fukai M, 2001, ARTERIOSCL THROM VAS, V21, P489, DOI 10.1161/01.ATV.21.4.489; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; Volker W, 1997, ATHEROSCLEROSIS, V130, P29, DOI 10.1016/S0021-9150(96)06039-X; Wernimont AK, 2000, NAT STRUCT BIOL, V7, P766; WINGE DR, 1985, J BIOL CHEM, V260, P4464; Winge DR, 1997, J BIOL INORG CHEM, V2, P2, DOI 10.1007/s007750050100	45	177	184	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9157	9167		10.1074/jbc.M709463200	http://dx.doi.org/10.1074/jbc.M709463200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18245776	Green Published, hybrid			2022-12-25	WOS:000254465800045
J	Sanderson, LM; de Groot, PJ; Hooiveld, GJEJ; Koppen, A; Kalkhoven, E; Muller, M; Kersten, S				Sanderson, Linda M.; de Groot, Philip J.; Hooiveld, Guido J. E. J.; Koppen, Arjen; Kalkhoven, Eric; Mueller, Michael; Kersten, Sander			Effect of Synthetic Dietary Triglycerides: A Novel Research Paradigm for Nutrigenomics	PLOS ONE			English	Article								Background: The effect of dietary fats on human health and disease are likely mediated by changes in gene expression. Several transcription factors have been shown to respond to fatty acids, including SREBP-1c, NF-kappa B, RXRs, LXRs, FXR, HNF4 alpha, and PPARs. However, it is unclear to what extent these transcription factors play a role in gene regulation by dietary fatty acids in vivo. Methodology/Principal Findings: Here, we take advantage of a unique experimental design using synthetic triglycerides composed of one single fatty acid in combination with gene expression profiling to examine the effects of various individual dietary fatty acids on hepatic gene expression in mice. We observed that the number of significantly changed genes and the fold-induction of genes increased with increasing fatty acid chain length and degree of unsaturation. Importantly, almost every single gene regulated by dietary unsaturated fatty acids remained unaltered in mice lacking PPAR alpha. In addition, the majority of genes regulated by unsaturated fatty acids, especially docosahexaenoic acid, were also regulated by the specific PPARa agonist WY14643. Excellent agreement was found between the effects of unsaturated fatty acids on mouse liver versus cultured rat hepatoma cells. Interestingly, using Nuclear Receptor PamChip (R) Arrays, fatty acid-and WY14643-induced interactions between PPARa and coregulators were found to be highly similar, although several PPAR alpha-coactivator interactions specific for WY14643 were identified. Conclusions/Significance: We conclude that the effects of dietary unsaturated fatty acids on hepatic gene expression are almost entirely mediated by PPAR alpha and mimic those of synthetic PPAR alpha agonists in terms of regulation of target genes and molecular mechanism. Use of synthetic dietary triglycerides may provide a novel paradigm for nutrigenomics research.	[Sanderson, Linda M.; de Groot, Philip J.; Hooiveld, Guido J. E. J.; Mueller, Michael; Kersten, Sander] Top Inst Food & Nutr, Nutrigenom Consortium, Wageningen, Netherlands; [Sanderson, Linda M.; de Groot, Philip J.; Hooiveld, Guido J. E. J.; Mueller, Michael; Kersten, Sander] Wageningen Univ, Div Human Nutrition, Nutrition, Metabolism & Genom Grp, Wageningen, Netherlands; [Koppen, Arjen; Kalkhoven, Eric] Univ Med Ctr UMC Utrecht, Dept Metabolic & Endocrine Dis, Utrecht, Netherlands	Top Institute Food & Nutrition; Wageningen University & Research	Sanderson, LM (corresponding author), Top Inst Food & Nutr, Nutrigenom Consortium, Wageningen, Netherlands.	sander.kersten@wur.nl	Kersten, Sander/A-1116-2011; Muller, Michael/B-5795-2008; Hooiveld, Guido JEJ/F-4912-2010; Muller, Michael/M-5724-2019; Koppen, Arjen/GLV-6743-2022	Kersten, Sander/0000-0003-4488-7734; Muller, Michael/0000-0002-5930-9905; Hooiveld, Guido JEJ/0000-0003-1954-3542; Muller, Michael/0000-0002-5930-9905; 				Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Berger JP, 2003, MOL ENDOCRINOL, V17, P662, DOI 10.1210/me.2002-0217; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Cheatham CL, 2006, AM J CLIN NUTR, V83, p1458S, DOI 10.1093/ajcn/83.6.1458S; de Urquiza AM, 2000, SCIENCE, V290, P2140, DOI 10.1126/science.290.5499.2140; Dhe-Paganon S, 2002, J BIOL CHEM, V277, P37973, DOI 10.1074/jbc.C200420200; Duez H, 2005, ARTERIOSCL THROM VAS, V25, P585, DOI 10.1161/01.ATV.0000154140.73570.00; Duval C, 2007, BBA-MOL CELL BIOL L, V1771, P961, DOI 10.1016/j.bbalip.2007.05.003; Egea PF, 2002, MOL ENDOCRINOL, V16, P987, DOI 10.1210/me.16.5.987; Fan YY, 2003, CARCINOGENESIS, V24, P1541, DOI 10.1093/carcin/bgg110; Feige JN, 2007, J BIOL CHEM, V282, P19152, DOI 10.1074/jbc.M702724200; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Goldstein JT, 2003, ARCH BIOCHEM BIOPHYS, V420, P185, DOI 10.1016/j.abb.2003.09.034; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; Goudriaan JR, 2002, MOL CELL BIOCHEM, V239, P199, DOI 10.1023/A:1020575412789; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; Hannah VC, 2001, J BIOL CHEM, V276, P4365, DOI 10.1074/jbc.M007273200; Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036; Harris WS, 2006, CURR OPIN LIPIDOL, V17, P387, DOI 10.1097/01.mol.0000236363.63840.16; Heneweer M, 2007, TOXICOL SCI, V99, P303, DOI 10.1093/toxsci/kfm151; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710; ISSEMANN I, 1993, J MOL ENDOCRINOL, V11, P37, DOI 10.1677/jme.0.0110037; KATAN MB, 1995, CAN J CARDIOL, V11, pG36; KATAN MB, 1994, AM J CLIN NUTR, V60, p1017S, DOI 10.1093/ajcn/60.6.1017S; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; Lambert MS, 1998, BRIT J NUTR, V79, P203, DOI 10.1079/BJN19980032; Leaf A, 2007, CURR OPIN LIPIDOL, V18, P31, DOI 10.1097/MOL.0b013e328012d61b; Lee HK, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-269; Lengqvist J, 2004, MOL CELL PROTEOMICS, V3, P692, DOI 10.1074/mcp.M400003-MCP200; Lichtenstein L, 2007, ARTERIOSCL THROM VAS, V27, P2420, DOI 10.1161/ATVBAHA.107.151894; Martin PGP, 2007, HEPATOLOGY, V45, P767, DOI 10.1002/hep.21510; Mozaffarian D, 2006, NEW ENGL J MED, V354, P1601, DOI 10.1056/NEJMra054035; Ou JF, 2001, P NATL ACAD SCI USA, V98, P6027, DOI 10.1073/pnas.111138698; Ouamrane L, 2003, BRIT J PHARMACOL, V138, P845, DOI 10.1038/sj.bjp.0705113; Patsouris D, 2006, ENDOCRINOLOGY, V147, P1508, DOI 10.1210/en.2005-1132; PEGORIER JP, 2006, NUCL RECEPTORS CONTR; Pounds S, 2004, BIOINFORMATICS, V20, P1737, DOI 10.1093/bioinformatics/bth160; Radominska-Pandya A, 2002, BIOCHEMISTRY-US, V41, P4883, DOI 10.1021/bi0121151; Ren B, 1997, J BIOL CHEM, V272, P26827, DOI 10.1074/jbc.272.43.26827; Ruxton CHS, 2004, J HUM NUTR DIET, V17, P449, DOI 10.1111/j.1365-277X.2007.00770.x; Sampath H, 2005, ANNU REV NUTR, V25, P317, DOI 10.1146/annurev.nutr.25.051804.101917; Smyth G.K., 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1027; Stafslien DK, 2007, MOL CELL ENDOCRINOL, V264, P82, DOI 10.1016/j.mce.2006.10.016; Storey JD, 2003, ANN STAT, V31, P2013, DOI 10.1214/aos/1074290335; Stuhlmeier KM, 1997, J BIOL CHEM, V272, P24679, DOI 10.1074/jbc.272.39.24679; Vanden Heuvel JP, 2006, TOXICOL SCI, V92, P476, DOI 10.1093/toxsci/kfl014; VONHEYDEBRECK A, 2004, BIOCONDUCTOR PROJECT, V7; Wang XW, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng154; Wieneke N, 2007, FEBS LETT, V581, P5617, DOI 10.1016/j.febslet.2007.11.011; Wisely GB, 2002, STRUCTURE, V10, P1225, DOI 10.1016/S0969-2126(02)00829-8; Worgall TS, 1998, J BIOL CHEM, V273, P25537, DOI 10.1074/jbc.273.40.25537; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Xu J, 1999, J BIOL CHEM, V274, P23577, DOI 10.1074/jbc.274.33.23577; Yahagi N, 1999, J BIOL CHEM, V274, P35840, DOI 10.1074/jbc.274.50.35840; Yoshikawa T, 2002, J BIOL CHEM, V277, P1705, DOI 10.1074/jbc.M105711200; Zhang F, 2007, PPAR RES, V2007, DOI 10.1155/2007/32696; Zhao A, 2004, DNA CELL BIOL, V23, P519, DOI 10.1089/1044549041562267	63	81	82	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2008	3	2							e1681	10.1371/journal.pone.0001681	http://dx.doi.org/10.1371/journal.pone.0001681			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XS	18301758	gold, Green Published, Green Submitted			2022-12-25	WOS:000260586500025
J	Delaunay, A; Bromberg, KD; Hayashi, Y; Mirabella, M; Burch, D; Kirkwood, B; Serra, C; Malicdan, MC; Mizisin, AP; Morosetti, R; Broccolini, A; Guo, LT; Jones, SN; Lira, SA; Puri, PL; Shelton, GD; Ronai, Z				Delaunay, Agnes; Bromberg, Kenneth D.; Hayashi, Yukiko; Mirabella, Massimiliano; Burch, Denise; Kirkwood, Brian; Serra, Carlo; Malicdan, May C.; Mizisin, Andrew P.; Morosetti, Roberta; Broccolini, Aldobrando; Guo, Ling T.; Jones, Stephen N.; Lira, Sergio A.; Puri, Pier Lorenzo; Shelton, G. Diane; Ronai, Ze'ev			The ER-Bound RING Finger Protein 5 (RNF5/RMA1) Causes Degenerative Myopathy in Transgenic Mice and Is Deregulated in Inclusion Body Myositis	PLOS ONE			English	Article								Growing evidence supports the importance of ubiquitin ligases in the pathogenesis of muscular disorders, although underlying mechanisms remain largely elusive. Here we show that the expression of RNF5 (aka RMA1), an ER-anchored RING finger E3 ligase implicated in muscle organization and in recognition and processing of malfolded proteins, is elevated and mislocalized to cytoplasmic aggregates in biopsies from patients suffering from sporadic-Inclusion Body Myositis (sIBM). Consistent with these findings, an animal model for hereditary IBM (hIBM), but not their control littermates, revealed deregulated expression of RNF5. Further studies for the role of RNF5 in the pathogenesis of s-IBM and more generally in muscle physiology were performed using RNF5 transgenic and KO animals. Transgenic mice carrying inducible expression of RNF5, under control of beta-actin or muscle specific promoter, exhibit an early onset of muscle wasting, muscle degeneration and extensive fiber regeneration. Prolonged expression of RNF5 in the muscle also results in the formation of fibers containing congophilic material, blue-rimmed vacuoles and inclusion bodies. These phenotypes were associated with altered expression and activity of ER chaperones, characteristic of myodegenerative diseases such as s-IBM. Conversely, muscle regeneration and induction of ER stress markers were delayed in RNF5 KO mice subjected to cardiotoxin treatment. While supporting a role for RNF5 Tg mice as model for s-IBM, our study also establishes the importance of RNF5 in muscle physiology and its deregulation in ER stress associated muscular disorders.	[Delaunay, Agnes; Burch, Denise; Kirkwood, Brian; Serra, Carlo; Puri, Pier Lorenzo; Ronai, Ze'ev] Burnham Inst Med Res, La Jolla, CA USA; [Bromberg, Kenneth D.] Mount Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY USA; [Hayashi, Yukiko; Malicdan, May C.] Natl Inst Neurosci, Tokyo, Japan; [Mirabella, Massimiliano; Morosetti, Roberta; Broccolini, Aldobrando] Catholic Univ, Dept Neurosci, Rome, Italy; [Mizisin, Andrew P.; Guo, Ling T.; Shelton, G. Diane] Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA USA; [Jones, Stephen N.] Univ Massachusetts, Med Sci, Dept Cell Biol, Worcester, MA USA; [Lira, Sergio A.] Mount Sinai Sch Med, Immunobiol Ctr, New York, NY USA; [Puri, Pier Lorenzo] Fdn European Brain Res Inst, Dulbecco Telethon Inst, Rome, Italy	Sanford Burnham Prebys Medical Discovery Institute; Icahn School of Medicine at Mount Sinai; National Center for Neurology & Psychiatry - Japan; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of California System; University of California San Diego; University of Massachusetts System; University of Massachusetts Worcester; Icahn School of Medicine at Mount Sinai; Fondazione Telethon; Dulbecco Telethon Institute (DTI)	Delaunay, A (corresponding author), Burnham Inst Med Res, La Jolla, CA USA.	ronai@burnham.org	MIRABELLA, Massimiliano/AAC-4016-2020; Broccolini, Aldobrando/ABE-1311-2021; MOROSETTI, ROBERTA/ABE-1045-2021; Malicdan, May Christine/AAK-7422-2021; Malicdan, May Christine/F-2806-2013; Delaunay-moisan, Agnes/GRX-7749-2022	MIRABELLA, Massimiliano/0000-0002-7783-114X; MOROSETTI, ROBERTA/0000-0001-5017-4904; Delaunay-moisan, Agnes/0000-0003-3105-221X; Puri, Pier Lorenzo/0000-0003-4964-0095; RONAI, ZEEV/0000-0002-3859-0400	NCI [CA097105]; Fondazione Telethon Funding Source: Custom; NATIONAL CANCER INSTITUTE [R01CA097105] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Fondazione Telethon(Fondazione Telethon); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Support by NCI (CA097105 to ZR) is gratefully acknowledged.	Acosta-Alvear D, 2007, MOL CELL, V27, P53, DOI 10.1016/j.molcel.2007.06.011; Askanas V, 2006, NEUROLOGY, V66, pS39, DOI 10.1212/01.wnl.0000192128.13875.1e; Blais A, 2005, GENE DEV, V19, P553, DOI 10.1101/gad.1281105; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Boonyarom O, 2006, ACTA PHYSIOL, V188, P77, DOI 10.1111/j.1748-1716.2006.01613.x; Broday L, 2004, J CELL BIOL, V165, P857, DOI 10.1083/jcb.200401133; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Clarke BA, 2007, CELL METAB, V6, P376, DOI 10.1016/j.cmet.2007.09.009; DALBIS A, 1989, DEV BIOL, V135, P320, DOI 10.1016/0012-1606(89)90182-6; Didier C, 2003, MOL CELL BIOL, V23, P5331, DOI 10.1128/MCB.23.15.5331-5345.2003; Dubowitz V., 1985, MUSCLE BIOPSY PRACTI; Fielitz J, 2007, P NATL ACAD SCI USA, V104, P4377, DOI 10.1073/pnas.0611726104; Frosk P, 2002, AM J HUM GENET, V70, P663, DOI 10.1086/339083; Ghersa P, 1998, GENE THER, V5, P1213, DOI 10.1038/sj.gt.3300713; Glass DJ, 2003, NAT CELL BIOL, V5, P87, DOI 10.1038/ncb0203-87; Gomez TS, 2005, NAT IMMUNOL, V6, P261, DOI 10.1038/ni1168; Gorza L, 2000, FASEB J, V14, P461, DOI 10.1096/fasebj.14.3.461; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Hishiya A, 2006, EMBO J, V25, P554, DOI 10.1038/sj.emboj.7600945; Iioka H, 2007, NAT CELL BIOL, V9, P813, DOI 10.1038/ncb1607; Jackman RW, 2004, AM J PHYSIOL-CELL PH, V287, pC834, DOI 10.1152/ajpcell.00579.2003; Janiesch PC, 2007, NAT CELL BIOL, V9, P379, DOI 10.1038/ncb1554; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kim JM, 2006, DNA RES, V13, P275, DOI 10.1093/dnares/dsl016; Kudryashova E, 2005, J MOL BIOL, V354, P413, DOI 10.1016/j.jmb.2005.09.068; Kyushiki H, 1997, CYTOGENET CELL GENET, V79, P114, DOI 10.1159/000134695; Landsverk ML, 2007, J CELL BIOL, V177, P205, DOI 10.1083/jcb.200607084; Malicdan MCV, 2007, HUM MOL GENET, V16, P2669, DOI 10.1093/hmg/ddm220; Matsuda N, 2001, J CELL SCI, V114, P1949; McElhinny AS, 2004, J CELL SCI, V117, P3175, DOI 10.1242/jcs.01158; Nagaraju K, 2005, ARTHRITIS RHEUM, V52, P1824, DOI 10.1002/art.21103; Nagaraju K, 2000, P NATL ACAD SCI USA, V97, P9209, DOI 10.1073/pnas.97.16.9209; Nakanishi K, 2005, J CELL BIOL, V169, P555, DOI 10.1083/jcb.200412024; Nakanishi K, 2007, FASEB J, V21, P2994, DOI 10.1096/fj.06-6408com; Nastasi T, 2004, DEV CELL, V6, P269, DOI 10.1016/S1534-5807(04)00020-6; Reid MB, 2005, AM J PHYSIOL-REG I, V288, pR1423, DOI 10.1152/ajpregu.00545.2004; Schoser BGH, 2005, ANN NEUROL, V57, P591, DOI 10.1002/ana.20441; Tarricone E, 2006, ANN NY ACAD SCI, V1069, P472, DOI 10.1196/annals.1351.046; Tisdale MJ, 1997, J NATL CANCER I, V89, P1763, DOI 10.1093/jnci/89.23.1763; Vattemi G, 2004, AM J PATHOL, V164, P1, DOI 10.1016/S0002-9440(10)63089-1; Watts GDJ, 2004, NAT GENET, V36, P377, DOI 10.1038/ng1332; Wiekowski MT, 2001, J IMMUNOL, V167, P7102, DOI 10.4049/jimmunol.167.12.7102; Witt SH, 2005, J MOL BIOL, V350, P713, DOI 10.1016/j.jmb.2005.05.021; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373; Younger JM, 2006, CELL, V126, P571, DOI 10.1016/j.cell.2006.06.041; ZENGEL JM, 1980, P NATL ACAD SCI-BIOL, V77, P852, DOI 10.1073/pnas.77.2.852	46	46	49	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1609	10.1371/journal.pone.0001609	http://dx.doi.org/10.1371/journal.pone.0001609			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270596	Green Published, gold, Green Submitted			2022-12-25	WOS:000260535900043
J	Hayden, JD; Ades, SE				Hayden, Jennifer D.; Ades, Sarah E.			The Extracytoplasmic Stress Factor, sigma(E), Is Required to Maintain Cell Envelope Integrity in Escherichia coli	PLOS ONE			English	Article							OUTER-MEMBRANE PROTEINS; PENICILLIN-BINDING-PROTEINS; ENZYME IIA(NTR); VESICLE PRODUCTION; SMALL RNA; IDENTIFICATION; RESPONSES; REGULON; COMPLEX; GENES	Extracytoplasmic function or ECF sigma factors are the most abundant class of alternative sigma factors in bacteria. Members of the rpoE subclass of ECF sigma factors are implicated in sensing stress in the cell envelope of Gram-negative bacteria and are required for virulence in many pathogens. The best-studied member of this family is rpoE from Escherichia coli, encoding the sigma(E) protein. sigma(E) has been well studied for its role in combating extracytoplasmic stress, and the members of its regulon have been largely defined. sigma(E) is required for viability of E. coli, yet none of the studies to date explain why sigma(E) is essential in seemingly unstressed cells. In this work we investigate the essential role of sigma(E) in E. coli by analyzing the phenotypes associated with loss of sigma(E) activity and isolating suppressors that allow cells to live in the absence of sigma(E). We demonstrate that when sigma(E) is inhibited, cell envelope stress increases and envelope integrity is lost. Many cells lyse and some develop blebs containing cytoplasmic material along their sides. To better understand the connection between transcription by sigma(E) and cell envelope integrity, we identified two multicopy suppressors of the essentiality of sigma(E), ptsN and yhbW. yhbW is a gene of unknown function, while ptsN is a member of the sigma(E) regulon. Overexpression of ptsN lowers the basal level of multiple envelope stress responses, but not that of a cytoplasmic stress response. Our results are consistent with a model in which overexpression of ptsN reduces stress in the cell envelope, thereby promoting survival in the absence of sigma(E).	[Hayden, Jennifer D.; Ades, Sarah E.] Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Hayden, JD (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.	ades@psu.edu			National Science Foundation [MCB-0347302]	National Science Foundation(National Science Foundation (NSF))	This work was supported by grant MCB-0347302 from the National Science Foundation. The funding agency did not play any role in this study or in preparation of the manuscript.	Ades SE, 1999, GENE DEV, V13, P2449, DOI 10.1101/gad.13.18.2449; Ades SE, 2003, J BACTERIOL, V185, P2512, DOI 10.1128/JB.185.8.2512-2519.2003; Alba BM, 2004, MOL MICROBIOL, V52, P613, DOI 10.1111/j.1365-2958.2003.03982.x; Alba BM, 2002, GENE DEV, V16, P2156, DOI 10.1101/gad.1008902; Alba BM, 2001, MOL MICROBIOL, V40, P1323, DOI 10.1046/j.1365-2958.2001.02475.x; ANDERSON MS, 1987, J BIOL CHEM, V262, P5159; Baba T, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100050; Beck BJ, 1997, J BACTERIOL, V179, P6504, DOI 10.1128/jb.179.21.6862-6864.1997; Bianchi AA, 1999, MOL MICROBIOL, V34, P1029, DOI 10.1046/j.1365-2958.1999.01664.x; Braun M, 2002, MOL MICROBIOL, V45, P1289, DOI 10.1046/j.1365-2958.2002.03091.x; Button JE, 2007, J BACTERIOL, V189, P1523, DOI 10.1128/JB.01534-06; Campbell EA, 2003, MOL CELL, V11, P1067, DOI 10.1016/S1097-2765(03)00148-5; Charlson ES, 2006, J BACTERIOL, V188, P7186, DOI 10.1128/JB.00571-06; Commichau FM, 2006, CURR OPIN MICROBIOL, V9, P167, DOI 10.1016/j.mib.2006.01.001; Costanzo A, 2006, J BACTERIOL, V188, P4627, DOI 10.1128/JB.01981-05; Csonka L. N., 1996, ESCHERICHIA COLI SAL, P1210; Danese PN, 1998, J BACTERIOL, V180, P831, DOI 10.1128/JB.180.4.831-839.1998; DANESE PN, 1995, GENE DEV, V9, P387, DOI 10.1101/gad.9.4.387; Dartigalongue C, 2001, J BIOL CHEM, V276, P20866, DOI 10.1074/jbc.M100464200; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DeLasPenas A, 1997, MOL MICROBIOL, V24, P373, DOI 10.1046/j.1365-2958.1997.3611718.x; Denome SA, 1999, J BACTERIOL, V181, P3981, DOI 10.1128/JB.181.13.3981-3993.1999; Doerrler WT, 2005, J BIOL CHEM, V280, P27679, DOI 10.1074/jbc.M504796200; El Ghachi M, 2005, J BIOL CHEM, V280, P18689, DOI 10.1074/jbc.M412277200; Flardh K, 1997, MOL MICROBIOL, V24, P927, DOI 10.1046/j.1365-2958.1997.4001762.x; Flynn JM, 2004, GENE DEV, V18, P2292, DOI 10.1101/gad.1240104; Gralla JD, 2006, EMBO J, V25, P1515, DOI 10.1038/sj.emboj.7601041; Grigorova IL, 2004, GENE DEV, V18, P2686, DOI 10.1101/gad.1238604; Humphreys S, 1999, INFECT IMMUN, V67, P1560; Johansen J, 2006, J MOL BIOL, V364, P1, DOI 10.1016/j.jmb.2006.09.004; Kanehara K, 2002, GENE DEV, V16, P2147, DOI 10.1101/gad.1002302; KELLENBERGER E, 1996, CELLULAR MOL BIOL, P17; Kitagawa M, 2005, DNA RES, V12, P291, DOI 10.1093/dnares/dsi012; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lee CR, 2007, P NATL ACAD SCI USA, V104, P4124, DOI 10.1073/pnas.0609897104; Lee CR, 2005, MOL MICROBIOL, V58, P334, DOI 10.1111/j.1365-2958.2005.04834.x; LIU D, 1994, MICROBIOL-UK, V140, P49, DOI 10.1099/13500872-140-1-49; Majdalani N, 2005, ANNU REV MICROBIOL, V59, P379, DOI 10.1146/annurev.micro.59.050405.101230; Majdalani N, 2002, MOL MICROBIOL, V46, P813, DOI 10.1046/j.1365-2958.2002.03203.x; Malinverni JC, 2006, MOL MICROBIOL, V61, P151, DOI 10.1111/j.1365-2958.2006.05211.x; McBroom AJ, 2007, MOL MICROBIOL, V63, P545, DOI 10.1111/j.1365-2958.2006.05522.x; McBroom AJ, 2006, J BACTERIOL, V188, P5385, DOI 10.1128/JB.00498-06; MECSAS J, 1993, GENE DEV, V7, P2618, DOI 10.1101/gad.7.12b.2618; MECSAS J, 1995, J BACTERIOL, V177, P799, DOI 10.1128/jb.177.3.799-804.1995; Meisel U, 2003, J BACTERIOL, V185, P5342, DOI 10.1128/JB.185.18.5342-5348.2003; Missiakas D, 1997, MOL MICROBIOL, V24, P355, DOI 10.1046/j.1365-2958.1997.3601713.x; Missiakas D, 1996, MOL MICROBIOL, V21, P871, DOI 10.1046/j.1365-2958.1996.561412.x; NIKAIDO H, 1994, J BIOL CHEM, V269, P3905; Nonaka G, 2006, GENE DEV, V20, P1776, DOI 10.1101/gad.1428206; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; POWELL BS, 1995, J BIOL CHEM, V270, P4822, DOI 10.1074/jbc.270.9.4822; Rabus R, 1999, J BIOL CHEM, V274, P26185, DOI 10.1074/jbc.274.37.26185; Raivio TL, 2005, MOL MICROBIOL, V56, P1119, DOI 10.1111/j.1365-2958.2005.04625.x; Raivio TL, 2000, MOL MICROBIOL, V37, P1186, DOI 10.1046/j.1365-2958.2000.02074.x; Rezuchova B, 2003, FEMS MICROBIOL LETT, V225, P1, DOI 10.1016/S0378-1097(03)00480-4; Rhodius VA, 2006, PLOS BIOL, V4, P43, DOI 10.1371/journal.pbio.0040002; Rouviere PE, 1996, GENE DEV, V10, P3170, DOI 10.1101/gad.10.24.3170; ROUVIERE PE, 1995, EMBO J, V14, P1032, DOI 10.1002/j.1460-2075.1995.tb07084.x; Rowley G, 2006, NAT REV MICROBIOL, V4, P383, DOI 10.1038/nrmicro1394; Ruiz N, 2006, NAT REV MICROBIOL, V4, P57, DOI 10.1038/nrmicro1322; Ruiz N, 2005, CURR OPIN MICROBIOL, V8, P122, DOI 10.1016/j.mib.2005.02.013; Sperandeo P, 2007, J BACTERIOL, V189, P244, DOI 10.1128/JB.01126-06; SPRATT BG, 1975, P NATL ACAD SCI USA, V72, P2999, DOI 10.1073/pnas.72.8.2999; Thompson KM, 2007, J BACTERIOL, V189, P4243, DOI 10.1128/JB.00020-07; Udekwu KI, 2007, NUCLEIC ACIDS RES, V35, P1279, DOI 10.1093/nar/gkl1154; Wade JT, 2006, NAT STRUCT MOL BIOL, V13, P806, DOI 10.1038/nsmb1130; Walsh NP, 2003, CELL, V113, P61, DOI 10.1016/S0092-8674(03)00203-4; Wood JM, 1999, MICROBIOL MOL BIOL R, V63, P230, DOI 10.1128/MMBR.63.1.230-262.1999; Wu T, 2006, P NATL ACAD SCI USA, V103, P11754, DOI 10.1073/pnas.0604744103	69	113	113	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2008	3	2							e1573	10.1371/journal.pone.0001573	http://dx.doi.org/10.1371/journal.pone.0001573			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367EQ	18253509	Green Published, Green Submitted, gold			2022-12-25	WOS:000260535700033
J	Macqueen, DJ; Johnston, IA				Macqueen, Daniel J.; Johnston, Ian A.			An Update on MyoD Evolution in Teleosts and a Proposed Consensus Nomenclature to Accommodate the Tetraploidization of Different Vertebrate Genomes	PLOS ONE			English	Article							MUSCLE REGULATORY FACTORS; GENE; DUPLICATION; FISH; EXPRESSION; HOMOLOGY	Background: MyoD is a muscle specific transcription factor that is essential for vertebrate myogenesis. In several teleost species, including representatives of the Salmonidae and Acanthopterygii, but not zebrafish, two or more MyoD paralogues are conserved that are thought to have arisen from distinct, possibly lineage-specific duplication events. Additionally, two MyoD paralogues have been characterised in the allotetraploid frog, Xenopus laevis. This has lead to a confusing nomenclature since MyoD paralogues have been named outside of an appropriate phylogenetic framework. Methods and Principal Findings: Here we initially show that directly depicting the evolutionary relationships of teleost MyoD orthologues and paralogues is hindered by the asymmetric evolutionary rate of Acanthopterygian MyoD2 relative to other MyoD proteins. Thus our aim was to confidently position the event from which teleost paralogues arose in different lineages by a comparative investigation of genes neighbouring myod across the vertebrates. To this end, we show that genes on the single myod-containing chromosome of mammals and birds are retained in both zebrafish and Acanthopterygian teleosts in a striking pattern of double conserved synteny. Further, phylogenetic reconstruction of these neighbouring genes using Bayesian and maximum likelihood methods supported a common origin for teleost paralogues following the split of the Actinopterygii and Sarcopterygii. Conclusion: Our results strongly suggest that myod was duplicated during the basal teleost whole genome duplication event, but was subsequently lost in the Ostariophysi ( zebrafish) and Protacanthopterygii lineages. We propose a sensible consensus nomenclature for vertebrate myod genes that accommodates polyploidization events in teleost and tetrapod lineages and is justified from a phylogenetic perspective.	[Macqueen, Daniel J.; Johnston, Ian A.] Univ St Andrews, Gatty Marine Lab, Sch Biol, St Andrews, Fife, Scotland	University of St Andrews	Macqueen, DJ (corresponding author), Univ St Andrews, Gatty Marine Lab, Sch Biol, St Andrews, Fife, Scotland.	iaj@st-andrews.ac.uk	Macqueen, Daniel/A-7456-2013; Johnston, Ian A./AAE-2044-2019; Johnston, Ian A/D-6592-2013	Johnston, Ian A/0000-0002-7796-5754	Natural Environment Research Council [NERC/S/A/2004/12435]	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	DJM was supported by a Natural Environment Research Council studentship (NERC/S/A/2004/12435).	ATCHLEY WR, 1994, P NATL ACAD SCI USA, V91, P11522, DOI 10.1073/pnas.91.24.11522; Fares MA, 2006, MOL BIOL EVOL, V23, P245, DOI 10.1093/molbev/msj027; Fernandes JMO, 2007, GENE, V391, P178, DOI 10.1016/j.gene.2006.12.015; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Hall TE, 2003, J EXP BIOL, V206, P3187, DOI 10.1242/jeb.00535; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Jaillon O, 2004, NATURE, V431, P946, DOI 10.1038/nature03025; Kassar-Duchossoy L, 2004, NATURE, V431, P466, DOI 10.1038/nature02876; Le Comber SC, 2004, BIOL J LINN SOC, V82, P431; LIN H, 1991, MOL CELL BIOL, V11, P267, DOI 10.1128/MCB.11.1.267; Macqueen DJ, 2007, J EXP BIOL, V210, P2781, DOI 10.1242/jeb.006981; Macqueen DJ, 2006, FEBS LETT, V580, P4996, DOI 10.1016/j.febslet.2006.08.016; Meyer A, 1999, CURR OPIN CELL BIOL, V11, P699, DOI 10.1016/S0955-0674(99)00039-3; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Otto SP, 2000, ANNU REV GENET, V34, P401, DOI 10.1146/annurev.genet.34.1.401; Pownall ME, 2002, ANNU REV CELL DEV BI, V18, P747, DOI 10.1146/annurev.cellbio.18.012502.105758; Rescan PY, 1996, COMP BIOCHEM PHYS B, V113, P711, DOI 10.1016/0305-0491(95)02087-X; SCALES JB, 1990, MOL CELL BIOL, V10, P1516, DOI 10.1128/MCB.10.4.1516; Spring J, 1997, FEBS LETT, V400, P2, DOI 10.1016/S0014-5793(96)01351-8; Steinke D, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-20; TAJIMA F, 1993, GENETICS, V135, P599; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; Tan XG, 2002, DEV GENES EVOL, V212, P207, DOI 10.1007/s00427-002-0224-5; Tapscott SJ, 2005, DEVELOPMENT, V132, P2685, DOI 10.1242/dev.01874; Taylor JS, 2003, GENOME RES, V13, P382, DOI 10.1101/gr.640303; Thisse B, 2004, ZFIN DIRECT DATA SUB; Van de Peer Y, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-12-250; Van de Peer Y, 2002, GENE, V295, P205, DOI 10.1016/S0378-1119(02)00689-3; Weinberg ES, 1996, DEVELOPMENT, V122, P271; Woods IG, 2005, GENOME RES, V15, P1307, DOI 10.1101/gr.4134305	30	31	31	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2008	3	2							e1567	10.1371/journal.pone.0001567	http://dx.doi.org/10.1371/journal.pone.0001567			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367EQ	18253507	Green Published, Green Submitted, gold			2022-12-25	WOS:000260535700031
J	Ropero, S; Ballestar, E; Alaminos, M; Arango, D; Schwartz, S; Esteller, M				Ropero, S.; Ballestar, E.; Alaminos, M.; Arango, D.; Schwartz, S., Jr.; Esteller, M.			Transforming pathways unleashed by a HDAC2 mutation in human cancer	ONCOGENE			English	Article						histone; HDAC2; deacetylase; epigenetics; chromatin	HISTONE MODIFICATIONS; ACETYLATION; EXPRESSION; EPIGENOMICS; BINDING	Although disruption of histone modi. cation patterns is a common hallmark of human cancer, our knowledge of the mechanistic role of histone-modifying enzymes in its generation is very limited. We have recently identified an inactivating mutation in the histone deacetylase-2 (HDAC2) in sporadic carcinomas with microsatellite instability and in tumors arising in individuals with hereditary nonpolyposis colorectal cancer syndrome. Since HDAC2 seems to be a central player in epigenetic gene repression, we wondered whether HDAC2-truncating mutations conferred a particular expression signature on these cancer cells. Using unsupervised clustering analysis in microsatellite-unstable colorectal cancer cell lines, we have found that HDAC2 mutant cells (RKO and Co115) show a characteristically different expression microarray signature from HDAC2 wild-type cells (HCT-116, SW48, HCT-15 and LoVo). HDAC2 mutant cells exhibit upregulation of tumor-promoting genes, such as those of tyrosine kinases, mediators of cell cycle progression and angiogenic factors. The overexpression of these genes is associated with a loss of HDAC2 recruitment and a gain of histone H4 hyperacetylation in their particular 5'-end promoters, as observed by chromatin immunoprecipitation. Transfection of wild-type HDAC2 in mutant cells reverted this epigenetic pattern by repressing the transforming genes in association with HDAC2 promoter occupancy. These results suggest a role for HDAC2 mutations in human tumorigenesis through the derepression of key genes from multiple cellular transformation pathways.	[Ropero, S.; Ballestar, E.; Esteller, M.] Spanish Natl Canc Ctr CNIO, Canc Epigenet Lab, Madrid 28029, Spain; [Alaminos, M.] Univ Granada, Dept Histol, Granada, Spain; [Alaminos, M.] Hosp Clin Fdn, Granada, Spain; [Alaminos, M.; Arango, D.] Hosp Univ Vall Hebron, Ctr Invest Bioquim & Biol Mol, Barcelona, Catalonia, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); University of Granada; Hospital Universitari Vall d'Hebron	Esteller, M (corresponding author), Spanish Natl Canc Ctr CNIO, Canc Epigenet Lab, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	mesteller@cnio.es	ALAMINOS, MIGUEL/N-9960-2016; Schwartz, Simo/H-7776-2012; Arango, Diego/M-5667-2016; Ballestar, Esteban/ABG-8561-2020; Esteller, Manel/L-5956-2014; Arango, Diego/AFW-0125-2022	ALAMINOS, MIGUEL/0000-0003-4876-2672; Arango, Diego/0000-0003-2953-3284; Esteller, Manel/0000-0003-4490-6093; Arango, Diego/0000-0003-2953-3284; Schwartz, Simo/0000-0001-8297-7971; Ballestar, Esteban/0000-0002-1400-2440	Direct For Biological Sciences [0757780] Funding Source: National Science Foundation	Direct For Biological Sciences(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO))		Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604; Dopazo J, 1997, J MOL EVOL, V44, P226, DOI 10.1007/PL00006139; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Fahrner JA, 2002, CANCER RES, V62, P7213; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Montgomery RL, 2007, GENE DEV, V21, P1790, DOI 10.1101/gad.1563807; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Ropero S, 2006, NAT GENET, V38, P566, DOI 10.1038/ng1773; Ropero S, 2007, MOL ONCOL, V1, P19, DOI 10.1016/j.molonc.2007.01.001; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Trivedi CM, 2007, NAT MED, V13, P324, DOI 10.1038/nm1552; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X	18	25	27	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2008	27	28					4008	4012		10.1038/onc.2008.31	http://dx.doi.org/10.1038/onc.2008.31			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	318JZ	18264134				2022-12-25	WOS:000257089000012
J	Yang, L; Reece, JM; Cho, J; Bortner, CD; Shears, SB				Yang, Ling; Reece, Jeff M.; Cho, Jaiesoon; Bortner, Carl D.; Shears, Stephen B.			The nucleolus exhibits an osmotically regulated gatekeeping activity that controls the spatial dynamics and functions of nucleolin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIS-DIPHOSPHOINOSITOL TETRAKISPHOSPHATE; INOSITOL POLYPHOSPHATE PHOSPHATASE; REPLICATION PROTEIN-A; HYPEROSMOTIC STRESS; COMPLEX-FORMATION; DNA-REPLICATION; CELL-DEATH; PYROPHOSPHATES; HEXAKISPHOSPHATE; PENTAKISPHOSPHATE	We demonstrate that physiologically relevant perturbations in the osmotic environment rheostatically regulate a gatekeeping function for the nucleolus that controls the spatial dynamics and functions of nucleolin. HeLa cells and U2-OS osteosarcoma cells were osmotically challenged with 100-200 mM sorbitol, and the intranuclear distribution of nucleolin was monitored by confocal microscopy. Nucleolin that normally resides in the innermost fibrillar core of the nucleolus, where it assists rDNA transcription and replication, was expelled within 30 min of sorbitol addition. The nucleolin was transferred into the nucleoplasm, but it distributed there non-uniformly; locally high levels accumulated in 4',6-diamidino-2-phenylindole-negative zones containing euchromatic (transcriptionally active) DNA. Inositol pyrophosphates also responded within 30 min of hyperosmotic stress: levels of bisdiphosphoinositol tetrakisphosphate increased 6-fold, and this was matched by decreased levels of its precursor, diphosphoinositol pentakisphosphate. Such fluctuations in inositol pyrophosphate levels are of considerable interest, because, according to previously published in vitro data, they regulate the degree of phosphorylation of nucleolin through a novel kinase-independent phosphotransferase reaction (Saiardi, A., Bhandari, A., Resnick, R., Cain, A., Snowman, A. M., and Snyder, S. H. (2004) Science 306, 2101-2105). However, by pharmacologically intervening in inositol pyrophosphate metabolism, we found that it did not supervise the osmotically driven switch in the biological activities of nucleolin in vivo.	[Yang, Ling; Cho, Jaiesoon; Shears, Stephen B.] NIEHS, Inositol Signaling Grp, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; [Bortner, Carl D.] NIEHS, Mol Endocrinol Grp, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; [Reece, Jeff M.] Reecent Technol LLC, Durham, NC 27713 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Shears, SB (corresponding author), NIEHS, Inositol Signaling Grp, NIH, Dept Hlth & Human Serv, POB 12233, Res Triangle Pk, NC 27709 USA.	Shears@niehs.nih.gov	Shears, Stephen B/C-6335-2019	Shears, Stephen B/0000-0001-7309-8916	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES102486, ZICES102486, Z01ES080046, ZIAES080046] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Alfieri RR, 2007, PFLUG ARCH EUR J PHY, V454, P173, DOI 10.1007/s00424-006-0195-x; Barker CJ, 2004, BIOCHEM J, V380, P465, DOI 10.1042/BJ20031872; Bennett M, 2006, CELL MOL LIFE SCI, V63, P552, DOI 10.1007/s00018-005-5446-z; Bhandari R, 2007, P NATL ACAD SCI USA, V104, P15305, DOI 10.1073/pnas.0707338104; Bourque CW, 1997, ANNU REV PHYSIOL, V59, P601, DOI 10.1146/annurev.physiol.59.1.601; Brehm MA, 2007, BIOCHEM J, V408, P335, DOI 10.1042/BJ20070382; Burg MB, 2007, PHYSIOL REV, V87, P1441, DOI 10.1152/physrev.00056.2006; Caffrey JJ, 1999, FEBS LETT, V442, P99, DOI 10.1016/S0014-5793(98)01636-6; Cho J, 2006, J BIOTECHNOL, V126, P248, DOI 10.1016/j.jbiotec.2006.04.028; Choi JH, 2007, J BIOL CHEM, V282, P30763, DOI 10.1074/jbc.M704655200; Craxton A, 1997, BIOCHEM J, V328, P75, DOI 10.1042/bj3280075; Daniely Y, 2000, J CELL BIOL, V149, P799, DOI 10.1083/jcb.149.4.799; Daniely Y, 2002, MOL CELL BIOL, V22, P6014, DOI 10.1128/MCB.22.16.6014-6022.2002; Darrow DC, 1935, J CLIN INVEST, V14, P266, DOI 10.1172/JCI100674; Fridy PC, 2007, J BIOL CHEM, V282, P30754, DOI 10.1074/jbc.M704656200; Gilbert DM, 2002, CURR OPIN CELL BIOL, V14, P377, DOI 10.1016/S0955-0674(02)00326-5; Ginisty H, 1999, J CELL SCI, V112, P761; Go WY, 2004, P NATL ACAD SCI USA, V101, P10673, DOI 10.1073/pnas.0403139101; Hand CE, 2007, BIOORG MED CHEM LETT, V17, P183, DOI 10.1016/j.bmcl.2006.09.066; Illies C, 2007, SCIENCE, V318, P1299, DOI 10.1126/science.1146824; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; Kim K, 2005, MOL CELL BIOL, V25, P2463, DOI 10.1128/MCB.25.6.2463-2474.2005; Kultz D, 2001, COMP BIOCHEM PHYS A, V130, P421, DOI 10.1016/S1095-6433(01)00440-8; Kultz D, 1998, J EXP BIOL, V201, P3015; Laussmann T, 1997, BIOCHEM J, V322, P31, DOI 10.1042/bj3220031; Lee YS, 2007, SCIENCE, V316, P109, DOI 10.1126/science.1139080; Maeno E, 2006, FEBS LETT, V580, P6513, DOI 10.1016/j.febslet.2006.10.074; MAJERUS PW, 2007, SCI STKE, pPE72; Mayer C, 2005, CELL CYCLE, V4, P1036, DOI 10.4161/cc.4.8.1925; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; Nagata E, 2005, J BIOL CHEM, V280, P1634, DOI 10.1074/jbc.M409416200; Pesesse X, 2005, BIOCHEM BIOPH RES CO, V336, P157, DOI 10.1016/j.bbrc.2005.08.049; Pesesse X, 2004, J BIOL CHEM, V279, P43378, DOI 10.1074/jbc.C400286200; Raboy Victor, 2006, V39, P71; Safrany ST, 2004, MOL PHARMACOL, V66, P1585, DOI 10.1124/mol.104.002667; Safrany ST, 1998, EMBO J, V17, P1710, DOI 10.1093/emboj/17.6.1710; Safrany ST, 1998, EMBO J, V17, P6599, DOI 10.1093/emboj/17.22.6599; Saiardi A, 2004, SCIENCE, V306, P2101, DOI 10.1126/science.1103344; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Schliess F, 2002, BIOL CHEM, V383, P577, DOI 10.1515/BC.2002.059; SHEARS SB, 1995, J BIOL CHEM, V270, P10489, DOI 10.1074/jbc.270.18.10489; Shears SB, 2001, CELL SIGNAL, V13, P151, DOI 10.1016/S0898-6568(01)00129-2; Shears SB, 2007, BIOCHEM SOC SYMP, V74, P211, DOI 10.1042/BSS2007c18; Song YL, 2001, J GEN PHYSIOL, V117, P573, DOI 10.1085/jgp.117.6.573; Tate MLK, 2003, J BIOMECH, V36, P1409, DOI 10.1016/S0021-9290(03)00123-4; Thiry M, 2005, TRENDS CELL BIOL, V15, P194, DOI 10.1016/j.tcb.2005.02.007; URBAN JPG, 1993, J CELL PHYSIOL, V154, P262, DOI 10.1002/jcp.1041540208; Valdez BC, 1995, MOL IMMUNOL, V32, P1207, DOI 10.1016/0161-5890(95)00093-3; Verbsky J, 2005, J BIOL CHEM, V280, P29263, DOI 10.1074/jbc.M503366200; Verbsky J, 2005, P NATL ACAD SCI USA, V102, P8448, DOI 10.1073/pnas.0503656102; Verbsky JW, 2005, J BIOL CHEM, V280, P1911, DOI 10.1074/jbc.M411528200; VOMDAHL S, 1991, BIOCHEM J, V280, P105, DOI 10.1042/bj2800105; Wang YZ, 2001, J BIOL CHEM, V276, P20579, DOI 10.1074/jbc.M100874200; York JD, 2004, SCIENCE, V306, P2053, DOI 10.1126/science.1107225	54	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11823	11831		10.1074/jbc.M800308200	http://dx.doi.org/10.1074/jbc.M800308200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18299322	hybrid, Green Published			2022-12-25	WOS:000255067400081
J	Desilets, A; Beliveau, F; Vandal, G; McDuff, FO; Lavigne, P; Leduc, R				Desilets, Antoine; Beliveau, Francois; Vandal, Guillaume; McDuff, Francois-Olivier; Lavigne, Pierre; Leduc, Richard			Mutation G827R in matriptase causing autosomal recessive ichthyosis with hypotrichosis yields an inactive protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR ACTIVATOR INHIBITOR-1; EPIDERMAL BARRIER FUNCTION; SERINE-PROTEASE; GROWTH; DOMAIN; EXPRESSION; RELEASE; ROLES; SITES; ST14	Matriptase is a member of the novel family of type II transmembrane serine proteases. It was recently shown that a rare genetic disorder, autosomal recessive ichthyosis with hypotrichosis, is caused by a mutation in the coding region of matriptase. However, the biochemical and functional consequences of the G827R mutation in the catalytic domain of the enzyme have not been reported. Here we expressed the G827R-matriptase mutant in bacterial cells and found that it did not undergo autocatalytic cleavage from its zymogen to its active form as did the wild-type matriptase. Enzymatic activity measurements showed that the G827R mutant was catalytically inactive. When expressed in HEK293 cells, G827R-matriptase remained inactive but was shed as a soluble form, suggesting that another protease cleaved the full-length mature form of matriptase. Molecular modeling based on the crystal structure of matriptase showed that replacing Gly(827) by Arg blocks access to the binding/catalytic cleft of the enzyme thereby preventing autocatalysis of the zymogen form. Our study, thus, provides direct evidence that the G827R mutation in patients with autosomal recessive ichthyosis with hypotrichosis leads to the expression of an inactive protease.	[Desilets, Antoine; Beliveau, Francois; Vandal, Guillaume; McDuff, Francois-Olivier; Lavigne, Pierre; Leduc, Richard] Univ Sherbrooke, Fac Med & Hlth Sci, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Leduc, R (corresponding author), 3001 12th Ave N, Sherbrooke, PQ J1H 5N4, Canada.	richard.leduc@usherbrooke.ca		Beliveau, Francois/0000-0001-6324-2363; Desilets, Antoine/0000-0001-5081-5564				Basel-Vanagaite L, 2007, AM J HUM GENET, V80, P467, DOI 10.1086/512487; Benaud C, 2001, EUR J BIOCHEM, V268, P1439, DOI 10.1046/j.1432-1327.2001.02016.x; Caubet C, 2004, J INVEST DERMATOL, V122, P1235, DOI 10.1111/j.0022-202X.2004.22512.x; Cho EG, 2001, J BIOL CHEM, V276, P44581, DOI 10.1074/jbc.M107059200; Desilets A, 2006, FEBS LETT, V580, P2227, DOI 10.1016/j.febslet.2006.03.030; Forbs D, 2005, INT J ONCOL, V27, P1061; Friedrich R, 2002, J BIOL CHEM, V277, P2160, DOI 10.1074/jbc.M109830200; Kang JY, 2003, CANCER RES, V63, P1101; Kim TS, 2006, MOL CELL BIOL, V26, P965, DOI 10.1128/MCB.26.3.965-975.2006; Komatsu N, 2007, EXP DERMATOL, V16, P513, DOI 10.1111/j.1600-0625.2007.00562.x; Leyvraz C, 2005, J CELL BIOL, V170, P487, DOI 10.1083/jcb.200501038; List K, 2002, ONCOGENE, V21, P3765, DOI 10.1038/sj.onc.1205502; List K, 2003, J CELL BIOL, V163, P901, DOI 10.1083/jcb.200304161; List K, 2005, GENE DEV, V19, P1934, DOI 10.1101/gad.1300705; List K, 2007, J BIOL CHEM, V282, P36714, DOI 10.1074/jbc.M705521200; List K, 2006, MOL MED, V12, P1, DOI 10.2119/2006-00022.List; Netzel-Arnett S, 2003, CANCER METAST REV, V22, P237, DOI 10.1023/A:1023003616848; Netzel-Arnett S, 2006, J BIOL CHEM, V281, P32941, DOI 10.1074/jbc.C600208200; Oberst MD, 2005, AM J PHYSIOL-CELL PH, V289, pC462, DOI 10.1152/ajpcell.00076.2005; Oberst MD, 2003, J BIOL CHEM, V278, P26773, DOI 10.1074/jbc.M304282200; Pearton DJ, 2002, J INVEST DERMATOL, V119, P661, DOI 10.1046/j.1523-1747.2002.01831.x; Qiu D, 2007, BIOCHEM SOC T, V35, P583, DOI 10.1042/BST0350583; Shia S, 2005, J MOL BIOL, V346, P1335, DOI 10.1016/j.jmb.2004.12.048; Shimomura T, 1999, J BIOCHEM-TOKYO, V126, P821, DOI 10.1093/oxfordjournals.jbchem.a022522; STEVEN AC, 1994, J CELL SCI, V107, P693; Szabo R, 2007, ONCOGENE, V26, P1546, DOI 10.1038/sj.onc.1209966; Szabo R, 2003, THROMB HAEMOSTASIS, V90, P185, DOI 10.1160/TH03-02-0071; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; Tanimoto H, 2005, BRIT J CANCER, V92, P278, DOI 10.1038/sj.bjc.6602320; Tsuzuki S, 2005, BIOCHEM J, V388, P679, DOI 10.1042/BJ20041639	30	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10535	10542		10.1074/jbc.M707012200	http://dx.doi.org/10.1074/jbc.M707012200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18263585	hybrid, Green Published			2022-12-25	WOS:000254894700035
J	Hu, JCC; Hu, YY; Smith, CE; Mckee, MD; Wright, JT; Yamakoshi, Y; Papagerakis, P; Hunter, GK; Feng, JQ; Yamakoshi, F; Simmer, JP				Hu, Jan C. -C.; Hu, Yuanyuan; Smith, Charles E.; Mckee, Marc D.; Wright, J. Timothy; Yamakoshi, Yasuo; Papagerakis, Petros; Hunter, Graeme K.; Feng, Jerry Q.; Yamakoshi, Fumiko; Simmer, James P.			Enamel defects and ameloblast-specific expression in Enam knock-out/lacZ knock-in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOMATURATION AMELOGENESIS-IMPERFECTA; DEVELOPING MOUSE MOLARS; PORCINE TOOTH GERMS; DENTAL ENAMEL; MANDIBULAR INCISORS; BETA-GALACTOSIDASE; MOLECULAR-CLONING; GENE-EXPRESSION; CALCIUM-BINDING; MUTATION	Enamelin is critical for proper dental enamel formation, and defects in the human enamelin gene cause autosomal dominant amelogenesis imperfecta. We used gene targeting to generate a knock-in mouse carrying a null allele of enamelin (Enam) that has a lacZ reporter gene replacing the Enam translation initiation site and gene sequences through exon 7. Correct targeting of the transgene was confirmed by Southern blotting and PCR analyses. No enamelin protein could be detected by Western blotting in the Enam-null mice. Histochemical 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-gal) staining demonstrated ameloblast-specific expression of enamelin. The enamel of the Enam(+/-) mice was nearly normal in the maxillary incisors, but the mandibular incisors were discolored and tended to wear rapidly where they contacted the maxillary incisors. The Enam(+/-) mice showed no true enamel. Radiography, microcomputed tomography, and light and scanning electron microscopy were used to document changes in the enamel of Enam(+/-) mice but did not discern any perturbations of bone, dentin, or any other tissue besides the enamel layer. Although a thick layer of enamel proteins covered normal-appearing dentin of unerupted teeth, von Kossa staining revealed almost a complete absence of mineral formation in this protein layer. However, a thin, highly irregular, mineralized crust covered the dentin on erupted teeth, apparently arising from the formation and fusion of small mineralization foci (calcospherites) in the deeper part of the accumulated enamel protein layer. These results demonstrate ameloblast-specific expression of enamelin and reveal that enamelin is essential for proper enamel matrix organization and mineralization.	[Hu, Jan C. -C.; Hu, Yuanyuan; Papagerakis, Petros; Yamakoshi, Fumiko] Univ Michigan, Dent Res Lab, Sch Dent, Dept Orthodont & Pediat Dent, Ann Arbor, MI 48108 USA; [Yamakoshi, Yasuo; Simmer, James P.] Univ Michigan, Sch Dent, Dept Biol & Mat Sci, Ann Arbor, MI 48108 USA; [Smith, Charles E.] Univ Montreal, Fac Med Dent, Lab Study Calcified Tissues & Biomat, Montreal, PQ H3C 3J7, Canada; [Mckee, Marc D.] McGill Univ, Fac Med Dent, Dept Anat & Cell Biol,McGill Ctr Bone & Peridodon, Jamson TN Wong Labs Calcified Tissue Res, Montreal, PQ H3A 2B2, Canada; [Mckee, Marc D.] McGill Univ, Fac Med Dent, Fonds Rech Sante Quebec Network Oral & Bone Hlth, Montreal, PQ H3A 2B2, Canada; [Wright, J. Timothy] Univ N Carolina, Dept Pediat Dent, Chapel Hill, NC 27599 USA; [Hunter, Graeme K.] Univ Western Ontario, Schulich Sch Med & Dent, Canadian Inst Hlth Res Grp Skeletal Dev & Remodel, London, ON N6A 5C1, Canada; [Feng, Jerry Q.] Baylor Coll Dent, Dept Biomed Sci, Dallas, TX 75246 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Universite de Montreal; McGill University; McGill University; University of North Carolina; University of North Carolina Chapel Hill; Western University (University of Western Ontario); Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Hu, JCC (corresponding author), Univ Michigan, Dent Res Lab, Sch Dent, Dept Orthodont & Pediat Dent, 1210 Eisenhower Pl, Ann Arbor, MI 48108 USA.	janhu@umich.edu	McKee, Marc D/E-2187-2011; Hu, Jan C-C./F-5679-2015; Testes, Olga/E-8912-2013; Wright, John Timothy/AAX-5755-2020	McKee, Marc D/0000-0001-8349-965X; Hu, Jan C-C./0000-0002-9294-0248; Simmer, James/0000-0002-7192-6105	NIDCR NIH HHS [DE 11301] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R29DE011301, R01DE011301, R56DE011301] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bartlett JD, 1996, GENE, V183, P123, DOI 10.1016/S0378-1119(96)00525-2; Bartlett JD, 2004, J DENT RES, V83, P909, DOI 10.1177/154405910408301204; Caterina JJ, 2002, J BIOL CHEM, V277, P49598, DOI 10.1074/jbc.M209100200; Chai Y, 2000, DEVELOPMENT, V127, P1671; DACULSI G, 1978, J ULTRA MOL STRUCT R, V65, P163, DOI 10.1016/S0022-5320(78)90053-9; DEUTSCH D, 2006, EUR J ORAL SCI, V114, P381; Deutsch D, 2006, EUR J ORAL SCI, V114, P183, DOI 10.1111/j.1600-0722.2006.00301.x; Dohi N, 1998, CELL TISSUE RES, V293, P313, DOI 10.1007/s004410051123; Fincham AG, 1999, J STRUCT BIOL, V126, P270, DOI 10.1006/jsbi.1999.4130; Fukae M, 1996, Adv Dent Res, V10, P111; Fukumoto S, 2004, J CELL BIOL, V167, P973, DOI 10.1083/jcb.200409077; Gibson CW, 2001, J BIOL CHEM, V276, P31871, DOI 10.1074/jbc.M104624200; GRYNPAS MD, 1988, J BONE MINER RES, V3, P159; Hart PS, 2004, J MED GENET, V41, P545, DOI 10.1136/jmg.2003.017657; Hart TC, 2003, J MED GENET, V40, P900, DOI 10.1136/jmg.40.12.900; Hu CC, 1998, CONNECT TISSUE RES, V39, P47, DOI 10.3109/03008209809023911; Hu CC, 1997, J DENT RES, V76, P1720, DOI 10.1177/00220345970760110201; Hu CC, 1997, J DENT RES, V76, P648, DOI 10.1177/00220345970760020501; Hu CC, 2000, J DENT RES, V79, P912, DOI 10.1177/00220345000790040501; Hu JCC, 2007, CELLS TISSUES ORGANS, V186, P78, DOI 10.1159/000102683; Hu JCC, 2002, EUR J ORAL SCI, V110, P307, DOI 10.1034/j.1600-0722.2002.21301.x; Hu JCC, 2005, CELLS TISSUES ORGANS, V181, P219, DOI 10.1159/000091383; Hu JCC, 2000, GENE, V251, P1, DOI 10.1016/S0378-1119(00)00203-1; Hu JCC, 2003, CRIT REV ORAL BIOL M, V14, P387, DOI 10.1177/154411130301400602; Hu JCC, 2001, EUR J ORAL SCI, V109, P125, DOI 10.1034/j.1600-0722.2001.00998.x; HU Y, IN PRESS EUR J ORAL; HWANG WSS, 1965, J DENT RES, V44, P42, DOI 10.1177/00220345650440012901; Iwata T, 2007, J DENT RES, V86, P153, DOI 10.1177/154405910708600209; Kawasaki K, 2003, P NATL ACAD SCI USA, V100, P4060, DOI 10.1073/pnas.0638023100; Kim JW, 2006, EUR J ORAL SCI, V114, P3, DOI 10.1111/j.1600-0722.2006.00278.x; Kim JW, 2005, J MED GENET, V42, P271, DOI 10.1136/jmg.2004.024505; Kim JW, 2005, J DENT RES, V84, P278, DOI 10.1177/154405910508400314; Krebsbach PH, 1996, J BIOL CHEM, V271, P4431; LAU EC, 1989, GENOMICS, V4, P162, DOI 10.1016/0888-7543(89)90295-4; Li Y., 2006, EUR J ORAL SCI, V114, P381; Li Y, 2006, EUR J ORAL SCI, V114, P190, DOI 10.1111/j.1600-0722.2006.00286.x; Lobe CG, 1999, DEV BIOL, V208, P281, DOI 10.1006/dbio.1999.9209; Masuya H, 2005, HUM MOL GENET, V14, P575, DOI 10.1093/hmg/ddi054; Moinichen CB, 1996, J ANAT, V189, P325; Nanci A, 2008, 10 CATES ORAL HISTOL, P141; NANCI A, 2003, 10 CATES ORAL HISTOL, P218; Nelson PS, 1999, P NATL ACAD SCI USA, V96, P3114, DOI 10.1073/pnas.96.6.3114; NESS A. R., 1965, ARCH ORAL BIOL, V10, P439, DOI 10.1016/0003-9969(65)90109-3; Obiezu CV, 2005, CLIN CHEM, V51, P1432, DOI 10.1373/clinchem.2005.049692; Ozdemir D, 2005, J DENT RES, V84, P1031, DOI 10.1177/154405910508401112; Ozdemir D, 2005, J DENT RES, V84, P1036, DOI 10.1177/154405910508401113; Pampena DA, 2004, BIOCHEM J, V378, P1083, DOI 10.1042/BJ20031150; Rajpar MH, 2001, HUM MOL GENET, V10, P1673, DOI 10.1093/hmg/10.16.1673; Risnes S, 1995, CONNECT TISSUE RES, V32, P183, DOI 10.3109/03008209509013722; ROBINSON C, 1988, CELL TISSUE RES, V254, P655; RONNHOLM E, 1962, J ULTRA MOL STRUCT R, V6, P249, DOI 10.1016/S0022-5320(62)80036-7; ROSEN D, 1981, NEUROPATH APPL NEURO, V7, P331, DOI 10.1111/j.1365-2990.1981.tb00236.x; Ryu OH, 1999, J DENT RES, V78, P743, DOI 10.1177/00220345990780030601; SALIDO EC, 1992, AM J HUM GENET, V50, P303; Seedorf H, 2007, J DENT RES, V86, P764, DOI 10.1177/154405910708600815; Simmer J. P., 2004, P 8 INT S BIOM NIIG, P348; SIMMER JP, 1994, CALCIFIED TISSUE INT, V54, P312, DOI 10.1007/BF00295956; Simmer JP, 1998, J DENT RES, V77, P377, DOI 10.1177/00220345980770020601; SIMMER JP, 1995, CRIT REV ORAL BIOL M, V6, P84, DOI 10.1177/10454411950060020701; Smith CE, 2005, J BONE MINER RES, V20, P240, DOI 10.1359/JBMR.041002; SNEAD ML, 1985, BIOCHEM BIOPH RES CO, V129, P812, DOI 10.1016/0006-291X(85)91964-3; SNEAD ML, 1983, P NATL ACAD SCI-BIOL, V80, P7254, DOI 10.1073/pnas.80.23.7254; TANABE T, 1990, CALCIFIED TISSUE INT, V46, P205, DOI 10.1007/BF02555046; UCHIDA T, 1991, HISTOCHEMISTRY, V96, P129, DOI 10.1007/BF00315983; UCHIDA T, 1991, ARCH HISTOL CYTOL, V54, P527, DOI 10.1679/aohc.54.527; Weiss DJ, 1999, HISTOCHEM J, V31, P231, DOI 10.1023/A:1003642025421; Wright JT, 2006, AM J MED GENET A, V140A, P2547, DOI 10.1002/ajmg.a.31358; YAMAKOSHI Y, 1995, CALCIFIED TISSUE INT, V56, P323, DOI 10.1007/BF00318054; Yamakoshi Y, 1998, CONNECT TISSUE RES, V39, P39, DOI 10.3109/03008209809023910; Yamakoshi Y, 2001, ARCH ORAL BIOL, V46, P1005, DOI 10.1016/S0003-9969(01)00070-X; YAMAKOSHI Y, 2001, P 8 INT S BIOM NIIG, P338; YAMAKOSHI Y, 2004, BIOMINERALIZATION FO, P326; Yamakoshi Y, 2006, EUR J ORAL SCI, V114, P266, DOI 10.1111/j.1600-0722.2006.00279.x; YOUNG DC, 1993, ANAL BIOCHEM, V215, P24, DOI 10.1006/abio.1993.1549; Zhang ZY, 2002, DEVELOPMENT, V129, P4135	75	123	127	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10858	10871		10.1074/jbc.M710565200	http://dx.doi.org/10.1074/jbc.M710565200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18252720	hybrid, Green Published			2022-12-25	WOS:000254894700068
J	Tsuchiya, H; Oka, T; Nakamura, K; Ichikawa, A; Saper, CB; Sugimoto, Y				Tsuchiya, Hiroyoshi; Oka, Takakazu; Nakamura, Kazuhiro; Ichikawa, Atsushi; Saper, Clifford B.; Sugimoto, Yukihiko			Prostaglandin E-2 attenuates preoptic expression of GABA(A) receptors via EP3 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FEBRILE RESPONSE; SUBTYPE EP3; RAT HYPOTHALAMUS; NERVOUS-SYSTEM; MESSENGER-RNA; AREA; FEVER; LOCALIZATION; NUCLEUS; NEURONS	Prostaglandin E-2 (PGE(2)) has been shown to produce fever by acting on EP3 receptors within the preoptic area of the brain. However, there is little information about the molecular events downstream of EP3 activation in preoptic neurons. As a first step toward this issue, we examined PGE(2)-induced gene expression changes at single-cell resolution in preoptic neurons expressing EP3. Brain sections of the preoptic area from PGE(2)- or saline-injected rats were stained with an anti-EP3 antibody, and the cell bodies of EP3-positive neurons were dissected and subjected to RNA amplification procedures. Microarray analysis of the amplified products demonstrated the possibility that gene expression of gamma-aminobutyric acid type A (GABA(A)) receptor subunits is decreased upon PGE(2) injection. Indeed, we found that most EP3-positive neurons in the mouse preoptic area are positive for the alpha 2 or gamma 2 GABA(A) receptor subunit. Moreover, PGE(2) decreased the preoptic gene expression of these GABA(A) subunits via an EP3-dependent and pertussis toxin-sensitive pathway. PGE(2) also attenuated the preoptic protein expression of the alpha 2 subunit in wild-type but not in EP3-deficient mice. These results indicate that PGE(2)-EP3 signaling elicits G(i/o) activation in preoptic thermocenter neurons, and we propose the possibility that a rapid decrease in preoptic GABA(A) expression may be involved in PGE(2)-induced fever.	[Tsuchiya, Hiroyoshi; Ichikawa, Atsushi; Sugimoto, Yukihiko] Kyoto Univ, Dept Physiol Chem, Grad Sch Pharmaceut Sci, Sakyo Ku, Kyoto 6068501, Japan; [Nakamura, Kazuhiro] Kyoto Univ, Mol Neurobiol Lab, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068501, Japan; [Oka, Takakazu; Saper, Clifford B.] Harvard Univ, Sch Med, Dept Neurol & Program Nerosci, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; [Oka, Takakazu] Univ Occupat & Environm Hlth, Dept Neurol, Div Psychosomat Med, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan	Kyoto University; Kyoto University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Occupational & Environmental Health - Japan	Sugimoto, Y (corresponding author), Kyoto Univ, Dept Physiol Chem, Grad Sch Pharmaceut Sci, Sakyo Ku, Kyoto 6068501, Japan.	ysugimot@pharm.kyoto-u.ac.jp	Nakamura, Kazuhiro/A-5431-2008; Sugimoto, Yukihiko/AAV-6470-2021; Saper, Clifford/L-3815-2019	Nakamura, Kazuhiro/0000-0002-6095-8996; Sugimoto, Yukihiko/0000-0001-6973-932X; 				Crino PB, 1996, P NATL ACAD SCI USA, V93, P14152, DOI 10.1073/pnas.93.24.14152; Elmquist JK, 1997, TRENDS NEUROSCI, V20, P565, DOI 10.1016/S0166-2236(97)01138-7; Fujimoto S, 2006, NEUROBIOL DIS, V22, P130, DOI 10.1016/j.nbd.2005.10.008; HALEY TJ, 1957, BRIT J PHARM CHEMOTH, V12, P12, DOI 10.1111/j.1476-5381.1957.tb01354.x; Kabashima K, 2002, J CLIN INVEST, V109, P883, DOI 10.1172/JCI14459; KLUGER MJ, 1991, PHYSIOL REV, V71, P93, DOI 10.1152/physrev.1991.71.1.93; Kunikata T, 2005, NAT IMMUNOL, V6, P524, DOI 10.1038/ni1188; Lazarus M, 2007, NAT NEUROSCI, V10, P1131, DOI 10.1038/nn1949; Marciano PG, 2004, J NEUROSCI, V24, P2866, DOI 10.1523/JNEUROSCI.5051-03.2004; MILTON AS, 1971, J PHYSIOL-LONDON, V218, P325, DOI 10.1113/jphysiol.1971.sp009620; Nakamura K, 2000, J COMP NEUROL, V421, P543, DOI 10.1002/(SICI)1096-9861(20000612)421:4<543::AID-CNE6>3.0.CO;2-3; Nakamura K, 2004, J NEUROSCI, V24, P5370, DOI 10.1523/JNEUROSCI.1219-04.2004; Nakamura K, 2002, J NEUROSCI, V22, P4600, DOI 10.1523/JNEUROSCI.22-11-04600.2002; Nakamura K, 1999, NEUROSCI LETT, V260, P117, DOI 10.1016/S0304-3940(98)00962-8; NEGISHI M, 1993, BIOCHIM BIOPHYS ACTA, V1175, P343, DOI 10.1016/0167-4889(93)90227-G; OKA T, 2003, J PHYSL, V55, P1945; Osaka T, 2004, AM J PHYSIOL-REG I, V287, pR306, DOI 10.1152/ajpregu.00003.2004; OSBORNE PG, 1994, BRAIN RES, V661, P237, DOI 10.1016/0006-8993(94)91200-9; Ranels HJ, 2003, BRAIN RES, V964, P42, DOI 10.1016/S0006-8993(02)04063-5; Rudolph U, 2006, CURR OPIN PHARMACOL, V6, P18, DOI 10.1016/j.coph.2005.10.003; Rudolph U, 2001, TRENDS PHARMACOL SCI, V22, P188, DOI 10.1016/S0165-6147(00)01646-1; SAPER CB, 1994, NEW ENGL J MED, V330, P1880; STITT JT, 1986, YALE J BIOL MED, V59, P137; SUGIMOTO Y, 1994, NEUROSCIENCE, V62, P919, DOI 10.1016/0306-4522(94)90483-9; Sugimoto Y, 2000, PROG LIPID RES, V39, P289, DOI 10.1016/S0163-7827(00)00008-4; Sugimoto Y, 2005, J IMMUNOL, V175, P2606, DOI 10.4049/jimmunol.175.4.2606; Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200; Tanaka S, 1998, J BIOL CHEM, V273, P8177, DOI 10.1074/jbc.273.14.8177; Ushikubi F, 1998, NATURE, V395, P281, DOI 10.1038/26233; WISDEN W, 1992, J NEUROSCI, V12, P1040; Yoshida K, 2003, EUR J NEUROSCI, V18, P1848, DOI 10.1046/j.1460-9568.2003.02919.x	31	13	15	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					11064	11071		10.1074/jbc.M801359200	http://dx.doi.org/10.1074/jbc.M801359200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18292084	hybrid			2022-12-25	WOS:000254894700086
J	Liu, K; Gualano, RC; Hibbs, ML; Anderson, GP; Bozinovski, S				Liu, Kenneth; Gualano, Rosa C.; Hibbs, Margaret L.; Anderson, Gary P.; Bozinovski, Steven			Epidermal growth factor receptor signaling to Erk1/2 and STATs control the intensity of the epithelial inflammatory responses to rhinovirus infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; INNATE IMMUNE-RESPONSES; C-ERBB RECEPTORS; VIRAL-INFECTIONS; BRONCHIAL EPITHELIUM; RESPIRATORY VIRUSES; NEGATIVE REGULATION; CIGARETTE-SMOKE; GM-CSF	Rhinovirus infection is the most common cause of acute exacerbations of inflammatory lung diseases, such as asthma and chronic obstructive pulmonary disease, where it provokes steroid refractory and abnormally intense neutrophilic inflammation that can be life threatening. Epidermal growth factor receptor (EGFR) expression correlates with disease severity and neutrophil infiltration in these conditions. However, the role of EGFR signaling in rhinovirus infection is unknown. We measured the key determinants of neutrophilic inflammation interleukin (IL)-8 and ICAM-1 in rhinovirus (RV16 serotype)- infected bronchial epithelial cells, BEAS-2B. RV16 infection stimulated IL-8 and ICAM-1 expression, which was further elevated (2-fold) by transient up-regulation of EGFR levels. Detection of viral RNA by quantitative real time PCR confirmed that enhanced expression was not associated with increased viral replication. EGFR ligands (epiregulin, amphiregulin, and heparin-binding epidermal growth factor) were induced by RV16 infection, and inhibition of metalloproteases responsible for ligand shedding partially suppressed this response. The EGFR inhibitor AG1478, completely blocked IL-8 and ICAM-1 expression to basal levels, as did the specific Erk1/2 inhibitor U0126. The p38 mitogen-activated protein kinase inhibitor SB203580 blocked IL-8 secretion but not ICAM-1 expression, whereas the PI3K inhibitor wortmannin was ineffective in both responses. Kinase inactive K721R EGFR, which is selectively deficient in STAT signaling, reversed RV16 responses associated with EGFR overexpression. In conclusion, RV16 infection rapidly promotes induction of EGFR ligands and utilizes EGFR signaling to increase IL-8 and ICAM-1 levels. These results suggest that targeting EGFR may provide a selective therapy that dampens neutrophil-driven inflammation without compromising essential antiviral pathways mediated by pathogen recognition receptors such as TLR3.	[Liu, Kenneth; Gualano, Rosa C.; Anderson, Gary P.; Bozinovski, Steven] Univ Melbourne, Dept Pharmacol, Melbourne, Vic 3010, Australia; [Hibbs, Margaret L.] Ludwig Inst Canc Res, Melbourne Branch, Parkville, Vic, Australia; [Anderson, Gary P.] Univ Melbourne, Dept Med, Melbourne, Vic 3010, Australia	University of Melbourne; Ludwig Institute for Cancer Research; University of Melbourne	Bozinovski, S (corresponding author), Univ Melbourne, Dept Pharmacol, Melbourne, Vic 3010, Australia.	bozis@unimelb.edu.au	Liu, Kenneth W/G-7973-2012; Hibbs, Margaret L/D-7013-2011	Hibbs, Margaret L/0000-0002-3751-6751; Bozinovski, Steven/0000-0001-6533-8641; Anderson, Gary/0000-0001-6580-3398				Anderson GP, 2003, TRENDS PHARMACOL SCI, V24, P71, DOI 10.1016/S0165-6147(02)00052-4; ARRUDA E, 1995, J INFECT DIS, V171, P1329, DOI 10.1093/infdis/171.5.1329; Atmar RL, 1998, ARCH INTERN MED, V158, P2453, DOI 10.1001/archinte.158.22.2453; Barsky SH, 1998, JNCI-J NATL CANCER I, V90, P1198, DOI 10.1093/jnci/90.16.1198; Bozinovski S, 2004, AM J PHYSIOL-LUNG C, V286, pL877, DOI 10.1152/ajplung.00275.2003; Bozinovski S, 2002, J BIOL CHEM, V277, P42808, DOI 10.1074/jbc.M207840200; CHEUNG D, 1995, AM J RESP CRIT CARE, V152, P1490, DOI 10.1164/ajrccm.152.5.7582282; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Covert MW, 2005, SCIENCE, V309, P1854, DOI 10.1126/science.1112304; Dagher H, 2004, J VIROL METHODS, V117, P113, DOI 10.1016/j.jviromet.2004.01.003; de Boer WI, 2006, AM J CLIN PATHOL, V125, P184, DOI 10.1039/W1AXKGT7UA37X257; Deb TB, 2001, J BIOL CHEM, V276, P15554, DOI 10.1074/jbc.M100928200; Donaldson GC, 2002, THORAX, V57, P847, DOI 10.1136/thorax.57.10.847; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; Fukao T, 2003, TRENDS IMMUNOL, V24, P358, DOI 10.1016/S1471-4906(03)00139-X; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; Griego SD, 2000, J IMMUNOL, V165, P5211, DOI 10.4049/jimmunol.165.9.5211; Grunberg K, 1999, AM J RESP CRIT CARE, V160, P1375; Grunberg K, 1997, AM J RESP CRIT CARE, V156, P609; Grunberg K, 1997, CLIN EXP ALLERGY, V27, P36, DOI 10.1111/j.1365-2222.1997.tb00670.x; Hamilton LM, 2003, CLIN EXP ALLERGY, V33, P233, DOI 10.1046/j.1365-2222.2003.01593.x; Hewson CA, 2005, J VIROL, V79, P12273, DOI 10.1128/JVI.79.19.12273-12279.2005; Holgate ST, 2000, CLIN EXP ALLERGY, V30, P1; HUCTHINSON AF, 2007, RESP MED, V101, P2472; Huguenel ED, 1997, AM J RESP CRIT CARE, V155, P1206, DOI 10.1164/ajrccm.155.4.9105055; Jeyaseelan S, 2007, J IMMUNOL, V178, P3153, DOI 10.4049/jimmunol.178.5.3153; Johnston NW, 2006, THORAX, V61, P722, DOI 10.1136/thx.2005.045161; Johnston Sebastian L, 2005, Proc Am Thorac Soc, V2, P150, DOI 10.1513/pats.200502-018AW; JOHNSTON SL, 1993, J CLIN MICROBIOL, V31, P111, DOI 10.1128/JCM.31.1.111-117.1993; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Korpi-Steiner NL, 2006, J LEUKOCYTE BIOL, V80, P1364, DOI 10.1189/jlb.0606412; LANNAN S, 1994, AM J PHYSIOL, V266, pL92, DOI 10.1152/ajplung.1994.266.1.L92; MacNee W, 2003, THORAX, V58, P261, DOI 10.1136/thorax.58.3.261; Mallia P, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-116; Mallia P, 2006, CHEST, V130, P1203, DOI 10.1378/chest.130.4.1203; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Nadel Jay A., 2001, Current Opinion in Pharmacology, V1, P254, DOI 10.1016/S1471-4892(01)00045-5; Naka T, 2005, ADV IMMUNOL, V87, P61, DOI 10.1016/S0065-2776(05)87003-8; Nakanaga T, 2007, AM J PHYSIOL-LUNG C, V292, pL1289, DOI 10.1152/ajplung.00356.2006; Newcomb DC, 2005, J BIOL CHEM, V280, P36952, DOI 10.1074/jbc.M502449200; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; O'Donnell RA, 2004, THORAX, V59, P1032, DOI 10.1136/thx.2004.028043; Oliver BGG, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-71; Ozes ON, 1999, NATURE, V401, P82; Papi A, 1999, J BIOL CHEM, V274, P9707, DOI 10.1074/jbc.274.14.9707; Papi A, 2006, AM J RESP CRIT CARE, V173, P1114, DOI 10.1164/rccm.200506-859OC; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Polosa R, 2002, J ALLERGY CLIN IMMUN, V109, P75, DOI 10.1067/mai.2002.120274; Polosa R, 1999, AM J RESP CELL MOL, V20, P914, DOI 10.1165/ajrcmb.20.5.3308; Proud D, 2006, AM J RESP CELL MOL, V35, P513, DOI 10.1165/rcmb.2006-0199TR; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; Robbins CS, 2004, AM J RESP CELL MOL, V30, P202, DOI 10.1165/rcmb.2003-0259OC; Rohde G, 2003, THORAX, V58, P37, DOI 10.1136/thorax.58.1.37; Sanders SP, 2001, J ALLERGY CLIN IMMUN, V107, P235, DOI 10.1067/mai.2001.112028; Schroth MK, 1999, AM J RESP CELL MOL, V20, P1220, DOI 10.1165/ajrcmb.20.6.3261; Seemungal T, 2001, AM J RESP CRIT CARE, V164, P1618, DOI 10.1164/ajrccm.164.9.2105011; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; SUBAUSTE MC, 1995, J CLIN INVEST, V96, P549, DOI 10.1172/JCI118067; Walker F, 1998, MOL CELL BIOL, V18, P7192, DOI 10.1128/MCB.18.12.7192; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Yu YM, 2003, AM J PHYSIOL-GASTR L, V285, pG282, DOI 10.1152/ajpgi.00503.2002	63	78	94	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9977	9985		10.1074/jbc.M710257200	http://dx.doi.org/10.1074/jbc.M710257200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18276593	hybrid			2022-12-25	WOS:000254671600054
J	Lu, TC; He, JC; Wang, ZH; Feng, X; Fukumi-Tominaga, T; Chen, N; Xu, J; Iyengar, R; Klotman, PE				Lu, Ting-chi; He, John Cijiang; Wang, Zhao-hui; Feng, Xiaobei; Fukumi-Tominaga, Tomoko; Chen, Nan; Xu, Jin; Iyengar, Ravi; Klotman, Paul E.			HIV-1 nef disrupts the podocyte actin cytoskeleton by interacting with diaphanous interacting protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING PATHWAY; RHO ACTIVITY; NEPHROPATHY; ACTIVATION; TYPE-1; INFECTION; RAC; ORGANIZATION; DISEASE; AIDS	The ability of the human immunodeficiency virus, type 1 (HIV-1) protein Nef to induce cytoskeleton changes in infected host cells is a key event in viral replication. In renal podocytes, we found that Nef induced loss of stress fibers and increased lamellipodia, pathological changes leading to proteinuria in HIV-associated nephropathy. These morphological changes were mediated by Nef-induced Rac1 activation and RhoA inhibition. We identified a new interaction between Nef and diaphanous interacting protein (DIP), a recently described regulator of Rho and Rac signaling. We found that the Src homology 3 binding domain of DIP and the Nef PXXP motif were required for this interaction. Nef also interacts with Vav2 in podocytes. DIP and Vav2 both interact directly with Nef in a competitive manner. DIP interacts with p190RhoGAP, and intact DIP was required for Nef-induced phosphorylation of p190RhoGAP. DIP also interacts with Vav2, and although DIP enhanced baseline phosphorylation of Vav2, it was not required for Nef- induced Vav2 activation. In Nef- infected podocytes, Src kinase induces phosphorylation of DIP, p190RhoGAP, and Vav2, leading to RhoA inhibition and Rac1 activation. Inhibition of the Nef- induced signaling pathway by using a dominant negative of either Src or DIP or siRNA for DIP or p190RhoAGAP restored RhoA activity and stress fiber formation in Nef- infected podocytes, whereas siRNA for Vav2 reduced Rac1 activity and formation of lamellipodia. We conclude that in HIV-infected podocytes, Nef, through the recruitment of DIP and p190RhoAGAP to Nef- Src complex, activates p190RhoAGAP and down-regulates RhoA activity.	[Lu, Ting-chi; He, John Cijiang; Wang, Zhao-hui; Feng, Xiaobei; Klotman, Paul E.] Mt Sinai Sch Med, Div Nephrol, Dept Med, New York, NY 10029 USA; [Iyengar, Ravi] Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA; [He, John Cijiang] James J Peters Vet Affair Med Ctr, Bronx, NY 10468 USA; [Wang, Zhao-hui; Feng, Xiaobei; Chen, Nan] Shanghai Jiao Tong Univ, Sch Med, Rui Jin Hosp, Dept Nephrol, Shanghai 200025, Peoples R China; [Fukumi-Tominaga, Tomoko] Natl Inst Nat Sci, Natl Inst Physiol Sci, Sect Cell Signalling, Okazaki, Aichi 4448585, Japan	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; US Department of Veterans Affairs; Veterans Health Administration (VHA); James J. Peters VA Medical Center; Shanghai Jiao Tong University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)	He, JC (corresponding author), Mt Sinai Sch Med, Div Nephrol, Dept Med, Box 1243,1 Gustave L Levy Pl, New York, NY 10029 USA.	Cijiang.he@mssm.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK065495, P01DK056492, R01DK078897, K08DK079781] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054508] Funding Source: NIH RePORTER; NIDDK NIH HHS [K08 DK 079781, P01 DK 056492, K08 DK 065495, R01 DK 078897] Funding Source: Medline; NIGMS NIH HHS [R01 GM054508, R01 GM 54508] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asanuma K, 2006, NAT CELL BIOL, V8, P485, DOI 10.1038/ncb1400; Asanuma K, 2005, J CLIN INVEST, V115, P1188, DOI 10.1172/JCI200523371; Barisoni L, 1999, J AM SOC NEPHROL, V10, P51; Barisoni L, 2000, KIDNEY INT, V58, P173, DOI 10.1046/j.1523-1755.2000.00152.x; Campbell EM, 2004, J VIROL, V78, P5745, DOI 10.1128/JVI.78.11.5745-5755.2004; CHANDER P, 1987, AM J PATHOL, V126, P513; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; Chuang PY, 2007, KIDNEY INT, V72, P965, DOI 10.1038/sj.ki.5002456; DAGATI V, 1989, KIDNEY INT, V35, P1358, DOI 10.1038/ki.1989.135; DAgati V, 1997, J AM SOC NEPHROL, V8, P138; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; Dennis CA, 2005, PROTEINS, V60, P658, DOI 10.1002/prot.20544; Fackler OT, 2002, IMMUNITY, V16, P493, DOI 10.1016/S1074-7613(02)00307-2; Fackler OT, 1997, EUR J BIOCHEM, V247, P843, DOI 10.1111/j.1432-1033.1997.00843.x; Fackler OT, 1999, MOL CELL, V3, P729, DOI 10.1016/S1097-2765(01)80005-8; Geyer M, 2001, EMBO REP, V2, P580, DOI 10.1093/embo-reports/kve141; Haller C, 2006, J BIOL CHEM, V281, P19618, DOI 10.1074/jbc.M513802200; Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1; He JCJ, 2004, J CLIN INVEST, V114, P643, DOI 10.1172/JCI200421004; Husain M, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000019642.55998.69; Ichimura K, 2003, J HISTOCHEM CYTOCHEM, V51, P1589, DOI 10.1177/002215540305101203; KAMINCHIK J, 1994, AIDS RES HUM RETROV, V10, P1003, DOI 10.1089/aid.1994.10.1003; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; Kos CH, 2003, J CLIN INVEST, V111, P1683, DOI 10.1172/JCI200317988; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; Liu LX, 2000, J VIROL, V74, P5310, DOI 10.1128/JVI.74.11.5310-5319.2000; Meng WX, 2004, EMBO J, V23, P760, DOI 10.1038/sj.emboj.7600095; Mundel P, 2002, J AM SOC NEPHROL, V13, P3005, DOI 10.1097/01.ASN.0000039661.06947.FD; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; Quaranta MG, 2003, FASEB J, V17, P2025, DOI 10.1096/fj.03-0272com; RAO TKS, 1987, NEW ENGL J MED, V316, P1062, DOI 10.1056/NEJM198704233161705; Renkema GH, 1999, CURR BIOL, V9, P1407, DOI 10.1016/S0960-9822(00)80086-X; RIDLEY AJ, 1992, COLD SPRING HARB SYM, V57, P661, DOI 10.1101/SQB.1992.057.01.072; Ridley AJ, 1999, NAT CELL BIOL, V1, pE64, DOI 10.1038/11034; Saleem MA, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133630; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Satoh S, 2001, J BIOL CHEM, V276, P39290, DOI 10.1074/jbc.M107026200; Schwartz EJ, 2001, J AM SOC NEPHROL, V12, P1677, DOI 10.1681/ASN.V1281677; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; Sunamoto M, 2003, KIDNEY INT, V64, P1695, DOI 10.1046/j.1523-1755.2003.00283.x; Thoulouze MI, 2006, IMMUNITY, V24, P547, DOI 10.1016/j.immuni.2006.02.016; Winston JA, 2001, NEW ENGL J MED, V344, P1979, DOI 10.1056/NEJM200106283442604; Ye HH, 2004, BIOCHEMISTRY-US, V43, P15775, DOI 10.1021/bi048712f; Zhong JY, 2005, KIDNEY INT, V68, P1048, DOI 10.1111/j.1523-1755.2005.00497.x; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775; Zuo YQ, 2006, J AM SOC NEPHROL, V17, P2832, DOI 10.1681/ASN.2005080878	47	71	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8173	8182		10.1074/jbc.M708920200	http://dx.doi.org/10.1074/jbc.M708920200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18234668	Green Published, hybrid			2022-12-25	WOS:000254288000014
J	Scheurwater, EM; Clarke, AJ				Scheurwater, Edie M.; Clarke, Anthony J.			The C-terminal domain of Escherichia coli YfhD functions as a lytic transglycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; PSEUDOMONAS-AERUGINOSA; MUREIN HYDROLASES; OUTER-MEMBRANE; PEPTIDOGLYCAN; IDENTIFICATION; MECHANISM; FAMILY; LYSIS; PURIFICATION	The hypothetical Escherichia coli protein YfhD has been identified as the archetype for the family 1B lytic transglycosylases despite a complete lack of experimental characterization. The yfhD gene was amplified from the genomic DNA of E. coli W3110 and cloned to encode a fusion protein with a C-terminal His(6) sequence. The enzyme was found to be localized to the outer membrane of E. coli, as would be expected for a lytic transglycosylase. Its gene was engineered for the production of a truncated soluble enzyme derivative lacking an N-terminal signal sequence and membrane anchor. The soluble YfhD derivative was purified to apparent homogeneity, and three separate in vitro assays involving high pressure liquid chromatography and matrix-assisted laser desorption ionization time-of-flight mass spectrometry were used to demonstrate the YfhD-catalyzed release of 1,6-anhydromuro-peptides from insoluble peptidoglycan. In addition, an in vivo bioassay developed using the bacteriophage lambda lysis system confirmed that the enzyme functions as an autolysin. Based on these data, the enzyme was renamed membrane-bound lytic transglycosylase F. The modular structure of MltF was investigated through genetic engineering for the separate production of identified N-terminal and C-terminal domains. The ability to bind peptidoglycan and lytic activity were only associated with the isolated C-terminal domain. The enzymatic properties of this lytic transglycosylase domain were found to be very similar to those of the wild-type enzyme. The one notable exception was that the N-terminal domain appears to modulate the lytic behavior of the C-terminal domain to permit continued lysis of insoluble peptidoglycan, a unique feature of MltF compared with other characterized lytic transglycosylases.	[Scheurwater, Edie M.; Clarke, Anthony J.] Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada	University of Guelph	Clarke, AJ (corresponding author), Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 1W1, Canada.	aclarke@uoguelph.ca						BERNADSKY G, 1994, J BACTERIOL, V176, P5225, DOI 10.1128/JB.176.17.5225-5232.1994; BIENKOWSKASZEWCZYK K, 1981, MOL GEN GENET, V184, P111, DOI 10.1007/BF00271205; Blackburn NT, 2002, BIOCHEMISTRY-US, V41, P1001, DOI 10.1021/bi011833k; Blackburn NT, 2001, J MOL EVOL, V52, P78, DOI 10.1007/s002390010136; Blackburn NT, 2000, ANAL BIOCHEM, V284, P388, DOI 10.1006/abio.2000.4707; Chaput C, 2007, J BACTERIOL, V189, P422, DOI 10.1128/JB.01270-06; CLARKE AJ, 1993, ANAL BIOCHEM, V212, P344, DOI 10.1006/abio.1993.1339; Clarke AJ, 2000, GLYCOMICROBIOLOGY, P187; Dijkstra AJ, 1996, MICROB DRUG RESIST, V2, P141, DOI 10.1089/mdr.1996.2.141; EHLERT K, 1995, MOL MICROBIOL, V16, P761, DOI 10.1111/j.1365-2958.1995.tb02437.x; HASH JH, 1967, J BACTERIOL, V93, P1201, DOI 10.1128/JB.93.3.1201-1202.1967; Heidrich C, 2002, J BACTERIOL, V184, P6093, DOI 10.1128/JB.184.22.6093-6099.2002; HILL CW, 1981, P NATL ACAD SCI-BIOL, V78, P7069, DOI 10.1073/pnas.78.11.7069; Hoang TT, 1998, GENE, V212, P77, DOI 10.1016/S0378-1119(98)00130-9; Holtje JV, 1998, MICROBIOL MOL BIOL R, V62, P181; KARKHANIS YD, 1978, ANAL BIOCHEM, V85, P595, DOI 10.1016/0003-2697(78)90260-9; KOONIN EV, 1994, TRENDS BIOCHEM SCI, V19, P106; Koraimann G, 2003, CELL MOL LIFE SCI, V60, P2371, DOI 10.1007/s00018-003-3056-1; Korsak D, 2005, ANTIMICROB AGENTS CH, V49, P1404, DOI 10.1128/AAC.49.4.1404-1409.2005; Kraft AR, 1998, J BACTERIOL, V180, P3441, DOI 10.1128/JB.180.13.3441-3447.1998; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lommatzsch J, 1997, J BACTERIOL, V179, P5465, DOI 10.1128/jb.179.17.5465-5470.1997; MASSAD G, 1994, GENE, V150, P101, DOI 10.1016/0378-1119(94)90866-4; OH BH, 1993, J BIOL CHEM, V268, P11348; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; Popham DL, 2003, CURR OPIN MICROBIOL, V6, P594, DOI 10.1016/j.mib.2003.10.002; Rahn A, 2003, MOL MICROBIOL, V47, P1045, DOI 10.1046/j.1365-2958.2003.03354.x; Reid CW, 2007, FEBS LETT, V581, P4988, DOI 10.1016/j.febslet.2007.09.037; Reid CW, 2006, BIOCHEMISTRY-US, V45, P2129, DOI 10.1021/bi052342t; Reid CW, 2004, BIOCHEMISTRY-US, V43, P11275, DOI 10.1021/bi049496d; SCHEURWATER E, 2008, IN PRESS INT J BIOCH; Smith LK, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r87; SUSSMAN R, 1962, CR HEBD ACAD SCI, V254, P1517; Ursinus A, 2004, J BACTERIOL, V186, P6728, DOI 10.1128/JB.186.20.6728-6737.2004; URSINUS A, 1994, J BACTERIOL, V176, P338, DOI 10.1128/JB.176.2.338-343.1994; WALDERICH B, 1991, J BACTERIOL, V173, P5668, DOI 10.1128/jb.173.18.5668-5676.1991; WATT SR, 1994, FEMS MICROBIOL LETT, V124, P113, DOI 10.1111/j.1574-6968.1994.tb07270.x; Watt SR, 1997, CAN J MICROBIOL, V43, P1054, DOI 10.1139/m97-150; Weadge JT, 2006, BIOCHEMISTRY-US, V45, P839, DOI 10.1021/bi051679s; YOUNG R, 1995, FEMS MICROBIOL REV, V17, P191, DOI 10.1016/0168-6445(94)00079-4; YOUNG RY, 1992, MICROBIOL REV, V56, P430, DOI 10.1128/MMBR.56.3.430-481.1992	41	42	44	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8363	8373		10.1074/jbc.M710135200	http://dx.doi.org/10.1074/jbc.M710135200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18234673	Green Published, hybrid			2022-12-25	WOS:000254288000034
J	Frund, I; Busch, NA; Schadow, J; Gruber, T; Korner, U; Herrmann, CS				Fruend, Ingo; Busch, Niko A.; Schadow, Jeanette; Gruber, Thomas; Koerner, Ursula; Herrmann, Christoph S.			Time Pressure Modulates Electrophysiological Correlates of Early Visual Processing	PLOS ONE			English	Article							OSCILLATORY BRAIN ACTIVITY; TOP-DOWN FACILITATION; GAMMA-BAND ACTIVITY; EVOKED GAMMA; RESPONSES; STATISTICS; VISION; TASK; EEG	Background: Reactions to sensory events sometimes require quick responses whereas at other times they require a high degree of accuracy-usually resulting in slower responses. It is important to understand whether visual processing under different response speed requirements employs different neural mechanisms. Methodology/Principal Findings: We asked participants to classify visual patterns with different levels of detail as real-world or non-sense objects. In one condition, participants were to respond immediately, whereas in the other they responded after a delay of 1 second. As expected, participants performed more accurately in delayed response trials. This effect was pronounced for stimuli with a high level of detail. These behavioral effects were accompanied by modulations of stimulus related EEG gamma oscillations which are an electrophysiological correlate of early visual processing. In trials requiring speeded responses, early stimulus-locked oscillations discriminated real-world and non-sense objects irrespective of the level of detail. For stimuli with a higher level of detail, oscillatory power in a later time window discriminated real-world and non-sense objects irrespective of response speed requirements. Conclusions/Significance: Thus, it seems plausible to assume that different response speed requirements trigger different dynamics of processing.	[Fruend, Ingo; Busch, Niko A.; Schadow, Jeanette; Herrmann, Christoph S.] Otto Von Guericke Univ, Dept Biol Psychol, Inst Psychol, Magdeburg, Germany; [Fruend, Ingo; Herrmann, Christoph S.] Bernstein Grp Computat Neurosci, Magdeburg, Germany; [Fruend, Ingo] Leibniz Inst Neurobiol, Magdeburg, Germany; [Busch, Niko A.] Univ Paul Sabatier, CNRS, Ctr Rech Cerveau Cognit, Toulouse, France; [Gruber, Thomas] Univ Leipzig, Inst Psychol 1, Leipzig, Germany; [Koerner, Ursula] Honda Res Inst, Offenbach, Germany; [Herrmann, Christoph S.] Ctr Behav Brain Sci, Magdeburg, Germany	Otto von Guericke University; Leibniz Institut fur Neurobiologie (LIN); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Leipzig University; Honda Motor Company	Frund, I (corresponding author), Otto Von Guericke Univ, Dept Biol Psychol, Inst Psychol, Magdeburg, Germany.	christoph.herrmann@ovgu.de		Herrmann, Christoph/0000-0003-0323-2272; Busch, Niko/0000-0003-4837-0345	German Research Foundation [HE3353/2-2]; BMBF Bernstein Group Magdeburg	German Research Foundation(German Research Foundation (DFG)); BMBF Bernstein Group Magdeburg	JS was supported by the German Research Foundation (DFG, grant HE3353/2-2). IF was supported by the national network on computational neuroscience (BMBF Bernstein Group Magdeburg).	Ahissar M, 2004, TRENDS COGN SCI, V8, P457, DOI 10.1016/j.tics.2004.08.011; Axmacher N, 2006, BRAIN RES REV, V52, P170, DOI 10.1016/j.brainresrev.2006.01.007; Bar M, 2003, J COGNITIVE NEUROSCI, V15, P600, DOI 10.1162/089892903321662976; Bar M, 2006, P NATL ACAD SCI USA, V103, P449, DOI 10.1073/pnas.0507062103; Basar E., 1980, EEG BRAIN DYNAMICS; BasarEroglu C, 1996, INT J PSYCHOPHYSIOL, V24, P101, DOI 10.1016/S0167-8760(96)00051-7; Busch NA, 2006, NEUROIMAGE, V29, P1106, DOI 10.1016/j.neuroimage.2005.09.009; Busch NA, 2004, CLIN NEUROPHYSIOL, V115, P1810, DOI 10.1016/j.clinph.2004.03.015; Busch NA, 2006, NEUROIMAGE, V33, P1169, DOI 10.1016/j.neuroimage.2006.07.034; Cariani PA, 2004, IEEE T NEURAL NETWOR, V15, P1100, DOI 10.1109/TNN.2004.833305; Doniger GM, 2000, J COGNITIVE NEUROSCI, V12, P615, DOI 10.1162/089892900562372; Engel AK, 2001, NAT REV NEUROSCI, V2, P704, DOI 10.1038/35094565; FIELD DJ, 1987, J OPT SOC AM A, V4, P2379, DOI 10.1364/JOSAA.4.002379; Field DJ, 1999, PHILOS T R SOC A, V357, P2527, DOI 10.1098/rsta.1999.0446; Fisher NI, 1995, STAT ANAL CIRCULAR D; Foxe JJ, 2002, EXP BRAIN RES, V142, P139, DOI 10.1007/s00221-001-0906-7; Frund I, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-27; Frund I, 2007, CLIN NEUROPHYSIOL, V118, P221, DOI 10.1016/j.clinph.2006.09.013; Gruber T, 2005, CEREB CORTEX, V15, P109, DOI 10.1093/cercor/bhh113; Gruber T, 2006, BRAIN RES, V1097, P194, DOI 10.1016/j.brainres.2006.04.069; Herrmann C. S., 2005, EVENT RELATED POTENT, P229; Herrmann CS, 2004, TRENDS COGN SCI, V8, P347, DOI 10.1016/j.tics.2004.06.006; Herrmann CS, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-13; Herrmann CS, 2000, INT J PSYCHOPHYSIOL, V38, P265, DOI 10.1016/S0167-8760(00)00170-7; Hochstein S, 2002, NEURON, V36, P791, DOI 10.1016/S0896-6273(02)01091-7; Keselman HJ, 1998, PSYCHOPHYSIOLOGY, V35, P470, DOI 10.1111/1469-8986.3540470; Kording KP, 2000, NEURAL NETWORKS, V13, P1, DOI 10.1016/S0893-6080(99)00088-X; Korner E, 1999, NEURAL NETWORKS, V12, P989, DOI 10.1016/S0893-6080(99)00049-0; Lamme VAF, 2000, TRENDS NEUROSCI, V23, P571, DOI 10.1016/S0166-2236(00)01657-X; Morup M, 2006, NEUROIMAGE, V29, P938, DOI 10.1016/j.neuroimage.2005.08.005; Rodemann T, 2003, NEUROCOMPUTING, V52-4, P901, DOI 10.1016/S0925-2312(02)00827-5; Rodemann T, 2001, NEUROCOMPUTING, V38, P1541, DOI 10.1016/S0925-2312(01)00554-9; Rossion B, 2004, PERCEPTION, V33, P217, DOI 10.1068/p5117; Tallon-Baudry C, 1998, J NEUROSCI, V18, P4244; Tallon-Baudry C, 1999, TRENDS COGN SCI, V3, P151, DOI 10.1016/S1364-6613(99)01299-1; TallonBaudry C, 1996, J NEUROSCI, V16, P4240; Thorpe S, 1996, NATURE, V381, P520, DOI 10.1038/381520a0; Thorpe S, 2001, NEURAL NETWORKS, V14, P715, DOI 10.1016/S0893-6080(01)00083-1; TIITINEN H, 1993, NATURE, V364, P59, DOI 10.1038/364059a0; VanRullen R, 2002, VISION RES, V42, P2593, DOI 10.1016/S0042-6989(02)00298-5	40	14	14	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2008	3	2							e1675	10.1371/journal.pone.0001675	http://dx.doi.org/10.1371/journal.pone.0001675			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	367XS	18301752	Green Published, Green Submitted, gold			2022-12-25	WOS:000260586500019
J	Janson, PCJ; Winerdal, ME; Marits, P; Thorn, M; Ohlsson, R; Winqvist, O				Janson, Peter C. J.; Winerdal, Malin E.; Marits, Per; Thorn, Magnus; Ohlsson, Rolf; Winqvist, Ola			FOXP3 Promoter Demethylation Reveals the Committed Treg Population in Humans	PLOS ONE			English	Article								Background: Naturally occurring thymus derived regulatory T cells (Tregs) are central in the maintenance of self-tolerance. The transcription factor FOXP3 is crucial for the suppressive activity of Tregs and is considered the most specific marker for this population. However, human non regulatory T cells upregulate FOXP3 transiently upon activation which calls for other means to identify the Treg population. Since epigenetic mechanisms are involved in the establishment of stable gene expression patterns during cell differentiation, we hypothesized that the methylation profile of the FOXP3 promoter would allow the distinction of truly committed Tregs. Methodology/Principal Findings: Human CD4(+) CD25(hi) Tregs displayed a demethylated FOXP3 promoter (1.4%+/-0.95% SEM methylated) in contrast to CD4(+) CD25(lo) T cells which were partially methylated (27.9%+/-7.1%). Furthermore, stimulated CD4(+)CD25(lo) T cells transiently expressed FOXP3 but remained partially methylated, suggesting promoter methylation as a mechanism for regulation of stable FOXP3 expression and Treg commitment. In addition, transient FOXP3 expressing cells exhibited suppressive abilities that correlate to the methylation status of the FOXP3 promoter. As an alternative to bisulphite sequencing, we present a restriction enzyme based screening method for the identification of committed Tregs and apply this method to evaluate the effect of various culturing conditions. We show that a partial demethylation occurs in long-term cultures after activation, whereas the addition of TGF-beta and/or IL-10 does not induce any additional change in methylation level. Conclusions/Significance: The unique FOXP3 promoter methylation profile in Tregs suggests that a demethylated pattern is a prerequisite for stable FOXP3 expression and suppressive phenotype. Presently, FOXP3 is used to identify Tregs in several human diseases and there are future implications for adoptive Treg transfer in immunotherapy. In these settings there is a need to distinguish true Tregs from transiently FOXP3(+) activated T cells. The screening method we present allows this distinction and enables the identification of cells suitable for in vitro expansions and clinical use.	[Janson, Peter C. J.; Winerdal, Malin E.; Marits, Per; Winqvist, Ola] Karolinska Inst, Dept Med, Clin Allergy Res Unit, Stockholm, Sweden; [Thorn, Magnus] South Stockholm Gen Hosp, Dept Surg, Stockholm, Sweden; [Ohlsson, Rolf] Uppsala Univ, Evol Biol Ctr, Dept Dev & Genet, Uppsala, Sweden	Karolinska Institutet; Uppsala University	Janson, PCJ (corresponding author), Karolinska Inst, Dept Med, Clin Allergy Res Unit, Stockholm, Sweden.	ola.winqvist@karolinska.se		winqvist, Ola/0000-0003-0842-4441	Swedish cancer society; Cancer and Allergy society; Hedlunds foundation; Lundberg foundation; Gustav V. foundation; Selander foundation; Soderbergs foundation	Swedish cancer society(Swedish Cancer Society); Cancer and Allergy society; Hedlunds foundation; Lundberg foundation(European Commission); Gustav V. foundation; Selander foundation; Soderbergs foundation	This work was supported by the Swedish cancer society, the Cancer and Allergy society, the Hedlunds foundation, the Lundberg foundation, Gustav V. foundation, the Selander foundation and the Soderbergs foundation.	Allan SE, 2007, INT IMMUNOL, V19, P345, DOI 10.1093/intimm/dxm014; Allan SE, 2005, J CLIN INVEST, V115, P3276, DOI 10.1172/JCI24685; Ansel KM, 2003, NAT IMMUNOL, V4, P616, DOI 10.1038/ni0703-616; Baecher-Allan C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/jimmunol.167.3.1245; Baron U, 2007, EUR J IMMUNOL, V37, P2378, DOI 10.1002/eji.200737594; Bas A, 2004, SCAND J IMMUNOL, V59, P566, DOI 10.1111/j.0300-9475.2004.01440.x; Beyer M, 2006, BLOOD, V108, P804, DOI 10.1182/blood-2006-02-002774; Bruniquel D, 2003, NAT IMMUNOL, V4, P235, DOI 10.1038/ni887; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Clark LB, 1999, J IMMUNOL, V162, P2546; Fantini MC, 2004, J IMMUNOL, V172, P5149, DOI 10.4049/jimmunol.172.9.5149; Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Fu S, 2004, AM J TRANSPLANT, V4, P1614, DOI 10.1111/j.1600-6143.2004.00566.x; Gambineri E, 2003, CURR OPIN RHEUMATOL, V15, P430, DOI 10.1097/00002281-200307000-00010; Gavin MA, 2006, P NATL ACAD SCI USA, V103, P6659, DOI 10.1073/pnas.0509484103; GODFREY VL, 1991, AM J PATHOL, V138, P1379; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Kim HP, 2007, J EXP MED, V204, P1543, DOI 10.1084/jem.20070109; Kim JM, 2006, IMMUNOL REV, V212, P86, DOI 10.1111/j.0105-2896.2006.00426.x; Kretschmer K, 2005, NAT IMMUNOL, V6, P1219, DOI 10.1038/ni1265; Kriegel MA, 2004, J EXP MED, V199, P1285, DOI 10.1084/jem.20032158; Lee GR, 2006, IMMUNITY, V24, P369, DOI 10.1016/j.immuni.2006.03.007; Mantel PY, 2006, J IMMUNOL, V176, P3593, DOI 10.4049/jimmunol.176.6.3593; Morgan ME, 2005, HUM IMMUNOL, V66, P13, DOI 10.1016/j.humimm.2004.05.016; Park HB, 2004, INT IMMUNOL, V16, P1203, DOI 10.1093/intimm/dxh123; Pillai V, 2007, CLIN IMMUNOL, V123, P18, DOI 10.1016/j.clim.2006.10.014; Radonic A, 2004, BIOCHEM BIOPH RES CO, V313, P856, DOI 10.1016/j.bbrc.2003.11.177; Ruprecht CR, 2005, J EXP MED, V201, P1793, DOI 10.1084/jem.20050085; Taams LS, 2002, EUR J IMMUNOL, V32, P1621, DOI 10.1002/1521-4141(200206)32:6<1621::AID-IMMU1621>3.0.CO;2-Q; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; TRAN DQ, 2007, BLOOD; Walker MR, 2005, P NATL ACAD SCI USA, V102, P4103, DOI 10.1073/pnas.0407691102; Walker MR, 2003, J CLIN INVEST, V112, P1437, DOI 10.1172/JCI200319441; Walther M, 2005, IMMUNITY, V23, P287, DOI 10.1016/j.immuni.2005.08.006; Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435; Wilson CB, 2005, SEMIN IMMUNOL, V17, P105, DOI 10.1016/j.smim.2005.01.005; Wu B, 2007, J IMMUNOL, V178, P3688, DOI 10.4049/jimmunol.178.6.3688; Yagi H, 2004, INT IMMUNOL, V16, P1643, DOI 10.1093/intimm/dxh165; Zorn E, 2006, BLOOD, V108, P1571, DOI 10.1182/blood-2006-02-004747	42	178	192	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1612	10.1371/journal.pone.0001612	http://dx.doi.org/10.1371/journal.pone.0001612			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286169	Green Submitted, Green Published, gold			2022-12-25	WOS:000260586400005
J	Guest, CB; Deszo, EL; Hartman, ME; York, JM; Kelley, KW; Freund, GG				Guest, Christopher B.; Deszo, Eric L.; Hartman, Matthew E.; York, Jason M.; Kelley, Keith W.; Freund, Gregory G.			Ca2+/Calmodulin-Dependent Kinase Kinase alpha Is Expressed by Monocytic Cells and Regulates the Activation Profile	PLOS ONE			English	Article							DEPENDENT PROTEIN-KINASE; MURINE PERITONEAL-MACROPHAGES; ADENYLATE-CYCLASE ACTIVITY; PHORBOL ESTERS; INTRACELLULAR CALCIUM; TYROSINE PHOSPHORYLATION; TRYPANOSOMA-CRUZI; MOLECULAR-CLONING; INTERFERON-GAMMA; C ACTIVATION	Macrophages are capable of assuming numerous phenotypes in order to adapt to endogenous and exogenous challenges but many of the factors that regulate this process are still unknown. We report that Ca2+/calmodulin-dependent kinase kinase a (CaMKK alpha) is expressed in human monocytic cells and demonstrate that its inhibition blocks type-II monocytic cell activation and promotes classical activation. Affinity chromatography with paramagnetic beads isolated an approximately 50 kDa protein from nuclear lysates of U937 human monocytic cells activated with phorbol-12-myristate-13-acetate (PMA). This protein was identified as CaMKK alpha by mass spectrometry and Western analysis. The function of CaMKK alpha in monocyte activation was examined using the CaMKK alpha inhibitors (STO-609 and forskolin) and siRNA knockdown. Inhibition of CaMKKa, enhanced PMA-dependent CD86 expression and reduced CD11b expression. In addition, inhibition was associated with decreased translocation of CaMKK alpha to the nucleus. Finally, to further examine monocyte activation profiles, TNF alpha and IL-10 secretion were studied. CaMKK alpha inhibition attenuated PMA-dependent IL-10 production and enhanced TNFa production indicating a shift from type-II to classical monocyte activation. Taken together, these findings indicate an important new role for CaMKK alpha in the differentiation of monocytic cells.	[Guest, Christopher B.; Freund, Gregory G.] Univ Illinois, Div Nutr Sci, Urbana, IL 61801 USA; [Deszo, Eric L.; Hartman, Matthew E.; York, Jason M.; Kelley, Keith W.; Freund, Gregory G.] Univ Illinois, Dept Animal Sci, Urbana, IL USA; [Freund, Gregory G.] Univ Illinois, Dept Pathol, Urbana, IL USA; [Guest, Christopher B.; Hartman, Matthew E.; Freund, Gregory G.] Univ Illinois, Dept Coll Med, Urbana, IL USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Guest, CB (corresponding author), Univ Illinois, Div Nutr Sci, Urbana, IL 61801 USA.	freun@uiuc.edu		Kelley, Keith W./0000-0002-6837-8793; Hartman, Matt/0000-0002-6238-1887	National Institutes of Health [DK064862, NS046227]; Ruth Kirschstein Institutional National Research Service Award [5T32 DK59802]; Division of Nutritional Sciences; University of Illinois Agricultural Experiment Station; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK059802, R01DK064862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F30NS046227] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ruth Kirschstein Institutional National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Division of Nutritional Sciences; University of Illinois Agricultural Experiment Station; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This research was supported by grants from the National Institutes of Health (DK064862 to G.G.F, NS046227 to M.E.H., Ruth Kirschstein Institutional National Research Service Award 5T32 DK59802 to the Division of Nutritional Sciences and Predoctoral Fellowship to C.B.G.), University of Illinois Agricultural Experiment Station (to G.G.F.).	Anderson CF, 2002, J LEUKOCYTE BIOL, V72, P101; Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; BUYS SS, 1984, CELL, V38, P569, DOI 10.1016/0092-8674(84)90511-7; CELADA A, 1986, J IMMUNOL, V137, P2373; Chen BC, 2002, J BIOL CHEM, V277, P24169, DOI 10.1074/jbc.M106014200; Chin D, 2002, BIOCHEMISTRY-US, V41, P14001, DOI 10.1021/bi025640o; Deszo EL, 2004, CELL SIGNAL, V16, P271, DOI 10.1016/S0898-6568(03)00137-2; Deszo EL, 2001, J BIOL CHEM, V276, P10212, DOI 10.1074/jbc.M010589200; Engels FHC, 1999, P NATL ACAD SCI USA, V96, P10332, DOI 10.1073/pnas.96.18.10332; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; Eto K, 1999, J BIOL CHEM, V274, P22556, DOI 10.1074/jbc.274.32.22556; FUKUDA N, 1989, JPN CIRC J, V53, P270, DOI 10.1253/jcj.53.270; Gerber JS, 2001, J IMMUNOL, V166, P6861, DOI 10.4049/jimmunol.166.11.6861; Goerdt S, 1999, PATHOBIOLOGY, V67, P222, DOI 10.1159/000028096; Gratchev A, 2001, SCAND J IMMUNOL, V53, P386, DOI 10.1046/j.1365-3083.2001.00885.x; HAMILTON TA, 1985, J IMMUNOL, V134, P2631; HAMILTON TA, 1985, J BIOL CHEM, V260, P1378; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; HATHCOCK KS, 1994, J EXP MED, V180, P631, DOI 10.1084/jem.180.2.631; Hesse M, 2001, J IMMUNOL, V167, P6533, DOI 10.4049/jimmunol.167.11.6533; HUANG FL, 1989, J BIOL CHEM, V264, P4238; Iribarren Pablo, 2002, BMC Immunol, V3, P6, DOI 10.1186/1471-2172-3-6; JOHNSON HM, 1985, P NATL ACAD SCI USA, V82, P5959, DOI 10.1073/pnas.82.17.5959; KARIMI K, 1995, J IMMUNOL, V155, P5786; Keenan C, 1997, IMMUNOLOGY, V90, P557, DOI 10.1046/j.1365-2567.1997.00198.x; KLEIN JB, 1990, J IMMUNOL, V144, P4305; Lin WW, 1998, BRIT J PHARMACOL, V125, P1601, DOI 10.1038/sj.bjp.0702219; MACNEIL S, 1985, CELL CALCIUM, V6, P213; MACNICOL M, 1992, J BIOL CHEM, V267, P12197; MALNOE A, 1985, J NEUROCHEM, V45, P1163, DOI 10.1111/j.1471-4159.1985.tb05537.x; Matsushita M, 1999, J BIOL CHEM, V274, P10086, DOI 10.1074/jbc.274.15.10086; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MOON SO, 1984, P NATL ACAD SCI-BIOL, V81, P2298, DOI 10.1073/pnas.81.8.2298; MOSES RM, 1995, DEV BIOL, V171, P111, DOI 10.1006/dbio.1995.1264; Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325; MUNOZFERNANDEZ MA, 1992, EUR J IMMUNOL, V22, P301, DOI 10.1002/eji.1830220203; Nakamura Y, 1996, NEUROSCI LETT, V204, P61, DOI 10.1016/0304-3940(96)12317-X; Opal SM, 2000, CHEST, V117, P1162, DOI 10.1378/chest.117.4.1162; PACE JL, 1983, J IMMUNOL, V130, P2011; Planelles L, 2003, CLIN EXP IMMUNOL, V131, P41, DOI 10.1046/j.1365-2249.2003.02022.x; Rousseau G, 2001, EUR J PHARMACOL, V422, P53, DOI 10.1016/S0014-2999(01)01073-1; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; Rutschman R, 2001, J IMMUNOL, V166, P2173, DOI 10.4049/jimmunol.166.4.2173; SAHYOUN N, 1991, P NATL ACAD SCI USA, V88, P2643, DOI 10.1073/pnas.88.7.2643; Sakagami H, 2000, EUR J NEUROSCI, V12, P89, DOI 10.1046/j.1460-9568.2000.00883.x; Schebesch C, 1997, IMMUNOLOGY, V92, P478, DOI 10.1046/j.1365-2567.1997.00371.x; SEBALDT RJ, 1990, J IMMUNOL, V145, P684; Skelton L, 2003, J IMMUNOL, V171, P1941, DOI 10.4049/jimmunol.171.4.1941; SMITH BM, 1983, CANCER RES, V43, P3385; SMITH BM, 1982, CELL CALCIUM, V3, P503, DOI 10.1016/0143-4160(82)90041-0; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; SOMERS SD, 1986, J IMMUNOL, V136, P4199; Song EW, 2000, CELL IMMUNOL, V204, P19, DOI 10.1006/cimm.2000.1687; Stout RD, 2005, J IMMUNOL, V175, P342, DOI 10.4049/jimmunol.175.1.342; Strle K, 2001, CRIT REV IMMUNOL, V21, P427; Tokumitsu H, 2000, J BIOL CHEM, V275, P20090, DOI 10.1074/jbc.M002193200; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; Tokumitsu H, 1997, BIOCHEMISTRY-US, V36, P12823, DOI 10.1021/bi971348i; Tokumitsu H, 2003, J BIOL CHEM, V278, P10908, DOI 10.1074/jbc.M213183200; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; TOKUMITSU H, 2002, BIOL CHEM, P277; Tzachanis D, 2002, BLOOD, V99, P1465, DOI 10.1182/blood.V99.4.1465; Uchi H, 2003, J INVEST DERMATOL, V120, P983, DOI 10.1046/j.1523-1747.2003.12250.x; Wayman GA, 1997, J BIOL CHEM, V272, P16073, DOI 10.1074/jbc.272.26.16073; WEIEL JE, 1985, J IMMUNOL, V134, P293; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147	66	11	11	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1606	10.1371/journal.pone.0001606	http://dx.doi.org/10.1371/journal.pone.0001606			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270593	Green Submitted, gold, Green Published			2022-12-25	WOS:000260535900040
J	Turner, EC; Snaddon, JL; Fayle, TM; Foster, WA				Turner, Edgar C.; Snaddon, Jake L.; Fayle, Tom M.; Foster, William A.			Oil Palm Research in Context: Identifying the Need for Biodiversity Assessment	PLOS ONE			English	Article							HABITAT; PLANTATIONS; DIVERSITY; FOREST; SABAH	Oil palm cultivation is frequently cited as a major threat to tropical biodiversity as it is centered on some of the world's most biodiverse regions. In this report, Web of Science was used to find papers on oil palm published since 1970, which were assigned to different subject categories to visualize their research focus. Recent years have seen a broadening in the scope of research, with a slight growth in publications on the environment and a dramatic increase in those on biofuel. Despite this, less than 1% of publications are related to biodiversity and species conservation. In the context of global vegetable oil markets, palm oil and soyabean account for over 60% of production but are the subject of less than 10% of research. Much more work must be done to establish the impacts of habitat conversion to oil palm plantation on biodiversity. Results from such studies are crucial for informing conservation strategies and ensuring sustainable management of plantations.	[Turner, Edgar C.; Snaddon, Jake L.; Fayle, Tom M.; Foster, William A.] Univ Museum Zool, Insect Ecol Grp, Cambridge, England	University of Cambridge	Turner, EC (corresponding author), Univ Museum Zool, Insect Ecol Grp, Cambridge, England.	ect23@cam.ac.uk	Fayle, Tom Maurice/A-2721-2009; Snaddon, Jake Lanion/C-8800-2011	Fayle, Tom Maurice/0000-0002-1667-1189; Snaddon, Jake Lanion/0000-0003-3549-5472; Turner, Edgar/0000-0003-2715-2234				Aratrakorn S, 2006, BIRD CONSERV INT, V16, P71, DOI 10.1017/S0959270906000062; Azlan JM, 2006, ORYX, V40, P36, DOI 10.1017/S0030605306000147; Balmford A, 2002, SCIENCE, V295, P2367; Basiron Y, 2007, EUR J LIPID SCI TECH, V109, P289, DOI 10.1002/ejlt.200600223; Chang MS, 1997, T ROY SOC TROP MED H, V91, P382, DOI 10.1016/S0035-9203(97)90248-0; Chapin FS, 1997, SCIENCE, V277, P500, DOI 10.1126/science.277.5325.500; Chung AYC, 2000, B ENTOMOL RES, V90, P475, DOI 10.1017/S0007485300000602; Davis ALV, 2005, ENVIRON ENTOMOL, V34, P1081, DOI 10.1603/0046-225X(2005)034[1081:EODOAS]2.0.CO;2; Donald PF, 2004, CONSERV BIOL, V18, P17, DOI 10.1111/j.1523-1739.2004.01803.x; Greathead D.J., 1983, Antenna, V7, P105; Hassall M, 2006, EUR J SOIL BIOL, V42, pS197, DOI 10.1016/j.ejsobi.2006.07.002; Henderson J, 2000, ENDEAVOUR, V24, P63, DOI 10.1016/S0160-9327(00)01293-X; Howard F.W., 2001, INSECTS PALMS, V131, DOI [10.1079/9780851993263.0000, DOI 10.1079/9780851993263.0000]; Koh LP, 2007, NATURE, V448, P993, DOI 10.1038/448993a; Landis DA, 2000, ANNU REV ENTOMOL, V45, P175, DOI 10.1146/annurev.ento.45.1.175; Linkie M, 2003, ORYX, V37, P41, DOI 10.1017/S0030605303000103; Liow LH, 2001, J APPL ECOL, V38, P180, DOI 10.1046/j.1365-2664.2001.00582.x; Mariau D., 2001, FAUNA OIL PALM COCON; Myers N, 2000, NATURE, V403, P853, DOI 10.1038/35002501; Peh KSH, 2006, DIVERS DISTRIB, V12, P572, DOI 10.1111/j.1366-9516.2006.00257.x; Rajaratnam R, 2007, J TROP ECOL, V23, P209, DOI 10.1017/S0266467406003841; Samways M.J., 2005, INSECT DIVERSITY CON; Sodhi NS, 2004, TRENDS ECOL EVOL, V19, P654, DOI 10.1016/j.tree.2004.09.006; Stone R, 2007, SCIENCE, V317, P1491, DOI 10.1126/science.317.5844.1491; 2008, WEB SCI ISI WEB SCI	25	51	54	0	44	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1572	10.1371/journal.pone.0001572	http://dx.doi.org/10.1371/journal.pone.0001572			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270566	Green Published, Green Submitted, gold			2022-12-25	WOS:000260535900011
J	Abtin, A; Eckhart, L; Mildner, M; Gruber, F; Schroder, JM; Tschachler, E				Abtin, Arby; Eckhart, Leopold; Mildner, Michael; Gruber, Florian; Schroeder, Jens-Michael; Tschachler, Erwin			Flagellin is the principal inducer of the antimicrobial peptide S100A7c (psoriasin) in human epidermal keratinocytes exposed to Escherichia coli	FASEB JOURNAL			English	Article						innate immunity; Toll-like receptor; TLR; pathogen-associated molecular pattern; PAMP; antimicrobial defense	TOLL-LIKE-RECEPTORS; INVASIVE BACTERIAL-INFECTION; INNATE IMMUNE-RESPONSE; EPITHELIAL-CELLS; MOLECULAR-CLONING; TLR EXPRESSION; BETA-DEFENSINS; HUMAN SKIN; KAPPA-B; DIFFERENTIATION	Epidermal keratinocytes (KCs) express antimicrobial peptides as a part of the innate immune response. It has recently been shown that the culture supernatant of Escherichia coli induces the expression of S100A7c (psoriasin) in KCs and that S100A7c efficiently kills E. coli. Here we have investigated which of the microbial components triggers the up-regulation of S100A7c expression. Exposure of human primary KCs to ligands of the human Toll-like receptors (TLRs) revealed that only the TLR5 ligand flagellin strongly induced the expression of S100A7c mRNA and protein, whereas all other TLR ligands had no significant effect. In contrast to the supernatant from flagellated wild-type (WT) E. coli, the supernatant of a flagellin-deficient E. coli strain (Delta FliC) did not induce S100A7c expression. Small interfering RNA-mediated knockdown of TLR5 expression suppressed the ability of KCs to up-regulate S100A7c expression in response to both flagellin and WT E. coli supernatant. Taken together, our data demonstrate that bacterial flagellin is essential and sufficient for the induction of S100A7c expression in KCs by E. coli.	[Abtin, Arby; Eckhart, Leopold; Mildner, Michael; Gruber, Florian; Tschachler, Erwin] Med Univ Vienna, Dept Dermatol, A-1090 Vienna, Austria; [Schroeder, Jens-Michael] Univ Kiel, Dept Dermatol, Univ Hosp Schleswig Holstein, D-2300 Kiel, Germany; [Tschachler, Erwin] Ctr Rech & Invest Epiderm & Sensorielles, Neuilly Sur Seine, France	Medical University of Vienna; University of Kiel; Schleswig Holstein University Hospital	Tschachler, E (corresponding author), Med Univ Vienna, Dept Dermatol, Waehringer Guertal 18-20, A-1090 Vienna, Austria.	erwin.tschachler@meduniwien.ac.at	Schroeder, Jens M/B-3994-2009	Gruber, Florian/0000-0003-1094-5641; Eckhart, Leopold/0000-0002-5645-2036; Mildner, Michael/0000-0002-6892-925X; Tschachler, Erwin/0000-0002-0248-1798				Akira S, 2003, IMMUNOL LETT, V85, P85, DOI 10.1016/S0165-2478(02)00228-6; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Baker BS, 2003, BRIT J DERMATOL, V148, P670, DOI 10.1046/j.1365-2133.2003.05287.x; Bates D, 2005, MOL MICROBIOL, V57, P380, DOI 10.1111/j.1365-2958.2005.04693.x; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; Bojar RA, 2002, WORLD J MICROB BIOT, V18, P889, DOI 10.1023/A:1021271028979; Boni R, 1997, BRIT J DERMATOL, V137, P39, DOI 10.1046/j.1365-2133.1997.17651853.x; Boniface K, 2007, J IMMUNOL, V178, P4615, DOI 10.4049/jimmunol.178.7.4615; Broome AM, 2003, J HISTOCHEM CYTOCHEM, V51, P675, DOI 10.1177/002215540305100513; Buechau AS, 2007, J INVEST DERMATOL, V127, P2596, DOI 10.1038/sj.jid.5700946; Chiller K, 2001, J INVEST DERM SYMP P, V6, P170, DOI 10.1046/j.0022-202x.2001.00043.x; Chromek M, 2006, NAT MED, V12, P636, DOI 10.1038/nm1407; Cole AM, 2001, FEBS LETT, V504, P5, DOI 10.1016/S0014-5793(01)02731-4; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; Eckert RL, 2004, J INVEST DERMATOL, V123, P23, DOI 10.1111/j.0022-202X.2004.22719.x; Erdag G, 2002, ANN SURG, V235, P113, DOI 10.1097/00000658-200201000-00015; Glaser R, 2005, NAT IMMUNOL, V6, P57, DOI 10.1038/ni1142; Gruber F, 2003, BLOOD, V101, P3042, DOI 10.1182/blood-2002-07-2331; Hahn Y, 2007, MOL BIOL EVOL, V24, P2203, DOI 10.1093/molbev/msm146; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hertz CJ, 2003, J IMMUNOL, V171, P6820, DOI 10.4049/jimmunol.171.12.6820; Huang YC, 2007, J BIOL CHEM, V282, P4626, DOI 10.1074/jbc.M607321200; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Kawai K, 2003, J INVEST DERMATOL, V121, P217, DOI 10.1046/j.1523-1747.2003.12305.x; Kollisch G, 2005, IMMUNOLOGY, V114, P531, DOI 10.1111/j.1365-2567.2005.02122.x; Kulski JK, 2003, J MOL EVOL, V56, P397, DOI 10.1007/s00239-002-2410-5; Lebre MC, 2007, J INVEST DERMATOL, V127, P331, DOI 10.1038/sj.jid.5700530; Lee RT, 1997, J IMMUNOL, V159, P5084; MADSEN P, 1991, J INVEST DERMATOL, V97, P701, DOI 10.1111/1523-1747.ep12484041; Martinsson H, 2005, EXP DERMATOL, V14, P161, DOI 10.1111/j.0906-6705.2005.00239.x; Mempel M, 2003, J INVEST DERMATOL, V121, P1389, DOI 10.1111/j.1523-1747.2003.12630.x; Miao EA, 2006, NAT IMMUNOL, V7, P569, DOI 10.1038/ni1344; Mildner M, 2006, BIOCHEM BIOPH RES CO, V348, P76, DOI 10.1016/j.bbrc.2006.07.035; Miller LS, 2007, SEMIN IMMUNOPATHOL, V29, P15, DOI 10.1007/s00281-007-0061-8; Miller LS, 2005, J IMMUNOL, V174, P6137, DOI 10.4049/jimmunol.174.10.6137; Moser C, 2002, INFECT IMMUN, V70, P3068, DOI 10.1128/IAI.70.6.3068-3072.2002; MURTHY ARK, 1993, J IMMUNOL, V151, P6291; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; O'Neil DA, 1999, J IMMUNOL, V163, P6718; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rendl M, 2002, J INVEST DERMATOL, V119, P1150, DOI 10.1046/j.1523-1747.2002.19532.x; Sahl HG, 2005, J LEUKOCYTE BIOL, V77, P466, DOI 10.1189/jlb.0804452; Schaefer TM, 2005, J IMMUNOL, V174, P992, DOI 10.4049/jimmunol.174.2.992; Schroder JM, 2006, CELL MOL LIFE SCI, V63, P469, DOI 10.1007/s00018-005-5364-0; Singh PK, 1998, P NATL ACAD SCI USA, V95, P14961, DOI 10.1073/pnas.95.25.14961; Tapping RI, 2000, J IMMUNOL, V165, P5780, DOI 10.4049/jimmunol.165.10.5780; Vora P, 2004, J IMMUNOL, V173, P5398, DOI 10.4049/jimmunol.173.9.5398; Voss E, 2006, J BIOL CHEM, V281, P2005, DOI 10.1074/jbc.M511044200; Wildman KAH, 2003, BIOCHEMISTRY-US, V42, P6545, DOI 10.1021/bi0273563; Wolf R, 2003, FASEB J, V17, P1969, DOI 10.1096/fj.03-0148fje; Wolf R, 2006, J INVEST DERMATOL, V126, P1600, DOI 10.1038/sj.jid.5700210; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	55	63	66	2	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2168	2176		10.1096/fj.07-104117	http://dx.doi.org/10.1096/fj.07-104117			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18263703				2022-12-25	WOS:000257292500009
J	Fligny, C; Fromes, Y; Bonnin, P; Darmon, M; Bayard, E; Launay, JM; Cote, F; Mallet, J; Vodjdani, G				Fligny, Cecile; Fromes, Yves; Bonnin, Philippe; Darmon, Michele; Bayard, Elisa; Launay, Jean-Marie; Cote, Francine; Mallet, Jacques; Vodjdani, Guilan			Maternal serotonin influences cardiac function in adult offspring	FASEB JOURNAL			English	Article						maternal effect; tryptophan hydroxylase 1-invalidated mouse; heart failure animal model; dilated cardiomyopathy	PRIMARY PULMONARY-HYPERTENSION; PLASMA SEROTONIN; 5-HT2B RECEPTOR; HEART-FAILURE; 2B RECEPTOR; 5-HYDROXYTRYPTAMINE; TRANSPORTER; CATECHOLAMINES; HYPERTROPHY; DISEASES	Using the Tph1-invalidated mouse line, in which blood is depleted in serotonin (5-hydroxytryptamine, 5-HT), we have demonstrated previously that maternal 5-HT is required for normal embryonic development. Here, we address the issue of the influence of the maternal 5-HT concentration on the cardiac function of the offspring as adults. We investigated the cardiac phenotype of Tph1-invalidated mice born to Tph1 heterozygous and null mothers. Functionally, all mutants display a significant decrease of cardiac contractility, indicative of impaired left ventricular function. They exhibit progressive dilated cardiomyopathy and are unable to adapt appropriately to a pharmacological stress. Moreover, we show that the cardiopathy is more severe in adult Tph1(-/-) mice born to homozygous mothers than to heterozygous mothers. Importantly, the severity of the cardiac phenotype is inversely correlated with the plasma 5-HT concentration but not the whole-blood 5-HT concentration. Thus, plasma 5-HT concentration may be a useful index of heart failure. These findings show that cardiac function, through the plasma 5-HT concentration, is influenced by the maternal serotonergic status.	[Fligny, Cecile; Bayard, Elisa; Cote, Francine; Mallet, Jacques; Vodjdani, Guilan] Univ Paris 06, Hop La Pitie Salpetriere, Lab Genet Mol Neurotransmission & Proc Neurodegen, CNRS,UMR 7091, F-75013 Paris, France; [Fromes, Yves] Univ Paris 06, INSERM, Inst Myol, U852, F-75013 Paris, France; [Darmon, Michele] Univ Paris 06, INSERM, UMR 677, F-75013 Paris, France; [Bonnin, Philippe] Univ Paris 07, INSERM, Ctr Rech Cardiovasc Physiol Explorat Fonctionnnel, U689, Paris, France; [Launay, Jean-Marie] Hop Lariboisiere, AP HP, Serv Biochim, F-75475 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	Launay, JM (corresponding author), Univ Paris 06, Hop La Pitie Salpetriere, Lab Genet Mol Neurotransmission & Proc Neurodegen, CNRS,UMR 7091, Batiment CERVI,83 Blvd Hop, F-75013 Paris, France.	mallet@chups.jussieu.fr; vodjdani@chups.jussieu.fr	VODJDANI, Guilan/GSN-1174-2022; Darmon, Michele/F-8708-2011; Bonnin, Philippe/Y-5872-2019; Fromes, Yves/J-9602-2013; FROMES, Yves/AAB-9267-2020	Darmon, Michele/0000-0001-9730-6273; Bonnin, Philippe/0000-0003-3184-3740; Fromes, Yves/0000-0002-6792-9549; 				Anderson GM, 2007, PEDIATR NEUROL, V36, P138, DOI 10.1016/j.pediatrneurol.2006.11.007; Bonnin P, 2007, ULTRASOUND MED BIOL, V33, P561, DOI 10.1016/j.ultrasmedbio.2006.09.010; Brattelid T, 2004, N-S ARCH PHARMACOL, V370, P157, DOI 10.1007/s00210-004-0963-0; Brenner B, 2007, J NEUROCHEM, V102, P206, DOI 10.1111/j.1471-4159.2007.04542.x; Brouri F, 2002, EUR J PHARMACOL, V456, P69, DOI 10.1016/S0014-2999(02)02643-2; Callebert J, 2006, J PHARMACOL EXP THER, V317, P724, DOI 10.1124/jpet.105.098269; Chakraborti S, 2000, CELL SIGNAL, V12, P499, DOI 10.1016/S0898-6568(00)00087-5; Chang AS, 1996, MOL BRAIN RES, V43, P185, DOI 10.1016/S0169-328X(96)00172-6; Choi DS, 1997, DEVELOPMENT, V124, P1745; Connors SL, 2006, PEDIATR NEUROL, V35, P182, DOI 10.1016/j.pediatrneurol.2006.02.010; Cote F, 2004, TRENDS MOL MED, V10, P232, DOI 10.1016/j.molmed.2004.03.007; Cote F, 2003, P NATL ACAD SCI USA, V100, P13525, DOI 10.1073/pnas.2233056100; Cote F, 2007, P NATL ACAD SCI USA, V104, P329, DOI 10.1073/pnas.0606722104; DAPRADA M, 1979, BRIT J PHARMACOL, V65, P653; GERSHON MD, 1965, SCIENCE, V149, P197, DOI 10.1126/science.149.3680.197; Gershon MD, 2007, GASTROENTEROLOGY, V132, P397, DOI 10.1053/j.gastro.2006.11.002; Guilluy C, 2007, J BIOL CHEM, V282, P2918, DOI 10.1074/jbc.M604195200; HERVE P, 1995, AM J MED, V99, P249, DOI 10.1016/S0002-9343(99)80156-9; Hoyer D, 2002, PHARMACOL BIOCHEM BE, V71, P533, DOI 10.1016/S0091-3057(01)00746-8; HOYER D, 1994, PHARMACOL REV, V46, P157; Jaffre F, 2004, CIRCULATION, V110, P969, DOI 10.1161/01.CIR.0000139856.20505.57; Kaumann AJ, 2006, PHARMACOL THERAPEUT, V111, P674, DOI 10.1016/j.pharmthera.2005.12.004; Kereveur A, 2000, ARTERIOSCL THROM VAS, V20, P2233, DOI 10.1161/01.ATV.20.10.2233; Launay JM, 2002, NAT MED, V8, P1129, DOI 10.1038/nm764; LECHIN F, 1994, J MED, V25, P181; Lechin F, 1996, ANN ALLERG ASTHMA IM, V77, P245, DOI 10.1016/S1081-1206(10)63263-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maurer-Spurej E, 2005, CELL MOL LIFE SCI, V62, P159, DOI 10.1007/s00018-004-4262-1; Mongue-Din H, 2007, PFLUG ARCH EUR J PHY, V454, P165, DOI 10.1007/s00424-006-0197-8; Nebigil CG, 2000, P NATL ACAD SCI USA, V97, P9508, DOI 10.1073/pnas.97.17.9508; Nebigil CG, 2003, CIRCULATION, V107, P3223, DOI 10.1161/01.CIR.0000074224.57016.01; Nebigil CG, 2001, CIRCULATION, V103, P2973, DOI 10.1161/01.CIR.103.24.2973; Qvigstad E, 2005, CIRC RES, V97, P268, DOI 10.1161/01.RES.0000176970.22603.8d; Qvigstad E, 2005, CARDIOVASC RES, V65, P869, DOI 10.1016/j.cardiores.2004.11.017; RAPPORT MM, 1948, J BIOL CHEM, V174, P735; RAPPORT MM, 1949, J BIOL CHEM, V180, P961; Sari Y, 2003, INT J DEV NEUROSCI, V21, P417, DOI 10.1016/j.ijdevneu.2003.10.002; Tevaearai HT, 2004, TRENDS CARDIOVAS MED, V14, P252, DOI 10.1016/j.tcm.2004.07.002; TWAROG BM, 1953, AM J PHYSIOL, V175, P157, DOI 10.1152/ajplegacy.1953.175.1.157; ULLMER C, 1995, FEBS LETT, V370, P215, DOI 10.1016/0014-5793(95)00828-W; Vialou V, 2007, NEUROSCIENCE, V144, P616, DOI 10.1016/j.neuroscience.2006.09.058; Villalon CM, 2007, N-S ARCH PHARMACOL, V376, P45, DOI 10.1007/s00210-007-0179-1; Walther DJ, 2003, SCIENCE, V299, P76, DOI 10.1126/science.1078197; Watts SW, 2005, CLIN SCI, V108, P399, DOI 10.1042/CS20040364; Zolkowska D, 2006, J PHARMACOL EXP THER, V318, P604, DOI 10.1124/jpet.106.101618	45	25	26	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2340	2349		10.1096/fj.07-100743	http://dx.doi.org/10.1096/fj.07-100743			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18267982				2022-12-25	WOS:000257292500026
J	Jiang, HM; Rhee, SM; Ho, CH; Grinnell, F				Jiang, Hongmei; Rhee, Sangmyung; Ho, Chin-Han; Grinnell, Frederick			Distinguishing fibroblast promigratory and procontractile growth factor environments in 3-D collagen matrices	FASEB JOURNAL			English	Article						cell migration; cell contraction; platelet-derived growth factor; lysophosphatidic acid; sphingosine-1-phosphate; wound repair	PROTEIN-COUPLED RECEPTOR; LYSOPHOSPHATIDIC ACID; SPHINGOSINE 1-PHOSPHATE; GEL CONTRACTION; BINDING PROTEIN; ENDOTHELIAL-CELLS; WOUND CONTRACTION; TISSUE-REPAIR; I COLLAGEN; MIGRATION	Understanding growth factor function during wound repair is necessary for the development of therapeutic interventions to improve healing outcomes. In the current study, we compare the effects of serum and purified growth factors on human fibroblast function in three different collagen matrix models: cell migration in nested matrices, floating matrix contraction, and stressed-released matrix contraction. The results of these studies indicate that platelet-derived growth factor (PDGF) is unique in its capacity to promote cell migration. Serum, lysophosphatidic acid, sphingosine-1-phophate (S1P), and endothelin-1 promote stressed-released matrix contraction but not cell migration. In addition, we found that S1P inhibits fibroblast migration and treatment of serum to remove lipid growth factors or treatment of cells to interfere with S1P(2) receptor function increases serum promigratory activity. Our findings suggest that different sets of growth factors generate promigratory and procontractile tissue environments for fibroblasts and that the balance between PDGF and S1P is a key determinant of fibroblast promigratory activity.	[Jiang, Hongmei; Rhee, Sangmyung; Ho, Chin-Han; Grinnell, Frederick] Univ Texas SW Med Sch, Dept Cell Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Grinnell, F (corresponding author), Univ Texas SW Med Sch, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	frederick.grinnell@utsouthwestern.edu			NIGMS NIH HHS [GM-31321] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031321, R37GM031321] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe M, 2003, J BIOL CHEM, V278, P47707, DOI 10.1074/jbc.M306228200; ABE M, 2007, J CELL BIOCH; Abraham David J, 2007, Curr Rheumatol Rep, V9, P136, DOI 10.1007/s11926-007-0008-z; Ahlfors JEW, 2007, BIOMATERIALS, V28, P2183, DOI 10.1016/j.biomaterials.2006.12.030; Aiba-Kojima E, 2007, WOUND REPAIR REGEN, V15, P511, DOI 10.1111/j.1524-475X.2007.00259.x; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; Arikawa K, 2003, J BIOL CHEM, V278, P32841, DOI 10.1074/jbc.M305024200; BAROCAS VH, 1995, J BIOMECH ENG-T ASME, V117, P161, DOI 10.1115/1.2795998; Beacham DA, 2005, SEMIN CANCER BIOL, V15, P329, DOI 10.1016/j.semcancer.2005.05.003; BELL E, 1983, J INVEST DERMATOL, V81, pS2, DOI 10.1111/1523-1747.ep12539993; BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; Chen WYJ, 2007, WOUND REPAIR REGEN, V15, P434, DOI 10.1111/j.1524-475X.2007.00250.x; Clark RAF, 2007, J INVEST DERMATOL, V127, P1018, DOI 10.1038/sj.jid.5700715; Comoglio PM, 2005, NAT MED, V11, P1156, DOI 10.1038/nm1105-1156; Cooke ME, 2000, J CELL SCI, V113, P2375; Cross KJ, 2003, SURG CLIN N AM, V83, P531, DOI 10.1016/S0039-6109(02)00202-5; Cukierman E, 2002, CURR OPIN CELL BIOL, V14, P633, DOI 10.1016/S0955-0674(02)00364-2; Darby IA, 2007, INT REV CYTOL, V257, P143, DOI 10.1016/S0074-7696(07)57004-X; Davidson Jeffrey M, 2007, Int J Low Extrem Wounds, V6, P8, DOI 10.1177/1534734607299180; Desmouliere A, 2005, WOUND REPAIR REGEN, V13, P7, DOI 10.1111/j.1067-1927.2005.130102.x; Diegelmann RF, 2004, FRONT BIOSCI-LANDMRK, V9, P283, DOI 10.2741/1184; EHRLICH HP, 1990, TISSUE CELL, V22, P407, DOI 10.1016/0040-8166(90)90070-P; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Fu XB, 2005, WOUND REPAIR REGEN, V13, P122, DOI 10.1111/j.1067-1927.2005.130202.x; Gao ZY, 2005, J BIOL CHEM, V280, P9375, DOI 10.1074/jbc.M413081200; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Goparaju SK, 2005, MOL CELL BIOL, V25, P4237, DOI 10.1128/MCB.25.10.4237-4249.2005; Grinnell F, 2006, EXP CELL RES, V312, P86, DOI 10.1016/j.yexcr.2005.010.001; Grinnell F, 2003, TRENDS CELL BIOL, V13, P264, DOI 10.1016/S0962-8924(03)00057-6; Grinnell F, 2003, MOL BIOL CELL, V14, P384, DOI 10.1091/mbc.E02-08-0493; Grinnell F, 1999, J BIOL CHEM, V274, P918, DOI 10.1074/jbc.274.2.918; Grinnell F, 1996, J INVEST DERMATOL, V106, P335, DOI 10.1111/1523-1747.ep12342990; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; GUIDRY C, 1991, J CELL BIOL, V115, P873, DOI 10.1083/jcb.115.3.873; Hinz B, 2007, J INVEST DERMATOL, V127, P526, DOI 10.1038/sj.jid.5700613; HUANG JS, 1983, J CELL BIOL, V97, P383, DOI 10.1083/jcb.97.2.383; JOHNSON TM, 1993, J DERMATOL SURG ONC, V19, P1074, DOI 10.1111/j.1524-4725.1993.tb01002.x; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Li J, 2007, CLIN DERMATOL, V25, P9, DOI 10.1016/j.clindermatol.2006.09.007; Li W, 2004, MOL BIOL CELL, V15, P294, DOI 10.1091/mbc.e03-05-0352; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Menke NB, 2007, CLIN DERMATOL, V25, P19, DOI 10.1016/j.clindermatol.2006.12.005; MOCHITATE K, 1991, EXP CELL RES, V193, P198, DOI 10.1016/0014-4827(91)90556-A; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; Olutoye OO, 1996, J PEDIATR SURG, V31, P91, DOI 10.1016/S0022-3468(96)90326-7; Osada M, 2002, BIOCHEM BIOPH RES CO, V299, P483, DOI 10.1016/S0006-291X(02)02671-2; Parizi M, 2000, EXP CELL RES, V254, P210, DOI 10.1006/excr.1999.4754; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Peters SLM, 2007, CURR OPIN PHARMACOL, V7, P186, DOI 10.1016/j.coph.2006.09.008; Rhee S, 2006, J CELL BIOL, V172, P423, DOI 10.1083/jcb.200505175; Rhee S, 2007, P NATL ACAD SCI USA, V104, P5425, DOI 10.1073/pnas.0608030104; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Roeder BA, 2002, J BIOMECH ENG-T ASME, V124, P214, DOI 10.1115/1.1449904; SEPPA H, 1982, J CELL BIOL, V92, P584, DOI 10.1083/jcb.92.2.584; Silver F.H., 2002, SKIN RES TECHNOL, V8, P1; Skuta G, 1999, J BIOL CHEM, V274, P30163, DOI 10.1074/jbc.274.42.30163; Smith KD, 2006, EXP CELL RES, V312, P1970, DOI 10.1016/j.yexcr.2006.02.022; Spiegel S, 2002, TRENDS CELL BIOL, V12, P236, DOI 10.1016/S0962-8924(02)02277-8; Sugimoto N, 2003, MOL CELL BIOL, V23, P1534, DOI 10.1128/MCB.23.5.1534-1545.2003; Takuwa Y, 2002, BBA-MOL CELL BIOL L, V1582, P112, DOI 10.1016/S1388-1981(02)00145-2; TINGSTROM A, 1992, J CELL SCI, V102, P315; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Wakatsuki T, 2000, BIOPHYS J, V79, P2353, DOI 10.1016/S0006-3495(00)76481-2; Watterson K, 2003, PROG LIPID RES, V42, P344, DOI 10.1016/S0163-7827(03)00015-8; Watterson KR, 2007, WOUND REPAIR REGEN, V15, P607, DOI 10.1111/j.1524-475X.2007.00292.x; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; Wilhelmi BJ, 1998, ANN PLAS SURG, V41, P215, DOI 10.1097/00000637-199808000-00019; WYSOCKI AB, 1993, J INVEST DERMATOL, V101, P64, DOI 10.1111/1523-1747.ep12359590; Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006; Yanase M, 2000, BIOCHEM BIOPH RES CO, V277, P72, DOI 10.1006/bbrc.2000.3634; Yatomi Y, 1997, J BIOCHEM, V121, P969; Yee HF, 2001, BIOCHEM BIOPH RES CO, V280, P1340, DOI 10.1006/bbrc.2001.4291	73	47	47	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2151	2160		10.1096/fj.07-097014	http://dx.doi.org/10.1096/fj.07-097014			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18272655				2022-12-25	WOS:000257292500007
J	Liu, YY; Yu, JY; Yin, DM; Patwardhan, GA; Gupta, V; Hirabayashi, Y; Holleran, WM; Giuliano, AE; Jazwinski, SM; Gouaze-Andersson, V; Consoli, DP; Cabot, MC				Liu, Yong-Yu; Yu, Jing Yuan; Yin, Dongmei; Patwardhan, Gauri Anand; Gupta, Vineet; Hirabayashi, Yoshio; Holleran, Walter M.; Giuliano, Armando E.; Jazwinski, S. Michal; Gouaze-Andersson, Valerie; Consoli, David P.; Cabot, Myles C.			A role for ceramide in driving cancer cell resistance to doxorubicin	FASEB JOURNAL			English	Article						glucosylceramide synthase; Sp1; transcription; gene regulation	GLUCOSYLCERAMIDE SYNTHASE EXPRESSION; MULTIDRUG-RESISTANCE; BREAST-CANCER; P-GLYCOPROTEIN; UP-REGULATION; ADRIAMYCIN RESISTANCE; ANTICANCER AGENTS; INDUCED APOPTOSIS; PROMOTER ACTIVITY; DRUG-RESISTANCE	Advanced cancers acquire resistance to chemotherapy, and this results in treatment failure. The cellular mechanisms of chemotherapy resistance are not well understood. Here, for the first time, we show that ceramide contributes to cellular resistance to doxorubicin through up-regulating the gene expression of glucosylceramide synthase (GCS). Ceramide, a cellular lipid messenger, modulates doxorubicin-induced cell death. GCS catalyzes ceramide glycosylation, converting ceramide to glucosylceramide; this process hastens ceramide clearance and limits ceramide-induced apoptosis. In the present study, we evaluated the role of the GCS gene in doxorubicin resistance using several paired wild-type and drug-resistant (doxorubicin-selected) cancer cell lines, including breast, ovary, cervical, and colon. GCS was overexpressed in all drug-resistant counterparts, and suppressing GCS overexpression using antisense oligonucleotide restored doxorubicin sensitivity. Characterizing the effect mechanism showed that doxorubicin exposure increased ceramide levels, enhanced GCS expression, and imparted cellular resistance. Exogenous C6-ceramide and sphingomyelinase treatments mimicked the influence of doxorubicin on GCS, activating the GCS promoter and upregulating GCS gene expression. Fumonisin B-1, an inhibitor of ceramide synthesis, significantly suppressed doxorubicin-up-regulated GCS expression. Promoter truncation, point mutation, gel-shift, and protein-DNA ELISA analysis showed that transcription factor Sp1 was essential for ceramide-induced GCS up-regulation. These data indicate that ceramide-governed GCS gene expression drives cellular resistance to doxorubicin.	[Liu, Yong-Yu; Yin, Dongmei; Patwardhan, Gauri Anand; Gupta, Vineet] Univ Louisiana Monroe, Dept Basic Pharmaceut Sci, Monroe, LA 71209 USA; [Yu, Jing Yuan; Giuliano, Armando E.; Gouaze-Andersson, Valerie; Consoli, David P.; Cabot, Myles C.] John Wayne Canc Inst, St Johns Hlth Ctr, Dept Expt Therapeut, Santa Monica, CA USA; [Hirabayashi, Yoshio] RIKEN Brain Sci Inst, Neuronal Circuit Mech Res Grp, Saitama, Japan; [Holleran, Walter M.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; [Holleran, Walter M.] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; [Jazwinski, S. Michal] Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA	University of Louisiana System; University of Louisiana Monroe; John Wayne Cancer Institute; RIKEN; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Tulane University	Liu, YY (corresponding author), Univ Louisiana Monroe, Dept Basic Pharmaceut Sci, 700 Univ Ave, Monroe, LA 71209 USA.	yliu@ulm.edu	Liu, Yong-Yu/H-8593-2014; Gouaze-Andersson, Valerie/O-9180-2014	Gouaze-Andersson, Valerie/0000-0002-1797-515X; Hirabayashi, Yoshio/0000-0002-5774-7354; Liu, Yong-Yu/0000-0002-7968-0162	NCRR NIH HHS [P20 RR16456, P20 RR016456] Funding Source: Medline; NIGMS NIH HHS [GM77391] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM077391] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe A, 1996, BBA-LIPID LIPID MET, V1299, P333, DOI 10.1016/0005-2760(95)00217-0; Adam D, 2002, TRENDS IMMUNOL, V23, P1, DOI 10.1016/S1471-4906(01)02091-9; AKIYAMA SI, 1985, SOMAT CELL MOLEC GEN, V11, P117, DOI 10.1007/BF01534700; Alesse E, 1998, CELL DEATH DIFFER, V5, P381, DOI 10.1038/sj.cdd.4400358; Bektas M, 2003, GLYCOCONJUGATE J, V20, P39, DOI 10.1023/B:GLYC.0000016741.88476.8b; Bourteele S, 1998, J BIOL CHEM, V273, P31245, DOI 10.1074/jbc.273.47.31245; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; Buzas B, 2002, NEUROREPORT, V13, P1707, DOI 10.1097/00001756-200210070-00003; Chen CC, 2001, MOL PHARMACOL, V59, P493, DOI 10.1124/mol.59.3.493; Daschner PJ, 1999, BREAST CANCER RES TR, V53, P229, DOI 10.1023/A:1006138803392; Deigner HP, 2001, FASEB J, V15, P807, DOI 10.1096/fj.15.3.807; Delpy E, 1999, CARDIOVASC RES, V43, P398, DOI 10.1016/S0008-6363(99)00142-X; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929; Gouaze V, 2005, CANCER RES, V65, P3861, DOI 10.1158/0008-5472.CAN-04-2329; Gouaze V, 2004, MOL CANCER THER, V3, P633; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1989, J BIOL CHEM, V264, P9960; Ichikawa S, 1998, BIOCHEM BIOPH RES CO, V253, P707, DOI 10.1006/bbrc.1998.9855; Itoh M, 2003, CLIN CANCER RES, V9, P415; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Kawase M, 2002, BBA-MOL CELL BIOL L, V1584, P104, DOI 10.1016/S1388-1981(02)00301-3; Kim WH, 2000, BIOCHEM CELL BIOL, V78, P127, DOI 10.1139/bcb-78-2-127; Kluza J, 2004, ONCOGENE, V23, P7018, DOI 10.1038/sj.onc.1207936; KOHNO K, 1989, BIOCHEM BIOPH RES CO, V165, P1415, DOI 10.1016/0006-291X(89)92761-7; Kok JW, 2000, INT J CANCER, V87, P172, DOI 10.1002/1097-0215(20000715)87:2<172::AID-IJC3>3.0.CO;2-K; Komori H, 2000, FEBS LETT, V475, P247, DOI 10.1016/S0014-5793(00)01696-3; Kourousis C, 1998, AM J CLIN ONCOL-CANC, V21, P226, DOI 10.1097/00000421-199806000-00003; Kudoh K, 2000, CANCER RES, V60, P4161; LAI GM, 1991, INT J CANCER, V49, P696, DOI 10.1002/ijc.2910490512; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; Liang Y, 2001, EUR J CANCER, V37, P1041, DOI 10.1016/S0959-8049(01)00086-7; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; Liu YY, 1999, EXP CELL RES, V252, P464, DOI 10.1006/excr.1999.4649; Liu YY, 2004, J LIPID RES, V45, P933, DOI 10.1194/jlr.M300486-JLR200; Liu YY, 1999, J BIOL CHEM, V274, P1140, DOI 10.1074/jbc.274.2.1140; Liu YY, 2001, FASEB J, V15, P719, DOI 10.1096/fj.00-0223com; Lucci A, 1999, CANCER-AM CANCER SOC, V86, P300, DOI 10.1002/(SICI)1097-0142(19990715)86:2<300::AID-CNCR14>3.0.CO;2-H; Lucci A, 1998, ANTICANCER RES, V18, P475; Maestre N, 2001, CANCER RES, V61, P2558; Makin G, 2001, TRENDS CELL BIOL, V11, pS22, DOI 10.1016/S0962-8924(01)82111-5; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Minotti G, 2004, PHARMACOL REV, V56, P185, DOI 10.1124/pr.56.2.6; Murate T, 2002, J BIOL CHEM, V277, P9936, DOI 10.1074/jbc.M111594200; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Ogretmen B, 1999, BIOCHEMISTRY-US, V38, P2189, DOI 10.1021/bi982236+; Ogretmen B, 2001, J BIOL CHEM, V276, P24901, DOI 10.1074/jbc.M100314200; Park IN, 2004, MOL PHARMACOL, V65, P1475, DOI 10.1124/mol.65.6.1475; Perez GI, 1997, NAT MED, V3, P1228, DOI 10.1038/nm1197-1228; Reynolds CP, 2004, CANCER LETT, V206, P169, DOI 10.1016/j.canlet.2003.08.034; ROGAN AM, 1984, SCIENCE, V224, P994, DOI 10.1126/science.6372095; Sanchenkov A, 2001, JNCI-J NATL CANCER I, V93, P347, DOI 10.1093/jnci/93.5.347; Scholl SM, 1995, EUR J CANCER, V31A, P1969, DOI 10.1016/0959-8049(95)00454-8; Senkal CE, 2007, MOL CANCER THER, V6, P712, DOI 10.1158/1535-7163.MCT-06-0558; Shabbits J A, 2001, Expert Rev Anticancer Ther, V1, P585, DOI 10.1586/14737140.1.4.585; SHEN DW, 1986, J BIOL CHEM, V261, P7762; Subbaramaiah K, 1998, J BIOL CHEM, V273, P32943, DOI 10.1074/jbc.273.49.32943; Sun YL, 2006, NEOPLASMA, V53, P1; Turton NJ, 2001, ONCOGENE, V20, P1300, DOI 10.1038/sj.onc.1204235; Uchida Y, 2004, CANCER RES, V64, P6271, DOI 10.1158/0008-5472.CAN-03-1476; Watanabe R, 1998, J BIOL CHEM, V273, P9651, DOI 10.1074/jbc.273.16.9651; Watts GS, 2001, J PHARMACOL EXP THER, V299, P434; Wooten LG, 2005, J BIOL CHEM, V280, P28867, DOI 10.1074/jbc.M413444200; Wu DY, 2003, J BIOL CHEM, V278, P10983, DOI 10.1074/jbc.M207470200	64	116	119	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2541	2551		10.1096/fj.07-092981	http://dx.doi.org/10.1096/fj.07-092981			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18245173				2022-12-25	WOS:000257292500045
J	Lofgren, K; Wahlstrom, A; Lundberg, P; Langel, U; Graslund, A				Lofgren, Kajsa; Wahlstrom, Anna; Lundberg, Pontus; Langel, Ulo; Graslund, Astrid			Antiprion properties of prion protein-derived cell-penetrating peptides	FASEB JOURNAL			English	Article						scrapie; prion conversion; N terminus; therapy; signal peptide	HEPARAN-SULFATE; CULTURED-CELLS; IN-VITRO; PRPC; TRANSLOCATION; RECEPTOR; BINDING; PART; PH	In prion diseases, the cellular prion protein (PrPC) becomes misfolded into the pathogenic scrapie isoform (PrPSc) responsible for prion infectivity. We show here that peptides derived from the prion protein N terminus have potent antiprion effects. These peptides are composed of a hydrophobic sequence followed by a basic segment. They are known to have cell-penetrating ability like regular cell-penetrating peptides (CPPs), short peptides that can penetrate cellular membranes. Healthy (GT1-1) and scrapie-infected (ScGT1-1) mouse neuronal hypothalamic cells were treated with various CPPs, including the prion protein-derived CPPs. Lysates were analyzed for altered protein levels of PrPC or PrPSc. Treatment with the prion protein-derived CPPs mouse mPrP(1-28) or bovine bPrP(1-30) significantly reduced PrPSc levels in prion-infected cells but had no effect on PrPC levels in noninfected cells. Further, presence of prion protein-derived CPPs significantly prolonged the time before infection was manifested when infecting GT1-1 cells with scrapie. Treatment with other CPPs (penetratin, transportan-10, or poly-L-arginine) or prion protein-derived peptides lacking CPP function (mPr(23-28), mPrP(19-30), or mPrP(23-50)) had no effect on PrPSc levels. The results suggest a mechanism by which the signal sequence guides the prion protein-derived CPP into a cellular compartment, where the basic segment binds specifically to PrPSc and disables formation of prions.	[Lofgren, Kajsa; Wahlstrom, Anna; Langel, Ulo; Graslund, Astrid] Stockholm Univ, Dept Biochem & Biophys, Arrhenius Labs, SE-10691 Stockholm, Sweden; [Lundberg, Pontus; Langel, Ulo] Stockholm Univ, Dept Neurochem & Neurotoxicol, SE-10691 Stockholm, Sweden	Stockholm University; Stockholm University	Graslund, A (corresponding author), Stockholm Univ, Dept Biochem & Biophys, Arrhenius Labs, SE-10691 Stockholm, Sweden.	astrid@dbb.su.se		Langel, Ulo/0000-0001-6107-0844				Ben-Zaken O, 2003, J BIOL CHEM, V278, P40041, DOI 10.1074/jbc.M301152200; Brown DR, 2001, TRENDS NEUROSCI, V24, P85, DOI 10.1016/S0166-2236(00)01689-1; Gilch S, 2007, J MOL BIOL, V371, P362, DOI 10.1016/j.jmb.2007.05.052; Goncalves E, 2005, BIOCHEMISTRY-US, V44, P2692, DOI 10.1021/bi048046i; Gu YP, 2003, NEUROBIOL DIS, V12, P133, DOI 10.1016/S0969-9961(02)00014-1; Gyllberg H, 2006, FEBS LETT, V580, P2603, DOI 10.1016/j.febslet.2006.03.092; Hornemann S, 1998, P NATL ACAD SCI USA, V95, P6010, DOI 10.1073/pnas.95.11.6010; Horonchik L, 2005, J BIOL CHEM, V280, P17062, DOI 10.1074/jbc.M500122200; Jackson GS, 2001, P NATL ACAD SCI USA, V98, P8531, DOI 10.1073/pnas.151038498; LANGEL U, 1992, INT J PEPT PROT RES, V39, P516; Lasmezas CI, 2003, BRIT MED BULL, V66, P61, DOI 10.1093/bmb/66.1.61; Lau AL, 2007, P NATL ACAD SCI USA, V104, P11551, DOI 10.1073/pnas.0704260104; Letoha T, 2005, J PEPT SCI, V11, P805, DOI 10.1002/psc.678; Lindegren H, 2003, J NEUROSCI RES, V71, P291, DOI 10.1002/jnr.10473; Lucero HA, 2004, ARCH BIOCHEM BIOPHYS, V426, P208, DOI 10.1016/j.abb.2004.03.020; Lundberg P, 2002, BIOCHEM BIOPH RES CO, V299, P85, DOI 10.1016/S0006-291X(02)02595-0; Magzoub M, 2004, Q REV BIOPHYS, V37, P147, DOI 10.1017/S0033583505004014; Magzoub M, 2005, BIOCHEMISTRY-US, V44, P14890, DOI 10.1021/bi051356w; Magzoub M, 2005, BBA-BIOMEMBRANES, V1716, P126, DOI 10.1016/j.bbamem.2005.09.009; Magzoub M, 2006, BIOCHEM BIOPH RES CO, V348, P379, DOI 10.1016/j.bbrc.2006.07.065; Oglecka K, 2008, BBA-BIOMEMBRANES, V1778, P206, DOI 10.1016/j.bbamem.2007.09.034; Ostlund P, 2001, J BIOL CHEM, V276, P36110, DOI 10.1074/jbc.M105710200; Pan T, 2002, BIOCHEM J, V368, P81, DOI 10.1042/BJ20020773; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Schatzl HM, 1997, J VIROL, V71, P8821; SHYNG SL, 1995, J BIOL CHEM, V270, P30221; Supattapone S, 2004, J MOL MED, V82, P348, DOI 10.1007/s00109-004-0534-3; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; Taylor DR, 2006, MOL MEMBR BIOL, V23, P89, DOI 10.1080/09687860500449994; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Ziegler A, 2005, BIOCHEMISTRY-US, V44, P138, DOI 10.1021/bi0491604; Zorko M, 2005, ADV DRUG DELIVER REV, V57, P529, DOI 10.1016/j.addr.2004.10.010	32	27	29	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2177	2184		10.1096/fj.07-099549	http://dx.doi.org/10.1096/fj.07-099549			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18296502				2022-12-25	WOS:000257292500010
J	Lo, YH; Wu, CC; Shih, HM; Lai, MZ				Lo, Y-H; Wu, C-C; Shih, H-M; Lai, M-Z			Selective activation of NFAT by promyelocytic leukemia protein	ONCOGENE			English	Article						PML; NFAT; CBP; tumor suppressor; transcription activation	ALPHA-INDUCED APOPTOSIS; T-CELLS; NUCLEAR-BODIES; KAPPA-B; DNA-DAMAGE; PML GENE; TRANSCRIPTION; DAXX; COACTIVATOR; EXPRESSION	Promyelocytic leukemia (PML) protein is a tumor suppressor with complicated action mechanisms not yet fully understood. In this study, we found that the nuclear factor of activated T cell ( NFAT) is an unexpected partner of PML: PML specifically enhanced the transcription activation of NFAT. In PML-null mouse embryonic fibroblasts, no transcription activity of NFAT could be detected. There was a selective requirement of PML isoform in NFAT activation: PML-I and PML-VI, but not PML-IV, increased NFAT transactivation. PML specifically promoted the expression of many, but not all, NFAT-targeted genes. We found a specific binding of PML to NFATc. The interaction of PML with NFATc in vivo was further confirmed by chromatin immunoprecipitation and DNA affinity precipitation assay analysis. The unexpected coupling of PML with NFAT reveals a novel mechanism underlying the diverse physiological functions of PML.	[Lo, Y-H; Wu, C-C; Lai, M-Z] Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan; [Lo, Y-H; Lai, M-Z] Natl Yang Ming Univ, Grad Inst Microbiol & Immunol, Taipei 112, Taiwan; [Shih, H-M] Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; [Lai, M-Z] Natl Taiwan Univ, Sch Med, Grad Inst Immunol, Taipei 10764, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; National Taiwan University	Lai, MZ (corresponding author), Acad Sinica, Inst Mol Biol, 128 Acad Rd,Sect 2, Taipei 11529, Taiwan.	mblai@imb.sinica.edu.tw	Shih, Hsiu-Ming/S-7023-2018; Lai, Ming-Zong/AAA-4408-2021	Lai, Ming-Zong/0000-0002-3237-4803				Avots A, 1999, IMMUNITY, V10, P515, DOI 10.1016/S1074-7613(00)80051-5; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Bruno S, 2003, BLOOD, V101, P3514, DOI 10.1182/blood-2002-11-3335; Buschbeck M, 2007, ONCOGENE, V26, P3415, DOI 10.1038/sj.onc.1210128; Cairo S, 2005, ONCOGENE, V24, P2195, DOI 10.1038/sj.onc.1208338; Condemine W, 2006, CANCER RES, V66, P6192, DOI 10.1158/0008-5472.CAN-05-3792; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Crowder C, 2005, BLOOD, V105, P1280, DOI 10.1182/blood-2004-04-1614; Dellaire G, 2004, BIOESSAYS, V26, P963, DOI 10.1002/bies.20089; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Garcia-Rodriguez C, 1998, J EXP MED, V187, P2031, DOI 10.1084/jem.187.12.2031; GODDARD AD, 1995, MAMM GENOME, V6, P732, DOI 10.1007/BF00354296; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Ho HY, 1997, EUR J IMMUNOL, V27, P222, DOI 10.1002/eji.1830270133; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Ishov AM, 2004, J CELL SCI, V117, P3807, DOI 10.1242/jcs.01230; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Lin DY, 2004, MOL CELL BIOL, V24, P10529, DOI 10.1128/MCB.24.24.10529-10541.2004; Lin DY, 2003, J BIOL CHEM, V278, P15958, DOI 10.1074/jbc.M300387200; Macian F, 2002, CELL, V109, P719, DOI 10.1016/S0092-8674(02)00767-5; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Moller A, 2003, CANCER RES, V63, P4310; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Salomoni P, 2005, BLOOD, V105, P3686, DOI 10.1182/blood-2004-09-3782; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; von Mikecz A, 2000, J CELL BIOL, V150, P265, DOI 10.1083/jcb.150.1.265; Wang J, 2004, J CELL BIOL, V164, P515, DOI 10.1083/jcb.200305142; Wang QD, 2000, BIOCHEM BIOPH RES CO, V276, P466, DOI 10.1006/bbrc.2000.3512; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wu CC, 2003, MOL CELL BIOL, V23, P6442, DOI 10.1128/MCB.23.18.6442-6454.2003; Wu WS, 2003, J BIOL CHEM, V278, P12294, DOI 10.1074/jbc.M211849200; Wu WS, 2002, ONCOGENE, V21, P3925, DOI 10.1038/sj.onc.1205491; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Youn HD, 2000, EMBO J, V19, P4323, DOI 10.1093/emboj/19.16.4323; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhu Y, 2002, J BIOL CHEM, V277, P6923, DOI 10.1074/jbc.M108075200	40	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2008	27	27					3821	3830		10.1038/onc.2008.2	http://dx.doi.org/10.1038/onc.2008.2			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18246125				2022-12-25	WOS:000256904700006
J	Alsheich-Bartok, O; Haupt, S; Alkalay-Snir, I; Saito, S; Appella, E; Haupt, Y				Alsheich-Bartok, O.; Haupt, S.; Alkalay-Snir, I.; Saito, S.; Appella, E.; Haupt, Y.			PML enhances the regulation of p53 by CK1 in response to DNA damage	ONCOGENE			English	Article						PML; CK1; p53; Mdm2; threonine 18 phosphorylation	ACUTE PROMYELOCYTIC LEUKEMIA; NUCLEAR-BODIES; PROTEIN-KINASE; HUMAN CANCERS; PHOSPHORYLATION; MDM2; BINDING; UBIQUITINATION; DEGRADATION; INHIBITOR	In response to stress, p53 is accumulated and activated to induce appropriate growth inhibitory responses. This requires the release of p53 from the constraints of its negative regulators Mdm2 and Mdm4. A key event in this dissociation is the phosphorylation of p53 at threonine residue (Thr18) within the Mdm2/4-binding domain. Casein kinase 1 (CK1) plays a major role in this phosphorylation. The promyelocytic leukemia protein (PML) regulates certain modi. cations of p53 in response to DNA damage. Here, we investigated the role of PML in the regulation of Thr18 phosphorylation. We found that PML enhances Thr18 phosphorylation of endogenous p53 in response to stress. On DNA damage, CK1 accumulates in the cell, with a proportion concentrated in the nucleus together with p53 and PML. Furthermore, CK1 interacts with endogenous p53 and PML, and this interaction is enhanced by genotoxic stress. Inhibition of CK1 impairs the protection of p53 by PML from Mdm2-mediated degradation. Our findings support a role for PML in the regulation of p53 by CK1. We propose that following DNA damage, PML facilitates Thr18 phosphorylation by recruiting p53 and CK1 into PML nuclear bodies, thereby protecting p53 from inhibition by Mdm2, leading to p53 activation.	[Alsheich-Bartok, O.; Haupt, S.; Alkalay-Snir, I.; Haupt, Y.] Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, Dept Immunol, IL-91120 Jerusalem, Israel; [Saito, S.; Appella, E.] NCI, Cell Biol Lab, Ctr Canc Res, Natl Inst Hlth, Bethesda, MD 20892 USA	Hebrew University of Jerusalem; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Haupt, Y (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, Dept Immunol, IL-91120 Jerusalem, Israel.	haupt@md.huji.ac.il		Haupt, Ygal/0000-0001-5925-0096	NATIONAL CANCER INSTITUTE [ZIABC005599, Z01BC005599] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behrend L, 2000, ONCOGENE, V19, P5303, DOI 10.1038/sj.onc.1203939; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; HOEKSTRA MF, 1994, MOL BIOL CELL, V5, P877, DOI 10.1091/mbc.5.8.877; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Knippschild U, 2005, CELL SIGNAL, V17, P675, DOI 10.1016/j.cellsig.2004.12.011; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Lai ZH, 2000, ARCH BIOCHEM BIOPHYS, V381, P278, DOI 10.1006/abbi.2000.1998; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Louria-Hayon I, 2003, J BIOL CHEM, V278, P33134, DOI 10.1074/jbc.M301264200; Marine JCW, 2007, J CELL SCI, V120, P371, DOI 10.1242/jcs.03362; Maritzen T, 2003, EUR J CELL BIOL, V82, P369, DOI 10.1078/0171-9335-00323; Mashhoon N, 2000, J BIOL CHEM, V275, P20052, DOI 10.1074/jbc.M001713200; Meek DW, 2004, DNA REPAIR, V3, P1049, DOI 10.1016/j.dnarep.2004.03.027; Muller S, 1998, BLOOD, V92, P4308, DOI 10.1182/blood.V92.11.4308.423k36_4308_4316; Rizzo MG, 1998, BRIT J CANCER, V77, P1429, DOI 10.1038/bjc.1998.236; Saito S, 2003, J BIOL CHEM, V278, P37536, DOI 10.1074/jbc.M305135200; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Salomoni P, 2002, NAT CELL BIOL, V4, pE152, DOI 10.1038/ncb0602-e152; Schon O, 2002, J MOL BIOL, V323, P491, DOI 10.1016/S0022-2836(02)00852-5; Sionov RV, 2001, MOL CELL BIOL, V21, P5869; Soubeyrand S, 2004, EUR J BIOCHEM, V271, P3776, DOI 10.1111/j.1432-1033.2004.04319.x; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Wang ZG, 1998, SCIENCE, V279, P1547; Wolff S, 2006, FEBS LETT, V580, P6477, DOI 10.1016/j.febslet.2006.10.068; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978; Zimber A, 2004, CELL SIGNAL, V16, P1085, DOI 10.1016/j.cellsig.2004.03.020	30	52	54	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2008	27	26					3653	3661		10.1038/sj.onc.1211036	http://dx.doi.org/10.1038/sj.onc.1211036			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18246126				2022-12-25	WOS:000256659300002
J	Botlagunta, M; Vesuna, F; Mironchik, Y; Raman, A; Lisok, A; Winnard, P; Mukadam, S; Van Diest, P; Chen, JH; Farabaugh, P; Patel, AH; Raman, V				Botlagunta, M.; Vesuna, F.; Mironchik, Y.; Raman, A.; Lisok, A.; Winnard, P., Jr.; Mukadam, S.; Van Diest, P.; Chen, J. H.; Farabaugh, P.; Patel, A. H.; Raman, V.			Oncogenic role of DDX3 in breast cancer biogenesis	ONCOGENE			English	Article						DDX3; breast cancer; BPDE	BOX RNA HELICASE; MAMMARY EPITHELIAL-CELLS; HEPATOCELLULAR-CARCINOMA; MESENCHYMAL TRANSITION; TOBACCO-SMOKE; DIOL-EPOXIDE; DNA-DAMAGE; IN-VITRO; EXPRESSION; TRANSFORMATION	Benzo[a] pyrene diol epoxide (BPDE), the active metabolite of benzo[a] pyrene present in tobacco smoke, is a major cancer-causing compound. To evaluate the effects of BPDE on human breast epithelial cells, we exposed an immortalized human breast cell line, MCF 10A, to BPDE and characterized the gene expression pattern. Of the differential genes expressed, we found consistent activation of DDX3, a member of the DEAD box RNA helicase family. Overexpression of DDX3 in MCF 10A cells induced an epithelial-mesenchymal- like transformation, exhibited increased motility and invasive properties, and formed colonies in soft-agar assays. Besides the altered phenotype, MCF 10A-DDX3 cells repressed E-cadherin expression as demonstrated by both immunoblots and by E-cadherin promoter-reporter assays. In addition, an in vivo association of DDX3 and the E-cadherin promoter was demonstrated by chromatin immunoprecipitation assays. Collectively, these results demonstrate that the activation of DDX3 by BPDE, can promote growth, proliferation and neoplastic transformation of breast epithelial cells.	[Botlagunta, M.; Vesuna, F.; Mironchik, Y.; Lisok, A.; Winnard, P., Jr.; Mukadam, S.] Johns Hopkins Univ, Sch Med, Dept Radiol & Radiol Sci, Baltimore, MD 21205 USA; [Raman, A.] Univ Maryland, Dept Biol, Baltimore, MD 21201 USA; [Van Diest, P.] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands; [Chen, J. H.] Tzu Chi Univ, Dept Life Sci, Hualien, Taiwan; [Patel, A. H.] Arvind Patel Inst Virol, Glasgow G11, Lanark, Scotland; [Raman, V.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA	Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; Utrecht University; Utrecht University Medical Center; Tzu Chi University; Johns Hopkins University	Raman, V (corresponding author), Johns Hopkins Univ, Sch Med, Dept Radiol & Radiol Sci, 720 Rutlands Ave,340 Traylor Bldg, Baltimore, MD 21205 USA.	vraman2@jhmi.edu	Botlagunta, Mahendran/R-5140-2018; Vesuna, Farhad/G-3179-2010	Botlagunta, Mahendran/0000-0002-0490-2832; Vesuna, Farhad/0000-0002-0356-5096; Farabaugh, Philip/0000-0002-5658-7141	Medical Research Council [MC_U130184144] Funding Source: Medline; NCI NIH HHS [R01 CA097226] Funding Source: Medline; MRC [MC_U130184144] Funding Source: UKRI; NATIONAL CANCER INSTITUTE [R01CA097226] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdelhaleem M, 2005, CLIN BIOCHEM, V38, P499, DOI 10.1016/j.clinbiochem.2005.01.010; Boffetta P, 2006, INT J CANCER, V119, P884, DOI 10.1002/ijc.21903; Bonner MR, 2005, CANCER CAUSE CONTROL, V16, P683, DOI 10.1007/s10552-005-1906-x; Burdick AD, 2006, CARCINOGENESIS, V27, P2331, DOI 10.1093/carcin/bgl083; Caruso JA, 2001, MUTAT RES-FUND MOL M, V473, P85, DOI 10.1016/S0027-5107(00)00140-8; Chang PC, 2006, ONCOGENE, V25, P1991, DOI 10.1038/sj.onc.1209239; Chao CH, 2006, CANCER RES, V66, P6579, DOI 10.1158/0008-5472.CAN-05-2415; Cordin O, 2006, GENE, V367, P17, DOI 10.1016/j.gene.2005.10.019; Duriseti S, 2006, NEOPLASIA, V8, P250, DOI 10.1593/neo.05766; Huang JS, 2004, BIOCHEM BIOPH RES CO, V315, P950, DOI 10.1016/j.bbrc.2004.01.151; Jeffy BD, 2002, CANCER RES, V62, P113; Jung JW, 2007, EUR J CANCER, V43, P1214, DOI 10.1016/j.ejca.2007.01.034; KROLEWSKI B, 1988, TERATOGEN CARCIN MUT, V8, P127, DOI 10.1002/tcm.1770080302; Linder P, 2006, NUCLEIC ACIDS RES, V34, P4168, DOI 10.1093/nar/gkl468; Marchetti A, 1996, ONCOGENE, V12, P1319; Margulis A, 2005, CANCER RES, V65, P1783, DOI 10.1158/0008-5472.CAN-04-3399; Mei JX, 2003, BREAST CANCER RES TR, V79, P95, DOI 10.1023/A:1023326121951; Mironchik Y, 2005, CANCER RES, V65, P10801, DOI 10.1158/0008-5472.CAN-05-0712; Myohanen S, 2001, J BIOL CHEM, V276, P1634, DOI 10.1074/jbc.M004481200; Norsa'adah B., 2005, SMJ Singapore Medical Journal, V46, P698; Owsianka AM, 1999, VIROLOGY, V257, P330, DOI 10.1006/viro.1999.9659; Parkin D M, 1992, IARC Sci Publ, P45; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; PHILLIPS PH, 1991, AM J EPIDEMIOL, V133, P757, DOI 10.1093/oxfordjournals.aje.a115954; Pirkle James L., 1996, JAMA (Journal of the American Medical Association), V275, P1233, DOI 10.1001/jama.275.16.1233; Rajendran RR, 2003, J BIOL CHEM, V278, P4628, DOI 10.1074/jbc.M210066200; Reynolds P, 2004, JNCI-J NATL CANCER I, V96, P29, DOI 10.1093/jnci/djh002; Sasco AJ, 2001, APMIS, V109, P321, DOI 10.1034/j.1600-0463.2001.090501.x; Sekiguchi T, 2007, BIOCHEM BIOPH RES CO, V356, P668, DOI 10.1016/j.bbrc.2007.03.038; SHIMOYAMA Y, 1989, CANCER RES, V49, P2128; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; Toretsky JA, 2006, CANCER RES, V66, P5574, DOI 10.1158/0008-5472.CAN-05-3293; Wang AJ, 2003, CARCINOGENESIS, V24, P225, DOI 10.1093/carcin/24.2.225; Whitbread AK, 2006, BIOL CHEM, V387, P707, DOI 10.1515/BC.2006.089; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776; YANG DJ, 1992, P NATL ACAD SCI USA, V89, P2237, DOI 10.1073/pnas.89.6.2237; Yang LQ, 2007, J BIOL CHEM, V282, P16811, DOI 10.1074/jbc.M610488200; Yang LQ, 2006, CELL, V127, P139, DOI 10.1016/j.cell.2006.08.036; Yang LQ, 2005, MOL CANCER RES, V3, P355, DOI 10.1158/1541-7786.MCR-05-0022; Yokoyama K, 2003, INT J ONCOL, V22, P891; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	41	156	163	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	28					3912	3922		10.1038/onc.2008.33	http://dx.doi.org/10.1038/onc.2008.33			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	318JZ	18264132	Green Accepted			2022-12-25	WOS:000257089000003
J	Tokunou, T; Miller, R; Patwari, P; Davis, ME; Segers, VFM; Grodzinsky, AJ; Lee, RT				Tokunou, Tomotake; Miller, Rachel; Patwari, Parth; Davis, Michael E.; Segers, Vincent F. M.; Grodzinsky, Alan J.; Lee, Richard T.			Engineering insulin-like growth factor-1 for local delivery	FASEB JOURNAL			English	Article						heparin binding domain; tissue repair; biosynthesis	HEPARIN-BINDING EGF; EMBRYONIC STEM-CELLS; ARTICULAR-CARTILAGE; SKELETAL-MUSCLE; RECEPTOR; IGF-1; HORMONE; REGENERATION; ACTIVATION; EXPRESSION	Insulin-like growth factor-1 (IGF-1) is a small protein that promotes cell survival and growth, often acting over long distances. Although for decades IGF-1 has been considered to have therapeutic potential, systemic side effects of IGF-1 are significant, and local delivery of IGF-1 for tissue repair has been a long-standing challenge. In this study, we designed and purified a novel protein, heparin-binding IGF-1 (XpHB-IGF-1), which is a fusion protein of native IGF-1 with the heparin-binding domain of heparin-binding epidermal growth factor-like growth factor. Xp-HB-IGF1 bound selectively to heparin as well as the cell surfaces of 3T3 fibroblasts, neonatal cardiac myocytes and differentiating ES cells. Xp-HB-IGF-1 activated the IGF-1 receptor and Akt with identical kinetics and dose response, indicating no compromise of biological activity due to the heparin-binding domain. Because cartilage is a proteoglycan-rich environment and IGF-1 is a known stimulus for chondrocyte biosynthesis, we then studied the effectiveness of Xp-HB-IGF-1 in cartilage. Xp-HB-IGF-1 was selectively retained by cartilage explants and led to sustained chondrocyte proteoglycan biosynthesis compared to IGF-1. These data show that the strategy of engineering a "long- distance" growth factor like IGF-1 for local delivery may be useful for tissue repair and minimizing systemic effects.	[Tokunou, Tomotake; Patwari, Parth; Davis, Michael E.; Segers, Vincent F. M.; Lee, Richard T.] Harvard Univ, Sch Med, Div Cardiovasc, Brigham & Womens Hosp,Dept Med, Boston, MA USA; [Miller, Rachel; Grodzinsky, Alan J.; Lee, Richard T.] MIT, Cambridge, MA 02139 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Massachusetts Institute of Technology (MIT)	Lee, RT (corresponding author), Partners Res Facil, 65 Landsdowne St, Cambridge, MA 02139 USA.	rlee@partners.org	Tokunou, Tomotake/AAG-3403-2019; Segers, Vincent F/J-1191-2019	Segers, Vincent F/0000-0001-7796-2222; Miller, Rachel/0000-0002-4486-5757; Lee, Richard/0000-0003-4687-1381	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL073574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB003805] Funding Source: NIH RePORTER; NHLBI NIH HHS [F32 HL073574, F32 HL073574-03] Funding Source: Medline; NIBIB NIH HHS [R01 EB003805, EB003805] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		BAYNE ML, 1989, J BIOL CHEM, V264, P11004; BESNER G, 1990, CELL REGUL, V1, P811, DOI 10.1091/mbc.1.11.811; Bhakta NR, 2000, J BIOL CHEM, V275, P5860, DOI 10.1074/jbc.275.8.5860; Bonassar LJ, 2000, ARCH BIOCHEM BIOPHYS, V379, P57, DOI 10.1006/abbi.2000.1820; Capito RM, 2007, GENE THER, V14, P721, DOI 10.1038/sj.gt.3302918; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Coffer PJ, 1998, BIOCHEM J, V335, P1; Delafontaine P, 2004, ARTERIOSCL THROM VAS, V24, P435, DOI 10.1161/01.ATV.0000105902.89459.09; Denley A, 2005, CYTOKINE GROWTH F R, V16, P421, DOI 10.1016/j.cytogfr.2005.04.004; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; Fraidenraich D, 2004, SCIENCE, V306, P247, DOI 10.1126/science.1102612; Frystyk J, 2004, GROWTH HORM IGF RES, V14, P337, DOI 10.1016/j.ghir.2004.06.001; GULER HP, 1988, P NATL ACAD SCI USA, V85, P4889, DOI 10.1073/pnas.85.13.4889; Hameed M, 2003, J PHYSIOL-LONDON, V547, P247, DOI 10.1113/jphysiol.2002.032136; Harmer NJ, 2003, BIOPHYS CHEM, V100, P545, DOI 10.1016/S0301-4622(02)00305-8; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; JABRI N, 1994, DIABETES, V43, P369, DOI 10.2337/diabetes.43.3.369; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; MILNER SJ, 1995, BIOCHEM J, V308, P865, DOI 10.1042/bj3080865; Milner SJ, 1999, BIOTECHNOL BIOENG, V62, P693; Mourkioti F, 2005, TRENDS IMMUNOL, V26, P535, DOI 10.1016/j.it.2005.08.002; Musaro A, 2007, EXP GERONTOL, V42, P76, DOI 10.1016/j.exger.2006.05.004; Nixon AJ, 2000, CLIN ORTHOP RELAT R, pS201, DOI 10.1097/00003086-200010001-00026; Ozdinler PH, 2006, NAT NEUROSCI, V9, P1371, DOI 10.1038/nn1789; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; Robinson CJ, 2006, J BIOL CHEM, V281, P1731, DOI 10.1074/jbc.M510760200; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAH RLY, 1989, J ORTHOPAED RES, V7, P619, DOI 10.1002/jor.1100070502; Schmidt MB, 2006, OSTEOARTHR CARTILAGE, V14, P403, DOI 10.1016/j.joca.2005.10.011; Shavlakadze T, 2005, GROWTH HORM IGF RES, V15, P4, DOI 10.1016/j.ghir.2004.11.001; Takahashi T, 2003, CIRCULATION, V107, P1912, DOI 10.1161/01.CIR.0000064899.53876.A3; THOMPSON SA, 1994, J BIOL CHEM, V269, P2541; Topalli I, 2004, BRAIN RES, V1030, P116, DOI 10.1016/j.brainres.2004.09.057; Vincent TL, 2007, OSTEOARTHR CARTILAGE, V15, P752, DOI 10.1016/j.joca.2007.01.021; Wilkinson-Berka JL, 2006, CURR MED CHEM, V13, P3307, DOI 10.2174/092986706778773086; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yoshioka J, 2005, P NATL ACAD SCI USA, V102, P10622, DOI 10.1073/pnas.0501198102	38	32	45	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					1886	1893		10.1096/fj.07-100925	http://dx.doi.org/10.1096/fj.07-100925			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18285400	Green Accepted			2022-12-25	WOS:000256352700028
J	Zabolotny, JM; Kim, YB; Welsh, LA; Kershaw, EE; Neel, BG; Kahn, BB				Zabolotny, Janice M.; Kim, Young-Bum; Welsh, Laura A.; Kershaw, Erin E.; Neel, Benjamin G.; Kahn, Barbara B.			Protein-tyrosine phosphatase 1B expression is induced by inflammation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; NECROSIS-FACTOR-ALPHA; INDUCED INSULIN-RESISTANCE; DIET-INDUCED OBESITY; KAPPA-B ACTIVATION; SKELETAL-MUSCLE; ADIPOSE-TISSUE; TNF-ALPHA; RECEPTOR SUBSTRATE-1; GLUCOSE-HOMEOSTASIS	Protein-tyrosine phosphatase 1B (PTP1B) is a major negative regulator of insulin and leptin sensitivity. PTP1B overexpression in adipose tissue and skeletal muscle of humans and rodents may contribute to insulin resistance and obesity. The mechanisms mediating PTP1B overexpression in obese and diabetic states have been unclear. We find that adipose tissue inflammation and the pro-inflammatory cytokine tumor necrosis factor alpha (TNF alpha) regulate PTP1B expression in vivo. High fat feeding of mice increased PTP1B expression 1.5- to 7-fold in adipose tissue, liver, skeletal muscle, and arcuate nucleus of hypothalamus. PTP1B overexpression in high fat-fed mice coincided with increased adipose tissue expression of the macrophage marker CD68 and TNF alpha, which is implicated in causing obesity-induced insulin resistance. TNF alpha increased PTP1B mRNA and protein levels by 2- to 5-fold in a dose-and time-dependent manner in adipocyte and hepatocyte cell lines. TNF alpha administration in mice increased PTP1B mRNA1.4- to 4-fold in adipose tissue, liver, skeletal muscle, and hypothalamic arcuate nucleus and PTP1B protein 2- fold in liver. Actinomycin D treatment blocked, and high dose salicylate treatment inhibited by 80%, TNF alpha-induced PTP1B expression in adipocyte cell lines, suggesting TNF alpha may induce PTP1B transcription via nuclear factor kappa B ( NF kappa B) activation. Chromatin immunoprecipitation from adipocyte cell lines and liver of mice demonstrated TNF alpha-induced recruitment of NF kappa B subunit p65 to the PTP1B promoter in vitro and in vivo. In mice with diet-induced obesity, TNF alpha deficiency also partly blocked PTP1B overexpression in adipose tissue. Our data suggest that PTP1B overexpression in multiple tissues in obesity is regulated by inflammation and that PTP1B may be a target of anti-inflammatory therapies.	[Zabolotny, Janice M.; Kim, Young-Bum; Welsh, Laura A.; Kershaw, Erin E.; Kahn, Barbara B.] Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA; [Neel, Benjamin G.] Beth Israel Deaconess Med Ctr, Dept Med, Canc Biol Program, Div Hematol Oncol, Boston, MA 02215 USA; [Neel, Benjamin G.] Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Zabolotny, JM (corresponding author), Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, N 325A,330 Brookline Ave, Boston, MA 02215 USA.	jzabolot@bidmc.harvard.edu	Kershaw, Erin E/G-9587-2013; Welsh, Laura/AAW-8481-2020	Kershaw, Erin E/0000-0002-3887-4868; Welsh, Laura/0000-0002-3987-2186	NATIONAL CANCER INSTITUTE [R01CA049152] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060838, R21DK073530, R01DK060839, P30DK057521, K01DK062212, K08DK065833, P30DK046200] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 049152] Funding Source: Medline; NIDDK NIH HHS [K08 DK 065833, R21 DK 073530, K08 DK065833-05, R01 DK 060838, R01 DK 060839, P30 DK 046200, P30 DK 057521, K08 DK065833, K01 DK 062212] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad F, 1997, METABOLISM, V46, P1140, DOI 10.1016/S0026-0495(97)90206-7; Ahmad F, 1997, J CLIN INVEST, V100, P449, DOI 10.1172/JCI119552; AHMAD F, 1995, AM J PHYSIOL-ENDOC M, V268, pE932, DOI 10.1152/ajpendo.1995.268.5.E932; AHMAD F, 1995, J CLIN INVEST, V95, P2806, DOI 10.1172/JCI117985; AHMAD F, 1995, METABOLISM, V44, P1175, DOI 10.1016/0026-0495(95)90012-8; Ahmad F, 1997, J CELL BIOCHEM, V64, P117, DOI 10.1002/(SICI)1097-4644(199701)64:1<117::AID-JCB14>3.0.CO;2-I; Ameloot P, 2002, EUR J IMMUNOL, V32, P2759, DOI 10.1002/1521-4141(2002010)32:10<2759::AID-IMMU2759>3.0.CO;2-L; Bence KK, 2006, NAT MED, V12, P917, DOI 10.1038/nm1435; Berg AH, 2004, AM J PHYSIOL-ENDOC M, V287, pE1178, DOI 10.1152/ajpendo.00002.2004; Bourdeau A, 2005, CURR OPIN CELL BIOL, V17, P203, DOI 10.1016/j.ceb.2005.02.001; Calera MR, 2000, J BIOL CHEM, V275, P6308, DOI 10.1074/jbc.275.9.6308; Chavey C, 2003, J BIOL CHEM, V278, P11888, DOI 10.1074/jbc.M209196200; Cheng A, 2002, DEV CELL, V2, P497, DOI 10.1016/S1534-5807(02)00149-1; Cheung A, 1999, J LAB CLIN MED, V134, P115, DOI 10.1016/S0022-2143(99)90115-4; Cheung AT, 2000, DIABETES, V49, P810, DOI 10.2337/diabetes.49.5.810; Cinti S, 2005, J LIPID RES, V46, P2347, DOI 10.1194/jlr.M500294-JLR200; Coppack SW, 2001, P NUTR SOC, V60, P349, DOI 10.1079/PNS2001110; Dadke S, 2007, NAT CELL BIOL, V9, P80, DOI 10.1038/ncb1522; Dadke SS, 2000, BIOCHEM BIOPH RES CO, V274, P583, DOI 10.1006/bbrc.2000.3188; DeFronzo RA, 1997, DIABETES REV, V5, P177; Delibegovic M, 2007, MOL CELL BIOL, V27, P7727, DOI 10.1128/MCB.00959-07; Dube N, 2005, BBA-PROTEINS PROTEOM, V1754, P108, DOI 10.1016/j.bbapap.2005.07.030; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Fantuzzi G, 2000, J LEUKOCYTE BIOL, V68, P437; FLICK DA, 1986, J IMMUNOPHARMACOL, V8, P89; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; Goldstein BJ, 2000, J BIOL CHEM, V275, P4283, DOI 10.1074/jbc.275.6.4283; Gouni-Berthold I, 2005, J INTERN MED, V257, P272, DOI 10.1111/j.1365-2796.2004.01446.x; Gum RJ, 2003, DIABETES, V52, P21, DOI 10.2337/diabetes.52.1.21; Haj FG, 2005, J BIOL CHEM, V280, P15038, DOI 10.1074/jbc.M413240200; Howard JK, 2004, NAT MED, V10, P734, DOI 10.1038/nm1072; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; Kipfer-Coudreau S, 2004, DIABETOLOGIA, V47, P1278, DOI 10.1007/s00125-004-1432-5; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Koza RA, 2000, J BIOL CHEM, V275, P34486, DOI 10.1074/jbc.M002136200; Kracht M, 2002, CYTOKINE, V20, P91, DOI 10.1006/cyto.2002.0895; KUSARI J, 1994, J CLIN INVEST, V93, P1156, DOI 10.1172/JCI117068; Lam NT, 2004, MOL ENDOCRINOL, V18, P1333, DOI 10.1210/me.2002-0193; Lam NT, 2006, J MOL ENDOCRINOL, V36, P163, DOI 10.1677/jme.1.01937; Lu T, 2004, ONCOGENE, V23, P2138, DOI 10.1038/sj.onc.1207332; Lukic M L, 1998, Dev Immunol, V6, P119, DOI 10.1155/1998/92198; Mantzoros C S, 1995, Adv Endocrinol Metab, V6, P193; Mensah-Brown EPK, 2002, MOL IMMUNOL, V38, P941, DOI 10.1016/S0161-5890(02)00021-4; Nieto-Vazquez I, 2007, DIABETES, V56, P404, DOI 10.2337/db06-0989; Nowak DE, 2005, BIOTECHNIQUES, V39, P715, DOI 10.2144/000112014; Obata T, 1998, J BIOCHEM-TOKYO, V123, P813; PANG XP, 1991, LYMPHOKINE CYTOK RES, V10, P301; Perkins ND, 2006, CELL DEATH DIFFER, V13, P759, DOI 10.1038/sj.cdd.4401838; Philip M, 2004, SEMIN CANCER BIOL, V14, P433, DOI 10.1016/j.semcancer.2004.06.006; Pickup JC, 1998, DIABETOLOGIA, V41, P1241, DOI 10.1007/s001250051058; Qi C, 2000, P SOC EXP BIOL MED, V223, P128, DOI 10.1046/j.1525-1373.2000.22318.x; Rabinovitch A, 1998, DIABETES METAB REV, V14, P129, DOI 10.1002/(SICI)1099-0895(199806)14:2<129::AID-DMR208>3.0.CO;2-V; Ruan H, 2002, DIABETES, V51, P1319, DOI 10.2337/diabetes.51.5.1319; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Santaniemi M, 2004, J INTERN MED, V256, P48, DOI 10.1111/j.1365-2796.2004.01339.x; SCHIEVELLA AR, 1993, CELL GROWTH DIFFER, V4, P239; Serino M, 2007, DIABETES, V56, P2541, DOI 10.2337/db07-0360; Sethi JK, 1999, SEMIN CELL DEV BIOL, V10, P19, DOI 10.1006/scdb.1998.0273; Shao J, 1998, Zhonghua Yi Xue Za Zhi, V78, P753; Shoelson SE, 2003, INT J OBESITY, V27, pS49, DOI 10.1038/sj.ijo.0802501; Sykiotis GP, 2001, MOL ENDOCRINOL, V15, P1864, DOI 10.1210/me.15.11.1864; Taghibiglou C, 2002, J BIOL CHEM, V277, P793, DOI 10.1074/jbc.M106737200; Thomas CR, 1998, BIOCHEM PHARMACOL, V56, P1145, DOI 10.1016/S0006-2952(98)00151-8; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Venable CL, 2000, J BIOL CHEM, V275, P18318, DOI 10.1074/jbc.M908392199; Ventre J, 1997, DIABETES, V46, P1526, DOI 10.2337/diabetes.46.9.1526; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wellen KE, 2003, J CLIN INVEST, V112, P1785, DOI 10.1172/JCI20514; Worm D, 1999, DIABETOLOGIA, V42, P1146; Wu Y, 2005, BRIT J PHARMACOL, V146, P234, DOI 10.1038/sj.bjp.0706306; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X; Zabolotny JM, 2004, J BIOL CHEM, V279, P24844, DOI 10.1074/jbc.M310688200; Ziotopoulou M, 2000, AM J PHYSIOL-ENDOC M, V279, pE838, DOI 10.1152/ajpendo.2000.279.4.E838	76	291	299	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14230	14241		10.1074/jbc.M800061200	http://dx.doi.org/10.1074/jbc.M800061200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18281274	hybrid, Green Published			2022-12-25	WOS:000255941400009
J	Dolniak, B; Katsoulidis, E; Carayol, N; Altman, JK; Redig, AJ; Tallman, MS; Ueda, T; Watanabe-Fukunaga, R; Fukunaga, R; Platanias, LC				Dolniak, Blazej; Katsoulidis, Efstratios; Carayol, Nathalie; Altman, Jessica K.; Redig, Amanda J.; Tallman, Martin S.; Ueda, Takeshi; Watanabe-Fukunaga, Rie; Fukunaga, Rikiro; Platanias, Leonidas C.			Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; ACTIVATED PROTEIN-KINASE; INITIATION-FACTOR 4E; ABL-EXPRESSING CELLS; CAP-BINDING PROTEIN; NF-KAPPA-B; HEMATOPOIETIC-CELLS; INDUCED APOPTOSIS; MYELOID-LEUKEMIA; INTERFERON-ALPHA	Arsenic trioxide (As2O3) is a potent inducer of apoptosis of malignant cells in vitro and in vivo, but the precise mechanisms by which it mediates such effects are not well defined. We provide evidence that As2O3 induces phosphorylation/ activation of the MAPK signal-integrating kinases (Mnks) 1 and 2 in leukemia cell lines. Such activation is defective in cells with targeted disruption of the p38 alpha MAPK gene, indicating that it requires upstream engagement of the p38 MAPK pathway. Studies using Mnk1(-/-) or Mnk2(-/-), or double Mnk1(-/-) Mnk2(-/-) knock-out cells, establish that activation of Mnk1 and Mnk2 by arsenic trioxide regulates downstream phosphorylation of the eukaryotic initiation factor 4E at Ser-209. Importantly, arsenic-induced apoptosis is enhanced in cells with targeted disruption of the Mnk1 and/or Mnk2 genes, suggesting that these kinases are activated in a negative-feedback regulatory manner, to control generation of arsenic trioxide responses. Consistent with this, pharmacological inhibition of Mnk activity enhances the suppressive effects of arsenic trioxide on primary leukemic progenitors from patients with acute leukemias. Taken together, these findings indicate an important role for Mnk kinases, acting as negative regulators for signals that control generation of arsenic trioxide-dependent apoptosis and antileukemic responses.	[Dolniak, Blazej; Katsoulidis, Efstratios; Carayol, Nathalie; Altman, Jessica K.; Redig, Amanda J.; Tallman, Martin S.; Platanias, Leonidas C.] Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Dolniak, Blazej; Katsoulidis, Efstratios; Carayol, Nathalie; Altman, Jessica K.; Redig, Amanda J.; Tallman, Martin S.; Platanias, Leonidas C.] Northwestern Univ, Sch Med, Div Hematol Oncol, Dept Med, Chicago, IL 60611 USA; [Dolniak, Blazej; Katsoulidis, Efstratios; Carayol, Nathalie; Altman, Jessica K.; Redig, Amanda J.; Tallman, Martin S.; Platanias, Leonidas C.] Jesse Brown Vet Affairs Med Ctr, Chicago, IL 60611 USA; [Ueda, Takeshi; Watanabe-Fukunaga, Rie; Fukunaga, Rikiro] Osaka Univ, Genet Lab, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center; Osaka University	Platanias, LC (corresponding author), Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, 303 E Superior St,Lurie 3-107, Chicago, IL 60611 USA.	l-platanias@northwestern.edu	Fukunaga, Rikiro/CAG-2891-2022	Ueda, Takeshi/0000-0001-9823-6764	NCI NIH HHS [CA77816, CA121192, CA100579] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA121192, R01CA100579, R01CA077816] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams RH, 2000, MOL CELL, V6, P109, DOI 10.1016/S1097-2765(00)00012-5; Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; Akao Y, 1998, BRIT J HAEMATOL, V102, P1055, DOI 10.1046/j.1365-2141.1998.00869.x; Beretta L, 1998, J IMMUNOL, V160, P3269; BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; Buxade M, 2005, IMMUNITY, V23, P177, DOI 10.1016/j.immuni.2005.06.009; Chen GQ, 1996, BLOOD, V88, P1052; Chen Z, 2002, SEMIN HEMATOL, V39, P22, DOI 10.1053/shem.2002.33611; Chrestensen CA, 2007, GENES CELLS, V12, P1133, DOI 10.1111/j.1365-2443.2007.01122.x; Davison K, 2004, BLOOD, V103, P3496, DOI 10.1182/blood-2003-05-1412; Davison K, 2002, SEMIN HEMATOL, V39, P3, DOI 10.1053/shem.2002.33610; Douer D, 2005, J CLIN ONCOL, V23, P2396, DOI 10.1200/JCO.2005.10.217; Evens AM, 2004, LEUKEMIA RES, V28, P891, DOI 10.1016/j.leukres.2004.01.011; FLYNN A, 1995, J BIOL CHEM, V270, P21684, DOI 10.1074/jbc.270.37.21684; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gartenhaus RB, 2002, CLIN CANCER RES, V8, P566; Giafis N, 2006, CANCER RES, V66, P6763, DOI 10.1158/0008-5472.CAN-05-3699; Grad JM, 2001, BLOOD, V98, P805, DOI 10.1182/blood.V98.3.805; Jauch R, 2006, EMBO J, V25, P4020, DOI 10.1038/sj.emboj.7601285; Jing Y, 2007, CURR TOP MICROBIOL, V313, P245; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Kandel EV, 1937, ARCH INTERN MED, V60, P846, DOI 10.1001/archinte.1937.00180050113008; Kannan-Thulasiraman P, 2006, J BIOL CHEM, V281, P22446, DOI 10.1074/jbc.M603111200; Kaur S, 2007, J BIOL CHEM, V282, P1757, DOI 10.1074/jbc.M607365200; Kerbauy DMB, 2005, BLOOD, V106, P3917, DOI 10.1182/blood-2005-04-1424; Knauf U, 2001, MOL CELL BIOL, V21, P5500, DOI 10.1128/MCB.21.16.5500-5511.2001; List A, 2003, LEUKEMIA, V17, P1499, DOI 10.1038/sj.leu.2403021; Mathas S, 2003, BLOOD, V102, P1028, DOI 10.1182/blood-2002-04-1154; Mayer IA, 2001, J BIOL CHEM, V276, P28570, DOI 10.1074/jbc.M011685200; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890-2904.2004; Muller-Tidow C, 2004, CLIN CANCER RES, V10, P1241, DOI 10.1158/1078-0432.CCR-0954-03; Nervi C, 1998, BLOOD, V92, P2244; Niu C, 1999, BLOOD, V94, P3315, DOI 10.1182/blood.V94.10.3315.422k16_3315_3324; Novick SC, 2000, SEMIN ONCOL, V27, P495; Platanias LC, 2003, PHARMACOL THERAPEUT, V98, P129, DOI 10.1016/S0163-7258(03)00016-0; Pyronnet S, 2001, GENE DEV, V15, P2083, DOI 10.1101/gad.889201; Ramos AM, 2005, BLOOD, V105, P4013, DOI 10.1182/blood-2004-07-2802; Reiling JH, 2005, CURR BIOL, V15, P24, DOI 10.1016/j.cub.2004.12.034; Scheper GC, 2001, MOL CELL BIOL, V21, P743, DOI 10.1128/MCB.21.3.743-754.2001; Shen Y, 2001, LEUKEMIA, V15, P735, DOI 10.1038/sj.leu.2402106; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Shenberger JS, 2007, INT J BIOCHEM CELL B, V39, P1828, DOI 10.1016/j.biocel.2007.05.001; Soignet SL, 2001, J CLIN ONCOL, V19, P3852, DOI 10.1200/JCO.2001.19.18.3852; Sun H. D., 1992, CHIN J INTEGRAT CHIN, V12, P170; Takei N, 2001, J BIOL CHEM, V276, P42818, DOI 10.1074/jbc.M103237200; Tallman MS, 2002, BLOOD, V99, P759, DOI 10.1182/blood.V99.3.759; Tallman MS, 2001, BLOOD REV, V15, P133, DOI 10.1054/blre.2001.0160; Tschopp C., 2000, Molecular Cell Biology Research Communications, V3, P205, DOI 10.1006/mcbr.2000.0217; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; Uddin S, 1997, BLOOD, V90, P2574; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Verma A, 2002, J BIOL CHEM, V277, P44988, DOI 10.1074/jbc.M207176200; Verma A, 2002, J BIOL CHEM, V277, P7726, DOI 10.1074/jbc.M106640200; Walsh D, 2004, GENE DEV, V18, P660, DOI 10.1101/gad.1185304; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wei LH, 2005, ONCOGENE, V24, P390, DOI 10.1038/sj.onc.1208192; Worch J, 2004, ONCOGENE, V23, P9162, DOI 10.1038/sj.onc.1208164; Yoon P, 2006, MOL CANCER THER, V5, P2815, DOI 10.1158/1535-7163.MCT-06-0263	60	32	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2008	283	18					12034	12042		10.1074/jbc.M708816200	http://dx.doi.org/10.1074/jbc.M708816200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	293MS	18299328	Green Published, hybrid			2022-12-25	WOS:000255340000019
J	Kelly, EM; Hou, ZJ; Bossuyt, J; Bers, DM; Robia, SL				Kelly, Eileen M.; Hou, Zhanjia; Bossuyt, Julie; Bers, Donald M.; Robia, Seth L.			Phospholamban oligomerization, quaternary structure, and sarco(endo) plasmic reticulum calcium ATPase binding measured by fluorescence resonance energy transfer in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-STATE NMR; CARDIAC SARCOPLASMIC-RETICULUM; LIPID-BILAYERS; MONOMERIC PHOSPHOLAMBAN; CA2+ PUMP; PROTEIN; MEMBRANES; DYNAMICS; INHIBITION; PENTAMER	Phospholamban (PLB) oligomerization, quaternary structure, and sarco(endo) plasmic reticulum calcium ATPase(SERCA) binding were quantified by fluorescence resonance energy transfer (FRET) in an intact cellular environment. FRET between cyan fluorescent protein-PLB and yellow fluorescent protein-PLB in AAV-293 cells showed hyperbolic dependence on protein concentration, with a maximum efficiency of 45.1 +/- 1.3%. The observed FRET corresponds to a probe separation distance of 58.7 +/- 0.5 angstrom, according to a computational model of intrapentameric FRET. This is consistent with models of the PLB pentamer in which cytoplasmic domains fan out from the central bundle of transmembrane helices. An I40A mutation of PLB did not alter pentamer conformation but increased the concentration of half-maximal FRET (K-D) by >4-fold. This is consistent with the previous observation that this putatively monomeric mutant still oligomerizes in intact membranes but forms more dynamic pentamers than wild type PLB. PLB association with SERCA, measured by FRET between cyan fluorescent protein-SERCA and yellow fluorescent protein-PLB, was increased by the I40A mutation without any detectable change in probe separation distance. The data indicate that the regulatory complex conformation is not altered by the I40A mutation. A naturally occurring human mutation (L39Stop) greatly reduced PLB oligomerization and SERCA binding and caused mislocalization of PLB to the cytoplasm and nucleus. Overall, the data suggest that the PLB pentamer adopts a "pinwheel" shape in cell membranes, as opposed to a more compact "bellflower" conformation. I40A mutation decreases oligomerization and increases PLB binding to SERCA. Truncation of the transmembrane domain by L39Stop mutation prevents anchoring of the protein in the membrane, greatly reducing PLB binding to itself or its regulatory target, SERCA.	[Kelly, Eileen M.; Hou, Zhanjia; Bossuyt, Julie; Bers, Donald M.; Robia, Seth L.] Loyola Univ, Dept Physiol, Maywood, IL 60153 USA	Loyola University Chicago	Robia, SL (corresponding author), Loyola Univ, Dept Physiol, 102-5609,2160 S 1st Ave, Maywood, IL 60153 USA.	srobia@lumc.edu	Bers, Donald M/C-4507-2012	Bossuyt, Julie/0000-0001-8874-4765; Bers, Donald/0000-0002-2237-9483	NHLBI NIH HHS [R01 HL092321, R01 HL106189] Funding Source: Medline; NIBIB NIH HHS [EB006061, K01 EB006061-02, K01 EB006061] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL092321, R01HL106189] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [K01EB006061] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Abu-Baker S, 2007, PROTEIN SCI, V16, P2345, DOI 10.1110/ps.072977707; Abu-Baker S, 2006, BIOCHEMISTRY-US, V45, P13312, DOI 10.1021/bi0614028; ARKIN IT, 1995, J MOL BIOL, V248, P824, DOI 10.1006/jmbi.1995.0263; Autry JM, 1997, J BIOL CHEM, V272, P15872, DOI 10.1074/jbc.272.25.15872; Bossuyt J, 2006, J BIOL CHEM, V281, P32765, DOI 10.1074/jbc.M606254200; Chen H, 2006, BIOPHYS J, V91, pL39, DOI 10.1529/biophysj.106.088773; Clayton JC, 2005, BIOCHEMISTRY-US, V44, P17016, DOI 10.1021/bi0511383; Cornea RL, 2000, J BIOL CHEM, V275, P41487, DOI 10.1074/jbc.M008195200; FUNG BKK, 1978, BIOCHEMISTRY-US, V17, P5241, DOI 10.1021/bi00617a025; Ha KN, 2007, J BIOL CHEM, V282, P37205, DOI 10.1074/jbc.M704056200; Haghighi K, 2003, J CLIN INVEST, V111, P869, DOI 10.1172/JCI200317892; Hughes E, 2005, BIOCHEMISTRY-US, V44, P4055, DOI 10.1021/bi0482351; INUI M, 1986, J BIOL CHEM, V261, P1794; Kang MS, 2005, J MOL CELL CARDIOL, V38, P753, DOI 10.1016/j.yjmcc.2005.02.017; Karim CB, 1998, BIOCHEMISTRY-US, V37, P12074, DOI 10.1021/bi980642n; Karim CB, 2004, P NATL ACAD SCI USA, V101, P14437, DOI 10.1073/pnas.0402801101; Kenworthy AK, 2001, METHODS, V24, P289, DOI 10.1006/meth.2001.1189; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; Koushik SV, 2006, BIOPHYS J, V91, pL99, DOI 10.1529/biophysj.106.096206; KUBITSCHECK U, 1991, BIOPHYS J, V60, P307, DOI 10.1016/S0006-3495(91)82055-0; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Li E, 2006, J MOL BIOL, V356, P600, DOI 10.1016/j.jmb.2005.11.077; Li M, 1999, BIOPHYS J, V76, P2587, DOI 10.1016/S0006-3495(99)77411-4; MacLennan DH, 2003, NAT REV MOL CELL BIO, V4, P566, DOI 10.1038/nrm1151; Mascioni A, 2002, J AM CHEM SOC, V124, P9392, DOI 10.1021/ja026507m; Merzlyakov M, 2006, J MOL BIOL, V358, P1, DOI 10.1016/j.jmb.2006.01.086; Mueller B, 2004, BIOCHEMISTRY-US, V43, P8754, DOI 10.1021/bi049732k; Nesmelov YE, 2007, BIOPHYS J, V93, P2805, DOI 10.1529/biophysj.107.108910; Oxenoid K, 2005, P NATL ACAD SCI USA, V102, P10870, DOI 10.1073/pnas.0504920102; Patterson GH, 2000, ANAL BIOCHEM, V284, P438, DOI 10.1006/abio.2000.4708; Pollesello P, 1999, BIOPHYS J, V76, P1784, DOI 10.1016/S0006-3495(99)77339-X; Reddy LG, 1999, BIOCHEMISTRY-US, V38, P3954, DOI 10.1021/bi981795d; Robia SL, 2007, CIRC RES, V101, P1123, DOI 10.1161/CIRCRESAHA.107.159947; Robia SL, 2005, BIOCHEMISTRY-US, V44, P4302, DOI 10.1021/bi0478446; SAFFMAN PG, 1975, P NATL ACAD SCI USA, V72, P3111, DOI 10.1073/pnas.72.8.3111; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; Thaler C, 2005, BIOPHYS J, V89, P2736, DOI 10.1529/biophysj.105.061853; Toyoshima C, 2003, P NATL ACAD SCI USA, V100, P467, DOI 10.1073/pnas.0237326100; Traaseth NJ, 2007, P NATL ACAD SCI USA, V104, P14676, DOI 10.1073/pnas.0701016104; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Van Munster EB, 2005, J MICROSC-OXFORD, V218, P253, DOI 10.1111/j.1365-2818.2005.01483.x; VOGEL SS, 2006, SCI STKE, pRE2, DOI DOI 10.1126/STKE.3312006RE2; Waggoner JR, 2004, PROTEIN EXPRES PURIF, V34, P56, DOI 10.1016/j.pep.2003.11.005; YOUNG RM, 1994, BIOPHYS J, V67, P881, DOI 10.1016/S0006-3495(94)80549-1; Zamoon J, 2003, BIOPHYS J, V85, P2589, DOI 10.1016/S0006-3495(03)74681-5; Zhai J, 2000, J BIOL CHEM, V275, P10538, DOI 10.1074/jbc.275.14.10538	47	47	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2008	283	18					12202	12211		10.1074/jbc.M707590200	http://dx.doi.org/10.1074/jbc.M707590200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	293MS	18287099	Green Published, hybrid			2022-12-25	WOS:000255340000036
J	Dang, Y; Siew, LM; Wang, XJ; Han, YX; Lampen, R; Zheng, YH				Dang, Ying; Siew, Lai Mun; Wang, Xiaojun; Han, Yanxing; Lampen, Russell; Zheng, Yong-Hui			Human cytidine deaminase APOBEC3H restricts HIV-1 replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 VIF; ANTIVIRAL ACTIVITY; REVERSE TRANSCRIPTION; ANTIRETROVIRAL FACTOR; LTR-RETROTRANSPOSON; POTENT INHIBITOR; ENZYME APOBEC3G; DNA; HYPERMUTATION; DEGRADATION	The human genome encodes seven APOBEC3 (A3) cytidine deaminases with potential antiretroviral activity: A3A, A3B, A3C, A3DE, A3F, A3G, and A3H. A3G was the first identified to block replication of human immunodeficiency virus type 1 (HIV-1) and many other retroviruses. A3F, A3B, and A3DE were shown later to have similar activities. HIV-1 produces a protein called Vif that is able to neutralize the antiretroviral activities of A3DE, A3F, and A3G, but not A3B. Only the antiretroviral activity of A3H remains to be defined due to its poor expression in cell culture. Here, we studied the mechanism impairing A3H expression. When primate A3H sequences were compared, a premature termination codon was identified on the fifth exon of the human and chimpanzee A3H genes, which significantly decreased their protein expression. It causes a 29-residue deletion from the C terminus, and this truncation did not reduce human A3H protein stability. However, the mRNA levels of the truncated gene were significantly decreased. Human A3H protein expression could be restored to a normal level either by repairing this truncation or through expression from a vector containing an intron from human cytomegalovirus. Once expression was optimized, human A3H could reduce HIV-1 infectivity up to 150-fold. Importantly, HIV-1 Vif failed to neutralize A3H activity. Nevertheless, extensive sequence analysis could not detect any significant levels of G-to-A mutation in the HIV-1 genome by human A3H. Thus, A3H inhibits HIV-1 replication potently by a cytidine deamination-independent mechanism, and optimizing A3H expression in vivo should represent a novel therapeutic strategy for HIV-1 treatment.	[Dang, Ying; Siew, Lai Mun; Wang, Xiaojun; Han, Yanxing; Zheng, Yong-Hui] Michigan State Univ, Coll Osteopath Med, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA; [Lampen, Russell] Michigan State Univ, Coll Osteopath Med, Div Infect Dis, E Lansing, MI 48824 USA	Michigan State University; Michigan State University College of Osteopathic Medicine; Michigan State University; Michigan State University College of Osteopathic Medicine	Zheng, YH (corresponding author), Michigan State Univ, Coll Osteopath Med, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA.	zhengyo@msu.edu	Han, Yanxing/GRO-5138-2022; Zheng, Yong-Hui/AAP-4492-2021	Zheng, Yong-Hui/0000-0002-1098-7385; Wang, Xiaojun/0000-0003-4521-4099	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI063944, R01AI063944, K02AI080225] Funding Source: NIH RePORTER; NIAID NIH HHS [AI063944, K02 AI080225, R01 AI063944-02, R01 AI063944] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bishop KN, 2004, CURR BIOL, V14, P1392, DOI 10.1016/j.cub.2004.06.057; Bogerd HP, 2006, P NATL ACAD SCI USA, V103, P8780, DOI 10.1073/pnas.0603313103; Bogerd HP, 2006, NUCLEIC ACIDS RES, V34, P89, DOI 10.1093/nar/gkj416; Chen H, 2006, CURR BIOL, V16, P480, DOI 10.1016/j.cub.2006.01.031; Dang Y, 2006, J VIROL, V80, P10522, DOI 10.1128/JVI.01123-06; Doehle BP, 2005, VIROLOGY, V339, P281, DOI 10.1016/j.virol.2005.06.005; Dutko JA, 2005, CURR BIOL, V15, P661, DOI 10.1016/j.cub.2005.02.051; Guo F, 2007, J VIROL, V81, P11322, DOI 10.1128/JVI.00162-07; Guo F, 2006, J VIROL, V80, P11710, DOI 10.1128/JVI.01038-06; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Hartikka J, 1996, HUM GENE THER, V7, P1205, DOI 10.1089/hum.1996.7.10-1205; Holmes RK, 2007, TRENDS BIOCHEM SCI, V32, P118, DOI 10.1016/j.tibs.2007.01.004; Iwatani Y, 2007, NUCLEIC ACIDS RES, V35, P7096, DOI 10.1093/nar/gkm750; Kidd JM, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030063; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; Liddament MT, 2004, CURR BIOL, V14, P1385, DOI 10.1016/j.cub.2004.06.050; Liu BD, 2005, J VIROL, V79, P9579, DOI 10.1128/JVI.79.15.9579-9587.2005; Luo K, 2007, J VIROL, V81, P7238, DOI 10.1128/JVI.02584-06; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; Mbisa JL, 2007, J VIROL, V81, P7099, DOI 10.1128/JVI.00272-07; Navarro F, 2005, VIROLOGY, V333, P374, DOI 10.1016/j.virol.2005.01.011; Newman ENC, 2005, CURR BIOL, V15, P166, DOI 10.1016/j.cub.2004.12.068; OhAinle M, 2006, J VIROL, V80, P3853, DOI 10.1128/JVI.80.8.3853-3862.2006; Opi S, 2007, J VIROL, V81, P8236, DOI 10.1128/JVI.02694-06; Sasada A, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-32; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Stenglein MD, 2006, J BIOL CHEM, V281, P16837, DOI 10.1074/jbc.M602367200; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; Wiegand HL, 2004, EMBO J, V23, P2451, DOI 10.1038/sj.emboj.7600246; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707; Zheng YH, 2004, J VIROL, V78, P6073, DOI 10.1128/JVI.78.11.6073-6076.2004	35	95	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11606	11614		10.1074/jbc.M707586200	http://dx.doi.org/10.1074/jbc.M707586200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18299330	Green Accepted, Green Published, hybrid			2022-12-25	WOS:000255067400061
J	Frese, MA; Schulz, S; Dierks, T				Frese, Marc-Andre; Schulz, Stefanie; Dierks, Thomas			Arylsulfatase G, a novel lysosomal sulfatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE; FORMYLGLYCINE; GENE; DEFICIENCY; EXPRESSION; MUTATIONS; MECHANISM; TRANSPORT; PROTEINS; BINDING	The sulfatases constitute a conserved family of enzymes that specifically hydrolyze sulfate esters in a wide variety of substrates such as glycosaminoglycans, steroid sulfates, or sulfolipids. By modifying the sulfation state of their substrates, sulfatases play a key role in the control of physiological processes, including cellular degradation, cell signaling, and hormone regulation. The loss of sulfatase activity has been linked with various severe pathophysiological conditions such as lysosomal storage disorders, developmental abnormalities, or cancer. A novel member of this family, arylsulfatase G (ASG), was initially described as an enzyme lacking in vitro arylsulfatase activity and localizing to the endoplasmic reticulum. Contrary to these results, we demonstrate here that ASG does indeed have arylsulfatase activity toward different pseudosubstrates like p-nitrocatechol sulfate and 4-methylumbelliferyl sulfate. The activity of ASG depends on the Cys-84 residue that is predicted to be post-translationally converted to the critical active site C-alpha-formylglycine. Phosphate acts as a strong, competitive ASG inhibitor. ASG is active as an unprocessed 63-kDa monomer and shows an acidic pH optimum as typically seen for lysosomal sulfatases. In transfected cells, ASG accumulates within lysosomes as indicated by indirect immunofluorescence microscopy. Furthermore, ASG is a glycoprotein that binds specifically to mannose 6-phosphate receptors, corroborating its lysosomal localization. ARSG mRNA expression was found to be tissue-specific with highest expression in liver, kidney, and pancreas, suggesting a metabolic role of ASG that might be associated with a so far non-classified lysosomal storage disorder.	[Frese, Marc-Andre; Dierks, Thomas] Univ Bielefeld, Fak Chem, D-33615 Bielefeld, Germany; [Schulz, Stefanie] Univ Gottingen, Biochem Abt 2, D-37073 Gottingen, Germany	University of Bielefeld; University of Gottingen	Dierks, T (corresponding author), Univ Bielefeld, Fak Chem, Univ Str 25, D-33615 Bielefeld, Germany.	dierks@uni-bielefeld.de	Dierks, Thomas/A-3596-2012; Schupke, Stefanie/G-8382-2016	Dierks, Thomas/0000-0001-6426-1339; Schupke, Stefanie/0000-0002-0294-2283				Ahmed S, 2002, CURR MED CHEM, V9, P263, DOI 10.2174/0929867023371210; Ai XB, 2007, DEVELOPMENT, V134, P3327, DOI 10.1242/dev.007674; CHATTARAJ S, 1992, ANALYST, V117, P413, DOI 10.1039/an9921700413; Chruszcz M, 2003, J INORG BIOCHEM, V96, P386, DOI 10.1016/S0162-0134(03)00176-4; Cosma MP, 2003, CELL, V113, P445, DOI 10.1016/S0092-8674(03)00348-9; Dhoot GK, 2001, SCIENCE, V293, P1663, DOI 10.1126/science.293.5535.1663; Dierks T, 1997, P NATL ACAD SCI USA, V94, P11963, DOI 10.1073/pnas.94.22.11963; Dierks T, 2005, CELL, V121, P541, DOI 10.1016/j.cell.2005.03.001; Dierks T, 2003, CELL, V113, P435, DOI 10.1016/S0092-8674(03)00347-7; Diez-Roux G, 2005, ANNU REV GENOM HUM G, V6, P355, DOI 10.1146/annurev.genom.6.080604.162334; Ferrante P, 2002, EUR J HUM GENET, V10, P813, DOI 10.1038/sj.ejhg.5200887; FRANCO B, 1995, CELL, V81, P15, DOI 10.1016/0092-8674(95)90367-4; Futerman AH, 2004, NAT REV MOL CELL BIO, V5, P554, DOI 10.1038/nrm1423; Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050; Hanson SR, 2004, ANGEW CHEM INT EDIT, V43, P5736, DOI 10.1002/anie.200300632; HOPWOOD JJ, 2001, METABOLIC MOL BASES, V3, P3725; Kollmann K, 2005, PROTEOMICS, V5, P3966, DOI 10.1002/pmic.200401247; KOSTER A, 1993, EMBO J, V12, P5219, DOI 10.1002/j.1460-2075.1993.tb06217.x; Lai JP, 2003, J BIOL CHEM, V278, P23107, DOI 10.1074/jbc.M302203200; Lamanna WC, 2007, J BIOTECHNOL, V129, P290, DOI 10.1016/j.jbiotec.2007.01.022; Lefrancois S, 2002, J BIOL CHEM, V277, P17188, DOI 10.1074/jbc.M200343200; Luzio JP, 2007, NAT REV MOL CELL BIO, V8, P622, DOI 10.1038/nrm2217; Medzihradszky KF, 2004, MOL CELL PROTEOMICS, V3, P429, DOI 10.1074/mcp.M300140-MCP200; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; Nawroth R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000392; PISONI RL, 1991, J BIOL CHEM, V266, P979; Preusser-Kunze A, 2005, J BIOL CHEM, V280, P14900, DOI 10.1074/jbc.M413383200; Sardiello M, 2005, HUM MOL GENET, V14, P3203, DOI 10.1093/hmg/ddi351; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; Settembre C, 2008, HUM MOL GENET, V17, P119, DOI 10.1093/hmg/ddm289; Sleat DE, 2005, PROTEOMICS, V5, P1520, DOI 10.1002/pmic.200401054; STECKEL F, 1983, J BIOL CHEM, V258, P4322; STEIN C, 1989, J BIOL CHEM, V264, P13865; STEIN C, 1989, J BIOL CHEM, V264, P1252; Via LE, 1998, J CELL SCI, V111, P897; Viviano BL, 2004, J BIOL CHEM, V279, P5604, DOI 10.1074/jbc.M310691200; von Bulow R, 2002, J BIOL CHEM, V277, P9455, DOI 10.1074/jbc.M111993200; Waldow A, 1999, J BIOL CHEM, V274, P12284, DOI 10.1074/jbc.274.18.12284; Wang SW, 2004, P NATL ACAD SCI USA, V101, P4833, DOI 10.1073/pnas.0401028101	39	38	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11388	11395		10.1074/jbc.M709917200	http://dx.doi.org/10.1074/jbc.M709917200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18283100	hybrid			2022-12-25	WOS:000255067400036
J	Oram, JF; Wolfbauer, G; Tang, C; Davidson, WS; Albers, JJ				Oram, John F.; Wolfbauer, Gertrud; Tang, Chongren; Davidson, W. Sean; Albers, John J.			An amphipathic helical region of the N-terminal barrel of phospholipid transfer protein is critical for ABCA1-dependent cholesterol efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CASSETTE TRANSPORTER A1; SURFACE BINDING-SITES; LIPID EFFLUX; APOLIPOPROTEIN AI; DEFICIENT MICE; HDL FORMATION; KINASE-C; ABCA1; MACROPHAGES	Phospholipid lipid transfer protein (PLTP) mimics high-density lipoprotein apolipoproteins in removing cholesterol and phospholipids from cells through the ATP-binding cassette transporter A1 (ABCA1). Because amphipathic alpha-helices are the structural determinants for ABCA1 interactions, we examined the ability of synthetic peptides corresponding to helices in PLTP to remove cellular cholesterol by the ABCA1 pathway. Of the seven helices tested, only one containing PLTP residues 144-163 (p144), located at the tip of the N-terminal barrel, promoted ABCA1-dependent cholesterol efflux and stabilized ABCA1 protein. Mutating methionine 159 (Met-159) in this helix in PLTP to aspartate (M159D) or glutamate (M159E) nearly abolished the ability of PLTP to remove cellular cholesterol and dramatically reduced PLTP binding to phospholipid vesicles and its phospholipid transfer activity. These mutations impaired PLTP binding to ABCA1-generated lipid domains and PLTP-mediated stabilization of ABCA1 but increased PLTP binding to ABCA1. PLTP interactions with ABCA1 also mimicked apolipoproteins in activating Janus kinase 2; however, the M159D/E mutants were also able to activate this kinase. Structural analyses showed that the M159D/E mutations had only minor effects on PLTP conformation. These findings indicate that PLTP helix 144-163 is critical for removing lipid domains formed by ABCA1, stabilizing ABCA1 protein, interacting with phospholipids, and promoting phospholipid transfer. Direct interactions with ABCA1 and activation of signaling pathways likely involve other structural determinants of PLTP.	[Oram, John F.; Wolfbauer, Gertrud; Tang, Chongren; Albers, John J.] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA; [Davidson, W. Sean] Univ Cincinnati, Dept Pathol & Lab Med, Cincinnati, OH 45237 USA	University of Washington; University of Washington Seattle; University System of Ohio; University of Cincinnati	Albers, JJ (corresponding author), Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Box 356426, Seattle, WA 98195 USA.	jja@u.washington.edu		Davidson, William/0000-0003-2756-2989	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055362, R01HL062542, P01HL030086, R01HL085437] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01HL030086, R01HL055362, R01HL085437, R01HL62542] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aiello RJ, 2003, ARTERIOSCL THROM VAS, V23, P972, DOI 10.1161/01.ATV.0000054661.21499.FB; ALBERS JJ, 1995, BBA-LIPID LIPID MET, V1258, P27, DOI 10.1016/0005-2760(95)00091-P; Arakawa R, 2004, J BIOL CHEM, V279, P6217, DOI 10.1074/jbc.C300553200; Arakawa R, 2002, J BIOL CHEM, V277, P22426, DOI 10.1074/jbc.M202996200; Cao GQ, 2002, J BIOL CHEM, V277, P39561, DOI 10.1074/jbc.M207187200; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Cheung MC, 1996, BBA-LIPID LIPID MET, V1303, P103, DOI 10.1016/0005-2760(96)00082-3; Chroni A, 2004, BIOCHEMISTRY-US, V43, P2126, DOI 10.1021/bi035813p; Davidson WS, 2006, J LIPID RES, V47, P440, DOI 10.1194/jlr.D500034-JLR200; DAY JR, 1994, J BIOL CHEM, V269, P9388; Desrumaux C, 2001, J BIOL CHEM, V276, P5908, DOI 10.1074/jbc.M008420200; Fitzgerald ML, 2004, J LIPID RES, V45, P287, DOI 10.1194/jlr.M300355-JLR200; Hailman E, 1996, J BIOL CHEM, V271, P12172, DOI 10.1074/jbc.271.21.12172; Hassan HH, 2007, J LIPID RES, V48, P2428, DOI 10.1194/jlr.M700206-JLR200; Huuskonen J, 1999, J LIPID RES, V40, P1123; Huuskonen J, 2000, CURR OPIN LIPIDOL, V11, P285, DOI 10.1097/00041433-200006000-00009; JAUHIAINEN M, 1993, J BIOL CHEM, V268, P4032; JIANG XC, 1995, J BIOL CHEM, V270, P17133, DOI 10.1074/jbc.270.29.17133; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Jiang XC, 2001, NAT MED, V7, P847, DOI 10.1038/89977; Jiang XC, 1996, J CLIN INVEST, V98, P2373, DOI 10.1172/JCI119050; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Laffitte BA, 2003, MOL CELL BIOL, V23, P2182, DOI 10.1128/MCB.23.6.2182-2191.2003; Lee-Rueckert M, 2006, J LIPID RES, V47, P1725, DOI 10.1194/jlr.M600051-JLR200; Liu RJ, 2007, ARTERIOSCL THROM VAS, V27, P190, DOI 10.1161/01.ATV.0000249721.96666.e5; Mak PA, 2002, J LIPID RES, V43, P2037, DOI 10.1194/jlr.C200014-JLR200; Mendez AJ, 1997, BBA-LIPID LIPID MET, V1346, P285, DOI 10.1016/S0005-2760(97)00031-3; MENDEZ AJ, 1994, J CLIN INVEST, V94, P1698, DOI 10.1172/JCI117515; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; O'Brien KD, 2003, CIRCULATION, V108, P270, DOI 10.1161/01.CIR.0000079163.97653.CD; Ogier N, 2007, ARTERIOSCL THROM VAS, V27, P2407, DOI 10.1161/ATVBAHA.107.151753; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 2005, PHYSIOL REV, V85, P1343, DOI 10.1152/physrev.00005.2005; Oram JF, 2003, J BIOL CHEM, V278, P52379, DOI 10.1074/jbc.M310695200; Remaley AT, 2003, J LIPID RES, V44, P828, DOI 10.1194/jlr.M200475-JLR200; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Setala NL, 2007, BIOCHEMISTRY-US, V46, P1312, DOI 10.1021/bi0621866; Shao BH, 2006, J BIOL CHEM, V281, P9001, DOI 10.1074/jbc.C600011200; Singaraja RR, 2003, ARTERIOSCL THROM VAS, V23, P1322, DOI 10.1161/01.ATV.0000078520.89539.77; Tang CR, 2006, J LIPID RES, V47, P107, DOI 10.1194/jlr.M500240-JLR200; Tang CR, 2004, J BIOL CHEM, V279, P7622, DOI 10.1074/jbc.M312571200; TU AY, 1993, J BIOL CHEM, V268, P23098; Valenta DT, 2008, J LIPID RES, V49, P24, DOI 10.1194/jlr.M700228-JLR200; Valenta DT, 2006, ARTERIOSCL THROM VAS, V26, P1572, DOI 10.1161/01.ATV.0000225700.43836.ae; van Haperen R, 2002, J BIOL CHEM, V277, P48938, DOI 10.1074/jbc.M209128200; van Tol A, 2002, CURR OPIN LIPIDOL, V13, P135, DOI 10.1097/00041433-200204000-00004; Vaughan AM, 2003, J LIPID RES, V44, P1373, DOI 10.1194/jlr.M300078-JLR200; Vedhachalam C, 2007, J BIOL CHEM, V282, P25123, DOI 10.1074/jbc.M704590200; Vedhachalam C, 2007, ARTERIOSCL THROM VAS, V27, P1603, DOI 10.1161/ATVBAHA.107.145789; Vikstedt R, 2007, BIOCHEMISTRY-US, V46, P11979, DOI 10.1021/bi700833h; Wang N, 2003, J CLIN INVEST, V111, P99, DOI 10.1172/JCI200316808; Wang YT, 2002, J BIOL CHEM, V277, P5692, DOI 10.1074/jbc.M109977200; WARNICK GR, 1982, CLIN CHEM, V28, P1379; Wolfbauer G, 1999, BBA-MOL CELL BIOL L, V1439, P65, DOI 10.1016/S1388-1981(99)00077-3; WOODY RW, 1995, METHOD ENZYMOL, V246, P34; Yamauchi Y, 2003, J BIOL CHEM, V278, P47890, DOI 10.1074/jbc.M306258200	56	43	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11541	11549		10.1074/jbc.M800117200	http://dx.doi.org/10.1074/jbc.M800117200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18287097	Green Published, hybrid			2022-12-25	WOS:000255067400054
J	Sikora, B; Chen, Y; Lichti, CF; Harrison, MK; Jennings, TA; Tang, Y; Tackett, AJ; Jordan, JB; Sakon, J; Cameron, CE; Raney, KD				Sikora, Bartek; Chen, Yingfeng; Lichti, Cheryl F.; Harrison, Melody K.; Jennings, Thomas A.; Tang, Yong; Tackett, Alan J.; Jordan, John B.; Sakon, Joshua; Cameron, Craig E.; Raney, Kevin D.			Hepatitis C virus NS3 helicase forms oligomeric structures that exhibit optimal DNA unwinding activity in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; PROTEASE DOMAIN; COLI UVRD; TRANSLOCATION; REPLICATION; MECHANISM; DUPLEX; MOLECULES; OLIGONUCLEOTIDE; DISPLACEMENT	HCV NS3 helicase exhibits activity toward DNA and RNA substrates. The DNA helicase activity of NS3 has been proposed to be optimal when multiple NS3 molecules are bound to the same substrate molecule. NS3 catalyzes little or no measurable DNA unwinding under single cycle conditions in which the concentration of substrate exceeds the concentration of enzyme by 5-fold. However, when NS3 (100 nM) is equimolar with the substrate, a small burst amplitude of similar to 8 nM is observed. The burst amplitude increases as the enzyme concentration increases, consistent with the idea that multiple molecules are needed for optimal unwinding. Protein-protein interactions may facilitate optimal activity, so the oligomeric properties of the enzyme were investigated. Chemical cross-linking indicates that full-length NS3 forms higher order oligomers much more readily than the NS3 helicase domain. Dynamic light scattering indicates that full-length NS3 exists as an oligomer, whereas NS3 helicase domain exists in a monomeric form in solution. Size exclusion chromatography also indicates that full-length NS3 behaves as an oligomer in solution, whereas the NS3 helicase domain behaves as a monomer. When NS3 was passed through a small pore filter capable of removing protein aggregates, greater than 95% of the protein and the DNA unwinding activity was removed from solution. In contrast, only similar to 10% of NS3 helicase domain and similar to 20% of the associated DNA unwinding activity was removed from solution after passage through the small pore filter. The results indicate that the optimally active form of full-length NS3 is part of an oligomeric species in vitro.	[Sikora, Bartek; Chen, Yingfeng; Lichti, Cheryl F.; Harrison, Melody K.; Jennings, Thomas A.; Tang, Yong; Tackett, Alan J.; Raney, Kevin D.] Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA; [Jordan, John B.; Sakon, Joshua] Univ Arkansas, Dept Chem & Biochem, Fayetteville, AR 72701 USA; [Cameron, Craig E.] Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Fayetteville; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Raney, KD (corresponding author), Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA.	raneykevind@uams.edu	Lichti, Cheryl/C-6359-2013; Sakon, Joshua/N-2289-2014	Sakon, Joshua/0000-0002-8373-969X; Lichti, Cheryl/0000-0003-4099-4954	NCRR NIH HHS [P20 RR015569-096068, P20 RR15569, P20RR016460, P20 RR015569] Funding Source: Medline; NIAID NIH HHS [AI060563, R56 AI060563, R01 AI060563] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015569, P20RR016460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060563, R56AI060563] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bartenschlager R, 2000, J GEN VIROL, V81, P1631, DOI 10.1099/0022-1317-81-7-1631; Beran RKF, 2006, J MOL BIOL, V358, P974, DOI 10.1016/j.jmb.2006.02.078; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; Byrd AK, 2005, BIOCHEMISTRY-US, V44, P12990, DOI 10.1021/bi050703z; Byrd AK, 2004, NAT STRUCT MOL BIOL, V11, P531, DOI 10.1038/nsmb774; Byrd AK, 2006, NUCLEIC ACIDS RES, V34, P3020, DOI 10.1093/nar/gkl369; Cheng W, 2001, J MOL BIOL, V310, P327, DOI 10.1006/jmbi.2001.4758; CHOO QL, 1990, BRIT MED BULL, V46, P423, DOI 10.1093/oxfordjournals.bmb.a072408; Delagoutte E, 2002, Q REV BIOPHYS, V35, P431, DOI 10.1017/S0033583502003852; Dillingham MS, 2002, BIOCHEMISTRY-US, V41, P643, DOI 10.1021/bi011137k; Dimitrova M, 2003, J VIROL, V77, P5401, DOI 10.1128/JVI.77.9.5401-5414.2003; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; Dumont S, 2006, NATURE, V439, P105, DOI 10.1038/nature04331; Ellis NA, 1997, CURR OPIN GENET DEV, V7, P354, DOI 10.1016/S0959-437X(97)80149-9; Eoff RL, 2005, BIOCHEMISTRY-US, V44, P666, DOI 10.1021/bi0484926; Fischer CJ, 2004, J MOL BIOL, V344, P1287, DOI 10.1016/j.jmb.2004.10.005; Frick DN, 2004, J BIOL CHEM, V279, P1269, DOI 10.1074/jbc.M310630200; Frick DN, 2003, DRUG NEWS PERSPECT, V16, P355, DOI 10.1358/dnp.2003.16.6.829307; Gwack Y, 1997, EUR J BIOCHEM, V250, P47, DOI 10.1111/j.1432-1033.1997.00047.x; Gwack Y, 1996, BIOCHEM BIOPH RES CO, V225, P654, DOI 10.1006/bbrc.1996.1225; Ishido S, 1998, BIOCHEM BIOPH RES CO, V244, P35, DOI 10.1006/bbrc.1998.8202; Jennings TA, 2008, BIOCHEMISTRY-US, V47, P1126, DOI 10.1021/bi701048a; Kang LW, 1998, ACTA CRYSTALLOGR D, V54, P121, DOI 10.1107/S0907444997008883; Khu YL, 2001, J VIROL, V75, P205, DOI 10.1128/JVI.75.1.205-214.2001; KIM DW, 1995, BIOCHEM BIOPH RES CO, V215, P160, DOI 10.1006/bbrc.1995.2447; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Levin MK, 1999, J BIOL CHEM, V274, P31839, DOI 10.1074/jbc.274.45.31839; Levin MK, 2004, J BIOL CHEM, V279, P26005, DOI 10.1074/jbc.M403257200; Mackintosh SG, 2006, J BIOL CHEM, V281, P3528, DOI 10.1074/jbc.M512100200; Maluf NK, 2003, J MOL BIOL, V325, P913, DOI 10.1016/S0022-2836(02)01277-9; McHutchison JG, 2004, AM J MANAG CARE, V10, pS21; Myong S, 2007, SCIENCE, V317, P513, DOI 10.1126/science.1144130; Nanduri B, 2002, P NATL ACAD SCI USA, V99, P14722, DOI 10.1073/pnas.232401899; Pang PS, 2002, EMBO J, V21, P1168, DOI 10.1093/emboj/21.5.1168; Patel SS, 2006, J BIOL CHEM, V281, P18265, DOI 10.1074/jbc.R600008200; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Pearlman BL, 2004, SOUTH MED J, V97, P365, DOI 10.1097/01.SMJ.0000118903.35704.30; Piccininni S, 2002, J BIOL CHEM, V277, P45670, DOI 10.1074/jbc.M204124200; Porter DJT, 1998, J BIOL CHEM, V273, P18906, DOI 10.1074/jbc.273.30.18906; Quinkert D, 2005, J VIROL, V79, P13594, DOI 10.1128/JVI.79.21.13594-13605.2005; Rajagopal V, 2008, J MOL BIOL, V376, P69, DOI 10.1016/j.jmb.2007.10.070; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P4128, DOI 10.1021/bi00066a039; Serebrov V, 2004, NATURE, V430, P476, DOI 10.1038/nature02704; Sikora B, 2006, J BIOL CHEM, V281, P36110, DOI 10.1074/jbc.M604412200; Singleton MR, 2007, ANNU REV BIOCHEM, V76, P23, DOI 10.1146/annurev.biochem.76.052305.115300; Soultanas P, 2001, TRENDS BIOCHEM SCI, V26, P47, DOI 10.1016/S0968-0004(00)01734-5; SUZICH JA, 1993, J VIROL, V67, P6152, DOI 10.1128/JVI.67.10.6152-6158.1993; Tackett AJ, 2005, J BIOL CHEM, V280, P10797, DOI 10.1074/jbc.M407971200; Tai CL, 1996, J VIROL, V70, P8477, DOI 10.1128/JVI.70.12.8477-8484.1996; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; Yao NH, 1999, STRUCTURE, V7, P1353, DOI 10.1016/S0969-2126(00)80025-8; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463; Zhang C, 2005, J VIROL, V79, P8687, DOI 10.1128/JVI.79.14.8687-8697.2005	53	35	36	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11516	11525		10.1074/jbc.M708125200	http://dx.doi.org/10.1074/jbc.M708125200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18283103	hybrid, Green Published			2022-12-25	WOS:000255067400051
J	Thom, SR; Bhopale, VM; Mancini, DJ; Milovanova, TN				Thom, Stephen R.; Bhopale, Veena M.; Mancini, D. Joshua; Milovanova, Tatyana N.			Actin S-nitrosylation inhibits neutrophil beta(2) integrin function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; HYPERBARIC-OXYGEN THERAPY; DEPENDENT PROTEIN-KINASE; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; PEPTIDE-STIMULATED NEUTROPHILS; INTEGRIN-MEDIATED ADHESION; MYOCARDIAL-INFARCTION; TYROSINE NITRATION; CHEMOTACTIC FACTOR; B-2 INTEGRINS	The focus of this work was to elucidate the mechanism for inhibition of neutrophil beta(2) integrin adhesion molecules by hyperoxia. Results demonstrate that exposure to high oxygen partial pressures increases synthesis of reactive species derived from type 2 nitric-oxide synthase and myeloperoxidase, leading to excessive S-nitrosylation of beta-actin and possibly profilin. Hyperoxia causes S-nitrosylation of the four cysteine moieties closest to the carboxyl-terminal end of actin, which results in formation of short actin filaments. This alters actin polymerization, network formation, and intracellular distribution, as well as inhibits beta(2) integrin clustering. If neutrophils are exposed to ultraviolet light to reverse S-nitrosylation, or are incubated with N-formyl-methionyl-leucine-phenylalanine to trigger "inside-out" activation, the effects of hyperoxia are reversed. We conclude that cytoskeletal changes triggered by hyperoxia inhibit beta(2) integrin-dependent neutrophil adhesion.	[Thom, Stephen R.; Bhopale, Veena M.; Mancini, D. Joshua; Milovanova, Tatyana N.] Univ Penn, Med Ctr, Inst Environm Med, Philadelphia, PA 19104 USA; [Thom, Stephen R.] Univ Penn, Med Ctr, Dept Emergency Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Thom, SR (corresponding author), Univ Penn, Med Ctr, Inst Environm Med, 1 John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	sthom@mail.med.upenn.edu						Abu-Soud HM, 2000, J BIOL CHEM, V275, P37524, DOI 10.1074/jbc.275.48.37524; Abu-Soud HM, 2001, BIOCHEMISTRY-US, V40, P6876, DOI 10.1021/bi010066m; Alex J, 2005, J THORAC CARDIOV SUR, V130, P1623, DOI 10.1016/j.jtcvs.2005.08.018; Andoh T, 2003, J BIOL CHEM, V278, P885, DOI 10.1074/jbc.M209914200; Aslan M, 2003, J BIOL CHEM, V278, P4194, DOI 10.1074/jbc.M208916200; Atochin DN, 2000, UNDERSEA HYPERBAR M, V27, P185; Banick PD, 1997, J CELL PHYSIOL, V172, P12, DOI 10.1002/(SICI)1097-4652(199707)172:1<12::AID-JCP2>3.0.CO;2-G; BATH PMW, 1991, ARTERIOSCLER THROMB, V11, P254, DOI 10.1161/01.ATV.11.2.254; Bengtsson T, 2006, CELL BIOL INT, V30, P154, DOI 10.1016/j.cellbi.2005.10.017; Blystone SD, 2004, BBA-MOL CELL RES, V1692, P47, DOI 10.1016/j.bbamcr.2004.04.011; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; Brown EJ, 1996, ANN MED, V28, P201, DOI 10.3109/07853899609033121; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Cambi A, 2006, MOL BIOL CELL, V17, P4270, DOI 10.1091/mbc.E05-12-1098; Chen QP, 1996, J PHARMACOL EXP THER, V276, P929; Clements MK, 2003, J LEUKOCYTE BIOL, V73, P344, DOI 10.1189/jlb.0802401; CRUZ EDL, 1994, BIOCHEMISTRY-US, V33, P14387; Dalle-Donne I, 2000, J MUSCLE RES CELL M, V21, P171, DOI 10.1023/A:1005671319604; Eisenmann KM, 2007, J BIOL CHEM, V282, P25152, DOI 10.1074/jbc.M703243200; Esue O, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.048301; Evans TJ, 1996, P NATL ACAD SCI USA, V93, P9553, DOI 10.1073/pnas.93.18.9553; Fekete Z, 2001, SHOCK, V16, P15, DOI 10.1097/00024382-200116010-00003; Galijasevic S, 2003, P NATL ACAD SCI USA, V100, P14766, DOI 10.1073/pnas.2435008100; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Goley ED, 2006, NAT REV MOL CELL BIO, V7, P713, DOI 10.1038/nrm2026; Greco TM, 2006, P NATL ACAD SCI USA, V103, P7420, DOI 10.1073/pnas.0600729103; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; Heijnen HFG, 2006, FREE RADICAL BIO MED, V40, P1903, DOI 10.1016/j.freeradbiomed.2005.09.006; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; JAMIESON D, 1986, ANNU REV PHYSIOL, V48, P703, DOI 10.1146/annurev.ph.48.030186.003415; JAMIESON D, 1963, J APPL PHYSIOL, V18, P869, DOI 10.1152/jappl.1963.18.5.869; JOHNSON G, 1991, CRIT CARE MED, V19, P244, DOI 10.1097/00003246-199102000-00021; Kalns J, 2002, IMMUNOL LETT, V83, P125, DOI 10.1016/S0165-2478(02)00068-8; Kerkhoff E, 2006, TRENDS CELL BIOL, V16, P477, DOI 10.1016/j.tcb.2006.07.005; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; Labrouche S, 1999, THROMB RES, V96, P309, DOI 10.1016/S0049-3848(99)00107-3; Lakshmi VM, 2005, J BIOL CHEM, V280, P1746, DOI 10.1074/jbc.M411263200; Lee SY, 2003, FASEB J, V17, P947, DOI 10.1096/fj.02-0807fje; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; Machesky Laura M., 1993, Trends in Cell Biology, V3, P381, DOI 10.1016/0962-8924(93)90087-H; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; Martin JD, 2002, AVIAT SPACE ENVIR MD, V73, P565; MILESKI WJ, 1990, SURGERY, V108, P206; MILESKI WJ, 1993, J SURG RES, V54, P349, DOI 10.1006/jsre.1993.1056; Niggli V, 1999, EXP CELL RES, V250, P558, DOI 10.1006/excr.1999.4548; PRUTZ WA, 1985, ARCH BIOCHEM BIOPHYS, V243, P125, DOI 10.1016/0003-9861(85)90780-5; PRYZWANSKY KB, 1990, BLOOD, V76, P612; PYSZNIAK AM, 1994, J IMMUNOL, V152, P5241; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; ROSS RM, 1965, LANCET, V1, P579; RuchaudSparagano MH, 1997, BRIT J HAEMATOL, V98, P612, DOI 10.1046/j.1365-2141.1997.2523070.x; Sampson JB, 1998, ARCH BIOCHEM BIOPHYS, V356, P207, DOI 10.1006/abbi.1998.0772; Schoenenberger CA, 1999, MICROSC RES TECHNIQ, V47, P38, DOI 10.1002/(SICI)1097-0029(19991001)47:1<38::AID-JEMT4>3.0.CO;2-5; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; Sengupta R, 2007, BIOCHEMISTRY-US, V46, P8472, DOI 10.1021/bi700449x; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; Shandling AH, 1997, AM HEART J, V134, P544, DOI 10.1016/S0002-8703(97)70093-0; Sharifi M, 2004, AM J CARDIOL, V93, P1533, DOI 10.1016/j.amjcard.2004.03.009; Sharifi Mohsen, 2002, Cardiovasc Radiat Med, V3, P124, DOI 10.1016/S1522-1865(03)00104-5; Sheikh S, 1997, BIOCHEM BIOPH RES CO, V238, P910, DOI 10.1006/bbrc.1997.7407; SHETERLINE P, 1994, ACTIN STRUCTURE PROT, P1; Stavitsky Y, 1998, CARDIOLOGY, V90, P131, DOI 10.1159/000006832; Tahepold P, 2003, J THORAC CARDIOV SUR, V125, P650, DOI 10.1067/mtc.2003.36; Tahepold P, 2001, LIFE SCI, V68, P1629, DOI 10.1016/S0024-3205(01)00964-X; TAIT JF, 1982, BIOCHEMISTRY-US, V21, P6046, DOI 10.1021/bi00267a004; Teubner A, 1996, BBA-PROTEIN STRUCT M, V1297, P214, DOI 10.1016/S0167-4838(96)00111-2; THOM SR, 1993, TOXICOL APPL PHARM, V123, P248, DOI 10.1006/taap.1993.1243; Thom SR, 2006, AM J PHYSIOL-HEART C, V290, pH1378, DOI 10.1152/ajpheart.00888.2005; Thom SR, 2004, P NATL ACAD SCI USA, V101, P13660, DOI 10.1073/pnas.0405642101; Thom SR, 2003, AM J PHYSIOL-HEART C, V284, pH1230, DOI 10.1152/ajpheart.01043.2002; Thom SR, 1997, CHEM RES TOXICOL, V10, P1023, DOI 10.1021/tx970041h; Thom SR, 1997, AM J PHYSIOL-CELL PH, V272, pC770, DOI 10.1152/ajpcell.1997.272.3.C770; Thom SR, 2002, J NEUROBIOL, V51, P85, DOI 10.1002/neu.10044; THOM SR, 1986, J INFECT DIS, V154, P504, DOI 10.1093/infdis/154.3.504; Ueno S, 1999, HEPATO-GASTROENTEROL, V46, P1798; van Kooyk Y, 1999, J BIOL CHEM, V274, P26869, DOI 10.1074/jbc.274.38.26869; WATTS RG, 1993, BLOOD, V81, P2750; WATTS RG, 1992, CELL MOTIL CYTOSKEL, V21, P25, DOI 10.1002/cm.970210104; Weaver LK, 2002, NEW ENGL J MED, V347, P1057, DOI 10.1056/NEJMoa013121; WHITE JR, 1983, J BIOL CHEM, V258, P4041; Wong Howard P., 1996, Surgical Forum, V47, P705; WYATT TA, 1991, J BIOL CHEM, V266, P21274; Yan SR, 1998, J LEUKOCYTE BIOL, V64, P401, DOI 10.1002/jlb.64.3.401; Yang CS, 2000, J CELL BIOL, V150, P1001, DOI 10.1083/jcb.150.5.1001; Yang ZJ, 2001, EUR J APPL PHYSIOL, V85, P96, DOI 10.1007/s004210100391; ZAFFRAN Y, 1993, J CELL SCI, V105, P675; ZAMBONI WA, 1993, PLAST RECONSTR SURG, V91, P1110, DOI 10.1097/00006534-199305000-00022; Zamir E, 2001, J CELL SCI, V114, P3583; Zhou JH, 2003, J IMMUNOL, V170, P3331, DOI 10.4049/jimmunol.170.6.3331	91	72	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10822	10834		10.1074/jbc.M709200200	http://dx.doi.org/10.1074/jbc.M709200200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18283105	hybrid			2022-12-25	WOS:000254894700065
J	Genge, BR; Wu, LNY; Wuthier, RE				Genge, Brian R.; Wu, Licia N. Y.; Wuthier, Roy E.			Mineralization of annexin-5-containing lipid-calcium-phosphate complexes - Modulation by varying lipid composition and incubation with cartilage collagens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-PLATE CARTILAGE; RELEASED MATRIX VESICLES; CII ANNEXIN-V; X-COLLAGEN; BINDING-PROTEINS; ANCHORIN-CII; FREEZE-SUBSTITUTION; NUCLEATIONAL CORE; PHOSPHATIDYLSERINE; CHONDROCYTES	Matrix vesicles (MVs) in the growth plate bind to cartilage collagens and initiate mineralization of the extracellular matrix. Native MVs have been shown to contain a nucleational core responsible for mineral formation that is comprised of Mg2+-containing amorphous calcium phosphate and lipid-calcium-phosphate complexes (CPLXs) and the lipid-dependent Ca2+-binding proteins, especially annexin-5 (Anx-5), which greatly enhances mineral formation. Incorporation of non-Ca2+-binding-MV lipids impedes mineral formation by phosphatidylserine (PS)-CPLX. In this study, nucleators based on amorphous calcium phosphate (with or without Anx-5) were prepared with PS alone, PS + phosphatidylethanolamine (PE), or PS + PE and other MV lipids. These were incubated in synthetic cartilage lymph containing no collagen or containing type II or type X collagen. Dilution of PS with PE and other MV lipids progressively retarded nucleation. Incorporation of Anx-5 restored nucleational activity to the PS: PE CPLX; thus PS and Anx-5 proved to be critical for nucleation of mineral. Without Anx-5, induction of mineral formation was slow unless high levels of Ca2+ were used. The presence of type II collagen in synthetic cartilage lymph improved both the rate and amount of mineral formation but did not enhance nucleation. This stimulatory effect required the presence of the nonhelical telopeptides. Although type X collagen slowed induction, it also increased the rate and amount of mineral formation. Both type II and X collagens markedly increased mineral formation by the MV-like CPLX, requiring Anx-5 to do so. Thus, Anx-5 enhances nucleation by the CPLXs and couples this to propagation of mineral formation by the cartilage collagens.	[Genge, Brian R.; Wu, Licia N. Y.; Wuthier, Roy E.] Univ S Carolina, Dept Chem & Biochem, Grad Sci Res Ctr, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Wuthier, RE (corresponding author), Univ S Carolina, Dept Chem & Biochem, Grad Sci Res Ctr, 631 Sumter St, Columbia, SC 29208 USA.	wuthier@mail.chem.sc.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR018983, R01AR042359] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 18983, AR 42359] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABRAMSON MB, 1964, J BIOL CHEM, V239, P70; ALI SY, 1970, P NATL ACAD SCI USA, V67, P1513, DOI 10.1073/pnas.67.3.1513; ANDERSON HC, 1988, RHEUM DIS CLIN N AM, V14, P303; ANDERSON HC, 1967, J CELL BIOL, V35, P81, DOI 10.1083/jcb.35.1.81; ARSENAULT AL, 1988, CALCIFIED TISSUE INT, V42, P119, DOI 10.1007/BF02556344; ARSENAULT AL, 1994, MICROSC RES TECHNIQ, V28, P409, DOI 10.1002/jemt.1070280507; Balcerzak M, 2007, ANAL BIOCHEM, V361, P176, DOI 10.1016/j.ab.2006.10.001; Blankenberg FG, 1998, P NATL ACAD SCI USA, V95, P6349, DOI 10.1073/pnas.95.11.6349; BONUCCI E, 1967, J ULTRA MOL STRUCT R, V20, P33, DOI 10.1016/S0022-5320(67)80034-0; BORG TK, 1981, ANAT REC, V199, P449, DOI 10.1002/ar.1091990402; BOSKEY AL, 1982, CALCIFIED TISSUE INT, V34, pS1; BOSKEY AL, 1977, CALC TISS RES, V22, P197; BOYANSALYERS BD, 1980, CALCIFIED TISSUE INT, V30, P167, DOI 10.1007/BF02408622; BRECEVIC L, 1972, CALC TISS RES, V10, P82, DOI 10.1007/BF02012538; COTMORE JM, 1971, SCIENCE, V172, P1339, DOI 10.1126/science.172.3990.1339; EANES ED, 1992, GLYCOBIOLOGY, V2, P571, DOI 10.1093/glycob/2.6.571; Ernst JD, 1998, ANAL BIOCHEM, V260, P18, DOI 10.1006/abio.1998.2677; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; GENGE BR, 1992, J BONE MINER RES, V7, P807, DOI 10.1002/jbmr.5650070710; Genge BR, 2003, ANAL BIOCHEM, V322, P104, DOI 10.1016/S0003-2697(03)00462-7; GENGE BR, 1990, J BIOL CHEM, V265, P4703; GENGE BR, 1989, J BIOL CHEM, V264, P10917; GENGE BR, 1991, J BIOL CHEM, V266, P10678; GENGE BR, 1988, J BIOL CHEM, V263, P18513; Genge BR, 2007, J BIOL CHEM, V282, P26035, DOI 10.1074/jbc.M701057200; Genge BR, 2007, ANAL BIOCHEM, V367, P159, DOI 10.1016/j.ab.2007.04.029; Glimcher M J, 1987, Instr Course Lect, V36, P49; Howell David S, 2002, Curr Rheumatol Rep, V4, P265, DOI 10.1007/s11926-002-0075-0; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; HUNZIKER EB, 1984, J CELL BIOL, V98, P267, DOI 10.1083/jcb.98.1.267; HUNZIKER EB, 1984, J CELL BIOL, V98, P277, DOI 10.1083/jcb.98.1.277; IANNOTTI JP, 1994, CLIN ORTHOP RELAT R, P222; ISHIKAWA Y, 1992, BONE MINER, V17, P152, DOI 10.1016/0169-6009(92)90727-U; KIRSCH T, 1990, BIOCHEM J, V265, P453, DOI 10.1042/bj2650453; KIRSCH T, 1994, J BIOL CHEM, V269, P11462; Kirsch T, 1997, BIOCHEMISTRY-US, V36, P3359, DOI 10.1021/bi9626867; KIRSCH T, 1992, FEBS LETT, V310, P143, DOI 10.1016/0014-5793(92)81316-E; Kirsch T, 2000, J BIOL CHEM, V275, P35577, DOI 10.1074/jbc.M005648200; Kirsch T, 1997, J CELL BIOL, V137, P1149, DOI 10.1083/jcb.137.5.1149; Kirsch T, 2003, J BONE MINER RES, V18, P1872, DOI 10.1359/jbmr.2003.18.10.1872; LANDIS WJ, 1991, CONNECT TISSUE RES, V25, P181, DOI 10.3109/03008209109029155; LANDIS WJ, 1991, J STRUCT BIOL, V107, P116, DOI 10.1016/1047-8477(91)90015-O; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAJESKA RJ, 1979, CALCIFIED TISSUE INT, V27, P41, DOI 10.1007/BF02441159; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; MOLLENHAUER J, 1984, J CELL BIOL, V98, P1572, DOI 10.1083/jcb.98.4.1572; NASH HA, 1964, P NATL ACAD SCI USA, V51, P476, DOI 10.1073/pnas.51.3.476; PERESS NS, 1974, CALC TISS RES, V14, P275, DOI 10.1007/BF02060301; PITA JC, 1970, J CLIN INVEST, V49, P2188, DOI 10.1172/JCI106437; POOLE AR, 1989, ANAT REC, V224, P167; SAUER GR, 1988, J BIOL CHEM, V263, P13718; SCHMID T M, 1991, In Vivo (Attiki), V5, P533; SCHMID TM, 1990, ANN NY ACAD SCI, V580, P64, DOI 10.1111/j.1749-6632.1990.tb17918.x; SCHMID TM, 1983, J BIOL CHEM, V258, P9504; Stuart MCA, 1998, EUR J CELL BIOL, V76, P77, DOI 10.1016/S0171-9335(98)80019-8; TANIMURA A, 1986, Journal of Experimental Pathology (New York), V2, P261; TANIMURA A, 1983, P SOC EXP BIOL MED, V172, P173; Taylor MG, 1998, CELL MOL LIFE SCI, V54, P196, DOI 10.1007/s000180050143; TERMINE JD, 1967, P SOC EXP BIOL MED, V125, P4; Wu LNY, 2008, J BIOL CHEM, V283, P3827, DOI 10.1074/jbc.M707653200; Wu LNY, 2002, J BIOL CHEM, V277, P5126, DOI 10.1074/jbc.M107899200; WU LNY, 1989, J BIOL CHEM, V264, P21346; Wu LNY, 2003, J INORG BIOCHEM, V94, P221, DOI 10.1016/S0162-0134(03)00003-5; WU LNY, 1993, J BIOL CHEM, V268, P25084; WU LNY, 1991, J BIOL CHEM, V266, P1195; WU LNY, 1991, J BIOL CHEM, V266, P1187; Wu LNY, 1996, CONNECT TISSUE RES, V35, P309, DOI 10.3109/03008209609029205; Wu LNY, 1997, J BIOL CHEM, V272, P4404, DOI 10.1074/jbc.272.7.4404; WUTHIER RE, 1975, BIOCHIM BIOPHYS ACTA, V409, P128, DOI 10.1016/0005-2760(75)90087-9; WUTHIER RE, 1977, CALC TISS RES, V23, P125, DOI 10.1007/BF02012777; WUTHIER RE, 1975, CALC TISS RES, V19, P197, DOI 10.1007/BF02564004; WUTHIER RE, 1978, BIOCHEMISTRY-US, V17, P1431, DOI 10.1021/bi00601a011; WUTHIER RE, 1985, CALCIFIED TISSUE INT, V37, P401, DOI 10.1007/BF02553710; WUTHIER RE, 1969, CALC TISS RES, V4, P20, DOI 10.1007/BF02279103; WUTHIER RE, 1977, CALC TISS RES, V24, P163, DOI 10.1007/BF02223311	76	31	31	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9737	9748		10.1074/jbc.M706523200	http://dx.doi.org/10.1074/jbc.M706523200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18250169	Green Published, hybrid			2022-12-25	WOS:000254671600028
J	Olson, LJ; Hindsgaul, O; Dahms, NM; Kim, JJP				Olson, Linda J.; Hindsgaul, Ole; Dahms, Nancy M.; Kim, Jung-Ja P.			Structural insights into the mechanism of pH-dependent ligand binding and release by the cation-dependent mannose 6-phosphate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION; LYSOSOMAL-ENZYMES; INSECT CELLS; PROTEIN; RESIDUES; SITE; OLIGOSACCHARIDES; IDENTIFICATION; REFINEMENT; TRANSPORT	The cation-dependent mannose 6-phosphate receptor (CD-MPR) is a key component of the lysosomal enzyme targeting system that binds newly synthesized mannose 6-phosphate (Man-6-P)-containing acid hydrolases and transports them to endosomal compartments. The interaction between the MPRs and its ligands is pH-dependent; the homodimeric CD-MPR binds lysosomal enzymes optimally in the pH environment of the trans Golgi network (pH similar to 6.5) and releases its cargo in acidic endosomal compartments (< pH 5.5) and at the cell surface. In addition, CD-MPR binding affinities are modulated by divalent cations. Our previous crystallographic studies have shown that at pH 6.5, the CD-MPR bound to Man-6-P adopts a significantly different quaternary conformation than the CD-MPR in a ligand-unbound state, a feature unique among known lectin structures. To determine whether different pH conditions elicit conformational changes in the receptor that alters ligand binding affinities, we have obtained additional crystal structures representative of the various environments encountered by the receptor including: 1) the CD-MPR bound at pH 6.5 (i.e. trans Golgi network) to a high affinity ligand (the terminally phosphorylated trisaccharide P-Man(alpha 1,2) Man(alpha 1,2) Man-O-(CH2)(8)COOMe), 2) the CD-MPR at pH 4.8 in an unbound state (i.e. endosome), and 3) the CD-MPR at pH 7.4 (i.e. cell surface). A detailed comparison of the available CD-MPR structures reveals the positional invariability of specific binding pocket residues and implicates intermonomer contact(s), as well as the protonation state of Man-6-P, as regulators of pH-dependent carbohydrate binding.	[Olson, Linda J.; Dahms, Nancy M.; Kim, Jung-Ja P.] Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; [Hindsgaul, Ole] Carlsberg Lab, DK-2500 Copenhagen, Denmark	Medical College of Wisconsin	Dahms, NM (corresponding author), Med Coll Wisconsin, Dept Biochem, 8701 Watertown plank Rd, Milwaukee, WI 53226 USA.	ndahms@mcw.edu; jjkim@mcw.edu			NCRR NIH HHS [P41 RR007707, RR 07707] Funding Source: Medline; NIDDK NIH HHS [R01 DK 42667, R01 DK042667] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR007707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042667] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		*ACC INC, 1995, INSIGHT 2 MOL MOD PR; Altmann F, 1999, GLYCOCONJUGATE J, V16, P109, DOI 10.1023/A:1026488408951; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chavez CA, 2007, BIOCHEMISTRY-US, V46, P12604, DOI 10.1021/bi7011806; DISTLER JJ, 1987, ANAL BIOCHEM, V166, P65, DOI 10.1016/0003-2697(87)90546-X; DISTLER JJ, 1991, J BIOL CHEM, V266, P21687; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050; Hancock MK, 2002, J BIOL CHEM, V277, P11255, DOI 10.1074/jbc.M109855200; IMORT M, 1983, BIOCHEM J, V214, P671, DOI 10.1042/bj2140671; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P208, DOI 10.1016/S0076-6879(97)77013-7; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Le Borgne R, 1998, BBA-MOL CELL RES, V1404, P195, DOI 10.1016/S0167-4889(98)00057-3; Loris R, 2002, BBA-GEN SUBJECTS, V1572, P198, DOI 10.1016/S0304-4165(02)00309-4; Marron-Terada PG, 1998, BIOCHEMISTRY-US, V37, P17223, DOI 10.1021/bi981883y; MCPHERSON A, 1990, EUR J BIOCHEM, V189, P1, DOI 10.1111/j.1432-1033.1990.tb15454.x; Mullins C, 2001, BIOESSAYS, V23, P333, DOI 10.1002/bies.1048; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Olson LJ, 2002, J BIOL CHEM, V277, P10156, DOI 10.1074/jbc.M112230200; Olson LJ, 1999, J BIOL CHEM, V274, P29889, DOI 10.1074/jbc.274.42.29889; Olson LJ, 1999, J BIOL CHEM, V274, P36905, DOI 10.1074/jbc.274.52.36905; Olson LJ, 2004, J BIOL CHEM, V279, P34000, DOI 10.1074/jbc.M404588200; Olson LJ, 2004, EMBO J, V23, P2019, DOI 10.1038/sj.emboj.7600215; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Roberts DL, 1998, CELL, V93, P639, DOI 10.1016/S0092-8674(00)81192-7; ROUSSEL A, 1994, TURBO FRODO SOFTWARE; SRIVASTAVA OP, 1987, CARBOHYD RES, V161, P195, DOI 10.1016/S0008-6215(00)90077-6; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; Sun GJ, 2005, GLYCOBIOLOGY, V15, P1136, DOI 10.1093/glycob/cwi098; TONG PY, 1989, J BIOL CHEM, V264, P7962; TONG PY, 1989, J BIOL CHEM, V264, P7970; VARKI A, 1980, J BIOL CHEM, V255, P847; WATANABE H, 1990, P NATL ACAD SCI USA, V87, P8036, DOI 10.1073/pnas.87.20.8036; WESTCOTT KR, 1987, J BIOL CHEM, V262, P6101; ZHANG Y, 1993, BIOCHEM J, V295, P841, DOI 10.1042/bj2950841	36	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					10124	10134		10.1074/jbc.M708994200	http://dx.doi.org/10.1074/jbc.M708994200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18272523	hybrid, Green Published			2022-12-25	WOS:000254671600066
J	Reiter, W; Watt, S; Dawson, K; Lawrence, CL; Bahler, J; Jones, N; Wilkinson, CRM				Reiter, Wolfgang; Watt, Stephen; Dawson, Keren; Lawrence, Clare L.; Bahler, Juerg; Jones, Nic; Wilkinson, Caroline R. M.			Fission yeast MAP kinase Sty1 is recruited to stress-induced genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MEIOTIC RECOMBINATION HOTSPOT; TRANSCRIPTION FACTOR ATF1; SCHIZOSACCHAROMYCES-POMBE; OSMOTIC-STRESS; ENVIRONMENTAL-STRESS; SEXUAL DEVELOPMENT; TARGET GENES; HOG1 KINASE; HOT-SPOT	The stress-induced expression of many fission yeast genes is dependent upon the Sty1 mitogen-activated protein kinase (MAPK) and Atf1 transcription factor. Atf1 is phosphorylated by Sty1 yet this phosphorylation is not required for stress-induced gene expression, suggesting another mechanism exists whereby Sty1 activates transcription. Here we show that Sty1 associates with Atf1-dependent genes and is recruited to both their promoters and coding regions. This occurs in response to various stress conditions coincident with the kinetics of the activation of Sty1. Association with promoters is not a consequence of increased nuclear accumulation of Sty1 nor does it require the phosphorylation of Atf1. However, recruitment is completely abolished in a mutant lacking Sty1 kinase activity. Both Atf1 and its binding partner Pcr1 are required for association of Sty1 with Atf1-dependent promoters, suggesting that this heterodimer must be intact for optimal recruitment of the MAPK. However, many Atf1-dependent genes are still expressed in a pcr1 Delta mutant but with significantly delayed kinetics, thus providing an explanation for the relatively mild stress sensitivity displayed by pcr1 Delta. Consistent with this delay, Sty1 and Atf1 cannot be detected at these promoters in this condition, suggesting that their association with chromatin is weak or transient in the absence of Pcr1.	[Reiter, Wolfgang; Dawson, Keren; Lawrence, Clare L.; Jones, Nic; Wilkinson, Caroline R. M.] Univ Manchester, Paterson Inst Canc Res, Manchester M20 4BX, Lancs, England; [Watt, Stephen; Bahler, Juerg] Welcome Trust Sanger Inst, Canc Res UK Fiss Yeast Genom Grp, Cambridge CB10 1HH, England	Paterson Institute for Cancer Research; University of Manchester; Wellcome Trust Sanger Institute	Jones, N (corresponding author), Univ Manchester, Paterson Inst Canc Res, Wilmslow Rd, Manchester M20 4BX, Lancs, England.	njones@picr.man.ac.uk; cwilkinson@picr.man.ac.uk	Bahler, Jurg/B-4572-2009	Bahler, Jurg/0000-0003-4036-1532; Reiter, Wolfgang/0000-0003-1266-8975; Lawrence, Clare/0000-0003-0170-0079	Cancer Research UK [A6517] Funding Source: Medline; Wellcome Trust [098051, 077118] Funding Source: Medline; Cancer Research UK [12485] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome TrustEuropean Commission); Cancer Research UK(Cancer Research UK)		Alepuz PM, 2003, EMBO J, V22, P2433, DOI 10.1093/emboj/cdg243; Alepuz PM, 2001, MOL CELL, V7, P767, DOI 10.1016/S1097-2765(01)00221-0; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Castillo EA, 2003, J BIOL CHEM, V278, P40565, DOI 10.1074/jbc.M305859200; Chen DR, 2003, MOL BIOL CELL, V14, P214, DOI 10.1091/mbc.E02-08-0499; Craven RA, 1998, GENE, V221, P59, DOI 10.1016/S0378-1119(98)00434-X; de Nadal E, 2004, NATURE, V427, P370, DOI 10.1038/nature02258; de Nadal E, 2003, MOL CELL BIOL, V23, P229, DOI 10.1128/MCB.23.1.229-237.2003; Degols G, 1996, MOL CELL BIOL, V16, P2870; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Edmunds JW, 2004, J CELL SCI, V117, P3715, DOI 10.1242/jcs.01346; Fox ME, 2000, GENETICS, V156, P59; Gaits F, 1999, MOL BIOL CELL, V10, P1395, DOI 10.1091/mbc.10.5.1395; Gaits F, 1998, GENE DEV, V12, P1464, DOI 10.1101/gad.12.10.1464; Gasch AP, 2007, YEAST, V24, P961, DOI 10.1002/yea.1512; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hohmann S, 2002, MICROBIOL MOL BIOL R, V66, P300, DOI 10.1128/MMBR.66.2.300-372.2002; Kato T, 1996, FEBS LETT, V378, P207, DOI 10.1016/0014-5793(95)01442-X; Kon N, 1998, MOL CELL BIOL, V18, P7575, DOI 10.1128/MCB.18.12.7575; Kon N, 1997, P NATL ACAD SCI USA, V94, P13765, DOI 10.1073/pnas.94.25.13765; Lawrence CL, 2007, J BIOL CHEM, V282, P5160, DOI 10.1074/jbc.M608526200; Li H, 2006, NATURE, V442, P1058, DOI 10.1038/nature05020; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Lyne R, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-27; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Nguyen AN, 2002, MOL BIOL CELL, V13, P2651, DOI 10.1091/mbc.02-03-0043; Ohmiya R, 1999, MOL GEN GENET, V261, P297, DOI 10.1007/s004380050970; Pascual-Ahuir A, 2007, EMBO J, V26, P3098, DOI 10.1038/sj.emboj.7601756; Petersen J, 2001, J CELL SCI, V114, P4371; Pokholok DK, 2006, SCIENCE, V313, P533, DOI 10.1126/science.1127677; Proft M, 2002, MOL CELL, V9, P1307, DOI 10.1016/S1097-2765(02)00557-9; Proft M, 2006, MOL CELL, V23, P241, DOI 10.1016/j.molcel.2006.05.031; Quinn J, 2002, MOL BIOL CELL, V13, P805, DOI 10.1091/mbc.01-06-0288; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; Simone C, 2004, NAT GENET, V36, P738, DOI 10.1038/ng1378; Toone WM, 1998, GENE DEV, V12, P1453, DOI 10.1101/gad.12.10.1453; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Vicent GP, 2006, MOL CELL, V24, P367, DOI 10.1016/j.molcel.2006.10.011; WAHLS WP, 1994, GENE DEV, V8, P1693, DOI 10.1101/gad.8.14.1693; Watanabe Y, 1996, MOL CELL BIOL, V16, P704; Wilkinson CRM, 1998, EMBO J, V17, P6465, DOI 10.1093/emboj/17.22.6465; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289; Yamada T, 2004, EMBO J, V23, P1792, DOI 10.1038/sj.emboj.7600138	46	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9945	9956		10.1074/jbc.M710428200	http://dx.doi.org/10.1074/jbc.M710428200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18252721	hybrid, Green Accepted			2022-12-25	WOS:000254671600051
J	Soto, A; Carman, GM				Soto, Anibal; Carman, George M.			Regulation of the Saccharomyces cerevisiae CKI1-encoded choline kinase by zinc depletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYTOPIC MEMBRANE-PROTEIN; DIACYLGLYCEROL PYROPHOSPHATE PHOSPHATASE; PHOSPHOLIPID BIOSYNTHESIS; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; TOPOLOGICAL ORGANIZATION; TRANSPORTER PROTEIN; NEGATIVE REGULATOR; CKI GENE; YEAST	In the yeast Saccharomyces cerevisiae, the CKI1-encoded choline kinase catalyzes the committed step in the synthesis of phosphatidylcholine via the CDP-choline branch of the Kennedy pathway. Analysis of a PCKI1-lacZ reporter gene revealed that CKI1 expression was regulated by intracellular levels of the essential mineral zinc. Zinc depletion resulted in a concentration-dependent induction of CKI1 expression. This regulation was mediated by the zinc-sensing and zinc-inducible transcriptional activator Zap1p. A purified Zap1p probe interacted with two putative UASZRE sequences (ZRE1 and ZRE2) in the CKI1 promoter. Mutations of ZRE1 and ZRE2 to a nonconsensus UASZRE attenuated the induction of CKI1 expression in response to zinc depletion. A UAS(INO) element in the CKI1 promoter was responsible for stimulating CKI1 expression, but this element was not involved with the regulation by zinc depletion. The induction of CKI1 expression in zinc-depleted cells translated into increased choline kinase activity in vitro and in vivo, and an increase in phosphatidylcholine synthesis via the Kennedy pathway.	[Soto, Anibal; Carman, George M.] Rutgers State Univ, Dept Food Sci, New Brunswick, NJ 08901 USA; [Soto, Anibal; Carman, George M.] Rutgers State Univ, Rutgers Ctr Lipid Res, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick	Carman, GM (corresponding author), Rutgers State Univ, Dept Food Sci, 65 Dubley Rd, New Brunswick, NJ 08901 USA.	carman@aesop.rutgers.edu			NIGMS NIH HHS [R01 GM028140, GM 75378, R01 GM028140-25, GM 28140] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM075378, R37GM028140, R01GM028140] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBROZIAK J, 1994, J BIOL CHEM, V269, P15344; Anderson MS, 1996, J BIOL CHEM, V271, P26596, DOI 10.1074/jbc.271.43.26596; BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; Bird A, 2000, J BIOL CHEM, V275, P16160, DOI 10.1074/jbc.M000664200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bogdanov M, 2002, EMBO J, V21, P2107, DOI 10.1093/emboj/21.9.2107; Bogdanov M, 1999, J BIOL CHEM, V274, P36827, DOI 10.1074/jbc.274.52.36827; Bogdanov M, 1996, J BIOL CHEM, V271, P11615, DOI 10.1074/jbc.271.20.11615; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carman GM, 2007, J BIOL CHEM, V282, P37293, DOI 10.1074/jbc.R700038200; Carman GM, 2007, BBA-MOL CELL BIOL L, V1771, P322, DOI 10.1016/j.bbalip.2006.05.006; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CHEN CC, 1984, J BIOL CHEM, V259, P150; Choi MG, 2005, J BIOL CHEM, V280, P26105, DOI 10.1074/jbc.M503551200; CULBERTSON MR, 1975, GENETICS, V80, P23; Devirgiliis C, 2004, BIOCHEM BIOPH RES CO, V323, P58, DOI 10.1016/j.bbrc.2004.08.051; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; Eide DJ, 2003, J NUTR, V133, p1532S, DOI 10.1093/jn/133.5.1532S; Ellis CD, 2005, J BIOL CHEM, V280, P28811, DOI 10.1074/jbc.M505500200; Ellis CD, 2004, J CELL BIOL, V166, P325, DOI 10.1083/jcb.200401157; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FANKHAUSER C, 1993, J BIOL CHEM, V268, P26365; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Guerinot ML, 1999, CURR OPIN PLANT BIOL, V2, P244, DOI 10.1016/S1369-5266(99)80042-9; Han GS, 2004, J BIOL CHEM, V279, P5338, DOI 10.1074/jbc.M311779200; Han GS, 2001, J BIOL CHEM, V276, P10126, DOI 10.1074/jbc.M011421200; Han SH, 2005, J BIOL CHEM, V280, P29017, DOI 10.1074/jbc.M505881200; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; Hernandez-Alcoceba R, 1999, CANCER RES, V59, P3112; HernandezAlcoceba R, 1997, ONCOGENE, V15, P2289, DOI 10.1038/sj.onc.1201414; HOSAKA K, 1990, J BACTERIOL, V172, P2005, DOI 10.1128/jb.172.4.2005-2012.1990; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Iwanyshyn WM, 2004, J BIOL CHEM, V279, P21976, DOI 10.1074/jbc.M402047200; Jesch SA, 2005, J BIOL CHEM, V280, P9106, DOI 10.1074/jbc.M411770200; Jesch SA, 2006, J BIOL CHEM, V281, P24070, DOI 10.1074/jbc.M604541200; Kersting MC, 2006, J BIOL CHEM, V281, P13110, DOI 10.1074/jbc.M601612200; Kim KH, 1998, J BIOL CHEM, V273, P6844, DOI 10.1074/jbc.273.12.6844; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; LAMPING E, 1994, GENETICS, V137, P55; LESTER RL, 1993, ADV LIPID RES, V26, P253; Lyons TJ, 2000, P NATL ACAD SCI USA, V97, P7957, DOI 10.1073/pnas.97.14.7957; MacDiarmid CW, 2003, J BIOL CHEM, V278, P15065, DOI 10.1074/jbc.M300568200; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MENON AK, 1992, J BIOL CHEM, V267, P15277; Miyabe S, 2000, BIOCHEM BIOPH RES CO, V276, P879, DOI 10.1006/bbrc.2000.3580; Miyabe S, 2001, BIOCHEM BIOPH RES CO, V282, P79, DOI 10.1006/bbrc.2001.4522; Muhlenhoff U, 2003, J BIOL CHEM, V278, P40612, DOI 10.1074/jbc.M307847200; Nakagami K, 1999, JPN J CANCER RES, V90, P1212, DOI 10.1111/j.1349-7006.1999.tb00698.x; Nakagami K, 1999, JPN J CANCER RES, V90, P419, DOI 10.1111/j.1349-7006.1999.tb00764.x; NIKAWA J, 1993, MOL MICROBIOL, V10, P955, DOI 10.1111/j.1365-2958.1993.tb00967.x; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; PORTER TJ, 1992, METHOD ENZYMOL, V209, P134; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; Sher RB, 2006, J BIOL CHEM, V281, P4938, DOI 10.1074/jbc.M512578200; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; Wagner C, 2001, MOL MICROBIOL, V41, P155, DOI 10.1046/j.1365-2958.2001.02495.x; Wang XY, 2002, EMBO J, V21, P5673, DOI 10.1093/emboj/cdf571; Waters BM, 2002, J BIOL CHEM, V277, P33749, DOI 10.1074/jbc.M206214200; WHITE MJ, 1991, J BIOL CHEM, V266, P863; Wu GS, 2008, J BIOL CHEM, V283, P1456, DOI 10.1074/jbc.M708766200; Yu Y, 2002, J BIOL CHEM, V277, P34978, DOI 10.1074/jbc.M205316200; Zhang W, 2005, J BIOL CHEM, V280, P26032, DOI 10.1074/jbc.M504929200; Zhang W, 2003, J BIOL CHEM, V278, P50128, DOI 10.1074/jbc.M309840200; Zhao H, 1998, J BIOL CHEM, V273, P28713, DOI 10.1074/jbc.273.44.28713; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	79	18	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					10079	10088		10.1074/jbc.M800502200	http://dx.doi.org/10.1074/jbc.M800502200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18276583	Green Published, hybrid, Green Accepted			2022-12-25	WOS:000254671600062
J	Zhou, W; Milder, JB; Freed, CR				Zhou, Wenbo; Milder, Julie B.; Freed, Curt R.			Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein - A progressive neurodegenerative model of diffuse Lewy body disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE NEURON DEATH; A-BETA COMPONENT; PARKINSONS-DISEASE; OXIDATIVE STRESS; AGGREGATE FORMATION; PRECURSOR PROTEIN; CROSS-LINKING; IN-VITRO; BODIES; DEMENTIA	Abnormal aggregation of human alpha-synuclein in Lewy bodies and Lewy neurites is a pathological hallmark of Parkinson disease and dementia with Lewy bodies. Studies have shown that oxidation and nitration of alpha-synuclein lead to the formation of stable dimers and oligomers through dityrosine cross-linking. Previously we have reported that tyrosine-to-cysteine mutations, particularly at the tyrosine 39 residue (Y39C), significantly enhanced alpha-synuclein fibril formation and neurotoxicity. In the current study, we have generated transgenic mice expressing the Y39C mutant human alpha-synuclein gene controlled by the mouse Thy1 promoter. Mutant human alpha-synuclein was widely expressed in transgenic mouse brain, resulting in 150% overexpression relative to endogenous mouse alpha-synuclein. At age 9 - 12 months, transgenic mice began to display motor dysfunction in rotarod testing. Older animals aged 15 - 18 months showed progressive accumulation of human alpha-synuclein oligomers, associated with worse motor function and cognitive impairment in the Morris water maze. By age 21 - 24 months, alpha-synuclein aggregates were further increased, accompanied by severe behavioral deficits. At this age, transgenic mice developed neuropathology, such as Lewy body-like alpha-synuclein and ubiquitin-positive inclusions, phosphorylation at Ser(129) of human alpha-synuclein, and increased apoptotic cell death. In summary, Y39C human alpha-synuclein transgenic mice show age-dependent, progressive neuronal degeneration with motor and cognitive deficits similar to diffuse Lewy body disease. The time course of alpha-synuclein oligomer accumulation coincided with behavioral and pathological changes, indicating that these oligomers may initiate protein aggregation, disrupt cellular function, and eventually lead to neuronal death.	[Zhou, Wenbo; Freed, Curt R.] Univ Colorado, Sch Med, Div Clin Pharmacol & Toxicol, Dept Med, Denver, CO 80262 USA; [Milder, Julie B.; Freed, Curt R.] Univ Colorado, Sch Med, Grad Program Neurosci, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Zhou, W (corresponding author), Univ Colorado, Sch Med, Div Clin Pharmacol & Toxicol, Dept Med, E 9th Ave, Denver, CO 80262 USA.	wenbo.zhou@uchsc.edu						Baba M, 1998, AM J PATHOL, V152, P879; Chandra S, 2005, CELL, V123, P383, DOI 10.1016/j.cell.2005.09.028; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Cooper AA, 2006, SCIENCE, V313, P324, DOI 10.1126/science.1129462; Dalfo E, 2004, J NEUROPATH EXP NEUR, V63, P302, DOI 10.1093/jnen/63.4.302; Di Rosa G, 2003, HISTOL HISTOPATHOL, V18, P1257, DOI 10.14670/HH-18.1257; Duda JE, 2000, AM J PATHOL, V157, P1439, DOI 10.1016/S0002-9440(10)64781-5; Fleming SM, 2004, J NEUROSCI, V24, P9434, DOI 10.1523/JNEUROSCI.3080-04.2004; Freichel C, 2007, NEUROBIOL AGING, V28, P1421, DOI 10.1016/j.neurobiolaging.2006.06.013; Galvin JE, 2001, ARCH NEUROL-CHICAGO, V58, P186, DOI 10.1001/archneur.58.2.186; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; Gispert S, 2003, MOL CELL NEUROSCI, V24, P419, DOI 10.1016/S1044-7431(03)00198-2; Hashimoto M, 1999, NEUROREPORT, V10, P717, DOI 10.1097/00001756-199903170-00011; Hsu LJ, 1998, J NEUROCHEM, V71, P338; Ihara M, 2007, NEURON, V53, P519, DOI 10.1016/j.neuron.2007.01.019; Ischiropoulos H, 2003, ANN NY ACAD SCI, V991, P93; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Krishnan S, 2003, BIOCHEMISTRY-US, V42, P829, DOI 10.1021/bi026528t; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lee MK, 2002, P NATL ACAD SCI USA, V99, P8968, DOI 10.1073/pnas.132197599; Li J, 2001, BIOCHEMISTRY-US, V40, P11604, DOI 10.1021/bi010616g; Martin LJ, 2006, J NEUROSCI, V26, P41, DOI 10.1523/JNEUROSCI.4308-05.2006; Maskri L, 2004, NEURODEGENER DIS, V1, P255, DOI 10.1159/000085064; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Munch G, 2000, J CHEM NEUROANAT, V20, P253, DOI 10.1016/S0891-0618(00)00096-X; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Paik SR, 2000, ARCH BIOCHEM BIOPHYS, V378, P269, DOI 10.1006/abbi.2000.1822; Paxinou E, 2001, J NEUROSCI, V21, P8053, DOI 10.1523/JNEUROSCI.21-20-08053.2001; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rockenstein E, 2002, J NEUROSCI RES, V68, P568, DOI 10.1002/jnr.10231; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Song DD, 2004, EXP NEUROL, V186, P158, DOI 10.1016/S0014-4886(03)00342-X; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Trojanowski JQ, 1998, ARCH NEUROL-CHICAGO, V55, P151, DOI 10.1001/archneur.55.2.151; Uversky VN, 2001, J BIOL CHEM, V276, P44284, DOI 10.1074/jbc.M105343200; van der Putten H, 2000, J NEUROSCI, V20, P6021, DOI 10.1523/JNEUROSCI.20-16-06021.2000; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795; Zhou WB, 2000, BRAIN RES, V866, P33, DOI 10.1016/S0006-8993(00)02215-0; Zhou WB, 2005, J BIOL CHEM, V280, P43150, DOI 10.1074/jbc.M507124200; Zhou WB, 2004, J BIOL CHEM, V279, P10128, DOI 10.1074/jbc.M307563200; Zhou WB, 1998, BRAIN RES, V792, P97, DOI 10.1016/S0006-8993(98)00125-5; Zhou WB, 2002, BRAIN RES, V926, P42, DOI 10.1016/S0006-8993(01)03292-9	47	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9863	9870		10.1074/jbc.M710232200	http://dx.doi.org/10.1074/jbc.M710232200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18238775	hybrid			2022-12-25	WOS:000254671600042
J	Babenko, AP				Babenko, Andrey P.			A novel ABCC8(SUR1)-dependent mechanism of metabolism excitation uncoupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-ATP CHANNELS; SENSITIVE POTASSIUM CHANNELS; NEONATAL DIABETES-MELLITUS; MULTIDRUG ABC TRANSPORTER; PANCREATIC BETA-CELLS; SULFONYLUREA RECEPTOR; INSULIN-SECRETION; TOLBUTAMIDE SITE; SUR1; REGULATOR	ATP/ADP-sensing ( sulfonylurea receptor ( SUR)/K(IR)6)(4) K-ATP channels regulate the excitability of our insulin secreting and other vital cells via the differential MgATP/ADP-dependent stimulatory actions of their tissue-specific ATP-binding cassette regulatory subunits ( sulfonylurea receptors), which counterbalance the nearly constant inhibitory action of ATP on the K+ inwardly rectifying pore. Mutations in SUR1 that abolish its stimulation have been found in infants persistently releasing insulin. Activating mutations in SUR1 have been shown to cause neonatal diabetes. Here, analyses of K(IR)6.2-based channels with diabetogenic receptors reveal that MgATP-dependent hyper-stimulation of mutant SUR can compromise the ability of KATP channels to function as metabolic sensors. I demonstrate that the channel hyperactivity rises exponentially with the number of hyperstimulating subunits, so small subpopulations of channels with more than two mutant SUR can dominate hyperpolarizing currents in heterozygous patients. I uncovered an attenuated tolbutamide inhibition of the hyperstimulated mutant, which is normally sensitive to the drug under non-stimulatory conditions. These findings show the key role of SUR in sensing the metabolic index in humans and urge others to ( re) test mutant SUR/K(IR)6 channels from probands in physiologic MgATP.	[Babenko, Andrey P.] Pacific NW Res Inst, Seattle, WA 98122 USA		Babenko, AP (corresponding author), 720 Broadway, Seattle, WA USA.	ababenko@pnri.org						AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Ashfield R, 1999, DIABETES, V48, P1341, DOI 10.2337/diabetes.48.6.1341; Babenko AP, 2006, NEW ENGL J MED, V355, P456, DOI 10.1056/NEJMoa055068; Babenko AP, 1998, ANNU REV PHYSIOL, V60, P667, DOI 10.1146/annurev.physiol.60.1.667; Babenko AP, 2003, J BIOL CHEM, V278, P41577, DOI 10.1074/jbc.C300363200; Babenko AP, 1999, FEBS LETT, V445, P131, DOI 10.1016/S0014-5793(99)00102-7; Babenko AP, 2001, J BIOL CHEM, V276, P49083, DOI 10.1074/jbc.M108763200; Babenko AP, 1999, FEBS LETT, V459, P367, DOI 10.1016/S0014-5793(99)01215-6; Christesen H. B. T., 2005, HORM RES, V64, P135; COOK DL, 1988, DIABETES, V37, P495, DOI 10.2337/diabetes.37.5.495; Dawson RJP, 2007, FEBS LETT, V581, P935, DOI 10.1016/j.febslet.2007.01.073; Dawson RJP, 2006, NATURE, V443, P180, DOI 10.1038/nature05155; de Wet H, 2007, FEBS J, V274, P3532, DOI 10.1111/j.1742-4658.2007.05879.x; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; Detimary P, 1998, J BIOL CHEM, V273, P33905, DOI 10.1074/jbc.273.51.33905; Fridlyand LE, 2005, AM J PHYSIOL-ENDOC M, V289, pE839, DOI 10.1152/ajpendo.00595.2004; Gribble FM, 2000, J BIOL CHEM, V275, P30046, DOI 10.1074/jbc.M001010200; Matsuo M, 2000, J BIOL CHEM, V275, P28757, DOI 10.1074/jbc.M004818200; Mikhailov MV, 2005, EMBO J, V24, P4166, DOI 10.1038/sj.emboj.7600877; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Oldham ML, 2007, NATURE, V450, P515, DOI 10.1038/nature06264; Rosenberg MF, 2004, J BIOL CHEM, V279, P39051, DOI 10.1074/jbc.M407434200; Schwanstecher M, 1998, EMBO J, V17, P5529, DOI 10.1093/emboj/17.19.5529; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Sperling MA, 2006, NEW ENGL J MED, V355, P507, DOI 10.1056/NEJMe068142; Ueda K, 1999, P NATL ACAD SCI USA, V96, P1268, DOI 10.1073/pnas.96.4.1268	26	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					8778	8782		10.1074/jbc.C700243200	http://dx.doi.org/10.1074/jbc.C700243200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18281290	Green Published, hybrid			2022-12-25	WOS:000254465800002
J	Folgueras, AR; Fueyo, A; Garcia-Suarez, O; Cox, J; Astudillo, A; Tortorella, P; Campestre, C; Gutierrez-Fernandez, A; Fanjul-Fernandez, M; Pennington, CJ; Edwards, DR; Overall, CM; Lopez-Otin, C				Folgueras, Alicia R.; Fueyo, Antonio; Garcia-Suarez, Olivia; Cox, Jennifer; Astudillo, Aurora; Tortorella, Paolo; Campestre, Cristina; Gutierrez-Fernandez, Ana; Fanjul-Fernandez, Miriam; Pennington, Caroline J.; Edwards, Dylan R.; Overall, Christopher M.; Lopez-Otin, Carlos			Collagenase-2 deficiency or inhibition impairs experimental autoimmune encephalomyelitis in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASES MMPS; MYELIN BASIC-PROTEIN; MULTIPLE-SCLEROSIS; GELATINASE-B; UP-REGULATION; EXPRESSION; INFLAMMATION; EXTRAVASATION; MINOCYCLINE; RESISTANCE	Matrix metalloproteinases (MMPs) have been implicated in a variety of human diseases, including neuroimmunological disorders such as multiple sclerosis. However, the recent finding that some MMPs play paradoxical protective roles in these diseases has made necessary the detailed study of the specific function of each family member in their pathogenesis. To determine the relevance of collagenase-2 (MMP-8) in experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis, we have performed two different analyses involving genetic and biochemical approaches. First, we have analyzed the development of EAE in mutant mouse deficient in MMP-8, with the finding that the absence of this proteolytic enzyme is associated with a marked reduction in the clinical symptoms of EAE. We have also found that MMP-8(-/-) mice exhibit a marked reduction in central nervous system-infiltrating cells and demyelinating lesions. As a second approach, we have carried out a pharmacological inhibition of MMP-8 with a selective inhibitor against this protease (IC50 = 0.4 nM). These studies have revealed that the administration of the MMP-8 selective inhibitor to mice with EAE also reduces the severity of the disease. Based on these findings, we conclude that MMP-8 plays an important role in EAE development and propose that this enzyme may be a novel therapeutic target in human neuro-inflammatory diseases such as multiple sclerosis.	[Folgueras, Alicia R.; Gutierrez-Fernandez, Ana; Fanjul-Fernandez, Miriam; Lopez-Otin, Carlos] Univ Oviedo, Inst Univ Oncol, Fac Med, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain; [Fueyo, Antonio] Univ Oviedo, Inst Univ Oncol, Fac Med, Dept Biol Func, E-33006 Oviedo, Spain; [Garcia-Suarez, Olivia; Astudillo, Aurora] Univ Oviedo, Hosp Cent Asturias, Serv Anat Patol, E-33006 Oviedo, Spain; [Cox, Jennifer; Overall, Christopher M.] Univ British Columbia, Dept Oral Biol & Med Sci, Vancouver, BC V6T 1Z3, Canada; [Cox, Jennifer; Overall, Christopher M.] Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; [Tortorella, Paolo] Univ Bari, Dipartimento Farm Chim, I-70125 Bari, Italy; [Campestre, Cristina] Univ G dAnnunzio, Dipartimento Sci Farm, I-66013 Chieti, Italy; [Pennington, Caroline J.; Edwards, Dylan R.] Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	University of Oviedo; Instituto Universitario de Oncologia de Asturias; University of Oviedo; Instituto Universitario de Oncologia de Asturias; Central University Hospital Asturias; University of Oviedo; University of British Columbia; University of British Columbia; Universita degli Studi di Bari Aldo Moro; G d'Annunzio University of Chieti-Pescara; University of East Anglia	Lopez-Otin, C (corresponding author), Univ Oviedo, Inst Univ Oncol, Fac Med, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain.	clo@uniovi.es	Folgueras, Alicia/B-3281-2017; Gutierrez-Fernandez, Ana/ABG-6678-2020; López-Otín, Carlos/AAB-2106-2020; Gutierrez-Fernandez, Ana/AAS-9954-2021; Fueyo, Antonio/ABH-3243-2020; Edwards, Dylan R/B-4734-2009	Folgueras, Alicia/0000-0003-3426-9502; López-Otín, Carlos/0000-0001-6964-1904; Gutierrez-Fernandez, Ana/0000-0002-9287-8843; Fueyo, Antonio/0000-0002-7121-9398; Edwards, Dylan R/0000-0002-3292-2064; Astudillo Gonzalez, Maria Aurora/0000-0001-8947-8809; Miriam, Fanjul Fernandez/0000-0002-0074-2325; CAMPESTRE, Cristina/0000-0001-5870-7509	Medical Research Council [G0100250] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Agrawal S, 2006, J EXP MED, V203, P1007, DOI 10.1084/jem.20051342; Balbin M, 2003, NAT GENET, V35, P252, DOI 10.1038/ng1249; Balbin M, 1998, J BIOL CHEM, V273, P23959, DOI 10.1074/jbc.273.37.23959; Balbin M, 2001, J BIOL CHEM, V276, P10253, DOI 10.1074/jbc.M009586200; Bar-Or A, 2003, BRAIN, V126, P2738, DOI 10.1093/brain/awg285; Bernard CCA, 1997, J MOL MED-JMM, V75, P77, DOI 10.1007/s001090050092; Bettelli E, 1998, J IMMUNOL, V161, P3299; Biasone A, 2007, BIOORGAN MED CHEM, V15, P791, DOI 10.1016/j.bmc.2006.10.047; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Brundula V, 2002, BRAIN, V125, P1297, DOI 10.1093/brain/awf133; D'Souza CA, 2002, J BIOL CHEM, V277, P13589, DOI 10.1074/jbc.M108817200; Dubois B, 1999, J CLIN INVEST, V104, P1507, DOI 10.1172/JCI6886; Esparza J, 2004, FASEB J, V18, P1682, DOI 10.1096/fj.04-2445com; Folgueras AR, 2004, INT J DEV BIOL, V48, P411, DOI 10.1387/ijdb.041811af; GIJBELS K, 1993, J NEUROSCI RES, V36, P432, DOI 10.1002/jnr.490360409; Giuliani F, 2005, J NEUROIMMUNOL, V165, P83, DOI 10.1016/j.jneuroim.2005.04.020; Graesser D, 2000, J NEUROIMMUNOL, V109, P121, DOI 10.1016/S0165-5728(00)00275-7; Gueders MM, 2005, J IMMUNOL, V175, P2589, DOI 10.4049/jimmunol.175.4.2589; Gutierrez-Fernandez A, 2007, FASEB J, V21, P2580, DOI 10.1096/fj.06-7860com; Hafler DA, 2005, IMMUNOL REV, V204, P208, DOI 10.1111/j.0105-2896.2005.00240.x; Hemmer B, 2002, NAT REV NEUROSCI, V3, P291, DOI 10.1038/nrn784; Liedtke W, 1998, ANN NEUROL, V44, P35, DOI 10.1002/ana.410440110; Lindberg RLP, 2001, BRAIN, V124, P1743, DOI 10.1093/brain/124.9.1743; McColl SR, 1998, J IMMUNOL, V161, P6421; Muller DM, 2005, J NEUROIMMUNOL, V160, P162, DOI 10.1016/j.jneuroim.2004.11.011; Nygardas PT, 2002, CLIN EXP IMMUNOL, V128, P245, DOI 10.1046/j.1365-2249.2002.01855.x; Opdenakker G, 2003, LANCET NEUROL, V2, P747, DOI 10.1016/S1474-4422(03)00587-8; Owen CA, 2004, J IMMUNOL, V172, P7791, DOI 10.4049/jimmunol.172.12.7791; Parks WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418; Pirila E, 2003, DIGEST DIS SCI, V48, P93, DOI 10.1023/A:1021790532723; PROOST P, 1993, BIOCHEM BIOPH RES CO, V192, P1175, DOI 10.1006/bbrc.1993.1540; Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108; Sorsa T, 2004, ORAL DIS, V10, P311, DOI 10.1111/j.1601-0825.2004.01038.x; Sospedra M, 2005, ANNU REV IMMUNOL, V23, P683, DOI 10.1146/annurev.immunol.23.021704.115707; Steinman L, 2002, ANNU REV NEUROSCI, V25, P491, DOI 10.1146/annurev.neuro.25.112701.142913; Tester AM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000312; Toft-Hansen H, 2004, J IMMUNOL, V173, P5209, DOI 10.4049/jimmunol.173.8.5209; Van Lint P, 2005, J IMMUNOL, V175, P7642, DOI 10.4049/jimmunol.175.11.7642; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Weaver A, 2005, FASEB J, V19, P1668, DOI 10.1096/fj.04-2030fje; Yong VW, 2007, J NEUROL SCI, V259, P79, DOI 10.1016/j.jns.2006.11.021; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Zhang KY, 2003, NAT NEUROSCI, V6, P1064, DOI 10.1038/nn1127	43	57	58	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9465	9474		10.1074/jbc.M709522200	http://dx.doi.org/10.1074/jbc.M709522200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18245084	hybrid, Green Published			2022-12-25	WOS:000254465800076
J	Pala, D; Kapoor, M; Woods, A; Kennedy, L; Liu, SX; Chen, S; Bursell, L; Lyons, KM; Carter, DE; Beier, F; Leask, A				Pala, Daphne; Kapoor, Mohit; Woods, Anita; Kennedy, Laura; Liu, Shangxi; Chen, Shioqiong; Bursell, Laura; Lyons, Karen M.; Carter, David E.; Beier, Frank; Leask, Andrew			Focal adhesion kinase/Src suppresses early chondrogenesis - Central role of CCN2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR CTGF; REGULATES CHONDROGENESIS; DIFFERENTIATION; EXPRESSION; GENE; CELLS; CYR61; SOX9; CONDENSATION; CHONDROCYTES	Adhesive signaling plays a key role in cellular differentiation, including in chondrogenesis. Herein, we probe the contribution to early chondrogenesis of two key modulators of adhesion, namely focal adhesion kinase ( FAK)/Src and CCN2 ( connective tissue growth factor, CTGF). We use the micromass model of chondrogenesis to show that FAK/Src signaling, which mediates cell/matrix attachment, suppresses early chondrogenesis, including the induction of Ccn2, Agc, and Sox6. The FAK/Src inhibitor PP2 elevates Ccn2, Agc, and Sox6 expression in wildtype mesenchymal cells in micromass culture, but not in cells lacking CCN2. Our results suggest a reduction in FAK/Src signaling is a critical feature permitting chondrogenic differentiation and that CCN2 operates downstream of this loss to promote chondrogenesis.	[Pala, Daphne; Woods, Anita; Kennedy, Laura; Bursell, Laura; Beier, Frank; Leask, Andrew] Univ Western Ontario, Schulich Sch Med & Dent, Canadian Inst Hlth Res, Dept Physiol & Pharmacol,Grp Skeletal Dev & Remod, London, ON N6A 5C1, Canada; [Kapoor, Mohit; Liu, Shangxi; Chen, Shioqiong; Leask, Andrew] Univ Western Ontario, Schulich Sch Med & Dent, Canadian Inst Hlth Res, Div Oral Biol,Grp Skeletal Dev & Remodeling, London, ON N6A 5C1, Canada; [Lyons, Karen M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; [Lyons, Karen M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Orthoped Surg, Los Angeles, CA 90095 USA; [Carter, David E.] London Reg Gen Ctr, London, ON N6A 5C1, Canada	Institute for Work & Health; Western University (University of Western Ontario); Institute for Work & Health; Western University (University of Western Ontario); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Leask, A (corresponding author), Univ Western Ontario, Schulich Sch Med & Dent, Canadian Inst Hlth Res, Dept Physiol & Pharmacol,Grp Skeletal Dev & Remod, London, ON N6A 5C1, Canada.	Andrew.Leask@schulich.uwo.ca	Leask, Andy/ABH-9433-2020; Leask, Andrew/G-5217-2015; Beier, Frank/T-4734-2019; Beier, Frank/G-4595-2013	Beier, Frank/0000-0002-8505-7537; Beier, Frank/0000-0002-8505-7537	NIAMS NIH HHS [R01 AR052686] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR052686] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; AHRENS PB, 1977, DEV BIOL, V60, P69, DOI 10.1016/0012-1606(77)90110-5; Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802; Aszodi A, 2003, GENE DEV, V17, P2465, DOI 10.1101/gad.277003; Bang OS, 2000, BIOCHEM BIOPH RES CO, V278, P522, DOI 10.1006/bbrc.2000.3831; Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169; Carlberg AL, 2001, DIFFERENTIATION, V67, P128, DOI 10.1046/j.1432-0436.2001.670405.x; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Chen YL, 2004, MOL BIOL CELL, V15, P5635, DOI 10.1091/mbc.E04-06-0490; Cohn MJ, 1996, TRENDS GENET, V12, P253, DOI 10.1016/0168-9525(96)10030-5; DeLise AM, 2000, OSTEOARTHR CARTILAGE, V8, P309, DOI 10.1053/joca.1999.0306; Friedrichsen S, 2003, CELL TISSUE RES, V312, P175, DOI 10.1007/s00441-003-0712-6; FURUTA Y, 1995, ONCOGENE, V11, P1989; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Gomes RR, 2003, CONNECT TISSUE RES, V44, P196, DOI 10.1080/03008200390181645; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; ILLC D, 1995, NATURE, V377, P539; Ivkovic S, 2003, DEVELOPMENT, V130, P2779, DOI 10.1242/dev.00505; James CG, 2005, MOL BIOL CELL, V16, P5316, DOI 10.1091/mbc.E05-01-0084; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Karsenty G, 2003, NATURE, V423, P316, DOI 10.1038/nature01654; Karsenty G, 1999, GENE DEV, V13, P3037, DOI 10.1101/gad.13.23.3037; Kawai J, 1999, EUR J CELL BIOL, V78, P707, DOI 10.1016/S0171-9335(99)80039-9; Kennedy L, 2007, EXP CELL RES, V313, P952, DOI 10.1016/j.yexcr.2006.12.006; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; Leask A, 2006, J CELL SCI, V119, P4803, DOI 10.1242/jcs.03270; Lefebvre V, 2001, OSTEOARTHR CARTILAGE, V9, pS69, DOI 10.1053/joca.2001.0447; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200; Nakanishi T, 2000, ENDOCRINOLOGY, V141, P264, DOI 10.1210/endo.141.1.7267; Nakanishi T, 2001, BIOCHEM BIOPH RES CO, V281, P678, DOI 10.1006/bbrc.2001.4379; Nicoll SB, 2002, BIOCHEM BIOPH RES CO, V292, P819, DOI 10.1006/bbrc.2002.6697; Okazaki K, 2004, CLIN ORTHOP RELAT R, pS123, DOI 10.1097/01.blo.0000144478.51284.f3; Perbal B, 2004, LANCET, V363, P62, DOI 10.1016/S0140-6736(03)15172-0; Seghatoleslami MR, 2003, J CELL BIOCHEM, V88, P1129, DOI 10.1002/jcb.10458; Shi-Wen X, 2006, J BIOL CHEM, V281, P10715, DOI 10.1074/jbc.M511343200; Smits P, 2001, DEV CELL, V1, P277, DOI 10.1016/S1534-5807(01)00003-X; Stanton LA, 2003, DEV BIOL, V263, P165, DOI 10.1016/S0012-1606(03)00321-X; Stanton LA, 2004, BIOCHEM J, V378, P53, DOI 10.1042/BJ20030874; Takigawa M, 2003, DRUG NEWS PERSPECT, V16, P11, DOI 10.1358/dnp.2003.16.1.829302; Takigawa M, 2003, J CELL PHYSIOL, V194, P256, DOI 10.1002/jcp.10206; Wagner EF, 2001, CURR OPIN GENET DEV, V11, P527, DOI 10.1016/S0959-437X(00)00228-8; Wang GY, 2007, DEV BIOL, V306, P612, DOI 10.1016/j.ydbio.2007.03.520; Wong M, 1997, DEV BIOL, V192, P492, DOI 10.1006/dbio.1997.8766; Woods A, 2005, J BIOL CHEM, V280, P11626, DOI 10.1074/jbc.M409158200; Woods A, 2006, J BIOL CHEM, V281, P13134, DOI 10.1074/jbc.M509433200; Woods A, 2007, J BIOL CHEM, V282, P23500, DOI 10.1074/jbc.M700680200; Yoon BS, 2004, J CELL BIOCHEM, V93, P93, DOI 10.1002/jcb.20211; Zelzer E, 2003, NATURE, V423, P343, DOI 10.1038/nature01659	50	43	44	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9239	9247		10.1074/jbc.M705175200	http://dx.doi.org/10.1074/jbc.M705175200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18276598	hybrid, Green Published			2022-12-25	WOS:000254465800054
J	Qiao, LP; Zou, CH; Shao, P; Schaack, J; Johnson, PF; Shao, JH				Qiao, Liping; Zou, Chenhui; Shao, Peng; Schaack, Jerome; Johnson, Peter F.; Shao, Jianhua			Transcriptional regulation of fatty acid Translocase/CD36 expression by CCAAT/Enhancer-binding protein alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPONECTIN GENE-EXPRESSION; SKELETAL-MUSCLE; C/EBP-BETA; SARCOLEMMAL FAT/CD36; ADIPOSE-TISSUE; NULL MUTATION; CD36; TRANSPORT; INSULIN; GLUCOSE	Fatty acid translocase (FAT/CD36) plays an important role in facilitating long chain fatty acid transport. FAT/CD36 gene deletion protects mice from high fat diet-induced obesity. In this study we have investigated the regulatory mechanism of FAT/CD36 expression at the transcription level. FAT/CD36 expression was activated during 3T3-L1 adipocyte differentiation, and FAT/CD36 protein levels were positively correlated with CCAAT/enhancer-binding protein alpha(C/EBP alpha) and peroxisome proliferator-activated receptor gamma. However, a negative correlation was detected between FAT/CD36 and C/EBP ss. Overexpression of C/EBP alpha or C/EBP ss increased FAT/CD36 mRNAand protein levels in several types of cells. Restoration of C/EBP alpha or C/EBP ss expression in C/EBP alpha- or C/EBP ss-deficient mouse embryonic fibroblasts increased FAT/CD36 expression. However, in mouse embryonic fibroblasts C/EBP alpha was a more potent activator of FAT/CD36 expression than was C/EBP alpha. Expression of C/EBP ss robustly increased FAT/CD36 proximal promoter- directed luciferase expression in human embryonic kidney 293 cells. A C/EBP-responsive element was identified in the FAT/CD36 promoter by using 5 ' and specific site mutations. The binding of C/EBP alpha in the FAT/CD36 promoter was detected by chromatin immunoprecipitation in 3T3-L1 adipocytes. These results demonstrated that C/EBP alpha regulates FAT/CD36 gene expression at the transcriptional level.	[Qiao, Liping; Zou, Chenhui; Shao, Peng; Shao, Jianhua] Univ Kentucky, Grad Ctr Nutr Sci, Lexington, KY 40536 USA; [Schaack, Jerome] Univ Colorado Denver, Dept Microbiol, Aurora, CO 80045 USA; [Schaack, Jerome] Hlth Sci Ctr, Aurora, CO 80045 USA; [Johnson, Peter F.] NCI Frederick, Natl Inst Hlth, Lab Prot Dynam & Signaling, Frederick, MD 21702 USA	University of Kentucky; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Shao, JH (corresponding author), Univ Kentucky, Grad Ctr Nutr Sci, 900 S Limestone, Lexington, KY 40536 USA.	JianhuaShao@uky.edu	Johnson, Peter/A-1940-2012	Johnson, Peter/0000-0002-4145-4725	NATIONAL CANCER INSTITUTE [ZIABC010328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK077643] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIDDK NIH HHS [R DK 077643 A] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Armesilla AL, 1996, J BIOL CHEM, V271, P7781, DOI 10.1074/jbc.271.13.7781; Bonen A, 2004, FASEB J, V18, P1144, DOI 10.1096/fj.03-1065fje; Bonen A, 2007, AM J PHYSIOL-ENDOC M, V292, pE1740, DOI 10.1152/ajpendo.00579.2006; Chabowski A, 2005, FEBS LETT, V579, P2428, DOI 10.1016/j.febslet.2004.11.118; Chabowski A, 2004, AM J PHYSIOL-ENDOC M, V287, pE781, DOI 10.1152/ajpendo.00573.2003; Chabowski A, 2006, AM J PHYSIOL-ENDOC M, V291, pE675, DOI 10.1152/ajpendo.00096.2006; Chen SS, 2000, MOL CELL BIOL, V20, P7292, DOI 10.1128/MCB.20.19.7292-7299.2000; Coburn CT, 2000, J BIOL CHEM, V275, P32523, DOI 10.1074/jbc.M003826200; Coort SLM, 2004, DIABETES, V53, P1655, DOI 10.2337/diabetes.53.7.1655; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; Griffin E, 2001, NAT MED, V7, P840, DOI 10.1038/89969; Hajri T, 2007, DIABETES, V56, P1872, DOI 10.2337/db06-1699; Ibrahimi A, 1999, J BIOL CHEM, V274, P26761, DOI 10.1074/jbc.274.38.26761; Ibrahimi A, 1996, P NATL ACAD SCI USA, V93, P2646, DOI 10.1073/pnas.93.7.2646; Koonen DPY, 2007, DIABETES, V56, P2863, DOI 10.2337/db07-0907; Liang CP, 2004, J CLIN INVEST, V113, P764, DOI [10.1172/JCI200419528, 10.1172/JCI19528]; McKnight SL, 2001, CELL, V107, P259, DOI 10.1016/S0092-8674(01)00543-8; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Orlicky DJ, 2001, J LIPID RES, V42, P910; Pohl J, 2005, MOL BIOL CELL, V16, P24, DOI 10.1091/mbc.E04-07-0616; Qiao LP, 2006, J BIOL CHEM, V281, P24390, DOI 10.1074/jbc.M603038200; Qiao LP, 2006, ENDOCRINOLOGY, V147, P3060, DOI 10.1210/en.2005-1507; Qiao LP, 2006, J BIOL CHEM, V281, P39915, DOI 10.1074/jbc.M607215200; Qiao LP, 2006, ENDOCRINOLOGY, V147, P865, DOI 10.1210/en.2005-1030; Qiao LP, 2005, DIABETES, V54, P1744, DOI 10.2337/diabetes.54.6.1744; Sampson MJ, 2003, ATHEROSCLEROSIS, V167, P129, DOI 10.1016/S0021-9150(02)00421-5; Sato O, 2002, J BIOL CHEM, V277, P15703, DOI 10.1074/jbc.M110158200; Schaffer JE, 2002, AM J PHYSIOL-ENDOC M, V282, pE239, DOI 10.1152/ajpendo.00462.2001; Schroeder-Gloeckler JM, 2007, J BIOL CHEM, V282, P15717, DOI 10.1074/jbc.M701329200; Sebastian T, 2005, EMBO J, V24, P3301, DOI 10.1038/sj.emboj.7600789; Sfeir Z, 1999, MOL CELL BIOCHEM, V192, P3, DOI 10.1023/A:1006811300125; Shao JH, 2005, DIABETES, V54, P976, DOI 10.2337/diabetes.54.4.976; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; Tao NB, 1996, J BIOL CHEM, V271, P22315, DOI 10.1074/jbc.271.37.22315; WAGATSUMA A, MOL CELL BIOCH, V304, P25	37	45	47	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					8788	8795		10.1074/jbc.M800055200	http://dx.doi.org/10.1074/jbc.M800055200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18263877	Green Published, hybrid			2022-12-25	WOS:000254465800004
J	Daadi, MM; Maag, AL; Steinberg, GK				Daadi, Marcel M.; Maag, Anne-Lise; Steinberg, Gary K.			Adherent Self-Renewable Human Embryonic Stem Cell-Derived Neural Stem Cell Line: Functional Engraftment in Experimental Stroke Model	PLOS ONE			English	Article							IN-VITRO DIFFERENTIATION; DOPAMINERGIC-NEURONS; PRECURSOR CELLS; GROWTH-FACTOR; TRANSPLANTATION; PROGENITORS; NICHE; NEUROGENESIS; POPULATION; EXPRESSION	Background: Human embryonic stem cells (hESCs) offer a virtually unlimited source of neural cells for structural repair in neurological disorders, such as stroke. Neural cells can be derived from hESCs either by direct enrichment, or by isolating specific growth factor-responsive and expandable populations of human neural stem cells (hNSCs). Studies have indicated that the direct enrichment method generates a heterogeneous population of cells that may contain residual undifferentiated stem cells that could lead to tumor formation in vivo. Methods/Principal Findings: We isolated an expandable and homogenous population of hNSCs (named SD56) from hESCs using a defined media supplemented with epidermal growth factor (EGF), basic fibroblast growth factor (bFGF) and leukemia inhibitory growth factor (LIF). These hNSCs grew as an adherent monolayer culture. They were fully neuralized and uniformly expressed molecular features of NSCs, including nestin, vimentin and radial glial markers. These hNSCs did not express the pluripotency markers Oct4 or Nanog, nor did they express markers for the mesoderm or endoderm lineages. The self-renewal property of the hNSCs was characterized by a predominant symmetrical mode of cell division. The SD56 hNSCs differentiated into neurons, astrocytes and oligodendrocytes throughout multiple passages in vitro, as well as after transplantation. Together, these criteria confirm the definitive NSC identity of the SD56 cell line. Importantly, they exhibited no chromosome abnormalities and did not form tumors after implantation into rat ischemic brains and into naive nude rat brains and flanks. Furthermore, hNSCs isolated under these conditions migrated toward the ischemia-injured adult brain parenchyma and improved the independent use of the stroke-impaired forelimb two months post-transplantation. Conclusions/Significance: The SD56 human neural stem cells derived under the reported conditions are stable, do not form tumors in vivo and enable functional recovery after stroke. These properties indicate that this hNSC line may offer a renewable, homogenous source of neural cells that will be valuable for basic and translational research.	[Daadi, Marcel M.; Maag, Anne-Lise; Steinberg, Gary K.] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA	Stanford University	Daadi, MM (corresponding author), Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA.	mdaadi@stanford.edu		Steinberg, Gary/0000-0001-6374-1058	William Randolph Hearst Foundation; Edward E. Hills Fund; NIH NINDS [RO1 NS27292, P01 NS37520]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS037520, R01NS027292] Funding Source: NIH RePORTER	William Randolph Hearst Foundation; Edward E. Hills Fund; NIH NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported in part by Russell and Elizabeth Siegelman, Bernard and Ronni Lacroute, the William Randolph Hearst Foundation, John and Dodie Rosekrans, the Edward E. Hills Fund, Gerald and Marjorie Burnett, and NIH NINDS grants RO1 NS27292 and P01 NS37520.	Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; Bendall SC, 2007, NATURE, V448, P1015, DOI 10.1038/nature06027; Bliss T, 2007, STROKE, V38, P817, DOI 10.1161/01.STR.0000247888.25985.62; Brederlau A, 2006, STEM CELLS, V24, P1433, DOI 10.1634/stemcells.2005-0393; Carpenter MK, 1999, EXP NEUROL, V158, P265, DOI 10.1006/exnr.1999.7098; Carson CT, 2006, NAT MED, V12, P1237, DOI 10.1038/nm1106-1237; Conti L, 2005, PLOS BIOL, V3, P1594, DOI 10.1371/journal.pbio.0030283; D'Amour KA, 2005, NAT BIOTECHNOL, V23, P1534, DOI 10.1038/nbt1163; Daadi M, 1998, NEUROSCIENCE, V86, P867, DOI 10.1016/S0306-4522(98)00102-X; Dihne M, 2006, STEM CELLS, V24, P1458, DOI 10.1634/stemcells.2005-0413; Erdo F, 2003, J CEREBR BLOOD F MET, V23, P780, DOI 10.1097/01.WCB.0000071886.63724.FB; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Guillaume DJ, 2006, J NEUROSCI RES, V84, P1165, DOI 10.1002/jnr.21022; Hayashi J, 2006, J CEREBR BLOOD F MET, V26, P906, DOI 10.1038/sj.jcbfm.9600247; Ikeda R, 2005, NEUROBIOL DIS, V20, P38, DOI 10.1016/j.nbd.2005.01.031; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Mori T, 2005, MOL CELL BIOL, V25, P5183, DOI 10.1128/MCB.25.12.5183-5195.2005; Morrison SJ, 2006, NATURE, V441, P1068, DOI 10.1038/nature04956; Okabe S, 1996, MECH DEVELOP, V59, P89, DOI 10.1016/0925-4773(96)00572-2; Ostenfeld T, 2004, STEM CELLS, V22, P798, DOI 10.1634/stemcells.22-5-798; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; PALMER TD, 1995, MOL CELL NEUROSCI, V6, P474, DOI 10.1006/mcne.1995.1035; Parker MA, 2005, EXP NEUROL, V194, P320, DOI 10.1016/j.expneurol.2005.04.018; Perrier AL, 2004, P NATL ACAD SCI USA, V101, P12543, DOI 10.1073/pnas.0404700101; Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; Roy NS, 2006, NAT MED, V12, P1259, DOI 10.1038/nm1495; Savitz Sean I, 2004, NeuroRx, V1, P406; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Schulz TC, 2004, STEM CELLS, V22, P1218, DOI 10.1634/stemcells.2004-0114; Shen Q, 2004, SCIENCE, V304, P1338, DOI 10.1126/science.1095505; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; Smukler SR, 2006, J CELL BIOL, V172, P79, DOI 10.1083/jcb.200508085; Sonntag KC, 2007, STEM CELLS, V25, P411, DOI 10.1634/stemcells.2006-0380; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; Suslov ON, 2002, P NATL ACAD SCI USA, V99, P14506, DOI 10.1073/pnas.212525299; Tabar V, 2005, NAT BIOTECHNOL, V23, P601, DOI 10.1038/nbt1088; TEMPLE S, 1989, NATURE, V340, P471, DOI 10.1038/340471a0; Thomson JA, 1998, SCIENCE, V282, P1827; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Wei L, 2005, NEUROBIOL DIS, V19, P183, DOI 10.1016/j.nbd.2004.12.016; Weissman IL, 2001, ANNU REV CELL DEV BI, V17, P387, DOI 10.1146/annurev.cellbio.17.1.387; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Xu RH, 2005, NAT METHODS, V2, P185, DOI 10.1038/NMETH744; Yan YP, 2005, STEM CELLS, V23, P781, DOI 10.1634/stemcells.2004-0365; Ying QL, 2003, NAT BIOTECHNOL, V21, P183, DOI 10.1038/nbt780; Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129	52	146	163	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1644	10.1371/journal.pone.0001644	http://dx.doi.org/10.1371/journal.pone.0001644			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286199	gold, Green Submitted, Green Published			2022-12-25	WOS:000260586400037
J	Fajardo, A; Martinez-Martin, N; Mercadillo, M; Galan, JC; Ghysels, B; Matthijs, S; Cornelis, P; Wiehlmann, L; Tummler, B; Baquero, F; Martinez, JL				Fajardo, Alicia; Martinez-Martin, Nadia; Mercadillo, Maria; Galan, Juan C.; Ghysels, Bart; Matthijs, Sandra; Cornelis, Pierre; Wiehlmann, Lutz; Tuemmler, Burkhard; Baquero, Fernando; Martinez, Jose L.			The Neglected Intrinsic Resistome of Bacterial Pathogens	PLOS ONE			English	Article							PSEUDOMONAS-AERUGINOSA; ANTIBIOTIC-RESISTANCE; CAENORHABDITIS-ELEGANS; MECHANISMS; MYCOBACTERIUM; INFECTIONS; SELECTION	Bacteria with intrinsic resistance to antibiotics are a worrisome health problem. It is widely believed that intrinsic antibiotic resistance of bacterial pathogens is mainly the consequence of cellular impermeability and activity of efflux pumps. However, the analysis of transposon-tagged Pseudomonas aeruginosa mutants presented in this article shows that this phenotype emerges from the action of numerous proteins from all functional categories. Mutations in some genes make P. aeruginosa more susceptible to antibiotics and thereby represent new targets. Mutations in other genes make P. aeruginosa more resistant and therefore define novel mechanisms for mutation-driven acquisition of antibiotic resistance, opening a new research field based in the prediction of resistance before it emerges in clinical environments. Antibiotics are not just weapons against bacterial competitors, but also natural signalling molecules. Our results demonstrate that antibiotic resistance genes are not merely protective shields and offer a more comprehensive view of the role of antibiotic resistance genes in the clinic and in nature.	[Fajardo, Alicia; Martinez-Martin, Nadia; Martinez, Jose L.] CSIC, Ctr Nacl Biotecnol, Dept Biotecnol Microbiana, Madrid, Spain; [Mercadillo, Maria; Galan, Juan C.; Baquero, Fernando; Martinez, Jose L.] Hosp Ramon & Cajal, CSIC, Unidad Asoc Ctr Nacl Biotecnol, Madrid, Spain; [Galan, Juan C.; Baquero, Fernando; Martinez, Jose L.] Hosp Ramon & Cajal, CIBERESP, Madrid, Spain; [Galan, Juan C.; Baquero, Fernando] Hosp Ramon & Cajal, Dept Microbiol, Madrid, Spain; [Ghysels, Bart; Matthijs, Sandra; Cornelis, Pierre] Free Univ Brussels, Flanders Interuniver, Inst Biotechnol, Dept Mol & Cell Interact, Lab Microb Interact, Brussels, Belgium; [Wiehlmann, Lutz; Tuemmler, Burkhard] Hannover Med Sch, Klin Forschergruppe, Hannover, Germany	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Consejo Superior de Investigaciones Cientificas (CSIC); Hospital Universitario Ramon y Cajal; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Hospital Universitario Ramon y Cajal; Hospital Universitario Ramon y Cajal; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Hannover Medical School	Fajardo, A (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Biotecnol Microbiana, Madrid, Spain.	jlmtnez@cnb.uam.es	Garcia-Armisen, Tamara/A-6173-2008; Cornelis, Pierre/H-3058-2019; Martinez, Jose L/C-4100-2008; Martinez, Jose L/A-4725-2013	Martinez, Jose L/0000-0001-8813-7607; Fajardo Lubian, Alicia/0000-0002-9537-4878	Spanish Ministerio de Educacion y Ciencia [fellowship];  [BIO2005-04278];  [LSHM-CT-2005-518152];  [LSHM-CT-2005-018705]	Spanish Ministerio de Educacion y Ciencia(Spanish Government); ; ; 	This work was supported by grants BIO2005-04278, LSHM-CT-2005-518152 and LSHM-CT-2005-018705. AF is the recipient of a fellowship from the Spanish Ministerio de Educacion y Ciencia. The funders did not play any role in this study, including those described above.	Ainsa JA, 1997, MOL MICROBIOL, V24, P431, DOI 10.1046/j.1365-2958.1997.3471717.x; Alonso A, 1999, ENVIRON MICROBIOL, V1, P421, DOI 10.1046/j.1462-2920.1999.00052.x; Alonso A, 2001, ENVIRON MICROBIOL, V3, P1, DOI 10.1046/j.1462-2920.2001.00161.x; Alonso A, 1999, MICROBIOL-SGM, V145, P2857, DOI 10.1099/00221287-145-10-2857; Atlas R. M., 1993, HDB MICROBIOLOGICAL; BENVENISTE R, 1973, P NATL ACAD SCI USA, V70, P2276, DOI 10.1073/pnas.70.8.2276; D'Costa VM, 2006, SCIENCE, V311, P374, DOI 10.1126/science.1120800; Davies JE, 1997, CIBA F SYMP, V207, P15; de Chial M, 2003, MICROBIOL-SGM, V149, P821, DOI 10.1099/mic.0.26136-0; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Gales AC, 2001, CLIN INFECT DIS, V32, pS146, DOI 10.1086/320186; Gatell J M, 1996, Semin Respir Infect, V11, P119; Gibson RL, 2003, AM J RESP CRIT CARE, V168, P918, DOI 10.1164/rccm.200304-505SO; Gould SJ, 1999, P NATL ACAD SCI USA, V96, P11904, DOI 10.1073/pnas.96.21.11904; Govan JRW, 1996, MICROBIOL REV, V60, P539, DOI 10.1128/MMBR.60.3.539-574.1996; Hancock REW, 2000, DRUG RESIST UPDATE, V3, P247, DOI 10.1054/drup.2000.0152; Hancock REW, 1998, CLIN INFECT DIS, V27, pS93, DOI 10.1086/514909; Hogan D, 2002, CURR OPIN MICROBIOL, V5, P472, DOI 10.1016/S1369-5274(02)00357-0; Lee N, 2003, DRUGS, V63, P1511, DOI 10.2165/00003495-200363140-00006; Levin BR, 2006, NAT REV MICROBIOL, V4, P556, DOI 10.1038/nrmicro1445; Levy SB, 1998, NEW ENGL J MED, V338, P1376, DOI 10.1056/NEJM199805073381909; Linares JF, 2006, P NATL ACAD SCI USA, V103, P19484, DOI 10.1073/pnas.0608949103; LURIA SE, 1957, J BACTERIOL, V74, P461, DOI 10.1002/path.1700740226; Macinga David R., 1999, Frontiers in Bioscience, V4, pD132, DOI 10.2741/Macinga; Mahajan-Miklos S, 1999, CELL, V96, P47, DOI 10.1016/S0092-8674(00)80958-7; MARTINEZ JL, 1994, EUR J CLIN MICROBIOL, V13, P1015, DOI 10.1007/BF02111820; Martinez JL, 2000, ANTIMICROB AGENTS CH, V44, P1771, DOI 10.1128/AAC.44.7.1771-1777.2000; Martinez JL, 2007, NAT REV MICROBIOL, V5, P958, DOI 10.1038/nrmicro1796; Morales G, 2004, J BACTERIOL, V186, P4228, DOI 10.1128/JB.186.13.4228-4237.2004; Navas A, 2007, P NATL ACAD SCI USA, V104, P13728, DOI 10.1073/pnas.0704497104; Navon-Venezia S, 2005, CURR OPIN INFECT DIS, V18, P306, DOI 10.1097/01.qco.0000171920.44809.f0; Nikaido H, 2001, SEMIN CELL DEV BIOL, V12, P215, DOI 10.1006/scdb.2000.0247; PANG Y, 1994, ANTIMICROB AGENTS CH, V38, P1408, DOI 10.1128/AAC.38.6.1408; Quinn JP, 1998, CLIN INFECT DIS, V27, pS117, DOI 10.1086/514912; RAHME LG, 1995, SCIENCE, V268, P1899, DOI 10.1126/science.7604262; Sambrook J, 2001, MOL CLONING LAB MANU; Sifri CD, 2005, TRENDS MICROBIOL, V13, P119, DOI 10.1016/j.tim.2005.01.003; Smith DL, 2004, P NATL ACAD SCI USA, V101, P3709, DOI 10.1073/pnas.0400456101; Spiers AJ, 2000, MICROBIOL-SGM, V146, P2345, DOI 10.1099/00221287-146-10-2345; Stover CK, 2000, NATURE, V406, P959, DOI 10.1038/35023079; Tan MW, 1999, P NATL ACAD SCI USA, V96, P715, DOI 10.1073/pnas.96.2.715; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639; WHO, 2000, OV ANT RES; WIEHLMANN L, 2002, GENOME LETT, V1, P1; Wiehlmann L, 2007, P NATL ACAD SCI USA, V104, P8101, DOI 10.1073/pnas.0609213104; Wiuff C, 2005, ANTIMICROB AGENTS CH, V49, P1483, DOI 10.1128/AAC.49.4.1483-1494.2005; Wright GD, 2007, NAT REV MICROBIOL, V5, P175, DOI 10.1038/nrmicro1614; Yim G, 2007, PHILOS T R SOC B, V362, P1195, DOI 10.1098/rstb.2007.2044	48	204	210	1	43	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1619	10.1371/journal.pone.0001619	http://dx.doi.org/10.1371/journal.pone.0001619			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286176	Green Published, gold			2022-12-25	WOS:000260586400012
J	Fehrmann, RSN; de Jonge, HJM; ter Elst, A; de Vries, A; Crijns, AGP; Weidenaar, AC; Gerbens, F; de Jong, S; van der Zee, AGJ; de Vries, EGE; Kamps, WA; Hofstra, RMW; Meerman, GJT; de Bont, ESJM				Fehrmann, Rudolf S. N.; de Jonge, Hendrik J. M.; ter Elst, Arja; de Vries, Andre; Crijns, Anne G. P.; Weidenaar, Alida C.; Gerbens, Frans; de Jong, Steven; van der Zee, Ate G. J.; de Vries, Elisabeth G. E.; Kamps, Willem A.; Hofstra, Robert M. W.; Meerman, Gerard J. te; de Bont, Eveline S. J. M.			A New Perspective on Transcriptional System Regulation (TSR): Towards TSR Profiling	PLOS ONE			English	Article							GENE-EXPRESSION; ORGANIZATION; REPLICATION; BIOLOGY	It has been hypothesized that the net expression of a gene is determined by the combined effects of various transcriptional system regulators (TSRs). However, characterizing the complexity of regulation of the transcriptome is a major challenge. Principal component analysis on 17,550 heterogeneous human microarray experiments revealed that 50 orthogonal factors (hereafter called TSRs) are able to capture 64% of the variability in expression in a wide range of experimental conditions and tissues. We identified gene clusters controlled in the same direction and show that gene expression can be conceptualized as a process influenced by a fairly limited set of TSRs. Furthermore, TSRs can be linked to biological functions, as we demonstrate a strong relation between TSR-related gene clusters and biological functionality as well as cellular localization, i.e. gene products of similarly regulated genes by a specific TSR are located in identical parts of a cell. Using 3,934 diverse mouse microarray experiments we found striking similarities in transcriptional system regulation between human and mouse. Our results give biological insights into regulation of the cellular transcriptome and provide a tool to characterize expression profiles with highly reliable TSRs instead of thousands of individual genes, leading to a >500-fold reduction of complexity with just 50 TSRs. This might open new avenues for those performing gene expression profiling studies.	[Fehrmann, Rudolf S. N.; de Vries, Andre; Gerbens, Frans; Hofstra, Robert M. W.; Meerman, Gerard J. te] Univ Groningen, Dept Genet, Univ Med Ctr Groningen, Groningen, Netherlands; [de Jonge, Hendrik J. M.; ter Elst, Arja; Weidenaar, Alida C.; Kamps, Willem A.; de Bont, Eveline S. J. M.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Dept Pediat, Div Pediat Oncol, Groningen, Netherlands; [Fehrmann, Rudolf S. N.; Crijns, Anne G. P.; van der Zee, Ate G. J.] Univ Groningen, Univ Med Ctr Groningen, Dept Gynecol, Groningen, Netherlands; [Fehrmann, Rudolf S. N.; de Jong, Steven; de Vries, Elisabeth G. E.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen; University of Groningen	Fehrmann, RSN (corresponding author), Univ Groningen, Dept Genet, Univ Med Ctr Groningen, Groningen, Netherlands.	e.de.bont@bkk.umcg.nl	Fehrmann, Rudolf/E-2551-2011	Fehrmann, Rudolf/0000-0002-7516-315X; Hofstra, Robert/0000-0001-7498-3829; de Vries, Elisabeth/0000-0002-8949-7425	Foundation for Pediatric Oncology Groningen; Dutch Cancer Society [3661]	Foundation for Pediatric Oncology Groningen; Dutch Cancer Society(KWF Kankerbestrijding)	H.J.M. de J is partially supported by the Foundation for Pediatric Oncology Groningen and E.S.J.M. de B is supported by a grant from the Dutch Cancer Society (grant number 3661). The funders had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript. An european patent application has been filed concerning diagnostic use of TSR's by the University of Groningen and the University Medical Center Groningen. The first and the last two authors could receive partial benefits of patent revenu in the future.	Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Alter O, 2000, P NATL ACAD SCI USA, V97, P10101, DOI 10.1073/pnas.97.18.10101; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Backes C, 2007, NUCL ACIDS RES; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Caron H, 2001, SCIENCE, V291, P1289, DOI 10.1126/science.1056794; Chakalova L, 2005, NAT REV GENET, V6, P669, DOI 10.1038/nrg1673; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; Cremer T, 2001, NAT REV GENET, V2, P292, DOI 10.1038/35066075; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; Draghici S, 2006, TRENDS GENET, V22, P101, DOI 10.1016/j.tig.2005.12.005; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; El-Osta A, 2000, GENE EXPRESSION, V9, P63; Gasch AP, 2002, GENOME BIOL, V3; Gaszner M, 2006, NAT REV GENET, V7, P703, DOI 10.1038/nrg1925; Ihmels J, 2002, NAT GENET, V31, P370, DOI 10.1038/ng941; L.I. Smith, 2002, TUTORIAL PRINCIPAL C; LORD FM, 1968, STATISTICAL THEORIES, P129; Meaburn KJ, 2007, NATURE, V445, P379, DOI 10.1038/445379a; Misteli T, 2007, CELL, V128, P787, DOI 10.1016/j.cell.2007.01.028; Rencher A.C., 1998, MULTIVARIATE STAT IN; Segal E, 2003, NAT GENET, V34, P166, DOI 10.1038/ng1165; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102	26	12	12	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1656	10.1371/journal.pone.0001656	http://dx.doi.org/10.1371/journal.pone.0001656			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18297136	Green Published, Green Submitted, gold			2022-12-25	WOS:000260586400046
J	Lee, JY; Muenzberg, H; Gavrilova, O; Reed, JA; Berryman, D; Villanueva, EC; Louis, GW; Leinninger, GM; Bertuzzi, S; Seeley, RJ; Robinson, GW; Myers, MG; Hennighausen, L				Lee, Ji-Yeon; Muenzberg, Heike; Gavrilova, Oksana; Reed, Jacquelyn A.; Berryman, Darlene; Villanueva, Eneida C.; Louis, Gwendolyn W.; Leinninger, Gina M.; Bertuzzi, Stefano; Seeley, Randy J.; Robinson, Gertraud W.; Myers, Martin G., Jr.; Hennighausen, Lothar			Loss of Cytokine-STAT5 Signaling in the CNS and Pituitary Gland Alters Energy Balance and Leads to Obesity	PLOS ONE			English	Article							CILIARY NEUROTROPHIC FACTOR; HYPOTHALAMIC ARCUATE NUCLEUS; TRANSCRIPTION 5B; NERVOUS-SYSTEM; FOOD-INTAKE; LEPTIN; PROLIFERATION; TRANSDUCER; ACTIVATOR; RECEPTOR	Signal transducers and activators of transcription (STATs) are critical components of cytokine signaling pathways. STAT5A and STAT5B (STAT5), the most promiscuous members of this family, are highly expressed in specific populations of hypothalamic neurons in regions known to mediate the actions of cytokines in the regulation of energy balance. To test the hypothesis that STAT5 signaling is essential to energy homeostasis, we used Cre-mediated recombination to delete the Stat5 locus in the CNS. Mutant males and females developed severe obesity with hyperphagia, impaired thermal regulation in response to cold, hyperleptinemia and insulin resistance. Furthermore, central administration of GM-CSF mediated the nuclear accumulation of STAT5 in hypothalamic neurons and reduced food intake in control but not in mutant mice. These results demonstrate that STAT5 mediates energy homeostasis in response to endogenous cytokines such as GM-CSF.	[Lee, Ji-Yeon; Robinson, Gertraud W.; Hennighausen, Lothar] NIDDK, Lab Genet & Physiol, Natl Inst Hlth, Bethesda, MD 20892 USA; [Muenzberg, Heike; Villanueva, Eneida C.; Louis, Gwendolyn W.; Leinninger, Gina M.; Myers, Martin G., Jr.] Univ Michigan, Dept Med & Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; [Gavrilova, Oksana] NIDDK, Mouse Metab Core Facil, Natl Inst Hlth, Bethesda, MD USA; [Reed, Jacquelyn A.; Seeley, Randy J.] Univ Cincinnati, Cincinnati, OH USA; [Berryman, Darlene] Ohio Univ, Athens, OH 45701 USA; [Bertuzzi, Stefano] Natl Inst Neurol Disorders & Stroke, Mammalian Dev Sect, Natl Inst Hlth, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University System of Ohio; University of Cincinnati; University System of Ohio; Ohio University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Lee, JY (corresponding author), NIDDK, Lab Genet & Physiol, Natl Inst Hlth, Bethesda, MD 20892 USA.	hennighausen@nih.gov	Muenzberg-Gruening, Heike/N-1978-2017; Robinson, Gertraud/I-2136-2012	Seeley, Randy/0000-0002-3721-5625; Hennighausen, Lothar/0000-0001-8319-9841	Federal Government of the USA; National Institutes of Health; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK061005, ZIADK061005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS002790, Z01NS002790] Funding Source: NIH RePORTER	Federal Government of the USA; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was funded by the Federal Government of the USA (intramural and extramural programs of the National Institutes of Health).	Anderson GM, 2006, ENDOCRINOLOGY, V147, P4996, DOI 10.1210/en.2005-0755; Anderson KD, 2003, J NEUROENDOCRINOL, V15, P649, DOI 10.1046/j.1365-2826.2003.01043.x; Bates SH, 2003, NATURE, V421, P856, DOI 10.1038/nature01388; Bates SH, 2004, DIABETES, V53, P3067, DOI 10.2337/diabetes.53.12.3067; Bennett E, 2005, J NEUROENDOCRINOL, V17, P186, DOI 10.1111/j.1365-2826.2005.01296.x; Cave BJ, 2005, NEUROREPORT, V16, P1423, DOI 10.1097/01.wnr.0000176516.19347.6f; Chen HC, 2002, J LIPID RES, V43, P986; Cui Y, 2004, MOL CELL BIOL, V24, P8037, DOI 10.1128/MCB.24.18.8037-8047.2004; Davey HW, 1999, MOL CELL ENDOCRINOL, V158, P111, DOI 10.1016/S0303-7207(99)00175-6; de Groot RP, 1998, CELL SIGNAL, V10, P619, DOI 10.1016/S0898-6568(98)00023-0; DeFalco J, 2001, SCIENCE, V291, P2608, DOI 10.1126/science.1056602; Dubois NC, 2006, GENESIS, V44, P355, DOI 10.1002/dvg.20226; Elmquist JK, 2005, J COMP NEUROL, V493, P63, DOI 10.1002/cne.20786; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; Friedman JM, 2002, NUTR REV, V60, pS1, DOI 10.1301/002966402320634878; Gao Q, 2004, P NATL ACAD SCI USA, V101, P4661, DOI 10.1073/pnas.0303992101; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; GONG Y, 2007, J BIOL CHEM; Lambert PD, 2001, P NATL ACAD SCI USA, V98, P4652, DOI 10.1073/pnas.061034298; Ma FY, 2005, ENDOCRINOLOGY, V146, P5112, DOI 10.1210/en.2005-0770; MARUSICH MF, 1994, J NEUROBIOL, V25, P143, DOI 10.1002/neu.480250206; Mori H, 2004, NAT MED, V10, P739, DOI 10.1038/nm1071; Munzberg H, 2004, ENDOCRINOLOGY, V145, P4880, DOI 10.1210/en.2004-0726; Reed JA, 2005, J CLIN INVEST, V115, P3035, DOI 10.1172/JCI25681; Sleeman MW, 2003, P NATL ACAD SCI USA, V100, P14297, DOI 10.1073/pnas.2335926100; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; XU AW, 2006, ENDOCRINOLOGY	27	70	76	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1639	10.1371/journal.pone.0001639	http://dx.doi.org/10.1371/journal.pone.0001639			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286195	Green Published, Green Submitted, gold			2022-12-25	WOS:000260586400032
J	Onaivi, ES; Ishiguro, H; Gong, JP; Patel, S; Meozzi, PA; Myers, L; Perchuk, A; Mora, Z; Tagliaferro, PA; Gardner, E; Brusco, A; Akinshola, BE; Hope, B; Lujilde, J; Inada, T; Iwasaki, S; Macharia, D; Teasenfitz, L; Arinami, T; Uhl, GR				Onaivi, Emmanuel S.; Ishiguro, Hiroki; Gong, Jian-Ping; Patel, Sejal; Meozzi, Paul A.; Myers, Lester; Perchuk, Alex; Mora, Zoila; Tagliaferro, Patricia A.; Gardner, Eileen; Brusco, Alicia; Akinshola, B. Emmanuel; Hope, Bruce; Lujilde, Javier; Inada, Toshiya; Iwasaki, Shinya; Macharia, David; Teasenfitz, Lindsey; Arinami, Tadao; Uhl, George R.			Brain Neuronal CB2 Cannabinoid Receptors in Drug Abuse and Depression: From Mice to Human Subjects	PLOS ONE			English	Article							ENDOCANNABINOID SYSTEM; EXPRESSION; GENE; DISORDERS; ALCOHOL; ANXIETY; CELLS; RISK; PAIN	Background: Addiction and major depression are mental health problems associated with stressful events in life with high relapse and reoccurrence even after treatment. Many laboratories were not able to detect the presence of cannabinoid CB2 receptors (CB2-Rs) in healthy brains, but there has been demonstration of CB2-R expression in rat microglial cells and other brain associated cells during inflammation. Therefore, neuronal expression of CB2-Rs had been ambiguous and controversial and its role in depression and substance abuse is unknown. Methodology/Principal Findings: In this study we tested the hypothesis that genetic variants of CB2 gene might be associated with depression in a human population and that alteration in CB2 gene expression may be involved in the effects of abused substances including opiates, cocaine and ethanol in rodents. Here we demonstrate that a high incidence of (Q63R) but not (H316Y) polymorphism in the CB2 gene was found in Japanese depressed subjects. CB2-Rs and their gene transcripts are expressed in the brains of naive mice and are modulated following exposure to stressors and administration of abused drugs. Mice that developed alcohol preference had reduced CB2 gene expression and chronic treatment with JWH015 a putative CB2-R agonist, enhanced alcohol consumption in stressed but not in control mice. The direct intracerebroventricular microinjection of CB2 anti-sense oligonucleotide into the mouse brain reduced mouse aversions in the plus-maze test, indicating the functional presence of CB2-Rs in the brain that modifies behavior. We report for the using electron microscopy the sub cellular localization of CB2-Rs that are mainly on post-synaptic elements in rodent brain. Conclusions/Significance: Our data demonstrate the functional expression of CB2-Rs in brain that may provide novel targets for the effects of cannabinoids in depression and substance abuse disorders beyond neuro-immunocannabinoid activity.	[Onaivi, Emmanuel S.; Patel, Sejal; Meozzi, Paul A.; Myers, Lester; Perchuk, Alex; Mora, Zoila; Gardner, Eileen; Macharia, David; Teasenfitz, Lindsey] William Paterson Univ, Dept Biol, Wayne, NJ 07470 USA; [Onaivi, Emmanuel S.; Ishiguro, Hiroki; Gong, Jian-Ping; Iwasaki, Shinya; Arinami, Tadao; Uhl, George R.] Natl Inst Drug Abuse, Mol Neurobiol Branch, Intramural Res Program, Natl Inst Hlth, Bethesda, MD USA; [Ishiguro, Hiroki] Univ Tsukuba, Dept Med Genet, Inst Basic Med Sci, Tsukuba, Ibaraki 305, Japan; [Tagliaferro, Patricia A.; Brusco, Alicia; Lujilde, Javier] Univ Buenos Aires, Fac Med, Buenos Aires, DF, Argentina; [Akinshola, B. Emmanuel] Howard Univ, Dept Pharmacol, Washington, DC 20059 USA; [Hope, Bruce] Natl Inst Drug Abuse, Behav Neurosci Branch, Intramural Res Program, Natl Inst Hlth, Bethesda, MD USA; [Inada, Toshiya] Teikyo Univ, Chiba Med Ctr, Chiba, Japan	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); University of Tsukuba; University of Buenos Aires; Howard University; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); Teikyo University	Onaivi, ES (corresponding author), William Paterson Univ, Dept Biol, Wayne, NJ 07470 USA.	OnaiviE@wpunj.edu	Hope, Bruce T/A-9223-2010; Ishiguro, Hiroki/Q-7532-2019; Onaivi, Emmanuel/Q-9679-2019	Hope, Bruce T/0000-0001-5804-7061; Inada, Toshiya/0000-0002-8427-5639	NIDA/IRP; William Paterson University center for research; Public interest trust; NATIONAL INSTITUTE ON DRUG ABUSE [Z01DA000401, ZIADA000467, ZIADA000492, ZIADA000401, Z01DA000492, Z01DA000165, ZIADA000165, Z01DA000467] Funding Source: NIH RePORTER	NIDA/IRP(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); William Paterson University center for research; Public interest trust; NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported in part by NIDA/IRP and ESO acknowledges financial support from William Paterson University center for research and the Dean, Dr. DeYoung, student worker fund. HI and TA acknowledge Public interest trust, Research aid fund for stress related diseases with commemoration of Imaikimi. The sponsors or funders had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript.	Ashton JC, 2006, NEUROSCI LETT, V396, P113, DOI 10.1016/j.neulet.2005.11.038; Beltramo M, 2006, EUR J NEUROSCI, V23, P1530, DOI 10.1111/j.1460-9568.2006.04684.x; Benito C, 2005, J NEUROSCI, V25, P2530, DOI 10.1523/JNEUROSCI.3923-04.2005; Benito C, 2003, J NEUROSCI, V23, P11136; Bovasso GB, 2001, AM J PSYCHIAT, V158, P2033, DOI 10.1176/appi.ajp.158.12.2033; Buckley  NE, 2000, EUR J PHARMACOL, V396, P141, DOI 10.1016/S0014-2999(00)00211-9; Degenhardt L, 2001, ADDICTION, V96, P1603, DOI 10.1046/j.1360-0443.2001.961116037.x; Ehrhart J, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-29; GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432-1033.1995.tb20780.x; Golech SA, 2004, MOL BRAIN RES, V132, P87, DOI 10.1016/j.molbrainres.2004.08.025; Gong JP, 2006, BRAIN RES, V1071, P10, DOI 10.1016/j.brainres.2005.11.035; Griffin G, 1999, EUR J PHARMACOL, V377, P117, DOI 10.1016/S0014-2999(99)00402-1; Ibrahim MM, 2003, P NATL ACAD SCI USA, V100, P10529, DOI 10.1073/pnas.1834309100; ISHIGURO H, 2006, PHARMACOGENOMICS J; Karsak M, 2005, HUM MOL GENET, V14, P3389, DOI 10.1093/hmg/ddi370; Manzanares J, 2004, NEUROTOX RES, V6, P213, DOI 10.1007/BF03033223; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Nieri P, 2003, N-S ARCH PHARMACOL, V368, P352, DOI 10.1007/s00210-003-0831-3; Nunez E, 2004, SYNAPSE, V53, P208, DOI 10.1002/syn.20050; Onaivi ES, 2006, ANN NY ACAD SCI, V1074, P514, DOI 10.1196/annals.1369.052; Onaivi ES, 2006, METH MOLEC MED, V123, P291; ONAIVI ES, 1990, J PHARMACOL EXP THER, V253, P1002; Onaivi ES, 2005, ENDOCANNABINOIDS BRA; Patton GC, 2002, BMJ-BRIT MED J, V325, P1195, DOI 10.1136/bmj.325.7374.1195; Paxinos G., 2005, RAT BRAIN STEREOTAXI, Vxliii; Pickel VM, 2006, J COMP NEUROL, V495, P299, DOI 10.1002/cne.20881; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; Sheng WS, 2005, GLIA, V49, P211, DOI 10.1002/glia.20108; Sipe JC, 2005, J LEUKOCYTE BIOL, V78, P231, DOI 10.1189/jlb.0205111; Valenzano KJ, 2005, NEUROPHARMACOLOGY, V48, P658, DOI 10.1016/j.neuropharm.2004.12.008; Van Sickle MD, 2005, SCIENCE, V310, P329, DOI 10.1126/science.1115740; Vinod KY, 2006, TRENDS PHARMACOL SCI, V27, P539, DOI 10.1016/j.tips.2006.08.006; Volkow ND, 2005, PHARMACOL THERAPEUT, V108, P3, DOI 10.1016/j.pharmthera.2005.06.021; Willner P, 2005, NEUROPSYCHOBIOLOGY, V52, P90, DOI 10.1159/000087097; Zhang PW, 2004, MOL PSYCHIATR, V9, P916, DOI 10.1038/sj.mp.4001560; Zhong LC, 2005, INVEST OPHTH VIS SCI, V46, P1988, DOI 10.1167/iovs.04-0651	36	199	204	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1640	10.1371/journal.pone.0001640	http://dx.doi.org/10.1371/journal.pone.0001640			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	367XR	18286196	gold, Green Submitted, Green Published			2022-12-25	WOS:000260586400033
J	Patthey, C; Gunhaga, L; Edlund, T				Patthey, Cedric; Gunhaga, Lena; Edlund, Thomas			Early Development of the Central and Peripheral Nervous Systems Is Coordinated by Wnt and BMP Signals	PLOS ONE			English	Article							NEURAL CREST; EXPRESSION PATTERNS; GENE-EXPRESSION; INDUCTION; SPECIFICATION; CHARACTER; CELLS; LENS; DIFFERENTIATION; MESODERM	The formation of functional neural circuits that process sensory information requires coordinated development of the central and peripheral nervous systems derived from neural plate and neural plate border cells, respectively. Neural plate, neural crest and rostral placodal cells are all specified at the late gastrula stage. How the early development of the central and peripheral nervous systems are coordinated remains, however, poorly understood. Previous results have provided evidence that at the late gastrula stage, graded Wnt signals impose rostrocaudal character on neural plate cells, and Bone Morphogenetic Protein (BMP) signals specify olfactory and lens placodal cells at rostral forebrain levels. By using in vitro assays of neural crest and placodal cell differentiation, we now provide evidence that Wnt signals impose caudal character on neural plate border cells at the late gastrula stage, and that under these conditions, BMP signals induce neural crest instead of rostral placodal cells. We also provide evidence that both caudal neural and caudal neural plate border cells become independent of further exposure to Wnt signals at the head fold stage. Thus, the status of Wnt signaling in ectodermal cells at the late gastrula stage regulates the rostrocaudal patterning of both neural plate and neural plate border, providing a coordinated spatial and temporal control of the early development of the central and peripheral nervous systems.	[Patthey, Cedric; Gunhaga, Lena; Edlund, Thomas] Umea Univ, Umea Ctr Mol Med, Umea, Sweden	Umea University	Patthey, C (corresponding author), Umea Univ, Umea Ctr Mol Med, Umea, Sweden.	thomas.edlund@ucmm.umu.se		Patthey, Cedric/0000-0002-2627-9578	Swedish Medical Research Council; Foundation for Strategic Research; European Union	Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Foundation for Strategic Research; European Union(European Commission)	TE is supported by the Swedish Medical Research Council, the Foundation for Strategic Research and European Union research programs.	Basch ML, 2006, NATURE, V441, P218, DOI 10.1038/nature04684; BEEBE DC, 1981, DEV BIOL, V84, P96, DOI 10.1016/0012-1606(81)90374-2; Bhattacharyya S, 2004, DEV BIOL, V271, P403, DOI 10.1016/j.ydbio.2004.04.010; Carmona-Fontaine C, 2007, DEV BIOL, V309, P208, DOI 10.1016/j.ydbio.2007.07.006; Chapman SC, 2004, DEV DYNAM, V229, P668, DOI 10.1002/dvdy.10491; Chapman SC, 2002, DEV BIOL, V245, P187, DOI 10.1006/dbio.2002.0641; Comte I, 2004, DEV BRAIN RES, V148, P1, DOI 10.1016/j.devbrainres.2003.08.011; COULY GF, 1985, DEV BIOL, V110, P422, DOI 10.1016/0012-1606(85)90101-0; COULY GF, 1993, DEVELOPMENT, V117, P409; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; Del Barrio MG, 2004, DEV DYNAM, V229, P136, DOI 10.1002/dvdy.10456; Endo Y, 2002, DEVELOPMENT, V129, P863; Ericson J, 1997, CELL, V90, P169, DOI 10.1016/S0092-8674(00)80323-2; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Faure S, 2002, DEV BIOL, V244, P44, DOI 10.1006/dbio.2002.0579; Garcia-Castro MI, 2002, SCIENCE, V297, P848, DOI 10.1126/science.1070824; Gunhaga L, 2003, NAT NEUROSCI, V6, P701, DOI 10.1038/nn1068; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Hidalgo-Sanchez M, 1999, MECH DEVELOP, V81, P175, DOI 10.1016/S0925-4773(98)00224-X; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Huang X, 2004, DEV BIOL, V275, P1, DOI 10.1016/j.ydbio.2004.07.033; Kiecker C, 2001, DEVELOPMENT, V128, P4189; Kos R, 2001, DEVELOPMENT, V128, P1467; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; Lekven AC, 2001, DEV CELL, V1, P103, DOI 10.1016/S1534-5807(01)00007-7; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Liu JP, 1998, DEVELOPMENT, V125, P5055; Marklund M, 2004, DEVELOPMENT, V131, P4323, DOI 10.1242/dev.01308; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Nordstrom U, 2002, NAT NEUROSCI, V5, P525, DOI 10.1038/nn854; Nordstrom U, 2006, PLOS BIOL, V4, P1438, DOI 10.1371/journal.pbio.0040252; Olander S, 2006, MECH DEVELOP, V123, P166, DOI 10.1016/j.mod.2005.11.001; Raible DW, 2005, SEMIN CELL DEV BIOL, V16, P673, DOI 10.1016/j.semcdb.2005.06.008; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Sela-Donenfeld D, 1999, DEVELOPMENT, V126, P4749; Sjodal M, 2007, DEV CELL, V13, P141, DOI 10.1016/j.devcel.2007.04.020; Taneyhill LA, 2005, MOL BIOL CELL, V16, P5283, DOI 10.1091/mbc.E05-03-0210; Weidinger G, 2005, CURR BIOL, V15, P489, DOI 10.1016/j.cub.2005.01.041; Wilson SI, 2000, CURR BIOL, V10, P421, DOI 10.1016/S0960-9822(00)00431-0; Wilson SI, 2001, NAT NEUROSCI, V4, P1161, DOI 10.1038/nn747; Wilson SI, 2001, NATURE, V411, P325, DOI 10.1038/35077115; Wu JL, 2005, DEV BIOL, V279, P220, DOI 10.1016/j.ydbio.2004.12.016	42	51	53	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1625	10.1371/journal.pone.0001625	http://dx.doi.org/10.1371/journal.pone.0001625			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286182	Green Submitted, gold, Green Published			2022-12-25	WOS:000260586400018
J	Phillipson, M; Kaur, J; Colarusso, P; Ballantyne, CM; Kubes, P				Phillipson, Mia; Kaur, Jaswinder; Colarusso, Pina; Ballantyne, Christie M.; Kubes, Paul			Endothelial Domes Encapsulate Adherent Neutrophils and Minimize Increases in Vascular Permeability in Paracellular and Transcellular Emigration	PLOS ONE			English	Article								Local edema, a cardinal sign of inflammation associates closely with neutrophil emigration. Neutrophil emigration has been described to occur primarily through endothelial junctions (paracellular) and more rarely directly through endothelial cells (transcellular). Recently, we reported that unlike in wild-type (wt) mice, Mac-1-/- (CD11b) neutrophils predominantly emigrated transcellularly and was significantly delayed taking 20-30 min longer than the paracellular emigration (wt). In the present study we noted significant anatomical disruption of the endothelium and hypothesized that transcellular emigration would greatly increase vascular permeability. Surprisingly, despite profound disruption of the endothelial barrier as the neutrophils moved through the cells, the changes in vascular permeability during transcellular emigration (Mac-1-/-) were not increased more than in wt mice. Instead increased vascular permeability completely tracked the number of emigrated cells and as such, permeability changes were delayed in Mac-1-/- mice. However, by 60 min neutrophils from both sets of mice were emigrating in large numbers. Electron-microscopy and spinning disk multichannel fluorescence confocal microscopy revealed endothelial docking structures that progressed to dome-like structures completely covering wt and Mac-1-/- neutrophils. These domes completely enveloped the emigrating neutrophils in both wt and Mac-1-/- mice making the mode of emigration underneath these structures extraneous to barrier function. In conclusion, predominantly paracellular versus predominantly transcellular emigration does not affect vascular barrier integrity as endothelial dome-like structures retain barrier function.	[Phillipson, Mia] Uppsala Univ, Dept Med Cell Biol, Uppsala, Sweden; [Kaur, Jaswinder; Colarusso, Pina; Kubes, Paul] Univ Calgary, Dept Physiol & Biophys, Immunol Res Grp, Calgary, AB, Canada; [Ballantyne, Christie M.] Baylor Coll Med, Methodist DeBakey Heart Ctr, Ctr Cardiovascular Dis Prevent, Houston, TX USA	Uppsala University; University of Calgary; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Methodist DeBakey Heart & Vascular Center	Phillipson, M (corresponding author), Uppsala Univ, Dept Med Cell Biol, Uppsala, Sweden.	pkubes@ucalgary.ca	Ballantyne, Christie/A-6599-2008	Ballantyne, Christie/0000-0002-6432-1730; Phillipson, Mia/0000-0002-2387-0266	Canadian Institute of Health Research (CIHR); Swedish Research Council [57X-20675-01-4, 57P-20680-01-4]; Swedish Society for Medical Research; Canadian Association of Gastroenterology [Postdoctoral fellow]; Alberta Heritage Foundation for Medical Research	Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Society for Medical Research; Canadian Association of Gastroenterology; Alberta Heritage Foundation for Medical Research(Alberta Heritage Foundation for Medical ResearchGeneral Electric)	This work was supported by the Canadian Institute of Health Research (CIHR), CIHR group grant and the CIHR training grant, Swedish Research Council (57X-20675-01-4, 57P-20680-01-4) and Swedish Society for Medical Research (SSMF). M. Phillipson is a Canadian Association of Gastroenterology Postdoctoral fellow. P.K. is an Alberta Heritage Foundation for Medical Research Scientist and a holder of a Canada Research Chair and the Phoebe, Calvin and Joan Snyder Chair in Critical Care Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ARFORS KE, 1987, BLOOD, V69, P338; Bonnardel-Phu E, 2000, J VASC RES, V37, P32, DOI 10.1159/000025711; Burns AR, 1997, J IMMUNOL, V159, P2893; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Cara DC, 2001, J IMMUNOL, V167, P6552, DOI 10.4049/jimmunol.167.11.6552; Carman CV, 2007, IMMUNITY, V26, P784, DOI 10.1016/j.immuni.2007.04.015; Carman CV, 2004, J CELL BIOL, V167, P377, DOI 10.1083/jcb.200404129; Cook-Mills JM, 2005, J LEUKOCYTE BIOL, V77, P487, DOI 10.1189/jlb.0904554; Engelhardt B, 2004, EUR J IMMUNOL, V34, P2955, DOI 10.1002/eji.200425327; Feng D, 1998, J EXP MED, V187, P903, DOI 10.1084/jem.187.6.903; Hordijk PL, 2006, FEBS J, V273, P4408, DOI 10.1111/j.1742-4658.2006.05440.x; Kanwar S, 1997, J EXP MED, V185, P1077, DOI 10.1084/jem.185.6.1077; KUROSE I, 1993, CIRC RES, V73, P164, DOI 10.1161/01.RES.73.1.164; LEWIS RE, 1989, MICROVASC RES, V37, P53, DOI 10.1016/0026-2862(89)90072-1; LEWIS RE, 1988, MICROVASC RES, V35, P27, DOI 10.1016/0026-2862(88)90048-9; LEY K, 1986, MICROVASC RES, V31, P84, DOI 10.1016/0026-2862(86)90009-9; Lister KJ, 2007, MICROCIRCULATION, V14, P709, DOI 10.1080/10739680701404879; Liu LX, 2005, J EXP MED, V201, P409, DOI 10.1084/jem.20040830; Millan J, 2006, NAT CELL BIOL, V8, P113, DOI 10.1038/ncb1356; Muller WA, 2003, TRENDS IMMUNOL, V24, P327, DOI 10.1016/S1471-4906(03)00117-0; Nieminen M, 2006, NAT CELL BIOL, V8, P156, DOI 10.1038/ncb1355; Petri B, 2006, FEBS J, V273, P4399, DOI 10.1111/j.1742-4658.2006.05439.x; Phillipson M, 2006, J EXP MED, V203, P2569, DOI 10.1084/jem.20060925; ROSENGREN S, 1991, J APPL PHYSIOL, V71, P1322, DOI 10.1152/jappl.1991.71.4.1322; Shaw SK, 2001, J IMMUNOL, V167, P2323, DOI 10.4049/jimmunol.167.4.2323; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Wang Q, 2002, ANTIOXID REDOX SIGN, V4, P39, DOI 10.1089/152308602753625843; Yang L, 2005, BLOOD, V106, P584, DOI 10.1182/blood-2004-12-4942	28	79	81	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1649	10.1371/journal.pone.0001649	http://dx.doi.org/10.1371/journal.pone.0001649			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18297135	Green Published, gold, Green Submitted			2022-12-25	WOS:000260586400042
J	Salvaing, J; Nagel, AC; Mouchel-Vielh, E; Bloyer, S; Maier, D; Preiss, A; Peronnet, F				Salvaing, Juliette; Nagel, Anja C.; Mouchel-Vielh, Emmanuele; Bloyer, Sebastien; Maier, Dieter; Preiss, Anette; Peronnet, Frederique			The Enhancer of Trithorax and Polycomb Corto Interacts with Cyclin G in Drosophila	PLOS ONE			English	Article							CONVEYS EPIGENETIC INHERITANCE; PROTEIN-INTERACTION MAP; BITHORAX COMPLEX; CELLULAR MEMORY; DNA-DAMAGE; TRANSCRIPTIONAL REGULATION; CHROMATIN-ASSOCIATION; GENE-EXPRESSION; A REPRESSION; PC-G	Background: Polycomb (PcG) and trithorax (trxG) genes encode proteins involved in the maintenance of gene expression patterns, notably Hox genes, throughout development. PcG proteins are required for long-term gene repression whereas TrxG proteins are positive regulators that counteract PcG action. PcG and TrxG proteins form large complexes that bind chromatin at overlapping sites called Polycomb and Trithorax Response Elements (PRE/TRE). A third class of proteins, so-called "Enhancers of Trithorax and Polycomb'' (ETP), interacts with either complexes, behaving sometimes as repressors and sometimes as activators. The role of ETP proteins is largely unknown. Methodology/Principal Findings: In a two-hybrid screen, we identified Cyclin G (CycG) as a partner of the Drosophila ETP Corto. Inactivation of CycG by RNA interference highlights its essential role during development. We show here that Corto and CycG directly interact and bind to each other in embryos and S2 cells. Moreover, CycG is targeted to polytene chromosomes where it co-localizes at multiple sites with Corto and with the PcG factor Polyhomeotic (PH). We observed that corto is involved in maintaining Abd-B repression outside its normal expression domain in embryos. This could be achieved by association between Corto and CycG since both proteins bind the regulatory element iab-7 PRE and the promoter of the Abd-B gene. Conclusions/Significance: Our results suggest that CycG could regulate the activity of Corto at chromatin and thus be involved in changing Corto from an Enhancer of TrxG into an Enhancer of PcG.	[Salvaing, Juliette; Mouchel-Vielh, Emmanuele; Bloyer, Sebastien; Peronnet, Frederique] Univ Paris 06, Dev Biol Lab, UMR 7622, CNRS, Paris, France; [Nagel, Anja C.; Maier, Dieter; Preiss, Anette] Univ Hohenheim, Inst Genetik 240, Stuttgart, Germany	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; University Hohenheim	Salvaing, J (corresponding author), Univ Paris 06, Dev Biol Lab, UMR 7622, CNRS, Paris, France.	Frederique.Peronnet@snv.jussieu.fr	Peronnet, Frederique/J-7101-2015; Nagel, Anja/AAA-4254-2022	Peronnet, Frederique/0000-0003-1354-240X; Nagel, Anja/0000-0002-2733-3249	CNRS; UPMC; ARC [4492]	CNRS(Centre National de la Recherche Scientifique (CNRS)); UPMC; ARC(Australian Research Council)	This work was supported by CNRS and UPMC and by grant 4492 from ARC to F.P. J.S. was partly supported by a scholarship from ARC	Baek WK, 2003, AM J OBSTET GYNECOL, V188, P634, DOI 10.1067/mob.2003.140; Bates S, 1996, ONCOGENE, V13, P1103; Bennin DA, 2002, J BIOL CHEM, V277, P27449, DOI 10.1074/jbc.M111693200; Bhat KM, 1996, DEVELOPMENT, V122, P1113; BRAND AH, 1993, DEVELOPMENT, V118, P401; Breiling A, 2004, EMBO REP, V5, P976, DOI 10.1038/sj.embor.7400260; Breiling A, 2001, NATURE, V412, P651, DOI 10.1038/35088090; Brock HW, 2005, DEV DYNAM, V232, P633, DOI 10.1002/dvdy.20298; Brumby AM, 2002, EMBO J, V21, P3377, DOI 10.1093/emboj/cdf334; Cavalli G, 1998, CELL, V93, P505, DOI 10.1016/S0092-8674(00)81181-2; Cavalli G, 1999, PRACT APPROACH SER, P20; CELNIKER SE, 1989, GENE DEV, V3, P1424, DOI 10.1101/gad.3.9.1424; Chun TH, 2005, FEBS LETT, V579, P5275, DOI 10.1016/j.febslet.2005.08.050; Coisy M, 2004, MOL CELL, V15, P43, DOI 10.1016/j.molcel.2004.06.022; Crosby MA, 2007, NUCLEIC ACIDS RES, V35, pD486, DOI 10.1093/nar/gkl827; Decoville M, 2001, GENETICS, V157, P237; Dejardin J, 2005, NATURE, V434, P533, DOI 10.1038/nature03386; Dejardin J, 2004, EMBO J, V23, P857, DOI 10.1038/sj.emboj.7600108; DELORENZI M, 1990, DEVELOPMENT, V108, P323; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; Finley RL, 1996, P NATL ACAD SCI USA, V93, P3011, DOI 10.1073/pnas.93.7.3011; GATTI M, 1989, GENE DEV, V3, P438, DOI 10.1101/gad.3.4.438; Gildea JJ, 2000, GENETICS, V156, P645; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Grimaud C, 2006, CHROMOSOME RES, V14, P363, DOI 10.1007/s10577-006-1069-y; Horne MC, 1996, J BIOL CHEM, V271, P6050, DOI 10.1074/jbc.271.11.6050; Huynh CQ, 1999, J MOL BIOL, V288, P13, DOI 10.1006/jmbi.1999.2674; INGHAM PW, 1985, J EMBRYOL EXP MORPH, V89, P349; Kimura SH, 2001, ONCOGENE, V20, P3290, DOI 10.1038/sj.onc.1204270; Kodjabachian L, 1998, EMBO J, V17, P1063, DOI 10.1093/emboj/17.4.1063; LaJeunesse D, 1996, DEVELOPMENT, V122, P2189; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Lessard J, 2003, EXP HEMATOL, V31, P567, DOI 10.1016/S0301-472X(03)00081-X; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Lopez A, 2001, MOL GENET GENOMICS, V266, P572, DOI 10.1007/s004380100572; Maeda RK, 2006, DEVELOPMENT, V133, P1413, DOI 10.1242/dev.02323; MARTIN CH, 1995, P NATL ACAD SCI USA, V92, P8398, DOI 10.1073/pnas.92.18.8398; Martinez AM, 2006, GENE DEV, V20, P501, DOI 10.1101/gad.357106; Maurange C, 2002, GENE DEV, V16, P2672, DOI 10.1101/gad.242702; MOEHRLE A, 1994, DEV GENET, V15, P478, DOI 10.1002/dvg.1020150606; Nagel AC, 2002, DEV GENES EVOL, V212, P93, DOI 10.1007/s00427-002-0210-y; Narbonne K, 2004, DEVELOPMENT, V131, P1389, DOI 10.1242/dev.01003; Negre N, 2006, PLOS BIOL, V4, P917, DOI 10.1371/journal.pbio.0040170; Nekrasov M, 2007, EMBO J, V26, P4078, DOI 10.1038/sj.emboj.7601837; O'Dor E, 2006, DEV BIOL, V290, P312, DOI 10.1016/j.ydbio.2005.11.015; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; Poux S, 2001, GENE DEV, V15, P2509, DOI 10.1101/gad.208901; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; Reimers L, 1999, J BIOL CHEM, V274, P11022, DOI 10.1074/jbc.274.16.11022; Remillieux-Leschelle N, 2002, GENETICS, V162, P1259; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Ringrose L, 2007, DEVELOPMENT, V134, P223, DOI 10.1242/dev.02723; Salamov AA, 1998, BIOINFORMATICS, V14, P384, DOI 10.1093/bioinformatics/14.5.384; Salvaing J, 2006, BMC BIOL, V4, DOI 10.1186/1741-7007-4-9; Salvaing J, 2003, NUCLEIC ACIDS RES, V31, P2873, DOI 10.1093/nar/gkg381; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; Schwartz YB, 2006, NAT GENET, V38, P700, DOI 10.1038/ng1817; Seo HR, 2006, CELL DEATH DIFFER, V13, P1475, DOI 10.1038/sj.cdd.4401822; Stanyon CA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-12-r96; TAMURA K, 1993, ONCOGENE, V8, P2113; Tolhuis B, 2006, NAT GENET, V38, P694, DOI 10.1038/ng1792; Tonini T, 2004, ONCOGENE, V23, P4930, DOI 10.1038/sj.onc.1207608; Voncken JW, 1999, J CELL SCI, V112, P4627; Voncken JW, 2005, J BIOL CHEM, V280, P5178, DOI 10.1074/jbc.M407155200	66	20	22	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1658	10.1371/journal.pone.0001658	http://dx.doi.org/10.1371/journal.pone.0001658			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286205	gold, Green Published, Green Submitted			2022-12-25	WOS:000260586400047
J	Folgiero, V; Avetrani, P; Bon, G; Di Carlo, SE; Fabi, A; Nistico, C; Vici, P; Melucci, E; Buglioni, S; Perracchio, L; Sperduti, I; Rosano, L; Sacchi, A; Mottolese, M; Falcioni, R				Folgiero, Valentina; Avetrani, Paolo; Bon, Giulia; Di Carlo, Selene E.; Fabi, Alessandra; Nistico, Cecilia; Vici, Patrizia; Melucci, Elisa; Buglioni, Simonetta; Perracchio, Letizia; Sperduti, Isabella; Rosano, Laura; Sacchi, Ada; Mottolese, Marcella; Falcioni, Rita			Induction of ErbB-3 Expression by alpha 6 beta 4 Integrin Contributes to Tamoxifen Resistance in ER beta 1-Negative Breast Carcinomas (Publication with Expression of Concern. See vol. 17, 2022)	PLOS ONE			English	Article; Publication with Expression of Concern							ESTROGEN-RECEPTOR-BETA; PHOSPHOINOSITIDE 3-OH KINASE; ALPHA(6)BETA(4) INTEGRIN; CELL-LINE; ER-BETA; CANCER; SURVIVAL; THERAPY; ALPHA; ACTIVATION	Background: Tamoxifen is still the most widely used drug in hormone therapy for the treatment of breast cancer. Its benefits in adjuvant treatment are well documented in controlled and randomized clinical studies, which have demonstrated an increase in disease-free intervals of patients with positive hormonal receptors. However, the mechanisms involved in endocrine resistance are not clear. Laboratory and clinical data now indicate that bi-directional molecular crosstalk between nuclear or membrane ER and growth factor receptor pathways may be involved in endocrine resistance. We recently found a functional interaction between alpha 6 beta 4 integrin and ErbB-3 receptor to maintain the PI3K/Akt survival pathway of mammary tumour cells. We sought to improve understanding of this process in order to provide the involvement of both receptors insight into mechanism of Tamoxifen resistance. Methods and Findings: Using human breast cancer cell lines displaying different levels of alpha 6 beta 4 and ErbB-3 receptors and a series of 232 breast cancer biopsies from patients submitted to adjuvant Tamoxifen monotherapy for five years, we evaluated the functional interaction between both receptors in relationship to Tamoxifen responsiveness. In mammary carcinoma cells, we evidenced that the a6b4 integrin strongly influence Akt phosphorylation through ErbB-3 protein regulation. Moreover, the ErbB-3 inactivation inhibits Akt phosphorylation, induces apoptosis and inhibits in vitro invasion favouring Tamoxifen responsiveness. The analysis of human tumors revealed a significant relationship between a6b4 and ErbB-3 in P-Akt-positive and ER beta 1-negative breast cancers derived from patients with lower disease free survival. Conclusions: We provided evidence that a strong relationship occurs between alpha 6 beta 4 and ErbB-3 positivity in ER beta 1-negative breast cancers. We also found that the association between ErbB-3 and P-Akt positivity mainly occurs in ER beta 1-negative breast cancer derived from patients with lower DFS indicating that both receptors are clinically relevant in predicting the response to Tamoxifen.	[Folgiero, Valentina; Avetrani, Paolo; Bon, Giulia; Di Carlo, Selene E.; Rosano, Laura; Sacchi, Ada; Falcioni, Rita] Regina Elena Inst Canc Res, Dept Expt Oncol, Rome, Italy; [Fabi, Alessandra; Nistico, Cecilia; Vici, Patrizia] Regina Elena Inst Canc Res, Dept Med Oncol, Rome, Italy; [Melucci, Elisa; Buglioni, Simonetta; Perracchio, Letizia; Mottolese, Marcella] Regina Elena Inst Canc Res, Dept Pathol, Rome, Italy; [Sperduti, Isabella] Regina Elena Inst Canc Res, Sci Direct, Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Folgiero, V (corresponding author), Regina Elena Inst Canc Res, Dept Expt Oncol, Rome, Italy.	falcioni@ifo.it	Rosanò, Laura/I-9266-2012; Falcioni, Rita/H-8869-2017; Rosanò, Laura/B-2863-2018; Fabi, Alessandra/AAC-1021-2019; Melucci, Elisa/K-5860-2016; Rosanò, Laura/AAB-7821-2019; ROSANO', Laura/AAK-1424-2020; Sperduti, Isabella/K-8902-2016; Bon, Giulia/ABH-6498-2020	Falcioni, Rita/0000-0002-3745-4327; Rosanò, Laura/0000-0002-9962-6411; Melucci, Elisa/0000-0003-4908-5271; Rosanò, Laura/0000-0002-3981-8593; ROSANO', Laura/0000-0002-9962-6411; Sperduti, Isabella/0000-0001-5115-3099; Bon, Giulia/0000-0002-5409-5864; Vici, Patrizia/0000-0001-7528-9783; buglioni, simonetta/0000-0002-5066-1523; di carlo, selene/0000-0001-5315-102X; Folgiero, Valentina/0000-0002-9838-1520; Fabi, Alessandra/0000-0002-0758-8033; Nistico, Cecilia/0000-0002-2379-5550	Italian Association for Cancer Research; Ministero della Salute; Alleanza contro il Cancro; Federazione Italiana Ricerca sul Cancro (FIRC) [fellowship]	Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro); Ministero della Salute(Ministry of Health, Italy); Alleanza contro il Cancro; Federazione Italiana Ricerca sul Cancro (FIRC)(Fondazione AIRC per la ricerca sul cancro)	This study was supported by Grant: Italian Association for Cancer Research and Ministero della Salute (R. Falcioni, M. Mottolese); Alleanza contro il Cancro (M. Mottolese); G. Bon is recipient of a fellowship from Federazione Italiana Ricerca sul Cancro (FIRC).	Bachelder RE, 1999, J CELL BIOL, V147, P1063, DOI 10.1083/jcb.147.5.1063; Barnes DM, 2004, ENDOCR-RELAT CANCER, V11, P85, DOI 10.1677/erc.0.0110085; Bertotti A, 2005, CANCER RES, V65, P10674, DOI 10.1158/0008-5472.CAN-05-2827; Bon G, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1651; Bon G, 2006, CLIN CANCER RES, V12, P3280, DOI 10.1158/1078-0432.CCR-05-2223; Campbell-Thompson M, 2001, CANCER RES, V61, P632; Chung J, 2002, J CELL BIOL, V158, P165, DOI 10.1083/jcb.200112015; Falcioni R, 1997, EXP CELL RES, V236, P76, DOI 10.1006/excr.1997.3695; Folgiero V, 2007, CANCER RES, V67, P1645, DOI 10.1158/0008-5472.CAN-06-2980; FRIEDRICHS K, 1995, CANCER RES, V55, P901; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; GRUNT TW, 1995, INT J CANCER, V63, P560, DOI 10.1002/ijc.2910630417; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Hellyer NJ, 1998, BIOCHEM J, V333, P757, DOI 10.1042/bj3330757; Hopp TA, 2004, CLIN CANCER RES, V10, P7490, DOI 10.1158/1078-0432.CCR-04-1114; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; LANGHOFER M, 1993, J CELL SCI, V105, P753; Lindberg MK, 2003, MOL ENDOCRINOL, V17, P203, DOI 10.1210/me.2002-0206; Lipscomb EA, 2005, CANCER RES, V65, P10970, DOI 10.1158/0008-5472.CAN-05-2327; Lipscomb EA, 2005, CANCER METAST REV, V24, P413, DOI 10.1007/s10555-005-5133-4; Liu BL, 2007, INT J CANCER, V120, P1874, DOI 10.1002/ijc.22423; Miller WR, 2006, BRIT J CANCER, V94, P1333, DOI 10.1038/sj.bjc.6603082; MILLER WR, 1996, ESTROGEN BREAST CANC, P151; Naidu R, 1998, BRIT J CANCER, V78, P1385, DOI 10.1038/bjc.1998.689; Nicholson RI, 2004, ENDOCR-RELAT CANCER, V11, P623, DOI 10.1677/erc.1.00778; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; PASLEAU F, 1993, ONCOGENE, V8, P849; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Ryden L, 2005, EUR J CANCER, V41, P256, DOI 10.1016/j.ejca.2004.06.030; Schiff R, 2005, BREAST CANCER RES, V7, P205, DOI 10.1186/bcr1287; Shaw LM, 2001, MOL CELL BIOL, V21, P5082, DOI 10.1128/MCB.21.15.5082-5093.2001; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Strom A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100; Tagliabue E, 1998, CLIN CANCER RES, V4, P407; TRAVASOLI FA, 2005, NATURE CLIN PRACTICE, V2, P116; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Witton CJ, 2003, J PATHOL, V200, P290, DOI 10.1002/path.1370; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	41	44	49	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1592	10.1371/journal.pone.0001592	http://dx.doi.org/10.1371/journal.pone.0001592			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270579	gold, Green Published, Green Submitted			2022-12-25	WOS:000260535900026
J	Lindqvist, L; Oberer, M; Reibarkh, M; Cencic, R; Bordeleau, ME; Vogt, E; Marintchev, A; Tanaka, J; Fagotto, F; Altmann, M; Wagner, G; Pelletier, J				Lindqvist, Lisa; Oberer, Monika; Reibarkh, Mikhail; Cencic, Regina; Bordeleau, Marie-Eve; Vogt, Emily; Marintchev, Assen; Tanaka, Junichi; Fagotto, Francois; Altmann, Michael; Wagner, Gerhard; Pelletier, Jerry			Selective Pharmacological Targeting of a DEAD Box RNA Helicase	PLOS ONE			English	Article								RNA helicases represent a large family of proteins implicated in many biological processes including ribosome biogenesis, splicing, translation and mRNA degradation. However, these proteins have little substrate specificity, making inhibition of selected helicases a challenging problem. The prototypical DEAD box RNA helicase, eIF4A, works in conjunction with other translation factors to prepare mRNA templates for ribosome recruitment during translation initiation. Herein, we provide insight into the selectivity of a small molecule inhibitor of eIF4A, hippuristanol. This coral-derived natural product binds to amino acids adjacent to, and overlapping with, two conserved motifs present in the carboxy-terminal domain of eIF4A. Mutagenesis of amino acids within this region allowed us to alter the hippuristanol-sensitivity of eIF4A and undertake structure/function studies. Our results provide an understanding into how selective targeting of RNA helicases for pharmacological intervention can be achieved.	[Lindqvist, Lisa; Cencic, Regina; Bordeleau, Marie-Eve; Pelletier, Jerry] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Oberer, Monika; Reibarkh, Mikhail; Marintchev, Assen; Wagner, Gerhard] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA USA; [Vogt, Emily; Fagotto, Francois] McGill Univ, Dept Biol, Montreal, PQ, Canada; [Tanaka, Junichi] Univ Ryukyus, Dept Chem, Biol, & Marine Sci, Nishihara, Okinawa, Japan; [Altmann, Michael] Univ Bern, Inst Biochem & Mol Med, Bern, Switzerland; [Pelletier, Jerry] McGill Univ, McGill Canc Ctr, Montreal, PQ, Canada	McGill University; Harvard University; Harvard Medical School; McGill University; University of the Ryukyus; University of Bern; McGill University	Lindqvist, L (corresponding author), McGill Univ, Dept Biochem, Montreal, PQ, Canada.	jerry.pelletier@mcgill.ca	Fagotto, Francois/AAA-9983-2021	Fagotto, Francois/0000-0002-1495-2112; Oberer, Monika/0000-0003-2525-9513; Tanaka, Junichi/0000-0002-8672-7379; Reibarkh, Mikhail/0000-0002-6589-707X; Marintchev, Assen/0000-0002-9901-3500	CIHR [fellowship, Post-doctoral Training Grant]; NSERC CGSM [fellowship]; Max Kade Foundation [post-doctoral fellowship]; NCIC [017099]; NIH [CA 68262]; NATIONAL CANCER INSTITUTE [R01CA068262] Funding Source: NIH RePORTER	CIHR(Canadian Institutes of Health Research (CIHR)); NSERC CGSM(Natural Sciences and Engineering Research Council of Canada (NSERC)); Max Kade Foundation; NCIC(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	LL was supported by a CIHR Chemical Biology and an NSERC CGSM fellowship. RC was supported by a CIHR Cancer Consortium Post-doctoral Training Grant Award. MO was supported by a post-doctoral fellowship from the Max Kade Foundation. This work was supported by a grant from NCIC (#017099) to JP and an NIH grant (#CA 68262) to GW.	ALTMANN M, 2002, CELL FREE TRANSLATIO; Andersen CBF, 2006, SCIENCE, V313, P1968, DOI 10.1126/science.1131981; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Bono F, 2006, CELL, V126, P713, DOI 10.1016/j.cell.2006.08.006; Bordeleau ME, 2006, NAT CHEM BIOL, V2, P213, DOI 10.1038/nchembio776; Bordeleau ME, 2005, P NATL ACAD SCI USA, V102, P10460, DOI 10.1073/pnas.0504249102; Cencic R, 2007, COMB CHEM HIGH T SCR, V10, P181, DOI 10.2174/138620707780126688; Chan CC, 2004, RNA, V10, P200, DOI 10.1261/rna.5230104; CONROY SC, 1990, ARCH BIOCHEM BIOPHYS, V282, P363, DOI 10.1016/0003-9861(90)90130-Q; COPPOLECCHIA R, 1993, EMBO J, V12, P4005, DOI 10.1002/j.1460-2075.1993.tb06078.x; Cordin O, 2006, GENE, V367, P17, DOI 10.1016/j.gene.2005.10.019; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; EDERY I, 1983, J BIOL CHEM, V258, P1398; Ferraiuolo MA, 2004, P NATL ACAD SCI USA, V101, P4118, DOI 10.1073/pnas.0400933101; Fukuda T, 2007, NAT CELL BIOL, V9, P604, DOI 10.1038/ncb1577; Giaever G, 1999, NAT GENET, V21, P278, DOI 10.1038/6791; GRIFO JA, 1982, J BIOL CHEM, V257, P5246; Linder P, 2006, NUCLEIC ACIDS RES, V34, P4168, DOI 10.1093/nar/gkl468; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2180, DOI 10.1021/bi972430g; Low WK, 2005, MOL CELL, V20, P709, DOI 10.1016/j.molcel.2005.10.008; Low WK, 2007, CHEM BIOL, V14, P715, DOI 10.1016/j.chembiol.2007.05.012; Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997-717; Oberer M, 2005, GENE DEV, V19, P2212, DOI 10.1101/gad.1335305; Oguro A, 2003, RNA, V9, P394, DOI 10.1261/rna.2161303; Otero LJ, 2001, RNA, V7, P1753; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Pestova TV, 2002, GENE DEV, V16, P2906, DOI 10.1101/gad.1020902; RAY BK, 1985, J BIOL CHEM, V260, P7651; Rocak S, 2004, NAT REV MOL CELL BIO, V5, P232, DOI 10.1038/nrm1335; Rogers GW, 1999, J BIOL CHEM, V274, P12236, DOI 10.1074/jbc.274.18.12236; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Sengoku T, 2006, CELL, V125, P287, DOI 10.1016/j.cell.2006.01.054; Shibuya T, 2006, RNA, V12, P360, DOI 10.1261/rna.2190706; Shibuya T, 2004, NAT STRUCT MOL BIOL, V11, P346, DOI 10.1038/nsmb750; Singleton MR, 2007, ANNU REV BIOCHEM, V76, P23, DOI 10.1146/annurev.biochem.76.052305.115300; SONENBERG N, 1981, NUCLEIC ACIDS RES, V9, P1643, DOI 10.1093/nar/9.7.1643; Svitkin YV, 2001, RNA, V7, P1743; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; YODERHILL J, 1993, J BIOL CHEM, V268, P5566	41	97	97	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1583	10.1371/journal.pone.0001583	http://dx.doi.org/10.1371/journal.pone.0001583			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270573	Green Published, gold, Green Submitted			2022-12-25	WOS:000260535900019
J	Neres, R; Marinho, CRF; Goncalves, LA; Catarino, MB; Penha-Goncalves, C				Neres, Rita; Marinho, Claudio R. F.; Goncalves, Ligia A.; Catarino, Manuela Beirao; Penha-Goncalves, Carlos			Pregnancy Outcome and Placenta Pathology in Plasmodium berghei ANKA Infected Mice Reproduce the Pathogenesis of Severe Malaria in Pregnant Women	PLOS ONE			English	Article								Pregnancy-associated malaria (PAM) is expressed in a range of clinical complications that include increased disease severity in pregnant women, decreased fetal viability, intra-uterine growth retardation, low birth weight and infant mortality. The physiopathology of malaria in pregnancy is difficult to scrutinize and attempts were made in the past to use animal models for pregnancy malaria studies. Here, we describe a comprehensive mouse experimental model that recapitulates many of the pathological and clinical features typical of human severe malaria in pregnancy. We used P. berghei ANKA-GFP infection during pregnancy to evoke a prominent inflammatory response in the placenta that entails CD11b mononuclear infiltration, up-regulation of MIP-1 alpha chemokine and is associated with marked reduction of placental vascular spaces. Placenta pathology was associated with decreased fetal viability, intra-uterine growth retardation, gross post-natal growth impairment and increased disease severity in pregnant females. Moreover, we provide evidence that CSA and HA, known to mediate P. falciparum adhesion to human placenta, are also involved in mouse placental malaria infection. We propose that reduction of maternal blood flow in the placenta is a key pathogenic factor in murine pregnancy malaria and we hypothesize that exacerbated innate inflammatory responses to Plasmodium infected red blood cells trigger severe placenta pathology. This experimental model provides an opportunity to identify cell and molecular components of severe PAM pathogenesis and to investigate the inflammatory response that leads to the observed fetal and placental blood circulation abnormalities.	[Neres, Rita; Marinho, Claudio R. F.; Goncalves, Ligia A.; Penha-Goncalves, Carlos] Gulbenkian Inst Sci, Oeiras, Portugal; [Catarino, Manuela Beirao] Univ Lisbon, Fac Farm, Lisbon, Portugal	Universidade de Lisboa	Neres, R (corresponding author), Gulbenkian Inst Sci, Oeiras, Portugal.	cpenha@igc.gulbenkian.pt	Penha-Goncalves, Carlos/F-4640-2012; Gonçalves, Lígia Antunes/F-6242-2014; Marinho, Claudio Romero Farias/F-7507-2012	Gonçalves, Lígia Antunes/0000-0001-9804-6899; Marinho, Claudio Romero Farias/0000-0002-1227-3845; Penha-Goncalves, Carlos/0000-0001-7225-1907; Neres, Rita/0000-0003-1794-4377	Fundacao para a Ciencia e Tecnologia, Portugal	Fundacao para a Ciencia e Tecnologia, Portugal(Portuguese Foundation for Science and Technology)	This work, RN and CRFM were supported by the Fundacao para a Ciencia e Tecnologia, Portugal. Fundacao para a Ciencia e Tecnologia had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript	Adachi M, 2000, J PARASITOL, V86, P1030, DOI 10.1645/0022-3395(2000)086[1030:SPIBCM]2.0.CO;2; Adamson SL, 2002, DEV BIOL, V250, P358, DOI 10.1006/dbio.2002.0773; AKINGBADE OA, 1992, J REPROD MED, V37, P273; Albieri A, 2005, REPROD BIOL ENDOCRIN, V3, DOI 10.1186/1477-7827-3-34; Alkhalil A, 2000, J BIOL CHEM, V275, P40357, DOI 10.1074/jbc.M006399200; Amarante-Paffaro A, 2004, REPRODUCTION, V128, P207, DOI 10.1530/rep.1.00214; Beeson JG, 2004, J INFECT DIS, V189, P169, DOI 10.1086/380975; Beeson JG, 2000, NAT MED, V6, P86, DOI 10.1038/71582; Benirschke K, 1998, CLIN ANAT, V11, P194, DOI 10.1002/(SICI)1098-2353(1998)11:3<194::AID-CA8>3.0.CO;2-T; Brabin BJ, 2004, ANN TROP PAEDIATR, V24, P311, DOI 10.1179/027249304225019136; Brabin BJ, 2004, PLACENTA, V25, P359, DOI 10.1016/j.placenta.2003.10.019; CHAOUAT G, 1983, IMMUNOL REV, V75, P31, DOI 10.1111/j.1600-065X.1983.tb01090.x; Cot M, 1998, ANN TROP MED PARASIT, V92, P37, DOI 10.1080/00034989860157; Cross JC, 2002, MOL CELL ENDOCRINOL, V187, P207, DOI 10.1016/S0303-7207(01)00703-1; CURRIE GA, 1967, LANCET, V1, P708; Davison BB, 2000, AM J TROP MED HYG, V63, P158, DOI 10.4269/ajtmh.2000.63.158; de Pee S, 2002, J NUTR, V132, P2215, DOI 10.1093/jn/132.8.2215; Desai M, 2007, LANCET INFECT DIS, V7, P93, DOI 10.1016/S1473-3099(07)70021-X; DESOWITZ RS, 1989, AM J TROP MED HYG, V41, P630, DOI 10.4269/ajtmh.1989.41.630; Desowitz RS, 1999, ANN TROP MED PARASIT, V93, P415, DOI 10.1080/00034989958429; DESOWITZ RS, 2001, MALARIA PREGNANCY; Diouf I, 2004, J INFECT DIS, V189, P2235, DOI 10.1086/420791; Engwerda CR, 2005, TRENDS PARASITOL, V21, P75, DOI 10.1016/j.pt.2004.11.008; Fievet N, 1995, AM J TROP MED HYG, V53, P612; Freyre A, 2006, EXP PARASITOL, V113, P154, DOI 10.1016/j.exppara.2005.12.019; Fried M, 2000, EXP PARASITOL, V95, P75, DOI 10.1006/expr.2000.4510; Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502; Fusai T, 2000, MOL BIOCHEM PARASIT, V108, P25, DOI 10.1016/S0166-6851(00)00199-7; Georgiades P, 2002, PLACENTA, V23, P3, DOI 10.1053/plac.2001.0738; GREENWOOD AM, 1992, T ROY SOC TROP MED H, V86, P483, DOI 10.1016/0035-9203(92)90078-Q; GUILBERT L, 1993, IMMUNOL CELL BIOL, V71, P49, DOI 10.1038/icb.1993.5; Guleria I, 2000, NAT MED, V6, P589, DOI 10.1038/75074; HIOKI A, 1990, J PROTOZOOL, V37, P163, DOI 10.1111/j.1550-7408.1990.tb01121.x; Hviid L, 2004, PARASITE IMMUNOL, V26, P477, DOI 10.1111/j.0141-9838.2004.00733.x; HVIID L, 2007, AM J PATHOL, V6, P6; Janse CJ, 2006, NAT PROTOC, V1, P614, DOI 10.1038/nprot.2006.88; Janse CJ, 2006, NAT PROTOC, V1, P346, DOI 10.1038/nprot.2006.53; JANSE CJ, 1994, METHOD CELL BIOL, V42, P295; Janse CJ, 2006, MOL BIOCHEM PARASIT, V145, P60, DOI 10.1016/j.molbiopara.2005.09.007; Krishnan L, 1996, J IMMUNOL, V156, P644; le Cessie S, 2002, ARCH DIS CHILD-FETAL, V86, P182, DOI 10.1136/fn.86.3.F182; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; MCGREGOR IA, 1983, T ROY SOC TROP MED H, V77, P232, DOI 10.1016/0035-9203(83)90081-0; MCGREGOR IA, 1984, AM J TROP MED HYG, V33, P517, DOI 10.4269/ajtmh.1984.33.517; MENENDEZ C, 1995, PARASITOL TODAY, V11, P178, DOI 10.1016/0169-4758(95)80151-0; Muthusamy A, 2004, AM J PATHOL, V164, P2013, DOI 10.1016/S0002-9440(10)63761-3; Muthusamy A, 2007, AM J PATHOL, V170, P1989, DOI 10.2353/ajpath.2007.061238; Ndam NGT, 2004, J INFECT DIS, V190, P2001, DOI 10.1086/425521; Nosten F, 2004, TRENDS PARASITOL, V20, P425, DOI 10.1016/j.pt.2004.06.007; ODUOLA AMJ, 1982, J PROTOZOOL, V29, P77, DOI 10.1111/j.1550-7408.1982.tb02883.x; ODUOLA AMJ, 1986, EXP PARASITOL, V62, P181, DOI 10.1016/0014-4894(86)90022-6; PATHAK G, 1990, Journal of Hygiene Epidemiology Microbiology and Immunology (Prague), V34, P139; PAVIA CS, 1991, AM J TROP MED HYG, V44, P176, DOI 10.4269/ajtmh.1991.44.176; Poovassery J, 2006, INFECT IMMUN, V74, P2839, DOI 10.1128/IAI.74.5.2839-2848.2006; Pouvelle B, 1998, INFECT IMMUN, V66, P4950, DOI 10.1128/IAI.66.10.4950-4956.1998; Rasti N, 2006, P NATL ACAD SCI USA, V103, P13795, DOI 10.1073/pnas.0601519103; RILEY EM, 1989, AM J TROP MED HYG, V40, P141, DOI 10.4269/ajtmh.1989.40.141; Rogerson SJ, 2007, LANCET INFECT DIS, V7, P105, DOI 10.1016/S1473-3099(07)70022-1; Rossant J, 2001, NAT REV GENET, V2, P538, DOI 10.1038/35080570; SALAFIA CM, 1995, AM J OBSTET GYNECOL, V173, P1058, DOI 10.1016/0002-9378(95)91326-2; Schofield L, 2005, NAT REV IMMUNOL, V5, P722, DOI 10.1038/nri1686; Schwarzer E, 2001, PARASITOLOGY, V123, P125, DOI 10.1017/S0031182001008216; Shulman CE, 1996, T ROY SOC TROP MED H, V90, P535, DOI 10.1016/S0035-9203(96)90312-0; Smith NC, 1996, PARASITOL TODAY, V12, P4, DOI 10.1016/0169-4758(96)80637-5; Steketee RW, 1996, AM J TROP MED HYG, V55, P33, DOI 10.4269/ajtmh.1996.55.33; Steketee RW, 2001, AM J TROP MED HYG, V64, P28, DOI 10.4269/ajtmh.2001.64.28; Suguitan AL, 2003, J INFECT DIS, V188, P1074, DOI 10.1086/378500; Sullivan AD, 2000, PLACENTA, V21, P417, DOI 10.1053/plac.1999.0479; Sullivan AD, 1999, J INFECT DIS, V179, P1580, DOI 10.1086/314752; TEGOSHI T, 1992, AM J TROP MED HYG, V47, P643, DOI 10.4269/ajtmh.1992.47.643; VANZON AAJC, 1980, TROPENMED PARASITOL, V31, P402; VANZON AAJC, 1980, INFECT IMMUN, V28, P630; WALTER PR, 1982, AM J PATHOL, V109, P330	73	81	83	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1608	10.1371/journal.pone.0001608	http://dx.doi.org/10.1371/journal.pone.0001608			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270595	Green Published, gold, Green Submitted			2022-12-25	WOS:000260535900042
J	Opiyo, N; Were, F; Govedi, F; Fegan, G; Wasunna, A; English, M				Opiyo, Newton; Were, Fred; Govedi, Fridah; Fegan, Greg; Wasunna, Aggrey; English, Mike			Effect of Newborn Resuscitation Training on Health Worker Practices in Pumwani Hospital, Kenya	PLOS ONE			English	Article							NEONATAL RESUSCITATION; DELIVERY; MULTICENTER	Background: Birth asphyxia kills 0.7 to 1.6 million newborns a year globally with 99% of deaths in developing countries. Effective newborn resuscitation could reduce this burden of disease but the training of health-care providers in low income settings is often outdated. Our aim was to determine if a simple one day newborn resuscitation training (NRT) alters health worker resuscitation practices in a public hospital setting in Kenya. Methods/Principal Findings: We conducted a randomised, controlled trial with health workers receiving early training with NRT (n = 28) or late training (the control group, n = 55). The training was adapted locally from the approach of the UK Resuscitation Council. The primary outcome was the proportion of appropriate initial resuscitation steps with the frequency of inappropriate practices as a secondary outcome. Data were collected on 97 and 115 resuscitation episodes over 7 weeks after early training in the intervention and control groups respectively. Trained providers demonstrated a higher proportion of adequate initial resuscitation steps compared to the control group (trained 66% vs control 27%; risk ratio 2.45, [95% CI 1.75-3.42], p<0.001, adjusted for clustering). In addition, there was a statistically significant reduction in the frequency of inappropriate and potentially harmful practices per resuscitation in the trained group (trained 0.53 vs control 0.92; mean difference 0.40, [95% CI 0.13-0.66], p = 0.004). Conclusions/Significance: Implementation of a simple, one day newborn resuscitation training can be followed immediately by significant improvement in health workers' practices. However, evidence of the effects on long term performance or clinical outcomes can only be established by larger cluster randomised trials.	[Opiyo, Newton; Fegan, Greg; English, Mike] Kenya Govt Med Res Ctr, Wellcome Trust Res Programme, Nairobi, Kenya; [Were, Fred; Wasunna, Aggrey] Univ Nairobi, Coll Hlth Sci, Dept Paediat & Child Hlth, Nairobi, Kenya; [Govedi, Fridah] Pumwani Maternity Hosp, Nairobi, Kenya; [Fegan, Greg] London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London, England; [English, Mike] Univ Oxford, Dept Paediat, Oxford, England	Kenya Medical Research Institute; University of Nairobi; University of London; London School of Hygiene & Tropical Medicine; University of Oxford	Opiyo, N (corresponding author), Kenya Govt Med Res Ctr, Wellcome Trust Res Programme, Nairobi, Kenya.	nopiyo@nairobi.kemri-wellcome.org	Fegan, Greg W/O-8079-2018	Fegan, Greg W/0000-0002-2663-2765; English, Michael/0000-0002-7427-0826	Laerdal Foundation of Acute Medicine, Norway; Wellcome Trust [076827]	Laerdal Foundation of Acute Medicine, Norway; Wellcome Trust(Wellcome TrustEuropean Commission)	This study was supported in part by a grant from the Laerdal Foundation of Acute Medicine, Norway and in part by a Wellcome Trust Senior Research Fellowship awarded to Mike English (#076827). The Laerdal foundation had no role in the design or conduct of the study, made no contribution to the data analysis nor report writing and their permission to publish the results was not sought.	Baskett PJF, 2005, RESUSCITATION, V67, pS181, DOI 10.1016/j.resuscitation.2005.10.006; BERDEN H, 1983, BRIT MED J, V306, P1576; Carbine DN, 2000, PEDIATRICS, V106, P654, DOI 10.1542/peds.106.4.654; Durojaiye L, 2002, J PAEDIATR CHILD H, V38, P241, DOI 10.1046/j.1440-1754.2002.00773.x; English M, 2004, LANCET, V364, P1622, DOI 10.1016/S0140-6736(04)17318-2; HALLIDAY HL, 2001, COCHRANE DATABASE SY, V2; Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319; *INT LIA COMM RES, 2005, RESUSCITATION, V67; Jabbour M, 1996, ANN EMERG MED, V28, P690, DOI 10.1016/S0196-0644(96)70095-1; Jewkes F, 2003, ARCH DIS CHILD, V88, P118, DOI 10.1136/adc.88.2.118; Kamenir SA, 1997, J TROP PEDIATRICS, V43, P170, DOI 10.1093/tropej/43.3.170; MCKENNA SP, 1985, J OCCUP PSYCHOL, V58, P109, DOI 10.1111/j.2044-8325.1985.tb00186.x; O'Hare BA, 2006, J TROP PEDIATRICS, V52, P376, DOI 10.1093/tropej/fml027; OPIYO N, 2006, T R SOC TROP MED HYG, V100, P899; Quan L, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.6.e110; Rowe AK, 2002, INT J QUAL HEALTH C, V14, P521, DOI 10.1093/intqhc/14.6.521; TAN A, 2004, COCHRANE DATABASE SY; Vain NE, 2004, LANCET, V364, P597, DOI 10.1016/S0140-6736(04)16852-9; *WHO, 1997, BAS NEWB RES PRACT G; Wiswell TE, 2000, PEDIATRICS, V105, P1, DOI 10.1542/peds.105.1.1; World Health Organization, 2005, WORLD HLTH REP 2005	21	48	48	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1599	10.1371/journal.pone.0001599	http://dx.doi.org/10.1371/journal.pone.0001599			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270586	Green Published, Green Accepted, Green Submitted, gold			2022-12-25	WOS:000260535900033
J	Koerner-Rettberg, C; Doths, S; Stroet, A; Schwarze, J				Koerner-Rettberg, Cordula; Doths, Sandra; Stroet, Anke; Schwarze, Juergen			Reduced Lung Function in a Chronic Asthma Model Is Associated with Prolonged Inflammation, but Independent of Peribronchial Fibrosis	PLOS ONE			English	Article								Background: In asthma, mechanisms contributing to chronicity remain to be determined. Recent models of sensitisation with prolonged airway allergen challenges reproduce typical features of chronic asthma. However, the interplay between inflammation, structural changes and lung function is poorly understood. This study was performed to delineate functional, structural and immunological airway changes after cessation of long term challenges to elucidate factors contributing to the development of prolonged lung function changes. Methodology/Principal Findings: Mice sensitised systemically were consecutively challenged intranasally with ovalbumin for two or eight weeks. After the end of challenges, lung function, airway inflammation, features of airway remodelling, local T-cell cytokines and systemic ovalbumin-specific antibodies were monitored. Long term challenges resulted in airway hyperresponsiveness lasting 2 weeks and reduced baseline lung function for 6 weeks after their cessation. In contrast, these changes resolved within one week after short term challenges. Prolonged transforming growth factor beta (TGF-beta)1 production and marked peribronchial fibrosis were only induced by long term challenges. Importantly, fibrosis became apparent only after the onset of lung function changes and outlasted them. Further, long term challenges led to prolonged and intense airway inflammation with marked lymphocytosis, but moderate eosinophilia, sustained IL-5 production and ovalbumin-specific IgG2a antibodies, the latter suggesting a Th1 component to the immune response. In contrast, following short term challenges airway inflammation was dominated by eosinophils and associated with a strong, but transient IL-13 response. Conclusions: Prolonged lung function changes after long term allergen challenges seem to develop and resolve independently of the persistent peribronchial fibrosis. They are more closely associated with intense airway inflammation, marked lymphocytosis, prolonged IL-5 and TGF-beta 1 production in the airways and a Th1 immune response.	[Koerner-Rettberg, Cordula; Doths, Sandra; Stroet, Anke; Schwarze, Juergen] Ruhr Univ Bochum, Childrens Hosp, Bochum, Germany; [Schwarze, Juergen] Univ Edinburgh, Queens Med Res Inst, Ctr Inflammation Res, Edinburgh, Midlothian, Scotland	Ruhr University Bochum; University of Edinburgh	Koerner-Rettberg, C (corresponding author), Ruhr Univ Bochum, Childrens Hosp, Bochum, Germany.	jurgen.schwarze@ed.ac.uk	Schwarze, Jürgen/F-7396-2011; Salmen, Anke/S-9681-2018; Koerner-Rettberg, Cordula/AGI-3532-2022	Salmen, Anke/0000-0002-4751-299X; Koerner-Rettberg, Cordula/0000-0003-0946-1009; Schwarze, Jurgen/0000-0002-6899-748X	Deutsche Forschungsgemeinschaft [Schw 597/2-1]; Bundesministerium fur Bildung und Forschung [01GC9802]; Wellcome Trust [067454]; Medical Research Council [G9900991B] Funding Source: researchfish	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); Wellcome Trust(Wellcome TrustEuropean Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	These studies were supported by the following grants to JS: Schw 597/2-1 from Deutsche Forschungsgemeinschaft, 01GC9802 from Bundesministerium fur Bildung und Forschung and 067454 from the Wellcome Trust.	[Anonymous], 1998, LANCET, V351, P1225; Bento AM, 1998, ALLERGY ASTHMA PROC, V19, P353, DOI 10.2500/108854198778612672; Branton MH, 1999, MICROBES INFECT, V1, P1349, DOI 10.1016/S1286-4579(99)00250-6; BRUSASCO V, 1990, J APPL PHYSIOL, V69, P2209, DOI 10.1152/jappl.1990.69.6.2209; CEMBRZYNSKANOWAK M, 1993, AM REV RESPIR DIS, V147, P291, DOI 10.1164/ajrccm/147.2.291; Cho JY, 2004, J CLIN INVEST, V113, P551, DOI 10.1172/JCI200419133; Cieslewicz G, 1999, J CLIN INVEST, V104, P301, DOI 10.1172/JCI7010; Corbel M, 2003, CLIN EXP ALLERGY, V33, P696, DOI 10.1046/j.1365-2222.2003.01581.x; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970, DOI 10.1164/ajrccm/141.4_Pt_1.; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hamelmann E, 1999, INT ARCH ALLERGY IMM, V118, P90, DOI 10.1159/000024037; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Hamelmann E, 2001, IMMUNOL REV, V179, P182, DOI 10.1034/j.1600-065X.2001.790118.x; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hansen G, 2000, J CLIN INVEST, V105, P61, DOI 10.1172/JCI7589; Henderson WR, 2002, AM J RESP CRIT CARE, V165, P108, DOI 10.1164/ajrccm.165.1.2105051; Jain VV, 2002, J ALLERGY CLIN IMMUN, V110, P867, DOI 10.1067/mai.2002.129371; Johnson JR, 2004, AM J RESP CRIT CARE, V169, P378, DOI 10.1164/rccm.200308-1094OC; KOVACS EJ, 1994, FASEB J, V8, P854, DOI 10.1096/fasebj.8.11.7520879; Kumar RK, 2004, AM J RESP CRIT CARE, V170, P1043, DOI 10.1164/rccm.200405-681OC; Kumar RK, 2002, CLIN EXP ALLERGY, V32, P1104, DOI 10.1046/j.1365-2222.2002.01420.x; Kumar RK, 2002, AM J RESP CELL MOL, V27, P267, DOI 10.1165/rcmb.F248; Leigh R, 2004, J APPL PHYSIOL, V97, P2258, DOI 10.1152/japplphysiol.00597.2004; Leigh R, 2004, AM J RESP CRIT CARE, V170, P851, DOI 10.1164/rccm.200311-1488OC; Leigh R, 2004, AM J RESP CRIT CARE, V169, P860, DOI 10.1164/rccm.200305-706OC; Leigh R, 2002, AM J RESP CELL MOL, V27, P526, DOI 10.1165/rcmb.2002-0048OC; Locke NR, 2007, AM J RESP CELL MOL, V36, P625, DOI 10.1165/rcmb.2006-0083OC; Mcmillan SJ, 2004, CLIN EXP ALLERGY, V34, P497, DOI 10.1111/j.1365-2222.2004.01895.x; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; Renauld JC, 2001, J CLIN PATHOL, V54, P577, DOI 10.1136/jcp.54.8.577; Richter A, 2001, AM J RESP CELL MOL, V25, P385, DOI 10.1165/ajrcmb.25.3.4437; ROCHE WR, 1989, LANCET, V1, P520; Shinagawa K, 2003, AM J RESP CRIT CARE, V168, P959, DOI 10.1164/rccm.200210-1188OC; Temelkovski J, 1998, THORAX, V53, P849, DOI 10.1136/thx.53.10.849; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; Wegmann M, 2005, CLIN EXP ALLERGY, V35, P1263, DOI 10.1111/j.1365-2222.2005.02306.x; Werfel T, 1996, J INVEST DERMATOL, V107, P871, DOI 10.1111/1523-1747.ep12331164	38	12	12	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2008	3	2							e1575	10.1371/journal.pone.0001575	http://dx.doi.org/10.1371/journal.pone.0001575			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367EQ	18253511	Green Published, Green Submitted, gold			2022-12-25	WOS:000260535700035
J	Martinelli, N; Trabetti, E; Pinotti, M; Olivieri, O; Sandri, M; Friso, S; Pizzolo, F; Bozzini, C; Caruso, PP; Cavallari, U; Cheng, S; Pignatti, PF; Bernardi, F; Corrocher, R; Girelli, D				Martinelli, Nicola; Trabetti, Elisabetta; Pinotti, Mirko; Olivieri, Oliviero; Sandri, Marco; Friso, Simonetta; Pizzolo, Francesca; Bozzini, Claudia; Caruso, Pier Paolo; Cavallari, Ugo; Cheng, Suzanne; Pignatti, Pier Franco; Bernardi, Francesco; Corrocher, Roberto; Girelli, Domenico			Combined Effect of Hemostatic Gene Polymorphisms and the Risk of Myocardial Infarction in Patients with Advanced Coronary Atherosclerosis	PLOS ONE			English	Article								Background. Relative little attention has been devoted until now to the combined effects of gene polymorphisms of the hemostatic pathway as risk factors for Myocardial Infarction (MI), the main thrombotic complication of Coronary Artery Disease (CAD). The aim of this study was to evaluate the combined effect of ten common prothrombotic polymorphisms as a determinant of MI. Methodology/Principal Findings. We studied a total of 804 subjects, 489 of whom with angiographically proven severe CAD, with or without MI (n=307; n=182; respectively). An additive model considering ten common polymorphisms [Prothrombin 20210G > A, PAI-1 4G/5G, Fibrinogen beta-455G > A, FV Leiden and "R2'', FVII-402G > A and -323 del/ins, Platelet ADP Receptor P2Y12-744T > C, Platelet Glycoproteins Ia (873G > A), and IIIa (1565T > C)] was tested. The prevalence of MI increased linearly with an increasing number of unfavorable alleles (chi(2) for trend=10.68; P=0.001). In a multiple logistic regression model, the number of unfavorable alleles remained significantly associated with MI after adjustment for classical risk factors. As compared to subjects with 3-7 alleles, those with few (<= 2) alleles had a decreased MI risk (OR 0.34, 95%CIs 0.13-0.93), while those with more (>= 8) alleles had an increased MI risk (OR 2.49, 95%CIs 1.03-6.01). The number of procoagulant alleles correlated directly (r=0.49, P=0.006) with endogenous thrombin potential. Conclusions. The combination of prothrombotic polymorphisms may help to predict MI in patients with advanced CAD.	[Martinelli, Nicola; Olivieri, Oliviero; Sandri, Marco; Friso, Simonetta; Pizzolo, Francesca; Bozzini, Claudia; Corrocher, Roberto; Girelli, Domenico] Univ Verona, Dept Clin & Expt Med, I-37100 Verona, Italy; [Trabetti, Elisabetta; Cavallari, Ugo; Pignatti, Pier Franco] Univ Verona, Dept Mother & Child & Biol Genet, Sect Biol & Genet, Verona, Italy; [Pinotti, Mirko; Caruso, Pier Paolo; Bernardi, Francesco] Univ Ferrara, Dept Biochem & Mol Biol, Ferrara, Italy; [Cheng, Suzanne] Roche Molecular Systems Inc, Dept Human Genet, Alameda, CA USA	University of Verona; University of Verona; University of Ferrara; Roche Holding	Martinelli, N (corresponding author), Univ Verona, Dept Clin & Expt Med, I-37100 Verona, Italy.		Martinelli, Nicola/J-5622-2016; Olivieri, Oliviero/A-9126-2008; Girelli, Domenico/B-1183-2008; bernardi, francesco/F-5443-2013; Friso, Simonetta/K-4715-2016; Sandri, Marco/L-2875-2013; Pizzolo, Francesca/AAF-6581-2020	Martinelli, Nicola/0000-0001-6465-5119; Olivieri, Oliviero/0000-0001-8209-9056; Girelli, Domenico/0000-0001-9684-1899; Sandri, Marco/0000-0002-1422-5695; Pizzolo, Francesca/0000-0003-4419-3994; Cavallari, Ugo/0000-0002-3395-4033; Pinotti, Mirko/0000-0002-4114-7055	Italian Ministry of University and Research [2005/065152]; Veneto Region; Cariverona Foundation, Verona, Italy	Italian Ministry of University and Research(Ministry of Education, Universities and Research (MIUR)); Veneto Region(Regione Veneto); Cariverona Foundation, Verona, Italy(Fondazione Cariverona)	Supported by grants from the Italian Ministry of University and Research (grant no. 2005/065152), the Veneto Region, and the Cariverona Foundation, Verona, Italy. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ajjan R, 2006, ATHEROSCLEROSIS, V186, P240, DOI 10.1016/j.atherosclerosis.2005.10.042; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; Bozzini C, 2004, THROMB HAEMOSTASIS, V92, P541, DOI 10.1160/Th04-02-0130; Brummel-Ziedins KE, 2005, J THROMB HAEMOST, V3, P2497, DOI 10.1111/j.1538-7836.2005.01584.x; Castoldi E, 2000, THROMB HAEMOSTASIS, V83, P362, DOI 10.1055/s-0037-1613821; Cheng S, 1999, GENOME RES, V9, P936, DOI 10.1101/gr.9.10.936; Colhoun HM, 2003, LANCET, V361, P865, DOI 10.1016/S0140-6736(03)12715-8; Collins A, 1996, P NATL ACAD SCI USA, V93, P9177, DOI 10.1073/pnas.93.17.9177; DAWSON SJ, 1993, J BIOL CHEM, V268, P10739; Eitzman DT, 2005, CIRCULATION, V111, P1822, DOI 10.1161/01.CIR.0000160854.75779.E8; Fontana P, 2003, CIRCULATION, V108, P2971, DOI 10.1161/01.CIR.0000106904.80795.35; Friedman JH, 2001, ANN STAT, V29, P1189, DOI 10.1214/aos/1013203451; Girelli D, 2000, NEW ENGL J MED, V343, P774, DOI 10.1056/NEJM200009143431104; Hemker HC, 2000, THROMB HAEMOSTASIS, V83, P589; Hemker HC, 2003, PATHOPHYSIOL HAEMO T, V33, P4, DOI 10.1159/000071636; Horvath S, 2001, EUR J HUM GENET, V9, P301, DOI 10.1038/sj.ejhg.5200625; Ioannidis JPA, 2003, LANCET, V361, P567, DOI 10.1016/S0140-6736(03)12516-0; Janssens ACJW, 2004, AM J HUM GENET, V74, P585, DOI 10.1086/382052; Lane DA, 2000, BLOOD, V95, P1517, DOI 10.1182/blood.V95.5.1517.005k48_1517_1532; Lentz SR, 2005, CIRCULATION, V111, P1733, DOI 10.1161/01.CIR.0000162489.34887.FA; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; MORANGE PE, 2006, J THROMB HAEMOS 0104; Morrison AC, 2007, AM J EPIDEMIOL, V166, P28, DOI 10.1093/aje/kwm060; MORTON NE, 1974, AM J HUM GENET, V26, P318; Naghavi M, 2003, CIRCULATION, V108, P1664, DOI 10.1161/01.CIR.0000087480.94275.97; Pharoah PDP, 2002, NAT GENET, V31, P33, DOI 10.1038/ng853; Pinotti M, 2000, BLOOD, V95, P3423, DOI 10.1182/blood.V95.11.3423.011k04_3423_3428; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; Regnault W, 2003, PATHOPHYSIOL HAEMO T, V33, P23, DOI 10.1159/000071638; Rosenberg RD, 1999, NEW ENGL J MED, V340, P1555, DOI 10.1056/NEJM199905203402007; Santoso S, 1999, BLOOD, V93, P2449, DOI 10.1182/blood.V93.8.2449.408k34_2449_2453; Scanavini D, 2004, ARTERIOSCL THROM VAS, V24, P200, DOI 10.1161/01.ATV.0000109750.34073.f6; Schettert IT, 2006, THROMB RES, V118, P679, DOI 10.1016/j.thromres.2005.11.009; Smith A, 2005, CIRCULATION, V112, P3080, DOI 10.1161/CIRCULATIONAHA.105.557132; van't Hooft FM, 1999, ARTERIOSCL THROM VAS, V19, P3063, DOI 10.1161/01.ATV.19.12.3063; van't Hooft FM, 1999, BLOOD, V93, P3432, DOI 10.1182/blood.V93.10.3432.410k16_3432_3441; Voetsch B, 2004, ARTERIOSCL THROM VAS, V24, P216, DOI 10.1161/01.ATV.0000107402.79771.fc; Watkins H, 2006, NAT REV GENET, V7, P163, DOI 10.1038/nrg1805; Weedon MN, 2006, PLOS MED, V3, P1877, DOI 10.1371/journal.pmed.0030374; Weiss EJ, 1996, NEW ENGL J MED, V334, P1090, DOI 10.1056/NEJM199604253341703; Yang QH, 2005, INT J EPIDEMIOL, V34, P1129, DOI 10.1093/ije/dyi130; Ye Z, 2006, LANCET, V367, P651, DOI 10.1016/S0140-6736(06)68263-9; Zee RYL, 2004, HUM MOL GENET, V13, P389, DOI 10.1093/hmg/ddh039	44	31	34	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2008	3	2							e1523	10.1371/journal.pone.0001523	http://dx.doi.org/10.1371/journal.pone.0001523			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367EQ	18253477	Green Published, Green Submitted, gold			2022-12-25	WOS:000260535700001
J	Santillan, M; Mackey, MC				Santillan, Moises; Mackey, Michael C.			A Proposed Mechanism for the Interaction of the Segmentation Clock and the Determination Front in Somitogenesis	PLOS ONE			English	Article							VERTEBRATE SEGMENTATION; PRESOMITIC MESODERM; GENE-EXPRESSION; WNT; HES1	Background: Recent discoveries in the field of somitogenesis have confirmed, for the most part, the feasibility of the clock and wavefront model. There are good candidates for both the clock (various genes expressed cyclically in the tail bud of vertebrate embryos have been discovered) and the wavefront (there are at least three different substances, whose expression levels vary along the presomitic mesoderm [PSM], that have important effects on the formation of somites). Nevertheless, the mechanisms through which the wavefront interacts with the clock to arrest the oscillations and induce somite formation have not yet been fully elucidated. Principal Findings: In this work, we propose a gene regulatory network which is consistent with all known experimental facts in embryonic mice, and whose dynamic behaviour provides a potential explanation for the periodic aggregation of PSM cells into blocks: the first step leading to the formation of somites. Significance: To our knowledge, this is the first proposed mechanism that fully explains how a block of PSM cells can stop oscillating simultaneously, and how this process is repeated periodically, via the interaction of the segmentation clock and the determination front.	[Santillan, Moises; Mackey, Michael C.] IPN, Ctr Invest & Estudios Avanzados, Apodaca, Nuevo Leon, Mexico; [Santillan, Moises] McGill Univ, Ctr Nonlinear Dynam, Montreal, PQ, Canada	Instituto Politecnico Nacional - Mexico; McGill University	Santillan, M (corresponding author), IPN, Ctr Invest & Estudios Avanzados, Campus Monterrey, Apodaca, Nuevo Leon, Mexico.	moises.santillan@mac.com	Santillan, Moises/A-2942-2008	Santillan, Moises/0000-0001-8605-7451; Mackey, Michael/0000-0002-8524-2396	Consejo Nacional de Ciencia y Tecnologia (CONACyT, MEXICO); National Science Foundation (USA) [PHY05-51164]; Mathematics of Information Technology and Complex Systems (MITACS) Canada; Natural Sciences and Engineering Research Council (NSERC) Canada	Consejo Nacional de Ciencia y Tecnologia (CONACyT, MEXICO)(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); National Science Foundation (USA)(National Science Foundation (NSF)); Mathematics of Information Technology and Complex Systems (MITACS) Canada; Natural Sciences and Engineering Research Council (NSERC) Canada(Natural Sciences and Engineering Research Council of Canada (NSERC))	This research was partially supported by Consejo Nacional de Ciencia y Tecnologia (CONACyT, MEXICO), the National Science Foundation (USA) under Grant No. PHY05-51164, the Mathematics of Information Technology and Complex Systems (MITACS) Canada, and the Natural Sciences and Engineering Research Council (NSERC) Canada.	Aulehla A, 2004, GENE DEV, V18, P2060, DOI 10.1101/gad.1217404; Aulehla A, 2003, DEV CELL, V4, P395, DOI 10.1016/S1534-5807(03)00055-8; Aulehla A, 2006, ANAT EMBRYOL, V211, pS3, DOI 10.1007/s00429-006-0124-y; Bernard S, 2006, PHILOS T R SOC A, V364, P1155, DOI 10.1098/rsta.2006.1761; COOKE J, 1976, J THEOR BIOL, V58, P455, DOI 10.1016/S0022-5193(76)80131-2; Diez del Corral R, 2004, BIOESSAYS, V26, P857, DOI 10.1002/bies.20080; Dubrulle J, 2001, CELL, V106, P219, DOI 10.1016/S0092-8674(01)00437-8; Galceran J, 2004, GENE DEV, V18, P2718, DOI 10.1101/gad.1249504; Giudicelli F, 2004, CURR OPIN GENET DEV, V14, P407, DOI 10.1016/j.gde.2004.06.014; Goldbeter A, 2007, DEV DYNAM, V236, P1495, DOI 10.1002/dvdy.21193; Hirata H, 2004, NAT GENET, V36, P750, DOI 10.1038/ng1372; Hofmann M, 2004, GENE DEV, V18, P2712, DOI 10.1101/gad.1248604; Ishikawa A, 2004, MECH DEVELOP, V121, P1443, DOI 10.1016/j.mod.2004.08.003; Lewis J, 2003, CURR BIOL, V13, P1398, DOI 10.1016/S0960-9822(03)00534-7; Monk NAM, 2003, CURR BIOL, V13, P1409, DOI 10.1016/S0960-9822(03)00494-9; Palmeirim I, 1997, CELL, V91, P639, DOI 10.1016/S0092-8674(00)80451-1; Pourquie O, 2001, ANNU REV CELL DEV BI, V17, P311, DOI 10.1146/annurev.cellbio.17.1.311; Rodriguez-Gonzalez JG, 2007, J THEOR BIOL, V248, P37, DOI 10.1016/j.jtbi.2007.05.003; Tiedemann HB, 2007, J THEOR BIOL, V248, P120, DOI 10.1016/j.jtbi.2007.05.014	19	27	27	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2008	3	2							e1561	10.1371/journal.pone.0001561	http://dx.doi.org/10.1371/journal.pone.0001561			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367EQ	18253505	gold, Green Submitted, Green Published			2022-12-25	WOS:000260535700029
J	Kump, E; Ji, J; Wernli, M; Hausermann, P; Erb, P				Kump, E.; Ji, J.; Wernli, M.; Haeusermann, P.; Erb, P.			Gli2 upregulates cFlip and renders basal cell carcinoma cells resistant to death ligand-mediated apoptosis	ONCOGENE			English	Article						Gli2; cFlip; apoptosis; basal cell carcinoma; gene silencing	HEDGEHOG SIGNALING PATHWAY; SKIN-CANCER; HUMAN EPIDERMIS; TUMOR-GROWTH; IN-VIVO; ACTIVATION; EXPRESSION; PROTEINS; INHIBITION; PROMOTER	Mutations in the Hedgehog signaling pathway is responsible for the formation of various cancers, including some forms of basal cell carcinoma (BCC). Uncontrolled Hedgehog signaling leads to overexpression of the zinc finger Gli transcription factors, among which Gli2 plays a central role. We found that high Gli2 expression induced the concomitant high expression of the caspase 8 inhibitor, cFlip, and thereby counteracts death-ligand-mediated apoptosis. By investigating the cFlip promoter, Gli2 binding sites were identified and confirmed. Gli2 gene silencing by RNA interference broke the apoptosis resistance via cFlip downregulation. The direct functional connection between Gli2 and cFlip was not only demonstrated in a keratinocytic cell line but also in BCC tissue. As cFlip and Bcl-2 are highly expressed in BCCs, as a consequence of high Gli2 expression, this may explain the marked resistance of the tumor to the extrinsic and intrinsic apoptotic pathway. We could now demonstrate that Gli2 gene silencing in BCC tissues made the tumor sensitive to TRAIL ( tumor necrosis factor-related apoptosis-inducing ligand)- mediated cell death by downregulating cFlip. As Gli2 silencing does not only downregulate cFlip, but also Bcl-2, Gli2 could be a key target for a novel therapeutic approach in tumors with dysregulated Hedgehog signaling.	[Kump, E.; Ji, J.; Wernli, M.; Erb, P.] Univ Basel, Dept Biomed, Inst Med Microbiol, CH-4003 Basel, Switzerland; [Haeusermann, P.] Univ Basel Hosp, Dept Dermatol, CH-4031 Basel, Switzerland	University of Basel; University of Basel	Erb, P (corresponding author), Univ Basel, Dept Biomed, Inst Med Microbiol, Peterspl 10, CH-4003 Basel, Switzerland.	peter.erb@unibas.ch						Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Bachmann F, 2001, J INVEST DERMATOL, V117, P59, DOI 10.1046/j.0022-202x.2001.01380.x; Bai CB, 2002, DEVELOPMENT, V129, P4753; Bigelow RLH, 2004, J BIOL CHEM, V279, P1197, DOI 10.1074/jbc.M310589200; Buechner SA, 1997, J CLIN INVEST, V100, P2691, DOI 10.1172/JCI119814; Callahan CA, 2001, CURR OPIN GENET DEV, V11, P541, DOI 10.1016/S0959-437X(00)00230-6; Cohen MM, 2003, AM J MED GENET A, V123A, P5, DOI 10.1002/ajmg.a.20495; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Daya-Grosjean L, 2005, CANCER LETT, V225, P181, DOI 10.1016/j.canlet.2004.10.003; Delehedde M, 1999, CANCER, V85, P1514, DOI 10.1002/(SICI)1097-0142(19990401)85:7<1514::AID-CNCR12>3.3.CO;2-H; Diepgen TL, 2002, BRIT J DERMATOL, V146, P1, DOI 10.1046/j.1365-2133.146.s61.2.x; Eichberger T, 2004, J INVEST DERMATOL, V122, P1180, DOI 10.1111/j.0022-202X.2004.22505.x; Eichberger T, 2006, GENOMICS, V87, P616, DOI 10.1016/j.ygeno.2005.12.003; Erb P, 2005, IMMUNOL LETT, V100, P68, DOI 10.1016/j.imlet.2005.06.008; Hutchin ME, 2005, GENE DEV, V19, P214, DOI 10.1101/gad.1258705; Igney FH, 2005, CANCER IMMUNOL IMMUN, V54, P1127, DOI 10.1007/s00262-005-0680-7; Ikram MS, 2004, J INVEST DERMATOL, V122, P1503, DOI 10.1111/j.0022-202X.2004.22612.x; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Ji J, 2005, GENE THER, V12, P678, DOI 10.1038/sj.gt.3302453; Ji J, 2008, INT J CANCER, V122, P50, DOI 10.1002/ijc.23023; Kasper M, 2006, EUR J CANCER, V42, P437, DOI 10.1016/j.ejca.2005.08.039; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; Mill P, 2003, GENE DEV, V17, P282, DOI 10.1101/gad.1038103; Miller KL, 2006, CARCINOGENESIS, V27, P1670, DOI 10.1093/carcin/bgi376; Nguyen V, 2005, DEVELOPMENT, V132, P3267, DOI 10.1242/dev.01905; Owens DM, 2003, NAT REV CANCER, V3, P444, DOI 10.1038/nrc1096; Park HL, 2000, DEVELOPMENT, V127, P1593; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; Regl G, 2004, CANCER RES, V64, P7724, DOI 10.1158/0008-5472.CAN-04-1085; Regl G, 2004, ONCOGENE, V23, P1263, DOI 10.1038/sj.onc.1207240; Trisciuoglio D, 2005, J CELL PHYSIOL, V205, P414, DOI 10.1002/jcp.20413; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	33	45	49	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2008	27	27					3856	3864		10.1038/onc.2008.5	http://dx.doi.org/10.1038/onc.2008.5			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18264131				2022-12-25	WOS:000256904700009
J	Badarau, A; Firbank, SJ; Waldron, KJ; Yanagisawa, S; Robinson, NJ; Banfield, MJ; Dennison, C				Badarau, Adriana; Firbank, Susan J.; Waldron, Kevin J.; Yanagisawa, Sachiko; Robinson, Nigel J.; Banfield, Mark J.; Dennison, Christopher			FutA2 is a ferric binding protein from Synechocystis PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDEPENDENT IRON COORDINATION; PATHOGENIC NEISSERIA; TRANSPORT PROTEIN; CRYSTAL-STRUCTURE; MANGANESE; IDENTIFICATION; MEMBRANE; ANION; IDIA; CYANOBACTERIA	Synechocystis PCC 6803 has a high demand for iron (10 times greater than Escherichia coli) to sustain photosynthesis and is unusual in possessing at least two putative iron-binding proteins of a type normally associated with ATP-binding cassette-type importers. It has been suggested that one of these, FutA2, binds ferrous iron, but herein we clearly demonstrate that this protein avidly binds Fe(III), the oxidation state preference of periplasmic iron-binding proteins. Structures of apo-FutA2 and Fe-FutA2 have been determined at 1.7 and 2.7 A, respectively. The metal ion is bound in a distorted trigonal bipyramidal arrangement with no exogenous anions as ligands. The metal-binding environment, including the second coordination sphere and charge properties, is consistent with a preference for Fe( III). Atypically, FutA2 has a Tat signal peptide, and its inability to coordinate divalent cations may be crucial to prevent metals from binding to the folded protein prior to export from the cytosol. A loop containing the His43 ligand undergoes considerable movement in apo-versus Fe-FutA2 and may control metal release to the importer. Although these data are consistent with FutA2 being the periplasmic component involved in iron uptake, deletion of another putative ferric binding protein, FutA1, has a greater effect on the accumulation of iron and is more analogous to a Delta futA1 Delta futA2 double mutant than Delta futA2. Here, we also discover that there is a reduced level of ferric FutA2 in the periplasm of the Delta futA1 mutant providing an explanation for its severe iron-uptake phenotype.	[Badarau, Adriana; Firbank, Susan J.; Waldron, Kevin J.; Yanagisawa, Sachiko; Robinson, Nigel J.; Banfield, Mark J.; Dennison, Christopher] Newcastle Univ, Sch Med, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Dennison, C (corresponding author), Newcastle Univ, Sch Med, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	christopher.dennison@ncl.ac.uk	Waldron, Kevin/J-2368-2016; Banfield, Mark/C-7453-2013; Waldron, Kevin John/HHM-8983-2022; Robinson, Nigel J/J-6363-2012	Waldron, Kevin/0000-0002-5577-7357; Banfield, Mark/0000-0001-8921-3835; Waldron, Kevin John/0000-0002-5577-7357; Robinson, Nigel J/0000-0001-5586-1092; Dennison, Christopher/0000-0001-8665-052X	Biotechnology and Biological Sciences Research Council [BB/E016529, BB/E016529/1, BB/E001688/1] Funding Source: Medline; BBSRC [BB/E001688/1, BB/E016529/1] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ADHIKARI P, 1995, J BIOL CHEM, V270, P25142, DOI 10.1074/jbc.270.42.25142; AISEN P, 1980, ANNU REV BIOCHEM, V49, P357, DOI 10.1146/annurev.bi.49.070180.002041; ANDERSON BF, 1987, P NATL ACAD SCI USA, V84, P1769, DOI 10.1073/pnas.84.7.1769; ANGERER A, 1990, J BACTERIOL, V172, P572, DOI 10.1128/jb.172.2.572-578.1990; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker E., 1994, ADV INORG CHEM, P389, DOI [10.1016/S0898-8838(08)60176-2, DOI 10.1016/S0898-8838(08)60176-2]; Baker EN, 1997, NAT STRUCT BIOL, V4, P869, DOI 10.1038/nsb1197-869; Baker HM, 2003, P NATL ACAD SCI USA, V100, P3579, DOI 10.1073/pnas.0637295100; Banci L, 2006, P NATL ACAD SCI USA, V103, P8320, DOI 10.1073/pnas.0600142103; Banerjee S, 2003, J MOL BIOL, V333, P1061, DOI 10.1016/j.jmb.2003.09.008; BARTSEVICH VV, 1995, EMBO J, V14, P1845, DOI 10.1002/j.1460-2075.1995.tb07176.x; Bartsevich VV, 1996, J BIOL CHEM, V271, P26057, DOI 10.1074/jbc.271.42.26057; Braun V, 1999, TRENDS BIOCHEM SCI, V24, P104, DOI 10.1016/S0968-0004(99)01359-6; Bruns CM, 1997, NAT STRUCT BIOL, V4, P919, DOI 10.1038/nsb1197-919; Bruns CM, 2001, BIOCHEMISTRY-US, V40, P15631, DOI 10.1021/bi0156759; CHEN CY, 1993, MOL MICROBIOL, V10, P311, DOI 10.1111/j.1365-2958.1993.tb01957.x; Clarke Teresa E., 2001, Current Topics in Medicinal Chemistry, V1, P7, DOI 10.2174/1568026013395623; Claverys JP, 2001, RES MICROBIOL, V152, P231, DOI 10.1016/S0923-2508(01)01195-0; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693; Fulda S, 2000, EUR J BIOCHEM, V267, P5900, DOI 10.1046/j.1432-1327.2000.01642.x; Guo ML, 2003, J BIOL CHEM, V278, P2490, DOI 10.1074/jbc.M208776200; HARRIS DC, 1973, BIOCHIM BIOPHYS ACTA, V329, P156, DOI 10.1016/0304-4165(73)90019-6; HARRIS WR, 1986, J INORG BIOCHEM, V27, P41, DOI 10.1016/0162-0134(86)80107-6; Huang F, 2006, PROTEOMICS, V6, P910, DOI 10.1002/pmic.200500114; Huang F, 2004, MOL CELL PROTEOMICS, V3, P586, DOI 10.1074/mcp.M300137-MCP200; Huang F, 2002, MOL CELL PROTEOMICS, V1, P956, DOI 10.1074/mcp.M200043-MCP200; Katoh H, 2001, PLANT CELL PHYSIOL, V42, P823, DOI 10.1093/pcp/pce106; Katoh H, 2001, J BACTERIOL, V183, P2779, DOI 10.1128/JB.183.9.2779-2784.2001; Keren N, 2004, PLANT PHYSIOL, V135, P1666, DOI 10.1104/pp.104.042770; Kleywegt G. J., 2001, INT TABLES CRYSTALLO, VF, P353, DOI DOI 10.1107/97809553602060000111; Koropatkin N, 2007, J BIOL CHEM, V282, P27468, DOI 10.1074/jbc.M704136200; Koster W, 2001, RES MICROBIOL, V152, P291, DOI 10.1016/S0923-2508(01)01200-1; Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; Lombardi A, 2000, P NATL ACAD SCI USA, V97, P11922, DOI 10.1073/pnas.97.22.11922; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Michel KP, 2004, PHYSIOL PLANTARUM, V120, P36, DOI 10.1111/j.0031-9317.2004.0229.x; Michel KP, 1998, PLANTA, V205, P73, DOI 10.1007/s004250050298; Miethke M, 2007, MICROBIOL MOL BIOL R, V71, P413, DOI 10.1128/MMBR.00012-07; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NEILANDS JB, 1981, ANNU REV BIOCHEM, V50, P715, DOI 10.1146/annurev.bi.50.070181.003435; NOWALK AJ, 1994, BIOCHEMISTRY-US, V33, P12769, DOI 10.1021/bi00209a007; Petrat F, 2003, J BIOL CHEM, V278, P46403, DOI 10.1074/jbc.M305291200; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Robinson C, 2004, BBA-MOL CELL RES, V1694, P135, DOI 10.1016/j.bbamcr.2004.03.010; Rukhman V, 2005, J MOL BIOL, V348, P961, DOI 10.1016/j.jmb.2005.03.006; Shouldice SR, 2005, J BIOL CHEM, V280, P5820, DOI 10.1074/jbc.M411238200; Shouldice SR, 2004, J BACTERIOL, V186, P3903, DOI 10.1128/JB.186.12.3903-3910.2004; Shouldice SR, 2003, J BIOL CHEM, V278, P41093, DOI 10.1074/jbc.M306821200; Srivastava R, 2005, PROTEOMICS, V5, P4905, DOI 10.1002/pmic.200500111; Taboy CH, 2001, J BIOL CHEM, V276, P2719, DOI 10.1074/jbc.M004763200; Tolle J, 2002, MICROBIOL-SGM, V148, P3293, DOI 10.1099/00221287-148-10-3293; Tom-Yew SAL, 2005, J BIOL CHEM, V280, P9283, DOI 10.1074/jbc.M412479200; Vogel AI, 1978, TXB QUANTITATIVE INO, P742; Waldron KJ, 2007, J BIOL CHEM, V282, P3837, DOI 10.1074/jbc.M609916200; Welch KD, 2002, ARCH BIOCHEM BIOPHYS, V397, P360, DOI 10.1006/abbi.2001.2694; [No title captured]	59	48	51	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2008	283	18					12520	12527		10.1074/jbc.M709907200	http://dx.doi.org/10.1074/jbc.M709907200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	293MS	18252722	hybrid			2022-12-25	WOS:000255340000068
J	Klopocki, AG; Yago, T; Mehta, P; Yang, J; Wu, T; Leppanen, A; Bovin, NV; Cummings, RD; Zhu, C; McEever, RP				Klopocki, Arkadiusz G.; Yago, Tadayuki; Mehta, Padmaja; Yang, Jun; Wu, Tao; Leppanen, Anne; Bovin, Nicolai V.; Cummings, Richard D.; Zhu, Cheng; McEever, Rodger P.			Replacing a lectin domain residue in L-selectin enhances binding to P-selectin glycoprotein ligand-1 but not to 6-sulfo-sialyl Lewis x	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; CATCH BONDS; KINETIC-ANALYSIS; THRESHOLD SHEAR; FLOW; GLYCOSULFOPEPTIDES; REQUIRES; AFFINITY; FORCE	Selectin-ligand interactions (bonds) mediate leukocyte rolling on vascular surfaces. The molecular basis for differential ligand recognition by selectins is poorly understood. Here, we show that substituting one residue (A108H) in the lectin domain of L-selectin increased its force-free affinity for a glycosulfopeptide binding site (2-GSP-6) on P-selectin glycoprotein ligand-1 (PSGL-1) but not for a sulfated-glycan binding site (6-sulfo-sialyl Lewis x) on peripheral node addressin. The increased affinity of L-selectinA108H for 2-GSP-6 was due to a faster on-rate and to a slower off-rate that increased bond lifetimes in the absence of force. Rather than first prolonging (catching) and then shortening (slipping) bond lifetimes, increasing force monotonically shortened lifetimes of L-selectinA108H bonds with 2-GSP-6. When compared with microspheres bearing L-selectin, L-selectinA108H microspheres rolled more slowly and regularly on 2-GSP-6 at low flow rates. A reciprocal substitution in P-selectin (H108A) caused faster microsphere rolling on 2-GSP-6. These results distinguish molecular mechanisms for L-selectin to bind to PSGL-1 and peripheral node addressin and explain in part the shorter lifetimes of PSGL-1 bonds with L-selectin than P-selectin.	[Klopocki, Arkadiusz G.; Yago, Tadayuki; Mehta, Padmaja; McEever, Rodger P.] Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; [Leppanen, Anne; Cummings, Richard D.; McEever, Rodger P.] Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; [Yang, Jun; Wu, Tao; Zhu, Cheng] Georgia Inst Technol, George W Woodruff Sch Mech Engn, Atlanta, GA 30332 USA; [Zhu, Cheng] Georgia Inst Technol, Coulter Dept Biomed Engn, Atlanta, GA 30332 USA; [Bovin, Nicolai V.] Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences	McEever, RP (corresponding author), Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.	rodger-mcever@omrf.org	Zhu, Cheng/A-5724-2011; Bovin, Nicolai/P-2948-2017	Bovin, Nicolai/0000-0001-8669-4477				Chen W, 2008, BIOPHYS J, V94, P694, DOI 10.1529/biophysj.107.117895; Finger EB, 1996, NATURE, V379, P266, DOI 10.1038/379266a0; Korchagina EY., 1992, SOVIET J BIOORG CHEM, V18, P153; Leppanen A, 2003, J BIOL CHEM, V278, P26391, DOI 10.1074/jbc.M303551200; Leppanen A, 1999, J BIOL CHEM, V274, P24838, DOI 10.1074/jbc.274.35.24838; Leppanen A, 2000, J BIOL CHEM, V275, P39569, DOI 10.1074/jbc.M005005200; Lou JZ, 2007, BIOPHYS J, V92, P1471, DOI 10.1529/biophysj.106.097048; Lou JZ, 2006, J CELL BIOL, V174, P1107, DOI 10.1083/jcb.200606056; Marshall BT, 2003, NATURE, V423, P190, DOI 10.1038/nature01605; McEver RP, 2005, NAT IMMUNOL, V6, P1067, DOI 10.1038/ni1105-1067; McEver RP, 2002, CURR OPIN CELL BIOL, V14, P581, DOI 10.1016/S0955-0674(02)00367-8; Mehta P, 1997, BLOOD, V90, P2381, DOI 10.1182/blood.V90.6.2381.2381_2381_2389; Mehta P, 1998, J BIOL CHEM, V273, P32506, DOI 10.1074/jbc.273.49.32506; Mitoma J, 2007, NAT IMMUNOL, V8, P409, DOI 10.1038/ni1442; Nicholson MW, 1998, J BIOL CHEM, V273, P763, DOI 10.1074/jbc.273.2.763; Phan UT, 2006, NAT IMMUNOL, V7, P883, DOI 10.1038/ni1366; Rosen SD, 2004, ANNU REV IMMUNOL, V22, P129, DOI 10.1146/annurev.immunol.21.090501.080131; Sarangapani KK, 2004, J BIOL CHEM, V279, P2291, DOI 10.1074/jbc.M310396200; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; Turk D., 1992, THESIS TU MUENCHEN; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Yago T, 2004, J CELL BIOL, V166, P913, DOI 10.1083/jcb.200403144; Yago T, 2002, J CELL BIOL, V158, P787, DOI 10.1083/jcb.200204041; Yago T, 2007, BIOPHYS J, V92, P330, DOI 10.1529/biophysj.106.090969	24	44	44	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11493	11500		10.1074/jbc.M709785200	http://dx.doi.org/10.1074/jbc.M709785200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18250165	Green Published, hybrid			2022-12-25	WOS:000255067400048
J	Ma, YL; Taylor, SS				Ma, Yuliang; Taylor, Susan S.			A molecular switch for targeting between endoplasmic reticulum (ER) and mitochondria - Conversion of a mitochondria-targeting element into an ER-targeting signal in DAKAP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; OUTER-MEMBRANE; MESSENGER-RNA; REGULATORY SUBUNITS; ANCHOR PROTEIN; CYCLIC-AMP; BINDING; PHOSPHORYLATION; SEQUENCE; IMPORT	DAKAP1 (AKAP121, S-AKAP84), a dual specificity PKA scaffold protein, exists in several forms designated as a, b, c, and d. Whether DAKAP1 targets to endoplasmic reticulum ( ER) or mitochondria depends on the presence of the N-terminal 33 amino acids (N1), and these N-terminal variants are generated by either alternative splicing and/or differential initiation of translation. The mitochondrial targeting motif, which is localized between residues 49 and 63, is comprised of a hydrophobic helix followed by positive charges (Ma, Y., and Taylor, S. ( 2002) J. Biol. Chem. 277, 27328-27336). DAKAP1 is located on the cytosolic surface of mitochondria outer membrane and both smooth and rough ER membrane. A single residue, Asp(31), within the first 33 residues of DAKAP1b is required for ER targeting. Asp(31), which functions as a separate motif from the mitochondrial targeting signal, converts the mitochondrial-targeting signal into a bipartite ER-targeting signal, without destroying the mitochondria-targeting signal. Therefore DAKAP1 possesses a single targeting element capable of targeting to both mitochondria and ER, with the ER signal overlapping the mitochondria signal. The specificity of ER or mitochondria targeting is determined and switched by the availability of the negatively charged residue, Asp(31).	[Taylor, Susan S.] Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; [Taylor, Susan S.] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; [Taylor, Susan S.] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Taylor, SS (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, 9500 Gilman Dr,MC 0654, La Jolla, CA 92093 USA.	staylor@ucsd.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK054441] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIDDK NIH HHS [DK54441, P01 DK054441] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Addya S, 1997, J CELL BIOL, V139, P589, DOI 10.1083/jcb.139.3.589; Alto N, 2002, DIABETES, V51, pS385, DOI 10.2337/diabetes.51.2007.S385; Anandatheerthavarada HK, 1999, EMBO J, V18, P5494, DOI 10.1093/emboj/18.20.5494; Bhagwat SV, 1999, J BIOL CHEM, V274, P24014, DOI 10.1074/jbc.274.34.24014; Borgese N, 2001, MOL BIOL CELL, V12, P2482, DOI 10.1091/mbc.12.8.2482; Cardone L, 2004, MOL CELL BIOL, V24, P4613, DOI 10.1128/MCB.24.11.4613-4626.2004; Cardone L, 2002, J MOL BIOL, V320, P663, DOI 10.1016/S0022-2836(02)00479-5; Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; Feliciello A, 2005, CELL SIGNAL, V17, P279, DOI 10.1016/j.cellsig.2004.09.009; Furusawa M, 2001, J BIOL CHEM, V276, P36647, DOI 10.1074/jbc.M103885200; Ginsberg MD, 2003, J MOL BIOL, V327, P885, DOI 10.1016/S0022-2836(03)00173-6; Graf SA, 2004, J BIOL CHEM, V279, P42954, DOI 10.1074/jbc.M405040200; Horie C, 2002, MOL BIOL CELL, V13, P1615, DOI 10.1091/mbc.01-12-0570; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; Huang LJS, 1999, J CELL BIOL, V145, P951, DOI 10.1083/jcb.145.5.951; Isenmann S, 1998, MOL BIOL CELL, V9, P1649, DOI 10.1091/mbc.9.7.1649; JANIAK F, 1994, J BIOL CHEM, V269, P9842; Kanaji S, 2000, J CELL BIOL, V151, P277, DOI 10.1083/jcb.151.2.277; Kaufmann T, 2003, J CELL BIOL, V160, P53, DOI 10.1083/jcb.200210084; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P3873, DOI 10.1093/nar/12.9.3873; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Kuroda R, 1998, J BIOL CHEM, V273, P31097, DOI 10.1074/jbc.273.47.31097; Langeberg LK, 2005, J CELL SCI, V118, P3217, DOI 10.1242/jcs.02416; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; Ma Y, 1999, CANCER RES, V59, P5341; Ma YL, 2002, J BIOL CHEM, V277, P27328, DOI 10.1074/jbc.M201421200; Makarova O, 2000, BIOTECHNIQUES, V29, P970, DOI 10.2144/00295bm08; MCBRIDE HM, 1992, J CELL BIOL, V119, P1451, DOI 10.1083/jcb.119.6.1451; MEINKOTH JL, 1993, MOL CELL BIOCHEM, V128, P179, DOI 10.1007/BF01076769; Meisinger C, 2001, MOL CELL BIOL, V21, P2337, DOI 10.1128/MCB.21.7.2337-2348.2001; Miyazaki E, 2005, MOL BIOL CELL, V16, P1788, DOI 10.1091/mbc.e04-08-0707; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Pagliarini DJ, 2005, MOL CELL, V19, P197, DOI 10.1016/j.molcel.2005.06.008; Pestov DG, 1999, BIOTECHNIQUES, V26, P102, DOI 10.2144/99261st04; Ranganathan G, 2002, J BIOL CHEM, V277, P43281, DOI 10.1074/jbc.M202560200; Rizzuto R, 1996, CURR BIOL, V6, P183, DOI 10.1016/S0960-9822(02)00451-7; Robin MA, 2002, J BIOL CHEM, V277, P40583, DOI 10.1074/jbc.M203292200; Scott JD, 2006, BIOCHEM SOC T, V34, P465, DOI 10.1042/BST0340465; SHARMA RN, 1978, J BIOL CHEM, V253, P2033; Smith FD, 2006, EUR J CELL BIOL, V85, P585, DOI 10.1016/j.ejcb.2006.01.011; Suzuki H, 2002, J CELL SCI, V115, P1895; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241	44	35	36	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11743	11751		10.1074/jbc.M710494200	http://dx.doi.org/10.1074/jbc.M710494200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18287098	Green Published, hybrid			2022-12-25	WOS:000255067400074
J	Bartholomaeus, I; Milan-Lobo, L; Nicke, A; Dutertre, S; Hastrup, H; Jha, A; Gether, U; Sitte, HH; Betz, H; Eulenburg, V				Bartholomaeus, Ingo; Milan-Lobo, Laura; Nicke, Annette; Dutertre, Sebastien; Hastrup, Hanne; Jha, Alok; Gether, Ulrik; Sitte, Harald H.; Betz, Heinrich; Eulenburg, Volker			Glycine transporter dimers - Evidence for occurrence in the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; HUMAN DOPAMINE TRANSPORTER; AMINOBUTYRIC-ACID TRANSPORTER-1; HUMAN SEROTONIN TRANSPORTER; RAT GABA TRANSPORTER-1; LIVING CELLS; NEUROTRANSMITTER TRANSPORTERS; HYDRODYNAMIC PROPERTIES; TRANSMEMBRANE SEGMENT; ENDOPLASMIC-RETICULUM	Different Na+/Cl--dependent neurotransmitter transporters of the SLC6a family have been shown to form dimers or oligomers in both intracellular compartments and at the cell surface. In contrast, the glycine transporters (GlyTs) GlyT1 and -2 have been reported to exist as monomers in the plasma membrane based on hydrodynamic and native gel electrophoretic studies. Here, we used cysteine substitution and oxidative cross-linking to show that of GlyT1 and GlyT2 also form dimeric complexes within the plasma membrane. GlyT oligomerization at the cell surface was confirmed for both GlyT1 and GlyT2 by fluorescence resonance energy transfer microscopy. Endoglycosidase treatment and surface biotinylation further revealed that complex-glycosylated GlyTs form dimers located at the cell surface. Furthermore, substitution of tryptophan 469 of GlyT2 by an arginine generated a transporter deficient in dimerization that was retained intracellulary. Based on these results and GlyT structures modeled by using the crystal structure of the bacterial homolog LeuT(Aa), as a template, residues located within the extracellular loop 3 and at the beginning of transmembrane domain 6 are proposed to contribute to the dimerization interface of GlyTs.	[Bartholomaeus, Ingo; Nicke, Annette; Dutertre, Sebastien; Betz, Heinrich; Eulenburg, Volker] Max Planck Inst Brain Res, Dept Neurochem, D-60529 Frankfurt, Germany; [Milan-Lobo, Laura; Jha, Alok; Sitte, Harald H.] Med Univ Vienna, Inst Pharmacol, Ctr Biomol Med & Pharmacol, A-1090 Vienna, Austria; [Hastrup, Hanne; Gether, Ulrik] Univ Copenhagen, Dept Pharmacol, Mol Neuropharmacol Grp, DK-2200 Copenhagen, Denmark; [Hastrup, Hanne; Gether, Ulrik] Univ Copenhagen, Mol Neuropharmacol Grp, DK-2200 Copenhagen, Denmark; [Hastrup, Hanne; Gether, Ulrik] Univ Copenhagen, Dept Pharmacol, Panum Inst, DK-2200 Copenhagen, Denmark	Max Planck Society; Medical University of Vienna; University of Copenhagen; University of Copenhagen; University of Copenhagen	Sitte, HH (corresponding author), Max Planck Inst Brain Res, Dept Neurochem, Deutschordenstr 46, D-60529 Frankfurt, Germany.	harald.sitte@meduniwien.ac.at; eulenburg@mpih-frankfurt.mpg.de	Sitte, Harald/N-2681-2013; Sitte, Harald/O-7025-2019; Eulenburg, Volker/B-7263-2013; Eulenburg, Volker/B-7263-2013	Sitte, Harald/0000-0002-1339-7444; Sitte, Harald/0000-0002-1339-7444; Eulenburg, Volker/0000-0002-4878-5746; Nicke, Annette/0000-0001-6798-505X; Dutertre, Sebastien/0000-0002-2945-1484; Eulenburg, Volker/0000-0001-6314-566X; Jha, Alok/0000-0001-7600-7127; Gether, Ulrik/0000-0002-0020-3807	Austrian Science Fund FWF [P 18706] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Aragon C, 1998, METHOD ENZYMOL, V296, P3; Armsen W, 2007, MOL CELL NEUROSCI, V36, P369, DOI 10.1016/j.mcn.2007.07.011; Cai GQ, 2005, FEBS J, V272, P1625, DOI 10.1111/j.1742-4658.2005.04595.x; Dingledine R, 1990, Adv Exp Med Biol, V268, P17; Dutertre S, 2005, J BIOL CHEM, V280, P30460, DOI 10.1074/jbc.M504229200; Ebihara S, 2004, BIOCHEM BIOPH RES CO, V317, P857, DOI 10.1016/j.bbrc.2004.03.125; Eulenburg V, 2005, TRENDS BIOCHEM SCI, V30, P325, DOI 10.1016/j.tibs.2005.04.004; Eulenburg V, 2006, BIOCHEM BIOPH RES CO, V348, P400, DOI 10.1016/j.bbrc.2006.07.080; Farhan H, 2006, HANDB EXP PHARM, V175, P233; Farhan H, 2007, J BIOL CHEM, V282, P7679, DOI 10.1074/jbc.M609720200; FERNANDEZ S, 2007, BIOCHEM J, V409, P669; Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8; Fornes A, 2004, J BIOL CHEM, V279, P22934, DOI 10.1074/jbc.M401337200; Gabernet L, 2005, NEUROSCI LETT, V373, P79, DOI 10.1016/j.neulet.2004.09.064; Gether U, 2006, TRENDS PHARMACOL SCI, V27, P375, DOI 10.1016/j.tips.2006.05.003; GIROS B, 1992, MOL PHARMACOL, V42, P383; Gomeza J, 2003, NEURON, V40, P785, DOI 10.1016/S0896-6273(03)00672-X; Gomeza J, 2003, NEURON, V40, P797, DOI 10.1016/S0896-6273(03)00673-1; Hahn MK, 2003, J NEUROSCI, V23, P4470; Hastrup H, 2003, J BIOL CHEM, V278, P45045, DOI 10.1074/jbc.C300349200; Hastrup H, 2001, P NATL ACAD SCI USA, V98, P10055, DOI 10.1073/pnas.181344298; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; Hein P, 2005, EMBO J, V24, P4106, DOI 10.1038/sj.emboj.7600870; Horiuchi M, 2001, P NATL ACAD SCI USA, V98, P1448, DOI 10.1073/pnas.041329498; Jess U, 1996, FEBS LETT, V394, P44, DOI 10.1016/0014-5793(96)00916-7; Just H, 2004, J BIOL CHEM, V279, P6650, DOI 10.1074/jbc.M306092200; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; Korkhov VM, 2006, J BIOL CHEM, V281, P13439, DOI 10.1074/jbc.M511382200; Korkhov VM, 2004, J BIOL CHEM, V279, P55728, DOI 10.1074/jbc.M409449200; LOPEZCORCUERA B, 1993, J BIOL CHEM, V268, P2239; Martinez-Maza R, 2001, J BIOL CHEM, V276, P2168, DOI 10.1074/jbc.M006774200; Miranda M, 2004, J BIOL CHEM, V279, P30760, DOI 10.1074/jbc.M312774200; NUNEZ E, 1994, J BIOL CHEM, V269, P16920; Rees MI, 2006, NAT GENET, V38, P801, DOI 10.1038/ng1814; Schmid JA, 2003, CURR OPIN ONCOL, V15, P55, DOI 10.1097/00001622-200301000-00008; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; Scholze P, 2002, J BIOL CHEM, V277, P43682, DOI 10.1074/jbc.M205602200; Seidel S, 2005, MOL PHARMACOL, V67, P140, DOI 10.1124/mol.67.1.140; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; Sorkina T, 2003, J BIOL CHEM, V278, P28274, DOI 10.1074/jbc.M210652200; Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200; Tsai G, 2004, P NATL ACAD SCI USA, V101, P8485, DOI 10.1073/pnas.0402662101; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978	45	47	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10978	10991		10.1074/jbc.M800622200	http://dx.doi.org/10.1074/jbc.M800622200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18252709	Green Accepted, hybrid, Green Published			2022-12-25	WOS:000254894700079
J	Piantadosi, CA; Suliman, HB				Piantadosi, Claude A.; Suliman, Hagir B.			Transcriptional regulation of SDHa flavoprotein by nuclear respiratory factor-1 prevents pseudo-hypoxia in aerobic cardiac cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR-I; CONTROLLING MITOCHONDRIAL BIOGENESIS; SUCCINATE-DEHYDROGENASE; GENE-EXPRESSION; COMPLEX-II; SIGNAL-TRANSDUCTION; PROLYL HYDROXYLASE; ACTIVATION; OXYGEN; CHAIN	Nuclear respiratory factor-1 (NRF-1) is integral to the transcriptional regulation of mitochondrial biogenesis, but its control over various respiratory genes overlaps other regulatory elements including those involved in O-2 sensing. Aerobic metabolism generally suppresses hypoxia-sensitive genes, e. g. via hypoxia-inducible factor-1 (HIF-1), but mutations in Complex II-succinate dehydrogenase (SDH), a tumor suppressor, stabilize HIF-1, producing pseudo-hypoxia. In aerobic cardiomyocytes, which rely on oxidative phosphorylation, we tested the hypothesis that NRF-1 regulates Complex II expression and opposes hypoxia-inducible factor-1. NRF-1 gene silencing blocked aerobic succinate oxidation, increasing nuclear HIF-1 alpha protein prior to the loss of Complex I function. We postulated that NRF-1 suppression either specifically decreases the expression of one or more SDH subunits and increases succinate availability to regulate HIF-1 prolyl hydroxylases, or stimulates mitochondrial reactive oxygen production, which interferes with HIF-1 alpha degradation. Using promoter analysis, gene silencing, and chromatin immunoprecipitation, NRF-1 was found to bind to the gene promoters of two of four nuclear-encoded Complex II subunits: SDHa and SDHd, but the enzyme activity was dynamically regulated through the catalytic SDHa flavoprotein. Complex II was inactivated by SDHa silencing, which led to aerobic HIF-1 alpha stabilization, nuclear translocation, and enhanced expression of glucose transporters and heme oxygenase-1. This was unrelated to mitochondrial ROS production, reversible by high alpha-ketoglutarate concentrations, and coherent with regulation of HIF-1 by succinate reported in tumor cells. These findings disclose a novel role for NRF-1 in the transcriptional control of Complex II and prevention of pseudo-hypoxic gene expression in aerobic cardiac cells.	[Piantadosi, Claude A.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Suliman, Hagir B.] Duke Univ, Sch Med, Dept Anesthesiol, Durham, NC 27710 USA; [Suliman, Hagir B.] Durham Veterans Adm Med Ctr, Durham, NC 27710 USA	Duke University; Duke University	Piantadosi, CA (corresponding author), Duke Univ, Med Ctr, Dept Med, CR 2 Bldg,Box 3315, Durham, NC 27710 USA.	piant001@mc.duke.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL090679] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL090679] Funding Source: Medline; PHS HHS [P01 42-444] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANGELINI C, 1993, JPN HEART J, V34, P63; Barish GD, 2006, J CLIN INVEST, V116, P590, DOI 10.1172/JCI27955; BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144; Briere JJ, 2005, HUM MOL GENET, V14, P3263, DOI 10.1093/hmg/ddi359; BROWN MD, 1994, J BIOENERG BIOMEMBR, V26, P273, DOI 10.1007/BF00763099; Cam H, 2004, MOL CELL, V16, P399, DOI 10.1016/j.molcel.2004.09.037; Cecchini G, 2002, BBA-BIOENERGETICS, V1553, P140, DOI 10.1016/S0005-2728(01)00238-9; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chen CH, 2001, J BIOL CHEM, V276, P9519, DOI 10.1074/jbc.M010144200; Doege K, 2005, BLOOD, V106, P2311, DOI 10.1182/blood-2005-03-1138; Frederiksen CM, 2003, J CANCER RES CLIN, V129, P263, DOI 10.1007/s00432-003-0434-x; Gao L, 2004, FEBS LETT, V569, P256, DOI 10.1016/j.febslet.2004.06.004; Gimenez-Roqueplo AP, 2001, AM J HUM GENET, V69, P1186, DOI 10.1086/324413; Gleyzer N, 2005, MOL CELL BIOL, V25, P1354, DOI 10.1128/MCB.25.4.1354-1366.2005; Green DR, 2005, J CLIN INVEST, V115, P2610, DOI 10.1172/JCI26321; Guzy RD, 2008, MOL CELL BIOL, V28, P718, DOI 10.1128/MCB.01338-07; Habano W, 2003, ONCOL REP, V10, P1375; Hagen T, 2003, SCIENCE, V302, P1975, DOI 10.1126/science.1088805; Hammerman PS, 2004, TRENDS BIOCHEM SCI, V29, P586, DOI 10.1016/j.tibs.2004.09.008; HOHL C, 1987, ARCH BIOCHEM BIOPHYS, V259, P527, DOI 10.1016/0003-9861(87)90519-4; Janssen RJRJ, 2004, EXPERT REV MOL DIAGN, V4, P143, DOI 10.1586/14737159.4.2.143; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Li HY, 2001, CELL MOTIL CYTOSKEL, V48, P11, DOI 10.1002/1097-0169(200101)48:1<11::AID-CM2>3.0.CO;2-I; Malhotra R, 1999, J BIOL CHEM, V274, P12567, DOI 10.1074/jbc.274.18.12567; Mathupala SP, 1997, J BIOL CHEM, V272, P22776, DOI 10.1074/jbc.272.36.22776; Menard C, 1999, J BIOL CHEM, V274, P29063, DOI 10.1074/jbc.274.41.29063; Mizuarai S, 2005, J BIOL CHEM, V280, P32434, DOI 10.1074/jbc.M503152200; Mole DR, 2003, BIOORG MED CHEM LETT, V13, P2677, DOI 10.1016/S0960-894X(03)00539-0; Penta JS, 2001, MUTAT RES-REV MUTAT, V488, P119, DOI 10.1016/S1383-5742(01)00053-9; Piantadosi CA, 2006, J BIOL CHEM, V281, P324, DOI 10.1074/jbc.M508805200; Pollard PJ, 2005, HUM MOL GENET, V14, P2231, DOI 10.1093/hmg/ddi227; Robey RB, 2005, CELL CYCLE, V4, P654, DOI 10.4161/cc.4.5.1678; Sabar M, 2005, PLANT J, V44, P893, DOI 10.1111/j.1365-313X.2005.02577.x; Scarpulla RC, 2002, BBA-GENE STRUCT EXPR, V1576, P1, DOI 10.1016/S0167-4781(02)00343-3; Scarpulla RC, 2002, GENE, V286, P81, DOI 10.1016/S0378-1119(01)00809-5; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Selak MA, 2006, BBA-BIOENERGETICS, V1757, P567, DOI 10.1016/j.bbabio.2006.05.015; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Srinivas V, 2001, J BIOL CHEM, V276, P21995, DOI 10.1074/jbc.C100177200; Suliman HB, 2007, J CELL SCI, V120, P299, DOI 10.1242/jcs.03318; Suliman HB, 2004, CARDIOVASC RES, V64, P279, DOI 10.1016/j.cardiores.2004.07.005; Suliman HB, 2003, J BIOL CHEM, V278, P41510, DOI 10.1074/jbc.M304719200; Suliman HB, 2003, AM J RESP CRIT CARE, V167, P570, DOI 10.1164/rccm.200206-518OC; Vaux EC, 2001, BLOOD, V98, P296, DOI 10.1182/blood.V98.2.296; Vercauteren K, 2006, MOL CELL BIOL, V26, P7409, DOI 10.1128/MCB.00585-06; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; Wang CG, 2006, P NATL ACAD SCI USA, V103, P11567, DOI 10.1073/pnas.0603363103; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605	53	37	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10967	10977		10.1074/jbc.M709741200	http://dx.doi.org/10.1074/jbc.M709741200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18252725	hybrid, Green Published			2022-12-25	WOS:000254894700078
J	Orfeo, T; Brummel-Ziedins, KE; Gissel, M; Butenas, S; Mann, KG				Orfeo, Thomas; Brummel-Ziedins, Kathleen E.; Gissel, Matthew; Butenas, Saulius; Mann, Kenneth G.			The nature of the stable blood clot procoagulant activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE FACTOR ACTIVITY; CELL-DERIVED MICROPARTICLES; HEPARIN COFACTOR-II; BOVINE FACTOR-V; FACTOR-X; BOUND THROMBIN; ANTITHROMBIN-III; FACTOR-VIIA; HUMAN PLATELETS; WHOLE-BLOOD	The function of tissue factor (Tf)-initiated coagulation is hemorrhage control through the formation and maintenance of an impermeable platelet-fibrin barrier. The catalytic processes involved in the clot maintenance function are not well defined, although the rebleeding problems characteristic of individuals with hemophilias A and B suggest a link between specific defects in the Tf-initiated process and defects in the maintenance function. We have previously demonstrated, using a methodology of "flow replacement" (or resupply) of ongoing Tf-initiated reactions with fresh reactants, that procoagulant complexes are produced during Tf-initiated coagulation, which are capable of reinitiating coagulation without input from extrinsic factor Xase activity (Orfeo, T., Butenas, S., Brummel-Ziedins, K. E., and Mann, K. G. (2005) J. Biol. Chem. 280, 42887 - 42896). Here we used Tf-initiated reactions in normal and hemophilia blood or in their corresponding proteome mixtures as sources of procoagulant end products and then varied the resupplying material to determine the identity of the catalysts that drive the new cycle of thrombin formation. The central findings are as follows: 1) the prothrombinase complex (fVa-fXa-Ca2+-membrane) accumulated during the episode of Tf-initiated coagulation is the primary catalyst responsible for the observed pattern of prothrombin activation after resupply; 2) impairments in intrinsic factor Xase function, i.e. hemophilias A and B, result in an impaired capacity to mount a resupply response; and 3) in normal hemostasis the intrinsic factor Xase function contributes to the durability of the resupply response.	[Orfeo, Thomas; Brummel-Ziedins, Kathleen E.; Gissel, Matthew; Butenas, Saulius; Mann, Kenneth G.] Univ Vermont, Dept Biochem, Colchester, VT 05446 USA	University of Vermont	Mann, KG (corresponding author), 208 S Pk Dr,Rm T227, Colchester, VT 05446 USA.	kenneth.mann@uvm.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046703] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 46703] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD SS, 1992, SEMIN THROMB HEMOST, V18, P311, DOI 10.1055/s-2007-1002570; BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; Balasubramanian V, 2002, BLOOD, V100, P2787, DOI 10.1182/blood-2002-03-0902; BENDAYAN P, 1994, THROMB HAEMOSTASIS, V71, P576; Berckmans RJ, 2002, ARTHRITIS RHEUM-US, V46, P2857, DOI 10.1002/art.10587; Berckmans RJ, 2001, THROMB HAEMOSTASIS, V85, P639; Betz A, 1999, BIOCHEMISTRY-US, V38, P14582, DOI 10.1021/bi990958a; Bogdanov VY, 2003, NAT MED, V9, P458, DOI 10.1038/nm841; BRAND K, 1991, MOL CELL BIOL, V11, P4732, DOI 10.1128/MCB.11.9.4732; Brummel KE, 1999, J BIOL CHEM, V274, P22862, DOI 10.1074/jbc.274.32.22862; Brummel KE, 2002, BLOOD, V100, P148, DOI 10.1182/blood.V100.1.148; Butenas S, 2005, BLOOD, V105, P2764, DOI 10.1182/blood-2004-09-3567; Butenas S, 1997, J BIOL CHEM, V272, P21527, DOI 10.1074/jbc.272.34.21527; Butenas S, 2003, ARTERIOSCL THROM VAS, V23, P123, DOI 10.1161/01.ATV.0000042081.57854.A2; Butenas S, 2002, BLOOD, V99, P923, DOI 10.1182/blood.V99.3.923; Camera M, 2003, ARTERIOSCL THROM VAS, V23, P1690, DOI 10.1161/01.ATV.0000085629.23209.AA; Cawthern KM, 1998, BLOOD, V91, P4581, DOI 10.1182/blood.V91.12.4581.412k12_4581_4592; Chou J, 2004, BLOOD, V104, P3190, DOI 10.1182/blood-2004-03-0935; CHURCH WR, 1988, BLOOD, V72, P1911; Day SM, 2005, BLOOD, V105, P192, DOI 10.1182/blood-2004-06-2225; del Conde I, 2005, BLOOD, V106, P1604, DOI 10.1182/blood-2004-03-1095; Diamant M, 2002, CIRCULATION, V106, P2442, DOI 10.1161/01.CIR.0000036596.59665.C6; DOOLITTLE RF, 1994, HAEMOSTASIS THROMBOS, P491; DRAKE TA, 1989, AM J PATHOL, V134, P1087; ELLIS V, 1982, BIOCHIM BIOPHYS ACTA, V701, P24; Falati S, 2003, J EXP MED, V197, P1585, DOI 10.1084/jem.20021868; Fay PJ, 1996, J BIOL CHEM, V271, P6027, DOI 10.1074/jbc.271.11.6027; FLECK RA, 1990, THROMB RES, V59, P421, DOI 10.1016/0049-3848(90)90148-6; FRANCIS CW, 1983, J LAB CLIN MED, V102, P220; Fredenburgh JC, 2004, BIOPHYS CHEM, V112, P277, DOI 10.1016/j.bpc.2004.07.031; Giesen PLA, 1999, P NATL ACAD SCI USA, V96, P2311, DOI 10.1073/pnas.96.5.2311; GITEL SN, 1984, J BIOL CHEM, V259, P6890; GRIFFITH MJ, 1985, J BIOL CHEM, V260, P2218; Hathcock JJ, 2004, BLOOD, V104, P123, DOI 10.1182/blood-2003-12-4352; HIBBARD LS, 1982, BIOCHEMISTRY-US, V21, P2285, DOI 10.1021/bi00539a003; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; Hockin MF, 2002, J BIOL CHEM, V277, P18322, DOI 10.1074/jbc.M201173200; Hoffman M, 2007, J THROMB HAEMOST, V5, P1403, DOI 10.1111/j.1538-7836.2007.02576.x; Hoffman M, 2001, THROMB HAEMOSTASIS, V85, P958, DOI 10.1055/s-0037-1615947; Hoffman M, 2006, BLOOD, V108, P3053, DOI 10.1182/blood-2006-05-020495; HOGG PJ, 1989, P NATL ACAD SCI USA, V86, P3619, DOI 10.1073/pnas.86.10.3619; HOJIMA Y, 1980, THROMB RES, V20, P149, DOI 10.1016/0049-3848(80)90381-3; Jesty J, 2005, ARTERIOSCL THROM VAS, V25, P2463, DOI 10.1161/01.ATV.0000187463.91403.b2; Kalafatis M, 1997, CRIT REV EUKAR GENE, V7, P241, DOI 10.1615/CritRevEukarGeneExpr.v7.i3.40; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; Komatsu Y, 2000, BIOL PHARM BULL, V23, P502; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; KUMAR R, 1994, THROMB HAEMOSTASIS, V72, P713; KUMAR R, 1995, THROMB HAEMOSTASIS, V74, P962; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1994, J BIOL CHEM, V269, P23357; Lundblad R L, 1976, Methods Enzymol, V45, P156; MANN KG, 1992, SEMIN HEMATOL, V29, P213; MIHALYI E, 1988, BIOCHEMISTRY-US, V27, P976, DOI 10.1021/bi00403a021; Muller I, 2003, FASEB J, V17, P476, DOI 10.1096/fj.02-0574fje; MUSTARD JF, 1972, BRIT J HAEMATOL, V22, P193, DOI 10.1111/j.1365-2141.1972.tb08800.x; NASKI MC, 1990, J BIOL CHEM, V265, P1401; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; OKAMOTO S, 1993, METHOD ENZYMOL, V222, P328; Orfeo T, 2005, J BIOL CHEM, V280, P42887, DOI 10.1074/jbc.M505506200; Orfeo T, 2004, J BIOL CHEM, V279, P19580, DOI 10.1074/jbc.M400727200; Osterud B, 2001, SEMIN HEMATOL, V38, P2, DOI 10.1016/S0037-1963(01)90139-8; Panes O, 2007, BLOOD, V109, P5242, DOI 10.1182/blood-2006-06-030619; Rand MD, 1996, BLOOD, V88, P3432, DOI 10.1182/blood.V88.9.3432.bloodjournal8893432; Santucci RA, 2000, THROMB HAEMOSTASIS, V83, P445, DOI 10.1055/s-0037-1613835; Schwertz H, 2006, J EXP MED, V203, P2433, DOI 10.1084/jem.20061302; SHAFER JA, 1988, CRIT REV CL LAB SCI, V26, P1; Siddiqui FA, 2002, PLATELETS, V13, P247, DOI 10.1080/09537100220146398; TAKAHASHI H, 1994, AM J HEMATOL, V46, P333, DOI 10.1002/ajh.2830460414; vantVeer C, 1997, J BIOL CHEM, V272, P4367, DOI 10.1074/jbc.272.7.4367; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; Wolberg AS, 2005, BRIT J HAEMATOL, V131, P645, DOI 10.1111/j.1365-2141.2005.05820.x; Zillmann A, 2001, BIOCHEM BIOPH RES CO, V281, P603, DOI 10.1006/bbrc.2001.4399	76	36	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9776	9786		10.1074/jbc.M707435200	http://dx.doi.org/10.1074/jbc.M707435200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18268016	hybrid, Green Published			2022-12-25	WOS:000254671600032
J	Li, Y; Wang, ZL; Furukawa, N; Escaron, P; Weiszmann, J; Lee, G; Lindstrom, M; Liu, JS; Liu, XH; Xu, HD; Plotnikova, O; Prasad, V; Walker, N; Learned, RM; Chen, JL				Li, Yang; Wang, Zhulun; Furukawa, Noboru; Escaron, Patrick; Weiszmann, Jennifer; Lee, Gary; Lindstrom, Michelle; Liu, Jinsong; Liu, Xiaohong; Xu, Haoda; Plotnikova, Olga; Prasad, Vidya; Walker, Nigel; Learned, R. Marc; Chen, Jin-Long			T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; LIGAND; NUCLEAR; THIAZOLIDINEDIONE; ANTAGONIST; SUBSTITUTION; SUMOYLATION; MECHANISMS; LXRS	The nuclear hormone receptor peroxisome proliferator-activated receptor gamma( PPAR gamma) plays central roles in adipogenesis and glucose homeostasis and is the molecular target for the thiazolidinedione (TZD) class of antidiabetic drugs. Activation of PPAR gamma by TZDs improves insulin sensitivity; however, this is accompanied by the induction of several undesirable side effects. We have identified a novel synthetic PPAR gamma ligand, T2384, to explore the biological activities associated with occupying different regions of the receptor ligand-binding pocket. X-ray crystallography studies revealed that T2384 can adopt two distinct binding modes, which we have termed "U" and "S", interacting with the ligand- binding pocket of PPAR gamma primarily via hydrophobic contacts that are distinct from full agonists. The different binding modes occupied by T2384 induced distinct patterns of coregulatory protein interaction with PPAR gamma in vitro and displayed unique receptor function in cell-based activity assays. We speculate that these unique biochemical and cellular activities may be responsible for the novel in vivo profile observed in animals treated systemically with T2384. When administered to diabetic KKAy mice, T2384 rapidly improved insulin sensitivity in the absence of weight gain, hemodilution, and anemia characteristics of treatment with rosiglitazone ( a TZD). Moreover, upon coadministration with rosiglitazone, T2384 was able to antagonize the side effects induced by rosiglitazone treatment alone while retaining robust effects on glucose disposal. These results are consistent with the hypothesis that interactions between ligands and specific regions of the receptor ligand- binding pocket might selectively trigger a subset of receptor-mediated biological responses leading to the improvement of insulin sensitivity, without eliciting less desirable responses associated with full activation of the receptor. We suggest that T2384 may represent a prototype for a novel class of PPAR gamma ligand and, furthermore, that molecules sharing some of these properties would be useful for treatment of type 2 diabetes.	[Li, Yang; Wang, Zhulun; Escaron, Patrick; Weiszmann, Jennifer; Lee, Gary; Lindstrom, Michelle; Liu, Jinsong; Liu, Xiaohong; Xu, Haoda; Plotnikova, Olga; Prasad, Vidya; Walker, Nigel; Learned, R. Marc; Chen, Jin-Long] Amgen Inc, San Francisco, CA 94080 USA; [Furukawa, Noboru] Japan Tobacco Inc, Tokyo 1058422, Japan	Amgen; Japan Tobacco Inc.	Li, Y (corresponding author), Amgen Inc, San Francisco, CA 94080 USA.	yangl@amgen.com						Argmann CA, 2005, EUR J CLIN INVEST, V35, P82, DOI 10.1111/j.1365-2362.2005.01456.x; Auwerx J, 1999, CELL, V97, P161; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Berger JP, 2003, MOL ENDOCRINOL, V17, P662, DOI 10.1210/me.2002-0217; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Deeb SS, 1998, NAT GENET, V20, P284, DOI 10.1038/3099; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Florez JC, 2004, J CLIN ENDOCR METAB, V89, P4234, DOI 10.1210/jc.2004-1402; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Ghisletti S, 2007, MOL CELL, V25, P57, DOI 10.1016/j.molcel.2006.11.022; Glass CK, 2006, J CLIN INVEST, V116, P556, DOI 10.1172/JCI27913; Knouff C, 2004, ENDOCR REV, V25, P899, DOI 10.1210/er.2003-0036; Lee G, 2002, J BIOL CHEM, V277, P19649, DOI 10.1074/jbc.M200743200; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; Masugi J, 2000, BIOCHEM BIOPH RES CO, V268, P178, DOI 10.1006/bbrc.2000.2096; Nesto RW, 2004, DIABETES CARE, V27, P256, DOI 10.2337/diacare.27.1.256; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Oberfield JL, 1999, P NATL ACAD SCI USA, V96, P6102, DOI 10.1073/pnas.96.11.6102; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Picard F, 2002, ANNU REV NUTR, V22, P167, DOI 10.1146/annurev.nutr.22.010402.102808; Ricote M, 2004, ARTERIOSCL THROM VAS, V24, P230, DOI 10.1161/01.ATV.0000103951.67680.B1; Rieusset J, 2002, MOL ENDOCRINOL, V16, P2628, DOI 10.1210/me.2002-0036; Rocchi S, 2001, MOL CELL, V8, P737, DOI 10.1016/S1097-2765(01)00353-7; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Semple RK, 2006, J CLIN INVEST, V116, P581, DOI 10.1172/JCI28003; Shimizu M, 2006, MOL CELL BIOCHEM, V286, P33, DOI 10.1007/s11010-005-9052-z; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a; Yamauchi T, 2001, J BIOL CHEM, V276, P41245, DOI 10.1074/jbc.M103241200; Zelcer N, 2005, CELL METAB, V2, P273, DOI 10.1016/j.cmet.2005.10.004	33	59	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9168	9176		10.1074/jbc.M800104200	http://dx.doi.org/10.1074/jbc.M800104200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18263587	hybrid			2022-12-25	WOS:000254465800046
J	Sprague, CR; Fraley, TS; Jang, HS; Lal, S; Greenwood, JA				Sprague, Chelsea R.; Fraley, Tamara S.; Jang, Hyo Sang; Lal, Sangeet; Greenwood, Jeffrey A.			Phosphoinositide binding to the substrate regulates susceptibility to proteolysis by calpain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ACTININ; CELL-MIGRATION; MU-CALPAIN; PROTEIN; KINASE; MEMBRANE; IDENTIFICATION; ACTIVATION; 3-KINASE; LOCALIZATION	Calpain-mediated proteolysis regulates cytoskeletal dynamics and is altered during aging and the progression of numerous diseases or pathological conditions. Although several cytoskeletal proteins have been identified as substrates, how localized calpain activity is regulated and the mechanisms controlling substrate recognition are not clear. In this study, we report that phosphoinositide binding regulates the susceptibility of the cytoskeletal adhesion protein alpha-actinin to proteolysis by calpains 1 and 2. At first, alpha-actinin did not appear to be a substrate for calpain 2; however, phosphatidylinositol 3,4,5-trisphosphate ( PtdIns( 3,4,5) P-3) binding to alpha-actinin resulted in nearly complete proteolysis of the full-length protein, producing stable breakdown products. Calpain 1 was able to cleave alpha-actinin in the absence of phosphoinositide binding; however, PtdIns( 3,4,5) P-3 binding increased the rate of proteolysis, and phosphatidylinositol 4,5-diphosphate ( PtdIns( 4,5)P-2) binding significantly inhibited cleavage. Phosphoinositide binding appeared to regulate calpain proteolysis of alpha-actinin by modulating the exposure of a highly sensitive cleavage site within the calponin homology 2 domain. In U87MG glioblastoma cells, which contain elevated levels of PtdIns( 3,4,5) P-3, alpha-actinin colocalized with calpain within dynamic actin cytoskeletal structures. Furthermore, proteolysis of alpha-actinin producing stable breakdown products was observed in U87MG cells treated with calcium ionophore to activate the calcium-dependent calpains. Additional evidence of PtdIns( 3,4,5) P-3-mediated calpain proteolysis of alpha-actinin was observed in rat embryonic fibroblasts. These results suggest that PtdIns( 3,4,5) P-3 binding is a critical determinant for alpha-actinin proteolysis by calpain. In conclusion, phosphoinositide binding to the substrate is a potential mechanism for regulating susceptibility to proteolysis by calpain.	[Sprague, Chelsea R.; Fraley, Tamara S.; Jang, Hyo Sang; Lal, Sangeet; Greenwood, Jeffrey A.] Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University	Greenwood, JA (corresponding author), Oregon State Univ, Dept Biochem & Biophys, ALS 2011, Corvallis, OR 97331 USA.	jeffrey.greenwood@orst.edu		Jang, Hyo Sang/0000-0003-0460-9924; Greenwood, Juliet/0000-0001-6438-964X	Howard Hughes Medical Institute [52003741] Funding Source: Medline; NIEHS NIH HHS [P30 ES 00210] Funding Source: Medline; NIGMS NIH HHS [GM 63711] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063711] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aki T, 2002, J BIOCHEM, V132, P921, DOI 10.1093/oxfordjournals.jbchem.a003305; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; Borrego-Diaz E, 2006, J STRUCT BIOL, V155, P230, DOI 10.1016/j.jsb.2006.01.013; Corgan AM, 2004, BIOCHEM J, V378, P1067, DOI 10.1042/BJ20031124; Dourdin N, 2001, J BIOL CHEM, V276, P48382, DOI 10.1074/jbc.M108893200; EDMUNDS T, 1991, BIOCHIM BIOPHYS ACTA, V1077, P197, DOI 10.1016/0167-4838(91)90059-9; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; Flanagan LA, 1997, BIOPHYS J, V73, P1440, DOI 10.1016/S0006-3495(97)78176-1; FOX JEB, 1985, J BIOL CHEM, V260, P1060; Fraley TS, 2005, J BIOL CHEM, V280, P15479, DOI 10.1074/jbc.M500631200; Fraley TS, 2003, J BIOL CHEM, V278, P24039, DOI 10.1074/jbc.M213288200; Franco S, 2004, EXP CELL RES, V299, P179, DOI 10.1016/j.yexcr.2004.05.021; Franco SJ, 2005, J CELL SCI, V118, P3829, DOI 10.1242/jcs.02562; Franco SJ, 2004, NAT CELL BIOL, V6, P977, DOI 10.1038/ncb1175; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Glading A, 2004, MOL CELL BIOL, V24, P2499, DOI 10.1128/MCB.24.6.2499-2512.2004; Glading A, 2001, J BIOL CHEM, V276, P23341, DOI 10.1074/jbc.M008847200; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Greenwood JA, 2000, J CELL BIOL, V150, P627, DOI 10.1083/jcb.150.3.627; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; Insall RH, 2001, DEV CELL, V1, P743, DOI 10.1016/S1534-5807(01)00086-7; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; MCGREGOR A, 1994, BIOCHEM J, V301, P225, DOI 10.1042/bj3010225; Nuzzi PA, 2007, MOL BIOL CELL, V18, P795, DOI 10.1091/mbc.E06-09-0876; OHALLORAN T, 1985, NATURE, V317, P449, DOI 10.1038/317449a0; ONJI T, 1987, BIOCHIM BIOPHYS ACTA, V912, P283, DOI 10.1016/0167-4838(87)90099-9; Palecek SP, 1998, J CELL SCI, V111, P929; Perrin BJ, 2006, MOL BIOL CELL, V17, P239, DOI 10.1091/mbc.e05-06-0488; Potter DA, 1998, J CELL BIOL, V141, P647, DOI 10.1083/jcb.141.3.647; Ronnstrand L, 2001, INT J CANCER, V91, P757, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1136>3.0.CO;2-J; SAIDO TC, 1991, BIOMED BIOCHIM ACTA, V50, P485; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; Selliah N, 1996, J IMMUNOL, V156, P3215; Shao HS, 2006, MOL CELL BIOL, V26, P5481, DOI 10.1128/MCB.02243-05; Shiraha H, 1999, J CELL BIOL, V146, P243; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Sun Y, 2007, J CELL BIOL, V178, P297, DOI 10.1083/jcb.200701078; Tang JH, 2001, J MOL BIOL, V310, P845, DOI 10.1006/jmbi.2001.4789; Tompa P, 2001, BIOCHEM BIOPH RES CO, V280, P1333, DOI 10.1006/bbrc.2001.4279; Van Haastert PJM, 2004, NAT REV MOL CELL BIO, V5, P626, DOI 10.1038/nrm1435; Van Keymeulen A, 2006, J CELL BIOL, V174, P437, DOI 10.1083/jcb.200604113; vonWillebrand M, 1996, EUR J BIOCHEM, V235, P828; Wu MQ, 2006, FEBS LETT, V580, P3246, DOI 10.1016/j.febslet.2006.05.003; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517; Young P, 2000, EMBO J, V19, P6331, DOI 10.1093/emboj/19.23.6331; Zamir E, 2001, J CELL SCI, V114, P3583	49	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9217	9223		10.1074/jbc.M707436200	http://dx.doi.org/10.1074/jbc.M707436200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18258589	Green Published, hybrid			2022-12-25	WOS:000254465800051
J	Blanco, S; Sanz-Garcia, M; Santos, CR; Lazo, PA				Blanco, Sandra; Sanz-Garcia, Marta; Santos, Claudio R.; Lazo, Pedro A.			Modulation of Interleukin-1 Transcriptional Response by the Interaction between VRK2 and the JIP1 Scaffold Protein	PLOS ONE			English	Article								Background: Cellular biological responses to specific stimulation are determined by a balance among signaling pathways. Protein interactions are likely to modulate these pathways. Vaccinia-related kinase-2 (VRK2) is a novel human kinase that can modulate different signaling pathways. Principal Findings: We report that in vivo, the activity of JIP1-JNK complexes is downregulated by VRK2 in response to interleukin-1 beta. Also the reduction of endogenous VRK2 with shRNA increases the transcriptional response to IL-1 beta. The JIP1 scaffold protein assembles three consecutive members of a given MAPK pathway forming signaling complexes and their signal can be modulated by interactions with regulatory proteins that remain to be identified. Knocking-down JIP1 with siRNA resulted in elimination of the AP1 transcriptional response to IL-1 beta. VRK2, a member of novel Ser-Thr kinase family, is able to stably interact with JIP1, TAK1 and MKK7, but not JNK, and can be isolated forming oligomeric complexes with different proportions of TAK1, MKK7 beta 1 and JNK. JIP1 assembles all these proteins in an oligomeric signalosome. VRK2 binding to the JIP1 signalosome prevents the association of JNK and results in a reduction in its phosphorylation and downregulation of AP1-dependent transcription. Conclusions/Significance: This work suggests that the intracellular level of VRK2 protein can modulate the flow through a signaling pathway and alter the response from a receptor that can be distributed by more than one pathway, and thus contribute to the cellular specificity of the response by forming alternative signaling complexes. Furthermore, the effect might be more general and affect other signaling routes assembled on the JIP1 scaffold protein for which a model is proposed.	[Blanco, Sandra; Sanz-Garcia, Marta; Santos, Claudio R.; Lazo, Pedro A.] Univ Salamanca, Program Oncol Traslac, Inst Biol Mol & Celular Canc, CSIC, E-37008 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Blanco, S (corresponding author), Univ Salamanca, Program Oncol Traslac, Inst Biol Mol & Celular Canc, CSIC, E-37008 Salamanca, Spain.	plazozbi@usal.es	2008, Ibsal/A-1268-2012; Blanco, Sandra/B-2070-2017; Lazo, Pedro A./M-6435-2014	Blanco, Sandra/0000-0001-7352-9392; Lazo, Pedro A./0000-0001-8997-3025	Ministerio de Educacion y Ciencia, CSIC (Spain) [predoctoral fellowships, SAF2004-02900, SAF2007-60242, CSD-2007-0017]; Fundacao para a Ciencia e a Tecnologia (Portugal) [predoctoral fellowships]; Fundacion de Investigacion Medica; Federacion de Cajas de Ahorro de Castilla y Leon	Ministerio de Educacion y Ciencia, CSIC (Spain)(Spanish Government); Fundacao para a Ciencia e a Tecnologia (Portugal)(Portuguese Foundation for Science and Technology); Fundacion de Investigacion Medica; Federacion de Cajas de Ahorro de Castilla y Leon	S.B., M.S-G, and C.R.S. have predoctoral fellowships from Ministerio de Educacion y Ciencia, CSIC (Spain) and Fundacao para a Ciencia e a Tecnologia (Portugal) respectively. This work was funded by grants from Ministerio de Educacion y Ciencia (SAF2004-02900, SAF2007-60242 and Consolider CSD-2007-0017), Fundacion de Investigacion Medica MM and Federacion de Cajas de Ahorro de Castilla y Leon to P.A.L.	Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Beutler B, 2006, ANNU REV IMMUNOL, V24, P353, DOI 10.1146/annurev.immunol.24.021605.090552; Blanco S, 2007, MOL CELL BIOL, V27, P7273, DOI 10.1128/MCB.00025-07; Blanco S, 2006, FEBS J, V273, P2487, DOI 10.1111/j.1742-4658.2006.05256.x; Bonny C, 2000, J BIOL CHEM, V275, P16466, DOI 10.1074/jbc.M908297199; Cheung PCF, 2003, EMBO J, V22, P5793, DOI 10.1093/emboj/cdg552; Cuevas BD, 2007, ONCOGENE, V26, P3159, DOI 10.1038/sj.onc.1210409; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dhanasekaran DN, 2007, ONCOGENE, V26, P3185, DOI 10.1038/sj.onc.1210411; Dhanasekaran DN, 2007, ONCOGENE, V26, P3097, DOI 10.1038/sj.onc.1210395; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Dong ZH, 2005, MOL BRAIN RES, V134, P282, DOI 10.1016/j.molbrainres.2004.10.039; Dunn C, 2002, CELL SIGNAL, V14, P585, DOI 10.1016/S0898-6568(01)00275-3; Eminel S, 2004, J BIOL CHEM, V279, P55385, DOI 10.1074/jbc.M405858200; Gorjanacz M, 2007, EMBO J, V26, P132, DOI 10.1038/sj.emboj.7601470; Haefliger JA, 2003, J CELL SCI, V116, P1463, DOI 10.1242/jcs.00356; Hammaker DR, 2004, J IMMUNOL, V172, P1612, DOI 10.4049/jimmunol.172.3.1612; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Helbecque N, 2003, MOL PSYCHIATR, V8, P413, DOI 10.1038/sj.mp.4001344; Holtmann H, 2001, J BIOL CHEM, V276, P3508, DOI 10.1074/jbc.M004376200; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Jensen LE, 2003, FEBS LETT, V545, P199, DOI 10.1016/S0014-5793(03)00533-7; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Kang TH, 2006, NAT CELL BIOL, V8, P863, DOI 10.1038/ncb1447; Karin M, 2005, IUBMB LIFE, V57, P283, DOI 10.1080/15216540500097111; Kim AH, 2003, J BIOL CHEM, V278, P29830, DOI 10.1074/jbc.M305349200; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; Kim JW, 2005, P NATL ACAD SCI USA, V102, P14308, DOI 10.1073/pnas.0501600102; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Kolch W, 2005, FEBS LETT, V579, P1891, DOI 10.1016/j.febslet.2005.02.002; KOLCH W, 2005, NAT REV MOL CELL BIO; Kristensen O, 2006, EMBO J, V25, P785, DOI 10.1038/sj.emboj.7600982; LAZO PA, 2005, AFCS NATURE MOL PAGE, DOI DOI 10.1038/:MP.A003025.003001; Li CH, 2005, J NEUROCHEM, V93, P290, DOI 10.1111/j.1471-4159.2005.03086.x; Liew FY, 2005, NAT REV IMMUNOL, V5, P446, DOI 10.1038/nri1630; Ling ZD, 2003, DIABETES, V52, P2497, DOI 10.2337/diabetes.52.10.2497; Liu J, 2005, CELL RES, V15, P36, DOI 10.1038/sj.cr.7290262; Lopez-Borges S, 2000, ONCOGENE, V19, P3656, DOI 10.1038/sj.onc.1203709; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Muzio M, 2000, J LEUKOCYTE BIOL, V67, P450, DOI 10.1002/jlb.67.4.450; Nakahira M, 2007, IMMUNITY, V26, P163, DOI 10.1016/j.immuni.2007.01.010; Nezu J, 1997, GENOMICS, V45, P327, DOI 10.1006/geno.1997.4938; Nichols RJ, 2006, MOL BIOL CELL, V17, P2451, DOI 10.1091/mbc.E05-12-1179; Nichols RJ, 2004, J BIOL CHEM, V279, P7934, DOI 10.1074/jbc.M310813200; Round JL, 2007, NAT IMMUNOL, V8, P154, DOI 10.1038/ni1422; Scheinfeld MH, 2002, J BIOL CHEM, V277, P3767, DOI 10.1074/jbc.M108357200; Scheinfeld MH, 2003, P NATL ACAD SCI USA, V100, P1729, DOI 10.1073/pnas.0437908100; Sevilla A, 2004, ONCOGENE, V23, P8950, DOI 10.1038/sj.onc.1208015; Sevilla A, 2004, J BIOL CHEM, V279, P27458, DOI 10.1074/jbc.M401009200; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Song JJ, 2005, J CELL BIOL, V170, P61, DOI 10.1083/jcb.200502070; Symons A, 2006, TRENDS IMMUNOL, V27, P40, DOI 10.1016/j.it.2005.11.007; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Valbuena A, 2006, MOL CELL BIOL, V26, P4782, DOI 10.1128/MCB.00069-06; Vega FM, 2004, MOL CELL BIOL, V24, P10366, DOI 10.1128/MCB.24.23.10366-10380.2004; Waeber G, 2000, NAT GENET, V24, P291, DOI 10.1038/73523; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Whitmarsh AJ, 2001, METHOD ENZYMOL, V332, P319; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Whitmarsh AJ, 2001, GENE DEV, V15, P2421, DOI 10.1101/gad.922801; WHITMARSH AJ, 1999, SCI STKE, pPE1, DOI DOI 10.1126/STKE.1999.1.PE1; Willoughby EA, 2003, J BIOL CHEM, V278, P10731, DOI 10.1074/jbc.M207324200; Windheim M, 2007, BIOCHEM J, V404, P179, DOI 10.1042/BJ20061704; Yamano S, 1999, J VIROL, V73, P10095, DOI 10.1128/JVI.73.12.10095-10103.1999; Yang SH, 2003, GENE, V320, P3, DOI 10.1016/S0378-1119(03)00816-3; Yao JH, 2007, J BIOL CHEM, V282, P6075, DOI 10.1074/jbc.M609039200; Yasuda J, 1999, MOL CELL BIOL, V19, P7245	69	50	54	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1660	10.1371/journal.pone.0001660	http://dx.doi.org/10.1371/journal.pone.0001660			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286207	Green Submitted, gold, Green Published			2022-12-25	WOS:000260586400049
J	Page, TJ; Humphreys, WF; Hughes, JM				Page, Timothy J.; Humphreys, William F.; Hughes, Jane M.			Shrimps Down Under: Evolutionary Relationships of Subterranean Crustaceans from Western Australia (Decapoda: Atyidae: Stygiocaris)	PLOS ONE			English	Article								Background: We investigated the large and small scale evolutionary relationships of the endemic Western Australian subterranean shrimp genus Stygiocaris (Atyidae) using nuclear and mitochondrial genes. Stygiocaris is part of the unique cave biota of the coastal, anchialine, limestones of the Cape Range and Barrow Island, most of whose nearest evolutionary relations are found in coastal caves of the distant North Atlantic. The dominance of atyids in tropical waters and their food resources suggest they are pivotal in understanding these groundwater ecosystems. Methodology/Principle Findings: Our nuclear and mitochondrial analyses all recovered the Mexican cave genus Typhlatya as the sister taxon of Stygiocaris, rather than any of the numerous surface and cave atyids from Australia or the Indo-Pacific region. The two described Stygiocaris species were recovered as monophyletic, and a third, cryptic, species was discovered at a single site, which has very different physiochemical properties from the sites hosting the two described species. Conclusions/Significance: Our findings suggest that Stygiocaris and Typhlatya may descend from a common ancestor that lived in the coastal marine habitat of the ancient Tethys Sea, and were subsequently separated by plate tectonic movements. This vicariant process is commonly thought to explain the many disjunct anchialine faunas, but has rarely been demonstrated using phylogenetic techniques. The Cape Range's geological dynamism, which is probably responsible for the speciation of the various Stygiocaris species, has also led to geographic population structure within species. In particular, Stygiocaris lancifera is split into northern and southern groups, which correspond to population splits within other sympatric subterranean taxa.	[Page, Timothy J.; Hughes, Jane M.] Griffith Univ, Australian Rivers Inst, Nathan, Qld 4111, Australia; [Humphreys, William F.] Western Australian Museum, Western Australia, Australia	Griffith University; Western Australian Museum	Page, TJ (corresponding author), Griffith Univ, Australian Rivers Inst, Nathan, Qld 4111, Australia.	t.page@griffith.edu.au	hughes, jane m/C-5321-2008; Page, Timothy/B-9000-2008	Page, Timothy/0000-0002-3521-3503; Humphreys, William/0000-0002-8998-9323	Butler Trust (WA Museum); Western Australian Museum; National Estate Grants Scheme; Australian National Parks and Wildlife Service; West Australian Petroleum Pty Ltd; Department of Defence; Waterhouse Club, South Australian Museum; Australian Rivers Institute, Griffith University	Butler Trust (WA Museum); Western Australian Museum; National Estate Grants Scheme; Australian National Parks and Wildlife Service; West Australian Petroleum Pty Ltd; Department of Defence; Waterhouse Club, South Australian Museum; Australian Rivers Institute, Griffith University(Griffith University)	Collections of Stygiocaris were made under funding from the Butler Trust (WA Museum), Western Australian Museum, National Estate Grants Scheme, Australian National Parks and Wildlife Service, West Australian Petroleum Pty Ltd and the Department of Defence. Field work in the Gibson Desert was supported by the Waterhouse Club, South Australian Museum. Lab work was funded by the Australian Rivers Institute, Griffith University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams M., 1993, Records of the Western Australian Museum Supplement, V45, P145; Avise John C., 1994, pi; Boulton A. J., 2003, Aquatic Ecosystem Health & Management, V6, P41, DOI 10.1080/14634980301475; Burns A, 2000, HYDROBIOLOGIA, V437, P83, DOI 10.1023/A:1026555501638; Castresana J, 2000, MOL BIOL EVOL, V17, P540, DOI 10.1093/oxfordjournals.molbev.a026334; Choy Satish C., 1996, Records of the Western Australian Museum, V18, P103; Clement M, 2000, MOL ECOL, V9, P1657, DOI 10.1046/j.1365-294x.2000.01020.x; Collins LB, 2006, SEDIMENT GEOL, V185, P1, DOI 10.1016/j.sedgeo.2005.10.005; Cook BD, 2008, MOL ECOL, V17, P1066, DOI 10.1111/j.1365-294X.2007.03637.x; Cooper SJB, 2007, MOL ECOL, V16, P1533, DOI 10.1111/j.1365-294X.2007.03261.x; Craft JD, 2008, LIMNOL OCEANOGR, V53, P675, DOI 10.4319/lo.2008.53.2.0675; CULVER DC, FRESHWATER IN PRESS, DOI DOI 10.1111/J.1365-2427.2007.01856.X; Danielopol DL, 2000, ZOOL SCR, V29, P1, DOI 10.1046/j.1463-6409.2000.00027.x; Danielopol DL, 2000, TRENDS ECOL EVOL, V15, P223, DOI 10.1016/S0169-5347(00)01868-1; Darwin C., 1859, ORIGIN SPECIES MEANS; Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214; Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088; Emerson BC, 2007, SYST BIOL, V56, P337, DOI 10.1080/10635150701258795; Finston TL, 2007, MOL ECOL, V16, P355, DOI 10.1111/j.1365-294X.2006.03123.x; Gibert J, 2002, BIOSCIENCE, V52, P473, DOI 10.1641/0006-3568(2002)052[0473:SEATFB]2.0.CO;2; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; GUZIK MT, INVERTEBRAT IN PRESS; Hamilton-Smith E., 1967, Journal of the Australian Entomological Society, V6, P103; Hamilton-Smith Elery, 2001, Records of the Western Australian Museum Supplement, V64, P85; Harzhauser M, 2007, ZOOL ANZ, V246, P241, DOI 10.1016/j.jcz.2007.05.001; Ho SYW, 2007, SYST BIOL, V56, P515, DOI 10.1080/10635150701435401; HOLTHUIS L. B., 1960, CRUSTACEANA, V1, P47, DOI 10.1163/156854060X00069; Holthuis LB, 1993, RECENT GENERA CARIDE; Hrbek T, 2003, J EVOLUTION BIOL, V16, P17, DOI 10.1046/j.1420-9101.2003.00475.x; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Humphreys W.F., 1993, Records of the Western Australian Museum Supplement, V45, P165; Humphreys W.F., 2001, Records of the Western Australian Museum Supplement, V64, P15; Humphreys WF, 2005, CRUSTACEANA, V78, P1339, DOI 10.1163/156854005776759861; Humphreys W.F., 2001, Records of the Western Australian Museum Supplement, V64, P63; Humphreys W.F., 1991, Records of the Western Australian Museum, V15, P383; Humphreys W. F., 1999, Journal of the Royal Society of Western Australia, V82, P89; Humphreys W.F., 1993, REC AUST MUS S, P25; Humphreys W. F, 1994, SUBTERRANEAN FAUNA C; Humphreys WF, 2006, AUST J BOT, V54, P115, DOI 10.1071/BT04151; Humphreys WF, 2000, ECOSY WORLD, V30, P581; Humphreys WF, 2001, ENVIRON BIOL FISH, V62, P297, DOI 10.1023/A:1011880726946; Humphreys WF., 2001, MEMOIRES BIOSPEOLOGI, V28, P107; HUMPHREYS WF, INVERTEBRAT IN PRESS; Hunter RL, 2008, J BIOGEOGR, V35, P65, DOI 10.1111/j.1365-2699.2007.01767.x; ILIFFE TM, 1984, MAR ENVIRON RES, V12, P173, DOI 10.1016/0141-1136(84)90002-3; Iliffe TM, 2000, ECOSY WORLD, V30, P59; Jaume D, 2001, ZOOL J LINN SOC-LOND, V133, P1, DOI 10.1006/zjls.2000.0288; Kano Y, 2004, ZOOL SCR, V33, P423, DOI 10.1111/j.0300-3256.2004.00159.x; KASS RE, 1995, J AM STAT ASSOC, V90, P773, DOI 10.1080/01621459.1995.10476572; Ketmaier V, 2003, MOL ECOL, V12, P547, DOI 10.1046/j.1365-294X.2003.01734.x; Knott Brenton, 1993, Records of the Western Australian Museum Supplement, V45, P109; Knowlton N, 1998, P ROY SOC B-BIOL SCI, V265, P2257, DOI 10.1098/rspb.1998.0568; Lefebure T, 2007, MOL PHYLOGENET EVOL, V42, P676, DOI 10.1016/j.ympev.2006.08.020; Lefebure T, 2006, MOL PHYLOGENET EVOL, V40, P435, DOI 10.1016/j.ympev.2006.03.014; Lefebure T, 2006, MOL ECOL, V15, P1797, DOI 10.1111/j.1365-294X.2006.02888.x; Leys R, 2003, EVOLUTION, V57, P2819, DOI 10.1111/j.0014-3820.2003.tb01523.x; MACIOLEK JA, 1983, B MAR SCI, V33, P606; McQuarrie N, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017992; Moritz C, 2004, PLOS BIOL, V2, P1529, DOI 10.1371/journal.pbio.0020354; Page TJ, 2007, MOL PHYLOGENET EVOL, V43, P645, DOI 10.1016/j.ympev.2006.08.007; Page TJ, 2007, INVERTEBR SYST, V21, P137, DOI 10.1071/IS06023; Page TJ, 2005, J BIOGEOGR, V32, P581, DOI 10.1111/j.1365-2699.2004.01226.x; Pohlman JW, 2000, ECOSY WORLD, V30, P345; Porter ML, 2005, MOL PHYLOGENET EVOL, V37, P355, DOI 10.1016/j.ympev.2005.06.021; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Proudlove G, 2003, TRENDS ECOL EVOL, V18, P272, DOI 10.1016/S0169-5347(03)00095-8; Rambaut A., 2007, TRACE V1 4; Santos SR, 2006, MOL ECOL, V15, P2699, DOI 10.1111/j.1365-294X.2006.02965.x; SANZ S, 1995, CONTRIB ZOOL, V65, P79; Schubart CD, 2000, MOL PHYLOGENET EVOL, V15, P179, DOI 10.1006/mpev.1999.0754; Seymour JR, 2007, AQUAT MICROB ECOL, V50, P11, DOI 10.3354/ame01153; SKET B, 1986, STYGOLOGIA, V2, P317; Sket B, 1996, TRENDS ECOL EVOL, V11, P221, DOI 10.1016/0169-5347(96)20031-X; SMITH MJ, 1981, HYDROBIOLOGIA, V85, P49, DOI 10.1007/BF00011344; STOCK JH, 1986, CRUSTACEAN BIOGEOGRA, P195; Sturmbauer C, 1996, P NATL ACAD SCI USA, V93, P10855, DOI 10.1073/pnas.93.20.10855; SWOFFORD DL, 2002, PAUP VERSION 4 0B5 P; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TRONTELJ P, FRESHWATER IN PRESS, DOI DOI 10.1111/J.1365-2427.2007.01877.X; Trontelj P, 2007, MOL ECOL, V16, P2841, DOI 10.1111/j.1365-294X.2007.03345.x; Trontelj P, 2007, ACTA CARSOLOGICA, V36, P183; van der Mark, 2005, MRBAYES 3 1 MANUAL, P1; von Rintelen K, 2007, BIOLOGY LETT, V3, P262, DOI 10.1098/rsbl.2006.0613; WEBB MS, 2003, THESIS TEXAS A M U C; WILLIAMS W. D., 1964, AUSTRALIAN J MAR FRESHWATER RES, V15, P93; Wyrwoll K-H, 1993, RECORDS W AUSTR MU S, V45, P1; Yam RSW, 2006, J N AM BENTHOL SOC, V25, P406, DOI 10.1899/0887-3593(2006)25[406:PDAGOA]2.0.CO;2; Zaksek V, 2007, MOL PHYLOGENET EVOL, V42, P223, DOI 10.1016/j.ympev.2006.07.009	88	68	77	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1618	10.1371/journal.pone.0001618	http://dx.doi.org/10.1371/journal.pone.0001618			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286175	Green Published, gold			2022-12-25	WOS:000260586400011
J	Scholz, B; Svensson, M; Alm, H; Skold, K; Falth, M; Kultima, K; Guigoni, C; Doudnikoff, E; Li, Q; Crossman, AR; Bezard, E; Andren, PE				Scholz, Birger; Svensson, Marcus; Alm, Henrik; Skold, Karl; Falth, Maria; Kultima, Kim; Guigoni, Celine; Doudnikoff, Evelyne; Li, Qin; Crossman, Alan R.; Bezard, Erwan; Andren, Per E.			Striatal Proteomic Analysis Suggests that First L-Dopa Dose Equates to Chronic Exposure	PLOS ONE			English	Article							LEVODOPA-INDUCED DYSKINESIA; PLASMA HOMOCYSTEINE LEVELS; LONG-TERM POTENTIATION; PARKINSONS-DISEASE; SYNAPTIC PLASTICITY; GENE-EXPRESSION; PROTEIN-SYNTHESIS; MODEL; BRAIN; ACID	L-3,4-dihydroxypheylalanine (L-dopa)-induced dyskinesia represent a debilitating complication of therapy for Parkinson's disease (PD) that result from a progressive sensitization through repeated L-dopa exposures. The MPTP macaque model was used to study the proteome in dopamine-depleted striatum with and without subsequent acute and chronic L-dopa treatment using two-dimensional difference in-gel electrophoresis (2D-DIGE) and mass spectrometry. The present data suggest that the dopamine-depleted striatum is so sensitive to de novo L-dopa treatment that the first ever administration alone would be able (i) to induce rapid post-translational modification-based proteomic changes that are specific to this first exposure and (ii), possibly, lead to irreversible protein level changes that would be not further modified by chronic L-dopa treatment. The apparent equivalence between first and chronic L-dopa administration suggests that priming would be the direct consequence of dopamine loss, the first L-dopa administrations only exacerbating the sensitization process but not inducing it.	[Scholz, Birger; Svensson, Marcus; Alm, Henrik; Skold, Karl; Falth, Maria; Kultima, Kim; Andren, Per E.] Uppsala Univ, Dept Pharmaceut Biosci, Uppsala Biomed Ctr BMC, Uppsala, Sweden; [Guigoni, Celine; Doudnikoff, Evelyne; Bezard, Erwan] Univ Victor Segalen Bordeaux 2, Ctr Natl Rech Scient, Bordeaux Inst Neurosci, UMR 5227, Bordeaux, France; [Li, Qin] China Acad Med Sci, Inst Lab Animal Sci, Beijing, Peoples R China; [Crossman, Alan R.] Univ Manchester, Fac Life Sci, Manchester, Lancs, England	Uppsala University; UDICE-French Research Universities; Universite de Bordeaux; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Laboratory Animal Science - CAMS; University of Manchester	Scholz, B (corresponding author), Uppsala Univ, Dept Pharmaceut Biosci, Uppsala Biomed Ctr BMC, Uppsala, Sweden.	erwan.bezard@u-bordeaux2.fr	Söderquist, Marcus/B-5202-2012; Bezard, Erwan/ABD-5153-2021; Bezard, Erwan/A-8173-2008	Söderquist, Marcus/0000-0001-7068-5429; Doudnikoff, Evelyne/0000-0002-3770-8585; Andren, Per/0000-0002-4062-7743; Kultima, Kim/0000-0002-0680-1410; Bezard, Erwan/0000-0002-0410-4638; Alm, Henrik/0000-0003-0287-8071	Michael J. Fox Foundation for Parkinson Research; Swedish Research Council [2002-6116, 2004-3417]; Swedish Foundation for International Cooperation in Research and Higher Education (STINT); K&A Wallenberg Foundation; Karolinska Institutet	Michael J. Fox Foundation for Parkinson Research; Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Foundation for International Cooperation in Research and Higher Education (STINT); K&A Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Karolinska Institutet(Karolinska Institutet)	We want to acknowledge the work (2D-DIGE separations) done by the Proteomic Resource Centre at Uppsala university, which was established with funding from Wallenberg Consortium North (WCN). This study was sponsored by the Michael J. Fox Foundation for Parkinson Research (ARC,EB), Swedish Research Council (VR) Grants 2002-6116 and 2004-3417 (PEA), the Swedish Foundation for International Cooperation in Research and Higher Education (STINT) Institutional grant (PEA), the K&A Wallenberg Foundation (PEA), Swedish Knowledge Foundation through the Industrial PhD program in Medical Bioinformatics at the Centre for Medical Innovations (CMI) at Karolinska Institutet (PEA).	Alm H, 2006, ENVIRON HEALTH PERSP, V114, P254, DOI 10.1289/ehp.8419; Andrieux A, 2002, GENE DEV, V16, P2350, DOI 10.1101/gad.223302; Aubert I, 2005, ANN NEUROL, V57, P17, DOI 10.1002/ana.20296; Aubert I, 2007, BIOL PSYCHIAT, V61, P836, DOI 10.1016/j.biopsych.2006.06.038; Berke JD, 1998, J NEUROSCI, V18, P5301, DOI 10.1523/JNEUROSCI.18-14-05301.1998; Bezard E, 2000, SYNAPSE, V38, P363, DOI 10.1002/1098-2396(20001201)38:3<363::AID-SYN16>3.3.CO;2-1; Bezard E, 2001, J NEUROSCI, V21, P6853, DOI 10.1523/JNEUROSCI.21-17-06853.2001; Bezard E, 2001, NAT REV NEUROSCI, V2, P577, DOI 10.1038/35086062; Bezard E, 2003, NAT MED, V9, P762, DOI 10.1038/nm875; BOLAM JP, 1992, EXPT NEUROANATOMY PR, P1; BOUNDY VA, 1993, MOL PHARMACOL, V43, P666; BROOKS DJ, 1990, ANN NEUROL, V28, P547, DOI 10.1002/ana.410280412; Brotchie JA, 2005, MOVEMENT DISORD, V20, P919, DOI 10.1002/mds.20612; Brown AM, 2005, EUR J NEUROSCI, V22, P247, DOI 10.1111/j.1460-9568.2005.04190.x; Calabresi P, 2007, TRENDS NEUROSCI, V30, P211, DOI 10.1016/j.tins.2007.03.001; Centonze D, 2001, EUR J NEUROSCI, V13, P1071, DOI 10.1046/j.0953-816x.2001.01485.x; CEPEDA C, 2006, SCI STKE; Cohen P, 2001, EUR J BIOCHEM, V268, P5001, DOI 10.1046/j.0014-2956.2001.02473.x; Day M, 2006, NAT NEUROSCI, V9, P251, DOI 10.1038/nn1632; Derkach VA, 2007, NAT REV NEUROSCI, V8, P101, DOI 10.1038/nrn2055; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Ernst J, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-191; Ernst J, 2005, BIOINFORMATICS, V21, pI159, DOI 10.1093/bioinformatics/bti1022; FRAUSCHER G, 1995, LIFE SCI, V57, P813, DOI 10.1016/0024-3205(95)02009-8; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; Gracy KN, 1999, NEUROSCIENCE, V90, P107, DOI 10.1016/S0306-4522(98)00440-0; Guigoni C, 2005, EUR J NEUROSCI, V22, P283, DOI 10.1111/j.1460-9568.2005.04196.x; Guigoni C, 2007, NEUROBIOL DIS, V26, P452, DOI 10.1016/j.nbd.2007.02.001; Guilloteau D, 1998, NUCL MED BIOL, V25, P331, DOI 10.1016/S0969-8051(97)00224-2; Guzowski JF, 2005, CURR OPIN NEUROBIOL, V15, P599, DOI 10.1016/j.conb.2005.08.018; Hallett PJ, 2005, NEUROPHARMACOLOGY, V48, P503, DOI 10.1016/j.neuropharm.2004.11.008; HERSCH SM, 1995, J NEUROSCI, V15, P5222; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; Julien C, 2006, NEUROCHEM INT, V48, P404, DOI 10.1016/j.neuint.2005.12.002; Karpova A, 2006, J NEUROSCI, V26, P4949, DOI 10.1523/JNEUROSCI.4573-05.2006; Kerr JND, 2001, J NEUROPHYSIOL, V85, P117, DOI 10.1152/jn.2001.85.1.117; KISH SJ, 1988, NEW ENGL J MED, V318, P876, DOI 10.1056/NEJM198804073181402; Kocher T, 2006, J PROTEOME RES, V5, P659, DOI 10.1021/pr0503836; Kultima K, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-475; LEVEY AI, 1993, P NATL ACAD SCI USA, V90, P8861, DOI 10.1073/pnas.90.19.8861; Lonnstedt I, 2002, STAT SINICA, V12, P31; Mann M, 2003, NAT BIOTECHNOL, V21, P255, DOI 10.1038/nbt0303-255; Marsden C.D., 1982, MOVEMENT DISORD, P96; NADJAR A, 2007, PROG NEUROBIOL UNPUB; Nadjar A, 2006, J NEUROSCI, V26, P8653, DOI 10.1523/JNEUROSCI.2582-06.2006; Picconi B, 2005, NEUROTOXICOLOGY, V26, P779, DOI 10.1016/j.neuro.2005.02.002; Picconi B, 2003, NAT NEUROSCI, V6, P501, DOI 10.1038/nn1040; Samadi P, 2006, ANN NEUROL, V59, P282, DOI 10.1002/ana.20738; Schneider JS, 2003, BRAIN RES, V990, P38, DOI 10.1016/S0006-8993(03)03382-1; Schuman EM, 2006, J NEUROSCI, V26, P7143, DOI 10.1523/JNEUROSCI.1796-06.2006; Siniscalchi A, 2006, NUTR NEUROSCI, V9, P11, DOI 10.1080/10284150600583446; Smyth G.K., 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1027; Smyth GK, 2005, BIOINFORMATICS, V21, P2067, DOI 10.1093/bioinformatics/bti270; Stephens B, 2005, NEUROSCIENCE, V132, P741, DOI 10.1016/j.neuroscience.2005.01.007; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tsokas P, 2005, J NEUROSCI, V25, P5833, DOI 10.1523/JNEUROSCI.0599-05.2005; van Rossum D, 1999, TRENDS NEUROSCI, V22, P290, DOI 10.1016/S0166-2236(99)01404-6; Waagepetersen HS, 1998, DEV NEUROSCI-BASEL, V20, P310, DOI 10.1159/000017326; Yudkoff M, 2005, J NUTR, V135, p1531S, DOI 10.1093/jn/135.6.1531S; Zoccolella S, 2006, CLIN CHEM LAB MED, V44, P863, DOI 10.1515/CCLM.2006.143	60	42	44	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1589	10.1371/journal.pone.0001589	http://dx.doi.org/10.1371/journal.pone.0001589			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270577	gold, Green Published			2022-12-25	WOS:000260535900023
J	Klinge, CM; Wickramasinghe, NS; Ivanova, MM; Dougherty, SM				Klinge, Carolyn M.; Wickramasinghe, Nalinie S.; Ivanova, Margarita M.; Dougherty, Susan M.			Resveratrol stimulates nitric oxide production by increasing estrogen receptor alpha-Src-caveolin-1 interaction and phosphorylation in human umbilical vein endothelial cells	FASEB JOURNAL			English	Article						nongenomic estrogen action; membrane-associated estrogen receptor; red wine polyphenols	ESTROGEN-RECEPTOR-BETA; INITIATED SIGNALING PATHWAYS; MODERATE WINE CONSUMPTION; PLASMA-MEMBRANE; RED WINE; TYROSINE PHOSPHORYLATION; NO SYNTHASE; GENE-EXPRESSION; PROTEIN-KINASE; CANCER CELLS	Epidemiological studies correlate moderate red wine consumption to reduced incidence of cardiovascular disease. Resveratrol is a polyphenolic compound in red wine that has cardioprotective effects in rodents. Although endothelial cell (EC) studies indicate that micromolar resveratrol has diverse biological activities, these concentrations are not physiologically relevant because human oral ingestion provides only brief exposure to nanomolar plasma levels. Previously, we reported that nanomolar resveratrol activated ERK1/2 signaling in bovine aortic ECs (BAECs). The goal of this study was to determine the mechanisms by which nanomolar resveratrol rapidly activates endothelial nitric oxide synthase (eNOS) in human umbilical vein ECs (HUVECs). We report for the first time that resveratrol increased interaction between estrogen receptor alpha (ER alpha), caveolin-1 (Cav-1) and c-Src, and increased phosphorylation of Cav-1, c-Src, and eNOS. Pretreatment with the lipid raft disruptor beta-methyl cyclodextrin or G alpha inhibitor pertussis toxin blocked resveratrol- and E-2-induced eNOS activation and NO production. Depletion of endogenous ER alpha, not ER beta, by siRNA attenuated resveratrol- and E2-induced ERK1/2, Src, and eNOS phosphorylation. Our data demonstrate that nanomolar resveratrol induces ER alpha-Cav-1-c-SRC interaction, resulting in NO production through a G alpha-protein-coupled mechanism. This study provides important new insights into mechanisms for the beneficial effects of resveratrol in ECs.	Univ Louisville, Dept Biochem & Mol Biol, Sch Med, Louisville, KY 40292 USA; Univ Louisville, Ctr Genet & Mol Med, Sch Med, Louisville, KY 40292 USA	University of Louisville; University of Louisville	Klinge, CM (corresponding author), Univ Louisville, Dept Biochem & Mol Biol, Sch Med, Louisville, KY 40292 USA.	carolyn.klinge@louisville.edu	Ivanova, Margarita/AAM-4510-2021	Klinge, Carolyn/0000-0002-3358-4378; Ivanova, Margarita/0000-0002-6197-8606				Aoki T, 1999, EXP CELL RES, V253, P629, DOI 10.1006/excr.1999.4652; Ashby J, 1999, J APPL TOXICOL, V19, P39, DOI 10.1002/(SICI)1099-1263(199901/02)19:1&lt;39::AID-JAT534&gt;3.0.CO;2-M; Baron-Menguy C, 2007, FASEB J, V21, P3511, DOI 10.1096/fj.06-7782com; Bowers JL, 2000, ENDOCRINOLOGY, V141, P3657, DOI 10.1210/en.141.10.3657; Bradamante S, 2003, EUR J PHARMACOL, V465, P115, DOI 10.1016/S0014-2999(03)01441-9; Bulayeva NN, 2005, AM J PHYSIOL-ENDOC M, V288, pE388, DOI 10.1152/ajpendo.00349.2004; Bulayeva NN, 2004, ENVIRON HEALTH PERSP, V112, P1481, DOI 10.1289/ehp.7175; Bulayeva NN, 2004, STEROIDS, V69, P181, DOI 10.1016/j.steroids.2003.12.003; Chambliss KL, 2002, ENDOCR REV, V23, P665, DOI 10.1210/er.2001-0045; Chambliss KL, 2005, MOL ENDOCRINOL, V19, P277, DOI 10.1210/me.2004-0008; Chambliss KL, 2002, STEROIDS, V67, P413, DOI 10.1016/S0039-128X(01)00177-5; Chen WP, 2007, EUR J PHARMACOL, V554, P196, DOI 10.1016/j.ejphar.2006.10.016; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Cordova AC, 2005, J AM COLL SURGEONS, V200, P428, DOI 10.1016/j.jamcollsurg.2004.10.030; FAWELL SE, 1990, P NATL ACAD SCI USA, V87, P6883, DOI 10.1073/pnas.87.17.6883; Fields TA, 1997, BIOCHEM J, V321, P561, DOI 10.1042/bj3210561; Filardo E, 2007, ENDOCRINOLOGY, V148, P3236, DOI 10.1210/en.2006-1605; Filardo EJ, 2002, MOL ENDOCRINOL, V16, P70, DOI 10.1210/me.16.1.70; Foley EF, 2000, CANCER RES, V60, P245; Fournier B, 2001, J BIOL CHEM, V276, P35444, DOI 10.1074/jbc.M105418200; Frasor J, 2003, ENDOCRINOLOGY, V144, P3159, DOI 10.1210/en.2002-0143; Gehm BD, 1997, P NATL ACAD SCI USA, V94, P14138, DOI 10.1073/pnas.94.25.14138; Gilad LA, 2007, J MOL ENDOCRINOL, V38, P603, DOI 10.1677/JME-06-0040; Gingerich S, 2005, ENDOCRINOLOGY, V146, P2933, DOI 10.1210/en.2004-1375; Gingerich S, 2006, HYPERTENSION, V48, P1130, DOI 10.1161/01.HYP.0000248754.67128.ff; Goldberg DA, 2003, CLIN BIOCHEM, V36, P79, DOI 10.1016/S0009-9120(02)00397-1; Greger JG, 2007, MOL CELL BIOL, V27, P1904, DOI 10.1128/MCB.01732-06; Greger JG, 2006, STEROIDS, V71, P317, DOI 10.1016/j.steroids.2005.09.016; Guo XM, 2005, J BIOL CHEM, V280, P19704, DOI 10.1074/jbc.M501244200; Hartman J, 2006, CANCER RES, V66, P11207, DOI 10.1158/0008-5472.CAN-06-0017; Hisamoto K, 2001, J BIOL CHEM, V276, P47642, DOI 10.1074/jbc.M103853200; Ihionkhan CE, 2002, CIRC RES, V91, P814, DOI 10.1161/01.RES.0000038304.62046.4C; Joy S, 2006, J BIOL CHEM, V281, P27335, DOI 10.1074/jbc.M602803200; Kim Jin Kyung, 2006, Nucl Recept Signal, V4, pe013; Kim Kyung Hee, 2005, Sci STKE, V2005, ppe28; Kiss AL, 2005, MOL CELL ENDOCRINOL, V245, P128, DOI 10.1016/j.mce.2005.11.005; Klinge CM, 2005, J BIOL CHEM, V280, P7460, DOI 10.1074/jbc.M411565200; Klinge CM, 2003, J AGR FOOD CHEM, V51, P1850, DOI 10.1021/jf0259821; Klinge CM, 2001, ARCH BIOCHEM BIOPHYS, V390, P64, DOI 10.1006/abbi.2001.2366; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; Levenson AS, 2002, CANCER RES, V62, P4419; Levin ER, 2005, MOL ENDOCRINOL, V19, P1951, DOI 10.1210/me.2004-0390; Levin ER, 2002, STEROIDS, V67, P471, DOI 10.1016/S0039-128X(01)00179-9; Li L, 2003, P NATL ACAD SCI USA, V100, P4807, DOI 10.1073/PNAS.0831079100; Li L, 2007, P NATL ACAD SCI USA, V104, P16468, DOI 10.1073/pnas.0704315104; Lin MT, 2003, MOL PHARMACOL, V64, P1029, DOI 10.1124/mol.64.5.1029; Marier JF, 2002, J PHARMACOL EXP THER, V302, P369, DOI 10.1124/jpet.102.033340; Matthews J, 2006, MOL ENDOCRINOL, V20, P534, DOI 10.1210/me.2005-0140; Mineo C, 2006, CARDIOVASC RES, V70, P31, DOI 10.1016/j.cardiores.2006.01.025; Morani A, 2006, P NATL ACAD SCI USA, V103, P7165, DOI 10.1073/pnas.0602194103; Moriarty K, 2006, ENDOCRINOLOGY, V147, P5557, DOI 10.1210/en.2006-0729; Niles RM, 2006, J NUTR, V136, P2542, DOI 10.1093/jn/136.10.2542; O'Lone R, 2007, MOL ENDOCRINOL, V21, P1281, DOI 10.1210/me.2006-0497; Orallo F, 2002, MOL PHARMACOL, V61, P294, DOI 10.1124/mol.61.2.294; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Pedram A, 2007, J BIOL CHEM, V282, P22278, DOI 10.1074/jbc.M611877200; Pedram A, 2006, MOL ENDOCRINOL, V20, P1996, DOI 10.1210/me.2005-0525; Pervaiz S, 2003, FASEB J, V17, P1975, DOI 10.1096/fj.03-0168rev; Podar K, 2004, CANCER RES, V64, P7500, DOI 10.1158/0008-5472.CAN-04-0124; Qing L, 2004, P NATL ACAD SCI USA, V101, P17126, DOI 10.1073/pnas.0407492101; Razandi M, 2003, MOL CELL BIOL, V23, P1633, DOI 10.1128/MCB.23.5.1633-1646.2003; Razandi M, 2004, MOL ENDOCRINOL, V18, P2854, DOI 10.1210/me.2004-0115; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Razandi M, 2003, J BIOL CHEM, V278, P2701, DOI 10.1074/jbc.M205692200; Reineri S, 2007, BBA-MOL CELL RES, V1773, P273, DOI 10.1016/j.bbamcr.2006.12.001; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Sacanella E, 2007, AM J CLIN NUTR, V86, P1463, DOI 10.1093/ajcn/86.5.1463; Sato M, 2002, ANN NY ACAD SCI, V957, P122, DOI 10.1111/j.1749-6632.2002.tb02911.x; Scobie GA, 2002, STEROIDS, V67, P985, DOI 10.1016/S0039-128X(02)00047-8; Signorelli P, 2005, J NUTR BIOCHEM, V16, P449, DOI 10.1016/j.jnutbio.2005.01.017; Sladek CD, 2008, FRONT NEUROENDOCRIN, V29, P114, DOI 10.1016/j.yfrne.2007.08.005; Stoclet JC, 2004, EUR J PHARMACOL, V500, P299, DOI 10.1016/j.ejphar.2004.07.034; van Deurs B, 2003, TRENDS CELL BIOL, V13, P92, DOI 10.1016/S0962-8924(02)00039-9; Watson CS, 2007, MOL CELL ENDOCRINOL, V274, P1, DOI 10.1016/j.mce.2007.05.011; Watson Cheryl S, 2005, EMBO Rep, V6, P116; Watson CS, 2005, STEROIDS, V70, P364, DOI 10.1016/j.steroids.2005.03.002; Weihua Zhang, 2001, Proceedings of the National Academy of Sciences of the United States of America, V98, P6330, DOI 10.1073/pnas.111150898; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200; Wyckoff MH, 2001, J BIOL CHEM, V276, P27071, DOI 10.1074/jbc.M100312200; Yu CW, 2002, PHARM RES-DORDR, V19, P1907, DOI 10.1023/A:1021414129280; Zhang WH, 2003, FEBS LETT, V546, P17, DOI 10.1016/S0014-5793(03)00436-8; Zhang WH, 2000, P NATL ACAD SCI USA, V97, P5936, DOI 10.1073/pnas.97.11.5936; Zhuang LY, 2002, CANCER RES, V62, P2227	85	132	136	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2185	2197		10.1096/fj.07-103366	http://dx.doi.org/10.1096/fj.07-103366			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18296501				2022-12-25	WOS:000257292500011
J	Sen, A; Heymann, JB; Cheng, NQ; Qiao, J; Mindich, L; Steven, AC				Sen, Anindito; Heymann, J. Bernard; Cheng, Naiqian; Qiao, Jian; Mindich, Leonard; Steven, Alasdair C.			Initial location of the RNA-dependent RNA polymerase in the bacteriophage Phi 6 procapsid determined by cryo-electron microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DSRNA BACTERIOPHAGE-PHI-6; PHI-6; COMPLEX; REPLICATION; SPECIFICITY; PARTICLES; PROTEINS; SEGMENTS; GENOME	The RNA-dependent RNA polymerases (RdRPs) of Cystoviridae bacteriophages, like those of eukaryotic viruses of the Reoviridae, function inside the inner capsid shell in both replication and transcription. In bacteriophage Phi 6, this inner shell is first assembled as an icosahedral procapsid with recessed 5-fold vertices that subsequently undergoes major structural changes during maturation. The tripartite genome is packaged as single-stranded RNA molecules via channels on the 5-fold vertices, and transcripts probably exit the mature capsid by the same route. The RdRP (protein P2) is assembled within the procapsid, and it was thought that it should be located on the 5-fold axes near the RNA entry and exit channels. To determine the initial location of the RdRP inside the procapsid of bacteriophage Phi 6, we performed cryo-electron microscopy of wild type and mutant procapsids and complemented these data with biochemical determinations of copy numbers. We observe ring-like densities on the 3-fold axes that are strong in a mutant that has similar to 10 copies of P2 per particle; faint in wild type, reflecting the lower copy number of similar to 3; and completely absent in a P2-null mutant. The dimensions and shapes of these densities match those of the known crystal structure of the P2 monomer. We propose that, during maturation, the P2 molecules rotate to occupy positions closer to adjacent 5-fold vertices where they conduct replication and transcription.	[Sen, Anindito; Heymann, J. Bernard; Cheng, Naiqian; Steven, Alasdair C.] NIAMS, Struct Biol Lab, NIH, Bethesda, MD 20892 USA; [Qiao, Jian; Mindich, Leonard] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol, Publ Hlth Res Inst Ctr, Newark, NJ 07103 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Rutgers State University New Brunswick; Rutgers State University Medical Center	Heymann, JB (corresponding author), NIAMS, Struct Biol Lab, NIH, Bldg 50,Rm 1515,50 S Dr,MSC 8025, Bethesda, MD 20892 USA.	Bernard_Heymann@nih.gov	Heymann, Bernard/F-6825-2011; Heymann, Bernard/H-8265-2019	Heymann, Bernard/0000-0002-8872-5326	Intramural NIH HHS Funding Source: Medline; NIGMS NIH HHS [GM34352] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR027002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034352] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Butcher SJ, 1997, EMBO J, V16, P4477, DOI 10.1093/emboj/16.14.4477; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; DAY LA, 1980, VIROLOGY, V103, P376, DOI 10.1016/0042-6822(80)90196-8; de Haas F, 1999, J MOL BIOL, V294, P357, DOI 10.1006/jmbi.1999.3260; GOTTLIEB P, 1994, VIROLOGY, V200, P42, DOI 10.1006/viro.1994.1160; GOTTLIEB P, 1990, J BACTERIOL, V172, P5774, DOI 10.1128/jb.172.10.5774-5782.1990; Heymann JB, 2007, J STRUCT BIOL, V157, P3, DOI 10.1016/j.jsb.2006.06.006; Huiskonen JT, 2007, J STRUCT BIOL, V158, P156, DOI 10.1016/j.jsb.2006.08.021; Ikonen T, 2003, J APPL CRYSTALLOGR, V36, P525, DOI 10.1107/S0021889803001857; JUUTI JT, 1995, J MOL BIOL, V249, P545, DOI 10.1006/jmbi.1995.0317; Juuti JT, 1997, J MOL BIOL, V266, P891, DOI 10.1006/jmbi.1996.0817; Mindich L, 2004, VIRUS RES, V101, P83, DOI 10.1016/j.virusres.2003.12.008; MINDICH L, 1994, VIROLOGY, V202, P258, DOI 10.1006/viro.1994.1341; MINDICH L, 1995, VIROLOGY, V212, P213, DOI 10.1006/viro.1995.1470; OLKKONEN VM, 1987, J VIROL, V61, P2362, DOI 10.1128/JVI.61.8.2362-2367.1987; Poranen MM, 2004, VIRUS RES, V101, P93, DOI 10.1016/j.virusres.2003.12.009; Qiao J, 2003, J BACTERIOL, V185, P4572, DOI 10.1128/JB.185.15.4572-4577.2003; Salgado PS, 2004, STRUCTURE, V12, P307, DOI 10.1016/j.str.2004.01.012; Taraporewala ZF, 2004, VIRUS RES, V101, P57, DOI 10.1016/j.virusres.2003.12.006; Zhang X, 2003, NAT STRUCT BIOL, V10, P1011, DOI 10.1038/nsb1009	20	38	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2008	283	18					12227	12231		10.1074/jbc.M710508200	http://dx.doi.org/10.1074/jbc.M710508200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	293MS	18287088	Green Published, hybrid			2022-12-25	WOS:000255340000038
J	Barroso, MMS; Freire, E; Limaverde, GSCS; Rocha, GM; Batista, EJO; Weissmuller, G; Andrade, LR; Coelho-Sampaio, T				Sant'Ana Barroso, Madalena Martins; Freire, Elisabete; Limaverde, Gabriel S. C. S.; Rocha, Gustavo Miranda; Batista, Evander J. O.; Weissmueller, Gilberto; Andrade, Leonardo Rodrigues; Coelho-Sampaio, Tatiana			Artificial laminin polymers assembled in acidic pH mimic basement membrane organization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHWANN-CELLS; RAT-BRAIN; BINDING; SITES; NEURITOGENESIS; MATRICES; HEPARIN; NETWORK	Natural laminin matrices are formed on cell membranes by a cooperative process involving laminin self-polymerization and binding to cognate cellular receptors. In a cell-free system, laminin can self-polymerize, given that a minimal critical concentration is achieved. We have previously described that pH acidification renders self-polymerization independent of protein concentration. Here we studied the ultrastructure of acid-induced laminin polymers using electron and atomic force microscopies. Polymers presented the overall appearance of natural matrices and could be described as homogeneous polygonal sheets, presenting struts of 21 +/- 5 and 86 +/- 3 nm of height, which approximately correspond to the sizes of the short and the long arms of the molecule, respectively. The addition of fragment E3 ( the distal two domains of the long arm) did not affect the polymerization in solution nor the formation of adsorbed matrices. On the other hand, the addition of fragment E1', which contains two intact short arms, completely disrupted polymerization. These results indicate that acid-induced polymers, like natural ones, involve only interactions between the short arms. The electrostatic surface map of laminin alpha 1 LG4-5 shows that acidification renders the distal end in the long arms exclusively positive, precluding homophylic interactions between them. Therefore, acidification reproduces in vitro, and at a physiological protein concentration, what receptor interaction does in the cellular context, namely, it prevents the long arm from disturbing formation of the homogeneous matrix involving the short arms only. We propose that acid-induced polymers are the best tool to study cellular response to laminin in the future.	[Sant'Ana Barroso, Madalena Martins; Freire, Elisabete; Andrade, Leonardo Rodrigues; Coelho-Sampaio, Tatiana] Univ Fed Rio de Janeiro, Inst Biomed Sci, BR-21941590 Rio De Janeiro, Brazil; [Limaverde, Gabriel S. C. S.; Rocha, Gustavo Miranda; Batista, Evander J. O.; Weissmueller, Gilberto] Univ Fed Rio de Janeiro, Inst Biophys Carlos Chagas Filho, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro	Coelho-Sampaio, T (corresponding author), Univ Fed Rio de Janeiro, Inst Biomed Sci, BR-21941590 Rio De Janeiro, Brazil.	tcsampaio@histo.ufrj.br	Andrade, Leonardo/C-9554-2011	Andrade, Leonardo/0000-0002-0004-5677				Aumailley M, 2005, MATRIX BIOL, V24, P326, DOI 10.1016/j.matbio.2005.05.006; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; COLOGNATOPYKE H, 1995, J BIOL CHEM, V270, P9398, DOI 10.1074/jbc.270.16.9398; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Freire E, 2004, J CELL SCI, V117, P4067, DOI 10.1242/jcs.01276; Freire E, 2002, J CELL SCI, V115, P4867, DOI 10.1242/jcs.00173; Freire E, 2000, J BIOL CHEM, V275, P817, DOI 10.1074/jbc.275.2.817; GARCIAABREU J, 1995, J NEUROSCI RES, V40, P471, DOI 10.1002/jnr.490400406; Harrison D, 2007, J BIOL CHEM, V282, P11573, DOI 10.1074/jbc.M610657200; KALB E, 1991, J BIOL CHEM, V266, P19047; Li SH, 2005, J CELL BIOL, V169, P179, DOI 10.1083/jcb.200501098; LuckenbillEdds L, 1997, BRAIN RES REV, V23, P1, DOI 10.1016/S0165-0173(96)00013-6; Mckee KK, 2007, J BIOL CHEM, V282, P21437, DOI 10.1074/jbc.M702963200; Miner JH, 2004, ANNU REV CELL DEV BI, V20, P255, DOI 10.1146/annurev.cellbio.20.010403.094555; MORRIS VJ, 1999, ATOMIC FORCE MICROSC, P44; STICHEL CC, 1994, J NEUROCYTOL, V23, P615, DOI 10.1007/BF01191556; Tisi D, 2000, EMBO J, V19, P1432, DOI 10.1093/emboj/19.7.1432; Tsiper MV, 2002, J CELL SCI, V115, P1005; YURCHENCO PD, 1992, J CELL BIOL, V117, P1119, DOI 10.1083/jcb.117.5.1119; YURCHENCO PD, 1985, J BIOL CHEM, V260, P7636; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767; ZHOU FC, 1990, DEV BRAIN RES, V55, P191, DOI 10.1016/0165-3806(90)90200-I	22	18	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11714	11720		10.1074/jbc.M709301200	http://dx.doi.org/10.1074/jbc.M709301200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18276595	hybrid			2022-12-25	WOS:000255067400071
J	Sirijovski, N; Lundqvist, J; Rosenback, M; Elmlund, H; Al-Karadaghi, S; Willows, RD; Hansson, M				Sirijovski, Nickolche; Lundqvist, Joakim; Rosenback, Matilda; Elmlund, Hans; Al-Karadaghi, Salam; Willows, Robert D.; Hansson, Mats			Substrate-binding model of the chlorophyll biosynthetic magnesium chelatase BchH subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOPORPHYRIN IX CHELATASE; MG-CHELATASE; ATPASE ACTIVITY; H-SUBUNIT; SYNECHOCYSTIS PCC6803; ENZYME; RESOLUTION; PROTEINS; CHLI; RECONSTITUTION	Photosynthetic organisms require chlorophyll and bacteriochlorophyll to harness light energy and to transform water and carbon dioxide into carbohydrates and oxygen. The biosynthesis of these pigments is initiated by magnesium chelatase, an enzyme composed of BchI, BchD, and BchH proteins, which catalyzes the insertion of Mg2+ into protoporphyrin IX ( Proto) to produce Mg-protoporphyrin IX. BchI and BchD form an ATP-dependent AAA(+) complex that transiently interacts with the Proto-binding BchH subunit, at which point Mg2+ is chelated. In this study, controlled proteolysis, electron microscopy of negatively stained specimens, and single-particle three-dimensional reconstruction have been used to probe the structure and substrate-binding mechanism of the BchH subunit to a resolution of 25 angstrom. The apo structure contains three major lobeshaped domains connected at a single point with additional densities at the tip of two lobes termed the "thumb" and "finger." With the independent reconstruction of a substratebound BchH complex (BchH.Proto), we observed a distinct conformational change in the thumb and finger subdomains. Prolonged proteolysis of native apo-BchH produced a stable C-terminal fragment of 45 kDa, and Proto was shown to protect the full-length polypeptide from degradation. Fitting of a truncated BchH polypeptide reconstruction identified the Nand C-terminal domains. Our results show that the N- and C-terminal domains play crucial roles in the substrate-binding mechanism.	[Sirijovski, Nickolche; Rosenback, Matilda; Hansson, Mats] Lund Univ, Ctr Mol Prot Sci, Dept Biochem, SE-22100 Lund, Sweden; [Lundqvist, Joakim; Elmlund, Hans; Al-Karadaghi, Salam] Lund Univ, Ctr Mol Prot Sci, Dept Mol Biophys, SE-22100 Lund, Sweden; [Elmlund, Hans] Karolinska Inst, Dept Biosci & Nutr, SE-14187 Huddinge, Sweden; [Elmlund, Hans] Royal Inst Technol, Sch Technol & Hlth, SE-14187 Huddinge, Sweden; [Willows, Robert D.] Macquarie Univ, Dept Chem & Biomol Sci, N Ryde, NSW 2109, Australia	Lund University; Lund University; Karolinska Institutet; Royal Institute of Technology; Macquarie University	Hansson, M (corresponding author), Lund Univ, Ctr Mol Prot Sci, Dept Biochem, Box 124, SE-22100 Lund, Sweden.	mats.hansson@biochemistry.lu.se	ELMLUND, HANS/AAA-6625-2021; Willows, Robert/C-1537-2010; Al-karadaghi, Salam/F-1492-2011	Willows, Robert/0000-0002-0731-2950; Al-karadaghi, Salam/0000-0001-8608-0635; Elmlund, Hans/0000-0002-6992-0601; Hansson, Mats/0000-0002-0168-9968; Sirijovski, Nick/0000-0002-6191-3845				Ahrman E, 2007, PROTEIN SCI, V16, P1464, DOI 10.1110/ps.072831607; BOLLIVAR DW, 1994, J MOL BIOL, V237, P622, DOI 10.1006/jmbi.1994.1260; BOLLIVAR DW, 2003, TETRAPYRROLE HDB, V2, P49; Burgess SA, 2004, J STRUCT BIOL, V147, P247, DOI 10.1016/j.jsb.2004.04.004; DEBUSSCHE L, 1992, J BACTERIOL, V174, P7445, DOI 10.1128/jb.174.22.7445-7451.1992; Drapeau G R, 1976, Methods Enzymol, V45, P469; Elmlund H, 2008, J MOL BIOL, V375, P934, DOI 10.1016/j.jmb.2007.11.028; FALK JE, 1964, PORPHYRINS METALLOPO; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Fodje MN, 2001, J MOL BIOL, V311, P111, DOI 10.1006/jmbi.2001.4834; Fontana A, 1997, FOLD DES, V2, pR17, DOI 10.1016/S1359-0278(97)00010-2; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Gibson LCD, 1999, BIOCHEM J, V337, P243, DOI 10.1042/0264-6021:3370243; Hansson A, 2002, P NATL ACAD SCI USA, V99, P13944, DOI 10.1073/pnas.212504499; Hansson MD, 2008, ANAL BIOCHEM, V375, P373, DOI 10.1016/j.ab.2007.12.005; Hinchigeri SB, 1997, FEBS LETT, V407, P337, DOI 10.1016/S0014-5793(97)00371-2; HUDSON A, 1993, EMBO J, V12, P3711, DOI 10.1002/j.1460-2075.1993.tb06048.x; Jensen PE, 1999, BIOCHEM J, V339, P127, DOI 10.1042/0264-6021:3390127; Jensen PE, 1998, BIOCHEM J, V334, P335, DOI 10.1042/bj3340335; Jensen PE, 1996, J BIOL CHEM, V271, P16662, DOI 10.1074/jbc.271.28.16662; Karger GA, 2001, BIOCHEMISTRY-US, V40, P9291, DOI 10.1021/bi010562a; Lake V, 2004, EUR J BIOCHEM, V271, P2182, DOI 10.1111/j.1432-1033.2004.04143.x; Larkin RM, 2003, SCIENCE, V299, P902, DOI 10.1126/science.1079978; Lebart L., 1984, MULTIVARIATE DESCRIP; Lecerof D, 2000, J MOL BIOL, V297, P221, DOI 10.1006/jmbi.2000.3569; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Medlock A, 2007, P NATL ACAD SCI USA, V104, P1789, DOI 10.1073/pnas.0606144104; Mochizuki N, 2001, P NATL ACAD SCI USA, V98, P2053, DOI 10.1073/pnas.98.4.2053; Moradian-Oldak J, 2001, BIOPOLYMERS, V58, P606, DOI 10.1002/1097-0282(200106)58:7<606::AID-BIP1034>3.0.CO;2-8; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Papenbrock J, 1997, PLANT J, V12, P981, DOI 10.1046/j.1365-313X.1997.12050981.x; Reid JD, 2003, BIOCHEMISTRY-US, V42, P6912, DOI 10.1021/bi034082q; Shen YY, 2006, NATURE, V443, P823, DOI 10.1038/nature05176; Shepherd M, 2005, FEBS J, V272, P4532, DOI 10.1111/j.1742-4658.2005.04873.x; Sirijovski N, 2006, BIOCHEM J, V400, P477, DOI 10.1042/BJ20061103; Strand A, 2003, NATURE, V421, P79, DOI 10.1038/nature01204; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P111, DOI 10.1016/0304-3991(87)90078-7; WALKER CJ, 1991, P NATL ACAD SCI USA, V88, P5789, DOI 10.1073/pnas.88.13.5789; WALKER CJ, 1991, PLANT PHYSIOL, V95, P1189, DOI 10.1104/pp.95.4.1189; Willows RD, 2004, J STRUCT BIOL, V146, P227, DOI 10.1016/j.jsb.2003.11.019; Willows RD, 1998, J BIOL CHEM, V273, P34206, DOI 10.1074/jbc.273.51.34206; Willows RD, 1996, EUR J BIOCHEM, V235, P438, DOI 10.1111/j.1432-1033.1996.00438.x; Willows RD, 2003, J BACTERIOL, V185, P3249, DOI 10.1128/JB.185.11.3249-3258.2003; WILLOWS RD, 2003, TETRAPYRROLE HDB, V2, P1; Yang SX, 2003, J STRUCT BIOL, V144, P162, DOI 10.1016/j.jsb.2003.09.016; ZSEBO KM, 1984, CELL, V37, P937, DOI 10.1016/0092-8674(84)90428-8	47	40	41	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11652	11660		10.1074/jbc.M709172200	http://dx.doi.org/10.1074/jbc.M709172200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18263581	hybrid			2022-12-25	WOS:000255067400066
J	Stoecklin, G; Tenenbaum, SA; Mayo, T; Chittur, SV; George, AD; Baroni, TE; Blackshear, PJ; Anderson, P				Stoecklin, Georg; Tenenbaum, Scott A.; Mayo, Thomas; Chittur, Sridar V.; George, Ajish D.; Baroni, Timothy E.; Blackshear, Perry J.; Anderson, Paul			Genome-wide analysis identifies interleukin-10 mRNA as target of tristetraprolin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; AU-RICH ELEMENT; ZINC-FINGER PROTEINS; PROBE LEVEL DATA; FACTOR-ALPHA; RIBONUCLEOPROTEIN COMPLEXES; DEGRADATION PATHWAY; BINDING PROTEINS; EXPRESSION; TURNOVER	Tristetraprolin (TTP) is an RNA-binding protein required for the rapid degradation of mRNAs containing AU-rich elements. Targets regulated by TTP include the mRNAs encoding tumor necrosis factor-alpha, granulocyte-macrophage colony-stimulating factor, interleukin-2 (IL-2), and immediate early response 3. To identify novel target mRNAs of TTP in macrophages, we used a genome-wide approach that combines RNA immunoprecipitation and microarray analysis. A list was compiled of 137 mRNAs that are associated with TTP with an estimated accuracy on the order of 90%. Sequence analysis revealed a highly significant enrichment of AU-rich element motifs, with AUUUA pentamers present in 96% and UUAUUUAUU nonamers present in 44% of TTP-associated mRNAs. We further show that IL-10 is a novel target regulated by TTP. IL-10 mRNA levels were found to be elevated because of a reduced decay rate in primary macrophages from TTP-/- mice. Our study demonstrates the importance of experimental approaches for identifying targets of RNA-binding proteins.	[Stoecklin, Georg] DKFZ ZMBH Alliance, German Canc Res Ctr, D-69120 Heidelberg, Germany; [Stoecklin, Georg; Mayo, Thomas; Anderson, Paul] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; [Tenenbaum, Scott A.; Chittur, Sridar V.; George, Ajish D.; Baroni, Timothy E.] SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Gen NY Sis Ctr Excellence Canc Genom, Rensselaer, NY 12144 USA; [Tenenbaum, Scott A.; Chittur, Sridar V.; George, Ajish D.; Baroni, Timothy E.] SUNY Albany, Sch Publ Hlth, Ctr Funct Genom, Rensselaer, NY 12144 USA; [Blackshear, Perry J.] NIEHS, NIH, Res Triangle Pk, NC 27709 USA	Helmholtz Association; German Cancer Research Center (DKFZ); Harvard University; Brigham & Women's Hospital; Harvard Medical School; State University of New York (SUNY) System; State University of New York (SUNY) Albany; State University of New York (SUNY) System; State University of New York (SUNY) Albany; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Stoecklin, G (corresponding author), DKFZ ZMBH Alliance, German Canc Res Ctr, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	g.stoecklin@dkfz.de	Blackshear, Perry J./C-6206-2019; /W-2676-2019; Tenenbaum, Scott A/H-4744-2019	Blackshear, Perry J./0000-0002-9561-8529; Stoecklin, Georg/0000-0001-9284-9834	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U01HG004571, R21HG003679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033600, R01AI050167, R56AI033600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090080, Z01ES090080] Funding Source: NIH RePORTER; NHGRI NIH HHS [U01HG004571, R21HG003679] Funding Source: Medline; NIAID NIH HHS [AI-33600, AI-50167] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bakheet T, 2003, NUCLEIC ACIDS RES, V31, P421, DOI 10.1093/nar/gkg023; Beaudoing E, 2000, GENOME RES, V10, P1001, DOI 10.1101/gr.10.7.1001; Blackshear PJ, 2002, BIOCHEM SOC T, V30, P945, DOI 10.1042/BST0300945; Bolstad B, 2005, BIOINFORMATICS COMPU; Brewer BY, 2004, J BIOL CHEM, V279, P27870, DOI 10.1074/jbc.M402551200; Briata P, 2003, MOL CELL, V12, P1201, DOI 10.1016/S1097-2765(03)00407-6; Brooks SA, 2004, J IMMUNOL, V172, P7263, DOI 10.4049/jimmunol.172.12.7263; Brooks SA, 2002, ARTHRITIS RHEUM, V46, P1362, DOI 10.1002/art.10235; Brown V, 2001, CELL, V107, P477, DOI 10.1016/S0092-8674(01)00568-2; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Cope LM, 2004, BIOINFORMATICS, V20, P323, DOI 10.1093/bioinformatics/btg410; de Silanes IL, 2005, MOL CELL BIOL, V25, P9520, DOI 10.1128/MCB.25.21.9520-9531.2005; Essafi-Benkhadir K, 2007, MOL BIOL CELL, V18, P4648, DOI 10.1091/mbc.E07-06-0570; Fechir M, 2005, MOL PHARMACOL, V67, P2148, DOI 10.1124/mol.104.008763; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; George Ajish D, 2006, RNA Biol, V3, P57; Gerber AP, 2004, PLOS BIOL, V2, P342, DOI 10.1371/journal.pbio.0020079; Gringhuis SI, 2005, MOL CELL BIOL, V25, P6454, DOI 10.1128/MCB.25.15.6454-6463.2005; Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; JALONEN U, 2006, MEDIAT INFLAMM, P1; Kedersha N, 2000, J CELL BIOL, V151, P1257, DOI 10.1083/jcb.151.6.1257; Keene JD, 2006, NAT PROTOC, V1, P302, DOI 10.1038/nprot.2006.47; Keene JD, 2002, MOL CELL, V9, P1161, DOI 10.1016/S1097-2765(02)00559-2; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Lai WS, 2006, MOL CELL BIOL, V26, P9196, DOI 10.1128/MCB.00945-06; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; Liu WM, 2002, BIOINFORMATICS, V18, P1593, DOI 10.1093/bioinformatics/18.12.1593; Marderosian M, 2006, ONCOGENE, V25, P6277, DOI 10.1038/sj.onc.1209645; Mazan-Mamczarz K, 2006, MOL CELL BIOL, V26, P2716, DOI 10.1128/MCB.26.7.2716-2727.2006; Mili S, 2004, RNA, V10, P1692, DOI 10.1261/rna.7151404; Ogilvie RL, 2005, J IMMUNOL, V174, P953, DOI 10.4049/jimmunol.174.2.953; PLATZER C, 1995, INT IMMUNOL, V7, P517, DOI 10.1093/intimm/7.4.517; Sawaoka H, 2003, J BIOL CHEM, V278, P13928, DOI 10.1074/jbc.M300016200; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Stoecklin G, 2000, MOL CELL BIOL, V20, P3753, DOI 10.1128/MCB.20.11.3753-3763.2000; Stoecklin G, 2004, EMBO J, V23, P1313, DOI 10.1038/sj.emboj.7600163; STOECKLIN G, 1994, J BIOL CHEM, V269, P28591; Stoecklin G, 2002, EMBO J, V21, P4709, DOI 10.1093/emboj/cdf444; Stoecklin G, 2001, RNA, V7, P1578; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; Tenenbaum SA, 2002, METHODS, V26, P191, DOI 10.1016/S1046-2023(02)00022-1; Tenenbaum SA, 2000, P NATL ACAD SCI USA, V97, P14085, DOI 10.1073/pnas.97.26.14085; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683; Yang E, 2003, GENOME RES, V13, P1863, DOI 10.1101/gr.1272403; Yu H, 2003, J BIOL CHEM, V278, P13912, DOI 10.1074/jbc.M213027200; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	52	195	196	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11689	11699		10.1074/jbc.M709657200	http://dx.doi.org/10.1074/jbc.M709657200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18256032	Green Published, hybrid			2022-12-25	WOS:000255067400069
J	Cotner-Gohara, E; Kim, IK; Tomkinson, AE; Ellenberger, T				Cotner-Gohara, Elizabeth; Kim, In-Kwon; Tomkinson, Alan E.; Ellenberger, Tom			Two DNA-binding and nick recognition modules in human DNA ligase III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; ZINC-FINGER DOMAIN; CRYSTAL-STRUCTURE; BRCT DOMAIN; POLY(ADP-RIBOSE) POLYMERASE-1; GENE ENCODES; REPAIR; ALPHA; REPLICATION; EXPRESSION	Human DNA ligase III contains an N-terminal zinc finger domain that binds to nicks and gaps in DNA. This small domain has been described as a DNA nick sensor, but it is not required for DNA nick joining activity in vitro. In light of new structural information for mammalian ligases, we measured the DNA binding affinity and specificity of each domain of DNA ligase III. These studies identified two separate, independent DNA-binding modules in DNA ligase III that each bind specifically to nicked DNA over intact duplex DNA. One of these modules comprises the zinc finger domain and DNA-binding domain, which function together as a single DNA binding unit. The catalytic core of ligase III is the second DNA nick-binding module. Both binding modules are required for ligation of blunt ended DNA substrates. Although the zinc finger increases the catalytic efficiency of nick ligation, it appears to occupy the same binding site as the DNA ligase III catalytic core. We present a jackknife model for ligase III that posits conformational changes during nick sensing and ligation to extend the versatility of the enzyme.	[Cotner-Gohara, Elizabeth] Harvard Univ, Sch Med, Biol & Biomed Sci Program, Boston, MA 02115 USA; [Cotner-Gohara, Elizabeth; Kim, In-Kwon; Ellenberger, Tom] Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; [Tomkinson, Alan E.] Univ Maryland, Sch Med, Dept Radiat Oncol, Radiat Oncol Res Lab, Baltimore, MD 21201 USA	Harvard University; Harvard Medical School; Washington University (WUSTL); University System of Maryland; University of Maryland Baltimore	Ellenberger, T (corresponding author), 660 S Euclid Ave,Campus Box 8231, St Louis, MO 63110 USA.	tome@biochem.wustl.edu	Classen, Scott/AAY-8176-2020		NCI NIH HHS [P01 CA092584] Funding Source: Medline; NIEHS NIH HHS [ES12512] Funding Source: Medline; NIGMS NIH HHS [GM52504] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA092584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012512] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahel I, 2006, NATURE, V443, P713, DOI 10.1038/nature05164; Audebert M, 2004, J BIOL CHEM, V279, P55117, DOI 10.1074/jbc.M404524200; BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; Bogenhagen DF, 2001, PROG NUCLEIC ACID RE, V68, P257; Chen L, 2000, J BIOL CHEM, V275, P26196, DOI 10.1074/jbc.M000491200; Date H, 2001, NAT GENET, V29, P184, DOI 10.1038/ng1001-184; Dulic A, 2001, BIOCHEMISTRY-US, V40, P5906, DOI 10.1021/bi002701e; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; Krishnan VV, 2001, BIOCHEMISTRY-US, V40, P13158, DOI 10.1021/bi010979g; Kulczyk AW, 2004, J MOL BIOL, V341, P723, DOI 10.1016/j.jmb.2004.06.035; Lakshmipathy U, 1999, MOL CELL BIOL, V19, P3869; Lakshmipathy U, 2001, NUCLEIC ACIDS RES, V29, P668, DOI 10.1093/nar/29.3.668; LECAM E, 1994, J MOL BIOL, V235, P1062, DOI 10.1006/jmbi.1994.1057; Lee JY, 2000, EMBO J, V19, P1119, DOI 10.1093/emboj/19.5.1119; Leppard JB, 2003, MOL CELL BIOL, V23, P5919, DOI 10.1128/MCB.23.16.5919-5927.2003; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; Mackenney VJ, 1997, J BIOL CHEM, V272, P11550; Mackey ZB, 1999, J BIOL CHEM, V274, P21679, DOI 10.1074/jbc.274.31.21679; Mackey ZB, 1997, MOL CELL BIOL, V17, P989, DOI 10.1128/MCB.17.2.989; Martin IV, 2002, GENOME BIOL, V3; MENISSIERDEMURCIA J, 1989, J MOL BIOL, V210, P229, DOI 10.1016/0022-2836(89)90302-1; Moreira MC, 2001, NAT GENET, V29, P189, DOI 10.1038/ng1001-189; Moser J, 2007, MOL CELL, V27, P311, DOI 10.1016/j.molcel.2007.06.014; Nair PA, 2007, NAT STRUCT MOL BIOL, V14, P770, DOI 10.1038/nsmb1266; Nandakumar J, 2007, MOL CELL, V26, P257, DOI 10.1016/j.molcel.2007.02.026; Nash RA, 1997, BIOCHEMISTRY-US, V36, P5207, DOI 10.1021/bi962281m; Odell M, 2000, MOL CELL, V6, P1183, DOI 10.1016/S1097-2765(00)00115-5; Odell M, 1999, J BIOL CHEM, V274, P14032, DOI 10.1074/jbc.274.20.14032; Pascal JM, 2004, NATURE, V432, P473, DOI 10.1038/nature03082; Pascal JM, 2006, MOL CELL, V24, P279, DOI 10.1016/j.molcel.2006.08.015; Petrucco S, 2003, NUCLEIC ACIDS RES, V31, P6689, DOI 10.1093/nar/gkg890; Petrucco S, 2002, J BIOL CHEM, V277, P23675, DOI 10.1074/jbc.M201411200; Puebla-Osorio N, 2006, MOL CELL BIOL, V26, P3935, DOI 10.1128/MCB.26.10.3935-3941.2006; Sekiguchi J, 1997, J VIROL, V71, P9679, DOI 10.1128/JVI.71.12.9679-9684.1997; Sekiguchi J, 1997, NUCLEIC ACIDS RES, V25, P727, DOI 10.1093/nar/25.4.727; Sleeth KM, 2004, BIOCHEMISTRY-US, V43, P12924, DOI 10.1021/bi0492612; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; Taylor RM, 1998, NUCLEIC ACIDS RES, V26, P4804, DOI 10.1093/nar/26.21.4804; Taylor RM, 2000, NUCLEIC ACIDS RES, V28, P3558, DOI 10.1093/nar/28.18.3558; Taylor RM, 1998, CURR BIOL, V8, P877, DOI 10.1016/S0960-9822(07)00350-8; Thornton KH, 2001, PROTEIN EXPRES PURIF, V21, P401, DOI 10.1006/prep.2001.1391; Tomkinson AE, 2006, CHEM REV, V106, P687, DOI 10.1021/cr040498d; Tomkinson AE, 1998, MUTAT RES-DNA REPAIR, V407, P1, DOI 10.1016/S0921-8777(97)00050-5; Tomkinson AE, 1997, BIOESSAYS, V19, P893, DOI 10.1002/bies.950191009; WAGA S, 1994, J BIOL CHEM, V269, P10923; Wang HC, 2005, CANCER RES, V65, P4020, DOI 10.1158/0008-5472.CAN-04-3055; Wang ML, 2006, NUCLEIC ACIDS RES, V34, P6170, DOI 10.1093/nar/gkl840; Windhofer F, 2007, J CELL PHYSIOL, V213, P475, DOI 10.1002/jcp.21120	49	46	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10764	10772		10.1074/jbc.M708175200	http://dx.doi.org/10.1074/jbc.M708175200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18238776	Green Published, hybrid			2022-12-25	WOS:000254894700059
J	Das, A; Davis, MA; Tomoda, H; Omura, S; Rudel, LL				Das, Akash; Davis, Matthew A.; Tomoda, Hiroshi; Omura, Satoshi; Rudel, Lawrence L.			Identification of the interaction site within acyl-CoA: Cholesterol acyltransferase 2 for the isoform-specific inhibitor pyripyropene A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY-ARTERY ATHEROSCLEROSIS; MICE; ACAT2; PRIMATES; ENZYME; CELLS; LIVER; HYPERCHOLESTEROLEMIA; LIPOPROTEIN; MEMBRANE	Targeted deletion of acyl-CoA: cholesterol acyltransferase 2 (ACAT2) (A2), especially in the liver, protects hyperlipidemic mice from diet-induced hypercholesterolemia and atherosclerosis, whereas the deletion of ACAT1 (A1) is not as effective, suggesting ACAT2 may be the more appropriate target for treatment of atherosclerosis. Among the numerous ACAT inhibitors known, pyripyropene A (PPPA) is the only compound that has high selectivity (> 2000-fold) for inhibition of ACAT2 compared with ACAT1. In the present study we sought to determine the PPPA interaction site of ACAT2. To achieve this goal we made several chimeric proteins where parts of ACAT2 were replaced by the analogous region of ACAT1. Differences in the amino acid sequence and the membrane topology were utilized to design the chimeras. Among chimeras, A2: 1-428/A1:444-550 had 50% reduced PPPA selectivity, whereas C-terminal-truncated ACAT2 mutant A2:1-504 (C-terminal last 22 amino acids were deleted) remained selectively inhibited, indicating the PPPA-sensitive site is located within a region between amino acids 440 and 504. Three additional chimeras within this region helped narrow down the PPPA-sensitive site to a region containing amino acids 480-504, representing the fifth putative transmembrane domain of ACAT2. Subsequently, for this region we made single amino acid mutants where each amino acid in ACAT2 was individually changed to its ACAT1 counterpart. Mutation of Q492L, V493L, S494A resulted in only 30, 50, and 70% inhibition of the activity by PPPA, respectively (as opposed to greater than 95% with the wild type enzyme), suggesting these three residues are responsible for the selective inhibition by PPPA of ACAT2. Additionally, we found that PPPA non-covalently interacts with ACAT2 apparently without altering the oligomeric structure of the protein. The present study provides the first evidence for a unique motif in ACAT2 that can be utilized for making an ACAT2-specific drug.	[Davis, Matthew A.; Rudel, Lawrence L.] Wake Forest Univ, Dept Pathol, Sect Lipid Sci, Sch Med, Winston Salem, NC 27157 USA; [Das, Akash; Rudel, Lawrence L.] Wake Forest Univ, Dept Biochem, Sect Lipid Sci, Sch Med, Winston Salem, NC 27157 USA; [Tomoda, Hiroshi] Kitasato Univ, Sch Pharm, Tokyo 1088641, Japan; [Omura, Satoshi] Kitasato Univ, Kitasato Inst Life Sci, Tokyo 1088641, Japan; [Omura, Satoshi] Kitasato Univ, Grad Sch Infect Control Sci, Tokyo 1088641, Japan	Wake Forest University; Wake Forest University; Kitasato University; Kitasato University; Kitasato University	Rudel, LL (corresponding author), Wake Forest Univ, Dept Pathol, Sect Lipid Sci, Sch Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	lrudel@wfubmc.edu			NHLBI NIH HHS [NIH-P01-HL49373] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049373] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bell TA, 2006, ARTERIOSCL THROM VAS, V26, P1814, DOI 10.1161/01.ATV.0000225289.30767.06; Buhman KF, 2000, BBA-MOL CELL BIOL L, V1529, P142, DOI 10.1016/S1388-1981(00)00144-X; Buhman KK, 2000, NAT MED, V6, P1341, DOI 10.1038/82153; CARR TP, 1992, ARTERIOSCLER THROMB, V12, P1274, DOI 10.1161/01.ATV.12.11.1274; DUGGLEBY RG, 1981, ANAL BIOCHEM, V110, P9, DOI 10.1016/0003-2697(81)90104-4; Fazio S, 2001, J CLIN INVEST, V107, P163, DOI 10.1172/JCI10310; Guo ZY, 2005, J BIOL CHEM, V280, P37814, DOI 10.1074/jbc.M508384200; Joyce CW, 2000, MOL BIOL CELL, V11, P3675, DOI 10.1091/mbc.11.11.3675; Lada AT, 2004, J LIPID RES, V45, P378, DOI 10.1194/jlr.D300037-JLR200; Lee RG, 2004, CIRC RES, V95, P998, DOI 10.1161/01.RES.0000147558.15554.67; Lee RG, 2000, J LIPID RES, V41, P1991; Lin S, 1999, J BIOL CHEM, V274, P23276, DOI 10.1074/jbc.274.33.23276; Lin S, 2003, MOL BIOL CELL, V14, P2447, DOI 10.1091/mbc.E02-11-0725; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; Parini P, 2004, CIRCULATION, V110, P2017, DOI 10.1161/01.CIR.0000143163.76212.0B; Rudel LL, 2005, ARTERIOSCL THROM VAS, V25, P1112, DOI 10.1161/01.ATV.0000166548.65753.1e; Rudel LL, 1998, PROG LIPID RES, V37, P353, DOI 10.1016/S0163-7827(98)00015-0; Rudel LL, 2002, J BIOL CHEM, V277, P31401, DOI 10.1074/jbc.M204106200; Rudel LL, 2001, CURR OPIN LIPIDOL, V12, P121, DOI 10.1097/00041433-200104000-00005; Sliskovic Drago R, 2002, Prog Med Chem, V39, P121, DOI 10.1016/S0079-6468(08)70070-5; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; Willner EL, 2003, P NATL ACAD SCI USA, V100, P1262, DOI 10.1073/pnas.0336398100; Yagyu H, 2000, J BIOL CHEM, V275, P21324, DOI 10.1074/jbc.M002541200; Yu CJ, 1999, J BIOL CHEM, V274, P36139, DOI 10.1074/jbc.274.51.36139	24	24	24	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10453	10460		10.1074/jbc.M709460200	http://dx.doi.org/10.1074/jbc.M709460200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18285335	Green Published, hybrid			2022-12-25	WOS:000254894700026
J	Perez, JC; Latifi, T; Groisman, EA				Perez, J. Christian; Latifi, Tammy; Groisman, Eduardo A.			Overcoming H-NS-mediated transcriptional silencing of horizontally acquired genes by the PhoP and SlyA proteins in Salmonella enterica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; RNA-POLYMERASE; ANTIMICROBIAL PEPTIDES; REGULATORY NETWORK; FOREIGN DNA; EXPRESSION; RESISTANCE; VIRULENCE; TYPHIMURIUM; SYSTEM	The acquisition of new traits through horizontal gene transfer depends on the ability of the recipient organism to express the incorporated genes. However, foreign DNA appears to be silenced by the histone-like nucleoid-structuring protein (H-NS) in several enteric pathogens, raising the question of how this silencing is overcome and the acquired genes are expressed at the right time and place. To address this question, we investigated transcription of the horizontally acquired ugtL and pagC genes from Salmonella enterica, which is dependent on the regulatory DNA-binding proteins PhoP and SlyA. We reconstituted transcription of the ugtL and pagC genes in vitro and determined occupancy of their respective promoters by PhoP, H-NS, and RNA polymerase in vivo. The SlyA protein counteracted H-NS-promoted repression in vitro but could not promote gene transcription by itself. PhoP-promoted transcription required SlyA when H-NS was present but not in its absence. In vivo, H-NS remained bound to the ugtL and pagC promoters under inducing conditions that promoted RNA polymerase recruitment and transcription of the ugtL and pagC genes. Our results indicate that relief of H-NS repression and recruitment of RNA polymerase are controlled by different regulatory proteins that act in concert to express horizontally acquired genes.	[Perez, J. Christian] Washington Univ, Sch Med, Howard Hughes Med Inst, Program Mol Genet & Genom, St Louis, MO 63110 USA; [Latifi, Tammy; Groisman, Eduardo A.] Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Microbiol, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Groisman, EA (corresponding author), Campus Box 8230,660 S Euclid Ave, St Louis, MO 63110 USA.	groisman@borcim.wustl.edu		Perez, J. Christian/0000-0001-5790-1481	Howard Hughes Medical Institute Funding Source: Medline; NIAID NIH HHS [R01 AI049561, AI49561, R01 AI042236-10, R01 AI049561-16, R01 AI042236] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042236, R01AI049561] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bouffartigues E, 2007, NAT STRUCT MOL BIOL, V14, P441, DOI 10.1038/nsmb1233; Boyle EC, 2007, J BACTERIOL, V189, P1489, DOI 10.1128/JB.01730-06; Chamnongpol S, 2000, J MOL BIOL, V300, P291, DOI 10.1006/jmbi.2000.3848; CHEREPANOV PP, 1995, GENE, V158, P9, DOI 10.1016/0378-1119(95)00193-A; Corbett D, 2007, J BIOL CHEM, V282, P33326, DOI 10.1074/jbc.M703465200; Dame RT, 2006, NATURE, V444, P387, DOI 10.1038/nature05283; Dame RT, 2002, J BIOL CHEM, V277, P2146, DOI 10.1074/jbc.C100603200; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Davis R., 1980, ADV BACTERIAL GENETI; Dorman CJ, 2007, NAT REV MICROBIOL, V5, P157, DOI 10.1038/nrmicro1598; Dorman CJ, 2004, NAT REV MICROBIOL, V2, P391, DOI 10.1038/nrmicro883; Ellison DW, 2006, CURR OPIN MICROBIOL, V9, P153, DOI 10.1016/j.mib.2006.02.003; Gourse RL, 2000, MOL MICROBIOL, V37, P687, DOI 10.1046/j.1365-2958.2000.01972.x; Grainger DC, 2006, NUCLEIC ACIDS RES, V34, P4642, DOI 10.1093/nar/gkl542; Groisman EA, 1996, CELL, V87, P791, DOI 10.1016/S0092-8674(00)81985-6; Groisman EA, 2001, J BACTERIOL, V183, P1835, DOI 10.1128/JB.183.6.1835-1842.2001; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Heroven AK, 2004, MOL MICROBIOL, V53, P871, DOI 10.1111/j.1365-2958.2004.04162.x; Kusano S, 1996, J BIOL CHEM, V271, P1998, DOI 10.1074/jbc.271.4.1998; Lithgow JK, 2007, MOL MICROBIOL, V66, P685, DOI 10.1111/j.1365-2958.2007.05950.x; Lucchini S, 2006, PLOS PATHOG, V2, P746, DOI 10.1371/journal.ppat.0020081; Navarre WW, 2007, GENE DEV, V21, P1456, DOI 10.1101/gad.1543107; Navarre WW, 2006, SCIENCE, V313, P236, DOI 10.1126/science.1128794; Navarre WW, 2005, MOL MICROBIOL, V56, P492, DOI 10.1111/j.1365-2958.2005.04553.x; Nishio M, 2005, MICROBIOL-SGM, V151, P863, DOI 10.1099/mic.0.27654-0; Noom MC, 2007, CURR BIOL, V17, pR913, DOI 10.1016/j.cub.2007.09.005; Norte VA, 2003, J BACTERIOL, V185, P3508, DOI 10.1128/JB.185.12.3508-3514.2003; Ochman H, 2000, NATURE, V405, P299, DOI 10.1038/35012500; Oshima T, 2006, DNA RES, V13, P141, DOI 10.1093/dnares/dsl009; Reusch RN, 2002, FEBS LETT, V527, P319, DOI 10.1016/S0014-5793(02)03236-2; Shi YX, 2004, J BIOL CHEM, V279, P38618, DOI 10.1074/jbc.M406149200; Shi YX, 2004, MOL MICROBIOL, V53, P229, DOI 10.1111/j.1365-2958.2004.04107.x; Shin D, 2005, J BIOL CHEM, V280, P4089, DOI 10.1074/jbc.M412741200; Shin D, 2006, SCIENCE, V314, P1607, DOI 10.1126/science.1134930; Shin M, 2005, GENE DEV, V19, P2388, DOI 10.1101/gad.1316305; SNAVELY MD, 1991, J BIOL CHEM, V266, P824; Soncini FC, 1996, J BACTERIOL, V178, P5092, DOI 10.1128/jb.178.17.5092-5099.1996; Sonnenfield JM, 2001, BIOCHIMIE, V83, P243, DOI 10.1016/S0300-9084(01)01232-9; Stapleton MR, 2002, J BIOL CHEM, V277, P17630, DOI 10.1074/jbc.M110178200; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Tran HJ, 2005, J BIOL CHEM, V280, P42423, DOI 10.1074/jbc.M504464200; Turner EC, 2007, J BACTERIOL, V189, P3403, DOI 10.1128/JB.01813-06; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X; Winfield MD, 2005, J BIOL CHEM, V280, P14765, DOI 10.1074/jbc.M413900200; Wosten MMSM, 1999, J BIOL CHEM, V274, P27185, DOI 10.1074/jbc.274.38.27185; Wyborn NR, 2004, J BACTERIOL, V186, P1620, DOI 10.1128/JB.186.6.1620-1628.2004; Yamamoto K, 2002, MOL MICROBIOL, V45, P423, DOI 10.1046/j.1365-2958.2002.03017.x; Zwir I, 2005, BIOINFORMATICS, V21, P4073, DOI 10.1093/bioinformatics/bti672; Zwir I, 2005, P NATL ACAD SCI USA, V102, P2862, DOI 10.1073/pnas.0408238102	49	77	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10773	10783		10.1074/jbc.M709843200	http://dx.doi.org/10.1074/jbc.M709843200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18270203	Green Accepted, Green Published, hybrid			2022-12-25	WOS:000254894700060
J	Bhattacharyya, S; Kotlo, K; Shukla, S; Danziger, RS; Tobacman, JK				Bhattacharyya, Sumit; Kotlo, Kumar; Shukla, Sagar; Danziger, Robert S.; Tobacman, Joanne K.			Distinct effects of N-acetylgalactosamine-4-sulfatase and galactose-6-sulfatase expression on chondroitin sulfates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYLSULFATASE-B; GROWTH-FACTOR; CELLS; SYNDECAN-1; ENDOCYTOSIS; DECORIN; HEPARIN; BINDING; PROTEOGLYCANS; CARCINOMA	The sulfatase enzymes, N-acetylgalactosamine-4-sulfatase (arylsulfatase B (ASB)) and galactose-6-sulfatase (GALNS) hydrolyze sulfate groups of CS. Deficiencies of ASB and GALNS are associated with the mucopolysaccharidoses. To determine if expression of ASB and GALNS impacts on glycosaminoglycans (GAGs) and proteoglycans beyond their association with the mucopolysaccharidoses, we modified the expression of ASB and GALNS by overexpression and by silencing with small interference RNA in MCF-7 cells. Content of total sulfated GAG (sGAG), chondroitin 4-sulfate (C4S), and total chondroitin sulfates (CSs) was measured following immunoprecipitation with C4S and CS antibodies and treatment with chondroitinase ABC. Following silencing of ASB or GALNS, total sGAG, C4S, and CS increased significantly. Following overexpression of ASB or GALNS, total sGAG, C4S, and CS declined significantly. Measurements following chondroitinase ABC treatment of the cell lysates demonstrated no change in the content of the other sGAG, including heparin, heparan sulfate, dermatan sulfate, and keratan sulfate. Following overexpression of ASB and immunoprecipitation with C4S antibody, virtually no sGAG was detectable. Total sGAG content increased to 23.39 (+/- 1.06) mu g/mg of protein from baseline of 12.47 (+/- 0.68) mu g/mg of protein following ASB silencing. mRNA expression of core proteins of the CS-containing proteoglycans, syndecan-1 and decorin, was significantly up-regulated following overexpression of ASB and GALNS. Soluble syndecan-1 protein increased following increases in ASB and GALNS and reduced following silencing, inversely to changes in CS. These findings demonstrate that modification of expression of the lysosomal sulfatases ASB and GALNS regulates the content of CSs.	[Bhattacharyya, Sumit; Kotlo, Kumar; Shukla, Sagar; Danziger, Robert S.; Tobacman, Joanne K.] Univ Illinois, Dept Med, Chicago, IL 60612 USA; [Danziger, Robert S.; Tobacman, Joanne K.] Univ Illinois, Jesse Brown Vet Affairs Med Ctr, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center	Tobacman, JK (corresponding author), Univ Illinois, Dept Med, 840 S Wood St,M-C 718,CSN 440, Chicago, IL 60612 USA.	jkt@uic.edu						Ai XB, 2003, J CELL BIOL, V162, P341, DOI 10.1083/jcb.200212083; AVNUR Z, 1984, CELL, V38, P811, DOI 10.1016/0092-8674(84)90276-9; Bhattacharyya S, 2007, CLIN CHIM ACTA, V380, P122, DOI 10.1016/j.cca.2007.01.021; Bhattacharyya S, 2007, J STEROID BIOCHEM, V103, P20, DOI 10.1016/j.jsbmb.2006.08.002; Burbach BJ, 2003, MATRIX BIOL, V22, P163, DOI 10.1016/S0945-053X(03)00009-X; Couchman JR, 2001, INT REV CYTOL, V207, P113; Deepa SS, 2004, J BIOL CHEM, V279, P37368, DOI 10.1074/jbc.M403031200; Hausser H, 1998, ARCH BIOCHEM BIOPHYS, V349, P363, DOI 10.1006/abbi.1997.0471; HAUSSER H, 1991, J CELL BIOL, V114, P45, DOI 10.1083/jcb.114.1.45; HAUSSER H, 1992, J BIOL CHEM, V267, P11559; Lai JP, 2004, ONCOGENE, V23, P1439, DOI 10.1038/sj.onc.1207258; Lai JP, 2003, J BIOL CHEM, V278, P23107, DOI 10.1074/jbc.M302203200; Li J, 2002, J CELL SCI, V115, P1951; Mahtouk K, 2007, BLOOD, V109, P4914, DOI 10.1182/blood-2006-08-043232; Morimoto-Tomita M, 2002, J BIOL CHEM, V277, P49175, DOI 10.1074/jbc.M205131200; Ohto T, 2002, GENES CELLS, V7, P173, DOI 10.1046/j.1356-9597.2001.00502.x; Samiric T, 2004, EUR J BIOCHEM, V271, P3612, DOI 10.1111/j.0014-2956.2004.04307.x; Tkachenko E, 2005, CIRC RES, V96, P488, DOI 10.1161/01.RES.0000159708.71142.c8; Tsanou E, 2004, J EXP CLIN CANC RES, V23, P641; Wilson VA, 2002, GLYCOCONJUGATE J, V19, P347, DOI 10.1023/A:1025325222530; Winter AD, 2000, MATRIX BIOL, V19, P129, DOI 10.1016/S0945-053X(00)00054-8; Yang Y, 2007, J BIOL CHEM, V282, P13326, DOI 10.1074/jbc.M611259200; Zimmermann P, 1999, FASEB J, V13, pS91	23	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9523	9530		10.1074/jbc.M707967200	http://dx.doi.org/10.1074/jbc.M707967200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18285341	hybrid			2022-12-25	WOS:000254671600005
J	Ekici, M; Hohl, M; Schuit, F; Martinez-Serrano, A; Thiel, G				Ekici, Myriam; Hohl, Mathias; Schuit, Frans; Martinez-Serrano, Alberto; Thiel, Gerald			Transcription of genes encoding synaptic vesicle proteins in human neural stem cells - Chromatin accessibility, histone methylation pattern, and the essential role of rest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUROBLASTOMA-CELLS; EPIDERMAL-GROWTH-FACTOR; BCL-X-L; NEURONAL DIFFERENTIATION; NEUROTROPHIC FACTOR; BIOLOGICAL-ACTIVITY; PROGENITOR CELLS; REPRESSOR REST; TARGET GENES; HUMAN CNS	Human HNSC. 100 neural stem cells up-regulate expression of GFAP following withdrawal of mitogens. Activation of the ERK signaling pathway prevented the up-regulation of GFAP expression. Incubation of cells with retinoic acid in the absence of mitogens enhanced basal neuronal differentiation that was accompanied by an up-regulation of neuronal gene expression and a down-regulation of GFAP and nestin expression. Retinoic acid treatment changed the histone code of neuronal genes encoding synapsin I, synaptophysin, and synaptotagmins II, IV, and VII from a transcriptionally inactive ( methylation of lysine residue 9 of histone 3) to a transcriptionally active state ( methylation of lysine residue 4 of histone 3). In contrast, the chromatin structure of the GFAP gene is transformed from a transcriptionally active state in unstimulated neural stem cells to a transcriptionally inactive state in retinoic acid-stimulated cells. Additionally, retinoic acid treatment reduced the binding of histone deacetylase-1 and REST to neuronal genes. The inhibition of histone deacetylase activity induced expression of genes encoding synaptic vesicle proteins in unstimulated neural stem cells. Similarly, neuronal gene transcription was enhanced following expression of a mutant of REST that contained a transcriptional activation domain. These data indicate that in undifferentiated human neural stem cells, neuronal genes encoding synaptic vesicle proteins are accessible for the REST mutant and are sensitive to enhanced histone acetylation.	[Ekici, Myriam; Hohl, Mathias; Thiel, Gerald] Univ Saarland, Med Ctr, Dept Med Biochem & Mol Biol, D-66421 Homburg, Germany; [Schuit, Frans] Katholieke Univ Leuven, Dept Mol Cell Biol, B-3000 Louvain, Belgium; [Martinez-Serrano, Alberto] UAM, CSIC, Ctr Mol Biol Severo Ochoa, Madrid 28049, Spain	Saarland University; KU Leuven; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Thiel, G (corresponding author), Univ Saarland, Med Ctr, Dept Med Biochem & Mol Biol, Bldg 44, D-66421 Homburg, Germany.	gerald.thiel@uniklinik-saarland.de	Martínez-Serrano, Alberto/J-8146-2014	Martinez Serrano, Alberto/0000-0003-3927-6699				Al-Sarraj A, 2005, J CELL BIOCHEM, V94, P153, DOI 10.1002/jcb.20305; Ballas N, 2005, CELL, V121, P645, DOI 10.1016/j.cell.2005.03.013; BALLAS N, 2006, CURR OPIN NEUROBIOL, V15, P1; Bauer I, 2007, J CELL BIOCHEM, V100, P242, DOI 10.1002/jcb.21075; Bruce AW, 2006, J NEUROCHEM, V98, P1828, DOI 10.1111/j.1471-4159.2006.04010.x; Cibelli G, 2002, J NEUROSCI RES, V67, P450, DOI 10.1002/jnr.10141; Denise A, 2004, NAT NEUROSCI, V7, P1233, DOI 10.1038/nn1340; Doetsch F, 2003, NAT NEUROSCI, V6, P1127, DOI 10.1038/nn1144; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Greenway DJ, 2007, STEM CELLS, V25, P354, DOI 10.1634/stemcells.2006-0207; Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042; Hohl M, 2005, EUR J NEUROSCI, V22, P2216, DOI 10.1111/j.1460-9568.2005.04404.x; Hsieh J, 2004, J CELL BIOL, V164, P111, DOI 10.1083/jcb.200308101; Hsieh J, 2004, P NATL ACAD SCI USA, V101, P16659, DOI 10.1073/pnas.0407643101; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; Kaufmann K, 2002, J CELL BIOCHEM, V85, P381, DOI 10.1002/jcb.10145; KITCHENS DL, 1994, J NEUROBIOL, V25, P797, DOI 10.1002/neu.480250705; Lietz M, 2003, EUR J BIOCHEM, V270, P2, DOI 10.1046/j.1432-1033.2003.03360.x; Lietz M, 2001, EUR J NEUROSCI, V14, P1303, DOI 10.1046/j.0953-816x.2001.01762.x; Liste I, 2007, CELL DEATH DIFFER, V14, P1880, DOI 10.1038/sj.cdd.4402205; Liste I, 2004, J NEUROSCI, V24, P10786, DOI 10.1523/JNEUROSCI.3208-04.2004; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; McMahon M, 2001, METHOD ENZYMOL, V332, P401; Nishikawa SI, 2007, NAT REV MOL CELL BIO, V8, P502, DOI 10.1038/nrm2189; Niwa H, 2007, GENE DEV, V21, P2071, DOI 10.1101/gad.1615707; Ooi L, 2007, NAT REV GENET, V8, P544, DOI 10.1038/nrg2100; Otto SJ, 2007, J NEUROSCI, V27, P6729, DOI 10.1523/JNEUROSCI.0091-07.2007; Rossler OG, 2008, ARCH BIOCHEM BIOPHYS, V470, P93, DOI 10.1016/j.abb.2007.11.008; Rossler OG, 2004, AM J PHYSIOL-CELL PH, V286, pC1118, DOI 10.1152/ajpcell.00301.2003; Rossler OG, 2004, J NEUROCHEM, V88, P1240, DOI 10.1046/j.1471-4159.2003.02255.x; Rubio FJ, 2000, MOL CELL NEUROSCI, V16, P1, DOI 10.1006/mcne.2000.0854; Sah DWY, 1997, NAT BIOTECHNOL, V15, P574, DOI 10.1038/nbt0697-574; Shi YH, 2004, NATURE, V427, P78, DOI 10.1038/nature02211; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Su XH, 2004, MOL CELL BIOL, V24, P8018, DOI 10.1128/MCB.24.18.8018-8025.2004; Thiel G, 1998, J BIOL CHEM, V273, P26891, DOI 10.1074/jbc.273.41.26891; Thiel G, 2004, EUR J BIOCHEM, V271, P2855, DOI 10.1111/j.1432-1033.2004.04174.x; Thiel G, 2006, TRANSCRIPTION FACTOR, P113; Vakoc CR, 2005, MOL CELL, V19, P381, DOI 10.1016/j.molcel.2005.06.011; Villa A, 2000, EXP NEUROL, V161, P67, DOI 10.1006/exnr.1999.7237	40	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9257	9268		10.1074/jbc.M709388200	http://dx.doi.org/10.1074/jbc.M709388200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18234667	hybrid, Green Published			2022-12-25	WOS:000254465800056
J	Gee, P; Chua, PK; Gevorkyan, J; Klumpp, K; Najera, I; Swinney, DC; Deval, J				Gee, Peter; Chua, Pong Kian; Gevorkyan, Jirair; Klumpp, Klaus; Najera, Isabel; Swinney, David C.; Deval, Jerome			Essential role of the N-terminal domain in the regulation of RIG-I ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-C-VIRUS; ANTIVIRAL SIGNALING PROTEIN; INNATE IMMUNITY; NS3 HELICASE; NONSTRUCTURAL PROTEIN-3; ADAPTER PROTEIN; BOX HELICASES; RNA VIRUSES; KAPPA-B; ACTIVATION	Retinoic acid-inducible gene I (RIG-I) is a cytosolic receptor that recognizes viral RNA and activates the interferon-mediated innate antiviral response. To understand the mechanism of signal activation at the receptor level, we cloned, expressed, and purified human RIG-I containing the two caspase activation and recruitment domains (CARDs) followed by the C-terminal helicase domain. We found that recombinant RIG-I is a functional protein that interacts with double-stranded RNA with substantially higher affinity as compared with single-stranded RNA structures unless they contain a 5'-triphosphate group. Viral RNA binding to RIG-I stimulates the velocity of ATP hydrolysis by 33-fold, which at the cellular level translates into a 43-fold increase of interferon-beta expression. In contrast, the isolated ATPase/helicase domain is constitutively activated while also retaining its RNA ligand binding properties. These results support the recent model by which RIG-I signaling is autoinhibited in the absence of RNA by intra-molecular interactions between the CARDs and the C terminus. Based on pH profile and metal ion dependence experiments, we propose that the active site of RIG-I cannot efficiently accommodate divalent cations under the RNA-free repressed conformation. Overall, these results show a direct correlation between RNA binding and ATPase enzymatic function leading to signal transduction and suggest that a tight control of ATPase activity by the CARDs prevents RIG-I signaling in the absence of viral RNA.	[Gee, Peter; Chua, Pong Kian; Gevorkyan, Jirair; Klumpp, Klaus; Najera, Isabel; Swinney, David C.; Deval, Jerome] Roche Palo Alto LLC, Palo Alto, CA 94304 USA	Roche Holding	Deval, J (corresponding author), Roche Palo Alto LLC, Palo Alto, CA 94304 USA.	jerome.deval@roche.com	Gee, Peter/H-5681-2013					Arimoto KI, 2007, P NATL ACAD SCI USA, V104, P7500, DOI 10.1073/pnas.0611551104; Bartelma G, 2002, VIROLOGY, V299, P122, DOI 10.1006/viro.2002.1504; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Cheng GF, 2007, P NATL ACAD SCI USA, V104, P9035, DOI 10.1073/pnas.0703285104; Cole JL, 2007, TRENDS BIOCHEM SCI, V32, P57, DOI 10.1016/j.tibs.2006.12.003; Du MX, 2002, BIOCHEM J, V363, P147, DOI 10.1042/0264-6021:3630147; Dumont S, 2006, NATURE, V439, P105, DOI 10.1038/nature04331; Frick DN, 2007, J MOL BIOL, V365, P1017, DOI 10.1016/j.jmb.2006.10.023; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; Gitlin L, 2006, P NATL ACAD SCI USA, V103, P8459, DOI 10.1073/pnas.0603082103; Hiscott J, 2006, TRENDS MOL MED, V12, P53, DOI 10.1016/j.molmed.2005.12.003; Hornung V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kato H, 2005, IMMUNITY, V23, P19, DOI 10.1016/j.immuni.2005.04.010; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Klumpp K, 2006, J BIOL CHEM, V281, P3793, DOI 10.1074/jbc.M510195200; Lam AMI, 2004, NUCLEIC ACIDS RES, V32, P4060, DOI 10.1093/nar/gkh743; Li XD, 2005, P NATL ACAD SCI USA, V102, P17717, DOI 10.1073/pnas.0508531102; Lin RT, 2006, J VIROL, V80, P6072, DOI 10.1128/JVI.02495-05; Loo YM, 2006, P NATL ACAD SCI USA, V103, P6001, DOI 10.1073/pnas.0601523103; Loo YM, 2008, J VIROL, V82, P335, DOI 10.1128/JVI.01080-07; Manelyte L, 2006, NUCLEIC ACIDS RES, V34, P5270, DOI 10.1093/nar/gkl489; Marques JT, 2006, NAT BIOTECHNOL, V24, P559, DOI 10.1038/nbt1205; McKenna SA, 2007, J BIOL CHEM, V282, P11474, DOI 10.1074/jbc.M700301200; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Picha KM, 1998, J BIOL CHEM, V273, P27315, DOI 10.1074/jbc.273.42.27315; Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998; Rothenfusser S, 2005, J IMMUNOL, V175, P5260, DOI 10.4049/jimmunol.175.8.5260; Saito T, 2007, P NATL ACAD SCI USA, V104, P582, DOI 10.1073/pnas.0606699104; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Stumper R, 2005, J VIROL, V79, P2689, DOI 10.1128/JVI.79.5.2689-2699.2005; Tanner NK, 2003, CELL CYCLE, V2, P16, DOI 10.4161/cc.2.1.296; Tanner NK, 2003, MOL CELL, V11, P127, DOI 10.1016/S1097-2765(03)00006-6; Wardell AD, 1999, J GEN VIROL, V80, P701, DOI 10.1099/0022-1317-80-3-701; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; Yoneyama M, 2005, J IMMUNOL, V175, P2851, DOI 10.4049/jimmunol.175.5.2851	40	57	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9488	9496		10.1074/jbc.M706777200	http://dx.doi.org/10.1074/jbc.M706777200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18268020	hybrid			2022-12-25	WOS:000254465800078
J	Fearnside, JF; Dumas, ME; Rothwell, AR; Wilder, SP; Cloarec, O; Toye, A; Blancher, C; Holmes, E; Tatoud, R; Barton, RH; Scott, J; Nicholson, JK; Gauguier, D				Fearnside, Jane F.; Dumas, Marc-Emmanuel; Rothwell, Alice R.; Wilder, Steven P.; Cloarec, Olivier; Toye, Ayo; Blancher, Christine; Holmes, Elaine; Tatoud, Roger; Barton, Richard H.; Scott, James; Nicholson, Jeremy K.; Gauguier, Dominique			Phylometabonomic Patterns of Adaptation to High Fat Diet Feeding in Inbred Mice	PLOS ONE			English	Article								Insulin resistance plays a central role in type 2 diabetes and obesity, which develop as a consequence of genetic and environmental factors. Dietary changes including high fat diet (HFD) feeding promotes insulin resistance in rodent models which present useful systems for studying interactions between genetic background and environmental influences contributing to disease susceptibility and progression. We applied a combination of classical physiological, biochemical and hormonal studies and plasma H-1 NMR spectroscopy-based metabonomics to characterize the phenotypic and metabotypic consequences of HFD (40%) feeding in inbred mouse strains (C57BL/6, 129S6, BALB/c, DBA/2, C3H) frequently used in genetic studies. We showed the wide range of phenotypic and metabonomic adaptations to HFD across the five strains and the increased nutrigenomic predisposition of 129S6 and C57BL/6 to insulin resistance and obesity relative to the other strains. In contrast mice of the BALB/c and DBA/2 strains showed relative resistance to HFD-induced glucose intolerance and obesity. Hierarchical metabonomic clustering derived from H-1 NMR spectral data of the strains provided a phylometabonomic classification of strain-specific metabolic features and differential responses to HFD which closely match SNP-based phylogenetic relationships between strains. Our results support the concept of genomic clustering of functionally related genes and provide important information for defining biological markers predicting spontaneous susceptibility to insulin resistance and pathological adaptations to fat feeding.	[Fearnside, Jane F.; Rothwell, Alice R.; Wilder, Steven P.; Toye, Ayo; Blancher, Christine; Gauguier, Dominique] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England; [Dumas, Marc-Emmanuel; Cloarec, Olivier; Holmes, Elaine; Barton, Richard H.; Nicholson, Jeremy K.] Imperial Coll London, Dept Biomol Med, Div Surg, Oncol, Reproduct Biol & Anaesthetics, Fac Med, London, England; [Dumas, Marc-Emmanuel] Ecole Normale Superieure Lyon, CRMN Lyon FRE 3008, Lab Chem UMR 5185, Lyon, France; [Tatoud, Roger; Scott, James] Imperial Coll London, Fac Med, London, England	University of Oxford; Wellcome Centre for Human Genetics; Imperial College London; Centre National de la Recherche Scientifique (CNRS); Universite Bordeaux-Montaigne; Ecole Normale Superieure de Lyon (ENS de LYON); Imperial College London	Fearnside, JF (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.	gdomi@well.ox.ac.uk; gdomi@well.ox.ac.uk	Dumas, Marc-Emmanuel/C-1736-2008; Nicholson, Jeremy K/B-3395-2012; Holmes, Elaine/A-2189-2015; Gauguier, Dominique/G-2190-2016; Holmes, Elaine/ABE-6606-2020	Dumas, Marc-Emmanuel/0000-0001-9523-7024; Nicholson, Jeremy K/0000-0002-8123-8349; Gauguier, Dominique/0000-0001-6156-9530; Holmes, Elaine/0000-0002-0556-8389; TATOUD, Roger/0000-0002-3999-8264; Barton, Richard H./0000-0001-7469-2845; Wilder, Steven/0000-0001-8049-2559; Tatoud, Roger/0000-0002-2394-6435	Wellcome Functional Genomics Initiative BAIR [066786]; Wellcome Prize Studentship; Wellcome Senior Fellowship in Basic Biomedical Science [057733]	Wellcome Functional Genomics Initiative BAIR; Wellcome Prize Studentship; Wellcome Senior Fellowship in Basic Biomedical Science	This work is supported by the Wellcome Functional Genomics Initiative BAIR (Biological Atlas of Insulin Resistance) (066786). Steven P. Wilder is the recipient of a Wellcome Prize Studentship in Bioinformatics and Statistical Genetics. Dominique Gauguier holds a Wellcome Senior Fellowship in Basic Biomedical Science (057733).	Albers JJ, 1999, J LIPID RES, V40, P295; Argmann CA, 2005, CELL METAB, V2, P349, DOI 10.1016/j.cmet.2005.11.002; Bell CG, 2005, NAT REV GENET, V6, P221, DOI 10.1038/nrg1556; Biddinger SB, 2005, DIABETES, V54, P1314, DOI 10.2337/diabetes.54.5.1314; Bogue M, 2003, J APPL PHYSIOL, V95, P1335, DOI 10.1152/japplphysiol.00562.2003; Churchill G, 2004, NAT GENET, V36, P1133, DOI 10.1038/ng1104-1133; Clayton TA, 2006, NATURE, V440, P1073, DOI 10.1038/nature04648; Cloarec O, 2005, ANAL CHEM, V77, P517, DOI 10.1021/ac048803i; COLEMAN DL, 1973, DIABETOLOGIA, V9, P287, DOI 10.1007/BF01221856; Dumas ME, 2007, NAT GENET, V39, P666, DOI 10.1038/ng2026; Dumas ME, 2006, P NATL ACAD SCI USA, V103, P12511, DOI 10.1073/pnas.0601056103; FERRANNINI E, 2007, J CLIN ENDOCRINOL ME; Freeman H, 2006, CELL METAB, V3, P35, DOI 10.1016/j.cmet.2005.10.008; Goren HJ, 2004, ENDOCRINOLOGY, V145, P3307, DOI 10.1210/en.2003-1400; Grupe A, 2001, SCIENCE, V292, P1915, DOI 10.1126/science.1058889; Lindblad-Toh K, 2000, NAT GENET, V24, P381, DOI 10.1038/74215; Martin FPJ, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100153; Muller M, 2003, NAT REV GENET, V4, P315, DOI 10.1038/nrg1047; Nandi A, 2004, PHYSIOL REV, V84, P623, DOI 10.1152/physrev.00032.2003; Nicholson JK, 2002, NAT REV DRUG DISCOV, V1, P153, DOI 10.1038/nrd728; Nicholson JK, 2003, NAT REV DRUG DISCOV, V2, P668, DOI 10.1038/nrd1157; NICHOLSON JK, 1995, ANAL CHEM, V67, P793, DOI 10.1021/ac00101a004; Perusse L, 2000, AM J CLIN NUTR, V72, p1285S, DOI 10.1093/ajcn/72.5.1285s; Petkov PM, 2005, PLOS GENET, V1, P312, DOI 10.1371/journal.pgen.0010033; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Rossmeisl M, 2003, DIABETES, V52, P1958, DOI 10.2337/diabetes.52.8.1958; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Shifman S, 2006, PLOS BIOL, V4, P2227, DOI 10.1371/journal.pbio.0040395; Singer JB, 2004, SCIENCE, V304, P445, DOI 10.1126/science.1093139; Solberg LC, 2006, MAMM GENOME, V17, P129, DOI 10.1007/s00335-005-0112-1; STERN MP, 1995, DIABETES, V44, P369, DOI 10.2337/diabetes.44.4.369; Toye AA, 2007, DIABETOLOGIA, V50, P1867, DOI 10.1007/s00125-007-0738-5; Valdar W, 2006, GENETICS, V174, P959, DOI 10.1534/genetics.106.060004; Valdar W, 2006, NAT GENET, V38, P879, DOI 10.1038/ng1840; WEST DB, 1992, AM J PHYSIOL, V262, pR1025, DOI 10.1152/ajpregu.1992.262.6.R1025; West DB, 1998, AM J CLIN NUTR, V67, p505S, DOI 10.1093/ajcn/67.3.505S; Wiltshire T, 2003, P NATL ACAD SCI USA, V100, P3380, DOI 10.1073/pnas.0130101100; Wold S, 1998, CHEMOMETR INTELL LAB, V44, P175, DOI 10.1016/S0169-7439(98)00109-9; Zhang JH, 2005, GENOME RES, V15, P241, DOI 10.1101/gr.2901705	39	82	82	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2008	3	2							e1668	10.1371/journal.pone.0001668	http://dx.doi.org/10.1371/journal.pone.0001668			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XS	18301746	gold, Green Published, Green Submitted			2022-12-25	WOS:000260586500013
J	Sodhi, NS; Bickford, D; Diesmos, AC; Lee, TM; Koh, LP; Brook, BW; Sekercioglu, CH; Bradshaw, CJA				Sodhi, Navjot S.; Bickford, David; Diesmos, Arvin C.; Lee, Tien Ming; Koh, Lian Pin; Brook, Barry W.; Sekercioglu, Cagan H.; Bradshaw, Corey J. A.			Measuring the Meltdown: Drivers of Global Amphibian Extinction and Decline	PLOS ONE			English	Article								Habitat loss, climate change, over-exploitation, disease and other factors have been hypothesised in the global decline of amphibian biodiversity. However, the relative importance of and synergies among different drivers are still poorly understood. We present the largest global analysis of roughly 45% of known amphibians (2,583 species) to quantify the influences of life history, climate, human density and habitat loss on declines and extinction risk. Multi-model Bayesian inference reveals that large amphibian species with small geographic range and pronounced seasonality in temperature and precipitation are most likely to be Red-Listed by IUCN. Elevated habitat loss and human densities are also correlated with high threat risk. Range size, habitat loss and more extreme seasonality in precipitation contributed to decline risk in the 2,454 species that declined between 1980 and 2004, compared to species that were stable (n = 1,545) or had increased (n = 28). These empirical results show that amphibian species with restricted ranges should be urgently targeted for conservation.	[Sodhi, Navjot S.; Bickford, David; Diesmos, Arvin C.] Natl Univ Singapore, Dept Biol Sci, Singapore 117548, Singapore; [Diesmos, Arvin C.] Natl Museum Philippines, Herpetol Sect, Div Zool, Manila, Philippines; [Lee, Tien Ming] Univ Calif San Diego, Div Biol Sci, Ecol Behav & Evolut Sect, La Jolla, CA 92093 USA; [Koh, Lian Pin] Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA; [Brook, Barry W.; Bradshaw, Corey J. A.] Univ Adelaide, Res Inst Climate Change & Sustainabil, Sch Earth & Environm Sci, Adelaide, SA, Australia; [Sekercioglu, Cagan H.] Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; [Bradshaw, Corey J. A.] Charles Darwin Univ, Sch Environm Res, Inst Adv Studies, Darwin, NT 0909, Australia	National University of Singapore; National Museum of the Philippines; University of California System; University of California San Diego; Princeton University; University of Adelaide; Stanford University; Charles Darwin University	Sodhi, NS (corresponding author), Natl Univ Singapore, Dept Biol Sci, Singapore 117548, Singapore.	dbsbdp@nus.edu.sg; dbsns@nus.edu.sg	Bickford, David P/A-5306-2011; Diesmos, Arvin C./AGG-8542-2022; Koh, Lian Pin/A-5794-2010; Sekercioglu, Cagan H/A-2331-2013; Bradshaw, Corey J.A./A-1311-2008; Brook, Barry W./G-2686-2011	Bickford, David P/0000-0003-1478-3387; Koh, Lian Pin/0000-0001-8152-3871; Sekercioglu, Cagan H/0000-0001-9639-294X; Bradshaw, Corey J.A./0000-0002-5328-7741; Brook, Barry W./0000-0002-2491-1517; Sekercioglu, Cagan H./0000-0003-3193-0377	National University of Singapore [R-154-000-264-112]; Singapore Ministry of Education [R-154-000-270-112]	National University of Singapore(National University of Singapore); Singapore Ministry of Education(Ministry of Education, Singapore)	The research was supported by the National University of Singapore (R-154-000-264-112) and the Singapore Ministry of Education (R-154-000-270-112).	Beebee TJC, 2005, BIOL CONSERV, V125, P271, DOI 10.1016/j.biocon.2005.04.009; Bickford DP, 2005, Ecology & Evolution in the Tropics: A Herpetological Perspective, P260; Bielby J, 2006, ANIM CONSERV, V9, P135, DOI 10.1111/j.1469-1795.2005.00013.x; Brook BW, 2006, ECOL LETT, V9, P375, DOI 10.1111/j.1461-0248.2006.00883.x; Buckley LB, 2007, P ROY SOC B-BIOL SCI, V274, P1167, DOI 10.1098/rspb.2006.0436; Burnham K.P., 2002, MODEL SELECTION MULT, DOI 10.1007/b97636; Burnham KP, 2004, SOCIOL METHOD RES, V33, P261, DOI 10.1177/0049124104268644; Cardillo M, 2005, SCIENCE, V309, P1239, DOI 10.1126/science.1116030; Cooper N, 2008, GLOBAL ECOL BIOGEOGR, V17, P211, DOI 10.1111/j.1466-8238.2007.00355.x; Crawley M. J, 2002, STAT COMPUTING INTRO; Elliott LP, 2007, BIOSCIENCE, V57, P608, DOI 10.1641/B570708; *EUR COMM JRC IES, 2002, GLC 2000 GLOB LAND C; FELSENSTEIN J, 1985, AM NAT, V70, P1; Hero JM, 2005, J ZOOL, V267, P221, DOI 10.1017/S0952836905007296; Hijmans RJ, 2005, INT J CLIMATOL, V25, P1965, DOI 10.1002/joc.1276; Hoekstra JM, 2005, ECOL LETT, V8, P23, DOI 10.1111/j.1461-0248.2004.00686.x; *IUCN CI NATURESER, 2006, GLOB AMPH ASS; Kiesecker JM, 2001, NATURE, V410, P681, DOI 10.1038/35070552; Linberger P., 2008, J BUS FINANCE LIBRAR, V5; Link WA, 2006, ECOLOGY, V87, P2626, DOI 10.1890/0012-9658(2006)87[2626:MWATFO]2.0.CO;2; Lips KR, 2005, BIOTROPICA, V37, P163, DOI 10.1111/j.1744-7429.2005.00023.x; Lips KR, 2003, CONSERV BIOL, V17, P1078, DOI 10.1046/j.1523-1739.2003.01623.x; Lukacs PM, 2007, J APPL ECOL, V44, P456, DOI 10.1111/j.1365-2664.2006.01267.x; Malcolm JR, 2006, CONSERV BIOL, V20, P538, DOI 10.1111/j.1523-1739.2006.00364.x; Mendelson JR, 2006, SCIENCE, V313, P48, DOI 10.1126/science.1128396; Murray BR, 2005, AUSTRAL ECOL, V30, P564, DOI 10.1111/j.1442-9993.2005.01471.x; Murray BR, 1998, J ANIM ECOL, V67, P567, DOI 10.1046/j.1365-2656.1998.00217.x; New M, 2002, CLIMATE RES, V21, P1, DOI 10.3354/cr021001; Payne JL, 2007, P NATL ACAD SCI USA, V104, P10506, DOI 10.1073/pnas.0701257104; Pounds JA, 2006, NATURE, V439, P161, DOI 10.1038/nature04246; Pounds JA, 2001, NATURE, V410, P639, DOI 10.1038/35070683; Purvis A, 2000, P ROY SOC B-BIOL SCI, V267, P1947, DOI 10.1098/rspb.2000.1234; *R DEV COR TEAM, 2004, R LANG ENV STAT COMP; Sodhi NS, 2008, DIVERS DISTRIB, V14, P1, DOI 10.1111/j.1472-4642.2007.00398.x; Sodhi NS, 2004, ANNU REV ECOL EVOL S, V35, P323, DOI 10.1146/annurev.ecolsys.35.112202.130209; Sodhi NS, 2004, TRENDS ECOL EVOL, V19, P654, DOI 10.1016/j.tree.2004.09.006; Stuart SN, 2004, SCIENCE, V306, P1783, DOI 10.1126/science.1103538; Whitfield SM, 2007, P NATL ACAD SCI USA, V104, P8352, DOI 10.1073/pnas.0611256104; Williams SE, 1998, P ROY SOC B-BIOL SCI, V265, P597, DOI 10.1098/rspb.1998.0336	39	320	343	2	135	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1636	10.1371/journal.pone.0001636	http://dx.doi.org/10.1371/journal.pone.0001636			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286193	Green Published, Green Submitted, gold			2022-12-25	WOS:000260586400029
J	Espinosa, JM				Espinosa, J. M.			Mechanisms of regulatory diversity within the p53 transcriptional network	ONCOGENE			English	Review						p21; ASPP; HZF; hCAS; serine 46; lysine 120	RNA-POLYMERASE-II; IN-VIVO; P53-DEPENDENT APOPTOSIS; DNA-DAMAGE; TUMOR-SUPPRESSOR; BINDING-SITES; GENE-EXPRESSION; MESSENGER-RNAS; CORE PROMOTER; TARGET GENES	p53 is arguably the most intensively studied protein to date, yet there is much that we ignore about its function as a transcription factor. The p53-dependent transcriptional program is remarkably flexible, as it varies with the nature of p53-activating stimuli, the cell type and the duration of the activation signal. This flexibility may allow cells to mount alternative responses to p53 activation, such as cell cycle arrest or apoptosis. Here, I organize the available data into two alternative models to explain how this regulatory diversity is achieved.	Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Espinosa, JM (corresponding author), Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA.	joaquin.espinosa@colorado.edu			NCI NIH HHS [R01 CA117907, R01-CA117907, R01 CA117907-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA117907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Alves NL, 2006, IMMUNITY, V24, P703, DOI 10.1016/j.immuni.2006.03.018; Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Bergamaschi D, 2006, NAT GENET, V38, P1133, DOI 10.1038/ng1879; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Brunkhorst A, 2004, BIOCHEM BIOPH RES CO, V325, P574, DOI 10.1016/j.bbrc.2004.10.078; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Butler JEF, 2001, GENE DEV, V15, P2515, DOI 10.1101/gad.924301; Butler JEF, 2002, GENE DEV, V16, P2583, DOI 10.1101/gad.1026202; Cain C, 2000, J BIOL CHEM, V275, P39944, DOI 10.1074/jbc.M002509200; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Das S, 2007, CELL, V130, P624, DOI 10.1016/j.cell.2007.06.013; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; Donner AJ, 2007, CELL CYCLE, V6, P2594, DOI 10.4161/cc.6.21.4893; Donner AJ, 2007, MOL CELL, V27, P121, DOI 10.1016/j.molcel.2007.05.026; Efeyan A, 2007, CANCER RES, V67, P7350, DOI 10.1158/0008-5472.CAN-07-0200; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Fei PW, 2002, CANCER RES, V62, P7316; Figueroa A, 2003, MOL CELL BIOL, V23, P4991, DOI 10.1128/MCB.23.14.4991-5004.2003; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Garneau NL, 2007, NAT REV MOL CELL BIO, V8, P113, DOI 10.1038/nrm2104; Gohler T, 2002, J BIOL CHEM, V277, P41192, DOI 10.1074/jbc.M202344200; Gomes NP, 2006, GENE DEV, V20, P601, DOI 10.1101/gad.1398206; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042; Hermeking H, 2007, CANCER CELL, V12, P414, DOI 10.1016/j.ccr.2007.10.028; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; Horvath MM, 2007, PLOS GENET, V3, P1284, DOI 10.1371/journal.pgen.0030127; Jett SD, 2000, J MOL BIOL, V299, P585, DOI 10.1006/jmbi.2000.3759; Jiang M, 2003, GENE DEV, V17, P832, DOI 10.1101/gad.252603; Johannessen LE, 1999, BIOCHEM J, V337, P599, DOI 10.1042/0264-6021:3370599; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kojima K, 2005, BLOOD, V106, P3150, DOI 10.1182/blood-2005-02-0553; Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305; Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916; Lemon B, 2001, NATURE, V414, P924, DOI 10.1038/414924a; Loncle N, 2007, EMBO J, V26, P1045, DOI 10.1038/sj.emboj.7601566; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Luecke HF, 2005, GENE DEV, V19, P1116, DOI 10.1101/gad.1297105; Mattia M, 2007, MOL CELL BIOL, V27, P1309, DOI 10.1128/MCB.01520-06; Mo XM, 2004, MOL CELL, V13, P241, DOI 10.1016/S1097-2765(03)00521-5; Moll UM, 2004, MOL CANCER RES, V2, P371; OBRIEN T, 1991, MOL CELL BIOL, V11, P5285, DOI 10.1128/MCB.11.10.5285; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Perez CA, 2007, ONCOGENE, V26, P7363, DOI 10.1038/sj.onc.1210561; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Senoo M, 2004, CANCER CELL, V6, P85, DOI 10.1016/j.ccr.2004.06.005; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Shi LF, 2005, J BIOL CHEM, V280, P18981, DOI 10.1074/jbc.M411034200; Shu LM, 2006, GENE DEV, V20, P2961, DOI 10.1101/gad.1463306; Slee EA, 2003, TOXICOL LETT, V139, P81, DOI 10.1016/S0378-4274(02)00421-6; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Tanaka T, 2007, CELL, V130, P638, DOI 10.1016/j.cell.2007.08.001; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Thompson T, 2004, J BIOL CHEM, V279, P53015, DOI 10.1074/jbc.M410233200; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Tovar C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI 10.1073/pnas.0507493103; Truong AB, 2006, GENE DEV, V20, P3185, DOI 10.1101/gad.1463206; van de Peppel J, 2005, MOL CELL, V19, P511, DOI 10.1016/j.molcel.2005.06.033; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vives V, 2006, GENE DEV, V20, P1262, DOI 10.1101/gad.374006; Vives V, 2006, CELL CYCLE, V5, P2187, DOI 10.4161/cc.5.19.3266; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Wang G, 2005, MOL CELL, V17, P683, DOI 10.1016/j.molcel.2005.02.010; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang XP, 2004, DALTON T, P1787, DOI 10.1039/b405981f; Zhang XT, 2005, MOL CELL, V19, P89, DOI 10.1016/j.molcel.2005.05.015; Zhao RB, 2000, GENE DEV, V14, P981; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	77	85	86	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2008	27	29					4013	4023		10.1038/onc.2008.37	http://dx.doi.org/10.1038/onc.2008.37			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321RV	18278067	Green Accepted			2022-12-25	WOS:000257325100001
J	Wakabayashi, H; Fay, PJ				Wakabayashi, Hironao; Fay, Philip J.			Identification of residues contributing to A2 domain-dependent structural stability in factor VIII and factor VIIIa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MILD HEMOPHILIA-A; ONE-STAGE; SUBUNIT DISSOCIATION; FAMILIAL DISCREPANCY; A1/A3-C1-C2 DIMER; CA2+ BINDING; FACTOR-IXA; MUTATIONS; MODEL; SITE	Factor VIII circulates as a heterodimer composed of heavy (A1A2B domains) and light (A3C1C2 domains) chains, whereas the contiguous A1A2 domains are separate subunits in the active cofactor, factor VIIIa. Whereas the A1 subunit maintains a stable interaction with the A3C1C2 subunit, the A2 subunit is weakly associated in factor VIIIa and its dissociation accounts for the labile activity of the cofactor. In examining the ceruloplasmin-based factor VIII A domain model, potential hydrogen bonding based upon spatial separations of < 2.8 angstrom were found between side chains of 14 A2 domain residues and 7 and 9 residues in the A1 and A3 domains, respectively. These residues were individually replaced with Ala, except Tyr residues were replaced with Phe, and proteins stably expressed to examine the contribution of each residue to protein stability. Factor VIII stability at 55 degrees C and factor VIIIa activity were monitored using factor Xa generation assays. Fourteen of 30 factor VIII mutants showed > 2-fold increases in either or both decay rates compared with wild type; whereas, 7 mutants showed > 2-fold increased rates in factor VIIIa decay compared with factor VIII decay. These results suggested that multiple residues at the A1-A2 and A2-A3 domain interfaces contribute to stabilizing the protein. Furthermore, these data discriminate residues that stabilize interactions in the procofactor from those in the cofactor, where hydrogen bonding in the latter appears to contribute more significantly to stability. This observation is consistent with an altered conformation involving new inter-subunit interactions involving A2 domain following procofactor activation.	[Wakabayashi, Hironao; Fay, Philip J.] Univ Rochester, Sch Med, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Fay, PJ (corresponding author), 601 Elmwood Ave, Rochester, NY 14642 USA.	philip_fay@urmc.rochester.edu			NHLBI NIH HHS [HL38199, HL76213] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076213, R01HL038199] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ansong C, 2005, BIOCHEMISTRY-US, V44, P8850, DOI 10.1021/bi050145o; Bajaj SP, 2001, J BIOL CHEM, V276, P16302, DOI 10.1074/jbc.M011680200; DUNCAN EM, 1994, BRIT J HAEMATOL, V87, P846, DOI 10.1111/j.1365-2141.1994.tb06749.x; Fay PJ, 1996, J BIOL CHEM, V271, P6027, DOI 10.1074/jbc.271.11.6027; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FAY PJ, 1991, J BIOL CHEM, V266, P8957; Fay PJ, 2004, BLOOD REV, V18, P1, DOI 10.1016/S0268-960X(03)00025-0; Fay PJ, 2001, J BIOL CHEM, V276, P12434, DOI 10.1074/jbc.M009539200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hakeos WH, 2002, THROMB HAEMOSTASIS, V88, P781, DOI 10.1055/s-0037-1613302; Kemball-Cook G, 1998, NUCLEIC ACIDS RES, V26, P216, DOI 10.1093/nar/26.1.216; LAMPHEAR BJ, 1992, J BIOL CHEM, V267, P3725; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1984, BLOOD, V63, P1303; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; Nogami K, 2003, J BIOL CHEM, V278, P1634, DOI 10.1074/jbc.M209811200; OVER J, 1984, SCAND J HAEMATOL, V33, P13; Pace CN, 1996, FASEB J, V10, P75, DOI 10.1096/fasebj.10.1.8566551; Parker ET, 2006, J BIOL CHEM, V281, P13922, DOI 10.1074/jbc.M513124200; Pemberton S, 1997, BLOOD, V89, P2413, DOI 10.1182/blood.V89.7.2413; Pipe SW, 2001, BLOOD, V97, P685, DOI 10.1182/blood.V97.3.685; Pipe SW, 1999, BLOOD, V93, P176, DOI 10.1182/blood.V93.1.176.401k07_176_183; Rudzki Z, 1996, BRIT J HAEMATOL, V94, P400, DOI 10.1046/j.1365-2141.1996.d01-1792.x; Shen BW, 2008, BLOOD, V111, P1240, DOI 10.1182/blood-2007-08-109918; Thurlkill RL, 2006, J MOL BIOL, V362, P594, DOI 10.1016/j.jmb.2006.07.056; Wakabayashi H, 2007, J THROMB HAEMOST, V5, P996, DOI 10.1111/j.1538-7836.2007.02458.x; Wakabayashi H, 2005, BIOCHEMISTRY-US, V44, P10298, DOI 10.1021/bi050638t; Wakabayashi H, 2001, BIOCHEMISTRY-US, V40, P10293, DOI 10.1021/bi010353q; Wakabayashi H, 2004, J BIOL CHEM, V279, P12677, DOI 10.1074/jbc.M311042200; Wakabayashi H, 2002, BIOCHEMISTRY-US, V41, P8485, DOI 10.1021/bi025589o; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051	32	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11645	11651		10.1074/jbc.M710252200	http://dx.doi.org/10.1074/jbc.M710252200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18299331	hybrid, Green Published			2022-12-25	WOS:000255067400065
J	Minicozzi, V; Stellato, F; Comai, M; Dalla Serra, M; Potrich, C; Meyer-Klaucke, W; Morante, S				Minicozzi, Velia; Stellato, Francesco; Comai, Massimiliano; Dalla Serra, Mauro; Potrich, Cristina; Meyer-Klaucke, Wolfram; Morante, Silvia			Identifying the minimal copper- and zinc-binding site sequence in amyloid-beta peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-ABSORPTION; MULTIPLE-SCATTERING THEORY; CURVED-WAVE THEORY; ALZHEIMERS-DISEASE; FINE-STRUCTURE; NEURODEGENERATIVE DISEASES; INFRARED-SPECTROSCOPY; METAL-BINDING; PRION PROTEIN; A-BETA	With a combination of complementary experimental techniques, namely sedimentation assay, Fourier transform infrared spectroscopy, and x-ray absorption spectroscopy, we are able to determine the atomic structure around the metal-binding site in samples where amyloid-beta (A beta) peptides are complexed with either Cu(II) or Zn(II). Exploiting information obtained on a selected set of fragments of the A beta peptide, we identify along the sequence the histidine residues coordinated to the metal in the various peptides we have studied (A beta(1-40), A beta(1-16), A beta(1-28), A beta(5-23), and A beta(17-40)). Our data can be consistently interpreted assuming that all of the peptides encompassing the minimal 1-16 amino acidic sequence display a copper coordination mode that involves three histidines (His(6), His(13), and His(14)). In zinc-A beta complexes, despite the fact that the metal coordination appears to be more sensitive to solution condition and shows a less rigid geometry around the binding site, a four-histidine coordination mode is seen to be preferred. Lacking a fourth histidine along the A beta peptide sequence, this geometrical arrangement hints at a Zn(II)-promoted interpeptide aggregation mode.	[Minicozzi, Velia; Stellato, Francesco; Morante, Silvia] Univ Roma Tor Vergata, Dipartimento Fis, I-00133 Rome, Italy; [Minicozzi, Velia; Stellato, Francesco; Morante, Silvia] Ist Nazl Fis Nucl, I-00133 Rome, Italy; [Comai, Massimiliano; Dalla Serra, Mauro; Potrich, Cristina] CNR, Fdn Bruno Kessler, Ist Biofis, Unita Trento, I-38100 Povo, TN, Italy; [Meyer-Klaucke, Wolfram] DESY, European Mol Biol Lab, D-22603 Hamburg, Germany; [Morante, Silvia] Univ Roma La Sapienza, Dipartimento Fis, I-00185 Rome, Italy	University of Rome Tor Vergata; Istituto Nazionale di Fisica Nucleare (INFN); Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR); Fondazione Bruno Kessler; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Sapienza University Rome	Morante, S (corresponding author), Univ Roma Tor Vergata, Dipartimento Fis, Via Ric Sci 1, I-00133 Rome, Italy.	silvia.morante@roma2.infn.it	Meyer-Klaucke, Wolfram/G-1148-2010; Stellato, Francesco/AAZ-4379-2020; Serra, Mauro Dalla/A-6218-2010; Serra, Mauro Dalla/AAK-9299-2021; Potrich, Cristina/AAR-7812-2020	Serra, Mauro Dalla/0000-0003-1048-2739; Serra, Mauro Dalla/0000-0003-1048-2739; Potrich, Cristina/0000-0002-0793-7547; Morante, Silvia/0000-0002-3913-5733; Minicozzi, Velia/0000-0001-9851-9932				Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; BENFATTO M, 1986, PHYS REV B, V34, P5774, DOI 10.1103/PhysRevB.34.5774; Benfatto M, 2004, BIOPHYS CHEM, V110, P191, DOI 10.1016/j.bpc.2004.02.003; BIANCONI A, 1986, P NATL ACAD SCI USA, V83, P7736, DOI 10.1073/pnas.83.20.7736; BINSTED N, 1992, BIOCHEMISTRY-US, V31, P12117, DOI 10.1021/bi00163a021; Binsted N., 1998, HIGH PERFORMANCE COM; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; Castagnetto JM, 2002, NUCLEIC ACIDS RES, V30, P379, DOI 10.1093/nar/30.1.379; Chauhan VPS, 2001, NEUROREPORT, V12, P587, DOI 10.1097/00001756-200103050-00031; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Danielsson J, 2007, FEBS J, V274, P46, DOI 10.1111/j.1742-4658.2006.05563.x; del Pino P, 2007, EUR BIOPHYS J BIOPHY, V36, P239, DOI 10.1007/s00249-006-0124-0; Dong J, 2003, BIOCHEMISTRY-US, V42, P2768, DOI 10.1021/bi0272151; Dong JJ, 2006, J AM CHEM SOC, V128, P3540, DOI 10.1021/ja055973j; FONDA L, 1992, J PHYS-CONDENS MAT, V4, P8269, DOI 10.1088/0953-8984/4/43/004; Gandy S, 2005, J CLIN INVEST, V115, P1121, DOI 10.1172/JCI200525100; Goormaghtigh E, 1994, Subcell Biochem, V23, P363; GURMAN SJ, 1986, J PHYS C SOLID STATE, V19, P1845, DOI 10.1088/0022-3719/19/11/021; Jacquamet L, 1998, BIOCHEMISTRY-US, V37, P2564, DOI 10.1021/bi9721344; Koningsberger D.C., 1988, XRAY ABSORPTION PRIN; Korbas M, 2006, REV SCI INSTRUM, V77, DOI 10.1063/1.2209954; Kowalik-Jankowska T, 2003, J INORG BIOCHEM, V95, P270, DOI 10.1016/S0162-0134(03)00128-4; LEE PA, 1975, PHYS REV B, V11, P2795, DOI 10.1103/PhysRevB.11.2795; LEE PA, 1981, REV MOD PHYS, V53, P769, DOI 10.1103/RevModPhys.53.769; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; Ma QF, 2006, BIOPOLYMERS, V83, P20, DOI 10.1002/bip.20523; Meneghini C, 1998, BIOPHYS J, V75, P1953, DOI 10.1016/S0006-3495(98)77636-2; Menestrina G, 1999, BIOCHEM BIOPH RES CO, V254, P174, DOI 10.1006/bbrc.1998.9898; MINICOZZI V, 2007, P NIC WORKSH, V36, P223; Miura T, 2000, BIOCHEMISTRY-US, V39, P7024, DOI 10.1021/bi0002479; Morante S, 2004, J BIOL CHEM, V279, P11753, DOI 10.1074/jbc.M312860200; NATOLI CR, 1986, J PHYS COLLQUES, V47, pC811; Opazo C, 2003, BIOMETALS, V16, P91, DOI 10.1023/A:1020795422185; Paradis E, 1996, J NEUROSCI, V16, P7533; Pepys MB, 2001, PHILOS T R SOC B, V356, P203, DOI 10.1098/rstb.2000.0766; Prusiner SB, 2001, NEW ENGL J MED, V344, P1516, DOI 10.1056/NEJM200105173442006; REHR JJ, 1990, PHYS REV B, V41, P8139, DOI 10.1103/PhysRevB.41.8139; Smith MA, 1997, P NATL ACAD SCI USA, V94, P9866, DOI 10.1073/pnas.94.18.9866; Stellato F, 2006, EUR BIOPHYS J BIOPHY, V35, P340, DOI 10.1007/s00249-005-0041-7; Suzuki K, 2001, BIOCHEM BIOPH RES CO, V285, P991, DOI 10.1006/bbrc.2001.5263; Syme CD, 2006, BBA-PROTEINS PROTEOM, V1764, P246, DOI 10.1016/j.bbapap.2005.09.012; Syme CD, 2004, J BIOL CHEM, V279, P18169, DOI 10.1074/jbc.M313572200; Tamm LK, 1997, Q REV BIOPHYS, V30, P365, DOI 10.1017/S0033583597003375; TEO BK, 1979, J AM CHEM SOC, V101, P2815, DOI 10.1021/ja00505a003; Trovato A, 2006, PLOS COMPUT BIOL, V2, P1608, DOI 10.1371/journal.pcbi.0020170; TYSON TA, 1992, PHYS REV B, V46, P5997, DOI 10.1103/PhysRevB.46.5997; Westermark P, 2007, AMYLOID, V14, P179, DOI 10.1080/13506120701460923; Wong BS, 2000, BIOCHEM BIOPH RES CO, V275, P249, DOI 10.1006/bbrc.2000.3158; Yoshiike Y, 2001, J BIOL CHEM, V276, P32293, DOI 10.1074/jbc.M010706200; Zirah S, 2006, J BIOL CHEM, V281, P2151, DOI 10.1074/jbc.M504454200	50	165	168	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10784	10792		10.1074/jbc.M707109200	http://dx.doi.org/10.1074/jbc.M707109200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18234670	hybrid			2022-12-25	WOS:000254894700061
J	Lakowski, TM; Frankel, A				Lakowski, Ted M.; Frankel, Adam			A kinetic study of human protein arginine N-methyltransferase 6 reveals a distributive mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEIN; S-ADENOSYLMETHIONINE; N-METHYLTRANSFERASE; SUBSTRATE-SPECIFICITY; HISTONE H3; SYMMETRIC DIMETHYLARGININE; METHYLATION; RESIDUES; PURIFICATION; PRMT6	Human protein arginine N-methyltransferase 6 (PRMT6) transfers methyl groups from the co-substrate S-adenosyl-L-methionine to arginine residues within proteins, forming S-adenosyl-L-homocysteine as well as omega-N-G-monomethylarginine (MMA) and asymmetric dimethylarginine (aDMA) residues in the process. We have characterized the kinetic mechanism of recombinant His-tagged PRMT6 using a mass spectrometry method for monitoring the methylation of a series of peptides bearing a single arginine, MMA, or aDMA residue. We find that PRMT6 follows an ordered sequential mechanism in which S-adenosyl-L-methionine binds to the enzyme first and the methylated product is the first to dissociate. Furthermore, we find that the enzyme displays a preference for the monomethylated peptide substrate, exhibiting both lower K-m and higher V-max values than what are observed for the unmethylated peptide. This difference in substrate K-m and V-max, as well as the lack of detectable aDMA-containing product from the unmethylated substrate, suggest a distributive rather than processive mechanism for multiple methylations of a single arginine residue. In addition, we speculate that the increased catalytic efficiency of PRMT6 for methylated substrates combined with lower K-m values for native protein methyl acceptors may obscure this distributive mechanism to produce an apparently processive mechanism.	[Lakowski, Ted M.; Frankel, Adam] Univ British Columbia, Fac Pharmaceut Sci, Div Biomol & Pharmaceut Chem, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Frankel, A (corresponding author), Univ British Columbia, Fac Pharmaceut Sci, Div Biomol & Pharmaceut Chem, 2146 E Mall, Vancouver, BC V6T 1Z3, Canada.	afrankel@interchange.ubc.ca		Lakowski, Ted/0000-0002-6625-6717				Bedford MT, 2005, MOL CELL, V18, P263, DOI 10.1016/j.molcel.2005.04.003; Boisvert FM, 2005, GENE DEV, V19, P671, DOI 10.1101/gad.1279805; Boisvert FM, 2002, J CELL BIOL, V159, P957, DOI 10.1083/jcb.200207028; Boisvert FM, 2003, MOL CELL PROTEOMICS, V2, P1319, DOI 10.1074/mcp.M300088-MCP200; Boulanger MC, 2005, J VIROL, V79, P124, DOI 10.1128/JVI.79.1.124-131.2005; Branscombe TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/jbc.M105412200; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Cheng DH, 2004, J BIOL CHEM, V279, P23892, DOI 10.1074/jbc.M401853200; Cheng X, 2000, S ADENOSYLMETHIONINE; Cook JR, 2006, BIOCHEM BIOPH RES CO, V342, P472, DOI 10.1016/j.bbrc.2006.01.167; Cote J, 2003, MOL BIOL CELL, V14, P274, DOI 10.1091/mbc.E02-08-0484; DAWSON MC, 1986, DATA BIOCH RES, P1; Dorgan KM, 2006, ANAL BIOCHEM, V350, P249, DOI 10.1016/j.ab.2006.01.004; Duan P, 2007, J IMMUNOL METHODS, V320, P132, DOI 10.1016/j.jim.2007.01.006; El-Andaloussi N, 2006, MOL CELL, V22, P51, DOI 10.1016/j.molcel.2006.02.013; FRANCIS DM, 1980, BIOCHEM J, V187, P819, DOI 10.1042/bj1870819; Frankel A, 2002, J BIOL CHEM, V277, P3537, DOI 10.1074/jbc.M108786200; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; Gehrig PM, 2004, J AM SOC MASS SPECTR, V15, P142, DOI 10.1016/j.jasms.2003.10.002; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GITOMER WL, 1986, BIOCHEM J, V233, P669, DOI 10.1042/bj2330669; Guccione E, 2007, NATURE, V449, P933, DOI 10.1038/nature06166; Hyllus D, 2007, GENE DEV, V21, P3369, DOI 10.1101/gad.447007; Iberg AN, 2008, J BIOL CHEM, V283, P3006, DOI 10.1074/jbc.C700192200; Invernizzi CF, 2007, AIDS, V21, P795, DOI 10.1097/QAD.0b013e32803277ae; Invernizzi CF, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-93; Kim S, 1997, BIOCHEMISTRY-US, V36, P5185, DOI 10.1021/bi9625509; Klein S, 2000, J BIOL CHEM, V275, P3150, DOI 10.1074/jbc.275.5.3150; KNOGGE W, 1984, EUR J BIOCHEM, V140, P113, DOI 10.1111/j.1432-1033.1984.tb08073.x; Krause CD, 2007, PHARMACOL THERAPEUT, V113, P50, DOI 10.1016/j.pharmthera.2006.06.007; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE HW, 1977, BIOCHEMISTRY-US, V16, P78, DOI 10.1021/bi00620a013; Lee J, 2005, J BIOL CHEM, V280, P32890, DOI 10.1074/jbc.M506944200; Lee JH, 2005, J BIOL CHEM, V280, P3656, DOI 10.1074/jbc.M405295200; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; LISCHWE MA, 1985, J BIOL CHEM, V260, P14304; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; McBride AE, 2005, J BIOL CHEM, V280, P30888, DOI 10.1074/jbc.M505831200; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; Miranda TB, 2005, BIOCHEM BIOPH RES CO, V336, P831, DOI 10.1016/j.bbrc.2005.08.179; Miranda TB, 2004, J BIOL CHEM, V279, P22902, DOI 10.1074/jbc.M312904200; Morris DP, 1995, J BIOL CHEM, V270, P30491, DOI 10.1074/jbc.270.51.30491; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; Osborne TC, 2007, BIOCHEMISTRY-US, V46, P13370, DOI 10.1021/bi701558t; Pahlich S, 2005, PROTEINS, V61, P164, DOI 10.1002/prot.20579; Pahlich S, 2006, BBA-PROTEINS PROTEOM, V1764, P1890, DOI 10.1016/j.bbapap.2006.08.008; Pal S, 2007, J CELL PHYSIOL, V213, P306, DOI 10.1002/jcp.21180; Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531; RAWAL N, 1995, BBA-PROTEIN STRUCT M, V1248, P11, DOI 10.1016/0167-4838(94)00213-Z; Sayegh J, 2007, J BIOL CHEM, V282, P36444, DOI 10.1074/jbc.M704650200; Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b; SEGEL IH, 1975, ENZYME KINETICS, P506; Sgarra R, 2006, J BIOL CHEM, V281, P3764, DOI 10.1074/jbc.M510231200; Shimizu Y, 2001, NAT BIOTECHNOL, V19, P751, DOI 10.1038/90802; Siebel CW, 1996, P NATL ACAD SCI USA, V93, P13641, DOI 10.1073/pnas.93.24.13641; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; Spannhoff A, 2007, J MED CHEM, V50, P2319, DOI 10.1021/jm061250e; Spannhoff A, 2007, BIOORG MED CHEM LETT, V17, P4150, DOI 10.1016/j.bmcl.2007.05.088; STEWART DJ, 1984, J NEURO-ONCOL, V2, P53, DOI 10.1007/BF00165158; Tamanoi F, 2006, ENZYMES, V24, pXI; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Watanabe K, 2006, J BIOL CHEM, V281, P34630, DOI 10.1074/jbc.M606141200; Weiss VH, 2000, NAT STRUCT BIOL, V7, P1165; Xie B, 2007, J VIROL, V81, P4226, DOI 10.1128/JVI.01888-06; YOUNG PR, 1988, BIOCHEM J, V250, P221, DOI 10.1042/bj2500221; Yue WW, 2007, EMBO J, V26, P4402, DOI 10.1038/sj.emboj.7601856; Zhang X, 2003, STRUCTURE, V11, P509, DOI 10.1016/S0969-2126(03)00071-6; Zhang X, 2000, EMBO J, V19, P3509, DOI 10.1093/emboj/19.14.3509	70	66	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					10015	10025		10.1074/jbc.M710176200	http://dx.doi.org/10.1074/jbc.M710176200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18263580	hybrid			2022-12-25	WOS:000254671600057
J	Ma, CL; Bower, KA; Chen, G; Shi, XL; Ke, ZJ; Luo, J				Ma, Cuiling; Bower, Kimberly A.; Chen, Gang; Shi, Xianglin; Ke, Zun-Ji; Luo, Jia			Interaction between ERK and GSK3 beta mediates basic fibroblast growth factor-induced apoptosis in SK-N-MC neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; GLYCOGEN-SYNTHASE KINASE-3-BETA; CISPLATIN-INDUCED APOPTOSIS; BETA-ARRESTIN; MAP KINASE; TAU PHOSPHORYLATION; GLIAL-CELLS; DEATH; SURVIVAL; FYN	The Ewing's sarcoma family of tumors ( ESFT) includes Ewing's sarcoma ( ES), Askin's tumor of the chest wall, and peripheral primitive neuroectodermal tumor. Basic fibroblast growth factor ( FGF2) suppresses the growth of ESFT cells and causes their apoptosis. The underlying mechanism is unclear. Using a human peripheral primitive neuroectodermal tumor cell line, SK-N-MC, we demonstrated FGF2 stimulated phosphorylation of ERK1 and ERK2 ( pERK1/2) and GSK3 beta ( pGSK3 beta( Tyr-216)), all of which were primarily retained in the cytoplasm. FGF2 promoted the association between ERK and pGSK3 beta( Tyr-216). Inhibitors for GSK3 beta( TDZD and LiCl) and ERK ( PD98059) protected cells from FGF2-induced apoptosis. On the other hand, inhibitors of GSK3 beta, but not PD98059 decreased ERK/pGSK3 beta( Tyr-216) association and caused a nuclear translocation of pERK1/2. Similarly, expression of a kinase-deficient ( K85R) GSK3 beta or GSK3 beta-small interfering RNA inhibited FGF2-regulated ERK/pGSK3 beta( Tyr-216) association and translocated pERK to the nucleus. Both K85R GSK3 beta and small interfering RNA offered protection against FGF2-induced cell death. In contrast, overexpression of wild-type GSK3 beta sensitized cells to FGF2 cytotoxicity. Hydrogen peroxide and ethanol enhanced FGF2-stimulated pGSK3 beta( Tyr-216), ERK/pGSK3 beta( Tyr-216) association, and cytoplasmic retention of pERK1/2. As a result, they potentiated FGF2-induced cell death. Taken together, our results suggested that FGF2-induced accumulation of pERK1/ 2 in the cytoplasm is toxic for SK-N-MC cells. The formation of an ERK center dot GSK3 beta complex retained pERK1/ 2 in the cytoplasm. In contrast, disruption of the ERK center dot GSK3 beta complex resulted in nuclear translocation of pERK1/ 2 and offered protection.	[Ma, Cuiling; Bower, Kimberly A.; Chen, Gang; Luo, Jia] W Virginia Univ, Sch Med, Robert C Byrd Hlth Sci Ctr, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA; [Ma, Cuiling] Xijing Hosp, Dept Dermatol, Xian 710032, Peoples R China; [Shi, Xianglin] Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; [Ke, Zun-Ji; Luo, Jia] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Shanghai 200031, Peoples R China	West Virginia University; Air Force Military Medical University; University of Kentucky; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Luo, J (corresponding author), W Virginia Univ, Sch Med, Robert C Byrd Hlth Sci Ctr, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA.	jluo@hsc.wvu.edu	Luo, Jia/E-4674-2012; He, Liuge/E-6385-2010; Ke, Zunji/E-4822-2010; Shi, Xianglin/B-8588-2012; Ke, Zun-Ji/N-5689-2014	Luo, Jia/0000-0002-6968-3618; Ke, Zunji/0000-0003-4038-2456; Ke, Zun-Ji/0000-0003-4038-2456	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA015407] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01 AA015407-03, R01 AA015407, AA 015407] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Abe JI, 2000, J BIOL CHEM, V275, P1739, DOI 10.1074/jbc.275.3.1739; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Burchill SA, 2002, APOPTOSIS, V7, P5, DOI 10.1023/A:1013548426273; Cai GQ, 2007, INT J ONCOL, V31, P657; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Chen G, 2004, FASEB J, V18, P1162, DOI 10.1096/fj.04-1551fje; Chen G, 2006, J BIOL CHEM, V281, P15909, DOI 10.1074/jbc.M600612200; Chen J, 2004, J BIOL CHEM, V279, P39317, DOI 10.1074/jbc.M403891200; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Dailey L, 2005, CYTOKINE GROWTH F R, V16, P233, DOI 10.1016/j.cytogfr.2005.01.007; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Ding QQ, 2005, MOL CELL, V19, P159, DOI 10.1016/j.molcel.2005.06.009; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Ferrer I, 2001, J NEURAL TRANSM, V108, P1397, DOI 10.1007/s007020100016; Ferrer I, 2001, BRAIN PATHOL, V11, P144; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Germain D, 2000, J BIOL CHEM, V275, P12074, DOI 10.1074/jbc.275.16.12074; Grose R, 2005, CYTOKINE GROWTH F R, V16, P179, DOI 10.1016/j.cytogfr.2005.01.003; Grothe C, 2001, ANAT EMBRYOL, V204, P171, DOI 10.1007/s004290100205; Hartigan JA, 1999, J BIOL CHEM, V274, P21395, DOI 10.1074/jbc.274.30.21395; Hochholdinger F, 1999, MOL CELL BIOL, V19, P8052; Jain AK, 2007, J BIOL CHEM, V282, P16502, DOI 10.1074/jbc.M611336200; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Kim MS, 2004, J PATHOL, V202, P103, DOI 10.1002/path.1497; Kim YK, 2005, J APPL TOXICOL, V25, P374, DOI 10.1002/jat.1081; LANDGREN E, 1995, ONCOGENE, V10, P2027; Ledoux Dominique, 1992, Progress in Growth Factor Research, V4, P107, DOI 10.1016/0955-2235(92)90026-E; Lesort M, 1999, J NEUROCHEM, V72, P576, DOI 10.1046/j.1471-4159.1999.0720576.x; Ma C, 2007, CANCER RES, V67, P7756, DOI 10.1158/0008-5472.CAN-06-4665; Maloof P, 1999, BREAST CANCER RES TR, V56, P153; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Nowak G, 2002, J BIOL CHEM, V277, P43377, DOI 10.1074/jbc.M206373200; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Russo VC, 2004, J CELL PHYSIOL, V199, P371, DOI 10.1002/jcp.10416; Sahni M, 2001, DEVELOPMENT, V128, P2119; Scurr M, 2006, ONCOLOGIST, V11, P65, DOI 10.1634/theoncologist.11-1-65; Shenoy SK, 2003, J BIOL CHEM, V278, P14498, DOI 10.1074/jbc.M209626200; Sinha D, 2004, J BIOL CHEM, V279, P10962, DOI 10.1074/jbc.M312048200; Sturla LM, 2000, CANCER RES, V60, P6160; Takahashi-Yanaga F, 2004, BIOCHEM BIOPH RES CO, V316, P411, DOI 10.1016/j.bbrc.2004.02.061; Tohgo A, 2003, J BIOL CHEM, V278, P6258, DOI 10.1074/jbc.M212231200; Valencia A, 2004, FREE RADICAL BIO MED, V36, P1112, DOI 10.1016/j.freeradbiomed.2004.02.013; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Wang YM, 2006, J INFRARED MILLIM W, V25, P50; Williamson AJK, 2004, J BIOL CHEM, V279, P47912, DOI 10.1074/jbc.M409035200; Zhu JH, 2002, AM J PATHOL, V161, P2087, DOI 10.1016/S0002-9440(10)64487-2; Zhuang SG, 2006, J PHARMACOL EXP THER, V319, P991, DOI 10.1124/jpet.106.107367	49	21	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9248	9256		10.1074/jbc.M707316200	http://dx.doi.org/10.1074/jbc.M707316200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18263590	Green Published, hybrid			2022-12-25	WOS:000254465800055
J	de Candia, P; Blekhman, R; Chabot, AE; Oshlack, A; Gilad, Y				de Candia, Paola; Blekhman, Ran; Chabot, Adrien E.; Oshlack, Alicia; Gilad, Yoav			A Combination of Genomic Approaches Reveals the Role of FOXO1a in Regulating an Oxidative Stress Response Pathway	PLOS ONE			English	Article								Background: While many of the phenotypic differences between human and chimpanzee may result from changes in gene regulation, only a handful of functionally important regulatory differences are currently known. As a first step towards identifying transcriptional pathways that have been remodeled in the human lineage, we focused on a transcription factor, FOXO1a, which we had previously found to be up-regulated in the human liver compared to that of three other primate species. We concentrated on this gene because of its known role in the regulation of metabolism and in longevity. Methodology: Using a combination of expression profiling following siRNA knockdown and chromatin immunoprecipitation in a human liver cell line, we identified eight novel direct transcriptional targets of FOXO1a. This set includes the gene for thioredoxin-interacting protein (TXNIP), the expression of which is directly repressed by FOXO1a. The thioredoxin-interacting protein is known to inhibit the reducing activity of thioredoxin (TRX), thereby hindering the cellular response to oxidative stress and affecting life span. Conclusions: Our results provide an explanation for the repeated observations that differences in the regulation of FOXO transcription factors affect longevity. Moreover, we found that TXNIP is down-regulated in human compared to chimpanzee, consistent with the up-regulation of its direct repressor FOXO1a in humans, and with differences in longevity between the two species.	[de Candia, Paola; Blekhman, Ran; Chabot, Adrien E.; Gilad, Yoav] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; [Oshlack, Alicia] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia	University of Chicago; Walter & Eliza Hall Institute	de Candia, P (corresponding author), Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA.	pdecandi@bsd.uchicago.edu; gilad@uchicago.edu	de Candia, Paola/HGC-8826-2022; Oshlack, Alicia/P-6139-2014; de Candia, Paola/Z-1498-2019	de Candia, Paola/0000-0003-4767-446X; Oshlack, Alicia/0000-0001-9788-5690; de Candia, Paola/0000-0003-4767-446X; Blekhman, Ran/0000-0003-3218-613X	NIH [GM077959]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM077959] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This research was supported by NIH grant GM077959.	Abzhanov A, 2004, SCIENCE, V305, P1462, DOI 10.1126/science.1098095; Barthel A, 2005, TRENDS ENDOCRIN MET, V16, P183, DOI 10.1016/j.tem.2005.03.010; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; BRITTEN RJ, 1971, Q REV BIOL, V46, P111, DOI 10.1086/406830; Carroll SB, 2003, NATURE, V422, P849, DOI 10.1038/nature01495; Cutler RG, 2005, ANN NY ACAD SCI, V1055, P93, DOI 10.1196/annals.1323.027; Dermitzakis ET, 2002, MOL BIOL EVOL, V19, P1114, DOI 10.1093/oxfordjournals.molbev.a004169; Giannakou ME, 2004, SCIENCE, V305, P361, DOI 10.1126/science.1098219; Gilad Y, 2006, NATURE, V440, P242, DOI 10.1038/nature04559; Gilad Y, 2005, GENOME RES, V15, P674, DOI 10.1101/gr.3335705; HARVEY PH, 1985, EVOLUTION, V39, P559, DOI 10.1111/j.1558-5646.1985.tb00395.x; Hill K, 2001, J HUM EVOL, V40, P437, DOI 10.1006/jhev.2001.0469; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; Huby T, 2001, J BIOL CHEM, V276, P22209, DOI 10.1074/jbc.M102204200; Iftikhar R, 2004, AM J GASTROENTEROL, V99, P1087, DOI 10.1111/j.1572-0241.2004.30572.x; Jee C, 2005, GENES CELLS, V10, P1203, DOI 10.1111/j.1365-2443.2005.00913.x; Jin W, 2001, NAT GENET, V29, P389, DOI 10.1038/ng766; Junger Martin A, 2003, J Biol, V2, P20, DOI 10.1186/1475-4924-2-20; Junn E, 2000, J IMMUNOL, V164, P6287, DOI 10.4049/jimmunol.164.12.6287; Kel AE, 2003, NUCLEIC ACIDS RES, V31, P3576, DOI 10.1093/nar/gkg585; KING MC, 1975, SCIENCE, V188, P107, DOI 10.1126/science.1090005; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kregel KC, 2007, AM J PHYSIOL-REG I, V292, pR18, DOI 10.1152/ajpregu.00327.2006; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Ludwig MZ, 2005, PLOS BIOL, V3, P588, DOI 10.1371/journal.pbio.0030093; Ludwig MZ, 2000, NATURE, V403, P564, DOI 10.1038/35000615; Mitsui A, 2002, ANTIOXID REDOX SIGN, V4, P693, DOI 10.1089/15230860260220201; Morris BJ, 2005, J HYPERTENS, V23, P1285, DOI 10.1097/01.hjh.0000173509.45363.dd; Murphy CT, 2006, EXP GERONTOL, V41, P910, DOI 10.1016/j.exger.2006.06.040; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Oh SW, 2006, NAT GENET, V38, P251, DOI 10.1038/ng1723; OSHLACK A, 2007, BIOINFORMATICS; Patwari P, 2006, J BIOL CHEM, V281, P21884, DOI 10.1074/jbc.M600427200; Rockman MV, 2005, PLOS BIOL, V3, P2208, DOI 10.1371/journal.pbio.0030387; Rockman MV, 2003, CURR BIOL, V13, P2118, DOI 10.1016/j.cub.2003.11.025; Seidman JG, 2002, J CLIN INVEST, V109, P451, DOI 10.1172/JC1200215043; Shapiro MD, 2004, NATURE, V428, P717, DOI 10.1038/nature02415; Shimokawa I, 2002, AM J PATHOL, V160, P2259, DOI 10.1016/S0002-9440(10)61173-X; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; SMYTH GK, 2004, STAT APPL GENET MOL, V3; Taron M, 2004, HUM MOL GENET, V13, P2443, DOI 10.1093/hmg/ddh260; TRAN H, 2003, SCI STKE, pRE5, DOI DOI 10.1126/STKE.2003.172.RE5; Vavouri T, 2005, CURR OPIN GENET DEV, V15, P395, DOI 10.1016/j.gde.2005.05.002; Yoshida T, 2003, ANTIOXID REDOX SIGN, V5, P563, DOI 10.1089/152308603770310211; Yoshida T, 2006, BIOFACTORS, V27, P47, DOI 10.1002/biof.5520270105; YU M, 2007, MAMM GENOME	48	39	39	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2008	3	2							e1670	10.1371/journal.pone.0001670	http://dx.doi.org/10.1371/journal.pone.0001670			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XS	18301748	Green Published, gold			2022-12-25	WOS:000260586500015
J	Limb, CJ; Braun, AR				Limb, Charles J.; Braun, Allen R.			Neural Substrates of Spontaneous Musical Performance: An fMRI Study of Jazz Improvisation	PLOS ONE			English	Article							ANTERIOR PREFRONTAL CORTEX; FUNCTIONAL NEUROANATOMY; COGNITIVE NEUROSCIENCE; BRAIN; ORGANIZATION; RESPONSES; CORRELATE; ANATOMY; IMAGERY	To investigate the neural substrates that underlie spontaneous musical performance, we examined improvisation in professional jazz pianists using functional MRI. By employing two paradigms that differed widely in musical complexity, we found that improvisation (compared to production of over-learned musical sequences) was consistently characterized by a dissociated pattern of activity in the prefrontal cortex: extensive deactivation of dorsolateral prefrontal and lateral orbital regions with focal activation of the medial prefrontal (frontal polar) cortex. Such a pattern may reflect a combination of psychological processes required for spontaneous improvisation, in which internally motivated, stimulus-independent behaviors unfold in the absence of central processes that typically mediate self-monitoring and conscious volitional control of ongoing performance. Changes in prefrontal activity during improvisation were accompanied by widespread activation of neocortical sensorimotor areas (that mediate the organization and execution of musical performance) as well as deactivation of limbic structures (that regulate motivation and emotional tone). This distributed neural pattern may provide a cognitive context that enables the emergence of spontaneous creative activity.	[Limb, Charles J.; Braun, Allen R.] Natl Inst Deafness & Other Commun Disorders, Language Sect, Voice Speech & Language Branch, NIH, Bethesda, MD USA; Johns Hopkins Univ, Dept Otolaryngol Head & Neck Surg, Peabody Conservatory Music, Baltimore, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Johns Hopkins University	Limb, CJ (corresponding author), Natl Inst Deafness & Other Commun Disorders, Language Sect, Voice Speech & Language Branch, NIH, Bethesda, MD USA.	climb@jhmi.edu			Division of Intramural Research; National Institute on Deafness and Other Communication Disorders; National Institutes of Health; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000031, ZIADC000031] Funding Source: NIH RePORTER	Division of Intramural Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute on Deafness and Other Communication Disorders(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	This research was funded solely by the Division of Intramural Research, National Institute on Deafness and Other Communication Disorders, National Institutes of Health.	Ashby FG, 1999, PSYCHOL REV, V106, P529, DOI 10.1037/0033-295X.106.3.529; Bengtsson SL, 2007, J COGNITIVE NEUROSCI, V19, P830, DOI 10.1162/jocn.2007.19.5.830; BERLINER P, 1994, THINKING JAZZ INFINI, pR19; Blakemore SJ, 1998, NEUROPSYCHOLOGIA, V36, P521, DOI 10.1016/S0028-3932(97)00145-0; Blood AJ, 1999, NAT NEUROSCI, V2, P382, DOI 10.1038/7299; Blood AJ, 2001, P NATL ACAD SCI USA, V98, P11818, DOI 10.1073/pnas.191355898; BRANSFORD J, 1993, IDEAL PROBLEM SOLVER, pR13; Braun AR, 1997, BRAIN, V120, P1173, DOI 10.1093/brain/120.7.1173; Braun AR, 2001, BRAIN, V124, P2028, DOI 10.1093/brain/124.10.2028; Bunge SA, 2001, BRAIN, V124, P2074, DOI 10.1093/brain/124.10.2074; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Carlsson ML, 2000, ACTA PSYCHIAT SCAND, V102, P401, DOI 10.1034/j.1600-0447.2000.102006401.x; Christoff K, 2000, PSYCHOBIOLOGY, V28, P168; Curtis CE, 2003, TRENDS COGN SCI, V7, P415, DOI 10.1016/S1364-6613(03)00197-9; Dietrich A, 2004, PSYCHON B REV, V11, P1011, DOI 10.3758/BF03196731; Dietrich A, 2003, CONSCIOUS COGN, V12, P231, DOI 10.1016/S1053-8100(02)00046-6; Friston KJ, 1999, NEUROIMAGE, V10, P385, DOI 10.1006/nimg.1999.0484; Goldberg II, 2006, NEURON, V50, P329, DOI 10.1016/j.neuron.2006.03.015; Guilford JP, 1950, AM PSYCHOL, V5, P444, DOI 10.1037/h0063487; Halpern AR, 1999, CEREB CORTEX, V9, P697, DOI 10.1093/cercor/9.7.697; HENTOFF N, 2004, AM MUSIC IS, pR19; Hobson JA, 2000, BEHAV BRAIN SCI, V23, P793, DOI 10.1017/S0140525X00003976; Hobson JA, 2000, BEHAV BRAIN SCI, V23, P951, DOI 10.1017/S0140525X00494021; Koechlin E, 1999, NATURE, V399, P148, DOI 10.1038/20178; Koelsch S, 2006, HUM BRAIN MAPP, V27, P239, DOI 10.1002/hbm.20180; Koelsch S, 2005, NEUROIMAGE, V25, P1068, DOI 10.1016/j.neuroimage.2004.12.050; Koelsch S, 2002, NEUROIMAGE, V17, P956, DOI 10.1016/S1053-8119(02)91154-7; Kringelbach ML, 2004, PROG NEUROBIOL, V72, P341, DOI 10.1016/j.pneurobio.2004.03.006; Nisenson E., 1995, ASCENSION J COLTRANE; Ozdemir E, 2006, NEUROIMAGE, V33, P628, DOI 10.1016/j.neuroimage.2006.07.013; Parsons LM, 2001, ANN NY ACAD SCI, V930, P211, DOI 10.1111/j.1749-6632.2001.tb05735.x; Passingham D, 2004, CURR OPIN NEUROBIOL, V14, P163, DOI 10.1016/j.conb.2004.03.003; Perry DW, 1999, NEUROREPORT, V10, P3453, DOI 10.1097/00001756-199911080-00035; Raichle ME, 2005, J COMP NEUROL, V493, P167, DOI 10.1002/cne.20752; Ramnani N, 2004, NAT REV NEUROSCI, V5, P184, DOI 10.1038/nrn1343; Sakai K, 2003, NAT NEUROSCI, V6, P75, DOI 10.1038/nn987; Schooler J.W., 1997, CREATIVE COGNITION A, P97; Shirley DA, 1996, PSYCHOL REP, V79, P563, DOI 10.2466/pr0.1996.79.2.563; Zatorre RJ, 1998, P NATL ACAD SCI USA, V95, P3172, DOI 10.1073/pnas.95.6.3172; Zatorre RJ, 2005, NEURON, V47, P9, DOI 10.1016/j.neuron.2005.06.013; Zatorre RJ, 2001, CEREB CORTEX, V11, P946, DOI 10.1093/cercor/11.10.946; Zatorre RJ, 2002, TRENDS COGN SCI, V6, P37, DOI 10.1016/S1364-6613(00)01816-7	43	368	375	1	70	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2008	3	2							e1679	10.1371/journal.pone.0001679	http://dx.doi.org/10.1371/journal.pone.0001679			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XS	18301756	Green Published, gold			2022-12-25	WOS:000260586500023
J	Minnhagen, P; Bernhardsson, S				Minnhagen, Petter; Bernhardsson, Sebastian			The Blind Watchmaker Network: Scale-Freeness and Evolution	PLOS ONE			English	Article							CONNECTIVITY	It is suggested that the degree distribution for networks of the cell-metabolism for simple organisms reflects a ubiquitous randomness. This implies that natural selection has exerted no or very little pressure on the network degree distribution during evolution. The corresponding random network, here termed the blind watchmaker network has a power-law degree distribution with an exponent gamma >= 2. It is random with respect to a complete set of network states characterized by a description of which links are attached to a node as well as a time-ordering of these links. No a priory assumption of any growth mechanism or evolution process is made. It is found that the degree distribution of the blind watchmaker network agrees very precisely with that of the metabolic networks. This implies that the evolutionary pathway of the cell-metabolism, when projected onto a metabolic network representation, has remained statistically random with respect to a complete set of network states. This suggests that even a biological system, which due to natural selection has developed an enormous specificity like the cellular metabolism, nevertheless can, at the same time, display well defined characteristics emanating from the ubiquitous inherent random element of Darwinian evolution. The fact that also completely random networks may have scale-free node distributions gives a new perspective on the origin of scale-free networks in general.	[Minnhagen, Petter; Bernhardsson, Sebastian] Umea Univ, Dept Theoret Phys, S-90187 Umea, Sweden; [Minnhagen, Petter; Bernhardsson, Sebastian] Ctr Models Life, Copenhagen, Denmark	Umea University	Minnhagen, P (corresponding author), Umea Univ, Dept Theoret Phys, S-90187 Umea, Sweden.	sebbeb@tp.umu.se			Swedish Research Council [50412501]	Swedish Research Council(Swedish Research CouncilEuropean Commission)	This work was supported by the Swedish Research Council through contract 50412501.	Albert R, 2002, REV MOD PHYS, V74, P47, DOI 10.1103/RevModPhys.74.47; Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Boccaletti S, 2006, PHYS REP, V424, P175, DOI 10.1016/j.physrep.2005.10.009; Cohen R, 2000, PHYS REV LETT, V85, P4626, DOI 10.1103/PhysRevLett.85.4626; Dawkins R., 1985, BLIND WATCHMAKER WHY; Dorogovtsev SN, 2003, EVOLUTION NETWORKS B; Gleiss PM, 2001, ADV COMPLEX SYST, V04, P207, DOI [10.1142/S0219525901000140, DOI 10.1142/S0219525901000140]; JAYNES ET, 1957, PHYS REV, V106, P620, DOI 10.1103/PhysRev.106.620; Jeong H, 2000, NATURE, V407, P651, DOI 10.1038/35036627; Ma HW, 2003, BIOINFORMATICS, V19, P270, DOI 10.1093/bioinformatics/19.2.270; Ma HW, 2003, BIOINFORMATICS, V19, P1423, DOI 10.1093/bioinformatics/btg177; MINNHAGEN P, 2007, EPL, V78; Minnhagen P, 2007, CHAOS, V17, DOI 10.1063/1.2720101; Newman MEJ, 2003, SIAM REV, V45, P167, DOI 10.1137/S003614450342480; Newman MEJ., 2006, STRUCTURE DYNAMICS N; Pfeiffer T, 2005, PLOS BIOL, V3, P1269, DOI 10.1371/journal.pbio.0030228; Smith E D, 2002, ADV COMPLEX SYST, V5, P43, DOI DOI 10.1142/S021952590200047X; Vazquez Alexei, 2003, ComPlexUs, V1, P38, DOI 10.1159/000067642; WAGNER A, 2003, SCI STKE, V41; Wagner A., 2005, ROBUSTNESS EVOLVABIL	21	12	12	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2008	3	2							e1690	10.1371/journal.pone.0001690	http://dx.doi.org/10.1371/journal.pone.0001690			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XS	18301767	Green Published, gold, Green Submitted			2022-12-25	WOS:000260586500034
J	Mangel, M; Bonsall, MB				Mangel, Marc; Bonsall, Michael B.			Phenotypic Evolutionary Models in Stem Cell Biology: Replacement, Quiescence, and Variability	PLOS ONE			English	Article							STOCHASTIC SIMULATION; SELECTION; MATHEMATICS; RADIATION; DYNAMICS; ECOLOGY; HISTORY; FITNESS; SYSTEMS	Phenotypic evolutionary models have been used with great success in many areas of biology, but thus far have not been applied to the study of stem cells except for investigations of cancer. We develop a framework that allows such modeling techniques to be applied to stem cells more generally. The fundamental modeling structure is the stochastic kinetics of stem cells in their niche and of transit amplifying and fully differentiated cells elsewhere in the organism, with positive and negative feedback. This formulation allows graded signals to be turned into all or nothing responses, and shows the importance of looking beyond the niche for understanding how stem cells behave. Using the deterministic version of this framework, we show how competition between different stem cell lines can be analyzed, and under what circumstances stem cells in a niche will be replaced by other stem cells with different phenotypic characteristics. Using the stochastic version of our framework and state dependent life history theory, we show that the optimal behavior of a focal stem cell will involve long periods of quiescence and that a population of identical stem cells will show great variability in the times at which activity occurs; we compare our results with classic ones on quiescence and variability in the hematopoietic system.	[Mangel, Marc] Univ Calif Santa Cruz, Ctr Biomol Sci & Engn, Dept Appl Math & Stat, Santa Cruz, CA 95064 USA; [Bonsall, Michael B.] Univ Oxford, Dept Zool, Math Ecol Res Grp, Oxford, England	University of California System; University of California Santa Cruz; University of Oxford	Mangel, M (corresponding author), Univ Calif Santa Cruz, Ctr Biomol Sci & Engn, Dept Appl Math & Stat, Santa Cruz, CA 95064 USA.	msmangel@ucsc.edu		Bonsall, Michael/0000-0003-0250-0423	NSF; Royal Society; Astor Travel Fund; University of Oxford	NSF(National Science Foundation (NSF)); Royal Society(Royal Society of London); Astor Travel Fund; University of Oxford	This work was supported by the NSF, Royal Society, and the Astor Travel Fund, University of Oxford.	Alon U, 2007, INTRO SYSTEMS BIOL D; Anderson DJ, 2001, NEURON, V30, P19, DOI 10.1016/S0896-6273(01)00260-4; ANVERSA P, 2006, ESSENTIALS STEM CELL, P425; Appelbaum FR, 2007, NEW ENGL J MED, V357, P1472, DOI 10.1056/NEJMp078166; Barbour A., 1974, ADV APPL PROBAB, V6, P21, DOI [DOI 10.2307/1426205, 10.2307/1426205]; BARBOUR AD, 1980, ADV APPL PROBAB, V12, P591, DOI 10.2307/1426422; Bonsall MB, 2004, P ROY SOC B-BIOL SCI, V271, P1143, DOI 10.1098/rspb.2004.2722; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; Clark CW, 2000, OX ECOL EV; Davey RE, 2007, FASEB J, V21, P2020, DOI 10.1096/fj.06-7852com; Dieckmann U, 1997, TRENDS ECOL EVOL, V12, P128, DOI 10.1016/S0169-5347(97)01004-5; DOBZHANSKY T, 1964, AM ZOOL, V4, P443; Fisher R.A., 1930, GENETICAL THEORY NAT; Frank S. A., 2007, DYNAMICS CANC INCIDE; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Gibson MA, 2000, J PHYS CHEM A, V104, P1876, DOI 10.1021/jp993732q; Gillespie DT, 2001, J CHEM PHYS, V115, P1716, DOI 10.1063/1.1378322; Gillespie DT, 2000, J CHEM PHYS, V113, P297, DOI 10.1063/1.481811; Gillespie DT, 2003, J CHEM PHYS, V119, P8229, DOI 10.1063/1.1613254; Grant P.R., 2007, WHY SPECIES MULTIPLY; Houston AI, 1999, MODELS ADAPTIVE BEHA; Kingsland S. E., 1985, MODELING NATURE EPIS; Kirouac DC, 2006, CURR OPIN BIOTECH, V17, P538, DOI 10.1016/j.copbio.2006.07.003; KURTZ TG, 1972, J CHEM PHYS, V57, P2976, DOI 10.1063/1.1678692; KURTZ TG, 1971, J APPL PROBAB, V8, P344, DOI 10.2307/3211904; KURTZ TG, 1970, J APPL PROBAB, V7, P49, DOI 10.2307/3212147; Lanza R., 2006, ESSENTIALS STEM CELL; LeGrand EK, 1997, Q REV BIOL, V72, P135, DOI 10.1086/419763; MacDonald N., 1989, BIOL DELAY SYSTEMS L; MADHAVI A, 2007, PLOS COMPUT BIOL, V3, P1; MANGEL M, 1994, THEOR POPUL BIOL, V45, P16, DOI 10.1006/tpbi.1994.1002; Mangel M, 2004, THEOR POPUL BIOL, V65, P353, DOI 10.1016/j.tpb.2003.07.005; Mangel M, 2006, THEORETICAL BIOLOGIST'S TOOLBOX: QUANTITATIVE METHODS FOR ECOLOGY AND EVOLUTIONARY BIOLOGY, P1, DOI 10.2277/ 0521537487; MANGEL M, 1992, ANNU REV ECOL SYST, V23, P507; Mangel M., 1988, DYNAMIC MODELING BEH; Mangel M, 2007, OIKOS, V116, P1779, DOI 10.1111/j.2007.0030-1299.16248.x; Mangel M, 2007, EVOLUTION, V61, P1208, DOI 10.1111/j.1558-5646.2007.00094.x; May RM, 2004, SCIENCE, V303, P790, DOI 10.1126/science.1094442; MAY RM, 2007, USES ABUSES MATH BIO; Mayr E., 1982, GROWTH BIOL THOUGHT; METZ JAJ, 1992, TRENDS ECOL EVOL, V7, P198, DOI 10.1016/0169-5347(92)90073-K; Murray JD, 2003, MATH BIOL, V3; Neff T, 2006, BLOOD, V107, P1751, DOI 10.1182/blood-2005-06-2335; Nowak MA, 2006, EVOLUTIONARY DYNAMIC; PAINTER PR, 1968, ANNU REV MICROBIOL, V22, P519, DOI 10.1146/annurev.mi.22.100168.002511; PIELOU E C, 1969, P286; Potten CS, 2002, J CELL SCI, V115, P2381; Potten CS, 2002, J INVEST DERMATOL, V119, P888, DOI 10.1046/j.1523-1747.2002.00020.x; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; POTTEN CS, 2006, ESSENTIALS STEM CELL, P11; Puterman M. L., 1994, MARKOV DECISION PROC; Raff M, 2003, ANNU REV CELL DEV BI, V19, P1, DOI 10.1146/annurev.cellbio.19.111301.143037; Robert JS, 2004, BIOESSAYS, V26, P1005, DOI 10.1002/bies.20100; Shostak S, 2006, BIOESSAYS, V28, P301, DOI 10.1002/bies.20376; THOMAS ED, 1957, NEW ENGL J MED, V257, P491, DOI 10.1056/NEJM195709122571102; TILL JE, 1964, P NATL ACAD SCI USA, V51, P29, DOI 10.1073/pnas.51.1.29; Venner S, 2006, J THEOR BIOL, V241, P725, DOI 10.1016/j.jtbi.2006.01.008; Vincent T. L., 2005, EVOLUTIONARY GAME TH; Viswanathan S, 2005, BIOTECHNOL APPL BIOC, V42, P119, DOI 10.1042/BA20040207; VOGEL H, 1969, J THEOR BIOL, V22, P249, DOI 10.1016/0022-5193(69)90004-6; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Wodarz D, 2005, LECT NOTES MATH MODE; Zandstra PW, 2001, ANNU REV BIOMED ENG, V3, P275, DOI 10.1146/annurev.bioeng.3.1.275	63	31	32	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1591	10.1371/journal.pone.0001591	http://dx.doi.org/10.1371/journal.pone.0001591			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270578	Green Published, gold			2022-12-25	WOS:000260535900025
J	Pezer, Z; Ugarkovic, D				Pezer, Zeljka; Ugarkovic, Durdica			RNA Pol II Promotes Transcription of Centromeric Satellite DNA in Beetles	PLOS ONE			English	Article								Transcripts of centromeric satellite DNAs are known to play a role in heterochromatin formation as well as in establishment of the kinetochore. However, little is known about basic mechanisms of satellite DNA expression within constitutive heterochromatin and its regulation. Here we present comprehensive analysis of transcription of abundant centromeric satellite DNA, PRAT from beetle Palorus ratzeburgii ( Coleoptera). This satellite is characterized by preservation and extreme sequence conservation among evolutionarily distant insect species. PRAT is expressed in all three developmental stages: larvae, pupae and adults at similar level. Transcripts are abundant comprising 0.033% of total RNA and are heterogeneous in size ranging from 0.5 kb up to more than 5 kb. Transcription proceeds from both strands but with 10 fold different expression intensity and transcripts are not processed into siRNAs. Most of the transcripts (80%) are not polyadenylated and remain in the nucleus while a small portion is exported to the cytoplasm. Multiple, irregularly distributed transcription initiation sites as well as termination sites have been mapped within the PRAT sequence using primer extension and RLM-RACE. The presence of cap structure as well as poly( A) tails in a portion of the transcripts indicate RNA polymerase II dependent transcription and a putative polymerase II promoter site overlaps the most conserved part of the PRAT sequence. The treatment of larvae with alpha-amanitin decreases the level of PRAT transcripts at concentrations that selectively inhibit pol II activity. In conclusion, stable, RNA polymerase II dependant transcripts of abundant centromeric satellite DNA, not regulated by RNAi, have been identified and characterized. This study offers a basic understanding of expression of highly abundant heterochromatic DNA which in beetle species constitutes up to 50% of the genome.	[Pezer, Zeljka; Ugarkovic, Durdica] Rudjer Boskovic Inst, Dept Mol Biol, Zagreb, Croatia	Rudjer Boskovic Institute	Pezer, Z (corresponding author), Rudjer Boskovic Inst, Dept Mol Biol, Zagreb, Croatia.	ugarkov@.irb.hr			Croatian Ministry of Science [00982604]; EU FP6 Marie Curie Transfer of Knowledge [MTKD-CT-2006-042248]	Croatian Ministry of Science(Ministry of Science, Education and Sports, Republic of Croatia); EU FP6 Marie Curie Transfer of Knowledge(European Commission)	Grants 00982604 from the Croatian Ministry of Science and EU FP6 Marie Curie Transfer of Knowledge Grant MTKD-CT-2006-042248	Bernstein E, 2005, GENE DEV, V19, P1635, DOI 10.1101/gad.1324305; BONACCORSI S, 1990, CHROMOSOMA, V99, P260, DOI 10.1007/BF01731701; Bouzinba-Segard H, 2006, P NATL ACAD SCI USA, V103, P8709, DOI 10.1073/pnas.0508006103; Chiodi I, 2004, NUCLEIC ACIDS RES, V32, P4127, DOI 10.1093/nar/gkh759; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COATS SR, 1994, NUCLEIC ACIDS RES, V22, P4697, DOI 10.1093/nar/22.22.4697; Ferbeyre G, 1998, MOL CELL BIOL, V18, P3880, DOI 10.1128/MCB.18.7.3880; Hamada M, 2001, MOL CELL BIOL, V21, P6870, DOI 10.1128/MCB.21.20.6870-6881.2001; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Henikoff S, 2005, CURR OPIN GENET DEV, V15, P177, DOI 10.1016/j.gde.2005.01.004; Kato H, 2005, SCIENCE, V309, P467, DOI 10.1126/science.1114955; Lee HR, 2006, MOL BIOL EVOL, V23, P2505, DOI 10.1093/molbev/msl127; Lorite P, 2002, GENOME, V45, P609, DOI 10.1139/G02-022; Lu J, 2007, J CELL BIOL, V179, P411, DOI 10.1083/jcb.200706176; Lynch JA, 2006, NAT PROTOC, V1, P486, DOI 10.1038/nprot.2006.70; May BP, 2005, PLOS GENET, V1, P705, DOI 10.1371/journal.pgen.0010079; Mestrovic N, 1998, MOL BIOL EVOL, V15, P1062, DOI 10.1093/oxfordjournals.molbev.a026005; Metz A, 2004, J CELL SCI, V117, P4551, DOI 10.1242/jcs.01329; Mravinac B, 2005, J MOL EVOL, V61, P542, DOI 10.1007/s00239-004-0342-y; Mravinac B, 2002, J MOL EVOL, V54, P774, DOI 10.1007/s0023901-0079-9; Noma KI, 2006, CELL, V125, P859, DOI 10.1016/j.cell.2006.04.028; Reese MG, 2001, COMPUT CHEM, V26, P51, DOI 10.1016/S0097-8485(01)00099-7; Renault S, 1999, INSECT BIOCHEM MOLEC, V29, P103, DOI 10.1016/S0965-1748(98)00113-1; RouleuxBonnin F, 1996, EUR J BIOCHEM, V238, P752, DOI 10.1111/j.1432-1033.1996.0752w.x; Scott KC, 2006, CURR BIOL, V16, P119, DOI 10.1016/j.cub.2005.11.065; SKINNER DM, 1977, BIOSCIENCE, V27, P790, DOI 10.2307/1297755; Topp CN, 2004, P NATL ACAD SCI USA, V101, P15986, DOI 10.1073/pnas.0407154101; TRAPITZ P, 1988, CHROMOSOMA, V96, P159, DOI 10.1007/BF00331048; Ugarkovic D, 2005, EMBO REP, V6, P1035, DOI 10.1038/sj.embor.7400558; UGARKOVIC DL, 1992, BIOCHIMIE, V74, P1075, DOI 10.1016/0300-9084(92)90005-Y; Verdel A, 2004, SCIENCE, V303, P672, DOI 10.1126/science.1093686; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Wang FW, 2006, MOL CELL BIOL, V26, P4028, DOI 10.1128/MCB.02189-05; Wong LH, 2007, GENOME RES, V17, P1146, DOI 10.1101/gr.6022807; Yasuhara JC, 2005, P NATL ACAD SCI USA, V102, P10958, DOI 10.1073/pnas.0503424102	35	31	31	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1594	10.1371/journal.pone.0001594	http://dx.doi.org/10.1371/journal.pone.0001594			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270581	Green Published, Green Submitted, gold			2022-12-25	WOS:000260535900028
J	Yang, DC; Tsay, HJ; Lin, SY; Chiou, SH; Li, MJ; Chang, TJ; Hung, SC				Yang, Der-Chih; Tsay, Huey-Jen; Lin, Shan-Yang; Chiou, Shih-Hwa; Li, Mei-Jane; Chang, Tai-Jay; Hung, Shih-Chieh			cAMP/PKA Regulates Osteogenesis, Adipogenesis and Ratio of RANKL/OPG mRNA Expression in Mesenchymal Stem Cells by Suppressing Leptin	PLOS ONE			English	Article								Background: Mesenchymal stem cells (MSCs) are a pluripotent cell type that can differentiate into adipocytes, osteoblasts and other cells. The reciprocal relationship between adipogenesis and osteogenesis was previously demonstrated; however, the mechanisms remain largely unknown. Methods and Findings: We report that activation of PKA by 3-isobutyl-1 methyl xanthine ( IBMX) and forskolin enhances adipogenesis, the gene expression of PPAR gamma 2 and LPL, and downregulates the gene expression of Runx2 and osteopontin, markers of osteogenesis. PKA activation also decreases the ratio of Receptor Activator of the NF-kappa B Ligand to Osteoprotegerin (RANKL/OPG) gene expression-the key factors of osteoclastogenesis. All these effects are mediated by the cAMP/PKA/CREB pathway by suppressing leptin, and may contribute to PKA stimulators-induced in vivo bone loss in developing zebrafish. Conclusions: Using MSCs, the center of a newly proposed bone metabolic unit, we identified cAMP/PKA signaling, one of the many signaling pathways that regulate bone homeostasis via controlling cyto-differentiation of MSCs and altering RANKL/OPG gene expression.	[Yang, Der-Chih; Chiou, Shih-Hwa; Hung, Shih-Chieh] Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan; [Hung, Shih-Chieh] Natl Yang Ming Univ, Inst Pharmacol, Taipei, Taiwan; [Tsay, Huey-Jen] Natl Yang Ming Univ, Inst Neurosci, Taipei, Taiwan; [Yang, Der-Chih; Lin, Shan-Yang; Chiou, Shih-Hwa; Li, Mei-Jane; Hung, Shih-Chieh] Natl Yang Ming Univ, Veterans Gen Hosp Taipei, Dept Med Res & Educ, Taipei, Taiwan; [Hung, Shih-Chieh] Natl Yang Ming Univ, Veterans Gen Hosp Taipei, Dept Orthopaed & Traumatol, Taipei, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Yang, DC (corresponding author), Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan.	hungsc@vghtpe.gov.tw			National Scientific Council [NSC-95-2314-B-075-047-MY3, NSC-95-2627-B-010-009-, NSC-96-2627-B-010-009-]; National Yang-Ming University; Ministry of Education; Aim for the Top University Plan; Veterans General Hospital-Taipei [V95E1-002, V95E1-003]	National Scientific Council; National Yang-Ming University; Ministry of Education; Aim for the Top University Plan(Ministry of Education, Taiwan); Veterans General Hospital-Taipei(Taipei Veterans General Hospital)	National Scientific Council (NSC-95-2314-B-075-047-MY3, NSC-95-2627-B-010-009-, NSC-96-2627-B-010-009-) and grants from National Yang-Ming University, Ministry of Education, Aim for the Top University Plan, and Veterans General Hospital-Taipei (V95E1-002 & V95E1-003).	Barr VA, 1997, ENDOCRINOLOGY, V138, P4463, DOI 10.1210/en.138.10.4463; BERESFORD JN, 1992, J CELL SCI, V102, P341; Burguera B, 2001, ENDOCRINOLOGY, V142, P3546, DOI 10.1210/en.142.8.3546; Chang YJ, 2006, STEM CELLS, V24, P679, DOI 10.1634/stemcells.2004-0308; Chu MS, 2006, CELL SIGNAL, V18, P519, DOI 10.1016/j.cellsig.2005.05.018; Corral DA, 1998, P NATL ACAD SCI USA, V95, P13835, DOI 10.1073/pnas.95.23.13835; Deng H, 1999, BIOPOLYMERS, V50, P656, DOI 10.1002/(SICI)1097-0282(199911)50:6<656::AID-BIP10>3.0.CO;2-9; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Felix R, 1996, EUR J ENDOCRINOL, V134, P143, DOI 10.1530/eje.0.1340143; FRIEDENSTEIN AJ, 1976, INT REV CYTOL, V47, P327, DOI 10.1016/S0074-7696(08)60092-3; Glasow A, 2001, J CLIN ENDOCR METAB, V86, P4472, DOI 10.1210/jc.86.9.4472; Hamrick MW, 2005, J BONE MINER RES, V20, P994, DOI 10.1359/JBMR.050103; Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955; Hung SC, 2004, INT J CANCER, V110, P313, DOI 10.1002/ijc.20126; Johnson RM, 2000, J EXP ZOOL, V286, P718, DOI 10.1002/(SICI)1097-010X(20000601)286:7&lt;718::AID-JEZ6&gt;3.0.CO;2-I; Kim G, 2002, MOL BRAIN RES, V109, P134, DOI 10.1016/S0169-328X(02)00550-8; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kvissel AK, 2004, CELL SIGNAL, V16, P577, DOI 10.1016/j.cellsig.2003.08.014; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Laharrague P, 1998, FASEB J, V12, P747, DOI 10.1096/fasebj.12.9.747; Lin SY, 2004, J BIOMED MATER RES B, V70B, P203, DOI 10.1002/jbm.b.30067; Martin A, 2005, ENDOCRINOLOGY, V146, P3652, DOI 10.1210/en.2004-1509; MEUNIER P, 1971, CLIN ORTHOP RELAT R, P147, DOI 10.1097/00003086-197110000-00021; NAKAHARA H, 1990, BONE, V11, P181, DOI 10.1016/8756-3282(90)90212-H; NEELON FA, 1973, LANCET, V1, P631; Nuttall ME, 2000, BONE, V27, P177, DOI 10.1016/S8756-3282(00)00317-3; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Reseland JE, 2001, J BONE MINER RES, V16, P1426, DOI 10.1359/jbmr.2001.16.8.1426; Reusch JEB, 2000, MOL CELL BIOL, V20, P1008, DOI 10.1128/MCB.20.3.1008-1020.2000; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Schoeller DA, 1997, J CLIN INVEST, V100, P1882, DOI 10.1172/JCI119717; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Sonoyama W, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000079; Steppan CM, 2000, REGUL PEPTIDES, V92, P73, DOI 10.1016/S0167-0115(00)00152-X; Szkudelski T, 2005, PHYSIOL RES, V54, P79, DOI 10.33549/physiolres.930570; Thomas T, 1999, ENDOCRINOLOGY, V140, P1630, DOI 10.1210/en.140.4.1630; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tuli R, 2003, STEM CELLS, V21, P681, DOI 10.1634/stemcells.21-6-681; Verma S, 2002, J CLIN PATHOL, V55, P693, DOI 10.1136/jcp.55.9.693; Watanabe M, 2003, BIOCHEM BIOPH RES CO, V300, P429, DOI 10.1016/S0006-291X(02)02860-7; Weisenhorn DMV, 2001, EXP NEUROL, V169, P44, DOI 10.1006/exnr.2001.7651; Yamauchi M, 2001, CLIN ENDOCRINOL, V55, P341, DOI 10.1046/j.1365-2265.2001.01361.x; Zhao YX, 2007, P NATL ACAD SCI USA, V104, P9673, DOI 10.1073/pnas.0703407104; Zoico E, 2003, CLIN ENDOCRINOL, V59, P97, DOI 10.1046/j.1365-2265.2003.01808.x	47	111	115	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2008	3	2							e1540	10.1371/journal.pone.0001540	http://dx.doi.org/10.1371/journal.pone.0001540			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367EQ	18253488	Green Published, gold, Green Submitted			2022-12-25	WOS:000260535700012
J	Shin, SS; Kim, TM; Kim, SY; Kim, TW; Seo, HW; Lee, SK; Kwon, SC; Lee, GS; Kim, H; Lim, JM; Han, JY				Shin, Sang Su; Kim, Tae Min; Kim, Sun Young; Kim, Tae Wan; Seo, Hee Won; Lee, Seul Ki; Kwon, Se Chang; Lee, Gwan Sun; Kim, Heebal; Lim, Jeong Mook; Han, Jae Yong			Generation of transgenic quail through germ cell-mediated germline transmission	FASEB JOURNAL			English	Article						primordial germ cells; lentiviral vector; avian transgenesis	LENTIVIRAL VECTORS; RECIPIENT EMBRYOS; GENE-TRANSFER; CHICK-EMBRYO; STEM-CELLS; IN-VITRO; EXPRESSION; CHIMERAS; GENOME; VIRUS	Here, we describe the production of transgenic quail via a germline transmission system using postmigratory gonadal primordial germ cells (gPGCs). gPGCs retrieved from the embryonic gonads of 5-day-old birds were transduced with a lentiviral vector and subsequently transferred into recipient embryos. Testcross and genetic analyses revealed that among three germline chimeric G0 quail, one male produced transgenic offspring; of 310 hatchlings from the transgenic germline chimera, 24 were identified as donor-derived offspring, and 6 were transgenic (6/310, 1.9%). Conventional transgenesis using stage X blastodermal embryos was also conducted, but the efficiency of transgenesis was similar between the two systems (< 1.6 vs. 1.9% for the conventional and gPGC-mediated systems, respectively). However, substantial advantages can be gained from gPGC-mediated method in that it enables an induced germline modification, whereas direct retroviral transfer to stage X embryos causes mosaic integration. The use of gonadal PGCs for transgenesis may lead to the production of bioreactors.	[Shin, Sang Su; Kim, Tae Min; Kim, Sun Young; Kim, Tae Wan; Seo, Hee Won; Kim, Heebal; Lim, Jeong Mook; Han, Jae Yong] Seoul Natl Univ, Dept Agr Biotechnol, Seoul 151921, South Korea; [Lee, Seul Ki] Avicore Biotechnol Inst Incorp, Gyeonggi Do, South Korea; [Kwon, Se Chang; Lee, Gwan Sun] Hanmi Pharm Co Ltd, Hanmi Res Ctr, Gyeonggi Do, South Korea	Seoul National University (SNU); Hanmi Pharmaceutical	Han, JY (corresponding author), Seoul Natl Univ, Dept Agr Biotechnol, Seoul 151921, South Korea.	jaehan@snu.ac.kr	Kim, Heebal/A-8889-2016; Kim, Tae Wan/GRK-0135-2022	Kim, Heebal/0000-0003-3064-1303; Kim, Tae Wan/0000-0002-0831-6881				Barr SD, 2005, J VIROL, V79, P12035, DOI 10.1128/JVI.79.18.12035-12044.2005; Chapman SC, 2005, DEVELOPMENT, V132, P935, DOI 10.1242/dev.01652; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; Gilbert N, 2004, CELL, V118, P555, DOI 10.1016/j.cell.2004.08.011; Han JY, 2002, THERIOGENOLOGY, V58, P1531, DOI 10.1016/S0093-691X(02)01061-0; Hofmann A, 2003, EMBO REP, V4, P1054, DOI 10.1038/sj.embor.7400007; Ivarie R, 2003, TRENDS BIOTECHNOL, V21, P14, DOI 10.1016/S0167-7799(02)00009-4; Karagenc L, 1996, DEV GENET, V19, P290, DOI 10.1002/(SICI)1520-6408(1996)19:4<290::AID-DVG2>3.3.CO;2-S; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; Kim MA, 2005, THERIOGENOLOGY, V63, P774, DOI 10.1016/j.theriogenology.2004.04.014; Koo BC, 2006, FASEB J, V20, P2251, DOI 10.1096/fj.06-5866com; LeDouarin NM, 1997, INT REV CYTOL, V175, P241, DOI 10.1016/S0074-7696(08)62128-2; Lillico SG, 2007, P NATL ACAD SCI USA, V104, P1771, DOI 10.1073/pnas.0610401104; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; McGrew MJ, 2004, EMBO REP, V5, P728, DOI 10.1038/sj.embor.7400171; MEYER DB, 1964, DEV BIOL, V10, P154, DOI 10.1016/0012-1606(64)90009-0; Mizuarai S, 2001, BIOCHEM BIOPH RES CO, V286, P456, DOI 10.1006/bbrc.2001.5422; Mozdziak PE, 2003, DEV DYNAM, V226, P439, DOI 10.1002/dvdy.10234; Opsahl ML, 2002, GENETICS, V160, P1107; Park TS, 2003, BIOL REPROD, V68, P1657, DOI 10.1095/biolreprod.102.006825; Pfeifer A, 2002, P NATL ACAD SCI USA, V99, P2140, DOI 10.1073/pnas.251682798; SALTER DW, 1987, VIROLOGY, V157, P236, DOI 10.1016/0042-6822(87)90334-5; Sang H, 2006, NAT BIOTECHNOL, V24, P955, DOI 10.1038/nbt0806-955; Scott BB, 2005, P NATL ACAD SCI USA, V102, P16443, DOI 10.1073/pnas.0508437102; SELLECK MAJ, 1996, METHODS CELL BIOL, V51; Smith J, 2000, ANIM GENET, V31, P96, DOI 10.1046/j.1365-2052.2000.00565.x; Sugiyama O, 2005, MOL THER, V11, P390, DOI 10.1016/j.ymthe.2004.10.019; Uchida N, 1998, P NATL ACAD SCI USA, V95, P11939, DOI 10.1073/pnas.95.20.11939; van de Lavoir MC, 2006, NATURE, V441, P766, DOI 10.1038/nature04831	29	55	58	4	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2435	2444		10.1096/fj.07-101485	http://dx.doi.org/10.1096/fj.07-101485			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18263695				2022-12-25	WOS:000257292500035
J	Cai, Z; Zhang, G; Zhou, Z; Bembas, K; Drebin, JA; Greene, MI; Zhang, H				Cai, Z.; Zhang, G.; Zhou, Z.; Bembas, K.; Drebin, J. A.; Greene, M. I.; Zhang, H.			Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185(her2/neu) and the EGFR-p185(her2/neu) complexes	ONCOGENE			English	Article						her2; Pertuzumab; heterodimer; 4D5	EPIDERMAL-GROWTH-FACTOR; EGF RECEPTOR; EXTRACELLULAR REGION; C-ERBB-2 ONCOGENE; BREAST; EXPRESSION; CANCER; P185NEU; PROTEIN; HER2	2C4 ( Pertuzumab, Omnitarg) is a monoclonal antibody targeting p185(her2/neu), which is overexpressed in 30% of invasive breast cancer. 2C4 is currently in phase II clinical trials for several types of cancers. This antibody has been reported to disrupt the association between p185(her2/neu) and ErbB3. In our studies of epidermal growth factor receptor ( EGFR)-p185(her2/neu) heterodimerization, we noted that 2C4 formed associations with the EGFR-p185(her2/neu) receptor complex. Our data argue against 2C4 as a universal heterodimerization blocker for p185(her2/neu), but indicate that cocktails of monoclonal antibodies binding distinct interaction surfaces of p185(her2/neu) will emerge as the most potent targeted therapy.	[Cai, Z.; Zhang, G.; Zhou, Z.; Bembas, K.; Greene, M. I.; Zhang, H.] Univ Penn, Sch Med, Dept Pathol Lab Med, Philadelphia, PA 19104 USA; [Drebin, J. A.] Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Zhang, H (corresponding author), Univ Penn, Sch Med, Dept Pathol Lab Med, 3620 Hamilton Walk,252 John Morgan Bldg, Philadelphia, PA 19104 USA.	zhanghon@mail.med.upenn.edu		Zhang, Hongtao/0000-0001-9173-0049	NATIONAL CANCER INSTITUTE [P01CA089480] Funding Source: NIH RePORTER; NCI NIH HHS [5P01 CA89480, P01 CA089480-04, P01 CA089480] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; Berezov A, 2002, J BIOL CHEM, V277, P28330, DOI 10.1074/jbc.M202880200; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Cho HS, 2002, SCIENCE, V297, P1330, DOI 10.1126/science.1074611; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; COHEN JA, 1989, ONCOGENE, V4, P81; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1988, ONCOGENE, V2, P273; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Franklin MC, 2004, CANCER CELL, V5, P317, DOI 10.1016/S1535-6108(04)00083-2; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Jackson JG, 2004, CANCER RES, V64, P2601, DOI 10.1158/0008-5472.CAN-03-3106; KATSUMATA M, 1995, NAT MED, V1, P644, DOI 10.1038/nm0795-644; KERN JA, 1990, CANCER RES, V50, P5184; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; LODATO RF, 1990, MODERN PATHOL, V3, P449; Mendoza N, 2002, CANCER RES, V62, P5485; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Sanner MF, 1999, J MOL GRAPH MODEL, V17, P57; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Takai N, 2005, CANCER-AM CANCER SOC, V104, P2701, DOI 10.1002/cncr.21533; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WADA T, 1990, ONCOGENE, V5, P489; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WILLIAMS TM, 1991, PATHOBIOLOGY, V59, P46, DOI 10.1159/000163614	30	30	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2008	27	27					3870	3874		10.1038/onc.2008.13	http://dx.doi.org/10.1038/onc.2008.13			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18264138	Green Accepted			2022-12-25	WOS:000256904700011
J	Brooks, JD; Milne, GL; Yin, HY; Sanchez, SC; Porter, NA; Morrow, JD				Brooks, Joshua D.; Milne, Ginger L.; Yin, Huiyong; Sanchez, Stephanie C.; Porter, Ned A.; Morrow, Jason D.			Formation of highly reactive cyclopentenone isoprostane compounds (A(3)/J(3)-isoprostanes) in vivo from eicosapentaenoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROSPRAY MASS-SPECTROMETRY; POLYUNSATURATED FATTY-ACIDS; SUDDEN CARDIAC DEATH; FISH-OIL; LIPID-PEROXIDATION; OXIDIZED OMEGA-3-FATTY-ACIDS; D-RING; IDENTIFICATION; PRODUCTS; N-3	Omega-3 (omega-3) polyunsaturated fatty acids (PUFAs) found in marine fish oils are known to suppress inflammation associated with a wide variety of diseases. Eicosapentaenoic acid (EPA) is one of the most abundant omega-3 fatty acids in fish oil, but the mechanism(s) by which EPA exerts its beneficial effects is unknown. Recent studies, however, have demonstrated that oxidized EPA, rather than native EPA, possesses anti-atherosclerotic, anti-inflammatory, and anti-proliferative effects. Very few studies to date have investigated which EPA oxidation products are responsible for this bioactivity. Our research group has previously reported that anti-inflammatory prostaglandin A(2)-like and prostaglandin J(2)-like compounds, termed A(2)/J(2)-isoprostanes (IsoPs), are produced in vivo by the free radical-catalyzed peroxidation of arachidonic acid and represent one of the major products resulting from the oxidation of this PUFA. Based on these observations, we questioned whether cyclopentenone-IsoP compounds are formed from the oxidation of EPA in vivo. Herein, we report the formation of cyclopentenone-IsoP molecules, termed A(3)/J(3)-IsoPs, formed in abundance in vitro and in vivo from EPA peroxidation. Chemical approaches coupled with gas chromatography/ mass spectrometry (GC/MS) and liquid chromatography/ mass spectrometry (LC/MS) were used to structurally characterize these compounds as A(3)/J(3)-IsoPs. We found that levels of these molecules increase similar to 200-fold with oxidation of EPA in vitro from a basal level of 0.8 +/- 0.4 ng/mg EPA to 196 +/- 23 ng/mg EPA after 36 h. We also detected these compounds in significant amounts in fresh liver tissue from EPA-fed rats at basal levels of 19 +/- 2 ng/g tissue. Amounts increased to 102 +/- 15 ng/g tissue in vivo in settings of oxidative stress. These studies have, for the first time, definitively characterized novel, highly reactive A/J-ring IsoP compounds that form in abundance from the oxidation of EPA in vivo.	[Brooks, Joshua D.; Milne, Ginger L.; Yin, Huiyong; Sanchez, Stephanie C.; Morrow, Jason D.] Vanderbilt Univ, Div Clin Pharmacol, Dept Med, Nashville, TN 37232 USA; [Brooks, Joshua D.; Milne, Ginger L.; Yin, Huiyong; Sanchez, Stephanie C.; Morrow, Jason D.] Vanderbilt Univ, Div Clin Pharmacol, Dept Pharmacol, Nashville, TN 37232 USA; [Porter, Ned A.] Vanderbilt Univ, Dept Chem, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Morrow, JD (corresponding author), Vanderbilt Univ, Div Clin Pharmacol, Dept Med, 532 RRB,23rd Ave S & Pierce Ave, Nashville, TN 37232 USA.	jason.morrow@vanderbilt.edu	Milne, Ginger/D-7648-2014	Milne, Ginger/0000-0003-3890-151X	NIDDK NIH HHS [DK48831] Funding Source: Medline; NIEHS NIH HHS [ES13125] Funding Source: Medline; NIGMS NIH HHS [GM15431] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES013125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431, P01GM015431] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Achard F, 1997, BIOCHEM BIOPH RES CO, V241, P513, DOI 10.1006/bbrc.1997.7848; Arita K, 2003, FREE RADICAL BIO MED, V35, P189, DOI 10.1016/S0891-5849(03)00310-1; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Calder PC, 2001, LIPIDS, V36, P1007, DOI 10.1007/s11745-001-0812-7; Calder PC, 2006, P NUTR SOC, V65, P264, DOI 10.1079/PNS2006500; Chaudhary A, 2004, NEPHRON EXP NEPHROL, V97, P136, DOI 10.1159/000079178; Chen Y, 1999, J BIOL CHEM, V274, P10863, DOI 10.1074/jbc.274.16.10863; Connor SL, 1997, AM J CLIN NUTR, V66, P1020; Das UN, 1999, PROSTAG LEUKOTR ESS, V61, P157, DOI 10.1054/plef.1999.0085; Davis TA, 2006, J AM CHEM SOC, V128, P14897, DOI 10.1021/ja064399o; Fam SS, 2002, J BIOL CHEM, V277, P36076, DOI 10.1074/jbc.M205638200; FITZPATRICK FA, 1983, J BIOL CHEM, V258, P1713; Gao L, 2007, J BIOL CHEM, V282, P2529, DOI 10.1074/jbc.M607622200; Gao L, 2006, J BIOL CHEM, V281, P14092, DOI 10.1074/jbc.M601035200; Harrison KA, 2000, J MASS SPECTROM, V35, P224, DOI 10.1002/(SICI)1096-9888(200002)35:2<224::AID-JMS933>3.0.CO;2-G; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; Kerwin JL, 1996, J MASS SPECTROM, V31, P184, DOI 10.1002/(SICI)1096-9888(199602)31:2<184::AID-JMS283>3.0.CO;2-2; Kerwin JL, 1996, ANAL BIOCHEM, V237, P56, DOI 10.1006/abio.1996.0200; KISERUD CE, 1995, THROMB RES, V80, P75, DOI 10.1016/0049-3848(95)00152-H; Kokura S, 2002, CANCER LETT, V185, P139, DOI 10.1016/S0304-3835(02)00262-8; Kris-Etherton PM, 2002, CIRCULATION, V106, P2747, DOI 10.1161/01.CIR.0000038493.65177.94; LANEUVILLE O, 1995, J BIOL CHEM, V270, P19330, DOI 10.1074/jbc.270.33.19330; Leaf A, 2003, PHARMACOL THERAPEUT, V98, P355, DOI 10.1016/S0163-7258(03)00039-1; Leaf A, 2003, CIRCULATION, V107, P2646, DOI 10.1161/01.CIR.0000069566.78305.33; Milne GL, 2005, J LIPID RES, V46, P307, DOI 10.1194/jlr.M400311-JLR200; Milne GL, 2001, LIPIDS, V36, P1265, DOI 10.1007/s11745-001-0841-2; Mishra A, 2004, ARTERIOSCL THROM VAS, V24, P1621, DOI 10.1161/01.ATV.0000137191.02577.86; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1994, J BIOL CHEM, V269, P4317; Oliw EH, 1998, LIPIDS, V33, P843, DOI 10.1007/s11745-998-0280-0; PORTER NA, 1984, METHOD ENZYMOL, V105, P273; PORTER NA, 1981, J AM CHEM SOC, V103, P6447, DOI 10.1021/ja00411a032; Pulfer M, 2003, MASS SPECTROM REV, V22, P332, DOI 10.1002/mas.10061; Reich EE, 2000, BIOCHEMISTRY-US, V39, P2376, DOI 10.1021/bi992000l; Roberts LJ, 1998, J BIOL CHEM, V273, P13605, DOI 10.1074/jbc.273.22.13605; Serhan CN, 2004, PROSTAG OTH LIPID M, V73, P155, DOI 10.1016/j.prostaglandins.2004.03.005; Serhan CN, 2003, CHEM IMMUNOL, V83, P115; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197; Sethi S, 2002, BLOOD, V100, P1340, DOI 10.1182/blood-2002-01-0316; Sethi S, 1996, J LAB CLIN MED, V128, P27, DOI 10.1016/S0022-2143(96)90111-0; Stafforini DM, 2006, J BIOL CHEM, V281, P4616, DOI 10.1074/jbc.M507340200; Subbanagounder G, 2002, J BIOL CHEM, V277, P7271, DOI 10.1074/jbc.M107602200; Sun YP, 2007, J BIOL CHEM, V282, P9323, DOI 10.1074/jbc.M609212200; Taber DF, 1997, PROSTAGLANDINS, V53, P63, DOI 10.1016/S0090-6980(97)00005-1; Uauy R, 1999, EUR J CLIN NUTR, V53, pS66, DOI 10.1038/sj.ejcn.1600745; Vallve JC, 2002, ATHEROSCLEROSIS, V164, P45, DOI 10.1016/S0021-9150(02)00046-1; Wada M, 2007, J BIOL CHEM, V282, P22254, DOI 10.1074/jbc.M703169200; Watson AD, 1999, J BIOL CHEM, V274, P24787, DOI 10.1074/jbc.274.35.24787; Waugh RJ, 1997, FREE RADICAL BIO MED, V23, P943, DOI 10.1016/S0891-5849(97)00133-0; Yang PY, 2004, J LIPID RES, V45, P1030, DOI 10.1194/jlr.M300455-JLR200; Yin HY, 2007, J BIOL CHEM, V282, P29890, DOI 10.1074/jbc.M703108200; Yokoyama M, 2007, LANCET, V369, P1090, DOI 10.1016/S0140-6736(07)60527-3; ZIRROLLI JA, 1990, J AM SOC MASS SPECTR, V1, P325, DOI 10.1016/1044-0305(90)85009-B	55	64	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2008	283	18					12043	12055		10.1074/jbc.M800122200	http://dx.doi.org/10.1074/jbc.M800122200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	293MS	18263929	Green Published, hybrid			2022-12-25	WOS:000255340000020
J	Means, CK; Miyamoto, S; Chun, J; Brown, JH				Means, Christopher Kable; Miyamoto, Shigeki; Chun, Jerold; Brown, Joan Heller			S1P(1) receptor localization confers selectivity for G(i)-mediated cAMP and contractile responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; BETA-GAMMA-SUBUNITS; HETEROTRIMERIC G-PROTEINS; SPHINGOSINE 1-PHOSPHATE; LYSOPHOSPHOLIPID RECEPTOR; CARDIAC MYOCYTES; ADENYLYL-CYCLASE; KINASE PATHWAY; IN-VIVO; PLASMALEMMAL CAVEOLAE	Adult mouse ventricular myocytes express S1P(1), S1P(2), and S1P(3) receptors. S1P activates Akt and ERK in adult mouse ventricular myocytes through a pertussis toxin-sensitive (G(i/o)-mediated) pathway. Akt and ERK activation by S1P are reduced similar to 30% in S1P(3) and 60% in S1P(2) receptor knock- out myocytes. With combined S1P(2,3) receptor deletion, activation of Akt is abolished and ERK activation is reduced by nearly 90%. Thus the S1P(1) receptor, while present in S1P(2,3) receptor knock- out myocytes, is unable to mediate Akt or ERK activation. In contrast, S1P induces pertussis toxin-sensitive inhibition of isoproterenol-stimulated cAMP accumulation in both WT and S1P(2,3) receptor knock- out myocytes demonstrating that the S1P(1) receptor can functionally couple to G(i). An S1P(1) receptor selective agonist, SEW2871, also decreased cAMP accumulation but failed to activate ERK or Akt. To determine whether localization of the S1P(1) receptor mediates this signaling specificity, methyl-beta-cyclodextrin (M beta CD) treatment was used to disrupt caveolae. The S1P(1) receptor was concentrated in caveolar fractions, and associated with caveolin-3 and this localization was disrupted by M beta CD. S1P-mediated activation of ERK or Akt was not diminished but inhibition of cAMP accumulation by S1P and SEW2871 was abolished by M beta CD treatment. S1P inhibits the positive inotropic response to isoproterenol and this response is also mediated through the S1P(1) receptor and lost following caveolar disruption. Thus localization of S1P(1) receptors to caveolae is required for the ability of this receptor to inhibit adenylyl cyclase and contractility but compromises receptor coupling to Akt and ERK.	[Means, Christopher Kable] Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA; [Means, Christopher Kable; Miyamoto, Shigeki; Brown, Joan Heller] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Chun, Jerold] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Research Institute	Brown, JH (corresponding author), 9500 Gilman Dr, La Jolla, CA 92093 USA.	jhbrown@ucsd.edu	Miyamoto, Shigeki/L-4004-2019; Chun, Jerold/Y-4670-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL028143, R01HL028143, P01HL046345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048478] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA019674] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28143, HL46345] Funding Source: Medline; NIDA NIH HHS [DA019674] Funding Source: Medline; NIGMS NIH HHS [T32 GM007752] Funding Source: Medline; NINDS NIH HHS [NS048478] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baudhuin LM, 2003, FASEB J, V17, P341, DOI 10.1096/fj.03-0302fje; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; Bommakanti RK, 2000, J BIOL CHEM, V275, P38870, DOI 10.1074/jbc.M007403200; BRODDE OE, 1988, AM J CARDIOL, V62, pC24, DOI 10.1016/S0002-9149(88)80063-8; BUXTON ILO, 1983, J BIOL CHEM, V258, P233; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Cohen AW, 2003, AM J PHYSIOL-CELL PH, V285, pC222, DOI 10.1152/ajpcell.00006.2003; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Goparaju SK, 2005, MOL CELL BIOL, V25, P4237, DOI 10.1128/MCB.25.10.4237-4249.2005; Gosens R, 2006, AM J PHYSIOL-LUNG C, V291, pL523, DOI 10.1152/ajplung.00013.2006; Head BP, 2006, J BIOL CHEM, V281, P26391, DOI 10.1074/jbc.M602577200; Hilal-Dandan R, 2000, J MOL CELL CARDIOL, V32, P1211, DOI 10.1006/jmcc.2000.1156; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; Igarashi J, 2000, J BIOL CHEM, V275, P32363, DOI 10.1074/jbc.M003075200; Ishii I, 2001, J BIOL CHEM, V276, P33697, DOI 10.1074/jbc.M104441200; Ishii I, 2004, ANNU REV BIOCHEM, V73, P321, DOI 10.1146/annurev.biochem.73.011303.073731; Ishii I, 2002, J BIOL CHEM, V277, P25152, DOI 10.1074/jbc.M200137200; Jo EJ, 2005, CHEM BIOL, V12, P703, DOI 10.1016/j.chembiol.2005.04.019; Kawamura S, 2003, J BIOL CHEM, V278, P31111, DOI 10.1074/jbc.M300725200; Kim S, 2004, J BIOL CHEM, V279, P4186, DOI 10.1074/jbc.M306162200; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1996, J BIOL CHEM, V271, P11272, DOI 10.1074/jbc.271.19.11272; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Means CK, 2007, AM J PHYSIOL-HEART C, V292, pH2944, DOI 10.1152/ajpheart.01331.2006; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; Nofer JR, 2004, J CLIN INVEST, V113, P569, DOI 10.1172/JCI200418004; O'Connell TD, 2003, J CLIN INVEST, V111, P1783, DOI 10.1172/JCI200316100; Okamoto H, 1999, BIOCHEM BIOPH RES CO, V260, P203, DOI 10.1006/bbrc.1999.0886; Ostrom RS, 2000, MOL PHARMACOL, V57, P1075; Patel HH, 2006, AM J PHYSIOL-HEART C, V291, pH344, DOI 10.1152/ajpheart.01100.2005; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; Rockman HA, 1996, J MOL MED-JMM, V74, P489, DOI 10.1007/BF00204974; Sanna MG, 2004, J BIOL CHEM, V279, P13839, DOI 10.1074/jbc.M311743200; Serriere-Lanneau V, 2007, FASEB J, V21, P2005, DOI 10.1096/fj.06-6889com; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Steinberg SF, 1999, CIRC RES, V85, P1101; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Sugden PH, 1997, CELL SIGNAL, V9, P337, DOI 10.1016/S0898-6568(96)00191-X; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; Tanimoto T, 2004, CIRC RES, V94, P1050, DOI 10.1161/01.RES.0000126404.41421.BE; Theilmeier G, 2006, CIRCULATION, V114, P1403, DOI 10.1161/CIRCULATIONAHA.105.607135; THORBURN J, 1994, BIOCHEM BIOPH RES CO, V202, P1586, DOI 10.1006/bbrc.1994.2113; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; ZHANG J, 2007, AM J PHYSIOL, V292, pH3150; Zhou YY, 2000, AM J PHYSIOL-HEART C, V279, pH429; Zondag GCM, 1998, BIOCHEM J, V330, P605, DOI 10.1042/bj3300605	52	62	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2008	283	18					11954	11963		10.1074/jbc.M707422200	http://dx.doi.org/10.1074/jbc.M707422200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	293MS	18296752	hybrid, Green Published			2022-12-25	WOS:000255340000011
J	Smith, AG; Luk, N; Newton, RA; Roberts, DW; Sturm, RA; Muscat, GEO				Smith, Aaron G.; Luk, Nicole; Newton, Richard A.; Roberts, Donald W.; Sturm, Richard A.; Muscat, George E. O.			Melanocortin-1 receptor signaling markedly induces the expression of the NR4A nuclear receptor subgroup in melanocytic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MC1R VARIANT ALLELES; SKIN-CANCER RISK; SKELETAL-MUSCLE; ULTRAVIOLET-RADIATION; STIMULATING HORMONE; MELANOMA-CELLS; DNA-DAMAGE; RED HAIR; HUMAN PIGMENTATION; NGFI-B	The melanocortin-1 receptor (MCIR) is a G-protein-coupled receptor expressed primarily in melanocytes and is known to play a pivotal role in the regulation of pigmentation in mammals. In humans MC1R has been found to be highly polymorphic with several functional variants associated with the phenotype of red hair color and fair skin, cutaneous UV sensitivity, and increased risk of developing melanoma and non-melanoma skin cancer. Recent evidence suggests that MC1R plays a photo-protective role in melanocytes in response to UV irradiation. Relatively few genetic targets of MC1R signaling have been identified independent of the pigmentation pathway. Here we show that MC1R signaling in B16 mouse melanoma cells and primary human melanocytes rapidly, and transiently, induces the transcription of the NR4A subfamily of orphan nuclear receptors. Furthermore, primary human melanocytes harboring homozygous RHC variant MC1R alleles exhibited an impaired induction of NR4A genes in response to the potent MC1R agonist (Nle4, D-Phe7)-alpha-melanocyte-stimulating hormone. Using small interference RNA-mediated attenuation of NR4A1 and NR4A2 expression in melanocytes, the ability to remove cyclobutane pyrimidine dimers following UV irradiation appeared to be impaired in the context of MC1R signaling. These data identify the NR4A receptor family as potential mediators of an MC1R-coordinated DNA damage response to UV exposure in melanocytic cells.	[Smith, Aaron G.; Luk, Nicole; Newton, Richard A.; Roberts, Donald W.; Sturm, Richard A.; Muscat, George E. O.] Univ Queensland, Inst Mol Biosci, Div Mol Genet & Dev, St Lucia, Qld 4072, Australia	University of Queensland	Smith, AG (corresponding author), Univ Queensland, Inst Mol Biosci, Div Mol Genet & Dev, St Lucia, Qld 4072, Australia.	a.smith@imb.uq.edu.au; r.sturm@imb.uq.edu.au; g.muscat@imb.uq.edu.au	Smith, Aaron/A-8329-2010; Sturm, Richard A/C-9943-2009; Muscat, George/A-6401-2017	Sturm, Richard A/0000-0003-1301-0294; Muscat, George/0000-0002-5829-5695; Smith, Aaron/0000-0003-2937-1713				April CS, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030009; April CS, 2006, PIGM CELL RES, V19, P194, DOI 10.1111/j.1600-0749.2006.00305.x; Armstrong BK, 2001, J PHOTOCH PHOTOBIO B, V63, P8, DOI 10.1016/S1011-1344(01)00198-1; Beaumont KA, 2005, HUM MOL GENET, V14, P2145, DOI 10.1093/hmg/ddi219; Beaumont KA, 2007, HUM MOL GENET, V16, P2249, DOI 10.1093/hmg/ddm177; Bennett DC, 2003, PIGM CELL RES, V16, P333, DOI 10.1034/j.1600-0749.2003.00067.x; Bohm M, 2005, J BIOL CHEM, V280, P5795, DOI 10.1074/jbc.M406334200; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Busca R, 2000, PIGM CELL RES, V13, P60, DOI 10.1034/j.1600-0749.2000.130203.x; Chintharlapalli S, 2005, J BIOL CHEM, V280, P24903, DOI 10.1074/jbc.M500107200; Cho SD, 2007, CANCER RES, V67, P674, DOI 10.1158/0008-5472.CAN-06-2907; Cook AL, 2003, J INVEST DERMATOL, V121, P1150, DOI 10.1046/j.1523-1747.2003.12562.x; Garcia-Borron JC, 2005, PIGM CELL RES, V18, P393, DOI 10.1111/j.1600-0749.2005.00278.x; Hauser JE, 2006, PIGM CELL RES, V19, P303, DOI 10.1111/j.1600-0749.2006.00315.x; Hearing VJ, 2005, J DERMATOL SCI, V37, P3, DOI 10.1016/j.jdermsci.2004.08.014; Hsu Hui-Chen, 2004, Current Drug Targets - Inflammation and Allergy, V3, P413, DOI 10.2174/1568010042634523; Kadekaro AL, 2005, CANCER RES, V65, P4292, DOI 10.1158/0008-5472.CAN-04-4535; Kadekaro AL, 2003, ANN NY ACAD SCI, V994, P359, DOI 10.1111/j.1749-6632.2003.tb03200.x; Kovalovsky D, 2002, MOL ENDOCRINOL, V16, P1638, DOI 10.1210/me.16.7.1638; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; Levy C, 2006, TRENDS MOL MED, V12, P406, DOI 10.1016/j.molmed.2006.07.008; Maira M, 1999, MOL CELL BIOL, V19, P7549; Martinez-Gonzalez J, 2005, CARDIOVASC RES, V65, P609, DOI 10.1016/j.cardiores.2004.10.002; Maxwell MA, 2005, J BIOL CHEM, V280, P12573, DOI 10.1074/jbc.M409580200; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; Morita K, 2005, BIOCHEM PHARMACOL, V71, P98, DOI 10.1016/j.bcp.2005.10.017; Myers SA, 2006, J BIOL CHEM, V281, P24149, DOI 10.1074/jbc.M601941200; Newton RA, 2005, PEPTIDES, V26, P1818, DOI 10.1016/j.peptides.2004.11.031; Newton RA, 2007, PEPTIDES, V28, P2387, DOI 10.1016/j.peptides.2007.10.003; Palmer JS, 2000, AM J HUM GENET, V66, P176, DOI 10.1086/302711; Pearen MA, 2006, ENDOCRINOLOGY, V147, P5217, DOI 10.1210/en.2006-0447; Pei LM, 2006, NAT MED, V12, P1048, DOI 10.1038/nm1471; Pei LM, 2005, J BIOL CHEM, V280, P29256, DOI 10.1074/jbc.M502606200; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; RANGNEKAR VV, 1992, J BIOL CHEM, V267, P6240; Ringholm A, 2004, J INVEST DERMATOL, V123, P917, DOI 10.1111/j.0022-202X.2004.23444.x; Roberts DW, 2008, J CELL PHYSIOL, V215, P344, DOI 10.1002/jcp.21318; Rouzaud F, 2005, MUTAT RES-FUND MOL M, V571, P133, DOI 10.1016/j.mrfmmm.2004.09.014; Rusciano D, 1999, J CELL SCI, V112, P623; Sanchez-Laorden BL, 2006, J INVEST DERMATOL, V126, P172, DOI 10.1038/sj.jid.5700036; Scott MC, 2002, J CELL SCI, V115, P2349; Smith AG, 2006, AM J PHYSIOL-CELL PH, V291, pC203, DOI 10.1152/ajpcell.00476.2005; Smith AG, 2005, INT J BIOCHEM CELL B, V37, P2047, DOI 10.1016/j.biocel.2005.03.002; Smith AG, 1998, MELANOMA RES, V8, P2, DOI 10.1097/00008390-199802000-00002; Sturm RA, 2003, PIGM CELL RES, V16, P266, DOI 10.1034/j.1600-0749.2003.00041.x; Sturm RA, 2003, ANN NY ACAD SCI, V994, P348, DOI 10.1111/j.1749-6632.2003.tb03199.x; Sturm RA, 2002, MELANOMA RES, V12, P405, DOI 10.1097/00008390-200209000-00001; Sturm RA, 2006, TRENDS GENET, V22, P464, DOI 10.1016/j.tig.2006.06.010; Tada A, 2002, J INVEST DERMATOL, V118, P316, DOI 10.1046/j.0022-202x.2001.01694.x; Wansa KDSA, 2005, J MOL ENDOCRINOL, V34, P835, DOI 10.1677/jme.1.01739; Wansa KDSA, 2003, J BIOL CHEM, V278, P24776, DOI 10.1074/jbc.M300088200; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Wong WS, 1996, INT J BIOCHEM CELL B, V28, P1223, DOI 10.1016/S1357-2725(96)00074-X; Yu H, 2007, CANCER BIOL THER, V6, P405, DOI 10.4161/cbt.6.3.3755	54	84	85	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2008	283	18					12564	12570		10.1074/jbc.M800480200	http://dx.doi.org/10.1074/jbc.M800480200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	293MS	18292087	hybrid			2022-12-25	WOS:000255340000073
J	Brown, JM; Bell, TA; Alger, HM; Sawyer, JK; Smith, TL; Kelley, K; Shah, R; Wilson, MD; Davis, MA; Lee, RG; Graham, MJ; Crooke, RM; Rudel, LL				Brown, J. Mark; Bell, Thomas A., III; Alger, Heather M.; Sawyer, Janet K.; Smith, Thomas L.; Kelley, Kathryn; Shah, Ramesh; Wilson, Martha D.; Davis, Matthew A.; Lee, Richard G.; Graham, Mark J.; Crooke, Rosanne M.; Rudel, Lawrence L.			Targeted depletion of hepatic ACAT2-driven cholesterol esterification reveals a non-biliary route for fecal neutral sterol loss	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-X-RECEPTOR; SMALL-INTESTINE; ACID SYNTHESIS; MICE; ACAT2; ABSORPTION; ATHEROSCLEROSIS; HYPERCHOLESTEROLEMIA; SECRETION; EXCRETION	Deletion of acyl-CoA: cholesterol O-acyltransferase 2 (ACAT2) in mice results in resistance to diet-induced hypercholesterolemia and protection against atherosclerosis. Recently, our group has shown that liver-specific inhibition of ACAT2 via antisense oligonucleotide (ASO)-mediated targeting likewise limits atherosclerosis. However, whether this atheroprotective effect was mediated by: 1) prevention of packaging of cholesterol into apoB-containing lipoproteins, 2) augmentation of nascent HDL cholesterol secretion, or 3) increased hepatobiliary sterol secretion was not examined. Therefore, the purpose of these studies was to determine whether hepatic ACAT2 is rate-limiting in all three of these important routes of cholesterol homeostasis. Liver-specific depletion of ACAT2 resulted in reduced packaging of cholesterol into apoB-containing lipoproteins (very low density lipoprotein, intermediate density lipoprotein, and low density lipoprotein), whereas high density lipoprotein cholesterol levels remained unchanged. In the liver of ACAT2 ASO-treated mice, cholesterol ester accumulation was dramatically reduced, yet there was no reciprocal accumulation of unesterified cholesterol. Paradoxically, ASO-mediated depletion of hepatic ACAT2 promoted fecal neutral sterol excretion without altering biliary sterol secretion. Interestingly, during isolated liver perfusion, ACAT2 ASO-treated livers had augmented secretion rates of unesterified cholesterol and phospholipid. Furthermore, we demonstrate that liver-derived cholesterol from ACAT2 ASO-treated mice is preferentially delivered to the proximal small intestine as a precursor to fecal excretion. Collectively, these studies provide the first insight into the hepatic itinerary of cholesterol when cholesterol esterification is inhibited only in the liver, and provide evidence for a novel non-biliary route of fecal sterol loss.	[Brown, J. Mark; Sawyer, Janet K.; Kelley, Kathryn; Shah, Ramesh; Wilson, Martha D.; Davis, Matthew A.; Rudel, Lawrence L.] Wake Forest Univ, Sch Med, Dept Pathol, Sect Lipid Sci, Winston Salem, NC 27157 USA; [Alger, Heather M.; Rudel, Lawrence L.] Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA; [Smith, Thomas L.] Wake Forest Univ, Sch Med, Dept Orthoped Surg, Winston Salem, NC 27157 USA; [Bell, Thomas A., III] Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; [Lee, Richard G.; Graham, Mark J.; Crooke, Rosanne M.] ISIS Pharmaceut Inc, Cardiovasc Grp, Antisense Drug Discovery, Carlsbad, CA 92008 USA	Wake Forest University; Wake Forest University; Wake Forest University; Scripps Research Institute; Isis Pharmaceuticals Inc	Rudel, LL (corresponding author), Wake Forest Univ, Sch Med, Dept Pathol, Sect Lipid Sci, Med Ctr Blvd, Winston Salem, NC 27157 USA.	lrudel@wfubmc.edu	Alger, Heather/AAK-1019-2020	Alger, Heather/0000-0003-1795-9675	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007115, P01HL049373, R00HL096166] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07115-28, P01-HL49373, R00 HL096166] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bell TA, 2007, ARTERIOSCL THROM VAS, V27, P1396, DOI 10.1161/ATVBAHA.107.142802; Bell TA, 2006, ARTERIOSCL THROM VAS, V26, P1814, DOI 10.1161/01.ATV.0000225289.30767.06; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN MS, 1981, SCIENCE, V212, P628, DOI 10.1126/science.6261329; Buhman KK, 2000, NAT MED, V6, P1341, DOI 10.1038/82153; Butler M, 1997, LAB INVEST, V77, P379; Chang CCY, 2000, J BIOL CHEM, V275, P28083; CHENG SH, 1959, P SOC EXP BIOL MED, V101, P223; Dawson PA, 2003, J BIOL CHEM, V278, P33920, DOI 10.1074/jbc.M306370200; Dietschy JM, 2002, J BIOL CHEM, V277, P3801, DOI 10.1074/jbc.R100057200; DIETSCHY JM, 1993, J LIPID RES, V34, P1637; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; JOHNSON FL, 1983, J CLIN INVEST, V72, P221, DOI 10.1172/JCI110961; Kruit JK, 2005, GASTROENTEROLOGY, V128, P147, DOI 10.1053/j.gastro.2004.10.006; Lee RG, 2005, J LIPID RES, V46, P1205, DOI 10.1194/jlr.M500018-JLR200; Lee RG, 2004, CIRC RES, V95, P998, DOI 10.1161/01.RES.0000147558.15554.67; Lee RG, 2000, J LIPID RES, V41, P1991; Parini P, 2004, CIRCULATION, V110, P2017, DOI 10.1161/01.CIR.0000143163.76212.0B; PERTSEMLIDIS D, 1973, J CLIN INVEST, V52, P2353, DOI 10.1172/JCI107424; Plosch T, 2002, J BIOL CHEM, V277, P33870, DOI 10.1074/jbc.M206522200; Repa JJ, 2004, HEPATOLOGY, V40, P1088, DOI 10.1002/hep.20439; Rudel LL, 1997, J CLIN INVEST, V100, P74, DOI 10.1172/JCI119524; Rudel LL, 2005, ARTERIOSCL THROM VAS, V25, P1112, DOI 10.1161/01.ATV.0000166548.65753.1e; Schwarz M, 1998, J LIPID RES, V39, P1833; SIMMONDS WJ, 1967, J CLIN INVEST, V46, P874, DOI 10.1172/JCI105587; SMITH JL, 1990, J LIPID RES, V31, P1993; Temel RE, 2005, J LIPID RES, V46, P2423, DOI 10.1194/jlr.M500232-JLR200; Temel RE, 2007, J CLIN INVEST, V117, P1968, DOI 10.1172/JCI30060; TURLEY SD, 1979, J LIPID RES, V20, P923; Turley SD, 2003, CURR OPIN LIPIDOL, V14, P233, DOI 10.1097/00041433-200306000-00002; Van der Velde AE, 2007, GASTROENTEROLOGY, V133, P967, DOI 10.1053/j.gastro.2007.06.019; Willner EL, 2003, P NATL ACAD SCI USA, V100, P1262, DOI 10.1073/pnas.0336398100	32	92	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10522	10534		10.1074/jbc.M707659200	http://dx.doi.org/10.1074/jbc.M707659200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18281279	Green Published, hybrid			2022-12-25	WOS:000254894700034
J	Keskiaho, K; Kukkola, L; Page, AP; Winter, AD; Vuoristo, J; Sormunen, R; Nissi, R; Riihimaa, P; Myllyharju, J				Keskiaho, Katriina; Kukkola, Liisa; Page, Antony P.; Winter, Alan D.; Vuoristo, Jussi; Sormunen, Raija; Nissi, Ritva; Riihimaa, Paeivi; Myllyharju, Johanna			Characterization of a novel Caenorhabditis elegans prolyl 4-hydroxylase with a unique substrate specificity and restricted expression in the pharynx and excretory duct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE-FACTOR; PROTEIN DISULFIDE-ISOMERASE; ALPHA-SUBUNIT ISOFORM; AMINO-ACID-SEQUENCE; GENE-EXPRESSION; BACULOVIRUS EXPRESSION; BINDING DOMAIN; BETA-SUBUNIT; ARABIDOPSIS-THALIANA; ENZYME TETRAMER	Collagen prolyl 4-hydroxylases (C-P4Hs) have a critical role in collagen synthesis, since 4-hydroxyproline residues are necessary for folding of the triple-helical molecules. Vertebrate C-P4Hs are alpha(2)beta(2) tetramers in which the beta subunit is identical to protein-disulfide isomerase (PDI). Three isoforms of the catalytic alpha subunit, PHY-1, PHY-2, and PHY-3, have been characterized from Caenorhabditis elegans, PHY-1 and PHY-2 being responsible for the hydroxylation of cuticle collagens, whereas PHY-3 is predicted to be involved in collagen synthesis in early embryos. We have characterized transcripts of two additional C. elegans alpha subunit-like genes, Y43F8B.4 and C14E2.4. Three transcripts were generated from Y43F8B.4, and a polypeptide encoded by one of them, named PHY-4.1, assembled into active (PHY-4.1)(2)/(PDI-2)(2) tetramers and PHY-4.1/PDI-2 dimers when coexpressed with C. elegans PDI-2 in insect cells. The C14E2.4 transcript was found to have a frameshift leading to the absence of codons for two residues critical for P4H catalytic activity. Thus, C. elegans has altogether four functional C-P4H alpha subunits, PHY-1, PHY-2, PHY-3, and PHY-4.1. The tetramers and dimers containing recombinant PHY-4.1 had a distinct substrate specificity from the other C-P4Hs in that they hydroxylated poly(L-proline) and certain other proline-rich peptides, including ones that are expressed in the pharynx, in addition to collagen-like peptides. These data and the observed restricted expression of the phy-4.1 transcript and PHY-4.1 polypeptide in the pharyngeal gland cells and the excretory duct suggest that in addition to collagens, PHY-4.1 may hydroxylate additional proline-rich proteins in vivo.	[Keskiaho, Katriina; Kukkola, Liisa; Nissi, Ritva; Riihimaa, Paeivi; Myllyharju, Johanna] Univ Oulu, Collagen Res Unit, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland; [Keskiaho, Katriina; Kukkola, Liisa; Vuoristo, Jussi; Sormunen, Raija; Nissi, Ritva; Riihimaa, Paeivi; Myllyharju, Johanna] Univ Oulu, Bioctr, FIN-90014 Oulu, Finland; [Sormunen, Raija] Univ Oulu, Dept Pathol, FIN-90014 Oulu, Finland; [Page, Antony P.; Winter, Alan D.] Univ Glasgow, Fac Vet Med, Inst Comparat Med, Glasgow G61 1QH, Lanark, Scotland	University of Oulu; University of Oulu; University of Oulu; University of Glasgow	Myllyharju, J (corresponding author), Univ Oulu, Collagen Res Unit, Dept Med Biochem & Mol Biol, POB 5000, FIN-90014 Oulu, Finland.	johanna.myllyharju@oulu.fi			Medical Research Council [G117/476] Funding Source: Medline; MRC [G117/476] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abrams EW, 2006, DEVELOPMENT, V133, P3517, DOI 10.1242/dev.02525; Abrams EW, 2002, MECH DEVELOP, V112, P165, DOI 10.1016/S0925-4773(01)00636-0; ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; Annunen P, 1997, J BIOL CHEM, V272, P17342, DOI 10.1074/jbc.272.28.17342; Annunen P, 1999, J BIOL CHEM, V274, P6790, DOI 10.1074/jbc.274.10.6790; Annunen P, 1998, J BIOL CHEM, V273, P5989, DOI 10.1074/jbc.273.11.5989; Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Berra E, 2006, EMBO REP, V7, P41, DOI 10.1038/sj.embor.7400598; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Centanin L, 2005, EMBO REP, V6, P1070, DOI 10.1038/sj.embor.7400528; CROSSEN R, 1998, BACULOVIRUS EXPRESSI; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Eriksson M, 1999, J BIOL CHEM, V274, P22131, DOI 10.1074/jbc.274.32.22131; Eschenlauer SCP, 2003, J BIOL CHEM, V278, P4227, DOI 10.1074/jbc.M210510200; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; Friedman L, 2000, P NATL ACAD SCI USA, V97, P4736, DOI 10.1073/pnas.97.9.4736; GuhaThakurta D, 2002, GENOME RES, V12, P701, DOI 10.1101/gr.228902; Gupta MC, 1997, J CELL BIOL, V137, P1185, DOI 10.1083/jcb.137.5.1185; HELAAKOSKI T, 1989, P NATL ACAD SCI USA, V86, P4392, DOI 10.1073/pnas.86.12.4392; HELAAKOSKI T, 1995, P NATL ACAD SCI USA, V92, P4427, DOI 10.1073/pnas.92.10.4427; Hieta R, 2003, J BIOL CHEM, V278, P34966, DOI 10.1074/jbc.M303624200; Hieta R, 2002, J BIOL CHEM, V277, P23965, DOI 10.1074/jbc.M201865200; Hill KL, 2000, GENETICS, V155, P1139; Holster T, 2007, J BIOL CHEM, V282, P2512, DOI 10.1074/jbc.M606608200; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; JOHN DCA, 1994, BIOCHEMISTRY-US, V33, P14018, DOI 10.1021/bi00251a009; Kaelin WG, 2005, ANNU REV BIOCHEM, V74, P115, DOI 10.1146/annurev.biochem.74.082803.133142; KESKIAHO K, 2007, J PLANT CELL, V19, P256; Kim SK, 2001, SCIENCE, V293, P2087, DOI 10.1126/science.1061603; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; Kukkola L, 2003, J BIOL CHEM, V278, P47685, DOI 10.1074/jbc.M306806200; LAMBERG A, 1995, J BIOL CHEM, V270, P9926, DOI 10.1074/jbc.270.17.9926; McDonough MA, 2006, P NATL ACAD SCI USA, V103, P9814, DOI 10.1073/pnas.0601283103; McKay SJ, 2003, COLD SPRING HARB SYM, V68, P159, DOI 10.1101/sqb.2003.68.159; Myllyharju J, 1999, EMBO J, V18, P306, DOI 10.1093/emboj/18.2.306; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Myllyharju J, 2002, J BIOL CHEM, V277, P29187, DOI 10.1074/jbc.M203824200; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; NELSON FK, 1983, J ULTRA MOL STRUCT R, V82, P156; Nissi R, 2001, J HISTOCHEM CYTOCHEM, V49, P1143, DOI 10.1177/002215540104900908; Nonet ML, 1997, J NEUROSCI, V17, P8061; Norman KR, 2000, DEV BIOL, V227, P690, DOI 10.1006/dbio.2000.9897; Pekkala M, 2004, J BIOL CHEM, V279, P52255, DOI 10.1074/jbc.M410007200; Riihimaa P, 2002, J BIOL CHEM, V277, P18238, DOI 10.1074/jbc.M200895200; ROGALSKI TM, 1993, GENE DEV, V7, P1471, DOI 10.1101/gad.7.8.1471; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Sulston J., 1988, NEMATODE CAENORHABDI, P587; Takeda K, 2006, MOL CELL BIOL, V26, P8336, DOI 10.1128/MCB.00425-06; Tiainen P, 2005, J BIOL CHEM, V280, P1142, DOI 10.1074/jbc.M411109200; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Van den Diepstraten C, 2003, CIRCULATION, V108, P508, DOI 10.1161/01.CIR.0000080883.53863.5C; Veijola J, 1996, BIOCHEM J, V317, P721, DOI 10.1042/bj3170721; VEIJOLA J, 1994, J BIOL CHEM, V269, P26746; Veit G, 2006, J BIOL CHEM, V281, P3494, DOI 10.1074/jbc.M509333200; Winter AD, 2000, MOL CELL BIOL, V20, P4084, DOI 10.1128/MCB.20.11.4084-4093.2000; Winter AD, 2003, J BIOL CHEM, V278, P2554, DOI 10.1074/jbc.M210381200; Winter AD, 2007, MATRIX BIOL, V26, P382, DOI 10.1016/j.matbio.2007.01.008	61	6	12	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10679	10689		10.1074/jbc.M800972200	http://dx.doi.org/10.1074/jbc.M800972200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18276589	hybrid			2022-12-25	WOS:000254894700050
J	Devi, L; Raghavendran, V; Prabhu, BM; Avadhani, NG; Anandatheerthavarada, HK				Devi, Latha; Raghavendran, Vijayendran; Prabhu, Badanavalu M.; Avadhani, Narayan G.; Anandatheerthavarada, Hindupur K.			Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; EARLY-ONSET PARKINSONISM; OXIDATIVE STRESS; CELL-DEATH; NEURODEGENERATIVE DISEASES; ENDOPLASMIC-RETICULUM; MUTATIONS; PHOSPHORYLATION; DJ-1; LOCALIZATION	alpha-Synuclein, a protein implicated in the pathogenesis of Parkinson disease ( PD), is thought to affect mitochondrial functions, although the mechanisms of its action remain unclear. In this study we show that the N-terminal 32 amino acids of human alpha-synuclein contain cryptic mitochondrial targeting signal, which is important for mitochondrial targeting of alpha-synuclein. Mitochondrial imported alpha-synuclein is predominantly associated with the inner membrane. Accumulation of wild-type alpha-synuclein in the mitochondria of human dopaminergic neurons caused reduced mitochondrial complex I activity and increased production of reactive oxygen species. However, these defects occurred at an early time point in dopaminergic neurons expressing familial alpha-synuclein with A53T mutation as compared with wild-type alpha-synuclein. Importantly, alpha-synuclein that lacks mitochondrial targeting signal failed to target to the mitochondria and showed no detectable effect on complex I function. The PD relevance of these results was investigated using mitochondria of substantia nigra, striatum, and cerebellum of postmortem late-onset PD and normal human brains. Results showed the constitutive presence of similar to 14- kDa alpha-synuclein in the mitochondria of all three brain regions of normal subjects. Mitochondria of PD-vulnerable substantia nigra and striatum but not cerebellum from PD subjects showed significant accumulation of alpha-synuclein and decreased complex I activity. Analysis of mitochondria from PD brain and alpha-synuclein expressing dopaminergic neuronal cultures using blue native gel electrophoresis and immunocapture technique showed the association of alpha-synuclein with complex I. These results provide evidence that mitochondrial accumulated alpha-synuclein may interact with complex I and interfere with its functions.	[Devi, Latha; Raghavendran, Vijayendran; Prabhu, Badanavalu M.; Avadhani, Narayan G.; Anandatheerthavarada, Hindupur K.] Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA	University of Pennsylvania	Anandatheerthavarada, HK (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, 3800 Spruce St, Philadelphia, PA 19104 USA.	ann1234@vet.upenn.edu	Raghavendran, Vijay/G-6425-2015	Raghavendran, Vijay/0000-0002-2021-2786	NATIONAL INSTITUTE ON AGING [R01AG021920] Funding Source: NIH RePORTER; NIA NIH HHS [AG 021920] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abou-Sleiman PM, 2006, ANN NEUROL, V60, P414, DOI 10.1002/ana.20960; Addya S, 1997, J CELL BIOL, V139, P589, DOI 10.1083/jcb.139.3.589; Ahn M, 2006, BIOCHEM BIOPH RES CO, V346, P1142, DOI 10.1016/j.bbrc.2006.05.213; ALI SF, 1994, SYNAPSE, V18, P27, DOI 10.1002/syn.890180105; Anandatheerthavarada HK, 1999, EMBO J, V18, P5494, DOI 10.1093/emboj/18.20.5494; Anandatheerthavarada HK, 2003, J CELL BIOL, V161, P41, DOI 10.1083/jcb.200207030; Anandatheerthavarada HK, 1997, ARCH BIOCHEM BIOPHYS, V339, P136, DOI 10.1006/abbi.1996.9855; Antonicka H, 2003, J BIOL CHEM, V278, P43081, DOI 10.1074/jbc.M304998200; Bennett MC, 2005, PHARMACOL THERAPEUT, V105, P311, DOI 10.1016/j.pharmthera.2004.10.010; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Bonifati V, 2003, NEUROL SCI, V24, P159, DOI 10.1007/s10072-003-0108-0; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Canet-Aviles RM, 2004, P NATL ACAD SCI USA, V101, P9103, DOI 10.1073/pnas.0402959101; Chicco AJ, 2007, AM J PHYSIOL-CELL PH, V292, pC33, DOI 10.1152/ajpcell.00243.2006; Cookson MR, 2005, ANNU REV BIOCHEM, V74, P29, DOI 10.1146/annurev.biochem.74.082803.133400; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Devi L, 2006, J NEUROSCI, V26, P9057, DOI 10.1523/JNEUROSCI.1469-06.2006; Ellis CE, 2005, MOL CELL BIOL, V25, P10190, DOI 10.1128/MCB.25.22.10190-10201.2005; Fiskum G, 2003, ANN NY ACAD SCI, V991, P111; Gasser T, 2001, J NEUROL, V248, P833, DOI 10.1007/s004150170066; Greenamyre JT, 2003, PARKINSONISM RELAT D, V9, pS59, DOI 10.1016/S1353-8020(03)00023-3; Gu M, 1997, MOVEMENT DISORD, V12, P418, DOI 10.1002/mds.870120323; Hsu LJ, 2000, AM J PATHOL, V157, P401, DOI 10.1016/S0002-9440(10)64553-1; Keeney PM, 2006, J NEUROSCI, V26, P5256, DOI 10.1523/JNEUROSCI.0984-06.2006; Kim TD, 2000, PROTEIN SCI, V9, P2489, DOI 10.1110/ps.9.12.2489; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRIGE D, 1992, ANN NEUROL, V32, P782, DOI 10.1002/ana.410320612; Li WW, 2007, NEUROREPORT, V18, P1543, DOI 10.1097/WNR.0b013e3282f03db4; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Martin LJ, 2006, J NEUROSCI, V26, P41, DOI 10.1523/JNEUROSCI.4308-05.2006; Moore DJ, 2005, HUM MOL GENET, V14, P71, DOI 10.1093/hmg/ddi007; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Ramakrishnan M, 2003, BIOCHEMISTRY-US, V42, P12919, DOI 10.1021/bi035048e; Recchia A, 2004, FASEB J, V18, P617, DOI 10.1096/fj.03-0338rev; Rehling P, 2004, NAT REV MOL CELL BIO, V5, P519, DOI 10.1038/nrm1426; Robin MA, 2003, J BIOL CHEM, V278, P18960, DOI 10.1074/jbc.M301807200; Robin MA, 2002, J BIOL CHEM, V277, P40583, DOI 10.1074/jbc.M203292200; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; Shults CW, 2006, P NATL ACAD SCI USA, V103, P1661, DOI 10.1073/pnas.0509567103; Silvestri L, 2005, HUM MOL GENET, V14, P3477, DOI 10.1093/hmg/ddi377; Smith WW, 2005, HUM MOL GENET, V14, P3801, DOI 10.1093/hmg/ddi396; Swerdlow RH, 1998, ANN NEUROL, V44, P873, DOI 10.1002/ana.410440605; Ugalde C, 2004, HUM MOL GENET, V13, P2461, DOI 10.1093/hmg/ddh262; Ulmer TS, 2005, J BIOL CHEM, V280, P43179, DOI 10.1074/jbc.M507624200; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Vogel RO, 2005, FEBS J, V272, P5317, DOI 10.1111/j.1742-4658.2005.04928.x; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; Wang Y, 2006, BIOCHEM PHARMACOL, V72, P881, DOI 10.1016/j.bcp.2006.06.032; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600	50	720	731	2	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9089	9100		10.1074/jbc.M710012200	http://dx.doi.org/10.1074/jbc.M710012200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18245082	Green Published, hybrid			2022-12-25	WOS:000254465800039
J	Voong, LN; Slater, AR; Kratovac, S; Cressman, DE				Voong, Lilien N.; Slater, Allison R.; Kratovac, Sebila; Cressman, Drew E.			Mitogen-activated protein kinase ERK1/2 regulates the class II transactivator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; BARE-LYMPHOCYTE-SYNDROME; CIITA GENE-EXPRESSION; HISTOCOMPATIBILITY COMPLEX EXPRESSION; CREB BINDING-PROTEIN; LEUCINE-RICH REPEATS; X-BOX REGION; IFN-GAMMA; GTP-BINDING; ANTIGEN PRESENTATION	The expression of major histocompatibility class II genes is necessary for proper antigen presentation and induction of an immune response. This expression is initiated by the class II transactivator, CIITA. The establishment of the active form of CIITA is controlled by a series of post-translational events, including GTP binding, ubiquitination, and dimerization. However, the role of phosphorylation is less clearly defined as are the consequences of phosphorylation on CIITA activity and the identity of the kinases involved. In this study we show that the extracellular signal-regulated kinases 1 and 2 ( ERK1/2) interact directly with CIITA, targeting serine residues in the amino terminus of the protein, including serine 288. Inhibition of this phosphorylation by dominant-negative forms of ERK or by treatment of cells with the ERK inhibitor PD98059 resulted in the increase in CIITA-mediated gene expression from a class II promoter, enhanced the nuclear concentration of CIITA, and impaired its ability to bind to the nuclear export factor, CRM1. In contrast, inhibition of ERK1/2 activity had little effect on serine-to-alanine mutant forms of CIITA. These data suggest a model whereby ERK1/2-mediated phosphorylation of CIITA down-regulates CIITA activity by priming it for nuclear export, thus providing a means for cells to tightly regulate the extent of antigen presentation.	[Voong, Lilien N.; Slater, Allison R.; Kratovac, Sebila; Cressman, Drew E.] Sarah Lawrence Coll, Dept Biol, Bronxville, NY 10708 USA	Sarah Lawrence College	Cressman, DE (corresponding author), 1 Mead Way, Bronxville, NY 10708 USA.	dcressma@slc.edu						Al-Kandari W, 2007, J MOL BIOL, V369, P1175, DOI 10.1016/j.jmb.2007.04.033; Bewry NN, 2007, J BIOL CHEM, V282, P26178, DOI 10.1074/jbc.M611747200; Boss JM, 2003, CURR OPIN IMMUNOL, V15, P105, DOI 10.1016/S0952-7915(02)00015-8; Boss JM, 1999, MICROBES INFECT, V1, P847, DOI 10.1016/S1286-4579(99)00234-8; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Brown JA, 1998, NUCLEIC ACIDS RES, V26, P4128, DOI 10.1093/nar/26.18.4128; Camacho-Carvajal MM, 2004, INT IMMUNOL, V16, P65, DOI 10.1093/intimm/dxh010; CHANG CH, 1995, J EXP MED, V181, P765, DOI 10.1084/jem.181.2.765; CHIN KC, 1994, IMMUNITY, V1, P687, DOI 10.1016/1074-7613(94)90039-6; Chin KC, 1997, J IMMUNOL, V159, P2789; Chin KC, 1997, P NATL ACAD SCI USA, V94, P2501, DOI 10.1073/pnas.94.6.2501; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; Cressman DE, 1999, IMMUNITY, V10, P163, DOI 10.1016/S1074-7613(00)80017-5; Cressman DE, 2001, J IMMUNOL, V167, P3626, DOI 10.4049/jimmunol.167.7.3626; DeSandro AM, 2000, MOL CELL BIOL, V20, P6587, DOI 10.1128/MCB.20.17.6587-6599.2000; Drozina G, 2006, J BIOL CHEM, V281, P39963, DOI 10.1074/jbc.M608538200; Fontes JD, 1999, MOL CELL BIOL, V19, P941; Giroux M, 2003, J IMMUNOL, V171, P4187, DOI 10.4049/jimmunol.171.8.4187; Greer SF, 2004, J IMMUNOL, V173, P376, DOI 10.4049/jimmunol.173.1.376; GRILLI M, 1993, INT REV CYTOL, V143, P1; Hake SB, 2000, MOL CELL BIOL, V20, P7716, DOI 10.1128/MCB.20.20.7716-7725.2000; Harton JA, 1999, SCIENCE, V285, P1402, DOI 10.1126/science.285.5432.1402; Harton JA, 2002, J IMMUNOL, V169, P4088, DOI 10.4049/jimmunol.169.8.4088; Harton JA, 2000, MOL CELL BIOL, V20, P6185, DOI 10.1128/MCB.20.17.6185-6194.2000; Jabrane-Ferrat N, 2003, INT IMMUNOL, V15, P467, DOI 10.1093/intimm/dxg048; Krawczyk M, 2006, TISSUE ANTIGENS, V67, P183, DOI 10.1111/j.1399-0039.2006.00557.x; Kretsovali A, 2001, J BIOL CHEM, V276, P32191, DOI 10.1074/jbc.M103164200; Kretsovali A, 1998, MOL CELL BIOL, V18, P6777, DOI 10.1128/MCB.18.11.6777; Kutay U, 2005, TRENDS CELL BIOL, V15, P121, DOI 10.1016/j.tcb.2005.01.005; Kwon MJ, 2007, MOL IMMUNOL, V44, P2841, DOI 10.1016/j.molimm.2007.01.035; Kwon MJ, 2006, J IMMUNOL, V177, P950, DOI 10.4049/jimmunol.177.2.950; Li GX, 2001, MOL CELL BIOL, V21, P4626, DOI 10.1128/MCB.21.14.4626-4635.2001; Linhoff MW, 2001, MOL CELL BIOL, V21, P3001, DOI 10.1128/MCB.21.9.3001-3011.2001; Lochamy J, 2007, MOL IMMUNOL, V44, P837, DOI 10.1016/j.molimm.2006.04.004; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; Mahanta SK, 1997, P NATL ACAD SCI USA, V94, P6324, DOI 10.1073/pnas.94.12.6324; MORENO CS, 1995, J IMMUNOL, V155, P4313; Moreno CS, 1999, IMMUNITY, V10, P143, DOI 10.1016/S1074-7613(00)80015-1; Mudhasani R, 2002, MOL CELL BIOL, V22, P5019, DOI 10.1128/MCB.22.14.5019-5026.2002; Nagarajan UM, 2002, J IMMUNOL, V169, P5078, DOI 10.4049/jimmunol.169.9.5078; Nekrep N, 2001, MOL CELL BIOL, V21, P5566, DOI 10.1128/MCB.21.16.5566-5576.2001; Nikodemova M, 2007, J BIOL CHEM, V282, P15208, DOI 10.1074/jbc.M611907200; Raval A, 2003, J IMMUNOL, V170, P922, DOI 10.4049/jimmunol.170.2.922; Reith W, 2001, ANNU REV IMMUNOL, V19, P331, DOI 10.1146/annurev.immunol.19.1.331; RILEY JL, 1995, IMMUNITY, V2, P533, DOI 10.1016/1074-7613(95)90033-0; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Scholl T, 1997, P NATL ACAD SCI USA, V94, P6330, DOI 10.1073/pnas.94.12.6330; Sisk TJ, 2001, MOL CELL BIOL, V21, P4919, DOI 10.1128/MCB.21.15.4919-4928.2001; Sisk TJ, 2003, INT IMMUNOL, V15, P1195, DOI 10.1093/intimm/dxg116; Spilianakis C, 2000, MOL CELL BIOL, V20, P8489, DOI 10.1128/MCB.20.22.8489-8498.2000; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; Taxman DJ, 2000, J IMMUNOL, V165, P1410, DOI 10.4049/jimmunol.165.3.1410; Tosi G, 2002, EMBO J, V21, P5467, DOI 10.1093/emboj/cdf557; Towey M, 2002, MOL IMMUNOL, V38, P627, DOI 10.1016/S0161-5890(01)00093-1; van den Elsen PJ, 2004, CURR OPIN IMMUNOL, V16, P67, DOI 10.1016/j.coi.2003.11.015; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; Yao YX, 2006, J IMMUNOL, V177, P70, DOI 10.4049/jimmunol.177.1.70; Zhao M, 2007, MOL IMMUNOL, V44, P2923, DOI 10.1016/j.molimm.2007.01.009; Zhao WL, 2007, J IMMUNOL, V179, P463, DOI 10.4049/jimmunol.179.1.463; ZHOU H, 1995, IMMUNITY, V2, P545, DOI 10.1016/1074-7613(95)90034-9; Zhu XS, 2000, MOL CELL BIOL, V20, P6051, DOI 10.1128/MCB.20.16.6051-6061.2000; Zika E, 2005, P NATL ACAD SCI USA, V102, P16321, DOI 10.1073/pnas.0505045102; Zika E, 2005, CURR OPIN IMMUNOL, V17, P58, DOI 10.1016/j.coi.2004.11.008; Zika E, 2003, MOL CELL BIOL, V23, P3091, DOI 10.1128/MCB.23.9.3091-3102.2003	67	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9031	9039		10.1074/jbc.M706487200	http://dx.doi.org/10.1074/jbc.M706487200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18245089	hybrid, Green Published			2022-12-25	WOS:000254465800033
J	Horisawa, K; Doi, N; Yanagawa, H				Horisawa, Kenichi; Doi, Nobuhide; Yanagawa, Hiroshi			Use of cDNA Tiling Arrays for Identifying Protein Interactions Selected by In Vitro Display Technologies	PLOS ONE			English	Article								In vitro display technologies such as mRNA display are powerful screening tools for protein interaction analysis, but the final cloning and sequencing processes represent a bottleneck, resulting in many false negatives. Here we describe an application of tiling array technology to identify specifically binding proteins selected with the in vitro virus (IVV) mRNA display technology. We constructed transcription-factor tiling (TFT) arrays containing similar to 1,600 open reading frame sequences of known and predicted mouse transcription-regulatory factors (334,372 oligonucleotides, 50-mer in length) to analyze cDNA fragments from mRNA-display screening for Jun-associated proteins. The use of the TFT arrays greatly increased the coverage of known Jun-interactors to 28% (from 14% with the cloning and sequencing approach), without reducing the accuracy (similar to 75%). This method could detect even targets with extremely low expression levels (less than a single mRNA copy per cell in whole brain tissue). This highly sensitive and reliable method should be useful for high-throughput protein interaction analysis on a genome-wide scale.	[Horisawa, Kenichi; Doi, Nobuhide; Yanagawa, Hiroshi] Keio Univ, Dept Biosci & Informat, Fac Sci & Technol, Yokohama, Kanagawa 223, Japan	Keio University	Horisawa, K (corresponding author), Keio Univ, Dept Biosci & Informat, Fac Sci & Technol, Yokohama, Kanagawa 223, Japan.	hyana@bio.keio.ac.jp	Doi, Nobuhide/C-4481-2014	Doi, Nobuhide/0000-0002-2402-6390	Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [Grant-in-Aid]; Research for Promoting Technological Seeds Program of the Japan Science and Technology Agency (JST)	Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Research for Promoting Technological Seeds Program of the Japan Science and Technology Agency (JST)(Japan Science & Technology Agency (JST))	This work was supported in part by a Grant-in-Aid for The 21st Century Center of Excellence (COE) Program entitled Understanding and Control of Life's Function via Systems Biology (Keio Univ.) of the Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT); The Keio University Global Center of Excellence (G-COE) Program entitled Center for Human Metabolomic Systems Biology of the MEXT; and The Research for Promoting Technological Seeds Program of the Japan Science and Technology Agency (JST).	CAMPBELL N, 1996, BIOLOGY; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; DAVYDOV IV, 1995, GENE, V161, P271, DOI 10.1016/0378-1119(95)00271-7; Doi N, 1999, FEBS LETT, V457, P227, DOI 10.1016/S0014-5793(99)01041-8; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fukuda I, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl618; Gachon F, 2004, GENE DEV, V18, P1397, DOI 10.1101/gad.301404; Gunji W, 2004, BIOCHEM BIOPH RES CO, V325, P265, DOI 10.1016/j.bbrc.2004.10.025; Hammond PW, 2001, J BIOL CHEM, V276, P20898, DOI 10.1074/jbc.M011641200; Hanes J, 1998, P NATL ACAD SCI USA, V95, P14130, DOI 10.1073/pnas.95.24.14130; Hanes J, 1997, P NATL ACAD SCI USA, V94, P4937, DOI 10.1073/pnas.94.10.4937; He MY, 1997, NUCLEIC ACIDS RES, V25, P5132, DOI 10.1093/nar/25.24.5132; Horisawa K, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh167; Horisawa K, 2005, J BIOCHEM, V137, P121, DOI 10.1093/jb/mvi023; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597; Keefe AD, 2001, NATURE, V410, P715, DOI 10.1038/35070613; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Lu R, 1997, MOL CELL BIOL, V17, P5117, DOI 10.1128/MCB.17.9.5117; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; Matsumura Nobutaka, 2006, Current Proteomics, V3, P199, DOI 10.2174/157016406779475371; MATTHEAKIS LC, 1994, P NATL ACAD SCI USA, V91, P9022, DOI 10.1073/pnas.91.19.9022; McPherson M, 2002, CHEM BIOL, V9, P691, DOI 10.1016/S1074-5521(02)00148-5; Miyamoto-Sato E, 2005, GENOME RES, V15, P710, DOI 10.1101/gr.3510505; Miyamoto-Sato E, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng078; Nemoto N, 1997, FEBS LETT, V414, P405, DOI 10.1016/S0014-5793(97)01026-0; Nuwaysir EF, 2002, GENOME RES, V12, P1749, DOI 10.1101/gr.362402; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Roberts RW, 1997, P NATL ACAD SCI USA, V94, P12297, DOI 10.1073/pnas.94.23.12297; Schrem H, 2004, PHARMACOL REV, V56, P291, DOI 10.1124/pr.56.2.5; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; 't Hoen PAC, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng020; Tateyama S, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj025	34	4	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1646	10.1371/journal.pone.0001646	http://dx.doi.org/10.1371/journal.pone.0001646			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286201	gold, Green Published, Green Submitted			2022-12-25	WOS:000260586400039
J	Mlisana, K; Auld, SC; Grobler, A; van Loggerenberg, F; Williamson, C; Iriogbe, I; Sobieszczyk, ME; Abdool Karim, SS				Mlisana, Koleka; Auld, Sara C.; Grobler, Anneke; van Loggerenberg, Francois; Williamson, Carolyn; Iriogbe, Itua; Sobieszczyk, Magdalena E.; Abdool Karim, Salim Safurdeen		CAPRISA 002 Acute Infection Study Team	Anaemia in Acute HIV-1 Subtype C Infection	PLOS ONE			English	Article								Background: The high prevalence of anaemia and the increased morbidity and mortality associated with anaemia during AIDS has been well described yet there has been little information about anaemia and changes in haemoglobin levels during acute and early HIV-1 infection. Methods: HIV-negative women (n = 245) were enrolled into an observational cohort as part of the Centre for the AIDS Programme of Research in South Africa (CAPRISA) Acute Infection Study. Acute infection was diagnosed following a positive HIV RNA PCR in the absence of antibodies, or detection of HIV-1 antibodies within 3 months of a previously negative antibody test. Haemotologic parameters were assessed before infection and at regular intervals in the first twelve months of HIV infection. Results: Fifty-seven participants with acute HIV infection were identified at a median of 14.5 days post-infection ( range 10-81) and were enrolled in the CAPRISA Acute Infection cohort at a median of 41 days post-infection (range 15-104). Mean haemoglobin prior to HIV-1 infection was 12.7 g/dL, with a mean decline of 0.46 g/dL following infection. The prevalence of anaemia increased from 25.0% prior to HIV-1 infection to 52.6% at 3 months post-infection, 61.1% at 6 months post-infection, and 51.4% at 12 months post-infection. Conclusions: Haematologic derangements and anaemia with a trend towards iron deficiency are common with acute HIV-1 subtype C infection in this small cohort. The negative impact of anaemia concurrent with established HIV infection upon morbidity and mortality has been well documented but the prognostic potential and long-term effects of anaemia during acute HIV-1 infection remain unknown.	[Mlisana, Koleka; Auld, Sara C.; Grobler, Anneke; van Loggerenberg, Francois; Iriogbe, Itua; Abdool Karim, Salim Safurdeen] Univ KwaZulu Natal, CAPRISA, Durban, South Africa; [Auld, Sara C.; Sobieszczyk, Magdalena E.; Abdool Karim, Salim Safurdeen] Columbia Univ, New York, NY USA; [Williamson, Carolyn] Univ Cape Town, Inst Infect Dis & Mol Med, Cape Town, South Africa	University of Kwazulu Natal; Columbia University; University of Cape Town	Mlisana, K (corresponding author), Univ KwaZulu Natal, CAPRISA, Durban, South Africa.	mlisanak@ukzn.ac.za	Karim, Salim Safurdeen Abdool/N-5947-2013; Karim, Salim Abdool/AAE-7118-2019; Karim, Salim Abdool/P-3117-2019; Mlisana, Koleka/N-6204-2013	Karim, Salim Safurdeen Abdool/0000-0002-4986-2133; Karim, Salim Abdool/0000-0002-4986-2133; Mlisana, Koleka/0000-0002-8436-3268; van Loggerenberg, Francois/0000-0001-5317-7983; Grobler, Anneke/0000-0002-7809-7688; , Carolyn/0000-0003-0125-1226	Centre for the AIDs Programme of Research in South Africa (CAPRISA) [AI51794]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI051794] Funding Source: NIH RePORTER	Centre for the AIDs Programme of Research in South Africa (CAPRISA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was funded by the Centre for the AIDs Programme of Research in South Africa (CAPRISA). CAPRISA is part of the Comprehensive International Program of Research on AIDS (CIPRA) and is supported by the National Institute of Allergy and Infectious Disease (NIAID), National Institutes of Health (NIH) and the US Department of Health and Human Services (DHHS)(grant# AI51794). The funders approved the design of the study and provided monitoring oversight thoughout the conduct of the study. The funders were not involved in the collection, analysis of data or in the preparation, review or approval of the manuscript.	Bahner I, 1997, BLOOD, V90, P1787, DOI 10.1182/blood.V90.5.1787; Berhane K, 2004, JAIDS-J ACQ IMM DEF, V37, P1245, DOI 10.1097/01.qai.0000134759.01684.27; Deschamps MM, 2000, AIDS, V14, P2515, DOI 10.1097/00002030-200011100-00014; Kreuzer KA, 1997, ANN HEMATOL, V75, P179, DOI 10.1007/s002770050340; Kreuzer KA, 1997, BRIT J HAEMATOL, V96, P235, DOI 10.1046/j.1365-2141.1997.d01-2031.x; Lau B, 2005, JAIDS-J ACQ IMM DEF, V39, P620; Lawn SD, 2001, CLIN MICROBIOL REV, V14, P753, DOI 10.1128/CMR.14.4.753-777.2001; Lundgren JD, 2003, CLIN INFECT DIS, V37, pS297, DOI 10.1086/376909; Mocroft A, 1999, AIDS, V13, P943, DOI 10.1097/00002030-199905280-00010; Moore RD, 1999, CLIN INFECT DIS, V29, P44, DOI 10.1086/520178; Moses A, 1998, BLOOD, V91, P1479, DOI 10.1182/blood.V91.5.1479.1479_1479_1495; Moses AV, 1996, BLOOD, V87, P919, DOI 10.1182/blood.V87.3.919.bloodjournal873919; O'Brien ME, 2005, JAIDS-J ACQ IMM DEF, V40, P219, DOI 10.1097/01.qai.0000166374.16222.a2; Savarino A, 1999, CELL BIOCHEM FUNCT, V17, P279, DOI 10.1002/(SICI)1099-0844(199912)17:4<279::AID-CBF833>3.0.CO;2-J; Semba RD, 2005, ARCH INTERN MED, V165, P2229, DOI 10.1001/archinte.165.19.2229; Semba RD, 2002, CLIN INFECT DIS, V34, P260, DOI 10.1086/338151; Sullivan PS, 1998, BLOOD, V91, P301, DOI 10.1182/blood.V91.1.301.301_301_308; World Health Organization, 1992, WHOMCHMSM922, V2nd; Zhou J, 2005, HIV MED, V6, P216, DOI 10.1111/j.1468-1293.2005.00292.x	19	12	12	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1626	10.1371/journal.pone.0001626	http://dx.doi.org/10.1371/journal.pone.0001626			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286183	Green Accepted, Green Published, gold			2022-12-25	WOS:000260586400019
J	Takeuchi, Y; Myers, R; Danos, O				Takeuchi, Yasuhiro; Myers, Richard; Danos, Olivier			Recombination and Population Mosaic of a Multifunctional Viral Gene, Adeno-Associated Virus cap	PLOS ONE			English	Article								Homologous recombination is a dominant force in evolution and results in genetic mosaics. To detect evidence of recombination events and assess the biological significance of genetic mosaics, genome sequences for various viral populations of reasonably large size are now available in the GenBank. We studied a multi-functional viral gene, the adeno-associated virus (AAV) cap gene, which codes for three capsid proteins, VP1, VP2 and VP3. VP1-3 share a common C-terminal domain corresponding to VP3, which forms the viral core structure, while the VP1 unique N-terminal part contains an enzymatic domain with phospholipase A2 activity. Our recombinant detection program (RecI) revealed five novel recombination events, four of which have their cross-over points in the N-terminal, VP1 and VP2 unique region. Comparison of phylogenetic trees for different cap gene regions confirmed discordant phylogenies for the recombinant sequences. Furthermore, differences in the phylogenetic tree structures for the VP1 unique (VP1u) region and the rest of cap highlighted the mosaic nature of cap gene in the AAV population: two dominant forms of VP1u sequences were identified and these forms are linked to diverse sequences in the rest of cap gene. This observation together with the finding of frequent recombination in the VP1 and 2 unique regions suggests that this region is a recombination hot spot. Recombination events in this region preserve protein blocks of distinctive functions and contribute to convergence in VP1u and divergence of the rest of cap. Additionally the possible biological significance of two dominant VP1u forms is inferred.	[Takeuchi, Yasuhiro; Myers, Richard; Danos, Olivier] UCL, MRC, UCL Ctr Med Mol Virol, Div Infect & Immunol, London, England; [Myers, Richard] Hlth Protect Agcy, Ctr Infect, London, England; [Danos, Olivier] Hop Necker Enfants Malad, INSERM, U781, Inst Fed Rech Necker Enfants Malad IFR 94, Paris, France	University of London; University College London; Health Protection Agency; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Takeuchi, Y (corresponding author), UCL, MRC, UCL Ctr Med Mol Virol, Div Infect & Immunol, London, England.	y.takeuchi@ucl.ac.uk	Takeuchi, Yasuhiro/C-1640-2008		UCL Clinical Research and Development Committee	UCL Clinical Research and Development Committee	This work was funded by UCL Clinical Research and Development Committee. This sponsor played no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript.	Bartosch B, 2004, J VIROL, V78, P13880, DOI 10.1128/JVI.78.24.13880-13890.2004; Chen CL, 2005, J VIROL, V79, P14781, DOI 10.1128/JVI.79.23.14781-14792.2005; deSouza SJ, 1996, P NATL ACAD SCI USA, V93, P14632, DOI 10.1073/pnas.93.25.14632; Erles K, 1999, J MED VIROL, V59, P406, DOI 10.1002/(SICI)1096-9071(199911)59:3&lt;406::AID-JMV22&gt;3.0.CO;2-N; Gao GP, 2003, P NATL ACAD SCI USA, V100, P6081, DOI 10.1073/pnas.0937739100; Gao GP, 2004, J VIROL, V78, P6381, DOI 10.1128/JVI.78.12.6381-6388.2004; Gilbert W, 1997, P NATL ACAD SCI USA, V94, P7698, DOI 10.1073/pnas.94.15.7698; Grieger JC, 2007, J VIROL, V81, P7833, DOI 10.1128/JVI.00580-07; Grieger JC, 2006, J VIROL, V80, P5199, DOI 10.1128/JVI.02723-05; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Hueffer K, 2003, CURR OPIN MICROBIOL, V6, P392, DOI 10.1016/S1369-5274(03)00083-3; Kohlbrenner E, 2005, MOL THER, V12, P1217, DOI 10.1016/j.ymthe.2005.08.018; Kronenberg S, 2005, J VIROL, V79, P5296, DOI 10.1128/JVI.79.9.5296-5303.2005; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Raj K, 2001, NATURE, V412, P914, DOI 10.1038/35091082; Shackelton LA, 2005, P NATL ACAD SCI USA, V102, P379, DOI 10.1073/pnas.0406765102; Sonntag F, 2006, J VIROL, V80, P11040, DOI 10.1128/JVI.01056-06; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Voigt CA, 2002, NAT STRUCT BIOL, V9, P553, DOI 10.1038/nsb805; Weitzman MD, 1996, J VIROL, V70, P1845, DOI 10.1128/JVI.70.3.1845-1854.1996; Wu ZJ, 2006, MOL THER, V14, P316, DOI 10.1016/j.ymthe.2006.05.009; Xiao WD, 1999, J VIROL, V73, P3994, DOI 10.1128/JVI.73.5.3994-4003.1999; Xie Q, 2002, P NATL ACAD SCI USA, V99, P10405, DOI 10.1073/pnas.162250899; YALKINOGLU AO, 1988, CANCER RES, V48, P3123; Yan ZY, 2005, J VIROL, V79, P364, DOI 10.1128/JVI.79.1.364-379.2005; Zadori Z, 2001, DEV CELL, V1, P291, DOI 10.1016/S1534-5807(01)00031-4; Zentilin L, 2001, J VIROL, V75, P12279, DOI 10.1128/JVI.75.24.12279-12287.2001	27	8	8	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1634	10.1371/journal.pone.0001634	http://dx.doi.org/10.1371/journal.pone.0001634			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286191	gold, Green Published, Green Submitted			2022-12-25	WOS:000260586400027
J	Ochsenreiter, T; Cipriano, M; Hajduk, SL				Ochsenreiter, Torsten; Cipriano, Michael; Hajduk, Stephen L.			Alternative mRNA Editing in Trypanosomes Is Extensive and May Contribute to Mitochondrial Protein Diversity	PLOS ONE			English	Article								The editing of trypanosome mitochondrial mRNAs produces transcripts necessary for mitochondrial functions including electron transport and oxidative phosphorylation. Precursor-mRNAs are often extensively edited by specific uridine insertion or deletion that is directed by small guide RNAs (gRNAs). Recently, it has been shown that cytochrome c oxidase subunit III (COXIII) mRNAs can be alternatively edited to encode a novel mitochondrial membrane protein composed of a unique hydrophilic N-terminal sequence of unknown function and the C-terminal hydrophobic segment of COXIII. To extend the analysis of alternative editing in Trypanosoma brucei we have constructed libraries with over 1100 full-length mitochondrial cDNAs and the sequences of over 1200 gRNA genes. Using this data, we show that alternative editing of COXIII, ATPase subunit 6 (A6), and NADH dehydrogenase subunits 7, 8 and 9 (ND7, 8, 9) mRNAs can produce novel open reading frames (ORFs). Several gRNAs potentially responsible for the alternative editing of these mRNAs were also identified. These findings show that alternative editing of mitochondrial mRNAs is common in T. brucei and expands the diversity of mitochondrial proteins in these organisms.	[Ochsenreiter, Torsten; Hajduk, Stephen L.] Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; [Cipriano, Michael] Univ Calif Davis, Dept Med Microbiol, Davis, CA USA	University System of Georgia; University of Georgia; University of California System; University of California Davis	Ochsenreiter, T (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA.	shajduk@bmb.uga.edu	Ochsenreiter, Torsten/E-6040-2010	Cipriano, Michael/0000-0001-8163-8812	National Institutes of Health [AI21401]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021401, R21AI021401] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by a grant from the National Institutes of Health (AI21401).	ABRAHAM JM, 1988, CELL, V55, P267, DOI 10.1016/0092-8674(88)90049-9; ALDRITT SM, 1989, MOL CELL BIOL, V9, P3614, DOI 10.1128/MCB.9.9.3614; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; Chang KJ, 2004, J BIOL CHEM, V279, P13778, DOI 10.1074/jbc.M311269200; Chaudhuri M, 2006, TRENDS PARASITOL, V22, P484, DOI 10.1016/j.pt.2006.08.007; CORELL RA, 1993, NUCLEIC ACIDS RES, V21, P4313, DOI 10.1093/nar/21.18.4313; DECKER CJ, 1990, CELL, V61, P1001, DOI 10.1016/0092-8674(90)90065-M; Edqvist J, 2000, J MOL BIOL, V297, P381, DOI 10.1006/jmbi.2000.3530; Fang J, 2001, EUR J BIOCHEM, V268, P3075, DOI 10.1046/j.1432-1327.2001.02205.x; FEAGIN JE, 1988, CELL, V53, P413, DOI 10.1016/0092-8674(88)90161-4; Kabat JL, 2006, PLOS COMPUT BIOL, V2, P734, DOI 10.1371/journal.pcbi.0020086; KOSLOWSKY DJ, 1992, MOL CELL BIOL, V12, P2043, DOI 10.1128/MCB.12.5.2043; KOSLOWSKY DJ, 1990, CELL, V62, P901, DOI 10.1016/0092-8674(90)90265-G; LANDWEBER LF, 1993, NATURE, V363, P179, DOI 10.1038/363179a0; Liu BY, 2005, TRENDS PARASITOL, V21, P363, DOI 10.1016/j.pt.2005.06.008; Lukes J, 2005, CURR GENET, V48, P277, DOI 10.1007/s00294-005-0027-0; Madison-Antenucci S, 2002, CELL, V108, P435, DOI 10.1016/S0092-8674(02)00653-0; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; Matthews KR, 2005, J CELL SCI, V118, P283, DOI 10.1242/jcs.01649; OCHSENREITER T, 2007, NUCL ACIDS MOL BIOL; Ochsenreiter T, 2007, RNA, V13, P1, DOI 10.1261/rna.232907; Ochsenreiter T, 2006, EMBO REP, V7, P1128, DOI 10.1038/sj.embor.7400817; Ogbadoyi EO, 2003, MOL BIOL CELL, V14, P1769, DOI 10.1091/mbc.E02-08-0525; READ LK, 1994, MOL BIOCHEM PARASIT, V68, P297, DOI 10.1016/0166-6851(94)90174-0; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; RILEY GR, 1995, NUCLEIC ACIDS RES, V23, P708, DOI 10.1093/nar/23.4.708; Simpson L, 2003, RNA, V9, P265, DOI 10.1261/rna.2178403; Stamm S, 2005, GENE, V344, P1, DOI 10.1016/j.gene.2004.10.022; Stuart KD, 2005, TRENDS BIOCHEM SCI, V30, P97, DOI 10.1016/j.tibs.2004.12.006; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M	30	47	47	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1566	10.1371/journal.pone.0001566	http://dx.doi.org/10.1371/journal.pone.0001566			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270563	Green Published, Green Submitted, gold			2022-12-25	WOS:000260535900008
J	Zheng, L; Wayper, PJ; Gibbs, AJ; Fourment, M; Rodoni, BC; Gibbs, MJ				Zheng, Linda; Wayper, Paul J.; Gibbs, Adrian J.; Fourment, Mathieu; Rodoni, Brendan C.; Gibbs, Mark J.			Accumulating Variation at Conserved Sites in Potyvirus Genomes Is Driven by Species Discovery and Affects Degenerate Primer Design	PLOS ONE			English	Article								Unknown and foreign viruses can be detected using degenerate primers targeted at conserved sites in the known viral gene sequences. Conserved sites are found by comparing sequences and so the usefulness of a set of primers depends crucially on how well the known sequences represent the target group including unknown sequences. Methodology/Principal Findings: We developed a method for assessing the apparent stability of consensus sequences at sites over time using deposition dates from Genbank. We tested the method using 17 conserved sites in potyvirus genomes. The accumulation of knowledge of sequence variants over 20 years caused 'consensus decay' of the sites. Rates of decay were rapid at all sites but varied widely and as a result, the ranking of the most conserved sites changed. The discovery and reporting of sequences from previously unknown and distinct species, rather than from strains of known species, dominated the decay, indicating it was largely a sampling effect related to the progressive discovery of species, and recent virus mutation was probably only a minor contributing factor. Conclusion/Significance: We showed that in the past, the sampling bias has misled the choice of the most conserved target sites for genus specific degenerate primers. The history of sequence discoveries indicates primer designs should be updated regularly and provides an additional dimension for improving the design of degenerate primers.	[Zheng, Linda; Wayper, Paul J.; Gibbs, Mark J.] Australian Natl Univ, Sch Bot & Zool, Canberra, ACT, Australia; [Fourment, Mathieu] Macquarie Univ, Dept Biol Sci, Sydney, NSW, Australia; [Rodoni, Brendan C.] Dept Primary Ind, Knoxfield, Victoria, Australia	Australian National University; Macquarie University	Zheng, L (corresponding author), Australian Natl Univ, Sch Bot & Zool, Canberra, ACT, Australia.	linda.zheng@anu.edu.au	Fourment, Mathieu/E-4665-2012	Fourment, Mathieu/0000-0001-8153-9822	Victorian State Government of The Commenwealth of Australia	Victorian State Government of The Commenwealth of Australia	This work is part of my PhD program which was supported by the Department of Primary Industries ("Our Rural Landscape") funded by the Victorian State Government of The Commenwealth of Australia. The funders of this study had no role in the design or conduct of this study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript.	Adams MJ, 2005, ARCH VIROL, V150, P459, DOI 10.1007/s00705-004-0440-6; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; [Anonymous], 1994, POTYVIRIDAE; Biebricher CK, 2006, CURR TOP MICROBIOL, V299, P1; Chen J, 2001, ARCH VIROL, V146, P757, DOI 10.1007/s007050170144; COLINET D, 1993, J VIROL METHODS, V45, P149, DOI 10.1016/0166-0934(93)90099-D; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Fauquet CM, 2005, VIRUS TAXONOMY 8 REP; French R, 2005, VIROLOGY, V343, P179, DOI 10.1016/j.virol.2005.08.037; Fuji S, 2003, ARCH VIROL, V148, P2249, DOI 10.1007/s00705-003-0169-7; Fuji S, 2003, ARCH VIROL, V148, P613, DOI 10.1007/s00705-002-0961-9; Garcia-Arenal F, 2001, ANNU REV PHYTOPATHOL, V39, P157, DOI 10.1146/annurev.phyto.39.1.157; Gibbs A, 1997, J VIROL METHODS, V63, P9, DOI 10.1016/S0166-0934(96)02103-9; Gibbs A, 1998, J VIROL METHODS, V74, P67, DOI 10.1016/S0166-0934(98)00070-6; Hall JS, 2001, VIROLOGY, V282, P230, DOI 10.1006/viro.2001.0841; Hall JS, 2001, J VIROL, V75, P10231, DOI 10.1128/JVI.75.21.10231-10243.2001; Hall T., 2005, BIOEDIT BIOL SEQUENC; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; LANGEVELD SA, 1991, J GEN VIROL, V72, P1531, DOI 10.1099/0022-1317-72-7-1531; NICOLAS O, 1991, J VIROL METHODS, V32, P57, DOI 10.1016/0166-0934(91)90185-3; PAPPU SS, 1993, J VIROL METHODS, V41, P9, DOI 10.1016/0166-0934(93)90158-N; Shannon C., 1949, MATH THEORY COMMUNIC, P379; Zanotto PMD, 1996, J VIROL, V70, P6083, DOI 10.1128/JVI.70.9.6083-6096.1996	23	36	41	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1586	10.1371/journal.pone.0001586	http://dx.doi.org/10.1371/journal.pone.0001586			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270574	Green Published, gold			2022-12-25	WOS:000260535900020
J	Engbert, R; Nuthmann, A				Engbert, Ralf; Nuthmann, Antje			Self-Consistent Estimation of Mislocated Fixations during Reading	PLOS ONE			English	Article							EYE-MOVEMENTS; SACCADE GENERATION; DYNAMICAL MODEL; INFORMATION; POSITIONS; TRACKING; WORDS; MIND	During reading, we generate saccadic eye movements to move words into the center of the visual field for word processing. However, due to systematic and random errors in the oculomotor system, distributions of within-word landing positions are rather broad and show overlapping tails, which suggests that a fraction of fixations is mislocated and falls on words to the left or right of the selected target word. Here we propose a new procedure for the self-consistent estimation of the likelihood of mislocated fixations in normal reading. Our approach is based on iterative computation of the proportions of several types of oculomotor errors, the underlying probabilities for word-targeting, and corrected distributions of landing positions. We found that the average fraction of mislocated fixations ranges from about 10% to more than 30% depending on word length. These results show that fixation probabilities are strongly affected by oculomotor errors.	[Engbert, Ralf; Nuthmann, Antje] Univ Potsdam, Dept Psychol, Potsdam, Germany	University of Potsdam	Engbert, R (corresponding author), Univ Potsdam, Dept Psychol, Potsdam, Germany.	Ralf.Engbert@uni-potsdam.de	Engbert, Ralf/AAC-4860-2020	Engbert, Ralf/0000-0002-2909-5811; Nuthmann, Antje/0000-0003-3338-3434	Deutsche Forschungsgemeinschaft [EN 471/2-1, KL 955/6-1, KL 955/14-1]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported by Deutsche Forschungsgemeinschaft (grants EN 471/2-1, KL 955/6-1, and KL 955/14-1).	Binder KS, 1999, J EXP PSYCHOL HUMAN, V25, P1162, DOI 10.1037/0096-1523.25.4.1162; Brysbaert M., 2005, COGNITIVE PROCESS, V16, P53, DOI DOI 10.1093/ACPROF:OSO/9780198566816.003.0003; Deubel H, 1996, VISION RES, V36, P1827, DOI 10.1016/0042-6989(95)00294-4; Drieghe D, 2008, Q J EXP PSYCHOL, V61, P1239, DOI 10.1080/17470210701467953; Engbert R, 2005, PSYCHOL REV, V112, P777, DOI 10.1037/0033-295X.112.4.777; Engbert R, 2002, VISION RES, V42, P621, DOI 10.1016/S0042-6989(01)00301-7; Engbert Ralf, 2007, P319, DOI 10.1016/B978-008044980-7/50016-1; Kliegl R, 2006, J EXP PSYCHOL GEN, V135, P12, DOI 10.1037/0096-3445.135.1.12; Kliegl R, 2004, EUR J COGN PSYCHOL, V16, P262, DOI 10.1080/09541440340000213; Kliegl R, 2007, J EXP PSYCHOL GEN, V136, P530, DOI 10.1037/0096-3445.136.3.530; MCCONKIE GW, 1988, VISION RES, V46, P245; Nuthmann A, 2005, VISION RES, V45, P2201, DOI 10.1016/j.visres.2005.02.014; NUTHMANN A, 2006, THESIS U POTSDAM GER; Nuthmann A, 2007, VISION RES, V47, P990, DOI 10.1016/j.visres.2006.11.005; Rayner K, 1998, PSYCHOL BULL, V124, P372, DOI 10.1037/0033-2909.124.3.372; RAYNER K, 1979, PERCEPTION, V8, P21, DOI 10.1068/p080021; RAYNER K, 2004, LEARN MEM COGN, V6, P1290; Rayner K, 2007, J EXP PSYCHOL GEN, V136, P520, DOI 10.1037/0096-3445.136.3.520; Reichle ED, 2003, BEHAV BRAIN SCI, V26, P445, DOI 10.1017/S0140525X03000104; Reichle ED, 1998, PSYCHOL REV, V105, P125, DOI 10.1037/0033-295X.105.1.125; Trukenbrod HA, 2007, VISION RES, V47, P2426, DOI 10.1016/j.visres.2007.05.010; Vitu F, 2001, VISION RES, V41, P3513, DOI 10.1016/S0042-6989(01)00166-3; White SJ, 2006, Q J EXP PSYCHOL, V59, P760, DOI 10.1080/02724980543000024; White SJ, 2006, VISION RES, V46, P426, DOI 10.1016/j.visres.2005.07.006; White SJ, 2004, EUR J COGN PSYCHOL, V16, P52, DOI 10.1080/09541440340000204	25	26	27	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2008	3	2							e1534	10.1371/journal.pone.0001534	http://dx.doi.org/10.1371/journal.pone.0001534			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	367EQ	18253482	Green Published, gold, Green Submitted			2022-12-25	WOS:000260535700006
J	Hiss, JA; Przyborski, JM; Schwarte, F; Lingelbach, K; Schneider, G				Hiss, Jan Alexander; Przyborski, Jude Marek; Schwarte, Florian; Lingelbach, Klaus; Schneider, Gisbert			The Plasmodium Export Element Revisited	PLOS ONE			English	Article							MALARIA PARASITE; VARIANT PROTEINS; FALCIPARUM; SIGNAL; TRAFFICKING; FAMILY; SURFACE; CYTOADHERENCE; EXPRESSION; PREDICTION	We performed a bioinformatical analysis of protein export elements (PEXEL) in the putative proteome of the malaria parasite Plasmodium falciparum. A protein family-specific conservation of physicochemical residue profiles was found for PEXEL-flanking sequence regions. We demonstrate that the family members can be clustered based on the flanking regions only and display characteristic hydrophobicity patterns. This raises the possibility that the flanking regions may contain additional information for a family-specific role of PEXEL. We further show that signal peptide cleavage results in a positional alignment of PEXEL from both proteins with, and without, a signal peptide.	[Hiss, Jan Alexander; Schwarte, Florian; Schneider, Gisbert] Goethe Univ Frankfurt, Inst Cell Biol & Neurosci, Ctr Membrane Prote, Frankfurt, Germany; [Przyborski, Jude Marek; Lingelbach, Klaus] Univ Marburg, Fac Biol, Marburg, Germany	Goethe University Frankfurt; Philipps University Marburg	Hiss, JA (corresponding author), Goethe Univ Frankfurt, Inst Cell Biol & Neurosci, Ctr Membrane Prote, Frankfurt, Germany.	hiss@bioinformatik.uni-frankfurt.de	Przyborski, Jude/ABC-9498-2021	Przyborski, Jude/0000-0002-3494-7767; Hiss, Jan Alexander/0000-0003-0559-4330; Schneider, Gisbert/0000-0001-6706-1084	Beilstein-Institut zur Forderung der Chemischen Wissenschaften; Centre for Membrane Proteomics at Goethe-University, Frankfurt am Main; DFG priority program [1131]	Beilstein-Institut zur Forderung der Chemischen Wissenschaften; Centre for Membrane Proteomics at Goethe-University, Frankfurt am Main; DFG priority program(German Research Foundation (DFG))	This research was supported by the Beilstein-Institut zur Forderung der Chemischen Wissenschaften, and the Centre for Membrane Proteomics at Goethe-University, Frankfurt am Main. J.M.P is supported by the DFG priority program (SPP) 1131.	Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ansorge I, 1996, BIOCHEM J, V315, P307, DOI 10.1042/bj3150307; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; Baumeister S, 1999, Novartis Found Symp, V226, P145; BAUMEISTER S, 1999, NOVART FDN SYMP, V226, P154; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; BENTING J, 1994, BIOCHEM J, V300, P821, DOI 10.1042/bj3000821; Cheng Q, 1998, MOL BIOCHEM PARASIT, V97, P161, DOI 10.1016/S0166-6851(98)00144-3; CHOTHIA C, 1975, NATURE, V254, P304, DOI 10.1038/254304a0; Cochrane G, 2006, NUCLEIC ACIDS RES, V34, pD10, DOI 10.1093/nar/gkj130; Cooke BM, 2004, TRENDS PARASITOL, V20, P581, DOI 10.1016/j.pt.2004.09.008; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Hegde RS, 2006, TRENDS BIOCHEM SCI, V31, P563, DOI 10.1016/j.tibs.2006.08.004; HENIKOFF S, 1993, PROTEINS, V17, P49, DOI 10.1002/prot.340170108; Hiller NL, 2004, SCIENCE, V306, P1934, DOI 10.1126/science.1102737; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Joannin N, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-19; JONES DD, 1975, J THEOR BIOL, V50, P167, DOI 10.1016/0022-5193(75)90031-4; Knuepfer E, 2005, MOL BIOCHEM PARASIT, V142, P258, DOI 10.1016/j.molbiopara.2005.04.005; KOHONEN T, 1982, BIOL CYBERN, V43, P59, DOI 10.1007/BF00337288; Kyes SA, 1999, P NATL ACAD SCI USA, V96, P9333, DOI 10.1073/pnas.96.16.9333; Marti M, 2005, J CELL BIOL, V171, P587, DOI 10.1083/jcb.200508051; Marti M, 2004, SCIENCE, V306, P1930, DOI 10.1126/science.1102452; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; NIELSEN H, 1998, P 6 INT C INT SYST M, P122; Nunes MC, 2007, MOL MICROBIOL, V63, P391, DOI 10.1111/j.1365-2958.2006.05521.x; Petter M, 2007, MOL BIOCHEM PARASIT, V156, P51, DOI 10.1016/j.molbiopara.2007.07.011; Przyborski JM, 2005, EMBO J, V24, P2306, DOI 10.1038/sj.emboj.7600720; Ralph SA, 2004, MOL BIOL EVOL, V21, P2183, DOI 10.1093/molbev/msh233; Rug M, 2004, INFECT IMMUN, V72, P6095, DOI 10.1128/IAI.72.10.6095-6105.2004; Sargeant TJ, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-2-r12; Sargent F, 2006, FEMS MICROBIOL LETT, V254, P198, DOI 10.1111/j.1574-6968.2005.00049.x; Schmuker M, 2007, J MOL MODEL, V13, P225, DOI 10.1007/s00894-006-0140-0; SCHNEIDER G, 1993, J MOL EVOL, V36, P586, DOI 10.1007/BF00556363; Schneider G, 1999, GENE, V237, P113, DOI 10.1016/S0378-1119(99)00310-8; Shanmugham A, 2006, BIOCHEMISTRY-US, V45, P2243, DOI 10.1021/bi052188a; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; Stoeckert CJ, 2006, TRENDS PARASITOL, V22, P543, DOI 10.1016/j.pt.2006.09.005; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; Wickham ME, 2001, EMBO J, V20, P5636, DOI 10.1093/emboj/20.20.5636; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3; Zuegge J, 2001, J MOL GRAPH MODEL, V19, P304, DOI 10.1016/S1093-3263(00)00074-7	43	19	21	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2008	3	2							e1560	10.1371/journal.pone.0001560	http://dx.doi.org/10.1371/journal.pone.0001560			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367EQ	18253504	Green Published, gold, Green Submitted			2022-12-25	WOS:000260535700028
J	Gardiner, A; Barker, D; Butlin, RK; Jordan, WC; Ritchie, MG				Gardiner, Anastasia; Barker, Daniel; Butlin, Roger K.; Jordan, William C.; Ritchie, Michael G.			Evolution of a Complex Locus: Exon Gain, Loss and Divergence at the Gr39a Locus in Drosophila	PLOS ONE			English	Article								Background. Gene families typically evolve by gene duplication followed by the adoption of new or altered gene functions. A different way to evolve new but related functions is alternative splicing of existing exons of a complex gene. The chemosensory gene families of animals are characterised by numerous loci of related function. Alternative splicing has only rarely been reported in chemosensory loci, for example in 5 out of around 120 loci in Drosophila melanogaster. The gustatory receptor gene Gr39a has four large exons that are alternatively spliced with three small conserved exons. Recently the genome sequences of eleven additional species of Drosophila have become available allowing us to examine variation in the structure of the Gr39a locus across a wide phylogenetic range of fly species. Methodology/Principal Findings. We describe a fifth exon and show that the locus has a complex evolutionary history with several duplications, pseudogenisations and losses of exons. PAML analyses suggested that the whole gene has a history of purifying selection, although this was less strong in exons which underwent duplication. Conclusions/Significance. Estimates of functional divergence between exons were similar in magnitude to functional divergence between duplicated genes, suggesting that exon divergence is broadly equivalent to gene duplication.	[Gardiner, Anastasia; Barker, Daniel; Ritchie, Michael G.] Univ St Andrews, Sch Biol, St Andrews, Fife, Scotland; [Butlin, Roger K.] Univ Sheffield, Dept Animal & Plant Sci, Sheffield, S Yorkshire, England; [Jordan, William C.] Zool Soc London, Inst Zool, London, England	University of St Andrews; University of Sheffield; Zoological Society of London	Gardiner, A (corresponding author), Univ St Andrews, Sch Biol, St Andrews, Fife, Scotland.	ag91@st-andrews.ac.uk	Butlin, Roger K/F-7709-2013; Ritchie, Michael G/F-7055-2013	Butlin, Roger K/0000-0003-4736-0954; Ritchie, Michael G/0000-0001-7913-8675	Natural Environment Research Council UK [NE/C003187/1]; Research Councils UK [Academic Fellowship]; Natural Environment Research Council [NE/C003187/1] Funding Source: researchfish; NERC [NE/C003187/1] Funding Source: UKRI	Natural Environment Research Council UK(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Research Councils UK(UK Research & Innovation (UKRI)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	This work was supported by the Natural Environment Research Council UK, grant NE/C003187/1. DB was supported by a Research Councils UK Academic Fellowship.	Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amrein H, 2004, CURR OPIN NEUROBIOL, V14, P435, DOI 10.1016/j.conb.2004.07.008; Birney E, 2004, GENOME RES, V14, P988, DOI 10.1101/gr.1865504; Clark AG, 2007, NATURE, V450, P203, DOI 10.1038/nature06341; Clyne PJ, 2000, SCIENCE, V287, P1830, DOI 10.1126/science.287.5459.1830; COX DR, 1962, J ROY STAT SOC B, V24, P406; Durand D, 2006, J COMPUT BIOL, V13, P320, DOI 10.1089/cmb.2006.13.320; Fox AN, 2001, P NATL ACAD SCI USA, V98, P14693, DOI 10.1073/pnas.261432998; GARDINER A, 2007, MOL ECOLOGY UNPUB; Gu X, 1999, MOL BIOL EVOL, V16, P1664, DOI 10.1093/oxfordjournals.molbev.a026080; Gu X, 2003, GENETICA, V118, P133, DOI 10.1023/A:1024197424306; Gu X, 2001, J COMPUT BIOL, V8, P221, DOI 10.1089/10665270152530827; Guo S, 2007, MOL BIOL EVOL, V24, P1198, DOI 10.1093/molbev/msm038; Hallem EA, 2004, TRENDS GENET, V20, P453, DOI 10.1016/j.tig.2004.06.015; Hill CA, 2002, SCIENCE, V298, P176, DOI 10.1126/science.1076196; HUGHES AL, 1994, P ROY SOC B-BIOL SCI, V256, P119, DOI 10.1098/rspb.1994.0058; Kondrashov FA, 2001, HUM MOL GENET, V10, P2661, DOI 10.1093/hmg/10.23.2661; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Letunic I, 2002, HUM MOL GENET, V11, P1561, DOI 10.1093/hmg/11.13.1561; Lynch M, 2000, GENETICS, V154, P459; McBride CS, 2007, GENETICS, V177, P1395, DOI 10.1534/genetics.107.078683; Nozawa M, 2007, P NATL ACAD SCI USA, V104, P7122, DOI 10.1073/pnas.0702133104; Ohno S., 1970, EVOLUTION GENE DUPLI; Pagel M, 2004, SYST BIOL, V53, P673, DOI 10.1080/10635150490522232; Proulx SR, 2006, EVOLUTION, V60, P881; Robertson HM, 2003, P NATL ACAD SCI USA, V100, P14537, DOI 10.1073/pnas.2335847100; Robertson HM, 2006, GENOME RES, V16, P1395, DOI 10.1101/gr.5057506; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; RUSSO CAM, 1995, MOL BIOL EVOL, V12, P391; Talavera D, 2007, PLOS COMPUT BIOL, V3, P375, DOI 10.1371/journal.pcbi.0030033; Tamura K, 2004, MOL BIOL EVOL, V21, P36, DOI 10.1093/molbev/msg236; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555; Yang ZH, 2000, TRENDS ECOL EVOL, V15, P496, DOI 10.1016/S0169-5347(00)01994-7	35	15	15	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1513	10.1371/journal.pone.0001513	http://dx.doi.org/10.1371/journal.pone.0001513			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SR	18231599	Green Published, Green Accepted, gold			2022-12-25	WOS:000260504200025
J	Shorter, K; Farjo, NP; Picksley, SM; Randall, VA				Shorter, Katie; Farjo, Nilofer P.; Picksley, Steven M.; Randall, Valerie A.			Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil	FASEB JOURNAL			English	Article						alopecia; hirsutism; tolbutamide; sulfonylurea receptors SUR1 and SUR2B	DERMAL PAPILLA CELLS; 2-PERCENT TOPICAL MINOXIDIL; ANDROGENETIC ALOPECIA; ORGAN-CULTURE; GROWTH-FACTOR; FOLLOW-UP; IN-VITRO; SULFONYLUREA; EXPRESSION; OPENERS	Hair disorders cause psychological distress but are generally poorly controlled; more effective treatments are required. Despite the long-standing use of minoxidil for balding, its mechanism is unclear; suggestions include action on vasculature or follicle cells. Similar drugs also stimulate hair, implicating ATP-sensitive potassium (KATP) channels. To investigate whether KATP channels are present in human follicles, we used organ culture, molecular biological, and immunohistological approaches. Minoxidil and tolbutamide, a KATP channel blocker, opposed each other's effects on the growing phase (anagen) of scalp follicles cultured in media with and without insulin. Reverse transcriptase-polymerase chain reaction identified KATP channel component gene expression including regulatory sulfonylurea receptors (SUR) SUR1 and SUR2B but not SUR2A and pore-forming subunits (Kir) Kir6.1 and Kir6.2. When hair bulb tissues were examined separately, epithelial matrix expressed SUR1 and Kir6.2, whereas both dermal papilla and sheath exhibited SUR2B and Kir6.1. Immunohistochemistry demonstrated similar protein distributions. Thus, human follicles respond biologically to KATP channel regulators in culture and express genes and proteins for two KATP channels, Kir6.2/SUR1 and Kir6.1/ SUR2B; minoxidil only stimulates SUR2 channels. These findings indicate that human follicular dermal papillae contain KATP channels that can respond to minoxidil and that tolbutamide may suppress hair growth clinically; novel drugs designed specifically for these channels could treat hair disorders.	[Shorter, Katie; Picksley, Steven M.; Randall, Valerie A.] Univ Bradford, Dept Biomed Sci, Bradford BD7 1DP, W Yorkshire, England; [Farjo, Nilofer P.] Farjo Med Ctr, Manchester, Lancs, England	University of Bradford	Randall, VA (corresponding author), Univ Bradford, Dept Biomed Sci, Bradford BD7 1DP, W Yorkshire, England.	v.a.randall@bradford.ac.uk						Ashcroft FM, 2000, TRENDS PHARMACOL SCI, V21, P439; Ashcroft FM, 2006, NATURE, V440, P440, DOI 10.1038/nature04707; Boyera N, 1997, SKIN PHARMACOL, V10, P206, DOI 10.1159/000211506; BUHL AE, 1993, J INVEST DERMATOL, V101, pS148, DOI 10.1111/1523-1747.ep12363290; BUHL AE, 1989, J INVEST DERMATOL, V92, P315, DOI 10.1111/1523-1747.ep12277095; BUNKER CB, 1987, BRIT J DERMATOL, V140, P294; BURTON JL, 1979, BRIT J DERMATOL, V101, P593, DOI 10.1111/j.1365-2133.1979.tb15106.x; CHADHURY S, 2001, J PROJ PSYCHOL MENT, V8, P143; CROFT NJ, 2003, HAIR SCI TECHNOLOGY, P69; Curley M, 2002, MOL HUM REPROD, V8, P941, DOI 10.1093/molehr/8.10.941; Dabrowski M, 2003, DIABETOLOGIA, V46, P1375, DOI 10.1007/s00125-003-1198-1; Davies GC, 2005, J INVEST DERMATOL, V124, P686, DOI 10.1111/j.0022-202X.2005.23643.x; Davis-Taber R, 2000, GENE, V256, P261, DOI 10.1016/S0378-1119(00)00338-3; Dorschner H, 1999, MOL PHARMACOL, V55, P1060; EDWARDS G, 1990, PHARMACOL THERAPEUT, V48, P237, DOI 10.1016/0163-7258(90)90082-D; Girman CJ, 1998, DERMATOLOGY, V197, P223, DOI 10.1159/000018001; GOLDBERG MR, 1988, J CARDIOVASC PHARM, V12, pS41, DOI 10.1097/00005344-198812002-00008; Han JH, 2004, J DERMATOL SCI, V34, P91, DOI 10.1016/j.jdermsci.2004.01.002; Hansen JB, 2006, CURR MED CHEM, V13, P361, DOI 10.2174/092986706775527947; IMAI R, 1993, ARCH DERMATOL RES, V284, P466, DOI 10.1007/BF00373358; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; Jahangir A, 2005, J MOL CELL CARDIOL, V39, P99, DOI 10.1016/j.yjmcc.2005.04.006; KLIGMAN AM, 1959, J INVEST DERMATOL, V33, P307, DOI 10.1038/jid.1959.156; KOBLENZER PJ, 1968, ANN NY ACAD SCI, V150, P373, DOI 10.1111/j.1749-6632.1968.tb19062.x; Kwon OS, 2006, ARCH DERMATOL RES, V297, P367, DOI 10.1007/s00403-005-0619-z; Kym PR, 1996, J MED CHEM, V39, P4897, DOI 10.1021/jm960300k; Lachgar S, 1998, BRIT J DERMATOL, V138, P407; Li M, 2001, J INVEST DERMATOL, V117, P1594, DOI 10.1046/j.0022-202x.2001.01570.x; LITT JZ, 2007, LITTS DRUG ERUPTION; Magerl M, 2004, EXP DERMATOL, V13, P635, DOI 10.1111/j.0906-6705.2004.00207.x; Malester B, 2007, FASEB J, V21, P2162, DOI 10.1096/fj.06-7821com; MEISHERI KD, 1993, BIOCHEM PHARMACOL, V45, P271, DOI 10.1016/0006-2952(93)90061-Z; Messenger AG, 2004, BRIT J DERMATOL, V150, P186, DOI 10.1111/j.1365-2133.2004.05785.x; Nagashima K, 2004, DIABETES RES CLIN PR, V66, pS75, DOI 10.1016/j.diabres.2003.12.011; Nakaya Y, 1994, J Dermatol Sci, V7 Suppl, pS104, DOI 10.1016/0923-1811(94)90041-8; Nichols CG, 2006, NATURE, V440, P470, DOI 10.1038/nature04711; OLSEN EA, 1990, J AM ACAD DERMATOL, V22, P643, DOI 10.1016/0190-9622(90)70089-Z; Olsen EA, 2002, J AM ACAD DERMATOL, V47, P377, DOI 10.1067/mjd.2002.124088; OLSEN EA, 1987, J AM ACAD DERMATOL, V16, P688, DOI 10.1016/S0190-9622(87)70089-9; Philpott MP, 1996, DERMATOL CLIN, V14, P595, DOI 10.1016/S0733-8635(05)70387-9; PHILPOTT MP, 1991, ANN NY ACAD SCI, V642, P148; PHILPOTT MP, 1994, J INVEST DERMATOL, V102, P857, DOI 10.1111/1523-1747.ep12382494; PHILPOTT MP, 1990, J CELL SCI, V97, P463; Price VH, 1999, J AM ACAD DERMATOL, V41, P717, DOI 10.1016/S0190-9622(99)70006-X; Randall VA, 2003, J INVEST DERM SYMP P, V8, P39, DOI 10.1046/j.1523-1747.2003.12170.x; Randall VA, 2001, LANCET, V358, P1922, DOI 10.1016/S0140-6736(01)06943-4; Randall VA, 2005, ENDOCRINOLOGY, P3295; Randall VA, 2007, SEMIN CELL DEV BIOL, V18, P274, DOI 10.1016/j.semcdb.2007.02.004; Reynolds AJ, 2004, DIFFERENTIATION, V72, P566, DOI 10.1111/j.1432-0436.2004.07209010.x; Reynolds AJ, 1999, NATURE, V402, P33, DOI 10.1038/46938; Ross EK, 2005, DERMATOL CLIN, V23, P227, DOI 10.1016/j.det.2004.09.008; SAITOH M, 1970, J INVEST DERMATOL, V54, P65, DOI 10.1111/1523-1747.ep12551679; Sakita S, 1999, BRIT J DERMATOL, V140, P294; Sanders DA, 1996, J INVEST DERMATOL, V107, P229, DOI 10.1111/1523-1747.ep12329697; Sato T, 1999, J DERMATOL SCI, V19, P123, DOI 10.1016/S0923-1811(98)00048-6; WESTER RC, 1984, J INVEST DERMATOL, V82, P515, DOI 10.1111/1523-1747.ep12261084; Yoshida H, 2004, J MOL CELL CARDIOL, V37, P857, DOI 10.1016/j.yjmcc.2004.05.022; Yunoki T, 2003, BRIT J PHARMACOL, V139, P652, DOI 10.1038/sj.bjp.0705268; ZINS GR, 1988, CLIN DERMATOL, V6, P132, DOI 10.1016/0738-081X(88)90078-8	61	80	85	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1725	1736		10.1096/fj.07-099424	http://dx.doi.org/10.1096/fj.07-099424			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18258787				2022-12-25	WOS:000256352700013
J	Black, SA; Trackman, PC				Black, Samuel A., Jr.; Trackman, Philip C.			Transforming growth factor-beta 1 (TGF beta 1) stimulates connective tissue growth factor (CCN2/CTGF) expression in human gingival fibroblasts through a RhoA-independent, Rac1/Cdc42-dependent mechanism - Statins with forskolin block TGF beta 1-induced CCN2/CTGF expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE INHIBITORS; COA REDUCTASE INHIBITORS; ACTIN STRESS FIBERS; LYSOPHOSPHATIDIC ACID; FACTOR-BETA; ATHEROSCLEROTIC LESIONS; SCLERODERMA FIBROBLASTS; CELLULAR-RESPONSES; EPITHELIAL-CELLS; FACTOR CTGF/CCN2	Regulation of connective tissue growth factor (CCN2/CTGF) in gingival fibroblasts is unique and may provide therapeutic opportunities to treat oral fibrotic diseases. RhoA was previously implicated in mediating the expression of CCN2/CTGF. We now present evidence that Rho family GTPases Rac1 and Cdc42 are the principal mediators of the transforming growth factor-beta 1 (TGF beta 1)-stimulated expression of CCN2/CTGF in primary human gingival fibroblasts. TGF beta 1 does not stimulate RhoA activation in gingival fibroblasts, and the overexpression of dominant-negative RhoA does not reduce CCN2/CTGF expression in response to TGF beta 1. In contrast, the overexpression of dominant-negative forms of Cdc42 or Rac1 results in a dramatic reduction of CCN2/CTGF protein levels. Lovastatin and a geranylgeranyltransferase inhibitor reduce the TGF beta 1-stimulated levels of CCN2/CTGF protein by similar to 75 and 100%, respectively. We previously demonstrated that JNK1 phosphorylation by TGF beta 1 is also critical for TGF beta 1-induced CCN2/CTGF expression, and forskolin partially reduces levels of phosphorylated JNK1. Inhibition of geranylgeranyltransferase has no effect on levels of JNK phosphorylation in response to TGF beta 1 suggesting Rho-GTPases act independently of JNK1. The combination of lova-statin and forskolin results in a greater inhibitory effect than each agent alone and reduces CCN2/CTGF mRNA and protein expression by greater than 90%. This novel combination has additive inhibitory effects on the TGF beta 1-stimulated expression of CCN2/ CTGF in human gingival fibroblasts through the simultaneous disruption of Rho-and JNK1-mediated pathways, respectively. This combination of available therapeutic compounds may therefore be useful in designing treatment strategies for oral fibrotic conditions in which gingival CCN2/CTGF is elevated.	[Black, Samuel A., Jr.; Trackman, Philip C.] Boston Univ, Goldman Sch Dent Med, Dept Periodontol & Oral Biol, Div Oral Biol, Boston, MA 02118 USA	Boston University	Trackman, PC (corresponding author), Boston Univ, Goldman Sch Dent Med, Dept Periodontol & Oral Biol, Div Oral Biol, 700 Albany St, Boston, MA 02118 USA.	trackman@bu.edu	Trackman, Philip C/AAX-9280-2021	Trackman, Philip C/0000-0001-5064-614X	NCRR NIH HHS [M01 RR00533] Funding Source: Medline; NIDCR NIH HHS [R01 DE11004, K08 DE016609-03, R01 DE011004-12, K08DE016609, R01 DE011004] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011004, K08DE016609] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abraham DJ, 2000, J BIOL CHEM, V275, P15220, DOI 10.1074/jbc.275.20.15220; AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; Allen JT, 1999, AM J RESP CELL MOL, V21, P693, DOI 10.1165/ajrcmb.21.6.3719; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Black SA, 2007, J BIOL CHEM, V282, P15416, DOI 10.1074/jbc.M610432200; Blom IE, 2001, J CLIN PATHOL-MOL PA, V54, P192, DOI 10.1136/mp.54.3.192; Blom IE, 2002, MATRIX BIOL, V21, P473, DOI 10.1016/S0945-053X(02)00055-0; Bonniaud P, 2005, J IMMUNOL, V175, P5390, DOI 10.4049/jimmunol.175.8.5390; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169; Chambers RC, 1998, BIOCHEM J, V333, P121, DOI 10.1042/bj3330121; Chan KKW, 2003, CLIN CANCER RES, V9, P10; Dabbagh K, 1998, THROMB HAEMOSTASIS, V79, P405; Dammeier J, 1998, INT J BIOCHEM CELL B, V30, P909, DOI 10.1016/S1357-2725(98)00046-6; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; di Mola FF, 1999, ANN SURG, V230, P63, DOI 10.1097/00000658-199907000-00010; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; Eberlein M, 2001, BRIT J PHARMACOL, V133, P1172, DOI 10.1038/sj.bjp.0704173; Essig M, 1998, J AM SOC NEPHROL, V9, P1377; Fischer DJ, 1998, MOL PHARMACOL, V54, P979, DOI 10.1124/mol.54.6.979; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; GERRARD JM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P282, DOI 10.1016/0005-2760(89)90112-4; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Goppelt-Struebe M, 2001, J CLIN PATHOL-MOL PA, V54, P176, DOI 10.1136/mp.54.3.176; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Hall EE, 1997, CURR OPIN PERIODONT, V4, P59; Hassell T M, 1981, Monogr Oral Sci, V9, P1; HASSELL T M, 1991, Critical Reviews in Oral Biology and Medicine, V2, P103; Heusinger-Ribeiro J, 2001, J AM SOC NEPHROL, V12, P1853, DOI 10.1681/ASN.V1291853; Holmes A, 2003, J BIOL CHEM, V278, P41728, DOI 10.1074/jbc.M305019200; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; Hong HH, 1999, LAB INVEST, V79, P1655; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; Jackson S M, 1997, Subcell Biochem, V28, P1; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; Kantarci A, 2006, J PATHOL, V210, P59, DOI 10.1002/path.2000; Kubota S, 2004, J BIOCHEM, V136, P279, DOI 10.1093/jb/mvh126; Lakos G, 2004, AM J PATHOL, V165, P203, DOI 10.1016/S0002-9440(10)63289-0; Lasky JA, 1998, AM J PHYSIOL-LUNG C, V275, pL365, DOI 10.1152/ajplung.1998.275.2.L365; Leask A, 2001, J CLIN PATHOL-MOL PA, V54, P180, DOI 10.1136/mp.54.3.180; Lee EH, 1999, INVEST OPHTH VIS SCI, V40, P2025; Leung T, 1998, MOL CELL BIOL, V18, P130, DOI 10.1128/MCB.18.1.130; Lobell RB, 2001, CANCER RES, V61, P8758; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Maesaki R, 1999, MOL CELL, V4, P793, DOI 10.1016/S1097-2765(00)80389-5; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Oemar BS, 1997, ARTERIOSCL THROM VAS, V17, P1483, DOI 10.1161/01.ATV.17.8.1483; Oemar BS, 1997, CIRCULATION, V95, P831; Ohnishi H, 1998, J MOL CELL CARDIOL, V30, P2411, DOI 10.1006/jmcc.1998.0799; Paradis V, 1999, HEPATOLOGY, V30, P968, DOI 10.1002/hep.510300425; Pendurthi UR, 2000, J BIOL CHEM, V275, P14632, DOI 10.1074/jbc.275.19.14632; Querfeld C, 1999, J DERMATOL SCI, V21, P13, DOI 10.1016/S0923-1811(99)00008-0; Rachfal AW, 2003, HEPATOL RES, V26, P1, DOI 10.1016/S1386-6346(03)00115-3; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Riser BL, 2000, J AM SOC NEPHROL, V11, P25, DOI 10.1681/ASN.V11125; Schober JM, 2002, BLOOD, V99, P4457, DOI 10.1182/blood.V99.12.4457; Sedlaczek N, 2001, AM J PATHOL, V158, P1239, DOI 10.1016/S0002-9440(10)64074-6; Tamatani T, 1998, BIOCHEM BIOPH RES CO, V251, P748, DOI 10.1006/bbrc.1998.9543; Tan I, 2001, MOL CELL BIOL, V21, P2767, DOI 10.1128/MCB.21.8.2767-2778.2001; Ueberham U, 2003, NEUROSCIENCE, V116, P1, DOI 10.1016/S0306-4522(02)00670-X; Uzel MI, 2001, J PERIODONTOL, V72, P921, DOI 10.1902/jop.2001.72.7.921; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; Watts KL, 2005, AM J RESP CELL MOL, V32, P290, DOI 10.1165/rcmb.2004-0127OC; Williams EJ, 2000, J HEPATOL, V32, P754, DOI 10.1016/S0168-8278(00)80244-5; Wong WWL, 2002, LEUKEMIA, V16, P508, DOI 10.1038/sj.leu.2402476; Xia Z, 2001, LEUKEMIA, V15, P1398, DOI 10.1038/sj.leu.2402196; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	73	46	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10835	10847		10.1074/jbc.M710363200	http://dx.doi.org/10.1074/jbc.M710363200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18287089	hybrid, Green Accepted, Green Published			2022-12-25	WOS:000254894700066
J	Cooper, SK; Pandhare, J; Donald, SP; Phang, JM				Cooper, Sandra K.; Pandhare, Jui; Donald, Steven P.; Phang, James M.			Novel function for hydroxyproline oxidase in apoptosis through generation of reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOXORUBICIN-INDUCED APOPTOSIS; PROLINE-OXIDASE; CELL-DEATH; ENZYMATIC SYNTHESIS; DNA-DAMAGE; TUMOR-CELL; METABOLISM; DELTA-1-PYRROLINE-3-HYDROXY-5-CARBOXYLATE; EXPRESSION; PATHWAYS	Proline and hydroxyproline are metabolized by distinct pathways. Proline is important for protein synthesis, as a source of glutamate, arginine, and tricarboxylic acid cycle intermediates, and for participating in a metabolic cycle that shuttles redox equivalents between mitochondria and cytosol. Hydroxyproline, in contrast, is not reutilized for protein synthesis. The first steps in the degradation of proline and hydroxyproline are catalyzed by proline oxidase (POX) and hydroxyproline oxidase (OH-POX), respectively. Because it is well documented that POX is induced by p53 and plays a role in apoptosis, we considered whether OH-POX also participates in the response to cytotoxic stress. In LoVo and RKO cells, which respond to adriamycin with a p53-mediated induction of POX and generation of reactive oxygen species, we found that adriamycin also induced OH-POX gene expression and markedly increased OH-POX catalytic activity, and this increase in activity was not observed in the cell lines HT29 and HCT15, which do not have a functional p53. We also observed an increase in reactive oxygen species generation and activation of caspase-9 with adriamycin in a hydroxyproline-dependent manner. Therefore, we hypothesize that OH-POX plays a role analogous to POX in growth regulation, ROS generation, and activation of the apoptotic cascade.	[Pandhare, Jui; Donald, Steven P.; Phang, James M.] Natl Inst Hlth, Comparat Carcinogenesis Lab, NCI, CCR, Ft Detrick, MD 21702 USA; [Cooper, Sandra K.] NCI, Basic Res Program, SAIC Frederick Inc, Natl Inst Hlth, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Phang, JM (corresponding author), Natl Inst Hlth, Comparat Carcinogenesis Lab, NCI, CCR, Bldg 538 Rm 144, Ft Detrick, MD 21702 USA.	phang@ncifcrf.gov		Pandhare, Jui/0000-0002-0356-064X	NATIONAL CANCER INSTITUTE [Z01BC010743, ZIABC010746] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS E, 1960, J BIOL CHEM, V235, P3492; ADAMS E, 1960, J BIOL CHEM, V235, P3504; ADAMS E, 1960, J BIOL CHEM, V235, P3499; Bender HU, 2005, AM J HUM GENET, V76, P409, DOI 10.1086/428142; Bhattacharjee A, 2005, IUBMB LIFE, V57, P161, DOI 10.1080/15216540500090710; Cho SG, 2002, J BIOCHEM MOL BIOL, V35, P24, DOI 10.5483/BMBRep.2002.35.1.024; Donald SP, 2001, CANCER RES, V61, P1810; DOWNING SJ, 1977, J CELL PHYSIOL, V91, P369, DOI 10.1002/jcp.1040910306; Gewirtz DA, 2000, BREAST CANCER RES TR, V62, P223, DOI 10.1023/A:1006414422919; Green PS, 2002, BBA-MOL BASIS DIS, V1588, P94, DOI 10.1016/S0925-4439(02)00144-8; HAGEDORN CH, 1983, ARCH BIOCHEM BIOPHYS, V225, P95, DOI 10.1016/0003-9861(83)90010-3; Hoogendoorn B, 2004, HUM MUTAT, V24, P35, DOI 10.1002/humu.20061; Ii M, 2006, EXP BIOL MED, V231, P20; Kalyanaraman B, 2002, MOL CELL BIOCHEM, V234, P119, DOI 10.1023/A:1015976430790; Kim SZ, 1997, J PEDIATR-US, V130, P437, DOI 10.1016/S0022-3476(97)70207-5; Koh DW, 2005, PHARMACOL RES, V52, P5, DOI 10.1016/j.phrs.2005.02.011; L'Ecuyer T, 2006, AM J PHYSIOL-HEART C, V291, pH1273, DOI 10.1152/ajpheart.00738.2005; Liu Y, 2006, ONCOGENE, V25, P5640, DOI 10.1038/sj.onc.1209564; Liu YM, 2005, CARCINOGENESIS, V26, P1335, DOI 10.1093/carcin/bgi083; Maxwell SA, 2000, P NATL ACAD SCI USA, V97, P13009, DOI 10.1073/pnas.230445997; Maxwell SA, 2003, J BIOL CHEM, V278, P9784, DOI 10.1074/jbc.M210012200; Mizutani H, 2005, LIFE SCI, V76, P1439, DOI 10.1016/j.lfs.2004.05.040; Pandhare J, 2006, J BIOL CHEM, V281, P2044, DOI 10.1074/jbc.M507867200; Paterlini M, 2005, NAT NEUROSCI, V8, P1586, DOI 10.1038/nn1562; PHANG JM, 1975, J LAB CLIN MED, V85, P312; PHANG JM, 1985, CURR TOP CELL REGUL, V25, P91; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Shen HM, 2006, FREE RADICAL BIO MED, V40, P928, DOI 10.1016/j.freeradbiomed.2005.10.056; Skulachev VP, 2006, APOPTOSIS, V11, P473, DOI 10.1007/s10495-006-5881-9; VALLE D, 1979, J CLIN INVEST, V64, P1365, DOI 10.1172/JCI109593; Wheeler DL, 2006, NUCLEIC ACIDS RES, V34, pD173, DOI 10.1093/nar/gkj158	31	35	35	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10485	10492		10.1074/jbc.M702181200	http://dx.doi.org/10.1074/jbc.M702181200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18287100	hybrid, Green Published			2022-12-25	WOS:000254894700030
J	Harkewicz, R; Hartvigsen, K; Almazan, F; Dennis, EA; Witztum, JL; Miller, YI				Harkewicz, Richard; Hartvigsen, Karsten; Almazan, Felicidad; Dennis, Edward A.; Witztum, Joseph L.; Miller, Yury I.			Cholesteryl ester hydroperoxides are biologically active components of minimally oxidized low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-DEFICIENT MICE; LDL RECEPTOR-DEFICIENT; APOLIPOPROTEIN-E; APOPTOTIC CELLS; OVEREXPRESS 15-LIPOXYGENASE; MEDIATED MODIFICATION; SELECTIVE UPTAKE; IN-VIVO; 12/15-LIPOXYGENASE; ATHEROSCLEROSIS	Oxidation of low density lipoprotein (LDL) occurs in vivo and significantly contributes to the development of atherosclerosis. An important mechanism of LDL oxidation in vivo is its modification with 12/15-lipoxygenase (LO). We have developed a model of minimally oxidized LDL (mmLDL) in which native LDL is modified by cells expressing 12/15LO. This mm LDL activates macrophages inducing membrane ruffling and cell spreading, activation of ERK1/2 and Akt signaling, and secretion of proinflammatory cytokines. In this study, we found that many of the biological activities of mmLDL were associated with cholesteryl ester (CE) hydroperoxides and were diminished by ebselen, a reducing agent. Liquid chromatography coupled with mass spectroscopy demonstrated the presence of many mono-and polyoxygenated CE species in mmLDL but not in native LDL. Nonpolar lipid extracts of mmLDL activated macrophages, although to a lesser degree than intact mmLDL. The macrophage responses were also induced by LDL directly modified with immobilized 12/15LO, and the nonpolar lipids extracted from 12/15LO-modified LDL contained a similar set of oxidized CE. Cholesteryl arachidonate modified with 12/15LO also activated macrophages and contained a similar collection of oxidized CE molecules. Remarkably, many of these oxidized CE were found in the extracts of atherosclerotic lesions isolated from hyperlipidemic apoE(-/-) mice. These results suggest that CE hydroperoxides constitute a class of biologically active components of mmLDL that may be relevant to proinflammatory activation of macrophages in atherosclerotic lesions.	[Harkewicz, Richard; Dennis, Edward A.] Univ Calif San Diego, Dept Pharmacol Chem & Biochem, La Jolla, CA 92093 USA; [Hartvigsen, Karsten; Almazan, Felicidad; Witztum, Joseph L.; Miller, Yury I.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Miller, YI (corresponding author), Univ Calif San Diego, Dept Pharmacol Chem & Biochem, 9500 Gilman Dr, La Jolla, CA 92093 USA.	yumiller@ucsd.edu	Dennis, Edward A./M-5554-2019	Dennis, Edward A./0000-0003-3738-3140	NHLBI NIH HHS [R01 HL081862-03, R01 HL081862, HL081862] Funding Source: Medline; NIGMS NIH HHS [GM069338, U54 GM069338] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM069338] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Belkner J, 1998, J BIOL CHEM, V273, P23225, DOI 10.1074/jbc.273.36.23225; BENZ DJ, 1995, J BIOL CHEM, V270, P5191, DOI 10.1074/jbc.270.10.5191; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bolick DT, 2005, ARTERIOSCL THROM VAS, V25, P2301, DOI 10.1161/01.ATV.0000186181.19909.a6; Boullier A, 2006, ARTERIOSCL THROM VAS, V26, P1169, DOI 10.1161/01.ATV.0000210279.97308.9a; Boullier A, 2005, J LIPID RES, V46, P969, DOI 10.1194/jlr.M400496-JLR200; Chang MK, 2004, J EXP MED, V200, P1359, DOI 10.1084/jem.20031763; Chen NG, 1999, BIOCHEM BIOPH RES CO, V263, P718, DOI 10.1006/bbrc.1999.1437; CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475; Cyrus T, 1999, J CLIN INVEST, V103, P1597, DOI 10.1172/JCI5897; Cyrus T, 2001, CIRCULATION, V103, P2277; EDENIUS C, 1991, EUR J BIOCHEM, V199, P401, DOI 10.1111/j.1432-1033.1991.tb16137.x; EZAKI M, 1995, J LIPID RES, V36, P1996; Fluiter K, 1999, J BIOL CHEM, V274, P8893, DOI 10.1074/jbc.274.13.8893; Folco G, 2006, PHARMACOL REV, V58, P375, DOI 10.1124/pr.58.3.8; Friedman P, 2002, J BIOL CHEM, V277, P7010, DOI 10.1074/jbc.M108860200; George J, 2001, CIRCULATION, V104, P1646, DOI 10.1161/hc3901.095772; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Harkewicz R, 2007, J BIOL CHEM, V282, P2899, DOI 10.1074/jbc.M610067200; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Huber J, 2002, ARTERIOSCL THROM VAS, V22, P581, DOI 10.1161/01.ATV.0000012782.59850.41; Huo YQ, 2004, CIRCULATION, V110, P2024, DOI 10.1161/01.CIR.0000143628.37680.F6; Jedidi I, 2006, BIOCHEM BIOPH RES CO, V351, P733, DOI 10.1016/j.bbrc.2006.10.122; Leitinger Norbert, 2003, Molecular Aspects of Medicine, V24, P239, DOI 10.1016/S0098-2997(03)00019-0; Letters JM, 1999, J LIPID RES, V40, P1104; Li XM, 2007, BIOCHEMISTRY-US, V46, P5009, DOI 10.1021/bi700163y; Liavonchanka A, 2006, J PLANT PHYSIOL, V163, P348, DOI 10.1016/j.jplph.2005.11.006; Michelsen KS, 2004, P NATL ACAD SCI USA, V101, P10679, DOI 10.1073/pnas.0403249101; Miller YI, 2003, MOL BIOL CELL, V14, P4196, DOI 10.1091/mbc.E03-02-0063; Miller YI, 2005, ARTERIOSCL THROM VAS, V25, P1213, DOI 10.1161/01.ATV.0000159891.73193.31; Miller YI, 2003, J BIOL CHEM, V278, P1561, DOI 10.1074/jbc.M209634200; Miller YI, 2001, J BIOL CHEM, V276, P19431, DOI 10.1074/jbc.M011276200; Miller YI, 2005, FUTUR CARDIOL, V1, P785, DOI 10.2217/14796678.1.6.785; MULLER A, 1984, BIOCHEM PHARMACOL, V33, P3235, DOI 10.1016/0006-2952(84)90083-2; Nigam S, 2004, J BIOL CHEM, V279, P29023, DOI 10.1074/jbc.M307576200; PARTHASARATHY S, 1990, EUR HEART J, V11, P83, DOI 10.1093/eurheartj/11.suppl_E.83; Pfister SL, 2003, ARCH BIOCHEM BIOPHYS, V420, P142, DOI 10.1016/j.abb.2003.09.026; Reilly KB, 2004, J BIOL CHEM, V279, P9440, DOI 10.1074/jbc.M303857200; SATTLER W, 1994, METHOD ENZYMOL, V233, P469; Scheidegger KJ, 1997, J BIOL CHEM, V272, P21609, DOI 10.1074/jbc.272.34.21609; Sigari F, 1997, ARTERIOSCL THROM VAS, V17, P3639, DOI 10.1161/01.ATV.17.12.3639; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Sultana C, 1996, J CELL PHYSIOL, V167, P477, DOI 10.1002/(SICI)1097-4652(199606)167:3<477::AID-JCP12>3.0.CO;2-1; Takahashi Y, 2005, BIOCHEM BIOPH RES CO, V338, P128, DOI 10.1016/j.bbrc.2005.07.182; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; Upston JM, 2002, AM J PATHOL, V160, P701, DOI 10.1016/S0002-9440(10)64890-0; Upston JM, 1997, J BIOL CHEM, V272, P30067, DOI 10.1074/jbc.272.48.30067; Walton KA, 2003, J BIOL CHEM, V278, P29661, DOI 10.1074/jbc.M300738200; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9; Yin HY, 2004, J BIOL CHEM, V279, P3766, DOI 10.1074/jbc.M307137200; Zhu H, 2003, J BIOL CHEM, V278, P13350, DOI 10.1074/jbc.M212104200	51	89	91	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10241	10251		10.1074/jbc.M709006200	http://dx.doi.org/10.1074/jbc.M709006200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18263582	Green Published, hybrid, Green Accepted			2022-12-25	WOS:000254894700005
J	Meharenna, YT; Slessor, KE; Cavaignac, SM; Poulos, TL; De Voss, JJ				Meharenna, Yergalem T.; Slessor, Kate E.; Cavaignac, Sonia M.; Poulos, Thomas L.; De Voss, James J.			The critical role of substrate-protein hydrogen bonding in the control of regioselective hydroxylation in P450cin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN CYTOCHROME P4502B4; DIVINYL ETHER SYNTHASE; BINDING FREE-ENERGIES; CRYSTAL-STRUCTURE; HYDROPEROXIDE LYASE; DIOXYGEN COMPLEX; WILD-TYPE; MUTANT; ACTIVATION; RESOLUTION	Cytochrome P450cin (CYP176A1) is a bacterial P450 isolated from Citrobacter braakii that catalyzes the hydroxylation of cineole to (S)-6 beta-hydroxycineole. This initiates the biodegradation of cineole, enabling C. braakii to live on cineole as its sole source of carbon and energy. P450cin lacks the almost universally conserved threonine residue believed to be involved in dioxygen activation and instead contains an asparagine at this position (Asn-242). To investigate the role of Asn-242 in P450cin catalysis, it was converted to alanine, and the resultant mutant was characterized. The characteristic CO-bound spectrum and spectrally determined K-D for substrate binding were unchanged in the mutant. The x-ray crystal structures of the substrate-free and -bound N242A mutant were determined and show that the only significant change is in a reorientation of the substrate such that (R)-6 alpha-hydroxycineole should be a major product. Molecular dynamics simulations of both wild type and mutant are consistent with the change in regio- and stereoselectivity predicted from the crystal structure. The mutation has only a modest effect on enzyme activity and on the diversion of the NADPH-reducing equivalent toward unproductive peroxide formation. Product profile analysis shows that (R)-6 alpha-hydroxycineole is the main product, which is consistent with the crystal structure. These results demonstrate that Asn-242 is not a functional replacement for the conserved threonine in other P450s but, rather, is critical in controlling regioselective substrate oxidation.	[Meharenna, Yergalem T.; Poulos, Thomas L.] Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; [Meharenna, Yergalem T.; Poulos, Thomas L.] Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA; [Meharenna, Yergalem T.; Poulos, Thomas L.] Univ Calif Irvine, Dept Pharmaceut Sci, Irvine, CA 92697 USA; [Slessor, Kate E.; Cavaignac, Sonia M.; De Voss, James J.] Univ Queensland, Sch Mol & Microbial Sci, Brisbane, Qld 4072, Australia	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of Queensland	Poulos, TL (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.	poulos@uci.edu; j.devoss@uq.edu.au			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033688] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33688] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN JF, 1993, BIOCHEMISTRY-US, V32, P1905, DOI 10.1021/bi00059a004; ATKINS WM, 1988, J BIOL CHEM, V263, P18842; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAPDEVILA JH, 1996, J BIOL CHEM, V271, P22633; CARMAN RM, 1984, AUST J CHEM, V37, P1117, DOI 10.1071/CH9841117; Cryle MJ, 2007, TETRAHEDRON-ASYMMETR, V18, P547, DOI 10.1016/j.tetasy.2007.01.034; CuppVickery JR, 1996, NAT STRUCT BIOL, V3, P632, DOI 10.1038/nsb0796-632; Davydov R, 2001, J AM CHEM SOC, V123, P1403, DOI 10.1021/ja003583l; Deprez E, 2002, J INORG BIOCHEM, V91, P597, DOI 10.1016/S0162-0134(02)00467-1; DeVoss JJ, 1997, J AM CHEM SOC, V119, P5489, DOI 10.1021/ja970349v; Grechkin AN, 2002, PROSTAG OTH LIPID M, V68-9, P457, DOI 10.1016/S0090-6980(02)00048-5; Harris DL, 2004, PROTEINS, V55, P895, DOI 10.1002/prot.20062; Hawkes DB, 2002, J BIOL CHEM, V277, P27725, DOI 10.1074/jbc.M203382200; Hawkes DB, 2003, THESIS U QUEENSLAND; Hishiki T, 2000, J BIOCHEM, V128, P965, DOI 10.1093/oxfordjournals.jbchem.a022848; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, INT CCP4 ESF EACMB N, V26; Li H, 1996, BIOCHIMIE, V78, P695, DOI 10.1016/S0300-9084(97)82526-6; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; Massova I, 1999, J AM CHEM SOC, V121, P8133, DOI 10.1021/ja990935j; Matsui K, 1996, FEBS LETT, V394, P21, DOI 10.1016/0014-5793(96)00924-6; Meharenna YT, 2004, BIOCHEMISTRY-US, V43, P9487, DOI 10.1021/bi049293p; Nagano S, 2005, J BIOL CHEM, V280, P22102, DOI 10.1074/jbc.M501732200; Nagano S, 2005, J BIOL CHEM, V280, P31659, DOI 10.1074/jbc.M505261200; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POULOS TL, 1986, BIOCHEMISTRY-US, V25, P5314, DOI 10.1021/bi00366a049; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; SALMON JA, 1982, METHOD ENZYMOL, V86, P91; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Scott EE, 2003, P NATL ACAD SCI USA, V100, P13196, DOI 10.1073/pnas.2133986100; Scott EE, 2004, J BIOL CHEM, V279, P27294, DOI 10.1074/jbc.M403349200; STARKOVICH JA, 1969, J FOOD SCI, V34, P194, DOI 10.1111/j.1365-2621.1969.tb00917.x; Stumpe M, 2001, FEBS LETT, V507, P371, DOI 10.1016/S0014-5793(01)03019-8; Tijet N, 2002, PROSTAG OTH LIPID M, V68-9, P423, DOI 10.1016/S0090-6980(02)00046-1; Truan G, 1998, ARCH BIOCHEM BIOPHYS, V349, P53, DOI 10.1006/abbi.1997.0400; Xiang H, 2000, J BIOL CHEM, V275, P35999, DOI 10.1074/jbc.M005811200	39	30	31	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10804	10812		10.1074/jbc.M709722200	http://dx.doi.org/10.1074/jbc.M709722200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18270198	Green Published, hybrid			2022-12-25	WOS:000254894700063
J	Stridh, MH; Tranberg, M; Weber, SG; Blomstrand, F; Sandberg, M				Stridh, Malin H.; Tranberg, Mattias; Weber, Stephen G.; Blomstrand, Fredrik; Sandberg, Mats			Stimulated efflux of amino acids and glutathione from cultured hippocampal slices by omission of extracellular calcium - Likely involvement of connexin hemichannels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION HEMICHANNELS; P2X(7) RECEPTOR; GLUTAMATE RELEASE; ATP RELEASE; REGIONAL VULNERABILITY; PURINERGIC RECEPTORS; METABOLIC INHIBITION; N-ACETYLASPARTATE; MEDIATED RELEASE; RAT-BRAIN	Omission of extracellular Ca2+ for 15 min from the incubation medium of cultured hippocampal slices stimulated the efflux of glutathione, phosphoethanolamine, hypotaurine, and taurine. The efflux was reduced by several blockers of gap junctions, i.e. carbenoxolone, flufenamic acid, and endothelin-1, and by the connexin43 hemichannel blocking peptide Gap26 but was unchanged by the P2X(7) receptor inhibitor oxidized ATP, a pannexin1 hemichannel blocking peptide and an inactive analogue of carbenoxolone. Pretreatment of the slices with the neurotoxin N-methyl-D-aspartate left the efflux by Ca2+ omission unchanged, indicating that the stimulated efflux primarily originated from glia. Elevated glutamate efflux was detected when Ca2+ omission was combined with the glutamate uptake blocker L-trans-pyrrolidine-2,4-dicarboxylate and when both Ca2+ and Mg2+ were omitted from the medium. Omission of Ca2+ for 15 min alone did not induce delayed toxicity, but in combination with blocked glutamate uptake, significant cell death was observed 24 h later. Our results indicate that omission of extracellular Ca2+ stimulates efflux of glutathione and specific amino acids including glutamate via opening of glial hemichannels. This type of efflux may have protective functions via glutathione efflux but can aggravate toxicity in situations when glutamate reuptake is impaired, such as following a stroke.	[Sandberg, Mats] Univ Gothenburg, Inst Biomed, SE-40530 Gothenburg, Sweden; [Stridh, Malin H.; Tranberg, Mattias; Blomstrand, Fredrik; Sandberg, Mats] Univ Gothenburg, Inst Neurosci & Physiol, SE-40530 Gothenburg, Sweden; [Weber, Stephen G.] Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA	University of Gothenburg; University of Gothenburg; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Sandberg, M (corresponding author), Univ Gothenburg, Inst Biomed, Box 420, SE-40530 Gothenburg, Sweden.	mats.sandberg@anatcell.gu.se	Weber, Stephen G/AAJ-9255-2020	Weber, Stephen/0000-0002-7970-2632	NIGMS NIH HHS [GM 44842] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044842] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bao XY, 2007, P NATL ACAD SCI USA, V104, P4919, DOI 10.1073/pnas.0603154104; Bennett MVL, 2003, TRENDS NEUROSCI, V26, P610, DOI 10.1016/j.tins.2003.09.008; Blomstrand F, 2006, J NEUROSCI RES, V83, P996, DOI 10.1002/jnr.20801; Blomstrand F, 2004, EUR J NEUROSCI, V19, P1005, DOI 10.1111/j.0953-816X.2004.03197.x; Bruzzone R, 2005, J NEUROCHEM, V92, P1033, DOI 10.1111/j.1471-4159.2004.02947.x; Chen HB, 2006, EUR J PHARMACOL, V550, P1, DOI 10.1016/j.ejphar.2006.08.039; Chessell IP, 1997, BRIT J PHARMACOL, V121, P1429, DOI 10.1038/sj.bjp.0701278; Contreras JE, 2003, P NATL ACAD SCI USA, V100, P11388, DOI 10.1073/pnas.1434298100; Contreras JE, 2002, P NATL ACAD SCI USA, V99, P495, DOI 10.1073/pnas.012589799; Cooper CD, 2002, J BIOL CHEM, V277, P44962, DOI 10.1074/jbc.M209427200; Dahl G, 2006, IUBMB LIFE, V58, P409, DOI 10.1080/15216540600794526; DAVIDSON JS, 1988, J PHARMACOL EXP THER, V246, P1104; Dringen R, 1999, J NEUROSCI, V19, P562, DOI 10.1523/jneurosci.19-02-00562.1999; Duan SM, 2003, J NEUROSCI, V23, P1320, DOI 10.1523/JNEUROSCI.23-04-01320.2003; Ebihara L, 2003, BIOPHYS J, V84, P277, DOI 10.1016/S0006-3495(03)74848-6; Egelman DM, 1999, BIOPHYS J, V76, P1856, DOI 10.1016/S0006-3495(99)77345-5; Ek-Vitorin JF, 2005, AM J PHYSIOL-CELL PH, V289, pC1535, DOI 10.1152/ajpcell.00182.2005; Eskandari S, 2002, J MEMBRANE BIOL, V185, P93, DOI 10.1007/s00232-001-0115-0; Fellin T, 2006, J BIOL CHEM, V281, P4274, DOI 10.1074/jbc.M510679200; Goldberg GS, 2002, J BIOL CHEM, V277, P36725, DOI 10.1074/jbc.M109797200; Goldberg GS, 1996, EXP CELL RES, V222, P48, DOI 10.1006/excr.1996.0006; Gomes P, 2005, INVEST OPHTH VIS SCI, V46, P1208, DOI 10.1167/iovs.04-1181; HANSEN AJ, 1985, PHYSIOL REV, V65, P101, DOI 10.1152/physrev.1985.65.1.101; Harks EGA, 2001, J PHARMACOL EXP THER, V298, P1033; Henke W, 1998, BBA-BIOENERGETICS, V1363, P209, DOI 10.1016/S0005-2728(97)00103-5; Huang Y, 2007, GLIA, V55, P46, DOI 10.1002/glia.20435; Huang YJ, 2007, P NATL ACAD SCI USA, V104, P6436, DOI 10.1073/pnas.0611280104; John SA, 1999, J BIOL CHEM, V274, P236, DOI 10.1074/jbc.274.1.236; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; LINDROTH P, 1979, ANAL CHEM, V51, P1667, DOI 10.1021/ac50047a019; Locovei S, 2007, FEBS LETT, V581, P483, DOI 10.1016/j.febslet.2006.12.056; Martin ME, 2005, J NEUROSCI RES, V82, P93, DOI 10.1002/jnr.20613; Molchanova SM, 2005, NEUROCHEM INT, V47, P343, DOI 10.1016/j.neuint.2005.04.027; Muyderman H, 2004, J NEUROSCI, V24, P8019, DOI 10.1523/JNEUROSCI.1103-04.2004; Noraberg J, 1999, BRAIN RES PROTOC, V3, P278, DOI 10.1016/S1385-299X(98)00050-6; OGITA K, 1995, J NEUROCHEM, V64, P1088; Paredes-Gamero EJ, 2004, J FLUORESC, V14, P711, DOI 10.1023/B:JOFL.0000047221.51493.e3; Parpura V, 2004, NEUROCHEM INT, V45, P259, DOI 10.1016/j.neuint.2003.12.011; Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378; Pomper JK, 2001, DEV BRAIN RES, V126, P109, DOI 10.1016/S0165-3806(00)00132-2; PUMAIN R, 1985, J NEUROPHYSIOL, V53, P1; Ranat S, 2007, NEUROSCI LETT, V415, P45, DOI 10.1016/j.neulet.2006.12.043; Regan RF, 1999, BRAIN RES, V817, P145, DOI 10.1016/S0006-8993(98)01252-9; Retamal MA, 2006, P NATL ACAD SCI USA, V103, P4475, DOI 10.1073/pnas.0511118103; Saez JC, 2005, BBA-BIOMEMBRANES, V1711, P215, DOI 10.1016/j.bbamem.2005.01.014; SANDBERG M, 1986, J NEUROCHEM, V47, P178; Spray DC, 2006, GLIA, V54, P758, DOI 10.1002/glia.20429; Srinivas M, 2006, J GEN PHYSIOL, V127, P67, DOI 10.1085/jgp.200509397; Steullet P, 2006, NEUROSCIENCE, V137, P807, DOI 10.1016/j.neuroscience.2005.10.014; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Suadicani SO, 2006, J NEUROSCI, V26, P1378, DOI 10.1523/JNEUROSCI.3902-05.2006; Tranberg M, 2005, ANAL BIOCHEM, V343, P179, DOI 10.1016/j.ab.2005.03.004; Tranberg M, 2004, NEUROCHEM INT, V45, P1195, DOI 10.1016/j.neuint.2004.06.005; Trexler EB, 1999, J GEN PHYSIOL, V113, P721; Vornov JJ, 1998, EXP NEUROL, V149, P109, DOI 10.1006/exnr.1997.6673; VORNOV JJ, 1991, EXP NEUROL, V114, P11, DOI 10.1016/0014-4886(91)90079-R; Wallin C, 2003, NEUROCHEM RES, V28, P281, DOI 10.1023/A:1022381318126; Wallin C, 1999, J NEUROCHEM, V73, P1566, DOI 10.1046/j.1471-4159.1999.0731566.x; Wang CM, 2003, CELL SIGNAL, V15, P1129, DOI 10.1016/S0898-6568(03)00112-8; Wang JJ, 2007, AM J PHYSIOL-CELL PH, V293, pC1112, DOI 10.1152/ajpcell.00097.2007; WHITAKER JR, 1980, ANAL BIOCHEM, V109, P156, DOI 10.1016/0003-2697(80)90024-X; Ye ZC, 2003, J NEUROSCI, V23, P3588, DOI 10.1523/jneurosci.23-09-03588.2003; Zampighi GA, 1999, J GEN PHYSIOL, V113, P507, DOI 10.1085/jgp.113.4.507; Zoidl G, 2007, NEUROSCIENCE, V146, P9, DOI 10.1016/j.neuroscience.2007.01.061	64	57	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10347	10356		10.1074/jbc.M704153200	http://dx.doi.org/10.1074/jbc.M704153200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18272524	Green Published, hybrid			2022-12-25	WOS:000254894700015
J	Antonson, P; Jakobsson, T; Almlof, T; Guldevall, K; Steffensen, KR; Gustafsson, JA				Antonson, Per; Jakobsson, Tomas; Almloef, Tova; Guldevall, Karolin; Steffensen, Knut R.; Gustafsson, Jan-Ake			RAP250 is a coactivator in the transforming growth factor beta signaling pathway that interacts with smad2 and smad3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR COACTIVATOR; CREB-BINDING PROTEIN; LIVER-X-RECEPTORS; LXXLL-MOTIF; TRANSCRIPTIONAL COACTIVATORS; COMPLEX; MICE; METABOLISM; ACTIVATION; GENE	RAP250 is a coactivator for nuclear receptors as well as other transcription factors. Recent studies have established RAP250 as an essential coactivator for many important biological processes, but its exact mechanism of action is not fully understood. To identify novel proteins that can associate with RAP250, we used a yeast two-hybrid system to screen cDNA libraries and identified the intracellular mediators of transforming growth factor-beta( TGF-beta) response Smad2 and Smad3 as direct interacting proteins. We show that the interaction between RAP250 and Smad2/3 is dependent upon the second LXXLL interaction motif in RAP250 and the MH2 domain in Smad2 and Smad3. Mouse embryonic fibroblasts lacking RAP250 have reduced expression of the TGF-beta target gene PAI-1 after stimulation by TGF-beta when compared with wild type cells. Furthermore, we demonstrate a cross-talk between TGF-beta and liver X receptors (LXR) signaling pathways and show that stimulation of cells with TGF-beta and LXR agonists have a synergistic effect on the expression of the LXR target gene ABCG1. Our data identify RAP250 as a new coactivator in the TGF-beta signaling pathway that binds Smad2 and Smad3. Our data also suggest that the interaction between RAP250, Smad2, and Smad3 constitutes an important bridging mechanism linking LXR and TGF-beta signaling pathways.	[Antonson, Per; Jakobsson, Tomas; Almloef, Tova; Guldevall, Karolin; Steffensen, Knut R.; Gustafsson, Jan-Ake] Karolinska Inst, Novum, Dept Biosci & Nutr, S-14157 Huddinge, Sweden	Karolinska Institutet	Antonson, P (corresponding author), Karolinska Inst, Novum, Dept Biosci & Nutr, S-14157 Huddinge, Sweden.	per.antonson@biosci.ki.se		Steffensen, Knut/0000-0001-6093-2801; Guldevall, Karolin/0000-0003-1016-2460; Antonson, Per/0000-0001-9335-9941				Alberti S, 2001, J CLIN INVEST, V107, P565, DOI 10.1172/JCI9794; Antonson P, 2003, MOL CELL BIOL, V23, P1260, DOI 10.1128/MCB.23.4.1260-1268.2003; Argmann CA, 2001, ARTERIOSCL THROM VAS, V21, P2011, DOI 10.1161/hq1201.099426; Caira F, 2000, J BIOL CHEM, V275, P5308, DOI 10.1074/jbc.275.8.5308; Collins JL, 2002, J MED CHEM, V45, P1963, DOI 10.1021/jm0255116; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Ito M, 2001, TRENDS ENDOCRIN MET, V12, P127, DOI 10.1016/S1043-2760(00)00355-6; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196; Kato Y, 2002, NATURE, V418, P641, DOI 10.1038/nature00969; Kim SW, 2003, MOL CELL BIOL, V23, P3583, DOI 10.1128/MCB.23.10.3583-3592.2003; Ko L, 2000, P NATL ACAD SCI USA, V97, P6212, DOI 10.1073/pnas.97.11.6212; Kuang SQ, 2002, J BIOL CHEM, V277, P45356, DOI 10.1074/jbc.C200509200; Lee SK, 2001, MOL ENDOCRINOL, V15, P241, DOI 10.1210/me.15.2.241; Li QT, 2007, MOL CELL BIOL, V27, P8073, DOI 10.1128/MCB.00451-07; Lonard DM, 2006, CELL, V125, P411, DOI 10.1016/j.cell.2006.04.021; Mahajan MA, 2005, ENDOCR REV, V26, P583, DOI 10.1210/er.2004-0012; Mahajan MA, 2004, MOL CELL BIOL, V24, P4994, DOI 10.1128/MCB.24.11.4994-5004.2004; Mahajan MA, 2000, MOL CELL BIOL, V20, P5048, DOI 10.1128/MCB.20.14.5048-5063.2000; Malik S, 2005, TRENDS BIOCHEM SCI, V30, P256, DOI 10.1016/j.tibs.2005.03.009; Matsuda T, 2001, J BIOL CHEM, V276, P42908, DOI 10.1074/jbc.M105316200; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Moustakas A, 2001, J CELL SCI, V114, P4359; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Panousis CG, 2001, J LIPID RES, V42, P856; Plevin MJ, 2005, TRENDS BIOCHEM SCI, V30, P66, DOI 10.1016/j.tibs.2004.12.001; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Randall RA, 2002, EMBO J, V21, P145, DOI 10.1093/emboj/21.1.145; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Savkur RS, 2004, J PEPT RES, V63, P207, DOI 10.1111/j.1399-3011.2004.00126.x; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Singh NN, 2006, ARTERIOSCL THROM VAS, V26, P1323, DOI 10.1161/01.ATV.0000220383.19192.55; Steffensen KR, 2006, FUTURE LIPIDOL, V1, P181, DOI 10.2217/17460875.1.2.181; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Wu G, 2000, SCIENCE, V287, P92, DOI 10.1126/science.287.5450.92; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Zhu YJ, 2003, J BIOL CHEM, V278, P1986, DOI 10.1074/jbc.C200634200; Zhu YJ, 2001, P NATL ACAD SCI USA, V98, P10380, DOI 10.1073/pnas.181347498	44	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					8995	9001		10.1074/jbc.M707203200	http://dx.doi.org/10.1074/jbc.M707203200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18263591	hybrid			2022-12-25	WOS:000254465800029
J	Huising, MO; Vaughan, JM; Shah, SH; Grillot, KL; Donaldson, CJ; Rivier, J; Flik, G; Vale, WW				Huising, Mark O.; Vaughan, Joan M.; Shah, Shaili H.; Grillot, Katherine L.; Donaldson, Cynthia J.; Rivier, Jean; Flik, Gert; Vale, Wylie W.			Residues of corticotropin releasing factor-binding protein (CRF-BP) that selectively abrogate binding to CRF but not to urocortin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPERIMENTAL HEART-FAILURE; ALZHEIMERS-DISEASE; HORMONE CRH; COUPLED RECEPTOR; HIGH-AFFINITY; HUMAN-PLASMA; UROTENSIN-I; PEPTIDE; ANTAGONISTS; LIGAND	Corticotropin releasing factor-binding protein ( CRF-BP) binds CRF and urocortin 1 ( Ucn 1) with high affinity, thus preventing CRF receptor ( CRFR) activation. Despite recent progress on the molecular details that govern interactions between CRF family neuropeptides and their cognate receptors, little is known concerning the mechanisms that allow CRF-BP to bind CRF and Ucn 1 with picomolar affinity. We conducted a comprehensive alanine scan of 76 evolutionarily conserved residues of CRF-BP and identified several residues that differentially affected the affinity for CRF over Ucn 1. We determined that both neuropeptides derive their similarly high affinity from distinct binding surfaces on CRF-BP. Alanine substitutions of arginine 56 ( R56A) and aspartic acid 62 ( D62A) reduce the affinity for CRF by similar to 100-fold, while only marginally affecting the affinity for Ucn 1. The selective reduction in affinity for CRF depends on glutamic acid 25 in the CRF peptide, as substitution of Glu(25) reduces the affinity for CRF-BP by approximately 2 orders of magnitude, but only in the presence of both Arg(56) and Asp(62) in human CRF-BP. We show that CRF-BPR56A and CRF-BPD62A have lost the ability to inhibit CRFR1-mediated responses to CRF that activate luciferase induction in HEK293T cells and ACTH release from cultured rat anterior pituitary cells. In contrast, both CRF- BP mutants retain the ability to inhibit Ucn 1-induced CRFR1 activation. Collectively our findings demonstrate that CRF- BP has distinct and separable binding surfaces for CRF and Ucn 1, opening new avenues for the design of ligand-specific antagonists based on CRF- BP.	[Huising, Mark O.; Vaughan, Joan M.; Shah, Shaili H.; Grillot, Katherine L.; Donaldson, Cynthia J.; Rivier, Jean; Vale, Wylie W.] Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA; [Huising, Mark O.; Flik, Gert] Radboud Univ Nijmegen, Dept Anim Physiol, NL-6525 ED Nijmegen, Netherlands	Salk Institute; Radboud University Nijmegen	Huising, MO (corresponding author), 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	huising@salk.edu	Flik, Gert/C-8229-2011; Huising, Mark O./H-3885-2019	Flik, Gert/0000-0001-9285-7957; Huising, Mark O./0000-0002-6594-2205	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK026741] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK 26741] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALDERMAN SL, 2007, COMP NEUROL, V502, P783; BEHAN DP, 1995, NATURE, V378, P284, DOI 10.1038/378284a0; Bilezikjian LM, 2001, ENDOCRINOLOGY, V142, P1065, DOI 10.1210/en.142.3.1065; Boorse GC, 2005, ENDOCRINOLOGY, V146, P4851, DOI 10.1210/en.2005-0497; Chen A, 2006, P NATL ACAD SCI USA, V103, P16580, DOI 10.1073/pnas.0607337103; DESOUZA EB, 1986, NATURE, V319, P593, DOI 10.1038/319593a0; DeSouza EB, 1995, PSYCHONEUROENDOCRINO, V20, P789, DOI 10.1016/0306-4530(95)00011-9; Doyon C, 2005, J ENDOCRINOL, V186, P123, DOI 10.1677/joe.1.06142; Eckart K, 2001, P NATL ACAD SCI USA, V98, P11142, DOI 10.1073/pnas.211424998; Fekete EM, 2007, FRONT NEUROENDOCRIN, V28, P1, DOI 10.1016/j.yfrne.2006.09.002; FISCHER WH, 1994, J BIOL CHEM, V269, P4313; Grace CRR, 2007, BIOPOLYMERS, V87, P196, DOI 10.1002/bip.20818; Grace CRR, 2007, P NATL ACAD SCI USA, V104, P4858, DOI 10.1073/pnas.0700682104; Grace CRR, 2004, P NATL ACAD SCI USA, V101, P12836, DOI 10.1073/pnas.0404702101; HOROVITZ A, 1990, J MOL BIOL, V216, P1031, DOI 10.1016/S0022-2836(99)80018-7; Hsu SY, 2001, NAT MED, V7, P605, DOI 10.1038/87936; Huising M, 2004, J MOL ENDOCRINOL, V32, P627, DOI 10.1677/jme.0.0320627; Huising MO, 2005, ENDOCRINOLOGY, V146, P2165, DOI 10.1210/en.2004-1514; Jahn O, 2002, P NATL ACAD SCI USA, V99, P12055, DOI 10.1073/pnas.192449299; Jahn O, 2001, PEPTIDES, V22, P47, DOI 10.1016/S0196-9781(00)00356-9; Kemp CF, 1998, PEPTIDES, V19, P1119, DOI 10.1016/S0196-9781(98)00057-6; Kobayashi T, 2005, WORLD J MICROB BIOT, V21, P961, DOI 10.1007/s11274-004-7162-5; LEAKE A, 1990, BIOL PSYCHIAT, V28, P603, DOI 10.1016/0006-3223(90)90398-L; Lewis K, 2001, P NATL ACAD SCI USA, V98, P7570, DOI 10.1073/pnas.121165198; LINTON EA, 1988, CLIN ENDOCRINOL, V28, P315, DOI 10.1111/j.1365-2265.1988.tb01218.x; MAY C, 1987, NEUROLOGY, V37, P535, DOI 10.1212/WNL.37.3.535; ORTH DN, 1987, BIOCHEM BIOPH RES CO, V143, P411, DOI 10.1016/0006-291X(87)91369-6; PALLAI PV, 1983, P NATL ACAD SCI-BIOL, V80, P6770, DOI 10.1073/pnas.80.22.6770; PERUTZ MF, 1990, ANNU REV PHYSIOL, V52, P1; POTTER E, 1991, NATURE, V349, P423, DOI 10.1038/349423a0; POTTER E, 1992, P NATL ACAD SCI USA, V89, P4192, DOI 10.1073/pnas.89.9.4192; Rademaker MT, 2005, EUR HEART J, V26, P2055, DOI 10.1093/eurheartj/ehi351; Rademaker MT, 2002, J AM COLL CARDIOL, V40, P1495, DOI 10.1016/S0735-1097(02)02170-8; Reyes TM, 2001, P NATL ACAD SCI USA, V98, P2843, DOI 10.1073/pnas.051626398; Rijkers DTS, 2004, CHEMBIOCHEM, V5, P340, DOI 10.1002/cbic.200300769; Rivier J, 2002, J MED CHEM, V45, P4737, DOI 10.1021/jm0202122; Ruhmann A, 1998, P NATL ACAD SCI USA, V95, P15264, DOI 10.1073/pnas.95.26.15264; SAPHIER PW, 1992, J ENDOCRINOL, V133, P487, DOI 10.1677/joe.0.1330487; Sauer RT, 1996, FASEB J, V10, P42, DOI 10.1096/fasebj.10.1.8566546; Schurmeyer T H, 1987, Horm Metab Res Suppl, V16, P24; Smith Sean M, 2006, Dialogues Clin Neurosci, V8, P383; SUDA T, 1988, J CLIN ENDOCR METAB, V67, P1278, DOI 10.1210/jcem-67-6-1278; SUDA T, 1989, BIOCHEM BIOPH RES CO, V165, P703, DOI 10.1016/S0006-291X(89)80023-3; SUTTON SW, 1995, ENDOCRINOLOGY, V136, P1097, DOI 10.1210/en.136.3.1097; VALE W, 1983, METHOD ENZYMOL, V103, P565; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VAUGHAN J, 1995, NATURE, V378, P287, DOI 10.1038/378287a0; VAUGHAN JM, 1989, ENDOCRINOLOGY, V125, P1660, DOI 10.1210/endo-125-3-1660; Webster EL, 1996, ENDOCRINOLOGY, V137, P5747, DOI 10.1210/en.137.12.5747; Woods RJ, 1999, J CLIN ENDOCR METAB, V84, P2788, DOI 10.1210/jc.84.8.2788; Yamada Y, 2004, J MED CHEM, V47, P1075, DOI 10.1021/jm034180+; Zorrilla EP, 2003, TRENDS PHARMACOL SCI, V24, P421, DOI 10.1016/S0165-6147(03)00177-9	52	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					8902	8912		10.1074/jbc.M709904200	http://dx.doi.org/10.1074/jbc.M709904200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18234674	Green Published, Green Submitted, hybrid			2022-12-25	WOS:000254465800018
J	Ivarsson, Y; Travaglini-Allocatelli, C; Brunori, M; Gianni, S				Ivarsson, Ylva; Travaglini-Allocatelli, Carlo; Brunori, Maurizio; Gianni, Stefano			Folding and misfolding in a naturally occurring circularly permuted PDZ domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL PROCESSING PROTEASE; ON-PATHWAY INTERMEDIATE; TRANSITION-STATE; PHOTOSYSTEM-II; SCENEDESMUS-OBLIQUUS; CONTACT ORDER; D1; MECHANISM; KINETICS; PERMUTATIONS	One of the most extreme and fascinating examples of naturally occurring mutagenesis is represented by circular permutation. Circular permutations involve the linking of two chain ends and cleavage at another site. Here we report the first description of the folding mechanism of a naturally occurring circularly permuted protein, a PDZ domain from the green alga Scenedesmus obliquus. Data reveal that the folding of the permuted protein is characterized by the presence of a low energy off-pathway kinetic trap. This finding contrasts with what was previously observed for canonical PDZ domains that, although displaying a similar primary structure when structurally re-aligned, fold via an on-pathway productive intermediate. Although circular permutation of PDZ domains may be necessary for a correct orientation of their functional sites in multidomain protein scaffolds, such structural rearrangement may compromise their folding pathway. This study provides a straightforward example of the divergent demands of folding and function.	[Ivarsson, Ylva; Travaglini-Allocatelli, Carlo; Brunori, Maurizio; Gianni, Stefano] Univ Roma La Sapienza, Dipartimento Sci Biochim A Rossi Fanelli, Ist Biol & Patol Mol, CNR, I-00185 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome	Gianni, S (corresponding author), Univ Roma La Sapienza, Dipartimento Sci Biochim A Rossi Fanelli, Ist Biol & Patol Mol, CNR, P Le A More 5, I-00185 Rome, Italy.	stefano.gianni@uniroma1.it	gianni, stefano/C-8536-2009; Ivarsson, Ylva/HGE-0283-2022	Ivarsson, Ylva/0000-0002-7081-3846; Gianni, Stefano/0000-0003-1653-1925; Brunori, Maurizio/0000-0002-7795-1635; Travaglini-Allocatelli, Carlo/0000-0001-8735-1126				ABKEVICH VI, 1994, BIOCHEMISTRY-US, V33, P10026, DOI 10.1021/bi00199a029; Baker D, 2000, NATURE, V405, P39, DOI 10.1038/35011000; Chi CN, 2007, FEBS LETT, V581, P1109, DOI 10.1016/j.febslet.2007.02.011; DINER BA, 1988, J BIOL CHEM, V263, P8972; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; FERREIRO DU, 2000, P NATL ACAD SCI USA, P19819; Fersht AR, 2004, P NATL ACAD SCI USA, V101, P7976, DOI 10.1073/pnas.0402684101; FERSHT AR, 1995, P NATL ACAD SCI USA, V92, P10869, DOI 10.1073/pnas.92.24.10869; FUJITA S, 1989, FEBS LETT, V255, P1, DOI 10.1016/0014-5793(89)81049-X; Gianni S, 2005, J BIOL CHEM, V280, P34805, DOI 10.1074/jbc.M506017200; Gianni S, 2005, PROTEIN ENG DES SEL, V18, P389, DOI 10.1093/protein/gzi047; Gianni S, 2007, P NATL ACAD SCI USA, V104, P128, DOI 10.1073/pnas.0602770104; Harris BZ, 2001, J CELL SCI, V114, P3219; Ivarsson Y, 2007, J BIOL CHEM, V282, P8568, DOI 10.1074/jbc.M611026200; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10436, DOI 10.1021/bi00107a011; Jemth P, 2004, P NATL ACAD SCI USA, V101, P6450, DOI 10.1073/pnas.0401732101; KIEFHABER T, 1995, P NATL ACAD SCI USA, V92, P9029, DOI 10.1073/pnas.92.20.9029; Li L, 2001, J MOL BIOL, V306, P121, DOI 10.1006/jmbi.2000.4375; Liao DI, 2000, NAT STRUCT BIOL, V7, P749, DOI 10.1038/78973; Lindberg M, 2002, NAT STRUCT BIOL, V9, P818, DOI 10.1038/nsb847; Lindberg MO, 2007, CURR OPIN STRUC BIOL, V17, P21, DOI 10.1016/j.sbi.2007.01.008; Lindberg MO, 2001, J MOL BIOL, V314, P891, DOI 10.1006/jmbi.2001.5186; Lindqvist Y, 1997, CURR OPIN STRUC BIOL, V7, P422, DOI 10.1016/S0959-440X(97)80061-9; Miller EJ, 2002, P NATL ACAD SCI USA, V99, P10359, DOI 10.1073/pnas.162219099; Oliveberg M, 2005, Q REV BIOPHYS, V38, P245, DOI 10.1017/S0033583506004185; Onuchic JN, 1997, ANNU REV PHYS CHEM, V48, P545, DOI 10.1146/annurev.physchem.48.1.545; Otzen DE, 1998, BIOCHEMISTRY-US, V37, P8139, DOI 10.1021/bi980250g; Pandya MJ, 1999, J BIOL CHEM, V274, P26828, DOI 10.1074/jbc.274.38.26828; Plaxco KW, 1998, J MOL BIOL, V277, P985, DOI 10.1006/jmbi.1998.1645; Silow M, 1997, P NATL ACAD SCI USA, V94, P6084, DOI 10.1073/pnas.94.12.6084; Trost JT, 1997, J BIOL CHEM, V272, P20348, DOI 10.1074/jbc.272.33.20348; Viguera AR, 1996, NAT STRUCT BIOL, V3, P874, DOI 10.1038/nsb1096-874; Vogel C, 2006, BIOESSAYS, V28, P973, DOI 10.1002/bies.20474; Wu Y, 2007, J MOL BIOL, V366, P1624, DOI 10.1016/j.jmb.2006.12.005; Yamamoto Y, 2001, J BIOL CHEM, V276, P7518, DOI 10.1074/jbc.M008877200	35	24	24	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					8954	8960		10.1074/jbc.M707424200	http://dx.doi.org/10.1074/jbc.M707424200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18263589	hybrid			2022-12-25	WOS:000254465800024
J	Song, DS; Lee, FS				Song, Daisheng; Lee, Frank S.			A role for IOP1 in mammalian cytosolic iron-sulfur protein biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; FE-S CLUSTER; REGULATORY PROTEIN-1; RESPONSIVE ELEMENTS; MOLECULAR CONTROL; SCAFFOLD PROTEIN; HOMEOSTASIS; MITOCHONDRIA; TRANSLATION; DEGRADATION	The biogenesis of cytosolic iron-sulfur ( Fe-S) proteins in mammalian cells is poorly understood. In Saccharomyces cerevisiae, there is a pathway dedicated to cytosolic Fe-S protein maturation that involves several essential proteins. One of these is Nar1, which intriguingly is homologous to iron-only hydrogenases, ancient enzymes that catalyze the formation of hydrogen gas in anaerobic bacteria. There are two orthologues of Nar1 in mammalian cells, iron-only hydrogenase-like protein 1 ( IOP1) and IOP2 ( also known as nuclear prelamin A recognition factor). We examined IOP1 for a potential role in mammalian cytosolic Fe-Sproteinbiogenesis. We found that knockdown of IOP1 in both HeLa and Hep3B cells decreases the activity of cytosolic aconitase, an Fe-S protein, but not that of mitochondrial aconitase. Knockdown of IOP2, in contrast, had no effect on either. The decrease in aconitase activity upon IOP1 knockdown is rescued by expression of a small interference RNA-resistant version of IOP1. Upon loss of its Fe-S cluster, cytosolic aconitase is known to be converted to iron regulatory protein 1, and consistent with this, we found that IOP1 knockdown increases transferrin receptor 1 mRNA levels and decreases ferritin heavy chain protein levels. IOP1 knockdown also leads to a decrease in activity of xanthine oxidase, a distinct cytosolic Fe-S protein. Taken together, these results provide evidence that IOP1 is involved in mammalian cytosolic Fe-S protein maturation.	[Song, Daisheng; Lee, Frank S.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Lee, FS (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 605 Stellar Chance Labs,422 Curie Blvd, Philadelphia, PA 19104 USA.	franklee@mail.med.upenn.edu		Lee, Frank/0000-0003-2511-1834	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071459] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM071459, R01 GM 71459] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balk J, 2005, MOL CELL BIOL, V25, P10833, DOI 10.1128/MCB.25.24.10833-10841.2005; Balk J, 2004, EMBO J, V23, P2105, DOI 10.1038/sj.emboj.7600216; Barton RM, 1999, J BIOL CHEM, V274, P30008, DOI 10.1074/jbc.274.42.30008; Biederbick A, 2006, MOL CELL BIOL, V26, P5675, DOI 10.1128/MCB.00112-06; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; Clarke SL, 2006, EMBO J, V25, P544, DOI 10.1038/sj.emboj.7600954; Drapier JC, 1996, METHOD ENZYMOL, V269, P26; Eisenstein RS, 2000, ANNU REV NUTR, V20, P627, DOI 10.1146/annurev.nutr.20.1.627; Fosset C, 2006, J BIOL CHEM, V281, P25398, DOI 10.1074/jbc.M602979200; GUO B, 1995, J BIOL CHEM, V270, P16529, DOI 10.1074/jbc.270.28.16529; Hausmann A, 2005, P NATL ACAD SCI USA, V102, P3266, DOI 10.1073/pnas.0406447102; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Huang JH, 2007, BIOCHEM J, V401, P341, DOI 10.1042/BJ20060635; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; Kispal G, 2005, EMBO J, V24, P589, DOI 10.1038/sj.emboj.7600541; Li KY, 2006, J BIOL CHEM, V281, P12344, DOI 10.1074/jbc.M600582200; Lill R, 2005, TRENDS BIOCHEM SCI, V30, P133, DOI 10.1016/j.tibs.2005.01.006; Lill R, 2006, ANNU REV CELL DEV BI, V22, P457, DOI 10.1146/annurev.cellbio.22.010305.104538; Liu LP, 2006, MOL CELL, V21, P521, DOI 10.1016/j.molcel.2006.01.010; Meyron-Holtz EG, 2004, EMBO J, V23, P386, DOI 10.1038/sj.emboj.7600041; Mueller S, 2002, METHOD ENZYMOL, V348, P324, DOI 10.1016/S0076-6879(02)48651-X; Netz DJA, 2007, NAT CHEM BIOL, V3, P278, DOI 10.1038/nchembio872; Rouault TA, 2005, NAT REV MOL CELL BIO, V6, P345, DOI 10.1038/nrm1620; Rouault TA, 2006, NAT CHEM BIOL, V2, P406, DOI 10.1038/nchembio807; Roy A, 2003, EMBO J, V22, P4826, DOI 10.1093/emboj/cdg455; Sanchez M, 2007, NAT STRUCT MOL BIOL, V14, P420, DOI 10.1038/nsmb1222; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SETCHENSKA MS, 1978, BIOCHEM J, V170, P193, DOI 10.1042/bj1700193; Tong WH, 2006, CELL METAB, V3, P199, DOI 10.1016/j.cmet.2006.02.003; Tong WH, 2003, P NATL ACAD SCI USA, V100, P9762, DOI 10.1073/pnas.1732541100; Wang J, 2007, MOL CELL BIOL, V27, P2423, DOI 10.1128/MCB.01111-06; Yarunin A, 2005, EMBO J, V24, P580, DOI 10.1038/sj.emboj.7600540; Yu F, 2001, CANCER RES, V61, P4136	34	60	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9231	9238		10.1074/jbc.M708077200	http://dx.doi.org/10.1074/jbc.M708077200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18270200	hybrid, Green Published			2022-12-25	WOS:000254465800053
J	Bethune, MT; Borda, JT; Ribka, E; Liu, MX; Phillippi-Falkenstein, K; Jandacek, RJ; Doxiadis, GGM; Gray, GM; Khosla, C; Sestak, K				Bethune, Michael T.; Borda, Juan T.; Ribka, Erin; Liu, Michael-Xun; Phillippi-Falkenstein, Kathrine; Jandacek, Ronald J.; Doxiadis, Gaby G. M.; Gray, Gary M.; Khosla, Chaitan; Sestak, Karol			A Non-Human Primate Model for Gluten Sensitivity	PLOS ONE			English	Article								Background and Aims: Gluten sensitivity is widespread among humans. For example, in celiac disease patients, an inflammatory response to dietary gluten leads to enteropathy, malabsorption, circulating antibodies against gluten and transglutaminase 2, and clinical symptoms such as diarrhea. There is a growing need in fundamental and translational research for animal models that exhibit aspects of human gluten sensitivity. Methods: Using ELISA-based antibody assays, we screened a population of captive rhesus macaques with chronic diarrhea of non-infectious origin to estimate the incidence of gluten sensitivity. A selected animal with elevated anti-gliadin antibodies and a matched control were extensively studied through alternating periods of gluten-free diet and gluten challenge. Blinded clinical and histological evaluations were conducted to seek evidence for gluten sensitivity. Results: When fed with a gluten-containing diet, gluten-sensitive macaques showed signs and symptoms of celiac disease including chronic diarrhea, malabsorptive steatorrhea, intestinal lesions and anti-gliadin antibodies. A gluten-free diet reversed these clinical, histological and serological features, while reintroduction of dietary gluten caused rapid relapse. Conclusions: Gluten-sensitive rhesus macaques may be an attractive resource for investigating both the pathogenesis and the treatment of celiac disease.	[Bethune, Michael T.; Khosla, Chaitan] Stanford Univ, Dept Biochem, Stanford, CA 94305 USA; [Borda, Juan T.; Ribka, Erin; Liu, Michael-Xun; Phillippi-Falkenstein, Kathrine; Sestak, Karol] Tulane Natl Primate Res Ctr, Covington, LA USA; [Jandacek, Ronald J.] Univ Cincinnati, Dept Pathol, Lab Med, Cincinnati, OH USA; [Doxiadis, Gaby G. M.] Biomed Primate Res Ctr, Rijswijk, Netherlands; [Gray, Gary M.] Stanford Univ, Dept Med, Stanford, CA USA; [Khosla, Chaitan] Stanford Univ, Dept Chem, Stanford, CA USA; [Khosla, Chaitan] Stanford Univ, Dept Chem Engn, Stanford, CA USA; [Sestak, Karol] Tulane Univ, Sch Med, Dept Microbiol & Immunol, New Orleans, LA USA	Stanford University; Tulane University; University System of Ohio; University of Cincinnati; Stanford University; Stanford University; Stanford University; Tulane University	Bethune, MT (corresponding author), Stanford Univ, Dept Biochem, Stanford, CA 94305 USA.	ksestak@tulane.edu		Khosla, Chaitan/0000-0001-6529-495X	TNPRC [R21 AI54146, R01 DK063158, P51 RR00164, U24 RR018111]; University of Cincinnati [DK59630]; NIH; NATIONAL CENTER FOR RESEARCH RESOURCES [U24RR018111, P51RR000164] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI054146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK076653, U24DK059630, U2CDK059630, R01DK063158] Funding Source: NIH RePORTER	TNPRC; University of Cincinnati; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Grant support: This research was jointly supported by R21 AI54146 to K.S., R01 DK063158 to C.K., grants P51 RR00164 and U24 RR018111 to the TNPRC, and DK59630 to the University of Cincinnati. M.T.B. was a recipient of an NIH Cellular and Molecular Biology Training Grant through Stanford University at the outset of this work.	Alaedini A, 2005, ANN INTERN MED, V142, P289, DOI 10.7326/0003-4819-142-4-200502150-00011; BATT RM, 1984, RES VET SCI, V37, P339, DOI 10.1016/S0034-5288(18)31875-7; BATT RM, 1987, DIGEST DIS SCI, V32, P184, DOI 10.1007/BF01297107; BETHUNE MT, 2008, PLOS ONE IN PRESS; Borda JT, 2004, AM J PATHOL, V165, P2111, DOI 10.1016/S0002-9440(10)63261-0; Cerf-Bensussan N, 2007, GUT, V56, P157, DOI 10.1136/gut.2005.090498; Corrao G, 2001, LANCET, V358, P356, DOI 10.1016/S0140-6736(01)05554-4; Dassanayake RP, 2005, J CLIN MICROBIOL, V43, P641, DOI 10.1128/JCM.43.2.641-649.2005; DICKE W K, 1953, Acta Paediatr, V42, P34, DOI 10.1111/j.1651-2227.1953.tb05563.x; Dieterich W, 1997, NAT MED, V3, P797, DOI 10.1038/nm0797-797; Green PHR, 2006, ANNU REV MED, V57, P207, DOI 10.1146/annurev.med.57.051804.122404; HALL EJ, 1992, GUT, V33, P198, DOI 10.1136/gut.33.2.198; HARRIS RL, 1984, LAB ANIM SCI, V34, P610; Jandacek RJ, 2004, GASTROENTEROLOGY, V127, P139, DOI 10.1053/j.gastro.2004.04.007; Johnston SD, 1998, QJM-MON J ASSOC PHYS, V91, P853, DOI 10.1093/qjmed/91.12.853; MAKI M, 1995, BAILLIERE CLIN GASTR, V9, P231, DOI 10.1016/0950-3528(95)90030-6; March JB, 2003, DIGEST DIS SCI, V48, P608, DOI 10.1023/A:1022565522441; Marietta E, 2004, J CLIN INVEST, V114, P1090, DOI 10.1172/JCI200421055; MARSH MN, 1992, GASTROENTEROLOGY, V102, P330, DOI 10.1016/0016-5085(92)91819-P; Piper JL, 2002, BIOCHEMISTRY-US, V41, P386, DOI 10.1021/bi011715x; Polvi A, 1998, TISSUE ANTIGENS, V52, P543, DOI 10.1111/j.1399-0039.1998.tb03085.x; Polvi A, 1997, TISSUE ANTIGENS, V49, P236, DOI 10.1111/j.1399-0039.1997.tb02744.x; Ramesh G, 2005, CLIN DIAGN LAB IMMUN, V12, P192, DOI 10.1128/CDLI.12.1.192-197.2005; Report of Working Group of European Society of Paediatric Gastroenterology and Nutrition, 1990, ARCH DIS CHILD, V65, P909; Rewers M, 2005, GASTROENTEROLOGY, V128, pS47, DOI 10.1053/j.gastro.2005.02.030; Schuppan Detlef, 2005, Nutr Clin Care, V8, P54; Sestak K, 2005, CURR HIV RES, V3, P199, DOI 10.2174/1570162054368084; Sestak K, 2003, INFECT IMMUN, V71, P4079, DOI 10.1128/IAI.71.7.4079-4086.2003; Shan L, 2002, SCIENCE, V297, P2275, DOI 10.1126/science.1074129; Sollid LM, 2005, NAT CLIN PRACT GASTR, V2, P140, DOI 10.1038/ncpgasthep0111; Sollid LM, 2002, NAT REV IMMUNOL, V2, P647, DOI 10.1038/nri885; SOLLID LM, 1989, J EXP MED, V169, P345, DOI 10.1084/jem.169.1.345; Spurkland A, 1997, TISSUE ANTIGENS, V49, P29, DOI 10.1111/j.1399-0039.1997.tb02706.x; Stepniak D, 2006, TRENDS BIOTECHNOL, V24, P433, DOI 10.1016/j.tibtech.2006.08.003; WAGNER JD, 1988, LAB ANIM SCI, V38, P592; Wahab PJ, 2002, AM J CLIN PATHOL, V118, P459	36	57	58	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1614	10.1371/journal.pone.0001614	http://dx.doi.org/10.1371/journal.pone.0001614			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286171	Green Published, Green Submitted, gold			2022-12-25	WOS:000260586400007
J	Pooggin, MM; Futterer, J; Hohn, T				Pooggin, Mikhail M.; Fuetterer, Johannes; Hohn, Thomas			Cross-Species Functionality of Pararetroviral Elements Driving Ribosome Shunting	PLOS ONE			English	Article								Background: Cauliflower mosaic virus (CaMV) and Rice tungro bacilliform virus (RTBV) belong to distinct genera of pararetroviruses infecting dicot and monocot plants, respectively. In both viruses, polycistronic translation of pregenomic (pg) RNA is initiated by shunting ribosomes that bypass a large region of the pgRNA leader with several short (s) ORFs and a stable stem-loop structure. The shunt requires translation of a 5'-proximal sORF terminating near the stem. In CaMV, mutations knocking out this sORF nearly abolish shunting and virus viability. Methodology/Principal Findings: Here we show that two distant regions of the CaMV leader that form a minimal shunt configuration comprising the sORF, a bottom part of the stem, and a shunt landing sequence can be replaced by heterologous sequences that form a structurally similar configuration in RTBV without any dramatic effect on shunt-mediated translation and CaMV infectivity. The CaMV-RTBV chimeric leader sequence was largely stable over five viral passages in turnip plants: a few alterations that did eventually occur in the virus progenies are indicative of fine tuning of the chimeric sequence during adaptation to a new host. Conclusions/Significance: Our findings demonstrate cross-species functionality of pararetroviral cis-elements driving ribosome shunting and evolutionary conservation of the shunt mechanism. We are grateful to Matthias Muller and Sandra Pauli for technical assistance. This work was initiated at Friedrich Miescher Institute (Basel, Switzerland). We thank Prof. Thomas Boller for hosting the group at the Institute of Botany.	[Pooggin, Mikhail M.; Hohn, Thomas] Univ Basel, Inst Bot, CH-4056 Basel, Switzerland; [Fuetterer, Johannes] ETH Zentrum, Inst Plant Sci, Zurich, Switzerland	University of Basel; Swiss Federal Institutes of Technology Domain; ETH Zurich	Pooggin, MM (corresponding author), Univ Basel, Inst Bot, Hebelstr 1, CH-4056 Basel, Switzerland.	Mikhail.Pooggin@unibas.ch		Pooggin, Mikhail/0000-0003-2308-393X	FEBS [fellowship]	FEBS	This work was initially supported a FEBS fellowship to MMP.	Babinger K, 2006, DEVELOPMENT, V133, P4045, DOI 10.1242/dev.02582; Blevins T, 2006, NUCLEIC ACIDS RES, V34, P6233, DOI 10.1093/nar/gkl886; BONNEVILLE JM, 1989, CELL, V59, P1135, DOI 10.1016/0092-8674(89)90769-1; Chappell SA, 2006, P NATL ACAD SCI USA, V103, P9488, DOI 10.1073/pnas.0603597103; de Breyne S, 2003, NUCLEIC ACIDS RES, V31, P608, DOI 10.1093/nar/gkg143; Dominguez DI, 1998, J BIOL CHEM, V273, P3669, DOI 10.1074/jbc.273.6.3669; DRIESEN M, 1993, VIROLOGY, V195, P203, DOI 10.1006/viro.1993.1361; FUTTERER J, 1990, EMBO J, V9, P1697, DOI 10.1002/j.1460-2075.1990.tb08293.x; FUTTERER J, 1991, EMBO J, V10, P3887, DOI 10.1002/j.1460-2075.1991.tb04958.x; FUTTERER J, 1993, CELL, V73, P789, DOI 10.1016/0092-8674(93)90257-Q; Futterer J, 1996, J VIROL, V70, P2999; FUTTERER J, 1994, VIROLOGY, V198, P663, DOI 10.1006/viro.1994.1078; Futterer J, 1997, J VIROL, V71, P7984; Geering ADW, 2005, ARCH VIROL, V150, P787, DOI 10.1007/s00705-004-0471-z; Guerra-Peraza O, 2000, J VIROL, V74, P2067, DOI 10.1128/JVI.74.5.2067-2072.2000; Hemmings-Mieszczak M, 1998, RNA, V4, P101; HemmingsMieszczak M, 1997, J MOL BIOL, V267, P1075, DOI 10.1006/jmbi.1997.0929; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Hull R., 1999, ENCYCL VIROL, V65, P1292; Hull R., 2002, MATTHEWS PLANT VIROL; KISSLASZLO Z, 1995, EMBO J, V14, P3552, DOI 10.1002/j.1460-2075.1995.tb07361.x; Lorkovic ZJ, 2000, TRENDS PLANT SCI, V5, P160, DOI 10.1016/S1360-1385(00)01595-8; Mize GJ, 1998, J BIOL CHEM, V273, P32500, DOI 10.1074/jbc.273.49.32500; Moissiard G, 2006, P NATL ACAD SCI USA, V103, P19593, DOI 10.1073/pnas.0604627103; Park HS, 2001, CELL, V106, P723, DOI 10.1016/S0092-8674(01)00487-1; Pauli S, 2004, J VIROL, V78, P12120, DOI 10.1128/JVI.78.22.12120-12128.2004; Pooggin MM, 2002, PLANT VIRUSES AS MOLECULAR PATHOGENS, P317; Pooggin MM, 2006, RNA, V12, P841, DOI 10.1261/rna.2285806; Pooggin MM, 2000, J BIOL CHEM, V275, P17288, DOI 10.1074/jbc.M001143200; Pooggin MM, 1999, J GEN VIROL, V80, P2217, DOI 10.1099/0022-1317-80-8-2217; Pooggin MM, 1998, J VIROL, V72, P4157, DOI 10.1128/JVI.72.5.4157-4169.1998; Pooggin MM, 2001, P NATL ACAD SCI USA, V98, P886, DOI 10.1073/pnas.98.3.886; Rogers GW, 2004, P NATL ACAD SCI USA, V101, P2794, DOI 10.1073/pnas.0308576101; ROTHNIE HM, 1994, EMBO J, V13, P2200, DOI 10.1002/j.1460-2075.1994.tb06497.x; Ryabova LA, 2000, GENE DEV, V14, P817; Ryabova LA, 2002, PROG NUCLEIC ACID RE, V72, P1, DOI 10.1016/S0079-6603(02)72066-7; Shababi M, 2006, J VIROL, V80, P3811, DOI 10.1128/JVI.80.8.3811-3822.2006; THIBEAULD O, 2008, ALTERNATIVE IN PRESS; Xi QR, 2005, J VIROL, V79, P5676, DOI 10.1128/JVI.79.9.5676-5683.2005; Yueh A, 2000, GENE DEV, V14, P414	40	12	12	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1650	10.1371/journal.pone.0001650	http://dx.doi.org/10.1371/journal.pone.0001650			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286203	gold, Green Published, Green Submitted			2022-12-25	WOS:000260586400043
J	Shindo, A; Yamamoto, TS; Ueno, N				Shindo, Asako; Yamamoto, Takamasa S.; Ueno, Naoto			Coordination of Cell Polarity during Xenopus Gastrulation	PLOS ONE			English	Article								Cell polarity is an essential feature of animal cells contributing to morphogenesis. During Xenopus gastrulation, it is known that chordamesoderm cells are polarized and intercalate each other allowing anterior-posterior elongation of the embryo proper by convergent extension (CE). Although it is well known that the cellular protrusions at both ends of polarized cells exert tractive force for intercalation and that PCP pathway is known to be essential for the cell polarity, little is known about what triggers the cell polarization and what the polarization causes to control intracellular events enabling the intercalation that leads to the CE. In our research, we used EB3 (end-binding 3), a member of + TIPs that bind to the plus end of microtubule (MT), to visualize the intracellular polarity of chordamesoderm cells during CE to investigate the trigger of the establishment of cell polarity. We found that EB3 movement is polarized in chordamesoderm cells and that the notochordsomite tissue boundary plays an essential role in generating the cell polarity. This polarity was generated before the change of cell morphology and the polarized movement of EB3 in chordamesoderm cells was also observed near the boundary between the chordamesoderm tissue and naive ectoderm tissue or lateral mesoderm tissues induced by a low concentration of nodal mRNA. These suggest that definitive tissue separation established by the distinct levels of nodal signaling is essential for the chordamesodermal cells to acquire mediolateral cell polarity.	[Shindo, Asako; Yamamoto, Takamasa S.; Ueno, Naoto] Natl Inst Basic Biol, Dept Dev Biol, Div Morphogenesis, Okazaki, Japan; [Shindo, Asako; Ueno, Naoto] Grad Univ Adv Stud SOKENDAI, Sch Life Sci, Dept Basic Biol, Okazaki, Aichi, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Graduate University for Advanced Studies - Japan	Shindo, A (corresponding author), Natl Inst Basic Biol, Dept Dev Biol, Div Morphogenesis, Okazaki, Japan.	nueno@nibb.ac.jp		Shindo, Asako/0000-0002-3314-7151; Ueno, Naoto/0000-0002-8375-2317	Ministry of Education, Culture, Sport, Science and Technology, Japan	Ministry of Education, Culture, Sport, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	A grant from the Ministry of Education, Culture, Sport, Science and Technology, Japan.	Adler PN, 2002, DEV CELL, V2, P525, DOI 10.1016/S1534-5807(02)00176-4; ARIIZUMI T, 1991, International Journal of Developmental Biology, V35, P407; Chung HA, 2005, DEV BIOL, V282, P95, DOI 10.1016/j.ydbio.2005.02.030; Dent EW, 2003, NEURON, V40, P209, DOI 10.1016/S0896-6273(03)00633-0; Hyodo-Miura J, 2006, DEV CELL, V11, P69, DOI 10.1016/j.devcel.2006.04.019; Iioka H, 2004, J CELL BIOL, V164, P169, DOI 10.1083/jcb.200310027; Jankovics F, 2006, DEV CELL, V11, P375, DOI 10.1016/j.devcel.2006.07.014; JONES CM, 1995, DEVELOPMENT, V121, P3651; KELLER R, 1989, J EXP ZOOL, V251, P134, DOI 10.1002/jez.1402510204; Keller R, 2002, SCIENCE, V298, P1950, DOI 10.1126/science.1079478; Keller R, 2000, PHILOS T R SOC B, V355, P897, DOI 10.1098/rstb.2000.0626; Kroboth K, 2007, MOL BIOL CELL, V18, P910, DOI 10.1091/mbc.E06-03-0179; Lane MC, 1997, DEVELOPMENT, V124, P895; Mimori-Kiyosue Y, 2000, J CELL BIOL, V148, P505, DOI 10.1083/jcb.148.3.505; Mlodzik M, 2002, TRENDS GENET, V18, P564, DOI 10.1016/S0168-9525(02)02770-1; Mogensen MM, 2002, J CELL BIOL, V157, P1041, DOI 10.1083/jcb.200203001; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Ninomiya H, 2004, NATURE, V430, P364, DOI 10.1038/nature02620; Nishimura T, 2004, NAT CELL BIOL, V6, P328, DOI 10.1038/ncb1118; Nutt SL, 2001, GENE DEV, V15, P1152, DOI 10.1101/gad.191301; Schambony A, 2007, DEV CELL, V12, P779, DOI 10.1016/j.devcel.2007.02.016; Seifert JRK, 2007, NAT REV GENET, V8, P126, DOI 10.1038/nrg2042; Skoglund P, 2006, DEV DYNAM, V235, P1974, DOI 10.1002/dvdy.20818; Skoglund P, 2007, DEV BIOL, V301, P404, DOI 10.1016/j.ydbio.2006.09.005; SMITH KJ, 1994, CANCER RES, V54, P3672; Stepanova T, 2003, J NEUROSCI, V23, P2655; Strong CF, 2000, DEV BIOL, V222, P405, DOI 10.1006/dbio.2000.9710; Tamai K, 1999, DEV GROWTH DIFFER, V41, P41; VASILIEV JM, 1991, J CELL SCI, V98, P1; Wallingford JB, 2002, DEV CELL, V2, P695, DOI 10.1016/S1534-5807(02)00197-1; Wallingford JB, 2000, NATURE, V405, P81, DOI 10.1038/35011077; WANG SX, 1994, NATURE, V369, P400, DOI 10.1038/369400a0; Wittmann T, 2001, J CELL SCI, V114, P3795; Yamamoto TS, 2001, DEVELOPMENT, V128, P2769; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	36	27	27	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1600	10.1371/journal.pone.0001600	http://dx.doi.org/10.1371/journal.pone.0001600			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270587	Green Submitted, Green Published, gold			2022-12-25	WOS:000260535900034
J	Callister, SJ; Mccue, LA; Turse, JE; Monroe, ME; Auberry, KJ; Smith, RD; Adkins, JN; Lipton, MS				Callister, Stephen J.; McCue, Lee Ann; Turse, Joshua E.; Monroe, Matthew E.; Auberry, Kenneth J.; Smith, Richard D.; Adkins, Joshua N.; Lipton, Mary S.			Comparative Bacterial Proteomics: Analysis of the Core Genome Concept	PLOS ONE			English	Article							CONSERVED HYPOTHETICAL PROTEINS; ACCURATE MASS; ESCHERICHIA-COLI; ESSENTIAL GENES; GEOBACTER-SULFURREDUCENS; NUMERICAL-ANALYSIS; IDENTIFICATION; SALMONELLA; TYPHIMURIUM; EVOLUTION	While comparative bacterial genomic studies commonly predict a set of genes indicative of common ancestry, experimental validation of the existence of this core genome requires extensive measurement and is typically not undertaken. Enabled by an extensive proteome database developed over six years, we have experimentally verified the expression of proteins predicted from genomic ortholog comparisons among 17 environmental and pathogenic bacteria. More exclusive relationships were observed among the expressed protein content of phenotypically related bacteria, which is indicative of the specific lifestyles associated with these organisms. Although genomic studies can establish relative orthologous relationships among a set of bacteria and propose a set of ancestral genes, our proteomics study establishes expressed lifestyle differences among conserved genes and proposes a set of expressed ancestral traits.	[Callister, Stephen J.; Turse, Joshua E.; Monroe, Matthew E.; Smith, Richard D.; Adkins, Joshua N.; Lipton, Mary S.] Pacific NW Natl Lab, Div Biol Sci, Richland, WA 99352 USA; [McCue, Lee Ann] Pacific NW Natl Lab, Comp Sci & Math Div, Richland, WA USA; [Auberry, Kenneth J.] Pacific NW Natl Lab, Environm Mol Sci Lab, Richland, WA USA	United States Department of Energy (DOE); Pacific Northwest National Laboratory; United States Department of Energy (DOE); Pacific Northwest National Laboratory; United States Department of Energy (DOE); Pacific Northwest National Laboratory	Adkins, JN (corresponding author), Pacific NW Natl Lab, Div Biol Sci, Richland, WA 99352 USA.	Joshua.Adkins@pnl.gov; mary.lipton@pnl.gov	Monroe, Matthew/L-1157-2019; , 0000-0001-7041-1823/B-9144-2014; Adkins, Joshua/B-9881-2013; Lipton, Mary S/H-3913-2012; Smith, Richard D/J-3664-2012	, 0000-0001-7041-1823/0000-0001-7041-1823; Adkins, Joshua/0000-0003-0399-0700; Smith, Richard D/0000-0002-2381-2349; McCue, Lee Ann/0000-0003-4456-517X	Environmental Molecular Sciences Laboratory; Department of Energy's Office of Biological and Environmental Research, Pacific Northwest National Laboratory [ER63232-1018220-0007203]; National Institute of Allergy and Infectious Diseases; NIH/DHHS [Y1-AI-4894-01]; NIH National Center for Research Resources [RR18522]; DOE [DE-AC05-76RLO 1830]; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR018522] Funding Source: NIH RePORTER	Environmental Molecular Sciences Laboratory; Department of Energy's Office of Biological and Environmental Research, Pacific Northwest National Laboratory; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/DHHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); DOE(United States Department of Energy (DOE)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	The research described in this paper was performed in the Environmental Molecular Sciences Laboratory, a national scientific user facility sponsored by the Department of Energy's Office of Biological and Environmental Research and located at Pacific Northwest National Laboratory. Portions of this work were supported by the Department of Energy Office of Biological and Environmental Research at PNNL grant (ER63232-1018220-0007203), the National Institute of Allergy and Infectious Diseases (NIH/DHHS through interagency agreement Y1-AI-4894-01) and the NIH National Center for Research Resources (RR18522). PNNL is a multi-program national laboratory operated by Battelle for the DOE under Contract DE-AC05-76RLO 1830.	Adkins JN, 2006, MOL CELL PROTEOMICS, V5, P1450, DOI 10.1074/mcp.M600139-MCP200; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANSONG C, 2007, J PROTEOME IN PRESS; Bernhardt TG, 2004, MOL MICROBIOL, V52, P1255, DOI 10.1111/j.1365-2958.2004.04063.x; Callister SJ, 2006, J MICROBIOL METH, V67, P424, DOI 10.1016/j.mimet.2006.04.021; Chang HR, 1997, INT J SYST BACTERIOL, V47, P1253, DOI 10.1099/00207713-47-4-1253; Cheng J, 2005, NUCLEIC ACIDS RES, V33, pW72, DOI 10.1093/nar/gki396; Clark MA, 2001, J BACTERIOL, V183, P1853, DOI 10.1128/JB.183.6.1853-1861.2001; COSTAS M, 1990, ELECTROPHORESIS, V11, P382, DOI 10.1002/elps.1150110507; CRUZ CMV, 1984, J GEN MICROBIOL, V130, P2983; Ding YHR, 2006, BBA-PROTEINS PROTEOM, V1764, P1198, DOI 10.1016/j.bbapap.2006.04.017; Elias DA, 2007, J MICROBIOL METH, V68, P367, DOI 10.1016/j.mimet.2006.09.023; Elias DA, 2006, J MICROBIOL METH, V66, P223, DOI 10.1016/j.mimet.2005.11.009; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fang G, 2005, MOL BIOL EVOL, V22, P2147, DOI 10.1093/molbev/msi211; Fang RH, 2006, MOL CELL PROTEOMICS, V5, P714, DOI 10.1074/mcp.M500301-MCP200; FITCH WM, 1970, SYST ZOOL, V19, P99, DOI 10.2307/2412448; Galperin MY, 2004, NUCLEIC ACIDS RES, V32, P5452, DOI 10.1093/nar/gkh885; Gerdes SY, 2003, J BACTERIOL, V185, P5673, DOI 10.1128/JB.185.19.5673-5684.2003; Giovannoni SJ, 2005, SCIENCE, V309, P1242, DOI 10.1126/science.1114057; Glass JI, 2006, P NATL ACAD SCI USA, V103, P425, DOI 10.1073/pnas.0510013103; Harris JK, 2003, GENOME RES, V13, P407, DOI 10.1101/gr.652803; Hutchison CA, 1999, SCIENCE, V286, P2165, DOI 10.1126/science.286.5447.2165; Jiang M, 2007, J BACTERIOL, V189, P3434, DOI 10.1128/JB.00090-07; Jordan IK, 2002, GENOME RES, V12, P962, DOI 10.1101/gr.87702; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Kiebel GR, 2006, PROTEOMICS, V6, P1783, DOI 10.1002/pmic.200500500; Klasson L, 2004, TRENDS MICROBIOL, V12, P37, DOI 10.1016/j.tim.2003.11.006; Knuth K, 2004, MOL MICROBIOL, V51, P1729, DOI 10.1046/j.1365-2958.2003.03944.x; Koonin EV, 2003, NAT REV MICROBIOL, V1, P127, DOI 10.1038/nrmicro751; Kyrpides N, 1999, J MOL EVOL, V49, P413, DOI 10.1007/PL00006564; Lefebure T, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r71; LOVLEY DR, 1993, ARCH MICROBIOL, V159, P336, DOI 10.1007/BF00290916; Luo Q, 2007, J PROTEOME RES, V6, P3042, DOI 10.1021/pr070127o; Manes NP, 2007, MOL CELL PROTEOMICS, V6, P717, DOI 10.1074/mcp.M600282-MCP200; Methe BA, 2003, SCIENCE, V302, P1967, DOI 10.1126/science.1088727; Mira A, 2005, MOL BIOL EVOL, V22, P2135, DOI 10.1093/molbev/msi209; Mira A, 2001, TRENDS GENET, V17, P589, DOI 10.1016/S0168-9525(01)02447-7; Monroe ME, 2007, BIOINFORMATICS, V23, P2021, DOI 10.1093/bioinformatics/btm281; Mulkidjanian AY, 2006, P NATL ACAD SCI USA, V103, P13126, DOI 10.1073/pnas.0605709103; Mushegian AR, 1996, P NATL ACAD SCI USA, V93, P10268, DOI 10.1073/pnas.93.19.10268; Owens RM, 2004, EMBO J, V23, P3375, DOI 10.1038/sj.emboj.7600343; Qian WJ, 2005, J PROTEOME RES, V4, P53, DOI 10.1021/pr0498638; RayChaudhuri D, 1999, EMBO J, V18, P2372, DOI 10.1093/emboj/18.9.2372; Reen FJ, 2005, APPL ENVIRON MICROB, V71, P1616, DOI 10.1128/AEM.71.3.1616-1625.2005; Remm M, 2001, J MOL BIOL, V314, P1041, DOI 10.1006/jmbi.2000.5197; Richter M, 2007, J BACTERIOL, V189, P4899, DOI 10.1128/JB.00119-07; Romine MF, 2004, OMICS, V8, P239, DOI 10.1089/omi.2004.8.239; Sarkar SF, 2004, APPL ENVIRON MICROB, V70, P1999, DOI 10.1128/AEM.70.4.1999-2012.2004; Schmid AK, 2005, J PROTEOME RES, V4, P709, DOI 10.1021/pr049815n; Shi L, 2006, J BIOL CHEM, V281, P29131, DOI 10.1074/jbc.M604640200; Silhavy D, 1998, CURR GENET, V33, P340, DOI 10.1007/s002940050345; Smith RD, 2002, PROTEOMICS, V2, P513, DOI 10.1002/1615-9861(200205)2:5<513::AID-PROT513>3.0.CO;2-W; STONE M, 2007, MICROBE, V2, P474; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; West-Eberhard Mary Jane, 2003, pi; Yang F, 2005, J PROTEOME RES, V4, P846, DOI 10.1021/pr0497475; Zhang WW, 2006, BIOCHEM BIOPH RES CO, V349, P1412, DOI 10.1016/j.bbrc.2006.09.019; Zhang WW, 2006, PROTEOMICS, V6, P4286, DOI 10.1002/pmic.200500930; Zimmer JSD, 2006, MASS SPECTROM REV, V25, P450, DOI 10.1002/mas.20071	60	54	55	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2008	3	2							e1542	10.1371/journal.pone.0001542	http://dx.doi.org/10.1371/journal.pone.0001542			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367EQ	18253490	Green Published, Green Submitted, gold			2022-12-25	WOS:000260535700014
J	Lakshmikuttyamma, A; Pastural, E; Takahashi, N; Sawada, K; Sheridan, DP; DeCoteau, JF; Geyer, CR				Lakshmikuttyamma, A.; Pastural, E.; Takahashi, N.; Sawada, K.; Sheridan, D. P.; DeCoteau, J. F.; Geyer, C. R.			Bcr-Abl induces autocrine IGF-1 signaling	ONCOGENE			English	Article						IGF-1; BCR-ABL; CML; autocrine signaling	GROWTH-FACTOR-I; CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE INHIBITOR; ACUTE LYMPHOBLASTIC-LEUKEMIA; COLONY-STIMULATING FACTOR; FACTOR 1 RECEPTOR; HEMATOPOIETIC-CELLS; BETA-CATENIN; PHILADELPHIA-CHROMOSOME	Bcr-Abl oncogene is responsible for the initial phase of chronic myelogenous leukemia (CML), which is effectively treated by the Bcr-Abl inhibitor imatinib. Over time patients become resistant to treatment and progress to blast crisis, an event that is driven by additional genetic and epigenetic aberrations. Recently, we showed that Riz1 expression decreases in blast crisis and that re-expression of Riz1 inhibits IGF-1 expression. IGF-1 signaling is required in many stages of hematopoiesis and inappropriate activation of autocrine IGF-1 signaling may facilitate transformation to blast crisis. We observed that in 8 out of 11 matched CML patient biopsies the IGF-1 expression is elevated in blast crisis. We examined mechanisms used by CML blast crisis cell lines to activate IGF-1 expression. We found that Bcr-Abl activates autocrine IGF- 1 signaling using Hck and Stat5b. Inhibition of these signaling components using small molecule drugs or shRNA decreases proliferation and enhances apoptosis. Together, our study suggests that aberrant IGF- 1 signaling is an important event in blast crisis transformation and it provides a mechanism to explain the activity of IGF-1R and Hck inhibitors in blocking CML blast crisis phenotypes.	[Lakshmikuttyamma, A.; Pastural, E.; Sheridan, D. P.; DeCoteau, J. F.; Geyer, C. R.] Univ Saskatchewan, Genom Med & Pathobiol Res Grp, Dept Biochem, Saskatoon, SK S7N 5E5, Canada; [Lakshmikuttyamma, A.; DeCoteau, J. F.] Univ Saskatchewan, Dept Pathol, Saskatoon, SK S7N 5E5, Canada; [Pastural, E.; Geyer, C. R.] Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada; [Sheridan, D. P.] Univ Saskatchewan, Dept Med, Saskatoon, SK S7N 5E5, Canada; [Takahashi, N.; Sawada, K.] Akita Univ, Sch Med, Akita 010, Japan	University of Saskatchewan; University of Saskatchewan; University of Saskatchewan; University of Saskatchewan; Akita University	Geyer, CR (corresponding author), Univ Saskatchewan, Genom Med & Pathobiol Res Grp, Dept Biochem, Hlth Sci Bldg,107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.	ron.geyer@usask.ca	Lakshmikuttyamma, Ashakumary/K-7164-2019	Lakshmikuttyamma, Ashakumary/0000-0001-8580-7855				AKAHANE K, 1987, EXP HEMATOL, V15, P797; Barnes DJ, 2002, ACTA HAEMATOL-BASEL, V108, P180, DOI 10.1159/000065655; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Chen J, 2005, J BIOL CHEM, V280, P29912, DOI 10.1074/jbc.M504516200; Coluccia AML, 2007, EMBO J, V26, P1456, DOI 10.1038/sj.emboj.7601485; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; Corey SJ, 1999, BLOOD, V93, P1, DOI 10.1182/blood.V93.1.1; DanhauserRiedl S, 1996, CANCER RES, V56, P3589; Danielpour D, 2006, CYTOKINE GROWTH F R, V17, P59, DOI 10.1016/j.cytogfr.2005.09.007; Deutsch E, 2004, BRIT J CANCER, V91, P1735, DOI 10.1038/sj.bjc.6602190; DiNoto R, 1997, LEUKEMIA, V11, P1554; Doepfner KT, 2007, LEUKEMIA, V21, P1921, DOI 10.1038/sj.leu.2404813; Drexler HG, 1999, LEUKEMIA RES, V23, P207; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Guilhot F, 2007, BLOOD, V109, P4143, DOI 10.1182/blood-2006-09-046839; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Herrington J, 2000, ONCOGENE, V19, P2585, DOI 10.1038/sj.onc.1203526; HIZUKA N, 1987, ENDOCRINOL JAPON, V34, P81; Hoelbl A, 2006, BLOOD, V107, P4898, DOI 10.1182/blood-2005-09-3596; Hu YG, 2004, NAT GENET, V36, P453, DOI 10.1038/ng1343; Hu YG, 2006, P NATL ACAD SCI USA, V103, P16870, DOI 10.1073/pnas.0606509103; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Jiang XY, 1999, P NATL ACAD SCI USA, V96, P12804, DOI 10.1073/pnas.96.22.12804; JOHNSON EW, 1992, J IMMUNOL, V148, P63; Jones HE, 2006, ENDOCR-RELAT CANCER, V13, pS45, DOI 10.1677/erc.1.01275; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; Klejman A, 2002, EMBO J, V21, P5766, DOI 10.1093/emboj/cdf562; Kofoed EM, 2003, NEW ENGL J MED, V349, P1139, DOI 10.1056/NEJMoa022926; Krystal GW, 2000, CLIN CANCER RES, V6, P3319; KURTZ A, 1988, P NATL ACAD SCI USA, V85, P7825, DOI 10.1073/pnas.85.20.7825; LEROITH D, 1991, TRENDS ENDOCRIN MET, V2, P134, DOI 10.1016/1043-2760(91)90003-6; Lionberger JM, 2000, J BIOL CHEM, V275, P18581, DOI 10.1074/jbc.C000126200; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Majka M, 2001, BLOOD, V97, P3075, DOI 10.1182/blood.V97.10.3075; Mayerhofer M, 2002, BLOOD, V100, P3767, DOI 10.1182/blood-2002-01-0109; MERCHAV S, 1988, BRIT J HAEMATOL, V70, P267, DOI 10.1111/j.1365-2141.1988.tb02480.x; MERCHAV S, 1988, J CLIN INVEST, V81, P791, DOI 10.1172/JCI113385; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Mori N, 1998, BLOOD, V92, P3405, DOI 10.1182/blood.V92.9.3405.421k44_3405_3409; Nam S, 2007, MOL CANCER THER, V6, P1400, DOI 10.1158/1535-7163.MCT-06-0446; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; Pastural E, 2007, ONCOGENE, V26, P1586, DOI 10.1038/sj.onc.1209959; PEPE MG, 1987, J CELL PHYSIOL, V133, P219, DOI 10.1002/jcp.1041330204; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; Sachdev D, 2007, MOL CANCER THER, V6, P1, DOI 10.1158/1535-7163.MCT-06-0080; SANDERS M, 1993, EXP HEMATOL, V21, P25; Scherr M, 2006, BLOOD, V107, P3279, DOI 10.1182/blood-2005-08-3087; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schwartz GN, 1996, STEM CELLS, V14, P337, DOI 10.1002/stem.140337; Scott SA, 2007, EXP HEMATOL, V35, P263, DOI 10.1016/j.exphem.2006.10.005; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHIMON I, 1995, LEUKEMIA RES, V19, P233, DOI 10.1016/0145-2126(94)00133-U; Siddiquee K, 2007, P NATL ACAD SCI USA, V104, P7391, DOI 10.1073/pnas.0609757104; SPECCHIA G, 1992, BRIT J HAEMATOL, V80, P310, DOI 10.1111/j.1365-2141.1992.tb08138.x; Steller MA, 1996, CANCER RES, V56, P5087; Takahashi N, 2006, BLOOD, V108, p605A, DOI 10.1182/blood.V108.11.2134.2134; Tazzari PL, 2007, LEUKEMIA, V21, P886, DOI 10.1038/sj.leu.2404643; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Wang Y, 2005, J BIOL CHEM, V280, P10955, DOI 10.1074/jbc.M412808200; Wilson MB, 2002, ONCOGENE, V21, P8075, DOI 10.1038/sj.onc.1206008; Woelfle J, 2003, J BIOL CHEM, V278, P51261, DOI 10.1074/jbc.M309486200; ZADIK Z, 1993, J PEDIATR ENDOCRINOL, V6, P79; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829; Zhang ZH, 2006, MOL PHARMACOL, V69, P1510, DOI 10.1124/mol.106.023721; Zumkeller W, 1999, BLOOD, V94, P3653, DOI 10.1182/blood.V94.11.3653.423k42_3653_3657	72	34	36	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2008	27	27					3831	3844		10.1038/onc.2008.8	http://dx.doi.org/10.1038/onc.2008.8			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18246120				2022-12-25	WOS:000256904700007
J	Coll, T; Eyre, E; Rodriguez-Calvo, R; Palomer, X; Sanchez, RM; Merlos, M; Laguna, JC; Vazquez-Carrera, M				Coll, Teresa; Eyre, Elena; Rodriguez-Calvo, Ricardo; Palomer, Xavier; Sanchez, Rosa M.; Merlos, Manuel; Laguna, Juan Carlos; Vazquez-Carrera, Manuel			Oleate reverses palmitate-induced insulin resistance and inflammation in skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED-RECEPTOR; PROTEIN-KINASE-C; FACTOR-KAPPA-B; MONOUNSATURATED FATTY-ACIDS; TUMOR-NECROSIS-FACTOR; TRIGLYCERIDE SYNTHESIS; CARNITINE PALMITOYLTRANSFERASE; GENE-TRANSCRIPTION; DIABETES-MELLITUS; ALPHA EXPRESSION	Here we report that in skeletal muscle cells the contribution to insulin resistance and inflammation of two common dietary long-chain fatty acids depends on the channeling of these lipids to distinct cellular metabolic fates. Exposure of cells to the saturated fatty acid palmitate led to enhanced diacylglycerol levels and the consequent activation of the protein kinase C theta/nuclear factor kappa B pathway, finally resulting in enhanced interleukin 6 secretion and down-regulation of the expression of genes involved in the control of the oxidative capacity of skeletal muscle (peroxisome proliferator-activated receptor (PPAR)gamma-coactivator 1 alpha) and triglyceride synthesis (acyl-coenzyme A: diacylglycerol acyltransferase 2). In contrast, exposure to the monounsaturated fatty acid oleate did not lead to these changes. Interestingly, co-incubation of cells with palmitate and oleate reversed both inflammation and impairment of insulin signaling by channeling palmitate into triglycerides and by up-regulating the expression of genes involved in mitochondrial beta-oxidation, thus reducing its incorporation into diacylglycerol. Our findings support a model of cellular lipid metabolism in which oleate protects against palmitate-induced inflammation and insulin resistance in skeletal muscle cells by promoting triglyceride accumulation and mitochondrial beta-oxidation through PPAR alpha- and protein kinase A-dependent mechanisms.	[Coll, Teresa; Eyre, Elena; Rodriguez-Calvo, Ricardo; Palomer, Xavier; Sanchez, Rosa M.; Merlos, Manuel; Laguna, Juan Carlos; Vazquez-Carrera, Manuel] Univ Barcelona, Fac Farm, Unitat Farmacol, Dept Pharmacol & Therapeut Chem, E-08028 Barcelona, Spain; [Coll, Teresa; Eyre, Elena; Rodriguez-Calvo, Ricardo; Palomer, Xavier; Sanchez, Rosa M.; Merlos, Manuel; Laguna, Juan Carlos; Vazquez-Carrera, Manuel] Inst Salud Carlos III, CIBERDEM, E-08028 Barcelona, Spain; [Coll, Teresa; Eyre, Elena; Rodriguez-Calvo, Ricardo; Palomer, Xavier; Sanchez, Rosa M.; Merlos, Manuel; Laguna, Juan Carlos; Vazquez-Carrera, Manuel] Inst Biomed UB, E-08028 Barcelona, Spain	University of Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERDEM; Instituto de Salud Carlos III	Vazquez-Carrera, M (corresponding author), Univ Barcelona, Fac Farm, Unitat Farmacol, Dept Pharmacol & Therapeut Chem, Diagonal 643, E-08028 Barcelona, Spain.	mvazquezcarrera@ub.edu	Merlos, Manuel/AAC-3064-2021; Tarridas, Xavier Palomer/H-1494-2015; Rodriguez-Calvo, Ricardo/AAB-4054-2019; Vázquez-Carrera, Manuel/H-2612-2015; Laguna, JCLaguna - Juan C./C-5481-2017; Rodriguez-Calvo, Ricardo/R-6645-2018	Merlos, Manuel/0000-0002-8423-3033; Rodriguez-Calvo, Ricardo/0000-0001-7513-0983; Vázquez-Carrera, Manuel/0000-0001-7138-8207; Laguna, JCLaguna - Juan C./0000-0002-7082-0704; Rodriguez-Calvo, Ricardo/0000-0001-7513-0983; Eyre Sanchez, Elena/0000-0002-5858-9036				Berry EM, 1997, AM J CLIN NUTR, V66, P991; BODEN G, 1995, J CLIN INVEST, V96, P1261, DOI 10.1172/JCI118160; BODEN G, 1991, J CLIN INVEST, V88, P960, DOI 10.1172/JCI115399; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; BRADY PS, 1992, BIOCHEM J, V286, P779, DOI 10.1042/bj2860779; Burns KA, 2007, BBA-MOL CELL BIOL L, V1771, P952, DOI 10.1016/j.bbalip.2007.04.018; Chang CH, 2000, AM J PHYSIOL-GASTR L, V279, pG295, DOI 10.1152/ajpgi.2000.279.2.G295; Chavez JA, 2003, ARCH BIOCHEM BIOPHYS, V419, P101, DOI 10.1016/j.abb.2003.08.020; Coll T, 2006, DIABETES, V55, P2779, DOI 10.2337/db05-1494; COTRIGHT RN, 2000, AM J PHYSIOL-ENDOC M, V278, pE553; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; Delerive P, 2000, J BIOL CHEM, V275, P36703, DOI 10.1074/jbc.M004045200; Finck BN, 2006, J CLIN INVEST, V116, P615, DOI 10.1172/JCI27794; Finck BN, 2002, J CLIN INVEST, V109, P121, DOI 10.1172/JCI200214080; Finck BN, 2005, CELL METAB, V1, P133, DOI 10.1016/j.cmet.2005.01.006; Freeman WM, 1999, BIOTECHNIQUES, V26, P112, DOI 10.2144/99261rv01; Gaster M, 2005, DIABETES, V54, P648, DOI 10.2337/diabetes.54.3.648; Gorski J, 1998, MOL CELL BIOCHEM, V178, P113, DOI 10.1023/A:1006820907955; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; Hansen JB, 2001, J BIOL CHEM, V276, P3175, DOI 10.1074/jbc.M005567200; Holland WL, 2007, CELL METAB, V5, P167, DOI 10.1016/j.cmet.2007.01.002; Hondares E, 2006, ENDOCRINOLOGY, V147, P2829, DOI 10.1210/en.2006-0070; Hu FB, 2001, DIABETOLOGIA, V44, P805, DOI 10.1007/s001250100547; HUNNICUTT JW, 1994, DIABETES, V43, P540, DOI 10.2337/diabetes.43.4.540; Itani SI, 2000, DIABETES, V49, P1353, DOI 10.2337/diabetes.49.8.1353; Jacob S, 1999, DIABETES, V48, P1113, DOI 10.2337/diabetes.48.5.1113; Jove M, 2006, ENDOCRINOLOGY, V147, P552, DOI 10.1210/en.2005-0440; Jove M, 2005, ENDOCRINOLOGY, V146, P3087, DOI 10.1210/en.2004-1560; Kern PA, 2001, AM J PHYSIOL-ENDOC M, V280, pE745; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Kim JK, 2004, J CLIN INVEST, V114, P823, DOI 10.1172/JCI200422230; Kim JK, 2001, J CLIN INVEST, V108, P437, DOI 10.1172/JCI11559; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Krogsdam AM, 2002, BIOCHEM J, V363, P157, DOI 10.1042/0264-6021:3630157; Lazennec G, 2000, MOL ENDOCRINOL, V14, P1962, DOI 10.1210/me.14.12.1962; Li Y, 2004, J BIOL CHEM, V279, P45304, DOI 10.1074/jbc.C400186200; Listenberger LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI 10.1073/pnas.0630588100; Liu L, 2007, J CLIN INVEST, V117, P1679, DOI 10.1172/JCI30565; Low CC, 1996, DIABETES, V45, P569, DOI 10.2337/diabetes.45.5.569; Man WC, 2006, J LIPID RES, V47, P1928, DOI 10.1194/jlr.M600172-JLR200; Mascaro C, 1998, J BIOL CHEM, V273, P8560, DOI 10.1074/jbc.273.15.8560; Montell E, 2001, AM J PHYSIOL-ENDOC M, V280, pE229, DOI 10.1152/ajpendo.2001.280.2.E229; PARILLO M, 1992, METABOLISM, V41, P1373, DOI 10.1016/0026-0495(92)90111-M; Perdomo G, 2004, J BIOL CHEM, V279, P27177, DOI 10.1074/jbc.M403566200; Perseghin G, 1999, DIABETES, V48, P1600, DOI 10.2337/diabetes.48.8.1600; Pickersgill L, 2007, J BIOL CHEM, V282, P12583, DOI 10.1074/jbc.M611157200; Pickup JC, 1997, DIABETOLOGIA, V40, P1286, DOI 10.1007/s001250050822; Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327; Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742; Ryan M, 2000, QJM-MON J ASSOC PHYS, V93, P85, DOI 10.1093/qjmed/93.2.85; Schenk S, 2007, J CLIN INVEST, V117, P1690, DOI 10.1172/JCI30566; Schmitz-Peiffer C, 1999, J BIOL CHEM, V274, P24202, DOI 10.1074/jbc.274.34.24202; Schuler M, 2006, CELL METAB, V4, P407, DOI 10.1016/j.cmet.2006.10.003; Sebastian D, 2007, AM J PHYSIOL-ENDOC M, V292, pE677, DOI 10.1152/ajpendo.00360.2006; Stone SJ, 2004, J BIOL CHEM, V279, P11767, DOI 10.1074/jbc.M311000200; Vessby B, 2001, DIABETOLOGIA, V44, P312, DOI 10.1007/s001250051620; Weigert C, 2004, J BIOL CHEM, V279, P23942, DOI 10.1074/jbc.M312692200; Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102; Yamagishi SI, 2001, J BIOL CHEM, V276, P25096, DOI 10.1074/jbc.M007383200; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620	61	258	272	0	47	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11107	11116		10.1074/jbc.M708700200	http://dx.doi.org/10.1074/jbc.M708700200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18281277	Green Published, hybrid			2022-12-25	WOS:000255067400006
J	Forouhar, F; Abashidze, M; Xu, HM; Grochowski, LL; Seetharaman, J; Hussain, M; Kuzin, A; Chen, YH; Zhou, W; Xiao, R; Acton, TB; Montelione, GT; Galinier, A; White, RH; Tong, L				Forouhar, Farhad; Abashidze, Mariam; Xu, Huimin; Grochowski, Laura L.; Seetharaman, Jayaraman; Hussain, Munif; Kuzin, Alexandre; Chen, Yang; Zhou, Weihong; Xiao, Rong; Acton, Thomas B.; Montelione, Gaetano T.; Galinier, Anne; White, Robert H.; Tong, Liang			Molecular insights into the biosynthesis of the F-420 coenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHANOCALDOCOCCUS-JANNASCHII; METHANOCOCCUS-JANNASCHII; PHOTOREACTIVATING ENZYME; BACILLUS-SUBTILIS; GENE-CLUSTER; PROTEIN; IDENTIFICATION; TUBERCULOSIS; PROGRAM; DEHYDROGENASE	Coenzyme F-420, a hydride carrier, is found in Archaea and some bacteria and has crucial roles in methanogenesis, antibiotic biosynthesis, DNA repair, and activation of antitubercular compounds. CofD, 2-phospho-L-lactate transferase, catalyzes the last step in the biosynthesis of F-420-0(F-420 without polyglutamate), by transferring the lactyl phosphate moiety of lactyl(2) diphospho-(5') guanosine to 7,8-didemethyl-8-hydroxy-5-deazariboflavin ribitol (Fo). CofD is highly conserved among F-420-producing organisms, and weak sequence homologs are also found in non-F-420-producing organisms. This superfamily does not share any recognizable sequence conservation with other proteins. Here we report the first crystal structures of CofD, the free enzyme and two ternary complexes, with Fo and Pi or with Fo and GDP, from Methanosarcina mazei. The active site is located at the C-terminal end of a Rossmann fold core, and three large insertions make significant contributions to the active site and dimer formation. The observed binding modes of Fo and GDP can explain known biochemical properties of CofD and are also supported by our binding assays. The structures provide significant molecular insights into the biosynthesis of the F-420 coenzyme. Large structural differences in the active site region of the non-F-420-producing CofD homologs suggest that they catalyze a different biochemical reaction.	[Forouhar, Farhad; Abashidze, Mariam; Seetharaman, Jayaraman; Hussain, Munif; Kuzin, Alexandre; Chen, Yang; Zhou, Weihong; Tong, Liang] Columbia Univ, Dept Biol Sci, NE Struct Genom Consortium, New York, NY 10027 USA; [Xu, Huimin; Grochowski, Laura L.; White, Robert H.] Virginia Polytech Inst & State Univ, Dept Biochem, Blacksburg, VA 24061 USA; [Xiao, Rong; Acton, Thomas B.; Montelione, Gaetano T.] Rutgers State Univ, Dept Mol Biol & Biochem, NE Struct Genom Consortium, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; [Galinier, Anne] CNRS, Inst Biol Struct & Microbiol, UPR 9043, Chim Bacterienne Lab, F-13009 Marseille, France	Columbia University; Virginia Polytechnic Institute & State University; Rutgers State University New Brunswick; Centre National de la Recherche Scientifique (CNRS)	Tong, L (corresponding author), Columbia Univ, Dept Biol Sci, NE Struct Genom Consortium, New York, NY 10027 USA.	ltong@columbia.edu		Montelione, Gaetano/0000-0002-9440-3059; Tong, Liang/0000-0002-0563-6468	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM074958, P50GM062413] Funding Source: NIH RePORTER; NIGMS NIH HHS [P50 GM062413, U54 GM074958] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acton TB, 2005, METHOD ENZYMOL, V394, P210, DOI 10.1016/S0076-6879(05)94008-1; Aufhammer SW, 2004, STRUCTURE, V12, P361, DOI 10.1016/j.str.2004.02.010; AUTHAMMER SW, 2006, PROTEIN SCI, V14, P1840; Bair TB, 2001, ARCH MICROBIOL, V176, P37, DOI 10.1007/s002030100290; Boshoff HIM, 2005, NAT REV MICROBIOL, V3, P70, DOI 10.1038/nrmicro1065; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COATS JH, 1989, J ANTIBIOT, V42, P472, DOI 10.7164/antibiotics.42.472; DeLano W.L., 2002, PYMOL MANUAL; DIMARCO AA, 1990, ANNU REV BIOCHEM, V59, P355, DOI 10.1146/annurev.biochem.59.1.355; DIVITA G, 1993, J BIOL CHEM, V268, P13178; Doublie S, 1996, FEBS LETT, V384, P219, DOI 10.1016/0014-5793(96)00316-X; EKER AP, 1988, BIOCHEMISTRY-US, V27, P1758, DOI 10.1021/bi00405a056; EKER APM, 1990, J BIOL CHEM, V265, P8009; Gorke B, 2005, MICROBIOL-SGM, V151, P3777, DOI 10.1099/mic.0.28172-0; Graham DE, 2003, ARCH MICROBIOL, V180, P455, DOI 10.1007/s00203-003-0614-8; Graham DE, 2002, NAT PROD REP, V19, P133, DOI 10.1039/b103714p; Graupner M, 2002, BIOCHEMISTRY-US, V41, P3754, DOI 10.1021/bi011937v; Graupner M, 2001, BIOCHEMISTRY-US, V40, P10859, DOI 10.1021/bi0107703; Grochowski LL, 2006, J BACTERIOL, V188, P2836, DOI 10.1128/JB.188.8.2836-2844.2006; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Ikeno S, 2006, J ANTIBIOT, V59, P18, DOI 10.1038/ja.2006.4; Jansson M, 1996, J BIOMOL NMR, V7, P131; Jogl G, 2001, ACTA CRYSTALLOGR D, V57, P1127, DOI 10.1107/S0907444901006783; Johnson EF, 2005, J BIOL CHEM, V280, P38776, DOI 10.1074/jbc.M503492200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lessner DJ, 2006, P NATL ACAD SCI USA, V103, P17921, DOI 10.1073/pnas.0608833103; Li H, 2003, P NATL ACAD SCI USA, V100, P9785, DOI 10.1073/pnas.1733391100; Li H, 2003, BIOCHEMISTRY-US, V42, P9771, DOI 10.1021/bi034779b; Manjunatha UH, 2006, P NATL ACAD SCI USA, V103, P431, DOI 10.1073/pnas.0508392103; MCCORMICK JRD, 1982, J AM CHEM SOC, V104, P4014, DOI 10.1021/ja00378a044; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PESCHKE U, 1995, MOL MICROBIOL, V16, P1137, DOI 10.1111/j.1365-2958.1995.tb02338.x; Pompeo F, 2007, J BACTERIOL, V189, P1154, DOI 10.1128/JB.01575-06; RHODES PM, 1981, J GEN MICROBIOL, V124, P329; Stover CK, 2000, NATURE, V405, P962, DOI 10.1038/35016103; Warkentin E, 2001, EMBO J, V20, P6561, DOI 10.1093/emboj/20.23.6561; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504	40	37	38	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11832	11840		10.1074/jbc.M710352200	http://dx.doi.org/10.1074/jbc.M710352200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18252724	hybrid, Green Published			2022-12-25	WOS:000255067400082
J	Mueckler, M; Makepeace, C				Mueckler, Mike; Makepeace, Carol			Transmembrane segment 6 of the Glut1 glucose transporter is an outer helix and contains amino acid side chains essential for transport activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SCANNING MUTAGENESIS; SUGAR PERMEATION PATHWAY; XENOPUS-OOCYTES; ESCHERICHIA-COLI; ACCESSIBILITY; MECHANISM; BINDING; PROTEINS; DOMAINS; FAMILY	Experimental data and homology modeling suggest a structure for the exofacial configuration of the Glut1 glucose transporter in which 8 transmembrane helices form an aqueous cavity in the bilayer that is stabilized by four outer helices. The role of transmembrane segment 6, predicted to be an outer helix in this model, was examined by cysteine-scanning mutagenesis and the substituted cysteine accessibility method using the membrane-impermeant, sulfhydryl-specific reagent, p-chloromercuribenzene-sulfonate (pCMBS). A fully functional Glut1 molecule lacking all 6 native cysteine residues was used as a template to produce a series of 21 Glut1 point mutants in which each residue along helix 6 was individually changed to cysteine. These mutants were expressed in Xenopus oocytes, and their expression levels, functional activities, and sensitivities to inhibition by pCMBS were determined. Cysteine substitutions at Leu(204) and Pro(205) abolished transport activity, whereas substitutions at Ile(192), Pro(196), Gln(200), and Gly(201) resulted in inhibition of activity that ranged from similar to 35 to similar to 80%. Cysteine substitutions at Leu(188), Ser(191), and Leu(199) moderately augmented specific transport activity relative to the control. These results were dramatically different from those previously reported for helix 12, the structural cognate of helix 6 in the pseudo-symmetrical structural model, for which none of the 21 single-cysteine mutants exhibited reduced activity. Only the substitution at Leu(188) conferred inhibition by pCMBS, suggesting that most of helix 6 is not exposed to the external solvent, consistent with its proposed role as an outer helix. These data suggest that helix 6 contains amino acid side chains that are critical for transport activity and that structurally analogous outer helices may play distinct roles in the function of membrane transporters.	[Mueckler, Mike; Makepeace, Carol] Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Mueckler, M (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	mike@cellbio.wustl.edu	Mueckler, Mike M/F-6115-2012		NIDDK NIH HHS [P30 DK056341, P30 DK056341-07, P30 DK056341-08] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; BALDWIN SA, 1989, METHOD ENZYMOL, V174, P39; BARNETT JEG, 1973, BIOCHEM J, V131, P211, DOI 10.1042/bj1310211; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; Heinze M, 2004, BIOCHEMISTRY-US, V43, P931, DOI 10.1021/bi030175w; HRESKO RC, 1994, J BIOL CHEM, V269, P32110; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; Hruz PW, 2000, BIOCHEMISTRY-US, V39, P9367, DOI 10.1021/bi000821g; Hruz PW, 1999, J BIOL CHEM, V274, P36176, DOI 10.1074/jbc.274.51.36176; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; KASAHARA M, 1977, J BIOL CHEM, V252, P7384; KELLER K, 1989, J BIOL CHEM, V264, P18884; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; Mueckler M, 1999, J BIOL CHEM, V274, P10923, DOI 10.1074/jbc.274.16.10923; Mueckler M, 1997, BIOCHEM SOC T, V25, P951, DOI 10.1042/bst0250951; Mueckler M, 2004, J BIOL CHEM, V279, P46876, DOI 10.1074/jbc.M408632200; Mueckler M, 2004, J BIOL CHEM, V279, P10494, DOI 10.1074/jbc.M310786200; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; Mueckler M, 2002, J BIOL CHEM, V277, P3498, DOI 10.1074/jbc.M109157200; MUECKLER M, 1994, J BIOL CHEM, V269, P20533; Mueckler M, 1997, J BIOL CHEM, V272, P30141, DOI 10.1074/jbc.272.48.30141; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; Mueckler M, 2005, J BIOL CHEM, V280, P39562, DOI 10.1074/jbc.M509050200; Mueckler M, 2006, J BIOL CHEM, V281, P36993, DOI 10.1074/jbc.M608158200; Olsowski A, 2000, BIOCHEMISTRY-US, V39, P2469, DOI 10.1021/bi992160x; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; Saier MH, 2000, MOL MICROBIOL, V35, P699, DOI 10.1046/j.1365-2958.2000.01759.x; Salas-Burgos A, 2004, BIOPHYS J, V87, P2990, DOI 10.1529/biophysj.104.047886; WELLNER M, 1995, FEBS LETT, V370, P19, DOI 10.1016/0014-5793(95)00783-6	32	30	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11550	11555		10.1074/jbc.M708896200	http://dx.doi.org/10.1074/jbc.M708896200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18245775	Green Published, hybrid			2022-12-25	WOS:000255067400055
J	Kelly, RM; Leemhuis, H; Gatjen, L; Dijkhuizen, L				Kelly, Ronan M.; Leemhuis, Hans; Gatjen, Linda; Dijkhuizen, Lubbert			Evolution toward small molecule inhibitor resistance affects native enzyme function and stability, generating acarbose-insensitive cyclodextrin glucanotransferase variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIBIOTIC-RESISTANCE; DRUG-RESISTANCE; DIRECTED EVOLUTION; BIOLOGICAL COST; ALPHA-AMYLASE; FITNESS COST; COMPENSATORY EVOLUTION; STAPHYLOCOCCUS-AUREUS; AMINOGLYCOSIDE ACTION; PROTEASE INHIBITORS	Small molecule inhibitors play an essential role in the selective inhibition of enzymes associated with human infection and metabolic disorders. Targeted enzymes may evolve toward inhibitor resistance through selective incorporation of mutations. Acquisition of insensitivity may, however, result in profound devolution of native enzyme function and stability. We therefore investigated the consequential effects on native function and stability by evolving a cyclodextrin glucanotransferase (CGTase) enzyme toward insensitivity to the small molecule inhibitor of the protein, acarbose. Error-prone PCR mutagenesis was applied to search the sequence space of CGTase for acarbose-insensitive variants. Our results show that all selected mutations were localized around the active site of the enzyme, and in particular, at the acceptor substrate binding sites, highlighting the regions importance in acarbose inhibition. Single mutations conferring increased resistance, K232E, F283L, and A230V, raised IC50 values for acarbose between 3,500- and 6,700-fold when compared with wild-type CGTase but at a significant cost to catalytic efficiency. In addition, the thermostability of these variants was significantly lowered. These results reveal not only the relative ease by which resistance may be acquired to small molecule inhibitors but also the considerable cost incurred to native enzyme function and stability, highlighting the subsequent constraints in the further evolutionary potential of inhibitor-resistant variants.	[Kelly, Ronan M.; Leemhuis, Hans; Gatjen, Linda; Dijkhuizen, Lubbert] Univ Groningen, Ctr Carbohydrate Bioproc, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen	Dijkhuizen, L (corresponding author), Univ Groningen, Ctr Carbohydrate Bioproc, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.	L.Dijkhuizen@rug.nl	Dijkhuizen, Lubbert/K-3539-2019; Dijkhuizen, Lubbert/E-9454-2014	Dijkhuizen, Lubbert/0000-0003-2312-7162; 				Aharoni A, 2005, NAT GENET, V37, P73, DOI 10.1038/ng1482; Andersson DI, 2006, CURR OPIN MICROBIOL, V9, P461, DOI 10.1016/j.mib.2006.07.002; Beadle BM, 2002, J MOL BIOL, V321, P285, DOI 10.1016/S0022-2836(02)00599-5; Bjorkholm B, 2001, P NATL ACAD SCI USA, V98, P14607, DOI 10.1073/pnas.241517298; Bloom JD, 2006, P NATL ACAD SCI USA, V103, P5869, DOI 10.1073/pnas.0510098103; Cong ME, 2007, J VIROL, V81, P3037, DOI 10.1128/JVI.02712-06; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Doyon L, 1996, J VIROL, V70, P3763, DOI 10.1128/JVI.70.6.3763-3769.1996; Eijsink VGH, 2005, BIOMOL ENG, V22, P21, DOI 10.1016/j.bioeng.2004.12.003; Fernandez A, 2005, J BIOMOL STRUCT DYN, V22, P615, DOI 10.1080/07391102.2005.10531228; Fisher TS, 2002, J VIROL, V76, P4068, DOI 10.1128/JVI.76.8.4068-4072.2002; Gagneux S, 2006, SCIENCE, V312, P1944, DOI 10.1126/science.1124410; Galan JC, 2003, ANTIMICROB AGENTS CH, V47, P2551, DOI 10.1128/AAC.47.8.2551-2557.2003; Ghadessy FJ, 2001, P NATL ACAD SCI USA, V98, P4552, DOI 10.1073/pnas.071052198; Gough K, 2002, EUR J PHYCOL, V37, P419, DOI 10.1017/S0967026202003797; Gupta ML, 2003, P NATL ACAD SCI USA, V100, P6394, DOI 10.1073/pnas.1131967100; Jana S, 2006, APPL MICROBIOL BIOT, V70, P140, DOI 10.1007/s00253-005-0279-0; Janecek S, 2003, EUR J BIOCHEM, V270, P635, DOI 10.1046/j.1432-1033.2003.03404.x; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kahne D, 2005, CHEM REV, V105, P425, DOI 10.1021/cr030103a; Kanai R, 2004, PROTEIN SCI, V13, P457, DOI 10.1110/ps.03408504; Kaper T, 2002, BIOCHEM J, V368, P461, DOI 10.1042/BJ20020726; Kawate H, 2002, J BIOL CHEM, V277, P36304, DOI 10.1074/jbc.M204956200; Kelly RM, 2007, BIOCHEMISTRY-US, V46, P11216, DOI 10.1021/bi701160h; Kikuchi M, 1999, GENE, V236, P159, DOI 10.1016/S0378-1119(99)00240-1; KNEGTEL RMK, 1995, J BIOL CHEM, V270, P29256, DOI 10.1074/jbc.270.49.29256; Leach KL, 2007, MOL CELL, V26, P393, DOI 10.1016/j.molcel.2007.04.005; Leemhuis H, 2004, BIOCHEMISTRY-US, V43, P13204, DOI 10.1021/bi049015q; Leemhuis H, 2004, PROTEINS, V54, P128, DOI 10.1002/prot.10516; Leemhuis H, 2003, BIOCATAL BIOTRANSFOR, V21, P261, DOI 10.1080/10242420310001614333; Leemhuis H, 2003, BIOCHEMISTRY-US, V42, P7518, DOI 10.1021/bi034439q; Leemhuis H, 2003, EUR J BIOCHEM, V270, P155, DOI 10.1046/j.1432-1033.2003.03376.x; Leemhuis H, 2002, FEBS LETT, V514, P189, DOI 10.1016/S0014-5793(02)02362-1; Lin C, 2004, J BIOL CHEM, V279, P17508, DOI 10.1074/jbc.M313020200; Liu FL, 2005, J MOL BIOL, V354, P789, DOI 10.1016/j.jmb.2005.09.095; Magnet S, 2005, CHEM REV, V105, P477, DOI 10.1021/cr0301088; Mahalingam B, 1999, EUR J BIOCHEM, V263, P238, DOI 10.1046/j.1432-1327.1999.00514.x; Maisnier-Patin S, 2005, NAT GENET, V37, P1376, DOI 10.1038/ng1676; Maisnier-Patin S, 2004, RES MICROBIOL, V155, P360, DOI 10.1016/j.resmic.2004.01.019; Maisnier-Patin S, 2007, J MOL BIOL, V366, P207, DOI 10.1016/j.jmb.2006.11.047; Marciano DC, 2007, GENETICS, V176, P2381, DOI 10.1534/genetics.106.069443; McCallum N, 2006, ANTIMICROB AGENTS CH, V50, P2352, DOI 10.1128/AAC.00073-06; NAKAMURA A, 1993, BIOCHEMISTRY-US, V32, P6624, DOI 10.1021/bi00077a015; Normark BH, 2002, J INTERN MED, V252, P91, DOI 10.1046/j.1365-2796.2002.01026.x; Paulander W, 2007, MOL MICROBIOL, V64, P1038, DOI 10.1111/j.1365-2958.2007.05713.x; Poole K, 2001, CURR OPIN MICROBIOL, V4, P500, DOI 10.1016/S1369-5274(00)00242-3; Sanchez IE, 2006, J MOL BIOL, V363, P422, DOI 10.1016/j.jmb.2006.08.020; Stam MR, 2006, PROTEIN ENG DES SEL, V19, P555, DOI 10.1093/protein/gzl044; Uitdehaag JCM, 1999, J BIOL CHEM, V274, P34868, DOI 10.1074/jbc.274.49.34868; van der Kaaij RA, 2007, EUKARYOT CELL, V6, P1178, DOI 10.1128/EC.00354-06; van der Veen BA, 2000, J MOL BIOL, V296, P1027, DOI 10.1006/jmbi.2000.3528; van der Veen BA, 2001, J BIOL CHEM, V276, P44557, DOI 10.1074/jbc.M107533200; VIKMON M, 1982, RAPID SIMPLE SPECTRO, P69; Walsh C, 2000, NATURE, V406, P775, DOI 10.1038/35021219; Wang XJ, 2002, J MOL BIOL, V320, P85, DOI 10.1016/S0022-2836(02)00400-X; Wehmeier UF, 2004, APPL MICROBIOL BIOT, V63, P613, DOI 10.1007/s00253-003-1477-2; Wichelhaus TA, 2002, ANTIMICROB AGENTS CH, V46, P3381, DOI 10.1128/AAC.46.11.3381-3385.2002; Wicki J, 2007, J AM CHEM SOC, V129, P4530, DOI 10.1021/ja0707254; Wilke MS, 2005, CURR OPIN MICROBIOL, V8, P525, DOI 10.1016/j.mib.2005.08.016; Yin PD, 2006, CELL MOL LIFE SCI, V63, P1706, DOI 10.1007/s00018-006-6009-7	60	9	9	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10727	10734		10.1074/jbc.M709287200	http://dx.doi.org/10.1074/jbc.M709287200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18283101	Green Submitted, Green Published, hybrid			2022-12-25	WOS:000254894700055
J	Kostka, M; Hogen, T; Danzer, KM; Levin, J; Habeck, M; Wirth, A; Wagner, R; Glabe, CG; Finger, S; Heinzelmann, U; Garidel, P; Duan, W; Ross, CA; Kretzschmar, H; Giese, A				Kostka, Marcus; Hoegen, Tobias; Danzer, Karin M.; Levin, Johannes; Habeck, Matthias; Wirth, Andreas; Wagner, Richard; Glabe, Charles G.; Finger, Sabine; Heinzelmann, Udo; Garidel, Patrick; Duan, Wenzhen; Ross, Christopher A.; Kretzschmar, Hans; Giese, Armin			Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTENSELY FLUORESCENT TARGETS; PROTEIN MISFOLDING DISEASES; SOLUBLE AMYLOID OLIGOMERS; PARKINSONS-DISEASE; COMMON MECHANISM; PRION PROTEIN; METAL-IONS; NEURODEGENERATIVE DISEASES; VESICLE PERMEABILIZATION; TRANSGENIC MICE	Aggregation of alpha-synuclein is a key event in several neurodegenerative diseases, including Parkinson disease. Recent findings suggest that oligomers represent the principal toxic aggregate species. Using confocal single-molecule fluorescence techniques, such as scanning for intensely fluorescent targets (SIFT) and atomic force microscopy, we monitored alpha-synuclein oligomer formation at the single particle level. Organic solvents were used to trigger aggregation, which resulted in small oligomers ("intermediate I"). Under these conditions, Fe3+ at low micromolar concentrations dramatically increased aggregation and induced formation of larger oligomers ("intermediate II"). Both oligomer species were on-pathway to amyloid fibrils and could seed amyloid formation. Notably, only Fe3+-induced oligomers were SDS-resistant and could form ion-permeable pores in a planar lipid bilayer, which were inhibited by the oligomer-specific A11 antibody. Moreover, baicalein and N'-benzylidenebenzohydrazide derivatives inhibited oligomer formation. Baicalein also inhibited alpha-synuclein-dependent toxicity in neuronal cells. Our results may provide a potential disease mechanism regarding the role of ferric iron and of toxic oligomer species in Parkinson diseases. Moreover, scanning for intensely fluorescent targets allows high throughput screening for aggregation inhibitors and may provide new approaches for drug development and therapy.	[Kostka, Marcus; Danzer, Karin M.; Finger, Sabine; Heinzelmann, Udo; Garidel, Patrick] Boehringer Ingelheim Pharma GmbH & Co KG, CNS Res, D-88397 Biberach, Germany; [Hoegen, Tobias; Habeck, Matthias; Kretzschmar, Hans; Giese, Armin] Univ Munich, Zentrum Neuropathol & Prionforsch, D-81377 Munich, Germany; [Levin, Johannes] Univ Munich, Klinikum Grosshadern, Neurol Klin, D-81377 Munich, Germany; [Wirth, Andreas] Ionovat GmbH, D-49084 Osnabruck, Germany; [Wagner, Richard] Univ Osnabruck, Dept Biophys, D-49078 Osnabruck, Germany; [Glabe, Charles G.] Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; [Duan, Wenzhen; Ross, Christopher A.] Johns Hopkins Univ, Sch Med, Dept Psychiat, Div Neurobiol, Baltimore, MD 21287 USA	Boehringer Ingelheim; University of Munich; University of Munich; University Osnabruck; University of California System; University of California Irvine; Johns Hopkins University	Kostka, M (corresponding author), Boehringer Ingelheim Pharma GmbH & Co KG, CNS Res, Birkendorferstr 65, D-88397 Biberach, Germany.	Marcus.Kostka@boehringer-ingelheim.com; Armin.Giese@med.uni-muenchen.de	Giese, Armin/F-3271-2010; Ross, Christopher A/H-8395-2013; Levin, Johannes/E-4052-2010	Giese, Armin/0000-0002-8238-4102; Levin, Johannes/0000-0001-5092-4306	NINDS NIH HHS [R21 NS055971] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Behrends C, 2006, MOL CELL, V23, P887, DOI 10.1016/j.molcel.2006.08.017; Ben Shachar D, 2004, NEUROPHARMACOLOGY, V46, P254, DOI 10.1016/j.neuropharm.2003.09.005; BENSHACHAR D, 1991, J NEUROCHEM, V56, P1441, DOI 10.1111/j.1471-4159.1991.tb11444.x; Berg D, 2007, NEUROCHEM RES, V32, P1646, DOI 10.1007/s11064-007-9346-5; Bertsch U, 2005, J VIROL, V79, P7785, DOI 10.1128/JVI.79.12.7785-7791.2005; Bieschke J, 2000, P NATL ACAD SCI USA, V97, P5468, DOI 10.1073/pnas.97.10.5468; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; COLTON RJ, 1997, PROCEDURES SCANNING; DEXTER DT, 1989, J NEUROCHEM, V52, P1830, DOI 10.1111/j.1471-4159.1989.tb07264.x; El-Agnaf OMA, 2004, FASEB J, V18, P1315, DOI 10.1096/fj.03-1346fje; El-Agnaf OMA, 2006, FASEB J, V20, P419, DOI 10.1096/fj.03-1449com; Fink AL, 2006, ACCOUNTS CHEM RES, V39, P628, DOI 10.1021/ar050073t; Forman MS, 2005, NEURON, V47, P479, DOI 10.1016/j.neuron.2005.07.021; Gaeta A, 2005, BRIT J PHARMACOL, V146, P1041, DOI 10.1038/sj.bjp.0706416; Giese A, 2005, BIOCHEM BIOPH RES CO, V333, P1202, DOI 10.1016/j.bbrc.2005.06.025; Giese A, 2004, BIOCHEM BIOPH RES CO, V320, P1240, DOI 10.1016/j.bbrc.2004.06.075; Glabe CG, 2006, NEUROLOGY, V66, pS74, DOI 10.1212/01.wnl.0000192103.24796.42; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; Gorell JM, 1997, NEUROLOGY, V48, P650, DOI 10.1212/WNL.48.3.650; Gosavi N, 2002, J BIOL CHEM, V277, P48984, DOI 10.1074/jbc.M208194200; Gotz ME, 2004, ANN NY ACAD SCI, V1012, P193, DOI 10.1196/annals.1306.017; Hasegawa T, 2004, BRAIN RES, V1013, P51, DOI 10.1016/j.brainres.2004.04.018; Kahle PJ, 2001, AM J PATHOL, V159, P2215, DOI 10.1016/S0002-9440(10)63072-6; Kask P, 1999, P NATL ACAD SCI USA, V96, P13756, DOI 10.1073/pnas.96.24.13756; Kaur D, 2003, NEURON, V37, P899, DOI 10.1016/S0896-6273(03)00126-0; Kaur D, 2007, NEUROBIOL AGING, V28, P907, DOI 10.1016/j.neurobiolaging.2006.04.003; Kayed R, 2004, J BIOL CHEM, V279, P46363, DOI 10.1074/jbc.C400260200; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kokubo H, 2005, BRAIN RES, V1031, P222, DOI 10.1016/j.brainres.2004.10.041; Koo EH, 1999, P NATL ACAD SCI USA, V96, P9989, DOI 10.1073/pnas.96.18.9989; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lashuel HA, 2002, J MOL BIOL, V322, P1089, DOI 10.1016/S0022-2836(02)00735-0; Lee MK, 2002, P NATL ACAD SCI USA, V99, P8968, DOI 10.1073/pnas.132197599; Levin J, 2005, BIOCHEM BIOPH RES CO, V329, P1200, DOI 10.1016/j.bbrc.2005.02.094; Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843; Meuser D, 1999, FEBS LETT, V462, P447, DOI 10.1016/S0014-5793(99)01579-3; Michaeli S, 2007, MOVEMENT DISORD, V22, P334, DOI 10.1002/mds.21227; Munishkina LA, 2003, BIOCHEMISTRY-US, V42, P2720, DOI 10.1021/bi027166s; Nuscher B, 2004, J BIOL CHEM, V279, P21966, DOI 10.1074/jbc.M401076200; Oakley AE, 2007, NEUROLOGY, V68, P1820, DOI 10.1212/01.wnl.0000262033.01945.9a; Obata T, 2006, EUR J PHARMACOL, V539, P34, DOI 10.1016/j.ejphar.2006.03.071; Ostrerova-Golts N, 2000, J NEUROSCI, V20, P6048, DOI 10.1523/JNEUROSCI.20-16-06048.2000; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Pountney DL, 2004, J NEUROCHEM, V90, P502, DOI 10.1111/j.1471-4159.2004.02533.x; RIEDERER P, 1989, J NEUROCHEM, V52, P515, DOI 10.1111/j.1471-4159.1989.tb09150.x; Sanbe A, 2004, P NATL ACAD SCI USA, V101, P10132, DOI 10.1073/pnas.0401900101; Schiffer NW, 2007, J BIOL CHEM, V282, P9195, DOI 10.1074/jbc.M607865200; Sharon R, 2003, NEURON, V37, P583, DOI 10.1016/S0896-6273(03)00024-2; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Smith WW, 2005, HUM MOL GENET, V14, P3801, DOI 10.1093/hmg/ddi396; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Tanaka Y, 2001, HUM MOL GENET, V10, P919, DOI 10.1093/hmg/10.9.919; Tofaris GK, 2007, ARCH NEUROL-CHICAGO, V64, P280, DOI 10.1001/archneur.64.2.280; Uversky VN, 2001, J BIOL CHEM, V276, P44284, DOI 10.1074/jbc.M105343200; Volles MJ, 2002, BIOCHEMISTRY-US, V41, P4595, DOI 10.1021/bi0121353; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509; WOODBURY DJ, 1988, BIOPHYS J, V54, P345, DOI 10.1016/S0006-3495(88)82965-5; Youdim MBH, 2004, ANN NY ACAD SCI, V1012, P306, DOI 10.1196/annals.1306.025; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795; ZAYED J, 1990, CAN J NEUROL SCI, V17, P286, DOI 10.1017/S0317167100030584; Zhang X, 2005, BIOCHEM BIOPH RES CO, V333, P544, DOI 10.1016/j.bbrc.2005.05.150; Zhu M, 2004, J BIOL CHEM, V279, P26846, DOI 10.1074/jbc.M403129200	64	188	197	1	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10992	11003		10.1074/jbc.M709634200	http://dx.doi.org/10.1074/jbc.M709634200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18258594	hybrid			2022-12-25	WOS:000254894700080
J	Dultz, E; Hildenbeutel, M; Martoglio, B; Hochman, J; Dobberstein, B; Kapp, K				Dultz, Elisa; Hildenbeutel, Markus; Martoglio, Bruno; Hochman, Jacob; Dobberstein, Bernhard; Kapp, Katja			The signal peptide of the mouse mammary tumor virus Rem protein is released from the endoplasmic reticulum membrane and accumulates in nucleoli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARENAVIRUS ENVELOPE GLYCOPROTEIN; T-CELL LYMPHOMAS; CORE PROTEIN; INTRAMEMBRANE PROTEOLYSIS; CLEAVAGE; B23; IDENTIFICATION; TRANSLOCATION; SEQUENCE; COMPLEX	N-terminal signal sequences mediate endoplasmic reticulum (ER) targeting and insertion of nascent secretory and membrane proteins and are, in most cases, cleaved off by signal peptidase. The mouse mammary tumor virus envelope protein and its alternative splice variant Rem have an unusually long signal sequence, which contains a nuclear localization signal. Although the envelope protein is targeted to the ER, inserted, and glycosylated, Rem has been described as a nuclear protein. Rem as well as a truncated version identical to the cleaved signal sequence have been shown to function as nuclear export factors for intron-containing transcripts. Using transiently transfected cells, we found that Rem is targeted to the ER, where the C-terminal portion is translocated and glycosylated. The signal sequence is cleaved off and accumulates in nucleoli. In a cell-free in vitro system, the generation of the Rem signal peptide depends on the presence of microsomal membranes. In vitro and in cells, the signal peptide initially accumulates in the membrane and is subsequently released into the cytosol. This release does not depend on processing by signal peptide peptidase, an intramembrane cleaving protease that can mediate the liberation of signal peptide fragments from the ER membrane. Our study suggests a novel pathway by which a signal peptide can be released from the ER membrane to fulfill a post-targeting function in a different compartment.	[Dultz, Elisa; Hildenbeutel, Markus; Dobberstein, Bernhard; Kapp, Katja] Univ Heidelberg ZMBH, Zentrum Mol Biol, D-69120 Heidelberg, Germany; [Martoglio, Bruno] Nova Pharma AG, Novartis Inst Biomed Res, CH-4002 Basel, Switzerland; [Hochman, Jacob] Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Cell & Anim Biol, IL-91904 Jerusalem, Israel	Ruprecht Karls University Heidelberg; Novartis; Hebrew University of Jerusalem	Kapp, K (corresponding author), Univ Heidelberg ZMBH, Zentrum Mol Biol, D-69120 Heidelberg, Germany.	k.kapp@zmbh.uni-heidelberg.de	Dultz, Elisa/AAQ-1918-2021	Dultz, Elisa/0000-0003-1114-5523				Agnihothram SS, 2006, J VIROL, V80, P5189, DOI 10.1128/JVI.00208-06; Ait-Goughoulte M, 2006, J GEN VIROL, V87, P855, DOI 10.1099/vir.0.81664-0; Bar-Sinai A, 2005, CANCER RES, V65, P7223, DOI 10.1158/0008-5472.CAN-04-3879; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DICKSON C, 1980, J VIROL, V35, P349, DOI 10.1128/JVI.35.2.349-361.1980; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; Eichler R, 2003, EMBO REP, V4, P1084, DOI 10.1038/sj.embor.7400002; Eichler R, 2003, FEBS LETT, V538, P203, DOI 10.1016/S0014-5793(03)00160-1; Fineberg K, 2003, BIOCHEMISTRY-US, V42, P2625, DOI 10.1021/bi0206199; Froeschke M, 2003, J BIOL CHEM, V278, P41914, DOI 10.1074/jbc.M302343200; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Hegde RS, 2006, TRENDS BIOCHEM SCI, V31, P563, DOI 10.1016/j.tibs.2006.08.004; Hoch-Marchaim H, 1998, VIROLOGY, V242, P246, DOI 10.1006/viro.1997.8997; Hoch-Marchaim H, 2003, VIROLOGY, V313, P22, DOI 10.1016/S0042-6822(03)00236-8; Indik S, 2005, VIROLOGY, V337, P1, DOI 10.1016/j.virol.2005.03.040; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lemberg MK, 2001, J IMMUNOL, V167, P6441, DOI 10.4049/jimmunol.167.11.6441; LOWER R, 1995, J VIROL, V69, P141; LYKO F, 1995, J BIOL CHEM, V270, P19873, DOI 10.1074/jbc.270.34.19873; MACKALL J, 1979, ANAL BIOCHEM, V95, P270, DOI 10.1016/0003-2697(79)90216-1; Majeau N, 2005, J GEN VIROL, V86, P3055, DOI 10.1099/vir.0.81174-0; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; McLauchlan J, 2002, EMBO J, V21, P3980, DOI 10.1093/emboj/cdf414; Mertz JA, 2005, J VIROL, V79, P14737, DOI 10.1128/JVI.79.23.14737-14747.2005; MICHALIDES R, 1982, J VIROL, V43, P819, DOI 10.1128/JVI.43.3.819-829.1982; RACEVSKIS J, 1982, J VIROL, V42, P804, DOI 10.1128/JVI.42.3.804-813.1982; REDMOND SMS, 1983, EMBO J, V2, P125, DOI 10.1002/j.1460-2075.1983.tb01393.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P379; Schrempf S, 2007, J VIROL, V81, P12515, DOI 10.1128/JVI.01481-07; Szebeni A, 1997, BIOCHEMISTRY-US, V36, P3941, DOI 10.1021/bi9627931; SZEBENI A, 1995, BIOCHEMISTRY-US, V34, P8037, DOI 10.1021/bi00025a009; Szebeni A, 1999, PROTEIN SCI, V8, P905; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Vauloup-Fellous C, 2006, J BIOL CHEM, V281, P27679, DOI 10.1074/jbc.M602587200; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WALTER P, 1983, METHOD ENZYMOL, V96, P84; Weihofen A, 2000, J BIOL CHEM, V275, P30951, DOI 10.1074/jbc.M005980200; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; York J, 2004, J VIROL, V78, P10783, DOI 10.1128/JVI.78.19.10783-10792.2004; York J, 2006, J VIROL, V80, P7775, DOI 10.1128/JVI.00642-06	41	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9966	9976		10.1074/jbc.M705712200	http://dx.doi.org/10.1074/jbc.M705712200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18270201	hybrid			2022-12-25	WOS:000254671600053
J	Holtje, M; Hofmann, F; Lux, R; Veh, RW; Just, I; Ahnert-Hilger, G				Hoeltje, Markus; Hofmann, Fred; Lux, Romy; Veh, Ruediger W.; Just, Ingo; Ahnert-Hilger, Gudrun			Glutamate uptake and release by Astrocytes are enhanced by Clostridium botulinum C3 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPSES; RHO	Inhibition of Rho activity by Clostridium botulinum C3 transferase ( C3bot) versatily changes functional properties of neural cells. Using cultivated mouse astrocytes, we show here that C3bot increases both uptake and secretion of glutamate. The enhanced glutamate uptake is initiated by an NF kappa B-dependent up-regulation of the glial glutamate transporter 1 that is efficaciously sorted to the plasma membrane. The increase in cytosolic glutamate concentration promotes vesicular glutamate storage in astrocytes treated with C3bot. Parallel to the increased storage, C3-induced impairment of Rho-dependent pathways strongly enhances Ca2+-dependent secretion of glutamate. This is accompanied by higher levels of the SNARE protein synaptobrevin. Synaptobrevin inactivation by botulinum neurotoxin D almost completely inhibits Ca2+-dependent glutamate secretion triggered by C3bot, indicating that the enhanced release of glutamate mainly originates from exocytosis. In addition, C3bot increases the exocytosis/endocytosis turnover, as analyzed by the stimulated accumulation of the fluorescent dye AM1-43. The release of glutamine, the main metabolite of glutamate, is only moderately affected by C3bot. In conclusion, inhibition of Rho-dependent pathways shifts astrocytes to a secretory active stage in which they may modulate neuronal excitability.	[Hoeltje, Markus; Lux, Romy; Veh, Ruediger W.; Ahnert-Hilger, Gudrun] Univ Berlin, Charite Med, Inst Integrat Neuroanat, Ctr Anat, D-10115 Berlin, Germany; [Hofmann, Fred; Just, Ingo] Med Hochschule Hannover, Inst Toxikol, D-30625 Hannover, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Hannover Medical School	Holtje, M (corresponding author), Univ Berlin, Charite Med, Inst Integrat Neuroanat, Ctr Anat, Philippstr 12, D-10115 Berlin, Germany.	markus.hoeltje@charite.de		Holtje, Markus/0000-0003-3193-4140; Veh, Rudiger/0000-0002-6253-9808				Abe K, 2003, DEV BRAIN RES, V143, P99, DOI 10.1016/S0165-3806(03)00096-8; Aktories K, 2005, CURR TOP MICROBIOL, V291, P113; Araque A, 1998, EUR J NEUROSCI, V10, P2129, DOI 10.1046/j.1460-9568.1998.00221.x; Bernstein BW, 1998, MOL BRAIN RES, V53, P236, DOI 10.1016/S0169-328X(97)00319-7; Bertrand J, 2007, NEUROBIOL DIS, V25, P65, DOI 10.1016/j.nbd.2006.08.008; Bezzi P, 2004, NAT NEUROSCI, V7, P613, DOI 10.1038/nn1246; Bezzi P, 1998, NATURE, V391, P281, DOI 10.1038/34651; Boquet P, 1998, CURR OPIN MICROBIOL, V1, P66, DOI 10.1016/S1369-5274(98)80144-6; Broer A, 2004, GLIA, V48, P298, DOI 10.1002/glia.20081; Chen XK, 2005, J NEUROSCI, V25, P9236, DOI 10.1523/JNEUROSCI.1640-05.2005; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; FIELDS R, 1971, BIOCHEM J, V124, P581, DOI 10.1042/bj1240581; Fischer D, 2004, J NEUROSCI, V24, P8726, DOI 10.1523/JNEUROSCI.2774-04.2004; Fritz G, 2001, J BIOL CHEM, V276, P3115, DOI 10.1074/jbc.M005058200; Gegelashvili G, 1997, MOL PHARMACOL, V52, P6, DOI 10.1124/mol.52.1.6; Gegelashvili G, 2001, Prog Brain Res, V132, P267; Harada A, 2000, J BIOL CHEM, V275, P36885, DOI 10.1074/jbc.M004069200; Holtje M, 2005, J NEUROCHEM, V95, P1237, DOI 10.1111/j.1471-4159.2005.03443.x; IINO M, 2001, SCIENCE, V5518, P926; Jourdain P, 2007, NAT NEUROSCI, V10, P331, DOI 10.1038/nn1849; Lehre KP, 1998, J NEUROSCI, V18, P8751, DOI 10.1523/jneurosci.18-21-08751.1998; Li LB, 2006, J NEUROCHEM, V97, P759, DOI 10.1111/j.1471-4159.2006.03743.x; Montana V, 2004, J NEUROSCI, V24, P2633, DOI 10.1523/JNEUROSCI.3770-03.2004; NAGLER K, 2001, J PHYSL, P665; Parpura V, 1995, FEBS LETT, V377, P489, DOI 10.1016/0014-5793(95)01401-2; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; POITRY Y, 2002, J NEUROCHEM, V4, P987; Ramakers GJA, 1998, EXP CELL RES, V245, P252, DOI 10.1006/excr.1998.4224; Rattan R, 2003, FREE RADICAL BIO MED, V35, P1037, DOI 10.1016/S0891-5849(03)00459-3; Renger JJ, 2001, NEURON, V29, P469, DOI 10.1016/S0896-6273(01)00219-7; Rodriguez-Kern A, 2003, NEUROCHEM INT, V43, P363, DOI 10.1016/S0197-0186(03)00023-8; Rothman DL, 2003, ANNU REV PHYSIOL, V65, P401, DOI 10.1146/annurev.physiol.65.092101.142131; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Sasaki S, 2000, ACTA NEUROPATHOL, V100, P138, DOI 10.1007/s004019900159; Sattler R, 2006, HANDB EXP PHARM, V175, P277; Shiga H, 2006, J NEUROSCI RES, V84, P338, DOI 10.1002/jnr.20885; Sitcheran R, 2005, EMBO J, V24, P510, DOI 10.1038/sj.emboj.7600555; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; Swanson RA, 1997, J NEUROSCI, V17, P932; Takano T, 2005, P NATL ACAD SCI USA, V102, P16466, DOI 10.1073/pnas.0506382102; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Ullian EM, 2004, MOL CELL NEUROSCI, V26, P544, DOI 10.1016/j.mcn.2004.05.002; Ventura R, 1999, J NEUROSCI, V19, P6897, DOI 10.1523/JNEUROSCI.19-16-06897.1999; VITALE ML, 1995, NEURON, V14, P353, DOI 10.1016/0896-6273(95)90291-0; Vogelsgesang M, 2007, N-S ARCH PHARMACOL, V374, P347, DOI 10.1007/s00210-006-0113-y; Winter S, 2005, J NEUROSCI, V25, P4672, DOI 10.1523/JNEUROSCI.0549-05.2005; Zschocke J, 2005, J BIOL CHEM, V280, P34924, DOI 10.1074/jbc.M502581200	48	29	30	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9289	9299		10.1074/jbc.M706499200	http://dx.doi.org/10.1074/jbc.M706499200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18234672	hybrid			2022-12-25	WOS:000254465800059
J	Kim, K; Choi, J; Heo, K; Kim, H; Levens, D; Kohno, K; Johnson, EM; Brock, HW; An, W				Kim, Kyunghwan; Choi, Jongkyu; Heo, Kyu; Kim, Hyunjung; Levens, David; Kohno, Kimitoshi; Johnson, Edward M.; Brock, Hugh W.; An, Woojin			Isolation and characterization of a novel H1.2 complex that acts as a repressor of p53-mediated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKER HISTONE FUNCTION; GENE-EXPRESSION; IN-VIVO; PUR-ALPHA; CHROMATIN-STRUCTURE; DNA-BINDING; POLY(ADP-RIBOSE) POLYMERASE; NUCLEOSOME; PROTEIN; P53	Linker histone H1 has been generally viewed as a global repressor of transcription by preventing the access of transcription factors to sites in chromatin. However, recent studies suggest that H1 can interact with other regulatory factors for its action as a negative modulator of specific genes. To investigate these aspects, we established a human cell line expressing H1.2, one of the H1 subtypes, for the purification of H1-interacting proteins. Our results showed that H1.2 can stably associate with sets of cofactors and ribosomal proteins that can significantly repress p53-dependent, p300-mediated chromatin transcription. This repressive action of H1.2 complex involves direct interaction of H1.2 with p53, which in turn blocks p300-mediated acetylation of chromatin. YB1 and PUR alpha, two factors present in the H1.2 complex, together with H1.2 can closely recapitulate the repressive action of the entire H1.2 complex in transcription. Chromatin immunoprecipitation and RNA interference analyses further confirmed that the recruitment of YB1, PUR alpha, and H1.2 to the p53 target gene Bax is required for repression of p53-induced transcription. Therefore, these results reveal a previously unrecognized function of H1 as a transcriptional repressor as well as the underlying mechanism involving specific sets of factors in this repression process.	[Kim, Kyunghwan; Choi, Jongkyu; Heo, Kyu; Kim, Hyunjung; An, Woojin] Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; [Levens, David] NCI, NIH, Pathol Lab, Bethesda, MD 20892 USA; [Kohno, Kimitoshi] Univ Occupat & Environm Hlth, Dept Mol Biol, Fukuoka 8078555, Japan; [Johnson, Edward M.] Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, Norfolk, VA 23501 USA; [Brock, Hugh W.] Univ British Columbia, Dept Zool, Vancouver, BC V6T 1Z3, Canada	University of Southern California; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Occupational & Environmental Health - Japan; Eastern Virginia Medical School; University of British Columbia	An, W (corresponding author), Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA.	woojinan@usc.edu	Levens, David/C-9216-2009	Levens, David/0000-0002-7616-922X; Heo, Kyu/0000-0001-8833-4731	NATIONAL CANCER INSTITUTE [Z01SC009144, ZIASC009144] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alami R, 2003, P NATL ACAD SCI USA, V100, P5920, DOI 10.1073/pnas.0736105100; An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; An WJ, 2004, METHOD ENZYMOL, V377, P460; An WJ, 2002, MOL CELL, V9, P811, DOI 10.1016/S1097-2765(02)00497-5; Angelov D, 2006, EMBO J, V25, P1669, DOI 10.1038/sj.emboj.7601046; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Barr SM, 2001, J CELL BIOCHEM, V81, P621, DOI 10.1002/jcb.1099; Barra JL, 2000, MOL CELL BIOL, V20, P61, DOI 10.1128/MCB.20.1.61-69.2000; Bauerle M, 2002, J BIOL CHEM, V277, P32480, DOI 10.1074/jbc.M202765200; Bednar J, 1998, P NATL ACAD SCI USA, V95, P14173, DOI 10.1073/pnas.95.24.14173; Brown DT, 2006, NAT STRUCT MOL BIOL, V13, P250, DOI 10.1038/nsmb1050; Brown DT, 2003, BIOCHEM CELL BIOL, V81, P221, DOI 10.1139/o03-049; Brown DT, 1996, NUCLEIC ACIDS RES, V24, P486, DOI 10.1093/nar/24.3.486; Bustin M, 2005, MOL CELL, V17, P617, DOI 10.1016/j.molcel.2005.02.019; Cho YS, 2006, J BIOL CHEM, V281, P17588, DOI 10.1074/jbc.M512616200; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Daniel DC, 2004, DNA CELL BIOL, V23, P858, DOI 10.1089/1044549042729577; Daujat S, 2005, J BIOL CHEM, V280, P38090, DOI 10.1074/jbc.C500229200; de Oca ROM, 2005, J BIOL CHEM, V280, P42252, DOI 10.1074/jbc.M509917200; Dowhan DH, 2005, MOL CELL, V17, P429, DOI 10.1016/j.molcel.2004.12.025; Fan YH, 2005, CELL, V123, P1199, DOI 10.1016/j.cell.2005.10.028; Fan YH, 2003, MOL CELL BIOL, V23, P4559, DOI 10.1128/MCB.23.13.4559-4572.2003; Georgel PT, 2001, BIOCHEM CELL BIOL, V79, P313, DOI 10.1139/bcb-79-3-313; Grenard P, 2001, J BIOL CHEM, V276, P33066, DOI 10.1074/jbc.M102553200; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Heo K, 2007, J BIOL CHEM, V282, P15476, DOI 10.1074/jbc.M610270200; Homer C, 2005, ONCOGENE, V24, P8314, DOI 10.1038/sj.onc.1208998; Huang JY, 2006, NUCLEIC ACIDS RES, V34, P2398, DOI 10.1093/nar/gkl241; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; Khochbin S, 2001, GENE, V271, P1, DOI 10.1016/S0378-1119(01)00495-4; Kim MY, 2004, CELL, V119, P803, DOI 10.1016/j.cell.2004.11.002; Knapp AM, 2006, J BIOL CHEM, V281, P7907, DOI 10.1074/jbc.M509682200; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lasham A, 2000, GENE, V252, P1, DOI 10.1016/S0378-1119(00)00220-1; Lee H, 2004, SCIENCE, V304, P1675, DOI 10.1126/science.1098096; Li BM, 2004, J BIOL CHEM, V279, P13659, DOI 10.1074/jbc.M311606200; Liu JH, 2000, MOL CELL, V5, P331, DOI 10.1016/S1097-2765(00)80428-1; Luger K, 2006, CHROMOSOME RES, V14, P5, DOI 10.1007/s10577-005-1026-1; Luger K, 1998, CURR OPIN STRUC BIOL, V8, P33, DOI 10.1016/S0959-440X(98)80007-9; Ma YM, 2005, J BIOL CHEM, V280, P33839, DOI 10.1074/jbc.M507113200; Meergans T, 1998, EUR J BIOCHEM, V256, P436, DOI 10.1046/j.1432-1327.1998.2560436.x; Moumen A, 2005, CELL, V123, P1065, DOI 10.1016/j.cell.2005.09.032; Ni JQ, 2006, GENE DEV, V20, P1959, DOI 10.1101/gad.390106; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; Parseghian MH, 2001, BIOCHEM CELL BIOL, V79, P289; Paulson JR, 1996, J CELL SCI, V109, P1437; Ponte I, 2003, MOL BIOL EVOL, V20, P371, DOI 10.1093/molbev/msg041; Safak R, 1999, MOL CELL BIOL, V19, P2712; Samuel S, 2005, BIOCHEM J, V388, P921, DOI 10.1042/BJ20041497; Shen XT, 1996, CELL, V86, P475, DOI 10.1016/S0092-8674(00)80120-8; Steinbach OC, 1997, NATURE, V389, P395, DOI 10.1038/38755; Ushinsky SC, 1997, YEAST, V13, P151, DOI 10.1002/(SICI)1097-0061(199702)13:2<151::AID-YEA94>3.0.CO;2-5; van Holde K.E., 1988, CHROMATIN; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Wesierska-Gadek J, 2000, J CELL BIOCHEM, V80, P85; Widlak P, 2005, BIOCHEMISTRY-US, V44, P7871, DOI 10.1021/bi050100n; Woodcock CL, 2006, CHROMOSOME RES, V14, P17, DOI 10.1007/s10577-005-1024-3; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545	60	87	90	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9113	9126		10.1074/jbc.M708205200	http://dx.doi.org/10.1074/jbc.M708205200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18258596	Green Published, hybrid			2022-12-25	WOS:000254465800041
J	Rakhimova, E; Munder, A; Wiehlmann, L; Bredenbruch, F; Tummler, B				Rakhimova, Elza; Munder, Antje; Wiehlmann, Lutz; Bredenbruch, Florian; Tuemmler, Burkhard			Fitness of Isogenic Colony Morphology Variants of Pseudomonas aeruginosa in Murine Airway Infection	PLOS ONE			English	Article							CYSTIC-FIBROSIS LUNG; BIOFILM FORMATION; ESCHERICHIA-COLI; INTRACLONAL DIVERSITY; FUNCTIONAL GENOMICS; STATIONARY-PHASE; GENETIC-ANALYSIS; HIGHLY ADHERENT; DNA RELEASE; EVOLUTION	Chronic lung infections with Pseudomonas aeruginosa are associated with the diversification of the persisting clone into niche specialists and morphotypes, a phenomenon called 'dissociative behaviour'. To explore the potential of P. aeruginosa to change its morphotype by single step loss-of-function mutagenesis, a signature-tagged mini-Tn5 plasposon library of the cystic fibrosis airway isolate TBCF10839 was screened for colony morphology variants under nine different conditions in vitro. Transposon insertion into 1% of the genome changed colony morphology into eight discernable morphotypes. Half of the 55 targets encode features of primary or secondary metabolism whereby quinolone production was frequently affected. In the other half the transposon had inserted into genes of the functional categories transport, regulation or motility/chemotaxis. To mimic dissociative behaviour of isogenic strains in lungs, pools of 25 colony morphology variants were tested for competitive fitness in an acute murine airway infection model. Six of the 55 mutants either grew better or worse in vivo than in vitro, respectively. Metabolic proficiency of the colony morphology variant was a key determinant for survival in murine airways. The most common morphotype of self-destructive autolysis did unexpectedly not impair fitness. Transposon insertions into homologous genes of strain PAO1 did not reproduce the TBCF10839 mutant morphotypes for 16 of 19 examined loci pointing to an important role of the genetic background on colony morphology. Depending on the chosen P. aeruginosa strain, functional genome scans will explore other areas of the evolutionary landscape. Based on our discordant findings of mutant phenotypes in P. aeruginosa strains PAO1, PA14 and TBCF10839, we conclude that the current focus on few reference strains may miss modes of niche adaptation and dissociative behaviour that are relevant for the microevolution of complex traits in the wild.	[Rakhimova, Elza; Munder, Antje; Wiehlmann, Lutz; Tuemmler, Burkhard] Hannover Med Sch, Clin Res Grp, Hannover, Germany; [Bredenbruch, Florian] Helmholtz Ctr Infect Res, Div Cell Biol & Immunol, Braunschweig, Germany	Hannover Medical School; Helmholtz Association; Helmholtz-Center for Infection Research	Rakhimova, E (corresponding author), Hannover Med Sch, Clin Res Grp, OE6710, Hannover, Germany.	tuemmler.burkhard@mh-hannover.de		Munder, Antje/0000-0002-3198-8336	Deutsche Forschungsgemeinschaft [SFB587, A9]; DFG-sponsored graduate college, project A3 [GK745]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); DFG-sponsored graduate college, project A3	This work was supported by a grant of the Deutsche Forschungsgemeinschaft (SFB587, A9). ER has received a stipend from the DFG-sponsored graduate college GK745, project A3.	ALLEFS JJHM, 1990, NUCLEIC ACIDS RES, V18, P3099, DOI 10.1093/nar/18.10.3099; Allesen-Holm M, 2006, MOL MICROBIOL, V59, P1114, DOI 10.1111/j.1365-2958.2005.05008.x; Alvarez-Ortega C, 2007, MOL MICROBIOL, V65, P153, DOI 10.1111/j.1365-2958.2007.05772.x; Arevalo-Ferro C, 2004, PROTEOMICS, V4, P1241, DOI 10.1002/pmic.200300709; BANERJEE PC, 1983, J BACTERIOL, V155, P238, DOI 10.1128/JB.155.1.238-245.1983; Bochner BR, 2001, GENOME RES, V11, P1246, DOI 10.1101/gr.186501; Bragonzi A, 2006, MICROBIOL-SGM, V152, P3261, DOI 10.1099/mic.0.29175-0; Bredenbruch F, 2005, J BACTERIOL, V187, P3630, DOI 10.1128/JB.187.11.3630-3635.2005; Brockhurst MA, 2005, P ROY SOC B-BIOL SCI, V272, P1385, DOI 10.1098/rspb.2005.3086; Buckling A, 2002, NATURE, V420, P496, DOI 10.1038/nature01164; Bush A., 2006, CYSTIC FIBROSIS 21 C; Chang YST, 2007, FEMS MICROBIOL LETT, V270, P201, DOI 10.1111/j.1574-6968.2007.00664.x; CHEN WP, 1993, NUCLEIC ACIDS RES, V21, P2260, DOI 10.1093/nar/21.9.2260; CUSKEY SM, 1985, J BACTERIOL, V162, P872, DOI 10.1128/JB.162.3.872-880.1985; D'Argenio DA, 2002, J BACTERIOL, V184, P6481, DOI 10.1128/JB.184.23.6481-6489.2002; De Vos D, 2001, ARCH MICROBIOL, V175, P384, DOI 10.1007/s002030100278; Denervaud V, 2004, J CLIN MICROBIOL, V42, P554, DOI 10.1128/JCM.42.2.554-562.2004; Dennis JJ, 1998, APPL ENVIRON MICROB, V64, P2710; Deziel E, 2005, MOL MICROBIOL, V55, P998, DOI 10.1111/j.1365-2958.2004.04448.x; Diaz E, 2007, CURR OPIN CRIT CARE, V13, P45, DOI 10.1097/MCC.0b013e3280121816; Diggle SP, 2003, MOL MICROBIOL, V50, P29, DOI 10.1046/j.1365-2958.2003.03672.x; Doyle TB, 2004, J BACTERIOL, V186, P6341, DOI 10.1128/JB.186.19.6341-6350.2004; Drenkard E, 2002, NATURE, V416, P740, DOI 10.1038/416740a; Enderle PJ, 1998, BIOTECHNIQUES, V25, P954, DOI 10.2144/98256bm05; Farrow JM, 2007, J BACTERIOL, V189, P3425, DOI 10.1128/JB.00209-07; Favre-Bonte S, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-33; Foster KR, 2007, CURR BIOL, V17, pR319, DOI 10.1016/j.cub.2007.03.005; Foster KR, 2007, TRENDS GENET, V23, P74, DOI 10.1016/j.tig.2006.12.003; Friedman L, 2004, J BACTERIOL, V186, P4457, DOI 10.1128/JB.186.14.4457-4465.2004; Friedman L, 2004, MOL MICROBIOL, V51, P675, DOI 10.1046/j.1365-2958.2003.03877.x; Gallagher LA, 2002, J BACTERIOL, V184, P6472, DOI 10.1128/JB.184.23.6472-6480.2002; Garrity-Ryan L, 2000, INFECT IMMUN, V68, P7100, DOI 10.1128/IAI.68.12.7100-7113.2000; Govan JRW, 1996, MICROBIOL REV, V60, P539, DOI 10.1128/MMBR.60.3.539-574.1996; Hansen SK, 2007, J BACTERIOL, V189, P4932, DOI 10.1128/JB.00041-07; Hansen SK, 2007, NATURE, V445, P533, DOI 10.1038/nature05514; Haussler S, 1999, CLIN INFECT DIS, V29, P621, DOI 10.1086/598644; Haussler S, 2003, J MED MICROBIOL, V52, P295, DOI 10.1099/jmm.0.05069-0; Haussler S, 2004, ENVIRON MICROBIOL, V6, P546, DOI 10.1111/j.1462-2920.2004.00618.x; Heeb S, 2000, MOL PLANT MICROBE IN, V13, P232, DOI 10.1094/MPMI.2000.13.2.232; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; Jacobs MA, 2003, P NATL ACAD SCI USA, V100, P14339, DOI 10.1073/pnas.2036282100; Kessler E, 1998, J BIOL CHEM, V273, P30225, DOI 10.1074/jbc.273.46.30225; King PT, 2007, RESP MED, V101, P1633, DOI 10.1016/j.rmed.2007.03.009; Klebensberger J, 2007, ENVIRON MICROBIOL, V9, P2247, DOI 10.1111/j.1462-2920.2007.01339.x; Knight CG, 2006, NAT GENET, V38, P1015, DOI 10.1038/ng1867; Kretzschmar U, 2002, MICROBIOL-SGM, V148, P3839, DOI 10.1099/00221287-148-12-3839; Kwon YM, 2000, J MICROBIOL METH, V41, P195, DOI 10.1016/S0167-7012(00)00159-7; Lee DG, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r90; Liberati NT, 2006, P NATL ACAD SCI USA, V103, P2833, DOI 10.1073/pnas.0511100103; Lieberman David, 2003, Am J Respir Med, V2, P459; Lyczak JB, 2002, CLIN MICROBIOL REV, V15, P194, DOI 10.1128/CMR.15.2.194-222.2002; MacLean RC, 2004, P NATL ACAD SCI USA, V101, P8072, DOI 10.1073/pnas.0307195101; Mashburn LM, 2005, NATURE, V437, P422, DOI 10.1038/nature03925; Mathee K, 1999, MICROBIOL-SGM, V145, P1349, DOI 10.1099/13500872-145-6-1349; Mazurkiewicz P, 2006, NAT REV GENET, V7, P929, DOI 10.1038/nrg1984; Merighi M, 2007, MOL MICROBIOL, V65, P876, DOI 10.1111/j.1365-2958.2007.05817.x; Munder A, 2005, MICROBES INFECT, V7, P600, DOI 10.1016/j.micinf.2004.12.021; Munder A, 2002, EXP TOXICOL PATHOL, V54, P127, DOI 10.1078/0940-2993-00240; Nakayama K, 1999, MOL MICROBIOL, V31, P399, DOI 10.1046/j.1365-2958.1999.01158.x; O'Toole G, 2000, ANNU REV MICROBIOL, V54, P49, DOI 10.1146/annurev.micro.54.1.49; OJENIYI B, 1991, APMIS, V99, P925, DOI 10.1111/j.1699-0463.1991.tb01280.x; Oliver A, 2000, SCIENCE, V288, P1251, DOI 10.1126/science.288.5469.1251; Palmer KL, 2007, J BACTERIOL, V189, P8079, DOI 10.1128/JB.01138-07; Palmer KL, 2005, J BACTERIOL, V187, P5267, DOI 10.1128/JB.187.15.5267-5277.2005; Pesci EC, 1999, P NATL ACAD SCI USA, V96, P11229, DOI 10.1073/pnas.96.20.11229; Rainey PB, 2003, NATURE, V425, P72, DOI 10.1038/nature01906; Raleigh E. A., 1997, CURRENT PROTOCOLS MO, V1; Ramos J, 2004, PSEUDOMONAS; Ravel J, 2003, TRENDS MICROBIOL, V11, P195, DOI 10.1016/S0966-842X(03)00076-3; Reva ON, 2006, J BACTERIOL, V188, P4079, DOI 10.1128/JB.00101-06; Sakuragi Y, 2007, J BACTERIOL, V189, P5383, DOI 10.1128/JB.00137-07; Salunkhe P, 2005, J BACTERIOL, V187, P4908, DOI 10.1128/JB.187.14.4908-4920.2005; Salunkhe P, 2005, J BACTERIOL, V187, P2565, DOI 10.1128/JB.187.8.2565-2572.2005; SEIFERT SH, 2006, EVOLUTION MICROBIAL; Shapiro JA, 1998, ANNU REV MICROBIOL, V52, P81, DOI 10.1146/annurev.micro.52.1.81; Simpson DA, 2000, INFECT IMMUN, V68, P2493, DOI 10.1128/IAI.68.5.2493-2502.2000; Smith EE, 2005, J BACTERIOL, V187, P2138, DOI 10.1128/JB.187.6.2138-2147.2005; Smith EE, 2006, P NATL ACAD SCI USA, V103, P8487, DOI 10.1073/pnas.0602138103; Solano C, 2002, MOL MICROBIOL, V43, P793, DOI 10.1046/j.1365-2958.2002.02802.x; Spencer DH, 2003, J BACTERIOL, V185, P1316, DOI 10.1128/JB.185.4.1316-1325.2003; Sriramulu DD, 2005, J MED MICROBIOL, V54, P667, DOI 10.1099/jmm.0.45969-0; Stover CK, 2000, NATURE, V406, P959, DOI 10.1038/35023079; Tummler B, 2006, PSEUDOMONAS, VOL 4: MOLECULAR BIOLOGY OF EMERGING ISSUES, P35; TUMMLER B, 1991, J CLIN MICROBIOL, V29, P1265; Vlamakis HC, 2005, NAT CELL BIOL, V7, P933, DOI 10.1038/ncb1005-933; von Gotz F, 2004, J BACTERIOL, V186, P3837, DOI 10.1128/JB.186.12.3837-3847.2004; Vulic M, 2001, GENETICS, V158, P519; Wade DS, 2005, J BACTERIOL, V187, P4372, DOI 10.1128/JB.187.13.4372-4380.2005; Wehmhoner D, 2003, J BACTERIOL, V185, P5807, DOI 10.1128/JB.185.19.5807-5814.2003; Wiehlmann L, 2007, INT J MED MICROBIOL, V297, P615, DOI 10.1016/j.ijmm.2007.03.014; Wiehlmann L, 2007, P NATL ACAD SCI USA, V104, P8101, DOI 10.1073/pnas.0609213104; Worlitzsch D, 2002, J CLIN INVEST, V109, P317, DOI 10.1172/JCI0213870; Xiao GP, 2006, MOL MICROBIOL, V62, P1689, DOI 10.1111/j.1365-2958.2006.05462.x; Yang L, 2007, MICROBIOL-SGM, V153, P1318, DOI 10.1099/mic.0.2006/004911-0; Yoon SS, 2002, DEV CELL, V3, P593, DOI 10.1016/S1534-5807(02)00295-2; Zhou L, 2003, J BACTERIOL, V185, P4956, DOI 10.1128/JB.185.16.4956-4972.2003; ZIERDT CH, 1964, J BACTERIOL, V87, P1003, DOI 10.1128/JB.87.5.1003-1010.1964; Zogaj X, 2001, MOL MICROBIOL, V39, P1452, DOI 10.1046/j.1365-2958.2001.02337.x	98	26	26	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2008	3	2							e1685	10.1371/journal.pone.0001685	http://dx.doi.org/10.1371/journal.pone.0001685			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XS	18301762	gold, Green Published, Green Submitted			2022-12-25	WOS:000260586500029
J	Bulwin, GC; Walter, S; Schlawinsky, M; Heinemann, T; Schulze, A; Hohne, W; Krause, G; Kalka-Moll, W; Fraser, P; Volk, HD; Lohler, J; Milford, EL; Utku, N				Bulwin, Grit-Carsta; Waelter, Stephanie; Schlawinsky, Mirko; Heinemann, Thomas; Schulze, Anke; Hoehne, Wolfgang; Krause, Gerd; Kalka-Moll, Wiltrud; Fraser, Patricia; Volk, Hans-Dieter; Loehler, Juergen; Milford, Edgar L.; Utku, Nalan			HLA-DR Alpha 2 Mediates Negative Signalling via Binding to Tirc7 Leading to Anti-Inflammatory and Apoptotic Effects in Lymphocytes In Vitro and In Vivo	PLOS ONE			English	Article								Classically, HLA-DR expressed on antigen presenting cells (APC) initiates lymphocyte activation via presentation of peptides to TCR bearing CD4+ T- Cells. Here we demonstrate that HLA-DR alpha 2 domain (sHLA-DR alpha 2) also induces negative signals by engaging TIRC7 on lymphocytes. This interaction inhibits proliferation and induces apoptosis in CD4+ and CD8+ T-cells via activation of the intrinsic pathway. Proliferation inhibition is associated with SHP-1 recruitment by TIRC7, decreased phosphorylation of STAT4, TCR-zeta chain & ZAP70, and inhibition of IFN-gamma and FasL expression. HLA-DR alpha 2 and TIRC7 co-localize at the APC-T cell interaction site. Triggering HLA-DR - TIRC7 pathway demonstrates that sHLA-DRa2 treatment inhibits proinflammatory-inflammatory cytokine expression in APC & T cells after lipopolysaccaride (LPS) stimulation in vitro and induces apoptosis in vivo. These results suggest a novel antiproliferative role for HLA-DR mediated via TIRC7, revise the notion of an exclusive stimulatory interaction of HLA-DR with CD4+ T cells and highlights a novel physiologically relevant regulatory pathway.	[Bulwin, Grit-Carsta; Waelter, Stephanie; Schlawinsky, Mirko; Schulze, Anke; Loehler, Juergen; Utku, Nalan] CellAct Pharma GmbH, Berlin, Germany; [Heinemann, Thomas] Univ Bonn, Kekule Inst Organ Chem Biochem, Bonn, Germany; [Hoehne, Wolfgang] Charite, Inst Biochem, Campus Mitte, Berlin, Germany; [Krause, Gerd] Leibniz Inst Mol Pharmacol, Berlin, Germany; [Kalka-Moll, Wiltrud] Klinikum Univ Koln, Med Mikrobiol, Cologne, Germany; [Fraser, Patricia] Brigham & Womens Hosp, Dept Med, Div Rheumatol, Boston, MA USA; [Volk, Hans-Dieter; Utku, Nalan] Humboldt Univ, Inst Med Immunol, Campus Mitte, Berlin, Germany; [Loehler, Juergen] Heinrich Pette Inst, Mol Pathol, Hamburg, Germany; [Milford, Edgar L.] Brigham & Womens Hosp, Dept Med, Renal Div, Boston, MA USA	University of Bonn; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Leibniz Forschungsinstitut furr Molekulare Pharmakologie (FMP); University of Cologne; Harvard University; Brigham & Women's Hospital; Humboldt University of Berlin; Heinrich Pette Institute; Harvard University; Brigham & Women's Hospital	Bulwin, GC (corresponding author), CellAct Pharma GmbH, Berlin, Germany.	nalan.utku@charite.de	volk, hans-dieter/AAV-8053-2021	volk, hans-dieter/0000-0002-7743-6668	German government for research and development [Bmbf future grant]	German government for research and development	Bmbf future grant (German government for research and development)	Brockdorff J, 1999, EUR J IMMUNOL, V29, P2539, DOI 10.1002/(SICI)1521-4141(199908)29:08<2539::AID-IMMU2539>3.0.CO;2-M; Bulwin GC, 2006, J IMMUNOL, V177, P6833, DOI 10.4049/jimmunol.177.10.6833; Dinges MM, 2001, INFECT IMMUN, V69, P1256, DOI 10.1128/IAI.69.3.1256-1264.2001; FREDERICK P, 1996, J IMMUNOL, V157, P4521; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Han YJ, 2006, BLOOD, V108, P2796, DOI 10.1182/blood-2006-04-017434; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; Hipfner DR, 2004, NAT REV MOL CELL BIO, V5, P805, DOI 10.1038/nrm1491; Hsu HC, 2001, J IMMUNOL, V166, P772, DOI 10.4049/jimmunol.166.2.772; IRWIN MJ, 1993, IMMUNOL REV, V131, P61, DOI 10.1111/j.1600-065X.1993.tb01530.x; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; KARP DR, 1990, NATURE, V346, P474, DOI 10.1038/346474a0; KIM JS, 1994, SCIENCE, V266, P1870, DOI 10.1126/science.7997880; Kovacs B, 1999, APOPTOSIS, V4, P327, DOI 10.1023/A:1009691120129; Kumamoto Y, 2004, AM J TRANSPLANT, V4, P505, DOI 10.1111/j.1600-6143.2004.00367.x; Li HM, 1999, ANNU REV IMMUNOL, V17, P435, DOI 10.1146/annurev.immunol.17.1.435; Marsh SG, 2000, HLA FACTS BOOK; Parham P, 1999, IMMUNOL REV, V167, P5, DOI 10.1111/j.1600-065X.1999.tb01378.x; Paul W., 1993, FUNDAMENTAL IMMUNOLO, P1211; RATHMELL JC, 2002, CELL S, V109, P97; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Szabo SJ, 2003, ANNU REV IMMUNOL, V21, P713, DOI 10.1146/annurev.immunol.21.120601.140942; Utku N, 2006, CLIN EXP IMMUNOL, V144, P142, DOI 10.1111/j.1365-2249.2006.03044.x; Utku N, 1998, IMMUNITY, V9, P509, DOI 10.1016/S1074-7613(00)80634-2; Wang LH, 1999, J IMMUNOL, V162, P3897; Watanabe N, 2003, NAT IMMUNOL, V4, P670, DOI 10.1038/ni944; Zhang Q, 2000, AM J PATHOL, V157, P1137, DOI 10.1016/S0002-9440(10)64629-9	27	10	10	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1576	10.1371/journal.pone.0001576	http://dx.doi.org/10.1371/journal.pone.0001576			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270567	Green Published, gold, Green Submitted			2022-12-25	WOS:000260535900012
J	Dolinay, T; Wu, W; Kaminski, N; Ifedigbo, E; Kaynar, AM; Szilasi, M; Watkins, SC; Ryter, SW; Hoetzel, A; Choi, AMK				Dolinay, Tamas; Wu, Wei; Kaminski, Naftali; Ifedigbo, Emeka; Kaynar, A. Murat; Szilasi, Maria; Watkins, Simon C.; Ryter, Stefan W.; Hoetzel, Alexander; Choi, Augustine M. K.			Mitogen-Activated Protein Kinases Regulate Susceptibility to Ventilator-Induced Lung Injury	PLOS ONE			English	Article								Background: Mechanical ventilation causes ventilator-induced lung injury in animals and humans. Mitogen-activated protein kinases have been implicated in ventilator-induced lung injury though their functional significance remains incomplete. We characterize the role of p38 mitogen-activated protein kinase/mitogen activated protein kinase kinase-3 and c-Jun-NH(2)-terminal kinase-1 in ventilator-induced lung injury and investigate novel independent mechanisms contributing to lung injury during mechanical ventilation. Methodology and Principle Findings: C57/BL6 wild-type mice and mice genetically deleted for mitogen-activated protein kinase kinase-3 (mkk-3(-/-)) or c-Jun-NH(2)-terminal kinase-1 (jnk1(-/-)) were ventilated, and lung injury parameters were assessed. We demonstrate that mkk3(-/-) or jnk1(-/-) mice displayed significantly reduced inflammatory lung injury and apoptosis relative to wild-type mice. Since jnk1(-/-) mice were highly resistant to ventilator-induced lung injury, we performed comprehensive gene expression profiling of ventilated wild- type or jnk1(-/-) mice to identify novel candidate genes which may play critical roles in the pathogenesis of ventilator-induced lung injury. Microarray analysis revealed many novel genes differentially expressed by ventilation including matrix metalloproteinase-8 (MMP8) and GADD45 alpha. Functional characterization of MMP8 revealed that mmp8(-/-) mice were sensitized to ventilator-induced lung injury with increased lung vascular permeability. Conclusions: We demonstrate that mitogen-activated protein kinase pathways mediate inflammatory lung injury during ventilator-induced lung injury. C-Jun-NH(2)-terminal kinase was also involved in alveolo-capillary leakage and edema formation, whereas MMP8 inhibited alveolo-capillary protein leakage.			Dolinay, T (corresponding author), Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15260 USA.	amchoi@rics.bwh.harvard.edu	Kaynar, Ata Murat/ABI-6877-2020; Dolinay, Tamas/ABG-1399-2020; Watkins, Simon/ABG-2590-2021	Kaynar, Ata Murat/0000-0001-8847-0450; Watkins, Simon/0000-0003-4092-1552; Kaminski, Naftali/0000-0001-5917-4601	NIH [R01-HL60234, R01-HL55330, R01-HL079904, P01-HL70807]; American Heart Association [0335035N]; Deutsche Forschungsgemeinschaft [HO 2464/1-1]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055330, R01HL079904, P01HL070807, R01HL060234] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	NIH grants R01-HL60234, R01-HL55330, R01-HL079904, and P01-HL70807 awarded to A.M.K. Choi, an award from the American Heart Association to S. W. Ryter, (AHA #0335035N) and a grant from the Deutsche Forschungsgemeinschaft to Alexander Hoetzel (DFG HO 2464/1-1).	Abdulnour REE, 2006, AM J PHYSIOL-LUNG C, V291, pL345, DOI 10.1152/ajplung.00453.2005; Altemeier WA, 2005, J IMMUNOL, V175, P3369, DOI 10.4049/jimmunol.175.5.3369; Belperio JA, 2002, J CLIN INVEST, V110, P1703, DOI 10.1172/JCI200215849; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Birukov KG, 2003, AM J PHYSIOL-LUNG C, V285, pL785, DOI 10.1152/ajplung.00336.2002; Bregeon F, 2002, RESP PHYSIOL NEUROBI, V132, P191, DOI 10.1016/S1569-9048(02)00069-1; Brower RG, 2004, NEW ENGL J MED, V351, P327; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Chess PR, 2005, J APPL PHYSIOL, V99, P1226, DOI 10.1152/japplphysiol.01105.2004; Crimi E, 2006, AM J RESP CRIT CARE, V174, P178, DOI 10.1164/rccm.200507-1178OC; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; de Prost N, 2007, J APPL PHYSIOL, V102, P794, DOI 10.1152/japplphysiol.00742.2006; Dolinay T, 2006, PHYSIOL GENOMICS, V26, P68, DOI 10.1152/physiolgenomics.00110.2005; Fayolle C, 2008, J INVEST DERMATOL, V128, P196, DOI 10.1038/sj.jid.5700963; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Grasso S, 2002, ANESTHESIOLOGY, V96, P795, DOI 10.1097/00000542-200204000-00005; Grigoryev DN, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-r34; Gutierrez-Fernandez A, 2007, FASEB J, V21, P2580, DOI 10.1096/fj.06-7860com; Hales CA, 2001, RESP PHYSIOL, V124, P159, DOI 10.1016/S0034-5687(00)00193-6; Imai Y, 2003, JAMA-J AM MED ASSOC, V289, P2104, DOI 10.1001/jama.289.16.2104; Jones JCR, 2005, J CELL SCI, V118, P2557, DOI 10.1242/jcs.02395; KOHNO K, 2004, AM J PHYSIOL-LUNG C, pL184; Li LF, 2004, AM J RESP CRIT CARE, V169, P518, DOI 10.1164/rccm.200305-660OC; Li LF, 2007, CRIT CARE, V11, DOI 10.1186/cc5704; Ma SF, 2005, AM J PHYSIOL-LUNG C, V289, pL468, DOI 10.1152/ajplung.00109.2005; Matthay MA, 2002, AM J PHYSIOL-LUNG C, V283, pL678, DOI 10.1152/ajplung.00154.2002; Matute-Bello G, 1999, J IMMUNOL, V163, P2217; MatuteBello G, 1997, AM J RESP CRIT CARE, V156, P1969, DOI 10.1164/ajrccm.156.6.96-12081; Mayr VD, 2006, CRIT CARE, V10, DOI 10.1186/cc5086; Moitra J, 2007, TRANSL RES, V150, P253, DOI 10.1016/j.trsl.2007.03.013; Morse D, 2003, J BIOL CHEM, V278, P36993, DOI 10.1074/jbc.M302942200; Morse D, 2003, AM J PHYSIOL-LUNG C, V285, pL250, DOI 10.1152/ajplung.00387.2002; Nakamura M, 2004, AM J PATHOL, V164, P1949, DOI 10.1016/S0002-9440(10)63755-8; Ning W, 2004, PHYSIOL GENOMICS, V18, P70, DOI 10.1152/physiolgenomics.00221.2003; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Otterbein LE, 2003, AM J PATHOL, V163, P2555, DOI 10.1016/S0002-9440(10)63610-3; Oudin S, 2002, AM J RESP CELL MOL, V27, P107, DOI 10.1165/ajrcmb.27.1.4766; Owen CA, 2004, J IMMUNOL, V172, P7791, DOI 10.4049/jimmunol.172.12.7791; Papa S, 2004, J CELL SCI, V117, P5197, DOI 10.1242/jcs.01483; Petrache I, 2003, AM J RESP CELL MOL, V28, P574, DOI 10.1165/rcmb.2002-0075OC; Quinn DA, 2002, J APPL PHYSIOL, V93, P517, DOI 10.1152/japplphysiol.00570.2001; Shaulian E, 1999, J BIOL CHEM, V274, P29595, DOI 10.1074/jbc.274.42.29595; Song RP, 2003, AM J PATHOL, V163, P231, DOI 10.1016/S0002-9440(10)63646-2; Tester AM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000312; Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259; Tschumperlin DJ, 2000, AM J RESP CRIT CARE, V162, P357, DOI 10.1164/ajrccm.162.2.9807003; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Uhlig U, 2002, EUR RESPIR J, V20, P946, DOI 10.1183/09031936.02.01612001; Usatyuk PV, 2004, J BIOL CHEM, V279, P11789, DOI 10.1074/jbc.M311184200; von Bethmann AN, 1998, AM J RESP CRIT CARE, V157, P263, DOI 10.1164/ajrccm.157.1.9608052; Winkler MK, 2003, AM J PHYSIOL-LUNG C, V284, pL557, DOI 10.1152/ajplung.00195.2002; Wu W, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-309; Yang KY, 2003, AM J RESP CRIT CARE, V167, P1567, DOI 10.1164/rccm.200207-664OC; Zerbini LF, 2004, P NATL ACAD SCI USA, V101, P13618, DOI 10.1073/pnas.0402069101	54	76	81	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1601	10.1371/journal.pone.0001601	http://dx.doi.org/10.1371/journal.pone.0001601			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270588	Green Published, gold, Green Accepted, Green Submitted			2022-12-25	WOS:000260535900035
J	Lemire, J; Mailloux, RJ; Appanna, VD				Lemire, Joseph; Mailloux, Ryan J.; Appanna, Vasu D.			Mitochondrial Lactate Dehydrogenase Is Involved in Oxidative-Energy Metabolism in Human Astrocytoma Cells (CCF-STTG1)	PLOS ONE			English	Article								Lactate has long been regarded as an end product of anaerobic energy production and its fate in cerebral metabolism has not been precisely delineated. In this report, we demonstrate, for the first time, the ability of a human astrocytic cell line (CCF-STTG1) to consume lactate and to generate ATP via oxidative phosphorylation. C-13-NMR and HPLC analyses aided in the identification of tricarboxylic acid (TCA) cyle metabolites and ATP in the astrocytic mitochondria incubated with lactate. Oxamate, an inhibitor of lactate dehydrogenase (LDH), abolished mitochondrial lactate consumption. Electrophoretic and fluorescence microscopic analyses helped localize LDH in the mitochondria. Taken together, this study implicates lactate as an important contributor to ATP metabolism in the brain, a finding that may significantly change our notion of how this important organ manipulates its energy budget.	[Lemire, Joseph; Mailloux, Ryan J.; Appanna, Vasu D.] Laurentian Univ, Dept Chem & Biochem, Sudbury, ON P3E 2C6, Canada	Laurentian University	Lemire, J (corresponding author), Laurentian Univ, Dept Chem & Biochem, Sudbury, ON P3E 2C6, Canada.	VAppanna@laurentian.ca		Mailloux, Ryan/0000-0003-3986-9830; Appanna, Vasu/0000-0002-0138-5665	Industry Canada; The Northern Ontario Heritage Fund	Industry Canada; The Northern Ontario Heritage Fund	Industry Canada and The Northern Ontario Heritage Fund	Aubert A, 2005, P NATL ACAD SCI USA, V102, P16448, DOI 10.1073/pnas.0505427102; Bakker J, 1996, AM J SURG, V171, P221, DOI 10.1016/S0002-9610(97)89552-9; Baumgart E, 1996, J BIOL CHEM, V271, P3846; Bergersen LH, 2007, NEUROSCIENCE, V145, P11, DOI 10.1016/j.neuroscience.2006.11.062; Bergman BC, 1999, J APPL PHYSIOL, V87, P1684, DOI 10.1152/jappl.1999.87.5.1684; Beriault R, 2005, ELECTROPHORESIS, V26, P2892, DOI 10.1002/elps.200500040; Berkich DA, 2005, J NEUROSCI RES, V79, P106, DOI 10.1002/jnr.20325; BIGNAMI A, 1991, ADV EXP MED BIOL, V296, P197; Bittar PG, 1996, J CEREBR BLOOD F MET, V16, P1079, DOI 10.1097/00004647-199611000-00001; Bouzier-Sore AK, 2006, EUR J NEUROSCI, V24, P1687, DOI 10.1111/j.1460-9568.2006.05056.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brooks GA, 1998, COMP BIOCHEM PHYS B, V120, P89, DOI 10.1016/S0305-0491(98)00025-X; BROOKS GA, 1986, FASEB J, V45, P2924; Brooks GA, 2002, BIOCHEM SOC T, V30, P258, DOI 10.1042/bst0300258; Brooks GA, 1999, P NATL ACAD SCI USA, V96, P1129, DOI 10.1073/pnas.96.3.1129; Brown AM, 2007, GLIA, V55, P1263, DOI 10.1002/glia.20557; Chatham JC, 2001, AM J PHYSIOL-ENDOC M, V281, pE794, DOI 10.1152/ajpendo.2001.281.4.E794; Dalsgaard MK, 2004, J PHYSIOL-LONDON, V554, P571, DOI 10.1113/jphysiol.2003.055053; Dienel GA, 2001, J NEUROSCI RES, V66, P824, DOI 10.1002/jnr.10079; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; GALLINA FG, 1994, ARCH BIOCHEM BIOPHYS, V308, P515, DOI 10.1006/abbi.1994.1072; Gladden LB, 2004, J PHYSIOL-LONDON, V558, P5, DOI 10.1113/jphysiol.2003.058701; Guzman M, 2001, TRENDS ENDOCRIN MET, V12, P169, DOI 10.1016/S1043-2760(00)00370-2; Hashimoto T, 2006, AM J PHYSIOL-ENDOC M, V290, pE1237, DOI 10.1152/ajpendo.00594.2005; Hertz L, 2004, J CEREBR BLOOD F MET, V24, P1241, DOI 10.1097/00004647-200411000-00008; Hu YB, 1997, J NEUROCHEM, V69, P1484; HURLEY BF, 1984, J APPL PHYSIOL, V56, P1260, DOI 10.1152/jappl.1984.56.5.1260; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Magistretti PJ, 1999, PHILOS T R SOC B, V354, P1155, DOI 10.1098/rstb.1999.0471; Mailloux R, 2007, CELL PHYSIOL BIOCHEM, V20, P627, DOI 10.1159/000107546; Mailloux RJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000690; Mailloux RJ, 2006, J BIOCHEM MOL TOXIC, V20, P198, DOI 10.1002/jbt.20137; MALMQVIST U, 1991, PFLUG ARCH EUR J PHY, V419, P230, DOI 10.1007/BF00371100; McClelland GB, 2003, BIOCHEM BIOPH RES CO, V304, P130, DOI 10.1016/S0006-291X(03)00550-3; McKenna MC, 2006, BIOCHEM PHARMACOL, V71, P399, DOI 10.1016/j.bcp.2005.10.011; Mentz S, 1999, J NEUROCHEM, V72, P980, DOI 10.1046/j.1471-4159.1999.0720980.x; Middaugh J, 2005, J BIOL CHEM, V280, P3159, DOI 10.1074/jbc.M411979200; Moyle GJ, 2002, AIDS, V16, P1341, DOI 10.1097/00002030-200207050-00005; ODONNELLTORMEY J, 1987, J EXP MED, V165, P500, DOI 10.1084/jem.165.2.500; Pellerin L, 2003, NEUROCHEM INT, V43, P331, DOI 10.1016/S0197-0186(03)00020-2; Pellerin L, 1998, DEV NEUROSCI-BASEL, V20, P291, DOI 10.1159/000017324; Pellerin L, 2007, GLIA, V55, P1251, DOI 10.1002/glia.20528; Popanda O, 1998, BBA-GENE STRUCT EXPR, V1397, P102, DOI 10.1016/S0167-4781(97)00229-7; Ramos M, 2003, DEV BRAIN RES, V143, P33, DOI 10.1016/S0165-3806(03)00097-X; Read JA, 2001, PROTEINS, V43, P175, DOI 10.1002/1097-0134(20010501)43:2<175::AID-PROT1029>3.0.CO;2-#; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SCHMITT J, 1975, HUMANGENETIK, V28, P239, DOI 10.1007/BF00278550; Schurr A, 2006, J CEREBR BLOOD F MET, V26, P142, DOI 10.1038/sj.jcbfm.9600174; SHANNON JE, 1978, CRYOBIOLOGY, V15, P239, DOI 10.1016/0011-2240(78)90032-9; Shi T, 2005, J BIOL CHEM, V280, P13560, DOI 10.1074/jbc.M414670200; Singh R, 2005, J BIOCHEM BIOPH METH, V64, P189, DOI 10.1016/j.jbbm.2005.07.005; WILKINSON JH, 1972, ENZYME, V13, P170, DOI 10.1159/000459658; Yates SP, 2005, ANAL BIOCHEM, V340, P41, DOI 10.1016/j.ab.2005.01.051	53	62	65	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2008	3	2							e1550	10.1371/journal.pone.0001550	http://dx.doi.org/10.1371/journal.pone.0001550			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367EQ	18253497	Green Published, gold, Green Submitted			2022-12-25	WOS:000260535700021
J	Pacheco, AG; Tuboi, SH; Faulhaber, JC; Harrison, LH; Schechter, M				Pacheco, Antonio G.; Tuboi, Suely H.; Faulhaber, Jose C.; Harrison, Lee H.; Schechter, Mauro			Increase in Non-AIDS Related Conditions as Causes of Death among HIV-Infected Individuals in the HAART Era in Brazil	PLOS ONE			English	Article								In 1996, Brazil became the first developing country to provide free and universal access to HAART. Although a decrease in overall mortality has been documented, there are no published data on the impact of HAART on causes of death among HIV-infected individuals in Brazil. We assessed temporal trends of mortality due to cardiovascular diseases (CVD), diabetes mellitus (DM) and other conditions generally not associated with HIV-infection among persons with and without HIV infection in Brazil between 1999 and 2004. Methodology/Principal Findings. Odds ratios were used to compare causes of death in individuals who had HIV/AIDS listed on any field of the death certificate with those who did not. Logistic regression models were fitted with generalized estimating equations to account for spatial correlation; co-variables were added to the models to control for potential confounding. Of 5,856,056 deaths reported in Brazil between 1999 and 2004 67,249 (1.15%) had HIV/AIDS listed on the death certificate and non-HIV-related conditions were listed on 16.3% in 1999, increasing to 24.1% by 2004 (p < 0.001). The adjusted average yearly increases were 8% and 0.8% for CVD (p < 0.001), and 12% and 2.8% for DM (p < 0.001), for those who had and did not have HIV/AIDS listed on the death certificate, respectively. Similar results were found for these conditions as underlying causes of death. Conclusions/Significance. In Brazil between 1999 and 2004 conditions usually considered not to be related to HIV-infection appeared to become more likely causes of death over time than reported causes of death among individuals who had HIV/AIDS listed on the death certificate than in those who did not. This observation has important programmatic implications for developing countries that are scaling-up access to antiretroviral therapy.	[Pacheco, Antonio G.] Oswaldo Cruz Fdn FIOCRUZ, Comp Sci Program, Natl Sch Publ Hlth, Dept Epidemiol & Quantitat Methods Hlth, Rio De Janeiro, Brazil; [Pacheco, Antonio G.; Tuboi, Suely H.; Harrison, Lee H.] Univ Pittsburgh, Sch Med, Grad Sch Publ Hlth, Infect Dis Epidemiol Res Unit, Pittsburgh, PA USA; [Tuboi, Suely H.; Faulhaber, Jose C.] Univ Fed Rio de Janeiro, Hosp Escola Sao Francisco de Assis, Proj Praca Onze, Rio De Janeiro, Brazil; [Schechter, Mauro] Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, AIDS Res Lab, Rio De Janeiro, Brazil	Fundacao Oswaldo Cruz; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro	Pacheco, AG (corresponding author), Oswaldo Cruz Fdn FIOCRUZ, Comp Sci Program, Natl Sch Publ Hlth, Dept Epidemiol & Quantitat Methods Hlth, Rio De Janeiro, Brazil.	apacheco@fiocruz.br	Pacheco, Antonio Guilherme/E-6378-2013; Schechter, Mauro/AAG-7445-2020	Pacheco, Antonio Guilherme/0000-0003-3095-1774; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI052788] Funding Source: NIH RePORTER; NIAID NIH HHS [K24 AI052788] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Braithwaite RS, 2005, AM J MED, V118, P890, DOI 10.1016/j.amjmed.2004.12.034; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Brito Ana Maria de, 2005, Braz J Infect Dis, V9, P9, DOI 10.1590/S1413-86702005000100004; Brown TT, 2005, ARCH INTERN MED, V165, P1179, DOI 10.1001/archinte.165.10.1179; *CDCP, 2007, HIV MORT 2004; *CDCP, 2007, HIV AIDS SURV REP 20, V17, P16; Crum NF, 2006, JAIDS-J ACQ IMM DEF, V41, P194, DOI 10.1097/01.qai.0000179459.31562.16; El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360; Friis-Moller N, 2003, NEW ENGL J MED, V349, P1993, DOI 10.1056/NEJMoa030218; Friis-Moller N, 2003, AIDS, V17, P1179, DOI 10.1097/00002030-200305230-00010; Friis-Moller N, 2007, NEW ENGL J MED, V356, P1723, DOI 10.1056/NEJMoa062744; Grangeiro A, 2006, REV SAUDE PUBL, V40, P60, DOI 10.1590/S0034-89102006000800009; Hammer SM, 2006, JAMA-J AM MED ASSOC, V296, P827, DOI 10.1001/jama.296.7.827; Haraki Cristianne Aparecida Costa, 2005, Rev. bras. epidemiol., V8, P19; *I BRAS GEOGR EST, 2006, PROJ POP; Johansson LA, 2002, J EPIDEMIOL COMMUN H, V56, P301, DOI 10.1136/jech.56.4.301; Jorge Maria Helena Prado de Mello, 2002, Rev. bras. epidemiol., V5, P197, DOI 10.1590/S1415-790X2002000200007; Lewden C, 2005, INT J EPIDEMIOL, V34, P121, DOI 10.1093/ije/dyh307; LOHSE N, 2007, J ANTIMICROB CHEMOTH; Marins JRP, 2003, AIDS, V17, P1675, DOI 10.1097/00002030-200307250-00012; MIETTINEN OS, 1981, AM J EPIDEMIOL, V114, P144, DOI 10.1093/oxfordjournals.aje.a113161; *MIN SAUD, 2007, MORT; *MIN SAUD SECR VIG, 2006, REC TER ANT AD AD IN; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Palella FJ, 2006, JAIDS-J ACQ IMM DEF, V43, P27, DOI 10.1097/01.qai.0000233310.90484.16; R Development Core Team, 2006, R LANG ENV STAT COMP; Sackoff JE, 2006, ANN INTERN MED, V145, P397, DOI 10.7326/0003-4819-145-6-200609190-00003; Schechter M, 2007, AIDS, V21, pS31, DOI 10.1097/01.aids.0000279704.16804.ae; Selik RM, 2002, J ACQ IMMUN DEF SYND, V29, P378, DOI 10.1097/00126334-200204010-00009; Smit C, 2006, AIDS, V20, P741, DOI 10.1097/01.aids.0000216375.99560.a2; Tuboi SH, 2005, JAIDS-J ACQ IMM DEF, V40, P324, DOI 10.1097/01.qai.0000182627.28595.01; *WHO, 2004, INT STAT CLASS DIS H, V2; *WHO, 2007, HLTH STAT HLHT INF S; World Health Organization, 2006, PROGR GLOB ACC HIV A; Yan J, 2004, STAT MED, V23, P859, DOI 10.1002/sim.1650; Yan J, 2004, STAT MED, V23, P879, DOI 10.1002/sim.1736	36	45	46	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1531	10.1371/journal.pone.0001531	http://dx.doi.org/10.1371/journal.pone.0001531			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SR	18231611	Green Accepted, Green Published, Green Submitted, gold			2022-12-25	WOS:000260504200038
J	Lei, M; Erikson, R				Lei, M.; Erikson, Rl			Plk1 depletion in nontransformed diploid cells activates the DNA-damage checkpoint	ONCOGENE			English	Article						checkpoint; DNA damage; nontransformed cell	POLO-LIKE KINASE-1; PROGNOSTIC-SIGNIFICANCE; CANCER-THERAPY; EXPRESSION; POLO-LIKE-KINASE-1; DIFFERENTIATION; TELOMERASE; CARCINOMAS; INHIBITOR; POTENT	We previously reported that polo-like kinase 1 (Plk1) depletion by lentivirus-based RNA interference led to mitotic arrest and apoptosis in cancer cells, whereas normal diploid cell lines, hTERT-RPE1 and MCF10A, survived a similar level of depletion. To study homogeneous cell lines, we generated several Plk1-depleted hTERT-RPE1 and MCF10A clones that were derived from single cells depleted of Plk1. We found that in the longterm, Plk1 depletion slowed proliferation of hTERT-RPE1 cells, apparently due to attenuated progression through S phase. These cells had altered morphology and were elongated compared with control. In contrast, MCF10A clones with mild levels of depletion showed no obvious phenotype. They appeared to have normal proliferation rates with no cell-cycle arrest. However, one MCF10A clone, which was severely depleted of Plk1, although viable, showed sporadic G2/M arrest and apoptosis. This MCF10A clone and all the hTERT-RPE1 clones displayed evidence of DNA-damage checkpoint activation. These data further support the interpretation that cancer cell lines have a much greater requirement for Plk1 than normal nontransformed diploid cells.	[Lei, M.; Erikson, Rl] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Lei, M (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Biolabs Room 2048,16 Divin Ave, Cambridge, MA 02138 USA.	minglei@fas.harvard.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059172] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM59172] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ando K, 2004, J BIOL CHEM, V279, P25549, DOI 10.1074/jbc.M314182200; Angelis KJ, 1999, ELECTROPHORESIS, V20, P2133, DOI 10.1002/(SICI)1522-2683(19990701)20:10<2133::AID-ELPS2133>3.0.CO;2-Q; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Castedo M, 2004, ONCOGENE, V23, P4353, DOI 10.1038/sj.onc.1207573; Eckerdt F, 2005, ONCOGENE, V24, P267, DOI 10.1038/sj.onc.1208273; Galy A, 2002, DEV BIOL, V248, P251, DOI 10.1006/dbio.2002.0736; GERDES J, 1984, J IMMUNOL, V133, P1710; Gumireddy K, 2005, CANCER CELL, V7, P275, DOI 10.1016/j.ccr.2005.02.009; Hardy CFJ, 1996, MOL CELL BIOL, V16, P6775; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Knecht R, 1999, CANCER RES, V59, P2794; Knecht R, 2000, INT J CANCER, V89, P535; Liu XQ, 2006, MOL CELL BIOL, V26, P2093, DOI 10.1128/MCB.26.6.2093-2108.2006; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Mamely I, 2006, CURR BIOL, V16, P1950, DOI 10.1016/j.cub.2006.08.026; Rak DJ, 2006, EXP EYE RES, V82, P648, DOI 10.1016/j.exer.2005.09.002; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; SOULE HD, 1990, CANCER RES, V50, P6075; Spankuch B, 2004, JNCI-J NATL CANCER I, V96, P862, DOI 10.1093/jnci/djh146; Steegmaier M, 2007, CURR BIOL, V17, P316, DOI 10.1016/j.cub.2006.12.037; Strebhardt K, 2006, NAT REV CANCER, V6, P321, DOI 10.1038/nrc1841; Strebhardt K, 2000, JAMA-J AM MED ASSOC, V283, P479, DOI 10.1001/jama.283.4.479; Takai N, 2005, ONCOGENE, V24, P287, DOI 10.1038/sj.onc.1208272; Tsvetkov L, 2005, J BIOL CHEM, V280, P11943, DOI 10.1074/jbc.M413514200; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; Weinstein IB, 2006, NAT CLIN PRACT ONCOL, V3, P448, DOI 10.1038/ncponc0558; Winkles JA, 2005, ONCOGENE, V24, P260, DOI 10.1038/sj.onc.1208219; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862	29	40	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2008	27	28					3935	3943		10.1038/onc.2008.36	http://dx.doi.org/10.1038/onc.2008.36			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	318JZ	18297112				2022-12-25	WOS:000257089000005
J	Biswas, G; Tang, W; Sondheimer, N; Guha, M; Bansal, S; Avadhani, NG				Biswas, Gopa; Tang, Weigang; Sondheimer, Neal; Guha, Manti; Bansal, Seema; Avadhani, Narayan G.			A distinctive physiological role for I kappa B beta in the propagation of mitochondrial respiratory stress signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-FACTOR; CANCER-CELLS; OXIDATIVE-PHOSPHORYLATION; INDUCED RESISTANCE; TUMOR PROGRESSION; PROSTATE-CANCER; ACTIVATION; APOPTOSIS; ALPHA; PATHWAY	The NF kappa Bs regulate an array of physiological and pathological processes, including propagation of mitochondrial respiratory stress signaling in mammalian cells. We showed previously that mitochondrial stress activates NF kappa B using a novel calcineurin-requiring pathway that is different from canonical or non-canonical pathways. This study shows that I kappa B beta is essential for the propagation of mitochondrial stress signaling. Knock down of I kappa B beta, but not I kappa B alpha, mRNA reduced the mitochondrial stress-mediated activation and nuclear translocation of cRel:p50, inhibiting expression of nuclear target genes RyR1 and cathepsin L. I kappa B beta mRNA knock down also reduced resistance to staurosporine-induced apoptosis and decreased in vitro invasiveness. Induced receptor switching to insulin-like growth factor-1 receptor and increased glucose uptake are hallmarks of mitochondrial stress. I kappa B beta mRNA knock down selectively abrogated the receptor switch and altered tubulin cytoskeletal organization. These results show that mitochondrial stress signaling uses an I kappa B beta-initiated NF kappa B pathway that is distinct from the other known NF kappa B pathways. Furthermore, our results demonstrate the distinctive physiological roles of the two inhibitory proteins I kappa B beta and I kappa B alpha	[Biswas, Gopa; Tang, Weigang; Guha, Manti; Bansal, Seema; Avadhani, Narayan G.] Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; [Biswas, Gopa; Tang, Weigang; Guha, Manti; Bansal, Seema; Avadhani, Narayan G.] Univ Penn, Sch Vet Med, Mari Lowe Ctr Comparat Oncol, Philadelphia, PA 19104 USA; [Sondheimer, Neal] Childrens Hosp Philadelphia, Sect Biochem Genet, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Avadhani, NG (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, 3800 Spruce St, Philadelphia, PA 19104 USA.	narayan@vet.upenn.edu	Sondheimer, Neal/X-7846-2019	Sondheimer, Neal/0000-0001-9982-5712	NCI NIH HHS [CA-22762] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA022762, R37CA022762] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amuthan G, 2001, EMBO J, V20, P1910, DOI 10.1093/emboj/20.8.1910; Arnould T, 2002, EMBO J, V21, P53, DOI 10.1093/emboj/21.1.53; Arnuthan G, 2002, ONCOGENE, V21, P7839, DOI 10.1038/sj.onc.1205983; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; Biswas G, 2003, J CELL BIOL, V161, P507, DOI 10.1083/jcb.200211104; Biswas G, 2005, GENE, V354, P132, DOI 10.1016/j.gene.2005.03.028; Biswas G, 2005, CELL DEATH DIFFER, V12, P266, DOI 10.1038/sj.cdd.4401553; Biswas G, 2008, P NATL ACAD SCI USA, V105, P186, DOI 10.1073/pnas.0706183104; BOETTIGER D, 1995, DEV BIOL, V169, P261, DOI 10.1006/dbio.1995.1142; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Coloff JL, 2006, J CELL BIOL, V175, P845, DOI 10.1083/jcb.200610119; Dey R, 2000, J BIOL CHEM, V275, P7087, DOI 10.1074/jbc.275.10.7087; Duffey DC, 1999, CANCER RES, V59, P3468; Epstein CB, 2001, MOL BIOL CELL, V12, P297, DOI 10.1091/mbc.12.2.297; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; GILOMRE TD, 2003, CANC TREAT RES, V115, P241; Girnita A, 2006, CLIN CANCER RES, V12, P1383, DOI 10.1158/1078-0432.CCR-05-1106; Greten FR, 2004, CANCER LETT, V206, P193, DOI 10.1016/j.canlet.2003.08.029; GRILLI M, 1993, INT REV CYTOL, V143, P1; Guha M, 2007, J BIOL CHEM, V282, P14536, DOI 10.1074/jbc.M611693200; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Kang BPS, 2003, AM J PHYSIOL-RENAL, V285, pF1013, DOI 10.1152/ajprenal.00209.2003; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kato T, 2003, MOL CELL, V12, P829, DOI 10.1016/S1097-2765(03)00358-7; Kim JY, 2002, ONCOGENE, V21, P3139, DOI 10.1038/sj.onc.1205406; Lind DS, 2001, SURGERY, V130, P363, DOI 10.1067/msy.2001.116672; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; Malek S, 2001, J BIOL CHEM, V276, P45225, DOI 10.1074/jbc.M105865200; May MJ, 2006, J IMMUNOL, V177, P7483, DOI 10.4049/jimmunol.177.11.7483; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; Miyamoto S, 1998, MOL CELL BIOL, V18, P19, DOI 10.1128/MCB.18.1.19; Modica-Napolitano JS, 2007, CURR MOL MED, V7, P121, DOI 10.2174/156652407779940495; Passes JF, 2007, BIOESSAYS, V29, P908, DOI 10.1002/bies.20634; Pelicano H, 2006, J CELL BIOL, V175, P913, DOI 10.1083/jcb.200512100; Perkins ND, 2006, CELL DEATH DIFFER, V13, P759, DOI 10.1038/sj.cdd.4401838; Perkins ND, 1997, INT J BIOCHEM CELL B, V29, P1433, DOI 10.1016/S1357-2725(97)00088-5; Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102; Romieu-Mourez R, 2002, CANCER RES, V62, P6770; Saccani S, 2003, MOL CELL, V11, P1563, DOI 10.1016/S1097-2765(03)00227-2; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Schoonbroodt S, 2000, J IMMUNOL, V164, P4292, DOI 10.4049/jimmunol.164.8.4292; Sekito T, 2002, MOL BIOL CELL, V13, P795, DOI 10.1091/mbc.01-10-0473; SHIRADA Y, 2005, CANCER RES, V65, P1655; Srinivasan S, 2007, ANN NY ACAD SCI, V1117, P51, DOI 10.1196/annals.1402.067; Stromberg T, 2006, BLOOD, V107, P669, DOI 10.1182/blood-2005-01-0306; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; Tergaonkar V, 2005, NAT CELL BIOL, V7, P921, DOI 10.1038/ncb1296; Tergaonkar V, 2003, MOL CELL BIOL, V23, P8070, DOI 10.1128/MCB.23.22.8070-8083.2003; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; van Waveren C, 2006, CARCINOGENESIS, V27, P409, DOI 10.1093/carcin/bgi242; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309	62	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2008	283	18					12586	12594		10.1074/jbc.M710481200	http://dx.doi.org/10.1074/jbc.M710481200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	293MS	18272519	Green Published, hybrid			2022-12-25	WOS:000255340000075
J	Wei, CC; Wang, ZQ; Tejero, J; Yang, YP; Hemann, C; Hille, R; Stuehr, DJ				Wei, Chin-Chuan; Wang, Zhi-Qiang; Tejero, Jesus; Yang, Ya-Ping; Hemann, Craig; Hille, Russ; Stuehr, Dennis J.			Catalytic reduction of a tetrahydrobiopterin radical within nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL NO SYNTHASE; HEME-DIOXY REDUCTION; HYDROXY-L-ARGININE; ELECTRON-TRANSFER; OMEGA-HYDROXYARGININE; OXYGEN; BINDING; DOMAIN; PTERIN; CYTOCHROME-P450	Nitric-oxide synthases (NOS) are catalytically self-sufficient flavo-heme enzymes that generate NO from arginine (Arg) and display a novel utilization of their tetrahydrobiopterin (H4B) cofactor. During Arg hydroxylation, H4B acts as a one-electron donor and is then presumed to redox cycle (i.e. be reduced back to H4B) within NOS before further catalysis can proceed. Whereas H4B radical formation is well characterized, the subsequent presumed radical reduction has not been demonstrated, and its potential mechanisms are unknown. We investigated radical reduction during a single turnover Arg hydroxylation reaction catalyzed by neuronal NOS to document the process, determine its kinetics, and test for involvement of the NOS flavoprotein domain. We utilized a freeze-quench instrument, the biopterin analog 5-methyl-H4B, and a method that could separately quantify the flavin and pterin radicals that formed in NOS during the reaction. Our results establish that the NOS flavoprotein domain catalyzes reduction of the biopterin radical following Arg hydroxylation. The reduction is calmodulin-dependent and occurs at a rate that is similar to heme reduction and fast enough to explain H4B redox cycling in NOS. These results, in light of existing NOS crystal structures, suggest a "through-heme" mechanism may operate for H4B radical reduction in NOS.	[Wei, Chin-Chuan] So Illinois Univ, Dept Chem, Edwardsville, IL 62026 USA; [Wang, Zhi-Qiang; Tejero, Jesus; Yang, Ya-Ping; Stuehr, Dennis J.] Cleveland Clin Fdn, Lerner Res Inst, Dept Pathobiol, Cleveland, OH 44195 USA; [Wang, Zhi-Qiang] Kent State Univ Tuscarawas, Dept Chem, New Philadelphia, OH 44663 USA; [Hille, Russ] Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA; [Hemann, Craig] Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA	Southern Illinois University System; Southern Illinois University Edwardsville; Cleveland Clinic Foundation; University System of Ohio; Kent State University; Kent State University Tuscarawas; University of California System; University of California Riverside; University System of Ohio; Ohio State University	Wei, CC (corresponding author), So Illinois Univ, Dept Chem, Edwardsville, IL 62026 USA.	cwei@siue.edu; stuehrd@ccf.org	Tejero, Jesus/G-3953-2017	Tejero, Jesus/0000-0003-3245-9978; Hemann, Craig/0000-0002-7380-4072; Wei, Chin-Chuan/0000-0001-6453-9409	NCI NIH HHS [CA53914] Funding Source: Medline; NHLBI NIH HHS [HL58883] Funding Source: Medline; NIEHS NIH HHS [ES012658] Funding Source: Medline; NIGMS NIH HHS [GM51491, GM075036] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053914, R29CA053914] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058883] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012658] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491, R01GM075036] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABU SH, 1993, P NATL ACAD SCI USA, V90, P10769; AbuSoud HM, 1997, BIOCHEMISTRY-US, V36, P10811, DOI 10.1021/bi971414g; Adak S, 1999, J BIOL CHEM, V274, P22313, DOI 10.1074/jbc.274.32.22313; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Berka V, 2004, BIOCHEMISTRY-US, V43, P13137, DOI 10.1021/bi049026j; Berka V, 2004, J BIOL CHEM, V279, P32243, DOI 10.1074/jbc.M404044200; Buga GM, 1996, AM J PHYSIOL-HEART C, V271, pH1988, DOI 10.1152/ajpheart.1996.271.5.H1988; Capeillere-Blandin C, 2005, BIOCHEM J, V392, P583, DOI 10.1042/BJ20050437; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Daff S, 2003, BIOCHEM SOC T, V31, P502, DOI 10.1042/bst0310502; Denisov IG, 2005, CHEM REV, V105, P2253, DOI 10.1021/cr0307143; Dunford AJ, 2007, BIOCHEMISTRY-US, V46, P5018, DOI 10.1021/bi7001339; Feng CJ, 2007, J AM CHEM SOC, V129, P5621, DOI 10.1021/ja068685b; FUKUSHIMA T, 1980, ANAL BIOCHEM, V102, P176, DOI 10.1016/0003-2697(80)90336-X; Galli C, 1996, BIOCHEMISTRY-US, V35, P2804, DOI 10.1021/bi9520444; Garcin ED, 2004, J BIOL CHEM, V279, P37918, DOI 10.1074/jbc.M406204200; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; Gorren ACF, 2001, NITRIC OXIDE-BIOL CH, V5, P176, DOI 10.1006/niox.2001.0332; Gorren ACF, 1996, BIOCHEMISTRY-US, V35, P16735, DOI 10.1021/bi961931j; Gorren ACF, 2007, BBA-GEN SUBJECTS, V1770, P432, DOI 10.1016/j.bbagen.2006.08.019; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; Hurshman AR, 2003, BIOCHEMISTRY-US, V42, P13287, DOI 10.1021/bi035491p; Konas DW, 2006, BIOCHEMISTRY-US, V45, P12596, DOI 10.1021/bi061011t; Konas DW, 2004, J BIOL CHEM, V279, P35412, DOI 10.1074/jbc.M400872200; List BM, 1997, BIOCHEM J, V323, P159, DOI 10.1042/bj3230159; Miller RT, 1999, BIOCHEM BIOPH RES CO, V265, P184, DOI 10.1006/bbrc.1999.1643; Moser CC, 2006, PHILOS T R SOC B, V361, P1295, DOI 10.1098/rstb.2006.1868; Ost TWB, 2005, J BIOL CHEM, V280, P965, DOI 10.1074/jbc.M411191200; Page CC, 2003, CURR OPIN CHEM BIOL, V7, P551, DOI 10.1016/j.cbpa.2003.08.005; Panda K, 2003, J BIOL CHEM, V278, P37122, DOI 10.1074/jbc.M304456200; Perry JM, 1998, CHEM BIOL, V5, P355, DOI 10.1016/S1074-5521(98)90069-2; Reif A, 1999, J BIOL CHEM, V274, P24921, DOI 10.1074/jbc.274.35.24921; Roman LJ, 2006, J BIOL CHEM, V281, P23111, DOI 10.1074/jbc.M603671200; Schmidt PP, 2001, J BIOL INORG CHEM, V6, P151, DOI 10.1007/s007750000185; Shimanuki T, 1999, J BIOL CHEM, V274, P26956, DOI 10.1074/jbc.274.38.26956; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; Tiso M, 2005, J BIOL CHEM, V280, P39208, DOI 10.1074/jbc.M507775200; Wei CC, 2005, J BIOL CHEM, V280, P8929, DOI 10.1074/jbc.M409737200; Wei CC, 2003, J BIOL CHEM, V278, P46668, DOI 10.1074/jbc.M307682200; Wei CC, 2003, BIOCHEMISTRY-US, V42, P1969, DOI 10.1021/bi026898h; Wei CC, 2001, J BIOL CHEM, V276, P315, DOI 10.1074/jbc.M008441200; Wei CC, 2003, CHEM REV, V103, P2365, DOI 10.1021/cr0204350; Witteveen CFB, 1996, J BIOL CHEM, V271, P4143; Witteveen CFB, 1999, J BIOL CHEM, V274, P29755, DOI 10.1074/jbc.274.42.29755	44	63	65	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11734	11742		10.1074/jbc.M709250200	http://dx.doi.org/10.1074/jbc.M709250200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18283102	Green Published, hybrid			2022-12-25	WOS:000255067400073
J	Xu, CY; Xu, WJ; Palmer, AE; Reed, JC				Xu, Chunyan; Xu, Wenjie; Palmer, Amy E.; Reed, John C.			BI-1 regulates endoplasmic reticulum Ca2+ Homeostasis downstream of bcl-2 family proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CELL-DEATH; MITOCHONDRIAL PERMEABILITY TRANSITION; BAX INHIBITOR-1; INOSITOL 1,4,5-TRISPHOSPHATE; FLUORESCENT INDICATORS; INDUCED APOPTOSIS; DOWN-REGULATION; PLANT HOMOLOG; MODULATION; STRESS	BI-1 (Bax inhibitor-1) is an evolutionarily conserved multi-transmembrane protein that resides in the endoplasmic reticulum (ER) and that has documented cytoprotective functions in both animals and plants. Recent studies indicate that BI-1 shares in common with Bcl-2/Bax family proteins the ability to regulate the amounts of Ca2+ that can be released from the ER by agents, such as the ER-Ca2+-ATPase (SERCA) inhibitor thapsigargin (TG). Using an ER-targeted, Ca2+ indicator (cameleon), with characteristics optimized for measuring ER Ca2+ ([Ca2+](er)), we studied the effects of BI-1 on [Ca2+](er) in resting and TG-treated cells. Similar to cells overexpressing antiapoptotic Bcl-2 or Bcl-XL, overexpression of BI-1 resulted in lower resting [Ca2+](er), with concomitantly less Ca2+ released into the cytosol upon stimulation by TG and with a higher rate of Ca2+ leakage from the ER. Co-expression of SERCA restored levels of [Ca2+](er) to normal, showing opposing actions of the ER-Ca2+ ATPase and BI-1 on ER Ca2+ homeostasis. Conversely, cells with deficient BI-1 have increased [Ca2+](er), and release more Ca2+ into the cytosol when challenged with TG. In BI-1-deficient cells, Bcl-XL fails to reduce [Ca2+](er), indicating that BI-1 functions downstream of Bcl-XL. In bax(-/-) bak(-/-) double knock-out cells, both BI-1 and Bcl-XL retained their ability to reduce [Ca2+](er), suggesting that BI-1 and Bcl-XL operate downstream of or parallel to Bax/Bak. The findings reveal a hierarchy of functional interactions of BI-1 with Bcl-2/Bax family proteins in regulating ER Ca2+ homeostasis.	[Xu, Chunyan; Xu, Wenjie; Reed, John C.] Burnham Inst Med Res, Program Apoptosis & Cell Death Res, La Jolla, CA 92037 USA; [Palmer, Amy E.] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego	Reed, JC (corresponding author), Burnham Inst Med Res, Program Apoptosis & Cell Death Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	reedoffice@burnham.org	Xu, Wenjie/F-5453-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM067488] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS027177, F32NS047855, R01NS027177] Funding Source: NIH RePORTER; NIGMS NIH HHS [F32-GM067488] Funding Source: Medline; NINDS NIH HHS [F32-NS047855, NS27177] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Arnaudeau S, 2002, J BIOL CHEM, V277, P46696, DOI 10.1074/jbc.M202395200; Bailly-Maitre B, 2006, P NATL ACAD SCI USA, V103, P2809, DOI 10.1073/pnas.0506854103; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Bassik MC, 2004, EMBO J, V23, P1207, DOI 10.1038/sj.emboj.7600104; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Bolduc N, 2003, PLANTA, V216, P377, DOI 10.1007/s00425-002-0879-1; Bolduc N, 2002, FEBS LETT, V532, P111, DOI 10.1016/S0014-5793(02)03650-5; Chae HJ, 2004, MOL CELL, V15, P355, DOI 10.1016/j.molcel.2004.06.038; Chae HJ, 2003, GENE, V323, P101, DOI 10.1016/j.gene.2003.09.011; Chami M, 2004, J BIOL CHEM, V279, P54581, DOI 10.1074/jbc.M409663200; Chen R, 2004, J CELL BIOL, V166, P193, DOI 10.1083/jcb.200309146; Dremina ES, 2006, BIOCHEMISTRY-US, V45, P175, DOI 10.1021/bi050800s; Dremina ES, 2004, BIOCHEM J, V383, P361, DOI 10.1042/BJ20040187; Filippin L, 2005, CELL CALCIUM, V37, P129, DOI 10.1016/j.ceca.2004.08.002; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Ihara-Ohori Y, 2007, PLANT PHYSIOL, V143, P650, DOI 10.1104/pp.106.090878; Jones RG, 2007, IMMUNITY, V27, P268, DOI 10.1016/j.immuni.2007.05.023; Kawai M, 1999, FEBS LETT, V464, P143, DOI 10.1016/S0014-5793(99)01695-6; Kawai-Yamada M, 2004, PLANT CELL, V16, P21, DOI 10.1105/tpc.014613; Kawai-Yamada M, 2001, P NATL ACAD SCI USA, V98, P12295, DOI 10.1073/pnas.211423998; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Li C, 2007, P NATL ACAD SCI USA, V104, P12565, DOI 10.1073/pnas.0702489104; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Matsumura H, 2003, PLANT J, V33, P425, DOI 10.1046/j.1365-313X.2003.01639.x; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Nakamura K, 2000, J CELL BIOL, V150, P731, DOI 10.1083/jcb.150.4.731; Oakes SA, 2005, P NATL ACAD SCI USA, V102, P105, DOI 10.1073/pnas.0408352102; Palmer AE, 2004, P NATL ACAD SCI USA, V101, P17404, DOI 10.1073/pnas.0408030101; Palmer AE, 2006, NAT PROTOC, V1, P1057, DOI 10.1038/nprot.2006.172; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Sanchez P, 2000, PLANT J, V21, P393, DOI 10.1046/j.1365-313x.2000.00690.x; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Vanden Abeele F, 2002, CANCER CELL, V1, P169; WALTER L, 1994, MAMM GENOME, V5, P216, DOI 10.1007/BF00360548; Watanabe N, 2006, PLANT J, V45, P884, DOI 10.1111/j.1365-313X.2006.02654.x; Westphalen BC, 2005, CELL DEATH DIFFER, V12, P304, DOI 10.1038/sj.cdd.4401547; White C, 2005, NAT CELL BIOL, V7, P1021, DOI 10.1038/ncb1302; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	54	90	93	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11477	11484		10.1074/jbc.M708385200	http://dx.doi.org/10.1074/jbc.M708385200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18299329	Green Published, hybrid			2022-12-25	WOS:000255067400046
J	Chen, S; Li, B; Grundke-Iqbal, I; Iqbal, K				Chen, She; Li, Bin; Grundke-Iqbal, Inge; Iqbal, Khalid			I-1(PP2A) affects Tau phosphorylation via association with the catalytic subunit of protein phosphatase 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; ALZHEIMER NEUROFIBRILLARY DEGENERATION; PAIRED HELICAL FILAMENTS; ACIDIC NUCLEAR-PROTEIN; LEUCINE-RICH REPEATS; HYPERPHOSPHORYLATED-TAU; RAT-BRAIN; ABNORMAL PHOSPHORYLATION; DISEASE BRAIN; 2A	In Alzheimer disease (AD) brain, the level of I-1(PP2A), a 249-amino acid long endogenous inhibitor of protein phosphatase 2A(PP2A), is increased, the activity of the phosphatase is decreased, and the microtubule-associated protein Tau is abnormally hyperphosphorylated. However, little is known about the detailed regulatory mechanism by which PP2A activity is inhibited by I-1(PP2A) and the consequent events in mammalian cells. In this study, we found that both I-1(PP2A) and its N-terminal half I-1(PP2A(1-120)), but neither I-1(PP2A(1-163)) nor I-1(PP2A(164-249)), inhibited PP2A activity in vitro, suggesting an autoinhibition by amino acid residues 121-163 and its neutralization by the C-terminal region. Furthermore, transfection of NIH3T3 cells produced a dose-dependent inhibition of PP2A activity by I-1(PP2A). I-1(PP2A) and PP2A were found to colocalize in PC12 cells. I-1(PP2A) could only interact with the catalytic subunit of PP2A (PP2Ac) and had no interaction with the regulatory subunits of PP2A (PP2A-A or PP2A-B) using a glutathione S-transferase-pulldown assay. The interaction was further confirmed by coimmunoprecipitation of I-1(PP2A) and PP2Ac from lysates of transiently transfected NIH3T3 cells. The N-terminal isotype specific region of I-1(PP2A) was required for its association with PP2Ac as well as PP2A inhibition. In addition, the phosphorylation of Tau was significantly increased in PC12/Tau441 cells transiently transfected with full-length I-1(PP2A) and with PP2Ac-interacting I-1(PP2A) deletion mutant 1-120 (I-1(PP2A)Delta C2). Double immunofluorescence staining showed that I-1(PP2A) and I-1(PP2A)Delta C2 increased Tau phosphorylation and impaired the microtubule network and neurite outgrowth in PC12 cells treated with nerve growth factor.	[Chen, She; Li, Bin; Grundke-Iqbal, Inge; Iqbal, Khalid] New York State Inst Basic Res Dev Disabil, Dept Neurochem, Staten Isl, NY 10314 USA	Institute for Basic Research in Developmental Disabilities	Iqbal, K (corresponding author), New York State Inst Basic Res Dev Disabil, Dept Neurochem, 1050 Forest Hill Rd, Staten Isl, NY 10314 USA.	iqbalk@wordlnet.att.net			NATIONAL INSTITUTE ON AGING [R01AG019158] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG019158-08, AG-019158, R01 AG019158] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALAFUZOFF I, 1987, ACTA NEUROPATHOL, V74, P209, DOI 10.1007/BF00688184; Alonso AD, 1997, P NATL ACAD SCI USA, V94, P298, DOI 10.1073/pnas.94.1.298; Alonso AD, 1996, NAT MED, V2, P783, DOI 10.1038/nm0796-783; ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Alonso AD, 2006, P NATL ACAD SCI USA, V103, P8864, DOI 10.1073/pnas.0603214103; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; Bennecib M, 2000, ALZHEIMERS REP, V3, P295; Bennecib M, 2000, FEBS LETT, V485, P87, DOI 10.1016/S0014-5793(00)02203-1; BRAAK H, 1986, NEUROSCI LETT, V65, P351, DOI 10.1016/0304-3940(86)90288-0; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Chen TH, 1996, MOL BIOL CELL, V7, P2045, DOI 10.1091/mbc.7.12.2045; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; GOEDERT M, 1995, J NEUROCHEM, V65, P2804; Gong CX, 2000, J BIOL CHEM, V275, P5535, DOI 10.1074/jbc.275.8.5535; Gong CX, 2000, BRAIN RES, V853, P299, DOI 10.1016/S0006-8993(99)02294-5; GONG CX, 1994, NEUROSCIENCE, V61, P765, DOI 10.1016/0306-4522(94)90400-6; GONG CX, 1995, J NEUROCHEM, V65, P732, DOI 10.1046/j.1471-4159.1995.65020732.x; GONG CX, 1993, J NEUROCHEM, V61, P921, DOI 10.1111/j.1471-4159.1993.tb03603.x; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; HASEGAWA M, 1993, J NEUROCHEM, V60, P2068, DOI 10.1111/j.1471-4159.1993.tb03491.x; Hong R, 2004, BIOCHEMISTRY-US, V43, P10157, DOI 10.1021/bi0493968; IQBAL K, 1986, LANCET, V2, P421; Iqbal K, 1998, J NEURAL TRANSM-SUPP, P169; Iqbal K, 2005, BBA-MOL BASIS DIS, V1739, P198, DOI 10.1016/j.bbadis.2004.09.008; IQBAL K, 1997, BRAIN MICROTUBULE AS, P95; Kins S, 2003, AM J PATHOL, V163, P833, DOI 10.1016/S0002-9440(10)63444-X; Kutney SN, 2004, J BIOL CHEM, V279, P30850, DOI 10.1074/jbc.M404969200; Li B, 2007, ACTA NEUROPATHOL, V113, P501, DOI 10.1007/s00401-007-0207-8; Li M, 1996, BIOCHEMISTRY-US, V35, P6998, DOI 10.1021/bi960581y; LI M, 1995, BIOCHEMISTRY-US, V34, P1988, DOI 10.1021/bi00006a020; Liang L, 2004, FEBS LETT, V566, P261, DOI 10.1016/j.febslet.2004.04.047; Liu F, 2005, EUR J NEUROSCI, V22, P1942, DOI 10.1111/j.1460-9568.2005.04391.x; Liu F, 2004, P NATL ACAD SCI USA, V101, P10804, DOI 10.1073/pnas.0400348101; Liu SJ, 2004, J BIOL CHEM, V279, P50078, DOI 10.1074/jbc.M406109200; Loring JF, 2001, DNA CELL BIOL, V20, P683, DOI 10.1089/10445490152717541; Matilla A, 2005, CEREBELLUM, V4, P7, DOI 10.1080/14734220410019020; MATSUOKA K, 1994, P NATL ACAD SCI USA, V91, P9670, DOI 10.1073/pnas.91.21.9670; Mencinger M, 1998, BBA-GENE STRUCT EXPR, V1395, P176, DOI 10.1016/S0167-4781(97)00165-6; Opal P, 2003, J BIOL CHEM, V278, P34691, DOI 10.1074/jbc.M302785200; Pei JJ, 2003, AM J PATHOL, V163, P845, DOI 10.1016/S0002-9440(10)63445-1; Pei JJ, 2003, ACTA NEUROPATHOL, V105, P381, DOI 10.1007/s00401-002-0657-y; SantaCruz K, 2005, SCIENCE, V309, P476, DOI 10.1126/science.1113694; Sengupta A, 2006, FEBS LETT, V580, P5925, DOI 10.1016/j.febslet.2006.09.060; Seo SB, 2002, J BIOL CHEM, V277, P14005, DOI 10.1074/jbc.M112455200; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; Sontag E, 1999, J BIOL CHEM, V274, P25490, DOI 10.1074/jbc.274.36.25490; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; Sontag E, 2004, J NEUROPATH EXP NEUR, V63, P287, DOI 10.1093/jnen/63.4.287; Tanaka T, 1998, FEBS LETT, V426, P248, DOI 10.1016/S0014-5793(98)00346-9; Tanimukai H, 2005, AM J PATHOL, V166, P1761, DOI 10.1016/S0002-9440(10)62486-8; Tanimukai H, 2004, MOL BRAIN RES, V126, P146, DOI 10.1016/j.molbrainres.2004.04.003; Tolnay M, 1999, NEUROPATH APPL NEURO, V25, P171; TOMLINSON BE, 1970, J NEUROL SCI, V11, P205, DOI 10.1016/0022-510X(70)90063-8; Tsujio I, 2005, FEBS LETT, V579, P363, DOI 10.1016/j.febslet.2004.11.097; Ulitzur N, 1997, J BIOL CHEM, V272, P30577, DOI 10.1074/jbc.272.48.30577; Ulitzur N, 1997, P NATL ACAD SCI USA, V94, P5084, DOI 10.1073/pnas.94.10.5084; VAESEN M, 1994, BIOL CHEM H-S, V375, P113, DOI 10.1515/bchm3.1994.375.2.113; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; Vogelsberg-Ragaglia V, 2001, EXP NEUROL, V168, P402, DOI 10.1006/exnr.2001.7630; WALENSKY LD, 1993, CANCER RES, V53, P4720; Wang JZ, 2007, EUR J NEUROSCI, V25, P59, DOI 10.1111/j.1460-9568.2006.05226.x; Wang JZ, 1996, MOL BRAIN RES, V38, P200, DOI 10.1016/0169-328X(95)00316-K; Yu LG, 2004, J BIOL CHEM, V279, P41377, DOI 10.1074/jbc.M400017200	64	59	64	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10513	10521		10.1074/jbc.M709852200	http://dx.doi.org/10.1074/jbc.M709852200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18245083	Green Published, hybrid			2022-12-25	WOS:000254894700033
J	Davis, MC; McColl, KS; Zhong, F; Wang, ZQ; Malone, MH; Distelhorst, CW				Davis, Michael C.; McColl, Karen S.; Zhong, Fei; Wang, Zhengqi; Malone, Michael H.; Distelhorst, Clark W.			Dexamethasone-induced inositol 1,4,5-trisphosphate receptor elevation in murine lymphoma cells is not required for dexamethasone-mediated calcium elevation and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID-INDUCED APOPTOSIS; ACUTE LYMPHOBLASTIC-LEUKEMIA; ENDOGENOUS ENDONUCLEASE ACTIVATION; TRISPHOSPHATE RECEPTORS; OLIGONUCLEOTIDE ARRAYS; EXPRESSION PATTERNS; MESSENGER-RNA; PROTEIN BIM; RESISTANT; GENES	Glucocorticosteroid hormones, including dexamethasone, have diverse effects on immature lymphocyte function that ultimately lead to cell death. Previous studies established that glucocorticoid-induced alterations in intracellular calcium homeostasis promote apoptosis, but the mechanism by which glucocorticoids disrupt calcium homeostasis is unknown. Through gene expression array analysis, we found that dexamethasone induces a striking elevation of inositol 1,4,5-trisphosphate receptor (IP3R) levels in two murine lymphoma cell lines, WEHI7.2 and S49.A2.IP3R elevation was confirmed at both mRNA and protein levels. However, there was not a strong correlation between IP3R elevation and altered calcium homeostasis in terms of either kinetics or dose response. Moreover, IP3R knockdown, by either antisense or small interfering RNA, did not prevent either calcium disruption or apoptosis. Finally, DT40 lymphoma cells lacking all three IP3R isoforms were just as sensitive to dexamethasone-induced apoptosis as wild-type DT40 cells expressing all three IP3R isoforms. Thus, although alterations in intracellular calcium homeostasis contribute to glucocorticoid-induced apoptosis, these calcium alterations are not directly attributable to IP3R elevation.	[Davis, Michael C.; McColl, Karen S.; Zhong, Fei; Wang, Zhengqi; Malone, Michael H.; Distelhorst, Clark W.] Case Western Reserve Univ, Ctr Comprehens Canc, Dept Med, Div Hematol Oncol, Cleveland, OH 44106 USA; [Davis, Michael C.; McColl, Karen S.; Zhong, Fei; Wang, Zhengqi; Malone, Michael H.; Distelhorst, Clark W.] Case Western Reserve Univ, Ctr Comprehens Canc, Dept Pharmacol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Distelhorst, CW (corresponding author), Case Western Reserve Univ, Ctr Comprehens Canc, Dept Med, Div Hematol Oncol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	cwd@case.edu	Davis, Michael C/L-8920-2013	Davis, Michael C/0000-0003-2293-5694	NCI NIH HHS [R01 CA042755] Funding Source: Medline; NHLBI NIH HHS [T32 HL07147, T32 HL007147] Funding Source: Medline; NIGMS NIH HHS [T32 GM007250] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042755] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007147] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrams MT, 2004, J BIOL CHEM, V279, P55809, DOI 10.1074/jbc.M411767200; Ashwell JD, 2000, ANNU REV IMMUNOL, V18, P309, DOI 10.1146/annurev.immunol.18.1.309; Assefa Z, 2004, J BIOL CHEM, V279, P43227, DOI 10.1074/jbc.M403872200; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bezprozvanny I, 2005, CELL CALCIUM, V38, P261, DOI 10.1016/j.ceca.2005.06.030; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; Carafoli E, 2002, P NATL ACAD SCI USA, V99, P1115, DOI 10.1073/pnas.032427999; Chauhan D, 2002, ONCOGENE, V21, P1346, DOI 10.1038/sj.onc.1205205; Chen R, 2004, J CELL BIOL, V166, P193, DOI 10.1083/jcb.200309146; Distelhorst CW, 2002, CELL DEATH DIFFER, V9, P6, DOI 10.1038/sj.cdd.4400969; FERNANDEZ A, 1995, J IMMUNOL, V155, P5133; Hirota J, 1999, J BIOL CHEM, V274, P34433, DOI 10.1074/jbc.274.48.34433; Hirota J, 1998, BIOCHEM J, V333, P615, DOI 10.1042/bj3330615; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; Jondal M, 2004, TRENDS IMMUNOL, V25, P595, DOI 10.1016/j.it.2004.09.003; Joseph SK, 2007, APOPTOSIS, V12, P951, DOI 10.1007/s10495-007-0719-7; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; Kumar R, 2005, J STEROID BIOCHEM, V94, P383, DOI 10.1016/j.jsbmb.2004.12.046; LAM M, 1993, MOL ENDOCRINOL, V7, P686, DOI 10.1210/me.7.5.686; Lencesova L, 2002, FEBS LETT, V531, P432, DOI 10.1016/S0014-5793(02)03579-2; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Malone MH, 2004, J BIOL CHEM, V279, P52850, DOI 10.1074/jbc.M408040200; Medh RD, 2003, GENOMICS, V81, P543, DOI 10.1016/S0888-7543(03)00045-4; Mountian I, 1999, CELL CALCIUM, V25, P371, DOI 10.1054/ceca.1999.0034; Obexer P, 2001, ONCOGENE, V20, P4324, DOI 10.1038/sj.onc.1204573; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Pui CH, 2006, NEW ENGL J MED, V354, P166, DOI 10.1056/NEJMra052603; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Roderick HL, 2003, BIOCHEM SOC T, V31, P950; Schmidt S, 2006, BLOOD, V107, P2061, DOI 10.1182/blood-2005-07-2853; Schmidt S, 2004, CELL DEATH DIFFER, V11, pS45, DOI 10.1038/sj.cdd.4401456; SIBLEY CH, 1974, CELL, V2, P213, DOI 10.1016/0092-8674(74)90013-0; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; Taylor CW, 1999, CELL CALCIUM, V26, P237, DOI 10.1054/ceca.1999.0090; Thompson E B, 1986, Adv Exp Med Biol, V196, P111; Tissing WJE, 2007, BLOOD, V109, P3929, DOI 10.1182/blood-2006-11-056366; Tome ME, 2001, CANCER RES, V61, P2766; Tonko M, 2001, FASEB J, V15, P693, DOI 10.1096/fj.00-0327com; Wang Z, 2006, ONCOGENE, V25, P1903, DOI 10.1038/sj.onc.1209218; Wang ZQ, 2003, J BIOL CHEM, V278, P23861, DOI 10.1074/jbc.M301843200; Wang ZQ, 2003, J BIOL CHEM, V278, P27053, DOI 10.1074/jbc.M303723200; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yoshida NL, 2002, BIOCHEM BIOPH RES CO, V293, P1254; Zhang LZ, 2004, J BIOL CHEM, V279, P20858, DOI 10.1074/jbc.M310643200; Zhong F, 2006, J CELL BIOL, V172, P127, DOI 10.1083/jcb.200506189	48	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10357	10365		10.1074/jbc.M800269200	http://dx.doi.org/10.1074/jbc.M800269200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18272518	Green Published, hybrid			2022-12-25	WOS:000254894700016
J	Moreno, I; Norambuena, L; Maturana, D; Toro, M; Vergara, C; Orellana, A; Zurita-Silva, A; Ordenes, VR				Moreno, Ignacio; Norambuena, Lorena; Maturana, Daniel; Toro, Mauricio; Vergara, Cecilia; Orellana, Ariel; Zurita-Silva, Andres; Ordenes, Viviana R.			AtHMA1 is a thapsigargin-sensitive Ca2+/heavy metal pump	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASES; SITE-DIRECTED MUTAGENESIS; CA2+ TRANSPORT ATPASE; ENDOPLASMIC-RETICULUM; SARCOPLASMIC-RETICULUM; BINDING DOMAIN; CALCIUM-PUMP; SACCHAROMYCES-CEREVISIAE; ARABIDOPSIS-THALIANA; P-1B-TYPE ATPASE	The Arabidopsis thaliana AtHMA1 protein is a member of the P-IB-ATPase family, which is implicated in heavy metal transport. However, sequence analysis reveals that AtHMA1 possesses a predicted stalk segment present in SERCA (sarcoplasmic/endoplasmic reticulum Ca2+ ATPase)-type pumps that is involved in inhibition by thapsigargin. To analyze the ion specificity of AtHMA1, we performed functional complementation assays using mutant yeast strains defective in Ca2+ homeostasis or heavy metal transport. The heterologous expression of AtHMA1 complemented the phenotype of both types of mutants and, interestingly, increased heavy metal tolerance of wildtype yeast. Biochemical analyses were performed to describe the activity of AtHMA1 in microsomal fractions isolated from complemented yeast. Zinc, copper, cadmium, and cobalt activate the ATPase activity of AtHMA1, which corroborates the results of metal tolerance assays. The outcome establishes the role of AtHMA1 in Cd2+ detoxification in yeast and suggests that this pump is able to transport other heavy metals ions. Further analyses were performed to typify the active Ca2+ transport mediated by AtHMA1. Ca2+ transport displayed high affinity with an apparent K-m of 370 nM and a V-max of 1.53 nmol mg(-1) min(-1). This activity was strongly inhibited by thapsigargin (IC50 = 16.74 nM), demonstrating the functionality of its SERCA-like stalk segment. In summary, these results demonstrate that AtHMA1 functions as a Ca2+/heavy metal pump. This protein is the first described plant P-type pump specifically inhibited by thapsigargin.	[Toro, Mauricio; Zurita-Silva, Andres; Ordenes, Viviana R.] Univ La Serena, Lab Biol Mol Vegetal, Ctr Estudios Avanzados Zonas Aridas CEAZA, La Serena 1720170, Chile; [Norambuena, Lorena] Univ Chile, Fac Ciencias, Lab Biol Mol Vegetal, Santiago 1720170, Chile; [Moreno, Ignacio; Maturana, Daniel; Vergara, Cecilia; Ordenes, Viviana R.] Univ Chile, Fac Ciencias, Lab Fisiol Celular, Santiago 7800024, Chile; [Orellana, Ariel] Univ Andres Bello, Ctr Biotecnol Vegetal, Millenium Nucleus Plant Cell Biotechnol, Santiago 8370146, Chile	Universidad de La Serena; Universidad de Chile; Universidad de Chile; Universidad Andres Bello	Ordenes, VR (corresponding author), Univ La Serena, Lab Biol Mol Vegetal, Ctr Estudios Avanzados Zonas Aridas CEAZA, Campus Andres Bello,Casilla 599, La Serena 1720170, Chile.	viviana.ordenes@ceaza.cl	Zurita-Silva, Andres/A-6879-2015; Vergara, Cecilia/H-6964-2014; Norambuena, Lorena/I-1248-2013; Zurita-Silva, Andres/O-4991-2019; Orellana, Ariel/AAE-4866-2021; Orellana, Ariel/E-2166-2014	Zurita-Silva, Andres/0000-0001-7274-2765; Vergara, Cecilia/0000-0002-4015-7438; Norambuena, Lorena/0000-0002-6031-2394; Zurita-Silva, Andres/0000-0001-7274-2765; Orellana, Ariel/0000-0002-9243-808X; Orellana, Ariel/0000-0002-9243-808X; Toro-Nahuelpan, Mauricio/0000-0001-5333-3640				ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; Apse MP, 1999, SCIENCE, V285, P1256, DOI 10.1126/science.285.5431.1256; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; Arguello JM, 2003, J MEMBRANE BIOL, V195, P93, DOI 10.1007/s00232-003-2048-2; Axelsen KB, 2001, PLANT PHYSIOL, V126, P696, DOI 10.1104/pp.126.2.696; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Bassham DC, 2000, PLANT PHYSIOL, V122, P999, DOI 10.1104/pp.122.4.999; BITTER GA, 1984, GENE, V32, P263, DOI 10.1016/0378-1119(84)90002-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cobbett CS, 2003, NEW PHYTOL, V159, P315, DOI 10.1046/j.1469-8137.2003.00785.x; Colangelo EP, 2006, CURR OPIN PLANT BIOL, V9, P322, DOI 10.1016/j.pbi.2006.03.015; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; Del Aguila EM, 2005, BMC MOL BIOL, V6, DOI 10.1186/1471-2199-6-9; Durr G, 1998, MOL BIOL CELL, V9, P1149, DOI 10.1091/mbc.9.5.1149; Efremov RG, 2004, BIOCHEM J, V382, P293, DOI 10.1042/BJ20040326; Eren E, 2004, PLANT PHYSIOL, V136, P3712, DOI 10.1104/pp.104.046292; Eren E, 2006, J BIOL CHEM, V281, P33881, DOI 10.1074/jbc.M605218200; Gaxiola RA, 1999, P NATL ACAD SCI USA, V96, P1480, DOI 10.1073/pnas.96.4.1480; Geisler M, 2000, BBA-BIOMEMBRANES, V1465, P52, DOI 10.1016/S0005-2736(00)00131-0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gravot A, 2004, FEBS LETT, V561, P22, DOI 10.1016/S0014-5793(04)00072-9; Harper JF, 1998, J BIOL CHEM, V273, P1099, DOI 10.1074/jbc.273.2.1099; HIGUCHI M, 2005, PHOTOSYNTHESIS FUNDA, P716; Jensen AML, 2006, EMBO J, V25, P2305, DOI 10.1038/sj.emboj.7601135; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Liang F, 1997, P NATL ACAD SCI USA, V94, P8579, DOI 10.1073/pnas.94.16.8579; Liang F, 1998, PLANT PHYSIOL, V118, P817, DOI 10.1104/pp.118.3.817; LODDENKOTTER B, 1993, P NATL ACAD SCI USA, V90, P2155, DOI 10.1073/pnas.90.6.2155; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Mills RF, 2005, FEBS LETT, V579, P783, DOI 10.1016/j.febslet.2004.12.040; Mills RF, 2003, PLANT J, V35, P164, DOI 10.1046/j.1365-313X.2003.01790.x; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Rutherford JC, 1999, J BIOL CHEM, V274, P25827, DOI 10.1074/jbc.274.36.25827; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAVINSKY MH, 2006, J BIOL CHEM, V281, P11161; Seigneurin-Berny D, 2006, J BIOL CHEM, V281, P2882, DOI 10.1074/jbc.M508333200; Seki M, 1998, PLANT J, V15, P707, DOI 10.1046/j.1365-313x.1998.00237.x; Seki M, 2002, SCIENCE, V296, P141, DOI 10.1126/science.1071006; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Stokes DL, 2003, ANNU REV BIOPH BIOM, V32, P445, DOI 10.1146/annurev.biophys.32.110601.142433; Tong L, 2002, J BACTERIOL, V184, P5027, DOI 10.1128/JB.184.18.5027-5035.2002; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Verret F, 2005, FEBS LETT, V579, P1515, DOI 10.1016/j.febslet.2005.01.065; WILLIAMS L, 2005, TRENDS PLANT SCI, V10, P1360; Wootton LL, 2006, J BIOL CHEM, V281, P6970, DOI 10.1074/jbc.M510978200; Wu ZY, 2002, PLANT PHYSIOL, V130, P128, DOI 10.1104/pp.004440; Xu C, 2004, J BIOL CHEM, V279, P17973, DOI 10.1074/jbc.M313263200; ZHANG ZY, 1993, FEBS LETT, V335, P261, DOI 10.1016/0014-5793(93)80742-D; Zhong L, 1998, J BIOL CHEM, V273, P12994, DOI 10.1074/jbc.273.21.12994	52	100	104	2	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9633	9641		10.1074/jbc.M800736200	http://dx.doi.org/10.1074/jbc.M800736200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18252706	hybrid			2022-12-25	WOS:000254671600017
J	Agarwal, R; Burley, SK; Swaminathan, S				Agarwal, Rakhi; Burley, Stephen K.; Swaminathan, Subramanyam			Structure of human dual specificity protein phosphatase 23, VHZ, enzyme-substrate/product complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; TRANSITION-STATE STRUCTURES; CRYSTAL-STRUCTURE; SPECIFICITY; PEPTIDE; RECOGNITION; MECHANISM; FAMILY; GENE	Protein phosphorylation plays a crucial role in mitogenic signal transduction and regulation of cell growth and differentiation. Dual specificity protein phosphatase 23 ( DUSP23) or VHZ mediates dephosphorylation of phospho-tyrosyl ( pTyr) and phospho-seryl/threonyl ( pSer/pThr) residues in specific proteins. In vitro, it can dephosphorylate p44ERK1 but not p54SAPK-beta and enhance activation of c-Jun N-terminal kinase ( JNK) and p38. Human VHZ, the smallest of the catalytically active protein-tyrosine phosphatases ( PTP) reported to date ( 150 residues), is a class I Cys-based PTP and bears the distinctive active site signature motif HCXXGXXRS( T). We present the crystal structure of VHZ determined at 1.93 angstrom resolution. The polypeptide chain adopts the typical alpha beta alpha PTP fold, giving rise to a shallow active site cleft that supports dual phosphorylated substrate specificity. Within our crystals, the Thr-135-Tyr-136 from a symmetry-related molecule bind in the active site with a malate ion, where they mimic the phosphorylated TY motif of the MAPK activation loop in an enzyme-substrate/product complex. Analyses of intermolecular interactions between the enzyme and this pseudo substrate/product along with functional analysis of Phe-66, Leu-97, and Phe-99 residues provide insights into the mechanism of substrate binding and catalysis in VHZ.	[Agarwal, Rakhi; Swaminathan, Subramanyam] Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; [Burley, Stephen K.] SGX Pharmaceut Inc, San Diego, CA 92121 USA	United States Department of Energy (DOE); Brookhaven National Laboratory	Swaminathan, S (corresponding author), Brookhaven Natl Lab, Dept Biol, Bldg 463, Upton, NY 11973 USA.	swami@bnl.gov		Burley, Stephen K./0000-0002-2487-9713	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM074945] Funding Source: NIH RePORTER; NIGMS NIH HHS [U54 GM 074945] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chen L, 1996, BIOCHEMISTRY-US, V35, P9349, DOI 10.1021/bi960700+; *COLL COMP PROJ NU, 1994, ACTA CRYSTALLOGR D, V70, P760; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DELANO WL, 2002, PY MOL USERS MANUAL; den Hertog J, 2003, EMBO REP, V4, P1027, DOI 10.1038/sj.embor.7400009; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; Hengge AC, 1996, BIOCHEMISTRY-US, V35, P7084, DOI 10.1021/bi960255i; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pedersen AK, 2004, BIOCHEM J, V378, P421, DOI 10.1042/BJ20030565; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Rossi R, 1998, J BIOL CHEM, V273, P19198, DOI 10.1074/jbc.273.30.19198; Sarmiento M, 2000, BIOCHEMISTRY-US, V39, P8171, DOI 10.1021/bi000319w; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Schumacher MA, 2002, BIOCHEMISTRY-US, V41, P3009, DOI 10.1021/bi015799l; Sun JP, 2003, J BIOL CHEM, V278, P12406, DOI 10.1074/jbc.M212491200; Takagaki K, 2004, BIOCHEM J, V383, P447, DOI 10.1042/BJ20040498; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tonks NK, 2006, NAT REV MOL CELL BIO, V7, P833, DOI 10.1038/nrm2039; Wu L, 1996, BIOCHEMISTRY-US, V35, P5426, DOI 10.1021/bi952885a; Wu QH, 2004, INT J BIOCHEM CELL B, V36, P1542, DOI 10.1016/j.biocel.2003.12.014; Yang J, 2001, J CELL BIOCHEM, V83, P14, DOI 10.1002/jcb.1195; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; ZHANG ZY, 1994, J BIOL CHEM, V269, P8140; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040; ZHANG ZY, 1995, J BIOL CHEM, V270, P11199, DOI 10.1074/jbc.270.19.11199; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; Zhang ZY, 1998, CRIT REV BIOCHEM MOL, V33, P1, DOI 10.1080/10409239891204161; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007; ZHOU GC, 1994, J BIOL CHEM, V269, P28084	34	20	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					8946	8953		10.1074/jbc.M708945200	http://dx.doi.org/10.1074/jbc.M708945200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18245086	hybrid			2022-12-25	WOS:000254465800023
J	Bose, M; Whittal, RM; Miller, WL; Bose, HS				Bose, Mahuya; Whittal, Randy M.; Miller, Walter L.; Bose, Himangshu S.			Steroidogenic activity of StAR requires contact with mitochondrial VDAC1 and phosphate carrier protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE REGULATORY PROTEIN; DEPENDENT ANION CHANNEL; BENZODIAZEPINE-RECEPTOR; CHOLESTEROL-BINDING; IMPORT; MEMBRANE; IDENTIFICATION; INHIBITION; TRANSPORT; SEQUENCE	The steroidogenic acute regulatory protein ( StAR) is required for adrenal and gonadal steroidogenesis and for male sexual differentiation. StAR acts on the outer mitochondrial membrane (OMM) to facilitate movement of cholesterol from the OMM to the inner mitochondrial membrane to be converted to pregnenolone, the precursor of all steroid hormones. The mechanisms of the action of StAR remain unclear; the peripheral benzodiazepine receptor, an OMM protein, appears to be involved, but the identity of OMM proteins that interact with StAR remain unknown. Here we demonstrate that phosphorylated StAR interacts with voltage-dependent anion channel 1 (VDAC1) on the OMM, which then facilitates processing of the 37-kDa phospho-StAR to the 32-kDa intermediate. In the absence of VDAC1, phospho-StAR is degraded by cysteine proteases prior to mitochondrial import. Phosphorylation of StAR by protein kinase A requires phosphate carrier protein on the OMM, which appears to interact with StAR before it interacts with VDAC1. VDAC1 and phosphate carrier protein are the first OMM proteins shown to contact StAR.	[Bose, Mahuya; Bose, Himangshu S.] Univ Florida, Dept Physiol & Func Genom, Gainesville, FL 32610 USA; [Whittal, Randy M.] Univ Alberta, Dept Chem, Edmonton, AB T6G 2E1, Canada; [Miller, Walter L.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	State University System of Florida; University of Florida; University of Alberta; University of California System; University of California San Francisco	Bose, HS (corresponding author), Mercer Univ, Sch Med, Dept Biomed Sci, 4700 Water Ave, Savannah, GA 31404 USA.	bosehi1@memorialhealth.com	Miller, Walter L/J-3696-2012	Whittal, Randy/0000-0003-1174-8172	Howard Hughes Medical Institute Funding Source: Medline; NIDDK NIH HHS [DK 37922] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037922] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alconada A, 1995, METHOD ENZYMOL, V260, P263, DOI 10.1016/0076-6879(95)60144-9; Anflous K, 2001, J BIOL CHEM, V276, P1954, DOI 10.1074/jbc.M006587200; Arakane F, 1997, J BIOL CHEM, V272, P32656, DOI 10.1074/jbc.272.51.32656; Arakane F, 1996, P NATL ACAD SCI USA, V93, P13731, DOI 10.1073/pnas.93.24.13731; Baker BY, 2005, J BIOL CHEM, V280, P41753, DOI 10.1074/jbc.M510241200; BLAHOS J, 1995, J BIOL CHEM, V270, P20285, DOI 10.1074/jbc.270.35.20285; Bose HS, 1999, P NATL ACAD SCI USA, V96, P7250, DOI 10.1073/pnas.96.13.7250; Bose HS, 2002, NATURE, V417, P87, DOI 10.1038/417087a; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; DOBLE A, 1987, MOL PHARMACOL, V31, P42; Galiegue S, 1999, J BIOL CHEM, V274, P2938, DOI 10.1074/jbc.274.5.2938; GENCHI G, 1988, BIOCHIM BIOPHYS ACTA, V936, P413, DOI 10.1016/0005-2728(88)90018-7; HARIKRISHNA JA, 1993, DNA CELL BIOL, V12, P371, DOI 10.1089/dna.1993.12.371; Hauet T, 2005, MOL ENDOCRINOL, V19, P540, DOI 10.1210/me.2004-0307; Jo Y, 2005, BIOL REPROD, V73, P244, DOI 10.1095/biolreprod.104.037721; Kallen CB, 1998, J BIOL CHEM, V273, P26285, DOI 10.1074/jbc.273.41.26285; KOLBE HVJ, 1985, J BIOL CHEM, V260, P5899; Krimmer T, 2001, J CELL BIOL, V152, P289, DOI 10.1083/jcb.152.2.289; Lacapere JJ, 2003, STEROIDS, V68, P569, DOI 10.1016/S0039-128X(03)00101-6; Li H, 2001, P NATL ACAD SCI USA, V98, P1267, DOI 10.1073/pnas.031461598; Lingappa VR, 2005, MT SINAI J MED, V72, P141; MANGAN PS, 1987, P NATL ACAD SCI USA, V84, P4896, DOI 10.1073/pnas.84.14.4896; Manna PR, 2006, MOL ENDOCRINOL, V20, P362, DOI 10.1210/me.2004-0526; MASACARDO RN, 1988, J PHARMACOL EXP THER, V244, P361; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; Miller WL, 2007, MOL ENDOCRINOL, V21, P589, DOI 10.1210/me.2006-0303; MURAKAMI H, 1990, NATURE, V347, P488, DOI 10.1038/347488a0; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Papadopoulos V, 2007, MOL CELL ENDOCRINOL, V265, P59, DOI 10.1016/j.mce.2006.12.004; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; STONER CD, 1973, J CELL BIOL, V56, P65, DOI 10.1083/jcb.56.1.65; Tamura Y, 2006, J CELL BIOL, V174, P631, DOI 10.1083/jcb.200603087; Wiedemann N, 2003, NATURE, V424, P565, DOI 10.1038/nature01753; Yaworsky DC, 2005, J BIOL CHEM, V280, P2045, DOI 10.1074/jbc.M410937200; Zara V, 1996, MOL CELL BIOL, V16, P6524	41	95	100	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					8837	8845		10.1074/jbc.M709221200	http://dx.doi.org/10.1074/jbc.M709221200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18250166	Green Published, hybrid			2022-12-25	WOS:000254465800010
J	Lin, YW; Bushman, JD; Yan, FF; Haidar, S; MacMullen, C; Ganguly, A; Stanley, CA; Shyng, SL				Lin, Yu-Wen; Bushman, Jeremy D.; Yan, Fei-Fei; Haidar, Sara; MacMullen, Courtney; Ganguly, Arupa; Stanley, Charles A.; Shyng, Show-Ling			Destabilization of ATP-sensitive potassium channel activity by novel KCNJ11 mutations identified in congenital hyperinsulinism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING MUTATIONS; FUNCTIONAL-ANALYSIS; SUBUNIT KIR6.2; K+ CHANNELS; STOICHIOMETRY; RECTIFICATION; DETERMINANTS; HYPOGLYCEMIA; TRAFFICKING; INFANCY	The inwardly rectifying potassium channel Kir6.2 is the pore-forming subunit of the ATP-sensitive potassium (K-ATP) channel, which controls insulin secretion by coupling glucose metabolism to membrane potential in beta-cells. Loss of channel function because of mutations in Kir6.2 or its associated regulatory subunit, sulfonylurea receptor 1, causes congenital hyperinsulinism (CHI), a neonatal disease characterized by persistent insulin secretion despite severe hypoglycemia. Here, we report a novel KATP channel gating defect caused by CHI-associated Kir6.2 mutations at arginine 301 ( to cysteine, glycine, histidine, or proline). These mutations in addition to reducing channel expression at the cell surface also cause rapid, spontaneous current decay, a gating defect we refer to as inactivation. Based on the crystal structures of Kir3.1 and KirBac1.1, Arg-301 interacts with several residues in the neighboring Kir6.2 subunit. Mutation of a subset of these residues also induces channel inactivation, suggesting that the disease mutations may cause inactivation by disrupting subunit-subunit interactions. To evaluate the effect of channel inactivation on beta-cell function, we expressed an alternative inactivation mutant R301A, which has equivalent surface expression efficiency as wild type channels, in the insulin-secreting cell line INS-1. Mutant expression resulted in more depolarized membrane potential and elevated insulin secretion at basal glucose concentration ( 3 mM) compared with cells expressing wild type channels, demonstrating that the inactivation gating defect itself is sufficient to cause loss of channel function and hyperinsulinism. Our studies suggest the importance of Kir6.2 subunit-subunit interactions in KATP channel gating and function and reveal a novel gating defect underlying CHI.	[Lin, Yu-Wen; Bushman, Jeremy D.; Yan, Fei-Fei; Haidar, Sara; Shyng, Show-Ling] Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, Portland, OR 97239 USA; [MacMullen, Courtney; Stanley, Charles A.] Childrens Hosp Philadelphia, Div Endocrinol Diabet, Philadelphia, PA 19104 USA; [Ganguly, Arupa] Univ Penn, Sch Med, Dept Geriatr, Philadelphia, PA 19104 USA	Oregon Health & Science University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Shyng, SL (corresponding author), Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	shyngs@ohsu.edu		STANLEY, CHARLES/0000-0003-4881-9392	NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024134] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053012, R01DK056268, R01DK066485] Funding Source: NIH RePORTER; NCRR NIH HHS [UL1 RR 024134] Funding Source: Medline; NIDDK NIH HHS [2R01 DK 53012-09, R01 DK 66485, 2R01 DK 56268-07] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; Ashcroft FM, 2005, J CLIN INVEST, V115, P2047, DOI 10.1172/JCI25495; Babenko AP, 2006, NEW ENGL J MED, V355, P456, DOI 10.1056/NEJMoa055068; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; Branstrom R, 1998, J BIOL CHEM, V273, P31395, DOI 10.1074/jbc.273.47.31395; Casamassima M, 2003, J BIOL CHEM, V278, P43533, DOI 10.1074/jbc.M306596200; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Cukras CA, 2002, J GEN PHYSIOL, V120, P437, DOI 10.1085/jgp.20028621; Dunne MJ, 2004, PHYSIOL REV, V84, P239, DOI 10.1152/physrev.00022.2003; Girard CAJ, 2006, PFLUG ARCH EUR J PHY, V453, P323, DOI 10.1007/s00424-006-0112-3; Gloyn AL, 2004, NEW ENGL J MED, V350, P1838, DOI 10.1056/NEJMoa032922; Haider S, 2007, EMBO J, V26, P3749, DOI 10.1038/sj.emboj.7601809; Henwood MJ, 2005, J CLIN ENDOCR METAB, V90, P789, DOI 10.1210/jc.2004-1604; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Huopio H, 2002, AM J PHYSIOL-ENDOC M, V283, pE207, DOI 10.1152/ajpendo.00047.2002; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; Leng Q, 2006, P NATL ACAD SCI USA, V103, P1982, DOI 10.1073/pnas.0510610103; Lin CW, 2006, DIABETES, V55, P1738, DOI 10.2337/db05-1571; Lin CW, 2005, DIABETES, V54, P2852, DOI 10.2337/diabetes.54.10.2852; Lin YW, 2003, J GEN PHYSIOL, V122, P225, DOI 10.1085/jgp.200308822; Lin YW, 2006, J BIOL CHEM, V281, P3006, DOI 10.1074/jbc.M511875200; Magge SN, 2004, J CLIN ENDOCR METAB, V89, P4450, DOI 10.1210/jc.2004-0441; Mankouri J, 2006, EMBO J, V25, P4142, DOI 10.1038/sj.emboj.7601275; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Nichols CG, 2006, NATURE, V440, P470, DOI 10.1038/nature04711; Nishida M, 2002, CELL, V111, P957, DOI 10.1016/S0092-8674(02)01227-8; Rapedius M, 2006, EMBO REP, V7, P611, DOI 10.1038/sj.embor.7400678; Riedel MJ, 2005, DIABETES, V54, P2070, DOI 10.2337/diabetes.54.7.2070; Shyng SL, 2000, J GEN PHYSIOL, V116, P599, DOI 10.1085/jgp.116.5.599; Shyng SL, 1998, DIABETES, V47, P1145, DOI 10.2337/diabetes.47.7.1145; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Tarasov A, 2004, DIABETES, V53, pS113, DOI 10.2337/diabetes.53.suppl_3.S113; Taschenberger G, 2002, J BIOL CHEM, V277, P17139, DOI 10.1074/jbc.M200363200; Tureckova J, 2001, J BIOL CHEM, V276, P39264, DOI 10.1074/jbc.M104991200; Yan FF, 2007, DIABETES, V56, P2339, DOI 10.2337/db07-0150	38	44	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9146	9156		10.1074/jbc.M708798200	http://dx.doi.org/10.1074/jbc.M708798200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18250167	Green Published, hybrid			2022-12-25	WOS:000254465800044
J	Magdesian, MH; Carvalho, MMVF; Mendes, FA; Saraiva, LM; Juliano, MA; Juliano, L; Garcia-Abreu, J; Ferreira, ST				Magdesian, Margaret H.; Carvalho, Milena M. V. F.; Mendes, Fabio A.; Saraiva, Leonardo M.; Juliano, Maria A.; Juliano, Luiz; Garcia-Abreu, Jose; Ferreira, Sergio T.			Amyloid-beta binds to the extracellular cysteine-rich domain of frizzled and inhibits wnt/beta-catenin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE-PROTEIN OLIGOMERS; LONG-TERM POTENTIATION; ALZHEIMERS-DISEASE; WNT PATHWAY; PEPTIDE NEUROTOXICITY; PHAGE DISPLAY; RECEPTOR; IDENTIFICATION; TRANSCRIPTION; TRANSDUCTION	The amyloid-beta peptide (A beta) plays a major role in neuronal dysfunction and neurotoxicity in Alzheimer disease. However, the signal transduction mechanisms involved in A beta-induced neuronal dysfunction remain to be fully elucidated. A major current unknown is the identity of the protein receptor(s) involved in neuronal A beta binding. Using phage display of peptide libraries, we have identified a number of peptides that bind A beta and are homologous to neuronal receptors putatively involved in A beta interactions. We report here on a cysteine-linked cyclic heptapeptide (denominated cSP5) that binds A beta with high affinity and is homologous to the extracellular cysteine-rich domain of several members of the Frizzled (Fz) family of Wnt receptors. Based on this homology, we investigated the interaction between A beta and Fz. The results show that A beta binds to the Fz cysteine-rich domain at or in close proximity to the Wnt-binding site and inhibits the canonical Wnt signaling pathway. Interestingly, the cSP5 peptide completely blocks A beta binding to Fz and prevents inhibition of Wnt signaling. These results indicate that the A beta- binding site in Fz is homologous to cSP5 and that this is a relevant target for A beta-instigated neurotoxicity. Furthermore, they suggest that blocking the interaction of A beta with Fz might lead to novel therapeutic approaches to prevent neuronal dysfunction in Alzheimer disease.	[Magdesian, Margaret H.; Carvalho, Milena M. V. F.; Saraiva, Leonardo M.; Ferreira, Sergio T.] Univ Fed Rio de Janeiro, Inst Bioquim Med, Programa Bioquim Biofis Celular, BR-21944 Rio De Janeiro, RJ, Brazil; [Mendes, Fabio A.; Garcia-Abreu, Jose] Univ Fed Rio de Janeiro, Dept Anat, BR-21944 Rio De Janeiro, RJ, Brazil; [Juliano, Maria A.; Juliano, Luiz] Univ Fed Sao Paulo, Escola Paulista Med, Dept Biofis, BR-04044 Sao Paulo, SP, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal de Sao Paulo (UNIFESP)	Ferreira, ST (corresponding author), Univ Fed Rio de Janeiro, Inst Bioquim Med, Programa Bioquim Biofis Celular, Bloco H,Sala 19,CCS, BR-21944 Rio De Janeiro, RJ, Brazil.	ferreira@bioqmed.ufrj.br	Mendes, Fabio/J-6911-2015; Ferreira, Sergio/AAZ-1576-2020; Abreu, Jose G/G-6159-2010; Complexos, INCT Fluidos/H-9172-2013; Juliano, Luiz/D-7204-2012; Abreu, Jose G/ABB-1199-2021; Neurociencia, Inct/I-1011-2013	Ferreira, Sergio/0000-0001-7160-9866; Abreu, Jose G/0000-0002-9875-7786; Juliano, Luiz/0000-0002-5589-2822; Abreu, Jose G/0000-0002-1363-1755; 	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; ALTSCHUL SF, 1997, NUCLEIC ACIDS RES, V25, P3402; Alvarez AR, 2004, EXP CELL RES, V297, P186, DOI 10.1016/j.yexcr.2004.02.028; Baum L, 1996, MOL CHEM NEUROPATHOL, V29, P253, DOI 10.1007/BF02815006; Bhat RV, 2002, NEUROSIGNALS, V11, P251, DOI 10.1159/000067423; Caricasole A, 2004, J NEUROSCI, V24, P6021, DOI 10.1523/JNEUROSCI.1381-04.2004; Caricasole A, 2003, TRENDS PHARMACOL SCI, V24, P233, DOI 10.1016/S0165-6147(03)00100-7; Chen JY, 2006, J BIOL CHEM, V281, P11910, DOI 10.1074/jbc.M511920200; Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601; De Felice FG, 2007, J BIOL CHEM, V282, P11590, DOI 10.1074/jbc.M607483200; De Ferrari GV, 2000, BRAIN RES REV, V33, P1, DOI 10.1016/S0165-0173(00)00021-7; DEFELICE FG, 2007, IN PRESS NEUROBIOL A; Ferreira ST, 2007, IUBMB LIFE, V59, P332, DOI 10.1080/15216540701283882; Fradkin LG, 2005, J NEUROSCI, V25, P10376, DOI 10.1523/JNEUROSCI.3429-05.2005; Fuentealba RA, 2004, BRAIN RES REV, V47, P275, DOI 10.1016/j.brainresrev.2004.07.018; Garrido JL, 2002, FASEB J, V16, P1982, DOI 10.1096/fj.02-0327fje; Golan T, 2004, J BIOL CHEM, V279, P14879, DOI 10.1074/jbc.M306421200; Gordon MD, 2006, J BIOL CHEM, V281, P22429, DOI 10.1074/jbc.R600015200; Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Inestrosa NC, 2007, IUBMB LIFE, V59, P316, DOI 10.1080/15216540701242490; Kang CK, 2003, NEUROBIOL DIS, V14, P146, DOI 10.1016/S0969-9961(03)00105-0; KLEIN WL, 2006, ALZHEIMERS DEMENT, P260; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Levesque G, 1999, J NEUROCHEM, V72, P999, DOI 10.1046/j.1471-4159.1999.0720999.x; Lie DC, 2005, NATURE, V437, P1370, DOI 10.1038/nature04108; Lima AR, 2004, PROTEIN J, V23, P287, DOI 10.1023/B:JOPC.0000027853.93513.34; Luo W, 2004, NEUROSIGNALS, V13, P99, DOI 10.1159/000076563; Magdesian MH, 2005, J BIOL CHEM, V280, P31085, DOI 10.1074/jbc.M502406200; Magdesian MH, 2001, J BIOL CHEM, V276, P19382, DOI 10.1074/jbc.M011474200; Mudher A, 2002, TRENDS NEUROSCI, V25, P22, DOI 10.1016/S0166-2236(00)02031-2; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Nishimura M, 1999, NAT MED, V5, P164, DOI 10.1038/5526; Orner BP, 2006, J AM CHEM SOC, V128, P11882, DOI 10.1021/ja0619861; Palacino JJ, 2001, J BIOL CHEM, V276, P38563, DOI 10.1074/jbc.M105376200; Patapoutian A, 2000, CURR OPIN NEUROBIOL, V10, P392, DOI 10.1016/S0959-4388(00)00100-8; Salins P, 2007, NEUROSCI LETT, V412, P211, DOI 10.1016/j.neulet.2006.07.045; Salomon D, 1997, J CELL BIOL, V139, P1325, DOI 10.1083/jcb.139.5.1325; Seifert JRK, 2007, NAT REV GENET, V8, P126, DOI 10.1038/nrg2042; Speese SD, 2007, TRENDS NEUROSCI, V30, P268, DOI 10.1016/j.tins.2007.04.003; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4	44	187	193	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9359	9368		10.1074/jbc.M707108200	http://dx.doi.org/10.1074/jbc.M707108200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18234671	Green Published, hybrid			2022-12-25	WOS:000254465800066
J	Crawford, LW; Ables, ET; Oh, YA; Boone, B; Levy, S; Gannon, M				Crawford, Laura Wilding; Ables, Elizabeth Tweedie; Oh, Young Ah; Boone, Braden; Levy, Shawn; Gannon, Maureen			Gene Expression Profiling of a Mouse Model of Pancreatic Islet Dysmorphogenesis	PLOS ONE			English	Article							STIMULATED INSULIN-SECRETION; BETA-CELLS; TRANSCRIPTION FACTORS; ENDOCRINE-CELLS; PLASMA-MEMBRANE; DIFFERENTIATION; MICE; GRANULES; GROWTH; PROLIFERATION	Background: In the past decade, several transcription factors critical for pancreas organogenesis have been identified. Despite this success, many of the factors necessary for proper islet morphogenesis and function remain uncharacterized. Previous studies have shown that transgenic over-expression of the transcription factor Hnf6 specifically in the pancreatic endocrine cell lineage resulted in disruptions in islet morphogenesis, including dysfunctional endocrine cell sorting, increased individual islet size, increased number of peripheral endocrine cell types, and failure of islets to migrate away from the ductal epithelium. The mechanisms whereby maintained Hnf6 causes defects in islet morphogenesis have yet to be elucidated. Methodology/Principal Findings: We exploited the dysmorphic islets in Hnf6 transgenic animals as a tool to identify factors important for islet morphogenesis. Genome-wide microarray analysis was used to identify differences in the gene expression profiles of late gestation and early postnatal total pancreas tissue from wild type and Hnf6 transgenic animals. Here we report the identification of genes with an altered expression in Hnf6 transgenic animals and highlight factors with potential importance in islet morphogenesis. Importantly, gene products involved in cell adhesion, cell migration, ECM remodeling and proliferation were found to be altered in Hnf6 transgenic pancreata, revealing specific candidates that can now be analyzed directly for their role in these processes during islet development. Conclusions/Significance: This study provides a unique dataset that can act as a starting point for other investigators to explore the role of the identified genes in pancreatogenesis, islet morphogenesis and mature beta cell function.	[Oh, Young Ah; Gannon, Maureen] Vanderbilt Univ, Med Ctr, Dept Med, Div Diabetes Endocrinol & Metabol, Nashville, TN 37203 USA; [Crawford, Laura Wilding; Ables, Elizabeth Tweedie; Boone, Braden; Levy, Shawn; Gannon, Maureen] Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN USA	Vanderbilt University; Vanderbilt University	Crawford, LW (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Diabetes Endocrinol & Metabol, Nashville, TN 37203 USA.	maureen.gannon@vanderbilt.edu	Gannon, Maureen A/F-9060-2012	Levy, Shawn/0000-0002-1369-5740; Ables, Elizabeth/0000-0002-6934-9302	NIH [DK065131]; JDRF Career Development Award [2-2002-583]; Vanderbilt Molecular Endocrinology [5-T32-DK07563]; Vanderbilt Training Program in Developmental Biology [5-T32-HD05702]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007563, R01DK065131] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); JDRF Career Development Award(Juvenile Diabetes Research Foundation); Vanderbilt Molecular Endocrinology; Vanderbilt Training Program in Developmental Biology; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by: NIH grant DK065131 and JDRF Career Development Award grant #2-2002-583 to M. Gannon; Vanderbilt Molecular Endocrinology Training Grant 5-T32-DK07563 to L. Crawford; Vanderbilt Training Program in Developmental Biology Grant 5-T32-HD05702 to E. Tweedie Ables.	Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Arava Y, 1999, DIABETES, V48, P552, DOI 10.2337/diabetes.48.3.552; Bennett M V, 1978, Neurosci Res Program Bull, V16, P1; Borisovska M, 2005, EMBO J, V24, P2114, DOI 10.1038/sj.emboj.7600696; BOSCO D, 1989, EXP CELL RES, V184, P72, DOI 10.1016/0014-4827(89)90365-0; Ching YP, 2002, J BIOL CHEM, V277, P15237, DOI 10.1074/jbc.C200032200; Chu K, 2005, DIABETES, V54, P1064, DOI 10.2337/diabetes.54.4.1064; Cirulli V, 2000, J CELL BIOL, V150, P1445, DOI 10.1083/jcb.150.6.1445; Dahl U, 1996, DEVELOPMENT, V122, P2895; DANIEL P, 2006, DEV DYNAM, V235, P1720; De Leon DD, 2006, PHYSIOL GENOMICS, V24, P133, DOI 10.1152/physiolgenomics.00156.2005; Easom RA, 2000, SEMIN CELL DEV BIOL, V11, P253, DOI 10.1006/scdb.2000.0174; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; Esni F, 1999, J CELL BIOL, V144, P325, DOI 10.1083/jcb.144.2.325; Gad JM, 2000, EXP EYE RES, V70, P711, DOI 10.1006/exer.2000.0823; Gannon M, 2000, DEVELOPMENT, V127, P2883; Gannon M, 2001, DEV BIOL, V238, P185, DOI 10.1006/dbio.2001.0359; Georgia S, 2004, J CLIN INVEST, V114, P963, DOI 10.1172/JCI200422098; Gerber SH, 2002, DIABETES, V51, pS3, DOI 10.2337/diabetes.51.2007.S3; Giampietro C, 2005, ENDOCRINOLOGY, V146, P1825, DOI 10.1210/en.2004-0972; Gomi H, 2005, J CELL BIOL, V171, P99, DOI 10.1083/jcb.200505179; Goulley J, 2007, CELL METAB, V5, P207, DOI 10.1016/j.cmet.2007.01.009; Gradwohl G, 2000, P NATL ACAD SCI USA, V97, P1607, DOI 10.1073/pnas.97.4.1607; Grove M, 2004, MOL CELL BIOL, V24, P10905, DOI 10.1128/MCB.24.24.10905-10922.2004; GU DL, 1993, DEVELOPMENT, V118, P33; Gu GQ, 2002, DEVELOPMENT, V129, P2447; HALBAN PA, 1982, ENDOCRINOLOGY, V111, P86, DOI 10.1210/endo-111-1-86; Hald J, 2003, DEV BIOL, V260, P426, DOI 10.1016/S0012-1606(03)00326-9; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Hart A, 2003, DEV DYNAM, V228, P185, DOI 10.1002/dvdy.10368; Holland AM, 2002, P NATL ACAD SCI USA, V99, P12236, DOI 10.1073/pnas.192255099; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jacquemin P, 2000, MOL CELL BIOL, V20, P4445, DOI 10.1128/MCB.20.12.4445-4454.2000; Jacquemin P, 2003, DEV BIOL, V258, P105, DOI 10.1016/S0012-1606(03)00115-5; Janson J, 2004, DIABETES, V53, P474, DOI 10.2337/diabetes.53.2.474; Jensen J, 2004, DEV DYNAM, V229, P176, DOI 10.1002/dvdy.10460; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Karnik SK, 2005, P NATL ACAD SCI USA, V102, P14659, DOI 10.1073/pnas.0503484102; Kasai K, 2005, J CLIN INVEST, V115, P388, DOI 10.1172/JCI200522955; Kassai Y, 2005, SCIENCE, V309, P2067, DOI 10.1126/science.1116848; Kushner JA, 2005, MOL CELL BIOL, V25, P3752, DOI 10.1128/MCB.25.9.3752-3762.2005; Laurikkala J, 2003, DEV BIOL, V264, P91, DOI 10.1016/j.ydbio.2003.08.011; Martelli AM, 2000, TRAFFIC, V1, P976, DOI 10.1034/j.1600-0854.2000.011207.x; MEISSNER HP, 1976, NATURE, V262, P502, DOI 10.1038/262502a0; Miralles F, 1998, J CELL BIOL, V143, P827, DOI 10.1083/jcb.143.3.827; Moussad EEDA, 2000, MOL GENET METAB, V71, P276, DOI 10.1006/mgme.2000.3059; Murtaugh LC, 2003, P NATL ACAD SCI USA, V100, P14920, DOI 10.1073/pnas.2436557100; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; Offield MF, 1996, DEVELOPMENT, V122, P983; Okamoto H, 1999, J Hepatobiliary Pancreat Surg, V6, P254, DOI 10.1007/s005340050115; Osumi N, 1997, DEVELOPMENT, V124, P2961; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; PICTET RL, 1972, DEV BIOL, V29, P436, DOI 10.1016/0012-1606(72)90083-8; Prado CL, 2004, P NATL ACAD SCI USA, V101, P2924, DOI 10.1073/pnas.0308604100; Qiu LH, 2005, MOL CELL PROTEOMICS, V4, P1311, DOI 10.1074/mcp.M500016-MCP200; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; RHODES CJ, 1987, J BIOL CHEM, V262, P10712; Roche E, 2000, J PHYSIOL BIOCHEM, V56, P119, DOI 10.1007/BF03179907; Ryan EA, 2005, DIABETES, V54, P2060, DOI 10.2337/diabetes.54.7.2060; SAMOLS E, 1988, J CLIN INVEST, V82, P350, DOI 10.1172/JCI113593; Schwitzgebel VM, 2000, DEVELOPMENT, V127, P3533; Sommer L, 1996, MOL CELL NEUROSCI, V8, P221, DOI 10.1006/mcne.1996.0060; Stenmark H, 2001, GENOME BIOL, V2; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Takahashi M, 2002, DEVELOPMENT, V129, P1327; Tan YJ, 2006, GASTROENTEROLOGY, V130, P1283, DOI 10.1053/j.gastro.2006.01.010; TEITELMAN G, 1987, DEV BIOL, V121, P454, DOI 10.1016/0012-1606(87)90182-5; TEITELMAN G, 1987, DEV BIOL, V120, P425, DOI 10.1016/0012-1606(87)90246-6; Thomas H, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh144; Tweedie E, 2006, DIABETES, V55, P3264, DOI 10.2337/db06-0090; Ubeda M, 2004, ENDOCRINOLOGY, V145, P3023, DOI 10.1210/en.2003-1522; Varadi A, 2005, MOL BIOL CELL, V16, P2670, DOI 10.1091/mbc.e04-11-1001; Wei FY, 2005, NAT MED, V11, P1104, DOI 10.1038/nm1299; Yaekura K, 2003, J BIOL CHEM, V278, P9715, DOI 10.1074/jbc.M211352200; Yi Z, 2002, MOL CELL BIOL, V22, P1858, DOI 10.1128/MCB.22.6.1858-1867.2002; Zhang PC, 2002, MOL CELL BIOL, V22, P3864, DOI 10.1128/MCB.22.11.3864-3874.2002; Zhang W, 2006, CELL METAB, V4, P491, DOI 10.1016/j.cmet.2006.11.002	80	14	14	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1611	10.1371/journal.pone.0001611	http://dx.doi.org/10.1371/journal.pone.0001611			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18297134	Green Submitted, Green Published, gold			2022-12-25	WOS:000260586400004
J	Detto, T; Hemmi, JM; Backwell, PRY				Detto, Tanya; Hemmi, Jan M.; Backwell, Patricia R. Y.			Colouration and Colour Changes of the Fiddler Crab, Uca capricornis: A Descriptive Study	PLOS ONE			English	Article								Colour changes in animals may be triggered by a variety of social and environmental factors and may occur over a matter of seconds or months. Crustaceans, like fiddler crabs (genus Uca), are particularly adept at changing their colour and have been the focus of numerous studies. However, few of these studies have attempted to quantitatively describe the individual variation in colour and pattern or their adaptive significance. This paper quantitatively describes the colour patterns of the fiddler crab Uca capricornis and their ability to change on a socially significant timescale. The most dramatic changes in colour pattern are associated with moulting. These ontogenetic changes result in a general reduction of the colour pattern with increasing size, although females are more colourful and variable than similarly-sized males. Uca capricornis are also capable of rapid colour changes in response to stress, but show no endogenous rhythms associated with the semilunar and tidal cycles commonly reported in other fiddler crabs. The extreme colour polymorphism and the relative stability of the colour patterns in Uca capricornis are consistent with their use in visually mediated mate recognition.	[Detto, Tanya; Hemmi, Jan M.] Australian Natl Univ, Res Sch Biol Sci, Ctr Visual Sci, Canberra, ACT 2601, Australia; [Detto, Tanya; Backwell, Patricia R. Y.] Australian Natl Univ, Sch Botany & Zool, Canberra, ACT, Australia; [Hemmi, Jan M.] Australian Natl Univ, Res Sch Biol Sci, ARC Ctr Excellence Vision Sci, Canberra, ACT, Australia	Australian National University; Australian National University; Australian National University	Detto, T (corresponding author), Australian Natl Univ, Res Sch Biol Sci, Ctr Visual Sci, Canberra, ACT 2601, Australia.	tanya.detto@anu.edu.au	Backwell, Patricia RY/C-8883-2009; Hemmi, Jan M/B-6458-2008	Hemmi, Jan M/0000-0003-4629-9362	Centre for Visual Sciences [ANU PhD Scholarship]; ARC Discovery; ARC Centre of Excellence for Vision Research	Centre for Visual Sciences; ARC Discovery(Australian Research Council); ARC Centre of Excellence for Vision Research(Australian Research Council)	This work was funded by an ANU PhD Scholarship with an additional contribution by the Centre for Visual Sciences (TKD), an ARC Discovery Grant (PRYB), and the ARC Centre of Excellence for Vision Research and Centre for Visual Sciences (JMH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adamo SA, 1996, ANIM BEHAV, V52, P73, DOI 10.1006/anbe.1996.0153; BAUER RT, 1981, MAR BIOL, V64, P141, DOI 10.1007/BF00397103; BEECHER MD, 1989, ANIM BEHAV, V38, P248, DOI 10.1016/S0003-3472(89)80087-9; BOOTH CL, 1990, BIOL J LINN SOC, V40, P125, DOI 10.1111/j.1095-8312.1990.tb01973.x; BROWN FA, 1953, J EXP ZOOL, V123, P29, DOI 10.1002/jez.1401230103; BROWN FA, 1948, PHYSIOL ZOOL, V21, P361, DOI 10.1086/physzool.21.4.30152015; Crane Jocelyn, 1944, ZOOLOGICA [NEW YORK], V29, P161; Detto T, 2007, P ROY SOC B-BIOL SCI, V274, P2785, DOI 10.1098/rspb.2007.1059; Detto T, 2006, P ROY SOC B-BIOL SCI, V273, P1661, DOI 10.1098/rspb.2006.3503; FINGERMAN M, 1965, PHYSIOL REV, V45, P296, DOI 10.1152/physrev.1965.45.2.296; George R.W., 1982, Records of the Western Australian Museum Supplement, V14, P1; Hemmi JM, 2006, J EXP BIOL, V209, P4140, DOI 10.1242/jeb.02483; Johnstone RA, 1997, P ROY SOC B-BIOL SCI, V264, P1547, DOI 10.1098/rspb.1997.0215; JORMALAINEN V, 1995, BIOL J LINN SOC, V55, P45, DOI 10.1111/j.1095-8312.1995.tb01049.x; Knowles FGW, 1940, J EXP BIOL, V17, P262; LAND M, 1995, J COMP PHYSIOL A, V177, P81, DOI 10.1007/BF00243400; LEE WL, 1966, ECOLOGY, V47, P930, DOI 10.2307/1935640; Merilaita S, 1997, ANIM BEHAV, V54, P769, DOI 10.1006/anbe.1996.0490; NOBLE G. K., 1939, BULL AMER MUS NAT HIST, V76, P1; O'Connor KI, 1999, ANIM BEHAV, V58, P1269, DOI 10.1006/anbe.1999.1260; Olendorf R, 2006, NATURE, V441, P633, DOI 10.1038/nature04646; Osorio D, 1997, TRENDS ECOL EVOL, V12, P167, DOI 10.1016/S0169-5347(97)01038-0; RAO KR, 1985, BIOL CRUSTACEA, V9, P395; Rust C. C., 1962, Journal of Mammalogy, V43, P323, DOI 10.2307/1376938; SCHOENER TW, 1976, EVOLUTION, V30, P650, DOI 10.1111/j.1558-5646.1976.tb00946.x; Shih HT, 1999, ZOOL STUD, V38, P164; Thurman C. L, 1990, ADAPTIVE COLORATION, P109; THURMAN CL, 1988, COMP BIOCHEM PHYS C, V91, P171, DOI 10.1016/0742-8413(88)90184-3; Tibbetts EA, 2004, P ROY SOC B-BIOL SCI, V271, P1955, DOI 10.1098/rspb.2004.2784; Todd PA, 2006, MAR BIOL, V148, P1357, DOI 10.1007/s00227-005-0159-2; Todd PA, 2005, ECOL RES, V20, P497, DOI 10.1007/s11284-004-0034-5; Warner GF, 1977, BIOL CRABS; WILKENS JL, 1965, BIOL BULL, V128, P133, DOI 10.2307/1539396; Zeil J, 2001, J EXP BIOL, V204, P2561; Zeil J, 1996, J EXP BIOL, V199, P1569; [No title captured]	36	49	49	3	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1629	10.1371/journal.pone.0001629	http://dx.doi.org/10.1371/journal.pone.0001629			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286186	Green Published, gold			2022-12-25	WOS:000260586400022
J	Palstra, RJ; Simonis, M; Klous, P; Brasset, E; Eijkelkamp, B; de Laat, W				Palstra, Robert-Jan; Simonis, Marieke; Klous, Petra; Brasset, Emilie; Eijkelkamp, Bart; de Laat, Wouter			Maintenance of Long-Range DNA Interactions after Inhibition of Ongoing RNA Polymerase II Transcription	PLOS ONE			English	Article								A relationship exists between nuclear architecture and gene activity and it has been proposed that the activity of ongoing RNA polymerase II transcription determines genome organization in the mammalian cell nucleus. Recently developed 3C and 4C technology allowed us to test the importance of transcription for nuclear architecture. We demonstrate that upon transcription inhibition binding of RNA polymerase II to gene regulatory elements is severely reduced. However, contacts between regulatory DNA elements and genes in the beta-globin locus are unaffected and the locus still interacts with the same genomic regions elsewhere on the chromosome. This is a general phenomenon since the great majority of intra- and interchromosomal interactions with the ubiquitously expressed Rad23a gene are also not affected. Our data demonstrate that without transcription the organization and modification of nucleosomes at active loci and the local binding of specific trans-acting factors is unaltered. We propose that these parameters, more than transcription or RNA polymerase II binding, determine the maintenance of long-range DNA interactions.	[Palstra, Robert-Jan; Simonis, Marieke; Klous, Petra; Brasset, Emilie; Eijkelkamp, Bart; de Laat, Wouter] Erasmus MC, Dept Cell Biol & Genet, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Palstra, RJ (corresponding author), Erasmus MC, Dept Cell Biol & Genet, Rotterdam, Netherlands.	w.delaat@erasmusmc.nl	Eijkelkamp, Bart/G-7109-2015; Brasset, Emilie/J-6684-2015	Eijkelkamp, Bart/0000-0003-0179-8977; de Laat, Wouter/0000-0002-6393-595X; Brasset, Emilie/0000-0003-2479-7969; Palstra, Robert-Jan/0000-0003-4600-2303	Netherlands Organisation for Scientific Research (NWO) [912-04-082, 815-02-013, 825-07-012]; Netherlands Genomics Initiative [050-71-324]	Netherlands Organisation for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); Netherlands Genomics Initiative	This work was supported by grants from the Netherlands Organisation for Scientific Research (NWO) (912-04-082 and 815-02-013), and the Netherlands Genomics Initiative (050-71-324). E.B. was supported by a Rubicon grant from the Netherlands Organisation for Scientific Research (NWO) (825-07-012). The funding organizations didn't have any role in preparation of the manuscript	Bender MA, 2006, BLOOD, V108, P1395, DOI 10.1182/blood-2006-04-014431; Branco MR, 2006, PLOS BIOL, V4, P780, DOI 10.1371/journal.pbio.0040138; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; Brown JM, 2006, J CELL BIOL, V172, P177, DOI 10.1083/jcb.200507073; Bushnell DA, 2002, P NATL ACAD SCI USA, V99, P1218, DOI 10.1073/pnas.251664698; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; Chakalova L, 2005, NAT REV GENET, V6, P669, DOI 10.1038/nrg1673; Chambeyron S, 2004, GENE DEV, V18, P1119, DOI 10.1101/gad.292104; CHODOSH LA, 1989, J BIOL CHEM, V264, P2250; Cook PR, 2003, J CELL SCI, V116, P4483, DOI 10.1242/jcs.00819; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; Cook PR, 2002, NAT GENET, V32, P347, DOI 10.1038/ng1102-347; COOK PR, 1995, J CELL SCI, V108, P2927; de Laat W, 2007, CURR OPIN GENET DEV, V17, P456, DOI 10.1016/j.gde.2007.07.009; Drissen R, 2004, GENE DEV, V18, P2485, DOI 10.1101/gad.317004; Englmann A, 2005, CHROMOSOME RES, V13, P183, DOI 10.1007/s10577-005-0845-4; Faro-Trindade I, 2006, BIOCHEM SOC T, V34, P1133, DOI 10.1042/BST0341133; Forsberg EC, 1999, J BIOL CHEM, V274, P26850, DOI 10.1074/jbc.274.38.26850; Giresi PG, 2007, GENOME RES, V17, P877, DOI 10.1101/gr.5533506; Gong XQ, 2004, J BIOL CHEM, V279, P27422, DOI 10.1074/jbc.M402163200; Gribnau J, 1998, EMBO J, V17, P6020, DOI 10.1093/emboj/17.20.6020; Hagege H, 2007, NAT PROTOC, V2, P1722, DOI 10.1038/nprot.2007.243; Hogan GJ, 2006, PLOS GENET, V2, P1433, DOI 10.1371/journal.pgen.0020158; Kimura H, 2002, J CELL BIOL, V159, P777, DOI 10.1083/jcb.200206019; Kooren J, 2007, J BIOL CHEM, V282, P16544, DOI 10.1074/jbc.M701159200; Lanctot C, 2007, NAT REV GENET, V8, P104, DOI 10.1038/nrg2041; Mahy NL, 2002, J CELL BIOL, V159, P753, DOI 10.1083/jcb.200207115; Marenduzzo D, 2006, BIOPHYS J, V90, P3712, DOI 10.1529/biophysj.105.077685; Marenduzzo D, 2007, TRENDS GENET, V23, P126, DOI 10.1016/j.tig.2007.01.007; Miles J, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000630; Misteli T, 2001, J CELL BIOL, V155, P181, DOI 10.1083/jcb.200108110; Misteli T, 2007, CELL, V128, P787, DOI 10.1016/j.cell.2007.01.028; Murrell A, 2004, NAT GENET, V36, P889, DOI 10.1038/ng1402; Nguyen VT, 1996, NUCLEIC ACIDS RES, V24, P2924, DOI 10.1093/nar/24.15.2924; NOORDERMEER D, 2008, PLOS GENET IN PRESS; Osborne CS, 2007, PLOS BIOL, V5, P1763, DOI 10.1371/journal.pbio.0050192; Palstra RJ, 2003, NAT GENET, V35, P190, DOI 10.1038/ng1244; Schubeler D, 2000, GENE DEV, V14, P940; Shopland LS, 2006, J CELL BIOL, V174, P27, DOI 10.1083/jcb.200603083; Simonis M, 2006, NAT GENET, V38, P1348, DOI 10.1038/ng1896; Spilianakis CG, 2004, NAT IMMUNOL, V5, P1017, DOI 10.1038/ni1115; Splinter E, 2006, GENE DEV, V20, P2349, DOI 10.1101/gad.399506; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; Trimborn T, 1999, GENE DEV, V13, P112, DOI 10.1101/gad.13.1.112; Vakoc CR, 2005, MOL CELL, V17, P453, DOI 10.1016/j.molcel.2004.12.028; van de Corput MPC, 2001, METHODS, V25, P111, DOI 10.1006/meth.2001.1220; Volpi EV, 2000, J CELL SCI, V113, P1565; West AG, 2005, HUM MOL GENET, V14, pR101, DOI 10.1093/hmg/ddi104; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; Xie SQ, 2006, MOL BIOL CELL, V17, P1723, DOI 10.1091/mbc.E05-08-0726; Zink D, 2004, J CELL BIOL, V166, P815, DOI 10.1083/jcb.200404107	51	100	105	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1661	10.1371/journal.pone.0001661	http://dx.doi.org/10.1371/journal.pone.0001661			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286208	Green Submitted, Green Published, gold			2022-12-25	WOS:000260586400050
J	Ungrin, MD; Joshi, C; Nica, A; Bauwens, C; Zandstra, PW				Ungrin, Mark D.; Joshi, Chirag; Nica, Andra; Bauwens, Celine; Zandstra, Peter W.			Reproducible, Ultra High-Throughput Formation of Multicellular Organization from Single Cell Suspension-Derived Human Embryonic Stem Cell Aggregates	PLOS ONE			English	Article							VISCERAL ENDODERM; DIFFERENTIATION; BODY; BODIES; EXPRESSION; SURVIVAL; CULTURE; AXIS; CARDIOMYOCYTES; MORPHOGENESIS	Background: Human embryonic stem cells (hESC) should enable novel insights into early human development and provide a renewable source of cells for regenerative medicine. However, because the three-dimensional hESC aggregates [embryoid bodies (hEB)] typically employed to reveal hESC developmental potential are heterogeneous and exhibit disorganized differentiation, progress in hESC technology development has been hindered. Methodology/Principal Findings: Using a centrifugal forced-aggregation strategy in combination with a novel centrifugal-extraction approach as a foundation, we demonstrated that hESC input composition and inductive environment could be manipulated to form large numbers of well-defined aggregates exhibiting multi-lineage differentiation and substantially improved self-organization from single-cell suspensions. These aggregates exhibited coordinated bi-domain structures including contiguous regions of extraembryonic endoderm- and epiblast-like tissue. A silicon wafer-based microfabrication technology was used to generate surfaces that permit the production of hundreds to thousands of hEB per cm(2). Conclusions/Significance:The mechanisms of early human embryogenesis are poorly understood. We report an ultra high throughput (UHTP) approach for generating spatially and temporally synchronised hEB. Aggregates generated in this manner exhibited aspects of peri-implantation tissue-level morphogenesis. These results should advance fundamental studies into early human developmental processes, enable high-throughput screening strategies to identify conditions that specify hESC-derived cells and tissues, and accelerate the pre-clinical evaluation of hESC-derived cells.	[Ungrin, Mark D.; Joshi, Chirag; Nica, Andra; Bauwens, Celine; Zandstra, Peter W.] Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON, Canada; [Bauwens, Celine; Zandstra, Peter W.] Univ Toronto, Dept Chem Engn & Appl Chem, Toronto, ON, Canada	University of Toronto; University of Toronto	Ungrin, MD (corresponding author), Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON, Canada.	peter.zandstra@utoronto.ca		Ungrin, Mark/0000-0002-7410-1491	Canadian Institutes of Health Research; Stem Cell Research Foundation; Canada Research Chair program; Canadian Microsystems Consortium [in-kind grant]; Canadian Stem Cell Network [in-kind grant]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Stem Cell Research Foundation; Canada Research Chair program(Canada Research Chairs); Canadian Microsystems Consortium; Canadian Stem Cell Network	Funding was provided by the Canadian Institutes of Health Research, the Stem Cell Research Foundation, the Canada Research Chair program, an in-kind grant from the Canadian Microsystems Consortium, and the Canadian Stem Cell Network. Sponsors and funders were not involved in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript.	Bauwens C, 2005, BIOTECHNOL BIOENG, V90, P452, DOI 10.1002/bit.20445; Blum B, 2007, STEM CELLS, V25, P1924, DOI 10.1634/stemcells.2007-0073; Bruder JM, 2006, LANGMUIR, V22, P8266, DOI 10.1021/la0608563; Burridge PW, 2007, STEM CELLS, V25, P929, DOI 10.1634/stemcells.2006-0598; Chadwick K, 2003, BLOOD, V102, P906, DOI 10.1182/blood-2003-03-0832; Chazaud C, 2006, DEV CELL, V10, P615, DOI 10.1016/j.devcel.2006.02.020; Chen SS, 2007, STEM CELLS, V25, P553, DOI 10.1634/stemcells.2006-0419; Chu JH, 2005, DEVELOPMENT, V132, P5539, DOI 10.1242/dev.02157; Conley BJ, 2004, FETAL DIAGN THER, V19, P218, DOI 10.1159/000076701; Conley BJ, 2007, BIOCHEM CELL BIOL, V85, P121, DOI 10.1139/O06-145; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; Coucouvanis E, 1999, DEVELOPMENT, V126, P535; D'Amour KA, 2005, NAT BIOTECHNOL, V23, P1534, DOI 10.1038/nbt1163; Dang SM, 2004, STEM CELLS, V22, P275, DOI 10.1634/stemcells.22-3-275; Dang SM, 2002, BIOTECHNOL BIOENG, V78, P442, DOI 10.1002/bit.10220; Duboc V, 2004, DEV CELL, V6, P397, DOI 10.1016/S1534-5807(04)00056-5; Eakin GS, 2004, SEMIN CELL DEV BIOL, V15, P619, DOI 10.1016/j.semcdb.2004.04.008; Fok EYL, 2005, STEM CELLS, V23, P1333, DOI 10.1634/stemcells.2005-0112; Gilbert S.F., 2000, DEV BIOL, V6th ed.; GOLDFARB M, 1991, ANN NY ACAD SCI, V638, P38, DOI 10.1111/j.1749-6632.1991.tb49016.x; Herzog W, 2004, DEVELOPMENT, V131, P3681, DOI 10.1242/dev.01235; Hirashima M, 2004, BLOOD, V104, P711, DOI 10.1182/blood-2004-01-0254; Ingber DE, 2006, INT J DEV BIOL, V50, P255, DOI 10.1387/ijdb.052044di; Ingber DE, 2007, DEVELOPMENT, V134, P2541, DOI 10.1242/dev.003707; Itskovitz-Eldor J, 2000, MOL MED, V6, P88, DOI 10.1007/BF03401776; Joannides AJ, 2007, STEM CELLS, V25, P731, DOI 10.1634/stemcells.2006-0562; Kanai-Azuma M, 2002, DEVELOPMENT, V129, P2367; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; Khademhosseini A, 2006, BIOMATERIALS, V27, P5968, DOI 10.1016/j.biomaterials.2006.06.035; Kimura-Yoshida C, 2007, P NATL ACAD SCI USA, V104, P5919, DOI 10.1073/pnas.0607779104; Koike M, 2005, CYTOTECHNOLOGY, V47, P3, DOI 10.1007/s10616-005-3743-x; Kovacs GTA, 1998, P IEEE, V86, P1536, DOI 10.1109/5.704259; Kurosawa H, 2003, J BIOSCI BIOENG, V96, P409, DOI 10.1263/jbb.96.409; Laflamme MA, 2005, NAT BIOTECHNOL, V23, P845, DOI 10.1038/nbt1117; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Lazarevich NL, 2000, BIOCHEMISTRY-MOSCOW+, V65, P117; Li L, 2004, DEVELOPMENT, V131, P5277, DOI 10.1242/dev.01415; Li XF, 2001, J CELL BIOL, V153, P811, DOI 10.1083/jcb.153.4.811; Mesnard D, 2006, DEVELOPMENT, V133, P2497, DOI 10.1242/dev.02413; Mohr JC, 2006, BIOMATERIALS, V27, P6032, DOI 10.1016/j.biomaterials.2006.07.012; Ng ES, 2005, BLOOD, V106, P1601, DOI 10.1182/blood-2005-03-0987; Niwa H, 2005, CELL, V123, P917, DOI 10.1016/j.cell.2005.08.040; Nussbaum J, 2007, FASEB J, V21, P1345, DOI 10.1096/fj.06-6769com; Peerani R, 2007, EMBO J, V26, P4744, DOI 10.1038/sj.emboj.7601896; Perea-Gomez A, 1999, DEVELOPMENT, V126, P4499; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Raikwar SP, 2006, PHYSIOLOGY, V21, P19, DOI 10.1152/physiol.00034.2005; Rossant J, 2003, PHILOS T ROY SOC B, V358, P1341, DOI 10.1098/rstb.2003.1329; Schohl A, 2003, EMBO J, V22, P3303, DOI 10.1093/emboj/cdg328; Seiler A, 2004, REPROD TOXICOL, V18, P231, DOI 10.1016/j.reprotox.2003.10.015; Sohn SK, 2003, BONE MARROW TRANSPL, V31, P967, DOI 10.1038/sj.bmt.1704042; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; UNGRIN M, 2007, CURR PROTOC STEM CEL, V2; Vallier L, 2005, J CELL SCI, V118, P4495, DOI 10.1242/jcs.02553; Walters MJ, 2001, MECH DEVELOP, V100, P263, DOI 10.1016/S0925-4773(00)00535-9; Wang LS, 2005, J EXP MED, V201, P1603, DOI 10.1084/jem.20041888; Wang XW, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng154; Watanabe K, 2007, NAT BIOTECHNOL, V25, P681, DOI 10.1038/nbt1310; Weitzer G, 2006, HANDB EXP PHARM, V174, P21; Wells JM, 2000, DEVELOPMENT, V127, P1563; Xu CH, 2002, CIRC RES, V91, P501, DOI 10.1161/01.RES.0000035254.80718.91; Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971; Yoon BS, 2006, DIFFERENTIATION, V74, P149, DOI 10.1111/j.1432-0436.2006.00063.x; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526	65	297	346	0	46	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1565	10.1371/journal.pone.0001565	http://dx.doi.org/10.1371/journal.pone.0001565			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270562	Green Submitted, Green Published, gold			2022-12-25	WOS:000260535900007
J	Di Ventura, B; Funaya, C; Antony, C; Knop, M; Serrano, L				Di Ventura, Barbara; Funaya, Charlotta; Antony, Claude; Knop, Michael; Serrano, Luis			Reconstitution of Mdm2-Dependent Post-Translational Modifications of p53 in Yeast	PLOS ONE			English	Article								p53 mediates cell cycle arrest or apoptosis in response to DNA damage. Its activity is subject to a tight regulation involving a multitude of post-translational modifications. The plethora of functional protein interactions of p53 at present precludes a clear understanding of regulatory principles in the p53 signaling network. To circumvent this complexity, we studied here the minimal requirements for functionally relevant p53 post-translational modifications by expressing human p53 together with its best characterized modifier Mdm2 in budding yeast. We find that expression of the human p53-Mdm2 module in yeast is sufficient to faithfully recapitulate key aspects of p53 regulation in higher eukaryotes, such as Mdm2-dependent targeting of p53 for degradation, sumoylation at lysine 386 and further regulation of this process by p14(ARF). Interestingly, sumoylation is necessary for the recruitment of p53-Mdm2 complexes to yeast nuclear bodies morphologically akin to human PML bodies. These results suggest a novel role for Mdm2 as well as for p53 sumoylation in the recruitment of p53 to nuclear bodies. The reductionist yeast model that was established and validated in this study will now allow to incrementally study simplified parts of the intricate p53 network, thus helping elucidate the core mechanisms of p53 regulation as well as test novel strategies to counteract p53 malfunctions.	[Di Ventura, Barbara; Funaya, Charlotta; Antony, Claude; Knop, Michael; Serrano, Luis] Univ Heidelberg BZH, Biochem Ctr, Heidelberg, Germany	Ruprecht Karls University Heidelberg	Di Ventura, B (corresponding author), Univ Heidelberg BZH, Biochem Ctr, Heidelberg, Germany.	barbara.diventura@bzh.uni-heidelberg.de	antony, claude/K-5342-2013	Fredriksson Funaya, Charlotta/0000-0003-1375-1287	EC [COMBIO]	EC(European CommissionEuropean Commission Joint Research Centre)	This work was partly financed by the EC grant COMBIO.	[Anonymous], 1991, Methods Enzymol, V194, P1; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Chen LH, 2003, ONCOGENE, V22, P5348, DOI 10.1038/sj.onc.1206851; Cooper B, 2003, VIROLOGY, V306, P87, DOI 10.1016/S0042-6822(02)00012-0; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Inoue T, 2001, J BIOL CHEM, V276, P45255, DOI 10.1074/jbc.M107477200; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Lahav G, 2004, NAT GENET, V36, P147, DOI 10.1038/ng1293; Liu G, 2006, J CELL BIOCHEM, V97, P448, DOI 10.1002/jcb.20700; Lu X, 2005, CURR OPIN GENET DEV, V15, P27, DOI 10.1016/j.gde.2004.12.008; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pearson GD, 1998, J BIOL CHEM, V273, P5431, DOI 10.1074/jbc.273.10.5431; Riedel CG, 2005, J BIOL CHEM, V280, P37846, DOI 10.1074/jbc.M504244200; Saville MK, 2004, J BIOL CHEM, V279, P42169, DOI 10.1074/jbc.M403362200; Shen TH, 2006, MOL CELL, V24, P331, DOI 10.1016/j.molcel.2006.09.013; Waddell S, 2001, ONCOGENE, V20, P6001, DOI 10.1038/sj.onc.1204702; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Xu Y, 2003, CELL DEATH DIFFER, V10, P1213, DOI 10.1038/sj.cdd.4401292	25	27	27	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1507	10.1371/journal.pone.0001507	http://dx.doi.org/10.1371/journal.pone.0001507			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SR	18231594	gold, Green Submitted, Green Published			2022-12-25	WOS:000260504200020
J	Monaci, P; Luzzago, A; Santini, C; De Pra, A; Arcuri, M; Magistri, F; Bellini, A; Ansuini, H; Ambrosio, M; Ammendola, V; Bigotti, MG; Cirillo, A; Nuzzo, M; Nasti, AA; Neuner, P; Orsatti, L; Pezzanera, M; Sbardellati, A; Silvestre, G; Uva, P; Viti, V; Barbato, G; Colloca, S; Demartis, A; De Rinaldis, E; Giampaoli, S; Lahm, A; Palombo, F; Talamo, F; Vitelli, A; Nicosia, A; Cortese, R				Monaci, Paolo; Luzzago, Alessandra; Santini, Claudia; De Pra, Alessandra; Arcuri, Mirko; Magistri, Francesca; Bellini, Alessandro; Ansuini, Helenia; Ambrosio, Maria; Ammendola, Virginia; Bigotti, Maria Giulia; Cirillo, Agostino; Nuzzo, Maurizio; Nasti, Annamaria Assunta; Neuner, Philippe; Orsatti, Laura; Pezzanera, Monica; Sbardellati, Andrea; Silvestre, Giuseppe; Uva, Paolo; Viti, Valentina; Barbato, Gaetano; Colloca, Stefano; Demartis, Anna; De Rinaldis, Emanuele; Giampaoli, Saverio; Lahm, Armin; Palombo, Fabio; Talamo, Fabio; Vitelli, Alessandra; Nicosia, Alfredo; Cortese, Riccardo			Differential Screening of Phage-Ab Libraries by Oligonucleotide Microarray Technology	PLOS ONE			English	Article								A novel and efficient tagArray technology was developed that allows rapid identification of antibodies which bind to receptors with a specific expression profile, in the absence of biological information. This method is based on the cloning of a specific, short nucleotide sequence (tag) in the phagemid coding for each phage-displayed antibody fragment (phage-Ab) present in a library. In order to set up and validate the method we identified about 10,000 different phage-Abs binding to receptors expressed in their native form on the cell surface (10 k Membranome collection) and tagged each individual phage-Ab. The frequency of each phage-Ab in a given population can at this point be inferred by measuring the frequency of its associated tag sequence through standard DNA hybridization methods. Using tiny amounts of biological samples we identified phage-Abs binding to receptors preferentially expressed on primary tumor cells rather than on cells obtained from matched normal tissues. These antibodies inhibited cell proliferation in vitro and tumor development in vivo, thus representing therapeutic lead candidates.	[Monaci, Paolo; Luzzago, Alessandra; Santini, Claudia; De Pra, Alessandra; Arcuri, Mirko; Magistri, Francesca; Bellini, Alessandro; Ansuini, Helenia; Bigotti, Maria Giulia; Cirillo, Agostino; Nuzzo, Maurizio; Neuner, Philippe; Orsatti, Laura; Pezzanera, Monica; Sbardellati, Andrea; Silvestre, Giuseppe; Uva, Paolo; Viti, Valentina; Barbato, Gaetano; Colloca, Stefano; Demartis, Anna; De Rinaldis, Emanuele; Giampaoli, Saverio; Lahm, Armin; Palombo, Fabio; Talamo, Fabio; Vitelli, Alessandra; Nicosia, Alfredo; Cortese, Riccardo] Ist Ric Biol Mol P Angeletti, Dept Biotechnol, Rome, Italy; [Ambrosio, Maria; Ammendola, Virginia; Bigotti, Maria Giulia; Nasti, Annamaria Assunta; Silvestre, Giuseppe] CEINGE, Naples, Italy	Merck & Company; CEINGE Biotecnologie Avanzate	Monaci, P (corresponding author), Ist Ric Biol Mol P Angeletti, Dept Biotechnol, Rome, Italy.	paolo_monaci@merck.com	Uva, Paolo/A-2877-2011; Barbato, Gaetano/G-4904-2011	Uva, Paolo/0000-0002-9524-8492; Barbato, Gaetano/0000-0001-9840-6858; ambrosio, maria rosaria/0000-0002-7911-9770; Palombo, Fabio/0000-0003-0473-4901; Bigotti, Giulia/0000-0001-9595-3338				Adams GP, 2005, NAT BIOTECHNOL, V23, P1147, DOI 10.1038/nbt1137; Brekke OH, 2003, NAT REV DRUG DISCOV, V2, P52, DOI 10.1038/nrd984; Brooks D, 1995, CLIN CANCER RES, V1, P1259; Buckhaults P, 2001, CANCER RES, V61, P6996; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CHOTHIA C, 1992, J MOL BIOL, V227, P799, DOI 10.1016/0022-2836(92)90224-8; Fuh G, 2007, EXPERT OPIN BIOL TH, V7, P73, DOI 10.1517/14712598.7.1.73; Gomme PT, 2005, DRUG DISCOV TODAY, V10, P267, DOI 10.1016/S1359-6446(04)03333-1; Hegmans JPJJ, 2002, J IMMUNOL METHODS, V262, P191, DOI 10.1016/S0022-1759(02)00005-4; Imai K, 2006, NAT REV CANCER, V6, P714, DOI 10.1038/nrc1913; Kall L, 2004, J MOL BIOL, V338, P1027, DOI 10.1016/j.jmb.2004.03.016; Kasibhatla S, 2005, P NATL ACAD SCI USA, V102, P12095, DOI 10.1073/pnas.0406731102; Lu P, 2007, NAT BIOTECHNOL, V25, P117, DOI 10.1038/nbt1270; Moura IC, 2004, BLOOD, V103, P1838, DOI 10.1182/blood-2003-07-2440; Rainov NG, 2005, CURR OPIN MOL THER, V7, P483; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; Schadt EE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r73; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; Xu JL, 2000, IMMUNITY, V13, P37, DOI 10.1016/S1074-7613(00)00006-6	20	6	6	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1508	10.1371/journal.pone.0001508	http://dx.doi.org/10.1371/journal.pone.0001508			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SR	18231595	Green Published, gold, Green Submitted			2022-12-25	WOS:000260504200021
J	Maedler, K; Schulthess, FT; Bielman, C; Berney, T; Bonny, C; Prentki, M; Donath, MY; Roduit, R				Maedler, Kathrin; Schulthess, Fabienne T.; Bielman, Christelle; Berney, Thierry; Bonny, Christophe; Prentki, Marc; Donath, Marc Y.; Roduit, Raphael			Glucose and leptin induce apoptosis in human beta-cells and impair glucose-stimulated insulin secretion through activation of c-Jun N-terminal kinases	FASEB JOURNAL			English	Article						diabetes; islets; capase 1	HUMAN PANCREATIC-ISLETS; MESSENGER-RNA LEVELS; CHRONIC HYPERGLYCEMIA; CHRONIC EXPOSURE; PROLONGED EXPOSURE; OXIDATIVE STRESS; GENE-EXPRESSION; NORMAL RATS; JNK; TOXICITY	c-Jun N-terminal kinases (SAPK/JNKs) are activated by inflammatory cytokines, and JNK signaling is involved in insulin resistance and beta-cell secretory function and survival. Chronic high glucose concentrations and leptin induce interleukin-1 beta (IL-1 beta) secretion from pancreatic islets, an event that is possibly causal in promoting beta-cell dysfunction and death. The present study provides evidence that chronically elevated concentrations of leptin and glucose induce beta-cell apoptosis through activation of the JNK pathway in human islets and in insulinoma (INS 832/13) cells. JNK inhibition by the dominant inhibitor JNK-binding domain of IB1/JIP-1 (JNKi) reduced JNK activity and apoptosis induced by leptin and glucose. Exposure of human islets to leptin and high glucose concentrations leads to a decrease of glucose-induced insulin secretion, which was partly restored by JNKi. We detected an interplay between the JNK cascade and the caspase 1/IL-1 beta-converting enzyme in human islets. The caspase 1 gene, which contains a potential activating protein-1 binding site, was up-regulated in pancreatic sections and in isolated islets from type 2 diabetic patients. Similarly, cultured human islets exposed to high glucose- and leptin-induced caspase 1 and JNK inhibition prevented this up-regulation. Therefore, JNK inhibition may protect beta-cells from the deleterious effects of high glucose and leptin in diabetes.	[Maedler, Kathrin; Schulthess, Fabienne T.] Univ Calif Los Angeles, Larry L Hillblom Islet Res Ctr, Los Angeles, CA USA; [Bielman, Christelle; Bonny, Christophe] Ctr Hosp Univ Vaudois Lausanne, Med Genet Serv, Lausanne, France; [Bonny, Christophe] Ctr Med Univ Geneva, Dept Surg, Geneva, Switzerland; [Prentki, Marc] Univ Montreal, Mol Nutr Unit, Montreal, PQ, Canada; [Prentki, Marc] Univ Montreal, Montreal Diabet Res Ctr, Montreal, PQ, Canada; [Prentki, Marc] Univ Montreal, Ctr Rech CHUM, Montreal, PQ, Canada; [Prentki, Marc] Univ Montreal, Dept Biochem & Nutr, Montreal, PQ, Canada; [Donath, Marc Y.] Univ Zurich, Univ Zurich Hosp, Div Endocrinol & Diabet, CH-8006 Zurich, Switzerland; [Roduit, Raphael] Inst Rech Ophtalmol, Sion, Switzerland	University of California System; University of California Los Angeles; University of Geneva; Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal; University of Zurich; University Zurich Hospital	Maedler, K (corresponding author), Univ Bremen, Ctr Biomol Interactions Bremen, NW2,Box 33 04 40, D-28334 Bremen, Germany.	kmaedler@uni-bremen.de	Maedler, Kathrin/ABE-3022-2021; Bonny, Christophe/AAV-7214-2021; Berney, Thierry/ABE-9450-2021; Roduit, Raphael/AAC-3890-2021	Maedler, Kathrin/0000-0002-7436-1197; Berney, Thierry/0000-0002-4230-9378; Roduit, Raphael/0000-0001-7440-2799				Abdelli S, 2004, DIABETES, V53, P2815, DOI 10.2337/diabetes.53.11.2815; Ammendrup A, 2000, DIABETES, V49, P1468, DOI 10.2337/diabetes.49.9.1468; Beltowski J, 2006, ATHEROSCLEROSIS, V189, P47, DOI 10.1016/j.atherosclerosis.2006.03.003; Bjorbaek C, 2001, J BIOL CHEM, V276, P4747, DOI 10.1074/jbc.M007439200; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Butler AE, 2004, DIABETES, V53, P1509, DOI 10.2337/diabetes.53.6.1509; Corazza N, 2006, J CLIN INVEST, V116, P2493, DOI 10.1172/JCI27726; De Marinis L, 2004, J CLIN ENDOCR METAB, V89, P174, DOI 10.1210/jc.2002-021308; Donath MY, 1999, DIABETES, V48, P738, DOI 10.2337/diabetes.48.4.738; Donath MY, 2005, DIABETES, V54, pS108, DOI 10.2337/diabetes.54.suppl_2.S108; Donath MY, 2004, DIABETOLOGIA, V47, P581, DOI 10.1007/s00125-004-1336-4; Efanova IB, 1998, J BIOL CHEM, V273, P33501, DOI 10.1074/jbc.273.50.33501; EIZIRIK DL, 1992, J CLIN INVEST, V90, P1263, DOI 10.1172/JCI115989; Eldor R, 2006, DIABETES RES CLIN PR, V74, pS3, DOI 10.1016/j.diabres.2006.06.004; Emilsson V, 1997, DIABETES, V46, P313, DOI 10.2337/diabetes.46.2.313; Federici M, 2001, DIABETES, V50, P1290, DOI 10.2337/diabetes.50.6.1290; Haefliger JA, 2003, J CELL SCI, V116, P1463, DOI 10.1242/jcs.00356; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Hotamisligil GS, 2005, DIABETES, V54, pS73, DOI 10.2337/diabetes.54.suppl_2.S73; Ingelsson E, 1998, IMMUNOL LETT, V63, P125, DOI 10.1016/S0165-2478(98)00062-5; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; KAISER N, 1991, ENDOCRINOLOGY, V129, P2067, DOI 10.1210/endo-129-4-2067; Kaneto H, 2004, NAT MED, V10, P1128, DOI 10.1038/nm1111; Kieffer TJ, 1997, DIABETES, V46, P1087, DOI 10.2337/diabetes.46.6.1087; Koyama K, 1997, DIABETES, V46, P1276, DOI 10.2337/diabetes.46.8.1276; Kulkarni RN, 1997, J CLIN INVEST, V100, P2729, DOI 10.1172/JCI119818; LEAHY JL, 1988, DIABETES, V37, P217, DOI 10.2337/diabetes.37.2.217; LEAHY JL, 1986, J CLIN INVEST, V77, P908, DOI 10.1172/JCI112389; LEAHY JL, 1992, DIABETES CARE, V15, P442, DOI 10.2337/diacare.15.3.442; Linetsky E, 1997, DIABETES, V46, P1120, DOI 10.2337/diabetes.46.7.1120; Ling ZD, 1996, DIABETES, V45, P1774, DOI 10.2337/diabetes.45.12.1774; Lupi R, 1999, BIOCHEM BIOPH RES CO, V256, P637, DOI 10.1006/bbrc.1999.0384; Maedler K, 2002, J CLIN INVEST, V110, P851, DOI 10.1172/JCI200215318; Maedler K, 2004, P NATL ACAD SCI USA, V101, P8138, DOI 10.1073/pnas.0305683101; Maedler K, 2001, DIABETES, V50, P69, DOI 10.2337/diabetes.50.1.69; Maedler K, 2001, DIABETES, V50, P1683, DOI 10.2337/diabetes.50.8.1683; Major CD, 2001, DIABETES, V50, P2721, DOI 10.2337/diabetes.50.12.2721; Marshak S, 1999, DIABETES, V48, P1230, DOI 10.2337/diabetes.48.6.1230; Matarese G., 2002, Current Drug Targets - Inflammation and Allergy, V1, P13, DOI 10.2174/1568010023344931; MINE T, 2004, DIABETES S2, V53, P2475; Monnier L, 2006, JAMA-J AM MED ASSOC, V295, P1681, DOI 10.1001/jama.295.14.1681; Nikulina MA, 2003, CYTOKINE, V24, P13, DOI 10.1016/S1043-4666(03)00242-4; Oberholzer J, 2000, TRANSPLANTATION, V69, P1115, DOI 10.1097/00007890-200003270-00016; Otero M, 2005, FEBS LETT, V579, P295, DOI 10.1016/j.febslet.2004.11.024; Pallett AL, 1997, BIOCHEM BIOPH RES CO, V238, P267, DOI 10.1006/bbrc.1997.7274; Papaccio G, 2005, J CELL PHYSIOL, V203, P94, DOI 10.1002/jcp.20198; Pickup JC, 2000, CLIN ENDOCRINOL, V52, P107, DOI 10.1046/j.1365-2265.2000.00921.x; Prentki M, 2006, J CLIN INVEST, V116, P1802, DOI 10.1172/JCI29103; Rhodes CJ, 2005, SCIENCE, V307, P380, DOI 10.1126/science.1104345; RICORDI C, 1988, DIABETES, V37, P413, DOI 10.2337/diabetes.37.4.413; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; Robertson RP, 2004, DIABETES, V53, pS119, DOI 10.2337/diabetes.53.2007.S119; ROBERTSON RP, 1992, J CLIN INVEST, V90, P320, DOI 10.1172/JCI115865; ROBERTSON RP, 1989, DIABETES, V38, P1501, DOI 10.2337/diabetes.38.12.1501; ROBERTSON RP, 1994, DIABETES, V43, P1085, DOI 10.2337/diabetes.43.9.1085; Roduit R, 1997, FEBS LETT, V415, P179, DOI 10.1016/S0014-5793(97)01115-0; ROSSETTI L, 1990, DIABETES CARE, V13, P610, DOI 10.2337/diacare.13.6.610; Seufert J, 2004, DIABETES, V53, pS152, DOI 10.2337/diabetes.53.2007.S152; Seufert J, 1999, J CLIN ENDOCR METAB, V84, P670, DOI 10.1210/jc.84.2.670; Seufert J, 1999, P NATL ACAD SCI USA, V96, P674, DOI 10.1073/pnas.96.2.674; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P9558, DOI 10.1073/pnas.95.16.9558; Storling J, 2005, ENDOCRINOLOGY, V146, P3026, DOI 10.1210/en.2005-0036; Tajiri Y, 1997, ENDOCRINOLOGY, V138, P273, DOI 10.1210/en.138.1.273; UNGER RH, 1985, DIABETOLOGIA, V28, P119; Waeber G, 2000, NAT GENET, V24, P291, DOI 10.1038/73523; Wang HY, 2005, J CELL SCI, V118, P3905, DOI 10.1242/jcs.02513	68	84	92	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					1905	1913		10.1096/fj.07-101824	http://dx.doi.org/10.1096/fj.07-101824			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18263705	Green Accepted			2022-12-25	WOS:000256352700030
J	Atkins, KM; Thomas, L; Youker, RT; Harriff, MJ; Pissani, F; You, HH; Thomas, G				Atkins, Katelyn M.; Thomas, Laurel; Youker, Robert T.; Harriff, Melanie J.; Pissani, Franco; You, Huihong; Thomas, Gary			HIV-1 Nef binds PACS-2 to assemble a multikinase cascade that triggers major histocompatibility complex class I (MHC-I) down-regulation - Analysis using short interfering RNA and knock-out mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 NEF; TRANS-GOLGI NETWORK; CELL-SURFACE; SH3 DOMAIN; PHOSPHOINOSITIDE 3-KINASE; CYTOPLASMIC TAIL; ACIDIC CLUSTER; AMINO-ACID; C-SRC; PROTEIN	Human immunodeficiency virus, type 1, negative factor (Nef) initiates down-regulation of cell-surface major histocompatibility complex-I (MHC-I) by assembling an Src family kinase (SFK)-ZAP70/Syk-phosphoinositide 3-kinase (PI3K) cascade through the sequential actions of two sites, Nef EEEE65 and PXXP75. The internalized MHC-I molecules are then sequestered in endosomal compartments by a process requiring Nef Met(20). How Nef assembles the multikinase cascade to trigger the MHC-I down-regulation pathway is unknown. Here we report that EEEE65-dependent binding to the sorting protein PACS-2 targets Nef to the paranuclear region, enabling PXXP75 to bind and activate a trans-Golgi network (TGN)-localized SFK. This SFK then phosphorylates ZAP-70 to recruit class I PI3K by interaction with the p85 C-terminal Src homology 2 domain. Using splenocytes and embryonic fibroblasts from PACS-2(-/-) mice, we confirm genetically that Nef requires PACS-2 to localize to the paranuclear region and assemble the multikinase cascade. Moreover, genetic loss of PACS-2 or inhibition of class I PI3K prevents Nef-mediated MHC-I down-regulation, demonstrating that short interfering RNA knockdown of PACS-2 phenocopies the gene knock-out. This PACS-2-dependent targeting pathway is not restricted to Nef, because PACS-2 is also required for trafficking of an endocytosed cation-independent mannose 6-phosphate receptor reporter from early endosomes to the TGN. Together, these results demonstrate PACS-2 is required for Nef action and sorting of itinerant membrane cargo in the TGN/endosomal system.	[Atkins, Katelyn M.; Thomas, Laurel; Youker, Robert T.; Harriff, Melanie J.; Pissani, Franco; You, Huihong; Thomas, Gary] Vollum Inst, Portland, OR 97239 USA		Thomas, G (corresponding author), Vollum Inst, 3181 Sam Jackson Pk Rd, Portland, OR 97239 USA.	thomasg@ohsu.edu	Youker, Robert/AAP-8725-2021	Pissani, Franco/0000-0001-8869-8455; Youker, Robert/0000-0002-3986-1655	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049793] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037274, F32DK076343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM071338] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007381] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI49793] Funding Source: Medline; NIDDK NIH HHS [R01 DK37274, DK076343] Funding Source: Medline; NIGMS NIH HHS [T32 GM71338] Funding Source: Medline; NINDS NIH HHS [T32 NS007381] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agopian K, 2007, VIROLOGY, V358, P119, DOI 10.1016/j.virol.2006.07.053; Akari H, 2000, J VIROL, V74, P2907, DOI 10.1128/JVI.74.6.2907-2912.2000; Arighi CN, 2004, J CELL BIOL, V165, P123, DOI 10.1083/jcb.200312055; Bard F, 2002, EUR J CELL BIOL, V81, P26, DOI 10.1078/0171-9335-00217; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; Benzinger A, 2005, MOL CELL PROTEOMICS, V4, P785, DOI 10.1074/mcp.M500021-MCP200; Blagoveshchenskaya AD, 2002, CELL, V111, P853, DOI 10.1016/S0092-8674(02)01162-5; Bonifacino JS, 2006, NAT REV MOL CELL BIO, V7, P568, DOI 10.1038/nrm1985; Bouard D, 2007, TRAFFIC, V8, P835, DOI 10.1111/j.1600-0854.2007.00581.x; Carlton J, 2004, CURR BIOL, V14, P1791, DOI 10.1016/j.cub.2004.09.077; Carreno S, 2000, J BIOL CHEM, V275, P36223, DOI 10.1074/jbc.M003901200; Chaudhuri R, 2007, J VIROL, V81, P3877, DOI 10.1128/JVI.02725-06; Coleman SH, 2006, J VIROL, V80, P1837, DOI 10.1128/JVI.80.4.1837-1849.2006; Crump CM, 2001, EMBO J, V20, P2191, DOI 10.1093/emboj/20.9.2191; Crump CM, 2003, J VIROL, V77, P11105, DOI 10.1128/JVI.77.20.11105-11113.2003; Das SR, 2005, INDIAN J MED RES, V121, P315; Doray B, 2007, MOL BIOL CELL, V18, P1887, DOI 10.1091/mbc.E07-01-0012; Feliciangeli SF, 2006, J BIOL CHEM, V281, P16108, DOI 10.1074/jbc.M600760200; Foster JL, 2007, ADV PHARMACOL, V55, P389, DOI 10.1016/S1054-3589(07)55011-8; Greenberg ME, 1998, EMBO J, V17, P2777, DOI 10.1093/emboj/17.10.2777; Hinners I, 2003, EMBO REP, V4, P1182, DOI 10.1038/sj.embor.7400018; Hiyoshi M, 2008, BLOOD, V111, P243, DOI 10.1182/blood-2007-04-086017; Hung CH, 2007, CELL HOST MICROBE, V1, P121, DOI 10.1016/j.chom.2007.03.004; Kasper MR, 2003, J VIROL, V77, P3041, DOI 10.1128/JVI.77.5.3041-3049.2003; Keele BF, 2006, SCIENCE, V313, P523, DOI 10.1126/science.1126531; Knight ZA, 2006, CELL, V125, P733, DOI 10.1016/j.cell.2006.03.035; Kottgen M, 2005, EMBO J, V24, P705, DOI 10.1038/sj.emboj.7600566; Larsen JE, 2004, MOL BIOL CELL, V15, P323, DOI 10.1091/mbc.E03-08-0578; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; Lerner EC, 2002, NAT STRUCT BIOL, V9, P365, DOI 10.1038/nsb782; Lubben NB, 2007, MOL BIOL CELL, V18, P3351, DOI 10.1091/mbc.E07-03-0218; Madrid R, 2005, J BIOL CHEM, V280, P5032, DOI 10.1074/jbc.M401202200; Mangasarian A, 1999, J VIROL, V73, P1964, DOI 10.1128/JVI.73.3.1964-1973.1999; Mansouri M, 2006, BLOOD, V108, P1932, DOI 10.1182/blood-2005-11-4404; Marsh JW, 1999, ARCH BIOCHEM BIOPHYS, V365, P192, DOI 10.1006/abbi.1999.1208; Molloy SS, 1998, J CELL BIOL, V142, P1399, DOI 10.1083/jcb.142.6.1399; Moon KD, 2005, J BIOL CHEM, V280, P1543, DOI 10.1074/jbc.M407805200; Peterlin BM, 2003, NAT REV IMMUNOL, V3, P97, DOI 10.1038/nri998; Piguet V, 2000, NAT CELL BIOL, V2, P163, DOI 10.1038/35004038; Popoff V, 2007, J CELL SCI, V120, P2022, DOI 10.1242/jcs.003020; Renkema GH, 2000, FRONT BIOSCI-LANDMRK, V5, pD268, DOI 10.2741/Renkema; Roeth JF, 2004, J CELL BIOL, V167, P903, DOI 10.1083/jcb.200407031; Schermer B, 2005, EMBO J, V24, P4415, DOI 10.1038/sj.emboj.7600885; Scott GK, 2003, EMBO J, V22, P6234, DOI 10.1093/emboj/cdg596; Scott GK, 2006, EMBO J, V25, P4423, DOI 10.1038/sj.emboj.7601336; Seaman MNJ, 2004, J CELL BIOL, V165, P111, DOI 10.1083/jcb.200312034; Sieburth D, 2005, NATURE, V436, P510, DOI 10.1038/nature03809; Simmen T, 2005, EMBO J, V24, P717, DOI 10.1038/sj.emboj.7600559; Simmen T, 1999, MOL CELL BIOL, V19, P3136; Sol-Foulon N, 2007, EMBO J, V26, P516, DOI 10.1038/sj.emboj.7601509; Stevenson M, 2003, NAT MED, V9, P853, DOI 10.1038/nm0703-853; Stove V, 2003, BLOOD, V102, P2925, DOI 10.1182/blood-2003-03-0833; Stumptner-Cuvelette P, 2003, MOL BIOL CELL, V14, P4857, DOI 10.1091/mbc.E03-04-0211; Thoulouze MI, 2006, IMMUNITY, V24, P547, DOI 10.1016/j.immuni.2006.02.016; Trible RP, 2006, J BIOL CHEM, V281, P27029, DOI 10.1074/jbc.M601128200; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; Ward S, 2003, CHEM BIOL, V10, P207, DOI 10.1016/S1074-5521(03)00048-6; Zauli G, 1999, BLOOD, V93, P1000, DOI 10.1182/blood.V93.3.1000.403a12_1000_1010	58	62	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11772	11784		10.1074/jbc.M707572200	http://dx.doi.org/10.1074/jbc.M707572200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18296443	Green Published, hybrid			2022-12-25	WOS:000255067400077
J	Whiteson, KL; Rice, PA				Whiteson, Katrine L.; Rice, Phoebe A.			Binding and catalytic contributions to site recognition by Flp recombinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOLLIDAY JUNCTION COMPLEX; DNA-SEQUENCE RECOGNITION; MUTATIONAL ANALYSIS; INDIRECT READOUT; CRE RECOMBINASE; SPECIFICITY; EVOLUTION; PROTEIN; ENZYME; MECHANISMS	Flp catalyzes site-specific recombination in a highly sequence-specific manner despite making few direct contacts to the bases within its binding site. Sequence discrimination could take place in the binding and/or the catalytic steps. In this study, we independently measure the binding affinity and initial cleavage rate of Flp recombinase with similar to 20 designed alternate target DNA sequences. Our results show that Flp specificity is largely, although not entirely, imparted at the binding step and is the result of a combination of direct and indirect readout. The Flp binding site includes an A/T-rich region that displays a characteristically narrow minor groove. We find that many A --> T changes are tolerated at the binding step, whereas C or G substitutions tend to decrease binding affinity. The effects of the latter can be alleviated by replacing guanine with inosine, which removes the N2 amino group that protrudes into the minor groove. Some A --> T changes reduce binding affinity, due to clashing with nearby residues, reinforcing that specificity requires avoiding negative contacts as well as creating positive ones. A tracts, which can lead to unusually rigid DNA structure, are tolerated during the binding step when placed within the region where the minor groove is already narrow. However, most A tracts slow catalysis more than C or G substitutions. Understanding what kind of sequence variation is tolerated in the binding and catalytic steps helps us understand how the target DNA is recognized by Flp and will be useful in guiding the design of Flp variants with altered specificities.	[Whiteson, Katrine L.; Rice, Phoebe A.] Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	University of Chicago	Rice, PA (corresponding author), 929 E 57th St,GCIS W136, Chicago, IL 60637 USA.	price@uchicago.edu		Whiteson, Katrine/0000-0002-5423-6014	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058827] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM058827] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akopian A, 2003, P NATL ACAD SCI USA, V100, P8688, DOI 10.1073/pnas.1533177100; Barbic A, 2003, P NATL ACAD SCI USA, V100, P2369, DOI 10.1073/pnas.0437877100; Buchholz F, 2001, NAT BIOTECHNOL, V19, P1047, DOI 10.1038/nbt1101-1047; Buchholz F, 1998, NAT BIOTECHNOL, V16, P657, DOI 10.1038/nbt0798-657; Chen Y, 2000, MOL CELL, V6, P885, DOI 10.1016/S1097-2765(05)00088-2; Chen Y, 2003, J BIOL CHEM, V278, P24800, DOI 10.1074/jbc.M300853200; Conway AB, 2003, J MOL BIOL, V326, P425, DOI 10.1016/S0022-2836(02)01370-0; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Fersht A., 1999, STRUCTURE MECH PROTE; FRATINI AV, 1982, J BIOL CHEM, V257, P4686; Goldhaber-Gordon I, 2003, BIOCHEMISTRY-US, V42, P14633, DOI 10.1021/bi035360o; Gordley RM, 2007, J MOL BIOL, V367, P802, DOI 10.1016/j.jmb.2007.01.017; GORIN AA, 1995, J MOL BIOL, V247, P34, DOI 10.1006/jmbi.1994.0120; Grindley NDF, 2006, ANNU REV BIOCHEM, V75, P567, DOI 10.1146/annurev.biochem.73.011303.073908; Kraut DA, 2003, ANNU REV BIOCHEM, V72, P517, DOI 10.1146/annurev.biochem.72.121801.161617; Krohn KA, 2003, NUCL MED BIOL, V30, P819, DOI 10.1016/S0969-8051(03)00132-X; Kurpiewski MR, 2004, STRUCTURE, V12, P1775, DOI 10.1016/j.str.2004.07.016; Lu XJ, 2003, NUCLEIC ACIDS RES, V31, P5108, DOI 10.1093/nar/gkg680; Lynch TW, 2003, J MOL BIOL, V330, P493, DOI 10.1016/S0022-2836(03)00529-1; Mauro SA, 2003, J BIOL CHEM, V278, P12955, DOI 10.1074/jbc.M212667200; MUNSON PJ, 1988, J RECEPTOR RES, V8, P533, DOI 10.3109/10799898809049010; Pabo CO, 2001, ANNU REV BIOCHEM, V70, P313, DOI 10.1146/annurev.biochem.70.1.313; Patikoglou GA, 1999, GENE DEV, V13, P3217, DOI 10.1101/gad.13.24.3217; Santoro SW, 2002, P NATL ACAD SCI USA, V99, P4185, DOI 10.1073/pnas.022039799; SENECOFF JF, 1988, J MOL BIOL, V201, P405, DOI 10.1016/0022-2836(88)90147-7; Swinger KK, 2007, J MOL BIOL, V365, P1005, DOI 10.1016/j.jmb.2006.10.024; Voziyanov Y, 2003, J MOL BIOL, V326, P65, DOI 10.1016/S0022-2836(02)01364-5; Voziyanov Y, 2002, NUCLEIC ACIDS RES, V30, P1656, DOI 10.1093/nar/30.7.1656; Wenz C, 1996, J BIOL CHEM, V271, P5565, DOI 10.1074/jbc.271.10.5565	29	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11414	11423		10.1074/jbc.M800106200	http://dx.doi.org/10.1074/jbc.M800106200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18276592	hybrid, Green Published			2022-12-25	WOS:000255067400039
J	Gusdon, AM; Votyakova, TV; Mathews, CE				Gusdon, Aaron M.; Votyakova, Tatyana V.; Mathews, Clayton E.			Mt-Nd2(a) suppresses reactive oxygen species production by mitochondrial complexes I and III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; HYDROGEN-PEROXIDE; DNA MUTATIONS; SUPEROXIDE-PRODUCTION; ANTIOXIDANT DEFENSE; ELECTRON-TRANSPORT; A/C POLYMORPHISM; HEART; NADH; GENERATION	Reactive oxygen species (ROS) play a critical role in the pathogenesis of human diseases. A cytosine to adenine transversion in the mitochondrially encoded NADH dehydrogenase subunit 2 (mt-ND2, human; mt-Nd2, mouse) gene results in resistance against type 1 diabetes and several additional ROS-associated conditions. Our previous studies have demonstrated that the adenine-containing allele (mt-Nd2(a)) is also strongly associated with resistance against type 1 diabetes in mice. In this report we have confirmed that the cytosine-containing allele (mt-Nd2(c)) results in elevated mitochondrial ROS production. Using inhibitors of the electron transport chain, we show that when in combination with nuclear genes from the alloxan-resistant (ALR) strain, mt-Nd2c increases ROS from complex III. Furthermore, by using alamethicin-permeabilized mitochondria, we measured a significant increase in electron transport chain-dependent ROS production from all mt-Nd2(c)-encoding strains including ALR. mt(NOD), non-obese diabetic (NOD), and C57BL/6 (B6). Studies employing alamethicin and inhibitors were able to again localize the heightened ROS production in ALR. mtNOD to complex III and identified complex I as the site of elevated ROS production from NOD and B6 mitochondria. Using submitochondrial particles, we confirmed that in the context of the NOD or B6 nuclear genomes, mt-Nd2(c) elevates complex I-specific ROS production. In all assays mitochondria from mt-Nd2(a)-encoding strains exhibited low ROS production. Our data suggest that lowering overall mitochondrial ROS production is a key mechanism of disease protection provided by mt-Nd2(a).	[Gusdon, Aaron M.; Mathews, Clayton E.] Univ Florida, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA; [Gusdon, Aaron M.; Votyakova, Tatyana V.; Mathews, Clayton E.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15213 USA	State University System of Florida; University of Florida; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Mathews, CE (corresponding author), 1600 SW Archer Rd,POB 100275, Gainesville, FL 32610 USA.	clayton.mathews@pathology.ufl.edu			NIAID NIH HHS [U19 AI056374] Funding Source: Medline; NIDDK NIH HHS [R01 DK074656, R01 DK74656] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI056374] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK074656] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMED I, 1992, FEBS LETT, V300, P275, DOI 10.1016/0014-5793(92)80862-B; Ardanaz N, 2006, EXP BIOL MED, V231, P237; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Bayir H, 2006, BBA-BIOENERGETICS, V1757, P648, DOI 10.1016/j.bbabio.2006.03.002; Boekema EJ, 2007, J BIOL CHEM, V282, P1, DOI 10.1074/jbc.R600031200; Briehl M M, 1995, Cell Death Differ, V2, P41; Briehl MM, 1996, CELL DEATH DIFFER, V3, P63; Butterfield DA, 1999, LIFE SCI, V65, P1883, DOI 10.1016/S0024-3205(99)00442-7; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; Chatterjee A, 2006, ONCOGENE, V25, P4663, DOI 10.1038/sj.onc.1209604; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; Dudkina NV, 2005, P NATL ACAD SCI USA, V102, P3225, DOI 10.1073/pnas.0408870102; Forster MJ, 1996, P NATL ACAD SCI USA, V93, P4765, DOI 10.1073/pnas.93.10.4765; Genova MW, 2003, EXP BIOL MED, V228, P506, DOI 10.1177/15353702-0322805-14; GONDAL JA, 1985, J BIOL CHEM, V260, P2690; Grivennikova VG, 2006, BBA-BIOENERGETICS, V1757, P553, DOI 10.1016/j.bbabio.2006.03.013; Gusdon AM, 2007, J BIOL CHEM, V282, P5171, DOI 10.1074/jbc.M609367200; Herrero A, 2000, J BIOENERG BIOMEMBR, V32, P609, DOI 10.1023/A:1005626712319; Kokaze A, 2004, J HUM HYPERTENS, V18, P41, DOI 10.1038/sj.jhh.1001632; Kokaze A, 2001, HUM GENET, V109, P521, DOI 10.1007/s004390100602; Krishnan KJ, 2007, ANN NY ACAD SCI, V1100, P227, DOI 10.1196/annals.1395.024; Kudin AP, 2004, J BIOL CHEM, V279, P4127, DOI 10.1074/jbc.M310341200; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Kussmaul L, 2006, P NATL ACAD SCI USA, V103, P7607, DOI 10.1073/pnas.0510977103; Kwong LK, 1998, ARCH BIOCHEM BIOPHYS, V350, P118, DOI 10.1006/abbi.1997.0489; Lee C., 1967, METHOD ENZYMOL, V10, P543; Liochev SI, 2002, FREE RADICAL BIO MED, V33, P137, DOI 10.1016/S0891-5849(02)00864-X; Mathews CE, 2005, DIABETOLOGIA, V48, P261, DOI 10.1007/s00125-004-1644-8; Mathews CE, 2003, IMMUNOGENETICS, V55, P491, DOI 10.1007/s00251-003-0603-8; Matsunaga H, 2001, DIABETES CARE, V24, P500, DOI 10.2337/diacare.24.3.500; Moreno-Loshuertos R, 2006, NAT GENET, V38, P1261, DOI 10.1038/ng1897; Mukae S, 2003, CIRC J, V67, P16, DOI 10.1253/circj.67.16; Muller FL, 2004, J BIOL CHEM, V279, P49064, DOI 10.1074/jbc.M407715200; NICOLLE MM, 2001, NEUROSCIENCE, V12, P345; Ohta S, 2006, ONCOGENE, V25, P4768, DOI 10.1038/sj.onc.1209602; Okun JG, 1999, J BIOL CHEM, V274, P2625, DOI 10.1074/jbc.274.5.2625; Pandya Dipak P., 2001, Comprehensive Therapy, V27, P284, DOI 10.1007/s12019-001-0026-0; Panov A, 2007, AM J PHYSIOL-CELL PH, V292, pC708, DOI 10.1152/ajpcell.00202.2006; Peterson JR, 2006, CURR HYPERTENS REP, V8, P232, DOI 10.1007/s11906-006-0056-1; Reyes-Toso CF, 2006, AMINO ACIDS, V31, P299, DOI 10.1007/s00726-005-0280-z; Schonfeld P, 2007, BBA-BIOENERGETICS, V1767, P1032, DOI 10.1016/j.bbabio.2007.04.005; Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Singhal SK, 2006, INDIAN J ENG MATER S, V13, P129; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; Steinberg D, 2002, CIRCULATION, V105, P2107, DOI 10.1161/01.CIR.0000014762.06201.06; Stroh A, 2004, J BIOL CHEM, V279, P5000, DOI 10.1074/jbc.M309505200; Surekha R. H., 2007, SMJ Singapore Medical Journal, V48, P137; Takagi K, 2004, ATHEROSCLEROSIS, V175, P281, DOI 10.1016/j.atherosclerosis.2004.03.008; Tanaka M, 2000, MECH AGEING DEV, V116, P65, DOI 10.1016/S0047-6374(00)00149-4; Tong JJY, 2007, NAT GENET, V39, P476, DOI 10.1038/ng2004; Tretter L, 2004, NEUROCHEM RES, V29, P569, DOI 10.1023/B:NERE.0000014827.94562.4b; Uchigata Y, 2002, DIABETES CARE, V25, P2106, DOI 10.2337/diacare.25.11.2106; Venardos KM, 2007, CURR MED CHEM, V14, P1539, DOI 10.2174/092986707780831078; Votyakova TV, 2004, ARCH BIOCHEM BIOPHYS, V431, P138, DOI 10.1016/j.abb.2004.07.025; Votyakova TV, 2005, J NEUROCHEM, V93, P526, DOI 10.1111/j.1471-4159.2005.03042.x; Votyakova TV, 2001, J NEUROCHEM, V79, P266, DOI 10.1046/j.1471-4159.2001.00548.x; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Zhang HF, 2007, AM J PATHOL, V170, P1108, DOI 10.2353/ajpath.2007.060960; Zimmerman MC, 2002, CIRC RES, V91, P1038, DOI 10.1161/01.RES.0000043501.47934.FA	62	41	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10690	10697		10.1074/jbc.M708801200	http://dx.doi.org/10.1074/jbc.M708801200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18281288	hybrid, Green Published			2022-12-25	WOS:000254894700051
J	Kourimate, S; Le May, C; Langhi, C; Jarnoux, AL; Ouguerram, K; Zaier, Y; Nguyen, P; Krempf, M; Cariou, B; Costet, P				Kourimate, Sanae; Le May, Cedric; Langhi, Cedric; Jarnoux, Anne Laure; Ouguerram, Khadija; Zaier, Yassine; Nguyen, Patrick; Krempf, Michel; Cariou, Bertrand; Costet, Philippe			Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; CORONARY-HEART-DISEASE; PROLIFERATOR-ACTIVATED RECEPTORS; COMBINED HYPERLIPIDEMIA; SECRETED PCSK9; FAMILIAL HYPERCHOLESTEROLEMIA; MICRONIZED FENOFIBRATE; DIABETES-MELLITUS; PLUS FENOFIBRATE; CONTROLLED-TRIAL	Proprotein convertase subtilisin/kexin type 9 (PCSK9) is associated with familial autosomal dominant hypercholesterolemia and is a natural inhibitor of the LDL receptor (LDLr). PCSK9 is degraded by other proprotein convertases: PC5/6A and furin. Both PCSK9 and the LDLr are up-regulated by the hypocholesterolemic statins. Thus, inhibitors or repressors of PCSK9 should amplify their beneficial effects. In the present study, we showed that PPAR alpha activation counteracts PCSK9 induction by statins by repressing PCSK9 promoter activity and by increasing PC5/6A and furin expression. Quantification of mRNA and protein levels showed that various fibrates decreased PCSK9 and increased PC5/6A and furin expression. Fenofibric acid (FA) reduced PCSK9 protein content in immortalized human hepatocytes (IHH) as well as its cellular secretion. FA suppressed PCSK9 induction by statins or by the liver X receptor agonist TO901317. PCSK9 repression is occurring at the promoter level. We showed that PC5/6A and furin fibrate-mediated up-regulation is PPAR alpha-dependent. As a functional test, we observed that FA increased by 30% the effect of pravastatin on the LDLr activity in vitro. In conclusion, fibrates simultaneously decreased PCSK9 expression while increasing PC5/6A and furin expression, indicating a broad action of PPAR alpha activation in proprotein convertase-mediated lipid homeostasis. Moreover, this study validates the functional relevance of a combined therapy associating PCSK9 repressors and statins.	[Kourimate, Sanae; Le May, Cedric; Langhi, Cedric; Ouguerram, Khadija; Zaier, Yassine; Krempf, Michel; Cariou, Bertrand; Costet, Philippe] INSERM, CHU Hotel Dieu, U915, F-44000 Nantes, France; [Jarnoux, Anne Laure] INSERM, U539, F-44000 Nantes, France; [Kourimate, Sanae; Costet, Philippe] CRNH Nantes, F-44000 Nantes, France; [Zaier, Yassine; Krempf, Michel; Cariou, Bertrand] CHU Nantes, Inst Thorax, Clin Endocrinol & Nutr, F-44000 Nantes, France; [Nguyen, Patrick] Ecole Natl Vet Nantes, F-44000 Nantes, France; [Ouguerram, Khadija; Krempf, Michel] Univ Nantes, Inst Thorax, Fac Med, F-44000 Nantes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Ecole Nationale Veterinaire, Agroalimentaire et de l'Alimentation Nantes-Atlantique; Nantes Universite; CHU de Nantes	Costet, P (corresponding author), INSERM, CHU Hotel Dieu, U915, 3ENORD,9 Quai Moncousu, F-44000 Nantes, France.	philippe.costet@univ-nantes.fr	Le May, cedric/D-2691-2009; costet, philippe/A-5314-2010	Le May, cedric/0000-0002-7554-792X; Langhi, Cedric/0000-0002-7732-3882; Cariou, Bertrand/0000-0002-1580-8040; Krempf, Michel/0000-0002-4353-9511				Abifadel M, 2003, NAT GENET, V34, P154, DOI 10.1038/ng1161; Ballantyne CM, 2005, AM J CARDIOL, V96, p14K, DOI 10.1016/j.amjcard.2005.08.003; Benjannet S, 2004, J BIOL CHEM, V279, P48865, DOI 10.1074/jbc.M409699200; Benjannet S, 2006, J BIOL CHEM, V281, P30561, DOI 10.1074/jbc.M606495200; Berge KE, 2006, ARTERIOSCL THROM VAS, V26, P1094, DOI 10.1161/01.ATV.0000204337.81286.1c; Brown JD, 2007, CIRCULATION, V115, P518, DOI 10.1161/CIRCULATIONAHA.104.475673; Cohen J, 2005, NAT GENET, V37, P328, DOI 10.1038/ng0305-328c; Cohen JC, 2006, NEW ENGL J MED, V354, P1264, DOI 10.1056/NEJMoa054013; Costet P, 2006, J BIOL CHEM, V281, P6211, DOI 10.1074/jbc.M508582200; Cunningham D, 2007, NAT STRUCT MOL BIOL, V14, P413, DOI 10.1038/nsmb1235; Derosa G, 2004, CLIN THER, V26, P1599, DOI 10.1016/j.clinthera.2004.10.008; Dubuc G, 2004, ARTERIOSCL THROM VAS, V24, P1454, DOI 10.1161/01.ATV.0000134621.14315.43; Essalmani R, 2006, MOL CELL BIOL, V26, P354, DOI 10.1128/MCB.26.1.354-361.2006; Farnier M, 2000, AM J CARDIOL, V85, P53, DOI 10.1016/S0002-9149(99)00606-2; Fasano T, 2007, ARTERIOSCL THROM VAS, V27, P677, DOI 10.1161/01.ATV.0000255311.26383.2f; Fisher TS, 2007, J BIOL CHEM, V282, P20502, DOI 10.1074/jbc.M701634200; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; Geyeregger R, 2006, CELL MOL LIFE SCI, V63, P524, DOI 10.1007/s00018-005-5398-3; Goto D, 1997, ARTERIOSCL THROM VAS, V17, P2707, DOI 10.1161/01.ATV.17.11.2707; Graham MJ, 2007, J LIPID RES, V48, P763, DOI 10.1194/jlr.C600025-JLR200; Grundy SM, 2005, AM J CARDIOL, V95, P462, DOI 10.1016/j.amjcard.2004.10.012; Guerin M, 1996, ARTERIOSCL THROM VAS, V16, P763, DOI 10.1161/01.ATV.16.6.763; Horton JD, 2007, TRENDS BIOCHEM SCI, V32, P71, DOI 10.1016/j.tibs.2006.12.008; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Ishimoto K, 2006, FEBS LETT, V580, P4929, DOI 10.1016/j.febslet.2006.08.010; Jin WJ, 2007, CELL METAB, V6, P129, DOI 10.1016/j.cmet.2007.07.009; Keech A, 2005, LANCET, V366, P1849, DOI 10.1016/S0140-6736(05)67667-2; Konig B, 2007, BIOCHEM PHARMACOL, V73, P574, DOI 10.1016/j.bcp.2006.10.027; Krempf M, 2000, DIABETES METAB, V26, P184; Lagace TA, 2006, J CLIN INVEST, V116, P2995, DOI 10.1172/JCI29383; Lalanne F, 2005, J LIPID RES, V46, P1312, DOI 10.1194/jlr.M400396-JLR200; Lambert G, 2006, TRENDS ENDOCRIN MET, V17, P79, DOI 10.1016/j.tem.2006.02.001; Lambert G, 2006, ENDOCRINOLOGY, V147, P4985, DOI 10.1210/en.2006-0098; Mascaro C, 1998, J BIOL CHEM, V273, P8560, DOI 10.1074/jbc.273.15.8560; Maxwell KN, 2005, P NATL ACAD SCI USA, V102, P2069, DOI 10.1073/pnas.0409736102; Maxwell KN, 2004, P NATL ACAD SCI USA, V101, P7100, DOI 10.1073/pnas.0402133101; Maxwell KN, 2003, J LIPID RES, V44, P2109, DOI 10.1194/jlr.M300203-JLR200; McNutt MC, 2007, J BIOL CHEM, V282, P20799, DOI 10.1074/jbc.C700095200; Naoumova RP, 2005, ARTERIOSCL THROM VAS, V25, P2654, DOI 10.1161/01.ATV.0000190668.94752.ab; Nassoury N, 2007, TRAFFIC, V8, P718, DOI 10.1111/j.1600-0854.2007.00562.x; Park SW, 2004, J BIOL CHEM, V279, P50630, DOI 10.1074/jbc.M410077200; Paumelle R, 2007, CIRC RES, V100, P1394, DOI 10.1161/01.RES.0000269334.42814.d2; Piper DE, 2007, STRUCTURE, V15, P545, DOI 10.1016/j.str.2007.04.004; Qian YW, 2007, J LIPID RES, V48, P1488, DOI 10.1194/jlr.M700071-JLR200; Rashid S, 2005, P NATL ACAD SCI USA, V102, P5374, DOI 10.1073/pnas.0501652102; Schippers IJ, 1997, CELL BIOL TOXICOL, V13, P375, DOI 10.1023/A:1007404028681; Seidah NG, 2007, J MOL MED, V85, P685, DOI 10.1007/s00109-007-0172-7; Seidah NG, 2003, P NATL ACAD SCI USA, V100, P928, DOI 10.1073/pnas.0335507100; Steinmetz A, 1996, J CARDIOVASC PHARM, V27, P563, DOI 10.1097/00005344-199604000-00016; Yano M, 2007, CIRC RES, V100, P1442, DOI 10.1161/01.RES.0000268411.49545.9c; Zhang DW, 2007, J BIOL CHEM, V282, P18602, DOI 10.1074/jbc.M702027200; Zhao ZZ, 2006, AM J HUM GENET, V79, P514, DOI 10.1086/507488	52	81	107	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9666	9673		10.1074/jbc.M705831200	http://dx.doi.org/10.1074/jbc.M705831200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18245819	hybrid			2022-12-25	WOS:000254671600021
J	Hoogeboom, D; Essers, MAG; Polderman, PE; Voets, E; Smits, LMM; Burgering, BMT				Hoogeboom, Diana; Essers, Marieke A. G.; Polderman, Paulien E.; Voets, Erik; Smits, Lydia M. M.; Burgering, Boudewijn M. Th.			Interaction of FOXO with beta-catenin inhibits beta-Catenin/T cell factor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTORS; WNT SIGNALING PATHWAY; PROTEIN-KINASE-B; F-BOX PROTEIN; OXIDATIVE STRESS; FUNCTIONAL INTERACTION; LIFE-SPAN; DROSOPHILA; WINGLESS; LEF-1	Wingless ( Wnt) signaling regulates many aspects of development and tissue homeostasis, and aberrant Wnt signaling can lead to cancer. Upon a Wnt signal beta-catenin degradation is halted and consequently the level of beta-catenin in the cytoplasm increases. This allows entry of beta-catenin into the nucleus where it can regulate gene transcription by direct binding to members of the lymphoid enhancer factor/T cell factor ( TCF) family of transcription factors. Recently, we identified Forkhead box-O ( FOXO) transcription factors as novel interaction partners of beta-catenin ( Essers, M. A., de Vries-Smits, L. M., Barker, N., Polderman, P. E., Burgering, B. M., and Korswagen, H. C. ( 2005) Science 308, 1181-1184). Here we show that the beta-catenin binding to FOXO serves a dual effect. beta-catenin, through binding, enhances FOXO transcriptional activity. In addition, FOXO competes with TCF for interaction with beta-catenin, thereby inhibiting TCF transcriptional activity. Reduced binding between TCF and beta-catenin is observed after FOXO overexpression and cellular oxidative stress, which simultaneously increases binding between beta-catenin and FOXO. Furthermore, small interfering RNA-mediated knock down of FOXO reverts loss of beta-catenin binding to TCF after cellular oxidative stress. Taken together, these results provide evidence for a cross-talk mechanism between FOXO and TCF signaling in which beta-catenin plays a central regulatory role.	[Hoogeboom, Diana; Essers, Marieke A. G.; Polderman, Paulien E.; Voets, Erik; Smits, Lydia M. M.; Burgering, Boudewijn M. Th.] Univ Utrecht, Med Ctr, Ctr Biomed Genet, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; [Essers, Marieke A. G.] Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland	Utrecht University; Swiss Institute Experimental Cancer Research	Burgering, BMT (corresponding author), Univ Utrecht, Med Ctr, Ctr Biomed Genet, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands.	b.m.t.burgering@umcutrecht.nl	Essers, Marieke A.G./B-7758-2017	Essers, Marieke A.G./0000-0003-3117-1809				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bois PRJ, 2003, EMBO J, V22, P1147, DOI 10.1093/emboj/cdg116; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Burgering BMT, 2003, J LEUKOCYTE BIOL, V73, P689, DOI 10.1189/jlb.1202629; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; Fukumoto S, 2001, J BIOL CHEM, V276, P17479, DOI 10.1074/jbc.C000880200; Funato Y, 2006, NAT CELL BIOL, V8, P501, DOI 10.1038/ncb1405; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Harwood AJ, 2001, CELL, V105, P821, DOI 10.1016/S0092-8674(01)00412-3; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Kaidi A, 2007, NAT CELL BIOL, V9, P210, DOI 10.1038/ncb1534; Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Nateri AS, 2005, NATURE, V437, P281, DOI 10.1038/nature03914; Oh SW, 2005, P NATL ACAD SCI USA, V102, P4494, DOI 10.1073/pnas.0500749102; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; Polakis P, 2000, GENE DEV, V14, P1837; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Shin SY, 2006, CELL SIGNAL, V18, P601, DOI 10.1016/j.cellsig.2005.06.001; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Vermeulen S, 1996, PATHOL RES PRACT, V192, P694, DOI 10.1016/S0344-0338(96)80091-4; Wang MC, 2003, DEV CELL, V5, P811, DOI 10.1016/S1534-5807(03)00323-X; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087	41	220	226	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9224	9230		10.1074/jbc.M706638200	http://dx.doi.org/10.1074/jbc.M706638200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18250171	hybrid			2022-12-25	WOS:000254465800052
J	Tabata, S; Kuroki, K; Wang, J; Kajikawa, M; Shiratori, I; Kohda, D; Arase, H; Maenaka, K				Tabata, Shigekazu; Kuroki, Kimiko; Wang, Jing; Kajikawa, Mizuho; Shiratori, Ikuo; Kohda, Daisuke; Arase, Hisashi; Maenaka, Katsumi			Biophysical characterization of O-glycosylated CD99 recognition by paired ig-like type 2 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-RECEPTORS; INHIBITORY RECEPTOR; SELECTIN BINDING; KINETIC-ANALYSIS; LOW-AFFINITY; PEPTIDE-MHC; THERMODYNAMICS; COMPLEX; LIGAND; CYTOMEGALOVIRUS	Paired Ig-like type 2 receptors ( PILRs) are one of the paired receptor families, which consist of two functionally opposite members, inhibitory ( PILR alpha) and activating ( PILR beta) receptors. PILRs are widely expressed in immune cells and recognize the sialylated O-glycosylated ligand CD99, which is expressed on activated T cells, to regulate immune responses. To date, their biophysical properties have not yet been examined. Here we report the affinity, kinetic, and thermodynamic analyses of PILR-CD99 interactions using surface plasmon resonance ( SPR) together with site-directed mutagenesis. The SPR analysis clearly demonstrated that inhibitory PILR alpha can bind to CD99 with low affinity ( K-d similar to 2.2 mu M), but activating PILR beta binds with similar to 40 times lower affinity ( K-d similar to 85 mu M). In addition to our previous mutagenesis study ( Wang, J., Shiratori, I., Saito, T., Lanier, L. L., and Arase, H. ( 2008) J. Immunol. 180, 1686 - 1693), the SPR analysis showed that PILR alpha can bind to each Ala mutant of the two CD99 O-glycosylated sites ( Thr-45 and Thr-50) with similar binding affinity to wild-type CD99. This indicated that both residues act as independent and equivalent PILR alpha binding sites, consistent with the highly flexible structure of CD99. On the other hand, it is further confirmed that PILR beta can bind the T50A mutant, but not the T45A mutant, indicating a recognition difference between PILR alpha and PILR beta. Kinetic studies demonstrated that the PILR-CD99 interactions show fast dissociation rates, typical of cell-cell recognition receptors. Thermodynamic analyses revealed that the PILR alpha-CD99 interaction is enthalpically driven with a large entropy loss (-T Delta S = 8.9 kcal.mol(-1)), suggesting the reduction of flexibility upon complex formation. This is in contrast to the entropically driven binding of selectins to sugar-modified ligands involved in leukocyte rolling and infiltration, which may reflect their functional differences.	[Tabata, Shigekazu; Kuroki, Kimiko; Kajikawa, Mizuho; Kohda, Daisuke; Maenaka, Katsumi] Kyushu Univ, Div Struct Biol, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan; [Wang, Jing; Shiratori, Ikuo; Arase, Hisashi] Osaka Univ, Dept Immunochem, Res Inst Microbial Dis, Suita, Osaka 5650871, Japan; [Arase, Hisashi] Osaka Univ, World Premier Int Immunol, Frontier Res Ctr, Suita, Osaka 5650871, Japan; [Arase, Hisashi] Japan Sci & Technol Agcy, Solut Oriented Res Sci & Technol, Kawaguchi, Saitama 3320012, Japan	Kyushu University; Osaka University; Osaka University; Japan Science & Technology Agency (JST)	Maenaka, K (corresponding author), Kyushu Univ, Div Struct Biol, Med Inst Bioregulat, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	kmaenaka@bioreg.kyushu-u.ac.jp	Kohda, Daisuke/I-4990-2019; Arase, Hisashi/C-8442-2009; Kuroki, Kimiko/F-6906-2012	Kohda, Daisuke/0000-0001-8234-3776; Arase, Hisashi/0000-0002-1153-3166; Shiratori, Ikuo/0000-0003-3713-4910; Wang, Jing/0000-0001-8758-1693				Adams EJ, 2007, P NATL ACAD SCI USA, V104, P10128, DOI 10.1073/pnas.0703735104; Anikeeva N, 2003, BIOCHEMISTRY-US, V42, P4709, DOI 10.1021/bi026864+; Arase H, 2002, MICROBES INFECT, V4, P1505, DOI 10.1016/S1286-4579(02)00033-3; Arase H, 2002, SCIENCE, V296, P1323, DOI 10.1126/science.1070884; Bakker TR, 2002, EUR J IMMUNOL, V32, P1924, DOI 10.1002/1521-4141(200207)32:7<1924::AID-IMMU1924>3.0.CO;2-N; Boniface JJ, 1999, P NATL ACAD SCI USA, V96, P11446, DOI 10.1073/pnas.96.20.11446; Chapman TL, 1999, IMMUNITY, V11, P603, DOI 10.1016/S1074-7613(00)80135-1; Dam TK, 2002, CHEM REV, V102, P387, DOI 10.1021/cr000401x; Davis-Harrison RL, 2005, J MOL BIOL, V346, P533, DOI 10.1016/j.jmb.2004.11.063; Diefenbach A, 2003, CURR OPIN IMMUNOL, V15, P37, DOI 10.1016/S0952-7915(02)00007-9; Fournier N, 2000, J IMMUNOL, V165, P1197, DOI 10.4049/jimmunol.165.3.1197; Gao GF, 2000, J BIOL CHEM, V275, P15232, DOI 10.1074/jbc.275.20.15232; Garcia KC, 2001, P NATL ACAD SCI USA, V98, P6818, DOI 10.1073/pnas.111161198; Lanier LL, 2001, NAT IMMUNOL, V2, P23, DOI 10.1038/83130; Lee JK, 2004, J EXP MED, V200, P1455, DOI 10.1084/jem.20041251; Maenaka K, 1999, J BIOL CHEM, V274, P28329, DOI 10.1074/jbc.274.40.28329; Maenaka K, 2001, J BIOL CHEM, V276, P44898, DOI 10.1074/jbc.M106819200; May AP, 1998, MOL CELL, V1, P719, DOI 10.1016/S1097-2765(00)80071-4; Mehta P, 1998, J BIOL CHEM, V273, P32506, DOI 10.1074/jbc.273.49.32506; Moretta A, 2001, ANNU REV IMMUNOL, V19, P197, DOI 10.1146/annurev.immunol.19.1.197; Mousseau DD, 2000, J BIOL CHEM, V275, P4467, DOI 10.1074/jbc.275.6.4467; Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026; Nicholson MW, 1998, J BIOL CHEM, V273, P763, DOI 10.1074/jbc.273.2.763; O'Callaghan CA, 2001, IMMUNITY, V15, P201, DOI 10.1016/S1074-7613(01)00187-X; Shiratori I, 2004, J EXP MED, V199, P525, DOI 10.1084/jem.20031885; Smith HRC, 2001, IMMUNOL REV, V181, P115, DOI 10.1034/j.1600-065X.2001.1810109.x; Stites WE, 1997, CHEM REV, V97, P1233, DOI 10.1021/cr960387h; Vales-Gomez M, 2000, HUM IMMUNOL, V61, P28, DOI 10.1016/S0198-8859(99)00159-7; vanderMerwe PA, 1997, J EXP MED, V185, P393, DOI 10.1084/jem.185.3.393; Wang J, 2008, J IMMUNOL, V180, P1686, DOI 10.4049/jimmunol.180.3.1686; Wild MK, 2001, J BIOL CHEM, V276, P31602, DOI 10.1074/jbc.M104844200; Willcox BE, 1999, IMMUNITY, V10, P357, DOI 10.1016/S1074-7613(00)80035-7	32	26	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					8893	8901		10.1074/jbc.M709793200	http://dx.doi.org/10.1074/jbc.M709793200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18234675	hybrid			2022-12-25	WOS:000254465800017
J	Herbeck, JT; Gottlieb, GS; Li, XH; Hu, Z; Detels, R; Phair, J; Rinaldo, C; Jacobson, LP; Margolick, JB; Mullins, JI				Herbeck, Joshua T.; Gottlieb, Geoffrey S.; Li, Xiuhong; Hu, Zheng; Detels, Roger; Phair, John; Rinaldo, Charles; Jacobson, Lisa P.; Margolick, Joseph B.; Mullins, James I.			Lack of Evidence for Changing Virulence of HIV-1 in North America	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CD4 CELL COUNTS; MULTICENTER AIDS COHORT; REPLICATIVE FITNESS; TEMPORAL TRENDS; NATURAL-HISTORY; ESCAPE MUTATION; VIRAL LOAD; SEROCONVERSION; INFECTION	Background. Several long-term cohort studies and in-vitro fitness assays have resulted in inconsistent reports on changes in HIV-1 virulence, including reports of decreasing, stable, and increasing virulence over the course of the AIDS pandemic. We tested the hypothesis of changing HIV-1 virulence by examining trends in prognostic clinical markers of disease progression from 1984 to 2005 among nearly 400 antiretroviral-naive participants in the United States Multicenter AIDS Cohort Study (MACS), a longitudinal study of HIV infection in men who have sex with men (MSM). Methodology/Principal Findings. Because clinical AIDS endpoints could not be used (due to antiretroviral therapies and prophylaxis), three prognostic markers of disease progression were used as proxies for HIV-1 virulence: plasma viral RNA load and CD4+ T cell count at "set point'' (between similar to 9 and similar to 15 months after seroconversion), and rate of CD4 cell decline within three years after seroconversion. We performed multivariate analyses of the association between these markers and seroconversion year, with covariates including MACS site, race/ethnic group, seroconversion age, and CCR5 Delta 32 status. No statistically significant association was found between year of seroconversion and "set point'' plasma viral load (at similar to 9 months after seroconversion: slope=-0.004 log(10) copies/mL/year, p=0.76; at similar to 15 months: slope=-0.005 log(10) copies/mL/year, p=0.71), CD4 cell count after seroconversion (at similar to 9 months: slope=-0.112 cells/mL/year, p=0.22; at similar to 15 months: slope=-0.047 cells/mL/year, p=0.64), or rate of CD4 cell decline over the first three years after seroconversion (slope=-0.010 cells/mu l/yr(2), p=0.88). Conclusions/Significance. The lack of significant trends from 1984 to 2005 in these prognostic markers of HIV disease progression suggests no major change in HIV-1 virulence over the AIDS pandemic in MSM in the US.	[Herbeck, Joshua T.; Gottlieb, Geoffrey S.; Mullins, James I.] Univ Washington, Sch Med, Seattle, WA 98195 USA; [Li, Xiuhong; Hu, Zheng; Jacobson, Lisa P.; Margolick, Joseph B.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Detels, Roger] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA USA; [Phair, John] Northwestern Univ, Med Sch, Chicago, IL USA; [Rinaldo, Charles] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA	University of Washington; University of Washington Seattle; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of California System; University of California Los Angeles; Northwestern University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Gottlieb, GS (corresponding author), Univ Washington, Sch Med, Seattle, WA 98195 USA.	gottlieb@u.washington.edu		Jacobson, Lisa P./0000-0003-1722-6826; Gottlieb, Geoffrey/0000-0002-5749-481X	NIH [T32 AI07140]; University of Washington CFAR [STD/HIV Training Grant]; National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Heart, Lung and Blood Institute;  [R01 AI058894];  [R37 AI47734];  [P01 AI57005];  [P30 AI27757];  [K08 AI049755];  [UO1-AI-35043];  [UO1-AI-37984];  [UO1-AI-35039];  [UO1-AI-35040];  [UO1-AI-37613];  [UO1-AI-35041]; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI049755, R01AI058894, R37AI047734, U01AI037984, P30AI027757, U01AI035040, T32AI007140, P01AI057005, U01AI035039, U01AI035043, U01AI035042, U01AI037613, U01AI035041] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Washington CFAR; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Heart, Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); ; ; ; ; ; ; ; ; ; ; ; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Funding for this study was provided to JIM by R01 AI058894, R37 AI47734, P01 AI57005, to JTH and JIM by P30 AI27757, to JTH by NIH T32 AI07140, STD/HIV Training Grant at University of Washington CFAR, and to GSG by K08 AI049755. The MACS is funded by the National Institute of Allergy and Infectious Diseases, with additional supplemental funding from the National Cancer Institute and the National Heart, Lung and Blood Institute. UO1-AI-35042, 5-MO1-RR-00722 (GCRC), UO1-AI-35043, UO1-AI-37984, UO1-AI-35039, UO1-AI-35040, UO1-AI-37613, UO1-AI-35041.	Allen TM, 2004, J VIROL, V78, P7069, DOI 10.1128/JVI.78.13.7069-7078.2004; Arien KK, 2007, NAT REV MICROBIOL, V5, P141, DOI 10.1038/nrmicro1594; Arien KK, 2005, AIDS, V19, P1555, DOI 10.1097/01.aids.0000185989.16477.91; Babiker A, 2000, LANCET, V355, P1131, DOI 10.1016/S0140-6736(00)02061-4; Baeten JM, 2007, J INFECT DIS, V195, P1177, DOI 10.1086/512682; Dolan MJ, 2007, NAT IMMUNOL, V8, P1324, DOI 10.1038/ni1521; Dorrucci M, 2005, AIDS, V19, P331; Dorrucci M, 2007, J INFECT DIS, V195, P525, DOI 10.1086/510911; EWALD PW, 1994, PHILOS T R SOC B, V346, P333, DOI 10.1098/rstb.1994.0150; FULTZ PN, 1990, AIDS, V4, P619, DOI 10.1097/00002030-199007000-00002; Galai N, 1996, AM J EPIDEMIOL, V143, P278; Gali Y, 2007, VIROLOGY, V364, P140, DOI 10.1016/j.virol.2007.02.021; GIORGI JV, 1990, CLIN IMMUNOL IMMUNOP, V55, P173, DOI 10.1016/0090-1229(90)90096-9; Gray RH, 2001, LANCET, V357, P1149, DOI 10.1016/S0140-6736(00)04331-2; Gupta SB, 2007, J INFECT DIS, V195, P546, DOI 10.1086/510909; Harrigan PR, 1998, J VIROL, V72, P3773, DOI 10.1128/JVI.72.5.3773-3778.1998; HOLMBERG SD, 1995, J ACQ IMMUN DEF SYND, V9, P291; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; Keet IPM, 1996, AIDS, V10, P1601, DOI 10.1097/00002030-199611000-00025; KESTENS L, 1995, J INFECT DIS, V172, P957, DOI 10.1093/infdis/172.4.957; Leslie AJ, 2004, NAT MED, V10, P282, DOI 10.1038/nm992; Lyles RH, 2000, J INFECT DIS, V181, P872, DOI 10.1086/315339; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MELLORS JW, 2007, J AM MED AS IN PRESS; Muller V, 2006, AIDS, V20, P889, DOI 10.1097/01.aids.0000218553.51908.6b; OBRIEN TR, 1995, AM J EPIDEMIOL, V142, P636, DOI 10.1093/oxfordjournals.aje.a117687; Pilcher CD, 2004, J INFECT DIS, V189, P1785, DOI 10.1086/386333; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Schacker TW, 1998, ANN INTERN MED, V128, P613, DOI 10.7326/0003-4819-128-8-199804150-00001; Sinicco A, 1997, BRIT MED J, V314, P1232, DOI 10.1136/bmj.314.7089.1232; Touloumi G, 2003, JAIDS-J ACQ IMM DEF, V34, P76, DOI 10.1097/00126334-200309010-00012; Vanhems P, 1999, J INFECT DIS, V180, P1803, DOI 10.1086/315110	32	34	34	10	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2008	3	2							e1525	10.1371/journal.pone.0001525	http://dx.doi.org/10.1371/journal.pone.0001525			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367EQ	18253479	Green Published, gold, Green Accepted			2022-12-25	WOS:000260535700003
J	Luo, DH; He, Y; Zhang, HF; Yu, LY; Chen, H; Xu, Z; Tang, SB; Urano, F; Min, W				Luo, Dianhong; He, Yun; Zhang, Haifeng; Yu, Luyang; Chen, Hong; Xu, Zhe; Tang, Shibo; Urano, Fumihiko; Min, Wang			AIP1 is critical in transducing IRE1-mediated endoplasmic reticulum stress response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISCHEMIA-MEDIATED ARTERIOGENESIS; UNFOLDED-PROTEIN RESPONSE; REGULATING KINASE 1; INDUCED ACTIVATION; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; CELL-DEATH; ER STRESS; TUMOR; ASK1	We have previously shown that ASK1-interacting protein 1 (AIP1) transduces tumor necrosis factor-induced ASK1-JNK signaling. Because endoplasmic reticulum (ER) stress activates ASK1-JNK signaling cascade, we investigated the role of AIP1 in ER stress-induced signaling. We created AIP1-deficient mice (AIP1-KO) from which mouse embryonic fibroblasts and vascular endothelial cells were isolated. AIP1-KO cells show dramatic reductions in ER stress-induced, but not oxidative stress-induced, ASK1-JNK activation and cell apoptosis. The ER stress-induced IRE1-JNK/XBP-1 axis, but not the PERK-CHOP1 axis, is blunted in AIP1-KO cells. ER stress induced formation of an AIP1-IRE1 complex, and the PH domain of AIP1 is critical for the IRE1 interaction. Furthermore, reconstitution of AIP1-KO cells with AIP1 wild type, not an AIP1 mutant with a deletion of the PH domain (AIP1-Delta PH), restores ER stress-induced IRE1-JNK/XBP-1 signaling. AIP1-IRE1 association facilitates IRE1 dimerization, a critical step for activation of IRE1 signaling. More importantly, AIP1-KO mice show impaired ER stress-induced IRE1-dependent signaling in vivo. We conclude that AIP1 is essential for transducing the IRE1-mediated ER stress response.	[Luo, Dianhong; He, Yun; Zhang, Haifeng; Yu, Luyang; Chen, Hong; Min, Wang] Yale Univ, Sch Med, Interdept Program Vasc Biol & Therapeut, Dept Pathol, New Haven, CT 06520 USA; [Xu, Zhe; Tang, Shibo] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Peoples R China; [Urano, Fumihiko] Univ Massachusetts, Sch Med, Program Gene Funct & Express, Worcester, MA 01605 USA	Yale University; Sun Yat Sen University; University of Massachusetts System; University of Massachusetts Worcester	Tang, SB (corresponding author), Yale Univ, Sch Med, Interdept Program Vasc Biol & Therapeut, Dept Pathol, 333 Cedar St, New Haven, CT 06520 USA.	tangsb@mail.sysu.edu.cn; wang.min@yale.edu	Longo, Kenneth A/A-5631-2010; TANG, Shi/GXH-5719-2022; Urano, Fumihiko/AAF-4492-2020	Yu, Luyang/0000-0002-1301-6285	NHLBI NIH HHS [R01 HL077357-1, R01 HL65978-05, P01 HL070295-6] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070295, R01HL065978, R01HL077357] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Credle JJ, 2005, P NATL ACAD SCI USA, V102, P18773, DOI 10.1073/pnas.0509487102; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; He Y, 2006, J BIOL CHEM, V281, P5559, DOI 10.1074/jbc.M512338200; He Y, 2006, J CLIN INVEST, V116, P2344, DOI 10.1172/JCI28123; Hetz C, 2006, SCIENCE, V312, P572, DOI 10.1126/science.1123480; Hu P, 2006, MOL CELL BIOL, V26, P3071, DOI 10.1128/MCB.26.8.3071-3084.2006; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kimata Y, 2004, J CELL BIOL, V167, P445, DOI 10.1083/jcb.200405153; Lim YC, 2003, AM J PATHOL, V162, P1591, DOI 10.1016/S0002-9440(10)64293-9; Lipson KL, 2006, CELL METAB, V4, P245, DOI 10.1016/j.cmet.2006.07.007; Liu CY, 2000, J BIOL CHEM, V275, P24881, DOI 10.1074/jbc.M004454200; Luo DH, 2006, AM J PATHOL, V169, P1886, DOI 10.2353/ajpath.2006.060603; Marciniak SJ, 2006, PHYSIOL REV, V86, P1133, DOI 10.1152/physrev.00015.2006; Matsuzawa A, 2002, ANTIOXID REDOX SIGN, V4, P415, DOI 10.1089/15230860260196218; Mauro C, 2006, J BIOL CHEM, V281, P2631, DOI 10.1074/jbc.M502181200; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Pan S, 2002, MOL CELL BIOL, V22, P7512, DOI 10.1128/MCB.22.21.7512-7523.2002; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Yang QF, 2006, EMBO REP, V7, P622, DOI 10.1038/sj.embor.7400687; Yoshida H, 2007, FEBS J, V274, P630, DOI 10.1111/j.1742-4658.2007.05639.x; Zhang HF, 2007, AM J PATHOL, V170, P1108, DOI 10.2353/ajpath.2007.060960; Zhang HF, 2004, J BIOL CHEM, V279, P44955, DOI 10.1074/jbc.M407617200; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhang R, 2003, J CLIN INVEST, V111, P1933, DOI 10.1172/JCI200317790; Zhang R, 2007, J BIOL CHEM, V282, P14788, DOI 10.1074/jbc.M701148200	30	84	96	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2008	283	18					11905	11912		10.1074/jbc.M710557200	http://dx.doi.org/10.1074/jbc.M710557200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	293MS	18281285	Green Published, hybrid			2022-12-25	WOS:000255340000006
J	Shi, L; Itoh, F; Itoh, S; Takahashi, S; Yamamoto, M; Kato, M				Shi, L.; Itoh, F.; Itoh, S.; Takahashi, S.; Yamamoto, M.; Kato, M.			Ephrin-A1 promotes the malignant progression of intestinal tumors in Apc(min/+) mice	ONCOGENE			English	Article						ephrin-A1; intestinal adenoma; invasion Apc(min/+) mice	EPHA2 OVEREXPRESSION; COLORECTAL-CANCER; GENE-EXPRESSION; RECEPTOR; CARCINOMA; CELLS; TUMORIGENESIS; ANGIOGENESIS; METASTASIS; REGULATOR	The ephrin-A1 and EphA receptors are frequently highly expressed in different human cancers, suggesting that they may promote tumor development and progression. We generated transgenic mice carrying Fabpl(4xat-132) ephrin-A1, which express ephrin-A1 in the intestinal epithelial cells. Those mice were then mated with Apc(min/+) mice to produce the compound mice, which overexpress ephrin-A1 in the intestinal tumors of Apc(min/+) mice. We compared the number, size and histopathological features of the intestinal tumors in the Fabpl(4xat-132) ephrin-A1/Apc(min/+) compound mice with those of the Apc(min/+) mice. The compound mice showed an increased number of intestinal tumors, significantly in the large intestine, and developed more invasive tumors. Among the 20 mice of each type examined, 5 Apc(min/+) mice developed 5 invasive tumors, 1 invasive tumor in each mouse, in the proximal or middle portions of the small intestine. On the other hand, 14 out of 20 compound mice developed 29 invasive tumors and 16 of them were in the distal small intestine and the large intestine, where transgenic ephrin-A1 was highly expressed. These results suggested that the increased expression of ephrin-A1 accelerated the malignant progression of the intestinal adenoma to invasive tumors.	[Shi, L.; Itoh, F.; Itoh, S.; Kato, M.] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Expt Pathol, Tsukuba, Ibaraki 3058575, Japan; [Takahashi, S.] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Anat, Tsukuba, Ibaraki 3058575, Japan; [Takahashi, S.] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Embryol, Tsukuba, Ibaraki 3058575, Japan; [Yamamoto, M.] Tohoku Univ, Grad Sch Med, Dept Med Biochem, Sendai, Miyagi 980, Japan; [Yamamoto, M.] Japan Sci & Technol Corp, ERATO Environm Response Project, Tsukuba, Ibaraki, Japan	University of Tsukuba; University of Tsukuba; University of Tsukuba; Tohoku University; Japan Science & Technology Agency (JST)	Kato, M (corresponding author), Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Expt Pathol, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	mit-kato@md.tsukuba.ac.jp		Itoh, Susumu/0000-0002-7967-0730; Itoh, Fumiko/0000-0002-6134-5331				Abraham S, 2006, CLIN CANCER RES, V12, P353, DOI 10.1158/1078-0432.CCR-05-1505; Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626; Brantley-Sieders DM, 2006, CANCER RES, V66, P10315, DOI 10.1158/0008-5472.CAN-06-1560; Brantley-Sieders DM, 2005, FASEB J, V19, P1884, DOI 10.1096/fj.05-4038fje; Coffman KT, 2003, CANCER RES, V63, P7907; DEBRUINE AP, 1993, INT J CANCER, V54, P765, DOI 10.1002/ijc.2910540510; Dobrzanski P, 2004, CANCER RES, V64, P910, DOI 10.1158/0008-5472.CAN-3430-2; Flanagan JG, 1997, CELL, V90, P403; Hamamoto T, 2002, CANCER RES, V62, P5955; Herath NI, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-144; Huusko P, 2004, NAT GENET, V36, P979, DOI 10.1038/ng1408; Kataoka H, 2004, CANCER SCI, V95, P136, DOI 10.1111/j.1349-7006.2004.tb03194.x; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Liu DP, 2007, INT J ONCOL, V30, P865; LUONGO C, 1994, CANCER RES, V54, P5947; Mellitzer G, 1999, NATURE, V400, P77, DOI 10.1038/21907; Murai KK, 2003, J CELL SCI, V116, P2823, DOI 10.1242/jcs.00625; Nakamura R, 2005, CANCER SCI, V96, P42, DOI 10.1111/j.1349-7006.2005.00007.x; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; Ogawa K, 2000, ONCOGENE, V19, P6043, DOI 10.1038/sj.onc.1204004; Parri M, 2005, J BIOL CHEM, V280, P34008, DOI 10.1074/jbc.M502879200; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; Potla L, 2002, CANCER LETT, V175, P187, DOI 10.1016/S0304-3835(01)00613-9; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Saam JR, 1999, J BIOL CHEM, V274, P38071, DOI 10.1074/jbc.274.53.38071; Simon TC, 1997, J BIOL CHEM, V272, P10652; Straume O, 2005, BRIT J CANCER, V93, P933, DOI 10.1038/sj.bjc.6602792; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Surawska H, 2004, CYTOKINE GROWTH F R, V15, P419, DOI 10.1016/j.cytogfr.2004.09.002; Swatek Jaroslaw, 2000, Polish Journal of Pathology, V51, P127; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; Wang YJ, 2002, BIOCHEM BIOPH RES CO, V296, P214, DOI 10.1016/S0006-291X(02)00806-9; Wu D, 2004, GYNECOL ONCOL, V94, P312, DOI 10.1016/j.ygyno.2004.05.019; Xu F, 2005, ANTICANCER RES, V25, P2943; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zelinski DP, 2001, CANCER RES, V61, P2301	37	16	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	23					3265	3273		10.1038/sj.onc.1210992	http://dx.doi.org/10.1038/sj.onc.1210992			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	304LQ	18246128				2022-12-25	WOS:000256111400005
J	Lee, JY; Retamal, C; Cuitino, L; Caruano-Yzermans, A; Shin, JE; van Kerkhof, P; Marzolo, MP; Bu, GJ				Lee, Jiyeon; Retamal, Claudio; Cuitino, Loreto; Caruano-Yzermans, Amy; Shin, Jung-Eun; van Kerkhof, Peter; Marzolo, Maria-Paz; Bu, Guojun			Adaptor protein sorting nexin 17 regulates amyloid precursor protein trafficking and processing in the early endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; CELL-SURFACE; LDL RECEPTOR; ALZHEIMERS-DISEASE; COATED PITS; P-SELECTIN; ENDOCYTOSIS; DISABLED-2; DOMAIN; FE65	Accumulation of extracellular amyloid beta peptide (A beta), generated from amyloid precursor protein (APP) processing by beta- and gamma-secretases, is toxic to neurons and is central to the pathogenesis of Alzheimer disease. Production of A beta from APP is greatly affected by the subcellular localization and trafficking of APP. Here we have identified a novel intracellular adaptor protein, sorting nexin 17 (SNX17), that binds specifically to the APP cytoplasmic domain via the YXNPXY motif that has been shown previously to bind several cell surface adaptors, including Fe65 and X11. Overexpression of a dominant-negative mutant of SNX17 and RNA interference knockdown of endogenous SNX17 expression both reduced steady-state levels of APP with a concomitant increase in A beta production. RNA interference knockdown of SNX17 also decreased APP half-life, which led to the decreased steady-state levels of APP. Immunofluorescence staining confirmed a colocalization of SNX17 and APP in the early endosomes. We also showed that a cell surface adaptor protein, Dab2, binds to the same YXNPXY motif and regulates APP endocytosis at the cell surface. Our results thus provide strong evidence that both cell surface and intracellular adaptor proteins regulate APP endocytic trafficking and processing to A beta. The identification of SNX17 as a novel APP intracellular adaptor protein highly expressed in neurons should facilitate the understanding of the relationship between APP intracellular trafficking and processing to A beta.	[Lee, Jiyeon; Caruano-Yzermans, Amy; Shin, Jung-Eun; Bu, Guojun] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Lee, Jiyeon; Caruano-Yzermans, Amy; Shin, Jung-Eun; Bu, Guojun] Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; [Retamal, Claudio; Cuitino, Loreto; Marzolo, Maria-Paz] Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Biol Celular & Mol,Ctr Regulac Celular & Pat, Millennium Inst Fundamental & Appl Biol, Santiago 340, Chile; [van Kerkhof, Peter] Univ Med Ctr, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; [van Kerkhof, Peter] Univ Med Ctr, Biomembrane Inst, NL-3584 CX Utrecht, Netherlands	Washington University (WUSTL); Washington University (WUSTL); Pontificia Universidad Catolica de Chile; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Bu, GJ (corresponding author), Washington Univ, Sch Med, Dept Pediat, Campus Box 8208,660 S Euclid Ave, St Louis, MO 63110 USA.	bu@wustl.edu		Lee, Jiyeon/0000-0002-8952-7938; Shin, Jung Eun/0000-0002-8502-7979; Retamal, Claudio/0000-0001-8618-2260; van Kerkhof, Peter/0000-0002-8954-2230; Cuitino, Loreto/0000-0003-2330-9732	FOGARTY INTERNATIONAL CENTER [R03TW006456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG027924] Funding Source: NIH RePORTER; FIC NIH HHS [TW006456] Funding Source: Medline; NIA NIH HHS [R01 AG027924] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Andersen OM, 2006, BIOCHEMISTRY-US, V45, P2618, DOI 10.1021/bi052120v; Andersen OM, 2005, P NATL ACAD SCI USA, V102, P13461, DOI 10.1073/pnas.0503689102; Borg JP, 1996, MOL CELL BIOL, V16, P6229; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; BU GJ, 1994, J BIOL CHEM, V269, P29874; Burden JJ, 2004, J BIOL CHEM, V279, P16237, DOI 10.1074/jbc.M313689200; Cam JA, 2005, J BIOL CHEM, V280, P15464, DOI 10.1074/jbc.M500613200; Cam JA, 2004, J BIOL CHEM, V279, P29639, DOI 10.1074/jbc.M313893200; Cam JA, 2006, MOL NEURODEGENER, V1, DOI 10.1186/1750-1326-1-8; Cuitino L, 2005, TRAFFIC, V6, P820, DOI 10.1111/j.1600-0854.2005.00320.x; Florian V, 2001, BIOCHEM BIOPH RES CO, V281, P1045, DOI 10.1006/bbrc.2001.4467; Fuentealba RA, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-14; Gallagher H, 2004, BIOCHIMIE, V86, P179, DOI 10.1016/j.biochi.2004.03.001; Haft CR, 1998, MOL CELL BIOL, V18, P7278, DOI 10.1128/MCB.18.12.7278; Hoe HS, 2006, J BIOL CHEM, V281, P35176, DOI 10.1074/jbc.M602162200; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Koo EH, 1996, J CELL SCI, V109, P991; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Maurer ME, 2006, J CELL SCI, V119, P4235, DOI 10.1242/jcs.03217; Melman L, 2002, MOL BIOL CELL, V13, P3325, DOI 10.1091/mbc.E02-03-0152; Miller CCJ, 2006, TRENDS NEUROSCI, V29, P280, DOI 10.1016/j.tins.2006.03.001; Mishra SK, 2002, EMBO J, V21, P4915, DOI 10.1093/emboj/cdf487; Morris SM, 2001, TRAFFIC, V2, P111, DOI 10.1034/j.1600-0854.2001.020206.x; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; Rogaeva E, 2007, NAT GENET, V39, P168, DOI 10.1038/ng1943; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; Seet LF, 2006, BBA-MOL CELL BIOL L, V1761, P878, DOI 10.1016/j.bbalip.2006.04.011; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shah S, 2006, MOL INTERV, V6, P74, DOI 10.1124/mi.6.2.4; Stockinger W, 2002, EMBO J, V21, P4259, DOI 10.1093/emboj/cdf435; van Kerkhof P, 2005, EMBO J, V24, P2851, DOI 10.1038/sj.emboj.7600756; Williams R, 2004, MOL BIOL CELL, V15, P3095, DOI 10.1091/mbc.E04-02-0143; Worby CA, 2002, NAT REV MOL CELL BIO, V3, P919, DOI 10.1038/nrm974; Xie ZC, 2007, J BIOL CHEM, V282, P4318, DOI 10.1074/jbc.M609293200; Yamazaki T, 1996, J CELL SCI, V109, P999; Yun M, 2003, J BIOL CHEM, V278, P36572, DOI 10.1074/jbc.M304384200; Zambrano N, 1997, J BIOL CHEM, V272, P6399, DOI 10.1074/jbc.272.10.6399; Zheng H, 2006, MOL NEURODEGENER, V1, DOI 10.1186/1750-1326-1-5	38	117	122	3	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11501	11508		10.1074/jbc.M800642200	http://dx.doi.org/10.1074/jbc.M800642200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18276590	Green Published, hybrid			2022-12-25	WOS:000255067400049
J	Lee, KG; Xu, S; Wong, ET; Tergaonkar, V; Lam, KP				Lee, Koon-Guan; Xu, Shengli; Wong, Ee-Tsin; Tergaonkar, Vinay; Lam, Kong-Peng			Bruton's tyrosine kinase separately regulates NF kappa B p65RelA activation and cytokine interleukin (IL)-10/IL-12 production in TLR9-stimulated B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CPG OLIGODEOXYNUCLEOTIDES; MOLECULAR-MECHANISMS; DENDRITIC CELLS; RECEPTOR; RESPONSES; LIPOPOLYSACCHARIDE; EXPRESSION; IL-10; DNA; AGAMMAGLOBULINEMIA	B lymphocytes express both B cell receptor and Toll-like receptors (TLR). We show here that Bruton's tyrosine kinase (Btk), a critical component in B cell receptor signaling, is also involved in TLR9 signaling in B cells. Stimulation of B cells with TLR9 ligand CpG oligodeoxynucleotide (ODN) leads to transient phosphorylation of Btk, and in the absence of Btk, TLR9-induced proliferation of B cells is impaired. Interestingly, Btk(-/-) B cells secrete significantly more interleukin (IL)-12 but much less IL-10 compared with wild type B cells upon TLR9 stimulation. Immunization of Btk(-/-) mice with CpG ODN also leads to elevated levels of IL-12 in vivo and consequently, a greater-fold increment in the production of Th1 type IgG2b and IgG3 antibodies in these mice compared with wild type controls. The addition of exogenous recombinant IL-10 could suppress IL-12 production by TLR9-activated Btk(-/-) B cells, suggesting that in B cells, Btk negatively regulates IL-12 through the induction of autocrine IL-10 production. TLR9 signaling also leads to the activation of NF kappa B, including the p65RelA subunit in wild type B cells. The lack of Btk signaling affects the activation of NF kappa B and impairs the translocation of the p65RelA subunit to the nucleus of B cells upon TLR9 stimulation. However, p65RelA(-/-) B cells could respond similarly to wild type B cells in terms of IL-10 and IL-12 secretion when stimulated with CpG ODN, suggesting that the defect in NF kappa B p65RelA activation is additional to the impairment in cytokine production in TLR9-activated Btk(-/-) B cells. Thus, Btk plays an important role in TLR9 signaling and acts separately to regulate NF kappa B RelA activation as well as IL-10 and IL-12 production in B cells.	[Lee, Koon-Guan; Xu, Shengli; Lam, Kong-Peng] Agcy Sci Technol & Res, Lab Immunol, Bioproc Technol Inst, Singapore 138648, Singapore; [Wong, Ee-Tsin; Tergaonkar, Vinay] Agcy Sci Technol & Res, Inst Mol & Cell Biol, Singapore 138648, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Bioprocessing Technology Institute (BTI); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Lam, KP (corresponding author), Agcy Sci Technol & Res, Lab Immunol, Bioproc Technol Inst, Singapore 138648, Singapore.	lam_kong_peng@immunol.a-star.edu.sg	Lam, Kong-Peng/G-5374-2012	Lam, Kong-Peng/0000-0002-1316-4333				Akdis CA, 2001, IMMUNOLOGY, V103, P131, DOI 10.1046/j.1365-2567.2001.01235.x; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Amedei A, 2001, EUR J IMMUNOL, V31, P1927, DOI 10.1002/1521-4141(200106)31:6<1927::AID-IMMU1927>3.0.CO;2-D; Aste-Amezaga M, 1998, J IMMUNOL, V160, P5936; Bajpai UD, 2000, J EXP MED, V191, P1735, DOI 10.1084/jem.191.10.1735; Chaung HC, 2006, INT IMMUNOPHARMACOL, V6, P1586, DOI 10.1016/j.intimp.2006.06.001; Christensen SR, 2005, J EXP MED, V202, P321, DOI 10.1084/jem.20050338; Doyle SL, 2007, J BIOL CHEM, V282, P36953, DOI 10.1074/jbc.M707682200; Doyle SL, 2005, J BIOL CHEM, V280, P23496, DOI 10.1074/jbc.C500053200; Dunzendorfer S, 2004, J IMMUNOL, V173, P1166, DOI 10.4049/jimmunol.173.2.1166; Fruman DA, 2000, IMMUNITY, V13, P1, DOI 10.1016/S1074-7613(00)00002-9; Gapuzan MER, 2002, ONCOGENE, V21, P2484, DOI 10.1038/sj.onc.1205333; Gloire G, 2006, BIOCHEM PHARMACOL, V72, P1081, DOI 10.1016/j.bcp.2006.06.017; Hasan M, 2008, IMMUNOLOGY, V123, P239, DOI 10.1111/j.1365-2567.2007.02693.x; Hata D, 1998, J EXP MED, V187, P1235, DOI 10.1084/jem.187.8.1235; Horwood NJ, 2006, J IMMUNOL, V176, P3635, DOI 10.4049/jimmunol.176.6.3635; Jefferies CA, 2003, J BIOL CHEM, V278, P26258, DOI 10.1074/jbc.M301484200; Kawakami Y, 2006, P NATL ACAD SCI USA, V103, P153, DOI 10.1073/pnas.0509784103; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; Klinman DM, 2006, INT REV IMMUNOL, V25, P135, DOI 10.1080/08830180600743057; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Lamphier MS, 2006, ANN NY ACAD SCI, V1082, P31, DOI 10.1196/annals.1348.005; Lijeroos M, 2007, CELL SIGNAL, V19, P625, DOI 10.1016/j.cellsig.2006.08.013; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; Mukhopadhyay S, 2002, J IMMUNOL, V168, P2914, DOI 10.4049/jimmunol.168.6.2914; Rallabhandi P, 2006, J IMMUNOL, V177, P322, DOI 10.4049/jimmunol.177.1.322; Roelofs MF, 2005, ARTHRITIS RHEUM, V52, P2313, DOI 10.1002/art.21278; Sabet M, 2006, FEMS IMMUNOL MED MIC, V47, P369, DOI 10.1111/j.1574-695X.2006.00096.x; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; Satterthwaite AB, 2000, IMMUNOL REV, V175, P120, DOI 10.1034/j.1600-065X.2000.017504.x; Schmidt NW, 2006, J IMMUNOL, V177, P7203, DOI 10.4049/jimmunol.177.10.7203; Snijders A, 1996, J IMMUNOL, V156, P1207; Sochorova K, 2007, BLOOD, V109, P2553, DOI 10.1182/blood-2006-07-037960; Szabo SJ, 2003, ANNU REV IMMUNOL, V21, P713, DOI 10.1146/annurev.immunol.21.120601.140942; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Trinchieri G, 1998, Int Rev Immunol, V16, P365, DOI 10.3109/08830189809043002; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Trinchieri G, 2003, IMMUNITY, V19, P641, DOI 10.1016/S1074-7613(03)00296-6; Verthelyi Daniela, 2006, V127, P139; Viglianti GA, 2003, IMMUNITY, V19, P837, DOI 10.1016/S1074-7613(03)00323-6; Wang JM, 2007, J IMMUNOL, V178, P6777, DOI 10.4049/jimmunol.178.11.6777	41	66	69	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11189	11198		10.1074/jbc.M708516200	http://dx.doi.org/10.1074/jbc.M708516200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18276597	hybrid			2022-12-25	WOS:000255067400014
J	Navaratnarajah, CK; Vongpunsawad, S; Oezguen, N; Stehle, T; Braun, W; Hashiguchi, T; Maenaka, K; Yanagi, Y; Cattaneo, R				Navaratnarajah, Chanakha K.; Vongpunsawad, Sompong; Oezguen, Numan; Stehle, Thilo; Braun, Werner; Hashiguchi, Takao; Maenaka, Katsumi; Yanagi, Yusuke; Cattaneo, Roberto			Dynamic interaction of the measles virus hemagglutinin with its receptor signaling lymphocytic activation molecule (SLAM, CD150)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; CD46 DOWN-REGULATION; CELLULAR RECEPTOR; RECOMBINANT VIRUS; CRYSTAL-STRUCTURE; AMINO-ACIDS; FUSION; STRAIN; SITES; CELLS	The interaction of measles virus with its receptor signaling lymphocytic activation molecule (SLAM) controls cell entry and governs tropism. We predicted potential interface areas of the measles virus attachment protein hemagglutinin to begin the investigation. We then assessed the relevance of individual amino acids located in these areas for SLAM-binding and SLAM-dependent membrane fusion, as measured by surface plasmon resonance and receptor-specific fusion assays, respectively. These studies identified one hemagglutinin protein residue, isoleucine 194, which is essential for primary binding. The crystal structure of the hemagglutinin-protein localizes Ile-194 at the interface of propeller blades 5 and 6, and our data indicate that a small aliphatic side chain of residue 194 stabilizes a protein conformation conducive to binding. In contrast, a quartet of residues previously shown to sustain SLAM-dependent fusion is not involved in binding. Instead, our data prove that after binding, this quartet of residues on propeller blade 5 conducts conformational changes that are receptor-specific. Our study sets a structure-based stage for understanding how the SLAM-elicited conformational changes travel through the H-protein ectodomain before triggering fusion protein unfolding and membrane fusion.	[Navaratnarajah, Chanakha K.; Vongpunsawad, Sompong; Cattaneo, Roberto] Mayo Clin, Dept Mol Med & Virol, Rochester, MN 55905 USA; [Oezguen, Numan; Braun, Werner] Univ Texas Galveston, Med Branch, Sealy Ctr Struct Biol, Galveston, TX 77555 USA; [Stehle, Thilo] Univ Tubingen, Interfak Inst Biochem, D-72076 Tubingen, Germany; [Stehle, Thilo] Vanderbilt Univ, Sch Med, Nashville, TN 37240 USA; [Maenaka, Katsumi] Kyushu Univ, Med Inst Bioregulat, Div Struct Biol, Fukuoka 8128582, Japan; [Hashiguchi, Takao; Yanagi, Yusuke] Kyushu Univ, Fac Med, Dept Virol, Fukuoka 8128582, Japan	Mayo Clinic; University of Texas System; University of Texas Medical Branch Galveston; Eberhard Karls University of Tubingen; Vanderbilt University; Kyushu University; Kyushu University	Cattaneo, R (corresponding author), 200 1st St SW,Guggenheim 1838, Rochester, MN 55905 USA.	cattaneo.roberto@mayo.edu	Braun, Werner/A-6642-2012; Navaratnarajah, Chanakha/AAB-6171-2019; Oezguen, Numan/C-9267-2009	Navaratnarajah, Chanakha/0000-0002-4513-8412; Oezguen, Numan/0000-0002-3175-2382; vongpunsawad, sompong/0000-0001-7520-8728; Hashiguchi, Takao/0000-0001-7578-7571; Yanagi, Yusuke/0000-0001-7815-1667	NCI NIH HHS [R01 CA090363] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartz R, 1996, VIROLOGY, V224, P334, DOI 10.1006/viro.1996.0538; BORROW P, 1995, CURR TOP MICROBIOL, V191, P85; Cathomen T, 1995, VIROLOGY, V214, P628, DOI 10.1006/viro.1995.0075; CATTANEO R, 1993, J VIROL, V67, P1493, DOI 10.1128/JVI.67.3.1493-1502.1993; Crennell S, 2000, NAT STRUCT BIOL, V7, P1068; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; Duclos P, 1998, DRUG SAFETY, V19, P435, DOI 10.2165/00002018-199819060-00002; Duprex WP, 1999, J VIROL, V73, P9568, DOI 10.1128/JVI.73.11.9568-9575.1999; Erlenhoefer C, 2001, J VIROL, V75, P4499, DOI 10.1128/JVI.75.10.4499-4505.2001; Hashiguchi T, 2007, P NATL ACAD SCI USA, V104, P19535, DOI 10.1073/pnas.0707830104; Hashimoto K, 2002, J VIROL, V76, P6743, DOI 10.1128/JVI.76.13.6743-6749.2002; Henzler-Wildman K, 2007, NATURE, V450, P964, DOI 10.1038/nature06522; Holmen SL, 1999, J VIROL, V73, P10051, DOI 10.1128/JVI.73.12.10051-10060.1999; Hsu EC, 2001, VIROLOGY, V279, P9, DOI 10.1006/viro.2000.0711; Hsu EC, 1998, J VIROL, V72, P2905, DOI 10.1128/JVI.72.4.2905-2916.1998; KUMAR R, 1989, MOL CELL BIOL, V9, P5713, DOI 10.1128/MCB.9.12.5713; Lecouturier V, 1996, J VIROL, V70, P4200, DOI 10.1128/JVI.70.7.4200-4204.1996; Masse N, 2004, J VIROL, V78, P9051, DOI 10.1128/JVI.78.17.9051-9063.2004; Nakamura T, 2005, NAT BIOTECHNOL, V23, P209, DOI 10.1038/nbt1060; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; Negi SS, 2007, BIOINFORMATICS, V23, P3397, DOI 10.1093/bioinformatics/btm474; Negi SS, 2007, J MOL MODEL, V13, P1157, DOI 10.1007/s00894-007-0237-0; Negi SS, 2006, J MOL MODEL, V12, P921, DOI 10.1007/s00894-006-0101-7; Ono N, 2001, J VIROL, V75, P4399, DOI 10.1128/JVI.75.9.4399-4401.2001; Plemper RK, 2000, J VIROL, V74, P6485, DOI 10.1128/JVI.74.14.6485-6493.2000; RADECKE F, 1995, EMBO J, V14, P5773, DOI 10.1002/j.1460-2075.1995.tb00266.x; Rager M, 2002, EMBO J, V21, P2364, DOI 10.1093/emboj/21.10.2364; Santiago C, 2002, J BIOL CHEM, V277, P32294, DOI 10.1074/jbc.M202973200; Schein CH, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-40; Schneider U, 2000, J VIROL, V74, P9928, DOI 10.1128/JVI.74.21.9928-9936.2000; Schneider U, 2002, J VIROL, V76, P7460, DOI 10.1128/JVI.76.15.7460-7467.2002; Seki F, 2006, J GEN VIROL, V87, P1643, DOI 10.1099/vir.0.81682-0; Simonis D, 2007, SEMIN THROMB HEMOST, V33, P534, DOI 10.1055/s-2007-982085; STREBEL PM, 2004, VACCINES, P389; Tatsuo H, 2000, NATURE, V406, P893, DOI 10.1038/35022579; Ungerechts G, 2007, CANCER RES, V67, P10939, DOI 10.1158/0008-5472.CAN-07-1252; Vongpunsawad S, 2004, J VIROL, V78, P302, DOI 10.1128/JVI.78.1.302-313.2004; Yin HS, 2006, NATURE, V439, P38, DOI 10.1038/nature04322	38	55	57	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11763	11771		10.1074/jbc.M800896200	http://dx.doi.org/10.1074/jbc.M800896200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18292085	Green Published, hybrid			2022-12-25	WOS:000255067400076
J	Bhattacharyya, S; Gill, R; Chen, ML; Zhang, F; Linhardt, RJ; Dudeja, PK; Tobacman, JK				Bhattacharyya, Sumit; Gill, Ravinder; Chen, Mei Ling; Zhang, Fuming; Linhardt, Robert J.; Dudeja, Pradeep K.; Tobacman, Joanne K.			Toll-like receptor 4 mediates induction of the Bcl10-NF kappa B-interleukin-8 inflammatory pathway by carrageenan in human intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-4; NF-KAPPA-B; ENDOTOXIN HYPORESPONSIVENESS; SIGNALING PATHWAYS; INSULIN-RESISTANCE; INNATE IMMUNITY; POLYMYXIN-B; LIPOPOLYSACCHARIDE; BCL10; ACTIVATION	The sulfated polysaccharide carrageenan (CGN) induces activation of NF kappa B and interleukin 8 (IL-8) in human colonic epithelial cells through a pathway of innate immunity mediated by Bcl10 (B-cell CLL/lymphoma 10). In this report, we identify Toll-like receptor 4 (TLR4), a member of the family of innate immune receptors, as the surface membrane receptor for CGN in human colonic epithelial cells. Experiments with fluorescence-tagged CGN demonstrated a marked reduction in binding of CGN to human intestinal epithelial cells and to RAW 264.7 mouse macrophages, following exposure to TLR4 blocking antibody (HTA-125). Binding of CGN to 10ScNCr/23 mouse macrophages, which are deficient in the genetic locus for TLR4, was absent. Additional experiments with TLR4 blocking antibody and TLR4 small interfering RNAs showed 80% reductions in CGN-induced increases in Bcl10 and IL-8. Transfection with dominant-negative MyD88 plasmid demonstrated MyD88 dependence of the CGN-TLR4-triggered increases in Bcl10 and IL-8. Therefore, these results indicate that CGN-induced inflammation in human colonocytes proceeds through a pathway of innate immunity, perhaps related to the unusual alpha-1,3-galactosidic linkage characteristic of CGN, and suggest how dietary CGN intake may contribute to human intestinal inflammation. Because CGN is a commonly used food additive in the Western diet, clarification of its effects and mechanisms of action are vital to issues of food safety.	[Bhattacharyya, Sumit; Gill, Ravinder; Dudeja, Pradeep K.; Tobacman, Joanne K.] Univ Illinois, Dept Med, Chicago, IL 60612 USA; [Chen, Mei Ling] Univ Illinois, Dept Anat & Cell Biol, Chicago, IL 60612 USA; [Dudeja, Pradeep K.; Tobacman, Joanne K.] Jesse Brown Vet Affairs Med Ctr, Chicago, IL 60612 USA; [Zhang, Fuming] Rensselaer Polytech Inst, Dept Chem & Chem Biol, Troy, NY 12180 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center; Rensselaer Polytechnic Institute	Tobacman, JK (corresponding author), Univ Illinois, Dept Med, 840 S Wood St,M C 718 440 Clin Sci N, Chicago, IL 60612 USA.	jkt@uic.edu			NHLBI NIH HHS [R01 HL062244, R01 HL062244-05A1, R01 HL052622-05, R01 HL052622] Funding Source: Medline; NIDDK NIH HHS [R01 DK054016, DK54016, P01 DK067887, R01 DK068324, DK68324] Funding Source: Medline; NIGMS NIH HHS [R01 GM038060, R01 GM038060-19] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062244, R01HL052622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054016, R01DK068324, P01DK067887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038060] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abreu MT, 2002, J BIOL CHEM, V277, P20431, DOI 10.1074/jbc.M110333200; Abreu MT, 2001, J IMMUNOL, V167, P1609, DOI 10.4049/jimmunol.167.3.1609; Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Bhattacharyya S, 2007, J IMMUNOASS IMMUNOCH, V28, P173, DOI 10.1080/15321810701454573; Bhattacharyya S, 2007, AM J PHYSIOL-GASTR L, V293, pG429, DOI 10.1152/ajpgi.00149.2007; Bocker U, 2003, INT J COLORECTAL DIS, V18, P25, DOI 10.1007/s00384-002-0415-6; Borthakur A, 2007, AM J PHYSIOL-GASTR L, V292, pG829, DOI 10.1152/ajpgi.00380.2006; Cario E, 2002, AM J PATHOL, V160, P165, DOI 10.1016/S0002-9440(10)64360-X; Dong W, 2006, J BIOL CHEM, V281, P26029, DOI 10.1074/jbc.M513057200; Galili U, 2005, IMMUNOL CELL BIOL, V83, P674, DOI 10.1111/j.1440-1711.2005.01366.x; Gewirtz AT, 2003, CURR PHARM DESIGN, V9, P1, DOI 10.2174/1381612033392422; GLABE CG, 1983, ANAL BIOCHEM, V130, P287, DOI 10.1016/0003-2697(83)90590-0; Guillot L, 2004, J BIOL CHEM, V279, P2712, DOI 10.1074/jbc.M305790200; Hornef MW, 2002, J EXP MED, V195, P559, DOI 10.1084/jem.20011788; Hornef MW, 2003, J EXP MED, V198, P1225, DOI 10.1084/jem.20022194; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; *JOINT FAO WHO EXP, 2007, SUMM CONCL 68 M JOIN, P1; Kim F, 2007, CIRC RES, V100, P1589, DOI 10.1161/CIRCRESAHA.106.142851; Klemm S, 2007, P NATL ACAD SCI USA, V104, P134, DOI 10.1073/pnas.0608388103; Leaphart CL, 2007, J IMMUNOL, V179, P4808, DOI 10.4049/jimmunol.179.7.4808; Lin WJ, 2005, SHOCK, V24, P206, DOI 10.1097/01.shk.0000180074.69143.77; Lorenz E, 2002, INFECT IMMUN, V70, P4892, DOI 10.1128/IAI.70.9.4892-4896.2002; Moyer MP, 1996, IN VITRO CELL DEV-AN, V32, P315; Naik S, 2001, J PEDIATR GASTR NUTR, V32, P449, DOI 10.1097/00005176-200104000-00011; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Osman N, 1997, P NATL ACAD SCI USA, V94, P14677, DOI 10.1073/pnas.94.26.14677; Paik YH, 2003, HEPATOLOGY, V37, P1043, DOI 10.1053/jhep.2003.50182; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Powers JP, 2006, BIOORG MED CHEM LETT, V16, P2842, DOI 10.1016/j.bmcl.2006.03.020; Sandrin Mauro S., 1997, Frontiers in Bioscience (online), V2, pE1; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Shi H, 2006, J CLIN INVEST, V116, P3015, DOI 10.1172/JCI28898; Song MJ, 2006, BIOCHEM BIOPH RES CO, V346, P739, DOI 10.1016/j.bbrc.2006.05.170; Tanemura M, 2000, J CLIN INVEST, V105, P301, DOI 10.1172/JCI7358; Taylor KR, 2007, J BIOL CHEM, V282, P18265, DOI 10.1074/jbc.M606352200; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Toiyama Y, 2006, SURG TODAY, V36, P287, DOI 10.1007/s00595-005-3144-y; Tsubery H, 2000, BIOCHEMISTRY-US, V39, P11837, DOI 10.1021/bi000386q; Tsuji RF, 2003, CLIN EXP ALLERGY, V33, P249, DOI 10.1046/j.1365-2222.2003.01575.x; Tsukumo DML, 2007, DIABETES, V56, P1986, DOI 10.2337/db06-1595; Tsuzuki H, 2001, J SURG RES, V100, P127, DOI 10.1006/jsre.2001.6227; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Yokoyama T, 2006, LIVER INT, V26, P467, DOI 10.1111/j.1478-3231.2006.01254.x; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273; Zughaier SM, 2005, INFECT IMMUN, V73, P2940, DOI 10.1128/IAI.73.5.2940-2950.2005	47	121	125	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10550	10558		10.1074/jbc.M708833200	http://dx.doi.org/10.1074/jbc.M708833200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18252714	Green Published, hybrid			2022-12-25	WOS:000254894700037
J	Gerson, KD; Foster, CD; Zhang, P; Zhang, ZG; Rosenblatt, MM; Guttentag, SH				Gerson, Kristin D.; Foster, Cherie D.; Zhang, Peggy; Zhang, Zhenguo; Rosenblatt, Michael M.; Guttentag, Susan H.			Pepsinogen C proteolytic processing of surfactant protein B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMELLAR BODY FORMATION; IN-VITRO; LUNG; GASTRICSIN; DEFICIENCY; EXPRESSION; NAPSIN; MICE	Surfactant protein B (SP-B) is essential to the function of pulmonary surfactant and to lamellar body genesis in alveolar epithelial type 2 cells. The bioactive, mature SP-B is derived from multistep post-translational proteolysis of a larger proprotein. The identity of the proteases involved in carboxyl-terminal cleavage of proSP-B remains uncertain. This cleavage event distinguishes SP-B production in type 2 cells from less complete processing in bronchiolar Clara cells. We previously identified pepsinogen C as an alveolar type 2 cell-specific protease that was developmentally regulated in the human fetal lung. We report that pepsinogen C cleaved recombinant proSP-B at Met(302) in addition to an amino-terminal cleavage at Ser(197). Using a well described model of type 2 cell differentiation, small interfering RNA knockdown of pepsinogen C inhibited production of mature SP-B, whereas overexpression of pepsinogen C increased SP-B production. Inhibition of SP-B production recapitulated the SP-B-deficient phenotype evident by aberrant lamellar body genesis. Together, these data support a primary role for pepsinogen C in SP-B proteolytic processing in alveolar type 2 cells.	[Gerson, Kristin D.; Foster, Cherie D.; Zhang, Peggy; Zhang, Zhenguo; Guttentag, Susan H.] Univ Penn, Sch Med, Dept Pediat, Div Neonatol, Philadelphia, PA 19104 USA; [Rosenblatt, Michael M.] Childrens Hosp Philadelphia, Protein Core Facil, Joseph Stokes Jr Res Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Guttentag, SH (corresponding author), Childrens Hosp Philadelphia, Abraham Res Ctr 416G, 3516 Civic Ctr Blvd, Philadelphia, PA 19104 USA.	guttentag@email.chop.edu	Guttentag, Susan/ABE-7405-2020; Guttentag, Susan H/D-8705-2013	Guttentag, Susan/0000-0003-4420-5879; Guttentag, Susan H/0000-0003-4420-5879	NHLBI NIH HHS [HL059959, HL077226, R01 HL059959] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059959, R56HL059959] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brasch F, 2003, J BIOL CHEM, V278, P49006, DOI 10.1074/jbc.M306844200; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; DEMELLO DE, 1994, AM J RESP CELL MOL, V11, P230, DOI 10.1165/ajrcmb.11.2.8049084; DIEZITZA I, 1993, BRIT J CANCER, V68, P637, DOI 10.1038/bjc.1993.399; ELJKING EP, 1991, EUR RESPIR J, V4, P1245; Foster C, 2004, AM J PHYSIOL-LUNG C, V286, pL382, DOI 10.1152/ajplung.00310.2003; Foster CD, 2003, AM J RESP CELL MOL, V29, P259, DOI 10.1165/rcmb.2002-0149OC; Foster CD, 2007, PEDIATR RES, V61, P404, DOI 10.1203/pdr.0b013e3180332c6d; Gonzales LW, 2002, AM J PHYSIOL-LUNG C, V283, pL940, DOI 10.1152/ajplung.00127.2002; Gunther A, 1996, AM J RESP CRIT CARE, V153, P176; Guttentag S, 2003, AM J RESP CELL MOL, V28, P69, DOI 10.1165/rcmb.2002-0111OC; Guttentag SH, 1998, AM J PHYSIOL-LUNG C, V275, pL559, DOI 10.1152/ajplung.1998.275.3.L559; Hawgood S, 1998, BBA-MOL BASIS DIS, V1408, P150, DOI 10.1016/S0925-4439(98)00064-7; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; HUANG WY, 1969, J BIOL CHEM, V244, P1085; Ingenito EP, 2001, AM J RESP CELL MOL, V25, P35, DOI 10.1165/ajrcmb.25.1.4021; Kageyama T, 2002, CELL MOL LIFE SCI, V59, P288, DOI 10.1007/s00018-002-8423-9; Korimilli A, 2000, J BIOL CHEM, V275, P8672, DOI 10.1074/jbc.275.12.8672; Lin S, 1996, J BIOL CHEM, V271, P19689, DOI 10.1074/jbc.271.33.19689; Nesslein LL, 2005, AM J PHYSIOL-LUNG C, V288, pL1154, DOI 10.1152/ajplung.00392.2004; NOGEE LM, 1994, J CLIN INVEST, V93, P1860, DOI 10.1172/JCI117173; Powers J C, 1977, Adv Exp Med Biol, V95, P141; RYLE AP, 1960, BIOCHEM J, V75, P145, DOI 10.1042/bj0750145; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sorensen OE, 2003, J BIOL CHEM, V278, P28540, DOI 10.1074/jbc.M301608200; Stahlman MT, 2000, LAB INVEST, V80, P395, DOI 10.1038/labinvest.3780044; TANG J, 1959, J BIOL CHEM, V234, P1174; Ueno T, 2004, J BIOL CHEM, V279, P16178, DOI 10.1074/jbc.M312029200; Weaver TE, 2001, ANNU REV PHYSIOL, V63, P555, DOI 10.1146/annurev.physiol.63.1.555; Weaver TE, 1998, BBA-MOL BASIS DIS, V1408, P173, DOI 10.1016/S0925-4439(98)00066-0; Zaltash S, 1998, FEBS LETT, V423, P1, DOI 10.1016/S0014-5793(97)01582-2; Zhai YF, 2000, BBA-REV BIOMEMBRANES, V1469, P87, DOI 10.1016/S0304-4157(00)00003-4	33	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10330	10338		10.1074/jbc.M707516200	http://dx.doi.org/10.1074/jbc.M707516200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18256027	hybrid, Green Published			2022-12-25	WOS:000254894700013
J	Jorgensen, R; Purdy, AE; Fieldhouse, RJ; Kimber, MS; Bartlett, DH; Merrill, AR				Jorgensen, Rene; Purdy, Alexandra E.; Fieldhouse, Robert J.; Kimber, Matthew S.; Bartlett, Douglas H.; Merrill, A. Rod			Cholix toxin, a novel ADP-ribosylating factor from Vibrio cholerae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA EXOTOXIN; VIRULENCE FACTORS; CRYSTAL-STRUCTURE; ENVIRONMENTAL STRAINS; INFECTIOUS-DISEASE; CATALYTIC DOMAIN; DIPHTHERIA-TOXIN; SECRETION SYSTEM; IN-VITRO; NON-O1	The ADP-ribosyltransferases are a class of enzymes that display activity in a variety of bacterial pathogens responsible for causing diseases in plants and animals, including those affecting mankind, such as diphtheria, cholera, and whooping cough. We report the characterization of a novel toxin from Vibrio cholerae, which we call cholix toxin. The toxin is active against mammalian cells (IC50 = 4.6 +/- 0.4 ng/ml) and crustaceans (Artemia nauplii LD50 = 10 +/- 2 mu g/ml). Here we show that this toxin is the third member of the diphthamide-specific class of ADP-ribose transferases and that it possesses specific ADP-ribose transferase activity against ribosomal eukaryotic elongation factor 2. We also describe the high resolution crystal structures of the multidomain toxin and its catalytic domain at 2.1- and 1.25-angstrom resolution, respectively. The new structural data show that cholix toxin possesses the necessary molecular features required for infection of eukaryotes by receptor-mediated endocytosis, translocation to the host cytoplasm, and inhibition of protein synthesis by specific modification of elongation factor 2. The crystal structures also provide important insight into the structural basis for activation of toxin ADP-ribosyltransferase activity. These results indicate that cholix toxin may be an important virulence factor of Vibrio cholerae that likely plays a significant role in the survival of the organism in an aquatic environment.	[Purdy, Alexandra E.; Bartlett, Douglas H.] Univ Calif San Diego, Marine Biol Res Div, Ctr Marine Biotechnol & Biomed, Biol Grade Scripps Inst Oceanog 8750, La Jolla, CA 92093 USA; [Jorgensen, Rene; Fieldhouse, Robert J.; Kimber, Matthew S.; Merrill, A. Rod] Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada	University of California System; University of California San Diego; Scripps Institution of Oceanography; University of Guelph	Bartlett, DH (corresponding author), Univ Calif San Diego, Marine Biol Res Div, Ctr Marine Biotechnol & Biomed, Biol Grade Scripps Inst Oceanog 8750, La Jolla, CA 92093 USA.	dbartlett@ucsd.edu	Kimber, Matthew/Q-8144-2019; Jørgensen, René/P-5619-2014; Merrill, Rod/M-8313-2014	Jørgensen, René/0000-0003-0672-466X; Kimber, Matthew/0000-0001-9454-5586	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046600] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIAID NIH HHS [AI46600-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; Alam M, 2006, APPL ENVIRON MICROB, V72, P4096, DOI 10.1128/AEM.00066-06; Alouf J. E, 1999, COMPREHENSIVE SOURCE, V2nd; Armstrong S, 2001, ANAL BIOCHEM, V292, P26, DOI 10.1006/abio.2001.5052; Beattie BK, 1996, BIOCHEMISTRY-US, V35, P9042, DOI 10.1021/bi960396k; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burns D., 2003, BACTERIAL PROTEIN TO; Chen Y, 2007, INFECT IMMUN, V75, P2645, DOI 10.1128/IAI.01317-06; CHIRON MF, 1994, J BIOL CHEM, V269, P18167; Chow KH, 2001, J CLIN MICROBIOL, V39, P2594, DOI 10.1128/JCM.39.7.2594-2597.2001; CHUNG DW, 1977, INFECT IMMUN, V16, P832, DOI 10.1128/IAI.16.3.832-841.1977; Collier RJ, 2001, TOXICON, V39, P1793, DOI 10.1016/S0041-0101(01)00165-9; Colwell RR, 1996, SCIENCE, V274, P2025, DOI 10.1126/science.274.5295.2025; Dalsgaard A, 2000, CLIN MICROBIOL INFEC, V6, P625, DOI 10.1046/j.1469-0691.2000.00174.x; DALSGAARD A, 1995, J CLIN MICROBIOL, V33, P2715, DOI 10.1128/JCM.33.10.2715-2722.1995; Dziejman M, 2005, P NATL ACAD SCI USA, V102, P3465, DOI 10.1073/pnas.0409918102; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Faruque SM, 2004, P NATL ACAD SCI USA, V101, P2123, DOI 10.1073/pnas.0308485100; GALLOWAY DR, 1989, J BIOL CHEM, V264, P14869; Halpern M, 2003, APPL ENVIRON MICROB, V69, P4200, DOI 10.1128/AEM.69.7.4200-4204.2003; Hessler JL, 1997, BIOCHEMISTRY-US, V36, P14577, DOI 10.1021/bi971447w; Hilbi H, 2007, ENVIRON MICROBIOL, V9, P563, DOI 10.1111/j.1462-2920.2007.01238.x; Hogan DA, 2002, SCIENCE, V296, P2229, DOI 10.1126/science.1070784; Huq A, 2005, APPL ENVIRON MICROB, V71, P4645, DOI 10.1128/AEM.71.8.4645-4654.2005; INOCENCIO NM, 1994, J BIOL CHEM, V269, P31831; Jander G, 2000, J BACTERIOL, V182, P3843, DOI 10.1128/JB.182.13.3843-3845.2000; Jorgensen R, 2006, BIOCHEM SOC T, V34, P1; Jorgensen R, 2005, NATURE, V436, P979, DOI 10.1038/nature03871; Jorgensen R, 2004, J BIOL CHEM, V279, P45919, DOI 10.1074/jbc.M406218200; KAPER JB, 1995, CLIN MICROBIOL REV, V8, P48, DOI 10.1128/CMR.8.1.48; Kirn TJ, 2005, NATURE, V438, P863, DOI 10.1038/nature04249; KONDO T, 1988, J BIOL CHEM, V263, P9470; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPPLA SH, 1978, BIOCHEM BIOPH RES CO, V81, P532, DOI 10.1016/0006-291X(78)91567-X; Li M, 1996, P NATL ACAD SCI USA, V93, P6902, DOI 10.1073/pnas.93.14.6902; LI M, 1995, P NATL ACAD SCI USA, V92, P9308, DOI 10.1073/pnas.92.20.9308; Lobitz B, 2000, P NATL ACAD SCI USA, V97, P1438, DOI 10.1073/pnas.97.4.1438; LORY S, 1980, INFECT IMMUN, V28, P494; Lyczak JB, 2000, MICROBES INFECT, V2, P1051, DOI 10.1016/S1286-4579(00)01259-4; Makri S, 2007, MICROBES INFECT, V9, P1351, DOI 10.1016/j.micinf.2007.06.011; Masignani V, 2004, INT J MED MICROBIOL, V293, P471, DOI 10.1078/1438-4221-00296; May P, 2007, ANN MED, V39, P219, DOI 10.1080/07853890701214881; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; MIDDLEBROOK JL, 1977, CAN J MICROBIOL, V23, P183, DOI 10.1139/m77-026; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OGATA M, 1990, J BIOL CHEM, V265, P20678; PERENTESIS JP, 1992, BIOFACTORS, V3, P173; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pukatzki S, 2006, P NATL ACAD SCI USA, V103, P1528, DOI 10.1073/pnas.0510322103; Purdy A, 2005, J BACTERIOL, V187, P2992, DOI 10.1128/JB.187.9.2992-3001.2005; RAHME LG, 1995, SCIENCE, V268, P1899, DOI 10.1126/science.7604262; Ruby EG, 2005, P NATL ACAD SCI USA, V102, P3004, DOI 10.1073/pnas.0409900102; Sarkar B, 2002, EPIDEMIOL INFECT, V129, P245, DOI 10.1017/S0950268802007392; Sharma C, 1998, J CLIN MICROBIOL, V36, P756, DOI 10.1128/JCM.36.3.756-763.1998; TAMPLIN ML, 1990, APPL ENVIRON MICROB, V56, P1977, DOI 10.1128/AEM.56.6.1977-1980.1990; Tang HB, 1996, INFECT IMMUN, V64, P37, DOI 10.1128/IAI.64.1.37-43.1996; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; WILSON BA, 1992, CURR TOP MICROBIOL, V175, P27; Yates SP, 2006, TRENDS BIOCHEM SCI, V31, P123, DOI 10.1016/j.tibs.2005.12.007; Yates SP, 2005, BIOCHEM J, V385, P667, DOI 10.1042/BJ20041480	61	100	107	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10671	10678		10.1074/jbc.M710008200	http://dx.doi.org/10.1074/jbc.M710008200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18276581	hybrid			2022-12-25	WOS:000254894700049
J	Thiaville, MM; Pan, YX; Gjymishka, A; Zhong, C; Kaufman, RJ; Kilberg, MS				Thiaville, Michelle M.; Pan, Yuan-Xiang; Gjymishka, Altin; Zhong, Can; Kaufman, Randal J.; Kilberg, Michael S.			MEK signaling is required for phosphorylation of eIF2 alpha following amino acid limitation of HepG2 human hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; INDUCED GENE-EXPRESSION; TRANSLATIONAL CONTROL; TRANSPORT SYSTEM; TRANSFER-RNA; DEPRIVATION; BINDING; KINASE; DEPHOSPHORYLATION; REINITIATION	The mammalian amino acid response (AAR) pathway is upregulated by protein or amino acid depletion. This pathway involves detection of uncharged tRNA by the GCN2 kinase, phosphorylation of the translation initiation factor eIF2 alpha (eukaryotic initiation factor 2 alpha), and, through subsequent translational control, enhanced de novo synthesis of the transcription factor ATF4. The present studies demonstrate that inhibition of MEK activation in HepG2 human hepatoma cells by PD98059 or U0126 blocked the increased phosphorylation of eIF2 alpha and ATF4 synthesis triggered by amino acid limitation, showing that the AAR requires activation of the MEK-ERK pathway. Inhibitors of the JNK or p38 MAPK pathways were ineffective. Consequently, inhibition of MEK activation blocked transcriptional induction of ATF4 target genes, but the induction was rescued by overexpression of ATF4 protein. Furthermore, the enhanced ERK phosphorylation following amino acid deprivation required GCN2 kinase activity and eIF2 alpha phosphorylation. Inhibition of protein phosphatase 1 action on phospho-eIF2 alpha by knockdown of GADD34 did not block the sensitivity to PD98059, suggesting that MEK functions to enhance GCN2-dependent eIF2 alpha phosphorylation rather than suppressing dephosphorylation. Collectively, these results document a critical interdependence between the MEK-ERK MAPK signaling pathway and the amino acid stress-activated pathway.	[Thiaville, Michelle M.; Pan, Yuan-Xiang; Gjymishka, Altin; Zhong, Can; Kilberg, Michael S.] Univ Florida, Coll Med, Dept Biochem & Mol Biol, Genet Inst,Shands Canc Ctr, Gainesville, FL 32610 USA; [Thiaville, Michelle M.; Pan, Yuan-Xiang; Gjymishka, Altin; Zhong, Can; Kilberg, Michael S.] Univ Florida, Coll Med, Ctr Nutr Sci, Gainesville, FL 32610 USA; [Kaufman, Randal J.] Univ Michigan, Ctr Med, Howard Hughes Med Inst, Dept Biol Chem, Ann Arbor, MI 48109 USA; [Kaufman, Randal J.] Univ Michigan, Ctr Med, Howard Hughes Med Inst, Dept Internal Med, Ann Arbor, MI 48109 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Kilberg, MS (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, Genet Inst,Shands Canc Ctr, Box 100245, Gainesville, FL 32610 USA.	mkilberg@ufl.edu	Pan, Yuan-Xiang/C-6576-2019	Pan, Yuan-Xiang/0000-0003-3219-4367	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052064, R01DK042394, R01DK070647, R37DK042394] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NHLBI NIH HHS [HL-52173] Funding Source: Medline; NIDDK NIH HHS [DK-42394, R01 DK052064, R01 DK070647, DK70647, DK-52064] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; Bain PJ, 2002, J NUTR, V132, P3023, DOI 10.1093/jn/131.10.3023; Brush MH, 2003, MOL CELL BIOL, V23, P1292, DOI 10.1128/MCB.23.4.1292-1303.2003; Chen H, 2004, J BIOL CHEM, V279, P50829, DOI 10.1074/jbc.M409173200; Franchi-Gazzola R, 1999, J BIOL CHEM, V274, P28922, DOI 10.1074/jbc.274.41.28922; Gaccioli F, 2006, J BIOL CHEM, V281, P17929, DOI 10.1074/jbc.M600341200; Gazzola RF, 2001, FEBS LETT, V490, P11; Hao SZ, 2005, SCIENCE, V307, P1776, DOI 10.1126/science.1104882; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Kilberg MS, 2005, ANNU REV NUTR, V25, P59, DOI 10.1146/annurev.nutr.24.012003.132145; KILBERG MS, 1989, METHOD ENZYMOL, V173, P564; Leung-Pineda V, 2004, BIOCHEM J, V379, P79, DOI 10.1042/BJ20031383; Leung-Pineda V, 2002, J BIOL CHEM, V277, P16585, DOI 10.1074/jbc.M110972200; Liang SH, 2006, BIOCHEM J, V393, P201, DOI 10.1042/BJ20050374; Lu PD, 2004, J CELL BIOL, V167, P27, DOI 10.1083/jcb.200408003; Maurin AC, 2005, CELL METAB, V1, P273, DOI 10.1016/j.cmet.2005.03.004; Monick MM, 2006, J IMMUNOL, V177, P1636, DOI 10.4049/jimmunol.177.3.1636; Natarajan K, 2001, MOL CELL BIOL, V21, P4347, DOI 10.1128/MCB.21.13.4347-4368.2001; Novoa I, 2003, EMBO J, V22, P1180, DOI 10.1093/emboj/cdg112; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200; Palii SS, 2006, BIOCHEM J, V395, P517, DOI 10.1042/BJ20051867; Palii SS, 2004, J BIOL CHEM, V279, P3463, DOI 10.1074/jbc.M310483200; Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Sharp JW, 2006, J COMP NEUROL, V494, P485, DOI 10.1002/cne.20817; Siu F, 2002, J BIOL CHEM, V277, P24120, DOI 10.1074/jbc.M201959200; STRAUS DS, 1993, ENDOCRINOLOGY, V132, P1090, DOI 10.1210/en.132.3.1090; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; Zykova TA, 2007, CARCINOGENESIS, V28, P1543, DOI 10.1093/carcin/bgm070	35	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10848	10857		10.1074/jbc.M708320200	http://dx.doi.org/10.1074/jbc.M708320200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18287093	Green Published, hybrid			2022-12-25	WOS:000254894700067
J	Zhao, YM; Zhang, JF; Li, HY; Li, YY; Ren, J; Luo, M; Zheng, X				Zhao, Yanmei; Zhang, Jinfang; Li, Huiying; Li, Yiyu; Ren, Jie; Luo, Ming; Zheng, Xiaofeng			An NADPH sensor protein (HSCARG) down-regulates nitric oxide synthesis by association with argininosuccinate synthetase and is essential for epithelial cell viability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; CANCER BIOLOGY; L-ARGININE; APOPTOSIS; EXPRESSION; SYNTHASE; BINDING; NO; BIOSYNTHESIS; REGENERATION	NADPH is an important cofactor in many biosynthesis pathways that control fundamental cellular processes. We recently determined the crystal structure of HSCARG, with functions previously unknown, and demonstrated it is an NADPH sensor, which undergoes restructuring and redistribution in response to changes of intracellular NADPH/NADP levels. In this study, we identified argininosuccinate synthetase (AS), a rate-limiting enzyme in nitric oxide synthesis, as capable of associating with HSCARG and demonstrated further that HSCARG decreased nitric oxide synthesis by down-regulating AS activity, whereas AS overexpression up-regulated hscarg mRNA transcription, suggesting a negative feedback mechanism. A decrease in the NADPH/NADP(+) ratio, induced by dehydroepiandrosterone treatment, enhanced the interaction between HSCARG and AS, which resulted in stronger inhibition of AS activity and nitric oxide production. The dimerization region of HSCARG, amino acids 153-189, was identified to undergo critical interactions with AS. Furthermore, the viability of HSCARG RNA interference-treated epithelial cells decreased significantly, accompanied by an increase of the activity of caspase-3, which suggested that the loss of viability was because of apoptosis. These results indicate that HSCARG regulation of AS activity is crucial for maintaining the intracellular balance between redox state and nitric oxide levels.	[Zhao, Yanmei; Zhang, Jinfang; Li, Huiying; Luo, Ming; Zheng, Xiaofeng] Natl Lab Prot Engn & Plant Genet Engn, Beijing 100871, Peoples R China; [Zhao, Yanmei; Zhang, Jinfang; Li, Huiying; Li, Yiyu; Ren, Jie; Zheng, Xiaofeng] Peking Univ, Coll Life Sci, Dept Biochem & Mol Biol, Beijing 100871, Peoples R China; [Luo, Ming] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA	Peking University; University of Alabama System; University of Alabama Birmingham	Zheng, X (corresponding author), Natl Lab Prot Engn & Plant Genet Engn, Beijing 100871, Peoples R China.	xiaofengz@pku.edu.cn						Berger F, 2004, TRENDS BIOCHEM SCI, V29, P111, DOI 10.1016/j.tibs.2004.01.007; Brasse-Lagnel C, 2006, BIOCHIMIE, V88, P607, DOI 10.1016/j.biochi.2005.11.005; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BURCH HB, 1967, J BIOL CHEM, V242, P4546; Christopherson KS, 1997, J CLIN INVEST, V100, P2424, DOI 10.1172/JCI119783; Clancy RM, 1998, ARTHRITIS RHEUM-US, V41, P1141, DOI 10.1002/1529-0131(199807)41:7<1141::AID-ART2>3.0.CO;2-S; Dai XY, 2006, PROTEIN PEPTIDE LETT, V13, P955, DOI 10.2174/092986606778256135; Dimmeler S, 1997, NITRIC OXIDE-BIOL CH, V1, P275, DOI 10.1006/niox.1997.0133; El Omari K, 2005, J BIOL CHEM, V280, P18229, DOI 10.1074/jbc.M501113200; Estrela JM, 2006, CRIT REV CL LAB SCI, V43, P143, DOI 10.1080/10408360500523878; Filomeni G, 2002, BIOCHEM PHARMACOL, V64, P1057, DOI 10.1016/S0006-2952(02)01176-0; Fjeld CC, 2003, P NATL ACAD SCI USA, V100, P9202, DOI 10.1073/pnas.1633591100; Goodwin BL, 2004, J BIOL CHEM, V279, P18353, DOI 10.1074/jbc.M308160200; Gow AJ, 2001, J CELL PHYSIOL, V187, P277, DOI 10.1002/jcp.1085; Haendeler J, 1997, NITRIC OXIDE-BIOL CH, V1, P282, DOI 10.1006/niox.1997.0134; Haendeler J, 1999, VITAM HORM, V57, P49; Hao G, 2004, J BIOL CHEM, V279, P36192, DOI 10.1074/jbc.M404866200; Harrison DG, 1997, J CLIN INVEST, V100, P2153, DOI 10.1172/JCI119751; HATTORI Y, 1994, J BIOL CHEM, V269, P9405; HECKER M, 1990, P NATL ACAD SCI USA, V87, P8612, DOI 10.1073/pnas.87.21.8612; Kim HM, 2007, DIABETES RES CLIN PR, V75, P111, DOI 10.1016/j.diabres.2006.04.009; Lamb HK, 2004, PROTEIN SCI, V13, P3127, DOI 10.1110/ps.04958904; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Mayer B, 1997, TRENDS BIOCHEM SCI, V22, P477, DOI 10.1016/S0968-0004(97)01147-X; Melino G, 2000, CELL MOL LIFE SCI, V57, P612, DOI 10.1007/PL00000723; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; Mocellin S, 2007, MED RES REV, V27, P317, DOI 10.1002/med.20092; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Mori M, 2000, BIOCHEM BIOPH RES CO, V275, P715, DOI 10.1006/bbrc.2000.3169; Mori M, 2007, J NUTR, V137, p1616S, DOI 10.1093/jn/137.6.1616S; Nardini M, 2003, EMBO J, V22, P3122, DOI 10.1093/emboj/cdg283; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; Pollak N, 2007, J BIOL CHEM, V282, P33562, DOI 10.1074/jbc.M704442200; Pollak N, 2007, BIOCHEM J, V402, P205, DOI 10.1042/BJ20061638; Shen YH, 1998, FEBS LETT, V433, P125, DOI 10.1016/S0014-5793(98)00844-8; Solomonson LP, 2003, J EXP BIOL, V206, P2083, DOI 10.1242/jeb.00361; Stammers DK, 2001, EMBO J, V20, P6619, DOI 10.1093/emboj/20.23.6619; Tian WN, 1998, J BIOL CHEM, V273, P10609, DOI 10.1074/jbc.273.17.10609; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Vallance P, 2001, HEART, V85, P342, DOI 10.1136/heart.85.3.342; VEECH RL, 1969, BIOCHEM J, V115, P609, DOI 10.1042/bj1150609a; Wang CCC, 2008, CANCER LETT, V259, P82, DOI 10.1016/j.canlet.2007.10.005; Wiley JW, 2007, NEUROGASTROENT MOTIL, V19, P541, DOI 10.1111/j.1365-2982.2007.00958.x; Xie LJ, 1997, J BIOL CHEM, V272, P16624, DOI 10.1074/jbc.272.26.16624; Ying WH, 2006, FRONT BIOSCI-LANDMRK, V11, P3129, DOI 10.2741/2038; Zhang QH, 2002, SCIENCE, V295, P1895; Zhao YM, 2005, J EXP BIOL, V208, P697, DOI 10.1242/jeb.01439; Zheng XF, 2007, P NATL ACAD SCI USA, V104, P8809, DOI 10.1073/pnas.0700480104; Ziegler M, 2000, EUR J BIOCHEM, V267, P1550, DOI 10.1046/j.1432-1327.2000.01187.x	50	34	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					11004	11013		10.1074/jbc.M708697200	http://dx.doi.org/10.1074/jbc.M708697200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18263583	hybrid			2022-12-25	WOS:000254894700081
J	Heine, GF; Horwitz, AA; Parvin, JD				Heine, George F.; Horwitz, Andrew A.; Parvin, Jeffrey D.			Multiple mechanisms contribute to inhibit transcription in response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CARBOXYL-TERMINAL DOMAIN; UBIQUITIN-PROTEIN LIGASE; LARGE SUBUNIT; IN-VITRO; INDUCED DEGRADATION; FACTOR TFIIH; BRCA1; PHOSPHORYLATION; COMPLEX	Cellular DNA damage elicits the phosphorylation and ubiquitination of RNA polymerase II (RNAPII), leading to the global repression of transcription. In this report we show that there are at least two different pathways to transcriptional repression, depending on the type of DNA damage. After H2O2 treatment, transcription was rapidly inhibited and rapidly restored. On the other hand, UV irradiation caused a much slower transcriptional inhibition, with a corresponding depletion of unphosphorylated RNAPII. We found that after UV treatment, but not treatment with H2O2, the inhibition of transcription was dependent on both the proteasome and new protein synthesis. In addition, RNAPII activity and ubiquitination were regulated through the phosphorylation of RNAPII by the P-TEFb kinase. These results highlight that multiple cellular pathways exist to globally repress transcriptional processes that might interfere with the repair of DNA damage.	[Heine, George F.; Parvin, Jeffrey D.] Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA; [Heine, George F.; Parvin, Jeffrey D.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; [Heine, George F.; Horwitz, Andrew A.; Parvin, Jeffrey D.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Heine, George F.; Horwitz, Andrew A.; Parvin, Jeffrey D.] Brigham & Womens Hosp, Boston, MA 02115 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Parvin, JD (corresponding author), 960 Biomed Res Tower,460 W 12th Ave, Columbus, OH 43210 USA.	Jeffrey.Parvin@OSUMC.edu	Parvin, Jeffrey D/C-8955-2009		NATIONAL CANCER INSTITUTE [R01CA090281, F32CA130302] Funding Source: NIH RePORTER; NCI NIH HHS [CA 130302, CA 90281] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anindya R, 2007, MOL CELL, V28, P386, DOI 10.1016/j.molcel.2007.10.008; Beaudenon SL, 1999, MOL CELL BIOL, V19, P6972; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; Horwitz AA, 2006, J BIOL CHEM, V281, P8317, DOI 10.1074/jbc.C500475200; Horwitz AA, 2007, P NATL ACAD SCI USA, V104, P6614, DOI 10.1073/pnas.0610481104; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; Inukai N, 2004, J BIOL CHEM, V279, P8190, DOI 10.1074/jbc.M311412200; Jung Y, 2006, J BIOL CHEM, V281, P1361, DOI 10.1074/jbc.M509688200; Kleiman FE, 2005, GENE DEV, V19, P1227, DOI 10.1101/gad.1309505; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Lee KB, 2002, P NATL ACAD SCI USA, V99, P4239, DOI 10.1073/pnas.072068399; Ljungman M, 1996, ONCOGENE, V13, P823; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; Luo ZH, 2001, MUTAT RES-DNA REPAIR, V486, P259, DOI 10.1016/S0921-8777(01)00097-0; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; McKay BC, 2001, MUTAT RES-DNA REPAIR, V485, P93, DOI 10.1016/S0921-8777(00)00064-1; Mitsui A, 1999, P NATL ACAD SCI USA, V96, P6054, DOI 10.1073/pnas.96.11.6054; Mondal N, 2001, NATURE, V413, P435, DOI 10.1038/35096590; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Proietti-De-Santis L, 2006, EMBO J, V25, P1915, DOI 10.1038/sj.emboj.7601071; Ratner JN, 1998, J BIOL CHEM, V273, P5184, DOI 10.1074/jbc.273.9.5184; Reid J, 2004, J BIOL CHEM, V279, P29875, DOI 10.1074/jbc.C400185200; Rockx DAP, 2000, P NATL ACAD SCI USA, V97, P10503, DOI 10.1073/pnas.180169797; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; Smogorzewska A, 2007, CELL, V129, P289, DOI 10.1016/j.cell.2007.03.009; Somesh BP, 2005, CELL, V121, P913, DOI 10.1016/j.cell.2005.04.010; Starita LM, 2005, J BIOL CHEM, V280, P24498, DOI 10.1074/jbc.M414020200; Tagwerker C, 2006, MOL CELL PROTEOMICS, V5, P737, DOI 10.1074/mcp.M500368-MCP200; Woudstra EC, 2002, NATURE, V415, P929, DOI 10.1038/415929a; Wu WW, 2007, CANCER RES, V67, P951, DOI 10.1158/0008-5472.CAN-06-3187; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000	39	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9555	9561		10.1074/jbc.M707700200	http://dx.doi.org/10.1074/jbc.M707700200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18281289	Green Published, hybrid			2022-12-25	WOS:000254671600008
J	Hsu, JL; Chen, HC; Peng, HL; Chang, HY				Hsu, Jye-Lin; Chen, Hsuan-Cheng; Peng, Hwei-Ling; Chang, Hwan-You			Characterization of the histidine-containing phosphotransfer protein B-mediated multistep phosphorelay system in Pseudomonas aeruginosa PAO1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; ESCHERICHIA-COLI; SERINE/THREONINE KINASE; SIGNAL-TRANSDUCTION; BACILLUS-SUBTILIS; TRANSCRIPTION FACTOR; 2-COMPONENT SYSTEMS; PHOSPHATASE 2C; EXPRESSION; VIRULENCE	Certain bacterial two-component sensor kinases possess a histidine-containing phosphotransfer (Hpt) domain to carry out a multistep phosphotransferring reaction to a cognate response regulator. Pseudomonas aeruginosa PAO1 contains three genes that encode proteins with an Hpt domain but lack a kinase domain. To identify the sensor kinase coupled to these Hpt proteins, a phosphorelay profiling assay was performed. Among the 12 recombinant orphan sensor kinases tested, 4 of these sensors (PA1611, PA1976, PA2824, and RetS) transferred the phosphoryl group to HptB (PA3345). The in vivo interaction between HptB and each of the sensors was also confirmed using the bacterial two-hybrid assay. Interestingly, the phosphoryl groups from these sensors all appeared to be transferred via HptB to PA3346, a novel phosphatase consisting of an N-terminal receiver domain and a eukaryotic type Ser/Thr phosphatase domain, and resulted in a significant increase of its phosphatase activity. The subsequent reverse transcription-PCR analysis revealed an operon structure of hptB-PA3346-PA3347, suggesting a coordinate expression of the three genes to carry out a signal transduction. The possibility was supported by the analysis showing PA3347 is able to be phosphorylated on Ser-56, and this phosphoryl group could be removed by PA3346 protein. Finally, analysis of PA3346 and PA3347 gene knock-out mutants revealed that these genes are associated with bacterial swarming activity and biofilm formation. Together, these results disclose a novel multistep phosphorelay system that is essential for P. aeruginosa to respond to a wide spectrum of environmental signals.	[Hsu, Jye-Lin; Chen, Hsuan-Cheng; Chang, Hwan-You] Natl Tsing Hua Univ, Inst Mol Med, Hsinchu 300, Taiwan; [Peng, Hwei-Ling] Natl Chiao Tung Univ, Dept Biol Sci & Technol, Hsinchu, Taiwan	National Tsing Hua University; National Yang Ming Chiao Tung University	Chang, HY (corresponding author), Natl Tsing Hua Univ, Inst Mol Med, 101 Guang Fu Rd 2nd Sec, Hsinchu 300, Taiwan.	hychang@life.nthu.edu.tw	Hsu, Jye-Lin/N-3641-2013					Adler E, 1997, MOL MICROBIOL, V23, P57, DOI 10.1046/j.1365-2958.1997.1801552.x; AKERLEY BJ, 1995, CELL, V80, P611, DOI 10.1016/0092-8674(95)90515-4; Arigoni F, 1996, P NATL ACAD SCI USA, V93, P3238, DOI 10.1073/pnas.93.8.3238; Bijisma JJE, 2003, TRENDS MICROBIOL, V11, P359, DOI 10.1016/S0966-842X(03)00176-8; Biondi EG, 2006, MOL MICROBIOL, V59, P386, DOI 10.1111/j.1365-2958.2005.04970.x; Bork P, 1996, PROTEIN SCI, V5, P1421, DOI 10.1002/pro.5560050720; Chang CH, 1996, J BACTERIOL, V178, P4710, DOI 10.1128/jb.178.15.4710-4716.1996; Chen YT, 2004, J MOL EVOL, V59, P725, DOI 10.1007/s00239-004-2663-2; Delumeau O, 2004, J BIOL CHEM, V279, P40927, DOI 10.1074/jbc.M405464200; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; Gee KR, 1999, ANAL BIOCHEM, V273, P41, DOI 10.1006/abio.1999.4202; Goodman AL, 2004, DEV CELL, V7, P745, DOI 10.1016/j.devcel.2004.08.020; Hoang TT, 1998, GENE, V212, P77, DOI 10.1016/S0378-1119(98)00130-9; Hughes KT, 1998, ANNU REV MICROBIOL, V52, P231, DOI 10.1146/annurev.micro.52.1.231; Janiak-Spens F, 2005, BIOCHEMISTRY-US, V44, P377, DOI 10.1021/bi048433s; Jesaitis AJ, 2003, J IMMUNOL, V171, P4329, DOI 10.4049/jimmunol.171.8.4329; Jin H, 2006, J MOL BIOL, V357, P1351, DOI 10.1016/j.jmb.2006.01.020; Kato M, 1997, CELL, V88, P717, DOI 10.1016/S0092-8674(00)81914-5; Kohler T, 2000, J BACTERIOL, V182, P5990, DOI 10.1128/JB.182.21.5990-5996.2000; Lai YC, 2003, J BACTERIOL, V185, P788, DOI 10.1128/JB.185.3.788-800.2003; Laskowski MA, 2004, MOL MICROBIOL, V54, P1090, DOI 10.1111/j.1365-2958.2004.04331.x; Lin CT, 2006, RES MICROBIOL, V157, P169, DOI 10.1016/j.resmic.2005.06.012; Lucet I, 1999, J BACTERIOL, V181, P3242, DOI 10.1128/JB.181.10.3242-3245.1999; Matsubara M, 2000, FEBS LETT, V470, P118, DOI 10.1016/S0014-5793(00)01303-X; Mougous JD, 2007, NAT CELL BIOL, V9, P797, DOI 10.1038/ncb1605; Mougous JD, 2006, SCIENCE, V312, P1526, DOI 10.1126/science.1128393; Mukhopadhyay S, 1999, J BACTERIOL, V181, P6615, DOI 10.1128/JB.181.21.6615-6622.1999; MUNOZDORADO J, 1991, CELL, V67, P995, DOI 10.1016/0092-8674(91)90372-6; Pastula C, 2003, COMB CHEM HIGH T SCR, V6, P341; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Rajagopal L, 2003, J BIOL CHEM, V278, P14429, DOI 10.1074/jbc.M212747200; Rodrigue A, 2000, TRENDS MICROBIOL, V8, P498, DOI 10.1016/S0966-842X(00)01833-3; Rogov VV, 2004, J MOL BIOL, V343, P1035, DOI 10.1016/j.jmb.2004.08.096; Sambrook J, 2001, MOL CLONING LAB MANU; Skerker JM, 2005, PLOS BIOL, V3, P1770, DOI 10.1371/journal.pbio.0030334; Stover CK, 2000, NATURE, V406, P959, DOI 10.1038/35023079; Takeda S, 2001, MOL MICROBIOL, V40, P440, DOI 10.1046/j.1365-2958.2001.02393.x; Ventre I, 2006, P NATL ACAD SCI USA, V103, P171, DOI 10.1073/pnas.0507407103; Vijay K, 2000, MOL MICROBIOL, V35, P180, DOI 10.1046/j.1365-2958.2000.01697.x; West AH, 2001, TRENDS BIOCHEM SCI, V26, P369, DOI 10.1016/S0968-0004(01)01852-7; Winstanley C, 2005, J MED MICROBIOL, V54, P519, DOI 10.1099/jmm.0.46005-0; Xu OP, 2003, STRUCTURE, V11, P1569, DOI 10.1016/j.str.2003.10.016; Yamamoto K, 2005, J BIOL CHEM, V280, P1448, DOI 10.1074/jbc.M410104200	43	69	70	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9933	9944		10.1074/jbc.M708836200	http://dx.doi.org/10.1074/jbc.M708836200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18256026	hybrid, Green Published			2022-12-25	WOS:000254671600050
J	Kim, YB; Choi, S; Choi, MC; Oh, MA; Lee, SA; Cho, M; Mizuno, K; Kim, SH; Lee, JW				Kim, Yong-Bae; Choi, Suyong; Choi, Moon-Chang; Oh, Min-A; Lee, Sin-Ae; Cho, Moonjae; Mizuno, Kensaku; Kim, Sung-Hoon; Lee, Jung Weon			Cell adhesion-dependent cofilin serine 3 phosphorylation by the integrin-linked kinase center dot c-Src complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED ACTIN REORGANIZATION; GASTRIC-CARCINOMA CELLS; PROTEIN-KINASE; FOCAL ADHESION; EPITHELIAL-CELLS; EGF RECEPTOR; ILK; INVASION; GROWTH; ACTOPAXIN	Integrin- linked kinase (ILK) is involved in signal transduction by integrin-mediated cell adhesion that leads to dynamic actin reorganization. Actin (de) polymerization is regulated by cofilin, the Ser(3) phosphorylation (pS(3) cofilin) of which inhibits its actin-severing activity. To determine how ILK regulates pS(3) cofilin, we examined the effects of ILK on pS(3) cofilin using normal RIE1 cells. Compared with suspended cells, fibronectin-adherent cells showed enhanced pS(3) cofilin, depending on ILK expression and c-Src activity. The ILK-mediated pS(3) cofilin in RIE1 cells did not involve Rho-associated kinase, LIM kinase, or testicular protein kinases, which are known to be upstream of cofilin. The kinase domain of ILK, including proline-rich regions, appeared to interact physically with the Src homology 3 domain of c-Src. In vitro kinase assay revealed that ILK immunoprecipitates phosphorylated the recombinant glutathione S-transferase-cofilin, which was abolished by c-Src inhibition. Interestingly, epidermal growth factor treatment abolished the ILK effects, indicating that the linkage from ILK to cofilin is biologically responsive to extracellular cues. Altogether, this study provides evidence for a new signaling connection from ILK to cofilin for dynamic actin polymerization during cell adhesion, depending on the activity of ILK-associated c-Src.	[Kim, Sung-Hoon] Kyung Hee Univ, Coll Oriental Med, Seoul 131701, South Korea; [Kim, Yong-Bae; Choi, Suyong; Choi, Moon-Chang; Oh, Min-A; Lee, Jung Weon] Seoul Natl Univ, Coll Med, Cell Dynam Res Ctr, Canc Res Inst,Dept Tumor Biol, Seoul 110799, South Korea; [Lee, Sin-Ae; Lee, Jung Weon] Seoul Natl Univ, Coll Med, Cell Dynam Res Ctr, Canc Res Inst,Dept Mol & Clin Oncol, Seoul 110799, South Korea; [Cho, Moonjae] Cheju Natl Univ, Dept Med, Cheju 690756, South Korea; [Mizuno, Kensaku] Tohoku Univ, Grad Sch Life Sci, Dept Biomol Sci, Sendai, Miyagi 9808578, Japan	Kyung Hee University; Seoul National University (SNU); Seoul National University (SNU); Jeju National University; Tohoku University	Kim, SH (corresponding author), Kyung Hee Univ, Coll Oriental Med, Seoul 131701, South Korea.	sungkim7@khu.ac.kr; jwl@snu.ac.kr	Lee, Jung Weon/AAC-1146-2020; Lee, Jung Weon/F-9149-2012; Mizuno, Kensaku/G-8631-2015	Lee, Jung Weon/0000-0003-2722-8200; 				Attwell S, 2003, MOL BIOL CELL, V14, P4813, DOI 10.1091/mbc.E03-05-0308; Boulter E, 2006, EUR J CELL BIOL, V85, P255, DOI 10.1016/j.ejcb.2005.09.002; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; Carragher NO, 2004, TRENDS CELL BIOL, V14, P241, DOI 10.1016/j.tcb.2004.03.011; Chan AY, 2000, J CELL BIOL, V148, P531, DOI 10.1083/jcb.148.3.531; Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Gilcrease MZ, 2007, CANCER LETT, V247, P1, DOI 10.1016/j.canlet.2006.03.031; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hehlgans S, 2007, BBA-REV CANCER, V1775, P163, DOI 10.1016/j.bbcan.2006.09.001; Huang TY, 2006, CURR OPIN CELL BIOL, V18, P26, DOI 10.1016/j.ceb.2005.11.005; Juliano RL, 2004, BIOCHEM SOC T, V32, P443, DOI 10.1042/BST0320443; Jung J, 2006, CELL SIGNAL, V18, P2033, DOI 10.1016/j.cellsig.2006.03.014; Kim HP, 2005, BBA-MOL CELL RES, V1743, P151, DOI 10.1016/j.bbamcr.2004.09.014; Kim YB, 2007, AM J PHYSIOL-CELL PH, V292, pC857, DOI 10.1152/ajpcell.00169.2006; LaLonde DP, 2005, J BIOL CHEM, V280, P21680, DOI 10.1074/jbc.m500752200; Lee JW, 2004, MOL CELLS, V17, P188; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; Lee MS, 2005, MOL CELL BIOL, V25, P6921, DOI 10.1128/MCB.25.16.6921-6936.2005; Legate KR, 2006, NAT REV MOL CELL BIO, V7, P20, DOI 10.1038/nrm1789; Leu TH, 2003, FRONT BIOSCI-LANDMRK, V8, pS28, DOI 10.2741/980; Marcoux N, 2005, CELL SIGNAL, V17, P1449, DOI 10.1016/j.cellsig.2005.03.001; Nikolopoulos SN, 2002, J BIOL CHEM, V277, P1568, DOI 10.1074/jbc.M108612200; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; Oh MA, 2007, J CELL SCI, V120, P2717, DOI 10.1242/jcs.003566; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Ohta Y, 2003, GENES CELLS, V8, P811, DOI 10.1046/j.1365-2443.2003.00678.x; Persad S, 2003, CANCER METAST REV, V22, P375, DOI 10.1023/A:1023777013659; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Qian Y, 2005, ONCOGENE, V24, P3154, DOI 10.1038/sj.onc.1208525; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Shattil SJ, 2005, TRENDS CELL BIOL, V15, P399, DOI 10.1016/j.tcb.2005.06.005; Toshima J, 2001, MOL BIOL CELL, V12, P1131, DOI 10.1091/mbc.12.4.1131; Van Rheenen J, 2007, J CELL BIOL, V179, P1247, DOI 10.1083/jcb.200706206; Wang WG, 2007, NAT REV CANCER, V7, P429, DOI 10.1038/nrc2148; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Zhan Q, 2003, CELL MOTIL CYTOSKEL, V54, P1, DOI 10.1002/cm.10079	37	42	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					10089	10096		10.1074/jbc.M708300200	http://dx.doi.org/10.1074/jbc.M708300200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18252715	Green Submitted, hybrid			2022-12-25	WOS:000254671600063
J	Taylor, EB; An, D; Kramer, HF; Yu, H; Fujii, NL; Roeckl, KSC; Bowles, N; Hirshman, MF; Xie, JX; Feener, EP; Goodyear, LJ				Taylor, Eric B.; An, Ding; Kramer, Henning F.; Yu, Haiyan; Fujii, Nobuharu L.; Roeckl, Katja S. C.; Bowles, Nicole; Hirshman, Michael F.; Xie, Jianxin; Feener, Edward P.; Goodyear, Laurie J.			Discovery of TBC1D1 as an insulin-, AICAR-, and contraction-stimulated signaling nexus in mouse skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; GLUT4 TRANSLOCATION; AKT SUBSTRATE; PHOSPHORYLATION ANALYSIS; GLUCOSE-TRANSPORT; AS160 PHOSPHORYLATION; KINASE; BINDING; DOMAIN; JAK2	The Akt substrate of 160 kDa (AS160) is phosphorylated on Akt substrate (PAS) motifs in response to insulin and contraction in skeletal muscle, regulating glucose uptake. Here we discovered a dissociation between AS160 protein expression and apparent AS160 PAS phosphorylation among soleus, tibialis anterior, and extensor digitorum longus muscles. Immuno-depletion of AS160 in tibialis anterior muscle lysates resulted in minimal depletion of the PAS band at 160 kDa, suggesting the presence of an additional PAS immunoreactive protein. By immunoprecipitation and mass spectrometry, we identified this protein as the AS160 paralog TBC1D1, an obesity candidate gene regulating GLUT4 translocation in adipocytes. TBC1D1 expression was severalfold higher in skeletal muscles compared with all other tissues and was the dominant protein detected by the anti-PAS antibody at 160 kDa in tibialis anterior and extensor digitorum longus but not soleus muscles. In vivo stimulation by insulin, contraction, and the AMP-activated protein kinase (AMPK) activator AICAR increased TBC1D1 PAS phosphorylation. Using mass spectrometry on TBC1D1 from mouse skeletal muscle, we identified several novel phosphorylation sites on TBC1D1 and found the majority were consensus or near consensus sites for AMPK. Semiquantitative analysis of spectra suggested that AICAR caused greater overall phosphorylation of TBC1D1 sites compared with insulin. Purified Akt and AMPK phosphorylated TBC1D1 in vitro, and AMPK, but not Akt, reduced TBC1D1 electrophoretic mobility. TBC1D1 is a major PAS immunoreactive protein in skeletal muscle that is phosphorylated in vivo by insulin, AICAR, and contraction. Both Akt and AMPK phosphorylate TBC1D1, but AMPK may be the more robust regulator.	[Taylor, Eric B.; An, Ding; Kramer, Henning F.; Yu, Haiyan; Fujii, Nobuharu L.; Roeckl, Katja S. C.; Bowles, Nicole; Hirshman, Michael F.; Goodyear, Laurie J.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Metab Sect, Boston, MA 02215 USA; [Feener, Edward P.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Proteom Core, Boston, MA 02215 USA; [Xie, Jianxin] Cell Signaling Technol Inc, Danvers, MA 01923 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Goodyear, LJ (corresponding author), 1 Joslin Pl, Boston, MA 02215 USA.	laurie.goodyear@joslin.harvard.edu	Fujii, Nobuharu/J-2724-2014	Fujii, Nobuharu/0000-0002-0974-3033; Taylor, Eric/0000-0003-4549-6567	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045670, R01AR042238, R29AR042238] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK075851, P30DK036836] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR045670, AR 42238, R01 AR042238, AR 45670] Funding Source: Medline; NIDDK NIH HHS [F32 DK075851, F32 DK 075851, DK 36836] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai L, 2007, CELL METAB, V5, P47, DOI 10.1016/j.cmet.2006.11.013; Bamman MM, 1999, ELECTROPHORESIS, V20, P466, DOI 10.1002/(SICI)1522-2683(19990301)20:3<466::AID-ELPS466>3.0.CO;2-7; Beausoleil SA, 2006, NAT BIOTECHNOL, V24, P1285, DOI 10.1038/nbt1240; Bouzakri K, 2006, DIABETES, V55, P785, DOI 10.2337/diabetes.55.03.06.db05-0796; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruss MD, 2005, DIABETES, V54, P41, DOI 10.2337/diabetes.54.1.41; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; Deshmukh A, 2006, DIABETES, V55, P1776, DOI 10.2337/db05-1419; Eguez L, 2005, CELL METAB, V2, P263, DOI 10.1016/j.cmet.2005.09.005; Feener EP, 2004, MOL CELL BIOL, V24, P4968, DOI 10.1128/MCB.24.11.4968-4978.2004; Gao BB, 2006, BIOCHEM J, V397, P337, DOI 10.1042/BJ20060095; Geraghty KM, 2007, BIOCHEM J, V407, P231, DOI 10.1042/BJ20070649; Greer EL, 2007, J BIOL CHEM, V282, P30107, DOI 10.1074/jbc.M705325200; Ishida-Takahashi R, 2006, MOL CELL BIOL, V26, P4063, DOI 10.1128/MCB.01589-05; Jessen N, 2005, J APPL PHYSIOL, V99, P330, DOI 10.1152/japplphysiol.00175.2005; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Karlsson HKR, 2006, DIABETES, V55, P1283, DOI 10.2337/db05-0853; Karlsson HKR, 2005, DIABETES, V54, P1692, DOI 10.2337/diabetes.54.6.1692; Karlsson HKR, 2005, DIABETES, V54, P1459, DOI 10.2337/diabetes.54.5.1459; Kennedy JW, 1999, DIABETES, V48, P1192, DOI 10.2337/diabetes.48.5.1192; Kramer HF, 2007, DIABETES, V56, P2854, DOI 10.2337/db07-0681; Kramer HF, 2006, J BIOL CHEM, V281, P31478, DOI 10.1074/jbc.M605461200; Kramer HF, 2006, DIABETES, V55, P2067, DOI 10.2337/db06-0150; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; Miinea CP, 2005, BIOCHEM J, V391, P87, DOI 10.1042/BJ20050887; Peck GR, 2006, MOL ENDOCRINOL, V20, P2576, DOI 10.1210/me.2005-0476; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Ramm G, 2006, J BIOL CHEM, V281, P29174, DOI 10.1074/jbc.M603274200; Richter EA, 2004, P NUTR SOC, V63, P211, DOI 10.1079/PNS2004343; Roach WG, 2007, BIOCHEM J, V403, P353, DOI 10.1042/BJ20061798; Sano H, 2003, J BIOL CHEM, V278, P14599, DOI 10.1074/jbc.C300063200; Sano H, 2007, CELL METAB, V5, P293, DOI 10.1016/j.cmet.2007.03.001; Steen H, 2006, MOL CELL PROTEOMICS, V5, P172, DOI 10.1074/mcp.M500135-MCP200; Stone S, 2006, HUM MOL GENET, V15, P2709, DOI 10.1093/hmg/ddl204; Thong FSL, 2007, DIABETES, V56, P414, DOI 10.2337/db06-0900; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Treebak JT, 2007, AM J PHYSIOL-ENDOC M, V292, pE715, DOI 10.1152/ajpendo.00380.2006; Treebak JT, 2006, DIABETES, V55, P2051, DOI 10.2337/db06-0175; Villen J, 2007, P NATL ACAD SCI USA, V104, P1488, DOI 10.1073/pnas.0609836104; Zeigerer A, 2004, MOL BIOL CELL, V15, P4406, DOI 10.1091/mbc.e04-04-0333	41	190	194	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9787	9796		10.1074/jbc.M708839200	http://dx.doi.org/10.1074/jbc.M708839200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18276596	Green Published, hybrid			2022-12-25	WOS:000254671600033
J	Beck, BD; Park, SJ; Lee, YJ; Roman, Y; Hromas, RA; Lee, SH				Beck, Brian D.; Park, Su-Jung; Lee, Young-Ju; Roman, Yaritzabel; Hromas, Robert A.; Lee, Suk-Hee			Human pso4 is a metnase (SETMAR)-binding partner that regulates metnase function in DNA repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE; REPLICATION PROTEIN-A; RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; U-BOX; MRE11 COMPLEX; DAMAGE; TRANSPOSASE; GENE; BINDING	Metnase, also known as SETMAR, is a SET and transposase fusion protein with an undefined role in mammalian DNA repair. The SET domain is responsible for histone lysine methyltransferase activity at histone 3K4 and K36, whereas the transposase domain possesses 5'-terminal inverted repeat (TIR)-specific DNA binding, DNA looping, and DNA cleavage activities. Although the transposase domain is essential for Metnase function in DNA repair, it is not clear how a protein with sequence-specific DNA binding activity plays a role in DNA repair. Here, we show that human homolog of the ScPSO4/PRP19 (hPso4) forms a stable complex with Metnase on both TIR and non-TIR DNA. The transposase domain essential for Metnase-TIR interaction is not sufficient for its interaction with non-TIRDNA in the presence of hPso4. In vivo, hPso4 is induced and co-localized with Metnase following ionizing radiation treatment. Cells treated with hPso4-siRNA failed to show Metnase localization at DSB sites and Metnase-mediated stimulation of DNA end joining coupled to genomic integration, suggesting that hPso4 is necessary to bring Metnase to the DSB sites for its function(s) in DNA repair.	[Beck, Brian D.; Park, Su-Jung; Lee, Young-Ju; Roman, Yaritzabel; Lee, Suk-Hee] Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; [Beck, Brian D.; Lee, Young-Ju; Lee, Suk-Hee] Indiana Univ, Sch Med, Walther Canc Inst, Indianapolis, IN 46202 USA; [Hromas, Robert A.] Univ New Mexico, Dept Internal Med, Albuquerque, NM 87131 USA; [Hromas, Robert A.] Univ New Mexico, Canc Treatment Res Ctr, Albuquerque, NM 87131 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; University of New Mexico; University of New Mexico	Lee, SH (corresponding author), IU Canc Res Inst, 1044 W Walnut St,Rm 153, Indianapolis, IN 46202 USA.	slee@iupui.edu			NATIONAL CANCER INSTITUTE [T32CA111198] Funding Source: NIH RePORTER; NCI NIH HHS [CA 92111, T32 CA 111198-01] Funding Source: Medline; NIDDK NIH HHS [T32 DK 0075-20] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ajuh P, 2000, EMBO J, V19, P6569, DOI 10.1093/emboj/19.23.6569; Brendel M, 2003, MUTAT RES-REV MUTAT, V544, P179, DOI 10.1016/j.mrrev.2003.06.018; Brendel M, 2001, MUTAT RES-REV MUTAT, V489, P79, DOI 10.1016/S1383-5742(01)00066-7; Chen Jake Y, 2006, Comput Syst Bioinformatics Conf, P389; Cordaux R, 2006, P NATL ACAD SCI USA, V103, P8101, DOI 10.1073/pnas.0601161103; Craigie R, 2001, J BIOL CHEM, V276, P23213, DOI 10.1074/jbc.R100027200; DASILVA KVCL, 1995, CURR GENET, V27, P207, DOI 10.1007/BF00326150; DEANDRADE HHR, 1989, MOL GEN GENET, V217, P419; Gerner C, 1999, J CELL BIOCHEM, V72, P470, DOI 10.1002/(SICI)1097-4644(19990315)72:4<470::AID-JCB3>3.0.CO;2-V; Gotzmann J, 2000, EXP CELL RES, V261, P166, DOI 10.1006/excr.2000.5025; Grey M, 1996, NUCLEIC ACIDS RES, V24, P4009, DOI 10.1093/nar/24.20.4009; Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151; HENRIQUES JAP, 1989, MUTAT RES, V218, P111, DOI 10.1016/0921-8777(89)90017-7; Jordan IK, 2006, P NATL ACAD SCI USA, V103, P7941, DOI 10.1073/pnas.0602656103; Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lee SH, 2005, P NATL ACAD SCI USA, V102, P18075, DOI 10.1073/pnas.0503676102; Leschziner AE, 1998, P NATL ACAD SCI USA, V95, P7345, DOI 10.1073/pnas.95.13.7345; Liu DX, 2007, MOL CELL BIOL, V27, P1125, DOI 10.1128/MCB.01899-06; Loscher M, 2005, BIOCHEM J, V388, P593, DOI 10.1042/BJ20041517; Lu XY, 2007, BIOCHEM BIOPH RES CO, V354, P968, DOI 10.1016/j.bbrc.2007.01.097; Mahajan KN, 1999, P NATL ACAD SCI USA, V96, P13926, DOI 10.1073/pnas.96.24.13926; Mahajan KN, 2003, P NATL ACAD SCI USA, V100, P10746, DOI 10.1073/pnas.1631060100; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; MEIRA LB, 1992, MOL GEN GENET, V235, P311, DOI 10.1007/BF00279375; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Morris JR, 2004, HUM MOL GENET, V13, P807, DOI 10.1093/hmg/ddh095; Murti KG, 1996, EXP CELL RES, V223, P279, DOI 10.1006/excr.1996.0083; Ohi MD, 2003, NAT STRUCT BIOL, V10, P250, DOI 10.1038/nsb906; Park JS, 1999, J BIOL CHEM, V274, P29075, DOI 10.1074/jbc.274.41.29075; Park SJ, 2004, J BIOL CHEM, V279, P6046, DOI 10.1074/jbc.M311054200; Polanowska J, 2006, EMBO J, V25, P2178, DOI 10.1038/sj.emboj.7601102; Robertson HM, 1997, GENE, V205, P203, DOI 10.1016/S0378-1119(97)00472-1; ROMAN Y, 2007, BIOCHEMISTRY; Roman Y, 2007, BIOCHEMISTRY-US, V46, P11369, DOI 10.1021/bi7005477; Skalka AM, 2005, CELL DEATH DIFFER, V12, P971, DOI 10.1038/sj.cdd.4401573; Vander Kooi CW, 2006, BIOCHEMISTRY-US, V45, P121, DOI 10.1021/bi051787e; VOS JC, 1994, EMBO J, V13, P6125, DOI 10.1002/j.1460-2075.1994.tb06959.x; Xiao TJ, 2003, GENE DEV, V17, P654, DOI 10.1101/gad.1055503; Zhang NX, 2005, J BIOL CHEM, V280, P40559, DOI 10.1074/jbc.M508453200; Zhang X, 2003, MOL CELL, V12, P177, DOI 10.1016/S1097-2765(03)00224-7	42	63	64	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9023	9030		10.1074/jbc.M800150200	http://dx.doi.org/10.1074/jbc.M800150200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18263876	Green Published, hybrid			2022-12-25	WOS:000254465800032
J	Lesica, NA; Grothe, B				Lesica, Nicholas A.; Grothe, Benedikt			Efficient Temporal Processing of Naturalistic Sounds	PLOS ONE			English	Article								In this study, we investigate the ability of the mammalian auditory pathway to adapt its strategy for temporal processing under natural stimulus conditions. We derive temporal receptive fields from the responses of neurons in the inferior colliculus to vocalization stimuli with and without additional ambient noise. We find that the onset of ambient noise evokes a change in receptive field dynamics that corresponds to a change from bandpass to lowpass temporal filtering. We show that these changes occur within a few hundred milliseconds of the onset of the noise and are evident across a range of overall stimulus intensities. Using a simple model, we illustrate how these changes in temporal processing exploit differences in the statistical properties of vocalizations and ambient noises to increase the information in the neural response in a manner consistent with the principles of efficient coding.	[Lesica, Nicholas A.; Grothe, Benedikt] Univ Munich, Dept Biol 2, Martinsried, Germany; [Lesica, Nicholas A.; Grothe, Benedikt] Bernstein Ctr Comput Neurosci, Munich, Germany	University of Munich	Lesica, NA (corresponding author), Univ Munich, Dept Biol 2, Martinsried, Germany.	lesica@zi.biologie.uni-muenchen.de	Grothe, Benedikt/A-7877-2010	Lesica, Nicholas/0000-0001-5238-4462; Grothe, Benedikt/0000-0001-7317-0615	Bernstein Center for Computational Neuroscience	Bernstein Center for Computational Neuroscience	NAL and BG were supported by the Bernstein Center for Computational Neuroscience.	ATTIAS H, 1997, ADV NEURAL INFORM PR, V9; Baccus SA, 2002, NEURON, V36, P909, DOI 10.1016/S0896-6273(02)01050-4; Barlow H. B., 1961, SENS COMMUN, P217, DOI DOI 10.7551/MITPRESS/9780262518420.003.0013; Borst A, 1999, NAT NEUROSCI, V2, P947, DOI 10.1038/14731; Caspary DM, 2002, HEARING RES, V168, P163, DOI 10.1016/S0378-5955(02)00363-5; Chander D, 2001, J NEUROSCI, V21, P9904, DOI 10.1523/JNEUROSCI.21-24-09904.2001; Dean I, 2005, NAT NEUROSCI, V8, P1684, DOI 10.1038/nn1541; Escabi MA, 2005, J NEUROSCI, V25, P9524, DOI 10.1523/JNEUROSCI.1804-05.2005; Escabi MA, 2003, J NEUROSCI, V23, P11489; Fairhall AL, 2001, NATURE, V412, P787, DOI 10.1038/35090500; Garcia-Lazaro JA, 2006, CURR BIOL, V16, P264, DOI 10.1016/j.cub.2005.12.013; GROTHE B, 1994, J NEUROPHYSIOL, V71, P706, DOI 10.1152/jn.1994.71.2.706; Kim KJ, 2003, J NEUROSCI, V23, P1506, DOI 10.1523/JNEUROSCI.23-04-01506.2003; Kim KJ, 2001, J NEUROSCI, V21, P287, DOI 10.1523/JNEUROSCI.21-01-00287.2001; Kvale MN, 2004, J NEUROPHYSIOL, V91, P604, DOI 10.1152/jn.00484.2003; LeBeau FEN, 1996, J NEUROPHYSIOL, V75, P902, DOI 10.1152/jn.1996.75.2.902; Lesica NA, 2007, NEURON, V55, P479, DOI 10.1016/j.neuron.2007.07.013; Lesica NA, 2006, NETWORK-COMP NEURAL, V17, P43, DOI 10.1080/09548980500328409; Mante V, 2005, NAT NEUROSCI, V8, P1690, DOI 10.1038/nn1556; Meister M, 1999, NEURON, V22, P435, DOI 10.1016/S0896-6273(00)80700-X; Nagel KI, 2006, NEURON, V51, P845, DOI 10.1016/j.neuron.2006.08.030; Pollak GD, 2003, TRENDS NEUROSCI, V26, P33, DOI 10.1016/S0166-2236(02)00009-7; REES A, 1987, HEARING RES, V27, P129, DOI 10.1016/0378-5955(87)90014-1; REES A, 1989, J ACOUST SOC AM, V85, P1978, DOI 10.1121/1.397851; Rieke F, 1995, P ROY SOC B-BIOL SCI, V262, P259, DOI 10.1098/rspb.1995.0204; SHAPLEY RM, 1978, J PHYSIOL-LONDON, V285, P275, DOI 10.1113/jphysiol.1978.sp012571; Singh NC, 2003, J ACOUST SOC AM, V114, P3394, DOI 10.1121/1.1624067; Siveke I, 2006, J NEUROPHYSIOL, V96, P1425, DOI 10.1152/jn.00713.2005; Smirnakis SM, 1997, NATURE, V386, P69, DOI 10.1038/386069a0; Smith EC, 2006, NATURE, V439, P978, DOI 10.1038/nature04485; Strong SP, 1998, PHYS REV LETT, V80, P197, DOI 10.1103/PhysRevLett.80.197; Theunissen FE, 2001, NETWORK-COMP NEURAL, V12, P289, DOI 10.1088/0954-898X/12/3/304; VANHATEREN JH, 1992, BIOL CYBERN, V68, P23, DOI 10.1007/BF00203134; VOSS RF, 1975, NATURE, V258, P317, DOI 10.1038/258317a0; Willmore B, 2003, NETWORK-COMP NEURAL, V14, P553, DOI 10.1088/0954-898X/14/3/309; Woolley SMN, 2005, NAT NEUROSCI, V8, P1371, DOI 10.1038/nn1536; Zaghloul KA, 2005, J NEUROSCI, V25, P860, DOI 10.1523/JNEUROSCI.2782-04.2005	37	40	40	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2008	3	2							e1655	10.1371/journal.pone.0001655	http://dx.doi.org/10.1371/journal.pone.0001655			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XS	18301738	Green Published, Green Submitted, gold			2022-12-25	WOS:000260586500005
J	Steiner, T; Hess, P; Bae, JH; Wiltschi, B; Moroder, L; Budisa, N				Steiner, Thomas; Hess, Petra; Bae, Jae Hyun; Wiltschi, Birgit; Moroder, Luis; Budisa, Nediljko			Synthetic Biology of Proteins: Tuning GFPs Folding and Stability with Fluoroproline	PLOS ONE			English	Article							PROLYL CIS/TRANS-ISOMERASES; CIS-TRANS ISOMERIZATION; PROLINE RESIDUES; FLUORESCENT; CONFORMATIONS; MUTATIONS; EVOLUTION; CATALYSIS; VARIANTS	Background: Proline residues affect protein folding and stability via cis/trans isomerization of peptide bonds and by the C-gamma-exo or -endo puckering of their pyrrolidine rings. Peptide bond conformation as well as puckering propensity can be manipulated by proper choice of ring substituents, e. g. C-gamma-fluorination. Synthetic chemistry has routinely exploited ring-substituted proline analogs in order to change, modulate or control folding and stability of peptides. Methodology/Principal Findings: In order to transmit this synthetic strategy to complex proteins, the ten proline residues of enhanced green fluorescent protein (EGFP) were globally replaced by (4R)- and (4S)-fluoroprolines (FPro). By this approach, we expected to affect the cis/trans peptidyl-proline bond isomerization and pyrrolidine ring puckering, which are responsible for the slow folding of this protein. Expression of both protein variants occurred at levels comparable to the parent protein, but the (4R)-FPro-EGFP resulted in irreversibly unfolded inclusion bodies, whereas the (4S)-FPro-EGFP led to a soluble fluorescent protein. Upon thermal denaturation, refolding of this variant occurs at significantly higher rates than the parent EGFP. Comparative inspection of the X-ray structures of EGFP and (4S)-FPro-EGFP allowed to correlate the significantly improved refolding with the C-gamma-endo puckering of the pyrrolidine rings, which is favored by 4S-fluorination, and to lesser extents with the cis/trans isomerization of the prolines. Conclusions/Significance: We discovered that the folding rates and stability of GFP are affected to a lesser extent by cis/trans isomerization of the proline bonds than by the puckering of pyrrolidine rings. In the C-gamma-endo conformation the fluorine atoms are positioned in the structural context of the GFP such that a network of favorable local interactions is established. From these results the combined use of synthetic amino acids along with detailed structural knowledge and existing protein engineering methods can be envisioned as a promising strategy for the design of complex tailor-made proteins and even cellular structures of superior properties compared to the native forms.	[Steiner, Thomas; Hess, Petra; Bae, Jae Hyun; Wiltschi, Birgit; Moroder, Luis; Budisa, Nediljko] Max Planck Inst Biochem, D-82152 Martinsried, Germany	Max Planck Society	Steiner, T (corresponding author), Max Planck Inst Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.	budisa@biochem.mpg.de	Budisa, Nediljko/AAG-7291-2019; Budisa, Nediljko/AAA-4634-2022; Budisa, Nediljko/T-4812-2017	Budisa, Nediljko/0000-0001-8437-7304; Budisa, Nediljko/0000-0001-8437-7304; Moroder, Luis/0000-0001-9570-5713; Wiltschi, Birgit/0000-0001-5230-0951	BioFuture Program of the Federal Ministry of Education and Research of Germany; Munich Center for Integrated Protein Science (CIPSM)	BioFuture Program of the Federal Ministry of Education and Research of Germany; Munich Center for Integrated Protein Science (CIPSM)	This work was supported by the BioFuture Program of the Federal Ministry of Education and Research of Germany and by the Munich Center for Integrated Protein Science (CIPSM).	Battistutta R, 2000, PROTEINS, V41, P429, DOI 10.1002/1097-0134(20001201)41:4<429::AID-PROT10>3.0.CO;2-D; Boulegue C, 2006, J MOL BIOL, V358, P846, DOI 10.1016/j.jmb.2006.02.031; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Budisa N, 2004, BIOL CHEM, V385, P191, DOI 10.1515/BC.2004.038; BUDISA N, 1995, EUR J BIOCHEM, V230, P788; Connor RE, 2007, POLYM REV, V47, P9, DOI 10.1080/15583720601109552; Dugave C, 2003, CHEM REV, V103, P2475, DOI 10.1021/cr0104375; Dunitz JD, 2004, CHEMBIOCHEM, V5, P614, DOI 10.1002/cbic.200300801; Eberhardt ES, 1996, J AM CHEM SOC, V118, P12261, DOI 10.1021/ja9623119; Elsliger MA, 1999, BIOCHEMISTRY-US, V38, P5296, DOI 10.1021/bi9902182; Eyles SJ, 2000, J MOL BIOL, V301, P737, DOI 10.1006/jmbi.2000.4002; Fischer G, 2004, REV PHYSIOL BIOCH P, V148, P105, DOI 10.1007/s10254-003-0011-3; Fischer G, 2000, CHEM SOC REV, V29, P119, DOI 10.1039/a803742f; FISCHER G, 1994, ANGEW CHEM INT EDIT, V33, P1415, DOI 10.1002/anie.199414151; Golbik R, 2005, BIOCHEMISTRY-US, V44, P16026, DOI 10.1021/bi051442w; Golbik R, 1999, PROTEIN SCI, V8, P1505, DOI 10.1110/ps.8.7.1505; Holmgren SK, 1998, NATURE, V392, P666, DOI 10.1038/33573; Holmgren SK, 1999, CHEM BIOL, V6, P63, DOI 10.1016/S1074-5521(99)80003-9; Iwai H, 2001, J BIOL CHEM, V276, P16548, DOI 10.1074/jbc.M011639200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mayer Marcus, 2004, Methods Mol Med, V94, P239; MILNERWHITE EJ, 1992, J MOL BIOL, V228, P725, DOI 10.1016/0022-2836(92)90859-I; Minks C, 1999, BIOCHEMISTRY-US, V38, P10649, DOI 10.1021/bi990580g; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pal D, 1999, J MOL BIOL, V294, P271, DOI 10.1006/jmbi.1999.3217; Palm GJ, 1999, METHOD ENZYMOL, V302, P378, DOI 10.1016/S0076-6879(99)02034-0; Pedelacq JD, 2006, NAT BIOTECHNOL, V24, P79, DOI 10.1038/nbt1172; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; Reid BG, 1997, BIOCHEMISTRY-US, V36, P6786, DOI 10.1021/bi970281w; Renner C, 2001, ANGEW CHEM INT EDIT, V40, P923, DOI 10.1002/1521-3773(20010302)40:5<923::AID-ANIE923>3.0.CO;2-#; SCHMID FX, 1993, ANNU REV BIOPH BIOM, V22, P123, DOI 10.1146/annurev.bb.22.060193.001011; Wedemeyer WJ, 2002, BIOCHEMISTRY-US, V41, P14637, DOI 10.1021/bi020574b; Wiltschi B, 2007, APPL MICROBIOL BIOT, V74, P739, DOI 10.1007/s00253-006-0823-6; WUTHRICH K, 1974, FEBS LETT, V43, P337, DOI 10.1016/0014-5793(74)80674-5; Yang TT, 1996, NUCLEIC ACIDS RES, V24, P4592, DOI 10.1093/nar/24.22.4592; Yoo TH, 2007, P NATL ACAD SCI USA, V104, P13887, DOI 10.1073/pnas.0701904104	38	78	81	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2008	3	2							e1680	10.1371/journal.pone.0001680	http://dx.doi.org/10.1371/journal.pone.0001680			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XS	18301757	Green Published, gold, Green Submitted			2022-12-25	WOS:000260586500024
J	Muleris, M; Chalastanis, A; Meyer, N; Lae, M; Dutrillaux, B; Sastre-Garau, X; Hamelin, R; Flejou, JF; Duval, A				Muleris, Martine; Chalastanis, Alexandra; Meyer, Nicolas; Lae, Marick; Dutrillaux, Bernard; Sastre-Garau, Xavier; Hamelin, Richard; Flejou, Jean-Francois; Duval, Alex			Chromosomal Instability in Near-Diploid Colorectal Cancer: A Link between Numbers and Structure	PLOS ONE			English	Article								Chromosomal instability (CIN) plays a crucial role in tumor development and occurs mainly as the consequence of either missegregation of normal chromosomes (MSG) or structural rearrangement (SR). However, little is known about the respective chromosomal targets of MSG and SR and the way these processes combined within tumors to generate CIN. To address these questions, we karyotyped a consecutive series of 96 near-diploid colorectal cancers (CRCs) and distinguished chromosomal changes generated by either MSG or SR in tumor cells. Eighty-three tumors (86%) presented with chromosomal abnormalities that contained both MSGs and SRs to varying degrees whereas all 13 others (14%) showed normal karyotype. Using a maximum likelihood statistical method, chromosomes affected by MSG or SR and likely to represent changes that are selected for during tumor progression were found to be different and mostly mutually exclusive. MSGs and SRs were not randomly associated within tumors, delineating two major pathways of chromosome alterations that consisted of either chromosome gains by MSG or chromosomal losses by both MSG and SR. CRCs showing microsatellite instability (MSI) presented with either normal karyotype or chromosome gains whereas MSS (microsatellite stable) CRCs exhibited a combination of the two pathways. Taken together, these data provide new insights into the respective involvement of MSG and SR in near-diploid colorectal cancers, showing how these processes target distinct portions of the genome and result in specific patterns of chromosomal changes according to MSI status.	[Muleris, Martine; Chalastanis, Alexandra; Hamelin, Richard; Flejou, Jean-Francois; Duval, Alex] CDR St Antoine, UMRS 762, INSERM, F-75012 Paris, France; [Muleris, Martine; Chalastanis, Alexandra; Hamelin, Richard; Flejou, Jean-Francois; Duval, Alex] UPMC Univ Paris 06, CDR, UMRS 762, Paris, France; [Meyer, Nicolas] Fac Med, Lab biostat informat med, Strasbourg, France; [Meyer, Nicolas] CHU, Dept Sante Publ, Strasbourg, France; [Lae, Marick; Sastre-Garau, Xavier] Inst Curie, Dept Biol Tumeurs, Serv Pathol, Paris, France; [Dutrillaux, Bernard] Museum Natl dHistoire Naturelle, OSEB, UMR 5202, Paris, France; [Flejou, Jean-Francois] Hop Saint Antoine, Serv dAnatom Pathol, F-75012 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; CHU Strasbourg; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Museum National d'Histoire Naturelle (MNHN); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	Muleris, M (corresponding author), CDR St Antoine, UMRS 762, INSERM, F-75012 Paris, France.	martine.muleris@cephb.fr		Sastre-Garau, Xavier/0000-0001-5992-2083	Association pour la Recherche contre le Cancer [3946]; GEFLUC; le Ministere Francais de la Recherche (MRT) [fellowship]	Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); GEFLUC; le Ministere Francais de la Recherche (MRT)	This work was partly supported by grants from the Association pour la Recherche contre le Cancer (ARC n 3946) and GEFLUC (groupement des entreprises francaises dans la lutte contre le cancer). AC was recipient of a fellowship from le Ministere Francais de la Recherche (MRT).	BAUER KD, 1993, CYTOMETRY, V14, P486, DOI 10.1002/cyto.990140506; Boardman LA, 2007, CLIN CANCER RES, V13, P2323, DOI 10.1158/1078-0432.CCR-06-2739; Buhard O, 2006, J CLIN ONCOL, V24, P241, DOI 10.1200/JCO.2005.02.7227; Camps J, 2006, CARCINOGENESIS, V27, P419, DOI 10.1093/carcin/bgi244; Chan TL, 2001, ONCOGENE, V20, P4871, DOI 10.1038/sj.onc.1204653; Chang SC, 2005, WORLD J GASTROENTERO, V11, P778, DOI 10.3748/wjg.v11.i6.778; Diep CB, 2006, GENE CHROMOSOME CANC, V45, P31, DOI 10.1002/gcc.20261; Douglas EJ, 2004, CANCER RES, V64, P4817, DOI 10.1158/0008-5472.CAN-04-0328; Duval A, 2002, CANCER RES, V62, P1609; Duval A, 2002, CANCER RES, V62, P2447; Georgiades IB, 1999, ONCOGENE, V18, P7933, DOI 10.1038/sj.onc.1203368; Goel A, 2003, CANCER RES, V63, P1608; Goel A, 2007, GASTROENTEROLOGY, V132, P127, DOI 10.1053/j.gastro.2006.09.018; Hoglund M, 2002, CANCER RES, V62, P5939; Jones AM, 2005, ONCOGENE, V24, P118, DOI 10.1038/sj.onc.1208194; Jourdan F, 2003, VIRCHOWS ARCH, V443, P115, DOI 10.1007/s00428-003-0833-z; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Matsuzaki K, 2005, CLIN CANCER RES, V11, P8564, DOI 10.1158/1078-0432.CCR-05-0859; MULERIS M, 1988, CANCER GENET CYTOGEN, V32, P43, DOI 10.1016/0165-4608(88)90310-X; MULERIS M, 1990, CANCER GENET CYTOGEN, V46, P143, DOI 10.1016/0165-4608(90)90100-O; MULERIS M, 1990, CANCER GENET CYTOGEN, V44, P107, DOI 10.1016/0165-4608(90)90203-M; REMVIKOS Y, 1995, GENE CHROMOSOME CANC, V12, P272, DOI 10.1002/gcc.2870120406; SCHAFFER LG, 2005, INT SYSTEM HUMAN CYT; Sugai T, 2000, INT J CANCER, V88, P614, DOI 10.1002/1097-0215(20001115)88:4<614::AID-IJC15>3.3.CO;2-S; Suraweera N, 2002, GASTROENTEROLOGY, V123, P1804, DOI 10.1053/gast.2002.37070; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Trautmann K, 2006, CLIN CANCER RES, V12, P6379, DOI 10.1158/1078-0432.CCR-06-1248; Tsafrir D, 2006, CANCER RES, V66, P2129, DOI 10.1158/0008-5472.CAN-05-2569; Yao J, 1999, INT J CANCER, V80, P667, DOI 10.1002/(SICI)1097-0215(19990301)80:5<667::AID-IJC6>3.0.CO;2-0	29	18	18	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1632	10.1371/journal.pone.0001632	http://dx.doi.org/10.1371/journal.pone.0001632			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286189	Green Submitted, Green Published, gold			2022-12-25	WOS:000260586400025
J	Ohkuni, K; Abdulle, R; Tong, AHY; Boone, C; Kitagawa, K				Ohkuni, Kentaro; Abdulle, Rashid; Tong, Amy Hin Yan; Boone, Charles; Kitagawa, Katsumi			Ybp2 Associates with the Central Kinetochore of Saccharomyces cerevisiae and Mediates Proper Mitotic Progression	PLOS ONE			English	Article								The spindle checkpoint ensures the accurate segregation of chromosomes by monitoring the status of kinetochore attachment to microtubules. Simultaneous mutations in one of several kinetochore and cohesion genes and a spindle checkpoint gene cause a synthetic-lethal or synthetic-sick phenotype. A synthetic genetic array (SGA) analysis using a mad2 Delta query mutant strain of yeast identified YBP2, a gene whose product shares sequence similarity with the product of YBP1, which is required for H2O2-induced oxidation of the transcription factor Yap1. ybp2 Delta was sensitive to benomyl and accumulated at the mitotic stage of the cell cycle. Ybp2 physically associates with proteins of the COMA complex (Ctf19, Okp1, Mcm21, and Ame1) and 3 components of the Ndc80 complex (Ndc80, Nuf2, and Spc25 but not Spc24) in the central kinetochore and with Cse4 (the centromeric histone and CENP-A homolog). Chromatin-immunoprecipitation analyses revealed that Ybp2 associates specifically with CEN DNA. Furthermore, ybp2 Delta showed synthetic-sick interactions with mutants of the genes that encode the COMA complex components. Ybp2 seems to be part of a macromolecular kinetochore complex and appears to contribute to the proper associations among the central kinetochore subcomplexes and the kinetochore-specific nucleosome.	[Ohkuni, Kentaro; Abdulle, Rashid; Kitagawa, Katsumi] St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA; [Tong, Amy Hin Yan; Boone, Charles] Univ Toronto, Banting & Best Dept Med Res, Toronto, ON, Canada; [Tong, Amy Hin Yan; Boone, Charles] Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON, Canada	St Jude Children's Research Hospital; University of Toronto; University of Toronto	Ohkuni, K (corresponding author), St Jude Childrens Res Hosp, Dept Mol Pharmacol, 332 N Lauderdale St, Memphis, TN 38105 USA.	katsumi.kitagawa@stjude.org			National Cancer Institute [CA21765]; NIH [GM68418]; American Lebanese Syrian Association Charities (ALSAC); Canadian Institutes of Health Research (CIHR); Genome Canada; Genome Ontario; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068418] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Lebanese Syrian Association Charities (ALSAC)(American Lebanese Syrian Associated Charities (ALSAC)); Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Genome Canada(Genome Canada); Genome Ontario; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	KK was supported by the Cancer Center Support Grant CA21765 from the National Cancer Institute, the NIH grant GM68418, and the American Lebanese Syrian Association Charities (ALSAC). CB was supported by grants from the Canadian Institutes of Health Research (CIHR) and Genome Canada and Genome Ontario.	Baetz KK, 2004, MOL CELL BIOL, V24, P1232, DOI 10.1128/MCB.24.3.1232-1244.2003; Bansal PK, 2004, MOL CELL BIOL, V24, P8069, DOI 10.1128/MCB.24.18.8069-8079.2004; Biggins S, 2003, CURR BIOL, V13, pR449, DOI 10.1016/S0960-9822(03)00369-5; Biggins S, 2001, GENE DEV, V15, P3118, DOI 10.1101/gad.934801; Cheeseman IM, 2006, CELL, V127, P983, DOI 10.1016/j.cell.2006.09.039; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; Daniel JA, 2006, GENETICS, V172, P53, DOI 10.1534/genetics.105.046441; De Wulf P, 2003, GENE DEV, V17, P2902, DOI 10.1101/gad.1144403; DeLuca JG, 2006, CELL, V127, P969, DOI 10.1016/j.cell.2006.09.047; Dong YM, 2007, NAT CELL BIOL, V9, P516, DOI 10.1038/ncb1576; GERRING SL, 1990, EMBO J, V9, P4347, DOI 10.1002/j.1460-2075.1990.tb07884.x; Goshima G, 2000, CELL, V100, P619, DOI 10.1016/S0092-8674(00)80699-6; Gulshan K, 2004, EUKARYOT CELL, V3, P318, DOI 10.1128/EC.3.2.318-330.2004; He XW, 2000, CELL, V101, P763, DOI 10.1016/S0092-8674(00)80888-0; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Hyland KM, 1999, J CELL BIOL, V145, P15, DOI 10.1083/jcb.145.1.15; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kitagawa K, 2003, MOL CELL, V11, P1201, DOI 10.1016/S1097-2765(03)00145-X; Kitagawa K, 1999, MOL CELL, V4, P21, DOI 10.1016/S1097-2765(00)80184-7; Kitagawa K, 2001, NAT REV MOL CELL BIO, V2, P678, DOI 10.1038/35089568; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; KOSHLAND D, 1987, METHOD ENZYMOL, V155, P351; Krogan NJ, 2004, P NATL ACAD SCI USA, V101, P13513, DOI 10.1073/pnas.0405753101; Kroll ES, 1996, GENETICS, V143, P95; Lee MS, 2004, P NATL ACAD SCI USA, V101, P10655, DOI 10.1073/pnas.0404102101; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mayer ML, 2001, MOL CELL, V7, P959, DOI 10.1016/S1097-2765(01)00254-4; McAinsh AD, 2003, ANNU REV CELL DEV BI, V19, P519, DOI 10.1146/annurev.cellbio.19.111301.155607; Measday V, 2005, P NATL ACAD SCI USA, V102, P13956, DOI 10.1073/pnas.0503504102; Measday V, 2004, NAT CELL BIOL, V6, P94, DOI 10.1038/ncb0204-94; Measday V, 2002, METHOD ENZYMOL, V350, P316, DOI 10.1016/S0076-6879(02)50971-X; Measday V, 2002, GENE DEV, V16, P101, DOI 10.1101/gad.949302; Meluh PB, 1997, GENE DEV, V11, P3401, DOI 10.1101/gad.11.24.3401; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Montpetit B, 2005, GENETICS, V171, P489, DOI 10.1534/genetics.105.045799; Montpetit B, 2006, J CELL BIOL, V174, P653, DOI 10.1083/jcb.200605019; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; PALMER RE, 1992, J CELL BIOL, V119, P583, DOI 10.1083/jcb.119.3.583; Pearson CG, 2001, J CELL BIOL, V152, P1255, DOI 10.1083/jcb.152.6.1255; Pot I, 2005, CELL CYCLE, V4, P1448, DOI 10.4161/cc.4.10.2106; Pot I, 2003, MOL BIOL CELL, V14, P460, DOI 10.1091/mbc.E02-08-0517; Rose MD., 1990, METHODS YEAST GENETI; Sharp JA, 2003, CURR TOP MICROBIOL, V274, P23; SIKORSKI RS, 1989, GENETICS, V122, P19; SPENCER F, 1990, GENETICS, V124, P237; Stegmeier F, 2002, CELL, V108, P207, DOI 10.1016/S0092-8674(02)00618-9; Sullivan M, 2001, NAT CELL BIOL, V3, P771, DOI 10.1038/ncb0901-771; Tanaka TU, 2000, NAT CELL BIOL, V2, P492, DOI 10.1038/35019529; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Uhlmann F, 2003, CURR BIOL, V13, pR104, DOI 10.1016/S0960-9822(03)00039-3; Veal EA, 2003, J BIOL CHEM, V278, P30896, DOI 10.1074/jbc.M303542200; Wei RR, 2007, NAT STRUCT MOL BIOL, V14, P54, DOI 10.1038/nsmb1186; Westermann S, 2007, ANNU REV BIOCHEM, V76, P563, DOI 10.1146/annurev.biochem.76.052705.160607	54	13	14	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1617	10.1371/journal.pone.0001617	http://dx.doi.org/10.1371/journal.pone.0001617			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286174	Green Published, Green Submitted, gold			2022-12-25	WOS:000260586400010
J	Vicente-Crespo, M; Pascual, M; Fernandez-Costa, JM; Garcia-Lopez, A; Monferrer, L; Miranda, ME; Zhou, L; Artero, RD				Vicente-Crespo, Marta; Pascual, Maya; Fernandez-Costa, Juan M.; Garcia-Lopez, Amparo; Monferrer, Lidon; Miranda, M. Eugenia; Zhou, Lei; Artero, Ruben D.			Drosophila Muscleblind Is Involved in troponin T Alternative Splicing and Apoptosis	PLOS ONE			English	Article							TRANSLATIONAL REPRESSOR BRUNO; MYOTONIC-DYSTROPHY TYPE-1; NUCLEAR FOCI; REPEAT TRANSCRIPTS; GENE-EXPRESSION; PRONEURAL GENE; RNA; PROTEINS; FAMILY; MODEL	Background: Muscleblind-like proteins (MBNL) have been involved in a developmental switch in the use of defined cassette exons. Such transition fails in the CTG repeat expansion disease myotonic dystrophy due, in part, to sequestration of MBNL proteins by CUG repeat RNA. Four protein isoforms (MblA-D) are coded by the unique Drosophila muscleblind gene. Methodology/Principal Findings: We used evolutionary, genetic and cell culture approaches to study muscleblind (mbl) function in flies. The evolutionary study showed that the MblC protein isoform was readily conserved from nematods to Drosophila, which suggests that it performs the most ancestral muscleblind functions. Overexpression of MblC in the fly eye precursors led to an externally rough eye morphology. This phenotype was used in a genetic screen to identify five dominant suppressors and 13 dominant enhancers including Drosophila CUG-BP1 homolog aret, exon junction complex components tsunagi and Aly, and pro-apoptotic genes Traf1 and reaper. We further investigated Muscleblind implication in apoptosis and splicing regulation. We found missplicing of troponin T in muscleblind mutant pupae and confirmed Muscleblind ability to regulate mouse fast skeletal muscle Troponin T (TnnT3) minigene splicing in human HEK cells. MblC overexpression in the wing imaginal disc activated apoptosis in a spatially restricted manner. Bioinformatics analysis identified a conserved FKRP motif, weakly resembling a sumoylation target site, in the MblC-specific sequence. Site-directed mutagenesis of the motif revealed no change in activity of mutant MblC on TnnT3 minigene splicing or aberrant binding to CUG repeat RNA, but altered the ability of the protein to form perinuclear aggregates and enhanced cell death-inducing activity of MblC overexpression. Conclusions/Significance: Taken together our genetic approach identify cellular processes influenced by Muscleblind function, whereas in vivo and cell culture experiments define Drosophila troponin T as a new Muscleblind target, reveal a potential involvement of MblC in programmed cell death and recognize the FKRP motif as a putative regulator of MblC function and/or subcellular location in the cell.	[Vicente-Crespo, Marta; Pascual, Maya; Fernandez-Costa, Juan M.; Garcia-Lopez, Amparo; Monferrer, Lidon; Miranda, M. Eugenia; Artero, Ruben D.] Univ Valencia, Dept Genet, Valencia, Spain; [Zhou, Lei] Univ Florida, Coll Med, Shands Canc Ctr, Gainesville, FL USA	University of Valencia; State University System of Florida; University of Florida	Vicente-Crespo, M (corresponding author), Univ Valencia, Dept Genet, Valencia, Spain.	ruben.artero@uv.es	Fernandez-Costa, Juan M/Q-1670-2015; Artero, Ruben/K-6815-2014; MONFERRER, LIDÓN/H-8107-2015; Vicente-Crespo, Marta/AAT-8644-2020	Fernandez-Costa, Juan M/0000-0002-1854-6082; Artero, Ruben/0000-0003-1596-047X; MONFERRER, LIDÓN/0000-0001-8117-6814; Vicente-Crespo, Marta/0000-0002-8381-6747	Generalitat Valenciana [GV04B164, predoctoral fellowship]; Ministerio de Educacion y Ciencia (MEC) [SAF2003-03536, SAF2006-09121, FPU fellowships]; Muscular Dystrophy Association (USA) [3315]	Generalitat Valenciana(Center for Forestry Research & Experimentation (CIEF)European Commission); Ministerio de Educacion y Ciencia (MEC)(Spanish Government); Muscular Dystrophy Association (USA)(Muscular Dystrophy Association)	Work supported by grants GV04B164 from the Generalitat Valenciana, SAF2003-03536 and SAF2006-09121 from the Ministerio de Educacion y Ciencia (MEC), and 3315 from the Muscular Dystrophy Association (USA). M.V.C. and A.G.L were supported by FPU fellowships from the MEC and J.M.F.C. by a predoctoral fellowship from the Generalitat Valenciana.	Adereth Y, 2005, NAT CELL BIOL, V7, P1240, DOI 10.1038/ncb1335; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Artero R, 1998, DEV BIOL, V195, P131, DOI 10.1006/dbio.1997.8833; Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; Begemann G, 1997, DEVELOPMENT, V124, P4321; Benoist P, 1998, J BIOL CHEM, V273, P7538, DOI 10.1074/jbc.273.13.7538; Bieri T, 2007, NUCLEIC ACIDS RES, V35, pD506, DOI 10.1093/nar/gkl818; Bossis G, 2005, MOL CELL BIOL, V25, P6964, DOI 10.1128/MCB.25.16.6964-6979.2005; BRAND AH, 1993, DEVELOPMENT, V118, P401; Charlet-B N, 2002, MOL CELL, V10, P45, DOI 10.1016/S1097-2765(02)00572-5; Chaudhuri T, 2005, J MOL BIOL, V352, P58, DOI 10.1016/j.jmb.2005.06.066; Cheah PY, 2000, DEVELOPMENT, V127, P3325; Chekulaeva M, 2006, CELL, V124, P521, DOI 10.1016/j.cell.2006.01.031; Crosby MA, 2007, NUCLEIC ACIDS RES, V35, pD486, DOI 10.1093/nar/gkl827; Dean B, 2007, AUST NZ J PSYCHIAT, V41, P308, DOI 10.1080/00048670701213245; Delaunay J, 2004, NUCLEIC ACIDS RES, V32, P3070, DOI 10.1093/nar/gkh627; Ebralidze A, 2004, SCIENCE, V303, P383, DOI 10.1126/science.1088679; Edgar AJ, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-1; Fardaei M, 2002, HUM MOL GENET, V11, P805, DOI 10.1093/hmg/11.7.805; Garcia-Casado Z, 2002, GENESIS, V34, P111, DOI 10.1002/gene.10147; GARCIALOPEZ LMA, PLOS ONE IN PRESS; Goulding SE, 2000, NEURON, V25, P69, DOI 10.1016/S0896-6273(00)80872-7; Grimaldi D.A., 1990, B AM MUSEUM NATURAL; Hay BA, 2004, NAT REV GENET, V5, P911, DOI 10.1038/nrg1491; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hayashi S, 2002, GENESIS, V34, P58, DOI 10.1002/gene.10137; Ho TH, 2004, EMBO J, V23, P3103, DOI 10.1038/sj.emboj.7600300; Houseley JM, 2005, HUM MOL GENET, V14, P873, DOI 10.1093/hmg/ddi080; Huang ML, 2000, NEURON, V25, P57, DOI 10.1016/S0896-6273(00)80871-5; Jiang H, 2004, HUM MOL GENET, V13, P3079, DOI 10.1093/hmg/ddh327; Kanadia RN, 2006, P NATL ACAD SCI USA, V103, P11748, DOI 10.1073/pnas.0604970103; Kanadia RN, 2003, SCIENCE, V302, P1978, DOI 10.1126/science.1088583; KANIA A, 1995, GENETICS, V139, P1663; Kim HJ, 2007, CELL DEATH DIFFER, V14, P103, DOI 10.1038/sj.cdd.4401935; Kino Y, 2004, HUM MOL GENET, V13, P495, DOI 10.1093/hmg/ddh056; Krol J, 2007, MOL CELL, V25, P575, DOI 10.1016/j.molcel.2007.01.031; Ladd AN, 2005, DEV DYNAM, V233, P783, DOI 10.1002/dvdy.20382; LEE KS, 2007, DIFFERENTIATION; Lin XY, 2006, HUM MOL GENET, V15, P2087, DOI 10.1093/hmg/ddl132; Machuca-Tzili L, 2006, HUM GENET, V120, P487, DOI 10.1007/s00439-006-0228-8; Mankodi A, 2005, CIRC RES, V97, P1152, DOI 10.1161/01.RES.0000193598.89753.e3; Mankodi A, 2001, HUM MOL GENET, V10, P2165, DOI 10.1093/hmg/10.19.2165; Miller JW, 2000, EMBO J, V19, P4439, DOI 10.1093/emboj/19.17.4439; Monferrer L, 2006, J HERED, V97, P67, DOI 10.1093/jhered/esj003; Mutsuddi M, 2004, CURR BIOL, V14, P302, DOI 10.1016/j.cub.2004.01.034; Osborne RJ, 2006, HUM MOL GENET, V15, pR162, DOI 10.1093/hmg/ddl181; Park JW, 2004, P NATL ACAD SCI USA, V101, P15974, DOI 10.1073/pnas.0407004101; Pascual M, 2006, DIFFERENTIATION, V74, P65, DOI 10.1111/j.1432-0436.2006.00060.x; Paul S, 2006, EMBO J, V25, P4271, DOI 10.1038/sj.emboj.7601296; Ran RQ, 2004, CELL STRESS CHAPERON, V9, P229, DOI 10.1379/CSC-19R.1; Ranum LPW, 2006, ANNU REV NEUROSCI, V29, P259, DOI 10.1146/annurev.neuro.29.051605.113014; Savkur RS, 2001, NAT GENET, V29, P40, DOI 10.1038/ng704; Schwerk C, 2005, MOL CELL, V19, P1, DOI 10.1016/j.molcel.2005.05.026; Shulman JM, 2003, GENETICS, V165, P1233; Squillace RM, 2002, DEV BIOL, V250, P218, DOI 10.1006/dbio.2002.0798; Strodicke M, 2000, MECH DEVELOP, V96, P67, DOI 10.1016/S0925-4773(00)00371-3; TANEJA KL, 1995, J CELL BIOL, V128, P995, DOI 10.1083/jcb.128.6.995; Toba G, 1999, GENETICS, V151, P725; Vicente M, 2007, DIFFERENTIATION, V75, P427, DOI 10.1111/j.1432-0436.2006.00156.x; Webster PJ, 1997, GENE DEV, V11, P2510, DOI 10.1101/gad.11.19.2510; Wilson VG, 2001, EXP CELL RES, V271, P57, DOI 10.1006/excr.2001.5366; Xue Y, 2006, NUCLEIC ACIDS RES, V34, pW254, DOI 10.1093/nar/gkl207; Yan N, 2004, GENETICS, V168, P1433, DOI 10.1534/genetics.104.033985; Yuan Y, 2007, NUCLEIC ACIDS RES, V35, P5474, DOI 10.1093/nar/gkm601; Zhou L, 2005, EMBO REP, V6, P769, DOI 10.1038/sj.embor.7400473	65	27	30	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1613	10.1371/journal.pone.0001613	http://dx.doi.org/10.1371/journal.pone.0001613			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286170	gold, Green Published, Green Submitted			2022-12-25	WOS:000260586400006
J	Wang, YZ; Wei, JH; Bisel, B; Tang, DM; Seemann, JC				Wang, Yanzhuang; Wei, Jen-Hsuan; Bisel, Blaine; Tang, Danming; Seemann, Joachim			Golgi Cisternal Unstacking Stimulates COPI Vesicle Budding and Protein Transport	PLOS ONE			English	Article								The Golgi apparatus in mammalian cells is composed of flattened cisternae that are densely packed to form stacks. We have used the Golgi stacking protein GRASP65 as a tool to modify the stacking state of Golgi cisternae. We established an assay to measure protein transport to the cell surface in post-mitotic cells in which the Golgi was unstacked. Cells with an unstacked Golgi showed a higher transport rate compared to cells with stacked Golgi membranes. Vesicle budding from unstacked cisternae in vitro was significantly increased compared to stacked membranes. These results suggest that Golgi cisternal stacking can directly regulate vesicle formation and thus the rate of protein transport through the Golgi. The results further suggest that at the onset of mitosis, unstacking of cisternae allows extensive and rapid vesiculation of the Golgi in preparation for its subsequent partitioning.	[Wang, Yanzhuang; Tang, Danming] Univ Michigan, Dept Mol, Cell & Developmental Biol, Ann Arbor, MI USA; [Wei, Jen-Hsuan; Bisel, Blaine; Seemann, Joachim] Univ Texas SW Med Ctr, Dept Cell Biol, Dallas, TX USA	University of Michigan System; University of Michigan; University of Texas System; University of Texas Southwestern Medical Center Dallas	Wang, YZ (corresponding author), Univ Michigan, Dept Mol, Cell & Developmental Biol, Ann Arbor, MI USA.	joachim.seemann@utsouthwestern.edu	Wang, Yanzhuang/AAE-5299-2019; Wei, Jen-Hsuan/AAG-2920-2021	Wang, Yanzhuang/0000-0002-1864-7094; Wei, Jen-Hsuan/0000-0001-8958-6455	Pardee Cancer Research Foundation; Virginia Murchison Lithicum Scholar in Medical Research	Pardee Cancer Research Foundation; Virginia Murchison Lithicum Scholar in Medical Research	Y.W. is supported by the Pardee Cancer Research Foundation. J.S. is a Virginia Murchison Lithicum Scholar in Medical Research.	Barr FA, 1997, CELL, V91, P253, DOI 10.1016/S0092-8674(00)80407-9; Cai HQ, 2007, DEV CELL, V12, P671, DOI 10.1016/j.devcel.2007.04.005; Colanzi A, 2003, CURR OPIN CELL BIOL, V15, P462, DOI 10.1016/S0955-0674(03)00067-X; Elsner M, 2003, MOL MEMBR BIOL, V20, P221, DOI 10.1080/0968768031000114024; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Kondylis V, 2005, MOL BIOL CELL, V16, P4061, DOI 10.1091/mbc.E04-10-0938; Lane JD, 2002, J CELL BIOL, V156, P495, DOI 10.1083/jcb.200110007; LIN CY, 2000, P NATL ACAD SCI US; Losev E, 2006, NATURE, V441, P1002, DOI 10.1038/nature04717; Lowe M, 1998, CELL, V94, P783, DOI 10.1016/S0092-8674(00)81737-7; Lowe M, 2007, NAT REV MOL CELL BIO, V8, P429, DOI 10.1038/nrm2179; Lupashin V, 2005, BBA-MOL CELL RES, V1744, P325, DOI 10.1016/j.bbamcr.2005.03.013; Malhotra V, 2006, NATURE, V441, P939, DOI 10.1038/441939a; Marsh BJ, 2004, P NATL ACAD SCI USA, V101, P5565, DOI 10.1073/pnas.0401242101; Martinez-Menarguez JA, 2001, J CELL BIOL, V155, P1213, DOI 10.1083/jcb.200108029; Matsuura-Tokita K, 2006, NATURE, V441, P1007, DOI 10.1038/nature04737; Mironov AA, 2005, BBA-MOL CELL RES, V1744, P340, DOI 10.1016/j.bbamcr.2005.03.005; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Pavel J, 1998, P NATL ACAD SCI USA, V95, P2140, DOI 10.1073/pnas.95.5.2140; Pfeffer SR, 2007, ANNU REV BIOCHEM, V76, P629, DOI 10.1146/annurev.biochem.76.061705.130002; Preisinger C, 2005, EMBO J, V24, P753, DOI 10.1038/sj.emboj.7600569; Puthenveedu MA, 2006, NAT CELL BIOL, V8, P238, DOI 10.1038/ncb1366; Rabouille C, 2003, MOL MEMBR BIOL, V20, P117, DOI 10.1080/0968768031000084163; Seemann J, 2000, MOL BIOL CELL, V11, P635, DOI 10.1091/mbc.11.2.635; Shima DT, 1998, J CELL BIOL, V141, P955, DOI 10.1083/jcb.141.4.955; Shorter J, 2002, ANNU REV CELL DEV BI, V18, P379, DOI 10.1146/annurev.cellbio.18.030602.133733; Shorter J, 2002, J CELL BIOL, V157, P45, DOI 10.1083/jcb.200112127; Shorter J, 1999, J CELL BIOL, V146, P57, DOI 10.1083/jcb.146.1.57; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; Sutterlin C, 2005, MOL BIOL CELL, V16, P3211, DOI 10.1091/mbc.E04-12-1065; TANG D, 2007, J BIOL CHEM; Trucco A, 2004, NAT CELL BIOL, V6, P1071, DOI 10.1038/ncb1180; Wang YZ, 2005, J BIOL CHEM, V280, P4921, DOI 10.1074/jbc.M412407200; Wang YZ, 2003, EMBO J, V22, P3279, DOI 10.1093/emboj/cdg317; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; Xiang Y, 2007, J BIOL CHEM, V282, P21829, DOI 10.1074/jbc.M611716200; Zaal KJM, 1999, CELL, V99, P589, DOI 10.1016/S0092-8674(00)81548-2	38	53	54	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1647	10.1371/journal.pone.0001647	http://dx.doi.org/10.1371/journal.pone.0001647			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18297130	Green Submitted, Green Published, gold			2022-12-25	WOS:000260586400040
J	Briedis, KM; Starr, A; Bourne, PE				Briedis, Kristine M.; Starr, Ayelet; Bourne, Philip E.			Analysis of the Human Kinome Using Methods Including Fold Recognition Reveals Two Novel Kinases	PLOS ONE			English	Article							CHOLINE PHOSPHOLIPID-METABOLISM; SEQUENCE; PROTEINS; CLASSIFICATION; RESOURCE; HOMOLOGY; DATABASE	Background: Protein sequence similarity is a commonly used criterion for inferring the unknown function of a protein from a protein of known function. However, proteins can diverge significantly over time such that sequence similarity is difficult, if not impossible, to find. In some cases, a structural similarity remains over long evolutionary time scales and once detected can be used to predict function. Methodology/Principal Findings: Here we employed a high-throughput approach to assign structural and functional annotation to the human proteome, focusing on the collection of human protein kinases, the human kinome. We compared human protein sequences to a library of domains from known structures using WU-BLAST, PSI-BLAST, and 123D. This approach utilized both sequence comparison and fold recognition methods. The resulting set of potential protein kinases was cross-checked against previously identified human protein kinases, and analyzed for conserved kinase motifs. Conclusions/Significance: We demonstrate that our structure-based method can be used to identify both typical and atypical human protein kinases. We also identify two potentially novel kinases that contain an interesting combination of kinase and acyl-CoA dehydrogenase domains.	[Briedis, Kristine M.] Univ Calif San Diego, Bioinformat Program, La Jolla, CA 92093 USA; [Starr, Ayelet] Univ Calif San Diego, Dept Bioengn, La Jolla, CA USA; [Bourne, Philip E.] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Briedis, KM (corresponding author), Univ Calif San Diego, Bioinformat Program, La Jolla, CA 92093 USA.	kbriedis@ucsd.edu	Bourne, Philip/ABG-8967-2021	Bourne, Philip/0000-0002-7618-7292; Briedis, Kasparas/0000-0003-0338-9544	NIH [GM63208]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM063208] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by NIH GM63208.	Ackerstaff E, 2003, J CELL BIOCHEM, V90, P525, DOI 10.1002/jcb.10659; Alexandrov N, 2003, BIOINFORMATICS, V19, P429, DOI 10.1093/bioinformatics/btg006; Alexandrov N N, 1996, Pac Symp Biocomput, P53; Altschul SF, 1998, TRENDS BIOCHEM SCI, V23, P444, DOI 10.1016/S0968-0004(98)01298-5; Aoyama C, 2004, PROG LIPID RES, V43, P266, DOI 10.1016/j.plipres.2003.12.001; Bartlett Gail J, 2003, Methods Biochem Anal, V44, P387; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Birney E, 2006, NUCLEIC ACIDS RES, V34, pD556, DOI 10.1093/nar/gkj133; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; Brenner SE, 1998, P NATL ACAD SCI USA, V95, P6073, DOI 10.1073/pnas.95.11.6073; Chandonia JM, 2006, SCIENCE, V311, P347, DOI 10.1126/science.1121018; Cheek S, 2005, BMC STRUCT BIOL, V5, DOI 10.1186/1472-6807-5-6; Daigle DM, 1999, CHEM BIOL, V6, P11, DOI 10.1016/S1074-5521(99)80016-7; Glunde K, 2004, CANCER RES, V64, P4270, DOI 10.1158/0008-5472.CAN-03-3829; Gough J, 2001, J MOL BIOL, V313, P903, DOI 10.1006/jmbi.2001.5080; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HOLM L, 1995, EMBO J, V14, P1287, DOI 10.1002/j.1460-2075.1995.tb07114.x; Hon WC, 1997, CELL, V89, P887, DOI 10.1016/S0092-8674(00)80274-3; Kannan N, 2005, J MOL BIOL, V351, P956, DOI 10.1016/j.jmb.2005.06.057; Li WW, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-8-r51; Lopez R, 2003, NUCLEIC ACIDS RES, V31, P3795, DOI 10.1093/nar/gkg573; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Rost B, 1999, PROTEIN ENG, V12, P85, DOI 10.1093/protein/12.2.85; Scheeff ED, 2005, PLOS COMPUT BIOL, V1, P359, DOI 10.1371/journal.pcbi.0010049; Wheeler DL, 2007, NUCLEIC ACIDS RES, V35, pD5, DOI 10.1093/nar/gkl1031; Wu CH, 2006, NUCLEIC ACIDS RES, V34, pD187, DOI 10.1093/nar/gkj161; Yang AS, 2000, J MOL BIOL, V301, P679, DOI 10.1006/jmbi.2000.3974; Ye X, 2004, MOL BIOL REP, V31, P191, DOI 10.1023/B:MOLE.0000043622.57408.6b; Yuan C, 2004, J BIOL CHEM, V279, P17801, DOI 10.1074/jbc.M401382200	31	8	8	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1597	10.1371/journal.pone.0001597	http://dx.doi.org/10.1371/journal.pone.0001597			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270584	Green Published, gold			2022-12-25	WOS:000260535900031
J	Jiang, YJ; Xu, DS; Zhao, Y; Zhang, LW				Jiang, Yanjun; Xu, Dongsheng; Zhao, Yong; Zhang, Luwen			Mutual Inhibition between Kaposi's Sarcoma-Associated Herpesvirus and Epstein-Barr Virus Lytic Replication Initiators in Dually-Infected Primary Effusion Lymphoma	PLOS ONE			English	Article								Background: Both Kaposi's sarcoma-associated herpesvirus ( KSHV) and Epstein-Barr virus (EBV) are members of the human gamma herpesvirus family: each is associated with various human cancers. The majority of AIDS-associated primary effusion lymphoma (PEL) are co-infected with both KSHV and EBV. Dually-infected PELs selectively switch from latency to lytic replication of either KSHV or EBV in response to chemical stimuli. KSHV replication and transcription activator (K-RTA) is necessary and sufficient for the switch from KSHV latency to lytic replication, while EBV BZLF1 gene product (EBV-Z) is a critical initiator for induction of EBV lytic replication. Methodology/Principal Findings: We show K-RTA and EBV-Z are co-localized and physically interact with each other in dually-infected PELs. K-RTA inhibits the EBV lytic replication by nullifying EBV-Z-mediated EBV lytic gene activation. EBV-Z inhibits KSHV lytic gene expression by blocking K-RTA-mediated transactivations. The physical interaction between K-RTA and EBV-Z are required for the mutual inhibition of the two molecules. The leucine heptapeptide repeat (LR) region in K-RTA and leucine zipper region in EBV-Z are involved in the physical interactions of the two molecules. Finally, initiation of KSHV lytic gene expression is correlated with the reduction of EBV lytic gene expression in the same PEL cells. Conclusions/Significance: In this report, how the two viruses interact with each other in dually infected PELs is addressed. Our data may provide a possible mechanism for maintaining viral latency and for selective lytic replication in dually infected PELs, i.e., through mutual inhibition of two critical lytic replication initiators. Our data about putative interactions between EBV and KSHV would be applicable to the majority of AIDS-associated PELs and may be relevant to the pathogenesis of PELs.	[Jiang, Yanjun; Xu, Dongsheng; Zhang, Luwen] Univ Nebraska, Nebraska Ctr Virol, Lincoln, NE 68583 USA; [Zhao, Yong; Zhang, Luwen] Univ Nebraska, Sch Biol Sci, Lincoln, NE USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln	Jiang, YJ (corresponding author), Univ Nebraska, Nebraska Ctr Virol, Lincoln, NE 68583 USA.	lzhang2@unlnotes.unl.edu			NIH [AI59132, CA108951]; NCRR COBRA [RR15635]; NATIONAL CANCER INSTITUTE [R01CA108951] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI059132] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCRR COBRA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported in part by grants from the NIH AI59132, CA108951, and NCRR COBRA grant RR15635 (LZ).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adamson AL, 1999, J VIROL, V73, P6551, DOI 10.1128/JVI.73.8.6551-6558.1999; Adamson AL, 2001, J VIROL, V75, P2388, DOI 10.1128/JVI.75.5.2388-2399.2001; Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; Bell P, 2000, J VIROL, V74, P11800, DOI 10.1128/JVI.74.24.11800-11810.2000; Borza CM, 2002, NAT MED, V8, P594, DOI 10.1038/nm0602-594; Bu W, 2007, J VIROL, V81, P5788, DOI 10.1128/JVI.00140-07; Carroll KD, 2006, J VIROL, V80, P9697, DOI 10.1128/JVI.00746-06; Cayrol C, 1996, J BIOL CHEM, V271, P31799, DOI 10.1074/jbc.271.50.31799; Cayrol C, 1996, EMBO J, V15, P2748, DOI 10.1002/j.1460-2075.1996.tb00635.x; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; Chang H, 2005, J VIROL, V79, P4651, DOI 10.1128/JVI.79.8.4651-4663.2005; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, INFECT AGENT DIS, V5, P215; CHEVALLIERGRECO A, 1986, EMBO J, V5, P3243, DOI 10.1002/j.1460-2075.1986.tb04635.x; COUNTRYMAN J, 1985, P NATL ACAD SCI USA, V82, P4085, DOI 10.1073/pnas.82.12.4085; COX MA, 1990, J VIROL, V64, P313, DOI 10.1128/JVI.64.1.313-321.1990; Deng HY, 2000, J GEN VIROL, V81, P3043, DOI 10.1099/0022-1317-81-12-3043; Deng HY, 2002, BLOOD, V100, P1919, DOI 10.1182/blood-2002-01-0015; Deng Z, 2001, J VIROL, V75, P10334, DOI 10.1128/JVI.75.21.10334-10347.2001; Dourmishev LA, 2003, MICROBIOL MOL BIOL R, V67, P175, DOI 10.1128/MMBR.67.2.175-212.2003; Drexler HG, 1998, LEUKEMIA, V12, P1507, DOI 10.1038/sj.leu.2401160; Fan W, 2005, J VIROL, V79, P1244, DOI 10.1128/JVI.79.2.1244-1251.2005; Feederle R, 2000, EMBO J, V19, P3080, DOI 10.1093/emboj/19.12.3080; FIXMAN ED, 1992, J VIROL, V66, P5030, DOI 10.1128/JVI.66.8.5030-5039.1992; FLEMINGTON E, 1990, J VIROL, V64, P1227, DOI 10.1128/JVI.64.3.1227-1232.1990; FLEMINGTON E, 1990, P NATL ACAD SCI USA, V87, P9459, DOI 10.1073/pnas.87.23.9459; Fujii K, 2000, J VIROL, V74, P2550, DOI 10.1128/JVI.74.6.2550-2557.2000; Gershburg E, 2002, J VIROL, V76, P998, DOI 10.1128/JVI.76.3.998-1003.2002; Gradoville L, 2000, J VIROL, V74, P6207, DOI 10.1128/JVI.74.13.6207-6212.2000; Groves AK, 2001, J VIROL, V75, P9446, DOI 10.1128/JVI.75.19.9446-9457.2001; Gwack Y, 2002, J BIOL CHEM, V277, P6438, DOI 10.1074/jbc.M108289200; Gwack Y, 2001, J VIROL, V75, P6245, DOI 10.1128/JVI.75.13.6245-6248.2001; Gwack Y, 2001, J VIROL, V75, P1909, DOI 10.1128/JVI.75.4.1909-1917.2001; HOLLEYGUTHRIE EA, 1990, J VIROL, V64, P3753, DOI 10.1128/JVI.64.8.3753-3759.1990; Hwang S, 2001, J VIROL, V75, P9509, DOI 10.1128/JVI.75.19.9509-9516.2001; Izumiya Y, 2003, J VIROL, V77, P1441, DOI 10.1128/JVI.77.2.1441-1451.2003; KENNEY S, 1988, P NATL ACAD SCI USA, V85, P1652, DOI 10.1073/pnas.85.5.1652; Kieff E, 1996, VIROLOGY, P2343; KOUZARIDES T, 1991, ONCOGENE, V6, P195; Krithivas A, 2000, J VIROL, V74, P9637, DOI 10.1128/JVI.74.20.9637-9645.2000; Lan K, 2005, J VIROL, V79, P7453, DOI 10.1128/JVI.79.12.7453-7465.2005; Liang YY, 2003, P NATL ACAD SCI USA, V100, P8490, DOI 10.1073/pnas.1432843100; Liang YY, 2002, GENE DEV, V16, P1977, DOI 10.1101/gad.996502; Liao W, 2003, J VIROL, V77, P3809, DOI 10.1128/JVI.77.6.3809-3815.2003; LIEBERMAN PM, 1990, J VIROL, V64, P1143, DOI 10.1128/JVI.64.3.1143-1155.1990; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LIEBERMAN PM, 1990, J VIROL, V64, P2560, DOI 10.1128/JVI.64.6.2560-2568.1990; Liu PF, 2003, VIROLOGY, V310, P199, DOI 10.1016/S0042-6822(03)00145-4; Lukac DM, 1999, J VIROL, V73, P9348, DOI 10.1128/JVI.73.11.9348-9361.1999; MANET E, 1989, EMBO J, V8, P1819, DOI 10.1002/j.1460-2075.1989.tb03576.x; Matsumura S, 2005, J VIROL, V79, P8493, DOI 10.1128/JVI.79.13.8493-8505.2005; Miller G, 1997, J VIROL, V71, P314, DOI 10.1128/JVI.71.1.314-324.1997; Moore P., 2001, VIROLOGY, P2803; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; Pagano JS, 1999, P ASSOC AM PHYSICIAN, V111, P573, DOI 10.1046/j.1525-1381.1999.t01-1-99220.x; PAGANO JS, 1991, TXB INTERNAL MED, V307, P1499; Park J, 2000, J VIROL, V74, P11977, DOI 10.1128/JVI.74.24.11977-11982.2000; RaabTraub N, 1996, SEMIN VIROL, V7, P315, DOI 10.1006/smvy.1996.0039; Rickinson AB, 1996, VIROLOGY, P2397; Sakakibara S, 2001, J VIROL, V75, P6894, DOI 10.1128/JVI.75.15.6894-6900.2001; Saveliev AK, 2002, VIROLOGY, V299, P301, DOI 10.1006/viro.2002.1561; Seaman WT, 1999, VIROLOGY, V263, P436, DOI 10.1006/viro.1999.9963; Sinclair AJ, 2003, J GEN VIROL, V84, P1941, DOI 10.1099/vir.0.19112-0; Sun R, 1998, P NATL ACAD SCI USA, V95, P10866, DOI 10.1073/pnas.95.18.10866; Sun R, 1999, J VIROL, V73, P2232, DOI 10.1128/JVI.73.3.2232-2242.1999; Trivedi P, 2004, BLOOD, V103, P313, DOI 10.1182/blood-2003-05-1710; TSURUMI T, 1994, J VIROL, V68, P3354, DOI 10.1128/JVI.68.5.3354-3363.1994; TSURUMI T, 1993, J VIROL, V67, P4651, DOI 10.1128/JVI.67.8.4651-4658.1993; TSURUMI T, 1993, J VIROL, V67, P7648, DOI 10.1128/JVI.67.12.7648-7653.1993; URIER G, 1989, EMBO J, V8, P1447, DOI 10.1002/j.1460-2075.1989.tb03527.x; Wang P, 2005, J VIROL, V79, P13298, DOI 10.1128/JVI.79.21.13298-13309.2005; Wang SE, 2003, J VIROL, V77, P600, DOI 10.1128/JVI.77.1.600-623.2003; Wang SZ, 2001, J VIROL, V75, P11961, DOI 10.1128/JVI.75.24.11961-11973.2001; Wang SZE, 2003, J VIROL, V77, P9590, DOI 10.1128/JVI.77.17.9590-9612.2003; West JT, 2003, ONCOGENE, V22, P5150, DOI 10.1038/sj.onc.1206555; Wu FY, 2003, J VIROL, V77, P8893, DOI 10.1128/JVI.77.16.8893-8914.2003; Wu FY, 2002, P NATL ACAD SCI USA, V99, P10683, DOI 10.1073/pnas.162352299; Xu DS, 2007, J VIROL, V81, P6068, DOI 10.1128/JVI.02743-06; Ye JJ, 2007, J VIROL, V81, P9279, DOI 10.1128/JVI.00982-07; Zacny VL, 1999, J VIROL, V73, P7271, DOI 10.1128/JVI.73.9.7271-7277.1999; Zerby D, 1999, MOL CELL BIOL, V19, P1617; Zhang J, 2005, J VIROL, V79, P5640, DOI 10.1128/JVI.79.9.5640-5652.2005; ZHANG L, 2000, J VIROL, V74, P5748; Zhang LW, 2001, J VIROL, V75, P12393, DOI 10.1128/JVI.75.24.12393-12401.2001; Zhang LW, 2001, J VIROL, V75, P341, DOI 10.1128/JVI.75.1.341-350.2001; Zhang LW, 1999, MOL CELL BIOL, V19, P3216; ZHANG Q, 1994, MOL CELL BIOL, V14, P1929, DOI 10.1128/MCB.14.3.1929; Zhu FX, 1999, J VIROL, V73, P5556, DOI 10.1128/JVI.73.7.5556-5567.1999	88	19	19	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2008	3	2							e1569	10.1371/journal.pone.0001569	http://dx.doi.org/10.1371/journal.pone.0001569			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367EQ	18253508	Green Published, gold			2022-12-25	WOS:000260535700032
J	Viengchareun, S; Servel, N; Feve, B; Freemark, M; Lombes, M; Binart, N				Viengchareun, Say; Servel, Nathalie; Feve, Bruno; Freemark, Michael; Lombes, Marc; Binart, Nadine			Prolactin Receptor Signaling Is Essential for Perinatal Brown Adipocyte Function: A Role for Insulin-like Growth Factor-2	PLOS ONE			English	Article							MESSENGER-RIBONUCLEIC-ACID; ADIPOSE-TISSUE; GENE-EXPRESSION; TRANSGENIC MICE; KNOCKOUT MICE; PRL RECEPTOR; DEFICIENT MICE; PPAR-GAMMA; FACTOR-II; HORMONE	Background. The lactogenic hormones prolactin (PRL) and placental lactogens (PL) play central roles in reproduction and mammary development. Their actions are mediated via binding to PRL receptor (PRLR), highly expressed in brown adipose tissue (BAT), yet their impact on adipocyte function and metabolism remains unclear. Methodology/Principal Findings. PRLR knockout (KO) newborn mice were phenotypically characterized in terms of thermoregulation and their BAT differentiation assayed for gene expression studies. Derived brown preadipocyte cell lines were established to evaluate the molecular mechanisms involved in PRL signaling on BAT function. Here, we report that newborn mice lacking PRLR have hypotrophic BAT depots that express low levels of adipocyte nuclear receptor PPAR gamma 2, its coactivator PGC-1 alpha, uncoupling protein 1 (UCP1) and the beta 3 adrenoceptor, reducing mouse viability during cold challenge. Immortalized PRLR KO preadipocytes fail to undergo differentiation into mature adipocytes, a defect reversed by reintroduction of PRLR. That the effects of the lactogens in BAT are at least partly mediated by Insulin-like Growth Factor-2 (IGF-2) is supported by: i) a striking reduction in BAT IGF-2 expression in PRLR KO mice and in PRLR-deficient preadipocytes; ii) induction of cellular IGF-2 expression by PRL through JAK2/STAT5 pathway activation; and iii) reversal of defective differentiation in PRLR KO cells by exogenous IGF-2. Conclusions. Our findings demonstrate that the lactogens act in concert with IGF-2 to control brown adipocyte differentiation and growth. Given the prominent role of brown adipose tissue during the perinatal period, our results identified prolactin receptor signaling as a major player and a potential therapeutic target in protecting newborn mammals against hypothermia.	[Servel, Nathalie; Freemark, Michael; Binart, Nadine] INSERM, U845, Paris, France; [Viengchareun, Say; Feve, Bruno; Lombes, Marc] Inserm, U693, Le Kremlin Bicetre, France; [Viengchareun, Say; Feve, Bruno; Lombes, Marc] Univ Paris Sud, Fac Med Paris Sud, UMR S693, Le Kremlin Bicetre, France; [Servel, Nathalie; Freemark, Michael; Binart, Nadine] Univ Paris 05, Fac de Med Rene Descartes, UMR S845, Site Necker, Paris, France; [Freemark, Michael] Duke Univ, Med Ctr, Div Pediat Endocrinol & Diabetes, Durham, NC USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Duke University	Binart, N (corresponding author), INSERM, U845, Paris, France.	binart@necker.fr	Viengchareun, Say/GOV-6812-2022; Lombes, Marc/L-5933-2018; Binart, Nadine/F-2949-2013; Viengchareun, Say/M-6612-2017	Lombes, Marc/0000-0003-3189-023X; Binart, Nadine/0000-0002-5606-3866; viengchareun, say/0000-0003-4280-3250; Feve, Bruno/0000-0001-6577-9009; Servel, Nathalie/0000-0001-6925-6256	NICHD NIH HHS [R01 HD024192, HD24192] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024192] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ben-Jonathan N, 2006, TRENDS ENDOCRIN MET, V17, P110, DOI 10.1016/j.tem.2006.02.005; Binart N, 2000, ENDOCRINOLOGY, V141, P2691, DOI 10.1210/en.141.7.2691; Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; Brisken C, 2002, DEV CELL, V3, P877, DOI 10.1016/S1534-5807(02)00365-9; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Cianfarani S, 2005, J CLIN ENDOCR METAB, V90, P6028, DOI 10.1210/jc.2005-0721; Collins S, 2004, MOL ENDOCRINOL, V18, P2123, DOI 10.1210/me.2004-0193; Efstratiadis A, 1998, INT J DEV BIOL, V42, P955; Flint DJ, 2006, J ENDOCRINOL, V191, P101, DOI 10.1677/joe.1.06939; Flint David J, 2003, Pituitary, V6, P97, DOI 10.1023/B:PITU.0000004800.57449.67; Fowden AL, 2006, J PHYSIOL-LONDON, V572, P5, DOI 10.1113/jphysiol.2005.104141; Frasca F, 1999, MOL CELL BIOL, V19, P3278, DOI 10.1128/mcb.19.5.3278; Freemark M, 1997, J CLIN INVEST, V99, P1107, DOI 10.1172/JCI119239; FREEMARK M, 1993, ENDOCRINOLOGY, V133, P1830, DOI 10.1210/en.133.4.1830; Freemark M, 2002, ENDOCRINOLOGY, V143, P1378, DOI 10.1210/en.143.4.1378; Freemark M, 2001, ENDOCRINOLOGY, V142, P532, DOI 10.1210/en.142.2.532; Goffin V, 1996, J BIOL CHEM, V271, P16573, DOI 10.1074/jbc.271.28.16573; Goffin V, 2002, ANNU REV PHYSIOL, V64, P47, DOI 10.1146/annurev.physiol.64.081501.131049; Golozoubova V, 2004, MOL ENDOCRINOL, V18, P384, DOI 10.1210/me.2003-0267; GRAY SL, 2006, ENDOCRINOLOGY; Guerra C, 2001, J CLIN INVEST, V108, P1205, DOI 10.1172/JCI200113103; Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037; Imai T, 2004, P NATL ACAD SCI USA, V101, P4543, DOI 10.1073/pnas.0400356101; Jimenez M, 2002, FEBS LETT, V530, P37, DOI 10.1016/S0014-5793(02)03387-2; Kang S, 2005, MOL CELL BIOL, V25, P1272, DOI 10.1128/MCB.25.4.1272-1282.2005; Kedzia U, 2005, CANCER RES, V65, P8497, DOI 10.1158/0008-5472.CAN-04-3937; Klein J, 1999, J BIOL CHEM, V274, P34795, DOI 10.1074/jbc.274.49.34795; Laustsen PG, 2002, GENE DEV, V16, P3213, DOI 10.1101/gad.1034802; LeBaron MJ, 2007, ENDOCRINOLOGY, V148, P989, DOI 10.1210/en.2006-1219; Lehr L, 2006, FEBS LETT, V580, P4661, DOI 10.1016/j.febslet.2006.07.037; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Ling C, 2000, ENDOCRINOLOGY, V141, P3564, DOI 10.1210/en.141.10.3564; Liu J, 2005, CELL METAB, V2, P165, DOI 10.1016/j.cmet.2005.08.006; LOMBES M, 1993, BIOCHEM J, V292, P577, DOI 10.1042/bj2920577; Miki H, 2001, MOL CELL BIOL, V21, P2521, DOI 10.1128/MCB.21.7.2521-2532.2001; MOHAN S, 1995, J CLIN ENDOCR METAB, V80, P637, DOI 10.1210/jc.80.2.637; Nanbu-Wakao R, 2000, MOL ENDOCRINOL, V14, P307, DOI 10.1210/me.14.2.307; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; Pandini G, 2003, J BIOL CHEM, V278, P42178, DOI 10.1074/jbc.M304980200; Pearce S, 2005, J ENDOCRINOL, V184, P351, DOI 10.1677/joe.1.05732; RICQUIER D, 2000, J PHYSL, V1, P3; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; ROYSTER M, 1995, ENDOCRINOLOGY, V136, P3892, DOI 10.1210/en.136.9.3892; Teixeira M, 2006, J BIOL CHEM, V281, P10496, DOI 10.1074/jbc.M512254200; Tseng YH, 2005, NAT CELL BIOL, V7, P601, DOI 10.1038/ncb1259; Vasavada RC, 2000, J BIOL CHEM, V275, P15399, DOI 10.1074/jbc.275.20.15399; Viengchareun S, 2004, J MOL ENDOCRINOL, V33, P679, DOI 10.1677/jme.1.01563; Zennaro MC, 1998, J CLIN INVEST, V101, P1254, DOI 10.1172/JCI1915	49	47	50	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2008	3	2							e1535	10.1371/journal.pone.0001535	http://dx.doi.org/10.1371/journal.pone.0001535			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367EQ	18253483	Green Published, Green Submitted, gold			2022-12-25	WOS:000260535700007
J	Yonehara, K; Shintani, T; Suzuki, R; Sakuta, H; Takeuchi, Y; Nakamura-Yonehara, K; Noda, M				Yonehara, Keisuke; Shintani, Takafumi; Suzuki, Ryoko; Sakuta, Hiraki; Takeuchi, Yasushi; Nakamura-Yonehara, Kayo; Noda, Masaharu			Expression of SPIG1 Reveals Development of a Retinal Ganglion Cell Subtype Projecting to the Medial Terminal Nucleus in the Mouse	PLOS ONE			English	Article							STARBURST AMACRINE CELLS; ACCESSORY OPTIC-SYSTEM; DENDRITIC STRATIFICATION; MORPHOLOGICAL PROPERTIES; DIRECTIONAL SELECTIVITY; TANGENTIAL DISPERSION; IMAGE MOTION; DIFFERENTIATION; DIVERSITY; RECEPTOR	Visual information is transmitted to the brain by roughly a dozen distinct types of retinal ganglion cells (RGCs) defined by a characteristic morphology, physiology, and central projections. However, our understanding about how these parallel pathways develop is still in its infancy, because few molecular markers corresponding to individual RGC types are available. Previously, we reported a secretory protein, SPIG1(clone name; D/Bsp120I #1), preferentially expressed in the dorsal region in the developing chick retina. Here, we generated knock-in mice to visualize SPIG1-expressing cells with green fluorescent protein. We found that the mouse retina is subdivided into two distinct domains for SPIG1 expression and SPIG1 effectively marks a unique subtype of the retinal ganglion cells during the neonatal period. SPIG1-positive RGCs in the dorsotemporal domain project to the dorsal lateral geniculate nucleus (dLGN), superior colliculus, and accessory optic system (AOS). In contrast, in the remaining region, here named the pan-ventronasal domain, SPIG1-positive cells form a regular mosaic and project exclusively to the medial terminal nucleus (MTN) of the AOS that mediates the optokinetic nystagmus as early as P1. Their dendrites costratify with ON cholinergic amacrine strata in the inner plexiform layer as early as P3. These findings suggest that these SPIG1-positive cells are the ON direction selective ganglion cells (DSGCs). Moreover, the MTN-projecting cells in the pan-ventronasal domain are apparently composed of two distinct but interdependent regular mosaics depending on the presence or absence of SPIG1, indicating that they comprise two functionally distinct subtypes of the ON DSGCs. The formation of the regular mosaic appears to be commenced at the end of the prenatal stage and completed through the peak period of the cell death at P6. SPIG1 will thus serve as a useful molecular marker for future studies on the development and function of ON DSGCs.	[Yonehara, Keisuke; Shintani, Takafumi; Suzuki, Ryoko; Sakuta, Hiraki; Takeuchi, Yasushi; Nakamura-Yonehara, Kayo; Noda, Masaharu] Natl Inst Basic Biol, Div Mol Neurobiol, Okazaki, Aichi 444, Japan; [Yonehara, Keisuke; Shintani, Takafumi; Sakuta, Hiraki; Noda, Masaharu] Grad Univ Adv Stud, Sch Life Sci, Okazaki, Aichi, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Graduate University for Advanced Studies - Japan	Noda, M (corresponding author), Natl Inst Basic Biol, Div Mol Neurobiol, Okazaki, Aichi 444, Japan.	madon@nibb.ac.jp	Noda, Masaharu/D-7146-2016	Noda, Masaharu/0000-0002-3796-524X; Sakuta, Hiraki/0000-0003-2375-0528; Yonehara, Keisuke/0000-0001-9541-6671; Shintani, Takafumi/0000-0002-6165-2307	Ministry of Education, Culture, Sports, Science and Technology of Japan; Core Research for Evolutional Science and Technology (CREST) program of the Japan Science and Technology Agency (JST); Japan Society for the Promotion of Science for Young Scientists [Research Fellowship]	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Core Research for Evolutional Science and Technology (CREST) program of the Japan Science and Technology Agency (JST)(Japan Science & Technology Agency (JST)Core Research for Evolutional Science and Technology (CREST)); Japan Society for the Promotion of Science for Young Scientists(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and from the Core Research for Evolutional Science and Technology (CREST) program of the Japan Science and Technology Agency (JST). This work was also supported by Research Fellowships of the Japan Society for the Promotion of Science for Young Scientists (KY).	Ackert JM, 2006, J NEUROSCI, V26, P4206, DOI 10.1523/JNEUROSCI.0496-06.2006; AUSTIN CP, 1995, DEVELOPMENT, V121, P3637; Badea TC, 2004, J COMP NEUROL, V480, P331, DOI 10.1002/cne.20304; Bansal A, 2000, J NEUROSCI, V20, P7672; BARLOW HB, 1964, J PHYSIOL-LONDON, V173, P377, DOI 10.1113/jphysiol.1964.sp007463; Bodnarenko SR, 1999, NEUROREPORT, V10, P2955, DOI 10.1097/00001756-199909290-00015; BODNARENKO SR, 1995, J NEUROSCI, V15, P7037; Bruhn SL, 1996, J NEUROSCI, V16, P1430; BUHL EH, 1986, J COMP NEUROL, V253, P163, DOI 10.1002/cne.902530204; Cellerino A, 2000, EUR J NEUROSCI, V12, P613, DOI 10.1046/j.1460-9568.2000.00944.x; Cook JE, 2001, VISUAL NEUROSCI, V18, P289, DOI 10.1017/S0952523801182131; Cook JE, 2000, TRENDS NEUROSCI, V23, P26, DOI 10.1016/S0166-2236(99)01487-3; Coombs J, 2006, NEUROSCIENCE, V140, P123, DOI 10.1016/j.neuroscience.2006.02.079; Coombs JL, 2007, J COMP NEUROL, V503, P803, DOI 10.1002/cne.21429; DANN JF, 1987, J COMP NEUROL, V262, P141, DOI 10.1002/cne.902620111; DANN JF, 1988, J NEUROSCI, V8, P1485; Demb JB, 2007, NEURON, V55, P179, DOI 10.1016/j.neuron.2007.07.001; Diao L, 2004, J NEUROBIOL, V61, P236, DOI 10.1002/neu.20041; DRAGER UC, 1985, PROC R SOC SER B-BIO, V224, P57, DOI 10.1098/rspb.1985.0021; Eglen SJ, 2006, MATH MED BIOL, V23, P79, DOI 10.1093/imammb/dql003; Erkman L, 2000, NEURON, V28, P779, DOI 10.1016/S0896-6273(00)00153-7; FAMIGLIETTI EV, 1983, VISION RES, V23, P1265, DOI 10.1016/0042-6989(83)90102-5; FAMIGLIETTI EV, 1992, J COMP NEUROL, V324, P322, DOI 10.1002/cne.903240303; FISHER LJ, 1979, J EMBRYOL EXP MORPH, V54, P219; Fried SI, 2002, NATURE, V420, P411, DOI 10.1038/nature01179; GalliResta L, 1997, J NEUROSCI, V17, P7831; Gross JM, 2005, P NATL ACAD SCI USA, V102, P4371, DOI 10.1073/pnas.0501061102; He SG, 1998, VISUAL NEUROSCI, V15, P369, DOI 10.1017/S095252389815215X; HINDS JW, 1974, DEV BIOL, V37, P381, DOI 10.1016/0012-1606(74)90156-0; Ishikane H, 2005, NAT NEUROSCI, V8, P1087, DOI 10.1038/nn1497; Jeyarasasingam G, 1998, J COMP NEUROL, V394, P335; Kong JH, 2005, J COMP NEUROL, V489, P293, DOI 10.1002/cne.20631; LEVICK WR, 1967, J PHYSIOL-LONDON, V188, P285, DOI 10.1113/jphysiol.1967.sp008140; LINDEN R, 1983, BRAIN RES, V272, P145, DOI 10.1016/0006-8993(83)90371-2; Masland RH, 2000, ANNU REV NEUROSCI, V23, P249, DOI 10.1146/annurev.neuro.23.1.249; Masland RH, 2001, NAT NEUROSCI, V4, P877, DOI 10.1038/nn0901-877; Masland RH, 2001, CURR OPIN NEUROBIOL, V11, P431, DOI 10.1016/S0959-4388(00)00230-0; MASLIM J, 1986, J COMP NEUROL, V254, P382, DOI 10.1002/cne.902540310; McLaughlin T, 2003, NEURON, V40, P1147, DOI 10.1016/S0896-6273(03)00790-6; Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027; Mumm JS, 2006, NEURON, V52, P609, DOI 10.1016/j.neuron.2006.10.004; NELSON R, 1978, J NEUROPHYSIOL, V41, P472, DOI 10.1152/jn.1978.41.2.472; OLNEY JW, 1968, INVEST OPHTH VISUAL, V7, P250; OYSTER CW, 1968, J PHYSIOL-LONDON, V199, P613, DOI 10.1113/jphysiol.1968.sp008671; OYSTER CW, 1980, J COMP NEUROL, V190, P49, DOI 10.1002/cne.901900105; OYSTER CW, 1972, VISION RES, V12, P183, DOI 10.1016/0042-6989(72)90110-1; Pak W, 2004, CELL, V119, P567, DOI 10.1016/j.cell.2004.10.026; PEI YF, 1970, ANAT REC, V168, P105, DOI 10.1002/ar.1091680109; Peters MA, 2002, DEV BIOL, V251, P59, DOI 10.1006/dbio.2002.0791; Quina LA, 2005, J NEUROSCI, V25, P11595, DOI 10.1523/JNEUROSCI.2837-05.2005; RAMOA AS, 1988, J NEUROSCI, V8, P4239; Raven MA, 2003, J COMP NEUROL, V461, P123, DOI 10.1002/cne.10693; REESE BE, 1995, P NATL ACAD SCI USA, V92, P2494, DOI 10.1073/pnas.92.7.2494; Reese BE, 2002, PROG RETIN EYE RES, V21, P153, DOI 10.1016/S1350-9462(01)00024-6; Reese BE, 1999, EUR J NEUROSCI, V11, P2965, DOI 10.1046/j.1460-9568.1999.00712.x; Resta V, 2005, DEVELOPMENT, V132, P2873, DOI 10.1242/dev.01855; Rockhill RL, 2000, P NATL ACAD SCI USA, V97, P2303, DOI 10.1073/pnas.030413497; Rockhill RL, 2002, J NEUROSCI, V22, P3831; Rodieck R.W., 1998, 1 STEPS SEEING; RODIECK RW, 1991, VISUAL NEUROSCI, V6, P95, DOI 10.1017/S095252380001049X; Roska B, 2001, NATURE, V410, P583, DOI 10.1038/35069068; Sakuta H, 2001, SCIENCE, V293, P111, DOI 10.1126/science.1058379; Sakuta H, 2006, J NEUROSCI, V26, P10868, DOI 10.1523/JNEUROSCI.3027-06.2006; Sernagor E, 2001, PROG RETIN EYE RES, V20, P139, DOI 10.1016/S1350-9462(00)00024-0; Sherry DM, 2003, J COMP NEUROL, V465, P480, DOI 10.1002/cne.10838; Shintani T, 2004, J NEUROBIOL, V59, P34, DOI 10.1002/neu.10338; SIMPSON JI, 1984, ANNU REV NEUROSCI, V7, P13, DOI 10.1146/annurev.ne.07.030184.000305; Stacy RC, 2003, J COMP NEUROL, V456, P154, DOI 10.1002/cne.10509; Sun WZ, 2006, J PHYSIOL-LONDON, V576, P197, DOI 10.1113/jphysiol.2006.115857; Sun WZ, 2002, J COMP NEUROL, V451, P115, DOI 10.1002/cne.10323; SZEL A, 1992, J COMP NEUROL, V325, P327, DOI 10.1002/cne.903250302; Taylor WR, 2003, TRENDS NEUROSCI, V26, P379, DOI 10.1016/S0166-2236(03)00167-X; VANDERTOGT C, 1993, J COMP NEUROL, V338, P175, DOI 10.1002/cne.903380204; Waid DK, 1998, DEVELOPMENT, V125, P1059; Wassle H, 2004, NAT REV NEUROSCI, V5, P747, DOI 10.1038/nrn1497; WASSLE H, 1991, PHYSIOL REV, V71, P447, DOI 10.1152/physrev.1991.71.2.447; WASSLE H, 1978, PROC R SOC SER B-BIO, V200, P441, DOI 10.1098/rspb.1978.0026; Weng SJ, 2005, J PHYSIOL-LONDON, V562, P915, DOI 10.1113/jphysiol.2004.076695; Yan Q, 1999, J HISTOCHEM CYTOCHEM, V47, P1495, DOI 10.1177/002215549904701201; Yoshida K, 2001, NEURON, V30, P771, DOI 10.1016/S0896-6273(01)00316-6; YOUNG RW, 1984, J COMP NEUROL, V229, P362, DOI 10.1002/cne.902290307	81	73	79	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2008	3	2							e1533	10.1371/journal.pone.0001533	http://dx.doi.org/10.1371/journal.pone.0001533			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367EQ	18253481	Green Published, Green Submitted, gold			2022-12-25	WOS:000260535700005
J	Randriamampita, C; Mouchacca, P; Malissen, B; Marguet, D; Trautmann, A; Lellouch, AC				Randriamampita, Clotilde; Mouchacca, Pierre; Malissen, Bernard; Marguet, Didier; Trautmann, Alain; Lellouch, Annemarie Coffman			A Novel ZAP-70 Dependent FRET Based Biosensor Reveals Kinase Activity at both the Immunological Synapse and the Antisynapse	PLOS ONE			English	Article								Many hypotheses attempting to explain the speed and sensitivity with which a T-cell discriminates the antigens it encounters include a notion of relative spatial and temporal control of particular biochemical steps involved in the process. An essential step in T-cell receptor (TCR) mediated signalling is the activation of the protein tyrosine kinase ZAP-70. ZAP-70 is recruited to the TCR upon receptor engagement and, once activated, is responsible for the phosphorylation of the protein adaptor, Linker for Activation of T-cells, or LAT. LAT phosphorylation results in the recruitment of a signalosome including PLC gamma 1, Grb2/SOS, GADS and SLP-76. In order to examine the real time spatial and temporal evolution of ZAP-70 activity following TCR engagement in the immune synapse, we have developed ROZA, a novel FRET-based biosensor whose function is dependent upon ZAP-70 activity. This new probe not only provides a measurement of the kinetics of ZAP-70 activity, but also reveals the subcellular localization of the activity as well. Unexpectedly, ZAP-70 dependent FRET was observed not only at the T-cell -APC interface, but also at the opposite pole of the cell or "antisynapse''.	[Randriamampita, Clotilde; Trautmann, Alain] Univ Paris 05, Inst Cochin, CNRS, UMR 8104, Paris, France; [Randriamampita, Clotilde; Trautmann, Alain] Inserm, U567, Paris, France; [Mouchacca, Pierre; Malissen, Bernard; Marguet, Didier; Lellouch, Annemarie Coffman] Univ Aix Marseille 2, Ctr dImmunologie Marseille Luminy, Marseille, France; [Mouchacca, Pierre; Malissen, Bernard; Marguet, Didier; Lellouch, Annemarie Coffman] Inserm, U631, Marseille, France; [Mouchacca, Pierre; Malissen, Bernard; Marguet, Didier; Lellouch, Annemarie Coffman] CNRS, UMR6102, Marseille, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS)	Randriamampita, C (corresponding author), Univ Paris 05, Inst Cochin, CNRS, UMR 8104, Paris, France.	randriamampita@cochin.inserm.fr; lellouch@marseille.inserm.fr	Marguet, Didier/B-9946-2008; Lellouch, Annemarie/E-9905-2014; Marguet, Didier/AGO-5421-2022; Malissen, Bernard/AAK-4659-2020	Marguet, Didier/0000-0003-3198-5095; Randriamampita, Clotilde/0000-0001-8594-7831; Malissen, Bernard/0000-0003-1340-9342	Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale, Ligue Nationale Contre le Cancer; Association pour la Recherche sur le Cancer; Ministere de la Recherche	Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale, Ligue Nationale Contre le Cancer(Institut National de la Sante et de la Recherche Medicale (Inserm)Centre National de la Recherche Scientifique (CNRS)); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Ministere de la Recherche(Ministry of Science and Innovation, Spain (MICINN)Ministry of Research, France)	This work was supported by institutional grants from Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale, Ligue Nationale Contre le Cancer (AT), Association pour la Recherche sur le Cancer (BM), and Ministere de la Recherche (AT & BM).	Altan-Bonnet G, 2005, PLOS BIOL, V3, P1925, DOI 10.1371/journal.pbio.0030356; Bunnell SC, 2002, J CELL BIOL, V158, P1263, DOI 10.1083/jcb.200203043; Burroughs NJ, 2007, IMMUNOL REV, V216, P69; Costello PS, 2002, NAT IMMUNOL, V3, P1082, DOI 10.1038/ni848; Deindl S, 2007, CELL, V129, P735, DOI 10.1016/j.cell.2007.03.039; Friedl P, 2005, NAT REV IMMUNOL, V5, P532, DOI 10.1038/nri1647; Horejsi V, 2004, NAT REV IMMUNOL, V4, P603, DOI 10.1038/nri1414; Kohler K, 2005, CHEMBIOCHEM, V6, P152, DOI 10.1002/cbic.200400241; Lee KH, 2002, SCIENCE, V295, P1539, DOI 10.1126/science.1067710; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; Meinhardt H, 2000, BIOESSAYS, V22, P753, DOI 10.1002/1521-1878(200008)22:8<753::AID-BIES9>3.0.CO;2-Z; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Paz PE, 2001, BIOCHEM J, V356, P461, DOI 10.1042/0264-6021:3560461; Revy P, 2001, NAT IMMUNOL, V2, P925, DOI 10.1038/ni713; Sato M, 2002, NAT BIOTECHNOL, V20, P287, DOI 10.1038/nbt0302-287; Sloan-Lancaster J, 1998, J CELL BIOL, V143, P613, DOI 10.1083/jcb.143.3.613; Stefanova I, 2003, NAT IMMUNOL, V4, P248, DOI 10.1038/ni895; Ting AY, 2001, P NATL ACAD SCI USA, V98, P15003, DOI 10.1073/pnas.211564598; Trautmann A, 2003, CURR OPIN IMMUNOL, V15, P249, DOI 10.1016/S0952-7915(03)00040-2; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; Violin JD, 2003, J CELL BIOL, V161, P899, DOI 10.1083/jcb.200302125; Wang YX, 2005, NATURE, V434, P1040, DOI 10.1038/nature03469; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	25	37	37	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1521	10.1371/journal.pone.0001521	http://dx.doi.org/10.1371/journal.pone.0001521			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SR	18231606	Green Published, gold, Green Submitted			2022-12-25	WOS:000260504200033
J	Nakajima, KI; Morita, Y; Koizumi, A; Asakura, T; Terada, T; Ito, K; Shimizu-Ibuka, A; Maruyama, JI; Kitamoto, K; Misaka, T; Abe, K				Nakajima, Ken-ichiro; Morita, Yuji; Koizumi, Ayako; Asakura, Tomiko; Terada, Tohru; Ito, Keisuke; Shimizu-Ibuka, Akiko; Maruyama, Jun-ichi; Kitamoto, Katsuhiko; Misaka, Takumi; Abe, Keiko			Acid-induced sweetness of neoculin is ascribed to its pH-dependent agonistic-antagonistic interaction with human sweet taste receptor	FASEB JOURNAL			English	Article						G protein-coupled receptors; histidine; sweet protein	MODIFYING ACTIVITY; ASPERGILLUS-ORYZAE; PROTEIN; T1R3; PURIFICATION; SUBUNITS; DOMAIN; MODEL; SITE	Neoculin (NCL) is a sweet protein that also has taste-modifying activity to convert sourness to sweetness. However, it has been unclear how NCL induces this unique sensation. Here we quantitatively evaluated the pH-dependent acid-induced sweetness of NCL using a cell-based assay system. The human sweet taste receptor, hT1R2-hT1R3, was functionally expressed in HEK293T cells together with G alpha protein. When NCL was applied to the cells under different pH conditions, it activated hT1R2-hT1R3 in a pH-dependent manner as the condition changed from pH 8 to 5. The pH-response sigmoidal curve resembled the imidazole titration curve, suggesting that His residues were involved in the taste-modifying activity. We then constructed an NCL variant in which all His residues were replaced with Ala and found that the variant elicited strong sweetness at neutral pH as well as at acidic pH. Since NCL and the variant elicited weak and strong sweetness at the same neutral pH, respectively, we applied different proportions of NCL-variant mixtures to the cells at this pH. As a result, NCL competitively inhibits the variant-induced receptor activation. All these data suggest that NCL acts as an hT1R2-hT1R3 agonist at acidic pH but functionally changes into its antagonist at neutral pH.	[Nakajima, Ken-ichiro; Morita, Yuji; Koizumi, Ayako; Asakura, Tomiko; Terada, Tohru; Ito, Keisuke; Misaka, Takumi; Abe, Keiko] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 1138657, Japan; [Terada, Tohru; Abe, Keiko] Univ Tokyo, Grad Sch Agr & Life Sci, Agr Bioinformat Res Unit, Tokyo 1138657, Japan; [Maruyama, Jun-ichi; Kitamoto, Katsuhiko] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biotechnol, Tokyo 1138657, Japan; [Shimizu-Ibuka, Akiko] Tokyo Univ Agr, Dept Nutr Sci, Tokyo, Japan	University of Tokyo; University of Tokyo; University of Tokyo; Tokyo University of Agriculture	Abe, K (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	aka7308@mail.ecc.u-tokyo.ac.jp	Terada, Tohru/W-2956-2019; Ito, Keisuke/J-5926-2013	Terada, Tohru/0000-0002-7091-0646; Nakajima, Ken-ichiro/0000-0003-1932-418X; SHIMIZU-IBUKA, Akiko/0000-0002-5310-9216; Ito, Keisuke/0000-0002-8719-9635; Misaka, Takumi/0000-0002-9547-5767				Albert Steven M, 2002, Curr Psychiatry Rep, V4, P64, DOI 10.1007/s11920-002-0015-8; CASE DA, 2004, AMBER 8; Chandrashekar J, 2006, NATURE, V444, P288, DOI 10.1038/nature05401; Cui M, 2006, CURR PHARM DESIGN, V12, P4591, DOI 10.2174/138161206779010350; Galindo-Cuspinera V, 2006, NATURE, V441, P354, DOI 10.1038/nature04765; Ito K, 2007, BIOCHEM BIOPH RES CO, V360, P407, DOI 10.1016/j.bbrc.2007.06.064; Jang HJ, 2007, P NATL ACAD SCI USA, V104, P15069, DOI 10.1073/pnas.0706890104; Jiang PH, 2005, J BIOL CHEM, V280, P34296, DOI 10.1074/jbc.M505255200; Jiang PH, 2004, J BIOL CHEM, V279, P45068, DOI 10.1074/jbc.M406779200; Jin FJ, 2007, APPL MICROBIOL BIOT, V76, P1059, DOI 10.1007/s00253-007-1088-4; Koizumi A, 2007, BIOCHEM BIOPH RES CO, V358, P585, DOI 10.1016/j.bbrc.2007.04.171; KURIHARA Y, 1992, CRIT REV FOOD SCI, V32, P231, DOI 10.1080/10408399209527598; Li XD, 2002, P NATL ACAD SCI USA, V99, P4692, DOI 10.1073/pnas.072090199; Nakajima K, 2006, NEUROREPORT, V17, P1241, DOI 10.1097/01.wnr.0000230513.01339.3b; Nakajima K, 2006, APPL ENVIRON MICROB, V72, P3716, DOI 10.1128/AEM.72.5.3716-3723.2006; Nie Y, 2005, CURR BIOL, V15, P1948, DOI 10.1016/j.cub.2005.09.037; Nie YL, 2006, CHEM SENSES, V31, P505, DOI 10.1093/chemse/bjj053; Onufriev A, 2004, PROTEINS, V55, P383, DOI 10.1002/prot.20033; Schiffman SS, 2000, PHYSIOL BEHAV, V68, P469, DOI 10.1016/S0031-9384(99)00205-X; Shimizu-Ibuka A, 2006, J MOL BIOL, V359, P148, DOI 10.1016/j.jmb.2006.03.030; Shirasuka Y, 2004, BIOSCI BIOTECH BIOCH, V68, P1403, DOI 10.1271/bbb.68.1403; Simmerling C, 2002, J AM CHEM SOC, V124, P11258, DOI 10.1021/ja0273851; STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038; Wang JM, 2000, J COMPUT CHEM, V21, P1049, DOI 10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F; Winnig M, 2007, BMC STRUCT BIOL, V7, DOI 10.1186/1472-6807-7-66; Xu H, 2004, P NATL ACAD SCI USA, V101, P14258, DOI 10.1073/pnas.0404384101; YAMASHITA H, 1990, J BIOL CHEM, V265, P15770	27	24	25	2	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2323	2330		10.1096/fj.07-100289	http://dx.doi.org/10.1096/fj.07-100289			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18263698				2022-12-25	WOS:000257292500024
J	Rozenfeld, R; Devi, LA				Rozenfeld, Raphael; Devi, Lakshmi A.			Regulation of CB1 cannabinoid receptor trafficking by the adaptor protein AP-3	FASEB JOURNAL			English	Article						endocannabinoid; G-protein-coupled receptors; intracellular signaling; lysosomal sorting; addiction; drug of abuse; THC	LYSOSOMAL MEMBRANE-GLYCOPROTEINS; DELTA-OPIOID RECEPTORS; COUPLED RECEPTORS; INTRACELLULAR-TRANSPORT; SIGNAL-TRANSDUCTION; SURFACE EXPRESSION; SYNAPTIC VESICLES; LIPID MEDIATORS; COMPLEX; CELLS	Cannabinoid receptor 1 (CB1) is an abundant G protein-coupled receptor, involved in a number of physiological processes. This receptor is localized at the plasma membrane, as well as in intracellular vesicles. The trafficking events leading to this intracellular localization remain controversial. In this study, we examine the differential trafficking of CB1 receptors and its implication on signaling. We find that the transfected tagged receptors are predominantly at the plasma membrane, whereas endogenous receptors exhibit an intracellular localization. We also find that intracellular endogenous CB1 receptors do not have an endocytic origin. Instead, these receptors associate with the adaptor protein AP-3 and traffic to the lysosomes. siRNA-mediated AP-3 delta knockdown leads to enhanced cell surface localization of CB1 receptors. Finally, we show that CB1 receptors in the late endosomal/lysosomal compartment are associated with heterotrimeric G proteins and mediate signal transduction. These results suggest that intracellular CB1 receptors are functional and that their spatial segregation is likely to significantly affect receptor function.	[Rozenfeld, Raphael; Devi, Lakshmi A.] Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Devi, LA (corresponding author), Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, 19-84 Annenberg Bldg,1 Gustave L Levy Pl, New York, NY 10029 USA.	lakshmi.devi@mssm.edu	Devi P, Lakshmi/GXM-5982-2022	Devi P, Lakshmi/0000-0001-9274-4776	NCI NIH HHS [R24 CA095823] Funding Source: Medline; NIDA NIH HHS [R01 DA011322, DA11322, R01 DA008863, DA08863, R37 DA008863, K05 DA019521-08, R01 DA008863-17, DA19521, K05 DA019521, R01 DA011322-12, R56 DA008863] Funding Source: Medline; NINDS NIH HHS [NS053751, R03 NS053751-01S1, R03 NS053751] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA095823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R03NS053751] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K05DA019521, R01DA011322, R01DA008863, R56DA008863, R37DA008863] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AHNERTHILGER G, 1994, EUR J CELL BIOL, V65, P26; ARONIN N, 1992, J NEUROSCI, V12, P3435; Beltramo M, 1997, SCIENCE, V277, P1094, DOI 10.1126/science.277.5329.1094; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Cahill CM, 2007, TRENDS PHARMACOL SCI, V28, P23, DOI 10.1016/j.tips.2006.11.003; Danglot L, 2007, BIOL CELL, V99, P349, DOI 10.1042/BC20070029; Darsow T, 1998, J CELL BIOL, V142, P913, DOI 10.1083/jcb.142.4.913; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Gobeil F, 2006, CAN J PHYSIOL PHARM, V84, P287, DOI 10.1139/Y05-127; Guan JS, 2005, CELL, V122, P619, DOI 10.1016/j.cell.2005.06.010; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; Heimann AS, 2007, P NATL ACAD SCI USA, V104, P20588, DOI 10.1073/pnas.0706980105; Hillard CJ, 1997, J NEUROCHEM, V69, P631, DOI 10.1046/j.1471-4159.1997.69020631.x; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; Kantheti P, 1998, NEURON, V21, P111, DOI 10.1016/S0896-6273(00)80519-X; Kreitzer AC, 2002, CURR OPIN NEUROBIOL, V12, P324, DOI 10.1016/S0959-4388(02)00328-8; Le Borgne R, 1998, J BIOL CHEM, V273, P29451, DOI 10.1074/jbc.273.45.29451; Leterrier C, 2006, J NEUROSCI, V26, P3141, DOI 10.1523/JNEUROSCI.5437-05.2006; Leterrier C, 2004, J BIOL CHEM, V279, P36013, DOI 10.1074/jbc.M403990200; Lloyd VK, 1999, GENOME, V42, P1183, DOI 10.1139/gen-42-6-1183; Macia E, 2006, DEV CELL, V10, P839, DOI 10.1016/j.devcel.2006.04.002; Marrache AM, 2005, ENDOTHELIUM-J ENDOTH, V12, P63, DOI 10.1080/10623320590933815; McDonald NA, 2007, MOL PHARMACOL, V71, P976, DOI 10.1124/mol.106.029348; Mechoulam R, 1998, EUR J PHARMACOL, V359, P1, DOI 10.1016/S0014-2999(98)00649-9; Miaczynska M, 2004, CURR OPIN CELL BIOL, V16, P400, DOI 10.1016/j.ceb.2004.06.005; Newell-Litwa K, 2007, J CELL SCI, V120, P531, DOI 10.1242/jcs.03365; Nyiri G, 2005, NEUROSCIENCE, V136, P811, DOI 10.1016/j.neuroscience.2005.01.026; O'Malley KL, 2003, J BIOL CHEM, V278, P28210, DOI 10.1074/jbc.M300792200; Odorizzi G, 1998, TRENDS CELL BIOL, V8, P282, DOI 10.1016/S0962-8924(98)01295-1; Ohno H, 1998, J BIOL CHEM, V273, P25915, DOI 10.1074/jbc.273.40.25915; Osten P, 1998, NEURON, V21, P99, DOI 10.1016/S0896-6273(00)80518-8; Peden AA, 2004, J CELL BIOL, V164, P1065, DOI 10.1083/jcb.200311064; Peden AA, 2002, J CELL BIOL, V156, P327, DOI 10.1083/jcb.200107140; Revankar CM, 2007, ACS CHEM BIOL, V2, P536, DOI 10.1021/cb700072n; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Rios C, 2006, BRIT J PHARMACOL, V148, P387, DOI 10.1038/sj.bjp.0706757; Rozenfeld R, 2007, FASEB J, V21, P2455, DOI 10.1096/fj.06-7793com; Scales SJ, 2000, INT REV CYTOL, V195, P67; Seong E, 2005, MOL BIOL CELL, V16, P128, DOI 10.1091/mbc.E04-10-0892; Spritz RA, 1999, TRENDS GENET, V15, P337, DOI 10.1016/S0168-9525(99)01785-0; Stasyk T, 2007, MOL CELL PROTEOMICS, V6, P908, DOI 10.1074/mcp.M600463-MCP200; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; THOMAS BF, 1990, J PHARMACOL EXP THER, V255, P624; TSUKAGUCHI H, 1995, J CLIN INVEST, V96, P2043, DOI 10.1172/JCI118252; Uberti MA, 2005, J PHARMACOL EXP THER, V313, P16, DOI 10.1124/jpet.104.079541; Uthayakumar S, 1995, CELL MOL BIOL RES, V41, P405; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Yang W, 2000, J CELL SCI, V113, P4077; Zhu T, 2006, CAN J PHYSIOL PHARM, V84, P377, DOI 10.1139/Y05-147	52	117	117	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2311	2322		10.1096/fj.07-102731	http://dx.doi.org/10.1096/fj.07-102731			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18267983	Green Accepted			2022-12-25	WOS:000257292500023
J	Delagoutte, E; Goellner, GM; Guo, J; Baldacci, G; McMurray, CT				Delagoutte, Emmanuelle; Goellner, Geoffrey M.; Guo, Jie; Baldacci, Giuseppe; McMurray, Cynthia T.			Single-stranded DNA-binding protein in vitro eliminates the orientation-dependent impediment to polymerase passage on CAG/CTG repeats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY-DISEASE GENES; TRIPLET REPEATS; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; TRINUCLEOTIDE REPEAT; CTG REPEATS; REPLICATION PROTEINS; SECONDARY STRUCTURE; DYNAMIC MUTATIONS; LEADING-STRAND	Small insertions and deletions of trinucleotide repeats (TNRs) can occur by polymerase slippage and hairpin formation on either template or newly synthesized strands during replication. Although not predicted by a slippage model, deletions occur preferentially when 5 '-CTG is in the lagging strand template and are highly favored over insertion events in rapidly replicating cells. The mechanism for the deletion bias and the orientation dependence of TNR instability is poorly understood. We report here that there is an orientation-dependent impediment to polymerase progression on 5 '-CAG and 5 '-CTG repeats that can be relieved by the binding of single-stranded DNA-binding protein. The block depends on the primary sequence of the TNR but does not correlate with the thermodynamic stability of hairpins. The orientation-dependent block of polymerase passage is the strongest when 5 '-CAG is the template. We propose a "template-push" model in which the slow speed of DNA polymerase across the 5 '-CAG leading strand template creates a threat to helicase-polymerase coupling. To prevent uncoupling, the TNR template is pushed out and by-passed. Hairpins do not cause the block, but appear to occur as a consequence of polymerase pass-over.	[Delagoutte, Emmanuelle; Guo, Jie; Baldacci, Giuseppe] Univ Paris 11, CNRS, Inst Curie, F-91405 Orsay, France; [Goellner, Geoffrey M.; McMurray, Cynthia T.] Mayo Clin & Mayo Fdn, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA; [Goellner, Geoffrey M.; McMurray, Cynthia T.] Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Mayo Clinic; Mayo Clinic	Delagoutte, E (corresponding author), Univ Paris 11, CNRS, Inst Curie, F-91405 Orsay, France.	emmanuelle.delagoutte@curie.u-psud.fr; mcmurray.cynthia@mayo.edu			NIGMS NIH HHS [GM066359] Funding Source: Medline; NINDS NIH HHS [NS40738] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066359] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040738] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Balakumaran BS, 2000, HUM MOL GENET, V9, P93, DOI 10.1093/hmg/9.1.93; Bichara M, 2006, MUTAT RES-FUND MOL M, V598, P144, DOI 10.1016/j.mrfmmm.2006.01.020; Bowater RP, 1997, NUCLEIC ACIDS RES, V25, P2861, DOI 10.1093/nar/25.14.2861; Cleary JD, 2002, NAT GENET, V31, P37, DOI 10.1038/ng870; Delagoutte E, 2001, BIOCHEMISTRY-US, V40, P4459, DOI 10.1021/bi001306l; Dixon MJ, 2004, NUCLEIC ACIDS RES, V32, P1289, DOI 10.1093/nar/gkh292; EliasArnanz M, 1997, EMBO J, V16, P5775, DOI 10.1093/emboj/16.18.5775; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; GACY AM, 1995, CELL, V81, P533; Gatchel JR, 2005, NAT REV GENET, V6, P743, DOI 10.1038/nrg1691; Goellner GM, 1997, AM J HUM GENET, V60, P879; Hartenstine MJ, 2002, J BIOL CHEM, V277, P41379, DOI 10.1074/jbc.M207013200; Iyer RR, 1999, J BIOL CHEM, V274, P3865, DOI 10.1074/jbc.274.6.3865; Jones CE, 2004, J BIOL CHEM, V279, P12067, DOI 10.1074/jbc.M313840200; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; Kovtun IV, 2007, NATURE, V447, P447, DOI 10.1038/nature05778; Kovtun Irina V., 2004, V277, P309; Kovtun IV, 2004, HUM MOL GENET, V13, P3057, DOI 10.1093/hmg/ddh325; Kovtun IV, 2001, NAT GENET, V27, P407, DOI 10.1038/86906; Lin YF, 2006, NAT STRUCT MOL BIOL, V13, P179, DOI 10.1038/nsmb1042; LIU B, 1995, SCIENCE, V267, P1131, DOI 10.1126/science.7855590; Malter HE, 1997, NAT GENET, V15, P165, DOI 10.1038/ng0297-165; Mangiarini L, 1997, NAT GENET, V15, P197, DOI 10.1038/ng0297-197; Minetti CASA, 2003, P NATL ACAD SCI USA, V100, P14719, DOI 10.1073/pnas.2336142100; Miret JJ, 1998, P NATL ACAD SCI USA, V95, P12438, DOI 10.1073/pnas.95.21.12438; Mirkin SM, 2007, NATURE, V447, P932, DOI 10.1038/nature05977; Moore H, 1999, P NATL ACAD SCI USA, V96, P1504, DOI 10.1073/pnas.96.4.1504; Nossal NG, 1995, METHOD ENZYMOL, V262, P560; Ohshima K, 1997, J BIOL CHEM, V272, P16798, DOI 10.1074/jbc.272.27.16798; Paiva AM, 2004, BIOCHEMISTRY-US, V43, P14218, DOI 10.1021/bi0494368; Pearson CE, 2005, NAT REV GENET, V6, P729, DOI 10.1038/nrg1689; Petruska J, 1996, NUCLEIC ACIDS RES, V24, P1992, DOI 10.1093/nar/24.11.1992; RICHETTI M, 1990, EMBO J, V9, P1583; Rolfsmeier ML, 2001, GENETICS, V157, P1569; Rossi ML, 2006, CHEM REV, V106, P453, DOI 10.1021/cr040497l; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; Schumacher S, 1998, J MOL BIOL, V279, P1101, DOI 10.1006/jmbi.1998.1827; SMITH GK, 1995, NUCLEIC ACIDS RES, V23, P4303; Spiro C, 1999, MOL CELL, V4, P1079, DOI 10.1016/S1097-2765(00)80236-1; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; Zahra R, 2007, GENETICS, V176, P27, DOI 10.1534/genetics.106.069724; Zheng MX, 1996, J MOL BIOL, V264, P323, DOI 10.1006/jmbi.1996.0643; Zhuang P, 2001, BIOCHEMISTRY-US, V40, P6660, DOI 10.1021/bi010005o	45	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2008	283	19					13341	13356		10.1074/jbc.M800153200	http://dx.doi.org/10.1074/jbc.M800153200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295UQ	18263578	Green Published, hybrid			2022-12-25	WOS:000255499800074
J	Chen, YC; Siems, WF; Pearce, G; Ryan, CA				Chen, Yu-Chi; Siems, William F.; Pearce, Gregory; Ryan, Clarence A.			Six peptide wound signals derived from a single precursor protein in Ipomoea batatas leaves activate the expression of the Defense gene sporamin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOMATO LEAVES; ARABIDOPSIS; PLANTS; BIOSYNTHESIS; POLYPEPTIDE; RESISTANCE; RECEPTOR; HORMONES; SURFACE	A mixture of three homologous bioactive hydroxyproline-rich glycopeptides (HypSys peptides) of 18 amino acids in length, differing only at two residues, was isolated from leaves of Ipomoea batatas, the common sweet potato. One of the peptides represented over 95% of the isolated isopeptides, which, at 2.5 nM concentration, induced the expression of sporamin, a major defense protein of I. batatas. The sequence of the major isoform was used to synthesize a primer that identified a cDNA encoding a precursor protein. The protein contained six proline-rich regions whose sequences suggested that they might be HypSys defense signals. One of the encoded peptides, called IbHypSys IV, was identical to one of two minor components of the isolated isopeptides, but neither the major isopeptide nor the other minor isoform was found within the precursor. The six peptides encoded by the precursor gene were synthesized but with hydroxyproline residues at positions found in the native isoforms and lacking carbohydrate moieties. All of the peptides were biologically active when supplied to leaves of sweet potato plants. The gene is the first ortholog of the preproHypSys gene family to be found outside of the Solanaceae family, and its encoded peptide precursor is the first example in plants of a precursor protein with six potential peptide defense signals, a scenario only found previously in animals. The data indicate that multiple copies of the HypSys peptides in a single precursor may have an important role in amplifying wound signaling in leaves in response to herbivore attacks.	[Chen, Yu-Chi; Pearce, Gregory; Ryan, Clarence A.] Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA; [Siems, William F.] Washington State Univ, Dept Chem, Pullman, WA 99164 USA	Washington State University; Washington State University	Chen, YC (corresponding author), Chinese Culture Univ, Dept Hort & Biotechnol, 55 Hwa Kang Rd, Taipei 111, Taiwan.	cyq12@faculty.pccu.edu.tw; pearce@wsu.edu			NCRR NIH HHS [1S10RR022538] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR022538] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Cai DG, 2003, PLANT MOL BIOL, V51, P839, DOI 10.1023/A:1023089017906; Conconi A, 1996, PLANT PHYSIOL, V111, P797, DOI 10.1104/pp.111.3.797; Felix G, 1999, PLANT J, V18, P265, DOI 10.1046/j.1365-313X.1999.00265.x; FELIX G, 1995, PLANT J, V7, P381, DOI 10.1046/j.1365-313X.1995.7030381.x; HORTON N, 2007, PLANT CELL, V19, P1709; Huffaker A, 2007, P NATL ACAD SCI USA, V104, P10732, DOI 10.1073/pnas.0703343104; Huffaker A, 2006, P NATL ACAD SCI USA, V103, P10098, DOI 10.1073/pnas.0603727103; McLaughlin PJ, 2006, HANDBOOK OF BIOLOGICALLY ACTIVE PEPTIDES, P1313, DOI 10.1016/B978-012369442-3/50185-9; Narvaez-Vasquez J, 2005, P NATL ACAD SCI USA, V102, P12974, DOI 10.1073/pnas.0505248102; Pearce G, 2003, J BIOL CHEM, V278, P30044, DOI 10.1074/jbc.M304159200; PEARCE G, 1991, SCIENCE, V253, P895, DOI 10.1126/science.253.5022.895; Pearce G, 2001, NATURE, V411, P817, DOI 10.1038/35081107; Pearce G, 2007, J BIOL CHEM, V282, P17777, DOI 10.1074/jbc.M701543200; Ren F, 2006, PLANT SCI, V171, P286, DOI 10.1016/j.plantsci.2006.04.001; Ryan CA, 2002, PLANT CELL, V14, pS251, DOI 10.1105/tpc.010484; Ryan CA, 2007, CELL MICROBIOL, V9, P1902, DOI 10.1111/j.1462-5822.2007.00991.x; Schaller A, 1999, PLANT CELL, V11, P263, DOI 10.1105/tpc.11.2.263; Scheer JM, 1999, PLANT CELL, V11, P1525, DOI 10.1105/tpc.11.8.1525; Shewry PR, 2003, ANN BOT-LONDON, V91, P755, DOI 10.1093/aob/mcg084; Wang SJ, 2002, PLANT MOL BIOL, V48, P223, DOI 10.1023/A:1013359227041; Wasternack C, 2007, ANN BOT-LONDON, V100, P681, DOI 10.1093/aob/mcm079; Yamaguchi Y, 2006, P NATL ACAD SCI USA, V103, P10104, DOI 10.1073/pnas.0603729103; Yeh KW, 1997, PLANT CELL REP, V16, P696, DOI 10.1007/s002990050304; Yeh KW, 1997, PLANT MOL BIOL, V33, P565, DOI 10.1023/A:1005764702510	24	49	50	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11469	11476		10.1074/jbc.M709002200	http://dx.doi.org/10.1074/jbc.M709002200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18299332	hybrid, Green Published			2022-12-25	WOS:000255067400045
J	Payandeh, J; Li, CH; Ramjeesingh, M; Poduch, E; Bear, CE; Pai, EF				Payandeh, Jian; Li, Canhui; Ramjeesingh, Mohabir; Poduch, Ewa; Bear, Christine E.; Pai, Emil F.			Probing structure-function relationships and gating mechanisms in the CorA Mg2+ transport system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; ENTERICA SEROVAR TYPHIMURIUM; YEAST PLASMA-MEMBRANE; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; SALMONELLA-ENTERICA; POTASSIUM-CHANNEL; SELECTIVITY FILTER; ESCHERICHIA-COLI; MAGNESIUM UPTAKE	Recent crystal structures of the CorA Mg2+ transport protein from Thermotoga maritima (TmCorA) revealed an unusually long ion pore putatively gated by hydrophobic residues near the intracellular end and by universally conserved asparagine residues at the periplasmic entrance. A conformational change observed in an isolated funnel domain structure also led to a proposal for the structural basis of gating. Because understanding the molecular mechanisms underlying ion channel and transporter gating remains an important challenge, we have undertaken a structure-guided engineering approach to probe structure-function relationships in TmCorA. The intracellular funnel domain is shown to constitute an allosteric regulatory module that can be engineered to promote an activated or closed state. A periplasmic gate centered about a proline-induced kink of the pore-lining helix is described where "helix-straightening" mutations produce a dramatic gain-of-function. Mutation to the narrowest constriction along the pore demonstrates that a hydrophobic gate is operational within this Mg2+-selective transport protein and likely forms an energetic barrier to ion flux. We also provide evidence that highly conserved acidic residues found in the short periplasmic loop are not essential for TmCorA function or Mg2+ selectivity but may be required for proper protein folding and stability. This work extends our gating model for the CorA-Alr1-Mrs2 superfamily and reveals features that are characteristic of an ion channel. Aspects of these results that have broader implications for a range of channel and transporter families are highlighted.	[Payandeh, Jian; Pai, Emil F.] Ontario Canc Inst, Med & Related Sci Ctr, Div Canc Genom & Proteom, Toronto, ON M5G 1L7, Canada; [Payandeh, Jian; Pai, Emil F.] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1L7, Canada; [Li, Canhui; Ramjeesingh, Mohabir; Bear, Christine E.; Pai, Emil F.] Univ Toronto, Dept Biochem, Toronto, ON M5G 1L7, Canada; [Pai, Emil F.] Univ Toronto, Dept Mol Genet, Toronto, ON M5G 1L7, Canada; [Li, Canhui; Bear, Christine E.] Hosp Sick Children, Mol Struct & Funct Programme, Toronto, ON M5G 1X8, Canada; [Li, Canhui; Ramjeesingh, Mohabir; Bear, Christine E.] Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; [Poduch, Ewa] Toronto Gen Res Inst, Ctr Mol Design & Preformulat, Toronto, ON M5G 1L7, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Payandeh, J (corresponding author), Ontario Canc Inst, Med & Related Sci Ctr, Div Canc Genom & Proteom, 101 Coll St, Toronto, ON M5G 1L7, Canada.	payandeh@uhnres.utoronto.ca; pai@hera.med.utoronto.ca	Pai, Emil F/D-2526-2013; Pai, Emil/R-8908-2019	Pai, Emil/0000-0002-1162-7242				Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Beckstein O, 2006, PHYS BIOL, V3, P147, DOI 10.1088/1478-3975/3/2/007; Boudker O, 2007, NATURE, V445, P387, DOI 10.1038/nature05455; Bui DM, 1999, J BIOL CHEM, V274, P20438, DOI 10.1074/jbc.274.29.20438; Chamnongpol S, 2002, MOL MICROBIOL, V44, P561, DOI 10.1046/j.1365-2958.2002.02917.x; Cho US, 2006, J MOL BIOL, V356, P1193, DOI 10.1016/j.jmb.2005.12.032; Cordero-Morales JF, 2006, NAT STRUCT MOL BIOL, V13, P311, DOI 10.1038/nsmb1069; Dann CE, 2007, CELL, V130, P878, DOI 10.1016/j.cell.2007.06.051; DeLano WL, 2002, PYMOL USERS MANUAL; Doyle DA, 2004, EUR BIOPHYS J BIOPHY, V33, P175, DOI 10.1007/s00249-003-0382-z; Eshaghi S, 2006, SCIENCE, V313, P354, DOI 10.1126/science.1127121; Froschauer EM, 2004, FEMS MICROBIOL LETT, V237, P49, DOI 10.1016/j.femsle.2004.06.013; Graschopf A, 2001, J BIOL CHEM, V276, P16216, DOI 10.1074/jbc.M101504200; Gregan J, 2001, GENE DEV, V15, P2229, DOI 10.1101/gad.201301; Gregan J, 2001, MOL GEN GENET, V264, P773, DOI 10.1007/s004380000366; Hartwig A, 2001, MUTAT RES-FUND MOL M, V475, P113, DOI 10.1016/S0027-5107(01)00074-4; Hattori M, 2007, NATURE, V448, P1072, DOI 10.1038/nature06093; Hollenstein K, 2007, NATURE, V446, P213, DOI 10.1038/nature05626; Hu J, 2007, PROTEIN SCI, V16, P2153, DOI 10.1110/ps.072996707; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Hvorup RN, 2007, SCIENCE, V317, P1387, DOI 10.1126/science.1145950; Ivanov I, 2007, J AM CHEM SOC, V129, P8217, DOI 10.1021/ja070778l; Jasti J, 2007, NATURE, V449, P316, DOI 10.1038/nature06163; Javelle A, 2007, J STRUCT BIOL, V158, P472, DOI 10.1016/j.jsb.2007.01.004; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Kehres DG, 2002, BIOMETALS, V15, P261, DOI 10.1023/A:1016078832697; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; Knoop V, 2005, MOL GENET GENOMICS, V274, P205, DOI 10.1007/s00438-005-0011-x; Kolisek M, 2003, EMBO J, V22, P1235, DOI 10.1093/emboj/cdg122; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kucharski LM, 2000, J BIOL CHEM, V275, P16767, DOI 10.1074/jbc.M001507200; Kuo AL, 2005, STRUCTURE, V13, P1463, DOI 10.1016/j.str.2005.07.011; LABARCA C, 1995, NATURE, V376, P514, DOI 10.1038/376514a0; Lee JM, 2006, CURR GENET, V49, P7, DOI 10.1007/s00294-005-0037-y; Li LG, 2001, PLANT CELL, V13, P2761, DOI 10.1105/tpc.13.12.2761; Liu GJ, 2002, FEMS MICROBIOL LETT, V213, P231; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Long SB, 2007, NATURE, V450, P376, DOI 10.1038/nature06265; Lunin VV, 2006, NATURE, V440, P833, DOI 10.1038/nature04642; MacDiarmid CW, 1998, J BIOL CHEM, V273, P1727, DOI 10.1074/jbc.273.3.1727; Maguire ME, 2006, CURR OPIN STRUC BIOL, V16, P432, DOI 10.1016/j.sbi.2006.06.006; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; Niegowski D, 2007, CELL MOL LIFE SCI, V64, P2564, DOI 10.1007/s00018-007-7174-z; Papp KM, 2004, J BACTERIOL, V186, P7653, DOI 10.1128/JB.186.22.7653-7658.2004; Papp-Wallace KM, 2007, MOL MEMBR BIOL, V24, P351, DOI 10.1080/09687680701441883; Payandeh J, 2006, ACTA CRYSTALLOGR F, V62, P148, DOI 10.1107/S1744309106000996; Payandeh J, 2006, EMBO J, V25, P3762, DOI 10.1038/sj.emboj.7601269; Perozo E, 2006, NAT REV MOL CELL BIO, V7, P109, DOI 10.1038/nrm1833; Pfeiffer J, 2002, INFECT IMMUN, V70, P3930, DOI 10.1128/IAI.70.7.3930-3934.2002; Purohit P, 2007, NATURE, V446, P930, DOI 10.1038/nature05721; Saparov SM, 2007, MOL CELL, V26, P501, DOI 10.1016/j.molcel.2007.03.022; Schindl R, 2007, BIOPHYS J, V93, P3872, DOI 10.1529/biophysj.107.112318; Schmitz C, 2007, MAGNESIUM RES, V20, P6; Sermon J, 2005, APPL ENVIRON MICROB, V71, P6515, DOI 10.1128/AEM.71.11.6515-6523.2005; Smart OS, 1996, J MOL GRAPH MODEL, V14, P354, DOI 10.1016/S0263-7855(97)00009-X; Smith RL, 1998, J BACTERIOL, V180, P2788, DOI 10.1128/JB.180.10.2788-2791.1998; Szegedy MA, 1999, J BIOL CHEM, V274, P36973, DOI 10.1074/jbc.274.52.36973; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tripathi VN, 2006, J BIOSCIENCES, V31, P61, DOI 10.1007/BF02705236; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; Wachek M, 2006, FEBS J, V273, P4236, DOI 10.1111/j.1742-4658.2006.05424.x; Weghuber J, 2006, FEBS J, V273, P1198, DOI 10.1111/j.1742-4658.2006.05157.x; Worlock AJ, 2002, J BACTERIOL, V184, P4369, DOI 10.1128/JB.184.16.4369-4373.2002; Zhou YF, 2003, J MOL BIOL, V333, P965, DOI 10.1016/j.jmb.2003.09.022	67	52	54	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11721	11733		10.1074/jbc.M707889200	http://dx.doi.org/10.1074/jbc.M707889200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18276588	hybrid			2022-12-25	WOS:000255067400072
J	Schuetz, A; Min, J; Allali-Hassani, A; Schapira, M; Shuen, M; Loppnau, P; Mazitschek, R; Kwiatkowski, NP; Lewis, TA; Maglathin, RL; McLean, TH; Bochkarev, A; Plotnikov, AN; Vedadi, M; Arrowsmith, CH				Schuetz, Anja; Min, Jinrong; Allali-Hassani, Abdellah; Schapira, Matthieu; Shuen, Michael; Loppnau, Peter; Mazitschek, Ralph; Kwiatkowski, Nick P.; Lewis, Timothy A.; Maglathin, Rebecca L.; McLean, Thomas H.; Bochkarev, Alexey; Plotnikov, Alexander N.; Vedadi, Masoud; Arrowsmith, Cheryl H.			Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CLASS-I; SUBSTRATE-SPECIFICITY; NUCLEAR EXPORT; INHIBITORS; HOMOLOG; COMPLEX; DIFFERENTIATION; AMIDOHYDROLASE; HYPERTROPHY	Histone deacetylases (HDACs) are protein deacetylases that play a role in repression of gene transcription and are emerging targets in cancer therapy. Here, we characterize the structure and enzymatic activity of the catalytic domain of human HDAC7(cdHDAC7). Although HDAC7 normally exists as part of a multiprotein complex, we show that cdHDAC7 has a low level of deacetylase activity which can be inhibited by known HDAC inhibitors. The crystal structures of human cdHDAC7 and its complexes with two hydroxamate inhibitors are the first structures of the catalytic domain of class IIa HDACs and demonstrate significant differences with previously reported class I and class IIb-like HDAC structures. We show that cdHDAC7 has an additional class IIa HDAC-specific zinc binding motif adjacent to the active site which is likely to participate in substrate recognition and protein-protein interaction and may provide a site for modulation of activity. Furthermore, a different active site topology results in modified catalytic properties and in an enlarged active site pocket. Our studies provide mechanistic insights into class IIa HDACs and facilitate the design of specific modulators.	[Schuetz, Anja; Min, Jinrong; Allali-Hassani, Abdellah; Schapira, Matthieu; Shuen, Michael; Loppnau, Peter; Bochkarev, Alexey; Plotnikov, Alexander N.; Vedadi, Masoud; Arrowsmith, Cheryl H.] Univ Toronto, Struct Genom Consortium, Toronto, ON M5G 1L5, Canada; [Mazitschek, Ralph; Kwiatkowski, Nick P.; Lewis, Timothy A.; Maglathin, Rebecca L.] MIT, Cambridge, MA 02142 USA; [Mazitschek, Ralph; Kwiatkowski, Nick P.; Lewis, Timothy A.; Maglathin, Rebecca L.; McLean, Thomas H.] Broad Inst Harvard, Chem Biol Program, Cambridge, MA 02142 USA; [Bochkarev, Alexey; Arrowsmith, Cheryl H.] Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L5, Canada; [Bochkarev, Alexey; Arrowsmith, Cheryl H.] Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5G 1L5, Canada; [Schapira, Matthieu] Univ Toronto, Dept Pharmacol, Toronto, ON M5G 1L5, Canada; [Min, Jinrong; Plotnikov, Alexander N.] Univ Toronto, Dept Physiol, Toronto, ON M5G 1L5, Canada	University of Toronto; Structural Genomics Consortium; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; University of Toronto; University of Toronto; University of Toronto; University of Toronto	Arrowsmith, CH (corresponding author), 100 Coll St, Toronto, ON M5G 1L5, Canada.	carrow@uhnresearch.ca	Mazitschek, Ralph/E-3741-2013; Min, Jinrong/G-3449-2011	Mazitschek, Ralph/0000-0002-1105-689X; Min, Jinrong/0000-0001-5210-3130; Arrowsmith, Cheryl/0000-0002-4971-3250; Schutz, Anja/0000-0002-0606-2574; Lewis, Timothy/0000-0001-9748-9575	NCI NIH HHS [N01-CO-12400] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission)		ABAGYAN R, 1994, J MOL BIOL, V235, P983, DOI 10.1006/jmbi.1994.1052; Bertos NR, 2001, BIOCHEM CELL BIOL, V79, P243, DOI 10.1139/bcb-79-3-243; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; CARDOZO T, 1995, PROTEINS, V23, P403, DOI 10.1002/prot.340230314; Chang SR, 2006, CELL, V126, P321, DOI 10.1016/j.cell.2006.05.040; Chang SR, 2004, MOL CELL BIOL, V24, P8467, DOI 10.1128/MCB.24.19.8467-8476.2004; Clemente S, 2001, BIOCHEMISTRY-US, V40, P10671, DOI 10.1021/bi0100844; Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fernandez-Recio J, 2003, PROTEINS, V52, P113, DOI 10.1002/prot.10383; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Fischle W, 2001, J BIOL CHEM, V276, P35826, DOI 10.1074/jbc.M104935200; Gregoire S, 2007, MOL CELL BIOL, V27, P1280, DOI 10.1128/MCB.00882-06; Gurvich N, 2004, CANCER RES, V64, P1079, DOI 10.1158/0008-5472.CAN-03-0799; Hildmann C, 2004, J BACTERIOL, V186, P2328, DOI 10.1128/JB.186.8.2328-2339.2004; Hildmann C, 2006, J BIOTECHNOL, V124, P258, DOI 10.1016/j.jbiotec.2006.01.030; Hu ED, 2003, J PHARMACOL EXP THER, V307, P720, DOI 10.1124/jpet.103.055541; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Kao HY, 2000, GENE DEV, V14, P55; Lahm A, 2007, P NATL ACAD SCI USA, V104, P17335, DOI 10.1073/pnas.0706487104; Marks PA, 2007, ONCOGENE, V26, P1351, DOI 10.1038/sj.onc.1210204; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Miller TA, 2003, J MED CHEM, V46, P5097, DOI 10.1021/jm0303094; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Moreth K, 2007, BIOCHEM J, V401, P659, DOI 10.1042/BJ20061239; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nielsen TK, 2007, ACTA CRYSTALLOGR F, V63, P270, DOI 10.1107/S1744309107012377; Nielsen TK, 2005, J MOL BIOL, V354, P107, DOI 10.1016/j.jmb.2005.09.065; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parra M, 2005, J BIOL CHEM, V280, P13762, DOI 10.1074/jbc.M413396200; Riester D, 2004, BIOCHEM BIOPH RES CO, V324, P1116, DOI 10.1016/j.bbrc.2004.09.155; Riester D, 2007, BIOCHEM BIOPH RES CO, V357, P439, DOI 10.1016/j.bbrc.2007.03.158; Somoza JR, 2004, STRUCTURE, V12, P1325, DOI 10.1016/j.str.2004.04.012; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vannini A, 2004, P NATL ACAD SCI USA, V101, P15064, DOI 10.1073/pnas.0404603101; Vannini A, 2007, EMBO REP, V8, P879, DOI 10.1038/sj.embor.7401047; Vedadi M, 2006, P NATL ACAD SCI USA, V103, P15835, DOI 10.1073/pnas.0605224103; Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024; Verdin E, 2003, TRENDS GENET, V19, P286, DOI 10.1016/S0168-9525(03)00073-8; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Yang XJ, 2005, MOL CELL BIOL, V25, P2873, DOI 10.1128/MCB.25.8.2873-2884.2005; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zhang Y, 2003, EMBO J, V22, P1168, DOI 10.1093/emboj/cdg115; Zhou XB, 2001, P NATL ACAD SCI USA, V98, P10572, DOI 10.1073/pnas.191375098	47	213	224	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11355	11363		10.1074/jbc.M707362200	http://dx.doi.org/10.1074/jbc.M707362200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18285338	Green Published, hybrid			2022-12-25	WOS:000255067400032
J	Kathrein, KL; Chari, S; Winandy, S				Kathrein, Katie L.; Chari, Sheila; Winandy, Susan			Ikaros directly represses the notch target gene Hes1 in a leukemia T cell line - Implications for CD4 regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; LYMPHOCYTE DEVELOPMENT; SIGNALING PATHWAY; MAMMALIAN NOTCH; RUNX PROTEINS; EXPRESSION; DIFFERENTIATION; ACTIVATION; MICE; MUTATIONS	Ikaros and Notch1, two regulators of gene transcription, are critically important at many stages of T cell development. Deregulation of Ikaros and Notch activities cooperate to promote T cell leukemogenesis, providing evidence that they function in converging pathways in developing T cells. In this report, a mechanism for Ikaros: Notch cooperativity is described, revealing a non-redundant role for Ikaros in regulating expression of the Notch target gene Hes1 in a leukemia T cell line. We provide evidence that Ikaros directly represses Hes1 in concert with the transcriptional repressor, RBP-J kappa, allowing for crosstalk between Notch and Ikaros that impacts regulation of CD4 expression. Taken together, these data describe a potential mechanism for Ikaros' function during T cell development and define Ikaros as an obligate repressor of Hes1.	[Kathrein, Katie L.; Chari, Sheila; Winandy, Susan] Northwestern Univ, Dept Microbiol Immunol, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Winandy, S (corresponding author), Northwestern Univ, Dept Microbiol Immunol, Feinberg Sch Med, Chicago, IL 60611 USA.	s-winandy@northwestern.edu			NATIONAL CANCER INSTITUTE [R01CA104962] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008061] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA104962-01A1] Funding Source: Medline; NIGMS NIH HHS [T32 GM08061] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen RD, 2001, MOL CELL BIOL, V21, P3071, DOI 10.1128/MCB.21.9.3071-3082.2001; Anderson AC, 2001, CURR OPIN GENET DEV, V11, P554, DOI 10.1016/S0959-437X(00)00232-X; Aster JC, 2001, CURR OPIN HEMATOL, V8, P237, DOI 10.1097/00062752-200107000-00010; Baron M, 2003, SEMIN CELL DEV BIOL, V14, P113, DOI 10.1016/S1084-9521(02)00179-9; Beverly LJ, 2004, TRENDS MOL MED, V10, P591, DOI 10.1016/j.molmed.2004.10.001; Beverly LJ, 2003, CANCER CELL, V3, P551, DOI 10.1016/S1535-6108(03)00137-5; Burns CE, 2005, GENE DEV, V19, P2331, DOI 10.1101/gad.1337005; Camos Mireia, 2006, Clin Transl Oncol, V8, P550, DOI 10.1007/s12094-006-0060-6; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; Dumortier A, 2006, MOL CELL BIOL, V26, P209, DOI 10.1128/MCB.26.1.209-220.2006; Felli MP, 1999, INT IMMUNOL, V11, P1017, DOI 10.1093/intimm/11.7.1017; Fryer CJ, 2004, MOL CELL, V16, P509, DOI 10.1016/j.molcel.2004.10.014; Georgopoulos K, 1997, ANNU REV IMMUNOL, V15, P155, DOI 10.1146/annurev.immunol.15.1.155; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Hruban RH, 1999, CURR OPIN GASTROEN, V15, P404, DOI 10.1097/00001574-199909000-00006; ISHIBASHI M, 1994, EMBO J, V13, P1799, DOI 10.1002/j.1460-2075.1994.tb06448.x; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Kageyama R, 1999, CELL RES, V9, P179, DOI 10.1038/sj.cr.7290016; Kathrein KL, 2005, MOL CELL BIOL, V25, P1645, DOI 10.1128/MCB.25.5.1645-1654.2005; Kim HK, 1998, MOL CELL BIOL, V18, P7166, DOI 10.1128/MCB.18.12.7166; Koipally J, 2002, J BIOL CHEM, V277, P13007, DOI 10.1074/jbc.M111371200; Lopez-Nieva P, 2004, CARCINOGENESIS, V25, P1299, DOI 10.1093/carcin/bgh124; Murata K, 2005, MOL CELL BIOL, V25, P4262, DOI 10.1128/MCB.25.10.4262-4271.2005; O'Neil J, 2006, BLOOD, V107, P781, DOI 10.1182/blood-2005-06-2553; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; Ong CT, 2006, J BIOL CHEM, V281, P5106, DOI 10.1074/jbc.M506108200; Pear WS, 2004, CURR OPIN HEMATOL, V11, P426, DOI 10.1097/01.moh.0000143965.90813.70; Pons M, 2006, Clin Transl Oncol, V8, P466, DOI 10.1007/s12094-006-0046-4; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Reizis B, 2002, GENE DEV, V16, P295, DOI 10.1101/gad.960702; Schweisguth F, 2004, CURR BIOL, V14, pR129, DOI 10.1016/j.cub.2004.01.023; Shattuck-Brandt RL, 1999, CURR OPIN GASTROEN, V15, P3, DOI 10.1097/00001574-199901000-00002; Sun L, 1999, P NATL ACAD SCI USA, V96, P680, DOI 10.1073/pnas.96.2.680; Sun L, 1999, J CLIN ONCOL, V17, P3753, DOI 10.1200/JCO.1999.17.12.3753; Taniuchi I, 2004, ONCOGENE, V23, P4341, DOI 10.1038/sj.onc.1207671; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Taniuchi I, 2002, MOL CELL, V10, P1083, DOI 10.1016/S1097-2765(02)00735-9; Tomita K, 1999, GENE DEV, V13, P1203, DOI 10.1101/gad.13.9.1203; Tomita K, 1996, NEURON, V16, P723, DOI 10.1016/S0896-6273(00)80093-8; Urban JA, 2004, J IMMUNOL, V173, P4470, DOI 10.4049/jimmunol.173.7.4470; Wang JH, 1996, IMMUNITY, V5, P537, DOI 10.1016/S1074-7613(00)80269-1; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; Winandy S, 1999, J EXP MED, V190, P1039, DOI 10.1084/jem.190.8.1039; Zweidler-McKay PA, 2004, SEMIN CANCER BIOL, V14, P329, DOI 10.1016/j.semcancer.2004.04.012	46	45	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10476	10484		10.1074/jbc.M709643200	http://dx.doi.org/10.1074/jbc.M709643200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18287091	hybrid, Green Published			2022-12-25	WOS:000254894700029
J	Smyth, VA; Di Lorenzo, D; Kennedy, BN				Smyth, Vincent A.; Di Lorenzo, David; Kennedy, Breandan N.			A novel, evolutionarily conserved enhancer of cone photoreceptor-specific expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPORTER GENE-EXPRESSION; TRANSGENE EXPRESSION; OPSIN PROMOTER; ALPHA-SUBUNIT; ROD PHOTORECEPTORS; NR2E3 FUNCTIONS; MOUSE RETINA; CIS-ELEMENTS; IN-VIVO; ZEBRAFISH	The alpha subunit of cone transducin (T alpha C) is expressed exclusively in cone photoreceptors of the eye and pineal. T alpha C is a key phototransduction protein, and inherited mutations in T alpha C cause total color blindness in humans. We use transgenic zebrafish to identify and characterize cone photoreceptor regulatory element 1 (CPRE-1) a novel 20-bp enhancer element in the T alpha C promoter (T alpha CP). CPRE-1 is located similar to 2.5 kb upstream of the translation start site and is necessary for strong cone photoreceptor-specific expression in vivo. CPRE-1 comprises of a modular arrangement of two 10-bp elements that have separate, but co-dependent transcriptional activities. In vitro, CPRE-1 specifically binds nuclear factors that are enriched in ocular tissue. Bioinformatic alignments reveal that CPRE-1 sites are evolutionarily conserved in the promoter regions of fish, rodent, and mammalian T alpha C orthologues and identify a 5'-CTGGAGTG(A/T) TGGA(G/A) GCAGGG(G/C) T-3' consensus sequence.	[Smyth, Vincent A.; Di Lorenzo, David; Kennedy, Breandan N.] Univ Coll Dublin, Conway Inst, Sch Biomol & Biomed Sci, Dublin 4, Ireland	University College Dublin	Kennedy, BN (corresponding author), Univ Coll Dublin, Conway Inst, Sch Biomol & Biomed Sci, Dublin 4, Ireland.	brendan.kennedy@ucd.ie	kennedy, Breandan/H-5643-2019	kennedy, Breandan/0000-0001-7991-4689				Babu S, 2006, FEBS LETT, V580, P1479, DOI 10.1016/j.febslet.2006.01.080; BARTHEL LK, 1990, J HISTOCHEM CYTOCHEM, V38, P1383, DOI 10.1177/38.9.2201738; Boatright J H, 1997, Mol Vis, V3, P15; BRANCHEK T, 1984, J COMP NEUROL, V224, P107, DOI 10.1002/cne.902240109; Brockerhoff SE, 2003, J NEUROSCI, V23, P470, DOI 10.1523/JNEUROSCI.23-02-00470.2003; CHEN J, 1994, P NATL ACAD SCI USA, V91, P2611, DOI 10.1073/pnas.91.7.2611; Chen JC, 2005, J NEUROSCI, V25, P118, DOI 10.1523/JNEUROSCI.3571-04.2005; Chen ZY, 2001, MOL THER, V3, P403, DOI 10.1006/mthe.2001.0278; Cheng H, 2004, HUM MOL GENET, V13, P1563, DOI 10.1093/hmg/ddh173; Collery RE, 2006, ADV EXP MED BIOL, V572, P201; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Forrester JVDA., 2002, EYE BASIC SCI PRACTI; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; Glushakova LG, 2006, INVEST OPHTH VIS SCI, V47, P3505, DOI 10.1167/iovs.05-1670; Goldsmith P, 2003, SEMIN CELL DEV BIOL, V14, P11, DOI 10.1016/S1084-9521(02)00167-2; GOURAS P, 1994, VISUAL NEUROSCI, V11, P1227, DOI 10.1017/S0952523800007021; Haider NB, 2000, NAT GENET, V24, P127, DOI 10.1038/72777; Haider NB, 2006, VISUAL NEUROSCI, V23, P917, DOI 10.1017/S095252380623027X; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Kennedy BN, 2007, INVEST OPHTH VIS SCI, V48, P522, DOI 10.1167/iovs.06-0975; Kimble TDH, 2000, ANAT EMBRYOL, V201, P305, DOI 10.1007/s004290050319; Kohl S, 2002, AM J HUM GENET, V71, P422, DOI 10.1086/341835; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Luo WQ, 2004, J BIOL CHEM, V279, P19286, DOI 10.1074/jbc.M400161200; Mears AJ, 2001, NAT GENET, V29, P447, DOI 10.1038/ng774; Michaelides M, 2003, BRIT J OPHTHALMOL, V87, P1317, DOI 10.1136/bjo.87.11.1317; Morris TA, 1997, INVEST OPHTH VIS SCI, V38, P196; Ng L, 2001, NAT GENET, V27, P94, DOI 10.1038/83829; Nikonov SS, 2005, J GEN PHYSIOL, V125, P287, DOI 10.1085/jgp.200409208; Oh ECT, 2007, P NATL ACAD SCI USA, V104, P1679, DOI 10.1073/pnas.0605934104; Peng GH, 2005, HUM MOL GENET, V14, P747, DOI 10.1093/hmg/ddi070; Pickrell SW, 2004, INVEST OPHTH VIS SCI, V45, P3877, DOI 10.1167/iovs.04-0663; Raymond PA, 2004, INT J DEV BIOL, V48, P935, DOI 10.1387/ijdb.041873pr; Riu ER, 2007, MOL THER, V15, P1348, DOI 10.1038/sj.mt.6300177; Roberts MR, 2006, P NATL ACAD SCI USA, V103, P6218, DOI 10.1073/pnas.0509981103; Silva E, 2000, INVEST OPHTH VIS SCI, V41, P2076; Tsujimura T, 2007, P NATL ACAD SCI USA, V104, P12813, DOI 10.1073/pnas.0704061104; Vihtelic TS, 1999, VISUAL NEUROSCI, V16, P571, DOI 10.1017/S0952523899163168; Weinstein LS, 2006, TRENDS PHARMACOL SCI, V27, P260, DOI 10.1016/j.tips.2006.03.005; Ying SX, 1998, CURR EYE RES, V17, P777, DOI 10.1076/ceyr.17.8.777.5158	40	11	12	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10881	10891		10.1074/jbc.M710454200	http://dx.doi.org/10.1074/jbc.M710454200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18272521	hybrid			2022-12-25	WOS:000254894700070
J	Chen, YQ; Kuo, MS; Li, SY; Bui, HH; Peake, DA; Sanders, PE; Thibodeaux, SJ; Chu, SY; Qian, YW; Zhao, Y; Bredt, DS; Moller, DE; Konrad, RJ; Beigneux, AP; Young, SG; Cao, GQ				Chen, Yan Qun; Kuo, Ming-Shang; Li, Shuyu; Bui, Hai H.; Peake, David A.; Sanders, Philip E.; Thibodeaux, Stefan J.; Chu, Shaoyou; Qian, Yue-Wei; Zhao, Yang; Bredt, David S.; Moller, David E.; Konrad, Robert J.; Beigneux, Anne P.; Young, Stephen G.; Cao, Guoqing			AGPAT6 is a novel microsomal glycerol-3-phosphate acyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOPHOSPHATIDIC ACID ACYLTRANSFERASE; TANDEM MASS-SPECTROMETRY; FUNCTIONAL-CHARACTERIZATION; TRIACYLGLYCEROL SYNTHESIS; HEPATIC STEATOSIS; ACYL-COA; II CELLS; IDENTIFICATION; CLONING; GENE	AGPAT6 is a member of the 1-acylglycerol-3-phosphate O-acyltransferase (AGPAT) family that appears to be important in triglyceride biosynthesis in several tissues, but the precise biochemical function of the enzyme is unknown. In the current study, we show that AGPAT6 is a microsomal glycerol-3-phosphate acyltransferase (GPAT). Membranes from HEK293 cells overexpressing human AGPAT6 had higher levels of GPAT activity. Substrate specificity studies suggested that AGPAT6 was active against both saturated and unsaturated long-chain fatty acyl-CoAs. Both glycerol 3-phosphate and fatty acyl-CoA increased the GPAT activity, and the activity was sensitive to N-ethylmaleimide, a sulfhydryl-modifying reagent. Purified AGPAT6 protein possessed GPAT activity but not AGPAT activity. Using [C-13(7)] oleic acid labeling and mass spectrometry, we found that overexpression of AGPAT6 increased both lysophosphatidic acid and phosphatidic acid levels in cells. In these studies, total triglyceride and phosphatidylcholine levels were not significantly altered, although there were significant changes in the abundance of specific phosphatidylcholine species. Human AGPAT6 is localized to endoplasmic reticulum and is broadly distributed in tissues. Membranes of mammary epithelial cells from Agpat6-deficient mice exhibited markedly reduced GPAT activity compared with membranes from wildtype mice. Reducing AGPAT6 expression in HEK293 cells through small interfering RNA knockdown suggested that AGPAT6 significantly contributed to HEK293 cellular GPAT activity. Our data indicate that AGPAT6 is a microsomal GPAT, and we propose renaming this enzyme GPAT4.	[Chen, Yan Qun; Kuo, Ming-Shang; Li, Shuyu; Bui, Hai H.; Peake, David A.; Thibodeaux, Stefan J.; Chu, Shaoyou; Qian, Yue-Wei; Zhao, Yang; Bredt, David S.; Moller, David E.; Konrad, Robert J.; Cao, Guoqing] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA; [Beigneux, Anne P.; Young, Stephen G.] Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiol, Dept Med, Los Angeles, CA 90095 USA	Eli Lilly; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Cao, GQ (corresponding author), Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA.	Guoqing_cao@lilly.com	lewchavaroj, runglawan/B-5191-2009	Chen, Yan Q/0000-0001-9311-6077; Young, Stephen/0000-0001-7270-3176	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL066621] Funding Source: NIH RePORTER; NHLBI NIH HHS [U01 HL 66621] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agarwal AK, 2007, J ENDOCRINOL, V193, P445, DOI 10.1677/JOe-07-0027; Aguado B, 1998, J BIOL CHEM, V273, P4096, DOI 10.1074/jbc.273.7.4096; Beigneux AP, 2006, J LIPID RES, V47, P734, DOI 10.1194/jlr.M500556-JLR200; Cao JS, 2006, P NATL ACAD SCI USA, V103, P19695, DOI 10.1073/pnas.0609140103; Cao JS, 2004, J BIOL CHEM, V279, P31727, DOI 10.1074/jbc.M402930200; Chen XN, 2006, P NATL ACAD SCI USA, V103, P11724, DOI 10.1073/pnas.0604946103; COLEMAN RA, 1978, J BIOL CHEM, V253, P7256; Coleman RA, 2004, PROG LIPID RES, V43, P134, DOI 10.1016/S0163-7827(03)00051-1; Eberhardt C, 1997, J BIOL CHEM, V272, P20299, DOI 10.1074/jbc.272.32.20299; Gonzalez-Baro MR, 2007, AM J PHYSIOL-GASTR L, V292, pG1195, DOI 10.1152/ajpgi.00553.2006; Gonzalez-Baro MR, 2001, J BIOL CHEM, V276, P43182, DOI 10.1074/jbc.M107885200; Hammond LE, 2002, MOL CELL BIOL, V22, P8204, DOI 10.1128/MCB.22.23.8204-8214.2002; Han XL, 2001, ANAL BIOCHEM, V295, P88, DOI 10.1006/abio.2001.5178; Igal RA, 2001, J BIOL CHEM, V276, P42205, DOI 10.1074/jbc.M103386200; Lewin TM, 2004, J BIOL CHEM, V279, P13488, DOI 10.1074/jbc.M314032200; Li D, 2003, J HUM GENET, V48, P438, DOI 10.1007/s10038-003-0045-z; Liebisch G, 2004, BBA-MOL CELL BIOL L, V1686, P108, DOI 10.1016/j.bbalip.2004.09.003; Linden D, 2004, J LIPID RES, V45, P1279, DOI 10.1194/jlr.M400010-JLR200; Linden D, 2006, FASEB J, V20, P434, DOI 10.1096/fj.05-4568com; Murata N, 1997, BBA-LIPID LIPID MET, V1348, P10, DOI 10.1016/S0005-2760(97)00115-X; Murphy RC, 2007, ANAL BIOCHEM, V366, P59, DOI 10.1016/j.ab.2007.03.012; Nakanishi H, 2006, J BIOL CHEM, V281, P20140, DOI 10.1074/jbc.M600225200; Neschen S, 2005, CELL METAB, V2, P55, DOI 10.1016/j.cmet.2005.06.006; SHIN DH, 1991, J BIOL CHEM, V266, P23834; Vergnes L, 2006, J LIPID RES, V47, P745, DOI 10.1194/jlr.M500553-JLR200; Wang S, 2007, ARCH BIOCHEM BIOPHYS, V465, P347, DOI 10.1016/j.abb.2007.06.033; YET SF, 1993, BIOCHEMISTRY-US, V32, P9486, DOI 10.1021/bi00087a029; Zheng ZF, 2001, J BIOL CHEM, V276, P41710, DOI 10.1074/jbc.M104749200	28	101	114	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					10048	10057		10.1074/jbc.M708151200	http://dx.doi.org/10.1074/jbc.M708151200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18238778	hybrid, Green Published			2022-12-25	WOS:000254671600059
J	Kol, S; Nouwen, N; Driessen, AJM				Kol, Stefan; Nouwen, Nico; Driessen, Arnold J. M.			The charge distribution in the cytoplasmic loop of subunit C of the F1F0 ATPase is a determinant for YidC targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN INSERTION; ESCHERICHIA-COLI YIDC; INNER MEMBRANE; M13 PROCOAT; F-0 COMPLEX; SYNTHASE; BIOGENESIS; PATHWAY; SRP; BACTERIOPHAGE-M13	YidC is a member of the Oxa1 family of proteins that facilitates the membrane insertion of a subset of inner membrane proteins in Escherichia coli. YidC acts as an insertase for membrane insertion of subunit c of the F1F0 ATP synthase (F(0)c), but the requirements for substrate recognition have remained unclear. Here, we have analyzed the role of the charged aminoacyl residues in F(0)c in YidC targeting and membrane insertion. Binding experiments demonstrate that F(0)c is targeted directly to YidC without the presence of a stable lipid surface-bound intermediate. Positive charges in the cytoplasmic loop of F(0)c are important determinants for YidC binding and subsequent membrane insertion. These data support a model in which F(0)c binds directly to YidC prior to its membrane insertion.	[Kol, Stefan; Nouwen, Nico; Driessen, Arnold J. M.] Univ Groningen, Dept Mol Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands; [Kol, Stefan; Nouwen, Nico; Driessen, Arnold J. M.] Univ Groningen, Zernike Inst Adv Mat, NL-9751 NN Haren, Netherlands	University of Groningen; University of Groningen	Driessen, AJM (corresponding author), Univ Groningen, Dept Mol Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands.	a.j.m.driessen@rug.nl	Institute, Zernike/W-7033-2019; Driessen, Arnold J.M./D-1876-2012	Kol, Stefan/0000-0002-1992-8242				BANEYX F, 1990, J BACTERIOL, V172, P491, DOI 10.1128/JB.172.1.491-494.1990; CAO GQ, 1994, J BIOL CHEM, V269, P26898; Capaldi RA, 2002, TRENDS BIOCHEM SCI, V27, P154, DOI 10.1016/S0968-0004(01)02051-5; Chen MY, 2003, J BIOL CHEM, V278, P23295, DOI 10.1074/jbc.M301008200; Chen MY, 2002, J BIOL CHEM, V277, P7670, DOI 10.1074/jbc.M110644200; CLARK AJ, 1963, GENETICS, V48, P105; de Gier JWL, 1998, P NATL ACAD SCI USA, V95, P14646, DOI 10.1073/pnas.95.25.14646; DeckersHebestreit G, 1996, ANNU REV MICROBIOL, V50, P791, DOI 10.1146/annurev.micro.50.1.791; Facey SJ, 2007, J MOL BIOL, V365, P995, DOI 10.1016/j.jmb.2006.10.083; Fillingame RH, 2002, BBA-BIOENERGETICS, V1555, P29, DOI 10.1016/S0005-2728(02)00250-5; GALLUSSER A, 1990, EMBO J, V9, P2723, DOI 10.1002/j.1460-2075.1990.tb07459.x; Jia LX, 2003, EMBO J, V22, P6438, DOI 10.1093/emboj/cdg624; Jiang FL, 2003, J BIOL CHEM, V278, P48965, DOI 10.1074/jbc.M307362200; Kol S, 2006, J BIOL CHEM, V281, P29762, DOI 10.1074/jbc.M605317200; KUHN A, 1990, EMBO J, V9, P2385, DOI 10.1002/j.1460-2075.1990.tb07413.x; KUHN A, 1986, NATURE, V322, P335, DOI 10.1038/322335a0; KUHN A, 1995, FEMS MICROBIOL REV, V17, P185; Luirink J, 2005, ANNU REV MICROBIOL, V59, P329, DOI 10.1146/annurev.micro.59.030804.121246; Meier T, 2005, SCIENCE, V308, P659, DOI 10.1126/science.1111199; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; Serek J, 2004, EMBO J, V23, P294, DOI 10.1038/sj.emboj.7600063; Stalz WD, 2003, J BIOL CHEM, V278, P27068, DOI 10.1074/jbc.M302027200; STEFFENS K, 1984, EUR J BIOCHEM, V138, P617, DOI 10.1111/j.1432-1033.1984.tb07959.x; Szyrach G, 2003, EMBO J, V22, P6448, DOI 10.1093/emboj/cdg623; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; van Bloois E, 2004, FEBS LETT, V576, P97, DOI 10.1016/j.febslet.2004.08.069; van der Laan M, 2005, CURR OPIN MICROBIOL, V8, P182, DOI 10.1016/j.mib.2005.02.004; van der Laan M, 2004, J CELL BIOL, V165, P213, DOI 10.1083/jcb.200402100; van der Laan M, 2003, P NATL ACAD SCI USA, V100, P5801, DOI 10.1073/pnas.0636761100; van der Laan M, 2001, EMBO REP, V2, P519, DOI 10.1093/embo-reports/kve106; WATTS SD, 1995, FEBS LETT, V368, P235, DOI 10.1016/0014-5793(95)00658-V; Weber J, 2003, FEBS LETT, V545, P61, DOI 10.1016/S0014-5793(03)00394-6	33	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9871	9877		10.1074/jbc.M709408200	http://dx.doi.org/10.1074/jbc.M709408200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18276587	Green Published, hybrid			2022-12-25	WOS:000254671600043
J	Takagi, S; Nakajima, M; Mohri, T; Yokoi, T				Takagi, Shingo; Nakajima, Miki; Mohri, Takuya; Yokoi, Tsuyoshi			Post-transcriptional regulation of human pregnane x receptor by micro-RNA affects the expression of cytochrome P450 3A4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR; TRANSCRIPTIONAL REGULATION; DRUG-INTERACTIONS; MESSENGER-RNA; HUMAN TISSUES; HUMAN LIVER; CYP3A4; PXR; METABOLISM; IDENTIFICATION	Pregnane X receptor (PXR) is a major transcription factor regulating the inducible expression of a variety of transporters and drug-metabolizing enzymes, including CYP3A4 (cytochrome P450 3A4). We first found that the PXR mRNA level was not correlated with the PXR protein level in a panel of 25 human livers, indicating the involvement of post-transcriptional regulation. Notably, a potential miR-148a recognition element was identified in the 3'-untranslated region of human PXR mRNA. We investigated whether PXR might be regulated by miR-148a. A reporter assay revealed that miR-148a could recognize the miR-148a recognition element of PXR mRNA. The PXR protein level was decreased by the overexpression of miR-148a, whereas it was increased by inhibition of miR-148a. The miR-148a-dependent decrease of PXR protein attenuated the induction CYP3A4 mRNA. Furthermore, the translational efficiency of PXR (PXR protein/PXR mRNA ratio) was inversely correlated with the expression levels of miR-148a in a panel of 25 human livers, supporting the miR-148a-dependent regulation of PXR in human livers. Eventually, the PXR protein level was significantly correlated with the CYP3A4 mRNA and protein levels. In conclusion, we found that miR-148a post-transcriptionally regulated human PXR, resulting in the modulation of the inducible and/or constitutive levels of CYP3A4 in human liver. This study will provide new insight into the unsolved mechanism of the large interindividual variability of CYP3A4 expression.	[Takagi, Shingo; Nakajima, Miki; Mohri, Takuya; Yokoi, Tsuyoshi] Kanazawa Univ, Grad Sch Med Sci, Div Pharmaceut Sci, Kanazawa, Ishikawa 9201192, Japan	Kanazawa University	Yokoi, T (corresponding author), Kanazawa Univ, Grad Sch Med Sci, Div Pharmaceut Sci, Kakuma Machi, Kanazawa, Ishikawa 9201192, Japan.	tyokoi@kenroku.kanazawa-u.ac.jp	Nakajima, Miki/C-3990-2015; yokoi, tsuyoshi/I-7115-2014	Yokoi, Tsuyoshi/0000-0002-3239-2817				Aouabdi S, 2006, DRUG METAB DISPOS, V34, P138, DOI 10.1124/dmd.105.006064; Barad O, 2004, GENOME RES, V14, P2486, DOI 10.1101/gr.2845604; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Dotzlaw H, 1999, CLIN CANCER RES, V5, P2103; Floyd MD, 2003, PHARMACOGENETICS, V13, P595, DOI 10.1097/00008571-200310000-00003; Goodwin B, 2001, MOL PHARMACOL, V60, P427; Goodwin B, 1999, MOL PHARMACOL, V56, P1329, DOI 10.1124/mol.56.6.1329; Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023; Kliewer SA, 2002, ENDOCR REV, V23, P687, DOI 10.1210/er.2001-0038; Kretschmer XC, 2005, CHEM-BIOL INTERACT, V155, P111, DOI 10.1016/j.cbi.2005.06.003; Lamba JK, 2002, PHARMACOGENETICS, V12, P121, DOI 10.1097/00008571-200203000-00006; Lamba V, 2004, TOXICOL APPL PHARM, V199, P251, DOI 10.1016/j.taap.2003.12.027; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Martinez-Jimenez CP, 2007, CURR DRUG METAB, V8, P185, DOI 10.2174/138920007779815986; Meijerman I, 2006, ONCOLOGIST, V11, P742, DOI 10.1634/theoncologist.11-7-742; Ozdemir V, 2000, PHARMACOGENETICS, V10, P373, DOI 10.1097/00008571-200007000-00001; Pascussi JM, 2000, MOL PHARMACOL, V58, P361, DOI 10.1124/mol.58.2.361; Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1261/rna.5248604; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Synold TW, 2001, NAT MED, V7, P584, DOI 10.1038/87912; Takada Tomonari, 2004, Drug Metab Pharmacokinet, V19, P103, DOI 10.2133/dmpk.19.103; Tsuchiya Y, 2004, CANCER RES, V64, P3119, DOI 10.1158/0008-5472.CAN-04-0166; Tsuchiya Y, 2006, CANCER RES, V66, P9090, DOI 10.1158/0008-5472.CAN-06-1403; Watanabe M, 2004, J PHARMACOL SCI, V94, P459, DOI 10.1254/jphs.94.459; Westlind-Johnsson A, 2003, DRUG METAB DISPOS, V31, P755, DOI 10.1124/dmd.31.6.755; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441	30	231	255	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9674	9680		10.1074/jbc.M709382200	http://dx.doi.org/10.1074/jbc.M709382200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18268015	hybrid, Green Submitted			2022-12-25	WOS:000254671600022
J	van Wonderen, JH; Burlat, B; Richardson, DJ; Cheesman, MR; Butt, JN				van Wonderen, Jessica H.; Burlat, Benedicte; Richardson, David J.; Cheesman, Myles R.; Butt, Julea N.			The nitric oxide reductase activity of cytochrome c nitrite reductase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN FILM VOLTAMMETRY; NITROSATIVE STRESS; NITRATE; FLAVORUBREDOXIN; REDOX; DETOXIFICATION; INHIBITION; MECHANISM; MYOGLOBIN; SYNTHASE	Cytochrome c nitrite reductase ( NrfA) from Escherichia coli has a well established role in the respiratory reduction of nitrite to ammonium. More recently the observation that anaerobically grown E. coli nrf mutants were more sensitive to NO center dot than the parent strain led to the proposal that NrfA might also participate in NO center dot detoxification. Here we describe protein film voltammetry that presents a quantitative description of NrfA NO center dot reductase activity. NO center dot reduction is initiated at similar potentials to NrfA-catalyzed reduction of nitrite and hydroxylamine. All three activities are strongly inhibited by cyanide. Together these results suggest a common site for reduction of all three substrates as axial ligands to the lysine-coordinated NrfA heme rather than nonspecific NO center dot reduction at one of the four His-His coordinated hemes also present in each NrfA subunit. NO center dot reduction by NrfA is described by a Km of the order of 300 mu M. The predicted turnover number of similar to 840 NO center dot s(-1) is much higher than that of the dedicated respiratory NO center dot reductases of denitrification and the flavorubredoxin and flavohemoglobin of E. coli that are also proposed to play roles in NO center dot detoxification. In considering the manner by which anaerobically growing E. coli might detoxify exogenously generated NO center dot encountered during invasion of a human host it appears that the periplasmically located NrfA should be effective in maintaining low NO center dot levels such that any NO center dot reaching the cytoplasm is efficiently removed by flavorubredoxin ( K-m similar to 0.4 mu M).	[van Wonderen, Jessica H.; Burlat, Benedicte; Richardson, David J.; Cheesman, Myles R.; Butt, Julea N.] Univ E Anglia, Sch Chem Sci & Pharm, Sch Biol Sci, Ctr Metalloprot Spect & Biol, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Butt, JN (corresponding author), Univ E Anglia, Sch Chem Sci & Pharm, Sch Biol Sci, Ctr Metalloprot Spect & Biol, Norwich NR4 7TJ, Norfolk, England.	j.butt@uea.ac.uk	Butt, Julea/E-2133-2011; Richardson, David J/E-2275-2011; van Wonderen, Jessica/A-9728-2013; Richardson, David/N-5129-2014	Butt, Julea/0000-0002-9624-5226; Richardson, David/0000-0002-7751-1058	Biotechnology and Biological Sciences Research Council [B18695] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Anderson LJ, 2001, BIOCHEMISTRY-US, V40, P11294, DOI 10.1021/bi002706b; Angove HC, 2002, J BIOL CHEM, V277, P23374, DOI 10.1074/jbc.M200495200; Bamford VA, 2002, BIOCHEMISTRY-US, V41, P2921, DOI 10.1021/bi015765d; BENJAMIN N, 1994, NATURE, V368, P502, DOI 10.1038/368502a0; Burlat B, 2005, BIOCHEM SOC T, V33, P137, DOI 10.1042/BST0330137; CLARKE TA, 2008, IN PRESS METHODS ENZ; COSTA C, 1990, FEBS LETT, V276, P67, DOI 10.1016/0014-5793(90)80508-G; da Costa PN, 2003, FEMS MICROBIOL LETT, V218, P385, DOI 10.1016/S0378-1097(02)01186-2; Donzelli S, 2006, ANTIOXID REDOX SIGN, V8, P1363, DOI 10.1089/ars.2006.8.1363; Einsle O, 2002, J AM CHEM SOC, V124, P11737, DOI 10.1021/ja0206487; Fujiwara T, 1996, J BACTERIOL, V178, P1866, DOI 10.1128/jb.178.7.1866-1871.1996; Gardner AM, 2002, J BIOL CHEM, V277, P8172, DOI 10.1074/jbc.M110471200; Gardner PR, 2005, J INORG BIOCHEM, V99, P247, DOI 10.1016/j.jinorgbio.2004.10.003; Gomes CM, 2002, J BIOL CHEM, V277, P25273, DOI 10.1074/jbc.M203886200; Gwyer JD, 2006, BIOPHYS J, V91, P3897, DOI 10.1529/biophysj.106.089755; Gwyer JD, 2006, BIOCHEM SOC T, V34, P133, DOI 10.1042/BST0340133; Gwyer JD, 2005, J AM CHEM SOC, V127, P14964, DOI 10.1021/ja054160s; Gwyer JD, 2004, BIOELECTROCHEMISTRY, V63, P43, DOI 10.1016/j.bioelechem.2003.10.013; Gwyer JD, 2004, BIOCHEMISTRY-US, V43, P15086, DOI 10.1021/bi049085x; HEISS B, 1989, J BACTERIOL, V171, P3288, DOI 10.1128/jb.171.6.3288-3297.1989; Justino MC, 2005, J BIOL CHEM, V280, P2636, DOI 10.1074/jbc.M411070200; KAJIE SI, 1986, EUR J BIOCHEM, V154, P457, DOI 10.1111/j.1432-1033.1986.tb09419.x; Kelm M, 1999, BBA-BIOENERGETICS, V1411, P273, DOI 10.1016/S0005-2728(99)00020-1; Millar SJ, 1996, MEAT SCI, V42, P277, DOI 10.1016/0309-1740(94)00045-X; Poock SR, 2002, J BIOL CHEM, V277, P23664, DOI 10.1074/jbc.M200731200; Poole RK, 2000, MOL MICROBIOL, V36, P775, DOI 10.1046/j.1365-2958.2000.01889.x; Poole RK, 2005, BIOCHEM SOC T, V33, P176, DOI 10.1042/BST0330176; Raines KW, 2006, INFECT IMMUN, V74, P2268, DOI 10.1128/IAI.74.4.2268-2276.2006; Ridnour LA, 2000, ANAL BIOCHEM, V281, P223, DOI 10.1006/abio.2000.4583; SEWARD HE, 1999, MAGNETO OPTICAL SPEC; Simon J, 2002, FEMS MICROBIOL REV, V26, P285, DOI 10.1111/j.1574-6976.2002.tb00616.x; SNYDER SH, 1992, SCI AM, V266, P68, DOI 10.1038/scientificamerican0592-68; Stach P, 2000, J INORG BIOCHEM, V79, P381, DOI 10.1016/S0162-0134(99)00248-2; Wilks JC, 2007, J BACTERIOL, V189, P5601, DOI 10.1128/JB.00615-07	35	84	87	4	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9587	9594		10.1074/jbc.M709090200	http://dx.doi.org/10.1074/jbc.M709090200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18245085	hybrid			2022-12-25	WOS:000254671600012
J	Zhao, JF; Gao, FQ; Zhang, YD; Wei, K; Liu, YH; Deng, XM				Zhao, Jinfeng; Gao, Fengqin; Zhang, Yangde; Wei, Kun; Liu, Yunhai; Deng, Xingming			Bcl2 inhibits abasic site repair by down-regulating APE1 endonuclease activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPAIR; TRANSCRIPTIONAL ACTIVITY; INTERPHASE NUCLEI; MISMATCH REPAIR; APOPTOSIS; PROTEIN; CELLS; LOCALIZATION; SPECIFICITY; SUPPRESSION	Bcl2 not only prolongs cell survival but also suppresses the repair of abasic (AP) sites of DNA lesions. Apurinic/apyrimidinic endonuclease 1 (APE1) plays a central role in the repair of AP sites via the base excision repair pathway. Here we found that Bcl2 down-regulates APE1 endonuclease activity in association with inhibition of AP site repair. Exposure of cells to nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone results in accumulation of Bcl2 in the nucleus and interaction with APE1, which requires all of the BH domains of Bcl2. Deletion of any of the BH domains from Bcl2 abrogates the ability of Bcl2 to interact with APE1 as well as the inhibitory effects of Bcl2 on APE1 activity and AP site repair. Overexpression of Bcl2 in cells reduces formation of the APE1 center dot XRCC1 complex, and purified Bcl2 protein directly disrupts the APE1 center dot XRCC1 complex with suppression of APE1 endonuclease activity in vitro. Importantly, specific knockdown of endogenous Bcl2 by RNA interference enhances APE1 endonuclease activity with accelerated AP site repair. Thus, Bcl2 inhibition of AP site repair may occur in a novel mechanism by down-regulating APE1 endonuclease activity, which may promote genetic instability and tumorigenesis.	[Zhao, Jinfeng; Gao, Fengqin; Deng, Xingming] Univ Florida, Univ Florida Shands Canc Ctr, Dept Med, Gainesville, FL 32610 USA; [Zhao, Jinfeng; Gao, Fengqin; Deng, Xingming] Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; [Zhao, Jinfeng; Gao, Fengqin; Zhang, Yangde] Cent S Univ, Xiangya Hosp, Dept Surg, Natl Hepatobillary & Enter Surg Res Ctr, Changsha 4100080, Peoples R China; [Wei, Kun] Coll Mat Sci & Engn, Guangzhou 510640, Peoples R China	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Central South University	Deng, XM (corresponding author), Univ Florida, Univ Florida Shands Canc Ctr, Dept Med, 1376 Mowry Rd,Canc Genet Res Complex,Rm 262, Gainesville, FL 32610 USA.	xdeng@ufl.edu			NATIONAL CANCER INSTITUTE [R01CA112183] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 112183] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Castelli M, 2004, CELL DEATH DIFFER, V11, P906, DOI 10.1038/sj.cdd.4401433; CHEBONNELLASSER.C, 1996, ONCOGENE, V13, P1489; Cullen BR, 2006, NAT METHODS, V3, P677, DOI 10.1038/NMETH913; Deng XM, 2006, MOL CELL BIOL, V26, P4421, DOI 10.1128/MCB.01647-05; Deng XM, 2004, P NATL ACAD SCI USA, V101, P153, DOI 10.1073/pnas.2533920100; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hoetelmans RWM, 2000, CELL DEATH DIFFER, V7, P384, DOI 10.1038/sj.cdd.4400664; Hou YZ, 2007, J BIOL CHEM, V282, P9279, DOI 10.1074/jbc.M608523200; Jin ZH, 2006, J BIOL CHEM, V281, P14446, DOI 10.1074/jbc.M511914200; JORQUERA R, 1994, CARCINOGENESIS, V15, P389, DOI 10.1093/carcin/15.2.389; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kelley MR, 2001, ANTIOXID REDOX SIGN, V3, P671, DOI 10.1089/15230860152543014; Kuo ML, 1999, MOL PHARMACOL, V55, P894; Lau JP, 2004, BRIT J CANCER, V91, P1166, DOI 10.1038/sj.bjc.6602080; LINETTE GP, 1995, BLOOD, V86, P1255, DOI 10.1182/blood.V86.4.1255.bloodjournal8641255; Liu YF, 1997, CANCER RES, V57, P1650; LOEB LA, 1985, CELL, V40, P483, DOI 10.1016/0092-8674(85)90191-6; Mijal RS, 2004, CHEM RES TOXICOL, V17, P424, DOI 10.1021/tx0342417; Saintigny Y, 2001, EMBO J, V20, P2596, DOI 10.1093/emboj/20.10.2596; Schandl CA, 1999, J HISTOCHEM CYTOCHEM, V47, P151, DOI 10.1177/002215549904700204; Semizarov D, 2003, P NATL ACAD SCI USA, V100, P6347, DOI 10.1073/pnas.1131959100; Tell G, 2005, ANTIOXID REDOX SIGN, V7, P367, DOI 10.1089/ars.2005.7.367; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; Vidal AE, 2001, EMBO J, V20, P6530, DOI 10.1093/emboj/20.22.6530; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; Youn CK, 2005, NAT CELL BIOL, V7, P137, DOI 10.1038/ncb1215; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	27	24	28	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9925	9932		10.1074/jbc.M708345200	http://dx.doi.org/10.1074/jbc.M708345200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18263880	Green Published, hybrid			2022-12-25	WOS:000254671600049
J	Harita, Y; Kurihara, H; Kosako, H; Tezuka, T; Sekine, T; Igarashi, T; Hattori, S				Harita, Yutaka; Kurihara, Hidetake; Kosako, Hidetaka; Tezuka, Tohru; Sekine, Takashi; Igarashi, Takashi; Hattori, Seisuke			Neph1, a component of the kidney slit diaphragm, is tyrosine-phosphorylated by the Src family tyrosine kinase and modulates intracellular signaling by binding to Grb2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL NEPHROTIC SYNDROME; MICE LACKING; ACTIN POLYMERIZATION; GLOMERULAR PODOCYTE; ADAPTER PROTEINS; EGF RECEPTOR; DOMAIN; ACTIVATION; JUNCTION; RECRUITMENT	There are several lines of evidence that the podocyte slit diaphragm ( SD), which serves as a structural framework for the filtration barrier in kidney glomerulus, also plays an essential role as a signaling platform. Several SD components including nephrin and TRPC6 are known to be phosphorylated by a Src family tyrosine kinase ( SFK), Fyn. Here we have characterized Neph1, another SD component, as a novel substrate of SFK. Fyn interacts with and phosphorylates the cytoplasmic domain of Neph1 in vitro and in intact cells. Peptide mass fingerprinting and site-directed mutagenesis identified several tyrosine phosphorylation sites. In pull-down assays using rat glomerular lysates, Neph1 but not nephrin specifically binds to adaptor protein Grb2 and tyrosine kinase Csk in a phosphorylation-dependent manner. Both tyrosine 637 and 638 of Neph1 are crucial for Neph1-Grb2 binding. Phosphorylation of tyrosine 637 is significantly up-regulated in in vivo models of podocyte injury. Furthermore, Neph1 attenuates ERK activation elicited by Fyn, and this inhibitory effect requires the intact binding motif for the Grb2 SH2 domain. Our results shown here demonstrate that Neph1 is a novel in vivo substrate of SFK and suggest that Neph1 modulates ERK signaling through phosphorylation-dependent interaction with Grb2. Thus, SFK orchestrates a wide spectrum of protein-protein interactions and intracellular signaling networks at SD through tyrosine phosphorylation.	[Harita, Yutaka; Kosako, Hidetaka; Hattori, Seisuke] Univ Tokyo, Inst Med Sci, Div Cellular Prote BML, Minato Ku, Tokyo 1088639, Japan; [Tezuka, Tohru] Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, Tokyo 1088639, Japan; [Harita, Yutaka; Sekine, Takashi; Igarashi, Takashi] Univ Tokyo, Grad Sch Med, Dept Pediat, Bunkyo Ku, Tokyo 1138655, Japan; [Kurihara, Hidetake] Juntendo Univ, Sch Med, Dept Pediat, Bunkyo Ku, Tokyo 1138421, Japan; [Hattori, Seisuke] Kitasato Univ, Sch Pharmaceut Sci, Dept Biochem, Minato Ku, Tokyo 1088641, Japan	University of Tokyo; University of Tokyo; University of Tokyo; Juntendo University; Kitasato University	Hattori, S (corresponding author), Univ Tokyo, Inst Med Sci, Div Cellular Prote BML, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	hattoris@ims.u-tokyo.ac.jp						Barletta GM, 2003, J BIOL CHEM, V278, P19266, DOI 10.1074/jbc.M301279200; Benzing T, 2004, J AM SOC NEPHROL, V15, P1382, DOI 10.1097/01.ASN.0000130167.30769.55; Buday L, 1999, BBA-REV BIOMEMBRANES, V1422, P187, DOI 10.1016/S0304-4157(99)00005-2; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Cao HM, 2002, J BIOL CHEM, V277, P8771, DOI 10.1074/jbc.C100661200; Chong YP, 2005, GROWTH FACTORS, V23, P233, DOI 10.1080/08977190500178877; Ciani L, 2003, MOL CELL BIOL, V23, P3575, DOI 10.1128/MCB.23.10.3575-3582.2003; Donoviel DB, 2001, MOL CELL BIOL, V21, P4829, DOI 10.1128/MCB.21.14.4829-4836.2001; Durvasula RV, 2006, CURR OPIN NEPHROL HY, V15, P1, DOI 10.1097/01.mnh.0000199012.79670.0b; Freeman M, 2000, NATURE, V408, P313, DOI 10.1038/35042500; Garg P, 2007, MOL CELL BIOL, V27, P8698, DOI 10.1128/MCB.00948-07; Gerard A, 2004, ONCOGENE, V23, P1594, DOI 10.1038/sj.onc.1207283; Gerke P, 2003, J AM SOC NEPHROL, V14, P918, DOI 10.1097/01.ASN.0000057853.05686.89; Guy GR, 2003, J CELL SCI, V116, P3061, DOI 10.1242/jcs.00652; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Hirabayashi S, 2005, LAB INVEST, V85, P1528, DOI 10.1038/labinvest.3700347; Hirabayashi S, 2003, MOL CELL BIOL, V23, P4267, DOI 10.1128/MCB.23.12.4267-4282.2003; Hisatsune C, 2004, J BIOL CHEM, V279, P18887, DOI 10.1074/jbc.M311274200; Honma M, 2006, GENES CELLS, V11, P143, DOI 10.1111/j.1365-2443.2006.00926.x; Huber TB, 2003, MOL CELL BIOL, V23, P4917, DOI 10.1128/MCB.23.14.4917-4928.2003; Huber TB, 2003, J BIOL CHEM, V278, P13417, DOI 10.1074/jbc.C200678200; Jones N, 2006, NATURE, V440, P818, DOI 10.1038/nature04662; Jones N, 1999, CURR BIOL, V9, P1057, DOI 10.1016/S0960-9822(99)80458-8; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; Koshikawa M, 2005, J AM SOC NEPHROL, V16, P2690, DOI 10.1681/ASN.2004121084; KURIHARA H, 1995, AM J PHYSIOL-RENAL, V268, pF514, DOI 10.1152/ajprenal.1995.268.3.F514; Lahdenpera J, 2003, KIDNEY INT, V64, P404, DOI 10.1046/j.1523-1755.2003.00097.x; Lehtonen S, 2005, P NATL ACAD SCI USA, V102, P9814, DOI 10.1073/pnas.0504166102; Liu G, 2003, J CLIN INVEST, V112, P209, DOI 10.1172/JCI200318242; Liu XL, 2005, FEBS J, V272, P228, DOI 10.1111/j.1432-1033.2004.04408.x; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Maekawa M, 2002, J BIOL CHEM, V277, P37783, DOI 10.1074/jbc.M204506200; Matsui I, 2007, LAB INVEST, V87, P273, DOI 10.1038/labinvest.3700518; Pavenstadt H, 2003, PHYSIOL REV, V83, P253, DOI 10.1152/physrev.00020.2002; Putaala H, 2001, HUM MOL GENET, V10, P1, DOI 10.1093/hmg/10.1.1; Reiser J, 2005, NAT GENET, V37, P739, DOI 10.1038/ng1592; Roselli S, 2004, MOL CELL BIOL, V24, P550, DOI 10.1128/MCB.24.2.550-560.2004; Schwarz K, 2001, J CLIN INVEST, V108, P1621, DOI 10.1172/JCI200112849; Sellin L, 2002, FASEB J, V16, P115, DOI 10.1096/fj.02-0242fje; Serizawa S, 2006, CELL, V127, P1057, DOI 10.1016/j.cell.2006.10.031; Shih NY, 2001, AM J PATHOL, V159, P2303, DOI 10.1016/S0002-9440(10)63080-5; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; Shilo BZ, 2005, DEVELOPMENT, V132, P4017, DOI 10.1242/dev.02006; Subramaniam S, 2004, J CELL BIOL, V165, P357, DOI 10.1083/jcb.200403028; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; Torii S, 2004, J BIOCHEM, V136, P557, DOI 10.1093/jb/mvh159; Verma R, 2006, J CLIN INVEST, V116, P1346, DOI 10.1172/JCI27414; Verma R, 2003, J BIOL CHEM, V278, P20716, DOI 10.1074/jbc.M301689200; Winn MP, 2005, SCIENCE, V308, P1801, DOI 10.1126/science.1106215; Yu CCK, 2001, CURR BIOL, V11, P34, DOI 10.1016/S0960-9822(00)00024-5; Zhou J, 2001, J BIOL CHEM, V276, P27793, DOI 10.1074/jbc.M102803200	52	59	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9177	9186		10.1074/jbc.M707247200	http://dx.doi.org/10.1074/jbc.M707247200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18258597	hybrid, Green Published			2022-12-25	WOS:000254465800047
J	Mallajosyula, JK; Kaur, D; Chinta, SJ; Rajagopalan, S; Rane, A; Nicholls, DG; Di Monte, DA; Macarthur, H; Andersen, JK				Mallajosyula, Jyothi K.; Kaur, Deepinder; Chinta, Shankar J.; Rajagopalan, Subramanian; Rane, Anand; Nicholls, David G.; Di Monte, Donato A.; Macarthur, Heather; Andersen, Julie K.			MAO-B Elevation in Mouse Brain Astrocytes Results in Parkinson's Pathology	PLOS ONE			English	Article								Age-related increases in monoamine oxidase B (MAO-B) may contribute to neurodegeneration associated with Parkinson's disease (PD). The MAO-B inhibitor deprenyl, a long-standing antiparkinsonian therapy, is currently used clinically in concert with the dopamine precursor L-DOPA. Clinical studies suggesting that deprenyl treatment alone is not protective against PD associated mortality were targeted to symptomatic patients. However, dopamine loss is at least 60% by the time PD is symptomatically detectable, therefore lack of effect of MAO-B inhibition in these patients does not negate a role for MAO-B in pre-symptomatic dopaminergic loss. In order to directly evaluate the role of age-related elevations in astroglial MAO-B in the early initiation or progression of PD, we created genetically engineered transgenic mice in which MAO-B levels could be specifically induced within astroglia in adult animals. Elevated astrocytic MAO-B mimicking age related increase resulted in specific, selective and progressive loss of dopaminergic neurons in the substantia nigra (SN), the same subset of neurons primarily impacted in the human condition. This was accompanied by other PD-related alterations including selective decreases in mitochondrial complex I activity and increased mitochondrial oxidative stress. Along with a global astrogliosis, we observed local microglial activation within the SN. These pathologies correlated with decreased locomotor activity. Importantly, these events occurred even in the absence of the PD-inducing neurotoxin MPTP. Our data demonstrates that elevation of murine astrocytic MAO-B by itself can induce several phenotypes of PD, signifying that MAO-B could be directly involved in multiple aspects of disease neuropathology. Mechanistically this may involve increases in membrane permeant H(2)O(2) which can oxidize dopamine within dopaminergic neurons to dopaminochrome which, via interaction with mitochondrial complex I, can result in increased mitochondrial superoxide. Our inducible astrocytic MAO-B transgenic provides a novel model for exploring pathways involved in initiation and progression of several key features associated with PD pathology and for therapeutic drug testing.	[Mallajosyula, Jyothi K.; Kaur, Deepinder; Chinta, Shankar J.; Rajagopalan, Subramanian; Rane, Anand; Nicholls, David G.; Andersen, Julie K.] Buck Inst Age Res, Novato, CA USA; [Di Monte, Donato A.] Parkinsons Inst, Basic Sci Res, Sunnyvale, CA USA; [Macarthur, Heather] Saint Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO USA	Buck Institute for Research on Aging; Saint Louis University	Mallajosyula, JK (corresponding author), Buck Inst Age Res, Novato, CA USA.	jandersen@buckinstitute.org	NICHOLLS, DAVID G/K-4300-2012; Rane, Anders/L-2675-2013; Zhu, Longjun/C-2938-2012	Di Monte, Donato/0000-0002-8296-836X; Andersen, Julie/0000-0003-1324-4875	National Parkinson's Foundation [R01 NS40057-04]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040057] Funding Source: NIH RePORTER	National Parkinson's Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	These studies were funded via R01 NS40057-04 (JKA) and the National Parkinson's Foundation (JKM).	ADAMS JD, 1991, FREE RADICAL BIO MED, V10, P161, DOI 10.1016/0891-5849(91)90009-R; Andrews ZB, 2005, J NEUROSCI, V25, P184, DOI 10.1523/JNEUROSCI.4269-04.2005; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; BUCKMAN TD, 1993, J NEUROCHEM, V60, P2046, DOI 10.1111/j.1471-4159.1993.tb03489.x; BUDD DC, 1995, J NEUROCHEM, V65, P615; Cicchetti F, 2002, EUR J NEUROSCI, V15, P991, DOI 10.1046/j.1460-9568.2002.01938.x; Cohen G, 1983, J Neural Transm Suppl, V19, P89; Cohen G, 1997, P NATL ACAD SCI USA, V94, P4890, DOI 10.1073/pnas.94.10.4890; Damier P, 1996, NEUROLOGY, V46, P1262, DOI 10.1212/WNL.46.5.1262; DOCHERTY M, 1991, J NEUROCHEM, V56, P1569, DOI 10.1111/j.1471-4159.1991.tb02053.x; FEARNLEY JM, 1991, BRAIN, V114, P2283, DOI 10.1093/brain/114.5.2283; FOWLER CJ, 1980, J NEURAL TRANSM, V49, P1, DOI 10.1007/BF01249185; Gainetdinov RR, 1997, J NEUROCHEM, V69, P1322; Gerlach M, 1996, NEUROLOGY, V47, pS137, DOI 10.1212/WNL.47.6_Suppl_3.137S; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Imai Y, 2002, GLIA, V40, P164, DOI 10.1002/glia.10149; IRWIN I, 1992, BRAIN RES, V572, P224, DOI 10.1016/0006-8993(92)90473-M; Kang YS, 1997, NEUROREPORT, V8, P2053, DOI 10.1097/00001756-199705260-00049; Kaur D, 2003, NEURON, V37, P899, DOI 10.1016/S0896-6273(03)00126-0; Kumar MJ, 2003, J BIOL CHEM, V278, P46432, DOI 10.1074/jbc.M306378200; Langston JW, 1999, ANN NEUROL, V46, P598, DOI 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F; LEVITT P, 1982, P NATL ACAD SCI-BIOL, V79, P6385, DOI 10.1073/pnas.79.20.6385; LEWITT PA, 1994, J NEURAL TRANSM-SUPP, P171; Magyar K, 2004, NEUROTOXICOLOGY, V25, P233, DOI 10.1016/S0161-813X(03)00102-5; MAKAR TK, 1994, J NEUROCHEM, V62, P45; Mandel S, 2003, CNS DRUGS, V17, P729, DOI 10.2165/00023210-200317100-00004; McGeer PL, 2003, ANN NEUROL, V54, P599, DOI 10.1002/ana.10728; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; Miller J.H., 1972, EXPT MOL GENETICS; Nirenberg MJ, 1996, J NEUROSCI, V16, P436; Nirenberg MJ, 1996, J NEUROSCI, V16, P4135; Ochs SD, 2005, J NEUROSCI METH, V142, P201, DOI 10.1016/j.jneumeth.2004.08.010; OLANOW CW, 1993, MOVEMENT DISORD, V8, pS1, DOI 10.1002/mds.870080503; Peng J, 2002, J BIOL CHEM, V277, P44285, DOI 10.1074/jbc.M207407200; Peng J, 2006, J NEUROSCI, V26, P11644, DOI 10.1523/JNEUROSCI.3447-06.2006; PICKEL VM, 1992, DEV BRAIN RES, V70, P75, DOI 10.1016/0165-3806(92)90105-6; Przedborski S, 2003, ANN NY ACAD SCI, V991, P189; RAPS SP, 1989, BRAIN RES, V493, P398, DOI 10.1016/0006-8993(89)91178-5; Riederer P, 1987, Adv Neurol, V45, P111; SAGARA J, 1993, J NEUROCHEM, V61, P1672, DOI 10.1111/j.1471-4159.1993.tb09802.x; SAURA J, 1994, J NEURAL TRANSM-SUPP, P89; Schneider E, 1995, J NEURAL TRANSM-SUPP, P391; SCHNEIDER JS, 1988, J NEUROPATH EXP NEUR, V47, P452, DOI 10.1097/00005072-198807000-00006; Sherer TB, 2003, J NEUROSCI, V23, P10756, DOI 10.1523/jneurosci.23-34-10756.2003; SHOULSON I, 1992, EUR NEUROL, V32, P46; Shoulson I, 1998, ANN NEUROL, V43, P318; Smith DW, 2004, NEUROREPORT, V15, P1025, DOI 10.1097/00001756-200404290-00018; SOONG NW, 1992, NAT GENET, V2, P318; Stence N, 2001, GLIA, V33, P256, DOI 10.1002/1098-1136(200103)33:3<256::AID-GLIA1024>3.0.CO;2-J; Sugama S, 2003, BRAIN RES, V964, P288, DOI 10.1016/S0006-8993(02)04085-4; Szende B, 2001, J NEURAL TRANSM, V108, P25, DOI 10.1007/s007020170094; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; Vindis C, 2001, KIDNEY INT, V59, P76, DOI 10.1046/j.1523-1755.2001.00468.x; Wei Q, 1996, J NEUROSCI RES, V46, P666; WESTLUND KN, 1988, NEUROSCIENCE, V25, P439, DOI 10.1016/0306-4522(88)90250-3; WESTLUND KN, 1985, SCIENCE, V230, P181, DOI 10.1126/science.3875898; WHITTEMORE ER, 1994, NEUROREPORT, V5, P1485, DOI 10.1097/00001756-199407000-00019; Wu RM, 1996, ANN NY ACAD SCI, V786, P379, DOI 10.1111/j.1749-6632.1996.tb39078.x; Yadava N, 2004, J BIOL CHEM, V279, P12406, DOI 10.1074/jbc.M313588200; Youdim MBH, 2006, BRIT J PHARMACOL, V147, pS287, DOI 10.1038/sj.bjp.0706464; Zoccarato F, 2005, J BIOL CHEM, V280, P15587, DOI 10.1074/jbc.M500657200	62	186	190	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1616	10.1371/journal.pone.0001616	http://dx.doi.org/10.1371/journal.pone.0001616			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286173	Green Submitted, gold, Green Published			2022-12-25	WOS:000260586400009
J	Alten, JA; Moran, A; Tsimelzon, AI; Mastrangelo, MAA; Hilsenbeck, SG; Poli, V; Tweardy, DJ				Alten, Jeffrey A.; Moran, Ana; Tsimelzon, Anna I.; Mastrangelo, Mary-Ann A.; Hilsenbeck, Susan G.; Poli, Valeria; Tweardy, David J.			Prevention of Hypovolemic Circulatory Collapse by IL-6 Activated Stat3	PLOS ONE			English	Article								Half of trauma deaths are attributable to hypovolemic circulatory collapse (HCC). We established a model of HCC in rats involving minor trauma plus severe hemorrhagic shock (HS). HCC in this model was accompanied by a 50% reduction in peak acceleration of aortic blood flow and cardiomyocyte apoptosis. HCC and apoptosis increased with increasing duration of hypotension. Apoptosis required resuscitation, which provided an opportunity to intervene therapeutically. Administration of IL-6 completely reversed HCC, prevented cardiac dysfunction and cardiomyocyte apoptosis, reduced mortality 5-fold and activated intracardiac signal transducer and activator of transcription (STAT) 3. Pre-treatment of rats with a selective inhibitor of Stat3, T40214, reduced the IL-6-mediated increase in cardiac Stat3 activity, blocked successful resuscitation by IL-6 and reversed IL-6-mediated protection from cardiac apoptosis. The hearts of mice deficient in the naturally occurring dominant negative isoform of Stat3, Stat3 beta, were completely resistant to HS-induced apoptosis. Microarray analysis of hearts focusing on apoptosis related genes revealed that expression of 29% of apoptosis related genes was altered in HS vs. sham rats. IL-6 treatment normalized the expression of these genes, while T40214 pretreatment prevented IL-6-mediated normalization. Thus, cardiac dysfunction, cardiomyocyte apoptosis and induction of apoptosis pathway genes are important components of HCC; IL-6 administration prevented HCC by blocking cardiomyocyte apoptosis and induction of apoptosis pathway genes via Stat3 and warrants further study as a resuscitation adjuvant for prevention of HCC and death in trauma patients.	[Alten, Jeffrey A.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Tsimelzon, Anna I.; Hilsenbeck, Susan G.] Baylor Coll Med, Breast Care Ctr, Dept Med, Houston, TX USA; [Moran, Ana; Mastrangelo, Mary-Ann A.; Tweardy, David J.] Baylor Coll Med, Dept Med, Houston, TX USA; [Tweardy, David J.] Baylor Coll Med, Dept Mol & Cell Biol, Houston, TX USA; [Poli, Valeria] Univ Turin, Dept Genet, Biol & Biochem, Turin, Italy	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Turin	Alten, JA (corresponding author), Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.	dtweardy@bcm.edu	Poli, Valeria/A-9215-2012; Tweardy, David/L-3929-2019	Poli, Valeria/0000-0002-3739-3966; 	National Heart, Lung and Blood Institute of the NIH [HL076169]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL066991, R01HL076169] Funding Source: NIH RePORTER	National Heart, Lung and Blood Institute of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported, in part, by grant HL076169 (DJT) from the National Heart, Lung and Blood Institute of the NIH.	Atweh N, 2000, J TRAUMA, V49, P53; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Brocheriou V, 2000, J GENE MED, V2, P326, DOI 10.1002/1521-2254(200009/10)2:5<326::AID-JGM133>3.0.CO;2-1; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Cheng LEC, 1997, EMBO J, V16, P1865, DOI 10.1093/emboj/16.8.1865; Darnell JE, 2005, NAT MED, V11, P595, DOI 10.1038/nm0605-595; Deb S, 1999, J TRAUMA, V46, P582, DOI 10.1097/00005373-199904000-00005; Harada M, 2005, NAT MED, V11, P305, DOI 10.1038/nm1199; HARTLEY CJ, 1995, AM J PHYSIOL-HEART C, V268, pH499, DOI 10.1152/ajpheart.1995.268.1.H499; Heckbert SR, 1998, J TRAUMA, V45, P545, DOI 10.1097/00005373-199809000-00022; Hierholzer C, 1998, J EXP MED, V187, P917, DOI 10.1084/jem.187.6.917; Hirano T, 1998, Int Rev Immunol, V16, P249; Holcroft JW, 1999, J TRAUMA, V46, P588; Hsu Hui-Chen, 2004, Current Drug Targets - Inflammation and Allergy, V3, P413, DOI 10.2174/1568010042634523; Ivanov VN, 2001, MOL CELL, V7, P517, DOI 10.1016/S1097-2765(01)00199-X; Jing NJ, 2004, CANCER RES, V64, P6603, DOI 10.1158/0008-5472.CAN-03-4041; LAMBERT CR, 1983, AM HEART J, V106, P136, DOI 10.1016/0002-8703(83)90451-9; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Maritano D, 2004, NAT IMMUNOL, V5, P401, DOI 10.1038/ni1052; MASTORAKOS G, 1993, J CLIN ENDOCR METAB, V77, P1690, DOI 10.1210/jc.77.6.1690; Minino Arialdi M, 2006, Natl Vital Stat Rep, V54, P1; Murray PJ, 2005, P NATL ACAD SCI USA, V102, P8686, DOI 10.1073/pnas.0500419102; Negoro S, 2001, CIRCULATION, V104, P979, DOI 10.1161/hc3401.095947; OHKURA N, 1994, BIOCHEM BIOPH RES CO, V205, P1959, DOI 10.1006/bbrc.1994.2900; Ono M, 2004, SHOCK, V21, P519, DOI 10.1097/01.shk.0000126905.75237.07; Peden M, 2002, INJURY LEADING CAUSE; PEITZMAN AB, 1995, CURR PROB SURG, V32, P930; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Sahai H., 2000, ANAL VARIANCE FIXED; Saura M, 2006, J BIOL CHEM, V281, P30057, DOI 10.1074/jbc.M606279200; Shao H, 2006, J IMMUNOL, V176, P2933, DOI 10.4049/jimmunol.176.5.2933; Subrato D, 2000, J TRAUMA, V49, P47, DOI 10.1097/00005373-200007000-00007; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; WIGGERS CJ, 1947, AM HEART J, V33, P633, DOI 10.1016/0002-8703(47)90079-3; Wu ZJ, 2005, J COMPUT BIOL, V12, P882, DOI 10.1089/cmb.2005.12.882; Yu ZY, 2002, BIOCHEM J, V367, P97, DOI 10.1042/BJ20020588; Zhao MM, 2004, PHYSIOL GENOMICS, V19, P93, DOI 10.1152/physiolgenomics.00040.2004	38	22	22	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1605	10.1371/journal.pone.0001605	http://dx.doi.org/10.1371/journal.pone.0001605			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270592	Green Published, Green Submitted, gold			2022-12-25	WOS:000260535900039
J	Wassie, L; Demissie, A; Aseffa, A; Abebe, M; Yamuah, L; Tilahun, H; Petros, B; Rook, G; Zumla, A; Andersen, P; Doherty, TM				Wassie, Liya; Demissie, Abebech; Aseffa, Abraham; Abebe, Markos; Yamuah, Lawrence; Tilahun, Hiwot; Petros, Beyene; Rook, Graham; Zumla, Alimuddin; Andersen, Peter; Doherty, T. Mark		VACSEL Study Grp	Ex Vivo Cytokine mRNA Levels Correlate with Changing Clinical Status of Ethiopian TB Patients and their Contacts Over Time	PLOS ONE			English	Article							INTERFERON-GAMMA PRODUCTION; DECREASED IFN-GAMMA; GROWTH-FACTOR-BETA; MYCOBACTERIUM-TUBERCULOSIS; SPLICE VARIANT; ACTIVE TUBERCULOSIS; ENCODING IL-4; CELLS; INFECTION; INTERLEUKIN-4	There is an increasing body of evidence which suggests that IL-4 plays a role in the pathogenesis of TB, but a general consensus on its role remains elusive. We have previously published data from a cohort of Ethiopian TB patients, their contacts, and community controls suggesting that enhanced IL-4 production is associated with infection with M. tuberculosis, rather than overt disease and that long-term protection in infected community controls is associated with co-production of the IL-4 antagonist IL-4 delta 2, alongside elevated IL-4. Here, for the first time, we compare data on expression of IFN-gamma, IL-4 and IL-4 delta 2 over time in TB patients and their household contacts. During the follow-up period, the TB patients completed therapy and ceased to display TB-like symptoms. This correlated with a decrease in the relative amount of IL- 4 expressed. Over the same period, the clinical status of some of their contacts also changed, with a number developing TB-like symptoms or clinically apparent TB. IL-4 expression was disproportionately increased in this group. The findings support the hypothesis that elevated IL-4 production is generally associated with infection, but that TB disease is associated with a relatively increased expression of IL-4 compared to IFN-gamma and IL-4 delta 2. However, the data also suggest that there are no clear-cut differences between groups: the immune response over time appears to include changes in the expression of IFN-gamma, IL-4 and IL-4 delta 2, and it is the relative, not absolute levels of cytokine expression that are characteristic of clinical status.	[Andersen, Peter; Doherty, T. Mark] Statens Serum Inst, Dept Infect Dis Immunol, DK-2300 Copenhagen, Denmark; [Wassie, Liya; Demissie, Abebech; Aseffa, Abraham; Abebe, Markos; Yamuah, Lawrence; Tilahun, Hiwot] Armauer Hansen Res Inst, Addis Ababa, Ethiopia; [Petros, Beyene] Addis Ababa Univ, Dept Biol, Addis Ababa, Ethiopia; [Rook, Graham; Zumla, Alimuddin] Royal Free Univ Coll, Med Sch, Windeyer Inst Med Sci, Ctr Infect Dis & Int Hlth, London, England	Statens Serum Institut; Addis Ababa University; University of London; University College London	Doherty, TM (corresponding author), Statens Serum Inst, Dept Infect Dis Immunol, DK-2300 Copenhagen, Denmark.	TMD@ssi.dk	ZUMLA, Alimuddin/ABA-8208-2020; Aseffa, Abraham/J-3248-2016	ZUMLA, Alimuddin/0000-0002-5111-5735; Aseffa, Abraham/0000-0002-8028-1150; Wassie, Liya/0000-0002-5494-5275; Andersen, Peter/0000-0002-5869-2551; Brookes, Roger/0000-0002-5361-0617; Rook, Graham/0000-0002-8041-8110	EU [ICA4-CT-1999-10005, IC4-2001-10050]	EU(European Commission)	This work was supported by the European commission through EU contracts ICA4-CT-1999-10005 and IC4-2001-10050. The funders had no role in study design, data collection and analysis,decision to publish, or preparation of the manuscript.	Andersen P, 2007, TRENDS MOL MED, V13, P175, DOI 10.1016/j.molmed.2007.03.004; Becerra MC, 2005, PUBLIC HEALTH REP, V120, P271, DOI 10.1177/003335490512000309; Bhattacharyya S, 1999, INFECT IMMUN, V67, P5597, DOI 10.1128/IAI.67.11.5597-5603.1999; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; Borgdorff MW, 2002, B WORLD HEALTH ORGAN, V80, P217; Demissie A, 2006, INFECT IMMUN, V74, P2817, DOI 10.1128/IAI.74.5.2817-2822.2006; Demissie A, 2004, J IMMUNOL, V172, P6938, DOI 10.4049/jimmunol.172.11.6938; Dheda K, 2004, BIOTECHNIQUES, V37, P112, DOI 10.2144/04371RR03; Dheda K, 2007, TUBERCULOSIS, V87, P237, DOI 10.1016/j.tube.2006.11.001; Doherty TM, 2005, CLIN MICROBIOL REV, V18, P687, DOI 10.1128/CMR.18.4.687-702.2005; Doherty TM, 2005, J IMMUNOL METHODS, V298, P129, DOI 10.1016/j.jim.2005.01.013; Doherty TM, 2002, CURR OPIN PULM MED, V8, P183, DOI 10.1097/00063198-200205000-00006; Doherty TM, 2002, J CLIN MICROBIOL, V40, P704, DOI 10.1128/JCM.40.2.704-706.2002; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Elias D, 2005, T ROY SOC TROP MED H, V99, P363, DOI 10.1016/j.trstmh.2004.08.006; Elias D, 2001, CLIN EXP IMMUNOL, V123, P219, DOI 10.1046/j.1365-2249.2001.01446.x; Fletcher HA, 2004, IMMUNOLOGY, V112, P669, DOI 10.1111/j.1365-2567.2004.01922.x; Fletcher HA, 2007, CURR MOL MED, V7, P319, DOI 10.2174/156652407780598520; FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Gong JH, 1996, INFECT IMMUN, V64, P913, DOI 10.1128/IAI.64.3.913-918.1996; Goter-Robinson C, 2006, VACCINE, V24, P3522, DOI 10.1016/j.vaccine.2006.02.005; Harries AD, 2006, ANN TROP MED PARASIT, V100, P415, DOI 10.1179/136485906X91477; Hervas-Stubbs S, 2006, INFECT IMMUN, V74, P3396, DOI 10.1128/IAI.02086-05; Hill PC, 2005, CLIN INFECT DIS, V40, P273, DOI 10.1086/427030; Hoft DF, 2002, J INFECT DIS, V186, P1448, DOI 10.1086/344359; Kawahara M, 2002, INFECT IMMUN, V70, P6614, DOI 10.1128/IAI.70.12.6614-6620.2002; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; Lienhardt C, 2002, EUR J IMMUNOL, V32, P1605, DOI 10.1002/1521-4141(200206)32:6<1605::AID-IMMU1605>3.0.CO;2-6; Martinez ON, 2001, AM J GASTROENTEROL, V96, P1665; McCarthy OR, 2001, J ROY SOC MED, V94, P413, DOI 10.1177/014107680109400813; Ordway DJ, 2004, J INFECT DIS, V190, P756, DOI 10.1086/422532; Rhodes SG, 2007, INFECT IMMUN, V75, P3006, DOI 10.1128/IAI.01932-06; Rieder HL, 2003, INT J TUBERC LUNG D, V7, pS333; Roberts T, 2007, J INFECT DIS, V195, P870, DOI 10.1086/511277; Schluger NW, 1998, AM J RESP CRIT CARE, V157, P679, DOI 10.1164/ajrccm.157.3.9708002; Seah GT, 2000, J INFECT DIS, V181, P385, DOI 10.1086/315200; Seah GT, 2001, AM J RESP CRIT CARE, V164, P1016, DOI 10.1164/ajrccm.164.6.2012138; Seah GT, 2001, SCAND J INFECT DIS, V33, P106, DOI 10.1080/003655401750065472; Seah GT, 1999, J IMMUNOL METHODS, V228, P139, DOI 10.1016/S0022-1759(99)00084-8; Smith SM, 2002, TUBERCULOSIS, V82, P7, DOI 10.1054/tube.2001.0317; Sodhi A, 1997, CLIN INFECT DIS, V25, P617, DOI 10.1086/513769; Sullivan BM, 2005, J IMMUNOL, V175, P4593, DOI 10.4049/jimmunol.175.7.4593; SURCEL HM, 1994, IMMUNOLOGY, V81, P171; Swaminathan S, 1999, CLIN INFECT DIS, V28, P1290, DOI 10.1086/514794; Tegbaru B, 2006, CLIN VACCINE IMMUNOL, V13, P784, DOI 10.1128/CVI.00098-06; van Crevel R, 2000, J INFECT DIS, V181, P1194, DOI 10.1086/315325; van Helden Paul D, 2006, Novartis Found Symp, V279, P17; VANHELDEN PD, 2006, NOVART FDN SYMP, V279, P216; VANHELDEN PD, 2006, NOVART FDN SYMP, V279, P31; Vordermeier HM, 2002, INFECT IMMUN, V70, P3026, DOI 10.1128/IAI.70.6.3026-3032.2002; Yoshikai Y, 2006, CRIT REV IMMUNOL, V26, P515, DOI 10.1615/CritRevImmunol.v26.i6.40	52	45	47	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1522	10.1371/journal.pone.0001522	http://dx.doi.org/10.1371/journal.pone.0001522			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SR	18231607	Green Published, Green Submitted, gold, Green Accepted			2022-12-25	WOS:000260504200034
J	Parasassi, T; De Spirito, M; Mei, G; Brunelli, R; Greco, G; Lenzi, L; Maulucci, G; Nicolai, E; Papi, M; Arcovito, G; Tosatto, SCE; Ursini, F				Parasassi, Tiziana; De Spirito, Marco; Mei, Giampiero; Brunelli, Roberto; Greco, Giulia; Lenzi, Laura; Maulucci, Giuseppe; Nicolai, Eleonora; Papi, Massimiliano; Arcovito, Giuseppe; Tosatto, Silvio C. E.; Ursini, Fulvio			Low density lipoprotein misfolding and amyloidogenesis	FASEB JOURNAL			English	Article						amyloidoses; atherogenesis; computational analysis; electronegative LDL; nucleation	HUMAN ATHEROSCLEROTIC LESIONS; ELECTRONEGATIVE LDL; PROTEIN AGGREGATION; SECONDARY STRUCTURE; HUMAN-DISEASE; PARTICLES; PREDICTION; MODEL; MECHANISMS; RETENTION	In early atherogenesis, subendothelial retention of lipidic droplets is associated with an inflammatory response-to-injury, culminating in the formation of foam cells and plaque. Low density lipoprotein (LDL) is the main constituent of subendothelial lipidic droplets. The process is believed to occur following LDL modification. Searching for a modified LDL in plasma, electronegative LDL [ LDL( -)] was identified and found to be associated with major risk biomarkers. The apoprotein in LDL( -) is misfolded, and we show here that this modification primes the aggregation of native LDL, conforming to the typical pattern of protein amyloidogenesis. After a lag phase, whose length depends on LDL( -) concentration, light scattering and atomic force microscopy reveal early exponential growth of intermediate globules, which evolve into fibrils. These globules are remarkably similar to subendothelial droplets in atheromatous lesions and different from those produced by oxidation or biochemical manipulation. During aggregation, ellipticity and tryptophan fluorescence measurements reveal a domino-style spread of apoprotein misfolding from LDL( -) to all of the LDL. Computational analysis of the apoprotein primary sequence predicts an unstable, aggregation-prone domain in the regulatory alpha 2 region. Apoprotein misfolding well represents an LDL modification able to transform this cholesterol carrier into a trigger for a response-to-injury in the artery wall.	[Parasassi, Tiziana; Greco, Giulia; Lenzi, Laura] CNR, Ist Neurobiol Med Mol, I-00133 Rome, Italy; [De Spirito, Marco; Maulucci, Giuseppe; Papi, Massimiliano; Arcovito, Giuseppe] Univ Cattolica Sacro Cuore, Fac Med & Chirurg, Ist Fis, Rome, Italy; [Mei, Giampiero; Nicolai, Eleonora] Univ Roma Tor Vergata, Dipartimento Med Sperimentale & Sci Biochim, Rome, Italy; [Brunelli, Roberto] Univ Roma La Sapienza, Dipartimento Sci Ginecol Perinatol & Puericultura, Rome, Italy; [Tosatto, Silvio C. E.] Univ Padua, Dipartimento Biol, Padua, Italy; [Tosatto, Silvio C. E.] Univ Padua, Ctr Biotecnol Innovat CRIBI, Padua, Italy; [Ursini, Fulvio] Univ Padua, Dipartimento Chim Biol, Padua, Italy	Consiglio Nazionale delle Ricerche (CNR); Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Rome Tor Vergata; Sapienza University Rome; University of Padua; University of Padua; University of Padua	Parasassi, T (corresponding author), CNR, Ist Neurobiol Med Mol, Via Fosso Cavaliere 100, I-00133 Rome, Italy.	t.parasassi@inmm.cnr.it	De Spirito, Marco/C-5386-2008; Papi, Massimiliano/B-3168-2012; Tosatto, Silvio/B-2840-2009; Nicolai, Eleonora/AAR-4554-2020; De Spirito, Marco/U-3817-2019; Papi, Massimiliano/AAC-3657-2022; Maulucci, Giuseppe/C-7400-2009	De Spirito, Marco/0000-0003-4260-5107; Tosatto, Silvio/0000-0003-4525-7793; Nicolai, Eleonora/0000-0003-1415-9808; De Spirito, Marco/0000-0003-4260-5107; Papi, Massimiliano/0000-0002-0029-1309; Maulucci, Giuseppe/0000-0002-2154-319X; Parasassi, Tiziana/0000-0002-9795-0568				Albrecht M, 2003, PROTEIN ENG, V16, P459, DOI 10.1093/protein/gzg063; Bader R, 2006, J MOL BIOL, V356, P189, DOI 10.1016/j.jmb.2005.11.034; Baglioni S, 2006, J NEUROSCI, V26, P8160, DOI 10.1523/JNEUROSCI.4809-05.2006; CHAO FF, 1990, AM J PATHOL, V136, P169; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; Clamp M, 2004, BIOINFORMATICS, V20, P426, DOI 10.1093/bioinformatics/btg430; De Spirito M, 2006, BIOPHYS J, V90, P4239, DOI 10.1529/biophysj.105.075788; Demuth K, 1996, ARTERIOSCL THROM VAS, V16, P773, DOI 10.1161/01.ATV.16.6.773; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Hevonoja T, 2000, BBA-MOL CELL BIOL L, V1488, P189, DOI 10.1016/S1388-1981(00)00123-2; Krisko A, 2007, PROTEINS, V66, P342, DOI 10.1002/prot.21229; Lee CC, 2007, BIOPHYS J, V92, P3448, DOI 10.1529/biophysj.106.098608; LeVine H, 1999, METHOD ENZYMOL, V309, P274; NIEVELSTEIN PFEM, 1991, ARTERIOSCLER THROMB, V11, P1795, DOI 10.1161/01.ATV.11.6.1795; Oorni K, 2000, J LIPID RES, V41, P1703; Oorni K, 2004, J BIOL CHEM, V279, P34776, DOI 10.1074/jbc.M310814200; Oorni K, 2007, ARTERIOSCL THROM VAS, V27, P445, DOI 10.1161/01.ATV.0000258412.58289.ee; Parasassi T, 2001, FREE RADICAL BIO MED, V31, P82, DOI 10.1016/S0891-5849(01)00555-X; Pentikainen MO, 1996, J LIPID RES, V37, P2638; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sanchez-Quesada JL, 1999, AM J CARDIOL, V84, P655, DOI 10.1016/S0002-9149(99)00411-7; Sanchez-Quesada JL, 2002, J LIPID RES, V43, P699; SanchezQuesada JL, 1996, DIABETOLOGIA, V39, P1469, DOI 10.1007/s001250050600; Segrest JP, 2001, J LIPID RES, V42, P1346; Sevanian A, 1996, ARTERIOSCL THROM VAS, V16, P784, DOI 10.1161/01.ATV.16.6.784; Sevanian A, 1999, BLOOD PURIFICAT, V17, P66, DOI 10.1159/000014378; Skalen K, 2002, NATURE, V417, P750, DOI 10.1038/nature00804; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Sun Y, 2005, FEBS J, V272, P2613, DOI 10.1111/j.1742-4658.2005.04708.x; TEIXEIRA J, 1988, J APPL CRYSTALLOGR, V21, P781, DOI 10.1107/S0021889888000263; Trovato A, 2006, PLOS COMPUT BIOL, V2, P1608, DOI 10.1371/journal.pcbi.0020170; Trovato A, 2007, PROTEIN ENG DES SEL, V20, P521, DOI 10.1093/protein/gzm042; Ursini F, 2002, BIOL CHEM, V383, P599, DOI 10.1515/BC.2002.062; Ursini F, 2002, TRENDS MOL MED, V8, P370, DOI 10.1016/S1471-4914(02)02382-1; Vullo A, 2006, NUCLEIC ACIDS RES, V34, pW164, DOI 10.1093/nar/gkl166; WEITZ DA, 1987, PHYSICS COMPLEX SUPE, P509; Williams KJ, 2005, ARTERIOSCL THROM VAS, V25, P1536, DOI 10.1161/01.ATV.0000174795.62387.d3	37	41	42	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2350	2356		10.1096/fj.07-097774	http://dx.doi.org/10.1096/fj.07-097774			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18292214	Green Submitted			2022-12-25	WOS:000257292500027
J	Whiteman, EL; Liu, CJ; Fearon, ER; Margolis, B				Whiteman, E. L.; Liu, C-J; Fearon, E. R.; Margolis, B.			The transcription factor snail represses Crumbs3 expression and disrupts apico-basal polarity complexes	ONCOGENE			English	Article						Crumbs; Snail; apico-basal polarity; tight junction; epithelial to mesenchymal transition	EPITHELIAL-MESENCHYMAL TRANSITIONS; E-CADHERIN; PROTEIN	In epithelial cells, the tight junction divides the plasma membrane into distinct apical and basolateral domains. Polarization is essential for epithelial cell function, and apico-basal cell polarity is lost during the epithelial to mesenchymal transition (EMT), a program of events characterized not only by loss of cell polarity, but also by enhanced cell motility and increased cell invasion. Among several apically localized protein complexes, the Crumbs and Par protein complexes have pivotal roles in control of epithelial polarity and apical membrane formation. Here, we demonstrate that the Snail transcriptional repressor antagonizes expression of the Crumbs polarity complex. We show that Snail abolishes localization of the Crumbs and Par complexes to the tight junction, decreases Crumbs complex protein levels and suppresses Crumbs3 transcription. Evidence that Snail acts directly to antagonize Crumbs3 promoter activity is presented. Strikingly, we note that reexpression of exogenous Crumbs3 in Snail- expressing Madin-Darby Canine Kidney cells partially restores cell-cell junctions. Moreover, we find that the EMT inducer transforming growth factor-beta elicits transcriptional repression of Crumbs3 and results in a measurable loss of Crumbs3 protein. Our findings provide new insights into the links between the transcriptional repression function of Snail and its role in antagonizing key apico-basal polarity factors during EMT.	[Margolis, B.] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; [Fearon, E. R.] Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; [Fearon, E. R.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Fearon, E. R.; Margolis, B.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; [Margolis, B.] Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Margolis, B (corresponding author), Univ Michigan, Sch Med, Dept Internal Med, 1528 Biomed Sci Res Bldg,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	bmargoli@umich.edu			NCI NIH HHS [T32 CA009676, 5-T32-CA09676] Funding Source: Medline; NIDDK NIH HHS [DK069605, R01 DK058208, P60 DK020572, 5-P60-DK20572, R01 DK058208-06, DK058208, R01 DK069605-04, R01 DK069605] Funding Source: Medline; NIGMS NIH HHS [F32 GM079906, 5-F32-GM07996] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572, R01DK058208, R01DK069605] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM079906] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Hajra KM, 2002, CANCER RES, V62, P1613; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Ohkubo T, 2004, J CELL SCI, V117, P1675, DOI 10.1242/jcs.01004; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Roh MH, 2002, J CELL BIOL, V157, P161, DOI 10.1083/jcb.200109010; Shin K, 2006, ANNU REV CELL DEV BI, V22, P207, DOI 10.1146/annurev.cellbio.22.010305.104219; Straight SW, 2006, J BIOL CHEM, V281, P37738, DOI 10.1074/jbc.M607059200; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Whiteman EL, 2003, ENDOCRINOLOGY, V144, P3811, DOI 10.1210/en.2003-0480	12	131	137	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2008	27	27					3875	3879		10.1038/onc.2008.9	http://dx.doi.org/10.1038/onc.2008.9			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18246119	Green Accepted			2022-12-25	WOS:000256904700012
J	Chatterjee, A; Chang, X; Nagpal, JK; Chang, S; Upadhyay, S; Califano, J; Trink, B; Sidransky, D				Chatterjee, A.; Chang, X.; Nagpal, J. K.; Chang, S.; Upadhyay, S.; Califano, J.; Trink, B.; Sidransky, D.			Targeting human 8-oxoguanine DNA glycosylase to mitochondria protects cells from 2-methoxyestradiol-induced-mitochondria-dependent apoptosis	ONCOGENE			English	Article						hOGG1; mitochondria; 2-methoxyestradiol; Fas activation	BASE-EXCISION-REPAIR; FAS-MEDIATED APOPTOSIS; HUMAN LEUKEMIA-CELLS; OXIDATIVE STRESS; ESCHERICHIA-COLI; CANCER-CELLS; MAMMALIAN-CELLS; SUPEROXIDE-DISMUTASE; IONIZING-RADIATION; CELLULAR-SURVIVAL	2-Methoxyestradiol (2-ME), an endogenous estrogen metabolite of 17 beta-estradiol, is known to induce mitochondria-mediated apoptosis through several mechanisms. We sought to study the effect of mitochondrialy targeted hOGG1 (MTS-hOGG1) on HeLa cells exposed to 2-ME. MTS-hOGG1-expressing cells exposed to 2-ME showed increased cellular survival and had significantly less G(2)/M cell cycle arrest compared to vector-only-transfected cells. In addition, 2-ME exposure resulted in an increase in mitochondrial membrane potential, increased apoptosis, accompanied by higher activation of caspase-3, -9, cleavage of Bid to tBid and protein poly(ADP-ribose) polymerase (PARP) cleavage in HeLa cells lacking MTS-hOGG1. Fas inhibitors cerulenin or C75 inhibited 2-ME-induced caspase activation, PARP cleavage, apoptosis and reversed mitochondrial membrane hyperpolarization, thereby recapitulating the increased expression of MTS-hOGG1. Hence, MTS-hOGG1 plays an important protective role against 2-ME-mediated mitochondrial damage by blocking apoptosis induced through the Fas pathway.	[Chatterjee, A.; Chang, X.; Nagpal, J. K.; Chang, S.; Upadhyay, S.; Califano, J.; Trink, B.; Sidransky, D.] Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Head & Neck Canc Res Div, Baltimore, MD 21231 USA	Johns Hopkins University	Sidransky, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Head & Neck Canc Res Div, 1550 Orleans St,Canc Res Bldg 2, Baltimore, MD 21231 USA.	dsidrans@jhmi.edu			NCI NIH HHS [5-PO1CA 77664] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077664] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achanta G, 2004, CANCER RES, V64, P6233, DOI 10.1158/0008-5472.CAN-04-0494; ALLEY MC, 1988, CANCER RES, V48, P589; Audebert M, 2002, DNA REPAIR, V1, P497, DOI 10.1016/S1568-7864(02)00034-4; Banki K, 1999, J IMMUNOL, V162, P1466; Blaisdell JO, 2001, P NATL ACAD SCI USA, V98, P7426, DOI 10.1073/pnas.131077798; Bohr VA, 2002, GENE, V286, P127, DOI 10.1016/S0378-1119(01)00813-7; Cadet J, 1997, Rev Physiol Biochem Pharmacol, V131, P1; Chatterjee A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-235; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHI NW, 1994, J BIOL CHEM, V269, P29984; CORRALDEBRINSKI M, 1994, GENOMICS, V23, P471, DOI 10.1006/geno.1994.1525; Davis RE, 1997, P NATL ACAD SCI USA, V94, P4526, DOI 10.1073/pnas.94.9.4526; Dhenaut A, 2000, MUTAT RES-DNA REPAIR, V461, P109, DOI 10.1016/S0921-8777(00)00042-2; Dhenaut A, 2001, ADV EXP MED BIOL, V500, P613; Dianov GL, 2001, PROG NUCLEIC ACID RE, V68, P285; DIZDAROGLU M, 1991, FREE RADICAL BIO MED, V10, P225, DOI 10.1016/0891-5849(91)90080-M; Djavaheri-Mergny M, 2003, ANN NY ACAD SCI, V1010, P159, DOI 10.1196/annals.1299.026; Djavaheri-Mergny M, 2003, ONCOGENE, V22, P2558, DOI 10.1038/sj.onc.1206356; Dobson AW, 2000, J BIOL CHEM, V275, P37518, DOI 10.1074/jbc.M000831200; Druzhyna NM, 2005, J BIOL CHEM, V280, P21673, DOI 10.1074/jbc.m411531200; Druzhyna NM, 2003, GLIA, V42, P370, DOI 10.1002/glia.10230; Dubey RK, 1998, HYPERTENSION, V31, P522, DOI 10.1161/01.HYP.31.1.522; Fanizza C, 2007, TOXICOL IN VITRO, V21, P586, DOI 10.1016/j.tiv.2006.12.002; Fishel ML, 2003, CANCER RES, V63, P608; Gao N, 2005, ONCOGENE, V24, P3797, DOI 10.1038/sj.onc.1208530; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; Gui Y, 2006, HYPERTENSION, V47, P271, DOI 10.1161/01.HYP.0000199656.99448.dc; Hagen T, 2004, BIOCHEM BIOPH RES CO, V322, P923, DOI 10.1016/j.bbrc.2004.07.204; Hazra TK, 2001, PROG NUCLEIC ACID RE, V68, P193; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; HUTCHIN T, 1995, P NATL ACAD SCI USA, V92, P6892, DOI 10.1073/pnas.92.15.6892; Ide H, 2004, BIOL PHARM BULL, V27, P480, DOI 10.1248/bpb.27.480; Itoh K, 2004, RHEUMATOLOGY, V43, P277, DOI 10.1093/rheumatology/keh039; Kachadourian R, 2001, ARCH BIOCHEM BIOPHYS, V392, P349, DOI 10.1006/abbi.2001.2455; Krokan HE, 2000, FEBS LETT, V476, P73, DOI 10.1016/S0014-5793(00)01674-4; Lambert C, 2004, INT J CANCER, V108, P493, DOI 10.1002/ijc.11579; Lambert C, 2002, EUR J MED RES, V7, P404; LaVallee TM, 2003, CANCER RES, V63, P468; Li L, 2004, ANTICANCER RES, V24, P3983; Li L, 2004, ANTICANCER RES, V24, P873; Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3; Mambo E, 2005, ONCOGENE, V24, P4496, DOI 10.1038/sj.onc.1208669; Mambo E, 2002, CANCER RES, V62, P1349; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; ModicaNapolitano JS, 1996, CANCER RES, V56, P544; Mooberry SL, 2003, DRUG RESIST UPDATE, V6, P355, DOI 10.1016/j.drup.2003.10.001; Morgunov I, 1998, J BIOL CHEM, V273, P29540, DOI 10.1074/jbc.273.45.29540; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; NABI ZF, 1986, CANCER, V58, P1461, DOI 10.1002/1097-0142(19861001)58:7<1461::AID-CNCR2820580714>3.0.CO;2-D; Pani G, 2000, CANCER RES, V60, P4654; Parlanti E, 2002, ONCOGENE, V21, P5204, DOI 10.1038/sj.onc.1205561; Pelicano H, 2003, J BIOL CHEM, V278, P37832, DOI 10.1074/jbc.M301546200; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Qanungo S, 2002, ONCOGENE, V21, P4149, DOI 10.1038/sj.onc.1205508; Rachek LI, 2002, J BIOL CHEM, V277, P44932, DOI 10.1074/jbc.M208770200; Rachek LI, 2006, DIABETES, V55, P1022, DOI 10.2337/diabetes.55.04.06.db05-0865; Rachek LI, 2006, FREE RADICAL BIO MED, V40, P754, DOI 10.1016/j.freeradbiomed.2005.09.028; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Rinne ML, 2005, NUCLEIC ACIDS RES, V33, P2859, DOI 10.1093/nar/gki601; Ruchko M, 2005, AM J PHYSIOL-LUNG C, V288, pL530, DOI 10.1152/ajplung.00255.2004; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Schapira AHV, 1999, BBA-BIOENERGETICS, V1410, P159, DOI 10.1016/S0005-2728(98)00164-9; SEGALBENDIRDJIAN E, 1988, CANCER RES, V48, P4982; Shimada K, 2004, MOL CARCINOGEN, V39, P1, DOI 10.1002/mc.10158; Shokolenko IN, 2003, DNA REPAIR, V2, P471, DOI 10.1016/S1568-7864(03)00019-3; Singh KK, 1999, ONCOGENE, V18, P6641, DOI 10.1038/sj.onc.1203056; Singh KK, 2001, NUCLEIC ACIDS RES, V29, P1381, DOI 10.1093/nar/29.6.1381; Srere P A, 1968, Biochem Soc Symp, V27, P11; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; Vidal AE, 2001, NUCLEIC ACIDS RES, V29, P1285, DOI 10.1093/nar/29.6.1285; Wallace DC, 2000, AM HEART J, V139, pS70, DOI 10.1067/mhj.2000.103934; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Yang N, 2004, DNA REPAIR, V3, P1323, DOI 10.1016/j.dnarep.2004.04.014	77	7	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	26					3710	3720		10.1038/onc.2008.3	http://dx.doi.org/10.1038/onc.2008.3			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18246124				2022-12-25	WOS:000256659300008
J	Cordle, J; Redfield, C; Stacey, M; van der Merwe, PA; Willis, AC; Champion, BR; Hambleton, S; Handford, PA				Cordle, Jemima; Redfield, Christina; Stacey, Martin; van der Merwe, P. Anton; Willis, Antony C.; Champion, Brian R.; Hambleton, Sophie; Handford, Penny A.			Localization of the delta-like-1-binding site in human notch-1 and its modulation by calcium affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; HUMAN FIBRILLIN-1; MARFAN-SYNDROME; O-FUCOSE; DOMAIN; RECEPTORS; DISEASE; REPEATS; PROTEOLYSIS; DROSOPHILA	The Notch signaling pathway plays a key role in a myriad of cellular processes, including cell fate determination. Despite extensive study of the downstream consequences of receptor activation, very little molecular data are available for the initial binding event between the Notch receptor and its ligands. In this study, we have expressed and purified a natively folded wildtype epidermal growth factor-like domain (EGF) 11-14 construct from human Notch-1 and have used flow cytometry and surface plasmon resonance analysis to demonstrate a calcium-dependent interaction with the human ligand Delta-like-1. Site-directed mutagenesis of three of the calcium-binding sites within the Notch-(11-14) fragment indicated that only loss of calcium binding to EGF12, and not EGF11 or EGF13, abrogates ligand binding. Further mapping of the ligand-binding site within this region by limited proteolysis of Notch wild-type and mutant fragments suggested that EGF12 rather than EGF11 contains the major Delta-like-1-binding site. Analysis of an extended fragment EGF-(10-14), where EGF11 is placed in a native context, surprisingly demonstrated a reduction in ligand binding, suggesting that EGF10 modulates binding by limiting access of ligand. This inhibition could be overcome by the introduction of a calcium binding mutation in EGF11, which decouples the EGF-(10-11) module interface. This study therefore demonstrates that long range calcium-dependent structural perturbations can influence the affinity of Notch for its ligand, in the absence of any post-translational modifications.	[Willis, Antony C.; Handford, Penny A.] Univ Oxford, Dept Biochem, Immunochem Unit, MRC, Oxford OX1 3QU, England; [Stacey, Martin; van der Merwe, P. Anton] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; [Champion, Brian R.] Celldex Therapeut Ltd, Cambridge CB4 0PE, England; [Hambleton, Sophie] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Human Immunol Unit,MRC, Oxford OX3 9DS, England	University of Oxford; University of Oxford; University of Oxford	Handford, PA (corresponding author), Univ Oxford, Dept Biochem, Immunochem Unit, MRC, S Parks Rd, Oxford OX1 3QU, England.	penny.handford@bioch.ox.ac.uk	van der Merwe, P. Anton/F-8539-2011		Medical Research Council [G9722488] Funding Source: Medline; Wellcome Trust [079440] Funding Source: Medline; MRC [G9722488] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abbott RJM, 2004, ACTA CRYSTALLOGR D, V60, P936, DOI 10.1107/S0907444904005098; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Bolos V, 2007, ENDOCR REV, V28, P339, DOI 10.1210/er.2006-0046; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; CORDLE JD, 2005, THESIS U OXFORD; Davis JA, 2007, J BIOL CHEM, V282, P28807, DOI 10.1074/jbc.M704015200; DE SB, 1999, NATURE, V398, P518; DECELIS JF, 1993, P NATL ACAD SCI USA, V90, P4037, DOI 10.1073/pnas.90.9.4037; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; Fleming RJ, 1998, SEMIN CELL DEV BIOL, V9, P599, DOI 10.1006/scdb.1998.0260; Gridley T, 2003, HUM MOL GENET, V12, pR9, DOI 10.1093/hmg/ddg052; Hambleton S, 2004, STRUCTURE, V12, P2173, DOI 10.1016/j.str.2004.09.012; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; Harper JA, 2003, CLIN GENET, V64, P461, DOI 10.1046/j.1399-0004.2003.00194.x; HENDERSON ST, 1994, DEVELOPMENT, V120, P2913; Joutel A, 1998, SEMIN CELL DEV BIOL, V9, P619, DOI 10.1006/scdb.1998.0261; Kettle S, 1999, J MOL BIOL, V285, P1277, DOI 10.1006/jmbi.1998.2368; Knott V, 1996, J MOL BIOL, V255, P22, DOI 10.1006/jmbi.1996.0003; Lei L, 2003, DEVELOPMENT, V130, P6411, DOI 10.1242/dev.00883; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; McGettrick AJ, 2000, HUM MOL GENET, V9, P1987, DOI 10.1093/hmg/9.13.1987; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Nichols JT, 2007, J CELL BIOL, V176, P445, DOI 10.1083/jcb.200609014; Rand MD, 2000, MOL CELL BIOL, V20, P1825, DOI 10.1128/MCB.20.5.1825-1835.2000; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; Reinhardt DP, 2000, J BIOL CHEM, V275, P12339, DOI 10.1074/jbc.275.16.12339; Shao L, 2003, J BIOL CHEM, V278, P7775, DOI 10.1074/jbc.M212221200; Shimizu K, 1999, J BIOL CHEM, V274, P32961, DOI 10.1074/jbc.274.46.32961; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Suk JY, 2004, J BIOL CHEM, V279, P51258, DOI 10.1074/jbc.M408156200; vanderMerwe PA, 1996, CURR OPIN IMMUNOL, V8, P257, DOI 10.1016/S0952-7915(96)80065-3; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; Whiteman P, 2001, J BIOL CHEM, V276, P17156, DOI 10.1074/jbc.M006547200; Xu AG, 2005, J BIOL CHEM, V280, P30158, DOI 10.1074/jbc.M505569200	35	71	74	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11785	11793		10.1074/jbc.M708424200	http://dx.doi.org/10.1074/jbc.M708424200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18296446	hybrid			2022-12-25	WOS:000255067400078
J	Cossette, C; Patel, P; Anumolu, JR; Sivendran, S; Lee, GJ; Gravel, S; Graham, FD; Lesimple, A; Mamer, OA; Rokach, J; Powell, WS				Cossette, Chantal; Patel, Pranav; Anumolu, Jaganmohan R.; Sivendran, Sashikala; Lee, Gue Jae; Gravel, Sylvie; Graham, Francois D.; Lesimple, Alain; Mamer, Orval A.; Rokach, Joshua; Powell, William S.			Human neutrophils convert the sebum-derived polyunsaturated fatty acid sebaleic acid to a potent granulocyte chemoattractant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SEBACEOUS GLAND; POLYMORPHONUCLEAR LEUKOCYTES; 5-OXO-6,8,11,14-EICOSATETRAENOIC ACID; LIQUID-CHROMATOGRAPHY; HUMAN EOSINOPHILS; ARACHIDONIC-ACID; LEPIDIUM-MEYENII; LEUKOTRIENE B-4; METABOLISM; 5-OXO-ETE	Sebaleic acid (5,8-octadecadienoic acid) is the major polyunsaturated fatty acid in human sebum and skin surface lipids. The objective of the present study was to investigate the metabolism of this fatty acid by human neutrophils and to determine whether its metabolites are biologically active. Neutrophils converted sebaleic acid to four major products, which were identified by their chromatographic properties, UV absorbance, and mass spectra as 5-hydroxy-(6E, 8Z)-octadecadienoic acid (5-HODE), 5-oxo-(6E, 8Z)-octadecadienoic acid (5-oxo-ODE), 5S, 18-dihydroxy-(6E, 8Z)-octadecadienoic acid, and 5-oxo-18-hydroxy-(6E, 8Z)-octadecadienoic acid. The identities of these metabolites were confirmed by comparison of their properties with those of authentic chemically synthesized standards. Both neutrophils and human keratinocytes converted 5-HODE to 5-oxo- ODE. This reaction was stimulated in neutrophils by phorbol myristate acetate and in keratinocytes by oxidative stress (t-butyl-hydroperoxide). Both treatments dramatically elevated intracellular levels of NADP(+), the cofactor required by 5-hydroxyeicosanoid dehydrogenase. In keratinocytes, this was accompanied by a rapid increase in intracellular GSSG levels, consistent with the involvement of glutathione peroxidase. 5-Oxo-ODE stimulated calcium mobilization in human neutrophils and induced desensitization to 5-oxo- 6,8,11,14-eicosatetraenoic acid but not leukotriene B-4, indicating that this effect was mediated by the OXE receptor. 5-Oxo-ODE and its 8-trans isomer were equipotent with 5-oxo- 6,8,11,14-eicosatetraenoic acid in stimulating actin polymerization and chemotaxis in human neutrophils, whereas 5-HODE, 5-oxo- 18-hydroxy(6E, 8Z)-octadecadienoic acid, and 5S, 18-dihydroxy-(6E, 8Z)-octadecadienoic acid were much less active. We conclude that neutrophil 5-lipoxygenase converts sebaleic acid to 5-HODE, which can be further metabolized to 5-oxo-ODE by 5-hydroxyeicosanoid dehydrogenase in neutrophils and keratinocytes. Because of its chemoattractant properties, sebum-derived 5-oxo-ODE could be involved in neutrophil infiltration in inflammatory skin diseases.	[Cossette, Chantal; Gravel, Sylvie; Graham, Francois D.; Powell, William S.] McGill Univ, Meakins Christie Labs, Dept Med, Montreal, PQ H2X 2P2, Canada; [Lesimple, Alain; Mamer, Orval A.] McGill Univ, Mass Spectrometry Unit, Montreal, PQ H3A 1A4, Canada; [Patel, Pranav; Anumolu, Jaganmohan R.; Sivendran, Sashikala; Lee, Gue Jae; Rokach, Joshua] Florida Inst Technol, Claude Pepper Inst, Melbourne, FL 32901 USA; [Patel, Pranav; Anumolu, Jaganmohan R.; Sivendran, Sashikala; Lee, Gue Jae; Rokach, Joshua] Florida Inst Technol, Dept Chem, Melbourne, FL 32901 USA	McGill University; McGill University; Florida Institute of Technology; Florida Institute of Technology	Powell, WS (corresponding author), McGill Univ, Meakins Christie Labs, Dept Med, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.	William.Powell@McGill.ca	Graham, François/AAP-2630-2020; Powell, William/AAE-9000-2020	Powell, William/0000-0002-8507-4038; Rokach, Joshu/0000-0003-1814-7505	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081873] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL81873] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alestas T, 2006, J MOL MED, V84, P75, DOI 10.1007/s00109-005-0715-8; BIANCHI A, 2003, B LATINOAM CARIBE PL, V2, P30; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P3213, DOI 10.1073/pnas.76.7.3213; Brink C, 2004, PHARMACOL REV, V56, P149, DOI 10.1124/pr.56.1.4; Erlemann KR, 2007, BIOCHEM J, V403, P157, DOI 10.1042/BJ20061617; Erlemann KR, 2007, FREE RADICAL BIO MED, V42, P654, DOI 10.1016/j.freeradbiomed.2006.12.006; Erlemann KR, 2006, BIOCHEM BIOPH RES CO, V350, P151, DOI 10.1016/j.bbrc.2006.09.011; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Ge L, 2003, J INVEST DERMATOL, V120, P707, DOI 10.1046/j.1523-1747.2003.12123.x; HAMBERG M, 1967, J BIOL CHEM, V242, P5329; HANSSON G, 1981, FEBS LETT, V130, P107, DOI 10.1016/0014-5793(81)80676-X; Hosoi T, 2005, BIOCHEM BIOPH RES CO, V334, P987, DOI 10.1016/j.bbrc.2005.06.191; Jones CE, 2003, MOL PHARMACOL, V63, P471, DOI 10.1124/mol.63.3.471; Khanapure SP, 1998, J ORG CHEM, V63, P337, DOI 10.1021/jo9716993; KOBAYASHI Y, 1994, BBA-LIPID LIPID MET, V1215, P280, DOI 10.1016/0005-2760(94)90054-X; LUDWIG SA, 1979, ARCH BIOCHEM BIOPHYS, V197, P333, DOI 10.1016/0003-9861(79)90253-4; MARPLES RR, 1971, J INVEST DERMATOL, V56, P127, DOI 10.1111/1523-1747.ep12260695; Monneret G, 2002, J IMMUNOL, V168, P3563, DOI 10.4049/jimmunol.168.7.3563; Muhammad I, 2002, PHYTOCHEMISTRY, V59, P105, DOI 10.1016/S0031-9422(01)00395-8; NICOLAIDES N, 1974, SCIENCE, V186, P19, DOI 10.1126/science.186.4158.19; O'Flaherty JT, 2000, J IMMUNOL, V164, P3345, DOI 10.4049/jimmunol.164.6.3345; OFLAHERTY JT, 1986, J IMMUNOL, V137, P3277; Pappas A, 2002, J INVEST DERMATOL, V118, P164, DOI 10.1046/j.0022-202x.2001.01612.x; Parmentier C, 1998, J CHROMATOGR B, V719, P37, DOI 10.1016/S0378-4347(98)00414-9; POWELL WS, 1994, J BIOL CHEM, V269, P25373; Powell WS, 1996, J PHARMACOL EXP THER, V276, P728; Powell WS, 2005, PROG LIPID RES, V44, P154, DOI 10.1016/j.plipres.2005.04.002; POWELL WS, 1980, PROSTAGLANDINS, V20, P947, DOI 10.1016/0090-6980(80)90144-6; POWELL WS, 1993, J BIOL CHEM, V268, P9280; Powell WS, 1996, J IMMUNOL, V156, P336; POWELL WS, 1992, J BIOL CHEM, V267, P19233; POWELL WS, 1987, BIOCHEM BIOPH RES CO, V145, P991, DOI 10.1016/0006-291X(87)91533-6; POWELL WS, 1987, ANAL BIOCHEM, V164, P117, DOI 10.1016/0003-2697(87)90375-7; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Schneider C, 2000, ANAL BIOCHEM, V287, P186, DOI 10.1006/abio.2000.4847; STEWART ME, 1978, BIOCHIM BIOPHYS ACTA, V529, P380, DOI 10.1016/0005-2760(78)90082-6; THODY AJ, 1989, PHYSIOL REV, V69, P383, DOI 10.1152/physrev.1989.69.2.383; Toyoda Masahiko, 2001, Medical Electron Microscopy, V34, P29, DOI 10.1007/s007950100002; Valentova Katerina, 2003, Biomedical Papers (Olomouc), V147, P119; Wille JJ, 2003, SKIN PHARMACOL APPL, V16, P176, DOI 10.1159/000069757; ZAMBONI R, 1982, TETRAHEDRON LETT, V23, P2631, DOI 10.1016/S0040-4039(00)87415-8; Zheng BL, 2000, UROLOGY, V55, P598, DOI 10.1016/S0090-4295(99)00549-X	42	27	27	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11234	11243		10.1074/jbc.M709531200	http://dx.doi.org/10.1074/jbc.M709531200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18287092	Green Published, hybrid			2022-12-25	WOS:000255067400019
J	Nishimura, S; Takahashi, S; Kamikatahira, H; Kuroki, Y; Jaalouk, DE; O'Brien, S; Koivunen, E; Arap, W; Pasqualini, R; Nakayama, H; Kuniyasu, A				Nishimura, Shinpei; Takahashi, Shunsuke; Kamikatahira, Hiromi; Kuroki, Yuko; Jaalouk, Diana E.; O'Brien, Susan; Koivunen, Erkki; Arap, Wadih; Pasqualini, Renata; Nakayama, Hitoshi; Kuniyasu, Akihiko			Combinatorial targeting of the macropinocytotic pathway in leukemia and lymphoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE-RICH PEPTIDES; ACUTE MYELOID-LEUKEMIA; CELLULAR UPTAKE; DRUG-DELIVERY; INTRACELLULAR TRAFFICKING; PENETRATING PEPTIDES; BLOOD-VESSELS; GENE DELIVERY; PHAGE DISPLAY; TAT PEPTIDE	Ligand-directed delivery of agents to leukemia and lymphoma cells has the potential to yield new mechanistic disease insights and targeted therapies. Here we set out to target the macropinocytotic pathway with a combinatorial approach. From the screening of acute T-lymphoblastic leukemia Molt-4 cells with a random phage-display peptide library, we isolated a phage displaying the sequence CAYHRLRRC. This peptide contains a lymph node-homing motif (Cys-Ala-Tyr) and a cell-penetrating motif (Arg-Leu-Arg-Arg). Binding of this ligand-directed phage to a large panel of leukemia/lymphoma cells and to patient-derived samples was much higher than to non-leukemia control cells. CAYHRLRRC phage internalization into Molt-4 cells is both energy- and temperature-dependent. Flow cytometry with fluorescein-labeled peptide and endocytosis blocking with specific inhibitors revealed that CAYHRLRRC is indeed taken up through macropinocytosis in Molt-4 and K562 human leukemia cells. Unexpectedly, the cell surface receptor for the CAYHRLRRC peptide is not a heparan sulfate proteoglycan as it would be predicted for other cell-penetrating peptides. Confirming this interpretation, a CAYHRLRRC-directed peptidomimetic-induced cell death in all the leukemia and lymphoma cells was evaluated, whereas a control transactivator of transcription protein (tat)-directed proapoptotic peptidomimetic was non-selective. In summary, the targeting peptide CAYHRLRRC is selectively internalized through macropinocytosis in leukemia and lymphoma cells and has potential as a drug lead for ligand-directed anti-leukemia therapies.	[Jaalouk, Diana E.; O'Brien, Susan; Koivunen, Erkki; Arap, Wadih; Pasqualini, Renata] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Nishimura, Shinpei; Takahashi, Shunsuke; Kamikatahira, Hiromi; Kuroki, Yuko; Nakayama, Hitoshi; Kuniyasu, Akihiko] Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Dept Mol Cell Funct, Kumamoto 8620973, Japan	University of Texas System; UTMD Anderson Cancer Center; Kumamoto University	Arap, W (corresponding author), Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.	warap@mdanderson.org; rpasqual@mdanderson.org; kuniyasu@gpo.kumamoto-u.ac.jp		Koivunen, Erkki/0000-0002-6443-9595				Amyere M, 2002, INT J MED MICROBIOL, V291, P487; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; Arap MA, 2004, CANCER CELL, V6, P275, DOI 10.1016/j.ccr.2004.08.018; Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Arap W, 2002, NAT MED, V8, P121, DOI 10.1038/nm0202-121; Ardelt PU, 2003, J UROLOGY, V169, P1535, DOI 10.1097/01.ju.0000055477.37115.66; Zhao B, 2006, J BIOL CHEM, V281, P15757, DOI 10.1074/jbc.M510714200; Christianson Dawn R, 2007, Methods Mol Biol, V357, P385; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Curnis F, 2002, CANCER RES, V62, P867; Dharmawardhane S, 2000, MOL BIOL CELL, V11, P3341, DOI 10.1091/mbc.11.10.3341; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140-6736(06)69780-8; FRA AM, 1994, J BIOL CHEM, V269, P30745; Fretz MM, 2007, BIOCHEM J, V403, P335, DOI 10.1042/BJ20061808; Futaki S, 2007, BIOCHEM SOC T, V35, P784, DOI 10.1042/BST0350784; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; Giordano RJ, 2001, NAT MED, V7, P1249, DOI 10.1038/nm1101-1249; GOLDMACHER VS, 1986, J CELL BIOL, V102, P1312, DOI 10.1083/jcb.102.4.1312; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Grimmer S, 2002, J CELL SCI, V115, P2953; Hajitou A, 2006, CELL, V125, P385, DOI 10.1016/j.cell.2006.02.042; Hajitou A, 2006, TRENDS CARDIOVAS MED, V16, P80, DOI 10.1016/j.tcm.2006.01.003; HEWLETT LJ, 1994, J CELL BIOL, V124, P689, DOI 10.1083/jcb.124.5.689; Hong FD, 2000, CANCER RES, V60, P6551; Jager S, 2007, LEUKEMIA, V21, P411, DOI 10.1038/sj.leu.2404548; Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018; Kawamura KS, 2006, BIOCHEMISTRY-US, V45, P1116, DOI 10.1021/bi051338e; Khalil IA, 2006, J BIOL CHEM, V281, P3544, DOI 10.1074/jbc.M503202200; Khalil IA, 2006, PHARMACOL REV, V58, P32, DOI 10.1124/pr.58.1.8; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; Koivunen E, 2001, J CELL BIOL, V153, P905, DOI 10.1083/jcb.153.5.905; Kolonin M, 2001, CURR OPIN CHEM BIOL, V5, P308, DOI 10.1016/S1367-5931(00)00207-6; Kolonin MG, 2006, CANCER RES, V66, P34, DOI 10.1158/0008-5472.CAN-05-2748; Kolonin MG, 2004, NAT MED, V10, P625, DOI 10.1038/nm1048; Kolonin MG, 2002, P NATL ACAD SCI USA, V99, P13055, DOI 10.1073/pnas.162468499; Lanzetti L, 2004, NATURE, V429, P309, DOI 10.1038/nature02542; Liu Y, 2007, MOL PHARMACEUT, V4, P435, DOI 10.1021/mp060122j; Marchio S, 2004, CANCER CELL, V5, P151, DOI 10.1016/S1535-6108(04)00025-X; McGuire MJ, 2006, EXP HEMATOL, V34, P443, DOI 10.1016/j.exphem.2005.12.013; Meade BR, 2007, ADV DRUG DELIVER REV, V59, P134, DOI 10.1016/j.addr.2007.03.004; Muller OJ, 2003, NAT BIOTECHNOL, V21, P1040, DOI 10.1038/nbt856; Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010; Nakase I, 2007, BIOCHEMISTRY-US, V46, P492, DOI 10.1021/bi0612824; Poon GMK, 2007, BIOCHEM SOC T, V35, P788, DOI 10.1042/BST0350788; Pui CH, 2007, NAT REV DRUG DISCOV, V6, P149, DOI 10.1038/nrd2240; Quintas-Cardama A, 2007, NAT REV DRUG DISCOV, V6, P834, DOI 10.1038/nrd2324; Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; Sergeeva A, 2006, ADV DRUG DELIVER REV, V58, P1622, DOI 10.1016/j.addr.2006.09.018; Snyder EL, 2003, J CONTROL RELEASE, V91, P45, DOI 10.1016/S0168-3659(03)00212-8; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1; Takahashi S, 2003, CANCER RES, V63, P5213; Tallman MS, 2005, BLOOD, V106, P1154, DOI 10.1182/blood-2005-01-0178; Trepel M, 2001, CANCER RES, V61, P8110; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Wadia JS, 2005, ADV DRUG DELIVER REV, V57, P579, DOI 10.1016/j.addr.2004.10.005; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; Xu W, 2006, BLOOD, V107, P4930, DOI 10.1182/blood-2005-10-4144; Zurita AJ, 2004, CANCER RES, V64, P435, DOI 10.1158/0008-5472.CAN-03-2675	61	44	48	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11752	11762		10.1074/jbc.M708849200	http://dx.doi.org/10.1074/jbc.M708849200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18292083	Green Published, hybrid			2022-12-25	WOS:000255067400075
J	Kim, HJ; Kirsch, T				Kim, Hyon Jong; Kirsch, Thorsten			Collagen/annexin V interactions regulate chondrocyte mineralization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN OSTEOARTHRITIC CARTILAGE; LARGE UNILAMELLAR VESICLES; GROWTH-PLATE CHONDROCYTES; CHICK-EMBRYO CHONDROCYTES; ANNEXIN-V; ASCORBIC-ACID; EXTRACELLULAR-MATRIX; II COLLAGEN; X-COLLAGEN; ANCHORIN-CII	Physiological mineralization in growth plate cartilage is highly regulated and restricted to terminally differentiated chondrocytes. Because mineralization occurs in the extracellular matrix, we asked whether major extracellular matrix components (collagens) of growth plate cartilage are directly involved in regulating the mineralization process. Our findings show that types II and X collagen interacted with cell surfaceexpressed annexin V. These interactions led to a stimulation of annexin Vmediated Ca2+ influx resulting in an increased intracellular Ca2+ concentration, [Ca2+](i), and ultimately increased alkaline phosphatase activity and mineralization of growth plate chondrocytes. Consequently, stimulation of these interactions (ascorbate to stimulate collagen synthesis, culturing cells on type II collagencoated dishes, or overexpression of fulllength annexin V) resulted in increase of [Ca2+](i), alkaline phosphatase activity, and mineralization of growth plate chondrocytes, whereas inhibition of these interactions (3,4dehydroLproline to inhibit collagen secretion, K201, a specific annexin channel blocker, overexpression of N terminusdeleted mutant annexin V that does not bind to type II collagen and shows reduced Ca2+ channel activities) decreased [Ca2+](i), alkaline phosphatase activity, and mineralization. In conclusion, the interactions between collagen and annexin V regulate mineralization of growth plate cartilage. Because annexin V is upregulated during pathological mineralization events of articular cartilage, it is possible that these interactions also regulate pathological mineralization.	[Kim, Hyon Jong; Kirsch, Thorsten] Univ Maryland, Sch Med, Dept Orthopaed, Musculoskeletal Res Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Kirsch, T (corresponding author), NYU, Hosp Joint Dis, Musculoskeletal Res Ctr, Dept Orthopaed Surg, 301 E 17th St,Suite 1500, New York, NY 10003 USA.	Thorsten.Kirsch@nyumc.org	Kirsch, Thorsten/GQP-1157-2022	Kim, Hyon Jong/0000-0002-3106-4977	NIAMS NIH HHS [R01AR046245, R01AR049074] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049074, R01AR046245] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abe T, 2001, J CELL PHYSIOL, V189, P144, DOI 10.1002/jcp.10011; AIGNER T, 1993, J CLIN INVEST, V91, P829, DOI 10.1172/JCI116303; ALINI M, 1992, CALCIFIED TISSUE INT, V50, P327, DOI 10.1007/BF00301630; Aurich M, 2002, ARTHRITIS RHEUM, V46, P2903, DOI 10.1002/art.10611; Baran DT, 2000, J CELL BIOCHEM, V78, P34, DOI 10.1002/(SICI)1097-4644(20000701)78:1<34::AID-JCB4>3.3.CO;2-Q; BERENDES R, 1993, FEBS LETT, V317, P131, DOI 10.1016/0014-5793(93)81507-V; Castro-Caldas M, 2002, MOL CELL BIOCHEM, V237, P31, DOI 10.1023/A:1016502120139; Chen NX, 2007, AM J PHYSIOL-RENAL, V292, pF599, DOI 10.1152/ajprenal.00303.2006; CHUNG CY, 1994, J CELL BIOL, V126, P539, DOI 10.1083/jcb.126.2.539; DURR J, 1993, EXP CELL RES, V207, P235, DOI 10.1006/excr.1993.1189; FRANCESCHI RT, 1994, J BONE MINER RES, V9, P843; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAJEK AS, 1977, J EXP ZOOL, V200, P377, DOI 10.1002/jez.1402000308; HARADA S, 1991, J BONE MINER RES, V6, P903; Hausler G, 2002, CALCIFIED TISSUE INT, V71, P212, DOI 10.1007/s00223-001-2083-x; IANNOTTI JP, 1989, J ORTHOPAED RES, V7, P511, DOI 10.1002/jor.1100070408; Kaneko N, 1997, BBA-BIOMEMBRANES, V1330, P1, DOI 10.1016/S0005-2736(97)00132-6; Kaneko N, 1997, J MOL BIOL, V274, P16, DOI 10.1006/jmbi.1997.1375; KERWAR SS, 1976, J BIOL CHEM, V251, P503; KIRSCH T, 1992, DIFFERENTIATION, V52, P89, DOI 10.1111/j.1432-0436.1992.tb00503.x; KIRSCH T, 1992, BONE MINER, V18, P107, DOI 10.1016/0169-6009(92)90851-4; Kirsch T, 1997, BIOCHEMISTRY-US, V36, P3359, DOI 10.1021/bi9626867; KIRSCH T, 1992, FEBS LETT, V310, P143, DOI 10.1016/0014-5793(92)81316-E; Kirsch T, 2000, OSTEOARTHR CARTILAGE, V8, P294, DOI 10.1053/joca.1999.0304; Kirsch T, 2000, J BIOL CHEM, V275, P35577, DOI 10.1074/jbc.M005648200; Kirsch T, 1997, J CELL BIOL, V137, P1149, DOI 10.1083/jcb.137.5.1149; KIVIRIKKO KI, 1987, METHOD ENZYMOL, V144, P96; LEBOY PS, 1989, J BIOL CHEM, V264, P17281; Lucic D, 2003, CONNECT TISSUE RES, V44, P225, DOI 10.1080/03008200390248632; MEIER S, 1978, J ULTRA MOL STRUCT R, V65, P48, DOI 10.1016/S0022-5320(78)90021-7; MILLS DK, 1993, CONNECT TISSUE RES, V30, P37, DOI 10.3109/03008209309032929; Mollenhauer J, 1999, J HISTOCHEM CYTOCHEM, V47, P209, DOI 10.1177/002215549904700209; MOLLENHAUER J, 1984, J CELL BIOL, V98, P1572, DOI 10.1083/jcb.98.4.1572; Mwale F, 2002, J BONE MINER RES, V17, P275, DOI 10.1359/jbmr.2002.17.2.275; Reid DL, 2000, J ORTHOPAED RES, V18, P364, DOI 10.1002/jor.1100180307; SCHMID TM, 1985, J CELL BIOL, V100, P598, DOI 10.1083/jcb.100.2.598; Siever DA, 1997, INT J BIOCHEM CELL B, V29, P1219, DOI 10.1016/S1357-2725(97)00057-5; SULLIVAN TA, 1994, J BIOL CHEM, V269, P22500; Takagi H, 2002, J CELL SCI, V115, P3309; Wang W, 2003, J BIOL CHEM, V278, P3762, DOI 10.1074/jbc.M208868200; Wang W, 2002, J CELL BIOL, V157, P1061, DOI 10.1083/jcb.200203014; Wang W, 2005, EXP CELL RES, V305, P156, DOI 10.1016/j.yexcr.2004.12.022; Wang W, 2006, J BIOL CHEM, V281, P30848, DOI 10.1074/jbc.M605937200; Xiao GZ, 1997, MOL ENDOCRINOL, V11, P1103, DOI 10.1210/me.11.8.1103; Zuscik MJ, 2002, EXP CELL RES, V276, P310, DOI 10.1006/excr.2002.5527	45	21	22	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10310	10317		10.1074/jbc.M708456200	http://dx.doi.org/10.1074/jbc.M708456200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18281278	Green Published, hybrid			2022-12-25	WOS:000254894700011
J	Smrz, D; Lebduska, P; Draberova, L; Korb, J; Draber, P				Smrz, Daniel; Lebduska, Pavel; Draberova, L'ubica; Korb, Jan; Draber, Petr			Engagement of phospholipid scramblase 1 in activated cells - Implication for phosphatidylserine externalization and exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RI; MEMBRANE PHOSPHOLIPID SCRAMBLASE-1; PLASMA-MEMBRANE; LIPID RAFTS; MAST-CELLS; HIGH-AFFINITY; GENE-EXPRESSION; IGE RECEPTOR; TYROSINE PHOSPHORYLATION; IMMUNOGLOBULIN-E	Phosphatidylserine (PS) in quiescent cells is predominantly confined to the inner leaflet of the plasma membrane. Externalization of PS is a marker of apoptosis, exocytosis, and some nonapoptotic activation events. It has been proposed that PS externalization is regulated by the activity of PLSCR1 (phospholipid scramblase 1), a Ca2+-dependent endofacial plasma membrane protein, which is tyrosine-phosphorylated in activated cells. It is, however, unclear how the phosphorylation of PLSCR1 is related to its membrane topography, PS externalization, and exocytosis. Using rat basophilic leukemia cells as a model, we show that nonapoptotic PS externalization induced through the high affinity IgE receptor(Fc epsilon RI) or the glycosylphosphatidylinositol-anchored protein Thy-1 does not correlate with enhanced tyrosine phosphorylation of PLSCR1. In addition, PS externalization in Fc epsilon RI-or Thy-1-activated cells is not associated with alterations of PLSCR1 fine topography as detected by electron microscopy on isolated plasma membrane sheets. In contrast, activation by calcium ionophore A23187 induces changes in the cellular distribution of PLSCR1. We also show for the first time that in pervanadate-activated cells, exocytosis occurs even in the absence of PS externalization. Finally, we document here that tyrosine-phosphorylated PLSCR1 is preferentially located in detergent-insoluble membranes, suggesting its involvement in the formation of membrane-bound signaling assemblies. The combined data indicate that changes in the topography of PLSCR1 and its tyrosine phosphorylation, PS externalization, and exocytosis are independent phenomena that could be distinguished by employing specific conditions of activation.	[Smrz, Daniel; Lebduska, Pavel; Draberova, L'ubica; Korb, Jan; Draber, Petr] Acad Sci Czech Republ, Inst Genet Mol, Dept Signal Transduct, CZ-14220 Prague 4, Czech Republic	Czech Academy of Sciences	Draber, P (corresponding author), Acad Sci Czech Republ, Inst Genet Mol, Dept Signal Transduct, Videnska 1083, CZ-14220 Prague 4, Czech Republic.	draberpe@img.cas.cz	Draber, Petr/E-1119-2018; Smrz, Daniel/D-4853-2014; Draberova, Lubica/G-3505-2014; Draber, Petr/G-3412-2014	Draber, Petr/0000-0002-3986-2025; Smrz, Daniel/0000-0003-0143-8744; Draberova, Lubica/0000-0002-2459-4435; Draber, Petr/0000-0002-3986-2025	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Amoui M, 1997, EUR J IMMUNOL, V27, P1881, DOI 10.1002/eji.1830270810; Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; BANIYASH M, 1987, J IMMUNOL, V138, P2999; Basse F, 1996, J BIOL CHEM, V271, P17205, DOI 10.1074/jbc.271.29.17205; Bevers EM, 1999, BBA-MOL CELL BIOL L, V1439, P317, DOI 10.1016/S1388-1981(99)00110-9; Bobek J, 2004, PROTEOMICS, V4, P3864, DOI 10.1002/pmic.200400818; Brdicka T, 2002, J EXP MED, V196, P1617, DOI 10.1084/jem.20021405; Brouckaert G, 2004, MOL BIOL CELL, V15, P1089, DOI 10.1091/mbc.E03-09-0668; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; Demo SD, 1999, CYTOMETRY, V36, P340, DOI 10.1002/(SICI)1097-0320(19990801)36:4<340::AID-CYTO9>3.0.CO;2-C; Dillon SR, 2000, J IMMUNOL, V164, P1322, DOI 10.4049/jimmunol.164.3.1322; DRABER P, 1980, J IMMUNOGENET, V7, P455; Draber P, 2002, MOL IMMUNOL, V38, P1247, DOI 10.1016/S0161-5890(02)00071-8; DRABEROVA L, 1991, EUR J IMMUNOL, V21, P1583, DOI 10.1002/eji.1830210703; Draberova L, 2004, EUR J IMMUNOL, V34, P2209, DOI 10.1002/eji.200322663; DRABEROVA L, 1989, EUR J IMMUNOL, V19, P1715, DOI 10.1002/eji.1830190928; DRABEROVA L, 1993, IMMUNOLOGY, V80, P103; Draberova L, 2007, J IMMUNOL, V179, P5169, DOI 10.4049/jimmunol.179.8.5169; Ehring GR, 2000, J IMMUNOL, V164, P679, DOI 10.4049/jimmunol.164.2.679; Elliott JI, 2005, NAT CELL BIOL, V7, P808, DOI 10.1038/ncb1279; Fattakhova G, 2006, TRAFFIC, V7, P673, DOI 10.1111/j.1600-0854.2006.00423.x; Field KA, 1999, J BIOL CHEM, V274, P1753, DOI 10.1074/jbc.274.3.1753; Fischer K, 2006, BLOOD, V108, P4094, DOI 10.1182/blood-2006-03-011742; Frasch SC, 2004, J BIOL CHEM, V279, P17625, DOI 10.1074/jbc.M313414200; Frigeri L, 1999, J IMMUNOL, V162, P2243; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; Gilfillan AM, 2006, NAT REV IMMUNOL, V6, P218, DOI 10.1038/nri1782; Goth SR, 2001, INFECT IMMUN, V69, P1109, DOI 10.1128/IAI.69.2.1109-1119.2001; Hehner SP, 1999, CELL DEATH DIFFER, V6, P833, DOI 10.1038/sj.cdd.4400559; Heneberg P, 2006, EUR J IMMUNOL, V36, P2795, DOI 10.1002/eji.200636159; Holowka D, 2000, J CELL SCI, V113, P1009; Huang Y, 2006, ONCOGENE, V25, P6618, DOI 10.1038/sj.onc.1209677; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Kametaka S, 2003, J BIOL CHEM, V278, P15239, DOI 10.1074/jbc.M208611200; Kantari C, 2007, BLOOD, V110, P4086, DOI 10.1182/blood-2007-03-080457; Kenis H, 2004, J BIOL CHEM, V279, P52623, DOI 10.1074/jbc.M409009200; KONVALINKA J, 1995, EUR J BIOCHEM, V228, P191, DOI 10.1111/j.1432-1033.1995.tb20249.x; Kovarova M, 2001, MOL CELL BIOL, V21, P8318, DOI 10.1128/MCB.21.24.8318-8328.2001; Kunzelmann-Marche C, 2001, J BIOL CHEM, V276, P5134, DOI 10.1074/jbc.M007924200; Lebduska P, 2007, J IMMUNOL METHODS, V328, P139, DOI 10.1016/j.jim.2007.08.015; LIU FT, 1980, J IMMUNOL, V124, P2728; Loo DT, 1998, METHOD CELL BIOL, V57, P251; Luciano F, 2001, ONCOGENE, V20, P4935, DOI 10.1038/sj.onc.1204661; Martin S, 2000, INT ARCH ALLERGY IMM, V123, P249, DOI 10.1159/000024451; MASON DW, 1980, BIOCHEM J, V187, P1; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; Nanjundan M, 2003, J BIOL CHEM, V278, P37413, DOI 10.1074/jbc.M306182200; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Pastorelli C, 2002, MOL IMMUNOL, V38, P1235, DOI 10.1016/S0161-5890(02)00069-X; Pastorelli C, 2001, J BIOL CHEM, V276, P20407, DOI 10.1074/jbc.M100790200; Patton WF, 2002, J CHROMATOGR B, V771, P3, DOI 10.1016/S1570-0232(02)00043-0; Philimonenko AA, 2000, J STRUCT BIOL, V132, P201, DOI 10.1006/jsbi.2000.4326; Pomorski T, 2006, CELL MOL LIFE SCI, V63, P2908, DOI 10.1007/s00018-006-6167-7; RIVERA J, 1988, MOL IMMUNOL, V25, P647, DOI 10.1016/0161-5890(88)90100-9; RUDOLPH AK, 1981, EUR J IMMUNOL, V11, P527, DOI 10.1002/eji.1830110617; Sahu SK, 2007, ARCH BIOCHEM BIOPHYS, V462, P103, DOI 10.1016/j.abb.2007.04.002; SANAN DA, 1991, J HISTOCHEM CYTOCHEM, V39, P1017, DOI 10.1177/39.8.1906908; SCHRAVEN B, 1994, J EXP MED, V180, P897, DOI 10.1084/jem.180.3.897; SEAGRAVE J, 1991, J CELL PHYSIOL, V148, P139, DOI 10.1002/jcp.1041480117; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SIRAGANIAN RP, 1982, FED PROC, V41, P30; Smrz D, 2007, J BIOL CHEM, V282, P10487, DOI 10.1074/jbc.M611090200; Stout JG, 1998, BIOCHEMISTRY-US, V37, P14860, DOI 10.1021/bi9812930; Sun J, 2002, BIOCHEMISTRY-US, V41, P6338, DOI 10.1021/bi025610l; Sun J, 2001, J BIOL CHEM, V276, P28984, DOI 10.1074/jbc.M102505200; Surviladze Z, 2001, EUR J IMMUNOL, V31, P1, DOI 10.1002/1521-4141(200101)31:1<1::AID-IMMU1>3.0.CO;2-W; TESHIMA R, 1994, BIOCHEM J, V302, P867, DOI 10.1042/bj3020867; Tolarova H, 2004, EUR J IMMUNOL, V34, P1627, DOI 10.1002/eji.200424991; van den Eijnde SM, 2001, J CELL SCI, V114, P3631; Vettermann C, 2002, ANAL BIOCHEM, V308, P381, DOI 10.1016/S0003-2697(02)00269-5; Vitale N, 2001, EMBO J, V20, P2424, DOI 10.1093/emboj/20.10.2424; Wienands J, 1996, P NATL ACAD SCI USA, V93, P7865, DOI 10.1073/pnas.93.15.7865; Wilson BS, 2000, J CELL BIOL, V149, P1131, DOI 10.1083/jcb.149.5.1131; Wilson BS, 2004, MOL BIOL CELL, V15, P2580, DOI 10.1091/mbc.E03-08-0574; Windmiller DA, 2003, J BIOL CHEM, V278, P11874, DOI 10.1074/jbc.M211787200; Wu Y, 2006, TRENDS CELL BIOL, V16, P189, DOI 10.1016/j.tcb.2006.02.003; Wurth GA, 2002, BIOCHEM J, V362, P701, DOI 10.1042/bj3620701; Yokoyama A, 2004, LEUKEMIA RES, V28, P149, DOI 10.1016/S0145-2126(03)00189-9; Zhao KW, 2004, BLOOD, V104, P3731, DOI 10.1182/blood-2004-04-1630; Zhou QS, 2005, J BIOL CHEM, V280, P35062, DOI 10.1074/jbc.M504821200; Zhou QS, 2002, BLOOD, V99, P4030, DOI 10.1182/blood-2001-12-0271; ZICK Y, 1990, BIOCHEMISTRY-US, V29, P10240, DOI 10.1021/bi00496a013; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121; Zwaal RFA, 2005, CELL MOL LIFE SCI, V62, P971, DOI 10.1007/s00018-005-4527-3	85	25	25	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10904	10918		10.1074/jbc.M710386200	http://dx.doi.org/10.1074/jbc.M710386200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18281686	hybrid			2022-12-25	WOS:000254894700072
J	Valton, J; Mathevon, C; Fontecave, M; Niviere, V; Ballou, DP				Valton, Julien; Mathevon, Carole; Fontecave, Marc; Niviere, Vincent; Ballou, David P.			Mechanism and regulation of the two-component FMN-dependent monooxygenase ActVA-ActVB from Streptomyces coelicolor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-HYDROXYPHENYLACETATE 3-HYDROXYLASE; PARA-HYDROXYBENZOATE HYDROXYLASE; ACINETOBACTER-BAUMANNII; ANTIBIOTIC ACTINORHODIN; PRISTINAMYCIN-IIB; ESCHERICHIA-COLI; REDUCED FLAVIN; REDUCTASE; BIOSYNTHESIS; OXYGEN	The ActVA-ActVB system from Streptomyces coelicolor is a two-component flavin-dependent monooxygenase involved in the antibiotic actinorhodin biosynthesis. ActVB is a NADH: flavin oxidoreductase that provides a reduced FMN to ActVA, the monooxygenase that catalyzes the hydroxylation of dihydrokalafungin, the precursor of actinorhodin. In this work, using stopped-flow spectrophotometry, we investigated the mechanism of hydroxylation of dihydrokalafungin catalyzed by ActVA and that of the reduced FMN transfer from ActVB to ActVA. Our results show that the hydroxylation mechanism proceeds with the participation of two different reaction intermediates in ActVA active site. First, a C(4a)-FMN-hydroperoxide species is formed after binding of reduced FMN to the monooxygenase and reaction with O-2. This intermediate hydroxylates the substrate and is transformed to a second reaction intermediate, a C(4a)-FMN-hydroxy species. In addition, we demonstrate that reduced FMN can be transferred efficiently from the reductase to the monooxygenase without involving any protein.protein complexes. The rate of transfer of reduced FMN from ActVB to ActVA was found to be controlled by the release of NAD(+) from ActVB and was strongly affected by NAD(+) concentration, with an IC50 of 40 mu M. This control of reduced FMN transfer by NAD(+) was associated with the formation of a strong charge.transfer complex between NAD(+) and reduced FMN in the active site of ActVB. These results suggest that, in Streptomyces coelicolor, the reductase component ActVB can act as a regulatory component of the monooxygenase activity by controlling the transfer of reduced FMN to the monooxygenase.	[Mathevon, Carole; Fontecave, Marc; Niviere, Vincent] iRTSV, DSV, CEA, Lab Chim Biol Metaux, F-38054 Grenoble, France; [Valton, Julien; Ballou, David P.] Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; [Mathevon, Carole; Fontecave, Marc; Niviere, Vincent] CNRS, UMR 5249, F-38054 Grenoble, France; [Mathevon, Carole; Fontecave, Marc; Niviere, Vincent] Univ Grenoble 1, F-38000 Grenoble, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); University of Michigan System; University of Michigan; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Niviere, V (corresponding author), iRTSV, DSV, CEA, Lab Chim Biol Metaux, 17 Ave Martyrs, F-38054 Grenoble, France.	vniviere@cea.fr; dballou@umich.edu		Niviere, Vincent/0000-0002-5132-457X; Valton, Julien/0000-0003-0826-5401	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064711] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM64711] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD H, 1992, BIOCHEMISTRY-US, V31, P3807, DOI 10.1021/bi00130a011; Alfieri A, 2007, P NATL ACAD SCI USA, V104, P1177, DOI 10.1073/pnas.0608381104; Ballou DP, 2005, BIOCHEM BIOPH RES CO, V338, P590, DOI 10.1016/j.bbrc.2005.09.081; BEATY NB, 1981, J BIOL CHEM, V256, P4619; Beltrametti F, 1997, APPL ENVIRON MICROB, V63, P2232, DOI 10.1128/AEM.63.6.2232-2239.1997; BLANC V, 1995, J BACTERIOL, V177, P5206, DOI 10.1128/jb.177.18.5206-5214.1995; BRUICE TC, 1984, ISRAEL J CHEM, V24, P54; Chaiyen P, 2001, EUR J BIOCHEM, V268, P5550, DOI 10.1046/j.1432-1033.2001.02490.x; COLE SP, 1987, J ANTIBIOT, V40, P340, DOI 10.7164/antibiotics.40.340; Eichhorn E, 1999, J BIOL CHEM, V274, P26639, DOI 10.1074/jbc.274.38.26639; Entsch B, 2005, ARCH BIOCHEM BIOPHYS, V433, P297, DOI 10.1016/j.abb.2004.09.029; ENTSCH B, 1989, BIOCHIM BIOPHYS ACTA, V999, P313, DOI 10.1016/0167-4838(89)90014-9; Fernandes RA, 2005, SYNLETT, P1281, DOI 10.1055/s-2005-868505; FERNANDEZMORENO MA, 1992, J BIOL CHEM, V267, P19278; Filisetti L, 2003, J BIOL CHEM, V278, P296, DOI 10.1074/jbc.M209689200; GHISLA S, 1977, EUR J BIOCHEM, V76, P139, DOI 10.1111/j.1432-1033.1977.tb11579.x; GIBIAN MJ, 1969, BIOCHEM BIOPH RES CO, V34, P594, DOI 10.1016/0006-291X(69)90779-7; Kantz A, 2005, ARCH BIOCHEM BIOPHYS, V442, P102, DOI 10.1016/j.abb.2005.07.020; KENDREW SG, 1995, J BIOL CHEM, V270, P17339, DOI 10.1074/jbc.270.29.17339; Kirchner U, 2003, J BIOL CHEM, V278, P47545, DOI 10.1074/jbc.M307397200; Louie TM, 2003, BIOCHEMISTRY-US, V42, P7509, DOI 10.1021/bi034092r; MASSEY V, 1994, J BIOL CHEM, V269, P22459; MASSEY V, 1973, FLAVIN FLAVOPROTEINS, P25; Moran GR, 1997, BIOCHEMISTRY-US, V36, P7548, DOI 10.1021/bi9706327; MULLER F, 1987, FREE RADICAL BIO MED, V3, P215, DOI 10.1016/0891-5849(87)90009-8; Palfey B. A., 1995, ACTIVE OXYGEN BIOCH, P37, DOI DOI 10.1007/978-94-011-0609-2_2; Panke S, 1998, APPL ENVIRON MICROB, V64, P2032; Parry RJ, 1997, J BIOL CHEM, V272, P23303, DOI 10.1074/jbc.272.37.23303; Patil PV, 2000, ANAL BIOCHEM, V286, P187, DOI 10.1006/abio.2000.4802; Sheng DW, 2001, BIOCHEMISTRY-US, V40, P11156, DOI 10.1021/bi011153h; Sucharitakul J, 2005, BIOCHEMISTRY-US, V44, P10434, DOI 10.1021/bi050615e; Sucharitakul J, 2007, BIOCHEMISTRY-US, V46, P8611, DOI 10.1021/bi7006614; Sucharitakul J, 2006, J BIOL CHEM, V281, P17044, DOI 10.1074/jbc.M512385200; TANAKA H, 1982, J ANTIBIOT, V35, P1565, DOI 10.7164/antibiotics.35.1565; THIBAUT D, 1995, J BACTERIOL, V177, P5199, DOI 10.1128/jb.177.18.5199-5205.1995; Valton J, 2006, J BIOL CHEM, V281, P27, DOI 10.1074/jbc.M506146200; Valton J, 2004, J BIOL CHEM, V279, P44362, DOI 10.1074/jbc.M407722200; van den Heuvel RHH, 2004, J BIOL CHEM, V279, P12860, DOI 10.1074/jbc.M313765200; Xi L, 1997, BIOCHEM BIOPH RES CO, V230, P73, DOI 10.1006/bbrc.1996.5878; Xun LY, 2000, APPL ENVIRON MICROB, V66, P481, DOI 10.1128/AEM.66.2.481-486.2000; Yeh E, 2006, BIOCHEMISTRY-US, V45, P7904, DOI 10.1021/bi060607d	42	55	59	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10287	10296		10.1074/jbc.M709730200	http://dx.doi.org/10.1074/jbc.M709730200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18245777	Green Submitted, hybrid, Green Published			2022-12-25	WOS:000254894700009
J	Chadli, A; Felts, SJ; Toft, DO				Chadli, Ahmed; Felts, Sara J.; Toft, David O.			GCUNC45 is the first Hsp90 co-chaperone to show alpha/beta isoform specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE; PROTEIN; EXPRESSION; RECEPTORS; UNC-45; MYOSIN; FAMILY	Hsp90 is an essential molecular chaperone required for the normal functioning of many key regulatory proteins in eukaryotic cells. Vertebrates have two closely related isoforms of cytosolic Hsp90 (Hsp90 alpha and Hsp90 beta). However, specific functions for each isoform are largely unknown, and no Hsp90 co-chaper-one has been reported to distinguish between the two isoforms. In this study, we show that the Hsp90 co-chaperone GCUNC45 bound preferentially to the beta isoform of Hsp90 in vitro. GCUNC45 efficiently blocked the progression of progesterone receptor chaperoning in an in vitro functional system when Hsp90 beta was used, but did so with much less efficacy when Hsp90 alpha was used. Knockdown experiments in HeLa cells showed that GCUNC45 is required for the normal cellular distribution of Hsp90 beta, but not Hsp90 alpha. This is the first example of a co-chaperone with isoform selectivity, and this approach may open novel avenues to understanding the functional differences between Hsp90 isoforms.	[Chadli, Ahmed; Felts, Sara J.; Toft, David O.] Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Chadli, A (corresponding author), Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA.	chadli.ahmed@mayo.edu			NIDDK NIH HHS [R01 DK 4624] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barral JM, 2004, SEMIN CELL DEV BIOL, V15, P17, DOI 10.1016/j.semcdb.2003.12.010; Barral JM, 2002, SCIENCE, V295, P669, DOI 10.1126/science.1066648; Chadli A, 2006, MOL CELL BIOL, V26, P1722, DOI 10.1128/MCB.26.5.1722-1730.2006; Chadli A, 2008, BIOCHEMISTRY-US, V47, P2850, DOI 10.1021/bi7023332; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; Eustace BK, 2004, NAT CELL BIOL, V6, P507, DOI 10.1038/ncb1131; Hutagalung AH, 2002, J CELL SCI, V115, P3983, DOI 10.1242/jcs.00107; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; MENDEL DB, 1988, J BIOL CHEM, V263, P6695; Millson SH, 2007, FEBS J, V274, P4453, DOI 10.1111/j.1742-4658.2007.05974.x; MINAMI Y, 1991, J BIOL CHEM, V266, P10099; Owen BAL, 2002, J BIOL CHEM, V277, P7086, DOI 10.1074/jbc.M111450200; PERDEW GH, 1993, EXP CELL RES, V209, P350, DOI 10.1006/excr.1993.1320; Pratt WB, 2004, CELL SIGNAL, V16, P857, DOI 10.1016/j.cellsig.2004.02.004; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Price MG, 2002, J CELL SCI, V115, P4013, DOI 10.1242/jcs.00108; SARTORIUS CA, 1994, CANCER RES, V54, P3868; Sreedhar AS, 2004, FEBS LETT, V562, P11; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Te JN, 2007, J PROTEOME RES, V6, P1963, DOI 10.1021/pr060595i; Vanmuylder N, 2002, ANAT EMBRYOL, V205, P301, DOI 10.1007/s00429-002-0258-5; Voss AK, 2000, DEVELOPMENT, V127, P1; Wegele H, 2004, REV PHYSIOL BIOCH P, V151, P1, DOI 10.1007/s10254-003-0021-1; Wright L, 2004, CHEM BIOL, V11, P775, DOI 10.1016/j.chembiol.2004.03.033	24	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9509	9512		10.1074/jbc.C800017200	http://dx.doi.org/10.1074/jbc.C800017200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18285346	Green Published, hybrid			2022-12-25	WOS:000254671600003
J	Higashi, S; Miyazaki, K				Higashi, Shouichi; Miyazaki, Kaoru			Identification of amino acid residues of the matrix metalloproteinase-2 essential for its selective inhibition by beta-amyloid precursor protein-derived inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1.8-ANGSTROM CRYSTAL-STRUCTURE; TISSUE INHIBITOR; EXTRACELLULAR-MATRIX; ALZHEIMERS-DISEASE; DEGRADING METALLOPROTEINASE; 1-MATRIX METALLOPROTEINASE; IV COLLAGENASE; CELL INVASION; GELATINASE-A; SURFACE	The extracellular domain of beta-amyloid precursor protein (APP) contains an inhibitor against matrix metalloproteinase-2 (MMP-2, gelatinase A). Our previous study (Higashi, S. and Miyazaki, K. (2003) J Biol Chem 278, 14020 - 14028) demonstrated that the inhibitor is localized within the ISYGN-DALMP sequence of APP, and a synthetic decapeptide containing this sequence (named APP-derived inhibitory peptide, APP-IP) selectively inhibits the activity of MMP-2. To determine the region of interaction that correlates with the selective inhibition, we constructed various MMP-2 mutants. An MMP-2 mutant, which had the hemopexin-like domain and three fibronectin-like type II domains of MMP-2 deleted, and native MMP-2 showed similar affinities for APP-IP, suggesting that only the catalytic domain of MMP-2 is essential for the interaction. Studies of chimeric proteases, consisting of various parts of the MMP-2 catalytic domain and those of MMP-7 (matrilysin) or MMP-9 (gelatinase B), further revealed that Ala88 and Gly94 in the non-prime side and Tyr145 and Thr146 in the prime side of the substrate- binding cleft of MMP-2 contribute separately to the selective inhibition. Replacement of the amino acid residue at position 94 of a chimeric MMP mutant affected its interaction with the C-terminal Pro(10) of APP-IP, whereas that of residues 145 148 affected the interaction with Tyr(3) of the inhibitor, suggesting that the N to C direction of APP-IP relative to the substrate- binding cleft of MMP is analogous to that of propeptide in proMMP, and opposite to that of substrate. When the APP-IP sequence was added to the N terminus of the catalytic domain of MMP-2, the activity of the protease was intramolecularly inhibited. We speculate that the direction of interaction makes the active site-bound APP-IP resistant to cleavage, thereby supporting the inhibitory action of the peptide inhibitor.	[Higashi, Shouichi; Miyazaki, Kaoru] Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan	Yokohama City University	Higashi, S (corresponding author), Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Totsuka Ku, 641-12 Maioka Cho, Yokohama, Kanagawa 2440813, Japan.	shigashi@yokohama-cu.ac.jp						Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Beher D, 1996, J BIOL CHEM, V271, P1613, DOI 10.1074/jbc.271.3.1613; Betz M, 1997, EUR J BIOCHEM, V247, P356, DOI 10.1111/j.1432-1033.1997.00356.x; Brandstetter H, 2001, J BIOL CHEM, V276, P17405, DOI 10.1074/jbc.M007475200; BROWNER MF, 1995, BIOCHEMISTRY-US, V34, P6602, DOI 10.1021/bi00020a004; Caceres J, 1997, J CELL BIOCHEM, V65, P145, DOI 10.1002/(SICI)1097-4644(199705)65:2<145::AID-JCB2>3.0.CO;2-U; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Finzel BC, 1998, PROTEIN SCI, V7, P2118, DOI 10.1002/pro.5560071008; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Hamze AB, 2007, PROTEIN SCI, V16, P1905, DOI 10.1110/ps.072978507; Higashi S, 2003, BIOCHEMISTRY-US, V42, P6514, DOI 10.1021/bi020643m; Higashi S, 2003, J BIOL CHEM, V278, P14020, DOI 10.1074/jbc.M212264200; Higashi S, 1999, J BIOL CHEM, V274, P10497, DOI 10.1074/jbc.274.15.10497; Jia MC, 2000, ADV EXP MED BIOL, V476, P181; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200; KIBBEY MC, 1993, P NATL ACAD SCI USA, V90, P10150, DOI 10.1073/pnas.90.21.10150; Kihira Y, 1996, Urol Oncol, V2, P20, DOI 10.1016/1078-1439(96)00030-0; Lee MH, 2003, J BIOL CHEM, V278, P40224, DOI 10.1074/jbc.M305678200; LIOTTA LA, 1986, CANCER RES, V46, P1; MIYAZAKI K, 1990, CANCER RES, V50, P7758; MIYAZAKI K, 1993, NATURE, V362, P839, DOI 10.1038/362839a0; Morgunova E, 2002, P NATL ACAD SCI USA, V99, P7414, DOI 10.1073/pnas.102185399; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Ohsawa I, 2001, J NEUROCHEM, V76, P1411, DOI 10.1046/j.1471-4159.2001.00144.x; Oneda H, 1999, J BIOCHEM-TOKYO, V126, P905, DOI 10.1093/oxfordjournals.jbchem.a022533; Overall CM, 2006, NAT REV CANCER, V6, P227, DOI 10.1038/nrc1821; Pei DQ, 1999, CELL RES, V9, P291, DOI 10.1038/sj.cr.7290028; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Rowsell S, 2002, J MOL BIOL, V319, P173, DOI 10.1016/S0022-2836(02)00262-0; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMALL DH, 1992, J NEUROSCI, V12, P4143; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; UMENISHI F, 1990, J BIOCHEM-TOKYO, V108, P537, DOI 10.1093/oxfordjournals.jbchem.a123238; Wei S, 2003, J BIOL CHEM, V278, P9831, DOI 10.1074/jbc.M211793200; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; Yamamoto K, 2006, J BIOL CHEM, V281, P9170, DOI 10.1074/jbc.M510377200; Yana I, 2002, CLIN EXP METASTAS, V19, P209, DOI 10.1023/A:1015527220537	44	19	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					10068	10078		10.1074/jbc.M709509200	http://dx.doi.org/10.1074/jbc.M709509200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18238779	hybrid			2022-12-25	WOS:000254671600061
J	Koide, K; Ito, K; Akiyama, Y				Koide, Kayo; Ito, Koreaki; Akiyama, Yoshinori			Substrate recognition and binding by RseP, an Escherichia coli intramembrane protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENVELOPE-STRESS-RESPONSE; ANTI-SIGMA FACTOR; GAMMA-SECRETASE; SITE-2 PROTEASE; ACTIVE-SITE; PDZ DOMAIN; TRANSMEMBRANE DOMAIN; RHOMBOID PROTEASE; PROTEOLYSIS; MEMBRANE	Escherichia coli RseP belongs to the S2P family of intramembrane cleaving proteases. RseP catalyzes proteolytic cleavage of the membrane-bound anti-sigma(E) E protein RseA as an essential step in transmembrane signal transduction in the sigma(E) extracytoplasmic stress response pathway. RseP cleaves transmembrane segments of membrane proteins, but the molecular mechanisms of its substrate recognition and proteolytic action remain largely unknown. Here we analyzed interaction between RseP and substrate membrane proteins. Co-immunoprecipitation assays showed that helix-destabilizing residues in a substrate transmembrane segment, which were previously shown to be required for efficient proteolysis of the substrate by RseP, stabilize the substrate-RseP interaction. Substitutions of certain amino acid residues, including those evolutionarily conserved, in the third transmembrane region (TM3) of RseP weakened the RseP-substrate interaction. Specific combinations of Cys substitutions in RseP TM3 and in the RseA transmembrane segment led to the formation of disulfide bonds upon oxidation, suggesting that TM3 of RseP directly binds the substrate. These results provide insights into the mechanism of membrane protein proteolysis by RseP.	[Koide, Kayo; Ito, Koreaki; Akiyama, Yoshinori] Kyoto Univ, Inst Virus Res, Kyoto 6068507, Japan	Kyoto University	Akiyama, Y (corresponding author), Kyoto Univ, Inst Virus Res, Kawara Chu, Kyoto 6068507, Japan.	yakiyama@virus.kyoto-u.ac.jp			Grants-in-Aid for Scientific Research [20247020] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Ades SE, 2004, CURR OPIN MICROBIOL, V7, P157, DOI 10.1016/j.mib.2004.02.010; Akiyama Y, 2004, EMBO J, V23, P4434, DOI 10.1038/sj.emboj.7600449; AKIYAMA Y, 1995, J BIOL CHEM, V270, P23485, DOI 10.1074/jbc.270.40.23485; AKIYAMA Y, 1985, EMBO J, V4, P3351, DOI 10.1002/j.1460-2075.1985.tb04088.x; Akiyama Y, 2007, MOL MICROBIOL, V64, P1028, DOI 10.1111/j.1365-2958.2007.05715.x; Alba BM, 2004, MOL MICROBIOL, V52, P613, DOI 10.1111/j.1365-2958.2003.03982.x; Alba BM, 2002, GENE DEV, V16, P2156, DOI 10.1101/gad.1008902; Bohn C, 2004, MOL MICROBIOL, V52, P427, DOI 10.1111/j.1365-2958.2004.03985.x; Bramkamp M, 2006, MOL MICROBIOL, V62, P580, DOI 10.1111/j.1365-2958.2006.05402.x; Chaba R, 2007, GENE DEV, V21, P124, DOI 10.1101/gad.1496707; Chen JC, 2005, MOL MICROBIOL, V55, P1085, DOI 10.1111/j.1365-2958.2004.04443.x; Davis R., 1980, ADV BACTERIAL GENETI; Dobrosotskaya IY, 2002, SCIENCE, V296, P879, DOI 10.1126/science.1071124; Feng L, 2007, SCIENCE, V318, P1608, DOI 10.1126/science.1150755; Flynn JM, 2004, GENE DEV, V18, P2292, DOI 10.1101/gad.1240104; Grigorova IL, 2004, GENE DEV, V18, P2686, DOI 10.1101/gad.1238604; Ha Y, 2007, CURR OPIN STRUC BIOL, V17, P405, DOI 10.1016/j.sbi.2007.06.010; Kanehara K, 2003, EMBO J, V22, P6389, DOI 10.1093/emboj/cdg602; Kanehara K, 2001, GENE, V281, P71, DOI 10.1016/S0378-1119(01)00823-X; Kanehara K, 2002, GENE DEV, V16, P2147, DOI 10.1101/gad.1002302; Kinch LN, 2006, PROTEIN SCI, V15, P84, DOI 10.1110/ps.051766506; Koide K, 2007, J BIOL CHEM, V282, P4553, DOI 10.1074/jbc.M607339200; Kondo S, 2005, NAT CELL BIOL, V7, P186, DOI 10.1038/ncb1213; Kornilova AY, 2005, P NATL ACAD SCI USA, V102, P3230, DOI 10.1073/pnas.0407640102; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lemberg MK, 2002, MOL CELL, V10, P735, DOI 10.1016/S1097-2765(02)00655-X; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; Liu LP, 1998, J BIOL CHEM, V273, P23645, DOI 10.1074/jbc.273.37.23645; Maegawa S, 2007, MOL MICROBIOL, V64, P435, DOI 10.1111/j.1365-2958.2007.05679.x; Rudner DZ, 1999, P NATL ACAD SCI USA, V96, P14765, DOI 10.1073/pnas.96.26.14765; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sato C, 2006, J NEUROSCI, V26, P12081, DOI 10.1523/JNEUROSCI.3614-06.2006; Sawano A, 2000, Nucleic Acids Res, V28, pE78, DOI 10.1093/nar/28.16.e78; Schobel S, 2004, MOL MICROBIOL, V52, P1091, DOI 10.1111/j.1365-2958.2004.04031.x; Seegmiller AC, 2002, DEV CELL, V2, P229, DOI 10.1016/S1534-5807(01)00119-8; Tolia A, 2006, J BIOL CHEM, V281, P27633, DOI 10.1074/jbc.M604997200; Urban S, 2003, MOL CELL, V11, P1425, DOI 10.1016/S1097-2765(03)00181-3; Walsh NP, 2003, CELL, V113, P61, DOI 10.1016/S0092-8674(03)00203-4; Wang YC, 2007, J MOL BIOL, V374, P1104, DOI 10.1016/j.jmb.2007.10.014; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7; Wolfe MS, 2004, SCIENCE, V305, P1119, DOI 10.1126/science.1096187; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Ye J, 2000, P NATL ACAD SCI USA, V97, P5123, DOI 10.1073/pnas.97.10.5123; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Zhang KZ, 2006, CELL, V124, P587, DOI 10.1016/j.cell.2005.11.040	45	32	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9562	9570		10.1074/jbc.M709984200	http://dx.doi.org/10.1074/jbc.M709984200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18268014	hybrid			2022-12-25	WOS:000254671600009
J	Leclercq, TM; Moretti, PAB; Vadas, MA; Pitson, SM				Leclercq, Tamara M.; Moretti, Paul A. B.; Vadas, Mathew A.; Pitson, Stuart M.			Eukaryotic elongation factor 1A interacts with sphingosine kinase and directly enhances its catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 4-KINASE; PHOSPHOLIPASE C-GAMMA-1; MOLECULAR-CLONING; CANCER CELLS; FACTOR-I; PROTEIN; PHOSPHORYLATION; FACTOR-1-ALPHA; ACTIVATION; BINDING	Sphingosine 1-phosphate (S1P) has many important roles in mammalian cells, including contributing to the control of cell survival and proliferation. S1P is generated by sphingosine kinases (SKs), of which two mammalian isoforms have been identified (SK1 and SK2). To gain a better understanding of SK regulation, we have used a yeast two-hybrid screen to identify SK1-interacting proteins and established elongation factor 1A (eEF1A) as one such protein that associates with both SK1 and SK2. We show the direct interaction of eEF1A with the SKs in vitro, whereas the physiological relevance of this association was demonstrated by co-immunoprecipitation of the endogenous proteins from cell lysates. Although the canonical role of eEF1A resides in protein synthesis, it has also been implicated in other roles, including regulating the activity of some signaling enzymes. Thus, we examined the potential role of eEF1A in regulation of the SKs and show that eEF1A is able to directly increase the activity of SK1 and SK2 similar to 3-fold in vitro. Substrate kinetics demonstrated that eEF1A increased the catalytic rate of both SKs, while having no observable effect on substrate affinities of these enzymes for either ATP or sphingosine. Overexpression of eEF1A in quiescent Chinese hamster ovary cells increased cellular SK activity, whereas a small interfering RNA-mediated decrease in eEF1A levels in MCF7 cells substantially reduced cellular SK activity and S1P levels, supporting the in vivo physiological relevance of this interaction. Thus, this study has established a novel mechanism of regulation of both SK1 and SK2 that is mediated by their interaction with eEF1A.	[Leclercq, Tamara M.; Moretti, Paul A. B.; Vadas, Mathew A.; Pitson, Stuart M.] Inst Med & Vet Sci, Div Human Immunol, Hanson Inst, Adelaide, SA 5000, Australia; [Leclercq, Tamara M.; Pitson, Stuart M.] Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia	Hanson Institute; Institute Medical & Veterinary Science Australia; University of Adelaide	Pitson, SM (corresponding author), Inst Med & Vet Sci, Div Human Immunol, Hanson Inst, Frome Rd, Adelaide, SA 5000, Australia.	stuart.pitson@imvs.sa.gov.au	Pitson, Stuart/B-9342-2009; Vadas, Mathew/R-1378-2019	Pitson, Stuart/0000-0002-9527-2740; 				Abbott CM, 2004, TRENDS BIOCHEM SCI, V29, P25, DOI 10.1016/j.tibs.2003.11.006; Andersen GR, 2003, TRENDS BIOCHEM SCI, V28, P434, DOI 10.1016/S0968-0004(03)00162-2; Baumruker T, 2005, IMMUNOL LETT, V96, P175, DOI 10.1016/j.imlet.2004.09.001; BRANDS JHGM, 1986, EUR J BIOCHEM, V155, P167, DOI 10.1111/j.1432-1033.1986.tb09472.x; CAVALLIUS J, 1986, EXP GERONTOL, V21, P149, DOI 10.1016/0531-5565(86)90068-9; Chang JS, 2002, J BIOL CHEM, V277, P19697, DOI 10.1074/jbc.M111206200; Dapas B, 2003, EUR J BIOCHEM, V270, P3251, DOI 10.1046/j.1432-1033.2003.03713.x; Ejiri S, 2002, BIOSCI BIOTECH BIOCH, V66, P1, DOI 10.1271/bbb.66.1; French KJ, 2003, CANCER RES, V63, P5962; Fujita T, 2004, BIOCHEM J, V382, P717, DOI 10.1042/BJ20040141; Fukuda Y, 2004, BBA-MOL CELL BIOL L, V1636, P12, DOI 10.1016/j.bbalip.2003.11.006; Gangwani L, 2001, NAT CELL BIOL, V3, P376, DOI 10.1038/35070059; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; Hait NC, 2006, BBA-BIOMEMBRANES, V1758, P2016, DOI 10.1016/j.bbamem.2006.08.007; Hayashi S, 2002, J BIOL CHEM, V277, P33319, DOI 10.1074/jbc.M201442200; Hong GY, 1999, FEBS LETT, V460, P513, DOI 10.1016/S0014-5793(99)01400-3; Izawa T, 2000, BIOCHEM BIOPH RES CO, V278, P72, DOI 10.1006/bbrc.2000.3772; Jeganathan S, 2007, J BIOL CHEM, V282, P372, DOI 10.1074/jbc.M602955200; KIELBASSA K, 1995, J BIOL CHEM, V270, P6156, DOI 10.1074/jbc.270.11.6156; Kim MJ, 1999, MOL CELLS, V9, P631; Lacana E, 2002, J BIOL CHEM, V277, P32947, DOI 10.1074/jbc.M202841200; LEE S, 1994, BIOCHEM BIOPH RES CO, V203, P1371, DOI 10.1006/bbrc.1994.2336; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Ma YF, 2005, J BIOL CHEM, V280, P26011, DOI 10.1074/jbc.M409081200; Maceyka M, 2004, FEBS LETT, V568, P30, DOI 10.1016/j.febslet.2004.04.093; Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016/S1388-1981(02)00341-4; Nava VE, 2002, EXP CELL RES, V281, P115, DOI 10.1006/excr.2002.5658; Olivera A, 2006, J BIOL CHEM, V281, P2515, DOI 10.1074/jbc.M508931200; Pitson SM, 2000, BIOCHEM J, V350, P429, DOI 10.1042/0264-6021:3500429; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559; Pitson SM, 2002, J BIOL CHEM, V277, P49545, DOI 10.1074/jbc.M206687200; Roberts JL, 2004, ANAL BIOCHEM, V331, P122, DOI 10.1016/j.ab.2004.03.030; Ruwisch L, 2001, N-S ARCH PHARMACOL, V363, P358, DOI 10.1007/s002100000365; SANDERS J, 1992, NUCLEIC ACIDS RES, V109, P1113; Spiegel S, 2002, TRENDS CELL BIOL, V12, P236, DOI 10.1016/S0962-8924(02)02277-8; Sukocheva OA, 2003, MOL ENDOCRINOL, V17, P2002, DOI 10.1210/me.2003-0119; Sun JX, 2006, CIRC RES, V99, P468, DOI 10.1161/01.RES.0000239410.65551.b3; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; Thornton S, 2003, J MOL MED, V81, P536, DOI 10.1007/s00109-003-0461-8; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; Urtz N, 2004, MOL CELL BIOL, V24, P8765, DOI 10.1128/MCB.24.19.8765-8777.2004; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; YANG W, 1994, J BIOL CHEM, V269, P3852; YANG WN, 1993, J BIOL CHEM, V268, P392	46	42	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9606	9614		10.1074/jbc.M708782200	http://dx.doi.org/10.1074/jbc.M708782200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18263879	Green Published, hybrid			2022-12-25	WOS:000254671600014
J	Minami, M; Shimizu, K; Okamoto, Y; Folco, E; Ilasaca, ML; Feinberg, MW; Aikawa, M; Libby, P				Minami, Manabu; Shimizu, Koichi; Okamoto, Yoshihisa; Folco, Eduardo; Ilasaca, Marco-Lopez; Feinberg, Mark W.; Aikawa, Masanori; Libby, Peter			Prostaglandin e receptor type 4-associated protein interacts directly with NF-kappa B1 and attenuates macrophage activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TNF-ALPHA; MATRIX METALLOPROTEINASE-1; ANKYRIN REPEAT; GENE; EXPRESSION; KINASE; SIGNAL; INFLAMMATION; P105	Macrophage activation participates pivotally in the pathophysiology of chronic inflammatory diseases, including atherosclerosis. Through the receptor EP4, prostaglandin E-2 (PGE(2)) exerts an anti-inflammatory action in macrophages, suppressing stimulus-induced expression of certain proinflammatory genes, including chemokines. We recently identified a novel EP4 receptor-associated protein (EPRAP), whose function in PGE(2)-mediated anti-inflammation remains undefined. Here we demonstrate that PGE(2) pretreatment selectively inhibits lipopolysaccharide (LPS)-induced nuclear factor kappa B1 (NF-kappa B1) p105 phosphorylation and degradation in mouse bone marrow-derived macrophages through EP4-dependent mechanisms. Similarly, directed EPRAP expression in RAW264.7 cells suppresses LPS-induced p105 phosphorylation and degradation, and subsequent activation of mitogen-activated protein kinase kinase 1/2. Forced expression of EPRAP also inhibits NF-kappa B activation induced by various proinflammatory stimuli in a concentration-dependent manner. In co-transfected cells, EPRAP, which contains multiple ankyrin repeat motifs, directly interacts with NF-kappa B1 p105/p50 and forms a complex with EP4. In EP4-overexpressing cells, PGE2 enhances the protective action of EPRAP against stimulus-induced p105 phosphorylation, whereas EPRAP silencing in RAW264.7 cells impairs the inhibitory effect of PGE(2)-EP4 signaling on LPS-induced p105 phosphorylation. Additionally, EPRAP knockdown as well as deficiency of NF-kappa B1 in macrophages attenuates the inhibitory effect of PGE2 on LPS-induced MIP-1 beta production. Thus, PGE2-EP4 signaling augments NF-kappa B1 p105 protein stability through EPRAP after proinflammatory stimulation, limiting macrophage activation.	[Minami, Manabu; Shimizu, Koichi; Okamoto, Yoshihisa; Folco, Eduardo; Ilasaca, Marco-Lopez; Feinberg, Mark W.; Aikawa, Masanori; Libby, Peter] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Cardiovasc Div, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Libby, P (corresponding author), 75 Ave Louis Pasture, Boston, MA 02115 USA.	plibby@rics.bwh.harvard.edu	Libby, Peter/AAY-6404-2021; Minami, Manabu/ABA-4357-2020	Libby, Peter/0000-0002-1502-502X; Minami, Manabu/0000-0003-0052-398X; Aikawa, Masanori/0000-0002-9275-2079; Feinberg, Mark/0000-0001-9523-3859	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034636, R37HL034636] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 34636] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aikawa M, 2004, CARDIOVASC PATHOL, V13, P125, DOI 10.1016/S1054-8807(04)00004-3; Andersohn F, 2006, CIRCULATION, V113, P1950, DOI 10.1161/CIRCULATIONAHA.105.602425; AOKI M, 1993, J BIOL CHEM, V268, P22723; Beinke S, 2004, BIOCHEM J, V382, P393, DOI 10.1042/BJ20040544; Beinke S, 2004, MOL CELL BIOL, V24, P9658, DOI 10.1128/MCB.24.21.9658-9667.2004; Beinke S, 2003, MOL CELL BIOL, V23, P4739, DOI 10.1128/MCB.23.14.4739-4752.2003; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Bhattacharyya S, 2004, BLOOD, V104, P1100, DOI 10.1182/blood-2003-12-4302; Cheon H, 2006, J IMMUNOL, V177, P1092, DOI 10.4049/jimmunol.177.2.1092; Colombo MP, 2005, CANCER RES, V65, P9113, DOI 10.1158/0008-5472.CAN-05-2714; D'Acquisto F, 1998, FEBS LETT, V440, P76, DOI 10.1016/S0014-5793(98)01407-0; Driessler F, 2004, CLIN EXP IMMUNOL, V135, P64, DOI 10.1111/j.1365-2249.2004.02342.x; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Feinberg MW, 2004, CIRC RES, V94, P601, DOI 10.1161/01.RES.0000119170.70818.4F; Ferrier R, 1999, ONCOGENE, V18, P995, DOI 10.1038/sj.onc.1202374; Fushimi K, 2007, J CELL BIOCHEM, V100, P783, DOI 10.1002/jcb.21099; Giulietti A, 2001, METHODS, V25, P386, DOI 10.1006/meth.2001.1261; Gomez PF, 2005, J IMMUNOL, V175, P6924, DOI 10.4049/jimmunol.175.10.6924; Hansson GK, 2006, NAT REV IMMUNOL, V6, P508, DOI 10.1038/nri1882; Heyninck K, 1999, J CELL BIOL, V145, P1471, DOI 10.1083/jcb.145.7.1471; Hubbard NE, 2001, PROSTAG LEUKOTR ESS, V65, P287, DOI 10.1054/plef.2001.0327; Ishikawa H, 1998, J EXP MED, V187, P985, DOI 10.1084/jem.187.7.985; Jiang BB, 2001, ARTERIOSCL THROM VAS, V21, P1915, DOI 10.1161/hq1201.099424; Kabashima K, 2002, J CLIN INVEST, V109, P883, DOI 10.1172/JCI14459; Kamimura M, 2005, CIRC RES, V97, P305, DOI 10.1161/01.RES.0000177893.24574.13; Kang YJ, 2006, J IMMUNOL, V177, P8111, DOI 10.4049/jimmunol.177.11.8111; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Lang V, 2003, MOL CELL BIOL, V23, P402, DOI 10.1128/MCB.23.1.402-413.2003; Largo R, 2004, ANN RHEUM DIS, V63, P1197, DOI 10.1136/ard.2003.011163; Li JN, 2006, BIOCHEMISTRY-US, V45, P15168, DOI 10.1021/bi062188q; Li ZQ, 2003, BIOCHEM BIOPH RES CO, V309, P980, DOI 10.1016/j.bbrc.2003.08.104; Liang CP, 2007, CIRC RES, V100, P1546, DOI 10.1161/CIRCRESAHA.107.152165; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Libby P, 2007, AM J CARDIOL, V99, p27B, DOI 10.1016/j.amjcard.2006.11.004; Lu DY, 2005, MOL CELL BIOL, V25, P6570, DOI 10.1128/MCB.25.15.6570-6577.2005; Maher JF, 2005, GYNECOL ENDOCRINOL, V21, P330, DOI 10.1080/09513590500431458; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Mosavi LK, 2004, PROTEIN SCI, V13, P1435, DOI 10.1110/ps.03554604; Murakami M, 2006, CURR PHARM DESIGN, V12, P943, DOI 10.2174/138161206776055912; Nguyen MT, 1997, NATURE, V390, P78, DOI 10.1038/36342; Parameswaran N, 2006, J BIOL CHEM, V281, P34159, DOI 10.1074/jbc.M605376200; Pillinger MH, 2003, J IMMUNOL, V171, P6080, DOI 10.4049/jimmunol.171.11.6080; Poligone B, 2001, J BIOL CHEM, V276, P38658, DOI 10.1074/jbc.M106599200; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Salmeron A, 2001, J BIOL CHEM, V276, P22215, DOI 10.1074/jbc.M101754200; Samuelsson B, 2007, PHARMACOL REV, V59, P207, DOI 10.1124/pr.59.3.1; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Shinomiya S, 2001, BIOCHEM PHARMACOL, V61, P1153, DOI 10.1016/S0006-2952(01)00586-X; Sica A, 2007, J CLIN INVEST, V117, P1155, DOI 10.1172/JCI31422; Solomon SD, 2006, CIRCULATION, V114, P1028, DOI 10.1161/CIRCULATIONAHA.106.636746; SPENCE AM, 1990, CELL, V60, P981, DOI 10.1016/0092-8674(90)90346-G; STRASSMANN G, 1994, J EXP MED, V180, P2365, DOI 10.1084/jem.180.6.2365; Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200; Takayama K, 2006, CIRC RES, V98, P499, DOI 10.1161/01.RES.0000204451.88147.96; Takayama K, 2002, J BIOL CHEM, V277, P44147, DOI 10.1074/jbc.M204810200; Uematsu S, 2002, J IMMUNOL, V168, P5811, DOI 10.4049/jimmunol.168.11.5811; Ventura-Holman T, 2005, TUMOR BIOL, V26, P294, DOI 10.1159/000089261; Ventura-Holman T, 1998, GENOMICS, V54, P221, DOI 10.1006/geno.1998.5569; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; WARREN MK, 1985, J IMMUNOL, V134, P982; Waterfield MR, 2003, MOL CELL, V11, P685, DOI 10.1016/S1097-2765(03)00070-4; Yoshida K, 2002, P NATL ACAD SCI USA, V99, P4580, DOI 10.1073/pnas.062053399	65	72	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9692	9703		10.1074/jbc.M709663200	http://dx.doi.org/10.1074/jbc.M709663200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18270204	Green Published, hybrid			2022-12-25	WOS:000254671600024
J	Shibata, H; Suzuki, H; Kakiuchi, T; Inuzuka, T; Yoshida, H; Mizuno, T; Maki, M				Shibata, Hideki; Suzuki, Hironori; Kakiuchi, Takeshi; Inuzuka, Tatsutoshi; Yoshida, Haruna; Mizuno, Takako; Maki, Masatoshi			Identification of Alix-type and non-Alix-type ALG-2-binding sites in human phospholipid scramblase 3 - Differential binding to an alternatively spliced isoform and amino acid-substituted mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT INTERACTION; APOPTOSIS-LINKED GENE-2; PROTEIN ALG-2 INTERACTS; RETICULUM EXIT SITES; TRANSBILAYER MOVEMENT; TERMINAL DOMAIN; ANNEXIN-VII; EF; ALIX/AIP1; CALPAIN	ALG-2, a prototypic member of the penta-EF-hand protein family, interacts with Alix at its C-terminal Pro-rich region containing four tandem PXY repeats. Human phospholipid scramblase 3 (PLSCR3) has a similar sequence (ABS-1) in its N-terminal region. In the present study, we found that ALG-2 interacts with PLSCR3 expressed in HEK293 cells in a Ca2+-dependent manner by co-immunoprecipitation, pulldown with glutathione S-transferase (GST) fused ALG-2 and an overlay assay using biotin-labeled ALG-2. The GST fusion protein of an alternatively spliced isoform of ALG-2, GST-ALG-2(Delta GF122), pulled down green fluorescent protein (GFP)-fused PLSCR3 but not GFP Alix. Deletion of a region containing ABS-1 was not sufficient to abrogate the binding. A second ALG-2-binding site (ABS-2) was essential for interaction with ALG-2(Delta GF122). Real-time interaction analyses with a surface plasmon resonance biosensor using synthetic oligopeptides and recombinant proteins corroborated direct Ca2+-dependent binding of ABS-1 to ALG-2 and that of ABS-2 to ALG-2 as well as to ALG-2(Delta GF122). The sequence of ABS-2 contains multiple prolines and two phenylalanines, among which Phe(49) was found to be critical, because its substitution with Ala or Tyr caused a loss of binding ability by pulldown assays using oligopeptide-immobilized beads. ALG-2-interacting proteins were classified into two groups based on binding ability to ALG-2(Delta GF122): (i) isoform-non-interactive (ABS-1) types, including Alix, annexin A7, annexin A11, and TSG101 and (ii) isoform-interactive (ABS-2) types including PLSCR3, PLSCR4 and Sec31A. GST-pulldown assays using single amino acid-substituted ALG-2 mutants revealed differences in binding specificities between the two groups, suggesting structural flexibility in ALG-2-ligand complex formation.	[Shibata, Hideki; Suzuki, Hironori; Kakiuchi, Takeshi; Inuzuka, Tatsutoshi; Yoshida, Haruna; Mizuno, Takako; Maki, Masatoshi] Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Chikusa Ku, Nagoya, Aichi 4648601, Japan	Nagoya University	Maki, M (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648601, Japan.	mmaki@agr.nagoya-u.ac.jp	Maki, Masatoshi/AAM-6839-2021	Maki, Masatoshi/0000-0001-9144-5491; Suzuki, Hironori/0000-0001-9754-4992				Bahler M, 2002, FEBS LETT, V513, P107, DOI 10.1016/S0014-5793(01)03239-2; Basse F, 1996, J BIOL CHEM, V271, P17205, DOI 10.1074/jbc.271.29.17205; Brownawell AM, 1997, J BIOL CHEM, V272, P22182, DOI 10.1074/jbc.272.35.22182; Chatellard-Causse C, 2002, J BIOL CHEM, V277, P29108, DOI 10.1074/jbc.M204019200; Chen CM, 2005, BIOCHEM BIOPH RES CO, V333, P51, DOI 10.1016/j.bbrc.2005.05.074; Dikic I, 2004, BIOESSAYS, V26, P604, DOI 10.1002/bies.20068; Fisher RD, 2007, CELL, V128, P841, DOI 10.1016/j.cell.2007.01.035; He Y, 2007, J CELL BIOCHEM, V101, P1210, DOI 10.1002/jcb.21243; He YW, 2005, CANCER RES, V65, P10016, DOI 10.1158/0008-5472.CAN-05-1688; Heizmann CW, 1998, BIOMETALS, V11, P383, DOI 10.1023/A:1009212521172; Hwang IS, 2002, FEBS LETT, V529, P183, DOI 10.1016/S0014-5793(02)03329-X; Ichioka F, 2007, ARCH BIOCHEM BIOPHYS, V457, P142, DOI 10.1016/j.abb.2006.11.008; Jang IK, 2002, MOL CELL BIOL, V22, P4094, DOI 10.1128/MCB.22.12.4094-4100.2002; Jekely G, 1999, J MOL EVOL, V49, P272, DOI 10.1007/PL00006549; Jia J, 2001, STRUCTURE, V9, P267, DOI 10.1016/S0969-2126(01)00585-8; Katoh K, 2005, BIOCHEM J, V391, P677, DOI 10.1042/BJ20050398; Katoh K, 2003, J BIOL CHEM, V278, P39104, DOI 10.1074/jbc.M301604200; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kitaura Y, 2002, ARCH BIOCHEM BIOPHYS, V399, P12, DOI 10.1006/abbi.2001.2736; Kitaura Y, 2001, J BIOL CHEM, V276, P14053, DOI 10.1074/jbc.M008649200; Kowanetz K, 2003, J BIOL CHEM, V278, P39735, DOI 10.1074/jbc.M304541200; la Cour JM, 2003, AM J PATHOL, V163, P81, DOI 10.1016/S0002-9440(10)63632-2; la Cour JM, 2007, BIOCHEM BIOPH RES CO, V353, P1063, DOI 10.1016/j.bbrc.2006.12.143; Lee S, 2007, NAT STRUCT MOL BIOL, V14, P194, DOI 10.1038/nsmb1203; Li YJ, 2006, MOL CELL BIOL, V26, P3401, DOI 10.1128/MCB.26.9.3401-3413.2006; Liu JH, 2005, BIOCHEM BIOPH RES CO, V330, P865, DOI 10.1016/j.bbrc.2005.03.048; Liu JH, 2003, MOL CANCER RES, V1, P892; Lo KWH, 1999, BIOCHEMISTRY-US, V38, P7498, DOI 10.1021/bi990034n; Mahul-Mellier AL, 2006, J NEUROSCI, V26, P542, DOI 10.1523/JNEUROSCI.3069-05.2006; Maki M, 2002, BBA-PROTEINS PROTEOM, V1600, P51, DOI 10.1016/S1570-9639(02)00444-2; Maki M, 1998, J BIOCHEM, V124, P1170, DOI 10.1093/oxfordjournals.jbchem.a022235; Maki M, 1997, BIOCHEM J, V328, P718; Maki M., 2007, CALCIUM BIND PROTEIN, V2, P4; Missotten M, 1999, CELL DEATH DIFFER, V6, P124, DOI 10.1038/sj.cdd.4400456; Montaville P, 2006, BBA-MOL CELL RES, V1763, P1335, DOI 10.1016/j.bbamcr.2006.09.003; Morita E, 2004, ANNU REV CELL DEV BI, V20, P395, DOI 10.1146/annurev.cellbio.20.010403.102350; Odorizzi G, 2006, J CELL SCI, V119, P3025, DOI 10.1242/jcs.03072; Ohkouchi S, 2001, J BIOCHEM-TOKYO, V130, P207, DOI 10.1093/oxfordjournals.jbchem.a002974; Rao RV, 2004, J BIOL CHEM, V279, P177, DOI 10.1074/jbc.M304490200; Sadoul R, 2006, BIOL CELL, V98, P69, DOI 10.1042/BC20050007; Satoh H, 2002, BBA-PROTEINS PROTEOM, V1600, P61, DOI 10.1016/S1570-9639(02)00445-4; Satoh H, 2002, BIOCHEM BIOPH RES CO, V291, P1166, DOI 10.1006/bbrc.2002.6600; Schmidt MHH, 2005, J BIOL CHEM, V280, P3414, DOI 10.1074/jbc.M409839200; Shibata H, 2004, J BIOCHEM, V135, P117, DOI 10.1093/jb/mvh014; Shibata H, 2007, BIOCHEM BIOPH RES CO, V353, P756, DOI 10.1016/j.bbrc.2006.12.101; Subramanian L, 2004, BIOCHEMISTRY-US, V43, P11175, DOI 10.1021/bi048848d; SUBRAMANIAN L, 1999, BIOCHEM BIOPH RES CO, V322, P1153; TAKANO E, 1995, FEBS LETT, V362, P93, DOI 10.1016/0014-5793(95)00219-Y; Tarabykina S, 2000, J BIOL CHEM, V275, P10514, DOI 10.1074/jbc.275.14.10514; Trioulier Y, 2004, J BIOL CHEM, V279, P2046, DOI 10.1074/jbc.M309243200; Vernarecci S, 2007, MOL MICROBIOL, V65, P1122, DOI 10.1111/j.1365-2958.2007.05852.x; Verzili D, 2000, FEBS LETT, V471, P197, DOI 10.1016/S0014-5793(00)01396-X; Vito P, 1999, J BIOL CHEM, V274, P1533, DOI 10.1074/jbc.274.3.1533; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1; Wiedmer T, 2000, BBA-BIOMEMBRANES, V1467, P244, DOI 10.1016/S0005-2736(00)00236-4; Wiedmer T, 2004, P NATL ACAD SCI USA, V101, P13296, DOI 10.1073/pnas.0405354101; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WORMMEESTER J, 1990, METHOD ENZYMOL, V184, P314; Yamasaki A, 2006, MOL BIOL CELL, V17, P4876, DOI 10.1091/mbc.E06-05-0444; YANG HQ, 1994, J BIOL CHEM, V269, P18977; Yap Kyoko L., 2000, Journal of Structural and Functional Genomics, V1, P8, DOI 10.1023/A:1011320027914; Zhou QS, 2005, J BIOL CHEM, V280, P35062, DOI 10.1074/jbc.M504821200; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240	64	41	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9623	9632		10.1074/jbc.M800717200	http://dx.doi.org/10.1074/jbc.M800717200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18256029	hybrid			2022-12-25	WOS:000254671600016
J	Georis, I; Tate, JJ; Cooper, TG; Dubois, E				Georis, Isabelle; Tate, Jennifer J.; Cooper, Terrance G.; Dubois, Evelyne			Tor pathway control of the nitrogen-responsive DAL5 gene bifurcates at the level of Gln3 and Gat1 regulation in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONINE SULFOXIMINE TREATMENT; RSP5-BUL1/2 UBIQUITIN LIGASE; CATABOLITE REPRESSION; NUCLEAR-LOCALIZATION; TRANSCRIPTION FACTORS; SIGNALING PATHWAY; CARBON STARVATION; 2A PHOSPHATASES; CELL-GROWTH; NPR1 KINASE	The Tor1,2 protein kinases globally influence many cellular processes including nitrogen-responsive gene expression that correlates with intracellular localization of GATA transcription activators Gln3 and Gat1/Nil1. Gln3-Myc(13) and Gat1-Myc(13) are restricted to the cytoplasm of cells provided with good nitrogen sources, e. g. glutamine. Following the addition of the Tor1,2 inhibitor, rapamycin, both transcription factors relocate to the nucleus. Gln3-Myc(13) localization is highly dependent upon Ure2 and type 2A-related phosphatase, Sit4. Ure2 is required for Gln3 to be restricted to the cytoplasm of cells provided with good nitrogen sources, and Sit4 is required for its location to the nucleus following rapamycin treatment. The paucity of analogous information concerning Gat1 regulation prompted us to investigate the effects of deleting SIT4 and URE2 on Gat1-Myc(13) localization, DNA binding, and NCR-sensitive transcription. Our data demonstrate that Tor pathway control of NCR-responsive transcription bifurcates at the regulation of Gln3 and Gat1. Gat1-Myc(13) localization is not strongly influenced by deleting URE2, nor is its nuclear targeting following rapamycin treatment strongly dependent on Sit4. ChIP experiments demonstrated that Gat1-Myc(13) can bind to the DAL5 promoter in the absence of Gln3. Gln3-Myc(13), on the other hand, cannot bind to DAL5 in the absence of Gat1. We conclude that: ( i) Tor pathway regulation of Gat1 differs markedly from that of Gln3, ( ii) nuclear targeting of Gln3-Myc(13) is alone insufficient for its recruitment to the DAL5 promoter, and ( iii) the Tor pathway continues to play an important regulatory role in NCR-sensitive transcription even after Gln3-Myc(13) is localized to the nucleus.	[Tate, Jennifer J.; Cooper, Terrance G.] Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA; [Georis, Isabelle; Dubois, Evelyne] Univ Libre Bruxelles, Microbiol Lab, Inst Rech Microbiol JM Wiame, B-1070 Brussels, Belgium	University of Tennessee System; University of Tennessee Health Science Center; Universite Libre de Bruxelles	Cooper, TG (corresponding author), Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA.	tcooper@utmem.edu		Cooper, Terrance G./0000-0002-7651-9963	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035642] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35642, R01 GM035642-20, R01 GM035642] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bertram PG, 2000, J BIOL CHEM, V275, P35727, DOI 10.1074/jbc.M004235200; Blinder D, 1996, J BACTERIOL, V178, P4734, DOI 10.1128/jb.178.15.4734-4736.1996; Boulay A, 2005, CLIN CANCER RES, V11, P5319, DOI 10.1158/1078-0432.CCR-04-2402; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Carvalho J, 2003, J BIOL CHEM, V278, P16878, DOI 10.1074/jbc.M300429200; Coffman JA, 1996, MOL CELL BIOL, V16, P847; COFFMAN JA, 1994, J BACTERIOL, V176, P7476, DOI 10.1128/JB.176.24.7476-7483.1994; COFFMAN JA, 1995, J BACTERIOL, V177, P6910, DOI 10.1128/jb.177.23.6910-6918.1995; Cooper TG, 2004, TOP CURR GENET, V7, P225; COOPER TG, 1989, MOL CELL BIOL, V9, P5440, DOI 10.1128/MCB.9.12.5440; COTLMAN JA, 1997, J BACTERIOL, V179, P3416; Cox KH, 2004, J BIOL CHEM, V279, P10270, DOI 10.1074/jbc.M312023200; Cox KH, 2002, J BIOL CHEM, V277, P37559, DOI 10.1074/jbc.M204879200; Cox KH, 2000, J BIOL CHEM, V275, P17611, DOI 10.1074/jbc.M001648200; Crespo JL, 2004, J BIOL CHEM, V279, P37512, DOI 10.1074/jbc.M407372200; Crespo JL, 2002, P NATL ACAD SCI USA, V99, P6784, DOI 10.1073/pnas.102687599; Cunningham TS, 2000, J BIOL CHEM, V275, P14408, DOI 10.1074/jbc.275.19.14408; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; DRILLIEN R, 1972, J BACTERIOL, V109, P203, DOI 10.1128/JB.109.1.203-208.1972; DRILLIEN R, 1973, BIOCHEM BIOPH RES CO, V53, P367, DOI 10.1016/0006-291X(73)90671-2; Feller A, 2006, J BIOL CHEM, V281, P28546, DOI 10.1074/jbc.M605551200; Foury F, 2001, J BIOL CHEM, V276, P7762, DOI 10.1074/jbc.M005804200; Giannattasio S, 2005, J BIOL CHEM, V280, P42528, DOI 10.1074/jbc.M509187200; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Hofman-Bang J, 1999, MOL BIOTECHNOL, V12, P35, DOI 10.1385/MB:12:1:35; Inoki K, 2005, MICROBIOL MOL BIOL R, V69, P79, DOI 10.1128/MMBR.69.1.79-100.2005; Jacinto E, 2001, MOL CELL, V8, P1017, DOI 10.1016/S1097-2765(01)00386-0; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Kulkarni A, 2006, FEMS YEAST RES, V6, P218, DOI 10.1111/j.1567-1364.2006.00031.x; Kulkarni AA, 2001, J BIOL CHEM, V276, P32136, DOI 10.1074/jbc.M104580200; Kuruvilla FG, 2001, P NATL ACAD SCI USA, V98, P7283, DOI 10.1073/pnas.121186898; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Lorber MI, 2005, TRANSPLANTATION, V80, P244, DOI 10.1097/01.TP.0000164352.65613.24; Magasanik B, 2002, GENE, V290, P1, DOI 10.1016/S0378-1119(02)00558-9; Morgensztern D, 2005, ANTI-CANCER DRUG, V16, P797, DOI 10.1097/01.cad.0000173476.67239.3b; RAI R, 1995, YEAST, V11, P247, DOI 10.1002/yea.320110307; Rai R, 1999, J BIOL CHEM, V274, P28026, DOI 10.1074/jbc.274.39.28026; Rohde JR, 2004, MOL CELL BIOL, V24, P8332, DOI 10.1128/MCB.24.19.8332-8341.2004; Scherens B, 2006, FEMS YEAST RES, V6, P777, DOI 10.1111/j.1567-1364.2006.00060.x; Schluter Michael, 2005, Am Heart Hosp J, V3, P182, DOI 10.1111/j.1541-9215.2005.04407.x; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Tate JJ, 2007, J BIOL CHEM, V282, P18467, DOI 10.1074/jbc.M609550200; Tate JJ, 2006, J BIOL CHEM, V281, P37980, DOI 10.1074/jbc.M606973200; Tate JJ, 2006, J BIOL CHEM, V281, P28460, DOI 10.1074/jbc.M604171200; Tate JJ, 2002, J BIOL CHEM, V277, P20477, DOI 10.1074/jbc.M200962200; Tate JJ, 2003, J BIOL CHEM, V278, P36924, DOI 10.1074/jbc.M301829200; Tate JJ, 2005, J BIOL CHEM, V280, P27195, DOI 10.1074/jbc.M504052200; THOMAS G, 2004, CURRENT TOPICS MICRO; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; Wang HM, 2003, MOL BIOL CELL, V14, P4342, DOI 10.1091/mbc.E03-02-0072	51	49	51	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					8919	8929		10.1074/jbc.M708811200	http://dx.doi.org/10.1074/jbc.M708811200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18245087	Green Published, hybrid			2022-12-25	WOS:000254465800020
J	Belenky, PA; Moga, TG; Brenner, C				Belenky, Peter A.; Moga, Tiberiu G.; Brenner, Charles			Saccharomyces cerevisiae YOR071C encodes the high affinity nicotinamide riboside transporter Nrt1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NAD(+) SALVAGE PATHWAY; URACIL PERMEASE GENE; YEAST; IDENTIFICATION; BIOSYNTHESIS; DEACETYLASE; EXPRESSION; SEQUENCE; DELETION; NRK	NAD(+) is an essential coenzyme for hydride transfer enzymes and a substrate of sirtuins and other NAD(+)-consuming enzymes. Nicotinamide riboside is a recently discovered eukaryotic NAD(+) precursor converted to NAD(+) via the nicotinamide riboside kinase pathway and by nucleosidase activity and nicotinamide salvage. Nicotinamide riboside supplementation of yeast extends replicative life span on high glucose medium. The molecular basis for nicotinamide riboside uptake was unknown in any eukaryote. Here, we show that deletion of a single gene, YOR071C, abrogates nicotinamide riboside uptake without altering nicotinic acid or nicotinamide import. The gene, which is negatively regulated by Sum1, Hst1, and Rfm1, fully restores nicotinamide riboside import and utilization when resupplied to mutant yeast cells. The encoded polypeptide, Nrt1, is a predicted deca-spanning membrane protein related to the thiamine transporter, which functions as a pH-dependent facilitator with a Km for nicotinamide riboside of 22 mu M. Nrt1-related molecules are conserved in particular fungi, suggesting a similar basis for nicotinamide riboside uptake.	[Brenner, Charles] Dartmouth Med Sch, Dept Genet, Lebanon, NH 03756 USA; Dartmouth Med Sch, Dept Biochem, Lebanon, NH 03756 USA; Dartmouth Med Sch, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA	Dartmouth College; Dartmouth College; Dartmouth College; Norris Cotton Cancer Center	Brenner, C (corresponding author), Dartmouth Med Sch, Dept Genet, Lebanon, NH 03756 USA.	charles.brenner@dartmouth.edu	Brenner, Charles/D-6339-2014	Brenner, Charles/0000-0002-4955-3226				Anderson RM, 2002, J BIOL CHEM, V277, P18881, DOI 10.1074/jbc.M111773200; Bedalov A, 2003, MOL CELL BIOL, V23, P7044, DOI 10.1128/MCB.23.19.7044-7054.2003; Belenky P, 2007, TRENDS BIOCHEM SCI, V32, P12, DOI 10.1016/j.tibs.2006.11.006; Belenky P, 2007, CELL, V129, P473, DOI 10.1016/j.cell.2007.03.024; Bieganowski P, 2004, CELL, V117, P495, DOI 10.1016/S0092-8674(04)00416-7; Brachmann CB, 1998, YEAST, V14, P115; CHEVALLIER MR, 1982, EMBO J, V1, P375, DOI 10.1002/j.1460-2075.1982.tb01177.x; Damaraju VL, 2005, MOL PHARMACOL, V67, P273, DOI 10.1124/mol.104.004408; DRILLIEN R, 1972, J BACTERIOL, V109, P203, DOI 10.1128/JB.109.1.203-208.1972; Elvehjem CA, 1938, J BIOL CHEM, V123, P137; Enjo F, 1997, J BIOL CHEM, V272, P19165, DOI 10.1074/jbc.272.31.19165; Ghislain M, 2002, YEAST, V19, P215, DOI 10.1002/yea.810; Herbert M, 2003, INFECT IMMUN, V71, P5398, DOI 10.1128/IAI.71.9.5398-5401.2003; HOPKINS P, 1988, FEMS MICROBIOL LETT, V49, P173; IWASHIMA A, 1973, BIOCHIM BIOPHYS ACTA, V330, P222, DOI 10.1016/0005-2736(73)90227-7; Kahsay RY, 2005, BIOINFORMATICS, V21, P1853, DOI 10.1093/bioinformatics/bti303; Llorente B, 2000, FEBS LETT, V475, P237, DOI 10.1016/S0014-5793(00)01698-7; Ma B, 2007, MOL MICROBIOL, V66, P14, DOI 10.1111/j.1365-2958.2007.05886.x; Marchal C, 1998, MOL CELL BIOL, V18, P314, DOI 10.1128/MCB.18.1.314; McCord R, 2003, MOL CELL BIOL, V23, P2009, DOI 10.1128/MCB.23.6.2009-2016.2003; Paluszynski JP, 2006, YEAST, V23, P707, DOI 10.1002/yea.1387; PREISS J, 1958, J BIOL CHEM, V233, P493; Rongvaux A, 2002, EUR J IMMUNOL, V32, P3225, DOI 10.1002/1521-4141(200211)32:11<3225::AID-IMMU3225>3.0.CO;2-L; ROWEN JW, 1951, A J BIOL CHEM, V193, P497; Sandmeier JJ, 2002, GENETICS, V160, P877; Sasaki Y, 2006, J NEUROSCI, V26, P8484, DOI 10.1523/JNEUROSCI.2320-06.2006; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; TEMPEL W, 2007, C PLOS BIOL, V5, pE263; Vickers MF, 2000, J BIOL CHEM, V275, P25931, DOI 10.1074/jbc.M000239200; WEBER E, 1990, MOL MICROBIOL, V4, P585, DOI 10.1111/j.1365-2958.1990.tb00627.x; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; YOO HS, 1992, YEAST, V8, P997, DOI 10.1002/yea.320081202	32	53	59	4	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8075	8079		10.1074/jbc.C800021200	http://dx.doi.org/10.1074/jbc.C800021200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18258590	hybrid			2022-12-25	WOS:000254288000003
J	Meyer, B; Kuever, J				Meyer, Birte; Kuever, Jan			Homology Modeling of Dissimilatory APS Reductases (AprBA) of Sulfur-Oxidizing and Sulfate-Reducing Prokaryotes	PLOS ONE			English	Article							WOLINELLA-SUCCINOGENES QUINOL; PROTEIN STRUCTURES; WEB SERVER; DESULFOVIBRIO-DESULFURICANS; ADENYLYLSULFATE REDUCTASES; ARCHAEOGLOBUS-FULGIDUS; ISOTOPE FRACTIONATION; ANAEROBIC OXIDATION; FUMARATE REDUCTASE; CRYSTAL-STRUCTURE	The dissimilatory adenosine-5 '-phosphosulfate (APS) reductase (cofactors flavin adenine dinucleotide, FAD, and two [4Fe-4S] centers) catalyzes the transformation of APS to sulfite and AMP in sulfate-reducing prokaryotes (SRP); in sulfur-oxidizing bacteria (SOB) it has been suggested to operate in the reverse direction. Recently, the three-dimensional structure of the Archaeoglobus fulgidus enzyme has been determined in different catalytically relevant states providing insights into its reaction cycle. Methodology/Principal Findings. Full-length AprBA sequences from 20 phylogenetically distinct SRP and SOB species were used for homology modeling. In general, the average accuracy of the calculated models was sufficiently good to allow a structural and functional comparison between the beta- and alpha-subunit structures (78.8-99.3% and 89.5-96.8% of the AprB and AprA main chain atoms, respectively, had root mean square deviations below 1 angstrom with respect to the template structures). Besides their overall conformity, the SRP- and SOB-derived models revealed the existence of individual adaptations at the electron-transferring AprB protein surface presumably resulting from docking to different electron donor/acceptor proteins. These structural alterations correlated with the protein phylogeny (three major phylogenetic lineages: (1) SRP including LGT-affected Archaeoglobi and SOB of Apr lineage II, (2) crenarchaeal SRP Caldivirga and Pyrobaculum, and (3) SOB of the distinct Apr lineage I) and the presence of potential APS reductase-interacting redox complexes. The almost identical protein matrices surrounding both [4Fe-4S] clusters, the FAD cofactor, the active site channel and center within the AprB/A models of SRP and SOB point to a highly similar catalytic process of APS reduction/sulfite oxidation independent of the metabolism type the APS reductase is involved in and the species it has been originated from. Conclusions. Based on the comparative models, there are no significant structural differences between dissimilatory APS reductases from SRP and SOB; this might be indicative for a similar catalytic process of APS reduction/sulfite oxidation.	[Meyer, Birte; Kuever, Jan] Bremen Inst Mat Testing, Bremen, Germany		Kuever, J (corresponding author), Bremen Inst Mat Testing, Bremen, Germany.	kuever@mpa-bremen.de			Max-Planck-Society; German Research Foundation	Max-Planck-Society(Max Planck SocietyFoundation CELLEX); German Research Foundation(German Research Foundation (DFG))	This study was funded by the Max-Planck-Society and the German Research Foundation.	Amo Taku, 2002, Archaea, V1, P113, DOI 10.1155/2002/616075; Brune DC, 1995, ANOXYGENIC PHOTOSYNT, P847, DOI 10.1007/0-306-47954-0_39; Bruser T., 2000, ENV TECHNOLOGIES TRE, P47; Canfield DE, 2001, REV MINERAL GEOCHEM, V43, P607, DOI 10.2138/gsrmg.43.1.607; Dahl C, 2001, METHOD ENZYMOL, V331, P427; DAHL C, 1994, METHOD ENZYMOL, V243, P400; DEISENHOFER J, 1989, EMBO J, V8, P2149, DOI 10.1002/j.1460-2075.1989.tb08338.x; Fiser A, 2001, COMPUTATIONAL BIOCHEMISTRY AND BIOPHYSICS, P275; Fitz-Gibbon ST, 2002, P NATL ACAD SCI USA, V99, P984, DOI 10.1073/pnas.241636498; Fritz G, 2000, FEBS LETT, V473, P63, DOI 10.1016/S0014-5793(00)01500-3; Fritz G, 2002, P NATL ACAD SCI USA, V99, P1836, DOI 10.1073/pnas.042664399; Fritz G, 2002, J BIOL CHEM, V277, P26066, DOI 10.1074/jbc.M203397200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352; Habicht KS, 2005, APPL ENVIRON MICROB, V71, P3770, DOI 10.1128/AEM.71.7.3770-3777.2005; Habicht KS, 2001, GEOLOGY, V29, P555, DOI 10.1130/0091-7613(2001)029<0555:IFBSRN>2.0.CO;2; HANSEN TA, 1994, ANTON LEEUW INT J G, V66, P165, DOI 10.1007/BF00871638; Haveman SA, 2004, J BACTERIOL, V186, P7944, DOI 10.1128/JB.186.23.7944-7950.2004; Hipp WM, 1997, MICROBIOL-UK, V143, P2891, DOI 10.1099/00221287-143-9-2891; Hooft RWW, 1996, J APPL CRYSTALLOGR, V29, P714, DOI 10.1107/S0021889896008631; HUBER H, 2002, PROKARYOTES EVOLVING; Itoh T, 2003, J BIOSCI BIOENG, V96, P203, DOI 10.1263/jbb.96.203; Krieger E., 2003, STRUCTURAL BIOINFORM; LAMPREIA J, 1994, METHOD ENZYMOL, V243, P241; Lancaster CRD, 2003, FEBS LETT, V555, P21, DOI 10.1016/S0014-5793(03)01100-1; Lancaster CRD, 2003, ADV PROTEIN CHEM, V63, P131; Lennon BW, 1999, PROTEIN SCI, V8, P2366; LESK AM, 1986, PHILOS T R SOC A, V317, P345, DOI 10.1098/rsta.1986.0044; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; Melo F, 1998, J MOL BIOL, V277, P1141, DOI 10.1006/jmbi.1998.1665; Meyer B, 2007, MICROBIOL-SGM, V153, P3478, DOI 10.1099/mic.0.2007/008250-0; Meyer B, 2007, MICROBIOL-SGM, V153, P2026, DOI 10.1099/mic.0.2006/003152-0; MICHAELS GB, 1970, BIOCHEM BIOPH RES CO, V39, P321, DOI 10.1016/0006-291X(70)90579-6; Mussmann M, 2005, J BACTERIOL, V187, P7126, DOI 10.1128/JB.187.20.7126-7137.2005; PECK HD, 1965, BIOCHIM BIOPHYS ACTA, V96, P429, DOI 10.1016/0005-2787(65)90561-7; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; Pires RH, 2003, BBA-BIOENERGETICS, V1605, P67, DOI 10.1016/S0005-2728(03)00065-3; Poirot O, 2004, NUCLEIC ACIDS RES, V32, pW37, DOI 10.1093/nar/gkh382; Poirot O, 2003, NUCLEIC ACIDS RES, V31, P3503, DOI 10.1093/nar/gkg522; RABUS R, 1999, PROKARYOTES EVOLVING, P1; SCHEDEL M, 1980, ARCH MICROBIOL, V124, P205, DOI 10.1007/BF00427728; Schiffer A, 2006, BIOCHEMISTRY-US, V45, P2960, DOI 10.1021/bi0521689; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Schwede T, 2000, RES MICROBIOL, V151, P107, DOI 10.1016/S0923-2508(00)00121-2; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Sperling D, 2001, METHOD ENZYMOL, V331, P419; TAYLOR BF, 1994, METHOD ENZYMOL, V243, P393; TINDALL BJ, 1991, SYST APPL MICROBIOL, V14, P218, DOI 10.1016/S0723-2020(11)80371-1; TRUPER HG, 1982, PHILOS T ROY SOC B, V298, P529, DOI 10.1098/rstb.1982.0095; van Gunsteren W, 1996, BIOMOLECULAR SIMULAT	51	26	26	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1514	10.1371/journal.pone.0001514	http://dx.doi.org/10.1371/journal.pone.0001514			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SR	18231600	gold, Green Published, Green Submitted			2022-12-25	WOS:000260504200026
J	Costoya, JA; Hobbs, RM; Pandolfi, PP				Costoya, J. A.; Hobbs, R. M.; Pandolfi, P. P.			Cyclin-dependent kinase antagonizes promyelocytic leukemia zinc-finger through phosphorylation	ONCOGENE			English	Article						POZ and Kruppel-type zinc finger domains; transcriptional repression; cell cycle; cyclin-dependent kinases; PEST domains; ubiquitination	HEMATOPOIETIC STEM-CELLS; TRANSCRIPTIONAL REPRESSION; PROTEIN PLZF; DNA-BINDING; GERM-CELLS; EXPRESSION; GENE; PROLIFERATION; GROWTH	Acute promyelocytic leukemia is associated with chromosomal translocations that involve the RAR alpha gene and several distinct loci producing a variety of fusion proteins. One such fusion partner is promyelocytic leukemia zinc finger gene ( PLZF), a member of the POK ( POZ and Kruppel) family of transcriptional repressors that is a key developmental regulator, stem cell maintenance factor and tumor suppressor. Overexpression of PLZF has been shown to induce cell cycle arrest at the G(1) to S transition and repress the expression of key pro-proliferative genes such as CCNA2 and MYC. However, given this data suggesting an important growth inhibitory role for PLZF, relatively little is known regarding regulation of its activity. Here we show that the main cyclin-dependent kinase involved at the G1 to S transition ( CDK2) phosphorylates PLZF at two consensus sites found within PEST domains present in the hinge region of the protein. This phosphorylation triggers the ubiquitination and subsequent degradation of PLZF, which impairs PLZF transcriptional repression ability and antagonizes its growth inhibitory effects. This critical mechanism of PLZF regulation may thus be relevant for cell cycle progression during the development and the pathogenesis of human cancer.	[Costoya, J. A.; Hobbs, R. M.; Pandolfi, P. P.] Mem Sloan Kettering Canc Ctr, Dept Pathol, Sloan Kettering Inst, Canc Biol & Genet Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Canc Genet Program, NRB-1036E,330 Brookline Ave, Boston, MA 02215 USA.	ppandolf@bidmc.harvard.edu	Costoya, Jose A./B-2718-2009; Hobbs, Robin/I-2577-2014	Costoya, Jose A./0000-0003-3691-6419; Hobbs, Robin/0000-0002-3853-2614	NCI NIH HHS [CA-71692] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071692, R37CA071692] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barna M, 2002, DEV CELL, V3, P499, DOI 10.1016/S1534-5807(02)00289-7; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; BONIFACINO JS, 2000, CURRENT PROTOCOLS CE; BRISSETTE JL, 1991, MOL CELL BIOL, V11, P5364, DOI 10.1128/MCB.11.10.5364; Buaas FW, 2004, NAT GENET, V36, P647, DOI 10.1038/ng1366; Chao TT, 2007, BIOCHEM BIOPH RES CO, V358, P475, DOI 10.1016/j.bbrc.2007.04.157; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367; Costoya JA, 2001, CURR OPIN HEMATOL, V8, P212, DOI 10.1097/00062752-200107000-00006; Deed RW, 1997, MOL CELL BIOL, V17, P6815, DOI 10.1128/MCB.17.12.6815; Filipponi D, 2007, MOL CELL BIOL, V27, P6770, DOI 10.1128/MCB.00479-07; Guidez F, 2005, MOL CELL BIOL, V25, P5552, DOI 10.1128/MCB.25.13.5552-5566.2005; Hock H, 2004, NATURE, V431, P1002, DOI 10.1038/nature02994; Johnson TK, 1999, J BIOL CHEM, V274, P36741, DOI 10.1074/jbc.274.51.36741; Kang SI, 2003, J BIOL CHEM, V278, P51479, DOI 10.1074/jbc.M309237200; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Nanba D, 2003, J CELL BIOL, V163, P489, DOI 10.1083/jcb.200303017; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; Piazza F, 2004, MOL CELL BIOL, V24, P10456, DOI 10.1128/MCB.24.23.10456-10469.2004; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Rogatsky I, 1999, J BIOL CHEM, V274, P22296, DOI 10.1074/jbc.274.32.22296; Senbonmatsu T, 2003, EMBO J, V22, P6471, DOI 10.1093/emboj/cdg637; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Ubersax JA, 2007, NAT REV MOL CELL BIO, V8, P530, DOI 10.1038/nrm2203; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747	31	32	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2008	27	27					3789	3796		10.1038/onc.2008.7	http://dx.doi.org/10.1038/onc.2008.7			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18246121				2022-12-25	WOS:000256904700003
J	Kawase, T; Ichikawa, H; Ohta, T; Nozaki, N; Tashiro, F; Ohki, R; Taya, Y				Kawase, T.; Ichikawa, H.; Ohta, T.; Nozaki, N.; Tashiro, F.; Ohki, R.; Taya, Y.			p53 target gene AEN is a nuclear exonuclease required for p53-dependent apoptosis	ONCOGENE			English	Article						p53; exonuclease; apoptosis; p53 phosphorylation	DNA-DAMAGE; NUCLEOLAR LOCALIZATION; CANDIDATE MEDIATOR; IONIZING-RADIATION; PHOSPHORYLATION; STRESS; ROLES; DEGRADATION; DOMAINS; POINT	DNA degradation is one of the biochemical hallmarks detected in apoptotic cells, and several nucleases have been reported to function cooperatively in this process. It has also been suggested that different sets of nucleases are activated by different stimuli, and induce distinct patterns of DNA degradation. Here we report that apoptosis-enhancing nuclease ( AEN) is a novel direct target gene of p53. AEN is induced by p53 with various DNA damage, and its expression is regulated by the phosphorylation status of p53. We demonstrate that AEN is a typical exonuclease with conserved exonuclease domains Exo I-III, and it targets both single- and double-stranded DNA and RNA. AEN induces apoptosis by itself, and the conserved domains are essential for both AEN nuclease activity and its apoptosis-inducing ability. AEN possesses nuclear and nucleolar localization signals, and it translocates from the nucleolus to nucleoplasm upon apoptosis induction. We also show the dislocation of nucleophosmin in conjunction with the translocation of AEN to the nucleoplasm, indicating the ability of AEN in nucleolus disruption. In addition, AEN is shown to be required for efficient DNA fragmentation in p53-dependent apoptosis. These results suggest that AEN is an important downstream mediator of p53 in apoptosis induction.	[Ohki, R.] Natl Canc Ctr, Res Inst, Div Radiobiol, Chuo Ku, Tokyo 1040045, Japan; [Ichikawa, H.] Natl Canc Ctr, Res Inst, Canc Transcriptome Project, Tokyo 1040045, Japan; [Ohta, T.] Natl Canc Ctr, Res Inst, Ctr Med Genom, Tokyo 1040045, Japan; [Nozaki, N.] Kanagawa Dent Coll, Dept Biochem & Mol Biol, Kanagawa, Japan; [Kawase, T.; Tashiro, F.] Tokyo Univ Sci, Fac Ind Sci & Technol, Dept Biol Sci & Technol, Chiba, Japan; [Kawase, T.; Ohki, R.; Taya, Y.] Japan Sci & Technol Agcy, SORST, Chiba, Japan	National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; Kanagawa Dental College; Tokyo University of Science; Japan Science & Technology Agency (JST)	Ohki, R (corresponding author), Natl Canc Ctr, Res Inst, Div Radiobiol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	rohki@gan2.res.ncc.go.jp			Direct For Mathematical & Physical Scien [1041698] Funding Source: National Science Foundation	Direct For Mathematical & Physical Scien(National Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS))		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Blander G, 2002, J BIOL CHEM, V277, P50934, DOI 10.1074/jbc.M210479200; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chao C, 2003, J BIOL CHEM, V278, P41028, DOI 10.1074/jbc.M306938200; Cordenonsi M, 2007, SCIENCE, V315, P840, DOI 10.1126/science.1135961; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; Houseley J, 2006, NAT REV MOL CELL BIO, V7, P529, DOI 10.1038/nrm1964; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Kaeser MD, 2004, J BIOL CHEM, V279, P7598, DOI 10.1074/jbc.M311732200; Karni-Schmidt O, 2007, ONCOGENE, V26, P3878, DOI 10.1038/sj.onc.1210162; Kawane K, 2006, NATURE, V443, P998, DOI 10.1038/nature05245; Kurki S, 2004, CELL CYCLE, V3, P976; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lee JH, 2005, BIOCHEM BIOPH RES CO, V337, P39, DOI 10.1016/j.bbrc.2005.08.264; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu G, 2006, J CELL BIOCHEM, V97, P448, DOI 10.1002/jcb.20700; MacPherson D, 2004, EMBO J, V23, P3689, DOI 10.1038/sj.emboj.7600363; Mayer C, 2005, CELL CYCLE, V4, P1036, DOI 10.4161/cc.4.8.1925; Mayo LD, 2005, J BIOL CHEM, V280, P25953, DOI 10.1074/jbc.M503026200; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; Nagata S, 2003, CELL DEATH DIFFER, V10, P108, DOI 10.1038/sj.cdd.4401161; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Ohki R, 2000, J BIOL CHEM, V275, P22627, DOI 10.1074/jbc.C000235200; Ohki R, 2007, CANCER SCI, V98, P189, DOI 10.1111/j.1349-7006.2006.00375.x; Parrish JZ, 2006, CHROMOSOMA, V115, P89, DOI 10.1007/s00412-005-0038-0; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Rowland RRR, 2003, VIRUS RES, V95, P23, DOI 10.1016/S0168-1702(03)00161-8; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Saito S, 2003, J BIOL CHEM, V278, P37536, DOI 10.1074/jbc.M305135200; Samejima K, 2005, NAT REV MOL CELL BIO, V6, P677, DOI 10.1038/nrm1715; Schaetzlein S, 2007, CELL, V130, P863, DOI 10.1016/j.cell.2007.08.029; Shmueli A, 2005, CELL, V121, P963, DOI 10.1016/j.cell.2005.06.018; Sun PQ, 2007, CELL, V128, P295, DOI 10.1016/j.cell.2006.11.050; TOUNEKTI O, 1995, EXP CELL RES, V217, P506, DOI 10.1006/excr.1995.1116; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864	40	51	54	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2008	27	27					3797	3810		10.1038/onc.2008.32	http://dx.doi.org/10.1038/onc.2008.32			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18264133				2022-12-25	WOS:000256904700004
J	Tucker, LA; Zhang, Q; Sheppard, GS; Lou, P; Jiang, F; McKeegan, E; Lesniewski, R; Davidsen, SK; Bell, RL; Wang, J				Tucker, L. A.; Zhang, Q.; Sheppard, G. S.; Lou, P.; Jiang, F.; McKeegan, E.; Lesniewski, R.; Davidsen, S. K.; Bell, R. L.; Wang, J.			Ectopic expression of methionine aminopeptidase-2 causes cell transformation and stimulates proliferation	ONCOGENE			English	Article						MetAP2; transformation; proliferation; IHC	ANGIOGENESIS INHIBITOR; CLINICAL DEVELOPMENT; TNP-470 AGM-1470; GROWTH ARREST; AGENT TNP-470; TUMOR-GROWTH; FUMAGILLIN; PROTEIN; TARGET; CANCER	Methionine aminopeptidase-2 (MetAP2) processes N-terminal methionine from nascent cellular proteins. Inhibition of MetAP2 has been shown to block angiogenesis and suppress tumor growth in preclinical tumor models. However, the biological role of MetAP2 in cancer is not well understood. We examined the effect of three distinct chemical classes of MetAP2 inhibitors on the growth of a panel of human cancer cells in vitro. All MetAP2 inhibitors caused inhibition of tumor cell growth in both anchorage-dependent and, particularly, in anchorage-independent manner. These data prompted us to examine the possible roles of MetAP2 in cancers. Ectopic expression of MetAP2 in NIH-3T3 cells caused transformation, evidenced by the formation of foci in monolayer culture and growth of large colonies in soft agar. Overexpression of MetAP2 in an immortalized bronchial epithelial cell line NL20 accelerated growth. These phenotypes induced by the overexpression of MetAP2 were reversed by the treatment with MetAP2 inhibitors, indicating that the catalytic function of MetAP2 was essential. Accordingly, overexpression of a catalytically inactive MetAP2 resulted in growth retardation of HT1080 tumor cells, suggesting a dominant-negative role of the inactive MetAP2 mutant. Finally, we analysed the expression of MetAP2 in patient cancer samples by immunohistochemistry. Moderate-to-high staining was identified in the majority of breast, colon, lung, ovarian and prostate carcinomas examined. These data suggest that MetAP2 plays an important role in tumor cell growth and may contribute to tumorigenesis.	[Tucker, L. A.; Zhang, Q.; Sheppard, G. S.; Lou, P.; Jiang, F.; McKeegan, E.; Lesniewski, R.; Davidsen, S. K.; Bell, R. L.; Wang, J.] Abbott Labs, GPRD, Canc Res, Abbott Pk, IL 60064 USA	Abbott Laboratories	Wang, J (corresponding author), Abbott Labs, GPRD, Canc Res, R47A,AP9-2124,100 Abbott Pk Rd, Abbott Pk, IL 60064 USA.	jieyi.wang@abbott.com						Arner ESJ, 2006, SEMIN CANCER BIOL, V16, P420, DOI 10.1016/j.semcancer.2006.10.009; Bernier SG, 2005, J CELL BIOCHEM, V95, P1191, DOI 10.1002/jcb.20493; Bradshaw RA, 2002, ESSAYS BIOCHEM, V38, P65, DOI 10.1042/bse0380065; Bradshaw RA, 1998, TRENDS BIOCHEM SCI, V23, P263, DOI 10.1016/S0968-0004(98)01227-4; Castronovo V, 1996, EUR J CANCER, V32A, P2520, DOI 10.1016/S0959-8049(96)00388-7; Catalano A, 2001, AM J PATHOL, V159, P721, DOI 10.1016/S0002-9440(10)61743-9; Datta B, 2000, BIOCHIMIE, V82, P95, DOI 10.1016/S0300-9084(00)00383-7; Datta B, 1999, EXP CELL RES, V246, P376, DOI 10.1006/excr.1998.4313; Griffith EC, 1998, P NATL ACAD SCI USA, V95, P15183, DOI 10.1073/pnas.95.26.15183; Griffith EC, 1997, CHEM BIOL, V4, P461, DOI 10.1016/S1074-5521(97)90198-8; Hannig G, 2006, INT J ONCOL, V28, P955; Hashimoto S, 2004, P NATL ACAD SCI USA, V101, P6647, DOI 10.1073/pnas.0401753101; Homsi J, 2007, EXPERT OPIN THER TAR, V11, P91, DOI 10.1517/14728222.11.1.91; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; Kanno T, 2002, LAB INVEST, V82, P893, DOI 10.1097/01.LAB.0000020419.25365.C4; Kruger EA, 2000, EXPERT OPIN INV DRUG, V9, P1383, DOI 10.1517/13543784.9.6.1383; KUSAKA M, 1994, BRIT J CANCER, V69, P212, DOI 10.1038/bjc.1994.41; Kwon YT, 2002, SCIENCE, V297, P96, DOI 10.1126/science.1069531; Leszczyniecka M, 2006, ONCOGENE, V25, P3471, DOI 10.1038/sj.onc.1209383; Liu SP, 1998, SCIENCE, V282, P1324, DOI 10.1126/science.282.5392.1324; Lowther WT, 2000, BBA-PROTEIN STRUCT M, V1477, P157, DOI 10.1016/S0167-4838(99)00271-X; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Mieulet V, 2007, AM J PHYSIOL-CELL PH, V293, pC712, DOI 10.1152/ajpcell.00499.2006; Resh MD, 2004, SUB CELL BIOCHEM, V37, P217; Selvakumar P, 2004, CLIN CANCER RES, V10, P2771, DOI 10.1158/1078-0432.CCR-03-0218; Sheppard GS, 2006, J MED CHEM, V49, P3832, DOI 10.1021/jm0601001; Sin N, 1997, P NATL ACAD SCI USA, V94, P6099, DOI 10.1073/pnas.94.12.6099; Varshavsky A, 2005, TRENDS BIOCHEM SCI, V30, P283, DOI 10.1016/j.tibs.2005.04.005; Vetro JA, 2005, J CELL BIOCHEM, V94, P656, DOI 10.1002/jcb.20285; Wang JY, 2000, J CELL BIOCHEM, V77, P465, DOI 10.1002/(SICI)1097-4644(20000601)77:3<465::AID-JCB11>3.3.CO;2-D; Wang JY, 2003, CANCER RES, V63, P7861; Wang JY, 2003, BIOCHEMISTRY-US, V42, P5035, DOI 10.1021/bi020670c; WU SY, 1993, J BIOL CHEM, V268, P10796; Yang G, 2001, BIOCHEMISTRY-US, V40, P10645, DOI 10.1021/bi010806r; Yeh JRJ, 2006, P NATL ACAD SCI USA, V103, P10379, DOI 10.1073/pnas.0511313103; Yeh JRJ, 2000, P NATL ACAD SCI USA, V97, P12782, DOI 10.1073/pnas.97.23.12782; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P6427, DOI 10.1073/pnas.97.12.6427	37	32	37	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2008	27	28					3967	3976		10.1038/onc.2008.14	http://dx.doi.org/10.1038/onc.2008.14			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	318JZ	18264137				2022-12-25	WOS:000257089000008
J	Wheeler, DL; Huang, S; Kruser, TJ; Nechrebecki, MM; Armstrong, EA; Benavente, S; Gondi, V; Hsu, KT; Harari, PM				Wheeler, D. L.; Huang, S.; Kruser, T. J.; Nechrebecki, M. M.; Armstrong, E. A.; Benavente, S.; Gondi, V.; Hsu, K-T; Harari, P. M.			Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members	ONCOGENE			English	Article						EGFR; cetuximab; acquired resistance	GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITOR; SQUAMOUS-CELL CARCINOMA; MONOCLONAL-ANTIBODY; ANTITUMOR-ACTIVITY; DOWN-REGULATION; CANCER-CELLS; GEFITINIB; EGFR; HYPOPHOSPHORYLATION	The epidermal growth factor receptor ( EGFR) is a central regulator of proliferation and progression in human cancers. Five EGFR inhibitors, two monoclonal antibodies and three TKIs, have recently gained FDA approval in oncology ( cetuximab, panitumumab, erlotinib, gefitinib and lapatinib). These strategies of EGFR inhibition demonstrate major tumor regressions in approximately 10-20% of advanced cancer patients. However, many tumors eventually manifest acquired resistance to treatment. In this study we established and characterized a model to study molecular mechanisms of acquired resistance to the EGFR monoclonal antibody cetuximab. Using high-throughput screening we examined the activity of 42 receptor tyrosine kinases in resistant tumor cells following chronic exposure to cetuximab. Cells developing acquired resistance to cetuximab exhibited increased steady-state EGFR expression secondary to alterations in trafficking and degradation. In addition, cetuximab-resistant cells manifested strong activation of HER2, HER3 and cMET. EGFR upregulation promoted increased dimerization with HER2 and HER3 leading to their transactivation. Blockade of EGFR and HER2 led to loss of HER3 and PI( 3) K/Akt activity. These data suggest that acquired resistance to cetuximab is accompanied by dysregulation of EGFR internalization/degradation and subsequent EGFR-dependent activation of HER3. Taken together these findings suggest a rationale for the clinical evaluation of combinatorial anti-HER targeting approaches in tumors manifesting acquired resistance to cetuximab.	[Wheeler, D. L.; Huang, S.; Kruser, T. J.; Nechrebecki, M. M.; Armstrong, E. A.; Benavente, S.; Gondi, V.; Hsu, K-T; Harari, P. M.] Univ Wisconsin, Ctr Comprehens Canc, Dept Human Oncol, Sch Med & Publ Hlth, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Harari, PM (corresponding author), Univ Wisconsin, Ctr Comprehens Canc, Dept Human Oncol, Sch Med & Publ Hlth, 600 Highland Ave, Madison, WI 53792 USA.	harari@humonc.wisc.edu	Wheeler, Deric/B-7175-2013; Kruser, Timothy/AAF-2155-2020; Benavente, Sergi/B-6470-2016	Wheeler, Deric/0000-0001-5915-3675; Kruser, Timothy/0000-0002-6006-2372; Benavente, Sergi/0000-0002-2700-3522	NATIONAL CANCER INSTITUTE [R01CA113448] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 113448-01, R01 CA113448, R01 CA113448-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baselga J, 2005, J CLIN ONCOL, V23, P2445, DOI 10.1200/JCO.2005.11.890; BENAVENTE S, 2004, AACR M ABSTRACTS, V2004, pA1230; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Christensen JG, 2003, CANCER RES, V63, P7345; Ciardiello F, 2004, CLIN CANCER RES, V10, P784, DOI 10.1158/1078-0432.CCR-1100-03; Citri A, 2003, EXP CELL RES, V284, P54, DOI 10.1016/S0014-4827(02)00101-5; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Erjala K, 2006, CLIN CANCER RES, V12, P4103, DOI 10.1158/1078-0432.CCR-05-2404; Franklin MC, 2004, CANCER CELL, V5, P317, DOI 10.1016/S1535-6108(04)00083-2; Fujimoto N, 2005, CANCER RES, V65, P11478, DOI 10.1158/0008-5472.CAN-05-1977; Furukawa M, 2007, DNA CELL BIOL, V26, P178, DOI 10.1089/dna.2006.0573; GONDI V, 2006, AACR M ABSTRACTS, V2006, pB294; Grandal MV, 2007, CARCINOGENESIS, V28, P1408, DOI 10.1093/carcin/bgm058; Grovdal LM, 2004, EXP CELL RES, V300, P388, DOI 10.1016/j.yexcr.2004.07.003; Han W, 2006, CANCER BIOL THER, V5, P1361, DOI 10.4161/cbt.5.10.3226; Huang SM, 2004, CANCER RES, V64, P5355, DOI 10.1158/0008-5472.CAN-04-0562; Matar P, 2004, CLIN CANCER RES, V10, P6487, DOI 10.1158/1078-0432.CCR-04-0870; Mendelsohn J, 2003, CANCER IMMUNOL IMMUN, V52, P342, DOI 10.1007/s00262-002-0354-7; Mendelsohn J, 2006, SEMIN ONCOL, V33, P369, DOI 10.1053/j.seminoncol.2006.04.003; Mukohara T, 2005, JNCI-J NATL CANCER I, V97, P1185, DOI 10.1093/jnci/dji238; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Peruzzi B, 2006, CLIN CANCER RES, V12, P3657, DOI 10.1158/1078-0432.CCR-06-0818; Reid A, 2007, EUR J CANCER, V43, P481, DOI 10.1016/j.ejca.2006.11.007; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; Sequist LV, 2007, J CLIN ONCOL, V25, P587, DOI 10.1200/JCO.2006.07.3585; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; SUNADA H, 1986, P NATL ACAD SCI USA, V83, P3825, DOI 10.1073/pnas.83.11.3825; Zhou BBS, 2006, CANCER CELL, V10, P39, DOI 10.1016/j.ccr.2006.05.024	30	415	437	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	28					3944	3956		10.1038/onc.2008.19	http://dx.doi.org/10.1038/onc.2008.19			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	318JZ	18297114	Green Accepted			2022-12-25	WOS:000257089000006
J	Yang, HB; Pesavento, JJ; Starnes, TW; Cryderman, DE; Wallrath, LL; Kelleher, NL; Mizzen, CA				Yang, Hongbo; Pesavento, James J.; Starnes, Taylor W.; Cryderman, Diane E.; Wallrath, Lori L.; Kelleher, Neil L.; Mizzen, Craig A.			Preferential dimethylation of histone H4 lysine 20 by Suv4-20	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRITHORAX-GROUP PROTEIN; H4 LYS-20; METHYLATION; METHYLTRANSFERASE; EXPRESSION; SET8; TRIMETHYLATION; ASH1; H3; MONOMETHYLATION	Post-translational modifications of histone tails direct nuclear processes including transcription, DNA repair, and chromatin packaging. Lysine 20 of histone H4 is mono-, di-, or trimethylated in vivo, but the regulation and significance of these methylations is poorly understood. The SET domain proteins PR-Set7 and Suv4-20 have been implicated in mono- and trimethylation, respectively; however, enzymes that dimethylate lysine 20 have not been identified. Here were port that Drosophila Suv4-20 is a mixed product specificity methyltransferase that dimethylates similar to 90% and trimethylates less than 5% of total H4 at lysine 20 in S2 cells. Trimethylation, but not dimethylation, is reduced in Drosophila larvae lacking HP1, suggesting that an interaction with HP1 regulates the product specificity of Suv4-20 and enrichment of trimethyllysine 20 within heterochromatin. Similar to the Drosophila enzyme, human Suv4-20h1/h2 enzymes generate di- and trimethyllysine 20. PR-Set7 and Suv4-20 are both required for normal levels of methylation, suggesting they have non-redundant functions. Alterations in the level of lysine 20 methylation following knock-down or overexpression of Suv4- 20 did not affect lysine 16 acetylation, revealing that these two modifications are not competitive in vivo. Depletion of Suv4-20 h1/h2 in HeLa cells impaired the formation of 53BP1 foci, suggesting dimethyllysine 20 is required for a proper DNA damage response. Collectively, the data indicate that Suv4-20 generates nearly ubiquitous dimethylation that facilitates the DNA damage response and selective trimethylation that is involved in heterochromatin formation.	[Yang, Hongbo; Starnes, Taylor W.; Mizzen, Craig A.] Univ Illinois, Dept Cell & Dev Biol, Urbana, IL 61801 USA; [Pesavento, James J.] Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA; [Kelleher, Neil L.] Univ Illinois, Dept Chem, Urbana, IL 61801 USA; [Kelleher, Neil L.; Mizzen, Craig A.] Univ Illinois, Inst Genom Biol, Urbana, IL 61801 USA; [Cryderman, Diane E.; Wallrath, Lori L.] Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Iowa	Mizzen, CA (corresponding author), B107 CLSL,MC123,601 S Goodwin Ave, Urbana, IL 61801 USA.	cmizzen@life.uiuc.edu		Wallrath, Lori/0000-0002-4391-7199; Pesavento, James/0000-0001-6107-3666	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008276, R01GM061513, R01GM067193] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM067193-05S1, GM067193-06, R01 GM067193, 5T32 GM 08276, GM61513] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Beisel C, 2002, NATURE, V419, P857, DOI 10.1038/nature01126; Benetti R, 2007, J CELL BIOL, V178, P925, DOI 10.1083/jcb.200703081; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Botuyan MV, 2006, CELL, V127, P1361, DOI 10.1016/j.cell.2006.10.043; Byrd KN, 2003, P NATL ACAD SCI USA, V100, P11535, DOI 10.1073/pnas.1933593100; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Couture JF, 2005, GENE DEV, V19, P1455, DOI 10.1101/gad.1318405; DELANGE RJ, 1969, J BIOL CHEM, V244, P319; Downs JA, 2007, NATURE, V447, P951, DOI 10.1038/nature05980; Fang J, 2002, CURR BIOL, V12, P1086, DOI 10.1016/S0960-9822(02)00924-7; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Gonzalo S, 2005, NAT CELL BIOL, V7, P420, DOI 10.1038/ncb1235; Groth A, 2007, CELL, V128, P721, DOI 10.1016/j.cell.2007.01.030; Isaac CE, 2006, MOL CELL BIOL, V26, P3659, DOI 10.1128/MCB.26.9.3659-3671.2006; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jorgensen S, 2007, J CELL BIOL, V179, P1337, DOI 10.1083/jcb.200706150; Juan G, 1998, METH MOL B, V91, P67; Julien E, 2004, MOL CELL, V14, P713, DOI 10.1016/j.molcel.2004.06.008; Karachentsev D, 2005, GENE DEV, V19, P431, DOI 10.1101/gad.1263005; Kohlmaier A, 2004, PLOS BIOL, V2, P991, DOI 10.1371/journal.pbio.0020171; Kourmouli N, 2004, J CELL SCI, V117, P2491, DOI 10.1242/jcs.01238; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Nabatiyan A, 2006, MOL CELL BIOL, V26, P1839, DOI 10.1128/MCB.26.5.1839-1849.2006; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; Pesavento JJ, 2008, MOL CELL BIOL, V28, P468, DOI 10.1128/MCB.01517-07; Pesavento JJ, 2007, MOL CELL PROTEOMICS, V6, P1510, DOI 10.1074/mcp.M600404-MCP200; Pesavento JJ, 2006, ANAL CHEM, V78, P4271, DOI 10.1021/ac0600050; Rayasam GV, 2003, EMBO J, V22, P3153, DOI 10.1093/emboj/cdg288; Rice JC, 2002, GENE DEV, V16, P2225, DOI 10.1101/gad.1014902; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Sakaguchi A, 2007, J CELL BIOL, V176, P155, DOI 10.1083/jcb.200607178; Sanders SL, 2004, CELL, V119, P603, DOI 10.1016/j.cell.2004.11.009; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Shi XB, 2007, MOL CELL, V27, P636, DOI 10.1016/j.molcel.2007.07.012; Sims JK, 2006, J BIOL CHEM, V281, P12760, DOI 10.1074/jbc.M513462200; Talasz H, 2005, J BIOL CHEM, V280, P38814, DOI 10.1074/jbc.M505563200; Tanaka Y, 2007, GENE, V397, P161, DOI 10.1016/j.gene.2007.04.027; Tardat M, 2007, J CELL BIOL, V179, P1413, DOI 10.1083/jcb.200706179; Tryndyak VP, 2006, CANCER BIOL THER, V5, P65, DOI 10.4161/cbt.5.1.2288; Vakoc CR, 2006, MOL CELL BIOL, V26, P9185, DOI 10.1128/MCB.01529-06; Xiao B, 2005, GENE DEV, V19, P1444, DOI 10.1101/gad.1315905; Yin YL, 2005, J BIOL CHEM, V280, P30025, DOI 10.1074/jbc.M501691200	47	102	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2008	283	18					12085	12092		10.1074/jbc.M707974200	http://dx.doi.org/10.1074/jbc.M707974200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	293MS	18296440	hybrid, Green Accepted, Green Published			2022-12-25	WOS:000255340000024
J	To, C; Kulkarni, S; Pawson, T; Honda, T; Gribble, GW; Sporn, MB; Wrana, JL; Di Guglielmo, GM				To, Ciric; Kulkarni, Sarang; Pawson, Tony; Honda, Tadashi; Gribble, Gordon W.; Sporn, Michael B.; Wrana, Jeffrey L.; Di Guglielmo, Gianni M.			The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid-imidazolide alters transforming growth factor beta-dependent signaling and cell migration by affecting the cytoskeleton and the polarity complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR ACTIVATION SARA; FYVE DOMAIN PROTEIN; BREAST-CANCER CELLS; TGF-BETA; UBIQUITIN LIGASE; EPITHELIAL-CELLS; EARLY ENDOSOMES; MICROTUBULE DYNAMICS; ENDOTHELIAL-CELLS; CDDO-IMIDAZOLIDE	The anti-tumor synthetic triterpenoid 2-cyano-3,12-dioxooleana1,9-dien-28-oic acid (CDDO)-imidazolide (CDDO-Im) ectopically activates the transforming growth factor beta (TGF beta)-Smad pathway and extends the duration of signaling by an undefined mechanism. Here we show that CDDO-Im-dependent persistence of Smad2 phosphorylation is independent of Smad2 phosphatase activity and correlates with delayed TGF beta receptor degradation and trafficking. Altered TGF beta trafficking parallels the dispersal of EEA1-positive endosomes from the perinuclear region of CDDO-Im-treated cells. The effect of CDDO-Im on the EEA1 compartment led to an analysis of the cytoskeleton, and we observed that CDDO-Im alters microtubule dynamics by disrupting the microtubule-capping protein, Clip-170. Interestingly, biotinylated triterpenoid was found to localize to the polarity complex at the leading edge of migrating cells. Furthermore, CDDO-Im disrupted the localization of IQGAP1, PKC zeta, Par6, and TGF beta receptors from the leading edge of migrating cells and inhibited TGF beta-dependent cell migration. Thus, the synthetic triterpenoid CDDO-Im interferes with TGF beta receptor trafficking and turnover and disrupts cell migration by severing the link between members of the polarity complex and the microtubule network.	[To, Ciric; Di Guglielmo, Gianni M.] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada; [Kulkarni, Sarang; Pawson, Tony; Wrana, Jeffrey L.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Programme Mol Biol & Canc, Toronto, ON M5G 1X5, Canada; [Honda, Tadashi; Gribble, Gordon W.] Dartmouth Coll, Dept Chem, Hanover, NH 03755 USA; [Sporn, Michael B.] Dartmouth Med Sch, Dept Pharmacol, Hanover, NH 03755 USA	Western University (University of Western Ontario); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Dartmouth College; Dartmouth College	Di Guglielmo, GM (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, Med Sci Bldg, London, ON N6A 5C1, Canada.	john.diguglielmo@schulich.uwo.ca	Pawson, Tony J/E-4578-2013; Wrana, Jeffrey/F-8857-2013; To, Ciric/AAE-7406-2019		NATIONAL CANCER INSTITUTE [P30CA023108, R01CA078814] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA078814, R01 CA78814, P30 CA023108] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Apodaca G, 2001, TRAFFIC, V2, P149, DOI 10.1034/j.1600-0854.2001.020301.x; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Barrios-Rodiles M, 2005, SCIENCE, V307, P1621, DOI 10.1126/science.1105776; Bose R, 2006, CURR OPIN CELL BIOL, V18, P206, DOI 10.1016/j.ceb.2006.02.005; Burkhardt JK, 1998, BBA-MOL CELL RES, V1404, P113, DOI 10.1016/S0167-4889(98)00052-4; Chen CL, 2006, J BIOL CHEM, V281, P11506, DOI 10.1074/jbc.M512821200; Cong F, 2004, P NATL ACAD SCI USA, V101, P2882, DOI 10.1073/pnas.0307344101; Contin MA, 1999, BIOCHEM J, V339, P463, DOI 10.1042/0264-6021:3390463; Couch RD, 2006, MOL PHARMACOL, V69, P1158, DOI 10.1124/mol.105.018572; DArrigo A, 1997, EUR J CELL BIOL, V72, P95; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; Galjart N, 2003, CURR OPIN CELL BIOL, V15, P48, DOI 10.1016/S0955-0674(02)00007-8; Galjart N, 2005, NAT REV MOL CELL BIO, V6, P487, DOI 10.1038/nrm1664; Goode BL, 2000, CURR OPIN CELL BIOL, V12, P63, DOI 10.1016/S0955-0674(99)00058-7; Hayes S, 2002, J CELL BIOL, V158, P1239, DOI 10.1083/jcb.200204088; Hyer ML, 2005, CANCER RES, V65, P4799, DOI 10.1158/0008-5472.CAN-04-3319; Ito T, 2004, J BIOL CHEM, V279, P25326, DOI 10.1074/jbc.M403135200; Itoh F, 2002, GENES CELLS, V7, P321, DOI 10.1046/j.1365-2443.2002.00519.x; Ji Y, 2006, MOL CANCER THER, V5, P1452, DOI 10.1158/1535-7163.MCT-06-0136; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Lapillonne H, 2003, CANCER RES, V63, P5926; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Levy L, 2005, MOL CELL BIOL, V25, P8108, DOI 10.1128/MCB.25.18.8108-8125.2005; Liby KT, 2007, NAT REV CANCER, V7, P357, DOI 10.1038/nrc2129; Lin HK, 2004, NATURE, V431, P205, DOI 10.1038/nature02783; Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044; Miura S, 2000, MOL CELL BIOL, V20, P9346, DOI 10.1128/MCB.20.24.9346-9355.2000; Mix KS, 2004, MOL PHARMACOL, V65, P309, DOI 10.1124/mol.65.2.309; Mundy DI, 2002, J CELL SCI, V115, P4327, DOI 10.1242/jcs.00117; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Murray JW, 2003, ADV DRUG DELIVER REV, V55, P1385, DOI 10.1016/j.addr.2003.07.008; Musch A, 2004, TRAFFIC, V5, P1, DOI 10.1046/j.1600-0854.2003.00149.x; Ogunjimi AA, 2005, MOL CELL, V19, P297, DOI 10.1016/j.molcel.2005.06.028; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Panopoulou E, 2002, J BIOL CHEM, V277, P18046, DOI 10.1074/jbc.M107983200; Pardali K, 2007, BBA-REV CANCER, V1775, P21, DOI 10.1016/j.bbcan.2006.06.004; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Pearson CG, 2004, NAT REV MOL CELL BIO, V5, P481, DOI 10.1038/nrm1402; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Perez F, 1999, CELL, V96, P517, DOI 10.1016/S0092-8674(00)80656-X; Place AE, 2003, CLIN CANCER RES, V9, P2798; Pol A, 2004, MOL BIOL CELL, V15, P99, DOI 10.1091/mbc.E03-06-0368; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Runyan CE, 2005, J BIOL CHEM, V280, P8300, DOI 10.1074/jbc.M407939200; Schwartz EA, 2005, BIOCHEM J, V390, P199, DOI 10.1042/BJ20041182; Siegrist SE, 2007, GENE DEV, V21, P483, DOI 10.1101/gad.1511207; Sporn MB, 2006, CYTOKINE GROWTH F R, V17, P3, DOI 10.1016/j.cytogfr.2005.09.012; Suh N, 2003, CANCER RES, V63, P1371; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tirnauer JS, 2000, J CELL BIOL, V149, P761, DOI 10.1083/jcb.149.4.761; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Verrills NM, 2005, CURR PHARM DESIGN, V11, P1719, DOI 10.2174/1381612053764706; Wang HR, 2006, METHOD ENZYMOL, V406, P437, DOI 10.1016/S0076-6879(06)06032-0; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Watanabe T, 2004, DEV CELL, V7, P871, DOI 10.1016/j.devcel.2004.10.017; Xu Z, 2003, CELL RES, V13, P343, DOI 10.1038/sj.cr.7290179; Yingling JM, 2004, NAT REV DRUG DISCOV, V3, P1011, DOI 10.1038/nrd1580; Yore MM, 2006, MOL CANCER THER, V5, P3232, DOI 10.1158/1535-7163.MCT-06-0444; Zhang XL, 2005, J BIOL CHEM, V280, P12239, DOI 10.1074/jbc.M413284200; Zhang Y, 2004, CELL CYCLE, V3, P391	63	28	43	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11700	11713		10.1074/jbc.M704064200	http://dx.doi.org/10.1074/jbc.M704064200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18283107	Green Published, hybrid			2022-12-25	WOS:000255067400070
J	Katsoulidis, E; Sassano, A; Majchrzak-Kita, B; Carayol, N; Yoon, P; Jordan, A; Druker, BJ; Fish, EN; Platanias, LC				Katsoulidis, Efstratios; Sassano, Antonella; Majchrzak-Kita, Beata; Carayol, Nathalie; Yoon, Patrick; Jordan, Alison; Druker, Brian J.; Fish, Eleanor N.; Platanias, Leonidas C.			Suppression of interferon (IFN)-inducible genes and IFN-mediated functional responses in BCR-ABL-expressing cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MYELOGENOUS LEUKEMIA-CELLS; CHRONIC MYELOID-LEUKEMIA; ALPHA/BETA-RECEPTOR INTERACTIONS; IMATINIB MESYLATE STI571; P70 S6 KINASE; I INTERFERONS; TYROSINE PHOSPHORYLATION; JAK-STAT; PHOSPHATIDYLINOSITOL 3-KINASE	The interferons (IFNs) are cytokines that play key roles in host defense against viral infections and immune surveillance against cancer. We report that BCR-ABL transformation of hematopoietic cells results in suppression of IFN-dependent responses, including transcription of IFN-inducible genes and generation of IFN-mediated antiviral effects. BCR-ABL transformation suppresses expression of several IFN-regulated genes containing IFN-sensitive response element (ISRE) or GAS elements in their promoters, including Isg15, Irf1, Irf9, and Ifit2 (interferon-induced protein with tetratricopeptide repeats 2). Suppression of transcription of ISRE-containing genes is also seen in cells expressing various BCR-ABL kinase domain mutants, including T315I, H396P, Y253F, and E255K, but not kinase-defective BCR-ABL. Such effects are associated with impaired IFN-dependent phosphorylation of Stat1 on Tyr(701) and Stat3 on Tyr(705) and defective binding of Stat complexes to ISRE or GAS elements. Beyond suppression of Stat activities, BCR-ABL inhibits IFN-inducible phosphorylation/activation of the p38 MAPK, suggesting a dual mechanism by which this abnormal fusion protein blocks IFN transcriptional responses. The inhibitory activities of BCR-ABL ultimately result in impaired IFN alpha-mediated protection against encephalomyocarditis virus infection and reversal of IFN-dependent growth suppression. Altogether, our data provide evidence for a novel mechanism by which BCR-ABL impairs host defenses and promotes malignant transformation, involving dual suppression of IFN-activated signaling pathways.	[Katsoulidis, Efstratios; Sassano, Antonella; Carayol, Nathalie; Yoon, Patrick; Jordan, Alison; Platanias, Leonidas C.] Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Katsoulidis, Efstratios; Sassano, Antonella; Carayol, Nathalie; Yoon, Patrick; Jordan, Alison; Platanias, Leonidas C.] Northwestern Univ, Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA; [Katsoulidis, Efstratios; Sassano, Antonella; Carayol, Nathalie; Yoon, Patrick; Jordan, Alison; Platanias, Leonidas C.] Lakeside Vet Adm Med Ctr, Chicago, IL 60611 USA; [Majchrzak-Kita, Beata; Fish, Eleanor N.] Univ Hlth Network, Toronto Res Inst, Div Cell & Mol Biol, Toronto, ON M5G 2M1, Canada; [Majchrzak-Kita, Beata; Fish, Eleanor N.] Univ Toronto, Dept Immunol, Toronto, ON M5G 2M1, Canada; [Druker, Brian J.] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97239 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Oregon Health & Science University	Platanias, LC (corresponding author), Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, 710 N Fairbanks St,Olson 8250, Chicago, IL 60611 USA.	l-platanias@northwestern.edu		Druker, Brian/0000-0001-8331-8206	NCI NIH HHS [CA100579, CA77816, CA121192] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA121192, R01CA077816, R01CA100579] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Barnes B, 2002, J INTERF CYTOK RES, V22, P59, DOI 10.1089/107999002753452665; Bassermann F, 2002, J BIOL CHEM, V277, P12437, DOI 10.1074/jbc.M112397200; BEN NY, 1986, SCIENCE, V233, P212; Brierley MM, 2002, J INTERF CYTOK RES, V22, P835, DOI 10.1089/107999002760274845; Brierley MM, 2005, J INTERF CYTOK RES, V25, P733, DOI 10.1089/jir.2005.25.733; Coppo P, 2006, BRIT J HAEMATOL, V134, P171, DOI 10.1111/j.1365-2141.2006.06161.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; de Lavallade H, 2007, BLOOD, V110, P2779, DOI 10.1182/blood-2007-06-094508; Deonarain R, 2002, CURR PHARM DESIGN, V8, P2131, DOI 10.2174/1381612023393288; Dorn A, 2005, J VIROL, V79, P2404, DOI 10.1128/JVI.79.4.2404-2412.2005; DRUKER B, 1992, BLOOD, V79, P2215; Fish EN, 1999, J BIOL CHEM, V274, P571, DOI 10.1074/jbc.274.2.571; Galligan CL, 2006, IMMUNOL RES, V35, P27, DOI 10.1385/IR:35:1:27; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; Grandvaux N, 2002, CURR OPIN INFECT DIS, V15, P259, DOI 10.1097/00001432-200206000-00008; Griswold IJ, 2006, MOL CELL BIOL, V26, P6082, DOI 10.1128/MCB.02202-05; Grumbach IM, 2001, BRIT J HAEMATOL, V112, P327, DOI 10.1046/j.1365-2141.2001.02556.x; Hochhaus A, 1997, LEUKEMIA, V11, P933, DOI 10.1038/sj.leu.2400723; Honda K, 2006, NAT REV IMMUNOL, V6, P644, DOI 10.1038/nri1900; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Katsoulidis E, 2005, J INTERF CYTOK RES, V25, P749, DOI 10.1089/jir.2005.25.749; Katze MG, 2002, NAT REV IMMUNOL, V2, P675, DOI 10.1038/nri888; Kaur S, 2005, J INTERF CYTOK RES, V25, P780, DOI 10.1089/jir.2005.25.780; Kaur S, 2007, J BIOL CHEM, V282, P1757, DOI 10.1074/jbc.M607365200; Kharas NG, 2005, CANCER RES, V65, P2047, DOI 10.1158/0008-5472.CAN-04-3888; Landolfo S, 2000, Hematol J, V1, P7, DOI 10.1038/sj.thj.6200004; Lekmine F, 2003, J BIOL CHEM, V278, P27772, DOI 10.1074/jbc.M301364200; Ly C, 2003, CANCER RES, V63, P5716; Malakhova OA, 2003, GENE DEV, V17, P455, DOI 10.1101/gad.1056303; Martensen PM, 2004, J INTERF CYTOK RES, V24, P1, DOI 10.1089/107999004772719864; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; Mayer IA, 2001, J BIOL CHEM, V276, P28570, DOI 10.1074/jbc.M011685200; Mohi MG, 2004, P NATL ACAD SCI USA, V101, P3130, DOI 10.1073/pnas.0400063101; Parmar S, 2005, BLOOD, V106, P2436, DOI 10.1182/blood-2004-10-4003; Parmar S, 2004, J BIOL CHEM, V279, P25345, DOI 10.1074/jbc.M400590200; Paun A, 2007, ADV VIRUS RES, V69, P1, DOI 10.1016/S0065-3527(06)69001-5; Pestka S, 2004, IMMUNOL REV, V202, P8, DOI 10.1111/j.0105-2896.2004.00204.x; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; Platanias LC, 2003, PHARMACOL THERAPEUT, V98, P129, DOI 10.1016/S0163-7258(03)00016-0; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Ramaraj P, 2004, CANCER RES, V64, P5322, DOI 10.1158/0008-5472.CAN-03-3656; Rhodes J, 2000, EXP HEMATOL, V28, P305, DOI 10.1016/S0301-472X(99)00148-4; Ritchie KJ, 2004, NAT MED, V10, P1374, DOI 10.1038/nm1133; Ritchie KJ, 2004, SEMIN CELL DEV BIOL, V15, P237, DOI 10.1016/j.semcdb.2003.12.005; Saha S, 2006, J GEN VIROL, V87, P3285, DOI 10.1099/vir.0.82107-0; Sakai I, 2002, BLOOD, V100, P2926, DOI 10.1182/blood-2002-01-0073; Sattler M, 1997, ONCOGENE, V15, P2379, DOI 10.1038/sj.onc.1201422; Sattler M, 1996, ONCOGENE, V12, P839; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Smith JB, 1996, ARCH BIOCHEM BIOPHYS, V330, P290, DOI 10.1006/abbi.1996.0256; Srivastava KK, 2004, J BIOL CHEM, V279, P29911, DOI 10.1074/jbc.M401997200; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Steelman LS, 2004, LEUKEMIA, V18, P189, DOI 10.1038/sj.leu.2403241; Terenzi F, 2005, VIROLOGY, V340, P116, DOI 10.1016/j.virol.2005.06.011; Theofilopoulos AN, 2005, ANNU REV IMMUNOL, V23, P307, DOI 10.1146/annurev.immunol.23.021704.115843; Tzoanopoulos D, 2002, BRIT J HAEMATOL, V119, P46, DOI 10.1046/j.1365-2141.2002.03829.x; Uddin S, 2000, J BIOL CHEM, V275, P27634; Uddin S, 1997, J IMMUNOL, V158, P2390; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; Uddin S, 2002, J BIOL CHEM, V277, P14408, DOI 10.1074/jbc.M109671200; van Boxel-Dezaire AHH, 2006, IMMUNITY, V25, P361, DOI 10.1016/j.immuni.2006.08.014; Verma A, 2002, LEUKEMIA LYMPHOMA, V43, P703, DOI 10.1080/10428190290016782; Verma A, 2002, J BIOL CHEM, V277, P7726, DOI 10.1074/jbc.M106640200; Wong S, 2003, BLOOD, V101, P4088, DOI 10.1182/blood-2002-11-3376; Yan M, 2007, BLOOD, V110, P305, DOI 10.1182/blood-2006-07-033209	73	20	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10793	10803		10.1074/jbc.M706816200	http://dx.doi.org/10.1074/jbc.M706816200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18287094	hybrid, Green Published			2022-12-25	WOS:000254894700062
J	Lawrence, AD; Deery, E; McLean, KJ; Munro, AW; Pickersgill, RW; Rigby, SEJ; Warren, MJ				Lawrence, Andrew D.; Deery, Evelyne; McLean, Kirsty J.; Munro, Andrew W.; Pickersgill, Richard W.; Rigby, Stephen E. J.; Warren, Martin J.			Identification, characterization, and structure/function analysis of a corrin reductase involved in adenosylcobalamin biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-PROTEIN COMPONENT ENZYME; PSEUDOMONAS-DENITRIFICANS; ESCHERICHIA-COLI; COB(I)ALAMIN ADENOSYLTRANSFERASE; RESONANCE SPECTROSCOPY; SALMONELLA-TYPHIMURIUM; COBALAMIN; REFINEMENT; 3-MONOOXYGENASE; VITAMIN-B-12	Vitamin B-12, the antipernicious anemia factor, is the cyano derivative of adenosylcobalamin, which is one of nature's most complex coenzymes. Adenosylcobalamin is made along one of two similar yet distinct metabolic pathways, which are referred to as the aerobic and anaerobic routes. The aerobic pathway for cobalamin biosynthesis proceeds via cobalt insertion into a ring-contracted macrocycle, which is closely followed by adenosylation of the cobalt ion. An important prerequisite for adenosylation is the reduction of the centrally chelated metal from Co(II) to a highly nucleophilic Co(I) form. We have cloned a gene, cobR, encoding a biosynthetic enzyme with this co(II)rrin reductase activity from Brucella melitensis. The protein has been overproduced, and the resulting flavoprotein has been purified, characterized, and crystallized and its structure determined to 1.6 angstrom resolution. Kinetic and EPR analysis reveals that the enzyme proceeds via a semiquinone form. It is proposed that CobR may interact with the adenosyltransferase to overcome the large thermodynamic barrier required for co(II)rrin reduction.	[Pickersgill, Richard W.; Rigby, Stephen E. J.] Univ London, Sch Biol & Chem Sci, London E1 4NS, England; [Lawrence, Andrew D.; Deery, Evelyne; Warren, Martin J.] Univ Kent, Dept Biosci, Prot Sci Grp, Canterbury CT2 7NJ, Kent, England; [McLean, Kirsty J.; Munro, Andrew W.] Univ Manchester, Manchester Interdisciplinary Bioctr, Fac Life Sci, Manchester M1 7DN, Lancs, England	University of London; University of Kent; University of Manchester	Pickersgill, RW (corresponding author), Univ London, Sch Biol & Chem Sci, Mile End Rd, London E1 4NS, England.	r.w.pickersgill@qmul.ac.uk; m.j.warren@kent.ac.uk	McLean, Kirsty J/GXI-2853-2022; Munro, Andrew/G-5639-2019	Munro, Andrew/0000-0002-4642-180X; McLean, Kirsty/0000-0002-7193-5044; Warren, Martin/0000-0002-6028-6456	BBSRC [BB/E002137/1, BB/E002889/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/E002889/1, BB/E002137/1] Funding Source: Medline	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ARUNACHALAM U, 1992, J BIOL CHEM, V267, P25848; Banerjee R, 2003, ANNU REV BIOCHEM, V72, P209, DOI 10.1146/annurev.biochem.72.121801.161828; Bauer CB, 2001, BIOCHEMISTRY-US, V40, P361, DOI 10.1021/bi002145o; BLANCHE F, 1995, ANGEW CHEM INT EDIT, V34, P383, DOI 10.1002/anie.199503831; BLANCHE F, 1992, J BACTERIOL, V174, P7452, DOI 10.1128/jb.174.22.7452-7454.1992; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; CROUZET J, 1991, J BACTERIOL, V173, P6074, DOI 10.1128/jb.173.19.6074-6087.1991; DEBUSSCHE L, 1993, J BACTERIOL, V175, P7430, DOI 10.1128/JB.175.22.7430-7440.1993; DEBUSSCHE L, 1991, J BACTERIOL, V173, P6300, DOI 10.1128/jb.173.19.6300-6302.1991; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DELANO WL, 2002, PYMOL MOL GRAPHICS; Dutton P L, 1978, Methods Enzymol, V54, P411; ESCALANTESEMERENA JC, 1990, J BACTERIOL, V172, P273, DOI 10.1128/JB.172.1.273-280.1990; Fonseca MV, 2001, J BIOL CHEM, V276, P32101, DOI 10.1074/jbc.M102510200; Fonseca MV, 2000, J BACTERIOL, V182, P4304, DOI 10.1128/JB.182.15.4304-4309.2000; Galan B, 2000, J BACTERIOL, V182, P627, DOI 10.1128/JB.182.3.627-636.2000; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kay CWM, 1999, BIOCHEMISTRY-US, V38, P16740, DOI 10.1021/bi991442u; Kim SH, 2003, ACTA CRYSTALLOGR D, V59, P2275, DOI 10.1107/S0907444903020821; KURRECK H, 1984, J AM CHEM SOC, V106, P737, DOI 10.1021/ja00315a048; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB; LEXA D, 1983, ACCOUNTS CHEM RES, V16, P235, DOI 10.1021/ar00091a001; Ludwig ML, 1997, BIOCHEMISTRY-US, V36, P1259, DOI 10.1021/bi962180o; MCCONNELL HM, 1956, J CHEM PHYS, V24, P764, DOI 10.1063/1.1742605; MULLER F, 1970, EUR J BIOCHEM, V14, P185, DOI 10.1111/j.1432-1033.1970.tb00277.x; Munro AW, 2001, BIOCHEMISTRY-US, V40, P1956, DOI 10.1021/bi001718u; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Okai M, 2006, BIOCHEMISTRY-US, V45, P5103, DOI 10.1021/bi052313i; Ost TWB, 2001, BIOCHEMISTRY-US, V40, P13421, DOI 10.1021/bi010716m; Palmer G., 1971, FLAVINS FLAVOPROTEIN, P123; Pratt J. M., 1999, Chemistry and biochemistry of B12., P113; PRIETO MA, 1994, J BIOL CHEM, V269, P22823; Sampson EM, 2005, MICROBIOL-SGM, V151, P1169, DOI 10.1099/mic.0.27755-0; Stich TA, 2005, J AM CHEM SOC, V127, P8710, DOI 10.1021/ja042142p; Thomas MG, 2000, J BACTERIOL, V182, P4227, DOI 10.1128/JB.182.15.4227-4233.2000; van den Heuvel RHH, 2004, J BIOL CHEM, V279, P12860, DOI 10.1074/jbc.M313765200; Warren MJ, 2002, NAT PROD REP, V19, P390, DOI 10.1039/B108967F; WEILBACHER E, 1988, MAGN RESON CHEM, V26, P64, DOI 10.1002/mrc.1260260115	40	21	21	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10813	10821		10.1074/jbc.M710431200	http://dx.doi.org/10.1074/jbc.M710431200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18263579	hybrid			2022-12-25	WOS:000254894700064
J	Taylor, AB; Hu, G; Hart, PJ; McAlister-Henn, L				Taylor, Alexander B.; Hu, Gang; Hart, P. John; McAlister-Henn, Lee			Allosteric motions in structures of yeast NAD(+)-specific isocitrate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; SACCHAROMYCES-CEREVISIAE; ANOMALOUS DIFFRACTION; BINDING-SITES; 3-DIMENSIONAL STRUCTURE; THERMUS-THERMOPHILUS; COMPARATIVE GENOMICS; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; KINETIC-ANALYSIS	Mitochondrial NAD(+)-specific isocitrate dehydrogenases (IDHs) are key regulators of flux through biosynthetic and oxidative pathways in response to cellular energy levels. Here we present the first structures of a eukaryotic member of this enzyme family, the allosteric, hetero-octameric, NAD(+)-specific IDH from yeast in three forms: 1) without ligands, 2) with bound analog citrate, and 3) with bound citrate + AMP. The structures reveal the molecular basis for ligand binding to homologous but distinct regulatory and catalytic sites positioned at the interfaces between IDH1 and IDH2 subunits and define pathways of communication between heterodimers and heterotetramers in the hetero-octamer. Disulfide bonds observed at the heterotetrameric interfaces in the unliganded IDH hetero-octamer are reduced in the ligand-bound forms, suggesting a redox regulatory mechanism that may be analogous to the "on-off" regulation of non-allosteric bacterial IDHs via phosphorylation. The results strongly suggest that eukaryotic IDH enzymes are exquisitely tuned to ensure that allosteric activation occurs only when concentrations of isocitrate are elevated.	[Taylor, Alexander B.; Hu, Gang; Hart, P. John; McAlister-Henn, Lee] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA; [Taylor, Alexander B.; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Xray Crystallog Core Lab, San Antonio, TX 78229 USA; [Hart, P. John] S Texas Vet Hlth Care Syst, Dept Vet Affairs, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Hart, PJ (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.	pjhart@biochem.uthscsa.edu; henn@uthscsa.edu		Taylor, Alexander/0000-0003-3517-6033	NIGMS NIH HHS [5R01GM051256] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; Anderson SL, 2002, BIOCHEMISTRY-US, V41, P7065, DOI 10.1021/bi0200662; BARNES LD, 1971, BIOCHEMISTRY-US, V10, P3939, DOI 10.1021/bi00797a022; BARNES LD, 1972, BIOCHEMISTRY-US, V11, P4322, DOI 10.1021/bi00773a019; Ceccarelli C, 2002, J BIOL CHEM, V277, P43454, DOI 10.1074/jbc.M207306200; CHEN FR, 1963, BIOCHEMISTRY-US, V2, P1023, DOI 10.1021/bi00905a020; CUPP JR, 1992, J BIOL CHEM, V267, P16417; CUPP JR, 1993, BIOCHEMISTRY-US, V32, P9323, DOI 10.1021/bi00087a010; CUPP JR, 1991, J BIOL CHEM, V266, P22199; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dujon B, 2005, CURR OPIN GENET DEV, V15, P614, DOI 10.1016/j.gde.2005.09.005; EHRLICH RS, 1981, J BIOL CHEM, V256, P1276; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; GABRIEL JL, 1986, METABOLISM, V35, P661, DOI 10.1016/0026-0495(86)90175-7; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hu G, 2006, ARCH BIOCHEM BIOPHYS, V453, P207, DOI 10.1016/j.abb.2006.06.022; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; IMADA K, 1991, J MOL BIOL, V222, P725, DOI 10.1016/0022-2836(91)90508-4; KEYS DA, 1990, J BACTERIOL, V172, P4280, DOI 10.1128/jb.172.8.4280-4287.1990; KIM YO, 1995, BIOCHEM J, V308, P63, DOI 10.1042/bj3080063; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; KUEHN GD, 1971, BIOCHEMISTRY-US, V10, P3945, DOI 10.1021/bi00797a023; LEE ME, 1995, BIOCHEMISTRY-US, V34, P378, DOI 10.1021/bi00001a046; Lin AP, 2003, J BIOL CHEM, V278, P12864, DOI 10.1074/jbc.M300154200; Lin AP, 2002, J BIOL CHEM, V277, P22475, DOI 10.1074/jbc.M202534200; Lin AP, 2001, BIOCHEMISTRY-US, V40, P14291, DOI 10.1021/bi0111707; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Miyazaki J, 2005, J BACTERIOL, V187, P6779, DOI 10.1128/JB.187.19.6779-6788.2005; NICHOLS BJ, 1995, BIOCHEM J, V310, P917, DOI 10.1042/bj3100917; NICHOLS BJ, 1993, BIOCHEM J, V295, P347, DOI 10.1042/bj2950347; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Panisko EA, 2001, J BIOL CHEM, V276, P1204, DOI 10.1074/jbc.M005056200; Piskur J, 2004, MOL MICROBIOL, V53, P381, DOI 10.1111/j.1365-2958.2004.04182.x; PLAUT GWE, 1970, CURR TOP CELL REGUL, V2, P1; Pronk JT, 1996, YEAST, V12, P1607, DOI 10.1002/(SICI)1097-0061(199612)12:16<1607::AID-YEA70>3.0.CO;2-4; RAMACHANDRAN N, 1980, J BIOL CHEM, V255, P8859; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; Schmidt B, 2006, BIOCHEMISTRY-US, V45, P7429, DOI 10.1021/bi0603064; Sols A., 1971, YEASTS, P271; Soundar S, 2003, J BIOL CHEM, V278, P52146, DOI 10.1074/jbc.M306178200; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; WALSH K, 1985, J BIOL CHEM, V260, P8430; Xu X, 2004, J BIOL CHEM, V279, P33946, DOI 10.1074/jbc.M404298200; Zhao WN, 1997, J BIOL CHEM, V272, P21811, DOI 10.1074/jbc.272.35.21811	47	38	38	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10872	10880		10.1074/jbc.M708719200	http://dx.doi.org/10.1074/jbc.M708719200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18256028	hybrid, Green Published			2022-12-25	WOS:000254894700069
J	Cubells, L; de Muga, SV; Tebar, F; Bonventre, JV; Balsinde, J; Pol, A; Grewal, T; Enrich, C				Cubells, Laia; de Muga, Sandra Vila; Tebar, Francesc; Bonventre, Joseph V.; Balsinde, Jesus; Pol, Albert; Grewal, Thomas; Enrich, Carlos			Annexin A6-induced inhibition of cytoplasmic phospholipase A(2) is linked to caveolin-1 export from the Golgi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; H-RAS; CHOLESTEROL; PROTEIN; TRAFFICKING; TRANSPORT; COMPLEX; VESICULATION; COMPARTMENTS; ASSOCIATION	] The molecular mechanisms regulating the exit of caveolin from the Golgi complex are not fully understood. Cholesterol and sphingolipid availability affects Golgi vesiculation events and involves the activity of cytoplasmic phospholipase A(2) (cPLA(2)). We recently demonstrated that high expression levels of annexin A6 (AnxA6) perturb the intracellular distribution of cellular cholesterol, thereby inhibiting caveolin export from the Golgi complex. In the present study we show that in Chinese hamster ovary cells overexpressing AnxA6, sequestration of cholesterol in late endosomes, leading to reduced amounts of cholesterol in the Golgi, inhibits cPLA2 activity and its association with the Golgi complex. This correlates with the blockage of caveolin export from the Golgi in cells treated with methyl arachidonyl fluorophosphonate, a Ca2+-dependent cPLA(2) inhibitor. AnxA6-mediated down-regulation of cPLA(2) activity was overcome upon the addition of exogenous cholesterol or transfection with small interfering RNA targeting AnxA6. These findings indicate that AnxA6 interferes with caveolin transport through the inhibition of cPLA(2).	[Grewal, Thomas] Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia; [Cubells, Laia; de Muga, Sandra Vila; Tebar, Francesc; Enrich, Carlos] Univ Barcelona, Dept Cellular Biol, Fac Med, Barcelona 08036, Spain; [Pol, Albert; Enrich, Carlos] Univ Barcelona, Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona 08036, Spain; [Bonventre, Joseph V.] Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA; [Balsinde, Jesus] Spanish Res Council, Inst Mol Biol & Genet, Toyota 47003, Japan; [Balsinde, Jesus] Univ Valladolid, Sch Med, Toyota 47003, Japan	University of Sydney; University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Harvard University; Brigham & Women's Hospital	Grewal, T (corresponding author), Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia.	tgrewal@pharm.usyd.edu.au	Pol, Albert/M-1865-2014; Tebar, Francesc/H-1498-2015; Balsinde, Jesús/C-7833-2018	Pol, Albert/0000-0002-1750-1085; Tebar, Francesc/0000-0002-9522-9726; Balsinde, Jesús/0000-0002-4157-6714; Grewal, Thomas/0000-0002-7937-8887; Enrich, Carlos/0000-0003-0382-2993				BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; Brown WJ, 2003, TRAFFIC, V4, P214, DOI 10.1034/j.1600-0854.2003.00078.x; Brugger B, 2000, J CELL BIOL, V151, P507, DOI 10.1083/jcb.151.3.507; Buckland AG, 1998, BIOCHEM J, V329, P369; Casas J, 2006, J BIOL CHEM, V281, P6106, DOI 10.1074/jbc.M505230200; Choudhury A, 2006, NAT CELL BIOL, V8, P317, DOI 10.1038/ncb1380; Cubells L, 2007, TRAFFIC, V8, P1568, DOI 10.1111/j.1600-0854.2007.00640.x; de Diego I, 2002, J BIOL CHEM, V277, P32187, DOI 10.1074/jbc.M205499200; de Figueiredo P, 2000, TRAFFIC, V1, P504, DOI 10.1034/j.1600-0854.2000.010608.x; de Figueiredo P, 1998, P NATL ACAD SCI USA, V95, P8642, DOI 10.1073/pnas.95.15.8642; Egea G, 2006, CURR OPIN CELL BIOL, V18, P168, DOI 10.1016/j.ceb.2006.02.007; Evans JH, 2004, J BIOL CHEM, V279, P6005, DOI 10.1074/jbc.M311246200; Gerke V, 2005, NAT REV MOL CELL BIO, V6, P449, DOI 10.1038/nrm1661; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Ghosh M, 2007, J BIOL CHEM, V282, P11676, DOI 10.1074/jbc.M608458200; Grewal T, 2000, J BIOL CHEM, V275, P33806, DOI 10.1074/jbc.M002662200; Grewal T, 2005, ONCOGENE, V24, P5809, DOI 10.1038/sj.onc.1208743; Grewal T, 2006, BIOESSAYS, V28, P1211, DOI 10.1002/bies.20503; Grimmer S, 2005, TRAFFIC, V6, P144, DOI 10.1111/j.1600-0854.2005.00258.x; Herbert SP, 2005, MOL BIOL CELL, V16, P3800, DOI 10.1091/mbc.E05-02-0164; Hill MM, 2008, CELL, V132, P113, DOI 10.1016/j.cell.2007.11.042; Kamal A, 1998, J CELL BIOL, V142, P937, DOI 10.1083/jcb.142.4.937; Kim SW, 2001, FEBS LETT, V489, P243, DOI 10.1016/S0014-5793(00)02326-7; Kim SW, 2001, J BIOL CHEM, V276, P15712, DOI 10.1074/jbc.M009905200; Klapisz E, 2000, J LIPID RES, V41, P1680; Liu L, 2007, J BIOL CHEM, V282, P31631, DOI 10.1074/jbc.M701165200; Llado A, 2004, MOL BIOL CELL, V15, P4877, DOI 10.1091/mbc.E04-02-0127; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maxfield FR, 2002, J CLIN INVEST, V110, P891, DOI 10.1172/JCI200216500; Nakatani Y, 2000, J BIOL CHEM, V275, P1161, DOI 10.1074/jbc.275.2.1161; Pettus BJ, 2004, J BIOL CHEM, V279, P11320, DOI 10.1074/jbc.M309262200; Pol A, 2005, MOL BIOL CELL, V16, P2091, DOI 10.1091/mbc.E04-08-0737; Pons M, 2000, EXP CELL RES, V257, P33, DOI 10.1006/excr.2000.4861; Pons M, 2001, EXP CELL RES, V269, P13, DOI 10.1006/excr.2001.5268; Rabut G., 2005, LIVE CELL IMAGING LA, P101; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Rentero C, 2006, CELL SIGNAL, V18, P1006, DOI 10.1016/j.cellsig.2005.08.008; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Sehgal PB, 2007, AM J PHYSIOL-LUNG C, V292, pL1526, DOI 10.1152/ajplung.00463.2006; Sheridan AM, 2001, MOL CELL BIOL, V21, P4470, DOI 10.1128/MCB.21.14.4470-4481.2001; Solito E, 1998, BRIT J PHARMACOL, V124, P1675, DOI 10.1038/sj.bjp.0701991; Stuven E, 2003, J BIOL CHEM, V278, P53112, DOI 10.1074/jbc.M300402200; Tebar F, 2002, MOL BIOL CELL, V13, P2057, DOI 10.1091/mbc.01-12-0571; Wang YZ, 2000, TRAFFIC, V1, P952, DOI 10.1034/j.1600-0854.2000.011205.x; White IJ, 2006, EMBO J, V25, P1, DOI 10.1038/sj.emboj.7600759; Yeung T, 2008, SCIENCE, V319, P210, DOI 10.1126/science.1152066	46	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					10174	10183		10.1074/jbc.M706618200	http://dx.doi.org/10.1074/jbc.M706618200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18245088	hybrid			2022-12-25	WOS:000254671600070
J	Robins, RJ; Petavy, F; Nemmaoui, Y; Ayadi, F; Silvestre, V; Zhang, BL				Robins, Richard J.; Petavy, Francois; Nemmaoui, Youssef; Ayadi, Farouk; Silvestre, Virginie; Zhang, Ben-Li			Non-equivalence of hydrogen transfer from glucose to the pro-R and pro-S methylene positions of ethanol during fermentation by Leuconostoc mesenteroides quantified by H-2 NMR at natural abundance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCOHOL-DEHYDROGENASE; LACTOCOCCUS-LACTIS; ALDEHYDE DEHYDROGENASE; IN-VIVO; PATHWAY; REGENERATION; SUBSTRATE; KINETICS; BACTERIA; NAD(P)H	The anaerobic fermentation of glucose by Leuconostoc mesenteroides via the reductive pentose phosphate pathway leads to the accumulation of lactic acid and ethanol. The isotope redistribution coefficients (a(ij)) that characterize the specific derivation of each hydrogen atom in ethanol in relation to the non-exchangeable hydrogen atoms in glucose and the medium water have been determined using quantitative H-2 NMR. First, it is confirmed that the hydrogens of the methylene group are related only to the 1 and 3 positions of glucose via the NAD(P)H pool and not to the 4 position, in contrast to ethanol produced by Saccharomyces cerevisiae. Second, it is found that the conversion factors (C-f) for the transfer of hydrogen to the pro-S and pro-R positions of the methylene group are not equivalent: the C-f- 1-R: C-f-1-S ratio is 2.1, whereas the Cf-3-R: Cf-3-S ratio is 0.8. It is shown that this non-equivalence is not determined by the stereochemistry of the terminal NADH- and NADPH-dependent alcohol dehydrogenases, but is dependent on the cofactor selectivities of the reductive and oxidative steps of the reduced nucleotide cycle.	[Robins, Richard J.; Petavy, Francois; Nemmaoui, Youssef; Ayadi, Farouk; Silvestre, Virginie; Zhang, Ben-Li] Univ Nantes, CNRS, UMR 6230, CEISAM,Elucidat Biosynth Isotop Spectrometry Grp, F-44322 Nantes, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Nantes Universite	Robins, RJ (corresponding author), Univ Nantes, CNRS, UMR 6230, CEISAM,Elucidat Biosynth Isotop Spectrometry Grp, 2 Rue Houssiniere,BP 92208, F-44322 Nantes, France.	richard.robins@univ-nantes.fr	; Ayadi, Farouk/N-6260-2015	Robins, Richard/0000-0002-5325-8983; Ayadi, Farouk/0000-0003-4904-2917				BRADSHAW CW, 1992, J ORG CHEM, V57, P1532, DOI 10.1021/jo00031a037; COGAN TM, 1994, J DAIRY SCI, V77, P2704, DOI 10.3168/jds.S0022-0302(94)77213-1; CRANS DC, 1990, BIOCHEMISTRY-US, V29, P6698, DOI 10.1021/bi00480a020; DARTOIS V, 1995, RES MICROBIOL, V146, P291, DOI 10.1016/0923-2508(96)81052-7; DEMOSS RD, 1954, J BACTERIOL, V68, P252, DOI 10.1128/JB.68.2.252-257.1954; DEMOSS RD, 1955, METHOD ENZYMOL, V1, P504, DOI 10.1016/0076-6879(55)01085-9; DEMOSS RD, 1955, METHOD ENZYMOL, V1, P328, DOI 10.1016/0076-6879(55)01047-1; Hirakawa H, 2004, J BIOSCI BIOENG, V97, P202, DOI 10.1263/jbb.97.202; KAZAHAYA T, 1972, J GEN APPL MICROBIOL, V18, P43, DOI 10.2323/jgam.18.43; Koebmann BJ, 2002, ANTON LEEUW INT J G, V82, P237, DOI 10.1023/A:1020643918089; MAHMOUD M, 2004, THESIS U NANTES NANT; Neves AR, 2002, J BIOL CHEM, V277, P28088, DOI 10.1074/jbc.M202573200; Neves AR, 2002, APPL ENVIRON MICROB, V68, P6332, DOI 10.1128/AEM.68.12.6332-6342.2002; Pionnier S, 2003, J AGR FOOD CHEM, V51, P2076, DOI 10.1021/jf0259617; Pionnier S, 2002, ANAL BIOCHEM, V307, P138, DOI 10.1016/S0003-2697(02)00005-2; RABILLER C, 1990, CHIRALITY, V2, P85, DOI 10.1002/chir.530020205; Robins Richard J., 2003, Phytochemistry Reviews, V2, P87, DOI 10.1023/B:PHYT.0000004301.52646.a8; Roger O, 2004, J BIOL CHEM, V279, P24923, DOI 10.1074/jbc.M401232200; Silvestre V, 2001, ANAL CHEM, V73, P1862, DOI 10.1021/ac0013204; TERZAGHI BE, 1975, APPL MICROBIOL, V29, P807, DOI 10.1128/AEM.29.6.807-813.1975; VEIGADACUNHA M, 1993, J BACTERIOL, V175, P3941, DOI 10.1128/JB.175.13.3941-3948.1993; WONG CH, 1982, J ORG CHEM, V47, P2816, DOI 10.1021/jo00135a037; WONG CH, 1985, J AM CHEM SOC, V107, P4028, DOI 10.1021/ja00299a044; Zhang BL, 2002, J AGR FOOD CHEM, V50, P1574, DOI 10.1021/jf010776z; ZHANG HL, 1995, J BIOL CHEM, V270, P16023, DOI 10.1074/jbc.270.27.16023	25	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9704	9712		10.1074/jbc.M710272200	http://dx.doi.org/10.1074/jbc.M710272200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18258593	hybrid			2022-12-25	WOS:000254671600025
J	Sivan, SS; Wachtel, E; Tsitron, E; Sakkee, N; van der Ham, F; DeGroot, J; Roberts, S; Maroudas, A				Sivan, Sarit-Sara; Wachtel, Ellen; Tsitron, Eve; Sakkee, Nico; van der Ham, Frits; DeGroot, Jeroen; Roberts, Sally; Maroudas, Alice			Collagen turnover in normal and degenerate human intervertebral discs as determined by the racemization of aspartic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARTICULAR-CARTILAGE; AGE-RELATED ACCUMULATION; PERFORMANCE LIQUID-CHROMATOGRAPHY; HYDROSTATIC-PRESSURE; PROTEOGLYCAN SYNTHESIS; AGGRECAN TURNOVER; MATRIX SYNTHESIS; PENTOSIDINE; PROTEIN; DENTIN	Knowledge of rates of protein turnover is important for a quantitative understanding of tissue synthesis and catabolism. In this work, we have used the racemization of aspartic acid as a marker for the turnover of collagen obtained from healthy and pathological human intervertebral disc matrices. We measured the ratio of the D- and L-isomers in collagen extracted from these tissues as a function of age between 16 and 77 years. For collagen taken from healthy discs, the fractional increase of D- Asp was found to be 6.74 x 10(-4)/year; for degenerate discs, the corresponding rate was 5.18 x 10(-4)/year. Using the racemization rate found previously for the stable population of collagen molecules in dentin, we found that the rate of collagen turnover (k(T)) in discs is not constant but rather a decreasing function of age. The average turnover rate in normal disc between the ages of 20 and 40 is 0.00728 +/- 0.00275/year, and that between the ages of 50 and 80 is 0.00323 +/- 0.000947/year, which correspond to average half-lives of 95 and 215 years, respectively. Turnover of collagen from degenerate discs may be more rapid than that found for normal discs; however, statistical analysis leaves this point uncertain. The finding of a similar correlation between the accumulation of D- Asp and that of pentosidine for three normal collagenous tissues further supports the idea that the accumulation of pentosidine in a particular tissue can, along with the racemization of aspartic acid, be used as a reliable measure of protein turnover.	[Sivan, Sarit-Sara] Univ Oxford, Dept Physiol Anat & Genet, Oxford OX1 3PT, England; [Sivan, Sarit-Sara; Tsitron, Eve; Roberts, Sally; Maroudas, Alice] Technion Israel Inst Technol, Dept Biomed Engn, IL-32000 Haifa, Israel; [Wachtel, Ellen] Weizmann Inst Sci, Fac Chem, IL-76100 Rehovot, Israel; [Sakkee, Nico; van der Ham, Frits; DeGroot, Jeroen] TNO, Qual Life Business Unit Biosci, NL-2301 CE Leiden, Netherlands; [Roberts, Sally] Robert Jones & Agnes Hunt Orthopaed Hosp, Ctr Spinal Studies, Oswestry SY10 7AG, Shrops, England; [Roberts, Sally] Keele Univ, Res Inst Sci & Technol, Stoke On Trent ST4 7QB, Staffs, England	University of Oxford; Technion Israel Institute of Technology; Weizmann Institute of Science; Netherlands Organization Applied Science Research; Keele University; Keele University	Sivan, SS (corresponding author), Univ Oxford, Dept Physiol Anat & Genet, Parks Rd, Oxford OX1 3PT, England.	sarit.sivan@dpag.ox.ac.uk	DeGroot, Jeroen/C-4585-2012	Sivan, Sarit/0000-0002-6074-8032				ADAMS P, 1976, ANN RHEUM DIS, V35, P289, DOI 10.1136/ard.35.4.289; Antoniou J, 1996, J CLIN INVEST, V98, P996, DOI 10.1172/JCI118884; Arany S, 2004, FORENSIC SCI INT, V141, P127, DOI 10.1016/j.forsciint.2004.01.017; Arrhenius S., 1889, Z PHYS CHEM, V4U, P226, DOI [10.1515/zpch-1889-0416, DOI 10.1515/ZPCH-1889-0416]; ASWAD DW, 1984, ANAL BIOCHEM, V137, P405, DOI 10.1016/0003-2697(84)90106-4; BADA JL, 1984, METHOD ENZYMOL, V106, P98; BADA JL, 1981, EARTH PLANET SC LETT, V55, P292, DOI 10.1016/0012-821X(81)90108-4; Bank RA, 1997, J CHROMATOGR B, V703, P37, DOI 10.1016/S0378-4347(97)00391-5; Bank RA, 1996, ANAL BIOCHEM, V240, P167, DOI 10.1006/abio.1996.0346; Handa T, 1997, SPINE, V22, P1085, DOI 10.1097/00007632-199705150-00006; HELFMAN PM, 1976, NATURE, V262, P279, DOI 10.1038/262279b0; HELFMAN PM, 1975, P NATL ACAD SCI USA, V72, P2891, DOI 10.1073/pnas.72.8.2891; HIRSCH C., 1953, ACTA ORTHOPAED SCAND, V22, P184; Ishihara H, 1996, J APPL PHYSIOL, V80, P839, DOI 10.1152/jappl.1996.80.3.839; Ishihara H, 1999, J ORTHOP RES, V17, P829, DOI 10.1002/jor.1100170607; Liu GZ, 2001, SPINE, V26, P134, DOI 10.1097/00007632-200101150-00005; MAN EH, 1983, SCIENCE, V220, P1407, DOI 10.1126/science.6857259; Maroudas A, 1998, ARCH BIOCHEM BIOPHYS, V350, P61, DOI 10.1006/abbi.1997.0492; MAROUDAS A, 1975, J ANAT, V120, P113; MAROUDAS A, 1992, CONNECT TISSUE RES, V28, P161, DOI 10.3109/03008209209015033; MASTERS PM, 1983, CALCIFIED TISSUE INT, V35, P43, DOI 10.1007/BF02405005; MASTERS PM, 1977, NATURE, V268, P71, DOI 10.1038/268071a0; MASTERS PM, 1982, NIH822221 PUBL, P120; Matsumoto T, 1999, SPINE, V24, P315, DOI 10.1097/00007632-199902150-00002; MIKAWA Y, 1986, ARCH ORTHOP TRAUM SU, V105, P343, DOI 10.1007/BF00449940; Ohtani S, 1998, J FORENSIC SCI, V43, P949; Ohtani S, 1998, AM J FOREN MED PATH, V19, P284, DOI 10.1097/00000433-199809000-00017; PFEIFFER H, 1995, INT J LEGAL MED, V108, P19, DOI 10.1007/BF01845611; POWELL JT, 1992, ATHEROSCLEROSIS, V97, P201, DOI 10.1016/0021-9150(92)90132-Z; PUUSTJARVI K, 1993, J ORTHOP RES, V11, P738, DOI 10.1002/jor.1100110516; Razaq S, 2003, EUR SPINE J, V12, P341, DOI 10.1007/s00586-003-0582-3; SCHMIDT MB, 1990, J ORTHOPAED RES, V8, P353, DOI 10.1002/jor.1100080307; Sivan SS, 2006, BIOCHEM J, V399, P29, DOI 10.1042/BJ20060579; Sivan SS, 2006, J BIOL CHEM, V281, P13009, DOI 10.1074/jbc.M600296200; STEGEMAN.H, 1967, CLIN CHIM ACTA, V18, P267, DOI 10.1016/0009-8981(67)90167-2; Verzijl N, 2000, BIOCHEM J, V350, P381, DOI 10.1042/0264-6021:3500381; Verzijl N, 2001, MATRIX BIOL, V20, P409, DOI 10.1016/S0945-053X(01)00158-5; Verzijl N, 2000, J BIOL CHEM, V275, P39027, DOI 10.1074/jbc.M006700200	38	90	91	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					8796	8801		10.1074/jbc.M709885200	http://dx.doi.org/10.1074/jbc.M709885200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18250164	hybrid, Green Published			2022-12-25	WOS:000254465800005
J	Banci, L; Bertini, I; Boca, M; Girotto, S; Martinelli, M; Valentine, JS; Vieru, M				Banci, Lucia; Bertini, Ivano; Boca, Mirela; Girotto, Stefania; Martinelli, Manuele; Valentine, Joan Selverstone; Vieru, Miguela			SOD1 and Amyotrophic Lateral Sclerosis: Mutations and Oligomerization	PLOS ONE			English	Article								There are about 100 single point mutations of copper, zinc superoxide dismutase 1 (SOD1) which are reported (http://alsod.iop.kcl.ac.uk/Als/index.aspx) to be related to the familial form (fALS) of amyotrophic lateral sclerosis (ALS). These mutations are spread all over the protein. It is well documented that fALS produces protein aggregates in the motor neurons of fALS patients, which have been found to be associated to mitochondria. We selected eleven SOD1 mutants, most of them reported as pathological, and characterized them investigating their propensity to aggregation using different techniques, from circular dichroism spectra to ThT-binding fluorescence, size-exclusion chromatography and light scattering spectroscopy. We show here that these eleven SOD1 mutants, only when they are in the metal-free form, undergo the same general mechanism of oligomerization as found for the WT metal-free protein. The rates of oligomerization are different but eventually they give rise to the same type of soluble oligomeric species. These oligomers are formed through oxidation of the two free cysteines of SOD1 (6 and 111) and stabilized by hydrogen bonds, between beta strands, thus forming amyloid-like structures. SOD1 enters the mitochondria as demetallated and mitochondria are loci where oxidative stress may easily occur. The soluble oligomeric species, formed by the apo form of both WT SOD1 and its mutants through an oxidative process, might represent the precursor toxic species, whose existence would also suggest a common mechanism for ALS and fALS. The mechanism here proposed for SOD1 mutant oligomerization is absolutely general and it provides a common unique picture for the behaviors of the many SOD1 mutants, of different nature and distributed all over the protein.	[Banci, Lucia; Bertini, Ivano; Boca, Mirela; Girotto, Stefania; Martinelli, Manuele; Vieru, Miguela] Univ Florence, Dept Chem, Magnet Resonance Ctr CERM, Florence, Italy; [Banci, Lucia] FiorGen Fdn, Florence, Italy; [Valentine, Joan Selverstone] Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA USA	University of Florence; University of California System; University of California Los Angeles	Banci, L (corresponding author), Univ Florence, Dept Chem, Magnet Resonance Ctr CERM, Florence, Italy.	bertini@cerm.unifi.it	Girotto, Stefania/F-5997-2012	martinelli, manuele/0000-0002-9371-076X; BANCI, LUCIA/0000-0003-0562-5774	NMR [LSHG-CT-2004-512052]; MIUR PRIN-2005 [2005039878]; Marie Curie Host Fellowship [MEST-CT-2004-504391]; National Institutes of Health [DK46828, NS049134]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS049134] Funding Source: NIH RePORTER	NMR; MIUR PRIN-2005(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); Marie Curie Host Fellowship(European Commission); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by the European Community Understanding Protein Misfolding and Aggregation by NMR UPMAN Grant LSHG CT 2004 512052 11-1-04 to 10-31-07 by MIUR PRIN 2005 2005039878 and by Marie Curie Host Fellowship for Early Stage Research Training MEST CT 2004 504391 NMR in Inorganic Structural Biology. It also was supported by National Institutes of Health Grants DK46828 and NS049134 to JSV	Andersen PM, 2006, CURR NEUROL NEUROSCI, V6, P37, DOI 10.1007/s11910-996-0008-9; Arnesano F, 2004, J BIOL CHEM, V279, P47998, DOI 10.1074/jbc.M406021200; BANCI L, 1991, EUR J BIOCHEM, V196, P123, DOI 10.1111/j.1432-1033.1991.tb15794.x; Banci L, 1998, BIOCHEMISTRY-US, V37, P11780, DOI 10.1021/bi9803473; Banci L, 2007, P NATL ACAD SCI USA, V104, P11263, DOI 10.1073/pnas.0704307104; Bertini I, 1998, ADV INORG CHEM, V45, P127, DOI 10.1016/S0898-8838(08)60026-4; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Culotta VC, 2006, BBA-MOL CELL RES, V1763, P747, DOI 10.1016/j.bbamcr.2006.05.003; DELEAGE G, 1993, COMPUT APPL BIOSCI, V9, P197; Ferri A, 2006, P NATL ACAD SCI USA, V103, P13860, DOI 10.1073/pnas.0605814103; Field LS, 2003, J BIOL CHEM, V278, P28052, DOI 10.1074/jbc.M304296200; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; Furukawa Y, 2005, J BIOL CHEM, V280, P17266, DOI 10.1074/jbc.M500482200; Krebs MRH, 2005, J STRUCT BIOL, V149, P30, DOI 10.1016/j.jsb.2004.08.002; Lindberg MJ, 2005, P NATL ACAD SCI USA, V102, P9754, DOI 10.1073/pnas.0501957102; Lindberg MJ, 2002, P NATL ACAD SCI USA, V99, P16607, DOI 10.1073/pnas.262527099; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Niwa J, 2007, J BIOL CHEM, V282, P28087, DOI 10.1074/jbc.M704465200; Ohi T, 2004, J NEUROL SCI, V225, P19, DOI 10.1016/j.jns.2004.06.008; Pasinelli P, 2004, NEURON, V43, P19, DOI 10.1016/j.neuron.2004.06.021; Potter SZ, 2003, J BIOL INORG CHEM, V8, P373, DOI 10.1007/s00775-003-0447-6; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Stathopulos PB, 2003, P NATL ACAD SCI USA, V100, P7021, DOI 10.1073/pnas.1237797100; Taylor JP, 2002, SCIENCE, V296, P1991, DOI 10.1126/science.1067122; Tiwari A, 2005, J BIOL CHEM, V280, P29771, DOI 10.1074/jbc.M504039200; Tu PH, 1996, P NATL ACAD SCI USA, V93, P3155, DOI 10.1073/pnas.93.7.3155; Valentine JS, 2003, P NATL ACAD SCI USA, V100, P3617, DOI 10.1073/pnas.0730423100; Valentine JS, 2005, ANNU REV BIOCHEM, V74, P563, DOI 10.1146/annurev.biochem.72.121801.161647	30	137	141	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2008	3	2							e1677	10.1371/journal.pone.0001677	http://dx.doi.org/10.1371/journal.pone.0001677			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XS	18301754	gold, Green Published, Green Submitted			2022-12-25	WOS:000260586500021
J	Barak, JD; Liang, AS				Barak, Jeri D.; Liang, Anita S.			Role of Soil, Crop Debris, and a Plant Pathogen in Salmonella enterica Contamination of Tomato Plants	PLOS ONE			English	Article							SEROVAR TYPHIMURIUM; FRESH FRUITS; SURVIVAL; VEGETABLES; STRAINS	Background: In the U. S., tomatoes have become the most implicated vehicle for produce-associated Salmonellosis with 12 outbreaks since 1998. Although unconfirmed, trace backs suggest pre-harvest contamination with Salmonella enterica. Routes of tomato crop contamination by S. enterica in the absence of direct artificial inoculation have not been investigated. Methodology/Principal Findings: This work examined the role of contaminated soil, the potential for crop debris to act as inoculum from one crop to the next, and any interaction between the seedbourne plant pathogen Xanthomonas campestris pv. vesicatoria and S. enterica on tomato plants. Our results show S. enterica can survive for up to six weeks in fallow soil with the ability to contaminate tomato plants. We found S. enterica can contaminate a subsequent crop via crop debris; however a fallow period between crop incorporation and subsequent seeding can affect contamination patterns. Throughout these studies, populations of S. enterica declined over time and there was no bacterial growth in either the phyllosphere or rhizoplane. The presence of X. campestris pv. vesicatoria on co-colonized tomato plants had no effect on the incidence of S. enterica tomato phyllosphere contamination. However, growth of S. enterica in the tomato phyllosphere occurred on co-colonized plants in the absence of plant disease. Conclusions/Significance: S. enterica contaminated soil can lead to contamination of the tomato phyllosphere. A six week lag period between soil contamination and tomato seeding did not deter subsequent crop contamination. In the absence of plant disease, presence of the bacterial plant pathogen, X. campestris pv. vesicatoria was beneficial to S. enterica allowing multiplication of the human pathogen population. Any event leading to soil contamination with S. enterica could pose a public health risk with subsequent tomato production, especially in areas prone to bacterial spot disease.	[Barak, Jeri D.; Liang, Anita S.] USDA ARS, Western Reg Res Ctr, Produce Safety & Microbiol Res Unit, Albany, CA USA	United States Department of Agriculture (USDA)	Barak, JD (corresponding author), USDA ARS, Western Reg Res Ctr, Produce Safety & Microbiol Res Unit, Albany, CA USA.	jbarak@pw.usda.gov			U.S. Department of Agriculture [5325-42000-044-00D]	U.S. Department of Agriculture(United States Department of Agriculture (USDA))	This work was supported by the U.S. Department of Agriculture (Agricultural Research Service CRIS project number 5325-42000-044-00D).	Anonymous, 2005, Morbidity and Mortality Weekly Report, V54, P325; Barak JD, 2005, APPL ENVIRON MICROB, V71, P5685, DOI 10.1128/AEM.71.10.5685-5691.2005; Barak JD, 2001, PLANT DIS, V85, P169, DOI 10.1094/PDIS.2001.85.2.169; Bidol S. A., 2007, Morbidity and Mortality Weekly Report, V56, P909; Brandl MT, 2006, ANNU REV PHYTOPATHOL, V44, P367, DOI 10.1146/annurev.phyto.44.070505.143359; Castillo A, 2004, J FOOD PROTECT, V67, P713, DOI 10.4315/0362-028X-67.4.713; Charkowski AO, 2002, APPL ENVIRON MICROB, V68, P3114, DOI 10.1128/AEM.68.6.3114-3120.2002; Cummings K, 2001, EMERG INFECT DIS, V7, P1046, DOI 10.3201/eid0706.010625; GILBERTSON RL, 1990, PLANT DIS, V74, P322, DOI 10.1094/PD-74-0322; Guo X, 2002, J FOOD PROTECT, V65, P274, DOI 10.4315/0362-028X-65.2.274; Guo X, 2001, APPL ENVIRON MICROB, V67, P4760, DOI 10.1128/AEM.67.10.4760-4764.2001; Guo XA, 2002, APPL ENVIRON MICROB, V68, P3639, DOI 10.1128/AEM.68.7.3639-3643.2002; Hirano SS, 2000, MICROBIOL MOL BIOL R, V64, P624, DOI 10.1128/MMBR.64.3.624-653.2000; Islam M, 2004, APPL ENVIRON MICROB, V70, P2497, DOI 10.1128/AEM.70.4.2497-2502.2004; Islam Mahbub, 2004, Foodborne Pathog Dis, V1, P27, DOI 10.1089/153531404772914437; Jaeger CH, 1999, APPL ENVIRON MICROB, V65, P2685; Jensen AN, 2006, APPL ENVIRON MICROB, V72, P1833, DOI 10.1128/AEM.72.3.1833-1842.2006; Melotto M, 2006, CELL, V126, P969, DOI 10.1016/j.cell.2006.06.054; Miller WG, 2000, MOL PLANT MICROBE IN, V13, P1243, DOI 10.1094/MPMI.2000.13.11.1243; Natvig EE, 2002, APPL ENVIRON MICROB, V68, P2737, DOI 10.1128/AEM.68.6.2737-2744.2002; Nicholson FA, 2005, BIORESOURCE TECHNOL, V96, P135, DOI 10.1016/j.biortech.2004.02.030; RUIZ BG, 1987, EPIDEMIOL INFECT, V98, P271, DOI 10.1017/S0950268800062026; Wells JM, 1999, PLANT DIS, V83, P722, DOI 10.1094/PDIS.1999.83.8.722; Wells JM, 1997, PLANT DIS, V81, P867, DOI 10.1094/PDIS.1997.81.8.867	24	110	113	1	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2008	3	2							e1657	10.1371/journal.pone.0001657	http://dx.doi.org/10.1371/journal.pone.0001657			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XS	18301739	gold, Green Published, Green Submitted			2022-12-25	WOS:000260586500006
J	Dinsdale, EA; Pantos, O; Smriga, S; Edwards, RA; Angly, F; Wegley, L; Hatay, M; Hall, D; Brown, E; Haynes, M; Krause, L; Sala, E; Sandin, SA; Thurber, RV; Willis, BL; Azam, F; Knowlton, N; Rohwer, F				Dinsdale, Elizabeth A.; Pantos, Olga; Smriga, Steven; Edwards, Robert A.; Angly, Florent; Wegley, Linda; Hatay, Mark; Hall, Dana; Brown, Elysa; Haynes, Matthew; Krause, Lutz; Sala, Enric; Sandin, Stuart A.; Thurber, Rebecca Vega; Willis, Bette L.; Azam, Farooq; Knowlton, Nancy; Rohwer, Forest			Microbial Ecology of Four Coral Atolls in the Northern Line Islands	PLOS ONE			English	Article							WHOLE-GENOME AMPLIFICATION; WHITE-BAND DISEASE; GREAT-BARRIER-REEF; ORGANIC-CARBON; NUTRIENT ENRICHMENT; COMMUNITY STRUCTURE; DIADEMA-ANTILLARUM; HIGH-THROUGHPUT; ELKHORN CORAL; DNA	Microbes are key players in both healthy and degraded coral reefs. A combination of metagenomics, microscopy, culturing, and water chemistry were used to characterize microbial communities on four coral atolls in the Northern Line Islands, central Pacific. Kingman, a small uninhabited atoll which lies most northerly in the chain, had microbial and water chemistry characteristic of an open ocean ecosystem. On this atoll the microbial community was equally divided between autotrophs (mostly Prochlorococcus spp.) and heterotrophs. In contrast, Kiritimati, a large and populated (similar to 5500 people) atoll, which is most southerly in the chain, had microbial and water chemistry characteristic of a near-shore environment. On Kiritimati, there were 10 times more microbial cells and virus-like particles in the water column and these microbes were dominated by heterotrophs, including a large percentage of potential pathogens. Culturable Vibrios were common only on Kiritimati. The benthic community on Kiritimati had the highest prevalence of coral disease and lowest coral cover. The middle atolls, Palmyra and Tabuaeran, had intermediate densities of microbes and viruses and higher percentages of autotrophic microbes than either Kingman or Kiritimati. The differences in microbial communities across atolls could reflect variation in 1) oceaonographic and/or hydrographic conditions or 2) human impacts associated with land-use and fishing. The fact that historically Kingman and Kiritimati did not differ strongly in their fish or benthic communities (both had large numbers of sharks and high coral cover) suggest an anthropogenic component in the differences in the microbial communities. Kingman is one of the world's most pristine coral reefs, and this dataset should serve as a baseline for future studies of coral reef microbes. Obtaining the microbial data set, from atolls is particularly important given the association of microbes in the ongoing degradation of coral reef ecosystems worldwide.	[Dinsdale, Elizabeth A.; Pantos, Olga; Angly, Florent; Wegley, Linda; Hatay, Mark; Hall, Dana; Brown, Elysa; Haynes, Matthew; Thurber, Rebecca Vega; Rohwer, Forest] San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; [Dinsdale, Elizabeth A.] Flinders Univ S Australia, Sch Biol Sci, Adelaide, SA, Australia; [Smriga, Steven; Sala, Enric; Sandin, Stuart A.; Azam, Farooq; Knowlton, Nancy] Univ Calif San Diego, Scripps Inst Oceanography, Ctr Marine Biodiv & Conservat, La Jolla, CA USA; [Edwards, Robert A.; Rohwer, Forest] San Diego State Univ, Ctr Microbial Sci, San Diego, CA USA; [Edwards, Robert A.] Fellowship Interpretation Genomes, Burr Ridge, IL USA; [Krause, Lutz] Bielefeld Univ, CeBiTec, Bielefeld, Germany; [Willis, Bette L.] James Cook Univ, Sch Marine & Trop Biol, Ctr Excellence Coral Reef Stud, ARC, Townsville, Qld, Australia	California State University System; San Diego State University; Flinders University South Australia; University of California System; University of California San Diego; Scripps Institution of Oceanography; California State University System; San Diego State University; University of Bielefeld; James Cook University	Dinsdale, EA (corresponding author), San Diego State Univ, Dept Biol, San Diego, CA 92182 USA.	Elizabeth_dinsdale@hotmail.com; frohwer@gmail.com	chen, qi/C-8585-2011; Krause, Lutz/M-7305-2015; Rohwer, Forest/AAC-5315-2019; Edwards, Robert/Q-1691-2019; Azam, Farooq/A-2306-2012; Krause, Lutz/G-6283-2013; Angly, Florent E/A-7717-2011	Krause, Lutz/0000-0003-3806-0845; Edwards, Robert/0000-0001-8383-8949; Krause, Lutz/0000-0003-3806-0845; Angly, Florent E/0000-0002-8999-0738; Rohwer, Forest/0000-0003-1548-5429; dinsdale, elizabeth/0000-0002-2177-203X	Marine Microbial Initiative of the Gordon and Betty Moore Foundation; Moore Family Foundation; Fairweather Foundation; National Geographic Society; Marine Managed Areas Science Project of Conservation International; Scripps Institution of Oceanography; NSF [Graduate Research Fellowship]	Marine Microbial Initiative of the Gordon and Betty Moore Foundation; Moore Family Foundation; Fairweather Foundation; National Geographic Society(National Geographic Society); Marine Managed Areas Science Project of Conservation International; Scripps Institution of Oceanography(University of California System); NSF(National Science Foundation (NSF))	The research was supported by the Marine Microbial Initiative of the Gordon and Betty Moore Foundation to FLR. Further support came from Moore Family Foundation, the Fairweather Foundation, National Geographic Society, the Marine Managed Areas Science Project of Conservation International, Scripps Institution of Oceanography, E. Scripps, I. Gayler, and several private donors. Additional support came from the Coral Reef Targeted Research Program's Coral Disease Working Group and an NSF Graduate Research Fellowship to SS.	Aeby GS, 2005, CORAL REEFS, V24, P481, DOI 10.1007/s00338-005-0493-3; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSON RM, 1981, PHILOS T R SOC B, V291, P451, DOI 10.1098/rstb.1981.0005; Angly FE, 2006, PLOS BIOL, V4, P2121, DOI 10.1371/journal.pbio.0040368; Aronson RB, 2001, HYDROBIOLOGIA, V460, P25, DOI 10.1023/A:1013103928980; Aronson RB, 2006, CORAL REEFS, V25, P441, DOI 10.1007/s00338-006-0122-9; AYUKAI T, 1995, CORAL REEFS, V14, P141, DOI 10.1007/BF00367231; Bak RPM, 1998, MAR ECOL PROG SER, V175, P285, DOI 10.3354/meps175285; Baker AC, 2003, ANNU REV ECOL EVOL S, V34, P661, DOI 10.1146/annurev.ecolsys.34.011802.132417; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; Beja O, 2000, SCIENCE, V289, P1902, DOI 10.1126/science.289.5486.1902; Ben-Haim Y, 2002, MAR BIOL, V141, P47, DOI 10.1007/s00227-002-0797-6; Bouman HA, 2006, SCIENCE, V312, P918, DOI 10.1126/science.1122692; Bourne DG, 2005, ENVIRON MICROBIOL, V7, P1162, DOI 10.1111/j.1462-2920.2005.00793.x; BRAINARD R, 2005, STATE CORAL REEF ECO, P338; Breitbart M, 2002, P NATL ACAD SCI USA, V99, P14250, DOI 10.1073/pnas.202488399; Cai YYC, 2003, FASEB J, V17, pA987; Carlson CA, 2002, AQUAT MICROB ECOL, V30, P19, DOI 10.3354/ame030019; Cole JR, 2005, NUCLEIC ACIDS RES, V33, pD294, DOI 10.1093/nar/gki038; COOK J, 1784, HIS MAJESTYS SHIPS R; Corbett DR, 1999, LIMNOL OCEANOGR, V44, P1045, DOI 10.4319/lo.1999.44.4.1045; Dhulipala PDK, 2003, FASEB J, V17, pA587; Edwards RA, 2005, NAT REV MICROBIOL, V3, P504, DOI 10.1038/nrmicro1163; EDWARDS RA, 2007, OCEANOGR, V20, P26; Edwards RA, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-57; Fabricius KE, 2005, MAR POLLUT BULL, V50, P125, DOI 10.1016/j.marpolbul.2004.11.028; Fabricius KE, 2003, ESTUAR COAST SHELF S, V57, P613, DOI 10.1016/S0272-7714(02)00400-6; FANNING E, 1833, VOYAGES WORLD SELECT; FARRELL A, 1928, J CAMERONS ODYSSEY; Fasham MJR, 2001, AMBIO, P4; Fontaine S, 2007, NATURE, V450, P277, DOI 10.1038/nature06275; FRIEDLANDER A, 1997, ECOLOGICAL SURVEYS C; Green EP, 2000, BIOL CONSERV, V96, P347, DOI 10.1016/S0006-3207(00)00073-2; Gunn MR, 2007, MOL ECOL NOTES, V7, P393, DOI 10.1111/j.1471-8286.2007.01696.x; Harvell CD, 1999, SCIENCE, V285, P1505, DOI 10.1126/science.285.5433.1505; Harvell D, 2007, OCEANOGRAPHY, V20, P172, DOI 10.5670/oceanog.2007.91; HODGSON G, 1990, MAR BIOL, V104, P493, DOI 10.1007/BF01314355; Holt J., 1994, BERGEYS MANUAL DETER; HUGHES TP, 1994, SCIENCE, V265, P1547, DOI 10.1126/science.265.5178.1547; Huson DH, 2007, GENOME RES, V17, P377, DOI 10.1101/gr.5969107; Jackson JBC, 2001, SCIENCE, V293, P629, DOI 10.1126/science.1059199; Kline DI, 2006, MAR ECOL PROG SER, V314, P119, DOI 10.3354/meps314119; Kumar G, 2007, NAT METHODS, pAN30; Kuntz NM, 2005, MAR ECOL PROG SER, V294, P173, DOI 10.3354/meps294173; Leplae R, 2004, NUCLEIC ACIDS RES, V32, pD45, DOI 10.1093/nar/gkh084; Lessios HA, 2005, CORAL REEFS, V24, P125, DOI 10.1007/s00338-004-0443-5; LESSIOS HA, 1988, ANNU REV ECOL SYST, V19, P371, DOI 10.1146/annurev.es.19.110188.002103; MARAGOS JE, 1997, ECOLOGICAL SURVEYS C; MORIARTY DJW, 1979, MAR BIOL, V53, P193, DOI 10.1007/BF00389189; MORIARTY DJW, 1985, MAR BIOL, V85, P285, DOI 10.1007/BF00393249; Nugues MM, 2004, ECOL LETT, V7, P919, DOI 10.1111/j.1461-0248.2004.00651.x; Overbeek R, 2005, NUCLEIC ACIDS RES, V33, P5691, DOI 10.1093/nar/gki866; Pandolfi JM, 2003, SCIENCE, V301, P955, DOI 10.1126/science.1085706; Pantos O, 2006, DIS AQUAT ORGAN, V69, P79, DOI 10.3354/dao069079; Patterson KL, 2002, P NATL ACAD SCI USA, V99, P8725, DOI 10.1073/pnas.092260099; PAUL JH, 1986, MAR ECOL PROG SER, V33, P29, DOI 10.3354/meps033029; Perna NT, 1998, INFECT IMMUN, V66, P3810, DOI 10.1128/IAI.66.8.3810-3817.1998; Pinard R, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-216; Preskitt Linda B., 2004, Pacific Science, V58, P201, DOI 10.1353/psc.2004.0021; Ravindran J, 2002, CORAL REEFS, V21, P252, DOI 10.1007/s00338-002-0247-4; Rocap G, 2003, NATURE, V424, P1042, DOI 10.1038/nature01947; Rodriguez-Brito B, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-162; Rohwer F, 2002, MAR ECOL PROG SER, V243, P1, DOI 10.3354/meps243001; Rohwer F, 2002, J BACTERIOL, V184, P4529, DOI 10.1128/JB.184.16.4529-4535.2002; Rosenberg E, 2004, ANNU REV MICROBIOL, V58, P143, DOI 10.1146/annurev.micro.58.030603.123610; Rosenberg E, 2002, ENVIRON MICROBIOL, V4, P318, DOI 10.1046/j.1462-2920.2002.00302.x; SAENGER C, 2006, SALINE SYS, V2; SANDIN SA, 2008, PLOS ONE IN PRESS; Sato M, 2005, BIOMOL ENG, V22, P129, DOI 10.1016/j.bioeng.2005.05.001; Scanlan DJ, 2002, FEMS MICROBIOL ECOL, V40, P1, DOI 10.1111/j.1574-6941.2002.tb00930.x; Seymour JR, 2005, MAR ECOL PROG SER, V288, P1, DOI 10.3354/meps288001; Shaw DR, 1999, AM J HUM GENET, V65, pA419; SHERR EB, 1993, CURRENT METHODS AQUA, P213; Smith JE, 2006, ECOL LETT, V9, P835, DOI 10.1111/j.1461-0248.2006.00937.x; SOROKIN YI, 1972, OCEANOLOGY-USSR, V12, P169; SOROKIN YI, 1973, NATURE, V242, P415, DOI 10.1038/242415a0; Thacker RW, 2001, CORAL REEFS, V19, P318, DOI 10.1007/s003380000122; Thompson FL, 2005, INT J SYST EVOL MICR, V55, P913, DOI 10.1099/ijs.0.63370-0; TRESILIAN FH, 1838, HAWAIIAN SPECTATOR, V1, P241; Trichet J, 2001, SEDIMENT GEOL, V140, P177, DOI 10.1016/S0037-0738(00)00177-9; Tringe SG, 2005, SCIENCE, V308, P554, DOI 10.1126/science.1107851; *UNESCO, 1994, IOC REP MAN GUID, V29; van Duyl FC, 2006, CORAL REEFS, V25, P23, DOI 10.1007/s00338-005-0066-5; Voss JD, 2006, CORAL REEFS, V25, P569, DOI 10.1007/s00338-006-0131-8; Ward JR, 2004, PLOS BIOL, V2, P542, DOI 10.1371/journal.pbio.0020120; Webster NS, 2007, ENVIRON MICROBIOL, V9, P1363, DOI 10.1111/j.1462-2920.2007.01303.x; Webster NS, 2002, MAR ECOL PROG SER, V232, P305, DOI 10.3354/meps232305; Wegley L, 2004, MAR ECOL PROG SER, V273, P89, DOI 10.3354/meps273089; Wegley L, 2007, ENVIRON MICROBIOL, V9, P2707, DOI 10.1111/j.1462-2920.2007.01383.x; Wilkinson C., 2004, STATUS CORAL REEFS W; Willis BL, 2004, CORAL HEALTH AND DISEASE, P69; Wuyts J, 2004, NUCLEIC ACIDS RES, V32, pD101, DOI 10.1093/nar/gkh065; Zubkov MV, 2003, APPL ENVIRON MICROB, V69, P1299, DOI 10.1128/AEM.69.2.1299-1304.2003	93	297	304	1	89	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2008	3	2							e1584	10.1371/journal.pone.0001584	http://dx.doi.org/10.1371/journal.pone.0001584			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XS	18301735	gold, Green Accepted, Green Published			2022-12-25	WOS:000260586500002
J	Hase, T; Niimura, Y; Kaminuma, T; Tanaka, H				Hase, Takeshi; Niimura, Yoshihito; Kaminuma, Tsuguchika; Tanaka, Hiroshi			Non-Uniform Survival Rate of Heterodimerization Links in the Evolution of the Yeast Protein-Protein Interaction Network	PLOS ONE			English	Article							SIMPLE DEPENDENCE; MODULARITY; TOPOLOGY; NUMBER; MAP	Protein-protein interaction networks (PINs) are scale-free networks with a small-world property. In a small-world network, the average cluster coefficient (< C >) is much higher than in a random network, but the average shortest path length (< L >) is similar between the two networks. To understand the evolutionary mechanisms shaping the structure of PINs, simulation studies using various network growth models have been performed. It has been reported that the heterodimerization (HD) model, in which a new link is added between duplicated nodes with a uniform probability, could reproduce scale-freeness and a high < C >. In this paper, however, we show that the HD model is unsatisfactory, because (i) to reproduce the high < C > in the yeast PIN, a much larger number (n(HI)) of HD links (links between duplicated nodes) are required than the estimated number of n(HI) in the yeast PIN and (ii) the spatial distribution of triangles in the yeast PIN is highly skewed but the HD model cannot reproduce the skewed distribution. To resolve these discrepancies, we here propose a new model named the non-uniform heterodimerization (NHD) model. In this model, an HD link is preferentially attached between duplicated nodes when they share many common neighbors. Simulation studies demonstrated that the NHD model can successfully reproduce the high < C >, the low n(HI), and the skewed distribution of triangles in the yeast PIN. These results suggest that the survival rate of HD links is not uniform in the evolution of PINs, and that an HD link between high-degree nodes tends to be evolutionarily conservative. The non-uniform survival rate of HD links can be explained by assuming a low mutation rate for a high-degree node, and thus this model appears to be biologically plausible.	[Hase, Takeshi; Niimura, Yoshihito; Kaminuma, Tsuguchika; Tanaka, Hiroshi] Tokyo Med & Dent Univ, Med Res Inst, Dept Bioinformat, Tokyo, Japan; [Tanaka, Hiroshi] Tokyo Med & Dental Univ, Sch Biomed Sci, Dept Bioinformat, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Hase, T (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Bioinformat, Tokyo, Japan.	niimura@bioinfo.tmd.ac.jp	Hase, Takeshi/AAB-9085-2022					Albert R, 2002, REV MOD PHYS, V74, P47, DOI 10.1103/RevModPhys.74.47; Albert R, 1999, NATURE, V401, P130, DOI 10.1038/43601; Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Chung F, 2002, P NATL ACAD SCI USA, V99, P15879, DOI 10.1073/pnas.252631999; Chung F, 2003, J COMPUT BIOL, V10, P677, DOI 10.1089/106652703322539024; Cohen R, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.058701; Costa LD, 2007, ADV PHYS, V56, P167, DOI 10.1080/00018730601170527; Eguiluz VM, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.018102; Forster AC, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100090; Fraser HB, 2005, NAT GENET, V37, P351, DOI 10.1038/ng1530; Fraser HB, 2002, SCIENCE, V296, P750, DOI 10.1126/science.1068696; Fraser HB, 2003, BMC EVOL BIOL, V3, DOI 10.1186/1471-2148-3-11; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Guldener U, 2006, NUCLEIC ACIDS RES, V34, pD436, DOI 10.1093/nar/gkj003; Han JDJ, 2004, NATURE, V430, P88, DOI 10.1038/nature02555; Ispolatov I, 2005, NEW J PHYS, V7, DOI 10.1088/1367-2630/7/1/145; Ispolatov I, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.061911; Ispolatov I, 2005, NUCLEIC ACIDS RES, V33, P3629, DOI 10.1093/nar/gki678; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Jeong H, 2000, NATURE, V407, P651, DOI 10.1038/35036627; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; Jordan IK, 2003, BMC EVOL BIOL, V3, DOI 10.1186/1471-2148-3-1; Kim J, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.055101; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; Maslov S, 2002, SCIENCE, V296, P910, DOI 10.1126/science.1065103; Middendorf M, 2005, P NATL ACAD SCI USA, V102, P3192, DOI 10.1073/pnas.0409515102; Newman MEJ, 2001, P NATL ACAD SCI USA, V98, P404, DOI 10.1073/pnas.021544898; Pastor-Satorras R, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.258701; Pastor-Satorras R, 2003, J THEOR BIOL, V222, P199, DOI 10.1016/S0022-5193(03)00028-6; Patil A, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-100; Prachumwat A, 2006, MOL BIOL EVOL, V23, P30, DOI 10.1093/molbev/msi249; Raval A, 2003, PHYS REV E, V68, DOI 10.1103/PhysRevE.68.066119; Rodriguez-Caso C, 2005, FEBS J, V272, P6423, DOI 10.1111/j.1742-4658.2005.05041.x; Smith E D, 2002, ADV COMPLEX SYST, V5, P43, DOI DOI 10.1142/S021952590200047X; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Vazquez A, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.056104; Vazquez Alexei, 2003, ComPlexUs, V1, P38, DOI 10.1159/000067642; Wagner A, 2001, MOL BIOL EVOL, V18, P1283, DOI 10.1093/oxfordjournals.molbev.a003913; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; WILLIAMS RJ, 2002, SCIENCE, V297, P1551; Yook SH, 2004, PROTEOMICS, V4, P928, DOI 10.1002/pmic.200300636	44	9	10	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2008	3	2							e1667	10.1371/journal.pone.0001667	http://dx.doi.org/10.1371/journal.pone.0001667			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XS	18301745	Green Submitted, Green Published, gold			2022-12-25	WOS:000260586500012
J	Leisner, C; Loeth, N; Lamberth, K; Justesen, S; Sylvester-Hvid, C; Schmidt, EG; Claesson, M; Buus, S; Stryhn, A				Leisner, Christian; Loeth, Nina; Lamberth, Kasper; Justesen, Sune; Sylvester-Hvid, Christina; Schmidt, Esben G.; Claesson, Mogens; Buus, Soren; Stryhn, Anette			One-Pot, Mix-and-Read Peptide-MHC Tetramers	PLOS ONE			English	Article							T-CELLS; IN-VIVO; ELISPOT ASSAY; BLOOD; BIOTINYLATION; PURIFICATION; LYMPHOCYTES; EXPRESSION; GENERATION; RESPONSES	Background: Cytotoxic T Lymphocytes (CTL) recognize complexes of peptide ligands and Major Histocompatibility Complex (MHC) class I molecules presented at the surface of Antigen Presenting Cells (APC). Detection and isolation of CTL's are of importance for research on CTL immunity, and development of vaccines and adoptive immune therapy. Peptide-MHC tetramers have become important reagents for detection and enumeration of specific CTL's. Conventional peptide-MHC-tetramer production involves recombinant MHC production, in vitro refolding, biotinylation and tetramerization; each step followed by various biochemical steps such as chromatographic purification, concentration etc. Such cumbersome production protocols have limited dissemination and restricted availability of peptide-MHC tetramers effectively precluding large-scale screening strategies involving many different peptide-MHC tetramers. Methodology/Principal Findings: We have developed an approach whereby any given tetramer specificity can be produced within 2 days with very limited effort and hands-on time. The strategy is based on the isolation of correctly oxidized, in vivo biotinylated recombinant MHC I heavy chain (HC). Such biotinylated MHC I HC molecules can be refolded in vitro, tetramerized with streptavidin, and used for specific T cell staining-all in a one-pot reaction without any intervening purification steps. Conclusions/Significance: We have developed an efficient "one-pot, mix-and-read'' strategy for peptide-MHC tetramer generation, and demonstrated specific T cell straining comparable to a commercially available MHC-tetramer. Here, seven peptide-MHC tetramers representing four different human MHC (HLA) class I proteins have been generated. The technique should be readily extendable to any binding peptide and pre-biotinylated MHC (at this time we have over 40 different pre-biotinylated HLA proteins). It is simple, robust, and versatile technique with a very broad application potential as it can be adapted both to small- and large-scale production of one or many different peptide-MHC tetramers for T cell isolation, or epitope screening.	[Leisner, Christian; Loeth, Nina; Lamberth, Kasper; Justesen, Sune; Sylvester-Hvid, Christina; Schmidt, Esben G.; Claesson, Mogens; Buus, Soren; Stryhn, Anette] Univ Copenhagen, Lab Experimental Immunol, Copenhagen, Denmark	University of Copenhagen	Leisner, C (corresponding author), Univ Copenhagen, Lab Experimental Immunol, Copenhagen, Denmark.	s.buus@immi.ku.dk	Buus, Soren/F-5446-2010	Buus, Soren/0000-0001-8363-1999; Stryhn, Anette/0000-0002-4581-3553	6FP EU [503231]; NIH [266200400025C]; Danish FTP [274-05-0582]; Danish Cancer Society [DP06015]	6FP EU; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Danish FTP; Danish Cancer Society(Danish Cancer Society)	This work was supported by the 6FP EU grant 503231, the NIH contract 266200400025C, the Danish FTP 274-05-0582 and by the Danish Cancer Society DP06015.	Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Cull MG, 2000, METHOD ENZYMOL, V326, P430; CZERKINSKY C, 1988, J IMMUNOL METHODS, V115, P31, DOI 10.1016/0022-1759(88)90306-7; Delon J, 1998, IMMUNITY, V9, P467, DOI 10.1016/S1074-7613(00)80630-5; Ferre H, 2003, PROTEIN SCI, V12, P551, DOI 10.1110/ps.0233003; Keenan RD, 2001, BRIT J HAEMATOL, V115, P428, DOI 10.1046/j.1365-2141.2001.03106.x; Markovic SN, 2006, CLIN EXP IMMUNOL, V145, P438, DOI 10.1111/j.1365-2249.2006.03157.x; OSTERBORG A, 1995, BRIT J HAEMATOL, V89, P110; Pedersen LO, 2001, EUR J IMMUNOL, V31, P2986, DOI 10.1002/1521-4141(2001010)31:10<2986::AID-IMMU2986>3.0.CO;2-R; Rodenko B, 2006, NAT PROTOC, V1, P1120, DOI 10.1038/nprot.2006.121; Romero P, 1998, MOL MED TODAY, V4, P305, DOI 10.1016/S1357-4310(98)01280-5; Savage P, 2002, BRIT J CANCER, V86, P1336, DOI 10.1038/sj.bjc.6600223; Savage P, 2007, TUMOR BIOL, V28, P70, DOI 10.1159/000099152; Scheibenbogen C, 1997, CLIN CANCER RES, V3, P221; Suni MA, 1998, J IMMUNOL METHODS, V212, P89, DOI 10.1016/S0022-1759(98)00004-0; Sylvester-Hvid C, 2002, TISSUE ANTIGENS, V59, P251, DOI 10.1034/j.1399-0039.2002.590402.x; Yang JB, 2004, HUM IMMUNOL, V65, P692, DOI 10.1016/j.humimm.2004.04.001	17	85	115	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2008	3	2							e1678	10.1371/journal.pone.0001678	http://dx.doi.org/10.1371/journal.pone.0001678			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XS	18301755	Green Submitted, gold, Green Published			2022-12-25	WOS:000260586500022
J	Chen, H; Xu, GZ; Zhao, Y; Tian, B; Lu, HM; Yu, XM; Xu, ZJ; Ying, NJ; Hu, SN; Hua, YJ				Chen, Huan; Xu, Guangzhi; Zhao, Ye; Tian, Bing; Lu, Huiming; Yu, Xiaomin; Xu, Zhenjian; Ying, Nanjiao; Hu, Songnian; Hua, Yuejin			A Novel OxyR Sensor and Regulator of Hydrogen Peroxide Stress with One Cysteine Residue in Deinococcus radiodurans	PLOS ONE			English	Article								In bacteria, OxyR is a peroxide sensor and transcription regulator, which can sense the presence of reactive oxygen species and induce antioxidant system. When the cells are exposed to H2O2, OxyR protein is activated via the formation of a disulfide bond between the two conserved cysteine residues (C199 and C208). In Deinococcus radiodurans, a previously unreported special characteristic of DrOxyR (DR0615) is found with only one conserved cysteine. dr0615 gene mutant is hypersensitive to H2O2, but only a little to ionizing radiation. Site-directed mutagenesis and subsequent in vivo functional analyses revealed that the conserved cysteine (C210) is necessary for sensing H2O2, but its mutation did not alter the binding characteristics of OxyR on DNA. Under oxidant stress, DrOxyR is oxidized to sulfenic acid form, which can be reduced by reducing reagents. In addition, quantitative real-time PCR and global transcription profile results showed that OxyR is not only a transcriptional activator (e.g., katE, drb0125), but also a transcriptional repressor (e.g., dps, mntH). Because OxyR regulates Mn and Fe ion transporter genes, Mn/Fe ion ratio is changed in dr0615 mutant, suggesting that the genes involved in Mn/Fe ion homeostasis, and the genes involved in antioxidant mechanism are highly cooperative under extremely oxidant stress. In conclusion, these findings expand the OxyR family, which could be divided into two classes: typical 2-Cys OxyR and 1-Cys OxyR.	[Chen, Huan; Xu, Guangzhi; Zhao, Ye; Tian, Bing; Lu, Huiming; Xu, Zhenjian; Ying, Nanjiao; Hua, Yuejin] Zhejiang Univ, Inst Nucl Agr Sci, Key Lab Chinese Minist Agr Nucl Agr Sci, Hangzhou, Zhejiang, Peoples R China; [Chen, Huan; Hu, Songnian] Zhejiang Univ, James D Watson Inst Genome Sci, Hangzhou, Peoples R China; [Yu, Xiaomin; Hu, Songnian] Chinese Acad Sci, Beijing Inst Genom, Key Lab Genome Sci & Informat, Beijing, Peoples R China	Zhejiang University; Zhejiang University; Chinese Academy of Sciences; Beijing Institute of Genomics, CAS	Chen, H (corresponding author), Zhejiang Univ, Inst Nucl Agr Sci, Key Lab Chinese Minist Agr Nucl Agr Sci, Hangzhou, Zhejiang, Peoples R China.	husn@big.ac.cn; yjhua@zju.edu.cn	Zhao, Ye/I-2936-2014; Lu, Huiming/ABG-1372-2021; Chen, Huan/CAH-8180-2022; LU, HUIMING/C-1996-2014; Hu, Songnian/C-6509-2013	Zhao, Ye/0000-0002-5455-2586; Lu, Huiming/0000-0002-2743-7419; Hu, Songnian/0000-0003-3966-3111	National Basic Research Program [2004CB19604]; National Hi-Tech Development Program [2007AA021305]; Distinguished Young Scientist [30425038]; National Natural Science Foundation of China [30330020]	National Basic Research Program(National Basic Research Program of China); National Hi-Tech Development Program(National High Technology Research and Development Program of China); Distinguished Young Scientist; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work is supported by a grant from the National Basic Research Program (2004CB19604), a grant from the National Hi-Tech Development Program (2007AA021305), a grant for Distinguished Young Scientist (30425038), and a key project from the National Natural Science Foundation of China (30330020) to YJH.	ANDERSON AW, 1956, FOOD TECHNOL-CHICAGO, V10, P575; Battista JR, 1999, TRENDS MICROBIOL, V7, P362, DOI 10.1016/S0966-842X(99)01566-8; Brenot A, 2005, MOL MICROBIOL, V55, P221, DOI 10.1111/j.1365-2958.2004.04370.x; Brune I, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-21; Bsat N, 1998, MOL MICROBIOL, V29, P189, DOI 10.1046/j.1365-2958.1998.00921.x; CHEN H, 2007, PROGR NATURAL SCI, V17, P525; Choi HJ, 2001, CELL, V105, P103, DOI 10.1016/S0092-8674(01)00300-2; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; CHRISTMAN MF, 1989, P NATL ACAD SCI USA, V86, P3484, DOI 10.1073/pnas.86.10.3484; Cuypers MG, 2007, J MOL BIOL, V371, P787, DOI 10.1016/j.jmb.2006.11.032; Daly MJ, 2007, PLOS BIOL, V5, P769, DOI 10.1371/journal.pbio.0050092; Daly MJ, 2004, SCIENCE, V306, P1025, DOI 10.1126/science.1103185; Diaz PI, 2006, J BACTERIOL, V188, P2454, DOI 10.1128/JB.188.7.2454-2462.2006; Du X, 2007, APPL MICROBIOL BIOT, V75, P1343, DOI 10.1007/s00253-007-0940-x; Earl AM, 2002, J BACTERIOL, V184, P1003, DOI 10.1128/jb.184.4.1003-1009.2002; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P15013, DOI 10.1021/bi972191x; Esposito R, 2003, INT ENDOD J, V36, P599, DOI 10.1046/j.1365-2591.2003.00692.x; Fuangthong M, 2002, P NATL ACAD SCI USA, V99, P6690, DOI 10.1073/pnas.102483199; Gao GJ, 2005, CHINESE SCI BULL, V50, P311, DOI 10.1360/982004-719; Ghosal D, 2005, FEMS MICROBIOL REV, V29, P361, DOI 10.1016/j.fmrre.2004.12.007; Harris DR, 2004, PLOS BIOL, V2, P1629, DOI 10.1371/journal.pbio.0020304; Harrison A, 2007, J BACTERIOL, V189, P1004, DOI 10.1128/JB.01040-06; HELMANN JD, 2002, SCI STKE, pPE46, DOI DOI 10.1126/STKE.20002.157.PE46; Hua YJ, 2003, BIOCHEM BIOPH RES CO, V306, P354, DOI 10.1016/S0006-291X(03)00965-3; Huang LF, 2007, DNA REPAIR, V6, P167, DOI 10.1016/j.dnarep.2006.09.006; Imlay JA, 2003, ANNU REV MICROBIOL, V57, P395, DOI 10.1146/annurev.micro.57.030502.090938; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kehres DG, 2002, J BACTERIOL, V184, P3151, DOI 10.1128/JB.184.12.3151-3158.2002; Kim SO, 2002, CELL, V109, P383, DOI 10.1016/S0092-8674(02)00723-7; Kim SG, 2006, J MOL BIOL, V361, P105, DOI 10.1016/j.jmb.2006.06.010; KULLIK I, 1995, J BACTERIOL, V177, P1285, DOI 10.1128/jb.177.5.1285-1291.1995; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; Lee CJ, 2004, NAT STRUCT MOL BIOL, V11, P1179, DOI 10.1038/nsmb856; Lee JW, 2007, P NATL ACAD SCI USA, V104, P8743, DOI 10.1073/pnas.0702081104; Liu YQ, 2003, P NATL ACAD SCI USA, V100, P4191, DOI 10.1073/pnas.0630387100; Ma JF, 1999, J BACTERIOL, V181, P3730, DOI 10.1128/JB.181.12.3730-3742.1999; Markillie LM, 1999, J BACTERIOL, V181, P666, DOI 10.1128/JB.181.2.666-669.1999; MINTON KW, 1994, MOL MICROBIOL, V13, P9, DOI 10.1111/j.1365-2958.1994.tb00397.x; Panmanee W, 2006, J BACTERIOL, V188, P1389, DOI 10.1128/JB.188.4.1389-1395.2006; RAAHAVE D, 1974, ANTIMICROB AGENTS CH, V6, P603, DOI 10.1128/AAC.6.5.603; Rocha ER, 2003, ANAEROBE, V9, P165, DOI 10.1016/S1075-9964(03)00118-5; Runyen-Janecky L, 2006, INFECT IMMUN, V74, P4666, DOI 10.1128/IAI.00562-06; Seib KL, 2007, MOL MICROBIOL, V63, P54, DOI 10.1111/j.1365-2958.2006.05478.x; Smyth GK, 2005, BIOINFORMATICS, V21, P2067, DOI 10.1093/bioinformatics/bti270; Tanaka M, 2005, J BACTERIOL, V187, P3693, DOI 10.1128/JB.187.11.3693-3697.2005; Tanaka M, 2004, GENETICS, V168, P21, DOI 10.1534/genetics.104.029249; Thompson DK, 2002, APPL ENVIRON MICROB, V68, P881, DOI 10.1128/AEM.68.2.881-892.2002; Tian B, 2004, LUMINESCENCE, V19, P78, DOI 10.1002/bio.761; TIMMINS J, 2007, EMBO J; TOLEDANO MB, 1994, CELL, V78, P897, DOI 10.1016/S0092-8674(94)90702-1; Tseng HJ, 2003, INFECT IMMUN, V71, P550, DOI 10.1128/IAI.71.1.550-556.2003; Veal EA, 2007, MOL CELL, V26, P1, DOI 10.1016/j.molcel.2007.03.016; Wallecha A, 2003, J BACTERIOL, V185, P2203, DOI 10.1128/JB.185.7.2203-2209.2003; Wang XD, 2006, J BACTERIOL, V188, P8335, DOI 10.1128/JB.01318-06; Wettenhall JM, 2004, BIOINFORMATICS, V20, P3705, DOI 10.1093/bioinformatics/bth449; Xu ZJ, 2007, MICROBIOL-SGM, V153, P1642, DOI 10.1099/mic.0.2006/002857-0; Zeller T, 2007, J BACTERIOL, V189, P3784, DOI 10.1128/JB.01795-06; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001	59	85	88	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1602	10.1371/journal.pone.0001602	http://dx.doi.org/10.1371/journal.pone.0001602			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270589	Green Published, gold, Green Submitted			2022-12-25	WOS:000260535900036
J	Garcia-Lopez, A; Monferrer, L; Garcia-Alcover, I; Vicente-Crespo, M; Alvarez-Abril, MC; Artero, RD				Garcia-Lopez, Amparo; Monferrer, Lidon; Garcia-Alcover, Irma; Vicente-Crespo, Marta; Carmen Alvarez-Abril, M.; Artero, Ruben D.			Genetic and Chemical Modifiers of a CUG Toxicity Model in Drosophila	PLOS ONE			English	Article								Non-coding CUG repeat expansions interfere with the activity of human Muscleblind-like (MBNL) proteins contributing to myotonic dystrophy 1 (DM1). To understand this toxic RNA gain-of-function mechanism we developed a Drosophila model expressing 60 pure and 480 interrupted CUG repeats in the context of a non-translatable RNA. These flies reproduced aspects of the DM1 pathology, most notably nuclear accumulation of CUG transcripts, muscle degeneration, splicing misregulation, and diminished Muscleblind function in vivo. Reduced Muscleblind activity was evident from the sensitivity of CUG-induced phenotypes to a decrease in muscleblind genetic dosage and rescue by MBNL1 expression, and further supported by the co-localization of Muscleblind and CUG repeat RNA in ribonuclear foci. Targeted expression of CUG repeats to the developing eye and brain mushroom bodies was toxic leading to rough eyes and semilethality, respectively. These phenotypes were utilized to identify genetic and chemical modifiers of the CUG-induced toxicity. 15 genetic modifiers of the rough eye phenotype were isolated. These genes identify putative cellular processes unknown to be altered by CUG repeat RNA, and they include mRNA export factor Aly, apoptosis inhibitor Thread, chromatin remodelling factor Nurf-38, and extracellular matrix structural component Viking. Ten chemical compounds suppressed the semilethal phenotype. These compounds significantly improved viability of CUG expressing flies and included non-steroidal anti-inflammatory agents (ketoprofen), muscarinic, cholinergic and histamine receptor inhibitors (orphenadrine), and drugs that can affect sodium and calcium metabolism such as clenbuterol and spironolactone. These findings provide new insights into the DM1 phenotype, and suggest novel candidates for DM1 treatments.	[Garcia-Lopez, Amparo; Monferrer, Lidon; Garcia-Alcover, Irma; Vicente-Crespo, Marta; Carmen Alvarez-Abril, M.; Artero, Ruben D.] Univ Valencia, Dept Genet, Burjassot, Spain	University of Valencia	Garcia-Lopez, A (corresponding author), Univ Valencia, Dept Genet, Burjassot, Spain.	ruben.artero@uv.es	Artero, Ruben/K-6815-2014; MONFERRER, LIDÓN/H-8107-2015; Vicente-Crespo, Marta/AAT-8644-2020	Artero, Ruben/0000-0003-1596-047X; MONFERRER, LIDÓN/0000-0001-8117-6814; Vicente-Crespo, Marta/0000-0002-8381-6747	Generalitat Valenciana [GV04B164, IIARC0/04/051]; Ministerio de Educacion y Ciencia (MEC) [SAF2003-03536, predoctoral fellowships]; Muscular Dystrophy Association [3315, 4127]	Generalitat Valenciana(Center for Forestry Research & Experimentation (CIEF)European Commission); Ministerio de Educacion y Ciencia (MEC)(Spanish Government); Muscular Dystrophy Association(Muscular Dystrophy Association)	Our work was supported by grants GV04B164 and IIARC0/04/051 from the Generalitat Valenciana, SAF2003-03536 from the Ministerio de Educacion y Ciencia (MEC), and Muscular Dystrophy Association (3315 and 4127). A.G.L and M.V. were recipients of predoctoral fellowships from the MEC.	BATE M, 1993, MESODERM ITS DERIVAT; Begemann G, 1997, DEVELOPMENT, V124, P4321; Bharathi V, 2004, J CELL SCI, V117, P1911, DOI 10.1242/jcs.01034; Dansithong W, 2005, J BIOL CHEM, V280, P5773, DOI 10.1074/jbc.M410781200; Desaphy JF, 2003, MOL PHARMACOL, V63, P659, DOI 10.1124/mol.63.3.659; Ebralidze A, 2004, SCIENCE, V303, P383, DOI 10.1126/science.1088679; Fardaei M, 2002, HUM MOL GENET, V11, P805, DOI 10.1093/hmg/11.7.805; Fergestad T, 2006, GENETICS, V172, P1031, DOI 10.1534/genetics.105.050625; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; Fischer W, 2001, N-S ARCH PHARMACOL, V363, P182, DOI 10.1007/s002100000341; Furuya H, 2005, BIOCHEM PHARMACOL, V69, P503, DOI 10.1016/j.bcp.2004.10.005; Garcia-Casado Z, 2002, GENESIS, V34, P111, DOI 10.1002/gene.10147; Gatfield D, 2002, J CELL BIOL, V159, P579, DOI 10.1083/jcb.200207128; Gelbart W, 2003, NUCLEIC ACIDS RES, V31, P172, DOI 10.1093/nar/gkg094; Gomes-Pereira M, 2006, MUTAT RES-FUND MOL M, V598, P15, DOI 10.1016/j.mrfmmm.2006.01.011; Gu HY, 2006, J NEUROSCI, V26, P265, DOI 10.1523/JNEUROSCI.4109-05.2006; Guichet A, 2001, DEV BIOL, V237, P93, DOI 10.1006/dbio.2001.0354; HARO MD, 2006, HUM MOL GENET; Harper PS, 2001, MYOTONIC DYSTROPHY; Ho TH, 2005, J CELL SCI, V118, P2923, DOI 10.1242/jcs.02404; Houseley JM, 2005, HUM MOL GENET, V14, P873, DOI 10.1093/hmg/ddi080; Jiang H, 2004, HUM MOL GENET, V13, P3079, DOI 10.1093/hmg/ddh327; Jin P, 2007, NEURON, V55, P556, DOI 10.1016/j.neuron.2007.07.020; Kanadia RN, 2006, P NATL ACAD SCI USA, V103, P11748, DOI 10.1073/pnas.0604970103; Kanadia RN, 2003, SCIENCE, V302, P1978, DOI 10.1126/science.1088583; Kanadia RN, 2003, GENE EXPR PATTERNS, V3, P459, DOI 10.1016/S1567-133X(03)00064-4; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Kurihara T, 2005, INTERNAL MED, V44, P1027, DOI 10.2169/internalmedicine.44.1027; Li H, 2000, CURR BIOL, V10, P211, DOI 10.1016/S0960-9822(00)00340-7; Lin XY, 2006, HUM MOL GENET, V15, P2087, DOI 10.1093/hmg/ddl132; Machuca-Tzili L, 2006, HUM GENET, V120, P487, DOI 10.1007/s00439-006-0228-8; Mahadevan MS, 2006, NAT GENET, V38, P1066, DOI 10.1038/ng1857; Mankodi A, 2000, SCIENCE, V289, P1769, DOI 10.1126/science.289.5485.1769; Mankodi A, 2005, CIRC RES, V97, P1152, DOI 10.1161/01.RES.0000193598.89753.e3; Marek KW, 2000, NEURON, V25, P537, DOI 10.1016/S0896-6273(00)81058-2; Mathews WR, 2006, DEVELOPMENT, V133, P1143, DOI 10.1242/dev.02256; Miller JW, 2000, EMBO J, V19, P4439, DOI 10.1093/emboj/19.17.4439; MOHLER J, 1995, DEVELOPMENT, V121, P237; Monferrer L, 2006, J HERED, V97, P67, DOI 10.1093/jhered/esj003; Neckameyer WS, 1998, LEARN MEMORY, V5, P157; Paul S, 2006, EMBO J, V25, P4271, DOI 10.1038/sj.emboj.7601296; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; Prokopenko SN, 2000, GENETICS, V156, P1691; Ranum L.P., 2006, ANN REV NEUROSCI; Read RD, 2004, MOL CELL BIOL, V24, P6676, DOI 10.1128/mcb.24.15.6676-6689.2004; Rhodes JD, 2006, HUM MOL GENET, V15, P3559, DOI 10.1093/hmg/ddl432; Sofola OA, 2007, NEURON, V55, P565, DOI 10.1016/j.neuron.2007.07.021; Tettamanti M, 1997, DEV GENES EVOL, V207, P242, DOI 10.1007/s004270050112; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; VICENTE M, 2007, DIFFERENTIATION; VICENTECRESPO M, PLOS ONE IN PRESS	51	89	93	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1595	10.1371/journal.pone.0001595	http://dx.doi.org/10.1371/journal.pone.0001595			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270582	Green Published, gold, Green Submitted			2022-12-25	WOS:000260535900029
J	Nakatsuji, T; Liu, YT; Huang, CP; Gallo, RL; Huang, CM				Nakatsuji, Teruaki; Liu, Yu-Tsueng; Huang, Cheng-Po; Gallo, Richard L.; Huang, Chun-Ming			Vaccination Targeting a Surface Sialidase of P. acnes: Implication for New Treatment of Acne Vulgaris	PLOS ONE			English	Article							TOLL-LIKE RECEPTOR; PROPIONIBACTERIUM-ACNES; STREPTOCOCCUS-PNEUMONIAE; ANTIBODY-RESPONSE; COMPLETE GENOME; HUMAN SKIN; INFECTION; CELLS; TISSUE; MODEL	Background: Acne vulgaris afflicts more than fifty million people in the United State and the severity of this disorder is associated with the immune response to Propionibacterium acnes (P. acnes). Systemic therapies for acne target P. acnes using antibiotics, or target the follicle with retinoids such as isotretinoin. The latter systemic treatment is highly effective but also carries a risk of side effects including immune imbalance, hyperlipidemia, and teratogenicity. Despite substantial research into potential new therapies for this common disease, vaccines against acne vulgaris are not yet available. Methods and Findings: Here we create an acne vaccine targeting a cell wall-anchored sialidase of P. acnes. The importance of sialidase to disease pathogenesis is shown by treatment of a human sebocyte cell line with recombinant sialidase that increased susceptibility to P. acnes cytotoxicity and adhesion. Mice immunized with sialidase elicit a detectable antibody; the anti-sialidase serum effectively neutralized the cytotoxicity of P. acnes in vitro and P. acnes-induced interleukin-8 (IL-8) production in human sebocytes. Furthermore, the sialidase-immunized mice provided protective immunity against P. acnes in vivo as this treatment blocked an increase in ear thickness and release of pro-inflammatory macrophage inflammatory protein (MIP-2) cytokine. Conclusions: Results indicated that acne vaccines open novel therapeutic avenues for acne vulgaris and other P. acnes-associated diseases.	[Nakatsuji, Teruaki; Gallo, Richard L.; Huang, Chun-Ming] Univ Calif San Diego, Dept Med, Div Dermatol, San Diego, CA 92103 USA; [Nakatsuji, Teruaki; Huang, Cheng-Po; Gallo, Richard L.; Huang, Chun-Ming] VA San Diego Healthcare Ctr, San Diego, CA USA; [Liu, Yu-Tsueng; Huang, Cheng-Po; Huang, Chun-Ming] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA USA; [Huang, Chun-Ming] La Jolla Inst Mol Med, San Diego, CA USA	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of California System; University of California San Diego	Nakatsuji, T (corresponding author), Univ Calif San Diego, Dept Med, Div Dermatol, San Diego, CA 92103 USA.	chunming@ucsd.edu	Zouboulis, Christos C./I-4493-2013; Nakatsuji, Teruaki/O-6794-2014; Gallo, Richard L/A-8931-2009; , Chun-Ming/AAM-1856-2020	Zouboulis, Christos C./0000-0003-1646-2608; Nakatsuji, Teruaki/0000-0002-6187-2991; Gallo, Richard L/0000-0002-1401-7861; , Chun-Ming/0000-0002-3352-5394	National Institutes of Health [R01-AI067395-01, R21-R022754-01, R21-I58002-01, P30-AI36214-12S1]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by National Institutes of Health Grants [R01-AI067395-01, R21-R022754-01, R21-I58002-01 (C-MH) and P30-AI36214-12S1 (Y-TL)].	Basal E, 2004, J MICROBIOL, V42, P117; Bruggemann H, 2005, SEMIN CUTAN MED SURG, V24, P67, DOI 10.1016/j.sder.2005.03.001; Bruggemann H, 2004, SCIENCE, V305, P671, DOI 10.1126/science.1100330; Cooper AJ, 1998, MED J AUSTRALIA, V169, P259, DOI 10.5694/j.1326-5377.1998.tb140250.x; DALEN A, 1980, ARCH DERMATOL RES, V269, P253, DOI 10.1007/BF00406418; El All HSA, 2007, DIAGN PATHOL, V2, DOI 10.1186/1746-1596-2-4; Gloor M, 2002, DERMATOLOGY, V205, P260, DOI 10.1159/000065856; Johansson BE, 2007, VACCINE, V25, P3062, DOI 10.1016/j.vaccine.2007.01.030; Kharat AS, 2003, INFECT IMMUN, V71, P2758, DOI 10.1128/IAI.71.5.2758-2765.2003; KOBAYASHI F, 1980, INFECT IMMUN, V27, P391, DOI 10.1128/IAI.27.2.391-396.1980; Kristian SA, 2003, J INFECT DIS, V188, P414, DOI 10.1086/376533; Layton AM, 2006, J EUR ACAD DERMATOL, V20, P773, DOI 10.1111/j.1468-3083.2006.01671.x; Loveckova Yvona, 2002, Biomedical Papers (Olomouc), V146, P29; MARCINKIEWICZ J, 1991, Medycyna Doswiadczalna i Mikrobiologia, V43, P167; MARTIN A, 1993, CYTOTECHNOLOGY, V11, P49, DOI 10.1007/BF00749057; Mirshahpanah P, 2007, CUTAN OCUL TOXICOL, V26, P195, DOI 10.1080/15569520701502815; Mochizuki H, 2005, FEMS IMMUNOL MED MIC, V43, P287, DOI 10.1016/j.femsim.2004.09.009; Nakano K, 2007, SKIN PHARMACOL PHYS, V20, P29, DOI 10.1159/000096169; Ochsendorf Falk, 2006, J Dtsch Dermatol Ges, V4, P828, DOI 10.1111/j.1610-0387.2006.06053.x; Oeff MK, 2006, DERMATOLOGY, V213, P266, DOI 10.1159/000095056; Perry AL, 2006, LETT APPL MICROBIOL, V42, P185, DOI 10.1111/j.1472-765X.2006.01866.x; Romics L, 2005, J LEUKOCYTE BIOL, V78, P1255, DOI 10.1189/jlb.0804448; Shi Y, 2007, PROTEOMICS, V7, P4589, DOI 10.1002/pmic.200700425; Sun BY, 2007, MOL CELL PROTEOMICS, V6, P141, DOI 10.1074/mcp.T600046-MCP200; Tai SS, 2006, CRIT REV MICROBIOL, V32, P139, DOI 10.1080/10408410600822942; TAKAOKI M, 1980, IMMUNOLOGY, V40, P27; Taylor G, 1996, CURR OPIN STRUC BIOL, V6, P830, DOI 10.1016/S0959-440X(96)80014-5; Thiboutot D, 2003, J INVEST DERMATOL, V120, P905, DOI 10.1046/j.1523-1747.2003.12244.x; Tong HH, 2005, INFECT IMMUN, V73, P7775, DOI 10.1128/IAI.73.11.7775-7778.2005; WEBSTER GF, 1981, APPL ENVIRON MICROB, V41, P1269, DOI 10.1128/AEM.41.5.1269-1270.1981; Winter C, 2006, J GEN VIROL, V87, P1209, DOI 10.1099/vir.0.81651-0; Wolska Katarzyna, 2006, Polish Journal of Microbiology, V55, P43; Zaluga E, 1998, Ann Acad Med Stetin, V44, P65; ZIMMERLI W, 1982, J INFECT DIS, V146, P487, DOI 10.1093/infdis/146.4.487	34	58	63	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2008	3	2							e1551	10.1371/journal.pone.0001551	http://dx.doi.org/10.1371/journal.pone.0001551			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367EQ	18253498	gold, Green Published, Green Submitted			2022-12-25	WOS:000260535700022
J	Villar-Garea, A; Imhof, A				Villar-Garea, Ana; Imhof, Axel			Fine Mapping of Posttranslational Modifications of the Linker Histone H1 from Drosophila melanogaster	PLOS ONE			English	Article								The linker histone H1 binds to the DNA in between adjacent nucleosomes and contributes to chromatin organization and transcriptional control. It is known that H1 carries diverse posttranslational modifications (PTMs), including phosphorylation, lysine methylation and ADP-ribosylation. Their biological functions, however, remain largely unclear. This is in part due to the fact that most of the studies have been performed in organisms that have several H1 variants, which complicates the analyses. We have chosen Drosophila melanogaster, a model organism, which has a single H1 variant, to approach the study of the role of H1 PTMs during embryonic development. Mass spectrometry mapping of the entire sequence of the protein showed phosphorylation only in the ten N-terminal amino acids, mostly at S10. For the first time, changes in the PTMs of a linker H1 during the development of a multicellular organism are reported. The abundance of H1 monophosphorylated at S10 decreases as the embryos age, which suggests that this PTM is related to cell cycle progression and/or cell differentiation. Additionally, we have found a polymorphism in the protein sequence that can be mistaken with lysine methylation if the analysis is not rigorous.	[Villar-Garea, Ana; Imhof, Axel] Univ Munich, Adolf Butenandt Inst, Histone Modificat Grp, Munich Ctr Integrated Prot Sci, Munich, Germany	University of Munich	Villar-Garea, A (corresponding author), Univ Munich, Adolf Butenandt Inst, Histone Modificat Grp, Munich Ctr Integrated Prot Sci, Marchioninistr 15, Munich, Germany.	Imhof@lmu.de	Imhof, Axel/AAU-5313-2021	Imhof, Axel/0000-0003-2993-8249; Villar Garea, Ana/0000-0001-8960-1635	European Union [LSHG-CT-2006-037415]; German research council [IM23/4-3]	European Union(European Commission); German research council(German Research Foundation (DFG))	The work was funded by grants from a European Union (LSHG-CT-2006-037415) and the German research council (IM23/4-3).	ANDERSON KV, 1980, CELL, V21, P717, DOI 10.1016/0092-8674(80)90435-3; Arrigoni G, 2006, PROTEOMICS, V6, P757, DOI 10.1002/pmic.200500073; Bharath MMS, 2002, BIOCHEMISTRY-US, V41, P7617, DOI 10.1021/bi025773+; BLUMENFELD M, 1979, BIOCHEM GENET, V17, P163, DOI 10.1007/BF00484482; BRESNICK EH, 1991, BIOCHEMISTRY-US, V30, P3490, DOI 10.1021/bi00228a020; Bustin M, 2005, MOL CELL, V17, P617, DOI 10.1016/j.molcel.2005.02.019; Daujat S, 2005, J BIOL CHEM, V280, P38090, DOI 10.1074/jbc.C500229200; Dou YL, 2005, MOL CELL BIOL, V25, P3914, DOI 10.1128/MCB.25.10.3914-3922.2005; Dou YL, 1999, MOL CELL, V4, P641, DOI 10.1016/S1097-2765(00)80215-4; DRAVES PH, 1992, J MOL BIOL, V225, P1105, DOI 10.1016/0022-2836(92)90108-V; Fan YH, 2005, CELL, V123, P1199, DOI 10.1016/j.cell.2005.10.028; Fan YH, 2003, MOL CELL BIOL, V23, P4559, DOI 10.1128/MCB.23.13.4559-4572.2003; Garcia BA, 2004, J PROTEOME RES, V3, P1219, DOI 10.1021/pr0498887; GIANCOTTI V, 1984, BIOCHEM J, V218, P321, DOI 10.1042/bj2180321; GURLEY LR, 1995, J BIOL CHEM, V270, P27653, DOI 10.1074/jbc.270.46.27653; Hale TK, 2006, MOL CELL, V22, P693, DOI 10.1016/j.molcel.2006.04.016; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; HARISANOVA NT, 1986, MOL BIOL REP, V11, P199, DOI 10.1007/BF00419597; Horn PJ, 2002, NAT STRUCT BIOL, V9, P263, DOI 10.1038/nsb776; IZAURRALDE E, 1989, J MOL BIOL, V210, P573, DOI 10.1016/0022-2836(89)90133-2; Jiang T, 2007, P NATL ACAD SCI USA, V104, P60, DOI 10.1073/pnas.0606775103; Kasinsky HE, 2001, FASEB J, V15, P34, DOI 10.1096/fj.00-0237rev; Koop R, 2003, EMBO J, V22, P588, DOI 10.1093/emboj/cdg052; Kuzmichev A, 2004, MOL CELL, V14, P183, DOI 10.1016/S1097-2765(04)00185-6; NER SS, 1994, EMBO J, V13, P1817, DOI 10.1002/j.1460-2075.1994.tb06450.x; Ner SS, 2001, J BIOL CHEM, V276, P37569, DOI 10.1074/jbc.M105635200; Ponte I, 2003, MOL BIOL EVOL, V20, P371, DOI 10.1093/molbev/msg041; Pruss D, 1996, SCIENCE, V274, P614, DOI 10.1126/science.274.5287.614; Sarg B, 2005, FEBS J, V272, P3673, DOI 10.1111/j.1742-4658.2005.04793.x; Steinbach OC, 1997, NATURE, V389, P395, DOI 10.1038/38755; Talasz H, 1996, BIOCHEMISTRY-US, V35, P1761, DOI 10.1021/bi951914e; Talasz H, 2005, J BIOL CHEM, V280, P38814, DOI 10.1074/jbc.M505563200; Talasz H, 2002, CELL DEATH DIFFER, V9, P27, DOI 10.1038/sj.cdd.4400925; TALMAGE DA, 1987, MOL CELL BIOL, V7, P4118, DOI 10.1128/MCB.7.11.4118; Th'ng JPH, 2005, J BIOL CHEM, V280, P27809, DOI 10.1074/jbc.M501627200; THOMAS JO, 1992, NUCLEIC ACIDS RES, V20, P187, DOI 10.1093/nar/20.2.187; Ura K, 1996, EMBO J, V15, P4959, DOI 10.1002/j.1460-2075.1996.tb00876.x; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Vermaak D, 1998, CURR BIOL, V8, P533, DOI 10.1016/S0960-9822(98)70206-4; Wisniewski JR, 2007, MOL CELL PROTEOMICS, V6, P72, DOI 10.1074/mcp.M600255-MCP200; Wolffe AP, 1997, INT J BIOCHEM CELL B, V29, P1463, DOI 10.1016/S1357-2725(97)00026-5; Woodcock CL, 2006, CHROMOSOME RES, V14, P17, DOI 10.1007/s10577-005-1024-3; Zlatanova J, 2000, FASEB J, V14, P1697, DOI 10.1096/fj.99-0869rev	43	25	25	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2008	3	2							e1553	10.1371/journal.pone.0001553	http://dx.doi.org/10.1371/journal.pone.0001553			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367EQ	18253500	Green Published, gold			2022-12-25	WOS:000260535700024
J	Vercammen, E; Staal, J; Van den Broeke, A; Haegman, M; Vereecke, L; Schotte, P; Beyaert, R				Vercammen, E.; Staal, J.; Van den Broeke, A.; Haegman, M.; Vereecke, L.; Schotte, P.; Beyaert, R.			Prolonged exposure to IL-1 beta and IFN gamma induces necrosis of L929 tumor cells via a p38MAPK/NF-kappa B/NO-dependent mechanism	ONCOGENE			English	Article						interleukin-1; interferon; necrosis; nitric oxide; NF-kappa B	NF-KAPPA-B; NITRIC-OXIDE SYNTHASE; ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION; INTERFERON-GAMMA; IMMUNE-RESPONSE; P38 MAPK; DEATH; EXPRESSION; INTERLEUKIN-1	Interleukin-1 beta (IL-1 beta)is a cytokine that shares with tumor necrosis factor (TNF) the ability to initiate largely similar signaling pathways, leading to proinflammatory gene expression. In contrast to TNF, however, IL-1 beta is not believed to induce tumor cell death. Here we demonstrate that prolonged treatment with IL-1 beta, in combination with interferon-gamma (IFN gamma), is cytotoxic for L929 tumor cells. IL-1 beta/IFN gamma- induced cytotoxicity requires only minimal amounts of IL-1b and shows morphological features of necrosis. Although TNF induces a similar response, we could exclude a contribution of endogenous TNF production in the effect of IL-1 beta/IFN gamma. Cell death in response to IL-1 beta/IFN gamma is independent of caspases, but requires the IL-1 beta/IFN gamma- induced production of inducible nitric oxide synthase ( iNOS) and NO. Moreover, necrosis and iNOS/ NO production could be prevented by treatment of the cells with a p38 mitogen activated protein kinase ( p38MAPK) or I kappa B kinase beta inhibitor. Altogether, these findings demonstrate that prolonged exposure to IL-1 beta plus IFN gamma induces L929 tumor cell necrosis, via a p38MAPK and nuclear factor-kappa B ( NF-kappa B)- dependent signaling pathway, leading to the expression of iNOS and the production of toxic NO levels.	[Vercammen, E.; Staal, J.; Van den Broeke, A.; Haegman, M.; Vereecke, L.; Schotte, P.; Beyaert, R.] Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, B-9052 Ghent, Zwijnaarde, Belgium; [Vercammen, E.; Staal, J.; Van den Broeke, A.; Haegman, M.; Vereecke, L.; Schotte, P.; Beyaert, R.] Univ Ghent, Dept Mol Biol, B-9000 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University	Beyaert, R (corresponding author), Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, Technol Pk 927, B-9052 Ghent, Zwijnaarde, Belgium.	rudi.beyaert@dmbr.ugent.be	Beyaert, Rudi/B-2589-2009; Vereecke, Lars/H-6639-2016; Staal, Jens/B-7383-2008; Vereecke, Lars/ABH-2926-2020	Staal, Jens/0000-0003-2664-3357; Vereecke, Lars/0000-0002-1593-862X; Beyaert, Rudi/0000-0002-5704-582X; Haegman, Mira/0000-0002-4883-312X				BEYAERT R, 1993, J IMMUNOL, V151, P291; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Beyaert R, 2002, INT REV CYTOL, V214, P225; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; Cnop M, 2005, DIABETES, V54, pS97, DOI 10.2337/diabetes.54.suppl_2.S97; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; DUNNE A, 2003, SCI STKE, pRE3, DOI DOI 10.1126/STKE.2003.171.RE3; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Eizirik DL, 2001, DIABETOLOGIA, V44, P2115, DOI 10.1007/s001250100021; Festjens N, 2006, BBA-BIOENERGETICS, V1757, P1371, DOI 10.1016/j.bbabio.2006.06.014; FRANSEN L, 1986, EUR J CANCER CLIN ON, V22, P419, DOI 10.1016/0277-5379(86)90107-0; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Golstein P, 2007, TRENDS BIOCHEM SCI, V32, P37, DOI 10.1016/j.tibs.2006.11.001; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Heitmeier MR, 1997, J BIOL CHEM, V272, P13697, DOI 10.1074/jbc.272.21.13697; Huang H, 2004, MOL PHARMACOL, V66, P302, DOI 10.1124/mol.66.2.302; Itoh S, 1999, J IMMUNOL, V162, P7434; Janik JE, 1996, JNCI-J NATL CANCER I, V88, P44, DOI 10.1093/jnci/88.1.44; Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4; Kim HJ, 2006, CELL DEATH DIFFER, V13, P738, DOI 10.1038/sj.cdd.4401877; Kim YS, 2007, MOL CELL, V26, P675, DOI 10.1016/j.molcel.2007.04.021; Kim YJ, 2006, J NEUROSCI RES, V84, P1037, DOI 10.1002/jnr.21011; Kishore N, 2003, J BIOL CHEM, V278, P32861, DOI 10.1074/jbc.M211439200; Kleinert H, 2004, EUR J PHARMACOL, V500, P255, DOI 10.1016/j.ejphar.2004.07.030; Kleinert H, 2003, BIOL CHEM, V384, P1343, DOI 10.1515/BC.2003.152; Kobayashi T, 2004, MICROBES INFECT, V6, P1333, DOI 10.1016/j.micinf.2004.09.001; Larsen CM, 1998, J BIOL CHEM, V273, P15294, DOI 10.1074/jbc.273.24.15294; Lejeune F J, 2006, Bull Cancer, V93, pE90; Lejeune Ferdy J, 2006, Cancer Immun, V6, P6; Liu DB, 2000, DIABETES, V49, P1116, DOI 10.2337/diabetes.49.7.1116; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; MORINAGA Y, 1989, J IMMUNOL, V143, P3538; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; O'Neill LAJ, 2006, NAT REV DRUG DISCOV, V5, P549, DOI 10.1038/nrd2070; ONOZAKI K, 1985, J IMMUNOL, V135, P3962; Perkins ND, 2006, CELL DEATH DIFFER, V13, P759, DOI 10.1038/sj.cdd.4401838; Rabinovitch A, 1998, BIOCHEM PHARMACOL, V55, P1139, DOI 10.1016/S0006-2952(97)00492-9; Ricci MS, 2006, ONCOLOGIST, V11, P342, DOI 10.1634/theoncologist.11-4-342; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Saldeen J, 2004, EUR CYTOKINE NETW, V15, P47; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SMITH JW, 1992, J CLIN ONCOL, V10, P1141, DOI 10.1200/JCO.1992.10.7.1141; VANHAESEBROECK B, 1992, J IMMUNOL, V148, P2785; VANHAESEBROECK B, 1991, CANCER RES, V51, P2229; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; YAMADA K, 1993, DIABETES, V42, P1026, DOI 10.2337/diabetes.42.7.1026; Yoshimura A, 2006, CANCER SCI, V97, P439, DOI 10.1111/j.1349-7006.2006.00197.x	50	15	16	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2008	27	27					3780	3788		10.1038/onc.2008.4	http://dx.doi.org/10.1038/onc.2008.4			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18246123				2022-12-25	WOS:000256904700002
J	Courel, M; Vasquez, MS; Hook, VY; Mahata, SK; Taupenot, L				Courel, Maite; Vasquez, Michael S.; Hook, Vivian Y.; Mahata, Sushil K.; Taupenot, Laurent			Sorting of the neuroendocrine secretory protein secretogranin II into the regulated secretory pathway - Role of N- and C-terminal alpha-helical domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE-BONDED LOOP; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; TRANS-GOLGI NETWORK; CHROMOGRANIN-A; GRANULE BIOGENESIS; CARBOXYPEPTIDASE-E; MEMBRANE-BINDING; NEUROPEPTIDE SECRETONEURIN; PROHORMONE CONVERTASES; CONFORMATIONAL-CHANGE	Secretogranin II (SgII) belongs to the granin family of prohormones widely distributed in dense-core secretory granules (DCGs) of endocrine, neuroendocrine, and neuronal cells, including sympathoadrenal chromaffin cells. The mechanisms by which secretory proteins, and granins in particular, are sorted into the regulated secretory pathway are unsettled. We designed a strategy based on novel chimeric forms of human SgII fused to fluorescent (green fluorescent protein) or chemiluminescent (embryonic alkaline phosphatase) reporters to identify trafficking determinants mediating DCG targeting of SgII in sympathoadrenal cells. Three-dimensional deconvolution fluorescence microscopy and secretagogue-stimulated release studies demonstrate that SgII chimeras are correctly targeted to DCGs and released by exocytosis in PC12 and primary chromaffin cells. Results from a Golgi-retained mutant form of SgII suggest that sorting of SgII into DCGs depends on a saturable sorting machinery at the trans-Golgi/trans-Golgi network. Truncation analyses reveal the presence of DCG-targeting signals within both the N- and C-terminal regions of SgII, with the putative alpha-helix-containing SgII-(25-41) and SgII-(334-348) acting as sufficient, independent sorting domains. This study defines sequence features of SgII mediating vesicular targeting in sympathoadrenal cells and suggests a mechanism by which discrete domains of the molecule function in sorting, perhaps by virtue of a particular arrangement in tertiary structure and/or interaction with a specific component of the DCG membrane.	[Courel, Maite; Mahata, Sushil K.; Taupenot, Laurent] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Vasquez, Michael S.] Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; [Hook, Vivian Y.] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Mahata, Sushil K.; Taupenot, Laurent] Vet Affairs San Diego Healthcare Syst, San Diego, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Taupenot, L (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr,0838, La Jolla, CA 92093 USA.	ltaupenot@ucsd.edu	Mahata, Sushil/AAF-8781-2021	Taupenot, Laurent/0000-0003-2316-3825	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK059628] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK59628] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; Blazquez M, 2000, BIOCHEM CELL BIOL, V78, P181, DOI 10.1139/bcb-78-3-181; CHANAT E, 1993, EMBO J, V12, P2159, DOI 10.1002/j.1460-2075.1993.tb05864.x; Choe CU, 2004, J BIOL CHEM, V279, P35551, DOI 10.1074/jbc.M311261200; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Cool DR, 1998, MOL CELL ENDOCRINOL, V139, P7, DOI 10.1016/S0303-7207(98)00081-1; COOL DR, 1995, J BIOL CHEM, V270, P8723, DOI 10.1074/jbc.270.15.8723; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; Courel M, 2006, J BIOL CHEM, V281, P38038, DOI 10.1074/jbc.M604037200; Cowley DJ, 2000, J BIOL CHEM, V275, P7743, DOI 10.1074/jbc.275.11.7743; Dannies PS, 1999, ENDOCR REV, V20, P3, DOI 10.1210/er.20.1.3; Dikeakos JD, 2007, J CELL BIOL, V177, P191, DOI 10.1083/jcb.200701024; Eskeland NL, 1996, J CLIN INVEST, V98, P148, DOI 10.1172/JCI118760; FISCHERCOLBRIE R, 1995, PROG NEUROBIOL, V46, P49, DOI 10.1016/0301-0082(94)00060-U; GERDES HH, 1989, J BIOL CHEM, V264, P12009; Glombik MM, 1999, EMBO J, V18, P1059, DOI 10.1093/emboj/18.4.1059; Glombik MM, 2000, BIOCHIMIE, V82, P315, DOI 10.1016/S0300-9084(00)00195-4; GORR SU, 1995, FEBS LETT, V361, P8, DOI 10.1016/0014-5793(95)00142-V; Gorr SU, 2001, MOL CELL ENDOCRINOL, V172, P1, DOI 10.1016/S0303-7207(00)00342-7; Hosaka M, 2005, J CELL SCI, V118, P4785, DOI 10.1242/jcs.02608; Hosaka M, 2002, MOL BIOL CELL, V13, P3388, DOI 10.1091/mbc.02-03-0040; Huh YH, 2003, J BIOL CHEM, V278, P40581, DOI 10.1074/jbc.M304942200; JUNG LJ, 1991, SCIENCE, V251, P1330, DOI 10.1126/science.2003219; Jutras I, 2000, J BIOL CHEM, V275, P40337, DOI 10.1074/jbc.M004757200; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; Kim MK, 1999, PROTEIN SCI, V8, P1492, DOI 10.1110/ps.8.7.1492; Kim T, 2006, MOL BIOL CELL, V17, P789, DOI 10.1091/mbc.E05-08-0755; Kirchmair R, 2004, CIRCULATION, V109, P777, DOI 10.1161/01.CIR.0000112574.07422.C1; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; Kromer A, 1998, J CELL BIOL, V140, P1331, DOI 10.1083/jcb.140.6.1331; Kuliawat R, 2000, MOL BIOL CELL, V11, P1959, DOI 10.1091/mbc.11.6.1959; Lacombe MJ, 2005, J BIOL CHEM, V280, P4803, DOI 10.1074/jbc.M408658200; Lang T, 1997, NEURON, V18, P857, DOI 10.1016/S0896-6273(00)80325-6; Laslop A, 1998, J NEUROCHEM, V70, P374; Lin CC, 2007, J CELL PHYSIOL, V211, P316, DOI 10.1002/jcp.20938; Mahapatra NR, 2005, J CLIN INVEST, V115, P1942, DOI 10.1172/JCI24354; Mouchantaf R, 2001, J BIOL CHEM, V276, P26308, DOI 10.1074/jbc.M102514200; Ng YK, 2002, J NEUROSCI, V22, P3890, DOI 10.1523/JNEUROSCI.22-10-03890.2002; Normant E, 1998, ENDOCRINOLOGY, V139, P2137, DOI 10.1210/en.139.4.2137; O'Connor DT, 2007, NAT PROTOC, V2, P1248, DOI 10.1038/nprot.2007.136; Park HY, 2002, BIOCHEMISTRY-US, V41, P1259, DOI 10.1021/bi0156963; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; Taupenot L, 2005, J BIOL CHEM, V280, P3885, DOI 10.1074/jbc.M408197200; Taupenot L, 2003, NEW ENGL J MED, V348, P1134, DOI 10.1056/NEJMra021405; Taupenot L, 2002, J CELL SCI, V115, P4827, DOI 10.1242/jcs.00140; Taupenot L, 1999, HYPERTENSION, V34, P1152, DOI 10.1161/01.HYP.34.5.1152; Thiele C, 1998, J BIOL CHEM, V273, P1223, DOI 10.1074/jbc.273.2.1223; Urbe S, 1997, BIOCHEM J, V321, P65, DOI 10.1042/bj3210065; Yoo SH, 2000, J BIOL CHEM, V275, P12553, DOI 10.1074/jbc.275.17.12553; Yoo SH, 1996, J BIOL CHEM, V271, P1558; YOO SH, 1995, J BIOL CHEM, V270, P12578, DOI 10.1074/jbc.270.21.12578; YOO SH, 1993, BIOCHEMISTRY-US, V32, P8213, DOI 10.1021/bi00083a023; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	53	40	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11807	11822		10.1074/jbc.M709832200	http://dx.doi.org/10.1074/jbc.M709832200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18299326	Green Published, hybrid			2022-12-25	WOS:000255067400080
J	Shtraizent, N; Eliyahu, E; Park, JH; He, X; Shalgi, R; Schuchman, EH				Shtraizent, Nataly; Eliyahu, Efrat; Park, Jae-Ho; He, Xingxuan; Shalgi, Ruth; Schuchman, Edward H.			Autoproteolytic cleavage and activation of human acid ceramidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL NUCLEOPHILE; TUMOR-GROWTH; OVEREXPRESSION; PURIFICATION; APOPTOSIS; CELLS	Herein we report the mechanism of human acid ceramidase (AC; N-acylsphingosine deacylase) cleavage and activation. A highly purified, recombinant human AC precursor underwent self-cleavage into alpha and beta subunits, similar to other members of the N-terminal nucleophile hydrolase superfamily. This reaction proceeded with first order kinetics, characteristic of self-cleavage. AC self-cleavage occurred most rapidly at acidic pH, but also at neutral pH. Site-directed mutagenesis and expression studies demonstrated that Cys-143 was an essential nucleophile that was required at the cleavage site. Other amino acids participating in AC cleavage included Arg-159 and Asp-162. Mutations at these three amino acids prevented AC cleavage and activity, the latter assessed using BODIPY-conjugated ceramide. We propose the following mechanism for AC self-cleavage and activation. Asp-162 likely forms a hydrogen bond with Cys-143, initiating a conformational change that allows Arg-159 to act as a proton acceptor. This, in turn, facilitates an intermediate thioether bond between Cys-143 and Ile-142, the site of AC cleavage. Hydrolysis of this bond is catalyzed by water. Treatment of recombinant AC with the cysteine protease inhibitor, methyl methanethiosulfonate, inhibited both cleavage and enzymatic activity, further indicating that cysteine-mediated self-cleavage is required for ceramide hydrolysis.	[Shtraizent, Nataly; Eliyahu, Efrat; Park, Jae-Ho; He, Xingxuan; Schuchman, Edward H.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA; [Shtraizent, Nataly; Shalgi, Ruth] Tel Aviv Univ, Fac Med, Dept Cell & Dev Biol, IL-66978 Tel Aviv, Israel	Icahn School of Medicine at Mount Sinai; Tel Aviv University	Schuchman, EH (corresponding author), Mt Sinai Sch Med, Dept Genet & Genom Sci, 1425 Madison Ave, New York, NY 10029 USA.	Edward.Schuchman@mssm.edu			NIDDK NIH HHS [DK54830] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054830, R56DK054830] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Auge N, 1999, J BIOL CHEM, V274, P21533, DOI 10.1074/jbc.274.31.21533; BERNARDO K, 1995, J BIOL CHEM, V270, P11098, DOI 10.1074/jbc.270.19.11098; Bielawska AE, 1997, AM J PATHOL, V151, P1257; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; Chavez JA, 2005, J BIOL CHEM, V280, P20148, DOI 10.1074/jbc.M412769200; Eliyahu E, 2007, FASEB J, V21, P1403, DOI 10.1096/fj.06-7016com; Elojeimy S, 2007, MOL THER, V15, P1259, DOI 10.1038/sj.mt.6300167; Ferlinz K, 2001, J BIOL CHEM, V276, P35352, DOI 10.1074/jbc.M103066200; He XX, 2003, J BIOL CHEM, V278, P32978, DOI 10.1074/jbc.M301936200; Huang Y, 2004, EUR J NEUROSCI, V20, P3489, DOI 10.1111/j.1460-9568.2004.03852.x; Lemansky P, 1998, EUR J CELL BIOL, V76, P53, DOI 10.1016/S0171-9335(98)80017-4; Linke, 2001, METABOLIC MOL BASES, P3573; Mallat Z, 2001, CIRC RES, V88, P998, DOI 10.1161/hh1001.090571; Marchler-Bauer A, 2005, NUCLEIC ACIDS RES, V33, pD192, DOI 10.1093/nar/gki069; Morales A, 2007, ONCOGENE, V26, P905, DOI 10.1038/sj.onc.1209834; Park JH, 2006, BBA-BIOMEMBRANES, V1758, P2133, DOI 10.1016/j.bbamem.2006.08.019; Pei JM, 2003, PROTEIN SCI, V12, P1131, DOI 10.1110/ps.0240803; Romiti E, 2000, BIOCHEM BIOPH RES CO, V275, P746, DOI 10.1006/bbrc.2000.3370; SAVTCHOUK IA, 2007, SCI STKE, V394, pJC1; Schulze H, 2007, BIOL CHEM, V388, P1333, DOI 10.1515/BC.2007.152; Seelan RS, 2000, GENE CHROMOSOME CANC, V29, P137, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1018>3.0.CO;2-E; Selzner M, 2001, CANCER RES, V61, P1233; Strelow A, 2000, J EXP MED, V192, P601, DOI 10.1084/jem.192.5.601; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97	25	58	67	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11253	11259		10.1074/jbc.M709166200	http://dx.doi.org/10.1074/jbc.M709166200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18281275	Green Published, hybrid			2022-12-25	WOS:000255067400021
J	Vogel, JT; Tan, BC; McCarty, DR; Klee, HJ				Vogel, Jonathan T.; Tan, Bao-Cai; McCarty, Donald R.; Klee, Harry J.			The carotenoid cleavage dioxygenase 1 enzyme has broad substrate specificity, cleaving multiple carotenoids at two different bond positions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABSCISIC-ACID BIOSYNTHESIS; 9-CIS-EPOXYCAROTENOID DIOXYGENASE; BETA-CAROTENE; FUNCTIONAL-CHARACTERIZATION; DROUGHT TOLERANCE; ORGANIC-SOLVENTS; LYCOPENE CYCLASE; GENE FAMILY; VITAMIN-A; IDENTIFICATION	In many organisms, various enzymes mediate site-specific carotenoid cleavage to generate biologically active apocarotenoids. These carotenoid-derived products include provitamin A, hormones, and flavor and fragrance molecules. In plants, the CCD1 enzyme cleaves carotenoids at 9,10 (9', 10')bonds to generate multiple apocarotenoid products. Here we systematically analyzed volatile apocarotenoids generated by maize CCD1 (ZmCCD1) from multiple carotenoid substrates. ZmCCD1 did not cleave geranylgeranyl diphosphate or phytoene but did cleave other linear and cyclic carotenoids, producing volatiles derived from 9,10 (9', 10') bond cleavage. Additionally the Arabidopsis, maize, and tomato CCD1 enzymes all cleaved lycopene to generate 6-methyl-5-hepten-2-one. 6-Methyl-5-hepten-2-one, an important flavor volatile in tomato, was produced by cleavage of the 5,6 or 5',6' bond positions of lycopene but not geranylgeranyl diphosphate, zeta-carotene, or phytoene. In vitro, ZmCCD1 cleaved linear and cyclic carotenoids with equal efficiency. Based on the pattern of apocarotenoid volatiles produced, we propose that CCD1 recognizes its cleavage site based on the saturation status between carbons 7 and 8 (7' and 8') and carbons 11 and 12 (11' and 12') as well as the methyl groups on carbons 5, 9, and 13 (5', 9', and 13').	[Vogel, Jonathan T.; Tan, Bao-Cai; McCarty, Donald R.; Klee, Harry J.] Univ Florida, Dept Hort Sci, Plant Mol & Cellular Biol Program, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Klee, HJ (corresponding author), Univ Florida, Dept Hort Sci, Plant Mol & Cellular Biol Program, POB 110690, Gainesville, FL 32611 USA.	hjklee@ifas.ufl.edu	Vogel, Jonathan/AAO-4748-2020; Klee, Harry/A-7912-2008	Vogel, Jonathan/0000-0001-8550-3923	Direct For Biological Sciences [0749266] Funding Source: National Science Foundation	Direct For Biological Sciences(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO))		Ansari M S, 2005, Future Oncol, V1, P425, DOI 10.1517/14796694.1.3.425; Auldridge ME, 2006, PLANT J, V45, P982, DOI 10.1111/j.1365-313X.2006.02666.x; Baldwin EA, 1998, J AM SOC HORTIC SCI, V123, P906, DOI 10.21273/JASHS.123.5.906; Booker J, 2004, CURR BIOL, V14, P1232, DOI 10.1016/j.cub.2004.06.061; Bouvier F, 2003, PLANT CELL, V15, P47, DOI 10.1105/tpc.006536; Bouwmeester HJ, 2007, TRENDS PLANT SCI, V12, P224, DOI 10.1016/j.tplants.2007.03.009; BRITTON G, 1998, CAROTENOIDS A, V1; CAMARA B, 1986, PLANT PHYSIOL, V80, P172, DOI 10.1104/pp.80.1.172; Chernys JT, 2000, PLANT PHYSIOL, V124, P343, DOI 10.1104/pp.124.1.343; Cunningham FX, 2007, PHOTOSYNTH RES, V92, P245, DOI 10.1007/s11120-007-9210-0; CUNNINGHAM FX, 1994, PLANT CELL, V6, P1107, DOI 10.1105/tpc.6.8.1107; Cunningham FX, 2001, P NATL ACAD SCI USA, V98, P2905, DOI 10.1073/pnas.051618398; Du YJ, 1998, J CHEM ECOL, V24, P1355, DOI 10.1023/A:1021278816970; Fraser PD, 2000, PLANT J, V24, P551, DOI 10.1111/j.1365-313X.2000.00896.x; FRENCH RC, 1992, MYCOLOGIA, V84, P277, DOI 10.2307/3760180; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; Gooday Graham W., 1997, Mycologist, V11, P126; Holger S, 2006, J BIOL CHEM, V281, P9845, DOI 10.1074/jbc.M511668200; Ibdah M, 2006, PHYTOCHEMISTRY, V67, P1579, DOI 10.1016/j.phytochem.2006.02.009; Iuchi S, 2001, PLANT J, V27, P325, DOI 10.1046/j.1365-313x.2001.01096.x; Kato M, 2006, J EXP BOT, V57, P2153, DOI 10.1093/jxb/erj172; Kevany BM, 2007, PLANT J, V51, P458, DOI 10.1111/j.1365-313X.2007.03170.x; KLINGNER A, 1995, PHYTOCHEMISTRY, V38, P53, DOI 10.1016/0031-9422(94)00538-5; Knudsen JT, 2006, BOT REV, V72, P1, DOI 10.1663/0006-8101(2006)72[1:DADOFS]2.0.CO;2; MAIER W, 1995, PLANT PHYSIOL, V109, P465, DOI 10.1104/pp.109.2.465; Marasco EK, 2006, J BIOL CHEM, V281, P31583, DOI 10.1074/jbc.M606299200; Mathieu S, 2005, J EXP BOT, V56, P2721, DOI 10.1093/jxb/eri265; Mathieu S, 2007, BIOTECHNOL LETT, V29, P837, DOI 10.1007/s10529-007-9315-8; Matusova R, 2005, PLANT PHYSIOL, V139, P920, DOI 10.1104/pp.105.061382; OLSON JA, 1989, J NUTR, V119, P105, DOI 10.1093/jn/119.1.105; Qin XQ, 2002, PLANT PHYSIOL, V128, P544, DOI 10.1104/pp.010663; Qin XQ, 1999, P NATL ACAD SCI USA, V96, P15354, DOI 10.1073/pnas.96.26.15354; Quiroz A, 1997, J CHEM ECOL, V23, P2599, DOI 10.1023/B:JOEC.0000006669.34845.0d; Redmond TM, 2001, J BIOL CHEM, V276, P6560, DOI 10.1074/jbc.M009030200; Schilling M, 2007, APPL MICROBIOL BIOT, V75, P829, DOI 10.1007/s00253-007-0878-z; Schmelz EA, 2001, PLANTA, V214, P171, DOI 10.1007/s004250100603; Schwartz SH, 2001, J BIOL CHEM, V276, P25208, DOI 10.1074/jbc.M102146200; Schwartz SH, 1997, SCIENCE, V276, P1872, DOI 10.1126/science.276.5320.1872; Simkin AJ, 2004, PLANT J, V40, P882, DOI 10.1111/j.1365-313X.2004.02263.x; Simkin AJ, 2004, PLANT PHYSIOL, V136, P3504, DOI 10.1104/pp.104.049718; SIMKIN AJ, 2008, IN PRESS J PLANT PHY; Sorefan K, 2003, GENE DEV, V17, P1469, DOI 10.1101/gad.256603; Stoeffler M, 2007, J CHEM ECOL, V33, P1382, DOI 10.1007/s10886-007-9315-0; Sun ZR, 1996, J BIOL CHEM, V271, P24349, DOI 10.1074/jbc.271.40.24349; Tan BC, 2003, PLANT J, V35, P44, DOI 10.1046/j.1365-313X.2003.01786.x; Tan BC, 1997, P NATL ACAD SCI USA, V94, P12235, DOI 10.1073/pnas.94.22.12235; Thompson AJ, 2000, PLANT J, V23, P363, DOI 10.1046/j.1365-313x.2000.00789.x; Turnbull CGN, 2002, PLANT J, V32, P255, DOI 10.1046/j.1365-313X.2002.01419.x; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; Wahlberg I., 1998, CAROTENOIDS, P195; ZEEVAART JAD, 1988, ANNU REV PLANT PHYS, V39, P439, DOI 10.1146/annurev.pp.39.060188.002255	51	192	209	5	76	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11364	11373		10.1074/jbc.M710106200	http://dx.doi.org/10.1074/jbc.M710106200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18285342	hybrid			2022-12-25	WOS:000255067400033
J	Yakovenko, O; Sharma, S; Forero, M; Tchesnokova, V; Aprikian, P; Kidd, B; Mach, A; Vogel, V; Sokurenko, E; Thomas, WE				Yakovenko, Olga; Sharma, Shivani; Forero, Manu; Tchesnokova, Veronika; Aprikian, Pavel; Kidd, Brian; Mach, Albert; Vogel, Viola; Sokurenko, Evgeni; Thomas, Wendy E.			FimH forms catch bonds that are enhanced by mechanical force due to allosteric regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; P-SELECTIN; RECEPTOR-BINDING; PHYSICAL MODELS; ADHESION; CELLS; PILI; FLOW; COLONIZATION; INFECTION	The bacterial adhesive protein, FimH, is the most common adhesin of Escherichia coli and mediates weak adhesion at low flow but strong adhesion at high flow. There is evidence that this occurs because FimH forms catch bonds, defined as bonds that are strengthened by tensile mechanical force. Here, we applied force to single isolated FimH bonds with an atomic force microscope in order to test this directly. If force was loaded slowly, most of the bonds broke up at low force (< 60 piconewtons of rupture force). However, when force was loaded rapidly, all bonds survived until much higher force (140-180 piconewtons of rupture force), behavior that indicates a catch bond. Structural mutations or pretreatment with a monoclonal antibody, both of which allosterically stabilize a high affinity conformation of FimH, cause all bonds to survive until high forces regardless of the rate at which force is applied. Pretreatment of FimH bonds with intermediate force has the same strengthening effect on the bonds. This demonstrates that FimH forms catch bonds and that tensile force induces an allosteric switch to the high affinity, strong binding conformation of the adhesin. The catch bond behavior of FimH, the amount of force needed to regulate FimH, and the allosteric mechanism all provide insight into how bacteria bind and form biofilms in fluid flow. Additionally, these observations may provide a means for designing antiadhesive mechanisms.	[Yakovenko, Olga; Sharma, Shivani; Kidd, Brian; Thomas, Wendy E.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; [Tchesnokova, Veronika; Aprikian, Pavel; Sokurenko, Evgeni] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA; [Forero, Manu; Vogel, Viola] ETH, Dept Mat, CH-8093 Zurich, Switzerland; [Mach, Albert] Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of California System; University of California Berkeley	Thomas, WE (corresponding author), 1705 NE Pacific St,Suite N430P, Seattle, WA 98195 USA.	wendyt@u.washington.edu	Vogel, Viola/O-8025-2015	Vogel, Viola/0000-0003-2898-7671; Kidd, Brian/0000-0003-2110-1145; Thomas, Wendy/0000-0001-8602-0819; Forero-Shelton, Manu/0000-0002-7989-0311	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050940] Funding Source: NIH RePORTER; NIAID NIH HHS [1R01 AI50940] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson BN, 2007, J BACTERIOL, V189, P1794, DOI 10.1128/JB.00899-06; Aprikian P, 2007, J BIOL CHEM, V282, P23437, DOI 10.1074/jbc.M702037200; Arya M, 2005, BIOPHYS J, V88, P4391, DOI 10.1529/biophysj.104.046318; Bartolo D, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.051910; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; Bouckaert J, 2005, MOL MICROBIOL, V55, P441, DOI 10.1111/j.1365-2958.2004.04415.x; Bouckaert J, 2006, MOL MICROBIOL, V61, P1556, DOI 10.1111/j.1365-2958.2006.05352.x; Chilkoti A, 1995, BIOPHYS J, V69, P2125, DOI 10.1016/S0006-3495(95)80083-4; Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; Connell H, 1996, P NATL ACAD SCI USA, V93, P9827, DOI 10.1073/pnas.93.18.9827; COSTERTON JW, 1983, PROG FOOD NUTR SCI, V7, P91; DALNOGARE AR, 1990, AM J RESP CELL MOL, V2, P433, DOI 10.1165/ajrcmb/2.5.433; DEMBO M, 1988, PROC R SOC SER B-BIO, V234, P55, DOI 10.1098/rspb.1988.0038; Doggett TA, 2002, BIOPHYS J, V83, P194, DOI 10.1016/S0006-3495(02)75161-8; Evans E, 1997, BIOPHYS J, V72, P1541, DOI 10.1016/S0006-3495(97)78802-7; Evans E, 2001, ANNU REV BIOPH BIOM, V30, P105, DOI 10.1146/annurev.biophys.30.1.105; Evans E, 2004, P NATL ACAD SCI USA, V101, P11281, DOI 10.1073/pnas.0401870101; Evans EB, 1999, BIOPHYS CHEM, V82, P83, DOI 10.1016/S0301-4622(99)00108-8; Forero M, 2004, NANO LETT, V4, P1593, DOI 10.1021/nl049329z; Forero M, 2006, PLOS BIOL, V4, P1509, DOI 10.1371/journal.pbio.0040298; Fritz J, 1998, P NATL ACAD SCI USA, V95, P12283, DOI 10.1073/pnas.95.21.12283; Guo B, 2006, P NATL ACAD SCI USA, V103, P9844, DOI 10.1073/pnas.0601255103; Hanley W, 2003, J BIOL CHEM, V278, P10556, DOI 10.1074/jbc.M213233200; Hung CS, 2002, MOL MICROBIOL, V44, P903, DOI 10.1046/j.1365-2958.2002.02915.x; ISAACSON RE, 1978, INFECT IMMUN, V21, P392, DOI 10.1128/IAI.21.2.392-397.1978; Isberg RR, 2002, CELL, V110, P1, DOI 10.1016/S0092-8674(02)00821-8; IWAHI T, 1983, INFECT IMMUN, V39, P1307, DOI 10.1128/IAI.39.3.1307-1315.1983; JACKSON MB, 2006, MOL CELLULAR BIOPHYS, P121; Jeffrey B, 2003, AM J PHYSIOL-GASTR L, V285, pG907, DOI 10.1152/ajpgi.00062.2003; KEITH BR, 1986, INFECT IMMUN, V53, P693, DOI 10.1128/IAI.53.3.693-696.1986; Langermann S, 2000, J INFECT DIS, V181, P774, DOI 10.1086/315258; Langermann S, 1997, SCIENCE, V276, P607, DOI 10.1126/science.276.5312.607; Lou JZ, 2007, BIOPHYS J, V92, P1471, DOI 10.1529/biophysj.106.097048; Lou JZ, 2006, J CELL BIOL, V174, P1107, DOI 10.1083/jcb.200606056; Marshall BT, 2003, NATURE, V423, P190, DOI 10.1038/nature01605; Merkel R, 1999, NATURE, V397, P50, DOI 10.1038/16219; Miller E, 2006, BIOPHYS J, V91, P3848, DOI 10.1529/biophysj.106.088989; MOY VT, 1994, SCIENCE, V266, P257, DOI 10.1126/science.7939660; Nilsson LM, 2006, J BIOL CHEM, V281, P16656, DOI 10.1074/jbc.M511496200; Nilsson LM, 2006, APPL ENVIRON MICROB, V72, P3005, DOI 10.1128/AEM.72.4.3005-3010.2006; OFEK I, 1977, NATURE, V265, P623, DOI 10.1038/265623a0; Phan UT, 2006, NAT IMMUNOL, V7, P883, DOI 10.1038/ni1366; Sarangapani KK, 2004, J BIOL CHEM, V279, P2291, DOI 10.1074/jbc.M310396200; Saterbak A, 1996, BIOTECHNOL PROGR, V12, P682, DOI 10.1021/bp960061u; Schembri MA, 2001, INFECT IMMUN, V69, P1322, DOI 10.1128/IAI.69.3.1322-1328.2001; Shapiro BE, 1997, BIOPHYS CHEM, V67, P211, DOI 10.1016/S0301-4622(97)00045-8; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; STOWELL CP, 1980, BIOCHEMISTRY-US, V19, P4899, DOI 10.1021/bi00562a030; Tchesnokova V, 2008, J BIOL CHEM, V283, P7823, DOI 10.1074/jbc.M707804200; Thomas W, 2006, BIOPHYS J, V90, P753, DOI 10.1529/biophysj.105.066548; Thomas WE, 2004, MOL MICROBIOL, V53, P1545, DOI 10.1111/j.1365-2958.2004.04226.x; Thomas WE, 2002, CELL, V109, P913, DOI 10.1016/S0092-8674(02)00796-1; Zhu C, 2005, BIORHEOLOGY, V42, P443; Zhu Cheng, 2005, Molecular & Cellular Biomechanics, V2, P91	54	159	162	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11596	11605		10.1074/jbc.M707815200	http://dx.doi.org/10.1074/jbc.M707815200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18292092	Green Published, hybrid			2022-12-25	WOS:000255067400060
J	Gyulkhandanyan, AV; Lu, HF; Lee, SC; Bhattacharjee, A; Wijesekara, N; Fox, JEM; MacDonald, PE; Chimienti, F; Dai, FF; Wheeler, MB				Gyulkhandanyan, Armen V.; Lu, Hongfang; Lee, Simon C.; Bhattacharjee, Alpana; Wijesekara, Nadeeja; Fox, Jocelyn E. Manning; MacDonald, Patrick E.; Chimienti, Fabrice; Dai, Feihan F.; Wheeler, Michael B.			Investigation of transport mechanisms and regulation of intracellular Zn2+ in pancreatic alpha-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOME-WIDE ASSOCIATION; MAMMALIAN ZINC TRANSPORTER; BETA-CELL; GLUCAGON-SECRETION; OXIDATIVE STRESS; ELECTRICAL-ACTIVITY; GLUCOSE-INHIBITION; ENDOCRINE PANCREAS; INTACT ISLETS; DELTA-CELLS	During insulin secretion, pancreatic alpha-cells are exposed to Zn2+ released from insulin-containing secretory granules. Although maintenance of Zn2+ homeostasis is critical for cell survival and glucagon secretion, very little is known about Zn2+-transporting pathways and the regulation of Zn2+ in alpha-cells. To examine the effect of Zn2+ on glucagon secretion and possible mechanisms controlling the intracellular Zn2+ level ([Zn2+](i)), we employed a glucagon-producing cell line (alpha-TC6) and mouse islets where non beta-cells were identified using islets expressing green fluorescent protein exclusively in beta-cells. In this study, we first confirmed that Zn2+ treatment resulted in the inhibition of glucagon secretion in alpha-TC6 cells and mouse islets in vitro. The inhibition of secretion was not likely via activation of KATP channels by Zn2+. We then determined that Zn2+ was transported into alpha-cells and was able to accumulate under both low and high glucose conditions, as well as upon depolarization of cells with KCl. The nonselective Ca2+ channel blocker Gd3+ partially inhibited Zn2+ influx in alpha-TC cells, whereas the L-type voltage-gated Ca2+ channel inhibitor nitren-dipine failed to block Zn2+ accumulation. To investigate Zn2+ transport further, we profiled alpha-cells for Zn2+ transporter transcripts from the two families that work in opposite directions, SLC39 (ZIP, Zrt/Irt-like protein) and SLC30 (ZnT, Zn2+ transporter). We observed that Zip1, Zip10, and Zip14 were the most abundantly expressed Zips and ZnT4, ZnT5, and ZnT8 the dominant ZnTs. Because the redox state of cells is also a major regulator of [Zn2+](i), we examined the effects of oxidizing agents on Zn2+ mobilization within alpha-cells. 2,2'-Dithiodipyridine (-SH group oxidant), menadione (superoxide generator), and SIN-1 (3-morpholinosydnonimine) (peroxynitrite generator) all increased [Zn2+](i) in alpha-cells. Together these results demonstrate that Zn2+ inhibits glucagon secretion, and it is transported into alpha-cells in part through Ca2+ channels. Zn2+ transporters and the redox state also modulate [Zn2+](i).	[Gyulkhandanyan, Armen V.; Lu, Hongfang; Lee, Simon C.; Bhattacharjee, Alpana; Wijesekara, Nadeeja; Dai, Feihan F.; Wheeler, Michael B.] Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; [Fox, Jocelyn E. Manning; MacDonald, Patrick E.] Univ Alberta, Dept Pharmacol, Edmonton, AB T6G 2E1, Canada; [Chimienti, Fabrice] CEA Grenoble, Mellitech, DRMF SC1B, F-38054 Grenoble, France	University of Toronto; University of Alberta; CEA	Wheeler, MB (corresponding author), Univ Toronto, Dept Physiol, 1 Kings Coll Circle,Rm 3352, Toronto, ON M5S 1A8, Canada.	michael.wheeler@utoronto.ca	Lu, Hongfang/GZG-7271-2022; MacDonald, Patrick/A-4154-2008; Wijesekara, Nadeeja/AAW-7230-2021	Lu, Hongfang/0000-0002-0350-6475; Wheeler, Michael B./0000-0002-7480-7267; MacDonald, Patrick/0000-0002-5439-6288; Chimienti, fabrice/0000-0002-9907-3394				ARSLAN P, 1985, J BIOL CHEM, V260, P2719; ATAR D, 1995, J BIOL CHEM, V270, P2473, DOI 10.1074/jbc.270.6.2473; BAETENS D, 1979, SCIENCE, V206, P1323, DOI 10.1126/science.390711; Barg S, 2000, DIABETES, V49, P1500, DOI 10.2337/diabetes.49.9.1500; Bode HP, 1999, PFLUG ARCH EUR J PHY, V437, P324, DOI 10.1007/s004240050786; Bossy-Wetzel E, 2004, NEURON, V41, P351, DOI 10.1016/S0896-6273(04)00015-7; Brissova M, 2005, J HISTOCHEM CYTOCHEM, V53, P1087, DOI 10.1369/jhc.5C6684.2005; Cabrera O, 2006, P NATL ACAD SCI USA, V103, P2334, DOI 10.1073/pnas.0510790103; Chang SA, 2004, METABOLISM, V53, P142, DOI 10.1016/S0026-0495(03)00314-7; Chimienti F, 2004, DIABETES, V53, P2330, DOI 10.2337/diabetes.53.9.2330; Chimienti F, 2006, J CELL SCI, V119, P4199, DOI 10.1242/jcs.03164; Cousins RJ, 2006, J BIOL CHEM, V281, P24085, DOI 10.1074/jbc.R600011200; Dineley KE, 2005, MITOCHONDRION, V5, P55, DOI 10.1016/j.mito.2004.11.001; Ducoudret O, 2003, BBA-BIOMEMBRANES, V1611, P171, DOI 10.1016/S0005-2736(03)00052-X; Dufner-Beattie J, 2004, J BIOL CHEM, V279, P49082, DOI 10.1074/jbc.M409962200; Dufner-Beattie J, 2003, J BIOL CHEM, V278, P50142, DOI 10.1074/jbc.M304163200; Eide DJ, 2006, BBA-MOL CELL RES, V1763, P711, DOI 10.1016/j.bbamcr.2006.03.005; Eide DJ, 2004, PFLUG ARCH EUR J PHY, V447, P796, DOI 10.1007/s00424-003-1074-3; Ellis CD, 2004, J CELL BIOL, V166, P325, DOI 10.1083/jcb.200401157; EMDIN SO, 1980, DIABETOLOGIA, V19, P174, DOI 10.1007/BF00275265; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Evans JL, 2002, ENDOCR REV, V23, P599, DOI 10.1210/er.2001-0039; FIGLEWICZ DP, 1980, DIABETES, V29, P767, DOI 10.2337/diacare.20.10.767; FOSTER MC, 1993, BIOPHYS J, V64, P525, DOI 10.1016/S0006-3495(93)81397-3; Fox JEM, 2006, ENDOCRINOLOGY, V147, P4655, DOI 10.1210/en.2006-0424; Franklin I, 2005, DIABETES, V54, P1808, DOI 10.2337/diabetes.54.6.1808; Frazzini V, 2006, BIOGERONTOLOGY, V7, P307, DOI 10.1007/s10522-006-9045-7; Gaither LA, 2001, J BIOL CHEM, V276, P22258, DOI 10.1074/jbc.M101772200; Gee KR, 2002, CELL CALCIUM, V31, P245, DOI 10.1016/S0143-4160(02)00053-2; GERICH JE, 1976, ANNU REV PHYSIOL, V38, P353, DOI 10.1146/annurev.ph.38.030176.002033; Gopel S, 2004, J PHYSIOL-LONDON, V556, P711, DOI 10.1113/jphysiol.2003.059675; Gopel SO, 2000, J PHYSIOL-LONDON, V528, P509, DOI 10.1111/j.1469-7793.2000.00509.x; Gromada J, 1997, J GEN PHYSIOL, V110, P217, DOI 10.1085/jgp.110.3.217; Gromada J, 2004, DIABETES, V53, pS181, DOI 10.2337/diabetes.53.suppl_3.S181; Gromada J, 2001, J PHYSIOL-LONDON, V535, P519, DOI 10.1111/j.1469-7793.2001.00519.x; Gromada J, 2007, ENDOCR REV, V28, P84, DOI 10.1210/er.2006-0007; Guan ZX, 2003, J INORG BIOCHEM, V97, P199, DOI 10.1016/S0162-0134(03)00291-5; Gyulkhandanyan AV, 2006, J BIOL CHEM, V281, P9361, DOI 10.1074/jbc.M508542200; Hara M, 2003, AM J PHYSIOL-ENDOC M, V284, pE177, DOI 10.1152/ajpendo.00321.2002; HESKETH TR, 1983, J BIOL CHEM, V258, P4876; Hjortoe GM, 2004, ACTA DIABETOL, V41, P185, DOI 10.1007/s00592-004-0164-9; HUTTON JC, 1983, BIOCHEM J, V210, P297, DOI 10.1042/bj2100297; Ishihara H, 2003, NAT CELL BIOL, V5, P330, DOI 10.1038/ncb951; Jiang DM, 2001, J BIOL CHEM, V276, P47524, DOI 10.1074/jbc.M108834200; Jiang GQ, 2003, AM J PHYSIOL-ENDOC M, V284, pE671, DOI 10.1152/ajpendo.00492.2002; Kambe T, 2002, J BIOL CHEM, V277, P19049, DOI 10.1074/jbc.M200910200; Kang YJ, 2006, EXP BIOL MED, V231, P1459, DOI 10.1177/153537020623100903; Kanno T, 2002, NEUROSCI RES, V42, P79, DOI 10.1016/S0168-0102(01)00318-2; Kirschke CP, 2003, J BIOL CHEM, V278, P4096, DOI 10.1074/jbc.M207644200; Leung YM, 2006, ENDOCRINOLOGY, V147, P2155, DOI 10.1210/en.2005-1249; Liuzzi JP, 2004, ANNU REV NUTR, V24, P151, DOI 10.1146/annurev.nutr.24.012003.132402; LUDVIGSEN C, 1979, DIABETES, V28, P570, DOI 10.2337/diab.28.6.570; Ma XS, 2005, MOL ENDOCRINOL, V19, P198, DOI 10.1210/me.2004-0059; Malaiyandi LM, 2005, J NEUROCHEM, V93, P1242, DOI 10.1111/j.1471-4159.2005.03116.x; Maret W, 2000, J NUTR, V130, p1455S, DOI 10.1093/jn/130.5.1455S; MARUYAMA H, 1984, J CLIN INVEST, V74, P2296, DOI 10.1172/JCI111658; Ohana E, 2004, J BIOL CHEM, V279, P4278, DOI 10.1074/jbc.M309229200; Olsen HL, 2005, ENDOCRINOLOGY, V146, P4861, DOI 10.1210/en.2005-0800; Palmiter RD, 2004, PFLUG ARCH EUR J PHY, V447, P744, DOI 10.1007/s00424-003-1070-7; Priel T, 2006, BIOCHEM BIOPH RES CO, V346, P205, DOI 10.1016/j.bbrc.2006.05.104; Quesada I, 1999, DIABETES, V48, P2390, DOI 10.2337/diabetes.48.12.2390; Ravier MA, 2005, DIABETES, V54, P1789, DOI 10.2337/diabetes.54.6.1789; Robertson RP, 2006, CURR OPIN PHARMACOL, V6, P615, DOI 10.1016/j.coph.2006.09.002; RORSMAN P, 1989, NATURE, V341, P233, DOI 10.1038/341233a0; SARIS NEL, 1994, FEBS LETT, V356, P195, DOI 10.1016/0014-5793(94)01256-3; Scott LJ, 2007, SCIENCE, V316, P1341, DOI 10.1126/science.1142382; Sekler I, 2007, MOL MED, V13, P337, DOI 10.2119/2007-00037.Sekler; Sensi SL, 2000, EUR J NEUROSCI, V12, P3813, DOI 10.1046/j.1460-9568.2000.00277.x; Sensi SL, 2003, P NATL ACAD SCI USA, V100, P6157, DOI 10.1073/pnas.1031598100; Sensi SL, 1997, J NEUROSCI, V17, P9554; Sensi SL, 2002, NEUROBIOL DIS, V10, P100, DOI 10.1006/nbdi.2002.0493; Sheline CT, 2002, NEUROBIOL DIS, V10, P41, DOI 10.1006/nbdi.2002.0497; Sladek R, 2007, NATURE, V445, P881, DOI 10.1038/nature05616; Smidt K, 2007, MOL CELL ENDOCRINOL, V264, P68, DOI 10.1016/j.mce.2006.10.010; Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; Wang FD, 2004, J BIOL CHEM, V279, P24631, DOI 10.1074/jbc.M400680200; Wendt A, 2004, DIABETES, V53, P1038, DOI 10.2337/diabetes.53.4.1038; Zeggini E, 2007, SCIENCE, V316, P1336, DOI 10.1126/science.1142364; Zhou HR, 2007, DIABETES, V56, P1107, DOI 10.2337/db06-1454	80	85	89	3	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					10184	10197		10.1074/jbc.M707005200	http://dx.doi.org/10.1074/jbc.M707005200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18250168	hybrid			2022-12-25	WOS:000254671600071
J	Mille, C; Bobrowicz, P; Trinel, PA; Li, H; Maes, E; Guerardel, Y; Fradin, C; Martinez-Esparaza, M; Davidson, RC; Janbon, G; Poulain, D; Wildt, S				Mille, Celine; Bobrowicz, Piotr; Trinel, Pierre-Andre; Li, Huijuan; Maes, Emmanuel; Guerardel, Yann; Fradin, Chantal; Martinez-Esparaza, Maria; Davidson, Robert C.; Janbon, Guilhem; Poulain, Daniel; Wildt, Stefan			Identification of a new family of genes involved in beta-1,2-mannosylation of Glycans in Pichia pastoris and Candida albicans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED OLIGOSACCHARIDES; CELL-WALL ANTIGENS; SACCHAROMYCES-CEREVISIAE; SEROTYPE-A; NIH B-792; OLIGOMANNOSYL RESIDUES; MONOCLONAL-ANTIBODIES; OVERLAP EXTENSION; YEAST; VIRULENCE	Structural studies of cell wall components of the pathogenic yeast Candida albicans have demonstrated the presence of beta-1,2-linked oligomannosides in phosphopeptidomannan and phospholipomannan. During C. albicans infection, beta-1,2-oligomannosides play an important role in host/pathogen interactions by acting as adhesins and by interfering with the host immune response. Despite the importance of beta-1,2-oligomannosides, the genes responsible for their synthesis have not been identified. The main reason is that the reference species Saccharomyces cerevisiae does not synthesize beta-linked mannoses. On the other hand, the presence of beta-1,2-oligomannosides has been reported in the cell wall of the more genetically tractable C. albicans relative, P. pastoris. Here we present the identification, cloning, and characterization of a novel family of fungal genes involved in beta-mannose transfer. Employing in silico analysis, we identified a family of four related new genes in P. pastoris and subsequently nine homologs in C. albicans. Biochemical, immunological, and structural analyses following deletion of four genes in P. pastoris and deletion of four genes acting specifically on C. albicans mannan demonstrated the involvement of these new genes in beta-1,2-oligomannoside synthesis. Phenotypic characterization of the strains deleted in beta- mannosyltransferase genes (BMTs) allowed us to describe the stepwise activity of Bmtps and acceptor specificity. For C. albicans, despite structural similarities between mannan and phospholipomannan, phospholipomannan beta-mannosylation was not affected by any of the CaBMT1-4 deletions. Surprisingly, depletion in mannan major beta-1,2-oligomannoside epitopes had little impact on cell wall surface beta-1,2-oligomannoside antigenic expression.	[Mille, Celine; Trinel, Pierre-Andre; Fradin, Chantal; Poulain, Daniel] Univ Lille 2, EA 2684, INSERM, U799,Unit Physiopathol Candidoses, F-59045 Lille, France; [Bobrowicz, Piotr; Li, Huijuan; Davidson, Robert C.; Wildt, Stefan] Merck & Co Inc, GlycoFi Inc, Lebanon, NH 03766 USA; [Maes, Emmanuel; Guerardel, Yann] CNRS, UMR 8576, Unit Glycobiol Struct & Fonctionnelle, F-59655 Villeneuve Dascq, France; [Martinez-Esparaza, Maria] Univ Murcia, Sch Med, Dept Biochem Mol Biol & Immunol, E-30100 Murcia, Spain; [Janbon, Guilhem] Inst Pasteur, Unit Mycol Mol, F-75015 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Merck & Company; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; University of Murcia; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Poulain, D (corresponding author), Univ Lille 2, EA 2684, INSERM, U799,Unit Physiopathol Candidoses, F-59045 Lille, France.	dpoulain@univ-lille2.fr	Fradin, Chantal/N-2382-2018; Janbon, Guilhem/AAW-7398-2021; Janbon, Guilhem/AAL-6607-2021; Poulain, Daniel/I-6095-2018	Fradin, Chantal/0000-0002-3883-4401; Janbon, Guilhem/0000-0002-4788-1154; Martinez-Esparza, Maria/0000-0001-5765-8231; Poulain, Daniel/0000-0002-0729-5468; Guerardel, Yann/0000-0003-4967-9512				Bates S, 2006, J BIOL CHEM, V281, P90, DOI 10.1074/jbc.M510360200; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; Calderone RA, 2001, TRENDS MICROBIOL, V9, P327, DOI 10.1016/S0966-842X(01)02094-7; Choi BK, 2003, P NATL ACAD SCI USA, V100, P5022, DOI 10.1073/pnas.0931263100; Davidson RC, 2004, GLYCOBIOLOGY, V14, P399, DOI 10.1093/glycob/cwh023; Dean N, 1999, BBA-GEN SUBJECTS, V1426, P309, DOI 10.1016/S0304-4165(98)00132-9; Dromer F, 2002, ANTIMICROB AGENTS CH, V46, P3869, DOI 10.1128/AAC.46.12.3869-3876.2002; DUBOIS M, 1951, NATURE, V168, P167, DOI 10.1038/168167a0; Edmond MB, 1999, CLIN INFECT DIS, V29, P239, DOI 10.1086/520192; Enjalbert B, 2006, MOL BIOL CELL, V17, P1018, DOI 10.1091/mbc.E05-06-0501; FAILLE C, 1992, CARBOHYD RES, V236, P17, DOI 10.1016/0008-6215(92)85004-J; Fradin C, 2000, INFECT IMMUN, V68, P4391, DOI 10.1128/IAI.68.8.4391-4398.2000; Gale CA, 1998, SCIENCE, V279, P1355, DOI 10.1126/science.279.5355.1355; Goins TL, 2000, J CLIN MICROBIOL, V38, P2862, DOI 10.1128/JCM.38.8.2862-2869.2000; Gola S, 2003, YEAST, V20, P1339, DOI 10.1002/yea.1044; Goldstein AL, 1999, YEAST, V15, P507, DOI 10.1002/(SICI)1097-0061(199904)15:6<507::AID-YEA369>3.0.CO;2-P; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; Han Y, 1997, INFECT IMMUN, V65, P4100, DOI 10.1128/IAI.65.10.4100-4107.1997; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hobson RP, 2004, J BIOL CHEM, V279, P39628, DOI 10.1074/jbc.M405003200; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Hoyer LL, 2001, TRENDS MICROBIOL, V9, P176, DOI 10.1016/S0966-842X(01)01984-9; Ibata-Ombetta S, 2003, J BIOL CHEM, V278, P13086, DOI 10.1074/jbc.M210680200; Jigami Y, 1999, BBA-GEN SUBJECTS, V1426, P335, DOI 10.1016/S0304-4165(98)00134-2; Jouault T, 2003, J INFECT DIS, V188, P165, DOI 10.1086/375784; Jouault T, 2000, INFECT IMMUN, V68, P965, DOI 10.1128/IAI.68.2.965-968.2000; KOBAYASHI H, 1992, INFECT IMMUN, V60, P2106, DOI 10.1128/IAI.60.5.2106-2109.1992; Kohatsu L, 2006, J IMMUNOL, V177, P4718, DOI 10.4049/jimmunol.177.7.4718; Latge JP, 1999, CLIN MICROBIOL REV, V12, P310, DOI 10.1128/CMR.12.2.310; LINDBERG B, 1988, CARBOHYD RES, V174, P313, DOI 10.1016/0008-6215(88)85100-0; Lorenz MC, 2001, NATURE, V412, P83, DOI 10.1038/35083594; Martinez-Esparza M, 2006, J IMMUNOL METHODS, V314, P90, DOI 10.1016/j.jim.2006.06.004; Mille C, 2004, J BIOL CHEM, V279, P47952, DOI 10.1074/jbc.M405534200; MOLINARI A, 1993, EUR J CELL BIOL, V60, P146; Murad AMA, 2000, YEAST, V16, P325, DOI 10.1002/1097-0061(20000315)16:4&lt;325::AID-YEA538&gt;3.0.CO;2-#; Naglik J, 2004, CELL MICROBIOL, V6, P915, DOI 10.1111/j.1462-5822.2004.00439.x; Nitz M, 2002, J BIOL CHEM, V277, P3440, DOI 10.1074/jbc.M109274200; Odani T, 1996, GLYCOBIOLOGY, V6, P805, DOI 10.1093/glycob/6.8.805; Oriol R, 2002, MOL BIOL EVOL, V19, P1451, DOI 10.1093/oxfordjournals.molbev.a004208; Papac DI, 1998, GLYCOBIOLOGY, V8, P445, DOI 10.1093/glycob/8.5.445; PONTON J, 1993, INFECT IMMUN, V61, P4842, DOI 10.1128/IAI.61.11.4842-4847.1993; Poulain D, 2004, CURR OPIN MICROBIOL, V7, P342, DOI 10.1016/j.mib.2004.06.011; Ralton JE, 2003, J BIOL CHEM, V278, P40757, DOI 10.1074/jbc.M307660200; Rouabhia M, 2005, INFECT IMMUN, V73, P4571, DOI 10.1128/IAI.73.8.4571-4580.2005; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanglard D, 1996, ANTIMICROB AGENTS CH, V40, P2300, DOI 10.1128/AAC.40.10.2300; Sernee MF, 2006, P NATL ACAD SCI USA, V103, P9458, DOI 10.1073/pnas.0603539103; SHIBATA N, 1985, ARCH BIOCHEM BIOPHYS, V243, P338, DOI 10.1016/0003-9861(85)90511-9; SHIBATA N, 1992, INFECT IMMUN, V60, P4100, DOI 10.1128/IAI.60.10.4100-4110.1992; SHIBATA N, 1992, BIOCHEMISTRY-US, V31, P5680, DOI 10.1021/bi00139a036; Sims CR, 2005, ARCH MED RES, V36, P660, DOI 10.1016/j.arcmed.2005.05.015; Singleton DR, 2005, EUKARYOT CELL, V4, P639, DOI 10.1128/EC.4.4.639-648.2005; Strahl-Bolsinger S, 1999, BBA-GEN SUBJECTS, V1426, P297, DOI 10.1016/S0304-4165(98)00131-7; Sundstrom P, 1999, CURR OPIN MICROBIOL, V2, P353, DOI 10.1016/S1369-5274(99)80062-9; SUZUKI S, 1995, YAKUGAKU ZASSHI, V115, P280, DOI 10.1248/yakushi1947.115.4_280; TRINEL PA, 1992, INFECT IMMUN, V60, P3845, DOI 10.1128/IAI.60.9.3845-3851.1992; Trinel PA, 2002, J BIOL CHEM, V277, P37260, DOI 10.1074/jbc.M202295200; Vinogradov E, 2000, CARBOHYD RES, V325, P216, DOI 10.1016/S0008-6215(99)00332-8; Whiteway M, 2000, CURR OPIN MICROBIOL, V3, P582, DOI 10.1016/S1369-5274(00)00144-2; Wildt S, 2005, NAT REV MICROBIOL, V3, P119, DOI 10.1038/nrmicro1087; Wilson RB, 1999, J BACTERIOL, V181, P1868, DOI 10.1128/JB.181.6.1868-1874.1999	62	70	104	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9724	9736		10.1074/jbc.M708825200	http://dx.doi.org/10.1074/jbc.M708825200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18234669	hybrid			2022-12-25	WOS:000254671600027
J	Fujishima, K; Sugahara, J; Tomita, M; Kanai, A				Fujishima, Kosuke; Sugahara, Junichi; Tomita, Masaru; Kanai, Akio			Sequence Evidence in the Archaeal Genomes that tRNAs Emerged Through the Combination of Ancestral Genes as 5 ' and 3 ' tRNA Halves	PLOS ONE			English	Article								The discovery of separate 5' and 3' halves of transfer RNA (tRNA) molecules-so-called split tRNA-in the archaeal parasite Nanoarchaeum equitans made us wonder whether ancestral tRNA was encoded on 1 or 2 genes. We performed a comprehensive phylogenetic analysis of tRNAs in 45 archaeal species to explore the relationship between the three types of tRNAs (nonintronic, intronic and split). We classified 1953 mature tRNA sequences into 22 clusters. All split tRNAs have shown phylogenetic relationships with other tRNAs possessing the same anticodon. We also mimicked split tRNA by artificially separating the tRNA sequences of 7 primitive archaeal species at the anticodon and analyzed the sequence similarity and diversity of the 5' and 3' tRNA halves. Network analysis revealed specific characteristics of and topological differences between the 5' and 3' tRNA halves: the 5' half sequences were categorized into 6 distinct groups with asequence similarity of >80%, while the 39 half sequences were categorized into 9 groups with a higher sequence similarity of >88%, suggesting different evolutionary backgrounds of the 2 halves. Furthermore, the combinations of 5' and 3' halves corresponded with the variation of amino acids in the codon table. We found not only universally conserved combinations of 5'-3' tRNA halves in tRNA(iMet), tRNA(Thr), tRNA(Ile), tRNA(Gly), tRNA(Gln), tRNA(Glu), tRNA(Asp), tRNA(Lys), tRNA(Arg) and tRNA(Leu) but also phylum-specific combinations in tRNA(Pro), tRNA(Ala), and tRNA(Trp). Our results support the idea that tRNA emerged through the combination of separate genes and explain the sequence diversity that arose during archaeal tRNA evolution.	[Fujishima, Kosuke; Sugahara, Junichi; Tomita, Masaru; Kanai, Akio] Keio Univ, Inst Adv Biosci, Yamagata, Japan; [Fujishima, Kosuke; Sugahara, Junichi; Tomita, Masaru; Kanai, Akio] Keio Univ, Grad Sch Media & Governance, Fujisawa, Kanagawa, Japan; [Tomita, Masaru; Kanai, Akio] Keio Univ, Dept Env & Informat, Fujisawa, Kanagawa, Japan	Keio University; Keio University; Keio University	Fujishima, K (corresponding author), Keio Univ, Inst Adv Biosci, Yamagata, Japan.	akio@sfc.keio.ac.jp	Kanai, Akio/C-4921-2014	Kanai, Akio/0000-0002-6362-2419; Fujishima, Kosuke/0000-0002-8844-812X	21st Century Center of Excellence (COE) Program, Keio University [Grant-in-Aid]; Yamagata Prefectural Government and Tsuruoka City, Japan	21st Century Center of Excellence (COE) Program, Keio University(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Yamagata Prefectural Government and Tsuruoka City, Japan	This research was supported in part by a Grant-in-Aid for Scientific Research on Priority Areas; a Grant-in-Aid for the 21st Century Center of Excellence (COE) Program, entitled Understanding and Control of Life's Function via Systems Biology (Keio University); research funds from the Yamagata Prefectural Government and Tsuruoka City, Japan; and a grant from Keio University.	Auchtung TA, 2006, APPL ENVIRON MICROB, V72, P5077, DOI 10.1128/AEM.00052-06; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Belfort M, 1997, CELL, V89, P1003, DOI 10.1016/S0092-8674(00)80287-1; Bingham J, 2000, BIOINFORMATICS, V16, P660, DOI 10.1093/bioinformatics/16.7.660; Brochier C, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-36; Chiang CC, 1997, MOL CELL BIOL, V17, P4526, DOI 10.1128/MCB.17.8.4526; Di Giulio M, 1999, J THEOR BIOL, V197, P403, DOI 10.1006/jtbi.1998.0882; Di Giulio M, 2006, J THEOR BIOL, V240, P343, DOI 10.1016/j.jtbi.2005.09.023; Di Giulio M, 2006, J THEOR BIOL, V242, P257, DOI 10.1016/j.jtbi.2006.01.034; Diener JL, 1998, MOL CELL, V1, P883, DOI 10.1016/S1097-2765(00)80087-8; DIGIULIO M, 1992, J THEOR BIOL, V159, P199; HIPPS D, 1995, P NATL ACAD SCI USA, V92, P5550, DOI 10.1073/pnas.92.12.5550; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; KACAR Y, 1995, GENE, V156, P129, DOI 10.1016/0378-1119(95)00079-L; Li H, 1998, SCIENCE, V280, P279, DOI 10.1126/science.280.5361.279; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; MAIZELS N, 1994, P NATL ACAD SCI USA, V91, P6729, DOI 10.1073/pnas.91.15.6729; Marck C, 2003, RNA, V9, P1516, DOI 10.1261/rna.5132503; Marck C, 2002, RNA, V8, P1189, DOI 10.1017/S1355838202022021; Nagaswamy U, 2003, ORIGINS LIFE EVOL B, V33, P199, DOI 10.1023/A:1024658727570; OHSHIMA K, 1993, P NATL ACAD SCI USA, V90, P6260, DOI 10.1073/pnas.90.13.6260; Pavlicek A, 2006, TRENDS GENET, V22, P69, DOI 10.1016/j.tig.2005.11.005; Randau L, 2005, P NATL ACAD SCI USA, V102, P17934, DOI 10.1073/pnas.0509197102; Randau L, 2005, FEBS LETT, V579, P2945, DOI 10.1016/j.febslet.2005.04.051; Randau L, 2005, NATURE, V433, P537, DOI 10.1038/nature03233; Schmitz J, 2004, GENOME RES, V14, P1911, DOI 10.1101/gr.2720104; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Soma A, 2007, SCIENCE, V318, P450, DOI 10.1126/science.1145718; Sugahara Junichi, 2006, In Silico Biology, V6, P411; Sugahara J, 2007, RNA, V13, P671, DOI 10.1261/rna.309507; Tang TH, 2002, NUCLEIC ACIDS RES, V30, P921, DOI 10.1093/nar/30.4.921; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tocchini-Valentini GD, 2005, P NATL ACAD SCI USA, V102, P15418, DOI 10.1073/pnas.0506750102; Wang SY, 1997, GENE, V196, P105, DOI 10.1016/S0378-1119(97)00214-X; Watanabe Y, 2002, FEBS LETT, V510, P27, DOI 10.1016/S0014-5793(01)03219-7; Waters E, 2003, P NATL ACAD SCI USA, V100, P12984, DOI 10.1073/pnas.1735403100; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Wei FP, 2006, MOL PHYLOGENET EVOL, V38, P1, DOI 10.1016/j.ympev.2005.09.017; Weiner AM, 1999, BIOL BULL, V196, P327, DOI 10.2307/1542962; Wilm A, 2006, ALGORITHM MOL BIOL, V1, DOI 10.1186/1748-7188-1-19; WONG JTF, 1975, P NATL ACAD SCI USA, V72, P1909, DOI 10.1073/pnas.72.5.1909; Yoshinari S, 2006, BIOCHEM BIOPH RES CO, V346, P1024, DOI 10.1016/j.bbrc.2006.06.011	42	33	36	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1622	10.1371/journal.pone.0001622	http://dx.doi.org/10.1371/journal.pone.0001622			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286179	Green Published, Green Submitted, gold			2022-12-25	WOS:000260586400015
J	Picardeau, M; Bulach, DM; Bouchier, C; Zuerner, RL; Zidane, N; Wilson, PJ; Creno, S; Kuczek, ES; Bommezzadri, S; Davis, JC; McGrath, A; Johnson, MJ; Boursaux-Eude, C; Seemann, T; Rouy, Z; Coppel, RL; Rood, JI; Lajus, A; Davies, JK; Medigue, C; Adler, B				Picardeau, Mathieu; Bulach, Dieter M.; Bouchier, Christiane; Zuerner, Richard L.; Zidane, Nora; Wilson, Peter J.; Creno, Sophie; Kuczek, Elizabeth S.; Bommezzadri, Simona; Davis, John C.; McGrath, Annette; Johnson, Matthew J.; Boursaux-Eude, Caroline; Seemann, Torsten; Rouy, Zoe; Coppel, Ross L.; Rood, Julian I.; Lajus, Aurelie; Davies, John K.; Medigue, Claudine; Adler, Ben			Genome Sequence of the Saprophyte Leptospira biflexa Provides Insights into the Evolution of Leptospira and the Pathogenesis of Leptospirosis	PLOS ONE			English	Article								Leptospira biflexa is a free-living saprophytic spirochete present in aquatic environments. We determined the genome sequence of L. biflexa, making it the first saprophytic Leptospira to be sequenced. The L. biflexa genome has 3,590 protein-coding genes distributed across three circular replicons: the major 3,604 chromosome, a smaller 278-kb replicon that also carries essential genes, and a third 74-kb replicon. Comparative sequence analysis provides evidence that L. biflexa is an excellent model for the study of Leptospira evolution; we conclude that 2052 genes (61%) represent a progenitor genome that existed before divergence of pathogenic and saprophytic Leptospira species. Comparisons of the L. biflexa genome with two pathogenic Leptospira species reveal several major findings. Nearly one-third of the L. biflexa genes are absent in pathogenic Leptospira. We suggest that once incorporated into the L. biflexa genome, laterally transferred DNA undergoes minimal rearrangement due to physical restrictions imposed by high gene density and limited presence of transposable elements. In contrast, the genomes of pathogenic Leptospira species undergo frequent rearrangements, often involving recombination between insertion sequences. Identification of genes common to the two pathogenic species, L. borgpetersenii and L. interrogans, but absent in L. biflexa, is consistent with a role for these genes in pathogenesis. Differences in environmental sensing capacities of L. biflexa, L. borgpetersenii, and L. interrogans suggest a model which postulates that loss of signal transduction functions in L. borgpetersenii has impaired its survival outside a mammalian host, whereas L. interrogans has retained environmental sensory functions that facilitate disease transmission through water.	[Picardeau, Mathieu; Bommezzadri, Simona] Inst Pasteur, Unite Biol Spirochetes, Paris, France; [Bulach, Dieter M.; Seemann, Torsten; Coppel, Ross L.; Rood, Julian I.; Davies, John K.; Adler, Ben] Monash Univ, Victorian Bioinformat Consort, Clayton, Vic, Australia; [Bulach, Dieter M.; Coppel, Ross L.; Rood, Julian I.; Davies, John K.; Adler, Ben] Monash Univ, Dept Microbiol, Australian Res Council, Ctr Excellence Struct & Funct Microb Genom, Clayton, Vic, Australia; [Bulach, Dieter M.; Rood, Julian I.; Davies, John K.; Adler, Ben] Monash Univ, Dept Microbiol, Australian Bacterial Pathogenesis Program, Clayton, Vic, Australia; [Bouchier, Christiane; Zidane, Nora; Creno, Sophie] Inst Pasteur, Plate forme Genom, Paris, France; [Zuerner, Richard L.] USDA, NADC, ARS, Bacter Dis Livestock Res Unit, Ames, IA USA; [Wilson, Peter J.; Kuczek, Elizabeth S.; Davis, John C.; McGrath, Annette; Johnson, Matthew J.] Univ Queensland, Gehrmann Lab, Australian Genome Res Facility, St Lucia, Qld, Australia; [Boursaux-Eude, Caroline] Inst Pasteur, Plate forme Integrat Analyse genom, Paris, France; [Rouy, Zoe; Lajus, Aurelie; Medigue, Claudine] Inst Genom, Lab Genom Comparat, Direct des Sci du Vivant, CEA, Evry, France; [Medigue, Claudine] CNRS, UMR8030, Evry, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Monash University; Monash University; Monash University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; United States Department of Agriculture (USDA); University of Queensland; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; CEA	Picardeau, M (corresponding author), Inst Pasteur, Unite Biol Spirochetes, Paris, France.	Ben.Adler@med.monash.edu.au	McGrath, Annette/T-7991-2018; Bulach, Dieter M/D-5793-2011; Seemann, Torsten/B-2318-2010; Coppel, Ross L/A-6626-2008; Zuerner, Richard/AAG-7645-2021; Rood, Julian I/A-4858-2008	McGrath, Annette/0000-0002-1765-7039; Bulach, Dieter M/0000-0001-9823-6078; Seemann, Torsten/0000-0001-6046-610X; Coppel, Ross L/0000-0002-4476-9124; Rood, Julian I/0000-0003-2126-7209; Kuczek, Elizabeth/0000-0002-5412-5509	National Health and Medical Research Council, Australia; Australian Research Council; U.S. Department of Agriculture; Institut Pasteur, Paris, France; French Ministry of Research ANR Jeunes Chercheurs [05-JCJC-0105-01]; Consortium National de Recherche en Genomique [RNG-20040057]; ACI IMPBio 2004 (MicroScope project)	National Health and Medical Research Council, Australia(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council(Australian Research Council); U.S. Department of Agriculture(United States Department of Agriculture (USDA)); Institut Pasteur, Paris, France; French Ministry of Research ANR Jeunes Chercheurs(French National Research Agency (ANR)Ministry of Research, France); Consortium National de Recherche en Genomique(General Electric); ACI IMPBio 2004 (MicroScope project)	This work was supported by the following: National Health and Medical Research Council, Australia; Australian Research Council; U.S. Department of Agriculture; Institut Pasteur, Paris, France; French Ministry of Research ANR Jeunes Chercheurs (no. 05-JCJC-0105-01); Consortium National de Recherche en Genomique (no. RNG-20040057); ACI IMPBio 2004 (MicroScope project). Funders had no role in the planning, performance or analysis of the work.	Babudieri B., 1961, STUDIO SEROLOGICO GR, P408; Barbosa AS, 2006, INFECT IMMUN, V74, P6356, DOI 10.1128/IAI.00460-06; Bocs S, 2003, NUCLEIC ACIDS RES, V31, P3723, DOI 10.1093/nar/gkg590; Bourhy P, 2005, J BACTERIOL, V187, P3931, DOI 10.1128/JB.187.12.3931-3940.2005; Bourhy P, 2007, INFECT IMMUN, V75, P677, DOI 10.1128/IAI.01067-06; Brenner DJ, 1999, INT J SYST BACTERIOL, V49, P839, DOI 10.1099/00207713-49-2-839; Bulach DM, 2006, P NATL ACAD SCI USA, V103, P14560, DOI 10.1073/pnas.0603979103; Choy HA, 2007, INFECT IMMUN, V75, P2441, DOI 10.1128/IAI.01635-06; Cullen PA, 2004, FEMS MICROBIOL REV, V28, P291, DOI 10.1016/j.femsre.2003.10.004; Cullen PA, 2003, INFECT IMMUN, V71, P2414, DOI 10.1128/IAI.71.5.2414-2421.2003; DELREAL G, 1989, INFECT IMMUN, V57, P2588, DOI 10.1128/IAI.57.8.2588-2590.1989; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Faine S, 1999, LEPTOSPIRA LEPTOSPIR, V2nd; Fuchsman CA, 2006, APPL ENVIRON MICROB, V72, P6841, DOI 10.1128/AEM.00429-06; Glockner G, 2004, NUCLEIC ACIDS RES, V32, P6038, DOI 10.1093/nar/gkh953; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Gordon D, 2001, GENOME RES, V11, P614, DOI 10.1101/gr.171401; Haake DA, 2004, J BACTERIOL, V186, P2818, DOI 10.1128/JB.186.9.2818-2828.2004; Ikegami A, 2004, INFECT IMMUN, V72, P4619, DOI 10.1128/IAI.72.8.4619-4627.2004; Kickstein E, 2007, MICROBIOL-SGM, V153, P2259, DOI 10.1099/mic.0.2007/005256-0; Levett PN, 2001, CLIN MICROBIOL REV, V14, P296, DOI 10.1128/CMR.14.2.296-326.2001; Louvel H, 2006, J BACTERIOL, V188, P7893, DOI 10.1128/JB.00711-06; LOUVEL H, 2007, CURRENT PROTOCOLS MI; Nascimento ALTO, 2004, J BACTERIOL, V186, P2164, DOI 10.1128/JB.186.7.2164-2172.2004; PASTER BJ, 1991, J BACTERIOL, V173, P6101, DOI 10.1128/JB.173.19.6101-6109.1991; RAMADASS P, 1992, INT J SYST BACTERIOL, V42, P215, DOI 10.1099/00207713-42-2-215; Ren SX, 2003, NATURE, V422, P888, DOI 10.1038/nature01597; Ristow P, 2007, PLOS PATHOG, V3, P894, DOI 10.1371/journal.ppat.0030097; Saint Girons I, 2000, J BACTERIOL, V182, P5700, DOI 10.1128/JB.182.20.5700-5705.2000; SAINTGIRONS I, 1990, RES MICROBIOL, V141, P1131, DOI 10.1016/0923-2508(90)90086-6; SEGERS RPAM, 1992, INFECT IMMUN, V60, P1707, DOI 10.1128/IAI.60.4.1707-1710.1992; SEGERS RPAM, 1990, INFECT IMMUN, V58, P2177, DOI 10.1128/IAI.58.7.2177-2185.1990; Stamm LA, 2004, MICROBES INFECT, V6, P1418, DOI 10.1016/j.micinf.2004.10.003; Stinear TP, 2007, GENOME RES, V17, P192, DOI 10.1101/gr.5942807; Trueba G, 2004, INT MICROBIOL, V7, P35; Vallenet D, 2006, NUCLEIC ACIDS RES, V34, P53, DOI 10.1093/nar/gkj406; Verma A, 2006, INFECT IMMUN, V74, P2659, DOI 10.1128/IAI.74.5.2659-2666.2006; ZUERNER RL, 1993, J BACTERIOL, V175, P5445, DOI 10.1128/JB.175.17.5445-5451.1993	38	221	639	1	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1607	10.1371/journal.pone.0001607	http://dx.doi.org/10.1371/journal.pone.0001607			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270594	Green Submitted, Green Published, gold			2022-12-25	WOS:000260535900041
J	Warden, CD; Kim, SH; Yi, SV				Warden, Charles D.; Kim, Seong-Ho; Yi, Soojin V.			Predicted Functional RNAs within Coding Regions Constrain Evolutionary Rates of Yeast Proteins	PLOS ONE			English	Article							NONCODING RNAS; SECONDARY STRUCTURES; SEQUENCE; IDENTIFICATION; DIVERGENCE; EXPRESSION; SELECTION; ELEMENTS; PACKAGE	Functional RNAs (fRNAs) are being recognized as an important regulatory component in biological processes. Interestingly, recent computational studies suggest that the number and biological significance of functional RNAs within coding regions (coding fRNAs) may have been underestimated. We hypothesized that such coding fRNAs will impose additional constraint on sequence evolution because the DNA primary sequence has to simultaneously code for functional RNA secondary structures on the messenger RNA in addition to the amino acid codons for the protein sequence. To test this prediction, we first utilized computational methods to predict conserved fRNA secondary structures within multiple species alignments of Saccharomyces sensu strico genomes. We predict that as much as 5% of the genes in the yeast genome contain at least one functional RNA secondary structure within their protein-coding region. We then analyzed the impact of coding fRNAs on the evolutionary rate of protein-coding genes because a decrease in evolutionary rate implies constraint due to biological functionality. We found that our predicted coding fRNAs have a significant influence on evolutionary rates (especially at synonymous sites), independent of other functional measures. Thus, coding fRNA may play a role on sequence evolution. Given that coding regions of humans and flies contain many more predicted coding fRNAs than yeast, the impact of coding fRNAs on sequence evolution may be substantial in genomes of higher eukaryotes.	[Warden, Charles D.; Yi, Soojin V.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; [Kim, Seong-Ho] Indiana Univ, Sch Med, Div Biostat, Indianapolis, IN USA	Princeton University; Indiana University System; Indiana University-Purdue University Indianapolis	Warden, CD (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.	soojinyi@gatech.edu		Warden, Charles/0000-0002-1827-4486				Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Blanchette M, 2004, GENOME RES, V14, P708, DOI 10.1101/gr.1933104; Cherry JM, 1997, NATURE, V387, P67, DOI 10.1038/387s067; Chung WY, 2007, PLOS COMPUT BIOL, V3, P855, DOI 10.1371/journal.pcbi.0030091; Deutschbauer AM, 2005, GENETICS, V169, P1915, DOI 10.1534/genetics.104.036871; Drummond DA, 2006, MOL BIOL EVOL, V23, P327, DOI 10.1093/molbev/msj038; Drummond DA, 2005, P NATL ACAD SCI USA, V102, P14338, DOI 10.1073/pnas.0504070102; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Giardine B, 2005, GENOME RES, V15, P1451, DOI 10.1101/gr.4086505; Griffiths-Jones S, 2007, ANNU REV GENOM HUM G, V8, P279, DOI 10.1146/annurev.genom.8.080706.092419; Gu ZL, 2002, TRENDS GENET, V18, P609, DOI 10.1016/S0168-9525(02)02837-8; Guan YF, 2007, GENETICS, V175, P933, DOI 10.1534/genetics.106.064329; Han JDJ, 2004, NATURE, V430, P88, DOI 10.1038/nature02555; Hertel J, 2006, BIOINFORMATICS, V22, pE197, DOI 10.1093/bioinformatics/btl257; Higuchi M, 2000, NATURE, V406, P78, DOI 10.1038/35017558; Hirsh AE, 2005, MOL BIOL EVOL, V22, P174, DOI 10.1093/molbev/msh265; HOFACKER IL, 1994, MONATSH CHEM, V125, P167, DOI 10.1007/BF00818163; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129; Katz L, 2003, GENOME RES, V13, P2042, DOI 10.1101/gr.1257503; Kawahara T, 1998, J BIOL CHEM, V273, P1802, DOI 10.1074/jbc.273.3.1802; Kim SH, 2007, GENETICA, V131, P151, DOI 10.1007/s10709-006-9125-2; Kim SH, 2006, MOL BIOL EVOL, V23, P1068, DOI 10.1093/molbev/msj115; Lin YS, 2007, MOL BIOL EVOL, V24, P1005, DOI 10.1093/molbev/msm019; Marais G, 2001, J MOL EVOL, V52, P275, DOI 10.1007/s002390010155; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; McCutcheon JP, 2003, NUCLEIC ACIDS RES, V31, P4119, DOI 10.1093/nar/gkg438; Mevik BH, 2007, J STAT SOFTW, V18, P1, DOI 10.18637/jss.v018.i02; Missal K, 2005, BIOINFORMATICS, V21, P77, DOI 10.1093/bioinformatics/bti1113; Namy O, 2004, MOL CELL, V13, P157, DOI 10.1016/S1097-2765(04)00031-0; Ouellet DL, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/69616; Pedersen JS, 2006, PLOS COMPUT BIOL, V2, P251, DOI 10.1371/journal.pcbi.0020033; Piriyapongsa J, 2007, GENETICS, V176, P1323, DOI 10.1534/genetics.107.072553; Pollard KS, 2006, PLOS GENET, V2, P1599, DOI 10.1371/journal.pgen.0020168; Pollard KS, 2006, NATURE, V443, P167, DOI 10.1038/nature05113; R Development Core Team, 2006, R LANG ENV STAT COMP; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; Siepel A, 2005, GENOME RES, V15, P1034, DOI 10.1101/gr.3715005; Stark A, 2007, NATURE, V450, P219, DOI 10.1038/nature06340; Steigele S, 2007, BMC BIOL, V5, DOI 10.1186/1741-7007-5-25; Storz G, 2005, ANNU REV BIOCHEM, V74, P199, DOI 10.1146/annurev.biochem.74.082803.133136; Wall DP, 2005, P NATL ACAD SCI USA, V102, P5483, DOI 10.1073/pnas.0501761102; Washietl S, 2005, NAT BIOTECHNOL, V23, P1383, DOI 10.1038/nbt1144; Washietl S, 2005, P NATL ACAD SCI USA, V102, P2454, DOI 10.1073/pnas.0409169102; Washietl S, 2007, GENOME RES, V17, P852, DOI 10.1101/gr.5650707; Weile C, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-244; Whittaker J, 1996, GRAPHICAL MODELS APP; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555; Zhang Z, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-S1-S14	49	14	15	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1559	10.1371/journal.pone.0001559	http://dx.doi.org/10.1371/journal.pone.0001559			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270559	gold, Green Published, Green Submitted			2022-12-25	WOS:000260535900004
J	Havasi, A; Li, ZJ; Wang, ZY; Martin, JL; Botla, V; Ruchalski, K; Schwartz, JH; Borkan, SC				Havasi, Andrea; Li, Zhijian; Wang, Zhiyong; Martin, Jody L.; Botla, Venugopal; Ruchalski, Kathleen; Schwartz, John H.; Borkan, Steven C.			Hsp27 inhibits Bax activation and apoptosis via a phosphatidylinositol 3-kinase-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; CELL-DEATH; POTENTIAL ROLE; ATP DEPLETION; BETA-CATENIN; PHOSPHORYLATION; TRANSLOCATION; STRESS; HEAT-SHOCK-PROTEIN-27; KINASE	Hsp27 inhibits mitochondrial injury and apoptosis in both normal and cancer cells by an unknown mechanism. To test the hypothesis that Hsp27 decreases apoptosis by inhibiting Bax, Hsp27 expression was manipulated in renal epithelial cells before transient metabolic stress, an insult that activates Bax, induces mitochondrial injury, and causes apoptosis. Compared with control, enhanced Hsp27 expression inhibited conformational Bax activation, oligomerization, and translocation to mitochondria, reduced the leakage of both cytochrome c and apoptosis-inducing factor, and significantly improved cell survival by > 50% after stress. In contrast, Hsp27 down-regulation using RNA-mediated interference promoted Bax activation, increased Bax translocation, and reduced cell survival after stress. Immunoprecipitation did not detect Hsp27-Bax interaction before, during, or after stress, suggesting that Hsp27 indirectly inhibits Bax. During stress, Hsp27 expression prevented the inactivation of Akt, a pro-survival kinase, and increased the interaction between Akt and Bax, an Akt substrate. In contrast, Hsp27 RNA-mediated interference promoted Akt inactivation during stress. Hsp27 up-or down-regulation markedly altered the activity of phosphatidylinositol 3-kinase (PI3-kinase), a major regulator of Akt. Furthermore, distinct PI3-kinase inhibitors completely abrogated the protective effect of Hsp27 expression on Akt activation, Bax inactivation, and cell survival. These data show that Hsp27 antagonizes Bax-mediated mitochondrial injury and apoptosis by promoting Akt activation via a PI3-kinase-dependent mechanism.	[Havasi, Andrea; Wang, Zhiyong; Botla, Venugopal; Ruchalski, Kathleen; Schwartz, John H.; Borkan, Steven C.] Boston Med Ctr, Boston, MA 02118 USA; [Li, Zhijian] Zhongshan Univ, Affiliated Hosp 1, Guangzhou 510080, Peoples R China; [Martin, Jody L.] Loyola Univ, Cardiovasc Inst, Maywood, IL 60153 USA	Boston Medical Center; Sun Yat Sen University; Loyola University Chicago	Borkan, SC (corresponding author), Boston Med Ctr, 650 Albany St,EBRC Rm 546, Boston, MA 02118 USA.	sborkan@bu.edu	Schwartz, John/AAO-8158-2021	Schwartz, John/0000-0002-1660-8681; Wang, Zhiyon/0000-0002-6471-266X; Borkan, Steven/0000-0003-3062-9486; Havasi, Andrea/0000-0002-8758-0823	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052898, R01DK053387] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-52898, DK-53387] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Adachi M, 2004, AM J PHYSIOL-GASTR L, V287, pG695, DOI 10.1152/ajpgi.00415.2003; Akbar MT, 2003, J BIOL CHEM, V278, P19956, DOI 10.1074/jbc.M207073200; Benn SC, 2002, NEURON, V36, P45, DOI 10.1016/S0896-6273(02)00941-8; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; BORKAN SC, 1993, AM J PHYSIOL, V265, pF333, DOI 10.1152/ajprenal.1993.265.3.F333; Brar BK, 1999, J MOL CELL CARDIOL, V31, P135, DOI 10.1006/jmcc.1998.0857; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Bush KT, 2000, AM J PHYSIOL-RENAL, V278, pF847, DOI 10.1152/ajprenal.2000.278.5.F847; Chiang GJ, 2005, BJU INT, V96, P416, DOI 10.1111/j.1464-410X.2005.05642.x; Concannon CG, 2001, GENE EXPRESSION, V9, P195, DOI 10.3727/000000001783992605; De Giorgi F, 2002, FASEB J, V16, P607, DOI 10.1096/fj.01-0269fje; Ferns G, 2006, INT J EXP PATHOL, V87, P253, DOI 10.1111/j.1365-2613.2006.00484.x; Gardai SJ, 2004, J BIOL CHEM, V279, P21085, DOI 10.1074/jbc.M400063200; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Garrido C, 1997, CANCER RES, V57, P2661; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Grzesiak JJ, 2005, INT J CANCER, V114, P522, DOI 10.1002/ijc.20748; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hetz C, 2005, J BIOL CHEM, V280, P42960, DOI 10.1074/jbc.M505843200; Hollander JM, 2004, CIRCULATION, V110, P3544, DOI 10.1161/01.CIR.0000148825.99184.50; Horbinski C, 2005, FREE RADICAL BIO MED, V38, P2, DOI 10.1016/j.freeradbiomed.2004.09.030; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Huang JH, 2005, CIRCULATION, V112, P76, DOI 10.1161/CIRCULATIONAHA.105.535740; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; Li F, 2002, AM J PHYSIOL-CELL PH, V283, pC917, DOI 10.1152/ajpcell.00517.2001; Lieberthal W, 1998, AM J PHYSIOL-RENAL, V275, pF691, DOI 10.1152/ajprenal.1998.275.5.F691; Lieberthal W, 1996, AM J PHYSIOL-RENAL, V271, pF477, DOI 10.1152/ajprenal.1996.271.3.F477; Linseman DA, 2004, J NEUROSCI, V24, P9993, DOI 10.1523/JNEUROSCI.2057-04.2004; Martin JL, 1999, GENE EXPRESSION, V7, P349; Martin JL, 1997, CIRCULATION, V96, P4343; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Munshi HG, 2002, J BIOL CHEM, V277, P38159, DOI 10.1074/jbc.M202384200; OESTERREICH S, 1993, CANCER RES, V53, P4443; Paul C, 2002, MOL CELL BIOL, V22, P816, DOI 10.1128/MCB.22.3.816-834.2002; Price VR, 2002, J AM SOC NEPHROL, V13, P1152, DOI 10.1097/01.ASN.0000012609.22035.44; Ruchalski K, 2006, J BIOL CHEM, V281, P7873, DOI 10.1074/jbc.M513728200; Ruchalski K, 2003, AM J PHYSIOL-CELL PH, V285, pC1483, DOI 10.1152/ajpcell.00049.2003; Saikumar P, 1998, ONCOGENE, V17, P3401, DOI 10.1038/sj.onc.1202590; Schwartz JH, 1999, J AM SOC NEPHROL, V10, P2297; Sinha D, 2003, AM J PHYSIOL-RENAL, V284, pF488, DOI 10.1152/ajprenal.00172.2002; Somasiri A, 2000, DIFFERENTIATION, V66, P116, DOI 10.1046/j.1432-0436.2000.660206.x; Suga H, 2005, ARCH BIOCHEM BIOPHYS, V438, P137, DOI 10.1016/j.abb.2005.04.002; Ueda N, 2000, AM J MED, V108, P403, DOI 10.1016/S0002-9343(00)00311-9; Wang YH, 1999, KIDNEY INT, V55, P2224, DOI 10.1046/j.1523-1755.1999.00476.x; Wang YH, 1996, AM J PHYSIOL-RENAL, V270, pF1057, DOI 10.1152/ajprenal.1996.270.6.F1057; Wolfs TGAM, 2005, AM J TRANSPLANT, V5, P68, DOI 10.1111/j.1600-6143.2004.00657.x; Wu R, 2007, J BIOL CHEM, V282, P21598, DOI 10.1074/jbc.M611316200	49	174	191	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2008	283	18					12305	12313		10.1074/jbc.M801291200	http://dx.doi.org/10.1074/jbc.M801291200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	293MS	18299320	hybrid, Green Published			2022-12-25	WOS:000255340000047
J	Clemencon, B; Rey, M; Dianoux, AC; Trezeguet, R; Lauquin, GJM; Brandolin, G; Pelosi, L				Clemencon, Benjamin; Rey, Martial; Dianoux, Anne-Christine; Trezeguet, Ronique; Lauquin, Guy J. -M.; Brandolin, Gerard; Pelosi, Ludovic			Structure-function relationships of the C-terminal end of the Saccharomyces cerevisiae ADP/ATP carrier isoform 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-ATP CARRIER; ADENINE-NUCLEOTIDE CARRIER; CONFORMATIONAL-CHANGES; N-ETHYLMALEIMIDE; MATRIX LOOP; YEAST; MITOCHONDRIA; PROTEIN; MEMBRANE; RESIDUES	The adenine nucleotide carrier (Ancp) catalyzes the transport of ADP and ATP across the mitochondrial inner membrane, thus playing an essential role in the cellular energy metabolism. Two regions of Anc2p from Saccharomyces cerevisiae are specifically photolabeled using a photoactivable ADP derivative; they are the central matrix loop, m2, and the C-terminal end. To get more insights into the structure-function relationships of the C-terminal region during nucleotide transport, we have developed two independent approaches. In the first we have deleted the last eight amino acids of Anc2p (Anc2p Delta Cter) and demonstrated that the C-terminal end of Anc2p plays an essential role in yeast growth on a non-fermentable carbon source. This resulted from impaired nucleotide binding properties of the Anc2p Delta Cter variant in line with conversion of ADP binding sites from high to low affinity. In the second we probed the ligand-induced conformational changes of Anc2p C-terminal end (i) by assessing its accessibility to anti-C-terminal antibodies and (ii) by measuring intrinsic fluorescence changes of an Anc2p mutant containing only one tryptophan residue located at its C-terminal end (Anc2p3Y-u). We show that the C- terminal region is no further accessible to antibodies when Anc2p binds nontransportable analogues of ADP. Besides, Trp-316 fluorescence is highly increased upon ligand binding, suggesting large conformational changes. Taken together, our results highlight the involvement of the Anc2p C- terminal region in nucleotide recognition, binding, and transport.	[Clemencon, Benjamin; Rey, Martial; Dianoux, Anne-Christine; Brandolin, Gerard; Pelosi, Ludovic] Univ Grenoble 1, CNRS Commissariat Energie Atom, UMR 5092, Lab Biochem & Biophys Syst Integres,Inst Rech Tec, F-38054 Grenoble 9, France; [Trezeguet, Ronique; Lauquin, Guy J. -M.] Univ Bordeaux 2, Inst Biochim & Genet Cellulaires, CNRS, UMR 5095,Lab Physiol Mol & Cellulaire, F-33077 Bordeaux, France	CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Pelosi, L (corresponding author), Univ Grenoble 1, CNRS Commissariat Energie Atom, UMR 5092, Lab Biochem & Biophys Syst Integres,Inst Rech Tec, F-38054 Grenoble 9, France.	ludovic.pelosi@cea.fr	Pelosi, Ludovic/AAB-9832-2020; Pelosi, Ludovic/M-6406-2014	Pelosi, Ludovic/0000-0002-4198-5681; Trezeguet, Veronique/0000-0003-2487-7571; Rey, Martial/0000-0002-7378-1106				Bamber L, 2007, J MOL BIOL, V371, P388, DOI 10.1016/j.jmb.2007.05.072; Bamber L, 2007, P NATL ACAD SCI USA, V104, P10830, DOI 10.1073/pnas.0703969104; Bamber L, 2006, P NATL ACAD SCI USA, V103, P16224, DOI 10.1073/pnas.0607640103; BLOCK MR, 1982, BIOCHEMISTRY-US, V21, P5451, DOI 10.1021/bi00265a011; BLOCK MR, 1984, BIOCHIM BIOPHYS ACTA, V767, P369, DOI 10.1016/0005-2728(84)90207-X; BLOCK MR, 1980, FEBS LETT, V117, P335, DOI 10.1016/0014-5793(80)80975-6; BOULAY F, 1984, BIOCHEMISTRY-US, V23, P4807, DOI 10.1021/bi00315a042; BRANDOLIN G, 1974, FEBS LETT, V46, P149, DOI 10.1016/0014-5793(74)80356-X; BRANDOLIN G, 1989, BIOCHEMISTRY-US, V28, P1093, DOI 10.1021/bi00429a025; BRANDOLIN G, 1993, BIOCHEM BIOPH RES CO, V192, P143, DOI 10.1006/bbrc.1993.1393; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; Dahout-Gonzalez C, 2006, PHYSIOLOGY, V21, P242, DOI 10.1152/physiol.00005.2006; Dahout-Gonzalez C, 2005, BIOCHEMISTRY-US, V44, P16310, DOI 10.1021/bi0514820; DALBON P, 1988, BIOCHEMISTRY-US, V27, P5141, DOI 10.1021/bi00414a029; DEMARCOS L, 2002, THESIS U  BORDEAUX 2; Dianoux AC, 2000, BIOCHEMISTRY-US, V39, P11477, DOI 10.1021/bi000618l; DRGON T, 1991, FEBS LETT, V289, P159, DOI 10.1016/0014-5793(91)81059-H; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Hatanaka T, 2001, BIOCHEM BIOPH RES CO, V286, P936, DOI 10.1006/bbrc.2001.5498; Iwahashi A, 2006, MITOCHONDRION, V6, P245, DOI 10.1016/j.mito.2006.07.007; Kihira Y, 2005, BIOCHEMISTRY-US, V44, P184, DOI 10.1021/bi0488653; Kihira Y, 2004, BIOCHEMISTRY-US, V43, P15204, DOI 10.1021/bi0494222; Kihira Y, 2007, BIOL PHARM BULL, V30, P885, DOI 10.1248/bpb.30.885; KLINGENBERG M, 1978, BIOCHIM BIOPHYS ACTA, V503, P193, DOI 10.1016/0005-2728(78)90182-2; LAUQUIN GJM, 1976, BIOCHEMISTRY-US, V15, P2316, DOI 10.1021/bi00656a011; LeSaux A, 1996, BIOCHEMISTRY-US, V35, P16116, DOI 10.1021/bi961714i; Lousa CD, 2002, BIOCHEMISTRY-US, V41, P14412, DOI 10.1021/bi02641490; MAJIMA E, 1993, J BIOL CHEM, V268, P22181; MAYER I, 1984, BIOCHEMISTRY-US, V23, P2436, DOI 10.1021/bi00306a018; PASSARELLA S, 1988, BIOCHEM BIOPH RES CO, V156, P978, DOI 10.1016/S0006-291X(88)80940-9; Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056; SCHLIMME E, 1983, FEBS LETT, V155, P6, DOI 10.1016/0014-5793(83)80197-5; WEIDEMAN.MJ, 1970, EUR J BIOCHEM, V16, P313, DOI 10.1111/j.1432-1033.1970.tb01086.x	33	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11218	11225		10.1074/jbc.M709565200	http://dx.doi.org/10.1074/jbc.M709565200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18299327	hybrid			2022-12-25	WOS:000255067400017
J	Ghosh, R; Chhabra, A; Phatale, PA; Samrat, SK; Sharma, J; Gosain, A; Mohanty, D; Saran, S; Gokhale, RS				Ghosh, Ratna; Chhabra, Arush; Phatale, Pallavi A.; Samrat, Subodh K.; Sharma, Jyoti; Gosain, Anuradha; Mohanty, Debasisa; Saran, Shweta; Gokhale, Rajesh S.			Dissecting the functional role of polyketide synthases in dictyostelium discoideum - Biosynthesis of the differentiation regulating factor 4-methyl-5-pentylbenzene-1,3-diol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR SLIME-MOLDS; ROOT HAIRS; MECHANISM; GENOME; MACHINERY; ACID	Dictyostelium discoideum exhibits the largest repository of polyketide synthase (PKS) proteins of all known genomes. However, the functional relevance of these proteins in the biology of this organism remains largely obscure. On the basis of computational, biochemical, and gene expression studies, we propose that the multifunctional Dictyostelium PKS (DiPKS) protein DiPKS1 could be involved in the biosynthesis of the differentiation regulating factor 4-methyl-5-pentylbenzene-1,3-diol (MPBD). Our cell-free reconstitution studies of a novel acyl carrier protein Type III PKS didomain from DiPKS1 revealed a crucial role of protein-protein interactions in determining the final biosynthetic product. Whereas the Type III PKS domain by itself primarily produces acyl pyrones, the presence of the interacting acyl carrier protein domain modulates the catalytic activity to produce the alkyl resorcinol scaffold of MPBD. Furthermore, we have characterized an O-methyltransferase (OMT12) from Dictyostelium with the capability to modify this resorcinol ring to synthesize a variant of MPBD. We propose that such a modification in vivo could in fact provide subtle variations in biological function and specificity. In addition, we have performed systematic computational analysis of 45 multidomain PKSs, which revealed several unique features in DiPKS proteins. Our studies provide a new perspective in understanding mechanisms by which metabolic diversity could be generated by combining existing functional scaffolds.	[Ghosh, Ratna; Chhabra, Arush; Phatale, Pallavi A.; Samrat, Subodh K.; Sharma, Jyoti; Mohanty, Debasisa; Gokhale, Rajesh S.] Natl Inst Immunol, New Delhi 110067, India; [Gosain, Anuradha; Saran, Shweta] Jawaharlal Nehru Univ, Sch Life Sci, New Delhi 110067, India; [Gokhale, Rajesh S.] Jawaharlal Nehru Ctr Adv Sci Res, Bangalore 560064, Karnataka, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII); Jawaharlal Nehru University, New Delhi; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Gokhale, RS (corresponding author), Natl Inst Immunol, Aruna Asaf Ali Marg, New Delhi 110067, India.	rsg@nii.res.in	Samrat, Subodh/AAA-2083-2021; Mohanty, Debasisa/A-1428-2009; samrat, subodh/AAN-1043-2021	Samrat, Subodh/0000-0002-8600-3901; MOHANTY, DEBASISA/0000-0002-3374-0588; Sharma, Jyoti/0000-0003-3299-9907	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Ansari MZ, 2004, NUCLEIC ACIDS RES, V32, pW405, DOI 10.1093/nar/gkh359; Austin MB, 2003, NAT PROD REP, V20, P79, DOI 10.1039/b100917f; Austin MB, 2006, NAT CHEM BIOL, V2, P494, DOI 10.1038/nchembio811; Baerson SR, 2008, J BIOL CHEM, V283, P3231, DOI 10.1074/jbc.M706587200; Cane DE, 1998, SCIENCE, V282, P63, DOI 10.1126/science.282.5386.63; Chisholm RL, 2006, NUCLEIC ACIDS RES, V34, pD423, DOI 10.1093/nar/gkj090; Cox RJ, 2007, ORG BIOMOL CHEM, V5, P2010, DOI 10.1039/b704420h; Dayan FE, 2007, J EXP BOT, V58, P3263, DOI 10.1093/jxb/erm173; Eichinger L, 2005, NATURE, V435, P43, DOI 10.1038/nature03481; FAUNAM EB, 1999, S ADENOSYLMETHIONINE, P1; Funa N, 2006, P NATL ACAD SCI USA, V103, P6356, DOI 10.1073/pnas.0511227103; Funa N, 2007, J BIOL CHEM, V282, P14476, DOI 10.1074/jbc.M701239200; Gabb HA, 1997, J MOL BIOL, V272, P106, DOI 10.1006/jmbi.1997.1203; Gaitatzis N, 2001, P NATL ACAD SCI USA, V98, P11136, DOI 10.1073/pnas.201167098; Gokhale RS, 2007, CURR OPIN STRUC BIOL, V17, P736, DOI 10.1016/j.sbi.2007.08.021; Gokhale RS, 2007, NAT PROD REP, V24, P267, DOI 10.1039/b616817p; Gruschow S, 2007, CHEMBIOCHEM, V8, P863, DOI 10.1002/cbic.200700026; Khosla C, 2007, ANNU REV BIOCHEM, V76, P195, DOI 10.1146/annurev.biochem.76.053105.093515; Kikuchi H, 2005, J ORG CHEM, V70, P8854, DOI 10.1021/jo051352x; Kikuchi H, 2002, TETRAHEDRON LETT, V43, P1477, DOI 10.1016/S0040-4039(02)00038-2; Kikuchi H, 2001, J ORG CHEM, V66, P6982, DOI 10.1021/jo015657x; Kopp F, 2006, J AM CHEM SOC, V128, P16478, DOI 10.1021/ja0667458; Kuspa Adam, 2006, V346, P15; MORRIS HR, 1988, BIOCHEM J, V249, P903, DOI 10.1042/bj2490903; Saito T, 2006, BBA-GEN SUBJECTS, V1760, P754, DOI 10.1016/j.bbagen.2005.12.006; Sankaranarayanan R, 2004, NAT STRUCT MOL BIOL, V11, P894, DOI 10.1038/nsmb809; Sankaranarayanan R, 2006, NAT CHEM BIOL, V2, P451, DOI 10.1038/nchembio0906-451; Saxena P, 2003, J BIOL CHEM, V278, P44780, DOI 10.1074/jbc.M306714200; Schracke N, 2005, BIOCHEMISTRY-US, V44, P8507, DOI 10.1021/bi050074t; Serafimidis I, 2005, DEV BIOL, V282, P432, DOI 10.1016/j.ydbio.2005.03.023; Shaulsky G, 2007, CURR BIOL, V17, pR684, DOI 10.1016/j.cub.2007.06.024; Song LJ, 2006, J AM CHEM SOC, V128, P14754, DOI 10.1021/ja065247w; Strmecki L, 2005, DEV BIOL, V284, P25, DOI 10.1016/j.ydbio.2005.05.011; Takaya Y, 2001, TETRAHEDRON LETT, V42, P61, DOI 10.1016/S0040-4039(00)01879-7; Takaya Y, 2000, J ORG CHEM, V65, P985, DOI 10.1021/jo991338i; Thompson CRL, 2000, MOL CELL, V6, P1509, DOI 10.1016/S1097-2765(00)00147-7; Trivedi OA, 2005, MOL CELL, V17, P631, DOI 10.1016/j.molcel.2005.02.009; Weijer CJ, 2004, CURR OPIN GENET DEV, V14, P392, DOI 10.1016/j.gde.2004.06.006; Yadav G, 2003, J MOL BIOL, V328, P335, DOI 10.1016/S0022-2836(03)00232-8	39	31	36	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11348	11354		10.1074/jbc.M709588200	http://dx.doi.org/10.1074/jbc.M709588200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18252726	hybrid			2022-12-25	WOS:000255067400031
J	Gorshkova, I; He, D; Berdyshev, E; Usatuyk, P; Burns, M; Kalari, S; Zhao, Y; Pendyala, S; Garcia, JGN; Pyne, NJ; Brindley, DN; Natarajan, V				Gorshkova, Irina; He, Donghong; Berdyshev, Evgeny; Usatuyk, Peter; Burns, Michael; Kalari, Satish; Zhao, Yutong; Pendyala, Srikanth; Garcia, Joe G. N.; Pyne, Nigel J.; Brindley, David N.; Natarajan, Viswanathan			Protein kinase C-epsilon regulates sphingosine 1-phosphate-mediated migration of human lung endothelial cells through activation of phospholipase D2, protein kinase C-zeta, and Rac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID PHOSPHATE PHOSPHATASE-1; BRONCHIAL EPITHELIAL-CELLS; FOCAL ADHESION KINASE; SMOOTH-MUSCLE CELLS; HAMSTER OVARY CELLS; GROWTH-FACTOR; INTERLEUKIN-8 SECRETION; LYSOPHOSPHATIDIC ACID; SIGNALING PATHWAYS; MAMMALIAN-CELLS	The signaling pathways by which sphingosine 1-phosphate (S1P) potently stimulates endothelial cell migration and angiogenesis are not yet fully defined. We, therefore, investigated the role of protein kinaseC(PKC) isoforms, phospholipase D(PLD), and Rac in S1P-induced migration of human pulmonary artery endothelial cells (HPAECs). S1P-induced migration was sensitive to S1P(1) small interfering RNA (siRNA) and pertussis toxin, demonstrating coupling of S1P(1) to G(i). Overexpression of dominant negative (dn) PKC-epsilon or -zeta, but not PKC-alpha or -delta, blocked S1P-induced migration. Although S1P activated both PLD1 and PLD2, S1P-induced migration was attenuated by knocking down PLD2 or expressing dnPLD2 but not PLD1. Blocking PKC-epsilon, but not PKC-zeta, activity attenuated S1P-mediated PLD stimulation, demonstrating that PKC-epsilon, but not PKC-zeta, was upstream of PLD. Transfection of HPAECs with dnRac1 or Rac1 siRNA attenuated S1P-induced migration. Furthermore, transfection with PLD2 siRNA, infection of HPAECs with dnPKC-zeta, or treatment with myristoylated PKC-zeta peptide inhibitor abrogated S1P-induced Rac1 activation. These results establish that S1P signals through S1P1 and Gi to activate PKC-epsilon and, subsequently, a PLD2-PKC-zeta-Rac1 cascade. Activation of this pathway is necessary to stimulate the migration of lung endothelial cells, a key component of the angiogenic process.	[Gorshkova, Irina; He, Donghong; Berdyshev, Evgeny; Usatuyk, Peter; Burns, Michael; Kalari, Satish; Zhao, Yutong; Pendyala, Srikanth; Garcia, Joe G. N.; Natarajan, Viswanathan] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Pyne, Nigel J.] Univ Strathclyde, Dept Physiol & Pharmacol, Glasgow G4 0NR, Lanark, Scotland; [Brindley, David N.] Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada	University of Chicago; University of Strathclyde; University of Alberta	Natarajan, V (corresponding author), Univ Chicago, Dept Med, CIS Bldg,Rm W408B,929 E 57th St, Chicago, IL 60637 USA.	vnataraj@medicine.bsd.uchicago.edu	Kalari, Satish/C-6967-2012; Garcia, Joe GN/E-8862-2010	Pyne, Nigel/0000-0002-5657-4578	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079396] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL R01 79396] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alvarez SE, 2007, TRENDS ENDOCRIN MET, V18, P300, DOI 10.1016/j.tem.2007.07.005; Banno Y, 2001, J BIOL CHEM, V276, P35622, DOI 10.1074/jbc.M105673200; Boguslawski G, 2002, EXP CELL RES, V274, P264, DOI 10.1006/excr.2002.5472; Chaudhuri P, 2005, CIRC RES, V97, P674, DOI 10.1161/01.RES.0000184667.82354.b1; Cockcroft S, 2001, CELL MOL LIFE SCI, V58, P1674, DOI 10.1007/PL00000805; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; Cummings R, 2002, MOL CELL BIOCHEM, V234, P99, DOI 10.1023/A:1015944828973; Cummings RJ, 2002, J BIOL CHEM, V277, P30227, DOI 10.1074/jbc.M111078200; Davis GE, 2005, CIRC RES, V97, P1093, DOI 10.1161/01.RES.0000191547.64391.e3; Delon C, 2004, J BIOL CHEM, V279, P44763, DOI 10.1074/jbc.M405771200; Donati C, 2006, BBA-BIOMEMBRANES, V1758, P2037, DOI 10.1016/j.bbamem.2006.06.015; Du GW, 2004, MOL BIOL CELL, V15, P1024, DOI 10.1091/mbc.E03-09-0673; English D, 2000, FASEB J, V14, P2255, DOI 10.1096/fj.00-0134com; English D, 1999, J HEMATOTH STEM CELL, V8, P627, DOI 10.1089/152581699319795; Freyberg Z, 2001, MOL BIOL CELL, V12, P943, DOI 10.1091/mbc.12.4.943; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Garrett TA, 2007, EXP CELL RES, V313, P3285, DOI 10.1016/j.yexcr.2007.05.027; Gonda K, 1999, BIOCHEM J, V337, P67, DOI 10.1042/0264-6021:3370067; GORSHKOVA IA, 2005, FASEB J, V19; Graler MH, 2003, J CELL BIOCHEM, V89, P507, DOI 10.1002/jcb.10537; Hirai T, 2003, J BIOCHEM, V133, P1, DOI 10.1093/jb/mvg017; Jaillard C, 2005, J NEUROSCI, V25, P1459, DOI 10.1523/JNEUROSCI.4645-04.2005; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Jenkins GM, 2005, CELL MOL LIFE SCI, V62, P2305, DOI 10.1007/s00018-005-5195-z; JONES GA, 1993, J BIOL CHEM, V268, P20845; Kanaho Y, 2007, METHOD ENZYMOL, V434, P155, DOI 10.1016/S0076-6879(07)34009-3; Kim JH, 1998, FEBS LETT, V430, P231, DOI 10.1016/S0014-5793(98)00661-9; Kishikawa K, 1999, J BIOL CHEM, V274, P21335, DOI 10.1074/jbc.274.30.21335; Kluk MJ, 2001, CIRC RES, V89, P496, DOI 10.1161/hh1801.096338; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; Kono M, 2004, J BIOL CHEM, V279, P29367, DOI 10.1074/jbc.M403937200; Lamalice L, 2007, CIRC RES, V100, P782, DOI 10.1161/01.RES.0000259593.07661.1e; Lee H, 2000, AM J PHYSIOL-CELL PH, V278, pC612, DOI 10.1152/ajpcell.2000.278.3.C612; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; Lee OH, 2000, BIOCHEM BIOPH RES CO, V268, P47, DOI 10.1006/bbrc.2000.2087; Lehman N, 2006, BLOOD, V108, P3564, DOI 10.1182/blood-2006-02-005959; Li YS, 2004, EXP CELL RES, V298, P107, DOI 10.1016/j.yexcr.2004.03.023; Li Z, 2005, PROSTAG OTH LIPID M, V76, P95, DOI 10.1016/j.prostaglandins.2005.02.002; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; Long JS, 2006, PROSTAG OTH LIPID M, V80, P74, DOI 10.1016/j.prostaglandins.2006.05.001; Michel MC, 2007, ACTA PAEDIATR, V96, P44, DOI 10.1111/j.1651-2227.2007.00207.x; MORITZ A, 1992, J BIOL CHEM, V267, P7207; Ohno S, 2002, J BIOCHEM, V132, P509, DOI 10.1093/oxfordjournals.jbchem.a003249; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OVERBECK AF, 1995, MOL REPROD DEV, V42, P468, DOI 10.1002/mrd.1080420415; Ozaki Harunobu, 2003, J Atheroscler Thromb, V10, P125; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; Panetti TS, 2000, ARTERIOSCL THROM VAS, V20, P1013, DOI 10.1161/01.ATV.20.4.1013; Pilquil C, 2006, J BIOL CHEM, V281, P38418, DOI 10.1074/jbc.M601670200; Porcelli AM, 2002, CELL SIGNAL, V14, P75, DOI 10.1016/S0898-6568(01)00222-4; Powner DJ, 2002, MOL BIOL CELL, V13, P1252, DOI 10.1091/mbc.01-05-0235; Pyne NJ, 2003, BIOCHEM SOC T, V31, P1220; Pyne S, 2000, PHARMACOL THERAPEUT, V88, P115, DOI 10.1016/S0163-7258(00)00084-X; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Ryu Y, 2002, CIRC RES, V90, P325, DOI 10.1161/hh0302.104455; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; Sanchez T, 2004, J CELL BIOCHEM, V92, P913, DOI 10.1002/jcb.20127; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; Schwartz BM, 2001, GYNECOL ONCOL, V81, P291, DOI 10.1006/gyno.2001.6124; Shikata Y, 2003, J APPL PHYSIOL, V94, P1193, DOI 10.1152/japplphysiol.00690.2002; Shizukuda Y, 1999, CIRC RES, V85, P247, DOI 10.1161/01.RES.85.3.247; Singleton PA, 2005, FASEB J, V19, P1646, DOI 10.1096/fj.05-3928com; Spiegel S, 2003, BIOCHEM SOC T, V31, P1216; Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200; STASEK JE, 1993, BIOCHEM BIOPH RES CO, V191, P134, DOI 10.1006/bbrc.1993.1194; Thompson B, 2006, PROSTAG OTH LIPID M, V80, P15, DOI 10.1016/j.prostaglandins.2006.03.002; Tolias KF, 1998, MOL CELL BIOL, V18, P762, DOI 10.1128/MCB.18.2.762; Usatyuk PV, 2006, J BIOL CHEM, V281, P35554, DOI 10.1074/jbc.M607305200; Wang F, 1999, EXP CELL RES, V247, P17, DOI 10.1006/excr.1998.4327; Wang LX, 2002, BIOCHEM J, V367, P751, DOI 10.1042/BJ20020586; Waters D, 2006, FASEB J, V20, pA1058; Yasui H, 2001, J BIOL CHEM, V276, P15298, DOI 10.1074/jbc.M008546200; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; Zhao YT, 2007, J BIOL CHEM, V282, P14165, DOI 10.1074/jbc.M701279200	76	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11794	11806		10.1074/jbc.M800250200	http://dx.doi.org/10.1074/jbc.M800250200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18296444	Green Published, hybrid			2022-12-25	WOS:000255067400079
J	Harayama, T; Shindou, H; Ogasawara, R; Suwabe, A; Shimizu, T				Harayama, Takeshi; Shindou, Hideo; Ogasawara, Rie; Suwabe, Akira; Shimizu, Takao			Identification of a novel noninflammatory biosynthetic pathway of platelet-activating factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); FACTOR RECEPTOR; LYSOPHOSPHATIDYLCHOLINE ACYLTRANSFERASE; II CELLS; PAF; ACID; COA; ACETYLTRANSFERASE; PHOSPHORYLATION; INFLAMMATION	Platelet-activating factor (PAF) is a potent lipid mediator playing various inflammatory and physiological roles. PAF is biosynthesized through two independent pathways called the de novo and remodeling pathways. Lyso-PAF acetyltransferase (lyso-PAF AT) was believed to biosynthesize PAF under inflammatory conditions, through the remodeling pathway. The first isolated lyso-PAF AT (LysoPAFAT/LPCAT2) had consistent properties. However, we show in this study the finding of a second lyso-PAF AT working under noninflammatory conditions. We partially purified a Ca2+-independent lyso-PAF AT from mouse lung. Immunoreactivity for lysophosphatidylcholine acyltransferase 1 (LPCAT1) was detected in the active fraction. Lpcat1-transfected Chinese hamster ovary cells exhibited both LPCAT and lyso-PAF AT activities. We confirmed that LPCAT1 transfers acetate from acetyl-CoA to lyso-PAF by the identification of an acetyl-CoA (and other acyl-CoAs) interacting site in LPCAT1. We further showed that LPCAT1 activity and expression are independent of inflammatory signals. Therefore, these results suggest the molecular diversity of lyso-PAF ATs is as follows: one (LysoPAFAT/LPCAT2) is inducible and activated by inflammatory stimulation, and the other (LPCAT1) is constitutively expressed. Each lyso-PAF AT biosynthesizes inflammatory and physiological amounts of PAF, depending on the cell type. These findings provide important knowledge for the understanding of the diverse pathological and physiological roles of PAF.	[Harayama, Takeshi; Shindou, Hideo; Shimizu, Takao] Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan; [Ogasawara, Rie; Suwabe, Akira] Iwate Med Univ, Sch Med, Dept Lab Med, Morioka, Iwate 0208505, Japan	University of Tokyo; Iwate Medical University	Shimizu, T (corresponding author), Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	tshimizu@m.u-tokyo.ac.jp	Harayama, Takeshi/AAD-8852-2022; Shimizu, Takao/AAV-7052-2021	Harayama, Takeshi/0000-0003-2255-4197; 				Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; AMMIT AJ, 1992, HUM REPROD, V7, P865, DOI 10.1093/oxfordjournals.humrep.a137751; BILLAH MM, 1983, BIOCHEM BIOPH RES CO, V113, P51, DOI 10.1016/0006-291X(83)90430-8; Chen C, 2001, J NEUROPHYSIOL, V85, P384, DOI 10.1152/jn.2001.85.1.384; Chen XN, 2006, P NATL ACAD SCI USA, V103, P11724, DOI 10.1073/pnas.0604946103; Dircks LK, 1999, J BIOL CHEM, V274, P34728, DOI 10.1074/jbc.274.49.34728; DOBBS LG, 1979, J CLIN INVEST, V63, P378, DOI 10.1172/JCI109313; DOMENECH C, 1987, J BIOL CHEM, V262, P5671; GOMEZCAMBRONERO J, 1985, BIOCHIM BIOPHYS ACTA, V845, P511, DOI 10.1016/0167-4889(85)90218-6; Grabarek Z, 2006, J MOL BIOL, V359, P509, DOI 10.1016/j.jmb.2006.03.066; Harrison KA, 1999, J MASS SPECTROM, V34, P330, DOI 10.1002/(SICI)1096-9888(199904)34:4<330::AID-JMS798>3.0.CO;2-#; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFFMAN DR, 1988, J BIOL CHEM, V263, P9316; Ishii S, 2000, PROG LIPID RES, V39, P41, DOI 10.1016/S0163-7827(99)00016-8; Ishii S, 1998, J EXP MED, V187, P1779, DOI 10.1084/jem.187.11.1779; Ishii S, 2004, J IMMUNOL, V172, P7095, DOI 10.4049/jimmunol.172.11.7095; Ishii S, 1997, EMBO J, V16, P133, DOI 10.1093/emboj/16.1.133; Iyer PP, 2001, J BACTERIOL, V183, P4244, DOI 10.1128/JB.183.14.4244-4250.2001; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; Kihara Y, 2005, J EXP MED, V202, P853, DOI 10.1084/jem.20050660; KING MT, 1985, ANAL BIOCHEM, V146, P173, DOI 10.1016/0003-2697(85)90412-9; KRAUSZ C, 1994, HUM REPROD, V9, P471, DOI 10.1093/oxfordjournals.humrep.a138529; Kume K, 1997, ANAL BIOCHEM, V246, P118, DOI 10.1006/abio.1996.9959; LANDS WEM, 1958, J BIOL CHEM, V231, P883; Lewin TM, 1999, BIOCHEMISTRY-US, V38, P5764, DOI 10.1021/bi982805d; MONTRUCCHIO G, 1986, PROSTAGLANDINS, V32, P539, DOI 10.1016/0090-6980(86)90036-5; Nagase T, 1999, J CLIN INVEST, V104, P1071, DOI 10.1172/JCI7727; Nakanishi H, 2006, J BIOL CHEM, V281, P20140, DOI 10.1074/jbc.M600225200; O'Neill C, 2005, HUM REPROD UPDATE, V11, P215, DOI 10.1093/humupd/dmi003; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; Rost B, 2004, NUCLEIC ACIDS RES, V32, pW321, DOI 10.1093/nar/gkh377; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; Schmitz F, 2004, EUR J IMMUNOL, V34, P2863, DOI 10.1002/eji.200425228; Shindou H, 2005, J IMMUNOL, V175, P1177, DOI 10.4049/jimmunol.175.2.1177; Shindou H, 2000, BIOCHEM BIOPH RES CO, V271, P812, DOI 10.1006/bbrc.2000.2723; Shindou H, 2007, J BIOL CHEM, V282, P6532, DOI 10.1074/jbc.M609641200; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; SNYDER F, 1995, BBA-LIPID LIPID MET, V1254, P231, DOI 10.1016/0005-2760(94)00192-2; Syrbu SI, 1999, J IMMUNOL, V162, P2334; WYKLE RL, 1980, J BIOL CHEM, V255, P256; Yamashita A, 2007, BBA-MOL CELL BIOL L, V1771, P1202, DOI 10.1016/j.bbalip.2007.07.002; ZHU YP, 1991, BIOL REPROD, V44, P39, DOI 10.1095/biolreprod44.1.39; Zimmerman GA, 2002, CRIT CARE MED, V30, pS294, DOI 10.1097/00003246-200205001-00020	43	95	99	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11097	11106		10.1074/jbc.M708909200	http://dx.doi.org/10.1074/jbc.M708909200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18285344	hybrid			2022-12-25	WOS:000255067400005
J	Sotillo, E; Garriga, J; Kurimchak, A; Grana, X				Sotillo, Elena; Garriga, Judit; Kurimchak, Alison; Grana, Xavier			Cyclin E and SV40 small t antigen cooperate to bypass quiescence and contribute to transformation by activating CDK2 in human fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR TFIIH; HUMAN CELL-TRANSFORMATION; SMALL TUMOR-ANTIGEN; DEPENDENT KINASE; MODULATES PHOSPHORYLATION; PHASE-TRANSITION; UBIQUITIN LIGASE; GENE-EXPRESSION; S-PHASE; MYC	Cyclin E overexpression is observed in multiple human tumors and linked to poor prognosis. We have previously shown that ectopic expression of cyclin E is sufficient to induce mitogen independent cell cycle entry in a variety of tumor/immortal cell lines. Here we have investigated the rate-limiting step leading to cell cycle entry in quiescent normal human fibroblasts (NHF) ectopically expressing cyclin E. We found that in serum-starved NHF, cyclin E forms inactive complexes with CDK2 and fails to induce DNA synthesis. Coexpression of SV40 small t antigen (st), but not other tested oncogenes, efficiently induces mitogen-independent CDK2 phosphorylation on Thr-160, CDK2 activation, and DNA synthesis. Additionally, in contact-inhibited NHF ectopically expressing cyclin E, st induces cell cycle entry, continued proliferation, and foci formation. Coexpression of cyclin E and st also bypasses G(0)/G(1) arrests induced by CDK inhibitors. Although CDK2 is dispensable for G(0)/G(1) cell cycle entry and normal proliferation in mammals, CDK2 activity is an essential rate-limiting step in NHF with deregulated cyclin E expression and altered PP2A activity, which endows primary cells with transformed features. Consequently, CDK2 could be targeted therapeutically in tumors that involve these alterations. These data also suggest that alterations prior to cyclin E deregulation facilitate proliferation of tumor cells by bypassing mitogenic requirements and negative regulation by adjacent cells.	[Sotillo, Elena; Garriga, Judit; Kurimchak, Alison; Grana, Xavier] Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; [Kurimchak, Alison; Grana, Xavier] Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Grana, X (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, AHP Bldg Rm 308,3307 N Broad St, Philadelphia, PA 19140 USA.	xavier@temple.edu		Grana, Xavier/0000-0001-7134-0473; Sotillo, Elena/0000-0002-3993-1932	NCI NIH HHS [R24 CA88261-01, CA095569] Funding Source: Medline; NIAID NIH HHS [KO2 AI01823] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA095569, R24CA088261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K02AI001823] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aleem E, 2005, NAT CELL BIOL, V7, P831, DOI 10.1038/ncb1284; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; Ausubel FM., 1988, CURRENT PROTOCOLS MO; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Bhattacharya S, 2003, ONCOGENE, V22, P2443, DOI 10.1038/sj.onc.1206339; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Calbo J, 2002, J BIOL CHEM, V277, P50263, DOI 10.1074/jbc.M209181200; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Coller HA, 2006, PLOS BIOL, V4, P329, DOI 10.1371/journal.pbio.0040083; Connell-Crowley L, 1998, CURR BIOL, V8, P65, DOI 10.1016/S0960-9822(98)70021-1; Deeb KK, 2007, CANCER RES, V67, P8065, DOI 10.1158/0008-5472.CAN-07-1515; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; Du JY, 2004, CANCER CELL, V6, P565, DOI 10.1016/j.ccr.2004.10.014; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Garriga J, 2004, CELL CYCLE, V3, P1320, DOI 10.4161/cc.3.10.1183; Garriga J, 2003, MOL CELL BIOL, V23, P5165, DOI 10.1128/MCB.23.15.5165-5173.2003; Geng Y, 2007, MOL CELL, V25, P127, DOI 10.1016/j.molcel.2006.11.029; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; Hwang HC, 2005, ONCOGENE, V24, P2776, DOI 10.1038/sj.onc.1208613; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Karsunky H, 1999, ONCOGENE, V18, P7816, DOI 10.1038/sj.onc.1203205; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Liu Y, 2004, J BIOL CHEM, V279, P4507, DOI 10.1074/jbc.M309995200; Macias E, 2007, CANCER RES, V67, P9713, DOI 10.1158/0008-5472.CAN-07-2119; Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; Moreno CS, 2004, CANCER RES, V64, P6978, DOI 10.1158/0008-5472.CAN-04-1150; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1996, CURR OPIN CELL BIOL, V8, P767, DOI 10.1016/S0955-0674(96)80076-7; MUNGRE S, 1994, J VIROL, V68, P1675, DOI 10.1128/JVI.68.3.1675-1681.1994; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Parreno M, 2001, ONCOGENE, V20, P4793, DOI 10.1038/sj.onc.1204644; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; Rank KB, 2000, BIOCHEM BIOPH RES CO, V271, P469, DOI 10.1006/bbrc.2000.2648; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; Spruck C, 2006, CANCER RES, V66, P7355, DOI 10.1158/0008-5472.CAN-05-3240; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; YU DH, 1994, CELL GROWTH DIFFER, V5, P431	55	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11280	11292		10.1074/jbc.M709055200	http://dx.doi.org/10.1074/jbc.M709055200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18276582	hybrid, Green Published			2022-12-25	WOS:000255067400024
J	Merkouropoulos, G; Andreasson, E; Hess, D; Boller, T; Peck, SC				Merkouropoulos, Georgios; Andreasson, Erik; Hess, Daniel; Boller, Thomas; Peck, Scott C.			An Arabidopsis protein phosphorylated in response to microbial elicitation, AtPHOS32, is a substrate of MAP kinases 3 and 6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNIVERSAL STRESS-PROTEIN; BACTERIAL ELICITOR FLAGELLIN; PLASMA-MEMBRANE; INNATE IMMUNITY; KINASE; PLANTS; THALIANA; PERCEPTION; CASCADES; ANIMALS	Although mitogen-activated protein kinases (MAPKs) have been shown to be activated by a wide range of biotic and abiotic stimuli in diverse plant species, few in vivo substrates for these kinases have been identified. While studying proteins that are differentially phosphorylated upon treatment of Arabidopsis suspension cultures with the general bacterial elicitor peptide flagellin-22 (flg22), we identified two proteins with endogenous nickel binding properties that become phosphorylated after flg22 elicitation. These highly related proteins, AtPHOS32 and AtPHOS34, show similarity to bacterial universal stress protein A. We identified one of the phosphorylation sites on AtPHOS32 by nanoelectrospray ionization tandem mass spectrometry. Phosphorylation in a phosphoSer-Pro motif indicated that this protein may be a substrate of MAPKs. Using in vitro kinase assays, we confirmed that AtPHOS32 is a substrate of both AtMPK3 and AtMPK6. Specificity of phosphorylation was demonstrated by site-directed mutagenesis of the first phosphorylation site. In addition, immunosubtraction of both MAPKs from protein extracts removed detectable kinase activity toward AtPHOS32, indicating that the two MAPKs were the predominate kinases recognizing the motif in this protein. Finally, the target phosphorylation site in AtPHOS32 is conserved in AtPHOS34 and among apparent orthologues from many plant species, indicating that phosphorylation of these proteins by AtMPK3 and AtMPK6 orthologues has been conserved throughout evolution.	[Merkouropoulos, Georgios; Andreasson, Erik; Peck, Scott C.] John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England; [Hess, Daniel] Friedrich Miescher Inst, CH-4058 Basel, Switzerland; [Boller, Thomas] Univ Basel, Inst Bot, CH-4056 Basel, Switzerland	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Friedrich Miescher Institute for Biomedical Research; University of Basel	Peck, SC (corresponding author), Univ Missouri, 271H Bond Life Sci Ctr, Columbia, MO 65211 USA.	pecks@missouri.edu	Boller, Thomas/G-3500-2012	Boller, Thomas/0000-0001-6768-7503; Andreasson, Erik/0000-0003-0666-7204	Biotechnology and Biological Sciences Research Council [p15616] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Asai T, 2002, NATURE, V415, P977, DOI 10.1038/415977a; Feilner T, 2005, MOL CELL PROTEOMICS, V4, P1558, DOI 10.1074/mcp.M500007-MCP200; Felix G, 1999, PLANT J, V18, P265, DOI 10.1046/j.1365-313X.1999.00265.x; Gomez-Gomez L, 2000, MOL CELL, V5, P1003, DOI 10.1016/S1097-2765(00)80265-8; Ichimura K, 2002, TRENDS PLANT SCI, V7, P301, DOI 10.1016/S1360-1385(02)02302-6; Kerk D, 2003, PLANT PHYSIOL, V131, P1209, DOI 10.1104/pp.102.016006; Kvint K, 2003, CURR OPIN MICROBIOL, V6, P140, DOI 10.1016/S1369-5274(03)00025-0; Liu YD, 2004, PLANT CELL, V16, P3386, DOI 10.1105/tpc.104.026609; Menke FLH, 2004, PLANT CELL, V16, P897, DOI 10.1105/tpc.015552; Nakagami H, 2005, TRENDS PLANT SCI, V10, P339, DOI 10.1016/j.tplants.2005.05.009; Nuhse TS, 2000, J BIOL CHEM, V275, P7521, DOI 10.1074/jbc.275.11.7521; Nuhse TS, 2004, PLANT CELL, V16, P2394, DOI 10.1105/tpc.104.023150; Nuhse TS, 2003, J BIOL CHEM, V278, P45248, DOI 10.1074/jbc.M307443200; Nurnberger T, 2004, IMMUNOL REV, V198, P249, DOI 10.1111/j.0105-2896.2004.0119.x; Peck SC, 2001, PLANT CELL, V13, P1467, DOI 10.1105/tpc.13.6.1467; Peck SC, 2003, CURR OPIN PLANT BIOL, V6, P334, DOI 10.1016/S1369-5266(03)00056-6; Rosso MG, 2003, PLANT MOL BIOL, V53, P247, DOI 10.1023/B:PLAN.0000009297.37235.4a; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Sousa MC, 2001, STRUCTURE, V9, P1135, DOI 10.1016/S0969-2126(01)00680-3; Tena G, 2001, CURR OPIN PLANT BIOL, V4, P392, DOI 10.1016/S1369-5266(00)00191-6; Wang HC, 2007, PLANT CELL, V19, P63, DOI 10.1105/tpc.106.048298; Zarembinski TI, 1998, P NATL ACAD SCI USA, V95, P15189, DOI 10.1073/pnas.95.26.15189; Zipfel C, 2005, CURR OPIN PLANT BIOL, V8, P353, DOI 10.1016/j.pbi.2005.05.004	24	57	63	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10493	10499		10.1074/jbc.M800735200	http://dx.doi.org/10.1074/jbc.M800735200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18285339	hybrid			2022-12-25	WOS:000254894700031
J	Wang, Z; Zhang, BC; Yang, LQ; Ding, J; Ding, HF				Wang, Zhe; Zhang, Baochun; Yang, Liqun; Ding, Jane; Ding, Han-Fei			Constitutive production of NF-kappa B2 p52 is not tumorigenic but predisposes mice to inflammatory autoimmune disease by repressing bim expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HUMAN BREAST-CANCER; FAMILY-MEMBER BIM; TRANSCRIPTION FACTOR; CELL-DEATH; APOPTOSIS; GENE; ACTIVATION; RESPONSES; PATHWAYS	Normal development of the immune system requires regulated processing of NF-kappa B2 p100 to p52, which activates NF-kappa B2 signaling. Constitutive production of p52 has been suggested as a major mechanism underlying lymphomagenesis induced by NF-kappa B2 mutations, which occur recurrently in a variety of human lymphoid malignancies. To test the hypothesis, we generated transgenic mice with targeted expression of p52 in lymphocytes. In contrast to their counterparts expressing the tumor-derived NF-kappa B2 mutant p80HT, which develop predominantly B cell tumors, p52 transgenic mice are not prone to lymphomagenesis. However, they are predisposed to inflammatory autoimmune disease characterized by multiorgan infiltration of activated lymphocytes, high levels of autoantibodies in the serum, and immune complex glomerulonephritis. p52, but not p80HT, represses Bim expression, leading to defects in apoptotic processes critical for elimination of autoreactive lymphocytes and control of immune response. These findings reveal distinct signaling pathways for actions of NF-kappa B2 mutants and p52 and suggest a causal role for sustained NF-kappa B2 activation in the pathogenesis of autoimmunity.	[Wang, Zhe; Zhang, Baochun; Yang, Liqun; Ding, Jane; Ding, Han-Fei] Univ Toledo, Coll Med, Dept Biochem & Canc Biol, Toledo, OH 43614 USA	University System of Ohio; University of Toledo	Ding, HF (corresponding author), Univ Toledo, Coll Med, Dept Biochem & Canc Biol, Hlth Sci Campus,BHSB 461,3035 Arlington Ave, Toledo, OH 43614 USA.	han-fei.ding@utoledo.edu		Ding, Han-Fei/0000-0001-5702-3439; Zhang, Baochun/0000-0003-1759-1161	NATIONAL CANCER INSTITUTE [R01CA106550] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA106550] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; Basak S, 2007, CELL, V128, P369, DOI 10.1016/j.cell.2006.12.033; BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1994, BIOCHEM PHARMACOL, V47, P145, DOI 10.1016/0006-2952(94)90448-0; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; CHANG CC, 1994, ONCOGENE, V9, P923; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; DEJARDIN E, 1995, ONCOGENE, V11, P1835; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Derudder E, 2003, BIOCHEM BIOPH RES CO, V308, P744, DOI 10.1016/S0006-291X(03)01474-8; Enders A, 2003, J EXP MED, V198, P1119, DOI 10.1084/jem.20030411; Epinat JC, 2000, ONCOGENE, V19, P599, DOI 10.1038/sj.onc.1203376; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; Hildeman DA, 2002, IMMUNITY, V16, P759, DOI 10.1016/S1074-7613(02)00322-9; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Kim KE, 2000, ONCOGENE, V19, P1334, DOI 10.1038/sj.onc.1203432; MIGLIAZZA A, 1994, BLOOD, V84, P3850, DOI 10.1182/blood.V84.11.3850.bloodjournal84113850; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; PIRCHER H, 1989, EMBO J, V8, P719, DOI 10.1002/j.1460-2075.1989.tb03431.x; Qing GL, 2007, P NATL ACAD SCI USA, V104, P5324, DOI 10.1073/pnas.0609914104; Rathmell JC, 2002, CELL, V109, pS97, DOI 10.1016/S0092-8674(02)00704-3; Reiner SL, 2007, CELL, V129, P33, DOI 10.1016/j.cell.2007.03.019; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; THAKUR S, 1994, ONCOGENE, V9, P2335; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang YQ, 2002, NAT CELL BIOL, V4, P888, DOI 10.1038/ncb872; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Zapata JM, 2007, ADV EXP MED BIOL, V597, P188; Zhang BC, 2007, BLOOD, V110, P743, DOI 10.1182/blood-2006-11-058446; Zhang BC, 2006, J BIOL CHEM, V281, P38617, DOI 10.1074/jbc.M606705200; ZHANG JD, 1994, ONCOGENE, V9, P1931	50	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10698	10706		10.1074/jbc.M800806200	http://dx.doi.org/10.1074/jbc.M800806200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18281283	Green Published, hybrid			2022-12-25	WOS:000254894700052
J	Zhang, HF; Bosch-Marce, M; Shimoda, LA; Tan, YS; Baek, JH; Wesley, JB; Gonzalez, FJ; Semenza, GL				Zhang, Huafeng; Bosch-Marce, Marta; Shimoda, Larissa A.; Tan, Yee Sun; Baek, Jin Hyen; Wesley, Jacob B.; Gonzalez, Frank J.; Semenza, Gregg L.			Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR 1-ALPHA; BH3-ONLY PROTEIN; GENE-EXPRESSION; COMPLEX-III; HIF-1; OXYGEN; TRANSCRIPTION; PATHWAY; FACTOR-1-ALPHA; HIF-1-ALPHA	Autophagy is a process by which cytoplasmic organelles can be catabolized either to remove defective structures or as a means of providing macromolecules for energy generation under conditions of nutrient starvation. In this study we demonstrate that mitochondrial autophagy is induced by hypoxia, that this process requires the hypoxia-dependent factor-1-dependent expression of BNIP3 and the constitutive expression of Beclin-1 and Atg5, and that in cells subjected to prolonged hypoxia, mitochondrial autophagy is an adaptive metabolic response which is necessary to prevent increased levels of reactive oxygen species and cell death.	[Zhang, Huafeng; Bosch-Marce, Marta; Tan, Yee Sun; Baek, Jin Hyen; Wesley, Jacob B.; Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Vasc Program, Inst Cell Engn, Baltimore, MD 21205 USA; [Zhang, Huafeng; Bosch-Marce, Marta; Tan, Yee Sun; Baek, Jin Hyen; Wesley, Jacob B.; Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA; [Shimoda, Larissa A.; Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Gonzalez, Frank J.] NCI, Lab Metab, Natl Inst Hlth, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Semenza, GL (corresponding author), Broadway Res Bldg,Suite 671,733 N Broadway, Baltimore, MD 21205 USA.	gsemenza@jhmi.edu	Zhang, Huafeng/A-7188-2012		NATIONAL CANCER INSTITUTE [P50CA103175, ZIABC005708] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA103175] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bohensky J, 2007, AUTOPHAGY, V3, P207, DOI 10.4161/auto.3708; Brahimi-Horn MC, 2007, FEBS LETT, V581, P3582, DOI 10.1016/j.febslet.2007.06.018; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Dann CE, 2005, BIOCHEM BIOPH RES CO, V338, P639, DOI 10.1016/j.bbrc.2005.08.140; DECKER RS, 1980, AM J PATHOL, V98, P425; DEDUVE C, 1966, ANNU REV PHYSIOL, V28, P435, DOI 10.1146/annurev.ph.28.030166.002251; Elvidge GP, 2006, J BIOL CHEM, V281, P15215, DOI 10.1074/jbc.M511408200; Feldser D, 1999, CANCER RES, V59, P3915; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047; Greijer AE, 2005, J PATHOL, V206, P291, DOI 10.1002/path.1778; Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001; Hamacher-Brady A, 2007, CELL DEATH DIFFER, V14, P146, DOI 10.1038/sj.cdd.4401936; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Kaelin WG, 2005, BIOCHEM BIOPH RES CO, V338, P627, DOI 10.1016/j.bbrc.2005.08.165; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Kundu M, 2005, CELL DEATH DIFFER, V12, P1484, DOI 10.1038/sj.cdd.4401780; Lee MJ, 2004, MOL CELL BIOL, V24, P3918, DOI 10.1128/MCB.24.9.3918-3927.2004; LEHNIGER AL, 1975, BIOCHEMISTRY; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Lum JJ, 2007, GENE DEV, V21, P1037, DOI 10.1101/gad.1529107; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Maiuri MC, 2007, AUTOPHAGY, V3, P374, DOI 10.4161/auto.4237; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Melillo G, 2004, CELL CYCLE, V3, P154; MENZIES RA, 1971, J BIOL CHEM, V246, P2425; Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200; Pan Y, 2007, MOL CELL BIOL, V27, P912, DOI 10.1128/MCB.01223-06; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Schofield CJ, 2005, BIOCHEM BIOPH RES CO, V338, P617, DOI 10.1016/j.bbrc.2005.08.111; Seagroves TN, 2001, MOL CELL BIOL, V21, P3436, DOI 10.1128/MCB.21.10.3436-3444.2001; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Sowter HM, 2001, CANCER RES, V61, P6669; Tracy K, 2007, MOL CELL BIOL, V27, P6229, DOI 10.1128/MCB.02246-06; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Yan L, 2005, P NATL ACAD SCI USA, V102, P13807, DOI 10.1073/pnas.0506843102; Yim SH, 2006, HEPATOLOGY, V44, P550, DOI 10.1002/hep.21284; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001; Zhu HX, 2007, J CLIN INVEST, V117, P1782, DOI 10.1172/JCI27523	45	1213	1268	7	116	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10892	10903		10.1074/jbc.M800102200	http://dx.doi.org/10.1074/jbc.M800102200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18281291	hybrid, Green Published			2022-12-25	WOS:000254894700071
J	Pasic, L; Kotova, T; Schafer, DA				Pasic, Lejla; Kotova, Tatyana; Schafer, Dorothy A.			Ena/VASP proteins capture actin filament barbed ends	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASODILATOR-STIMULATED PHOSPHOPROTEIN; CAPPING PROTEIN; ADP-ACTIN; F-ACTIN; BINDING; PROFILIN; POLYMERIZATION; MONOMERS; FORMIN; LOCALIZATION	Ena/VASP (vasodialator-stimulated protein) proteins regulate many actin-dependent events, including formation of protrusive structures, fibroblast migration, neurite extension, cell-cell adhesion, and Listeria pathogenesis. In vitro, Ena/VASP activities on actin are complex and varied. They promote actin assembly, protect filaments from cappers, bundle filaments, and inhibit filament branching. To determine the mechanisms by which Ena/VASP proteins regulate actin dynamics at barbed ends, we monitored individual actin filaments growing in the presence of VASP and profilin using total internal reflection fluorescence microscopy. Filament growth was unchanged by VASP, but filaments grew faster in profilin-actin and VASP than with profilin-actin alone. Actin filaments were captured directly by VASP-coated surfaces via interactions with growing barbed ends. End-attached filaments transiently paused but resumed growth after becoming bound to the surface via a filament side attachment. Thus, Ena/VASP proteins promote actin assembly by interacting directly with actin filament barbed ends, recruiting profilin-actin, and blocking capping.	[Pasic, Lejla; Kotova, Tatyana; Schafer, Dorothy A.] Univ Virginia, Dept Biol, Charlottesville, VA 22903 USA; [Schafer, Dorothy A.] Univ Virginia, Dept Cell Biol, Charlottesville, VA 22903 USA	University of Virginia; University of Virginia	Schafer, DA (corresponding author), Univ Virginia, Dept Biol, Gilmer Hall,McCormick Rd, Charlottesville, VA 22901 USA.	das9w@virginia.edu			NIGMS NIH HHS [R01 GM 067222] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067222] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amann KJ, 2001, P NATL ACAD SCI USA, V98, P15009, DOI 10.1073/pnas.211556398; Applewhite DA, 2007, MOL BIOL CELL, V18, P2579, DOI 10.1091/mbc.e06-11-0990; Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; Barzik M, 2005, J BIOL CHEM, V280, P28653, DOI 10.1074/jbc.M503957200; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Chereau D, 2006, J STRUCT BIOL, V155, P195, DOI 10.1016/j.jsb.2006.01.012; Co C, 2007, CELL, V128, P901, DOI 10.1016/j.cell.2006.12.049; Dickinson RB, 2004, BIOPHYS J, V87, P2838, DOI 10.1529/biophysj.104.045211; Ferron F, 2007, EMBO J, V26, P4597, DOI 10.1038/sj.emboj.7601874; Gates J, 2007, DEVELOPMENT, V134, P2027, DOI 10.1242/dev.02849; Gutsche-Perelroizen I, 1999, J BIOL CHEM, V274, P6234, DOI 10.1074/jbc.274.10.6234; Han YH, 2002, J BIOL CHEM, V277, P49877, DOI 10.1074/jbc.M209107200; Harris ES, 2004, J BIOL CHEM, V279, P20076, DOI 10.1074/jbc.M312718200; Huttelmaier S, 1999, FEBS LETT, V451, P68, DOI 10.1016/S0014-5793(99)00546-3; Kang F, 1997, BIOCHEMISTRY-US, V36, P8384, DOI 10.1021/bi970065n; Kim K, 2007, J BIOL CHEM, V282, P5871, DOI 10.1074/jbc.M609850200; Kovar DR, 2003, J CELL BIOL, V161, P875, DOI 10.1083/jcb.200211078; Kovar DR, 2004, P NATL ACAD SCI USA, V101, P14725, DOI 10.1073/pnas.0405902101; Kragtorp KA, 2006, DEVELOPMENT, V133, P685, DOI 10.1242/dev.02230; Kuhn JR, 2007, J BIOL CHEM, V282, P28014, DOI 10.1074/jbc.M705287200; Kuhn JR, 2005, BIOPHYS J, V88, P1387, DOI 10.1529/biophysj.104.047399; Kwiatkowski AV, 2007, NEURON, V56, P441, DOI 10.1016/j.neuron.2007.09.008; Lacayo CI, 2007, PLOS BIOL, V5, P2035, DOI 10.1371/journal.pbio.0050233; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Lu J, 2001, MOL BIOL CELL, V12, P1161, DOI 10.1091/mbc.12.4.1161; Mahaffy RE, 2006, BIOPHYS J, V91, P3519, DOI 10.1529/biophysj.106.080937; Michelot A, 2007, CURR BIOL, V17, P825, DOI 10.1016/j.cub.2007.04.037; Palmgren S, 2001, J CELL BIOL, V155, P251, DOI 10.1083/jcb.200106157; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; Romero S, 2004, CELL, V119, P419, DOI 10.1016/j.cell.2004.09.039; Samarin S, 2003, J CELL BIOL, V163, P131, DOI 10.1083/jcb.200303191; Schirenbeck A, 2005, BIOCHEM SOC T, V33, P1256, DOI 10.1042/BST0331256; Schirenbeck A, 2006, P NATL ACAD SCI USA, V103, P7694, DOI 10.1073/pnas.0511243103; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Veigel C, 1998, BIOPHYS J, V75, P1424, DOI 10.1016/S0006-3495(98)74061-5; Walders-Harbeck B, 2002, FEBS LETT, V529, P275, DOI 10.1016/S0014-5793(02)03356-2; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417	38	70	72	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9814	9819		10.1074/jbc.M710475200	http://dx.doi.org/10.1074/jbc.M710475200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18283104	hybrid, Green Published			2022-12-25	WOS:000254671600036
J	Ray, P; Basu, U; Ray, A; Majumdar, R; Deng, HT; Maitra, U				Ray, Partha; Basu, Uttiya; Ray, Anirban; Majumdar, Romit; Deng, Haiteng; Maitra, Umadas			The Saccharomyces cerevisiae 60 S ribosome biogenesis factor Tif6p is regulated by Hrr25p-mediated phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-I; SACCHAROMYCES-CEREVISIAE HOMOLOG; EUKARYOTIC INITIATION FACTOR-6; BUDDING YEAST; NEGATIVE REGULATION; DISSOCIATION FACTOR; PROTEIN-KINASE; PRE-RIBOSOMES; WHEAT-GERM; SUBUNIT	The biosynthesis of 60 S ribosomal subunits in Saccharomyces cerevisiae requires Tif6p, the yeast homologue of mammalian eIF6. This protein is necessary for the formation of 60 S ribosomal subunits because it is essential for the processing of 35 S pre-rRNA to the mature 25 S and 5.8 S rRNAs. In the present work, using molecular genetic and biochemical analyses, we show that Hrr25p, an isoform of yeast casein kinase I, phosphorylates Tif6p both in vitro and in vivo. Tryptic phosphopeptide mapping of in vitro phosphorylated Tif6p by Hrr25p and P-32-labeled Tif6p isolated from yeast cells followed by mass spectrometric analysis revealed that phosphorylation occurred on a single tryptic peptide at Ser-174. Sucrose gradient fractionation and coimmunoprecipitation experiments demonstrate that a small but significant fraction of Hrr25p is bound to 66 S pre-ribosomal particles that also contain bound Tif6p. Depletion of Hrr25p from a conditional yeast mutant that fails to phosphorylate Tif6p was unable to process pre-rRNAs efficiently, resulting in significant reduction in the formation of 25 S rRNA. These results along with our previous observations that phosphorylatable Ser-174 is required for yeast cell growth and viability, suggest that Hrr25p-mediated phosphorylation of Tif6p plays a critical role in the biogenesis of 60 S ribosomal subunits in yeast cells.	[Deng, Haiteng] Rockefeller Univ, Proteom Res Ctr, New York, NY 10021 USA; [Ray, Partha; Basu, Uttiya; Ray, Anirban; Majumdar, Romit; Maitra, Umadas] Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Rockefeller University; Yeshiva University; Albert Einstein College of Medicine	Maitra, U (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA.	maitra@aecom.yu.edu	Ray, Partha/AAK-4883-2020	Ray, Partha/0000-0002-7075-5463; Deng, Haiteng/0000-0001-9496-1280	NCI NIH HHS [P30 CA 13330] Funding Source: Medline; NIGMS NIH HHS [GM 15399] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015399] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Basu U, 2003, MOL CELL BIOL, V23, P6187, DOI 10.1128/MCB.23.17.6187-6199.2003; Basu U, 2001, MOL CELL BIOL, V21, P1453, DOI 10.1128/MCB.21.5.1453-1462.2001; DEMAGGIO AJ, 1992, P NATL ACAD SCI USA, V89, P7008, DOI 10.1073/pnas.89.15.7008; EVANS CF, 1990, METHOD ENZYMOL, V181, P439; Gross SD, 1999, J CELL SCI, V112, P2647; Gross SD, 1997, J CELL SCI, V110, P3083; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Harnpicharnchai P, 2001, MOL CELL, V8, P505, DOI 10.1016/S1097-2765(01)00344-6; Ho Y, 1997, P NATL ACAD SCI USA, V94, P581, DOI 10.1073/pnas.94.2.581; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; Kafadar KA, 2003, GENE DEV, V17, P2698, DOI 10.1101/gad.1140603; Kressler D, 1999, MOL CELL BIOL, V19, P7897; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Maiti T, 2003, YEAST, V20, P97, DOI 10.1002/yea.937; McKay RM, 2001, DEV BIOL, V235, P378, DOI 10.1006/dbio.2001.0307; McKay RM, 2001, DEV BIOL, V235, P388, DOI 10.1006/dbio.2001.0308; Menne TF, 2007, NAT GENET, V39, P486, DOI 10.1038/ng1994; Merrick WC., 1996, TRANSLATION CONTROL, P31; Moriya H, 2004, P NATL ACAD SCI USA, V101, P1572, DOI 10.1073/pnas.0305901101; Murakami A, 1999, J BIOL CHEM, V274, P3804, DOI 10.1074/jbc.274.6.3804; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Petronczki M, 2006, CELL, V126, P1049, DOI 10.1016/j.cell.2006.07.029; RAYCHAUDHURI P, 1984, J BIOL CHEM, V259, P1930; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; ROBINSON LC, 1992, P NATL ACAD SCI USA, V89, P28, DOI 10.1073/pnas.89.1.28; ROSBASH M, 2003, NOVART FDN SYMP, V253, P102; ROSBASH M, 2003, NOVART FDN SYMP, V253, P252; ROSBASH M, 2003, NOVART FDN SYMP, V253, P232; Rosbash Michael, 2003, Novartis Found Symp, V253, P223; RUSSELL DW, 1979, J BIOL CHEM, V254, P8796; RUSSELL DW, 1980, ARCH BIOCHEM BIOPHYS, V201, P518, DOI 10.1016/0003-9861(80)90540-8; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanvito F, 1999, J CELL BIOL, V144, P823, DOI 10.1083/jcb.144.5.823; Schafer T, 2003, EMBO J, V22, P1370, DOI 10.1093/emboj/cdg121; Schafer T, 2006, NATURE, V441, P651, DOI 10.1038/nature04840; Si K, 1997, P NATL ACAD SCI USA, V94, P14285, DOI 10.1073/pnas.94.26.14285; Si K, 1999, MOL CELL BIOL, V19, P1416; Tschochner H, 2003, TRENDS CELL BIOL, V13, P255, DOI 10.1016/S0962-8924(03)00054-0; UDEM SA, 1972, J MOL BIOL, V65, P227, DOI 10.1016/0022-2836(72)90279-3; VALENZUELA DM, 1982, J BIOL CHEM, V257, P7712; VANCURA A, 1994, J BIOL CHEM, V269, P19271; Venema J, 1998, METH MOL B, V77, P257; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; Vilardell J, 2000, RNA, V6, P1773, DOI 10.1017/S135583820000145X; Wang XM, 1996, MOL CELL BIOL, V16, P5375; [No title captured]	47	28	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9681	9691		10.1074/jbc.M710294200	http://dx.doi.org/10.1074/jbc.M710294200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18256024	hybrid, Green Published			2022-12-25	WOS:000254671600023
J	Smith, AE; Hurd, PJ; Bannister, AJ; Kouzarides, T; Ford, KG				Smith, Alexander E.; Hurd, Paul J.; Bannister, Andrew J.; Kouzarides, Tony; Ford, Kevin G.			Heritable gene repression through the action of a directed DNA methyltransferase at a chromosomal locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSINE METHYLATION; EXPRESSION; CELLS; REPLICATION; SEQUENCES; PROMOTER; SETDB1	The ability to exogenously impose targeted epigenetic changes in the genome represents an attractive route for the simulation of genomic de novo epigenetic events characteristic of some diseases and for the study of their downstream effects and also provides a potential therapeutic approach for the heritable repression of selected genes. Here we demonstrate for the first time the ability of zinc finger peptides to deliver DNA cytosine methylation in vivo to a genomic integrated target promoter when expressed as fusions with a mutant prokaryotic DNA cytosine methyltransferase enzyme, thus mimicking cellular genomic de novo methylation events and allowing a direct analysis of the mechanics of de novo DNA methylation-mediated gene silencing at a genomic locus. We show that targeted methylation leads to gene silencing via the initiation of a repressive chromatin signature at the targeted genomic locus. This repression is maintained after the loss of targeted methyltransferase enzyme from the cell, confirming epigenetic maintenance purely through the action of cellular enzymes. The inherited DNA methylation pattern is restricted only to targeted sites, suggesting that the establishment of repressive chromatin structure does not drive further de novo DNA methylation in this system. As well as demonstrating the potential of these enzymes as tools for the exogenous, heritable control of cellular gene expression, this work also provides the most definitive confirmation to date for a transcriptionally repressive role for de novo DNA methylation in the cell and lends some weight to the hypothesis that the aberrant methylation associated with certain diseases may well be a cause rather than a consequence of transcriptional gene repression.	[Smith, Alexander E.; Ford, Kevin G.] Kings Coll London, Rayne Inst, Dept Haematol Med, London SE5 9NU, England; [Smith, Alexander E.; Ford, Kevin G.] St Thomas Sch Med, London SE5 9NU, England; [Hurd, Paul J.; Bannister, Andrew J.; Kouzarides, Tony] Univ Cambridge, Wellcome Trust & Canc Res UK Gardon Inst Canc & D, Cambridge CB2 1QN, England; [Hurd, Paul J.; Bannister, Andrew J.; Kouzarides, Tony] Univ Cambridge, Dept Pathol, Cambridge CB2 1QN, England	University of London; King's College London; University of London; King's College London; University of Cambridge; University of Cambridge	Ford, KG (corresponding author), Kings Coll London, Rayne Inst, Dept Haematol Med, 123 Coldharbour Lane, London SE5 9NU, England.	kevin.ford@kcl.ac.uk		Kouzarides, Tony/0000-0002-8918-4162; Hurd, Paul/0000-0003-1112-9347; Bannister, Andrew/0000-0002-6312-4436	Biotechnology and Biological Sciences Research Council [47/GTH12521] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Carvin CD, 2003, NUCLEIC ACIDS RES, V31, P6493, DOI 10.1093/nar/gkg853; Choo Y, 1997, J MOL BIOL, V273, P525, DOI 10.1006/jmbi.1997.1339; CHOO Y, 1994, NATURE, V372, P642, DOI 10.1038/372642a0; Cuthbert GL, 2004, CELL, V118, P545, DOI 10.1016/j.cell.2004.08.020; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Hermann A, 2004, CELL MOL LIFE SCI, V61, P2571, DOI 10.1007/s00018-004-4201-1; Ishii T, 2004, CANCER LETT, V212, P211, DOI 10.1016/j.canlet.2004.03.001; Jamieson AC, 2003, NAT REV DRUG DISCOV, V2, P361, DOI 10.1038/nrd1087; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kawasaki H, 2004, NATURE, V431, P211, DOI 10.1038/nature02889; Li FY, 2007, NUCLEIC ACIDS RES, V35, P100, DOI 10.1093/nar/gkl1035; Li HW, 2006, J BIOL CHEM, V281, P19489, DOI 10.1074/jbc.M513249200; Liang GG, 2002, METHODS, V27, P150, DOI 10.1016/S1046-2023(02)00068-3; Lombardo A, 2007, NAT BIOTECHNOL, V25, P1298, DOI 10.1038/nbt1353; Lorincz MC, 2004, NAT STRUCT MOL BIOL, V11, P1068, DOI 10.1038/nsmb840; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; McNamara AR, 2002, NUCLEIC ACIDS RES, V30, P3818, DOI 10.1093/nar/gkf501; McNamara AR, 2000, NUCLEIC ACIDS RES, V28, P4865, DOI 10.1093/nar/28.24.4865; Minczuk M, 2006, P NATL ACAD SCI USA, V103, P19689, DOI 10.1073/pnas.0609502103; Morris KV, 2004, SCIENCE, V305, P1289, DOI 10.1126/science.1101372; Park CW, 2004, BIOCHEM BIOPH RES CO, V323, P275, DOI 10.1016/j.bbrc.2004.08.096; Quesnel B, 1998, BLOOD, V91, P2985, DOI 10.1182/blood.V91.8.2985.2985_2985_2990; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Sarraf SA, 2004, MOL CELL, V15, P595, DOI 10.1016/j.molcel.2004.06.043; Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727; Smith AEF, 2005, BIOL CHEM, V386, P95, DOI 10.1515/BC.2005.012; Smith AE, 2007, NUCLEIC ACIDS RES, V35, P740, DOI 10.1093/nar/gkl1053; Spada F, 2006, ADV ENZYME REGUL, V46, P224, DOI 10.1016/j.advenzreg.2006.01.011; Stedman W, 2004, J VIROL, V78, P12566, DOI 10.1128/JVI.78.22.12566-12575.2004; Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690; Svoboda P, 2004, NUCLEIC ACIDS RES, V32, P3601, DOI 10.1093/nar/gkh697; Ting AH, 2005, NAT GENET, V37, P906, DOI 10.1038/ng1611; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Xu GL, 1997, NAT GENET, V17, P376, DOI 10.1038/ng1297-376; Yao XM, 2003, J CLIN INVEST, V111, P265, DOI 10.1172/JCI200315109; ZION M, 1994, P NATL ACAD SCI USA, V91, P10722, DOI 10.1073/pnas.91.22.10722	40	34	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9878	9885		10.1074/jbc.M710393200	http://dx.doi.org/10.1074/jbc.M710393200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18272522	hybrid			2022-12-25	WOS:000254671600044
J	Malakhova, OA; Zhang, DE				Malakhova, Oxana A.; Zhang, Dong-Er			ISG15 inhibits Nedd4 ubiquitin E3 activity and enhances the innate antiviral response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GENE-15; IN-VIVO; PROTEIN; RELEASE; IDENTIFICATION; UBIQUITYLATION; INTERFERONS; CONJUGATION; EXPRESSION; INFLUENZA	Interferons regulate diverse immune functions through the transcriptional activation of hundreds of genes involved in antiviral responses. The interferon-inducible ubiquitin-like protein ISG15 is expressed in cells in response to a variety of stress conditions like viral or bacterial infection and is present in its free form or is conjugated to cellular proteins. In addition, protein ubiquitination plays a regulatory role in the immune system. Many viruses modulate the ubiquitin (Ub) pathway to alter cellular signaling and the antiviral response. Ubiquitination of retroviral group-specific antigen precursors and matrix proteins of the Ebola, vesicular stomatitis, and rabies viruses by Nedd4 family HECT domain E3 ligases is an important step in facilitating viral release. We found that Nedd4 is negatively regulated by ISG15. Free ISG15 specifically bound to Nedd4 and blocked its interaction with Ub-E2 molecules, thus preventing further Ub transfer from E2 to E3. Furthermore, overexpression of ISG15 diminished the ability of Nedd4 to ubiquitinate viral matrix proteins and led to a decrease in the release of Ebola VP40 virus-like particles from the cells. These results point to a mechanistically novel function of ISG15 in the enhancement of the innate antiviral response through specific inhibition of Nedd4 Ub-E3 activity. To our knowledge, this is the first example of a Ub-like protein with the ability to interfere with Ub-E2 and E3 interaction to inhibit protein ubiquitination.	[Zhang, Dong-Er] Univ Calif San Diego, Moores Canc Ctr, Dept Pathol, La Jolla, CA 92093 USA; [Zhang, Dong-Er] Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA; [Malakhova, Oxana A.; Zhang, Dong-Er] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Research Institute	Zhang, DE (corresponding author), Univ Calif San Diego, Moores Canc Ctr, Dept Pathol, Rm 5328,Mail Stop 0815,3855 Hlth Sci Dr, La Jolla, CA 92093 USA.	d7zhang@ucsd.edu			NATIONAL CANCER INSTITUTE [R01CA079849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066955] Funding Source: NIH RePORTER; NCI NIH HHS [CA 079849] Funding Source: Medline; NIGMS NIH HHS [GM 066955] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anan T, 1998, GENES CELLS, V3, P751, DOI 10.1046/j.1365-2443.1998.00227.x; Bieniasz PD, 2006, VIROLOGY, V344, P55, DOI 10.1016/j.virol.2005.09.044; Biron CA, 2001, IMMUNITY, V14, P661, DOI 10.1016/S1074-7613(01)00154-6; DCunha J, 1996, J IMMUNOL, V157, P4100; Fang S, 2004, CELL MOL LIFE SCI, V61, P1546, DOI 10.1007/s00018-004-4129-5; Flores SY, 2003, PFLUG ARCH EUR J PHY, V446, P334, DOI 10.1007/s00424-003-1027-x; HAAS AL, 1987, J BIOL CHEM, V262, P11315; Harty RN, 2001, J VIROL, V75, P10623, DOI 10.1128/JVI.75.22.10623-10629.2001; Harvey KF, 1999, TRENDS CELL BIOL, V9, P166, DOI 10.1016/S0962-8924(99)01541-X; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Kim KI, 2004, MOL CELL BIOL, V24, P9592, DOI 10.1128/MCB.24.21.9592-9600.2004; Kim KI, 2005, J IMMUNOL, V175, P847, DOI 10.4049/jimmunol.175.2.847; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Lenschow DJ, 2007, P NATL ACAD SCI USA, V104, P1371, DOI 10.1073/pnas.0607038104; Lenschow DJ, 2005, J VIROL, V79, P13974, DOI 10.1128/JVI.79.22.13974-13983.2005; Malakhov MP, 2002, J BIOL CHEM, V277, P9976, DOI 10.1074/jbc.M109078200; Malakhova OA, 2006, EMBO J, V25, P2358, DOI 10.1038/sj.emboj.7601149; Narasimhan J, 1996, J BIOL CHEM, V271, P324, DOI 10.1074/jbc.271.1.324; Okumura A, 2006, P NATL ACAD SCI USA, V103, P1440, DOI 10.1073/pnas.0510518103; Pestka S, 2004, IMMUNOL REV, V202, P8, DOI 10.1111/j.0105-2896.2004.00204.x; Ritchie KJ, 2004, SEMIN CELL DEV BIOL, V15, P237, DOI 10.1016/j.semcdb.2003.12.005; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; Timmins J, 2001, VIROLOGY, V283, P1, DOI 10.1006/viro.2001.0860; WARD CL, 1995, CELL, V83, P12; Yasuda J, 2003, J VIROL, V77, P9987, DOI 10.1128/JVI.77.18.9987-9992.2003; Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362; Zou WG, 2006, J BIOL CHEM, V281, P3989, DOI 10.1074/jbc.M510787200	27	144	153	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					8783	8787		10.1074/jbc.C800030200	http://dx.doi.org/10.1074/jbc.C800030200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18287095	Green Published, hybrid			2022-12-25	WOS:000254465800003
J	Jiao, JW; Nakajima, A; Janssen, WGM; Bindokas, VP; Xiong, XL; Morrison, JH; Brorson, JR; Tang, YP				Jiao, Jianwei; Nakajima, Akira; Janssen, William G. M.; Bindokas, Vytautas P.; Xiong, Xiaoli; Morrison, John H.; Brorson, James R.; Tang, Ya-Ping			Expression of NR2B in Cerebellar Granule Cells Specifically Facilitates Effect of Motor Training on Motor Learning	PLOS ONE			English	Article								It is believed that gene/environment interaction (GEI) plays a pivotal role in the development of motor skills, which are acquired via practicing or motor training. However, the underlying molecular/neuronal mechanisms are still unclear. Here, we reported that the expression of NR2B, a subunit of NMDA receptors, in cerebellar granule cells specifically enhanced the effect of voluntary motor training on motor learning in the mouse. Moreover, this effect was characterized as motor learning-specific and developmental stage-dependent, because neither emotional/spatial memory was affected nor was the enhanced motor learning observed when the motor training was conducted starting at the age of 3 months old in these transgenic mice. These results indicate that changes in the expression of gene(s) that are involved in regulating synaptic plasticity in cerebellar granule cells may constitute a molecular basis for the cerebellum to be involved in the GEI by facilitating motor skill learning.	[Jiao, Jianwei; Nakajima, Akira; Xiong, Xiaoli; Tang, Ya-Ping] Univ Chicago, Dept Psychiat, Chicago, IL 60637 USA; [Janssen, William G. M.; Morrison, John H.] Mount Sinai Sch Med, Dept Neurosci, New York, NY USA; [Bindokas, Vytautas P.] Univ Chicago, Dept Neurobiol, Pharmacol, & Physiol, Chicago, IL USA; [Brorson, James R.] Univ Chicago, Dept Neurol, Chicago, IL USA	University of Chicago; Icahn School of Medicine at Mount Sinai; University of Chicago; University of Chicago	Jiao, JW (corresponding author), Univ Chicago, Dept Psychiat, Chicago, IL 60637 USA.	yptang@bsd.uchicago.edu	Nakajima, Akira/I-7077-2014; Tang, Ya-Ping/A-1035-2011; Morrison, John/F-9229-2012	Xiong, Xiaoli/0000-0002-4623-4326; Tang, Ya-Ping/0000-0002-0445-4072	NIMH/NIH [MH066243]; Alzheimer's Association [NIRG-02-4368]; NSF [0213112]; Brain Research Foundation (Chicago); Louis Block Foundation; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH066243] Funding Source: NIH RePORTER	NIMH/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Alzheimer's Association(Alzheimer's Association); NSF(National Science Foundation (NSF)); Brain Research Foundation (Chicago); Louis Block Foundation; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This study was partially supported by grants from NIMH/NIH (MH066243), Alzheimer's Association (NIRG-02-4368), NSF (0213112), Brain Research Foundation (Chicago), and Louis Block Foundation, all to YPT.	AIBA A, 1994, CELL, V79, P365, DOI 10.1016/0092-8674(94)90204-6; ALBUS J S, 1971, Mathematical Biosciences, V10, P25, DOI 10.1016/0025-5564(71)90051-4; Bahn S, 1997, P NATL ACAD SCI USA, V94, P9417, DOI 10.1073/pnas.94.17.9417; Baizer JS, 1999, J NEUROPHYSIOL, V81, P1960, DOI 10.1152/jn.1999.81.4.1960; Bao SW, 2002, P NATL ACAD SCI USA, V99, P1592, DOI 10.1073/pnas.032655399; BARNES R H, 1970, Journal of Nutrition, V100, P149; Barria A, 2005, NEURON, V48, P289, DOI 10.1016/j.neuron.2005.08.034; Ben Mamou C, 2006, NAT NEUROSCI, V9, P1237, DOI 10.1038/nn1778; Bergersen L, 2003, EUR J NEUROSCI, V18, P931, DOI 10.1046/j.1460-9568.2003.02828.x; Bizzi E, 2000, NAT REV NEUROSCI, V1, P101, DOI 10.1038/35039000; Bloedel JR, 2004, PROG BRAIN RES, V143, P319, DOI 10.1016/S0079-6123(03)43031-8; Bouchard TJ, 2003, J NEUROBIOL, V54, P4, DOI 10.1002/neu.10160; Boyden ES, 2006, NEURON, V51, P823, DOI 10.1016/j.neuron.2006.08.026; Boyden ES, 2004, ANNU REV NEUROSCI, V27, P581, DOI 10.1146/annurev.neuro.27.070203.144238; BRORSON JR, 1991, J NEUROSCI, V11, P4024; Brutsaert TD, 2006, RESP PHYSIOL NEUROBI, V151, P109, DOI 10.1016/j.resp.2005.12.013; Butefisch CM, 2004, J NEUROPHYSIOL, V91, P2110, DOI 10.1152/jn.01038.2003; Chen GX, 2000, BRAIN RES, V887, P144, DOI 10.1016/S0006-8993(00)03005-5; CHEN Q, 2007, NEUROBIOL DIS; Cull-Candy Stuart G, 2004, Sci STKE, V2004, pre16, DOI 10.1126/stke.2552004re16; Dang MT, 2006, P NATL ACAD SCI USA, V103, P15254, DOI 10.1073/pnas.0601758103; Davids K, 2003, SPORTS MED, V33, P245, DOI 10.2165/00007256-200333040-00001; Deary IJ, 2006, EUR J HUM GENET, V14, P690, DOI 10.1038/sj.ejhg.5201588; DEZEEUW CI, 1989, J COMP NEUROL, V284, P12, DOI 10.1002/cne.902840103; Doyon J, 2005, CURR OPIN NEUROBIOL, V15, P161, DOI 10.1016/j.conb.2005.03.004; Eichenbaum H, 2000, NAT REV NEUROSCI, V1, P41, DOI 10.1038/35036213; Ekerot CF, 2003, CEREBELLUM, V2, P101, DOI 10.1080/14734220309411; FLEISHMAN EA, 1960, J EXP PSYCHOL, V60, P162, DOI 10.1037/h0044953; Fox PW, 1996, NATURE, V384, P356, DOI 10.1038/384356a0; Ge SY, 2007, NEURON, V54, P559, DOI 10.1016/j.neuron.2007.05.002; Hansel C, 2000, NEURON, V26, P473, DOI 10.1016/S0896-6273(00)81179-4; Hansel C, 2006, NEURON, V51, P835, DOI 10.1016/j.neuron.2006.08.013; Heck AL, 2004, NUTRITION, V20, P598, DOI 10.1016/j.nut.2004.04.010; Hilber P, 2001, NEUROSCIENCE, V102, P615, DOI 10.1016/S0306-4522(00)00509-1; HOGAN B, 1994, MANIPULATION MOUSE E; Ito M, 2001, PHYSIOL REV, V81, P1143, DOI 10.1152/physrev.2001.81.3.1143; Ito M, 2006, PROG NEUROBIOL, V78, P272, DOI 10.1016/j.pneurobio.2006.02.006; Janssen WGM, 2005, EXP NEUROL, V191, pS28, DOI 10.1016/j.expneurol.2004.08.020; Jorntell H, 2006, NEURON, V52, P227, DOI 10.1016/j.neuron.2006.09.032; Kishimoto Y, 1997, NEUROREPORT, V8, P3717, DOI 10.1097/00001756-199712010-00012; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Krakauer JW, 2006, TRENDS NEUROSCI, V29, P58, DOI 10.1016/j.tins.2005.10.003; Levin SI, 2006, J NEUROPHYSIOL, V96, P785, DOI 10.1152/jn.01193.2005; Llansola M, 2005, CEREBELLUM, V4, P154, DOI 10.1080/14734220510007996; Llinas R, 1993, Curr Opin Neurobiol, V3, P958, DOI 10.1016/0959-4388(93)90168-X; Maia JAR, 2002, AM J PREV MED, V23, P87, DOI 10.1016/S0749-3797(02)00478-6; MARR D, 1969, J PHYSIOL-LONDON, V202, P437, DOI 10.1113/jphysiol.1969.sp008820; Massey PV, 2007, TRENDS NEUROSCI, V30, P176, DOI 10.1016/j.tins.2007.02.005; Mauk MD, 1997, NEURON, V18, P343, DOI 10.1016/S0896-6273(00)81235-0; McGue M, 1998, ANNU REV NEUROSCI, V21, P1, DOI 10.1146/annurev.neuro.21.1.1; MEIRI N, 1994, P NATL ACAD SCI USA, V91, P3196, DOI 10.1073/pnas.91.8.3196; Merrill KA, 1999, BEHAV GENET, V29, P95, DOI 10.1023/A:1021656405314; Montgomery H, 1999, LANCET, V353, P541, DOI 10.1016/S0140-6736(98)07131-1; Nader K, 2000, NAT REV NEUROSCI, V1, P216, DOI 10.1038/35044580; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Nyberg L, 2006, NEUROPSYCHOLOGIA, V44, P711, DOI 10.1016/j.neuropsychologia.2005.08.006; Pang TYC, 2006, NEUROSCIENCE, V141, P569, DOI 10.1016/j.neuroscience.2006.04.013; Perez-Otano I, 2005, TRENDS NEUROSCI, V28, P229, DOI 10.1016/j.tins.2005.03.004; PERUSSE L, 1989, AM J EPIDEMIOL, V129, P1012, DOI 10.1093/oxfordjournals.aje.a115205; Rampon C, 2000, NAT NEUROSCI, V3, P238, DOI 10.1038/72945; Rogers RG, 2006, OBSTET GYN CLIN N AM, V33, P297, DOI 10.1016/j.ogc.2006.02.004; Rondi-Reig L, 2002, BEHAV BRAIN RES, V132, P11, DOI 10.1016/S0166-4328(01)00381-3; Shimizu E, 2000, SCIENCE, V290, P1170, DOI 10.1126/science.290.5494.1170; Takehara K, 2004, NEUROSCI LETT, V364, P43, DOI 10.1016/j.neulet.2004.04.024; Tang YP, 1999, NATURE, V401, P63, DOI 10.1038/43432; Thomas CG, 2006, J NEUROPHYSIOL, V95, P1727, DOI 10.1152/jn.00771.2005; Toga AW, 2005, ANNU REV NEUROSCI, V28, P1, DOI 10.1146/annurev.neuro.28.061604.135655; Tulving E, 1998, HIPPOCAMPUS, V8, P198, DOI 10.1002/(SICI)1098-1063(1998)8:3<198::AID-HIPO2>3.3.CO;2-J; Wallen K, 1996, HORM BEHAV, V30, P364, DOI 10.1006/hbeh.1996.0042; WATANABE M, 1994, J COMP NEUROL, V343, P513, DOI 10.1002/cne.903430402; Wei F, 2001, NAT NEUROSCI, V4, P164, DOI 10.1038/83993; Welsh JP, 2005, P NATL ACAD SCI USA, V102, P17166, DOI 10.1073/pnas.0508191102; Wong RWC, 2002, P NATL ACAD SCI USA, V99, P14500, DOI 10.1073/pnas.222371099; Yamamoto M, 2003, J NEUROSCI, V23, P6759	74	11	12	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2008	3	2							e1684	10.1371/journal.pone.0001684	http://dx.doi.org/10.1371/journal.pone.0001684			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XS	18301761	Green Published, Green Submitted, gold			2022-12-25	WOS:000260586500028
J	Dewals, B; Boudry, C; Farnir, F; Drion, PV; Vanderplasschen, A				Dewals, Benjamin; Boudry, Christel; Farnir, Frederic; Drion, Pierre-Vincent; Vanderplasschen, Alain			Malignant Catarrhal Fever Induced by Alcelaphine herpesvirus 1 Is Associated with Proliferation of CD8(+) T Cells Supporting a Latent Infection	PLOS ONE			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; BLUE WILDEBEEST; NUCLEAR ANTIGEN; HTLV-I; VIRUS; DNA; LYMPHOCYTES; EXPRESSION; GENES; BROMODEOXYURIDINE	Alcelaphine herpesvirus 1 (AlHV-1), carried by wildebeest asymptomatically, causes malignant catarrhal fever (WD-MCF) when cross-species transmitted to a variety of susceptible species of the Artiodactyla order. Experimentally, WD-MCF can be induced in rabbits. The lesions observed are very similar to those described in natural host species. Here, we used the rabbit model and in vivo 5-Bromo-2'-Deoxyuridine (BrdU) incorporation to study WD-MCF pathogenesis. The results obtained can be summarized as follows. (i) AlHV-1 infection induces CD8(+) T cell proliferation detectable as early as 15 days post-inoculation. (ii) While the viral load in peripheral blood mononuclear cells remains below the detection level during most of the incubation period, it increases drastically few days before death. At that time, at least 10% of CD8(+) cells carry the viral genome; while CD11b(+), IgM(+) and CD4(+) cells do not. (iii) RT-PCR analyses of mononuclear cells isolated from the spleen and the popliteal lymph node of infected rabbits revealed no expression of ORF25 and ORF9, low or no expression of ORF50, and high or no expression of ORF73. Based on these data, we propose a new model for the pathogenesis of WD-MCF. This model relies on proliferation of infected CD8(+) cells supporting a predominantly latent infection.	[Dewals, Benjamin; Boudry, Christel; Vanderplasschen, Alain] Univ Liege, Fac Vet Med, Dept Infect & Parasit Dis, Liege, Belgium; [Farnir, Frederic] Univ Liege, Fac Vet Med, Dept Clin Sci, Biostat B43, Liege, Belgium; [Drion, Pierre-Vincent] Univ Liege, Animal Fac B23, Liege, Belgium	University of Liege; University of Liege; University of Liege	Dewals, B (corresponding author), Univ Liege, Fac Vet Med, Dept Infect & Parasit Dis, Immunol Vaccinol B43b, Liege, Belgium.	A.vdplasschen@ulg.ac.be	Dewals, Benjamin G./AAL-5754-2021	Dewals, Benjamin G./0000-0003-1497-0799	Fonds National Belge de la Recherche Scientifique (FNRS); Fonds pour la formation a la Recherche dans lIndustrie et dans lAgriculture (FRIA) [research fellow]	Fonds National Belge de la Recherche Scientifique (FNRS)(Fonds de la Recherche Scientifique - FNRS); Fonds pour la formation a la Recherche dans lIndustrie et dans lAgriculture (FRIA)(Fonds de la Recherche Scientifique - FNRS)	B. Dewals is a Postdoctoral Researcher of the Fonds National Belge de la Recherche Scientifique (FNRS). C. Boudry is a Research Fellow of the Fonds pour la formation a la Recherche dans lIndustrie et dans lAgriculture (FRIA). This work was supported by various grants of the FNRS.	Ballestas ME, 1999, SCIENCE, V284, P641, DOI 10.1126/science.284.5414.641; Boudry C, 2007, J GEN VIROL, V88, P3224, DOI 10.1099/vir.0.83153-0; BRIDGEN A, 1992, J COMP PATHOL, V106, P351, DOI 10.1016/0021-9975(92)90021-L; BUXTON D, 1980, VET REC, V106, P243, DOI 10.1136/vr.106.11.243; Calderwood M, 2005, J GEN VIROL, V86, P2703, DOI 10.1099/vir.0.81230-0; Castro AE, 1985, BOVINE PRACT, V20, P162; Collins CM, 2002, J GEN VIROL, V83, P2269, DOI 10.1099/0022-1317-83-9-2269; Collins CM, 2002, ADV CANCER RES, V84, P155, DOI 10.1016/S0065-230X(02)84005-2; Dewals B, 2006, J GEN VIROL, V87, P509, DOI 10.1099/vir.0.81465-0; Ebrahimi B, 2003, J GEN VIROL, V84, P99, DOI 10.1099/vir.0.18639-0; EDINGTON N, 1979, EUR J CANCER, V15, P1515, DOI 10.1016/0014-2964(79)90033-1; FRAME FM, 2007, VET RES COMMUN; Gillet L, 2004, J VIROL, V78, P2336, DOI 10.1128/JVI.78.5.2336-2347.2004; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; Grundhoff A, 2004, J CLIN INVEST, V113, P124, DOI 10.1172/JCI200417803; Hair JR, 2007, J GEN VIROL, V88, P1689, DOI 10.1099/vir.0.82548-0; Hanon E, 2000, IMMUNITY, V13, P657, DOI 10.1016/S1074-7613(00)00065-0; Hanon E, 1996, J VIROL, V70, P4116, DOI 10.1128/JVI.70.6.4116-4120.1996; Hanon E, 2000, BLOOD, V95, P1386, DOI 10.1182/blood.V95.4.1386.004k22_1386_1392; Holm M, 1998, CYTOMETRY, V32, P28, DOI 10.1002/(SICI)1097-0320(19980501)32:1<28::AID-CYTO4>3.0.CO;2-B; Krishnan HH, 2004, J VIROL, V78, P3601, DOI 10.1128/JVI.78.7.3601-3620.2004; KRISS JP, 1962, CANCER RES, V22, P254; LI H, 1995, J GEN VIROL, V76, P123, DOI 10.1099/0022-1317-76-1-123; Li H, 2000, J CLIN MICROBIOL, V38, P1313, DOI 10.1128/JCM.38.4.1313-1318.2000; Liu SF, 2000, J VIROL, V74, P2029, DOI 10.1128/JVI.74.4.2029-2037.2000; Lu F, 2006, J VIROL, V80, P5273, DOI 10.1128/JVI.02541-05; NAKAJIMA Y, 1994, J VET MED SCI, V56, P1065, DOI 10.1292/jvms.56.1065; PATEL JR, 1981, ARCH VIROL, V68, P321, DOI 10.1007/BF01314589; PLOWRIGHT W, 1960, NATURE, V188, P1167, DOI 10.1038/1881167a0; Plowright W., 1990, Virus infections of ruminants., P123; PLOWRIGHT W, 1968, J AM VET MED ASSOC, V152, P795; PLOWRIGHT W, 1975, RES VET SCI, V19, P159, DOI 10.1016/S0034-5288(18)33526-4; PLOWRIGHT W, 1965, RES VET SCI, V6, P56; Raftery MJ, 1999, J EXP MED, V190, P1103, DOI 10.1084/jem.190.8.1103; Renne R, 1998, J VIROL, V72, P5182, DOI 10.1128/JVI.72.6.5182-5188.1998; ROCHA B, 1990, EUR J IMMUNOL, V20, P1697, DOI 10.1002/eji.1830200812; Rosbottom J, 2002, J GEN VIROL, V83, P2999, DOI 10.1099/0022-1317-83-12-2999; Rossiter P B, 1985, Prog Vet Microbiol Immunol, V1, P121; Schock A, 1996, VET MICROBIOL, V53, P111, DOI 10.1016/S0378-1135(96)01239-4; Simon S, 2003, J GEN VIROL, V84, P2009, DOI 10.1099/vir.0.19048-0; SIVAKUMAR R, 2007, J VIROL; Swa S, 2001, IMMUNOLOGY, V102, P44, DOI 10.1046/j.1365-2567.2001.01154.x; Thonur L, 2006, VIRUS GENES, V32, P27, DOI 10.1007/s11262-005-5842-3; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; Traul DL, 2005, J VIROL METHODS, V129, P186, DOI 10.1016/j.jviromet.2005.05.021; VONBOEHMER H, 1993, J EXP MED, V177, P891, DOI 10.1084/jem.177.4.891; Zhao TM, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-34	47	37	37	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1627	10.1371/journal.pone.0001627	http://dx.doi.org/10.1371/journal.pone.0001627			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286184	Green Published, Green Submitted, gold			2022-12-25	WOS:000260586400020
J	Mathevon, N; Aubin, T; Vielliard, J; da Silva, ML; Sebe, F; Boscolo, D				Mathevon, Nicolas; Aubin, Thierry; Vielliard, Jacques; da Silva, Maria-Luisa; Sebe, Frederic; Boscolo, Danilo			Singing in the Rain Forest: How a Tropical Bird Song Transfers Information	PLOS ONE			English	Article							ACOUSTIC-SIGNAL; HABITAT; SELECTION; EVOLUTION; ECOLOGY; SOUND; CALL	How information transmission processes between individuals are shaped by natural selection is a key question for the understanding of the evolution of acoustic communication systems. Environmental acoustics predict that signal structure will differ depending on general features of the habitat. Social features, like individual spacing and mating behavior, may also be important for the design of communication. Here we present the first experimental study investigating how a tropical rainforest bird, the white-browed warbler Basileuterus leucoblepharus, extracts various information from a received song: species-specific identity, individual identity and location of the sender. Species-specific information is encoded in a resistant acoustic feature and is thus a public signal helping males to reach a wide audience. Conversely, individual identity is supported by song features susceptible to propagation: this private signal is reserved for neighbors. Finally, the receivers can locate the singers by using propagation-induced song modifications. Thus, this communication system is well matched to the acoustic constraints of the rain forest and to the ecological requirements of the species. Our results emphasize that, in a constraining acoustic environment, the efficiency of a sound communication system results from a coding/decoding process particularly well tuned to the acoustic properties of this environment.	[Mathevon, Nicolas; Aubin, Thierry; Sebe, Frederic] Univ Paris 11, CNRS, Equipe Commun Acoust NAMC, UMR8620, F-91405 Orsay, France; [Mathevon, Nicolas] Univ St Etienne, Lab Ecol & Neuro Ethol Sensorielles, EA 3988, St Etienne, France; [Vielliard, Jacques] Univ Estadual Campinas, Inst Biol, Lab Bioacust, Sao Paulo, Brazil; [da Silva, Maria-Luisa] Univ Sao Paulo, Inst Biol, Lab Ecol Paisagem Conserv, Sao Paulo, Brazil; [da Silva, Maria-Luisa] Univ Fed Para, Campus Univ Guama, Ctr Ciencias Biol, Belem, Para, Brazil	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Universite Jean Monnet; Universidade de Sao Paulo; Universidade Estadual de Campinas; Universidade de Sao Paulo; Universidade Federal do Para	Mathevon, N (corresponding author), Univ Paris 11, CNRS, Equipe Commun Acoust NAMC, UMR8620, F-91405 Orsay, France.	mathevon@univ-st-etienne.fr; thierry.aubin@u-psud.fr	Boscolo, Danilo/I-8655-2019	Boscolo, Danilo/0000-0002-0741-501X; SEBE, Frederic/0000-0003-0264-9519; Mathevon, Nicolas/0000-0003-0219-6601	Centre National de la Recherche Scientifique (CNRS) in France; BIOTA-FAPESP program in Brazil	Centre National de la Recherche Scientifique (CNRS) in France(Centre National de la Recherche Scientifique (CNRS)); BIOTA-FAPESP program in Brazil	This study was supported by the Centre National de la Recherche Scientifique (CNRS) in France and the BIOTA-FAPESP program in Brazil.	Aubin T, 2004, AN ACAD BRAS CIENC, V76, P335, DOI 10.1590/S0001-37652004000200022; Aubin T, 2002, J EXP BIOL, V205, P3793; AUBIN T, 1994, BIOACOUSTICS, V6, P80; Becker P.H., 1982, P213; Boncoraglio G, 2007, FUNCT ECOL, V21, P134, DOI 10.1111/j.1365-2435.2006.01207.x; Boscolo D, 2006, AN ACAD BRAS CIENC, V78, P629, DOI 10.1590/S0001-37652006000400003; BOWMAN R I, 1979, Journal fuer Ornithologie, V120, P353, DOI 10.1007/BF01642911; Castellan NJ, 1988, NONPARAMETRIC STAT B; Charrier I, 2001, NATURE, V412, P873, DOI 10.1038/35091136; CLARK CW, 1987, ETHOLOGY, V76, P101; Davis CC, 2005, AM NAT, V165, pE36, DOI 10.1086/428296; Grant PR, 2002, SCIENCE, V296, P707, DOI 10.1126/science.1070315; Hauser, 1996, EVOL COMMUN; Hauser MD, 2002, SCIENCE, V298, P1569, DOI 10.1126/science.298.5598.1569; Khanna H., 1997, Bioacoustics, V7, P209; Kroodsma Donald E., 1996, P269; Marler P., 2004, NATURES MUSIC SCI BI; MARTEN K, 1977, BEHAV ECOL SOCIOBIOL, V2, P291, DOI 10.1007/BF00299741; McGregor Peter K., 1996, P409; McGregor PK, 2005, ANIMAL COMMUNICATION; Miller E.H., 1982, P253; MORTON ES, 1975, AM NAT, V109, P17, DOI 10.1086/282971; Myers Norman, 2000, Nature (London), V403, P853, DOI 10.1038/35002501; Naguib M, 2001, ANIM BEHAV, V62, P825, DOI 10.1006/anbe.2001.1860; Rizzini CT, 1997, TRATADO FITOGEOGRAFI; Slabbekoorn H, 2003, NATURE, V424, P267, DOI 10.1038/424267a; Slabbekoorn H, 2002, PHILOS T R SOC B, V357, P493, DOI 10.1098/rstb.2001.1056; Slabbekoorn H, 2002, EVOLUTION, V56, P1849; Specht R., 2004, AVISOFT SAS LAB PRO; Uezu A, 2005, BIOL CONSERV, V123, P507, DOI 10.1016/j.biocon.2005.01.001; Vignal C, 2004, NATURE, V430, P448, DOI 10.1038/nature02645; Wiley R. H., 1982, ACOUSTIC COMMUNICATI, P131; WILLIAMS JM, 1993, IBIS, V135, P202, DOI 10.1111/j.1474-919X.1993.tb02833.x; [No title captured]; [No title captured]	35	43	45	0	54	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1580	10.1371/journal.pone.0001580	http://dx.doi.org/10.1371/journal.pone.0001580			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270571	Green Submitted, gold, Green Published			2022-12-25	WOS:000260535900016
J	Woo, H; Okamoto, S; Guiney, D; Gunn, JS; Fierer, J				Woo, Heungjeong; Okamoto, Sharon; Guiney, Donald; Gunn, John S.; Fierer, Joshua			A Model of Salmonella Colitis with Features of Diarrhea in SLC11A1 Wild-Type Mice	PLOS ONE			English	Article							SEROVAR TYPHIMURIUM COLITIS; EPITHELIAL-CELLS; PATHOGENICITY ISLAND-1; RESISTANCE; INFECTION; DISEASE; PROTEIN; VIRULENCE; GENES; PATHOGENESIS	Background: Mice do not get diarrhea when orally infected with S. enterica, but pre-treatment with oral aminoglycosidesmakes them susceptible to Salmonella colitis. However, genetically susceptible ItyS mice (Nramp1(G169D) allele) die from systemic infection before they develop diarrhea, so a new model is needed to study the pathogenesis of diarrhea. We pretreated ItyR mice (Nramp1(G169)) with oral kanamycin prior to infecting them with virulent S. Typhimurium strain 14028s in order to study Salmonella-induced diarrhea. We used both a visual scoring system and the measurement of fecal water content to measure diarrhea. BALB/c.D2(Nramp1) congenic started losing weight 5 days post-infection and they began to die from colitis 10-14 days after infection. A SPI-1 (invA) mutant caused cecal, but not colonic inflammation and did not cause diarrhea. A phoP-mutant did not cause manifestations of diarrhea in either normal or NADPH-deficient (gp91(phox)) mice. However, strain 14028s caused severe colitis and diarrhea in gp91(phox)-deficient mice on an ItyR background. pmr A and F mutants, which are less virulent in orally infected BALB/c mice, were fully virulent in this model of colitis. Conclusions: S. enterica must be able to invade the colonic epithelium and to persist in the colon in order to cause colitis with manifestations of diarrhea. The NADPH oxidase is not required for diarrhea in Salmonella colitis. Furthermore, a Salmonella phoP mutant can be cleared from the colon by non-oxidative host defenses.	[Woo, Heungjeong; Okamoto, Sharon; Fierer, Joshua] VA Healthcare, Dept Infect Dis, San Diego, CA USA; [Guiney, Donald; Fierer, Joshua] Univ Calif San Diego, Sch Med, Dept Med, Div Infect Dis, San Diego, CA USA; [Gunn, John S.] Ohio State Univ, Ctr Microb Interface Biol, Dept Mol Virol, Immunol, & Med Genet, Columbus, OH USA	University of California System; University of California San Diego; University System of Ohio; Ohio State University	Woo, H (corresponding author), VA Healthcare, Dept Infect Dis, San Diego, CA USA.	jfierer@ucsd.edu	Gunn, John/E-3167-2011; , jfierer/W-2823-2019		 [AI047884];  [AI32178];  [DK35108];  [AI043521]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047884, R01AI032178, R29AI043521, R56AI032178, R01AI043521] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK035108] Funding Source: NIH RePORTER	; ; ; ; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported in part by AI047884 (JF), AI32178 and DK35108 (DG), and AI043521 (JSG).	Barthel M, 2003, INFECT IMMUN, V71, P2839, DOI 10.1128/IAI.71.5.2839-2858.2003; BEHLAU I, 1993, J BACTERIOL, V175, P4475, DOI 10.1128/JB.175.14.4475-4484.1993; Bertelsen LS, 2004, AM J PHYSIOL-CELL PH, V287, pC939, DOI 10.1152/ajpcell.00413.2003; BOHNHOFF M, 1954, P SOC EXP BIOL MED, V86, P132, DOI 10.3181/00379727-86-21030; Browne SH, 2002, INFECT IMMUN, V70, P7126, DOI 10.1128/IAI.70.12.7126-7135.2002; Chao HC, 2000, PEDIATR INFECT DIS J, V19, P1158, DOI 10.1097/00006454-200012000-00008; Coburn B, 2005, INFECT IMMUN, V73, P3219, DOI 10.1128/IAI.73.6.3219-3227.2005; Coombes BK, 2005, INFECT IMMUN, V73, P7161, DOI 10.1128/IAI.73.11.7161-7169.2005; DAY DW, 1978, HISTOPATHOLOGY, V2, P117, DOI 10.1111/j.1365-2559.1978.tb01700.x; Dinauer MC, 1997, J IMMUNOL, V158, P5581; ECKMANN L, 1993, INFECT IMMUN, V61, P4569, DOI 10.1128/IAI.61.11.4569-4574.1993; Elewaut D, 1999, J IMMUNOL, V163, P1457; Ernst RK, 2001, MICROBES INFECT, V3, P1327, DOI 10.1016/S1286-4579(01)01494-0; Foster N, 2006, CYTOKINE, V36, P134, DOI 10.1016/j.cyto.2006.11.005; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; GALAN JE, 1992, J BACTERIOL, V174, P4338; GALAN JE, 1989, P NATL ACAD SCI USA, V86, P6383, DOI 10.1073/pnas.86.16.6383; Garg P, 2006, J IMMUNOL, V177, P4103, DOI 10.4049/jimmunol.177.6.4103; Govoni G, 1996, INFECT IMMUN, V64, P2923, DOI 10.1128/IAI.64.8.2923-2929.1996; Gunn JS, 1996, J BACTERIOL, V178, P6857, DOI 10.1128/jb.178.23.6857-6864.1996; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guttman JA, 2006, CELL MICROBIOL, V8, P634, DOI 10.1111/j.1462-5822.2005.00656.x; Hapfelmeier S, 2005, J IMMUNOL, V174, P1675, DOI 10.4049/jimmunol.174.3.1675; Hapfelmeier S, 2004, INFECT IMMUN, V72, P795, DOI 10.1128/IAI.72.2.795-809.2004; HEFFERNAN EJ, 1987, J INFECT DIS, V155, P1254, DOI 10.1093/infdis/155.6.1254; Helms M, 2005, EMERG INFECT DIS, V11, P859, DOI 10.3201/eid1106.041017; JONES BD, 1993, P NATL ACAD SCI USA, V90, P10390, DOI 10.1073/pnas.90.21.10390; JUNG HC, 1995, J CLIN INVEST, V95, P55, DOI 10.1172/JCI117676; Kato A, 2004, GENE DEV, V18, P2302, DOI 10.1101/gad.1230804; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kunzelmann K, 2002, PHYSIOL REV, V82, P245, DOI 10.1152/physrev.00026.2001; Lesnick ML, 2001, MOL MICROBIOL, V39, P1464, DOI 10.1046/j.1365-2958.2001.02360.x; MCGOVERN VJ, 1979, AM J SURG PATHOL, V3, P483, DOI 10.1097/00000478-197912000-00001; Mead PS, 1999, EMERG INFECT DIS, V5, P607, DOI 10.3201/eid0505.990502; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; Nakao M, 2002, NUTRITION, V18, P35, DOI 10.1016/S0899-9007(01)00715-8; Nishimuta M, 2006, J NUTR SCI VITAMINOL, V52, P121, DOI 10.3177/jnsv.52.121; POTTER M, 1983, INFECT IMMUN, V40, P1234, DOI 10.1128/IAI.40.3.1234-1235.1983; ROBERTS T, 1989, AM J AGR ECON, V71, P468, DOI 10.2307/1241614; Rollenhagen C, 2006, INFECT IMMUN, V74, P1649, DOI 10.1128/IAI.74.3.1649-1660.2006; Roy MF, 2002, GENES IMMUN, V3, P381, DOI 10.1038/sj.gene.6363924; RUITENBERG EJ, 1971, BRIT J EXP PATHOL, V52, P192; Schlumberger MC, 2006, CURR OPIN MICROBIOL, V9, P46, DOI 10.1016/j.mib.2005.12.006; Shi YX, 2004, MOL MICROBIOL, V53, P229, DOI 10.1111/j.1365-2958.2004.04107.x; Shiloh MU, 1999, IMMUNITY, V10, P29, DOI 10.1016/S1074-7613(00)80004-7; Stecher B, 2006, INFECT IMMUN, V74, P5047, DOI 10.1128/IAI.00072-06; Tsolis RM, 1999, INFECT IMMUN, V67, P4879, DOI 10.1128/IAI.67.9.4879-4885.1999; Uematsu S, 2006, NAT IMMUNOL, V7, P868, DOI 10.1038/ni1362; Valle E, 2005, INFECT IMMUN, V73, P2835, DOI 10.1128/IAI.73.5.2835-2840.2005; Varma JK, 2005, EMERG INFECT DIS, V11, P943; Vassiloyanakopoulos AP, 1998, P NATL ACAD SCI USA, V95, P7676, DOI 10.1073/pnas.95.13.7676; Vazquez-Torres A, 1999, NATURE, V401, P804, DOI 10.1038/44593; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; Winkelstein JA, 2000, MEDICINE, V79, P155, DOI 10.1097/00005792-200005000-00003	54	31	32	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1603	10.1371/journal.pone.0001603	http://dx.doi.org/10.1371/journal.pone.0001603			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270590	gold, Green Published, Green Submitted			2022-12-25	WOS:000260535900037
J	Michels, G; Er, F; Khan, IF; Endres-Becker, J; Brandt, MC; Gassanov, N; Johns, DC; Hoppe, UC				Michels, Guido; Er, Fikret; Khan, Ismail F.; Endres-Becker, Jeannette; Brandt, Mathias C.; Gassanov, Natig; Johns, David C.; Hoppe, Uta C.			K+ Channel Regulator KCR1 Suppresses Heart Rhythm by Modulating the Pacemaker Current I-f	PLOS ONE			English	Article								Hyperpolarization-activated, cyclic nucleotide sensitive (HCN) channels underlie the pacemaker current I-f, which plays an essential role in spontaneous cardiac activity. HCN channel subunits (HCN1-4) are believed to be modulated by additional regulatory proteins, which still have to be identified. Using biochemistry, molecularbiology and electrophysiology methods we demonstrate a protein-protein interaction between HCN2 and the K+ channel regulator protein 1, named KCR1. In coimmunoprecipitation experiments we show that KCR1 and HCN2 proteins are able to associate. Heterologously expressed HCN2 whole-cell current density was significantly decreased by KCR1. KCR1 profoundly suppressed I-HCN2 single-channel activity, indicating a functional interaction between KCR1 and the HCN2 channel subunit. Endogenous KCR1 expression could be detected in adult and neonatal rat ventriculocytes. Adenoviral-mediated overexpression of KCR1 in rat cardiomyocytes (i) reduced I-f whole-cell currents, (ii) suppressed most single-channel gating parameters, (iii) altered the activation kinetics, (iv) suppressed spontaneous action potential activity, and (v) the beating rate. More importantly, siRNA-based knock-down of endogenous KCR1 increased the native I-f current size and single-channel activity and accelerated spontaneous beating rate, supporting an inhibitory action of endogenous KCR1 on native I-f. Our observations demonstrate for the first time that KCR1 modulates I-HCN2/I-f channel gating and indicate that KCR1 serves as a regulator of cardiac automaticity.	[Michels, Guido; Er, Fikret; Khan, Ismail F.; Endres-Becker, Jeannette; Brandt, Mathias C.; Gassanov, Natig; Hoppe, Uta C.] Univ Cologne, Dept Internal Med 3, Cologne, Germany; [Johns, David C.] Johns Hopkins Univ, Gene Vector Ctr, Baltimore, MD USA; [Hoppe, Uta C.] Univ Cologne, Ctr Mol Med, Cologne, Germany	University of Cologne; Johns Hopkins University; University of Cologne	Hoppe, UC (corresponding author), Univ Cologne, Dept Internal Med 3, Cologne, Germany.	uta.hoppe@uni-koeln.de	Brandt, Mathias/ABF-6631-2021		Deutsche Forschungsgemeinschaft [Ho 2146/3-1]; Koln Fortune; Marga und Walter Boll-Stiftung	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Koln Fortune; Marga und Walter Boll-Stiftung	This study was supported by a grant from the Deutsche Forschungsgemeinschaft (Ho 2146/3-1), by Koln Fortune, and by the Marga und Walter Boll-Stiftung. Funders were not involved in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript.	Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; BUGAISKY LB, 1989, CIRC RES, V64, P493, DOI 10.1161/01.RES.64.3.493; Chu SH, 2005, LIFE SCI, V76, P2735, DOI 10.1016/j.lfs.2004.12.013; Decher N, 2003, PFLUG ARCH EUR J PHY, V446, P633, DOI 10.1007/s00424-003-1127-7; Dekker JP, 2006, J GEN PHYSIOL, V128, P561, DOI 10.1085/jgp.200609599; DiFrancesco D, 2005, CIRCULATION, V112, pE72, DOI 10.1161/CIRCULATIONAHA.105.541367; DIFRANCESCO D, 1986, NATURE, V324, P470, DOI 10.1038/324470a0; DIFRANCESCO D, 1994, J PHYSIOL-LONDON, V474, P473, DOI 10.1113/jphysiol.1994.sp020038; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; Er F, 2003, CIRCULATION, V107, P485, DOI 10.1161/01.CIR.0000045672.32920.CB; Er F, 2004, CIRCULATION, V110, P3100, DOI 10.1161/01.CIR.0000146900.84943.E0; Fischer M, 2005, J MOL DIAGN, V7, P89, DOI 10.1016/S1525-1578(10)60013-X; Fowler MA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000573; Gauss R, 1998, NATURE, V393, P583, DOI 10.1038/31248; Gravante B, 2004, J BIOL CHEM, V279, P43847, DOI 10.1074/jbc.M401598200; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hoppe UC, 1998, CIRCULATION, V97, P55, DOI 10.1161/01.CIR.97.1.55; Hoppe UC, 2000, J CLIN INVEST, V105, P1077, DOI 10.1172/JCI8757; Hoppe UC, 1999, CIRC RES, V84, P964; Hoppe UC, 2001, P NATL ACAD SCI USA, V98, P5335, DOI 10.1073/pnas.091239098; HORN R, 1987, BIOPHYS J, V51, P255, DOI 10.1016/S0006-3495(87)83331-3; Hoshi N, 1998, J BIOL CHEM, V273, P23080, DOI 10.1074/jbc.273.36.23080; Hullin R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000292; Ishii TM, 1999, J BIOL CHEM, V274, P12835, DOI 10.1074/jbc.274.18.12835; Kagan A, 2002, EMBO J, V21, P1889, DOI 10.1093/emboj/21.8.1889; Kimura K, 2004, GENES CELLS, V9, P631, DOI 10.1111/j.1356-9597.2004.00752.x; Kole MHP, 2006, J NEUROSCI, V26, P1677, DOI 10.1523/JNEUROSCI.3664-05.2006; Kupershmidt S, 2003, FASEB J, V17, P2263, DOI 10.1096/fj.02-1057fje; Lam JS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001009; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Michels G, 2005, CIRCULATION, V111, P399, DOI 10.1161/01.CIR.0000153799.65783.3A; Michels G, 2002, MOL PHARMACOL, V61, P682, DOI 10.1124/mol.61.3.682; Michels G, 2006, ENDOCRINOLOGY, V147, P5160, DOI 10.1210/en.2006-0186; Nakajima T, 2007, J BIOL CHEM, V282, P5506, DOI 10.1074/jbc.M605976200; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; Qu JH, 2004, J BIOL CHEM, V279, P43497, DOI 10.1074/jbc.M405018200; Riessland M, 2006, HUM GENET, V120, P101, DOI 10.1007/s00439-006-0186-1; Santoro B, 2004, J NEUROSCI, V24, P10750, DOI 10.1523/JNEUROSCI.3300-04.2004; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; Seifert R, 1999, P NATL ACAD SCI USA, V96, P9391, DOI 10.1073/pnas.96.16.9391; Simeone TA, 2005, J PHYSIOL-LONDON, V568, P371, DOI 10.1113/jphysiol.2005.093161; Stieber J, 2003, P NATL ACAD SCI USA, V100, P15235, DOI 10.1073/pnas.2434235100; Tu HY, 2004, J NEUROSCI RES, V76, P713, DOI 10.1002/jnr.20109; Vasilyev DV, 2002, J NEUROSCI, V22, P8992; Wible BA, 1998, J BIOL CHEM, V273, P11745, DOI 10.1074/jbc.273.19.11745; Yu H, 2001, CIRC RES, V88, pE84, DOI 10.1161/hh1201.093511	47	24	26	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1511	10.1371/journal.pone.0001511	http://dx.doi.org/10.1371/journal.pone.0001511			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SR	18231597	Green Published, gold, Green Submitted			2022-12-25	WOS:000260504200023
J	Cen, H; Mao, F; Aronchik, I; Fuentes, RJ; Firestone, GL				Cen, Hui; Mao, Fei; Aronchik, Ida; Fuentes, Rholinelle Joy; Firestone, Gary L.			DEVD-NucView488: a novel class of enzyme substrates for real-time detection of caspase-3 activity in live cells	FASEB JOURNAL			English	Article						apoptosis; fluorescence; imaging; nucleic acid; nucleus	THIAZOLE ORANGE; APOPTOSIS; DNA; ACTIVATION; EXPRESSION; BINDING; CALCIUM; DYE	Live-cell detection of intracellular enzyme activity requires that substrates are cell-permeable and that the generated products are easily detected and retained in cells. Our objective was to create a novel fluorogenic substrate that could be used for real-time detection of apoptosis in living cells. We have synthesized a highly cell-permeable caspase-3 substrate, DEVD-NucView488, by linking a fluorogenic DNA-binding dye to the caspase-3 recognition sequence that renders the dye nonfunctional. On substrate cleavage, the dye is released and becomes highly fluorescent on binding to DNA. DEVD-NucView488 detected caspase-3 activation within a live-cell population much earlier and with higher sensitivity compared with other apoptosis reagents that are currently available. Furthermore, cells incubated with DEVD-NucView488 exhibited no toxicity and normal apoptotic progression. DEVD-NucView488 is an ideal substrate for kinetic studies of caspase-3 activation because it detects caspase-3 activity in real-time and also efficiently labels DNA in nuclei of caspase-3-activated cells for real-time fluorescent visualization of apoptotic morphology. The strategy utilized in the design of this fluorogenic substrate can be applied in future endeavors to develop substrates for detecting real-time intracellular enzyme activity.	[Cen, Hui; Mao, Fei; Fuentes, Rholinelle Joy] Biotium Inc, Hayward, CA 94545 USA; [Aronchik, Ida; Firestone, Gary L.] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Cen, H (corresponding author), Biotium Inc, 3423 Investment Blvd,Ste 8, Hayward, CA 94545 USA.	dcen@biotium.com			NATIONAL CANCER INSTITUTE [R01CA102360] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA102360, R01 CA102360-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Armitage BA, 2005, TOP CURR CHEM, V253, P55, DOI 10.1007/b100442; Bedner E, 2000, EXP CELL RES, V259, P308, DOI 10.1006/excr.2000.4955; Benetti L, 2007, J VIROL, V81, P10242, DOI 10.1128/JVI.00820-07; Bonnesen C, 2001, CANCER RES, V61, P6120; BORLE AB, 1982, SCIENCE, V217, P252, DOI 10.1126/science.6806904; Bosch M, 2007, P NATL ACAD SCI USA, V104, P18327, DOI 10.1073/pnas.0705826104; Cai SX, 2001, BIOORG MED CHEM LETT, V11, P39, DOI 10.1016/S0960-894X(00)00590-4; Carreon JR, 2004, ORG LETT, V6, P517, DOI 10.1021/ol0362818; GRASSMANN A, 1971, H-S Z PHYSIOL CHEM, V352, P527, DOI 10.1515/bchm2.1971.352.1.527; Hawkins RB, 2005, INT J RADIAT ONCOL, V63, P529, DOI 10.1016/j.ijrobp.2005.05.055; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; LEE LG, 1986, CYTOMETRY, V7, P508, DOI 10.1002/cyto.990070603; Liu LZ, 2002, NAT MED, V8, P185, DOI 10.1038/nm0202-185; Messerli SM, 2004, NEOPLASIA, V6, P95, DOI 10.1593/neo.03214; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Paez PM, 2007, J NEUROSCI, V27, P12690, DOI 10.1523/JNEUROSCI.2381-07.2007; Smolewski P, 2002, CYTOMETRY, V47, P143, DOI 10.1002/cyto.10062; TENG H, 2007, J CEREB BLOOD FLOW M; Vuorinen K, 2007, EXP LUNG RES, V33, P357, DOI 10.1080/01902140701634827; Zhang HZ, 2003, BIOCONJUGATE CHEM, V14, P458, DOI 10.1021/bc0256188; ZHANG YZ, 1991, FASEB J, V5, P3108, DOI 10.1096/fasebj.5.15.1720751	21	62	66	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2243	2252		10.1096/fj.07-099234	http://dx.doi.org/10.1096/fj.07-099234			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18263700				2022-12-25	WOS:000257292500017
J	Gunning, AP; Chambers, S; Pin, C; Man, AL; Morris, VJ; Nicoletti, C				Gunning, A. Patrick; Chambers, Stephen; Pin, Carmen; Man, Angela L.; Morris, Victor J.; Nicoletti, Claudio			Mapping specific adhesive interactions on living human intestinal epithelial cells with atomic force microscopy	FASEB JOURNAL			English	Article						AFM; caco-2; force mapping; lectin-carbohydrate interactions	COLLOID PROBE; SPECTROSCOPY; RECEPTOR; CACO-2; GUT; ANTIBODIES; MEMBRANES; STRENGTH; ANTIGEN; BINDING	Specific molecular-receptor interactions with gut epithelium cells are important in understanding bioactivity of food components and drugs, binding of commensal microflora, attachment and initiation of defense mechanisms against pathogenic bacteria and for development of targeted delivery systems to the gut. However, methods for probing such interactions are lacking. Methodology has been developed and validated to measure specific molecular-receptor interactions on living human colorectal cancer cells as in vitro models for the gut epithelium. Atomic force microscopy (AFM) was used to measure ligand-receptor interactions and to map receptor locations on cell surfaces. Measurements were made using silica beads attached to the AFM tip- cantilever assembly, which were functionalized by coupling of ligands to the bead surface. Wheat germ agglutinin (WGA) binds to the glycosylated extracellular domain III of the epidermal growth factor receptor. Methodology was tested by measuring binding of WGA to the surface of confluent monolayers of living Caco-2 human intestinal epithelial cells. The measured modal detachment force of 125 pN is typical of values expected for single molecule interactions. Adhesive events were used to map the location of binding sites on the cell surface revealing heterogeneity in their distribution within and between cells within the monolayer.			Gunning, AP (corresponding author), Inst Food Res, Inst Food Res, Norwich Res Pk, Norwich NR4 7UA, Norfolk, England.	patrick.gunning@bbsrc.ac.uk	pin, carmen/C-8959-2014	Man, Angela/0000-0002-9596-0068	Biotechnology and Biological Sciences Research Council Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Benoit M, 2000, NAT CELL BIOL, V2, P313, DOI 10.1038/35014000; BHATIA SK, 1989, ANAL BIOCHEM, V178, P408, DOI 10.1016/0003-2697(89)90662-3; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BUTT HJ, 1995, NANOTECHNOLOGY, V6, P1, DOI 10.1088/0957-4484/6/1/001; CHAMOW SM, 1992, J BIOL CHEM, V267, P15916; Dammer U, 1996, BIOPHYS J, V70, P2437, DOI 10.1016/S0006-3495(96)79814-4; Didierlaurent A, 2002, CELL MICROBIOL, V4, P61, DOI 10.1046/j.1462-5822.2002.00177.x; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; Foster N, 2005, ADV DRUG DELIVER REV, V57, P431, DOI 10.1016/j.addr.2004.09.009; Frey A, 1996, J EXP MED, V184, P1045, DOI 10.1084/jem.184.3.1045; Gabor F, 1998, J CONTROL RELEASE, V55, P131, DOI 10.1016/S0168-3659(98)00043-1; Gabor F, 2002, INT J PHARM, V237, P227, DOI 10.1016/S0378-5173(02)00049-2; HAN T, 1995, ANAL CHIM ACTA, V307, P365, DOI 10.1016/0003-2670(94)00671-8; Hinterdorfer P, 1996, P NATL ACAD SCI USA, V93, P3477, DOI 10.1073/pnas.93.8.3477; HUTTER JL, 1993, REV SCI INSTRUM, V64, P1868, DOI 10.1063/1.1143970; Kaiserlian D, 1999, CURR TOP MICROBIOL, V236, P55; Kerneis S, 1997, SCIENCE, V277, P949, DOI 10.1126/science.277.5328.949; LEE GU, 1994, SCIENCE, V266, P771, DOI 10.1126/science.7973628; Lochner N, 2003, PHARM RES-DORDR, V20, P833, DOI 10.1023/A:1023406224028; MADARA JL, 1990, J MEMBRANE BIOL, V116, P117; McNamee CE, 2006, BIOPHYS J, V91, P1960, DOI 10.1529/biophysj.106.082420; McNamee CE, 2006, COLLOID SURFACE B, V48, P176, DOI 10.1016/j.colsurfb.2006.01.014; McNamee CE, 2006, COLLOID SURFACE B, V47, P85, DOI 10.1016/j.colsurfb.2005.11.023; MEYER G, 1988, APPL PHYS LETT, V53, P1045, DOI 10.1063/1.100061; O'Hara AM, 2006, EMBO REP, V7, P688, DOI 10.1038/sj.embor.7400731; PETERSON MD, 1993, J CELL SCI, V105, P445; PINTO, 1983, BIOL CELL, V47, P322; Puntheeranurak T, 2006, J CELL SCI, V119, P2960, DOI 10.1242/jcs.03035; Shao L, 2001, SEMIN IMMUNOL, V13, P163, DOI 10.1006/smim.2000.0311; Sulchek T, 2006, BIOPHYS J, V90, P4686, DOI 10.1529/biophysj.105.080291; Touhami A, 2003, MICROBIOL-SGM, V149, P2873, DOI 10.1099/mic.0.26431-0; Touhami A, 2003, LANGMUIR, V19, P1745, DOI 10.1021/la026145w; Williams JM, 1996, LANGMUIR, V12, P1291, DOI 10.1021/la950500j; Williams PM, 2003, ANAL CHIM ACTA, V479, P107, DOI 10.1016/S0003-2670(02)01569-6; Zhang XH, 2004, AM J PHYSIOL-HEART C, V286, pH359, DOI 10.1152/ajpheart.00491.2003; Zhang XH, 2002, BIOPHYS J, V83, P2270, DOI 10.1016/S0006-3495(02)73987-8	36	29	30	0	31	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2331	2339		10.1096/fj.07-100578	http://dx.doi.org/10.1096/fj.07-100578			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18263697				2022-12-25	WOS:000257292500025
J	Grady, WM; Parkin, RK; Mitchell, PS; Lee, JH; Kim, YH; Tsuchiya, KD; Washington, MK; Paraskeva, C; Willson, JKV; Kaz, AM; Kroh, EM; Allen, A; Fritz, BR; Markowitz, SD; Tewari, M				Grady, W. M.; Parkin, R. K.; Mitchell, P. S.; Lee, J. H.; Kim, Y-H; Tsuchiya, K. D.; Washington, M. K.; Paraskeva, C.; Willson, J. K. V.; Kaz, A. M.; Kroh, E. M.; Allen, A.; Fritz, B. R.; Markowitz, S. D.; Tewari, M.			Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer	ONCOGENE			English	Article						microRNA; epigenetic; colorectal cancer; colon cancer; methylation; apoptosis	OLIGONUCLEOTIDE ARRAYS; EXPRESSION PROFILES; COLON-CANCER; IDENTIFICATION; TARGETS; TUMOR; HYPERMETHYLATION; SIGNATURE; NEOPLASIA; MECHANISM	MicroRNAs are small, non-coding RNAs that influence gene regulatory networks by post-transcriptional regulation of specific messenger RNA targets. MicroRNA expression is dysregulated in human malignancies, frequently leading to loss of expression of certain microRNAs. We report that expression of hsa-miR-342, a microRNA encoded in an intron of the gene EVL, is commonly suppressed in human colorectal cancer. The expression of hsa-miR- 342 is coordinated with that of EVL and our results indicate that the mechanism of silencing is CpG island methylation upstream of EVL. We found methylation at the EVL/hsa-miR-342 locus in 86% of colorectal adenocarcinomas and in 67% of adenomas, indicating that it is an early event in colorectal carcinogenesis. In addition, we observed a higher frequency of methylation ( 56%) in histologically normal colorectal mucosa from individuals with concurrent cancer compared to mucosa from individuals without colorectal cancer ( 12%), suggesting the existence of a 'field defect' involving methylated EVL/hsa-miR-342. Furthermore, reconstitution of hsa-miR- 342 in the colorectal cancer cell line HT-29 induced apoptosis, suggesting that this microRNA could function as a proapoptotic tumor suppressor. In aggregate, these results support a novel mechanism for silencing intronic microRNAs in cancer by epigenetic alterations of cognate host genes.	[Grady, W. M.; Lee, J. H.; Kim, Y-H; Tsuchiya, K. D.; Kaz, A. M.; Tewari, M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; [Grady, W. M.; Kaz, A. M.] Univ Washington, Sch Med, Div Gastroenterol, Seattle, WA USA; [Grady, W. M.; Kaz, A. M.] VA Puget Sound Healthcare Syst, Seattle, WA USA; [Parkin, R. K.; Mitchell, P. S.; Kroh, E. M.; Fritz, B. R.; Tewari, M.] Fred Hutchinson Canc Res Ctr, Human Biol Div, Seattle, WA 98109 USA; [Lee, J. H.; Kim, Y-H] Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Seoul, South Korea; [Tsuchiya, K. D.] Seattle Childrens Hosp & Reg Med Ctr, Seattle, WA USA; [Washington, M. K.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Paraskeva, C.] Univ Bristol, Bristol, Avon, England; [Willson, J. K. V.] Univ Texas SW, Sch Med, Dallas, TX USA; [Allen, A.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA; [Markowitz, S. D.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA; [Markowitz, S. D.] Univ Hosp Cleveland, Cleveland, OH 44106 USA; [Markowitz, S. D.] Howard Hughes Med Inst, Cleveland, OH USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; Fred Hutchinson Cancer Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Seattle Children's Hospital; Vanderbilt University; University of Bristol; University of Texas System; University of Texas Southwestern Medical Center Dallas; Fred Hutchinson Cancer Center; Case Western Reserve University; University Hospitals of Cleveland; Howard Hughes Medical Institute	Tewari, M (corresponding author), Fred Hutchinson Canc Res Ctr, Human Biol & Clin Res Div, 1100 Fairview Ave N,Mailstop D4-100, Seattle, WA 98109 USA.	mtewari@fhcrc.org		Mitchell, Patrick/0000-0001-8375-9060	NCI NIH HHS [P30 CA015704] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Bandres E, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-29; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brueckner B, 2007, CANCER RES, V67, P1419, DOI 10.1158/0008-5472.CAN-06-4074; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; Grady WM, 2001, CANCER RES, V61, P900; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Kim YH, 2006, GENE CHROMOSOME CANC, V45, P781, DOI 10.1002/gcc.20341; Kim YK, 2007, EMBO J, V26, P775, DOI 10.1038/sj.emboj.7601512; Kondo Y, 2004, CANCER METAST REV, V23, P29, DOI 10.1023/A:1025806911782; Krause M, 2003, ANNU REV CELL DEV BI, V19, P541, DOI 10.1146/annurev.cellbio.19.050103.103356; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218; Michael MZ, 2003, MOL CANCER RES, V1, P882; Myohanen SK, 1998, CANCER RES, V58, P591; Notterman DA, 2001, CANCER RES, V61, P3124; Ohm JE, 2007, CELL CYCLE, V6, P1040, DOI 10.4161/cc.6.9.4210; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704; Saini HK, 2007, P NATL ACAD SCI USA, V104, P17719, DOI 10.1073/pnas.0703890104; Saito Y, 2006, CELL CYCLE, V5, P2220, DOI 10.4161/cc.5.19.3340; Toyota M, 1999, CANCER RES, V59, P2307; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Wijnhoven BPL, 2007, BRIT J SURG, V94, P23, DOI 10.1002/bjs.5673; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028; Zou TT, 2002, ONCOGENE, V21, P4855, DOI 10.1038/sj.onc.1205613	29	228	246	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2008	27	27					3880	3888		10.1038/onc.2008.10	http://dx.doi.org/10.1038/onc.2008.10			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18264139				2022-12-25	WOS:000256904700013
J	Goodger, SJ; Robinson, CJ; Murphy, KJ; Gasiunas, N; Harmer, NJ; Blundell, TL; Pye, DA; Gallagher, JT				Goodger, Sarah J.; Robinson, Christopher J.; Murphy, Kevin J.; Gasiunas, Nijole; Harmer, Nicholas J.; Blundell, Tom L.; Pye, David A.; Gallagher, John T.			Evidence that heparin saccharides promote FGF2 mitogenesis through two distinct mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; FLAVOBACTERIUM-HEPARINUM; SULFATE OLIGOSACCHARIDES; CRYSTAL-STRUCTURE; BASIC FGF; RECEPTOR; BINDING; SPECIFICITY; ANGIOGENESIS; COMPLEX	Heparin-like saccharides play an essential role in binding to both fibroblast growth factors (FGF) and their receptors at the cell surface. In this study we prepared a series of heparin oligosaccharides according to their size and sulfation level. We then investigated their affinity for FGF2 and their ability to support FGF2 mitogenesis of heparan sulfate-deficient cells expressing FGFR1c. Tetra- and hexasaccharides bound FGF2, but failed to dimerize the growth factor. Nevertheless, these saccharides promoted FGF2-mediated cell growth. Furthermore, whereas enzymatic removal of the non-reducing end 2-O-sulfate group had little effect on the 1: 1 interaction with FGF2, it eliminated the mitogenic activity of these saccharides. This evidence supports the symmetric two-end model of ternary complex formation. In contrast, even at very low concentrations, octasaccharide and larger heparin fragments conferred a potent mitogenic activity that was independent of terminal 2-O-sulfation. This correlated with the ability to dimerize FGF2 in an apparently cooperative manner. This data suggests that potent mitogenic signaling results from heparin-mediated trans-dimerization of FGF2, consistent with the asymmetric model of ternary complex formation. We propose that, depending on saccharide structure, there are different architectures and modes of ternary complex assembly that differ in stability and/or efficiency of transmembrane signaling.	[Goodger, Sarah J.; Robinson, Christopher J.; Gasiunas, Nijole; Gallagher, John T.] Univ Manchester, Paterson Inst Canc Res, Sch Canc & Imaging Sci, Canc Res UK Glycooncol Grp, Manchester M20 4BX, Lancs, England; [Murphy, Kevin J.; Pye, David A.] Univ Huddersfield, Dept Chem & Biol Sci, Huddersfield HD1 3DH, W Yorkshire, England; [Harmer, Nicholas J.; Blundell, Tom L.] Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; [Harmer, Nicholas J.] Univ Exeter, Exeter EX4 4QD, Devon, England	Paterson Institute for Cancer Research; University of Manchester; University of Huddersfield; University of Cambridge; University of Exeter	Robinson, CJ (corresponding author), Univ Manchester, Paterson Inst Canc Res, Sch Canc & Imaging Sci, Canc Res UK Glycooncol Grp, Manchester M20 4BX, Lancs, England.	christopher.robinson@manchester.ac.uk		Robinson, Christopher/0000-0001-6146-566X	Cancer Research UK Funding Source: Medline	Cancer Research UK(Cancer Research UK)		BIELICKI J, 1993, BIOCHEM J, V289, P241, DOI 10.1042/bj2890241; Browder T, 2000, J BIOL CHEM, V275, P1521, DOI 10.1074/jbc.275.3.1521; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; DELL KR, 1992, J BIOL CHEM, V267, P21225; DESAI UR, 1993, ARCH BIOCHEM BIOPHYS, V306, P461, DOI 10.1006/abbi.1993.1538; DESAI UR, 1993, BIOCHEMISTRY-US, V32, P8140, DOI 10.1021/bi00083a012; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; DUAN DSR, 1992, J BIOL CHEM, V267, P16076; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Goger B, 2002, BIOCHEMISTRY-US, V41, P1640, DOI 10.1021/bi011944j; Grose R, 2005, CYTOKINE GROWTH F R, V16, P179, DOI 10.1016/j.cytogfr.2005.01.003; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Guimond SE, 1999, CURR BIOL, V9, P1343, DOI 10.1016/S0960-9822(00)80060-3; Harmer NJ, 2006, BIOCHEM J, V393, P741, DOI 10.1042/BJ20050985; Harmer NJ, 2004, J MOL BIOL, V339, P821, DOI 10.1016/j.jmb.2004.04.031; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kreuger J, 2006, J CELL BIOL, V174, P323, DOI 10.1083/jcb.200604035; Manetti F, 2000, CURR PHARM DESIGN, V6, P1897, DOI 10.2174/1381612003398528; Ornitz DM, 2001, GENOME BIOL, V2; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; Ostrovsky O, 2002, J BIOL CHEM, V277, P2444, DOI 10.1074/jbc.M108540200; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Pellegrini L, 2001, CURR OPIN STRUC BIOL, V11, P629, DOI 10.1016/S0959-440X(00)00258-X; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Presta M, 2005, CYTOKINE GROWTH F R, V16, P159, DOI 10.1016/j.cytogfr.2005.01.004; Pye DA, 2000, GLYCOBIOLOGY, V10, P1183, DOI 10.1093/glycob/10.11.1183; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; Robinson CJ, 2005, J BIOL CHEM, V280, P42274, DOI 10.1074/jbc.M505720200; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Scotet E, 1998, ONCOGENE, V17, P67, DOI 10.1038/sj.onc.1201908; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Zhang XQ, 2006, J BIOL CHEM, V281, P15694, DOI 10.1074/jbc.M601252200	35	69	71	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2008	283	19					13001	13008		10.1074/jbc.M704531200	http://dx.doi.org/10.1074/jbc.M704531200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295UQ	18281281	hybrid			2022-12-25	WOS:000255499800037
J	Gordon, AR; Outram, SV; Keramatipour, M; Goddard, CA; Colledge, WH; Metcalfe, JC; Hager-Theodorides, AL; Crompton, T; Kemp, PR				Gordon, Adele R.; Outram, Susan V.; Keramatipour, Mohammad; Goddard, Catherine A.; Colledge, William H.; Metcalfe, James C.; Hager-Theodorides, Ariadne L.; Crompton, Tessa; Kemp, Paul R.			Splenomegaly and modified erythropoiesis in KLF13(-/-) mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR KLF13; T-LYMPHOCYTES; IN-VIVO; EXPRESSION; GLOBIN; GATA-1; DIFFERENTIATION; PRECURSORS; ELEMENTS; RFLAT-1	To study the function of the Kruppel-like transcription factor KLF13 in vivo, we generated mice with a disrupted Klf13 allele. Although Klf13(-/-) mice are viable, fewer mice were present at 3 weeks than predicted by Mendelian inheritance. Viable Klf13(-/-) mice had reduced numbers of circulating erythrocytes and a larger spleen. The spleen contained an increased number of Ter119(med)CD71(hi), Ter119(hi)CD71(hi), and Ter119(hi)CD71(med) cells but not Ter119(hi)CD71(-) cells, indicating an increase in less mature erythroblasts. A higher proportion of the Ter119(med)CD71(hi) cells were proliferating, indicating that the mice were under a degree of erythropoietic stress. These data indicate that KLF13 is involved in the normal control of erythropoiesis.	[Kemp, Paul R.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW7 2AZ, England; [Gordon, Adele R.; Keramatipour, Mohammad; Goddard, Catherine A.; Metcalfe, James C.] Univ Cambridge, Dept Biochem, Sect Cardiovasc Biol, Cambridge CB2 1QW, England; [Outram, Susan V.; Hager-Theodorides, Ariadne L.; Crompton, Tessa] Univ London Imperial Coll Sci Technol & Med, Div Cell & Mol Biol, London SW7 2AZ, England; [Colledge, William H.] Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge CB2 3EG, England	Imperial College London; University of Cambridge; Imperial College London; University of Cambridge	Kemp, PR (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, S Kensington Campus, London SW7 2AZ, England.	p.kemp@imperial.ac.uk	Colledge, William/X-4976-2019; Hager-Theodorides, Ariande/AAM-1160-2021; Hager-Theodorides, Ariadne L./AAM-4671-2021	Colledge, William/0000-0002-9603-4429; Hager-Theodorides, Ariadne L./0000-0002-8480-3200; Crompton, Tessa/0000-0002-8973-4021; Kemp, Paul/0000-0001-8975-7293	Biotechnology and Biological Sciences Research Council [BB/D522770/1] Funding Source: Medline; British Heart Foundation [PG/02/135/14620] Funding Source: Medline; Medical Research Council [G0000121] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G0000121] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Asano H, 2000, BLOOD, V95, P3578, DOI 10.1182/blood.V95.11.3578.011k48_3578_3584; Diwan A, 2007, P NATL ACAD SCI USA, V104, P6794, DOI 10.1073/pnas.0610666104; Ellenrieder V, 2002, EMBO J, V21, P2451, DOI 10.1093/emboj/21.10.2451; Ellis PD, 2004, J BIOL CHEM, V279, P36660, DOI 10.1074/jbc.M405380200; Feinberg MW, 2005, J BIOL CHEM, V280, P38247, DOI 10.1074/jbc.M509378200; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; HARA H, 1976, AM J HEMATOL, V1, P453, DOI 10.1002/ajh.2830010410; Ingley E, 2005, ONCOGENE, V24, P336, DOI 10.1038/sj.onc.1208199; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kam HY, 1999, J APPL PHYSIOL, V87, P1901, DOI 10.1152/jappl.1999.87.5.1901; Koury MJ, 2002, CURR OPIN HEMATOL, V9, P93, DOI 10.1097/00062752-200203000-00002; Lavallee G, 2006, EMBO J, V25, P5201, DOI 10.1038/sj.emboj.7601379; Martin KM, 2001, MECH DEVELOP, V103, P149, DOI 10.1016/S0925-4773(01)00343-4; Matsumura T, 2005, J BIOL CHEM, V280, P12123, DOI 10.1074/jbc.M410578200; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Moritz KM, 1997, AM J PHYSIOL-REG I, V273, pR1829, DOI 10.1152/ajpregu.1997.273.6.R1829; Nikolcheva T, 2002, J CLIN INVEST, V110, P119, DOI 10.1172/JCI200215336; Perkins A, 1999, INT J BIOCHEM CELL B, V31, P1175, DOI 10.1016/S1357-2725(99)00083-7; PERKINS AC, 1995, NATURE, V375, P318; Perry C, 2002, EUR J BIOCHEM, V269, P3607, DOI 10.1046/j.1432-1033.2002.02999.x; Rhodes MM, 2005, BLOOD, V106, P1857, DOI 10.1182/blood-2004-11-4344; Song A, 1999, IMMUNITY, V10, P93, DOI 10.1016/S1074-7613(00)80010-2; Song CZ, 2003, J MOL BIOL, V329, P207, DOI 10.1016/S0022-2836(03)00429-7; Takahashi S, 1998, BLOOD, V92, P434, DOI 10.1182/blood.V92.2.434.414k24_434_442; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; Wani MA, 1998, TRANSGENIC RES, V7, P229, DOI 10.1023/A:1008809809843; Zhang J, 2003, BLOOD, V102, P3938, DOI 10.1182/blood-2003-05-1479; Zhang P, 2005, BLOOD CELL MOL DIS, V35, P227, DOI 10.1016/j.bcmd.2005.04.009; Zhou MX, 2007, J IMMUNOL, V178, P5496, DOI 10.4049/jimmunol.178.9.5496	29	28	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2008	283	18					11897	11904		10.1074/jbc.M709569200	http://dx.doi.org/10.1074/jbc.M709569200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	293MS	18285334	hybrid			2022-12-25	WOS:000255340000005
J	Lee, SH; Kim, T; Jeong, D; Kim, N; Choi, YW				Lee, Seoung Hoon; Kim, Taesoo; Jeong, Daewon; Kim, Nacksung; Choi, Yongwon			The Tec family tyrosine kinase Btk regulates RANKL-induced osteoclast maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; CELL ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; ADAPTER PROTEINS; BONE HOMEOSTASIS; DC-STAMP; T-CELL; DIFFERENTIATION; MICE; FUSION	A spontaneous mutation in Bruton's tyrosine kinase (Btk) induces a defect in B-cell development that results in the immunodeficiency diseases X-linked agammaglobulinemia in humans and X-linked immunodeficiency (Xid) in mice. Here we show an unexpected role of Btk in osteoclast formation. When bone marrow cells derived from Xid mice were stimulated with receptor activator of NF-kappa B ligand, an osteoclast differentiation factor, they did not completely differentiate into mature multinucleated osteoclasts. Moreover, we found that the defects appeared to occur at the stage in which mononuclear preosteoclasts fuse to generate multinucleated cells. Supporting this notion, macrophages from Xid mice also failed to form multinucleated foreign body giant cells. The fusion defect of the Xid mutant osteoclasts was caused by decreased expression of nuclear factor of activated T cells c1 (NFATc1), a master regulator of osteoclast differentiation, as well as reduced expression of various osteoclast fusion-related molecules, such as the d2 isoform of vacuolar H+-ATPase V0 domain and the dendritic cell-specific transmembrane protein. This deficiency was completely rescued by the introduction of a constitutively active form of NFATc1 into bone marrow-derived macrophages. Our data provide strong evidence that Btk plays a critical role in osteoclast multinucleation by modulating the activity of NFATc1.	[Lee, Seoung Hoon; Kim, Taesoo; Choi, Yongwon] Univ Penn, Sch Med, Dept Pathol, Philadelphia, PA 19104 USA; [Lee, Seoung Hoon; Kim, Taesoo; Choi, Yongwon] Univ Penn, Sch Med, Dept Lab Med, Philadelphia, PA 19104 USA; [Jeong, Daewon] Yeungnam Univ, Coll Med, Dept Microbiol, Taegu 705717, South Korea; [Jeong, Daewon] Yeungnam Univ, Coll Med, Aging Associated Dis Res Ctr, Taegu 705717, South Korea; [Kim, Nacksung] Chonnam Natl Univ, Sch Med, Natl Res Lab Regulat Bone Metab & Dis, Kwangju 501746, South Korea	University of Pennsylvania; University of Pennsylvania; Yeungnam University; Yeungnam University; Chonnam National University	Choi, YW (corresponding author), Rm 308,BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	ychoi3@mail.med.upenn.edu						Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; CAMPANA D, 1990, J IMMUNOL, V145, P1675; Conley ME, 1998, CURR OPIN IMMUNOL, V10, P399, DOI 10.1016/S0952-7915(98)80112-X; Felices M, 2007, ADV IMMUNOL, V93, P145, DOI 10.1016/S0065-2776(06)93004-1; Fodor S, 2006, IMMUNOL LETT, V104, P29, DOI 10.1016/j.imlet.2005.11.001; Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200; Kaifu T, 2003, J CLIN INVEST, V111, P323, DOI 10.1172/JCI200316923; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007-0237; Kim N, 2000, P NATL ACAD SCI USA, V97, P10905, DOI 10.1073/pnas.200294797; Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978; Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444; Komarova SV, 2005, P NATL ACAD SCI USA, V102, P2643, DOI 10.1073/pnas.0406874102; Kurosaki T, 2002, NAT REV IMMUNOL, V2, P354, DOI 10.1038/nri801; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; Kurosaki T, 2000, IMMUNITY, V12, P1, DOI 10.1016/S1074-7613(00)80153-3; Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514; Mao DL, 2006, J CLIN INVEST, V116, P2869, DOI 10.1172/JCI28775; McVicar DW, 1998, J BIOL CHEM, V273, P32934, DOI 10.1074/jbc.273.49.32934; Mocsai A, 2004, P NATL ACAD SCI USA, V101, P6158, DOI 10.1073/pnas.0401602101; Nieswandt B, 2003, BLOOD, V102, P449, DOI 10.1182/blood-2002-12-3882; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; RETH M, 1995, IMMUNOL TODAY, V16, P310; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; Schmidt U, 2004, INT ARCH ALLERGY IMM, V134, P65, DOI 10.1159/000078339; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646; Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645	36	88	100	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11526	11534		10.1074/jbc.M708935200	http://dx.doi.org/10.1074/jbc.M708935200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18281276	Green Published, hybrid			2022-12-25	WOS:000255067400052
J	Waraich, RS; Weigert, C; Kalbacher, H; Hennige, AM; Lutz, SZ; Haring, HU; Schleicher, ED; Voelter, W; Lehmann, R				Waraich, Rizwana Sanaullah; Weigert, Cora; Kalbacher, Hubert; Hennige, Anita M.; Lutz, Stefan Z.; Haering, Hans-Ulrich; Schleicher, Erwin D.; Voelter, Wolfgang; Lehmann, Rainer			Phosphorylation of Ser(357) of rat insulin receptor substrate-1 mediates adverse effects of protein kinase C-delta on insulin action in skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; TYROSINE PHOSPHORYLATION; SERINE PHOSPHORYLATION; GLUCOSE-TRANSPORT; ISOFORMS ALPHA; IRS PROTEINS; RESISTANCE; ACTIVATION; THETA; INHIBITION	The activation of the protein kinase C (PKC) family of serine/threonine kinases contributes to the modulation of insulin signaling, and the PKC-dependent phosphorylation of insulin receptor substrate (IRS)-1 has been implicated in the development of insulin resistance. Here we demonstrate Ser(357) of rat IRS-1 as a novel PKC-delta-dependent phosphorylation site in skeletal muscle cells upon stimulation with insulin and phorbol ester using Ser(P)(357) antibodies and active and kinase dead mutants of PKC-delta. Phosphorylation of this site was simulated using IRS-1 Glu(357) and shown to reduce insulin-induced tyrosine phosphorylation of IRS-1, to decrease activation of Akt, and to subsequently diminish phosphorylation of glycogen synthase kinase-3. When the phosphorylation was prevented by mutation of Ser(357) to alanine, these effects of insulin were enhanced. When the adjacent Ser(358), present in mouse and rat IRS-1, was mutated to alanine, which is homologous to the human sequence, the insulin-induced phosphorylation of glycogen synthase kinase-3 or tyrosine phosphorylation of IRS-1 was not increased. Moreover, both active PKC-delta and phosphorylation of Ser357 were shown to be necessary for the attenuation of insulin-stimulated Akt phosphorylation. The phosphorylation of Ser357 could lead to increased association of PKC-delta to IRS-1 upon insulin stimulation, which was demonstrated with IRS-1 Glu(357). Together, these data suggest that phosphorylation of Ser(357) mediates at least in part the adverse effects of PKC-delta activation on insulin action.	[Waraich, Rizwana Sanaullah; Weigert, Cora; Schleicher, Erwin D.; Lehmann, Rainer] Univ Tubingen, Dept Internal Med 4, Div Clin Chem & Pathobiochem, D-72076 Tubingen, Germany; [Kalbacher, Hubert; Voelter, Wolfgang] Univ Tubingen, Dept Internal Med 4, Interfacultary Inst Biochem, D-72076 Tubingen, Germany; [Kalbacher, Hubert] Univ Tubingen, Dept Internal Med 4, Med & Nat Sci Res Ctr, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Weigert, C (corresponding author), Univ Tubingen, Dept Internal Med 4, Div Clin Chem & Pathobiochem, Otfried Mueller Str 10, D-72076 Tubingen, Germany.	Cora.Weigert@med.uni-tuebingen.de	waraich, rizwana/A-8470-2012	waraich, rizwana/0000-0002-5560-5053				Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Bandyopadhyay G, 1997, ENDOCRINOLOGY, V138, P4721, DOI 10.1210/en.138.11.4721; Beck A, 2003, J AM SOC MASS SPECTR, V14, P401, DOI 10.1016/S1044-0305(03)00122-3; BERTI L, 1994, J BIOL CHEM, V269, P3381; Bouzakri K, 2006, CELL METAB, V4, P89, DOI 10.1016/j.cmet.2006.04.008; Braiman L, 1999, MOL ENDOCRINOL, V13, P2002, DOI 10.1210/me.13.12.2002; Braiman L, 2001, MOL ENDOCRINOL, V15, P565, DOI 10.1210/me.15.4.565; Brand C, 2006, BIOCHEM BIOPH RES CO, V349, P954, DOI 10.1016/j.bbrc.2006.08.100; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; CHIN JE, 1993, J BIOL CHEM, V268, P6338; Ciaraldi TP, 2007, ENDOCRINOLOGY, V148, P4393, DOI 10.1210/en.2006-0932; Eitel K, 2003, DIABETES, V52, P991, DOI 10.2337/diabetes.52.4.991; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; Farese RV, 2007, J CLIN INVEST, V117, P2289, DOI 10.1172/JCI31408; Greene MW, 2006, BIOCHEM BIOPH RES CO, V349, P976, DOI 10.1016/j.bbrc.2006.08.158; Greene MW, 2004, BIOCHEM J, V378, P105, DOI 10.1042/BJ20031493; Greene MW, 2002, BIOCHEMISTRY-US, V41, P7082, DOI 10.1021/bi015992f; Greene MW, 2003, J BIOL CHEM, V278, P8199, DOI 10.1074/jbc.M209153200; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; Gual P, 2005, BIOCHIMIE, V87, P99, DOI 10.1016/j.biochi.2004.10.019; Heled Y, 2003, METABOLISM, V52, P1028, DOI 10.1016/S0026-0495(03)00154-9; Hennige AM, 2006, FASEB J, V20, P1206, DOI 10.1096/fj.05-4635fje; Herschkovitz A, 2007, J BIOL CHEM, V282, P18018, DOI 10.1074/jbc.M610949200; Hill MM, 2001, J BIOL CHEM, V276, P25643, DOI 10.1074/jbc.C100174200; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; Kellerer M, 1998, DIABETOLOGIA, V41, P833, DOI 10.1007/s001250050995; Kim JK, 2004, J CLIN INVEST, V114, P823, DOI 10.1172/JCI200422230; Kroder G, 1996, J CLIN INVEST, V97, P1471, DOI 10.1172/JCI118569; Lam TKT, 2002, AM J PHYSIOL-ENDOC M, V283, pE682, DOI 10.1152/ajpendo.00038.2002; Laybutt DR, 1999, AM J PHYSIOL-ENDOC M, V277, pE1070, DOI 10.1152/ajpendo.1999.277.6.E1070; Letiges M, 2002, MOL ENDOCRINOL, V16, P847, DOI 10.1210/me.16.4.847; Li Y, 2004, J BIOL CHEM, V279, P45304, DOI 10.1074/jbc.C400186200; Liu YF, 2004, MOL CELL BIOL, V24, P9668, DOI 10.1128/MCB.24.21.9668-9681.2004; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; Moeschel K, 2004, J BIOL CHEM, V279, P25157, DOI 10.1074/jbc.M402477200; Morino K, 2006, DIABETES, V55, pS9, DOI 10.2337/db06-S002; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; Rosenzweig T, 2002, DIABETES, V51, P1921, DOI 10.2337/diabetes.51.6.1921; Sampson SR, 2006, MOL GENET METAB, V89, P32, DOI 10.1016/j.ymgme.2006.04.017; Samuel VT, 2007, J CLIN INVEST, V117, P739, DOI 10.1172/JCI30400; Schmitz-Peiffer C, 2002, ANN NY ACAD SCI, V967, P146; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837; Tzatsos A, 2006, MOL CELL BIOL, V26, P63, DOI 10.1128/MCB.26.1.63-76.2006; Weigert C, 2006, J BIOL CHEM, V281, P7060, DOI 10.1074/jbc.M509782200; Weigert C, 2005, J BIOL CHEM, V280, P37393, DOI 10.1074/jbc.M506134200; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200	49	33	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11226	11233		10.1074/jbc.M708588200	http://dx.doi.org/10.1074/jbc.M708588200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18285345	hybrid			2022-12-25	WOS:000255067400018
J	Li, QX; Zhang, N; Zhang, DW; Wang, YQ; Lin, TW; Wang, YH; Zhou, HM; Ye, ZY; Zhang, FM; Lin, SC; Han, J				Li, Qinxi; Zhang, Na; Zhang, Duanwu; Wang, Yuqian; Lin, Tianwei; Wang, Yanhai; Zhou, Huamin; Ye, Zhiyun; Zhang, Faming; Lin, Sheng-Cai; Han, Jiahuai			Determinants that control the distinct subcellular localization of p38 alpha-PRAK and p38 beta-PRAK complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; P38 MAP KINASE; NUCLEAR IMPORT; CRYSTALLOGRAPHIC ANALYSIS; KARYOPHERIN ALPHA; TUMOR SUPPRESSION; PHOSPHORYLATION; RECOGNITION; EXPORT; MNK1	p38 alpha and p38 beta MAPKs (mitogen-activated protein kinases) share about 80% of their protein sequence identity, but have quite different biological functions. One such difference is in regulating the subcellular localization of their downstream kinases, such as PRAK (p38-regulated/activated protein kinase or MK5). The p38 alpha-PRAK complex is found in the nucleus, whereas the p38 beta-PRAK complex is exclusively localized to the cytosol. By generating a series of chimeric and point mutants of p38 alpha and p38 beta, we found two amino acid residues (Asp(145) and Leu(156) in p38 alpha, Gly(145) and Val(156) in p38 beta) that determine the distinct subcellular locations of p38 alpha-PRAK and p38 beta-PRAK. The subcellular localization of MK2 (MAPK-activated protein kinase 2), another downstream kinase of p38, was regulated in the same manner as that of PRAK. We found that nuclear import, but not export, determines the subcellular localization of p38 alpha-PRAK and p38 beta-PRAK. The published structure of the p38 alpha-MK2 complex suggests Leu(156) of p38 alpha is involved in the interaction with the nuclear localization signal in PRAK. The difference at this residue between p38 alpha and p38 beta may affect the nuclear localization signal in PRAK differently, and thereby influence the import of the complexes. Asp(145) in p38 alpha (or Gly(145) in p38 beta) is located on a different surface patch, and further random mutagenesis revealed that mutation of Asp(145), Thr(123), and Gln(325), the residues that can directly interact with importin alpha as predicted by modeling, but not mutation of the other 7 amino acid residues that cannot reach importin alpha, re-locate p38 alpha-PRAK to the cytosol, suggesting that interaction with import machinery is involved in determining the subcellular localization of the p38 alpha-PRAK and p38 beta-PRAK complexes. Last, we show that nuclear localization of PRAK is required for its role in inhibiting the proliferation of NIH3T3 cells. In conclusion, multiple determinants control the distinct subcellular localization of p38 alpha-PRAK and p38 beta-PRAK complexes, and the location of PRAK plays a role in its function.	[Li, Qinxi; Zhang, Na; Zhang, Duanwu; Wang, Yuqian; Lin, Tianwei; Wang, Yanhai; Zhou, Huamin; Ye, Zhiyun; Lin, Sheng-Cai; Han, Jiahuai] Xiamen Univ, Sch Life Sci, Key Lab Minist Educ Cell Biol & Tumor Cell Engn, Xiamen 361005, Peoples R China; [Zhang, Faming] Indiana Univ, Dept Chem, Bloomington, IN 47405 USA	Xiamen University; Indiana University System; Indiana University Bloomington	Han, J (corresponding author), Xiamen Univ, Sch Life Sci, Key Lab Minist Educ Cell Biol & Tumor Cell Engn, Xiamen 361005, Peoples R China.	jhan@xmu.edu.cn	Lin, SC/G-4666-2010; Li, QX/G-4669-2010; Han, J/G-4671-2010; Zhang, Duanwu/AAH-1627-2020	Zhang, Duanwu/0000-0003-2946-846X				Asally M, 2005, EXP CELL RES, V308, P357, DOI 10.1016/j.yexcr.2005.05.011; Ashwell JD, 2006, NAT REV IMMUNOL, V6, P532, DOI 10.1038/nri1865; BEN LR, 1998, CURR BIOL, V8, P1049; Chen G, 2000, J BIOL CHEM, V275, P38973, DOI 10.1074/jbc.M002856200; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Conti E, 2000, STRUCTURE, V8, P329, DOI 10.1016/S0969-2126(00)00107-6; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Fontes MRM, 2000, J MOL BIOL, V297, P1183, DOI 10.1006/jmbi.2000.3642; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; HAAR ET, 2007, J BIOL CHEM, V282, P9733; Han JH, 2007, TRENDS BIOCHEM SCI, V32, P364, DOI 10.1016/j.tibs.2007.06.007; LA BS, 1999, EMBO J, V18, P480; Lusk CP, 2007, NAT REV MOL CELL BIO, V8, P414, DOI 10.1038/nrm2165; Moroianu J, 1998, J CELL BIOCHEM, V70, P231; Natale DR, 2004, DEV BIOL, V268, P76, DOI 10.1016/j.ydbio.2003.12.011; New L, 2003, MOL BIOL CELL, V14, P2603, DOI 10.1091/mbc.E02-08-0538; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; O'Loghlen A, 2004, EXP CELL RES, V299, P343, DOI 10.1016/j.yexcr.2004.06.006; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; Smith S, 1999, J CELL SCI, V112, P3649; Sun PQ, 2007, CELL, V128, P295, DOI 10.1016/j.cell.2006.11.050; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; White A, 2007, P NATL ACAD SCI USA, V104, P6353, DOI 10.1073/pnas.0701679104; Yazicioglu MN, 2007, J BIOL CHEM, V282, P28759, DOI 10.1074/jbc.M703460200; Yoneda Y, 2000, GENES CELLS, V5, P777, DOI 10.1046/j.1365-2443.2000.00366.x; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257	29	26	28	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					11014	11023		10.1074/jbc.M709682200	http://dx.doi.org/10.1074/jbc.M709682200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18268017	hybrid			2022-12-25	WOS:000254894700082
J	Foley, JH; Kim, P; Nesheim, ME				Foley, Jonathan H.; Kim, Paula; Nesheim, Michael E.			Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRINSIC ENZYMATIC-ACTIVITY; PROCARBOXYPEPTIDASE-U TAFI; PLASMA CARBOXYPEPTIDASE; PLASMINOGEN-ACTIVATOR; ANTIFIBRINOLYTIC ACTIVITY; DEGRADATION-PRODUCTS; THERMAL-STABILITY; PROTEIN-C; MECHANISM; SYSTEM	Activated thrombin-activable fibrinolysis inhibitor (TAFIa) plays a significant role in the prolongation of fibrinolysis. During fibrinolysis, plasminogen is activated to plasmin, which lyses a clot by cleaving fibrin after selected arginine and lysine residues. TAFIa attenuates fibrinolysis by removing the exposed C-terminal lysine residues. It was recently reported that TAFI zymogen possesses sufficient carboxypeptidase activity to attenuate fibrinolysis through a mechanism similar to TAFIa. Here, we show with a recently developed TAFIa assay that when thrombin is used to clot TAFI-deficient plasma supplemented with TAFI, there is some TAFI activation. The extent of activation was dependent upon the concentration of zymogen present in the plasma, and lysis times were prolonged by TAFIa in a concentration-dependent manner. Potato tuber carboxypeptidase inhibitor, an inhibitor of TAFIa but not TAFI, abolished the prolongation of lysis in TAFI-deficient plasma supplemented with TAFI zymogen. In addition, TAFIa but not TAFI catalyzed release of plasminogen bound to soluble fibrin degradation products. The data presented confirm that TAFI zymogen is effective in cleaving a small substrate but does not play a role in the attenuation of fibrinolysis because of its inability to cleave plasmin-modified fibrin degradation products.	[Foley, Jonathan H.; Kim, Paula; Nesheim, Michael E.] Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; [Nesheim, Michael E.] Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Nesheim, ME (corresponding author), Queens Univ, Dept Biochem, A212 Botterell Hall, Kingston, ON K7L 3N6, Canada.	nesheimm@queensu.ca		Foley, Jonathan/0000-0002-4593-0469	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046703] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL 046703] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Bajzar L, 1996, BLOOD, V88, P2093, DOI 10.1182/blood.V88.6.2093.bloodjournal8862093; BAJZAR L, 1990, J BIOL CHEM, V265, P16948; Boffa MB, 1998, J BIOL CHEM, V273, P2127, DOI 10.1074/jbc.273.4.2127; Boffa MB, 2000, J BIOL CHEM, V275, P12868, DOI 10.1074/jbc.275.17.12868; EATON DL, 1991, J BIOL CHEM, V266, P21833; HENDRIKS D, 1990, BIOCHIM BIOPHYS ACTA, V1034, P86, DOI 10.1016/0304-4165(90)90157-R; Horrevoets AJG, 1997, J BIOL CHEM, V272, P2183; Horrevoets AJG, 1997, J BIOL CHEM, V272, P2176; Kim PYG, 2008, ANAL BIOCHEM, V372, P32, DOI 10.1016/j.ab.2007.09.034; Leurs J, 2004, J THROMB HAEMOST, V2, P416, DOI 10.1111/j.1538-7836.2004.00605.x; Mao SS, 1999, J BIOL CHEM, V274, P35046, DOI 10.1074/jbc.274.49.35046; Neill EKT, 2004, ANAL BIOCHEM, V330, P332, DOI 10.1016/j.ab.2004.04.007; REDLITZ A, 1995, J CLIN INVEST, V96, P2534, DOI 10.1172/JCI118315; Reverter D, 1997, FEBS LETT, V420, P7, DOI 10.1016/S0014-5793(97)01476-2; Sakharov DV, 1997, J BIOL CHEM, V272, P14477, DOI 10.1074/jbc.272.22.14477; Schneider M, 2002, J BIOL CHEM, V277, P1021, DOI 10.1074/jbc.M104444200; Schneider M, 2002, J BIOL CHEM, V277, P9944, DOI 10.1074/jbc.M111685200; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; Valnickova Z, 2007, J THROMB HAEMOST, V5, P1336, DOI 10.1111/j.1538-7836.2007.02593.x; Valnickova Z, 2007, J BIOL CHEM, V282, P3066, DOI 10.1074/jbc.M606559200; Walker JB, 2007, J THROMB HAEMOST, V5, P1257, DOI 10.1111/j.1538-7836.2007.02541.x; Walker JB, 1999, J BIOL CHEM, V274, P5201, DOI 10.1074/jbc.274.8.5201; Walker JB, 2004, J BIOL CHEM, V279, P27896, DOI 10.1074/jbc.M401027200; Walker JB, 2001, J BIOL CHEM, V276, P3138, DOI 10.1074/jbc.M005876200; Wang W, 1998, J BIOL CHEM, V273, P27176, DOI 10.1074/jbc.273.42.27176; WANG W, 1994, J BIOL CHEM, V269, P15937; Willemse JL, 2007, J THROMB HAEMOST, V5, P1334, DOI 10.1111/j.1538-7836.2007.02539.x; Willemse JL, 2006, ANAL BIOCHEM, V356, P157, DOI 10.1016/j.ab.2006.05.020	31	21	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					8863	8867		10.1074/jbc.M800127200	http://dx.doi.org/10.1074/jbc.M800127200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18252711	Green Published, hybrid			2022-12-25	WOS:000254465800013
J	de Miranda, MP; Alenquer, M; Marques, S; Rodrigues, L; Lopes, F; Bustelo, XR; Simas, JP				de Miranda, Marta Pires; Alenquer, Marta; Marques, Sofia; Rodrigues, Lenia; Lopes, Filipa; Bustelo, Xose R.; Simas, J. Pedro			The Gammaherpesvirus m2 Protein Manipulates the Fyn/Vav Pathway through a Multidocking Mechanism of Assembly	PLOS ONE			English	Article								To establish latent infections in B-cells, gammaherpesviruses express proteins in the infected B-cells of the host that spuriously activate signalling pathways located downstream of the B-cell receptor. One such protein is M2, a murine gammaherpesvirus 68-encoded molecule that activates the Vav1/Rac1 pathway via the formation of trimolecular complexes with Scr family members. Previous reports have shown that the formation of this heteromolecular complex involves interactions between a proline rich region of M2 and the Vav1 and Fyn SH3 domains. Here, we show that the optimal association of these proteins requires a second structural motif encompassing two tyrosine residues (Tyr120 and 129). These residues are inducibly phosphorylated by Fyn in non-hematopoietic cells and constitutively phosphorylated in B-cells. We also demonstrate that the phosphorylation of Tyr120 creates specific docking sites for the SH2 domains of both Vav1 and Fyn, a condition sine qua non for the optimal association of these two signalling proteins in vivo. Interestingly, signaling experiments indicate that the expression of M2 in B-cells promotes the tyrosine phosphorylation of Vav1 and additional signaling proteins, a biological process that requires the integrity of both the M2 phosphotyrosine and proline rich region motifs. By infecting mice with viruses mutated in the m2 locus, we show that the integrity of each of these two M2 docking motifs is essential for the early steps of murine gammaherpesvirus-68 latency. Taken together, these results indicate that the M2 phosphotyrosine motif and the previously described M2 proline rich region work in a concerted manner to manipulate the signaling machinery of the host B-cell.	[de Miranda, Marta Pires; Alenquer, Marta; Marques, Sofia; Rodrigues, Lenia; Lopes, Filipa; Simas, J. Pedro] Univ Lisbon, Fac Med, Inst Microbiol, P-1699 Lisbon, Portugal; [de Miranda, Marta Pires; Alenquer, Marta; Marques, Sofia; Rodrigues, Lenia; Lopes, Filipa; Simas, J. Pedro] Inst Gulbenkian Ciencias, Oeiras, Portugal; [Bustelo, Xose R.] Univ Salamanca, CSIC, Ctr Investigac Canc, Inst Biol Mol Cel Canc, Salamanca, Spain	Universidade de Lisboa; Instituto Gulbenkian de Ciencia; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); University of Salamanca	de Miranda, MP (corresponding author), Univ Lisbon, Fac Med, Inst Microbiol, P-1699 Lisbon, Portugal.	xbustelo@usal.es; psimas@fm.ul.pt	Bustelo, Xose R./A-9526-2010; Simas, J Pedro/M-5157-2013; Bustelo, Xose R./AAD-2081-2022	Bustelo, Xose R./0000-0001-9398-6072; Simas, J Pedro/0000-0001-6982-9253; Bustelo, Xose R./0000-0001-9398-6072; Alenquer, Marta/0000-0003-3062-1222; Marques, Sofia/0000-0003-1467-1529; Rodrigues, Lenia/0000-0003-4233-6170; Pires de Miranda, Marta/0000-0003-3733-4963	Portuguese Fundacao para a Ciencia e Tecnologia [POCI/SAU-IMI/57365/2004]; US National Cancer Institute/NIH [5R01-CA73735-11]; Spanish Ministry of Education and Science [SAF2006-01789]; Castilla-Leon Autonomous Government [SA053A05]; Red Tematica de Investigacion Cooperativa en Cancer (RTICC) [RD06/0020/0001]; Fondo de Investigaciones Sanitarias; Carlos III Institute; Spanish Ministry of Health; NATIONAL CANCER INSTITUTE [R01CA073735] Funding Source: NIH RePORTER	Portuguese Fundacao para a Ciencia e Tecnologia(Portuguese Foundation for Science and TechnologyEuropean Commission); US National Cancer Institute/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Spanish Ministry of Education and Science(Spanish Government); Castilla-Leon Autonomous Government; Red Tematica de Investigacion Cooperativa en Cancer (RTICC)(European Commission); Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); Carlos III Institute(Instituto de Salud Carlos III); Spanish Ministry of Health(Instituto de Salud Carlos IIISpanish Government); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a grant to J.P.S. from the Portuguese Fundacao para a Ciencia e Tecnologia (POCI/SAU-IMI/57365/2004). X.R.B.'s work is supported by grants from the US National Cancer Institute/NIH (5R01-CA73735-11), the Spanish Ministry of Education and Science (MES) (SAF2006-01789), the Castilla-Leon Autonomous Government (SA053A05), and the Red Tematica de Investigacion Cooperativa en Cancer (RTICC) (RD06/0020/0001, Fondo de Investigaciones Sanitarias (FIS), Carlos III Institute, Spanish Ministry of Health). All Spanish funding is co-sponsored by the European Union FEDER program. M.P.M., M.A., S.M., L.R. and F.L. were recipients of fellowships from the Fundacao para a Ciencia e Tecnologia.	Adler H, 2000, J VIROL, V74, P6964, DOI 10.1128/JVI.74.15.6964-6974.2000; Adler H, 2001, J VIROL, V75, P5692, DOI 10.1128/JVI.75.12.5692-5696.2001; Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; Billadeau DD, 2000, J EXP MED, V192, P381, DOI 10.1084/jem.192.3.381; Bowden RJ, 1997, J GEN VIROL, V78, P1675, DOI 10.1099/0022-1317-78-7-1675; Brinkmann MM, 2006, J GEN VIROL, V87, P1047, DOI 10.1099/vir.0.81598-0; Bustelo XR, 2007, BIOESSAYS, V29, P356, DOI 10.1002/bies.20558; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Bustelo XR, 2001, ONCOGENE, V20, P6372, DOI 10.1038/sj.onc.1204780; Caldwell RG, 1998, IMMUNITY, V9, P405, DOI 10.1016/S1074-7613(00)80623-8; Crespo P, 1996, ONCOGENE, V13, P455; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Damania B, 2004, NAT REV MICROBIOL, V2, P656, DOI 10.1038/nrmicro958; Flano E, 2003, J IMMUNOL, V170, P3828, DOI 10.4049/jimmunol.170.7.3828; Flano E, 2002, J EXP MED, V196, P1363, DOI 10.1084/jem.20020890; Fruehling S, 1997, VIROLOGY, V235, P241, DOI 10.1006/viro.1997.8690; Herskowitz J, 2005, J VIROL, V79, P2261, DOI 10.1128/JVI.79.4.2261-2273.2005; Husain SM, 1999, P NATL ACAD SCI USA, V96, P7508, DOI 10.1073/pnas.96.13.7508; Jacoby MA, 2002, J VIROL, V76, P1790, DOI 10.1128/JVI.76.4.1790-1801.2002; Jumaa H, 2005, ANNU REV IMMUNOL, V23, P415, DOI 10.1146/annurev.immunol.23.021704.115606; KIM KJ, 1979, J IMMUNOL, V122, P549; Lagunoff M, 1999, P NATL ACAD SCI USA, V96, P5704, DOI 10.1073/pnas.96.10.5704; Lee BS, 2005, J VIROL, V79, P12173, DOI 10.1128/JVI.79.19.12173-12184.2005; Lee H, 1998, MOL CELL BIOL, V18, P5219, DOI 10.1128/MCB.18.9.5219; Liang XZ, 2006, J VIROL, V80, P5862, DOI 10.1128/JVI.02732-05; Liang XZ, 2004, J VIROL, V78, P12416, DOI 10.1128/JVI.78.22.12416-12427.2004; Llorca O, 2005, EMBO J, V24, P1330, DOI 10.1038/sj.emboj.7600617; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Macrae AI, 2003, J VIROL, V77, P9700, DOI 10.1128/JVI.77.17.9700-9709.2003; Marques S, 2003, J VIROL, V77, P7308, DOI 10.1128/JVI.77.13.7308-7318.2003; Meng WX, 2004, EMBO J, V23, P760, DOI 10.1038/sj.emboj.7600095; Merchant M, 2001, Int Rev Immunol, V20, P805, DOI 10.3109/08830180109045591; RICKINSON AB, 2007, FIELDS VIROLOGY, P2655; Rodrigues L, 2006, J VIROL, V80, P6123, DOI 10.1128/JVI.02700-05; Simas JP, 2004, J GEN VIROL, V85, P2789, DOI 10.1099/vir.0.80138-0; Simas JP, 1998, J GEN VIROL, V79, P149, DOI 10.1099/0022-1317-79-1-149; Simas JP, 1998, TRENDS MICROBIOL, V6, P276; Simas JP, 1999, J GEN VIROL, V80, P75, DOI 10.1099/0022-1317-80-1-75; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Stevenson PG, 2005, VIRAL IMMUNOL, V18, P445, DOI 10.1089/vim.2005.18.445; SUNILCHANDRA NP, 1992, J GEN VIROL, V73, P2347, DOI 10.1099/0022-1317-73-9-2347; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; Tomlinson CC, 2004, J VIROL, V78, P1918, DOI 10.1128/JVI.78.4.1918-1927.2004; Virgin HW, 1997, J VIROL, V71, P5894, DOI 10.1128/JVI.71.8.5894-5904.1997; Willer DO, 2003, J VIROL, V77, P8310, DOI 10.1128/JVI.77.15.8310-8321.2003; YANG WY, 1995, J BIOL CHEM, V270, P20832, DOI 10.1074/jbc.270.35.20832; Zugaza JL, 2002, J BIOL CHEM, V277, P45377, DOI 10.1074/jbc.M208039200	49	24	24	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2008	3	2							e1654	10.1371/journal.pone.0001654	http://dx.doi.org/10.1371/journal.pone.0001654			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XS	18301737	Green Published, Green Submitted, gold			2022-12-25	WOS:000260586500004
J	Larouche, M; Beffert, U; Herz, J; Hawkes, R				Larouche, Matt; Beffert, Uwe; Herz, Joachim; Hawkes, Richard			The Reelin Receptors Apoer2 and Vldlr Coordinate the Patterning of Purkinje Cell Topography in the Developing Mouse Cerebellum	PLOS ONE			English	Article								The adult cerebellar cortex is comprised of reproducible arrays of transverse zones and parasagittal stripes of Purkinje cells. Adult stripes are created through the perinatal rostrocaudal dispersion of embryonic Purkinje cell clusters, triggered by signaling through the Reelin pathway. Reelin is secreted by neurons in the external granular layer and deep cerebellar nuclei and binds to two high affinity extracellular receptors on Purkinje cells-the Very low density lipoprotein receptor (Vldlr) and apolipoprotein E receptor 2 (Apoer2). In mice null for either Reelin or double null for Vldlr and Apoer2, Purkinje cell clusters fail to disperse. Here we report that animals null for either Vldlr or Apoer2 individually, exhibit specific and parasagittally-restricted Purkinje cell ectopias. For example, in mice lacking Apoer2 function immunostaining reveals ectopic Purkinje cells that are largely restricted to the zebrin II-immunonegative population of the anterior vermis. In contrast, mice null for Vldlr have a much larger population of ectopic Purkinje cells that includes members from both the zebrin II-immunonegative and -immunopositive phenotypes. HSP25 immunoreactivity reveals that in Vldlr null animals a large portion of zebrin II-immunopositive ectopic cells are probably destined to become stripes in the central zone (lobules VI-VII). A small population of ectopic zebrin II-immunonegative Purkinje cells is also observed in animals heterozygous for both receptors (Apoer2(+/-): Vldlr(+/-)), but no ectopia is present in mice heterozygous for either receptor alone. These results indicate that Apoer2 and Vldlr coordinate the dispersal of distinct, but overlapping subsets of Purkinje cells in the developing cerebellum.	[Larouche, Matt; Hawkes, Richard] Univ Calgary, Fac Med, Genes & Dev Res Grp, Calgary, AB, Canada; [Beffert, Uwe; Herz, Joachim] Univ Texas SW Med Ctr, Dept Mol Genet, Dallas, TX USA	University of Calgary; University of Texas System; University of Texas Southwestern Medical Center Dallas	Larouche, M (corresponding author), Univ Calgary, Fac Med, Genes & Dev Res Grp, Calgary, AB, Canada.	rhawkes@ucalgary.ca	Hawkes, Richard/F-7971-2011	Beffert, Uwe/0000-0001-5877-922X	Canadian Institutes of Health Research; NIH; CIHR; HFSP; American Heart Association; Humboldt Foundation [Wolfgang Paul Award]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL063762] Funding Source: NIH RePORTER	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CIHR(Canadian Institutes of Health Research (CIHR)); HFSP(Human Frontier Science Program); American Heart Association(American Heart Association); Humboldt Foundation(Alexander von Humboldt Foundation); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	These studies were supported by grants from the Canadian Institutes of Health Research (RH). Supported by grants from the NIH (to J.H.), CIHR (to U.B.) and the HFSP (to U.B.). J.H. is an Established Investigator of the American Heart Association and the recipient of a Wolfgang Paul Award from the Humboldt Foundation.	AHN AH, 1994, DEVELOPMENT, V120, P2081; ALTMAN J, 1978, J COMP NEUROL, V179, P23, DOI 10.1002/cne.901790104; Armstrong C, 2001, J COMP NEUROL, V439, P151, DOI 10.1002/cne.1339; Armstrong CL, 2000, J COMP NEUROL, V416, P383, DOI 10.1002/(SICI)1096-9861(20000117)416:3<383::AID-CNE9>3.0.CO;2-M; Armstrong CL, 2005, J COMP NEUROL, V491, P69, DOI 10.1002/cne.20703; Beffert U, 2006, J NEUROSCI, V26, P2041, DOI 10.1523/JNEUROSCI.4566-05.2006; Beffert U, 2006, CURR BIOL, V16, P2446, DOI 10.1016/j.cub.2006.10.029; Beierbach E, 2001, J COMP NEUROL, V436, P42; Bock HH, 2003, CURR BIOL, V13, P18, DOI 10.1016/S0960-9822(02)01403-3; Boycott KM, 2005, AM J HUM GENET, V77, P477, DOI 10.1086/444400; BROCHU G, 1990, J COMP NEUROL, V291, P538, DOI 10.1002/cne.902910405; CADDY KWT, 1979, PHILOS T ROY SOC B, V287, P167, DOI 10.1098/rstb.1979.0055; Chung S, 2007, BRAIN RES, V1140, P120, DOI 10.1016/j.brainres.2006.01.100; DArcangelo G, 1997, J NEUROSCI, V17, P23, DOI 10.1523/JNEUROSCI.17-01-00023.1997; DECAMILLI P, 1984, NEUROSCIENCE, V11, P761, DOI 10.1016/0306-4522(84)90193-3; EDWARDS MA, 1994, ANAT EMBRYOL, V190, P417; Eisenman LM, 1998, J COMP NEUROL, V394, P106, DOI 10.1002/(SICI)1096-9861(19980427)394:1<106::AID-CNE8>3.0.CO;2-4; EISENMAN LM, 1993, J COMP NEUROL, V335, P586, DOI 10.1002/cne.903350410; FALCONER DS, 1951, J GENET, V50, P192, DOI 10.1007/BF02996215; Fink AJ, 2006, J NEUROSCI, V26, P3066, DOI 10.1523/JNEUROSCI.5203-05.2006; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; Gallagher E, 1998, J COMP NEUROL, V402, P238; GOFFINET AM, 1984, BRAIN RES REV, V7, P261, DOI 10.1016/0165-0173(84)90013-4; Goldowitz D, 1997, J NEUROSCI, V17, P8767; Hack I, 2007, DEVELOPMENT, V134, P3883, DOI 10.1242/dev.005447; Hartfuss E, 2003, DEVELOPMENT, V130, P4597, DOI 10.1242/dev.00654; Hashimoto M, 2003, J NEUROSCI, V23, P11342; Hawkes R, 1997, PERSPECT DEV NEUROBI, V5, P95; HAWKES R, 1994, ACTA ANAT, V151, P139; HAWKES R, 1991, PROG NEUROBIOL, V36, P309, DOI 10.1016/0301-0082(91)90004-K; Hawkes R, 1997, PROG BRAIN RES, V114, P39; HECKROTH JA, 1989, J COMP NEUROL, V279, P546, DOI 10.1002/cne.902790404; Herrup K, 1997, ANNU REV NEUROSCI, V20, P61, DOI 10.1146/annurev.neuro.20.1.61; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Howell BW, 1999, GENE DEV, V13, P643, DOI 10.1101/gad.13.6.643; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Ino H, 2004, J HISTOCHEM CYTOCHEM, V52, P311, DOI 10.1177/002215540405200302; INOUYE M, 1980, J COMP NEUROL, V194, P499, DOI 10.1002/cne.901940302; Jensen P, 2002, J NEUROSCI, V22, P8110; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P14598, DOI 10.1073/pnas.93.25.14598; LANE PW, 1992, J HERED, V83, P315, DOI 10.1093/oxfordjournals.jhered.a111221; Larouche M, 2006, J COMP NEUROL, V494, P215, DOI 10.1002/cne.20791; Larouche M, 2006, CEREBELLUM, V5, P77, DOI 10.1080/14734220600804668; Luque JM, 2007, BRAIN RES, V1140, P41, DOI 10.1016/j.brainres.2006.02.056; MARIANI J, 1977, PHILOS T R SOC B, V281, P1, DOI 10.1098/rstb.1977.0121; MIALE IL, 1961, EXP NEUROL, V4, P277, DOI 10.1016/0014-4886(61)90055-3; Miyata T, 1997, J NEUROSCI, V17, P3599; Nakamura M, 2004, EUR J NEUROSCI, V20, P2929, DOI 10.1111/j.1460-9568.2004.03768.x; Napieralski JA, 1996, J COMP NEUROL, V364, P718, DOI 10.1002/(SICI)1096-9861(19960122)364:4<718::AID-CNE9>3.0.CO;2-6; Nunzi MG, 1999, J COMP NEUROL, V404, P97; Oberdick J, 1998, TRENDS NEUROSCI, V21, P383, DOI 10.1016/S0166-2236(98)01325-3; Ozol K, 1999, J COMP NEUROL, V412, P95; Park C, 2002, NAT GENET, V31, P279, DOI 10.1038/ng908; Park C, 2002, GENESIS, V32, P32, DOI 10.1002/gene.10024; PATIL N, 1995, NAT GENET, V11, P126, DOI 10.1038/ng1095-126; Perez-Garcia CG, 2004, EUR J NEUROSCI, V20, P2827, DOI 10.1111/j.1460-9568.2004.03733.x; Rice DS, 1998, DEVELOPMENT, V125, P3719; Sarna JR, 2006, J COMP NEUROL, V496, P303, DOI 10.1002/cne.20912; SEIL FJ, 1995, J COMP NEUROL, V356, P398, DOI 10.1002/cne.903560307; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; Sillitoe RV, 2005, PROG BRAIN RES, V148, P283, DOI 10.1016/S0079-6123(04)48022-4; Sillitoe RV, 2002, J HISTOCHEM CYTOCHEM, V50, P235, DOI 10.1177/002215540205000211; Singec I, 2003, J COMP NEUROL, V459, P278, DOI 10.1002/cne.10600; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; WASSEF M, 1990, J COMP NEUROL, V294, P223, DOI 10.1002/cne.902940207; WATSON JB, 1990, J NEUROSCI RES, V26, P397, DOI 10.1002/jnr.490260402; Yang HT, 2002, J NEUROSCI, V22, P464, DOI 10.1523/JNEUROSCI.22-02-00464.2002; YUASA S, 1993, ANAT EMBRYOL, V188, P317; Zuo J, 1997, NATURE, V388, P769, DOI 10.1038/42009	69	34	35	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2008	3	2							e1653	10.1371/journal.pone.0001653	http://dx.doi.org/10.1371/journal.pone.0001653			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XS	18301736	gold, Green Submitted, Green Published			2022-12-25	WOS:000260586500003
J	Hiroyama, T; Miharada, K; Sudo, K; Danjo, I; Aoki, N; Nakamura, Y				Hiroyama, Takashi; Miharada, Kenichi; Sudo, Kazuhiro; Danjo, Inaho; Aoki, Naoko; Nakamura, Yukio			Establishment of Mouse Embryonic Stem Cell-Derived Erythroid Progenitor Cell Lines Able to Produce Functional Red Blood Cells	PLOS ONE			English	Article								Background. The supply of transfusable red blood cells (RBCs) is not sufficient in many countries. If erythroid cell lines able to produce transfusable RBCs in vitro were established, they would be valuable resources. However, such cell lines have not been established. To evaluate the feasibility of establishing useful erythroid cell lines, we attempted to establish such cell lines from mouse embryonic stem (ES) cells. Methodology/Principal Findings. We developed a robust method to obtain differentiated cell lines following the induction of hematopoietic differentiation of mouse ES cells and established five independent hematopoietic cell lines using the method. Three of these lines exhibited characteristics of erythroid cells. Although their precise characteristics varied, each of these lines could differentiate in vitro into more mature erythroid cells, including enucleated RBCs. Following transplantation of these erythroid cells into mice suffering from acute anemia, the cells proliferated transiently, subsequently differentiated into functional RBCs, and significantly ameliorated the acute anemia. In addition, we did not observe formation of any tumors following transplantation of these cells. Conclusion/Significance. To the best of our knowledge, this is the first report to show the feasibility of establishing erythroid cell lines able to produce mature RBCs. Considering the number of human ES cell lines that have been established so far, the intensive testing of a number of these lines for erythroid potential may allow the establishment of human erythroid cell lines similar to the mouse erythroid cell lines described here. In addition, our results strongly suggest the possibility of establishing useful cell lines committed to specific lineages other than hematopoietic progenitors from human ES cells.	[Hiroyama, Takashi; Miharada, Kenichi; Sudo, Kazuhiro; Danjo, Inaho; Aoki, Naoko; Nakamura, Yukio] RIKEN, BioResource Ctr, Cell Engn Div, Tsukuba, Ibaraki, Japan	RIKEN	Nakamura, Y (corresponding author), RIKEN, BioResource Ctr, Cell Engn Div, Tsukuba, Ibaraki, Japan.	yukionak@brc.riken.jp	Nakamura, Yukio/A-5263-2016; Miharada, Kenichi/C-1397-2014	Nakamura, Yukio/0000-0001-8056-4946; Miharada, Kenichi/0000-0001-8073-4001	Ministry of Education, Culture, Sports, Science, and Technology in Japan	Ministry of Education, Culture, Sports, Science, and Technology in Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by grants from the Ministry of Education, Culture, Sports, Science, and Technology in Japan.	ALTER BP, 1982, EXP HEMATOL, V10, P754; Boyd AS, 2005, ADV DRUG DELIVER REV, V57, P1944, DOI 10.1016/j.addr.2005.08.004; Carotta S, 2004, BLOOD, V104, P1873, DOI 10.1182/blood-2004-02-0570; Cerdan C, 2004, BLOOD, V103, P2504, DOI 10.1182/blood-2003-07-2563; Chadwick K, 2003, BLOOD, V102, P906, DOI 10.1182/blood-2003-03-0832; Drukker M, 2004, TRENDS BIOTECHNOL, V22, P136, DOI 10.1016/j.tibtech.2004.01.003; Giarratana MC, 2005, NAT BIOTECHNOL, V23, P69, DOI 10.1038/nbt1047; Hentze H, 2007, TRENDS BIOTECHNOL, V25, P24, DOI 10.1016/j.tibtech.2006.10.010; Hiroyama T, 2006, EXP HEMATOL, V34, P760, DOI 10.1016/j.exphem.2006.03.004; Kaufman DS, 2001, P NATL ACAD SCI USA, V98, P10716, DOI 10.1073/pnas.191362598; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KODAMA H, 1994, EXP HEMATOL, V22, P979; Kurita R, 2006, STEM CELLS, V24, P2014, DOI 10.1634/stemcells.2005-0499; Lansdorp PM, 2005, ANN NY ACAD SCI, V1044, P220, DOI 10.1196/annals.1349.027; Li F, 2001, BLOOD, V98, P335, DOI 10.1182/blood.V98.2.335; Maherali N, 2007, CELL STEM CELL, V1, P55, DOI 10.1016/j.stem.2007.05.014; Miharada K, 2005, FASEB J, V19, P1881, DOI 10.1096/fj.05-3809fje; Miharada K, 2006, NAT BIOTECHNOL, V24, P1255, DOI 10.1038/nbt1245; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; NAKANO T, 1994, SCIENCE, V265, P1098, DOI 10.1126/science.8066449; Nakano T, 1996, SCIENCE, V272, P722, DOI 10.1126/science.272.5262.722; Neildez-Nguyen TMA, 2002, NAT BIOTECHNOL, V20, P467, DOI 10.1038/nbt0502-467; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Olivier EN, 2006, EXP HEMATOL, V34, P1635, DOI 10.1016/j.exphem.2006.07.003; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; Schuldiner M, 2003, STEM CELLS, V21, P257, DOI 10.1634/stemcells.21-3-257; Sudo K, 2007, STEM CELLS, V25, P1610, DOI 10.1634/stemcells.2006-0504; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Umeda K, 2004, DEVELOPMENT, V131, P1869, DOI 10.1242/dev.01065; Vodyanik MA, 2005, BLOOD, V105, P617, DOI 10.1182/blood-2004-04-1649; Vogel G, 2005, SCIENCE, V308, P1534, DOI 10.1126/science.308.5728.1534; Wang LS, 2005, J EXP MED, V201, P1603, DOI 10.1084/jem.20041888; Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944	33	64	71	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2008	3	2							e1544	10.1371/journal.pone.0001544	http://dx.doi.org/10.1371/journal.pone.0001544			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367EQ	18253492	Green Published, Green Submitted, gold			2022-12-25	WOS:000260535700016
J	Egawa, T; Kreslavsky, T; Littman, DR; von Boehmer, H				Egawa, Takeshi; Kreslavsky, Taras; Littman, Dan R.; von Boehmer, Harald			Lineage Diversion of T Cell Receptor Transgenic Thymocytes Revealed by Lineage Fate Mapping	PLOS ONE			English	Article								Background. The binding of the T cell receptor (TCR) to major histocompatibility complex (MHC) molecules in the thymus determines fates of lymphocytes that subsequently home to secondary lymphoid tissue. TCR transgenic models have been used to study thymic selection and lineage commitment. Most TCR transgenic mice express the rearranged TCR alpha beta prematurely at the double negative stage and abnormal TCR alpha beta populations of T cells that are not easily detected in non-transgenic mice have been found in secondary lymphoid tissue of TCR transgenic mice. Methodology and Principal Findings. To determine developmental pathways of TCR-transgenic thymocytes, we used Cre-LoxP-mediated fate mapping and show here that premature expression of a transgenic TCR alpha beta diverts some developing thymocytes to a developmental pathway which resembles that of gamma delta cells. We found that most peripheral T cells with the HY-TCR in male mice have bypassed the ROR gamma t-positive CD4(+)8(+) ( double positive, DP) stage to accumulate either as CD4(-)8(-) ( double negative, DN) or as CD8 alpha(+) T cells in lymph nodes or gut epithelium. Likewise, DN TCR alpha beta cells in lymphoid tissue of female mice were not derived from DP thymocytes. Conclusion. The results further support the hypothesis that the premature expression of the TCR alpha beta can divert DN thymocytes into gamma delta lineage cells.	[Egawa, Takeshi; Littman, Dan R.] NYU, Sch Med, Skirball Inst Biomol Med, Helen L & Martin S Kimmel Ctr Biol & Med,Mol Path, New York, NY 10003 USA; [Littman, Dan R.] NYU, Sch Med, Skirball Inst Biomol Med, Helen L & Martin S Kimmel Ctr Biol & Med, New York, NY USA; [Kreslavsky, Taras; von Boehmer, Harald] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA	New York University; New York University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Littman, DR (corresponding author), NYU, Sch Med, Skirball Inst Biomol Med, Helen L & Martin S Kimmel Ctr Biol & Med,Mol Path, New York, NY 10003 USA.	littman@saturn.med.nyu.edu; harald_von_boehmer@dfci.harvard.edu		Kreslavsky, Taras/0000-0002-6672-1914	Human Frontier Science Program [LT00278/202]; Leukemia and Lymphoma Society [3547-07]; National Institutes of Health [R01AI45846]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045846] Funding Source: NIH RePORTER	Human Frontier Science Program(Human Frontier Science Program); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by postdoctoral fellowships from the Human Frontier Science Program (LT00278/202) and the Leukemia and Lymphoma Society (3547-07) to TE and by a grant from the National Institutes of Health (R01AI45846) to HvB. DRL is an investigator of the Howard Hughes Medical Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aifantis I, 2006, J EXP MED, V203, P1543, DOI 10.1084/jem.20051711; Anrather J, 2005, J BIOL CHEM, V280, P244, DOI 10.1074/jbc.M409344200; Baldwin TA, 2005, J EXP MED, V202, P111, DOI 10.1084/jem.20050359; BORGULYA P, 1991, EMBO J, V10, P913, DOI 10.1002/j.1460-2075.1991.tb08024.x; Bruno L, 1996, IMMUNITY, V5, P343, DOI 10.1016/S1074-7613(00)80260-5; CROOKS MEC, 1994, IMMUNITY, V1, P277; Eberl G, 2004, SCIENCE, V305, P248, DOI 10.1126/science.1096472; Egawa T, 2005, IMMUNITY, V22, P705, DOI 10.1016/j.immuni.2005.03.011; Guy-Grand D, 2004, SCIENCE, V305, P185, DOI 10.1126/science.1100890; He YW, 1998, IMMUNITY, V9, P797, DOI 10.1016/S1074-7613(00)80645-7; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; KILLEEN N, 1992, J EXP MED, V176, P89, DOI 10.1084/jem.176.1.89; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; Melichar HJ, 2007, SCIENCE, V315, P230, DOI 10.1126/science.1135344; ROCHA B, 1992, P NATL ACAD SCI USA, V89, P5336, DOI 10.1073/pnas.89.12.5336; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; TAKAHAMA Y, 1992, SCIENCE, V258, P653, DOI 10.1126/science.1357752; Teh H S, 1990, Dev Immunol, V1, P1, DOI 10.1155/1990/18208; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; Terrence K, 2000, J EXP MED, V192, P537, DOI 10.1084/jem.192.4.537; Villey I, 1999, EUR J IMMUNOL, V29, P4072, DOI 10.1002/(SICI)1521-4141(199912)29:12<4072::AID-IMMU4072>3.0.CO;2-E; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; VONBOEHMER H, 1991, J EXP MED, V174, P1001, DOI 10.1084/jem.174.5.1001; Yamagata T, 2004, NAT IMMUNOL, V5, P597, DOI 10.1038/ni1070	26	38	41	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1512	10.1371/journal.pone.0001512	http://dx.doi.org/10.1371/journal.pone.0001512			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SR	18231598	Green Submitted, Green Published, gold			2022-12-25	WOS:000260504200024
J	Zhao, DW; Richer, E; Antich, PP; Mason, RP				Zhao, Dawen; Richer, Edmond; Antich, Peter P.; Mason, Ralph P.			Antivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging and confirmed by MRI	FASEB JOURNAL			English	Article						breast tumor; vascular targeting agent; vascular disrupting agent; pharmacodynamics	VASCULAR-TARGETING AGENTS; QUANTITATIVE ASSESSMENT; NORMAL-TISSUES; A-4 PHOSPHATE; LUNG-CANCER; TUMOR; RAT; THERAPIES; INHIBITION; EXPRESSION	Bioluminescence imaging (BLI) has found significant use in evaluating long-term cancer therapy in small animals. We have now tested the feasibility of using BLI to assess acute effects of the vascular disrupting agent combretastatin A4 phosphate (CA4P) on luciferase-expressing MDA-MB-231 human breast tumor cells growing as xenografts in mice. Following administration of luciferin substrate, there is a rapid increase in light emission reaching a maximum after about 6 min, which gradually decreases over the following 20 min. The kinetics of light emission are highly reproducible; however, following i.p. administration of CA4P (120 mg/kg), the detected light emission was decreased between 50 and 90%, and time to maximum was significantly delayed. Twenty-four hours later, there was some recovery of light emission following further administration of luciferin substrate. Comparison with dynamic contrast-enhanced MRI based on the paramagnetic contrast agent Omniscan showed comparable changes in the tumors consistent with the previous literature. Histology also confirmed shutdown of tumor vascular perfusion. We believe this finding provides an important novel application for BLI that could have widespread application in screening novel therapeutics expected to cause acute vascular changes in tumors.	Univ Texas SW Med Ctr Dallas, Dept Radiol, Dallas, TX 75390 USA; Univ Texas SW Med Ctr Dallas, Simmons Canc Ctr, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Mason, RP (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Radiol, 5523 Harry Hines, Dallas, TX 75390 USA.	ralph.mason@utsouthwestern.edu	Mason, Ralph/C-8472-2012	Mason, Ralph/0000-0001-7517-3721	NATIONAL CANCER INSTITUTE [U24CA126608, P20CA086354] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002584] Funding Source: NIH RePORTER; NCI NIH HHS [P20 CA086354-03, U24 CA126608-01, P20 CA086354, U24 CA126608] Funding Source: Medline; NCRR NIH HHS [P41 RR002584] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Anderson HL, 2003, J CLIN ONCOL, V21, P2823, DOI 10.1200/JCO.2003.05.186; Beauregard DA, 2002, NMR BIOMED, V15, P99, DOI 10.1002/nbm.723; BOLLINGER RA, 2006, THESIS U TEXAS SW; Chen CC, 2007, NUCL INSTRUM METH A, V571, P437, DOI 10.1016/j.nima.2006.10.129; Contag CH, 2002, J MAGN RESON IMAGING, V16, P378, DOI 10.1002/jmri.10178; Dark GG, 1997, CANCER RES, V57, P1829; DENEKAMP J, 1990, CANCER METAST REV, V9, P267, DOI 10.1007/BF00046365; Dikmen ZG, 2005, CANCER RES, V65, P7866, DOI 10.1158/0008-5472.CAN-05-1215; Folkman J, 2003, SEMIN CANCER BIOL, V13, P159, DOI 10.1016/S1044-579X(02)00133-5; Galbraith SM, 2003, J CLIN ONCOL, V21, P2831, DOI 10.1200/JCO.2003.05.187; Goertz DE, 2002, CANCER RES, V62, P6371; Horsman MR, 2006, CANCER RES, V66, P11520, DOI 10.1158/0008-5472.CAN-06-2848; Hsu AR, 2007, J NUCL MED, V48, P445; Jenkins DE, 2003, CLIN EXP METASTAS, V20, P745, DOI 10.1023/B:CLIN.0000006817.25962.87; KIM JG, 2006, BIOM OPT TOP M FORT, P19; Kragh M, 2002, NEOPLASIA, V4, P263, DOI 10.1038/sj.neo.7900230; Ley CD, 2007, NEOPLASIA, V9, P108, DOI 10.1593/neo.06733; Li JZ, 2005, J GENE MED, V7, P792, DOI 10.1002/jgm.720; Lipshutz GS, 2001, MOL THER, V3, P284, DOI 10.1006/mthe.2001.0267; Maxwell RJ, 2002, NMR BIOMED, V15, P89, DOI 10.1002/nbm.754; McIntyre DJO, 2004, NEOPLASIA, V6, P150, DOI 10.1593/neo.03247; Mi J, 2006, J SURG RES, V131, P97, DOI 10.1016/j.jss.2005.09.008; Ng QS, 2007, INT J RADIAT ONCOL, V67, P1375, DOI 10.1016/j.ijrobp.2006.11.028; Padhani AR, 2003, BRIT J RADIOL, V76, pS60, DOI 10.1259/bjr/15334380; Paroo Z, 2004, MOL IMAGING, V3, P117, DOI 10.1162/1535350041464865; Prise VE, 2002, INT J ONCOL, V21, P717; Rehemtulla A, 2000, NEOPLASIA, V2, P491, DOI 10.1038/sj.neo.7900121; Rice BW, 2001, J BIOMED OPT, V6, P432, DOI 10.1117/1.1413210; Robinson SP, 2003, BRIT J CANCER, V88, P1592, DOI 10.1038/sj.bjc.6600926; Rustin GJS, 2003, J CLIN ONCOL, V21, P2815, DOI 10.1200/JCO.2003.05.185; Siemann DW, 2005, CLIN CANCER RES, V11, P416; Szentirmai O, 2006, NEUROSURGERY, V58, P365, DOI 10.1227/01.NEU.0000195114.24819.4F; Thorne SH, 2005, P IEEE, V93, P750, DOI 10.1109/JPROC.2005.844261; Thorpe PE, 2004, CLIN CANCER RES, V10, P415, DOI 10.1158/1078-0432.CCR-0642-03; Tozer GM, 1999, CANCER RES, V59, P1626; Tozer GM, 2001, CANCER RES, V61, P6413; Verneris MR, 2005, CLIN CANCER RES, V11, P4561, DOI 10.1158/1078-0432.CCR-05-0157; Wang Y, 2007, BIOTECHNOL LETT, V29, P1665, DOI 10.1007/s10529-007-9452-0; Zhao DW, 2005, INT J RADIAT ONCOL, V62, P872, DOI 10.1016/j.ijrobp.2005.03.009	39	55	59	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2445	2451		10.1096/fj.07-103713	http://dx.doi.org/10.1096/fj.07-103713			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18263704	Green Accepted			2022-12-25	WOS:000257292500036
J	Kang, J; Rychahou, PG; Ishola, TA; Mourot, JM; Evers, BM; Chung, DH				Kang, J.; Rychahou, P. G.; Ishola, T. A.; Mourot, J. M.; Evers, B. M.; Chung, D. H.			N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma	ONCOGENE			English	Article						angiogenesis; PI3K/Akt; MYCN; VEGF; neuroblastoma	ENDOTHELIAL GROWTH-FACTOR; HYPOXIA-INDUCIBLE FACTOR; TUMOR ANGIOGENESIS; MAMMALIAN TARGET; DOWN-REGULATION; C-MYC; CELLS; AMPLIFICATION; INHIBITION; PROGRESSION	Angiogenesis in neuroblastoma (NB) correlates with increased expression of vascular endothelial growth factor (VEGF) and a worse clinical outcome. Other cellular markers, such as Akt activation and MYCN amplification, are also associated with poor prognosis in NB; therefore, we sought to determine the role of N-myc in the regulation of the phosphatidylinositol 3-kinase (PI3K)/Akt/ VEGF pathway. PI3K inhibition, using small-molecule inhibitors or phosphatase and tensin homolog adenovirus, led to decreased levels of VEGF mRNA and/or protein by reducing phosphorylation of Akt and mammalian target of rapamycin (mTOR), and attenuating hypoxia-inducible factor 1 alpha expression. Moreover, PI3K inhibition decreased levels of N-myc expression in MYCN-amplified cells. To further clarify the importance of N-myc as a target of PI3K in VEGF regulation, we inhibited N-myc expression by siRNA transfection. MYCN siRNA significantly blocked VEGF secretion, irrespective of serum conditions, in MYCN-amplified NB cells; this effect was enhanced when combined with rapamycin, an mTOR inhibitor. Interestingly, in cells with low-N-myc expression, MYCN siRNA reduction of VEGF secretion was only effective with MYCN overexpression or insulin-like growth factor-1 stimulation. Our results show that N-myc plays an important role in the PI3K-mediated VEGF regulation in NB cells. Targeting MYCN, as a novel effector of PI3K-mediated angiogenesis, has significant potential for the treatment of highly vascularized, malignant NB.	[Kang, J.; Rychahou, P. G.; Ishola, T. A.; Mourot, J. M.; Evers, B. M.; Chung, D. H.] Univ Texas Med Branch, Dept Surg, Galveston, TX 77555 USA; [Chung, D. H.] Univ Texas Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Chung, DH (corresponding author), Univ Texas Med Branch, Dept Surg, 301 Univ Blvd, Galveston, TX 77555 USA.	dhchung@utmb.edu		Rychahou, Piotr/0000-0001-7352-9122	NATIONAL CANCER INSTITUTE [R01CA104748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK035608, R01DK061470, R01DK048498] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA104748, R01 CA104748-04] Funding Source: Medline; NIDDK NIH HHS [R01 DK61470, P01 DK35608, R01 DK048498-12, R01 DK061470, F31 DK079422, P01 DK035608, R01 DK48498, R01 DK048498, P01 DK035608-210001, R01 DK061470-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; Beppu Y, 2005, CANCER RES, V65, P4775, DOI 10.1158/0008-5472.CAN-04-3332; Brodeur GM, 1990, BRAIN PATHOL, V1, P47, DOI 10.1111/j.1750-3639.1990.tb00638.x; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Chesler L, 2006, CANCER RES, V66, P8139, DOI 10.1158/0008-5472.CAN-05-2769; Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855; Fotsis T, 1999, EUR J BIOCHEM, V263, P757, DOI 10.1046/j.1432-1327.1999.00575.x; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Fukuzawa M, 2002, J PEDIATR SURG, V37, P1747, DOI 10.1053/jpsu.2002.36712; Goodman LA, 1997, CLIN EXP METASTAS, V15, P130, DOI 10.1023/A:1018448710006; Hamada K, 2005, GENE DEV, V19, P2054, DOI 10.1101/gad.1308805; Hatzi E, 2000, ADV EXP MED BIOL, V476, P239; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Kang JH, 2006, BIOCHEM BIOPH RES CO, V351, P192, DOI 10.1016/j.bbrc.2006.10.020; Kang JH, 2007, CANCER LETT, V253, P273, DOI 10.1016/j.canlet.2007.02.007; Kang J, 2006, ANTICANCER RES, V26, P1903; Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891; Kurmasheva RT, 2007, MOL CANCER THER, V6, P1620, DOI 10.1158/1535-7163.MCT-06-0646; Langer I, 2000, MED PEDIATR ONCOL, V34, P386, DOI 10.1002/(SICI)1096-911X(200006)34:6<386::AID-MPO2>3.0.CO;2-3; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Marimpietri D, 2005, ONCOGENE, V24, P6785, DOI 10.1038/sj.onc.1208829; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Meitar D, 1996, J CLIN ONCOL, V14, P405, DOI 10.1200/JCO.1996.14.2.405; Misawa A, 2003, INT J CANCER, V104, P233, DOI 10.1002/ijc.10914; Nakamura K, 2006, CANCER RES, V66, P4249, DOI 10.1158/0008-5472.CAN-05-2789; Nara K, 2007, INT J ONCOL, V30, P1189; Oikawa T, 1996, EUR J PHARMACOL, V318, P93, DOI 10.1016/S0014-2999(96)00864-3; Opel D, 2007, CANCER RES, V67, P735, DOI 10.1158/0008-5472.CAN-06-2201; Pession A, 1997, J PATHOL, V183, P339; Pore N, 2006, MOL CANCER RES, V4, P471, DOI 10.1158/1541-7786.MCR-05-0234; POWIS G, 1994, CANCER RES, V54, P2419; RASCHELLA G, 1991, CANCER LETT, V56, P45, DOI 10.1016/0304-3835(91)90192-K; Ribatti D, 2002, INT J CANCER, V102, P351, DOI 10.1002/ijc.10742; Schwab M, 2003, LANCET ONCOL, V4, P472, DOI 10.1016/S1470-2045(03)01166-5; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; von Rahden BHA, 2006, NEOPLASIA, V8, P702, DOI 10.1593/neo.06277; ZAIZEN Y, 1993, J PEDIATR SURG, V28, P766, DOI 10.1016/0022-3468(93)90321-B	40	81	86	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	28					3999	4007		10.1038/onc.2008.15	http://dx.doi.org/10.1038/onc.2008.15			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	318JZ	18278068	Green Accepted			2022-12-25	WOS:000257089000011
J	Maghzal, GJ; Thomas, SR; Hunt, NH; Stocker, R				Maghzal, Ghassan J.; Thomas, Shane R.; Hunt, Nicholas H.; Stocker, Roland			Cytochrome b(5), not superoxide anion radical, is a major reductant of indoleamine 2,3-dioxygenase in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPTOPHAN-METABOLISM; INTERFERON-GAMMA; DIHYDROFLAVIN MONONUCLEOTIDE; POSTTRANSLATIONAL REGULATION; KYNURENINE PATHWAY; METHYLENE-BLUE; NITRIC-OXIDE; IN-VIVO; ENZYME; HYDROETHIDINE	The heme protein indoleamine 2,3-dioxygenase (IDO) initiates oxidative metabolism of tryptophan along the kynurenine pathway, and this requires reductive activation of Fe3+-IDO. The current dogma is that superoxide anion radical (O-2(radical anion)) is responsible for this activation, based largely on previous work employing purified rabbit IDO and rabbit enterocytes. We have re-investigated this role of O-2(radical anion). using purified recombinant human IDO (rhIDO), rabbit enterocytes that constitutively express IDO, human endothelial cells, and monocyte-derived macrophages treated with interferon-gamma to induce IDO expression, and two cell lines transfected with the human IDO gene. Both potassium superoxide and O-2(radical anion) generated by xanthine oxidase modestly activated rhIDO, in reactions thatwerepreventedcompletelybysuperoxidedismutase(SOD). In contrast, SOD mimetics had no effect on IDO activity in enterocytes and interferon-gamma-treated human cells, despite significantly decreasing cellular O-2(radical anion). Similarly, cellular IDO activity was unaffected by increasing SOD activity via co-expression of Cu, Zn-SOD or by increasing cellular O-2(radical anion) via treatment of cells with menadione. Other reductants, such as tetrahydrobiopterin, ascorbate, and cytochrome P450 reductase, were ineffective in activating cellular IDO. However, recombinant human cytochrome b(5) plus cytochrome P450 reductase and NADPH reduced Fe3+-IDO to Fe2+-IDO and activated rhIDO in a reconstituted system, a reaction inhibited marginally by SOD. Additionally, short interfering RNA-mediated knockdown of microsomal cytochrome b(5) significantly decreased IDO activityin IDO-transfected cells. Together, our data show that cytochrome b(5) rather than O-2(radical anion) plays a major role in the activation of IDO in human cells.	[Maghzal, Ghassan J.; Stocker, Roland] Univ Sydney, Sch Med Sci, Ctr Vasc Res, Sydney, NSW 2006, Australia; [Hunt, Nicholas H.] Univ Sydney, Sch Med Sci, Bosch Inst, Mol Immunopathol Unit, Sydney, NSW 2006, Australia; [Hunt, Nicholas H.] Univ Sydney, Sch Med Sci, Discipline Pathol, Sydney, NSW 2006, Australia; [Maghzal, Ghassan J.; Thomas, Shane R.; Stocker, Roland] Univ New S Wales, Fac Med, Ctr Vasc Res, Sydney, NSW 2052, Australia	University of Sydney; University of Sydney; University of Sydney; University of New South Wales Sydney	Stocker, R (corresponding author), Univ Sydney, Sch Med Sci, Ctr Vasc Res, Bosch Inst, Med Fdn Bldg,92-94 Parramatta Rd, Camperdown, NSW 2006, Australia.	rstocker@med.usyd.edu.au	maghzal, ghassan/A-9692-2015; Stocker, Roland/AAV-4489-2021; Hunt, Nick H/A-3636-2011					BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; Bolton JL, 2000, CHEM RES TOXICOL, V13, P135, DOI 10.1021/tx9902082; CHRISTEN S, 1994, J CLIN INVEST, V93, P2149, DOI 10.1172/JCI117211; Fago A, 2006, FEBS LETT, V580, P4884, DOI 10.1016/j.febslet.2006.08.003; FAULKNER KM, 1994, J BIOL CHEM, V269, P23471; HALLIWELL B, 2007, FREE RADICAL BIO MED, P82; Hansen AM, 2004, INT J PARASITOL, V34, P1309, DOI 10.1016/j.ijpara.2004.07.008; Harvey EJ, 2005, CARDIOVASC RES, V67, P11, DOI 10.1016/j.cardiores.2005.04.019; HAYAISHI O, 1977, J BIOL CHEM, V252, P3548; HIRATA F, 1977, J BIOL CHEM, V252, P4637; HIRATA F, 1975, J BIOL CHEM, V250, P5960; Hultquist D E, 1981, Prog Clin Biol Res, V55, P291; Iwamoto Y, 1996, ADV EXP MED BIOL, V398, P441; KUMA F, 1981, J BIOL CHEM, V256, P5518; Littlejohn TK, 2000, PROTEIN EXPRES PURIF, V19, P22, DOI 10.1006/prep.2000.1214; LIVINGSTON DJ, 1985, J BIOL CHEM, V260, P5699; Maghzal GJ, 2007, FREE RADICAL BIO MED, V43, P1095, DOI 10.1016/j.freeradbiomed.2007.06.023; MARKLUND S, 1974, EUR J BIOCHEM, V47, P469; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; ODONNELL VB, 1994, MOL PHARMACOL, V46, P778; OHNISHI T, 1977, J BIOL CHEM, V252, P4643; OZAKI Y, 1986, BIOCHEM BIOPH RES CO, V137, P1106, DOI 10.1016/0006-291X(86)90339-6; OZAKI Y, 1987, ARCH BIOCHEM BIOPHYS, V257, P207, DOI 10.1016/0003-9861(87)90560-1; Papadopoulou ND, 2005, BIOCHEMISTRY-US, V44, P14318, DOI 10.1021/bi0513958; Pyatt DW, 2000, BIOCHEM BIOPH RES CO, V274, P513, DOI 10.1006/bbrc.2000.3149; SAKAI N, 1993, BIOCHEM J, V295, P543, DOI 10.1042/bj2950543; Salvemini D, 2002, PULM PHARMACOL THER, V15, P439, DOI 10.1006/pupt.2002.0374; Schenkman JB, 2003, PHARMACOL THERAPEUT, V97, P139, DOI 10.1016/S0163-7258(02)00327-3; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SONO M, 1980, J BIOL CHEM, V255, P1339; SONO M, 1989, J BIOL CHEM, V264, P1616; Stocker R, 2004, PHYSIOL REV, V84, P1381, DOI 10.1152/physrev.00047.2003; Sugimoto H, 2006, P NATL ACAD SCI USA, V103, P2611, DOI 10.1073/pnas.0508996103; Suzuki T, 1998, J PROTEIN CHEM, V17, P817, DOI 10.1023/A:1020782403070; Suzuki T, 1998, COMP BIOCHEM PHYS B, V121, P117, DOI 10.1016/S0305-0491(98)10086-X; Takikawa O, 2005, BIOCHEM BIOPH RES CO, V338, P12, DOI 10.1016/j.bbrc.2005.09.032; TANIGUCHI T, 1979, J BIOL CHEM, V254, P3288; TANIGUCHI T, 1977, J BIOL CHEM, V252, P2774; Tarpey MM, 2001, CIRC RES, V89, P224, DOI 10.1161/hh1501.094365; Terentis AC, 2002, J BIOL CHEM, V277, P15788, DOI 10.1074/jbc.M200457200; TEW DG, 1993, BIOCHEMISTRY-US, V32, P10209, DOI 10.1021/bi00089a042; Thomas SR, 2007, J BIOL CHEM, V282, P23778, DOI 10.1074/jbc.M700669200; Thomas SR, 2001, J IMMUNOL, V166, P6332, DOI 10.4049/jimmunol.166.10.6332; Thomas SR, 1999, REDOX REP, V4, P199, DOI 10.1179/135100099101534927; VERGERES G, 1995, BIOCHIMIE, V77, P604, DOI 10.1016/0300-9084(96)88176-4; Vottero E, 2006, FEBS LETT, V580, P2265, DOI 10.1016/j.febslet.2006.03.034; Warburg O, 1930, BIOCHEM Z, V227, P245; WERNER ER, 1989, BIOCHEM J, V262, P861, DOI 10.1042/bj2620861; Werner ER, 2007, CURR DRUG METAB, V8, P201, DOI 10.2174/138920007780362482; Xue LL, 1999, BIOCHEMISTRY-US, V38, P11961, DOI 10.1021/bi990893b; YAMAMOTO S, 1967, J BIOL CHEM, V242, P5260; Zhao HT, 2005, P NATL ACAD SCI USA, V102, P5727, DOI 10.1073/pnas.0501719102; Zielonka J, 2006, ARCH BIOCHEM BIOPHYS, V456, P39, DOI 10.1016/j.abb.2006.09.031; Zielonka J, 2006, FREE RADICAL BIO MED, V41, P1050, DOI 10.1016/j.freeradbiomed.2006.04.017	54	66	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2008	283	18					12014	12025		10.1074/jbc.M710266200	http://dx.doi.org/10.1074/jbc.M710266200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	293MS	18299324	hybrid			2022-12-25	WOS:000255340000017
J	Boisvert-Adamo, K; Aplin, AE				Boisvert-Adamo, K.; Aplin, A. E.			Mutant B-RAF mediates resistance to anoikis via Bad and Bim	ONCOGENE			English	Article						apoptosis; Bad; Bim; B-RAF; melanoma	BCL-2 FAMILY-MEMBERS; MELANOMA-CELLS; MULTIPLE-MYELOMA; EPITHELIAL-CELLS; SURVIVAL SIGNALS; CYCLIN D1; APOPTOSIS; DEATH; PHOSPHORYLATION; PATHWAY	Normal cells undergo anoikis when they lose adhesion to or encounter an inappropriate extracellular matrix. By contrast, oncogenic signaling in tumor cells enables resistance to anoikis, a trait that contributes to tumor progression. The B-RAF serine-threonine kinase is mutated in multiple cancers and functions as an oncogene in melanoma. Previously, we demonstrated that B-RAF and downstream mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) signaling are necessary for protection from anoikis in mutant B-RAF-expressing melanoma cells. Regulation of Bcl-2 family members in melanoma and their role in B-RAF-mediated survival is poorly defined. Here, we provide evidence that B-RAFMEK signaling protects against anoikis through alterations in two proapoptotic Bcl-2 family proteins: Bcl-xL/Bcl-2-associated death promoter ( Bad) and Bcl-2-interacting mediator of cell death (Bim). B-RAF-MEK signaling regulates phosphorylation of the inhibitory serine-75 residue of Bad, and decreases Bad mRNA expression. RNA interference and overexpression experiments demonstrate that Bad contributes to the susceptibility of B-RAF-depleted cells to anoikis. Additionally, B-RAF-MEK signaling regulates the expression of Bim(EL), mainly through control of protein turnover. Increased BimEL levels induce apoptosis in suspended cells and are required for anoikis in B-RAF-depleted cells. Depletion of Bim together with Bad has an additive effect on protecting B-RAF knockdown cells from anoikis. Together, our data show that Bad and Bim are major B-RAF responsive proteins regulating apoptosis in melanoma cells.	[Boisvert-Adamo, K.; Aplin, A. E.] Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA	Albany Medical College	Aplin, AE (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, 47 New Scotland Ave,MC-165, Albany, NY 12208 USA.	aplina@mail.amc.edu			NIGMS NIH HHS [R01 GM067893, GM067893] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067893] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akiyama T, 2003, EMBO J, V22, P6653, DOI 10.1093/emboj/cdg635; Amiri KI, 2004, CANCER RES, V64, P4912, DOI 10.1158/0008-5472.CAN-04-0673; Berenson JR, 2006, J CLIN ONCOL, V24, P937, DOI 10.1200/JCO.2005.03.2383; Bhatt KV, 2007, ONCOGENE, V26, P1056, DOI 10.1038/sj.onc.1209861; Bhatt KV, 2005, ONCOGENE, V24, P3459, DOI 10.1038/sj.onc.1208544; Boisvert-Adamo K, 2006, ONCOGENE, V25, P4848, DOI 10.1038/sj.onc.1209493; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Conner SR, 2003, J BIOL CHEM, V278, P34548, DOI 10.1074/jbc.M305797200; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cowburn AS, 2002, BLOOD, V100, P2607, DOI 10.1182/blood-2001-11-0122; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dong JL, 2003, CANCER RES, V63, P3883; Eisenmann KM, 2003, CANCER RES, V63, P8330; El Chami N, 2005, J CELL BIOL, V171, P651, DOI 10.1083/jcb.200507076; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fukazawa H, 2002, MOL CANCER THER, V1, P303; Fukazawa H, 2004, MOL CANCER THER, V3, P1281; Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jiang P, 2006, MOL CELL BIOL, V26, P9071, DOI 10.1128/MCB.01025-06; Kropff MH, 2005, LEUKEMIA RES, V29, P587, DOI 10.1016/j.leukres.2004.11.004; Letai A, 2005, J CLIN INVEST, V115, P2648, DOI 10.1172/JCI26250; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Marani M, 2004, ONCOGENE, V23, P2431, DOI 10.1038/sj.onc.1207364; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oliviero R, 1997, BIOCHEM J, V324, P75, DOI 10.1042/bj3240075; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676; Quadros MR, 2006, CANCER BIOL THER, V5, P498, DOI 10.4161/cbt.5.5.2567; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Troppmair J, 2003, BIOCHEM PHARMACOL, V66, P1341, DOI 10.1016/S0006-2952(03)00483-0; Wang PB, 2004, J BIOL CHEM, V279, P41280, DOI 10.1074/jbc.C400248200; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Weston CR, 2003, ONCOGENE, V22, P1281, DOI 10.1038/sj.onc.1206261; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	40	78	80	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	23					3301	3312		10.1038/sj.onc.1211003	http://dx.doi.org/10.1038/sj.onc.1211003			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	304LQ	18246127				2022-12-25	WOS:000256111400009
J	Choi, RCY; Simon, J; Tsim, KWK; Barnard, EA				Choi, Roy C. Y.; Simon, Joseph; Tsim, Karl W. K.; Barnard, Eric A.			Constitutive and agonist-induced dimerizations of the P2Y(1) receptor - Relationship to internalization and scaffolding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; GREEN-FLUORESCENT PROTEIN; NUCLEOTIDE RECEPTOR; DIFFERENTIAL REGULATION; LIVING CELLS; INTERNATIONAL UNION; ATP RELEASE; OLIGOMERIZATION; ACTIVATION; MECHANISMS	In living cells, P2Y(1) receptor dimerization was quantitated by an improved version of fluorescence resonance energy transfer donor photobleaching analysis. 44% of the P2Y(1) receptors expressed in HEK293 cell membranes exist as dimers in the resting state, inducible by agonist exposure to give 85-100% dimerization. Monomer and constitutive dimers are fully active. Agonist-induced dimerization follows desensitization and is fully reversible upon withdrawal of agonist. Receptor dimers are required for internalization at 37 degrees C but are not sufficient; at 20 degrees C dimerization also occurs, but endocytosis is abolished. Removal of the C-terminal 19 amino acids abolished both dimerization and internalization, whereas full activation by agonists was retained up to a loss of 39 amino acids, confirming active monomers. This receptor is known to bind through its last four amino acids (DTSL) to a scaffolding protein, Na/H exchanger regulatory factor-2, which was endogenous here, and DTSL removal blocked constitutive dimerization specifically. Distinction should therefore be made between the following: 1) constitutive dimers tethered to a scaffolding protein, together with effector proteins, within a signaling micro-domain, and 2) free dimers in the cell membrane, which here are inducible by agonist exposure. For the class A G-protein-coupled receptors, we suggest that the percentages of free monomers, and in many cases of induced free dimers, commonly become artifactually increased; this would arise from an excess there of the receptor over its specific scaffold and from a lack of the native targeting of the receptor to that site.	[Choi, Roy C. Y.; Simon, Joseph; Barnard, Eric A.] Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England; [Tsim, Karl W. K.] Univ Sci & Technol, Dept Biol, Hong Hom, Hong Kong, Peoples R China	University of Cambridge; Hong Kong University of Science & Technology	Barnard, EA (corresponding author), Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England.	eb247@cam.ac.uk		Tsim, Karl/0000-0003-4808-1674	Wellcome Trust [081706, 076139] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abbracchio MP, 2006, PHARMACOL REV, V58, P281, DOI 10.1124/pr.58.3.3; Ayoub MA, 2004, MOL PHARMACOL, V66, P312, DOI 10.1124/mol.104.000398; Ayyanathan K, 1996, BIOCHEM BIOPH RES CO, V218, P783, DOI 10.1006/bbrc.1996.0139; Barnard EA, 1997, MOL NEUROBIOL, V15, P103, DOI 10.1007/BF02740631; Baurand A, 2005, MOL PHARMACOL, V67, P721, DOI 10.1124/mol.104.004846; Brinson AE, 2001, J BIOL CHEM, V276, P11939, DOI 10.1074/jbc.M009909200; Bulenger S, 2005, TRENDS PHARMACOL SCI, V26, P131, DOI 10.1016/j.tips.2005.01.004; Canals M, 2004, J NEUROCHEM, V88, P726, DOI 10.1046/j.1471-4159.2003.02200.x; Choi RCY, 2003, J NEUROSCI, V23, P4445; Delmas P, 2004, TRENDS NEUROSCI, V27, P41, DOI 10.1016/j.tins.2003.10.013; Ding ZG, 2005, AM J PHYSIOL-CELL PH, V288, pC559, DOI 10.1152/ajpcell.00401.2004; Fam SR, 2005, P NATL ACAD SCI USA, V102, P8042, DOI 10.1073/pnas.0408818102; Fam SR, 2003, J NEUROSCI, V23, P4437; Filippov AK, 2006, J NEUROSCI, V26, P9340, DOI 10.1523/JNEUROSCI.2635-06.2006; Flores RV, 2005, MOL CELL BIOCHEM, V280, P35, DOI 10.1007/s11010-005-8050-5; Fotiadis D, 2004, FEBS LETT, V564, P281, DOI 10.1016/S0014-5793(04)00194-2; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; Gehret AU, 2006, J BIOL CHEM, V281, P20698, DOI 10.1074/jbc.M513642200; Grant M, 2004, J BIOL CHEM, V279, P38636, DOI 10.1074/jbc.M406276200; Hardy AR, 2005, BLOOD, V105, P3552, DOI 10.1182/blood-2004-07-2893; Hoffmann C, 2005, NAT METHODS, V2, P171, DOI 10.1038/NMETH742; James JR, 2006, NAT METHODS, V3, P1001, DOI 10.1038/nmeth978; Jares-Erijman EA, 2003, NAT BIOTECHNOL, V21, P1387, DOI 10.1038/nbt896; Joseph SM, 2003, J BIOL CHEM, V278, P23331, DOI 10.1074/jbc.M302680200; Lau AG, 2001, BIOCHEMISTRY-US, V40, P8572, DOI 10.1021/bi0103516; Lavoie C, 2002, J BIOL CHEM, V277, P35402, DOI 10.1074/jbc.M204163200; Law PY, 2005, J BIOL CHEM, V280, P11152, DOI 10.1074/jbc.M500171200; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; MEADOWS DL, 1991, J IMMUNOL METHODS, V143, P263, DOI 10.1016/0022-1759(91)90051-G; Meyer BH, 2006, P NATL ACAD SCI USA, V103, P2138, DOI 10.1073/pnas.0507686103; MILLIGAN G, 2007, BIOCHIM BIOPHYS ACTA, V68, P825; Mousavi SA, 2004, BIOCHEM J, V377, P1, DOI 10.1042/BJ20031000; Mundell SJ, 2006, TRAFFIC, V7, P1420, DOI 10.1111/j.1600-0854.2006.00469.x; Mundell SJ, 2006, MOL PHARMACOL, V70, P1132, DOI 10.1124/mol.106.023549; Nandanan E, 2000, J MED CHEM, V43, P829, DOI 10.1021/jm990249v; Okada SF, 2006, J BIOL CHEM, V281, P22992, DOI 10.1074/jbc.M603019200; Otero M, 2000, MOL CELL BIOCHEM, V205, P115, DOI 10.1023/A:1007018001735; Percherancier Y, 2005, J BIOL CHEM, V280, P9895, DOI 10.1074/jbc.M411151200; Pfleger KDG, 2005, BIOCHEM J, V385, P625, DOI 10.1042/BJ20041361; Pin JP, 2007, PHARMACOL REV, V59, P5, DOI 10.1124/pr.59.1.5; Rochais F, 2007, J CLIN INVEST, V117, P229, DOI 10.1172/JCI30012; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Sellers LK, 2001, J BIOL CHEM, V276, P16379, DOI 10.1074/jbc.M006617200; Simon J, 2002, J BIOL CHEM, V277, P31390, DOI 10.1074/jbc.M110714200; Tulapurkar ME, 2005, CELL MOL LIFE SCI, V62, P1388, DOI 10.1007/s00018-005-5052-0; van Rijn RM, 2006, MOL PHARMACOL, V70, P604, DOI 10.1124/mol.105.020818; Vohringer C, 2000, BIOCHEM PHARMACOL, V59, P791, DOI 10.1016/S0006-2952(99)00390-1; Wade JB, 2003, AM J PHYSIOL-CELL PH, V285, pC1494, DOI 10.1152/ajpcell.00092.2003; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; Yoshioka K, 2002, FEBS LETT, V523, P147, DOI 10.1016/S0014-5793(02)02965-4; Zhang JM, 2003, NEURON, V40, P971, DOI 10.1016/S0896-6273(03)00717-7	51	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					11050	11063		10.1074/jbc.M709266200	http://dx.doi.org/10.1074/jbc.M709266200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18270199	hybrid			2022-12-25	WOS:000254894700085
J	Hall, MC; Jeong, DE; Henderson, JT; Choi, E; Bremmer, SC; Iliuk, AB; Charbonneau, H				Hall, Mark C.; Jeong, Dah-Eun; Henderson, James T.; Choi, Eunyoung; Bremmer, Steven C.; Iliuk, Anton B.; Charbonneau, Harry			Cdc28 and Cdc14 control stability of the anaphase-promoting complex inhibitor Acm1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; PROTEOMIC ANALYSIS; S-PHASE; YEAST; APC/C; PHOSPHORYLATION; PROTEINS; COMPLEX/CYCLOSOME; 14-3-3-PROTEINS	The anaphase-promoting complex (APC) regulates the eukaryotic cell cycle by targeting specific proteins for proteasomal degradation. Its activity must be strictly controlled to ensure proper cell cycle progression. The co-activator proteins Cdc20 and Cdh1 are required for APC activity and are important regulatory targets. Recently, budding yeast Acm1 was identified as a Cdh1 binding partner and APC(Cdh1) inhibitor. Acm1 disappears in late mitosis when APC(Cdh1) becomes active and contains conserved degron-like sequences common to APC substrates, suggesting it could be both an inhibitor and substrate. Surprisingly, we found that Acm1 proteolysis is independent of APC. A major determinant of Acm1 stability is phosphorylation at consensus cyclin-dependent kinase sites. Acm1 is a substrate of Cdc28 cyclin-dependent kinase and Cdc14 phosphatase both in vivo and in vitro. Mutation of Cdc28 phosphorylation sites or conditional inactivation of Cdc28 destabilizes Acm1. In contrast, inactivation of Cdc14 prevents Acm1 dephosphorylation and proteolysis. Cdc28 stabilizes Acm1 in part by promoting binding of the 14-3-3 proteins Bmh1 and Bmh2. We conclude that the opposing actions of Cdc28 and Cdc14 are primary factors limiting Acm1 to the interval from G(1)/S to late mitosis and are capable of establishing APC-independent expression patterns similar to APC substrates.	[Hall, Mark C.; Jeong, Dah-Eun; Henderson, James T.; Choi, Eunyoung; Bremmer, Steven C.; Iliuk, Anton B.; Charbonneau, Harry] Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA; [Hall, Mark C.; Charbonneau, Harry] Purdue Univ, Purdue Canc Ctr, W Lafayette, IN 47907 USA; [Hall, Mark C.] Purdue Univ, Bindley Biosci Ctr, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Hall, MC (corresponding author), 175 S Univ St, W Lafayette, IN 47907 USA.	mchall@purdue.edu	Hall, Mark C./D-1698-2011	Iliuk, Anton/0000-0002-2914-1363; Hall, Mark/0000-0001-6429-2506	NATIONAL CANCER INSTITUTE [R29CA059935, R01CA059935] Funding Source: NIH RePORTER; NCI NIH HHS [CA59935] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aitken A, 2006, SEMIN CANCER BIOL, V16, P162, DOI 10.1016/j.semcancer.2006.03.005; Amon A, 2002, METHOD ENZYMOL, V351, P457; Bishop AC, 2000, NATURE, V407, P395, DOI 10.1038/35030148; Brachmann CB, 1998, YEAST, V14, P115; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burton JL, 2007, GENE DEV, V21, P655, DOI 10.1101/gad.1511107; Dial JM, 2007, J BIOL CHEM, V282, P5237, DOI 10.1074/jbc.M606589200; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; FLINT AJ, 2003, HDB CELL SIGNALING, P671; Gray CH, 2003, EMBO J, V22, P3524, DOI 10.1093/emboj/cdg348; Hall MC, 2004, CELL CYCLE, V3, P1278, DOI 10.4161/cc.3.10.1153; Hall MC, 2003, J BIOL CHEM, V278, P16698, DOI 10.1074/jbc.M213109200; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; HARTWELL LH, 1973, GENETICS, V74, P267; Hermeking H, 2006, SEMIN CANCER BIOL, V16, P183, DOI 10.1016/j.semcancer.2006.03.002; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; Izawa D, 2005, NATURE, V434, P529, DOI 10.1038/nature03406; Jaquenoud M, 2002, EMBO J, V21, P6515, DOI 10.1093/emboj/cdf634; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; Kaiser BK, 2002, MOL BIOL CELL, V13, P2289, DOI 10.1091/mbc.01-11-0535; Kakiuchi K, 2007, BIOCHEMISTRY-US, V46, P7781, DOI 10.1021/bi700501t; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; Listovsky T, 2004, EMBO J, V23, P1619, DOI 10.1038/sj.emboj.7600149; Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302; Mailand N, 2005, CELL, V122, P915, DOI 10.1016/j.cell.2005.08.013; Martinez JS, 2006, MOL CELL BIOL, V26, P9162, DOI 10.1128/MCB.00603-06; Meek SEM, 2004, J BIOL CHEM, V279, P32046, DOI 10.1074/jbc.M403044200; Miller JJ, 2006, GENE DEV, V20, P2410, DOI 10.1101/gad.1454006; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Pfleger CM, 2000, GENE DEV, V14, P655; Prinz S, 1998, CURR BIOL, V8, P750, DOI 10.1016/S0960-9822(98)70298-2; Rape M, 2004, NATURE, V432, P588, DOI 10.1038/nature03023; Reimann JDR, 2001, GENE DEV, V15, P3278, DOI 10.1101/gad.945701; Rubio MP, 2004, BIOCHEM J, V379, P395, DOI 10.1042/bj20031797; Schmidt A, 2005, GENE DEV, V19, P502, DOI 10.1101/gad.320705; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; Searle JS, 2004, NAT CELL BIOL, V6, P138, DOI 10.1038/ncb1092; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Shoji S, 2006, EMBO J, V25, P834, DOI 10.1038/sj.emboj.7600953; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; Tang ZY, 2004, MOL CELL, V16, P387, DOI 10.1016/j.molcel.2004.09.031; Traverso EE, 2001, J BIOL CHEM, V276, P21924, DOI 10.1074/jbc.M011689200; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Vodermaier HC, 2004, CURR BIOL, V14, pR787, DOI 10.1016/j.cub.2004.09.020; Woodbury EL, 2007, NAT CELL BIOL, V9, P106, DOI 10.1038/ncb1523; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yamasaki L, 2004, CURR OPIN CELL BIOL, V16, P623, DOI 10.1016/j.ceb.2004.08.005; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721	60	30	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10396	10407		10.1074/jbc.M710011200	http://dx.doi.org/10.1074/jbc.M710011200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18287090	Green Published, hybrid			2022-12-25	WOS:000254894700020
J	Seth, P; Miller, HB; Lasda, EL; Pearson, JL; Garcia-Blanco, MA				Seth, Puneet; Miller, Heather B.; Lasda, Erika L.; Pearson, James L.; Garcia-Blanco, Mariano A.			Identification of an intronic splicing enhancer essential for the inclusion of FGFR2 exon IIIc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR-2; MECHANISM; TIA-1; ACTIVATION; SEQUENCES	The ligand specificity of fibroblast growth factor receptor 2 (FGFR2) is determined by the alternative splicing of exons 8 (IIIb) or 9 (IIIc). Exon IIIb is included in epithelial cells, whereas exon IIIc is included in mesenchymal cells. Although a number of cis elements and trans factors have been identified that play a role in exon IIIb inclusion in epithelium, little is known about the activation of exon IIIc in mesenchyme. We report here the identification of a splicing enhancer required for IIIc inclusion. This 24-nucleotide (nt) downstream intronic splicing enhancer (DISE) is located within intron 9 immediately downstream of exon IIIc. DISE was able to activate the inclusion of heterologous exons rat FGFR2 IIIb and human beta-globin exon 2 in cell lines from different tissues and species and also in HeLa cell nuclear extracts in vitro. DISE was capable of replacing the intronic activator sequence 1 (IAS1), a known IIIb splicing enhancer and vice versa. This fact, together with the requirement for DISE to be close to the 5'-splice site and the ability of DISE to promote binding of U1 snRNP, suggested that IAS1 and DISE belong to the same class of cis-acting elements.	[Seth, Puneet; Miller, Heather B.; Lasda, Erika L.; Garcia-Blanco, Mariano A.] Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA; [Garcia-Blanco, Mariano A.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Seth, Puneet; Miller, Heather B.; Lasda, Erika L.; Pearson, James L.; Garcia-Blanco, Mariano A.] Duke Univ, Med Ctr, Ctr RNA Biol, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Garcia-Blanco, MA (corresponding author), Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Box 3053 424 CARL,Res Dr, Durham, NC 27710 USA.	garci001@mc.duke.edu	Miller, Heather B./M-1540-2019; Miller, Heather/R-4812-2019	Miller, Heather/0000-0003-1400-7716	NIGMS NIH HHS [R01 GM 63090] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063090] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baraniak AP, 2006, MOL CELL BIOL, V26, P1209, DOI 10.1128/MCB.26.4.1209-1222.2006; Baraniak AP, 2003, MOL CELL BIOL, V23, P9327, DOI 10.1128/MCB.23.24.9327-9337.2003; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; BLACK DL, 1992, CELL, V69, P795, DOI 10.1016/0092-8674(92)90291-J; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; Bonano VI, 2006, RNA, V12, P2073, DOI 10.1261/rna.248506; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Carlo T, 1996, RNA, V2, P342; Carstens RP, 1998, MOL CELL BIOL, V18, P2205, DOI 10.1128/MCB.18.4.2205; Carstens RP, 2000, MOL CELL BIOL, V20, P7388, DOI 10.1128/MCB.20.19.7388-7400.2000; Del Gato-Konczak F, 2000, MOL CELL BIOL, V20, P6287, DOI 10.1128/MCB.20.17.6287-6299.2000; DelGatto F, 1996, NUCLEIC ACIDS RES, V24, P2017, DOI 10.1093/nar/24.11.2017; DELGATTO F, 1995, MOL CELL BIOL, V15, P4825; DelGatto F, 1997, MOL CELL BIOL, V17, P5106, DOI 10.1128/MCB.17.9.5106; DELGATTO F, 1995, GENOMICS, V27, P558, DOI 10.1006/geno.1995.1095; DELL KR, 1992, J BIOL CHEM, V267, P21225; Fededa JP, 2005, MOL CELL, V19, P393, DOI 10.1016/j.molcel.2005.06.035; Garcia-Blanco MA, 2004, NAT BIOTECHNOL, V22, P535, DOI 10.1038/nbt964; Goldstrohm AC, 2001, GENE, V277, P31, DOI 10.1016/S0378-1119(01)00695-3; Han K, 2005, PLOS BIOL, V3, P843, DOI 10.1371/journal.pbio.0030158; Le Guienr C, 2001, J BIOL CHEM, V276, P40638, DOI 10.1074/jbc.M105642200; Le Guiner C, 2003, J BIOL CHEM, V278, P10465, DOI 10.1074/jbc.M212378200; Matlin AJ, 2005, NAT REV MOL CELL BIO, V6, P386, DOI 10.1038/nrm1645; Merendino L, 1999, NATURE, V402, P838, DOI 10.1038/45602; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Mistry N, 2003, RNA, V9, P209, DOI 10.1261/rna.2470903; Natalizio BJ, 2005, METHODS, V37, P314, DOI 10.1016/j.ymeth.2005.07.013; Oldridge M, 1999, AM J HUM GENET, V64, P446, DOI 10.1086/302245; Oltean S, 2006, P NATL ACAD SCI USA, V103, P14116, DOI 10.1073/pnas.0603090103; Ule J, 2006, NATURE, V444, P580, DOI 10.1038/nature05304; Wagner EJ, 1999, ELECTROPHORESIS, V20, P1082, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<1082::AID-ELPS1082>3.0.CO;2-#; Wagner EJ, 2005, J BIOL CHEM, V280, P14017, DOI 10.1074/jbc.M414492200; Wagner EJ, 2002, MOL CELL, V10, P943, DOI 10.1016/S1097-2765(02)00645-7	33	13	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					10058	10067		10.1074/jbc.M800087200	http://dx.doi.org/10.1074/jbc.M800087200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18256031	Green Published, hybrid			2022-12-25	WOS:000254671600060
J	Wollers, S; Heidenreich, T; Zarepour, M; Zachmann, D; Kraft, C; Zhao, YD; Mendel, RR; Bittner, F				Wollers, Silke; Heidenreich, Torsten; Zarepour, Maryam; Zachmann, Dieter; Kraft, Claudia; Zhao, Yunde; Mendel, Ralf R.; Bittner, Florian			Binding of sulfurated molybdenum cofactor to the C-terminal domain of ABA3 from Arabidopsis thaliana provides insight into the mechanism of molybdenum cofactor sulfuration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACIDOVORANS XANTHINE DEHYDROGENASE; NITRATE REDUCTASE; ALDEHYDE OXIDASE; BIOCHEMICAL-CHARACTERIZATION; RHODOBACTER-CAPSULATUS; MOLYBDOPTERIN COFACTOR; CLASSICAL XANTHINURIA; ESCHERICHIA-COLI; SULFITE OXIDASE; GENE	The molybdenum cofactor sulfurase ABA3 from Arabidopsis thaliana is needed for post-translational activation of aldehyde oxidase and xanthine dehydrogenase by transferring a sulfur atom to the desulfo-molybdenum cofactor of these enzymes. ABA3 is a two-domain protein consisting of an NH2-terminal NifS-like cysteine desulfurase domain and a C-terminal domain of yet undescribed function. The NH2-terminal domain of ABA3 decomposes L-cysteine to yield elemental sulfur, which subsequently is bound as persulfide to a conserved protein cysteinyl residue within this domain. In vivo, activation of aldehyde oxidase and xanthine dehydrogenase also depends on the function of the C-terminal domain, as can be concluded from the A. thaliana aba3/sir3-3 mutant. sir3-3 plants are strongly reduced in aldehyde oxidase and xanthine dehydrogenase activities due to a substitution of arginine 723 by a lysine within the C-terminal domain of the ABA3 protein. Here we present first evidence for the function of the C-terminal domain and show that molybdenum cofactor is bound to this domain with high affinity. Furthermore, cyanide-treated ABA3 C terminus was shown to release thiocyanate, indicating that the molybdenum cofactor bound to the C-terminal domain is present in the sulfurated form. Co-incubation of partially active aldehyde oxidase and xanthine dehydrogenase with ABA3 C terminus carrying sulfurated molybdenum cofactor resulted in stimulation of aldehyde oxidase and xanthine dehydrogenase activity. The data of this work suggest that the C-terminal domain of ABA3 might act as a scaffold protein where prebound desulfo-molybdenum cofactor is converted into sulfurated cofactor prior to activation of aldehyde oxidase and xanthine dehydrogenase.	[Wollers, Silke; Heidenreich, Torsten; Zarepour, Maryam; Mendel, Ralf R.; Bittner, Florian] Tech Univ Carolo Wilhelmina Braunschweig, Dept Plant Biol, D-38023 Braunschweig, Germany; [Zachmann, Dieter; Kraft, Claudia] Tech Univ Carolo Wilhelmina Braunschweig, Dept Environm Geol, D-38023 Braunschweig, Germany; [Zhao, Yunde] Univ Calif San Diego, Sect Cell & Dev Biol, La Jolla, CA 92093 USA	Braunschweig University of Technology; Braunschweig University of Technology; University of California System; University of California San Diego	Mendel, RR (corresponding author), Tech Univ Carolo Wilhelmina Braunschweig, Dept Plant Biol, Humboldtstr 1, D-38023 Braunschweig, Germany.	r.mendel@tu-bs.de	Zhao, Yunde/AAC-5360-2019		NIGMS NIH HHS [R01 GM068631] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amrani L, 2000, MOL MICROBIOL, V38, P114, DOI 10.1046/j.1365-2958.2000.02119.x; Anantharaman V, 2002, FEMS MICROBIOL LETT, V207, P55, DOI 10.1016/S0378-1097(01)00515-8; Bittner F, 2001, J BIOL CHEM, V276, P40381, DOI 10.1074/jbc.C100472200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Dai XH, 2005, P NATL ACAD SCI USA, V102, P3129, DOI 10.1073/pnas.0500185102; Eilers T, 2001, J BIOL CHEM, V276, P46989, DOI 10.1074/jbc.M108078200; Fischer K, 2006, J BIOL CHEM, V281, P30186, DOI 10.1074/jbc.M603919200; Garrett RM, 1996, J BIOL CHEM, V271, P7387, DOI 10.1074/jbc.271.13.7387; Havemeyer A, 2006, J BIOL CHEM, V281, P34796, DOI 10.1074/jbc.M607697200; Heidenreich T, 2005, J BIOL CHEM, V280, P4213, DOI 10.1074/jbc.M411195200; Hesberg C, 2004, J BIOL CHEM, V279, P13547, DOI 10.1074/jbc.M312929200; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; Ichida K, 2001, BIOCHEM BIOPH RES CO, V282, P1194, DOI 10.1006/bbrc.2001.4719; Ivanov NV, 2004, PROTEIN EXPRES PURIF, V37, P72, DOI 10.1016/j.pep.2004.05.002; Ivanov NV, 2003, EUR J BIOCHEM, V270, P4744, DOI 10.1046/j.1432-1033.2003.03875.x; JOHNSON JL, 1982, P NATL ACAD SCI-BIOL, V79, P6856, DOI 10.1073/pnas.79.22.6856; Kisker C, 1997, ANNU REV BIOCHEM, V66, P233, DOI 10.1146/annurev.biochem.66.1.233; Koiwai H, 2000, J BIOCHEM-TOKYO, V127, P659, DOI 10.1093/oxfordjournals.jbchem.a022654; Komoto N, 2003, INSECT BIOCHEM MOLEC, V33, P417, DOI 10.1016/S0965-1748(03)00006-7; Koshiba T, 1996, PLANT PHYSIOL, V110, P781, DOI 10.1104/pp.110.3.781; Leimkuhler S, 1999, J BACTERIOL, V181, P2745; NASON A, 1971, P NATL ACAD SCI USA, V68, P3242, DOI 10.1073/pnas.68.12.3242; Neumann M, 2006, J BIOL CHEM, V281, P15701, DOI 10.1074/jbc.M601617200; Palmer T, 1996, MOL MICROBIOL, V20, P875, DOI 10.1111/j.1365-2958.1996.tb02525.x; Peretz H, 2007, MOL GENET METAB, V91, P23, DOI 10.1016/j.ymgme.2007.02.005; Sagi M, 1999, PLANT PHYSIOL, V120, P571, DOI 10.1104/pp.120.2.571; Sagi M, 2002, PLANT J, V31, P305, DOI 10.1046/j.1365-313X.2002.01363.x; Schwartz SH, 1997, PLANT PHYSIOL, V114, P161, DOI 10.1104/pp.114.1.161; Schwarz G, 1997, J BIOL CHEM, V272, P26811, DOI 10.1074/jbc.272.43.26811; Schwarz G, 2006, ANNU REV PLANT BIOL, V57, P623, DOI 10.1146/annurev.arplant.57.032905.105437; STEWART V, 1982, J BACTERIOL, V151, P788, DOI 10.1128/JB.151.2.788-799.1982; WAHL RC, 1982, J BIOL CHEM, V257, P3958; Watanabe T, 2000, J BIOL CHEM, V275, P21789, DOI 10.1074/jbc.C000230200	33	58	61	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9642	9650		10.1074/jbc.M708549200	http://dx.doi.org/10.1074/jbc.M708549200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18258600	hybrid			2022-12-25	WOS:000254671600018
J	Gillet, L; Colaco, S; Stevenson, PG				Gillet, Laurent; Colaco, Susanna; Stevenson, Philip G.			The Murid Herpesvirus-4 gH/gL Binds to Glycosaminoglycans	PLOS ONE			English	Article								The first contact a virus makes with cells is an important determinant of its tropism. Murid Herpesvirus-4 (MuHV-4) is highly dependent on glycosaminoglycans (GAGs) for cell binding. Its first contact is therefore likely to involve a GAG-binding virion glycoprotein. We have previously identified two such proteins, gp70 and gp150. Gp70 binds strongly to GAGs. However, deleting it makes little difference to MuHV-4 cell binding or GAG-dependence. Deleting gp150, by contrast, frees MuHV-4 from GAG dependence. This implies that GAGs normally displace gp150 to allow GAG-independent cell binding. But the gp150 GAG interaction is weak, and so would seem unlikely to make an effective first contact. Since neither gp70 nor gp150 matches the expected profile of a first contact glycoprotein, our understanding of MuHV-4 GAG interactions must be incomplete. Here we relate the seemingly disconnected gp70 and gp150 GAG interactions by showing that the MuHV-4 gH/gL also binds to GAGs. gH/gL-blocking and gp70-blocking antibodies individually had little effect on cell binding, but together were strongly inhibitory. Thus, there was redundancy in GAG binding between gp70 and gH/gL. Gp150-deficient MuHV-4 largely resisted blocks to gp70 and gH/gL binding, consistent with its GAG independence. The failure of wild-type MuHV-4 to do the same argues that gp150 is normally engaged only down-stream of gp70 or gH/gL. MuHV-4 GAG dependence is consequently two-fold: gp70 or gH/gL binding provides virions with a vital first foothold, and gp150 is then engaged to reveal GAG-independent binding.	[Gillet, Laurent; Colaco, Susanna; Stevenson, Philip G.] Univ Liege, Fac Vet Med, Liege, Belgium	University of Liege	Gillet, L (corresponding author), Univ Liege, Fac Vet Med, Liege, Belgium.	pgs27@cam.ac.uk	Stevenson, Philip/F-6651-2011; Stevenson, Philip g/F-9688-2014	Stevenson, Philip g/0000-0002-3520-5060; Gillet, Laurent/0000-0002-1047-2525	Fonds National Belge de la Recherche Scientifique (FNRS); Wellcome Trust Senior Clinical Fellow [GR076956MA]; Medical Research Council [G0400427, G9800903]; Cancer Research UK [C19612/A6189]; Medical Research Council [G9800943] Funding Source: researchfish; MRC [G0400427, G9800943] Funding Source: UKRI	Fonds National Belge de la Recherche Scientifique (FNRS)(Fonds de la Recherche Scientifique - FNRS); Wellcome Trust Senior Clinical Fellow(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Laurent Gillet is a Postdoctoral Researcher of the Fonds National Belge de la Recherche Scientifique (FNRS). Philip Stevenson is a Wellcome Trust Senior Clinical Fellow (GR076956MA). This work was also supported by Medical Research Council grants G0400427 and G9800903 and by Cancer Research UK grant C19612/A6189.	Adler H, 2000, J VIROL, V74, P6964, DOI 10.1128/JVI.74.15.6964-6974.2000; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Blom AM, 2007, ADV EXP MED BIOL, V598, P105; De Lima BD, 2004, J VIROL, V78, P5103, DOI 10.1128/JVI.78.10.5103-5112.2004; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Gill MB, 2006, J GEN VIROL, V87, P1465, DOI 10.1099/vir.0.81760-0; Gillet L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000899; Gillet L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000705; Gillet L, 2007, EMBO J, V26, P5131, DOI 10.1038/sj.emboj.7601925; Gillet L, 2007, J VIROL, V81, P13082, DOI 10.1128/JVI.01141-07; Gillet L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000347; Gillet L, 2007, J VIROL, V81, P280, DOI 10.1128/JVI.01616-06; Gillet L, 2006, J GEN VIROL, V87, P3515, DOI 10.1099/vir.0.82313-0; Heldwein EE, 2006, SCIENCE, V313, P217, DOI 10.1126/science.1126548; HUTCHINSON L, 1992, J VIROL, V66, P2240, DOI 10.1128/JVI.66.4.2240-2250.1992; Kapadia SB, 1999, J VIROL, V73, P7658, DOI 10.1128/JVI.73.9.7658-7670.1999; KAYE JF, 1992, J GEN VIROL, V73, P2693, DOI 10.1099/0022-1317-73-10-2693; Kraehenbuhl JP, 2000, ANNU REV CELL DEV BI, V16, P301, DOI 10.1146/annurev.cellbio.16.1.301; Lopes FB, 2004, J VIROL, V78, P13370, DOI 10.1128/JVI.78.23.13370-13375.2004; Mark L, 2006, MOL IMMUNOL, V43, P1665, DOI 10.1016/j.molimm.2005.09.016; May JS, 2005, J VIROL, V79, P3459, DOI 10.1128/JVI.79.6.3459-3467.2005; MOORE MD, 1989, J BIOL CHEM, V264, P20576; Parry C, 2005, J GEN VIROL, V86, P7, DOI 10.1099/vir.0.80567-0; Roche S, 2007, SCIENCE, V315, P843, DOI 10.1126/science.1135710; Shannon-Lowe CD, 2006, P NATL ACAD SCI USA, V103, P7065, DOI 10.1073/pnas.0510512103; Shukla D, 2001, J CLIN INVEST, V108, P503, DOI 10.1172/JCI13799; Spillmann D, 2001, BIOCHIMIE, V83, P811, DOI 10.1016/S0300-9084(01)01290-1; Stevenson PG, 2002, NAT IMMUNOL, V3, P733, DOI 10.1038/ni818; SUNILCHANDRA NP, 1992, J GEN VIROL, V73, P2347, DOI 10.1099/0022-1317-73-9-2347; TRYBALA E, 1993, J VIROL, V67, P1278, DOI 10.1128/JVI.67.3.1278-1285.1993; Turk SM, 2006, J VIROL, V80, P9628, DOI 10.1128/JVI.00622-06; Wadstrom T, 1999, J MED MICROBIOL, V48, P223, DOI 10.1099/00222615-48-3-223	32	27	27	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2008	3	2							e1669	10.1371/journal.pone.0001669	http://dx.doi.org/10.1371/journal.pone.0001669			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XS	18301747	Green Submitted, Green Published, gold			2022-12-25	WOS:000260586500014
J	Sandin, SA; Smith, JE; DeMartini, EE; Dinsdale, EA; Donner, SD; Friedlander, AM; Konotchick, T; Malay, M; Maragos, JE; Obura, D; Pantos, O; Paulay, G; Richie, M; Rohwer, F; Schroeder, RE; Walsh, S; Jackson, JBC; Knowlton, N; Sala, E				Sandin, Stuart A.; Smith, Jennifer E.; DeMartini, Edward E.; Dinsdale, Elizabeth A.; Donner, Simon D.; Friedlander, Alan M.; Konotchick, Talina; Malay, Machel; Maragos, James E.; Obura, David; Pantos, Olga; Paulay, Gustav; Richie, Morgan; Rohwer, Forest; Schroeder, Robert E.; Walsh, Sheila; Jackson, Jeremy B. C.; Knowlton, Nancy; Sala, Enric			Baselines and Degradation of Coral Reefs in the Northern Line Islands	PLOS ONE			English	Article							BIODIVERSITY LOSS; BIOMASS; ECOSYSTEM; COMMUNITIES; IMPACTS; DECLINE; FISHES; COVER; TRAJECTORIES; PRODUCTIVITY	Effective conservation requires rigorous baselines of pristine conditions to assess the impacts of human activities and to evaluate the efficacy of management. Most coral reefs are moderately to severely degraded by local human activities such as fishing and pollution as well as global change, hence it is difficult to separate local from global effects. To this end, we surveyed coral reefs on uninhabited atolls in the northern Line Islands to provide a baseline of reef community structure, and on increasingly populated atolls to document changes associated with human activities. We found that top predators and reef-building organisms dominated unpopulated Kingman and Palmyra, while small planktivorous fishes and fleshy algae dominated the populated atolls of Tabuaeran and Kiritimati. Sharks and other top predators overwhelmed the fish assemblages on Kingman and Palmyra so that the biomass pyramid was inverted (top-heavy). In contrast, the biomass pyramid at Tabuaeran and Kiritimati exhibited the typical bottom-heavy pattern. Reefs without people exhibited less coral disease and greater coral recruitment relative to more inhabited reefs. Thus, protection from overfishing and pollution appears to increase the resilience of reef ecosystems to the effects of global warming.	[Sandin, Stuart A.; Konotchick, Talina; Richie, Morgan; Walsh, Sheila; Jackson, Jeremy B. C.; Knowlton, Nancy; Sala, Enric] Scripps Inst Oceanog, Ctr Marine Biodivers & Conservat, La Jolla, CA USA; [Smith, Jennifer E.] Univ Calif Santa Barbara, National Ctr Ecol Anal & Synthesis, Santa Barbara, CA USA; [DeMartini, Edward E.] Pacific Islands Fisheries Sci Ctr, NOAA, Honolulu, HI USA; [Dinsdale, Elizabeth A.; Pantos, Olga; Rohwer, Forest] San Diego State Univ, Dept Biol, San Diego, CA USA; [Donner, Simon D.] Princeton Univ, Woodrow Wilson Sch, Princeton, NJ USA; [Friedlander, Alan M.] Ocean Inst, Natl Ctr Coastal Ocean Sci Biogeography Team, NOAA, Waimanalo, HI USA; [Malay, Machel; Paulay, Gustav] Univ Florida, Florida Museum Natural History, Gainesville, FL USA; [Maragos, James E.] US Fish & Wildlife Serv, Pacific Remote Islands, Natl Wildlife Refuge Complex, Honolulu, HI USA; [Obura, David] CORDIO East Africa, Mombasa, Kenya; [Schroeder, Robert E.] NOAA, Joint Inst Marine & Atmospheric Res, Pacific Islands Fisheries Sci Ctr, Honolulu, HI USA; [Jackson, Jeremy B. C.; Knowlton, Nancy] Smithsonian Trop Res Inst, Balboa, Panama; [Sala, Enric] CSIC, Ctr dEstudis Avancats Blanes, Blanes, Spain	University of California System; University of California San Diego; Scripps Institution of Oceanography; National Center for Ecological Analysis & Synthesis; University of California System; University of California Santa Barbara; National Oceanic Atmospheric Admin (NOAA) - USA; California State University System; San Diego State University; Princeton University; National Oceanic Atmospheric Admin (NOAA) - USA; State University System of Florida; University of Florida; United States Department of the Interior; US Fish & Wildlife Service; National Oceanic Atmospheric Admin (NOAA) - USA; Smithsonian Institution; Smithsonian Tropical Research Institute; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centre d'Estudis Avancats de Blanes (CEAB)	Sandin, SA (corresponding author), Scripps Inst Oceanog, Ctr Marine Biodivers & Conservat, La Jolla, CA USA.	esala@ucsd.edu	Rohwer, Forest/AAC-5315-2019; Smith, Jennifer/E-5207-2013; Malay, Maria Celia/ABF-2001-2020	Malay, Maria Celia/0000-0003-0219-4788; dinsdale, elizabeth/0000-0002-2177-203X; Obura, David/0000-0003-2256-6649; Rohwer, Forest/0000-0003-1548-5429	Moore Family Foundation; Gordon and Betty Moore Foundation; Fairweather Foundation; National Geographic Society; Marine Managed Areas Science Project of Conservation International; Scripps Institution of Oceanography	Moore Family Foundation; Gordon and Betty Moore Foundation(Gordon and Betty Moore Foundation); Fairweather Foundation; National Geographic Society(National Geographic Society); Marine Managed Areas Science Project of Conservation International; Scripps Institution of Oceanography(University of California System)	This research was supported by the Moore Family Foundation, the Gordon and Betty Moore Foundation, the Fairweather Foundation, National Geographic Society, the Marine Managed Areas Science Project of Conservation International, Scripps Institution of Oceanography, E. Scripps, I. Gayler, and several private donors.	Anderson MJ, 2001, AUSTRAL ECOL, V26, P32, DOI 10.1046/j.1442-9993.2001.01070.x; [Anonymous], 1988, P 6 INT CORAL REEF S; Ballantyne F, 2004, J THEOR BIOL, V226, P349, DOI 10.1016/j.jtbi.2003.09.013; Bascompte J, 2005, P NATL ACAD SCI USA, V102, P5443, DOI 10.1073/pnas.0501562102; Behrenfeld MJ, 2006, NATURE, V442, P1025, DOI 10.1038/nature05083; Birkeland C, 2004, BIOSCIENCE, V54, P1021, DOI 10.1641/0006-3568(2004)054[1021:RDTCR]2.0.CO;2; BRAINARD R, 2005, STATE CORAL REEF ECO, P338; Brown Barbara, 1997, P65; Brown JH, 2004, ECOLOGY, V85, P1771, DOI 10.1890/03-9000; Bruno JF, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000711; Byrnes JE, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000295; Castellan NJ, 1988, NONPARAMETRIC STAT B; Christensen NL, 1996, ECOL APPL, V6, P665, DOI 10.2307/2269460; CONNELL JH, 1978, SCIENCE, V199, P1302, DOI 10.1126/science.199.4335.1302; Corbett DR, 1999, LIMNOL OCEANOGR, V44, P1045, DOI 10.4319/lo.1999.44.4.1045; Dayton PK, 1998, ECOL APPL, V8, P309, DOI 10.1890/1051-0761(1998)008[0309:SBGARE]2.0.CO;2; Duffy JE, 2003, ECOL LETT, V6, P680, DOI 10.1046/j.1461-0248.2003.00494.x; Dulvy NK, 2004, ECOL LETT, V7, P410, DOI 10.1111/j.1461-0248.2004.00593.x; Edinger EN, 1998, MAR POLLUT BULL, V36, P617, DOI 10.1016/S0025-326X(98)00047-2; Evans SL, 2006, HYDROBIOLOGIA, V569, P151, DOI 10.1007/s10750-006-0129-9; FARRELL A, 1928, J CAMERONS ODYSSEY; FRIEDLANDER A, 1997, ECOLOGICAL SURVEYS C; Friedlander AM, 2002, MAR ECOL PROG SER, V230, P253, DOI 10.3354/meps230253; FROESE R, 2007, FISHBASE; Gardner TA, 2003, SCIENCE, V301, P958, DOI 10.1126/science.1086050; GLYNN PW, 1993, CORAL REEFS, V12, P1, DOI 10.1007/BF00303779; Graham NAJ, 2006, P NATL ACAD SCI USA, V103, P8425, DOI 10.1073/pnas.0600693103; Graham NAJ, 2007, ENVIRON BIOL FISH, V78, P57, DOI 10.1007/s10641-006-9077-5; GRIGG RW, 1974, ECOLOGY, V55, P387, DOI 10.2307/1935226; GRIGGS R A, 1984, Current Psychological Research and Reviews, V3, P3, DOI 10.1007/BF02686552; Hoegh-Guldberg O, 2004, SYMBIOSIS, V37, P1; HOLMHANSEN O, 1978, OIKOS, V30, P438, DOI 10.2307/3543338; Jackson JBC, 2001, SCIENCE, V293, P629, DOI 10.1126/science.1059199; Jennings S, 1998, ADV MAR BIOL, V34, P201, DOI 10.1016/S0065-2881(08)60212-6; Jennings S, 1997, CORAL REEFS, V16, P71, DOI 10.1007/s003380050061; Jones GP, 2004, P NATL ACAD SCI USA, V101, P8251, DOI 10.1073/pnas.0401277101; Kulbicki M, 2005, CYBIUM, V29, P235; Lapointe BE, 1997, LIMNOL OCEANOGR, V42, P1119, DOI 10.4319/lo.1997.42.5_part_2.1119; Legendre P., 1998, NUMERICAL ECOLOGY, V24; MAC ARTHUR ROBERT H., 1967; MARAGOS JE, 1997, ECOLOGICAL SURVEYS C; McClanahan T, 2002, CONSERV ECOL, V6; McClanahan TR, 2007, MAR ECOL PROG SER, V337, P1, DOI 10.3354/meps337001; McClanahan TR, 2007, ECOL APPL, V17, P1055, DOI 10.1890/06-1450; McClanahan TR, 2005, MAR ECOL PROG SER, V294, P241, DOI 10.3354/meps294241; McClanahan TR, 1999, BIOL CONSERV, V89, P161, DOI 10.1016/S0006-3207(98)00123-2; Moore MM, 1999, ECOL APPL, V9, P1266, DOI 10.1890/1051-0761(1999)009[1266:RCAERA]2.0.CO;2; Mumby PJ, 2006, SCIENCE, V311, P98, DOI 10.1126/science.1121129; Myers RA, 2003, NATURE, V423, P280, DOI 10.1038/nature01610; Myers RA, 2007, SCIENCE, V315, P1846, DOI 10.1126/science.1138657; Newman MJH, 2006, ECOL LETT, V9, P1216, DOI 10.1111/j.1461-0248.2006.00976.x; ODUM E. P, 1959, FUNDAMENTALS ECOLOGY; ODUM HT, 1955, ECOL MONOGR, V25, P291, DOI 10.2307/1943285; Pandolfi JM, 2003, SCIENCE, V301, P955, DOI 10.1126/science.1085706; Pauly D, 1998, SCIENCE, V279, P860, DOI 10.1126/science.279.5352.860; POLOVINA JJ, 1984, CORAL REEFS, V3, P1, DOI 10.1007/BF00306135; Preskitt Linda B., 2004, Pacific Science, V58, P201, DOI 10.1353/psc.2004.0021; PRESTON FW, 1962, ECOLOGY, V43, P185, DOI 10.2307/1931976; RICKER WE, 1946, ECOL MONOGR, V16, P373, DOI 10.2307/1961642; Stevenson C, 2007, CORAL REEFS, V26, P47, DOI 10.1007/s00338-006-0158-x; Swetnam TW, 1999, ECOL APPL, V9, P1189, DOI 10.1890/1051-0761(1999)009[1189:AHEUTP]2.0.CO;2; Tittensor DP, 2007, ECOL LETT, V10, P760, DOI 10.1111/j.1461-0248.2007.01076.x; Vitousek PM, 1997, ECOL APPL, V7, P737, DOI 10.2307/2269431; WILLIAMS DM, 1983, MAR ECOL PROG SER, V10, P239, DOI 10.3354/meps010239; Williams ID, 2001, MAR ECOL PROG SER, V222, P187, DOI 10.3354/meps222187; Williams ID, 2001, CORAL REEFS, V19, P358, DOI 10.1007/s003380000121; Willis BL, 2004, CORAL HEALTH AND DISEASE, P69; Wilmers CC, 2005, PLOS BIOL, V3, P571, DOI 10.1371/journal.pbio.0030092; Wilson SK, 2006, GLOBAL CHANGE BIOL, V12, P2220, DOI 10.1111/j.1365-2486.2006.01252.x; Worm B, 2006, SCIENCE, V314, P787, DOI 10.1126/science.1132294; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	79	647	661	3	347	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2008	3	2							e1548	10.1371/journal.pone.0001548	http://dx.doi.org/10.1371/journal.pone.0001548			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XS	18301734	Green Published, gold, Green Submitted			2022-12-25	WOS:000260586500001
J	Kawa, S; Kitahara, K; Hamano, H; Ozaki, Y; Arakura, N; Yoshizawa, K; Umemura, T; Ota, M; Mizoguchi, S; Shimozuru, Y; Bahram, S				Kawa, Shigeyuki; Kitahara, Kei; Hamano, Hideaki; Ozaki, Yayoi; Arakura, Norikazu; Yoshizawa, Kaname; Umemura, Takeji; Ota, Masao; Mizoguchi, Sadaaki; Shimozuru, Yasunori; Bahram, Seiamak			A Novel Immunoglobulin-Immunoglobulin Interaction in Autoimmunity	PLOS ONE			English	Article								Well over six decades since its first description, the Rheumatoid Factor (RF)-autoantibodies recognizing Fc (constant) portion of IgG through their own Fab (antigen binding variable segments)-is believed to have come of age. Autoimmune pancreatitis is a unique form of pancreatitis, biologically characterized by an elevated serum IgG4 concentration. Given the fact that IgG4 myeloma proteins can act as RF, we initially hypothesized that IgG4 in autoimmune pancreatitis might do likewise, hence potentially contributing to disease pathogenesis. Indeed Western blotting clearly showed that IgG4 binds to IgG1 kappa, IgG2 kappa, IgG3 kappa myeloma proteins, as well as to IgG Fc, in line with a typical RF activity. Further experiments however unraveled the unexpected fact that unlike hitherto known RF, IgG4 does not engage IgG Fc through its Fab, but its very own Fc. These data therefore collectively describe a Novel RF (NRF) in autoimmune pancreatitis. In the future, the relevance of NRF, beyond autoimmune pancreatitis, in both diagnosis/prognosis as well as pathophysiology of autoimmune and other systemic diseases where IgG4's role seems paramount, needs to be systematically assessed.	[Kawa, Shigeyuki] Shinshu Univ, Ctr Hlth Safety & Environm Management, Matsumoto, Nagano 390, Japan; [Kitahara, Kei; Hamano, Hideaki; Ozaki, Yayoi; Arakura, Norikazu; Yoshizawa, Kaname; Umemura, Takeji] Shinshu Univ, Dept Med, Sch Med, Matsumoto, Nagano 390, Japan; [Ota, Masao] Shinshu Univ, Dept Legal Med, Sch Med, Matsumoto, Nagano 390, Japan; [Mizoguchi, Sadaaki; Shimozuru, Yasunori] Eisai & Co Ltd, Tsukuba Res Labs, Tsukuba, Ibaraki, Japan; [Bahram, Seiamak] Hop Univ Strasbourg, Lab Cent Immunol, Strasbourg, France; [Bahram, Seiamak] Ctr Rech Immunol & Hematol, Strasbourg, France	Shinshu University; Shinshu University; Shinshu University; Eisai Co Ltd; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Kawa, S (corresponding author), Shinshu Univ, Ctr Hlth Safety & Environm Management, Matsumoto, Nagano 390, Japan.	skawapc@hsp.md.shinshu-u.ac.jp; siamak@hemato-ulp.u-strasbg.fr	Bahram, Seiamak/GZA-7150-2022	Umemura, Takeji/0000-0001-7985-919X; Bahram, Seiamak/0000-0002-6928-9952	Ministry of Education, Science, Sports and Culture of Japan [12670471, 13557047, 15659167, 16390205]; Japan Health Sciences Foundation [KH21022]; Research on Specific Diseases, Health and Labour Sciences Research Grant, Japan	Ministry of Education, Science, Sports and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Health Sciences Foundation; Research on Specific Diseases, Health and Labour Sciences Research Grant, Japan	This work was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan (12670471, 13557047, 15659167 and 16390205) and from the Japan Health Sciences Foundation (KH21022), and by a Research on Specific Diseases, Health and Labour Sciences Research Grant, Japan. Seiamak Bahram's laboratory is supported by the Hopitaux Universitaires de Strasbourg, the Association Francaise du Gougerot Sjogren et des syndromes secs, the Ligue contre le Cancer, the Association pour la recherche sur le Cancer (ARC), the Agence de Biomedecine and the Agence Nationale de la Recherche (ANR).	AALBERSE RC, 1993, ALLERGY, V48, P559, DOI 10.1111/j.1398-9995.1993.tb00749.x; Aalberse RC, 2002, IMMUNOLOGY, V105, P9, DOI 10.1046/j.0019-2805.2001.01341.x; Abraham SC, 2003, AM J SURG PATHOL, V27, P110, DOI 10.1097/00000478-200301000-00012; Asada M, 2006, PANCREAS, V33, P20, DOI 10.1097/01.mpa.0000226881.48204.fd; COHEN PL, 1987, J IMMUNOL, V139, P1466; Davidson A, 2001, NEW ENGL J MED, V345, P340, DOI 10.1056/NEJM200108023450506; Detrick B, 2006, MANUAL OF MOLECULAR AND CLINICAL LABORATORY IMMUNOLOGY, 7TH EDITION, pXXV; Dorner T, 2004, CURR OPIN RHEUMATOL, V16, P246; Erkelens GW, 1999, LANCET, V354, P43, DOI 10.1016/S0140-6736(99)00603-0; Finkelberg DL, 2006, NEW ENGL J MED, V355, P2670, DOI 10.1056/NEJMra061200; Fujii H, 2003, KIDNEY INT, V64, P1662, DOI 10.1046/j.1523-1755.2003.00252.x; Goodnow CC, 2007, CELL, V130, P25, DOI 10.1016/j.cell.2007.06.033; Hamano H, 2002, LANCET, V359, P1403, DOI 10.1016/S0140-6736(02)08359-9; Hamano H, 2001, NEW ENGL J MED, V344, P732, DOI 10.1056/NEJM200103083441005; Hennig C, 2000, LANCET, V355, P1617, DOI 10.1016/S0140-6736(00)02223-6; Horiuchi A, 1998, AM J GASTROENTEROL, V93, P260, DOI 10.1016/S0002-9270(97)00067-1; Horiuchi A, 2002, GASTROINTEST ENDOSC, V55, P494, DOI 10.1067/mge.2002.122653; Kamisawa T, 2003, GUT, V52, P683, DOI 10.1136/gut.52.5.683; Kawa S, 2002, GASTROENTEROLOGY, V122, P1264, DOI 10.1053/gast.2002.33022; KAWAGUCHI K, 1991, HUM PATHOL, V22, P387, DOI 10.1016/0046-8177(91)90087-6; Kolfschoten MV, 2007, SCIENCE, V317, P1554, DOI 10.1126/science.1144603; Komatsu K, 2005, DIGEST DIS SCI, V50, P1052, DOI 10.1007/s10620-005-2703-9; Muraki T, 2006, PANCREAS, V32, P16, DOI 10.1097/01.mpa.0000188308.75043.e4; NISONOFF A, 1960, ARCH BIOCHEM BIOPHYS, V88, P241, DOI 10.1016/0003-9861(60)90229-0; Njoku DB, 2006, CLIN VACCINE IMMUNOL, V13, P258, DOI 10.1128/CVI.13.2.258-265.2006; Okazaki K, 2000, GASTROENTEROLOGY, V118, P573, DOI 10.1016/S0016-5085(00)70264-2; Okazaki K, 2006, J GASTROENTEROL, V41, P626, DOI 10.1007/s00535-006-1868-0; Oliveira DBG, 1998, LANCET, V351, P670, DOI 10.1016/S0140-6736(97)04122-6; Ota M, 2007, IMMUNOGENETICS, V59, P45, DOI 10.1007/s00251-006-0178-2; OTTESEN EA, 1985, J IMMUNOL, V134, P2707; Pickartz T, 2007, NAT CLIN PRACT GASTR, V4, P314, DOI 10.1038/ncpgasthep0837; PIKE RM, 1949, J IMMUNOL, V63, P447; PORTER RR, 1959, BIOCHEM J, V73, P119, DOI 10.1042/bj0730119; ROCK B, 1989, NEW ENGL J MED, V320, P1463, DOI 10.1056/NEJM198906013202206; ROSE HM, 1948, P SOC EXP BIOL MED, V68, P1; Saegusa H, 2003, PANCREAS, V27, P20, DOI 10.1097/00006676-200307000-00003; Stanley JR, 2006, NEW ENGL J MED, V355, P1800, DOI 10.1056/NEJMra061111; Sutton B, 2000, IMMUNOL TODAY, V21, P177, DOI 10.1016/S0167-5699(00)01589-9; Takeda S, 2004, NEPHROL DIAL TRANSPL, V19, P474, DOI 10.1093/ndt/gfg477; Umemura T, 2006, GUT, V55, P1367, DOI 10.1136/gut.2006.095059; van der Vliet HJJ, 2004, ANN INTERN MED, V141, P896, DOI 10.7326/0003-4819-141-11-200412070-00033; Waaler E, 1940, ACTA PATHOL MIC SC, V17, P172, DOI DOI 10.1111/J.1699-0463.1940.TB01475.X; YOSHIDA K, 1995, DIGEST DIS SCI, V40, P1561, DOI 10.1007/BF02285209; Yoshimura Y, 2006, INTERNAL MED, V45, P897, DOI 10.2169/internalmedicine.45.1752; ZACK DJ, 1995, J IMMUNOL, V155, P5057	45	70	83	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1637	10.1371/journal.pone.0001637	http://dx.doi.org/10.1371/journal.pone.0001637			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18297131	gold, Green Published, Green Submitted			2022-12-25	WOS:000260586400030
J	He, X; Han, B; Mura, M; Li, L; Cypel, M; Soderman, A; Picha, K; Yang, J; Liu, MY				He, Xiaolin; Han, Bing; Mura, Marco; Li, Li; Cypel, Marcelo; Soderman, Avery; Picha, Kristen; Yang, Jing; Liu, Mingyao			Anti-Human Tissue Factor Antibody Ameliorated Intestinal Ischemia Reperfusion-Induced Acute Lung Injury in Human Tissue Factor Knock-In Mice	PLOS ONE			English	Article								Interaction between the coagulation and inflammation systems plays an important role in the development of acute respiratory distress syndrome ( ARDS). Anti-coagulation is an attractive option for ARDS treatment, and this has promoted development of new antibodies. However, preclinical trials for these antibodies are often limited by the high cost and availability of non-human primates. In the present study, we developed a novel alternative method to test the role of a humanized anti-tissue factor mAb in acute lung injury with transgenic mice. Methodology/Principal Findings. Human tissue factor knock-in (hTF-KI) transgenic mice and a novel humanized anti-human tissue factor mAb (anti-hTF mAb, CNTO859) were developed. The hTF-KI mice showed a normal and functional expression of hTF. The anti-hTF mAb specifically blocked the pro-coagulation activity of brain extracts from the hTF-KI mice and human, but not from wild type mice. An extrapulmonary ARDS model was used by intestinal ischemia-reperfusion. Significant lung tissue damage in hTF-KI mice was observed after 2 h reperfusion. Administration of CNTO859 (5 mg/kg, i.v.) attenuated the severity of lung tissue injury, decreased the total cell counts and protein concentration in bronchoalveolar lavage fluid, and reduced Evans blue leakage. In addition, the treatment significantly reduced alveolar fibrin deposition, and decreased tissue factor and plasminogen activator inhibitor-1 activity in the serum. This treatment also down-regulated cytokine expression and reduced cell death in the lung. Conclusions. This novel anti-hTF antibody showed beneficial effects on intestinal ischemia-reperfusion induced acute lung injury, which merits further investigation for clinical usage. In addition, the use of knock-in transgenic mice to test the efficacy of antibodies against human-specific proteins is a novel strategy for preclinical studies.	[He, Xiaolin; Han, Bing; Mura, Marco; Cypel, Marcelo; Liu, Mingyao] Univ Toronto, Univ Hlth Network Toronto, Gen Res Inst, Dept Surg,Latner Thorac Surg Res Labs, Toronto, ON, Canada; [Li, Li] Therakos, Exton, PA USA; [Soderman, Avery; Picha, Kristen; Yang, Jing] Centocor Inc, Malvern, PA USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc	Liu, MY (corresponding author), Univ Toronto, Univ Hlth Network Toronto, Gen Res Inst, Dept Surg,Latner Thorac Surg Res Labs, Toronto, ON, Canada.	mingyao.liu@utoronto.ca	Mura, Marco/G-5729-2013	Mura, Marco/0000-0002-2159-7083; Liu, Mingyao/0000-0002-9188-8417; Li, Li/0000-0001-9844-7692; Cypel, Marcelo/0000-0001-5652-1938	Canadian Institutes of Health Research [MOP-13270, MOP-42546]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This work was funded by Canadian Institutes of Health Research Grants MOP-13270 and MOP-42546.	Abraham E, 2000, AM J RESP CELL MOL, V22, P401, DOI 10.1165/ajrcmb.22.4.f184; Bastarache JA, 2007, THORAX, V62, P608, DOI 10.1136/thx.2006.063305; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; Carraway MS, 2003, AM J RESP CRIT CARE, V167, P1200, DOI 10.1164/rccm.200204-287OC; Cho HY, 2002, AM J RESP CELL MOL, V26, P42, DOI 10.1165/ajrcmb.26.1.4536; Choi G, 2006, ANESTHESIOLOGY, V105, P689, DOI 10.1097/00000542-200610000-00013; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Fang CH, 1996, THROMB HAEMOSTASIS, V76, P361; Fischer S, 2000, ANN SURG, V231, P424, DOI 10.1097/00000658-200003000-00016; He XL, 2007, SHOCK, V28, P106, DOI 10.1097/SHK.0b013e3180310f3a; Levi M, 2004, CIRCULATION, V109, P2698, DOI 10.1161/01.CIR.0000131660.51520.9A; Liu MY, 2005, AM J RESP CRIT CARE, V171, P298, DOI 10.1164/rccm.2412002; Luther T, 1996, AM J PATHOL, V149, P101; MORRISSEY JH, 1995, THROMB HAEMOSTASIS, V74, P185; Muller AM, 2002, RESPIRATION, V69, P526, DOI 10.1159/000066471; Mura M, 2004, J APPL PHYSIOL, V97, P1605, DOI 10.1152/japplphysiol.00202.2004; Mura M, 2007, SHOCK, V28, P227, DOI 10.1097/SHK.0b013e318033e927; Mura M, 2006, CRIT CARE, V10, DOI 10.1186/cc5042; Ngo CV, 2007, INT J CANCER, V120, P1261, DOI 10.1002/ijc.22426; Okutani D, 2006, AM J PHYSIOL-LUNG C, V291, pL129, DOI 10.1152/ajplung.00261.2005; OLSEN EGJ, 1975, LAB INVEST, V32, P323; Oltrona L, 1997, CIRCULATION, V96, P646; Pawlinski R, 2004, BLOOD, V103, P1342, DOI 10.1182/blood-2003-09-3051; Petersen LC, 2005, THROMB RES, V116, P75, DOI 10.1016/j.thromres.2004.11.003; Pusztaszeri MP, 2006, J HISTOCHEM CYTOCHEM, V54, P385, DOI 10.1369/jhc.4A6514.2005; Quadri SM, 2005, AM J TRANSPLANT, V5, P292, DOI 10.1111/j.1600-6143.2004.00701.x; Riewald M, 2001, P NATL ACAD SCI USA, V98, P7742, DOI 10.1073/pnas.141126698; Rijneveld AW, 2006, CRIT CARE MED, V34, P1725, DOI 10.1097/01.CCM.0000218807.20570.C2; Schultz MJ, 2004, THORAX, V59, P130, DOI 10.1136/thorax.2003.013888; Schultz MJ, 2006, CRIT CARE MED, V34, P871, DOI 10.1097/01.CCM.0000202136.91651.34; Siegbahn A, 2005, THROMB HAEMOSTASIS, V93, P27, DOI 10.1160/TH04-07-0405; SNYDER LA, 2007, J THROMB HAEMOST; Tang PS, 2006, J CELL PHYSIOL, V209, P457, DOI 10.1002/jcp.20751; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Ware LB, 2006, AM J PHYSIOL-LUNG C, V291, pL307, DOI 10.1152/ajplung.00157.2006; Welty-Wolf KE, 2001, AM J RESP CRIT CARE, V164, P1988, DOI 10.1164/ajrccm.164.10.2105027; Welty-Wolf KE, 2006, AM J PHYSIOL-LUNG C, V290, pL21, DOI 10.1152/ajplung.00155.2005; Xu J, 2007, J BIOL CHEM, V282, P16401, DOI 10.1074/jbc.M701684200	40	25	26	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1527	10.1371/journal.pone.0001527	http://dx.doi.org/10.1371/journal.pone.0001527			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SR	18231608	gold, Green Published, Green Submitted			2022-12-25	WOS:000260504200035
J	Lynnerup, N; Kjeldsen, H; Heegaard, S; Jacobsen, C; Heinemeier, J				Lynnerup, Niels; Kjeldsen, Henrik; Heegaard, Steffen; Jacobsen, Christina; Heinemeier, Jan			Radiocarbon Dating of the Human Eye Lens Crystallines Reveal Proteins without Carbon Turnover throughout Life	PLOS ONE			English	Article								Lens crystallines are special proteins in the eye lens. Because the epithelial basement membrane (lens capsule) completely encloses the lens, desquamation of aging cells is impossible, and due to the complete absence of blood vessels or transport of metabolites in this area, there is no subsequent remodelling of these fibers, nor removal of degraded lens fibers. Human tissue ultimately derives its C-14 content from the atmospheric carbon dioxide. The C-14 content of the lens proteins thus reflects the atmospheric content of C-14 when the lens crystallines were formed. Precise radiocarbon dating is made possible by comparing the C-14 content of the lens crystallines to the so-called bomb pulse, i.e. a plot of the atmospheric C-14 content since the Second World War, when there was a significant increase due to nuclear-bomb testing. Since the change in concentration is significant even on a yearly basis this allows very accurate dating. Methodology/Principal Findings. Our results allow us to conclude that the crystalline formation in the lens nucleus almost entirely takes place around the time of birth, with a very small, and decreasing, continuous formation throughout life. The close relationship may be further expressed as a mathematical model, which takes into account the timing of the crystalline formation. Conclusions/Significance. Such a lifelong permanence of human tissue has hitherto only been described for dental enamel. In confront to dental enamel it must be held in mind that the eye lens is a soft structure, subjected to almost continuous deformation, due to lens accommodation, yet its most important constituent, the lens crystalline, is never subject to turnover or remodelling once formed. The determination of the C-14 content of various tissues may be used to assess turnover rates and degree of substitution (for example for brain cell DNA). Potential targets may be nervous tissues in terms of senile or pre-senile degradation, as well as other highly specialised structures of the eyes. The precision with which the year of birth may be calculated points to forensic uses of this technique.	[Lynnerup, Niels; Jacobsen, Christina] Univ Copenhagen, Dept Forens Med, Copenhagen, Denmark; [Kjeldsen, Henrik; Heinemeier, Jan] Univ Aarhus, Dept Phys & Anat, AMS 14C Dating Ctr, Aarhus, Denmark; [Heegaard, Steffen] Univ Copenhagen, Dept Neurosci & Pharmacol, Eye Pathol Sect, Copenhagen, Denmark	University of Copenhagen; Aarhus University; University of Copenhagen	Lynnerup, N (corresponding author), Univ Copenhagen, Dept Forens Med, Copenhagen, Denmark.	n.lynnerup@antrolab.ku.dk		Jacobsen, Christina/0000-0001-7257-0772	Danish Medical Association Fund	Danish Medical Association Fund	The Danish Medical Association Fund (private non-commercial foundation)	BEBE DC, 2003, ST LOUIS ADLERS PHYS, P117; Cook GT, 2006, RADIOCARBON, V48, P305, DOI 10.1017/S0033822200038765; DEVRIES H, 1958, SCIENCE, V128, P1550, DOI 10.1126/science.128.3338.1550; Goodsite ME, 2001, RADIOCARBON, V43, P495; Kueppers LM, 2004, OECOLOGIA, V141, P641, DOI 10.1007/s00442-004-1689-x; Levin I, 2004, RADIOCARBON, V46, P1261, DOI 10.1017/S0033822200033130; Pau H, 2006, OPHTHALMOLOGICA, V220, P1, DOI 10.1159/000089267; Ramsey CB, 2001, RADIOCARBON, V43, P355; Ramsey CB, 1995, RADIOCARBON, V37, P425, DOI 10.1017/S0033822200030903; SMEETS MH, 1993, BIOCHIM BIOPHYS ACTA, V1164, P236, DOI 10.1016/0167-4838(93)90254-O; Spalding KL, 2005, NATURE, V437, P333, DOI 10.1038/437333a; Spalding KL, 2005, CELL, V122, P133, DOI 10.1016/j.cell.2005.04.028	12	161	163	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1529	10.1371/journal.pone.0001529	http://dx.doi.org/10.1371/journal.pone.0001529			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SR	18231610	Green Published, Green Submitted, gold			2022-12-25	WOS:000260504200037
J	Gottlieb, Y; Ghanim, M; Gueguen, G; Kontsedalov, S; Vavre, F; Fleury, F; Zchori-Fein, E				Gottlieb, Yuval; Ghanim, Murad; Gueguen, Gwenaelle; Kontsedalov, Svetlana; Vavre, Fabrice; Fleury, Frederic; Zchori-Fein, Einat			Inherited intracellular ecosystem: symbiotic bacteria share bacteriocytes in whiteflies	FASEB JOURNAL			English	Article						Bemisia tabaci; fluorescent in situ hybridization; spatial distribution; vertical transmission	BEMISIA-TABACI HOMOPTERA; EVOLUTIONARY RELATIONSHIPS; ENDOSYMBIOTIC BACTERIA; SCAPHOIDEUS-TITANUS; SECONDARY SYMBIONT; PEA APHID; WOLBACHIA; HEMIPTERA; PARTHENOGENESIS; ULTRASTRUCTURE	Symbiotic relationships with bacteria are common within the Arthropoda, with interactions that substantially influence the biology of both partners. The symbionts' spatial distribution is essential for understanding key aspects of this relationship, such as bacterial transmission, phenotype, and dynamics. In this study, fluorescence in situ hybridization was used to localize five secondary symbionts from various populations and biotypes of the sweet potato whitefly Bemisia tabaci: Hamiltonella, Arsenophonus, Cardinium, Wolbachia, and Rickettsia. All five symbionts were found to be located with the primary symbiont Portiera inside the bacteriocytes-cells specifically modified to house bacteria-but within these cells, they occupied various niches. The intrabacteriocyte distribution pattern of Rickettsia differed from what has been described previously. Cardinium and Wolbachia were found in other host tissues as well. Because all symbionts share the same cell, bacteriocytes in B. tabaci represent a unique intracellular ecosystem. This phenomenon may be a result of the direct enclosure of the bacteriocyte in the egg during oogenesis, providing a useful mechanism for efficient vertical transmission by "hitching a ride" with Portiera. On the other hand, cohabitation in the same cell provides ample opportunities for interactions among symbionts that can either facilitate (cooperation) or limit (warfare) symbiotic existence.	[Gottlieb, Yuval; Ghanim, Murad; Kontsedalov, Svetlana] Agr Res Org, Volcani Ctr, Dept Entomol, IL-50250 Bet Dagan, Israel; [Gueguen, Gwenaelle; Vavre, Fabrice; Fleury, Frederic] Univ Lyon 1, Lab Biometrie & Biol Evolut, CNRS, UMR 5558, F-69622 Villeurbanne, France; [Zchori-Fein, Einat] Agr Res Org, Dept Entomol, Newe Yaar Res Ctr, Ramat Yishay, Israel	VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; VetAgro Sup	Gottlieb, Y (corresponding author), Agr Res Org, Volcani Ctr, Dept Entomol, POB 6, IL-50250 Bet Dagan, Israel.	yuvalgd@yahoo.com	vavre, fabrice/N-2945-2017; Gueguen, Gwenaelle/E-9787-2011; Gottlieb, Yuval/H-6461-2013	vavre, fabrice/0000-0003-0909-2936; 				Anselme C, 2006, APPL ENVIRON MICROB, V72, P6766, DOI 10.1128/AEM.00942-06; Bao SN, 1996, J INVERTEBR PATHOL, V67, P309, DOI 10.1006/jipa.1996.0047; Baumann P, 2005, ANNU REV MICROBIOL, V59, P155, DOI 10.1146/annurev.micro.59.030804.121041; Bigliardi E, 2006, TISSUE CELL, V38, P257, DOI 10.1016/j.tice.2006.06.001; Bordenstein SR, 2005, NAT REV MICROBIOL, V3, P688, DOI 10.1038/nrmicro1233; Braendle C, 2003, PLOS BIOL, V1, P70, DOI 10.1371/journal.pbio.0000021; Buchner P., 1965, ENDOSYMBIOSIS ANIMAL; Chiel E, 2007, B ENTOMOL RES, V97, P407, DOI 10.1017/S0007485307005159; Clark ME, 2002, MECH DEVELOP, V111, P3, DOI 10.1016/S0925-4773(01)00594-9; Costa HS, 1995, PROTOPLASMA, V189, P194, DOI 10.1007/BF01280174; De Barro PJ, 2000, B ENTOMOL RES, V90, P103, DOI 10.1017/S0007485300000201; Everett KDE, 2005, INT J SYST EVOL MICR, V55, P1581, DOI 10.1099/ijs.0.63454-0; Ferree PM, 2005, PLOS PATHOG, V1, P111, DOI 10.1371/journal.ppat.0010014; Ghanim M, 2001, J MORPHOL, V248, P22, DOI 10.1002/jmor.1018; Gomez-Valero L, 2004, J BACTERIOL, V186, P6626, DOI 10.1128/JB.186.19.6626-6633.2004; Gottlieb Y, 2006, APPL ENVIRON MICROB, V72, P3646, DOI 10.1128/AEM.72.5.3646-3652.2006; Heddi A, 2005, CELL MICROBIOL, V7, P293, DOI 10.1111/j.1462-5822.2004.00461.x; Heddi A, 1999, P NATL ACAD SCI USA, V96, P6814, DOI 10.1073/pnas.96.12.6814; HUNTER MS, 2006, INSECT SYMBIOSIS, V2, P39; Hypsa V, 1997, INT J SYST BACTERIOL, V47, P1140, DOI 10.1099/00207713-47-4-1140; Ijichi N, 2002, APPL ENVIRON MICROB, V68, P4074, DOI 10.1128/AEM.68.8.4074-4080.2002; Ishikawa H, 2003, CONT T ENT, P1; Marzorati M, 2006, APPL ENVIRON MICROB, V72, P1467, DOI 10.1128/AEM.72.2.1467-1475.2006; Matalon Y, 2007, J INVERTEBR PATHOL, V96, P106, DOI 10.1016/j.jip.2007.02.010; Miller WJ, 2006, APPL ENVIRON MICROB, V72, P826, DOI 10.1128/AEM.72.1.826-835.2006; Min KT, 1997, P NATL ACAD SCI USA, V94, P10792, DOI 10.1073/pnas.94.20.10792; Mitsuhashi W, 2002, INSECT MOL BIOL, V11, P577, DOI 10.1046/j.1365-2583.2002.00368.x; Moran NA, 2005, P NATL ACAD SCI USA, V102, P16919, DOI 10.1073/pnas.0507029102; Moran NA, 2005, APPL ENVIRON MICROB, V71, P3302, DOI 10.1128/AEM.71.6.3302-3310.2005; Morin S, 1999, VIROLOGY, V256, P75, DOI 10.1006/viro.1999.9631; Oliver KM, 2003, P NATL ACAD SCI USA, V100, P1803, DOI 10.1073/pnas.0335320100; Perlman SJ, 2006, P ROY SOC B-BIOL SCI, V273, P2097, DOI 10.1098/rspb.2006.3541; Perotti MA, 2006, FASEB J, V20, P2372, DOI 10.1096/fj.06-5870fje; Perring TM, 2001, CROP PROT, V20, P725, DOI 10.1016/S0261-2194(01)00109-0; SACCHI L, 2008, TISSUE CELL IN PRESS; Stouthamer R, 1999, ANNU REV MICROBIOL, V53, P71, DOI 10.1146/annurev.micro.53.1.71; Szklarzewicz T, 2001, PROTOPLASMA, V218, P45, DOI 10.1007/BF01288359; Thao ML, 2004, APPL ENVIRON MICROB, V70, P3401, DOI 10.1128/AEM.70.6.3401-3406.2004; Thao MLL, 2004, CURR MICROBIOL, V48, P140, DOI 10.1007/s00284-003-4157-7; Tsuchida T, 2005, MICROB ECOL, V49, P126, DOI 10.1007/s00248-004-0216-2; Tsuchida T, 2002, MOL ECOL, V11, P2123, DOI 10.1046/j.1365-294X.2002.01606.x; Vautrin E, 2008, J EVOLUTION BIOL, V21, P145, DOI 10.1111/j.1420-9101.2007.01460.x; Veneti Z, 2004, APPL ENVIRON MICROB, V70, P5366, DOI 10.1128/AEM.70.9.5366-5372.2004; Weeks AR, 2003, CONT T ENT, P165; Wernegreen JJ, 2004, PLOS BIOL, V2, P307, DOI 10.1371/journal.pbio.0020068; Wu D, 2006, PLOS BIOL, V4, P1079, DOI 10.1371/journal.pbio.0040188; Zchori-Fein E, 2001, P NATL ACAD SCI USA, V98, P12555, DOI 10.1073/pnas.221467498; Zchori-Fein E, 1998, CURR MICROBIOL, V36, P1, DOI 10.1007/s002849900270; Zchori-Fein E, 2002, ANN ENTOMOL SOC AM, V95, P711, DOI 10.1603/0013-8746(2002)095[0711:DOPAWB]2.0.CO;2	49	172	183	2	69	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2591	2599		10.1096/fj.07-101162	http://dx.doi.org/10.1096/fj.07-101162			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18285399				2022-12-25	WOS:000257292500050
J	Bi, S; Earl, LA; Jacobs, L; Baum, LG				Bi, Shuguang; Earl, Lesley A.; Jacobs, Linsey; Baum, Linda G.			Structural features of galectin-9 and galectin-1 that determine distinct T cell death pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; GALACTOSIDE-BINDING LECTIN; THYMIC EPITHELIAL-CELLS; CORE-2 O-GLYCANS; ENDOGENOUS LECTIN; MURINE MODEL; APOPTOSIS; EXPRESSION; ADHESION; GROWTH	The galectin family of lectins regulates multiple biologic functions, such as development, inflammation, immunity, and cancer. One common function of several galectins is the ability to trigger T cell death. However, differences among the death pathways triggered by various galectins with regard to glycoprotein receptors, intracellular death pathways, and target cell specificity are not well understood. Specifically, galectin-9 and galectin-1 both kill thymocytes, peripheral T cells, and T cell lines; however, we have found that galectin-9 and galectin-1 require different glycan ligands and glycoprotein receptors to trigger T cell death. The two galectins also utilize different intracellular death pathways, as galectin-9, but not galectin-1, T cell death was blocked by intracellular Bcl-2, whereas galectin-1, but not galectin-9, T cell death was blocked by intracellular galectin-3. Target cell susceptibility also differed between the two galectins, as galectin-9 and galectin-1 killed different subsets of murine thymocytes. To define structural features responsible for distinct activities of the tandem repeat galectin-9 and dimeric galectin-1, we created a series of bivalent constructs with galectin-9 and galectin-1 carbohydrate recognition domains connected by different peptide linkers. We found that the N-terminal carbohydrate recognition domain and linker peptide contributed to the potency of these constructs. However, we found that the C-terminal carbohydrate recognition domain was the primary determinant of receptor recognition, death pathway signaling, and target cell susceptibility. Thus, carbohydrate recognition domain specificity, presentation, and valency make distinct contributions to the specific effects of different galectins in initiating T cell death.	[Bi, Shuguang; Earl, Lesley A.; Jacobs, Linsey; Baum, Linda G.] Univ Calif Los Angeles, Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Baum, LG (corresponding author), 10833 LeConte Ave, Los Angeles, CA 90095 USA.	lbaum@mednet.ucla.edu			NATIONAL CANCER INSTITUTE [P30CA016042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028697] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063281] Funding Source: NIH RePORTER; NCI NIH HHS [CA-16042] Funding Source: Medline; NIAID NIH HHS [AI28697] Funding Source: Medline; NIGMS NIH HHS [R01 GM63281] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amano M, 2003, J BIOL CHEM, V278, P7469, DOI 10.1074/jbc.M209595200; Bao Q, 1999, GLYCOBIOLOGY, V9, P489, DOI 10.1093/glycob/9.5.489; Battig P, 2004, MOL IMMUNOL, V41, P9, DOI 10.1016/j.molimm.2004.02.004; BAUM LG, 1995, J EXP MED, V181, P877, DOI 10.1084/jem.181.3.877; Cabrera PV, 2006, BLOOD, V108, P2399, DOI 10.1182/blood-2006-04-018556; Camby I, 2006, GLYCOBIOLOGY, V16, p137R, DOI 10.1093/glycob/cwl025; CHO MJ, 1995, J BIOL CHEM, V270, P5198, DOI 10.1074/jbc.270.10.5198; Fukumori T, 2003, CANCER RES, V63, P8302; Fulcher JA, 2006, J IMMUNOL, V177, P216, DOI 10.4049/jimmunol.177.1.216; Galvan M, 2000, J BIOL CHEM, V275, P16730, DOI 10.1074/jbc.M001117200; Garin MI, 2007, BLOOD, V109, P2058, DOI 10.1182/blood-2006-04-016451; Hadari YR, 2000, J CELL SCI, V113, P2385; Hahn HP, 2004, CELL DEATH DIFFER, V11, P1277, DOI 10.1038/sj.cdd.4401485; Hernandez JD, 2002, GLYCOBIOLOGY, V12, p127R, DOI 10.1093/glycob/cwf081; Hernandez JD, 2006, J IMMUNOL, V177, P5328, DOI 10.4049/jimmunol.177.8.5328; Hirabayashi J, 2002, BBA-GEN SUBJECTS, V1572, P232, DOI 10.1016/S0304-4165(02)00311-2; Hirashima M, 2002, GLYCOCONJUGATE J, V19, P593, DOI 10.1023/B:GLYC.0000014090.63206.2f; Hotta K, 2001, J BIOL CHEM, V276, P34089, DOI 10.1074/jbc.M105097200; Hsu DK, 2000, AM J PATHOL, V156, P1073, DOI 10.1016/S0002-9440(10)64975-9; Kashio Y, 2003, J IMMUNOL, V170, P3631, DOI 10.4049/jimmunol.170.7.3631; Katoh S, 2007, AM J RESP CRIT CARE, V176, P27, DOI 10.1164/rccm.200608-1243OC; Kohatsu L, 2006, J IMMUNOL, V177, P4718, DOI 10.4049/jimmunol.177.7.4718; Kuwabara I, 2002, J BIOL CHEM, V277, P3487, DOI 10.1074/jbc.M109360200; LEFFLER H, 1986, J BIOL CHEM, V261, P119; LIAO DI, 1994, P NATL ACAD SCI USA, V91, P1428, DOI 10.1073/pnas.91.4.1428; Liu FT, 2005, NAT REV CANCER, V5, P29, DOI 10.1038/nrc1527; Lopez E, 2006, J IMMUNOL, V176, P1943, DOI 10.4049/jimmunol.176.3.1943; Lu LH, 2007, J BIOCHEM, V141, P157, DOI 10.1093/jb/mvm019; Matsumoto R, 1998, J BIOL CHEM, V273, P16976, DOI 10.1074/jbc.273.27.16976; Miyanishi N, 2007, GLYCOBIOLOGY, V17, P423, DOI 10.1093/glycob/cwm001; Nagae M, 2008, J MOL BIOL, V375, P119, DOI 10.1016/j.jmb.2007.09.060; Nguyen JT, 2001, J IMMUNOL, V167, P5697, DOI 10.4049/jimmunol.167.10.5697; Okudaira T, 2007, INT J CANCER, V120, P2251, DOI 10.1002/ijc.22534; Opferman JT, 2008, CELL DEATH DIFFER, V15, P234, DOI 10.1038/sj.cdd.4402182; Pace KE, 2000, J IMMUNOL, V165, P2331, DOI 10.4049/jimmunol.165.5.2331; Pace KE, 2003, METHOD ENZYMOL, V363, P499; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; Perillo NL, 1997, J EXP MED, V185, P1851, DOI 10.1084/jem.185.10.1851; Rabinovich GA, 2002, GLYCOCONJUGATE J, V19, P565, DOI 10.1023/B:GLYC.0000014087.41914.72; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Rubinstein N, 2004, CANCER CELL, V5, P241, DOI 10.1016/S1535-6108(04)00024-8; Sato M, 2002, GLYCOBIOLOGY, V12, P191, DOI 10.1093/glycob/12.3.191; Spitzenberger F, 2001, BIOCHIMIE, V83, P851, DOI 10.1016/S0300-9084(01)01335-9; Starr TK, 2003, ANNU REV IMMUNOL, V21, P139, DOI 10.1146/annurev.immunol.21.120601.141107; Stillman BN, 2006, J IMMUNOL, V176, P778, DOI 10.4049/jimmunol.176.2.778; Sturm A, 2004, J IMMUNOL, V173, P3825, DOI 10.4049/jimmunol.173.6.3825; Thijssen VLJL, 2006, P NATL ACAD SCI USA, V103, P15975, DOI 10.1073/pnas.0603883103; Toscano MA, 2007, NAT IMMUNOL, V8, P825, DOI 10.1038/ni1482; Tribulatti MV, 2007, GLYCOBIOLOGY, V17, P1404, DOI 10.1093/glycob/cwm104; Tsuboi Y, 2007, CLIN IMMUNOL, V124, P221, DOI 10.1016/j.clim.2007.04.015; Tsuchiyama Y, 2000, KIDNEY INT, V58, P1941, DOI 10.1111/j.1523-1755.2000.00366.x; Tureci O, 1997, J BIOL CHEM, V272, P6416, DOI 10.1074/jbc.272.10.6416; van der Leij J, 2007, MOL IMMUNOL, V44, P506, DOI 10.1016/j.molimm.2006.02.011; Vespa GNR, 1999, J IMMUNOL, V162, P799; Wada J, 1997, J CLIN INVEST, V99, P2452, DOI 10.1172/JCI119429; Walzel H, 2000, GLYCOBIOLOGY, V10, P131, DOI 10.1093/glycob/10.2.131; Walzel H, 2006, GLYCOBIOLOGY, V16, P1262, DOI 10.1093/glycob/cwl037; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; Zhu C, 2005, NAT IMMUNOL, V6, P1245, DOI 10.1038/ni1271; Zhuo LS, 2006, J BIOL CHEM, V281, P20303, DOI 10.1074/jbc.M506703200	61	105	114	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2008	283	18					12248	12258		10.1074/jbc.M800523200	http://dx.doi.org/10.1074/jbc.M800523200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	293MS	18258591	Green Published, hybrid			2022-12-25	WOS:000255340000041
J	Blasiole, DA; Oler, AT; Attie, AD				Blasiole, Daniel A.; Oler, Angie T.; Attie, Alan D.			Regulation of ApoB secretion by the low density lipoprotein receptor requires exit from the endoplasmic reticulum and interaction with ApoE or ApoB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOSOMAL RECESSIVE HYPERCHOLESTEROLEMIA; APOLIPOPROTEIN-B; LDL RECEPTOR; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN-FIBROBLASTS; IN-VIVO; MICE; VLDL; DEGRADATION; PROTEIN	Apolipoprotein B (apoB) is required for the hepatic assembly and secretion of very low density lipoprotein (VLDL). The LDL receptor (LDLR) promotes post-translational degradation of apoB and thereby reduces VLDL particle secretion. We investigated the trafficking pathways and ligand requirements for the LDLR to promote degradation of apoB. We first tested whether the LDLR drives apoB degradation in an endoplasmic reticulum (ER)-associated pathway. Primary mouse hepatocytes harboring an ethyl-nitrosourea-induced, ER-retained mutant LDLR secreted comparable levels of apoB with LDLR-null hepatocytes, despite reduced secretion from cells expressing the wild-type LDLR. Additionally, treatment of cells with brefeldin A inhibited LDLR-dependent degradation. However, this rescue was reversible, and degradation of apoB occurred upon removal of brefeldin A. To characterize the lipoprotein reuptake pathway of degradation, we employed an LDLR mutant defective in constitutive endocytosis and internalization of apoB. This mutant was as effective in reducing apoB secretion as the wild-type LDLR. However, the effect was dependent on apolipoprotein E (apoE) as only the wild-type LDLR, and not the endocytic mutant, reduced apoB secretion in apoE-null cells. Treatment with heparin rescued a pool of apoB in cells expressing the endocytic mutant, indicating that reuptake of VLDL via apoE still occurs with this mutant. Finally, an LDLR mutant defective in binding apoB but not apoE reduced apoB secretion in an apoE-dependent manner. Together, these data suggest that the LDLR directs apoB to degradation in a post-ER compartment. Furthermore, the reuptake mechanism of degradation occurs via internalization of apoB through a constitutive endocytic pathway and apoE through a ligand-dependent pathway.	[Blasiole, Daniel A.; Oler, Angie T.; Attie, Alan D.] Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Attie, AD (corresponding author), 433 Babcock Dr, Madison, WI 53706 USA.	adattie@wisc.edu			NHLBI NIH HHS [HL56593, T32 HL07936] Funding Source: Medline; NIA NIH HHS [T32 AG20013] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056593, T32HL007936] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON RGW, 1982, J CELL BIOL, V93, P523, DOI 10.1083/jcb.93.3.523; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; Benjannet S, 2004, J BIOL CHEM, V279, P48865, DOI 10.1074/jbc.M409699200; Blasiole DA, 2007, MOL BIOSYST, V3, P608, DOI 10.1039/b700706j; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; Boren J, 1998, J CLIN INVEST, V101, P1084, DOI 10.1172/JCI1847; BROWN MS, 1976, CELL, V9, P663, DOI 10.1016/0092-8674(76)90130-6; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; Dirlam KA, 1996, PROTEIN EXPRES PURIF, V8, P489, DOI 10.1016/S1046-5928(96)90129-1; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; Gillian-Daniel DL, 2002, P NATL ACAD SCI USA, V99, P4337, DOI 10.1073/pnas.072557199; GOLDSTEIN JL, 1976, CELL, V7, P85, DOI 10.1016/0092-8674(76)90258-0; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; He GC, 2002, J BIOL CHEM, V277, P44044, DOI 10.1074/jbc.M208539200; HOPKINS CR, 1985, J CELL SCI, P173; Horton JD, 1999, J CLIN INVEST, V103, P1067, DOI 10.1172/JCI6246; Huang YD, 1999, ARTERIOSCL THROM VAS, V19, P2952, DOI 10.1161/01.ATV.19.12.2952; JAMES RW, 1989, J LIPID RES, V30, P159; Jiang XC, 2001, NAT MED, V7, P847, DOI 10.1038/89977; Jones C, 2003, J BIOL CHEM, V278, P29024, DOI 10.1074/jbc.M304855200; Jones C, 2007, J CLIN INVEST, V117, P165, DOI 10.1172/JCI29415; Kuipers F, 1997, J CLIN INVEST, V100, P2915, DOI 10.1172/JCI119841; Lagace TA, 2006, J CLIN INVEST, V116, P2995, DOI 10.1172/JCI29383; Larsson SL, 2004, J BIOL CHEM, V279, P831, DOI 10.1074/jbc.M303057200; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maugeais C, 2000, J LIPID RES, V41, P1673; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; Maxwell KN, 2005, P NATL ACAD SCI USA, V102, P2069, DOI 10.1073/pnas.0409736102; Mensenkamp AR, 2004, J HEPATOL, V40, P599, DOI 10.1016/j.jhep.2003.12.011; Mensenkamp AR, 2001, ARTERIOSCL THROM VAS, V21, P1366, DOI 10.1161/hq0801.093864; Michaely P, 2007, EMBO J, V26, P3273, DOI 10.1038/sj.emboj.7601769; Millar JS, 2005, ARTERIOSCL THROM VAS, V25, P560, DOI 10.1161/01.ATV.0000155323.18856.a2; Mishra SK, 2002, P NATL ACAD SCI USA, V99, P16099, DOI 10.1073/pnas.252630799; Nassir F, 2004, J LIPID RES, V45, P1649, DOI 10.1194/jlr.M300505-JLR200; Nassoury N, 2007, TRAFFIC, V8, P718, DOI 10.1111/j.1600-0854.2007.00562.x; Park SW, 2004, J BIOL CHEM, V279, P50630, DOI 10.1074/jbc.M410077200; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SATO R, 1990, J BIOL CHEM, V265, P11880; Svenson KL, 2007, J APPL PHYSIOL, V102, P2369, DOI 10.1152/japplphysiol.01077.2006; Teusink B, 2001, J BIOL CHEM, V276, P40693, DOI 10.1074/jbc.M106396200; Tremblay AJ, 2004, J LIPID RES, V45, P866, DOI 10.1194/jlr.M300448-JLR200; Twisk J, 2000, J CLIN INVEST, V105, P521, DOI 10.1172/JCI8623; Urlinger S, 2000, P NATL ACAD SCI USA, V97, P7963, DOI 10.1073/pnas.130192197; WILLIAMS KJ, 1990, J BIOL CHEM, V265, P16741; Wu XJ, 1997, J BIOL CHEM, V272, P11575	50	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11374	11381		10.1074/jbc.M710457200	http://dx.doi.org/10.1074/jbc.M710457200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18272520	hybrid, Green Published			2022-12-25	WOS:000255067400034
J	Yoshitake, F; Itoh, S; Narita, H; Ishihara, K; Ebisu, S				Yoshitake, Fumio; Itoh, Shousaku; Narita, Hiroko; Ishihara, Katsuhiko; Ebisu, Shigeyuki			Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-kappa B signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLASTIC CELLS; STAT3 ACTIVATION; PROTEIN-KINASE; FAMILY; IL-6; CYTOKINE; SPECIFICITY; EXPRESSION; INDUCTION; NUCLEAR	Interleukin-6 (IL-6) is a multifunctional cytokine produced by various cells to regulate hematopoiesis, inflammation, immune responses, and bone homeostasis. IL-6 is also known to modulate the differentiation of osteoblasts and osteoclasts. IL-6 is believed to play a positive regulatory role in osteoclast differentiation by inducing the expression of receptor activator of NF-kappa B ligand ( RANKL) on the surface of osteoblasts: RANKL then interacts with RANK expressed on osteoclast progenitors, inducing osteoclast differentiation via the RANK signaling pathway, which involves NF-kappa B, JNK, and p38. In this report, we demonstrate that IL-6 can also directly act on osteoclast progenitors to suppress their differentiation via an inhibition of RANK signaling pathways. IL-6 specifically suppressed RANK-mediated I kappa B degradation and JNK activation. Microarray analysis revealed that costimulation with IL-6 and RANKL up-regulates the transcription of MKP1 and MKP7, which encode enzymes that dephosphorylate JNK, and down-regulates the transcription of Senp2 and Cul4A, which are related to the ubiquitin pathway. Thus, IL-6 directly acts on osteoclast progenitors and suppresses their differentiation by regulating the transcription of specific genes related to MAPK phosphatases and the ubiquitin pathway.	[Yoshitake, Fumio; Itoh, Shousaku; Narita, Hiroko; Ebisu, Shigeyuki] Osaka Univ, Grad Sch Dent, Dept Restorat Dent & Endodontol, Suita, Osaka 5650871, Japan; [Ishihara, Katsuhiko] Kawasaki Med Sch, Dept Immunol & Mol Genet, Okayama, Japan	Osaka University; Kawasaki Medical School	Itoh, S (corresponding author), Osaka Univ, Grad Sch Dent, Dept Restorat Dent & Endodontol, 1-8 Yamadaoka, Suita, Osaka 5650871, Japan.	ito@dent.osaka-u.ac.jp	Ishihara, Katsuhiko/AAL-8175-2021					Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Ishihara K, 2002, CYTOKINE GROWTH F R, V13, P357, DOI 10.1016/S1359-6101(02)00027-8; Ishihara K, 2002, BBA-MOL CELL RES, V1592, P281, DOI 10.1016/S0167-4889(02)00321-X; Itoh S, 2002, J IMMUNOL, V168, P5110, DOI 10.4049/jimmunol.168.10.5110; Itoh S, 2007, J BONE MINER METAB, V25, P81, DOI 10.1007/s00774-006-0731-y; Itoh S, 2006, BONE, V39, P505, DOI 10.1016/j.bone.2006.02.074; Katagiri C, 2005, J BIOL CHEM, V280, P14716, DOI 10.1074/jbc.M500200200; Kawasaki K, 1997, ENDOCRINOLOGY, V138, P4959, DOI 10.1210/en.138.11.4959; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; KITAMURA H, 1995, AM J PATHOL, V147, P1682; Kotake S, 1996, J BONE MINER RES, V11, P88; MANOLAGAS SC, 1995, BONE, V17, pS63, DOI 10.1016/8756-3282(95)00180-L; Nishida K, 2003, CANCER SCI, V94, P1029, DOI 10.1111/j.1349-7006.2003.tb01396.x; Nishimura R, 1998, J BONE MINER RES, V13, P777, DOI 10.1359/jbmr.1998.13.5.777; O'Brien CA, 1999, J BIOL CHEM, V274, P19301, DOI 10.1074/jbc.274.27.19301; Palmqvist P, 2002, J IMMUNOL, V169, P3353, DOI 10.4049/jimmunol.169.6.3353; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; UDAGAWA N, 1995, J EXP MED, V182, P1461, DOI 10.1084/jem.182.5.1461; Wagner EF, 2001, CURR OPIN GENET DEV, V11, P527, DOI 10.1016/S0959-437X(00)00228-8; Yamamoto A, 2002, J BONE MINER RES, V17, P612, DOI 10.1359/jbmr.2002.17.4.612; Zhang ZY, 2005, BIOCHEM BIOPH RES CO, V328, P800, DOI 10.1016/j.bbrc.2005.01.019	28	195	212	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11535	11540		10.1074/jbc.M607999200	http://dx.doi.org/10.1074/jbc.M607999200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18296709	hybrid			2022-12-25	WOS:000255067400053
J	Kim, SI; Kwak, JH; Wang, L; Choi, ME				Kim, Sung Il; Kwak, Joon Hyeok; Wang, Lin; Choi, Mary E.			Protein phosphatase 2A is a negative regulator of transforming growth factor-beta 1-induced TAK1 activation in mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE KINASE KINASE; I-KAPPA-B; FACTOR-BETA; CATALYTIC SUBUNIT; FIBRONECTIN SYNTHESIS; SIGNAL-TRANSDUCTION; PHOSPHORYLATION; SMAD; IL-1; PATHWAYS	TAK1 (transforming growth factor (TGF)-beta-activated kinase 1) is a serine/threonine kinase that is rapidly activated by TGF-beta 1 and plays a vital function in its signal transduction. Once TAK1 is activated, efficient down-regulation of TAK1 activity is important to prevent excessive TGF-beta 1 responses. The regulatory mechanism of TAK1 inactivation following TGF-beta 1 stimulation has not been elucidated. Here we demonstrate that protein phosphatase 2A (PP2A) plays a pivotal role as a negative regulator of TAK1 activation in response to TGF-beta 1 in mesangial cells. Treatment with okadaic acid (OA) induces autophosphorylation of Thr-187 in the activation loop of TAK1. In vitro dephosphorylation assay suggests that Thr-187 in TAK1 is a major dephosphorylation target of PP2A. TGF-beta 1 stimulation rapidly activates TAK1 in a biphasic manner, indicating that TGF-beta 1-induced TAK1 activation is tightly regulated. The association of PP2A(C) with TAK1 is enhanced in response to TGF-beta 1 stimulation and closely parallels TGF-beta 1-induced TAK1 activity. Attenuation of PP2A activity by OA treatment or targeted knockdown of PP2AC with small interfering RNA enhances TGF-beta 1-induced phosphorylation of TAK1 at Thr-187 and MKK3 (MAPK kinase 3). Endogenous TAK1 co-precipitates with PP2AC but not PP6(C), another OA-sensitive protein phosphatase, and knockdown of PP6C by small interfering RNA does not affect TGF-beta 1-induced phosphorylation of TAK1 at Thr-187 and MKK3. Moreover, ectopic expression of phosphatase-deficient PP2AC enhances TAK1-mediated MKK3 phosphorylation by TGF-beta 1 stimulation, whereas the expression of wild-type PP2AC suppresses the MKK3 phosphorylation. Taken together, our data indicate that PP2A functions as a negative regulator in TGF-beta 1-induced TAK1 activation.	[Kim, Sung Il; Kwak, Joon Hyeok; Choi, Mary E.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Renal,Dept Med, 4 Blackfan Circle,HIM-5, Boston, MA 02115 USA; [Kim, Sung Il; Kwak, Joon Hyeok; Wang, Lin; Choi, Mary E.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Choi, ME (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Renal,Dept Med, 4 Blackfan Circle,HIM-5, Boston, MA 02115 USA.	mchoi@rics.bwh.harvard.edu			NIDDK NIH HHS [R01 DK57661] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057661] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abecassis L, 2004, J BIOL CHEM, V279, P30474, DOI 10.1074/jbc.M403294200; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Brown K, 2005, J MOL BIOL, V354, P1013, DOI 10.1016/j.jmb.2005.09.098; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Cheng JF, 2002, EXP BIOL MED, V227, P943, DOI 10.1177/153537020222701102; Cheung PCF, 2004, BIOCHEM J, V378, P27, DOI 10.1042/BJ20031794; Chin BY, 2001, AM J PHYSIOL-RENAL, V280, pF495, DOI 10.1152/ajprenal.2001.280.3.F495; Chung HY, 1999, BIOCHEMISTRY-US, V38, P10371, DOI 10.1021/bi990902g; Chung HY, 1999, CELL SIGNAL, V11, P575, DOI 10.1016/S0898-6568(99)00033-9; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dowdy SC, 2003, J BIOL CHEM, V278, P44377, DOI 10.1074/jbc.M307202200; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; FAVRE B, 1994, J BIOL CHEM, V269, P16311; Griswold-Prenner I, 1998, MOL CELL BIOL, V18, P6595, DOI 10.1128/MCB.18.11.6595; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; Hanada M, 2001, J BIOL CHEM, V276, P5753, DOI 10.1074/jbc.M007773200; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hastie CJ, 1998, FEBS LETT, V431, P357, DOI 10.1016/S0014-5793(98)00775-3; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 2005, J BIOL CHEM, V280, P25920, DOI 10.1074/jbc.M501150200; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hoffmann A, 2005, J BIOL CHEM, V280, P27271, DOI 10.1074/jbc.M503368200; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Irie T, 2000, FEBS LETT, V467, P160, DOI 10.1016/S0014-5793(00)01146-7; Ishitani T, 2003, EMBO J, V22, P6277, DOI 10.1093/emboj/cdg605; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Jin G, 2004, P NATL ACAD SCI USA, V101, P2028, DOI 10.1073/pnas.0307314101; Kajino T, 2007, J BIOL CHEM, V282, P9475, DOI 10.1074/jbc.M700875200; Kajino T, 2006, J BIOL CHEM, V281, P39891, DOI 10.1074/jbc.M608155200; Kim SI, 2007, AM J PHYSIOL-RENAL, V292, pF1471, DOI 10.1152/ajprenal.00485.2006; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Kobayashi Y, 2005, J BIOL CHEM, V280, P11395, DOI 10.1074/jbc.M411189200; Li MG, 2003, J BIOL CHEM, V278, P12013, DOI 10.1074/jbc.M211474200; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; MULDER KM, 1992, J BIOL CHEM, V267, P5029; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Oliver Carey J., 1998, Frontiers in Bioscience, V3, pD961; Ono K, 2003, BIOCHEM BIOPH RES CO, V307, P332, DOI 10.1016/S0006-291X(03)01207-5; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; Petritsch C, 2000, GENE DEV, V14, P3093, DOI 10.1101/gad.854200; Resjo S, 1999, BIOCHEM J, V341, P839, DOI 10.1042/0264-6021:3410839; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; Sakurai H, 2000, FEBS LETT, V474, P141, DOI 10.1016/S0014-5793(00)01588-X; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Singhirunnusorn P, 2005, J BIOL CHEM, V280, P7359, DOI 10.1074/jbc.M407537200; Stefansson B, 2006, J BIOL CHEM, V281, P22624, DOI 10.1074/jbc.M601772200; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Terada Y, 1999, KIDNEY INT, V56, P1378, DOI 10.1046/j.1523-1755.1999.00665.x; Tolstykh T, 2000, EMBO J, V19, P5682, DOI 10.1093/emboj/19.21.5682; Ugi S, 2002, MOL CELL BIOL, V22, P2375, DOI 10.1128/MCB.22.7.2375-2387.2002; Van Berlo JH, 2005, HUM MOL GENET, V14, P2839, DOI 10.1093/hmg/ddi316; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; Wang L, 2002, J BIOL CHEM, V277, P47257, DOI 10.1074/jbc.M208573200; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yi JY, 2005, J BIOL CHEM, V280, P10870, DOI 10.1074/jbc.M413223200; Zhang D, 2000, NAT MED, V6, P556, DOI 10.1038/75037	67	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10753	10763		10.1074/jbc.M801263200	http://dx.doi.org/10.1074/jbc.M801263200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18299321	hybrid, Green Published			2022-12-25	WOS:000254894700058
J	Neco, P; Fernandez-Peruchena, C; Navas, S; Gutierrez, LM; de Toledo, GA; Ales, E				Neco, Patricia; Fernandez-Peruchena, Carlos; Navas, Sergio; Gutierrez, Luis M.; de Toledo, Guillermo Alvarez; Ales, Eva			Myosin II contributes to fusion pore expansion during exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; PROTEIN-KINASE-C; MEMBRANE-FUSION; CATECHOLAMINE RELEASE; NEUROENDOCRINE CELLS; ACTIN CYTOSKELETON; PATCH AMPEROMETRY; VESICLE MEMBRANE; DYNAMICS; SECRETION	During exocytosis, the fusion pore expands to allow release of neurotransmitters and hormones to the extracellular space. To understand the process of synaptic transmission, it is of outstanding importance to know the properties of the fusion pore and how these properties affect the release process. Many proteins have been implicated in vesicle fusion; however, there is little evidence for proteins involved in fusion pore expansion. Myosin II has been shown to participate in the transport of vesicles and, surprisingly, in the final phases of exocytosis, affecting the kinetics of catecholamine release in adrenal chromaffin cells as measured by amperometry. Here, we have studied single vesicle exocytosis in chromaffin cells overexpressing an unphosphorylatable form (T18AS19A RLC-GFP) of myosin II that produces an inactive protein by patch amperometry. This method allows direct determination of fusion pore expansion by measuring its conductance, whereas the release of catecholamines is recorded simultaneously by amperometry. Here we demonstrated that the fusion pore is of critical importance to control the release of catecholamines during single vesicle secretion in chromaffin cells. We proved that myosin II acts as a molecular motor on the fusion pore expansion by hindering its dilation when it lacks the phosphorylation sites.	[Fernandez-Peruchena, Carlos; Navas, Sergio; de Toledo, Guillermo Alvarez; Ales, Eva] Univ Seville, Dpto Fisiol Med & Biofis, E-41009 Seville, Spain; [Neco, Patricia; Gutierrez, Luis M.] CSIC, Ctr Mixto Univ Miguel Hernandez, Inst Neurociencias, Alicante 03550, Spain	University of Sevilla; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN)	Ales, E (corresponding author), Univ Seville, Dpto Fisiol Med & Biofis, E-41009 Seville, Spain.	eales@us.es	Peruchena, Carlos M. Fernández/ABF-2123-2020; Gutierrez, Luis/K-8633-2014; Ales, Eva/E-6315-2010; Alvarez de Toledo, Guillermo/I-2888-2015	Peruchena, Carlos M. Fernández/0000-0003-4801-4375; Gutierrez, Luis/0000-0002-0512-7858; Ales, Eva/0000-0002-5536-4616; Alvarez de Toledo, Guillermo/0000-0001-7193-2663				Albillos A, 1997, NATURE, V389, P509, DOI 10.1038/39081; Ales E, 1999, NAT CELL BIOL, V1, P40, DOI 10.1038/9012; Amatore C, 1999, CHEM-EUR J, V5, P2151, DOI 10.1002/(SICI)1521-3765(19990702)5:7<2151::AID-CHEM2151>3.3.CO;2-I; Amatore C, 2007, BIOPHYS CHEM, V129, P181, DOI 10.1016/j.bpc.2007.05.018; An S, 2004, CURR OPIN NEUROBIOL, V14, P522, DOI 10.1016/j.conb.2004.08.008; Bai JH, 2004, NEURON, V41, P929, DOI 10.1016/S0896-6273(04)00117-5; Barclay JW, 2004, J BIOL CHEM, V279, P41495, DOI 10.1074/jbc.M406670200; Burgoyne RD, 2001, BIOCHEM SOC T, V29, P467, DOI 10.1042/BST0290467; CHANDLER DE, 1980, J CELL BIOL, V86, P666, DOI 10.1083/jcb.86.2.666; Chapman ER, 2002, NAT REV MOL CELL BIO, V3, P498, DOI 10.1038/nrm855; CHEEK TR, 1986, FEBS LETT, V207, P110, DOI 10.1016/0014-5793(86)80022-9; CHOW RH, 1994, P NATL ACAD SCI USA, V91, P12765, DOI 10.1073/pnas.91.26.12765; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; Dernick G, 2003, NAT CELL BIOL, V5, P358, DOI 10.1038/ncb956; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; Dillon C, 2005, ANNU REV NEUROSCI, V28, P25, DOI 10.1146/annurev.neuro.28.061604.135757; Fernandez-Peruchena C, 2005, BRAIN RES REV, V49, P406, DOI 10.1016/j.brainresrev.2004.12.037; GERHARDT G, 1982, ANAL CHEM, V54, P2618, DOI 10.1021/ac00251a054; Giner D, 2007, NEUROSCIENCE, V146, P659, DOI 10.1016/j.neuroscience.2007.02.039; Giner D, 2005, J CELL SCI, V118, P2871, DOI 10.1242/jcs.02419; Gong LW, 2007, NAT CELL BIOL, V9, P915, DOI 10.1038/ncb1617; Gullo F, 2002, FASEB J, V16, P330, DOI 10.1096/fj.02-0200fje; Haller M, 1998, BIOPHYS J, V74, P2100, DOI 10.1016/S0006-3495(98)77917-2; LESZCZYSZYN DJ, 1991, J NEUROCHEM, V56, P1855, DOI 10.1111/j.1471-4159.1991.tb03441.x; LINDAU M, 1995, CURR OPIN CELL BIOL, V7, P509, DOI 10.1016/0955-0674(95)80007-7; LOLLIKE K, 1995, J CELL BIOL, V129, P99, DOI 10.1083/jcb.129.1.99; MONCK JR, 1992, J CELL BIOL, V119, P1395, DOI 10.1083/jcb.119.6.1395; Monck JR, 1996, CURR OPIN CELL BIOL, V8, P524, DOI 10.1016/S0955-0674(96)80031-7; Morgan A, 2005, BIOCHEM SOC T, V33, P1341, DOI 10.1042/BST0331341; Neco P, 2004, J BIOL CHEM, V279, P27450, DOI 10.1074/jbc.M311462200; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; ORNBERG RL, 1981, J CELL BIOL, V90, P40, DOI 10.1083/jcb.90.1.40; Pawlu C, 2004, NEURON, V42, P607, DOI 10.1016/S0896-6273(04)00269-7; Prekeris R, 1997, J CELL BIOL, V137, P1589, DOI 10.1083/jcb.137.7.1589; Scepek S, 1998, EMBO J, V17, P4340, DOI 10.1093/emboj/17.15.4340; Schneider SW, 1997, P NATL ACAD SCI USA, V94, P316, DOI 10.1073/pnas.94.1.316; SPRUCE AE, 1990, NEURON, V4, P643, DOI 10.1016/0896-6273(90)90192-I; Tabares L, 2003, BIOCHEM SOC T, V31, P837, DOI 10.1042/bst0310837; Tabares L, 2001, J BIOL CHEM, V276, P39974, DOI 10.1074/jbc.M106498200; TRIFARO JM, 1993, TRENDS NEUROSCI, V16, P466, DOI 10.1016/0166-2236(93)90079-2; VITALE ML, 1991, J CELL BIOL, V113, P1057, DOI 10.1083/jcb.113.5.1057; Wang CT, 2001, SCIENCE, V294, P1111, DOI 10.1126/science.1064002; Xu JH, 1999, J BIOL CHEM, V274, P19095, DOI 10.1074/jbc.274.27.19095	43	75	76	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10949	10957		10.1074/jbc.M709058200	http://dx.doi.org/10.1074/jbc.M709058200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18283106	hybrid			2022-12-25	WOS:000254894700076
J	Deng, H; Dokshin, GA; Lei, J; Goldsmith, AM; Bitar, KN; Fingar, DC; Hershenson, MB; Bentley, JK				Deng, Huan; Dokshin, Gregoriy A.; Lei, Jing; Goldsmith, Adam M.; Bitar, Khalil N.; Fingar, Diane C.; Hershenson, Marc B.; Bentley, J. Kelley			Inhibition of glycogen synthase kinase-3 beta is sufficient for airway smooth muscle hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; GROWTH-FACTOR-BETA; KINASE 3-BETA; MYOTUBE HYPERTROPHY; CARDIAC MYOCYTES; BRONCHIAL-ASTHMA; GENE-EXPRESSION; PHOSPHORYLATION; PROTEIN; TRANSCRIPTION	We examined the role of glycogen synthase kinase-3 beta(GSK-3 beta) inhibition in airway smooth muscle hypertrophy, a structural change found in patients with severe asthma. LiCl, SB216763, and specific small interfering RNA ( siRNA) against GSK-3 beta, each of which inhibit GSK-3 beta activity or expression, increased human bronchial smooth muscle cell size, protein synthesis, and expression of the contractile proteins alpha-smooth muscle actin, myosin light chain kinase, smooth muscle myosin heavy chain, and SM22. Similar results were obtained following treatment of cells with cardiotrophin (CT)-1, a member of the interleukin-6 superfamily, and transforming growth factor (TGF)-beta, a proasthmatic cytokine. GSK-3 beta inhibition increased mRNA expression of alpha-actin and transactivation of nuclear factors of activated T cells and serum response factor. siRNA against eukaryotic translation initiation factor 2B epsilon (eIF2B epsilon) attenuated LiCl- and SB216763-induced protein synthesis and expression of alpha-actin and SM22, indicating that eIF2B is required for GSK-3 beta-mediated airway smooth muscle hypertrophy. eIF2B epsilon siRNA also blocked CT-1- but not TGF-beta-induced protein synthesis. Infection of human bronchial smooth muscle cells with pMSCV GSK-3 beta-A9, a retroviral vector encoding a constitutively active, nonphosphorylatable GSK-3 beta, blocked protein synthesis and alpha-actin expression induced by LiCl, SB216763, and CT-1- but not TGF-alpha. Finally, lungs from ovalbumin-sensitized and -challenged mice demonstrated increased alpha-actin and CT-1 mRNA expression, and airway myocytes isolated from ovalbumin-treated mice showed increased cell size and GSK-3 beta phosphorylation. These data suggest that inhibition of the GSK-3 beta/eIF2B epsilon translational control pathway contributes to airway smooth muscle hypertrophy in vitro and in vivo. On the other hand, TGF-beta-induced hypertrophy does not depend on GSK-3 beta/eIF2B signaling.	[Deng, Huan; Dokshin, Gregoriy A.; Lei, Jing; Goldsmith, Adam M.; Bitar, Khalil N.; Hershenson, Marc B.; Bentley, J. Kelley] Univ Michigan, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA; [Hershenson, Marc B.] Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; [Fingar, Diane C.] Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Hershenson, MB (corresponding author), 1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	mhershen@umich.edu		Bentley, John Kelley/0000-0001-8865-7979; Dokshin, Gregoriy/0000-0002-8780-7143	NHLBI NIH HHS [R01 HL079339, HL 79339] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079339] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antos CL, 2002, P NATL ACAD SCI USA, V99, P907, DOI 10.1073/pnas.231619298; Armstrong DD, 2005, AM J PHYSIOL-CELL PH, V289, pC853, DOI 10.1152/ajpcell.00093.2005; Badorff C, 2002, J CLIN INVEST, V109, P373, DOI 10.1172/JCI200213779; Bao JJ, 2002, P NATL ACAD SCI USA, V99, P9556, DOI 10.1073/pnas.142298599; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Bosc LVG, 2005, J BIOL CHEM, V280, P26113, DOI 10.1074/jbc.M411972200; Camoretti-Mercado B, 2006, J BIOL CHEM, V281, P20383, DOI 10.1074/jbc.M602748200; Cho JY, 2004, AM J RESP CELL MOL, V30, P651, DOI 10.1165/rcmb.2003-0066OC; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Dominguez I, 2001, DEV BIOL, V235, P303, DOI 10.1006/dbio.2001.0317; EBINA M, 1993, AM REV RESPIR DIS, V148, P720, DOI 10.1164/ajrccm/148.3.720; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Goldsmith AM, 2006, AM J RESP CELL MOL, V34, P247, DOI 10.1165/rcmb.2005-0166OC; Halayko AJ, 2004, AM J RESP CELL MOL, V31, P266, DOI 10.1165/rcmb.2003-0272OC; Haq S, 2003, P NATL ACAD SCI USA, V100, P4610, DOI 10.1073/pnas.0835895100; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Hardt SE, 2004, CIRC RES, V94, P926, DOI 10.1161/01.RES.0000124977.59827.80; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Jope RS, 2003, TRENDS PHARMACOL SCI, V24, P441, DOI 10.1016/S0165-6147(03)00206-2; Leigh R, 2002, AM J RESP CELL MOL, V27, P526, DOI 10.1165/rcmb.2002-0048OC; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; Morisco C, 2001, J BIOL CHEM, V276, P28586, DOI 10.1074/jbc.M103166200; Morisco C, 2000, J BIOL CHEM, V275, P14466, DOI 10.1074/jbc.275.19.14466; Nomura A, 2002, CLIN EXP ALLERGY, V32, P860, DOI 10.1046/j.1365-2745.2002.01404.x; Ohno I, 1996, AM J RESP CELL MOL, V15, P404, DOI 10.1165/ajrcmb.15.3.8810646; Rochat A, 2004, MOL BIOL CELL, V15, P4544, DOI 10.1091/mbc.E03-11-0816; Shaw M, 1999, FEBS LETT, V461, P120, DOI 10.1016/S0014-5793(99)01434-9; Silver DL, 1997, J BIOL CHEM, V272, P25353, DOI 10.1074/jbc.272.40.25353; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Tillie-Leblond I, 1999, AM J RESP CRIT CARE, V159, P487, DOI 10.1164/ajrccm.159.2.9805115; TSUNEKAWA S, 1989, FEBS LETT, V250, P493, DOI 10.1016/0014-5793(89)80783-5; Vyas DR, 2002, AM J PHYSIOL-CELL PH, V283, pC545, DOI 10.1152/ajpcell.00049.2002; Wada H, 2002, J CELL BIOL, V156, P983, DOI 10.1083/jcb.200106057; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; Woodruff PG, 2004, AM J RESP CRIT CARE, V169, P1001, DOI 10.1164/rccm.200311-1529OC; Zheng XY, 2004, AM J PHYSIOL-LUNG C, V287, pL1165, DOI 10.1152/ajplung.00171.2004; Zhou DY, 2003, BRIT J PHARMACOL, V140, P1237, DOI 10.1038/sj.bjp.0705562; Zhou LM, 2005, AM J RESP CELL MOL, V33, P195, DOI 10.1165/rcmb.2004-0411OC; Zhou LM, 2004, AM J RESP CRIT CARE, V169, P703, DOI 10.1164/rccm.200307-964OC; Zhou LM, 2003, RESP PHYSIOL NEUROBI, V137, P295, DOI 10.1016/S1569-9048(03)00154-X	42	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					10198	10207		10.1074/jbc.M800624200	http://dx.doi.org/10.1074/jbc.M800624200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18252708	Green Published, hybrid			2022-12-25	WOS:000254671600072
J	Malawista, SE; Chevance, AD				Malawista, Stephen E.; Chevance, Anne de Boisfleury			Clocking the Lyme Spirochete	PLOS ONE			English	Article								In order to clear the body of infecting spirochetes, phagocytic cells must be able to get hold of them. In real-time phase-contrast videomicroscopy we were able to measure the speed of Borrelia burgdorferi (Bb), the Lyme spirochete, moving back and forth across a platelet to which it was tethered. Its mean crossing speed was 1,636 mu m/min (N = 28), maximum, 2800 mm/min (N = 3). This is the fastest speed recorded for a spirochete, and upward of two orders of magnitude above the speed of a human neutrophil, the fastest cell in the body. This alacrity and its interpretation, in an organism with bidirectional motor capacity, may well contribute to difficulties in spirochete clearance by the host.	[Malawista, Stephen E.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; [Chevance, Anne de Boisfleury] Hop La Pitie Salpetriere, Ctr Ecol Cellulaire, Paris, France	Yale University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Malawista, SE (corresponding author), Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA.	stephen.malawista@yale.edu			USPHS [AR-10493, AI-43558]; G. Harold and Leila Y. Mathers Charitable Foundation; Eshe Fund; John Simon Guggenheim Memorial Foundation [fellow]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR010493] Funding Source: NIH RePORTER	USPHS(United States Department of Health & Human ServicesUnited States Public Health Service); G. Harold and Leila Y. Mathers Charitable Foundation; Eshe Fund; John Simon Guggenheim Memorial Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported in part by the USPHS (AR-10493, AI-43558), the G. Harold and Leila Y. Mathers Charitable Foundation, and the Eshe Fund. Dr. Malawista was a Fellow of the John Simon Guggenheim Memorial Foundation.	BARBOUR AG, 1983, INFECT IMMUN, V41, P795, DOI 10.1128/IAI.41.2.795-804.1983; CASSIMERIS L, 1990, J CELL BIOL, V110, P1067, DOI 10.1083/jcb.110.4.1067; Charon NW, 2002, ANNU REV GENET, V36, P47, DOI 10.1146/annurev.genet.36.041602.134359; CHARON NW, 1981, P NATL ACAD SCI-BIOL, V78, P7166, DOI 10.1073/pnas.78.11.7166; COBURN J, 1994, INFECT IMMUN, V62, P5559, DOI 10.1128/IAI.62.12.5559-5567.1994; GOLDSTEIN SF, 1994, P NATL ACAD SCI USA, V91, P3433, DOI 10.1073/pnas.91.8.3433; GRULER H, 1987, Z NATURFORSCH C, V42, P1126; KIMSEY RB, 1990, J INFECT DIS, V162, P1205, DOI 10.1093/infdis/162.5.1205; Li CH, 2000, J MOL MICROB BIOTECH, V2, P345; Li YM, 2002, J IMMUNOL, V168, P816, DOI 10.4049/jimmunol.168.2.816; MONTGOMERY RR, 1993, J IMMUNOL, V150, P909; Montgomery RR, 2002, J INFECT DIS, V185, P1773, DOI 10.1086/340826	12	12	12	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1633	10.1371/journal.pone.0001633	http://dx.doi.org/10.1371/journal.pone.0001633			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286190	Green Published, Green Submitted, gold			2022-12-25	WOS:000260586400026
J	Shen, RL; Ye, Y; Chen, L; Yan, QT; Barsky, SH; Gao, JX				Shen, Rulong; Ye, Yin; Chen, Li; Yan, Qingtao; Barsky, Sanford H.; Gao, Jian-Xin			Precancerous Stem Cells Can Serve As Tumor Vasculogenic Progenitors	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; IN-VIVO; BONE-MARROW; THERAPEUTIC IMPLICATIONS; DENDRITIC CELLS; BLOOD-VESSELS; FACTOR VEGF; ANGIOGENESIS; CANCER; RECEPTOR	Tumor neo-vascularization is critical for tumor growth, invasion and metastasis, which has been considered to be mediated by a mechanism of angiogenesis. However, histopathological studies have suggested that tumor cells might be the progenitor for tumor vasculature. Recently, we have reported that the precancerous stem cells (pCSCs) representing the early stage of developing cancer stem cells (CSCs), have the potential for both benign and malignant differentiation. Therefore, we investigated whether pCSCs serve as progenitors for tumor vasculogenesis. Herein, we report that in the pCSC-derived tumors, most blood vessels were derived from pCSCs. Some pCSCs constitutively expressed vasculogenic receptor VEGFR-2, which can be up-regulated by hypoxia and angiogenesis-promoting cytokines, such as GM-CSF, Flt3 ligand, and IL-13. The pCSCs are much more potent in tumor vasculogenesis than the differentiated tumor monocytic cells (TMCs) from the same tumor, which had comparable or even higher capacity to produce some vascular growth factors, suggesting that the potent tumor vasculogenesis of pCSCs is associated with their intrinsic stem-like property. Consistently tumor vasculogenesis was also observed in human cancers such as cervical cancer and breast cancer and xenograft lymphoma. Our studies indicate that pCSCs can serve as tumor vasculogenic stem/progenitor cells (TVPCs), and may explain why anti-angiogenic cancer therapy trials are facing challenge.	[Shen, Rulong; Ye, Yin; Chen, Li; Yan, Qingtao; Barsky, Sanford H.; Gao, Jian-Xin] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Shen, RL (corresponding author), Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA.	Sanford.Barsky@osumc.edu; Jian-Xin.Gao@osumc.edu	Shen, Rulong/E-4079-2011		SIG OSU; Immunology Program Award; American Cancer society [IRG-112367]; Davis/Bremer Medical Research	SIG OSU; Immunology Program Award; American Cancer society(American Cancer Society); Davis/Bremer Medical Research	The work is supported from Strategy Initiative Grant(SIG, OSU), 2006/2007 (JXG); Immunology Program Award 2007 (OSUCCC)(JXG); American Cancer society Grant #IRG-112367 (JXG); Davis/Bremer Medical Research Grant, OSU (RS); and SIG 2006(SHB).	Al-Rawi MAA, 2005, INT J ONCOL, V27, P721; Medina MA, 2007, J CELL MOL MED, V11, P374, DOI 10.1111/j.1582-4934.2007.00056.x; Bailey AS, 2006, P NATL ACAD SCI USA, V103, P13156, DOI 10.1073/pnas.0604203103; Bailey AS, 2003, EXP HEMATOL, V31, P987, DOI 10.1016/j.exphem.2003.07.001; Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bertolini F, 2006, NAT REV CANCER, V6, P833, DOI 10.1039/nrc1971; Blouw B, 2003, CANCER CELL, V4, P133, DOI 10.1016/S1535-6108(03)00194-6; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chang YS, 2000, P NATL ACAD SCI USA, V97, P14608, DOI 10.1073/pnas.97.26.14608; Chen L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000293; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Clauss M, 2000, SEMIN THROMB HEMOST, V26, P561, DOI 10.1055/s-2000-13213; Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854; Deininger MWN, 2001, CANCER RES, V61, P8005; Dentelli P, 1999, J IMMUNOL, V163, P2151; Dome B, 2007, AM J PATHOL, V170, P1, DOI 10.2353/ajpath.2007.060302; Eubank TD, 2004, IMMUNITY, V21, P831, DOI 10.1016/j.immuni.2004.10.011; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FUKUMURA D, 2007, MICROVASC RES; Fukushi J, 2000, J IMMUNOL, V165, P2818, DOI 10.4049/jimmunol.165.5.2818; Gao JX, 2003, J IMMUNOL, V170, P5927, DOI 10.4049/jimmunol.170.12.5927; GAO JX, 2007, J CELL MOL MED ONLIN; GAO JX, 2007, J CELL MOL IN PRESS; Gottfried E, 2007, SCAND J IMMUNOL, V65, P329, DOI 10.1111/j.1365-3083.2007.01903.x; HAMMERSEN F, 1985, INT J MICROCIRC, V4, P31; Hashizume H, 2000, AM J PATHOL, V156, P1363, DOI 10.1016/S0002-9440(10)65006-7; Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092; Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081; Hilbe W, 2004, J CLIN PATHOL, V57, P965, DOI 10.1136/jcp.2004.016444; Hong DL, 2008, SCIENCE, V319, P336, DOI 10.1126/science.1150648; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Klug CA, 2000, BLOOD, V96, P894, DOI 10.1182/blood.V96.3.894.015k35_894_901; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; Larrivee B, 2005, J IMMUNOL, V175, P2890, DOI 10.4049/jimmunol.175.5.2890; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; McClintock JY, 2005, J APPL PHYSIOL, V99, P861, DOI 10.1152/japplphysiol.00006.2005; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Nolan DJ, 2007, GENE DEV, V21, P1546, DOI 10.1101/gad.436307; O'Farrell AM, 2003, BLOOD, V101, P3597, DOI 10.1182/blood-2002-07-2307; Papetti M, 2002, AM J PHYSIOL-CELL PH, V282, pC947, DOI 10.1152/ajpcell.00389.2001; Peters KG, 2004, RECENT PROG HORM RES, V59, P51, DOI 10.1210/rp.59.1.51; Pezzolo A, 2007, J CLIN ONCOL, V25, P376, DOI 10.1200/JCO.2006.09.0696; Pujol BF, 2000, DIFFERENTIATION, V65, P287, DOI 10.1046/j.1432-0436.2000.6550287.x; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Reyes M, 2002, J CLIN INVEST, V109, P337, DOI 10.1172/JCI200214327; Ribatti D, 2007, LEUKEMIA, V21, P2085, DOI 10.1038/sj.leu.2404900; Rini BI, 2005, J CLIN ONCOL, V23, P1028, DOI 10.1200/JCO.2005.01.186; Sakurai Y, 2005, P NATL ACAD SCI USA, V102, P1076, DOI 10.1073/pnas.0404984102; Shaw JP, 2004, BLOOD CELL MOL DIS, V32, P168, DOI 10.1016/j.bcmd.2003.10.003; Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25; Stratmann A, 2001, INT J CANCER, V91, P273, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1054>3.0.CO;2-Q; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; Valdembri D, 2001, FASEB J, V15, P225, DOI 10.1096/fj.01-0633fje; Volpert OV, 1998, J EXP MED, V188, P1039, DOI 10.1084/jem.188.6.1039; Warner JK, 2004, ONCOGENE, V23, P7164, DOI 10.1038/sj.onc.1207933; Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568; Yang XJ, 1996, J NEUROSCI, V16, P6089	63	78	82	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1652	10.1371/journal.pone.0001652	http://dx.doi.org/10.1371/journal.pone.0001652			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286204	Green Published, gold, Green Submitted			2022-12-25	WOS:000260586400045
J	Zhu, J; He, FH; Wang, J; Yu, J				Zhu, Jiang; He, Fuhong; Wang, Jing; Yu, Jun			Modeling Transcriptome Based on Transcript-Sampling Data	PLOS ONE			English	Article							HIGH-THROUGHPUT ANALYSIS; GENE-EXPRESSION; SERIAL ANALYSIS; HUMAN-GENOME; SAGE; DNA; IDENTIFICATION; SEQUENCES; ABUNDANCE; LONGSAGE	Background: Newly-evolved multiplex sequencing technology has been bringing transcriptome sequencing into an unprecedented depth. Millions of transcript tags now can be acquired in a single experiment through parallelization. The significant increase in throughput and reduction in cost required us to address some fundamental questions, such as how many transcript tags do we have to sequence for a given transcriptome? How could we estimate the total number of unique transcripts for different cell types (transcriptome diversity) and the distribution of their copy numbers (transcriptome dynamics)? What is the probability that a transcript with a given expression level to be detected at a certain sampling depth? Methodology/Principal Findings: We developed a statistical model to evaluate these parameters based on transcriptome-sampling data. Three mixture models were exploited for their potentials to model the sampling frequencies. We demonstrated that relative abundances of all transcripts in a transcriptome follow the generalized inverse Gaussian distribution. The widely known beta and gamma distributions failed to fulfill the singular characteristics of relative abundance distribution, i.e., highly skewed toward zero and with a long tail. An estimator of transcriptome diversity and an analytical form of sampling growth curve were proposed in a coherent framework. Experimental data fitted this model very well and Monte Carlo simulations based on this model replicated sampling experiments in a remarkable precision. Conclusions: Taking human embryonic stem cell as a prototype, we demonstrated that sequencing tens of thousands of transcript tags in an ordinary EST/SAGE experiment was far from sufficient. In order to fully characterize a human transcriptome, millions of transcript tags had to be sequenced. This model lays a statistical basis for transcriptome-sampling experiments and in essence can be used in all sampling-based data.	[Zhu, Jiang; He, Fuhong; Wang, Jing; Yu, Jun] Chinese Acad Sci, CAS Key Lab Genome Sci & Informat, Beijing Inst Gen, Beijing, Peoples R China; [Zhu, Jiang; He, Fuhong] Chinese Acad Sci, Grad Univ, Beijing, Peoples R China	Chinese Academy of Sciences; Beijing Institute of Genomics, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Zhu, J (corresponding author), Chinese Acad Sci, CAS Key Lab Genome Sci & Informat, Beijing Inst Gen, Beijing, Peoples R China.	wangjing@big.ac.cn; junyu@big.ac.cn	郑, 征/C-8514-2011; Zhu, Jiang/E-3049-2013; He, Fuhong/HHZ-2474-2022; He, Fuhong/T-4887-2019	He, Fuhong/0000-0002-3176-8309	National Natural Science Foundation of China (NSFC) [90608003, 30221004]; National Basic Research Program of China [2006CB910404]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China(National Basic Research Program of China)	This work was supported by the National Natural Science Foundation of China (NSFC) (Grant No. 90608003, 30221004) and the National Basic Research Program of China (973 Program) (Grant No. 2006CB910404).	ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ATKINSON AC, 1982, J AM STAT ASSOC, V77, P153, DOI 10.2307/2287782; Bertone P, 2004, SCIENCE, V306, P2242, DOI 10.1126/science.1103388; BISHOP JO, 1974, NATURE, V250, P199, DOI 10.1038/250199a0; BISHOP JO, 1978, PHILOS T ROY SOC B, V283, P373, DOI 10.1098/rstb.1978.0039; Blazej RG, 2006, P NATL ACAD SCI USA, V103, P7240, DOI 10.1073/pnas.0602476103; Boon K, 2002, P NATL ACAD SCI USA, V99, P11287, DOI 10.1073/pnas.152324199; Brandenberger Ralph, 2004, BMC Developmental Biology, V4, P1; Brenner S, 2000, P NATL ACAD SCI USA, V97, P1665, DOI 10.1073/pnas.97.4.1665; Brenner S, 2000, NAT BIOTECHNOL, V18, P630, DOI 10.1038/76469; BURRELL QL, 1993, J AM SOC INFORM SCI, V44, P61, DOI 10.1002/(SICI)1097-4571(199303)44:2<61::AID-ASI1>3.0.CO;2-J; Carpenter MK, 2004, DEV DYNAM, V229, P243, DOI 10.1002/dvdy.10431; Chen JJ, 2002, P NATL ACAD SCI USA, V99, P12257, DOI 10.1073/pnas.192436499; Cheng J, 2005, SCIENCE, V308, P1149, DOI 10.1126/science.1108625; Colinge J, 2001, BIOINFORMATICS, V17, P840, DOI 10.1093/bioinformatics/17.9.840; Eyras E, 2004, GENOME RES, V14, P976, DOI 10.1101/gr.1862204; Harbers M, 2005, NAT METHODS, V2, P495, DOI 10.1038/NMETH768; Hirst M, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-6-r113; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Khattra J, 2007, GENOME RES, V17, P108, DOI 10.1101/gr.5488207; Kim JW, 2005, NAT METHODS, V2, P47, DOI 10.1038/NMETH726; Kim N, 2005, GENOME RES, V15, P566, DOI 10.1101/gr.3030405; Kuznetsov VA, 2002, GENETICS, V161, P1321; Lee S, 2002, GENOMICS, V79, P598, DOI 10.1006/geno.2002.6730; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; Morris JS, 2003, BIOMETRICS, V59, P476, DOI 10.1111/1541-0420.00057; Nam DK, 2002, P NATL ACAD SCI USA, V99, P6152, DOI 10.1073/pnas.092140899; Ng P, 2005, NAT METHODS, V2, P105, DOI 10.1038/NMETH733; Ng P, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl444; Pauws E, 2001, NUCLEIC ACIDS RES, V29, P1690, DOI 10.1093/nar/29.8.1690; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Ruan YJ, 2004, TRENDS BIOTECHNOL, V22, P23, DOI 10.1016/j.tibtech.2003.11.002; Saha S, 2002, NAT BIOTECHNOL, V20, P508, DOI 10.1038/nbt0502-508; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Shendure J, 2005, SCIENCE, V309, P1728, DOI 10.1126/science.1117389; Shiraki T, 2003, P NATL ACAD SCI USA, V100, P15776, DOI 10.1073/pnas.2136655100; Sichel H. S., 1986, MATH SCI, V11, P45; SICHEL HS, 1975, J AM STAT ASSOC, V70, P542, DOI 10.2307/2285930; SICHEL HS, 1992, INFORM PROCESS MANAG, V28, P5, DOI 10.1016/0306-4573(92)90088-H; Silva APM, 2004, NUCLEIC ACIDS RES, V32, P6104, DOI 10.1093/nar/gkh937; Sorek R, 2003, NUCLEIC ACIDS RES, V31, P1067, DOI 10.1093/nar/gkg170; STEIN GZ, 1987, J AM STAT ASSOC, V82, P938; Stern MD, 2003, BIOINFORMATICS, V19, P443, DOI 10.1093/bioinformatics/btg018; Thygesen HH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-157; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Wei CL, 2004, P NATL ACAD SCI USA, V101, P11701, DOI 10.1073/pnas.0403514101; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043	50	17	20	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1659	10.1371/journal.pone.0001659	http://dx.doi.org/10.1371/journal.pone.0001659			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286206	Green Submitted, Green Published, gold			2022-12-25	WOS:000260586400048
J	Yu, XH; Koczan, D; Sulonen, AM; Akkad, DA; Kroner, A; Comabella, M; Costa, G; Corongiu, D; Goertsches, R; Camina-Tato, M; Thiesen, HJ; Nyland, HI; Mork, SJ; Montalban, X; Rieckmann, P; Marrosu, MG; Myhr, KM; Epplen, JT; Saarela, J; Ibrahim, SM				Yu, Xinhua; Koczan, Dirk; Sulonen, Anna-Maija; Akkad, Denis A.; Kroner, Antje; Comabella, Manuel; Costa, Gianna; Corongiu, Daniela; Goertsches, Robert; Camina-Tato, Montserrat; Thiesen, Hans-Juergen; Nyland, Harald I.; Mork, Sverre J.; Montalban, Xavier; Rieckmann, Peter; Marrosu, Maria G.; Myhr, Kjell-Morten; Epplen, Joerg T.; Saarela, Janna; Ibrahim, Saleh M.			mtDNA nt13708A Variant Increases the Risk of Multiple Sclerosis	PLOS ONE			English	Article								Background: Mitochondrial DNA (mtDNA) polymorphism is a possible factor contributing to the maternal parent-of-origin effect in multiple sclerosis (MS) susceptibility. Methods and Findings: In order to investigate the role of mtDNA variations in MS, we investigated six European MS case-control cohorts comprising > 5,000 individuals. Three well matched cohorts were genotyped with seven common, potentially functional mtDNA single nucleotide polymorphisms (SNPs). A SNP, nt13708 G/A, was significantly associated with MS susceptibility in all three cohorts. The nt 13708A allele was associated with an increased risk of MS (OR = 1.71, 95% Cl 1.28-2.26, P = 0.0002). Subsequent sequencing of the mtDNA of 50 individuals revealed that the nt13708 itself, rather than SNPs linked to it, was responsible for the association. However, the association of nt13708 G/A with MS was not significant in MS cohorts which were not well case-control matched, indicating that the significance of association was affected by the population structure of controls. Conclusions: Taken together, our finding identified the nt13708A variant as a susceptibility allele to MS, which could contribute to defining the role of the mitochondrial genome in MS pathogenesis.	[Yu, Xinhua; Ibrahim, Saleh M.] Univ Rostock, Sect Immunogenet, Rostock, Germany; [Koczan, Dirk; Goertsches, Robert; Thiesen, Hans-Juergen] Univ Rostock, Dept Immunol, Rostock, Germany; [Sulonen, Anna-Maija; Saarela, Janna] Natl Publ Hlth Inst, Dept Mol Med, Helsinki, Finland; [Akkad, Denis A.; Epplen, Joerg T.] Ruhr Univ, IGSN, Dept Human Genet, Bochum, Germany; [Kroner, Antje; Rieckmann, Peter] Univ Wurzburg, Dept Neurol, Clin Res Grp MS & Neuroimmunol, Wurzburg, Germany; [Comabella, Manuel; Camina-Tato, Montserrat; Montalban, Xavier] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Unit Neuroimmunol Clin, Barcelona, Spain; [Costa, Gianna; Corongiu, Daniela; Marrosu, Maria G.] Univ Cagliari, Dipart Sci Cardiovascol Neurol, Centro Sclerosi Multipla, Cagliari, Italy; [Nyland, Harald I.; Myhr, Kjell-Morten] Univ Bergen, Haukeland Univ Hosp, Dept Neurol, Bergen, Norway; [Nyland, Harald I.; Myhr, Kjell-Morten] Univ Bergen, Dept Clin Med, Bergen, Norway; [Mork, Sverre J.] Univ Bergen, Gades Inst, Haukeland Univ Hosp, Dept Pathol, Bergen, Norway	University of Rostock; University of Rostock; Finland National Institute for Health & Welfare; Ruhr University Bochum; University of Wurzburg; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; University of Cagliari; University of Bergen; Haukeland University Hospital; University of Bergen; University of Bergen; Haukeland University Hospital	Yu, XH (corresponding author), Univ Rostock, Sect Immunogenet, Rostock, Germany.	saleh.ibrahim@med.uni-rostock.de	Saarela, Janna S/E-5369-2014; Myhr, Kjell-Morten/H-1528-2018; Mörk, Sverre Jarl/AAW-1330-2020; Ibrahim, Saleh/AAO-9541-2020; Montalban, Xavier/J-5938-2016; Yu, Xinhua/F-6125-2011	Myhr, Kjell-Morten/0000-0002-0980-510X; Montalban, Xavier/0000-0002-0098-9918; Ibrahim, Saleh/0000-0001-7827-2290; Saarela, Janna/0000-0002-0853-6219; Marrosu, Maria Giovanna/0000-0003-2334-2081; Sulonen, Anna-Maija/0000-0002-5518-1975; Comabella Lopez, Manuel/0000-0002-2373-6657; Epplen, Joerg T./0000-0002-6087-3327	EU FP6 (EURO-RA); Hertie Stiftung	EU FP6 (EURO-RA)(European Commission); Hertie Stiftung(Austrian Science Fund (FWF))	This work was supported by grants from EU FP6 (EURO-RA) and Hertie Stiftung.	Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; De Benedictis G, 1999, FASEB J, V13, P1532, DOI 10.1096/fasebj.13.12.1532; Ebers GC, 2004, LANCET, V363, P1773, DOI 10.1016/S0140-6736(04)16304-6; FERRIS SD, 1982, NATURE, V295, P163, DOI 10.1038/295163a0; Houshmand M, 2005, MULT SCLER J, V11, P728, DOI 10.1191/1352458505ms1228sr; Howell N, 2005, TRENDS GENET, V21, P583, DOI 10.1016/j.tig.2005.08.012; JOHNS DR, 1991, BIOCHEM BIOPH RES CO, V174, P1324, DOI 10.1016/0006-291X(91)91567-V; Kalman B, 1995, Mult Scler, V1, P32; Kalman B, 1997, Mult Scler, V2, P267; Kalman B, 1998, ACTA NEUROL SCAND, V98, P232, DOI 10.1111/j.1600-0404.1998.tb07301.x; Kalman B, 1999, ACTA NEUROL SCAND, V99, P16; KELLARWOOD H, 1994, ANN NEUROL, V36, P109, DOI 10.1002/ana.410360121; LEES F, 1964, J NEUROL NEUROSUR PS, V27, P415, DOI 10.1136/jnnp.27.5.415; Lodi R, 2000, BRAIN, V123, P1896, DOI 10.1093/brain/123.9.1896; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; Mihailova SM, 2007, EUR J NEUROL, V14, P44, DOI 10.1111/j.1468-1331.2006.01541.x; Mohlke KL, 2005, HUM GENET, V118, P245, DOI 10.1007/s00439-005-0046-4; Niemi AK, 2003, HUM GENET, V112, P29, DOI 10.1007/s00439-002-0843-y; Pakendorf B, 2005, ANNU REV GENOM HUM G, V6, P165, DOI 10.1146/annurev.genom.6.080604.162249; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; Reynier P, 1999, EUR J HUM GENET, V7, P404, DOI 10.1038/sj.ejhg.5200293; SADOVNICK AD, 1991, ANN NEUROL, V29, P252, DOI 10.1002/ana.410290304; Samuels DC, 2006, AM J HUM GENET, V78, P713, DOI 10.1086/502682; SHOFFNER JM, 1993, GENOMICS, V17, P171, DOI 10.1006/geno.1993.1299; Silander K, 2003, TWIN RES, V6, P391, DOI 10.1375/136905203770326394; Sumelahti ML, 2000, NEUROEPIDEMIOLOGY, V19, P67, DOI 10.1159/000026241; Torroni A, 1996, GENETICS, V144, P1835; Torroni A, 1997, AM J HUM GENET, V60, P1107; TORRONI A, 1994, AM J HUM GENET, V55, P760; van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937; Vogler S, 2006, AM J PATHOL, V168, P1570, DOI 10.2353/ajpath.2006.051069; Vogler S, 2005, J MOL MED, V83, P806, DOI 10.1007/s00109-005-0661-5; Wallace DC, 2001, MENT RETARD DEV D R, V7, P158, DOI 10.1002/mrdd.1023	33	72	79	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1530	10.1371/journal.pone.0001530	http://dx.doi.org/10.1371/journal.pone.0001530			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270557	Green Submitted, gold, Green Published			2022-12-25	WOS:000260535900001
J	Chen, XW; Liu, M; Ward, R				Chen, Xue-wen; Liu, Mei; Ward, Robert			Protein Function Assignment through Mining Cross-Species Protein-Protein Interactions	PLOS ONE			English	Article							FUNCTION PREDICTION; SEMANTIC SIMILARITY; GENE ONTOLOGY; DATABASE; GENOMES; CYCLIN; IDENTIFICATION; LOCALIZATION; ANNOTATION; EXPRESSION	Background: As we move into the post genome-sequencing era, an immediate challenge is how to make best use of the large amount of high-throughput experimental data to assign functions to currently uncharacterized proteins. We here describe CSIDOP, a new method for protein function assignment based on shared interacting domain patterns extracted from cross-species protein-protein interaction data. Methodology/Principal Findings: The proposed method is assessed both biologically and statistically over the genome of H. sapiens. The CSIDOP method is capable of making protein function prediction with accuracy of 95.42% using 2,972 gene ontology (GO) functional categories. In addition, we are able to assign novel functional annotations for 181 previously uncharacterized proteins in H. sapiens. Furthermore, we demonstrate that for proteins that are characterized by GO, the CSIDOP may predict extra functions. This is attractive as a protein normally executes a variety of functions in different processes and its current GO annotation may be incomplete. Conclusions/Significance: It can be shown through experimental results that the CSIDOP method is reliable and practical in use. The method will continue to improve as more high quality interaction data becomes available and is readily scalable to a genome-wide application.	[Chen, Xue-wen; Liu, Mei] Univ Kansas, Bioinformat & Computat Life Sci Lab, ITTC, Dept Elect Engn & Comp Sci, Lawrence, KS 66045 USA; [Ward, Robert] Univ Kansas, Dept Mol Biosci, Lawrence, KS USA	University of Kansas; University of Kansas	Chen, XW (corresponding author), Univ Kansas, Bioinformat & Computat Life Sci Lab, ITTC, Dept Elect Engn & Comp Sci, Lawrence, KS 66045 USA.	xwchen@ku.edu			NSF [IIS-0644366]	NSF(National Science Foundation (NSF))	NSF award IIS-0644366. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; *AMIGO, GEN ONT AMIGO; Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-2; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Brown MPS, 2000, P NATL ACAD SCI USA, V97, P262, DOI 10.1073/pnas.97.1.262; Brun C, 2004, GENOME BIOL, V5; Chen XW, 2005, BIOINFORMATICS, V21, P4394, DOI 10.1093/bioinformatics/bti721; Chen Y, 2004, NUCLEIC ACIDS RES, V32, P6414, DOI 10.1093/nar/gkh978; Costanzo MC, 2000, NUCLEIC ACIDS RES, V28, P73, DOI 10.1093/nar/28.1.73; Crosby MA, 2007, NUCLEIC ACIDS RES, V35, pD486, DOI 10.1093/nar/gkl827; Deng MH, 2004, BIOINFORMATICS, V20, P895, DOI 10.1093/bioinformatics/btg500; Deng MH, 2003, J COMPUT BIOL, V10, P947, DOI 10.1089/106652703322756168; Ellis PJI, 2005, HUM MOL GENET, V14, P2705, DOI 10.1093/hmg/ddi304; Enright AJ, 1999, NATURE, V402, P86, DOI 10.1038/47056; GALLANT P, 1994, EMBO J, V13, P595, DOI 10.1002/j.1460-2075.1994.tb06297.x; Galperin MY, 2000, NAT BIOTECHNOL, V18, P609, DOI 10.1038/76443; Hishigaki H, 2001, YEAST, V18, P523, DOI 10.1002/yea.706; Holzl H, 2000, J CELL BIOL, V150, P119, DOI 10.1083/jcb.150.1.119; Jacobs HW, 1998, GENE DEV, V12, P3741, DOI 10.1101/gad.12.23.3741; Kraut R, 2001, CURR BIOL, V11, P417, DOI 10.1016/S0960-9822(01)00124-5; Lee H, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-269; Lee MO, 2002, MOL CELL ENDOCRINOL, V188, P47, DOI 10.1016/S0303-7207(01)00753-5; Letovsky S, 2003, BIOINFORMATICS, V19, pi197, DOI 10.1093/bioinformatics/btg1026; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; Marcotte EM, 1999, NATURE, V402, P83, DOI 10.1038/47048; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; McDermott J, 2005, BIOINFORMATICS, V21, P3217, DOI 10.1093/bioinformatics/bti514; Mewes HW, 2002, NUCLEIC ACIDS RES, V30, P31, DOI 10.1093/nar/30.1.31; Nariai N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000337; O'Brien KP, 2005, NUCLEIC ACIDS RES, V33, pD476, DOI 10.1093/nar/gki107; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Pellegrini M, 1999, P NATL ACAD SCI USA, V96, P4285, DOI 10.1073/pnas.96.8.4285; Pereira-Leal JB, 2005, GENOME RES, V15, P552, DOI 10.1101/gr.3102105; Pereira-Leal JB, 2004, PROTEINS, V54, P49, DOI 10.1002/prot.10505; Peri S, 2003, GENOME RES, V13, P2363, DOI 10.1101/gr.1680803; POLLER W, 1989, HUM GENET, V83, P93, DOI 10.1007/BF00274157; *QUICKGO, GO BROWS; Ramirez F, 2007, PROTEOMICS, V7, P2541, DOI 10.1002/pmic.200600924; Resnik P, 1999, J ARTIF INTELL RES, V11, P95, DOI 10.1613/jair.514; Salwinski L, 2004, NUCLEIC ACIDS RES, V32, pD449, DOI 10.1093/nar/gkh086; Schlicker A, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-302; Schlicker A, 2007, BIOINFORMATICS, V23, P859, DOI 10.1093/bioinformatics/btm012; Schwikowski B, 2000, NAT BIOTECHNOL, V18, P1257, DOI 10.1038/82360; Spirin V, 2003, P NATL ACAD SCI USA, V100, P12123, DOI 10.1073/pnas.2032324100; Stark C, 2006, NUCLEIC ACIDS RES, V34, pD535, DOI 10.1093/nar/gkj109; Troyanskaya OG, 2003, P NATL ACAD SCI USA, V100, P8348, DOI 10.1073/pnas.0832373100; Tschop K, 2006, FEBS J, V273, P1681, DOI 10.1111/j.1742-4658.2006.05184.x; Vazquez A, 2003, NAT BIOTECHNOL, V21, P697, DOI 10.1038/nbt825; Wang JZ, 2007, BIOINFORMATICS, V23, P1274, DOI 10.1093/bioinformatics/btm087; Wojcik J, 2001, Bioinformatics, V17 Suppl 1, pS296; Zanzoni A, 2002, FEBS LETT, V513, P135, DOI 10.1016/S0014-5793(01)03293-8	54	20	20	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2008	3	2							e1562	10.1371/journal.pone.0001562	http://dx.doi.org/10.1371/journal.pone.0001562			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367EQ	18253506	gold, Green Published, Green Submitted			2022-12-25	WOS:000260535700030
J	Geiger, T; Sabanay, H; Kravchenko-Balasha, N; Geiger, B; Levitzki, A				Geiger, Tamar; Sabanay, Helena; Kravchenko-Balasha, Nataly; Geiger, Benjamin; Levitzki, Alexander			Anomalous Features of EMT during Keratinocyte Transformation	PLOS ONE			English	Article								During the evolution of epithelial cancers, cells often lose their characteristic features and acquire a mesenchymal phenotype, in a process known as epithelial-mesenchymal transition (EMT). In the present study we followed early stages of keratinocyte transformation by HPV16, and observed diverse cellular changes, associated with EMT. We compared primary keratinocytes with early and late passages of HF1 cells, a cell line of HPV16-transformed keratinocytes. We have previously shown that during the progression from the normal cells to early HF1 cells, immortalization is acquired, while in the progression to late HF1, cells become anchorage independent. We show here that during the transition from the normal state to late HF1 cells, there is a progressive reduction in cytokeratin expression, desmosome formation, adherens junctions and focal adhesions, ultimately leading to poorly adhesive phenotype, which is associated with anchorage-independence. Surprisingly, unlike "conventional EMT'', these changes are associated with reduced Rac1-dependent cell migration. We monitored reduced Rac1-dependent migration also in the cervical cancer cell line SiHa. Therefore we can conclude that up to the stage of tumor formation migratory activity is eliminated.	[Geiger, Tamar; Kravchenko-Balasha, Nataly; Levitzki, Alexander] Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; [Sabanay, Helena; Geiger, Benjamin] Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel	Hebrew University of Jerusalem; Weizmann Institute of Science	Geiger, T (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.	levitzki@vms.huji.ac.il	Kravchenko-Balasha, Nataly/D-7683-2016; Geiger, Tamar/C-2349-2014	Kravchenko-Balasha, Nataly/0000-0001-6943-7479; Geiger, Tamar/0000-0002-9526-197X	Hebrew University; Algen Biopharmaceuticals Ltd	Hebrew University; Algen Biopharmaceuticals Ltd	This study was supported by funds from the Hebrew University and Algen Biopharmaceuticals Ltd.	Alazawi WOF, 2003, VIRCHOWS ARCH, V443, P51, DOI 10.1007/s00428-003-0771-9; Bauer NN, 2007, EXP CELL RES, V313, P3832, DOI 10.1016/j.yexcr.2007.08.017; BenBassat H, 1997, CANCER RES, V57, P3741; Bindels S, 2006, ONCOGENE, V25, P4975, DOI 10.1038/sj.onc.1209511; Braga VMM, 1999, MOL BIOL CELL, V10, P9, DOI 10.1091/mbc.10.1.9; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; CARICO E, 1993, GYNECOL ONCOL, V49, P61, DOI 10.1006/gyno.1993.1087; Cote JF, 2002, J CELL SCI, V115, P4901, DOI 10.1242/jcs.00219; Daniel B, 1997, J GEN VIROL, V78, P1095, DOI 10.1099/0022-1317-78-5-1095; Faraldo MM, 2001, EMBO REP, V2, P431, DOI 10.1093/embo-reports/kve086; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Geiger T, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000605; GIGILEITNER O, 1986, DIFFERENTIATION, V31, P191, DOI 10.1111/j.1432-0436.1986.tb00400.x; Green KJ, 1996, FASEB J, V10, P871, DOI 10.1096/fasebj.10.8.8666164; Guo FK, 2006, J BIOL CHEM, V281, P18652, DOI 10.1074/jbc.M603508200; Hirohashi S, 2003, CANCER SCI, V94, P575, DOI 10.1111/j.1349-7006.2003.tb01485.x; HODIVALA KJ, 1994, ONCOGENE, V9, P943; HUSZAR M, 1986, DIFFERENTIATION, V31, P141, DOI 10.1111/j.1432-0436.1986.tb00395.x; Jamora C, 2002, NAT CELL BIOL, V4, pE101, DOI 10.1038/ncb0402-e101; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; Kirfel G, 2004, PROTOPLASMA, V223, P67, DOI 10.1007/s00709-003-0031-5; Kokkinos MI, 2007, CELLS TISSUES ORGANS, V185, P191, DOI 10.1159/000101320; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Lee TK, 2006, CLIN CANCER RES, V12, P5369, DOI 10.1158/1078-0432.CCR-05-2722; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MITRANIROSENBAUM S, 1992, INTERVIROLOGY, V33, P76, DOI 10.1159/000150234; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Mizrachy-Schwartz S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000628; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Peluso JJ, 2001, BIOL REPROD, V64, P1183, DOI 10.1095/biolreprod64.4.1183; Perez-Moreno M, 2006, DEV CELL, V11, P601, DOI 10.1016/j.devcel.2006.10.010; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; van Dorst EBL, 1998, J CLIN PATHOL, V51, P679, DOI 10.1136/jcp.51.9.679; VANWAES C, 1995, CANCER RES, V55, P5434; Vernon AE, 2004, CURR BIOL, V14, pR719, DOI 10.1016/j.cub.2004.08.048; WILBANKS GD, 1976, CANCER RES, V36, P2485; WOODWORTH CD, 1990, CANCER RES, V50, P3709; Yamazaki D, 2005, CANCER SCI, V96, P379, DOI 10.1111/j.1349-7006.2005.00062.x; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	45	33	37	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2008	3	2							e1574	10.1371/journal.pone.0001574	http://dx.doi.org/10.1371/journal.pone.0001574			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367EQ	18253510	Green Published, gold, Green Submitted			2022-12-25	WOS:000260535700034
J	Flierl, MA; Rittirsch, D; Gao, HW; Hoesel, LM; Nadeau, BA; Day, DE; Zetoune, FS; Sarma, JV; Huber-Lang, MS; Ferrara, JLM; Ward, PA				Flierl, Michael A.; Rittirsch, Daniel; Gao, Hongwei; Hoesel, Laszlo M.; Nadeau, Brian A.; Day, Danielle E.; Zetoune, Firas S.; Sarma, J. Vidya; Huber-Lang, Markus S.; Ferrara, James L. M.; Ward, Peter A.			Adverse functions of IL-17A in experimental sepsis	FASEB JOURNAL			English	Article						gamma delta; T cells; survival; colony-forming units; cytokines; chemokines	DELTA T-LYMPHOCYTES; CENTRAL-NERVOUS-SYSTEM; VERSUS-HOST-DISEASE; GROWTH-FACTOR-BETA; EPITHELIAL-CELLS; HELPER-CELLS; INTERLEUKIN-17; INFLAMMATION; NEUTROPHILS; MORTALITY	IL-17A is a proinflammatory cytokine produced by a variety of cells. In the current study, we examined the role of IL-17A in sepsis induced in mice by cecal ligation and puncture (CLP). IL-17A levels, which rose time-dependently in plasma after CLP, were not affected in the absence of alpha beta T cells or neutrophils. In sharp contrast, gamma delta T cell-knockout or gamma delta T cell-depleted mice displayed baseline IL-17A plasma levels after CLP. Neutralization of IL-17A by two different antibodies improved sepsis (survival from similar to 10% to nearly 60%). Unexpectedly, antibody treatment was protective, even when administration of anti-IL-17A was delayed for up to 12 h after CLP. These protective effects of IL-17A blockade were associated with substantially reduced levels of bacteremia together with significant reductions of systemic proinflammatory cytokines and chemokines in plasma. In vitro incubation of mouse peritoneal macrophages with lipopolysaccharide (LPS) in the copresence of IL-17A substantially increased the production of TNF-alpha, IL-1 beta, and IL-6 by these cells. These data suggest that, during experimental sepsis, gamma delta T cell-derived IL-17A promotes high levels of proinflammatory mediators and bacteremia, resulting in enhanced lethality. IL-17A may be a potential therapeutic target in sepsis.	[Flierl, Michael A.; Rittirsch, Daniel; Hoesel, Laszlo M.; Nadeau, Brian A.; Day, Danielle E.; Zetoune, Firas S.; Sarma, J. Vidya; Ward, Peter A.] Univ Michigan, Dept Pathol, Sch Med, Ann Arbor, MI 48109 USA; [Ferrara, James L. M.] Univ Michigan, Dept Pediat & Internal Med, Sch Med, Ann Arbor, MI 48109 USA; [Gao, Hongwei] Univ N Dakota, Sch Med, Dept Biochem & Mol Biol, Grand Forks, ND 58201 USA; [Huber-Lang, Markus S.] Univ Ulm, Sch Med, Dept Traumatol Hand & Reconstruct Surg, Ulm, Germany	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of North Dakota Grand Forks; Ulm University	Ward, PA (corresponding author), Univ Michigan, Dept Pathol, Sch Med, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.	pward@umich.edu	Huber-Lang, Markus/AAJ-2209-2020	Rittirsch, Daniel/0000-0002-1185-2431	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031963] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061656, R37GM029507, R01GM029507] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-31963, P01 HL031963] Funding Source: Medline; NIGMS NIH HHS [GM29507, R01 GM029507, R01 GM061656, GM61656] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663; Awane M, 1999, J IMMUNOL, V162, P5337; BAKER CC, 1983, SURGERY, V94, P331; Batten M, 2006, NAT IMMUNOL, V7, P929, DOI 10.1038/ni1375; Benchetrit F, 2002, BLOOD, V99, P2114, DOI 10.1182/blood.V99.6.2114; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Bettelli E, 2007, NAT IMMUNOL, V8, P345, DOI 10.1038/ni0407-345; Chabaud M, 1998, J IMMUNOL, V161, P409; Chung CS, 2006, AM J PHYSIOL-REG I, V291, pR1338, DOI 10.1152/ajpregu.00283.2006; Denning TL, 2007, NAT IMMUNOL, V8, P1086, DOI 10.1038/ni1511; Dombrovskiy VY, 2007, CRIT CARE MED, V35, P1244, DOI 10.1097/01.CCM.0000261890.41311.E9; Dong C, 2006, NAT REV IMMUNOL, V6, P329, DOI 10.1038/nri1807; Ferretti S, 2003, J IMMUNOL, V170, P2106, DOI 10.4049/jimmunol.170.4.2106; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Hartupee J, 2007, J IMMUNOL, V179, P4135, DOI 10.4049/jimmunol.179.6.4135; Huber-Lang MS, 2002, J IMMUNOL, V169, P3223, DOI 10.4049/jimmunol.169.6.3223; Hunter CA, 2007, NAT IMMUNOL, V8, P232, DOI 10.1038/ni0307-232; Iwakura Y, 2006, J CLIN INVEST, V116, P1218, DOI 10.1172/JCI28508; Kebir H, 2007, NAT MED, V13, P1173, DOI 10.1038/nm1651; Kochanek Kenneth D, 2004, Natl Vital Stat Rep, V52, P1; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Linden A, 2001, INT ARCH ALLERGY IMM, V126, P179, DOI 10.1159/000049511; Linden A, 2005, EUR RESPIR J, V25, P159, DOI 10.1183/09031936.04.00032904; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Maeda Y, 2005, BLOOD, V106, P749, DOI 10.1182/blood-2004-10-4087; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Matsushima A, 2004, SHOCK, V22, P11, DOI 10.1097/01.shk.0000129203.84330.b3; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Qian YC, 2007, NAT IMMUNOL, V8, P247, DOI 10.1038/ni1439; Riedemann NC, 2003, J CLIN INVEST, V112, P460, DOI 10.1172/JCI200319523; SAKAI T, 1995, EUR J IMMUNOL, V25, P87, DOI 10.1002/eji.1830250117; Schwarzenberger P, 1998, J IMMUNOL, V161, P6383; Shibata K, 2007, J IMMUNOL, V178, P4466, DOI 10.4049/jimmunol.178.7.4466; Stark MA, 2005, IMMUNITY, V22, P285, DOI 10.1016/j.immuni.2005.01.011; Stumhofer JS, 2006, NAT IMMUNOL, V7, P937, DOI 10.1038/ni1376; Van Kooten C, 1998, J AM SOC NEPHROL, V9, P1526; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Ward PA, 2004, NAT REV IMMUNOL, V4, P133, DOI 10.1038/nri1269; Weaver CT, 2007, ANNU REV IMMUNOL, V25, P821, DOI 10.1146/annurev.immunol.25.022106.141557; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497; Wynn TA, 2005, NAT IMMUNOL, V6, P1069, DOI 10.1038/ni1105-1069; Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519; Yokota N, 2002, TRANSPLANTATION, V74, P759, DOI 10.1097/00007890-200209270-00005; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488	46	148	167	2	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2198	2205		10.1096/fj.07-105221	http://dx.doi.org/10.1096/fj.07-105221			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18299333	Green Submitted			2022-12-25	WOS:000257292500012
J	Shimizu, H; Nakagami, H; Osako, MK; Hanayama, R; Kunugiza, Y; Kizawa, T; Tomita, T; Yoshikawa, H; Ogihara, T; Morishita, R				Shimizu, Hideo; Nakagami, Hironori; Osako, Mariana Kiomy; Hanayama, Rie; Kunugiza, Yasuo; Kizawa, Takuji; Tomita, Tetsuya; Yoshikawa, Hideki; Ogihara, Toshio; Morishita, Ryuichi			Angiotensin II accelerates osteoporosis by activating osteoclasts	FASEB JOURNAL			English	Article						hypertension; renin-angiotensin system; RANKL; ARB; TRAP activity	HIGH EXTRACELLULAR CALCIUM; ESSENTIAL-HYPERTENSION; BONE-RESORPTION; SENSING RECEPTOR; IONIZED CALCIUM; PROTEIN-KINASE; BETA-BLOCKERS; CORTICAL BONE; CELLS; INHIBITOR	Recent clinical studies suggest that several antihypertensive drugs, especially angiotensin-converting enzyme inhibitors, reduced bone fractures. To clarify the relationship between hypertension and osteoporosis, we focused on the role of angiotensin II (Ang II) on bone metabolism. In bone marrow-derived mononuclear cells, Ang II (1 x 10(-6) M) significantly increased tartrate-resistant acid phosphatase (TRAP)-positive multinuclear osteoclasts. Of importance, Ang II significantly induced the expression of receptor activator of NF-kappa B ligand (RANKL) in osteoblasts, leading to the activation of osteoclasts, whereas these effects were completely blocked by an Ang II type 1 receptor blockade (olmesartan) and mitogen-activated protein kinase kinase inhibitors. In a rat ovariectomy model of estrogen deficiency, administration of Ang II (200 ng/kg/min) accelerated the increase in TRAP activity, accompanied by a significant decrease in bone density and an increase in urinary deoxypyridinoline. In hypertensive rats, treatment with olmesartan attenuated the ovariectomy-induced decrease in bone density and increase in TRAP activity and urinary deoxypyridinoline. Furthermore, in wild-type mice ovariectomy with five-sixths nephrectomy decreased bone volume by microcomputed tomography, whereas these change was not detect in Ang II type 1a receptor-deficient mice. Overall, Ang II accelerates osteoporosis by activating osteoclasts via RANKL induction. Blockade of Ang II might become a novel therapeutic approach to prevent osteoporosis in hypertensive patients.	[Shimizu, Hideo; Osako, Mariana Kiomy; Hanayama, Rie; Morishita, Ryuichi] Osaka Univ, Grad Sch Med, Div Clin Gene Therapy, Osaka 5650871, Japan; [Shimizu, Hideo; Ogihara, Toshio] Osaka Univ, Grad Sch Med, Dept Geriatr Med, Osaka 5650871, Japan; [Nakagami, Hironori] Osaka Univ, Grad Sch Med, Div Gene Therapy Sci, Osaka 5650871, Japan; [Kunugiza, Yasuo; Kizawa, Takuji; Tomita, Tetsuya; Yoshikawa, Hideki] Osaka Univ, Grad Sch Med, Dept Orthoped Surg, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University; Osaka University	Morishita, R (corresponding author), Osaka Univ, Grad Sch Med, Div Clin Gene Therapy, 2-2 Yamadaoka, Osaka 5650871, Japan.	morishit@cgt.med.osaka-u.ac.jp	Osako, Mariana/G-2853-2013; Nakagami, Hironori/GLU-0570-2022; Osako, Mariana Kiomy/H-3337-2019; Osako, Mariana/B-9572-2009; Osako, Mariana Kiomy/AGX-6892-2022	Nakagami, Hironori/0000-0003-4494-3601; Osako, Mariana Kiomy/0000-0002-5021-8433				Broulik PD, 2001, PHYSIOL RES, V50, P353; Cappuccio FP, 2000, J NEPHROL, V13, P169; DUARTE CG, 1971, NEW ENGL J MED, V284, P828, DOI 10.1056/NEJM197104152841506; Hatton R, 1997, J ENDOCRINOL, V152, P5, DOI 10.1677/joe.0.1520005; Hiruma Y, 1997, BIOCHEM BIOPH RES CO, V230, P176, DOI 10.1006/bbrc.1996.5914; Ibrahim HN, 1998, J AM SOC NEPHROL, V9, P72; Inagami T, 1999, J AM SOC NEPHROL, V10, pS57; Kaji H, 1996, J BONE MINER RES, V11, P912; Kameda T, 1998, BIOCHEM BIOPH RES CO, V245, P419, DOI 10.1006/bbrc.1998.8448; Kim YH, 2003, BIOCHEM BIOPH RES CO, V304, P729, DOI 10.1016/S0006-291X(03)00661-2; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Liu HW, 2002, HYPERTENSION, V40, P451, DOI 10.1161/01.HYP.0000033466.05496.89; Liu XS, 2002, J CARDIOVASC PHARM, V40, P448, DOI 10.1097/00005344-200209000-00014; Lynn H, 2006, BONE, V38, P584, DOI 10.1016/j.bone.2005.09.011; MACGREGOR GA, 1993, J HYPERTENS, V11, P781, DOI 10.1097/00004872-199308000-00003; MCCARRON DA, 1980, HYPERTENSION, V2, P162, DOI 10.1161/01.HYP.2.2.162; MCCARRON DA, 1982, NEW ENGL J MED, V307, P226, DOI 10.1056/NEJM198207223070405; Nakagami H, 2000, J HYPERTENS, V18, P1411, DOI 10.1097/00004872-200018100-00008; Nakagami H, 2003, J MOL CELL CARDIOL, V35, P851, DOI 10.1016/S0022-2828(03)00145-7; PARFITT AM, 1983, J CLIN INVEST, V72, P1396, DOI 10.1172/JCI111096; Reid IR, 2000, AM J MED, V109, P362, DOI 10.1016/S0002-9343(00)00510-6; Rejnmark L, 2006, J HYPERTENS, V24, P581, DOI 10.1097/01.hjh.0000203845.26690.cb; RESNICK LM, 1983, NEW ENGL J MED, V309, P888, DOI 10.1056/NEJM198310133091504; RIGGS BL, 1992, NEW ENGL J MED, V327, P620; Schlienger RG, 2004, JAMA-J AM MED ASSOC, V292, P1326, DOI 10.1001/jama.292.11.1326; Schoofs MWCJ, 2003, ANN INTERN MED, V139, P476, DOI 10.7326/0003-4819-139-6-200309160-00010; Shimizu H, 2006, GENE THER, V13, P933, DOI 10.1038/sj.gt.3302711; SHIMIZU H, 1990, J BONE MINER RES, V5, P411, DOI 10.1002/jbmr.5650050415; Sone T, 2004, BONE, V35, P432, DOI 10.1016/j.bone.2004.05.011; SUGAYA T, 1995, J BIOL CHEM, V270, P18719, DOI 10.1074/jbc.270.32.18719; Takeda-Matsubara Y, 2002, HYPERTENSION, V39, P41, DOI 10.1161/hy1201.097197; Taylor A, 2007, CALCIFIED TISSUE INT, V80, P132, DOI 10.1007/s00223-006-0245-6; VANDERPLUIJM G, 1991, ENDOCRINOLOGY, V129, P1596; Venken K, 2005, BONE, V36, P663, DOI 10.1016/j.bone.2005.01.003; Xiang A, 2007, BONE, V40, P1231, DOI 10.1016/j.bone.2007.01.010; Yamaguchi T, 2000, BIOCHEM BIOPH RES CO, V279, P363, DOI 10.1006/bbrc.2000.3955; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	37	204	235	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2465	2475		10.1096/fj.07-098954	http://dx.doi.org/10.1096/fj.07-098954			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18256306				2022-12-25	WOS:000257292500038
J	Tan, WF; Palmby, TR; Gavard, J; Amornphimoltham, P; Zheng, Y; Gutkind, JS				Tan, Wenfu; Palmby, Todd R.; Gavard, Julie; Amornphimoltham, Panomwat; Zheng, Yi; Gutkind, J. Silvio			An essential role for Rac1 in endothelial cell function and vascular development	FASEB JOURNAL			English	Article						angiogenesis; S1P; VEGF; migration; cytoskeleton	IN-VIVO; TRANSGENIC MICE; ANGIOGENESIS; RHO; MIGRATION; ADHESION; GROWTH; VEGF; SPHINGOSINE-1-PHOSPHATE; VASCULOGENESIS	Numerous cell surface receptors, including tyrosine kinase and G protein-coupled receptors, play critical roles in endothelial cell function and blood vessel development. These receptors share the ability of stimulating an intricate network of intracellular signaling pathways, including the activation of members of the Ras and Rho family of small GTPases. However, the contribution of these signaling molecules to the numerous biological activities performed by endothelial cells is still not fully understood. Here, we have used a conditional Cre/ Flox approach, enabling the deletion of the Rac1 gene in endothelial cells, to examine the role of the Rho-related GTPase Rac1 in endothelial cell function and vascular development. Rac1 excision in primary endothelial cells in vitro revealed that Rac1 plays a central role in endothelial cell migration, tubulogenesis, adhesion, and permeability in response to vascular endothelial growth factor (VEGF) and sphingosine-1-phosphate (S1P), which is likely due to the inability of Rac1-deficient endothelial cells to form lamellipodial structures and focal adhesions, and to remodel their cell-cell contacts. Importantly, endothelial-specific excision of Rac1 results in embryonic lethality in midgestation (around E9.5), and defective development of major vessels and complete lack of small branched vessels was readily observed in these endothelial Rac1-deficient embryos and their yolk sacs. These findings provide direct evidence that the activity of Rac1 in endothelial cells is essential for vascular development and suggest that Rac1 and its downstream targets may represent promising therapeutic targets for the treatment of numerous human diseases that involve aberrant neovascularization.	[Tan, Wenfu; Palmby, Todd R.; Gavard, Julie; Amornphimoltham, Panomwat; Gutkind, J. Silvio] Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; [Zheng, Yi] Univ Cincinnati, Childrens Hosp, Med Ctr, Div Expt Hematol, Cincinnati, OH USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Gutkind, JS (corresponding author), Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Room 211, Bethesda, MD 20892 USA.	sg39v@nih.gov	Zheng, Yi/J-7235-2015; Amornphimoltham, Walt/AAP-9654-2020; Gavard, Julie/I-5487-2012; Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016; Gavard, Julie/I-5487-2012	Zheng, Yi/0000-0001-7089-6074; Gavard, Julie/0000-0002-7985-9007; Gutkind, J. Silvio/0000-0002-5150-4482; Gavard, Julie/0000-0003-3107-2026	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Basile JR, 2005, MOL CELL BIOL, V25, P6889, DOI 10.1128/MCB.25.16.6889-6898.2005; Beck L, 1997, FASEB J, V11, P365, DOI 10.1096/fasebj.11.5.9141503; Braga VMM, 1999, MOL BIOL CELL, V10, P9, DOI 10.1091/mbc.10.1.9; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; Castilho RM, 2007, ONCOGENE, V26, P5078, DOI 10.1038/sj.onc.1210322; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Coultas L, 2005, NATURE, V438, P937, DOI 10.1038/nature04479; Crowther M, 2001, J LEUKOCYTE BIOL, V70, P478; Dominguez MG, 2007, P NATL ACAD SCI USA, V104, P3243, DOI 10.1073/pnas.0611510104; Drake Christopher J., 2003, Birth Defects Research, V69, P73, DOI 10.1002/bdrc.10003; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; Gu Y, 2003, SCIENCE, V302, P445, DOI 10.1126/science.1088485; Guleng B, 2005, CANCER RES, V65, P5864, DOI 10.1158/0008-5472.CAN-04-3833; Hartwell DM, 1998, J CELL BIOL, V143, P1129, DOI 10.1083/jcb.143.4.1129; Hla T, 2003, PHARMACOL RES, V47, P401, DOI 10.1016/S1043-6618(03)00046-X; Kisanuki YY, 2001, DEV BIOL, V230, P230, DOI 10.1006/dbio.2000.0106; Koni PA, 2001, J EXP MED, V193, P741, DOI 10.1084/jem.193.6.741; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Mao XH, 1999, P NATL ACAD SCI USA, V96, P5037, DOI 10.1073/pnas.96.9.5037; Red-Horse K, 2007, DEV CELL, V12, P181, DOI 10.1016/j.devcel.2007.01.013; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; Rosenfeldt HM, 2001, BIOCHEM SOC T, V29, P836, DOI 10.1042/0300-5127:0290836; SCHLAEGER TM, 1995, DEVELOPMENT, V121, P1089; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; Shen TL, 2005, J CELL BIOL, V169, P941, DOI 10.1083/jcb.200411155; SHIRSAT NV, 1990, ONCOGENE, V5, P769; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; van Hinsbergh VWM, 2001, ANN NY ACAD SCI, V936, P426; Visvader JE, 1998, GENE DEV, V12, P473, DOI 10.1101/gad.12.4.473; Weiss-Haljiti C, 2004, J BIOL CHEM, V279, P43273, DOI 10.1074/jbc.M402924200; Williams DA, 2000, BLOOD, V96, P1646; Yancopoulos GD, 1998, CELL, V93, P661, DOI 10.1016/S0092-8674(00)81426-9; Yang FC, 2001, P NATL ACAD SCI USA, V98, P5614, DOI 10.1073/pnas.101546898	42	170	178	1	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1829	1838		10.1096/fj.07-096438	http://dx.doi.org/10.1096/fj.07-096438			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18245172				2022-12-25	WOS:000256352700023
J	Yu, HY; Konigshoff, M; Jayachandran, A; Handley, D; Seeger, W; Kaminski, N; Eickelberg, O				Yu, Haiying; Koenigshoff, Melanie; Jayachandran, Aparna; Handley, Dan; Seeger, Werner; Kaminski, Naftali; Eickelberg, Oliver			Transgelin is a direct target of TGF-beta/Smad3-dependent epithelial cell migration in lung fibrosis	FASEB JOURNAL			English	Article						alveolar epithelial cell; signal transduction; bleomycin	IDIOPATHIC PULMONARY-FIBROSIS; GROWTH-FACTOR-BETA; SMOOTH-MUSCLE; MESENCHYMAL TRANSITION; TRANSCRIPTION FACTORS; CLINICAL-RELEVANCE; TGF-BETA; EXPRESSION; GENE; SM22-ALPHA	Enhanced transforming growth factor (TGF) -beta signaling contributes to idiopathic pulmonary fibrosis (IPF), a progressive and fatal disease characterized by alveolar epithelial type II (ATII) cell hyperplasia, (myo) fibroblast accumulation, and excessive extracellular matrix deposition. TGF-beta is a potent inducer of lung fibrosis, and it regulates the ATII cell phenotype; however, direct TGF-beta target genes controlling the ATII cell phenotype remain elusive. Here, we identified the transgelin (tagln) gene as a novel immediate target of TGF-beta/Smad3-dependent gene expression in ATII cells using a Smad3 chromatin immunoprecipitation (ChIP) screen. Direct ChIP confirmed the rapid and specific binding of Smad3 to the tagln promoter. Luciferase assays demonstrated transactivation of the tagln promoter by activin-like kinase (Alk) 5-mediated TGF-beta signaling. TGF-beta treatment resulted in rapid up-regulation of tagln, but not tagln2, mRNA and protein expression, assessed by reverse transcription-polymerase chain reaction (RT-PCR), Western blotting, and immunofluorescence. In vivo, tagln expression was significantly increased in ATII cells of mice during bleomycin-induced lung fibrosis, as well as in lung specimen obtained from IPF patients, as assessed by RT-PCR and immunohistochemistry. Knockdown of tagln using siRNA inhibited TGF-beta-induced migration of lung epithelial A549 cells, as well as primary ATII cells. We thus identified tagln as a novel target of TGF-beta/Smad3-dependent gene expression in ATII cells. Increased ATII cell expression of tagln in experimental and idiopathic pulmonary fibrosis may contribute to TGF-beta-dependent ATII cell injury, repair, and migration in lung fibrosis.	[Yu, Haiying; Koenigshoff, Melanie; Jayachandran, Aparna; Seeger, Werner; Eickelberg, Oliver] Univ Giessen, Lung Ctr, Dept Med 2, D-35392 Giessen, Germany; [Handley, Dan; Kaminski, Naftali] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA	Justus Liebig University Giessen; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Eickelberg, O (corresponding author), Univ Giessen, Lung Ctr, Dept Med 2, Aulweg 123,Rm 6-11, D-35392 Giessen, Germany.	oliver.eickelberg@innere.med.uni-giessen.de	Eickelberg, Oliver/A-5461-2013	Eickelberg, Oliver/0000-0001-7170-0360; Seeger, Werner/0000-0003-1946-0894; Kaminski, Naftali/0000-0001-5917-4601	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073745] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R01LM009657] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL073745] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		American Thoracic Society, 2002, AM J RESP CRIT CARE, V165, P277, DOI DOI 10.1164/ajrccm.165.2.ats01; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Camoretti-Mercado B, 1998, GENOMICS, V49, P452, DOI 10.1006/geno.1998.5267; Cevallos M, 2006, DIFFERENTIATION, V74, P552, DOI 10.1111/j.1432-0436.2006.00089.x; Chapman HA, 2004, J CLIN INVEST, V113, P148, DOI 10.1172/JCI200420729; Chen SY, 2003, NUCLEIC ACIDS RES, V31, P1302, DOI 10.1093/nar/gkg224; Chua F, 2005, AM J RESP CELL MOL, V33, P9, DOI 10.1165/rcmb.2005-0062TR; Frances R, 2006, MOL IMMUNOL, V43, P2124, DOI 10.1016/j.molimm.2005.12.011; Hashimoto N, 2004, J CLIN INVEST, V113, P243, DOI 10.1172/JCI200418847; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Katzenstein ALA, 1998, AM J RESP CRIT CARE, V157, P1301, DOI 10.1164/ajrccm.157.4.9707039; Kim IY, 2005, J BIOCHEM MOL BIOL, V38, P1; Kim KK, 2006, P NATL ACAD SCI USA, V103, P13180, DOI 10.1073/pnas.0605669103; Konigshoff M, 2007, AM J RESP CELL MOL, V37, P640, DOI 10.1165/rcmb.2006-0379TR; Lee Chun Geun, 2006, Proc Am Thorac Soc, V3, P418, DOI 10.1513/pats.200602-017AW; LEESMILLER JP, 1987, J BIOL CHEM, V262, P2988; LEESMILLER JP, 1987, BIOCHEM J, V244, P705, DOI 10.1042/bj2440705; Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Selman M, 2001, ANN INTERN MED, V134, P136, DOI 10.7326/0003-4819-134-2-200101160-00015; Sheppard Dean, 2006, Proc Am Thorac Soc, V3, P413, DOI 10.1513/pats.200601-008AW; Shields JM, 2002, J BIOL CHEM, V277, P9790, DOI 10.1074/jbc.M110086200; Sinha S, 2004, AM J PHYSIOL-CELL PH, V287, pC1560, DOI 10.1152/ajpcell.00221.2004; SOLWAY J, 1995, J BIOL CHEM, V270, P13460, DOI 10.1074/jbc.270.22.13460; Strieter RM, 2005, CHEST, V128, p526S, DOI 10.1378/chest.128.5_suppl_1.526S; Strieter RM, 2007, J CLIN INVEST, V117, P549, DOI 10.1172/JCI30562; TEN DP, 2004, TRENDS BIOCHEM SCI, V29, P265; Teng YQ, 2007, J CLIN INVEST, V117, P304, DOI 10.1172/JCI31200; Thannickal VJ, 2004, ANNU REV MED, V55, P395, DOI 10.1146/annurev.med.55.091902.103810; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Untergasser G, 2005, MECH AGEING DEV, V126, P59, DOI 10.1016/j.mad.2004.09.023; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Willis BC, 2005, AM J PATHOL, V166, P1321, DOI 10.1016/S0002-9440(10)62351-6; Willis BC, 2007, AM J PHYSIOL-LUNG C, V293, pL525, DOI 10.1152/ajplung.00163.2007; Willis Brigham C, 2006, Proc Am Thorac Soc, V3, P377, DOI 10.1513/pats.200601-004TK; Zhang JCL, 2001, MOL CELL BIOL, V21, P1336, DOI 10.1128/MCB.2001.21.4.1336-1344.2001	37	110	115	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					1778	1789		10.1096/fj.07-083857	http://dx.doi.org/10.1096/fj.07-083857			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18245174				2022-12-25	WOS:000256352700018
J	Alibin, CP; Kopilas, MA; Anderson, HDI				Alibin, Caroline P.; Kopilas, Melanie A.; Anderson, Hope D. I.			Suppression of cardiac myocyte hypertrophy by conjugated linoleic acid - Role of peroxisome proliferator-activated receptors alpha and gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C ISOFORMS; PPAR-GAMMA; DIACYLGLYCEROL-KINASE; PLASMA-LIPOPROTEINS; FATTY-ACIDS; IN-VITRO; INHIBITION; EXPRESSION; AGONIST; HEART	Conjugated linoleic acid (CLA) refers to a naturally occurring mixture of positional and geometric isomers of linoleic acid. Evidence suggests that CLA is a dietary constituent and nutraceutical with anti-cancer, insulin-sensitizing, immunomodulatory, weight-partitioning, and cardioprotective properties. The aim of this study was to evaluate the effects of intervention with CLA on cardiac hypertrophy. In vitro, CLA prevented indicators of cardiomyocyte hypertrophy elicited by endothelin-1, including cell size augmentation, protein synthesis, and fetal gene activation. Similar anti-hypertrophic effects of CLA were observed in hypertrophy induced by angiotensin II, fibroblast growth factor, and mechanical strain. CLA may inhibit hypertrophy through activation of peroxisome proliferator-activated receptors (PPARs). CLA stimulated PPAR activity in cardiomyocytes, and the anti-hypertrophic effects of CLA were blocked by genetic and pharmacological inhibitors of PPAR isoforms alpha and gamma. CLA may disrupt hypertrophic signaling by stimulating diacylglycerol kinase zeta, which decreases availability of diacylglycerol and thereby inhibits the protein kinase C epsilon pathway. In vivo, dietary CLA supplementation significantly reduced blood pressure and cardiac hypertrophy in spontaneously hypertensive heart failure rats. These data suggest that dietary supplementation with CLA may be a viable strategy to prevent pathological cardiac hypertrophy, a major risk factor for heart failure.	St Boniface Gen Hosp, Res Ctr, Canadian Ctr Agri Food Res Hlth & Med, Winnipeg, MB R2H 2A6, Canada; Univ Manitoba, Fac Pharm, Winnipeg, MB R2H 2A6, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba	Anderson, HDI (corresponding author), St Boniface Gen Hosp, Res Ctr, Canadian Ctr Agri Food Res Hlth & Med, 351 Tache Ave, Winnipeg, MB R2H 2A6, Canada.	handerson@sbrc.ca		Anderson, Hope/0000-0001-6570-6678				Anderson HDI, 2004, J BIOL CHEM, V279, P9287, DOI 10.1074/jbc.M309227200; Arimoto T, 2006, CIRCULATION, V113, P60, DOI 10.1161/CIRCULATIONAHA.105.560771; Asakawa M, 2002, CIRCULATION, V105, P1240, DOI 10.1161/hc1002.105225; Bassaganya-Riera J, 2004, GASTROENTEROLOGY, V127, P777, DOI 10.1053/j.gastro.2004.06.049; BENES AJ, 1985, J CELL SCI, V75, P35; Benito P, 2001, LIPIDS, V36, P229, DOI 10.1007/s11745-001-0712-x; Bhattacharya A, 2006, J NUTR BIOCHEM, V17, P789, DOI 10.1016/j.jnutbio.2006.02.009; Chen H, 2003, J BIOL CHEM, V278, P45021, DOI 10.1074/jbc.M307878200; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Cimini AM, 2005, INT J CANCER, V117, P923, DOI 10.1002/ijc.21272; Clerk A, 1996, BIOCHEM J, V317, P109, DOI 10.1042/bj3170109; CLERK A, 1994, J BIOL CHEM, V269, P32848; De Caterina R, 2006, AM J CLIN NUTR, V83, p421S; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; Doyle L, 2005, EUR J CLIN NUTR, V59, P432, DOI 10.1038/sj.ejcn.1602093; Duan SZ, 2005, CIRC RES, V97, P372, DOI 10.1161/01.RES.0000179226.34112.6d; Frey N, 2004, CIRCULATION, V109, P1580, DOI 10.1161/01.CIR.0000120390.68287.BB; Herbel BK, 1998, AM J CLIN NUTR, V67, P332, DOI 10.1093/ajcn/67.2.332; HO KKL, 1993, J AM COLL CARDIOL, V22, pA6, DOI 10.1016/0735-1097(93)90455-A; Houseknecht KL, 1998, BIOCHEM BIOPH RES CO, V244, P678, DOI 10.1006/bbrc.1998.8303; Ichihara S, 2006, J MOL CELL CARDIOL, V41, P318, DOI 10.1016/j.yjmcc.2006.05.013; Inoue N, 2004, BIOCHEM BIOPH RES CO, V323, P679, DOI 10.1016/j.bbrc.2004.08.139; Irukayama-Tomobe Y, 2004, CIRCULATION, V109, P904, DOI 10.1161/01.CIR.0000112596.06954.00; Kamlage B, 2000, J NUTR, V130, P2036, DOI 10.1093/jn/130.8.2036; Kehrer JP, 2001, BIOCHEM J, V356, P899, DOI 10.1042/0264-6021:3560899; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kritchevsky D, 2000, J AM COLL NUTR, V19, p472S, DOI 10.1080/07315724.2000.10718950; Lai KL, 2005, LIPIDS, V40, P1107, DOI 10.1007/s11745-005-1474-1; LaPointe MC, 2005, PEPTIDES, V26, P944, DOI 10.1016/j.peptides.2004.08.028; Lee KC, 2001, TRENDS ENDOCRIN MET, V12, P191, DOI 10.1016/S1043-2760(01)00392-7; LEVY D, 1990, NEW ENGL J MED, V0322; Liang FQ, 2003, ENDOCRINOLOGY, V144, P4187, DOI 10.1210/en.2002-0217; LITWIN SE, 1991, CIRCULATION, V83, P1028, DOI 10.1161/01.CIR.83.3.1028; Lockhart LK, 1999, J PHARMACOL EXP THER, V289, P721; MEERSON F Z, 1961, Cor Vasa, V3, P161; Miller A, 2002, ANTICANCER RES, V22, P3879; Moya-Camarena SY, 1999, BBA-MOL CELL BIOL L, V1436, P331, DOI 10.1016/S0005-2760(98)00121-0; Moya-Camarena SY, 1999, J LIPID RES, V40, P1426; Nagao K, 2003, BIOCHEM BIOPH RES CO, V310, P562, DOI 10.1016/j.bbrc.2003.09.044; Nicolosi RJ, 1997, ARTERY, V22, P266; OSLER WO, 1892, PRINCIPLES PRACTICE, P735; Pariza MW, 2004, AM J CLIN NUTR, V79, p1132S, DOI 10.1093/ajcn/79.6.1132S; Planavila A, 2005, CARDIOVASC RES, V65, P832, DOI 10.1016/j.cardiores.2004.11.011; PUCEAT M, 1994, J BIOL CHEM, V269, P16938; Reffelmann T, 2003, BASIC RES CARDIOL, V98, P275, DOI 10.1007/s00395-003-0401-3; SAKAI S, 2002, CLIN SCI LOND S48, V103, P16; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Takahashi H, 2005, CIRCULATION, V111, P1510, DOI 10.1161/01.CIR.0000159339.00703.22; Takano H, 2000, CIRC RES, V87, P596, DOI 10.1161/01.RES.87.7.596; Takeishi Y, 2007, PHARMACOL THERAPEUT, V115, P352, DOI 10.1016/j.pharmthera.2007.04.010; Toomey S, 2003, BIOCHEM SOC T, V31, P1075, DOI 10.1042/BST0311075; Verrier E, 2004, CIRC RES, V94, P1515, DOI 10.1161/01.RES.0000130527.92537.06; Wargent Ed, 2005, Lipids Health Dis, V4, P3, DOI 10.1186/1476-511X-4-3; Wayman NS, 2002, FASEB J, V16, P1027, DOI 10.1096/fj.01-0793com; WU JP, 1989, J BIOL CHEM, V264, P6472; Xiao YF, 1997, P NATL ACAD SCI USA, V94, P4182, DOI 10.1073/pnas.94.8.4182; Xiao YF, 1998, P NATL ACAD SCI USA, V95, P2680, DOI 10.1073/pnas.95.5.2680; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Yamamoto K, 2001, CIRCULATION, V104, P1670, DOI 10.1161/hc4001.097186; Yu Y, 2002, BBA-MOL CELL BIOL L, V1581, P89, DOI 10.1016/S1388-1981(02)00126-9	60	35	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10707	10715		10.1074/jbc.M800035200	http://dx.doi.org/10.1074/jbc.M800035200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18283099	hybrid			2022-12-25	WOS:000254894700053
J	Brocker, MJ; Virus, S; Ganskow, S; Heathcote, P; Heinz, DW; Schubert, WD; Jahn, D; Moser, J				Broecker, Markus J.; Virus, Simone; Ganskow, Stefanie; Heathcote, Peter; Heinz, Dirk W.; Schubert, Wolf-Dieter; Jahn, Dieter; Moser, Juergen			ATP-driven reduction by dark-operative protochlorophyllide oxidoreductase from Chlorobium tepidum mechanistically resembles nitrogenase catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; ELECTRON-TRANSFER; IRON PROTEIN; BIOSYNTHESIS; CLUSTER; IDENTIFICATION; CHLOROPHYLL; SUBSTRATE; PHOTOSYNTHESIS; MOLYBDOPTERIN	During chlorophyll and bacteriochlorophyll biosynthesis in gymnosperms, algae, and photosynthetic bacteria, dark-operative protochlorophyllide oxidoreductase (DPOR) reduces ring D of aromatic protochlorophyllide stereospecifically to produce chlorophyllide. We describe the heterologous overproduction of DPOR subunits BchN, BchB, and BchL from Chlorobium tepidum in Escherichia coli allowing their purification to apparent homogeneity. The catalytic activity was found to be 3.15 nmol min(-1)mg(-1) with K-m values of 6.1 mu M for protochlorophyllide, 13.5 mu M for ATP, and 52.7 mu M for the reductant dithionite. To identify residues important in DPOR function, 21 enzyme variants were generated by site-directed mutagenesis and investigated for their metal content, spectroscopic features, and catalytic activity. Two cysteine residues (Cys(97) and Cys(131)) of homodimeric BchL(2) are found to coordinate an intersubunit [4Fe-4S] cluster, essential for low potential electron transfer to (BchNB)(2) as part of the reduction of the protochlorophyllide substrate. Similarly, Lys(10) and Leu(126) are crucial to ATP-driven electron transfer from BchL(2). The activation energy of DPOR electron transfer is 22.2 kJ mol(-1) indicating a requirement for 4 ATP per catalytic cycle. At the amino acid level, BchL is 33% identical to the nitrogenase subunit NifH allowing a first tentative structural model to be proposed. In (BchNB)(2), we find that four cysteine residues, three from BchN (Cys(21), Cys(46), and Cys(103)) and one from BchB (Cys(94)), coordinate a second intersubunit [4Fe-4S] cluster required for catalysis. No evidence for any type of molybdenum-containing cofactor was found, indicating that the DPOR subunit BchN clearly differs from the homologous nitrogenase subunit NifD. Based on the available data we propose an enzymatic mechanism of DPOR.	[Broecker, Markus J.; Virus, Simone; Jahn, Dieter; Moser, Juergen] Tech Univ Carolo Wilhelmina Braunschweig, Inst Microbiol, D-38106 Braunschweig, Germany; [Ganskow, Stefanie] Humboldt Univ, Inst Biol, D-10115 Berlin, Germany; [Heathcote, Peter] Queen Mary Univ London, Sch Biol Sci, London E1 4NS, England; [Heinz, Dirk W.; Schubert, Wolf-Dieter] Helmholtz Ctr Infect Res, Div Struct Biol, D-38124 Braunschweig, Germany	Braunschweig University of Technology; Humboldt University of Berlin; University of London; Queen Mary University London; Helmholtz Association; Helmholtz-Center for Infection Research	Moser, J (corresponding author), Tech Univ Carolo Wilhelmina Braunschweig, Inst Microbiol, Spielmannstr 7, D-38106 Braunschweig, Germany.	j.moser@tu-bs.de	Heathcote, Peter/B-3749-2011; Schubert, Wolf-Dieter/A-5617-2009	Schubert, Wolf-Dieter/0000-0003-4998-519X; Jahn, Dieter/0000-0002-4064-9205				Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; ANDERSON GL, 1984, BIOCHEMISTRY-US, V23, P2118, DOI 10.1021/bi00305a002; Apel K, 2001, ADV PHOTOSYNTH, V11, P235; Belyaeva OB, 2001, BIOCHEMISTRY-MOSCOW+, V66, P173, DOI 10.1023/A:1002891531118; BOLLIVAR DW, 1994, J MOL BIOL, V237, P622, DOI 10.1006/jmbi.1994.1260; BURKE DH, 1993, J BACTERIOL, V175, P2414, DOI 10.1128/JB.175.8.2414-2422.1993; BURKE DH, 1993, P NATL ACAD SCI USA, V90, P7134, DOI 10.1073/pnas.90.15.7134; CAMPBELL AM, 1985, P NATL ACAD SCI USA, V82, P227, DOI 10.1073/pnas.82.1.227; Dammeyer T, 2006, J BIOL CHEM, V281, P27081, DOI 10.1074/jbc.M605154200; DEAN DR, 1993, J BACTERIOL, V175, P6737, DOI 10.1128/jb.175.21.6737-6744.1993; Fisher K, 2006, BIOCHEMISTRY-US, V45, P4190, DOI 10.1021/bi0514109; Fujita Y, 2000, J BIOL CHEM, V275, P23583, DOI 10.1074/jbc.M002904200; FUJITA Y, 1993, PLANT CELL PHYSIOL, V34, P305; Fujita Y, 1996, PLANT CELL PHYSIOL, V37, P411, DOI 10.1093/oxfordjournals.pcp.a028962; Hanzelmann P, 2004, J BIOL CHEM, V279, P34721, DOI 10.1074/jbc.M313398200; Havemeyer A, 2006, J BIOL CHEM, V281, P34796, DOI 10.1074/jbc.M607697200; Heinemann IU, 2007, BIOCHEM J, V402, P575, DOI 10.1042/BJ20061321; Heyes DJ, 2003, NAT STRUCT BIOL, V10, P491, DOI 10.1038/nsb929; Heyes DJ, 2002, P NATL ACAD SCI USA, V99, P11145, DOI 10.1073/pnas.182274199; Igarashi RY, 2003, CRIT REV BIOCHEM MOL, V38, P351, DOI 10.1080/10409230390242380; Kim J, 2004, FEMS MICROBIOL REV, V28, P455, DOI 10.1016/j.femsre.2004.03.001; Kurnikov IV, 2001, J PHYS CHEM B, V105, P5359, DOI 10.1021/jp002540o; Lanzilotta WN, 1997, J BIOL CHEM, V272, P4157, DOI 10.1074/jbc.272.7.4157; Lanzilotta WN, 1998, BIOCHEMISTRY-US, V37, P399, DOI 10.1021/bi971681m; Layer G, 2002, J BIOL CHEM, V277, P34136, DOI 10.1074/jbc.M205247200; LI JG, 1982, BIOCHEMISTRY-US, V21, P4393, DOI 10.1021/bi00261a031; Llamas A, 2006, J BIOL CHEM, V281, P18343, DOI 10.1074/jbc.M601415200; LOVENBERG W, 1963, J BIOL CHEM, V238, P3899; Masuda T, 2004, PHOTOSYNTH RES, V81, P1, DOI 10.1023/B:PRES.0000028392.80354.7c; MCFEETERS RF, 1971, PLANT PHYSIOL, V47, P609, DOI 10.1104/pp.47.5.609; MENSINK RE, 1992, EUR J BIOCHEM, V208, P295, DOI 10.1111/j.1432-1033.1992.tb17186.x; Moulis JM, 1996, J BIOL INORG CHEM, V1, P2, DOI 10.1007/s007750050017; Nichols J, 2002, J BIOL CHEM, V277, P24995, DOI 10.1074/jbc.M203238200; Nomata J, 2005, BBA-BIOENERGETICS, V1708, P229, DOI 10.1016/j.bbabio.2005.02.002; Nomata J, 2006, FEBS LETT, V580, P6151, DOI 10.1016/j.febslet.2006.10.014; PETERS JW, 1995, ANNU REV MICROBIOL, V49, P335, DOI 10.1146/annurev.mi.49.100195.002003; RAJAGOPALAN KV, 1982, FED PROC, V41, P2608; Rees D. C., 2005, PHILOS T A, V363; Rees DC, 2005, PHILOS T R SOC A, V363, P971, DOI 10.1098/rsta.2004.1539; Reichelt J, 2005, BIOINFORMATICS, V21, P1291, DOI 10.1093/bioinformatics/bti138; RUDIGER W, 2003, PORPHYRIN HDB, V13, P71; Ryle MJ, 1996, BIOCHEMISTRY-US, V35, P4766, DOI 10.1021/bi960026w; Ryle MJ, 1996, BIOCHEMISTRY-US, V35, P9424, DOI 10.1021/bi9608572; Schmid B, 2002, BIOCHEMISTRY-US, V41, P15557, DOI 10.1021/bi026642b; Schoefs B, 2001, PHOTOSYNTH RES, V70, P257, DOI 10.1023/A:1014769707404; Schwarz G, 1997, J BIOL CHEM, V272, P26811, DOI 10.1074/jbc.272.43.26811; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shen G, 2007, J BIOL CHEM, V282, P31909, DOI 10.1074/jbc.M705554200; Simons A, 2002, BIOCHEMISTRY-US, V41, P9310, DOI 10.1021/bi0258647; STEWART V, 1982, J BACTERIOL, V151, P788, DOI 10.1128/JB.151.2.788-799.1982; Sun W, 2005, J CHEM SCI, V117, P317, DOI 10.1007/BF02708444; Suzuki JY, 1997, ANNU REV GENET, V31, P61, DOI 10.1146/annurev.genet.31.1.61; Xiong J, 1998, P NATL ACAD SCI USA, V95, P14851, DOI 10.1073/pnas.95.25.14851; Yu SW, 1999, BIOCHEM J, V341, P755, DOI 10.1042/0264-6021:3410755	54	45	48	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10559	10567		10.1074/jbc.M708010200	http://dx.doi.org/10.1074/jbc.M708010200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18252716	hybrid			2022-12-25	WOS:000254894700038
J	Karpichev, IV; Durand-Heredia, JM; Luo, Y; Small, GM				Karpichev, Igor V.; Durand-Heredia, Jorge M.; Luo, Yi; Small, Gillian M.			Binding characteristics and regulatory mechanisms of the transcription factors controlling oleate-responsive genes in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODING PEROXISOMAL PROTEINS; BETA-OXIDATION; ACID INDUCTION; IDENTIFY GENES; FATTY-ACIDS; PROLIFERATION; ADR1; ACTIVATION; PIP2P; DNA	Transcriptional activation of many genes involved in peroxisome-related functions is regulated by the Oaf1p, Pip2p, and Adr1p transcription factors in Saccharomyces cerevisiae. We have analyzed the in vivo binding characteristics of Oaf1p-Pip2p and found that this complex is recruited to its target oleate-response element (ORE) under all growth conditions tested. In addition, this complex also binds to ORE-containing genes that do not appear to be regulated by these proteins, as well as to some genes lacking conventional OREs. The recruitment of the Oaf1p-Pip2p complex was greatly increased upon glucose derepression, possibly due to Oaf1p phosphorylation with only moderate increases upon oleate induction. Thus, this complex may receive a nutritional cue while it is already bound to DNA, suggesting that, in addition to the increase in Oaf1p-Pip2p binding, other mechanism(s) such as enhanced Adr1p association may drive the expression of highly inducible fatty acid-responsive genes. Adr1p binds to target genes in an oleate-dependent fashion and is involved in Oaf1p-Pip2p binding. In turn, the Oaf1p-Pip2p complex appears to be important for Adr1p binding to a subset of oleate-responsive genes. Adr1p is a positive regulator of ORE-containing genes, but it also acts as a negative factor in expression of some of these genes. Finally, we have also shown that Adr1p is directly involved in mediating oleate induction of Oaf1p-Pip2p target genes.	[Karpichev, Igor V.; Durand-Heredia, Jorge M.; Luo, Yi; Small, Gillian M.] CUNY City Coll, Dept Biol, New York, NY 10031 USA	City University of New York (CUNY) System; City College of New York (CUNY)	Small, GM (corresponding author), 535 E 80th St, New York, NY 10075 USA.	Gillian.small@mail.cuny.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM008168] Funding Source: NIH RePORTER; NCRR NIH HHS [RCMI RR 03060] Funding Source: Medline; NIGMS NIH HHS [S06 GM-08168] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agricola E, 2004, BIOCHEMISTRY-US, V43, P8878, DOI 10.1021/bi049577+; APARICIO O, 2005, CURRENT PROTOCOLS MO; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Baumgartner U, 1999, J BIOL CHEM, V274, P22208, DOI 10.1074/jbc.274.32.22208; CHENG C, 1994, MOL CELL BIOL, V14, P3842, DOI 10.1128/MCB.14.6.3842; CIRIACY M, 1975, MOL GEN GENET, V138, P157, DOI 10.1007/BF02428119; DENIS CL, 1983, MOL CELL BIOL, V3, P360, DOI 10.1128/MCB.3.3.360; EINERHAND AWC, 1993, EUR J BIOCHEM, V214, P323, DOI 10.1111/j.1432-1033.1993.tb17927.x; FILIPITS M, 1993, GENE, V132, P49, DOI 10.1016/0378-1119(93)90513-3; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; Geisberg J. V., 2005, CURR PROTOC MOL BIOL, P8; Gunji L, 2004, DNA RES, V11, P163, DOI 10.1093/dnares/11.3.163; Gurvitz A, 2001, J BIOL CHEM, V276, P31825, DOI 10.1074/jbc.M105989200; Gurvitz A, 2006, BBA-MOL CELL RES, V1763, P1392, DOI 10.1016/j.bbamcr.2006.07.011; Gurvitz Aner, 2000, Molecular Cell Biology Research Communications, V4, P81, DOI 10.1006/mcbr.2000.0261; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; ISSEMANN I, 1993, J MOL ENDOCRINOL, V11, P37, DOI 10.1677/jme.0.0110037; Kal AJ, 1999, MOL BIOL CELL, V10, P1859, DOI 10.1091/mbc.10.6.1859; Karpichev IV, 1997, MOL CELL BIOL, V17, P69, DOI 10.1128/MCB.17.1.69; Karpichev IV, 1998, MOL CELL BIOL, V18, P6560, DOI 10.1128/MCB.18.11.6560; Karpichev IV, 2002, J BIOL CHEM, V277, P19609, DOI 10.1074/jbc.M202045200; KIRKPATRICK CR, 1995, MOL CELL BIOL, V15, P4021; Koerkamp MG, 2002, MOL BIOL CELL, V13, P2783, DOI 10.1091/mbc.E02-02-0075; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Luo Y, 1996, J BIOL CHEM, V271, P12068, DOI 10.1074/jbc.271.20.12068; LUO Y, 1997, THESIS MOUNT SINAI S; MacPherson S, 2006, MICROBIOL MOL BIOL R, V70, P583, DOI 10.1128/MMBR.00015-06; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; Phelps C, 2006, P NATL ACAD SCI USA, V103, P7077, DOI 10.1073/pnas.0510080103; Reddy JK, 2001, ANNU REV NUTR, V21, P193, DOI 10.1146/annurev.nutr.21.1.193; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Robert F, 2004, MOL CELL, V16, P199, DOI 10.1016/j.molcel.2004.09.021; Rottensteiner H, 1997, EUR J BIOCHEM, V247, P776, DOI 10.1111/j.1432-1033.1997.00776.x; Rottensteiner H, 1996, EMBO J, V15, P2924, DOI 10.1002/j.1460-2075.1996.tb00655.x; Rottensteiner H, 2003, J BIOL CHEM, V278, P27605, DOI 10.1074/jbc.M304097200; Schuller HJ, 2003, CURR GENET, V43, P139, DOI 10.1007/s00294-003-0381-8; Sellick CA, 2005, TRENDS BIOCHEM SCI, V30, P405, DOI 10.1016/j.tibs.2005.05.007; Sellick CA, 2003, EMBO J, V22, P5147, DOI 10.1093/emboj/cdg480; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMON M, 1991, MOL CELL BIOL, V11, P699, DOI 10.1128/MCB.11.2.699; SIMON M, 1992, YEAST, V8, P303, DOI 10.1002/yea.320080407; SIMON MM, 1995, MOL GEN GENET, V249, P289, DOI 10.1007/BF00290529; SKONECZNY M, 1988, EUR J BIOCHEM, V174, P297, DOI 10.1111/j.1432-1033.1988.tb14097.x; Smith JJ, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb1400157; Smith JJ, 2002, J CELL BIOL, V158, P259, DOI 10.1083/jcb.200204059; SZE JY, 1992, SCIENCE, V258, P1143, DOI 10.1126/science.1439822; Tachibana C, 2005, MOL CELL BIOL, V25, P2138, DOI 10.1128/MCB.25.6.2138-2146.2005; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; Young ET, 2003, J BIOL CHEM, V278, P26146, DOI 10.1074/jbc.M301981200	51	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10264	10275		10.1074/jbc.M708215200	http://dx.doi.org/10.1074/jbc.M708215200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18285336	Green Published, hybrid			2022-12-25	WOS:000254894700007
J	Chung, MC; Popova, TG; Jorgensen, SC; Dong, L; Chandhoke, V; Bailey, CL; Popov, SG				Chung, Myung-Chul; Popova, Taissia G.; Jorgensen, Shelley C.; Dong, Li; Chandhoke, Vikas; Bailey, Charles L.; Popov, Serguei G.			Degradation of circulating von Willebrand factor and its regulator ADAMTS13 implicates secreted Bacillus anthracis metalloproteases in anthrax consumptive coagulopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBOTIC THROMBOCYTOPENIC PURPURA; HEMOLYTIC-UREMIC SYNDROME; RICKETTSIA-RICKETTSII INFECTION; VONWILLEBRAND-FACTOR MULTIMERS; INHALATIONAL ANTHRAX; LETHAL TOXIN; GLYCOPROTEIN-IB; PLATELET-AGGREGATION; VACCINE CANDIDATES; IN-VITRO	Pathology data from the anthrax animal models show evidence of significant increases in vascular permeability coincident with hemostatic imbalances manifested by thrombocytopenia, transient leucopenia, and aggressive disseminated intravascular coagulation. In this study we hypothesized that anthrax infection modulates the activity of von Willebrand factor (VWF) and its endogenous regulator ADAMTS13, which play important roles in hemostasis and thrombosis, including interaction of endothelial cells with platelets. We previously demonstrated that purified anthrax neutral metalloproteases Npr599 and InhA are capable of cleaving a variety of host structural and regulatory proteins. Incubation of human plasma with these proteases at 37 C in the presence of urea as a mild denaturant results in proteolysis of VWF. Also in these conditions, InhA directly cleaves plasma ADAMTS13 protein. Npr599 and InhA digest synthetic VWF substrate FRETS-VWF73. Amino acid sequencing of VWF fragments produced by InhA suggests that one of the cleavage sites of VWF is located at domain A2, the target domain of ADAMTS13. Proteolysis of VWF by InhA impairs its collagen binding activity (VWF: CBA) and ristocetin-induced platelet aggregation activity. In plasma from anthrax spore-challenged DBA/2 mice, VWF antigen levels increase up to 2-fold at day 3 post-infection with toxigenic Sterne 34F(2) strain, whereas VWF: CBA levels drop in a time-dependent manner, suggesting dysfunction of VWF instead of its quantitative deficiency. This conclusion is further supported by significant reduction in the amount of VWF circulating in blood in the ultra-large forms. In addition, Western blot analysis shows proteolytic depletion of ADAMTS13 from plasma of spore-challenged mice despite its increased expression in the liver. Our results suggest a new mechanism of anthrax coagulopathy affecting the levels and functional activities of both VWF and its natural regulator ADAMTS13. This mechanism may contribute to hemorrhage and thrombosis typical in anthrax.	[Chung, Myung-Chul; Popova, Taissia G.; Jorgensen, Shelley C.; Dong, Li; Chandhoke, Vikas; Bailey, Charles L.; Popov, Serguei G.] George Mason Univ, Coll Sci, Natl Ctr Biodefense & Infect Dis, Manassas, VA 20110 USA	George Mason University	Popov, SG (corresponding author), George Mason Univ, Coll Sci, Natl Ctr Biodefense & Infect Dis, 10900 Univ Blvd, Manassas, VA 20110 USA.	spopov@gmu.edu						ABRAMOVA FA, 1993, P NATL ACAD SCI USA, V90, P2291, DOI 10.1073/pnas.90.6.2291; Alam S, 2006, BIOCHEM BIOPH RES CO, V339, P107, DOI 10.1016/j.bbrc.2005.11.008; Ariel N, 2003, INFECT IMMUN, V71, P4563, DOI 10.1128/IAI.71.8.4563-4579.2003; Banno F, 2006, BLOOD, V107, P3161, DOI 10.1182/blood-2005-07-2765; Bergmeier W, 2006, P NATL ACAD SCI USA, V103, P16900, DOI 10.1073/pnas.0608207103; Borio L, 2001, JAMA-J AM MED ASSOC, V286, P2554, DOI 10.1001/jama.286.20.2554; Chitlaru T, 2007, INFECT IMMUN, V75, P2841, DOI 10.1128/IAI.02029-06; Chitlaru T, 2006, J BACTERIOL, V188, P3551, DOI 10.1128/JB.188.10.3551-3571.2006; Chung MC, 2006, J BIOL CHEM, V281, P31408, DOI 10.1074/jbc.M605526200; Crawley JTB, 2005, BLOOD, V105, P1085, DOI 10.1182/blood-2004-03-1101; Culley NC, 2005, INFECT IMMUN, V73, P7006, DOI 10.1128/IAI.73.10.7006-7010.2005; DALLDORF FG, 1967, ARCH PATHOL, V83, P154; Denis C, 1998, P NATL ACAD SCI USA, V95, P9524, DOI 10.1073/pnas.95.16.9524; DENT JA, 1991, J CLIN INVEST, V88, P774, DOI 10.1172/JCI115376; Donadelli R, 2006, BLOOD, V107, P1943, DOI 10.1182/blood-2005-07-2972; FEDERICI AB, 1989, BRIT J HAEMATOL, V73, P93, DOI 10.1111/j.1365-2141.1989.tb00226.x; Furlan M, 1996, BLOOD, V87, P4223, DOI 10.1182/blood.V87.10.4223.bloodjournal87104223; Galbusera M, 1999, J AM SOC NEPHROL, V10, P1234; Gat O, 2006, INFECT IMMUN, V74, P3987, DOI 10.1128/IAI.00174-06; Groot E, 2007, CURR OPIN HEMATOL, V14, P284, DOI 10.1097/MOH.0b013e3280dce531; Guarner J, 2003, AM J PATHOL, V163, P701, DOI 10.1016/S0002-9440(10)63697-8; HANNA PC, 1993, P NATL ACAD SCI USA, V90, P10198, DOI 10.1073/pnas.90.21.10198; Heffernan BJ, 2007, FEMS MICROBIOL LETT, V271, P98, DOI 10.1111/j.1574-6968.2007.00713.x; Hollestelle MJ, 2006, BRIT J HAEMATOL, V133, P562, DOI 10.1111/j.1365-2141.2006.06067.x; Jy W, 1998, AM J HEMATOL, V57, P33, DOI 10.1002/(SICI)1096-8652(199801)57:1<33::AID-AJH6>3.3.CO;2-1; Kau JH, 2005, J INFECT DIS, V192, P1465, DOI 10.1086/491477; Kirby JE, 2004, INFECT IMMUN, V72, P430, DOI 10.1128/IAI.72.1.430-439.2004; Klichko VI, 2003, BIOCHEM BIOPH RES CO, V303, P855, DOI 10.1016/S0006-291X(03)00440-6; Kokame K, 2005, BRIT J HAEMATOL, V129, P93, DOI 10.1111/j.1365-2141.2005.05420.x; Kokame K, 2004, BLOOD, V103, P607, DOI 10.1182/blood-2003-08-2861; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Majerus EM, 2005, J BIOL CHEM, V280, P21773, DOI 10.1074/jbc.M502529200; MANNUCCI PM, 1989, BLOOD, V74, P978; Mina B, 2002, JAMA-J AM MED ASSOC, V287, P858, DOI 10.1001/jama.287.7.858; Moayeri M, 2004, CURR OPIN MICROBIOL, V7, P19, DOI 10.1016/j.mib.2003.12.001; Neugebauer BM, 2002, SEMIN THROMB HEMOST, V28, P139, DOI 10.1055/s-2002-27816; Ni HY, 2000, J CLIN INVEST, V106, P385, DOI 10.1172/JCI9896; Nishio K, 2004, P NATL ACAD SCI USA, V101, P10578, DOI 10.1073/pnas.0402041101; Nolasco LH, 2005, BLOOD, V106, P4199, DOI 10.1182/blood-2005-05-2111; Ono T, 2006, BLOOD, V107, P528, DOI 10.1182/blood-2005-03-1087; Perutelli P, 2005, BLOOD COAGUL FIBRIN, V16, P607, DOI 10.1097/01.mbc.0000187251.32630.1f; Popov SG, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-25; Popov SG, 2004, CELL MICROBIOL, V6, P225, DOI 10.1046/j.1462-5822.2003.00358.x; Popova TG, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-8; Ruggeri ZM, 2003, J THROMB HAEMOST, V1, P1335, DOI 10.1046/j.1538-7836.2003.00260.x; Sadler JE, 2005, ANNU REV MED, V56, P173, DOI 10.1146/annurev.med.56.082103.104713; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; Sejvar JJ, 2005, LANCET INFECT DIS, V5, P287, DOI 10.1016/S1473-3099(05)70113-4; SMITH H, 1967, FED PROC, V26, P1554; SPORN LA, 1991, BLOOD, V78, P2595; SPORN LA, 1994, BLOOD, V83, P1527; Stearns-Kurosawa DJ, 2006, AM J PATHOL, V169, P433, DOI 10.2353/ajpath.2006.051330; Tsai HM, 2006, ANNU REV MED, V57, P419, DOI 10.1146/annurev.med.57.061804.084505; Tsai HM, 1996, BLOOD, V87, P4235, DOI 10.1182/blood.V87.10.4235.bloodjournal87104235; Warfel JM, 2005, AM J PATHOL, V166, P1871, DOI 10.1016/S0002-9440(10)62496-0; WARKENTIN TE, 1992, LANCET, V340, P35, DOI 10.1016/0140-6736(92)92434-H; WELKOS SL, 1986, INFECT IMMUN, V51, P795, DOI 10.1128/IAI.51.3.795-800.1986; Wu YP, 2000, ARTERIOSCL THROM VAS, V20, P1661, DOI 10.1161/01.ATV.20.6.1661; Yang H, 2006, J THROMB HAEMOST, V4, P2230, DOI 10.1111/j.1538-7836.2006.02116.x	59	32	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9531	9542		10.1074/jbc.M705871200	http://dx.doi.org/10.1074/jbc.M705871200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18263586	hybrid			2022-12-25	WOS:000254671600006
J	Hejna, J; Holtorf, M; Hines, J; Mathewson, L; Hemphill, A; Al-Dhalimy, M; Olson, SB; Moses, RE				Hejna, James; Holtorf, Megan; Hines, Jennie; Mathewson, Lauren; Hemphill, Aaron; Al-Dhalimy, Muhsen; Olson, Susan B.; Moses, Robb E.			Tip60 is required for DNA interstrand cross-link repair in the Fanconi anemia pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE; DAMAGE RESPONSE; COMPLEX; PROTEIN; CHROMATIN; IDENTIFICATION; FANCD2; BRCA1; H2AX; LOCALIZATION	The disease Fanconi anemia is a genome instability syndrome characterized by cellular sensitivity to DNA interstrand cross-linking agents, manifest by decreased cellular survival and chromosomal aberrations after such treatment. There are at least 13 proteins acting in the pathway, with the FANCD2 protein apparently functioning as a late term effecter in the maintenance of genome stability. We find that the chromatin remodeling protein, Tip60, interacts directly with the FANCD2 protein in a yeast two-hybrid system. This interaction has been confirmed by co-immunoprecipitation and co-localization using both endogenous and epitope-tagged FANCD2 and Tip60 from human cells. The observation of decreased cellular survival after exposure to mitomycin C in normal fibroblasts depleted for Tip60 indicates a direct function in interstrand cross-link repair. The coincident function of Tip60 and FANCD2 in one pathway is supported by the finding that depletion of Tip60 in Fanconi anemia cells does not increase sensitivity to DNA cross-links. However, depletion of Tip60 did not reduce monoubiquitination of FANCD2 or its localization to nuclear foci following DNA damage. The observations indicate that Fanconi anemia proteins act in concert with chromatin remodeling functions to maintain genome stability after DNA cross-link damage.	[Hejna, James; Holtorf, Megan; Hines, Jennie; Mathewson, Lauren; Hemphill, Aaron; Al-Dhalimy, Muhsen; Olson, Susan B.; Moses, Robb E.] OHSU, Dept Mol & Med Genet, Portland, OR 97239 USA	Oregon Health & Science University	Moses, RE (corresponding author), OHSU, Dept Mol & Med Genet, 3181 Sam Jackson Pkway, Portland, OR 97239 USA.	mosesr@ohsu.edu			NHLBI NIH HHS [1P01 HL 48546, P01 HL048546-130001] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048546] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bao YH, 2007, CURR OPIN GENET DEV, V17, P126, DOI 10.1016/j.gde.2007.02.010; Bruun D, 2003, DNA REPAIR, V2, P1007, DOI 10.1016/S1568-7864(03)00112-5; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; D'Andrea A, 2003, CURR BIOL, V13, pR546, DOI 10.1016/S0960-9822(03)00467-6; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; de Oca RM, 2005, BLOOD, V105, P1003, DOI 10.1182/blood-2003-11-3997; Doyon Y, 2004, CURR OPIN GENET DEV, V14, P147, DOI 10.1016/j.gde.2004.02.009; Doyon Y, 2004, MOL CELL BIOL, V24, P1884, DOI 10.1128/MCB.24.5.1884-1896.2004; Folias A, 2002, HUM MOL GENET, V11, P2591, DOI 10.1093/hmg/11.21.2591; FRANGIONI JV, 1993, J CELL SCI, V105, P481; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Godthelp BC, 2006, MUTAT RES-FUND MOL M, V594, P39, DOI 10.1016/j.mrfmmm.2005.07.008; Grossmann KF, 2001, MUTAT RES-DNA REPAIR, V487, P73, DOI 10.1016/S0921-8777(01)00106-9; Hejna JA, 2000, AM J HUM GENET, V66, P1540, DOI 10.1086/302896; Hussain S, 2004, HUM MOL GENET, V13, P1241, DOI 10.1093/hmg/ddh135; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Ikura T, 2007, MOL CELL BIOL, V27, P7028, DOI 10.1128/MCB.00579-07; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; KUSHCH T, 2004, SCIENCE, V306, P2084; Logan IR, 2004, J BIOL CHEM, V279, P11696, DOI 10.1074/jbc.M312712200; Medhurst AL, 2001, HUM MOL GENET, V10, P423, DOI 10.1093/hmg/10.4.423; Meetei AR, 2003, MOL CELL BIOL, V23, P3417, DOI 10.1128/MCB.23.10.3417-3426.2003; Mi J, 2005, BLOOD, V105, P759, DOI 10.1182/blood-2004-01-0001; Miller John, 2004, Methods Mol Biol, V261, P247; Osley MA, 2007, MUTAT RES-FUND MOL M, V618, P65, DOI 10.1016/j.mrfmmm.2006.07.011; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Sapountzi V, 2006, INT J BIOCHEM CELL B, V38, P1496, DOI 10.1016/j.biocel.2006.03.003; Schmutte C, 2001, J BIOL CHEM, V276, P33011, DOI 10.1074/jbc.M102670200; Smogorzewska A, 2007, CELL, V129, P289, DOI 10.1016/j.cell.2007.03.009; Squatrito M, 2006, TRENDS CELL BIOL, V16, P433, DOI 10.1016/j.tcb.2006.07.007; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Thomashevski A, 2004, J BIOL CHEM, V279, P26201, DOI 10.1074/jbc.M400091200; Wang HY, 2005, J CELL PHYSIOL, V202, P492, DOI 10.1002/jcp.20141; Wang Y, 2000, GENE DEV, V14, P927; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595	37	25	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9844	9851		10.1074/jbc.M709076200	http://dx.doi.org/10.1074/jbc.M709076200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18263878	Green Published, hybrid, Green Accepted			2022-12-25	WOS:000254671600040
J	Simonsen, SM; Sando, L; Rosengren, KJ; Wang, CK; Colgrave, ML; Daly, NL; Craik, DJ				Simonsen, Shane M.; Sando, Lillian; Rosengren, K. Johan; Wang, Conan K.; Colgrave, Michelle L.; Daly, Norelle L.; Craik, David J.			Alanine scanning mutagenesis of the prototypic cyclotide reveals a cluster of residues essential for bioactivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMR STRUCTURE CALCULATION; POLYPEPTIDE KALATA B1; CYCLIC CYSTINE-KNOT; TORSION ANGLE DYNAMICS; MACROCYCLIC PEPTIDES; OLDENLANDIA-AFFINIS; STRUCTURAL MOTIF; PLANT CYCLOTIDES; CYCLOVIOLACIN O2; ACYCLIC PERMUTANTS	The cyclotides are stable plant-derived mini-proteins with a topologically circular peptide backbone and a knotted arrangement of three disulfide bonds that form a cyclic cystine knot structural framework. They display a wide range of pharmaceutically important bioactivities, but their natural function is in plant defense as insecticidal agents. To determine the influence of individual residues on structure and activity in the prototypic cyclotide kalata B1, all 23 non-cysteine residues were successively replaced with alanine. The structure was generally tolerant of modification, indicating that the framework is a viable candidate for the stabilization of bioactive peptide epitopes. Remarkably, insecticidal and hemolytic activities were both dependent on a common, well defined cluster of hydrophilic residues on one face of the cyclotide. Interestingly, this cluster is separate from the membrane binding face of the cyclotides. Overall, the mutagenesis data provide an important insight into cyclotide biological activity and suggest that specific self-association, in combination with membrane binding mediates cyclotide bioactivities.	[Simonsen, Shane M.; Sando, Lillian; Rosengren, K. Johan; Wang, Conan K.; Colgrave, Michelle L.; Daly, Norelle L.; Craik, David J.] Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia	University of Queensland	Craik, DJ (corresponding author), Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia.	d.craik@imb.uq.edu.au	Daly, Norelle L/D-4302-2013; Rosengren, K. Johan/P-4450-2016; Wang, Conan K/D-1481-2010; Colgrave, Michelle/A-5710-2012; Craik, David/B-1695-2010	Daly, Norelle L/0000-0002-4697-6602; Rosengren, K. Johan/0000-0002-5007-8434; Wang, Conan K/0000-0002-7973-7632; Colgrave, Michelle/0000-0001-8463-805X; Craik, David/0000-0003-0007-6796				Bokesch HR, 2001, J NAT PROD, V64, P249, DOI 10.1021/np000372l; Broussalis AM, 2001, PHYTOCHEMISTRY, V58, P47, DOI 10.1016/S0031-9422(01)00173-X; Brunger AT, 1997, STRUCTURE, V5, P325, DOI 10.1016/S0969-2126(97)00190-1; Colgrave ML, 2004, BIOCHEMISTRY-US, V43, P5965, DOI 10.1021/bi049711q; Craik DJ, 1999, J MOL BIOL, V294, P1327, DOI 10.1006/jmbi.1999.3383; Craik DJ, 2006, SCIENCE, V311, P1563, DOI 10.1126/science.1125248; Craik DJ, 2001, TOXICON, V39, P43, DOI 10.1016/S0041-0101(00)00160-4; Craik DJ, 2002, CURR OPIN DRUG DI DE, V5, P251; Daly NL, 2000, J BIOL CHEM, V275, P19068, DOI 10.1074/jbc.M000450200; Daly NL, 1999, BIOCHEMISTRY-US, V38, P10606, DOI 10.1021/bi990605b; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; Ghirardi ML, 1998, BIOCHEMISTRY-US, V37, P13559, DOI 10.1021/bi980358w; Goransson U, 2004, J NAT PROD, V67, P1287, DOI 10.1021/np0499719; Gran L, 2000, J ETHNOPHARMACOL, V70, P197, DOI 10.1016/S0378-8741(99)00175-0; Gran L., 1970, MEDDELELSER NORSK FA, V12, P173; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GUSTAFSON KR, 1994, J AM CHEM SOC, V116, P9337, DOI 10.1021/ja00099a064; Hernandez JF, 2000, BIOCHEMISTRY-US, V39, P5722, DOI 10.1021/bi9929756; Herrmann A, 2006, CELL MOL LIFE SCI, V63, P235, DOI 10.1007/s00018-005-5486-4; Jennings C, 2001, P NATL ACAD SCI USA, V98, P10614, DOI 10.1073/pnas.191366898; Jennings CV, 2005, BIOCHEMISTRY-US, V44, P851, DOI 10.1021/bi047837h; Kamimori H, 2005, ANAL BIOCHEM, V337, P149, DOI 10.1016/j.ab.2004.10.028; Kimura RH, 2006, ANGEW CHEM INT EDIT, V45, P973, DOI 10.1002/anie.200503882; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lindholm P, 2002, MOL CANCER THER, V1, P365; Linge JP, 1999, J BIOMOL NMR, V13, P51, DOI 10.1023/A:1008365802830; McIntosh JM, 2000, EUR J PHARMACOL, V393, P205, DOI 10.1016/S0014-2999(99)00887-0; Millard EL, 2004, EUR J BIOCHEM, V271, P2320, DOI 10.1111/j.1432-1033.2004.04148.x; Mulvenna JP, 2006, NUCLEIC ACIDS RES, V34, pD192, DOI 10.1093/nar/gkj005; Nair SS, 2006, BBA-PROTEINS PROTEOM, V1764, P1568, DOI 10.1016/j.bbapap.2006.07.009; Nourse A, 2004, J BIOL CHEM, V279, P562, DOI 10.1074/jbc.M306826200; OJCIUS DM, 1991, TRENDS BIOCHEM SCI, V16, P225, DOI 10.1016/0968-0004(91)90090-I; Plan MRR, 2007, CHEMBIOCHEM, V8, P1001, DOI 10.1002/cbic.200700097; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Rosengren KJ, 2003, J BIOL CHEM, V278, P8606, DOI 10.1074/jbc.M211147200; SAETHER O, 1995, BIOCHEMISTRY-US, V34, P4147, DOI 10.1021/bi00013a002; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; Schoepke T., 1993, SCI PHARM, V61, P145; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Shenkarev ZO, 2006, FEBS J, V273, P2658, DOI 10.1111/j.1742-4658.2006.05282.x; Simonsen SM, 2005, PLANT CELL, V17, P3176, DOI 10.1105/tpc.105.034678; Simonsen SM, 2004, FEBS LETT, V577, P399, DOI 10.1016/j.febslet.2004.10.034; Skjeldal L, 2002, ARCH BIOCHEM BIOPHYS, V399, P142, DOI 10.1006/abbi.2002.2769; Stein EG, 1997, J MAGN RESON, V124, P154, DOI 10.1006/jmre.1996.1027; Svangard E, 2007, J NAT PROD, V70, P643, DOI 10.1021/np070007v; Tam JP, 1998, PROTEIN SCI, V7, P1583, DOI 10.1002/pro.5560070712; Tam JP, 1999, P NATL ACAD SCI USA, V96, P8913, DOI 10.1073/pnas.96.16.8913; Tam JP, 1997, TETRAHEDRON LETT, V38, P5599, DOI 10.1016/S0040-4039(97)01271-9; Trabi M, 2002, TRENDS BIOCHEM SCI, V27, P132, DOI 10.1016/S0968-0004(02)02057-1; Trabi M, 2004, PLANT CELL, V16, P2204, DOI 10.1105/tpc.104.021790; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WITHERUP KM, 1994, J NAT PRODUCTS, V57, P1619, DOI 10.1021/np50114a002	52	136	141	2	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9805	9813		10.1074/jbc.M709303200	http://dx.doi.org/10.1074/jbc.M709303200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18258598	hybrid, Green Published			2022-12-25	WOS:000254671600035
J	Ravaud, S; Stjepanovic, G; Wild, K; Sinning, I				Ravaud, Stephanie; Stjepanovic, Goran; Wild, Klemens; Sinning, Irmgard			The crystal structure of the periplasmic domain of the Escherichia coli membrane protein insertase YidC contains a substrate binding cleft	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTALLOGRAPHIC STRUCTURE DETERMINATION; SOLID-STATE NMR; ENDOPLASMIC-RETICULUM; PEPTIDE DEFORMYLASE; CONDUCTING CHANNEL; BACTERIAL YIDC; NASCENT FTSQ; M13 PROCOAT; RECOGNITION; BIOGENESIS	In bacteria the biogenesis of inner membrane proteins requires targeting and insertion factors such as the signal recognition particle and the Sec translocon. YidC is an essential membrane protein involved in the insertion of inner membrane proteins together with the Sec translocon, but also as a separate entity. YidC of Escherichia coli is a member of the conserved YidC (in bacteria)/Oxa1 (in mitochondria)/Alb3 (in chloroplasts) protein family and contains six transmembrane segments and a large periplasmic domain (P1). We determined the crystal structure of the periplasmic domain of YidC from E. coli (P1D) at 1.8 A resolution. The structure of P1D shows the conserved beta-supersandwich fold of carbohydrate-binding proteins and an alpha-helical linker region at the C terminus that packs against the beta-supersandwich by a highly conserved interface. P1D exhibits an elongated cleft of similar architecture as found in the structural homologs. However, the electrostatic properties and molecular details of the cleft make it unlikely to interact with carbohydrate substrates. The cleft in P1D is occupied by a polyethylene glycol molecule suggesting an elongated peptide or acyl chain as a natural ligand. The region of P1D previously reported to interact with SecF maps to a surface area in the vicinity of the cleft. The conserved C-terminal region of the P1 domain was reported to be essential for the membrane insertase function of YidC. The analysis of this region suggests a role in membrane interaction and/or in the regulation of YidC interaction with binding partners.	[Ravaud, Stephanie; Stjepanovic, Goran; Wild, Klemens; Sinning, Irmgard] Univ Heidelberg, Zentrum Biochem, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Sinning, I (corresponding author), Univ Heidelberg, Zentrum Biochem, Lm Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	irmi.sinning@bzh.uni-heidelberg.de	Stjepanovic, Goran/A-7902-2010; Sinning, Irmgard/A-2982-2010	Stjepanovic, Goran/0000-0002-4841-9949; 				Adams PD, 2004, J SYNCHROTRON RADIAT, V11, P53, DOI 10.1107/S0909049503024130; Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; Aleshin AE, 2003, J MOL BIOL, V327, P61, DOI 10.1016/S0022-2836(03)00084-6; Bechinger B, 2001, FEBS LETT, V504, P161, DOI 10.1016/S0014-5793(01)02741-7; Beck K, 2001, EMBO REP, V2, P709, DOI 10.1093/embo-reports/kve154; Becker A, 1998, J BIOL CHEM, V273, P11413, DOI 10.1074/jbc.273.19.11413; Becker A, 1998, NAT STRUCT BIOL, V5, P1053, DOI 10.1038/4162; Bourne Y, 2001, J BIOL CHEM, V276, P11949, DOI 10.1074/jbc.M009373200; Chen MY, 2005, BIOCHEMISTRY-US, V44, P10741, DOI 10.1021/bi047418k; Chen MY, 2003, J BIOL CHEM, V278, P23295, DOI 10.1074/jbc.M301008200; Chen MY, 2002, BIOL CHEM, V383, P1565, DOI 10.1515/BC.2002.176; Chen MY, 2002, J BIOL CHEM, V277, P7670, DOI 10.1074/jbc.M110644200; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Dalbey RE, 2004, BBA-MOL CELL RES, V1694, P37, DOI 10.1016/j.bbamcr.2004.03.009; Dalbey RE, 2004, J CELL BIOL, V166, P769, DOI 10.1083/jcb.200405161; Dollins DE, 2005, J BIOL CHEM, V280, P30438, DOI 10.1074/jbc.M503761200; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Facey SJ, 2007, J MOL BIOL, V365, P995, DOI 10.1016/j.jmb.2006.10.083; Froderberg L, 2004, J BIOL CHEM, V279, P31026, DOI 10.1074/jbc.M403229200; Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556; Hidaka M, 2004, STRUCTURE, V12, P937, DOI 10.1016/j.str.2004.03.027; Holm L, 1996, METHOD ENZYMOL, V266, P653; Imamura H, 2003, J BIOL CHEM, V278, P19378, DOI 10.1074/jbc.M213134200; Jia LX, 2003, EMBO J, V22, P6438, DOI 10.1093/emboj/cdg624; Jiang FL, 2003, J BIOL CHEM, V278, P48965, DOI 10.1074/jbc.M307362200; Jiang FL, 2002, J BIOL CHEM, V277, P19281, DOI 10.1074/jbc.M110857200; Juers DH, 1999, PROTEIN SCI, V8, P122; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kiefer D, 2007, INT REV CYTOL, V259, P113, DOI 10.1016/S0074-7969(06)59003-5; Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Kuhn A, 2003, TRENDS CELL BIOL, V13, P510, DOI 10.1016/j.tcb.2003.08.005; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Lo Conte L, 2000, NUCLEIC ACIDS RES, V28, P257, DOI 10.1093/nar/28.1.257; Lotz M, 2008, J MOL BIOL, V375, P901, DOI 10.1016/j.jmb.2007.10.089; Luirink J, 2005, ANNU REV MICROBIOL, V59, P329, DOI 10.1146/annurev.micro.59.030804.121246; Luirink J, 2001, FEBS LETT, V501, P1, DOI 10.1016/S0014-5793(01)02616-3; Mogensen JE, 2005, MOL MICROBIOL, V57, P326, DOI 10.1111/j.1365-2958.2005.04674.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nouwen N, 2002, MOL MICROBIOL, V44, P1397, DOI 10.1046/j.1365-2958.2002.02972.x; Oliveira MA, 2006, J MOL BIOL, V359, P433, DOI 10.1016/j.jmb.2006.03.054; Oliver DC, 2008, J BIOL CHEM, V283, P5208, DOI 10.1074/jbc.M708936200; Parlitz R, 2007, J BIOL CHEM, V282, P32176, DOI 10.1074/jbc.M705430200; Preuss M, 2005, J BIOL CHEM, V280, P13004, DOI 10.1074/jbc.M414093200; Qiu W, 2007, J BIOL CHEM, V282, P8368, DOI 10.1074/jbc.M606784200; Ravaud S, 2008, ACTA CRYSTALLOGR F, V64, P144, DOI 10.1107/S1744309108002364; Rost B, 2004, NUCLEIC ACIDS RES, V32, pW321, DOI 10.1093/nar/gkh377; Rudenko G, 1999, CELL, V99, P93, DOI 10.1016/S0092-8674(00)80065-3; Saaf A, 1998, J BIOL CHEM, V273, P30415, DOI 10.1074/jbc.273.46.30415; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; Schrag JD, 2001, MOL CELL, V8, P633, DOI 10.1016/S1097-2765(01)00318-5; Serek J, 2004, EMBO J, V23, P294, DOI 10.1038/sj.emboj.7600063; Takeda K, 2003, EMBO J, V22, P3199, DOI 10.1093/emboj/cdg324; Tanaka S, 2007, ACTA CRYSTALLOGR D, V63, P1109, DOI 10.1107/S090744490704228X; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Urbanus ML, 2002, J BIOL CHEM, V277, P12718, DOI 10.1074/jbc.M200311200; Urbanus ML, 2001, EMBO REP, V2, P524, DOI 10.1093/embo-reports/kve108; van Bloois E, 2006, J BIOL CHEM, V281, P10002, DOI 10.1074/jbc.M511357200; van Bloois E, 2007, BIOCHEM BIOPH RES CO, V362, P727, DOI 10.1016/j.bbrc.2007.08.053; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; van der Laan M, 2005, CURR OPIN MICROBIOL, V8, P182, DOI 10.1016/j.mib.2005.02.004; van der Laan M, 2004, J CELL BIOL, V165, P213, DOI 10.1083/jcb.200402100; van der Laan M, 2001, EMBO REP, V2, P519, DOI 10.1093/embo-reports/kve106; Veenendaal AKJ, 2004, BBA-MOL CELL RES, V1694, P81, DOI 10.1016/j.bbamcr.2004.02.009; Velloso LM, 2002, J BIOL CHEM, V277, P15979, DOI 10.1074/jbc.M112098200; Vogt B, 2000, BIOPHYS J, V79, P2644, DOI 10.1016/S0006-3495(00)76503-9; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Walton TA, 2004, MOL CELL, V15, P367, DOI 10.1016/j.molcel.2004.07.023; Wild K, 2004, NAT STRUCT MOL BIOL, V11, P1049, DOI 10.1038/nsmb853; Xie K, 2006, BIOCHEMISTRY-US, V45, P13401, DOI 10.1021/bi060826z; Yi L, 2005, MOL MEMBR BIOL, V22, P101, DOI 10.1080/09687860500041718; Yuan J, 2007, J BACTERIOL, V189, P8961, DOI 10.1128/JB.01365-07	74	46	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9350	9358		10.1074/jbc.M710493200	http://dx.doi.org/10.1074/jbc.M710493200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18234665	hybrid			2022-12-25	WOS:000254465800065
J	Theodore, M; Kawai, Y; Yang, JQ; Kleshchenko, Y; Reddy, SP; Villalta, F; Arinze, IJ				Theodore, Melanie; Kawai, Yumiko; Yang, Jianqi; Kleshchenko, Yuliya; Reddy, Sekhar P.; Villalta, Fernando; Arinze, Ifeanyi J.			Multiple nuclear localization signals function in the nuclear import of the transcription factor nrf2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE ADAPTER PROTEIN; NF-KAPPA-B; GENE-EXPRESSION; EXPORT SIGNALS; RESPONSIVE ELEMENTS; FAMILY-MEMBERS; KINASE-C; KEAP1; IDENTIFICATION; ACTIVATION	Nuclear factor erythroid 2-related factor 2 ( Nrf2) mediates the transcriptional response of cells to oxidative stress and is translocated into the nucleus following, or concomitant with, its activation by electrophiles or reactive oxygen species. The mechanism of its translocation into the nucleus is not entirely elucidated. Here we have identified two novel nuclear localization signal ( NLS) motifs in murine Nrf2, one located near the N-terminal region ( amino acid residues 42-53) and the other ( residues 587-593) located near the C-terminal region. Imaging of green fluorescent protein ( GFP)-tagged Nrf2 revealed that mutation(s) in any of these sequences resulted in decreased nuclear fluorescence intensity compared with the wild-type Nrf2 when Nrf2 activation was induced with the electrophile tert-butylhydroquinone. The mutations also impaired Nrf2-induced transactivation of antioxidant response element-driven reporter gene expression to the same extent as the Nrf2 construct bearing mutation in a previously identified bipartite NLS that maps at residues 494-511. When linked to GFP or to GFPPEPCK-C each of the novel NLS motifs was sufficient to drive nuclear translocation of the fusion proteins. Co-immunoprecipitation assays demonstrated that importins alpha 5 and beta 1 associate with Nrf2, an interaction that was blocked by the nuclear import inhibitor SN50. SN50 also blocked tert-butylhydroquinone-induced nuclear fluorescence of GFP-Nrf2 in cells transfected with wild-type GFP-Nrf2. Overall these results reveal that multiple NLS motifs in Nrf2 function in its nuclear translocation in response to pro-oxidant stimuli and that the importin alpha-beta heterodimer nuclear import receptor system plays a critical role in the import process.	[Theodore, Melanie; Kawai, Yumiko; Kleshchenko, Yuliya; Villalta, Fernando; Arinze, Ifeanyi J.] Meharry Med Coll, Sch Med, Nashville, TN 37208 USA; [Yang, Jianqi] Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; [Reddy, Sekhar P.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth, Baltimore, MD 21205 USA	Meharry Medical College; Case Western Reserve University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Arinze, IJ (corresponding author), Meharry Med Coll, Sch Med, Nashville, TN 37208 USA.	iarinze@mmc.edu		Villalta, Fernando/0000-0002-6232-0574	NCI NIH HHS [U54 CA091408, U54 CA 91408] Funding Source: Medline; NCRR NIH HHS [U54 RR 019192-04, G12 RR003032, G12 RR 03032-19, U54 RR019192] Funding Source: Medline; NHLBI NIH HHS [HL 66109, T32 HL 007737] Funding Source: Medline; NIDDK NIH HHS [DK 07319] Funding Source: Medline; NIGMS NIH HHS [S06 GM 08037, 5R25 GM 059994] Funding Source: Medline; NINDS NIH HHS [U54 NS041071, U54 NS 041071-06] Funding Source: Medline; PHS HHS [D34 HP 00003] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U54CA091408] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003032, U54RR019192] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007737, R01HL066109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM059994, S06GM008037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U54NS041071] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alvarez-Maqueda M, 2004, J BIOL CHEM, V279, P21929, DOI 10.1074/jbc.M400492200; Arinze IJ, 2005, J BIOL CHEM, V280, P9786, DOI 10.1074/jbc.M414006200; Arinze IJ, 2003, J BIOL CHEM, V278, P17785, DOI 10.1074/jbc.M209430200; Bedard JEJ, 2007, HUM MOL GENET, V16, P187, DOI 10.1093/hmg/ddl461; Bloom DA, 2003, J BIOL CHEM, V278, P44675, DOI 10.1074/jbc.M307633200; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; Cui P, 2004, EXP CELL RES, V293, P154, DOI 10.1016/j.yexcr.2003.09.023; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Davis MG, 2000, BIOCHEM J, V346, P455, DOI 10.1042/0264-6021:3460455; Do HJ, 2006, FEBS LETT, V580, P1865, DOI 10.1016/j.febslet.2006.02.049; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; Goldfarb DS, 2004, TRENDS CELL BIOL, V14, P505, DOI 10.1016/j.tcb.2004.07.016; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Hanover JA, 2007, J BIOL CHEM, V282, P33743, DOI 10.1074/jbc.M705875200; Herrmann F, 2005, J BIOL CHEM, V280, P38005, DOI 10.1074/jbc.M502458200; Hong F, 2005, J BIOL CHEM, V280, P31768, DOI 10.1074/jbc.M503346200; Hu W, 2005, MOL CELL BIOL, V25, P3087, DOI 10.1128/MCB.25.8.3087-3108.2005; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 2003, GENES CELLS, V8, P379, DOI 10.1046/j.1365-2443.2003.00640.x; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; Jain AK, 2007, J BIOL CHEM, V282, P16502, DOI 10.1074/jbc.M611336200; Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200; Jones SM, 2003, J BIOL CHEM, V278, P10257, DOI 10.1074/jbc.M211021200; Kang MI, 2004, P NATL ACAD SCI USA, V101, P2046, DOI 10.1073/pnas.0308347100; Karapetian RN, 2005, MOL CELL BIOL, V25, P1089, DOI 10.1128/MCB.25.3.1089-1099.2005; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; Katoh Y, 2005, ARCH BIOCHEM BIOPHYS, V433, P342, DOI 10.1016/j.abb.2004.10.012; Kawai Y, 2006, CANCER RES, V66, P6563, DOI 10.1158/0008-5472.CAN-06-0814; Kobayashi A, 2006, MOL CELL BIOL, V26, P221, DOI 10.1128/MCB.26.1.221-229.2006; Kohler M, 1999, MOL CELL BIOL, V19, P7782; Kohler M, 1997, FEBS LETT, V417, P104, DOI 10.1016/S0014-5793(97)01265-9; Krauer K, 2004, J GEN VIROL, V85, P165, DOI 10.1099/vir.0.19549-0; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Lange A, 2007, J BIOL CHEM, V282, P5101, DOI 10.1074/jbc.R600026200; Lee JM, 2005, FASEB J, V19, P1061, DOI 10.1096/fj.04-2591hyp; Li J, 2002, J BIOL CHEM, V277, P388, DOI 10.1074/jbc.M109380200; Li WG, 2006, J BIOL CHEM, V281, P27251, DOI 10.1074/jbc.M602746200; Li WG, 2005, J BIOL CHEM, V280, P28430, DOI 10.1074/jbc.M410601200; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Liu XY, 2000, J BIOL CHEM, V275, P16774; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Maertens G, 2004, J BIOL CHEM, V279, P33421, DOI 10.1074/jbc.M404700200; Malnou CE, 2007, J BIOL CHEM, V282, P31046, DOI 10.1074/jbc.M702833200; Moehlenkamp JD, 1999, ARCH BIOCHEM BIOPHYS, V363, P98, DOI 10.1006/abbi.1998.1046; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Mosammaparast N, 2004, TRENDS CELL BIOL, V14, P547, DOI 10.1016/j.tcb.2004.09.004; Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003; Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Nguyen T, 2005, J BIOL CHEM, V280, P32485, DOI 10.1074/jbc.M503074200; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Ossareh-Nazari B, 2001, TRAFFIC, V2, P684, DOI 10.1034/j.1600-0854.2001.21002.x; PAPAIAHGARI S, 2004, ARCH BIOCHEM BIOPHYS, V363, P98; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; Riddick G, 2005, J CELL BIOL, V168, P1027, DOI 10.1083/jcb.200409024; Russo G, 1997, J BIOL CHEM, V272, P5229, DOI 10.1074/jbc.272.8.5229; Savory JGA, 1999, MOL CELL BIOL, V19, P1025; Stewart D, 2003, J BIOL CHEM, V278, P2396, DOI 10.1074/jbc.M209195200; Stewart M, 2001, FEBS LETT, V498, P145, DOI 10.1016/S0014-5793(01)02489-9; Torgerson TR, 1998, J IMMUNOL, V161, P6084; VANDROMME M, 1995, P NATL ACAD SCI USA, V92, P4646, DOI 10.1073/pnas.92.10.4646; Velichkova M, 2005, MOL CELL BIOL, V25, P4501, DOI 10.1128/MCB.25.11.4501-4513.2005; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Watai Y, 2007, GENES CELLS, V12, P1163, DOI 10.1111/j.1365-2443.2007.01118.x; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Yang JQ, 2001, J BIOL CHEM, V276, P25742, DOI 10.1074/jbc.M102821200; Zhang DD, 2005, J BIOL CHEM, V280, P30091, DOI 10.1074/jbc.M501279200; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004; Zhang DD, 2006, DRUG METAB REV, V38, P769, DOI 10.1080/03602530600971974; Zipper LM, 2003, TOXICOL SCI, V73, P124, DOI 10.1093/toxsci/kfg083	73	134	140	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					8984	8994		10.1074/jbc.M709040200	http://dx.doi.org/10.1074/jbc.M709040200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18238777	Green Published, hybrid			2022-12-25	WOS:000254465800028
J	Delhey, K; Peters, A				Delhey, Kaspar; Peters, Anne			Quantifying Variability of Avian Colours: Are Signalling Traits More Variable?	PLOS ONE			English	Article								Background: Increased variability in sexually selected ornaments, a key assumption of evolutionary theory, is thought to be maintained through condition-dependence. Condition-dependent handicap models of sexual selection predict that (a) sexually selected traits show amplified variability compared to equivalent non-sexually selected traits, and since males are usually the sexually selected sex, that (b) males are more variable than females, and (c) sexually dimorphic traits more variable than monomorphic ones. So far these predictions have only been tested for metric traits. Surprisingly, they have not been examined for bright coloration, one of the most prominent sexual traits. This omission stems from computational difficulties: different types of colours are quantified on different scales precluding the use of coefficients of variation. Methodology/Principal Findings: Based on physiological models of avian colour vision we develop an index to quantify the degree of discriminable colour variation as it can be perceived by conspecifics. A comparison of variability in ornamental and non-ornamental colours in six bird species confirmed (a) that those coloured patches that are sexually selected or act as indicators of quality show increased chromatic variability. However, we found no support for (b) that males generally show higher levels of variability than females, or (c) that sexual dichromatism per se is associated with increased variability. Conclusions/Significance: We show that it is currently possible to realistically estimate variability of animal colours as perceived by them, something difficult to achieve with other traits. Increased variability of known sexually-selected/quality-indicating colours in the studied species, provides support to the predictions borne from sexual selection theory but the lack of increased overall variability in males or dimorphic colours in general indicates that sexual differences might not always be shaped by similar selective forces.	[Delhey, Kaspar; Peters, Anne] Max Planck Inst Ornithol, Vogelwarte Radolfzell, Radolfzell, Germany	Max Planck Society	Delhey, K (corresponding author), Max Planck Inst Ornithol, Vogelwarte Radolfzell, Radolfzell, Germany.	delhey@orn.mpg.de	Delhey, Kaspar/AAZ-5362-2020; Delhey, Kaspar/F-6515-2010; Peters, Anne/A-1821-2010	Delhey, Kaspar/0000-0001-5190-5406; Peters, Anne/0000-0001-8071-0560	Max Planck Society	Max Planck Society(Max Planck Society)	This study was funded by the Max Planck Society. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALATALO RV, 1988, BIOL J LINN SOC, V34, P363, DOI 10.1111/j.1095-8312.1988.tb01969.x; Amundsen T, 2000, TRENDS ECOL EVOL, V15, P149, DOI 10.1016/S0169-5347(99)01800-5; Arden R, 2006, PERS INDIV DIFFER, V41, P39, DOI 10.1016/j.paid.2005.11.027; Blanco G, 2002, ANIM BEHAV, V63, P217, DOI 10.1006/anbe.2001.1909; Campenhausen MV, 1998, J COMP PHYSIOL A, V183, P1; Cotton S, 2004, P ROY SOC B-BIOL SCI, V271, P771, DOI 10.1098/rspb.2004.2688; Cotton S, 2004, EVOLUTION, V58, P1038, DOI 10.1111/j.0014-3820.2004.tb00437.x; Cotton S, 2007, CURR BIOL, V17, pR335, DOI 10.1016/j.cub.2007.03.004; Cuervo JJ, 1999, BIOL J LINN SOC, V68, P505, DOI 10.1111/j.1095-8312.1999.tb01186.x; Cuthill IC, 2006, BIRD COLORATION, V1, P3; Dale J., 2006, BIRD COLORATION, V2, P36; Darwin G., 1871, P423; Doucet SM, 2007, AM NAT, V169, pS62, DOI 10.1086/510162; Dunn PO, 2001, EVOLUTION, V55, P161; Eaton MD, 2005, P NATL ACAD SCI USA, V102, P10942, DOI 10.1073/pnas.0501891102; Ellegren H, 1997, NAT GENET, V17, P182, DOI 10.1038/ng1097-182; ENDLER JA, 1993, ECOL MONOGR, V63, P1, DOI 10.2307/2937121; Endler JA, 2005, EVOLUTION, V59, P1795, DOI 10.1111/j.0014-3820.2005.tb01827.x; Endler JA, 1996, AM NAT, V148, P421, DOI 10.1086/285934; Endler JA, 2005, BIOL J LINN SOC, V86, P405, DOI 10.1111/j.1095-8312.2005.00540.x; EVANS MR, 1995, BIOL J LINN SOC, V54, P371, DOI 10.1111/j.1095-8312.1995.tb01043.x; Fitzpatrick S, 1997, BIOL J LINN SOC, V62, P145; Gonzalez-Solis J, 2004, OIKOS, V105, P247, DOI 10.1111/j.0030-1299.2004.12997.x; Grafen A., 2002, MODERN STAT LIFE SCI; Gray DA, 1996, AM NAT, V148, P453, DOI 10.1086/285935; Griffith SC, 2006, ANIM BEHAV, V71, P749, DOI 10.1016/j.anbehav.2005.07.016; GRIFFITH SC, 2006, BIRD COLORATION, V2, P233; Griffiths R, 1998, MOL ECOL, V7, P1071, DOI 10.1046/j.1365-294x.1998.00389.x; GUILFORD T, 1991, ANIM BEHAV, V42, P1, DOI 10.1016/S0003-3472(05)80600-1; Hart NS, 2000, J COMP PHYSIOL A, V186, P375, DOI 10.1007/s003590050437; Hart NS, 2001, PROG RETIN EYE RES, V20, P675, DOI 10.1016/S1350-9462(01)00009-X; Hastad O, 2005, P NATL ACAD SCI USA, V102, P6391, DOI 10.1073/pnas.0409228102; Heinsohn R, 2005, SCIENCE, V309, P617, DOI 10.1126/science.1112774; Hill GE., 2006, BIRD COLOURATION, P507, DOI [10.4159/9780674273788, DOI 10.4159/9780674273788]; HILL GE, 2006, BIRD COLORATION, P589; HUNT GR, 1993, EMU, V93, P71, DOI 10.1071/MU9930071; Jawor JM, 2003, AUK, V120, P249, DOI 10.1642/0004-8038(2003)120[0249:MOHASS]2.0.CO;2; Kahn NW, 1998, AUK, V115, P1074; Kelber A, 2003, BIOL REV, V78, P81, DOI 10.1017/S1464793102005985; Kemp DJ, 2006, EVOL ECOL RES, V8, P515; KIRKPATRICK M, 1991, NATURE, V350, P33, DOI 10.1038/350033a0; Komdeur J, 2005, BEHAV ECOL, V16, P805, DOI 10.1093/beheco/ari059; Kraaijeveld K, 2007, ANIM BEHAV, V74, P657, DOI 10.1016/j.anbehav.2006.12.027; MAIER EJ, 1993, J COMP PHYSIOL A, V172, P295, DOI 10.1007/BF00216611; Merila J, 1999, HEREDITY, V83, P103, DOI 10.1038/sj.hdy.6885850; Merilaita S, 2003, EVOLUTION, V57, P1248; MOLLER AP, 1991, EVOLUTION, V45, P1823, DOI 10.1111/j.1558-5646.1991.tb02690.x; Montgomerie R., 2006, BIRD COLORATION, P90; Odeen A, 2003, MOL BIOL EVOL, V20, P855, DOI 10.1093/molbev/msg108; Osorio D, 1999, EVOL ECOL, V13, P673, DOI 10.1023/A:1011059715610; Owens IPF, 1998, P ROY SOC B-BIOL SCI, V265, P397, DOI 10.1098/rspb.1998.0308; POMIANKOWSKI A, 1995, P ROY SOC B-BIOL SCI, V260, P21, DOI 10.1098/rspb.1995.0054; Quintana F, 2003, J FIELD ORNITHOL, V74, P370, DOI 10.1648/0273-8570-74.4.370; RICE WR, 1994, P NATL ACAD SCI USA, V91, P225, DOI 10.1073/pnas.91.1.225; Rowe L, 1996, P ROY SOC B-BIOL SCI, V263, P1415, DOI 10.1098/rspb.1996.0207; Schaefer HM, 2006, BEHAV ECOL, V17, P784, DOI 10.1093/beheco/arl011; Siddiqi A, 2004, J EXP BIOL, V207, P2471, DOI 10.1242/jeb.01047; Sokal R. R, 1981, BIOMETRY; TAYLOR PD, 1982, THEOR POPUL BIOL, V22, P392, DOI 10.1016/0040-5809(82)90052-1; Vorobyev M, 1998, P ROY SOC B-BIOL SCI, V265, P351, DOI 10.1098/rspb.1998.0302; Vorobyev M, 1998, J COMP PHYSIOL A, V183, P621, DOI 10.1007/s003590050286	61	45	47	0	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2008	3	2							e1689	10.1371/journal.pone.0001689	http://dx.doi.org/10.1371/journal.pone.0001689			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XS	18301766	Green Published, gold, Green Submitted			2022-12-25	WOS:000260586500033
J	Chao, YC; Huang, CS; Lee, CN; Chang, SY; King, CC; Kao, CL				Chao, Yuan-Chang; Huang, Ching-Shan; Lee, Chun-Nan; Chang, Sui-Yuan; King, Chwan-Chuen; Kao, Chuan-Liang			Higher Infection of Dengue Virus Serotype 2 in Human Monocytes of Patients with G6PD Deficiency	PLOS ONE			English	Article							GLUCOSE-6-PHOSPHATE-DEHYDROGENASE DEFICIENCY; NEUTROPHIL DYSFUNCTION; REPLICATION; ANEMIA; FEVER	The prevalence of glucose-6-phosphate dehydrogenase (G6PD) deficiency is high in Asia. An ex vivo study was conducted to elucidate the association of G6PD deficiency and dengue virus (DENV) infection when many Asian countries are hyperendemic. Human monocytes from peripheral mononuclear cells collected from 12 G6PD-deficient patients and 24 age-matched controls were infected with one of two DENV serotype 2 (DENV-2) strains-the New Guinea C strain (from a case of dengue fever) or the 16681 strain (from a case of dengue hemorrhagic fever) with a multiplicity of infection of 0.1. The infectivity of DENV-2 in human monocytes was analyzed by flow cytometry. Experimental results indicated that the monocytes of G6PD-deficient patients exhibited a greater levels of infection with DENV-2 New Guinea C strain than did those in healthy controls [mean +/- SD: 33.6%+/- 3.5 (27.2%similar to 39.2%) vs 20.3%+/- 6.2 (8.0%similar to 30.4%), P < 0.01]. Similar observations were made of infection with the DENV-2 16681 strain [40.9%+/- 3.9 (35.1%similar to 48.9%) vs 27.4%+/- 7.1 (12.3%similar to 37.1%), P < 0.01]. To our knowledge, this study demonstrates for the first time higher infection of human monocytes in G6PD patients with the dengue virus, which may be important in increasing epidemiological transmission and perhaps with the potential to develop more severe cases pathogenically.	[Chao, Yuan-Chang; Lee, Chun-Nan; Chang, Sui-Yuan; Kao, Chuan-Liang] Natl Taiwan Univ, Coll Med, Dept Clin Lab Sci & Med Biotechnol, Taipei 10764, Taiwan; [Chao, Yuan-Chang; Lee, Chun-Nan; Chang, Sui-Yuan; Kao, Chuan-Liang] NTU Hosp, Dept Lab Med, Taipei, Taiwan; [Huang, Ching-Shan] Fooyin Univ, Dept Med Technol, Kaohsiung, Taiwan; [King, Chwan-Chuen; Kao, Chuan-Liang] NTU, Coll Publ Hlth, Grad Inst Epidemiol, Taipei, Taiwan	National Taiwan University; National Taiwan University; Fooyin University; National Taiwan University	Chao, YC (corresponding author), Natl Taiwan Univ, Coll Med, Dept Clin Lab Sci & Med Biotechnol, Taipei 10764, Taiwan.	chuanliang@ntu.edu.tw	Huang, Ching-Shan/AAJ-3698-2021	KAO, CHUAN-LIANG/0000-0002-1020-2605; King, Chwan-Chuen/0000-0002-6078-2601; CHANG, SUI-YUAN/0000-0002-6009-6724	NHRI [NHRI-CN-CL9302P]	NHRI(National Health Research Institutes - Taiwan)	The authors would like to thank NHRI for their financial support (NHRI-CN-CL9302P) of this study.	ABUOSBA YK, 1989, J PEDIATR-US, V114, P748, DOI 10.1016/S0022-3476(89)80131-3; [Anonymous], 1989, B WORLD HEALTH ORGAN, V67, P601; BEUTLER E, 1994, BLOOD, V84, P3613, DOI 10.1182/blood.V84.11.3613.bloodjournal84113613; CHEN TP, 1993, PEDIATR RES, V34, P544, DOI 10.1203/00006450-199310000-00032; Chen YC, 1999, J VIROL, V73, P2650, DOI 10.1128/JVI.73.4.2650-2657.1999; Chiang Szu-Hui, 1999, Southeast Asian Journal of Tropical Medicine and Public Health, V30, P72; Choi JN, 2004, HEPATOLOGY, V39, P81, DOI 10.1002/hep.20001; CORRONS JLV, 1982, BLOOD, V59, P428; Costa E, 2002, J PEDIAT HEMATOL ONC, V24, P164, DOI 10.1097/00043426-200202000-00023; Gotsman I, 2001, J GASTROEN HEPATOL, V16, P1239, DOI 10.1046/j.1440-1746.2001.02611.x; GRAY GR, 1973, LANCET, V2, P530; Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480; Gubler DJ, 2004, COMP IMMUNOL MICROB, V27, P319, DOI 10.1016/j.cimid.2004.03.013; Gubler Duane J., 2002, Trends in Microbiology, V10, P100, DOI 10.1016/S0966-842X(01)02288-0; HALSTEAD SB, 1989, REV INFECT DIS, V11, pS830; Hayes JM, 2006, T ROY SOC TROP MED H, V100, P559, DOI 10.1016/j.trstmh.2005.08.013; Ho LJ, 2001, J IMMUNOL, V166, P1499, DOI 10.4049/jimmunol.166.3.1499; Huang CS, 2002, GASTROENTEROLOGY, V123, P127, DOI 10.1053/gast.2002.34173; Iwai K, 2001, HUM GENET, V108, P445, DOI 10.1007/s004390100527; Kao CL, 2001, J CLIN MICROBIOL, V39, P3672, DOI 10.1128/JCM.39.10.3672-3677.2001; King Chwan-Chuen, 2000, Dengue Bulletin, V24, P1; Kung CM, 2007, J MED VIROL, V79, P60, DOI 10.1002/jmv.20761; Kwan WH, 2005, J VIROL, V79, P7291, DOI 10.1128/JVI.79.12.7291-7299.2005; LaFleur C, 2002, HUM IMMUNOL, V63, P1039, DOI 10.1016/S0198-8859(02)00682-1; Lindgren H, 2004, INFECT IMMUN, V72, P7172, DOI 10.1128/IAI.72.12.7172-7182.2004; MAMLOK RJ, 1987, J PEDIATR-US, V111, P852, DOI 10.1016/S0022-3476(87)80203-2; Mehta A, 2000, BEST PRACT RES CL HA, V13, P21, DOI 10.1053/beha.1999.0055; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; SCOTT RM, 1980, J INFECT DIS, V141, P1, DOI 10.1093/infdis/141.1.1; Tanphaichitr Voravarn S., 2002, Journal of the Medical Association of Thailand, V85, pS522; van Bruggen R, 2002, BLOOD, V100, P1026, DOI 10.1182/blood.V100.3.1026; Wang WK, 2003, VIROLOGY, V305, P330, DOI 10.1006/viro.2002.1704	32	27	30	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1557	10.1371/journal.pone.0001557	http://dx.doi.org/10.1371/journal.pone.0001557			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270558	Green Published, Green Submitted, gold			2022-12-25	WOS:000260535900002
J	Trimarchi, JM; Stadler, MB; Cepko, CL				Trimarchi, Jeffrey M.; Stadler, Michael B.; Cepko, Constance L.			Individual Retinal Progenitor Cells Display Extensive Heterogeneity of Gene Expression	PLOS ONE			English	Article							FORKHEAD TRANSCRIPTION FACTOR; ANAPHASE-PROMOTING COMPLEX; HOMEOBOX GENE; SINGLE-CELL; RAT RETINA; PHOTORECEPTOR DIFFERENTIATION; FATE DETERMINATION; DNA-REPLICATION; NEURAL RETINA; IN-VIVO	The development of complex tissues requires that mitotic progenitor cells integrate information from the environment. The highly varied outcomes of such integration processes undoubtedly depend at least in part upon variations among the gene expression programs of individual progenitor cells. To date, there has not been a comprehensive examination of these differences among progenitor cells of a particular tissue. Here, we used comprehensive gene expression profiling to define these differences among individual progenitor cells of the vertebrate retina. Retinal progenitor cells (RPCs) have been shown by lineage analysis to be multipotent throughout development and to produce distinct types of daughter cells in a temporal, conserved order. A total of 42 single RPCs were profiled on Affymetrix arrays. In situ hybridizations performed on both retinal sections and dissociated retinal cells were used to validate the results of the microarrays. An extensive amount of heterogeneity in gene expression among RPCs, even among cells isolated from the same developmental time point, was observed. While many classes of genes displayed heterogeneity of gene expression, the expression of transcription factors constituted a significant amount of the observed heterogeneity. In contrast to previous findings, individual RPCs were found to express multiple bHLH transcription factors, suggesting alternative models to those previously developed concerning how these factors may be coordinated. Additionally, the expression of cell cycle related transcripts showed differences among those associated with G2 and M, versus G1 and S phase, suggesting different levels of regulation for these genes. These data provide insights into the types of processes and genes that are fundamental to cell fate choices, proliferation decisions, and, for cells of the central nervous system, the underpinnings of the formation of complex circuitry.	[Trimarchi, Jeffrey M.; Cepko, Constance L.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; [Stadler, Michael B.] Friedrich Miescher Inst Biomed Res, Basel, Switzerland; [Cepko, Constance L.] Harvard Med Sch, Howard Hughes Med Inst, Boston, MA USA	Harvard University; Harvard Medical School; Friedrich Miescher Institute for Biomedical Research; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Trimarchi, JM (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.	cepko@genetics.med.harvard.edu		Trimarchi, Jeffrey/0000-0001-7923-1538	National Eye Institute [EY08064]; Ruth L. Kirchenstein National Research Service Award [F32 EY014495]; NATIONAL EYE INSTITUTE [R01EY008064, F32EY014495] Funding Source: NIH RePORTER	National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Ruth L. Kirchenstein National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported by a National Eye Institute grant EY08064 and a Ruth L. Kirchenstein National Research Service Award F32 EY014495 (JMT).	Al-Bader MD, 2005, DEV BRAIN RES, V156, P38, DOI 10.1016/j.devbrainres.2005.01.010; Alexiades MR, 1997, DEVELOPMENT, V124, P1119; Alexiades MR, 1996, DEV DYNAM, V205, P293, DOI 10.1002/(SICI)1097-0177(199603)205:3<293::AID-AJA9>3.0.CO;2-D; ALTSHULER DM, 1991, P RET RES F, V3, P37; Bae SK, 2000, DEVELOPMENT, V127, P2933; Bao ZZ, 1997, J NEUROSCI, V17, P1425; Bartel FO, 2000, ONCOGENE, V19, P6443, DOI 10.1038/sj.onc.1204038; Bastians H, 1999, MOL BIOL CELL, V10, P3927, DOI 10.1091/mbc.10.11.3927; Belliveau M. J., 1999, DEVELOPMENT IN PRESS; Belliveau MJ, 2000, J NEUROSCI, V20, P2247; BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Blackshaw S, 2004, PLOS BIOL, V2, P1411, DOI 10.1371/journal.pbio.0020247; Blackshaw S, 2001, CELL, V107, P579, DOI 10.1016/S0092-8674(01)00574-8; BRADY G, 1993, METHOD ENZYMOL, V225, P611; BreitenederGeleff S, 1997, AM J PATHOL, V151, P1141; Brent AE, 2003, CELL, V113, P235, DOI 10.1016/S0092-8674(03)00268-X; Brown NL, 1998, DEVELOPMENT, V125, P4821; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burmeister M, 1996, NAT GENET, V12, P376, DOI 10.1038/ng0496-376; Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780; Cayouette M, 2003, NEURON, V40, P897, DOI 10.1016/S0896-6273(03)00756-6; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; Cepko CL, 1999, CURR OPIN NEUROBIOL, V9, P37, DOI 10.1016/S0959-4388(99)80005-1; Chiang MK, 2003, DEV CELL, V4, P383, DOI 10.1016/S1534-5807(03)00035-2; Chowers I, 2003, INVEST OPHTH VIS SCI, V44, P3732, DOI 10.1167/iovs.02-1080; Decembrini S, 2006, PLOS BIOL, V4, P1562, DOI 10.1371/journal.pbio.0040272; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Dyer MA, 2001, NAT REV NEUROSCI, V2, P333, DOI 10.1038/35072555; Dyer MA, 2001, J NEUROSCI, V21, P4259, DOI 10.1523/JNEUROSCI.21-12-04259.2001; Edlund T, 1999, CELL, V96, P211, DOI 10.1016/S0092-8674(00)80561-9; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; el-Ghissassi F, 2002, ONCOGENE, V21, P6772, DOI 10.1038/sj.onc.1205888; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; Ezzeddine ZD, 1997, DEVELOPMENT, V124, P1055; FIELDSBERRY SC, 1992, P NATL ACAD SCI USA, V89, P693, DOI 10.1073/pnas.89.2.693; Freund CL, 1997, CELL, V91, P543, DOI 10.1016/S0092-8674(00)80440-7; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; Gieffers C, 1999, P NATL ACAD SCI USA, V96, P11317, DOI 10.1073/pnas.96.20.11317; Ginsberg SD, 2005, J COMP NEUROL, V487, P107, DOI 10.1002/cne.20535; Gouge A, 2001, MECH DEVELOP, V107, P203, DOI 10.1016/S0925-4773(01)00465-8; HANNAN AJ, 1995, MOL CELL NEUROSCI, V6, P397, DOI 10.1006/mcne.1995.1030; Hatakeyama J, 2004, SEMIN CELL DEV BIOL, V15, P83, DOI 10.1016/j.semcdb.2003.09.005; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; Hu H, 2006, NAT IMMUNOL, V7, P819, DOI 10.1038/ni1358; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Huang S, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.128701; Humbert PO, 2000, GENE DEV, V14, P690; Hyatt GA, 1996, P NATL ACAD SCI USA, V93, P13298, DOI 10.1073/pnas.93.23.13298; Iacopetti P, 1999, P NATL ACAD SCI USA, V96, P4639, DOI 10.1073/pnas.96.8.4639; Irniger S, 2002, FEBS LETT, V532, P7, DOI 10.1016/S0014-5793(02)03657-8; Isshiki T, 2001, CELL, V106, P511, DOI 10.1016/S0092-8674(01)00465-2; JASKULSKI D, 1988, J BIOL CHEM, V263, P10175; Jaszai J, 2002, MECH DEVELOP, V113, P73, DOI 10.1016/S0925-4773(01)00655-4; Kalma Y, 2001, ONCOGENE, V20, P1379, DOI 10.1038/sj.onc.1204230; Kamme F, 2003, J NEUROSCI, V23, P3607; KELLEY MW, 1994, DEVELOPMENT, V120, P2091; Kelley MW, 1999, NEUROREPORT, V10, P2389, DOI 10.1097/00001756-199908020-00031; Korver W, 1997, NUCLEIC ACIDS RES, V25, P1715, DOI 10.1093/nar/25.9.1715; Kouadjo KE, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-127; Laoukili J, 2007, BBA-REV CANCER, V1775, P92, DOI 10.1016/j.bbcan.2006.08.006; Le TT, 2006, DEV BIOL, V295, P764, DOI 10.1016/j.ydbio.2006.03.055; Lee PD, 2002, GENOME RES, V12, P292, DOI 10.1101/gr.217802; Lei M, 2005, CURR CANCER DRUG TAR, V5, P365, DOI 10.2174/1568009054629654; Levine EM, 2004, SEMIN CELL DEV BIOL, V15, P63, DOI 10.1016/j.semcdb.2003.09.001; Li SG, 2004, NEURON, V43, P795, DOI 10.1016/j.neuron.2004.08.041; LINSER P, 1979, P NATL ACAD SCI USA, V76, P6476, DOI 10.1073/pnas.76.12.6476; LIU ISC, 1994, NEURON, V13, P377, DOI 10.1016/0896-6273(94)90354-9; Livesey FJ, 2004, P NATL ACAD SCI USA, V101, P1374, DOI 10.1073/pnas.0307014101; Livesey FJ, 2001, NAT REV NEUROSCI, V2, P109, DOI 10.1038/35053522; Maiorano D, 2006, CURR OPIN CELL BIOL, V18, P130, DOI 10.1016/j.ceb.2006.02.006; Marquardt T, 2001, CELL, V105, P43, DOI 10.1016/S0092-8674(01)00295-1; MARSHARMSTRONG N, 1994, P NATL ACAD SCI USA, V91, P7286, DOI 10.1073/pnas.91.15.7286; Martinez-Morales JR, 2005, DEV CELL, V8, P565, DOI 10.1016/j.devcel.2005.01.022; Martins RAP, 2006, EUR J NEUROSCI, V24, P969, DOI 10.1111/j.1460-9568.2006.04966.x; Masland RH, 2000, ANNU REV NEUROSCI, V23, P249, DOI 10.1146/annurev.neuro.23.1.249; Mathers PH, 2000, CELL MOL LIFE SCI, V57, P186, DOI 10.1007/PL00000683; Matsuda T, 2004, P NATL ACAD SCI USA, V101, P16, DOI 10.1073/pnas.2235688100; Matter-Sadzinski L, 2005, DEVELOPMENT, V132, P3907, DOI 10.1242/dev.01960; Moore KB, 2002, NEURON, V34, P183, DOI 10.1016/S0896-6273(02)00666-9; Morrow EM, 1999, DEVELOPMENT, V126, P23; Murtaugh LC, 1999, GENE DEV, V13, P225, DOI 10.1101/gad.13.2.225; Nagaraj R, 2007, DEVELOPMENT, V134, P825, DOI 10.1242/dev.02788; Nishida A, 2003, NAT NEUROSCI, V6, P1255, DOI 10.1038/nn1155; OHSAWA R, 2007, BRAIN RES; Oshima A, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.034397; Otteson DC, 2005, BMC MOL BIOL, V6, DOI 10.1186/1471-2199-6-15; Otteson DC, 2004, INVEST OPHTH VIS SCI, V45, P2522, DOI 10.1167/iovs.04-0072; Pearson BJ, 2003, NATURE, V425, P624, DOI 10.1038/nature01910; Pei L, 2001, J BIOL CHEM, V276, P8484, DOI 10.1074/jbc.M009654200; Perron M, 2000, CELL MOL LIFE SCI, V57, P215, DOI 10.1007/PL00000685; Porter FD, 1997, DEVELOPMENT, V124, P2935; Punzo C, 2007, INVEST OPHTH VIS SCI, V48, P849, DOI 10.1167/iovs.05-1555; Ramos CA, 2006, PLOS GENET, V2, P1487, DOI 10.1371/journal.pgen.0020159; Rapaport DH, 2001, J NEUROBIOL, V49, P129, DOI 10.1002/neu.1070; Reddy SK, 2007, NATURE, V446, P921, DOI 10.1038/nature05734; Rodieck R.W., 1998, 1 STEPS SEEING; Rowan S, 2004, DEV BIOL, V271, P388, DOI 10.1016/j.ydbio.2004.03.039; Saari JC, 2001, NEURON, V29, P739, DOI 10.1016/S0896-6273(01)00248-3; Sano M, 2006, ONCOL REP, V16, P1093; Sen J, 2005, DEVELOPMENT, V132, P5147, DOI 10.1242/dev.02100; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sidman RL, 1961, STRUCTURE EYE, P487; Steele BK, 2002, ANAL BIOCHEM, V307, P341, DOI 10.1016/S0003-2697(02)00045-3; Stolt CC, 2005, DEV BIOL, V281, P309, DOI 10.1016/j.ydbio.2005.03.010; Stolt CC, 2004, DEVELOPMENT, V131, P2349, DOI 10.1242/dev.01114; Taranova OV, 2006, GENE DEV, V20, P1187, DOI 10.1101/gad.1407906; Teng SC, 2006, J MOL HISTOL, V37, P293, DOI 10.1007/s10735-006-9032-y; Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7; Tietjen I, 2003, NEURON, V38, P161, DOI 10.1016/S0896-6273(03)00229-0; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Trimarchi JM, 2007, J COMP NEUROL, V502, P1047, DOI 10.1002/cne.21368; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Tseng SF, 2005, J BIOL CHEM, V280, P39594, DOI 10.1074/jbc.M508425200; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; Valente T, 2001, MECH DEVELOP, V108, P207, DOI 10.1016/S0925-4773(01)00492-0; VANDERWEYDEN L, 2007, BIOCH BIOPHYS ACTA; VARDIMON L, 1986, P NATL ACAD SCI USA, V83, P9060, DOI 10.1073/pnas.83.23.9060; Vetter ML, 2001, SEMIN CELL DEV BIOL, V12, P491, DOI 10.1006/scdb.2001.0273; Voas MG, 2004, DEV DYNAM, V229, P162, DOI 10.1002/dvdy.10449; Wakioka T, 2001, NATURE, V412, P647, DOI 10.1038/35088082; WALTHER C, 1991, DEVELOPMENT, V113, P1435; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215; YOUNG RW, 1985, DEV BRAIN RES, V21, P229, DOI 10.1016/0165-3806(85)90211-1; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4; Yu JD, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r65; Zaki PA, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-46	129	132	132	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1588	10.1371/journal.pone.0001588	http://dx.doi.org/10.1371/journal.pone.0001588			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270576	Green Published, Green Submitted, gold			2022-12-25	WOS:000260535900022
J	Jones, RB; Garrison, KE; Wong, JC; Duan, EH; Nixon, DF; Ostrowski, MA				Jones, R. Brad; Garrison, Keith E.; Wong, Jessica C.; Duan, Erick H.; Nixon, Douglas F.; Ostrowski, Mario A.			Nucleoside Analogue Reverse Transcriptase Inhibitors Differentially Inhibit Human LINE-1 Retrotransposition	PLOS ONE			English	Article							MATERNAL-FETAL TRANSFER; AMNIOTIC-FLUID ACCUMULATION; L1 RETROTRANSPOSITION; ORF1 PROTEIN; CHAPERONE ACTIVITY; DYSTROPHIN GENE; INSERTION; SEQUENCE; ELEMENT; LAMIVUDINE	Background: Intact LINE-1 elements are the only retrotransposons encoded by the human genome known to be capable of autonomous replication. Numerous cases of genetic disease have been traced to gene disruptions caused by LINE-1 retrotransposition events in germ-line cells. In addition, genomic instability resulting from LINE-1 retrotransposition in somatic cells has been proposed as a contributing factor to oncogenesis and to cancer progression. LINE-1 element activity may also play a role in normal physiology. Methods and Principal Findings: Using an in vitro LINE-1 retrotransposition reporter assay, we evaluated the abilities of several antiretroviral compounds to inhibit LINE-1 retrotransposition. The nucleoside analogue reverse transcriptase inhibitors (nRTIs): stavudine, zidovudine, tenofovir disoproxil fumarate, and lamivudine all inhibited LINE-1 retrotransposition with varying degrees of potencies, while the non-nucleoside HIV-1 reverse transcriptase inhibitor nevirapine showed no effect. Conclusions/Significance: Our data demonstrates the ability for nRTIs to suppress LINE-1 retrotransposition. This is immediately applicable to studies aimed at examining potential roles for LINE-1 retrotransposition in physiological processes. In addition, our data raises novel safety considerations for nRTIs based on their potential to disrupt physiological processes involving LINE-1 retrotransposition.	[Jones, R. Brad; Wong, Jessica C.; Duan, Erick H.; Ostrowski, Mario A.] Univ Toronto, Dept Immunol, Toronto, ON, Canada; [Garrison, Keith E.; Nixon, Douglas F.] Univ Calif San Francisco, Dept Med, Div Expt Med, San Francisco, CA USA; [Ostrowski, Mario A.] St Michaels Hosp, Toronto, ON, Canada	University of Toronto; University of California System; University of California San Francisco; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Jones, RB (corresponding author), Univ Toronto, Dept Immunol, Med Sci Bldg, Toronto, ON, Canada.	brad.jones@utoronto.ca	Nixon, Douglas/AAU-5734-2020	Nixon, Douglas/0000-0002-2801-1786	Canadian Institutes for Health Research (CIHR); UCSF AIDS Research Institute (ARI); Pfizer; Ontario HIV Treatment Network (OHTN) [studentship]	Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); UCSF AIDS Research Institute (ARI); Pfizer(Pfizer); Ontario HIV Treatment Network (OHTN)	This work was supported by funds from the Canadian Institutes for Health Research (CIHR), and funds from the UCSF AIDS Research Institute (ARI). M.A.O and D.F.N receive funding from Pfizer under a sponsored research agreement. M.A.O receives salary support from the Ontario HIV Treatment Network (OHTN) and the CIHR. R.B.J receives a studentship from the OHTN. Biosafety level 3 laboratory space and equipment was provided by the Canadian Foundation for HIV Research (CANFAR) in partnership with the Canadian Foundation for Innovation and the Ontario Innovation Trust. The following reagents were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: Stavudine, Nevirapine, Lamivudine, Tenofovir Disoproxil Fumarate, Integrase Inhibitor II8-D-24.	Barret B, 2003, AIDS, V17, P1769, DOI 10.1097/00002030-200308150-00006; Basame S, 2006, J MOL BIOL, V357, P351, DOI 10.1016/j.jmb.2005.12.063; BAWDON RE, 1994, GYNECOL OBSTET INVES, V38, P1, DOI 10.1159/000292432; Bloom SL, 1997, AM J OBSTET GYNECOL, V176, P291, DOI 10.1016/S0002-9378(97)70487-3; *BRISTOLMYERSSQUIB, 2006, ZER STAV; Brouha B, 2003, P NATL ACAD SCI USA, V100, P5280, DOI 10.1073/pnas.0831042100; Chappuy H, 2004, ANTIMICROB AGENTS CH, V48, P4332, DOI 10.1128/AAC.48.11.4332-4336.2004; Cherry CL, 2006, JAIDS-J ACQ IMM DEF, V42, P435, DOI 10.1097/01.qai.0000224974.67962.ce; Cost GJ, 2002, EMBO J, V21, P5899, DOI 10.1093/emboj/cdf592; DREW RH, 1989, ANTIMICROB AGENTS CH, V33, P1801, DOI 10.1128/AAC.33.10.1801; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; *GILEADSCIENCES, 2007, VIR; *GLAXOSMITHKLINE, 2001, RETR PRESCR INF; *GLAXOSMITHKLINE, 2001, EP PRESCR INF; HEIDMANN T, 1988, P NATL ACAD SCI USA, V85, P2219, DOI 10.1073/pnas.85.7.2219; Hohjoh H, 1997, EMBO J, V16, P6034, DOI 10.1093/emboj/16.19.6034; Jurka J, 1997, P NATL ACAD SCI USA, V94, P1872, DOI 10.1073/pnas.94.5.1872; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; Kolosha VO, 1997, P NATL ACAD SCI USA, V94, P10155, DOI 10.1073/pnas.94.19.10155; Kubo S, 2006, P NATL ACAD SCI USA, V103, P8036, DOI 10.1073/pnas.0601954103; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Mandelbrot L, 2001, AM J OBSTET GYNECOL, V184, P153, DOI 10.1067/mob.2001.108344; Mangiacasale R, 2003, ONCOGENE, V22, P2750, DOI 10.1038/sj.onc.1206354; Martin SL, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/45621; Martin SL, 2000, J MOL BIOL, V304, P11, DOI 10.1006/jmbi.2000.4182; Martin SL, 2005, J MOL BIOL, V348, P549, DOI 10.1016/j.jmb.2005.03.003; Martin SL, 2003, P NATL ACAD SCI USA, V100, P13815, DOI 10.1073/pnas.2336221100; Martin SL, 2001, MOL CELL BIOL, V21, P467, DOI 10.1128/MCB.21.2.467-475.2001; Meischl C, 2000, EUR J HUM GENET, V8, P697, DOI 10.1038/sj.ejhg.5200523; MIKI Y, 1992, CANCER RES, V52, P643; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4; Muotri AR, 2005, NATURE, V435, P903, DOI 10.1038/nature03663; Musova Z, 2006, BIOCHEM BIOPH RES CO, V347, P145, DOI 10.1016/j.bbrc.2006.06.071; NARITA N, 1993, J CLIN INVEST, V91, P1862, DOI 10.1172/JCI116402; Ostertag EM, 2000, NUCLEIC ACIDS RES, V28, P1418, DOI 10.1093/nar/28.6.1418; Patterson TA, 2000, TERATOLOGY, V62, P93, DOI 10.1002/1096-9926(200008)62:2<93::AID-TERA5>3.3.CO;2-D; PRESCOTT LM, 1995, J INT ASS PHYS AIDS, V1, P34; Roman-Gomez J, 2005, ONCOGENE, V24, P7213, DOI 10.1038/sj.onc.1208866; Sassaman DM, 1997, NAT GENET, V16, P37, DOI 10.1038/ng0597-37; SMERDON SJ, 1994, P NATL ACAD SCI USA, V91, P3911, DOI 10.1073/pnas.91.9.3911; SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321; Szak ST, 2002, GENOME BIOL, V3; van den Hurk JAJM, 2007, HUM MOL GENET, V16, P1587, DOI 10.1093/hmg/ddm108; XIE H, 1995, ANTIVIR RES, V28, P113, DOI 10.1016/0166-3542(95)00042-K	45	61	62	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2008	3	2							e1547	10.1371/journal.pone.0001547	http://dx.doi.org/10.1371/journal.pone.0001547			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367EQ	18253495	gold, Green Published, Green Submitted			2022-12-25	WOS:000260535700019
J	Della Bella, S; Taddeo, A; Calabro, ML; Brambilla, L; Bellinvia, M; Bergamo, E; Clerici, M; Villa, ML				Della Bella, Silvia; Taddeo, Adriano; Calabro, Maria L.; Brambilla, Lucia; Bellinvia, Monica; Bergamo, Elisa; Clerici, Mario; Villa, Maria L.			Peripheral Blood Endothelial Progenitors as Potential Reservoirs of Kaposi's Sarcoma-Associated Herpesvirus	PLOS ONE			English	Article								The cellular reservoirs of Kaposi's sarcoma-associated herpesvirus (KSHV) and the exact nature of the putative KSHV-infected circulating precursor of spindle cells of Kaposi's sarcoma (KS) still remain poorly defined. Because KS spindle cells are thought to be of endothelial origin, and because mature endothelial cells do not sustain persistent KSHV-infection, our attention was focalized on circulating hematopoietic precursors able to differentiate into endothelial lineage. Methods and Findings. Late endothelial progenitor cells (late-EPCs) were cultured from the peripheral blood mononuclear cells of 16 patients with classic KS. The presence and load of KSHV genomes were analyzed by real-time polymerase chain reaction in DNA extracted from cells and supernatants of late-EPC cultures obtained from 7 patients. Endothelial colonies cultured from the peripheral blood of KS patients were found to satisfy all requisites to be defined late-EPCs: they appeared from the CD14-negative fraction of adherent cells after 11-26 days of culture, could be serially expanded in vitro, expressed high levels of endothelial antigens but lacked leukocyte markers. Late-EPC cultures were found to harbor KSHV-DNA at variable levels and to retain the virus after multiple passages in cells as well as in supernatants, suggesting that a quote of KSHV lytic infection may spontaneously occur. Lytic phase induction or hypoxia could amplify virus release in supernatants. Conclusion. Our results suggest that circulating endothelial progenitors from KS patients are KSHV-infected and support viral productive replication and may therefore represent potential virus reservoirs and putative precursors of KS spindle cells.	[Della Bella, Silvia; Taddeo, Adriano; Clerici, Mario; Villa, Maria L.] Univ Milan, Dipartimento Sci & Tecnol Biomed, Immunol Lab, Milan, Italy; [Calabro, Maria L.; Bergamo, Elisa] IRCCS, Ist Oncol Veneto, UOC Immunol & Diagnostic Mol Oncol, Padua, Italy; [Brambilla, Lucia; Bellinvia, Monica] IRCCS Ospedale Maggiore, Dept Dermatol, Milan, Italy; [Clerici, Mario] IRCCS Fdn Don Gnocchi, Ctr Santa Maria Nascente, Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Milan; IRCCS Istituto Oncologico Veneto (IOV); IRCCS Fondazione Don Carlo Gnocchi Onlus	Della Bella, S (corresponding author), Univ Milan, Dipartimento Sci & Tecnol Biomed, Immunol Lab, Milan, Italy.	silvia.dellabella@unimi.it	Taddeo, Adriano/AAW-3861-2021; Bella, Silvia Della/AAB-7904-2019; Calabrò, Maria Luisa/H-6015-2016	Taddeo, Adriano/0000-0003-3281-1548; Calabrò, Maria Luisa/0000-0001-9401-6182; Della Bella, Silvia/0000-0003-0818-5049; Clerici, Mario/0000-0001-5920-6191	Ministero dell Istruzione, dell Universita e della Ricerca [2003069391-001, 2006065944-002]; Fondazione Cariplo (Milan, Italy) [1055/104878-2005]; Istituto Superiore di Sanita [50G.3]; AIRC	Ministero dell Istruzione, dell Universita e della Ricerca(Ministry of Education, Universities and Research (MIUR)); Fondazione Cariplo (Milan, Italy)(Fondazione Cariplo); Istituto Superiore di Sanita; AIRC(Fondazione AIRC per la ricerca sul cancro)	Supported by grants 2003069391-001 and 2006065944-002 from Ministero dell Istruzione, dell Universita e della Ricerca (MLV and SDB); by grant 1055/104878-2005 from Fondazione Cariplo (Milan, Italy) (MLV); by grant 50G.3 from Istituto Superiore di Sanita (MLC) and by funds from AIRC (MLC).	Aluigi MG, 1996, RES VIROLOGY, V147, P267, DOI 10.1016/0923-2516(96)82285-0; Antman K, 2000, NEW ENGL J MED, V342, P1027, DOI 10.1056/NEJM200004063421407; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Bardin N, 2001, BLOOD, V98, P3677, DOI 10.1182/blood.V98.13.3677; Barozzi P, 2003, NAT MED, V9, P554, DOI 10.1038/nm862; Bertolini F, 2006, NAT REV CANCER, V6, P833, DOI 10.1039/nrc1971; Brambilla L, 2003, EUR J DERMATOL, V13, P83; Brambilla L, 2006, J DERMATOL, V33, P451, DOI 10.1111/j.1346-8138.2006.00108.x; Calabro ML, 2001, J NATL CANCER I, V93, P154, DOI 10.1093/jnci/93.2.154; Davis DA, 2001, BLOOD, V97, P3244, DOI 10.1182/blood.V97.10.3244; Della Bella S, 2004, BLOOD, V104, P4020, DOI 10.1182/blood-2004-03-0885; Della Bella S, 2001, CLIN EXP RHEUMATOL, V19, P647; Della Bella S, 2006, CLIN IMMUNOL, V119, P317, DOI 10.1016/j.clim.2006.01.011; Duprez R, 2007, JNCI-J NATL CANCER I, V99, P1086, DOI 10.1093/jnci/djm045; Flamand L, 1996, J ACQ IMMUN DEF SYND, V13, P194, DOI 10.1097/00042560-199610010-00011; Foubert P, 2007, J CLIN INVEST, V117, P1527, DOI 10.1172/JCI28338; Ganem D, 1997, CELL, V91, P157, DOI 10.1016/S0092-8674(00)80398-0; Gasperini P, 2005, J CLIN MICROBIOL, V43, P2866, DOI 10.1128/JCM.43.6.2866-2875.2005; Gill PS, 2007, J NATL CANCER I, V99, P1063, DOI 10.1093/jnci/djm063; Grundhoff A, 2004, J CLIN INVEST, V113, P124, DOI 10.1172/JCI200417803; Gulati R, 2003, CIRC RES, V93, P1023, DOI 10.1161/01.RES.0000105569.77539.21; Henry M, 1999, J INVEST DERMATOL, V113, P613, DOI 10.1046/j.1523-1747.1999.00733.x; Ingram DA, 2005, BLOOD, V106, P1525, DOI 10.1182/blood-2005-04-1509; Ingram DA, 2004, BLOOD, V104, P2752, DOI 10.1182/blood-2004-04-1396; Lebbe C, 1997, ARCH DERMATOL RES, V289, P421, DOI 10.1007/s004030050215; Lin Y, 2002, BLOOD, V99, P457, DOI 10.1182/blood.V99.2.457; Monini P, 1999, BLOOD, V93, P4044; Mutlu AD, 2007, CANCER CELL, V11, P245, DOI 10.1016/j.ccr.2007.01.015; Pellet C, 2006, J INVEST DERMATOL, V126, P621, DOI 10.1038/sj.jid.5700083; Schatteman GC, 2007, AM J PHYSIOL-HEART C, V292, pH1, DOI 10.1152/ajpheart.00662.2006; TADDEO A, 2008, J INVEST DE IN PRESS; Timmermans F, 2007, ARTERIOSCL THROM VAS, V27, P1572, DOI 10.1161/ATVBAHA.107.144972; Webster-Cyriaque J, 2002, NEW ENGL J MED, V346, P1207, DOI 10.1056/NEJMoa012125; Wu W, 2006, BLOOD, V108, P141, DOI 10.1182/blood-2005-04-1697; Yoder MC, 2007, BLOOD, V109, P1801, DOI 10.1182/blood-2006-08-043471	35	33	33	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1520	10.1371/journal.pone.0001520	http://dx.doi.org/10.1371/journal.pone.0001520			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SR	18231605	Green Submitted, Green Published, gold			2022-12-25	WOS:000260504200032
J	Yan, WX; Armishaw, C; Goyette, J; Yang, Z; Cai, H; Alewood, P; Geczy, CL				Yan, Wei Xing; Armishaw, Chris; Goyette, Jesse; Yang, Zheng; Cai, Hong; Alewood, Paul; Geczy, Carolyn L.			Mast cell and monocyte recruitment by S100A12 and its hinge domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AIRWAY SMOOTH-MUSCLE; IMMUNE-RESPONSE; PROTEIN S100A12; BONE-MARROW; EN-RAGE; RECEPTOR; MIGRATION; ACTIVATION; EXPRESSION; FAMILY	S100A12 is expressed at sites of acute, chronic, and allergic inflammation. S100 proteins have regions of high sequence homology, but the "hinge" region between the conserved calcium binding domains is structurally and functionally divergent. Because the murine S100A8 hinge domain ( mS100A8(42-55)) is a monocyte chemoattractant whereas the human sequence ( hS100A8(43-56)) is inactive, we postulated that common hydrophobic amino acids within the S100A12 hinge sequence may be functional. The hinge domain, S100A12(38-53), was chemotactic for human monocytes and murine mast cells in vitro. S100A12(38-53) provoked an acute inflammatory response similar to that elicited by S100A12 in vivo and caused edema and leukocyte and mast cell recruitment. Circular dichroism studies showed that S100A12(38-53) had increased helical structure in hydrophobic environments. Mutations in S100A12(38-53) produced using an alanine scan confirmed that specific hydrophobic residues ( I44A, I47A, and I53A) on the same face of the helix were critical for monocyte chemotaxis in vitro and generation of edema in vivo. In a hydrophobic environment such as the cell membrane, these critical residues would likely align on one face of an alpha-helix to facilitate receptor interaction. Interaction is unlikely to occur via the receptor for advanced glycation end products but, rather, via a G- protein- coupled mechanism.	[Yan, Wei Xing; Goyette, Jesse; Yang, Zheng; Cai, Hong; Geczy, Carolyn L.] Univ New S Wales, Inflammatory Dis Res Unit, Ctr Infect & Inflammat Res, Sydney, NSW 2052, Australia; [Armishaw, Chris; Alewood, Paul] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia	University of New South Wales Sydney; University of Queensland	Geczy, CL (corresponding author), Univ New S Wales, Inflammatory Dis Res Unit, Ctr Infect & Inflammat Res, Sydney, NSW 2052, Australia.	geczy@unsw.edu.au	Goyette, Jesse/AAW-4701-2021; Alewood, Paul F/J-2412-2014	Goyette, Jesse/0000-0002-1008-1890; Yang, Zheng/0000-0003-4275-0590				Berger P, 2003, FASEB J, V17, P2139, DOI 10.1096/fj.03-0041fje; Brightling CE, 2005, AM J RESP CRIT CARE, V171, P1103, DOI 10.1164/rccm.200409-1220OC; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Cornish CJ, 1996, J CELL PHYSIOL, V166, P427, DOI 10.1002/(SICI)1097-4652(199602)166:2<427::AID-JCP21>3.0.CO;2-6; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; El-Shazly A, 2006, J IMMUNOL, V176, P1860, DOI 10.4049/jimmunol.176.3.1860; Foell D, 2004, CLIN CHIM ACTA, V344, P37, DOI 10.1016/j.cccn.2004.02.023; Foell D, 2003, THORAX, V58, P613, DOI 10.1136/thorax.58.7.613; Foell D, 2007, J LEUKOCYTE BIOL, V81, P28, DOI 10.1189/jlb.0306170; Gordon JR, 2000, J ALLERGY CLIN IMMUN, V106, P110; Hasegawa T, 2003, ATHEROSCLEROSIS, V171, P211, DOI 10.1016/j.atherosclerosis.2003.08.021; HE D, 1990, J INVEST DERMATOL, V95, P178, DOI 10.1111/1523-1747.ep12477951; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Ishihara K, 2003, FEBS LETT, V550, P107, DOI 10.1016/S0014-5793(03)00846-9; Itou H, 2002, J MOL BIOL, V316, P265, DOI 10.1006/jmbi.2001.5340; Jackson NE, 2005, EUR J IMMUNOL, V35, P2376, DOI 10.1002/eji.200526154; Kitaura J, 2005, BLOOD, V105, P3222, DOI 10.1182/blood-2004-11-4205; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; LACKMANN M, 1993, J IMMUNOL, V150, P2981; LAU W, 1995, J CLIN INVEST, V95, P1957, DOI 10.1172/JCI117879; Lazoura E, 2000, J PEPT RES, V55, P411, DOI 10.1034/j.1399-3011.2000.00690.x; Leukert N, 2006, J MOL BIOL, V359, P961, DOI 10.1016/j.jmb.2006.04.009; Liliensiek B, 2004, J CLIN INVEST, V113, P1641, DOI 10.1172/JCI200418704; Markowitz J, 2004, J MED CHEM, V47, P5085, DOI 10.1021/jm0497038; Meyers HV, 1995, MOL DIVERS, V1, P13, DOI 10.1007/BF01715805; Moroz OV, 2002, ACTA CRYSTALLOGR D, V58, P407, DOI 10.1107/S0907444901021278; Moroz OV, 2003, MICROSC RES TECHNIQ, V60, P581, DOI 10.1002/jemt.10300; MURAKAMI M, 1995, J EXP MED, V182, P197, DOI 10.1084/jem.182.1.197; MURPHY PM, 1992, J BIOL CHEM, V267, P7637; Nilsson G, 1999, BLOOD, V93, P2791; Pozdnyakov N, 1998, BIOCHEMISTRY-US, V37, P10701, DOI 10.1021/bi9802115; Rajagopalan L, 2004, J BIOL CHEM, V279, P30000, DOI 10.1074/jbc.M313883200; Ravasi T, 2004, GENOMICS, V84, P10, DOI 10.1016/j.ygeno.2004.02.002; Robinson MJ, 2000, BIOCHEM BIOPH RES CO, V275, P865, DOI 10.1006/bbrc.2000.3407; Rouleau P, 2003, CLIN IMMUNOL, V107, P46, DOI 10.1016/S1521-6616(02)00043-8; Ryckman C, 2003, ARTHRITIS RHEUM-US, V48, P2310, DOI 10.1002/art.11079; Vogl T, 1999, J BIOL CHEM, V274, P25291, DOI 10.1074/jbc.274.36.25291; Wang HW, 1998, J CLIN INVEST, V102, P1617, DOI 10.1172/JCI3704; Wright NT, 2005, J MOL BIOL, V353, P410, DOI 10.1016/j.jmb.2005.08.027; Xie J, 2007, J BIOL CHEM, V282, P4218, DOI 10.1074/jbc.M608888200; Yang Z, 2001, J LEUKOCYTE BIOL, V69, P986; Yang Z, 2007, J ALLERGY CLIN IMMUN, V119, P106, DOI 10.1016/j.jaci.2006.08.021; Yokomizo T, 2001, LIFE SCI, V68, P2207, DOI 10.1016/S0024-3205(01)01007-4	44	55	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2008	283	19					13035	13043		10.1074/jbc.M710388200	http://dx.doi.org/10.1074/jbc.M710388200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295UQ	18292089	hybrid			2022-12-25	WOS:000255499800041
J	Das, A; Base, C; Manna, D; Cho, W; Dubreuil, RR				Das, Amlan; Base, Christine; Manna, Debasis; Cho, Wonhwa; Dubreuil, Ronald R.			Unexpected complexity in the mechanisms that target assembly of the spectrin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; BRONCHIAL EPITHELIAL-CELLS; DROSOPHILA BETA-SPECTRIN; AXON INITIAL SEGMENTS; ALPHA-SPECTRIN; PLASMA-MEMBRANE; LATERAL MEMBRANE; EMBRYONIC CNS; II-SPECTRIN; ANKYRIN-G	The spectrin cytoskeleton assembles within discrete regions of the plasma membrane in a wide range of animal cell types. Although recent studies carried out in vertebrate systems indicate that spectrin assembly occurs indirectly through the adapter protein ankyrin, recent studies in Drosophila have established that spectrin can also assemble through a direct ankyrin-independent mechanism. Here we tested specific regions of the spectrin molecule for a role in polarized assembly and function. First, we tested mutant beta-spectrins lacking ankyrin binding activity and/or the COOH-terminal pleckstrin homology (PH) domain for their assembly competence in midgut, salivary gland, and larval brain. Remarkably, three different assembly mechanisms operate in these three cell types: 1) neither site was required for assembly in salivary gland; 2) only the PH domain was required in midgut copper cells; and 3) either one of the two sites was sufficient for spectrin assembly in larval brain. Further characterization of the PH domain revealed that it binds strongly to lipid mixtures containing phosphatidylinositol 4,5-bisphosphate (PIP2) but not phosphatidylinositol 3,4,5-trisphosphate. A K8Q mutation in the lipid binding region of the PH domain eliminated the PIP2 interaction in vitro, yet the mutant protein retained full biological function in vivo. Reporter gene studies revealed that PIP2 and the spectrin PH domain codistribute with one another in cells but not with authentic wild type alpha beta-spectrin. Thus, it appears that the PH domain imparts membrane targeting activity through a second mechanism that takes precedence over its PIP2 binding activity.	Univ Illinois, Mol Biol Lab, Chicago, IL 60607 USA; Univ Illinois, Dept Biol Sci, Chicago, IL 60607 USA; [Manna, Debasis; Cho, Wonhwa] Univ Illinois, Dept Chem, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Dubreuil, RR (corresponding author), 900 S Ashland Ave,Rm 4152 MBRB,MC 567, Chicago, IL 60607 USA.	ron@uic.edu		Manna, Debasis/0000-0002-6920-9000	NIGMS NIH HHS [GM68849, GM49301] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068849, R01GM049301] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albertson R, 2003, NAT CELL BIOL, V5, P166, DOI 10.1038/ncb922; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Berger C, 2007, DEV DYNAM, V236, P3562, DOI 10.1002/dvdy.21372; Cho WW, 2001, ANAL BIOCHEM, V296, P153, DOI 10.1006/abio.2001.5225; Das A, 2006, J CELL BIOL, V175, P325, DOI 10.1083/jcb.200602095; DAVIS LH, 1994, J BIOL CHEM, V269, P4409; DUBREUIL R, 1987, J CELL BIOL, V105, P2095, DOI 10.1083/jcb.105.5.2095; Dubreuil RR, 2006, J MEMBRANE BIOL, V211, P151, DOI 10.1007/s00232-006-0863-y; DUBREUIL RR, 1994, P NATL ACAD SCI USA, V91, P10285, DOI 10.1073/pnas.91.22.10285; Dubreuil RR, 2000, J CELL BIOL, V149, P647, DOI 10.1083/jcb.149.3.647; Dubreuil RR, 1997, MOL BIOL CELL, V8, P1933, DOI 10.1091/mbc.8.10.1933; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Garbe DS, 2007, DEVELOPMENT, V134, P273, DOI 10.1242/dev.02653; Gassama-Diagne A, 2006, NAT CELL BIOL, V8, P963, DOI 10.1038/ncb1461; GUMBINER B, 1985, TRENDS BIOCHEM SCI, V10, P435, DOI 10.1016/0968-0004(85)90026-X; Hammarlund M, 2007, J CELL BIOL, V176, P269, DOI 10.1083/jcb.200611117; Hulsmeier J, 2007, DEVELOPMENT, V134, P713, DOI 10.1242/dev.02758; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; Kizhatil K, 2004, J BIOL CHEM, V279, P16706, DOI 10.1074/jbc.M314296200; Kizhatil K, 2007, J BIOL CHEM, V282, P2029, DOI 10.1074/jbc.M608921200; Lacas-Gervais S, 2004, J CELL BIOL, V166, P983, DOI 10.1083/jcb.200408007; LEE JK, 1993, J CELL BIOL, V123, P1797, DOI 10.1083/jcb.123.6.1797; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; LOMBARDO CR, 1994, J BIOL CHEM, V269, P29212; Lux SE, 1995, BLOOD PRINCIPLES PRA, P1701; Martin-Belmonte F, 2007, CELL, V128, P383, DOI 10.1016/j.cell.2006.11.051; Mohler PJ, 2004, J BIOL CHEM, V279, P40185, DOI 10.1074/jbc.M406018200; Phillips MD, 2006, J CELL SCI, V119, P1361, DOI 10.1242/jcs.02839; Pielage J, 2006, J CELL BIOL, V175, P491, DOI 10.1083/jcb.200607036; Pinal N, 2006, CURR BIOL, V16, P140, DOI 10.1016/j.cub.2005.11.068; Salomao M, 2006, P NATL ACAD SCI USA, V103, P643, DOI 10.1073/pnas.0507661103; Sherman DL, 2005, NEURON, V48, P737, DOI 10.1016/j.neuron.2005.10.019; Stahelin RV, 2006, J BIOL CHEM, V281, P39396, DOI 10.1074/jbc.M607079200; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; TEPASS U, 1994, DEV BIOL, V161, P563, DOI 10.1006/dbio.1994.1054; TSE WT, 1990, J CLIN INVEST, V86, P909, DOI 10.1172/JCI114792; Tse WT, 2001, J BIOL CHEM, V276, P23974, DOI 10.1074/jbc.M009307200; Wang DS, 1996, BIOCHEM BIOPH RES CO, V225, P420, DOI 10.1006/bbrc.1996.1189; Williams JA, 2004, J CELL SCI, V117, P771, DOI 10.1242/jcs.00922; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097; Yang Y, 2004, J NEUROSCI, V24, P7230, DOI 10.1523/JNEUROSCI.2125-04.2004; Yang Y, 2007, J CELL BIOL, V176, P509, DOI 10.1083/jcb.200610128; ZHANG P, 1995, STRUCTURE, V3, P1185, DOI 10.1016/S0969-2126(01)00254-4	43	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2008	283	18					12643	12653		10.1074/jbc.M800094200	http://dx.doi.org/10.1074/jbc.M800094200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	293MS	18287096	Green Published, hybrid			2022-12-25	WOS:000255340000081
J	Hsu, HJ; Tsai, KC; Sun, YK; Chang, HJ; Huang, YJ; Yu, HM; Lin, CH; Mao, SS; Yang, AS				Hsu, Hung-Ju; Tsai, Keng-Chang; Sun, Yi-Kun; Chang, Hung-Ju; Huang, Yi-Jen; Yu, Hui-Ming; Lin, Chun-Hung; Mao, Shi-Shan; Yang, An-Suei			Factor Xa active site substrate specificity with substrate phage display and computational molecular modeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROMOLECULAR SUBSTRATE; PROTHROMBINASE COMPLEX; PROTEASE SPECIFICITY; GENETIC ALGORITHM; SERINE PROTEASES; INHIBITORS; RECOGNITION; LIBRARIES; CLEAVAGE; IDENTIFICATION	Structural origin of substrate-enzyme recognition remains incompletely understood. In the model enzyme system of serine protease, canonical anti-parallel beta-structure substrate-enzyme complex is the predominant hypothesis for the substrate-enzyme interaction at the atomic level. We used factor Xa (fXa), a key serine protease of the coagulation system, as a model enzyme to test the canonical conformation hypothesis. More than 160 fXa-cleavable substrate phage variants were experimentally selected from three designed substrate phage display libraries. These substrate phage variants were sequenced and their specificities to the model enzyme were quantified with quantitative enzyme-linked immunosorbent assay for substrate phage- enzyme reaction kinetics. At least three substrate-enzyme recognition modes emerged from the experimental data as necessary to account for the sequence-dependent specificity of the model enzyme. Computational molecular models were constructed, with both energetics and pharmacophore criteria, for the substrate-enzyme complexes of several of the representative substrate peptide sequences. In contrast to the canonical conformation hypothesis, the binding modes of the substrates to the model enzyme varied according to the substrate peptide sequence, indicating that an ensemble of binding modes underlay the observed specificity of the model serine protease.	[Hsu, Hung-Ju; Tsai, Keng-Chang; Sun, Yi-Kun; Chang, Hung-Ju; Huang, Yi-Jen; Yu, Hui-Ming; Mao, Shi-Shan; Yang, An-Suei] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; [Lin, Chun-Hung] Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; [Huang, Yi-Jen] Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 112, Taiwan; [Hsu, Hung-Ju] Natl Def Med Univ, Grad Inst Life Sci, Taipei 114, Taiwan	Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Yang Ming Chiao Tung University; National Defense Medical Center	Yang, AS (corresponding author), Acad Sinica, Genom Res Ctr, 128 Acad Rd,Sect 2, Taipei 115, Taiwan.	yangas@gate.sinica.edu.tw		Tsai, Keng-Chang/0000-0001-8277-9174; Chang, Hung-Ju/0000-0003-2062-9212; Yang, An-Suei/0000-0002-4699-873X				Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; Bianchini EP, 2005, P NATL ACAD SCI USA, V102, P10099, DOI 10.1073/pnas.0504704102; Bianchini EP, 2002, J BIOL CHEM, V277, P20527, DOI 10.1074/jbc.M201139200; Bock PE, 2007, J THROMB HAEMOST, V5, P81, DOI 10.1111/j.1538-7836.2007.02496.x; Brandstetter H, 1996, J BIOL CHEM, V271, P29988, DOI 10.1074/jbc.271.47.29988; Bromfield KM, 2006, CHEM BIOL DRUG DES, V68, P11, DOI 10.1111/j.1747-0285.2006.00404.x; Coombs GS, 1999, J BIOL CHEM, V274, P24074, DOI 10.1074/jbc.274.34.24074; CORNELL WD, 1995, J AM CHEM SOC, V117, P5197; Deperthes D, 2002, BIOL CHEM, V383, P1107, DOI 10.1515/BC.2002.119; Ding XC, 2006, BIOORG CHEM, V34, P410, DOI 10.1016/j.bioorg.2006.10.002; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Hacisalihoglu A, 2007, J BIOL CHEM, V282, P32974, DOI 10.1074/jbc.M706529200; Harris JL, 2000, P NATL ACAD SCI USA, V97, P7754, DOI 10.1073/pnas.140132697; Hedstrom L, 2002, CHEM REV, V102, P4501, DOI 10.1021/cr000033x; HERTZBERG M, 1994, BLOOD REV, V8, P56, DOI 10.1016/0268-960X(94)90007-8; JONES G, 1995, J MOL BIOL, V245, P43, DOI 10.1016/S0022-2836(95)80037-9; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; Kontogiorgis CA, 2004, MED RES REV, V24, P687, DOI 10.1002/med.20006; Krishnaswamy S, 2005, J THROMB HAEMOST, V3, P54, DOI 10.1111/j.1538-7836.2004.01021.x; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Laskowski M, 2000, BBA-PROTEIN STRUCT M, V1477, P324, DOI 10.1016/S0167-4838(99)00284-8; Li H., 1999, PHARMACOPHORE PERCEP, P173; Ma JC, 1997, CHEM REV, V97, P1303, DOI 10.1021/cr9603744; Maignan Sebastien, 2001, Current Topics in Medicinal Chemistry, V1, P161, DOI 10.2174/1568026013395461; Marlowe CK, 2000, BIOORG MED CHEM LETT, V10, P13, DOI 10.1016/S0960-894X(99)00582-X; Marnett AB, 2005, TRENDS BIOTECHNOL, V23, P59, DOI 10.1016/j.tibtech.2004.12.010; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; Ohkubo S, 2001, COMB CHEM HIGH T SCR, V4, P573; Orcutt SJ, 2002, J BIOL CHEM, V277, P46191, DOI 10.1074/jbc.M208677200; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PERONA JJ, 1995, PROTEIN SCI, V4, P337; Rodi DJ, 2002, J MOL BIOL, V322, P1039, DOI 10.1016/S0022-2836(02)00844-6; Sharkov NA, 2001, J BIOL CHEM, V276, P10788, DOI 10.1074/jbc.M011772200; Sidhu SS, 2004, PHAGE DISPLAY, V1st, P27; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; Tyndall JDA, 2005, CHEM REV, V105, P973, DOI 10.1021/cr040669e; Wei AZ, 1998, J MOL BIOL, V283, P147, DOI 10.1006/jmbi.1998.2069; Wolber G, 2005, J CHEM INF MODEL, V45, P160, DOI 10.1021/ci049885e	39	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2008	283	18					12343	12353		10.1074/jbc.M708843200	http://dx.doi.org/10.1074/jbc.M708843200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	293MS	18296445	hybrid, Green Published			2022-12-25	WOS:000255340000051
J	Humphries, SM; Lu, YH; Canty, EG; Kadler, KE				Humphries, Sally M.; Lu, Yinhui; Canty, Elizabeth G.; Kadler, Karl E.			Active negative control of collagen fibrillogenesis in vivo - Intracellular cleavage of the type I procollagen propeptides in tendon fibroblasts without intracellular fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; CELL-SURFACE; FIBRONECTIN; PROTEINASE; POLYMERIZATION; PURIFICATION	It is established fact that type I collagen spontaneously self-assembles in vitro in the absence of cells or other macromolecules. Whether or not this is the situation in vivo was unknown. Recent evidence shows that intracellular cleavage of procollagen (the soluble precursor of collagen) to collagen can occur in embryonic tendon cells in vivo, and when this occurs, intracellular collagen fibrils are observed. A cause-and-effect relationship between intracellular collagen and intracellular fibrils was not established. Here we show that intracellular cleavage of procollagen to collagen occurs in postnatal murine tendon cells in situ. Pulse-chase analyses showed cleavage of procollagen to collagen via its two propeptide-retained intermediates. Furthermore, immunoelectron microscopy, using an antibody that recognizes the triple helical domain of collagen, shows collagen molecules in large-diameter transport compartments close to the plasma membrane. However, neither intracellular fibrils nor fibripositors (collagen fibril-containing plasma membrane protrusions) were observed. The results show that intracellular collagen occurs in murine tendon in the absence of intracellular fibrillogenesis and fibripositor formation. Furthermore, the results show that murine postnatal tendon cells have a high capacity to prevent intracellular collagen fibrillogenesis.	[Humphries, Sally M.; Lu, Yinhui; Canty, Elizabeth G.; Kadler, Karl E.] Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Kadler, KE (corresponding author), Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	karl.kadler@manchester.ac.uk	Laird, Elizabeth/AAX-7280-2020; KADLER, KARL/ABI-2403-2020	Laird, Elizabeth/0000-0001-5041-1316; KADLER, KARL/0000-0003-4977-4683	Biotechnology and Biological Sciences Research Council Funding Source: Medline; Wellcome Trust Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		BELLAMY G, 1971, P NATL ACAD SCI USA, V68, P1138, DOI 10.1073/pnas.68.6.1138; BIRK DE, 1986, J CELL BIOL, V103, P231, DOI 10.1083/jcb.103.1.231; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; Canty EG, 2004, J CELL BIOL, V165, P553, DOI 10.1083/jcb.200312071; Canty EG, 2006, J BIOL CHEM, V281, P38592, DOI 10.1074/jbc.M607581200; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; Di Lullo GA, 2002, J BIOL CHEM, V277, P4223, DOI 10.1074/jbc.M110709200; FESSLER JH, 1978, ANNU REV BIOCHEM, V47, P129, DOI 10.1146/annurev.bi.47.070178.001021; Greenspan DS, 2005, TOP CURR CHEM, V247, P149, DOI 10.1007/b103822; Halasz K, 2007, J BIOL CHEM, V282, P31166, DOI 10.1074/jbc.M705735200; HOJIMA Y, 1994, J BIOL CHEM, V269, P11381; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; Kadler KE, 1996, BIOCHEM J, V316, P1; KADLER KE, 1987, J BIOL CHEM, V262, P15696; Leighton M, 2003, J BIOL CHEM, V278, P18478, DOI 10.1074/jbc.M213021200; Li SH, 2003, AM J PATHOL, V163, P1045, DOI 10.1016/S0002-9440(10)63464-5; NAKAGAWA Y, 1994, ACTA PHYSIOL SCAND, V152, P307, DOI 10.1111/j.1748-1716.1994.tb09810.x; Pankov R, 2000, J CELL BIOL, V148, P1075, DOI 10.1083/jcb.148.5.1075; Richardson SH, 2007, MOL CELL BIOL, V27, P6218, DOI 10.1128/MCB.00261-07; Starkuviene V, 2007, TRAFFIC, V8, P1035, DOI 10.1111/j.1600-0854.2007.00582.x; TRELSTAD RL, 1979, DEV BIOL, V71, P228, DOI 10.1016/0012-1606(79)90166-0; Velling T, 2002, J BIOL CHEM, V277, P37377, DOI 10.1074/jbc.M206286200; Wenstrup RJ, 2004, J BIOL CHEM, V279, P53331, DOI 10.1074/jbc.M409622200	23	28	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2008	283	18					12129	12135		10.1074/jbc.M708198200	http://dx.doi.org/10.1074/jbc.M708198200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	293MS	18285337	hybrid			2022-12-25	WOS:000255340000029
J	Azam, L; Yoshikami, D; McIntosh, JM				Azam, Layla; Yoshikami, Doju; McIntosh, J. Michael			Amino acid residues that confer high selectivity of the alpha 6 nicotinic acetylcholine receptor subunit to alpha-conotoxin MII[S4A, E11A, L15A]	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL-CHANGES; NIGROSTRIATAL DAMAGE; CRYSTAL-STRUCTURE; MII BINDING; DETERMINANTS; RELEASE; ACHBP; SENSITIVITY; DECREASES; TARGETS	Nicotinic acetylcholine receptors (nAChRs) containing alpha 3 and beta 2 subunits are found in autonomic ganglia and mediate ganglionic transmission. The closely related alpha 6 nAChR subtype is found in the central nervous system where changes in its level of expression are observed in Parkinson's disease. To obtain a ligand that discriminates between these two receptors, we designed and synthesized a novel analog of alpha-conotoxin MII, MII[ S4A, E11A, L15A], and tested it on nAChRs expressed in Xenopus oocytes. The peptide blocked chimeric alpha 6/alpha 3 beta 2 beta 3 nAChRs with an IC50 of 1.2 nM; in contrast, its IC50 on the closely related alpha 3 beta 2 as well as non-alpha 6 nAChRs was three orders of magnitude higher. We identified the residues in the receptors that are responsible for their differential sensitivity to the peptide. We constructed chimeras with increasingly longer fragments of the N-terminal ligand binding domain of the alpha 3 subunit inserted into the homologous positions of the alpha 6 subunit, and these were used to determine that the region downstream of the first 140 amino acids was involved. Further mutagenesis of this region revealed that the alpha 6 subunit residues Glu-152, Asp-184, and Thr-195 were critical, and replacement of these three residues with their homologs from the alpha 3 subunit increased the IC(5)0 of the peptide by> 1000-fold. Conversely, when these key residues in alpha 3 were replaced with those from alpha 6, the IC50 decreased by almost 150-fold. Similar effects were seen with other alpha 6- selective conotoxins, suggesting the general importance of these alpha 6 residues in conferring selective binding.	[Azam, Layla; Yoshikami, Doju; McIntosh, J. Michael] Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; [McIntosh, J. Michael] Univ Utah, Dept Psychiat, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Azam, L (corresponding author), Univ Utah, Dept Biol, 257 S 1400 E, Salt Lake City, UT 84112 USA.	layla_azam@yahoo.com			NIDA NIH HHS [F32 DA016835, F32 DA016835-03, DA 016835, F32 DA016835-02, F32 DA016835-01] Funding Source: Medline; NIGMS NIH HHS [P01 GM048677, P01 GM048677-160012, GM48677] Funding Source: Medline; NIMH NIH HHS [R01 MH053631, R01 MH053631-13, MH53631, R01 MH053631-11S1] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH053631, R29MH053631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [F32DA016835] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Azam L, 2005, J PHARMACOL EXP THER, V312, P231, DOI 10.1124/jpet.104.071456; Azam L, 2002, J COMP NEUROL, V444, P260, DOI 10.1002/cne.10138; Azam L, 2006, MOL PHARMACOL, V70, P967, DOI 10.1124/mol.106.024513; Bordia T, 2007, MOL PHARMACOL, V72, P52, DOI 10.1124/mol.107.035998; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; Celie PHN, 2004, NEURON, V41, P907, DOI 10.1016/S0896-6273(04)00115-1; Celie PHN, 2005, NAT STRUCT MOL BIOL, V12, P582, DOI 10.1038/nsmb951; Dani JA, 2007, ANNU REV PHARMACOL, V47, P699, DOI 10.1146/annurev.pharmtox.47.120505.105214; De Biasi M, 2002, J NEUROBIOL, V53, P568, DOI 10.1002/neu.10145; De Biasi M, 2002, CNS NEUROL DISORD-DR, V1, P331, DOI 10.2174/1568007023339148; Dowell C, 2003, J NEUROSCI, V23, P8445; Everhart D, 2003, J PHARMACOL EXP THER, V306, P664, DOI 10.1124/jpet.103.051656; Gao F, 2005, J BIOL CHEM, V280, P8443, DOI 10.1074/jbc.M412389200; Hansen SB, 2005, EMBO J, V24, P3635, DOI 10.1038/sj.emboj.7600828; Harvey SC, 1997, MOL PHARMACOL, V51, P336, DOI 10.1124/mol.51.2.336; Lai A, 2005, MOL PHARMACOL, V67, P1639, DOI 10.1124/mol.104.006429; LeNovere N, 1996, EUR J NEUROSCI, V8, P2428; Lester HA, 2004, TRENDS NEUROSCI, V27, P329, DOI 10.1016/j.tins.2004.04.002; Luetje CW, 1998, MOL PHARMACOL, V53, P1112; McIntosh JM, 2004, MOL PHARMACOL, V65, P944, DOI 10.1124/mol.65.4.944; Mugnaini M, 2006, NEUROSCIENCE, V137, P565, DOI 10.1016/j.neuroscience.2005.09.008; Perry DC, 2007, J PHARMACOL EXP THER, V322, P306, DOI 10.1124/jpet.107.121228; Quik M, 2006, J PHARMACOL EXP THER, V316, P481, DOI 10.1124/jpet.105.094375; Quik M, 2001, J NEUROSCI, V21, P5494, DOI 10.1523/JNEUROSCI.21-15-05494.2001; Salminen O, 2004, MOL PHARMACOL, V65, P1526, DOI 10.1124/mol.65.6.1526; Shi JX, 2006, J BIOL CHEM, V281, P12170, DOI 10.1074/jbc.M600154200; Ulens C, 2006, P NATL ACAD SCI USA, V103, P3615, DOI 10.1073/pnas.0507889103; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031	29	36	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11625	11632		10.1074/jbc.M710288200	http://dx.doi.org/10.1074/jbc.M710288200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18299323	Green Published, hybrid			2022-12-25	WOS:000255067400063
J	Dewire, SM; Kim, J; Whalen, EJ; Ahn, S; Chen, M; Lefkowitz, RJ				Dewire, Scott M.; Kim, Jihee; Whalen, Erin J.; Ahn, Seungkirl; Chen, Minyong; Lefkowitz, Robert J.			beta-arrestin-mediated signaling regulates protein synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 4E; SMOOTH-MUSCLE-CELLS; ANGIOTENSIN-II; PHOSPHATIDYLINOSITOL 3-KINASE; RECEPTOR TRANSACTIVATION; CARDIAC MYOCYTES; ERK ACTIVATION; MESSENGER-RNA; MNK1; PHOSPHORYLATION	Seven transmembrane receptors (7TMRs) exert strong regulatory influences on virtually all physiological processes. Although it is historically assumed that heterotrimeric G proteins mediate these actions, there is a newer appreciation that beta-arrestins, originally thought only to desensitize G protein signaling, also serve as independent receptor signal transducers. Recently, we found that activation of ERK1/2 by the angiotensin receptor occurs via both of these distinct pathways. In this work, we explore the physiological consequences of beta-arrestin ERK1/2 signaling and delineate a pathway that regulates mRNA translation and protein synthesis via Mnk1, a protein that both physically interacts with and is activated by beta-arrestins. We show that beta-arrestin-dependent activation of ERK1/2, Mnk1, and eIF4E are responsible for increasing translation rates in both human embryonic kidney 293 and rat vascular smooth muscle cells. This novel demonstration that beta-arrestins regulate protein synthesis reveals that the spectrum of beta-arrestin-mediated signaling events is broader than previously imagined.	[Dewire, Scott M.; Ahn, Seungkirl; Lefkowitz, Robert J.] Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; [Kim, Jihee; Whalen, Erin J.; Chen, Minyong; Lefkowitz, Robert J.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Lefkowitz, Robert J.] Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Box 3821, Durham, NC 27710 USA.	lefko001@receptor-biol.duke.edu	Lefkowitz, Robert/AAW-2649-2021	DeWire, Scott/0000-0002-1357-4543	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL070631, R01HL016037] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NHLBI NIH HHS [HL16037, HL70631] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn S, 2003, P NATL ACAD SCI USA, V100, P1740, DOI 10.1073/pnas.262789099; Ahn S, 2004, J BIOL CHEM, V279, P7807, DOI 10.1074/jbc.C300443200; Ahn SK, 2004, J BIOL CHEM, V279, P35518, DOI 10.1074/jbc.M405878200; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Chrestensen CA, 2007, J BIOL CHEM, V282, P4243, DOI 10.1074/jbc.M607368200; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2007, ANNU REV PHYSIOL, V69, P535, DOI 10.1146/annurev.physiol.69.022405.154804; DeWire SM, 2007, ANNU REV PHYSIOL, V69, P483, DOI 10.1146/annurev.physiol.69.022405.154749; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gaborik Z, 2003, ENDOCRINOLOGY, V144, P2220, DOI 10.1210/en.2002-0135; Gesty-Palmer D, 2005, J BIOL CHEM, V280, P32157, DOI 10.1074/jbc.M507460200; Ishida M, 2003, CIRC RES, V93, P1218, DOI 10.1161/01.RES.0000105570.34585.F2; Knauf U, 2001, MOL CELL BIOL, V21, P5500, DOI 10.1128/MCB.21.16.5500-5511.2001; Lefkowitz RJ, 2006, MOL CELL, V24, P643, DOI 10.1016/j.molcel.2006.11.007; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Mendez M, 2005, AM J PHYSIOL-HEART C, V288, pH2111, DOI 10.1152/ajpheart.00838.2004; Miller WE, 2001, J BIOL CHEM, V276, P27770, DOI 10.1074/jbc.M102264200; Miura S, 2004, HYPERTENS RES, V27, P765, DOI 10.1291/hypres.27.765; O'Loghlen A, 2004, FEBS LETT, V578, P31, DOI 10.1016/j.febslet.2004.10.063; Povsic TJ, 2003, J BIOL CHEM, V278, P51334, DOI 10.1074/jbc.M309968200; Proud CG, 2007, BIOCHEM J, V403, P217, DOI 10.1042/BJ20070024; Rajagopal K, 2006, P NATL ACAD SCI USA, V103, P16284, DOI 10.1073/pnas.0607583103; Scheper GC, 2002, EUR J BIOCHEM, V269, P5350, DOI 10.1046/j.1432-1033.2002.03291.x; Scheper GC, 2002, J BIOL CHEM, V277, P3303, DOI 10.1074/jbc.M103607200; Spruill LS, 2006, FASEB J, V20, P2133, DOI 10.1096/fj.06-6245fje; Tohgo A, 2003, J BIOL CHEM, V278, P6258, DOI 10.1074/jbc.M212231200; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Tuxworth WJ, 2004, BIOCHEM J, V378, P73, DOI 10.1042/BJ20031027; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Violin JD, 2006, J BIOL CHEM, V281, P36411, DOI 10.1074/jbc.M607956200; Voisin L, 2002, AM J PHYSIOL-CELL PH, V283, pC446, DOI 10.1152/ajpcell.00261.2001; Wada H, 1996, J BIOL CHEM, V271, P8359, DOI 10.1074/jbc.271.14.8359; Wang XM, 2006, PHYSIOLOGY, V21, P362, DOI 10.1152/physiol.00024.2006; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100; WISLER JW, 2007, P NATL ACAD SCI US; Yamakawa T, 2003, EUR J PHARMACOL, V478, P39, DOI 10.1016/j.ejphar.2003.08.044; Yee DK, 2006, MOL ENDOCRINOL, V20, P1924, DOI 10.1210/me.2006-0018	40	74	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10611	10620		10.1074/jbc.M710515200	http://dx.doi.org/10.1074/jbc.M710515200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18276584	hybrid, Green Published			2022-12-25	WOS:000254894700043
J	Mishra, R; Cool, BL; Laderoute, KR; Foretz, M; Viollet, B; Simonson, MS				Mishra, Rangnath; Cool, Barbara L.; Laderoute, Keith R.; Foretz, Marc; Viollet, Benoit; Simonson, Michael S.			AMP-activated protein kinase inhibits transforming growth factor-beta-induced Smad3-dependent transcription and myofibroblast transdifferentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; DIABETIC-NEPHROPATHY; MESANGIAL CELLS; FIBROTIC RESPONSE; SKELETAL-MUSCLE; RENAL FIBROSIS; IN-VITRO; SMAD3; FIBRONECTIN; COLLAGEN	In wound healing, myofibroblast transdifferentiation (MFT) is a metaplastic change in phenotype producing profibrotic effector cells that secrete and remodel the extracellular matrix. Unlike pathways that induce MFT, the molecular mechanisms that negatively regulate MFT are poorly understood. Here, we report that AMP-activated protein kinase (AMPK) blocks MFT in response to transforming growth factor-beta (TGF beta). Pharmacological activation of AMPK inhibited TGF beta-induced secretion of extracellular matrix proteins collagen types I and IV and fibronectin. AMPK activation also prevented induction of the myofibroblast phenotype markers alpha-smooth muscle actin and the ED-A fibronectin splice variant. AMPK activators did not prevent MFT in cells transduced with an adenovirus expressing dominant negative, kinase-dead AMPK alpha 2. Moreover, AMPK activators did not inhibit MFT induction in AMPK(alpha 1,2)(-/-) fibroblasts, demonstrating a requirement for AMPK alpha expression. Adenoviral transduction of constitutively active AMPK(alpha 2) was sufficient to prevent TGF beta-induced collagen I, alpha-smooth muscle actin, and ED-A fibronectin. AMPK did not reduce TGF beta-stimulated Smad3 COOH-terminal phosphorylation and nuclear translocation, which are necessary for MFT. However, AMPK activation inhibited TGF beta-induced transcription driven by Smad3-binding cis-elements. Consistent with a role for AMPK in transcriptional regulation, nuclear translocation of AMPK alpha 2 correlated with the appearance of active AMPK alpha in the nucleus. Collectively, these results demonstrate that AMPK inhibits TGF beta-induced transcription downstream of Smad3 COOH-terminal phosphorylation and nuclear translocation. Furthermore, activation of AMPK is sufficient to negatively regulate MFT in vitro.	[Mishra, Rangnath; Simonson, Michael S.] Case Western Reserve Univ, Div Nephrol & Hypertens, Dept Med, Cleveland, OH 44106 USA; [Mishra, Rangnath; Simonson, Michael S.] Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA; [Cool, Barbara L.] Abbott Labs, Dept Metab Dis Res, Abbott Pk, IL 60064 USA; [Laderoute, Keith R.] SRI Int, Menlo Pk, CA 94025 USA; [Foretz, Marc; Viollet, Benoit] Univ Paris 05, Inst Cochin, CNRS, UMR 8104, F-75014 Paris, France; [Foretz, Marc; Viollet, Benoit] INSERM, U567, F-75014 Paris, France	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University Hospital; Abbott Laboratories; SRI International; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Simonson, MS (corresponding author), Case Western Reserve Univ, Dept Med, Div Nephrol, Biomed Res Bldg,Rm 427, Cleveland, OH 44106 USA.	mss5@po.cwru.edu	Viollet, Benoit/O-6927-2017; FORETZ, Marc/O-7334-2017; Viollet, Benoit/N-2397-2019	Viollet, Benoit/0000-0002-0121-0224; FORETZ, Marc/0000-0001-7017-9032; Viollet, Benoit/0000-0002-0121-0224; , Keith/0000-0002-5121-8072				ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Baelde HJ, 2004, J PATHOL, V204, P248, DOI 10.1002/path.1653; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Bjarnegard M, 2004, DEVELOPMENT, V131, P1847, DOI 10.1242/dev.01080; Cool B, 2006, CELL METAB, V3, P403, DOI 10.1016/j.cmet.2006.05.005; Dai CS, 2004, J AM SOC NEPHROL, V15, P2637, DOI 10.1097/01.ASN.0000139479.09658.EE; Dai CS, 2004, J AM SOC NEPHROL, V15, P1402, DOI 10.1097/01.ASN.0000130568.53923.FD; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 2005, ONCOGENE, V24, P1936, DOI 10.1038/sj.onc.1208343; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; Eddy AA, 2005, PEDIATR NEPHROL, V20, P1369, DOI 10.1007/s00467-005-1995-5; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Flanders KC, 2004, INT J EXP PATHOL, V85, P47, DOI 10.1111/j.0959-9673.2004.00377.x; Foretz M, 2005, DIABETES, V54, P1331, DOI 10.2337/diabetes.54.5.1331; Hardie DG, 2006, J PHYSIOL-LONDON, V574, P7, DOI 10.1113/jphysiol.2006.108944; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hardie DG, 1999, BIOCHEM J, V338, P717, DOI 10.1042/0264-6021:3380717; HARDIE DG, 1989, TRENDS BIOCHEM SCI, V14, P20; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; HAYMAN EG, 1981, J CELL BIOL, V88, P352, DOI 10.1083/jcb.88.2.352; Hinz B, 2007, AM J PATHOL, V170, P1807, DOI 10.2353/ajpath.2007.070112; Huang YF, 2003, J CLIN INVEST, V112, P379, DOI 10.1172/JCI200318038; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; JOHNSON RJ, 1992, J AM SOC NEPHROL, V2, pS190; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Keller CD, 2007, AM J PATHOL, V170, P281, DOI 10.2353/ajpath.2007.060485; Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06; Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev; Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537; Longnus SL, 2003, AM J PHYSIOL-REG I, V284, pR936, DOI 10.1152/ajpregu.00319.2002; Maeda A, 2005, CELL BIOL INT, V29, P422, DOI 10.1016/j.cellbi.2005.01.005; Mason RM, 2003, J AM SOC NEPHROL, V14, P1358, DOI 10.1097/01.ASN.0000065640.77499.D7; Matsuo S, 2005, KIDNEY INT, V67, P2221, DOI 10.1111/j.1523-1755.2005.00327.x; MENE P, 1989, PHYSIOL REV, V69, P1347, DOI 10.1152/physrev.1989.69.4.1347; Mishra R, 2005, MOL PHARMACOL, V67, P2049, DOI 10.1124/mol.104.010546; Mishra R, 2007, AM J PHYSIOL-CELL PH, V292, pC1361, DOI 10.1152/ajpcell.00370.2006; Mizui M, 2006, KIDNEY INT, V70, P298, DOI 10.1038/sj.ki.5001541; Momcilovic M, 2006, J BIOL CHEM, V281, P25336, DOI 10.1074/jbc.M604399200; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Nagata D, 2003, J BIOL CHEM, V278, P31000, DOI 10.1074/jbc.M300643200; Narbonne P, 2006, DEVELOPMENT, V133, P611, DOI 10.1242/dev.02232; Ng CP, 2005, J CELL SCI, V118, P4731, DOI 10.1242/jcs.02605; Offersen BV, 2003, AM J PATHOL, V163, P1887, DOI 10.1016/S0002-9440(10)63547-X; Ramirez AM, 2006, AM J TRANSPLANT, V6, P2080, DOI 10.1111/j.1600-6143.2006.01430.x; Roberts AB, 2003, ANN NY ACAD SCI, V995, P1, DOI 10.1111/j.1749-6632.2003.tb03205.x; Salt I, 1998, BIOCHEM J, V334, P177, DOI 10.1042/bj3340177; SCHULTZ PJ, 1988, AM J PHYSIOL, V255, pF674; Serini G, 1998, J CELL BIOL, V142, P873, DOI 10.1083/jcb.142.3.873; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Simonson MS, 2007, KIDNEY INT, V71, P846, DOI 10.1038/sj.ki.5002180; Suzuki A, 2005, J BIOL CHEM, V280, P31557, DOI 10.1074/jbc.M503714200; Suzuki A, 2007, MOL CELL BIOL, V27, P4317, DOI 10.1128/MCB.02222-06; Thornton C, 1998, J BIOL CHEM, V273, P12443, DOI 10.1074/jbc.273.20.12443; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; VINCENT MF, 1991, ADV EXP MED BIOL, V309, P359; Viollet B, 2006, J PHYSIOL-LONDON, V574, P41, DOI 10.1113/jphysiol.2006.108506; Walker GA, 2001, CURR TOP DEV BIOL, V51, P91, DOI 10.1016/S0070-2153(01)51003-0; Wang Y, 1996, MOL CELL BIOL, V16, P5915; Weill FX, 1997, LAB INVEST, V77, P63; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Young Martin E., 1996, Biochemical Society Transactions, V24, p268S; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zeisberg M, 2001, AM J PATHOL, V159, P1313, DOI 10.1016/S0002-9440(10)62518-7; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zheng F, 2002, AM J PHYSIOL-RENAL, V282, pF639, DOI 10.1152/ajprenal.00189.2001	66	99	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10461	10469		10.1074/jbc.M800902200	http://dx.doi.org/10.1074/jbc.M800902200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18250161	hybrid			2022-12-25	WOS:000254894700027
J	Lee, YM; Park, SH; Shin, DI; Hwang, JY; Park, B; Park, YJ; Lee, TH; Chae, HZ; Jin, BK; Oh, TH; Oh, YJ				Lee, Young Mook; Park, Seong H.; Shin, Dong-Ik; Hwang, Jee-Yeon; Park, BoKyung; Park, Yun-Jong; Lee, Tae H.; Chae, Ho Z.; Jin, Byung K.; Oh, Tae H.; Oh, Young J.			Oxidative modification of peroxiredoxin is associated with drug-induced apoptotic signaling in experimental models of Parkinson disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SULFINIC ACID; MESENCEPHALIC DOPAMINERGIC-NEURONS; AMYOTROPHIC-LATERAL-SCLEROSIS; THIOL-SPECIFIC ANTIOXIDANT; HUMAN SUBSTANTIA-NIGRA; CELL-DEATH; HYDROGEN-PEROXIDE; IN-VIVO; SACCHAROMYCES-CEREVISIAE; GLUTATHIONE-PEROXIDASE	The aim of this study was to investigate changes in protein profiles during the early phase of dopaminergic neuronal death using two-dimensional gel electrophoresis in conjunction with mass spectrometry. Several protein spots were identified whose expression was significantly altered following treatment of MN9D dopaminergic neuronal cells with 6-hydroxydopamine (6-OHDA). In particular, we detected oxidative modification of thioredoxin-dependent peroxidases (peroxiredoxins; PRX) in treated MN9D cells. Oxidative modification of PRX induced by 6-OHDA was blocked in the presence of N-acetylcysteine, suggesting that reactive oxygen species (ROS) generated by 6-OHDA induce oxidation of PRX. These findings were confirmed in primary cultures of mesencephalic neurons and in rat brain injected stereotaxically. Overexpression of PRX1 in MN9D cells (MN9D/PRX1) exerted neuroprotective effects against death induced by 6-OHDA through scavenging of ROS. Consequently, generation of both superoxide anion and hydrogen peroxide following 6-OHDA treatment was decreased in MN9D/PRX1. Furthermore, overexpression of PRX1 protected cells against 6-OHDA-induced activation of p38MAPKand subsequent activation of caspase-3. In contrast, 6-OHDA-induced apoptotic death signals were enhanced by RNA interference-targeted reduction of PRX1 in MN9D cells. Taken together, our data suggest that the redox state of PRX may be intimately involved in 6-OHDA-induced dopaminergic neuronal cell death and also provide a molecular mechanism by which PRX1 exerts a protective role in experimental models of Parkinson disease.	[Lee, Young Mook; Park, Seong H.; Shin, Dong-Ik; Hwang, Jee-Yeon; Park, BoKyung; Park, Yun-Jong; Lee, Tae H.; Oh, Young J.] Yonsei Univ, Coll Sci, Dept Biol, Seoul 120749, South Korea; [Chae, Ho Z.] Chonnam Natl Univ, Dept Biol Sci, Kwangju 500757, South Korea; [Jin, Byung K.] Ajou Univ, Brain Dis Res Ctr, Suwon 441749, South Korea; [Oh, Tae H.] Kyung Hee Univ, Aging & Brain Dis Res Ctr, Seoul 130701, South Korea	Yonsei University; Chonnam National University; Ajou University; Kyung Hee University	Oh, YJ (corresponding author), Yonsei Univ, Coll Sci, Dept Biol, 134 Shinchon Dong, Seoul 120749, South Korea.	yjoh@yonsei.ac.kr	/ABD-1619-2021					Allen S, 2003, J BIOL CHEM, V278, P6371, DOI 10.1074/jbc.M209915200; AMBANI LM, 1975, ARCH NEUROL-CHICAGO, V32, P114, DOI 10.1001/archneur.1975.00490440064010; Bai J, 2007, ANTIOXID REDOX SIGN, V9, P603, DOI 10.1089/ars.2006.1513; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Basso M, 2004, PROTEOMICS, V4, P3943, DOI 10.1002/pmic.200400848; BENSHACHAR D, 1991, J NEUROCHEM, V56, P1441, DOI 10.1111/j.1471-4159.1991.tb11444.x; Biteau B, 2003, NATURE, V425, P980, DOI 10.1038/nature02075; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; Bozonet SM, 2005, J BIOL CHEM, V280, P23319, DOI 10.1074/jbc.M502757200; CEBALLOS I, 1990, LANCET, V335, P1035, DOI 10.1016/0140-6736(90)91099-V; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; Chae HZ, 1999, DIABETES RES CLIN PR, V45, P101, DOI 10.1016/S0168-8227(99)00037-6; Chang JW, 2001, BIOCHEM BIOPH RES CO, V289, P507, DOI 10.1006/bbrc.2001.5989; Chevallet M, 2003, J BIOL CHEM, V278, P37146, DOI 10.1074/jbc.M305161200; CHOI HK, 1992, P NATL ACAD SCI USA, V89, P8943, DOI 10.1073/pnas.89.19.8943; CHOI HK, 1991, BRAIN RES, V552, P67, DOI 10.1016/0006-8993(91)90661-E; Choi J, 2006, J BIOL CHEM, V281, P10816, DOI 10.1074/jbc.M509079200; Choi J, 2005, J BIOL CHEM, V280, P11648, DOI 10.1074/jbc.M414327200; Choi J, 2004, J BIOL CHEM, V279, P13256, DOI 10.1074/jbc.M314124200; Choi SH, 2003, J NEUROSCI, V23, P5877; Choi WS, 1999, J NEUROSCI RES, V57, P86, DOI 10.1002/(SICI)1097-4547(19990701)57:1<86::AID-JNR9>3.0.CO;2-E; Choi WS, 2004, J BIOL CHEM, V279, P20451, DOI 10.1074/jbc.M311164200; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; Conway JP, 2006, J BIOL CHEM, V281, P27991, DOI 10.1074/jbc.M605026200; DAMIER P, 1993, NEUROSCIENCE, V52, P1, DOI 10.1016/0306-4522(93)90175-F; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; FAHN S, 1992, ANN NEUROL, V32, P804, DOI 10.1002/ana.410320616; Findlay VJ, 2005, BIOMED PHARMACOTHER, V59, P374, DOI 10.1016/j.biopha.2005.07.003; Floor E, 1998, J NEUROCHEM, V70, P268; Fujii J, 2002, REDOX REP, V7, P123, DOI 10.1179/135100002125000352; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; GRAHAM DG, 1978, MOL PHARMACOL, V14, P633; Han BS, 2003, J NEUROSCI, V23, P5069; Han BS, 2003, NEUROSCI LETT, V341, P99, DOI 10.1016/S0304-3940(03)00173-3; Hattori F, 2003, J NEUROCHEM, V86, P860, DOI 10.1046/j.1471-4159.2003.01918.x; Jin MH, 2005, NEUROSCI LETT, V381, P252, DOI 10.1016/j.neulet.2005.02.048; Kang SW, 2004, J BIOL CHEM, V279, P2535, DOI 10.1074/jbc.M307698200; Kim H, 2000, J BIOL CHEM, V275, P18266, DOI 10.1074/jbc.275.24.18266; Kim SH, 2001, J NEURAL TRANSM-SUPP, P223; Kim YJ, 2006, CANCER RES, V66, P7136, DOI 10.1158/0008-5472.CAN-05-4446; KISH SJ, 1985, NEUROSCI LETT, V58, P343, DOI 10.1016/0304-3940(85)90078-3; Krapfenbauer K, 2003, BRAIN RES, V967, P152, DOI 10.1016/S0006-8993(02)04243-9; LaVoie MJ, 2005, NAT MED, V11, P1214, DOI 10.1038/nm1314; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Liu ZH, 2005, CANCER RES, V65, P1647, DOI 10.1158/0008-5472.CAN-04-1754; Lotharius J, 1999, J NEUROSCI, V19, P1284; Masutani H, 2005, CELL DEATH DIFFER, V12, P991, DOI 10.1038/sj.cdd.4401625; Masutani H, 2004, MOL NEUROBIOL, V29, P229, DOI 10.1385/MN:29:3:229; Mitsumoto A, 2001, FREE RADICAL RES, V35, P301, DOI 10.1080/10715760100300831; Mizusawa H, 2000, NEUROSCI LETT, V283, P57, DOI 10.1016/S0304-3940(00)00910-1; Moore DJ, 2005, ANNU REV NEUROSCI, V28, P57, DOI 10.1146/annurev.neuro.28.061604.135718; Nakashima I, 2005, ARCH BIOCHEM BIOPHYS, V434, P3, DOI 10.1016/j.abb.2004.06.016; Oh YJ, 1995, NEUROBIOL DIS, V2, P157, DOI 10.1006/nbdi.1995.0017; Pak JH, 2002, J BIOL CHEM, V277, P49927, DOI 10.1074/jbc.M204222200; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Plaisant F, 2003, FREE RADICAL BIO MED, V34, P862, DOI 10.1016/S0891-5849(02)01440-5; Qu D, 2007, NEURON, V55, P37, DOI 10.1016/j.neuron.2007.05.033; Rabilloud T, 2002, J BIOL CHEM, V277, P19396, DOI 10.1074/jbc.M106585200; Rhee SG, 2005, FREE RADICAL BIO MED, V38, P1543, DOI 10.1016/j.freeradbiomed.2005.02.026; Saito Y, 2007, FREE RADICAL BIO MED, V42, P675, DOI 10.1016/j.freeradbiomed.2006.12.004; Sanchez-Font MF, 2003, CELL MOL LIFE SCI, V60, P1513, DOI 10.1007/s00018-003-3048-1; Sarafian TA, 1999, J NEUROSCI RES, V56, P206, DOI 10.1002/(SICI)1097-4547(19990415)56:2<206::AID-JNR1>3.0.CO;2-X; Schapira AHV, 2001, ADV NEUROL, V86, P155; SOFIC E, 1992, NEUROSCI LETT, V142, P128, DOI 10.1016/0304-3940(92)90355-B; Strey CW, 2004, AM J PATHOL, V165, P1701, DOI 10.1016/S0002-9440(10)63426-8; Veal EA, 2004, MOL CELL, V15, P129, DOI 10.1016/j.molcel.2004.06.021; Woo HA, 2003, J BIOL CHEM, V278, P47361, DOI 10.1074/jbc.C300428200; Woo HA, 2003, SCIENCE, V300, P653, DOI 10.1126/science.1080273; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Yang KS, 2002, J BIOL CHEM, V277, P38029, DOI 10.1074/jbc.M206626200; Yuan J, 2004, BBA-MOL CELL RES, V1693, P37, DOI 10.1016/j.bbamcr.2004.04.006; Zhou Y, 2000, BIOCHEM BIOPH RES CO, V268, P921, DOI 10.1006/bbrc.2000.2231	74	87	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9986	9998		10.1074/jbc.M800426200	http://dx.doi.org/10.1074/jbc.M800426200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18250162	hybrid			2022-12-25	WOS:000254671600055
J	Babu, DA; Chakrabarti, SK; Garmey, JC; Mirmira, RG				Babu, Daniella A.; Chakrabarti, Swarup K.; Garmey, James C.; Mirmira, Raghavendra G.			Pdx1 and BETA2/NeuroD1 participate in a transcriptional complex that mediates short-range DNA looping at the insulin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; IN-VITRO; GLOBIN LOCUS; DIFFERENTIATION; PROMOTER; P300; MICE; HOMEODOMAIN; METHYLATION; ACTIVATION	The activity of the insulin gene, Ins, in islet beta cells is thought to arise in part from the synergistic action of the transcription factors Pdx1 and BETA2/NeuroD1. We asked how the binding of these factors to A and E elements many tens or hundreds of base pairs upstream of the start site could influence activity of transcriptional machinery. We therefore tested the hypothesis that the complex of Pdx1 and BETA2/NeuroD1 maintains a DNA conformation such that distal regions of the gene are brought into proximity of the promoter and coding region. We show by coimmunoprecipitation that Pdx1 and BETA2/NeuroD1 exist within a complex and that the two physically interact with one another in this complex as assessed by fluorescence resonance energy transfer. Consistent with this interaction, we found that the two factors simultaneously occupy the same fragment of the Ins gene in beta cell lines using the chromatin immunoprecipitation/re-chromatin immunoprecipitation assay. Using a modification of the chromosome conformation capture assay in vitro and in beta cells, we observed that Pdx1 and BETA2/NeuroD1 mediate looping of a segment of Ins that brings EcoRI sites located at -623 and -761 bp (relative to the transcriptional start site) in proximity to one another. This looping appears to be dependent in vitro upon an intact A3 binding element, but not upon the E2 element. Based on our findings, we propose a model whereby Pdx1 and BETA2/NeuroD1 physically interact to form a nucleoprotein complex on the Ins gene that mediates formation of a short DNA loop. Our results suggest that such short loop conformations may be a general mechanism to permit interactions between transcription factors and basal transcriptional machinery.	[Babu, Daniella A.; Mirmira, Raghavendra G.] Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA; [Chakrabarti, Swarup K.; Garmey, James C.; Mirmira, Raghavendra G.] Univ Virginia, Dept Med, Charlottesville, VA 22908 USA; [Chakrabarti, Swarup K.; Garmey, James C.; Mirmira, Raghavendra G.] Univ Virginia, Ctr Diabet, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Mirmira, RG (corresponding author), Indiana Univ, Sch Med, 635 Barnhill Dr,Rm 2031B, Indianapolis, IN 46202 USA.	rmirmira@iupui.edu	Mirmira, Raghavendra G/AAD-7592-2020	Mirmira, Raghavendra G/0000-0002-5013-6075	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060581] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007055] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 60581] Funding Source: Medline; NIGMS NIH HHS [T32 GM 007055] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Babu DA, 2007, MOL GENET METAB, V92, P43, DOI 10.1016/j.ymgme.2007.06.008; Chakrabarti SK, 2003, TRENDS ENDOCRIN MET, V14, P78, DOI 10.1016/S1043-2760(02)00039-5; Chakrabarti SK, 2002, J BIOL CHEM, V277, P13286, DOI 10.1074/jbc.M111857200; Day RN, 2005, MOL ENDOCRINOL, V19, P1675, DOI 10.1210/me.2005-0028; Dekker J, 2003, TRENDS BIOCHEM SCI, V28, P277, DOI 10.1016/S0968-0004(03)00089-6; Elangovan M, 2003, METHODS, V29, P58, DOI 10.1016/S1046-2023(02)00283-9; Francis J, 2005, J BIOL CHEM, V280, P36244, DOI 10.1074/jbc.M505741200; Francis J, 2006, MOL ENDOCRINOL, V20, P3133, DOI 10.1210/me.2006-0126; Gasa R, 2004, P NATL ACAD SCI USA, V101, P13245, DOI 10.1073/pnas.0405301101; GASA R, 2007, DIFFERENTIATION; Glick E, 2000, J BIOL CHEM, V275, P2199, DOI 10.1074/jbc.275.3.2199; Hagege H, 2007, NAT PROTOC, V2, P1722, DOI 10.1038/nprot.2007.243; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; Hay CW, 2006, DIABETES, V55, P3201, DOI 10.2337/db06-0788; Huang HP, 2002, MOL ENDOCRINOL, V16, P541, DOI 10.1210/me.16.3.541; Iype T, 2005, J BIOL CHEM, V280, P16798, DOI 10.1074/jbc.M414381200; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; Kouskouti A, 2005, EMBO J, V24, P347, DOI 10.1038/sj.emboj.7600516; Macfarlane WM, 1999, J BIOL CHEM, V274, P1011, DOI 10.1074/jbc.274.2.1011; Malecki MT, 1999, NAT GENET, V23, P323, DOI 10.1038/15500; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Offield MF, 1996, DEVELOPMENT, V122, P983; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; Ohneda K, 2000, SEMIN CELL DEV BIOL, V11, P227, DOI 10.1006/scdb.2000.0171; Prentki M, 2006, J CLIN INVEST, V116, P1802, DOI 10.1172/JCI29103; Qiu Y, 1998, MOL CELL BIOL, V18, P2957, DOI 10.1128/MCB.18.5.2957; Qiu Y, 2002, MOL CELL BIOL, V22, P412, DOI 10.1128/MCB.22.2.412-420.2002; Qiu Y, 2004, J BIOL CHEM, V279, P9796, DOI 10.1074/jbc.M307577200; Sharma S, 1997, MOL CELL BIOL, V17, P2598, DOI 10.1128/MCB.17.5.2598; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; Vakoc CR, 2005, MOL CELL, V17, P453, DOI 10.1016/j.molcel.2004.12.028; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; YOSHIDA T, 1994, AM J PATHOL, V145, P671	35	35	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8164	8172		10.1074/jbc.M800336200	http://dx.doi.org/10.1074/jbc.M800336200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18252719	hybrid, Green Published			2022-12-25	WOS:000254288000013
J	Reynolds, JG; McCalmon, SA; Donaghey, JA; Naya, FJ				Reynolds, Joseph G.; McCalmon, Sarah A.; Donaghey, Julie A.; Naya, Francisco J.			Deregulated protein kinase A signaling and myospryn expression in muscular dystrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; GLYCOPROTEIN COMPLEX; GENE-EXPRESSION; BINDING PARTNER; MUSCLE; PHOSPHORYLATION; IDENTIFICATION; PATHOLOGY; SURVIVAL	Alterations in signaling pathway activity have been implicated in the pathogenesis of Duchenne muscular dystrophy, a degenerative muscle disease caused by a deficiency in the costameric protein dystrophin. Accordingly, the notion of the dystrophin-glycoprotein complex, and by extension the costamere, as harboring signaling components has received increased attention in recent years. The localization of most, if not all, signaling enzymes to this subcellular region relies on interactions with scaffolding proteins directly or indirectly associated with the dystrophin-glycoprotein complex. One of these scaffolds is myospryn, a large, muscle-specific protein kinase A (PKA) anchoring protein or AKAP. Previous studies have demonstrated a dysregulation of myospryn expression in human Duchenne muscular dystrophy, suggesting a connection to the pathophysiology of the disorder. Here we report that dystrophic muscle exhibits reduced PKA activity resulting, in part, from severely mislocalized myospryn and the type II regulatory subunit (RII alpha) of PKA. Furthermore, we show that myospryn and dystrophin coimmunoprecipitate in native muscle extracts and directly interact in vitro. Our findings reveal for the first time abnormalities in the PKA signal transduction pathway and myospryn regulation in dystrophin deficiency.	[Reynolds, Joseph G.; McCalmon, Sarah A.; Donaghey, Julie A.; Naya, Francisco J.] Boston Univ, Dept Biol, Cell & Mol Biol Program, Boston, MA 02215 USA	Boston University	Naya, FJ (corresponding author), Boston Univ, Dept Biol, Cell & Mol Biol Program, 24 Cummington St, Boston, MA 02215 USA.	fnaya@bu.edu						Acharyya S, 2007, J CLIN INVEST, V117, P889, DOI 10.1172/JCI30556; Batchelor CL, 2006, TRENDS CELL BIOL, V16, P198, DOI 10.1016/j.tcb.2006.02.001; Benson MA, 2004, J BIOL CHEM, V279, P10450, DOI 10.1074/jbc.M312664200; Berdeaux R, 2007, NAT MED, V13, P597, DOI 10.1038/nm1573; Blake DJ, 2002, PHYSIOL REV, V82, P291, DOI 10.1152/physrev.00028.2001; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Ceccarini M, 2007, J MOL BIOL, V371, P1174, DOI 10.1016/j.jmb.2007.06.019; Chakkalakal JV, 2004, HUM MOL GENET, V13, P379, DOI 10.1093/hmg/ddh037; Chang WJ, 1996, P NATL ACAD SCI USA, V93, P9142, DOI 10.1073/pnas.93.17.9142; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; Crawford GE, 2000, J CELL BIOL, V150, P1399, DOI 10.1083/jcb.150.6.1399; Dalkilic I, 2003, CURR OPIN GENET DEV, V13, P231, DOI 10.1016/S0959-437X(03)00048-0; Davies KE, 2006, NAT REV MOL CELL BIO, V7, P762, DOI 10.1038/nrm2024; Durbeej M, 2002, CURR OPIN GENET DEV, V12, P349, DOI 10.1016/S0959-437X(02)00309-X; Durham JT, 2006, J BIOL CHEM, V281, P6841, DOI 10.1074/jbc.M510499200; Ervasti JM, 2007, BBA-MOL BASIS DIS, V1772, P108, DOI 10.1016/j.bbadis.2006.05.010; Ervasti JM, 2003, J BIOL CHEM, V278, P13591, DOI 10.1074/jbc.R200021200; Haslett JN, 2002, P NATL ACAD SCI USA, V99, P15000, DOI 10.1073/pnas.192571199; Heydemann A, 2007, TRENDS CARDIOVAS MED, V17, P55, DOI 10.1016/j.tcm.2006.12.002; Johnson BD, 2005, P NATL ACAD SCI USA, V102, P4191, DOI 10.1073/pnas.0409695102; Judge LM, 2006, J CELL SCI, V119, P1537, DOI 10.1242/jcs.02857; Kolodziejczyk SM, 2001, CURR BIOL, V11, P1278, DOI 10.1016/S0960-9822(01)00397-9; Kouloumenta A, 2007, J BIOL CHEM, V282, P35211, DOI 10.1074/jbc.M704733200; Kramerova I, 2007, BBA-MOL BASIS DIS, V1772, P128, DOI 10.1016/j.bbadis.2006.07.002; Langenbach KJ, 2002, MUSCLE NERVE, V26, P644, DOI 10.1002/mus.10258; Lapidos KA, 2004, CIRC RES, V94, P1023, DOI 10.1161/01.RES.0000126574.61061.25; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Michalak M, 1996, BIOCHEM CELL BIOL, V74, P431, DOI 10.1139/o96-047; Parsons SA, 2007, J BIOL CHEM, V282, P10068, DOI 10.1074/jbc.M609368200; Rando TA, 2001, MUSCLE NERVE, V24, P1575, DOI 10.1002/mus.1192; Reynolds JG, 2007, BBA-MOL CELL RES, V1773, P891, DOI 10.1016/j.bbamcr.2007.04.004; Russell MA, 2006, ARCH BIOCHEM BIOPHYS, V456, P204, DOI 10.1016/j.abb.2006.06.010; SENTER L, 1995, BIOCHEM BIOPH RES CO, V206, P57, DOI 10.1006/bbrc.1995.1009; Sweeney HL, 2000, P NATL ACAD SCI USA, V97, P13464, DOI 10.1073/pnas.011510597; Tkatchenko AV, 2001, NEUROMUSCULAR DISORD, V11, P269, DOI 10.1016/S0960-8966(00)00198-X; Wang XW, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng154; Wong W, 2004, NAT REV MOL CELL BIO, V5, P959, DOI 10.1038/nrm1527	37	47	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8070	8074		10.1074/jbc.C700221200	http://dx.doi.org/10.1074/jbc.C700221200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18252718	hybrid, Green Published			2022-12-25	WOS:000254288000002
J	Barney, JN; Whitlow, TH; Lembo, AJ				Barney, Jacob N.; Whitlow, Thomas H.; Lembo, Arthur J., Jr.			Revealing Historic Invasion Patterns and Potential Invasion Sites for Two Non-Native Plant Species	PLOS ONE			English	Article							ALIEN PLANTS; SPREAD; CONSEQUENCES; DISPERSAL; BIOLOGY	The historical spatio-temporal distribution of invasive species is rarely documented, hampering efforts to understand invasion dynamics, especially at regional scales. Reconstructing historical invasions through use of herbarium records combined with spatial trend analysis and modeling can elucidate spreading patterns and identify susceptible habitats before invasion occurs. Two perennial species were chosen to contrast historic and potential phytogeographies: Japanese knotweed (Polygonum cuspidatum), introduced intentionally across the US; and mugwort (Artemisia vulgaris), introduced largely accidentally to coastal areas. Spatial analysis revealed that early in the invasion, both species have a stochastic distribution across the contiguous US, but east of the 90(th) meridian, which approximates the Mississippi River, quickly spread to adjacent counties in subsequent decades. In contrast, in locations west of the 90(th) meridian, many populations never spread outside the founding county, probably a result of encountering unfavorable environmental conditions. Regression analysis using variables categorized as environmental or anthropogenic accounted for 24% (Japanese knotweed) and 30% (mugwort) of the variation in the current distribution of each species. Results show very few counties with high habitat suitability (>= 80%) remain un-invaded (5 for Japanese knotweed and 6 for mugwort), suggesting these perennials are reaching the limits of large-scale expansion. Despite differences in initial introduction loci and pathways, Japanese knotweed and mugwort demonstrate similar historic patterns of spread and show declining rates of regional expansion. Invasion mitigation efforts should be concentrated on areas identified as highly susceptible that border invaded regions, as both species demonstrate secondary expansion from introduction loci.	[Barney, Jacob N.] Univ Calif Davis, Dept Plant Sci, Davis, CA 95616 USA; [Whitlow, Thomas H.] Cornell Univ, Dept Hort, Ithaca, NY USA; [Lembo, Arthur J., Jr.] Cornell Univ, Dept Crop & Soil Sci, Ithaca, NY USA	University of California System; University of California Davis; Cornell University; Cornell University	Barney, JN (corresponding author), Univ Calif Davis, Dept Plant Sci, Davis, CA 95616 USA.	jbarney@ucdavis.edu	Barney, Jacob/C-2412-2008	Barney, Jacob/0000-0003-2949-5003				Baker H., 1986, ECOLOGY BIOL INVASIO, P44; Baker H. G., 1975, Annual Review of Ecology and Systematics, V5, P1, DOI 10.1146/annurev.es.05.110174.000245; Barney JN, 2006, CAN J PLANT SCI, V86, P887, DOI 10.4141/P05-170; Barney JN, 2006, BIOL INVASIONS, V8, P703, DOI 10.1007/s10530-005-3174-9; Barney JN, 2003, CAN J PLANT SCI, V83, P205, DOI 10.4141/P01-098; Bollmann J., 2004, Feddes Repertorium, V115, P178; Chauvel B, 2006, J BIOGEOGR, V33, P665, DOI 10.1111/j.1365-2699.2005.01401.x; Colautti RI, 2006, BIOL INVASIONS, V8, P45, DOI 10.1007/s10530-005-0236-y; Dark SJ, 2004, DIVERS DISTRIB, V10, P1, DOI 10.1111/j.1472-4642.2004.00054.x; Delisle F, 2003, J BIOGEOGR, V30, P1033, DOI 10.1046/j.1365-2699.2003.00897.x; Drake JM, 2004, BIOSCIENCE, V54, P931, DOI 10.1641/0006-3568(2004)054[0931:TPDOZM]2.0.CO;2; Durka W, 2005, MOL ECOL, V14, P1697, DOI 10.1111/j.1365-294X.2005.02521.x; Holt JS, 2000, WEED SCI, V48, P43, DOI 10.1614/0043-1745(2000)048[0043:PFSOAT]2.0.CO;2; Mack R.N., 2000, BIOL INVASIONS, V2, P111, DOI DOI 10.1023/A:1010088422771; Mack RN, 2000, ECOL APPL, V10, P689, DOI 10.1890/1051-0761(2000)010[0689:BICEGC]2.0.CO;2; Mack RN, 2001, BIOSCIENCE, V51, P95, DOI 10.1641/0006-3568(2001)051[0095:HAGPDG]2.0.CO;2; Menard S.W., 1995, APPL LOGISTIC REGRES, V2nd ed.; Mihulka S, 2001, J BIOGEOGR, V28, P597, DOI 10.1046/j.1365-2699.2001.00574.x; Morisette JT, 2006, FRONT ECOL ENVIRON, V4, P11, DOI 10.1890/1540-9295(2006)004[0012:ATHSMF]2.0.CO;2; Nathan R, 2000, TRENDS ECOL EVOL, V15, P278, DOI 10.1016/S0169-5347(00)01874-7; Novak SJ, 2001, BIOSCIENCE, V51, P114, DOI 10.1641/0006-3568(2001)051[0114:TPIASG]2.0.CO;2; O'sullivan D., 2003, GEOGRAPHIC INFORM AN; Pauchard A, 2006, BIOL INVASIONS, V8, P399, DOI 10.1007/s10530-005-6419-8; Peterson AT, 2003, WEED SCI, V51, P863, DOI 10.1614/P2002-081; Peterson AT, 2001, BIOSCIENCE, V51, P363, DOI 10.1641/0006-3568(2001)051[0363:PSIUEN]2.0.CO;2; Peterson AT, 2003, Q REV BIOL, V78, P419, DOI 10.1086/378926; Pimentel D, 2000, BIOSCIENCE, V50, P53, DOI 10.1641/0006-3568(2000)050[0053:EAECON]2.3.CO;2; Ricciardi A, 2003, FRESHWATER BIOL, V48, P972, DOI 10.1046/j.1365-2427.2003.01071.x; RICH T C G, 1992, Watsonia, V19, P73; Sheeley SE, 1996, B TORREY BOT CLUB, V123, P148, DOI 10.2307/2996072	30	17	19	0	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1635	10.1371/journal.pone.0001635	http://dx.doi.org/10.1371/journal.pone.0001635			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286192	Green Submitted, Green Published, gold			2022-12-25	WOS:000260586400028
J	Leroy, V; Ekouevi, DK; Becquet, R; Viho, I; Dequae-Merchadou, L; Tonwe-Gold, B; Rouet, F; Sakarovitch, C; Horo, A; Timite-Konan, M; Rouzioux, C; Dabis, F				Leroy, Valeriane; Ekouevi, Didier K.; Becquet, Renaud; Viho, Ida; Dequae-Merchadou, Laurence; Tonwe-Gold, Besigin; Rouet, Francois; Sakarovitch, Charlotte; Horo, Appolinaire; Timite-Konan, Marguerite; Rouzioux, Christine; Dabis, Francois		ANRS 1201 1202 DITRAME PLUS Study	18-Month Effectiveness of Short-Course Antiretroviral Regimens Combined with Alternatives to Breastfeeding to Prevent HIV Mother-to-Child Transmission	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SINGLE-DOSE NEVIRAPINE; COTE-DIVOIRE; POSTNATAL TRANSMISSION; RANDOMIZED-TRIAL; ORAL ZIDOVUDINE; DOUBLE-BLIND; EFFICACY; ABIDJAN; ACCEPTABILITY	Objective: We assessed the 18-month effectiveness of short-course (sc) antiretroviral peripartum regimens combined with alternatives to prolonged breastfeeding to prevent mother-to-child transmission (MTCT) of HIV-1 in Abidjan, Cote d'Ivoire. Methodology: HIV-1 infected pregnant women received from >= 32-36 weeks of gestation scZidovudine (ZDV)+/-Lamivudine (3TC)+single-dose Nevirapine (sdNVP) at delivery within the ANRS 1201/1202 DITRAME-Plus cohort (2001-2003). Neonates received a sdNVP+7-day ZDV prophylaxis. Two infant-feeding interventions were systematically offered free of charge: formula-feeding or exclusive shortened breastfeeding with early cessation from four months. The reference group was the ANRS 049a DITRAME cohort (1994-2000) exposed to scZDV from 36 weeks, then to prolonged breastfeeding. Pediatric HIV infection was defined by a positive plasma HIV-1 RNA at any age, or if aged >= 18 months, a positive HIV-1 serology. Turnbull estimates of cumulative transmission risks (CTR) and effectiveness (HIV-free survival) were compared by exposure group using a Cox model. Findings: Among 926 live-born children enrolled, 107 (11.6%) were HIV-infected at 18 months. CTRs were 22.3% (95% confidence interval[CI]: 16-30%) in the 238 ZDV long-term breastfed reference group, 15.9% (CI: 10-27%) in the 169 ZDV+sdNVP shortened breastfed group; 9.4% (CI: 6-14%) in the 195 ZDV+sdNVP formula-fed group; 6.8% (CI: 4-11%) in the 198 ZDV+3TC+sdNVP shortened breastfed group, and 5.6% (CI: 2-10%) in the 126 ZDV+3TC+sdNVP formula-fed group. Each combination had a significantly higher effectiveness than the ZDV long-term breastfed group except for ZDV+sdNVP shortened breastfed children, ranging from 51% (CI: 20-70%) for ZDV+sdNVP formula fed children to 63% (CI: 40-80%) for ZDV+3TC+NVPsd shortened breastfed children, after adjustment for maternal eligibility for antiretroviral therapy (ART), home delivery and low birth-weight. Substantial MTCT risk reductions are reachable in Africa, even in short-term breastfed children. The two sc antiretroviral combinations associated to any of the two infant feeding interventions, formula-feeding and shortened breastfeeding, reduce significantly MTCT with long-term benefit until age 18 months and without increasing mortality.	[Leroy, Valeriane; Becquet, Renaud; Dequae-Merchadou, Laurence; Sakarovitch, Charlotte; Dabis, Francois] French Natl Inst Hlth & Med Res INSERM, U897, Ctr Rech Epidemiol & Biostat, Bordeaux, France; [Leroy, Valeriane; Becquet, Renaud; Dequae-Merchadou, Laurence; Tonwe-Gold, Besigin; Sakarovitch, Charlotte; Dabis, Francois] Univ Victor Segalen Bordeaux 2, ISPED, Bordeaux, France; [Ekouevi, Didier K.; Viho, Ida; Tonwe-Gold, Besigin] Univ Treichville, Ctr Hosp, ANRS, Programme PACCI, Abidjan, Cote Ivoire; [Rouet, Francois] Univ Treichville, Ctr Hosp, CeDReS, Abidjan, Cote Ivoire; [Horo, Appolinaire] Univ Yopougon, Ctr Hosp, Serv Gyn Obstet, Abidjan, Cote Ivoire; [Timite-Konan, Marguerite] Univ Yopougon, Ctr Hosp, Serv Pediat, Abidjan, Cote Ivoire; [Rouzioux, Christine] Univ Necker Enfants Malades, Ctr Hosp, Lab Virol Med, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Leroy, V (corresponding author), French Natl Inst Hlth & Med Res INSERM, U897, Ctr Rech Epidemiol & Biostat, Bordeaux, France.	valeriane.leroy@isped.u-bordeaux2.fr	Mandelbrot, Laurent/AAD-3554-2019; Leroy, Valeriane/GQB-1102-2022; Leroy, Valeriane/AAO-5175-2020; Tonwe-Gold, Besigin/AAL-8438-2020; Becquet, Renaud/F-4837-2013; Leroy, Valeriane/F-8129-2013; EKOUEVI, Didier K/E-7960-2014; DABIS, FRANCOIS/S-9298-2019	Mandelbrot, Laurent/0000-0002-5883-7597; Leroy, Valeriane/0000-0003-3542-8616; Leroy, Valeriane/0000-0003-3542-8616; Becquet, Renaud/0000-0003-3277-0985; Leroy, Valeriane/0000-0003-3542-8616; DABIS, FRANCOIS/0000-0002-1614-8857	French Ministry of Foreign Affairs; French Ministry of Education, Research and Technology [fellow]; SIDACTION [fellow]	French Ministry of Foreign Affairs; French Ministry of Education, Research and Technology; SIDACTION	The primary sponsor of the ANRS 1201/1202 Ditrame-Plus Cohort was the Agence Nationale de Recherches sur le Sida (ANRS), from 2000 to 2005. Laurence Bequet and Francois Rouet were supported by the French Ministry of Foreign Affairs. Renaud Becquet was a fellow of the French Ministry of Education, Research and Technology and is now a post-doctoral fellow of the French charity SIDACTION. Didier K. Ekouevi was a fellow of the French charity SIDACTION. Zidovudine and lamivudine were provided by Glaxo Smith Kline International.	Alioum A, 2003, AM J EPIDEMIOL, V158, P596, DOI 10.1093/aje/kwg188; Becquet R, 2005, JAIDS-J ACQ IMM DEF, V40, P600, DOI 10.1097/01.qai.0000171726.17436.82; BECQUET R, 12011202 ANRS; Chaix ML, 2006, J INFECT DIS, V193, P482, DOI 10.1086/499966; COFFIE P, 2008, SHORT COURSE ZIDOVUD; Coutsoudis A, 2004, J INFECT DIS, V189, P2154, DOI 10.1086/420834; Dabis F, 2005, AIDS, V19, P309; Dabis F, 1999, LANCET, V353, P786, DOI 10.1016/S0140-6736(98)11046-2; Ekouevi DK, 2004, AIDS, V18, P697, DOI 10.1097/00002030-200403050-00018; Farquhar C, 2001, AIDS, V15, P815, DOI 10.1097/00002030-200104130-00027; Fawzi WW, 1998, LANCET, V351, P1477, DOI 10.1016/S0140-6736(98)04197-X; Gaillard P, 2001, STAT MED, V20, P3525, DOI 10.1002/sim.1092; Jackson JB, 2003, LANCET, V362, P859, DOI 10.1016/S0140-6736(03)14341-3; Lallemant M, 2004, NEW ENGL J MED, V351, P217, DOI 10.1056/NEJMoa033500; Leroy V, 2005, AIDS, V19, P1865, DOI 10.1097/01.aids.0000188423.02786.55; Leroy V, 2003, AIDS, V17, P1493, DOI 10.1097/00002030-200307040-00010; Leroy V, 2002, AIDS, V16, P631, DOI 10.1097/00002030-200203080-00016; Leroy V, 2007, JAIDS-J ACQ IMM DEF, V44, P77, DOI 10.1097/01.qai.0000243115.37035.97; Mandelbrot L, 2001, JAMA-J AM MED ASSOC, V285, P2083, DOI 10.1001/jama.285.16.2083; Meda N, 2002, AIDS, V16, P2323, DOI 10.1097/00002030-200211220-00013; Msellati P, 2006, INT J STD AIDS, V17, P57, DOI 10.1258/095646206775220559; Nduati R, 2000, JAMA-J AM MED ASSOC, V283, P1167, DOI 10.1001/jama.283.9.1167; Rouet F, 2005, J CLIN MICROBIOL, V43, P2709, DOI 10.1128/JCM.43.6.2709-2717.2005; Rouet F, 2004, J CLIN MICROBIOL, V42, P4147, DOI 10.1128/JCM.42.9.4147-4153.2004; Rouet F, 2001, AIDS, V15, P1849, DOI 10.1097/00002030-200109280-00015; Saba J, 2002, LANCET, V359, P1178; Shapiro RL, 2005, J INFECT DIS, V192, P713, DOI 10.1086/432489; Shapiro RL, 2005, J INFECT DIS, V192, P720, DOI 10.1086/432483; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; Thior I, 2006, JAMA-J AM MED ASSOC, V296, P794, DOI 10.1001/jama.296.7.794; Tonwe-Gold B, 2007, PLOS MED, V4, P1362, DOI 10.1371/journal.pmed.0040257; *UNICEF UNAIDS WHO, 1998, 9892 WHOFRHNUTCHD UN; *WHO, 2006, WHO HIV INF FEED TEC; *WHO UNAIDS UNICEF, 1998, 982 WHOFRHNUTCHD UNA; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9; World Health Organization Occupational and Environmental Health Team, 2006, WORLD HEAL ORGAN FOO, DOI DOI 10.1016/0004-6981(88)90109-6; World Health Organization & Unicef, 1993, BREASTF COUNS TRAIN; World Health Organization (WHO), 2004, EM SCAL UP ANT THER	38	31	32	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1645	10.1371/journal.pone.0001645	http://dx.doi.org/10.1371/journal.pone.0001645			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286200	Green Submitted, Green Published, gold			2022-12-25	WOS:000260586400038
J	Lipson, KL; Ghosh, R; Urano, F				Lipson, Kathryn L.; Ghosh, Rajarshi; Urano, Fumihiko			The Role of IRE1 alpha in the Degradation of Insulin mRNA in Pancreatic beta-Cells	PLOS ONE			English	Article								Background: The endoplasmic reticulum (ER) is a cellular compartment for the biosynthesis and folding of newly synthesized secretory proteins such as insulin. Perturbations to ER homeostasis cause ER stress and subsequently activate cell signaling pathways, collectively known as the Unfolded Protein Response (UPR). IRE1 alpha is a central component of the UPR. In pancreatic beta-cells, IRE1 alpha also functions in the regulation of insulin biosynthesis. Principal Findings: Here we report that hyperactivation of IRE1 alpha caused by chronic high glucose treatment or IRE1 alpha overexpression leads to insulin mRNA degradation in pancreatic beta-cells. Inhibition of IRE1 alpha signaling using its dominant negative form prevents insulin mRNA degradation. Islets from mice heterozygous for IRE1 alpha retain expression of more insulin mRNA after chronic high glucose treatment than do their wild-type littermates. Conclusions/Significance: These results reveal a role of IRE1 alpha in insulin mRNA expression under ER stress conditions caused by chronic high glucose. The rapid degradation of insulin mRNA could provide immediate relief for the ER and free up the translocation machinery. Thus, this mechanism would preserve ER homeostasis and help ensure that the insulin already inside the ER can be properly folded and secreted. This adaptation may be crucial for the maintenance of beta-cell homeostasis and may explain why the beta-cells of type 2 diabetic patients with chronic hyperglycemia stop producing insulin in the absence of apoptosis. This mechanism may also be involved in suppression of the autoimmune type 1 diabetes by reducing the amount of misfolded insulin, which could be a source of "neo-autoantigens.''	[Lipson, Kathryn L.; Ghosh, Rajarshi; Urano, Fumihiko] Univ Massachusetts, Sch Med, Program Gene Funct & Express, Worcester, MA 01605 USA; [Urano, Fumihiko] Univ Massachusetts, Med Sch, Program Mol Med, Worcester, MA USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Lipson, KL (corresponding author), Univ Massachusetts, Sch Med, Program Gene Funct & Express, Worcester, MA 01605 USA.	urano@erstress.com	Urano, Fumihiko/AAF-4492-2020	Ghosh, Rajarshi/0000-0002-5780-8241	NIH [R01DK067493]; NIH-NIDDK Diabetes and Endocrinology Research Center at the UMass Medical School [DK032520]; Juvenile Diabetes Research Foundation Innovative Award; Iacocca Foundation/JDRF; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520, R01DK067493] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH-NIDDK Diabetes and Endocrinology Research Center at the UMass Medical School; Juvenile Diabetes Research Foundation Innovative Award(Juvenile Diabetes Research Foundation); Iacocca Foundation/JDRF(Juvenile Diabetes Research Foundation); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Research in the laboratory of F. Urano is supported by an NIH R01DK067493 grant, NIH-NIDDK Diabetes and Endocrinology Research Center at the UMass Medical School (DK032520), a Juvenile Diabetes Research Foundation Innovative Award, and an Iacocca Foundation/JDRF joint Grant.	Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Hollien J, 2006, SCIENCE, V313, P104, DOI 10.1126/science.1129631; Iwawaki T, 2001, NAT CELL BIOL, V3, P158, DOI 10.1038/35055065; Kaneto H, 2002, J BIOL CHEM, V277, P30010, DOI 10.1074/jbc.M202066200; Kataoka K, 2002, J BIOL CHEM, V277, P49903, DOI 10.1074/jbc.M206796200; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; LEAHY JL, 2004, DIABETES MELLITUS FU, P115; Lipson KL, 2006, CELL METAB, V4, P245, DOI 10.1016/j.cmet.2006.07.007; MATSUOKA TA, 2007, MOL ENDOCRINOL; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Olbrot M, 2002, P NATL ACAD SCI USA, V99, P6737, DOI 10.1073/pnas.102168499; OLSON LK, 1995, P NATL ACAD SCI USA, V92, P9127, DOI 10.1073/pnas.92.20.9127; OLSON LK, 1993, J CLIN INVEST, V92, P514, DOI 10.1172/JCI116596; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Pirot P, 2007, DIABETOLOGIA, V50, P1006, DOI 10.1007/s00125-007-0609-0; Poitout V, 1996, J CLIN INVEST, V97, P1041, DOI 10.1172/JCI118496; RHODES CJ, 2005, JOSLINS DIABETES MEL, P65; Robertson RP, 2004, DIABETES MELLITUS, P129; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Rutkowski DT, 2007, TRENDS BIOCH SCI; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1127, DOI 10.1210/me.9.9.1127; Tirasophon W, 2000, GENE DEV, V14, P2725, DOI 10.1101/gad.839400; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0	26	137	144	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1648	10.1371/journal.pone.0001648	http://dx.doi.org/10.1371/journal.pone.0001648			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286202	gold, Green Published, Green Submitted			2022-12-25	WOS:000260586400041
J	Desset, S; Buchon, N; Meignin, C; Coiffet, M; Vaury, C				Desset, Sophie; Buchon, Nicolas; Meignin, Carine; Coiffet, Michael; Vaury, Chantal			In Drosophila melanogaster the COM Locus Directs the Somatic Silencing of Two Retrotransposons through both Piwi-Dependent and -Independent Pathways	PLOS ONE			English	Article							RNA-INTERFERENCE; ENDOGENOUS RETROVIRUS; ZAM; MOBILIZATION; ELEMENTS; PROTEIN; LINE	Background. In the Drosophila germ line, repeat-associated small interfering RNAs (rasiRNAs) ensure genomic stability by silencing endogenous transposable elements. This RNA silencing involves small RNAs of 26-30 nucleotides that are mainly produced from the antisense strand and function through the Piwi protein. Piwi belongs to the subclass of the Argonaute family of RNA interference effector proteins, which are expressed in the germline and in surrounding somatic tissues of the reproductive apparatus. In addition to this germ-line expression, Piwi has also been implicated in diverse functions in somatic cells. Principal Findings. Here, we show that two LTR retrotransposons from Drosophila melanogaster, ZAM and Idefix, are silenced by an RNA silencing pathway that has characteristics of the rasiRNA pathway and that specifically recognizes and destroys the sense-strand RNAs of the retrotransposons. This silencing depends on Piwi in the follicle cells surrounding the oocyte. Interestingly, this silencing is active in all the somatic tissues examined from embryos to adult flies. In these somatic cells, while the silencing still involves the strict recognition of sense-strand transcripts, it displays the marked difference of being independent of the Piwi protein. Finally, we present evidence that in all the tissues examined, the repression is controlled by the heterochromatic COM locus. Conclusion. Our data shed further light on the silencing mechanism that acts to target Drosophila LTR retrotransposons in somatic cells throughout fly development. They demonstrate that different RNA silencing pathways are involved in ovarian versus other somatic tissues, since Piwi is necessary for silencing in the former tissues but is dispensable in the latter. They further demonstrate that these pathways are controlled by the heterochromatic COM locus which ensures the overall protection of Drosophila against the detrimental effects of random retrotransposon mobilization.	[Desset, Sophie; Coiffet, Michael; Vaury, Chantal] Clermont Univ, CNRS, UMR6247, GReD, Clermont Ferrand, France; [Buchon, Nicolas] Ecole Polytech Fed de Lausanne, Lausanne, Switzerland; [Meignin, Carine] Univ Oxford, Dept Biochem, Oxford, England	Centre National de la Recherche Scientifique (CNRS); Universite Clermont Auvergne (UCA); Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Oxford	Vaury, C (corresponding author), Clermont Univ, CNRS, UMR6247, GReD, BP38, Clermont Ferrand, France.	Chantal.VAURY@inserm.u-clermont1.fr	Vaury, Chantal/I-4658-2015; Buchon, Nicolas/AAE-9323-2019; desset, sophie/G-5756-2013; Desset, Sophie/AAM-8212-2021	Vaury, Chantal/0000-0002-7725-5760; Buchon, Nicolas/0000-0003-3636-8387; desset, sophie/0000-0002-4897-4977; Desset, Sophie/0000-0002-4897-4977; Meignin, Carine/0000-0002-6588-9045	CNRS [GDR2157]; Association pour la Recherche contre le Cancer [ARC 3441]; Action Concertee Incitative [ACI BCMS408]; Canceropole Lyon Auvergne Rhone-Alpes; Region Auvergne; Ministere de lEnseignement Superieur et de la Recherche (MESR)	CNRS(Centre National de la Recherche Scientifique (CNRS)); Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); Action Concertee Incitative; Canceropole Lyon Auvergne Rhone-Alpes; Region Auvergne(Region Auvergne-Rhone-Alpes); Ministere de lEnseignement Superieur et de la Recherche (MESR)(Ministry of Research, France)	CV is supported by CNRS (GDR2157), Association pour la Recherche contre le Cancer (ARC 3441), Action Concertee Incitative (ACI BCMS408), Canceropole Lyon Auvergne Rhone-Alpes (CLARA, Projet EpiPro), and Region Auvergne. NB received a grant from the Ministere de lEnseignement Superieur et de la Recherche (MESR).	Ahmad K, 1996, GENETICS, V144, P657; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Aravin AA, 2001, CURR BIOL, V11, P1017, DOI 10.1016/S0960-9822(01)00299-8; Aravin AA, 2004, MOL CELL BIOL, V24, P6742, DOI 10.1128/MCB.24.15.6742-6750.2004; Aravin A, 2006, NATURE, V442, P203, DOI 10.1038/nature04916; Bernstein E, 2001, RNA, V7, P1509; Biemont C, 2006, NATURE, V443, P521, DOI 10.1038/443521a; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brennecke J, 2007, CELL, V128, P1089, DOI 10.1016/j.cell.2007.01.043; Desset S, 1999, MOL BIOL EVOL, V16, P54, DOI 10.1093/oxfordjournals.molbev.a026038; Desset S, 2003, GENETICS, V164, P501; Du TT, 2005, DEVELOPMENT, V132, P4645, DOI 10.1242/dev.02070; Girard A, 2006, NATURE, V442, P199, DOI 10.1038/nature04917; Grimaud C, 2006, CELL, V124, P957, DOI 10.1016/j.cell.2006.01.036; Gunawardane LS, 2007, SCIENCE, V315, P1587, DOI 10.1126/science.1140494; Kalmykova AI, 2005, NUCLEIC ACIDS RES, V33, P2052, DOI 10.1093/nar/gki323; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; Leblanc P, 2000, J VIROL, V74, P10658, DOI 10.1128/JVI.74.22.10658-10669.2000; Leblanc P, 1997, EMBO J, V16, P7521, DOI 10.1093/emboj/16.24.7521; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Meignin C, 2004, NUCLEIC ACIDS RES, V32, P3799, DOI 10.1093/nar/gkh708; Pal-Bhadpa M, 2004, COLD SPRING HARB SYM, V69, P433, DOI 10.1101/sqb.2004.69.433; Pal-Bhadra M, 2004, SCIENCE, V303, P669, DOI 10.1126/science.1092653; Pal-Bhadra M, 2002, MOL CELL, V9, P315, DOI 10.1016/S1097-2765(02)00440-9; Pelisson A, 2007, J VIROL, V81, P1951, DOI 10.1128/JVI.01980-06; Robert V, 2001, GENETICS, V158, P701; Saito K, 2006, GENE DEV, V20, P2214, DOI 10.1101/gad.1454806; Sarot E, 2004, GENETICS, V166, P1313, DOI 10.1534/genetics.166.3.1313; Vagin VV, 2006, SCIENCE, V313, P320, DOI 10.1126/science.1129333; Williams RW, 2002, P NATL ACAD SCI USA, V99, P6889, DOI 10.1073/pnas.072190799; Yin H, 2007, NATURE, V450, P304, DOI 10.1038/nature06263	32	42	44	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2008	3	2							e1526	10.1371/journal.pone.0001526	http://dx.doi.org/10.1371/journal.pone.0001526			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367EQ	18253480	gold, Green Published, Green Submitted			2022-12-25	WOS:000260535700004
J	Dos Vultos, T; Mestre, O; Rauzier, J; Golec, M; Rastogi, N; Rasolofo, V; Tonjum, T; Sola, C; Matic, I; Gicquel, B				Dos Vultos, Tiago; Mestre, Olga; Rauzier, Jean; Golec, Marcin; Rastogi, Nalin; Rasolofo, Voahangy; Tonjum, Tone; Sola, Christophe; Matic, Ivan; Gicquel, Brigitte			Evolution and Diversity of Clonal Bacteria: The Paradigm of Mycobacterium tuberculosis	PLOS ONE			English	Article								Background. Mycobacterium tuberculosis complex species display relatively static genomes and 99.9% nucleotide sequence identity. Studying the evolutionary history of such monomorphic bacteria is a difficult and challenging task. Principal Findings. We found that single-nucleotide polymorphism (SNP) analysis of DNA repair, recombination and replication (3R) genes in a comprehensive selection of M. tuberculosis complex strains from across the world, yielded surprisingly high levels of polymorphisms as compared to house-keeping genes, making it possible to distinguish between 80% of clinical isolates analyzed in this study. Bioinformatics analysis suggests that a large number of these polymorphisms are potentially deleterious. Site frequency spectrum comparison of synonymous and non-synonymous variants and Ka/Ks ratio analysis suggest a general negative/purifying selection acting on these sets of genes that may lead to suboptimal 3R system activity. In turn, the relaxed fidelity of 3R genes may allow the occurrence of adaptive variants, some of which will survive. Furthermore, 3R-based phylogenetic trees are a new tool for distinguishing between M. tuberculosis complex strains. Conclusions/Significance. This situation, and the consequent lack of fidelity in genome maintenance, may serve as a starting point for the evolution of antibiotic resistance, fitness for survival and pathogenicity, possibly conferring a selective advantage in certain stressful situations. These findings suggest that 3R genes may play an important role in the evolution of highly clonal bacteria, such as M. tuberculosis. They also facilitate further epidemiological studies of these bacteria, through the development of high-resolution tools. With many more microbial genomes being sequenced, our results open the door to 3R gene-based studies of adaptation and evolution of other, highly clonal bacteria.	[Dos Vultos, Tiago; Mestre, Olga; Rauzier, Jean; Golec, Marcin; Sola, Christophe; Gicquel, Brigitte] Inst Pasteur, Unite Genet Mycobacterienne, Paris, France; [Rastogi, Nalin; Rasolofo, Voahangy] Inst Pasteur Guadeloupe, Unite TB Mycobacter, Abymes, Guadeloupe, France; Inst Pasteur Madagascar, Unite TB Mycobacter, Antananarivo, Madagascar; [Tonjum, Tone] Univ Oslo, Inst Microbiol, Ctr Mol Biol & Neurosci, Oslo, Norway; [Tonjum, Tone] Inst Microbiol, Ctr Mol Biol & Neurosci, Oslo, Norway; [Matic, Ivan] Univ Paris 05, Fac Med, Inst Natl Sante Rech Med U571, Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Madagascar; University of Oslo; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Gicquel, B (corresponding author), Inst Pasteur, Unite Genet Mycobacterienne, Paris, France.	bgicquel@pasteur.fr	RASTOGI, NALIN/AAP-1958-2020; Sola, Christophe/A-7992-2016; Tønjum, Tone/J-4581-2014; Mestre, Olga/D-7418-2013	RASTOGI, NALIN/0000-0002-7199-7747; Sola, Christophe/0000-0003-4672-2140; Mestre, Olga/0000-0002-0993-2248; Tonjum, Tone/0000-0002-1709-6921	European Commission [LSHP-CT-2006-037919, ICA4-CT-2002-10052]; European Commission [LSHP-CT-2006-037919, ICA4-CT-2002-10052]	European Commission(European CommissionEuropean Commission Joint Research Centre); European Commission(European CommissionEuropean Commission Joint Research Centre)	This work received support from the European Commission (TB Adapt project LSHP-CT-2006-037919 and VACSIS project ICA4-CT-2002-10052).	Baker L, 2004, EMERG INFECT DIS, V10, P1568, DOI 10.3201/eid1009.040046; Bandelt HJ, 1999, MOL BIOL EVOL, V16, P37, DOI 10.1093/oxfordjournals.molbev.a026036; Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299; Brudey K, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-23; Denamur E, 2006, MOL MICROBIOL, V60, P820, DOI 10.1111/j.1365-2958.2006.05150.x; Dos Vultos T, 2006, J BACTERIOL, V188, P3159, DOI 10.1128/JB.188.8.3159-3161.2006; Eisen JA, 1999, MUTAT RES-DNA REPAIR, V435, P171, DOI 10.1016/S0921-8777(99)00050-6; Filliol I, 2006, J BACTERIOL, V188, P759, DOI 10.1128/JB.188.2.759-772.2006; Frothingham R, 1998, MICROBIOL-UK, V144, P1189, DOI 10.1099/00221287-144-5-1189; GROENEN PMA, 1993, MOL MICROBIOL, V10, P1057, DOI 10.1111/j.1365-2958.1993.tb00976.x; Gutacker MM, 2002, GENETICS, V162, P1533; Hanekom M, 2007, J CLIN MICROBIOL, V45, P1483, DOI 10.1128/JCM.02191-06; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Liu XM, 2006, J BACTERIOL, V188, P8169, DOI 10.1128/JB.01062-06; Mizrahi V, 1998, MOL MICROBIOL, V29, P1331, DOI 10.1046/j.1365-2958.1998.01038.x; Nielsen R, 2005, ANNU REV GENET, V39, P197, DOI 10.1146/annurev.genet.39.073003.112420; Rad ME, 2003, EMERG INFECT DIS, V9, P838, DOI 10.3201/eid0907.020803; Rocha EPC, 2006, J THEOR BIOL, V239, P226, DOI 10.1016/j.jtbi.2005.08.037; Rosas-Magallanes V, 2006, MOL BIOL EVOL, V23, P1129, DOI 10.1093/molbev/msj120; Roumagnac P, 2006, SCIENCE, V314, P1301, DOI 10.1126/science.1134933; Rozas J, 2003, BIOINFORMATICS, V19, P2496, DOI 10.1093/bioinformatics/btg359; Sreevatsan S, 1997, P NATL ACAD SCI USA, V94, P9869, DOI 10.1073/pnas.94.18.9869; Supply P, 2000, MOL MICROBIOL, V36, P762, DOI 10.1046/j.1365-2958.2000.01905.x; Tonjum Tone, 2001, Trends in Microbiology, V9, P356, DOI 10.1016/S0966-842X(01)02099-6; TYE BK, 1978, P NATL ACAD SCI USA, V75, P233, DOI 10.1073/pnas.75.1.233	25	101	103	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2008	3	2							e1538	10.1371/journal.pone.0001538	http://dx.doi.org/10.1371/journal.pone.0001538			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367EQ	18253486	Green Published, Green Submitted, gold			2022-12-25	WOS:000260535700010
J	Kotera, M; McDonald, AG; Boyce, S; Tipton, KF				Kotera, Masaaki; McDonald, Andrew G.; Boyce, Sinead; Tipton, Keith F.			Functional Group and Substructure Searching as a Tool in Metabolomics	PLOS ONE			English	Article								Background. A direct link between the names and structures of compounds and the functional groups contained within them is important, not only because biochemists frequently rely on literature that uses a free-text format to describe functional groups, but also because metabolic models depend upon the connections between enzymes and substrates being known and appropriately stored in databases. Methodology. We have developed a database named "Biochemical Substructure Search Catalogue'' (BiSSCat), which contains 489 functional groups, >200,000 compounds and >1,000,000 different computationally constructed substructures, to allow identification of chemical compounds of biological interest. Conclusions. This database and its associated web-based search program (http://bisscat.org/) can be used to find compounds containing selected combinations of substructures and functional groups. It can be used to determine possible additional substrates for known enzymes and for putative enzymes found in genome projects. Its applications to enzyme inhibitor design are also discussed.	[Kotera, Masaaki; McDonald, Andrew G.; Boyce, Sinead; Tipton, Keith F.] Trinity Coll Dublin, Sch Biochem & Immunol, Dublin, Ireland	Trinity College Dublin	Kotera, M (corresponding author), Trinity Coll Dublin, Sch Biochem & Immunol, Dublin, Ireland.	koteram@tcd.ie	Kotera, Masaaki/AAJ-9938-2020	McDonald, Andrew/0000-0003-2727-176X	Science Foundation Ireland [SFI 02/IN.1/B043- Tipton]	Science Foundation Ireland(Science Foundation IrelandEuropean Commission)	We are grateful to Science Foundation Ireland (grant No. SFI 02/IN.1/B043- Tipton) for support.	Allen F.H., 1993, CHEM DESIGN AUTOMATI, V8, P1; Allen F.H., 1993, CHEM DESIGN AUTOMATI, V8, P31; Antal J, 2001, ANAL BIOCHEM, V288, P156, DOI 10.1006/abio.2000.4886; Arimoto R, 2006, CURR TOP MED CHEM, V6, P1609, DOI 10.2174/156802606778108951; Ash S, 1997, J CHEM INF COMP SCI, V37, P71, DOI 10.1021/ci960109j; BARNARD JM, 1989, ACS SYM SER, V400, P76; Bayada DM, 1999, J CHEM INF COMP SCI, V39, P1, DOI 10.1021/ci980109e; Brown RD, 1997, J CHEM INF COMP SCI, V37, P1, DOI 10.1021/ci960373c; Brown RD, 1996, J CHEM INF COMP SCI, V36, P572, DOI 10.1021/ci9501047; BUSH BL, 1993, J CHEM INF COMP SCI, V33, P756, DOI 10.1021/ci00015a015; Chang C, 2006, ADV DRUG DELIVER REV, V58, P1431, DOI 10.1016/j.addr.2006.09.006; Chen B, 2007, J COMPUT AID MOL DES, V21, P53, DOI 10.1007/s10822-006-9096-5; Coles SJ, 2005, ORG BIOMOL CHEM, V3, P1832, DOI 10.1039/b502828k; DALBY A, 1992, J CHEM INF COMP SCI, V32, P244, DOI 10.1021/ci00007a012; Ellis LBM, 2006, NUCLEIC ACIDS RES, V34, pD517, DOI 10.1093/nar/gkj076; Flower DR, 1998, J CHEM INF COMP SCI, V38, P379, DOI 10.1021/ci970437z; FOX RB, NOMENCLATURE ORGANIC; GREENE N, 1999, KNOWLEDGE BASED EXPE, P289; Hattori M, 2003, J AM CHEM SOC, V125, P11853, DOI 10.1021/ja036030u; Hofmann O, 2005, BIOINFORMATICS, V21, P2059, DOI 10.1093/bioinformatics/bti284; Hult K, 2007, TRENDS BIOTECHNOL, V25, P231, DOI 10.1016/j.tibtech.2007.03.002; IHLENFELDT WD, 1994, J COMPUT CHEM, V15, P793, DOI 10.1002/jcc.540150802; Ihlenfeldt WD, 2002, J CHEM INF COMP SCI, V42, P46, DOI 10.1021/ci010056s; International Union of Pure and Applied Chemistry, 1979, NOM ORG CHEM; James C.A., 2000, DAYLIGHT THEORY MANU, DOI 10.1002/mus.23684; Kanehisa M, 2006, NUCLEIC ACIDS RES, V34, pD354, DOI 10.1093/nar/gkj102; Khedkar SA, 2007, MED CHEM, V3, P187, DOI 10.2174/157340607780059521; Klopman Gilles, 1997, Environmental Toxicology and Chemistry, V16, P1829, DOI 10.1897/1551-5028(1997)016<1829:SBSACA>2.3.CO;2; Kotera M, 2004, J AM CHEM SOC, V126, P16487, DOI 10.1021/ja0466457; Kotera M, 2004, GENOME INFORM, V15, pP062; Leigh G.J., 1998, PRINCIPLES CHEM NOME; Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1; McDonald Andrew G, 2007, BMC Biochem, V8, P14, DOI 10.1186/1471-2091-8-14; Muegge I, 2002, CHEM-EUR J, V8, P1976, DOI 10.1002/1521-3765(20020503)8:9<1976::AID-CHEM1976>3.0.CO;2-K; NICOLAOU CA, 2007, CURR OPIN DRUG DISC, P10; Oellien F, 2005, J CHEM INF MODEL, V45, P1456, DOI 10.1021/ci050202k; Polanski J, 2003, ADV DRUG DELIVER REV, V55, P1149, DOI 10.1016/S0169-409X(03)00116-9; Poolman MG, 2006, IEE P SYST BIOL, V153, P379, DOI 10.1049/ip-syb:20060012; Poroikov VV, 2003, J CHEM INF COMP SCI, V43, P228, DOI 10.1021/ci020048r; Raymond JW, 2002, J COMPUT AID MOL DES, V16, P521, DOI 10.1023/A:1021271615909; Raymond JW, 2002, J CHEM INF COMP SCI, V42, P305, DOI 10.1021/ci010381f; Raymond JW, 2002, COMPUT J, V45, P631, DOI 10.1093/comjnl/45.6.631; Richmond NJ, 2006, J COMPUT AID MOL DES, V20, P567, DOI 10.1007/s10822-006-9082-y; Schwab W, 2003, PHYTOCHEMISTRY, V62, P837, DOI 10.1016/S0031-9422(02)00723-9; WEININGER D, 1990, J CHEM INF COMP SCI, V30, P237, DOI 10.1021/ci00067a005; WEININGER D, 1988, J CHEM INF COMP SCI, V28, P31, DOI 10.1021/ci00057a005; Wild DJ, 2000, J CHEM INF COMP SCI, V40, P155, DOI 10.1021/ci990086j; WISNIEWSKI JL, 1998, ENCY COMPUTATIONAL C, P1881; Wiswesser W.J., 1954, LINE FORMULA CHEM NO; WISWESSER WJ, 1982, J CHEM INF COMP SCI, V22, P88, DOI 10.1021/ci00034a005; WISWESSER WJ, 1985, J CHEM INF COMP SCI, V25, P258, DOI 10.1021/ci00047a023	51	18	18	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2008	3	2							e1537	10.1371/journal.pone.0001537	http://dx.doi.org/10.1371/journal.pone.0001537			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367EQ	18253485	gold, Green Published			2022-12-25	WOS:000260535700009
J	Brosnan, SF; Grady, MF; Lambeth, SP; Schapiro, SJ; Beran, MJ				Brosnan, Sarah F.; Grady, Mark F.; Lambeth, Susan P.; Schapiro, Steven J.; Beran, Michael J.			Chimpanzee Autarky	PLOS ONE			English	Article							PAN-TROGLODYTES; EXCHANGE; RECIPROCITY; MONKEYS; OBJECTS	Economists believe that barter is the ultimate cause of social wealth-and even much of our human culture-yet little is known about the evolution and development of such behavior. It is useful to examine the circumstances under which other species will or will not barter to more fully understand the phenomenon. Chimpanzees (Pan troglodytes) are an interesting test case as they are an intelligent species, closely related to humans, and known to participate in reciprocal interactions and token economies with humans, yet they have not spontaneously developed costly barter. Methodology/Principle Findings. Although chimpanzees do engage in noncostly barter, in which otherwise value-less tokens are exchanged for food, this lack of risk is not typical of human barter. Thus, we systematically examined barter in chimpanzees to ascertain under what circumstances chimpanzees will engage in costly barter of commodities, that is, trading food items for other food items with a human experimenter. We found that chimpanzees do barter, relinquishing lower value items to obtain higher value items (and not the reverse). However, they do not trade in all beneficial situations, maintaining possession of less preferred items when the relative gains they stand to make are small. Conclusions/Significance. Two potential explanations for this puzzling behavior are that chimpanzees lack ownership norms, and thus have limited opportunity to benefit from the gains of trade, and that chimpanzees' risk of defection is sufficiently high that large gains must be imminent to justify the risk. Understanding the conditions that support barter in chimpanzees may increase understanding of situations in which humans, too, do not maximize their gains.	[Brosnan, Sarah F.] Emory Univ, Dept Anthropol, Atlanta, GA 30322 USA; [Brosnan, Sarah F.; Lambeth, Susan P.; Schapiro, Steven J.] Univ Texas, MD Anderson Canc Ctr, Michale E Keeling Ctr Compar Med & Res, Houston, TX USA; [Brosnan, Sarah F.; Beran, Michael J.] Georgia State Univ, Language Res Ctr, Atlanta, GA USA; [Grady, Mark F.] Univ Calif Los Angeles, Ctr Law & Econ, Los Angeles, CA USA	Emory University; University of Texas System; UTMD Anderson Cancer Center; University System of Georgia; Georgia State University; University of California System; University of California Los Angeles	Brosnan, SF (corresponding author), Emory Univ, Dept Anthropol, Atlanta, GA 30322 USA.	sbrosnan@gsu.edu	Beran, Michael J./M-8743-2016; Beran, Michael J./ABY-1786-2022	Beran, Michael J./0000-0002-2504-0338; Beran, Michael J./0000-0002-2504-0338; Schapiro, Steven J./0000-0001-5406-1739	NSF [SES 0729244, BCS-0634662]; NIH/NIGMS [IRACDA]; NICHD [HD-38051]; NIH/NCRR; College of Arts and Sciences, Georgia State University; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD038051] Funding Source: NIH RePORTER	NSF(National Science Foundation (NSF)); NIH/NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIH/NCRR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); College of Arts and Sciences, Georgia State University; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	SFB was supported by NSF grant SES 0729244 and an NIH/NIGMS IRACDA grant awarded to Emory University. MJB was supported by NICHD grant HD-38051, and NSF grants BCS-0634662 and SES 0729244. The Bastrop colony was supported by NIH/NCRR. The LRC colony was supported by NICHD HD-38051 and the College of Arts and Sciences, Georgia State University.	ADDESSI E, 2007, P ROY SOC LOND B BIO, V274, P2709; Beran MJ, 2006, BEHAV PROCESS, V73, P315, DOI 10.1016/j.beproc.2006.07.005; Brauer J, 2006, P ROY SOC B-BIOL SCI, V273, P3123, DOI 10.1098/rspb.2006.3693; Brosnan SF, 2007, CURR BIOL, V17, P1704, DOI 10.1016/j.cub.2007.08.059; Brosnan SF, 2005, PRIMATES, V46, P173, DOI 10.1007/s10329-005-0125-0; Brosnan SF, 2004, FOLIA PRIMATOL, V75, P317, DOI 10.1159/000080209; Brosnan SF, 2004, J COMP PSYCHOL, V118, P133, DOI 10.1037/0735-7036.118.2.133; Brosnan SF, 2005, P ROY SOC B-BIOL SCI, V272, P253, DOI 10.1098/rspb.2004.2947; Brosnan SF, 2003, NATURE, V425, P297, DOI 10.1038/nature01963; Chalmeau R, 1998, PRIMATES, V39, P389, DOI 10.1007/BF02557563; DEWAAL FBM, 1989, J HUM EVOL, V18, P433, DOI 10.1016/0047-2484(89)90074-2; DEWAAL FBM, 1988, ETHOL SOCIOBIOL, V9, P101, DOI 10.1016/0162-3095(88)90016-7; Duffy KG, 2007, CURR BIOL, V17, pR586, DOI 10.1016/j.cub.2007.06.001; Dufour V, 2007, J COMP PSYCHOL, V121, P145, DOI 10.1037/0735-7036.121.2.145; Glazko GV, 2003, MOL BIOL EVOL, V20, P424, DOI 10.1093/molbev/msg050; HYATT CW, 1988, BEHAV PROCESS, V42, P177; LEFEBVRE L, 1982, J HUM EVOL, V11, P195, DOI 10.1016/S0047-2484(82)80036-5; Mitani JC, 2006, COOPERATION IN PRIMATES AND HUMANS: MECHANISMS AND EVOLUTIONS, P107, DOI 10.1007/3-540-28277-7_6; Paquette D., 1992, Human Evolution, V7, P11, DOI 10.1007/BF02436256; Rumbaugh D. M., 2003, INTELLIGENCE APES OT; SAVAGERUMBAUGH ES, 1978, BEHAV BRAIN SCI, V1, P539, DOI 10.1017/S0140525X00076536; Smith A, 2004, WEALTH NATIONS; Sousa C, 2001, Anim Cogn, V4, P213, DOI 10.1007/s100710100104; THEIRRY B, 1989, BEHAVIOUR, V110, P294; TOMASELLO M, 1993, CHILD DEV, V64, P1688, DOI 10.1111/j.1467-8624.1993.tb04207.x; Watts DP, 2002, BEHAVIOUR, V139, P343, DOI 10.1163/156853902760102708; WESTERGAARD GC, 2007, TOKEN MEDIATED TOOL	27	19	19	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1518	10.1371/journal.pone.0001518	http://dx.doi.org/10.1371/journal.pone.0001518			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	366SR	18231604	Green Published, gold			2022-12-25	WOS:000260504200030
J	Chesler, AT; Le Pichon, CE; Brann, JH; Araneda, RC; Zou, DJ; Firestein, S				Chesler, Alexander T.; Le Pichon, Claire E.; Brann, Jessica H.; Araneda, Ricardo C.; Zou, Dong-Jing; Firestein, Stuart			Selective Gene Expression by Postnatal Electroporation during Olfactory Interneuron Neurogenesis	PLOS ONE			English	Article								Neurogenesis persists in the olfactory system throughout life. The mechanisms of how new neurons are generated, how they integrate into circuits, and their role in coding remain mysteries. Here we report a technique that will greatly facilitate research into these questions. We found that electroporation can be used to robustly and selectively label progenitors in the Subventicular Zone. The approach was performed postnatally, without surgery, and with near 100% success rates. Labeling was found in all classes of intemeurons in the olfactory bulb, persisted to adulthood and had no adverse effects. The broad utility of electroporation was demonstrated by encoding a calcium sensor and markers of intracellular organelles. The approach was found to be effective in wildtype and transgenic mice as well as rats. Given its versatility, robustness, and both time and cost effectiveness, this method offers a powerful new way to use genetic manipulation to understand adult neurogenesis.	[Chesler, Alexander T.; Le Pichon, Claire E.; Brann, Jessica H.; Zou, Dong-Jing; Firestein, Stuart] Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; [Araneda, Ricardo C.] Univ Maryland, Dept Biol, College Pk, MD USA	Columbia University; University System of Maryland; University of Maryland College Park	Firestein, S (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	sjf24@columbia.edu	Araneda, Ricardo/AAN-1051-2020; Brann, Jessica/B-4031-2010; Le Pichon, Claire/ABB-9829-2020; Chesler, Alexander/V-2748-2019	Araneda, Ricardo/0000-0001-8728-3063; Le Pichon, Claire/0000-0002-9274-3615; Chesler, Alexander/0000-0002-3131-0728	NIH; NIDCD	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDCD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	NIH, NIDCD	Belluzzi O, 2003, J NEUROSCI, V23, P10411; Borrell V, 2005, J NEUROSCI METH, V143, P151, DOI 10.1016/j.jneumeth.2004.09.027; Carleton A, 2003, NAT NEUROSCI, V6, P507, DOI 10.1038/nn1048; Diez-Garcia J, 2007, NEUROIMAGE, V34, P859, DOI 10.1016/j.neuroimage.2006.10.021; Doetsch F, 2005, CURR OPIN NEUROBIOL, V15, P121, DOI 10.1016/j.conb.2005.01.018; Ehlers MD, 2007, NEURON, V55, P686, DOI 10.1016/j.neuron.2007.08.009; Haas K, 2001, NEURON, V29, P583, DOI 10.1016/S0896-6273(01)00235-5; Konishi Y, 2004, SCIENCE, V303, P1026, DOI 10.1126/science.1093712; Lee MY, 2006, P NATL ACAD SCI USA, V103, P13232, DOI 10.1073/pnas.0605757103; Lledo PM, 2006, NAT REV NEUROSCI, V7, P179, DOI 10.1038/nrn1867; Matsuda T, 2004, P NATL ACAD SCI USA, V101, P16, DOI 10.1073/pnas.2235688100; Matsuda T, 2007, P NATL ACAD SCI USA, V104, P1027, DOI 10.1073/pnas.0610155104; Merkle FT, 2007, SCIENCE, V317, P381, DOI 10.1126/science.1144914; Miyasaka N, 1999, NEUROREPORT, V10, P2319, DOI 10.1097/00001756-199908020-00018; Potter SM, 2001, J NEUROSCI, V21, P9713, DOI 10.1523/JNEUROSCI.21-24-09713.2001; Puopolo M, 1998, EUR J NEUROSCI, V10, P1073, DOI 10.1046/j.1460-9568.1998.00115.x; Qiu DL, 2007, J NEUROSCI, V27, P3408, DOI 10.1523/JNEUROSCI.4831-06.2007; Swartz M, 2001, DEV BIOL, V233, P13, DOI 10.1006/dbio.2001.0181; Tallini YN, 2006, P NATL ACAD SCI USA, V103, P4753, DOI 10.1073/pnas.0509378103; Ye B, 2007, CELL, V130, P717, DOI 10.1016/j.cell.2007.06.032; Young KM, 2007, J NEUROSCI, V27, P8286, DOI 10.1523/JNEUROSCI.0476-07.2007	21	39	39	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1517	10.1371/journal.pone.0001517	http://dx.doi.org/10.1371/journal.pone.0001517			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SR	18231603	Green Published, Green Submitted, gold			2022-12-25	WOS:000260504200029
J	Deshpande, A; Win, KM; Busciglio, J				Deshpande, Atul; Win, Khin May; Busciglio, Jorge			Tau isoform expression and regulation in human cortical neurons	FASEB JOURNAL			English	Article						tauopathy; Alzheimer; phosphorylation; phosphatase; cytoskeleton	PAIRED HELICAL FILAMENTS; PROTEIN PHOSPHATASE 2A; MICROTUBULE-ASSOCIATED PROTEINS; INHERITED DEMENTIA FTDP-17; ALZHEIMERS-DISEASE; MESSENGER-RNA; PHOSPHORYLATION STATE; NEURODEGENERATIVE DISEASES; FUNCTIONAL DIFFERENCES; MONOCLONAL-ANTIBODIES	Differential expression, activity, phosphorylation, and oligomerization of tau play a critical role during neuronal development and in a number of age-related neurodegenerative diseases. An experimental system that accurately models the molecular changes involved in tauopathies, particularly changes in tau isoform activity, requires the expression at physiological levels of the full complement of tau isoforms present in the adult human brain. To this end, we analyzed tau expression in human cortical neurons (HCNs) in culture. Here, we show that the isoform profile of tau in HCNs is similar to that in the adult human brain and that isoform expression is regulated during neuronal development and by cellular substrates. Interestingly, 4R tau exhibited a distinct pattern of expression and subcellular localization, suggesting the presence of specific functional roles for tau isoforms in HCNs. Tau phosphorylation, microtubule binding, and subcellular localization were markedly altered by pharmacological manipulation of tau-directed phosphatase activities, which also induced the appearance of tau oligomeric forms associated with memory loss in animal models of tauopathy. Thus, experimentally induced changes in tau activity and function in HCNs recapitulate critical features of tauopathies that may lead to neuronal dysfunction and degeneration in the human brain.	Univ Calif Irvine, Dept Neurobiol & Behav, Irvine, CA 92697 USA; Univ Calif Irvine, Inst Brain Aging & Dementia, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Busciglio, J (corresponding author), Univ Calif Irvine, Dept Neurobiol & Behav, MH 2205, Irvine, CA 92697 USA.	jbuscigl@uci.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038466] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-38466] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALONSO A, 2006, ALZHEIMERS DEMENT, V2, pS29; ANDREADIS A, 1992, BIOCHEMISTRY-US, V31, P10626, DOI 10.1021/bi00158a027; Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; Baba Y, 2005, BIOORGAN MED CHEM, V13, P5164, DOI 10.1016/j.bmc.2005.05.013; Berger Z, 2007, J NEUROSCI, V27, P3650, DOI 10.1523/JNEUROSCI.0587-07.2007; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; BUSCIGLIO J, 1995, NEURON, V14, P879, DOI 10.1016/0896-6273(95)90232-5; COUCHIE D, 1985, J CELL BIOL, V101, P2095, DOI 10.1083/jcb.101.6.2095; D'Souza I, 1999, P NATL ACAD SCI USA, V96, P5598, DOI 10.1073/pnas.96.10.5598; Davies P, 2000, ANN NY ACAD SCI, V924, P8, DOI 10.1111/j.1749-6632.2000.tb05553.x; de Silva R, 2003, NEUROPATH APPL NEURO, V29, P288, DOI 10.1046/j.1365-2990.2003.00463.x; Deshpande A, 2006, J NEUROSCI, V26, P6011, DOI 10.1523/JNEUROSCI.1189-06.2006; DiTella MC, 1996, J CELL SCI, V109, P467; DOTTI CG, 1988, J NEUROSCI, V8, P1454; ENAN E, 1992, BIOCHEM PHARMACOL, V43, P1777, DOI 10.1016/0006-2952(92)90710-Z; Fujino Y, 2005, J NEUROPATH EXP NEUR, V64, P209, DOI 10.1093/jnen/64.3.209; GOEDERT M, 1995, J NEUROCHEM, V65, P2804; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOEDERT M, 1992, FEBS LETT, V312, P95, DOI 10.1016/0014-5793(92)81418-L; Goode BL, 2000, J BIOL CHEM, V275, P38182, DOI 10.1074/jbc.M007489200; Grace EA, 2003, J NEUROSCI, V23, P493, DOI 10.1523/JNEUROSCI.23-02-00493.2003; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; Grover A, 1999, J BIOL CHEM, V274, P15134, DOI 10.1074/jbc.274.21.15134; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; Hall GF, 2000, J CELL SCI, V113, P1373; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; HONKANEN RE, 1993, FEBS LETT, V330, P283, DOI 10.1016/0014-5793(93)80889-3; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Ingelsson M, 2006, ACTA NEUROPATHOL, V112, P439, DOI 10.1007/s00401-006-0095-3; Iqbal K, 2006, J ALZHEIMERS DIS, V9, P219; Johnson GVW, 2004, J CELL SCI, V117, P5721, DOI 10.1242/jcs.01558; Kampers T, 1999, FEBS LETT, V451, P39, DOI 10.1016/S0014-5793(99)00522-0; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kins S, 2001, J BIOL CHEM, V276, P38193; KOSIK KS, 1989, NEURON, V2, P1389, DOI 10.1016/0896-6273(89)90077-9; KOSIK KS, 1986, P NATL ACAD SCI USA, V83, P4044, DOI 10.1073/pnas.83.11.4044; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Levy SF, 2005, J BIOL CHEM, V280, P13520, DOI 10.1074/jbc.M413490200; LI YM, 1993, BIOCHEM PHARMACOL, V46, P1435, DOI 10.1016/0006-2952(93)90109-A; Liao H, 1998, J BIOL CHEM, V273, P21901, DOI 10.1074/jbc.273.34.21901; Liu F, 2005, EUR J NEUROSCI, V22, P1942, DOI 10.1111/j.1460-9568.2005.04391.x; Makrides V, 2003, J BIOL CHEM, V278, P33298, DOI 10.1074/jbc.M305207200; MAWALDEWAN M, 1994, J BIOL CHEM, V269, P30981; MCKEE AC, 1991, ANN NEUROL, V30, P156, DOI 10.1002/ana.410300206; Mills JC, 1998, J CELL SCI, V111, P625; NEVE RL, 1986, MOL BRAIN RES, V1, P271, DOI 10.1016/0169-328X(86)90033-1; Pelsman A, 2003, INT J DEV NEUROSCI, V21, P117, DOI 10.1016/S0736-5748(03)00031-5; PENG I, 1985, BRAIN RES, V361, P200, DOI 10.1016/0006-8993(85)91290-9; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; Sennvik K, 2007, FASEB J, V21, P2149, DOI 10.1096/fj.06-7735com; Sergeant N, 2001, HUM MOL GENET, V10, P2143, DOI 10.1093/hmg/10.19.2143; SMITH CJ, 1995, FEBS LETT, V375, P243, DOI 10.1016/0014-5793(95)01221-Y; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; Stoothoff WH, 2005, BBA-MOL BASIS DIS, V1739, P280, DOI 10.1016/j.bbadis.2004.06.017; Takanashi M, 2002, MOL BRAIN RES, V104, P210, DOI 10.1016/S0169-328X(02)00382-0; Thies E, 2007, J NEUROSCI, V27, P2896, DOI 10.1523/JNEUROSCI.4674-06.2007; Utton MA, 2001, J BIOL CHEM, V276, P34288, DOI 10.1074/jbc.M011384200; Vogelsberg-Ragaglia V, 2001, EXP NEUROL, V168, P402, DOI 10.1006/exnr.2001.7630; Wen ZX, 2004, NEURON, V43, P835, DOI 10.1016/j.neuron.2004.08.037; Yasojima K, 1999, BRAIN RES, V831, P301, DOI 10.1016/S0006-8993(99)01486-9; Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010	69	31	34	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2357	2367		10.1096/fj.07-096909	http://dx.doi.org/10.1096/fj.07-096909			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18263702				2022-12-25	WOS:000257292500028
J	Jacob, E; Hod-Dvorai, R; Schif-Zuck, S; Avni, O				Jacob, Eyal; Hod-Dvorai, Reut; Schif-Zuck, Sagie; Avni, Orly			Unconventional association of the polycomb group proteins with cytokine genes in differentiated T helper cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							TRANSCRIPTION FACTOR YY1; LOCUS-CONTROL REGION; RANGE INTRACHROMOSOMAL INTERACTIONS; HISTONE METHYLTRANSFERASE ACTIVITY; EMBRYONIC STEM-CELLS; INTERFERON-GAMMA; TH2 CELLS; DROSOPHILA-MELANOGASTER; RESPONSE ELEMENTS; DEVELOPMENTAL REGULATORS	The cytokine transcription profiles of developing T helper 1 and T helper 2 cells are imprinted and induced appropriately following stimulation of differentiated cells. Epigenetic regulation combines several mechanisms to ensure the inheritance of transcriptional programs. We found that the expression of the polycomb group proteins, whose role in maintaining gene silencing is well documented, was induced during development in both T helper lineages. Nevertheless, the polycomb proteins, YY1, Mel-18, Ring1A, Ezh2, and Eed, bound to the Il4 and Ifng loci in a differential pattern. In contrast to the prevailing dogma, the binding activity of the polycomb proteins in differentiated T helper cells was associated with cytokine transcription. The polycomb proteins bound to the cytokine genes under resting conditions, and their binding was induced dynamically following stimulation. The recruitment of the polycomb proteins Mel-18 and Ezh2 to the cytokine promoters was inhibited in the presence of cyclosporine A, suggesting the involvement of NFAT. Considering their binding pattern at the cytokine genes and their known function in higher order folding of regulatory elements, we propose a model whereby the polycomb proteins, in some contexts, positively regulate gene expression by mediating long-distance chromosomal interactions.	[Jacob, Eyal; Hod-Dvorai, Reut; Schif-Zuck, Sagie; Avni, Orly] Technion Israel Inst Technol, Rappaport Fac Med, Dept Immunol, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Avni, O (corresponding author), Efron 1 St, IL-31096 Haifa, Israel.	oavni@tx.technion.ac.il	Hod-Dvorai, Reut/H-9791-2019	Hod-Dvorai, Reut/0000-0001-6748-5733; Schif-Zuck, Sagie/0000-0001-5415-9488				Afkarian M, 2002, NAT IMMUNOL, V3, P549, DOI 10.1038/ni794; Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Agarwal S, 2000, IMMUNITY, V12, P643, DOI 10.1016/S1074-7613(00)80215-0; Akasaka T, 1996, DEVELOPMENT, V122, P1513; Akasaka T, 1997, IMMUNITY, V7, P135, DOI 10.1016/S1074-7613(00)80516-6; Ansel KM, 2006, ANNU REV IMMUNOL, V24, P607, DOI 10.1146/annurev.immunol.23.021704.115821; Ansel KM, 2004, NAT IMMUNOL, V5, P1251, DOI 10.1038/ni1135; Avni O, 2002, NAT IMMUNOL, V3, P643, DOI 10.1038/ni808; Bantignies F, 2006, CURR OPIN CELL BIOL, V18, P275, DOI 10.1016/j.ceb.2006.04.003; Ben-Saadon R, 2006, MOL CELL, V24, P701, DOI 10.1016/j.molcel.2006.10.022; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Brock HW, 2005, DEV DYNAM, V232, P633, DOI 10.1002/dvdy.20298; Buchenau P, 1998, J CELL BIOL, V141, P469, DOI 10.1083/jcb.141.2.469; Buchwald G, 2006, EMBO J, V25, P2465, DOI 10.1038/sj.emboj.7601144; Cai ST, 2006, NAT GENET, V38, P1278, DOI 10.1038/ng1913; Calame K, 2007, GENE DEV, V21, P1145, DOI 10.1101/gad.1559007; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002; Chang SJ, 2007, NAT IMMUNOL, V8, P723, DOI 10.1038/ni1473; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; de Napoles M, 2004, DEV CELL, V7, P663, DOI 10.1016/j.devcel.2004.10.005; Dietzel S, 1999, CHROMOSOMA, V108, P83, DOI 10.1007/s004120050355; Djuretic IM, 2007, NAT IMMUNOL, V8, P145, DOI 10.1038/ni1424; Donohoe ME, 1999, MOL CELL BIOL, V19, P7237; Eivazova ER, 2007, GENES IMMUN, V8, P35, DOI 10.1038/sj.gene.6364349; Eivazova ER, 2004, P NATL ACAD SCI USA, V101, P251, DOI 10.1073/pnas.0303919101; Ficz G, 2005, DEVELOPMENT, V132, P3963, DOI 10.1242/dev.01950; Fields PE, 2004, IMMUNITY, V21, P865, DOI 10.1016/j.immuni.2004.10.015; Fields PE, 2002, J IMMUNOL, V169, P647, DOI 10.4049/jimmunol.169.2.647; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; Fujimura Y, 2006, DEVELOPMENT, V133, P2371, DOI 10.1242/dev.02405; Gordon S, 2006, ONCOGENE, V25, P1125, DOI 10.1038/sj.onc.1209080; Grimaud C, 2006, CELL, V124, P957, DOI 10.1016/j.cell.2006.01.036; Grimaud C, 2006, CHROMOSOME RES, V14, P363, DOI 10.1007/s10577-006-1069-y; Guo J, 2001, J BIOL CHEM, V276, P48871, DOI 10.1074/jbc.M101592200; Guo LY, 2004, IMMUNITY, V20, P193, DOI 10.1016/S1074-7613(04)00025-1; Ho IC, 2007, CELL MOL IMMUNOL, V4, P15; Hobert O, 1996, MOL CELL BIOL, V16, P3066; Hosokawa H, 2006, J IMMUNOL, V177, P7656, DOI 10.4049/jimmunol.177.11.7656; Kajiume T, 2004, EXP HEMATOL, V32, P571, DOI 10.1016/j.exphem.2004.03.001; Kimura M, 2001, IMMUNITY, V15, P275, DOI 10.1016/S1074-7613(01)00182-0; Kosak ST, 2002, SCIENCE, V296, P158, DOI 10.1126/science.1068768; Koyanagi M, 2005, J BIOL CHEM, V280, P31470, DOI 10.1074/jbc.M504766200; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Kuzmichev A, 2004, MOL CELL, V14, P183, DOI 10.1016/S1097-2765(04)00185-6; Lee DU, 2004, P NATL ACAD SCI USA, V101, P16010, DOI 10.1073/pnas.0407031101; Lee DU, 2004, J BIOL CHEM, V279, P4802, DOI 10.1074/jbc.M307904200; Lee GR, 2006, IMMUNITY, V24, P369, DOI 10.1016/j.immuni.2006.03.007; Lee GR, 2005, NAT IMMUNOL, V6, P42, DOI 10.1038/ni1148; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Lessard J, 2003, EXP HEMATOL, V31, P567, DOI 10.1016/S0301-472X(03)00081-X; Levine SS, 2004, TRENDS BIOCHEM SCI, V29, P478, DOI 10.1016/j.tibs.2004.07.007; Lighvani AA, 2001, P NATL ACAD SCI USA, V98, P15137, DOI 10.1073/pnas.261570598; Liu HF, 2007, GENE DEV, V21, P1179, DOI 10.1101/gad.1529307; Lorente MD, 2000, DEVELOPMENT, V127, P5093; Martinez AM, 2006, CELL CYCLE, V5, P1189, DOI 10.4161/cc.5.11.2781; Messi M, 2003, NAT IMMUNOL, V4, P78, DOI 10.1038/ni872; Miyagishima H, 2003, HISTOCHEM CELL BIOL, V120, P111, DOI 10.1007/s00418-003-0551-2; Monticelli S, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-r71; Muller J, 2006, CURR OPIN GENET DEV, V16, P476, DOI 10.1016/j.gde.2006.08.005; Mullen AC, 2002, NAT IMMUNOL, V3, P652, DOI 10.1038/ni807; Mullen AC, 2001, SCIENCE, V292, P1907, DOI 10.1126/science.1059835; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Negre N, 2006, PLOS BIOL, V4, P917, DOI 10.1371/journal.pbio.0040170; Ogawa M, 2003, IMMUNOL LETT, V86, P57, DOI 10.1016/S0165-2478(02)00293-6; Otte AP, 2003, CURR OPIN GENET DEV, V13, P448, DOI 10.1016/S0959-437X(03)00108-4; Pai SY, 2004, P NATL ACAD SCI USA, V101, P1993, DOI 10.1073/pnas.0308697100; Palko L, 2004, J CELL SCI, V117, P465, DOI 10.1242/jcs.00870; Raaphorst FM, 2001, TRENDS IMMUNOL, V22, P682, DOI 10.1016/S1471-4906(01)02082-8; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Razin SV, 2007, J MOL BIOL, V369, P597, DOI 10.1016/j.jmb.2007.04.003; Rezai-Zadeh N, 2003, GENE DEV, V17, P1019, DOI 10.1101/gad.1068003; Rincon-Arano H, 2005, J MOL BIOL, V349, P961, DOI 10.1016/j.jmb.2005.04.040; Ringrose L, 2004, MOL CELL, V16, P641, DOI 10.1016/j.molcel.2004.10.015; Ringrose L, 2007, DEVELOPMENT, V134, P223, DOI 10.1242/dev.02723; Schoorlemmer J, 1997, EMBO J, V16, P5930, DOI 10.1093/emboj/16.19.5930; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; Schwartz YB, 2007, NAT REV GENET, V8, P9, DOI 10.1038/nrg1981; Schwartz YB, 2006, NAT GENET, V38, P700, DOI 10.1038/ng1817; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shi Y, 1997, BBA-REV CANCER, V1332, pF49, DOI 10.1016/S0304-419X(96)00044-3; Silva J, 2003, DEV CELL, V4, P481, DOI 10.1016/S1534-5807(03)00068-6; Skok JA, 2007, NAT IMMUNOL, V8, P378, DOI 10.1038/ni1448; Solymar DC, 2002, IMMUNITY, V17, P41, DOI 10.1016/S1074-7613(02)00334-5; Soutto M, 2002, J IMMUNOL, V169, P4205, DOI 10.4049/jimmunol.169.8.4205; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Spilianakis CG, 2004, NAT IMMUNOL, V5, P1017, DOI 10.1038/ni1115; Spilianakis CG, 2005, NATURE, V435, P637, DOI 10.1038/nature03574; Su I, 2005, CELL, V121, P425, DOI 10.1016/j.cell.2005.02.029; Su IH, 2003, NAT IMMUNOL, V4, P124, DOI 10.1038/ni876; Sweetser MT, 1998, J BIOL CHEM, V273, P34775, DOI 10.1074/jbc.273.52.34775; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Szabo SJ, 2002, SCIENCE, V295, P338, DOI 10.1126/science.1065543; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; Tolhuis B, 2006, NAT GENET, V38, P694, DOI 10.1038/ng1792; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Voncken JW, 1999, J CELL SCI, V112, P4627; Voncken JW, 2005, J BIOL CHEM, V280, P5178, DOI 10.1074/jbc.M407155200; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Witte V, 2004, MOL CELL, V13, P179, DOI 10.1016/S1097-2765(04)00004-8; Yamashita M, 2004, J BIOL CHEM, V279, P26983, DOI 10.1074/jbc.M403688200; Yamashita M, 2004, J BIOL CHEM, V279, P39454, DOI 10.1074/jbc.M405989200; Yamashita M, 2002, J BIOL CHEM, V277, P42399, DOI 10.1074/jbc.M205876200; Yamashita M, 2006, IMMUNITY, V24, P611, DOI 10.1016/j.immuni.2006.03.017; Ye JP, 1996, MOL CELL BIOL, V16, P4744; Zhu JF, 2004, NAT IMMUNOL, V5, P1157, DOI 10.1038/ni1128	107	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2008	283	19					13471	13481		10.1074/jbc.M709886200	http://dx.doi.org/10.1074/jbc.M709886200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295UQ	18285333	hybrid			2022-12-25	WOS:000255499800086
J	Yoo, YG; Na, TY; Seo, HW; Seong, JK; Park, CK; Shin, YK; Lee, MO				Yoo, Y-G; Na, T-Y; Seo, H-W; Seong, J. K.; Park, C. K.; Shin, Y. K.; Lee, M-O			Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells	ONCOGENE			English	Article						HBx; metastasis-associated protein; histone deacetylase; hepatitis B virus; hypoxia-inducible factor-1 alpha	HISTONE DEACETYLASE INHIBITORS; INDUCIBLE FACTOR 1-ALPHA; HBX PROTEIN; HEPATOMA-CELLS; GROWTH-FACTOR; METASTASIS; ACETYLATION; GENE; HIF-1-ALPHA; ACTIVATION	Expression level of metastasis-associated protein 1 (MTA1) is closely related to tumor growth and metastasis in various cancers. Although increased expression level of MTA1 was observed in hepatocellular carcinoma (HCC), role of MTA1 complex containing histone deacetylase (HDAC) in hepatitis B virus (HBV)-associated hepatocarcinogenesis has not been studied. Here, we demonstrated that HBx strongly induced the expression of MTA1 and HDAC1 genes at transcription level. MTA1 and HDAC1/2 physically associated with hypoxia-inducible factor-1 alpha (HIF-1 alpha) in vivo in the presence of HBx, which was abolished by knockdown of MTA1 by short interfering RNA (siRNA). HBx induced deacetylation of the oxygen-dependent degradation domain of HIF-1 alpha, which was accompanied with dissociation of prolyl hydroxylases and von Hippel-Lindau tumor suppressor from HIF-1 alpha. These results indicate that HBx-induced deacetylation is important for proteasomal degradation of HIF-1 alpha. Further, we observed that protein levels of MTA1 and HDAC1 were increased in the liver of HBx-transgenic mice. Also, there was a higher expression of HDAC1 in HCC than in the adjacent non-tumorous cirrhotic nodules in 10 out of 12 human HBV-associated HCC specimens. Together, our data indicate a positive cross talk between HBx and the MTA1/HDAC complex in stabilizing HIF-1 alpha, which may play a critical role in angiogenesis and metastasis of HBV-associated HCC.	[Yoo, Y-G; Na, T-Y; Seo, H-W; Shin, Y. K.; Lee, M-O] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea; [Yoo, Y-G; Na, T-Y; Seo, H-W; Lee, M-O] Seoul Natl Univ, Bio MAX Inst, Seoul 151742, South Korea; [Seong, J. K.] Seoul Natl Univ, Coll Vet Med, Seoul 151742, South Korea; [Park, C. K.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Sungkyunkwan University (SKKU); Samsung Medical Center	Lee, MO (corresponding author), Seoul Natl Univ, Coll Pharm, San 56-1 Shillim Dong, Seoul 151742, South Korea.	molee@snu.ac.kr	Shin, Young Kee/C-8929-2011	Shin, Young Kee/0000-0003-0896-718X; Seong, Je Kyung/0000-0003-1177-6958				Armeanu S, 2005, J HEPATOL, V42, P210, DOI 10.1016/j.jhep.2004.10.020; Arnesen T, 2005, FEBS LETT, V579, P6428, DOI 10.1016/j.febslet.2005.10.036; Bilton R, 2005, J BIOL CHEM, V280, P31132, DOI 10.1074/jbc.M504482200; Bilton R, 2006, TRENDS CELL BIOL, V16, P616, DOI 10.1016/j.tcb.2006.10.002; Brahimi-Horn C, 2005, CELL SIGNAL, V17, P1, DOI 10.1016/j.cellsig.2004.04.010; Caron C, 2003, BIOESSAYS, V25, P58, DOI 10.1002/bies.10202; Chan DW, 2006, J PATHOL, V208, P372, DOI 10.1002/path.1901; Chang CC, 2006, JNCI-J NATL CANCER I, V98, P984, DOI 10.1093/jnci/djj242; Chung TW, 2004, FASEB J, V18, P1123, DOI 10.1096/fj.03-1429fje; Cougot D, 2005, J CLIN VIROL, V34, pS75, DOI 10.1016/S1386-6532(05)80014-9; Fath DM, 2006, J BIOL CHEM, V281, P13612, DOI 10.1074/jbc.M600456200; Fisher TS, 2005, J BIOL CHEM, V280, P17749, DOI 10.1074/jbc.M412055200; Frati A, 2002, J EXP CLIN CANC RES, V21, P321; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Hamatsu T, 2003, ONCOL REP, V10, P599; Huang GW, 2005, WORLD J GASTROENTERO, V11, P1705; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Kim SH, 2007, ONCOL REP, V17, P647; KONDO Y, 1991, HUM PATHOL, V22, P125, DOI 10.1016/0046-8177(91)90033-L; Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006; Kumar R, 2003, SEMIN ONCOL, V30, P30, DOI 10.1053/j.seminoncol.2003.08.005; Lara-Pezzi E, 2002, J CLIN INVEST, V110, P1831, DOI 10.1172/JCI200215887; Lara-Pezzi E, 2001, J HEPATOL, V34, P409, DOI 10.1016/S0168-8278(00)00090-8; Lara-Pezzi E, 2001, ONCOGENE, V20, P3323, DOI 10.1038/sj.onc.1204451; Maxwell PH, 2005, SEMIN CELL DEV BIOL, V16, P523, DOI 10.1016/j.semcdb.2005.03.001; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Mishra SK, 2003, J BIOL CHEM, V278, P19209, DOI 10.1074/jbc.M301968200; Moon EJ, 2003, FASEB J, V17, P382, DOI 10.1096/fj.03-0153fje; Moon WS, 2004, HUM PATHOL, V35, P424, DOI 10.1016/j.humpath.2003.11.007; Murakami S, 2001, J GASTROENTEROL, V36, P651, DOI 10.1007/s005350170027; Murray-Rust TA, 2006, FEBS LETT, V580, P1911, DOI 10.1016/j.febslet.2006.02.012; Nicolson GL, 2003, CLIN EXP METASTAS, V20, P19, DOI 10.1023/A:1022534217769; Ou DP, 2006, DIGEST LIVER DIS, V38, P262, DOI 10.1016/j.dld.2005.10.027; Pathil A, 2006, HEPATOLOGY, V43, P425, DOI 10.1002/hep.21054; Qian DZ, 2006, CANCER RES, V66, P8814, DOI 10.1158/0008-5472.CAN-05-4598; Toh Y, 1999, BRIT J CANCER, V79, P1723, DOI 10.1038/sj.bjc.6690274; TOH Y, 1994, J BIOL CHEM, V269, P22958; Wada H, 2006, LIVER INT, V26, P414, DOI 10.1111/j.1478-3231.2006.01243.x; Wang LH, 2007, CLIN CANCER RES, V13, P102, DOI 10.1158/1078-0432.CCR-06-1467; Wu BK, 2006, BIOCHEM BIOPH RES CO, V340, P916, DOI 10.1016/j.bbrc.2005.12.089; Yeo MG, 2005, MOL ENDOCRINOL, V19, P950, DOI 10.1210/me.2004-0209; Yoo YG, 2006, EMBO J, V25, P1231, DOI 10.1038/sj.emboj.7601025; Yoo YG, 2004, FEBS LETT, V577, P121, DOI 10.1016/j.febslet.2004.10.004; Yoo YG, 2003, J BIOL CHEM, V278, P39076, DOI 10.1074/jbc.M305101200; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; Yu FL, 2005, J HEPATOL, V42, P520, DOI 10.1016/j.jhep.2004.11.031; Yun C, 2002, CANCER LETT, V184, P97, DOI 10.1016/S0304-3835(02)00187-8; Zhang XD, 2006, J LAB CLIN MED, V147, P58, DOI 10.1016/j.lab.2005.10.003	50	131	140	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	24					3405	3413		10.1038/sj.onc.1211000	http://dx.doi.org/10.1038/sj.onc.1211000			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18264140				2022-12-25	WOS:000256309900005
J	Zhang, Y; Mckay, SE; Bewley, B; Kaczmarek, LK				Zhang, Yalan; Mckay, Sharen E.; Bewley, Benoit; Kaczmarek, Leonard K.			Repetitive firing triggers clustering of kv2.1 potassium channels in aplysia neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BAG CELL NEURONS; DELAYED-RECTIFIER PROPERTIES; K+ CHANNEL; HIPPOCAMPAL-NEURONS; PEPTIDERGIC NEURONS; ABDOMINAL-GANGLION; EXPRESSION; AFTERDISCHARGE; LOCALIZATION; MODULATION	The Kv2.1 gene encodes a highly conserved delayed rectifier potassium channel that is widely expressed in neurons of the central nervous system. In the bag cell neurons of Aplysia, Kv2.1 channels contribute to the repolarization of action potentials during a prolonged after discharge that triggers a series of reproductive behaviors. Partial inactivation of Aplysia Kv2.1 during repetitive firing produces frequency-dependent broadening of action potentials during the after discharge. We have now found that, as in mammalian neurons, Kv2.1 channels in bag cell neurons are localized to ring-like clusters in the plasma membrane of the soma and proximal dendrites. Either elevation of cyclic AMP levels or direct electrical stimulation of after discharge rapidly enhanced formation of these clusters on the somata of these neurons. In contrast, injection of a 13-amino acid peptide corresponding to a region in the C terminus that is required for clustering of Kv2.1 channels produced disassociation of the clusters, resulting in a more uniform distribution over the somata. Voltage clamp recordings demonstrated that peptide-induced dissociation of the Kv2.1 clusters is associated with an increase in the amplitude of delayed rectifier current and a shift of activation toward more negative potentials. In current clamp recording, injection of the unclustering peptide reduced the width of action potentials and reduced frequency-dependent broadening of action potentials. Our results suggest that rapid redistribution of Kv2.1 channels occurs during physiological changes in neuronal excitability.	[Zhang, Yalan; Bewley, Benoit; Kaczmarek, Leonard K.] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; [Mckay, Sharen E.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA	Yale University; Yale University	Kaczmarek, LK (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.	leonard.kaczmarek@yale.edu						Antonucci DE, 2001, NEUROSCIENCE, V108, P69, DOI 10.1016/S0306-4522(01)00476-6; ARCH S, 1989, BRAIN RES REV, V14, P181, DOI 10.1016/0165-0173(89)90014-3; AZHDERIAN EM, 1994, NEURON, V12, P1223, DOI 10.1016/0896-6273(94)90439-1; Blaine JT, 2001, J NEUROSCI, V21, P1473, DOI 10.1523/JNEUROSCI.21-05-01473.2001; CHIU AY, 1981, J NEUROSCI, V1, P812; CHUN JY, 1994, NEURON, V12, P831, DOI 10.1016/0896-6273(94)90336-0; CONN PJ, 1989, MOL NEUROBIOL, V3, P237, DOI 10.1007/BF02740607; Du J, 1998, NEUROSCIENCE, V84, P37, DOI 10.1016/S0306-4522(97)00519-8; Du J, 2000, J PHYSIOL-LONDON, V522, P19, DOI 10.1111/j.1469-7793.2000.t01-2-00019.xm; DUDEK FE, 1976, SCIENCE, V192, P1009, DOI 10.1126/science.1273581; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; Jonas EA, 1996, J NEUROSCI, V16, P1645; Ju M, 2003, J BIOL CHEM, V278, P12769, DOI 10.1074/jbc.M212973200; KACZMAREK LK, 1981, J NEUROSCI, V1, P626; KACZMAREK LK, 1978, P NATL ACAD SCI USA, V75, P5200, DOI 10.1073/pnas.75.10.5200; KACZMAREK LK, 1984, J NEUROPHYSIOL, V52, P340, DOI 10.1152/jn.1984.52.2.340; KACZMAREK LK, 1979, J NEUROBIOL, V10, P535, DOI 10.1002/neu.480100604; KACZMAREK LK, 1982, BRAIN RES, V238, P105, DOI 10.1016/0006-8993(82)90774-0; KUPFERMANN I, 1970, J NEUROPHYSIOL, V33, P865, DOI 10.1152/jn.1970.33.6.865; Lim ST, 2000, NEURON, V25, P385, DOI 10.1016/S0896-6273(00)80902-2; LOECHNER KJ, 1990, BRAIN RES, V532, P1, DOI 10.1016/0006-8993(90)91733-W; Misonou H, 2005, NEUROTOXICOLOGY, V26, P743, DOI 10.1016/j.neuro.2005.02.003; Misonou H, 2004, NAT NEUROSCI, V7, P711, DOI 10.1038/nn1260; NAGLE GT, 1990, J BIOL CHEM, V265, P22329; PAK MD, 1991, J NEUROSCI, V11, P869; Park KS, 2006, SCIENCE, V313, P976, DOI 10.1126/science.1124254; QUATTROCKI EA, 1994, NEURON, V12, P73, DOI 10.1016/0896-6273(94)90153-8; Scannevin RH, 1996, J CELL BIOL, V135, P1619, DOI 10.1083/jcb.135.6.1619; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; Trimmer JS, 2004, ANNU REV PHYSIOL, V66, P477, DOI 10.1146/annurev.physiol.66.032102.113328; TRIMMER JS, 1990, DEV BIOL, V142, P360, DOI 10.1016/0012-1606(90)90356-N; Tsuk S, 2005, MOL PHARMACOL, V67, P480, DOI 10.1124/mol.104.005314; TSUNODA S, 1995, J NEUROSCI, V15, P5209; Wayne NL, 1998, GEN COMP ENDOCR, V109, P356, DOI 10.1006/gcen.1997.7040; White BH, 1997, J NEUROSCI, V17, P1582; WILSON WA, 1975, J NEUROBIOL, V6, P411, DOI 10.1002/neu.480060406	36	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10632	10641		10.1074/jbc.M800253200	http://dx.doi.org/10.1074/jbc.M800253200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18276591	hybrid			2022-12-25	WOS:000254894700045
J	Wong, CF; Tellam, RL				Wong, Chung Fai; Tellam, Ross L.			MicroRNA-26a targets the histone methyltransferase Enhancer of Zeste homolog 2 during myogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE DEVELOPMENT; GROUP PROTEIN EZH2; MESSENGER-RNA; CAENORHABDITIS-ELEGANS; DIFFERENTIATION; EXPRESSION; GENE; TRANSCRIPTION; MIR-206; CANCER	MicroRNA ( miRNA) are important regulators of many biological processes, but the targets for most miRNA are still poorly defined. In this study, we profiled the expression of miRNA during myogenesis, from proliferating myoblasts through to terminally differentiated myotubes. Microarray results identified six significantly differentially expressed miRNA that were more than 2-fold different in myotubes. From this list, miRNA-26a (miR-26a), an up-regulated miRNA, was further examined. Overexpression of miR-26a in murine myogenic C2C12 cells induced creatine kinase activity, an enzyme that markedly increases during myogenesis. Further, myoD and myogenin mRNA expression levels were also up-regulated. These results suggest that increased expression of miR-26a promotes myogenesis. Through a bioinformatics approach, we identified the histone methyltransferase, Enhancer of Zeste homolog 2 (Ezh2), as a potential target of miR-26a. Overexpression of miR-26a suppressed the activity of a luciferase reporter construct fused with the 3'-untranslated region of Ezh2. In addition, miR-26a overexpression decreased Ezh2 mRNA expression. These results reveal a model of regulation during myogenesis whereby the up-regulation of miR-26a acts to post-transcriptionally repress Ezh2, a known suppressor of skeletal muscle cell differentiation.	[Wong, Chung Fai; Tellam, Ross L.] Queensland Biosci Precinct, CSIRO Liverstock Ind, St Lucia, Qld 4067, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Tellam, RL (corresponding author), Queensland Biosci Precinct, CSIRO Liverstock Ind, 306 Carmody Rd,St, St Lucia, Qld 4067, Australia.	Ross.Tellam@csiro.Au	Tellam, Ross/H-2798-2013; Tellam, Ross/T-2423-2019	Tellam, Ross/0000-0003-2353-1640; 				Anderson C, 2006, NUCLEIC ACIDS RES, V34, P5863, DOI 10.1093/nar/gkl743; Barad O, 2004, GENOME RES, V14, P2486, DOI 10.1101/gr.2845604; Berry FB, 2001, J BIOL CHEM, V276, P25057, DOI 10.1074/jbc.M010378200; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Caretti G, 2004, GENE DEV, V18, P2627, DOI 10.1101/gad.1241904; Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242; Castoldi M, 2006, RNA, V12, P913, DOI 10.1261/rna.2332406; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Esau C, 2004, J BIOL CHEM, V279, P52361, DOI 10.1074/jbc.C400438200; EULALI A, 2007, GENE DEV, V20, P2258; Fisher CL, 1997, BIOTECHNIQUES, V23, P570, DOI 10.2144/97234bm01; Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Hartigan J. A., 1979, Applied Statistics, V28, P100, DOI 10.2307/2346830; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hornstein E, 2005, NATURE, V438, P671, DOI 10.1038/nature04138; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; KHANNA KK, 1995, ONCOGENE, V11, P609; Kim HK, 2006, J CELL BIOL, V174, P677, DOI 10.1083/jcb.200603008; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lagos-Quintana M, 2003, RNA, V9, P175, DOI 10.1261/rna.2146903; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Naguibneva I, 2006, NAT CELL BIOL, V8, P278, DOI 10.1038/ncb1373; Nakajima N, 2006, BIOCHEM BIOPH RES CO, V350, P1006, DOI 10.1016/j.bbrc.2006.09.153; O'Rourke JR, 2007, DEV BIOL, V311, P359, DOI 10.1016/j.ydbio.2007.08.032; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Rao PK, 2006, P NATL ACAD SCI USA, V103, P8721, DOI 10.1073/pnas.0602831103; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Rosenberg MI, 2006, J CELL BIOL, V175, P77, DOI 10.1083/jcb.200603039; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; Sokol NS, 2005, GENE DEV, V19, P2343, DOI 10.1101/gad.1356105; Tang XH, 2004, ONCOGENE, V23, P5759, DOI 10.1038/sj.onc.1207706; Tapscott SJ, 2005, DEVELOPMENT, V132, P2685, DOI 10.1242/dev.01874; Tomczak KK, 2003, FASEB J, V17, P403, DOI 10.1096/f.03-0568fje; Tonini T, 2004, ONCOGENE, V23, P4930, DOI 10.1038/sj.onc.1207608; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Visser HPJ, 2001, BRIT J HAEMATOL, V112, P950, DOI 10.1046/j.1365-2141.2001.02641.x; Vuocolo T, 2007, PHYSIOL GENOMICS, V28, P253, DOI 10.1152/physiolgenomics.00121.2006; Wilson DL, 2003, BIOINFORMATICS, V19, P1325, DOI 10.1093/bioinformatics/btg146; Wong CF, 2004, BIOCHEM BIOPH RES CO, V324, P497, DOI 10.1016/j.bbrc.2004.09.084; Wu LG, 2006, P NATL ACAD SCI USA, V103, P4034, DOI 10.1073/pnas.0510928103; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434; Zeng Y, 2003, P NATL ACAD SCI USA, V100, P9779, DOI 10.1073/pnas.1630797100	63	259	279	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9836	9843		10.1074/jbc.M709614200	http://dx.doi.org/10.1074/jbc.M709614200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18281287	hybrid			2022-12-25	WOS:000254671600039
J	Chavez, JA; Roach, WG; Keller, SR; Lane, WS; Lienhard, GE				Chavez, Jose A.; Roach, William G.; Keller, Susanna R.; Lane, William S.; Lienhard, Gustav E.			Inhibition of GLUT4 translocation by Tbc1d1, a Rab GTPase-activating protein abundant in skeletal muscle, is partially relieved by AMP-activated protein kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-STIMULATED PHOSPHORYLATION; GLUCOSE-TRANSPORT; 3T3-L1 ADIPOCYTES; AS160 PHOSPHORYLATION; AKT SUBSTRATE; CONTRACTION; DIFFERENTIATION; EXPRESSION; MEMBRANE; VESICLES	Insulin increases glucose transport by stimulating the trafficking of intracellular GLUT4 to the cell surface, a process known as GLUT4 translocation. A key protein in signaling this process is AS160, a Rab GTPase-activating protein ( GAP) whose activity appears to be suppressed by Akt phosphorylation. Tbc1d1 is a Rab GAP with a sequence highly similar to that of AS160 and with the same Rab specificity as that of AS160. The role of Tbc1d1 in regulating GLUT4 trafficking has been unclear. Our previous study showed that overexpressed Tbc1d1 inhibited insulin-stimulated GLUT4 translocation in 3T3-L1 adipocytes, even though insulin caused phosphorylation on its single canonical Akt motif. In the present study, we show in 3T3-L1 adipocytes that Tbc1d1 is only 1/20 as abundant as AS160, that knockdown of Tbc1d1 has no effect on insulin-stimulated GLUT4 translocation, and that overexpressed Tbc1d1 also inhibits GLUT4 translocation elicited by activated Akt expression. These results indicate that endogenous Tbc1d1 does not participate in insulin-regulated GLUT4 translocation in adipocytes and suggest that the GAP activity of Tbc1d1 is not suppressed by Akt phosphorylation. In addition, we discovered that Tbc1d1 is much more highly expressed in skeletal muscle than fat and that the AMP-activated protein kinase ( AMPK) activator 5'-aminoimidazole-4-carboxamide ribonucleoside partially reversed the inhibition of insulin-stimulated GLUT4 translocation by overexpressed Tbc1d1 in 3T3-L1 adipocytes. 5'-Aminoimidazole-4-carboxamide ribonucleoside activation of the kinase AMPK is known to cause GLUT4 translocation in muscle. The above findings strongly suggest that Tbc1d1 is a component in the signal transduction pathway leading to AMPK-stimulated GLUT4 translocation in muscle.	[Chavez, Jose A.; Roach, William G.; Lienhard, Gustav E.] Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA; [Keller, Susanna R.] Univ Virginia, Dept Med, Div Endocrinol, Charlottesville, VA 22908 USA; [Lane, William S.] Harvard Univ, Ctr Syst Biol, Mass Spectrometry & Prote Resource Lab, Cambridge, MA 02138 USA	Dartmouth College; University of Virginia; Harvard University	Lienhard, GE (corresponding author), Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA.	gustav.e.lienhard@dartmouth.edu			NCI NIH HHS [P30 CA023108] Funding Source: Medline; NIDDK NIH HHS [DK 42816, DK 25336, R56 DK025336, R01 DK042816, R01 DK025336] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK025336, R56DK042816, R01DK025336, R56DK025336, R01DK042816] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bruss MD, 2005, DIABETES, V54, P41, DOI 10.2337/diabetes.54.1.41; Chen SA, 2008, BIOCHEM J, V409, P449, DOI 10.1042/BJ20071114; Eguez L, 2005, CELL METAB, V2, P263, DOI 10.1016/j.cmet.2005.09.005; El-Jack AK, 1999, MOL BIOL CELL, V10, P1581, DOI 10.1091/mbc.10.5.1581; FROST SC, 1985, J BIOL CHEM, V260, P2646; Fujii N, 2006, AM J PHYSIOL-ENDOC M, V291, pE867, DOI 10.1152/ajpendo.00207.2006; Guo XM, 2000, GENE, V251, P45, DOI 10.1016/S0378-1119(00)00192-X; Horman S, 2002, CURR BIOL, V12, P1419, DOI 10.1016/S0960-9822(02)01077-1; Huang SH, 2007, CELL METAB, V5, P237, DOI 10.1016/j.cmet.2007.03.006; Jessen N, 2005, J APPL PHYSIOL, V99, P330, DOI 10.1152/japplphysiol.00175.2005; Jiang L, 2008, J BIOL CHEM, V283, P8508, DOI 10.1074/jbc.M708688200; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Karlsson HKR, 2005, DIABETES, V54, P1692, DOI 10.2337/diabetes.54.6.1692; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kramer HF, 2007, DIABETES, V56, P2854, DOI 10.2337/db07-0681; Kramer HF, 2006, J BIOL CHEM, V281, P31478, DOI 10.1074/jbc.M605461200; Kramer HF, 2006, DIABETES, V55, P2067, DOI 10.2337/db06-0150; LAMPHERE L, 1992, ENDOCRINOLOGY, V131, P2196, DOI 10.1210/en.131.5.2196; Mitra P, 2004, J BIOL CHEM, V279, P37431, DOI 10.1074/jbc.C400180200; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Ramm G, 2006, J BIOL CHEM, V281, P29174, DOI 10.1074/jbc.M603274200; Roach WG, 2007, BIOCHEM J, V403, P353, DOI 10.1042/BJ20061798; Salt IP, 2000, DIABETES, V49, P1649, DOI 10.2337/diabetes.49.10.1649; Sano H, 2003, J BIOL CHEM, V278, P14599, DOI 10.1074/jbc.C300063200; Sano H, 2007, CELL METAB, V5, P293, DOI 10.1016/j.cmet.2007.03.001; Towler MC, 2007, CIRC RES, V100, P328, DOI 10.1161/01.RES.0000256090.42690.05; Treebak JT, 2006, DIABETES, V55, P2051, DOI 10.2337/db06-0175; Yamaguchi S, 2005, AM J PHYSIOL-ENDOC M, V289, pE643, DOI 10.1152/ajpendo.00456.2004; Zeigerer A, 2004, MOL BIOL CELL, V15, P4406, DOI 10.1091/mbc.e04-04-0333	30	124	126	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9187	9195		10.1074/jbc.M708934200	http://dx.doi.org/10.1074/jbc.M708934200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18258599	Green Published, hybrid			2022-12-25	WOS:000254465800048
J	Zhao, B; Lin, X; Lei, L; Lamb, DC; Kelly, SL; Waterman, MR; Cane, DE				Zhao, Bin; Lin, Xin; Lei, Li; Lamb, David C.; Kelly, Steven L.; Waterman, Michael R.; Cane, David E.			Biosynthesis of the sesquiterpene antibiotic albaflavenone in Streptomyces coelicolor A3(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-P450 COMPLEMENT CYPOME; COMPLETE GENOME SEQUENCE; MOLECULAR-CLONING; AVERMITILIS; ACID; HYDROXYLATIONS; METABOLITES; MECHANISM; PATHWAY; BINDING	Cytochrome P450 170A1 (CYP170A1) is encoded by the sco5223 gene of the Gram-positive, soil-dwelling bacterium Streptomyces coelicolor A3(2) as part of a two-gene cluster with the sco5222 gene. The SCO5222 protein is a sesquiterpene synthase that catalyzes the cyclization of farnesyl diphosphate to the novel tricyclic hydrocarbon, epi-isozizaene (Lin, X., Hopson, R., and Cane, D. E. (2006) J. Am. Chem. Soc. 128, 6022 - 6023). The presence of CYP170A1 (sco5223) suggested that epiisozizaene might be further oxidized by the transcriptionally coupled P450. We have now established that purified CYP170A1 carries out two sequential allylic oxidations to convert epi-isozizaene to an epimeric mixture of albaflavenols and thence to the sesquiterpene antibiotic albaflavenone. Gas chromatography/ mass spectrometry analysis of S. coelicolor culture extracts established the presence of albaflavenone in the wildtype strain, along with its precursors epi-isozizaene and the albaflavenols. Disruption of the CYP170A1 gene abolished biosynthesis of both albaflavenone and the albaflavenols, but not epi-isozizaene. The combined results establish for the first time the presence of albaflavenone in S. coelicolor and clearly demonstrate that the biosynthesis of this antibiotic involves the coupled action of epi-isozizaene synthase and CYP170A1.	[Zhao, Bin; Lei, Li; Waterman, Michael R.] Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; [Zhao, Bin; Lei, Li; Waterman, Michael R.] Vanderbilt Univ, Sch Med, Inst Biol Chem, Nashville, TN 37232 USA; [Zhao, Bin; Lei, Li; Waterman, Michael R.] Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA; [Lin, Xin; Cane, David E.] Brown Univ, Dept Chem, Providence, RI 02912 USA; [Lamb, David C.; Kelly, Steven L.] Univ Wales Swansea, Swansea Med Sch, Inst Life Sci, Swansea SA2 8PP, W Glam, Wales	Vanderbilt University; Vanderbilt University; Vanderbilt University; Brown University; Swansea University	Zhao, B (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 864 Robinson Res Bldg,23rd & Pierce Aves, Nashville, TN 37232 USA.	bin.zhao@vanderbilt.edu			NIEHS NIH HHS [ES 00267] Funding Source: Medline; NIGMS NIH HHS [GM 30301, GM 69970] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030301, R37GM030301, R01GM069970] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bellucci G, 1996, CHEM RES TOXICOL, V9, P871, DOI 10.1021/tx9600053; Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; Berdy J, 2005, J ANTIBIOT, V58, P1, DOI 10.1038/ja.2005.1; Dewick PM, 2002, NAT PROD REP, V19, P181, DOI 10.1039/b002685i; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; Dubey VS, 2003, J BIOSCIENCES, V28, P637, DOI 10.1007/BF02703339; Groves J. T., 2005, CYTOCHROME P450, P1, DOI DOI 10.1007/0-387-27447-2_1; GURTLER H, 1994, J ANTIBIOT, V47, P434; Helliwell CA, 2001, P NATL ACAD SCI USA, V98, P2065, DOI 10.1073/pnas.041588998; Ikeda H, 2003, NAT BIOTECHNOL, V21, P526, DOI 10.1038/nbt820; KARP F, 1990, ARCH BIOCHEM BIOPHYS, V276, P219, DOI 10.1016/0003-9861(90)90029-X; Kieser T, 2000, PRACTICAL STREPTOMYC, P405; Lamb DC, 2003, BIOCHEM BIOPH RES CO, V307, P610, DOI 10.1016/S0006-291X(03)01231-2; Lamb DC, 2002, BIOCHEM J, V364, P555, DOI 10.1042/BJ20011380; Lamb DC, 2002, J BIOL CHEM, V277, P24000, DOI 10.1074/jbc.M111109200; Lin X, 2006, J AM CHEM SOC, V128, P6022, DOI 10.1021/ja061292s; Nishihara K, 1998, APPL ENVIRON MICROB, V64, P1694; OMURA T, 1964, J BIOL CHEM, V239, P2370; Pikuleva IA, 1998, J BIOL CHEM, V273, P18153, DOI 10.1074/jbc.273.29.18153; Quaderer R, 2006, J AM CHEM SOC, V128, P13036, DOI 10.1021/ja0639214; Ro DK, 2006, NATURE, V440, P940, DOI 10.1038/nature04640; Scholler CEG, 2002, J AGR FOOD CHEM, V50, P2615, DOI 10.1021/jf0116754; Solenberg PJ, 1997, CHEM BIOL, V4, P195, DOI 10.1016/S1074-5521(97)90288-X; Takahashi S, 2007, J BIOL CHEM, V282, P31744, DOI 10.1074/jbc.M703378200; Watve MG, 2001, ARCH MICROBIOL, V176, P386, DOI 10.1007/s002030100345; Wise M. L., 1999, COMPREHENSIVE NATURA, P97, DOI DOI 10.1016/B978-0-08-091283-7.00038-2; WOOD AW, 1988, J BIOL CHEM, V263, P17322; Zhao B, 2005, J BIOL CHEM, V280, P11599, DOI 10.1074/jbc.M410933200	28	112	118	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8183	8189		10.1074/jbc.M710421200	http://dx.doi.org/10.1074/jbc.M710421200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18234666	Green Published, hybrid			2022-12-25	WOS:000254288000015
J	Holland, RA; Kirschvink, JL; Doak, TG; Wikelski, M				Holland, Richard A.; Kirschvink, Joseph L.; Doak, Thomas G.; Wikelski, Martin			Bats Use Magnetite to Detect the Earth's Magnetic Field	PLOS ONE			English	Article							LOGGERHEAD SEA-TURTLES; ORIENTATION; COMPASS; MAGNETORECEPTION; BIRDS; MAP; NAVIGATION; INTENSITY; PIGEONS; PULSE	While the role of magnetic cues for compass orientation has been confirmed in numerous animals, the mechanism of detection is still debated. Two hypotheses have been proposed, one based on a light dependent mechanism, apparently used by birds and another based on a "compass organelle'' containing the iron oxide particles magnetite (Fe3O4). Bats have recently been shown to use magnetic cues for compass orientation but the method by which they detect the Earth's magnetic field remains unknown. Here we use the classic "Kalmijn-Blakemore'' pulse re-magnetization experiment, whereby the polarity of cellular magnetite is reversed. The results demonstrate that the big brown bat Eptesicus fuscus uses single domain magnetite to detect the Earths magnetic field and the response indicates a polarity based receptor. Polarity detection is a prerequisite for the use of magnetite as a compass and suggests that big brown bats use magnetite to detect the magnetic field as a compass. Our results indicate the possibility that sensory cells in bats contain freely rotating magnetite particles, which appears not to be the case in birds. It is crucial that the ultrastructure of the magnetite containing magnetoreceptors is described for our understanding of magnetoreception in animals.	[Holland, Richard A.; Doak, Thomas G.; Wikelski, Martin] Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA; [Holland, Richard A.] Univ Leeds, Inst Integrative & Comparative Biol, Leeds, W Yorkshire, England; [Kirschvink, Joseph L.] CALTECH, Div Geol & Planetary Sci, Pasadena, CA USA	Princeton University; University of Leeds; California Institute of Technology	Holland, RA (corresponding author), Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.	rahollan@Princeton.edu	Holland, Richard A/A-6107-2010; Kirschvink, Joseph L/U-5844-2017	Holland, Richard A/0000-0003-4495-8061; Kirschvink, Joseph/0000-0001-9486-6689; Doak, Thomas/0000-0001-5487-553X	Marie Curie Outgoing international fellowship; Bat Conservation; National Geographic society; NSF	Marie Curie Outgoing international fellowship(European Commission); Bat Conservation; National Geographic society(National Geographic Society); NSF(National Science Foundation (NSF))	Richard Holland was funded by a Marie Curie Outgoing international fellowship and a Bat Conservation international grant. Martin Wikelski was funded by the National Geographic society and NSF. None of these funding bodies had any influence on the manuscript	Batschelet E, 1981, CIRCULAR STAT BIOL; Bazylinski DA, 2000, CHEM GEOL, V169, P319, DOI 10.1016/S0009-2541(00)00211-4; BEASON RC, 1995, J EXP BIOL, V198, P141; Beason RC, 1996, J EXP BIOL, V199, P1241; BLAKEMORE R, 1975, SCIENCE, V190, P377, DOI 10.1126/science.170679; BLAKEMORE RP, 1982, ANNU REV MICROBIOL, V36, P217, DOI 10.1146/annurev.mi.36.100182.001245; BLAKEMORE RP, 1980, NATURE, V286, P384, DOI 10.1038/286384a0; Buchler E. R., 1985, MAGNETITE BIOMINERAL, P483; Cochran WW, 2004, SCIENCE, V304, P405, DOI 10.1126/science.1095844; Dennis TE, 2007, P ROY SOC B-BIOL SCI, V274, P1153, DOI 10.1098/rspb.2007.3768; DIAZRICCI JC, 1991, APPL ENVIRON MICROB, V57, P3248; Fleissner G, 2007, NATURWISSENSCHAFTEN, V94, P631, DOI 10.1007/s00114-007-0236-0; Fleming TH, 2003, BAT ECOLOGY, P156; GOULD JL, 1980, J EXP BIOL, V86, P1; Holland RA, 2003, J EXP BIOL, V206, P1773, DOI 10.1242/jeb.00365; Holland RA, 2007, BEHAV ECOL SOCIOBIOL, V61, P653, DOI 10.1007/s00265-006-0297-7; Holland RA, 2006, NATURE, V444, P702, DOI 10.1038/444702b; Irwin WP, 2005, J COMP PHYSIOL A, V191, P475, DOI 10.1007/s00359-005-0609-9; Kalmijn A., 1978, ANIMAL MIGRATION NAV; Kirschvink JL, 2001, CURR OPIN NEUROBIOL, V11, P462, DOI 10.1016/S0959-4388(00)00235-X; KIRSCHVINK JL, 1979, EARTH PLANET SC LETT, V44, P193, DOI 10.1016/0012-821X(79)90168-7; KIRSCHVINK JL, 1982, TRENDS NEUROSCI, V5, P160, DOI 10.1016/0166-2236(82)90090-X; KIRSCHVINK JL, 1981, BIOSYSTEMS, V13, P181, DOI 10.1016/0303-2647(81)90060-5; KIRSCHVINK JL, 1992, BIOELECTROMAGNETICS, V13, P401, DOI 10.1002/bem.2250130507; KIRSCHVINK JL, 1991, AM ZOOL, V31, P169; KIRSCHVINK JL, 1985, MAGNETITE BIOMINERAL, P243; Kramer G., 1953, Journal fuer Ornithologie, V94, P201, DOI 10.1007/BF01922508; LEASK MJM, 1977, NATURE, V267, P144, DOI 10.1038/267144a0; LIGHT P, 1993, J EXP BIOL, V182, P1; Lohmann KJ, 2004, NATURE, V428, P909, DOI 10.1038/428909a; LOHMANN KJ, 1995, J EXP BIOL, V198, P2041; MARHOLD S, 1997, 5 ROYAL I NAV; Mora CV, 2004, NATURE, V432, P508, DOI 10.1038/nature03077; Munro U, 1997, NATURWISSENSCHAFTEN, V84, P26, DOI 10.1007/s001140050343; Nemec P, 2001, SCIENCE, V294, P366, DOI 10.1126/science.1063351; PHILLIPS JB, 1986, SCIENCE, V233, P765, DOI 10.1126/science.3738508; QUINN TP, 1982, J COMP PHYSIOL, V147, P547, DOI 10.1007/BF00612020; Thalau P, 2006, J R SOC INTERFACE, V3, P583, DOI 10.1098/rsif.2006.0130; Walker MM, 2008, J THEOR BIOL, V250, P85, DOI 10.1016/j.jtbi.2007.09.030; Walker MM, 1997, NATURE, V390, P371, DOI 10.1038/37057; WALLRAFF HG, 1979, BEHAV ECOL SOCIOBIOL, V5, P201, DOI 10.1007/BF00293306; Wallraff HG., 2005, AVIAN NAVIGATION PIG; Wang YN, 2007, P R SOC B, V274, P2901, DOI 10.1098/rspb.2007.0904; Wegner RE, 2006, J EXP BIOL, V209, P4747, DOI 10.1242/jeb.02573; WILLIAMS TC, 1967, SCIENCE, V155, P1435, DOI 10.1126/science.155.3768.1435; WILTSCHK.W, 1972, SCIENCE, V176, P62, DOI 10.1126/science.176.4030.62; Wiltschko R, 2006, BIOESSAYS, V28, P157, DOI 10.1002/bies.20363; WILTSCHKO R, 1994, BEHAV ECOL SOCIOBIOL, V35, P63, DOI 10.1007/s002650050071; Wiltschko W, 1998, J EXP BIOL, V201, P3257; Wiltschko W, 2002, J EXP BIOL, V205, P3031; Wiltschko W, 2002, NATURE, V419, P467, DOI 10.1038/nature00958; Wiltschko W, 2006, P R SOC B, V273, P2815, DOI 10.1098/rspb.2006.3651	52	89	93	1	50	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2008	3	2							e1676	10.1371/journal.pone.0001676	http://dx.doi.org/10.1371/journal.pone.0001676			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XS	18301753	gold, Green Published, Green Accepted, Green Submitted			2022-12-25	WOS:000260586500020
J	Hughes, DA; Tang, K; Strotmann, R; Schoneberg, T; Prenen, J; Nilius, B; Stoneking, M				Hughes, David A.; Tang, Kun; Strotmann, Rainer; Schoneberg, Torsten; Prenen, Jean; Nilius, Bernd; Stoneking, Mark			Parallel Selection on TRPV6 in Human Populations	PLOS ONE			English	Article							RECENT POSITIVE SELECTION; EPITHELIAL CALCIUM-CHANNEL; LINKAGE-DISEQUILIBRIUM; NATURAL-SELECTION; HUMAN GENOME; CA2+ ENTRY; ECAC1; CELL; ADAPTATION; EVOLUTION	We identified and examined a candidate gene for local directional selection in Europeans, TRPV6, and conclude that selection has acted on standing genetic variation at this locus, creating parallel soft sweep events in humans. A novel modification of the extended haplotype homozygosity (EHH) test was utilized, which compares EHH for a single allele across populations, to investigate the signature of selection at TRPV6 and neighboring linked loci in published data sets for Europeans, Asians and African-Americans, as well as in newly-obtained sequence data for additional populations. We find that all non-African populations carry a signature of selection on the same haplotype at the TRPV6 locus. The selective footprints, however, are significantly differentiated between non-African populations and estimated to be younger than an ancestral population of non-Africans. The possibility of a single selection event occurring in an ancestral population of non-Africans was tested by simulations and rejected. The putatively-selected TRPV6 haplotype contains three candidate sites for functional differences, namely derived non-synonymous substitutions C157R, M378V and M681T. Potential functional differences between the ancestral and derived TRPV6 proteins were investigated by cloning the ancestral and derived forms, transfecting cell lines, and carrying out electrophysiology experiments via patch clamp analysis. No statistically-significant differences in biophysical channel function were found, although one property of the protein, namely Ca2+ dependent inactivation, may show functionally relevant differences between the ancestral and derived forms. Although the reason for selection on this locus remains elusive, this is the first demonstration of a widespread parallel selection event acting on standing genetic variation in humans, and highlights the utility of between population EHH statistics.	[Hughes, David A.; Tang, Kun; Stoneking, Mark] Max Planck Inst Evolutionary Anthropol, Leipzig, Germany; [Strotmann, Rainer; Schoneberg, Torsten] Univ Leipzig, Inst Biochem, Mol Biochem, Med Fac, Leipzig, Germany; [Prenen, Jean; Nilius, Bernd] Katholieke Univ Leuven, Dept Physiol, Leuven, Belgium	Max Planck Society; Leipzig University; KU Leuven	Hughes, DA (corresponding author), Max Planck Inst Evolutionary Anthropol, Leipzig, Germany.	hughes@eva.mpg.de	Tang, Kun/GSD-3218-2022; Hughes, David/E-7190-2015	Hughes, David/0000-0002-9644-8998	Max Planck Society; Bundesministerium fur Bildung und Forschung; Human Frontiers Science Programme [RGP 32/2004]; Belgian Federal Government; Flemish Government; Onderzoeksraad KU Leuven [GOA 2004/07, G.0214.99, G. 0136.00, G.0172.03]; Poles of Attraction Program, Prime Ministers Office IUAP [3P4/23]; Excellentiefinanciering [EF/95/010]	Max Planck Society(Max Planck SocietyFoundation CELLEX); Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); Human Frontiers Science Programme(Human Frontier Science Program); Belgian Federal Government; Flemish Government(European Commission); Onderzoeksraad KU Leuven(KU Leuven); Poles of Attraction Program, Prime Ministers Office IUAP; Excellentiefinanciering(KU Leuven)	The work by DAH, KT and MS was funded by the Max Planck Society. The work of RS and TS is funded by the Bundesministerium fur Bildung und Forschung and the work of JP and BN was supported by the Human Frontiers Science Programme (RGP 32/2004), the Belgian Federal Government, the Flemish Government and the Onderzoeksraad KU Leuven (GOA 2004/07, F.W.O. G.0214.99, F.W.O. G. 0136.00; F.W.O. G.0172.03, Poles of Attraction Program, Prime Ministers Office IUAP Nr.3P4/23, Excellentiefinanciering EF/95/010).	Akey JM, 2004, PLOS BIOL, V2, P1591, DOI 10.1371/journal.pbio.0020286; Akey JM, 2002, GENOME RES, V12, P1805, DOI 10.1101/gr.631202; Akey JM, 2006, HUM MOL GENET, V15, P2106, DOI 10.1093/hmg/ddl134; Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Bersaglieri T, 2004, AM J HUM GENET, V74, P1111, DOI 10.1086/421051; Bessou-Touya S, 1998, J INVEST DERMATOL, V111, P1103, DOI 10.1046/j.1523-1747.1998.00405.x; Bustamante CD, 2005, NATURE, V437, P1153, DOI 10.1038/nature04240; Cann HM, 2002, SCIENCE, V296, P261; Carlson CS, 2005, GENOME RES, V15, P1553, DOI 10.1101/gr.4326505; Clark AG, 2003, SCIENCE, V302, P1960, DOI 10.1126/science.1088821; Colosimo PF, 2005, SCIENCE, V307, P1928, DOI 10.1126/science.1107239; Diamond J, 2003, SCIENCE, V300, P597, DOI 10.1126/science.1078208; Erler I, 2004, J BIOL CHEM, V279, P34456, DOI 10.1074/jbc.M404778200; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Fry AE, 2006, AM J HUM GENET, V78, P1053, DOI 10.1086/504160; Goebel T, 2003, SCIENCE, V301, P501, DOI 10.1126/science.1086555; Harpending HC, 1998, P NATL ACAD SCI USA, V95, P1961, DOI 10.1073/pnas.95.4.1961; Haynes G., 2002, EARLY SETTLEMENT N A; Hermisson J, 2005, GENETICS, V169, P2335, DOI 10.1534/genetics.104.036947; Hoenderop JGJ, 2005, PHYSIOL REV, V85, P373, DOI 10.1152/physrev.00003.2004; Hoenderop JGJ, 2001, J PHYSIOL-LONDON, V537, P747; Hope G.S., 2005, PAPUAN PASTS CULTURA, P541; Hudson RR, 2002, BIOINFORMATICS, V18, P337, DOI 10.1093/bioinformatics/18.2.337; Jorde LB, 1998, BIOESSAYS, V20, P126, DOI 10.1002/(SICI)1521-1878(199802)20:2<126::AID-BIES5>3.0.CO;2-R; Kayser M, 2003, MOL BIOL EVOL, V20, P893, DOI 10.1093/molbev/msg092; Lehen'kyi V, 2007, ONCOGENE, V26, P7380, DOI 10.1038/sj.onc.1210545; Lehen'kyi V, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M611398200; Marth GT, 2004, GENETICS, V166, P351, DOI 10.1534/genetics.166.1.351; Minwalla L, 2001, J INVEST DERMATOL, V117, P341, DOI 10.1046/j.0022-202x.2001.01411.x; Muller D, 2002, NEPHROL DIAL TRANSPL, V17, P1614, DOI 10.1093/ndt/17.9.1614; Nielsen R, 2005, PLOS BIOL, V3, P976, DOI 10.1371/journal.pbio.0030170; Niemeyer BA, 2001, P NATL ACAD SCI USA, V98, P3600, DOI 10.1073/pnas.051511398; Nijenhuis T, 2003, PFLUG ARCH EUR J PHY, V446, P401, DOI 10.1007/s00424-003-1038-7; Nilius B, 2000, J PHYSIOL-LONDON, V527, P239, DOI 10.1111/j.1469-7793.2000.00239.x; Nilius B, 2003, PFLUG ARCH EUR J PHY, V445, P584, DOI 10.1007/s00424-002-0923-9; Nilius B, 2002, J BIOL CHEM, V277, P30852, DOI 10.1074/jbc.M202418200; Nilius B, 2001, CELL CALCIUM, V29, P417, DOI 10.1054/ceca.2001.0201; Nilius B, 2001, J BIOL CHEM, V276, P1020, DOI 10.1074/jbc.M006184200; Oota H, 2005, PLOS BIOL, V3, P536, DOI 10.1371/journal.pbio.0030071; Orr HA, 2001, GENETICS, V157, P875; Pennings PS, 2006, PLOS GENET, V2, P1998, DOI 10.1371/journal.pgen.0020186; Prevarskaya N, 2007, BBA-MOL BASIS DIS, V1772, P937, DOI 10.1016/j.bbadis.2007.05.006; Prugnolle F, 2005, CURR BIOL, V15, pR159, DOI 10.1016/j.cub.2005.02.038; Pruitt KD, 2005, NUCLEIC ACIDS RES, V33, pD501, DOI 10.1093/nar/gki025; Przeworski M, 2005, EVOLUTION, V59, P2312, DOI 10.1554/05-273.1; Ptak SE, 2004, GENETICS, V167, P387, DOI 10.1534/genetics.167.1.387; Ray N, 2005, GENOME RES, V15, P1161, DOI 10.1101/gr.3708505; Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590; Sabeti PC, 2006, SCIENCE, V312, P1614, DOI 10.1126/science.1124309; Sabeti PC, 2002, NATURE, V419, P832, DOI 10.1038/nature01140; Schaffner SF, 2005, GENOME RES, V15, P1576, DOI 10.1101/gr.3709305; Schwarz EC, 2006, CELL CALCIUM, V39, P163, DOI 10.1016/j.ceca.2005.10.006; Stajich JE, 2005, MOL BIOL EVOL, V22, P63, DOI 10.1093/molbev/msh252; Stephens JC, 2001, SCIENCE, V293, P489, DOI 10.1126/science.1059431; Stephens M, 2005, AM J HUM GENET, V76, P449, DOI 10.1086/428594; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; STONEKING M, 1990, GENETICS, V124, P717; Storz JF, 2004, MOL BIOL EVOL, V21, P1800, DOI 10.1093/molbev/msh192; Tang K, 2007, PLOS BIOL, V5, P1587, DOI 10.1371/journal.pbio.0050171; Teshima KM, 2006, GENOME RES, V16, P702, DOI 10.1101/gr.5105206; THOMSON G, 1977, GENETICS, V85, P753; van de Graaf SFJ, 2004, J STEROID BIOCHEM, V89-90, P303, DOI 10.1016/j.jsbmb.2004.03.029; Vennekens R, 2001, J PHYSIOL-LONDON, V530, P183, DOI 10.1111/j.1469-7793.2001.0183l.x; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; Voets T, 2003, J GEN PHYSIOL, V121, P245, DOI 10.1085/jgp.20028752; VOETS T, 2003, BIOPHYS J; Voight BF, 2006, PLOS BIOL, V4, P446, DOI 10.1371/journal.pbio.0040072; Walsh EC, 2006, HUM GENET, V119, P92, DOI 10.1007/s00439-005-0090-0; Wang Y, 2006, AM J HUM GENET, V78, P615, DOI 10.1086/502632; Yang ZH, 2002, MOL BIOL EVOL, V19, P908, DOI 10.1093/oxfordjournals.molbev.a004148; Zhivotovsky LA, 2003, AM J HUM GENET, V72, P1171, DOI 10.1086/375120; Zhivotovsky LA, 2000, MOL BIOL EVOL, V17, P757, DOI 10.1093/oxfordjournals.molbev.a026354	72	32	32	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2008	3	2							e1686	10.1371/journal.pone.0001686	http://dx.doi.org/10.1371/journal.pone.0001686			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XS	18301763	Green Published, gold, Green Submitted			2022-12-25	WOS:000260586500030
J	Du, J; Cai, X; Yao, J; Ding, X; Wu, Q; Pei, S; Jiang, K; Zhang, Y; Wang, W; Shi, Y; Lai, Y; Shen, J; Teng, M; Huang, H; Fei, Q; Reddy, ES; Zhu, J; Jin, C; Yao, X				Du, J.; Cai, X.; Yao, J.; Ding, X.; Wu, Q.; Pei, S.; Jiang, K.; Zhang, Y.; Wang, W.; Shi, Y.; Lai, Y.; Shen, J.; Teng, M.; Huang, H.; Fei, Q.; Reddy, E. S.; Zhu, J.; Jin, C.; Yao, X.			The mitotic checkpoint kinase NEK2A regulates kinetochore microtubule attachment stability	ONCOGENE			English	Article						chromosome instability; mitosis; kinetochore-microtubule attachment; Hec1; NEK2A; phosphorylation	CELL-DIVISION; SPINDLE; MITOSIS; HEC1; PHOSPHORYLATION; CHROMOSOMES; CENTROSOME; INTERACTS; MOVEMENT; COMPLEX	Loss or gain of whole chromosome, the form of chromosome instability commonly associated with cancers is thought to arise from aberrant chromosome segregation during cell division. Chromosome segregation in mitosis is orchestrated by the interaction of kinetochores with spindle microtubules. Our studies show that NEK2A is a kinetochore-associated protein kinase essential for faithful chromosome segregation. However, it was unclear how NEK2A ensures accurate chromosome segregation in mitosis. Here we show that NEK2A-mediated Hec1 ( highly expressed in cancer) phosphorylation is essential for faithful kinetochore microtubule attachments in mitosis. Using phospho-specific antibody, our studies show that NEK2A phosphorylates Hec1 at Ser165 during mitosis. Although such phosphorylation is not required for assembly of Hec1 to the kinetochore, expression of non-phosphorylatable mutant Hec1(S165) perturbed chromosome congression and resulted in a dramatic increase in microtubule attachment errors, including syntelic and monotelic attachments. Our in vitro reconstitution experiment demonstrated that Hec1 binds to microtubule in low affinity and phosphorylation by NEK2A, which prevents aberrant kinetochore-microtubule connections in vivo, increases the affinity of the Ndc80 complex for microtubules in vitro. Thus, our studies illustrate a novel regulatory mechanism in which NEK2A kinase operates a faithful chromosome attachment to spindle microtubule, which prevents chromosome instability during cell division.	[Ding, X.; Wang, W.] Beijing Univ Chinese Med, Dept Med, Beijing, Peoples R China; [Du, J.; Cai, X.; Yao, J.; Wu, Q.; Pei, S.; Jiang, K.; Zhang, Y.; Shi, Y.; Lai, Y.; Shen, J.; Teng, M.; Jin, C.; Yao, X.] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230026, Peoples R China; [Cai, X.; Ding, X.; Wu, Q.; Jiang, K.; Reddy, E. S.; Yao, X.] Morehouse Sch Med, Canc Biol Program, Atlanta, GA 30310 USA; [Huang, H.] Zhejiang Univ, Affiliated Hosp 1, Dept Hematol, Hangzhou, Peoples R China; [Fei, Q.; Zhu, J.] Shanghai Jiao Tong Univ, Shanghai Canc Inst, Canc Epigenet Program, Shanghai 200030, Peoples R China; [Yao, X.] Cellular Dynam, Hefei, Peoples R China	Beijing University of Chinese Medicine; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Morehouse School of Medicine; Zhejiang University; Shanghai Jiao Tong University	Ding, X (corresponding author), Beijing Univ Chinese Med, Dept Med, Beijing, Peoples R China.	xiading6@yahoo.com; jincj@ustc.edu.cn; yaoxb@ustc.edu.cn	Lai, Ying/E-5220-2015; PEI, SHANSHAN/D-8200-2016; Lai, YING/J-4019-2014	Lai, Ying/0000-0001-5347-5155; PEI, SHANSHAN/0000-0001-9619-2614; 	NCI NIH HHS [CA92080, CA132389, U56 CA092080, CA89019, P50 CA089019, P20 CA132389] Funding Source: Medline; NCRR NIH HHS [G12 RR003034, G-12-RR03034] Funding Source: Medline; NIDDK NIH HHS [R01 DK056292, DK56292] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA089019, P20CA132389] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056292] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AULT JG, 1994, CURR OPIN CELL BIOL, V6, P41, DOI 10.1016/0955-0674(94)90114-7; AULT JG, 1989, CHROMOSOMA, V98, P33, DOI 10.1007/BF00293332; Cheeseman IM, 2006, CELL, V127, P983, DOI 10.1016/j.cell.2006.09.039; Chen YM, 2002, J BIOL CHEM, V277, P49408, DOI 10.1074/jbc.M207069200; Ciferri C, 2005, J BIOL CHEM, V280, P29088, DOI 10.1074/jbc.M504070200; Ciferri C, 2007, FEBS LETT, V581, P2862, DOI 10.1016/j.febslet.2007.05.012; DeLuca JG, 2006, CELL, V127, P969, DOI 10.1016/j.cell.2006.09.047; DeLuca JG, 2005, MOL BIOL CELL, V16, P519, DOI 10.1091/mbc.E04-09-0852; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fang L, 2007, CELL RES, V17, P664, DOI 10.1038/cr.2007.68; Fry AM, 2002, ONCOGENE, V21, P6184, DOI 10.1038/sj.onc.1205711; Fu GS, 2007, CELL RES, V17, P608, DOI 10.1038/cr.2007.55; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Hayward DG, 2006, CANCER LETT, V237, P155, DOI 10.1016/j.canlet.2005.06.017; Ke YW, 2003, CELL RES, V13, P69, DOI 10.1038/sj.cr.7290152; Lampson MA, 2005, NAT CELL BIOL, V7, P93, DOI 10.1038/ncb1208; Liu D, 2007, J BIOL CHEM, V282, P21415, DOI 10.1074/jbc.M609026200; Lou Y, 2004, J BIOL CHEM, V279, P20049, DOI 10.1074/jbc.M314205200; Mao YH, 2003, CELL, V114, P87, DOI 10.1016/S0092-8674(03)00475-6; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Nicklas R. B., 1971, Adv Cell Biol, V2, P225; NICKLAS RB, 1985, CHROMOSOMA, V92, P313, DOI 10.1007/BF00329815; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Storchova Z, 2006, NATURE, V443, P541, DOI 10.1038/nature05178; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518	25	56	61	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 3	2008	27	29					4107	4114		10.1038/onc.2008.34	http://dx.doi.org/10.1038/onc.2008.34			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321RV	18297113	Green Accepted			2022-12-25	WOS:000257325100010
J	Edirisinghe, I; Yang, SR; Yao, H; Rajendrasozhan, S; Caito, S; Adenuga, D; Wong, C; Rahman, A; Phipps, RP; Jin, ZG; Rahman, I				Edirisinghe, Indika; Yang, Se-Ran; Yao, Hongwei; Rajendrasozhan, Saravanan; Caito, Samuel; Adenuga, David; Wong, Chelsea; Rahman, Arshad; Phipps, Richard P.; Jin, Zheng-Gen; Rahman, Irfan			VEGFR-2 inhibition augments cigarette smoke-induced oxidative stress and inflammatory responses leading to endothelial dysfunction	FASEB JOURNAL			English	Article						oxidants; eNOS; angiogenesis	NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; PROINFLAMMATORY CYTOKINE RELEASE; GROWTH-FACTOR; IN-VITRO; PULMONARY-HYPERTENSION; INDUCED EMPHYSEMA; NAD(P)H OXIDASE; RAT LUNGS; RECEPTOR	Vascular endothelial growth factor (VEGF) induces phosphorylation of VEGF receptor-2 (VEGFR-2) and activates the downstream signaling pathway resulting in endothelial cell migration, proliferation, and survival. Cigarette smoking is associated with abnormal vascular and endothelial function, leading to airspace enlargement. Herein, we investigated the mechanism of cigarette smoke (CS) -induced endothelial dysfunction by studying the VEGF-VEGFR-2 signaling in mouse lung and human endothelial cells. CS exposure caused oxidative stress, as shown by increased levels of 4-hydroxy-2-nonenal-adducts in mouse lung and reactive oxygen species generation in human lung microvascular endothelial cells (HMVEC-Ls). Inhibition of VEGFR-2 by a specific kinase inhibitor (NVP-AAD777) enhanced the CS-induced oxidative stress, causing augmented inflammatory cell influx and proinflammatory mediators release in mouse lung. The levels of endothelial nitric oxide synthase (eNOS) and phosphorylated (p) -eNOS in the lungs of mice exposed to CS and/or treated with VEGFR-2 inhibitor were decreased. CS down-regulated VEGFR-2 expression, eNOS levels, and VEGF-induced VEGFR-2 phosphorylation in HMVEC-Ls, resulting in impaired VEGF-induced endothelial cell migration and angiogenesis. Overall, these data show that inhibition of VEGFR-2 augmented CS-induced oxidative stress and inflammatory responses leading to endothelial dysfunction. This explains the mechanism of endothelial dysfunction in smokers and has implications in understanding the pathogenesis of pulmonary and cardiovascular diseases.	[Edirisinghe, Indika; Yang, Se-Ran; Yao, Hongwei; Rajendrasozhan, Saravanan; Caito, Samuel; Adenuga, David; Phipps, Richard P.; Rahman, Irfan] Univ Rochester, Dept Environm Med, Lung Biol & Dis Program, Med Ctr, Rochester, NY 14642 USA; [Wong, Chelsea; Jin, Zheng-Gen] Univ Rochester, Med Ctr, Cardiovasc Res Inst, Rochester, NY 14642 USA; [Wong, Chelsea; Jin, Zheng-Gen] Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA; [Rahman, Arshad] Univ Rochester, Med Ctr, Dept Pediat, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester	Rahman, I (corresponding author), Univ Rochester, Dept Environm Med, Lung Biol & Dis Program, Med Ctr, Box 850,601 Elmwood Ave, Rochester, NY 14642 USA.	irfan_rahman@urmc.rochester.edu	Yao, Hongwei/G-6444-2010; Rajendrasozhan, Saravanan/ABC-5213-2020	Rajendrasozhan, Saravanan/0000-0002-4234-9417; Adenuga, David/0000-0002-8153-0235	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001247] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL080611] Funding Source: Medline; NIEHS NIH HHS [T32 ES007026, P30 ES001247, ES01247, ES07026, R01 ES007026] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ambrose JA, 2004, J AM COLL CARDIOL, V43, P1731, DOI 10.1016/j.jacc.2003.12.047; Arnal JF, 1999, CELL MOL LIFE SCI, V55, P1078, DOI 10.1007/s000180050358; CARP H, 1978, AM REV RESPIR DIS, V118, P617; Gerber HP, 1999, DEVELOPMENT, V126, P1149; Jakkula M, 2000, AM J PHYSIOL-LUNG C, V279, pL600, DOI 10.1152/ajplung.2000.279.3.L600; Jayachandran M, 2001, BIOCHEM BIOPH RES CO, V280, P589, DOI 10.1006/bbrc.2000.4177; Jin ZG, 2003, CIRC RES, V93, P354, DOI 10.1161/01.RES.0000089257.94002.96; Kasahara Y, 2000, J CLIN INVEST, V106, P1311, DOI 10.1172/JCI10259; Kasahara Y, 2001, AM J RESP CRIT CARE, V163, P737, DOI 10.1164/ajrccm.163.3.2002117; Koyama S, 2002, AM J RESP CRIT CARE, V166, P382, DOI 10.1164/rccm.2103112; Kranenburg AR, 2005, THORAX, V60, P106, DOI 10.1136/thx.2004.023986; Lee LH, 2005, AM J RESP CRIT CARE, V172, P987, DOI 10.1164/rccm.200501-041OC; LIEBOW AA, 1959, AM REV RESPIR DIS, V80, P67; Marwick JA, 2006, AM J PHYSIOL-LUNG C, V290, pL897, DOI 10.1152/ajplung.00116.2005; Mathew Rajamma, 2007, Cardiol Rev, V15, P143, DOI 10.1097/01.crd.0000249381.49138.b9; Michaud SE, 2006, J MOL CELL CARDIOL, V41, P275, DOI 10.1016/j.yjmcc.2006.05.004; Moodie FM, 2004, FASEB J, V18, P1897, DOI 10.1096/fj.04-1506fje; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Orosz Z, 2007, AM J PHYSIOL-HEART C, V292, pH130, DOI 10.1152/ajpheart.00599.2006; Papaioannou AI, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-128; PRYOR WA, 1993, ANN NY ACAD SCI, V686, P12, DOI 10.1111/j.1749-6632.1993.tb39148.x; Puranik R, 2003, PROG CARDIOVASC DIS, V45, P443, DOI 10.1053/pcad.2003.YPCAD13; Rahman I, 2002, AM J RESP CRIT CARE, V166, P490, DOI 10.1164/rccm.2110101; Rahman I, 2003, J BIOCHEM MOL BIOL, V36, P95; Sakurai Y, 2005, P NATL ACAD SCI USA, V102, P1076, DOI 10.1073/pnas.0404984102; Santos S, 2003, AM J RESP CRIT CARE, V167, P1250, DOI 10.1164/rccm.200210-1233OC; Shen BQ, 1999, J BIOL CHEM, V274, P33057, DOI 10.1074/jbc.274.46.33057; Su YC, 1998, AM J RESP CELL MOL, V19, P819, DOI 10.1165/ajrcmb.19.5.3091; Su YC, 2004, AM J PHYSIOL-LUNG C, V287, pL794, DOI 10.1152/ajplung.00079.2004; Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200; Tanriverdi H, 2006, CIRC J, V70, P593, DOI 10.1253/circj.70.593; Thatcher TH, 2005, AM J PHYSIOL-LUNG C, V289, pL322, DOI 10.1152/ajplung.00039.2005; Thatcher TH, 2007, AM J PATHOL, V170, P855, DOI 10.2353/ajpath.2007.060391; Thejass P, 2007, INTEGR CANCER THER, V6, P389, DOI 10.1177/1534735407309084; Thejass P, 2007, INT IMMUNOPHARMACOL, V7, P295, DOI 10.1016/j.intimp.2006.10.011; Tuder RM, 2003, AM J RESP CELL MOL, V29, P88, DOI 10.1165/rcmb.2002-0228OC; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; Ucuzian AA, 2007, WORLD J SURG, V31, P654, DOI 10.1007/s00268-006-0763-4; Ushio-Fukai M, 2002, CIRC RES, V91, P1160, DOI 10.1161/01.RES.0000046227.65158.F8; Ushio-Fukai M, 2007, ANTIOXID REDOX SIGN, V9, P731, DOI 10.1089/ars.2007.1556; Voelkel NF, 2006, AM J PHYSIOL-LUNG C, V290, pL209, DOI 10.1152/ajplung.00185.2005; Voelkel NF, 2003, EUR RESPIR J, V22, p28S, DOI 10.1183/09031936.03.00000503; Wagner L, 2007, ENDOTHELIUM-J ENDOTH, V14, P245, DOI 10.1080/10623320701606707; Wright JL, 2006, J APPL PHYSIOL, V100, P672, DOI 10.1152/japplphysiol.00274.2005; Yamaguchi Y, 2007, J PHARMACOL SCI, V103, P275, DOI 10.1254/jphs.FP0061055; Yamato H, 1996, LAB INVEST, V75, P211; Yang SR, 2007, AM J PHYSIOL-LUNG C, V292, pL567, DOI 10.1152/ajplung.00308.2006; Yang SR, 2006, AM J PHYSIOL-LUNG C, V291, pL46, DOI 10.1152/ajplung.00241.2005; ZEIHER AM, 1995, CIRCULATION, V92, P1094, DOI 10.1161/01.CIR.92.5.1094	49	74	77	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2297	2310		10.1096/fj.07-099481	http://dx.doi.org/10.1096/fj.07-099481			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18263699	Green Accepted			2022-12-25	WOS:000257292500022
J	Kelly, K; Brader, P; Rein, A; Shah, JP; Wong, RJ; Fong, YM; Gil, Z				Kelly, Kaitlyn; Brader, Peter; Rein, Avigail; Shah, Jatin P.; Wong, Richard J.; Fong, Yuman; Gil, Ziv			Attenuated multimutated herpes simplex virus-1 effectively treats prostate carcinomas with neural invasion while preserving nerve function	FASEB JOURNAL			English	Article						perineural invasion; gene therapy; prostate cancer; oncolytic therapy; erectile dysfunction	PERINEURAL INVASION; PROGNOSTIC-SIGNIFICANCE; RADICAL PROSTATECTOMY; BETA-GALACTOSIDASE; RADIATION-THERAPY; GENE DELIVERY; BRAIN-TUMORS; PHASE-I; CANCER; G207	Many cancers can cause disability and pain by invading nerves. In particular, prostate carcinoma has a high propensity for neural invasion (NI) at an early stage. Attempted surgical treatment of tumors with NI often leads to erectile dysfunction and deteriorated quality of life. Therefore, there is a need for novel modalities that will selectively target cancer cells while preserving neural function. Herpes simplex viruses (HSVs) have a natural trophism for peripheral nerves. We hypothesized that oncolytic therapy using HSV engineered to minimize neurotoxicity would be appropriate for this clinical setting. Attenuated HSV (NV1023) injected to sciatic nerves of nude mice had no toxic effect on nerve function (n = 30). NV1023 had significant oncolytic effect on prostate carcinoma cells (PC3, DU145, and LNCap) in vitro. An in vivo model of NI was established by implanting prostate carcinoma cells in the sciatic nerves of nude mice. Mice were treated with NV1023 or saline 7 days after establishment of tumors. Significant reduction in tumor size and inhibition of NI was found 6 -8 wk after treatment (P< 0.005). All animals treated with saline developed complete paralysis < 5 wk post-treatment, whereas most NV1023-treated animals had preserved nerve function > 12 wk after treatment (P< 0.0001). We conclude that oncolytic therapy effectively treats prostate carcinomas with NI in an in vivo murine model while preserving neural function. These findings may hold significant clinical implications for patients with prostate cancer or other neurotrophic tumors.	[Kelly, Kaitlyn; Rein, Avigail; Shah, Jatin P.; Wong, Richard J.; Fong, Yuman; Gil, Ziv] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10065 USA; [Brader, Peter] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Gil, Z (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10065 USA.	gilz@mskcc.org		Shah, Jatin/0000-0002-6444-6592				AMERICAN CANCER SOCIETY, 2007, CANC FACTS FIG; Bennett JJ, 2004, FASEB J, V18, P1001, DOI 10.1096/fj.02-1080fje; Blank SV, 2002, HUM GENE THER, V13, P627, DOI 10.1089/10430340252837224; Bonin SR, 1997, CANCER-AM CANCER SOC, V79, P75, DOI 10.1002/(SICI)1097-0142(19970101)79:1<75::AID-CNCR11>3.0.CO;2-3; Chahlavi Ali, 1999, Neoplasia (New York), V1, P162, DOI 10.1038/sj.neo.7900016; Chang S S, 1999, Curr Opin Urol, V9, P391, DOI 10.1097/00042307-199909000-00004; CHEN XW, 1995, J VIROL, V69, P7899, DOI 10.1128/JVI.69.12.7899-7908.1995; Cinatl J, 2003, CANCER RES, V63, P1508; Conlon KC, 1996, ANN SURG, V223, P273, DOI 10.1097/00000658-199603000-00007; Cooperberg MR, 2005, J CLIN ONCOL, V23, P8146, DOI 10.1200/JCO.2005.02.9751; DOBSON AT, 1990, NEURON, V5, P353, DOI 10.1016/0896-6273(90)90171-B; GELLER AI, 1988, SCIENCE, V241, P1667, DOI 10.1126/science.2843986; Hu D, 1997, ANESTHESIOLOGY, V86, P957, DOI 10.1097/00000542-199704000-00026; Jarnagin WR, 2006, CANCER GENE THER, V13, P326, DOI 10.1038/sj.cgt.7700890; Jeyaretna Deva S, 2007, Neurosurg Focus, V22, pE4; Kemeny N, 2006, HUM GENE THER, V17, P1214, DOI 10.1089/hum.2006.17.1214; Kim SH, 2000, CANCER GENE THER, V7, P1279, DOI 10.1038/sj.cgt.7700231; Kooby DA, 1999, FASEB J, V13, P1325, DOI 10.1096/fasebj.13.11.1325; Kravchick S, 2003, BJU INT, V92, P28, DOI 10.1046/j.1464-410X.2003.04276.x; Maguire-Zeiss KA, 2001, CURR OPIN MOL THER, V3, P482; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; Maru N, 2001, HUM PATHOL, V32, P828, DOI 10.1053/hupa.2001.26456; Mashour GA, 2001, EXP NEUROL, V169, P64, DOI 10.1006/exnr.2001.7641; MEIGNIER B, 1990, J INFECT DIS, V162, P313, DOI 10.1093/infdis/162.2.313; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; Parker JN, 2000, P NATL ACAD SCI USA, V97, P2208, DOI 10.1073/pnas.040557897; Penson DF, 2003, J CLIN ONCOL, V21, P1147, DOI 10.1200/JCO.2003.07.139; Perez MCP, 2004, GENE THER, V11, P1023, DOI 10.1038/sj.gt.3302258; Quinn DI, 2003, CANCER-AM CANCER SOC, V97, P1884, DOI 10.1002/cncr.11263; Ram Z, 1997, NAT MED, V3, P1354, DOI 10.1038/nm1297-1354; RAMAKRISHNAN R, 1994, J VIROL, V68, P1864, DOI 10.1128/JVI.68.3.1864-1873.1994; Rigor BM, 2000, J SURG ONCOL, V75, P280, DOI 10.1002/1096-9098(200012)75:4<280::AID-JSO13>3.0.CO;2-Q; Shen Y, 2006, CANCER GENE THER, V13, P975, DOI 10.1038/sj.cgt.7700946; SINGER PA, 1991, J CLIN ONCOL, V9, P328, DOI 10.1200/JCO.1991.9.2.328; TANAKA A, 1994, CANCER-AM CANCER SOC, V73, P550, DOI 10.1002/1097-0142(19940201)73:3<550::AID-CNCR2820730309>3.0.CO;2-0; Thompson IM, 2003, NEW ENGL J MED, V349, P215, DOI 10.1056/NEJMoa030660; Tobisu Kenichi, 2006, Int J Clin Oncol, V11, P351, DOI 10.1007/s10147-006-0614-1; Toyoizumi T, 1999, HUM GENE THER, V10, P3013, DOI 10.1089/10430349950016410; VANDERWAL JE, 1990, CANCER, V66, P2031, DOI 10.1002/1097-0142(19901101)66:9<2031::AID-CNCR2820660931>3.0.CO;2-7; Wong RJ, 2001, HUM GENE THER, V12, P253, DOI 10.1089/10430340150218396; Yu ZK, 2004, INT J CANCER, V112, P525, DOI 10.1002/ijc.20421	41	14	15	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					1839	1848		10.1096/fj.07-097808	http://dx.doi.org/10.1096/fj.07-097808			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18234972				2022-12-25	WOS:000256352700024
J	Jablonka-Shariff, A; Pearl, CA; Comstock, A; Boime, I				Jablonka-Shariff, Albina; Pearl, Christopher A.; Comstock, Anna; Boime, Irving			A carboxyl-terminal sequence in the lutropin beta subunit contributes to the sorting of lutropin to the regulated pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; HAMSTER OVARY CELLS; HUMAN LUTEINIZING-HORMONE; SECRETORY GRANULES; ENDOPLASMIC-RETICULUM; GLYCOPROTEIN HORMONES; MOLECULAR-CLONING; ALPHA-SUBUNIT; SINGLE-CHAIN; GH(3) CELLS	Although synthesized in the same pituitary gonadotropes, the secretion profiles of lutropin (LH) and follitropin (FSH) differ. LH is secreted through a regulated pathway and associated with a bolus release at mid-estrous cycle. In contrast, the majority of FSH is secreted constitutively with an incremental increase until ovulation. Both share an identical alpha subunit, and thus the beta subunit contains determinants for sorting into the regulated pathway. Previously, we demonstrated that a hydrophobic carboxyl-terminal heptapeptide of the LH beta subunit (Leu-Ser-Gly-Leu-Leu-Phe-Leu), not found in the FSH beta subunit, influences the intracellular behavior of the LH dimer. To test the hypothesis that the peptide contributes to differential sorting, we monitored the fates of LH and LH Delta T (LH beta subunit lacking the carboxyl-terminal seven amino acids) dimers in the rat somatotrope-derived GH(3) cell line in which both the regulated and constitutive secretory pathways operate. Pulse-chase labeling demonstrated that the LH Delta T dimer was diverted to the constitutive pathway, resulting in a significant decrease in the corresponding intracellular pool. Forskolin stimulated LH dimer release 3-fold, which was accompanied by a parallel decrease of intracellular LH; only marginal forskolin stimulation of LH Delta T was seen. Immunofluorescence after cycloheximide treatment demonstrated decreased retention of LH Delta T compared with LH, consistent with increased constitutive secretion of LH Delta T. We also demonstrated that fusing the heptapeptide to the carboxyl terminus of the FSH beta subunit resulted in an increased regulated secretion of this FSH analog compared with wild-type FSH. These data are the first to identify a novel structural determinant responsible for the sorting of a member of the glycoprotein hormone family into the regulated secretory pathway.	[Jablonka-Shariff, Albina; Pearl, Christopher A.; Comstock, Anna; Boime, Irving] Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL)	Boime, I (corresponding author), 660 S Euclid Ave,Box 8103, St Louis, MO 63110 USA.	iboime@wustl.edu			NICHD NIH HHS [T32HD049305-03] Funding Source: Medline; NINDS NIH HHS [NS057105] Funding Source: Medline; PHS HHS [DR065155] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD049305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS057105] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arvan P, 2002, CURR OPIN CELL BIOL, V14, P448, DOI 10.1016/S0955-0674(02)00344-7; Assadi M, 2004, BIOCHEMISTRY-US, V43, P7798, DOI 10.1021/bi036331g; Avezov E, 2008, MOL BIOL CELL, V19, P216, DOI 10.1091/mbc.E07-05-0505; BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; BAENZIGER JU, 1994, FASEB J, V8, P1019, DOI 10.1096/fasebj.8.13.7926366; BIELINSKA M, 1994, MOL ENDOCRINOL, V8, P919, DOI 10.1210/me.8.7.919; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Brechler V, 1996, J BIOL CHEM, V271, P20636, DOI 10.1074/jbc.271.34.20636; Bundgaard JR, 2004, J BIOL CHEM, V279, P5488, DOI 10.1074/jbc.M310547200; Cabral CM, 2000, J BIOL CHEM, V275, P25015, DOI 10.1074/jbc.M910172199; CHILDS GV, 1985, ENDOCRINOLOGY, P499; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; CORLESS CL, 1987, J CELL BIOL, V104, P1173, DOI 10.1083/jcb.104.5.1173; CURRIE RJW, 1995, J ENDOCRINOL, V147, P259, DOI 10.1677/joe.0.1470259; Dannies PS, 1999, ENDOCR REV, V20, P3, DOI 10.1210/er.20.1.3; Dannies PS, 2001, MOL CELL ENDOCRINOL, V177, P87, DOI 10.1016/S0303-7207(01)00437-3; Dikeakos JD, 2007, J BIOL CHEM, V282, P1136, DOI 10.1074/jbc.M605718200; FARNWORTH PG, 1995, J ENDOCRINOL, V145, P387, DOI 10.1677/joe.0.1450387; Garcia-Campayo V, 2004, J BIOL CHEM, V279, P44286, DOI 10.1074/jbc.M408386200; GREEN ED, 1986, MOL CELL BIOCHEM, V72, P81; Griffiths G, 1996, PROTOPLASMA, V195, P37, DOI 10.1007/BF01279185; HAYASHIZAKI Y, 1985, FEBS LETT, V188, P394, DOI 10.1016/0014-5793(85)80409-9; HO MK, 1983, J BIOL CHEM, V258, P2766; Jablonka-Shariff A, 2006, MOL ENDOCRINOL, V20, P1437, DOI 10.1210/me.2005-0537; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; KAETZEL DM, 1989, MOL ENDOCRINOL, V3, P1765, DOI 10.1210/mend-3-11-1765; Kamhi-Nesher S, 2001, MOL BIOL CELL, V12, P1711, DOI 10.1091/mbc.12.6.1711; KEENE JL, 1989, J BIOL CHEM, V264, P4769; KESSLER MJ, 1979, J BIOL CHEM, V254, P7909; KEUTMANN HT, 1979, BIOCHEM BIOPH RES CO, V90, P842, DOI 10.1016/0006-291X(79)91904-1; KVIST S, 1982, CELL, V29, P61, DOI 10.1016/0092-8674(82)90090-3; Luderer U., 1992, SER S FSH REG SECR M, P1; MATZUK MM, 1989, J CELL BIOL, V109, P1429, DOI 10.1083/jcb.109.4.1429; MATZUK MM, 1987, P NATL ACAD SCI USA, V84, P6354, DOI 10.1073/pnas.84.18.6354; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; MUYAN M, 1994, MOL ENDOCRINOL, V8, P1789, DOI 10.1210/me.8.12.1789; Muyan M, 1996, MOL ENDOCRINOL, V10, P1678, DOI 10.1210/me.10.12.1678; Nakatsu F, 2003, CELL STRUCT FUNCT, V28, P419, DOI 10.1247/csf.28.419; Pantel J, 1998, ENDOCRINOLOGY, V139, P527, DOI 10.1210/en.139.2.527; PARSONS TF, 1980, P NATL ACAD SCI-BIOL, V77, P7089, DOI 10.1073/pnas.77.12.7089; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; SAIRAM MR, 1983, HORMONAL PROTEINS PE, P1; Shimizu Y, 2007, ADV EXP MED BIOL, V594, P37; SITIA R, 1992, MOL BIOL CELL, V3, P1067, DOI 10.1091/mbc.3.10.1067; TALMADGE K, 1984, NATURE, V307, P37, DOI 10.1038/307037a0; TARTAKOFF A, 1979, J CELL BIOL, V83, P284, DOI 10.1083/jcb.83.2.284; Thomas SG, 1997, ENDOCRINOLOGY, V138, P1347, DOI 10.1210/en.138.3.1347; Tooze SA, 2001, TRENDS CELL BIOL, V11, P116, DOI 10.1016/S0962-8924(00)01907-3; Watanabe N, 2007, COMP BIOCHEM PHYS A, V146, P105, DOI 10.1016/j.cbpa.2006.09.011	49	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11485	11492		10.1074/jbc.M800654200	http://dx.doi.org/10.1074/jbc.M800654200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18292086	hybrid, Green Published			2022-12-25	WOS:000255067400047
J	Shen, XR; Li, HM; Ou, Y; Tao, WB; Dong, A; Kong, JL; Ji, CN; Yu, SN				Shen, Xianrong; Li, Huiming; Ou, Yan; Tao, Wenbing; Dong, Aichun; Kong, Jilie; Ji, Chaoneng; Yu, Shaoning			The secondary structure of calcineurin regulatory region and conformational change induced by calcium/calmodulin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP RECEPTOR PROTEIN; AUTOINHIBITORY DOMAIN; PHOSPHATASE-ACTIVITY; ESCHERICHIA-COLI; CALMODULIN; CALCIUM; NFAT; COMPLEX; FAMILY	The protein serine/threonine phosphatase calcineurin (CN) is activated by calmodulin (CaM) in response to intracellular calcium mobilization. A widely accepted model for CN activation involves displacement of the CN autoinhibitory peptide (CN467-486) from the active site upon binding of CaM. However, CN activation requires calcium binding both to the low affinity sites of CNB and to CaM, and previous studies did not dissect the individual contributions of CNB and CaM to displacement of the autoinhibitory peptide from the active site. In this work we have produced separate CN fragments corresponding to the CNA regulatory region (CNRR381-521, residues 381-521), the CNA catalytic domain truncated at residue 341, and the CNA-CNB heterodimer with CNA truncated at residue 380 immediately after the CNB binding helix. We show that the separately expressed regulatory region retains its ability to inhibit CN phosphatase activity of the truncated CN341 and CN380 and that the inhibition can be reversed by calcium/CaM binding. Tryptophan fluorescence quenching measurements further indicate that the isolated regulatory region inhibits CN activity by occluding the catalytic site and that CaM binding exposes the catalytic site. The results provide new support for a model in which calcium binding to CNB enables CaM binding to the CNA regulatory region, and CaM binding then instructs an activating conformational change of the regulatory region that does not depend further on CNB. Moreover, the secondary structural content of the CNRR381-521 was tentatively addressed by Fourier transform infrared spectroscopy. The results indicate that the secondary structure of CNRR381-521 fragment is predominantly random coil, but with significant amount of beta-strand and alpha-helix structures.	[Shen, Xianrong; Ou, Yan; Tao, Wenbing; Kong, Jilie; Yu, Shaoning] Fudan Univ, Dept Chem, Shanghai 200433, Peoples R China; [Shen, Xianrong; Ou, Yan; Tao, Wenbing; Kong, Jilie; Yu, Shaoning] Fudan Univ, Inst Biomed Sci, Shanghai 200433, Peoples R China; [Ji, Chaoneng] Fudan Univ, Inst Genet, Sch Life Sci, Shanghai 200433, Peoples R China; [Li, Huiming] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA; [Dong, Aichun] Univ No Colorado, Dept Chem & Biochem, Greeley, CO 80639 USA	Fudan University; Fudan University; Fudan University; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; University of Northern Colorado	Yu, SN (corresponding author), Fudan Univ, Dept Chem, Shanghai 200433, Peoples R China.	yushaoning@fudan.edu.cn						Aramburu J, 2000, CURR TOP CELL REGUL, V36, P237; Chen R, 2003, J BIOL CHEM, V278, P13235, DOI 10.1074/jbc.M211551200; Cohen P T, 1996, Adv Pharmacol, V36, P67; DONG A, 1990, BIOCHEMISTRY-US, V29, P3303, DOI 10.1021/bi00465a022; Dong AC, 2002, BIOCHEMISTRY-US, V41, P6660, DOI 10.1021/bi020036z; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; Hogan PG, 2005, CURR BIOL, V15, pR442, DOI 10.1016/j.cub.2005.06.006; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; KINCAID R, 1993, ADV SEC MESS PHOSPH, V27, P1; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Li HM, 2004, J MOL BIOL, V342, P1659, DOI 10.1016/j.jmb.2004.07.068; Lin X, 1999, J BIOL CHEM, V274, P36125, DOI 10.1074/jbc.274.51.36125; Perrino BA, 1999, ARCH BIOCHEM BIOPHYS, V372, P159, DOI 10.1006/abbi.1999.1485; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; STEMMER PM, 1994, BIOCHEMISTRY-US, V33, P6859, DOI 10.1021/bi00188a015; Yang SA, 2000, BIOCHEMISTRY-US, V39, P16147, DOI 10.1021/bi001321q	21	32	33	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11407	11413		10.1074/jbc.M708513200	http://dx.doi.org/10.1074/jbc.M708513200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18296442	hybrid			2022-12-25	WOS:000255067400038
J	Liang, F; Luo, Y; Dong, YS; Walls, CD; Liang, J; Jiang, HY; Sanford, JR; Wek, RC; Zhang, ZY				Liang, Fubo; Luo, Yong; Dong, Yuanshu; Walls, Chad D.; Liang, Jiao; Jiang, Hao-Yuan; Sanford, Jeremy R.; Wek, Ronald C.; Zhang, Zhong-Yin			Translational control of C-terminal Src kinase (Csk) expression by PRL3 phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; MESSENGER-RNA TRANSLATION; MOUSE MELANOMA-CELLS; MALIGNANT-TRANSFORMATION; COLORECTAL-CANCER; IN-VIVO; METASTASIS; CARCINOMA; GENE; MIGRATION	Phosphatase of regenerating liver 3 (PRL3) is up-regulated in cancer metastases. However, little is known of PRL3-mediated cellular signaling pathways. We previously reported that elevated PRL3 expression increases Src kinase activity, which likely contributes to the increased tumorigenesis and metastasis potential of PRL3. PRL3-induced Src activation is proposed to be indirect through down-regulation of Csk, a negative regulator of Src. Given the importance of PRL3 in tumor metastasis and the role of Csk in controlling Src activity, we addressed the mechanism by which PRL3 mediates Csk down-regulation. PRL3 is shown to exert a negative effect on Csk protein synthesis, rather than regulation of Csk mRNA levels or protein turnover. Interestingly, the preferential decrease in Csk protein synthesis is a consequence of increased eIF2 phosphorylation resulting from PRL3 expression. Reduced Csk synthesis also occurs in response to cellular stress that induces eIF2 phosphorylation, indicating that this regulatory mechanism may occur in response to a wider spectrum of cellular conditions known to direct translational control. Thus, we have uncovered a previously uncharacterized role for PRL3 in the gene-specific translational control of Csk expression.	[Liang, Fubo; Luo, Yong; Dong, Yuanshu; Walls, Chad D.; Liang, Jiao; Jiang, Hao-Yuan; Sanford, Jeremy R.; Wek, Ronald C.; Zhang, Zhong-Yin] Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Zhang, ZY (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.	zyzhang@iupui.edu			NATIONAL CANCER INSTITUTE [R01CA069202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM049164, R01GM049164] Funding Source: NIH RePORTER; NCI NIH HHS [CA69202] Funding Source: Medline; NIGMS NIH HHS [GM49164] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Blais JD, 2006, MOL CELL BIOL, V26, P9517, DOI 10.1128/MCB.01145-06; Cam WR, 2001, CANCER, V92, P61, DOI 10.1002/1097-0142(20010701)92:1<61::AID-CNCR1292>3.0.CO;2-D; Chen XY, 2004, MOL CELL, V16, P839, DOI 10.1016/j.molcel.2004.11.011; Clemens MJ, 2004, ONCOGENE, V23, P3180, DOI 10.1038/sj.onc.1207544; Cole PA, 2003, CURR OPIN CHEM BIOL, V7, P580, DOI 10.1016/j.cbpa.2003.08.009; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; Glaser T, 2001, ONCOGENE, V20, P4757, DOI 10.1038/sj.onc.1204498; Gonzalez-Cabrera PJ, 2007, J BIOL CHEM, V282, P7254, DOI 10.1074/jbc.M610581200; Holland EC, 2004, ONCOGENE, V23, P3138, DOI 10.1038/sj.onc.1207590; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Inoki K, 2006, TRENDS CELL BIOL, V16, P206, DOI 10.1016/j.tcb.2006.02.002; Jousse C, 2003, J CELL BIOL, V163, P767, DOI 10.1083/jcb.200308075; Kato H, 2004, CLIN CANCER RES, V10, P7318, DOI 10.1158/1078-0432.CCR-04-0485; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Kubens BS, 1998, CANCER LETT, V131, P55, DOI 10.1016/S0304-3835(98)00201-8; Kwok JC, 2004, MOL PHARMACOL, V65, P181, DOI 10.1124/mol.65.1.181; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Liang FB, 2007, J BIOL CHEM, V282, P5413, DOI 10.1074/jbc.M608940200; Marciniak SJ, 2006, PHYSIOL REV, V86, P1133, DOI 10.1152/physrev.00015.2006; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Masaki T, 1999, HEPATOLOGY, V29, P379, DOI 10.1002/hep.510290239; Miskad UA, 2004, PATHOBIOLOGY, V71, P176, DOI 10.1159/000078671; Nakagawa T, 2000, INT J CANCER, V88, P384, DOI 10.1002/1097-0215(20001101)88:3<384::AID-IJC10>3.3.CO;2-2; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Parker BS, 2004, CANCER RES, V64, P7857, DOI 10.1158/0008-5472.CAN-04-1976; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; Polato F, 2005, CLIN CANCER RES, V11, P6835, DOI 10.1158/1078-0432.CCR-04-2357; Proud CG, 2005, SEMIN CELL DEV BIOL, V16, P3, DOI 10.1016/j.semcdb.2004.11.004; Qian F, 2007, MOL MED, V13, P151, DOI 10.2119/2006-00076.Qian; Rengifo-Cam W, 2004, ONCOGENE, V23, P289, DOI 10.1038/sj.onc.1207041; Rouleau C, 2006, MOL CANCER THER, V5, P219, DOI 10.1158/1535-7163.MCT-05-0289; Sager JA, 2004, CANCER BIOL THER, V3, P952, DOI 10.4161/cbt.3.10.1115; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Schwering I, 2003, MOL MED, V9, P85, DOI 10.1007/BF03402041; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Stephens BJ, 2005, MOL CANCER THER, V4, P1653, DOI 10.1158/1535-7163.MCT-05-0248; SU Q, 2004, P NATL ACAD SCI USA, V103, P63; Tan M, 2005, CANCER RES, V65, P1858, DOI 10.1158/0008-5472.CAN-04-2353; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; Wu XP, 2004, AM J PATHOL, V164, P2039, DOI 10.1016/S0002-9440(10)63763-7; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Zeng Q, 2003, CANCER RES, V63, P2716	47	29	30	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10339	10346		10.1074/jbc.M708285200	http://dx.doi.org/10.1074/jbc.M708285200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18268019	Green Published, hybrid			2022-12-25	WOS:000254894700014
J	Song, JK; Bettendorff, L; Tonelli, M; Markley, JL				Song, Jikui; Bettendorff, Lucien; Tonelli, Marco; Markley, John L.			Structural basis for the catalytic mechanism of mammalian 25-kDa thiamine triphosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUNNEL METALLOENZYME SUPERFAMILY; YEAST RNA TRIPHOSPHATASE; TORSION ANGLE DYNAMICS; RAT-BRAIN; NMR; PROTEIN; PURIFICATION; TISSUES; PHOSPHATE; SYSTEM	Mammalian soluble thiamine triphosphatase (ThTPase) is a 25-kDa cytosolic enzyme that specifically catalyzes the conversion of thiamine triphosphate (ThTP) to thiamine diphosphate and has an absolute requirement for divalent cations. We have investigated the kinetic properties of recombinant mouse thiamine triphosphatase (mThTPase) and determined its solution structure by NMR spectroscopy. Residues responsible for binding Mg2+ and ThTP were determined from NMR titration experiments. The binding of Mg2+ induced only a minor local conformational change, whereas ThTP binding was found to cause a more global conformational change. We derived a structural model for the mThTPase.ThTP.Mg2+ ternary complex and concluded from this that whereas free mThTPase has an open cleft fold, the enzyme in the ternary complex adopts a tunnel fold. Our results provide a functional rationale for a number of conserved residues and suggest an essential role for Mg2+ in catalysis. We propose a mechanism underlying the high substrate specificity of mThTPase and discuss the possible role of water molecules in enzymatic catalysis.	[Tonelli, Marco; Markley, John L.] Univ Wisconsin, Dept Biochem, Natl Magnet Resonance Facil Madison, Madison, WI 53706 USA; [Song, Jikui; Markley, John L.] Univ Wisconsin, Ctr Eukaryot Struct Genom, Madison, WI 53706 USA; [Bettendorff, Lucien] Univ Liege, Ctr Cellular & Mol Neurobiol, B-4000 Liege, Belgium	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Liege	Markley, JL (corresponding author), Univ Wisconsin, Dept Biochem, Natl Magnet Resonance Facil Madison, 433 Babcock Dr, Madison, WI 53706 USA.	markley@nmrfam.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM064598, U54GM074901] Funding Source: NIH RePORTER; NIGMS NIH HHS [P50 GM64598, U54 GM074901] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARCHI RL, 1976, J BIOL CHEM, V251, P193; Bettendorff L, 2003, ANAL BIOCHEM, V322, P190, DOI 10.1016/j.ab.2003.08.013; BETTENDORFF L, 1993, J NEUROCHEM, V60, P423, DOI 10.1111/j.1471-4159.1993.tb03168.x; Bisaillon M, 2003, J BIOL CHEM, V278, P33963, DOI 10.1074/jbc.M303007200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Gallagher DT, 2006, J MOL BIOL, V362, P114, DOI 10.1016/j.jmb.2006.07.008; Gong CL, 2006, RNA, V12, P1468, DOI 10.1261/rna.119806; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HASHITANI Y, 1972, J BIOL CHEM, V247, P2117; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; IWATA H, 1985, NEUROCHEM RES, V10, P779, DOI 10.1007/BF00964535; Iyer LM, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-33; Jeon Won Bae, 2005, Journal of Structural and Functional Genomics, V6, P143, DOI 10.1007/s10969-005-1908-7; Keppetipola N, 2007, J BIOL CHEM, V282, P11941, DOI 10.1074/jbc.M611328200; Lakaye B, 2004, INT J BIOCHEM CELL B, V36, P1348, DOI 10.1016/j.biocel.2003.11.013; Lakaye B, 2004, J BIOL CHEM, V279, P17142, DOI 10.1074/jbc.M313569200; Lakaye B, 2002, J BIOL CHEM, V277, P13771, DOI 10.1074/jbc.M111241200; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lima CD, 1999, CELL, V99, P533, DOI 10.1016/S0092-8674(00)81541-X; MAKARCHIKOV AF, 1992, BIOCHIM BIOPHYS ACTA, V1117, P326, DOI 10.1016/0304-4165(92)90032-P; Nghiem HO, 2000, FASEB J, V14, P543, DOI 10.1096/fasebj.14.3.543; PENTTINEN HK, 1981, MED BIOL, V59, P177; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Sousa MC, 1998, BIOCHEMISTRY-US, V37, P15392, DOI 10.1021/bi981510x; Sreenath HK, 2005, PROTEIN EXPRES PURIF, V40, P256, DOI 10.1016/j.pep.2004.12.022; Szyniarowski P, 2005, BBA-GEN SUBJECTS, V1725, P93, DOI 10.1016/j.bbagen.2005.05.026; Thao Sandy, 2004, Journal of Structural and Functional Genomics, V5, P267, DOI 10.1007/s10969-004-7148-4; Zolnai Zsolt, 2003, Journal of Structural and Functional Genomics, V4, P11, DOI 10.1023/A:1024684404761; Zwahlen C, 1997, J AM CHEM SOC, V119, P6711, DOI 10.1021/ja970224q	32	18	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10939	10948		10.1074/jbc.M709675200	http://dx.doi.org/10.1074/jbc.M709675200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18276586	Green Published, hybrid			2022-12-25	WOS:000254894700075
J	Lai, LS; Xu, ZH; Zhou, JH; Lee, KD; Amidon, GL				Lai, Longsheng; Xu, Zhaohui; Zhou, Jiahai; Lee, Kyung-Dall; Amidon, Gordon L.			Molecular basis of prodrug activation by human valacyclovirase, an alpha-amino acid ester hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-VALYL ESTER; TRICORN PROTEASE; SERINE HYDROLASE; VALACICLOVIR; ACYCLOVIR; PHARMACOKINETICS; VALGANCICLOVIR; IDENTIFICATION; ENZYMES; ACETYLCHOLINESTERASE	Chemical modification to improve biopharmaceutical properties, especially oral absorption and bioavailability, is a common strategy employed by pharmaceutical chemists. The approach often employs a simple structural modification and utilizes ubiquitous endogenous esterases as activation enzymes, although such enzymes are often unidentified. This report describes the crystal structure and specificity of a novel activating enzyme for valacyclovir and valganciclovir. Our structural insights show that human valacyclovirase has a unique binding mode and specificity for amino acid esters. Biochemical data demonstrate that the enzyme hydrolyzes esters of alpha-amino acids exclusively and displays a broad specificity spectrum for the aminoacyl moiety similar to tricorn-interacting aminopeptidase F1. Crystal structures of the enzyme, two mechanistic mutants, and a complex with a product analogue, when combined with biochemical analysis, reveal the key determinants for substrate recognition; that is, a flexible and mostly hydrophobic acyl pocket, a localized negative electrostatic potential, a large open leaving group-accommodating groove, and a pivotal acidic residue, Asp-123, after the nucleophile Ser-122. This is the first time that a residue immediately after the nucleophile has been found to have its side chain directed into the substrate binding pocket and play an essential role in substrate discrimination in serine hydrolases. These results as well as a phylogenetic analysis establish that the enzyme functions as a specific alpha-amino acid ester hydrolase. Valacyclovirase is a valuable target for amino acid ester prodrug-based oral drug delivery enhancement strategies.	[Lai, Longsheng; Lee, Kyung-Dall; Amidon, Gordon L.] Univ Michigan, Dept Pharmaceut Sci, Ann Arbor, MI 48109 USA; [Lai, Longsheng; Lee, Kyung-Dall; Amidon, Gordon L.] Univ Michigan, Ctr Mol Drug Targeting, Ann Arbor, MI 48109 USA; [Xu, Zhaohui; Zhou, Jiahai] Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; [Xu, Zhaohui; Zhou, Jiahai] Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Amidon, GL (corresponding author), Univ Michigan, Dept Pharmaceut Sci, 428 Church St, Ann Arbor, MI 48109 USA.	glamidon@umich.edu			NIGMS NIH HHS [GM 37188] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037188] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Balimane PV, 1998, BIOCHEM BIOPH RES CO, V250, P246, DOI 10.1006/bbrc.1998.9298; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURNETTE TC, 1995, J BIOL CHEM, V270, P15827, DOI 10.1074/jbc.270.26.15827; CROOKS RJ, 1994, ANTIVIR CHEM CHEMOTH, V5, P31; Curran M, 2001, DRUGS, V61, P1145, DOI 10.2165/00003495-200161080-00013; DEMIRANDA P, 1983, J ANTIMICROB CHEMOTH, V12, P29, DOI 10.1093/jac/12.suppl_B.29; Ettmayer P, 2004, J MED CHEM, V47, P2393, DOI 10.1021/jm0303812; Goettig P, 2002, EMBO J, V21, P5343, DOI 10.1093/emboj/cdf552; Han HK, 1998, PHARMACEUT RES, V15, P1154, DOI 10.1023/A:1011919319810; Harding MM, 2006, ACTA CRYSTALLOGR D, V62, P678, DOI 10.1107/S0907444906014594; Harding MM, 2001, ACTA CRYSTALLOGR D, V57, P401, DOI 10.1107/S0907444900019168; Hendrickson WA, 1997, METHOD ENZYMOL, V276, P494, DOI 10.1016/S0076-6879(97)76074-9; Hernaez MJ, 2000, J BACTERIOL, V182, P5448, DOI 10.1128/JB.182.19.5448-5453.2000; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Huhtinen K, 2002, J BIOL CHEM, V277, P3424, DOI 10.1074/jbc.M109040200; Imai T, 2006, DRUG METAB PHARMACOK, V21, P173, DOI 10.2133/dmpk.21.173; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jung D, 1999, J CLIN PHARMACOL, V39, P800, DOI 10.1177/00912709922008452; Kim I, 2003, J BIOL CHEM, V278, P25348, DOI 10.1074/jbc.M302055200; Kim I, 2004, MOL PHARMACEUT, V1, P117, DOI 10.1021/mp0499757; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li J, 1996, BIOCHEMISTRY-US, V35, P9967, DOI 10.1021/bi9605292; Liederer BM, 2006, J PHARM SCI-US, V95, P1177, DOI 10.1002/jps.20542; Nandhagopal N, 2001, J MOL BIOL, V309, P1139, DOI 10.1006/jmbi.2001.4737; Nardini M, 1999, CURR OPIN STRUC BIOL, V9, P732, DOI 10.1016/S0959-440X(99)00037-8; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pescovitz MD, 2000, ANTIMICROB AGENTS CH, V44, P2811, DOI 10.1128/AAC.44.10.2811-2815.2000; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Puente XS, 1998, GENOMICS, V51, P459, DOI 10.1006/geno.1998.5351; PUENTE XS, 1995, J BIOL CHEM, V270, P12926, DOI 10.1074/jbc.270.21.12926; RIPOLL DR, 1993, P NATL ACAD SCI USA, V90, P5128, DOI 10.1073/pnas.90.11.5128; Satoh T, 1998, ANNU REV PHARMACOL, V38, P257, DOI 10.1146/annurev.pharmtox.38.1.257; SHAFFERMAN A, 1992, J BIOL CHEM, V267, P17640; SOULLAWTON J, 1995, ANTIMICROB AGENTS CH, V39, P2759, DOI 10.1128/AAC.39.12.2759; Stella V., 2007, PRODRUGS CHALLENGES; Sugawara M, 2000, J PHARM SCI-US, V89, P781, DOI 10.1002/(SICI)1520-6017(200006)89:6<781::AID-JPS10>3.0.CO;2-7; Tamura N, 1998, CELL, V95, P637, DOI 10.1016/S0092-8674(00)81634-7; Tamura T, 1996, FEBS LETT, V398, P101, DOI 10.1016/S0014-5793(96)01163-5; TAN RC, 1993, BIOCHEMISTRY-US, V32, P401, DOI 10.1021/bi00053a003; WELLER S, 1993, CLIN PHARMACOL THER, V54, P595, DOI 10.1038/clpt.1993.196	43	50	54	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9318	9327		10.1074/jbc.M709530200	http://dx.doi.org/10.1074/jbc.M709530200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18256025	Green Published, hybrid			2022-12-25	WOS:000254465800062
J	Reddy, VS; Singh, AK; Rajasekharan, R				Reddy, Venky Sreedhar; Singh, Arjun Kumar; Rajasekharan, Ram			The Saccharomyces cerevisiae PHM8 gene encodes a soluble magnesium-dependent lysophosphatidic acid phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; RHODOBACTER-SPHAEROIDES; LIPID COMPOSITION; BIOSYNTHESIS; ACCUMULATION; ARABIDOPSIS; STARVATION; YEAST; PURIFICATION; LIMITATION	Phosphate is the essential macronutrient required for the growth of all organisms. In Saccharomyces cerevisiae, phosphatases are up-regulated, and the level of lysophosphatidic acid (LPA) is drastically decreased under phosphate-starved conditions. The reduction in the LPA level is attributed to PHM8, a gene of unknown function. phm8 Delta yeast showed a decreased LPA-hydrolyzing activity under phosphate-limiting conditions. Overexpression of PHM8 in yeast resulted in an increase in the LPA phosphatase activity in vivo. In vitro assays of the purified recombinant Phm8p revealed magnesium-dependent LPA phosphatase activity, with maximal activity at pH 6.5. The purified Phm8p did not hydrolyze any lipid phosphates other than LPA. In silico analysis suggest that Phm8p is a soluble protein with no transmembrane domain. Site-directed mutational studies revealed that aspartate residues in a DXDXT motif are important for the catalysis. These findings indicated that LPA plays a direct role in phosphate starvation. This is the first report of the identification and characterization of magnesium-dependent soluble LPA phosphatase.	[Reddy, Venky Sreedhar; Singh, Arjun Kumar; Rajasekharan, Ram] Indian Inst Sci, Dept Biochem, Lipid Lab, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Rajasekharan, R (corresponding author), Indian Inst Sci, Dept Biochem, Lipid Lab, Bangalore 560012, Karnataka, India.	lipid@biochem.iisc.ernet.in	Rajasekharan, Ram/R-2257-2019; R, Rajasekharan/D-3420-2009	Rajasekharan, Ram/0000-0002-2124-6013; Ram, Rajasekharan/0000-0002-4114-0654				ALEXANDER D R, 1990, New Biologist, V2, P1049; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BENNING C, 1993, P NATL ACAD SCI USA, V90, P1561, DOI 10.1073/pnas.90.4.1561; BENNING C, 1995, ARCH BIOCHEM BIOPHYS, V317, P103, DOI 10.1006/abbi.1995.1141; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; Collet JF, 1998, J BIOL CHEM, V273, P14107, DOI 10.1074/jbc.273.23.14107; Dillon DA, 1996, J BIOL CHEM, V271, P30548, DOI 10.1074/jbc.271.48.30548; Fiske CH, 1925, J BIOL CHEM, V66, P375; Furneisen JM, 2000, BBA-MOL CELL BIOL L, V1484, P71, DOI 10.1016/S1388-1981(99)00202-4; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; Han GS, 2007, J BIOL CHEM, V282, P37026, DOI 10.1074/jbc.M705777200; Han GS, 2006, J BIOL CHEM, V281, P9210, DOI 10.1074/jbc.M600425200; Hartel H, 2000, P NATL ACAD SCI USA, V97, P10649, DOI 10.1073/pnas.180320497; HAYASHI E, 1976, J BIOL CHEM, V251, P5759; Hiroyama M, 1998, BIOCHEM J, V336, P483, DOI 10.1042/bj3360483; Hiroyama R, 1999, J BIOL CHEM, V274, P29172, DOI 10.1074/jbc.274.41.29172; HUNTER K, 1972, BIOCHIM BIOPHYS ACTA, V260, P639, DOI 10.1016/0005-2760(72)90013-6; ILLINGWO.RF, 1973, J BACTERIOL, V113, P373, DOI 10.1128/JB.113.1.373-386.1973; Khozin-Goldberg I, 2006, PHYTOCHEMISTRY, V67, P696, DOI 10.1016/j.phytochem.2006.01.010; KOONIN EV, 1994, J MOL BIOL, V244, P125, DOI 10.1006/jmbi.1994.1711; Lenburg ME, 1996, TRENDS BIOCHEM SCI, V21, P383, DOI 10.1016/S0968-0004(96)90127-9; Lu ZB, 2005, BIOCHEMISTRY-US, V44, P8684, DOI 10.1021/bi050009j; Mahuren JD, 2001, ANAL BIOCHEM, V298, P241, DOI 10.1006/abio.2001.5402; Nakamura Y, 2005, J BIOL CHEM, V280, P7469, DOI 10.1074/jbc.M408799200; Ndubuisil MI, 2002, BIOCHEMISTRY-US, V41, P7841, DOI 10.1021/bi0255064; Newman JW, 2003, P NATL ACAD SCI USA, V100, P1558, DOI 10.1073/pnas.0437724100; Ogawa N, 2000, MOL BIOL CELL, V11, P4309, DOI 10.1091/mbc.11.12.4309; Oshima Y, 1997, GENES GENET SYST, V72, P323, DOI 10.1266/ggs.72.323; PALTAUF F, 1970, Biochimica et Biophysica Acta, V218, P424, DOI 10.1016/0005-2760(70)90005-6; PATTON JL, 1995, J BACTERIOL, V177, P3379, DOI 10.1128/jb.177.12.3379-3385.1995; RAMSAY AM, 1979, GEN MICROBIOL, V110, P185; Reddy MM, 2006, ARCH BIOCHEM BIOPHYS, V455, P99, DOI 10.1016/j.abb.2006.09.009; ROSE AH, 1989, MICROBIAL LIPIDS, V2, P255; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Selengut JD, 2000, BIOCHEMISTRY-US, V39, P8315, DOI 10.1021/bi0005052; Shekar S, 2002, PLANT PHYSIOL, V128, P988, DOI 10.1104/pp.010654; TAMAI Y, 1985, J BACTERIOL, V164, P964, DOI 10.1128/JB.164.2.964-968.1985; VELDHUIZEN RAW, 1991, BIOCHIM BIOPHYS ACTA, V1083, P211, DOI 10.1016/0005-2760(91)90045-J	41	30	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					8846	8854		10.1074/jbc.M706752200	http://dx.doi.org/10.1074/jbc.M706752200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18234677	hybrid			2022-12-25	WOS:000254465800011
J	Kar, NS; Ashraf, MZ; Valiyaveettil, M; Podrez, EA				Kar, Niladri S.; Ashraf, Mohammad Z.; Valiyaveettil, Manojkumar; Podrez, Eugene A.			Mapping and characterization of the binding site for specific oxidized phospholipids and oxidized low density lipoprotein of scavenger receptor CD36	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATHEROSCLEROTIC LESIONS; CRYSTAL-STRUCTURE; OXIDANT STRESS; LECTIN-LIKE; IDENTIFICATION; ADHESION; LIGAND; DOMAIN; LDL; FAMILY	Recent studies have identified a novel family of oxidized phosphatidylcholines (oxPC(CD36)) that serve as highly specific ligands for scavenger receptor CD36.oxPC(CD36) accumulate in vivo and mediate macrophage foam cell formation as well as promote platelet hyper-reactivity in hyperlipidemia via CD36. The structural basis of oxPCCD36 binding to CD36 has not been elucidated. We used liquid-phase binding to glutathione S-transferase fusion proteins containing various regions of CD36 to initially identify the region spanning CD36 amino acids 157 171 to contain a major binding site for oxPCCD36. A bell-shaped pH profile and salt concentration dependence suggest an electrostatic mechanism of the binding. Two conserved, positively charged amino acids in the region 157-171 (lysines at positions 164 and 166) were identified as critical for oxPCCD36 and oxidized low density lipoprotein (oxLDL) binding to CD36. Lysine neutralization with chemical modifier or site-directed mutagenesis of lysine 164/166 to alanine or glutamate, but not to arginine, abolished binding. Cells expressing full-length CD36 with mutated lysines (164 and 166) failed to recognize oxPCCD36 and oxLDL. Synthetic peptides mimicking the CD36 binding site, but not mutated or scrambled peptides, effectively prevented: (i) oxLDL binding to CD36, (ii) macrophage foam cell formation induced by oxLDL, and (iii) platelet activation by oxPCCD36. These data indicate that CD36 (160-168) represents the core of the oxPCCD36 binding site with lysines 164/166 being indispensable for the binding.	[Kar, Niladri S.; Ashraf, Mohammad Z.; Valiyaveettil, Manojkumar; Podrez, Eugene A.] Cleveland Clin Fdn, Dept Mol Cardiol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Podrez, EA (corresponding author), Cleveland Clin Fdn, Dept Mol Cardiol, Lerner Res Inst, 9500 Euclid Ave,ND50, Cleveland, OH 44195 USA.	podreze@ccf.org			NHLBI NIH HHS [HL 077213, HL 053315, R01 HL077213] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077213, R01HL053315] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abumrad NA, 2005, PROSTAG OTH LIPID M, V77, P77, DOI 10.1016/j.prostaglandins.2004.09.012; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; ASCH AS, 1993, SCIENCE, V262, P1436, DOI 10.1126/science.7504322; Bodart V, 2002, CIRC RES, V90, P844, DOI 10.1161/01.RES.0000016164.02525.B4; Boullier A, 2000, J BIOL CHEM, V275, P9163, DOI 10.1074/jbc.275.13.9163; Chen MY, 2001, FEBS LETT, V499, P215, DOI 10.1016/S0014-5793(01)02557-1; Daviet L, 1997, THROMB HAEMOSTASIS, V78, P65; Demers A, 2004, BIOCHEM J, V382, P417, DOI 10.1042/BJ20040036; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253; Li XM, 2007, BIOCHEMISTRY-US, V46, P5009, DOI 10.1021/bi700163y; Marleau Sylvie, 2005, FASEB J, V19, P1869; Matsuno K, 1996, BRIT J HAEMATOL, V92, P960, DOI 10.1046/j.1365-2141.1996.422962.x; Navazo MDP, 1996, J BIOL CHEM, V271, P15381, DOI 10.1074/jbc.271.26.15381; Navazo MDP, 1996, ARTERIOSCL THROM VAS, V16, P1033, DOI 10.1161/01.ATV.16.8.1033; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; OCKENHOUSE CF, 1989, SCIENCE, V243, P1469, DOI 10.1126/science.2467377; Ohki I, 2005, STRUCTURE, V13, P905, DOI 10.1016/j.str.2005.03.016; Park H, 2005, J BIOL CHEM, V280, P13593, DOI 10.1074/jbc.M500768200; PEARCE SFA, 1995, J BIOL CHEM, V270, P2981, DOI 10.1074/jbc.270.7.2981; Pearce SFA, 1998, J BIOL CHEM, V273, P34875, DOI 10.1074/jbc.273.52.34875; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; Podrez EA, 2000, J CLIN INVEST, V105, P1095, DOI 10.1172/JCI8574; Podrez EA, 2002, J BIOL CHEM, V277, P38517, DOI 10.1074/jbc.M205924200; Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200; Podrez EA, 2007, NAT MED, V13, P1086, DOI 10.1038/nm1626; Stewart BW, 2006, MOL IMMUNOL, V43, P255, DOI 10.1016/j.molimm.2005.02.007; Sun MJ, 2006, J BIOL CHEM, V281, P4222, DOI 10.1074/jbc.M509769200; Tanaka T, 2001, J LIPID RES, V42, P751; TANDON NN, 1989, J BIOL CHEM, V264, P7576	33	74	75	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8765	8771		10.1074/jbc.M709195200	http://dx.doi.org/10.1074/jbc.M709195200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18245080	Green Published, hybrid			2022-12-25	WOS:000254288000074
J	Mappes, T; Koivula, M; Koskela, E; Oksanen, TA; Savolainen, T; Sinervo, B				Mappes, Tapio; Koivula, Minna; Koskela, Esa; Oksanen, Tuula A.; Savolainen, Tiina; Sinervo, Barry			Frequency and Density-Dependent Selection on Life-History Strategies - A Field Experiment	PLOS ONE			English	Article								Negative frequency-dependence, which favors rare genotypes, promotes the maintenance of genetic variability and is of interest as a potential explanation for genetic differentiation. Density-dependent selection may also promote cyclic changes in frequencies of genotypes. Here we show evidence for both density-dependent and negative frequency-dependent selection on opposite life-history tactics (low or high reproductive effort, RE) in the bank vole (Myodes glareolus). Density-dependent selection was evident among the females with low RE, which were especially favored in low densities. Instead, both negative frequency-dependent and density-dependent selection were shown in females with high RE, which were most successful when they were rare in high densities. Furthermore, selection at the individual level affected the frequencies of tactics at the population level, so that the frequency of the rare high RE tactic increased significantly at high densities. We hypothesize that these two selection mechanisms (density- and negative frequency-dependent selection) may promote genetic variability in cyclic mammal populations. Nevertheless, it remains to be determined whether the origin of genetic variance in life-history traits is causally related to density variation (e.g. population cycles).	[Mappes, Tapio; Koskela, Esa; Oksanen, Tuula A.; Savolainen, Tiina] Univ Jyvaskyla, Dept Biol & Environm Sci, Jyvaskyla, Finland; [Koivula, Minna] MTT Biotechnol & Food Res, Jokioinen, Finland; [Sinervo, Barry] Univ Calif Santa Cruz, Dept Ecol & Evolutionary Biol, Santa Cruz, CA USA	University of Jyvaskyla; Natural Resources Institute Finland (Luke); University of California System; University of California Santa Cruz	Mappes, T (corresponding author), Univ Jyvaskyla, Dept Biol & Environm Sci, Jyvaskyla, Finland.	tmappes@bytl.jyu.fi	Mappes, Tapio/B-9780-2013	Koskela, Esa/0000-0002-9418-5733; Oksanen, Tuula/0000-0003-3481-6158; Mappes, Tapio/0000-0002-5936-7355	Academy of Finland [206091, 118603, 109165, 100143, 78777, 103148, 115961]; Centre of Excellence of Evolutionary Research of the Academy of Finland	Academy of Finland(Academy of Finland); Centre of Excellence of Evolutionary Research of the Academy of Finland(Academy of Finland)	Financial supported by the Academy of Finland (grant no. 206091, 118603, 109165 to T.M; 100143, 78777, 103148, 115961 to E.K.) and Centre of Excellence of Evolutionary Research of the Academy of Finland.	ANTONOVICS J, 1984, EVOLUTION, V38, P103, DOI 10.1111/j.1558-5646.1984.tb00263.x; BUJALSKA G, 1970, Acta Theriologica, V15, P381; Bulmer MG, 1985, MATH THEORY QUANTITA; Burger R, 2004, GENETICS, V167, P1425, DOI 10.1534/genetics.103.018986; Chitty D., 1967, Proceedings of the Ecological Society of Australia, V2, P51; Falconer D. S, 1996, INTRO QUANTITATIVE G; GUSTAFSSON L, 1986, AM NAT, V128, P761, DOI 10.1086/284601; Hanski I, 2001, ECOLOGY, V82, P1505, DOI 10.1890/0012-9658(2001)082[1505:SRDAP]2.0.CO;2; HANSSON L, 1985, OECOLOGIA, V67, P394, DOI 10.1007/BF00384946; HANSSON L, 1979, OIKOS, V33, P55, DOI 10.2307/3544511; Hopfner R, 2006, J MATH BIOL, V52, P439, DOI 10.1007/s00285-005-0361-3; HUITU O, 2006, OIKOS IN PRESS; Jonsson P, 2002, EVOL ECOL, V16, P455, DOI 10.1023/A:1020854525220; Kleiber M, 1961, FIRE LIFE; Koivula M, 2003, ECOLOGY, V84, P398, DOI 10.1890/0012-9658(2003)084[0398:CORITW]2.0.CO;2; Kopp M, 2006, EVOLUTION, V60, P1537; Korpimaki E, 2005, P ROY SOC B-BIOL SCI, V272, P193, DOI 10.1098/rspb.2004.2860; Koskela E, 1999, J ANIM ECOL, V68, P513, DOI 10.1046/j.1365-2656.1999.00308.x; Koskela E, 1997, J ANIM ECOL, V66, P341, DOI 10.2307/5980; KRUCZEK M, 1986, BIOL REPROD, V35, P537, DOI 10.1095/biolreprod35.3.537; Lidicker WZ, 2000, ECOSCIENCE, V7, P247, DOI 10.1080/11956860.2000.11682594; MANI GS, 1990, PROC R SOC SER B-BIO, V240, P15, DOI 10.1098/rspb.1990.0024; MAPPES T, 1995, P ROY SOC B-BIOL SCI, V261, P19, DOI 10.1098/rspb.1995.0111; Mappes T, 2004, EVOLUTION, V58, P645, DOI 10.1111/j.0014-3820.2004.tb01686.x; Maynard Smith J., 1982, EVOLUTION THEORY GAM; McCleery RH, 2004, AM NAT, V164, pE62, DOI 10.1086/422660; Merila J, 2000, AM NAT, V155, P301, DOI 10.1086/303330; MILLAR JS, 1977, EVOLUTION, V31, P370, DOI 10.2307/2407759; Mills SC, 2007, P ROY SOC B-BIOL SCI, V274, P143, DOI 10.1098/rspb.2006.3639; MOUSSEAU TA, 1987, HEREDITY, V59, P181, DOI 10.1038/hdy.1987.113; Oksanen TA, 2002, EVOLUTION, V56, P1530; Oksanen TA, 2003, J ANIM ECOL, V72, P321, DOI 10.1046/j.1365-2656.2003.00703.x; Oksanen TA, 2007, EVOLUTION, V61, P2822, DOI 10.1111/j.1558-5646.2007.00245.x; Olendorf R, 2006, NATURE, V441, P633, DOI 10.1038/nature04646; OSTFELD RS, 1990, TRENDS ECOL EVOL, V5, P411, DOI 10.1016/0169-5347(90)90026-A; Paterson S, 2003, TRENDS PARASITOL, V19, P370, DOI 10.1016/S1471-4922(03)00149-1; POIKONEN T, 2008, EVOLUTION IN PRESS; PRICE T, 1991, EVOLUTION, V45, P853, DOI 10.1111/j.1558-5646.1991.tb04354.x; REZNICK D, 1985, OIKOS, V44, P257, DOI 10.2307/3544698; Roff Derek, 2002, pi; Roff Derek A., 1992; RUEFFLER C, 2003, THEORETICAL POPULATI, V65, P165; Sinervo B, 1996, NATURE, V380, P240, DOI 10.1038/380240a0; Sinervo B, 2001, GENETICA, V112, P417, DOI 10.1023/A:1013360426789; Sinervo B, 2001, EVOLUTION, V55, P2040; Sinervo B, 2000, NATURE, V406, P985, DOI 10.1038/35023149; Sinervo B, 2007, AM NAT, V170, P663, DOI 10.1086/522092; STENSETH NC, 1985, ANN ZOOL FENN, V22, P215; Trotter MV, 2007, GENETICS, V176, P1729, DOI 10.1534/genetics.107.073072; Turchin P, 2001, ECOLOGY, V82, P1521, DOI 10.2307/2679797; WILLIAMS GC, 1966, AM NAT, V100, P687, DOI 10.1086/282461; Wojcik AM, 2006, EVOLUTION, V60, P1925; WOLFF JO, 1993, OIKOS, V68, P364, DOI 10.2307/3544853	53	31	31	0	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2008	3	2							e1687	10.1371/journal.pone.0001687	http://dx.doi.org/10.1371/journal.pone.0001687			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XS	18301764	Green Published, gold			2022-12-25	WOS:000260586500031
J	Macedo-Ribeiro, S; Almeida, C; Calisto, BM; Friedrich, T; Mentele, R; Sturzebecher, J; Fuentes-Prior, P; Pereira, PJB				Macedo-Ribeiro, Sandra; Almeida, Carla; Calisto, Barbara M.; Friedrich, Thomas; Mentele, Reinhard; Stuerzebecher, Jorg; Fuentes-Prior, Pablo; Barbosa Pereira, Pedro Jose			Isolation, Cloning and Structural Characterisation of Boophilin, a Multifunctional Kunitz-Type Proteinase Inhibitor from the Cattle Tick	PLOS ONE			English	Article							PANCREATIC TRYPSIN-INHIBITOR; FACTOR PATHWAY INHIBITOR; RAY CRYSTAL-STRUCTURE; HUMAN ALPHA-THROMBIN; PROTEOLYTIC-ENZYME INHIBITOR; BOVINE BETA-TRYPSIN; SALIVARY-GLANDS; PROTEASE INHIBITOR; COMPLEX; MICROPLUS	Inhibitors of coagulation factors from blood-feeding animals display a wide variety of structural motifs and inhibition mechanisms. We have isolated a novel inhibitor from the cattle tick Boophilus microplus, one of the most widespread parasites of farm animals. The inhibitor, which we have termed boophilin, has been cloned and overexpressed in Escherichia coli. Mature boophilin is composed of two canonical Kunitz-type domains, and inhibits not only the major procoagulant enzyme, thrombin, but in addition, and by contrast to all other previously characterised natural thrombin inhibitors, significantly interferes with the proteolytic activity of other serine proteinases such as trypsin and plasmin. The crystal structure of the bovine alpha-thrombin.bophilin complex, refined at 2.35 angstrom resolution reveals a non-canonical binding mode to the proteinase. The N-terminal region of the mature inhibitor, Q16-R17-N18, binds in a parallel manner across the active site of the proteinase, with the guanidinium group of R17 anchored in the S-1 pocket, while the C-terminal Kunitz domain is negatively charged and docks into the basic exosite I of thrombin. This binding mode resembles the previously characterised thrombin inhibitor, ornithodorin which, unlike boophilin, is composed of two distorted Kunitz modules. Unexpectedly, both boophilin domains adopt markedly different orientations when compared to those of ornithodorin, in its complex with thrombin. The N-terminal boophilin domain rotates 9 degrees and is displaced by 6 angstrom, while the C-terminal domain rotates almost 6 degrees accompanied by a 3 angstrom displacement. The reactive-site loop of the N-terminal Kunitz domain of boophilin with its P-1 residue, K31, is fully solvent exposed and could thus bind a second trypsin-like proteinase without sterical restraints. This finding explains the formation of a ternary thrombin.boophilin. trypsin complex, and suggests a mechanism for prothrombinase inhibition in vivo.	[Macedo-Ribeiro, Sandra; Almeida, Carla] Ctr Neurociencias & Biol Celular CNC, Coimbra, Portugal; [Macedo-Ribeiro, Sandra; Calisto, Barbara M.; Barbosa Pereira, Pedro Jose] Univ Porto, IBMC, Porto, Portugal; [Friedrich, Thomas] BASF AG, Ludwigshafen, Germany; [Mentele, Reinhard] Univ Munich, Munich, Germany; [Stuerzebecher, Jorg] Zentrum Vask Biol & Med, Erfurt, Germany; [Fuentes-Prior, Pablo] ICCC, CSIC, Barcelona, Spain	Universidade de Coimbra; Universidade do Porto; BASF; University of Munich; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Institut Catala de Ciencies Cardiovasculars (ICCC)	Macedo-Ribeiro, S (corresponding author), Ctr Neurociencias & Biol Celular CNC, Coimbra, Portugal.	PFuentes@csic-iccc.org; ppereira@ibmc.up.pt	Pereira, Pedro/F-8972-2011; Macedo-Ribeiro, Sandra/D-9258-2011	Pereira, Pedro/0000-0003-0969-5438; Macedo-Ribeiro, Sandra/0000-0002-7698-1170; Calisto, Barbara/0000-0003-1732-571X; Fuentes-Prior, Pablo/0000-0002-6618-3204	Fundacao para a Ciencia e a Tecnologia (Portugal) [POCTI/MGI/38108/2001, POCTI/BME/45559/2002]; Ministerio de Educacion y Ciencia [SAF2004-00543]	Fundacao para a Ciencia e a Tecnologia (Portugal)(Portuguese Foundation for Science and Technology); Ministerio de Educacion y Ciencia(Spanish Government)	This work had the financial support of grants POCTI/MGI/38108/2001 (S.M.-R.) and POCTI/BME/45559/2002 (P.J.B.P.) from Fundacao para a Ciencia e a Tecnologia (Portugal), and of Plan Nacional SAF2004-00543 from Ministerio de Educacion y Ciencia (P.F.-P.). The funding bodies had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Adler M, 2000, BIOCHEMISTRY-US, V39, P12534, DOI 10.1021/bi001477q; ANTONINI E, 1983, BIOPOLYMERS, V22, P363, DOI 10.1002/bip.360220147; Ascenzi P, 2003, CURR PROTEIN PEPT SC, V4, P231, DOI 10.2174/1389203033487180; ASCENZI P, 1988, BIOCHIM BIOPHYS ACTA, V956, P156, DOI 10.1016/0167-4838(88)90262-2; Bah A, 2007, P NATL ACAD SCI USA, V104, P11603, DOI 10.1073/pnas.0704409104; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bock PE, 2007, J THROMB HAEMOST, V5, P81, DOI 10.1111/j.1538-7836.2007.02496.x; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; Bode W, 2000, BBA-PROTEIN STRUCT M, V1477, P241, DOI 10.1016/S0167-4838(99)00276-9; Bork P, 1996, Q REV BIOPHYS, V29, P119, DOI 10.1017/S0033583500005783; BRANDSTETTER H, 1992, J MOL BIOL, V226, P1085, DOI 10.1016/0022-2836(92)91054-S; BROZE GJ, 1995, ANNU REV MED, V46, P103, DOI 10.1146/annurev.med.46.1.103; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burgering MJM, 1997, J MOL BIOL, V269, P395, DOI 10.1006/jmbi.1997.1029; Ciprandi A, 2006, EXP PARASITOL, V114, P40, DOI 10.1016/j.exppara.2006.02.010; Czapinska H, 1999, EUR J BIOCHEM, V260, P571, DOI 10.1046/j.1432-1327.1999.00160.x; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; EVANS R, 1990, VIA, V11, P134; Fogaca AC, 2006, PEPTIDES, V27, P667, DOI 10.1016/j.peptides.2005.07.013; Francischetti IMB, 2002, BLOOD, V99, P3602, DOI 10.1182/blood-2001-12-0237; Francischetti IMB, 2005, INSECT BIOCHEM MOLEC, V35, P1142, DOI 10.1016/j.ibmb.2005.05.007; Francischetti NMB, 2004, THROMB HAEMOSTASIS, V91, P886, DOI 10.1160/TH03-11-0715; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; FuentesPrior P, 1997, P NATL ACAD SCI USA, V94, P11845, DOI 10.1073/pnas.94.22.11845; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; Grzesiak A, 2000, J BIOL CHEM, V275, P33346, DOI 10.1074/jbc.M006085200; Grzesiak A, 2000, J MOL BIOL, V301, P205, DOI 10.1006/jmbi.2000.3935; Guerrero FD, 2005, INSECT BIOCHEM MOLEC, V35, P585, DOI 10.1016/j.ibmb.2005.01.020; GUINTO ER, 1994, J BIOL CHEM, V269, P18395; Helland R, 1999, J MOL BIOL, V287, P923, DOI 10.1006/jmbi.1999.2654; Horn F, 2000, ARCH BIOCHEM BIOPHYS, V384, P68, DOI 10.1006/abbi.2000.2076; HUBER R, 1974, J MOL BIOL, V89, P73, DOI 10.1016/0022-2836(74)90163-6; HYNES TR, 1990, BIOCHEMISTRY-US, V29, P10018, DOI 10.1021/bi00495a002; Jittapalapong S, 2004, ANN NY ACAD SCI, V1026, P312, DOI 10.1196/annals.1307.048; Lai R, 2004, GENE, V342, P243, DOI 10.1016/j.gene.2004.07.012; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LEBONNIEC BF, 1993, J BIOL CHEM, V268, P19055; LESLIE AG, 1992, JOINT CCP4 ESF EAMCB, V26; Malkowski MG, 1997, PROTEIN SCI, V6, P1438, DOI 10.1002/pro.5560060708; Mans BJ, 2002, INSECT BIOCHEM MOLEC, V32, P821, DOI 10.1016/S0965-1748(01)00169-2; Martin PD, 1997, STRUCTURE, V5, P1681, DOI 10.1016/S0969-2126(97)00314-6; Maskos K, 2003, J MOL BIOL, V325, P495, DOI 10.1016/S0022-2836(02)01248-2; Merigeau K, 1998, ACTA CRYSTALLOGR D, V54, P306, DOI 10.1107/S0907444997010846; Mine S, 2002, BIOCHEMISTRY-US, V41, P78, DOI 10.1021/bi011299g; Monteiro RQ, 2005, BIOCHEM J, V387, P871, DOI 10.1042/BJ20041738; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nienaber J, 1999, EXP PARASITOL, V93, P82, DOI 10.1006/expr.1999.4448; Parkin S, 1996, ACTA CRYSTALLOGR D, V52, P18, DOI 10.1107/S0907444995008675; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; PINTIGNY D, 1992, EUR J BIOCHEM, V207, P89, DOI 10.1111/j.1432-1033.1992.tb17024.x; Richardson JL, 2000, EMBO J, V19, P5650, DOI 10.1093/emboj/19.21.5650; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; Santos IKFD, 2004, ANN NY ACAD SCI, V1026, P242, DOI 10.1196/annals.1307.037; Sasaki SD, 2004, BIOCHIMIE, V86, P643, DOI 10.1016/j.biochi.2004.09.010; Scheidig AJ, 1997, PROTEIN SCI, V6, P1806, DOI 10.1002/pro.5560060902; Schmidt AE, 2005, J BIOL CHEM, V280, P27832, DOI 10.1074/jbc.M504105200; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sichler K, 2002, FEBS LETT, V530, P220, DOI 10.1016/S0014-5793(02)03495-6; SIEKMANN J, 1987, BIOL CHEM H-S, V368, P1589, DOI 10.1515/bchm3.1987.368.2.1589; Sonenshine DE, 2005, TICK-BORNE DISEASES OF HUMANS, P12; Tanaka AS, 1999, IMMUNOPHARMACOLOGY, V45, P171, DOI 10.1016/S0162-3109(99)00074-0; Valenzuela JG, 2002, J EXP BIOL, V205, P2843; VANDELOCHT A, 1995, EMBO J, V14, P5149, DOI 10.1002/j.1460-2075.1995.tb00199.x; vandeLocht A, 1996, EMBO J, V15, P6011, DOI 10.1002/j.1460-2075.1996.tb00989.x; vandeLocht A, 1997, EMBO J, V16, P2977, DOI 10.1093/emboj/16.11.2977; Venclovas C, 2003, PROTEINS, V53, P585, DOI 10.1002/prot.10530; VERMEULEN NMJ, 1988, INT J BIOCHEM, V20, P621, DOI 10.1016/0020-711X(88)90102-4; VILJOEN GJ, 1985, INSECT BIOCHEM, V15, P475, DOI 10.1016/0020-1790(85)90060-5; Wei AZ, 1998, J MOL BIOL, V283, P147, DOI 10.1006/jmbi.1998.2069; WILLADSEN P, 1979, BIOCHEM J, V177, P41, DOI 10.1042/bj1770041; WILLADSEN P, 1980, BIOCHEM J, V189, P295, DOI 10.1042/bj1890295; WILLADSEN P, 1983, AUST J EXP BIOL MED, V61, P231, DOI 10.1038/icb.1983.21; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Xu YB, 1998, J MOL BIOL, V276, P955, DOI 10.1006/jmbi.1997.1582; Zhang E, 1999, J MOL BIOL, V285, P2089, DOI 10.1006/jmbi.1998.2452	76	87	94	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1624	10.1371/journal.pone.0001624	http://dx.doi.org/10.1371/journal.pone.0001624			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286181	Green Submitted, Green Published, gold			2022-12-25	WOS:000260586400017
J	Marstrand, TT; Frellsen, J; Moltke, I; Thiim, M; Valen, E; Retelska, D; Krogh, A				Marstrand, Troels T.; Frellsen, Jes; Moltke, Ida; Thiim, Martin; Valen, Eivind; Retelska, Dorota; Krogh, Anders			Asap: A Framework for Over-Representation Statistics for Transcription Factor Binding Sites	PLOS ONE			English	Article							GENOME-WIDE ANALYSIS; REGULATORY ELEMENTS; DISCOVERY; DATABASE; TOOLS; MODEL	Background: In studies of gene regulation the efficient computational detection of over-represented transcription factor binding sites is an increasingly important aspect. Several published methods can be used for testing whether a set of hypothesised co-regulated genes share a common regulatory regime based on the occurrence of the modelled transcription factor binding sites. However there is little or no information available for guiding the end users choice of method. Furthermore it would be necessary to obtain several different software programs from various sources to make a well-founded choice. Methodology: We introduce a software package, Asap, for fast searching with position weight matrices that include several standard methods for assessing over-representation. We have compared the ability of these methods to detect over-epresented transcription factor binding sites in artificial promoter sequences. Controlling all aspects of our input data we are able to identify the optimal statistics across multiple threshold values and for sequence sets containing different distributions of transcription factor binding sites. Conclusions: We show that our implementation is significantly faster than more naive scanning algorithms when searching with many weight matrices in large sequence sets. When comparing the various statistics, we show that those based on binomial over-representation and Fisher's exact test performs almost equally good and better than the others. An online server is available at http://servers.binf.ku.dk/asap/.	[Marstrand, Troels T.; Frellsen, Jes; Moltke, Ida; Thiim, Martin; Valen, Eivind; Krogh, Anders] Univ Copenhagen, Dept Mol Biol, Bioinformat Ctr, Copenhagen, Denmark; [Retelska, Dorota] ISREC, Swiss Inst Bioinformat, Epalinges, Switzerland	University of Copenhagen; Swiss Institute Experimental Cancer Research; Swiss Institute of Bioinformatics	Marstrand, TT (corresponding author), Univ Copenhagen, Dept Mol Biol, Bioinformat Ctr, Copenhagen, Denmark.	dolle@binf.ku.dk	Sandelin, Albin/G-2881-2011; Marstrand, Troels/C-7039-2011; Valen, Eivind/A-8617-2011; Moltke, Ida/C-6158-2011; Frellsen, Jes/K-4337-2014; Krogh, Anders/M-1541-2014	Sandelin, Albin/0000-0002-7109-7378; Moltke, Ida/0000-0001-7052-8554; Frellsen, Jes/0000-0001-9224-1271; Krogh, Anders/0000-0002-5147-6282; Valen, Eivind/0000-0003-1840-6108; Marstrand, Troels/0000-0002-8290-223X	Novo Nordisk Foundation; SNSF [PBLAA-109445]	Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); SNSF(Swiss National Science Foundation (SNSF))	This work was supported by a grant from the Novo Nordisk Foundation. DR was supported by the SNSF grant PBLAA-109445. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aerts S, 2003, NUCLEIC ACIDS RES, V31, P1753, DOI 10.1093/nar/gkg268; Beckstette M, 2004, P GERM C BIOINF, P53; BRYNE JC, 2007, NUCL ACIDS RES; Carninci P, 2006, NAT GENET, V38, P626, DOI 10.1038/ng1789; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Chang LW, 2006, GENOME RES, V16, P405, DOI 10.1101/gr.4303406; Clarke ND, 2003, BIOINFORMATICS, V19, P212, DOI 10.1093/bioinformatics/19.2.212; Davidson EH, 2002, SCIENCE, V295, P1669, DOI 10.1126/science.1069883; Down TA, 2005, NUCLEIC ACIDS RES, V33, P1445, DOI 10.1093/nar/gki282; Freberg CT, 2007, MOL BIOL CELL, V18, P1543, DOI 10.1091/mbc.E07-01-0029; Gerasimova TI, 2001, ANNU REV GENET, V35, P193, DOI 10.1146/annurev.genet.35.102401.090349; Kasai T., 2001, Combinatorial Pattern Matching. 12th Annual Symposium, CPM 2001. Proceedings (Lecture Notes in Computer Science Vol. 2089), P181; Loots GG, 2002, GENOME RES, V12, P832, DOI 10.1101/gr.225502; Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pD91, DOI 10.1093/nar/gkh012; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pW249, DOI 10.1093/nar/gkh372; Sharan R, 2004, NUCLEIC ACIDS RES, V32, pW253, DOI 10.1093/nar/gkh385; Sui SJH, 2007, NUCLEIC ACIDS RES, V35, pW245, DOI 10.1093/nar/gkm427; Suzuki Y, 2002, NUCLEIC ACIDS RES, V30, P328, DOI 10.1093/nar/30.1.328; Tada T, 2006, JNCI-J NATL CANCER I, V98, P396, DOI 10.1093/jnci/djj093; TEAM RDC, 2006, R LANGUAGE ENVIROMEN; Thijs G, 2001, BIOINFORMATICS, V17, P1113, DOI 10.1093/bioinformatics/17.12.1113; Tompa M, 2005, NAT BIOTECHNOL, V23, P137, DOI 10.1038/nbt1053; Ureta-Vidal A, 2003, NAT REV GENET, V4, P251, DOI 10.1038/nrg1043; Wasserman WW, 2004, NAT REV GENET, V5, P276, DOI 10.1038/nrg1315; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043	26	33	33	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1623	10.1371/journal.pone.0001623	http://dx.doi.org/10.1371/journal.pone.0001623			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286180	Green Published, gold, Green Submitted			2022-12-25	WOS:000260586400016
J	Bandhakavi, S; Xie, HW; O'Callaghan, B; Sakurai, H; Kim, DH; Griffin, TJ				Bandhakavi, Sricharan; Xie, Hongwei; O'Callaghan, Brennon; Sakurai, Hiroshi; Kim, Do-Hyung; Griffin, Timothy J.			Hsf1 Activation Inhibits Rapamycin Resistance and TOR Signaling in Yeast Revealed by Combined Proteomic and Genetic Analysis	PLOS ONE			English	Article							SHOCK TRANSCRIPTION FACTOR; CEREVISIAE HEAT-SHOCK; GENOME-WIDE ANALYSIS; DNA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; CELL-GROWTH; MAMMALIAN TOR; AMINO-ACID; TARGET; EXPRESSION	TOR kinases integrate environmental and nutritional signals to regulate cell growth in eukaryotic organisms. Here, we describe results from a study combining quantitative proteomics and comparative expression analysis in the budding yeast, S. cerevisiae, to gain insights into TOR function and regulation. We profiled protein abundance changes under conditions of TOR inhibition by rapamycin treatment, and compared this data to existing expression information for corresponding gene products measured under a variety of conditions in yeast. Among proteins showing abundance changes upon rapamycin treatment, almost 90% of them demonstrated homodirectional (i. e., in similar direction) transcriptomic changes under conditions of heat/oxidative stress. Because the known downstream responses regulated by Tor1/2 did not fully explain the extent of overlap between these two conditions, we tested for novel connections between the major regulators of heat/oxidative stress response and the TOR pathway. Specifically, we hypothesized that activation of regulator(s) of heat/oxidative stress responses phenocopied TOR inhibition and sought to identify these putative TOR inhibitor(s). Among the stress regulators tested, we found that cells (hsf1-R206S, F256S and ssa1-3 ssa2-2) constitutively activated for heat shock transcription factor 1, Hsf1, inhibited rapamycin resistance. Further analysis of the hsf1-R206S, F256S allele revealed that these cells also displayed multiple phenotypes consistent with reduced TOR signaling. Among the multiple Hsf1 targets elevated in hsf1-R206S, F256S cells, deletion of PIR3 and YRO2 suppressed the TOR-regulated phenotypes. In contrast to our observations in cells activated for Hsf1, constitutive activation of other regulators of heat/oxidative stress responses, such as Msn2/4 and Hyr1, did not inhibit TOR signaling. Thus, we propose that activated Hsf1 inhibits rapamycin resistance and TOR signaling via elevated expression of specific target genes in S. cerevisiae. Additionally, these results highlight the value of comparative expression analyses between large-scale proteomic and transcriptomic datasets to reveal new regulatory connections.	[Bandhakavi, Sricharan; Xie, Hongwei; O'Callaghan, Brennon; Kim, Do-Hyung; Griffin, Timothy J.] Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; [Sakurai, Hiroshi] Kanazawa Univ, Fac Med, Sch Hlth Sci, Kanazawa, Ishikawa, Japan	University of Minnesota System; University of Minnesota Twin Cities; Kanazawa University	Bandhakavi, S (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA.	tgriffin@umn.edu	SAKURAI, Hiroshi/L-3693-2015	Griffin, Timothy/0000-0001-6801-2559; Sakurai, Hiroshi/0000-0002-0336-2301; O'Callaghan, Brennon L/0000-0002-0800-5856; Kim, Do-Hyung/0000-0002-2924-4370	Biomedical Genomics Center at the University of Minnesota [0755679Z]; American Heart Association [0755679Z]; NIH [DK073731]; Eli Lili & Company	Biomedical Genomics Center at the University of Minnesota; American Heart Association(American Heart Association); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Eli Lili & Company	This work was funded in part by a proteomics seed grant from the Biomedical Genomics Center at the University of Minnesota, American Heart Association grant 0755679Z, NIH grant DK073731, and a grant to TJG from Eli Lili & Company.	Albanese V, 2006, CELL, V124, P75, DOI 10.1016/j.cell.2005.11.039; Avery AM, 2004, J BIOL CHEM, V279, P46652, DOI 10.1074/jbc.M408340200; Bandhakavi S, 2003, FEBS LETT, V554, P295, DOI 10.1016/S0014-5793(03)01165-7; Bandhakavi S, 2003, J BIOL CHEM, V278, P2829, DOI 10.1074/jbc.M206662200; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bertram PG, 2000, J BIOL CHEM, V275, P35727, DOI 10.1074/jbc.M004235200; BONNER JJ, 1994, MOL CELL BIOL, V14, P501, DOI 10.1128/MCB.14.1.501; BOORSTEIN WR, 1990, J BIOL CHEM, V265, P18912; Boy-Marcotte E, 1999, MOL MICROBIOL, V33, P274, DOI 10.1046/j.1365-2958.1999.01467.x; Boy-Marcotte E, 1998, J BACTERIOL, V180, P1044, DOI 10.1128/JB.180.5.1044-1052.1998; Butcher RA, 2006, NAT CHEM BIOL, V2, P103, DOI 10.1038/nchembio762; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Chan TF, 2000, P NATL ACAD SCI USA, V97, P13227, DOI 10.1073/pnas.240444197; Cooper TG, 2002, FEMS MICROBIOL REV, V26, P223, DOI 10.1111/j.1574-6976.2002.tb00612.x; DAMBERGER FF, 1994, PROTEIN SCI, V3, P1806, DOI 10.1002/pro.5560031020; Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; Dilova I, 2004, J BIOL CHEM, V279, P46527, DOI 10.1074/jbc.M409012200; Eastmond DL, 2006, J BIOL CHEM, V281, P32909, DOI 10.1074/jbc.M602454200; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Estruch F, 2000, FEMS MICROBIOL REV, V24, P469, DOI 10.1016/S0168-6445(00)00035-8; ESTRUCH F, 1993, MOL CELL BIOL, V13, P3872, DOI 10.1128/MCB.13.7.3872; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Fujimoto M, 2005, J BIOL CHEM, V280, P34908, DOI 10.1074/jbc.M506288200; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Griffin TJ, 2002, MOL CELL PROTEOMICS, V1, P323, DOI 10.1074/mcp.M200001-MCP200; Grolleau A, 2002, J BIOL CHEM, V277, P22175, DOI 10.1074/jbc.M202014200; Hahn JS, 2004, MOL CELL BIOL, V24, P5249, DOI 10.1128/MCB.24.12.5249-5256.2004; HALLADAY JT, 1995, MOL CELL BIOL, V15, P4890; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Hashikawa N, 2006, J BIOL CHEM, V281, P3936, DOI 10.1074/jbc.M510827200; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; Huang J, 2004, P NATL ACAD SCI USA, V101, P16594, DOI 10.1073/pnas.0407117101; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; Imazu H, 2005, EUKARYOT CELL, V4, P1050, DOI 10.1128/EC.4.6.1050-1056.2005; Inoki K, 2005, MICROBIOL MOL BIOL R, V69, P79, DOI 10.1128/MMBR.69.1.79-100.2005; Iser WB, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001240; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Kamada Y, 2003, CURR TOP MICROBIOL, V279, P73; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Keller G, 2001, J BIOL CHEM, V276, P38697, DOI 10.1074/jbc.M107131200; Keogh MC, 2006, NATURE, V439, P497, DOI 10.1038/nature04384; Kunz J, 2000, J BIOL CHEM, V275, P37011, DOI 10.1074/jbc.M007296200; Kuranda K, 2006, MOL MICROBIOL, V61, P1147, DOI 10.1111/j.1365-2958.2006.05300.x; Littlefield O, 1999, NAT STRUCT BIOL, V6, P464; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Magasanik B, 2002, GENE, V290, P1, DOI 10.1016/S0378-1119(02)00558-9; Marion RM, 2004, P NATL ACAD SCI USA, V101, P14315, DOI 10.1073/pnas.0405353101; Martin DE, 2004, CELL, V119, P969, DOI 10.1016/j.cell.2004.11.047; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; Mason DE, 2003, J PROTEOME RES, V2, P265, DOI 10.1021/pr0255856; Morano KA, 1999, MOL CELL BIOL, V19, P402; Morley JF, 2004, MOL BIOL CELL, V15, P657, DOI 10.1091/mbc.E03-07-0532; NELSON RJ, 1992, GENETICS, V131, P277; Parsons AB, 2004, NAT BIOTECHNOL, V22, P62, DOI 10.1038/nbt919; Peng JM, 2003, J PROTEOME RES, V2, P43, DOI 10.1021/pr025556v; Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Preiss T, 2003, NAT STRUCT BIOL, V10, P1039, DOI 10.1038/nsb1015; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Reinders J, 2006, J PROTEOME RES, V5, P1543, DOI 10.1021/pr050477f; Rimoldi M, 2001, BRAIN RES BULL, V56, P353, DOI 10.1016/S0361-9230(01)00602-5; Schawalder SB, 2004, NATURE, V432, P1058, DOI 10.1038/nature03200; Schmelzle T, 2004, MOL CELL BIOL, V24, P338, DOI 10.1128/MCB.24.1.338-351.2004; Schmitt AP, 1996, P NATL ACAD SCI USA, V93, P5777, DOI 10.1073/pnas.93.12.5777; SEWELL AK, 1995, J BIOL CHEM, V270, P25079, DOI 10.1074/jbc.270.42.25079; Shamji AF, 2000, CURR BIOL, V10, P1574, DOI 10.1016/S0960-9822(00)00866-6; SORGER PK, 1990, CELL, V62, P793, DOI 10.1016/0092-8674(90)90123-V; SORGER PK, 1987, EMBO J, V6, P3035, DOI 10.1002/j.1460-2075.1987.tb02609.x; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; Tate JJ, 2002, J BIOL CHEM, V277, P20477, DOI 10.1074/jbc.M200962200; TOHE A, 1993, YEAST, V9, P481, DOI 10.1002/yea.320090504; Torres J, 2002, J BIOL CHEM, V277, P43495, DOI 10.1074/jbc.M205408200; Vellai T, 2003, NATURE, V426, P620, DOI 10.1038/426620a; Wang LH, 2003, P NATL ACAD SCI USA, V100, P11249, DOI 10.1073/pnas.1534805100; Wedaman KP, 2003, MOL BIOL CELL, V14, P1204, DOI 10.1091/mbc.E02-09-0609; Westerheide SD, 2004, J BIOL CHEM, V279, P56053, DOI 10.1074/jbc.M409267200; Westerheide SD, 2005, J BIOL CHEM, V280, P33097, DOI 10.1074/jbc.R500010200; Wilson WA, 2002, MOL CELL PROTEOMICS, V1, P232, DOI 10.1074/mcp.M100024-MCP200; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Xie HW, 2005, ANAL CHEM, V77, P3198, DOI 10.1021/ac0482256; Xie MW, 2005, P NATL ACAD SCI USA, V102, P7215, DOI 10.1073/pnas.0500297102; Yamamoto A, 2005, J BIOL CHEM, V280, P11911, DOI 10.1074/jbc.M411256200; Yamamoto A, 2006, BIOCHEM BIOPH RES CO, V346, P1324, DOI 10.1016/j.bbrc.2006.06.057; Yun DJ, 1997, P NATL ACAD SCI USA, V94, P7082, DOI 10.1073/pnas.94.13.7082; Zarzov P, 1997, J CELL SCI, V110, P1879; Zohlnhofer D, 2004, MOL PHARMACOL, V65, P880, DOI 10.1124/mol.65.4.880	90	36	36	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1598	10.1371/journal.pone.0001598	http://dx.doi.org/10.1371/journal.pone.0001598			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270585	Green Submitted, gold, Green Published			2022-12-25	WOS:000260535900032
J	Laxmi, A; Pan, JW; Morsy, M; Chen, RJ				Laxmi, Ashverya; Pan, Jianwei; Morsy, Mustafa; Chen, Rujin			Light Plays an Essential Role in Intracellular Distribution of Auxin Efflux Carrier PIN2 in Arabidopsis thaliana	PLOS ONE			English	Article							ROOT GRAVITROPISM; GENE-EXPRESSION; CELL POLARITY; TRANSPORT; PROTEINS; COP1; PHOTOMORPHOGENESIS; PHOTOTROPISM; DEGRADATION; ENDOCYTOSIS	Background. Light plays a key role in multiple plant developmental processes. It has been shown that root development is modulated by shoot-localized light signaling and requires shoot-derived transport of the plant hormone, auxin. However, the mechanism by which light regulates root development is not largely understood. In plants, the endogenous auxin, indole-3-acetic acid, is directionally transported by plasma-membrane (PM)-localized auxin influx and efflux carriers in transporting cells. Remarkably, the auxin efflux carrier PIN proteins exhibit asymmetric PM localization, determining the polarity of auxin transport. Similar to PM-resident receptors and transporters in animal and yeast cells, PIN proteins undergo constitutive cycling between the PM and endosomal compartments. Auxin plays multiple roles in PIN protein intracellular trafficking, inhibiting PIN2 endocytosis at some concentrations and promoting PIN2 degradation at others. However, how PIN proteins are turned over in plant cells is yet to be addressed. Methodology and Principle Findings. Using laser confocal scanning microscopy, and physiological and molecular genetic approaches, here, we show that in dark-grown seedlings, the PM localization of auxin efflux carrier PIN2 was largely reduced, and, in addition, PIN2 signal was detected in vacuolar compartments. This is in contrast to light-grown seedlings where PIN2 was predominantly PM-localized. In light-grown plants after shift to dark or to continuous red or far-red light, PIN2 also accumulated in vacuolar compartments. We show that PIN2 vacuolar targeting was derived from the PM via endocytic trafficking and inhibited by HY5-dependent light signaling. In addition, the ubiquitin 26S proteasome is involved in the process, since its inhibition by mutations in COP9 and a proteasome inhibitor MG132 impaired the process. Conclusions and Significance. Collectively, our data indicate that light plays an essential role in PIN2 intracellular trafficking, promoting PM-localization in the presence of light and, on the other hand, vacuolar targeting for protein degradation in the absence of light. Based on these results, we postulate that light regulation of root development is mediated at least in part by changes in the intracellular distribution of auxin efflux carriers, PIN proteins, in response to the light environment.	[Laxmi, Ashverya; Pan, Jianwei; Morsy, Mustafa; Chen, Rujin] Samuel Roberts Noble Fdn Inc, Div Plant Biol, Ardmore, OK 73402 USA	Noble Research Institute	Chen, RJ (corresponding author), Samuel Roberts Noble Fdn Inc, Div Plant Biol, POB 2180, Ardmore, OK 73402 USA.	rchen@noble.org	Chen, Rujin/AAT-8254-2020; Morsy, Mustafa R/E-6245-2013	Morsy, Mustafa R/0000-0003-1803-4893	National Science Foundation [DBI-00400580]; Samuel Roberts Noble Foundation	National Science Foundation(National Science Foundation (NSF)); Samuel Roberts Noble Foundation	Funds were provided by the National Science Foundation (DBI-00400580) for purchasing the Laser Confocal Scanning Microscope used in this study. Financial support for the work done in the corresponding author's laboratory was from the Samuel Roberts Noble Foundation.	Abas L, 2006, NAT CELL BIOL, V8, P249, DOI 10.1038/ncb1369; Ang LH, 1998, MOL CELL, V1, P213, DOI 10.1016/S1097-2765(00)80022-2; Benfey PN, 2002, CURR BIOL, V12, pR389, DOI 10.1016/S0960-9822(02)00881-3; Blakeslee JJ, 2005, CURR OPIN PLANT BIOL, V8, P494, DOI 10.1016/j.pbi.2005.07.014; Blilou I, 2005, NATURE, V433, P39, DOI 10.1038/nature03184; Boutte Y, 2006, J CELL SCI, V119, P1255, DOI 10.1242/jcs.02847; Chamovitz DA, 1996, CELL, V86, P115, DOI 10.1016/S0092-8674(00)80082-3; Chen M, 2004, ANNU REV GENET, V38, P87, DOI 10.1146/annurev.genet.38.072902.092259; Chen RJ, 2006, PLANT CELL MONOGR, V1, P139, DOI 10.1007/7089_009; Chen RJ, 1998, P NATL ACAD SCI USA, V95, P15112, DOI 10.1073/pnas.95.25.15112; Chory J, 1996, P NATL ACAD SCI USA, V93, P12066, DOI 10.1073/pnas.93.22.12066; Cluis CP, 2004, PLANT J, V38, P332, DOI 10.1111/j.1365-313X.2004.02052.x; Correll MJ, 2005, PLANT CELL PHYSIOL, V46, P317, DOI 10.1093/pcp/pci038; Correll MJ, 2003, ADV SPACE RES, V31, P2203, DOI 10.1016/S0273-1177(03)00245-X; Cutler SR, 2000, P NATL ACAD SCI USA, V97, P3718, DOI 10.1073/pnas.97.7.3718; Daniels MJ, 1996, PLANT CELL, V8, P587, DOI 10.1105/tpc.8.4.587; DHONUKSHE P, 2007, CURR BIOL; Duek PD, 2004, CURR BIOL, V14, P2296, DOI 10.1016/j.cub.2004.12.026; Dupre S, 2004, BBA-MOL CELL RES, V1695, P89, DOI 10.1016/j.bbamcr.2004.09.024; Estelle M, 2001, NATURE, V413, P374, DOI 10.1038/35096672; Friml J, 2003, CURR OPIN PLANT BIOL, V6, P7, DOI 10.1016/S1369526602000031; Friml J, 2004, SCIENCE, V306, P862, DOI 10.1126/science.1100618; Friml J, 2002, NATURE, V415, P806, DOI 10.1038/415806a; Friml J, 2002, CELL, V108, P661, DOI 10.1016/S0092-8674(02)00656-6; Geisler M, 2005, PLANT J, V44, P179, DOI 10.1111/j.1365-313X.2005.02519.x; Geldner N, 2001, NATURE, V413, P425, DOI 10.1038/35096571; Geldner N, 2003, CELL, V112, P219, DOI 10.1016/S0092-8674(03)00003-5; Golan A, 1996, PLANT PHYSIOL, V112, P901, DOI 10.1104/pp.112.3.901; Heisler MG, 2005, CURR BIOL, V15, P1899, DOI 10.1016/j.cub.2005.09.052; Holm M, 2002, GENE DEV, V16, P1247, DOI 10.1101/gad.969702; Jaillais Y, 2007, CELL, V130, P1057, DOI 10.1016/j.cell.2007.08.040; Jaillais Y, 2006, NATURE, V443, P106, DOI 10.1038/nature05046; Jang IC, 2005, GENE DEV, V19, P593, DOI 10.1101/gad.1247205; Jensen PJ, 1998, PLANT PHYSIOL, V116, P455, DOI 10.1104/pp.116.2.455; Jones AM, 1998, SCIENCE, V282, P2201, DOI 10.1126/science.282.5397.2201; Kircher S, 1999, PLANT CELL, V11, P1445, DOI 10.1105/tpc.11.8.1445; Leyser O, 2006, CURR BIOL, V16, pR424, DOI 10.1016/j.cub.2006.05.014; Lin RC, 2005, PLANT PHYSIOL, V138, P949, DOI 10.1104/pp.105.061572; Luschnig C, 1998, GENE DEV, V12, P2175, DOI 10.1101/gad.12.14.2175; Michniewicz M, 2007, CELL, V130, P1044, DOI 10.1016/j.cell.2007.07.033; Morelli G, 2002, TRENDS PLANT SCI, V7, P399, DOI 10.1016/S1360-1385(02)02314-2; Muday GK, 2002, PLANT CELL, V14, P293, DOI 10.1105/tpc.140230; Muller A, 1998, EMBO J, V17, P6903, DOI 10.1093/emboj/17.23.6903; Nakamoto D, 2006, PLANT PHYSIOL, V141, P456, DOI 10.1104/pp.105.076273; Noh B, 2001, PLANT CELL, V13, P2441, DOI 10.1105/tpc.13.11.2441; Paciorek T, 2005, NATURE, V435, P1251, DOI 10.1038/nature03633; Paciorek T, 2006, J CELL SCI, V119, P1199, DOI 10.1242/jcs.02910; Petrasek J, 2006, SCIENCE, V312, P914, DOI 10.1126/science.1123542; Rashotte AM, 2000, PLANT PHYSIOL, V122, P481, DOI 10.1104/pp.122.2.481; Ruppel NJ, 2001, PLANTA, V212, P424, DOI 10.1007/s004250000410; Sabatini S, 1999, CELL, V99, P463, DOI 10.1016/S0092-8674(00)81535-4; Salisbury FJ, 2007, PLANT J, V50, P429, DOI 10.1111/j.1365-313X.2007.03059.x; Sauer M, 2006, GENE DEV, V20, P2902, DOI 10.1101/gad.390806; Schumacher K, 1999, GENE DEV, V13, P3259, DOI 10.1101/gad.13.24.3259; Seo HS, 2003, NATURE, V423, P995, DOI 10.1038/nature01696; Shin H, 2005, PLANT J, V42, P188, DOI 10.1111/j.1365-313X.2005.02369.x; Sidler M, 1998, PLANT CELL, V10, P1623, DOI 10.1105/tpc.10.10.1623; Staub O, 2006, PHYSIOL REV, V86, P669, DOI 10.1152/physrev.00020.2005; Takano J, 2005, P NATL ACAD SCI USA, V102, P12276, DOI 10.1073/pnas.0502060102; Tamura K, 2003, PLANT J, V35, P545, DOI 10.1046/j.1365-313X.2003.01822.x; TANAKA H, 2006, CELL MOL LIFE SCI; Teh OK, 2007, NATURE, V448, P493, DOI 10.1038/nature06023; Tian Q, 2001, J PLANT GROWTH REGUL, V20, P274, DOI 10.1007/s003440010022; Utsuno K, 1998, PLANT CELL PHYSIOL, V39, P1111, DOI 10.1093/oxfordjournals.pcp.a029310; Vitha S, 2000, PLANT PHYSIOL, V122, P453, DOI 10.1104/pp.122.2.453; vonArnim A, 1996, ANNU REV PLANT PHYS, V47, P215, DOI 10.1146/annurev.arplant.47.1.215; VONARNIM AG, 1994, CELL, V79, P1035, DOI 10.1016/0092-8674(94)90034-5; Wang XL, 2006, SCIENCE, V313, P1118, DOI 10.1126/science.1127593; Wisniewska J, 2006, SCIENCE, V312, P883, DOI 10.1126/science.1121356; Xu J, 2006, SCIENCE, V311, P385, DOI 10.1126/science.1121790; Yamada K, 2005, PLANT J, V41, P888, DOI 10.1111/j.1365-313X.2005.02349.x; Yang JP, 2005, PLANT CELL, V17, P804, DOI 10.1105/tpc.104.030205; Yi CL, 2005, TRENDS CELL BIOL, V15, P618, DOI 10.1016/j.tcb.2005.09.007	73	176	187	1	54	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1510	10.1371/journal.pone.0001510	http://dx.doi.org/10.1371/journal.pone.0001510			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SR	18231596	Green Published, Green Submitted, gold			2022-12-25	WOS:000260504200022
J	Rolfs, A; Hu, Y; Ebert, L; Hoffmann, D; Zuo, D; Ramachandran, N; Raphael, J; Kelley, F; McCarron, S; Jepson, DA; Shen, B; Baqui, MMA; Pearlberg, J; Taycher, E; DeLoughery, C; Hoerlein, A; Korn, B; LaBaer, J				Rolfs, Andreas; Hu, Yanhui; Ebert, Lars; Hoffmann, Dietmar; Zuo, Dongmei; Ramachandran, Niro; Raphael, Jacob; Kelley, Fontina; McCarron, Seamus; Jepson, Daniel A.; Shen, Binghua; Baqui, Munira M. A.; Pearlberg, Joseph; Taycher, Elena; DeLoughery, Craig; Hoerlein, Andreas; Korn, Bernhard; LaBaer, Joshua			A Biomedically Enriched Collection of 7000 Human ORF Clones	PLOS ONE			English	Article							NONREDUNDANT SEQUENCE DATABASE; HUMAN ORFEOME; REFSEQ; TRANSCRIPTS; REPOSITORY; CLONING; GENOMES	We report the production and availability of over 7000 fully sequence verified plasmid ORF clones representing over 3400 unique human genes. These ORF clones were derived using the human MGC collection as template and were produced in two formats: with and without stop codons. Thus, this collection supports the production of either native protein or proteins with fusion tags added to either or both ends. The template clones used to generate this collection were enriched in three ways. First, gene redundancy was removed. Second, clones were selected to represent the best available GenBank reference sequence. Finally, a literature-based software tool was used to evaluate the list of target genes to ensure that it broadly reflected biomedical research interests. The target gene list was compared with 4000 human diseases and over 8500 biological and chemical MeSH classes in,15 Million publications recorded in PubMed at the time of analysis. The outcome of this analysis revealed that relative to the genome and the MGC collection, this collection is enriched for the presence of genes with published associations with a wide range of diseases and biomedical terms without displaying a particular bias towards any single disease or concept. Thus, this collection is likely to be a powerful resource for researchers who wish to study protein function in a set of genes with documented biomedical significance.	[Rolfs, Andreas; Hu, Yanhui; Zuo, Dongmei; Ramachandran, Niro; Raphael, Jacob; Kelley, Fontina; McCarron, Seamus; Jepson, Daniel A.; Shen, Binghua; Baqui, Munira M. A.; Pearlberg, Joseph; Taycher, Elena; LaBaer, Joshua] Harvard Univ, Sch Med, Harvard Inst Prote, Cambridge, MA 02138 USA; [Ebert, Lars; Hoerlein, Andreas; Korn, Bernhard] RZPD, Heidelberg, Germany; [Hoffmann, Dietmar; DeLoughery, Craig] Sanofi Aventis, Cambridge, MA USA	Harvard University; Harvard Medical School; Sanofi-Aventis	LaBaer, J (corresponding author), Harvard Univ, Sch Med, Harvard Inst Prote, Cambridge, MA 02138 USA.	Joshua_labaer@hms.harvard.edu	Baqui, Munira M. A/H-5243-2013	Baqui, Munira M. A/0000-0002-7945-2899; Hu, Yanhui/0000-0003-1494-1402	Sanofi-Aventis; Breast Cancer Research Foundation; German Ministry of Science, NGFN2 [01GR0413, 01GR0420]	Sanofi-Aventis(Sanofi-Aventis); Breast Cancer Research Foundation; German Ministry of Science, NGFN2	We would like to thank Sanofi-Aventis and the Breast Cancer Research Foundation for generous support of this project. The project has partly been funded by the German Ministry of Science, NGFN2 (grants 01GR0413 and 01GR0420).	Baross A, 2004, GENOME RES, V14, P2083, DOI 10.1101/gr.2473704; Collins JE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r84; De Los Rios P, 2005, BIOPHYS J, V89, P14, DOI 10.1529/biophysj.104.055004; Gerhard DS, 2004, GENOME RES, V14, P2121, DOI 10.1101/gr.2596504; Haas S, 1998, NUCLEIC ACIDS RES, V26, P3006, DOI 10.1093/nar/26.12.3006; Harrison OJ, 2005, J CELL SCI, V118, P4123, DOI 10.1242/jcs.02539; Hegde RS, 2006, TRENDS BIOCHEM SCI, V31, P563, DOI 10.1016/j.tibs.2006.08.004; Hu YH, 2007, GENOME RES, V17, P536, DOI 10.1101/gr.6037607; Hu YH, 2003, J PROTEOME RES, V2, P405, DOI 10.1021/pr0340227; Lamesch P, 2007, GENOMICS, V89, P307, DOI 10.1016/j.ygeno.2006.11.012; Murthy T, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000577; Park J, 2005, P NATL ACAD SCI USA, V102, P8114, DOI 10.1073/pnas.0503141102; Pennisi E, 2007, SCIENCE, V316, P1113; Pruitt KD, 2001, NUCLEIC ACIDS RES, V29, P137, DOI 10.1093/nar/29.1.137; Pruitt KD, 2005, NUCLEIC ACIDS RES, V33, pD501, DOI 10.1093/nar/gki025; Pruitt KD, 2003, NUCLEIC ACIDS RES, V31, P34, DOI 10.1093/nar/gkg111; Pruitt KD, 2007, NUCLEIC ACIDS RES, V35, pD61, DOI 10.1093/nar/gkl842; Ramachandran N, 2004, SCIENCE, V305, P86, DOI 10.1126/science.1097639; Rual JF, 2004, GENOME RES, V14, P2128, DOI 10.1101/gr.2973604; Staden R, 2001, Methods Biochem Anal, V43, P303; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Taycher E, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-198; Temple G, 2006, HUM MOL GENET, V15, pR31, DOI 10.1093/hmg/ddl048; Witt AE, 2006, J PROTEOME RES, V5, P599, DOI 10.1021/pr050395r	24	20	21	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1528	10.1371/journal.pone.0001528	http://dx.doi.org/10.1371/journal.pone.0001528			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SR	18231609	Green Published, gold, Green Submitted			2022-12-25	WOS:000260504200036
J	Koehl, M; Meerlo, P; Gonzales, D; Rontal, A; Turek, FW; Abrous, DN				Koehl, M.; Meerlo, P.; Gonzales, D.; Rontal, A.; Turek, F. W.; Abrous, D. N.			Exercise-induced promotion of hippocampal cell proliferation requires beta-endorphin	FASEB JOURNAL			English	Article						running; opioids; cell survival; adult neurogenesis; homeostatic balance	MU-OPIOID RECEPTORS; SPONTANEOUSLY HYPERTENSIVE-RAT; SPRAGUE-DAWLEY RATS; MOUSE DENTATE GYRUS; VOLUNTARY EXERCISE; ADULT HIPPOCAMPUS; PHYSICAL-ACTIVITY; ENVIRONMENTAL ENRICHMENT; INCREASE NEUROGENESIS; ENHANCES NEUROGENESIS	variety of stimuli, including exercise, but the mechanisms by which running affects neurogenesis are not yet fully understood. Because beta-endorphin, which is released in response to exercise, increases cell proliferation in vitro, we hypothesized that it could exert a similar effect in vivo and mediate the stimulatory effects of running on neurogenesis. We thus analyzed the effects of voluntary wheel-running on adult neurogenesis (proliferation, differentiation, survival/death) in wild-type and beta-endorphin-deficient mice. In wild-type mice, exercise promoted cell proliferation evaluated by sacrificing animals 24 h after the last 5-bromo-2'-deoxyuridine (BrdU) pulse and by using endogenous cell cycle markers (Ki67 and pH(3)). This was accompanied by an increased survival of 4-wk-old BrdU-labeled cells, leading to a net increase of neurogenesis. beta-Endorphin deficiency had no effect in sedentary mice, but it completely blocked the running-induced increase in cell proliferation; this blockade was accompanied by an increased survival of 4-wk-old cells and a decreased cell death. Altogether, adult neurogenesis was increased in response to exercise in knockout mice. We conclude that beta-endorphin released during running is a key factor for exercise-induced cell proliferation and that a homeostatic balance may regulate the final number of new neurons.	[Koehl, M.] INSERM, Ctr Rech, U862, F-33077 Bordeaux, France; [Koehl, M.; Gonzales, D.; Abrous, D. N.] Univ Bordeaux, Bordeaux, France; [Meerlo, P.] Univ Groningen, Dept Mol Neurobiol, Haren, Netherlands; [Rontal, A.; Turek, F. W.] Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; University of Groningen; Northwestern University	Koehl, M (corresponding author), INSERM, Ctr Rech, U862, 146 Rue Leo Saignat, F-33077 Bordeaux, France.	koehl@bordeaux.inserm.fr	Abrous, Nora-Djoher/N-6977-2017; Koehl, Muriel/C-3698-2011; Koehl, Muriel/ABI-2043-2020	Koehl, Muriel/0000-0002-7601-1422; Koehl, Muriel/0000-0002-7601-1422; abrous, nora/0000-0002-8589-305X; Meerlo, Peter/0000-0002-8330-6050				ABLEITNER A, 1992, J PHARMACOL EXP THER, V262, P415; Abrous DN, 2005, PHYSIOL REV, V85, P523, DOI 10.1152/physrev.00055.2003; AKANA SF, 1983, ENDOCRINOLOGY, V113, P2226, DOI 10.1210/endo-113-6-2226; AKANA SF, 1983, ENDOCRINOLOGY, V113, P2232, DOI 10.1210/endo-113-6-2232; Babyak M, 2000, PSYCHOSOM MED, V62, P633, DOI 10.1097/00006842-200009000-00006; Belvindrah R, 2002, J NEUROSCI, V22, P3594; Bjornebekk A, 2005, INT J NEUROPSYCHOPH, V8, P357, DOI 10.1017/S1461145705005122; Brown J, 2003, EUR J NEUROSCI, V17, P2042, DOI 10.1046/j.1460-9568.2003.02647.x; Ciaroni S, 2002, MECH AGEING DEV, V123, P1341, DOI 10.1016/S0047-6374(02)00070-2; COLT EWD, 1981, LIFE SCI, V28, P1637, DOI 10.1016/0024-3205(81)90319-2; Cooper-Kuhn CM, 2004, J NEUROSCI RES, V77, P155, DOI 10.1002/jnr.20116; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; Drake CT, 2002, HIPPOCAMPUS, V12, P119, DOI 10.1002/hipo.1107; Drake CT, 1999, BRAIN RES, V849, P203, DOI 10.1016/S0006-8993(99)01910-1; Drapeau E, 2007, J NEUROSCI, V27, P6037, DOI 10.1523/JNEUROSCI.1031-07.2007; Droste SK, 2003, ENDOCRINOLOGY, V144, P3012, DOI 10.1210/en.2003-0097; Dupret D, 2007, PLOS BIOL, V5, P1683, DOI 10.1371/journal.pbio.0050214; Eisch AJ, 2006, HIPPOCAMPUS, V16, P271, DOI 10.1002/hipo.20161; Fabel K, 2003, EUR J NEUROSCI, V18, P2803, DOI 10.1111/j.1460-9568.2003.03041.x; Farmer J, 2004, NEUROSCIENCE, V124, P71, DOI 10.1016/j.neuroscience.2003.09.029; Ferreira A, 2006, EUR PSYCHIAT, V21, P580, DOI 10.1016/j.eurpsy.2005.02.003; Goldfarb AH, 1997, SPORTS MED, V24, P8, DOI 10.2165/00007256-199724010-00002; Gomez F, 1996, NEUROENDOCRINOLOGY, V63, P327, DOI 10.1159/000126973; Greenwood BN, 2003, J NEUROSCI, V23, P2889; Harburg GC, 2007, NEUROSCIENCE, V144, P77, DOI 10.1016/j.neuroscience.2006.09.018; Hayward MD, 2002, J NEUROSCI, V22, P8251; HOFFMANN P, 1990, REGUL PEPTIDES, V28, P233, DOI 10.1016/0167-0115(90)90021-N; Holmes MM, 2004, J NEUROSCI RES, V76, P216, DOI 10.1002/jnr.20039; Holmes MM, 2002, BEHAV NEUROSCI, V116, P160, DOI 10.1037//0735-7044.116.1.160; JANAL MN, 1984, PAIN, V19, P13, DOI 10.1016/0304-3959(84)90061-7; Jonsdottir IH, 2000, LIFE SCI, V66, P1231, DOI 10.1016/S0024-3205(00)00428-8; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Kempermann G, 2004, TRENDS NEUROSCI, V27, P447, DOI 10.1016/j.tins.2004.05.013; Kim JJ, 2002, NAT REV NEUROSCI, V3, P453, DOI 10.1038/nrn849; Kim SH, 2002, LIFE SCI, V71, P1331, DOI 10.1016/S0024-3205(02)01849-0; Kitamura T, 2003, NEUROSCI RES, V47, P55, DOI 10.1016/S0168-0102(03)00171-8; Knubben K, 2007, BRIT J SPORT MED, V41, P29, DOI 10.1136/bjsm.2006.030130; Kronenberg G, 2003, J COMP NEUROL, V467, P455, DOI 10.1002/cne.10945; Kronenberg G, 2006, NEUROBIOL AGING, V27, P1505, DOI 10.1016/j.neurobiolaging.2005.09.016; LAPCHAK PA, 1989, NEUROSCIENCE, V31, P313, DOI 10.1016/0306-4522(89)90376-X; Laurin D, 2001, ARCH NEUROL-CHICAGO, V58, P498, DOI 10.1001/archneur.58.3.498; Lemaire V, 2000, P NATL ACAD SCI USA, V97, P11032, DOI 10.1073/pnas.97.20.11032; Lemaire V, 1999, EUR J NEUROSCI, V11, P4006, DOI 10.1046/j.1460-9568.1999.00833.x; Li G, 2004, PHYSIOL BEHAV, V83, P515, DOI 10.1016/j.physbeh.2004.09.003; MANSOUR A, 1994, J COMP NEUROL, V350, P412, DOI 10.1002/cne.903500307; MARTINSEN EW, 1990, SPORTS MED, V9, P380, DOI 10.2165/00007256-199009060-00006; MATSUMOTO M, 1994, BRAIN RES, V636, P1, DOI 10.1016/0006-8993(94)90169-4; Mayo W, 2005, NEUROBIOL AGING, V26, P103, DOI 10.1016/j.neurobiolaging.2004.03.013; Molteni R, 2002, EUR J NEUROSCI, V16, P1107, DOI 10.1046/j.1460-9568.2002.02158.x; Naylor AS, 2005, J NEUROPHYSIOL, V93, P2406, DOI 10.1152/jn.01085.2004; Olson AK, 2006, HIPPOCAMPUS, V16, P250, DOI 10.1002/hipo.20157; Persson AI, 2003, EUR J NEUROSCI, V17, P1159, DOI 10.1046/j.1460-9568.2003.02538.x; Persson AI, 2003, MOL CELL NEUROSCI, V23, P360, DOI 10.1016/S1044-7431(03)00061-7; Rao MS, 2004, EUR J NEUROSCI, V19, P234, DOI 10.1111/j.0953-816X.2003.03123.x; Rhodes JS, 2003, BEHAV NEUROSCI, V117, P1006, DOI 10.1037/0735-7044.117.5.1006; Rizk P, 2006, NEUROPSYCHOPHARMACOL, V31, P1146, DOI 10.1038/sj.npp.1300954; Rubinstein M, 1996, P NATL ACAD SCI USA, V93, P3995, DOI 10.1073/pnas.93.9.3995; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Stranahan AM, 2006, NAT NEUROSCI, V9, P526, DOI 10.1038/nn1668; Svoboda KR, 1999, J NEUROSCI, V19, P85, DOI 10.1523/JNEUROSCI.19-01-00085.1999; Svoboda KR, 1998, J NEUROSCI, V18, P7084; van der Borght K, 2006, BEHAV BRAIN RES, V167, P36, DOI 10.1016/j.bbr.2005.08.012; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 2005, J NEUROSCI, V25, P8680, DOI 10.1523/JNEUROSCI.1731-05.2005; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Vreugdenhil E, 2007, EUR J NEUROSCI, V25, P635, DOI 10.1111/j.1460-9568.2007.05318.x; Walker TL, 2007, J NEUROSCI, V27, P3734, DOI 10.1523/JNEUROSCI.5060-06.2007; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998	69	69	74	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2253	2262		10.1096/fj.07-099101	http://dx.doi.org/10.1096/fj.07-099101			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18263701				2022-12-25	WOS:000257292500018
J	Meyer-Hoffert, U; Hornef, M; Henriques-Normark, B; Normark, S; Andersson, M; Putsep, K				Meyer-Hoffert, Ulf; Hornef, Mathias; Henriques-Normark, Birgitta; Normark, Staffan; Andersson, Mats; Putsep, Katrin			Identification of heparin/heparan sulfate interacting protein as a major broad-spectrum antimicrobial protein in lung and small intestine	FASEB JOURNAL			English	Article						epithelial defense; innate immunity; HIP/RPL29; ribosomal protein; mucosa	UTERINE EPITHELIAL-CELLS; HEPARIN-BINDING PROTEIN; HIGH-AFFINITY BINDING; HOST-DEFENSE; CDNA CLONING; RIBOSOMAL-PROTEINS; SURFACE EXPRESSION; HISTONE H2A; PEPTIDE; ANTIBACTERIAL	The lungs are continuously exposed to a broad array of microbes through inhalation, and microorganisms that escape clearance by the upper airway mucociliary motion will deposit in the alveolar compartment of the lower airways. The pulmonary epithelium in the alveolar compartment is covered by a thin aqueous layer that contains surfactant proteins but also microbicidal components. We have here identified the epithelial cell surface-expressed heparin/heparan sulfate interacting protein (HIP/RPL29) by high-performance liquid chromatography-fractionation, N-terminal sequencing, and mass spectrometry analysis as a major antimicrobial component in extracts of mouse lung tissue. HIP/RPL29 was also detected in extracts of mouse small intestinal tissue. HIP/RPL29 exhibited broad antibacterial activity, notably against Pseudomonas aeruginosa strains. Human recombinant HIP/RPL29 exhibited killing activity in the same order of magnitude. The HIP/RPL29 protein was demonstrated to be localized to the epithelial cells and cell surface of the lungs and intestines by immunohistochemistry. We suggest that HIP/RPL29 fulfills a function as an abundant antibacterial factor of the epithelial innate defense shield against invading bacteria in both the lungs and the small intestine.	[Meyer-Hoffert, Ulf; Henriques-Normark, Birgitta; Normark, Staffan; Andersson, Mats; Putsep, Katrin] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden; [Hornef, Mathias; Henriques-Normark, Birgitta] Swedish Inst Infect Dis Control, Stockholm, Sweden; [Hornef, Mathias] Hannover Med Sch, Inst Med Microbiol, D-3000 Hannover, Germany; [Hornef, Mathias] Hannover Med Sch, Hosp Epidemiol, D-3000 Hannover, Germany; [Meyer-Hoffert, Ulf] Univ Clin Schleswig Holstein, Dept Dermatol, Kiel, Germany	Karolinska Institutet; Swedish Institute for Infectious Disease Control; Hannover Medical School; Hannover Medical School; University of Kiel; Schleswig Holstein University Hospital	Meyer-Hoffert, U (corresponding author), Univ Hosp Schleswig Holstein, Dept Dermatol, Campus Kiel,Schittenhelmstr 7D, D-24105 Kiel, Germany.	umeyerhoffert@dermatology.uni-kiel.de	Meyer-Hoffert, Ulf/F-4623-2012; Andersson, Mats L/M-9124-2014	Meyer-Hoffert, Ulf/0000-0003-2305-1428; Andersson, Mats L/0000-0001-7582-8791; Hornef, Mathias/0000-0001-6096-9110				ANDERSSON M, 1995, EMBO J, V14, P1615, DOI 10.1002/j.1460-2075.1995.tb07150.x; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Bergsson G, 2005, FEBS J, V272, P4960, DOI 10.1111/j.1742-4658.2005.04906.x; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; FUJITA Y, 1994, BIOCHEM BIOPH RES CO, V199, P706, DOI 10.1006/bbrc.1994.1286; Harder J, 2000, AM J RESP CELL MOL, V22, P714, DOI 10.1165/ajrcmb.22.6.4023; HIEMSTRA PS, 1993, INFECT IMMUN, V61, P3038, DOI 10.1128/IAI.61.7.3038-3046.1993; Hiemstra PS, 1999, J LEUKOCYTE BIOL, V66, P423, DOI 10.1002/jlb.66.3.423; Hoke DE, 2000, BIOCHEMISTRY-US, V39, P15686, DOI 10.1021/bi0009688; Hoke DE, 1998, J BIOL CHEM, V273, P25148, DOI 10.1074/jbc.273.39.25148; Hornef MW, 2004, NAT IMMUNOL, V5, P836, DOI 10.1038/ni1094; Howell SJ, 2003, PEPTIDES, V24, P1763, DOI 10.1016/j.peptides.2003.07.028; HULTMARK D, 1983, EMBO J, V2, P571, DOI 10.1002/j.1460-2075.1983.tb01465.x; Julian J, 2001, BIOL REPROD, V64, P1165, DOI 10.1095/biolreprod64.4.1165; Kim HS, 1996, BIOCHEM BIOPH RES CO, V229, P381, DOI 10.1006/bbrc.1996.1814; Kirn-Safran CB, 2007, DEV DYNAM, V236, P447, DOI 10.1002/dvdy.21046; Kirn-Safran CB, 2002, DEV DYNAM, V223, P70, DOI 10.1002/dvdy.1226; Kirn-Safran CB, 2000, GENOMICS, V68, P210, DOI 10.1006/geno.2000.6283; LANDOWSKI TH, 1995, CLIN EXP METASTAS, V13, P357; Law PTW, 1996, BBA-GENE STRUCT EXPR, V1305, P105, DOI 10.1016/0167-4781(95)00224-3; Liu SC, 1996, J BIOL CHEM, V271, P11817, DOI 10.1074/jbc.271.20.11817; Liu SC, 1998, J BIOL CHEM, V273, P9718, DOI 10.1074/jbc.273.16.9718; Liu SC, 1997, J BIOL CHEM, V272, P25856, DOI 10.1074/jbc.272.41.25856; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Nuding S, 2007, GUT, V56, P1240, DOI 10.1136/gut.2006.118646; Oppenheim JJ, 2007, ADV EXP MED BIOL, V601, P185; Park IY, 1998, FEBS LETT, V437, P258, DOI 10.1016/S0014-5793(98)01238-1; Patat SA, 2004, EUR J BIOCHEM, V271, P4825, DOI 10.1111/j.1432-1033.2004.04448.x; Putsep K, 1999, NATURE, V398, P671, DOI 10.1038/19439; Putsep K, 2000, J BIOL CHEM, V275, P40478, DOI 10.1074/jbc.M007816200; Putsep K, 2002, LANCET, V360, P1144, DOI 10.1016/S0140-6736(02)11201-3; Rogan MP, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-29; Rohde LH, 1996, J BIOL CHEM, V271, P11824, DOI 10.1074/jbc.271.20.11824; Rose FRAJ, 1998, INFECT IMMUN, V66, P3255, DOI 10.1128/IAI.66.7.3255-3263.1998; Salzman NH, 2003, NATURE, V422, P522, DOI 10.1038/nature01520; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; Schutte BC, 2002, P NATL ACAD SCI USA, V99, P2129, DOI 10.1073/pnas.042692699; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; Swidsinski A, 2005, WORLD J GASTROENTERO, V11, P1131, DOI 10.3748/wjg.v11.i8.1131; Tollin M, 2003, PEPTIDES, V24, P523, DOI 10.1016/S0196-9781(03)00114-1; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; Wool IG, 1995, BIOCHEM CELL BIOL, V73, P933, DOI 10.1139/o95-101; Yang D, 2004, ANNU REV IMMUNOL, V22, P181, DOI 10.1146/annurev.immunol.22.012703.104603; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zimmermann RA, 2003, CELL, V115, P130, DOI 10.1016/S0092-8674(03)00804-3	47	6	6	2	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2427	2434		10.1096/fj.07-103440	http://dx.doi.org/10.1096/fj.07-103440			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18299334				2022-12-25	WOS:000257292500034
J	Peng, Z; Fernandez, P; Wilder, T; Yee, H; Chiriboga, L; Chan, ESL; Cronstein, BN				Peng, Zhongsheng; Fernandez, Patricia; Wilder, Tuere; Yee, Herman; Chiriboga, Luis; Chan, Edwin S. L.; Cronstein, Bruce N.			Ecto-5 '-nucleotidase (CD73)-mediated extracellular adenosine production plays a critical role in hepatic fibrosis	FASEB JOURNAL			English	Article						stellate cell; carbon tetrachloride; thioacetamide	INDUCED MOTOR INCOORDINATION; LIVER FIBROSIS; STELLATE CELLS; ALKALINE-PHOSPHATASE; MOLECULAR-MECHANISMS; RECEPTOR BLOCKADE; TISSUE FIBROSIS; NG108-15 CELLS; RAT-LIVER; TGF-BETA	Adenosine is a potent endogenous regulator of tissue repair that is released from injured cells and tissues. Hepatic fibrosis results from chronic hepatic injury, and we have previously reported that endogenously generated adenosine, acting at A(2A) receptors, plays a role in toxin-induced hepatic fibrosis. Adenosine may form intracellularly and then be transported to the extracellular space or it may form extracellularly from adenine nucleotides released from injured cells. Because ecto-5'-nucleotidase (CD73) catalyzes the terminal step in extracellular adenosine formation from AMP, we determined whether CD73 plays a role in the development of hepatic fibrosis. Mice were treated overnight with PBS, CCl4, ethanol, or thioacetamide (TAA); their livers were harvested, and slices were incubated in medium for 20 h before adenosine concentration in the supernatant was measured by HPLC. Hepatic fibrosis was induced by CCl4 or TAA treatment in CD73 knockout (CD73KO and C57BL/6 background) and C57BL/6 control mice [wild-type (WT)] mice and quantified by digital analysis of picrosirius red stained slides and hydroxyproline content. mRNA expression was quantified by real-time polymerase chain reaction, and protein was quantified by Western blot or enzyme-linked immunosorbent assay. Livers from WT mice treated with CCl4, ethanol, and TAA released 2- to 3-fold higher levels of adenosine than livers from comparably treated CD73KO mice. CD73KO mice were protected from fibrosis with significantly less collagen content in the livers of CD73KO than WT mice after treatment with either CCl4 or TAA. There were far fewer alpha-smooth muscle actin positive hepatic stellate cells in CCl4-treated KO mice than that in WT mice. After CCl4 treatment, the mRNA level of A(1), A(2A), A(2B), and A(3) adenosine receptors, tumor necrosis factor-alpha, interleukin (IL) -1 beta, IL-13r alpha 1, matrix metalloproteinase (MMP)-2, MMP-14, tissue inhibitor of metalloproteinase (TIMP) -1, and TIMP-2, and IL-13 level increased markedly in both CD73KO and WT mice, but Co11 alpha 1, Co13 alpha 1, and transforming growth factor-beta 1 mRNA increased much more in WT mice than that in KO mice. Moreover, IL-13r alpha 1, MMP-13 mRNA, and MMP-13 protein were higher in KO mice than that in WT mice. These results indicate that adenosine, formed extracellularly from adenine nucleotides, plays a major role in the pathogenesis of hepatic fibrosis and that inhibition of adenosine production or blockade of adenosine receptors may help prevent hepatic fibrosis.	[Peng, Zhongsheng; Fernandez, Patricia; Wilder, Tuere; Chan, Edwin S. L.; Cronstein, Bruce N.] New York Univ, Div Clin Pharmacol & Rheumatol, Dept Med, Sch Med, New York, NY 10016 USA; [Yee, Herman; Chiriboga, Luis] New York Univ, Sch Med, Dept Pathol, New York, NY 10016 USA	New York University; New York University	Cronstein, BN (corresponding author), New York Univ, Div Clin Pharmacol, Dept Med, Sch Med, 550 1st Ave, New York, NY 10016 USA.	cronsb01@med.nyu.edu		Cronstein, Bruce/0000-0002-4295-7383; Chiriboga, Luis/0000-0002-2028-6873	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000096] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR056672, R01AR041911] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA013336] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR00096] Funding Source: Medline; NIAAA NIH HHS [AA13336] Funding Source: Medline; NIAMS NIH HHS [AR41911, R01 AR056672] Funding Source: Medline; NIGMS NIH HHS [GM56268] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrews AL, 2006, J ALLERGY CLIN IMMUN, V118, P858, DOI 10.1016/j.jaci.2006.06.041; Arthur MJP, 2000, AM J PHYSIOL-GASTR L, V279, pG245; Arvilommi AM, 1997, EUR J IMMUNOL, V27, P248, DOI 10.1002/eji.1830270137; Bachmann S, 1997, KIDNEY INT, V51, P479, DOI 10.1038/ki.1997.66; Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; Blackburn MR, 2003, J CLIN INVEST, V112, P332, DOI 10.1172/JCI200316815; BRUNDEGE JM, 1995, NEUROSCI LETT, V186, P214, DOI 10.1016/0304-3940(95)11320-V; Carmichael F J, 1993, Alcohol Alcohol Suppl, V2, P411; Castrop H, 2004, J CLIN INVEST, V114, P634, DOI 10.1172/JCI200421851; Chan ESL, 2006, ARTHRITIS RHEUM-US, V54, P2632, DOI 10.1002/art.21974; Chan ESL, 2006, BRIT J PHARMACOL, V148, P1144, DOI 10.1038/sj.bjp.0706812; Che J, 2007, MOL PHARMACOL, V72, P1626, DOI 10.1124/mol.107.038760; Chunn JL, 2005, J IMMUNOL, V175, P1937, DOI 10.4049/jimmunol.175.3.1937; Connole L, 2004, BASIC CLIN PHARMACOL, V95, P299, DOI 10.1111/j.1742-7843.2004.pto950509.x; Corrao G, 2001, ANN EPIDEMIOL, V11, P458, DOI 10.1016/S1047-2797(01)00223-X; CRONSTEIN BN, 1991, P NATL ACAD SCI USA, V88, P2441, DOI 10.1073/pnas.88.6.2441; Dar M S, 1993, Alcohol Alcohol Suppl, V2, P425; Dar MS, 2006, BRAIN RES BULL, V71, P287, DOI 10.1016/j.brainresbull.2006.09.016; Dar MS, 2002, BRAIN RES, V957, P53, DOI 10.1016/S0006-8993(02)03599-0; DIAMOND I, 1994, EXS, V71, P175; El Yacoubi M, 2003, NEUROPHARMACOLOGY, V45, P977, DOI 10.1016/S0028-3908(03)00254-5; Eltzschig HK, 2003, J EXP MED, V198, P783, DOI 10.1084/jem.20030891; Faller J, 1984, Adv Exp Med Biol, V165 Pt A, P457; Fallowfield JA, 2007, J IMMUNOL, V178, P5288, DOI 10.4049/jimmunol.178.8.5288; FORTUNA R, 1980, CALCIFIED TISSUE INT, V30, P217, DOI 10.1007/BF02408631; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Gallus S, 2002, ANN EPIDEMIOL, V12, P202, DOI 10.1016/S1047-2797(01)00304-0; Gordon A S, 1990, Biochem Soc Symp, V56, P117; GORDON AS, 1991, ADV EXP MED BIOL, V309, P387; Gressner AM, 2002, FRONT BIOSCI-LANDMRK, V7, pD793, DOI 10.2741/gressner; Hashmi AZ, 2007, AM J PHYSIOL-GASTR L, V292, pG395, DOI 10.1152/ajpgi.00208.2006; Hasko G, 2004, TRENDS IMMUNOL, V25, P33, DOI 10.1016/j.it.2003.11.003; IHRKE G, 1993, J CELL BIOL, V123, P1761, DOI 10.1083/jcb.123.6.1761; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; JAMES J, 1990, LIVER, V10, P1; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; Kaviratne M, 2004, J IMMUNOL, V173, P4020, DOI 10.4049/jimmunol.173.6.4020; KELLY E, 1995, BRIT J PHARMACOL, V114, P1433, DOI 10.1111/j.1476-5381.1995.tb13366.x; Klatsky A L, 1993, Ann Epidemiol, V3, P375, DOI 10.1016/1047-2797(93)90064-B; KLATSKY AL, 1992, AM J EPIDEMIOL, V136, P1248, DOI 10.1093/oxfordjournals.aje.a116433; Klatsky AL, 2006, ARCH INTERN MED, V166, P1190, DOI 10.1001/archinte.166.11.1190; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; Koszalka P, 2004, CIRC RES, V95, P814, DOI 10.1161/01.RES.0000144796.82787.6f; Lappas CM, 2005, EXPERT OPIN INV DRUG, V14, P797, DOI 10.1517/13543784.14.7.797; Ledoux S, 2003, CIRC RES, V92, P848, DOI 10.1161/01.RES.0000069022.95401.FE; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; Linden J, 2005, MOL PHARMACOL, V67, P1385, DOI 10.1124/mol.105.011783; Mato JM, 1997, PHARMACOL THERAPEUT, V73, P265, DOI 10.1016/S0163-7258(96)00197-0; MENG ZH, 1995, ALCOHOL CLIN EXP RES, V19, P892, DOI 10.1111/j.1530-0277.1995.tb00964.x; Mentink-Kane MM, 2004, IMMUNOL REV, V202, P191, DOI 10.1111/j.0105-2896.2004.00210.x; Morabito L, 1998, J CLIN INVEST, V101, P295, DOI 10.1172/JCI1554; Nagy L E, 1993, Alcohol Alcohol Suppl, V2, P419; NAGY LE, 1989, MOL PHARMACOL, V36, P744; NAGY LE, 1991, MOL PHARMACOL, V40, P812; NAGY LE, 1990, J BIOL CHEM, V265, P1946; NAITO Y, 1981, BIOCHEMISTRY-US, V20, P5188, DOI 10.1021/bi00521a014; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; Picher M, 2003, J BIOL CHEM, V278, P13468, DOI 10.1074/jbc.M300569200; PUIG JG, 1984, J CLIN INVEST, V74, P936, DOI 10.1172/JCI111512; Rivkees SA, 2001, MOL GENET METAB, V74, P160, DOI 10.1006/mgme.2001.3217; Ruhl CE, 2005, GASTROENTEROLOGY, V129, P1928, DOI 10.1053/j.gastro.2005.08.056; SAPRU MK, 1994, J PHARMACOL EXP THER, V271, P542; SCHELL MJ, 1992, J CELL BIOL, V119, P1173, DOI 10.1083/jcb.119.5.1173; SCHMID TC, 1994, HISTOCHEMISTRY, V101, P439, DOI 10.1007/BF00269494; Sharp DS, 1999, ANN EPIDEMIOL, V9, P391; Siegmund SV, 2005, DIGEST DIS, V23, P264, DOI 10.1159/000090174; Song ZY, 2007, BIOCHEM PHARMACOL, V74, P521, DOI 10.1016/j.bcp.2007.05.005; STEGEMAN.H, 1967, CLIN CHIM ACTA, V18, P267, DOI 10.1016/0009-8981(67)90167-2; Sugimoto R, 2005, LIVER INT, V25, P420, DOI 10.1111/j.1478-3231.2005.01087.x; Sun CX, 2006, J CLIN INVEST, V116, P2173, DOI 10.1172/JCI27303; Synnestvedt K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337; Thompson LF, 2004, J EXP MED, V200, P1395, DOI 10.1084/Jem.20040915; Tverdal A, 2003, ANN EPIDEMIOL, V13, P419, DOI 10.1016/S1047-2797(02)00462-3; Volmer JB, 2006, J IMMUNOL, V176, P4449, DOI 10.4049/jimmunol.176.7.4449; Zhou XY, 2004, LIVER INT, V24, P492, DOI 10.1111/j.1478-3231.2004.0946.x; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309	76	91	93	2	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2263	2272		10.1096/fj.07-100685	http://dx.doi.org/10.1096/fj.07-100685			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18263696				2022-12-25	WOS:000257292500019
J	Gupta, A; Rozenfeld, R; Gomes, I; Raehal, KM; Decaillot, FM; Bohn, LM; Devi, LA				Gupta, Achla; Rozenfeld, Raphael; Gomes, Ivone; Raehal, Kirsten M.; Decaillot, Fabien M.; Bohn, Laura M.; Devi, Lakshmi A.			Post-activation-mediated changes in opioid receptors detected by N-terminal antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; CRYSTAL-STRUCTURE; INVERSE AGONIST; DOWN-REGULATION; DESENSITIZATION; INTERNALIZATION; HETERODIMERIZATION; MUTATIONS; RHODOPSIN; SEGMENT-6	The majority of studies examining activity-induced conformational changes in G protein-coupled receptors have focused on transmembrane helices or intracellular regions. Relatively few studies have examined the involvement of the extracellular region in general and the N-terminal region in particular in this process. To begin to address this, we generated a series of antibodies to the N-terminal region of opioid receptors. Characterization of these antibodies revealed that they differentially recognize activated receptors. Recently, we generated monoclonal antibodies that recognize regions proximal to glycosylation sites in the receptor N terminus. Characterization of these antibodies revealed that agonist treatment leads to a decrease in epitope recognition by the antibody presumably because of a movement of the region of the N terminus proximal to glycosylation sites. The time course of the decrease in antibody recognition suggested that it could be due to a post-activation-mediated event. Examination of the involvement of receptor residues in the C-tail and beta-arrestin binding using site-directed mutagenesis and cells or tissues lacking beta-arrestin 2 suggests a role for these desensitization-related mechanisms in governing antibody binding to the receptor. Thus, these N-terminally directed antibodies can differentially recognize post-activation-mediated changes in the C-terminal (intracellular) region of the receptor. Therefore, these conformation-sensitive antibodies represent powerful reagents to probe receptor activation states and provide a potential tool for identifying and characterizing new compounds of therapeutic interest.	[Gupta, Achla; Rozenfeld, Raphael; Gomes, Ivone; Decaillot, Fabien M.; Devi, Lakshmi A.] Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA; [Raehal, Kirsten M.; Bohn, Laura M.] Ohio State Univ, Coll Med & Publ Hlth, Dept Pharmacol & Psychiat, Columbus, OH 43210 USA	Icahn School of Medicine at Mount Sinai; University System of Ohio; Ohio State University	Devi, LA (corresponding author), Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, 19-84 Annenberg Bldg,1 Gustave L Levy Pl, New York, NY 10029 USA.	lakshmi.devi@mssm.edu	Devi P, Lakshmi/GXM-5982-2022; Bohn, Laura M/A-7483-2014	Devi P, Lakshmi/0000-0001-9274-4776; Bohn, Laura M/0000-0002-6474-8179	NIDA NIH HHS [K01 DA014600, DA08863, DA18860, DA19521, R01 DA018860, DA021952, DA14600, K01 DA014600-06, R01 DA018860-04] Funding Source: Medline; NINDS NIH HHS [NS053751] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [F31DA021952, R37DA008863, R56DA008863, R01DA018860, K01DA014600, R01DA008863, K05DA019521] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Alvarez VA, 2002, J NEUROSCI, V22, P5769; Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; Borgland S, 2001, CLIN EXP PHARMACOL P, V28, P147, DOI 10.1046/j.1440-1681.2001.03418.x; Brillet Karl, 2003, BMC Pharmacology, V3, P14, DOI 10.1186/1471-2210-3-14; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Debic HH, 2005, J NEUROSCI, V25, P7847, DOI 10.1523/JNEUROSCI.5045-04.2005; Decaillot FM, 2003, NAT STRUCT BIOL, V10, P629, DOI 10.1038/nsb950; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; Gainetdinov RR, 2004, ANNU REV NEUROSCI, V27, P107, DOI 10.1146/annurev.neuro.27.070203.144206; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gomes I, 2004, P NATL ACAD SCI USA, V101, P5135, DOI 10.1073/pnas.0307601101; Gomes I, 2002, METHODS, V27, P358, DOI 10.1016/S1046-2023(02)00094-4; Gupta A, 2007, J BIOL CHEM, V282, P5116, DOI 10.1074/jbc.M609254200; Gupta A, 2006, MT SINAI J MED, V73, P673; Heimann AS, 2007, P NATL ACAD SCI USA, V104, P20588, DOI 10.1073/pnas.0706980105; HILL SJ, 2006, BRIT J PHARMACOL, V27, pS37; Jensen AD, 2001, J BIOL CHEM, V276, P9279, DOI 10.1074/jbc.M004871200; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kovoor A, 1998, MOL PHARMACOL, V54, P704; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Law PY, 2000, J BIOL CHEM, V275, P32057, DOI 10.1074/jbc.M002395200; Lecat S, 2002, J BIOL CHEM, V277, P42034, DOI 10.1074/jbc.M203606200; Levin MC, 2002, J BIOL CHEM, V277, P30429, DOI 10.1074/jbc.M200681200; Li J, 2001, BIOCHEMISTRY-US, V40, P12039, DOI 10.1021/bi0100945; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Rozenfeld R, 2007, FASEB J, V21, P2455, DOI 10.1096/fj.06-7793com; ROZENFLED R, 2008, IN PRESS FASEB J; Salom D, 2006, P NATL ACAD SCI USA, V103, P16123, DOI 10.1073/pnas.0608022103; Silve C, 2005, J BIOL CHEM, V280, P37917, DOI 10.1074/jbc.M506263200; Trapaidze N, 2000, DNA CELL BIOL, V19, P93, DOI 10.1089/104454900314609; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; Vassart G, 2004, TRENDS BIOCHEM SCI, V29, P119, DOI 10.1016/j.tibs.2004.01.006; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157	34	18	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10735	10744		10.1074/jbc.M709454200	http://dx.doi.org/10.1074/jbc.M709454200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18256033	Green Published, hybrid			2022-12-25	WOS:000254894700056
J	Hu, J; Hu, K; Williams, DC; Komlosh, ME; Cai, M; Clore, GM				Hu, Jun; Hu, Kaifeng; Williams, David C., Jr.; Komlosh, Michal E.; Cai, Mengli; Clore, G. Marius			Solution NMR structures of productive and non-productive complexes between the A and B domains of the cytoplasmic subunit of the mannose transporter of the Escherichia coli phosphotransferase system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYL TRANSFER COMPLEX; BACTERIAL PHOSPHOENOLPYRUVATE; 3-DIMENSIONAL STRUCTURES; DIPOLAR COUPLINGS; STEREOCHEMICAL COURSE; DISTANCE GEOMETRY; PROTEIN COMPLEXES; IIAB(MAN) SUBUNIT; MACROMOLECULES; REFINEMENT	Solution structures of complexes between the isolated A (IIA(Man)) and B (IIBMan) domains of the cytoplasmic component of the mannose transporter of Escherichia coli have been solved by NMR. The complex of wild-type IIA(Man) and IIBMan is a mixture of two species comprising a productive, phosphoryl transfer competent complex and a non-productive complex with the two active site histidines, His-10 of IIA(Man) and His-175 of IIBMan, separated by similar to 25 angstrom. Mutation of the active site histidine, His-10, of IIA(Man) to a glutamate, to mimic phosphorylation, results in the formation of a single productive complex. The apparent equilibrium dissociation constants for the binding of both wild-type and H10E IIA(Man) to IIBMan are approximately the same (K-D similar to 0.5mM). The productive complex can readily accommodate a transition state involving a pentacoordinate phosphoryl group with trigonal bipyramidal geometry bonded to the N epsilon 2 atom of His-10 of IIA(Man) and the N delta 1 atom of His-175 of IIBMan with negligible (< 0.2 angstrom) local backbone conformational changes in the immediate vicinity of the active site. The non-productive complex is related to the productive one by a similar to 90 rotation and similar to 37 angstrom translation of IIBMan relative to IIA(Man), leaving the active site His-175 of IIBMan fully exposed to solvent in the non-productive complex. The interaction surface on IIA(Man) for the non-productive complex comprises a subset of residues used in the productive complex and in both cases involves both subunits of IIA(Man). The selection of the productive complex by IIA(Man)(H10E) can be attributed to neutralization of the positively charged Arg-172 of IIBMan at the center of the interface. The non-productive IIA(Man)-IIBMan complex may possibly be relevant to subsequent phosphoryl transfer from His-175 of IIBMan to the incoming sugar located on the transmembrane IICMan-IIDMan complex.	[Hu, Jun; Hu, Kaifeng; Williams, David C., Jr.; Komlosh, Michal E.; Cai, Mengli; Clore, G. Marius] NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Clore, GM (corresponding author), NIDDK, Chem Phys Lab, NIH, Bldg 5,B1-301, Bethesda, MD 20892 USA.	mariusc@intra.niddk.nih.gov	Clore, G. Marius/A-3511-2008; Clore, G Marius/L-2546-2018	Clore, G. Marius/0000-0003-3809-1027; Clore, G Marius/0000-0003-3809-1027	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK029043, ZIADK029023, Z01DK029023] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bax A, 2001, METHOD ENZYMOL, V339, P127, DOI 10.1016/S0076-6879(01)39313-8; BAX A, 1994, METHOD ENZYMOL, V239, P79; BEGLEY GS, 1982, BIOCHEMISTRY-US, V21, P5552, DOI 10.1021/bi00265a026; Cai M, 1998, NAT STRUCT BIOL, V5, P903, DOI 10.1038/2345; Cai ML, 2003, J BIOL CHEM, V278, P25191, DOI 10.1074/jbc.M302677200; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P979; Clore GM, 2000, P NATL ACAD SCI USA, V97, P9021, DOI 10.1073/pnas.97.16.9021; CLORE GM, 1986, EMBO J, V5, P2729, DOI 10.1002/j.1460-2075.1986.tb04557.x; Clore GM, 1998, J MAGN RESON, V133, P216, DOI 10.1006/jmre.1998.1419; CLORE GM, 1995, FASEB J, V9, P57, DOI 10.1096/fasebj.9.1.7821760; Clore GM, 1998, J MAGN RESON, V131, P159, DOI 10.1006/jmre.1997.1345; Clore GM, 1999, J AM CHEM SOC, V121, P9008, DOI 10.1021/ja991789k; Clore GM, 2002, J MAGN RESON, V154, P329, DOI 10.1006/jmre.2001.2489; Clore GM, 2002, J AM CHEM SOC, V124, P2866, DOI 10.1021/ja017712p; Clore GM, 1998, TRENDS BIOTECHNOL, V16, P22, DOI 10.1016/S0167-7799(97)01135-9; Clore GM, 1998, J AM CHEM SOC, V120, P10571, DOI 10.1021/ja982592f; CLORE GM, 1987, EMBO J, V6, P529, DOI 10.1002/j.1460-2075.1987.tb04785.x; CLORE GM, 1991, ANNU REV BIOPHYS BIO, V20, P29, DOI 10.1146/annurev.biophys.20.1.29; Cornilescu G, 2002, J BIOL CHEM, V277, P42289, DOI 10.1074/jbc.M207314200; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Deutscher J, 2006, MICROBIOL MOL BIOL R, V70, P939, DOI 10.1128/MMBR.00024-06; ERNI B, 1989, J BIOL CHEM, V264, P18733; ERNI B, 1987, J BIOL CHEM, V262, P5238; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Garrett DS, 1999, NAT STRUCT BIOL, V6, P166; Goto NK, 1999, J BIOMOL NMR, V13, P369, DOI 10.1023/A:1008393201236; Grishaev A, 2004, J AM CHEM SOC, V126, P7281, DOI 10.1021/ja0319994; Gutknecht R, 1999, J BIOL CHEM, V274, P6091, DOI 10.1074/jbc.274.10.6091; Gutknecht R, 1998, J BIOL CHEM, V273, P12234, DOI 10.1074/jbc.273.20.12234; HOLLFELDER F, 1995, BIOCHEMISTRY-US, V34, P12255, DOI 10.1021/bi00038a021; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Kay LE, 2005, J MAGN RESON, V173, P193, DOI 10.1016/j.jmr.2004.11.021; KUSZEWSKI J, 1995, J MAGN RESON SER B, V106, P92, DOI 10.1006/jmrb.1995.1017; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Legler PM, 2004, J BIOL CHEM, V279, P39115, DOI 10.1074/jbc.M406764200; MAO QC, 1995, J BIOL CHEM, V270, P5258, DOI 10.1074/jbc.270.10.5258; MARKOVICHOUSLEY Z, 1994, BIOCHEMISTRY-US, V33, P10977, DOI 10.1021/bi00202a017; MARTINVERSTRAETE I, 1990, J MOL BIOL, V214, P657, DOI 10.1016/0022-2836(90)90284-S; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MUELLER EG, 1990, BIOCHEMISTRY-US, V29, P6892, DOI 10.1021/bi00481a019; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; NILGES M, 1993, PROTEINS, V17, P297, DOI 10.1002/prot.340170307; Nunn RS, 1996, J MOL BIOL, V259, P502, DOI 10.1006/jmbi.1996.0335; Orriss GL, 2003, J MOL BIOL, V327, P1111, DOI 10.1016/S0022-2836(03)00215-8; Quillin ML, 2000, ACTA CRYSTALLOGR D, V56, P791, DOI 10.1107/S090744490000679X; RHIEL E, 1994, BIOL CHEM H-S, V375, P551, DOI 10.1515/bchm3.1994.375.8.551; Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h; Schauder S, 1998, J MOL BIOL, V276, P591, DOI 10.1006/jmbi.1997.1544; Schwieters CD, 2006, PROG NUCL MAG RES SP, V48, P47, DOI 10.1016/j.pnmrs.2005.10.001; Schwieters CD, 2001, J MAGN RESON, V152, P288, DOI 10.1006/jmre.2001.2413; Schwieters CD, 2001, J MAGN RESON, V149, P239, DOI 10.1006/jmre.2001.2300; Schwieters CD, 2008, J PHYS CHEM B, V112, P6070, DOI 10.1021/jp076244o; Siebold C, 2001, FEBS LETT, V504, P104, DOI 10.1016/S0014-5793(01)02705-3; Suh JY, 2007, P NATL ACAD SCI USA, V104, P3153, DOI 10.1073/pnas.0609103104; Suh JY, 2006, J BIOL CHEM, V281, P8939, DOI 10.1074/jbc.M513466200; vanMontfort RLM, 1997, STRUCTURE, V5, P217, DOI 10.1016/S0969-2126(97)00180-9; VRIEND G, 1993, J APPL CRYSTALLOGR, V26, P47, DOI 10.1107/S0021889892008240; Wang GS, 2000, EMBO J, V19, P5635, DOI 10.1093/emboj/19.21.5635; WEHMEIER UF, 1994, BBA-PROTEIN STRUCT M, V1208, P348, DOI 10.1016/0167-4838(94)90124-4; Williams DC, 2005, J BIOL CHEM, V280, P20775, DOI 10.1074/jbc.M501986200; WILLIAMS N, 1986, P NATL ACAD SCI USA, V83, P8934, DOI 10.1073/pnas.83.23.8934	63	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					11024	11037		10.1074/jbc.M800312200	http://dx.doi.org/10.1074/jbc.M800312200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18270202	Green Published, hybrid			2022-12-25	WOS:000254894700083
J	Kumanovics, A; Chen, OS; Li, LT; Bagley, D; Adkins, EM; Lin, HL; Dingra, NN; Outten, CE; Keller, G; Winge, D; Ward, DM; Kaplan, J				Kumanovics, Attila; Chen, Opal S.; Li, Liangtao; Bagley, Dustin; Adkins, Erika M.; Lin, Huilan; Dingra, Nin N.; Outten, Caryn E.; Keller, Greg; Winge, Dennis; Ward, Diane M.; Kaplan, Jerry			Identification of FRA1 and FRA2 as genes involved in regulating the yeast iron regulon in response to decreased mitochondrial iron-sulfur cluster synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN BIOGENESIS; OXIDATIVE STRESS; ACTIVE-SITE; TRANSCRIPTION; AFT1P; LOCALIZATION; EXPRESSION; MEDIATOR; SYSTEM	The nature of the connection between mitochondrial Fe-S cluster synthesis and the iron-sensitive transcription factor Aft1 in regulating the expression of the iron transport system in Saccharomyces cerevisiae is not known. Using a genetic screen, we identified two novel cytosolic proteins, Fra1 and Fra2, that are part of a complex that interprets the signal derived from mitochondrial Fe-S synthesis. We found that mutations in FRA1 (YLL029W) and FRA2 (YGL220W) led to an increase in transcription of the iron regulon. In cells incubated in high iron medium, deletion of either FRA gene results in the translocation of the low iron-sensing transcription factor Aft1 into the nucleus, where it occupies the FET3 promoter. Deletion of either FRA gene has the same effect on transcription as deletion of both genes and is not additive with activation of the iron regulon due to loss of mitochondrial Fe-S cluster synthesis. These observations suggest that the FRA proteins are in the same signal transduction pathway as Fe-S cluster synthesis. We show that Fra1 and Fra2 interact in the cytosol in an iron-independent fashion. The Fra1-Fra2 complex binds to Grx3 and Grx4, two cytosolic monothiol glutaredoxins, in an iron-independent fashion. These results show that the Fra-Grx complex is an intermediate between the production of mitochondrial Fe-S clusters and transcription of the iron regulon.	[Kumanovics, Attila; Chen, Opal S.; Li, Liangtao; Bagley, Dustin; Adkins, Erika M.; Lin, Huilan; Ward, Diane M.; Kaplan, Jerry] Univ Utah, Dept Pathol, Salt Lake City, UT 84132 USA; [Keller, Greg; Winge, Dennis] Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA; [Keller, Greg; Winge, Dennis] Univ Utah, Dept Med, Salt Lake City, UT 84132 USA; [Dingra, Nin N.; Outten, Caryn E.] Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Kaplan, J (corresponding author), Univ Utah, Dept Pathol, Salt Lake City, UT 84132 USA.	jerry.kaplan@path.utah.edu	Outten, Caryn E./I-9433-2019; Winge, Dennis/G-3611-2010; Lin, Huilan/B-7671-2013	Outten, Caryn E./0000-0003-0335-6531; 	NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052380, R37DK030534, R01DK030534, T32DK007115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K22ES013780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM083292] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA 42014] Funding Source: Medline; NIDDK NIH HHS [DK30534, DK52380, T32 DK07115-29] Funding Source: Medline; NIEHS NIH HHS [K22 ES013780, ES13780] Funding Source: Medline; NIGMS NIH HHS [GM083292] Funding Source: Medline; PHS HHS [5P30KD72437] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Blaiseau PL, 2001, J BIOL CHEM, V276, P34221, DOI 10.1074/jbc.M104987200; Chen OS, 2004, J BIOL CHEM, V279, P29513, DOI 10.1074/jbc.M403209200; Chen OS, 2002, P NATL ACAD SCI USA, V99, P16922, DOI 10.1073/pnas.232392299; Crisp RJ, 2006, EMBO J, V25, P512, DOI 10.1038/sj.emboj.7600961; Crisp RJ, 2003, J BIOL CHEM, V278, P45499, DOI 10.1074/jbc.M307229200; Feng YG, 2006, BIOCHEMISTRY-US, V45, P7998, DOI 10.1021/bi060444t; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Huynen MA, 2005, FEBS LETT, V579, P591, DOI 10.1016/j.febslet.2004.11.111; Johansson C, 2007, J BIOL CHEM, V282, P3077, DOI 10.1074/jbc.M608179200; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Layer G, 2007, J BIOL CHEM, V282, P13342, DOI 10.1074/jbc.M608555200; Lesuisse E, 2005, GENETICS, V169, P107, DOI 10.1534/genetics.104.035873; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; Lill R, 2006, ANNU REV CELL DEV BI, V22, P457, DOI 10.1146/annurev.cellbio.22.010305.104538; Luk E, 2003, P NATL ACAD SCI USA, V100, P10353, DOI 10.1073/pnas.1632471100; Meisinger C, 2000, ANAL BIOCHEM, V287, P339, DOI 10.1006/abio.2000.4868; Molina MM, 2004, J BIOL CHEM, V279, P51923, DOI 10.1074/jbc.M410219200; Ojeda L, 2006, J BIOL CHEM, V281, P17661, DOI 10.1074/jbc.M602165200; Outten FW, 2003, J BIOL CHEM, V278, P45713, DOI 10.1074/jbc.M308004200; Pujol-Carrion N, 2006, J CELL SCI, V119, P4554, DOI 10.1242/jcs.03229; Rutherford JC, 2005, J BIOL CHEM, V280, P10135, DOI 10.1074/jbc.M413731200; Rutherford JC, 2001, P NATL ACAD SCI USA, V98, P14322, DOI 10.1073/pnas.261381198; Schilke B, 1999, P NATL ACAD SCI USA, V96, P10206, DOI 10.1073/pnas.96.18.10206; Sipos K, 2002, J BIOL CHEM, V277, P26944, DOI 10.1074/jbc.M200677200; Ueta R, 2007, MOL BIOL CELL, V18, P2980, DOI 10.1091/mbc.E06-11-1054; van de Peppel J, 2005, MOL CELL, V19, P511, DOI 10.1016/j.molcel.2005.06.033; Van Ho A, 2002, ANNU REV MICROBIOL, V56, P237, DOI 10.1146/annurev.micro.56.012302.160847; Yamaguchi-Iwai Y, 2002, J BIOL CHEM, V277, P18914, DOI 10.1074/jbc.M200949200; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; Ye H, 2006, J BIOL CHEM, V281, P8958, DOI 10.1074/jbc.M512737200	34	172	187	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10276	10286		10.1074/jbc.M801160200	http://dx.doi.org/10.1074/jbc.M801160200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18281282	Green Published, hybrid			2022-12-25	WOS:000254894700008
J	Shank, LC; Kelley, JB; Gioeli, D; Yang, CS; Spencer, A; Allison, LA; Paschal, BM				Shank, Leonard C.; Kelley, Joshua B.; Gioeli, Daniel; Yang, Chun-Song; Spencer, Adam; Allison, Lizabeth A.; Paschal, Bryce M.			Activation of the DNA-dependent protein kinase stimulates nuclear export of the androgen receptor in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPORT; GLUCOCORTICOID-RECEPTOR; PROSTATE-CANCER; PROGESTERONE-RECEPTORS; BINDING DOMAIN; MOLECULAR CHAPERONES; ESTROGEN-RECEPTOR; RESPONSE ELEMENT; LIGAND-BINDING; LIVING CELLS	The androgen receptor undergoes nuclear import in response to ligand, but the mechanism by which it undergoes nuclear export is poorly understood. We developed a permeabilized cell assay to characterize nuclear export of the androgen receptor in LNCaP prostate cancer cells. We found that nuclear export of endogenous androgen receptor can be stimulated by short double-stranded DNA oligonucleotides. This androgen receptor export pathway is dependent on ATP hydrolysis and is enhanced by phosphatase inhibition with okadaic acid. Fluorescence recovery after photobleaching in permeabilized cells, under the conditions that stimulate androgen receptor export, suggested that double-stranded DNA-dependent export does not simply reflect the relief of a nuclear retention mechanism. A radiolabeled androgen was used to show that the androgen receptor remains ligand-bound during translocation through the nuclear pore complex. A specific inhibitor to the DNA-dependent protein kinase, NU7026, inhibits androgen receptor export and phosphorylation. In living cells, NU7026 treatment increases androgen-dependent transcription from endogenous genes that are regulated by androgen receptor. We suggest that DNA-dependent protein kinase phosphorylation of the androgen receptor, or an interacting component, helps target the androgen receptor for export from the nucleus.	Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Genet, Ctr Cell Signaling, Charlottesville, VA 22908 USA; [Gioeli, Daniel; Paschal, Bryce M.] Univ Virginia, Hlth Sci Ctr, Ctr Canc, Charlottesville, VA 22908 USA; [Allison, Lizabeth A.] Coll William & Mary, Dept Biol, Williamsburg, VA 23187 USA	University of Virginia; University of Virginia; William & Mary	Paschal, BM (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Genet, Ctr Cell Signaling, Charlottesville, VA 22908 USA.	paschal@virginia.edu	Kelley, Joshua Brian/S-1031-2019	Kelley, Joshua Brian/0000-0002-5700-1173	NATIONAL CANCER INSTITUTE [R01CA124706] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA124706] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcazar-Roman AR, 2006, NAT CELL BIOL, V8, P711, DOI 10.1038/ncb1427; ARNOLD SF, 1995, J STEROID BIOCHEM, V52, P159, DOI 10.1016/0960-0760(94)00166-J; BAGCHI MK, 1992, P NATL ACAD SCI USA, V89, P2664, DOI 10.1073/pnas.89.7.2664; Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; Bentel JM, 1996, J ENDOCRINOL, V151, P1, DOI 10.1677/joe.0.1510001; Black BE, 2001, CURR BIOL, V11, P1749, DOI 10.1016/S0960-9822(01)00537-1; Brinkmann AO, 2000, NAT MED, V6, P628, DOI 10.1038/76194; Brinkmann AO, 2001, MOL CELL ENDOCRINOL, V179, P105, DOI 10.1016/S0303-7207(01)00466-X; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CARTER TH, 1988, BIOCHEM BIOPH RES CO, V157, P535, DOI 10.1016/S0006-291X(88)80282-1; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; CLAESSENS F, 1989, BIOCHEM BIOPH RES CO, V164, P833, DOI 10.1016/0006-291X(89)91534-9; Collis SJ, 2005, ONCOGENE, V24, P949, DOI 10.1038/sj.onc.1208332; Culig Z, 2000, UROL RES, V28, P211, DOI 10.1007/s002400000111; Daniel R, 1999, SCIENCE, V284, P644, DOI 10.1126/science.284.5414.644; DEFRANCO DB, 1991, MOL ENDOCRINOL, V5, P1215, DOI 10.1210/mend-5-9-1215; Elbi C, 2004, P NATL ACAD SCI USA, V101, P2876, DOI 10.1073/pnas.0400116101; Englmeier L, 1999, CURR BIOL, V9, P30, DOI 10.1016/S0960-9822(99)80044-X; Farla P, 2005, J CELL SCI, V118, P4187, DOI 10.1242/jcs.02546; Farla P, 2004, J STRUCT BIOL, V147, P50, DOI 10.1016/j.jsb.2004.01.002; Freedman ND, 2004, MOL BIOL CELL, V15, P2276, DOI 10.1091/mbc.E03-11-0839; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Giffin W, 1997, J BIOL CHEM, V272, P5647, DOI 10.1074/jbc.272.9.5647; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; Gioeli D, 2006, MOL ENDOCRINOL, V20, P503, DOI 10.1210/me.2005-0351; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Guo ZY, 2006, CANCER CELL, V10, P309, DOI 10.1016/j.ccr.2006.08.021; Hammarsten O, 2000, J BIOL CHEM, V275, P1541, DOI 10.1074/jbc.275.3.1541; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Holaska JM, 2001, J CELL BIOL, V152, P127, DOI 10.1083/jcb.152.1.127; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Hsiao PW, 1999, J BIOL CHEM, V274, P20229, DOI 10.1074/jbc.274.29.20229; Itoh M, 2002, MOL ENDOCRINOL, V16, P2382, DOI 10.1210/me.2002-0144; Kehlenbach RH, 1998, J CELL BIOL, V141, P863, DOI 10.1083/jcb.141.4.863; Kesler CT, 2007, MOL ENDOCRINOL, V21, P2071, DOI 10.1210/me.2007-0240; Leahy JJJ, 2004, BIOORG MED CHEM LETT, V14, P6083, DOI 10.1016/j.bmcl.2004.09.060; Lee H, 2002, MOL CELL BIOL, V22, P5835, DOI 10.1128/MCB.22.16.5835-5845.2002; Leuther KK, 1999, EMBO J, V18, P1114, DOI 10.1093/emboj/18.5.1114; Liu JM, 2000, MOL ENDOCRINOL, V14, P40, DOI 10.1210/me.14.1.40; Love DC, 1998, P NATL ACAD SCI USA, V95, P10608, DOI 10.1073/pnas.95.18.10608; Marcelli M, 2006, J CELL BIOCHEM, V98, P770, DOI 10.1002/jcb.20593; Martensson S, 2002, J BIOL CHEM, V277, P3020, DOI 10.1074/jbc.M106711200; Mayeur GL, 2005, J BIOL CHEM, V280, P10827, DOI 10.1074/jbc.M413336200; Okazaki T, 2003, BIOCHEM BIOPH RES CO, V304, P632, DOI 10.1016/S0006-291X(03)00651-X; Olefsky JM, 2001, J BIOL CHEM, V276, P36863, DOI 10.1074/jbc.R100047200; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; PETERSON SR, 1995, J BIOL CHEM, V270, P1449, DOI 10.1074/jbc.270.3.1449; Prescott J, 2006, CANCER LETT, V231, P12, DOI 10.1016/j.canlet.2004.12.037; Qiu M, 2003, MOL ENDOCRINOL, V17, P628, DOI 10.1210/me.2002-0378; Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842; Sackey FNA, 1996, MOL ENDOCRINOL, V10, P1191, DOI 10.1210/me.10.10.1191; Sarkaria JN, 1998, CANCER RES, V58, P4375; Sartorius CA, 2000, J MOL ENDOCRINOL, V24, P165, DOI 10.1677/jme.0.0240165; Savory JGA, 1999, MOL CELL BIOL, V19, P1025; Schoenmakers E, 2000, J BIOL CHEM, V275, P12290, DOI 10.1074/jbc.275.16.12290; Shank LC, 2005, CRIT REV EUKAR GENE, V15, P49, DOI 10.1615/CritRevEukaryotGeneExpr.v15.i1.40; Stavreva DA, 2004, MOL CELL BIOL, V24, P2682, DOI 10.1128/MCB.24.7.2682-2697.2004; Tomura A, 2001, J BIOL CHEM, V276, P28395, DOI 10.1074/jbc.M101755200; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; Veuger SJ, 2003, CANCER RES, V63, P6008; Walther RF, 2003, J BIOL CHEM, V278, P37858, DOI 10.1074/jbc.M306356200; Weigel NL, 2007, MOL ENDOCRINOL, V21, P2311, DOI 10.1210/me.2007-0101; Weirich CS, 2006, NAT CELL BIOL, V8, P668, DOI 10.1038/ncb1424; Yang CS, 2007, MOL CELL BIOL, V27, P3390, DOI 10.1128/MCB.02411-06; Yang J, 1997, J CELL BIOL, V137, P523, DOI 10.1083/jcb.137.3.523; YLIKOMI T, 1992, EMBO J, V11, P3681, DOI 10.1002/j.1460-2075.1992.tb05453.x; Zhang LQ, 2003, CANCER RES, V63, P4552; ZHOU ZX, 1994, J BIOL CHEM, V269, P13115	70	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10568	10580		10.1074/jbc.M800810200	http://dx.doi.org/10.1074/jbc.M800810200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18270197	Green Accepted, Green Published, hybrid			2022-12-25	WOS:000254894700039
J	Markman, S; Leitner, S; Catchpole, C; Barnsley, S; Muller, CT; Pascoe, D; Buchanan, KL				Markman, Shai; Leitner, Stefan; Catchpole, Clive; Barnsley, Sara; Mueller, Carsten T.; Pascoe, David; Buchanan, Katherine L.			Pollutants Increase Song Complexity and the Volume of the Brain Area HVC in a Songbird	PLOS ONE			English	Article							SEASONAL PLASTICITY; CHEMICALS; FEMINIZATION; DDT	Environmental pollutants which alter endocrine function are now known to decrease vertebrate reproductive success. There is considerable evidence for endocrine disruption from aquatic ecosystems, but knowledge is lacking with regard to the interface between terrestrial and aquatic ecosystems. Here, we show for the first time that birds foraging on invertebrates contaminated with environmental pollutants, show marked changes in both brain and behaviour. We found that male European starlings (Sturnus vulgaris) exposed to environmentally relevant levels of synthetic and natural estrogen mimics developed longer and more complex songs compared to control males, a sexually selected trait important in attracting females for reproduction. Moreover, females preferred the song of males which had higher pollutant exposure, despite the fact that experimentally dosed males showed reduced immune function. We also show that the key brain area controlling male song complexity (HVC) is significantly enlarged in the contaminated birds. This is the first evidence that environmental pollutants not only affect, but paradoxically enhance a signal of male quality such as song. Our data suggest that female starlings would bias their choice towards exposed males, with possible consequences at the population level. As the starling is a migratory species, our results suggest that transglobal effects of pollutants on terrestrial vertebrate physiology and reproduction could occur in birds.	[Markman, Shai; Barnsley, Sara; Mueller, Carsten T.; Pascoe, David; Buchanan, Katherine L.] Cardiff Univ, Sch Biosci, Cardiff, S Glam, Wales; [Leitner, Stefan; Catchpole, Clive] Univ London, Sch Biol Sci, Egham, Surrey, England; [Leitner, Stefan] Max Planck Inst Ornithol, Dept Behav Neurobiol, Seewiesen, Germany	Cardiff University; University of London; Royal Holloway University London; Max Planck Society	Markman, S (corresponding author), Cardiff Univ, Sch Biosci, Cardiff, S Glam, Wales.	buchanankl1@Cardiff.ac.uk	Müller, Carsten T/A-7114-2010; Buchanan, Kate/A-8178-2012; Leitner, Stefan/D-2129-2012	Müller, Carsten T/0000-0003-0455-7132; Buchanan, Kate/0000-0002-6648-5819; Leitner, Stefan/0000-0002-9482-0362	BBSRC [S18938, C500260]; Biotechnology and Biological Sciences Research Council [S18938] Funding Source: researchfish	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This project was supported by BBSRC research grants S18938 and C500260.	Airey DC, 2000, J NEUROBIOL, V44, P1; Andersson Malte, 1994; ARNOLD AP, 1993, BRAIN BEHAV EVOLUT, V42, P231, DOI 10.1159/000114157; Birkett J.W., 2003, ENDOCRINE DISRUPTERS, DOI DOI 10.1016/0015-1882(91)80016-X; Casto JM, 1996, HORM BEHAV, V30, P387, DOI 10.1006/hbeh.1996.0044; Chalubinski M, 2006, ALLERGY, V61, P1326, DOI 10.1111/j.1398-9995.2006.01135.x; Darwin Charles, 1871, DESCENT MAN; Deerenberg C, 1997, P ROY SOC B-BIOL SCI, V264, P1850; Desbrow C, 1998, ENVIRON SCI TECHNOL, V32, P1549, DOI 10.1021/es9707973; Eens M, 1997, ADV STUD BEHAV, V26, P355, DOI 10.1016/S0065-3454(08)60384-8; Feare C.J., 1984, STARLING; Fisher JS, 2004, REPRODUCTION, V127, P305, DOI 10.1530/rep.1.00025; FRY DM, 1981, SCIENCE, V213, P922, DOI 10.1126/science.7256288; Fusani L, 2006, NEUROSCIENCE, V138, P939, DOI 10.1016/j.neuroscience.2005.08.041; Granbom M, 2005, BEHAV ECOL, V16, P497, DOI 10.1093/beheco/arh137; Hayes T, 2002, NATURE, V419, P895, DOI 10.1038/419895a; Iwaniuk AN, 2006, BEHAV BRAIN RES, V173, P1, DOI 10.1016/j.bbr.2006.05.026; Jarvis Erich D., 2004, P226, DOI 10.1016/B978-012473070-0/50011-6; Jiang JQ, 2005, CHEMOSPHERE, V61, P544, DOI 10.1016/j.chemosphere.2005.02.029; Jobling S, 1998, ENVIRON SCI TECHNOL, V32, P2498, DOI 10.1021/es9710870; Learner MA, 1998, J APPL ECOL, V35, P720, DOI 10.1046/j.1365-2664.1998.355342.x; LOCHMILLER RL, 1993, AUK, V110, P503, DOI 10.2307/4088414; Markman S, 2007, CHEMOSPHERE, V70, P119, DOI 10.1016/j.chemosphere.2007.06.045; PARKINSON TJ, 1995, P ROY SOC B-BIOL SCI, V259, P1, DOI 10.1098/rspb.1995.0001; Robinson RA, 2005, BIRD STUDY, V52, P252, DOI 10.1080/00063650509461398; SCHLINGER BA, 1991, P NATL ACAD SCI USA, V88, P4191, DOI 10.1073/pnas.88.10.4191; Schlinger BA, 1997, J NEUROBIOL, V33, P619, DOI 10.1002/(SICI)1097-4695(19971105)33:5<619::AID-NEU9>3.0.CO;2-7; Smits JE, 1999, FUNCT ECOL, V13, P567, DOI 10.1046/j.1365-2435.1999.00338.x; Soma KK, 2004, J NEUROBIOL, V58, P413, DOI 10.1002/neu.10288; Sower SA, 2000, ENVIRON HEALTH PERSP, V108, P1085; Sumpter J.P., 1996, TOXICOLOGY AQUATIC P, P205, DOI [10.1017/CBO9780511735516.011, DOI 10.1017/CBO9780511735516.011]; Tabb MM, 2006, MOL ENDOCRINOL, V20, P475, DOI 10.1210/me.2004-0513; Tramontin AD, 2000, TRENDS NEUROSCI, V23, P251, DOI 10.1016/S0166-2236(00)01558-7; Wikelski M, 2002, NATURE, V417, P607, DOI 10.1038/417607a	34	73	73	1	51	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2008	3	2							e1674	10.1371/journal.pone.0001674	http://dx.doi.org/10.1371/journal.pone.0001674			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XS	18301751	Green Published, Green Accepted, gold			2022-12-25	WOS:000260586500018
J	Yamahara, K; Sone, M; Itoh, H; Yamashita, JK; Yurugi-Kobayashi, T; Homma, K; Chao, TH; Miyashita, K; Park, K; Oyamada, N; Sawada, N; Taura, D; Fukunaga, Y; Tamura, N; Nakao, K				Yamahara, Kenichi; Sone, Masakatsu; Itoh, Hiroshi; Yamashita, Jun K.; Yurugi-Kobayashi, Takami; Homma, Koichiro; Chao, Ting-Hsing; Miyashita, Kazutoshi; Park, Kwijun; Oyamada, Naofumi; Sawada, Naoya; Taura, Daisuke; Fukunaga, Yasutomo; Tamura, Naohisa; Nakao, Kazuwa			Augmentation of Neovascularizaiton in Hindlimb Ischemia by Combined Transplantation of Human Embryonic Stem Cells-Derived Endothelial and Mural Cells	PLOS ONE			English	Article								Background: We demonstrated that mouse embryonic stem (ES) cells-derived vascular endothelial growth factor receptor-2 (VEGF-R2) positive cells could differentiate into both endothelial cells (EC) and mural cells (MC), and termed them as vascular progenitor cells (VPC). Recently, we have established a method to expand monkey and human ES cells-derived VPC with the proper differentiation stage in a large quantity. Here we investigated the therapeutic potential of human VPC-derived EC and MC for vascular regeneration. Methods and Results: After the expansion of human VPC-derived vascular cells, we transplanted these cells to nude mice with hindlimb ischemia. The blood flow recovery and capillary density in ischemic hindlimbs were significantly improved in human VPC-derived EC-transplanted mice, compared to human peripheral and umbilical cord blood-derived endothelial progenitor cells (pEPC and uEPC) transplanted mice. The combined transplantation of human VPC-derived EC and MC synergistically improved blood flow of ischemic hindlimbs remarkably, compared to the single cell transplantations. Transplanted VPC-derived vascular cells were effectively incorporated into host circulating vessels as EC and MC to maintain long-term vascular integrity. Conclusions: Our findings suggest that the combined transplantation of human ES cells-derived EC and MC can be used as a new promising strategy for therapeutic vascular regeneration in patients with tissue ischemia.	[Yamahara, Kenichi; Sone, Masakatsu; Itoh, Hiroshi; Miyashita, Kazutoshi; Park, Kwijun; Oyamada, Naofumi; Sawada, Naoya; Taura, Daisuke; Fukunaga, Yasutomo; Tamura, Naohisa; Nakao, Kazuwa] Kyoto Univ, Grad Sch Med, Dept Med & Clin Sci, Kyoto, Japan; [Itoh, Hiroshi; Homma, Koichiro; Miyashita, Kazutoshi] Keio Univ, Sch Med, Dept Internal Med, Tokyo, Japan; [Yamashita, Jun K.; Yurugi-Kobayashi, Takami] Kyoto Univ, Inst Frontier Med Sci, Stem Cell Res Ctr, Lab Stem Cell Differentiation, Kyoto, Japan; [Chao, Ting-Hsing] Natl Cheng Kung Univ, Med Ctr, Dept Internal Med, Div Cardiol, Tainan, Taiwan	Kyoto University; Keio University; Kyoto University; National Cheng Kung University	Yamahara, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Med & Clin Sci, Kyoto, Japan.	hrith@sc.itc.keio.ac.jp	Homma, Koichiro/J-3146-2015	Miyashita, Kazutoshi/0000-0003-3757-4334	Japanese Ministry of Education, Culture, Sports, Science and Technology [grant-in-aid]; 21st COE Program for Integration of Transplantation Therapy and Regenerative Medicine, Japan Society for the Promotion of Science; Japan Foundation for Aging and Health	Japanese Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); 21st COE Program for Integration of Transplantation Therapy and Regenerative Medicine, Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Japan Foundation for Aging and Health	This work is supported by a grant-in-aid for scientific research (the Japanese Ministry of Education, Culture, Sports, Science and Technology), a research grant from them 21st COE Program for Integration of Transplantation Therapy and Regenerative Medicine (Japan Society for the Promotion of Science), a research grant from the Project for Development of Regenerative Medicine (the Japanese Ministry of Education, Culture, Sports, Science and Technology), and a research grant from the Japan Foundation for Aging and Health (the Japanese Ministry of Health, Labor and Welfare).	Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Chan-Ling T, 2004, AM J PATHOL, V165, P1301, DOI 10.1016/S0002-9440(10)63389-5; Ferreira LS, 2007, CIRC RES, V101, P286, DOI 10.1161/CIRCRESAHA.107.150201; FINA L, 1990, BLOOD, V75, P2417; FRID MG, 1992, DEV BIOL, V153, P185, DOI 10.1016/0012-1606(92)90104-O; Fukino K, 2003, BIOCHEM BIOPH RES CO, V310, P143, DOI 10.1016/j.bbrc.2003.08.134; Hughes S, 2004, INVEST OPHTH VIS SCI, V45, P2795, DOI 10.1167/iovs.03-1312; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kato H, 2003, CANCER SCI, V94, P1059, DOI 10.1111/j.1349-7006.2003.tb01401.x; Kehat I, 2001, J CLIN INVEST, V108, P407, DOI 10.1172/JCI12131; Miwa Y, 2000, MOL PHARMACOL, V58, P837, DOI 10.1124/mol.58.4.837; Motoike T, 2003, GENESIS, V35, P153, DOI 10.1002/gene.10175; Murohara T, 2000, J CLIN INVEST, V105, P1527, DOI 10.1172/JCI8296; Nishikawa S, 1998, DEVELOPMENT, V125, P1747; Rehman J, 2003, CIRCULATION, V107, P1164, DOI 10.1161/01.CIR.0000058702.69484.A0; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; SAKATA N, 1990, EXP MOL PATHOL, V52, P179, DOI 10.1016/0014-4800(90)90003-V; Sawano A, 2001, BLOOD, V97, P785, DOI 10.1182/blood.V97.3.785; Sone M, 2003, CIRCULATION, V107, P2085, DOI 10.1161/01.CIR.0000070022.78747.1B; Sone M, 2007, ARTERIOSCL THROM VAS, V27, P2127, DOI 10.1161/ATVBAHA.107.143149; Xiao QZ, 2007, AM J PHYSIOL-CELL PH, V292, pC342, DOI 10.1152/ajpcell.00341.2006; Yamahara K, 2003, P NATL ACAD SCI USA, V100, P3404, DOI 10.1073/pnas.0538059100; Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568; Yurugi-Kobayashi T, 2003, BLOOD, V101, P2675, DOI 10.1182/blood-2002-06-1877	24	81	92	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2008	3	2							e1666	10.1371/journal.pone.0001666	http://dx.doi.org/10.1371/journal.pone.0001666			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XS	18301744	Green Published, gold, Green Submitted			2022-12-25	WOS:000260586500011
J	Cottingham, MG; Andersen, RF; Spencer, AJ; Saurya, S; Furze, J; Hill, AVS; Gilbert, SC				Cottingham, Matthew G.; Andersen, Rikke F.; Spencer, Alexandra J.; Saurya, Saroj; Furze, Julie; Hill, Adrian V. S.; Gilbert, Sarah C.			Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA)	PLOS ONE			English	Article							PRIME-BOOST IMMUNIZATION; STEROID-HORMONE SYNTHESIS; CELL IMMUNE-RESPONSES; HOST-RANGE SELECTION; MEMORY T-CELLS; SMALLPOX VACCINATION; ESCHERICHIA-COLI; GENOMIC SEQUENCE; MALARIA VACCINES; FOWLPOX VIRUS	The production, manipulation and rescue of a bacterial artificial chromosome clone of Vaccinia virus (VAC-BAC) in order to expedite construction of expression vectors and mutagenesis of the genome has been described (Domi & Moss, 2002, PNAS 99 12415-20). The genomic BAC clone was 'rescued' back to infectious virus using a Fowlpox virus helper to supply transcriptional machinery. We apply here a similar approach to the attenuated strain Modified Vaccinia virus Ankara (MVA), now widely used as a safe non-replicating recombinant vaccine vector in mammals, including humans. Four apparently full-length, rescuable clones were obtained, which had indistinguishable immunogenicity in mice. One clone was shotgun sequenced and found to be identical to the parent. We employed GalK recombination-mediated genetic engineering (recombineering) of MVA-BAC to delete five selected viral genes. Deletion of C12L, A44L, A46R or B7R did not significantly affect CD8(+) T cell immunogenicity in BALB/c mice, but deletion of B15R enhanced specific CD8(+) T cell responses to one of two endogenous viral epitopes (from the E2 and F2 proteins), in accordance with published work (Staib et al., 2005, J. Gen. Virol. 86, 1997-2006). In addition, we found a higher frequency of triple-positive IFN-gamma, TNF-alpha and IL-2 secreting E3-specific CD8(+) T-cells 8 weeks after vaccination with MVA lacking B15R. Furthermore, a recombinant vaccine capable of inducing CD8(+) T cells against an epitope from Plasmodium berghei was created using GalK counterselection to insert an antigen expression cassette lacking a tandem marker gene into the traditional thymidine kinase locus of MVA-BAC. MVA continues to feature prominently in clinical trials of recombinant vaccines against diseases such as HIV-AIDS, malaria and tuberculosis. Here we demonstrate in proof-of-concept experiments that MVA-BAC recombineering is a viable route to more rapid and efficient generation of new candidate mutant and recombinant vaccines based on a clinically deployable viral vector.	[Cottingham, Matthew G.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England; Univ Oxford, Jenner Inst, Oxford, England	University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; Jenner Institute	Cottingham, MG (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.	matt.cottingham@well.ox.ac.uk	Andersen, Rikke/GRS-3064-2022; Gilbert, Sarah C./H-2857-2019; Balasubramanian, Madhan/E-7255-2010; Cottingham, Matthew/F-1218-2011; Spencer, Alexandra/AAE-6494-2019	Gilbert, Sarah C./0000-0002-6823-9750; Spencer, Alexandra/0000-0001-7958-6961; Andersen, Rikke Fredslund/0000-0002-5894-7745; Cottingham, Matthew/0000-0003-0766-6465	Wellcome Trust; Foundation for the National Institutes of Health [Grand Challenges in Global Health]	Wellcome Trust(Wellcome TrustEuropean Commission); Foundation for the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Funded by the Wellcome Trust and a Grand Challenges in Global Health grant from the Foundation for the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abaitua F, 2006, VIRUS RES, V116, P11, DOI 10.1016/j.virusres.2005.08.008; Alcami A, 1999, J GEN VIROL, V80, P949, DOI 10.1099/0022-1317-80-4-949; ALCAMI A, 1992, CELL, V71, P153, DOI 10.1016/0092-8674(92)90274-G; Alcami A, 2000, J VIROL, V74, P11230, DOI 10.1128/JVI.74.23.11230-11239.2000; Alejo A, 2006, P NATL ACAD SCI USA, V103, P5995, DOI 10.1073/pnas.0510462103; Anderson RJ, 2004, J IMMUNOL, V172, P3094, DOI 10.4049/jimmunol.172.5.3094; Antoine G, 1998, VIROLOGY, V244, P365, DOI 10.1006/viro.1998.9123; Bejon P, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010029; Bowie A, 2000, P NATL ACAD SCI USA, V97, P10162, DOI 10.1073/pnas.160027697; Carroll MW, 1997, VIROLOGY, V238, P198, DOI 10.1006/viro.1997.8845; Chavan R, 2006, J VIROL, V80, P7676, DOI 10.1128/JVI.02748-05; Chen RAJ, 2006, J GEN VIROL, V87, P1451, DOI 10.1099/vir.0.81736-0; Clark RH, 2006, J GEN VIROL, V87, P29, DOI 10.1099/vir.0.81417-0; Cooray S, 2007, J GEN VIROL, V88, P1656, DOI 10.1099/vir.0.82772-0; Cosma A, 2007, AIDS RES HUM RETROV, V23, P782, DOI 10.1089/aid.2006.0226; Cottingham MG, 2006, CLIN VACCINE IMMUNOL, V13, P747, DOI 10.1128/CVI.00088-06; Coupar BEH, 2000, J GEN VIROL, V81, P431, DOI 10.1099/0022-1317-81-2-431; Darrah PA, 2007, NAT MED, V13, P843, DOI 10.1038/nm1592; Domi A, 2005, NAT METHODS, V2, P95, DOI 10.1038/NMETH734; Domi A, 2002, P NATL ACAD SCI USA, V99, P12415, DOI 10.1073/pnas.192420599; Drexler I, 2004, CURR OPIN BIOTECH, V15, P506, DOI 10.1016/j.copbio.2004.09.001; Drexler I, 1998, J GEN VIROL, V79, P347, DOI 10.1099/0022-1317-79-2-347; Earl PL, 2004, NATURE, V428, P182, DOI 10.1038/nature02331; FALKNER FG, 1990, J VIROL, V64, P3108, DOI 10.1128/JVI.64.6.3108-3111.1990; Froggatt GC, 2007, J GEN VIROL, V88, P1917, DOI 10.1099/vir.0.82815-0; Garnett CT, 2006, CURR PHARM DESIGN, V12, P351, DOI 10.2174/138161206775201929; Gilbert SC, 2006, VACCINE, V24, P4554, DOI 10.1016/j.vaccine.2005.08.048; Gomez CE, 2001, VACCINE, V20, P961, DOI 10.1016/S0264-410X(01)00389-9; Haga IR, 2005, PARASITOLOGY, V130, pS11, DOI 10.1017/S0031182005008127; Hanke T, 2007, J GEN VIROL, V88, P1, DOI 10.1099/vir.0.82493-0; Hartley JL, 2000, GENOME RES, V10, P1788, DOI 10.1101/gr.143000; Hill AVS, 2006, NAT REV IMMUNOL, V6, P21, DOI 10.1038/nri1746; Hirsch VM, 1996, J VIROL, V70, P3741, DOI 10.1128/JVI.70.6.3741-3752.1996; Jarmin SA, 2006, J GEN VIROL, V87, P3545, DOI 10.1099/vir.0.82373-0; Keating SM, 2005, J IMMUNOL, V175, P5675, DOI 10.4049/jimmunol.175.9.5675; Kent S, 2007, CURR OPIN INVEST DR, V8, P159; Kettle S, 1997, J GEN VIROL, V78, P677, DOI 10.1099/0022-1317-78-3-677; Kong YP, 1999, J VIROL METHODS, V80, P129, DOI 10.1016/S0166-0934(99)00033-6; KOTWAL GJ, 1990, SCIENCE, V250, P827, DOI 10.1126/science.2237434; Kudo-Saito C, 2006, VACCINE, V24, P4975, DOI 10.1016/j.vaccine.2006.03.042; Ma A, 2006, ANNU REV IMMUNOL, V24, P657, DOI 10.1146/annurev.immunol.24.021605.090727; Mayr A, 2003, COMP IMMUNOL MICROB, V26, P423, DOI 10.1016/S0147-9571(03)00025-0; MAYR A, 1978, ZBL BAKT MIK HYG B, V167, P375; McShane H, 2005, MICROBES INFECT, V7, P962, DOI 10.1016/j.micinf.2005.03.009; MERCHLINSKY M, 1989, J VIROL, V63, P1595, DOI 10.1128/JVI.63.4.1595-1603.1989; MOORE JB, 1992, EMBO J, V11, P1973, DOI 10.1002/j.1460-2075.1992.tb05251.x; Okeke MI, 2006, J GEN VIROL, V87, P21, DOI 10.1099/vir.0.81479-0; Perera LP, 2007, J VIROL, V81, P8774, DOI 10.1128/JVI.00538-07; Ramirez JC, 2000, J VIROL, V74, P923, DOI 10.1128/JVI.74.2.923-933.2000; Reading PC, 2003, J VIROL, V77, P9960, DOI 10.1128/JVI.77.18.9960-9968.2003; Reading PC, 2003, J EXP MED, V197, P1269, DOI 10.1084/jem.20022201; Reyes-Sandoval A, 2004, J VIROL, V78, P7392, DOI 10.1128/JVI.78.14.7392-7399.2004; Reyes-Sandoval A, 2007, IMMUNOLOGY, V121, P158, DOI 10.1111/j.1365-2567.2006.02552.x; ROMERO P, 1990, IMMUNOL LETT, V25, P27, DOI 10.1016/0165-2478(90)90086-6; Roper RL, 2006, J VIROL, V80, P306, DOI 10.1128/JVI.80.1.306-313.2006; Seet BT, 2003, ANNU REV IMMUNOL, V21, P377, DOI 10.1146/annurev.immunol.21.120601.141049; Semprini S, 2007, NUCLEIC ACIDS RES, V35, P1402, DOI 10.1093/nar/gkl1108; Skeiky YAW, 2006, NAT REV MICROBIOL, V4, P469, DOI 10.1038/nrmicro1419; SMITH GL, 1983, NATURE, V302, P490, DOI 10.1038/302490a0; SMITH GL, 1983, P NATL ACAD SCI-BIOL, V80, P7155, DOI 10.1073/pnas.80.23.7155; Smith VP, 2000, J GEN VIROL, V81, P1223, DOI 10.1099/0022-1317-81-5-1223; Stack J, 2005, J EXP MED, V201, P1007, DOI 10.1084/jem.20041442; Staib C, 2000, BIOTECHNIQUES, V28, P1137, DOI 10.2144/00286st04; Staib C, 2005, J GEN VIROL, V86, P1997, DOI 10.1099/vir.0.80646-0; Staib C, 2003, BIOTECHNIQUES, V34, P694, DOI 10.2144/03344bm02; SUTTER G, 1994, VACCINE, V12, P1032, DOI 10.1016/0264-410X(94)90341-7; Symons JA, 2002, J GEN VIROL, V83, P1953, DOI 10.1099/0022-1317-83-8-1953; Tscharke DC, 2006, J VIROL, V80, P6318, DOI 10.1128/JVI.00427-06; Tscharke DC, 2005, J EXP MED, V201, P95, DOI 10.1084/jem.20041912; Tscharke DC, 2002, J GEN VIROL, V83, P1977, DOI 10.1099/0022-1317-83-8-1977; Warming S, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni035; Webb LMC, 2005, MINI-REV MED CHEM, V5, P833, DOI 10.2174/1389557054867110; Wyatt LS, 1998, VIROLOGY, V251, P334, DOI 10.1006/viro.1998.9397; Zimmerli SC, 2005, P NATL ACAD SCI USA, V102, P7239, DOI 10.1073/pnas.0502393102	74	74	84	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1638	10.1371/journal.pone.0001638	http://dx.doi.org/10.1371/journal.pone.0001638			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286194	Green Published, gold, Green Submitted			2022-12-25	WOS:000260586400031
J	Gerstner, JR; Bremer, QZ; Vander Heyden, WM; LaVaute, TM; Yin, JC; Landry, CF				Gerstner, Jason R.; Bremer, Quentin Z.; Vander Heyden, William M.; LaVaute, Timothy M.; Yin, Jerry C.; Landry, Charles F.			Brain Fatty Acid Binding Protein (Fabp7) Is Diurnally Regulated in Astrocytes and Hippocampal Granule Cell Precursors in Adult Rodent Brain	PLOS ONE			English	Article							PROLIFERATOR-ACTIVATED RECEPTORS; GENE-EXPRESSION; MESSENGER-RNA; COCAINE SENSITIZATION; NEURONAL-ACTIVITY; LIPID-METABOLISM; CIRCADIAN GENES; AMIDE HYDROLASE; CLOCK GENE; SLEEP	Brain fatty acid binding protein (Fabp7), which is important in early nervous system development, is expressed in astrocytes and neuronal cell precursors in mature brain. We report here that levels of Fabp7 mRNA in adult murine brain change over a 24 hour period. Unlike Fabp5, a fatty acid binding protein that is expressed widely in various cell types within brain, RNA analysis revealed that Fabp7 mRNA levels were elevated during the light period and lower during dark in brain regions involved in sleep and activity mechanisms. This pattern of Fabp7 mRNA expression was confirmed using in situ hybridization and found to occur throughout the entire brain. Changes in the intracellular distribution of Fabp7 mRNA were also evident over a 24 hour period. Diurnal changes in Fabp7, however, were not found in postnatal day 6 brain, when astrocytes are not yet mature. In contrast, granule cell precursors of the subgranular zone of adult hippocampus did undergo diurnal changes in Fabp7 expression. These changes paralleled oscillations in Fabp7 mRNA throughout the brain suggesting that cell-coordinated signals likely control brain-wide Fabp7 mRNA expression. Immunoblots revealed that Fabp7 protein levels also underwent diurnal changes in abundance, with peak levels occurring in the dark period. Of clock or clock-regulated genes, the synchronized, global cycling pattern of Fabp7 expression is unique and implicates glial cells in the response or modulation of activity and/or circadian rhythms.	[Gerstner, Jason R.] Univ Wisconsin, Neurosci Training Program, Madison, WI 53706 USA; [Gerstner, Jason R.; Yin, Jerry C.] Univ Wisconsin, Dept Genet, Madison, WI USA; [Gerstner, Jason R.; Bremer, Quentin Z.; Vander Heyden, William M.; LaVaute, Timothy M.; Landry, Charles F.] Univ Wisconsin, Dept Psychiat, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Gerstner, JR (corresponding author), Univ Wisconsin, Neurosci Training Program, Madison, WI 53706 USA.	clandry@wisc.edu	Gerstner, Jason/J-3778-2013	Gerstner, Jason/0000-0003-3113-6974	National Institutes of Health [5 P50 CA084724-04, DA19153]; NATIONAL CANCER INSTITUTE [P50CA084724] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH067774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA019153] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by National Institutes of Health grant 5 P50 CA084724-04 (JRG) and DA19153 (CFL).	Abarca C, 2002, P NATL ACAD SCI USA, V99, P9026, DOI 10.1073/pnas.142039099; Adida A, 2006, BBA-MOL CELL BIOL L, V1761, P172, DOI 10.1016/j.bbalip.2006.02.006; Andretic R, 1999, SCIENCE, V285, P1066, DOI 10.1126/science.285.5430.1066; Anthony TE, 2004, NEURON, V41, P881, DOI 10.1016/S0896-6273(04)00140-0; Anthony TE, 2005, GENE DEV, V19, P1028, DOI 10.1101/gad.1302105; Arai Y, 2005, J NEUROSCI, V25, P9752, DOI 10.1523/JNEUROSCI.2512-05.2005; ASTONJONES G, 1981, J NEUROSCI, V1, P876; BENNETT E, 1994, J NEUROCHEM, V63, P1616; Bernlohr DA, 1997, ANNU REV NUTR, V17, P277, DOI 10.1146/annurev.nutr.17.1.277; Bisogno T, 2002, CURR PHARM DESIGN, V8, P533, DOI 10.2174/1381612023395655; Bowser DN, 2007, J GEN PHYSIOL, V129, P485, DOI 10.1085/jgp.200709780; Brown RE, 2001, PROG NEUROBIOL, V63, P637, DOI 10.1016/S0301-0082(00)00039-3; Canaple L, 2006, MOL ENDOCRINOL, V20, P1715, DOI 10.1210/me.2006-0052; Chen C, 2005, PROSTAG OTH LIPID M, V77, P65, DOI 10.1016/j.prostaglandins.2005.07.001; Chen C, 2002, J NEUROPHYSIOL, V87, P2851, DOI 10.1152/jn.2002.87.6.2851; Chmurzynska A, 2006, J APPL GENET, V47, P39, DOI 10.1007/BF03194597; de Mendonca A, 2002, BRAIN RES, V932, P56, DOI 10.1016/S0006-8993(02)02281-3; Dudley CA, 2003, SCIENCE, V301, P379, DOI 10.1126/science.1082795; Feillet CA, 2006, CURR BIOL, V16, P2016, DOI 10.1016/j.cub.2006.08.053; FENG L, 1994, NEURON, V12, P895, DOI 10.1016/0896-6273(94)90341-7; Field MD, 2000, NEURON, V25, P437, DOI 10.1016/S0896-6273(00)80906-X; Fontaine C, 2003, J BIOL CHEM, V278, P37672, DOI 10.1074/jbc.M304664200; Garcia JA, 2000, SCIENCE, V288, P2226, DOI 10.1126/science.288.5474.2226; Gerstner JR, 2006, NEUROSCIENCE, V139, P1435, DOI 10.1016/j.neuroscience.2006.01.020; Gerstner JR, 2007, DEV NEUROSCI-BASEL, V29, P203, DOI 10.1159/000096389; Gerstner JR, 2007, NEUROCHEM RES, V32, P241, DOI 10.1007/s11064-006-9271-z; Giudicelli F, 2004, CURR OPIN GENET DEV, V14, P407, DOI 10.1016/j.gde.2004.06.014; GLATZ JFC, 1984, J BIOL CHEM, V259, P4295; Guthrie PB, 1999, J NEUROSCI, V19, P520, DOI 10.1523/jneurosci.19-02-00520.1999; Huang ZL, 2007, CURR OPIN PHARMACOL, V7, P33, DOI 10.1016/j.coph.2006.09.004; Huitron-Resendiz S, 2004, SLEEP, V27, P857, DOI 10.1093/sleep/27.5.857; HUYNH HT, 1995, CANCER RES, V55, P2225; Inoue I, 2005, J ATHEROSCLER THROMB, V12, P169, DOI 10.5551/jat.12.169; Josephson R, 1998, DEVELOPMENT, V125, P3087; Kempermann G, 2004, TRENDS NEUROSCI, V27, P447, DOI 10.1016/j.tins.2004.05.013; KHAN SH, 1994, P NATL ACAD SCI USA, V91, P848, DOI 10.1073/pnas.91.3.848; Kohsaka A, 2007, TRENDS ENDOCRIN MET, V18, P4, DOI 10.1016/j.tem.2006.11.005; KURTZ A, 1994, DEVELOPMENT, V120, P2637; Liang Y, 2005, P NATL ACAD SCI USA, V102, P5814, DOI 10.1073/pnas.0402870102; LIN JS, 1988, NEUROPHARMACOLOGY, V27, P111, DOI 10.1016/0028-3908(88)90159-1; Liu Y, 2000, BRAIN RES, V852, P16, DOI 10.1016/S0006-8993(99)02158-7; Liu Y, 1997, J NEUROSCI RES, V48, P551, DOI 10.1002/(SICI)1097-4547(19970615)48:6<551::AID-JNR8>3.0.CO;2-9; Marshall CAG, 2003, GLIA, V43, P52, DOI 10.1002/glia.10213; McClung CA, 2005, P NATL ACAD SCI USA, V102, P9377, DOI 10.1073/pnas.0503584102; Murillo-Rodriguez E, 2007, EUR J PHARMACOL, V562, P82, DOI 10.1016/j.ejphar.2007.01.076; Oishi K, 2005, BIOCHEM J, V386, P575, DOI 10.1042/BJ20041150; Owada Y, 2006, EUR J NEUROSCI, V24, P175, DOI 10.1111/j.1460-9568.2006.04855.x; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; PANULA P, 1984, P NATL ACAD SCI-BIOL, V81, P2572, DOI 10.1073/pnas.81.8.2572; Pascual O, 2005, SCIENCE, V310, P113, DOI 10.1126/science.1116916; Plumpe T, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-77; Prinsen CFM, 1998, BIOCHEM J, V329, P265; Prolo LM, 2005, J NEUROSCI, V25, P404, DOI 10.1523/JNEUROSCI.4133-04.2005; Qi KM, 2002, CURR OPIN CLIN NUTR, V5, P133, DOI 10.1097/00075197-200203000-00003; Sakai T, 2004, P NATL ACAD SCI USA, V101, P16058, DOI 10.1073/pnas.0401472101; Sarov-Blat L, 2000, CELL, V101, P647, DOI 10.1016/S0092-8674(00)80876-4; Schiltz CA, 2007, BMC BIOL, V5, DOI 10.1186/1741-7007-5-16; Shieh KR, 2005, J BIOMED SCI, V12, P209, DOI 10.1007/s11373-004-8176-6; So WV, 1997, EMBO J, V16, P7146, DOI 10.1093/emboj/16.23.7146; Steiner B, 2006, GLIA, V54, P805, DOI 10.1002/glia.20407; Straub SV, 2007, TRENDS CARDIOVAS MED, V17, P183, DOI 10.1016/j.tcm.2007.05.001; Suri V, 2000, J NEUROSCI, V20, P7547; Tan NS, 2002, MOL CELL BIOL, V22, P5114, DOI 10.1128/MCB.22.14.5114-5127.2002; Tang MK, 2004, CELL TISSUE RES, V316, P339, DOI 10.1007/s00441-004-0881-y; Turek FW, 2005, SCIENCE, V308, P1043, DOI 10.1126/science.1108750; Ueda HR, 2002, NATURE, V418, P534, DOI 10.1038/nature00906; Valenti M, 2004, CELL MOL LIFE SCI, V61, P945, DOI 10.1007/s00018-003-3453-5; Veerkamp JH, 2001, J MOL NEUROSCI, V16, P133, DOI 10.1385/JMN:16:2-3:133; Wenger T, 2002, PROSTAG LEUKOTR ESS, V66, P301, DOI 10.1054/plef.2001.0353; Winship IR, 2007, J NEUROSCI, V27, P6268, DOI 10.1523/JNEUROSCI.4801-06.2007; Wolfrum C, 2001, P NATL ACAD SCI USA, V98, P2323, DOI 10.1073/pnas.051619898; Yan LL, 2000, J NEUROSCI RES, V59, P291, DOI 10.1002/(SICI)1097-4547(20000115)59:2<291::AID-JNR16>3.0.CO;2-O	72	33	34	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1631	10.1371/journal.pone.0001631	http://dx.doi.org/10.1371/journal.pone.0001631			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286188	Green Published, gold, Green Submitted			2022-12-25	WOS:000260586400024
J	Landi, MT; Dracheva, T; Rotunno, M; Figueroa, JD; Liu, H; Dasgupta, A; Mann, FE; Fukuoka, J; Hames, M; Bergen, AW; Murphy, SE; Yang, P; Pesatori, AC; Consonni, D; Bertazzi, PA; Wacholder, S; Shih, JH; Caporaso, NE; Jen, J				Landi, Maria Teresa; Dracheva, Tatiana; Rotunno, Melissa; Figueroa, Jonine D.; Liu, Huaitian; Dasgupta, Abhijit; Mann, Felecia E.; Fukuoka, Junya; Hames, Megan; Bergen, Andrew W.; Murphy, Sharon E.; Yang, Ping; Pesatori, Angela C.; Consonni, Dario; Bertazzi, Pier Alberto; Wacholder, Sholom; Shih, Joanna H.; Caporaso, Neil E.; Jen, Jin			Gene Expression Signature of Cigarette Smoking and Its Role in Lung Adenocarcinoma Development and Survival	PLOS ONE			English	Article								Background: Tobacco smoking is responsible for over 90% of lung cancer cases, and yet the precise molecular alterations induced by smoking in lung that develop into cancer and impact survival have remained obscure. Methodology/Principal Findings: We performed gene expression analysis using HG-U133A Affymetrix chips on 135 fresh frozen tissue samples of adenocarcinoma and paired noninvolved lung tissue from current, former and never smokers, with biochemically validated smoking information. ANOVA analysis adjusted for potential confounders, multiple testing procedure, Gene Set Enrichment Analysis, and GO-functional classification were conducted for gene selection. Results were confirmed in independent adenocarcinoma and non-tumor tissues from two studies. We identified a gene expression signature characteristic of smoking that includes cell cycle genes, particularly those involved in the mitotic spindle formation (e. g., NEK2, TTK, PRC1). Expression of these genes strongly differentiated both smokers from non-smokers in lung tumors and early stage tumor tissue from non-tumor tissue (p<0.001 and fold-change >1.5, for each comparison), consistent with an important role for this pathway in lung carcinogenesis induced by smoking. These changes persisted many years after smoking cessation. NEK2 (p<0.001) and TTK (p = 0.002) expression in the noninvolved lung tissue was also associated with a 3-fold increased risk of mortality from lung adenocarcinoma in smokers. Conclusions/Significance: Our work provides insight into the smoking-related mechanisms of lung neoplasia, and shows that the very mitotic genes known to be involved in cancer development are induced by smoking and affect survival. These genes are candidate targets for chemoprevention and treatment of lung cancer in smokers.	[Landi, Maria Teresa; Rotunno, Melissa; Figueroa, Jonine D.; Dasgupta, Abhijit; Bergen, Andrew W.; Wacholder, Sholom; Caporaso, Neil E.] NCI, Div Canc Epidemiol & Genet, NIH, DHHS, Bethesda, MD 20892 USA; [Dracheva, Tatiana; Mann, Felecia E.; Fukuoka, Junya; Hames, Megan; Jen, Jin] NCI, Ctr Canc Res, NIH, DHHS, Bethesda, MD USA; [Figueroa, Jonine D.] NIH, NCI, Canc Prevent Fellowship, DHHS, Bethesda, MD USA; [Liu, Huaitian; Shih, Joanna H.] NCI, Div Canc Treatment & Diagnosis, NIH, DHHS, Bethesda, MD USA; [Murphy, Sharon E.] Univ Minnesota, Canc Ctr, Minneapolis, MN USA; [Yang, Ping] Mayo Clin, Dept Hlth Sci, Rochester, MN USA; [Pesatori, Angela C.; Consonni, Dario; Bertazzi, Pier Alberto] Univ Milan, Fdn OM Policlin, Milan, Italy	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Minnesota System; University of Minnesota Twin Cities; Mayo Clinic; University of Milan	Landi, MT (corresponding author), NCI, Div Canc Epidemiol & Genet, NIH, DHHS, Bethesda, MD 20892 USA.	landim@mail.nih.gov	Fukuoka, Junya/AAT-2924-2021; Dasgupta, Abhijit/W-7750-2019; Figueroa, Jonine/GWD-1322-2022; Consonni, Dario/AAM-2947-2020; Figueroa, Jonine/AAG-1065-2022; bertazzi, pietro alberto/D-5039-2017; Figueroa, Jonine/AFK-2752-2022; Dasgupta, Abhijit/J-6400-2014; pesatori, angela/K-5742-2016	Dasgupta, Abhijit/0000-0001-6062-9896; Figueroa, Jonine/0000-0002-5100-623X; Consonni, Dario/0000-0002-8935-3843; Figueroa, Jonine/0000-0002-5100-623X; bertazzi, pietro alberto/0000-0003-3475-2449; Figueroa, Jonine/0000-0002-5100-623X; Dasgupta, Abhijit/0000-0002-1388-4779; Fukuoka, Junya/0000-0002-2496-3050; Bergen, Andrew/0000-0002-1237-7644; pesatori, angela/0000-0002-0261-3252	Intramural Research Program, NIH; National Cancer Institute, Division of Cancer Epidemiology and Genetics [NIH-R01-84354, Cancer Prevention Fellowship]; Center for Cancer Research; NATIONAL CANCER INSTITUTE [Z01CP010163] Funding Source: NIH RePORTER	Intramural Research Program, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute, Division of Cancer Epidemiology and Genetics(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the Intramural Research Program of NIH, National Cancer Institute, Division of Cancer Epidemiology and Genetics and the Center for Cancer Research, and from the NIH-R01-84354 grant to P.Y. J.F. was supported by the Cancer Prevention Fellowship Program, National Cancer Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Baonza A, 2002, NAT CELL BIOL, V4, P976, DOI 10.1038/ncb887; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Borczuk Alain C, 2007, Proc Am Thorac Soc, V4, P127, DOI 10.1513/pats.200607-143JG; Bryant A, 2007, CHEST, V132, P185, DOI 10.1378/chest.07-0442; COX DR, 1972, J R STAT SOC B, V34, P187; Goga A, 2007, NAT MED, V13, P820, DOI 10.1038/nm1606; Gruss OJ, 2004, J CELL BIOL, V166, P949, DOI 10.1083/jcb.200312112; Harvey BG, 2007, J MOL MED, V85, P39, DOI 10.1007/s00109-006-0103-z; Hecht SS, 1999, CANCER RES, V59, P590; Heguy A, 2006, J MOL MED, V84, P318, DOI 10.1007/s00109-005-0008-2; Hochreiter S, 2006, BIOINFORMATICS, V22, P943, DOI 10.1093/bioinformatics/btl033; Keen N, 2004, NAT REV CANCER, V4, P927, DOI 10.1038/nrc1502; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Lampe JW, 2004, CANCER EPIDEM BIOMAR, V13, P445; Lerman MI, 2000, CANCER RES, V60, P6116; Lou Y, 2004, J BIOL CHEM, V279, P20049, DOI 10.1074/jbc.M314205200; Miura K, 2002, CANCER RES, V62, P3244; Perez de Castro I, 2007, CARCINOGENESIS, V28, P899, DOI 10.1093/carcin/bgm019; Petersen S, 2000, BRIT J CANCER, V82, P65; Powell CA, 2003, AM J RESP CELL MOL, V29, P157, DOI 10.1165/rcmb.2002-0183RC; Santamaria A, 2007, MOL BIOL CELL, V18, P4024, DOI 10.1091/mbc.E07-05-0517; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Spira A, 2004, P NATL ACAD SCI USA, V101, P10143, DOI 10.1073/pnas.0401422101; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tonon G, 2005, P NATL ACAD SCI USA, V102, P9625, DOI 10.1073/pnas.0504126102; Wistuba II, 2000, CANCER RES, V60, P1949; Woenckhaus M, 2006, J PATHOL, V210, P192, DOI 10.1002/path.2039; Woodruff PG, 2005, AM J RESP CRIT CARE, V172, P1383, DOI 10.1164/rccm.200505-686OC; Zeeberg BR, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r28	30	487	505	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1651	10.1371/journal.pone.0001651	http://dx.doi.org/10.1371/journal.pone.0001651			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18297132	Green Published, Green Submitted, gold			2022-12-25	WOS:000260586400044
J	Spor, A; Wang, S; Dillmann, C; de Vienne, D; Sicard, D				Spor, Ayme; Wang, Shaoxiao; Dillmann, Christine; de Vienne, Dominique; Sicard, Delphine			"Ant'' and "Grasshopper'' Life-History Strategies in Saccharomyces cerevisiae	PLOS ONE			English	Article							TRADE-OFF; CELL-SIZE; EXPERIMENTAL POPULATIONS; PHENOTYPIC PLASTICITY; NATURAL-SELECTION; K-SELECTION; R-SELECTION; GROWTH-RATE; GLUCOSE; ACCUMULATION	From the evolutionary and ecological points of view, it is essential to distinguish between the genetic and environmental components of the variability of life-history traits and of their trade-offs. Among the factors affecting this variability, the resource uptake rate deserves particular attention, because it depends on both the environment and the genetic background of the individuals. In order to unravel the bases of the life-history strategies in yeast, we grew a collection of twelve strains of Saccharomyces cerevisiae from different industrial and geographical origins in three culture media differing for their glucose content. Using a population dynamics model to fit the change of population size over time, we estimated the intrinsic growth rate (r), the carrying capacity (K), the mean cell size and the glucose consumption rate per cell. The life-history traits, as well as the glucose consumption rate, displayed large genetic and plastic variability and genetic-by-environment interactions. Within each medium, growth rate and carrying capacity were not correlated, but a marked trade-off between these traits was observed over the media, with high K and low r in the glucose rich medium and low K and high r in the other media. The cell size was tightly negatively correlated to carrying capacity in all conditions. The resource consumption rate appeared to be a clear-cut determinant of both the carrying capacity and the cell size in all media, since it accounted for 37% to 84% of the variation of those traits. In a given medium, the strains that consume glucose at high rate have large cell size and low carrying capacity, while the strains that consume glucose at low rate have small cell size but high carrying capacity. These two contrasted behaviors may be metaphorically defined as "ant'' and "grasshopper'' strategies of resource utilization. Interestingly, a strain may be "ant'' in one medium and "grasshopper'' in another. These life-history strategies are discussed with regards to yeast physiology, and in an evolutionary perspective.	[Spor, Ayme; Wang, Shaoxiao; Dillmann, Christine; de Vienne, Dominique; Sicard, Delphine] Univ Paris 11, INRA, CNRS, UMR Genet Vegetale,AgroParisTech, Gif Sur Yvette, France; [Wang, Shaoxiao] Louisiana State Univ, Hlth Sci Ctr, Shreveport, LA USA	AgroParisTech; Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite Paris Saclay; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Spor, A (corresponding author), Univ Paris 11, INRA, CNRS, UMR Genet Vegetale,AgroParisTech, Gif Sur Yvette, France.	spor@moulon.inra.fr	wang, shaoxiao/N-7126-2013; Spor, Aymé/A-6271-2012	wang, shaoxiao/0000-0002-0195-6210; Spor, Aymé/0000-0002-4707-9559; Dillmann, Christine/0000-0002-9025-341X	French Agence Nationale de la Recherche [NT05-4_45721]; Ministere de lEnseignement Superieur et de la Recherche [PhD fellowship]	French Agence Nationale de la Recherche(French National Research Agency (ANR)); Ministere de lEnseignement Superieur et de la Recherche(Estonian Research CouncilEuropean Commission)	This work was supported by the French Agence Nationale de la Recherche (ANR Project ADAPTALEVURE n NT05-4_45721) and a PhD fellowship of the Ministere de lEnseignement Superieur et de la Recherche to AS.	Azumi M, 2001, YEAST, V18, P1145, DOI 10.1002/yea.767; Ben-Ari G, 2005, HEREDITY, V95, P493, DOI 10.1038/sj.hdy.6800759; Blionis GJ, 2005, PLANT ECOL, V178, P77, DOI 10.1007/s11258-004-2495-6; Borderia AV, 2002, INFECT GENET EVOL, V2, P137, DOI 10.1016/S1567-1348(02)00094-1; Brown CJ, 1998, MOL BIOL EVOL, V15, P931, DOI 10.1093/oxfordjournals.molbev.a026009; CVRCKOVA F, 1993, EMBO J, V12, P5277, DOI 10.1002/j.1460-2075.1993.tb06223.x; DAMORE T, 1988, APPL ENVIRON MICROB, V54, P110, DOI 10.1128/AEM.54.1.110-114.1988; de Jong G, 2005, NEW PHYTOL, V166, P101, DOI 10.1111/j.1469-8137.2005.01322.x; De Paepe M, 2006, PLOS BIOL, V4, P1248, DOI 10.1371/journal.pbio.0040193; del Monte-Luna P, 2004, GLOBAL ECOL BIOGEOGR, V13, P485, DOI 10.1111/j.1466-822X.2004.00131.x; Dihazi H, 2004, J BIOL CHEM, V279, P23961, DOI 10.1074/jbc.M312974200; Dihazi H, 2003, BIOCHEMISTRY-US, V42, P6275, DOI 10.1021/bi034167r; DYKHUIZEN DE, 1987, GENETICS, V115, P25; Fay JC, 2005, PLOS GENET, V1, P66, DOI 10.1371/journal.pgen.0010005; Fisher R.A., 1930, GENETICAL THEORY NAT; Flick K, 1998, MOL CELL BIOL, V18, P2492, DOI 10.1128/MCB.18.5.2492; Ghalambor CK, 2007, FUNCT ECOL, V21, P394, DOI 10.1111/j.1365-2435.2007.01283.x; Goncalves P, 1998, TRENDS MICROBIOL, V6, P314, DOI 10.1016/S0966-842X(98)01305-5; James J., 1974, AUST J BIOL SCI, V27, P99; Koots KR, 1996, GENETICS, V143, P1409; Landry CR, 2006, MOL ECOL, V15, P575, DOI 10.1111/j.1365-294X.2006.02778.x; Legras JL, 2007, MOL ECOL, V16, P2091, DOI 10.1111/j.1365-294X.2007.03266.x; LUCKINBILL LS, 1984, ECOLOGY, V65, P1170, DOI 10.2307/1938325; LUCKINBILL LS, 1978, ECOLOGY, V59, P1271, DOI 10.2307/1938241; MAC ARTHUR ROBERT H., 1967; MacLean RC, 2008, HEREDITY, V100, P233, DOI 10.1038/sj.hdy.6801073; Merico A, 2007, FEBS J, V274, P976, DOI 10.1111/j.1742-4658.2007.05645.x; Mueller LD, 1997, ANNU REV ECOL SYST, V28, P269, DOI 10.1146/annurev.ecolsys.28.1.269; MUELLER LD, 1991, SCIENCE, V253, P433, DOI 10.1126/science.1907401; MUELLER LD, 1981, P NATL ACAD SCI-BIOL, V78, P1303, DOI 10.1073/pnas.78.2.1303; MUELLER LD, 1981, GENETICS, V97, P667; Myers DK, 1997, APPL ENVIRON MICROB, V63, P145, DOI 10.1128/AEM.63.1.145-150.1997; Newcomb LL, 2003, EUKARYOT CELL, V2, P143, DOI 10.1128/EC.2.1.143-149.2003; Novak M, 2006, AM NAT, V168, P242, DOI 10.1086/506527; Nystrom T, 2004, MOL MICROBIOL, V54, P855, DOI 10.1111/j.1365-2958.2004.04342.x; PIANKA ER, 1970, AM NAT, V104, P592, DOI 10.1086/282697; Portner HO, 2008, SCIENCE, V322, P690, DOI 10.1126/science.1163156; POSTMA E, 1989, APPL ENVIRON MICROB, V55, P468, DOI 10.1128/AEM.55.2.468-477.1989; Roff Derek, 2002, pi; Rupes I, 2002, TRENDS GENET, V18, P479, DOI 10.1016/S0168-9525(02)02745-2; Saccheri I, 2006, TRENDS ECOL EVOL, V21, P341, DOI 10.1016/j.tree.2006.03.018; Schneider BL, 2004, MOL CELL BIOL, V24, P10802, DOI 10.1128/MCB.24.24.10802-10813.2004; Sgro CM, 2004, HEREDITY, V93, P241, DOI 10.1038/sj.hdy.6800532; SOLBRIG OT, 1974, J ECOL, V62, P473, DOI 10.2307/2258993; Stearns S.C., 1992, pi; STUCKI JW, 1980, EUR J BIOCHEM, V109, P257, DOI 10.1111/j.1432-1033.1980.tb04791.x; Waddell TG, 1999, BIOCHEM EDUC, V27, P12, DOI 10.1016/S0307-4412(98)00266-0; Waddington CH, 1942, NATURE, V150, P563, DOI 10.1038/150563a0; WADDINGTON CH, 1952, NATURE, V169, P278, DOI 10.1038/169278a0; Wegmann D, 2006, GENETICS, V174, P2009, DOI 10.1534/genetics.106.062851; White EP, 2007, TRENDS ECOL EVOL, V22, P323, DOI 10.1016/j.tree.2007.03.007; Zeyl C, 2006, FEMS YEAST RES, V6, P685, DOI 10.1111/j.1567-1364.2006.00061.x	53	29	29	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1579	10.1371/journal.pone.0001579	http://dx.doi.org/10.1371/journal.pone.0001579			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270570	Green Submitted, gold, Green Published			2022-12-25	WOS:000260535900015
J	Schwachtje, J; Kutschbach, S; Baldwin, IT				Schwachtje, Jens; Kutschbach, Susan; Baldwin, Ian T.			Reverse Genetics in Ecological Research	PLOS ONE			English	Article							MANDUCA-SEXTA LEPIDOPTERA; HOST NICOTIANA-ATTENUATA; AGROBACTERIUM-MEDIATED TRANSFORMATION; LARGE-SCALE CHANGES; MOLECULAR-INTERACTIONS; MICROARRAY ANALYSIS; TRANSCRIPTIONAL RESPONSES; PLANT TRANSFORMATION; SOMACLONAL VARIATION; FITNESS COSTS	By precisely manipulating the expression of individual genetic elements thought to be important for ecological performance, reverse genetics has the potential to revolutionize plant ecology. However, untested concerns about possible side-effects of the transformation technique, caused by Agrobacterium infection and tissue culture, on plant performance have stymied research by requiring onerous sample sizes. We compare 5 independently transformed Nicotiana attenuata lines harboring empty vector control (EVC) T-DNA lacking silencing information with isogenic wild types (WT), and measured a battery of ecologically relevant traits, known to be important in plant-herbivore interactions: phytohormones, secondary metabolites, growth and fitness parameters under stringent competitive conditions, and transcriptional regulation with microarrays. As a positive control, we included a line silenced in trypsin proteinase inhibitor gene (TPI) expression, a potent anti-herbivore defense known to exact fitness costs in its expression, in the analysis. The experiment was conducted twice, with 10 and 20 biological replicates per genotype. For all parameters, we detected no difference between any EVC and WT lines, but could readily detect a fitness benefit of silencing TPI production. A statistical power analyses revealed that the minimum sample sizes required for detecting significant fitness differences between EVC and WT was 2-3 orders of magnitude larger than the 10 replicates required to detect a fitness effect of TPI silencing. We conclude that possible side-effects of transformation are far too low to obfuscate the study of ecologically relevant phenotypes.	[Schwachtje, Jens; Kutschbach, Susan; Baldwin, Ian T.] Max Planck Inst Chem Ecol, Dept Mol Ecol, Jena, Germany	Max Planck Society	Baldwin, IT (corresponding author), Max Planck Inst Chem Ecol, Dept Mol Ecol, Jena, Germany.	baldwin@ice.mpg.de	Baldwin, Ian T/K-1809-2013	Baldwin, Ian/0000-0001-5371-2974	Max-Planck-Society	Max-Planck-Society(Max Planck SocietyFoundation CELLEX)	This work was supported by the Max-Planck-Society.	BALDWIN IT, 1994, J CHEM ECOL, V20, P2139, DOI 10.1007/BF02066250; Bhat SR, 2002, PLANT SCI, V163, P673, DOI 10.1016/S0168-9452(02)00152-8; Bubner B, 2006, PLANT CELL REP, V25, P668, DOI 10.1007/s00299-005-0111-4; Butaye KMJ, 2005, MOL BREEDING, V16, P79, DOI 10.1007/s11032-005-4929-9; Cellini F, 2004, FOOD CHEM TOXICOL, V42, P1089, DOI 10.1016/j.fct.2004.02.003; Filipecki M, 2006, J APPL GENET, V47, P277, DOI 10.1007/BF03194637; Gelvin SB, 2003, MICROBIOL MOL BIOL R, V67, P16, DOI 10.1128/MMBR.67.1.16-37.2003; Halitschke R, 2004, PLANT J, V40, P35, DOI 10.1111/j.1365-313X.2004.02185.x; Halitschke R, 2003, PLANT PHYSIOL, V131, P1894, DOI 10.1104/pp.102.018184; Heidel AJ, 2004, PLANT CELL ENVIRON, V27, P1362, DOI 10.1111/j.1365-3040.2004.01228.x; Hermsmeier D, 2001, PLANT PHYSIOL, V125, P683, DOI 10.1104/pp.125.2.683; Hui DQ, 2003, PLANT PHYSIOL, V131, P1877, DOI 10.1104/pp.102.018176; Kaeppler SM, 2000, PLANT MOL BIOL, V43, P179, DOI 10.1023/A:1006423110134; Kang JH, 2006, PLANT CELL, V18, P3303, DOI 10.1105/tpc.106.041103; Keinanen M, 2001, J AGR FOOD CHEM, V49, P3553, DOI 10.1021/jf010200+; Kirik A, 2000, EMBO J, V19, P5562, DOI 10.1093/emboj/19.20.5562; Krugel T, 2002, CHEMOECOLOGY, V12, P177, DOI 10.1007/PL00012666; LARKIN PJ, 1981, THEOR APPL GENET, V60, P197, DOI 10.1007/BF02342540; Latham JR, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/25376; Miki D, 2005, PLANT PHYSIOL, V138, P1903, DOI 10.1104/pp.105.063933; Pandey SP, 2007, PLANT J, V50, P40, DOI 10.1111/j.1365-313X.2007.03030.x; Preston CA, 1999, ECOLOGY, V80, P481, DOI 10.1890/0012-9658(1999)080[0481:PANSRG]2.0.CO;2; Purrington CB, 1997, GENETICS, V145, P807; RAMULU KS, 1985, PLANT SCI, V41, P69, DOI 10.1016/0168-9452(85)90067-6; Roda AL, 2003, BASIC APPL ECOL, V4, P15, DOI 10.1078/1439-1791-00130; Rogan GJ, 2000, J AGR FOOD CHEM, V48, P5936, DOI 10.1021/jf000742b; Ruebelt MC, 2006, J AGR FOOD CHEM, V54, P2169, DOI 10.1021/jf052358q; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; SANDOVAL J, 1995, PLANT GROWTH REGUL, V17, P219, DOI 10.1007/BF00024729; Schittko U, 2001, PLANT PHYSIOL, V125, P701, DOI 10.1104/pp.125.2.701; Schmidt DD, 2005, PLANT PHYSIOL, V138, P1763, DOI 10.1104/pp.105.061192; Schwachtje J, 2006, P NATL ACAD SCI USA, V103, P12935, DOI 10.1073/pnas.0602316103; Shepherd LVT, 2006, TRANSGENIC RES, V15, P409, DOI 10.1007/s11248-006-0012-5; SIME KR, 2003, BMC ECOLOGY, V3; STEPPUHN A, 2007, COSTS BENEFITS 2 DIR; Steppuhn A, 2007, ECOL LETT, V10, P499, DOI 10.1111/j.1461-0248.2007.01045.x; Tian D, 2003, NATURE, V423, P74, DOI 10.1038/nature01588; Tzfira T, 2006, CURR OPIN BIOTECH, V17, P147, DOI 10.1016/j.copbio.2006.01.009; Van Dam NM, 2001, J CHEM ECOL, V27, P547, DOI 10.1023/A:1010341022761; Voelckel C, 2004, ECOL LETT, V7, P770, DOI 10.1111/j.1461-0248.2004.00633.x; Voelckel C, 2004, PLANT J, V38, P650, DOI 10.1111/j.1365-313X.2004.02077.x; Watson JM, 2005, FEBS LETT, V579, P5982, DOI 10.1016/j.febslet.2005.08.014; Wu JQ, 2007, PLANT CELL, V19, P1096, DOI 10.1105/tpc.106.049353; Zavala JA, 2004, P NATL ACAD SCI USA, V101, P1607, DOI 10.1073/pnas.0305096101; Zavala Jorge A., 2004, BMC Ecology, V4, P11, DOI 10.1186/1472-6785-4-11	46	26	27	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2008	3	2							e1543	10.1371/journal.pone.0001543	http://dx.doi.org/10.1371/journal.pone.0001543			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367EQ	18253491	Green Submitted, gold, Green Published			2022-12-25	WOS:000260535700015
J	De Langhe, SP; Carraro, G; Tefft, D; Li, CG; Xu, X; Chai, Y; Minoo, P; Hajihosseini, MK; Drouin, J; Kaartinen, V; Bellusci, S				De Langhe, Stijn P.; Carraro, Gianni; Tefft, Denise; Li, Changgong; Xu, Xin; Chai, Yang; Minoo, Parviz; Hajihosseini, Mohammad K.; Drouin, Jacques; Kaartinen, Vesa; Bellusci, Saverio			Formation and Differentiation of Multiple Mesenchymal Lineages during Lung Development Is Regulated by beta-catenin Signaling	PLOS ONE			English	Article								The role of beta-catenin signaling in mesodermal lineage formation and differentiation has been elusive. Methodology. To define the role of beta-catenin signaling in these processes, we used a Dermo1(Twist2)(Cre/+) line to target a floxed beta-catenin allele, throughout the embryonic mesenchyme. Strikingly, the Dermo1(Cre/+); beta-catenin(f/-) conditional Knock Out embryos largely phenocopy Pitx1(-/-)/Pitx2(-/-) double knockout embryos, suggesting that beta-catenin signaling in the mesenchyme depends mostly on the PITX family of transcription factors. We have dissected this relationship further in the developing lungs and find that mesenchymal deletion of beta-catenin differentially affects two major mesenchymal lineages. The amplification but not differentiation of Fgf10-expressing parabronchial smooth muscle progenitor cells is drastically reduced. In the angioblast-endothelial lineage, however, only differentiation into mature endothelial cells is impaired. Conclusion. Taken together these findings reveal a hierarchy of gene activity involving beta-catenin and PITX, as important regulators of mesenchymal cell proliferation and differentiation.	[De Langhe, Stijn P.; Carraro, Gianni; Tefft, Denise; Kaartinen, Vesa; Bellusci, Saverio] Childrens Hosp Los Angeles, Saban Res Inst, Dept Surg, Dev Biol Program, Los Angeles, CA 90027 USA; [Li, Changgong; Minoo, Parviz] USC, Keck Sch Med, Womens & Child Hosp, Dept Pediat, Los Angeles, CA USA; [Xu, Xin; Chai, Yang] USC, Sch Dentistry, Ctr Craniofacial Mol Biol, Los Angeles, CA USA; [Hajihosseini, Mohammad K.] UEA, Sch Biol Sci, Norwich, Norfolk, England; [Drouin, Jacques] IRCM, Lab Genet, Montreal, PQ, Canada	Children's Hospital Los Angeles; University of Southern California; University of Southern California Keck Hospital; University of Southern California; University of East Anglia; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Bellusci, S (corresponding author), Childrens Hosp Los Angeles, Saban Res Inst, Dept Surg, Dev Biol Program, Los Angeles, CA 90027 USA.	SBellusci@chla.usc.edu	Kaartinen, Vesa/AAU-5396-2021; De Langhe, Stijn/ABH-6876-2020	De Langhe, Stijn/0000-0003-3867-4572; Carraro, Gianni/0000-0003-0824-7692; Kaartinen, Vesa/0000-0002-9432-510X; Drouin, Jacques/0000-0001-8226-5691	ALA [Senior Research Training Fellowship]; CHLA [Career Development Fellowship]; AHA; NIH [RO1 HL074832, HL056590, 073471, HL074862]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056590, R01HL074832, R01HL073471, R01HL074862] Funding Source: NIH RePORTER	ALA; CHLA; AHA(American Heart Association); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	SDL acknowledges the support of ALA Senior Research Training Fellowship and CHLA Career Development Fellowship. This work was funded by AHA and an NIH RO1 HL074832 (to SB), HL056590 and 073471 (to PM) and HL074862 (VK).	Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; Bellusci S, 1997, DEVELOPMENT, V124, P4867; Bhushan A, 2001, DEVELOPMENT, V128, P5109; Briata P, 2003, MOL CELL, V12, P1201, DOI 10.1016/S1097-2765(03)00407-6; Cardoso WV, 2006, DEVELOPMENT, V133, P1611, DOI 10.1242/dev.02310; Cattelino A, 2003, J CELL BIOL, V162, P1111, DOI 10.1083/jcb.200212157; Colvin JS, 2001, DEVELOPMENT, V128, P2095; DasGupta R, 1999, DEVELOPMENT, V126, P4557; De Langhe SP, 2005, DEV BIOL, V277, P316, DOI 10.1016/j.ydbio.2004.09.023; De Langhe SP, 2006, DEV BIOL, V299, P52, DOI 10.1016/j.ydbio.2006.07.001; del Moral PM, 2006, DEV BIOL, V293, P77, DOI 10.1016/j.ydbio.2006.01.020; Driskell RR, 2004, AM J PHYSIOL-LUNG C, V287, pL752, DOI 10.1152/ajplung.00026.2004; DUMONT DJ, 1995, DEV DYNAM, V203, P80, DOI 10.1002/aja.1002030109; Gage PJ, 1999, DEVELOPMENT, V126, P4643; Harada H, 2002, DEVELOPMENT, V129, P1533; Hjalt TA, 2000, DEV DYNAM, V218, P195, DOI 10.1002/(SICI)1097-0177(200005)218:1<195::AID-DVDY17>3.0.CO;2-C; Jakkaraju S, 2005, DEV CELL, V9, P39, DOI 10.1016/j.devcel.2005.04.015; Kelly RG, 2001, DEV CELL, V1, P435, DOI 10.1016/S1534-5807(01)00040-5; Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X; Kitamura K, 1999, DEVELOPMENT, V126, P5749; Lebeche D, 1999, MECH DEVELOP, V86, P125, DOI 10.1016/S0925-4773(99)00124-0; Lebel M, 2001, J NEUROCHEM, V77, P558, DOI 10.1046/j.1471-4159.2001.00257.x; Li CG, 2005, DEV BIOL, V287, P86, DOI 10.1016/j.ydbio.2005.08.035; Lin CR, 1999, NATURE, V401, P279, DOI 10.1038/45803; Liu CY, 2001, DEVELOPMENT, V128, P2039; Lu MF, 1999, NATURE, V401, P276, DOI 10.1038/45797; Mailleux AA, 2005, DEVELOPMENT, V132, P2157, DOI 10.1242/dev.01795; Mailleux AA, 2001, MECH DEVELOP, V102, P81, DOI 10.1016/S0925-4773(01)00286-6; Marcil A, 2003, DEVELOPMENT, V130, P45, DOI 10.1242/dev.00192; Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100; Moorman AFM, 2001, J HISTOCHEM CYTOCHEM, V49, P1, DOI 10.1177/002215540104900101; Mucenski ML, 2003, J BIOL CHEM, V278, P40231, DOI 10.1074/jbc.M305892200; Norgaard GA, 2003, DEV BIOL, V264, P323, DOI 10.1016/j.ydbio.2003.08.013; Okubo T, 2005, DEVELOPMENT, V132, P1363, DOI 10.1242/dev.01678; Okubo Tadashi, 2004, J Biol, V3, P11, DOI 10.1186/jbiol3; PERSSON H, 1984, SCIENCE, V225, P687, DOI 10.1126/science.6431612; SATO TN, 1993, ADV EXP MED BIOL, V331, P183; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shu WG, 2005, DEV BIOL, V283, P226, DOI 10.1016/j.ydbio.2005.04.014; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Tebar M, 2001, MECH DEVELOP, V109, P437, DOI 10.1016/S0925-4773(01)00556-1; Tremblay JJ, 1998, MOL ENDOCRINOL, V12, P428, DOI 10.1210/me.12.3.428; Wang ZS, 2005, MOL CELL BIOL, V25, P5022, DOI 10.1128/MCB.25.12.5022-5030.2005; Weaver M, 2003, DEV BIOL, V258, P169, DOI 10.1016/S0012-1606(03)00117-9; White AC, 2006, DEVELOPMENT, V133, P1507, DOI 10.1242/dev.02313; Yang Y, 1998, DEVELOPMENT, V125, P2621; Yang Y, 2000, J CLIN INVEST, V106, P1321, DOI 10.1172/JCI8893; Yu K, 2003, DEVELOPMENT, V130, P3063, DOI 10.1242/dev.00491	48	83	84	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1516	10.1371/journal.pone.0001516	http://dx.doi.org/10.1371/journal.pone.0001516			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SR	18231602	Green Submitted, Green Published, gold			2022-12-25	WOS:000260504200028
J	Hruz, PW; Yan, QY; Struthers, H; Jay, PY				Hruz, Paul W.; Yan, Qingyun; Struthers, Heidi; Jay, Patrick Y.			HIV protease inhibitors that block GLUT4 precipitate acute, decompensated heart failure in a mouse model of dilated cardiomyopathy	FASEB JOURNAL			English	Article						insulin resistance; glucose transport; diastolic dysfunction; ritonavir; atazanavir; pulmonary edema	IMMUNODEFICIENCY-VIRUS-INFECTION; INSULIN-RESISTANCE; DIABETIC CARDIOMYOPATHY; GLUCOSE DISPOSAL; RITONAVIR; INDINAVIR; RATS; METABOLISM; MORTALITY; QUANTIFICATION	The clinical use of HIV protease inhibitors is associated with insulin resistance and other metabolic changes that increase long-term cardiovascular risk. Since the failing heart has increased reliance on glucose, the influence of drug exposure on glucose homeostasis, myocardial glucose uptake, cardiac function, and survival was determined in TG9 mice, an established transgenic model of dilated cardiomyopathy generated by cardiac-specific overexpression of Cre-recombinase, as these animals progressed to overt heart failure. Beginning on day of life 75, TG9 mice and nontransgenic littermate controls were given a daily 10 mg/kg intraperitoneal injection of HIV protease inhibitors (ritonavir, lopinavir/ritonavir 4: 1, atazanavir, atazanavir/ritonavir 4: 1) or vehicle. Glucose tolerance testing, measurement of in vivo myocardial 2-deoxyglucose uptake, and echocardiography were performed before and 30 min following drug administration. The progression of dilated cardiomyopathy in TG9 animals was accompanied by impaired glucose tolerance, which was acutely exacerbated by exposure to ritonavir. Ritonavir and lopinavir precipitated acute, decompensated heart failure and death from pulmonary edema in TG9 mice. However, atazanavir, which does not inhibit glucose transport, had no effect. These studies demonstrate that, in the presence of dilated cardiomyopathy, HIV protease inhibitors that impair glucose transport induce acute, decompensated heart failure. The potential for HIV protease inhibitors to contribute to or exacerbate cardiomyopathy in human patients warrants further investigation.	[Hruz, Paul W.; Yan, Qingyun; Struthers, Heidi; Jay, Patrick Y.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Hruz, Paul W.] Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; [Jay, Patrick Y.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Hruz, PW (corresponding author), 660 S Euclid Ave,Campus Box 8208, St Louis, MO 63110 USA.	hruz_p@kids.wustl.edu		Hruz, Paul/0000-0002-1478-3355	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K12HD001487] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064572, P30DK056341, P30DK052574] Funding Source: NIH RePORTER; NICHD NIH HHS [K12-HD001487] Funding Source: Medline; NIDDK NIH HHS [P30 DK056341-08, P30 DK056341-07, P30DK056341, DK64572, P30DK052574] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abel ED, 2004, FRONT BIOSCI-LANDMRK, V9, P201, DOI 10.2741/1216; An D, 2006, AM J PHYSIOL-HEART C, V291, pH1489, DOI 10.1152/ajpheart.00278.2006; Boudina S, 2007, CIRCULATION, V115, P3213, DOI 10.1161/CIRCULATIONAHA.106.679597; Buerger A, 2006, J CARD FAIL, V12, P392, DOI 10.1016/j.cardfail.2006.03.002; CURRIE PF, 1994, BRIT MED J, V309, P1605, DOI 10.1136/bmj.309.6969.1605; *DADSG, 2007, NEW ENGL J MED, V356, P1723; Denissen JF, 1997, DRUG METAB DISPOS, V25, P489; Foisy ML, 1999, J CHROMATOGR B, V721, P239, DOI 10.1016/S0378-4347(98)00451-4; Gandhi SK, 2001, NEW ENGL J MED, V344, P17, DOI 10.1056/NEJM200101043440103; Guery BP, 1998, J APPL PHYSIOL, V85, P842, DOI 10.1152/jappl.1998.85.3.842; Hadigan C, 2001, CLIN INFECT DIS, V32, P130, DOI 10.1086/317541; HOM FG, 1984, DIABETES, V33, P141, DOI 10.2337/diabetes.33.2.141; Hruz PW, 2002, DIABETES, V51, P937, DOI 10.2337/diabetes.51.4.937; Kim J, 2006, HYPERTENS RES, V29, P775, DOI 10.1291/hypres.29.775; Lee GA, 2004, ANTIVIR THER, V9, pL6; Lee GA, 2007, AIDS, V21, P2183, DOI 10.1097/QAD.0b013e32826fbc54; Lee GA, 2006, CLIN INFECT DIS, V43, P658, DOI 10.1086/505974; Lewis W, 2006, AIDS, V20, P675, DOI 10.1097/01.aids.0000216367.23325.58; Liao YL, 2002, AM J PHYSIOL-HEART C, V282, pH1703, DOI 10.1152/ajpheart.00238.2001; Lipshultz SE, 2000, CIRCULATION, V102, P1542, DOI 10.1161/01.CIR.102.13.1542; McMullen JR, 2007, P NATL ACAD SCI USA, V104, P612, DOI 10.1073/pnas.0606663104; Mulder P, 2006, ADV CARDIOL, V43, P97, DOI 10.1159/000095431; Murata H, 2000, J BIOL CHEM, V275, P20251, DOI 10.1074/jbc.C000228200; Murata H, 2002, AIDS, V16, P859, DOI 10.1097/00002030-200204120-00005; Nanavati Kinjal A, 2004, Am J Cardiovasc Drugs, V4, P315, DOI 10.2165/00129784-200404050-00004; Noor MA, 2002, AIDS, V16, pF1, DOI 10.1097/00002030-200203290-00002; Noor MA, 2006, AIDS, V20, P1813, DOI 10.1097/01.aids.0000244200.11006.55; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Rogers JH, 1999, J CLIN INVEST, V104, P567, DOI 10.1172/JCI6713; Silva-Cardoso J, 1998, J Card Fail, V4, P19, DOI 10.1016/S1071-9164(98)90504-8; SMITH SA, 1986, BIOCHEM J, V237, P789, DOI 10.1042/bj2370789; Tan QY, 2005, JAIDS-J ACQ IMM DEF, V40, P398, DOI 10.1097/01.qai.0000176654.97392.c7; Van Bilsen M, 2004, ANN NY ACAD SCI, V1015, P238, DOI 10.1196/annals.1302.020; Zile MR, 2004, NEW ENGL J MED, V350, P1953, DOI 10.1056/NEJMoa032566	34	24	25	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2161	2167		10.1096/fj.07-102269	http://dx.doi.org/10.1096/fj.07-102269			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18256305				2022-12-25	WOS:000257292500008
J	Huellner, MW; Schrepfer, S; Weyand, M; Weiner, H; Wimplinger, I; Eschenhagen, T; Rau, T				Huellner, Martin W.; Schrepfer, Sonja; Weyand, Michael; Weiner, Henry; Wimplinger, Isabella; Eschenhagen, Thomas; Rau, Thomas			Inhibition of aldehyde dehydrogenase type 2 attenuates vasodilatory action of nitroglycerin in human veins	FASEB JOURNAL			English	Article						nitric oxide; organic nitrates; pharmacodynamics; biotransformation; capacitance vessels	TRINITRATE-INDUCED VASODILATION; SOLUBLE GUANYLATE-CYCLASE; NITRIC-OXIDE; NITRATE TOLERANCE; GLYCERYL TRINITRATE; ORGANIC NITRATES; OXIDATIVE STRESS; SMOOTH-MUSCLE; RELAXING FACTOR; BIOTRANSFORMATION	Recent studies suggest that the mitochondrial aldehyde dehydrogenase (ALDH) 2 is involved in vascular bioactivation of nitroglycerin (GTN). However, neither expression of ALDH2 nor its functional role in GTN bioactivation has been reported for the main drug target in humans, namely capacitance vessels. We investigated whether ALDH2 is expressed in human veins and whether inhibition of the enzyme attenuates nitroglycerin effects in these vessels. We determined expression of ALDH2 and dehydrogenase activity in human veins by reverse transcriptase-polymerase chain reaction, Western blotting, and immunofluorescence microscopy. In vitro contraction experiments were performed in the presence or absence of the ALDH inhibitors chloral hydrate, cyanamide, and ethoxycyclopropanol. Concentration response curves were determined for the alpha-agonist phenylephrine, nitroglycerin, and the direct NO donor diethylamine NONOate (DEA-NONOate). ALDH2 expression was largely confined to smooth muscle cells as determined by confocal immunofluorescence microscopy. Contractile responses to phenylephrine were unaffected by all ALDH inhibitors tested. In clear contrast, the ALDH inhibitors significantly reduced the potency of nitroglycerin by approximately 1 order of magnitude (P <= 0.01). Neither of the inhibitors affected the potency of the direct NO donor DEA-NONOate, which ruled out nonspecific effects on the NO signaling cascade. In human capacitance vessels, ALDH2 is a key enzyme in the biotransformation of the frequently used antianginal drug nitroglycerin.	[Huellner, Martin W.; Eschenhagen, Thomas; Rau, Thomas] Univ Med Ctr Hamburg Eppendorf, Inst Expt & Clin Pharmacol, D-20246 Hamburg, Germany; [Wimplinger, Isabella] Univ Med Ctr Hamburg Eppendorf, Inst Human Genet, Hamburg, Germany; [Weyand, Michael] Univ Erlangen Nurnberg, Dept Cardiovasc Surg, Erlangen, Germany; [Weiner, Henry] Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Erlangen Nuremberg; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Rau, T (corresponding author), Univ Med Ctr Hamburg Eppendorf, Inst Expt & Clin Pharmacol, Martinistr 52, D-20246 Hamburg, Germany.	t.rau@uke.uni-hamburg.de						ABRAMS J, 1985, AM HEART J, V110, P216, DOI 10.1016/0002-8703(85)90490-9; Artz JD, 2002, J BIOL CHEM, V277, P18253, DOI 10.1074/jbc.C200170200; BRESLOW R, 1967, J AM CHEM SOC, V89, P3073, DOI 10.1021/ja00988a063; BRIEN JF, 1988, J PHARMACOL EXP THER, V244, P322; Chen ZQ, 2006, TRENDS CARDIOVAS MED, V16, P259, DOI 10.1016/j.tcm.2006.05.001; Chen ZQ, 2005, P NATL ACAD SCI USA, V102, P12159, DOI 10.1073/pnas.0503723102; Chen ZQ, 2002, P NATL ACAD SCI USA, V99, P8306, DOI 10.1073/pnas.122225199; Daiber A, 2005, MOL PHARMACOL, V68, P579, DOI 10.1124/mol.105.011585; Daiber A, 2004, MOL PHARMACOL, V66, P1372, DOI 10.1124/mol.104.002600; de la Lande IS, 2004, EUR J PHARMACOL, V496, P141, DOI 10.1016/j.ejphar.2004.06.010; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; KAWAMOTO JH, 1990, J CARDIOVASC PHARM, V15, P714, DOI 10.1097/00005344-199005000-00005; Kleschyov AL, 2003, CIRC RES, V93, pE104, DOI 10.1161/01.RES.0000100067.62876.50; Kollau A, 2005, BIOCHEM J, V385, P769, DOI 10.1042/BJ20041354; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li YF, 2006, J CLIN INVEST, V116, P506, DOI 10.1172/JCI26564; Mackenzie IS, 2005, ARTERIOSCL THROM VAS, V25, P1891, DOI 10.1161/01.ATV.0000179599.71086.89; MCDONALD BJ, 1993, BIOCHEM PHARMACOL, V45, P268, DOI 10.1016/0006-2952(93)90403-J; MCDONALD BJ, 1990, CAN J PHYSIOL PHARM, V68, P1552, DOI 10.1139/y90-236; McGuire JJ, 1998, BIOCHEM PHARMACOL, V56, P881, DOI 10.1016/S0006-2952(98)00216-0; Millar TM, 1998, FEBS LETT, V427, P225, DOI 10.1016/S0014-5793(98)00430-X; MUKERJEE N, 1994, J BIOL CHEM, V269, P21664; Munzel T, 2005, CIRC RES, V97, P618, DOI 10.1161/01.RES.0000184694.03262.6d; Murad F, 1978, Adv Cyclic Nucleotide Res, V9, P145; Nunez C, 2005, CIRC RES, V97, P1063, DOI 10.1161/01.RES.0000190588.84680.34; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PIETRUSZKO R, 1995, ADV EXP MED BIOL, V372, P25; SAMBROOK J, 1989, MOL CLONING, V1, P7; Schulz E, 2002, CIRCULATION, V105, P1170, DOI 10.1161/hc1002.105186; SETH P, 1993, BIOCHEM PHARMACOL, V46, P1481, DOI 10.1016/0006-2952(93)90115-D; Sydow K, 2004, J CLIN INVEST, V113, P482, DOI 10.1172/JCI200419267; THIEMANN T, 2000, J CHEM SOC P1, V17, P2968; TSUCHIDA S, 1990, J BIOL CHEM, V265, P7150; Wenzel P, 2007, BRIT J PHARMACOL, V150, P526, DOI 10.1038/sj.bjp.0707116; Wenzel P, 2007, J BIOL CHEM, V282, P792, DOI 10.1074/jbc.M606477200; YEATES RA, 1989, BIOCHEM PHARMACOL, V38, P1749, DOI 10.1016/0006-2952(89)90408-5; Zhang J, 2004, CIRCULATION, V110, P750, DOI 10.1161/01.CIR.0000138105.17864.6B; ZHENG CF, 1993, ALCOHOL CLIN EXP RES, V17, P828, DOI 10.1111/j.1530-0277.1993.tb00849.x	40	22	23	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2561	2568		10.1096/fj.07-098830	http://dx.doi.org/10.1096/fj.07-098830			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18272654				2022-12-25	WOS:000257292500047
J	Liu, G; Park, YJ; Abraham, E				Liu, Gang; Park, Young-Jun; Abraham, Edward			Interleukin-1 receptor-associated kinase (IRAK)-1-mediated NF-kappa B activation requires cytosolic and nuclear activity	FASEB JOURNAL			English	Article						transcription; histone H3; nuclear translocation; Toll-like receptor	TOLL-LIKE RECEPTORS; IL-1 RECEPTOR; ADAPTER PROTEIN; GENE-EXPRESSION; INNATE IMMUNITY; HISTONE H3; TRANSCRIPTIONAL ACTIVATION; SIGNALING PATHWAYS; IRAK FAMILY; PHOSPHORYLATION	Interleukin-1 receptor-associated kinase (IRAK) -1 plays an essential role in Toll-like receptor/interleukin-1 receptor (TLR/IL-1R) -associated NF-kappa B activation through its involvement in IKK activation, which then leads to subsequent I kappa B degradation and NF-kappa B nuclear translocation. In the present studies, we demonstrate a novel pathway in which IRAK-1 present in the nucleus participates in NF-kappa B-dependent gene expression. Nuclear localization of IRAK-1 is increased on cellular stimulation with IL-1 and LPS, or CRM-1-dependent nuclear export blockade. Induction of IRAK-1 produces enhanced NF-kappa B transcriptional activity that precedes I kappa B-alpha degradation and nuclear translocation of NF-kappa B. IRAK-1 binds to the promoter of NF-kappa B-regulated gene, I kappa B-alpha, and enhances binding of the NF-kappa B p65 subunit to NF-kappa B responsive elements within the I kappa B-alpha promoter. IRAK-1 phosphorylates histone H3 in vitro and is required for IL-1-induced phosphorylation of histone H3 at serine 10 in vivo. These data indicate that both cytosolic and nuclear actions of IRAK-1 participate in the activation of NF kappa B-dependent transcriptional events.	[Abraham, Edward] Univ Alabama, Dept Med, Sch Med, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Abraham, E (corresponding author), Univ Alabama, Dept Med, Sch Med, 420 Boshell Bldg,1808 7th Ave S, Birmingham, AL 35294 USA.	eabraham@uab.edu		, Gang/0000-0002-6999-7633; Liu, Gang/0000-0003-2615-131X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL068743, R01HL062221] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-62221, HL-068743] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Arcaroli J, 2006, AM J RESP CRIT CARE, V173, P1335, DOI 10.1164/rccm.200603-341OC; Asehnoune K, 2004, J IMMUNOL, V172, P2522, DOI 10.4049/jimmunol.172.4.2522; Bol GF, 2000, FEBS LETT, V477, P73, DOI 10.1016/S0014-5793(00)01759-2; Burns K, 2003, J EXP MED, V197, P263, DOI 10.1084/jem.20021790; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Dong ZG, 2006, MOL CARCINOGEN, V45, P416, DOI 10.1002/mc.20220; Emerson BM, 2002, CELL, V109, P267, DOI 10.1016/S0092-8674(02)00740-7; Gan L, 2006, IMMUNOL RES, V35, P295, DOI 10.1385/IR:35:3:295; Geetha T, 2005, EMBO J, V24, P3859, DOI 10.1038/sj.emboj.7600845; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; Hoffmann A, 2006, ONCOGENE, V25, P6706, DOI 10.1038/sj.onc.1209933; Honda K, 2006, NAT REV IMMUNOL, V6, P644, DOI 10.1038/nri1900; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; Huang YS, 2004, J BIOL CHEM, V279, P51697, DOI 10.1074/jbc.M410369200; Jacinto R, 2002, J IMMUNOL, V168, P6136, DOI 10.4049/jimmunol.168.12.6136; Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4; Kadam S, 2002, CURR OPIN CELL BIOL, V14, P262, DOI 10.1016/S0955-0674(02)00330-7; Kanakaraj P, 1998, J EXP MED, V187, P2073, DOI 10.1084/jem.187.12.2073; Knop J, 1999, FEBS LETT, V448, P81, DOI 10.1016/S0014-5793(99)00322-1; Knop J, 1998, EUR J IMMUNOL, V28, P3100, DOI 10.1002/(SICI)1521-4141(199810)28:10<3100::AID-IMMU3100>3.0.CO;2-7; Kollewe C, 2004, J BIOL CHEM, V279, P5227, DOI 10.1074/jbc.M309251200; Li LW, 2000, J BIOL CHEM, V275, P23340, DOI 10.1074/jbc.M001950200; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Li XX, 1999, MOL CELL BIOL, V19, P4643; Li XX, 2001, P NATL ACAD SCI USA, V98, P4461, DOI 10.1073/pnas.071054198; Maschera B, 1999, BIOCHEM J, V339, P227, DOI 10.1042/0264-6021:3390227; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Moynagh PN, 2005, TRENDS IMMUNOL, V26, P469, DOI 10.1016/j.it.2005.06.009; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Natoli G, 2005, NAT IMMUNOL, V6, P439, DOI 10.1038/ni1196; Nowak SJ, 2004, TRENDS GENET, V20, P214, DOI 10.1016/j.tig.2004.02.007; O'Neill L, 2000, BIOCHEM SOC T, V28, P557, DOI 10.1042/bst0280557; O'Neill LAJ, 2006, CURR OPIN IMMUNOL, V18, P3, DOI 10.1016/j.coi.2005.11.012; Ordureau A, 2008, BIOCHEM J, V409, P43, DOI 10.1042/BJ20071365; Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937; Prigent C, 2003, J CELL SCI, V116, P3677, DOI 10.1242/jcs.00735; Qian YC, 2001, J BIOL CHEM, V276, P41661, DOI 10.1074/jbc.M102262200; Quivy V, 2004, BIOCHEM PHARMACOL, V68, P1221, DOI 10.1016/j.bcp.2004.05.039; Sanjabi S, 2005, GENE DEV, V19, P2138, DOI 10.1101/gad.1329805; Su JM, 2007, MOL IMMUNOL, V44, P900, DOI 10.1016/j.molimm.2006.03.021; Suzuki N, 2002, TRENDS IMMUNOL, V23, P503, DOI 10.1016/S1471-4906(02)02298-6; Swantek JL, 2000, J IMMUNOL, V164, P4301, DOI 10.4049/jimmunol.164.8.4301; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Thomas JA, 1999, J IMMUNOL, V163, P978; Trinchieri G, 2007, NAT REV IMMUNOL, V7, P179, DOI 10.1038/nri2038; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Viatour P, 2003, LEUKEMIA, V17, P1349, DOI 10.1038/sj.leu.2402982; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Yamamoto M, 2004, MOL IMMUNOL, V40, P861, DOI 10.1016/j.molimm.2003.10.006; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540	59	52	54	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2285	2296		10.1096/fj.07-101816	http://dx.doi.org/10.1096/fj.07-101816			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18276832				2022-12-25	WOS:000257292500021
J	Chiaverini, C; Beuret, L; Flori, E; Busca, R; Abbe, P; Bille, K; Bahadoran, P; Ortonne, JP; Bertolotto, C; Ballotti, R				Chiaverini, Christine; Beuret, Laurent; Flori, Enrica; Busca, Roser; Abbe, Patricia; Bille, Karine; Bahadoran, Philippe; Ortonne, Jean-Paul; Bertolotto, Corine; Ballotti, Robert			Microphthalmia-associated transcription factor regulates RAB27A gene expression and controls melanosome transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP; MASTER REGULATOR; MET EXPRESSION; FACTOR MITF; MELANOCYTE; ELEMENTS; DEFECTS; CELLS; RAB8; CAMP	Melanosomes are lysosome-related organelles specialized in melanin synthesis and transport. In this study, we show that microphthalmia-associated transcription factor ( MITF) silencing induces melanosome gathering around the nucleus and causes the relocalization of Rab27A, Slac2a-Mlph, and Myo5a that control the transport of melanosomes on the actin network. In an attempt to elucidate the mechanism by which MITF controls melanosome distribution, we identify RAB27A as a new MITF target gene. Indeed, MITF silencing leads to a dramatic decrease in Rab27A expression and blocks the stimulation of Rab27A expression evoked by cAMP. Further, forced expression of MITF increases Rab27A expression, indicating that MITF is required and sufficient for Rab27A expression in melanoma cells. MITF binds to two E-boxes in the proximal region of the Rab27A promoter and stimulates its transcriptional activity. Finally, re-expression of Rab27A, in MITF-depleted cells, restores the transport of melanosomes to the cell periphery. These results show that RAB27A is a new direct transcriptional target of MITF and link MITF to melanosome transport, another key parameter of melanocyte differentiation and skin pigmentation. Interestingly, Rab27A is involved in other fundamental physiological functions, such as the transport of lytic granules and insulin secretion. Thus our results, deciphering the mechanism of Rab27A transcriptional regulation, have an interest that goes beyond the skin pigmentation field.	[Chiaverini, Christine; Beuret, Laurent; Busca, Roser; Abbe, Patricia; Bille, Karine; Bahadoran, Philippe; Ortonne, Jean-Paul; Bertolotto, Corine; Ballotti, Robert] INSERM, U895, F-06107 Nice 2, France; [Chiaverini, Christine; Beuret, Laurent; Abbe, Patricia; Bille, Karine; Bahadoran, Philippe; Ortonne, Jean-Paul; Bertolotto, Corine; Ballotti, Robert] Univ Nice Sophia Antipolis, UFR Med, F-06107 Nice, France; [Chiaverini, Christine; Bahadoran, Philippe; Ortonne, Jean-Paul; Bertolotto, Corine; Ballotti, Robert] CHU Nice, Dept Dermatol, F-06200 Nice, France; [Flori, Enrica] IRCCS, Ist Dermatol San Gallicano, Lab Fisiopatol Cutanea, I-00153 Rome, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS San Gallicano Dermatological Institute (ISG)	Ballotti, R (corresponding author), INSERM, U895, 28 Ave Valombrose, F-06107 Nice 2, France.	ballotti@unice.fr	BALLOTTI, Robert/F-8825-2013; Bertolotto, Corine/AAF-6634-2021; Flori, Enrica/H-4417-2014; Bertolotto-Ballotti, Corine/O-2155-2016	Bertolotto, Corine/0000-0001-6971-7753; Flori, Enrica/0000-0002-9275-1041; BALLOTTI, Robert/0000-0002-7322-4908; Bahadoran, Philippe/0000-0002-2481-0556				Aksan I, 1998, MOL CELL BIOL, V18, P6930, DOI 10.1128/MCB.18.12.6930; Bahadoran P, 2003, J BIOL CHEM, V278, P11386, DOI 10.1074/jbc.M211996200; Bahadoran P, 2001, J CELL BIOL, V152, P843, DOI 10.1083/jcb.152.4.843; Barral DC, 2004, PIGM CELL RES, V17, P111, DOI 10.1111/j.1600-0749.2004.00138.x; Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747; Bertolotto C, 1998, MOL CELL BIOL, V18, P694, DOI 10.1128/MCB.18.2.694; Bertolotto C, 1998, J CELL BIOL, V142, P827, DOI 10.1083/jcb.142.3.827; Beuret L, 2007, J BIOL CHEM, V282, P14140, DOI 10.1074/jbc.M611563200; Busca R, 2005, J CELL BIOL, V170, P49, DOI 10.1083/jcb.200501067; Busca R, 2000, PIGM CELL RES, V13, P60, DOI 10.1034/j.1600-0749.2000.130203.x; Carreira S, 2005, NATURE, V433, P764, DOI 10.1038/nature03269; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Chabrillat ML, 2005, MOL BIOL CELL, V16, P1640, DOI 10.1091/mbc.e04-09-0770; Chakraborty AK, 2003, CELL TISSUE RES, V314, P381, DOI 10.1007/s00441-003-0773-6; Chen YR, 2002, J INVEST DERMATOL, V118, P933, DOI 10.1046/j.1523-1747.2002.01754.x; Chu K, 2001, RECENT PROG HORM RES, V56, P23, DOI 10.1210/rp.56.1.23; de la Serna IL, 2006, J BIOL CHEM, V281, P20233, DOI 10.1074/jbc.M512052200; Du JY, 2004, CANCER CELL, V6, P565, DOI 10.1016/j.ccr.2004.10.014; Gaggioli C, 2003, PIGM CELL RES, V16, P374, DOI 10.1034/j.1600-0749.2003.00057.x; Garcia-Borron JC, 2005, PIGM CELL RES, V18, P393, DOI 10.1111/j.1600-0749.2005.00278.x; Goding CR, 2007, INT J BIOCHEM CELL B, V39, P275, DOI 10.1016/j.biocel.2006.10.003; Huan CM, 2006, NAT IMMUNOL, V7, P1082, DOI 10.1038/ni1378; Hume AN, 2007, J CELL SCI, V120, P3111, DOI 10.1242/jcs.010207; Jordens I, 2006, PIGM CELL RES, V19, P412, DOI 10.1111/j.1600-0749.2006.00329.x; Kuroda TS, 2004, NAT CELL BIOL, V6, P1195, DOI 10.1038/ncb1197; Larribere L, 2005, GENE DEV, V19, P1980, DOI 10.1101/gad.335905; Levy C, 2006, TRENDS MOL MED, V12, P406, DOI 10.1016/j.molmed.2006.07.008; McGill GG, 2006, J BIOL CHEM, V281, P10365, DOI 10.1074/jbc.M513094200; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Menasche G, 2002, AM J HUM GENET, V71, P1237, DOI 10.1086/344140; Nagashima K, 2002, FEBS LETT, V517, P233, DOI 10.1016/S0014-5793(02)02634-0; Passeron T, 2004, FASEB J, V18, P989, DOI 10.1096/fj.03-1240fje; Scott G, 2001, J INVEST DERMATOL, V116, P296, DOI 10.1046/j.1523-1747.2001.01221.x; Seabra MC, 2004, TRAFFIC, V5, P393, DOI 10.1111/j.1398-9219.2004.00190.x; Stinchcombe JC, 2001, J CELL BIOL, V152, P825, DOI 10.1083/jcb.152.4.825; Tolmachova T, 1999, GENE, V239, P109, DOI 10.1016/S0378-1119(99)00371-6; Wilson SM, 2000, P NATL ACAD SCI USA, V97, P7933, DOI 10.1073/pnas.140212797; Yi Z, 2002, MOL CELL BIOL, V22, P1858, DOI 10.1128/MCB.22.6.1858-1867.2002	38	81	85	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2008	283	18					12635	12642		10.1074/jbc.M800130200	http://dx.doi.org/10.1074/jbc.M800130200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	293MS	18281284	hybrid			2022-12-25	WOS:000255340000080
J	Gregg, KJ; Finn, R; Abbott, DW; Boraston, AB				Gregg, Katie J.; Finn, Ron; Abbott, D. Wade; Boraston, Alisdair B.			Divergent modes of glycan recognition by a new family of carbohydrate-binding modules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSTRIDIUM-PERFRINGENS; STRUCTURAL BASIS; OLIGOSACCHARIDE RECOGNITION; GLYCOSIDE HYDROLASE; REPLACEMENT; SPECIFICITY; REFINEMENT; ALIGNMENT; SEQUENCE	The genomes of myonecrotic Clostridium perfringens isolates contain genes encoding a large and fascinating array of highly modular glycoside hydrolase enzymes. Although the catalytic activities of many of these enzymes are somewhat predictable based on their amino acid sequences, the functions of their abundant ancillary modules are not and remain poorly studied. Here, we present the structural and functional analysis of a new family of ancillary carbohydrate-binding modules (CBMs), CBM51, which was previously annotated in data bases as the novel putative CBM domain. The high resolution crystal structures of two CBM51 members, GH95CBM51 and GH98CBM51, from a putative family 95 alpha-fucosidase and from a family 98 blood group A/B antigen-specific endo-beta-galactosidase, respectively, showed them to have highly similar beta-sandwich folds. However, GH95CBM51 was shown by glycan microarray screening, isothermal titration calorimetry, and x-ray crystallography to bind galactose residues, whereas the same analyses of GH98CBM51 revealed specificity for the blood group A/B antigens through non-conserved interactions. Overall, this work identifies a new family of CBMs with many members having apparent specificity for eukaryotic glycans, in keeping with the glycan-rich environment C. perfringens would experience in its host. However, a wider bioinformatic analysis of this CBM family also indicated a large number of members in non-pathogenic environmental bacteria, suggesting a role in the recognition of environmental glycans.	[Gregg, Katie J.; Finn, Ron; Abbott, D. Wade; Boraston, Alisdair B.] Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada	University of Victoria	Boraston, AB (corresponding author), Univ Victoria, Dept Biochem & Microbiol, POB 3055 STN CSC, Victoria, BC V8W 3P6, Canada.	boraston@uvic.ca		Boraston, Alisdair/0000-0001-6417-0592; Abbott, Wade/0000-0003-4893-5799	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62116] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1997, NUCLEIC ACIDS RES, V25, P3402; Anderson KM, 2005, J BIOL CHEM, V280, P7720, DOI 10.1074/jbc.M414099200; Bolam DN, 1998, BIOCHEM J, V331, P775, DOI 10.1042/bj3310775; Boraston AB, 2002, J MOL BIOL, V319, P1143, DOI 10.1016/S0022-2836(02)00374-1; Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892; Boraston AB, 2007, BIOCHEMISTRY-US, V46, P11352, DOI 10.1021/bi701317g; Boraston AB, 2006, J BIOL CHEM, V281, P35263, DOI 10.1074/jbc.M607620200; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Cao S, 2007, J VIROL, V81, P5949, DOI 10.1128/JVI.00219-07; Chitayat S, 2008, J MOL BIOL, V375, P20, DOI 10.1016/j.jmb.2007.10.031; Choi JH, 2000, BIOINFORMATICS, V16, P1056, DOI 10.1093/bioinformatics/16.11.1056; Cowtan KD, 1999, PROG BIOPHYS MOL BIO, V72, P245, DOI 10.1016/S0079-6107(99)00008-5; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evans G, 2002, ACTA CRYSTALLOGR D, V58, P976, DOI 10.1107/S0907444902005486; Ficko-Blean E, 2006, J BIOL CHEM, V281, P37748, DOI 10.1074/jbc.M606126200; Henshaw J, 2006, J BIOL CHEM, V281, P17099, DOI 10.1074/jbc.M600702200; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Kulkarni KA, 2007, PROTEINS, V68, P762, DOI 10.1002/prot.21428; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Myers GSA, 2006, GENOME RES, V16, P1031, DOI 10.1101/gr.5238106; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Petit L, 1999, TRENDS MICROBIOL, V7, P104, DOI 10.1016/S0966-842X(98)01430-9; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Rigden DJ, 2005, FEBS LETT, V579, P5466, DOI 10.1016/j.febslet.2005.09.011; Rood JI, 1998, ANNU REV MICROBIOL, V52, P333, DOI 10.1146/annurev.micro.52.1.333; Shimizu T, 2002, P NATL ACAD SCI USA, V99, P996, DOI 10.1073/pnas.022493799; Simpson PJ, 2000, J BIOL CHEM, V275, P41137, DOI 10.1074/jbc.M006948200; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; van Bueren AL, 2004, J MOL BIOL, V340, P869, DOI 10.1016/j.jbm.2004.05.038; van Bueren AL, 2007, NAT STRUCT MOL BIOL, V14, P76, DOI 10.1038/nsmb1187; Walser PJ, 2004, STRUCTURE, V12, P689, DOI 10.1016/j.str.2004.03.002; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Zdobnov EM, 2001, BIOINFORMATICS, V17, P847, DOI 10.1093/bioinformatics/17.9.847	35	35	35	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2008	283	18					12604	12613		10.1074/jbc.M709865200	http://dx.doi.org/10.1074/jbc.M709865200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	293MS	18292090	Green Published, hybrid			2022-12-25	WOS:000255340000077
J	Ashraf, MZ; Kar, NS; Chen, X; Choi, J; Salomon, RG; Febbraio, M; Podrez, EA				Ashraf, Mohammad Z.; Kar, Niladri S.; Chen, Xi; Choi, Jaewoo; Salomon, Robert G.; Febbraio, Maria; Podrez, Eugene A.			Specific oxidized phospholipids inhibit scavenger receptor BI-mediated selective uptake of cholesteryl esters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; SR-BI; ATHEROSCLEROTIC LESIONS; DEFICIENT MICE; CD36; BINDING; LDL; EXPRESSION; IDENTIFICATION; MACROPHAGES	We have recently demonstrated that specific oxidized phospholipids (oxPC(CD36)) accumulate at sites of oxidative stress in vivo such as within atherosclerotic lesions, hyperlipidemic plasma, and plasma with low high-density lipoprotein levels. oxPC(CD36) serve as high affinity ligands for the scavenger receptor CD36, mediate uptake of oxidized low density lipoprotein by macrophages, and promote a pro-thrombotic state via platelet scavenger receptor CD36. We now report that oxPC(CD36) represent ligands for another member of the scavenger receptor class B, type I (SR-BI). oxPC(CD36) prevent binding to SR-BI of its physiological ligand, high density lipoprotein, because of the close proximity of the binding sites for these two ligands on SR-BI. Furthermore, oxPC(CD36) interfere with SR-BI-mediated selective uptake of cholesteryl esters in hepatocytes. Thus, oxidative stress and accumulation of specific oxidized phospholipids in plasma may have an inhibitory effect on reverse cholesterol transport.	[Ashraf, Mohammad Z.; Kar, Niladri S.; Podrez, Eugene A.] Cleveland Clin, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA; [Febbraio, Maria] Cleveland Clin, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA; [Chen, Xi; Choi, Jaewoo; Salomon, Robert G.] Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western Reserve University	Podrez, EA (corresponding author), Cleveland Clin, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA.	podreze@ccf.org	Salomon, Robert G/C-3463-2008	Salomon, Robert/0000-0001-9456-3557	NHLBI NIH HHS [R01 HL077213, HL077213, R01 HL070083, HL053315, HL70083, HL53315] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077213, R01HL070083, R01HL053315] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Arai T, 1999, J BIOL CHEM, V274, P2366, DOI 10.1074/jbc.274.4.2366; ASHKENAS J, 1993, J LIPID RES, V34, P983; Berliner JA, 2005, NEW ENGL J MED, V353, P9, DOI 10.1056/NEJMp058118; Calvo D, 1998, J LIPID RES, V39, P777; Chang MK, 2004, J EXP MED, V200, P1359, DOI 10.1084/jem.20031763; Connelly MA, 2004, CURR OPIN LIPIDOL, V15, P287, DOI 10.1097/00041433-200406000-00008; Gillotte-Taylor K, 2001, J LIPID RES, V42, P1474; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Greene DJ, 2001, J BIOL CHEM, V276, P4804, DOI 10.1074/jbc.M008725200; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; Gu XJ, 2000, J BIOL CHEM, V275, P29993, DOI 10.1074/jbc.275.39.29993; Han JH, 2001, J BIOL CHEM, V276, P16567, DOI 10.1074/jbc.M011302200; Hoff HF, 2003, ARTERIOSCL THROM VAS, V23, P275, DOI 10.1161/01.ATV.0000051407.42536.73; Huszar D, 2000, ARTERIOSCL THROM VAS, V20, P1068, DOI 10.1161/01.ATV.20.4.1068; Jessup W, 2006, CURR OPIN LIPIDOL, V17, P247, DOI 10.1097/01.mol.0000226116.35555.eb; Kozarsky KF, 2000, ARTERIOSCL THROM VAS, V20, P721, DOI 10.1161/01.ATV.20.3.721; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; Ohgami N, 2001, J BIOL CHEM, V276, P13348, DOI 10.1074/jbc.M011613200; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; Podrez EA, 2000, J CLIN INVEST, V105, P1095, DOI 10.1172/JCI8574; Podrez EA, 2002, J BIOL CHEM, V277, P38517, DOI 10.1074/jbc.M205924200; Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200; Podrez EA, 2007, NAT MED, V13, P1086, DOI 10.1038/nm1626; Rigotti A, 2003, ENDOCR REV, V24, P357, DOI 10.1210/er.2001-0037; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Shetty S, 2006, ARTERIOSCL THROM VAS, V26, P2125, DOI 10.1161/01.ATV.0000233335.26362.37; Ueda Y, 2000, J BIOL CHEM, V275, P20368, DOI 10.1074/jbc.M000730200; Yancey PG, 2003, ARTERIOSCL THROM VAS, V23, P712, DOI 10.1161/01.ATV.0000057572.97137.DD	32	47	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10408	10414		10.1074/jbc.M710474200	http://dx.doi.org/10.1074/jbc.M710474200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18285332	Green Published, hybrid			2022-12-25	WOS:000254894700021
J	Dou, ZC; Heinhorst, S; Williams, EB; Murin, CD; Shively, JM; Cannon, GC				Dou, Zhicheng; Heinhorst, Sabine; Williams, Eric B.; Murin, C. Daniel; Shively, Jessup M.; Cannon, Gordon C.			CO2 fixation kinetics of Halothiobacillus neapolitanus mutant carboxysomes lacking carbonic anhydrase suggest the shell acts as a diffusional barrier for CO2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INORGANIC CARBON; CONCENTRATING MECHANISMS; SYNECHOCOCCUS PCC7942; THIOBACILLUS; GENE; CARBOXYLASE; PHOTOSYNTHESIS; PROKARYOTES; ORGANELLES; DIVERSITY	The widely accepted models for the role of carboxysomes in the carbon-concentrating mechanism of autotrophic bacteria predict the carboxysomal carbonic anhydrase to be a crucial component. The enzyme is thought to dehydrate abundant cytosolic bicarbonate and provide ribulose 1.5-bisphosphate carboxylase/ oxygenase (RubisCO) sequestered within the carboxysome with sufficiently high concentrations of its substrate, CO2, to permit its efficient fixation onto ribulose 1,5-bisphosphate. In this study, structure and function of carboxysomes purified from wild type Halothiobacillus neapolitanus and from a high CO2-requiring mutant that is devoid of carboxysomal carbonic anhydrase were compared. The kinetic constants for the carbon fixation reaction confirmed the importance of a functional carboxysomal carbonic anhydrase for efficient catalysis by RubisCO. Furthermore, comparisons of the reaction in intact and broken microcompartments and by purified carboxysomal RubisCO implicated the protein shell of the microcompartment as impeding diffusion of CO2 into and out of the carboxysome interior.	[Dou, Zhicheng; Heinhorst, Sabine; Williams, Eric B.; Murin, C. Daniel; Shively, Jessup M.; Cannon, Gordon C.] Univ So Mississippi, Dept Chem & Biochem, Hattiesburg, MS 39406 USA; [Shively, Jessup M.] Clemson Univ, Dept Genet & Biochem, Clemson, SC 29634 USA	University of Southern Mississippi; Clemson University	Cannon, GC (corresponding author), Univ So Mississippi, Dept Chem & Biochem, 118 Coll Dr 5043, Hattiesburg, MS 39406 USA.	gordon.cannon@usm.edu	Murin, Charles Daniel/ABA-2861-2020					Ausubel FM, 1998, CURRENT PROTOCOLS MO; Badger MR, 2002, FUNCT PLANT BIOL, V29, P161, DOI 10.1071/PP01213; Badger MR, 2003, J EXP BOT, V54, P609, DOI 10.1093/jxb/erg076; Baker SH, 2000, ARCH MICROBIOL, V173, P278, DOI 10.1007/s002030000141; Baker SH, 1999, ARCH MICROBIOL, V172, P233, DOI 10.1007/s002030050765; BAKER SH, 1998, GENETICS, P102; BEUDEKER RF, 1980, ARCH MICROBIOL, V124, P185, DOI 10.1007/BF00427725; Bobik TA, 2006, APPL MICROBIOL BIOT, V70, P517, DOI 10.1007/s00253-005-0295-0; Cai F, 2008, ARCH MICROBIOL, V189, P141, DOI 10.1007/s00203-007-0305-y; CANNON GC, 1983, ARCH MICROBIOL, V134, P52, DOI 10.1007/BF00429407; Cannon GC, 2003, CURR MICROBIOL, V46, P115, DOI 10.1007/s00284-002-3825-3; Cannon GC, 2001, APPL ENVIRON MICROB, V67, P5351, DOI 10.1128/AEM.67.12.5351-5361.2001; Dean J. A., 1999, LANGES HDB CHEM; Dobrinski KP, 2005, J BACTERIOL, V187, P5761, DOI 10.1128/JB.187.16.5761-5766.2005; ENGLISH RS, 1995, APPL ENVIRON MICROB, V61, P3256, DOI 10.1128/AEM.61.9.3256-3260.1995; FUKUZAWA H, 1992, P NATL ACAD SCI USA, V89, P4437, DOI 10.1073/pnas.89.10.4437; Heinhorst S., 2006, COMPLEX INTRACELLULA, P141, DOI [10.1007/7171_023, DOI 10.1007/7171_023]; Heinhorst S, 2006, J BACTERIOL, V188, P8087, DOI 10.1128/JB.00990-06; HOLTHUIJZEN YA, 1987, ARCH MICROBIOL, V147, P285, DOI 10.1007/BF00463489; HOLTHUIJZEN YA, 1987, FEMS MICROBIOL LETT, V42, P121; Kerfeld CA, 2005, SCIENCE, V309, P936, DOI 10.1126/science.1113397; KHALIFAH RG, 1971, J BIOL CHEM, V246, P2561; Long BM, 2007, J BIOL CHEM, V282, P29323, DOI 10.1074/jbc.M703896200; PRICE GD, 1989, PLANT PHYSIOL, V91, P514, DOI 10.1104/pp.91.2.514; PRICE GD, 1992, PLANT PHYSIOL, V100, P784, DOI 10.1104/pp.100.2.784; PRICE GD, 1991, CAN J BOT, V69, P963, DOI 10.1139/b91-124; PRICE GD, 1993, J BACTERIOL, V175, P2871, DOI 10.1128/JB.175.10.2871-2879.1993; PRICE GD, 2007, J EXP BOT; REINHOLD L, 1991, CAN J BOT, V69, P984, DOI 10.1139/b91-126; REINHOLD L, 1989, PLANT PHYSIOL BIOCH, V27, P945; Sawaya MR, 2006, J BIOL CHEM, V281, P7546, DOI 10.1074/jbc.M510464200; SHIVELY JM, 1973, J BACTERIOL, V116, P1405, DOI 10.1128/JB.116.3.1405-1411.1973; SHIVELY JM, 1973, SCIENCE, V182, P584, DOI 10.1126/science.182.4112.584; So AKC, 2004, J BACTERIOL, V186, P623, DOI 10.1128/JB.186.3.623-630.2004; STONER MT, 1993, FEMS MICROBIOL LETT, V107, P287, DOI 10.1016/0378-1097(93)90324-U; Tanaka S, 2008, SCIENCE, V319, P1083, DOI 10.1126/science.1151458; TAYLOR LA, 1988, NUCLEIC ACIDS RES, V16, P358, DOI 10.1093/nar/16.1.358; Tsai Y, 2007, PLOS BIOL, V5, P1345, DOI 10.1371/journal.pbio.0050144; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; YU JW, 1992, PLANT PHYSIOL, V100, P794, DOI 10.1104/pp.100.2.794	40	123	126	3	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10377	10384		10.1074/jbc.M709285200	http://dx.doi.org/10.1074/jbc.M709285200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18258595	hybrid, Green Published			2022-12-25	WOS:000254894700018
J	Jewell, JL; Luo, W; Oh, EJ; Wang, ZX; Thurmond, DC				Jewell, Jenna L.; Luo, Wei; Oh, Eunjin; Wang, Zhanxiang; Thurmond, Debbie C.			Filamentous actin regulates insulin exocytosis through direct interaction with syntaxin 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; LIPID RAFTS; BETA-CELLS; GLUCOSE; SECRETION; PROTEIN; GRANULES; RELEASE; CDC42; MICROTUBULES	Glucose-induced insulin exocytosis is coupled to associations between F-actin and SNARE proteins, although the nature and function of these interactions remains unknown. Toward this end we show here that both Syntaxin 1A and Syntaxin 4 associated with F-actin in MIN6 cells and that each interaction was rapidly and transiently diminished by stimulation of cells with D-glucose. Of the two isoforms, only Syntaxin 4 was capable of interacting directly with F-actin in an in vitro sedimentation assay, conferred by the N-terminal 39-112 residues of Syntaxin 4. The 39-112 fragment was capable of selective competitive inhibitory action, disrupting endogenous F-actin-Syntaxin 4 binding in MIN6 cells. Disruption of F-actin-Syntaxin 4 binding correlated with enhanced glucose-stimulated insulin secretion, mediated by increased granule accumulation at the plasma membrane and increased Syntaxin 4 accessibility under basal conditions. However, no increase in basal level Syntaxin 4-VAMP2 association occurred with either latrunculin treatment or expression of the 39-112 fragment. Taken together, these data disclose a new underlying mechanism by which F-actin negatively regulates exocytosis via binding and blocking Syntaxin 4 accessibility, but they also reveal the existence of additional signals and/or steps required to trigger the subsequent docking and fusion steps of exocytosis.	[Jewell, Jenna L.; Oh, Eunjin; Wang, Zhanxiang; Thurmond, Debbie C.] Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Diabet Res Ctr, Indianapolis, IN 46202 USA; [Luo, Wei] GebScript Corp, Piscataway, NJ 08854 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Thurmond, DC (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Diabet Res Ctr, 635 Barnhill Dr,MS4053, Indianapolis, IN 46202 USA.	dthurmon@iupui.edu			NIDDK NIH HHS [R01 DK076614, R01 DK067912, DK-067912, R01 DK076614-01A2, DK-76614, R01 DK067912-04] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067912, R01DK076614] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUNIS D, 1988, J EXP BIOL, V139, P253; Bader MF, 2004, BBA-MOL CELL RES, V1742, P37, DOI 10.1016/j.bbamcr.2004.09.028; Barg S, 2002, DIABETES, V51, pS74, DOI 10.2337/diabetes.51.2007.S74; BEEST MB, 2005, MOL BIOL CELL, V16, P5784; Betz A, 1997, J BIOL CHEM, V272, P2520; Bruun TZ, 2000, EUR J PHARMACOL, V403, P221, DOI 10.1016/S0014-2999(00)00602-6; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; Daniel S, 1999, DIABETES, V48, P1686, DOI 10.2337/diabetes.48.9.1686; Eitzen G, 2003, BBA-MOL CELL RES, V1641, P175, DOI 10.1016/S0167-4889(03)00087-9; Fujita Y, 1998, NEURON, V20, P905, DOI 10.1016/S0896-6273(00)80472-9; Gasman S, 2004, MOL BIOL CELL, V15, P520, DOI 10.1091/mbc.E03-06-0402; Giraudo CG, 2006, SCIENCE, V313, P676, DOI 10.1126/science.1129450; HOWELL SL, 1979, BIOCHEM J, V178, P367, DOI 10.1042/bj1780367; Hu SH, 2007, P NATL ACAD SCI USA, V104, P8773, DOI 10.1073/pnas.0701124104; Isgandarova S, 2007, J BIOL CHEM, V282, P30466, DOI 10.1074/jbc.M704117200; Ivarsson R, 2005, TRAFFIC, V6, P1027, DOI 10.1111/j.1600-0854.2005.00342.x; Jahn R, 2006, NAT REV MOL CELL BIO, V7, P631, DOI 10.1038/nrm2002; Kang Y, 2002, DIABETOLOGIA, V45, P231, DOI 10.1007/s00125-001-0718-0; Kasai K, 2005, J CLIN INVEST, V115, P388, DOI 10.1172/JCI200522955; Kashima Y, 2001, J BIOL CHEM, V276, P46046, DOI 10.1074/jbc.M108378200; Ke B, 2007, J BIOL CHEM, V282, P21786, DOI 10.1074/jbc.M701661200; KELLY RB, 1990, CELL, V61, P5, DOI 10.1016/0092-8674(90)90206-T; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; LACY PE, 1972, DIABETES, V21, P987, DOI 10.2337/diab.21.10.987; LACY PE, 1968, NATURE, V219, P1177, DOI 10.1038/2191177a0; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Li GD, 1996, BIOCHEM J, V316, P345, DOI 10.1042/bj3160345; Liu LB, 2006, MOL BIOL CELL, V17, P4249, DOI 10.1091/mbc.E06-04-0278; Low SH, 2006, MOL BIOL CELL, V17, P977, DOI 10.1091/mbc.E05-05-0462; MALAISSE WJ, 1975, ANN NY ACAD SCI, V253, P630, DOI 10.1111/j.1749-6632.1975.tb19234.x; Mitchell KJ, 2004, DIABETES, V53, P393, DOI 10.2337/diabetes.53.2.393; Mulder H, 2001, J BIOL CHEM, V276, P6479, DOI 10.1074/jbc.M010364200; Mundy DI, 2002, J CELL SCI, V115, P4327, DOI 10.1242/jcs.00117; Nakano M, 2001, BIOCHEM BIOPH RES CO, V288, P468, DOI 10.1006/bbrc.2001.5795; Nevins AK, 2005, J BIOL CHEM, V280, P1944, DOI 10.1074/jbc.M409528200; Nevins AK, 2003, AM J PHYSIOL-CELL PH, V285, pC698, DOI 10.1152/ajpcell.00093.2003; Nevins AK, 2006, J BIOL CHEM, V281, P18961, DOI 10.1074/jbc.M603604200; Ohara-Imaizumi M, 2007, J CELL BIOL, V177, P695, DOI 10.1083/jcb.200608132; ORCI L, 1972, SCIENCE, V175, P1128, DOI 10.1126/science.175.4026.1128; Sieber JJ, 2006, BIOPHYS J, V90, P2843, DOI 10.1529/biophysj.105.079574; SNABES MC, 1982, BIOCHEM BIOPH RES CO, V104, P207, DOI 10.1016/0006-291X(82)91960-X; SOMERS G, 1979, ENDOCRINOLOGY, V104, P255, DOI 10.1210/endo-104-1-255; Spurlin BA, 2006, MOL ENDOCRINOL, V20, P183, DOI 10.1210/me.2005-0157; Spurlin BA, 2003, DIABETES, V52, P1910, DOI 10.2337/diabetes.52.8.1910; Straub SG, 2004, DIABETES, V53, P3179, DOI 10.2337/diabetes.53.12.3179; SWANSTONFLATT SK, 1980, FEBS LETT, V117, P299, DOI 10.1016/0014-5793(80)80966-5; Thurmond DC, 2003, MOL ENDOCRINOL, V17, P732, DOI 10.1210/me.2002-0333; Tomas A, 2006, J CELL SCI, V119, P2156, DOI 10.1242/jcs.02942; Tsuboi T, 2003, J BIOL CHEM, V278, P52042, DOI 10.1074/jbc.M307800200; Varadi A, 2005, MOL BIOL CELL, V16, P2670, DOI 10.1091/mbc.e04-11-1001; Vikman J, 2006, J MOL ENDOCRINOL, V36, P503, DOI 10.1677/jme.1.01978; WANG JL, 1990, BIOCHEM BIOPH RES CO, V171, P424, DOI 10.1016/0006-291X(90)91410-T; Wang ZX, 2007, J BIOL CHEM, V282, P9536, DOI 10.1074/jbc.M610553200; Waselle L, 2003, MOL BIOL CELL, V14, P4103, DOI 10.1091/mbc.E03-01-0022; Xia FZ, 2004, J BIOL CHEM, V279, P24685, DOI 10.1074/jbc.M314314200; Yang XF, 2006, J BIOL CHEM, V281, P15457, DOI 10.1074/jbc.M513246200	56	87	88	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10716	10726		10.1074/jbc.M709876200	http://dx.doi.org/10.1074/jbc.M709876200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18285343	Green Published, hybrid, Green Accepted			2022-12-25	WOS:000254894700054
J	Kwon, YH; Seong, C; Chi, P; Greene, EC; Klein, H; Sung, P				Kwon, YoungHo; Seong, Changhyun; Chi, Peter; Greene, Eric C.; Klein, Hannah; Sung, Patrick			ATP-dependent chromatin remodeling by the Saccharomyces cerevisiae homologous recombination factor Rdh54	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA STRAND EXCHANGE; RAD51 RECOMBINASE; NUCLEOPROTEIN FILAMENT; NUCLEOSOME CORE; HISTONE OCTAMER; SNF2 FAMILY; YEAST RAD51; PROTEINS; COMPLEX; REPAIR	Saccharomyces cerevisiae RDH54 is a key member of the evolutionarily conserved RAD52 epistasis group of genes needed for homologous recombination and DNA double strand break repair. The RDH54-encoded protein possesses a DNA translocase activity and functions together with the Rad51 recombinase in the D-loop reaction. By chromatin immunoprecipitation (ChIP), we show that Rdh54 is recruited, in a manner that is dependent on Rad51 and Rad52, to a site-specific DNA double strand break induced by the HO endonuclease. Because of its relatedness to Swi2/ Snf2 chromatin remodelers, we have asked whether highly purified Rdh54 possesses chromatin-remodeling activity. Importantly, our results show that Rdh54 can mobilize a mononucleosome along DNA and render nucleosomal DNA accessible to a restriction enzyme, indicative of a chromatin-remodeling function. Moreover, Rdh54 co-operates with Rad51 in the utilization of naked or chromatinized DNA as template for D-loop formation. We also provide evidence for a strict dependence of the chromatin-remodeling attributes of Rdh54 on its ATPase activity and N-terminal domain. Interestingly, an N-terminal deletion mutant (rdh54 Delta 102) is unable to promote Rad51-mediated D-loop formation with a chromatinized template, while retaining substantial activity with naked DNA. These features of Rdh54 suggest a role of this protein factor in chromatin rearrangement during DNA recombination and repair.	[Kwon, YoungHo; Seong, Changhyun; Chi, Peter; Sung, Patrick] Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; [Greene, Eric C.] Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; [Klein, Hannah] NYU, Sch Med, Dept Biochem, New York, NY 10016 USA; [Klein, Hannah] NYU, Sch Med, Kaplan Canc Ctr, New York, NY 10016 USA	Yale University; Columbia University; New York University; New York University	Sung, P (corresponding author), Yale Univ, Sch Med, Dept Mol Biophys & Biochem, 333 Cedar St,SHM-C130, New Haven, CT 06520 USA.	Patrick.Sung@yale.edu	Chi, Peter/AAI-1580-2019; Huang, Wenchi/F-3981-2010	Chi, Peter/0000-0001-9229-8729; Huang, Wenchi/0000-0001-5556-1460; Klein, Hannah/0000-0003-4228-8535	NIEHS NIH HHS [ES07061] Funding Source: Medline; NIGMS NIH HHS [GM074739, GM57814, GM53738] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM074739, R01GM053738, R01GM057814] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexeev A, 2003, NAT STRUCT BIOL, V10, P182, DOI 10.1038/nsb901; Alexiadis V, 2004, J BIOL CHEM, V279, P27824, DOI 10.1074/jbc.M402648200; Alexiadis V, 2002, GENE DEV, V16, P2767, DOI 10.1101/gad.1032102; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Bugreev DV, 2006, NATURE, V442, P590, DOI 10.1038/nature04889; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; Chi P, 2006, J BIOL CHEM, V281, P26268, DOI 10.1074/jbc.M602983200; Durr H, 2006, NUCLEIC ACIDS RES, V34, P4160, DOI 10.1093/nar/gkl540; Eberharter A, 2004, METHOD ENZYMOL, V377, P344; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Flaus A, 2003, BIOPOLYMERS, V68, P563, DOI 10.1002/bip.10323; Flaus A, 2004, CURR OPIN GENET DEV, V14, P165, DOI 10.1016/j.gde.2004.01.007; Flaus A, 2006, NUCLEIC ACIDS RES, V34, P2887, DOI 10.1093/nar/gkl295; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; Heyer WD, 2006, NUCLEIC ACIDS RES, V34, P4115, DOI 10.1093/nar/gkl481; Holzen TM, 2006, GENE DEV, V20, P2593, DOI 10.1101/gad.1447106; Jaskelioff M, 2003, J BIOL CHEM, V278, P9212, DOI 10.1074/jbc.M211545200; Krogh BO, 2004, ANNU REV GENET, V38, P233, DOI 10.1146/annurev.genet.38.072902.091500; Kwon Y, 2007, DNA REPAIR, V6, P1496, DOI 10.1016/j.dnarep.2007.04.012; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; Lisby M, 2004, CELL, V118, P699, DOI 10.1016/j.cell.2004.08.015; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Nimonkar AV, 2007, J BIOL CHEM, V282, P30776, DOI 10.1074/jbc.M704767200; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Petukhova G, 2000, GENE DEV, V14, P2206, DOI 10.1101/gad.826100; Prasad TK, 2007, J MOL BIOL, V369, P940, DOI 10.1016/j.jmb.2007.04.005; Raschle M, 2004, J BIOL CHEM, V279, P51973, DOI 10.1074/jbc.M410101200; Richmond TJ, 2003, NATURE, V423, P145, DOI 10.1038/nature01595; Ristic D, 2001, P NATL ACAD SCI USA, V98, P8454, DOI 10.1073/pnas.151056798; Saha A, 2006, NAT REV MOL CELL BIO, V7, P437, DOI 10.1038/nrm1945; Shinohara M, 1997, GENETICS, V147, P1545; Solinger JA, 2002, MOL CELL, V10, P1175, DOI 10.1016/S1097-2765(02)00743-8; Solinger JA, 2001, J MOL BIOL, V307, P1207, DOI 10.1006/jmbi.2001.4555; STEIN A, 1989, METHOD ENZYMOL, V170, P585; Sugawara N, 2003, MOL CELL, V12, P209, DOI 10.1016/S1097-2765(03)00269-7; Sung P, 1996, J BIOL CHEM, V271, P27983, DOI 10.1074/jbc.271.45.27983; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; Tanaka K, 2002, NUCLEIC ACIDS RES, V30, P1346, DOI 10.1093/nar/30.6.1346; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; Wittmeyer J, 2004, METHOD ENZYMOL, V377, P322; Wolner B, 2003, MOL CELL, V12, P221, DOI 10.1016/S1097-2765(03)00242-9; Zhang ZQ, 2007, NAT STRUCT MOL BIOL, V14, P397, DOI 10.1038/nsmb1223	43	28	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10445	10452		10.1074/jbc.M800082200	http://dx.doi.org/10.1074/jbc.M800082200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18292093	Green Published, hybrid			2022-12-25	WOS:000254894700025
J	Saras, A; Gisselmann, G; Vogt-Eisele, AK; Erlkamp, KS; Kletke, O; Pusch, H; Hatt, H				Saras, Arunesh; Gisselmann, Guenter; Vogt-Eisele, Angela K.; Erlkamp, Katja S.; Kletke, Olaf; Pusch, Hermann; Hatt, Hanns			Histamine action on vertebrate GABA(A) receptors - Direct channel gating and potentiation of GABA responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED ION CHANNELS; DROSOPHILA-MELANOGASTER; CHLORIDE CHANNEL; XENOPUS-OOCYTES; SUBUNITS; EXPRESSION; PROPOFOL; IDENTIFICATION; TRANSMISSION; ANESTHETICS	Histamine is not only a crucial cytokine in the periphery but also an important neurotransmitter and neuromodulator in the brain. It is known to act on metabotropic H1-H4 receptors, but the existence of directly histamine-gated chloride channels in mammals has been suspected for many years. However, the molecular basis of such mammalian channels remained elusive, whereas in invertebrates, genes for histamine-gated channels have been already identified. In this report, we demonstrated that histamine can directly open vertebrate ion channels and identified beta subunits of GABA(A) receptors as potential candidates for histamine-gated channels. In Xenopus oocytes expressing homomultimeric beta channels, histamine evoked currents with an EC50 of 212 mu M (beta(2)) and 174 mu M (beta(3)), whereas GABA is only a very weak partial agonist. We tested several known agonists and antagonists for the histamine-binding site of H1-H4 receptors and described for beta channels a unique pharmacological profile distinct from either of these receptors. In heteromultimeric channels composed of alpha(1)beta(2) or alpha(1)beta(2)gamma(2) subunits, we found that histamine is a modulator of the GABA response rather than an agonist as it potentiates GABA-evoked currents in a gamma(2) subunit-controlled manner. Despite the vast number of synthetic modulators of GABAA receptors widely used in medicine, which act on several distinct sites, only a few endogenous modulators have yet been identified. We show here for the first time that histamine modulates heteromultimeric GABAA receptors and may thus represent an endogenous ligand for an allosteric site.	[Saras, Arunesh; Gisselmann, Guenter; Vogt-Eisele, Angela K.; Erlkamp, Katja S.; Kletke, Olaf; Pusch, Hermann; Hatt, Hanns] Ruhr Univ Bochum, Lehrstuhl Zellphysiol, D-44780 Bochum, Germany	Ruhr University Bochum	Gisselmann, G (corresponding author), Ruhr Univ Bochum, Lehrstuhl Zellphysiol, Univ Str 150, D-44780 Bochum, Germany.	guenter.gisselmann@rub.de		Kletke, Olaf/0000-0002-7825-1278				Boileau AJ, 2002, NEUROPHARMACOLOGY, V43, P695, DOI 10.1016/S0028-3908(02)00036-9; Borycz JA, 2005, J NEUROPHYSIOL, V93, P1611, DOI 10.1152/jn.00894.2004; Brown RE, 2001, PROG NEUROBIOL, V63, P637, DOI 10.1016/S0301-0082(00)00039-3; Cannon KE, 2004, LIFE SCI, V75, P2551, DOI 10.1016/j.lfs.2004.05.020; Cestari IN, 1996, NEUROREPORT, V7, P943, DOI 10.1097/00001756-199603220-00023; Chen ZW, 2007, J NEUROCHEM, V100, P279, DOI 10.1111/j.1471-4159.2006.04206.x; Davies PA, 2003, J BIOL CHEM, V278, P712, DOI 10.1074/jbc.M208814200; Gengs CX, 2002, J BIOL CHEM, V277, P42113, DOI 10.1074/jbc.M207133200; Gisselmann G, 2004, NEUROSCI LETT, V372, P151, DOI 10.1016/j.neulet.2004.09.031; Gisselmann G, 2004, BRIT J PHARMACOL, V142, P409, DOI 10.1038/sj.bjp.0705818; Gisselmann G, 2002, NAT NEUROSCI, V5, P11, DOI 10.1038/nn787; Haas H, 2003, NAT REV NEUROSCI, V4, P121, DOI 10.1038/nrn1034; Hatton GI, 2001, J NEUROSCI, V21, P2974, DOI 10.1523/JNEUROSCI.21-09-02974.2001; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Korpi ER, 2002, PROG NEUROBIOL, V67, P113, DOI 10.1016/S0301-0082(02)00013-8; Koutsoviti-Papadopoulou M, 2003, PHARMACOL RES, V48, P279, DOI 10.1016/S1043-6618(03)00148-8; Krasowski MD, 1998, MOL PHARMACOL, V53, P530, DOI 10.1124/mol.53.3.530; Lam DW, 1998, BRAIN RES, V784, P179, DOI 10.1016/S0006-8993(97)01334-6; Lambert JJ, 2003, PROG NEUROBIOL, V71, P67, DOI 10.1016/j.pneurobio.2003.09.001; Martinez-Torres A, 2004, P NATL ACAD SCI USA, V101, P3220, DOI 10.1073/pnas.0308682101; Miko A, 2004, J BIOL CHEM, V279, P22833, DOI 10.1074/jbc.M402577200; Olsen RW, 2004, BIOCHEM PHARMACOL, V68, P1675, DOI 10.1016/j.bcp.2004.07.026; Olsen RW, 1998, TOXICOL LETT, V101, P193, DOI 10.1016/S0378-4274(98)00185-4; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; Rossi DJ, 1998, NEURON, V20, P783, DOI 10.1016/S0896-6273(00)81016-8; SANNA E, 1995, MOL PHARMACOL, V47, P213; Schnizler K, 2005, J BIOL CHEM, V280, P16254, DOI 10.1074/jbc.M411759200; Sharonova IN, 1998, EUR J NEUROSCI, V10, P522, DOI 10.1046/j.1460-9568.1998.00057.x; Sigel E, 1997, TRENDS PHARMACOL SCI, V18, P425, DOI 10.1016/S0165-6147(97)90675-1; TALEB O, 1994, EMBO J, V13, P1318, DOI 10.1002/j.1460-2075.1994.tb06384.x; Taylor PM, 1999, J NEUROSCI, V19, P6360; van der Goot H, 2000, EUR J MED CHEM, V35, P5, DOI 10.1016/S0223-5234(00)00101-X; Whiting PJ, 1999, ANN NY ACAD SCI, V868, P645, DOI 10.1111/j.1749-6632.1999.tb11341.x; WILLIAMS K, 1994, MOL PHARMACOL, V46, P531; Witte I, 2002, J NEUROCHEM, V83, P504, DOI 10.1046/j.1471-4159.2002.01076.x; Wooltorton JRA, 1997, EUR J NEUROSCI, V9, P2225, DOI 10.1111/j.1460-9568.1997.tb01641.x; Zheng YC, 2002, J BIOL CHEM, V277, P2000, DOI 10.1074/jbc.M107635200	37	57	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10470	10475		10.1074/jbc.M709993200	http://dx.doi.org/10.1074/jbc.M709993200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18281286	hybrid			2022-12-25	WOS:000254894700028
J	Sugaya, N; Habuchi, H; Nagai, N; Ashikari-Hada, S; Kimata, K				Sugaya, Noriko; Habuchi, Hiroko; Nagai, Naoko; Ashikari-Hada, Satoko; Kimata, Koji			6-O-sulfation of heparan sulfate differentially regulates various fibroblast growth factor-dependent signalings in culture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR SPECIFICITY; EXPRESSION PATTERNS; CRYSTAL-STRUCTURE; BINDING SITES; FGF; 6-O-SULFOTRANSFERASE; OLIGOSACCHARIDES; PROTEOGLYCANS; PROTEINS; QSULF1	Heparan sulfate (HS) interacts with diverse heparin-binding growth factors and thereby regulates their bioactivities. These interactions depend on the structures characterized by the sulfation pattern and isomer of uronic acid residues. One of the biosynthetic modifications of HS, namely 6-O-sulfation, is catalyzed by three isoforms of HS6-O-sulfotransferase. We generated HS6ST-1- and/ or HS6ST-2-deficient mice (6ST1-KO, 6ST2-KO, and double knock-out (dKO)) that exhibited different phenotypes. We examined the effects of HS 6-O-sulfation in heparin-binding growth factor signaling using fibroblasts derived from these mutant mice. Mouse embryonic fibroblasts (MEF) prepared from E14.5 dKO mice produced HS with little 6-O-sulfate, whereas 2-O-sulfation in HS from dKO-MEF(dKOHS) was increased by 1.9-fold. HS6-O-sulfotransferase activity in the dKO-MEF was hardly detected, and HS2-O-sulfotransferase activity was 1.5-fold higher than that in wild type (WT)MEFs. The response of dKO-MEFs to fibroblast growth factors (FGFs) was distinct from that of WT-MEFs; in dKO-MEFs, FGF-4-and FGF-2-dependent signalings were reduced to similar to 30 and 60% of WT-MEFs, respectively, and FGF-1-dependent signaling was moderately reduced compared with that of WT-MEFs but only at the lower FGF-1 concentrations. Analysis with a surface plasmon resonance biosensor demonstrated that the apparent affinity of dKO-HS for FGF-4 was markedly reduced and was also reduced for FGF-1. In contrast, the affinity of dKO-HS for FGF-2 was 2.5-fold higher than that of HS from WT-MEFs. Thus, 6-O-sulfate in HS may regulate the signalings of some of HB-GFs, including FGFs, by inducing different interactions between ligands and their receptors.	[Sugaya, Noriko; Habuchi, Hiroko; Nagai, Naoko; Ashikari-Hada, Satoko; Kimata, Koji] Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan	Aichi Medical University	Kimata, K (corresponding author), Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan.	kimata@aichi-med-u.ac.jp						Ai XB, 2003, J CELL BIOL, V162, P341, DOI 10.1083/jcb.200212083; Allen BL, 2001, J CELL BIOL, V155, P845, DOI 10.1083/jcb.200106075; Allen BL, 2003, J CELL BIOL, V163, P637, DOI 10.1083/jcb.200307053; ASHIKARI S, 1995, J BIOL CHEM, V270, P29586, DOI 10.1074/jbc.270.49.29586; Ashikari-Hada S, 2004, J BIOL CHEM, V279, P12346, DOI 10.1074/jbc.M313523200; Aviezer D, 1999, BIOCHEM BIOPH RES CO, V263, P621, DOI 10.1006/bbrc.1999.1434; Bellosta P, 2001, MOL CELL BIOL, V21, P5946, DOI 10.1128/MCB.21.17.5946-5957.2001; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bink RJ, 2003, J BIOL CHEM, V278, P31118, DOI 10.1074/jbc.M213124200; Bishop JR, 2007, NATURE, V446, P1030, DOI 10.1038/nature05817; Bulow HE, 2004, NEURON, V41, P723, DOI 10.1016/S0896-6273(04)00084-4; Chen E, 2005, DEV BIOL, V284, P364, DOI 10.1016/j.ydbio.2005.05.032; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; Dhoot GK, 2001, SCIENCE, V293, P1663, DOI 10.1126/science.293.5535.1663; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Habuchi H, 2004, GLYCOCONJUGATE J, V21, P47, DOI 10.1023/B:GLYC.0000043747.87325.5e; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; Habuchi H, 2003, BIOCHEM J, V371, P131, DOI 10.1042/BJ20021259; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; Ilan N, 2006, INT J BIOCHEM CELL B, V38, P2018, DOI 10.1016/j.biocel.2006.06.004; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P817, DOI 10.1093/glycob/4.6.817; Jastrebova N, 2006, J BIOL CHEM, V281, P26884, DOI 10.1074/jbc.M600806200; Kamimura K, 2001, J BIOL CHEM, V276, P17014, DOI 10.1074/jbc.M011354200; Kamimura K, 2006, J CELL BIOL, V174, P773, DOI 10.1083/jcb.200603129; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; Kobayashi T, 2007, J BIOL CHEM, V282, P19589, DOI 10.1074/jbc.M610707200; Kreuger J, 2006, J CELL BIOL, V174, P323, DOI 10.1083/jcb.200604035; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; Lundin L, 2000, J BIOL CHEM, V275, P24653, DOI 10.1074/jbc.M908930199; MacArthur JM, 2007, J CLIN INVEST, V117, P153, DOI 10.1172/JCI29154; Merry CLR, 2001, J BIOL CHEM, V276, P35429, DOI 10.1074/jbc.M100379200; Morimoto-Tomita M, 2002, J BIOL CHEM, V277, P49175, DOI 10.1074/jbc.M205131200; Nakato H, 2002, BBA-GEN SUBJECTS, V1573, P312, DOI 10.1016/S0304-4165(02)00398-7; Nogami K, 2004, J BIOL CHEM, V279, P8219, DOI 10.1074/jbc.M307304200; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Parish CR, 2006, NAT REV IMMUNOL, V6, P633, DOI 10.1038/nri1918; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Powell AK, 2004, GLYCOBIOLOGY, V14, p17R, DOI 10.1093/glycob/cwh051; Pratt T, 2006, J NEUROSCI, V26, P6911, DOI 10.1523/JNEUROSCI.0505-06.2006; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; Robinson CJ, 2005, J BIOL CHEM, V280, P42274, DOI 10.1074/jbc.M505720200; Rong JH, 2001, BIOCHEMISTRY-US, V40, P5548, DOI 10.1021/bi002926p; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Sedita J, 2004, DEV DYNAM, V231, P782, DOI 10.1002/dvdy.20173; Shipp EL, 2007, CHEM BIOL, V14, P195, DOI 10.1016/j.chembiol.2006.12.009; Sugahara K, 2002, IUBMB LIFE, V54, P163, DOI 10.1080/15216540214928; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; Viviano BL, 2004, J BIOL CHEM, V279, P5604, DOI 10.1074/jbc.M310691200; Wang SW, 2004, P NATL ACAD SCI USA, V101, P4833, DOI 10.1073/pnas.0401028101; Wu ZLL, 2003, J BIOL CHEM, V278, P17121, DOI 10.1074/jbc.M212590200; Zhang XQ, 2006, J BIOL CHEM, V281, P15694, DOI 10.1074/jbc.M601252200	55	78	79	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10366	10376		10.1074/jbc.M705948200	http://dx.doi.org/10.1074/jbc.M705948200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18281280	hybrid			2022-12-25	WOS:000254894700017
J	Shen, XZ; Lukacher, AE; Billet, S; Williams, IR; Bernstein, KE				Shen, Xiao Z.; Lukacher, Aron E.; Billet, Sandrine; Williams, Ifor R.; Bernstein, Kenneth E.			Expression of angiotensin-converting enzyme changes major histocompatibility complex class I peptide presentation by modifying C termini of peptide precursors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RESPONSES; ANTIGEN PRESENTATION; DENDRITIC CELLS; ENDOPLASMIC-RETICULUM; LYMPHOCYTES; MOLECULES; EPITOPE; MICE; AMINOPEPTIDASE; MACROPHAGE	We recently reported a mouse model called ACE 10/10 in which macrophages overexpress the carboxypeptidase angiotensin-converting enzyme (ACE). These mice have an enhanced inflammatory response to tumors that markedly inhibits tumor growth. Here, we show that ACE modifies the C termini of peptides for presentation by major histocompatibility complex (MHC) class I molecules. The peptide-processing activity of ACE applies to antigens from either the extracellular environment (cross-presentation) or antigens produced endogenously. Consistent with its role in MHC class I antigen processing, ACE localizes to the endoplasmic reticulum. ACE overexpression does not appear to change the overall supply of peptides available to MHC class I molecules. The immunization of wild type mice previously given ACE 10/10 macrophages enhances the efficiency of antigen-specific CD8(+) T cell priming. These data reveal that ACE is a dynamic participant in fashioning the peptide repertoire for MHC class I molecules by modifying the C termini of peptide precursors. Manipulation of peptidase expression by antigen-presenting cells may ultimately prove a useful strategy to enhance the immune response.	[Shen, Xiao Z.; Lukacher, Aron E.; Billet, Sandrine; Williams, Ifor R.; Bernstein, Kenneth E.] Emory Univ, Dept Pathol, Sch Med, Atlanta, GA 30322 USA	Emory University	Bernstein, KE (corresponding author), Emory Univ, Dept Pathol, Sch Med, Rm 7107A WMB,101 Woodruff Circle, Atlanta, GA 30322 USA.	kbernst@emory.edu	Williams, Ifor R/D-3648-2011	Williams, Ifor R/0000-0002-8810-2911; Bernstein, Kenneth/0000-0001-8097-3272	NIDDK NIH HHS [R01 DK 051445, R01 DK 039777] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039777, R01DK051445] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; Cascio P, 2001, EMBO J, V20, P2357, DOI 10.1093/emboj/20.10.2357; Cole J, 2000, J CLIN INVEST, V106, P1391, DOI 10.1172/JCI10557; Cole JM, 2003, AM J PHYSIOL-RENAL, V284, pF599, DOI 10.1152/ajprenal.00308.2002; CORVOL P, 1995, METHOD ENZYMOL, V248, P283; Daniels MD, 2007, CURR PHARM DESIGN, V13, P1299, DOI 10.2174/138161207780618812; Danilov SM, 2003, EXP HEMATOL, V31, P1301, DOI 10.1016/j.exphem.2003.08.018; Drake DR, 2000, J VIROL, V74, P4093, DOI 10.1128/JVI.74.9.4093-4101.2000; EISENLOHR LC, 1992, CELL, V71, P963, DOI 10.1016/0092-8674(92)90392-P; Hammer GE, 2007, IMMUNITY, V26, P397, DOI 10.1016/j.immuni.2007.04.003; Harmer D, 2002, FEBS LETT, V532, P107, DOI 10.1016/S0014-5793(02)03640-2; HOOPER NM, 1991, INT J BIOCHEM, V23, P641, DOI 10.1016/0020-711X(91)90032-I; Kemball CC, 2005, J IMMUNOL, V174, P7950, DOI 10.4049/jimmunol.174.12.7950; KOZLOWSKI S, 1992, J EXP MED, V175, P1417, DOI 10.1084/jem.175.6.1417; Lukacher AE, 1998, J IMMUNOL, V160, P1724; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; Nakagawa Y, 2000, IMMUNOLOGY, V101, P76, DOI 10.1046/j.1365-2567.2000.00092.x; Obeid D, 2007, ONCOGENE, V26, P102, DOI 10.1038/sj.onc.1209779; OKABE T, 1987, JPN J MED, V26, P140, DOI 10.2169/internalmedicine1962.26.140; Porgador A, 1997, IMMUNITY, V6, P715, DOI 10.1016/S1074-7613(00)80447-1; Rammensee HG, 2006, IMMUNITY, V25, P693, DOI 10.1016/j.immuni.2006.10.008; Rock KL, 2005, IMMUNOL REV, V207, P166, DOI 10.1111/j.0105-2896.2005.00301.x; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Rock KL, 2004, NAT IMMUNOL, V5, P670, DOI 10.1038/ni1089; Romer F K, 1984, Acta Med Scand Suppl, V690, P3; Saijonmaa O, 2007, AM J PHYSIOL-HEART C, V292, pH1917, DOI 10.1152/ajpheart.00920.2006; Saric T, 2002, NAT IMMUNOL, V3, P1169, DOI 10.1038/ni859; Scharfstein J, 2007, SCAND J IMMUNOL, V66, P128, DOI 10.1111/j.1365-3083.2007.01983.x; Serwold T, 2002, NATURE, V419, P480, DOI 10.1038/nature01074; Shen LJ, 2006, CURR OPIN IMMUNOL, V18, P85, DOI 10.1016/j.coi.2005.11.003; Shen XZ, 2007, AM J PATHOL, V170, P2122, DOI 10.2353/ajpath.2007.061205; Skidgel R A, 1989, Adv Exp Med Biol, V247A, P25; Sousa CRE, 1999, CURR OPIN IMMUNOL, V11, P392, DOI 10.1016/S0952-7915(99)80066-1; Stevanovic S, 2005, TRANSPL IMMUNOL, V14, P171, DOI 10.1016/j.trim.2005.03.018; Towne CF, 2007, J IMMUNOL, V178, P6923, DOI 10.4049/jimmunol.178.11.6923; WEI L, 1991, J BIOL CHEM, V266, P5540; Yewdell JW, 2005, ANNU REV IMMUNOL, V23, P651, DOI 10.1146/annurev.immunol.23.021704.115702; York IA, 1999, IMMUNOL REV, V172, P49, DOI 10.1111/j.1600-065X.1999.tb01355.x; York IA, 2006, J IMMUNOL, V177, P1434, DOI 10.4049/jimmunol.177.3.1434	40	38	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9957	9965		10.1074/jbc.M709574200	http://dx.doi.org/10.1074/jbc.M709574200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18252713	Green Published, hybrid			2022-12-25	WOS:000254671600052
J	Yao, ZQ; Xing, LP; Qin, CL; Schwarz, EM; Boyce, BF				Yao, Zhenqiang; Xing, Lianping; Qin, Chunlin; Schwarz, Edward M.; Boyce, Brendan F.			Osteoclast precursor interaction with bone matrix induces osteoclast formation directly by an interleukin-1-mediated autocrine mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; C-FOS; FACTOR-ALPHA; OSTEOPROTEGERIN LIGAND; RHEUMATOID-ARTHRITIS; OSTEOBLASTIC CELLS; RECEPTOR ACTIVATOR; SIBLING PROTEINS; TRANSGENIC MICE	Interleukin-1 (IL-1) and tumor necrosis factor (TNF) mediate bone resorption in a variety of diseases affecting bone. Like TNF, IL-1 is secreted by osteoclast precursors (OCPs), but unlike TNF, it does not induce osteoclast formation directly from OCPs in vitro. TNF induces IL-1 expression and activates c-Fos, a transcription factor required in OCPs for osteoclast formation. Here, we examined whether IL-1 can induce osteoclast formation directly from OCPs overexpressing c-Fos and whether interaction with bone matrix affects OCP cytokine expression. We infected OCPs with c-Fos or green fluorescent protein retrovirus, cultured them with macrophage colony-stimulating factor and IL-1 on bone slices or plastic dishes, and assessed osteoclast and resorption pit formation and expression of IL-1 by OCPs. We used a Transwell assay to determine whether OCPs secrete IL-1 when they interact with bone matrix. IL-1 induced osteoclast formation directly from c-Fos-expressing OCPs on plastic. c-Fos-expressing OCPs formed osteoclasts spontaneously on bone slices without addition of cytokines. OCPs on bone secreted IL-1, which induced osteoclast formation from c-Fos-expressing OCPs in the lower Transwell dishes. The bone matrix proteins dentin sialoprotein and osteopontin, but not transforming growth factor-beta, stimulated OCP expression of IL-1 and induced c-Fos-expressing OCP differentiation into osteoclasts. Osteoclasts eroding inflamed joints have higher c-Fos expression compared with osteoclasts inside bone. We conclude that OCPs expressing c-Fos may induce their differentiation directly into osteoclasts by an autocrine mechanism in which they produce IL-1 through interaction with bone matrix. TNF could induce c-Fos expression in OCPs at sites of inflammation in bone to promote this autocrine mechanism and thus amplify bone loss.	[Yao, Zhenqiang; Xing, Lianping; Boyce, Brendan F.] Univ Rochester, Med Ctr, Dept Pathol, Rochester, NY 14642 USA; [Yao, Zhenqiang; Xing, Lianping; Boyce, Brendan F.] Univ Rochester, Med Ctr, Lab Med, Rochester, NY 14642 USA; [Schwarz, Edward M.; Boyce, Brendan F.] Univ Rochester, Med Ctr, Ctr Musculoskeletal Res, Rochester, NY 14642 USA; [Qin, Chunlin] Texas A&M Univ, Syst Hlth Sci Ctr, Dept Biomed Sci, Baylor Coll Dent, Dallas, TX 75246 USA	University of Rochester; University of Rochester; University of Rochester; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Boyce, BF (corresponding author), Univ Rochester, Med Ctr, Dept Pathol, 601 Elmwood Ave,POB 626, Rochester, NY 14642 USA.	Brenden_Boyce@urmc.rochester.edu			NIAMS NIH HHS [AR 48697, AR 43510] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043510, R01AR048697] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741; Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150; Baron R, 2004, NAT MED, V10, P458, DOI 10.1038/nm0504-458; Boyce BF, 2005, J BONE MINER METAB, V23, P11, DOI 10.1007/BF03026317; BOYCE BF, 1989, ENDOCRINOLOGY, V125, P1142, DOI 10.1210/endo-125-3-1142; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; CHAMBERS TJ, 1981, J PATHOL, V135, P1, DOI 10.1002/path.1711350102; CLOHISY JC, 1992, MOL ENDOCRINOL, V6, P1834, DOI 10.1210/me.6.11.1834; Fisher LW, 2001, BIOCHEM BIOPH RES CO, V280, P460, DOI 10.1006/bbrc.2000.4146; Goldring SR, 2003, CALCIFIED TISSUE INT, V73, P97, DOI 10.1007/s00223-002-1049-y; Hauge EM, 2001, J BONE MINER RES, V16, P1575, DOI 10.1359/jbmr.2001.16.9.1575; Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756-3282(99)00162-3; HUGHES DE, 1995, J BONE MINER RES, V10, P1478; Ishijima M, 2001, J EXP MED, V193, P399, DOI 10.1084/jem.193.3.399; Jimi E, 1999, EXP CELL RES, V247, P84, DOI 10.1006/excr.1998.4320; Jimi E, 1999, J IMMUNOL, V163, P434; JIMI E, 1995, ENDOCRINOLOGY, V136, P808, DOI 10.1210/en.136.2.808; Johnson MR, 2000, ANAL BIOCHEM, V278, P175, DOI 10.1006/abio.1999.4461; Kaplan C, 2003, FRONT BIOSCI-LANDMRK, V8, pD1018, DOI 10.2741/1102; Kapur RP, 2004, J BONE MINER RES, V19, P1689, DOI 10.1359/JBMR.040713; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978; Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LEE E, 1994, BIOCHEM BIOPH RES CO, V202, P128, DOI 10.1006/bbrc.1994.1902; Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514; Lee SH, 2002, J BIOCHEM, V131, P161, DOI 10.1093/oxfordjournals.jbchem.a003071; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Li P, 2004, ARTHRITIS RHEUM, V50, P265, DOI 10.1002/art.11419; Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; MUNDY GR, 1990, ANN NY ACAD SCI, V593, P91, DOI 10.1111/j.1749-6632.1990.tb16102.x; Qin C, 2002, J DENT RES, V81, P392, DOI 10.1177/154405910208100607; Qin C, 2004, CRIT REV ORAL BIOL M, V15, P126, DOI 10.1177/154411130401500302; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; Sato K, 2006, CURR OPIN RHEUMATOL, V18, P419, DOI 10.1097/01.bor.0000231912.24740.a5; Sfikakis PP, 2003, CURR OPIN RHEUMATOL, V15, P380, DOI 10.1097/00002281-200307000-00003; Silva TA, 2005, J DENT RES, V84, P79, DOI 10.1177/154405910508400114; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a; Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001; Teitelbaum SL, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1857; Teitelbaum SL, 2000, J BONE MINER METAB, V18, P344, DOI 10.1007/s007740070007; Teitelbaum SL, 2006, ANN NY ACAD SCI, V1068, P95, DOI 10.1196/annals.1346.017; Valverde P, 2006, J BONE MINER RES, V21, pS167; Valverde P, 2005, J BONE MINER RES, V20, P1669, DOI 10.1359/JBMR.050511; Wei S, 2005, J CLIN INVEST, V115, P282, DOI 10.1172/JCI200523394; Xing LP, 2005, IMMUNOL REV, V208, P19, DOI 10.1111/j.0105-2896.2005.00336.x; Xing LP, 2002, J BONE MINER RES, V17, P1200, DOI 10.1359/jbmr.2002.17.7.1200; Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200; Yao ZQ, 2006, J BIOL CHEM, V281, P11846, DOI 10.1074/jbc.M512624200; Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012; Zwerina J, 2004, ARTHRITIS RHEUM, V50, P277, DOI 10.1002/art.11487	57	77	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9917	9924		10.1074/jbc.M706415200	http://dx.doi.org/10.1074/jbc.M706415200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18250170	hybrid, Green Published			2022-12-25	WOS:000254671600048
J	Hakizimana, P; Masureel, M; Gbaguidi, B; Ruysschaert, JM; Govaerts, C				Hakizimana, Pierre; Masureel, Matthieu; Gbaguidi, Benedicte; Ruysschaert, Jean-Marie; Govaerts, Cedric			Interactions between phosphatidylethanolamine headgroup and LmrP, a multidrug transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; MEMBRANE PHOSPHOLIPID-COMPOSITION; METAL-TETRACYCLINE/H+ ANTIPORTER; ESCHERICHIA-COLI; LACTOSE PERMEASE; TOPOLOGICAL ORGANIZATION; CONFORMATIONAL-CHANGES; BIOLOGICAL-MEMBRANES; SECONDARY STRUCTURE; PROTEIN STRUCTURE	In a number of cases, the function of membrane proteins appears to require the presence of specific lipid species in the bilayer. We have shown that the secondary multidrug transporter LmrP requires the presence of phosphatidylethanolamine (PE), as its replacement by phosphatidylcholine (PC) inhibits transport activity and directly affects its structure, although the underlying mechanism was unknown. Here, we show that the effect of PE on the structure and the function of LmrP is mediated by interactions between the lipid headgroup and the protein. We used methyl-PE and dimethyl-PE analogs of PE to show that only replacement of the three hydrogens by methyl moieties leads to changes in the biochemical and biophysical properties of the reconstituted protein. This suggests that LmrP does not depend on the bulk properties of the phospholipids tested but solely on the hydrogen bonding ability of the headgroup. We then show that a single point mutation in LmrP, D68C, is sufficient to recapitulate precisely every biochemical and biophysical effect observed when PE is replaced by PC, including energy transfer between the protein tryptophan residues and the lipid headgroups. We conclude that the negatively charged Asp-68 is likely to participate in the interaction with PE and that such interaction is required for proton gradient sensing, substrate binding, and transport. Because Asp-68 belongs to a highly conserved motif in the Major Facilitator Superfamily (which includes LacY and EmrD), this interaction might be a general feature of these transporters that is involved in proton gradient sensing and lipid dependence.	[Hakizimana, Pierre; Masureel, Matthieu; Gbaguidi, Benedicte; Ruysschaert, Jean-Marie; Govaerts, Cedric] Univ Libre Bruxelles, Struct Biol & Bioinformat Ctr, Dept Struct & Funct Biol Membranes, B-1050 Brussels, Belgium	Universite Libre de Bruxelles	Ruysschaert, JM (corresponding author), Univ Libre Bruxelles, Struct Biol & Bioinformat Ctr, Dept Struct & Funct Biol Membranes, CP206-2,Blvd Triomphe, B-1050 Brussels, Belgium.	jmruyss@ulb.ac.be		Hakizimana, Pierre/0000-0001-9615-3885				Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Bapna A, 2007, J MOL MICROB BIOTECH, V12, P197, DOI 10.1159/000099641; Bechinger B, 1999, BIOPHYS J, V76, P552, DOI 10.1016/S0006-3495(99)77223-1; Bolhuis H, 1996, J BIOL CHEM, V271, P24123, DOI 10.1074/jbc.271.39.24123; BOLHUIS H, 1995, J BIOL CHEM, V270, P26092, DOI 10.1074/jbc.270.44.26092; CHEN CC, 1984, J BIOL CHEM, V259, P150; deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; EFTINK MR, 1987, BIOCHIM BIOPHYS ACTA, V916, P343, DOI 10.1016/0167-4838(87)90179-8; Elmore DE, 2001, BIOPHYS J, V81, P1345, DOI 10.1016/S0006-3495(01)75791-8; Gbaguidi B, 2007, CELL MOL LIFE SCI, V64, P1571, DOI 10.1007/s00018-007-7031-0; Gbaguidi B, 2004, CELL MOL LIFE SCI, V61, P2646, DOI 10.1007/s00018-004-4298-2; Goormaghtigh E, 1999, BBA-REV BIOMEMBRANES, V1422, P105, DOI 10.1016/S0304-4157(99)00004-0; Goormaghtigh E, 1994, Subcell Biochem, V23, P363; Goormaghtigh E, 1994, Subcell Biochem, V23, P405; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V193, P409, DOI 10.1111/j.1432-1033.1990.tb19354.x; Grimard V, 2004, J BIOL CHEM, V279, P5528, DOI 10.1074/jbc.M311014200; Grimard V, 2001, BIOCHEMISTRY-US, V40, P11876, DOI 10.1021/bi010017+; Hamai C, 2006, BIOPHYS J, V90, P1241, DOI 10.1529/biophysj.105.069435; Hsieh CH, 1995, BIOPHYS J, V69, P2521, DOI 10.1016/S0006-3495(95)80123-2; JESSENMARSHALL AE, 1995, J BIOL CHEM, V270, P16251, DOI 10.1074/jbc.270.27.16251; Kimura-Someya T, 1998, J BIOL CHEM, V273, P32806, DOI 10.1074/jbc.273.49.32806; Krishnamurthy SS, 1999, FEMS MICROBIOL LETT, V173, P475, DOI 10.1111/j.1574-6968.1999.tb13541.x; Kusube M, 2006, CHEM PHYS LIPIDS, V142, P94, DOI 10.1016/j.chemphyslip.2006.03.004; Lange C, 2001, EMBO J, V20, P6591, DOI 10.1093/emboj/20.23.6591; Lee AG, 2005, MOL BIOSYST, V1, P203, DOI 10.1039/b504527d; Lee AG, 2004, BBA-BIOMEMBRANES, V1666, P62, DOI 10.1016/j.bbamem.2004.05.012; Lee AG, 2003, BBA-BIOMEMBRANES, V1612, P1, DOI 10.1016/S0005-2736(03)00056-7; Lemieux MJ, 2007, MOL MEMBR BIOL, V24, P333, DOI 10.1080/09687680701496507; LEMIEUX MJ, 2005, J ELECT MICROSC T S1, V54, P143; Mazurkiewicz P, 2004, J BIOL CHEM, V279, P103, DOI 10.1074/jbc.M306579200; Mazurkiewicz P, 2002, J BIOL CHEM, V277, P26081, DOI 10.1074/jbc.M203141200; McAuley KE, 1999, P NATL ACAD SCI USA, V96, P14706, DOI 10.1073/pnas.96.26.14706; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; Pazdernik NJ, 2000, J MEMBRANE BIOL, V174, P31, DOI 10.1007/s002320001029; Putman M, 1999, BIOCHEMISTRY-US, V38, P13900, DOI 10.1021/bi991262k; Putman M, 1999, BIOCHEMISTRY-US, V38, P1002, DOI 10.1021/bi981863w; Raussens V, 1997, J BIOL CHEM, V272, P262; Raussens V, 1998, J BIOL CHEM, V273, P25825, DOI 10.1074/jbc.273.40.25825; SQUIER TC, 1988, J BIOL CHEM, V263, P9178; Wang XY, 2002, EMBO J, V21, P5673, DOI 10.1093/emboj/cdf571; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P19155; Yin Y, 2006, SCIENCE, V312, P741, DOI 10.1126/science.1125629; Zhang W, 2005, J BIOL CHEM, V280, P26032, DOI 10.1074/jbc.M504929200; Zhang W, 2003, J BIOL CHEM, V278, P50128, DOI 10.1074/jbc.M309840200; Zhou FF, 2007, PHARM RES-DORDR, V24, P28, DOI 10.1007/s11095-006-9144-9	46	60	62	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9369	9376		10.1074/jbc.M708427200	http://dx.doi.org/10.1074/jbc.M708427200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18234676	hybrid			2022-12-25	WOS:000254465800067
J	Tomida, J; Masuda, Y; Hiroaki, H; Ishikawa, T; Song, I; Tsurimoto, T; Tateishi, S; Shiomi, T; Kamei, Y; Kim, J; Kamiya, K; Vaziri, C; Ohmori, H; Todo, T				Tomida, Junya; Masuda, Yuji; Hiroaki, Hidekazu; Ishikawa, Tomoko; Song, Ihnyoung; Tsurimoto, Toshiki; Tateishi, Satoshi; Shiomi, Tadahiro; Kamei, Yasuhiro; Kim, Jinhyeong; Kamiya, Kenji; Vaziri, Cyrus; Ohmori, Haruo; Todo, Takeshi			DNA damage-induced ubiquitylation of RFC2 subunit of replication factor C complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; PROTEIN-A; SACCHAROMYCES-CEREVISIAE; POLYMERASE-DELTA; UBIQUITIN LIGASE; CLAMP LOADERS; HUMAN SHPRH; PCNA; REPAIR; CHECKPOINTS	Many proteins involved in DNA replication and repair undergo post-translational modifications such as phosphorylation and ubiquitylation. Proliferating cell nuclear antigen ( PCNA; a homotrimeric protein that encircles double-stranded DNA to function as a sliding clamp for DNA polymerases) is monoubiquitylated by the RAD6-RAD18 complex and further polyubiquitylated by the RAD5-MMS2-UBC13 complex in response to various DNA-damaging agents. PCNA mono- and polyubiquitylation activate an error-prone translesion synthesis pathway and an error-free pathway of damage avoidance, respectively. Here we show that replication factor C ( RFC; a heteropentameric protein complex that loads PCNA onto DNA) was also ubiquitylated in a RAD18-dependent manner in cells treated with alkylating agents or H2O2. A mutant form of RFC2 with a D228A substitution ( corresponding to a yeast Rfc4 mutation that reduces an interaction with replication protein A ( RPA), a single-stranded DNA-binding protein) was heavily ubiquitylated in cells even in the absence of DNA damage. Furthermore RFC2 was ubiquitylated by the RAD6-RAD18 complex in vitro, and its modification was inhibited in the presence of RPA. The inhibitory effect of RPA on RFC2 ubiquitylation was relatively specific because RAD6-RAD18-mediated ubiquitylation of PCNA was RPA-insensitive. Our findings suggest that RPA plays a regulatory role in DNA damage responses via repression of RFC2 ubiquitylation in human cells.	[Ishikawa, Tomoko; Kamei, Yasuhiro; Kim, Jinhyeong; Todo, Takeshi] Osaka Univ, Grad Sch Med, Dept Radiat Biol & Med Genet, Osaka 5650871, Japan; [Tomida, Junya; Ishikawa, Tomoko; Kamei, Yasuhiro; Kim, Jinhyeong; Todo, Takeshi] Kyoto Univ, Ctr Radiat Biol, Kyoto 6068501, Japan; [Tomida, Junya; Ohmori, Haruo] Kyoto Univ, Inst Virus Res, Kyoto 6068501, Japan; [Masuda, Yuji; Tateishi, Satoshi; Kamiya, Kenji] Hiroshima Univ, Res Inst Radiat Biol & Med, Hiroshima 7348553, Japan; [Hiroaki, Hidekazu] Kobe Univ, Grad Sch Med, Dept Biotechnol & Mol Biol, Div Struct Biol, Kobe, Hyogo 6500017, Japan; [Song, Ihnyoung; Vaziri, Cyrus] Boston Univ, Sch Med, Dept Genet & Genom, Boston, MA 02118 USA; [Tsurimoto, Toshiki] Kyushu Univ, Sch Sci, Dept Biol, Fukuoka 8128581, Japan; [Tateishi, Satoshi] Kumamoto Univ, Inst Mol Embryol & Genet, Kumamoto 8600811, Japan; [Shiomi, Tadahiro] Natl Inst Radiol Sci, Chiba 2638555, Japan	Osaka University; Kyoto University; Kyoto University; Hiroshima University; Kobe University; Boston University; Kyushu University; Kumamoto University; National Institutes for Quantum Science & Technology	Todo, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Radiat Biol & Med Genet, B4,2-2 Yamada Oka, Osaka 5650871, Japan.	todo@radbio.med.osaka-u.ac.jp	Kamei, Yasuhiro/AAD-9281-2019; Ishikawa-Fujiwara, Tomoko/GLS-9481-2022; Hiroaki, Hidekazu/G-9564-2012; Masuda, Yuji/I-6315-2014; HIROAKI, HIDEKAZU/N-1658-2019	Kamei, Yasuhiro/0000-0001-6382-1365; Masuda, Yuji/0000-0002-6229-1988; HIROAKI, HIDEKAZU/0000-0003-1621-5893; Tsurimoto, Toshiki/0000-0001-7597-2216; Tomida, Junya/0000-0002-0813-5757	NIEHS NIH HHS [ES 12917, ES 09558] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009558, R29ES009558, R01ES012917] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bienko M, 2005, SCIENCE, V310, P1821, DOI 10.1126/science.1120615; Binz SK, 2004, DNA REPAIR, V3, P1015, DOI 10.1016/j.dnarep.2004.03.028; Bochkareva E, 2002, EMBO J, V21, P1855, DOI 10.1093/emboj/21.7.1855; Bowman GD, 2005, FEBS LETT, V579, P863, DOI 10.1016/j.febslet.2004.11.038; Bowman GD, 2004, NATURE, V429, P724, DOI 10.1038/nature02585; Carr AM, 2002, DNA REPAIR, V1, P983, DOI 10.1016/S1568-7864(02)00165-9; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8; Friedberg EC, 2005, MOL CELL, V18, P499, DOI 10.1016/j.molcel.2005.03.032; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; Gomes XV, 2001, J BIOL CHEM, V276, P34768, DOI 10.1074/jbc.M011631200; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HARRISON SD, 1995, GENETICS, V139, P1701; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; IMAI N, 1992, GENE, V118, P279, DOI 10.1016/0378-1119(92)90200-9; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; KELMAN Z, 1995, NUCLEIC ACIDS RES, V23, P3613, DOI 10.1093/nar/23.18.3613; Kim HS, 2001, MOL CELL BIOL, V21, P3725, DOI 10.1128/MCB.21.11.3725-3737.2001; Kim JY, 2003, CURR BIOL, V13, pR873, DOI 10.1016/j.cub.2003.10.048; Koradi R, 1996, J MOL GRAPHICS, V14, P29; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Krokan HE, 2000, FEBS LETT, V476, P73, DOI 10.1016/S0014-5793(00)01674-4; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Majka J, 2004, PROG NUCLEIC ACID RE, V78, P227, DOI 10.1016/S0079-6603(04)78006-X; Masuda Y, 2007, NUCLEIC ACIDS RES, V35, P6904, DOI 10.1093/nar/gkm822; Moldovan GL, 2007, CELL, V129, P665, DOI 10.1016/j.cell.2007.05.003; Motegi A, 2006, J CELL BIOL, V175, P703, DOI 10.1083/jcb.200606145; Neuwald AF, 1999, GENOME RES, V9, P27; Podust VN, 1998, J BIOL CHEM, V273, P31992, DOI 10.1074/jbc.273.48.31992; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shiomi Y, 2002, GENES CELLS, V7, P861, DOI 10.1046/j.1365-2443.2002.00566.x; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Stojic L, 2004, DNA REPAIR, V3, P1091, DOI 10.1016/j.dnarep.2004.06.006; Tomii K, 2004, BIOINFORMATICS, V20, P594, DOI 10.1093/bioinformatics/btg474; Trojan J, 2002, GASTROENTEROLOGY, V122, P211, DOI 10.1053/gast.2002.30296; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; Unk I, 2006, P NATL ACAD SCI USA, V103, P18107, DOI 10.1073/pnas.0608595103; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Watanabe K, 2004, EMBO J, V23, P3886, DOI 10.1038/sj.emboj.7600383; Wu XM, 2005, ONCOGENE, V24, P4728, DOI 10.1038/sj.onc.1208674; Wyatt MD, 2006, CHEM RES TOXICOL, V19, P1580, DOI 10.1021/tx060164e; WYMAN C, 1995, CURR BIOL, V5, P334, DOI 10.1016/S0960-9822(95)00065-0; Yuzhakov A, 1999, EMBO J, V18, P6189, DOI 10.1093/emboj/18.21.6189; ZernikKobak M, 1997, J BIOL CHEM, V272, P23896, DOI 10.1074/jbc.272.38.23896; Zou Y, 2006, J CELL PHYSIOL, V208, P267, DOI 10.1002/jcp.20622	51	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9071	9079		10.1074/jbc.M709835200	http://dx.doi.org/10.1074/jbc.M709835200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18245774	Green Published, hybrid			2022-12-25	WOS:000254465800037
J	Smith, DO; Rosenheimer, JL; Kalil, RE				Smith, Dean O.; Rosenheimer, Julie L.; Kalil, Ronald E.			Delayed Rectifier and A-Type Potassium Channels Associated with Kv 2.1 and Kv 4.3 Expression in Embryonic Rat Neural Progenitor Cells	PLOS ONE			English	Article							KV2.1 K+ CHANNEL; SUBVENTRICULAR ZONE; STEM-CELLS; VOLTAGE; CURRENTS; DIFFERENTIATION; PRECURSOR; BRAIN; IDENTIFICATION; POPULATION	Background: Because of the importance of voltage-activated K+ channels during embryonic development and in cell proliferation, we present here the first description of these channels in E15 rat embryonic neural progenitor cells derived from the subventricular zone (SVZ). Activation, inactivation, and single-channel conductance properties of recorded progenitor cells were compared with those obtained by others when these Kv gene products were expressed in oocytes. Methodology/Principal Findings: Neural progenitor cells derived from the subventricular zone of E15 embryonic rats were cultured under conditions that did not promote differentiation. Immunocytochemical and Western blot assays for nestin expression indicated that almost all of the cells available for recording expressed this intermediate filament protein, which is generally accepted as a marker for uncommitted embryonic neural progenitor cells. However, a very small numbers of the cells expressed GFAP, a marker for astrocytes, O4, a marker for immature oligodendrocytes, and beta III-tubulin, a marker for neurons. Using immunocytochemistry and Western blots, we detected consistently the expression of Kv2.1, and 4.3. In whole-cell mode, we recorded two outward currents, a delayed rectifier and an A-type current. Conclusions/Significance: We conclude that Kv2.1, and 4.3 are expressed in E15 SVZ neural progenitor cells, and we propose that they may be associated with the delayed-rectifier and the A-type currents, respectively, that we recorded. These results demonstrate the early expression of delayed rectifier and A-type K+ currents and channels in embryonic neural progenitor cells prior to the differentiation of these cells.	[Smith, Dean O.] Univ Hawaii Manoa, Stem Cell Res Lab, Manoa, HI USA; [Rosenheimer, Julie L.] Univ Hawaii Manoa, Dept Anat, Manoa, HI USA; [Kalil, Ronald E.] Univ Wisconsin Madison, Dept Ophthalmol & Visual Sci, Madison, WI USA	University of Hawaii System; University of Hawaii Manoa; University of Hawaii System; University of Hawaii Manoa; University of Wisconsin System; University of Wisconsin Madison	Smith, DO (corresponding author), Univ Hawaii Manoa, Stem Cell Res Lab, Manoa, HI USA.	dean.smith@ttu.edu			University of Hawaiis Chancellors Office; Retina Research Foundation	University of Hawaiis Chancellors Office; Retina Research Foundation	Funding was provided by the University of Hawaiis Chancellors Office and the Retina Research Foundation. Neither had any role in any aspect of this study.	BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; Cai JL, 2004, J NEUROCHEM, V88, P212, DOI 10.1046/j.1471-4159.2003.02184.x; Feldman DH, 1996, EXP NEUROL, V140, P206, DOI 10.1006/exnr.1996.0130; FICKER E, 1992, J PHYSIOL-LONDON, V445, P431, DOI 10.1113/jphysiol.1992.sp018932; Franqueza L, 1999, CARDIOVASC RES, V41, P212, DOI 10.1016/S0008-6363(98)00220-X; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; Ghiani CA, 1999, J NEUROSCI, V19, P5380; Gutman GA, 2003, PHARMACOL REV, V55, P583, DOI 10.1124/pr.55.4.9; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEINEMANN SH, 1992, METHOD ENZYMOL, V207, P131; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Holmqvist MH, 2002, P NATL ACAD SCI USA, V99, P1035, DOI 10.1073/pnas.022509299; HWANG PM, 1993, J NEUROSCI, V13, P1569; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Koopmann R, 2001, J MEMBRANE BIOL, V182, P49, DOI 10.1007/s00232-001-0029-X; KUES WA, 1992, EUR J NEUROSCI, V4, P1296, DOI 10.1111/j.1460-9568.1992.tb00155.x; Liebau S, 2006, J NEUROCHEM, V99, P426, DOI 10.1111/j.1471-4159.2006.03967.x; Lowe DL, 1997, MOL BRAIN RES, V48, P37, DOI 10.1016/S0169-328X(97)00072-7; Luskin MB, 1997, MOL CELL NEUROSCI, V8, P351, DOI 10.1006/mcne.1996.0592; Murakoshi H, 1999, J NEUROSCI, V19, P1728; Murakoshi H, 1997, MOL PHARMACOL, V52, P821, DOI 10.1124/mol.52.5.821; Okabe S, 1996, MECH DEVELOP, V59, P89, DOI 10.1016/0925-4773(96)00572-2; Pardo LA, 2004, PHYSIOLOGY, V19, P285, DOI 10.1152/physiol.00011.2004; Piper DR, 2000, J NEUROPHYSIOL, V84, P534, DOI 10.1152/jn.2000.84.1.534; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; Sah DWY, 1997, J NEUROBIOL, V32, P95, DOI 10.1002/(SICI)1097-4695(199701)32:1<95::AID-NEU9>3.0.CO;2-9; Salinas M, 1997, J BIOL CHEM, V272, P24371, DOI 10.1074/jbc.272.39.24371; Serodio P, 1998, J NEUROPHYSIOL, V79, P1081, DOI 10.1152/jn.1998.79.2.1081; SERODIO P, 1994, J NEUROPHYSIOL, V72, P1516, DOI 10.1152/jn.1994.72.4.1516; SHI GY, 1994, J BIOL CHEM, V269, P23204; Spitzer NC, 2002, CURR OPIN NEUROBIOL, V12, P315, DOI 10.1016/S0959-4388(02)00330-6; SPITZER NC, 1981, STUDIES DEV NEUROBIO, P261; Spitzer NC, 2006, NATURE, V444, P707, DOI 10.1038/nature05300; Stewart RR, 1999, J NEUROPHYSIOL, V81, P95, DOI 10.1152/jn.1999.81.1.95; SURMEIER DJ, 1994, METH NEUROSCI, V19, P39; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; Wang DD, 2003, J NEUROPHYSIOL, V90, P2291, DOI 10.1152/jn.01116.2002; Wang K, 2005, STEM CELLS, V23, P1526, DOI 10.1634/stemcells.2004-0299; Wang SM, 2004, J PHYSIOL-LONDON, V557, P705, DOI 10.1113/jphysiol.2003.058578; Whittemore SR, 1999, EXP CELL RES, V252, P75, DOI 10.1006/excr.1999.4621; Wonderlin WF, 1996, J MEMBRANE BIOL, V154, P91, DOI 10.1007/s002329900135; YOOL AJ, 1988, J NEUROSCI, V8, P1971	42	29	32	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1604	10.1371/journal.pone.0001604	http://dx.doi.org/10.1371/journal.pone.0001604			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270591	Green Published, Green Submitted, gold			2022-12-25	WOS:000260535900038
J	Wesolowski, LG; MacKellar, DA; Ethridge, SF; Zhu, JH; Owen, SM; Sullivan, PS				Wesolowski, Laura G.; MacKellar, Duncan A.; Ethridge, Steven F.; Zhu, Julia H.; Owen, S. Michele; Sullivan, Patrick S.		Post Mkt Surveillance Team	Repeat Confirmatory Testing for Persons with Discordant Whole Blood and Oral Fluid Rapid HIV Test Results: Findings from Post Marketing Surveillance	PLOS ONE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; TRANSUDATE; ANTIBODIES	Background. Reactive oral fluid and whole blood rapid HIV tests must be followed with a confirmatory test (Western blot (WB), immunofluorescent assay (IFA) or approved nucleic acid amplification test (NAAT)). When the confirmatory result is negative or indeterminate (i.e. discordant with rapid result), repeat confirmatory testing should be conducted using a follow-up specimen. Previous reports have not described whether repeat testing adequately resolves the HIV-infection status of persons with discordant results. Methodology. Post-marketing surveillance was conducted in 368 testing sites affiliated with 14 state and 2 city health departments from August 11, 2004 to June 30, 2005 and one health department through December 31, 2005. For persons with discordant results, data were collected on demographics, risk behaviors, HIV test results and specimen types. Persons with repeat confirmatory results were classified as HIV-infected or uninfected. Regression models were created to assess risk factors for not having repeat testing. Principal Findings. Of 167,371 rapid tests conducted, 2589 (1.6%) were reactive: of these, 2417 (93%) had positive WB/IFA, 172 (7%) had negative or indeterminate WB/IFA. Of 89/172 (52%) persons with a repeat confirmatory test: 17 (19%) were HIV-infected, including 3 with indeterminate WB and positive NAAT; 72 (81%) were uninfected, including 12 with repeat indeterminate WB. Factors associated with HIV-infection included having an initial indeterminate WB/IFA (vs. negative) (p < 0.001) and having an initial oral fluid WB (vs. serum) (p, 0.001). Persons who had male-female sex (vs. male-male sex) were at increased risk for not having a repeat test [adjusted OR 2.6, 95% CI (1.3, 4.9)]. Conclusions. Though only half of persons with discordant results had repeat confirmatory testing, of those who did, nearly one in five were HIV-infected. These findings underscore the need for rapid HIV testing programs to increase repeat confirmatory testing for persons with discordant results. Because of the lower sensitivity of oral fluid WBs, confirmatory testing following a reactive rapid test should be conducted using serum or plasma, when possible.	[Wesolowski, Laura G.; MacKellar, Duncan A.; Ethridge, Steven F.; Zhu, Julia H.; Owen, S. Michele; Sullivan, Patrick S.] Ctr Dis Control & Prevent, STD & TB Prevent, Natl Ctr HIV, Div HIV AIDS Prevent, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Wesolowski, LG (corresponding author), Ctr Dis Control & Prevent, STD & TB Prevent, Natl Ctr HIV, Div HIV AIDS Prevent, Atlanta, GA 30333 USA.	lig7@cdc.gov		Sullivan, Patrick Sean/0000-0002-7728-0587	Centers for Disease Control and Prevention.	Centers for Disease Control and Prevention.(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	Funding for this project was provided by the Centers for Disease Control and Prevention.	Centers of Disease Control and Prevention, 2001, MMWR Recomm Rep, V50, P1, DOI 10.1103/PhysRevE.106.055304; *CDC, CLIA CERT WAIV FACT; CDC, 2007, QUAL ASS GUID TEST U; CDC, 2004, MMWR-MORBID MORTAL W, V53, P221; *CDC, 2005, MMWR-MORBID MORTAL W, V54, P1287; CELUM CL, 1991, J INFECT DIS, V164, P656, DOI 10.1093/infdis/164.4.656; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P1051; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; Delaney KP, 2006, AIDS, V20, P1655, DOI 10.1097/01.aids.0000238412.75324.82; Gallo D, 1997, JAMA-J AM MED ASSOC, V277, P254, DOI 10.1001/jama.277.3.254; *GENPROBE INC, 2006, APT HIV 1 RNA QUAL A; Granade TC, 1998, CLIN DIAGN LAB IMMUN, V5, P171, DOI 10.1128/CDLI.5.2.171-175.1998; Jafa K, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000185; MacKellar D. A., 2006, Morbidity and Mortality Weekly Report, V55, P673; *OR TECHN INC, 2004, ORAQUICK ADV RAP HIV; SOTORAMIREZ LE, 1992, J CLIN MICROBIOL, V30, P2780; Stekler J, 2007, ANN INTERN MED, V147, P147, DOI 10.7326/0003-4819-147-2-200707170-00022; WESOLOWSKI LG, 2006, POSTMARKETING SURVEI, P1661; ORASURE HIV 1 W BLOT	19	4	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2008	3	2							e1524	10.1371/journal.pone.0001524	http://dx.doi.org/10.1371/journal.pone.0001524			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367EQ	18253478	Green Submitted, Green Published, gold			2022-12-25	WOS:000260535700002
J	Garofalo, M; Quintavalle, C; Di Leva, G; Zanca, C; Romano, G; Taccioli, C; Liu, CG; Croce, CM; Condorelli, G				Garofalo, M.; Quintavalle, C.; Di Leva, G.; Zanca, C.; Romano, G.; Taccioli, C.; Liu, C. G.; Croce, C. M.; Condorelli, G.			MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer	ONCOGENE			English	Article						microRNA; non-small cell lung cancer; apoptosis	CHRONIC LYMPHOCYTIC-LEUKEMIA; KINASE INHIBITOR P27(KIP1); PROTEIN EXPRESSION; INDUCED APOPTOSIS; KIT RECEPTOR; IN-VIVO; DEATH; GROWTH; P27; DIFFERENTIATION	To de. ne novel pathways that regulate susceptibility to tumor necrosis factor ( TNF)-related apoptosis-inducing ligand ( TRAIL) in non-small cell lung cancer (NSCLC), we have performed genome-wide expression pro. ling of microRNAs (miRs). We show that in TRAIL- resistant NSCLC cells, levels of different miRs are increased, and in particular, miR-221 and -222. We demonstrate that these miRs impair TRAIL- dependent apoptosis by inhibiting the expression of key functional proteins. Indeed, transfection with anti-miR-221 and -222 rendered CALU-1-resistant cells sensitive to TRAIL. Conversely, H460-sensitive cells treated with -221 and -222 pre-miRs become resistant to TRAIL. miR-221 and -222 target the 3'- UTR of Kit and p27(kip1) mRNAs, but interfere with TRAIL signaling mainly through p27kip1. In conclusion, we showthat high expression levels of miR-221 and -222 are needed to maintain the TRAIL- resistant phenotype, thus making these miRs as promising therapeutic targets or diagnostic tool for TRAIL resistance in NSCLC.	[Garofalo, M.; Quintavalle, C.; Zanca, C.; Romano, G.; Condorelli, G.] Univ Naples Federico 2, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; [Garofalo, M.; Quintavalle, C.; Zanca, C.; Romano, G.; Condorelli, G.] IEOS, CNR, Ist Endocrinol & Oncol Sperimentale, Naples, Italy; [Garofalo, M.; Di Leva, G.; Taccioli, C.; Liu, C. G.; Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Human Canc Genet Program, Columbus, OH 43210 USA; [Condorelli, G.] Univ Naples Federico 2, Fac Sci Biotecnol, I-80131 Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Naples Federico II	Condorelli, G (corresponding author), Univ Naples Federico 2, Dipartimento Biol & Patol Cellulare & Mol, Via Pansini 5, I-80131 Naples, Italy.	gecondor@unina.it	Taccioli, Cristian/F-8801-2010; Taccioli, Cristian/ABC-3379-2020; Young, Richard A/F-6495-2012; Condorelli, Gerolama/AAC-3472-2022	Taccioli, Cristian/0000-0003-2995-5612; Taccioli, Cristian/0000-0003-2995-5612; Young, Richard A/0000-0001-8855-8647; Condorelli, Gerolama/0000-0003-0177-8829; Di Leva, Gianpiero/0000-0001-6759-8682	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Blain SW, 2003, CANCER CELL, V3, P111, DOI 10.1016/S1535-6108(03)00026-6; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Corsten MF, 2007, CANCER RES, V67, P8994, DOI 10.1158/0008-5472.CAN-07-1045; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; Dresios J, 2005, P NATL ACAD SCI USA, V102, P1865, DOI 10.1073/pnas.0409764102; Eymin B, 1999, ONCOGENE, V18, P4839, DOI 10.1038/sj.onc.1202860; Falschlehner C, 2007, INT J BIOCHEM CELL B, V39, P1462, DOI 10.1016/j.biocel.2007.02.007; Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102; Fulda S, 2000, CANCER RES, V60, P3947; Galardi S, 2007, J BIOL CHEM, V282, P23716, DOI 10.1074/jbc.M701805200; Garofalo M, 2007, INT J CANCER, V120, P1215, DOI 10.1002/ijc.22495; Ghobrial IM, 2005, CA-CANCER J CLIN, V55, P178, DOI 10.3322/canjclin.55.3.178; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Katayose Y, 1997, CANCER RES, V57, P5441; Koschny R, 2007, J MOL MED, V85, P923, DOI 10.1007/s00109-007-0194-1; le Sage C, 2007, EMBO J, V26, P3699, DOI 10.1038/sj.emboj.7601790; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436; Ovcharenko D, 2007, CANCER RES, V67, P10782, DOI 10.1158/0008-5472.CAN-07-1484; Poliseno L, 2006, BLOOD, V108, P3068, DOI 10.1182/blood-2006-01-012369; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Schaefer U, 2007, FRONT BIOSCI, V12, P3813, DOI 10.2741/2354; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Smirnova L, 2005, EUR J NEUROSCI, V21, P1469, DOI 10.1111/j.1460-9568.2005.03978.x; StCroix B, 1996, NAT MED, V2, P1204; Tamborini E, 2004, CLIN CANCER RES, V10, P8214, DOI 10.1158/1078-0432.CCR-04-1013; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Woltman AM, 2003, BLOOD, V101, P1439, DOI 10.1182/blood-2002-06-1688; Xu PZ, 2003, CURR BIOL, V13, P790, DOI 10.1016/S0960-9822(03)00250-1; Xu PZ, 2004, TRENDS GENET, V20, P617, DOI 10.1016/j.tig.2004.09.010	39	222	260	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2008	27	27					3845	3855		10.1038/onc.2008.6	http://dx.doi.org/10.1038/onc.2008.6			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18246122	Green Published			2022-12-25	WOS:000256904700008
J	Luo, GZ; Gruhler, A; Liu, Y; Jensen, ON; Dickson, RC				Luo, Guangzuo; Gruhler, Albrecht; Liu, Ying; Jensen, Ole N.; Dickson, Robert C.			The sphingolipid long-chain base-Pkh1/2-Ypk1/2 signaling pathway regulates eisosome assembly and turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN PROTEINS SLM1; SACCHAROMYCES-CEREVISIAE; PKH-KINASES; YEAST; ENDOCYTOSIS; PHOSPHORYLATION; PHOSPHOPEPTIDES; IDENTIFICATION; DOWNSTREAM; EXTRACTION	Eisosomes are recently described fungal structures that play roles in the organization of the plasma membrane and endocytosis. Their major protein components are Pil1 and Lsp1, and previous studies showed that these proteins are phosphorylated by the sphingolipid long-chain base-activated Pkh1 and Pkh2 protein kinases in vitro. We show that Pkh1 and Pkh2 phosphorylate Pil1 and Lsp1 in vivo to produce species B, and that heat stress, which activates Pkh1 and Pkh2, generates a more highly phosphorylated species, C. Cells with low Pkh activity lack species B and C and contain abnormally organized eisosomes. To verify that Pil1 phosphorylation is essential for correct eisosome organization, phosphorylated serine and threonine residues were identified and changed to alanines. A variant Pil1 protein lacking five phosphorylation sites did not form eisosomes during log phase growth, indicating that phosphorylation is critical for eisosome organization. We also found that eisosomes are dynamic structures and disassemble when the Ypk protein kinases, which are activated by the sphingolipid-Pkh signaling pathway, are inactivated or when the sphingolipid signal is pharmacologically blocked with myriocin. We conclude that eisosome formation and turnover are regulated by the sphingolipid-Pkh1/2-Ypk1/2 signaling pathway. These data and previous data showing that endocytosis is regulated by the sphingolipid-Pkh1/2-Ypk1/2 signaling pathway suggest that Pkh1 and -2 respond to changes in membrane sphingolipids and transmit this information to eisosomes via Pil1 phosphorylation. Eisosomes then control endocytosis to align the composition and function of the plasma membrane to match demand.	[Luo, Guangzuo; Liu, Ying; Dickson, Robert C.] Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; [Gruhler, Albrecht; Jensen, Ole N.] Univ So Denmark, Protein Res Grp, Dept Biochem & Mol Biol, Odense, Denmark	University of Kentucky; University of Southern Denmark	Dickson, RC (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.	bobd@uky.edu	Jensen, Ole N/J-1763-2012	Jensen, Ole N/0000-0003-1862-8528; Luo, Guangzuo/0000-0002-8518-5766	NCRR NIH HHS [P20-RR020171] Funding Source: Medline; NIGMS NIH HHS [GM41302] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041302] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brachmann CB, 1998, YEAST, V14, P115; Bultynck G, 2006, MOL CELL BIOL, V26, P4729, DOI 10.1128/MCB.01973-05; Casamayor A, 1999, CURR BIOL, V9, P186, DOI 10.1016/S0960-9822(99)80088-8; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Daquinag A, 2007, MOL CELL BIOL, V27, P633, DOI 10.1128/MCB.00461-06; deHart AKA, 2002, J CELL BIOL, V156, P241, DOI 10.1083/jcb.200107135; Dickson RC, 2006, PROG LIPID RES, V45, P447, DOI 10.1016/j.plipres.2006.03.004; Fabrizio P, 2003, GENETICS, V163, P35; Fabrizio P, 2001, SCIENCE, V292, P288, DOI 10.1126/science.1059497; Fadri M, 2005, MOL BIOL CELL, V16, P1883, DOI 10.1091/mbc.e04-07-0564; Friant S, 2001, EMBO J, V20, P6783, DOI 10.1093/emboj/20.23.6783; Grossmann G, 2007, EMBO J, V26, P1, DOI 10.1038/sj.emboj.7601466; Gruhler A, 2005, MOL CELL PROTEOMICS, V4, P310, DOI 10.1074/mcp.M400219-MCP200; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; HUGHES TR, 2006, NATURE, V440, P637; Inagaki M, 1999, MOL CELL BIOL, V19, P8344; Ingrell CR, 2007, BIOINFORMATICS, V23, P895, DOI 10.1093/bioinformatics/btm020; Jelinsky SA, 2000, MOL CELL BIOL, V20, P8157, DOI 10.1128/MCB.20.21.8157-8167.2000; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; Kjellstrom S, 2004, ANAL CHEM, V76, P5109, DOI 10.1021/ac0400257; Krogan NJ, 2006, NATURE, V440, P637, DOI 10.1038/nature04670; Kushnirov VV, 2000, YEAST, V16, P857, DOI 10.1002/1097-0061(20000630)16:9<857::AID-YEA561>3.0.CO;2-B; Larsen MR, 2005, MOL CELL PROTEOMICS, V4, P873, DOI 10.1074/mcp.T500007-MCP200; Levin DE, 2005, MICROBIOL MOL BIOL R, V69, P262, DOI 10.1128/MMBR.69.2.262-291.2005; Liu K, 2005, J BIOL CHEM, V280, P22679, DOI 10.1074/jbc.M502972200; Mann M, 2003, NAT BIOTECHNOL, V21, P255, DOI 10.1038/nbt0303-255; Morandell S, 2006, PROTEOMICS, V6, P4047, DOI 10.1002/pmic.200600058; Neville DCA, 1997, PROTEIN SCI, V6, P2436; Pinkse MWH, 2004, ANAL CHEM, V76, P3935, DOI 10.1021/ac0498617; Powers RW, 2006, GENE DEV, V20, P174, DOI 10.1101/gad.1381406; Rappsilber J, 2003, ANAL CHEM, V75, P663, DOI 10.1021/ac026117i; Rep M, 2000, J BIOL CHEM, V275, P8290, DOI 10.1074/jbc.275.12.8290; Roelants FM, 2002, MOL BIOL CELL, V13, P3005, DOI 10.1091/mbc.E02-04-0201; Schmelzle T, 2002, MOL CELL BIOL, V22, P1329, DOI 10.1128/MCB.22.5.1329-1339.2002; SIKORSKI RS, 1989, GENETICS, V122, P19; Stensballe A, 2001, PROTEOMICS, V1, P207, DOI 10.1002/1615-9861(200102)1:2<207::AID-PROT207>3.3.CO;2-V; Tabuchi M, 2006, MOL CELL BIOL, V26, P5861, DOI 10.1128/MCB.02403-05; Walther TC, 2006, NATURE, V439, P998, DOI 10.1038/nature04472; Walther TC, 2007, EMBO J, V26, P4946, DOI 10.1038/sj.emboj.7601933; Yale J, 2001, J BIOL CHEM, V276, P15996, DOI 10.1074/jbc.M008209200; YU W, 1993, ANAL CHEM, V65, P3015, DOI 10.1021/ac00069a014; Zhang XP, 2004, J BIOL CHEM, V279, P22030, DOI 10.1074/jbc.M400299200	43	90	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10433	10444		10.1074/jbc.M709972200	http://dx.doi.org/10.1074/jbc.M709972200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18296441	Green Published, hybrid			2022-12-25	WOS:000254894700024
J	Goyon, V; Fronzes, R; Salin, B; Di-Rago, JP; Velours, J; Brethes, D				Goyon, Vanessa; Fronzes, Remi; Salin, Benedicte; Di-Rago, Jean-Paul; Velours, Jean; Brethes, Daniel			Yeast cells depleted in atp14p fail to assemble Atp6p within the ATP synthase and exhibit altered mitochondrial cristae morphology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SUBUNIT-H; PERIPHERAL STALK; F1FO-ATP SYNTHASE; GENE; COMPLEX; IDENTIFICATION; EXPRESSION; ROTATION; BIOGENESIS	Within the yeast mitochondrial ATP synthase, subunit h is a small nuclear encoded protein belonging to the so-called "peripheral stalk" that connects the enzyme catalytic F-1 component to the mitochondrial inner membrane. This study examines the role of subunit h in ATP synthase function and assembly using a regulatable, doxycycline-repressible subunit h gene to overcome the strong instability of the mtDNA previously observed in strains lacking the native subunit h gene. Yeast cells expressing less than 3% of subunit h, but still containing intact mitochondrial genomes, grew poorly on respiratory substrates because of a major impairment of ATP synthesis originating from the ATP synthase, whereas the respiratory chain complexes were not affected. The lack of ATP synthesis in the subunit h-depleted (delta h) mitochondria was attributed to defects in the assembly/stability of the ATP synthase. A main feature of delta h-mitochondria was a very low content (< 6%) in the mitochondrially encoded Atp6p subunit, an essential component of the enzyme proton channel, which was in large part because of a slowing down in translation. Interestingly, depletion of subunit h resulted in dramatic changes in mitochondrial cristae morphology, which further supports the existence of a link between the ATP synthase and the folding/biogenesis of the inner mitochondrial membrane.	[Goyon, Vanessa; Fronzes, Remi; Salin, Benedicte; Di-Rago, Jean-Paul; Velours, Jean; Brethes, Daniel] Univ Bordeaux 2, CNRS, Inst Biochim & Genet Cellulaires, UMR5095, F-33077 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Brethes, D (corresponding author), Univ Bordeaux 2, CNRS, Inst Biochim & Genet Cellulaires, UMR5095, 1 Rue Camille St Saens, F-33077 Bordeaux, France.	daniel.brethes@ibgc.u-bordeaux2.fr	Fronzes, Rémi/GLS-0406-2022; Fronzes, Remi/T-2578-2019; fronzes, Rémi/A-4311-2009	Fronzes, Remi/0000-0003-3031-9824				Ackerman SH, 2005, PROG NUCLEIC ACID RE, V80, P95, DOI 10.1016/S0079-6603(05)80003-0; ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; Ackerman SH, 2002, BBA-BIOENERGETICS, V1555, P101, DOI 10.1016/S0005-2728(02)00262-1; ALLEN RD, 1995, PROTOPLASMA, V189, P1, DOI 10.1007/BF01280286; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Arselin G, 2004, J BIOL CHEM, V279, P40392, DOI 10.1074/jbc.M404316200; Arselin G, 1996, J BIOL CHEM, V271, P20284, DOI 10.1074/jbc.271.34.20284; Barrientos A, 2004, EMBO J, V23, P3472, DOI 10.1038/sj.emboj.7600358; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Brunner S, 2002, J BIOL CHEM, V277, P48484, DOI 10.1074/jbc.M209382200; Chateaubodeau G A, 1976, Biochimie, V58, P601, DOI 10.1016/S0300-9084(76)80230-1; Dickson VK, 2006, EMBO J, V25, P2911, DOI 10.1038/sj.emboj.7601177; Drapier D, 2007, EMBO J, V26, P3581, DOI 10.1038/sj.emboj.7601802; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Duvezin-Caubet S, 2003, P NATL ACAD SCI USA, V100, P13235, DOI 10.1073/pnas.2135169100; EGNER R, 1995, MOL CELL BIOL, V15, P5879; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; Fronzes R, 2003, BIOCHEMISTRY-US, V42, P12038, DOI 10.1021/bi035270j; Fronzes R, 2006, BIOCHEMISTRY-US, V45, P6715, DOI 10.1021/bi0601407; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GrandierVazeille X, 1996, ANAL BIOCHEM, V242, P248, DOI 10.1006/abio.1996.0460; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; HADIKUSUMO RG, 1988, BIOCHIM BIOPHYS ACTA, V933, P212, DOI 10.1016/0005-2728(88)90072-2; Helfenbein KG, 2003, J BIOL CHEM, V278, P19751, DOI 10.1074/jbc.M301679200; Kun E, 1979, Methods Enzymol, V55, P115; Law RHP, 1995, METHOD ENZYMOL, V260, P133, DOI 10.1016/0076-6879(95)60135-X; Lefebvre-Legendre L, 2005, J BIOL CHEM, V280, P18386, DOI 10.1074/jbc.M410789200; Lefebvre-Legendre L, 2001, J BIOL CHEM, V276, P6789, DOI 10.1074/jbc.M009557200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; ORIAN JM, 1984, J BIOENERG BIOMEMBR, V16, P561, DOI 10.1007/BF00743246; Osman C, 2007, MOL BIOL CELL, V18, P627, DOI 10.1091/mbc.E06-09-0839; PAUL MF, 1989, EUR J BIOCHEM, V185, P163, DOI 10.1111/j.1432-1033.1989.tb15098.x; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; Rak M, 2007, J BIOL CHEM, V282, P10853, DOI 10.1074/jbc.M608692200; RIGOULET M, 1979, FEBS LETT, V102, P18, DOI 10.1016/0014-5793(79)80919-9; Rubinstein JL, 2005, J MOL BIOL, V345, P513, DOI 10.1016/j.jmb.2004.10.060; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P379; Silvester JA, 2006, ACTA CRYSTALLOGR F, V62, P530, DOI 10.1107/S1744309106015338; SOMLO M, 1968, EUR J BIOCHEM, V5, P276, DOI 10.1111/j.1432-1033.1968.tb00368.x; Soubannier V, 1999, BIOCHEMISTRY-US, V38, P15017, DOI 10.1021/bi9916067; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Tzagoloff A, 2004, J BIOL CHEM, V279, P19775, DOI 10.1074/jbc.M401506200; Velours J, 2001, J BIOL CHEM, V276, P8602, DOI 10.1074/jbc.M008123200; Velours J, 2000, J BIOENERG BIOMEMBR, V32, P383, DOI 10.1023/A:1005580020547; Venard R, 2003, BIOCHEMISTRY-US, V42, P7626, DOI 10.1021/bi034394t; Wittig I, 2005, PROTEOMICS, V5, P4338, DOI 10.1002/pmic.200500081; Zeng XM, 2007, GENETICS, V175, P55, DOI 10.1534/genetics.106.065821; Zeng XM, 2007, MOL BIOL CELL, V18, P617, DOI 10.1091/mbc.E06-09-0801; Zhou YT, 1996, BBA-BIOENERGETICS, V1275, P96, DOI 10.1016/0005-2728(96)00056-4	53	16	16	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9749	9758		10.1074/jbc.M800204200	http://dx.doi.org/10.1074/jbc.M800204200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18252710	hybrid, Green Published			2022-12-25	WOS:000254671600029
J	Gupta, MP; Samant, SA; Smith, SH; Shroff, SG				Gupta, Mahesh P.; Samant, Sadhana A.; Smith, Stephen H.; Shroff, Sanjeev G.			HDAC4 and PCAF bind to cardiac sarcomeres and play a role in regulating myofilament contractile activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II HISTONE DEACETYLASES; ACTIN CAPPING PROTEIN; TROPONIN-I; DILATED CARDIOMYOPATHY; LENGTH-DEPENDENCE; MUSCLE; PHOSPHORYLATION; ACETYLATION; HYPERTROPHY; TITIN	Reversible acetylation of lysine residues within a protein is considered a biologically relevant modification that rivals phosphorylation (Kouzarides, T. (2000) EMBO J. 19, 1176-1179). The enzymes responsible for such protein modification are called histone acetyltransferases (HATs) and deacetylases (HDACs). A role of protein phosphorylation in regulating muscle contraction is well established (Solaro, R. J., Moir, A. J., and Perry, S. V. (1976) Nature 262, 615 - 617). Here we show that reversible protein acetylation carried out by HATs and HDACs also plays a role in regulating the myofilament contractile activity. We found that a Class II HDAC, HDAC4, and an HAT, PCAF, associate with cardiac myofilaments. Primary cultures of cardiomyocytes as well as mouse heart sections examined by immunohistochemical and electron microscopic analyses revealed that both HDAC4 and PCAF associate with the Z-disc and I- and A-bands of cardiac sacromeres. Increased acetylation of sarcomeric proteins by HDAC inhibition (using class I and II HDAC inhibitors or anti-HDAC4 antibody) enhanced the myofilament calcium sensitivity. We identified the Z-disc-associated protein, MLP, a sensor of cardiac mechanical stretch, as an acetylated target of PCAF and HDAC4. We also show that trichostatin-A, a class I and II HDAC inhibitor, increases myofilament calcium sensitivity of wild- type, but not of MLP knock-out mice, thus demonstrating a role of MLP in acetylation-dependent increased contractile activity of myofilaments. These studies provide the first evidence that HATs and HDACs play a role in regulation of muscle contraction.	[Gupta, Mahesh P.; Samant, Sadhana A.] Univ Chicago, Dept Surg, Div Biol Sci, Committee Mol Med, Chicago, IL 60637 USA; [Smith, Stephen H.; Shroff, Sanjeev G.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15261 USA	University of Chicago; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Gupta, MP (corresponding author), 5841 S Maryland Ave, Chicago, IL 60637 USA.	mgupta@surgery.bsd.uchicago.edu			NHLBI NIH HHS [HL 77788, HL 83423, R01 HL 68083] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077788, R01HL068083, R01HL083423] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bakin RE, 2004, J BIOL CHEM, V279, P51218, DOI 10.1074/jbc.M409271200; Basile V, 2006, J BIOL CHEM, V281, P2347, DOI 10.1074/jbc.M507712200; Bertos NR, 2004, J BIOL CHEM, V279, P48246, DOI 10.1074/jbc.M408583200; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; Clark KA, 2002, ANNU REV CELL DEV BI, V18, P637, DOI 10.1146/annurev.cellbio.18.012502.105840; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Davis FJ, 2003, J BIOL CHEM, V278, P20047, DOI 10.1074/jbc.M209998200; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Fischle W, 2001, BIOCHEM CELL BIOL, V79, P337, DOI 10.1139/bcb-79-3-337; Flick MJ, 2000, J CELL SCI, V113, P1553; Fukuda N, 2005, PFLUG ARCH EUR J PHY, V449, P449, DOI 10.1007/s00424-004-1354-6; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Granzier H, 2007, MUSCLE NERVE, V36, P740, DOI 10.1002/mus.20886; Gupta MP, 1997, MOL CELL BIOL, V17, P3924, DOI 10.1128/MCB.17.7.3924; HARRISON SM, 1988, J PHYSIOL-LONDON, V401, P115, DOI 10.1113/jphysiol.1988.sp017154; Hoshijima M, 2006, AM J PHYSIOL-HEART C, V290, pH1313, DOI 10.1152/ajpheart.00816.2005; Kajiwara H, 2000, BIOCHEM BIOPH RES CO, V272, P104, DOI 10.1006/bbrc.2000.2741; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Knoll R, 2002, CELL, V111, P943, DOI 10.1016/s0092-8674(02)01226-6; Kong YL, 2006, CIRCULATION, V113, P2579, DOI 10.1161/CIRCULATIONAHA.106.625467; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Lahm A, 2007, P NATL ACAD SCI USA, V104, P17335, DOI 10.1073/pnas.0706487104; Layland J, 2005, CARDIOVASC RES, V66, P12, DOI 10.1016/j.cardiores.2004.12.022; Little GH, 2007, J BIOL CHEM, V282, P7219, DOI 10.1074/jbc.M604281200; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Mitcheson JS, 1998, CARDIOVASC RES, V39, P280, DOI 10.1016/S0008-6363(98)00128-X; Mohapatra B, 2003, MOL GENET METAB, V80, P207, DOI 10.1016/S1096-7192(03)00142-2; Pyle WG, 2006, J MOL CELL CARDIOL, V41, P537, DOI 10.1016/j.yjmcc.2006.06.006; Pyle WG, 2002, CIRC RES, V90, P1299, DOI 10.1161/01.RES.0000024389.03152.22; SOLARO RJ, 1976, NATURE, V262, P615, DOI 10.1038/262615a0; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Yang WM, 2002, J BIOL CHEM, V277, P9447, DOI 10.1074/jbc.M105993200; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P14329, DOI 10.1073/pnas.250494697	37	123	129	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					10135	10146		10.1074/jbc.M710277200	http://dx.doi.org/10.1074/jbc.M710277200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18250163	hybrid, Green Published			2022-12-25	WOS:000254671600067
J	Sahin, A; Espiau, B; Tetaud, E; Cuvillier, A; Lartigue, L; Ambit, A; Robinson, DR; Merlin, G				Sahin, Annelise; Espiau, Benoit; Tetaud, Emmanuel; Cuvillier, Armelle; Lartigue, Lydia; Ambit, Audrey; Robinson, Derrick R.; Merlin, Gilles			The Leishmania ARL-1 and Golgi Traffic	PLOS ONE			English	Article								We present here the characterisation of the Leishmania small G protein ADP-Ribosylation Factor-Like protein 1 (ARL-1). The ARL-1 gene is present in one copy per haploid genome and conserved among trypanosomatids. It encodes a protein of 20 kDa, which is equally expressed in the insect promastigote and mammalian amastigote forms of the parasite. ARL-1 localises to the Trans-Golgi Network (TGN); N-terminal myristoylation is essential for TGN localisation. In vivo expression of the LdARL-1/Q74L and LdARL-1/T51N mutants (GTP- and GDP-bound blocked forms respectively) shows that GDP/GTP cycling occurs entirely within the TGN. This is contrary to previous reports in yeast and mammals, where the mutant empty form devoid of nucleotide has been considered as the GDP-blocked form. The dominant-negative empty form mutant LdARL-1/T34N inhibits endocytosis and intracellular trafficking from the TGN to the Lysosome/Multivesicular Tubule and to the acidocalcisomes; these defects are probably related to a mislocalisation of the GRIP domain-containing vesicle tethering factors which cannot be recruited to the TGN by the cytoplasmic LdARL-1/T34N. Thus, besides the functional characterization of a new mutant and a better understanding of ARL-1 GDP/GTP cycling, this work shows that Leishmania ARL-1 is a key component of an essential pathway worth future study.	[Sahin, Annelise; Espiau, Benoit; Tetaud, Emmanuel; Cuvillier, Armelle; Lartigue, Lydia; Ambit, Audrey; Robinson, Derrick R.; Merlin, Gilles] Univ Bordeaux 2, UMR CNRS 5234, Lab Microbiol Cell Mol Pathogen, Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Sahin, A (corresponding author), Univ Bordeaux 2, UMR CNRS 5234, Lab Microbiol Cell Mol Pathogen, Bordeaux, France.	merlin@u-bordeaux2.fr	lartigue, lydia/I-9548-2014		CNRS; Universite Bordeaux2; Region Aquitaine; Ministere de lEducation Nationale, de la Recherche et de la Technologie [fellowship]	CNRS(Centre National de la Recherche Scientifique (CNRS)); Universite Bordeaux2; Region Aquitaine(Region Nouvelle-Aquitaine); Ministere de lEducation Nationale, de la Recherche et de la Technologie	The work was funded by CNRS, Universite Bordeaux2 and Region Aquitaine. A. Cuvillier and A. Sahin were recipients of fellowships of the Ministere de lEducation Nationale, de la Recherche et de la Technologie.	Abudugupur A, 2002, CELL DEATH DIFFER, V9, P158, DOI 10.1038/sj.cdd.4400942; Allen CL, 2003, EMBO J, V22, P4991, DOI 10.1093/emboj/cdg481; Amor JC, 2001, J BIOL CHEM, V276, P42477, DOI 10.1074/jbc.M106660200; Bakalara N, 1995, EXP PARASITOL, V81, P302, DOI 10.1006/expr.1995.1121; Barr FA, 2003, CURR OPIN CELL BIOL, V15, P405, DOI 10.1016/S0955-0674(03)00054-1; Berriman M, 2005, SCIENCE, V309, P416, DOI 10.1126/science.1112642; Boutin JA, 1997, CELL SIGNAL, V9, P15, DOI 10.1016/S0898-6568(96)00100-3; Bringaud F, 2007, PLOS PATHOG, V3, P1291, DOI 10.1371/journal.ppat.0030136; Briones MRS, 1999, MOL BIOCHEM PARASIT, V104, P219, DOI 10.1016/S0166-6851(99)00155-3; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Cuvillier A, 2000, J CELL SCI, V113, P2065; D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910; DELAFAILLE MAC, 1992, P NATL ACAD SCI USA, V89, P2703, DOI 10.1073/pnas.89.7.2703; Ding M, 1996, J BIOL CHEM, V271, P24005, DOI 10.1074/jbc.271.39.24005; Docampo R, 2005, NAT REV MICROBIOL, V3, P251, DOI 10.1038/nrmicro1097; El-Sayed NM, 2005, SCIENCE, V309, P409, DOI 10.1126/science.1112631; Espiau B, 2006, J BIOL CHEM, V281, P1516, DOI 10.1074/jbc.M506947200; Gleeson PA, 2004, TRAFFIC, V5, P315, DOI 10.1111/j.1398-9219.2004.00182.x; Graham TR, 2004, CURR BIOL, V14, pR483, DOI 10.1016/j.cub.2004.06.017; Haynes LP, 2005, J BIOL CHEM, V280, P6047, DOI 10.1074/jbc.M413090200; Honda A, 2005, J CELL BIOL, V168, P1039, DOI 10.1083/jcb.200409138; Hong JX, 1998, J BIOL CHEM, V273, P15872, DOI 10.1074/jbc.273.25.15872; Howell GJ, 2006, INT REV CYTOL, V252, P1, DOI 10.1016/S0074-7696(06)52005-4; Ilgoutz SC, 1999, EMBO J, V18, P2746, DOI 10.1093/emboj/18.10.2746; Ilgoutz SC, 1999, EMBO J, V18, P3643, DOI 10.1093/emboj/18.13.3643; Ivens AC, 2005, SCIENCE, V309, P436, DOI 10.1126/science.1112680; Jackson CL, 2003, CURR BIOL, V13, pR174, DOI 10.1016/S0960-9822(03)00116-7; Jochum A, 2002, MOL CELL BIOL, V22, P4914, DOI 10.1128/MCB.22.13.4914-4928.2002; Kahn RA, 2006, J CELL BIOL, V172, P645, DOI 10.1083/jcb.200512057; KELLY JM, 1992, NUCLEIC ACIDS RES, V20, P3963, DOI 10.1093/nar/20.15.3963; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; Kjer-Nielsen L, 1999, J CELL SCI, V112, P1645; Klein S, 2006, J BIOL CHEM, V281, P12352, DOI 10.1074/jbc.M601021200; LAKE JA, 1988, P NATL ACAD SCI USA, V85, P4779, DOI 10.1073/pnas.85.13.4779; Lee FJS, 1997, J BIOL CHEM, V272, P30998, DOI 10.1074/jbc.272.49.30998; Lemercier G, 2002, J BIOL CHEM, V277, P37369, DOI 10.1074/jbc.M204744200; Li YW, 2004, FASEB J, V18, P1834, DOI 10.1096/fj.04-2273com; Liu YW, 2005, MOL BIOL CELL, V16, P4024, DOI 10.1091/mbc.E05-01-0023; LODES MJ, 1995, MOL CELL BIOL, V15, P6845; Lowe SL, 1996, J CELL SCI, V109, P209; Lu L, 2003, MOL BIOL CELL, V14, P3767, DOI 10.1091/mbc.E03-01-0864; Lu L, 2001, J CELL SCI, V114, P4543; Ma DQ, 1997, J BIOL CHEM, V272, P3799, DOI 10.1074/jbc.272.6.3799; Macia E, 2004, J CELL SCI, V117, P2389, DOI 10.1242/jcs.01090; McConville MJ, 2002, EUR J CELL BIOL, V81, P485, DOI 10.1078/0171-9335-00268; Morgan GW, 2001, J CELL SCI, V114, P2605; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Mullin KA, 2001, MOL BIOL CELL, V12, P2364, DOI 10.1091/mbc.12.8.2364; Munro S, 2005, BIOCHEM SOC T, V33, P601, DOI 10.1042/BST0330601; Nie ZZ, 2003, CURR OPIN CELL BIOL, V15, P396, DOI 10.1016/S0955-0674(03)00071-1; Overath P, 2004, MOL MICROBIOL, V53, P735, DOI 10.1111/j.1365-2958.2004.04224.x; Panic B, 2003, MOL CELL, V12, P863, DOI 10.1016/S1097-2765(03)00356-3; Panic B, 2003, CURR BIOL, V13, P405, DOI 10.1016/S0960-9822(03)00091-5; Pasqualato S, 2002, EMBO REP, V3, P1035, DOI 10.1093/embo-reports/kvf221; Peacock CS, 2007, NAT GENET, V39, P839, DOI 10.1038/ng2053; Porter-Kelley JM, 2004, TRAFFIC, V5, P868, DOI 10.1111/j.1600-0854.2004.00229.x; Price HP, 2007, MOL BIOCHEM PARASIT, V155, P123, DOI 10.1016/j.molbiopara.2007.06.009; Price HP, 2007, MOL BIOL CELL, V18, P864, DOI 10.1091/mbc.E06-08-0736; Price HP, 2005, J CELL SCI, V118, P831, DOI 10.1242/jcs.01624; Price HP, 2003, J BIOL CHEM, V278, P7206, DOI 10.1074/jbc.M211391200; Prina E, 1996, J IMMUNOL, V156, P4318; ROBINSON DR, 1994, J CELL BIOL, V126, P641, DOI 10.1083/jcb.126.3.641; Rosenwald AG, 2002, YEAST, V19, P1039, DOI 10.1002/yea.897; Sahin A, 2005, J CHROMATOGR B, V818, P19, DOI 10.1016/j.jchromb.2004.10.022; Sahin A, 2008, MOL BIOCHEM PARASIT, V157, P83, DOI 10.1016/j.molbiopara.2007.08.003; SCHURMANN A, 1994, J BIOL CHEM, V269, P15683; Setty SRG, 2004, NAT CELL BIOL, V6, P414, DOI 10.1038/ncb1121; Setty SRG, 2003, CURR BIOL, V13, P401, DOI 10.1016/S0960-9822(03)00089-7; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; Tetaud E, 2002, MOL BIOCHEM PARASIT, V120, P195, DOI 10.1016/S0166-6851(02)00002-6; Van Valkenburgh H, 2001, J BIOL CHEM, V276, P22826, DOI 10.1074/jbc.M102359200; Vaughan M, 1997, ADV EXP MED BIOL, V419, P315; Vichi A, 2005, P NATL ACAD SCI USA, V102, P1945, DOI 10.1073/pnas.0409800102; Waller RF, 2002, INT J PARASITOL, V32, P1435, DOI 10.1016/S0020-7519(02)00140-6; Wu MS, 2004, NAT STRUCT MOL BIOL, V11, P86, DOI 10.1038/nsmb714	75	26	26	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2008	3	2							e1620	10.1371/journal.pone.0001620	http://dx.doi.org/10.1371/journal.pone.0001620			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XR	18286177	gold, Green Published, Green Submitted			2022-12-25	WOS:000260586400013
J	Ibrahim, B; Diekmann, S; Schmitt, E; Dittrich, P				Ibrahim, Bashar; Diekmann, Stephan; Schmitt, Eberhard; Dittrich, Peter			In-Silico Modeling of the Mitotic Spindle Assembly Checkpoint	PLOS ONE			English	Article							ANAPHASE-PROMOTING COMPLEX; HUMAN MPS1 KINASE; KINETOCHORE LOCALIZATION; PROTEIN BUBR1; AURORA-B; CHROMOSOME MISSEGREGATION; MAD2 ACTIVATION; MOTOR PROTEINS; CDC20; INHIBITION	Background: The Mitotic Spindle Assembly Checkpoint ( M SAC) is an evolutionary conserved mechanism that ensures the correct segregation of chromosomes by restraining cell cycle progression from entering anaphase until all chromosomes have made proper bipolar attachments to the mitotic spindle. Its malfunction can lead to cancer. Principle Findings: We have constructed and validated for the human M SAC mechanism an in silico dynamical model, integrating 11 proteins and complexes. The model incorporates the perspectives of three central control pathways, namely Mad1/Mad2 induced Cdc20 sequestering based on the Template Model, MCC formation, and APC inhibition. Originating from the biochemical reactions for the underlying molecular processes, non-linear ordinary differential equations for the concentrations of 11 proteins and complexes of the M SAC are derived. Most of the kinetic constants are taken from literature, the remaining four unknown parameters are derived by an evolutionary optimization procedure for an objective function describing the dynamics of the APC: Cdc20 complex. MCC: APC dissociation is described by two alternatives, namely the "Dissociation'' and the "Convey'' model variants. The attachment of the kinetochore to microtubuli is simulated by a switching parameter silencing those reactions which are stopped by the attachment. For both, the Dissociation and the Convey variants, we compare two different scenarios concerning the microtubule attachment dependent control of the dissociation reaction. Our model is validated by simulation of ten perturbation experiments. Conclusion: Only in the controlled case, our models show M SAC behaviour at meta-to anaphase transition in agreement with experimental observations. Our simulations revealed that for M SAC activation, Cdc20 is not fully sequestered; instead APC is inhibited by MCC binding.	[Ibrahim, Bashar; Dittrich, Peter] Univ Jena, Bio Syst Anal Grp, Inst Comp Sci, Jena, Germany; [Ibrahim, Bashar; Dittrich, Peter] JCB, Jena, Germany; [Diekmann, Stephan; Schmitt, Eberhard] FLI, Leibniz Inst Age Res, Jena, Germany	Friedrich Schiller University of Jena; Friedrich Loeffler Institute; Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI)	Ibrahim, B (corresponding author), Univ Jena, Bio Syst Anal Grp, Inst Comp Sci, Jena, Germany.	dittrich@minet.uni-jena.de	Ibrahim, Bashar/A-6926-2011; Ibrahim, Bashar/R-7112-2016	Ibrahim, Bashar/0000-0001-7773-0122	DAAD, German Academic Exchange Service [A/04/31166]; DFG, German Research Foundation [Di 852/4-x]; BMBF, Federal Ministry of Education and Research of Germany [0312704A]; EU, ESIGNET [12789]	DAAD, German Academic Exchange Service(Deutscher Akademischer Austausch Dienst (DAAD)); DFG, German Research Foundation(German Research Foundation (DFG)); BMBF, Federal Ministry of Education and Research of Germany(Federal Ministry of Education & Research (BMBF)); EU, ESIGNET	We acknowledge funding by the DAAD (German Academic Exchange Service, grant A/04/31166) the DFG (German Research Foundation, grant Di 852/4-x), the BMBF (Federal Ministry of Education and Research of Germany, grant 0312704A), and the EU (ESIGNET, grant 12789).	Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Acquaviva C, 2004, NAT CELL BIOL, V6, P892, DOI 10.1038/ncb1167; Baker DJ, 2004, NAT GENET, V36, P744, DOI 10.1038/ng1382; Basu J, 1999, J CELL BIOL, V146, P13, DOI 10.1083/jcb.146.1.13; Biggins S, 2001, GENE DEV, V15, P3118, DOI 10.1101/gad.934801; Bolanos-Garcia VM, 2005, BIOPHYS J, V89, P2640, DOI 10.1529/biophysj.105.063511; Boronat S, 2007, MOL CELL BIOL, V27, P1158, DOI 10.1128/MCB.01745-05; Burton JL, 2007, GENE DEV, V21, P655, DOI 10.1101/gad.1511107; Chan GK, 2005, TRENDS CELL BIOL, V15, P589, DOI 10.1016/j.tcb.2005.09.010; Chang L, 2001, MOL CELL BIOL, V21, P6681, DOI 10.1128/MCB.21.19.6681-6694.2001; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; Chen KC, 2004, MOL BIOL CELL, V15, P3841, DOI 10.1091/mbc.E03-11-0794; Chen RH, 1999, MOL BIOL CELL, V10, P2607, DOI 10.1091/mbc.10.8.2607; Chen RH, 2002, J CELL BIOL, V158, P487, DOI 10.1083/jcb.200204048; Chung EN, 2003, NAT CELL BIOL, V5, P748, DOI 10.1038/ncb1022; Ciliberto A, 2005, CELL CYCLE, V4, P1107; Compton DA, 2006, NAT CELL BIOL, V8, P308, DOI 10.1038/ncb0406-308; D'Angiolella V, 2003, GENE DEV, V17, P2520, DOI 10.1101/gad.267603; Davenport J, 2006, EXP CELL RES, V312, P1831, DOI 10.1016/j.yexcr.2006.02.018; De Antoni A, 2005, CURR BIOL, V15, P214, DOI 10.1016/j.cub.2005.01.038; DeAntoni A, 2005, PHILOS T R SOC B, V360, P637, DOI 10.1098/rstb.2004.1618; DEANTONI A, 2005, PHILOS T R SOC LON B, V360, P447; Diaz-Martinez LA, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-23; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Doncic A, 2005, P NATL ACAD SCI USA, V102, P6332, DOI 10.1073/pnas.0409142102; Dorer RK, 2005, CURR BIOL, V15, P1070, DOI 10.1016/j.cub.2005.05.020; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fisk HA, 2004, CURR BIOL, V14, pR1058, DOI 10.1016/j.cub.2004.11.047; Fisk HA, 2004, CELL CYCLE, V3, P439; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Fraschini R, 2001, EMBO J, V20, P6648, DOI 10.1093/emboj/20.23.6648; Griffis ER, 2007, J CELL BIOL, V177, P1005, DOI 10.1083/jcb.200702062; Gupta A, 2003, ONCOGENE, V22, P7593, DOI 10.1038/sj.onc.1206880; Habu T, 2002, EMBO J, V21, P6419, DOI 10.1093/emboj/cdf659; Hagan RS, 2005, NATURE, V434, P575, DOI 10.1038/434575a; Hanks S, 2004, NAT GENET, V36, P1159, DOI 10.1038/ng1449; Hansen N, 2004, LECT NOTES COMPUT SC, V3242, P282; Hansen N, 2003, EVOL COMPUT, V11, P1, DOI 10.1162/106365603321828970; Hardwick KC, 2000, J CELL BIOL, V148, P871, DOI 10.1083/jcb.148.5.871; Hardwick KG, 2005, CURR BIOL, V15, pR122, DOI 10.1016/j.cub.2005.02.008; HARDWICK KG, 1995, J CELL BIOL, V131, P709, DOI 10.1083/jcb.131.3.709; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; He XW, 1997, P NATL ACAD SCI USA, V94, P7965, DOI 10.1073/pnas.94.15.7965; Heald R, 2006, SCIENCE, V311, P343, DOI 10.1126/science.1123525; Hoffman DB, 2001, MOL BIOL CELL, V12, P1995, DOI 10.1091/mbc.12.7.1995; Howell BJ, 2000, J CELL BIOL, V150, P1233, DOI 10.1083/jcb.150.6.1233; Howell BJ, 2001, J CELL BIOL, V155, P1159, DOI 10.1083/jcb.200105093; Howell BJ, 2004, CURR BIOL, V14, P953, DOI 10.1016/j.cub.2004.05.053; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; IBRAHIM B, 2007, BIOPHYS CHEM UNPUB; IBRAHIM B, 2007, MCC ASSEMBLY I UNPUB; Ibrahim B, 2007, J INTEGR BIOINFORMAT, V4; Iwanaga Y, 2002, J BIOL CHEM, V277, P31005, DOI 10.1074/jbc.M110666200; Iwanaga Y, 2007, CANCER RES, V67, P160, DOI 10.1158/0008-5472.CAN-06-3326; Kalitsis P, 2000, GENE DEV, V14, P2277, DOI 10.1101/gad.827500; Kallio MJ, 2002, CURR BIOL, V12, P900, DOI 10.1016/S0960-9822(02)00887-4; Kallio MJ, 2002, J CELL BIOL, V158, P841, DOI 10.1083/jcb.200201135; Kienitz A, 2005, ONCOGENE, V24, P4301, DOI 10.1038/sj.onc.1208589; Kim M, 2005, CANCER BIOL THER, V4, P164; King EMJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000342; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Lampson MA, 2004, NAT CELL BIOL, V6, P232, DOI 10.1038/ncb1102; Larsen NA, 2007, P NATL ACAD SCI USA, V104, P1201, DOI 10.1073/pnas.0610358104; Lee MS, 2004, P NATL ACAD SCI USA, V101, P10655, DOI 10.1073/pnas.0404102101; Lenart P, 2006, CURR BIOL, V16, pR412, DOI 10.1016/j.cub.2006.05.008; Liu ST, 2003, MOL BIOL CELL, V14, P1638, DOI 10.1091/mbc.02-05-0074; Luo XL, 2004, NAT STRUCT MOL BIOL, V11, P338, DOI 10.1038/nsmb748; Luo XL, 2000, NAT STRUCT BIOL, V7, P224; Mapelli M, 2006, EMBO J, V25, P1273, DOI 10.1038/sj.emboj.7601033; Michel L, 2004, P NATL ACAD SCI USA, V101, P4459, DOI 10.1073/pnas.0306069101; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Millband DN, 2002, MOL CELL BIOL, V22, P2728, DOI 10.1128/MCB.22.8.2728-2742.2002; Mondal G, 2007, CARCINOGENESIS, V28, P81, DOI 10.1093/carcin/bgl100; Mondal Gourish, 2003, International Journal of Human Genetics, V3, P89; Morrow CJ, 2005, J CELL SCI, V118, P3639, DOI 10.1242/jcs.02487; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Nasmyth K, 2005, CELL, V120, P739, DOI 10.1016/j.cell.2005.03.006; Nezi L, 2006, J CELL BIOL, V174, P39, DOI 10.1083/jcb.200602109; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; Palframan WJ, 2006, SCIENCE, V313, P680, DOI 10.1126/science.1127205; Passmore LA, 2004, BIOCHEM SOC T, V32, P724, DOI 10.1042/BST0320724; Pinsky BA, 2005, TRENDS CELL BIOL, V15, P486, DOI 10.1016/j.tcb.2005.07.005; Poddar A, 2005, EUKARYOT CELL, V4, P867, DOI 10.1128/EC.4.5.867-878.2005; Reddy SK, 2007, NATURE, V446, P921, DOI 10.1038/nature05734; Schmidt M, 2006, CELL CYCLE, V5, P159, DOI 10.4161/cc.5.2.2309; Sear RP, 2006, P NATL ACAD SCI USA, V103, P16758, DOI 10.1073/pnas.0603174103; Shah JV, 2004, CURR BIOL, V14, P942, DOI 10.1016/j.cub.2004.05.046; Shannon KB, 2002, MOL BIOL CELL, V13, P3706, DOI 10.1091/mbc.E02-03-0137; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; Sironi L, 2001, EMBO J, V20, P6371, DOI 10.1093/emboj/20.22.6371; Stegmeier F, 2007, NATURE, V446, P876, DOI 10.1038/nature05694; Steuerwald N, 2005, CYTOGENET GENOME RES, V111, P256, DOI 10.1159/000086897; Stucke VM, 2004, CHROMOSOMA, V113, P1, DOI 10.1007/s00412-004-0288-2; Stucke VM, 2002, EMBO J, V21, P1723, DOI 10.1093/emboj/21.7.1723; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Tanaka TU, 2002, CELL, V108, P317, DOI 10.1016/S0092-8674(02)00633-5; Tang ZY, 2004, MOL CELL, V16, P387, DOI 10.1016/j.molcel.2004.09.031; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Taylor SS, 2004, CHROMOSOME RES, V12, P599, DOI 10.1023/B:CHRO.0000036610.78380.51; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; Vigneron S, 2004, MOL BIOL CELL, V15, P4584, DOI 10.1091/mbc.E04-01-0051; Vink M, 2006, CURR BIOL, V16, P755, DOI 10.1016/j.cub.2006.03.057; Wang Q, 2004, BLOOD, V103, P1278, DOI 10.1182/blood-2003-06-2158; Weaver BAA, 2005, CANCER CELL, V8, P7, DOI 10.1016/j.ccr.2005.06.011; Xia GH, 2004, EMBO J, V23, P3133, DOI 10.1038/sj.emboj.7600322; Yang MJ, 2007, CELL, V131, P744, DOI 10.1016/j.cell.2007.08.048; Yu H, 2007, MOL CELL, V27, P3, DOI 10.1016/j.molcel.2007.06.009; Zhang YK, 2001, MOL CELL BIOL, V21, P5190, DOI 10.1128/MCB.21.15.5190-5199.2001; Zhu CJ, 2005, MOL BIOL CELL, V16, P3187, DOI 10.1091/mbc.E05-02-0167	113	36	36	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2008	3	2							e1555	10.1371/journal.pone.0001555	http://dx.doi.org/10.1371/journal.pone.0001555			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367EQ	18253502	Green Published, Green Submitted, gold			2022-12-25	WOS:000260535700026
J	Coussens, M; Maresh, JG; Yanagimachi, R; Maeda, G; Allsopp, R				Coussens, Matthew; Maresh, John G.; Yanagimachi, Ryuzo; Maeda, Gregg; Allsopp, Richard			Sirt1 Deficiency Attenuates Spermatogenesis and Germ Cell Function	PLOS ONE			English	Article								In mammals, Sirt1, a member of the sirtuin family of proteins, functions as a nicotinamide adenine dinucleotide-dependent protein deactylase, and has important physiological roles, including the regulation of glucose metabolism, cell survival, and mitochondrial respiration. The initial investigations of Sirt1 deficient mice have revealed a phenotype that includes a reduced lifespan, small size, and an increased frequency of abnormal sperm. We have now performed a detailed analysis of the molecular and functional effects of Sirt1 deficiency in the germ line of Sirt1 knock-out (-/-) mice. We find that Sirt1 deficiency markedly attenuates spermatogenesis, but not oogenesis. Numbers of mature sperm and spermatogenic precursors, as early as d15.5 of development, are significantly reduced (similar to 2-10-fold less; P <= 0.004) in numbers in Sirt1-/- mice, whereas Sirt1 deficiency did not effect the efficiency oocyte production following superovulation of female mice. Furthermore, the proportion of mature sperm with elevated DNA damage (similar to 7.5% of total epididymal sperm; P = 0.02) was significantly increased in adult Sirt1-/- males. Analysis of global gene expression by microarray analysis in Sirt1 deficient testis revealed dysregulated expression of 85 genes, which were enriched (P < 0.05) for genes involved in spermatogenesis and protein sumoylation. To assess the function of Sirt1 deficient germ cells, we compared the efficiency of generating embryos and viable offspring in in vitro fertilization (IVF) experiments using gametes from Sirt1-/- and sibling Sirt1+/- mice. While viable animals were derived in both Sirt1-/- X wild type and Sirt1-/- X Sirt1-/- crosses, the efficiency of producing both 2-cell zygotes and viable offspring was diminished when IVF was performed with Sirt1-/- sperm and/or oocytes. Together, these data support an important role for Sirt1 in spermatogenesis, including spermatogenic stem cells, as well as germ cell function.	[Coussens, Matthew; Maresh, John G.; Yanagimachi, Ryuzo; Maeda, Gregg; Allsopp, Richard] Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA; [Coussens, Matthew; Allsopp, Richard] Univ Hawaii, Inst Biogen Res, Honolulu, HI USA	University of Hawaii System; University of Hawaii System	Coussens, M (corresponding author), Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA.	allsopp@hawaii.edu		Whitman, Mary/0000-0001-6297-7499	NIH [P20 RR16467-05]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016467] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work was supported by NIH grant P20 RR16467-05 to RA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; ASHBURNER M, NAT GENET, V25, P25; Bordone L, 2006, PLOS BIOL, V4, P210, DOI 10.1371/journal.pbio.0040031; Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Chen J, 2005, J BIOL CHEM, V280, P40364, DOI 10.1074/jbc.M509329200; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Chua KF, 2005, CELL METAB, V2, P67, DOI 10.1016/j.cmet.2005.06.007; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Coussens M, 2006, BIOL REPROD, V75, P785, DOI 10.1095/biolreprod.106.052167; Guarente L, 2006, NATURE, V444, P868, DOI 10.1038/nature05486; HOPPE PC, 1973, BIOL REPROD, V8, P420, DOI 10.1093/biolreprod/8.4.420; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Kennedy BK, 2005, CELL, V123, P548, DOI 10.1016/j.cell.2005.11.002; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kitamura YI, 2005, CELL METAB, V2, P153, DOI 10.1016/j.cmet.2005.08.004; Li HZ, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1632; Lin SY, 2003, CELL, V113, P881, DOI 10.1016/S0092-8674(03)00430-6; McBurney MW, 2003, MOL CELL BIOL, V23, P38, DOI 10.1128/MCB.23.1.38-54.2003; Mendoza-Lujambio I, 2002, HUM MOL GENET, V11, P1647, DOI 10.1093/hmg/11.14.1647; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Nagy A., 2002, MANIPULATING MOUSE E; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; SHORE D, 1984, EMBO J, V3, P2817, DOI 10.1002/j.1460-2075.1984.tb02214.x; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Stankovic-Valentin N, 2007, MOL CELL BIOL, V27, P2661, DOI 10.1128/MCB.01098-06; Szabo PE, 2002, MECH DEVELOP, V115, P157, DOI 10.1016/S0925-4773(02)00087-4; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468; WELCH JE, 1990, BIOL REPROD, V43, P569, DOI 10.1095/biolreprod43.4.569; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Yuan Z, 2007, MOL CELL, V27, P149, DOI 10.1016/j.molcel.2007.05.029	34	129	136	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1571	10.1371/journal.pone.0001571	http://dx.doi.org/10.1371/journal.pone.0001571			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18612420	Green Published, Green Submitted, gold			2022-12-25	WOS:000260535900010
